@article {pmid41780984,
year = {2026},
author = {Kudeken, N},
title = {Long COVID and Sex Differences: A Narrative Review.},
journal = {Internal medicine (Tokyo, Japan)},
volume = {65},
number = {20},
pages = {2652-2657},
doi = {10.2169/internalmedicine.6969-25},
pmid = {41780984},
issn = {1349-7235},
mesh = {Humans ; *COVID-19/epidemiology/diagnosis/immunology ; Post-Acute COVID-19 Syndrome ; Female ; Sex Factors ; Male ; SARS-CoV-2 ; *Sex Characteristics ; },
abstract = {Long COVID (post-COVID-19 condition) is a heterogeneous syndrome of persistent or new symptoms after severe acute respiratory syndrome coronavirus 2 infection. While men have higher risks of severe acute COVID-19 and mortality, epidemiological studies consistently show a female predominance in Long COVID, especially among middle-aged women. Interpretation is complicated by variable case definitions (World Health Organization, Centers for Disease Control and Prevention, National Institute for Health and Care Excellence) and variant-era differences; however, sex disparities persist across both pre-Omicron and Omicron periods. We review evidence on sex differences in epidemiology, symptom clusters, and longitudinal trajectories, incorporating recent RECOVER findings and emerging data from Japanese cohorts. Potential mechanisms include sexually dimorphic antiviral immunity, hormonal and X-chromosome-linked immunoregulation, autoimmunity, autonomic dysfunction, and gender-related social exposures and health-care access. Recognizing sex- and gender-related determinants can improve differential diagnosis, risk stratification, and individualized management, and should be embedded as core variables in future mechanistic studies and clinical trials.},
}
@article {pmid42858306,
year = {2026},
author = {Menter, T and Mertz, K and Tzankov, A},
title = {Insights into the pathophysiology of post-COVID lung disease from the perspective of histopathology.},
journal = {Pathobiology : journal of immunopathology, molecular and cellular biology},
volume = {},
number = {},
pages = {1},
doi = {10.1159/pat/aehag004},
pmid = {42858306},
issn = {1423-0291},
abstract = {The COVID-19 pandemic has caused a broad range of respiratory complications. Among the spectrum of COVID-associated pulmonary conditions, severe bilateral pneumonitis that might progress to acute respiratory distress syndrome (ARDS) represents the most critical manifestation. A substantial proportion of survivors of severe COVID-19 continue to experience persistent respiratory symptoms and functional limitations. These findings are referred to as post-acute sequelae of COVID-19 (PASC). These residual post-COVID lung abnormalities are mechanistically linked to the structural changes of acute lung injury, but also to persistent systemic inflammatory signatures, and are reflected in a range of histopathological patterns, including pulmonary fibrosis, hyperinflammation, angiopathic and immunothrombotic tissue responses. This review focuses on the current knowledge of the pathogenesis and pathophysiology of post-COVID lung disease. We also schematically delineate the broad spectrum of post-COVID lung disease and explain the underlying pathomechanisms.},
}
@article {pmid42858449,
year = {2026},
author = {Maria, LFBS and Naves, MCX and Duarte, EC and Carvalho, IPSF and Peixoto, HM},
title = {Does COVID-19 Vaccination Protect Against Post-COVID Cardiovascular Conditions?.},
journal = {Reviews in medical virology},
volume = {36},
number = {6},
pages = {e70219},
pmid = {42858449},
issn = {1099-1654},
support = {Process: 445276/2023-1;//Conselho Nacional de Desenvolvimento Científico e Tecnológico/ ; Process: 445276/2023-1//Department of Science and Technology under the Secretariat of Science, Technology, Innovation, and Health Complex of the Ministry of Health/ ; //Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/ ; },
mesh = {Humans ; *COVID-19 Vaccines/administration & dosage/immunology ; *COVID-19/complications/prevention & control/immunology ; *Cardiovascular Diseases/prevention & control/etiology/epidemiology/virology ; Vaccination ; SARS-CoV-2/immunology/pathogenicity ; Post-Acute COVID-19 Syndrome ; },
abstract = {Cardiovascular diseases, such as acute myocardial infarction, heart failure, and arrhythmias, have been associated with SARS-CoV-2 infection, representing an important cause of long-term morbidity and mortality. In addition to preventing primary infection, COVID-19 vaccination has emerged as a protective factor against post-COVID cardiovascular outcomes. This study aims to analyse the evidence supporting a causal relationship between COVID-19 vaccination and the prevention of post-COVID cardiovascular conditions, based on classical and contemporary epidemiological criteria, including the Bradford Hill criteria (BHC) and the sufficient component cause (SCC) model. A qualitative synthesis of the evidence was performed according to the nine BHC and the SCC model. Scientific evidence indicates that COVID-19 vaccination meets four of the nine BHC as a protective factor against post-COVID cardiovascular conditions, namely strength of association, consistency, temporality, and biological gradient. Three criteria, biological plausibility, coherence, and analogy, were partially met. Specificity and experimental evidence were not supported by the available literature. The SCC model highlights the fundamental role of vaccination as a preventive causal component. It also contributes to two criteria, strength of association and temporality, while emphasising the limitation of specificity in causal inference. COVID-19 vaccination has proven effective beyond the acute phase of the disease, with protection extending to a reduced risk of post-COVID cardiovascular conditions. Comprehensive immunisation strategies and reinfection prevention are essential to mitigate the burden of post-COVID conditions. Additional studies are needed to explore the underlying biological mechanisms, interactions, and the role of COVID-19 vaccination in preventing post-COVID complications.},
}
@article {pmid42858831,
year = {2026},
author = {Ghimire, B and Anil, A and Bhandari, M and Yadav, KK},
title = {Turkey Coronavirus: Current Knowledge, Critical Gaps, and Future Directions in Transmission Biology and Pathogenesis.},
journal = {Veterinary journal (London, England : 1997)},
volume = {},
number = {},
pages = {106927},
doi = {10.1016/j.tvjl.2026.106927},
pmid = {42858831},
issn = {1532-2971},
abstract = {Turkey coronavirus (TCoV) is an enteric gammacoronavirus that has become a re-emerging pathogen of major economic importance in commercial turkey production. First identified in the 1970s, TCoV continues to circulate endemically and periodically resurges as a primary viral contributor to poult enteritis complex (PEC) and poult enteritis mortality syndrome (PEMS). The continuous need to understand TCoV is highlighted by its severe enterotropism, quick fecal-oral transmission and capacity to propagate covertly among older turkeys and spillover hosts like chickens. Despite more than fifty years of research, key aspects of TCoV pathogenesis and ecology remain unresolved, including receptor usage, host-range determinants, age-dependent susceptibility, environmental persistence and the evolutionary origins of its highly recombinant genome. These persistent gaps are mostly caused by TCoV's absence of a reliable in vitro culture system, which restricts the use of recent advances in virology, glycomics, whole genome sequencing, and reverse genetics techniques that have revolutionized research on other coronaviruses. With current technological advancements, and after nearly a decade-long gap in research publications, the field is now regaining momentum and is positioned to revisit fundamental questions that were previously inaccessible. The USPOULTRY Research Initiative recently designated TCoV as a top research priority because of its influence on flock performance, production costs and supply-chain stability. Hence, this review summarizes current knowledge on TCoV epidemiology, evolution, transmission biology, pathogenesis, diagnostics, industry impact and outlines the critical research gaps necessary to be addressed for the long-term sustainability of the turkey industry.},
}
@article {pmid42859407,
year = {2026},
author = {Špelić, M and Krajinović, V},
title = {Antimicrobial stewardship challenges during the COVID-19 pandemic: implications of antibiotic overuse and antimicrobial resistance.},
journal = {Arhiv za higijenu rada i toksikologiju},
volume = {77},
number = {3},
pages = {160-168},
pmid = {42859407},
issn = {1848-6312},
mesh = {Humans ; *Antimicrobial Stewardship ; *Anti-Bacterial Agents/therapeutic use ; *COVID-19/epidemiology ; *Inappropriate Prescribing/statistics & numerical data/prevention & control ; Pandemics ; *Bacterial Infections/drug therapy ; Coinfection/drug therapy ; *Practice Patterns, Physicians'/statistics & numerical data ; Drug Resistance, Bacterial ; SARS-CoV-2 ; *Drug Resistance, Microbial ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic significantly influenced antimicrobial prescribing practices worldwide, raising concerns about antimicrobial resistance (AMR). This narrative review assesses the relationship between COVID-19 and antibiotic use, focusing on bacterial co-infections, prescribing patterns, long-term implications for AMR, and the role of multidisciplinary antimicrobial and diagnostic stewardship, preventive strategies, and the One Health approach in reducing disproportionate antibiotic exposure. To this end we ran a subject search across PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Database of Systematic Reviews, Ovid, and Google Scholar for studies selected according to predefined inclusion and exclusion criteria. Despite relatively low rates of confirmed bacterial co-infections, antibiotic use remained disproportionately high, particularly during the early stages of the pandemic, highlighting challenges in clinical decision-making under diagnostic uncertainty. Excessive and inappropriate antibiotic prescribing may have contributed to the global AMR burden. Strengthening antimicrobial stewardship programmes, improving diagnostic accuracy and promoting evidence-based prescribing are therefore essential. Multidisciplinary antimicrobial stewardship interventions, rapid molecular diagnostics and vaccination-associated reductions in antibiotic prescribing emerge as complementary strategies for limiting unnecessary antimicrobial exposure, while the environmental consequences of antibiotic use further emphasise the relevance of the One Health approach. Continued surveillance and research are needed to better understand the long-term impact of the pandemic on AMR.},
}
@article {pmid42859504,
year = {2026},
author = {Addamo, AP and D'Angeli, F and Genovese, C},
title = {Molecular biophysics of viral proteins: From mechanistic insights to microbiological and clinical applications.},
journal = {AIMS microbiology},
volume = {12},
number = {3},
pages = {682-717},
pmid = {42859504},
issn = {2471-1888},
abstract = {Viral proteins are dynamic molecular machines that couple molecular-scale events to microbiological phenotypes, including host-cell tropism, entry efficiency, environmental persistence, strain-specific immune escape, and antiviral resistance. In this review, we critically evaluated how experimental, computational, and biochemical approaches define these links and support clinical translation. We organized the evidence around four key observables: Structure, dynamics, mechanics, and thermodynamics. We then assessed which conclusions remained robust across methods and viral families. Nuclear magnetic resonance spectroscopy, cryogenic electron microscopy, atomic force microscopy, calorimetry, all-atom molecular dynamics (MD), coarse-grained MD, structural bioinformatics, artificial intelligence, and biochemical reconstitution were compared in terms of resolution, sampling, assumptions, and validation requirements. Human immunodeficiency virus type 1 and severe acute respiratory syndrome coronavirus 2 were used as data-rich exemplars, but the resulting conclusions were tested against influenza virus, hepatitis B virus (HBV), human papillomavirus (HPV), Ebola virus, adenovirus, bacteriophages, and other systems. Particular attention was given to force-field selection, enhanced sampling, free-energy calculations, convergence, experimentally restrained modeling, and the multiscale relationship between all-atom and coarse-grained simulations. We also examined integrative workflows, the licensed HBV and HPV virus-like particle (VLP) vaccines, emerging dengue and coronavirus VLP platforms, and clinically validated structure-guided antivirals and prefusion-stabilized antigens. The analysis identified where evidence converges, where method-specific biases or limited taxonomic sampling constrain generalization, and which measurements are required to connect a molecular mechanism to infection, transmission-relevant traits, surveillance, or therapeutic performance. This critical, experimentally anchored framework defines the distinctive contribution of the review.},
}
@article {pmid42859537,
year = {2026},
author = {García-de-Santiago, E and García-Lledó, A},
title = {Vaccination as a Strategy for Cardiovascular Prevention: Closing a Gap in Clinical Practice.},
journal = {Reviews in cardiovascular medicine},
volume = {27},
number = {9},
pages = {54010},
pmid = {42859537},
issn = {2153-8174},
abstract = {Prevention of the consequences of atherosclerotic disease has traditionally focused on controlling individual risk factors such as dyslipidaemia, hypertension and diabetes. In recent years, the term residual risk has been used to describe the persistence of cardiovascular events despite the optimal management of these classical risk factors, with particular attention given to inflammation. Far less attention, however, has been paid to environmental risk factors, which affect entire populations and may account for a substantial proportion of temporal variations in event incidence, as well as the marked seasonal fluctuations in hospital admissions for cardiovascular disease that periodically place considerable pressure on healthcare systems. Temperature, air pollution and infectious diseases-particularly respiratory infections-may help explain why an individual with a given baseline risk experiences an event in one month rather than another. Some environmental factors may promote the development of classical risk factors, whereas others may contribute directly to atherosclerosis. All of them may act either as triggers for acute ischemic events or as destabilising factors in previously stable patients, for example those with heart failure. Infections, especially those of respiratory tract, play a key role in the natural history of cardiovascular disease. Growing evidence indicates that preventing infections through vaccination can reduce the risk of acute ischemic events, hospitalisation and death. Nevertheless, vaccination coverage for many infections, including influenza and Coronavirus disease 2019 (COVID-19), remains low. In addition, pseudo-scientific campaigns continue to spread misinformation about vaccines, thereby reducing patient adherence. Leading cardiology societies now recognise vaccination against certain infections as an evidence-based strategy for cardiovascular prevention. It is therefore essential that this information be widely disseminated among healthcare professionals, patients and the general public. Of all the available measures to control environmental risk factors, vaccination is the only intervention that clinicians can directly implement in routine clinical practice. Vaccination recommendations should therefore be regarded with the same importance as advice on diet, exercise and smoking cessation.},
}
@article {pmid42851730,
year = {2026},
author = {Gao, Z and Wang, S and Zhang, Y and Wang, S and Qiu, D and Yao, L and Ma, T and Cao, W and Deng, W and Wei, X and Li, M and Xie, Y},
title = {Strengthening patient safety through biosafety and infection prevention measures during COVID-19: a policy and practice review.},
journal = {Frontiers in health services},
volume = {6},
number = {},
pages = {1914377},
pmid = {42851730},
issn = {2813-0146},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placed substantial pressure on global healthcare systems, biosafety management, and the delivery of safe clinical services. As a critical component of infection prevention and control (IPC), biosafety contributes not only to limiting pathogen exposure but also to protecting healthcare workers, maintaining reliable diagnostic pathways, and supporting patient safety and health-service continuity. This Policy and Practice Review presents a structured narrative synthesis of a sample of literature published primarily between January 2020 and August 2026, supplemented by selected earlier foundational studies and relevant public-health guidance. The review focuses on respiratory exposure control, appropriate use and oversight of personal protective equipment (PPE), airway-management safety, emergency respirator decontamination and reuse strategies including ultraviolet germicidal irradiation (UVGI), specimen collection and transport, laboratory biosafety, and emerging diagnostic technologies. The evidence indicates that safe practice requires layered, risk-based measures adapted to the exposure context and specific clinical or laboratory activity. During severe PPE shortages, UVGI was investigated as a contingency strategy for respirator decontamination, but microbial inactivation, preservation of filtration performance, and maintenance of fit or seal integrity represent distinct outcomes and require separate validation. Safe specimen pathways similarly depend on validated collection, transport, storage, and laboratory procedures that preserve both worker safety and diagnostic reliability. Emerging CRISPR- and nanomaterial-enabled technologies may improve diagnostic accessibility or turnaround time, but their contribution to patient safety depends on clinical validation, quality assurance, regulatory oversight, and successful integration into healthcare workflows. Overall, lessons from the COVID-19 pandemic support a multilayered, activity-specific approach to biosafety that integrates occupational protection, diagnostic safety, patient safety, and health-system resilience.},
}
@article {pmid42852104,
year = {2026},
author = {Grossi, C and Spahiu, O and Riva, G and Crupi, A and Arduino, PG and Pecorari, G and Ricardi, U and Iorio, GC},
title = {Hypofractionated radiotherapy in head and neck cancer: current evidence and future directions, with a focus on laryngeal cancer.},
journal = {Frontiers in oncology},
volume = {16},
number = {},
pages = {1953291},
pmid = {42852104},
issn = {2234-943X},
abstract = {Radiotherapy (RT) remains a cornerstone in the management of head and neck squamous cell carcinoma (HNSCC) across both definitive and multimodality treatment settings. While hypofractionated radiotherapy (HFRT) has become an established standard of care for several solid tumors, including prostate, breast, lung, and rectal cancers, its adoption in HNSCC has been more cautious owing to the complex anatomy of the head and neck region, the proximity of numerous critical organs at risk, and concerns regarding severe late toxicity. However, major advances in intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), image guidance, adaptive radiotherapy, and radiobiological understanding have renewed interest in HFRT as a strategy to maintain oncological efficacy while reducing overall treatment time. Additional drivers include the need to optimize healthcare resource utilization, improve access to radiotherapy in low- and middle-income countries, and minimize hospital visits, as highlighted during the COVID-19 pandemic. Recent prospective evidence has further strengthened the rationale for carefully selected hypofractionated approaches in HNSCC. In elderly and frail patients, the phase III ELAN-RT trial has also provided prospective evidence regarding a tailored hypofractionated approach for patients unable to undergo standard treatment. Among head and neck subsites, laryngeal cancer-particularly early-stage glottic carcinoma-represents the most mature clinical model for HFRT and therefore constitutes the principal focus of this review, while evidence from other HNSCC subsites is examined to assess the broader applicability of hypofractionated treatment strategies. This review critically summarizes the radiobiological rationale, current clinical evidence, technological advances, and ongoing challenges surrounding radical HFRT in HNSCC, with particular emphasis on laryngeal cancer, and discusses future directions for its broader implementation in clinical practice.},
}
@article {pmid42852841,
year = {2026},
author = {Wannachalee, T and Charoensri, S and Plongla, R and Snabboon, T and Sunthornyothin, S and Parksook, WW},
title = {Adrenal Infections: An Underrecognized Cause of Primary Adrenal Insufficiency.},
journal = {Clinical endocrinology},
volume = {},
number = {},
pages = {},
doi = {10.1111/cen.70222},
pmid = {42852841},
issn = {1365-2265},
abstract = {INTRODUCTION: Adrenal infections are an underrecognized but clinically significant cause of primary adrenal insufficiency (PAI).<br><br>OBJECTIVES: This review proposes a diagnostic algorithm for the evaluation of suspected cases.<br><br>RESULTS: The most common causative pathogens are Mycobacterium tuberculosis and Histoplasma capsulatum; however, bacterial infections and viral pathogens such as cytomegalovirus (CMV) and SARS-CoV-2 (COVID-19) have also been reported. These infections, particularly in tuberculosis and histoplasmosis, can induce granulomatous inflammation, tissue necrosis, and destruction of the adrenal glands, leading to systemic symptoms and hormonal deficiency. The prevalence of adrenal insufficiency varies widely, ranging from 14% to 100%, depending on the study population and diagnostic criteria. Affected patients may present across a broad clinical spectrum, from chronic adrenal insufficiency to adrenal crisis, and some patients may be identified incidentally through imaging performed for unrelated indications. Computed tomography is the primary imaging modality for diagnosing adrenal infection, typically demonstrating bilateral adrenal lesions characterized by hypodensity with central necrosis, peripheral rim enhancement, and calcification. In contrast, during the late phase, the adrenal glands progressively decrease in size and may become atrophic, particularly in tuberculosis, and often with persistent calcifications. Tissue biopsy with histopathological examination and culture remains the definitive diagnostic tool to confirm the infectious etiology.<br><br>CONCLUSIONS: Early recognition is essential, as management requires two complementary approaches: 1. antimicrobial therapy directed at the causative pathogen, and 2. hormonal replacement in patients with established adrenal insufficiency and longitudinal hormonal surveillance in those with preserved adrenal reserve at initial presentation.},
}
@article {pmid42855617,
year = {2026},
author = {Chopra, A and Bonilla, HF and Cheng, AL},
title = {Long COVID in Primary Care: A Practical Approach to Evaluation and Management.},
journal = {Journal of general internal medicine},
volume = {},
number = {},
pages = {},
pmid = {42855617},
issn = {1525-1497},
support = {U18HS029911/HS/AHRQ HHS/United States ; U18HS029930/HS/AHRQ HHS/United States ; U18HS029904/HS/AHRQ HHS/United States ; },
abstract = {Long COVID is a multi-system, heterogeneous condition that manifests as new or worsened symptoms lasting at least 3 months following acute SARS-CoV-2 infection, often despite normal results on routine diagnostic testing. Common manifestations include fatigue, post-exertional malaise, cognitive impairment, and orthostatic intolerance. Primary care clinicians are uniquely positioned to identify and manage Long COVID due to their longitudinal relationships with patients and holistic understanding of their patients' health. However, diagnostic uncertainty, time constraints, and limited access to specialty care present significant challenges, and sometimes hesitation, to addressing Long COVID in the primary care setting. This focused narrative review provides a pragmatic, primary care-focused approach for the evaluation and management of Long COVID. Using patient-centered vignettes, we first describe common clinical presentations. Next, we provide a framework for the pathophysiological mechanisms suspected to contribute to persistent symptoms after SARS-CoV-2 infection. We then present a simple approach to Long COVID diagnosis and management that leverages primary care clinicians' skillset and highlights unique aspects of Long COVID care (e.g., diagnostic workup to evaluate for competing or coexisting diagnoses; management strategies focused on validation and supportive care, including activity pacing, multidisciplinary rehabilitation, and consideration of symptom-based medication trials). We offer practical strategies to effectively, yet efficiently, address a possible Long COVID diagnosis within the context of brief primary care visits (e.g., prioritize the most bothersome or addressable symptom(s) first, focus on one or two symptoms each visit, leverage longitudinal follow-up). We conclude with evidence-based strategies for prevention counseling, including infection prevention and early outpatient treatment during acute infection. While we remain optimistic that reliable diagnostic biomarkers and curative treatments will one day be available, until then, this primer supports primary care clinicians in recognizing Long COVID and supporting their patients who are living with it, despite the constraints of our current healthcare environment.},
}
@article {pmid42856052,
year = {2026},
author = {Chua, CE and Low, SY and Peh, AL and Fitria, N and Tan, RH and Ko, SQ},
title = {Perioperative Hospital-at-Home Program: A Scoping Review.},
journal = {World journal of surgery},
volume = {},
number = {},
pages = {},
doi = {10.1002/wjs.70589},
pmid = {42856052},
issn = {1432-2323},
abstract = {BACKGROUND: Hospital-at-Home (HaH) is an established model of care for medical patients, particularly following rapid expansion during the COVID-19 pandemic. In contrast, perioperative HaH remains in its early stages, with limited understanding of appropriate care delivery models, staffing, feasibility, cost-effectiveness, and relevant clinical outcomes. Surgical-specific demands limit the operational transferability of HaH from nonsurgical care. This scoping review synthesizes existing evidence on perioperative HaH to clarify current practices and identify key domains for future research and implementation.<br><br>METHODS: A systematic search strategy was developed for MEDLINE (via PubMed) and adapted for Embase and Scopus to identify studies involving adults undergoing surgery who received HaH care. After data extraction, a narrative synthesis was conducted to map care delivery and staffing models and the domains of reported clinical outcome measures.<br><br>RESULTS: The search identified 5612 records, of which 18 studies met the inclusion criteria. The studies were published between 1991 and 2024 and originated mainly from the United Kingdom, Spain, and the United States. Care-delivery models and clinical outcome measures were heterogeneous, particularly those relating to patient safety. Orthopedic procedures were most common, followed by bariatric surgery and other general surgical specialties. Most studies evaluated postoperative HaH pathways, with only two examining preoperative models. Surgical admissions were predominantly elective, although some included emergency populations.<br><br>CONCLUSION: Perioperative HaH shows promise as a rapidly evolving model of perioperative care, but the current evidence base is limited by small, largely noncomparative studies and a lack of standardized outcome measures. This is the first scoping review to systematically map perioperative-specific HaH models across pre- and postoperative phases and surgical specialties. Strengthening the quality of evidence is essential to inform policy, guide best practices, and support the safe and scalable adoption of perioperative HaH programs.},
}
@article {pmid42856812,
year = {2026},
author = {Eisa, N and Khoury, M},
title = {Multisystem effects of sodium-glucose cotransporter-2 inhibitors beyond glycaemic control: an umbrella review of systematic reviews and meta-analyses.},
journal = {Journal of diabetes and metabolic disorders},
volume = {25},
number = {2},
pages = {283},
pmid = {42856812},
issn = {2251-6581},
abstract = {PURPOSE: To map benefits and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors beyond glucose lowering and assess evidence certainty.<br><br>METHODS: We searched PubMed/MEDLINE through 24 April 2026 and checked references. Two reviewers screened records and verified extracted data. Review methods were appraised with AMSTAR-2, and outcome certainty was judged using GRADE domains. Overlapping, non-interchangeable review estimates were not re-pooled. PROSPERO registration occurred after review initiation (CRD420261378845; 25 April 2026; retrospectively registered).<br><br>RESULTS: Twelve PubMed-indexed reviews were included. Representative estimates showed fewer cardiovascular death or first heart-failure hospitalisation events (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.72-0.82), major adverse cardiovascular events (HR 0.91, 95% CI 0.87-0.96), and kidney disease progression (risk ratio [RR] 0.63, 95% CI 0.58-0.69). Liver fat decreased by 2.05% points (95% CI 1.48-2.61), but this was an imaging outcome, predominantly in type 2 diabetes. The RCT-only subgroup of a mixed-design gout review reported HR 0.74 (95% CI 0.55-0.98). Genital infection increased (RR 3.30, 95% CI 2.74-3.99); urinary tract infection and diabetic ketoacidosis estimates were imprecise or compatible with no difference. SGLT2 inhibition did not clearly reduce 28-day mortality in hospitalised COVID-19 (odds ratio 0.93, 95% CI 0.79-1.08). All reviews had critically low AMSTAR-2 confidence.<br><br>CONCLUSION: Cardiorenal benefits are supported in the studied heart-failure and chronic-kidney-disease populations, including prespecified non-diabetic subgroups. Evidence for liver fat and gout is narrower and does not establish universal multisystem benefit.<br><br>GRAPHICAL ABSTRACT: Outcome-specific summary of the strongest cardiorenal evidence, narrower extra-cardiorenal findings, and principal safety signal.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02097-x.},
}
@article {pmid42857654,
year = {2026},
author = {Kusmiati, M and Gaffar, S and Kusuma, SAF},
title = {Immunoglobulin-Y in Infectious Disease Diagnostics: The Ethical, Sustainability and Conditions Does It Outperform Conventional Antibodies.},
journal = {Infection and drug resistance},
volume = {19},
number = {},
pages = {644269},
pmid = {42857654},
issn = {1178-6973},
abstract = {Infectious diseases remain a major global health challenge, and effective control depends on early and accurate diagnosis. However, conventional immunodiagnostic platforms rely heavily on mammalian antibodies, which may present limitations related to animal welfare, production, and nonspecific immunological interactions. Immunoglobulin Y (IgY), isolated from the yolk of eggs collected non-invasively from immunized hens, has emerged as a potential alternative, although its advantages over conventional mammalian antibodies appear to be context-dependent rather than universal. This narrative review synthesizes current evidence on IgY production, diagnostic performance, comparative advantages and limitations, and ethical and sustainability considerations. A structured literature search of PubMed and Scopus covering January 2016 to February 2026 identified 66 records. Of these, 25 articles underwent full-text eligibility assessment, and 17 studies met the inclusion criteria and were included in the qualitative synthesis. Additional supporting literature identified through hand-searching was used for mechanistic and contextual interpretation but was not counted among the 17 included studies. Across the diagnostic studies, IgY demonstrated favorable performance in selected immunoassay platforms, particularly where reduced interaction with mammalian Fc receptors, rheumatoid factor, or complement may decrease nonspecific interference. High diagnostic performance was reported for applications including bovine coronavirus detection (97.7% sensitivity and 98.2% specificity) and SARS-CoV-2 detection (>90% sensitivity and specificity). However, IgY did not consistently outperform mammalian antibodies across all applications, with limitations observed in free-solution turbidimetric assays, selected in vivo models, and certain engineered antibody formats. Two included studies addressed ethical and sustainability considerations, with quantitative sustainability assessment indicating advantages for IgY-based approaches, although the evidence remains limited. Overall, IgY represents a promising but context-dependent alternative to conventional antibodies. Further head-to-head comparative studies, standardized production and validation protocols, and larger-scale clinical evaluation are required to define the diagnostic settings in which IgY provides a meaningful advantage.},
}
@article {pmid42849730,
year = {2026},
author = {Mansur, DS and Trowbridge, B and Oliveira, JHM and Guabiraba, R and Ferguson, BJ},
title = {Pattern recognition receptors and divergent disease severity in zoonotic viral infections.},
journal = {The Journal of biological chemistry},
volume = {},
number = {},
pages = {113618},
doi = {10.1016/j.jbc.2026.113618},
pmid = {42849730},
issn = {1083-351X},
abstract = {Zoonotic viruses continue to emerge unpredictably, cross species barriers, and inflict major health, economic, and ecological burdens. Recent outbreaks of SARS-CoV-2, H5N1 avian influenza virus (AIV), monkeypox, and Zika virus underscore the unpredictability of viral emergence and the urgent need to understand host/pathogen interactions. This review focuses on how innate immune sensing via pattern recognition receptors (PRRs) shapes disease severity across different species. While PRRs initiate antiviral defenses (interferons, ISGs), inflammatory cytokines, and programmed cell death, host outcomes diverge widely, shaped by genetic variation in PRR pathways and their regulators. Dysregulated inflammatory responses and inflammatory cell death can contribute substantially to severe disease independently of viral load, as demonstrated in influenza and coronavirus infections. Viral effectors that suppress or alter PRR signaling can show species-specific efficacy, and these mismatches can be critical determinants of disease when viruses jump hosts. Using avian influenza as an example, we highlight how disease outcomes vary with viral strain, host species, response timing, and tissue context. Overall, we propose that differential disease severity across host species reflects the balance among PRR-mediated resistance, the efficiency of viral immune evasion in the relevant host, and innate disease-tolerance mechanisms that limit tissue damage. Understanding these dynamics could enhance our ability to predict zoonotic emergence and mitigate the impact of viral pandemics.},
}
@article {pmid42850372,
year = {2026},
author = {Goonaratne, E and Bhinder, J and McGrath, K and Astray, D and Sharma, K and Sferrazza, D and Botea, A and Tse, SSW and Lee, SF and Chan, AW and Jefford, M and Chan, RJ and Chow, E and Alkhaifi, M and Wong, HCY},
title = {The impact of the COVID-19 pandemic on breast cancer survivorship: a scoping review.},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
volume = {34},
number = {11},
pages = {},
pmid = {42850372},
issn = {1433-7339},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Quality of Life ; Female ; *Breast Neoplasms/psychology/therapy ; *Cancer Survivors/psychology ; Survivorship ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has affected how cancer care is delivered globally. This scoping review aimed to evaluate the impact of COVID-19 on breast cancer survivors (BCS), specifically regarding their quality of life (QoL), follow-up care, and interventions to address their supportive care needs.<br><br>METHODS: This review was prepared following PRISMA guidelines. Embase, MEDLINE, CINAHL, and Web of Science were searched from January 2020 to February 2025. Primary studies in English that specifically commented on the impact of COVID-19 on the above outcomes were included.<br><br>RESULTS: Of the 40 studies included in this review, the most common designs were cross-sectional (n&#x2009;=&#x2009;14), prospective cohort (n&#x2009;=&#x2009;10), and qualitative (n&#x2009;=&#x2009;7), with four randomized controlled trials. Thirty-five studies examined the impact of the COVID-19 pandemic on the quality of life (QoL) of breast cancer survivors (BCS). Twenty studies reported worsened psychological well-being, with increased stress, anxiety, depression, and loneliness. Stressors included fear of COVID-19 exposure during in-person care and concern over service disruptions. Fifteen studies described interruptions to follow-up care, including appointment cancellations and reduced access to surveillance. Eighteen studies noted broader changes to the care model, including virtual interventions and telemedicine, with five evaluating at-home programs and two reporting positive experiences with phone-based follow-up. Five studies addressed concerns about cancer recurrence, with no observed increases but heightened fear. Notably, three studies published after 2023 reported longer-term impacts, such as persistent anxiety, reduced healthcare access, and declines in functional well-being.<br><br>CONCLUSION: COVID-19 has negatively impacted the QoL and the care delivery of BCS. Virtual follow-up and interventions were well-received by BCS, and may be recommended as an alternative to in-person care.},
}
@article {pmid42851058,
year = {2026},
author = {Du, Y and Yu, M},
title = {[The role of TMPRSS2 in tumor development and viral infection].},
journal = {Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology},
volume = {42},
number = {10},
pages = {938-942},
pmid = {42851058},
issn = {1007-8738},
mesh = {Humans ; *Serine Endopeptidases/chemistry/metabolism/genetics/physiology ; *Neoplasms/enzymology ; *SARS-CoV-2/physiology ; Animals ; *COVID-19/virology ; Virus Internalization ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {TMPRSS2 is a member of a family of proteins localized to the cell membrane and characterized by a conserved serine protease domain. Previous studies have demonstrated its involvement in the initiation and progression of various cancers in the human body. Its serine protease activity can degrade extracellular matrix components, disrupt the integrity of the basement membrane, and promote tumor cell invasion and metastasis. In addition, its expression level is closely related to the degree of immune cell infiltration and may affect tumor immune escape by regulating local inflammatory responses. In terms of viral infection, TMPRSS2 also plays a critical role, especially in the process of coronavirus infection, where it can stimulate the activation of viral particles and enhance infection. Recent studies on COVID-19 have further shown that TMPRSS2-mediated cleavage of the viral spike protein is essential for the activation and entry of the SARS-CoV-2 into the host cells. This review summarizes the current understanding of the structure and function of TMPRSS2, as well as its role in SARS-CoV-2 infection, with the aim of elucidating the underlying mechanisms by which TMPRSS2 facilitates viral entry and propagation within the host. These insights may contribute to the development of targeted therapeutics and vaccines.},
}
@article {pmid42841343,
year = {2026},
author = {Chen, N and Zhang, B and Yu, Z and Tong, G and Jin, J and Jiang, Q and Chen, X},
title = {Non-coding RNA-mediated tug-of-war between emerging viruses and host antiviral defense: lessons from animal viruses.},
journal = {Emerging microbes &amp; infections},
volume = {},
number = {},
pages = {2746261},
doi = {10.1080/22221751.2026.2746261},
pmid = {42841343},
issn = {2222-1751},
abstract = {Emerging animal viruses pose persistent threats to livestock breeding and public health, underscoring the need for a deeper understanding of virus-host interactions. Nevertheless, the regulatory roles and conserved mechanisms of host non-coding RNAs (ncRNAs) during animal virus infections remain fragmented, and ncRNA-mediated mechanisms for emerging animal viruses are particularly poorly characterized, with no systematic collation or theoretical summarization available. Studies indicate that ncRNAs, including miRNAs, lncRNAs, and circRNAs, have emerged as important regulators of the interplay between animal viruses and their hosts. This review synthesizes evidence from eleven animal viruses covering swine, poultry, ruminant, feline, canine, and mink hosts, with emphasis on virus-induced changes in ncRNA expression and their antiviral or proviral functions. Across diverse virus-host systems, three recurring regulatory paradigms are identified: host antiviral defense, viral hijacking, and viral antagonism. Host cells can dynamically reshape their ncRNA expression to regulate host restriction factors, proviral host factors, and other ncRNAs, thereby influencing innate immune signaling, viral replication cycles, autophagy, apoptosis, and metabolic reprogramming. Conversely, animal viruses, including PEDV, PRRSV, PRV, SVA, AIV, ALV-J, NDV, BVDV, FHV-1, CIV, and MEV, have evolved sophisticated strategies to hijack host ncRNA networks or antagonize ncRNA-mediated antiviral immunity, and remodel the intracellular microenvironment to facilitate viral replication. These paradigms provide a unified theoretical system for understanding and predicting ncRNA-mediated regulatory mechanisms in emerging animal viruses. They also offer references for dissecting the pathogenic patterns of ASFV, SADS-CoV, and future unknown emerging viruses, as well as, for mining, screening, and identifying potential antiviral drug targets.},
}
@article {pmid42842033,
year = {2026},
author = {Singh, A and Kumari, S and Dujawara, A and Kulshrestha, A and Shandilya, G and Sharma, A},
title = {Smartphone addiction and metabolic health risk in pediatrics.},
journal = {European journal of pediatrics},
volume = {185},
number = {11},
pages = {},
pmid = {42842033},
issn = {1432-1076},
mesh = {Humans ; Adolescent ; Child ; *Smartphone/statistics &amp; numerical data ; *Behavior, Addictive/epidemiology ; Screen Time ; *Internet Addiction Disorder/epidemiology ; COVID-19/epidemiology ; Pediatric Obesity/epidemiology ; Risk Factors ; Metabolic Syndrome/epidemiology ; *Metabolic Diseases/epidemiology ; },
abstract = {UNLABELLED: Smartphone ownership among children and adolescents has risen sharply over the past decade, coinciding with a parallel rise in pediatric metabolic disorders, including obesity, hypertension, insulin resistance, and early markers of metabolic syndrome. Whether these two trends are mechanistically related has become a question of growing clinical and public health relevance. This study synthesizes evidence on the association between problematic smartphone use in children and adolescents and metabolic health outcomes, with attention to the behavioral, neurobiological, and psychiatric pathways that may connect the two. Peer-reviewed studies published between 2019 and 2026 were identified through structured searches of PubMed, Scopus, Web of Science, Google Scholar, and IEEE Xplore, using combinations of terms related to smartphone addiction, problematic smartphone use, screen time, and pediatric metabolic outcomes. Fourteen studies meeting predefined eligibility criteria (original research; participants aged 5-18 years; a quantitatively examined association between smartphone use and a metabolic or closely related outcome) constituted the primary evidence base. This base was supplemented with additional targeted literature on diagnostic classification, neurobiology, psychiatric comorbidity, and intervention, cited separately, to address conceptual and clinical gaps identified during peer review. Across the included studies, the prevalence of problematic smartphone use ranged from approximately 22% to 53%, varying by instrument, cutoff score, and cultural context. Problematic use was consistently associated with obesity, hypertension, unfavorable dietary patterns, sleep disruption, and reduced physical activity; evidence for a direct association with insulin resistance was more limited and inconsistent. The COVID-19 pandemic was associated with a marked, temporary increase in both screen time and addiction prevalence. Proposed mechanisms include displacement of physical activity, altered dietary behavior, circadian disruption via melatonin suppression, and dysregulation of reward and stress-response circuitry, occurring within an apparently bidirectional relationship with psychiatric symptoms such as anxiety, depression, and attention-deficit/hyperactivity disorder.<br><br>CONCLUSION: &#xa0;Problematic smartphone use appears to be a plausible, modifiable contributor to pediatric metabolic risk, operating through overlapping behavioral, neurobiological, and psychosocial pathways. Because most available evidence is cross-sectional and drawn from a limited number of heterogeneous studies, causal inference is not currently possible, and the associations reported here should be interpreted as correlational rather than confirmed pathogenic relationships. Longitudinal and mechanistic research, alongside coordinated clinical screening and family-centered intervention, is needed to clarify and act on this relationship.<br><br>WHAT IS KNOWN: &#x2022; Previous studies have investigated the role of how excessive use of smartphones has progressively become common among children and adolescents worldwide. &#x2022; The researches also demonstrated how excessive smartphone use may negatively affect overall well-being in pediatric populations.<br><br>WHAT IS NEW: &#x2022; In this review, all the recent studies on smartphone addiction and metabolic health risk in pediatrics are highlighted. &#x2022; Unlike previous studies that have focused on individual outcomes, this review combines evidence on sleep disturbances, sedentary behavior, psychological factors, dietary pattern, obesity, hypertension, diabetes, and other health consequences within a single framework. &#x2022; The review highlights the diverse impact of smartphone addiction and identifies important gaps for future research.},
}
@article {pmid42842561,
year = {2026},
author = {Rolling, T and Brehm, TT and Krammer, F and Addo, M and Schmiedel, S and Salzer, H},
title = {Emerging respiratory infectious diseases: Clinical aspects for rapid identification and management.},
journal = {Respiration; international review of thoracic diseases},
volume = {},
number = {},
pages = {1},
doi = {10.1159/res/aepag021},
pmid = {42842561},
issn = {1423-0356},
abstract = {Emerging respiratory infectious diseases increasingly arise at the human-animal-environment interface and challenge clinicians with rapidly evolving diagnostic, therapeutic, and infection-control decisions. This narrative review summarizes clinically relevant viral and bacterial pathogens that may present as severe respiratory disease, but are easily mistaken for common community-acquired infections during early illness. We focus on zoonotic influenza A viruses, including contemporary H5N1, Middle East respiratory syndrome coronavirus (MERS-CoV), hantaviruses, Nipah virus, and inhalational bacterial threats such as anthrax, pneumonic plague, tularemia, and melioidosis. These infections may progress from non-specific symptoms to severe pneumonia, acute respiratory distress syndrome, shock, neurological complications, disseminated infection, or death. Timely recognition depends on careful assessment of travel, occupational and recreational exposures, animal contact, outbreak signals, and pathogen-specific syndromic clues. Multiplex molecular diagnostics can support early triage and exclusion of common pathogens, but targeted PCR, culture, serology, sequencing, and reference laboratory confirmation remain essential. Management requires prompt supportive care, appropriate isolation, public health notification, and pathogen-directed antimicrobial, antiviral, antitoxin, or prophylactic strategies where available. By integrating clinical presentation, diagnostics, treatment, vaccines, and One Health considerations, this review aims to translate knowledge on emerging infections into practical bedside preparedness.},
}
@article {pmid42842819,
year = {2026},
author = {Paccalin, M and Loubet, P},
title = {[Vaccination against respiratory infections in older adults: Covid-19, respiratory syncytial virus, influenza and pneumococcus].},
journal = {Geriatrie et psychologie neuropsychiatrie du vieillissement},
volume = {24},
number = {3},
pages = {261-270},
doi = {10.1684/pnv.2026.1300},
pmid = {42842819},
issn = {2115-7863},
mesh = {Aged ; Aged, 80 and over ; Humans ; *COVID-19/prevention &amp; control ; COVID-19 Vaccines ; France ; *Influenza Vaccines ; *Influenza, Human/prevention &amp; control/epidemiology ; Pandemics ; *Pneumococcal Infections/prevention &amp; control/epidemiology ; *Pneumococcal Vaccines ; Pneumonia, Viral/prevention &amp; control ; *Respiratory Syncytial Virus Infections/prevention &amp; control/epidemiology ; *Respiratory Tract Infections/prevention &amp; control ; *Vaccination ; },
abstract = {Population aging increases the risk of severe respiratory infections and their complications in older adults, largely because of immunosenescence. Beyond pneumonia, these infections can lead to cardiac and respiratory decompensation, acute cardiovascular events, loss of functional independence, and institutionalization. Vaccination remains the cornerstone of prevention. This review provides an update on four vaccine-preventable respiratory infections that are particularly common or severe in older adults: coronavirus disease 2019 (COVID-19), respiratory syncytial virus (RSV) infection, seasonal influenza, and pneumococcal disease. For each infection, we review the epidemiological burden, associated complications-particularly cardiovascular and functional outcomes-as well as recent real-world evidence on vaccine effectiveness and the 2026 French recommendations. The evidence is consistent: safe and effective vaccines are available for all four infections, yet vaccination coverage remains far below target among older adults and is even lower among healthcare workers, a situation that has worsened since the COVID-19 pandemic. The pandemic has durably reshaped attitudes towards vaccination, shifting from initial acceptance to growing hesitancy. Improving information and education for both the public and healthcare professionals, particularly those working in geriatric care settings, appears to be the most effective strategy for reducing this preventable burden. Clear, consistent communication and the integration of vaccination into personalized care plans are essential to translate well-established recommendations into effective protection.},
}
@article {pmid42843467,
year = {2026},
author = {Li, B and Zhao, L},
title = {Mechanisms of accelerated biological aging and premature cardiovascular events in young and middle-aged post-COVID-19 survivors.},
journal = {Ageing research reviews},
volume = {123},
number = {},
pages = {103396},
doi = {10.1016/j.arr.2026.103396},
pmid = {42843467},
issn = {1872-9649},
abstract = {This review evaluates the impact of Post-Acute Sequelae of SARS-CoV-2 on adults aged 25-55, focusing on the potential for accelerated biological aging and an increased incidence of acute cardiovascular events. By synthesizing evidence from 110 epidemiological and mechanistic studies, we examine the interplay between viral-induced immune dysregulation, endothelial injury, and systemic physiological decline in a demographic previously considered low-risk for severe outcomes. Our analysis indicates that chronic systemic inflammation, potentially maintained by persistent viral reservoirs in immune-privileged sites, may drive aging-associated molecular changes. While accelerated telomere attrition and altered DNA methylation patterns are reported, applying validated epigenetic clocks (e.g., Horvath's, PhenoAge) yields divergent results, ranging from no disparity to slight but significant epigenetic age acceleration. Alongside these evolving metrics, elevated neurofilament light chain and GDF-15 may indicate ongoing neuronal injury and cellular stress. Concurrently, the findings highlight an elevation in cardiovascular relative risks, where sustained endothelial dysfunction and microthrombi formation appear to contribute to a higher frequency of acute events, including myocardial infarction and ischemic stroke, within these younger cohorts. The review concludes that Post-Acute Sequelae of SARS-CoV-2 may represent an emerging driver of premature biological aging and heightened vascular vulnerability. We propose an exploratory clinical framework that prioritizes targeted, symptom-driven care pathways. While early pharmacological interventions remain strictly hypothesis-generating and confined to clinical trials to prevent iatrogenic harm, utilizing advanced biomarkers to evaluate high-risk phenotypes in symptomatic patients may guide future multidisciplinary research to mitigate the long-term societal burden of post-viral decline.},
}
@article {pmid42843657,
year = {2026},
author = {Zhang, M and Tan, C and Tang, Y and Cao, J and Li, W and Liu, P},
title = {Respiratory viruses and pulmonary diseases: Mechanisms, therapies, and metabolic reprogramming.},
journal = {Microbial pathogenesis},
volume = {221},
number = {},
pages = {108866},
doi = {10.1016/j.micpath.2026.108866},
pmid = {42843657},
issn = {1096-1208},
abstract = {Respiratory viral infections constitute a substantial global health challenge, extending their impact beyond acute inflammation to encompass long-term pulmonary sequelae. Recent evidence highlights that respiratory viruses such as influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 reprogram host metabolism to facilitate their replication, with significant alterations in glucose metabolism playing a critical role. This metabolic reprogramming augments glucose metabolism via activation of core signaling pathways including PI3K/Akt/mTOR, HIF-1α, and c-Myc. Beyond facilitating viral proliferation, these metabolic changes crosstalk with oncogenic signaling. By triggering chronic inflammation, oxidative stress and genomic damage, they disrupt the pulmonary immune microenvironment and ultimately promote the pathogenesis of lung cancer and chronic obstructive pulmonary disease (COPD). The pathogenesis of these symptoms is multifactorial and is influenced by genetic susceptibility, environmental exposure, and key interactions between persistent viral infection and the host's immune system. In this review, we synthesize recent advancements on the molecular mechanisms linking virus-induced metabolic alterations to the progression of pulmonary diseases. Furthermore, we discuss novel therapeutic strategies aimed at targeting these metabolic vulnerabilities to mitigate the long-term risks associated with respiratory infections.},
}
@article {pmid42845066,
year = {2026},
author = {Tadesse, TM and Wakjira, OG},
title = {Acute Respiratory Distress Syndrome and Corticosteroids: Reconciling Conflicting Evidence.},
journal = {Acta medica Indonesiana},
volume = {58},
number = {3},
pages = {470-478},
pmid = {42845066},
issn = {2338-2732},
mesh = {Humans ; *Respiratory Distress Syndrome/drug therapy/therapy/physiopathology/diagnosis ; *Glucocorticoids/therapeutic use ; COVID-19/complications ; *Adrenal Cortex Hormones/therapeutic use ; SARS-CoV-2 ; Respiration, Artificial ; Dexamethasone/therapeutic use ; },
abstract = {Acute respiratory distress syndrome (ARDS) is a life-threatening form of acute inflammatory lung injury in which loss of alveolar-capillary membrane integrity produces protein-rich pulmonary edema, refractory hypoxemia, and reduced lung compliance, typically within 6-72 hours of a precipitating insult. The 2012 Berlin criteria defined ARDS by acute onset within one week of a known insult, bilateral opacities not fully explained by effusion, atelectasis, or cardiac failure, and a PaO2/FiO2 ratio of 300 mmHg or less with a minimum PEEP of 5 cmH2O. The 2023 global definition expands this framework by accepting SpO2/FiO2 of 315 or less when SpO2 is 97% or below, including patients supported with high-flow nasal oxygen at 30 L/min or more, permitting thoracic ultrasonography as an alternative imaging modality, and waiving the PEEP requirement in resource-limited settings. These revisions are particularly relevant to practice in low- and middle-income countries, where arterial blood gas analysis and mechanical ventilation may be unavailable. Management remains anchored in lung-protective ventilation, conservative fluid strategy, and prone positioning. Glucocorticoids remain the most contested pharmacological intervention: evidence from dexamethasone trials in ARDS and in COVID-19 suggests benefit in selected populations, yet questions persist regarding optimal agent, dose, timing relative to symptom onset, duration, the influence of ARDS subphenotypes, and the risk of secondary infection and neuromuscular weakness. This narrative review summarizes the pathophysiology, evolving diagnostic criteria, imaging findings, and current evidence on corticosteroid therapy, and considers how hyperinflammatory and hypoinflammatory subphenotypes may guide future trial design and individualized treatment.},
}
@article {pmid42846789,
year = {2026},
author = {Ma, X and Wu, D and Lv, S},
title = {Carrageenan-induced immunothrombotic models in rodents (Review).},
journal = {Experimental and therapeutic medicine},
volume = {32},
number = {5},
pages = {305},
pmid = {42846789},
issn = {1792-1015},
abstract = {Carrageenan (CGN)-induced immunothrombotic models are used in rodent thrombosis research. They enable both mechanistic dissection of inflammation-coagulation crosstalk and high-throughput screening of antithrombotic agents. The present narrative review summarizes current knowledge on modeling approaches, thrombotic mechanisms, quality determinants and translational relevance of the CGN model. CGN is a sulfated linear galactan that can be administered by intraperitoneal injection, tail vein injection or subcutaneous injection. Amongst these, intraperitoneal injection of κ-CGN (20-100 mg/kg in mice) is the most widely used due to its simplicity and superior reproducibility. Tail vein injection of CGN (1 mg/kg in rats) combined with ligation results in rapid model formation and is suitable for studying the intrinsic pathway of coagulation, whereas subcutaneous injection is mainly used for exploring mechanisms of local inflammatory thrombosis. By contrast, CGN combined with lipopolysaccharides can be used to establish a disseminated intravascular coagulation model, replicating consumptive coagulopathy and multi-organ microthrombosis. The thrombotic mechanisms of CGN involve Toll-like receptor 4/NF-κB pathway-mediated inflammatory cytokine release, upregulation of tissue factor and endothelial injury caused by the release of neutrophil extracellular traps following intraperitoneal CGN administration, direct activation of coagulation factor XII (which initiates the intrinsic coagulation pathway following tail vein administration) and direct activation of the platelet C-type lectin-like receptor 2 pathway. Model quality is influenced by multiple factors, including the subtype and molecular weight of CGN, animal strain (Kunming mice have the highest sensitivity), sex, age, administration parameters and observation time window (24-72 h). This model simulates the pathological process of sterile inflammation-driven thrombosis and shares similar mechanisms with clinical conditions, such as antiphospholipid syndrome and severe Coronavirus disease-19 coagulopathy. However, limitations exist in terms of anatomical site, hemodynamics, chronic etiology and species differences, which restrict its direct extrapolation to clinical settings. The adoption of a multi-model validation strategy and screening of target patient populations based on inflammatory markers are recommended to improve clinical translation.},
}
@article {pmid42847395,
year = {2026},
author = {Chen, YC and Yang, HT and Wu, CF and Kuo, CC},
title = {Exercise effectiveness on fatigue in Long-COVID: systematic review and meta-analysis.},
journal = {Annals of behavioral medicine : a publication of the Society of Behavioral Medicine},
volume = {60},
number = {1},
pages = {},
doi = {10.1093/abm/kaag048},
pmid = {42847395},
issn = {1532-4796},
mesh = {Humans ; *Exercise Therapy/methods ; *Fatigue/therapy/etiology ; *Post-Acute COVID-19 Syndrome/complications/therapy ; Quality of Life ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Patients with Long COVID commonly experience fatigue-related distress, often leading to low energy, reduced activity endurance, and exertional dyspnea, all of which negatively impact quality of life. Although studies have increasingly explored the effects of exercise on Long COVID-related fatigue, a comprehensive synthesis of the evidence is lacking.<br><br>PURPOSE: To examine the effectiveness of exercise in improving fatigue among patients with Long COVID through a systematic review and meta-analysis.<br><br>METHODS: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Joanna Briggs Institute (JBI) methodology for systematic reviews of effectiveness. Airiti Library, Cumulative Index to Nursing and Allied Health, Cochrane Library, Embase, PubMed, ProQuest, and Index of the Taiwan Periodical Literature System databases were searched before July 2025. Two reviewers used the JBI randomized controlled trial checklist to assess the methodological quality of included studies. Extracted data were entered and analyzed using RevMan 5.4 software. Inverse variance and Mantel-Haenzel random effect model was used to estimate effect sizes. Subgroup and sensitivity analysis were performed.<br><br>RESULTS: Fourteen randomized controlled trials were reviewed. Meta-analysis reveals that the exercise training group significantly improved fatigue severity (standardized mean difference [SMD]&#x2009;=&#x2009;-0.59, P&#x2009;=&#x2009;.002) and dyspnea severity (SMD&#x2009;=&#x2009;-0.89, P&#x2009;=&#x2009;.005) compared to the usual care group. Improvements were also observed in muscle strength and endurance.<br><br>CONCLUSIONS: Exercise training may help reduce physiological and psychological fatigue in patients with Long COVID. The available evidence suggests that individualized single-modality and multimodal exercise programs may be beneficial for patients experiencing fatigue symptoms. The included interventions generally consisted of 30-60&#x2009;min sessions, performed 3-6 times per week over at least 8-12&#x2009;weeks. However, given the moderate-to-very-low certainty of the evidence, exercise programs should be individualized based on patient response and tolerance. Particular attention should be paid to preventing postexertional malaise, with the goal of reducing fatigue and supporting the recovery of daily functioning in patients with Long COVID.<br><br>TRIAL REGISTRATION: PROSPERO: CRD420251113419 https://www.crd.york.ac.uk/PROSPERO/view/CRD420251113419.},
}
@article {pmid42847604,
year = {2026},
author = {Lee, EA and Park, JH and Kwack, SJ and Lee, SK and Lee, BM and Kim, HS},
title = {Toxicological insights and health risks of Didecyldimethylammonium Chloride (DDAC): an integrative review.},
journal = {Journal of toxicology and environmental health. Part B, Critical reviews},
volume = {},
number = {},
pages = {1-34},
doi = {10.1080/10937404.2026.2740461},
pmid = {42847604},
issn = {1521-6950},
abstract = {Didecyldimethylammonium chloride (DDAC) is a broad-spectrum quaternary ammonium compound (QAC) extensively utilized as a disinfectant and biocide. Widespread use of DDAC, significantly amplified during COVID-19 pandemic, increased human and environmental exposures, indicating need for updated, quantitative risk assessments. To comprehensively evaluate toxicological profile, exposure pathways, and risk characterization of DDAC, this integrative review synthesized regulatory databases (EPA, ECHA), peer-reviewed literature, and large-scale European Food Safety Authority (EFSA) monitoring data (>200,000 samples). Data demonstrated that DDAC exhibited low systemic absorption (<10%) and rapid fecal excretion, with no apparent evidence of carcinogenic, genotoxic or reproductive toxicity. Reported no observed adverse effect level (NOAEL) varied depending upon species, study design, exposure route, and toxicological endpoint, with regulatory studies reporting values ranging from approximately 10 to 93.1 mg/kg/day. Quantitative margin of exposure (MOE) analyses confirm both (1)dietary intake, despite sporadic high residues in specific animal products, and (2) routine occupational dermal exposures maintained large safety margins. Conversely, aerosol-generating applications, such as fogging and humidifier use, present narrower margins, emphasizing critical role of ventilation parameters. Overall, DDAC exhibited low systemic toxicity under typical exposure conditions due to limited absorption and rapid elimination. However, accumulating mechanistic evidence indicates that DDAC might initiate portal-of-entry toxicity, including dermal, ocular, and respiratory irritation related to membrane disruption, mitochondrial dysfunction, oxidative stress, and inflammatory responses. Integrating regulatory evaluations with recent mechanistic findings provides a more comprehensive understanding of DDAC-induced toxicity, identifies important uncertainties regarding chronic aerosol exposure and environmental persistence, supporting continued refinement of human health and environmental risk assessments.},
}
@article {pmid42841057,
year = {2026},
author = {Patrick, T and John, OB and Dominique, BB and Raoul, RZ},
title = {Adverse Events Following Immunization: Mechanisms, Clinical Manifestations, Surveillance, and Public Health Management-A Narrative Review.},
journal = {Infection and drug resistance},
volume = {19},
number = {},
pages = {642114},
pmid = {42841057},
issn = {1178-6973},
abstract = {Immunization is a cornerstone of global public health, preventing substantial morbidity and mortality worldwide. However, the long-term success of immunization programs depends not only on vaccine effectiveness but also on robust systems for monitoring and managing vaccine safety. Adverse Events Following Immunization (AEFIs), defined by the World Health Organization (WHO) as any untoward medical occurrence that follows immunization and does not necessarily have a causal relationship with vaccine use, remain an important challenge for vaccine safety surveillance and public confidence. This narrative review synthesizes evidence on the classification, biological and immunological mechanisms, clinical manifestations, surveillance, causality assessment, and public health management of AEFIs. Literature was identified through searches of PubMed/MEDLINE and Scopus, complemented by relevant grey literature from authoritative organizations, including WHO and the United States Centers for Disease Control and Prevention (CDC). The review considers evidence from both COVID-19 and non-COVID-19 vaccination programs, with emphasis on vaccine safety surveillance, pharmacovigilance, clinical assessment, and public health response. AEFIs were examined according to the WHO classification framework, comprising vaccine product-related, vaccine quality defect-related, immunization error-related, immunization anxiety-related, and coincidental events. Biological and immunological mechanisms range from expected innate inflammatory responses to rare immune-mediated and hypersensitivity reactions. Although most AEFIs are mild and self-limiting, rare serious events require timely recognition, investigation, and appropriate clinical management. Global vaccine safety monitoring capacity remains uneven, with substantial differences in reporting, surveillance infrastructure, diagnostic capacity, and health-system resources across settings. Strengthening pharmacovigilance, active and passive surveillance, healthcare worker training, causality assessment, and transparent risk communication is essential to ensure vaccine safety, sustain public confidence, and support the continued success of immunization programs worldwide.},
}
@article {pmid42841133,
year = {2026},
author = {da Silva, LG and Oliveira, JCM and Fini, BCD and Porto, AA and Costa, DS and de Miranda, DM and Romano-Silva, MA and de Paula, JJ},
title = {Prior COVID-19 vaccination and cognitive outcomes after SARS-CoV-2 infection: a mini-review.},
journal = {Dementia &amp; neuropsychologia},
volume = {20},
number = {},
pages = {e20260494},
pmid = {42841133},
issn = {1980-5764},
abstract = {COVID-19 infection has been frequently associated with cognitive deficits that persist for months after the acute phase, but the impact of vaccination on preventing these deficits remains uncertain. Evidence suggests that immunization reduces the incidence and severity of post-COVID symptoms, yet few studies have evaluated its influence on cognition using objective measures. To address this gap, a mini-review was conducted using a systematic search strategy, following PRISMA recommendations where applicable, with a protocol registered in PROSPERO (CRD42025636772). Searches were carried out in the PubMed/MEDLINE and Scopus databases, and eligible studies were those that assessed cognition using objective measures and compared vaccinated and unvaccinated individuals at the time of infection. A total of 1,796 records were identified, of which only five met the inclusion criteria. The included studies varied considerably in cognitive assessment tools, study designs, and sample sizes. Four of the five studies found no association between prior vaccination and cognitive deficits, whereas the only study that identified a subtle difference among individuals who had received at least two doses of the vaccine had a substantially larger sample than all the others combined. Methodological inconsistencies in cognitive assessment, variability in the definitions of vaccination status, and the lack of stratification by specific cognitive domains limit the interpretation of the current findings. Although vaccination may play a role in protecting against cognitive deficits following COVID-19 infection, the evidence remains limited and inconclusive. Further studies with standardized definitions of vaccination status and comprehensive objective assessments are needed to clarify this relationship.},
}
@article {pmid42831545,
year = {2026},
author = {Klika, JB and Lee, JY and Chang, OD and Kirsch, J and Lee, SJ},
title = {Child Maltreatment During COVID-19: Triangulating Data Across Reporting Sources.},
journal = {Child maltreatment},
volume = {31},
number = {4},
pages = {793-815},
doi = {10.1177/10775595251370230},
pmid = {42831545},
issn = {1552-6119},
mesh = {Child ; Humans ; *Child Abuse/statistics &amp; numerical data ; *Child Welfare/statistics &amp; numerical data ; *COVID-19/epidemiology ; Pandemics ; United States/epidemiology ; },
abstract = {The COVID-19 pandemic created enormous challenges for families across the United States. Economic concerns related to job loss and unemployment, social isolation and school closures were just some of the stressors facing families and children. Because many of these factors are known correlates of child abuse and neglect, some were concerned that child abuse and neglect would significantly increase during the COVID-19 pandemic. A rigorous and comprehensive systematic review of scientific literature was conducted to triangulate hospital, child welfare, and self-report data on child maltreatment rates during COVID-19. Using PRISMA criteria for conducting systematic reviews, the current study reviewed scientific literature on changes in child maltreatment rates during COVID-19. Of the 4,193 unique studies identified, 73 studies met eligibility criteria. Data from child welfare sources suggested declining child maltreatment immediately after COVID-19 onset, while self-report studies document an increasing trend. Hospital data findings were largely mixed with more studies reporting decreased child maltreatment during COVID-19. Interpretation of child maltreatment surveillance data from COVID-19 must account for evidence from multiple data sources which could affect resulting conclusions.},
}
@article {pmid42832903,
year = {2026},
author = {Valentine Gunasari, LF and Chuang, TW and Wiratama, BS and Rahmanti, AR and Nurmansyah, D and Tunggul Satoto, TB},
title = {Machine learning for risk prediction of infectious diseases: a scoping review of application, predictive performance, and reporting gaps.},
journal = {International journal of medical informatics},
volume = {223},
number = {},
pages = {106720},
doi = {10.1016/j.ijmedinf.2026.106720},
pmid = {42832903},
issn = {1872-8243},
abstract = {BACKGROUND: Infectious diseases remain a major cause of global morbidity and mortality, with machine learning (ML) emerging as a promising approach for risk prediction. However, the heterogeneity of ML applications across diseases, algorithms, and validation practices impedes evidence synthesis and identification of best practices.<br><br>OBJECTIVE: This scoping review aims to systematically map the application of ML algorithms for infectious disease risk prediction, describe disease targets, study populations, data sources, performance metrics, and identify methodological strengths, limitations, and research gaps.<br><br>METHOD: We conducted a scoping review following JBI methodology and PRISMAScR guidelines. Four databases (PubMed, Scopus, Science Direct, IEEE Xplore) were searched from inception to 31 May 2026. Two reviewers independently screened records, extracted data, and assessed quality using PROBAST&#xa0;+&#xa0;AI.<br><br>RESULTS: From 168 included studies, ML prediction spanned individual (13.7%), population (56.0%), and spatial (30.4%) levels. Respiratory infections (44.6%) and COVID-19 (23.8%) dominated, while neglected tropical diseases comprised 19.1%. XGBoost, Random Forest and LSTM variants showed high performance, with spatial models yielding the highest median AUC (&#x223c;0.90), followed by population (0.84) and individual (0.82) models. Critical gaps included rare calibration reporting (3.0%), limited external validation (10.7%), and severe geographic skew-43.5% from China/USA, only 8 from low-income countries.<br><br>CONCLUSION: ML demonstrates substantial potential for infectious disease risk prediction. However, methodological improvements-especially calibration assessment, external validation, and standardized reporting-are urgently needed. Future research should prioritize multi-level modeling approaches and contextually adapted models for high-burden regions.},
}
@article {pmid42833395,
year = {2026},
author = {Kashyap, R and Kar, RK},
title = {Plasmonic biosensor platforms for next-generation personalized medical diagnostics.},
journal = {Drug discovery today},
volume = {},
number = {},
pages = {104825},
doi = {10.1016/j.drudis.2026.104825},
pmid = {42833395},
issn = {1878-5832},
abstract = {The increasing healthcare burden demands precise diagnostics for early detection and longitudinal disease monitoring. Although conventional assays such as ELISA and PCR offer precision, they require intensive sample preparation, bulkier instrumentation and prolonged assay times. This review examines plasmonic biosensors as a transformative alternative for personalized and point-of-care diagnostics. We comprehensively examine recent advancements, such as the integration of nanomaterials, microfabrication strategies, advanced surface chemistry and prototype miniaturization, and consider examples for the detection of cancer biomarkers (microRNA-21 and alpha-fetoprotein), viral proteins (respiratory syncytial virus and SARS-CoV-2), and inflammatory biomarkers (C-reactive protein). Furthermore, we address the critical aspects that hinder the clinical translation of plasmonic biosensors. The review concludes that, despite significant laboratory-scale progress, standardized manufacturing, scalable nanofabrication and the inclusion of artificial intelligence/machine learning frameworks remain essential for the widespread utilization of plasmonic technology in personalized medicine and diagnostics.},
}
@article {pmid42835826,
year = {2026},
author = {Asadipooya, K and Sriramula, S},
title = {Endocrine complications of COVID-19: diabetes, musculoskeletal, thyroid, pituitary, adrenal, and gonadal disorders.},
journal = {Journal of the Endocrine Society},
volume = {10},
number = {10},
pages = {bvag219},
pmid = {42835826},
issn = {2472-1972},
abstract = {COVID-19 is generally associated with both short- and long-term complications. It can affect multiple organ systems and lead to severe or prolonged organ dysfunction, including the endocrine system. It also places a substantial burden on individuals and the health-care system. Therefore, providing up-to-date information for health-care providers is valuable. In this review, we aim to consolidate the current literature regarding the endocrine complications of acute SARS-CoV-2 infection, with a particular focus on diabetes, calcium homeostasis, pituitary, thyroid, adrenal, and gonadal disorders. Although current therapeutic approaches for COVID-19 are mainly limited to antivirals, symptomatic therapies, and supportive care, advances in understanding the mechanisms of SARS-CoV-2 entry and immune responses may support a more effective and personalized approach to clinical care.},
}
@article {pmid42836613,
year = {2026},
author = {Wang, M and Wang, W and Chen, Z and Lu, L and Liu, Z and Jiang, S},
title = {Toward broad-spectrum coronavirus vaccines: navigating viral evolution from past epidemics to future resilience.},
journal = {Microbiology and molecular biology reviews : MMBR},
volume = {},
number = {},
pages = {e0010025},
doi = {10.1128/mmbr.00100-25},
pmid = {42836613},
issn = {1098-5557},
abstract = {SUMMARYNewly emerged highly pathogenic coronavirus species, including SARS-CoV, MERS-CoV, and SARS-CoV-2, have successively triggered outbreaks worldwide over the past 25 years. Recently, several MERS-related coronaviruses have been identified from bats or pangolins. These viruses, along with previously found SARS-related coronaviruses, pose significant potential to infect humans and trigger pandemics. Therefore, it is necessary to develop broad-spectrum vaccines that can combat both currently circulating coronaviruses and those that may emerge in the future. Currently, approved COVID-19 vaccines provide strong protection against pre-Omicron variants, while their effectiveness against post-Omicron variants is reduced, and cross-protection against other potential coronaviruses remains limited. In the present review, we discuss vaccine research on SARS-CoV and MERS-CoV prior to the COVID-19 outbreak, as well as vaccine development following the outbreak. We also focus on strategies for developing broad-spectrum coronavirus vaccines and provide a perspective on future directions for coronavirus vaccine development.},
}
@article {pmid41847737,
year = {2026},
author = {Vanderauwera, J and Vanden Bempt, F and D'haenens, W and Leysen, H and Leclercq, AL and Van Eerdenbrugh, S},
title = {The effectiveness of telepractice for speech-language pathology intervention with children younger than 12 years: A meta-analysis.},
journal = {Journal of telemedicine and telecare},
volume = {32},
number = {9},
pages = {743-756},
doi = {10.1177/1357633X261426068},
pmid = {41847737},
issn = {1758-1109},
mesh = {Humans ; *Speech-Language Pathology/methods ; Child ; *Telemedicine ; Child, Preschool ; COVID-19/epidemiology ; SARS-CoV-2 ; },
abstract = {BackgroundSince Coronavirus disease 2019, telepractice delivery has become increasingly integrated in the standard practice of speech-language pathologists and audiologists. It is therefore important to synthesize existing knowledge on this intervention modality. However, limited evidence exists regarding its use in children. This meta-analysis evaluated evidence on the effectiveness of telepractice compared to in-person intervention for children aged ≤ 12 years.MethodA systematic search was conducted for systematic reviews, meta-analyses and randomized controlled trials comparing telepractice and in-person intervention for children ≤12 years. Eight databases were searched: PsychINFO, Linguistics and Language Behaviour Abstracts, Education Resources Information Centre, Web of Sciences, PubMed, Embase, the Joanna Briggs Institute database, and Cumulative Index to Nursing and Allied Health Literature.ResultsSeven studies on speech-language pathology intervention met the inclusion criteria; no audiology studies could be included. Effect sizes were calculated for 31 outcomes reported across both conditions (telepractice and in-person intervention). Eight effect sizes were inverted, allowing all positive values to indicate favourable intervention outcomes. Overall, interventions resulted in moderate to high effects, with telepractice intervention resulting in equal or larger effect sizes compared to in-person intervention.ConclusionTelepractice intervention demonstrated outcomes comparable or better than in-person intervention across speech-language pathology subdomains. This applies to both child-related and caregiver-related outcomes, as well as for child-directed (typically for children ≥ 4 years) and caregiver-mediated approaches, where caregivers are trained to implement the strategies at home with their child. These findings suggest that telepractice intervention is an effective alternative to in-person intervention.},
}
@article {pmid42432685,
year = {2026},
author = {Zhou, Z and Luo, B and Zhang, X and Li, Q and Huang, Y and Yang, Y and Qiu, H and Xue, M and Xie, J},
title = {Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis.},
journal = {Annals of clinical microbiology and antimicrobials},
volume = {25},
number = {1},
pages = {},
pmid = {42432685},
issn = {1476-0711},
support = {2023ZD0506500//Noncommunicable Chronic Diseases-National Science and Technology Major Project/ ; 2024ZD0522700//Noncommunicable Chronic Diseases-National Science and Technology Major Project/ ; 82272210//National Natural Science Foundation of China/ ; },
mesh = {Humans ; *Invasive Pulmonary Aspergillosis/mortality/epidemiology ; *Critical Illness/mortality ; Risk Factors ; *COVID-19/complications/epidemiology/mortality ; Incidence ; Intensive Care Units ; Respiration, Artificial/adverse effects ; SARS-CoV-2 ; Male ; Female ; },
abstract = {BACKGROUND: Invasive pulmonary aspergillosis (IPA) represents a growing threat to critically ill patients, with mortality rates exceeding 50%. The burden of IPA has been exacerbated during the COVID-19 era due to prolonged ICU stays and widespread use of immunosuppressive therapies. This systematic review and meta-analysis aimed to synthesize global evidence on the incidence, mortality, and risk factors of IPA in ICU patients.<br><br>METHODS: Observational studies reporting IPA incidence, mortality, or risk factors in ICU settings from their inception between November 1, 2019 to October 11, 2024 for eligible studies were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analyses were performed using R software to calculate pooled estimates with 95% confidence intervals (CI). Multiple subgroup analysis was conducted.<br><br>RESULTS: Fifty-six studies involving 15,385 ICU patients (2,381 IPA cases) were included. The pooled incidence of IPA was 11.9% (95% CI: 9.7-14.6%). Subgroup analyses revealed higher incidence in mechanically ventilated patients (15.0%, 95% CI: 11.7-19.0%). Factors associated with an increased risk of IPA included male sex (OR&#x2009;=&#x2009;1.29), smoking history (OR&#x2009;=&#x2009;1.52), chronic lung diseases (OR&#x2009;=&#x2009;1.30), chronic kidney disease (OR&#x2009;=&#x2009;1.70), chronic liver disease (OR&#x2009;=&#x2009;1.79), heart disease (OR&#x2009;=&#x2009;1.20), malignant tumor (OR&#x2009;=&#x2009;1.75), hematological malignancy (OR&#x2009;=&#x2009;2.65), glucocorticoids use before ICU (OR&#x2009;=&#x2009;2.13), immunosuppression (OR&#x2009;=&#x2009;2.26), EORTC host factors (OR&#x2009;=&#x2009;2.13), vasopressor use (OR&#x2009;=&#x2009;3.28), mechanical ventilation (OR&#x2009;=&#x2009;3.69), and renal replacement therapy (OR&#x2009;=&#x2009;2.31). The overall mortality rate was 59.6% (95% CI: 55.0-64.0%), escalating to 61.9% in mechanically ventilated patients. Mortality-associated factors included age&#x2009;&#x2265;&#x2009;65 years (OR&#x2009;=&#x2009;2.85), ICU-administered glucocorticoids (OR&#x2009;=&#x2009;1.95) and mechanical ventilation (OR&#x2009;=&#x2009;1.93).<br><br>CONCLUSIONS: During the COVID-19 era, IPA remains a life-threatening complication in critically ill patients, particularly those with COVID-19, and is associated with immunosuppression, organ dysfunction, and invasive therapies. Our findings, predominantly reflecting CAPA epidemiology, generate the hypothesis that early screening in high-risk populations and tailored antifungal strategies warrant prospective evaluation to determine whether they improve outcomes.<br><br>TRIAL REGISTRATION: Ethical approval and patient consent were not required for this meta-analysis, as it was based on previously published studies. The protocol for this meta-analysis was registered on PROSPERO: International prospective register of systematic reviews (CRD42025631579).},
}
@article {pmid42535313,
year = {2026},
author = {Farkouh, A and Seibly, E and Buell, MI and Jhang, D and Amasyali, AS and Okhunov, Z and Baldwin, DD},
title = {The Effect of Vitamin C Supplements on Urinary Stone Risk: A Systematic Review and Meta-Analysis.},
journal = {Journal of endourology},
volume = {40},
number = {11},
pages = {1242-1253},
doi = {10.1177/08927790261471733},
pmid = {42535313},
issn = {1557-900X},
mesh = {*Ascorbic Acid/adverse effects/administration &amp; dosage ; Humans ; *Dietary Supplements/adverse effects ; *Urinary Calculi/urine/epidemiology ; Calcium/urine ; Oxalates/urine ; COVID-19 ; },
abstract = {INTRODUCTION AND OBJECTIVE: With the increased intake of vitamin C supplements during the COVID pandemic, physicians have reported an increase in stone incidence and complexity. The purpose of this systematic review and meta-analysis was to study the effect of vitamin C supplements on urine parameters associated with stone formation.<br><br>METHODS: A comprehensive review was performed to retrieve relevant articles published from 1965 until February 2023. Studies were included if they were interventional studies investigating the effect of vitamin C supplements on 24-hour urinary parameters (oxalate, citrate, and calcium) in both stone formers (SFs) and nonstone formers (NSFs), compared with either baseline values or a placebo group. Meta-analyses were performed to calculate the mean difference (MD) measuring the effect of vitamin C supplements on these parameters.<br><br>RESULTS: The initial database search yielded 808 titles and after rigorous screening, nine studies were included. Pooled analysis revealed a significant increase in urinary oxalate after vitamin C supplementation compared with baseline (MD = 9.72 mg/24 h; p < 0.001). When compared with placebo, vitamin C also significantly increases urinary oxalate excretion (MD = 6.45 mg/24 h; p < 0.001). Subgroup analyses of both comparisons showed that vitamin C increases urinary oxalate in both SFs and NSFs (p < 0.05 for all). Analyses of studies reporting on 24-hour urinary citrate or calcium revealed no significant effect of vitamin C on either parameter.<br><br>CONCLUSIONS: Vitamin C supplements significantly increase urinary oxalate excretion in both SFs and NSFs. This may contribute to stone formation and may worsen stone presentation among those who consume these supplements.},
}
@article {pmid42830086,
year = {2026},
author = {Veretova, N and Samigullina, A and Baialieva, A and Abdyldaev, R and Muratbekova, B},
title = {PSYCHONEUROLOGICAL THERAPY FOR POST-COVID SYNDROME: A COMPREHENSIVE REVIEW OF METHODS AND CLINICAL EFFECTIVENESS.},
journal = {Georgian medical news},
volume = {},
number = {376-377},
pages = {445-451},
pmid = {42830086},
issn = {1512-0112},
mesh = {Humans ; *COVID-19/complications/psychology ; Post-Acute COVID-19 Syndrome ; *Depression/therapy/etiology ; *Anxiety/therapy/etiology ; SARS-CoV-2 ; *Cognitive Dysfunction/therapy/etiology ; *Psychotherapy/methods ; Fatigue/therapy/etiology ; Sleep Wake Disorders/therapy/etiology ; Treatment Outcome ; },
abstract = {BACKGROUND: Post-COVID syndrome has emerged as a major global health issue characterized by long-lasting psychoneurological symptoms, including cognitive impairment, anxiety, depression, sleep disturbances, and fatigue. These symptoms can persist regardless of the severity of the initial SARS-CoV-2 infection and often result in long-term functional limitations. The purpose of this review was to summarize current evidence on psychoneurological therapeutic approaches used to manage post-COVID syndrome and evaluate their clinical effectiveness.<br><br>METHODS: A structured literature review was conducted using PubMed, Scopus, MEDLINE, and Google Scholar. Eligible studies included randomized controlled trials, observational studies, and clinical reports published up to 2024 that examined pharmacological, psychotherapeutic, physical, complementary, or neuromodulation-based treatments for adults with persistent psychoneurological symptoms after COVID-19. The review followed standard ethical practices for narrative reviews; no new human or animal data were collected, and therefore ethical approval or CTRI registration was not required. Findings were synthesized narratively by therapy category.<br><br>RESULTS: The review identified consistent evidence supporting the efficacy of multiple therapeutic modalities. Pharmacological agents including SSRIs, SNRIs, anxiolytics, and nootropics reduced anxiety, depression, and cognitive dysfunction. Psychotherapeutic methods such as cognitive behavioral therapy, psychodynamic therapy, and mindfulness-based interventions improved emotional regulation and coping. Physical rehabilitation, aerobic exercise, and breathing practices enhanced endurance and reduced fatigue. Complementary approaches (e.g., acupuncture, massage) provided additional symptom relief. Neuromodulation techniques, including transcranial magnetic stimulation and electroconvulsive therapy, demonstrated benefits in treatment-resistant cases.<br><br>CONCLUSION: Psychoneurological therapy for post-COVID syndrome requires a multimodal approach that integrates pharmacological, psychological, physical, and neuromodulatory interventions. Current evidence suggests that individualized, combined strategies are most effective for improving cognitive, emotional, and functional outcomes. Further research is needed to optimize treatment protocols and evaluate long-term effectiveness.},
}
@article {pmid42830637,
year = {2026},
author = {Plavina, S and Malakovska, D and Kalnina, J and Trapina, I and Leonova, E and Habib, M and Schifmann, S and Paramonovs, J and Sjakste, N and Vassetzky, Y and Drouet, E and Paramonova, N},
title = {Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».},
journal = {Reviews in medical virology},
volume = {36},
number = {6},
pages = {e70212},
pmid = {42830637},
issn = {1099-1654},
support = {SARSTUBVAR//Agence Nationale de Recherches sur le Sida et les H&#xe9;patites Virales/ ; 0088-2025-0010//IDB RAS Government basic research program/ ; },
mesh = {Humans ; *Multiple Sclerosis/virology/immunology/etiology ; *Virus Diseases/complications/virology/immunology ; Herpesvirus 4, Human/pathogenicity/immunology ; Herpesviridae/pathogenicity/immunology ; Endogenous Retroviruses/pathogenicity/immunology ; Animals ; SARS-CoV-2/pathogenicity/immunology ; Genetic Predisposition to Disease ; },
abstract = {Multiple sclerosis (MS) is a complex, multifactorial neurodegenerative disease with an aetiology that is still partially elusive. Several risk factors are associated with MS development including genetic predisposition and various environmental stressors; however, recently, viral infections have gained significant attention as a crucial environmental trigger. Despite the well-established link between Epstein-Barr virus (EBV) and MS susceptibility, a single-pathogen model fails to clearly characterise the molecular cascades driving the disease, suggesting that the transition from infection to autoimmune response involves more than one viral agent. In this review we examine the speculation that the interactions among different neurotropic viruses could serve a collective causative role in MS, which is under-researched in the literature at present. We summarise contradictory evidence on the role of different viral agents, including the Herpesviridae family (Human Cytomegalovirus, EBV, Herpes Simplex Viruses HSV-1 and HSV-2, and Varicella Zoster Virus), Paramyxoviridae family (Measles Virus and Rubella Virus), Influenza virus, SARS-CoV-2, and Human Endogenous Retroviruses (HERVs). Through interplay within shared molecular pathways, immune modulation, and activation of latent infections, these viruses may collectively influence the inflammatory and demyelinating processes that characterise MS. This review evaluates the etiological role of viral interplay in MS through the cumulative and interactive effects of these pathogens. The available epidemiological, immunological, and experimental data converge on the concept that viral co-exposures act synergistically to shape MS susceptibility in genetically predisposed individuals. Characterising these viral interactions presents a new research direction for the identification of novel biomarkers and the development of preventative strategies through the targeted control of viral networks.},
}
@article {pmid42831296,
year = {2026},
author = {Satkunam, S and Dimitriou, I and Shaikh, M},
title = {Eye Movement Desensitisation and Reprocessing (EMDR) for ICU-related psychological distress among adult intensive care survivors: a scoping review.},
journal = {European journal of psychotraumatology},
volume = {17},
number = {1},
pages = {2732465},
pmid = {42831296},
issn = {2000-8066},
mesh = {Humans ; *Eye Movement Desensitization Reprocessing/methods ; *Intensive Care Units ; *Stress Disorders, Post-Traumatic/therapy ; *Survivors/psychology ; *Critical Care/psychology ; *COVID-19/psychology ; *Psychological Distress ; Adult ; Depression/therapy ; Anxiety/therapy ; },
abstract = {Background: Psychological morbidity is common following admission to adult intensive care units (ICUs), with many patients experiencing post-traumatic stress disorder (PTSD), anxiety, and depression as part of post-intensive care syndrome. Eye Movement Desensitisation and Reprocessing (EMDR) is an established trauma-focused psychological therapy; however, its evidence base within critical care populations remains emerging.Objectives: This scoping review aimed to map the extent, characteristics, and findings of the available literature on the use of EMDR for ICU-related psychological distress.Methods: A scoping review was conducted in accordance with Joanna Briggs Institute methodology and reported following the PRISMA-ScR guidelines. The review aimed to systematically identify and synthesise evidence relating to the application and reported outcomes of EMDR in ICU survivors.Results: Seven publications representing six independent study populations were included. Participants included adult ICU patients experiencing PTSD symptoms, delirium-related psychological disturbances, and COVID-19-related distress. EMDR was delivered using either standard protocols or the Recent Traumatic Episode Protocol (R-TEP). Across the evidence base, EMDR was associated with reductions in trauma-related distress, although evidence for improvements in anxiety and depression was less consistent. Where qualitative data were available, participants additionally reported improved integration and processing of ICU experiences. Overall, methodological heterogeneity, overlapping samples, small sample sizes, and limited controlled evidence restrict the strength of conclusions that can be drawn.Conclusions: This review highlights growing but preliminary evidence supporting the feasibility and potential utility of EMDR, including R-TEP, for ICU-related psychological distress. While findings are promising, the current evidence base remains insufficient to determine effectiveness. Future research should prioritise adequately powered controlled studies, standardised outcome measures, longer-term follow-up, and more diverse ICU populations to strengthen the evidence base and inform clinical implementation.},
}
@article {pmid39871573,
year = {2026},
author = {Thai, KM and Duong, CQ and Mai, TT and Le, MT and Tran, VT and Nguyen, PV and Tuong, LT},
title = {Achievements and Approaches in the Search for Small-Molecule Dengue NS2B/NS3 Inhibitors.},
journal = {Current medicinal chemistry},
volume = {33},
number = {14},
pages = {2721-2757},
pmid = {39871573},
issn = {1875-533X},
mesh = {*Viral Nonstructural Proteins/antagonists &amp; inhibitors/metabolism ; *Dengue Virus/drug effects/enzymology ; Humans ; Serine Endopeptidases/metabolism/chemistry ; Viral Proteases ; *Antiviral Agents/chemistry/pharmacology ; *Small Molecule Libraries/chemistry/pharmacology ; Dengue/drug therapy ; Nucleoside-Triphosphatase ; *Protease Inhibitors/chemistry/pharmacology ; RNA Helicases/antagonists &amp; inhibitors/metabolism ; DEAD-box RNA Helicases ; Animals ; Drug Discovery ; },
abstract = {With the escalation of viral infections in recent decades, including the COVID- 19 pandemic, viral infectious diseases have increasingly become a global concern, attracting significant attention. Among many viral epidemics, the dengue virus, an RNA virus from the Flaviviridae family, has been reported by the WHO as one of the most prevalent mosquito-borne diseases, infecting roughly 400 million people yearly and spreading across all continents worldwide. In the last two decades, researchers from academia and industry have diligently studied many aspects of the virus, including its structure, life cycle, potential therapeutic agents, and vaccines. Dengvaxia[®] and Qdenga[®], approved vaccines for DENV-4, have been a milestone in dengue prevention and treatment. However, these vaccines have some noticeable drawbacks, including Dengvaxia[®] being a monovalent vaccine against DENV-4 with a risk of severe dengue infection following the first use, Qdenga[®] being mainly effective for all 4 serotypes only in the cases of previously infected patients while being effective against only DENV-1 and DENV-2 in dengue-naïve patients. Additionally, no drug against dengue has been approved. Thus, numerous screening campaigns have been conducted on both natural and synthesized substances to search for anti-dengue agents, especially those targeting the virus's key protease (NS2B/NS3), to mitigate the dengue fever epidemic. As hit screening is only the first step in the drug discovery and development cycle, subsequent in-depth analyses (using a wide range of approaches from computational simulations to protein-ligand co-crystallization) have been conducted to provide more insights into the characteristics of optimal DENV NS2B/NS3 protease inhibitors. This review discusses recent discoveries in the search for novel inhibitors and highlights the importance of understanding the structural relationship between hits and the NS2B/NS3 protease for effective lead optimization.},
}
@article {pmid40910289,
year = {2026},
author = {Kumar, D and Gupta, V and Tanwar, R and Gupta, S},
title = {Needle-Free Future: Revolutionizing Immunization with Vaccine Creams.},
journal = {Recent advances in drug delivery and formulation},
volume = {20},
number = {3},
pages = {203-206},
pmid = {40910289},
issn = {2667-3886},
mesh = {Humans ; Animals ; Staphylococcus epidermidis/immunology/genetics ; *Vaccines/administration &amp; dosage/immunology ; *Vaccination/methods ; *Skin Cream/administration &amp; dosage ; Administration, Cutaneous ; },
abstract = {For centuries, injections have been the primary method for vaccination; however, these traditional approaches present challenges due to pain, fear, and difficulties in administration. Scientists from Stanford University have developed vaccine creams, representing a revolutionary approach to the field of vaccination. Genetically modified Staphylococcus epidermidis forms the basis of these cream products, which support skin-based, painless vaccination without invasive procedures, while playing an essential role in the immune response. Scientists using tetanus as a test subject have obtained positive data from animal studies demonstrating effective immune responses to vaccination, indicating potential future applications for treating diseases, such as influenza, COVID-19, and cancer. Vaccination creams outperform classic injections in several ways, as they eliminate needle-related concerns while reducing adverse reactions, streamlining mass vaccination programs, and making the delivery of immunizations simpler, especially for populations that lack regular access to healthcare. Several key barriers continue to hinder the development of vaccine creams, including regulatory hurdles, stability concerns, production scalability, and public acceptance. Research discusses how vaccine creams revolutionize immunization processes by improving treatment accessibility, affordability, and broader acceptance rates.},
}
@article {pmid41220262,
year = {2026},
author = {Maideen, NMP and Jumale, AH and Albasti, AK and Abdul Kadir, DA and Alkhawalda, MY and Canani, M and Shokr, AF},
title = {Potential Benefits of Nigella sativa (Black Seeds) in the Management of Coronavirus Disease-2019 (COVID-19)-Associated New-Onset Diabetes Mellitus (NODM): An Overview.},
journal = {Infectious disorders drug targets},
volume = {26},
number = {4},
pages = {e18715265400793},
doi = {10.2174/0118715265400793251021092651},
pmid = {41220262},
issn = {2212-3989},
mesh = {Humans ; *Nigella sativa/chemistry ; COVID-19/complications ; *Diabetes Mellitus/drug therapy/etiology/virology ; *Hypoglycemic Agents/therapeutic use/pharmacology ; Seeds/chemistry ; SARS-CoV-2 ; *Plant Extracts/therapeutic use/pharmacology ; Blood Glucose/drug effects ; Phytotherapy ; *COVID-19 Drug Treatment ; },
abstract = {After recovering from COVID-19, several patients experienced beta-cell dysfunction, insulin resistance, pancreatic dysfunction, reduced insulin production, and New Onset Diabetes Mellitus (NODM). The purpose of this review was to examine the potential advantages of black seeds (Nigella sativa or N. sativa) in the treatment of post-COVID NODM. With a focus on pertinent publications, the literature search was carried out utilizing electronic databases such as Medline, PubMed, PMC, Scopus, Web of Science, Science Direct, Google Scholar, and reference lists. Numerous RCTs, systematic reviews, and meta-analyses have established N. sativa's antidiabetic potential as well as its other pleiotropic effects, such as its anti-inflammatory, antioxidant, and anti-COVID properties. Through a variety of possible mechanisms, N. sativa may reduce glycated Hemoglobin (HbA1c), Postprandial Blood Glucose (PPBG), Fasting Blood Glucose (FBG), and other indices. The longterm effects of N. sativa in the treatment of COVID-associated NODM should be investigated in future studies.},
}
@article {pmid41664366,
year = {2026},
author = {Macedo, BVS and Macedo, ES and Diniz, MC and Mendes, RL},
title = {Hydrazones as Potential Antimelanoma Prototypes: A Systematic and Patent Review.},
journal = {Anti-cancer agents in medicinal chemistry},
volume = {26},
number = {14},
pages = {1312-1328},
pmid = {41664366},
issn = {1875-5992},
mesh = {Humans ; *Hydrazones/pharmacology/chemistry/therapeutic use ; *Antineoplastic Agents/pharmacology/chemistry/therapeutic use ; *Melanoma/drug therapy/pathology ; Patents as Topic ; Animals ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Molecular Structure ; },
abstract = {INTRODUCTION: Hydrazones are chemical compounds with the potential to inhibit various neoplasms, including melanoma, a highly metastatic and multidrug-resistant cancer. This study aimed to systematically review the literature and analyze patents to assess the potential of hydrazones as prototype anti-melanoma agents.<br><br>METHODS: Following PRISMA guidelines (OSF registration: DOI 10.17605/OSF.IO/3AWR9), a systematic search was conducted in PubMed/Medline, Web of Science, ScienceDirect, and Scopus for studies published from January 2019 to February 2024 using the terms "hydrazone" and "melanoma". Only original Englishlanguage studies with experimental evaluation of anti-melanoma activity, in vitro and/or in vivo, were included. Patent searches were also carried out in ESPACENET, WIPO, LENS, and Google Patents using the IPC code A61P35/00.<br><br>RESULTS: From 1,072 records, 35 articles met eligibility criteria. All studies reported in vitro anti-melanoma activity of hydrazones; however, none included in vivo assays. N-acylhydrazones were the most frequently investigated subclass, featured in 19 studies. The patent analysis identified 41 filings using the combined terms "hydrazone AND melanoma", with Google Patents accounting for the majority (29 filings).<br><br>DISCUSSION: Hydrazones, particularly N-acylhydrazones, showed significant in vitro activity and selectivity, surpassing traditional drugs like cisplatin in some cases. The limited number of patent filings might indicate difficulties with protecting intellectual property, including effects from the COVID-19 pandemic. However, methodological differences and the lack of in vivo data are still major challenges. This emphasizes the need for more consistent and applicable research.<br><br>CONCLUSION: Despite their potential, further studies are needed to validate hydrazones as a distinct class of antineoplastic agents.},
}
@article {pmid42441796,
year = {2026},
author = {da Costa, ECR and Santana, RF and Rembold, SM and Sales, FM and Cavalcante, RB},
title = {Nursing Diagnosis "Maladaptive Coping with Infodemic": A Concept Analysis.},
journal = {International journal of nursing knowledge},
volume = {37},
number = {3},
pages = {466-479},
doi = {10.1177/20473087261443259},
pmid = {42441796},
issn = {2047-3095},
mesh = {*Adaptation, Psychological ; Humans ; Coping Skills ; *Nursing Diagnosis ; COVID-19/psychology/epidemiology ; },
abstract = {ObjectivesTo analyze the concept of infodemic in health as a theoretical basis for proposing the nursing diagnosis "Maladaptive Coping with the Infodemic".MethodsA conceptual analysis guided by the Walker and Avant method was conducted, following the steps of identifying the uses of the concept, attributes, antecedents, consequences, empirical referents, and model and contrary cases. To construct the definitions, an integrative literature review was carried out in June 2024.ResultsThirty-three studies addressing the concept of infodemic in individual health were identified. The core elements of the concept include information overload, disinformation, misinformation, fake news. The antecedents include the pandemic, low educational level, low income, and low health literacy with depression identified as an associated condition. The consequences include incorrect health actions (e.g., refusal to vaccinate), risk-prone behaviors (e.g., lack of protective measures), anxiety, stress, fear, social isolation, and insomnia, substance abuse.ConclusionsThe proposed nursing diagnosis, "Maladaptive Coping with the Infodemic," provides a theoretical framework to support nurses in identifying behaviors and psychological impacts associated with misinformation and to guide targeted nursing interventions.},
}
@article {pmid42546559,
year = {2026},
author = {Barone, MTU and Prates, EJS and Gomide, MHM and da Silva, TMR},
title = {Integrating vaccination into strategies to protect people living with noncommunicable diseases.},
journal = {Public health},
volume = {259},
number = {},
pages = {106430},
doi = {10.1016/j.puhe.2026.106430},
pmid = {42546559},
issn = {1476-5616},
mesh = {Humans ; *Noncommunicable Diseases/prevention &amp; control/mortality ; *Vaccination ; COVID-19/prevention &amp; control ; Influenza, Human/prevention &amp; control ; },
abstract = {OBJECTIVES: Reducing premature mortality from noncommunicable diseases (NCDs) is a global priority under Sustainable Development Goal target 3.4. Individuals with NCDs face increased risks of severe outcomes from common infections.<br><br>STUDY DESIGN: Short communication examining the role of vaccination as an underutilized strategy to protect people living with NCDs.<br><br>METHODS: We reviewed evidence on the interactions between infectious diseases and NCDs and examined the potential contribution of vaccination to reducing adverse health outcomes among high-risk populations.<br><br>RESULTS: Vaccination against influenza, pneumococcal disease, COVID-19, and other pathogens reduces hospitalizations, complications, and mortality among people living with NCDs. However, vaccination remains insufficiently integrated into NCD prevention and management frameworks.<br><br>CONCLUSIONS: Strengthening the integration of vaccination into NCD strategies could reduce avoidable morbidity and mortality and support progress toward global NCD targets.},
}
@article {pmid42649099,
year = {2026},
author = {, and Kassardjian, CD and Desai, U and Živković, SA and Simmons, Z and Narayanaswami, P},
title = {It's Virtually Here: Telemedicine, Virtual Care, and Neuromuscular Disease.},
journal = {Muscle &amp; nerve},
volume = {74},
number = {5},
pages = {1318-1327},
doi = {10.1002/mus.70382},
pmid = {42649099},
issn = {1097-4598},
mesh = {Humans ; *Neuromuscular Diseases/therapy/diagnosis ; *Telemedicine/trends ; *COVID-19/epidemiology ; Digital Health ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic forced a partial shift in neuromuscular clinical practice away from in-person care to remote means. However, this shift was unexpected, abrupt, reactive to the emergency of a pandemic, and disruptive to the usual manner of care, without adequate time to adapt or study the optimal manner to provide care remotely. While traditionally associated with hub-and-spoke telemedicine models, the pandemic popularized direct-to-home virtual care, mostly unsupported by on-site examiners or standardized platforms. In chronic neuromuscular disorders such as amyotrophic lateral sclerosis (ALS) and myasthenia gravis (MG), virtual care has demonstrated feasibility, patient satisfaction, and potential cost savings, particularly for geographically or functionally disadvantaged populations. Disease-specific adaptations such as the Myasthenia Gravis Core Exam and wearable-based assessments (e.g., home spirometry, grip strength monitoring, and digital outcome measures) have enabled more structured remote evaluations. However, diagnostic accuracy may be compromised by the inability to perform detailed neurological examinations or electrodiagnostic studies. Equity concerns persist due to variability in digital literacy, internet and digital device access, and socioeconomic status. Post-pandemic, patients with disabilities may continue to benefit in a combined virtual/in-person paradigm of care. More evidence is required to evaluate the impact of virtual care on neuromuscular practice quality of care and outcomes. We outline some of the questions that require further study, hoping to spur research and quality improvement investigations of these new care models.},
}
@article {pmid42827462,
year = {2026},
author = {Huang, P and Sun, X and Peng, J and Tian, W},
title = {ADAMTS13 as a thromboinflammatory brake at the vascular-immune interface: from viral immunothrombosis to the tumor microenvironment.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1922929},
pmid = {42827462},
issn = {1664-3224},
mesh = {Humans ; *ADAMTS13 Protein/metabolism/immunology ; *Tumor Microenvironment/immunology ; *Neoplasms/immunology ; von Willebrand Factor/metabolism/immunology ; Animals ; *COVID-19/immunology ; *Thromboinflammation/immunology ; Purpura, Thrombotic Thrombocytopenic/immunology ; *Thrombosis/immunology ; },
abstract = {ADAMTS13 is conventionally regarded as the protease whose severe deficiency causes thrombotic thrombocytopenic purpura (TTP). By cleaving shear-unfolded ultra-large and high-molecular-weight von Willebrand factor (VWF), ADAMTS13 limits a platelet- and leukocyte-adhesive vascular scaffold. We propose a narrower and testable extension of this biology to cancer: an imbalance between VWF burden and ADAMTS13 processing capacity may act as a context-dependent modifier or amplifier of thromboinflammation in selected VWF-rich, shear-exposed tumor vascular niches, but is not established as an initiating or universally rate-limiting cause of cancer-associated thrombosis. We define "relative ADAMTS13 insufficiency" as a research phenotype rather than a diagnosis or evidence of causality. It refers to ADAMTS13 activity outside the severe-deficiency range, typically ≥10%, together with increased VWF burden and a disproportionately low ADAMTS13 activity/VWF antigen ratio (ADAMTS13:Act/VWF: Ag). This phenotype is mechanistically nonspecific and may reflect increased VWF release, impaired whole-molecule VWF clearance, reduced ADAMTS13 production, stability, or availability, functional inhibition of proteolysis, reduced VWF susceptibility to cleavage, or shared upstream inflammation. Human evidence from COVID-19 and cancer remains predominantly associative, whereas tumor-relevant perturbation studies provide preclinical causal support in defined models. The causal importance of the VWF-ADAMTS13 axis in human tumors nevertheless remains unproven. We therefore position this module within a broader thromboinflammatory network that includes complement activation, neutrophil extracellular traps, platelet activation, and tissue factor-thrombin-fibrin pathways. ICI-associated endothelial phenotypes are distinguished from rare ICI-associated immune TTP with categorical severe ADAMTS13 deficiency. Candidate interventions are accordingly presented as mechanistic research nodes requiring staged validation rather than as established oncology therapies.},
}
@article {pmid42827737,
year = {2026},
author = {Mansur, MA and Oddo, VM},
title = {The Triple Burden of Malnutrition among Children and Adolescents in Indonesia during the COVID-19 Pandemic: A Narrative Review.},
journal = {Current developments in nutrition},
volume = {10},
number = {9},
pages = {109515},
pmid = {42827737},
issn = {2475-2991},
abstract = {Children and adolescents in Indonesia are experiencing the triple burden of malnutrition (TBM), resulting from an increasing prevalence of overweight and obesity paired with persistent undernutrition and anemia. The extent to which the coronavirus disease 2019 (COVID-19) further exacerbated TBM within this group, because of lifestyle changes and increased food insecurity, has not been well documented. This narrative review aimed to fill that gap by exploring components of TBM (i.e., undernutrition, anemia, and overweight and obesity), its determinants (e.g., diet), and related nutrition policies and programs among school-aged children and adolescents in Indonesia during the pandemic. We reviewed a total of 10 peer-reviewed articles published between 2021 and 2025 on children and adolescents' nutrition status and TBM-related determinants. Results suggested that during COVID-19, children and adolescents in Indonesia experienced a high prevalence of undernutrition, overweight and obesity, and anemia. Most children and adolescents also faced higher levels of food insecurity and lower physical activity. The implementation of online learning halted several school-based nutrition programs, including iron‒folic acid supplementation. Nutrition-sensitive programs, such as conditional cash transfers and food assistance, were poorly distributed and contained processed foods, respectively. Nevertheless, some positive changes were also observed, including innovations in the delivery of nutrition education. Dietary changes were mixed. Although some reported a higher consumption of deep-fried foods and snacks, more frequent vegetable consumption and less frequent consumption of sugary drinks were also reported. Future research is needed to understand the mixed findings related to dietary changes and how this contributes to TBM in Indonesia at the national level. Additionally, it is crucial to strengthen children and adolescent nutrition policies and programs that target TBM simultaneously.},
}
@article {pmid42828219,
year = {2026},
author = {Amsalu, E and Yeshambaw, M and Jirata, D},
title = {Impact of COVID-19 on TB and HIV/AIDS severity in low- and middle-income countries: a systematic review.},
journal = {Dialogues in health},
volume = {9},
number = {},
pages = {100349},
pmid = {42828219},
issn = {2772-6533},
abstract = {BACKGROUND: Beyond its profound health, social, and economic consequences, COVID-19 poses a serious threat to the management of tuberculosis (TB) and HIV/AIDS. However, empirical evidence remains limited. This study evaluates the impact of the COVID-19 pandemic on TB and HIV/AIDS service delivery across low- and middle-income countries.<br><br>METHODS: This systematic review protocol was registered with PROSPERO (CRD42021266242). Following PRISMA guidelines, we searched databases-including PubMed, ClinicalTrials.gov, and CINAHL-for studies on TB and HIV/AIDS services published between January 1, 2019, and January 8, 2024. A random-effects model calculated pooled relative risks to evaluate overall TB/HIV outcome severity, and subgroup analyses were performed to evaluate regional risk variations.<br><br>RESULTS: In low- and middle-income countries, non-TB patients with COVID-19 had a lower risk of severe outcomes compared to those with TB (pooled OR&#xa0;=&#xa0;0.71, 95% CI: 0.60-0.83). Conversely, HIV patients with COVID-19 faced an increased risk of severe disease (pooled RR&#xa0;=&#xa0;1.78, 95% CI: 1.45-2.19). By region, the pooled OR for severe COVID-19 in patients with TB was 0.83 (95% CI: 0.63-1.08) in Asia and 0.64 (95% CI: 0.51-0.79) in Africa. For HIV patients with COVID-19, the risk of severe disease was 1.73 (95% CI: 1.38-2.18) in Asia and 1.98 (95% CI: 1.26-3.10) in Africa.<br><br>CONCLUSION: In low- and middle-income countries, COVID-19 patients with underlying conditions were significantly more likely to experience severe outcomes than those without comorbidities. Furthermore, the pandemic severely disrupted fragile health systems in these regions, exacerbating the burden of tuberculosis and HIV/AIDS.},
}
@article {pmid42828225,
year = {2026},
author = {Kłodnicka, K and Januszewski, J and Tyczyńska, M and Teresińska, B and Trzaskacz, P and Forma, A and Flieger, J and Baj, J},
title = {Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics.},
journal = {Biochemia medica},
volume = {36},
number = {3},
pages = {030502},
pmid = {42828225},
issn = {1846-7482},
mesh = {Humans ; *Guillain-Barre Syndrome/virology/diagnosis/etiology/immunology ; COVID-19/complications ; Clinical Laboratory Techniques ; *Virus Diseases/complications ; SARS-CoV-2 ; Biomarkers/blood ; Autoantibodies/immunology ; },
abstract = {Guillain-Barré syndrome (GBS) is a leading cause of acquired acute neuromuscular paralysis and is an immune-mediated disorder of the peripheral nervous system (PNS). Accumulating evidence indi-cates that GBS is often preceded by infectious events that trigger autoimmune responses through mechanisms such as molecular mimicry and autoantibody production. Campylobacter jejuni remains the most common bacterial agent, but viral pathogens also contribute to the development of GBS. This review summarizes the current evidence regarding viruses as triggers of GBS, including herpes-viruses, hepatotropic viruses (A, B, C, and E), human immunodeficiency virus, Zika virus, influenza virus, varicella-zoster virus, and the coronavirus SARS-CoV-2. Emphasis is placed on laboratory test results related to viral GBS, including antiganglioside antibodies, serological markers of recent in-fection, molecular diagnostic methods, and cerebrospinal fluid analysis. From the standpoint of la-boratory medicine, both the clinical diagnosis and the distinction of GBS subtypes can be supported by the identification of recent viral infections and the detection of immunological biomarkers. How-ever, cross-reactivity, extended antibody persistence, and inadequate assay standardization frequently make it difficult to interpret laboratory test results. In patients with probable viral GBS, this review shows the diagnostic significance and limitations of routine laboratory testing. It also highlights the significance of close coordination between laboratory professionals and clinicians.},
}
@article {pmid42828520,
year = {2026},
author = {Modesto, HC and Modesto, LC and Castanho, LC and Pereira, LJM and Norte, RSG and Pereira, JAC and Andriolo, RB},
title = {Noninvasive Neuromodulation Techniques in the Recovery of Olfactory Dysfunction in Long COVID: A Systematic Review and Bayesian Meta-Analysis.},
journal = {Neuromodulation : journal of the International Neuromodulation Society},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.neurom.2026.08.006},
pmid = {42828520},
issn = {1525-1403},
abstract = {OBJECTIVES: Long COVID is a multisystemic condition in which olfactory disorders are among the most prevalent manifestations. Noninvasive neuromodulation has emerged as a promising therapeutic approach for post-COVID sequelae. This systematic review and Bayesian meta-analysis aimed to synthesize the available evidence on neuromodulation for olfactory improvement in patients with Long COVID.<br><br>MATERIALS AND METHODS: A systematic search was conducted in PubMed and/or MEDLINE, Embase, and Cochrane Library from inception through January 22, 2026, in accordance with Preferred Reporting items for Systematic Reviews and Meta-Analyses 2020 guidelines. Studies were eligible if they included patients with Long COVID undergoing any noninvasive neuromodulation modality for olfactory disturbances and had a control group. Risk of bias was assessed using Cochrane risk of bias 2 tool for randomized controlled trials and the risk of bias in nonrandomized studies of interventions tool for nonrandomized intervention studies. A Bayesian random-effects meta-analysis was performed using the brms package in R, with risk ratios (RRs) and 95% credible intervals (CrIs) as effect measures.<br><br>RESULTS: A total of four studies were included, using heterogeneous neuromodulation modalities. The pooled RR for complete olfactory recovery (normosmia) was 1.59 (95% CrI, 0.41-6.28), with a 73.9% posterior probability of benefit (RR > 1); however, the CrI included the null value. For clinically meaningful olfactory improvement, the pooled RR was 2.20 (95% CrI, 0.63-7.52), with an 88.8% posterior probability of benefit, although the interval marginally included the null value. Sensitivity analyses using wider priors yielded substantially different estimates, indicating that the results were prior-dependent. No serious adverse events were reported across the studies.<br><br>CONCLUSIONS: The available evidence suggests a possible favorable direction of effect of noninvasive neuromodulation on olfactory dysfunction in Long COVID, but the certainty is very low. These findings should be interpreted as hypothesis-generating. Larger trials using standardized olfactory testing and prespecified stimulation protocols are warranted before any clinical recommendations can be made.},
}
@article {pmid42828827,
year = {2026},
author = {Austin, AE and Hergenrother, LC and Honaker, SJ and Shanahan, ME and Chandler, CE},
title = {The impact of social safety net policies on mental health and suicide outcomes in the United States: A scoping review.},
journal = {Social science &amp; medicine (1982)},
volume = {409},
number = {},
pages = {119895},
doi = {10.1016/j.socscimed.2026.119895},
pmid = {42828827},
issn = {1873-5347},
abstract = {Existing evidence indicates that there are reciprocal relationships between economic insecurity and poor mental health and suicidal behavior. In the United States, prior research shows that state and federal policies that increase social safety net program benefits or eligibility contribute to improved economic security. Thus, these policies may affect mental health and suicide outcomes. The aim of this scoping review was to synthesize the state of the evidence on the impact of state and federal social safety net policies on mental health, suicidal behavior, and suicide death. Of 64 identified studies, state or federal social safety net policies examined included those specific Earned Income Tax Credits (EITC; N = 14), minimum wage (N = 11), paid family or sick leave (N = 9), the 2021 Child Tax Credit (CTC; N = 8), the Supplemental Nutrition Assistance Program (SNAP; N = 6), unemployment insurance benefits (N = 5), Temporary Assistance for Needy Families (TANF; N = 3), economic stimulus payments (N = 2) and eviction moratoriums (N = 2) during the COVID-19 pandemic, and multiple programs (N = 4). Most studies examined a single policy (N = 60), and more studies examined mental health outcomes (N = 53) than suicide outcomes (N = 15). Most studies that examined state or federal EITC, paid family or medical leave, the 2021 CTC, SNAP, TANF, unemployment insurance benefit, COVID-19 economic impact payment, and COVID-19 eviction moratorium policies found decreases in at least one measure of poor mental health, suicidal behavior, or suicide death. Studies that examined state minimum wage policies had mixed results. This body of research can be used to inform current policy debates and advance evidence-driven policymaking.},
}
@article {pmid42829141,
year = {2026},
author = {Lu, D and Liao, H and Hannan, AJ},
title = {Paternal infections and immune activation program offspring neurobehavior in a sex-dependent manner.},
journal = {Neuroscience and biobehavioral reviews},
volume = {191},
number = {},
pages = {107018},
doi = {10.1016/j.neubiorev.2026.107018},
pmid = {42829141},
issn = {1873-7528},
abstract = {Preconception immune challenges in fathers are increasingly recognized as biologically meaningful determinants of offspring neurodevelopment, behavior, and immunity. However, the field still lacks a unifying framework to explain the recurrent sex dependence of these inherited outcomes. Here, we synthesize evidence across paternal infection and immune activation paradigms, including SARS-CoV-2 infection, parasitic infection, fungal infection, polymicrobial sepsis, and pathogen mimic-induced models of immune activation. We treat offspring sex as a central organizing variable rather than a secondary feature. Across models, inherited effects may be male biased, female biased, or shared but expressed in different physiological domains, arguing against a single narrative of male vulnerability or female resilience. Causal sperm RNA studies after paternal viral and parasitic infection support a transmission-versus-decoding framework in which germline signals can be shared while developmental interpretation diverges between male and female offspring. Evidence from paternal stress, metabolic disturbance, and toxicant exposure reveals related patterns of sperm epigenetic remodeling and sex-biased offspring outcomes, suggesting that similar transmission and developmental decoding mechanisms may operate across diverse paternal exposures. We further integrate evidence that paternal immune challenges differ in immune polarity, producing offspring immune priming in some models and tolerization in others, often with sex-dependent strength and direction. Finally, we discuss candidate mechanisms of sex-specific decoding, including placental dimorphism, hormone-immune interactions, and sex chromosome biology, and outline priorities for future studies combining longitudinal sperm profiling with sex-stratified embryonic, placental, behavioral and immune phenotyping.},
}
@article {pmid42829647,
year = {2026},
author = {Sica, R and Catamerò, F and Foti Randazzese, S and Galletta, F and Licari, A and Marseglia, GL and Mori, F and Poto, R and Pulvirenti, F and Ricci, S and Giovannini, M and Manti, S},
title = {Exploring the Potential Benefits of Biologic Therapies Beyond Respiratory Allergy.},
journal = {ImmunoTargets and therapy},
volume = {15},
number = {},
pages = {624173},
pmid = {42829647},
issn = {2253-1556},
abstract = {Severe pediatric asthma is a heterogeneous inflammatory disease that is most commonly driven by type 2 (T2) inflammation. Because respiratory viral infections are the leading triggers of asthma exacerbations in children, this review examines the effects of biologic therapies on infection-related outcomes and antiviral immune function, beyond their established role in asthma control. We conducted a structured narrative review of literature published from January 2000 through February 2026 using PubMed/MEDLINE, EMBASE, Scopus, and the Cochrane Library databases. Studies evaluating infection-related outcomes and immune effects of biologic therapies in pediatric asthma were analyzed. Available evidence consistently indicates that biologics have favorable infectious safety profiles without increasing the risk of serious or opportunistic infections. Anti-IgE therapy (omalizumab) showed the strongest evidence of direct immunomodulatory effects, including restoration of interferon-mediated antiviral responses and reduction of virus-triggered asthma exacerbations. Anti-IL-5 and anti-IL-5 receptor therapies have corticosteroid-sparing effects and preserve immune competence despite eosinophil depletion. Dupilumab and tezepelumab similarly provide sustained efficacy and stable safety profiles without increasing infectious burden. Real-world evidence from the COVID-19 pandemic further indicates that biologic-treated children do not have greater susceptibility to SARS-CoV-2 infection or more severe disease. Overall, biologic therapies appear to provide targeted immunomodulation rather than broad immunosuppression, preserving host defense while controlling severe pediatric asthma. These findings suggest that biologic therapies may positively influence immune competence beyond asthma control, with implications for infection susceptibility and antiviral defense. Further prospective pediatric studies with standardized endpoints and long-term follow-up are needed to define their immunological impact and optimize precision-medicine strategies.},
}
@article {pmid41140075,
year = {2026},
author = {Adhikary, K and Barman, S and Chowdhury, SR and Ganguly, K and Mohanty, S and Gupta, M and Mukherjee, T and Dhua, R and Banerjee, P and Maiti, R},
title = {Emerging Vector-Borne Nipah Virus Infection: Unexplored Hazards, Diagnostic Challenges, and the Potential of Phytomedicine-Based Therapeutics.},
journal = {Current pharmaceutical design},
volume = {32},
number = {32},
pages = {2662-2688},
pmid = {41140075},
issn = {1873-4286},
mesh = {Humans ; *Nipah Virus/drug effects/genetics ; Animals ; *Henipavirus Infections/drug therapy/diagnosis/epidemiology ; *Antiviral Agents/therapeutic use/pharmacology ; *Phytochemicals/therapeutic use/pharmacology ; COVID-19/diagnosis ; *Phytotherapy ; },
abstract = {INTRODUCTION: Millions of people have died from zoonotic illnesses, like COVID-19 and Nipah virus infection (NiV), throughout history. Fruit bats (Pteropus sp.) are the main reservoir host for NiV, an RNA virus belonging to the Henipavirus group, which causes extremely infectious illnesses, such as COVID- 19. NiV outbreaks have posed significant public health concerns, especially in South and Southeast Asia. The Nipah virus (NiV) infection is caused by a virus that belongs to the Paramyxoviridae family's Henipavirus genus. It is the source of zoonosis, which causes respiratory and neurological symptoms.<br><br>METHODS: This study has reviewed the epidemiology, pathophysiology, genetic diversity, and phylogenetics of NiV. It has explored NiV's clinical features, cellular monitoring, infection factors, and the virus' reservoir host.<br><br>RESULTS: Phylogenetic analysis has identified two circulating NiV lineages. Additionally, the study has examined the role of phytochemicals in combating viral infections. Despite the absence of a focused therapy for COVID-19, phytochemicals have been investigated for their potential antiviral properties. Evidence suggests that plants and their components may possess resistance against NiV by modulating the immune system and inhibiting viral replication.<br><br>DISCUSSION: The investigation into plant-derived compounds has offered a novel direction for NiV treatment, potentially enhancing viral resistance through immune modulation. Continued research on natural antivirals could bridge current gaps in therapeutic options for emerging zoonotic diseases.<br><br>CONCLUSION: The study has highlighted the transmission risk, detection challenges, and the potential of phytochemicals in managing NiV infections. The therapeutic potential of plants and their antiviral properties offer promising insights into future treatments for serious viral diseases, like NiV.},
}
@article {pmid42635998,
year = {2026},
author = {Chung, TH and Raj, SR},
title = {Postural Orthostatic Tachycardia Syndrome (POTS): A Review.},
journal = {JAMA},
volume = {336},
number = {13},
pages = {1149-1164},
doi = {10.1001/jama.2026.14809},
pmid = {42635998},
issn = {1538-3598},
mesh = {Humans ; *Postural Orthostatic Tachycardia Syndrome/diagnosis/therapy/epidemiology/physiopathology/complications/drug therapy ; Adolescent ; Female ; Prevalence ; Young Adult ; Quality of Life ; Male ; Child ; },
abstract = {IMPORTANCE: Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder characterized by excessive orthostatic tachycardia and multisystem symptoms that affects an estimated 0.1% to 1% of the US population. POTS can substantially impair daily functioning and quality of life.<br><br>OBSERVATIONS: Consensus criteria define POTS by chronic symptoms of orthostatic intolerance accompanied by a sustained heart rate increase of at least 30 beats/min (&#x2265;40 beats/min in adolescents aged 12-19 years) within 10 minutes of standing or head-up tilt from a supine position in the absence of orthostatic hypotension, defined as a decrease in either systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg with positional change. POTS symptoms may include palpitations, lightheadedness, nausea, vomiting, gastroparesis, anorexia, generalized weakness, and muscle pain, despite absence of structural pathology within cardiovascular, gastrointestinal, and neurological organs. POTS predominantly affects females (approximately 90% of cases), with peak incidence from ages 13 to 29 years. However, the true prevalence remains uncertain partly due to underrecognition and lack of a specific diagnostic code for POTS until 2022. Common symptoms include lightheadedness, palpitations, fatigue, cognitive dysfunction ("brain fog"), exercise intolerance, nausea, bloating, constipation, diarrhea, and sleep disturbance. In a survey of 4835 patients, approximately 70% reported substantial functional impairment and loss of school or work participation, and median diagnostic delay was 24 months. In 30% to 40% of cases, symptoms began within 3 months after infections, such as SARS-CoV-2, Epstein-Barr virus, and influenza. Initial evaluation should exclude other conditions that cause sinus tachycardia, including thyroid disease, adrenal insufficiency, pheochromocytoma, cardiomyopathy, valvular heart disease, congenital heart disease, chronic lung disease, medication effects (eg, stimulants, norepinephrine reuptake inhibitors, and diuretics), anemia, and dehydration. First-line treatment includes nonpharmacological strategies to improve cardiac preload, including increased fluid and sodium intake, lower-body compression garments; avoidance of heat exposure, dehydration, and prolonged standing; and structured supervised aerobic training. Pharmacological therapies should be individualized and may include &#x3b2;-blockers, ivabradine, midodrine, fludrocortisone, and pyridostigmine, although evidence supporting many therapeutic interventions is limited by small studies and lack of large, randomized trials.<br><br>CONCLUSIONS AND RELEVANCE: POTS is a chronic autonomic disorder associated with functional impairment and reduced quality of life that is diagnosed based on characteristic orthostatic symptoms in the absence of orthostatic hypotension after excluding alternative causes of sinus tachycardia. Treatment involves nonpharmacological measures (such as increased fluid and sodium intake), lower-body compression garments, structured exercise training, and individualized pharmacological therapy.},
}
@article {pmid42826220,
year = {2026},
author = {Bhuiya, S and Shuvo, TA and Hassan, MZ and Aleem, MA and Mamun, GMS and Zakaria, AFM and Rahman, M and Chowdhury, F},
title = {The Impermanence of Public Health Gains-Lessons Learned from Measles Resurgence, Bangladesh, 2026.},
journal = {Emerging infectious diseases},
volume = {32},
number = {11},
pages = {},
doi = {10.3201/eid3211.261019},
pmid = {42826220},
issn = {1080-6059},
abstract = {The global resurgence of measles is a major public health concern. After the success of its Expanded Programme on Immunization, Bangladesh experienced a measles resurgence in 2026. The country faced major setbacks after measles vaccination coverage declined because of political instability, discontent among field-level staff, change in procurement policy, COVID-19-related service disruptions, and delayed supplementary immunization campaigns. During March 15-September 13, 2026, Bangladesh reported 170,638 suspected and 20,006 confirmed measles cases, including 919 deaths among suspected and 100 deaths among laboratory-confirmed cases. The outbreak disproportionately affected unvaccinated and underimmunized children. Political turmoil during 2024-2025 disrupted vaccine procurement, delayed mass vaccination campaigns, weakened the health workforce, and compromised financial and logistic continuity. Simultaneously, disruptions in vitamin A supplementation and worsening child malnutrition amplified disease severity. To prevent future resurgence, immunization programs must be depoliticized, supported by buffer vaccine stocks, strengthened through microlevel surveillance, and integrated with nutrition and primary healthcare services.},
}
@article {pmid42827170,
year = {2026},
author = {Fazekas, A and Grasmuk-Siegl, E and Moser, D},
title = {Serum cholinesterase as a prognostic marker in respiratory critical illness: a narrative review.},
journal = {Wiener klinische Wochenschrift},
volume = {},
number = {},
pages = {},
pmid = {42827170},
issn = {1613-7671},
abstract = {Prognostication in respiratory critical care rests largely on composite severity scores derived from mixed medical, surgical or sepsis populations. Serum butyrylcholinesterase (pseudocholinesterase) is a liver-synthesized plasma enzyme, a negative acute-phase reactant and an established index of hepatic synthesis and nutrition, and has re-emerged as a candidate prognostic biomarker in critical illness. A direct cytokine-driven mechanism is inferred, not demonstrated, and whether the circulating enzyme modulates the cholinergic anti-inflammatory axis is unproven. This narrative review synthesizes the evidence across community-acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease and acute respiratory failure including coronavirus disease 2019 (COVID-19). A reproducible inverse association between enzyme activity and mortality or disease severity emerges, but it rests on small, mostly retrospective single-center studies with heterogeneous assays and data-derived thresholds. The review therefore asks one decisive question, almost never addressed in respiratory cohorts: whether the enzyme adds information beyond albumin and established severity scores, judged by incremental discrimination and reclassification. On that test it is a consistent signal in search of methodological rigour rather than an established independent marker. Prospective, setting-specific and adequately adjusted validation is required before clinical adoption, capturing the activity nadir and the slope of any recovery, whose prognostic role is untested. Mislabelling could influence decisions on escalation and limitation of treatment.},
}
@article {pmid42432664,
year = {2026},
author = {Chandak, A and Chandak, P and Patil, A and Varma, R},
title = {Digital health literacy among university students: a systematic review of global trends, determinants, measurement, and the literacy-to-intervention gap.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42432664},
issn = {1471-2458},
mesh = {Humans ; *Health Literacy/trends/statistics &amp; numerical data ; *Students/statistics &amp; numerical data/psychology ; Universities ; Digital Health ; Evidence Gaps ; },
abstract = {INTRODUCTION: University students interact with the complexities of public health knowledge in digital environments. Digital health literacy (DHL), in this regard, is crucial as an upstream skill for ensuring safe, inclusive, and knowledgeable health care engagement among university students where mis-information, algorithm amplification, and AI-based content exist.<br><br>OBJECTIVE: This systematic review synthesizes global evidence on DHL among university students. It examines measurement approaches, socio-demographic determinants, online health information-seeking behaviours, mental health and well-being correlates, and the gap between literacy assessment and tested university-based interventions.<br><br>METHODS: This systematic review followed PRISMA 2020 guidance. Searches were conducted in PubMed, Scopus, and Web of Science for peer-reviewed studies indexed up to March 31, 2024; backward and forward citation tracking was updated to January 2025 to capture directly related empirical papers. Two reviewers independently performed screening, data extraction, and quality appraisal using design-appropriate tools: JBI for analytical cross-sectional studies, CASP for qualitative evidence, and AMSTAR 2-informed criteria for review-derived or pilot evidence. Because of heterogeneity in design, instruments, and outcomes, findings were synthesized narratively and thematically.<br><br>RESULTS: Twenty-one studies met the eligibility criteria. Most were cross-sectional studies conducted during or after the COVID-19 pandemic. Five themes were identified: DHL as a competence for appraising online health information; socioeconomic, gender, health-status, and contextual determinants of DHL; associations with mental health, well-being, fear, and sense of coherence; measurement heterogeneity and psychometric maturation; and a persistent literacy-to-intervention gap.<br><br>CONCLUSION: DHL is a relevant competency for Health Promoting Universities, but the current evidence base remains dominated by descriptive self-report and cross-sectional designs. Future research should prioritize longitudinal studies, objective task-based competence assessment, and theory-driven intervention trials embedded within campus health systems, library infrastructures, and digital mental health pathways. The future research must focus on conducting longitudinal research, assessing task-based competency objectively, and testing theory-based interventions that operate through campus health systems, library infrastructure, and pathways for digital mental health.},
}
@article {pmid42545025,
year = {2026},
author = {Portaccio, I and Piastra, M and Spadaro, S and Ferrone, G and Zito Marinosci, G and Moggia, S and Chidini, G and Bitondo, MM and Bonanomi, E and Visconti, F and Tipo, V and Maglione, M and Giannattasio, A and Morena, TC and Picconi, E and Tosi, F and Mensi, S and Chioffi, M and Lecci, F and Genovese, O and Conti, G and Spinazzola, G},
title = {Necrotizing pneumonia in children: a comprehensive narrative review of current challenges and future perspectives.},
journal = {Minerva anestesiologica},
volume = {92},
number = {9},
pages = {890-903},
doi = {10.23736/S0375-9393.26.19635-7},
pmid = {42545025},
issn = {1827-1596},
mesh = {Humans ; Child ; *Pneumonia, Necrotizing/diagnosis/therapy/epidemiology/etiology ; Community-Acquired Pneumonia ; COVID-19/complications/epidemiology ; Forecasting ; },
abstract = {Necrotizing pneumonia (NP) represents an uncommon but severe complication of community-acquired pneumonia (CAP) in children, characterized by the destruction of lung parenchyma and formation of multiple thin-walled cavities. Despite its rarity, the incidence of pediatric NP has increased substantially over the past two decades, creating major diagnostic and treatment challenges. The COVID-19 pandemic has further altered the epidemiological landscape, with unique patterns of respiratory pathogen circulation. This narrative review synthesizes current evidence on pediatric necrotizing pneumonia through a comprehensive literature search of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library for articles published between January 1994 and January 2025. Search terms included "necrotizing pneumonia," "necrotising pneumonia," and "cavitary pneumonia" paired with "child," "pediatric," or "paediatric," along with specific terms for etiology, diagnosis, treatment, and outcomes. We included English-language original research articles, systematic reviews, and case series with at least 10 patients. Streptococcus pneumoniae continues to dominate as the primary pathogen, accounting for 30-60% of cases, though the emergence of Mycoplasma pneumoniae as a major cause in Asia, with macrolide resistance exceeding 85%, presents new therapeutic challenges. Diagnostic approaches have evolved significantly, with lung ultrasound demonstrating comparable accuracy to CT (κ=0.85) while avoiding radiation exposure. Novel biomarkers including presepsin, copeptin, and fetuin-A show promise for early detection and prognostication. Treatment outcomes remain encouraging, with most cases (80%) successfully managed conservatively using prolonged antibiotics for a median duration of 28 days. Surgery is reserved for specific complications, and long-term outcomes are favorable with normal pulmonary function in 80-90% of children at one-year follow-up. While pediatric necrotizing pneumonia remains a serious condition, recent advances in non-invasive diagnostics, biomarker development, and understanding of post-pandemic epidemiology offer opportunities for improved outcomes. Future research should focus on validating AI-powered diagnostic tools, optimizing antimicrobial therapy in the era of resistance, and establishing evidence-based surgical intervention criteria. The integration of lung ultrasound as a radiation-free diagnostic modality represents a paradigm shift in pediatric pneumonia management.},
}
@article {pmid42824475,
year = {2026},
author = {Ibrahim, MA and Zaib, A and Asif, T and Dengel, A and Posma, J and Ruf, W and Asim, MN},
title = {Computational identification of B- and T-cell epitopes: a unified task taxonomy and review of databases, datasets, predictive pipelines, and gaps.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1873135},
pmid = {42824475},
issn = {1664-3224},
mesh = {*Epitopes, T-Lymphocyte/immunology ; Humans ; *Epitopes, B-Lymphocyte/immunology ; Immunoinformatics ; Artificial Intelligence ; *SARS-CoV-2/immunology ; T-Lymphocytes/immunology ; COVID-19/immunology ; Computational Biology/methods ; Epitope Mapping ; Prediction Algorithms ; },
abstract = {The immune system leverages B and T cells to recognize specific molecular patterns, known as epitopes, on pathogens and cancer cells to effectively combat infections and diseases. The critical success of immunotherapies in cancer treatment and COVID-19 vaccine development has established precise epitope identification as a central and rapidly growing priority in therapeutic design. Because traditional wet-lab based identification of B- and T-cell epitopes is expensive and timeconsuming, our systematic literature search (2015-2026) identified 148 Artificial Intelligence (AI) based linear B-cell, conformational B-cell, and T-cell epitope prediction models within the stated search scope. However, the true potential of these models remains unclear due to fragmented evaluation practices, with models rarely tested across a comprehensive range of datasets, insufficient comparison with existing predictors, systematic under-utilization of available public databases, and other methodological inconsistencies across five different stages of the predictive pipeline. Moreover, the 7 existing review papers fail to adequately highlight these research gaps or to support the development of robust AI models. This review paper consolidates the computational landscape of B-cell and T-cell epitope recognition and introduces a unified taxonomy that organises the field into twelve prediction tasks: linear and conformational B-cell prediction together with ten T-cell subtasks (T1-T10) that span the antigen-recognition cascade from human leukocyte antigen (HLA) typing to vaccine design. It analyses these twelve tasks across five major stages of a shared predictive pipeline. Within this taxonomy, the recognition sub-tasks (T1-T7) apply to the epitopes of any antigen, whereas neoantigen identification (T8) and tumor T-cell antigen (TTCA) classification (T9) are oncology-specific translational applications and multi-epitope vaccine design (T10) spans infectious-disease and cancer targets. It systematically examines 155 studies published from 2015 to 2026 to perform comprehensive categorization of 43 dedicated epitope/immunology databases, 144 benchmark datasets, 272 representation learning approaches, 148 classifiers, 54 evaluation and optimization approaches, and 148 predictive models accessibility status across all twelve prediction tasks. Additionally, it highlights persistent challenges across each stage of the predictive pipeline and offers key directions for improvement. This comprehensive analysis provides actionable recommendations for developing more robust, generalizable epitope predictors, and it ultimately accelerates the translation of computational predictions into effective immunotherapies against diverse diseases.},
}
@article {pmid42824498,
year = {2026},
author = {Bansal, S and Jakhetiya, A and Managutti, A and Rai, M},
title = {Understanding the Interplay: A Descriptive Synthesis of COVID-19-Associated Mucormycosis in Diabetic Patients.},
journal = {Journal of maxillofacial and oral surgery},
volume = {25},
number = {5},
pages = {1622-1632},
pmid = {42824498},
issn = {0972-8279},
abstract = {BACKGROUND: During the COVID-19 pandemic, COVID-19-associated mucormycosis (CAM) emerged as a severe and often fatal complication, particularly among patients with diabetes mellitus. The increase in invasive fungal infections has been strongly linked to diabetes, COVID-19-related immune dysregulation, hyperglycaemia, and widespread corticosteroid use. This systematic review provides a descriptive synthesis of the relationship between COVID-19, mucormycosis, and diabetes, focusing on epidemiology, clinical features, management, and outcomes.<br><br>METHODS: A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library was conducted for studies published between 1 April 2020 and 30 November 2025. Studies reporting CAM in diabetic patients were included. Eligible designs comprised case reports, case series, and observational studies. Study selection followed PRISMA 2020 guidelines, and findings were synthesized qualitatively, with stratification by evidence level (case reports/series vs. cohort and cross-sectional studies).<br><br>RESULTS: Thirty-six studies met the inclusion criteria. Diabetes was present in most CAM cases, with poor glycaemic control and diabetic ketoacidosis frequently reported. Corticosteroid therapy was identified as a major contributing factor. Rhino-orbital-cerebral mucormycosis was the most common presentation. Early antifungal treatment, surgical debridement, and strict glycaemic control were associated with improved outcomes, whereas delayed diagnosis and cerebral involvement were linked to increased mortality. Approximately 40% of the included studies were case reports or case series (Level 4 evidence), necessitating cautious interpretation of findings.<br><br>CONCLUSION: Diabetes significantly influences the development and outcomes of CAM. Judicious corticosteroid use, optimal glycaemic control, early diagnosis, and multidisciplinary management are essential to reduce morbidity and mortality. Although conclusions are limited by the predominance of lower-level evidence, consistent patterns highlight diabetes and corticosteroid exposure as major risk factors.},
}
@article {pmid42824842,
year = {2026},
author = {Chen, N and Zhang, B and Chen, X and Zhang, H and Yu, Z},
title = {Non-coding RNAs: master regulators in the battle between host antiviral defense and viral replication.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1908472},
pmid = {42824842},
issn = {1664-3224},
mesh = {Humans ; *Virus Replication/genetics/immunology ; *RNA, Untranslated/genetics/immunology ; *Virus Diseases/immunology/genetics/virology ; *Host-Pathogen Interactions/immunology/genetics ; Immunity, Innate ; Animals ; },
abstract = {Viral infectious diseases pose serious threats to global public health. Host non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, circRNAs, and vtRNAs, act as master regulators of host antiviral defense and viral replication. Current studies on ncRNA-virus interactions are generally fragmented, and most reviews focus on a single virus or a single class of ncRNAs, without combining ncRNA expression dynamics with their biological functions for systematic collation. Herein, we establish a novel four-category classification framework based on ncRNA expression patterns and functional characteristics upon viral infection. To counteract viral infections, the host dynamically modulates the expression of distinct ncRNAs to target proviral host factors, host restriction factors, other ncRNAs, micropeptides, and lipids, thereby orchestrating antiviral innate immune signaling pathways, viral replication cycles, autophagy, apoptosis, metabolic reprogramming, and stress granule formation to establish a multilayered antiviral defense system. Concurrently, representative viruses posing severe threats to global public health, including IAV, DENV, HCV, ZIKV, HIV-1, and SARS-CoV-2, have evolved sophisticated strategies to hijack host ncRNA networks and antagonize host antiviral defenses. This review systematically summarizes and elaborates the conserved regulatory principles of various ncRNAs in the host antiviral response, clarifies the molecular mechanisms by which viruses hijack and antagonize host ncRNAs, further refines the theoretical framework of host ncRNA-virus interactions centered on viral replication regulation, discusses the future research directions under this system, and thus provides a theoretical basis for the development of host ncRNA-based antiviral drugs.},
}
@article {pmid42825909,
year = {2026},
author = {Eslami, Z and Mirghani, SJ and Eghbal Moghanlou, A and Ghaderi, M},
title = {The Role of Circulating Therapeutic MicroRNAs in Pulmonary and Muscular Function in Post-COVID-19 Athletes.},
journal = {Iranian journal of allergy, asthma, and immunology},
volume = {25},
number = {Sup 11},
pages = {21-27},
doi = {10.18502/ijaai.v25is11.22480},
pmid = {42825909},
issn = {1735-5249},
mesh = {Humans ; *COVID-19/physiopathology/genetics ; *Athletes ; *Circulating MicroRNA/blood ; *SARS-CoV-2 ; *Exercise/physiology ; *Muscle, Skeletal/metabolism/physiopathology ; *Lung/physiopathology/metabolism ; Post-Acute COVID-19 Syndrome ; *MicroRNAs/blood ; },
abstract = {SARS-CoV-2 infection causes significant acute and long-term morbidity, including persistent pulmonary and muscular dysfunction in athletes. Physical exercise alters circulating microRNA (miR) profiles, and specific microRNAs have documented roles in inflammation, immune regulation, muscle metabolism, and regeneration. This study characterizes circulating microRNAs relevant to COVID-19 pathogenesis and post-viral recovery, including miR-155, miR-146a, the let-7 family, miR-21, miR-424, miR-1, miR-133, miR-499, miR-208, miR-486, and miR-22, and examines how different exercise modalities may modulate these microRNAs to support pulmonary and muscular function in post-COVID-19 athletes. miR-155 and miR-146a are highlighted as modulators of innate and adaptive inflammatory signaling and as mediators of cytokine responses implicated in severe COVID-19. Moreover, several microRNAs, such as miR-21, miR-155, miR-146a, and the let-7 family, converge on NF-κB and related pathways, linking altered miR expression to immune dysregulation and cytokine-driven tissue injury. Additionally, muscle-enriched and metabolism-associated microRNAs regulate myogenesis, mitochondrial biogenesis, and key metabolic pathways (PGC-1α, AMPK, mTOR)-processes essential for muscle repair, endurance recovery, and respiratory muscle support after SARS-CoV-2 infection. Different types of exercise produce distinct miR signatures; notably, moderate-intensity exercise consistently promotes anti-inflammatory and pro-repair miR patterns. We emphasize the therapeutic potential of moderate-intensity exercise as a non-pharmacological strategy to regulate miR expression, reduce cytokine-mediated damage, and support functional recovery in post-COVID-19 athletes. To our knowledge, this is the first study to link exercise-driven miR changes with functional pulmonary and muscular recovery in athletic populations recovering from COVID-19, supporting moderate-intensity exercise as a promising strategy for rehabilitation and performance restoration.},
}
@article {pmid42825912,
year = {2026},
author = {Sowti, R and Najafipour, F and Ghaffarzadeh Rad, S and Ghorbani, H and Amirazad, H},
title = {Associations between Inflammatory Markers, Micronutrients, and Disease Severity in COVID-19 Patients with Type 2 Diabetes Mellitus.},
journal = {Iranian journal of allergy, asthma, and immunology},
volume = {25},
number = {Sup 11},
pages = {28-43},
doi = {10.18502/ijaai.v25is11.22481},
pmid = {42825912},
issn = {1735-5249},
mesh = {Humans ; *Diabetes Mellitus, Type 2/immunology/blood/complications ; *COVID-19/immunology ; *Micronutrients/blood ; Biomarkers/blood ; SARS-CoV-2 ; Severity of Illness Index ; Cytokines/blood ; *Inflammation/immunology ; Zinc/blood ; C-Reactive Protein ; },
abstract = {The management of treatment strategies in COVID-19 is critical, especially in patients with type 2 diabetes. Non-enzymatic glycation of transmembrane protease serine 2 and angiotensin-converting enzyme 2 during COVID-19 in patients with diabetes may exacerbate immune dysregulation and inflammation. Elevated inflammatory cytokines such as IL-1, IL-2, IL-6, IL-7, and IL-10, tumor necrosis factor-α, interferon-γ, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1 have been observed in COVID-19 patients. This review aims to assess the relationship between inflammatory markers, including C-reactive protein, and micronutrients (vitamins D and C, zinc, and copper) with the severity of COVID-19 infection in patients with type 2 diabetes. A narrative review was conducted through a comprehensive literature search of English-language articles published between 2000 and 2025. The databases searched included PubMed, Scopus, the ISI Web of Science, Cochrane, and Embase. Search terms included COVID-19, infections, type 2 diabetes mellitus, interleukins, and micronutrients. English-language scientific articles, systematic reviews, and meta-analyses were included, while studies lacking sufficient information, letters, comments, and editorials were excluded. Evidence suggests that immune-boosting components such as proteins, vitamins, and minerals can enhance immunity to infections. Vitamins D and C, zinc, and copper play supportive roles in immune function, potentially modulating the inflammatory response in COVID-19 patients with type 2 diabetes. High levels of inflammatory cytokines correlate with increased disease severity in this population. Understanding the interplay between inflammatory markers and micronutrients may guide improved therapeutic strategies for managing COVID-19 in diabetic patients. Further research is warranted to clarify these relationships and optimize clinical outcomes.},
}
@article {pmid42824280,
year = {2026},
author = {Lal, B and Naik, D and Alagarsamy, R and Sharma, S},
title = {Custom-Made Subperiosteal Implant-Assisted Rehabilitation in Post COVID-19 Rhino-orbital Mucormycosis Defects: A Systematic Review.},
journal = {Journal of maxillofacial and oral surgery},
volume = {25},
number = {5},
pages = {1539-1548},
pmid = {42824280},
issn = {0972-8279},
abstract = {BACKGROUND: Custom-made subperiosteal dental implants (CMSDIs) have shown potential as a reconstructive solution for rehabilitating maxillary defects following post-COVID-19 rhino-orbital mucormycosis (PCROM). This systematic review evaluates the clinical outcomes of CMSDIs in such defects.<br><br>MATERIALS AND METHODS: A systematic search was conducted across PubMed, Google Scholar, Semantic Scholar, and the Cochrane Library for studies published through March 2025. Data regarding patient demographics, implant materials, design techniques, surgical approaches, prosthetic rehabilitation, and postoperative complications were extracted. A descriptive analysis of the included studies was performed.<br><br>RESULTS: A total of seven studies (two case series and five case reports) were published between 2022 and 2024, involving 46 patients (aged 30-67 years). All studies were from India. The software used for planning and designing included Mimics[&#xae;](n&#x2009;=&#x2009;2), Exocad(n&#x2009;=&#x2009;1), and Geomagic(n&#x2009;=&#x2009;1). Titanium implants were used, milled(N&#x2009;=&#x2009;1), and 3D printed(N&#x2009;=&#x2009;6). CMSDI placement was performed between 6 and 12 months post-surgery in 93.47% (43/46). Abutments were cement retained(n&#x2009;=&#x2009;41) and screw-retained(n&#x2009;=&#x2009;5). Rehabilitation was performed immediately(n&#x2009;=&#x2009;20), <&#x2009;1 month(n&#x2009;=&#x2009;2), 1 to 4 months(n&#x2009;=&#x2009;22), and after 4 months(n&#x2009;=&#x2009;1). The overall complication rate was 26.08%(12/46), and complications were prosthetic-related (66.66%,8/12), surgical (25%, n&#x2009;=&#x2009;3), and implant-related (8.33%, n&#x2009;=&#x2009;1). Follow-up duration ranged from three to 12 months.<br><br>CONCLUSION: CMSDIs demonstrate potential as a reconstructive option for PCROM defects, with a complication rate of 26.08%, predominantly prosthetic-related. However, the evidence remains preliminary, derived exclusively from case reports and case series with short follow-up and restricted to Indian populations, limiting generalizability. Well-designed multi-center prospective trials are urgently required to validate long-term effectiveness and comparative advantages of CMSDIs.<br><br>TRIAL REGISTRATION: Prospero No: CRD420251022490.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s12663-026-03111-8.},
}
@article {pmid42824417,
year = {2026},
author = {Akbarzadeh, A and Razeghian, M and Hajiabadi, F and Dehghan, P and Ahmadi-Mazhin, S and Eshaghzadeh, M and Poursadeqiyan, M and Shabestan, R},
title = {Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies.},
journal = {Health science reports},
volume = {9},
number = {10},
pages = {e73316},
pmid = {42824417},
issn = {2398-8835},
abstract = {BACKGROUND AND AIM: Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients with COVID-19.<br><br>METHODS: A systematic search was performed across the Cochrane Library, Web of Science, PubMed, and medRxiv from inception to July 2024. Data from the identified studies were analyzed using Comprehensive Meta-Analysis (CMA) software.<br><br>RESULTS: Thirteen studies involving 4583 patients were included in the final analysis. Compared with remdesivir, Paxlovid was associated with a significant reduction in mortality (odds ratio [OR]&#x2009;=&#x2009;0.36, 95% confidence interval [CI]: 0.18-0.73), time to SARS-CoV-2 negative conversion (standardized mean differences [SMD] = -1.44, 95% CI: -1.54 to -1.33), hospitalization (OR&#x2009;=&#x2009;0.34, 95% CI: 0.16-0.74), intensive care unit admission (OR&#x2009;=&#x2009;0.10, 95% CI: 0.01-0.53), and the need for oxygen therapy (OR&#x2009;=&#x2009;0.06, 95% CI: 0.02-0.16). No statistically significant difference was observed between the two treatments regarding polymerase chain reaction negativity rate (OR&#x2009;=&#x2009;1.45, 95% CI: 0.73-2.86). However, adverse events were higher among patients receiving Paxlovid (OR&#x2009;=&#x2009;6.60, 95% CI: 3.24-13.42). The certainty of evidence for the evaluated outcomes ranged from low to moderate.<br><br>CONCLUSION: In patients with COVID-19, Paxlovid may offer potential benefits over remdesivir for certain clinical outcomes, though it may also be accompanied by a higher rate of adverse events. These findings are based on retrospective studies, which carry risks of selection bias, confounding, and heterogeneity.},
}
@article {pmid42594440,
year = {2027},
author = {Li, L and Liu, F and He, X and Yuan, D and Hao, S and Wang, L and Li, X and Mao, B},
title = {Recent advances in lateral flow immunoassay for virus detection: current achievements, challenges and future prospects.},
journal = {Talanta},
volume = {312},
number = {Pt B},
pages = {130402},
doi = {10.1016/j.talanta.2026.130402},
pmid = {42594440},
issn = {1873-3573},
mesh = {Immunoassay/methods/trends ; Humans ; Rapid Diagnostic Tests ; Point-of-Care Testing ; *Viruses/isolation &amp; purification ; *COVID-19/diagnosis ; },
abstract = {Infectious diseases continue to pose significant global public health challenges, highlighting the urgent need for rapid, accessible, and scalable diagnostic strategies. Lateral flow immunoassay (LFIA), characterized by its rapid response, low cost, and instrument-free operation, has been widely adopted for infectious disease detection. However, it is still predominantly regarded as a point-of-care testing (POCT) tool, while its broader role in public health systems remains underappreciated. In this review, LFIA is repositioned as a point-of-need (PoN) self-testing platform with the potential to enable large-scale screening, which is critical for epidemic surveillance and pandemic preparedness. We systematically summarize recent advances in LFIA from three key perspectives: (i) signal generation and transduction strategies based on diverse nanomaterials, including colorimetric, fluorescent, magnetic, SERS, and photothermal systems; (ii) multimodal and multiplex detection approaches for improving sensitivity, accuracy, and throughput; and (iii) the integration of machine learning (ML) for signal interpretation and system optimization. In addition, we comprehensively review the applications of LFIA in detecting viral antigens, antibodies, and nucleic acids. Finally, the current limitations of LFIA, including sensitivity constraints, target specificity, and practical challenges related to cost, usability, and stability, are critically discussed. Future development directions are proposed, emphasizing advanced nanomaterials, intelligent data processing, and multi-target detection strategies. Overall, this review highlights the transformative potential of LFIA, particularly colorimetric LFIA, as an emergency pandemic screening tool, as well as its growing significance in routine decentralized testing and strengthening global public health preparedness.},
}
@article {pmid42816812,
year = {2026},
author = {Krishnan, H and Gadikota, P and Gue, S and Wallen, M},
title = {Global research trends in violence against emergency department healthcare workers.},
journal = {International journal of emergency medicine},
volume = {19},
number = {1},
pages = {},
pmid = {42816812},
issn = {1865-1372},
abstract = {BACKGROUND: Violence in emergency departments (EDs) threatens healthcare worker safety, workforce well-being, and the quality of patient care. This study characterized the growth, geographic distribution, influential contributors, and thematic evolution of research addressing violence in ED settings, with particular emphasis on healthcare workers.<br><br>METHODS: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on June 16, 2026, and included publications from 1984 to 2026. Records were analyzed descriptively and mapped with VOSviewer to examine publication output, subject categories, journals, authors, countries, co-authorship patterns, keyword co-occurrence, and highly cited publications. Reporting was guided by the BIBLIO recommendations.<br><br>RESULTS: The search identified 1,074 publications. Annual output increased substantially after 2020 and peaked at 113 publications in 2025. Nursing and emergency medicine were the leading subject categories, and the Journal of Emergency Nursing was the most productive journal. The United States contributed 498 publications, followed by Australia and China. Gloria Gillespie was the most productive author. Network analyses demonstrated a dense workplace-violence and healthcare-worker-safety core alongside partially distinct clusters related to behavioral health, substance use, intimate partner violence, agitation management, and COVID-19. Collaboration between major thematic communities appeared limited.<br><br>CONCLUSIONS: Research on violence in ED settings has expanded rapidly, particularly since the COVID-19 pandemic. The literature remains concentrated in high-income countries and is dominated by descriptive and prevalence-focused work. Future research should prioritize multicenter intervention studies, implementation science, cross-disciplinary collaboration, and greater representation of low- and middle-income settings.},
}
@article {pmid42819314,
year = {2026},
author = {Penberthy, WT and Vorwaller, CE},
title = {The importance of power in photobiomodulation: a systematic review and meta-analysis of high-intensity laser therapy.},
journal = {Frontiers in integrative neuroscience},
volume = {20},
number = {},
pages = {1914223},
pmid = {42819314},
issn = {1662-5145},
abstract = {INTRODUCTION: Low-level laser therapy (LLLT; ≤ 0.5 W) is guideline-recommended in the United States for shallow-tissue oral mucositis and other superficial pathologies but has generally failed in trials for deeper tissue conditions due to limited penetration and subtherapeutic dosing. By contrast, Class IV high-intensity laser therapy (HILT; ≥ 0.5-80 W), typically at ∼100-fold higher power, has proven successful for many of these deeper tissue indications.<br><br>METHODS: We systematically searched PubMed, Google Scholar, and the Cochrane Database for Class IV HILT trials published from 2018 to April 2026, classifying interventions as effective when they showed large effect sizes (Cohen's d > 0.8).<br><br>RESULTS: Across 105 included studies (n = 2,710 HILT; n = 2,925 controls), no serious adverse events were reported. HILT reduced pain in all randomized trials of knee (k = 27), spine/neuromuscular (k = 20), shoulder/arm (k = 20), and wounds (k = 2), with > 90% showing large effect sizes. Additional benefits were observed in disorders of the feet (k = 13), hand/wrist (k = 8), face/jaw (k = 7), osteoporosis (k = 2), endometriosis, coronary artery disease, cognitive impairment, fibromyalgia, COVID-19, and obesity. HILT yielded durable analgesia, with large VAS pain reductions at end of treatment, < 3-month, and &#x2265; 3-month follow-ups (SMD -0.98, -1.18, and -1.01; k = 50, 19, and 21, respectively). Functional outcomes improved consistently, including range of motion (92%; k = 26), functional performance (84%; k = 57), and quality of life (85%; k = 25). Structural and physiological changes were observed, including increased knee cartilage thickness, reduced rotator cuff tear size, weight loss, and improved nerve conduction. Comparative trials showed HILT produced greater pain reduction than LLLT in 13/13 studies, all with large effect sizes. Mean HILT power was 9.3 W (median 10.0; range 0.5-30), and mean power density was 19.5 W/cm[2] (median 10; range 0.1-52.5).<br><br>CONCLUSION: Class IV high-intensity laser therapy appears effective and safe for durable pain reduction across deep-tissue musculoskeletal pathologies, supporting its recognition in clinical practice and coverage by payers as a valuable therapeutic option. Further multicenter trials are needed to refine treatment protocols.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251021772, identifier CRD420251021772.},
}
@article {pmid42819921,
year = {2026},
author = {Wang, N and Lan, X and Zhong, J and Fan, X and Xing, Y and Dang, S and Wang, Z},
title = {Persistent socio-demographic inequalities in depression among older adults in China during and after COVID-19: a systematic review and meta-analysis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1929179},
pmid = {42819921},
issn = {2296-2565},
mesh = {Humans ; China/epidemiology ; *COVID-19/epidemiology/psychology ; *Depression/epidemiology ; Socioeconomic Disparities in Health ; Aged ; Female ; Prevalence ; Socioeconomic Factors ; Middle Aged ; Male ; },
abstract = {OBJECTIVE: To examine socio-demographic inequalities in depressive symptoms among older adults in China during and after the COVID-19 pandemic and assess whether these inequalities remained stable or changed over time.<br><br>METHODOLOGY: This systematic review and meta-analysis followed PRISMA guidelines. Nine English and Chinese databases were searched from 1 January 2020 to 15 June 2026. Eligible studies were conducted among community-dwelling adults aged &#x2265;60&#x202f;years in mainland China, used probability sampling and standardized measures of depressive symptoms, and reported cross-sectional data. Study quality was assessed using the 11-item Agency for Healthcare Research and Quality checklist. Potential publication bias was assessed using Begg's and Egger's tests and trim-and-fill analysis. Year-stratified prevalence and pooled odds ratios (ORs) were estimated for disparities by gender, marital status, urban-rural residence, living arrangement and educational attainment.<br><br>RESULTS: Seventy-nine studies involving 199,116 older adults from 21 provincial-level regions were included; 52 studies were rated as high quality and 27 as moderate quality, with none rated as low quality. Pooled prevalence fluctuated across investigation years, from 16.6% (95% CI 12.1-22.4) in 2022 to 22.9% (95% CI 18.3-28.3) in 2024-2025, with substantial between-study heterogeneity (overall I[2] =&#x202f;99.55%). Higher odds of depressive symptoms were observed among women, unmarried older adults, rural residents, those living alone and those with lower educational attainment. The largest disparities were related to education (OR 1.693, 95% CI 1.388-2.060), living arrangement (OR 1.671, 95% CI 1.437-1.945) and marital status (OR 1.652, 95% CI 1.467-1.860). Year-level analyses suggested limited temporal variation overall: marital-status-related inequality showed a small upward trend, whereas living-arrangement-related inequality showed a non-significant tendency toward attenuation. No broad systematic restructuring was observed.<br><br>CONCLUSION: Depressive symptoms among older adults in China fluctuated across the pandemic and post-pandemic periods, while socio-demographic inequalities remained broadly stable. Major public health disruption appeared more likely to expose and prolong pre-existing inequalities than fundamentally reshape them in the short term. These findings provide a useful comparative reference for understanding mental health vulnerability in aging societies facing public health emergencies.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD42025642200; identifier: CRD42025642200.},
}
@article {pmid42820600,
year = {2026},
author = {Costa, ARD and Pedrotti, CHS and Accorsi, TAD},
title = {Artificial Intelligence in Telemedicine: philosophical, ethical, and epistemological dimensions of a transforming practice.},
journal = {Einstein (Sao Paulo, Brazil)},
volume = {24},
number = {spe1},
pages = {eAE2371},
doi = {10.31744/einstein_journal/2026AE2371},
pmid = {42820600},
issn = {2317-6385},
mesh = {Humans ; *Artificial Intelligence/ethics ; *Telemedicine/ethics ; COVID-19 ; Pandemics ; SARS-CoV-2 ; *Coronavirus Infections/epidemiology ; *Pneumonia, Viral/epidemiology ; Algorithms ; Betacoronavirus ; Generative Artificial Intelligence ; },
abstract = {In the aftermath of the COVID-19 pandemic, telemedicine has evolved from a contingency-based alternative into a structural pillar of healthcare delivery, increasingly being integrated with artificial intelligence. Algorithms for triage, clinical decision support, remote monitoring, and generative language models now actively participate in medical care. This integration is more than just functional; it reorganizes the foundational aspects of medicine-ontological, ethical, and epistemological-by redefining what qualifies as valid knowledge, who has legitimate authority, and how care is organized when an algorithmic agent facilitates the clinical interaction. This article critically examines the emergence of the patient-clinician-algorithm triad in telemedicine, and analyzes its implications for autonomy, informed consent, epistemic trust, privacy, justice, responsibility, and the phenomenology of care. It argues that the future of medicine will not be human or algorithmic but human-algorithmic, provided clinical judgment, explainability, and moral responsibility remain central.},
}
@article {pmid42820844,
year = {2026},
author = {Tunney, E and Kane, D and Geary, M},
title = {When doctors falter: Resilience in modern obstetrics and gynecology, a narrative review.},
journal = {International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics},
volume = {175},
number = {1},
pages = {86-92},
pmid = {42820844},
issn = {1879-3479},
support = {//NA/ ; },
mesh = {Obstetrics/trends ; Gynecology/trends ; Humans ; *Burnout, Professional/epidemiology/psychology ; *Gynecologists/psychology/supply &amp; distribution ; *Obstetricians/psychology/supply &amp; distribution ; *Resilience, Psychological ; Working Conditions/psychology ; },
abstract = {The practice of obstetrics and gynecology (O&amp;G) is frequently regarded as one of the most demanding medical specialties, with physicians being called to duty at any hour of the day or night, with acute patient demands requiring prompt management. Consequently, high levels of physician burnout and psychological distress have been reported among O&amp;G healthcare professionals, with these challenges further compounded by the COVID-19 pandemic. Despite the prevalence of mental health difficulties, many healthcare professionals do not seek out professional intervention and support. Within O&amp;G, trainees appear vulnerable, with studies reporting significant rates of stress, anxiety, depression, and burnout. These mental health challenges contribute to reduced job satisfaction, increased intentions to leave specialist training programs, and growing concerns regarding physician attrition and workforce retention. In this context, physician resilience (i.e., the ability to excel in the face of adversity) emerges as an area worthy of exploration. This narrative review explores the multifaceted emotional and practical elements of physician resilience and grit in contemporary obstetrics and gynecology practice. A comprehensive literature search was conducted using PubMed and the Royal College of Surgeons in Ireland library database, employing terms related to physician wellbeing, burnout and interventions specifically related to obstetrics and gynecology. Inclusion criteria were limited to full text, English-language articles published within the past 10 years to ensure relevance to contemporary practice. The review examines the interrelationship between physician burnout, mental health challenges among O&amp;G trainees, and their impact on attrition rates. We aim to highlight the need for practical interventions at institutional levels with consideration of environmental/workplace factors, which might improve physician wellbeing and grit, strengthen workforce retention, and ultimately optimize patient care.},
}
@article {pmid42822767,
year = {2026},
author = {Jana, S and Hoogenboom, R},
title = {Poly(2-oxazoline)s and poly(2-oxazine)s: An overview of stealth properties, pharmacokinetics, and immunogenicity.},
journal = {Advanced drug delivery reviews},
volume = {},
number = {},
pages = {115975},
doi = {10.1016/j.addr.2026.115975},
pmid = {42822767},
issn = {1872-8294},
abstract = {For over four decades, poly(ethylene glycol) (PEG) has been the undisputed gold standard for conferring stealth properties to nanomedicines and polymer therapeutics. However, the widespread presence of pre-existing anti-PEG antibodies in the general population, which was intensified by recent mRNA COVID-19 vaccination campaigns, has exposed critical immunological liabilities, including accelerated blood clearance, hypersensitivity reactions and reduced therapeutic efficacy. Poly(2-oxazoline)s, particularly poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx), have emerged as promising PEG alternatives. Their hydrolytically stable amide backbone, absence of ether oxygens (key recognition motifs for anti-PEG antibodies), tunable hydrophilicity, chemical versatility, tailor-made properties and excellent antifouling characteristics position them as ideal stealth candidates. This review discusses the progress that has been made on poly(2-oxazoline)s as alternative to PEG by discussing the state-of-the-art in poly(2-oxazoline) stealth/antifouling properties, pharmacokinetics, and immunogenicity, structured by polymer type, namely PMeOx, PEtOx, and other polymers, such as chiral poly(2-oxazoline)s and poly(2-oxazine)s. This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as source of inspiration for future research in the area.},
}
@article {pmid42823699,
year = {2026},
author = {Lewandrowski, LS and Klingelhöfer, D and Brüggmann, D and Groneberg, DA},
title = {Post-traumatic stress disorder: outline and updated insights focusing on occupational factors.},
journal = {Journal of occupational medicine and toxicology (London, England)},
volume = {21},
number = {1},
pages = {},
pmid = {42823699},
issn = {1745-6673},
abstract = {BACKGROUND: Posttraumatic stress disorder (PTSD) is a stress-related disorder associated with substantial psychological distress and functional impairment, and it carries major relevance for occupational health because it frequently follows traumatic exposure in both high-risk professions and occupations not traditionally classified as high risk. This narrative review focuses on occupational risk factors, prevalence, work capacity, and implications for workers' compensation and return to work.<br><br>METHODS: A non-systematic (narrative) literature search was conducted in PubMed/MEDLINE and Google Scholar for English- and German-language articles, with supplementary hand-searching of reference lists and institutional/guideline sources (e.g., WHO, AWMF). No protocol was registered, consistent with conventions for narrative reviews. Reporting follows the general principles of the Scale for the Assessment of Narrative Review Articles (SANRA), the checklist commonly used to appraise this review type, rather than PRISMA, which applies to systematic reviews.<br><br>RESULTS: Occupational risk is particularly elevated in military service (including soldiers and veterans), public safety and disaster management, and occupations with structurally frequent severe incidents (e.g., transport, construction, industrial production), while unpredictable bystander events can also trigger PTSD in occupations not traditionally classified as high risk settings. Risk is shaped by trauma type, severity, and recurrence, as well as pre-traumatic, peri-traumatic, and post-traumatic factors. Prevalence varies substantially by context and is not directly comparable across studies, which differ markedly in population, exposure severity, diagnostic method, and assessment period. With this caveat, particularly high burden is reported in conflict-affected populations, healthcare workers during the COVID-19 pandemic, and trauma-exposed occupational groups such as military personnel, police officers, paramedics, train drivers, construction workers and industrial workers. Established treatments (trauma-focused psychotherapy, with pharmacotherapy as an adjunct) are distinct from early post-event interventions such as screening and Psychological First Aid, which aim to prevent chronicity rather than treat established illness. Routine single-session debriefing is not supported by the evidence. Occupational medicine must also address work capacity, return to work, compensation, and rehabilitation, since symptomatic improvement does not necessarily restore functional ability.<br><br>CONCLUSION: Stronger workplace prevention, early screening after traumatic exposure, organizational support, and clearer compensation and return-to-work pathways are needed to reduce the long-term occupational consequences of PTSD. Evidence specifically comparing treatment of occupational versus non-occupational PTSD remains limited, and prevalence estimates should be interpreted in light of substantial heterogeneity across the underlying studies.},
}
@article {pmid42823741,
year = {2026},
author = {Siebner, AS and Rubio-Casillas, A and Raszek, M and Cowley, D and Fabrowski, M and Piscopo, M and Brogna, C and Uversky, VN and Redwan, EM and Genova, SN},
title = {Beyond correlation and causation: epistemic caution, anomalous findings, and COVID-19 vaccine safety.},
journal = {Philosophy, ethics, and humanities in medicine : PEHM},
volume = {21},
number = {1},
pages = {},
pmid = {42823741},
issn = {1747-5341},
mesh = {Humans ; *COVID-19 Vaccines/adverse effects ; *COVID-19/prevention &amp; control ; *Causality ; BNT162 Vaccine/adverse effects ; },
abstract = {The COVID-19 pandemic exposed science's adaptive strengths and epistemic limits. In fact, in the pandemic, mRNA vaccines are attributed to have saved millions of lives. The maxim "correlation does not imply causation" is an essential safeguard against premature causal inference. However, its use may become epistemically restrictive when the absence of established causality is treated as sufficient reason not to investigate (severe) vaccine adverse events. This article examines the conditions under which a valid cautionary principle may have contributed to premature epistemic closure. Thomas Kuhn's theory of scientific paradigms is used as one interpretative lens rather than as an empirical explanation of institutional behaviour. We argue that the correlation-causation distinction can shift from a heuristic of caution to an instrument of epistemic conservatism, reinforcing prevailing frameworks and discouraging exploration of anomalies. A published autopsy case report involving multifocal necrotizing encephalitis and myocarditis after BNT162b2 vaccination is examined as an illustrative and hypothesis-generating case, not as representative evidence of systematic institutional conduct. A qualitative approach using Bradford Hill's criteria provides partial, inconclusive evidence of a causal relationship while also exposing the methodological limits of the tool employed. The results of the analysis showed that one of the nine criteria demonstrated support of causality, seven were partially supported, and one did not support causality. The analysis suggests, but does not prove, a causal relationship between the BNT162b2 vaccine and multifocal necrotizing encephalitis. The absence of the nucleocapsid protein does not provide definitive evidence to demonstrate a vaccine origin. Analytical methods are described which can distinguish between the wild-type SARS-CoV-2 spike protein and the recombinant spike protein expressed following mRNA vaccination. The absence of evidence does not mean evidence of absence and we must keep an open mind to this when reviewing such evidence on causality.},
}
@article {pmid42748381,
year = {2026},
author = {Philips, EA and Stream, S and Pillinger, MH and Samuels, J},
title = {Cytokine panels in the treatment and diagnosis of rheumatic diseases: current practices and future promise.},
journal = {Bulletin of the Hospital for Joint Disease (2013)},
volume = {84},
number = {3},
pages = {117-120},
pmid = {42748381},
issn = {2328-5273},
mesh = {Humans ; *Cytokines/blood ; COVID-19 ; *Rheumatic Diseases/diagnosis/blood/immunology/therapy ; Biomarkers/blood ; Pandemics ; SARS-CoV-2 ; *Coronavirus Infections/epidemiology/immunology/diagnosis/blood ; *Pneumonia, Viral/epidemiology/immunology/diagnosis/blood ; *Betacoronavirus ; Predictive Value of Tests ; },
abstract = {Cytokine panels measure plasma levels of a set of soluble cell-effector biomarkers and are designed to provide a snapshot of the inflammatory milieu present in a patient at the time of sampling. During the uncertainty of the COVID-19 pandemic, patients demonstrated an inflammatory response with unequivocal marked cytokine storm. Thus, physicians and investigators ordered a superfluity of cytokine panels to gain mechanistic understanding of the pathology driven by the deadly viral infection. Although cases of COVID-19 have since waned, physicians continue to send cytokine panels with evolving evidence-based indications to evaluate other inflammatory syndromes. Cytokine panels hold diagnostic utility and promise, but more research is needed to determine the extent to which these panels can be used and the clinical contexts in which they can improve diagnostic and management capabilities.},
}
@article {pmid42811620,
year = {2026},
author = {de la Cruz-Potenciano, &#xc1; and Maldonado, M and Camarasa, MJ and de Castro, S},
title = {Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins.},
journal = {ChemMedChem},
volume = {21},
number = {19},
pages = {e70507},
pmid = {42811620},
issn = {1860-7187},
support = {SAF2015-64629-C2-1R//Ministerio de Ciencia e Innovaci&#xf3;n/ ; PID2019-104070RB-C21//Ministerio de Ciencia e Innovaci&#xf3;n/ ; SAF2009-13914-C02//Ministerio de Econom&#xed;a y Competitividad/ ; SAF2012-39760-C02//Ministerio de Econom&#xed;a y Competitividad/ ; PID2022-136307OB-C21//MICIU/ ; PLATESA2-CM S2018/BAA-4370//Comunidad de Madrid/ ; BIPPED-CM S-BIO-0214-2006//Comunidad de Madrid/ ; BIPPED-2 S2010/BMD-2457//Comunidad de Madrid/ ; PIE 201280E093//Consejo Superior de Investigaciones Cient&#xed;ficas/ ; PIE-201980E028//Consejo Superior de Investigaciones Cient&#xed;ficas/ ; PIE201980E028//Consejo Superior de Investigaciones Cient&#xed;ficas/ ; },
mesh = {*Antiviral Agents/pharmacology/chemistry ; Humans ; *Coronavirus/drug effects ; *Viral Proteins/antagonists &amp; inhibitors/metabolism ; },
abstract = {Human coronaviruses include both endemic respiratory pathogens and highly pathogenic viruses with pandemic potential, underscoring the need for antiviral agents with activity beyond single viral species. This review focuses on selected, representative antiviral inhibitors directed against viral proteins of human coronaviruses. Accordingly, the review examines representative inhibitors targeting viral proteins essential for coronavirus infection and propagation. The discussion includes inhibitors acting at different functional levels of the viral life cycle, such as entry, genome replication, RNA processing and particle assembly, and reflects the range of molecular entities reported to date. By organizing known inhibitors according to their viral protein targets, this review provides an integrated overview of current antiviral candidates and illustrates the central role of viral proteins as points of intervention. Overall, the review aims to consolidate existing knowledge on antiviral inhibitors across human coronaviruses, offering a coherent framework for appreciating their scope and diversity.},
}
@article {pmid42811656,
year = {2026},
author = {Tao, P and Zang, YA and Wang, J and Cong, F and Liao, M},
title = {Systematic Review and Meta-Analysis of Emerging Viral Zoonotic Diseases, 2016-2026.},
journal = {Transboundary and emerging diseases},
volume = {2026},
number = {1},
pages = {e9884191},
pmid = {42811656},
issn = {1865-1682},
support = {2025A04J0379//Guangzhou Municipal Science and Technology Project/ ; KA26YY15030//Guangdong Provincial Special Project in Key Fields for General Higher Education Institutions/ ; KA26YY00106-2026//Zhongkai Scholars Program/ ; },
mesh = {Animals ; Humans ; *Communicable Diseases, Emerging/epidemiology/virology/veterinary ; *Viral Zoonoses/epidemiology/virology ; *Zoonoses/epidemiology/virology ; },
abstract = {Emerging viral zoonoses-infections caused by viruses that cross the species barrier from animal reservoirs into human populations-account for the majority of emerging infectious disease (EID) events and now constitute a defining threat to global health security. Over the past decade the tempo of these spillovers has increased, propelled by land-use change, agricultural intensification, wildlife trade, and climate change, while reverse zoonosis-the transmission of human pathogens back into animal populations-has created novel animal reservoirs capable of seeding future outbreaks. Against this backdrop, we systematically reviewed and meta-analyzed epidemiological evidence on emerging viral zoonoses from January 2016 through June 2026, searching five bibliographic databases and synthesizing 312 included studies. Annual high-consequence spillover events increased by 4.98% (95% CI 3.22%-6.76%), and the decade saw five Public Health Emergency of International Concern (PHEIC) declarations, alongside other high-consequence spillovers such as the 2026 Bundibugyo virus outbreak (case fatality rate [CFR] 30.9%) and the expansion of H5N1 highly pathogenic avian influenza into dairy cattle. Bat-origin viruses exhibited the highest pooled CFR (29.86%), whereas primate-origin viruses demonstrated greater transmissibility, supporting a virulence-transmissibility trade-off. Land-use change emerged as the dominant anthropogenic driver, increasing zoonotic host diversity by 18%-72%. White-tailed deer SARS-CoV-2 seroprevalence reached 32.7% (95% CI 21.4%-46.1%), with confirmed deer-to-human spillback. Nonpharmaceutical interventions (NPIs) collectively reduced the effective reproduction number by up to 82%, and prevention-oriented One Health strategies yielded returns exceeding 1100% on investment. Viral zoonoses are accelerating under anthropogenic pressure, and upstream prevention with integrated One Health surveillance represents the most cost-effective pandemic preparedness strategy.},
}
@article {pmid42811997,
year = {2026},
author = {Ma, J and Wang, K and Li, G and Wang, F},
title = {Mechanisms of Complement Activation and NETosis Interplay in Early Pregnancy Loss: From Autoimmunity to Thrombogenesis.},
journal = {Frontiers in bioscience (Landmark edition)},
volume = {31},
number = {9},
pages = {49518},
doi = {10.31083/FBL49518},
pmid = {42811997},
issn = {2768-6698},
support = {YJS-BD-19//Science Foundation of Lanzhou University Second Hospital/ ; },
mesh = {Humans ; *Extracellular Traps/immunology ; Female ; *Complement Activation/immunology ; Pregnancy ; *Autoimmunity/immunology ; *Abortion, Spontaneous/immunology ; *Thrombosis/immunology ; Animals ; },
abstract = {Early Pregnancy Loss (EPL) represents a formidable challenge in reproductive medicine. Its complex pathophysiology is primarily characterized by dysregulation of both the immune and coagulation systems. In recent years, abnormal activation of the complement system and neutrophil extracellular trap formation (NETosis) have received increasing scientific attention as key molecular events underlying EPL. This interest is fueled significantly by compelling evidence from non-pregnant models, such as antiphospholipid syndrome (APS) and severe infections (e.g., COVID-19), which demonstrate a pathogenic synergy between complement and NETosis in thrombo-inflammatory pathways. Dysregulation of the complement system can trigger strong inflammatory responses and promote a prothrombotic state. Similarly, excessive NETosis acts as a significant driver of tissue damage and thrombosis. This review aims to systematically delineate the complex crosstalk between complement activation and NETosis in EPL, with particular emphasis on their bidirectional regulatory relationship within autoimmune and thrombo-inflammatory pathways. By thoroughly analyzing the critical pathological role of this "complement-NETosis axis" in disrupting uteroplacental interface homeostasis and ultimately causing pregnancy failure, this review not only presents an integrative conceptual framework for comprehensively understanding the molecular mechanisms of EPL, but, more importantly, proposes a novel hypothesis, based on mechanistic insights derived from non-pregnant models, that this axis may play acentral role in EPL. This perspective provides a framework for future research, encompassing the validation of associated potential biomarkers and the exploration of targeted intervention strategies, thereby holding promise for advancing precise clinical intervention paradigms for specific EPL subtypes.},
}
@article {pmid42812460,
year = {2026},
author = {Korkmaz, MF and Terzi, HZ and Özdel, ZGE and Özay, HB and Boran, P},
title = {Prevalence of sleep disorders in Turkish children and adolescents: a national systematic review and meta-analysis.},
journal = {Sleep and biological rhythms},
volume = {24},
number = {4},
pages = {439-450},
pmid = {42812460},
issn = {1446-9235},
abstract = {PURPOSE: The prevalence of sleep disturbances in children is recognized as far higher than previously estimated. Furthermore, data previously collected in Türkiye have not been thoroughly consolidated, and there are notable variations across research reporting prevalence rates. This meta-analysis seeks to assess the general prevalence of sleep disturbances among children and adolescents in Türkiye and to identify factors that may contribute to potential heterogeneity.<br><br>METHODS: The meta-analysis was performed as a systematic review adhering to PRISMA guidelines and PROSPERO registration. Studies were performed in international platforms (PubMed, Scopus, Web of Science) and local academic portals (TR Index, T&#xfc;rkiye At&#x131;f Endeksi) including research published till September 2025. The study included all relevant observational studies performed in T&#xfc;rkiye that involved children or adolescents and evaluated sleep disorders utilizing validated scales.<br><br>RESULTS: Fourteen studies that satisfied the inclusion criteria for the systematic review were analyzed, and ten studies including a total of 11,665 participants were included in the final meta-analysis. The combined prevalence of sleep disorders was 51.6% (95% CI: 34.8-68.3). Significant heterogeneity was observed among the studies (I[2]&#x2009;=&#x2009;99.3%, p&#x2009;<&#x2009;0.001). In subgroup analyzes, differences in prevalence estimates were observed according to age group, study period, and type of measurement tool; however, these variables did not fully explain the heterogeneity in the meta-regression model. Higher prevalence estimates were observed particularly in adolescent populations, during the COVID-19/post-pandemic period, and in studies using self-report instruments.<br><br>CONCLUSION: Sleep-related problems among Turkish children and adolescents may represent an important and underrecognized public health concern. Prevalence estimates varied across age groups, assessment methods, and study periods, although these factors did not fully explain the observed heterogeneity. These findings highlight the importance of integrating culturally appropriate screening tools into routine pediatric practice to facilitate early identification and intervention.<br><br>REGISTRATION: PROSPERO (CRD420251129775).},
}
@article {pmid42812549,
year = {2026},
author = {Yao, Y},
title = {Teacher resilience and adaptation in digital teaching contexts: a systematic review of research trends, psychological constructs, and evidence gaps.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1950412},
pmid = {42812549},
issn = {1664-1078},
abstract = {UNLABELLED: Digital teaching expanded rapidly during the COVID-19 emergency and continues through hybrid, robot-mediated, metaverse, and artificial-intelligence-supported education. Yet evidence about teacher resilience and adaptation remains conceptually and methodologically dispersed. This PRISMA 2020-guided systematic review mapped how resilience and adaptation are conceptualized, which psychological constructs and indirect statistical pathways have been studied, and where important evidence gaps remain. Web of Science and Scopus records exported on 21 and 23 February 2026 yielded 4,465 records; 27 English-language empirical studies were included after duplicate removal, screening, retrieval, and full-text eligibility assessment. Data were extracted into a structured matrix, synthesized descriptively and thematically, and appraised with the Mixed Methods Appraisal Tool (MMAT) 2018. The corpus comprised 11 qualitative, 9 quantitative non-randomized, 5 mixed-methods, and 2 quantitative descriptive studies, involving at least 11,199 teachers or teacher educators. Twenty-one studies concerned COVID-19/emergency remote teaching and six examined emerging technologies. Six non-mutually-exclusive themes were identified: personal psychological resources and coping (22/27), pedagogical adaptation, agency, and innovation (21/27), digital competence, self-efficacy, and readiness (19/27), contextual and structural constraints (18/27), wellbeing-related outcomes (16/27), and social or institutional support (13/27). Seven studies tested indirect effects, but all used cross-sectional quantitative components; none formally tested contextual moderation or evaluated an intervention. MMAT findings supported qualitative coherence while highlighting confounding, representativeness, nonresponse, and weakest-component limitations in quantitative and mixed-methods evidence. The evidence therefore supports a context-embedded descriptive account of resilience and adaptation. Future research should prioritize longitudinal, intervention, and explicitly technology-specific designs.<br><br>https://osf.io/xf2ve/overview, xf2ve.},
}
@article {pmid42812866,
year = {2026},
author = {Price, I and Smith, PK and Tan, A and Suarez-Rocha, A and Baig, M and Athouriste, Z and Aziz, C and Razzaque, N and Sadik, S and Breeland, S and Gilbert, B and De Gaetano, JS},
title = {Measles Vaccine Boosters in Immunocompromised Adults to Reduce Morbidity and Mortality From Acute Measles Infection: A Scoping Review.},
journal = {Cureus},
volume = {18},
number = {8},
pages = {e115440},
pmid = {42812866},
issn = {2168-8184},
abstract = {Measles is a highly contagious viral illness associated with significant global mortality, despite the availability of an effective vaccine. As vaccine hesitancy continues to increase following the COVID-19 pandemic, combined with a lack of measles-specific antiviral agents, the risk of outbreaks and epidemics remains elevated. Immunocompromised individuals have a higher risk of serious complications from measles, especially because the live-attenuated measles, mumps, and rubella vaccine may be contraindicated in severely immunocompromised patients. As such, these individuals depend on herd immunity. This scoping review aims to identify the potential need for a measles booster dose among immunocompromised adults in the United States by providing an overview of current vaccine indications and outcomes. EMBASE, Web of Science, and Ovid MEDLINE were searched using search terms specific to measles booster doses and immunocompromised adults. In total, 2,335 articles were imported to Rayyan, and after a two-tiered review, seven articles met the full inclusion criteria. The results revealed that individuals with chronic immunocompromising illnesses were often not fully protected against measles, leaving them vulnerable to infection. The findings from this review suggest that clinicians may consider a booster dose of vaccine for immunocompromised individuals to help restore their protection against measles. Meanwhile, further research utilizing larger sample sizes and diverse patient populations is warranted based on these findings. We believe that additional studies should aim to clarify current guidelines to improve the care of immunocompromised patients who may be exposed to measles.},
}
@article {pmid42813072,
year = {2026},
author = {Carrero, AM and Agredo, JF and Martínez Ruiz, LC and González, JA},
title = {Telepsychology and digital mental health communication: an exploratory mixed-methods study of tikTok content.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1900544},
pmid = {42813072},
issn = {2673-253X},
abstract = {BACKGROUND: Telepsychology consolidated as a mainstream mental health care modality following the COVID-19 pandemic, supported by evidence of clinical efficacy comparable to in-person therapy and a recognized potential to democratize access to care. Against this evolving clinical landscape, social media platforms have simultaneously emerged as major environments for the public circulation of psychological knowledge.<br><br>OBJECTIVE: To explore the relationship between scientific evidence on telepsychology and its discursive representation in highly viewed Spanish-language TikTok content, and to identify implications for digital mental health literacy and professional communication practices.<br><br>METHODS: An exploratory mixed-methods design with qualitative emphasis integrated a scoping review (PRISMA-ScR) across Scopus, Web of Science, and PubMed (2020-2025; n&#x2009;=&#x2009;39 articles) and an inductive thematic analysis of TikTok content (N&#x2009;=&#x2009;50 videos; 1,286,360 total views). Searches were conducted from a newly created TikTok account with no prior interaction history, configured in Colombia, to reduce algorithmic personalization bias. Three exploratory corpus-descriptive indicators-the Telepsychology Gap Index (TGI), Digital Telepsychology Legitimacy Index (DTLI), and Simplified Circulation Index (SCI)-were computed as heuristic comparators.<br><br>RESULTS: The scientific literature consistently supported the clinical viability and democratizing potential of telepsychology. Within the TikTok corpus, 64% of content featured simplified definitions or subjectivist experiential narratives with minimal reference to ethical or regulatory frameworks. Corpus-descriptive indicators revealed a substantial gap between scientific representation and digital circulation (TGI&#x2009;=&#x2009;0.80), limited presence of clinical foundations in digital discourse (DTLI&#x2009;=&#x2009;0.36), and a predominance of simplified over technically grounded content (SCI&#x2009;=&#x2009;1.78).<br><br>CONCLUSIONS: Within the analyzed corpus, telepsychology undergoes a process of digital discursive reinterpretation in which communicative accessibility and immediate subjective experience displace clinical precision as central evaluative criteria. These findings underscore the need to strengthen digital mental health literacy and professionals' evidence-based communication skills online. Given the exploratory design, findings are specific to a non-probabilistic Spanish-language TikTok corpus and are not generalizable prevalence estimates. Future research should extend this agenda through larger multilingual samples, additional platforms, computational social science approaches, and longitudinal designs examining how digital representations of telepsychology shape users' expectations and engagement with digital mental health care.},
}
@article {pmid42815505,
year = {2026},
author = {El-Kafrawy, SA and El-Daly, MM and El-Kafrawy, MS and Azhar, EI},
title = {MERS-CoV in Africa: a One Health review of the silent reservoir.},
journal = {The Lancet. Microbe},
volume = {},
number = {},
pages = {101530},
doi = {10.1016/j.lanmic.2026.101530},
pmid = {42815505},
issn = {2666-5247},
abstract = {Africa harbours more than 80% of the world's dromedary camels, with a pooled MERS-CoV seroprevalence of 73·7%; however, no autochthonous outbreak in humans has been documented. In this Review, we weigh five interacting explanations for the absence of documented human outbreaks based on the strength of the evidence for each explanation. The primary explanation is virological; many, although not all, African clade C MERS-CoV strains show reduced replication competence in human respiratory tissues, and clade C strains have not become established in Arabian camels or humans despite decades of large-scale export from the Horn of Africa into the world's most intensively monitored MERS-CoV surveillance system. Environmental contexts, including dry-season herd aggregation, drought, and calving-linked shedding, influence when MERS-CoV exposure occurs in humans. Surveillance limitations, dispersed exposure among the African population particularly pastoralists, lower comorbidity burden than that in affected populations in the Arabian regions, and absent nosocomial amplification are secondary explanations, largely downstream of the primary factors. Although longitudinal cohort studies using enhanced diagnostics detected sporadic spillover in Africa, these infections were asymptomatic. The presence of clade B strains and interclade B×C recombinants in Egyptian camels are surveillance priorities and not evidence of MERS-CoV emergence in humans. Africa's silent reservoir is therefore not a safe one: continued clade C circulation, alongside emerging clade B introductions and interclade recombinants, could shift this balance, underscoring the need for sustained genomic and human surveillance of the reservoir.},
}
@article {pmid42815744,
year = {2026},
author = {Youssef, P and Broussous, F},
title = {Cardiac Paroxysmal Orthodeoxia Syndrome: A comprehensive process of this challenging disease starting from the clinical suspicion till the therapeutic procedure.},
journal = {Current problems in cardiology},
volume = {},
number = {},
pages = {103475},
doi = {10.1016/j.cpcardiol.2026.103475},
pmid = {42815744},
issn = {1535-6280},
abstract = {BACKGROUND: The platypnea-orthodeoxia syndrome is a rare disorder characterized by both dyspnea and arterial desaturation in the upright position that is relieved by returning to a recumbent position. In addition to PFO (as discussed in our case) and other interatrial defects, this syndrome has also been described with intrapulmonary shunting and with disorders such as pericardial effusion, constrictive pericarditis, emphysema, amiodarone pulmonary toxicity, pneumonectomy, and cirrhosis.<br><br>METHODS: We describe a case of platypnea-orthodeoxia syndrome (POS) due to patent foramen ovale (PFO) occurring during the preoperative evaluation of an elderly patient who presented to the emergency department for a femoral neck fracture. Initial evaluation was shifted to a pulmonary embolism or COVID-19 infection that were excluded by a chest CT with IV contrast and RT-PCR for COVID-19. 12-leads ECG and TTE were unremarkable.<br><br>RESULTS: During hospital stay, the patient complains of positional dyspnoea that develops upon sitting up, accompanied with refractory hypoxaemia that reverts on recumbent position. Following a high clinical suspicion of POS, a bubble contrast echocardiogram was performed and showed important patent foramen ovale (PFO) highlighted by an abundant passage of contrast from the right atrium to the left associated with hyperdynamic interatrial septum. An urgent percutaneous closure was performed, and marked improvement of patient's symptoms has been noted since then.<br><br>CONCLUSION: The diagnosis of POS has been challenging especially during the current pandemic. Our case emphasizes on the importance of a detailed history and physical exam, the role of multimodality imaging techniques to diagnose POS and the high success rate of percutaneous methods for PFO closure.},
}
@article {pmid42815830,
year = {2026},
author = {Yang, R and Bao, F and Chen, Z and Wu, H and Zhu, L and Bao, RA and Huang, X and Peng, L and Liu, A},
title = {Global Emergence and Expansion of the Beijing Lineage of Mycobacterium tuberculosis: A Systematic Review and Meta-Analysis.},
journal = {Journal of global antimicrobial resistance},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jgar.2026.09.010},
pmid = {42815830},
issn = {2213-7173},
abstract = {OBJECTIVES: The Beijing Lineage of Mycobacterium tuberculosis is a globally widespread family of strains, notable for its high transmissibility and association with multidrug resistance. Its ongoing expansion threatens global tuberculosis control, necessitating an updated understanding of its prevalence and distribution to guide public health interventions.<br><br>METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines, searching PubMed, Embase, Web of Science, and Scopus for genotyping-based studies on Beijing Lineage prevalence published before December 31, 2024. Pooled prevalence was calculated using a random-effects model. Subgroup analyses were performed by Molecular typing method, WHO region, and time period. Heterogeneity (I&#xb2;) and publication bias were assessed.<br><br>RESULTS: Analysis of 356 studies yielded a global pooled Beijing Lineage prevalence of 41% (95% CI 38%-43%), but this estimate should be interpreted with caution given substantial heterogeneity (I&#xb2;&#x202f;=&#x202f;99.8%) and publication bias.Prevalence varied significantly by WHO region, being highest in the Western Pacific (63%) and lowest in the Eastern Mediterranean (6%). High-resolution genotyping (whole-genome sequencing) reported a higher prevalence (47%) compared to low-resolution methods (31%), suggesting that WGS should be considered the gold standard for accurate detection. A temporal peak of 48% was observed in 2014-2018, declining to 42% in 2019-2024, potentially linked to COVID-19 disruptions. WHO region was the primary source of heterogeneity. Publication bias was present.<br><br>CONCLUSIONS: This systematic evaluation demonstrated a 41% global prevalence of the Beijing lineage of M.tuberculosis with substantial geographical variation and the critical impact of genotyping methodology on prevalence estimates, providing essential evidence for targeted tuberculosis control strategies.},
}
@article {pmid42186818,
year = {2026},
author = {Shimagami, H and Kumanogoh, A and Nishide, M},
title = {Granulocyte heterogeneity in immune-mediated and inflammatory diseases: insights from single-cell transcriptomic analyses.},
journal = {International immunology},
volume = {38},
number = {10},
pages = {585-593},
pmid = {42186818},
issn = {1460-2377},
support = {JP24K11596//Japan Society for the Promotion of Science (JSPS) KAKENHI/ ; JP18H05282//Japan Society for the Promotion of Science (JSPS) KAKENHI/ ; //Takeda Science Foundation/ ; //Japan Science and Technology Agency/ ; //FOREST Program/ ; 24ek0410124//Japan Agency for Medical Research and Development/ ; 25gm7110005//Japan Agency for Medical Research and Development/ ; 223fa627002//Japan Agency for Medical Research and Development/ ; 22gm1810003//Japan Agency for Medical Research and Development/ ; JPMJSP2138//JST SPRING/ ; //The Nippon Foundation/ ; //University of Osaka/ ; },
mesh = {Humans ; Single-Cell Analysis/methods ; Single-Cell Gene Expression Analysis ; *Inflammation/immunology/genetics ; Animals ; *Granulocytes/immunology ; Transcriptome ; COVID-19/immunology/genetics ; Gene Expression Profiling ; Eosinophils/immunology ; SARS-CoV-2/immunology ; },
abstract = {Neutrophils and eosinophils have long been regarded as terminal effectors of innate immunity. Technical advances in single-cell RNA sequencing define transcriptome-based granulocyte subsets beyond classical density- and surface marker-based classifications. These approaches reveal substantial heterogeneity in granulocyte differentiation states, activation programs, and tissue adaptation across human diseases. In microscopic polyangiitis, type II interferon (IFN) pathways shape a pathogenic neutrophil activation state, and serum IFNγ levels at disease onset may serve as a potential biomarker for subsequent relapse. In infectious diseases, including coronavirus disease 2019 (COVID-19) and sepsis, the expansion of immunosuppressive ARG1- and IL1R2-expressing neutrophils is reported in severe disease and may reflect altered immune responses. MMP9-high neutrophils are enriched in cardiovascular disorders and may be linked to thrombosis and ischemic injury. In allergic diseases, spatial and single-cell analyses identify tissue-specific eosinophil states and their interactions with epithelial and macrophage compartments, highlighting context-dependent eosinophil activation within inflamed tissues. Despite emerging evidence for disease-associated granulocyte heterogeneity, whether these populations causally contribute to disease pathophysiology remains largely unclear. Experimentally validated functions and clinically applicable surrogate markers, such as surface markers or circulating proteins, are still needed. This review summarizes recent advances and current limitations in understanding granulocyte heterogeneity across immune-mediated and inflammatory diseases and discusses how integrative single-cell approaches may support the development of clinically relevant biomarkers and targeted therapeutic strategies.},
}
@article {pmid42681987,
year = {2026},
author = {Stoppe, C and Gundogan, K and Marelli, S},
title = {Micronutrients in adult critically ill patients: lessons learned and the path toward precision.},
journal = {Current opinion in clinical nutrition and metabolic care},
volume = {29},
number = {6},
pages = {510-518},
pmid = {42681987},
issn = {1473-6519},
mesh = {Humans ; *Critical Illness/therapy ; *Micronutrients/administration &amp; dosage/therapeutic use/deficiency ; *Dietary Supplements ; *Precision Medicine/methods ; Biomarkers/blood ; Trace Elements/deficiency ; Sepsis ; Carnitine/deficiency ; Ascorbic Acid/administration &amp; dosage ; COVID-19/therapy ; Vitamin D/administration &amp; dosage/therapeutic use ; Selenium/administration &amp; dosage ; Thiamine/administration &amp; dosage ; },
abstract = {PURPOSE OF REVIEW: Despite strong biological plausibility, empiric high-dose micronutrient supplementation has failed to improve outcomes in critically ill patients. This review synthesizes evidence from the past 18 months and outlines the necessary transition toward biomarker-guided precision nutrition.<br><br>RECENT FINDINGS: Recent evidence has further challenged routine high-dose micronutrient therapy. High-dose intravenous vitamin C failed to improve outcomes and was associated with potential harm in patients with sepsis, COVID-19, severe burns, and post-cardiac arrest syndrome. In contrast, a 2025 meta-analysis reported reduced short-term mortality and shorter ICU stay with vitamin D supplementation in patients on mechanical ventilation. Thiamine may shorten the duration of shock without affecting mortality. Observational studies suggest that carnitine deficiency is common during critical illness, and both deficiency and excess may be associated with adverse outcomes in critically ill patients. Selenium supplementation continues to show no clinical benefits in multiple sepsis phenotypes and high-risk surgical populations. Novel evidence also links trace element dysregulation to critical illness-acquired weakness, implicating copper-dependent cuproptosis, zinc homeostasis, and iron metabolism in the pathogenesis of muscle dysfunction. Advances in biomarkers (e.g. hepcidin, soluble transferrin receptor, ferritin, and selenoprotein P) are enabling more accurate identification of true deficiency states and targeted replacement strategies.<br><br>SUMMARY: Current evidence does not support routine high-dose single-micronutrient therapy in critically ill patients and suggests potential harm with pharmacological doses of vitamin C. Clinicians should ensure that daily baseline requirements are met and reserve supplementation only for patients with biomarker-confirmed deficiency or biologically defined high-risk phenotypes. Future research should prioritize precision nutritional approaches based on validated biomarkers and individualized metabolic profiling.},
}
@article {pmid42682167,
year = {2026},
author = {Talreja, T and Gupta, L and Balse, R and Miller, FW and Rider, LG and Schiffenbauer, A},
title = {Environmental exposures and risks for the idiopathic inflammatory myopathies and its phenotypes: a narrative review.},
journal = {Current opinion in rheumatology},
volume = {38},
number = {6},
pages = {437-447},
doi = {10.1097/BOR.0000000000001184},
pmid = {42682167},
issn = {1531-6963},
mesh = {Humans ; *Myositis/immunology/etiology/epidemiology/genetics ; *Environmental Exposure/adverse effects ; Phenotype ; Autoantibodies/immunology ; Risk Factors ; Gene-Environment Interaction ; Occupational Exposure/adverse effects ; },
abstract = {PURPOSE OF REVIEW: The delineation of myositis-specific autoantibody (MSA) subgroups over the past two decades has reframed environmental research in idiopathic inflammatory myopathies (IIMs), making it plausible to examine discrete exposure-phenotype pairings within serologically defined subgroups. This review synthesises evidence on environmental, occupational, infectious, and pharmacological exposures, with attention to phenotypic specificity.<br><br>RECENT FINDINGS: Ultraviolet radiation shapes MSA-specific geographic distributions at the population level and associates with dermatomyositis onset at the individual level. Disease onset follows MSA-specific seasonal patterns, replicated across geographically independent cohorts. Smoking amplifies antisynthetase syndrome risk through a gene-environment interaction with HLA-DRB1*03:01, whilst protecting against anti-TIF1-&#x3b3; autoantibodies. Gestational and early-life tobacco smoke exposure is consistently implicated as risks for juvenile IIM. Occupational silica exposure associates with antisynthetase syndrome and overlap myositis, with synergistic lung disease risk when combined with smoking. Statins, immune checkpoint inhibitors, anti-TNF&#x3b1; agents, and interferons each induce immunopathologically distinct myositis phenotypes. Postpandemic surveillance has documented a rise in anti-MDA5 autoantibody-positive disease following SARS-CoV-2 infection.<br><br>SUMMARY: Environmental exposures in IIM act preferentially in specific serological and genetic contexts, consistent with discrete exposure-phenotype pairings shaped by genetic background and age at exposure. Prospective, MSA-stratified studies with direct exposure quantification represent priority directions for the field.},
}
@article {pmid42755257,
year = {2026},
author = {Ulasi, II and Onu, UC and Ijoma, CK},
title = {The feasibility of telenephrology solutions for rural patients.},
journal = {Current opinion in nephrology and hypertension},
volume = {35},
number = {6},
pages = {626-634},
doi = {10.1097/MNH.0000000000001226},
pmid = {42755257},
issn = {1473-6543},
mesh = {Humans ; *Telemedicine/organization &amp; administration ; *Nephrology/organization &amp; administration/methods ; *Renal Insufficiency, Chronic/therapy/diagnosis/epidemiology ; Health Services Accessibility ; *COVID-19/epidemiology ; *Rural Health Services/organization &amp; administration ; Healthcare Disparities ; Resource-Limited Settings ; },
abstract = {PURPOSE OF REVIEW: Chronic kidney disease (CKD) is a worsening global health problem that disproportionately affects rural populations, especially in low-income and middle-income countries (LMICs). Managing patients with CKD presents significant challenges, including limited access to healthcare. Key contributing factors include geographical barriers, a shortage of nephrology specialists, and insufficient healthcare infrastructure. As CKD is projected to become the fifth leading cause of death by 2040, it is crucial to develop innovative alternatives to the traditional care model to help bridge the gap in care in line with SDG 3.<br><br>RECENT FINDINGS: Lessons learned from the COVID-19 pandemic include the successful use of telemedicine-telenephrology for healthcare delivery. However, uptake among underserved populations remains challenging. However, a review of evidence suggests that such challenges are surmountable, as telenephrology has been practised in some resource-constrained remote areas. The results across these populations included shorter waiting times, lower costs, reduced health-related travel, higher overall satisfaction, and lower mortality rates.<br><br>SUMMARY: These findings portray telenephrology as a technological solution for kidney health inequities. However, government support, digital infrastructure development, bridging of the digital divide, and community engagement are essential.},
}
@article {pmid42755282,
year = {2026},
author = {Mirza, SH},
title = {Parsonage-turner syndrome: a pulmonologist's guide to the forgotten diaphragm.},
journal = {Current opinion in pulmonary medicine},
volume = {32},
number = {6},
pages = {536-542},
doi = {10.1097/MCP.0000000000001305},
pmid = {42755282},
issn = {1531-6971},
mesh = {Humans ; *Brachial Plexus Neuritis/diagnosis/therapy/physiopathology/complications ; *Diaphragm/physiopathology/diagnostic imaging/innervation ; *COVID-19/prevention &amp; control/epidemiology ; Phrenic Nerve/physiopathology/diagnostic imaging ; Pulmonologists ; Dyspnea/etiology ; Ultrasonography ; },
abstract = {PURPOSE OF REVIEW: Parsonage-Turner syndrome (PTS), or neuralgic amyotrophy, is framed as a shoulder disorder owned by neurology, and that framing has cost pulmonologists patients. Roughly 1 in 13 develops phrenic neuropathy, and many patients referred for unexplained dyspnea, orthopnea, or rapid eye movement (REM)-predominant sleep-disordered breathing have an undiagnosed, treatable inflammatory neuropathy. This review reframes PTS for pulmonologists.<br><br>RECENT FINDINGS: Three developments have reshaped practice. High-resolution neuromuscular ultrasound and MR neurography now identify the hourglass constrictions and fascicular entwinement of PTS at the bedside, including in the phrenic nerve. COVID-19 infection and SARS-CoV-2 vaccination produced a global cluster, expanding the phenotype toward bilateral and respiratory-predominant disease. Large Dutch cohort data have replaced anecdote with structure: roughly 60% of patients with phrenic involvement recover meaningfully within 2 years, while the remainder respond best to early noninvasive ventilation and, in refractory cases, diaphragmatic plication.<br><br>SUMMARY: Every pulmonologist evaluating unexplained dyspnea, disproportionate orthopnea, or REM-predominant hypopneas should ask one question: was there severe shoulder or neck pain in the weeks before the breathing changed? If yes, screen with upright and supine spirometry and diaphragm ultrasound. The diagnosis is reachable in a single visit, the immunomodulation window is short, and the cost of missing it is years of avoidable disability.},
}
@article {pmid42807221,
year = {2026},
author = {Domnich, A and Orsi, A},
title = {mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1965512},
pmid = {42807221},
issn = {1664-3224},
mesh = {Humans ; *Influenza Vaccines/immunology/adverse effects ; *Influenza, Human/prevention &amp; control/immunology ; Vaccine Efficacy ; *Immunogenicity, Vaccine ; *RNA, Messenger/immunology/genetics ; Vaccines, Synthetic/immunology ; Animals ; mRNA Vaccines/immunology ; },
abstract = {Available seasonal influenza vaccines, most of which are still produced in eggs, have several limitations. Messenger RNA (mRNA) technology has emerged as a transformative approach capable of overcoming some of these shortcomings. This overview synthesizes clinical trials evaluating the immunogenicity, efficacy, and safety of standalone and combination mRNA influenza vaccines. Moderna's mRNA-1010 (now approved in the United States) and Pfizer's modified-nucleoside RNA candidate (modRNA) represent the most advanced standalone platforms, while Moderna's combination influenza and COVID-19 vaccine, mRNA-1083, was recently granted European authorization. Following iterative platform optimization, these vaccines induce robust humoral and cell-mediated responses, especially against influenza A strains, characterized by extended germinal center reactions, continuous somatic hypermutation, enhanced Fc-mediated effector functions, and strong T helper 1 engagement. In phase III relative efficacy trials, an optimized mRNA-1010 formulation achieved superiority over standard-dose vaccines with a relative efficacy of 26.6% (95% CI: 16.7%, 35.4%) in adults aged ≥50 years. Pfizer's first-generation quadrivalent modRNA candidate showed 34.5% (95% CI: 7.4%, 53.9%) relative efficacy against a standard-dose comparator in younger adults aged 18-64 years, but failed to demonstrate non-inferiority in older adults (≥65 years), showing a relative efficacy of -5.8% (95% CI: -47.2%, 23.8%). However, whether mRNA platforms offer incremental benefits over enhanced formulations (such as high-dose, adjuvanted, or recombinant vaccines), which are the preferred options in some countries for older adults, remains to be established. The safety profile aligns with licensed COVID-19 mRNA vaccines; although reactogenicity is higher than with conventional vaccines, adverse reactions are predominantly mild-to-moderate and transient. Operationally, transitioning to single-dose pre-filled syringes alongside expanding refrigerated stability data significantly mitigates historical cold-chain bottlenecks. However, while standalone and combination mRNA platforms represent a major technological advance, real-world implementation challenges may affect their broader global health impact.},
}
@article {pmid42808340,
year = {2026},
author = {Robinson, D and Robinson, R},
title = {Internet Addiction Disorder and Cybersecurity Risk: A Neurobiological and Behavioral Review.},
journal = {Cyberpsychology, behavior and social networking},
volume = {},
number = {},
pages = {21522715261494036},
doi = {10.1177/21522715261494036},
pmid = {42808340},
issn = {2152-2723},
abstract = {Internet addiction disorder (IAD) has attracted substantial clinical and scientific interest over the past two decades. Although the condition remains outside formal diagnostic frameworks in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, accumulating neuroimaging evidence demonstrates that compulsive Internet use is associated with disruptions in dopaminergic reward circuitry and prefrontal cortical function that closely parallel those observed in substance use disorders. These neurobiological changes, encompassing impaired executive function, elevated impulsivity, and heightened reward sensitivity, may carry implications for cybersecurity. Available evidence suggests that individuals exhibiting addictive patterns of Internet use show reduced compliance with security protocols, increased vulnerability to social engineering, and elevated engagement in risky online behaviors, although directionality cannot be established with confidence given the predominantly cross-sectional evidence base. The present narrative review synthesizes evidence from addiction neuroscience, clinical psychology, and cybersecurity research to propose a mechanistic account of the IAD-cybersecurity risk relationship. The review identifies impaired prefrontal inhibitory control as the central neurobiological mediator linking IAD to cybersecurity vulnerability, mediated primarily through impulsivity and compounded by the attentional and affective characteristics that render addicted individuals susceptible to social engineering. Drawing on literature spanning 2017-2026, the review also situates this account within a contemporary regulatory context, including the documented acceleration of problematic Internet use during the COVID-19 pandemic, Australia's landmark social media minimum age legislation, and an influential 2026 civil verdict in which a U.S. jury found major platform operators liable for harms arising from addictive design. Clinical, organizational, and policy implications are discussed.},
}
@article {pmid42808628,
year = {2026},
author = {Casimir, G},
title = {[Inflammation: effective response or vulnerability related to sex?].},
journal = {La Revue du praticien},
volume = {76},
number = {7},
pages = {769-771},
pmid = {42808628},
issn = {2101-017X},
mesh = {Humans ; *Inflammation/therapy/diagnosis/epidemiology/etiology ; COVID-19/complications/epidemiology ; Female ; Male ; Sex Factors ; *Sex Characteristics ; },
abstract = {Life expectancy is sex-dependent: women live longer than men, and even though it is improving in both sexes, this difference remains true.The recent Covid-19 crisis has been pathognomonic of this. The essential element of this dimorphism is the way in which each sex controls inflammatory homeostasis, both in terms of kinetics and intensity. This review evaluates the mechanistic literature on the subject, the diagnostic, regulatory, and therapeutic aspects; it concludes with future prospects for the management of patients with severe infections or other concerning inflammatory disorders.},
}
@article {pmid42810091,
year = {2026},
author = {Ghalyanchi Langeroudi, A and Najafi, H and Malekahmadi, K and Khanizadeh, S and Pouladi, I},
title = {Molecular epidemiology and genetic diversity of infectious bronchitis virus in Iranian poultry: A systematic review.},
journal = {Poultry science},
volume = {105},
number = {12},
pages = {107786},
doi = {10.1016/j.psj.2026.107786},
pmid = {42810091},
issn = {1525-3171},
abstract = {Infectious bronchitis virus (IBV) is a highly contagious avian coronavirus that causes substantial economic losses in poultry production due to respiratory disease, reduced performance, and impaired egg production. In Iran, IBV has been repeatedly reported over the past two decades; however, evidence on diagnostic approaches and circulating lineages remains fragmented. This systematic review aimed to summarize the available Iranian literature on the molecular epidemiology and genetic diversity of IBV in poultry. We conducted a comprehensive search for relevant papers that reported the identification or molecular characterization of infectious bronchitis virus in Iranian poultry using key scientific databases and associated resources. We included 32 studies published between 2003 and 2022. Most investigations were conducted in broiler flocks, and most studies used molecular diagnostic methods, with RT-PCR being the most frequently reported approach, followed by real-time RT-PCR and nested RT-PCR; ELISA was used in a limited number of studies. Diverse circulating lineages were reported; GI-1 (Massachusetts-type), GI-13 (793/B-type), GI-19 (QX-like), and GI-23 (Variant-2/IS-1494/06-like) strains were often documented, suggesting co-circulation of many lineages in Iranian poultry populations. Genotype reporting was inconsistent across studies, and several investigations lacked complete molecular characterization. Additionally, quantitative synthesis of prevalence estimates could not be performed because the extracted dataset did not consistently report denominators (sample size) and numbers of positive samples. Overall, the evidence suggests sustained circulation of genetically diverse IBV lineages in Iran, supporting the need for continuous molecular surveillance, harmonized reporting, and vaccination strategies aligned with locally circulating strains to improve control of infectious bronchitis in Iranian poultry.},
}
@article {pmid42810289,
year = {2026},
author = {McCready-Branch, B and Bhattacharyya, DS and Rajeswaran, T and Jobaida, B and Ponrajah, L and Guglietti, V and Mac, C and Islam, MA and Iftikhar, L and Butt, ZA},
title = {Global pandemic preparedness frameworks in the 21st century: A scoping review.},
journal = {Public health},
volume = {260},
number = {},
pages = {106511},
doi = {10.1016/j.puhe.2026.106511},
pmid = {42810289},
issn = {1476-5616},
abstract = {OBJECTIVES: The COVID-19 pandemic exposed profound deficiencies in global health preparedness for infectious disease outbreaks. While progress has been made in creating pandemic preparedness frameworks at various scales, there is a lack of a comprehensive overview of the similarities and differences among these frameworks. This scoping review aims to address this gap by mapping pandemic preparedness frameworks to identify key components.<br><br>STUDY DESIGN: Scoping Review.<br><br>METHODS: Using the methodological framework proposed by Arksey and O'Malley, this scoping review mapped the peer-reviewed and grey literature presenting pandemic preparedness frameworks across world regions published between January 2000 and June 2025. A thematic framework was prepared outlining four domains of pandemic preparedness (Predict, Prevent, Detect, and Respond) based on the ten pillars of the World Health Organization (WHO) COVID-19 Strategic Preparedness and Response Plan (SPRP). Braun and Clark's thematic analysis method was used to analyze the results of the included studies.<br><br>RESULTS: This scoping review identified 41 articles presenting pandemic preparedness frameworks, with most scaled for national implementation (n&#x202f;=&#x202f;25), followed by global (n&#x202f;=&#x202f;13) and regional (n&#x202f;=&#x202f;3) implementation. Key components of the identified frameworks were grouped into themes under the four domains, including multi-sectoral collaboration (n&#x202f;=&#x202f;13), surveillance programs (n&#x202f;=&#x202f;13), and social media risk communication (n&#x202f;=&#x202f;9).<br><br>CONCLUSIONS: Findings revealed that pandemic preparedness is a multidimensional, multisectoral process, as the reviewed frameworks emphasize complementary strategies across prediction, prevention, detection, and response domains. Further research should evaluate the effectiveness and contextual applicability of individual strategies.},
}
@article {pmid42810473,
year = {2026},
author = {Matta, A and Nader, V and Ferrières, D and Ferrières, J},
title = {Personalized Primary Cardiovascular Prevention: The Convergences of Risk Scores, Coronary Calcium Scoring and Lipoprotein (a).},
journal = {Current problems in cardiology},
volume = {},
number = {},
pages = {103469},
doi = {10.1016/j.cpcardiol.2026.103469},
pmid = {42810473},
issn = {1535-6280},
abstract = {Despite major advances in the prevention and management of cardiovascular disease (CVD), it remains the leading cause of death worldwide, exceeding mortality attributable to COVID-19. Importantly, a substantial proportion of cardiovascular events are preventable, underscoring the critical importance of effective primary prevention. This brief review summarizes the latest European and American guideline recommendations, with a particular focus on cardiovascular risk assessment, the emerging roles of coronary artery calcium scoring, lipoprotein(a) and apolipoprotein B, and indications for statin therapy in the setting of primary cardiovascular prevention. In addition, it provides a practical, stepwise approach to assist clinicians in implementing individualized primary prevention strategies in routine practice.},
}
@article {pmid42323864,
year = {2026},
author = {Cilloniz, C and Ho, A and Rhee, C},
title = {Human metapneumovirus: an underestimated cause of severe respiratory infection.},
journal = {Annals of the American Thoracic Society},
volume = {23},
number = {10},
pages = {1414-1426},
doi = {10.1093/annalsats/aaoag172},
pmid = {42323864},
issn = {2325-6621},
support = {MC_UU_00034/6//MRC/ ; },
mesh = {Humans ; *Metapneumovirus ; *Paramyxoviridae Infections/epidemiology/diagnosis/prevention &amp; control/therapy ; *Respiratory Tract Infections/virology/epidemiology/diagnosis ; COVID-19/epidemiology ; SARS-CoV-2 ; Pandemics ; Pneumonia, Viral/epidemiology ; Hospitalization/statistics &amp; numerical data ; },
abstract = {Since its identification in 2001, human metapneumovirus (hMPV) has been recognized as an important cause of acute respiratory tract infection in all age groups. Although infection is often mild in healthy adults, hMPV can cause severe lower respiratory tract disease, including pneumonia, in young children, older adults, individuals with chronic diseases and immunocompromising conditions, and residents of long-term care facilities. Accumulating evidence demonstrates that hMPV contributes substantially to hospitalization, intensive care unit admission, and mortality in these high-risk populations. Globally, hMPV circulates seasonally, most commonly in late winter and spring, contributing to both community- and healthcare-associated respiratory infections; however, the COVID-19 pandemic disrupted established epidemiology, resulting in shifts in epidemic timing, off-season resurgences, genotype replacement, and increased overlap with other respiratory viruses, while also providing insights into viral interference and multivirus cocirculation. Clinical manifestations of hMPV overlap with other respiratory viruses, including influenza virus and SARS-CoV-2, and selective diagnostic practices contribute to underrecognition and undertesting. Although no specific antiviral therapies or licensed vaccines are currently available, identification of hMPV has important implications for diagnostic accuracy, prognosis, antimicrobial stewardship, and infection prevention, particularly in hospital and long-term care settings. This review summarizes current evidence on the virology, epidemiology, post-COVID-19 trends, clinical manifestations, outcomes, diagnosis, and prevention of hMPV, with a particular focus on adults and other high-risk populations. We also review the current landscape of hMPV vaccine development and its potential implications for clinical practice and public health.},
}
@article {pmid42403377,
year = {2026},
author = {Das, B and Moodley, M},
title = {Post-COVID paediatric dysautonomia: never the heart, always the brain-myth or maxim?.},
journal = {Cardiology in the young},
volume = {36},
number = {7},
pages = {1329-1339},
doi = {10.1017/S1047951126113900},
pmid = {42403377},
issn = {1467-1107},
mesh = {Humans ; *Primary Dysautonomias/diagnosis/physiopathology/therapy/etiology/epidemiology ; Child ; *COVID-19/complications/epidemiology ; Post-Acute COVID-19 Syndrome ; Adolescent ; SARS-CoV-2 ; },
abstract = {Paediatric dysautonomia has become increasingly recognised in children and adolescents, particularly in the post-COVID era. Affected patients commonly present with dizziness, palpitations, exercise intolerance, fatigue, and syncope, although reported prevalence varies widely because of evolving definitions and heterogeneous referral patterns. Contemporary evidence suggests that post-COVID dysautonomia arises from complex interactions among central autonomic network dysfunction, neurovascular dysregulation, impaired venous return, endothelial injury, hypovolemia, and altered cerebral perfusion, with tachycardia often representing a compensatory physiological response rather than a primary cardiac abnormality. Clinical phenotypes include postural orthostatic tachycardia syndrome, neurocardiogenic syncope, orthostatic hypotension, inappropriate sinus tachycardia, and undifferentiated orthostatic intolerance, frequently accompanied by fatigue, cognitive dysfunction, gastrointestinal symptoms, sleep disturbances, and post-exertional symptom exacerbation. Paediatric dysautonomia is best conceptualised as a distributed brain-heart-vascular network disorder that requires mechanistic understanding, standardised orthostatic assessment, and careful exclusion of structural heart disease and arrhythmia. The rapid expansion of specialised dysautonomia programmes and direct-to-consumer diagnostic pathways has also contributed to broader, and occasionally premature, application of autonomic diagnoses. Management should follow a stepwise, mechanism-guided approach emphasising patient education, trigger avoidance, hydration and salt optimisation, lower-body compression, individualised exercise rehabilitation, pacing strategies when post-exertional symptom exacerbation is present, school accommodations, and phenotype-directed pharmacotherapy for persistent functional impairment. Although post-COVID dysautonomia shares features with established paediatric autonomic disorders, important gaps remain in disease definitions, mechanistic understanding, and evidence-based treatment, underscoring the need for multidisciplinary care, standardised diagnostic frameworks, and prospective paediatric research.},
}
@article {pmid42720199,
year = {2026},
author = {Januszewski, M and Ziuzia-Januszewska, L and Jakimiuk, AJ},
title = {COVID-19 and pregnancy: is a "forgotten" disease still a threat?.},
journal = {Ginekologia polska},
volume = {97},
number = {9},
pages = {768-774},
doi = {10.5603/gpl.110960},
pmid = {42720199},
issn = {2543-6767},
mesh = {Humans ; Female ; Pregnancy ; *COVID-19/prevention &amp; control/epidemiology/complications/transmission ; *Pregnancy Complications, Infectious/prevention &amp; control/epidemiology/virology ; SARS-CoV-2 ; Infectious Disease Transmission, Vertical/prevention &amp; control ; Pregnancy Outcome ; Maternal Mortality ; },
abstract = {Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly affected global health, including maternal and perinatal outcomes. Although the acute phase of the pandemic has subsided, the continued emergence of new viral variants, waning population immunity, and suboptimal vaccination coverage among women of reproductive age suggest that COVID-19 in pregnancy may remain a clinically relevant problem. This review summarizes current evidence regarding the clinical course, complications, and prevention of SARS-CoV-2 infection during pregnancy, addressing whether COVID-19 should be considered a "forgotten" obstetric disease. Most pregnant women develop asymptomatic or mild infection; however, pregnancy is associated with an increased risk of severe disease, intensive care unit admission, mechanical ventilation, and maternal mortality, particularly among women of advanced maternal age, with obesity, comorbidities, or without vaccination. SARS-CoV-2 infection during pregnancy is consistently linked with a higher incidence of preeclampsia, including severe forms such as eclampsia and HELLP syndrome, increased rates of cesarean delivery and, in many populations, preterm birth. Vertical transmission is uncommon but documented. Severe placental involvement, referred to as COVID-19 placentitis, may result in placental insufficiency, fetal hypoxia, and stillbirth. Expression of angiotensin-converting enzyme 2 within the placenta provides a biological basis for viral tropism and potential disruption of placental defense mechanisms, contributing to adverse perinatal outcomes. COVID-19 vaccination before conception, during pregnancy, and throughout breastfeeding is safe and effective. Immunization significantly reduces the risk of severe maternal disease, preterm birth, emergency cesarean delivery, stillbirth, and neonatal hospitalization, while also conferring passive protection to infants. Maintaining up-to-date vaccination remains essential for preventing maternal and perinatal complications associated with SARS-CoV-2 infection.},
}
@article {pmid42800936,
year = {2026},
author = {Syailatussuraya, MS and Mutakin, M and Asman, S and Hasanah, AN},
title = {Piperine: From Green Extraction to Clinical Translation-A Review.},
journal = {Drug design, development and therapy},
volume = {20},
number = {},
pages = {639169},
pmid = {42800936},
issn = {1177-8881},
mesh = {*Benzodioxoles/pharmacology/isolation &amp; purification/chemistry/pharmacokinetics ; *Alkaloids/pharmacology/isolation &amp; purification/chemistry/pharmacokinetics ; *Polyunsaturated Alkamides/pharmacology/isolation &amp; purification/chemistry/pharmacokinetics ; Humans ; *Piperidines/pharmacology/isolation &amp; purification/chemistry/pharmacokinetics ; Animals ; *Green Chemistry Technology ; },
abstract = {BACKGROUND: Piperine has diverse pharmacological and bioenhancing activities, but poor aqueous solubility, variable exposure, interaction liability, and discontinuity across production, formulation, and clinical evaluation limit translation. This review integrates these frequently separated stages.<br><br>METHODS: A structured narrative PubMed search covered English-language studies published from 1 January 2021 to 27 April 2026, supplemented by ClinicalTrials.gov records checked through 13 June 2026, backward citation searching, and selected earlier seminal studies. Evidence was synthesized by experimental level, methodological limitations, and translational relevance.<br><br>KEY FINDINGS: In one solvent-circulation study, response surface methodology optimization increased the reported piperine yield from 3.87% to 5.20% of dry material, although external batch or production-scale validation was not reported. In rats, a solid piperine self-nanoemulsifying drug delivery system produced 4.92-fold higher relative oral bioavailability than pure piperine dispersion, without human pharmacokinetic validation. Preclinical studies reported anticancer, anti-inflammatory, neuroprotective, anti-infective, and metabolic effects. Head-and-neck cancer-cell IC50 ranges were 102.8-176.0&#xa0;&#xb5;M in HEp-2 cells and 121.0-249.9&#xa0;&#xb5;M in SCC-25 cells, without exposure-matched in vivo confirmation. Published trials included COVID-19 (n=140), sepsis (n=66), and ischemic stroke (66 randomized; 56 completed); these trials evaluated curcumin-piperine combinations. A 2025 meta-analysis of 18 curcuminoid-piperine trials reported pooled reductions in AST and IL-6 but not ALT, ALP, CRP, or TNF-&#x3b1;.<br><br>CHALLENGES: Extraction comparisons were limited by differences in botanical material, process conditions, and analytical methods. Other gaps included production-to-formulation continuity, stand-alone human exposure-response data, substrate-dependent interactions, long-term safety, and predominantly small or combination-based clinical studies.<br><br>CONCLUSION: Current evidence supports further development but not established stand-alone pharmaceutical efficacy. Translation requires standardized materials, scalable production, exposure-guided formulations, longer-term safety and interaction studies, and adequately powered trials with piperine-specific comparators.},
}
@article {pmid42800997,
year = {2026},
author = {Far, SST and Alizadeh, M and Kharazmi, E and Kavosi, Z},
title = {An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review.},
journal = {Health science reports},
volume = {9},
number = {10},
pages = {e73220},
pmid = {42800997},
issn = {2398-8835},
abstract = {BACKGROUND AND AIMS: Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.<br><br>METHODS: In this systematic review, articles published from 2018 to 2023 were reviewed by searching relevant keywords based on the PRISMA guidelines. The systematic search was conducted using English-language texts related to the research question, "What are the factors reducing hospital services?" and electronic databases such as PubMed, Scopus, Science Direct, ProQuest, and Web of Science. The CASP checklist was used to evaluate the methodological quality of the included studies. Two researchers performed all the stages; finally, the selected articles were summarized in tables.<br><br>RESULTS: The database search yielded a total of 3705 articles, of which 30 were included in the review. The results of extracting the findings from the articles indicated four main concepts of factors reducing hospital services: "therapeutic factors," "administrative-support factors," "preventive factors," and "technological factors." The studies assessed the impact of medications, treatment pathways, guidelines and standards, and treatment methods as effective therapeutic factors. Regulations were considered administrative or support factors, while health measures to control the spread of COVID-19 and various vaccines were shown as preventive factors. Additionally, remote care and the use of new tools were categorized as technological factors influencing the reduction of hospital services.<br><br>CONCLUSION: Therapeutic factors such as medications, managerial factors like regulations, preventive factors like vaccines, and factors related to new tools such as artificial intelligence were shown to be among the factors which reduce the use of hospital services. Therefore, if the focus on reducing services is hospital-centered, these factors should be considered in policy-making related to health service delivery.},
}
@article {pmid42801203,
year = {2026},
author = {Ardila Jara, AR and Barbosa Malagon, C and Castillo Moreno, LD and Rojas, FA and Beltrán Rojas, GC and Medina Adam, A and Romero Troya, MJ and Aguiar Martinez, LG},
title = {Left Without Being Seen: A Scoping Review of a Silent Crisis in Emergency Departments.},
journal = {Open access emergency medicine : OAEM},
volume = {18},
number = {},
pages = {604937},
pmid = {42801203},
issn = {1179-1500},
abstract = {BACKGROUND: Left Without Being Seen (LWBS) rates are widely recognized as a key quality indicator in Emergency Departments (ED) worldwide. Their clinical relevance is substantial, given the documented association between LWBS and increased morbidity and mortality among patients presenting to the ED. However, the available evidence is extensive and highly heterogeneous; therefore, a scoping review represents a more appropriate approach for synthesizing the evidence than a systematic review or meta-analysis.<br><br>OBJECTIVE: This scoping review aims to synthesize current evidence regarding population characteristics, underlying determinants, and potential interventions associated with LWBS rates, pondering the need to strengthen strategies for identifying and reducing these events.<br><br>DESIGN: Scoping review conducted according to PRISMA-ScR guidelines. We searched four databases (PubMed, Scopus, Oxford Academic, and EBSCO) between Jan 01, 2020 - Dec 31,2025. To meet the eligibility criteria, studies were required to be observational analytical, interventional, or evidence synthesis, given the limited evidence found, posters involving studies of human participants in ED settings.<br><br>RESULTS: Ninety-four publications were included with de eligibility criteria Most studies were interventional and conducted in North America; however, systematic reviews and additional studies from Europe, Asia, Australia, South America, and the Middle East were also identified. Reported LWBS rates varied widely across settings and were influenced by both community-level and individual-level factors, including demographic characteristics, EDs staffing, time of presentation, chief complaint, and facility resources, as well as contextual factors such as the COVID-19 pandemic. The available evidence demonstrated considerable heterogeneity in the definition and characterization of LWBS causes, largely due to differences in reporting practices, documentation, and descriptions of events related to this outcome. Numerous interventions aimed at reducing LWBS rates were described.<br><br>CONCLUSION: LWBS is a key emergency care quality indicator driven by waiting times, crowding, and temporal factors. It predominantly affects low-acuity, socioeconomically vulnerable adults. Physician-in-triage reduces LWBS, while predictive models identify high-risk patients. Associated with revisits and mortality, LWBS requires flow optimization and context-adapted strategies. Standardized frameworks are needed to strengthen evidence.},
}
@article {pmid42803424,
year = {2026},
author = {McGannan, M and Barber-Fleming, V and Fearon, D and Grant, L},
title = {A decade of palliative care needs in humanitarian settings: A systematic scoping review of literature between 2012 and 2022.},
journal = {Palliative &amp; supportive care},
volume = {24},
number = {},
pages = {e238},
doi = {10.1017/S1478951526103617},
pmid = {42803424},
issn = {1478-9523},
mesh = {Humans ; *Palliative Care/trends/methods ; *Altruism ; *Health Services Needs and Demand/trends ; COVID-19 ; },
abstract = {OBJECTIVES: To better understand the palliative care needs of people with serious and/or chronic conditions, and their families, in humanitarian settings in low-and middle-income countries between 2012 and 2022.<br><br>METHODS: A systematic scoping review methodology was employed to enable a wide-ranging search of this under-researched area. Databases and websites were systematically searched, in addition to correspondence to key experts.<br><br>RESULTS: Eighty-eight documents were included, comprising 63 publications in peer-reviewed journals, 5 conference abstracts, 4 conference posters, 7 case reports, 5 reports, 2 research snapshots, 1 survey report, and 1 master's thesis. The majority of literature was from the Public Health Emergency setting including 42 documents related to COVID and 30 to Ebola. Significantly less literature was identified from other settings: refugee populations (n&#xa0;=&#xa0;10), multiple settings (n&#xa0;=&#xa0;3), natural disaster contexts (n&#xa0;=&#xa0;2), and conflict settings (n&#xa0;=&#xa0;1). Sixty-four documents considered patient needs, 17 considered combined patient/family needs and 7 focused on family needs. Forty-six documents focused on adults, 25 on adults/children, 6 on children with 11 having no age specification. Findings from individual humanitarian contexts were mapped to palliative care domains and themes presented narratively.<br><br>SIGNIFICANCE OF RESULTS: The literature from Public Health Emergencies (Ebola and COVID) overshadowed other humanitarian contexts, demonstrating the comparative paucity of research in refugee, natural disaster, and conflict settings. The voice of children appeared under-represented, as did the perspective of family/caregivers. While there was strong research on pain and physical symptoms, holistic needs were also identified, highlighting the diversity of palliative care needs in humanitarian settings.},
}
@article {pmid42804114,
year = {2026},
author = {Wu, Z and Lou, J and Cheng, Y and Li, M and Wang, Z and Liu, N and Gao, X and Zheng, A and Zhang, H},
title = {mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.},
journal = {Molecular biomedicine},
volume = {7},
number = {1},
pages = {},
pmid = {42804114},
issn = {2662-8651},
support = {82473861//Innovative Research Group Project of the National Natural Science Foundation of China/ ; },
mesh = {Humans ; *COVID-19 Vaccines/immunology ; *Lipids/chemistry ; *Nanoparticles/chemistry ; Nanovaccines ; *RNA, Messenger/chemistry/immunology/genetics ; Animals ; *COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; Vaccines, Synthetic/immunology ; Liposomes ; },
abstract = {mRNA vaccines have become a clinically validated vaccine platform, as demonstrated by the success of COVID-19 vaccines such as Comirnaty and Spikevax, owing to their rapid design, manufacturing scalability, and capacity to induce in situ antigen expression. A key factor underlying this success is the lipid nanoparticle (LNP) delivery system, which protects mRNA from degradation and promotes efficient cellular uptake and cytoplasmic delivery, thereby enabling the full potential of mRNA technology. The continued advancement of mRNA-LNP vaccines requires integrated optimization of mRNA design, LNP composition, and delivery strategies to achieve improved stability, efficient intracellular delivery, and balanced immune responses. Despite remarkable progress, challenges related to formulation stability, long-term storage stability, safety and reactogenicity concerns, and durability of immune protection continue to hinder the broader application of mRNA-LNP vaccine platforms. This review provides an integrated overview of recent advances in mRNA-LNP vaccines, covering mRNA molecular engineering, LNP composition and delivery mechanisms, immune responses, clinical progress, and current developmental challenges. Furthermore, emerging strategies, including thermostable formulations, next-generation LNPs with improved targeting capability, emerging RNA platforms, and artificial intelligence-assisted optimization of RNA sequences and lipid materials, are discussed. By summarizing current achievements and future opportunities, this review highlights key principles guiding the rational design of safer, more stable, and more precise mRNA-LNP vaccine platforms and provides insights into accelerating their clinical translation.},
}
@article {pmid42804126,
year = {2026},
author = {Murugan, AK and Afnan, R and Alzahrani, AS},
title = {COVID-19 vaccine-associated autoimmune thyroid eye disease: Graves' orbitopathy.},
journal = {Endocrine},
volume = {91},
number = {1},
pages = {},
pmid = {42804126},
issn = {1559-0100},
mesh = {Humans ; *Graves Ophthalmopathy/etiology/immunology/chemically induced/epidemiology ; *COVID-19 Vaccines/adverse effects ; *COVID-19/prevention &amp; control ; Risk Factors ; SARS-CoV-2 ; Autoimmune Diseases ; },
abstract = {Thyroid eye disease (TED) is an autoimmune disorder commonly associated with hyperthyroidism of Graves' disease. The global outbreak of SARS-CoV-2 resulted in an unparalleled public health emergency. The rapid development and widespread administration of COVID-19 vaccines were instrumental in controlling viral transmission and decreasing severe disease outcomes and deaths. Although these vaccines have demonstrated strong safety and effective prevention, isolated cases of uncommon adverse events have been reported. Notably, instances of new-onset or worsening autoimmune disorders, including TED, after vaccination have drawn considerable research interest. In this review, we describe the common risk factors (age, sex, genetics, ethnicity, dysthyroid status, high serum cholesterol, oxidative stress, pregnancy, psychological stress, radioiodine therapy, trauma, systemic disease, and virus) of TED and outline the constituents of COVID-19 vaccines and the current global vaccination scenario. We further explain autoimmune mechanisms as central drivers of classical TED, particularly through the activation of autoreactive T-cells and the production of autoantibodies targeting shared antigens in orbital fibroblasts, leading to inflammation, tissue remodeling, and orbital expansion. Besides, we discuss molecular signaling (MAPK, PI3K/Akt, NF-κB, and JAK/STAT) implicated in TED. Moreover, we critically examine published case reports (n = 30) to identify shared features and potential factors associated with the onset of this autoimmune condition. We delineate the autoimmune-mediated molecular mechanisms in the development of COVID-19 vaccine-associated TED. The therapeutic management approaches and clinical outcomes related to COVID-19 vaccine-associated TED are also thoroughly examined and discussed. Improved understanding of these mechanisms may refine patient risk stratification, optimize clinical management, and inform vaccination strategies.},
}
@article {pmid42804450,
year = {2026},
author = {Johnson, G and Edwards, S and Jarman, H and Peel, E and Pino, M},
title = {Understanding delivery of bad news in the emergency department: A scoping review.},
journal = {PloS one},
volume = {21},
number = {9},
pages = {e0358343},
pmid = {42804450},
issn = {1932-6203},
mesh = {Humans ; *Emergency Service, Hospital ; *Truth Disclosure ; Communication ; *COVID-19 ; },
abstract = {BACKGROUND: Breaking bad news is a core component of emergency care, but the emergency department (ED) environment of urgency, crowding, and limited privacy presents challenges for sensitive communication. Many communication frameworks originate from other specialities, but the ED has limited evidence and guidance tailored to its context.<br><br>OBJECTIVE: This scoping review aimed to map the extent, nature, and characteristics of the literature on delivery of bad news in EDs, including terminology, frameworks, stakeholder perspectives, barriers and facilitators, educational resources, reported metrics, and evidence gaps.<br><br>METHODS: The review followed Joanna Briggs Institute (JBI) methodology and was prospectively registered on the Open Science Framework (OSF https://osf.io/f6q59/overview). Four databases (MEDLINE, EMBASE, EMCARE, CINAHL) and grey literature sources were searched in July 2025. Eligible sources included empirical studies, training evaluations, reviews, guidelines, consensus statements, editorials, commentaries, opinion pieces, educational articles, conference abstracts, and relevant grey literature reporting on adult patients, relatives, or clinicians in ED contexts. Data were charted and synthesised narratively.<br><br>RESULTS: From 7985 records, 156 publications were included. Studies originated from 26 countries, though the United States of America (USA) (n&#x2009;=&#x2009;85) and United Kingdom (UK) (n&#x2009;=&#x2009;18) dominated the literature. There was a rise in publications from 2010, particularly post-COVID-19. Twenty-five communication frameworks were identified; most were adapted from oncology (with SPIKES most frequently cited). Three frameworks developed specifically for ED practice (GRIEV_ING, 8S, EMTalk) were identified. Stakeholder perspectives were unevenly represented, with a predominance of healthcare professional perspectives. Reported metrics centred on clinician confidence; patient- and family-centred studies were uncommon. Barriers to effective communication consistently included time scarcity, lack of privacy, and insufficient training.<br><br>CONCLUSIONS: Research on delivering bad news in EDs is dominated by educational and simulation-based studies, and is largely clinician-centred, with limited evidence of patient and family perspectives, with no studies examining long-term outcomes. Reliance on frameworks from other specialties risks overlooking the contextual specifics of emergency care. Future research should prioritise ED-centred frameworks, patient outcomes, and systemic enablers to support compassionate, effective communication in this demanding environment.},
}
@article {pmid42805095,
year = {2026},
author = {Malik, ZK and Ahmad, K and Ahmed, S},
title = {AI-driven drug repurposing: Methods, platforms, and translational applications.},
journal = {Computational biology and chemistry},
volume = {126},
number = {Pt 1},
pages = {109444},
doi = {10.1016/j.compbiolchem.2026.109444},
pmid = {42805095},
issn = {1476-928X},
abstract = {The conventional drug discovery pipeline is resource-intensive, time-consuming, and characterized by high attrition rates, often requiring more than a decade and billions of dollars to bring a single therapeutic agent to market. Drug repurposing identifying new therapeutic indications for approved or investigational drugs offers a pragmatic alternative by leveraging established safety profiles and known pharmacokinetics. Despite growing interest, comprehensive syntheses that span the full spectrum of artificial intelligence (AI) methodologies from classical machine learning (ML) through deep learning (DL), graph neural networks (GNNs), and generative AI while also critically evaluating platforms, validation status, and translational readiness remain limited. This review addresses that gap. A narrative review methodology was employed. Literature was searched across PubMed, Scopus, Web of Science, and Google Scholar using a structured keyword strategy (terms: drug repurposing, AI drug discovery, machine learning, deep learning, graph neural networks, generative AI, reinforcement learning, clinical translation combined with Boolean operators). Studies published between 2018 and 2025 were prioritized, with foundational works included regardless of date. Inclusion criteria encompassed primary research articles, systematic reviews, and platform descriptions reporting AI-based drug repurposing methods or outcomes. Non-English publications, conference abstracts without full text, and purely theoretical works without empirical validation were excluded. We identified and synthesized evidence across six thematic domains: (1) classical ML strategies, including target-based and phenotypic screening; (2) DL architectures, including convolutional and recurrent networks; (3) GNNs for biological network modeling; (4) generative AI and reinforcement learning for de novo molecular design; (5) disease-specific applications in oncology, neurology, and COVID-19; and (6) bioinformatics databases underpinning model development. We explicitly compared ML, DL, GNN, and generative AI approaches in terms of data requirements, interpretability, scalability, and translational readiness and summarized these dimensions in a comparative table. Key platforms reviewed RepurposeDrugs, NeuroCADR, and COVID-19 repurposing frameworks were selected using predefined criteria that emphasized methodological transparency, accessibility, and reported validation. Across approaches, AI models frequently demonstrate strong internal predictive performance in silico, with graph-based and transformer models representing the current state of the art on benchmark datasets. However, external validation, reproducibility, and successful clinical implementation remain comparatively scarce. We therefore place particular emphasis on external cohort validation, prospective and experimental follow-up, and the distinction between computational promise and realized clinical benefit. Persistent challenges include dataset bias, limited model interpretability, regulatory uncertainty, and infrastructure gaps in low-resource settings. AI-driven drug repurposing holds considerable translational promise, but many claims remain preliminary. Interdisciplinary collaboration, shared benchmarks, transparent reporting of negative results, and prospective clinical validation frameworks are essential for realizing the full therapeutic potential of these approaches.},
}
@article {pmid42805654,
year = {2026},
author = {Dankers, A and Yildirim, D and Dijkstra, S and Ngongalah, L and Connolly, MA and Duggan, J and Zander, A and van Loenen, T and Boucherie, RJ and Timen, A},
title = {Performance indicators for evaluating and optimising hospital services during COVID-19: a scoping review.},
journal = {BMJ open},
volume = {16},
number = {9},
pages = {e122362},
doi = {10.1136/bmjopen-2026-122362},
pmid = {42805654},
issn = {2044-6055},
mesh = {*COVID-19/epidemiology/therapy ; Humans ; Pandemics ; *Quality Indicators, Health Care ; SARS-CoV-2 ; *Hospitals/standards ; *Delivery of Health Care/standards ; },
abstract = {OBJECTIVES: To identify which logistical and clinical healthcare key performance indicators (KPIs) were applied in hospitals during the COVID-19 pandemic and how frequently they were used when evaluating and optimising hospital care services.<br><br>DESIGN: Scoping review reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework.<br><br>DATA SOURCES: The search was performed in PubMed, CINAHL, EMBASE, Scopus and Web of Science and included articles published from the beginning of the COVID-19 pandemic, that is, 1 January 2020, until 11 November 2024, the date of the final search. The search strategy combined terms related to (1) COVID-19/pandemic, (2) performance and (3) hospital care.<br><br>ELIGIBILITY CRITERIA: Eligible studies were peer-reviewed, English-language publications that reported measurable performance indicators evaluating or optimising hospital care services during the COVID-19 pandemic. Studies had to explicitly define or evaluate KPIs and focus on inpatient hospital settings (&#x2265;1 overnight stay) in countries within the European Union, the European Economic Area, the Schengen area or the UK. Multicountry or global studies were included when they contained relevant European data or when the geographical context was not determinant (eg, modelling studies). Exclusion criteria included non-peer-reviewed publications, conference abstracts, organisational reports, literature reviews, studies without original results, studies without accessible full text and non-English publications.<br><br>DATA EXTRACTION AND SYNTHESIS: Titles, abstracts and full texts were screened independently by three reviewers. Disagreements were resolved through discussion and consultation with two additional reviewers. Relevant study characteristics and KPI-related information were extracted using a predefined data extraction form. KPIs were categorised inductively into thematic categories. Structured data were analysed at both the study and KPI-category level. Data without a predefined structure, such as KPI definitions and key findings, were analysed manually at the KPI-category level.<br><br>RESULTS: Across 94 included studies, 459 distinct KPIs were extracted. Given substantial heterogeneity, KPIs were grouped inductively into six main categories: (1) clinical outcomes, (2) resources and capacity, (3) care delivery volumes, (4) care delivery performance, (5) access time and sojourn time and (6) other indicators. KPIs were reported in diverse formats, including volumes, percentages, scores, scales, characteristics and binary outcomes. Identical KPIs were sometimes defined differently across studies, while similar measures were reported under different terminology. The most common reason for KPI use was for the comparison between pre-COVID-19 and COVID-19 periods, followed by supporting optimisation and exploring quality of care during the pandemic. Most studies emphasised either clinical or logistical indicators, with limited integration of both perspectives within a single performance assessment. The majority of KPIs were not pandemic-specific but reflected indicators already used in routine hospital performance monitoring.<br><br>CONCLUSIONS: Hospital performance during COVID-19 was evaluated using a wide range of heterogeneous KPIs, with substantial variation in definitions and reporting practices. Greater transparency and standardisation in KPI definitions may improve comparability, reproducibility and preparedness for future health crises. Integrating clinical and logistical performance perspectives may provide a broader view of hospital performance and support decision-making during pandemics.},
}
@article {pmid42807192,
year = {2026},
author = {Wu, M and Rahman, A and Lim, EG and Yan, R},
title = {The impact of social support on anxiety and depression under the context of COVID-19 pandemic: a systematic review and meta-analysis.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1836327},
pmid = {42807192},
issn = {1664-1078},
abstract = {INTRODUCTION: The COVID-19 pandemic created an extreme and prolonged context of collective stress while simultaneously disrupting ordinary sources of interpersonal support. Although social support is widely associated with better mental health, it remains unclear how consistently this association was observed across populations and contexts during the pandemic and what the findings may imply for future crisis preparedness.<br><br>METHODS: This systematic review and meta-analysis followed PRISMA 2020 guidelines. Six databases (PubMed, Web of Science, PsycINFO, Taylor &amp; Francis Online, ScienceDirect, and ERIC) were searched for studies published between February 2020 and June 2022. Eligible studies quantitatively examined the association between social support and anxiety and/or depression using validated measures. Study quality was assessed with the Newcastle-Ottawa Scale. Random-effects models were applied to calculate pooled correlations, with subgroup, sensitivity, and publication bias analyses conducted.<br><br>RESULTS: Sixty studies comprising 64,693 participants met inclusion criteria. Social support was significantly associated with lower anxiety (&#x3c1; = -0.30, 95% CI [-0.33, -0.26]) and lower depression (&#x3c1; = -0.33, 95% CI [-0.37, -0.27]). Subgroup analyses showed consistent protective effects across age groups and occupations, particularly among college students and medical workers. Family support demonstrated the strongest associations. Heterogeneity was high (I[2] > 90%), and publication bias was detected, though trim-and-fill analyses did not alter overall results.<br><br>CONCLUSION: Higher social support was consistently associated with lower anxiety and depression during the COVID-19 pandemic. Viewed as evidence from an extreme and prolonged context of collective stress, these findings may inform mental health preparedness for future public health emergencies and other large-scale crises. However, substantial heterogeneity indicates that the magnitude of the association varies across populations and contexts. Because the pooled estimates were based on bivariate correlations, the findings should not be interpreted as evidence that social support causally was associated with lower symptoms of specific pandemic-related stressors.},
}
@article {pmid39223825,
year = {2026},
author = {Clausen, TM and Fargen, KM and Primiani, CT and Sattur, M and Amans, MR and Hui, FK},
title = {Post-acute sequelae of COVID infection and cerebral venous outflow disorders: Overlapping symptoms and mechanisms?.},
journal = {Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences},
volume = {32},
number = {5},
pages = {2314-2321},
pmid = {39223825},
issn = {2385-2011},
mesh = {Humans ; *COVID-19/complications ; Post-Acute COVID-19 Syndrome ; *Cerebral Veins/diagnostic imaging/physiopathology ; *Cerebrovascular Disorders/diagnostic imaging/etiology ; Jugular Veins/diagnostic imaging ; Diagnosis, Differential ; },
abstract = {Neurological long Covid (NLC) is a major post-acute sequela of SARS-CoV-2 infection, affecting up to 10% of infected patients. The clinical presentation of patients with NLC is varied, but general NLC symptoms have been noted to closely mimic symptoms of cerebral venous outflow disorders (CVD). Here we review key literature and discuss evidence supporting this comparison. We also aimed to describe the similarity between CVD symptomatology and neuro-NLC symptoms from two perspectives: a Twitter-distributed survey for long covid sufferers to estimate nature and frequency of neurological symptoms, and through a small cohort of patients with long covid who underwent CVD work up per our standard workflow. Over 700 patients responded, and we argue that there is a close symptom overlap with those of CVD. CVD workup in a series of 6 patients with neurological long COVID symptoms showed jugular vein stenosis by CT venography and varying degrees of increased intracranial pressure. Finally, we discuss the potential pathogenic association between vascular inflammation, associated with COVID-19 infection, venous outflow congestion, and its potential involvement in NLC.},
}
@article {pmid42448200,
year = {2026},
author = {Murugan, AK},
title = {Oral disease-associated proteins implicated in neuronal disorders: Emerging roles in diagnosis and treatment.},
journal = {International journal of biological macromolecules},
volume = {377},
number = {},
pages = {153500},
doi = {10.1016/j.ijbiomac.2026.153500},
pmid = {42448200},
issn = {1879-0003},
mesh = {Humans ; *Neurodegenerative Diseases/diagnosis/metabolism/therapy ; COVID-19/metabolism ; SARS-CoV-2 ; *Mouth Diseases/metabolism/therapy/diagnosis ; Animals ; },
abstract = {Oral health plays a crucial role in maintaining cognitive functions, reflecting a complex interplay between the oral cavity and brain health. Emerging evidence indicates that various oral disease-associated protein molecules are implicated in the pathogenesis of diverse neuronal disorders, including neurodegenerative diseases. This review comprehensively summarizes oral disease-related protein molecules involved in several neuronal disorders, including Alzheimer's disease, Parkinson's disease, neurodegeneration, neuroinflammation, dementia, cognitive decline, and brain fog in two different contexts. Firstly, it describes protein molecules under the classical oral disease condition [Aβ42, total-Tau, phosphorylated-Tau, α-synuclein, DJ-1, lactoferrin, MMP-2/8/9, IL-6, IL-1β, TNF-α, CRP, S100A8, S100A9, S100B, RAGE, LCN2, cathepsin B/L, HSP70/90, NfL, CXCL2/8, C3/4, defensins (α and β), and lysozyme]. Secondly, it explains in COVID-19 context [ACE2, TMPRSS2, furin-1, NRP1, spike, T1R, and T2R]. The review explores oral proteins implicated in neuronal disorders, highlighting their roles in activating inflammatory pathways, contributing to memory impairment, and mediating taste dysfunction in the context of COVID-19. Furthermore, the review delineates the mechanisms underlying the oral-brain axis, highlighting the roles of systemic inflammation, microbial interactions, and blood-brain barrier dysfunction in mediating these effects. It also highlights the innovative diagnostic potential of oral disease-associated proteins as non-invasive biomarkers for early detection and monitoring of neuronal disorders in both classical and COVID-19 contexts. In addition, the emerging therapeutic significance of these proteins is discussed, emphasizing their potential as molecular targets for the prevention and treatment of neurological diseases. Understanding oral disease-associated protein molecules provides novel insights into early diagnosis and progression of neuronal disorders.},
}
@article {pmid42473775,
year = {2026},
author = {Olabosipo, J and Zhu, C and Telischi, J and Aston, SA and Cheng, H and Hoa, M},
title = {Uncommon Hearing Instability Disorders: A Scoping Review.},
journal = {The Annals of otology, rhinology, and laryngology},
volume = {135},
number = {11},
pages = {880-886},
doi = {10.1177/00034894261470539},
pmid = {42473775},
issn = {1943-572X},
mesh = {Humans ; *Hearing Loss/etiology/diagnosis ; *Hearing Loss, Sudden/etiology ; Auditory Acuity ; Neoplasms/complications ; },
abstract = {OBJECTIVE: The aim of this scoping review is to identify and categorize uncommon disorders of hearing instability, enabling a better understanding of their clinical presentations and treatments.<br><br>METHODS: The framework for the review was developed using the PRISMA-ScR. Literature was pulled from Medline, Web of Science, Embase, and Cochrane Central and screened independently by 3 reviewers with an extended inclusion and exclusion criteria. Once included, data extraction included etiological category of the disease, hearing loss type (sudden, fluctuating, or both), associated symptoms, comorbidities, treatments administered, and hearing recovery outcomes.<br><br>RESULTS: A total of 334 studies were included after screening, and data from 2247 patients was extracted. The most common etiologies per study were infectious (30.2%, n&#x2009;=&#x2009;101 studies), neoplastic (29.6%, n&#x2009;=&#x2009;99 studies), and vascular (28.1%, n&#x2009;=&#x2009;94 studies). Average age across cases was 45.9&#x2009;years (range: 0-90). Among patients, 89.8% exhibited sudden hearing loss, while 8.18% experienced fluctuating hearing loss. Neoplastic-related hearing instability had the highest number of total patients (n&#x2009;=&#x2009;1101 patients), predominantly involving vestibular schwannomas (n&#x2009;=&#x2009;582 patients) while infectious diseases had the second highest number of patients (n&#x2009;=&#x2009;493 patients), with COVID-19 as the most reported infection (n&#x2009;=&#x2009;146 patients). Causes identified without a known association with hearing loss in other literature include acute or chronic myeloid leukemia (n&#x2009;=&#x2009;24), metastatic tumor disease (n&#x2009;=&#x2009;10), or infective endocarditis (n&#x2009;=&#x2009;3).<br><br>CONCLUSION: Hearing instability can arise from a variety of uncommon causes. Increased awareness of these conditions may help clinicians initiate appropriate treatment sooner, potentially improving patient outcomes.},
}
@article {pmid42679879,
year = {2026},
author = {Oliveira, NC and Sanesi, G and Paiva, TCB and Alvim, DS and Bargos, DC and Fontana, CF and Aranha, S and Lafortezza, R and Ferreira, ML},
title = {Urban green spaces: lessons from COVID-19 for future public health crises.},
journal = {Environmental research},
volume = {308},
number = {Pt 1},
pages = {125585},
doi = {10.1016/j.envres.2026.125585},
pmid = {42679879},
issn = {1096-0953},
mesh = {*COVID-19/epidemiology/prevention &amp; control ; Humans ; *Public Health ; *Pandemics ; SARS-CoV-2 ; *Parks, Recreational ; },
abstract = {The COVID-19 pandemic constituted a global socioeconomic crisis with long-lasting consequences. In response to the rapid spread of the virus, governments implemented containment measures such as social distancing, mask mandates, and mobility restrictions, which also affected access to urban green spaces (UGS). This systematic review aimed to identify key lessons from the pandemic regarding the role of UGS during public health crises. The analysis included 155 studies published between 2020 and 2025, grouped into four main research domains: visitation patterns (n = 88), planning and management of UGS (n = 15), associations with viral transmission (n = 11), and health benefits (n = 41). The findings indicated substantial geographical disparities in scientific production and showed that the pandemic reshaped UGS visitation patterns, with proximity to residential areas becoming an important determinant of outdoor activities such as physical exercise and recreation. The literature also revealed persistent inequalities in access to urban nature, particularly among low-income communities, ethnic minorities, and other socially vulnerable groups. Drawing on different forms of evidence, five policy recommendations emerge: i) ensuring equitable access to UGS; ii) improving their quality and spatial distribution; iii) integrating UGS into emergency preparedness strategies; iv) implementing context-sensitive visitation and management protocols; and v) actively supporting health-promoting behaviors compatible with safe use of green environments. The applicability of these lessons to future crises will depend on pathogen characteristics, transmission routes, urban form, restriction policies, and governance capacity. The findings reinforce that equitable access to high-quality UGS should be recognized as a strategic priority for urban governance and public health resilience.},
}
@article {pmid42798114,
year = {2026},
author = {Li, J and Ai, F and Li, Y and Cheng, B and Chen, Z},
title = {1000 highly cited articles in depression research (2016-2026): A bibliometric and scoping review (global depression research: 2016-2026).},
journal = {Medicine},
volume = {105},
number = {39},
pages = {e50921},
pmid = {42798114},
issn = {1536-5964},
mesh = {*Bibliometrics ; Humans ; COVID-19 ; *Depression/therapy/epidemiology ; *Biomedical Research/statistics &amp; numerical data ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Depression is one of the world's leading causes of disability, creating significant challenges for individuals and society. Although research in this field has grown rapidly, we still lack a complete understanding of how depression research has evolved globally over the past decade, especially regarding the long-term effects of the Coronavirus disease 2019pandemic.<br><br>METHODS: We collected data from the Web of Science Core Collection as of April 28, 2026. After careful screening, we included 1000 highly cited articles. Using bibliometric methods and visualization tools, we analyzed collaboration networks, keyword patterns, emerging topics, and timeline developments.<br><br>RESULTS: Our analysis shows that the United States produces more than half of the world's high-impact depression research. Research focus has shifted from traditional theories to new areas like brain-immune connections and gut bacteria, leading to comprehensive treatment approaches that combine digital technology. The Coronavirus disease 2019 pandemic served as a major turning point, significantly reshaping research priorities and accelerating the integration of medicine and data science.<br><br>CONCLUSIONS: Over the past decade, depression research has dynamically evolved in response to external challenges. Exploring basic biological mechanisms and combining knowledge from different fields have become central trends. Our comprehensive analysis provides valuable insights for planning future research, developing policies, and understanding the direction toward "multimodal integration" in depression treatment.},
}
@article {pmid42798382,
year = {2026},
author = {Pu, J and Chen, W and Jiang, H and Yang, H},
title = {A dual-database bibliometric analysis of post-COVID-19 condition and cognitive dysfunction (2021-2025).},
journal = {Frontiers in neurology},
volume = {17},
number = {},
pages = {1844317},
pmid = {42798382},
issn = {1664-2295},
mesh = {*Bibliometrics ; Humans ; *COVID-19/complications ; *Cognitive Dysfunction/etiology/epidemiology ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a substantial global health challenge. Cognitive dysfunction is a prevalent and disabling manifestation of post-COVID-19 condition (PCC). This study aims to conduct a comprehensive bibliometric analysis of research on PCC and cognitive dysfunction.<br><br>METHODS: Publications on PCC and cognitive dysfunction published between 2021 and 2025 were retrieved from the Web of Science Core Collection (WoSCC) and Scopus. After screening according to inclusion criteria, Bibliometrix (R package), VOSviewer, and CiteSpace were employed for bibliometric and visualization analysis.<br><br>RESULTS: 746 publications from the WoSCC and 1,117 publications from Scopus were included. Over the past 5&#x202f;years, the number of publications on PCC-related cognitive dysfunction has exhibited a gradual upward trend. The United States showed the highest publication output, while the University of London demonstrated the highest number of publications among institutions in this network. The Journal of Clinical Medicine showed prominent publication and citation-related indicators in this field. Keyword analysis revealed three primary theme domains, including psychological factors, oxidative stress and neuroinflammation. Keyword burst detection revealed that blood-brain barrier, choroid plexus, and endothelial cells represent emerging research frontiers.<br><br>CONCLUSION: This bibliometric analysis systematically maps the global research landscape and evolving trends in PCC-related cognitive dysfunction. Our findings provide a broad overview of research development, collaboration patterns, and emerging topics, which may help generate hypotheses for future mechanistic investigations and clinical research.},
}
@article {pmid42798424,
year = {2026},
author = {Slaunwhite, A and Hoolsema, S and Ogiral, A and Roth, K and Smith, S and Krishnamoorthy, A and Mead, A and Martin, RE},
title = {The health status of incarcerated people in Canada: a narrative review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1902956},
pmid = {42798424},
issn = {2296-2565},
mesh = {Humans ; Canada/epidemiology ; *Prisoners/statistics &amp; numerical data ; *Health Status ; COVID-19/epidemiology ; Health Services for Prisoners ; Patient Acceptance of Health Care/statistics &amp; numerical data ; Mental Disorders/epidemiology ; },
abstract = {BACKGROUND: People who experience incarceration in Canada have been historically more likely to experience poor health than community-based populations. Although incarcerated people are entitled to health care equivalent to community standards, evidence suggests this is inconsistently achieved in Canada. We conducted a narrative review to synthesize contemporary evidence on health status and health care utilization by incarcerated people in Canada, including changes observed during and after the COVID-19 pandemic.<br><br>METHODS: We searched MEDLINE, PsycINFO, CINAHL, Scopus, and Web of Science for peer-reviewed literature published between January 1, 2014 and July 22, 2026 on the health of adults incarcerated in Canadian provincial, territorial, and federal correctional centers. Both title/abstract and full-text screening were completed independently by two reviewers, and findings were extracted and synthesized thematically across major health domains.<br><br>RESULTS: Across the 167 included articles, incarcerated people in Canada experience significantly higher rates of mental illness, substance use disorders, chronic disease, hepatitis C virus infection, and HIV. Mental health and substance use disorders were highly prevalent and often concurrent. Access to reproductive health care and maternal care in custody was limited compared to community care. Health care continuity was disrupted at admission, transfer, and release from correctional centers. These disparities were closely tied to community-based social determinants of health such as poverty, unstable housing, and systemic racism, and mortality risk was highest during transitions in and out of custody, when the risk of overdose death in the weeks following release was greatest.<br><br>INTERPRETATION: Incarceration is an important structural determinant of health in Canada that intersects with community-based social determinants of health, contributing to health inequities. To reduce preventable death among people who experience incarceration in Canada, efforts are required to strengthen continuity of care, evaluate the quality of services in correctional centers, and address the social determinants of health and structural inequities that contribute to premature mortality.},
}
@article {pmid42798495,
year = {2026},
author = {Al Mahtab, M and Akbar, SM and Rubido, JC and Yoshida, O and Huq, AKMF and Khan, S and Mahtab, M and Nieto, GE},
title = {Preventive and Therapeutic Vaccination for COVID-19 Using NASVAC.},
journal = {Euroasian journal of hepato-gastroenterology},
volume = {16},
number = {1},
pages = {124-130},
pmid = {42798495},
issn = {2231-5047},
abstract = {AIMS AND BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the coronavirus family, suddenly emerged in China and neighboring regions towards the end of 2019. It disrupted the entire world within weeks to months, and finally became a pandemic that continued for about 3 years.<br><br>PATIENTS AND METHODS: One year after the commencement of infection, a vaccine surfaced on a global basis that imparted its effect on the progression of the infection. At the same time, symptomatic treatment was initiated to treat the patients and prevent progression to severe forms. Subsequently, antiviral drugs of different paradigms were used with mixed outcomes. Finally, immune modulators were mainly used to delay complications and reduce mortality.<br><br>RESULTS: Despite all these approaches, there have been nearly one billion infections and almost one million fatalities due to the pandemic of COVID-19. Two years after the containment of the virus, if the entire episode is considered holistically, it becomes evident that more insights are required to develop preventive and therapeutic measures against the sudden appearance of some microbe.<br><br>CONCLUSION: This is the initial theological approach, and more sophisticated drugs may be developed based on this principle.},
}
@article {pmid42798753,
year = {2026},
author = {Yerkenova, S and Lokshin, V and Aldangarova, G and Skakova, R and Koshkimbayeva, G and Mireeva, A and Nurseitova, L and Dzhardemaliyeva, N and Akhmentayeva, D and Maimakova, A and Suieubekov, B and Moiynbayeva, S},
title = {COVID-19 and female reproductive health: pathophysiological mechanisms and clinical reproductive outcomes.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1911269},
pmid = {42798753},
issn = {2296-858X},
abstract = {Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised important concerns regarding its potential effects on female reproductive health. This review aimed to synthesize current evidence on the biological mechanisms, clinical manifestations, ovarian reserve, fertility potential, and assisted reproductive technology (ART) outcomes associated with COVID-19. A comprehensive literature search of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar was conducted for studies published between January 2020 and March 2026. Current evidence suggests that SARS-CoV-2 may affect female reproductive tissues through multiple interconnected pathways, including ACE2/TMPRSS2-mediated tissue susceptibility, immune dysregulation, oxidative stress, endothelial dysfunction, neuroendocrine disturbances, and potentially autoimmune mechanisms. Menstrual disturbances, such as changes in cycle length, menstrual flow, and dysmenorrhea, are among the most frequently reported reproductive manifestations, although most appear transient and reversible. Several studies have reported reductions in anti-Müllerian hormone (AMH) and hormonal alterations, particularly following severe infection; however, findings remain inconsistent. Importantly, most investigations demonstrate preserved ovarian reserve, fertility potential, and ART outcomes, including ovarian response, embryo development, clinical pregnancy, and live birth rates. Overall, current evidence suggests that COVID-19 may cause temporary reproductive alterations rather than permanent impairment of female fertility. Nevertheless, large prospective longitudinal studies are required to clarify long-term reproductive consequences and identify women at increased risk of persistent reproductive dysfunction.},
}
@article {pmid42799123,
year = {2026},
author = {Rakhimzhanova, AS and Pustolaikina, IA and Kurmanova, AF and Muzaparov, RA and Kapishnikova, DD and Stalinskaya, AL and Kulakov, IV},
title = {The Epoxybenzooxocine Core of Integrastatins and Analogs: A Comprehensive Review of Structure, Synthetic Approaches, and Biological Applications.},
journal = {ACS omega},
volume = {11},
number = {37},
pages = {54847-54869},
pmid = {42799123},
issn = {2470-1343},
abstract = {Integrastatins and their biogenetic counterparts possess a rare heterotetracyclic framework containing an unprecedented [6/6/6/6]-tetracyclic skeleton and a central [3/3/1]-bicyclic ketal core with high pharmaceutical potential, particularly due to their potent anti-HIV-1 integrase activity. Despite their promising scaffolds, a systematic consolidation of their chemistry and biology has been entirely lacking, creating a critical gap between the complex architecture of these natural polyketides and the targeted design of drug-like inhibitors. Herein, we present the first comprehensive review of this field, systematically analyzing 42 peer-reviewed publications from 1999 to 2025 retrieved from the Scopus, Web of Science, PubMed, and PubChem databases. Structural analysis confirms that while these rigid, nonplanar V-shaped molecules comply with Lipinski's Rule of Five as a baseline filter for drug-likeness, deeper ADMET profiling further highlights their high predicted human intestinal absorption (HIA) alongside a low risk of cardiotoxicity. Synthetically, we detail how the field has fundamentally evolved from an arduous 11-step sequence in 2003 to highly streamlined, atom-economical one-step protocols in 2008 and 2021, culminating in the 2025 total syntheses that successfully resolved long-standing structural misinterpretations of epicoccolide A and epicocconigrone A. Furthermore, a comparative assessment across eight critical synthetic parameters highlights the operational trade-offs between step efficiency, scalability, and functional group tolerance in current cascade cyclizations. Biologically, we evaluate the extensive in vitro and in silico profiling of over 30 synthetic derivatives, highlighting their antimicrobial (M. bovis, S. aureus, P. carotovorum, C. albicans), antitubercular, and antiviral (SARS-CoV-2 and HIV-1 integrase inhibition) potencies. Integrating pharmacophore mapping with in silico ADMET profiling demonstrates that despite favorable absorption and cardiac safety, predicted liabilities such as human hepatotoxicity, carcinogenicity, and skin sensitization highlight critical areas for targeted structural modification. Ultimately, by bridging synthetic methodology with in silico and experimental bioactivity evaluation, this review establishes epoxybenzooxocine-based heterocycles as viable early-stage lead platforms and outlines strategic directions to advance these scaffolds in targeted drug discovery.},
}
@article {pmid42799772,
year = {2026},
author = {Filippatos, F and Venieri, D and Tsigkrou, E and Karava, V and Miliaraki, M and Kakleas, K},
title = {Infectious triggers in IgA vasculitis in children: current evidence, causal attribution and immunopathogenic mechanisms.},
journal = {Rheumatology international},
volume = {46},
number = {10},
pages = {},
pmid = {42799772},
issn = {1437-160X},
mesh = {Humans ; Child ; *IgA Vasculitis/immunology/microbiology/epidemiology ; *Immunoglobulin A/immunology ; },
abstract = {IgA vasculitis (IgAV) is the most common systemic vasculitis in childhood. Its seasonal distribution and frequent respiratory or gastrointestinal prodromes implicate environmental exposures. However, microbiological detection temporally proximate to disease onset is insufficient to establish causality in an individual patient. To critically evaluate infectious exposures associated with pediatric IgAV, we distinguished epidemiological associations from incidental detection and infectious mimics, and separate direct IgAV evidence from mechanisms extrapolated from IgA nephropathy or general mucosal immunology. PubMed and MEDLINE were searched from inception through 6 August 2026 and supplemented by backward and forward citation tracking. Controlled-vocabulary and free-text terms addressed IgAV, pediatric populations, infection, specific pathogens, microbiota, vaccination, and immune mechanisms. The broad query retrieved 1,174 records before deduplication. Because screening was not prospectively logged, deduplicated screening and full-text counts could not be reconstructed; accordingly, no systematic-review or PRISMA completeness claim is made. Comparative evidence was most consistent for group A streptococcal exposure and population-level circulation of seasonal respiratory bacteria. Evidence for Mycoplasma pneumoniae, Helicobacter pylori in selected phenotypes, SARS-CoV-2, and specific enteric or parasitic infections was of lower certainty and was frequently case-based. Pediatric vaccine studies did not demonstrate a consistent excess risk. Evidence supports convergence of mucosal IgA induction, IgA1-containing immune complexes, complement activation, FcαRI-mediated myeloid signaling, neutrophil extracellular traps, and endothelial injury. Causal attribution requires integrated assessment of temporality, anatomical source, microbiological specificity, background exposure prevalence, and alternative diagnoses. Infectious investigations should be restricted to circumstances in which identification of a treatable infection, persistent antigen source, or immunosuppression-related hazard would alter management.},
}
@article {pmid37018525,
year = {2024},
author = {Bawand, R and Ghiasian, M and Samadyan, M},
title = {Concurrent Diffuse Dural and Leptomeningeal Enhancements in Brain Magnetic Resonance Imaging Following a Mild COVID-19 Infection: A Novel Case Report and Review of Literature.},
journal = {Current medical imaging},
volume = {20},
number = {},
pages = {e280323215040},
doi = {10.2174/1573405620666230328110847},
pmid = {37018525},
issn = {1573-4056},
mesh = {Humans ; Female ; Middle Aged ; *COVID-19/complications/diagnostic imaging ; *Magnetic Resonance Imaging/methods ; *Dura Mater/diagnostic imaging ; *Headache/etiology/diagnostic imaging ; SARS-CoV-2 ; *Meninges/diagnostic imaging ; Pandemics ; *Brain/diagnostic imaging ; *Coronavirus Infections/complications/diagnostic imaging ; *Pneumonia, Viral/complications/diagnostic imaging ; Betacoronavirus ; },
abstract = {INTRODUCTION: During the COVID-19 pandemic, various complications have been reported in patients with this infection worldwide, including a wide range of neurological disorders. In this study, we have reported a novel neurological complication in a 46-years-old woman who was referred due to a headache following a mild COVID-19 infection. Also, we have had a quick review of previous reports of dural and leptomeningeal involvements in COVID-19 patients.<br><br>CASE REPORT: The patient's headache was persistent, global, and compressive with radiation to the eyes. The severity of the headache was increased during the disease course and was exacerbated by walking, coughing, and sneezing but decreased with rest. The high severity of the headache disrupted the patient's sleep. Neurological examinations were completely normal, and laboratory tests did not have abnormal findings except for an inflammatory pattern. Finally, in the brain MRI, a concurrent diffuse dural enhancement and leptomeningeal involvement were observed, which is a new finding in COVID-19 patients and has not been reported so far. The patient was hospitalized and treated with Methylprednisolone pulses. After completing the therapeutic course, she was discharged from the hospital in good condition and with an improved headache. A repeated brain MRI was requested 2 months after discharge, which was completely normal and showed no evidence of dural and leptomeningeal involvements.<br><br>CONCLUSION: Inflammatory complications of the central nervous system caused by COVID-19 can occur in different forms and types, and clinicians should consider them.},
}
@article {pmid42797632,
year = {2026},
author = {Georgakopoulou, VE and Pitiriga, VC},
title = {Complementary Roles of RT-PCR and Next-Generation Sequencing in Post-Vaccination SARS-CoV-2 Infection: Clinical Diagnosis, Genomic Characterization, and Surveillance.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
pmid = {42797632},
issn = {2076-393X},
abstract = {SARS-CoV-2 infection after vaccination remains a clinical and public-health challenge because protection against infection may vary with time since vaccination, host factors, previous infection, and ongoing viral evolution. Although vaccination substantially reduces the risk of severe COVID-19, post-vaccination infections may still occur and may be mild, atypical, or asymptomatic. This narrative review examines the complementary roles of reverse-transcription polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) in the diagnosis, genomic characterization, and surveillance of post-vaccination SARS-CoV-2 infection. RT-PCR remains the first-line method for confirming acute infection because it is rapid, widely available, and clinically actionable, although its clinical performance depends on appropriate specimen collection and timing. NGS complements RT-PCR by providing viral genomic characterization, including lineage assignment, mutation detection, investigation of suspected transmission clusters, and population-level surveillance. Sequencing may provide additional value in selected settings, particularly suspected reinfection, persistent infection in selected immunocompromised patients, outbreak investigations, and representative or event-triggered genomic surveillance. Its use should therefore be guided by a predefined clinical, epidemiological, or surveillance objective rather than applied routinely to all post-vaccination infections. An integrated strategy combining first-line RT-PCR with objective-driven sequencing can preserve diagnostic efficiency while providing genomic information when it is most likely to influence patient-level investigation, infection-control assessment, or public-health surveillance.},
}
@article {pmid42797646,
year = {2026},
author = {Jiang, S and Liu, Y and Cui, R},
title = {Immunogenicity and Safety of RSVPreF3 OA Coadministration Versus Sequential Administration in Adults: A Systematic Review and Meta-Analysis.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
pmid = {42797646},
issn = {2076-393X},
support = {NJ2028YB080//The 2025 Municipal Philosophy and Social Sciences Planning Project of Neijiang City/ ; Project No. 39//This work was supported by the Neijiang Municipal Science and Technology Bureau under the 2025 Second Batch Science and Technology Program Project/ ; },
abstract = {BACKGROUND/OBJECTIVES: Adults eligible for respiratory syncytial virus (RSV) vaccination may also receive influenza, COVID-19, pneumococcal, or herpes zoster vaccines. We compared immunogenicity and safety between coadministration and sequential schedules.<br><br>METHODS: We searched PubMed, Embase, Web of Science, Scopus, and CENTRAL from inception to 3 August 2026 for randomized trials in adults aged 50 years or older. Eligible trials compared RSVPreF3 OA coadministration with sequential administration of the partner vaccine followed by RSVPreF3 OA. Random-effects models pooled neutralizing-antibody geometric mean ratios (GMRs; coadministration/sequential) separately for RSV-A and RSV-B and risk ratios for safety outcomes. Risk of bias and certainty were assessed using RoB 2 and GRADE, respectively.<br><br>RESULTS: Six trials randomized 5455 participants. Pooled RSV-A and RSV-B GMRs were 0.895 (95% CI 0.816-0.983) and 0.922 (95% CI 0.837-1.016), respectively. In trial-specific per-protocol analyses, non-inferiority criteria were met for recombinant zoster vaccine (RZV) and 20-valent pneumococcal conjugate vaccine (PCV20) antibody endpoints, but non-inferiority was not demonstrated for SARS-CoV-2 XBB.1.5 neutralizing antibodies (GMR 0.763, 95% CI 0.662-0.885) or the adjuvanted quadrivalent influenza vaccine A/H3N2 response. The pooled risk ratio for serious adverse events was 0.831 (95% CI 0.530-1.303), with limited precision. Certainty was low for RSV-A and very low for RSV-B, mainly reflecting risk of bias and inconsistency.<br><br>CONCLUSIONS: In adults aged 50 years or older, same-day RSVPreF3 OA coadministration was associated with lower RSV-neutralizing antibody responses than sequential administration, while partner-vaccine immunogenicity varied by product and antigen. Non-inferiority was not demonstrated for the SARS-CoV-2 XBB.1.5 and adjuvanted-QIV A/H3N2 antibody endpoints. No clear safety difference between schedules was identified, and the clinical significance of the antibody differences remains uncertain.<br><br>REGISTRATION: PROSPERO CRD420261470812.},
}
@article {pmid42797648,
year = {2026},
author = {Poddine, G and Bellinato, F and Gisondi, P and Girolomoni, G},
title = {New-Onset Pemphigus Following Drug Exposure and Vaccination: A Systematic Review of Reported Cases.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
pmid = {42797648},
issn = {2076-393X},
abstract = {BACKGROUND: Although an increasing number of cases of new-onset pemphigus have been reported following drug exposure or vaccination, the available evidence remains fragmented and distinguishing true trigger-associated disease from coincidental onset continues to represent a major clinical challenge. We performed a systematic review to evaluate the available evidence on drug- and vaccine-associated new-onset pemphigus and to compare their clinical characteristics, management, and outcomes.<br><br>METHODS: This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261307622). PubMed was searched from database inception to 30 April 2026. Studies reporting individual patients with new-onset pemphigus temporally associated with drug exposure or vaccination were included. Demographic, clinical, immunopathological, therapeutic, and outcome data were extracted and synthesized descriptively because of the anticipated heterogeneity of the available evidence.<br><br>RESULTS: A total of 20 drug-associated and 26 vaccine-associated cases identified from primary reports were included in the descriptive synthesis. Drug-associated cases demonstrated marked heterogeneity in the implicated agents, broader clinical variability, and a longer median latency, with frequent clinical improvement following withdrawal of the suspected drug when reported. In contrast, vaccine-associated cases occurred predominantly after SARS-CoV-2 vaccination, displayed a substantially shorter latency, and were mainly represented by pemphigus vulgaris and pemphigus foliaceus. Across both groups, systemic corticosteroids constituted the mainstay of treatment, with generally favorable outcomes among patients with available follow-up. However, the available evidence consisted almost exclusively of case reports and small case series, precluding reliable assessment of incidence or causality.<br><br>CONCLUSIONS: Current evidence suggests that drugs and vaccines may act as potential triggers of new-onset pemphigus in susceptible individuals; however, the strength of evidence differs substantially between the two settings. Drug-associated cases generally provide more convincing clinical support for a trigger-related mechanism, whereas vaccine-associated cases require more cautious interpretation because temporal association alone cannot establish causality. Standardized case reporting, prospective pharmacovigilance, and mechanistic studies are needed to strengthen causal inference and improve the recognition and management of trigger-associated pemphigus.},
}
@article {pmid42797823,
year = {2026},
author = {Shaw, M and Fehr, AR},
title = {SARS-CoV-2 Drug-Resistant Mutations in Non-Structural Proteins.},
journal = {Viruses},
volume = {18},
number = {9},
pages = {},
pmid = {42797823},
issn = {1999-4915},
support = {2515959//U.S. National Science Foundation/ ; },
mesh = {Humans ; *Viral Nonstructural Proteins/genetics/metabolism ; *Drug Resistance, Viral/genetics ; *Antiviral Agents/pharmacology/therapeutic use ; *Mutation ; *SARS-CoV-2/genetics/drug effects ; Virus Replication/drug effects ; COVID-19 Drug Treatment ; RNA-Dependent RNA Polymerase/genetics ; RNA Replication ; COVID-19/virology ; },
abstract = {Various antiviral drug therapies have been developed for the treatment of coronaviruses, particularly SARS-CoV-2. However, the emergence of drug-resistant mutations is detrimental to clinical efficacy and global public health. Antiviral usage exerts selective pressures on viruses that manufacture an environment for resistant strains to emerge, in some cases at a fitness cost. However, the appearance of a compensatory mutation can restore or improve viral fitness, allowing the strain to persist and spread in a population. Here we evaluate the drug resistance mechanisms of multiple SARS-CoV-2 non-structural proteins, including the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRP), which drive polyprotein processing and viral RNA replication, as well as PLPro, EndoU, and Mac1, which contribute to viral replication and counter host innate immune responses. We also discuss several methods that could be used to avoid drug resistance in the future. By integrating the understanding of molecular mechanisms of antiviral treatment with surveillance of resistance-associated mutations and new drug therapies, appropriate clinical approaches can be developed to reduce the impact of drug resistance.},
}
@article {pmid42797853,
year = {2026},
author = {Galati, G and Pavan, G},
title = {Can Non-Thermal Microwave Irradiation Inactivate Viruses? A Review with Some Computations.},
journal = {Viruses},
volume = {18},
number = {9},
pages = {},
pmid = {42797853},
issn = {1999-4915},
mesh = {*Microwaves ; Humans ; *Virus Inactivation/radiation effects ; *Viruses/radiation effects ; SARS-CoV-2/radiation effects ; },
abstract = {The use of non-thermal, human-safe electromagnetic (e.m.) waves in the GHz range to inactivate viruses has been proposed by a few groups. It is allegedly based on a transformation of a microwave photon into a phonon, which would produce a so-called Structure Resonance Energy Transfer (SRET) strong enough to break the capsid due to Confined Acoustic Vibration (CAV) at virus-specific frequencies. However, it is well known that e.m. photons' absorption in water or in organic media does not generate single phonons at the same frequency. Rather, it generates many thermal phonons across a wide frequency spectrum according to the widely known microwave heating effect, as exploited, inter alia, in the microwave oven. However, there remains interest in proposed usages of non-thermal microwave fields to inactivate respiratory viruses for air sanitization purposes. Hence, this paper poses the question: can human-safe microwave irradiation inactivate viruses?},
}
@article {pmid42797858,
year = {2026},
author = {Alousi, FF and Alli, AA},
title = {Role of Ion Channels in the Pathophysiology of SARS-CoV-2.},
journal = {Viruses},
volume = {18},
number = {9},
pages = {},
pmid = {42797858},
issn = {1999-4915},
mesh = {Humans ; *Ion Channels/metabolism ; *SARS-CoV-2/physiology ; *COVID-19/physiopathology/virology ; Virus Replication ; Viroporin Proteins/metabolism ; Immune Evasion ; *Betacoronavirus/physiology ; Viral Proteins/metabolism ; Animals ; },
abstract = {In the pathophysiology of SARS-CoV-2, the critical role of ion channels has become increasingly evident during the COVID-19 crisis. This review offers a comprehensive analysis of the functions of ion channels, including viroporins, in both the viral life cycle and the host immune response. It explores how ion channels facilitate viral replication, assembly, and immune evasion. Moreover, this review critically examines the molecular mechanisms underpinning SARS-CoV-2 infection, with a particular emphasis on the integral role of viral proteins exhibiting membrane-interacting properties, collectively named viroporins, in promoting viral survival and triggering host defense mechanisms, highlighting their potential as therapeutic targets. By unraveling these complex interactions, this review aims to increase our understanding of COVID-19 pathophysiology.},
}
@article {pmid42797597,
year = {2026},
author = {Lo Moro, G and Butnaru, AM and Toffanin, C and Cataldo, A and Mazzeo, S and Martella, M and Scaioli, G and Bert, F and Siliquini, R},
title = {Guidelines on Immunization of People with Chronic Neurological Disorders: A Systematic Review.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/vaccines14090777},
pmid = {42797597},
issn = {2076-393X},
abstract = {BACKGROUND: People with chronic neurological disorders may be vulnerable to severe outcomes from vaccine-preventable infections. However, immunization recommendations for these patients may be difficult to identify and apply. This systematic review aimed to identify and describe official guidelines on preventive active immunization for individuals with chronic neurological disorders.<br><br>METHODS: This systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 and registered in the PROSPERO International prospective register of systematic reviews (CRD420251005848). Bibliographic databases (PubMed, Embase, Scopus) and grey literature sources were searched to identify official national or international clinical practice guidelines or comparable structured guidance documents providing recommendations relevant to chronic neurological disorders. The search was restricted to countries with a Human Development Index greater than 0.8, to allow comparison across broadly comparable healthcare and socioeconomic contexts. Data were extracted on document characteristics, neurological conditions addressed, vaccines covered, and vaccination-related recommendations.<br><br>RESULTS: Overall, 12 unique documents were included. Four were vaccination-focused documents including recommendations for neurological disorders, four were disease-management guidelines including vaccination-related recommendations, and four specifically addressed vaccination in selected neurological diseases. Guidance was unevenly distributed across countries, neurological conditions, and document types. Influenza and COVID-19 vaccination were the most consistently addressed vaccines. Multiple sclerosis was the condition with the most detailed guidance, especially regarding vaccination before disease-modifying therapies, live attenuated vaccines, vaccine timing in relation to immunosuppression or relapse, and protection of close contacts.<br><br>CONCLUSIONS: Official immunization guidance for people with chronic neurological disorders remains limited and heterogeneous. Future guidelines should provide clearer and regularly updated recommendations to support vaccination assessment, treatment-sensitive planning, and multidisciplinary coordination.},
}
@article {pmid42797601,
year = {2026},
author = {Cai, D and Li, X and Wang, R and Lin, C and Wen, J and Tian, B},
title = {Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/vaccines14090781},
pmid = {42797601},
issn = {2076-393X},
support = {No. S202610626016//the Sichuan Provincial College Students Innovation and Entrepreneurship Training Program/ ; 2521993028/2025//Sichuan University/ ; },
abstract = {RNA vaccines-comprising linear mRNA, self-amplifying RNA, and circular RNA (circRNA)-constitute a core next-generation platform for the prevention and control of viral diseases; among these, circRNA vaccines possess notable structural stability, yet their technical bottlenecks and application prospects in veterinary medicine have not been systematically reviewed. This review synthesizes current research on circRNA vaccine design, circularization strategies, translation mechanisms, delivery systems, and immunological outcomes, and compares their antiviral performance with that of linear mRNA vaccines. Owing to their covalently closed circular conformation, circRNA vaccines exhibit enhanced resistance to nucleases and superior thermal stability, enabling sustained transfection activity at ambient temperatures without reliance on strict cold chains; through cap-independent translation driven by internal ribosome entry sites or N[6]-methyladenosine modifications, and in conjunction with optimized circularization protocols and lipid nanoparticle carriers, circRNA vaccines elicit substantially higher antiviral IgG titers and durable antigen-specific T-cell memory relative to linear mRNA vaccines. These vaccines have been deployed against COVID-19, monkeypox, influenza, and livestock viral diseases, demonstrating strong adaptability to viral variants and compatibility with mucosal or needle-free administration routes. CircRNA vaccines are well suited for both emergency outbreak response and routine immunization programs; nevertheless, challenges persist, including low circularization efficiency for long sequences, elevated manufacturing costs, and inadequate quality control standards. Addressing these issues through improved production workflows and delivery technologies adapted to resource-limited settings will be critical to establishing circRNA vaccines as a pillar of livestock disease management and as a strategic reserve for emerging zoonotic threats.},
}
@article {pmid42797619,
year = {2026},
author = {Dillard, JA and Saldivar, RA and Heise, MT and Baxter, VK},
title = {Vaccine-Associated Enhanced Respiratory Disease: From Animal Models to Human Health.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/vaccines14090799},
pmid = {42797619},
issn = {2076-393X},
support = {1P01AI158571-01/NH/NIH HHS/United States ; 3U19AI100625-10/NH/NIH HHS/United States ; 5R01AI157253-05/NH/NIH HHS/United States ; 5U19AI109680-05/NH/NIH HHS/United States ; 7K01OD026529-06/NH/NIH HHS/United States ; 5T32AI007419-30/NH/NIH HHS/United States ; 5T32GM008719-25/NH/NIH HHS/United States ; 4P30CA016086-50/NH/NIH HHS/United States ; 5U01AI149644-05/NH/NIH HHS/United States ; 3U54CA260543-02/NH/NIH HHS/United States ; Infectious Disease Drug Discovery Program (ID3)//University of North Carolina System/ ; Rapidly Emerging Antiviral Drug Development Initiative (READDI)//Rapidly Emerging Antiviral Drug Development Initiative (READDI)/ ; North Carolina Translational Clinical Sciences Institute (NCTraCS)//University of North Carolina System/ ; Emerging Challenges in Biomedical Research COVID Pilot Award//University of North Carolina System/ ; Junior Investigator Development Award//University of North Carolina System/ ; Contract #95928//American Cancer Society/ ; },
abstract = {Vaccines are a safe and highly effective tool for protecting both humans and animals against infectious diseases. Although vaccines currently in use in humans have robust safety records, historical examples show that some vaccines have resulted in adverse outcomes, including vaccine-associated enhanced respiratory disease (VAERD). VAERD occurs when preexisting vaccine-induced immunity worsens respiratory disease, rather than conferring protection during infection. Enhanced disease in the lower respiratory tract characteristic of VAERD includes worsened clinical manifestations such as pneumonia and bronchiolitis, as well as increased pulmonary pathology in vaccinated, infected individuals compared with their unvaccinated, infected counterparts. Mechanistically, VAERD has been associated with TH2-mediated immunopathology or antibody-dependent enhancement and is primarily associated with specific virus families, including Pneumoviridae, Orthomyxoviridae and Coronaviridae. Notable cases of VAERD have been associated with a respiratory syncytial virus vaccine candidate evaluated in clinical trials in the 1960s, experimental coronavirus vaccines in animal models, and in veterinary vaccines for influenza virus in swine. Existing approved vaccines are safe and highly effective tools for protecting both humans and animals against respiratory pathogens. However, as new respiratory vaccines are developed, they must also undergo careful testing for VAERD or other adverse outcomes. This review aims to provide the field with an overview of VAERD as a resource to support vaccine development and safety studies.},
}
@article {pmid42780769,
year = {2026},
author = {Amiri, M and Cheraghi, M and Khalili, F and D'Ambrosio, L and Centis, R and Dinh-Xuan, AT and Venketaraman, V and Nasiri, MJ and Migliori, GB},
title = {Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.},
journal = {Respiratory research &amp; clinical practice},
volume = {52},
number = {1},
pages = {e20250438},
pmid = {42780769},
issn = {3086-3910},
support = {R15 HL143545/HL/NHLBI NIH HHS/United States ; },
mesh = {Humans ; *Acetylcysteine/therapeutic use ; *Intensive Care Units/trends ; Hospital Mortality/trends ; Length of Stay ; Respiration, Artificial ; Randomized Controlled Trials as Topic/methods ; *Expectorants/therapeutic use ; Critical Illness ; *Respiratory Tract Diseases/drug therapy/mortality ; },
abstract = {OBJECTIVE: Critically ill patients with respiratory disease often experience impaired airway clearance, which contributes to adverse clinical outcomes. N-acetylcysteine (NAC) has mucolytic and antioxidant properties, and may have therapeutic potential in this setting. This study evaluated the impact of NAC on clinical outcomes in ICU patients with underlying respiratory disease.<br><br>METHODS: A systematic literature search was conducted in PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from January of 2000 to July of 2025 in order to identify randomized controlled trials evaluating NAC in ICU patients with respiratory conditions. Primary outcomes included hospital mortality, duration of mechanical ventilation, ICU length of stay (LOS), and hospital LOS. Data were synthesized using fixed- or random-effects models based on heterogeneity. Subgroup analyses were performed based on the route of NAC administration.<br><br>RESULTS: Five randomized controlled trials comprising 340 patients were included. Hospital mortality was 44.76% in the NAC group and 47.61% in the control group (OR = 0.87; 95% CI: 0.49-1.53). No significant differences were observed in ventilation duration (mean difference [MD] = 0.79 days; 95% CI: -2.87 to 4.44) or ICU LOS (MD = 0.21 days; 95% CI: -3.75 to 4.17). However, NAC was associated with a shorter hospital stay (MD = -3.84 days; 95% CI: -7.44 to -0.24). Subgroup analysis suggested variability in mortality outcomes based on administration route.<br><br>CONCLUSIONS: NAC may reduce hospital LOS in critically ill patients with respiratory disease, although its effects on mortality and ventilation duration remain inconclusive. These findings may inform future research, particularly in patients with post-infectious lung damage such as that seen in COVID-19 or tuberculosis.},
}
@article {pmid42780929,
year = {2026},
author = {Mokwele, ML and Van Niekerk, A},
title = {Organisational change and employee mental health: a conceptual framework integrating conservation of resources theory and the job demands-resources model.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1925071},
pmid = {42780929},
issn = {2296-2565},
mesh = {Humans ; *Organizational Innovation ; *Mental Health ; COVID-19/epidemiology ; Working Conditions ; *Workplace/psychology ; Psychological Safety ; Leadership ; *Occupational Health ; *Workload/psychology ; SARS-CoV-2 ; },
abstract = {Organisational change has intensified in recent years in response to shifting workplace expectations, rapid technological developments, the effects of COVID-19, and evolving work patterns. While such transformation is often necessary for organisational sustainability, it can increase uncertainty, alter job demands, and place emotional pressure on employees. Drawing on Conservation of Resources theory, this article suggests that employees may view change as a threat to valued personal and work resources, heightening stress responses. The Job Demands-Resources model further illustrates how increased demands such as digital overload and rising performance pressures can affect wellbeing unless balanced with appropriate resources, including autonomy, clarity, and supportive work relationships. A range of organisational factors can shape how employees experience these changes. Leadership behaviours, communication practises, opportunities for involvement, and levels of engagement all influence how employees interpret and respond to shifting demands. These factors interact with job demands and resources by shaping perceptions of fairness, predictability, psychological safety, and support during periods of transition. Rather than functioning independently, these elements combine to influence employee wellbeing and adjustment. The article presents a framework in which the impact of organisational change on wellbeing is understood through the interplay between demands, available resources, and the broader relational and communicative environment. It highlights the enduring effects of recent disruptions, which have increased the need to understand how employees adapt to continuous change. The paper concludes by identifying future research directions aimed at improving organisational practises that support employee wellbeing throughout ongoing transformation.},
}
@article {pmid42781593,
year = {2026},
author = {Tapchaisri, P and Theeraroungchaisri, A},
title = {Regulatory evolution and service delivery models of telepharmacy in Thailand: a review of pandemic responses and future policy directions.},
journal = {Journal of pharmaceutical policy and practice},
volume = {19},
number = {1},
pages = {2731648},
pmid = {42781593},
issn = {2052-3211},
abstract = {BACKGROUND: The COVID-19 pandemic accelerated digital health adoption in Thailand, disrupting traditional healthcare delivery and prompting rapid pharmaceutical system reforms. Prior to 2020, telepharmacy was virtually non-existent due to strict regulations mandating in-person dispensing at licensed premises; however, the public health crisis prompted policy changes, leading to regulatory relaxation and the formal establishment of telepharmacy standards. To understand these transformative shifts, this review examines the regulatory evolution of telepharmacy in Thailand, classifies diverse service delivery models implemented across hospital and community pharmacy settings, and synthesises effectiveness evidence to inform future pharmaceutical policy and sustainable system integration.<br><br>METHODS: An integrative narrative review using documentary analysis of official policy and regulatory documents was conducted. Studies evaluating telepharmacy or medication delivery services were identified through PRISMA-guided searches of Thai-Journal Citation Index (TCI), PubMed, and Google Scholar (2020-2025).<br><br>RESULTS: Thailand implemented a phased policy response progressing from emergency regulatory flexibility toward institutionalised governance. Seven hospital-based telepharmacy models were identified. Synthesis of 31 included studies (14 pharmacist-led and 17 telemedicine with medication delivery or medication delivery without pharmacist counselling studies) suggested that telepharmacy and medication delivery services generally supported continuity of care for chronic diseases. Studies involving pharmacist interventions more frequently reported favourable outcomes, although findings varied across service models. Implementation relied largely on social media platforms and proprietary applications, though independent pharmacies faced financial barriers to accessing certified platforms.<br><br>CONCLUSION: While telepharmacy has been integrated into routine care under the Universal Coverage Scheme (UCS), an institutionalisation gap remains regarding sustainable public financing and digital infrastructure. Addressing regulatory clarity, reimbursement mechanisms, digital equity, and platform interoperability will be essential for the long-term and equitable integration of telepharmacy.},
}
@article {pmid42781939,
year = {2026},
author = {Sällberg, M},
title = {Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID-19 Pandemic.},
journal = {Acta paediatrica (Oslo, Norway : 1992)},
volume = {},
number = {},
pages = {},
doi = {10.1111/apa.70762},
pmid = {42781939},
issn = {1651-2227},
support = {23-3071//Cancerfonden/ ; 2025-06729//Vetenskapsr&#xe5;det/ ; },
abstract = {Vaccines have been a cornerstone of human health for more than 200 years and one of the most important tools to reduce childhood deaths caused by pathogens. The concept of vaccines is basically to take something safe, make it immunogenic and induce an immune response in the host that will protect it against something dangerous. Live attenuated vaccines were the only option two centuries ago. These are excellent, and possibly the best vaccine platform, but they have limitations as they cannot always be given to everyone safely, for example due to deficient immunity or pregnancy. That is why newer platforms, such as killed or inactivated vaccines, were developed. These provide better all-round safety, but are often less immunogenic and require additional doses. Subcomponent vaccines were then developed in the 1980s. These only used parts of the virus, further improving safety and introducing the possibility of producing vaccines using gene technology. Adding genetic vaccines to the toolbox revolutionized the way that we handled the COVID-19 pandemic. The host became the producer of the vaccine, which better mimicked the immune responses induced by the live attenuated vaccines. All these platforms will be discussed in this mini-review.},
}
@article {pmid42782353,
year = {2026},
author = {Diederich, NJ and Pauly, C},
title = {Stress and Parkinson's disease: from dysfunctional detection to impaired handling: a narrative review.},
journal = {Journal of neural transmission (Vienna, Austria : 1996)},
volume = {},
number = {},
pages = {},
pmid = {42782353},
issn = {1435-1463},
abstract = {Stress can precipitate Parkinson's disease (PD), and conversely, PD imposes substantial stress on affected individuals. Controlled studies support this bidirectional relationship. Recent observations during the Covid‑19 pandemic suggested that PD patients may sometimes display an unexpected resilience to stressful events (SE), in particular in terms of missing motor deterioration. However, this "favorable" interpretation can be misleading as PD is characterized by dysfunctional stress detection and stress processing. Furthermore, reduced stress‑related cardiac morbidity has not been demonstrated uncontestably. Indeed, detailed analyses indicate that involvement of non‑dopaminergic systems modifies-rather than mitigates-stress responses. Lewy body pathology already compromises activation of the hypothalamic-pituitary-adrenal (HPA) axis, while autonomic cardiac responses are blunted. Dysfunction of the superior colliculi impairs instant detection of stress events (SE); degeneration of the pedunculopontine nucleus disrupts appropriate motivational appraisal of the SE. Impaired contrast discrimination and olfaction hinder immediate perceptual SE assessment. Locus coeruleus involvement reduces alertness, further limiting SE evaluation. Finally, at the nexus of stress handling, dysfunctional amygdalar networks contribute to diminished autonomic reactivity and altered emotional processing. This review synthesizes current knowledge on peripheral and central stress‑related systems affected by PD pathophysiology. It outlines established, emerging, and theoretical therapeutic strategies, including approaches informed by the Stress Reduction Theory and the Attention Restoration Theory. It underscores the need for systematic investigation into stress mechanisms in PD, an area that remains insufficiently explored.},
}
@article {pmid42782808,
year = {2026},
author = {Santos, P and Almeida, F},
title = {Hijacking Host Communication: The Central Role of Extracellular Vesicles in Infectious Disease Pathogenesis.},
journal = {Cells},
volume = {15},
number = {18},
pages = {},
pmid = {42782808},
issn = {2073-4409},
support = {2021/06794-5//Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo/ ; },
mesh = {*Extracellular Vesicles/metabolism/immunology ; Humans ; *Host-Pathogen Interactions/immunology ; Animals ; *Communicable Diseases/immunology/parasitology ; *Cell Communication ; Immune Evasion ; },
abstract = {Extracellular vesicles (EVs) have emerged as fundamental mediators of intercellular communication during infectious diseases, acting as vehicles for proteins, lipids, and nucleic acids that profoundly influence host-pathogen interactions. In recent years, accumulating evidence has revealed that pathogens from distinct biological kingdoms, including protozoan parasites, viruses, and bacteria, either release their own EVs or exploit host-derived EVs to manipulate immune responses, promote infection, and sustain chronic disease. This review provides a comprehensive and integrative overview of the roles of EVs in infectious diseases, with particular emphasis on immune modulation, immune evasion, pathogenesis, and translational applications. We summarize current knowledge on EV-mediated communication in infections caused by major protozoan parasites (Trypanosoma cruzi, Plasmodium spp., Toxoplasma gondii, and Leishmania spp.), highlighting how parasite- and host-derived EVs regulate inflammatory responses, facilitate intracellular survival, and shape disease outcomes. We further examine viral infections, including HIV, HPV, HCV, and airborne respiratory viruses such as SARS-CoV-2, where EVs contribute to viral persistence, immune dysfunction, oncogenesis, and long-term sequelae. In addition, we discuss bacterial infections, focusing on Mycobacterium tuberculosis, Streptococcus pneumoniae, and Helicobacter pylori, illustrating how EVs can function both as vectors of virulence factors and as components of host defense mechanisms. Finally, we explore the emerging translational potential of EVs as non-invasive biomarkers for disease diagnosis and prognosis, as well as their application as therapeutic and vaccine platforms. By integrating findings across diverse pathogens, this review highlights extracellular vesicles as widely implicated and dynamic contributors of infectious disease biology and underscores their relevance as targets and tools for next-generation diagnostic and therapeutic strategies.},
}
@article {pmid42783445,
year = {2026},
author = {Minoretti, P and Emanuele, E},
title = {COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {5},
pages = {},
doi = {10.3390/medsci14050572},
pmid = {42783445},
issn = {2076-3271},
mesh = {Humans ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology/therapeutic use ; SARS-CoV-2/immunology ; *Drug Repositioning ; *Immunologic Factors/therapeutic use ; mRNA Vaccines/immunology ; RNA, Messenger/immunology ; Vaccines, Synthetic/immunology ; Pandemics ; },
abstract = {Since 2020, billions of doses of COVID-19 messenger RNA (mRNA) lipid nanoparticle vaccines have been administered worldwide, generating one of the largest pharmacovigilance databases for a modern therapeutic class. Intriguingly, their immunopharmacologic profile-including the engagement of innate nucleic acid sensors, systemic type I interferon signaling, dendritic cell-mediated cross-priming of CD8+ T cells, and upregulation of programmed cell death ligand 1 (PD-L1)-may extend beyond COVID-19 prophylaxis. Retrospective evidence from six independent cohorts, one of which is a multinational health-data network, indicated that vaccination within 100 days of immune checkpoint inhibitor (ICI) initiation may improve survival of patients with malignancies, including in immunologically cold tumors, although a substantial fraction of the original effect may be attributed to pandemic-era selection bias. Here, we examine the mechanistic basis and available evidence for the repurposing of licensed COVID-19 mRNA vaccines as antigen-agnostic immunomodulators. We identified five candidate contexts for prospective evaluation-namely, (1) PD-L1-negative non-small cell lung cancer initiating ICI therapy, (2) perioperative immune dysfunction in major cardiac surgery, (3) chronic hepatitis B, (4) chronic HIV with persistent immune exhaustion, and (5) sepsis-induced immunoparalysis. Methodological foundations for confirmatory assessment-comprising target trial emulation, Mendelian randomization, and pragmatic trial design-are now sufficiently developed to enable implementation. Prospective evaluation of the antigen-agnostic repurposing hypothesis is operationally feasible, albeit constrained by residual confounding and uncertainty about the durability of vaccine-induced innate reprogramming.},
}
@article {pmid42783492,
year = {2026},
author = {Śliwiński, W and Pura, W and Matecka, D and Kosowski, M and Chołuj, D and Marciniak, J and Mazur, J and Zarówna, K and Damodaran, L and Szejko, N},
title = {Neurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review.},
journal = {Journal of personalized medicine},
volume = {16},
number = {9},
pages = {},
doi = {10.3390/jpm16090461},
pmid = {42783492},
issn = {2075-4426},
abstract = {Background: Pediatric inflammatory multisystem syndrome (PIMS), also referred to as multisystem inflammatory syndrome in children (MIS-C), is a rare but serious post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection characterized by systemic hyperinflammation and multiorgan involvement. New-onset neurological and psychiatric symptoms have emerged as critical clinical features, occurring in approximately 12-27% of pediatric patients aged 2-15 years (median age, 10 years) and often indicating a more severe disease course. This narrative review aims to provide a comprehensive overview of the current literature regarding the neurological and psychiatric manifestations of PIMS/MIS-C, focusing on epidemiology, pathophysiology, clinical presentation, neuroimaging findings, biomarkers, treatment strategies, and outcomes. Methods: A narrative literature review was conducted to synthesize current evidence on the neurological and psychiatric spectrum of PIMS/MIS-C. Evaluated parameters included clinical presentations ranging from common symptoms (such as headache, encephalopathy, altered mental status, and seizures) to rare complications (such as ischemic stroke, acute disseminated encephalomyelitis, Guillain-Barré syndrome, and cerebral edema), alongside associated psychiatric disturbances, diagnostic findings, and therapeutic approaches. Results: Neurological and psychiatric manifestations significantly impact the clinical trajectory of PIMS/MIS-C. Acute symptoms include headache, encephalopathy, seizures, and psychiatric disturbances like behavioral changes, hallucinations, delirium, anxiety, and sleep disorders. Neuroimaging in many cases reveals reversible lesions of the splenium of the corpus callosum, while electroencephalography typically demonstrates diffuse slowing consistent with encephalopathy. Early recognition and prompt administration of immunomodulatory therapy-primarily intravenous immunoglobulin and corticosteroids-correlate with favorable neurological recovery in the majority of patients. However, current evidence remains largely observational and heterogeneous, precluding definitive causal conclusions regarding this treatment-outcome relationship. Affected children more frequently require intensive care unit admission and remain at risk for persistent cognitive, behavioral, and psychiatric sequelae. Conclusions: Neurological and psychiatric complications in PIMS/MIS-C are clinically significant indicators of disease severity that require vigilant monitoring and early immunomodulatory intervention. Continued multidisciplinary follow-up and prospective studies are essential to elucidate the long-term neurodevelopmental and psychiatric consequences and to optimize therapeutic strategies for these patients.},
}
@article {pmid42786345,
year = {2026},
author = {Stengel, S and Lindner, N},
title = {[Diagnosis of Long Covid/Post Covid in Primary Care Settings - Recognition, Classification, and Differentiation].},
journal = {MMW Fortschritte der Medizin},
volume = {168},
number = {16},
pages = {38-41},
doi = {10.1007/s15006-026-6215-1},
pmid = {42786345},
issn = {1613-3560},
}
@article {pmid42786507,
year = {2026},
author = {Kim, DY and Hong, JJ},
title = {Rethinking non-human primate models for emerging viral infections after COVID-19.},
journal = {Laboratory animal research},
volume = {42},
number = {1},
pages = {},
pmid = {42786507},
issn = {1738-6055},
support = {RS-2022-NR067509//Bio &amp; Medical Technology Development Program of the National Research Foundation (NRF)/ ; KGM 4572431//Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Programs/ ; },
abstract = {Non-human primates (NHPs) retain particular value in emerging viral infection research when questions require integrated analysis of systemic viral kinetics, protective immunity, tissue pathology, or longitudinal outcomes. However, their cost, limited availability, specialized husbandry, and ethical constraints preclude their routine use as default screening platforms. Using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a case study, we compare how rhesus macaques, cynomolgus macaques, African green monkeys, baboons, and marmosets have contributed to studies of pathogenesis, vaccine protection, therapeutic efficacy, immune memory, and post-acute outcomes. We emphasize that these species-question relationships cannot be transferred uncritically to future pathogens; model suitability must be re-established according to receptor usage, tissue tropism, disease phenotype, and experimental objective. AI-guided prediction, human organoids, and organ-on-chip systems can support this process by prioritizing variants and candidates, identifying tissue-specific mechanisms, and refining endpoints before NHP studies begin. We therefore propose a question-driven workflow in which computational and human-relevant platforms narrow the evidence gap before fit-for-purpose NHP validation. This strategy can improve interpretability, reproducibility, and alignment with the 3Rs while preserving NHP use for questions that require intact organism-level biology.},
}
@article {pmid42787466,
year = {2026},
author = {Geza, W and Dirwai, TL and Dlamini, N and Sobratee-Fajurally, N and Mabhaudhi, T},
title = {Enhancing youth resilience to agri-food system shocks: a pathway to climate justice.},
journal = {Environmental research. Food systems},
volume = {3},
number = {4},
pages = {042001},
pmid = {42787466},
issn = {2976-601X},
abstract = {Meaningful youth engagement in climate policy, resilience-building, and agrifood system transformation is vital to ensuring that young people are prioritised in national and global agendas. This review situates youth resilience within the context of climate justice, recognising that those in low- and middle-income countries (LMICs) disproportionately experience climate-related shocks due to systemic inequalities. Guided by the Preferred Reporting Items for Systematic and Meta-Analyses Protocol framework, a scoping review was undertaken to examine how youth in LMICs experience and respond to agrifood system vulnerabilities arising from climate change, economic disruptions (including COVID-19), and conflict, with a focus on education and employment outcomes. Systems thinking served as the central analytical approach to identify interdependencies, feedback loops, leverage points, and resilience pathways. The findings reveal limited research quantifying youth-specific vulnerabilities and resilience strategies within agrifood systems. While broad impacts are recognised, youth agency and adaptive capacities remain underexplored. The interactions among climate impacts, contextual vulnerability, health-productivity constraints, food insecurity and governance conditions create compounding risks that exacerbate food insecurity and social inequity among rural and urban youth. To address these gaps, the study proposes a conceptual framework that integrates climate justice principles into resilience-building strategies, promoting equitable access to resources, inclusive governance, and youth-led adaptation. By mapping interconnections across agrifood systems, climate, equity, education, and employment, the study charts resilience pathways toward socially inclusive, climate-adaptive, and economically sustainable food systems, underscoring the need for policies and research that centre youth agency and lived experiences.},
}
@article {pmid42787611,
year = {2026},
author = {Gulubova, MV and Ignatova, MK and Dimitrova, DN and Ananiev, JR},
title = {Immune cell interactions and lung damage in SARS-CoV-2 special attention on monocytes/macrophages, T and B lymphocytes, dendritic cells and Toll-like receptors in SARS-CoV-2.},
journal = {American journal of clinical and experimental immunology},
volume = {15},
number = {4},
pages = {290-306},
pmid = {42787611},
issn = {2164-7712},
abstract = {Coronavirus disease 2019 (COVID-19) is caused by a novel human virus - SARS-CoV-2, is characterized in severe cases by dysregulated innate and adaptive immune responses leading to lung injury and systemic hyperinflammation. This review summarizes the roles of monocyte/macrophages, T and B lymphocytes, dendritic cells, and Toll-like receptor signaling in the immunopathogenesis of severe COVID-19. Severe COVID-19 is characterized by light neutrophilia, reduced numbers of transitional and non-classical monocytes, lymphopenia and diminished conventional and plasmacytoid dendritic cells (DCs). Inflammatory monocytes/macrophage activation and excessive cytokine production contribute to alveolar damage and cytokine storm. Alveolar macrophages (AMs) are abortively infected by the virus in an ACE2-dependent manner, but still no virus replication has been detected. AMs produce high quantities of IL-6 TNF-α, and IL-1β promoting cytokine storm. T lymphocytes dysregulation is associated with lymphopenia, impaired antiviral responses, and T-cell exhaustion. Severe COVID-19 infection causes a disproportionate decrease of CD4[+] T cells, reduced CD8[+] T cells and alteration of T cell subsets i.e. Tregs decrease and stimulation of Th1, Th2 and Th17. TLR3 and TLR7 are broadly expressed on human immune cells and recognize dsRNA and ssRNA in the endosome. Since TLR7 duplicated genes are localized on the X-chromosome, the disease is more expressed in men. B cell responses are characterized by impaired germinal center formation and extrafollicular antibody production. B cells produce neutralizing antibodies having little somatic hypermutations (SHM) that block the virus in the extra-follicular space. The activation of B cells via contact with Tfh cells antigen and BCR antigen is described. The reduction of germinal centers in thoracic lymph nodes and spleen is discussed. DCs depletion and dysfunction reduce antigen-presentation and interferon responses. A significant reduction of conventional DCs1 and DCs2 and of pDCs in blood is detected. Simultaneously, CD1c[+] DCs are recruited and increased in the lung in severe COVID-19. Toll-like receptor pathways further amplify inflammatory signaling and immune imbalance. Collectively, these immune alterations contribute to defective viral clearance and progressive lung injury. Understanding the interactions between innate and adaptive immune responses in COVID-19 may support the development of targeted immunomodulatory therapies and provide broader insights into viral immunopathology.},
}
@article {pmid42787723,
year = {2026},
author = {Roberts, K and Goodman, A and Ferguson, A and Kaminski, A and Spellman, T and Luba, R},
title = {De-implementation of inequitable methadone policy and treatment: lessons learned from COVID-19 to support a more just methadone treatment system in the United States.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1951510},
pmid = {42787723},
issn = {2296-2565},
mesh = {*Methadone/therapeutic use ; Humans ; United States ; *Opiate Substitution Treatment ; *Opioid-Related Disorders/drug therapy ; *COVID-19/epidemiology ; *Health Policy ; SARS-CoV-2 ; },
abstract = {Despite decades of evidence supporting methadone as a life-saving treatment for opioid use disorder, its delivery in the US has been stymied by stigmatizing dispensation policies that are neither evidence-based nor person-centered. Implementation failures and regulatory challenges have resulted in a significant treatment gap in the US and less than 30% of people with OUD enter and remain in treatment. In this article, we provide a historical overview of the methadone treatment (MT) system in the US and outline why it requires de-implementation. We present the COVID-19 public health emergency as a naturalistic experiment in de-implementation, outline evidence from this period on how COVID-19 related flexibilities influenced treatment outcomes and patient experiences and present a de-implementation framework to contextualize these changes while imagining further expansion of de-implementation efforts to support sustained change. We highlight how patient advocacy can shape further de-implementation while noting current threats to progress.},
}
@article {pmid42788521,
year = {2026},
author = {Rolim, M and Leite, AB and Perdigão Neto, LV and Levin, AS},
title = {COVID-19 AND IBD: LOOK BEYOND THE VIRUS. A SYSTEMATIC REVIEW AND META-ANALYSIS FOCUSED ON BIOLOGIC THERAPY CONTINUITY.},
journal = {Arquivos de gastroenterologia},
volume = {63},
number = {},
pages = {e25147},
doi = {10.1590/S0004-2803.24612025-147},
pmid = {42788521},
issn = {1678-4219},
mesh = {Humans ; *Inflammatory Bowel Diseases/complications/drug therapy/therapy ; *COVID-19/complications ; *Biological Therapy ; Biological Products/therapeutic use ; },
abstract = {BACKGROUND/OBJECTIVE: Whether COVID-19 worsens the longterm course of inflammatory bowel disease (IBD) remains uncertain. We synthesized comparative cohorts to assess IBD outcomes after SARS-CoV-2 infection versus noninfected IBD controls and to evaluate the impact of biologic discontinuation.<br><br>METHODS: Systematic review (PRISMA 2020). Adult IBD cohorts with vs without prior SARS-CoV-2. Databases: MEDLINE (PubMed), Web of Science, and Scopus; reference lists screened. Time window: Jan 2020 to Dec 2024. Risk of bias: Newcastle-Ottawa. Randomeffects Mantel-Haenszel with REML variance and Hartung-Knapp adjustment; heterogeneity by I2/&#x3c4;2/Q. Zero events handled via 0.5 continuity correction; sensitivity analyses reported risk differences (percentage points) and studylevel effects for sparse outcomes. Certainty graded with GRADE.<br><br>RESULTS: Four matched cohorts (n&#x2248;1.3k; Italy/USA). Prior SARS-CoV-2 did not worsen IBD clinical course (OR: 1.06; 95%CI: 0.76-1.49), nor alter UC extent (OR: 1.26; 95%CI: 0.33-4.83) or CD location/behavior (OR: 1.00; 95%CI: 0.06-16.15 / OR: 1.00; 95%CI: 0.46-2.18). Conversely, COVID-19 associated with biologic delay/discontinuation (OR: 10.44; 95%CI: 3.56-30.62). Across studies, flares were more frequent when biologics were delayed/stopped (~52% vs ~18%; RD &#x2248; +34 p.p.).<br><br>CONCLUSION: COVID-19 per se does not appear to aggravate IBD outcomes; the clinically actionable signal is treatment continuity. In IBD patients without highrisk features for severe COVID-19, maintaining biologics should be considered to prevent flares.},
}
@article {pmid42789649,
year = {2026},
author = {Ebell, MH and Grad, R},
title = {Top 20 Research Studies of 2025 for Primary Care Physicians.},
journal = {American family physician},
volume = {114},
number = {2},
pages = {175-183},
pmid = {42789649},
issn = {1532-0650},
mesh = {Humans ; Female ; *Primary Health Care ; COVID-19/prevention &amp; control ; Male ; },
abstract = {This article summarizes the top 20 research studies of 2025 identified as POEMs (patient-oriented evidence that matters). Treating male sex partners of female patients with oral and topical medication reduces recurrence of bacterial vaginosis. Anti-influenza drugs do not reduce hospitalizations or mortality. COVID-19 vaccines still improve mortality and reduce hospitalizations. Influenza vaccines are safe in pregnancy. Vaginal estrogen appears to be safe in breast cancer survivors. Women with normal bone density given zoledronic acid every 5 years have fewer fractures. Early post-partum insertion of a long-acting reversible contraceptive is associated with fewer pregnancies vs delayed insertion. Early medication abortion before pregnancy confirmation is safe and effective. After stent placement in patients with atherosclerotic coronary vascular disease who are taking an anticoagulant, adding aspirin worsens outcomes. After catheter ablation for atrial fibrillation, discontinuing anticoagulants after 1 year is safe if atrial arrhythmia does not recur, whereas left atrial appendage closure is superior to oral anticoagulation. For patients with provoked venous thromboembolism and at least one ongoing risk factor, 12 months of apixaban is better than 3 months. Clopidogrel is slightly more effective than aspirin for the secondary prevention of myocardial infarction and stroke over 3 years. Intensive blood pressure lowering decreases cardiovascular events but increases rates of hypotension and syncope, and there are concerns about the applicability of the data to the United States. Duloxetine, milnacipran, and pregabalin provide meaningful pain reduction in adults with fibromyalgia. Amyloid-directed monoclonal antibodies do not provide clinically meaningful cognitive benefits and may cause harms. Bright light therapy is effective for nonseasonal depression. Water exposure 6 hours after cutaneous surgery does not increase the risk of complications. A meta-analysis of platelet-rich plasma injections for knee osteoarthritis concluded that high-quality studies found no meaningful pain improvement. Using an oral challenge to rule out sulfonamide allergy is safe when used with a risk assessment tool.},
}
@article {pmid42790130,
year = {2026},
author = {Schaffner, W and Gravenstein, S and Kissler, S and Cornely, OA and Mehta, D and Cenoz, MG and Vicic, N and Rudin, D},
title = {Multicomponent vaccination against seasonal influenza and COVID-19: a strategy to address the continued global burden of disease in adults.},
journal = {Vaccine},
volume = {93},
number = {},
pages = {129082},
doi = {10.1016/j.vaccine.2026.129082},
pmid = {42790130},
issn = {1873-2518},
abstract = {Seasonal influenza and SARS-CoV-2 are respiratory viruses that represent a global health concern, causing substantial numbers of hospitalizations and mortality, particularly among high-risk groups, including infants and older adults. Together these associated respiratory diseases and related complications are among the leading causes of morbidity and mortality. Although effective vaccines are available for protection against influenza and COVID-19, vaccine uptake remains below the levels recommended by the World Health Organization (WHO). Increasing vaccination coverage is critical for protecting vulnerable populations and reducing strain on healthcare systems. To improve vaccine uptake, the WHO recommends co-administering influenza and COVID-19 vaccines when epidemiologically justified. A multicomponent vaccine approach in adults could go beyond the current co-administration approach, as it has the potential to streamline delivery, reduce missed vaccination opportunities, and enhance vaccine coverage among individuals at risk. This manuscript reviews the current evidence on multicomponent vaccination for protection against seasonal influenza and COVID-19. We summarize published literature on the potential public health impacts of a multicomponent vaccination approach, discuss associated challenges, and review multicomponent vaccines currently in development. The studies in this review highlight various potential benefits of a multicomponent approach, including simplified dosing, greater vaccination coverage, and reduced disease burden and costs. Healthcare workers expressed a preference for a combination vaccine over standalone influenza or COVID-19 vaccines, indicating a high likelihood of recommending it to patients. Consumers also showed strong interest. For multicomponent vaccination to succeed, key considerations include the optimal timing of administration and appropriate strain selection for both the influenza and SARS-CoV-2 viruses. Promising multicomponent influenza-COVID-19 vaccine candidates currently being evaluated in clinical trials may represent an important advancement in adult immunization strategy, and a meaningful opportunity to strengthen protection against two of the most consequential respiratory pathogens worldwide.},
}
@article {pmid42791422,
year = {2026},
author = {Khalil, M and Bannout, Z and Jaber, N and Obeid, D and Mhanna, Z and Madani, A and Srour, D and Arzouni, A and Abdallah, H and Mahdi, L and Karaki, H and Safa, L and Mchiek, A and Lakiss, H and Di Ciaula, A and Portincasa, P},
title = {The 2024 Lebanon conflict: a multidimensional assessment of syndemic impacts on public health and sustainable development goals.},
journal = {Internal and emergency medicine},
volume = {},
number = {},
pages = {},
pmid = {42791422},
issn = {1970-9366},
abstract = {Lebanon entered the 2024 armed conflict with health, environmental, and social systems already weakened by successive crises, including the COVID-19 pandemic, prolonged economic collapse, and the 2020 Beirut Port explosion. This narrative review aimed to synthesize evidence on the documented and anticipated effects of the conflict on public health, healthcare services, the environment, food security, education, and progress toward the Sustainable Development Goals (SDGs). Evidence was drawn from peer-reviewed studies and reports issued by governmental institutions and international organizations. Documented damage to hospitals and primary healthcare facilities, together with disruptions to medical supply chains, affected routine and emergency care and complicated the management of chronic diseases. Population displacement, overcrowding, and interruptions to essential services also increased the risk of infectious disease transmission and created conditions that may facilitate the spread and emergence of antimicrobial resistance, particularly in displaced and otherwise vulnerable populations. Concurrently, explosive weapons, fires, and infrastructure damage affected air, water, soil, agricultural land, and ecosystems. These environmental and agricultural impacts created plausible pathways linking conflict-related damage to food security, livelihoods, and long-term population health, although direct epidemiological evidence remains limited. Overall, the conflict generated interconnected pressures across health, environmental, and social systems and compounded pre-existing vulnerabilities. Coordinated recovery efforts should restore healthcare capacity, protect environmental and agricultural resources, strengthen surveillance, and support essential social services to reduce long-term harm and promote sustainable recovery.},
}
@article {pmid42791937,
year = {2026},
author = {Elhanashi, A and Saponara, S},
title = {Intelligent Real-Time Healthcare and Biomedical Monitoring Systems: A Narrative Review of AI, IoT, and Emerging Technologies.},
journal = {Bioengineering (Basel, Switzerland)},
volume = {13},
number = {9},
pages = {},
doi = {10.3390/bioengineering13091065},
pmid = {42791937},
issn = {2306-5354},
abstract = {BACKGROUND: Chronic disease management, an ageing global population, and the aftermath of the COVID-19 pandemic have pushed real-time, continuous health monitoring from a research curiosity toward routine clinical practice. Artificial intelligence (AI), the Internet of Medical Things (IoMT), edge computing, and next-generation wireless networks are converging to enable systems that sense, interpret, and act on physiological data outside the traditional hospital setting.<br><br>METHODS: This is a narrative review, not a PRISMA-guided systematic or scoping review; it synthesises 75 sources (a mixture of primary studies, systematic/scoping reviews, and meta-analyses), individually verified against their published record. The topics span IoMT system architecture and security, wearable and implantable sensing, deep learning for electrocardiogram (ECG), fall-related and human-activity signal analysis, edge and TinyML deployment, federated learning, blockchain-based health-record security, medical imaging diagnostics, explainable AI (XAI), continuous glucose monitoring, 5G/6G-enabled telemonitoring, digital twins, consumer-grade and contactless cardiac sensing, neurological and mental health monitoring, and the materials, regulatory, and acute care infrastructure surrounding real-time deployment. Studies were organised into a five-layer architectural taxonomy spanning perception, edge, network, cloud, and application layers.<br><br>RESULTS: Reported accuracies for deep learning models on ECG arrhythmia classification range from 91% to 99.5% across the reviewed studies, but the figures come from different datasets, class definitions, and validation protocols and are therefore not directly comparable; within this heterogeneous evidence, edge-deployed models report accuracies in the 85-96% range at substantially reduced power budgets. Deep-learning-based fall detection and chest radiograph classification are each reported, in the individual studies reviewed, to outperform threshold-based or classical alternatives, though this has not been established through head-to-head comparison across the full evidence base. Federated learning and blockchain are discussed as technical mechanisms that can contribute to data privacy and record integrity; neither constitutes regulatory compliance with frameworks such as HIPAA or the GDPR on its own. Persistent obstacles identified across the reviewed literature include dataset heterogeneity, limited external clinical validation, energy-constrained edge hardware, low clinician trust in opaque models, and fragmented interoperability standards.<br><br>CONCLUSIONS: The evidence reviewed here is consistent with, but does not by itself establish, a layered, privacy-preserving, and explainable architecture that couples lightweight on-device inference with federated or blockchain-secured cloud learning as a design direction for future real-time healthcare monitoring systems. Future work should prioritise standardised benchmarking, prospective clinical validation, and regulatory-aligned data-governance frameworks.},
}
@article {pmid42792830,
year = {2026},
author = {Aladag, E and Karakulak, UN and Haznedaroglu, IC},
title = {Spike Protein at the Crossroads of Long-COVID and Vaccine-Induced Immune Thrombotic Thrombocytopenia Syndromes: A Cardio-Hematological Perspective.},
journal = {Biomedicines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/biomedicines14092090},
pmid = {42792830},
issn = {2227-9059},
abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein is central to viral infectivity, host-pathogen interactions, and immune recognition. Beyond its indispensable role in viral entry, accumulating experimental and clinical evidence indicates that spike protein may exert pleiotropic biological effects involving endothelial, cardiovascular, hematological, neurological, and immunological pathways. During natural infection, these effects occur in the context of active viral replication, additional viral antigens, and systemic inflammation, whereas vaccination induces a fundamentally different, transient exposure to a prefusion-stabilized spike antigen without viral propagation. In this review, we critically examine the molecular and clinicopathological properties of the SARS-CoV-2 spike protein and the biological differences between infection-derived and vaccine-derived spike exposure. Particular emphasis is placed on endothelial dysfunction, platelet and complement activation, immune-thrombosis, persistent viral antigens and tissue reservoirs in Long-COVID, and the distinct anti-PF4-mediated pathophysiology of vaccine-induced immune thrombotic thrombocytopenia (VITT). Emerging evidence suggests that persistent or dysregulated spike-related antigen exposure may contribute to chronic multisystem manifestations in a subset of individuals following SARS-CoV-2 infection; however, evidence linking persistent vaccine-derived spike to chronic clinical syndromes remains substantially more limited and does not currently establish causality. Integrating these observations, we propose the 'Long-Spike' hypothesis as a hypothesis-generating conceptual framework rather than a defined clinical syndrome. Further prospective studies integrating ultrasensitive antigen detection, tissue-based analyses, immunophenotyping, and cardiovascular and hematological biomarkers are required to determine the clinical relevance and causal significance of persistent spike-related antigens.},
}
@article {pmid42793280,
year = {2026},
author = {Dutta, S and Dutta, S and Han, Y and Zhu, Y and Almuntashiri, S and Somanath, PR and Narayanan, SP and Islam, S and Wang, X and Zhang, D},
title = {Extracellular Vesicles as Molecular Regulators of Viral Infection: Implications for COVID-19 and Future Viral Pandemics.},
journal = {Current issues in molecular biology},
volume = {48},
number = {9},
pages = {},
doi = {10.3390/cimb48090924},
pmid = {42793280},
issn = {1467-3045},
support = {R56HL163607//National Heart Lung and Blood Institute/ ; },
abstract = {Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), exposed critical gaps in global preparedness for rapidly evolving viral pandemics. Though current antiviral treatments have shown some efficacy in managing COVID-19, substantial limitations, such as inefficient targeted drug delivery, aberrant host immune responses, and inadequate preparedness for future viral pandemics, were also evident. These challenges underscore the urgent need for target-specific, precise and efficient therapeutic strategies to modulate viral entry and immune dysregulation. Extracellular vesicles (EVs), cell-released cargo-carrying nanoscale vesicles, can both facilitate and inhibit viral infection depending on their cargo composition. Thus, endogenous EVs can promote or inhibit COVID-19 pathogenesis by modulating critical pathways, including angiotensin-converting enzyme 2 (ACE2)-mediated viral entry, transmembrane protease serine 2 (TMPRSS2)- dependent spike protein activation, nuclear factor kappa B (NF-κB)-driven inflammatory signaling, and NLRP3 inflammasome activation. In contrast, engineered EVs, such as ACE2-expressing EVs, mesenchymal stem cell-derived EVs and microRNA-enriched EVs, have therapeutic potential as they can facilitate antiviral defense through immune modulation, viral neutralization and suppression of cytokine storm. Moreover, EV-associated nucleic acids, proteins and lipids can act as biomarkers for disease detection and severity stratification. A deeper understanding of EV-virus mechanistic insights can enhance preparedness for similar viral diseases. In this review, we provide a comprehensive analysis of the molecular mechanisms underlying EV-virus interactions highlighting the therapeutic and diagnostic potential of EVs in tackling COVID-19 and future viral pandemics.},
}
@article {pmid42794587,
year = {2026},
author = {Bizerea-Moga, TO and Chișavu, F and Chișavu, L and Pitulice, L and Moga, TV and Bugi, MA and Foghiș, CF and Isac, R and Mărginean, O and Balica, NC},
title = {Obesity, Oxidative Stress, and Inflammation in Precocious Puberty: Do All Roads Lead to the Hypothalamus?.},
journal = {International journal of molecular sciences},
volume = {27},
number = {18},
pages = {},
doi = {10.3390/ijms27188159},
pmid = {42794587},
issn = {1422-0067},
mesh = {Humans ; *Puberty, Precocious/metabolism/pathology/etiology ; *Oxidative Stress ; Animals ; *Inflammation/metabolism/complications ; *Hypothalamus/metabolism/pathology ; *Obesity/metabolism/complications ; Hypothalamic-Pituitary-Gonadal Axis ; Female ; },
abstract = {Childhood obesity is consistently associated with earlier pubertal timing, particularly in girls, whereas its relationship with true central precocious puberty (CPP), defined by premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, is less clearly established. An increased frequency of CPP diagnoses and referrals was reported during the COVID-19 pandemic, alongside changes in body weight, lifestyle, sleep, and psychosocial exposures. Human studies link excess adiposity to hyperleptinemia, insulin resistance, reduced adiponectin, altered sex-steroid bioavailability, and systemic low-grade inflammation, and associate these features with earlier pubertal development-consistently in girls, less so in boys. However, such associations do not establish that obesity directly induces premature hypothalamic activation. Mechanistic understanding of how these peripheral signals may influence pubertal timing derives predominantly from experimental models. The arcuate nucleus kisspeptin/neurokinin B/dynorphin (KNDy) network, a key component of the gonadotropin-releasing hormone (GnRH) pulse generator, interacts with hypothalamic metabolic circuits. In animal models of obesity and overnutrition, altered leptin and insulin signaling, mitochondrial reactive oxygen species generation, and activation of microglia and astrocytes remodel the mediobasal hypothalamus through inflammatory and stress-responsive pathways, including IKKβ/NF-κB and JNK signaling and altered Nrf2-mediated antioxidant defenses. At the molecular level, metabolic status interacts with the epigenetic machinery governing Kiss1 expression: in rodent models of overnutrition, accelerated loss of SIRT1-mediated repression at the Kiss1 promoter facilitates pubertal activation. Human genetic evidence establishes MKRN3 and DLK1 as causes of familial CPP, but evidence that obesity modifies these pathways to induce sporadic CPP is insufficient. Similarly, gut microbial metabolites have been linked experimentally to pubertal timing, and antioxidant micronutrients such as selenium, zinc, and vitamins C and E may be altered in pediatric obesity, yet a specific role in CPP remains unproven. Collectively, current evidence supports a working model in which metabolic, inflammatory, redox, glial, and epigenetic pathways may converge on hypothalamic reproductive circuits to influence pubertal timing in susceptible children. Direct evidence in children with CPP-of hypothalamic oxidative stress, glial activation, Nrf2 dysfunction, SIRT1 remodeling, or microbiome-mediated activation-remains limited or absent. Lifestyle optimization is appropriate for improving metabolic health in children with obesity, whereas antioxidant, micronutrient, and microbiome-targeted interventions should be considered investigational with respect to CPP. Longitudinal pediatric studies that distinguish earlier pubertal timing from true CPP, and that integrate metabolic phenotyping with validated measures of HPG-axis activation, are needed to test this framework.},
}
@article {pmid42795466,
year = {2026},
author = {Onodera, T and Seo, S and Sakudo, A and Toniolo, A},
title = {Hyperglycemia in Cats Infected by SARS-CoV-2: Pancreatic Alterations and Potential Antiviral Therapeutics.},
journal = {Microorganisms},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/microorganisms14091884},
pmid = {42795466},
issn = {2076-2607},
abstract = {Cats represent a susceptible host and a possible translational model for investigating coronavirus pathogenesis and therapeutics. Recent immunohistochemical (IHC) and histopathological studies in both human and feline tissues have demonstrated SARS-CoV-2 nucleocapsid protein (NP) and spike protein expression within pancreatic islet cells, following a classic temporal infection course. Notably, IHC analysis also reveals NP expression within exocrine ductal epithelial cells. Given that ductal epithelium functions as an islet progenitor pool during tissue injury or metabolic stress, pancreotropic coronaviruses may gain access to the endocrine compartment by exploiting this intrinsic cellular differentiation pathway. Although the precise mechanisms governing intra-islet viral entry remain to be elucidated, this review highlights the capacity of SARS-CoV-2 to compromise both the exocrine (digestive) and endocrine functions of the pancreas. Finally, we evaluate the therapeutic potential of direct-acting antivirals-specifically RNA-dependent RNA polymerase (RdRp) and protease inhibitors-as monotherapies and in synergistic combination to limit pancreatic injury and mitigate the diabetogenic effects of coronaviruses across both acute infection and post-acute sequelae, such as human long-COVID syndrome.},
}
@article {pmid42795472,
year = {2026},
author = {Feng, Z and Qiu, C and Zhou, Z and Yang, M and Wang, H and Zhou, Y},
title = {The Interplay Between Autophagy and Porcine Epidemic Diarrhea Virus: From Molecular Mechanisms to Therapeutic Perspectives.},
journal = {Microorganisms},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/microorganisms14091890},
pmid = {42795472},
issn = {2076-2607},
support = {26CXNH001//Gansu Provincial Science and Technology Department/ ; GSXM&#x2011;2026&#x2011;KYTD&#x2011;08//the Key Scientific and Technological Innovation Team Project of Gansu Polytechnic College of Animal Husbandry and Engineering/ ; 25KJA180004//the Basic Science (Natural Science) Research Project of Higher Education Institutions in Jiangsu Province/ ; },
abstract = {Autophagy is a highly conserved degradation and recycling process in eukaryotic cells that plays a critical role in maintaining cellular homeostasis and responding to external stress. During viral infection, autophagy exhibits a classic "double-edged sword" effect-it can act as a host defense mechanism by directly degrading viral components, but it can also be hijacked by viruses to promote their own replication. Porcine epidemic diarrhea virus (PEDV), an important enteric coronavirus that severely affects the global swine industry, engages in a complex and sophisticated interplay with the host autophagy system. This review systematically dissects the dual regulatory mechanisms of autophagy during PEDV infection and reveals two intertwined functional axes. On one hand, PEDV utilizes multiple viral proteins to cooperatively manipulate the autophagic pathway-inducing mitophagy to suppress innate immune responses, utilizing autophagic membranes to construct replication platforms, and blocking autophagic flux to evade degradation-thereby establishing a multi-level pro-viral network. On the other hand, host cells deploy a unified molecular axis of "ubiquitination-autophagy receptor-lysosome" by mobilizing a broad array of restriction factors to target and degrade viral proteins, forming a coordinated defense system. These two axes converge at the oxidative stress-endoplasmic reticulum stress-autophagy hub, where PEDV NSP1 and NSP2 synergistically inhibit the NRF2 antioxidant system to trigger this cascade, while host factors such as DDX6 and ACE2 finely regulate the process. Based on this mechanistic framework, we discuss the therapeutic implications of targeting autophagy for PEDV intervention, with particular emphasis on the development of selective autophagy modulators as potential antiviral agents. We also identify key knowledge gaps and propose future research directions to translate these mechanistic insights into clinical or field applications. This review synthesizes the peer-reviewed literature published between 2013 and 2026, identified through systematic searches of PubMed, Web of Science, and Scopus databases. Notably, the majority of mechanistic findings discussed are derived from in vitro cell culture models, and their translation to in vivo settings remains a significant challenge. Bridging this gap will require validation in physiologically relevant models, such as porcine intestinal organoids and controlled piglet challenge studies, to assess the efficacy and safety of autophagy-targeting interventions in the context of intestinal homeostasis and mucosal immunity.},
}
@article {pmid42795534,
year = {2026},
author = {Crispino, P and Viceconti, A and Camardo, V},
title = {Increase in Healthcare-Associated Infections: Is COVID-19 Responsible? A Narrative Review.},
journal = {Microorganisms},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/microorganisms14091952},
pmid = {42795534},
issn = {2076-2607},
abstract = {During the COVID-19 pandemic, healthcare-associated infections (HAIs) showed a significant increase, exacerbated by the prevalence of multidrug-resistant (MDR) organisms. Antibiotic overuse and infection control practices influenced HAI incidence rates, alongside the rising prevalence of resistant pathogens such as methicillin-resistant Staphylococcus aureus. Antibiotic-resistant pathogens causing healthcare-associated infections in COVID-19 patients include-in addition to methicillin-resistant Staphylococcus aureus-metallo-β-lactamase-producing carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, extended-spectrum β-lactamase-producing Klebsiella pneumoniae, and vancomycin-resistant enterococci. COVID-19 impacted bacterial healthcare-associated infections in various ways, with an increase in the incidence of metallo-β-lactamase-producing, carbapenem-resistant organisms-a trend already noted prior to the pandemic. Furthermore, the pandemic laid the groundwork for future challenges in HAI management, highlighting the need for rigorous infection prevention and control protocols. Poorer outcomes were observed in hospitalized COVID-19 patients with antibiotic-resistant infections. Although increased infection prevention and control (IPC) measures led to a reduction in certain site-specific hospital-acquired infections, in other contexts, COVID-19 was associated with an increased incidence of bacterial hospital-acquired infections. Further research is needed to determine the cost-benefit ratio of maintaining COVID-19-related infection prevention and control protocols beyond the pandemic in order to reduce the impact of hospital-acquired infections. Furthermore, it is necessary to assess the long-term impact of the high usage of certain broad-spectrum antibiotics during the COVID-19 pandemic.},
}
@article {pmid42795536,
year = {2026},
author = {Akhmedova, N and Kholov, G and Ochilov, U and Shonazarova, N and Yuldashev, O and Olimova, G and Istamova, S and Mukhammadiyeva, S and Kenjayeva, N and Sharipov, J},
title = {Airway and Gut Dysbiosis, Infectious Exacerbations and Pulmonary Vascular Remodelling in COPD-Associated Pulmonary Hypertension: Microbial Mechanisms, Causal Uncertainty and Therapeutic Implications.},
journal = {Microorganisms},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/microorganisms14091954},
pmid = {42795536},
issn = {2076-2607},
abstract = {Pulmonary hypertension complicating chronic obstructive pulmonary disease (COPD-PH) has a worse prognosis than airflow limitation alone but its pathogenesis is thought to be primarily due to alveolar hypoxia affecting pulmonary circulation. Two observations are not fully explained by this model. First, the majority of exacerbations of COPD are infectious and there is a stable frequent-exacerbator phenotype that is not fully accounted for by spirometric severity. Second, the airways of COPD are not sterile. They are home to a resident microbial community that changes as the disease progresses and the gut microbial community also undergoes disease-associated changes. This review examines whether microbial factors actively contribute to pulmonary vascular remodelling or merely reflect advanced disease. Three candidate exposures are considered: chronic airway colonisation, dysbiosis of the airway and gut communities and recurrent infectious exacerbation. We then examine the virulence mechanisms and host-recognition pathways of non-typeable Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa, rhinovirus, influenza viruses, respiratory syncytial virus and SARS-CoV-2. We then trace the pathways linking microbial recognition to vascular injury: Toll-like receptor signalling and NF-κB activation; interleukin-6, tumour necrosis factor-α and interleukin-1β; endothelin-1 upregulation against nitric oxide depletion; reactive oxygen species and hypoxia-inducible factor signalling converging with hypoxic pulmonary vasoconstriction; and, along the gut-lung axis, lipopolysaccharide translocation, trimethylamine N-oxide and depletion of short-chain fatty acid-producing taxa. Therapeutically, there is evidence and a vascular rationale for interventions that decrease exacerbation frequency. Pulmonary vasodilators have a sound physiological rationale, although their clinical efficacy is frequently limited by worsening ventilation-perfusion mismatch. Current evidence supports biological plausibility rather than demonstrated causality: no direct longitudinal human study has established that microbial alterations or microbial exposure cause pulmonary vascular remodelling in COPD-PH. We identify study designs capable of directly testing this hypothesis.},
}
@article {pmid42795935,
year = {2026},
author = {Bralic, M and Silconi, FI and Vuletic, V and Kovacic, S},
title = {Neurological Manifestations of Long COVID: Current Evidence, Emerging Concepts, and Future Perspectives.},
journal = {Journal of clinical medicine},
volume = {15},
number = {18},
pages = {},
doi = {10.3390/jcm15187163},
pmid = {42795935},
issn = {2077-0383},
abstract = {Six years after the onset of the COVID-19 pandemic, many individuals continue to experience persistent neurological symptoms that extend beyond the acute phase of infection, affecting daily life, work, and overall functioning, thereby representing a substantial long-term health burden. Cognitive impairment, fatigue, headache, and autonomic dysfunction are among the most frequently reported neurological features, often persisting despite the absence of clear diagnostic findings. Although Long COVID is recognized as a distinct clinical entity, the underlying pathophysiological mechanisms remain incompletely understood. This narrative review provides a critical synthesis of current literature regarding the clinical presentations, potential mechanisms, and biomarkers associated with neurological involvement in Long COVID. Reflecting the high heterogeneity of the available evidence, it is important to note that no neurological biomarker or disease-modifying therapy has yet been clinically validated. Ultimately, characterizing these pathways may help define disease heterogeneity, support patient stratification, and guide future personalized therapeutic approaches.},
}
@article {pmid42796374,
year = {2026},
author = {Runzer-Colmenares, FM and Cahuapaza-Gutierrez, NL and Calderon-Hernandez, CC and Umeres-Bravo, MM and Rojas-De la Cruz, RA and Villavicencio-Escudero, TV and Pajuelo-Vasquez, R and Enciso, N},
title = {Rhabdomyolysis Reported in Association with SARS-CoV-2 Infection and COVID-19 Vaccination: A Systematic Review.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {9},
pages = {},
doi = {10.3390/medicina62091769},
pmid = {42796374},
issn = {1648-9144},
mesh = {Humans ; *Rhabdomyolysis/etiology/epidemiology ; *COVID-19 Vaccines/adverse effects ; *COVID-19/prevention &amp; control/complications/epidemiology ; Male ; Middle Aged ; *Vaccination/adverse effects ; Adult ; SARS-CoV-2 ; Female ; },
abstract = {Background and Objectives: The association between SARS-CoV-2 infection, COVID-19 vaccination, and the development of rhabdomyolysis remains unclear. This systematic review aimed to comprehensively synthesize and analyze the available evidence on the occurrence of rhabdomyolysis in the context of SARS-CoV-2 infection and COVID-19 vaccination. Materials and Methods: A literature search was conducted in PubMed, Scopus, EMBASE, and Web of Science. The review followed PRISMA 2020 guidelines, assessing methodological quality. Statistical analyses were performed using STATA v18. Results: A total of 133 patients with rhabdomyolysis associated with SARS-CoV-2 infection were identified from 93 case reports and 7 case series; the median age was 45.5 years (IQR: 24-62), with a predominance of males (72.9%). Additionally, 13 observational studies comprising 818 patients with rhabdomyolysis associated with SARS-CoV-2 infection were included. Among cases associated with SARS-CoV-2 vaccination, 20 patients were identified from 20 case reports; the median age was 52.5 years (IQR: 22.5-76.5), with a predominance of males (75%). These cases were primarily associated with mRNA-based vaccines, particularly Pfizer-BioNTech BNT162b2 (50%) and Moderna (20%), and occurred predominantly after the first and second doses. The most frequent clinical manifestations in both groups were fever, myalgia, and dark urine. Clinical outcomes were favorable in most patients, both among infection-associated cases (72.2%) and vaccination-associated cases (80%). Conclusions: Rhabdomyolysis has been documented during SARS-CoV-2 infection, although its true frequency remains uncertain, whereas cases following COVID-19 vaccination do not establish causality or platform-specific risks.},
}
@article {pmid42796658,
year = {2026},
author = {Prezioso, C and Frezza, F and Aquaro, S and Nencioni, L and Mariconda, A and Amantea, D and Catalano, A and Longo, P and Sinicropi, MS and Checconi, P},
title = {Investigating the Role of microRNA in Host-Influenza A and Other Respiratory RNA Virus Interactions.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {9},
pages = {},
doi = {10.3390/pathogens15090889},
pmid = {42796658},
issn = {2076-0817},
mesh = {*MicroRNAs/genetics/metabolism ; Humans ; *Influenza, Human/virology/genetics/immunology ; *Host-Pathogen Interactions/genetics ; *Influenza A virus/genetics/physiology ; Virus Replication ; SARS-CoV-2/genetics ; RNA, Viral/genetics ; Signal Transduction ; Animals ; RNA Replication ; },
abstract = {Respiratory RNA viruses extensively reprogram host regulatory networks, thereby influencing viral replication, immune evasion, and disease severity. This review examines microRNAs (miRNAs) as regulatory interfaces in host-virus interactions, focusing on influenza A virus as a paradigmatic model while integrating evidence from other respiratory RNA viruses as SARS-CoV-2 and respiratory syncytial virus. After outlining canonical miRNA biogenesis and its manipulation during infection, we discuss how respiratory RNA viruses converge on shared miRNA-regulated pathways, including interferon and NF-κB signaling, apoptosis, autophagy, cellular metabolism, and redox homeostasis. Within these networks, host miRNAs can directly target viral RNAs and modulate antiviral defenses and inflammation, whereas viruses can reshape miRNA expression to facilitate replication, influencing immunopathology. The possibility that RNA viruses encode authentic miRNAs is also critically evaluated; current evidence indicates that manipulating host miRNA biogenesis machinery and remodeling miRNA networks are more prevalent than producing canonical viral miRNAs. Finally, the potential of circulating miRNAs as diagnostic and prognostic biomarkers is considered, as well as the capability of miRNA mimics and antagomiRs to function as host-directed therapeutic strategies. Their clinical translation, however, will require standardized validation, cell- and time-resolved studies, efficient delivery systems, and a careful assessment of specificity, safety, and context-dependent effects.},
}
@article {pmid42796662,
year = {2026},
author = {Vincenzi, F and Crobu, MG and Tonello, S and Vercellino, N and Grossini, E and Ravanini, P and Minisini, R and Boglione, L and Pirisi, M and Sainaghi, PP and Smirne, C},
title = {The Modulatory Role of Vitamin D in the Molecular Mechanisms of Sepsis and Infections with Focus on Viral Pathogenesis: A Narrative Review.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {9},
pages = {},
doi = {10.3390/pathogens15090894},
pmid = {42796662},
issn = {2076-0817},
mesh = {Humans ; *Vitamin D/immunology/therapeutic use ; *Sepsis/immunology/virology ; Vitamin D Deficiency/immunology/complications ; *Virus Diseases/immunology/virology ; Immunity, Innate ; Animals ; COVID-19 ; Adaptive Immunity ; },
abstract = {Viral infections are a widely recognized cause of mortality. Recently it has been demonstrated that vitamin D plays an important immuno-modulatory role in both innate and adaptive immune responses against infections, by reducing excessive inflammation and enhancing defense mechanisms. Specifically, exacerbation of infections may cause sepsis, characterized by a dysregulated immune response with hyperinflammation and immune exhaustion. Vitamin D can modulate these processes through various mechanisms, such as enhancing antiviral protection, promoting anti-inflammatory responses, protecting endothelial barriers, and modulating T-cells. This has been demonstrated for various viral infections, including influenza viruses, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus. Although vitamin D deficiency has been associated with increased susceptibility to viral infections and immune cells of infected patients are highly responsive to vitamin D, the clinical benefits of its supplementation to vitamin D-deficient infected individuals are uncertain and, most importantly, direct evidence linking vitamin D to viral sepsis specifically remains particularly limited, with most mechanistic inference extrapolated from non-septic viral infection and bacterial sepsis literature. Based on these assumptions, this review will outline the present understanding about vitamin D regulatory effects on immune system and the possible connection between its serum levels and viral infections, while also addressing controversial issues.},
}
@article {pmid42796669,
year = {2026},
author = {Sole, E and Montalbano, G and Motta, G and Pansera, MM and Midiri, A and Iacopino, M and Liotta, P and Mancuso, G and Biondo, C},
title = {Drivers of Viral Spillover: An Examination of How Pathogens Spread.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {9},
pages = {},
doi = {10.3390/pathogens15090901},
pmid = {42796669},
issn = {2076-0817},
mesh = {Humans ; Animals ; *Viral Zoonoses/transmission/virology/epidemiology ; *Zoonoses/transmission/virology ; SARS-CoV-2 ; COVID-19/transmission ; Pandemics ; Disease Reservoirs/virology ; *Coronavirus Infections/transmission ; },
abstract = {The occurrence of viral zoonotic spillover (the transmission of viruses from animals to humans) has attracted worldwide attention due to mounting concerns regarding viral threats such as avian influenza, Hendra, monkeypox, Nipah and bat coronaviruses. It is evident that these events deviate significantly from natural occurrences, being the conflation of ecological, environmental and social factors that are profoundly altering the boundaries between the animal and human domains. Consequently, in order to comprehend both the contemporary and prospective drivers of zoonotic viral spillover, a coordinated, comprehensive global One Health response is essential. The purpose of the present review is to analyze prevailing pathways of transmission between animal reservoirs and human populations. This examination involves the analysis of historical cases, including those of SARS and Ebola, as well as recent occurrences, such as the global pandemic of SARS-CoV-2 (COVID-19). A secondary objective of this review is to comprehend the fundamental mechanisms of cross-species transmission. The development of effective strategies to mitigate the emergence of zoonotic viruses and prevent future pandemics is contingent on a robust understanding of these mechanisms. This analysis is key to identifying pandemic pathogens and preventing the spread of zoonotic viruses. In conclusion, the review provides a thorough evaluation of current global strategies to prevent the spread of zoonotic viruses, highlighting gaps in our understanding and areas for further research.},
}
@article {pmid42796671,
year = {2026},
author = {Samrat, SK and Srivastava, G and Zhang, R and Li, Z and Li, H},
title = {Target-Based Antiviral Drug Development Against Human Respiratory Viruses.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {9},
pages = {},
doi = {10.3390/pathogens15090903},
pmid = {42796671},
issn = {2076-0817},
support = {AI177149 and AI175435//University of Arizona/ ; },
mesh = {Humans ; *Antiviral Agents/pharmacology/therapeutic use/chemistry ; *Drug Development ; Drug Discovery/methods ; *Respiratory Tract Infections/drug therapy/virology ; Viral Proteins/antagonists &amp; inhibitors ; Coronavirus/drug effects ; Drug Design ; },
abstract = {Human respiratory viruses represent a major global health burden, causing millions of severe infections and deaths annually. Despite the central role of vaccines in prevention, their limitations, such as incomplete coverage, waning immunity, and vulnerability to viral evolution, underscore the urgent need for effective antiviral therapeutics. This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets. Key viral proteins, including RNA-dependent RNA polymerases, proteases, and fusion glycoproteins, are analyzed across major virus families such as coronaviruses, paramyxoviruses, and adenoviruses, highlighting their structural features, functional constraints, and therapeutic potential. We further explore the integration of high-throughput screening and rational drug design, supported by advances in structural biology, cryo-electron microscopy, and computational approaches, including artificial intelligence-driven drug discovery. These methodologies collectively enhance the precision and efficiency of antiviral development. However, significant challenges remain, particularly the conflict between viral mutation and target conservation, the rapid emergence of drug resistance, and the safety limitations of host-targeted therapies. Finally, we discuss emerging strategies to overcome these barriers, including combination therapies and the development of broad-spectrum antivirals targeting conserved molecular mechanisms. This paper highlights a framework for the rational design of durable antiviral interventions capable of addressing both existing and emerging respiratory viral threats.},
}
@article {pmid42796724,
year = {2026},
author = {Joan, J and Chandra, C and Wibisono, CA and Gunawan, HD and Chang, V and Sumarpo, A},
title = {Complete Blood Count-Derived Inflammatory Markers in Pediatric Lower Respiratory Tract Infection: A Narrative Review.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {9},
pages = {},
doi = {10.3390/pathogens15090956},
pmid = {42796724},
issn = {2076-0817},
mesh = {Humans ; *Respiratory Tract Infections/blood/diagnosis/microbiology ; Biomarkers/blood ; Child ; Blood Cell Count ; Infant ; Child, Preschool ; Neutrophils ; *Inflammation/blood ; Adolescent ; Infant, Newborn ; },
abstract = {Lower respiratory tract infections (LRTIs) are a leading infectious cause of death in children worldwide. Complete blood count (CBC)-derived inflammatory ratios are low-cost and widely available, yet their reported performance varies. We reviewed 46 PubMed-indexed studies (2016-2026) in children aged 0-18 years with viral, bacterial, or mycobacterial LRTI. The findings were mapped across diagnosis, etiological differentiation, severity, and outcome prediction. The neutrophil-to-lymphocyte ratio (NLR) was the most investigated marker, with the broadest evidence base for severity assessment and for separating bacterial from viral disease, although its performance remained pathogen-, population-, and endpoint-dependent; it was elevated in severe pertussis, tuberculosis, Mycoplasma pneumoniae, Streptococcus pneumoniae, and SARS-CoV-2 infection, whereas findings in respiratory syncytial virus infection were conflicting. The platelet-to-lymphocyte ratio had the next broadest evidence base for severity, and the systemic immune-inflammation index was consistently elevated in Mycoplasma pneumoniae and SARS-CoV-2 infection. No single ratio performed consistently across all etiologies. Ratios governed by one dominant immunopathogenic mechanism behaved predictably; those whose numerator and denominator respond to the same process did not. Cut-offs were neither standardized, age-specific, nor externally validated, and most estimates derived from retrospective cohorts in few countries; reported values therefore represent association and discrimination rather than validated prediction. Standardized, age-specific thresholds are needed before these markers can support routine risk stratification.},
}
@article {pmid42797547,
year = {2026},
author = {Runzer-Colmenares, FM and Cahuapaza-Gutierrez, NL and Calderon-Hernandez, CC and Hilares-Jorge, CM},
title = {Association Between Respiratory Vaccines and Risk of Cognitive Impairment, Dementia and Alzheimer's Disease: A Scoping Review.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/vaccines14090726},
pmid = {42797547},
issn = {2076-393X},
abstract = {Background/Objectives: Neurocognitive disorders represent a growing burden among older adults. Although respiratory vaccines have demonstrated efficacy and safety in preventing acute respiratory events, their potential impact on the development of chronic neurocognitive disorders, such as cognitive impairment, dementia, and Alzheimer's disease (AD), has not been extensively explored. The objective of this scoping review was to synthesize and analyze the available evidence on the association between respiratory vaccination and the risk of developing cognitive impairment, dementia, and Alzheimer's disease. Methods: A scoping review was conducted in accordance with the PRISMA-ScR guidelines. A literature search was performed in the PubMed, Scopus, and Web of Science databases through 15 June 2026. Studies involving older adults (≥60 years), irrespective of their baseline neurocognitive status, were included. Observational studies (cohort and case-control studies) were considered. Editorials, narrative reviews, and other non-original articles were excluded. Results: Eighteen studies were included, with cohort studies being the predominant design. Four main categories of respiratory vaccines were evaluated: influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal vaccines, in relation to the risk of cognitive impairment, dementia, and AD. Influenza vaccination was associated with a lower risk of dementia and AD, with a potential dose-response relationship observed, whereby a greater number of vaccinations was associated with a greater reduction in risk. Pneumococcal vaccination was also associated with a lower risk of dementia and AD, particularly among individuals who received a greater number of vaccine doses. In contrast, the evidence regarding COVID-19 and RSV vaccines was limited and yielded heterogeneous findings. Conclusions: Influenza and pneumococcal vaccination maybe associated with a lower risk of Alzheimer's disease and dementia. However, the evidence regarding COVID-19 and RSV vaccines remains limited, and additional studies are needed to clarify their impact on the risk of developing neurocognitive disorders.},
}
@article {pmid42797552,
year = {2026},
author = {Hou, J and Li, Y and Tao, M},
title = {COVID-19 Vaccination and Pulmonary Nodules: A Narrative Review of Causality, Detection Bias and Thoracic Imaging Pitfalls.},
journal = {Vaccines},
volume = {14},
number = {9},
pages = {},
doi = {10.3390/vaccines14090731},
pmid = {42797552},
issn = {2076-393X},
abstract = {Background/Objectives: Concern that COVID-19 vaccination causes pulmonary nodules persists because vaccination coincided with expanded computed tomography (CT), low-dose CT (LDCT) screening, post-COVID imaging and artificial intelligence (AI)-assisted detection. This review asks whether the current literature supports causality and how vaccination history should inform thoracic imaging. Methods: A focused search of PubMed, PubMed Central and the Cochrane Library was performed through 15 July 2026. Evidence was classified as direct or contextual; no PRISMA screening, risk-of-bias scoring or quantitative synthesis was performed. Results: Direct evidence remains sparse. One case report was too confounded for inference. A two-sample Mendelian randomization study found no broad lung disease risk signal, but nodules were not modeled and the heterogeneous endpoints were exploratory. An ecological study of 1,616,750 samples linked rising detection to SARS-CoV-2 infection waves and AI-assisted reading; lacking individual vaccination data, it cannot establish whether vaccination affected detection. Screening interruption produced the opposite pattern: Lung-RADS 4 nodules rose from 8% to 29%. The most reproducible post-vaccination thoracic finding is regional lymph-node activation on [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT), an expected immune response rather than a parenchymal nodule. Conclusions: Current evidence is insufficient to establish vaccination as an independent, population-level cause of pulmonary nodules. Vaccination history should guide [18F]FDG-PET/CT interpretation; CT-detected parenchymal nodules warrant standard risk stratification.},
}
@article {pmid42165881,
year = {2026},
author = {Di Stadio, A and Brenner, MJ and De Luca, P and D'Ascanio, L and Patel, ZM},
title = {Regenerating smell in neurodegenerative disease -translating theory into therapy.},
journal = {European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery},
volume = {283},
number = {9},
pages = {6103-6108},
pmid = {42165881},
issn = {1434-4726},
mesh = {Humans ; *Olfaction Disorders/therapy/etiology/physiopathology ; *Neurodegenerative Diseases/complications/therapy/physiopathology ; COVID-19/complications ; *Platelet-Rich Plasma ; Olfactory Training ; SARS-CoV-2 ; *Smell/physiology ; },
abstract = {PURPOSE: Quantitative and qualitative olfactory dysfunction are one of the earliest and most prevalent symptoms across neurodegenerative diseases, notably Parkinson's and Alzheimer's disease. These pathologies may spread bidirectionally between the peripheral olfactory system and central brain regions, supporting a model in which the olfactory system represents both an early marker and a conduit for disease propagation. This short communication aims to investigate the potential of Platelet Rich Plasma (PRP) to treat smell alteration in the neurodegenerative diseases.<br><br>METHOD: We conducted a review of the literature to extract articles that discussed PRP use in the context of olfactory disorders.<br><br>RESULTS: 12 studies were identified; 7 studies on COVID-19, 2 on unspecific smell loss, 1 on traumatic anosmia, 1 on nasal polyposis and 1 illustrated the use of PRP in long-term persistent anosmia (> 25 years).<br><br>CONCLUSION: Post COVID-19 olfactory impairment has provided insights into mechanisms of smell loss and therapeutic strategies. While olfactory training remains the best studied intervention, its benefits are modest, inconsistent, and often limited in cases with central nervous system involvement. PRP has emerged as a promising candidate due to its growth factors and immunomodulatory properties. Preclinical studies demonstrate that intranasal PRP can enhance neurogenesis, reduce neuroinflammation, and improve olfactory and cognitive outcomes in animal models of Parkinson's and Alzheimer's disease. Early clinical observations also suggest potential benefit in longstanding anosmia of diverse etiologies. Future research should define optimal delivery routes, dosing, and long-term efficacy, with well-designed clinical trials needed to translate these experimental findings into therapeutic applications.},
}
@article {pmid42304586,
year = {2026},
author = {Gibson, M and Carlson, K},
title = {Big Bill, Bigger Consequences: One Big Beautiful Bill Act (OBBBA) and Opioid Use Disorder Treatment-A Critical Review.},
journal = {Policy, politics &amp; nursing practice},
volume = {27},
number = {4},
pages = {252-257},
doi = {10.1177/15271544261458768},
pmid = {42304586},
issn = {1552-7468},
mesh = {Humans ; *Opioid-Related Disorders/drug therapy/therapy/epidemiology ; United States/epidemiology ; *Medicaid/legislation &amp; jurisprudence/economics ; *Health Services Accessibility/legislation &amp; jurisprudence ; Opiate Substitution Treatment ; COVID-19/epidemiology ; Health Policy ; },
abstract = {The United States continues to struggle with the opioid crisis, exacerbated by shifting political priorities and the aftermath of the COVID-19 pandemic. This critical review analyzes the One Big Beautiful Bill Act (OBBBA) and its implications for opioid use disorder (OUD) treatment through the lens of the Multiple Streams Framework. Drawing on Medicaid data, and evidence from state-level implementation, most notably Arkansas, this article evaluates how work requirements and administrative restructuring threaten access to medications for opioid use disorder (MOUD), harm reduction services, and continuity of care. Medicaid expansion has been influential in increasing treatment availability, reducing overdose deaths, and supporting rural health systems; however, OBBA's mandated community engagement requirements threaten the progress made in combatting this epidemic. These restrictions are projected to cause 11.8 million Americans to lose health insurance, disproportionately affecting individuals with OUD who already encounter significant barriers to care. Prior evidence demonstrates that similar policies failed to increase employment, generated widespread confusion, and produced significant losses in coverage. The losses in coverage lead to delayed care, medication interruptions, and worsened health outcomes. There are also substantial financial and operational burdens associated with national implementation, including an estimated $200 million in administrative costs, diversion of resources away from clinical services, and reduced capacity for evidence-based treatment. This analysis concludes that OBBBA is likely to undermine progress in reducing overdose mortality, amplify health disparities, and place added strain on healthcare systems, particularly in rural communities, which have experienced the most significant effects of the opioid epidemic.},
}
@article {pmid42772154,
year = {2026},
author = {Lee, S and Batule, BS and Seok, Y},
title = {A review of portable molecular diagnostics: Paper and smartphone synergy for pathogen detection.},
journal = {Biosensors &amp; bioelectronics},
volume = {315},
number = {},
pages = {119238},
doi = {10.1016/j.bios.2026.119238},
pmid = {42772154},
issn = {1873-4235},
abstract = {Molecular diagnostics (MDx) enables sensitive and specific pathogen detection, but conventional laboratory-based methods require specialized instruments, trained personnel, and centralized infrastructure, limiting their accessibility in resource-limited settings. Paper-based MDx platforms offer low-cost, portable, and user-friendly alternatives for decentralized point-of-care testing (POCT); however, many systems still rely on subjective visual readout, partial workflow integration, and limited standardization. This review summarizes representative paper-based molecular diagnostic platforms for pathogen detection and critically examines how smartphone integration can support signal acquisition, quantitative or semi-quantitative analysis, data processing, and field deployability when imaging conditions and calibration strategies are appropriately controlled. We discuss paper-compatible nucleic acid amplification and molecular detection strategies, including loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), CRISPR-assisted assays, and amplification-free strand-displacement systems. Emphasis is placed on colorimetric and fluorescence-based readouts, smartphone-assisted image acquisition, app-based interpretation, and optical setup design. Representative examples demonstrate sensitive and rapid detection of pathogens such as SARS-CoV-2, MRSA, HIV-1, and Escherichia coli across diverse human-derived, food, environmental, and agricultural sample matrices. Rather than solely reporting analytical sensitivity, we compare platforms in terms of detection modality, smartphone role, data-processing strategy, workflow integration, real-sample validation, and practical deployment constraints. Remaining challenges include incomplete sample-to-answer integration, sample preparation bottlenecks, smartphone-to-smartphone variability, calibration robustness, reagent stability, and limited field validation. Overall, smartphone-integrated paper-based MDx provides a promising route toward accessible POCT, but future progress will depend on system-level co-optimization of paper architecture, molecular assay chemistry, optical acquisition, software analysis, and user-centered workflow design.},
}
@article {pmid42772206,
year = {2026},
author = {Greaves, PJ and Erfani, G and Simpson, D and Hill, B and Conner, T and Nemeckova, M and McCerery, A and Rolf, F and Monk, D and Steven, A},
title = {Nursing in adult critical care services - safe staffing evidence: A rapid review.},
journal = {Intensive &amp; critical care nursing},
volume = {98},
number = {},
pages = {104585},
doi = {10.1016/j.iccn.2026.104585},
pmid = {42772206},
issn = {1532-4036},
abstract = {AIM: This rapid review was conducted for the NHS England Safer Staffing Programme (2024) England (2024) [1] to evaluate the evidence base for adult critical care nurse staffing. The review addressed four objectives: 1) identifying current staffing decision-making processes; 2) evaluating the impact of staffing models on patient outcomes and service efficiency; 3) assessing effects on burnout and staff retention; 4) identifying effective staffing responses during the COVID-19 pandemic.<br><br>METHODS: A rapid systematic review following PRISMA guidelines was conducted across MEDLINE, CINAHL Plus, PsycINFO, and Scopus (2012-2024). Studies examining quantitative, qualitative, and mixed-methods research on registered nurse staffing in adult intensive care were included.<br><br>FINDINGS: Eighty-six studies met the inclusion criteria. Current staffing guidelines predominantly rely on expert consensus (Level 7 evidence) with day-to-day adaptation by senior nurse managers. Emerging empirical data (Level 4-5) suggest an association between nurse-to-patient ratios of 1:1 or higher and reduced mortality and nosocomial infections, though heterogeneity across studies precludes defining an optimal ratio. Workload intensity may be a more sensitive predictor of outcomes than static ratios. High nursing workloads are associated with increased burnout and turnover. Pandemic responses demonstrated that while "upskilling" non-ICU nurses supported surge capacity, it increased the psychological burden on experienced ICU staff.<br><br>CONCLUSIONS: While current guidelines rely heavily on expert opinion, there is some evidence from the literature to suggest that moving toward objective, workload-based frameworks might address limitations in current consensus-based models. However, the existing evidence base is largely observational, necessitating further high-quality research to confirm these associations.<br><br>Healthcare organisations should consider integrating objective workload measurement tools to supplement the professional judgement of the Nurse in Charge. Such an approach may provide a more defensible basis for workforce planning and help mitigate the impact of rising patient acuity on staff retention.},
}
@article {pmid42775578,
year = {2026},
author = {Cristancho, SM},
title = {Brittle threshold: When adaptive success is the warning sign.},
journal = {Medical education},
volume = {},
number = {},
pages = {},
doi = {10.1111/medu.70322},
pmid = {42775578},
issn = {1365-2923},
abstract = {CONTEXT: What happens when a system keeps working-not because it is well designed but because people keep absorbing the strain? That question stayed with me after studying a community-led vaccination clinic during the COVID-19 pandemic. It delivered hundreds of vaccinations a day, with no formal chain of command or protocols. By any measure, it was a success. What it cost to sustain that success was never examined. Across my empirical work, I kept encountering the same pattern: systems functioning because people stretched roles, coordinated through workarounds and relied on relationships that were not designed to carry the full load. These adaptations were effective. Yet they were also hiding strain.<br><br>CONCEPTUAL CONTRIBUTION: In this paper, I introduce Brittle Threshold as a concept for attending to this condition. Rather than treating adaptive action as evidence of success, Brittle Threshold frames adaptive action as diagnostic information: evidence of how a system is coping and how close it may be operating to its limits. Drawing on resilience engineering and on empirical patterns from studies of team adaptation and community crisis response, I argue that adaptive success and vulnerability regularly coexist. The more smoothly work appears to run, the more it may depend on fragile support.<br><br>IMPLICATIONS: Brittle Threshold offers three contributions. It translates what adaptive success conceals in health professions education, it shifts what counts as evidence of system strain and it unsettles the moralisation of endurance as professional virtue. The question it opens is not why systems fail, but when is endurance no longer enough?},
}
@article {pmid42776600,
year = {2026},
author = {Nakachwa, SM and Okorobe, PM and Onama, J},
title = {Vaccination coverage among migrant and refugee populations in Uganda: A narrative review of challenges and recommendations.},
journal = {Global public health},
volume = {21},
number = {1},
pages = {2735676},
doi = {10.1080/17441692.2026.2735676},
pmid = {42776600},
issn = {1744-1706},
mesh = {Humans ; Uganda/epidemiology ; *Refugees/statistics &amp; numerical data ; *Transients and Migrants/statistics &amp; numerical data ; *Vaccination Coverage/statistics &amp; numerical data ; Health Services Accessibility ; COVID-19/epidemiology ; },
abstract = {Uganda hosts one of Africa's largest refugee populations, yet displaced and migrant communities face persistent barriers to routine immunisation. Despite commitments to vaccine equity, many remain unprotected against preventable diseases. This narrative review synthesises evidence from peer-reviewed studies, national surveys, and institutional reports up to September 2025 to assess immunisation coverage, challenges, and potential solutions among refugees and migrants in Uganda. The findings indicate that vaccination rates in refugee communities are generally lower than national averages due to administrative barriers, vaccine shortages, long distances to health facilities, language difficulties, misinformation, and challenges intensified during the COVID-19 pandemic. Economic hardship further limits healthcare access. However, several strategies show promise: integrating refugees into national immunisation systems, simplifying registration processes, strengthening mobile outreach, engaging community health workers, and improving cross-border data coordination. Addressing these inequities requires both technical and social commitment through adequate financing, inclusive policies, and meaningful community engagement. Achieving equitable immunisation for refugees in Uganda is essential for public health protection and the realisation of universal health coverage.},
}
@article {pmid42776863,
year = {2026},
author = {Heijkoop, MLA and Phan, TA and Woltman, AM and Versmissen, J and van Rosse, F},
title = {Audio-podcasts as a teaching tool in undergraduate health professions education - a scoping review.},
journal = {Medical teacher},
volume = {},
number = {},
pages = {1-18},
doi = {10.1080/0142159X.2026.2733141},
pmid = {42776863},
issn = {1466-187X},
abstract = {INTRODUCTION: Audio podcasts are increasingly popular, leading to increased use in health professions education (HPE), offering flexible, asynchronous learning. Their adoption accelerated during the COVID-19 pandemic, yet guidance on how to purposefully integrate podcasts into undergraduate curricula remains limited. This review aims to map the existing literature on the integration, design and evaluation of audio podcasts as instructor-delivered teaching tools for undergraduate students in HPE.<br><br>METHODS: We conducted a scoping review following PRISMA-ScR guidelines. Eligible studies included empirical research on instructor-delivered audio podcasts for undergraduate students in HPE programmes. Studies were excluded if they focused on video podcasts, if the creation of a podcast by students was the learning activity, or when the article lacked data evaluating the podcast. We searched 5 databases without date limits. Data were charted using a structured Excel form capturing study characteristics, podcast design, integration approach, and evaluation outcomes. All interventions were classified according to the PICRAT model to classify student interaction and pedagogical impact.<br><br>RESULTS: Our search identified 3395 records, of which 54 studies met inclusion criteria, spanning 13 HPE disciplines, predominantly medicine and nursing. Podcast formats ranged from lecture recordings to radio documentaries. Integration was mainly Passive-Replaces (n&#x2009;=&#x2009;24) or Passive-Amplify (n&#x2009;=&#x2009;17), with fewer Interactive (n&#x2009;=&#x2009;3) or Creative (n&#x2009;=&#x2009;8) uses. We identified four categories of learning activities in which podcasts were used, with listening as a standalone learning activity and listing as part of an assignment being most common. Podcasts were able to amplify and transform teaching by creating insights into the lives and experiences of patients and their families or into clinical practice.<br><br>DISCUSSION: Podcasts can supplement or replace traditional teaching and address challenges in HPE. Their greatest potential lies in providing learning experiences that are difficult to recreate through conventional teaching. Purposeful integration guided by educational theory is essential to maximize impact.},
}
@article {pmid42778035,
year = {2026},
author = {Qaid, EYA and Long, I},
title = {The Gut-Lung Axis in Respiratory Diseases: Mechanisms, Microbiome Dysbiosis, and Therapeutic Implications. A Comprehensive Review.},
journal = {Respiratory medicine},
volume = {},
number = {},
pages = {109167},
doi = {10.1016/j.rmed.2026.109167},
pmid = {42778035},
issn = {1532-3064},
abstract = {The gut and lung, though anatomically distinct, are connected through a dynamic, bidirectional communication network known as the gut-lung axis, whereby intestinal microbiota, immune cells, and microbial metabolites regulate pulmonary immunity and homeostasis, while pulmonary perturbations reciprocally alter gut microbial composition and barrier integrity. This narrative review synthesises current evidence on the mechanisms underlying this crosstalk, including immune cell trafficking, short-chain fatty acid and other microbial metabolite signalling, vagal neuroimmune communication, and epigenetic regulation of gut and lung tissues. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library from inception to March 2025, supplemented by manual reference screening, yielding 146 included studies. We examine disease-specific patterns of gut dysbiosis and altered gut-lung signalling across asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, respiratory infections, COVID-19 and post-COVID sequelae, obstructive sleep apnoea, and lung cancer, alongside the reverse pathway by which pulmonary disease and critical illness disrupt intestinal homeostasis. We further review microbiome-targeted therapeutic strategies, including probiotics, prebiotics, dietary interventions, faecal microbiota transplantation, and vagus nerve stimulation, and discuss their current evidentiary limitations. Persistent challenges include predominantly observational study designs, inconsistent methodology, limited multi-omics integration, and a paucity of human mechanistic data. We conclude that the gut-lung axis represents a central, bidirectional framework for understanding respiratory disease pathogenesis, and that future progress will depend on longitudinal, multi-omics, and microbiome-stratified interventional studies to enable precision, microbiome-informed respiratory therapeutics.},
}
@article {pmid42778265,
year = {2026},
author = {Xiang, Y and Zhu, Q and Mou, C and Shi, K and Chen, Z},
title = {Commandeering the controller: The ubiquitin-proteasome tug-of-war between coronavirus and host.},
journal = {Advances in virus research},
volume = {125},
number = {},
pages = {29-67},
doi = {10.1016/bs.aivir.2026.07.001},
pmid = {42778265},
issn = {1557-8399},
mesh = {*Proteasome Endopeptidase Complex/metabolism/immunology ; *Ubiquitin/metabolism ; Humans ; Ubiquitination ; Immunity, Innate ; Interferons/metabolism/immunology ; *Host-Pathogen Interactions ; Animals ; Signal Transduction ; Immune Evasion ; *SARS-CoV-2/immunology ; Virus Replication ; *Coronavirus/immunology ; Viral Proteins/metabolism ; COVID-19/immunology/virology ; },
abstract = {The ubiquitin-proteasome system (UPS) plays a pivotal role in the precise regulation of innate immunity. Within the spatiotemporal framework of coronavirus (CoV) infection, the UPS emerges as a critical arena and a molecular switch, dynamically mediating the balance between host antiviral defense and viral replication alongside immune evasion. The host leverages the UPS to activate interferon (IFN) signaling pathways and to directly target viral proteins for degradation. Conversely, CoVs have developed sophisticated mechanisms to exploit this system, either by degrading antiviral proteins or by encoding viral deubiquitinases (DUBs) to counteract host ubiquitination signals. Notably, CoV proteins themselves undergo ubiquitination, which can lead to either their functional activation or proteasomal degradation, underscoring the dual-edged nature of the UPS. In this review, we initially examined the mechanisms by which the UPS regulates the IFN system. Subsequently, we highlighted the strategies employed by CoVs to inhibit the IFN system through the manipulation of the UPS. Thirdly, we synthesized findings regarding how the UPS specifically targets and degrades the principal virulence proteins of CoVs. Finally, we investigated the potential of the UPS as a therapeutic target for developing resistance against CoV infections.},
}
@article {pmid42779283,
year = {2026},
author = {Safi, D and Toutounji, K and Arabi, M},
title = {Serious cardiac events in the COVID-19 era in the paediatric population: what did we learn?.},
journal = {Cardiology in the young},
volume = {},
number = {},
pages = {1-17},
doi = {10.1017/S1047951126123956},
pmid = {42779283},
issn = {1467-1107},
abstract = {BACKGROUND: Serious cardiac events, which are frequently associated with myocarditis or arrhythmias, pose serious public health concerns. COVID-19 can increase cardiovascular risks by causing cardiac damage, arrhythmias, and multisystem inflammatory syndrome in children. However, important knowledge gaps about the long-term cardiac effects of COVID-19 still exist. These lead to the possibility of unusual or delayed cardiac consequences and the requirement for specialised monitoring techniques to reduce potential risks, particularly in high-risk populations. This narrative review compares serious cardiac event incidence, mechanisms, and outcomes in adults and children.<br><br>METHODS: Data were gathered from peer-reviewed studies between 2019 and 2025, such as systematic reviews, clinical reports, and cohort analyses. Focus was placed on the potential contribution of COVID-19-related cardiac events. Key research and clinical practice gaps were identified by analysing paediatric and adult populations in terms of diagnostic methods, management techniques, and long-term results.<br><br>RESULTS: While vaccine-related cardiac complications are still uncommon, COVID-19 infection is linked to an increased risk of serious cardiac events in adults. Paediatric serious cardiac events, on the other hand, are rare but frequently associated with multisystem inflammatory syndrome in children, and there have been rare, documented vaccine-associated deaths in this population.<br><br>CONCLUSION: Significant findings reveal clear patterns in serious cardiac events mechanisms, with age-dependent differences in the severity and prognosis of COVID-19-related myocarditis, arrhythmias, and long QT syndrome, among others. These variations highlight the necessity of age-appropriate risk assessment and management techniques. In the context of COVID-19, these findings highlight distinct risk profiles for serious cardiac events, underscoring the need for targeted screening methods and focused public health initiatives.},
}
@article {pmid42766785,
year = {2026},
author = {Kao, S and Metaxa, AM and Soliman, R},
title = {Effectiveness of Telehealth Care Interventions for Women's Mental Health During and After the COVID-19 Pandemic: Systematic Review and Meta-Analysis.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e85494},
pmid = {42766785},
issn = {1438-8871},
mesh = {Humans ; *COVID-19/psychology ; Female ; *Telemedicine ; Anxiety/therapy ; Depression/therapy ; Pandemics ; *Mental Health ; Stress, Psychological/therapy ; *Women's Health ; Mental Health Teletherapy ; SARS-CoV-2 ; Adult ; },
abstract = {BACKGROUND: The COVID-19 pandemic has increased telemental health interventions. However, evidence of effectiveness in improving women's mental health outcomes, acceptability, and user satisfaction remains fragmented.<br><br>OBJECTIVE: This study examined the effectiveness of telehealth interventions in alleviating depression, anxiety, and stress in women during and after the pandemic and descriptively summarized the acceptability of and satisfaction with these interventions.<br><br>METHODS: This systematic review and meta-analysis compared telemental health interventions with control conditions (waitlists or standard care) for women experiencing anxiety, depression, or stress. Databases (PubMed/MEDLINE, Embase, Web of Science, PsycINFO, and Cochrane Central Register of Controlled Trials) were searched through March 19, 2026. Eligible studies evaluated interventions in women aged 18 to 64 years (&#x2265;80% female participants and female-specific outcomes) and included randomized controlled trials (RCTs), nonrandomized trials, and observational studies with &#x2265;5 participants using outcome measures. Random-effects meta-analyses were conducted for depression, anxiety, and stress using RCT data. Risk of bias was assessed using Cochrane tools and certainty of evidence using Grading of Recommendations, Assessment, Development and Evaluation.<br><br>RESULTS: Fifty-seven studies (N=13,457) from 24 countries, reported the effectiveness, acceptability, and satisfaction with telehealth interventions. Meta-analysis of 23 studies (n=3269) demonstrated significant benefits of telehealth interventions for depression, anxiety, and stress. Depression showed the greatest improvements, with a moderate reduction in symptoms (Hedges g=-0.56, 95% CI -0.86 to -0.26; P<.001), followed by anxiety (small to moderate reduction; Hedges g=-0.45, 95% CI -0.62 to -0.28; P<.001). Stress showed a smaller effect (Hedges g=-0.25, 95% CI -0.47 to -0.04; P=.02), indicating modest benefits. Heterogeneity was high, with 95% prediction intervals of -1.97 to 0.84, -1.11 to 0.21, and -0.98 to 0.40 for depression, anxiety, and stress, respectively. Subgroup analyses favored telehealth over waitlist and standard care for depression (waitlist: Hedges g=-0.60, 95% CI -0.86 to -0.33; standard care: Hedges g=-0.57, 95% CI -1.11 to -0.02; both P<.001) and anxiety (waitlist: Hedges g=-0.47, 95% CI -0.68 to -0.25; standard care: Hedges g=-0.52, 95% CI -0.80 to -0.25; both P <.001). Insufficient studies were available to evaluate stress in subgroup analyses. Treatment effects remained significant in female-only and predominantly female samples. Evidence certainty was downgraded due to heterogeneity, risk of bias, and methodological limitations.<br><br>CONCLUSIONS: This is the first systematic review and meta-analysis focused on telemental health interventions for women. Telehealth was associated with moderate, small to moderate, and modest reductions in depression, anxiety, and stress, respectively, with benefits across female-only and predominantly female samples. Moderate to high heterogeneity in average effects (CIs), wide distributions of effects across settings (prediction intervals), and risk of bias resulted in moderate certainty of evidence. Overall, telehealth is a scalable approach for improving access to mental health care for women, although high-quality research is needed to strengthen the evidence base.},
}
@article {pmid42767409,
year = {2026},
author = {Costa, T and Ditadi, B and Premi, E and Manuello, J and Crocetta, A and Cauda, F and Duca, S and Liloia, D},
title = {The Post-Acute Effects of COVID-19 Are Not Associated with Robust Long-Term Regional or Global Brain Volumetric Changes: A Bayesian Meta-Analytic Evidence.},
journal = {Neuroscience and biobehavioral reviews},
volume = {},
number = {},
pages = {106986},
doi = {10.1016/j.neubiorev.2026.106986},
pmid = {42767409},
issn = {1873-7528},
abstract = {Acute respiratory and systemic manifestations associated with SARS-CoV-2 infection have been extensively investigated, including their potential effects on brain structure. However, whether structural magnetic resonance imaging (MRI) studies converge towards reproducible long-term neuroanatomical alterations following COVID-19 remains unclear, mostly due to high variability in methods and reported results across neuroimaging investigations. The present study applied a Bayesian meta-analytic approach to quantify the strength of the evidence supporting the presence or absence of reproducible brain volumetric alterations following COVID-19 infection. The systematic literature search identified nine independent magnetic resonance imaging (MRI) experiments reporting whole-brain volumetric measures and 12 MRI experiments reporting regional volumetric measures (i.e., for specific regions of interest), including a total of 1107 subjects with a history of COVID-19 disease and 609 control participants. The results reported in the selected studies were quantitatively synthesized using the Rouder-Morey common-effect Bayesian meta-analytic framework. Bayes' Factors (BF) were computed to quantify how strongly the available evidence supported the alternative hypothesis of volumetric differences relative to the null hypothesis of no differences. Global analyses provided limited evidence of volumetric differences, with BF10 = 3.286 for whole-brain volume and BF10 = 1.206 for total gray matter volume, corresponding to moderate and anecdotal evidence in favor of the alternative hypothesis, respectively. Regional analyses did not identify reproducible volumetric alterations in any of the 26 examined regions of interest. Overall, the present findings indicate that although several studies reported brain abnormalities detectable by MRI following COVID-19, the available volumetric evidence does not support a consistent pattern.},
}
@article {pmid42767650,
year = {2026},
author = {Lau, G},
title = {Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes.},
journal = {Journal of gastroenterology and hepatology},
volume = {},
number = {},
pages = {},
doi = {10.1111/jgh.70742},
pmid = {42767650},
issn = {1440-1746},
support = {//Humanity and Health Clinical Trial Center, Hong Kong SAR, China/ ; },
abstract = {Over four decades, translational hepatology has evolved from empirical observations into an evidence-driven discipline. This review synthesizes key bedside discoveries, mechanistic studies, prospective cohorts, cross-regional health-economic evaluations, and landmark randomized controlled trials (RCTs) by our team that have helped to reshape regulatory drug approvals, Boxed Warnings, and international practice guidelines across APASL, AASLD, and EASL. First, clinical trials established the biphasic model and risk predictors of immunosuppression-induced hepatitis B virus (HBV) reactivation, proving that pre-emptive nucleos(t)ide analogue (NUC) prophylaxis prevents liver failure and antineoplastic disruptions. Second, multinational Phase III registration trials of finite 48-week pegylated interferon alfa-2a (Peg-IFN α-2a) in chronic hepatitis B (CHB)-combined with intrahepatic cccDNA kinetics, adoptive immunity transfer, and 30-year Asia-Pacific Markov health-economic modeling-established response-guided rules and validated finite Peg-IFN switch/add-on strategies as clinically dominant and cost-effective. Third, prospective cohorts uncovered direct-acting antiviral (DAA)-induced HBV reactivation during HCV clearance, establishing mandatory regulatory Boxed Warnings and pre-DAA screening. Fourth, the Phase III HIMALAYA study and pooled Greater China (Mainland China, Hong Kong, Taiwan) cohorts validated the STRIDE regimen (single-dose tremelimumab plus regular durvalumab) as frontline dual immunotherapy for unresectable hepatocellular carcinoma (uHCC), establishing marked survival benefit in HBV-predominant populations (median OS 25.26 vs. 14.09 months) alongside a vascular endothelial growth factor (VEGF)-free standard for cirrhotic portal hypertension within APASL guidelines. Finally, translational insights across metabolic dysfunction, COVID-19, ACLF, artificial intelligence (AI), and functional cure frameworks inform the APASL 2026 "treat-all" CHB paradigm.},
}
@article {pmid42769092,
year = {2026},
author = {Li, S and Bai, R},
title = {Lipid droplet-mitochondria contact sites as druggable spatial-pharmacology targets in respiratory disease: cross-cell-type mechanisms and translational strategies.},
journal = {Frontiers in cell and developmental biology},
volume = {14},
number = {},
pages = {1935993},
pmid = {42769092},
issn = {2296-634X},
abstract = {Lipid droplets and mitochondria form regulated contact sites whose molecular composition, phosphorylation state and spatial geometry now behave as measurable, druggable variables in living cells. The molecular toolkit has been mapped in liver, muscle and adipose tissue, yet its application to respiratory disease has lagged despite a lung-specific dependence on lipid biology that spans surfactant biogenesis, alveolar-macrophage lipid handling and fibroblast-driven remodelling. This review argues that the lipid-droplet-mitochondria contact site is an emerging spatial-pharmacology target in respiratory medicine, and organises the evidence into a three-way matrix with explicit grading of direct, indirect and cross-tissue evidence. A common molecular toolkit built around perilipin-family scaffolds, mitochondrial-outer-membrane tethers, an endoplasmic-reticulum bridging apparatus and the PFKL-PLIN2-CPT1A flux node (mechanistically established in hepatocellular carcinoma and inferred in lung) is rewired into cell-type-specific configurations across alveolar type 2 cells, macrophages, fibroblasts, endothelium and lung adenocarcinoma. That toolkit acquires a distinct disease role across idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome, tuberculosis, severe acute respiratory syndrome coronavirus two infection and lung cancer, generating a matrix of cell-type-by-disease configurations that no prior review has systematized. Four target axes, namely, tether occupancy, lipid flux, redox coupling and cell-type-precise delivery, converge geometrically at the interface and motivate combination strategies rather than pan-mitochondrial single-agent approaches. Inhaled lipid nanoparticles, mucus-penetrating carriers and engineered extracellular vesicles bring these targets within reach with cell-type precision. Endothelial contact-site biology is identified as the largest evidence gap and discussed candidly. The framework is offered as a roadmap for tether-axis compound development, contact-site engagement biomarkers and dual-axis inhaled therapeutics.},
}
@article {pmid42769528,
year = {2026},
author = {Kamb, A and Welch, JS},
title = {The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1799525},
pmid = {42769528},
issn = {1664-3224},
mesh = {Humans ; *Nanoparticles/chemistry/administration &amp; dosage ; *Leukemia, Myeloid, Acute/therapy/immunology ; *Immunotherapy/methods ; Animals ; *Lipids/chemistry ; COVID-19 Vaccines/immunology/administration &amp; dosage ; RNA, Messenger/administration &amp; dosage ; T-Lymphocytes/immunology ; COVID-19/immunology/prevention &amp; control ; Liposomes ; },
abstract = {T-cell engagers and engineered cell therapies have yet to deliver the same spectacular results in acute myeloid leukemia (AML) that they have in other hematologic malignancies. In this review, we analyze the challenges with AML immunotherapy development, including on-target, off-tumor toxicity, cytokine release syndrome (CRS), and the "myeloid sink." We then discuss the emergence of two technologies that could address the major challenges with investigational AML therapeutics: targeted, lipid nanoparticles (LNPs) loaded with specific mRNAs and a type of synthetic logic gate (a NOT gate). This approach builds on recent advancements of mRNA-loaded LNPs that developed with the COVID19 vaccines and evolved into vehicles for delivery to T cells. The LNP modality offers a new opportunity for effective treatment of patients with AML.},
}
@article {pmid42769543,
year = {2026},
author = {Calderón-Sandate, DN and Huerta-Garza, MJ and Márquez-Reyna, BA and Cañedo-Figueroa, DM and Hernández-Rodríguez, X and Lira-Hernández, FI and Osuna-Ramos, JF and Cardoso-Ortiz, J and Del Ángel, RM and Santos-Mena, AO and De Jesús-González, LA},
title = {The kynurenine pathway in RNA virus infection: immunometabolic control of antiviral defense and viral persistence.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1923351},
pmid = {42769543},
issn = {1664-3224},
mesh = {Humans ; *Kynurenine/metabolism/immunology ; Animals ; *RNA Virus Infections/immunology/metabolism/virology ; Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism/immunology ; Tryptophan/metabolism/immunology ; Signal Transduction/immunology ; *RNA Viruses/immunology/physiology ; Receptors, Aryl Hydrocarbon/metabolism ; Immunity, Innate ; Tryptophan Oxygenase/metabolism/immunology ; Host-Pathogen Interactions/immunology ; Virus Replication ; Protein Serine-Threonine Kinases ; },
abstract = {RNA virus infections are shaped by the interplay among viral replication, innate immune sensing, and host metabolism, which together determine the magnitude, duration, and quality of antiviral responses. The tryptophan-kynurenine (Trp-Kyn) pathway has emerged as an important immunometabolic axis linking interferon-driven inflammation, amino acid availability, immune-cell function, tissue homeostasis, and viral persistence. This review examines the roles of indoleamine 2,3-dioxygenase 1 (IDO1), IDO2, tryptophan 2,3-dioxygenase (TDO), Trp depletion, general control nonderepressible 2 (GCN2) signaling, mechanistic target of rapamycin complex 1 (mTORC1), Kyn-derived metabolites, and aryl hydrocarbon receptor (AhR) activation in host responses to RNA virus infection. We integrate genetic, pharmacological, cellular, animal, and clinical evidence across positive-sense and negative-sense single-stranded RNA viruses, double-stranded RNA viruses, and reverse-transcribing RNA viruses, including SARS-CoV-2, dengue virus, Zika virus, hepatitis C virus, influenza A virus, respiratory syncytial virus, rotavirus, reovirus, HIV-1, and SIV. Across these systems, the Trp-Kyn-AhR axis can influence interferon responses, viral replication, immune-cell function, tissue injury, and disease outcome. EMCV myocarditis provides causal proof of principle, whereas other RNA-virus models provide complementary functional and clinical evidence. Importantly, pathway activation does not confer a uniform antiviral or pathogenic phenotype; its biological consequences depend on viral class, tissue tropism, viral burden, inflammatory intensity, cell type, and disease stage. On this basis, we propose a time-phase model in which early or excessive IDO1-Kyn-AhR signaling may impair type I interferon responses, NK-cell function, CD8+ T-cell expansion, and viral clearance, whereas appropriately regulated activation during later inflammatory or resolution phases may limit immunopathology, support epithelial repair, and preserve tissue homeostasis. Persistent or dysregulated activation may instead contribute to exhaustion-like immune states, chronic inflammation, neuroimmune dysfunction, and post-acute viral sequelae. Finally, we discuss phase-adapted therapeutic strategies, including IDO1 inhibition, AhR agonism or antagonism, KMO-directed modulation, Trp-based entry inhibitors, and biomarker-guided combination approaches. Together, these findings position the Trp-Kyn-AhR axis as a dynamic, context-dependent target for precision host-directed antiviral immunometabolism.},
}
@article {pmid42769913,
year = {2026},
author = {Mammas, IN and Kramvis, A and Stouraiti, A and Dalianis, T and Koletsi, P and Papaioannou, G and Papatheodoropoulou, A and Koutsaftiki, C and Korovessi, P and Drysdale, SB and Theodoridou, M and Spandidos, DA},
title = {Promoting expertise knowledge sharing in paediatric virology: An update (Review).},
journal = {Experimental and therapeutic medicine},
volume = {32},
number = {4},
pages = {293},
pmid = {42769913},
issn = {1792-1015},
abstract = {Knowledge sharing in medical education is a continuous exchange of skills and expertise between scientists. Paediatric virology is a rapidly developing, new scientific field of medicine, which enhances multidisciplinary, expertise knowledge sharing between paediatric health professionals and scientists of different subspecialties. The present review discusses the recent core topics in paediatric viral infectious diseases discussed during the 11th Workshop on Paediatric Virology organised by the Institute of Paediatric Virology and presents its key messages, including: i) The history of smallpox vaccination; ii) the role of viral co-infections triggering invasive bacterial diseases; iii) the surge of invasive group A streptococcal disease during the post-coronavirus disease 2019 (COVID-19) era; iv) foetal brain imaging findings in maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; v) the diabetogenic role of Coxsackie viruses in childhood; vi) adenovirus-related central nervous system manifestations in the paediatric population; vii) new challenges and opportunities of hepatis D virus infection in children; viii) the Swedish up-to-date human papillomavirus vaccination experience in childhood.},
}
@article {pmid42770643,
year = {2026},
author = {Khawandi, J and Patel, K and Azzam, M and Nazzal, J and Lam, GY and Al Khader, A and Kawtharany, H and Al Zabibi, MA and Ahmad, J and Kivan, H and Al Hussein, S and Rehman, AU and Piché, A and Vasquez Camargo, A and McNaughton, C and Oudit, GY and Kamrul, R and Afzal, S and Schunemann, H and Wiercioch, W and Nieuwlaat, R and Brignardello-Petersen, R and Falcone, EL and Mustafa, RA},
title = {The role of 6-minute walk test and pulmonary function testing in patients with post COVID-19 condition: a systematic review and meta-analysis.},
journal = {Family practice},
volume = {43},
number = {5},
pages = {},
pmid = {42770643},
issn = {1460-2229},
support = {//Public Health Agency of Canada/ ; },
mesh = {Humans ; *COVID-19/complications/physiopathology ; *Walk Test/methods ; *Respiratory Function Tests/methods ; Post-Acute COVID-19 Syndrome ; Oximetry ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND AND OBJECTIVE: Post-COVID-19 condition (PCC) is a complication of acute COVID-19 infection, which often presents with respiratory symptoms. This review aimed to assess the prevalence of abnormal pulmonary function test (PFTs) and 6-minute walk test (6MWT) with oximetry findings, and their respective prevalence and magnitude of abnormalities in patients with PCC, compared to patients without PCC.<br><br>METHODS: We searched three databases. Two reviewers independently screened articles using LASER Al and extracted relevant data using a piloted Excel sheet. We performed meta-analysis using OpenMeta and RevManWeb and a subgroup analysis based on patients' settings during acute COVID-19. We assessed the risk of bias using the Hoy et al. tool and the certainty using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.<br><br>RESULTS: We included 30 studies that reported on the prevalence of abnormal PFTs and/or 6MWT in patients with PCC. Outcomes within PFTs and 6MWT showed that patients with PCC have a higher probability of having abnormal tests, with those hospitalized during their acute COVID-19 infection showing a higher probability of having abnormal tests. The overall certainty of the evidence was very low due to the high risk of bias, indirectness, and imprecision.<br><br>CONCLUSION: This review provides insight into the utilization of PFTs and 6MWT and the frequency of test abnormalities in patients with PCC. Despite existing evidence, there is a need for future studies to assess the diagnostic test accuracy of these tests in PCC.},
}
@article {pmid42771023,
year = {2026},
author = {Pohl, EE and Groschner, K},
title = {Biophysics Austria: 65 years history.},
journal = {European biophysics journal : EBJ},
volume = {},
number = {},
pages = {},
pmid = {42771023},
issn = {1432-1017},
abstract = {The Austrian Biophysical Society (Biophysics Austria) was founded in 1961, making it one of the oldest national biophysical societies in Europe. It hosted the first European Meeting in Biophysics in Baden near Vienna in 1971 and celebrated its 60th anniversary by hosting the 13th European Biophysics Congress in Vienna as a hybrid event during the COVID-19 pandemic in 2021. In 2026, the society is celebrating its 65th anniversary. This review reflects on the society´s history and highlights events, milestones, and people who have contributed to its development.},
}
@article {pmid42669998,
year = {2026},
author = {Yiannakopoulou, E},
title = {Targeting Immunomodulation by Glutathione: A Possible Therapeutic Strategy against COVID-19.},
journal = {Endocrine, metabolic &amp; immune disorders drug targets},
volume = {26},
number = {},
pages = {e18715303400155},
doi = {10.2174/0118715303400155251202063218},
pmid = {42669998},
issn = {2212-3873},
mesh = {Humans ; *Glutathione/therapeutic use/metabolism/pharmacology ; COVID-19/immunology ; SARS-CoV-2/drug effects ; *Immunomodulation/drug effects/physiology ; Oxidative Stress/drug effects ; Antioxidants/therapeutic use ; *COVID-19 Drug Treatment ; Animals ; Pandemics ; Antiviral Agents ; *Coronavirus Infections/drug therapy/immunology ; *Betacoronavirus/drug effects/immunology ; *Pneumonia, Viral/drug therapy/immunology ; Immunomodulating Agents ; },
abstract = {The severe acute respiratory syndrome coronavirus SARS-CoV-2, which causes COVID-19, has attracted the interest of the scientific community since 2019. In fact, in the majority of cases, COVID-19 results in a mildly symptomatic disease that needs no treatment. However, patients with comorbidities have an increased risk of severe manifestations of COVID-19. Although research progress in the field has been successfully accomplished, novel therapeutic strategies are still required. Treatment efforts are needed against the severe manifestations of the disease, such as the severe respiratory distress syndrome. The tripeptide glutathione could be a promising therapeutic approach against COVID-19. Glutathione is a multitarget agent that exhibits antiviral activity against SARS-CoV-2 and modulates the host response to SARS-CoV-2. Oxidative stress and glutathione deficiency have been implicated in the pathophysiology of severe COVID-19 disease. Thus, a possible therapeutic strategy could be the enhancement of the antioxidant defenses of the host through the treatment with nonenzymatic antioxidants. Apart from functioning as a scavenging agent, glutathione plays a central role in cellular signalling. As a redox regulator, glutathione also acts as a signalling molecule, thus modulating innate and T cell immunity, with implications for SARS-CoV-2 infection. Existing clinical data, although limited, provide evidence that the modulation of glutathione levels could be a preventive or adjunctive therapeutic strategy against SARS-CoV-2 infection.},
}
@article {pmid42765958,
year = {2026},
author = {Masotta, V and Azzellino, G and Paoli, I and Caponnetto, V and Laurenza, E and Palma, L and Ciangoli, A and Petrucci, C and Lancia, L and Dante, A},
title = {[Simulation in nursing education in Italy: a scoping review].},
journal = {Assistenza infermieristica e ricerca : AIR},
volume = {45},
number = {3},
pages = {113-134},
doi = {10.1702/4774.47961},
pmid = {42765958},
issn = {2038-1778},
mesh = {Italy ; Humans ; *Education, Nursing/methods ; *COVID-19/epidemiology ; *Simulation Training/methods ; },
abstract = {UNLABELLED: . Simulation in nursing education in Italy: a scoping review.<br><br>INTRODUCTION: Simulation represents a cornerstone in contemporary nursing education, yet no comprehensive synthesis is currently available describing how it is used, in which settings it is applied, and outcomes assessed in Italy.<br><br>OBJECTIVE: To map the available literature on simulation in Italian nursing education and practice, examining study designs, participant characteristics, simulation modalities, theoretical and evidence-based underpinnings, outcome measures, and key educational insights.<br><br>METHODS: The scoping review followed the Joanna Briggs Institute (JBI) methodology and was reported according to the PRISMA-ScR checklist. Searches were conducted in PubMed, Scopus, and EBSCOhost. Primary studies conducted in Italy, published in Italian or English, and focused on the use of simulation in nursing education, training, or practice were included.<br><br>RESULTS: Thirty-three studies were included. Scientific production increased over time, with a marked peak during the covid-19 pandemic. Most studies were observational, monocentric, and conducted in academic settings, mainly within undergraduate nursing programmes. High-fidelity simulation was the most frequently used modality, whereas digital, immersive, and hybrid technologies were less represented. Outcomes mainly addressed the first two levels of Kirkpatrick's model, while transfer to practice and patient or organizational outcomes were rarely investigated.<br><br>CONCLUSIONS: Italian research on nursing simulation is growing and shows signs of maturation but remains predominantly single-centre and academically focused. As in the international literature, transfer to practice and impact on patient outcomes remain poorly documented. Pedagogical design appears generally sound, whereas reporting and alignment among objectives, modalities, fidelity, and evaluation remain areas for improvement.},
}
@article {pmid42766407,
year = {2026},
author = {Jardín, I and Macias-Díaz, A and Jimenez-Velarde, V and Fuentes-Mateos, M and Smani, T and Rosado, JA},
title = {Targeting the Orai1 CRAC channel: translating molecular insights into therapeutic progress.},
journal = {Expert opinion on therapeutic targets},
volume = {},
number = {},
pages = {},
doi = {10.1080/14728222.2026.2738180},
pmid = {42766407},
issn = {1744-7631},
abstract = {INTRODUCTION: The Ca[2+] release-activated Ca[2+] (CRAC) channel, triggered by the interaction between the Ca[2+] sensor STIM1 and Orai1, is the primary mediator of store-operated calcium entry (SOCE). Dysregulation of this process drives numerous human pathologies, particularly immune disorders and cancer hallmarks. Due to its role, Orai1 has emerged as an attractive target for precision therapeutics.<br><br>AREAS COVERED: This review outlines the pharmacological evolution of CRAC channel modulators, tracing their development from early chemical tools, such as SKF-96365, that exhibits several off-target effects, to more selective second-generation pore blockers, including Synta66, RO2959 or GSK-7975A. Particular attention is paid to third-generation inhibitors, especially CM4620 (zegocractin), evaluating data from recent Phase 2 clinical trials in acute pancreatitis (CARPO), severe COVID-19 pneumonia (CARDEA), and acute kidney injury (KOURAGE). We describe emerging orally bioavailable candidates like CM5480 aimed at chronic cardiopulmonary remodeling.<br><br>EXPERT OPINION: Clinical experience reveals that targeting ubiquitous Ca[2+] pathways, such as SOCE, demands specific trial design, transitioning toward biomarker-driven stratification of patient cohorts. Over the coming years, the pharmacological design will diverge into acute intravenous critical care and chronic oral immunomodulation. Ultimately, the exploitation of tissue-specific Orai2 and Orai3 isoform profiles represents the next frontier to enhance therapeutic efficacy across distinct disorders.},
}
@article {pmid42766503,
year = {2026},
author = {Muthuka, J and Muthoni, A and Ng'eno, L and Chebungei, L and Mbari, D and Nabaweesi, R},
title = {Maternal Serum Hemoglobin Levels Relative to Anemia Interventions in the COVID-19 Era: A Systematic Review and Meta-Analysis.},
journal = {Journal of health care for the poor and underserved},
volume = {37},
number = {1},
pages = {24-43},
doi = {10.1353/hpu.2026.a982955},
pmid = {42766503},
issn = {1548-6869},
mesh = {Humans ; Female ; *Hemoglobins/analysis ; *COVID-19/epidemiology ; Pregnancy ; *Anemia/therapy/blood ; Dietary Supplements ; *Pregnancy Complications, Hematologic/therapy/blood ; },
abstract = {In this literature review, we examined the impact of maternal anemia interventions on serum hemoglobin levels during the COVID-19 pandemic. We identified studies from various databases, spanning January 2020 to December 2022, and performed statistical analysis using Rev-Man 5.4.1 and JASP 0.9.95.4.0 softwares, employing both random and fixed effect models. Heterogeneity was assessed using the Cochran Q statistic and Higgins test. Overall, maternal anemia interventions significantly improved serum hemoglobin levels, with a standardized mean difference (SMD) of 0.93 (95% CI: 0.57, 1.30). Specific intervention effects included dietary iron supplements (SMD 1.16; 95% CI: -0.97, 3.28), educational information (SMD 0.75; 95% CI: 0.12, 1.37), intravenous ferric carboxyl-maltose (SMD 1.33; 95% CI: 0.28, 2.38), intravenous iron sucrose (SMD 0.82; 95% CI: 0.56, 1.09), and herbal substances (SMD 0.42; 95% CI: 0.24, 0.61). Although parenteral (injected) maternal anemia interventions marginally improved serum hemoglobin levels, multifaceted randomized controlled trials (RCTs) are essential to validate these findings.},
}
@article {pmid42766504,
year = {2026},
author = {Komeiha, M and Artyukh, I and Ogundele, OJ and Zhao, QJ and Massaquoi, N and Straus, S and Razak, F and Hosseini, B and Eissa, A and Isabel, M and Pinto, AD},
title = {Unveiling the Impact: A Scoping Review of the COVID-19 Pandemic's Effects on Low-Income Populations in Canada.},
journal = {Journal of health care for the poor and underserved},
volume = {37},
number = {1},
pages = {44-72},
doi = {10.1353/hpu.2026.a982956},
pmid = {42766504},
issn = {1548-6869},
mesh = {Humans ; *COVID-19/epidemiology/mortality ; Canada/epidemiology ; *Poverty/statistics &amp; numerical data ; Social Determinants of Health ; Mental Health ; Low Socioeconomic Status ; Socioeconomic Disparities in Health ; },
abstract = {OBJECTIVES: This scoping review examines the impact of the COVID-19 pandemic on low-income populations in Canada.<br><br>METHODS: We conducted the scoping review using the Joanna Briggs Institute (JBI) methodology and adhered to the PRISMA-ScR guidelines for reporting. The review included studies focusing on generally healthy, low-income populations residing in Canada. The definition of low income varied among the included articles.<br><br>RESULTS: A total of 7,054 citations were screened, resulting in six peer-reviewed studies selected for data extraction and analysis. The grey literature search produced ten reports that were included. Findings resulted in three categories: (1) COVID-19 morbidity and mortality rates, (2) impact on mental health, and (3) impact on social determinants of health.<br><br>CONCLUSION: Urgent policy interventions are needed to mitigate the negative impacts of future health care crises on low-income individuals. Implementing livable wage mandates and paid sick leave policies could facilitate equitable recovery.},
}
@article {pmid42766505,
year = {2026},
author = {Shukor, A and Biotech, M and Majid, U and Jameel, B and Klazinga, N and Martins, DSK},
title = {The Impact of the COVID-19 Pandemic on Community Health Centers in Canada and the United States: A Scoping Review.},
journal = {Journal of health care for the poor and underserved},
volume = {37},
number = {1},
pages = {73-110},
doi = {10.1353/hpu.2026.a982957},
pmid = {42766505},
issn = {1548-6869},
mesh = {Humans ; *COVID-19/epidemiology ; United States/epidemiology ; Canada/epidemiology ; *Community Health Centers/organization &amp; administration ; Health Services Accessibility/organization &amp; administration ; Quality of Health Care ; Quality Indicators, Health Care ; },
abstract = {Community health centers (CHCs) play a critical role in addressing the health needs of diverse and underserved communities. However, there remains a significant gap in the literature examining their resilience, particularly in crises such as COVID-19. This scoping review analyzed 68 articles to identify which performance indicators have been used to assess the impact of the pandemic on CHCs, and to understand what these indicators reveal about the CHCs' performance and resilience. The findings revealed that most performance indicators focused on access, availability, and quality of care, highlighting CHCs' role in maintaining essential services for underserved communities. However, critical upstream primary care performance indicators related to governance, financing, workforce planning, and building resilience were largely absent in the literature reviewed. This gap indicates a need to broaden performance indicators to holistically address all key performance and resilience dimensions, including upstream factors essential for sustaining long-term resilience and equity.},
}
@article {pmid42762709,
year = {2026},
author = {Zanette, M and Enns, B and Carter, A and Compton, M and Daly, P and Davison, C and Gustafson, R and Hedden, L and Kerr, T and Schnepel, K and Nosyk, B},
title = {A review of policy actions implemented during a toxic drug public health emergency in British Columbia, Canada (2016-2024).},
journal = {The International journal on drug policy},
volume = {157},
number = {Pt A},
pages = {105509},
doi = {10.1016/j.drugpo.2026.105509},
pmid = {42762709},
issn = {1873-4758},
abstract = {BACKGROUND: During a decade-long public health emergency, driven by a highly unpredictable unregulated drug supply, drug toxicity remains the leading cause of unnatural death in British Columbia (BC), Canada. In response, the province implemented a multi-faceted approach to prevent toxic drug harms and save lives. Our objective was to review all relevant provincial policy actions since the declaration of the emergency and identify evaluations of implementation and effectiveness.<br><br>METHODS: We identified provincial-level policy actions related to unregulated substance use between 04/2016-12/2024 through a list provided by the BC Ministry of Health and searches of peer-reviewed and grey literature. We classified actions into nine provincial response domains, summarized over time, and noted if the policy change was evaluated.<br><br>FINDINGS: We identified 146 policy actions concentrated primarily in three domains: treatment and recovery (n = 51 (35%)), overdose prevention services (n = 26 (18%)), and social stabilization (n = 21 (14%)). Actions slowed at the onset of the COVID-19 pandemic, resuming in 2021-24. Most actions (n = 85, 58%) have not yet undergone evaluations of implementation or effectiveness.<br><br>CONCLUSION: Despite a broad and innovative provincial response, the toxic drug crisis remains a significant challenge across BC. More evaluation is urgently needed to identify the effects of policy actions to date.},
}
@article {pmid42762925,
year = {2026},
author = {Carreras, F and Salvatici, M and Corrado, C and Sansico, FD and Drago, L},
title = {Macrotroponin and antibody-mediated interference: An underrecognized cause of discordant cardiac troponin results.},
journal = {International journal of cardiology},
volume = {},
number = {},
pages = {134783},
doi = {10.1016/j.ijcard.2026.134783},
pmid = {42762925},
issn = {1874-1754},
abstract = {BACKGROUND: High-sensitivity cardiac troponin (hs-cTn) assays have improved the detection of myocardial injury, but have also increased the recognition of clinically discordant results. Among the causes of such discrepancies, analytical interferences remain underrecognized. Macrotroponin, a complex formed between cardiac troponin and immunoglobulins, represents a circulating immunoreactive complex of uncertain biological significance that remains analytically detectable and may lead to persistently elevated and non-dynamic cTn concentrations in the absence of myocardial injury.<br><br>CONTENT: This narrative review summarizes current clinical evidence on macrotroponin-associated interference in cTn immunoassays, predominantly derived from selected cohorts, case reports, and analytical studies. We describe proposed mechanisms, including autoantibody formation and immune complex persistence, and discuss assay-dependent variability. We examine key clinical scenarios in which macrotroponin should be suspected, including post-inflammatory states, autoimmune diseases, SARS-CoV-2-related settings, and physiological stress such as endurance exercise. Finally, we outline practical laboratory approaches for detection, including polyethylene glycol precipitation, immunoglobulin depletion, and size-exclusion techniques, and propose a clinically oriented diagnostic workflow.<br><br>SUMMARY: Macrotroponin represents an important and often overlooked cause of persistent or discordant cTn elevation. Recognition of this phenomenon is essential to avoid misdiagnosis and unnecessary investigations. Integration of biomarker kinetics, clinical context, and targeted laboratory testing is critical for accurate interpretation. Further studies are needed to define its prevalence, biological determinants, and standardized diagnostic strategies.},
}
@article {pmid42763918,
year = {2026},
author = {Kwon, Y and Gang, M},
title = {Effects of suicide prevention programs on suicidal ideation and attempts in military personnel: a systematic review and meta-analysis.},
journal = {Journal of mental health (Abingdon, England)},
volume = {},
number = {},
pages = {1-12},
doi = {10.1080/09638237.2026.2732884},
pmid = {42763918},
issn = {1360-0567},
abstract = {BACKGROUND: Suicide among military personnel is a pervasive and urgent issue.<br><br>AIMS: This study analyzed the effects of suicide prevention programs on suicidal ideation and attempts among military personnel and identified program characteristics associated with greater efficacy.<br><br>METHODS: PsycINFO, PubMed, Web of Science, EMBASE, and Google Scholar were searched for randomized controlled trials involving active-duty or retired military personnel. Fourteen studies were included in the systematic review, and 10 in the meta-analysis. Primary outcomes were suicidal ideation and attempts. Data were analyzed using a random-effects model, with subgroup analyses based on program type, delivery method, and implementation site.<br><br>RESULTS: Suicide prevention programs significantly reduced suicidal ideation and suicide attempts (Hedges's g&#x2009;=&#x2009;-0.33, 95% CI: -0.62 to -0.03, p&#x2009;=&#x2009;.029; I[2] = 73). Cognitive behavioral therapy (CBT)-based interventions showed a small effect on ideation (Hedges's g&#x2009;=&#x2009;-0.33) and a moderate effect on attempts (Hedges's g&#x2009;=&#x2009;-0.67). Face-to-face and blended programs were the most effective, whereas non-face-to-face programs were ineffective. Furthermore, military base-based interventions outperformed those at healthcare institutions.<br><br>CONCLUSIONS: Suicide prevention programs, particularly CBT-based and multi-component interventions delivered face-to-face or blended within military units, are effective. Future research should optimize remote strategies and enhance long-term effectiveness.<br><br>PRISMA/PROSPERO: Regarding registration in PROSPERO, while we did attempt the registration for this systematic review, it was ultimately not possible for two primary reasons. First, the PROSPERO registration review at the time we applied prioritized COVID-19-related research. This, therefore, delayed the review process for this study's suicide-related topic. Second, a systematic review protocol with a similar title had already been registered. Consequently, we never received a registration number. Notably, while a similarly titled protocol exists, our study specifically employs a comprehensive meta-analysis approach to address this topic, thus ensuring a distinct methodology.},
}
@article {pmid42764017,
year = {2026},
author = {Calderón-Larrañaga, S and Bakhti, R and Etemadi, M and Fakih, L and Vandeskog, HO and Shrestha, P and He, S and Chua, AQ and Heymann, D and Tangcharoensathien, V and Mahendradhata, Y and Cook, AR and Engebretsen, E and Eshete, MT and García-Basteiro, AL and Rando, K and Adeyi, O and Fukuda-Parr, S and Lee, K and Wamoyi, J and Haldane, V and Jung, AS and Rahman-Shepherd, A and Schenck, M and Tian, M and Hsu, LY and Ng, ISL and Valderas, JM and Leo, YS and Lee, V and Nordström, A and Kazatchkine, M and Teo, YY and Clark, H and Legido-Quigley, H and , },
title = {The NUS-Lancet PRIME Commission: transforming pandemic readiness for equity.},
journal = {Lancet (London, England)},
volume = {},
number = {},
pages = {},
doi = {10.1016/S0140-6736(26)01146-3},
pmid = {42764017},
issn = {1474-547X},
}
@article {pmid42764130,
year = {2026},
author = {Podolsky, AS and Zhou, MH and Freeman, EE and Rosenbach, M and Tyring, SK and Wanat, KA and Lupi, O and Lipner, SR},
title = {Dermatological Manifestations of Emergent Viruses. Part I: Common and Vaccine-Preventable Viral Infections.},
journal = {Journal of the American Academy of Dermatology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jaad.2026.09.054},
pmid = {42764130},
issn = {1097-6787},
abstract = {Viral infections frequently present with mucocutaneous manifestations that may provide diagnostic clues and guide timely management. However, the expanding therapeutic landscape and evolving public health recommendations highlight the need for an updated evidence-based review for dermatologists. Herein, we summarize the epidemiology, clinical presentation, diagnosis, management, and prevention of common and vaccine-preventable viral infections with dermatologic relevance, including Coronavirus Disease-2019 (COVID-19), mpox, measles, and rubella. Advances in antiviral therapies, immunomodulators, vaccination, and post-exposure prophylaxis have improved outcomes for several infections. Recognition of characteristic skin findings, familiarity with current diagnostic approaches, and implementation of evidence-based prevention strategies are essential for early diagnosis, appropriate treatment, and limiting disease transmission.},
}
@article {pmid42764981,
year = {2026},
author = {Seger, F and Gutschi, LM and Seneff, S},
title = {Lipid nanoparticles as active biointerfaces: From membrane interaction to systemic dysregulation.},
journal = {Acta pharmaceutica Sinica. B},
volume = {16},
number = {9},
pages = {5674-5708},
pmid = {42764981},
issn = {2211-3835},
abstract = {Lipid nanoparticles (LNPs) are central to modern mRNA therapeutics, including COVID-19 vaccines. Far from passive carriers, their ionizable lipids actively interact with cellular membranes. Evidence from cellular, transcriptomic, and proteomic studies indicates that LNPs, with or without nucleic acid, alter gene and protein expression, thereby initiating inflammatory, detoxification, and stress responses at the membrane. Key pathways affected include lipid metabolism and detoxification, with roles for Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and cytochrome P450 enzymes. We hypothesize that the phosphatidylinositol (PI) cycle is the primary site of LNP-induced perturbations, regulating membrane restructuring and organelle trafficking during endocytosis. Disruption of this cycle triggers downstream signaling cascades, including nuclear factor kappa B (NF-κB), mitogen-activated protein kinases (MAPKs), Janus kinase/signal transducers and activators of transcription (JAK/STAT), and mechanistic target of rapamycin (mTOR). We term this systemic effect lipid-nanoparticle-driven membrane dysfunction (L-DMD), characterized by dysregulated cellular communication, stress responses, and energy balance. This review provides a mechanistic framework for understanding the persistent biological effects of modified modRNA-LNP exposure and emphasizes a systems-level intracellular perspective.},
}
@article {pmid42765443,
year = {2026},
author = {Dejen, GM},
title = {mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.},
journal = {Immunity, inflammation and disease},
volume = {14},
number = {9},
pages = {e70511},
pmid = {42765443},
issn = {2050-4527},
mesh = {Humans ; *RNA, Messenger/therapeutic use/genetics ; Animals ; Immunotherapy/methods ; Precision Medicine/methods ; COVID-19 ; Neoplasms/therapy/genetics ; Nanoparticles ; SARS-CoV-2 ; Communicable Diseases/therapy ; Drug Delivery Systems ; *Genetic Therapy/methods ; },
abstract = {BACKGROUND: Messenger RNA (mRNA) therapeutics have rapidly evolved from experimental nucleic acid constructs into a clinically validated therapeutic platform. Their successful application during the COVID-19 pandemic accelerated interest in broader therapeutic uses beyond infectious diseases.<br><br>AIMS: This review summarizes the expanding therapeutic applications of mRNA technologies, recent technological advances, translational progress, current challenges, and future prospects across diverse medical fields.<br><br>MATERIALS AND METHODS: A comprehensive review of the published literature was conducted, synthesizing evidence from preclinical investigations, clinical studies, and recent advances in mRNA engineering, delivery systems, and translational research.<br><br>RESULTS: Advances in mRNA design, nucleoside modification, codon optimization, and delivery platforms, particularly lipid nanoparticles and emerging organ-targeted carriers, have expanded applications to cancer immunotherapy, personalized vaccines, autoimmune and inflammatory diseases, protein replacement therapy, cardiovascular regeneration, neurological disorders, and rare genetic diseases. Emerging technologies, including self-amplifying and circular RNA systems, further enhance therapeutic potential.<br><br>DISCUSSION: Despite significant progress, challenges remain, including optimization of targeted delivery, long-term safety, repeat-dose tolerability, manufacturing complexity, cold-chain requirements, production costs, and equitable global access. Continued technological innovation and regulatory harmonization are critical for successful clinical translation.<br><br>CONCLUSION: mRNA therapeutics are transitioning from a vaccine-centered technology to a versatile platform for precision medicine. Advances in delivery systems, scalable manufacturing, and artificial intelligence-assisted sequence design are expected to accelerate their integration into the treatment of chronic, genetic, and regenerative diseases.},
}
@article {pmid42753364,
year = {2026},
author = {Sardar, N and Manzoor, S},
title = {Self-amplifying RNA and circular RNA vaccines: mechanisms, delivery strategies, and prospects for long-lasting immunity.},
journal = {Human immunology},
volume = {87},
number = {11},
pages = {112083},
doi = {10.1016/j.humimm.2026.112083},
pmid = {42753364},
issn = {1879-1166},
abstract = {Messenger RNA vaccines have demonstrated extraordinary success during the COVID-19 pandemic, yet conventional mRNA platforms exhibit inherent limitations including modest molecular stability, stringent cold-chain requirements, waning antibody responses, and the necessity for relatively high doses to achieve protective immunity. Next-generation RNA technologies-specifically self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines-address these shortcomings through fundamentally distinct molecular designs that enhance antigen expression kinetics and prolong immunological persistence. Self-amplifying RNA vaccines incorporate viral replicase elements derived from alphaviruses, enabling intracellular amplification of the antigen-encoding sequence and sustained protein production at doses substantially lower than conventional mRNA. Circular RNA vaccines feature covalently closed loop structures that confer complete resistance to exonuclease-mediated degradation, extending translational half-life and maintaining antigen presentation over extended periods. This review provides a comprehensive examination of the molecular architecture, intracellular processing mechanisms, and immune activation pathways characteristic of both platforms. We critically evaluate formulation and delivery strategies, with particular emphasis on lipid nanoparticles and emerging carrier systems, and assess manufacturing challenges related to scalability, purity, and quality control. The preclinical and early clinical evidence supporting both platforms is synthesized and compared, highlighting the dose-sparing capacity of self-amplifying RNA and the exceptional durability of circular RNA-induced responses. Persistent obstacles-including reactogenicity modulation, circularization efficiency, replicase-associated innate suppression, and regulatory standardization-are analyzed in depth. We conclude by identifying priority research directions essential for clinical translation, including optimized delivery systems, refined safety profiling, and cold-chain-independent formulations that will enable global vaccine accessibility.},
}
@article {pmid42753425,
year = {2026},
author = {Orzeł, U and Wójcik, E and Filipek, S and Moreira, IS},
title = {ACE2 dysregulation and lipid metabolism: Mechanistic interplay between COVID-19 and neurodegeneration.},
journal = {Molecular aspects of medicine},
volume = {112},
number = {},
pages = {101519},
doi = {10.1016/j.mam.2026.101519},
pmid = {42753425},
issn = {1872-9452},
abstract = {Angiotensin-converting enzyme 2 (ACE2) is the primary cellular receptor of SARS-CoV-2. It is a key regulator of the renin-angiotensin system (RAS) and modulates blood pressure and inflammatory pathways. ACE2 converts pro-inflammatory angiotensin II into the vasoprotective peptide, angiotensin (1-7). This is strongly influenced by the lipid composition of the plasma membrane. Cholesterol-rich lipid rafts play an important role in determining receptor localisation and viral accessibility. Dyslipidaemia, which is common in obesity, diabetes, and metabolic syndrome, has been associated with an increased susceptibility to severe COVID-19 and may amplify systemic inflammation. Aberrant lipid metabolism also contributes to neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, which drive neuroinflammation, synaptic dysfunction, and blood-brain barrier impairment. Notably, similar disturbances and systemic inflammation are increasingly recognised in patients with Long COVID, suggesting overlapping mechanisms that may exacerbate or accelerate neurodegenerative processes. This review explores the interplay between ACE2 regulation, lipid metabolism, and systemic inflammation in COVID-19, with a particular focus on their implications for neurological health. Uniquely, we highlighted the intersection of ACE2 and lipid-related alterations in patients with Long COVID and their potential contribution to the progression of neurodegenerative diseases. In addition, we reviewed therapeutic strategies targeting ACE2, including recombinant soluble ACE2, ACE2-based nanotherapeutics, and lipid-focused interventions, aimed at mitigating acute infection, systemic inflammation, and persistent neurological sequelae. Understanding these mechanisms is essential to prevent long-term neurological consequences of the COVID-19 pandemic.},
}
@article {pmid42753783,
year = {2026},
author = {Colombo, F and Cecchini, M and Elgar, K and Segal, AB and Sutherland, E},
title = {Fit for the future: from siloed to integrated public health systems.},
journal = {The Lancet. Public health},
volume = {},
number = {},
pages = {},
doi = {10.1016/S2468-2667(26)00161-1},
pmid = {42753783},
issn = {2468-2667},
abstract = {Despite compelling evidence on the value of prevention, public health remains chronically underfunded and structurally deprioritised. Spending on prevention has remained stable at around 3% of total health expenditure across Organisation for Economic Co-operation and Development countries for the past two decades, and despite a temporary doubling of spending during the COVID-19 pandemic, this trend has already reversed. The central challenge for the next decade lies not in the absence of evidence, but rather the absence of political will and systems capable of translating evidence into action. Three interconnected priorities stand out: (1) embedding public health in cross-sectoral governance frameworks so that prevention is assessed on equal terms with curative care; (2) strengthening data to support public health investment and budgeting, especially in a highly volatile fiscal environment for many countries; and (3) accelerating digital transformation to increase analytical ability, targeted public health intervention, and public trust. Progress in all three areas requires strong political leadership and rethinking current systems to ensure that they are fit for the future.},
}
@article {pmid42756063,
year = {2026},
author = {Castle, VE and Sideropoulos, V and Jones, C and Zhang, D and Van Herwegen, J and Palikara, O},
title = {The Impact of COVID-19 on the Mental Health and Wellbeing of Children with Special Education Needs and Disabilities: A Systematic Review.},
journal = {Review journal of autism and developmental disorders},
volume = {13},
number = {3},
pages = {607-631},
pmid = {42756063},
issn = {2195-7185},
abstract = {The COVID-19 pandemic has impacted greatly the mental health of children. We performed a systematic review to better understand the impact of the pandemic on children with special educational needs and disabilities (SEND) across different SEND categories. Following PRISMA guidelines, of 1699 search results, 66 studies were included in our analysis as they met our inclusion criteria concerning: a) children with SEND; b) focus on COVID-19; c) longitudinal or cross-sectional design; d) quantitative or qualitative measures; and e) mental health or well-being outcomes. Our review suggests that there was a typically negative impact on mental health and well-being for children with SEND, yet experiences varied on the basis of individual differences, rather than category of SEND. Findings highlight the need for interventions and policy implementations to improve the everyday mental well-being of this population.},
}
@article {pmid42756240,
year = {2026},
author = {Kou, Z and Liu, Y and Qian, W and Zhang, S and Lou, S and Shao, D},
title = {Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1919677},
pmid = {42756240},
issn = {1664-3224},
mesh = {Humans ; *Hemorrhagic Fever, Ebola/therapy/immunology/epidemiology ; Bibliometrics ; *Ebolavirus/immunology ; *Antibodies, Monoclonal/therapeutic use ; Disease Outbreaks ; *Antibodies, Viral/therapeutic use ; },
abstract = {BACKGROUND: Antibody-based therapies have become a cornerstone of Ebola virus disease (EVD) treatment and prevention, particularly following the successful clinical development of monoclonal antibody therapeutics against Zaire ebolavirus. However, despite substantial advances, the global research landscape, collaboration patterns, and evolving thematic trends of Ebola antibody therapy have not been systematically characterized. The ongoing 2026 Bundibugyo ebolavirus outbreak, for which no licensed vaccines or therapeutics currently exist, further underscores the importance of understanding the development trajectory of this field.<br><br>METHODS: Publications related to antibody therapy for EVD published between 1990 and 2026 were retrieved from the Web of Science Core Collection, PubMed, and Scopus databases. Following data integration, format conversion, and deduplication, a total of 1,350 unique publications were included. Bibliometric analyses were conducted using CiteSpace, VOSviewer, and Bibliometrix, complemented by Google Trends data to evaluate public interest and outbreak-related attention.<br><br>RESULTS: The field exhibited dynamic outbreak-driven growth, with major publication surges corresponding to the 2014-2016 West African Ebola epidemic and the period surrounding 2020. Although annual publication output declined after 2020, renewed public attention emerged during the 2026 Bundibugyo outbreak. The United States dominated both publication productivity and citation impact, followed by China, the United Kingdom, and Canada. Harvard University, the University of Texas System, and Scripps Research Institute were identified as leading institutions. Keyword co-occurrence and clustering analyses revealed five major thematic domains: fundamental virology and glycoprotein research, immunity and vaccination, infection and therapeutic development, cross-viral research involving COVID-19 and HIV, and clinically oriented studies focused on neutralizing antibodies, clinical trials, and convalescent plasma. Temporal analyses demonstrated a clear evolution from basic virology toward translational and clinical applications.<br><br>CONCLUSIONS: Ebola antibody therapy research has undergone substantial expansion over the past three decades, driven largely by major outbreak events and advances in antibody engineering technologies. The current Bundibugyo outbreak highlights persistent vulnerabilities in existing countermeasure strategies and emphasizes the urgent need for broadly protective pan-ebolavirus antibody therapeutics. These findings provide a comprehensive overview of the intellectual structure, global collaborations, research hotspots, and future directions of antibody-based interventions against Ebola virus disease.},
}
@article {pmid42756354,
year = {2026},
author = {Kalinowski, O and Rössler, W},
title = {Gender differences in the effects of economic inequality on mental conditions: a multivariate meta-analysis of Gini index and relative income position in high-income OECD countries.},
journal = {Frontiers in psychiatry},
volume = {17},
number = {},
pages = {1835495},
pmid = {42756354},
issn = {1664-0640},
abstract = {BACKGROUND: Economic inequalities are established determinants of mental conditions, yet the role of gender remains insufficiently examined. In this article, we suggest that women experience a "double risk" in contexts of economic inequality: higher exposure to economic disadvantage and greater vulnerability to its mental health effects.<br><br>METHODS: We conducted a two-step synthesis. First, we analyzed sex differences in relative poverty across high-income OECD countries. Mean differences were assessed using Welch t-tests, with sensitivity analyses across COVID-19 periods. Second, we performed a systematic review and multivariate random-effects meta-analysis following PRISMA guidelines. We included 21 studies reporting gender-disaggregated associations between income rank and income inequality and ICD-/DSM-based mental conditions. Effect sizes were transformed to log odds ratios and analyzed using multilevel models accounting for within-study dependencies. Gender was examined as a moderator.<br><br>RESULTS: Women exhibited higher relative poverty rates than men (20.5% vs. 18.3%; mean difference: 2.2 percentage points; p < 0.001). The meta-analysis (46 effect sizes) showed a significant association between lower income and poorer mental health (log(OR)=0.55, 95% CI 0.26-0.85), with substantial heterogeneity. Gender did not moderate effects across all outcomes. However, in depression-specific analyses (k=17), gender significantly moderated the association (p=0.016), with stronger effects in women. Income inequality (Gini index) showed no overall association with mental health, but gender still emerged as a significant moderator, with effects concentrated among women in adjusted models.<br><br>CONCLUSIONS: Gender shapes both exposure to economic disadvantage and vulnerability to its mental health consequences. While income-related mental health inequalities affect both sexes, women appear disproportionately impacted, particularly regarding depression. These findings highlight the importance of integrating gender-sensitive approaches into research and policy addressing socioeconomic determinants of mental health.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251123692, identifier CRD420251123692.},
}
@article {pmid42760256,
year = {2026},
author = {de Lima Brum, R and Saes-Silva, E and Neves, RG and da Silva Freitas, L and da Silva Bonifácio, A and da Silva Júnior, FMR},
title = {Exploring climate, air pollution, and respiratory disease hospitalizations in Brazil: a scoping review.},
journal = {Expert review of respiratory medicine},
volume = {},
number = {},
pages = {},
doi = {10.1080/17476348.2026.2736890},
pmid = {42760256},
issn = {1747-6356},
abstract = {INTRODUCTION: Air pollution is the leading environmental risk factor for mortality worldwide, contributing to 7.9 million deaths in 2023. In Brazil, studies evaluating the combined relationship between air pollution, climate variables, and respiratory disease hospitalizations remain fragmented and regionally concentrated.<br><br>AREAS COVERED: This scoping review mapped the Brazilian literature on air pollution, climate, and respiratory hospitalizations across multiple scientific databases. A total of 1,179 studies were identified, of which 129&#x2009;met the eligibility criteria after screening and full-text assessment. Respiratory infections, including pneumonia and COVID-19, followed by asthma, were the most frequently investigated outcomes, with children representing the main target population. The review also revealed geographical asymmetry, as a single federative unit concentrated more than one-third of all published studies. Overall, 117 studies (90.70%) reported positive associations between environmental exposures and hospitalizations, of which 112 reported significant results.<br><br>EXPERT OPINION: Environmental epidemiology in Brazil remains limited by methodological fragmentation, territorial inequalities, and insufficient local coverage, with only 42 municipalities (0.75% of the Brazilian municipalities) individually identified among municipal-scale studies. Although the literature establishes an important epidemiological baseline, substantial structural gaps still hinder advances in the field, reinforcing the urgent need for decentralized research strategies, methodological modernization, and integrated climate-health approaches.},
}
@article {pmid42761183,
year = {2026},
author = {Kim, J and Son, B and Yoo, W and Shin, H},
title = {Gut microbiome-immune-metabolic axis in fatigue: mechanistic insights and food science approaches.},
journal = {Food science and biotechnology},
volume = {35},
number = {12},
pages = {3449-3463},
pmid = {42761183},
issn = {2092-6456},
abstract = {Fatigue is a heterogeneous symptom associated with lifestyle, infection, exercise, and chronic disease, but its biological links with the gut microbiome remain incompletely defined. This review summarizes clinical and mechanistic evidence connecting gut microbiome alterations with fatigue-related phenotypes, focusing on myalgic encephalomyelitis/chronic fatigue syndrome, post-acute COVID-19 syndrome, general adult fatigue, and exercise-induced fatigue. Evidence was interpreted according to fatigue-related phenotype, microbiome function, microbial metabolite, gut barrier marker, inflammatory response, and food-based intervention. Current studies suggest that reduced short-chain fatty acid production, impaired butyrate-producing capacity, gut barrier dysfunction, microbial translocation, low-grade inflammation, altered tryptophan metabolism, host energy imbalance, and gut-brain/gut-muscle axis signaling may contribute to fatigue-related physiological vulnerability. Food components/ingredients, including dietary fiber, fermented food, prebiotic, probiotic, postbiotic, polyphenol, and polysaccharide, may support microbiome-mediated recovery pathways. Further controlled, phenotype-specific, multi-omics intervention studies are required.},
}
@article {pmid42761488,
year = {2026},
author = {Xu, S and Li, X and Li, W and Huang, R},
title = {A narrative discussion on the impact of respiratory infectious diseases on dental education in China: implications for curriculum design and student outcomes.},
journal = {Frontiers in dental medicine},
volume = {7},
number = {},
pages = {1897947},
pmid = {42761488},
issn = {2673-4915},
abstract = {OBJECTIVE: Recent outbreaks of respiratory infectious diseases, transmitted via aerosols, have placed dental healthcare workers at high risk. Traditional dental education, based on student-teacher-patient interactions, faces unprecedented challenges across all stages. From admissions to classroom teaching, laboratory instruction, clinical training, and final examinations, every aspect of dental education is undergoing significant challenges and is in urgent need of change.<br><br>METHODS: This narrative review with content analysis synthesized literature on the impact of respiratory infections on dental education. We systematically searched PubMed, Web of Science, and CNKI (2020-2026) using relevant keywords. Two reviewers independently screened and selected studies. Data were thematically analyzed into five core domains: classroom teaching, laboratory teaching, clinical teaching, student admissions/assessment, and licensing examinations.<br><br>RESULTS: In classroom teaching, online platforms and AI-augmented PBL/CBL were rapidly adopted, yet persistent issues included network instability, limited interaction, digital inequities, and heavy reliance on student self-discipline. In laboratory teaching, AR/VR and iLab-X enabled remote training, but were constrained by high costs, poor haptic realism, inability to replicate patient emotions, and equipment dependence. In clinical teaching, enhanced infection controls-including PPE, rubber dams, and HEPA filtration-were implemented, though bio-aerosol risks, reduced patient flow, and limited clinical exposure remained. In admissions, online exams with dual-camera proctoring, open-ended questions, AI-generated items, and virtual OSCEs were adopted, while challenges persisted in cheating prevention, subjective scoring, validity, and privacy. Licensing examinations remained in-person with strict protection; VSP showed promise but lacked robust evidence and incurred high costs. Overall, technological innovations enabled educational continuity, yet significant infrastructure gaps, inequities, and unresolved validity issues persist across all domains.<br><br>CONCLUSION: China's dental education rapidly adapted to respiratory epidemics through online teaching, simulation, and enhanced infection control, yet persistent challenges remain in digital equity, cost, validity, and infrastructure. These innovations are important primarily because they directly influence student learning outcomes-including knowledge acquisition, clinical reasoning, and skill retention-while also shaping curriculum design. Future preparedness requires sustained investment, faculty development, equitable access, and rigorous longitudinal research to validate skill transfer to clinical practice, ensuring that technological advances ultimately translate into measurable improvements in student competency and patient safety.},
}
@article {pmid42761556,
year = {2026},
author = {Abdi, YH and Issack, ZI},
title = {Converging infectious disease threats in the post-COVID era: surveillance fragility, pandemic risk, and global preparedness.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1916865},
pmid = {42761556},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology ; Pandemic Preparedness ; *Pandemics ; *Global Health ; Zoonoses/epidemiology ; Animals ; Public Health Infrastructure ; SARS-CoV-2 ; *Communicable Diseases/epidemiology ; },
abstract = {The COVID-19 pandemic exposed profound weaknesses in global infectious disease surveillance yet, in its aftermath, pandemic-prone threats have intensified rather than receded. This narrative review synthesizes contemporary evidence on three converging drivers of pandemic risk zoonotic emergence, antimicrobial resistance, and climate-sensitive disease expansion and examines how structural failures in surveillance and global health governance amplify their impact. Drawing on recent epidemiological analyses, policy reports, and One Health evaluations, the review maps post-COVID surges in zoonotic outbreaks, drug-resistant infections, and vector and water-borne diseases, and links these trends to fragmented laboratory networks, inequitable genomic capacity, and weak integration across human, animal, and environmental systems. It further interrogates the geopolitical and socioeconomic determinants of vulnerability, including conflict-related surveillance collapse, vaccine inequity, and the political economy of pandemic financing. Emerging digital tools from AI-enabled forecasting to wastewater and social media surveillance are assessed not only for their technical promise but also for risks related to data bias, extractives, and governance gaps. The review argues that without redistributive investment in One Health integration, regional genomic platforms, community-based surveillance, and enforceable IHR-based accountability, the world will continue to detect converging threats late and respond inequitably, leaving pandemic preparedness structurally fragile in the post-COVID era.},
}
@article {pmid42751133,
year = {2026},
author = {Zarbatan, FA and Alawam, K and Hakamy, A},
title = {Pulmonary sequelae of SARS-CoV-2 infection: a narrative review of long-term functional, radiological, and clinical outcomes in COVID-19 survivors, with a regional focus on Saudi Arabia.},
journal = {Frontiers in physiology},
volume = {17},
number = {},
pages = {1916914},
pmid = {42751133},
issn = {1664-042X},
abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has left an enduring legacy of pulmonary morbidity among millions of survivors worldwide. While the acute phase of COVID-19 has been extensively characterized, the long-term pulmonary sequelae collectively termed post-acute sequelae of SARS-CoV-2 infection (PASC) or long COVID remain incompletely understood, particularly across diverse geographic and demographic populations. This narrative review synthesizes current evidence on the long-term pulmonary consequences of SARS-CoV-2 infection, with emphasis on functional, radiological, and clinical outcomes in survivors. Literature was identified through systematic searches of PubMed, Scopus, and Google Scholar covering publications from January 2020 to September 2025, using pre-specified search terms related to long COVID pulmonary outcome; studies involving adult survivors with objectively assessed pulmonary outcomes were prioritized. This review addresses the pathophysiological mechanisms underlying pulmonary injury, the definition and clinical spectrum of long COVID, the trajectory of pulmonary function test (PFT) abnormalities-particularly reductions in diffusing capacity for carbon monoxide (DLCO) and radiological findings detected on high-resolution computed tomography (HRCT). Risk factors for persistent pulmonary dysfunction, the impact on health-related quality of life (HRQoL) and functional capacity, emerging evidence supporting structured pulmonary rehabilitation, and the specific context of Saudi Arabia and the Jizan region are also examined. A particular focus on the Arabian Peninsula is warranted given that regional populations carry a high burden of metabolic comorbidities including obesity, diabetes mellitus, and hypertension that may amplify pulmonary vulnerability to SARS-CoV-2 yet remain substantially underrepresented in the current literature. The available evidence suggests that impaired gas exchange most consistently reflected by reduced DLCO may represent the most prevalent long-term pulmonary consequence of COVID-19, with restrictive ventilatory patterns predominating over obstructive defects. Significant gaps persist regarding the long-term trajectory of these abnormalities, population-specific risk stratification, and the efficacy of targeted rehabilitation. Structured, longitudinal, multicenter research incorporating standardized PFT protocols is urgently needed to address these unresolved questions and guide evidence-based post-COVID pulmonary care.},
}
@article {pmid42751188,
year = {2026},
author = {Xu, Q and Zhang, J and Hou, Y and Tan, Z and Gao, H and Silva-Júnior, EF and Gao, S and Zhan, P and Liu, X},
title = {The substrate envelope strategy: Structural basis for resistance mitigation in antiviral drug design.},
journal = {Pharmaceutical science advances},
volume = {4},
number = {},
pages = {100147},
pmid = {42751188},
issn = {2773-2169},
abstract = {Drug resistance remains a major hurdle in antiviral drug development. This review highlights the "substrate envelope hypothesis", a structure-based drug design (SBDD) paradigm that constrains the spatial boundaries and binding footprint of inhibitors within the conserved active site volume defined by natural viral substrates. By restricting inhibitor interactions to evolutionarily conserved residues, this approach ensures that mutations abrogating drug binding simultaneously impair natural substrate processing. This imposes an insurmountable fitness cost on the virus, thereby mitigating resistance. Through the analysis of viral enzyme-substrate co-crystal structures, we systematically review the application of this framework in human immunodeficiency.virus (HIV) protease, hepatitis C virus (HCV) NS3/4A protease, influenza virus (IFV) neuraminidase (NA), and severe acute respiratory Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) main protease, illustrating how substrate envelope-guided design achieves high potency while circumventing resistance. Additionally, we extend this strategy from traditional protease targets to non-protease enzymes. By integrating molecular dynamics and structural biology, this framework offers a rational approach for developing next-generation antivirals.},
}
@article {pmid42751394,
year = {2026},
author = {Chan, KK},
title = {Narrative Review: Telemedicine for Reducing Travel-Related Out-of-Pocket Costs Among Hong Kong Urological Patients and a Customized Tiered Consultation Pathway.},
journal = {Research and reports in urology},
volume = {18},
number = {},
pages = {645326},
pmid = {42751394},
issn = {2253-2447},
abstract = {PURPOSE: The COVID-19 pandemic disrupted routine urological outpatient services in Hong Kong, imposing disproportionate travel burdens on outlying island and cross-border patients who rely on multi-stage ferry and bus journeys. Globally, existing teleurology cost evidence is dominated by Western private-vehicle models, and to date no peer-reviewed review has investigated teleurology cost outcomes in Hong Kong. This narrative review addresses this regional research gap by synthesizing international evidence and proposing a tiered workflow aligned with the Hospital Authority's 2022-2027 Smart Care strategy.<br><br>PATIENTS AND METHODS: PubMed, CINAHL Complete and MEDLINE were searched for primary quantitative studies published between January 2012 and December 2022. Studies were screened following standard PRISMA protocols, and methodological quality was appraised using CASP and JBI checklists. Findings were aggregated via narrative thematic synthesis.<br><br>RESULTS: Eleven eligible studies (9 cohort studies, 1 randomized controlled trial, 1 cross-sectional survey) were included in the final analysis. Four core patient cost themes were identified by evidence strength: travel time savings (81.8% of studies), direct transport expenditure reduction (72.7%), travel distance reduction (54.5%), and lost work opportunity cost (45.5%). Western mileage-based cost frameworks have limited applicability to Hong Kong's ferry-dominated public transit ecosystem.<br><br>CONCLUSION: Evidence drawn predominantly from Western populations suggests that teleurology may reduce travel-related time and financial burdens for urology patients, with potential applicability to Hong Kong's remote island and cross-border patient groups. The proposed tiered consultation pathway represents a theoretically evidence-informed framework aligned with local digital healthcare policy, to support future telehealth pilot implementation and service optimization. As all included studies were conducted in North America and the United Kingdom, and the pathway has not been locally validated, its real-world effectiveness and cost-saving magnitude in Hong Kong remain to be confirmed in future primary research. Although this study focuses on the public healthcare setting in Hong Kong, the proposed telemedicine consultation pathway may serve as a reference clinical and operational blueprint for other highly urbanized regions with outlying islands or cross-border patient demographics.},
}
@article {pmid42735469,
year = {2026},
author = {Li, A and Ren, J and Guyatt, GH and Busse, JW and Sadeghirad, B and Patwardhan, B and Chaturvedi, S and Cheung, AM and Ge, L and Hao, Q and Thabane, L and Vohra, S and Brinkhaus, B and Chu, DK and Witt, CM and Li, Y and Krishnan, G and Kong, L and Wieland, LS and Agoritsas, T and Kothari, KU and Lee, MS and Okwen, PM and Ang, L and Zeng, Z and Gao, J and Wang, S and Cui, M and Zhai, C and Lozano, LEC and Fang, F and Pan, W and Yang, P and Wen, C and Rugolo, JM and Ren, Y and Kang, YK and Yong, NB and Fang, M and He, Q and Zhang, YQ},
title = {Traditional, complementary, and integrative medicine therapies for mild/moderate acute COVID-19: a systematic review and network meta-analysis.},
journal = {Phytomedicine : international journal of phytotherapy and phytopharmacology},
volume = {161},
number = {},
pages = {158764},
doi = {10.1016/j.phymed.2026.158764},
pmid = {42735469},
issn = {1618-095X},
mesh = {Humans ; *Integrative Medicine/methods ; *Complementary Therapies/methods ; COVID-19/therapy ; *COVID-19 Drug Treatment ; SARS-CoV-2 ; Phytotherapy ; Randomized Controlled Trials as Topic ; },
abstract = {BACKGROUND: Although the use of Traditional, Complementary, and Integrative Medicine (TCIM) interventions to treat coronavirus disease 2019 (COVID-19) is common, the effectiveness of these interventions is unclear.<br><br>OBJECTIVE: To compare different TCIM interventions for the treatment of mild/moderate acute COVID-19.<br><br>DATA SOURCES: EMBASE (Elsevier), Medline (OVID), VHL TCIM database, Cochrane Central, ClinicalTrials.gov, ICTRP, as of April 29th, 2025, as well as eight Chinese and four Korean databases.<br><br>STUDY SELECTION: Randomized controlled trials comparing a TCIM intervention with another, the standard of care (SoC), placebo, or conventional medicine in participants with suspected, probable, or confirmed mild/moderate acute COVID-19.<br><br>DATA EXTRACTION: Reviewers worked in pairs and independently extracted data and assessed the risk of bias and rated the certainty of the evidence for each outcome.<br><br>RESULTS: One hundred fifty-five trials evaluating 142 TCIM therapies were eligible for review, of which 69 (45%) trials enrolling 18,627 patients met criteria for analysis, contributing at least 80 participants or 20 events to one intervention. All the following estimates come from direct evidence, as networks were sparse. Compared with SoC or placebo, high to moderate certainty evidence showed that three TCIM add-on interventions probably reduced time to symptom resolution: Lianhua Qingwen (mean difference [MD] -2.82 days, 95% confidence interval -3.14 to -2.50, high certainty); Kovir capsule (MD -3.14 days, -3.67 to -2.61, moderate certainty); and honey and Nigella sativa (MD -3.00 days, -4.12 to -1.88, moderate certainty). Using conversion to severe cases as a proxy for hospitalization, Andrographis paniculata extract probably reduced hospital admission (risk difference -15 per 1000, -24.9 to 12.3, moderate certainty) for patients at moderate risk of hospitalization. No compelling evidence supports that any TCIM intervention reduced hospital admissions for patients at low or high risk of hospitalization, or reduced mortality and mechanical ventilation requirement across all patients. High to moderate certainty evidence showed that Lianhua Qingwen, Kovir capsule, COROPROTECT kit, and Shen Cao Gan Jiang likely did not increase adverse events leading to drug discontinuation; evidence for other TCIM interventions was insufficient to inform adverse events leading to discontinuation. High to moderate certainty evidence supported that Lianhua Qingwen was effective in resolving cough (MD -1.62 days, -1.80 to -1.45, high certainty) and probably effective in resolving fatigue (MD -1.41 days, -1.73 to -1.08, moderate certainty), honey and Nigella sativa was probably effective in resolving fever (MD -4.00 days, -4.72 to -3.28, moderate certainty), and Jinghua Jiedu was probably effective in resolving cough (MD -1.72 days, -2.23 to -1.21, moderate certainty). Other TCIM interventions were either ineffective, or of uncertain effectiveness.<br><br>CONCLUSION: Adding Lianhua Qingwen, Kovir capsule, or honey and Nigella sativa to SoC likely reduces symptomatic duration of mild/moderate acute COVID-19. Andrographis paniculata extract probably decreases hospital admissions among patients at moderate risk of hospitalization. Replication of positive findings is warranted.<br><br>REGISTRATION: PROSPERO (CRD42024517321).},
}
@article {pmid42750687,
year = {2026},
author = {Harrison, ML},
title = {Breaking Trust: How Covid-19 Communication Failures Undermined Public Confidence in US Health Officials-A Narrative Review.},
journal = {Public health challenges},
volume = {5},
number = {3},
pages = {e70373},
pmid = {42750687},
issn = {2769-2450},
abstract = {National polling shows US citizens increasingly distrust those tasked with making our public health decisions. This dilemma appears to have been driven in part by evolving policy recommendations, communications from health officials and medical agencies that were confusing to some, and seemingly hypocritical behavior among US political leaders during the Covid-19 pandemic. The following review provides a chronological timeline of multiple pandemic-era events as well as communication and behavior missteps potentially responsible for the growing public distrust. It also suggests possible solutions to ameliorate the problem going forward.},
}
@article {pmid42750745,
year = {2026},
author = {Al Qaf'an, E and Alford, S and Mack, HA and Lim, D},
title = {Decision-Making in Public Health Crises: A Qualitative Systematic Review and Meta-Ethnography.},
journal = {Public health challenges},
volume = {5},
number = {3},
pages = {e70358},
pmid = {42750745},
issn = {2769-2450},
abstract = {INTRODUCTION: Decision-making (DM) during public health crises occurs under uncertainty, time pressure and resource constraints. Although numerous studies examine leadership and governance during crises, evidence remains fragmented and has not been systematically synthesised to integrate the DM models used in practice with the factors that shape those decisions. This qualitative systematic review addresses this gap by examining how health system leaders make decisions during public health crises.<br><br>METHODS: A qualitative systematic review using a meta-ethnographic approach was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The protocol was registered in PROSPERO (CRD42023475382). PubMed, Medline, Embase, Scopus, Business Source, CINAHL and ProQuest were searched for English-language qualitative studies published since 1962.<br><br>RESULTS: Twenty-one studies were included with seven DM models and eight prioritised decision factors identified. Adaptive and evidence-based models predominated, reflecting the need to act under conditions of urgency while continuously incorporating emerging information. Knowledge and urgency emerged as key, interdependent drivers shaping model selection, highlighting that effective crisis DM depends not only on the choice of model but also on how the tension between rapid action and informed judgement is managed.<br><br>LIMITATIONS: Non-English literature was excluded, and the evidence base was dominated by COVID-19 studies and developed-country settings, which may limit transferability to lower resource contexts.<br><br>CONCLUSION: This review provides an integrated synthesis of DM models and prioritised decision factors during public health crises. The findings underscore the importance of strengthening real-time evidence systems and adaptive decision capacity to support timely, accountable and context-sensitive crisis decisions.},
}
@article {pmid42750993,
year = {2026},
author = {Phan, TP and Dinh, A and Dinh-Xuan, AT},
title = {Mechanisms of Mycobacterium tuberculosis disease and the impact of co-infections and post-TB complications.},
journal = {Breathe (Sheffield, England)},
volume = {22},
number = {3},
pages = {260060},
pmid = {42750993},
issn = {1810-6838},
abstract = {BACKGROUND: Mycobacterium tuberculosis (Mtb) remains a leading cause of global morbidity and mortality. Viral, bacterial, fungal, and parasitic co-infections substantially modify tuberculosis (TB) pathogenesis, and an increasingly recognised population of TB survivors develops post-TB lung disease (PTLD), which predisposes them to recurrent respiratory infections.<br><br>OBJECTIVES: To summarise current evidence on 1) Mtb pathophysiology and immunopathogenesis; 2) mechanisms by which major viral, bacterial, fungal, and parasitic co-infections alter TB progress; and 3) infectious complications associated with PTLD.<br><br>CONTENT: Mtb exploits innate immune evasion, altered macrophage activation, and granuloma remodelling in order to persist. Viral co-infections, particularly HIV, influenza, and severe acute respiratory syndrome coronavirus 2, impair T-helper 1 immunity, disrupt cytokine signalling, increase bacterial load, and drive progression to severe or disseminated TB. Bacterial pathogens (e.g. Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa) complicate diagnosis, increase severity, and contribute to antimicrobial resistance. Fungal and parasitic infections skew immunity and can delay diagnosis or reduce vaccine efficacy. PTLD results from sustained inflammation, matrix metalloproteinase activation, fibrosis, bronchiectasis, and cavitation; these structural changes favour chronic colonisation by opportunistic bacteria and long-term functional impairment.<br><br>CONCLUSIONS: TB pathogenesis is profoundly influenced by co-infections, and PTLD is an under-recognised driver of chronic respiratory morbidity. Integrated diagnostics, coordinated management of multimorbidity, and tailored strategies for PTLD are essential to reduce TB-related burden.},
}
@article {pmid42751000,
year = {2026},
author = {Frazier, K and Pulsipher, A and Orlandi, RR and Smith, KA},
title = {Temporal and Geographic Variations and Patient Factors in Acute Invasive Fungal Sinusitis: A Scoping Review.},
journal = {Therapeutic advances in allergy and rhinology},
volume = {17},
number = {},
pages = {27534030261450420},
pmid = {42751000},
issn = {2753-4030},
abstract = {BACKGROUND: The relationship between temporal and geographical variations and the incidence of acute invasive fungal sinusitis (AIFS) remains unclear. Furthermore, the impact of social determinants of health on AIFS outcomes is poorly understood. The objective of this scoping review was to summarize the literature on these topics using the Preferred Reporting Items for Systematic and Meta-Analyses Extension for Scoping Reviews guidelines.<br><br>METHODS: A scoping review was conducted using PubMed, Elsevier, and Wiley Online Library during August 2023 for articles that included the following variables related to AIFS: (1) temporal/geographic variations and (2) patient factors.<br><br>RESULTS: Sixteen studies were identified for inclusion. Associations between AIFS and COVID-19 were observed in certain geographic regions, particularly during the onset of the pandemic when high-dose oral corticosteroids were frequently used. No studies specifically examined the impact of geographic location on the incidence or outcomes in AIFS. Two studies reviewed the relationship between AIFS incidence and season, producing varied results. While both demonstrated seasonal variation in the incidence of AIFS, the findings appeared to be dependent on local climate conditions. Female sex and Black and Hispanic race appeared to be significant prognostic indicators for worse AIFS outcomes. A predominant number of studies included did not report the social determinants of health.<br><br>CONCLUSION: This review identifies a lack of comprehensive research on the role of geographic, temporal, and social determinants in AIFS and calls for further studies to bridge these knowledge gaps.},
}
@article {pmid42751095,
year = {2026},
author = {Hui, X and Gao, S and Ding, S and Li, M and Tian, X},
title = {N6-methyladenosine as a potential epitranscriptomic immune rheostat during SARS-CoV-2 infection.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1878455},
pmid = {42751095},
issn = {1664-3224},
mesh = {Humans ; *Adenosine/analogs &amp; derivatives/immunology/metabolism/genetics ; *SARS-CoV-2/immunology ; *COVID-19/immunology/genetics ; Epitranscriptome ; Immunity, Innate/genetics ; Epitranscriptomics ; RNA Methylation ; Animals ; Signal Transduction ; Interferon Type I ; },
abstract = {N6-methyladenosine (m[6]A), the most abundant internal RNA modification in eukaryotic cells, has emerged as a critical regulator of antiviral host defense. Increasing evidence indicates that m[6]A functions beyond conventional post-transcriptional regulation by dynamically coordinating the magnitude, timing, and duration of immune responses during viral infection. In SARS-CoV-2 infection, dysregulated antiviral immunity is characterized by delayed interferon activation together with sustained inflammatory responses, suggesting the existence of regulatory mechanisms that continuously calibrate immune signaling rather than simply switching it on or off. In this review, we propose the concept of m6A as a potential "epitranscriptomic immune rheostat," representing a conceptual framework in which m6A may fine-tune antiviral immunity through coordinated regulation of RNA stability, translational efficiency, and transcript turnover. We summarize how m[6]A shapes multiple layers of innate immune responses, including pattern recognition receptor sensing, type I interferon signaling, inflammatory buffering, and immune resolution. We further discuss emerging evidence suggesting that SARS-CoV-2 infection is associated with dynamic modulation of the m[6]A regulatory machinery and viral RNA methylation landscapes, while emphasizing that many mechanistic insights remain to be experimentally validated in SARS-CoV-2 models. In addition, we highlight the interplay between m[6]A regulation and immunometabolic remodeling, while distinguishing direct SARS-CoV-2 evidence from findings derived from other viral systems or broader m[6]A biology. Selected comparisons with Influenza A virus are discussed as complementary evidence to explore potentially conserved principles of m[6]A-mediated immune regulation among RNA viruses rather than as direct evidence for SARS-CoV-2 infection. Finally, we discuss the therapeutic implications of targeting the m[6]A regulatory network to recalibrate immune responses with temporal and cellular precision, while noting that current m[6]A-targeting strategies remain at the preclinical proof-of-concept stage and require further evaluation regarding specificity, safety, and translational feasibility. Collectively, this review provides a hypothesis-driven conceptual framework for understanding how m[6]A integrates RNA fate control with antiviral immunity and immunopathology during SARS-CoV-2 infection.},
}
@article {pmid42643057,
year = {2026},
author = {Henry, R and Collins, ME and Connor, KA and Gronvall, GK and Sell, TK},
title = {US Public School Operations During the COVID-19 Pandemic: A Scoping Review.},
journal = {Health security},
volume = {24},
number = {4},
pages = {311-321},
doi = {10.1177/23265094261475505},
pmid = {42643057},
issn = {2326-5108},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *Schools/organization &amp; administration ; United States/epidemiology ; Quarantine ; SARS-CoV-2 ; Contact Tracing ; Education, Distance/organization &amp; administration ; Pandemics ; },
abstract = {The COVID-19 pandemic forced the sudden closure of schools and a transition to remote learning across the United States. The suspension of in-person education not only altered the delivery of education for millions of students, but it effectively separated many students from vital services and functions that supported their ability to learn and develop. Given the unique role that schools play in educating children and young adults, as well as providing important nonacademic services, their closures led to disruptions in learning, added familial responsibilities, and reduced access to critical social services for students. The reopening of schools for in-person learning or the continuation of remote learning during a public health emergency requires careful planning and consideration to not only ensure the health and safety of students and staff, but also ensure equitable continuation of education and access to nonacademic services. We conducted a scoping review to identify and characterize the literature related to the implementation and impact of interventions and policies used to operate K-12 public schools in the United States during the first 2 years of the COVID-19 pandemic. Through thematic analysis, we found that masking, ventilation, physical distancing, testing, contact tracing, quarantine and isolation, and vaccination interventions allowed schools to safely conduct in-person learning during the pandemic. Findings from the literature suggest that there are suitable mitigation measures that allowed for the safe operation of public schools during the COVID-19 pandemic. The effective implementation of these measures required adequate resources, leadership commitment, and community buy-in.},
}
@article {pmid42750060,
year = {2026},
author = {Zhou, Z and Liu, Y and Yang, M and Qiu, C and Xia, J and Huang, Y and Zhou, Y},
title = {Mechanisms of antibody-dependent enhancement and its research progress in animal coronaviruses.},
journal = {Veterinary research},
volume = {57},
number = {1},
pages = {},
pmid = {42750060},
issn = {1297-9716},
support = {No.25KJA180004//Basic Science (Natural Science) Research Project of Universities in Jiangsu Province/ ; },
mesh = {Animals ; *Coronavirus Infections/veterinary/immunology/virology ; *Coronavirus/immunology ; *Antibody-Dependent Enhancement ; *Antibodies, Viral/immunology ; SARS-CoV-2 ; COVID-19/immunology ; *Betacoronavirus/immunology ; },
abstract = {Animal coronaviruses are associated with serious diseases in livestock and poultry, resulting in substantial economic losses worldwide. Antibody-dependent enhancement (ADE) is a phenomenon whereby pre‑existing pathogen specific antibodies may paradoxically exacerbate viral infections. In this review, we synthesize current classifications of ADE mechanisms, presenting a unified framework comprising two major categories subdivided into five distinct mechanistic subsets. Given the limited research on ADE in animal coronaviruses, we use SARS‑CoV‑2 as a case study to explore five potential ADE mechanisms associated with coronavirus infection. This review aims to provide a valuable reference for elucidating ADE mechanisms in animal coronaviruses.},
}
@article {pmid42750070,
year = {2026},
author = {Meyer, S and Liwanag, HJ and Schürch, K and Minder, B and von Groote, P and Schlaufer, C and Frahsa, A},
title = {Formal and informal science-policy interaction during public health emergencies of international concern: a scoping review.},
journal = {BMC global and public health},
volume = {4},
number = {1},
pages = {},
pmid = {42750070},
issn = {2731-913X},
abstract = {BACKGROUND: Interaction between science and policy might be a crucial asset for policy decisions during public health emergencies. Much work has been published about processes and forms of science-policy interaction on the one hand and challenges of public health emergency contexts on the other. However, more knowledge is needed to understand the challenges that arise when these two issues intersect.<br><br>METHODS: We conducted a scoping review informed by the Johanna-Briggs-Institute protocol and searched seven databases to identify formal and informal approaches to organising science-policy interaction. The original search was conducted in April 2022 and updated in March 2026. The searches included Embase.com, Medline, the Cochrane Library, Web of Science Social Science Citation Index, ERIC, Global Health, and Google Scholar. Systematic reviews, articles related to endemic diseases, on clinical and hospital contexts, and impact evaluations of research evidence in decision-making processes were excluded. Information on defined procedures for science policy interaction, form of interaction, selection process of interaction participants, perception of interaction, and barriers and facilitators of the interaction was extracted. Inclusion criteria were a) describe interaction/s of researcher/s and policymaker/s, and b) describe the study setting of a public health emergency. Data analysis followed qualitative content analysis.<br><br>RESULTS: 87 relevant studies were identified. Most included studies focused on the COVID-19 pandemic, with Scientific Advisory Committees (hereafter SACs) as the dominant mode of interaction. Informal mechanisms, such as committees without formal remit and unclear or undisclosed practices, were less frequently reported but played key roles. Common challenges included unclear roles, political interference, and limited communication. Key requirements are role transparency, formalisation, and institutionalisation of science-policy interaction.<br><br>CONCLUSIONS: Science-policy interactions during public health emergencies are shaped by dominant formal structures and underexplored informal practices. Strengthening inclusive, transparent, and interdisciplinary advisory systems is key to improving preparedness for future crises.},
}
@article {pmid42750274,
year = {2026},
author = {Ghafari, M and Watson, OJ and Dascalu, S and Mon, SHH and Abeler-Dörner, L and Rezaee-Zavareh, MS and Pley, C and Kordasti, S and Abbas, K and Madani, K and Panovska-Griffiths, J},
title = {Global vaccine readiness: equity-by-design in pandemic preparedness and response.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2732508},
doi = {10.1080/14760584.2026.2732508},
pmid = {42750274},
issn = {1744-8395},
mesh = {Humans ; Pandemic Preparedness ; *COVID-19/prevention &amp; control ; *Pandemics/prevention &amp; control ; *Vaccine Development ; Global Health ; *Vaccines/administration &amp; dosage ; *COVID-19 Vaccines/administration &amp; dosage ; Public Health ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: COVID-19 showed that rapid vaccine development and roll-out, while lifesaving, can still yield large, avoidable harms when equity is not considered from the outset. Disparities in vaccine timing and coverage, especially in low-resource settings, amplified health and economic burdens, highlighting the need for preparedness frameworks that combine speed with fairness.<br><br>AREAS COVERED: We synthesize evidence from literature and policy reports regarding global vaccine roll-out, focusing on avertable mortality under alternative sharing scenarios, procurement design, pooled mechanisms such as COVAX, and the role of distributed manufacturing and delivery capacity. We also examine how transparent data-sharing, effective public communication, genomic surveillance, adaptive trial designs, and modeling hubs can support more responsive and equitable vaccine deployment. Across six reflection points, we translate these lessons into practical priorities for future pandemic readiness, including strengthening healthcare infrastructure, equitable procurement, data transparency, and safeguarding public health decision-making from political and commercial distortion.<br><br>EXPERT OPINION: We argue that equity-by-design is essential if vaccine innovation is to deliver equitable public health impact. This requires geographically distributed manufacturing, transparency, equity-conditioned advance purchase agreements, and pre-agreed, epidemiology-triggered allocation of vaccines. We recommend institutionalizing disaggregated reporting, standardized data-sharing, greater pathogen genomic sequencing capacity, and communication strategies that support public health protection while countering misinformation.},
}
@article {pmid42750333,
year = {2026},
author = {Fan, Z and Chai, Y and Li, Q and Chen, Y and Gao, Z and Shi, T and Niu, J and Pu, X},
title = {[Advances in the mechanistic researches of neutrophil extracellular trap in pulmonary diseases].},
journal = {Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology},
volume = {42},
number = {9},
pages = {837-843},
pmid = {42750333},
issn = {1007-8738},
mesh = {Humans ; *Extracellular Traps/metabolism/immunology ; *Lung Diseases/immunology/metabolism ; *Neutrophils/metabolism/immunology ; Animals ; Autophagy ; Immunity, Innate ; Blood Platelets/metabolism ; },
abstract = {Neutrophil extracellular trap (NET), as an important effector mechanism of innate immunity, plays a critical regulatory role in various pulmonary diseases, including coronavirus disease-associated acute respiratory distress syndrome, bacterial pneumonia, sepsis, pulmonary fibrosis (PF), and chronic obstructive pulmonary disease. NET can be released by activated neutrophils through multiple mechanisms. Among them, classical suicidal NETosis represents one of the major pathways and contributes substantially to host defense against infection. However, the excessive accumulation of NET can lead to tissue damage, immunothrombosis, and chronic inflammation. By amplifying inflammatory cascades, disrupting tissue homeostasis, and triggering immunothrombotic processes, aberrant NET formation can also promote the development and progression of lung diseases. This review systematically summarizes the mechanisms of NET formation, metabolic regulation, autophagy, and their interactions with platelets. It provides an in-depth discussion of the roles and clinical significance of NET in both acute and chronic pulmonary diseases. Furthermore, potential therapeutic strategies targeting NET are highlighted. These strategies aim to offer new theoretical foundations and interventional perspectives for the prevention and treatment of pulmonary diseases.},
}
@article {pmid42739898,
year = {2026},
author = {Choudhury, S and Nawaar, N and Chowdhury, WR and Roy, P and Khan, AS and Ali, S and Zaki, RM and Raihan, T and Mishra, M and Rabbee, MF and Baek, KH},
title = {COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.},
journal = {Journal of clinical medicine},
volume = {15},
number = {17},
pages = {},
pmid = {42739898},
issn = {2077-0383},
support = {PSAU/2026/R/1447//Prince Sattam Bin Abdulaziz University/ ; KFU26//King Faisal University/ ; RS-2025-02223124//Rural Development Administration/ ; },
abstract = {From a health perspective, the 21st century has witnessed the emergence and global impact of several major viral diseases, most notably coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, which has been associated with a substantial burden of secondary fungal infections. Patients suffering from COVID-19 illnesses frequently developed fungal co-infections, which can worsen clinical outcomes and complicate therapeutic efforts. Hospitalized individuals with viral infections are particularly susceptible to invasive fungal pathogens, including Aspergillus, Candida, and Mucorales species. The co-pathogenesis between respiratory virus and fungi is complex, involving dynamic interactions among the pathogens and the host immune system. Opportunistic fungal infections were found to be more prevalent in COVID-19-infected individuals, who require mechanical ventilation, have diabetes, or exhibit neutropenia. This review aims to provide a comprehensive overview of fungal co-infections associated with COVID-19 disease, with a focus on their pathogenesis, biomarkers, diagnostic approaches, and potential treatment strategies. Overall, the available evidence indicates that viral-induced immune dysregulation, epithelial barrier damage, and clinical risk factors contribute to the development and severity of fungal co-infections in COVID-19 patients. Early recognition using reliable biomarkers and standardized diagnostic approaches, together with timely and pathogen-directed antifungal therapy, are essential for improving clinical outcomes.},
}
@article {pmid42741467,
year = {2026},
author = {Tasnim, S and Shammy, SS and Haider, N and Uddin, MJ},
title = {Epidemiology of Human Metapneumovirus Infection-A Systematic Review and Meta-Analysis.},
journal = {Health science reports},
volume = {9},
number = {9},
pages = {e73234},
pmid = {42741467},
issn = {2398-8835},
abstract = {BACKGROUND: Human metapneumovirus (hMPV) is a globally circulating respiratory pathogen. The objective of this systematic review is to evaluate the prevalence, case fatality rate, age-related severity, and seasonality of hMPV in the group of Acute Respiratory Infections (ARIs) and Community-Acquired Pneumonia (CAP).<br><br>METHODS: We conducted a systematic review and meta-analysis of articles on hMPV published from January 2001 to June 2025. Following PRISMA 2020 guidelines, we systematically searched PubMed and ScienceDirect for eligible articles using strict inclusion and exclusion criteria. Random-effects meta-analysis was performed to estimate pooled prevalence, and subgroup analyses were conducted by study group, geographic region, COVID-19 period, and age group.<br><br>RESULTS: One hundred one studies met the inclusion criteria, of which 96 contributed to the meta-analysis. The pooled global prevalence of hMPV was 6% (95% CI: 5%-7%). Prevalence estimates were highest in patients with respiratory tract infections (RTIs) patients (6%) and in South America (10%). Age-stratified analysis showed a high prevalence in children under 5 years (7%). Seroprevalence studies demonstrated low hMPV antibody prevalence in young children less than 1 year. The case fatality rate ranged from 2.5% in elderly populations to 4.4% in severe pediatric cases. hMPV mainly affects children under 2 years, with a smaller burden in older adults. Seasonal peaks were typically observed in late winter to early spring.<br><br>CONCLUSION: hMPV remains an important cause of respiratory disease worldwide, with a disproportionate burden on children. The significant heterogeneity across studies and evidence of publication bias highlight the need for standardized surveillance.},
}
@article {pmid42741759,
year = {2026},
author = {Effraimidis, G and Kasotas, A and Markantes, GK and Karapanou, O and Saltiki, K and Michalaki, M},
title = {How to manage subacute thyroiditis.},
journal = {Drugs in context},
volume = {15},
number = {},
pages = {},
pmid = {42741759},
issn = {1745-1981},
abstract = {Subacute thyroiditis (SAT) is a self-limited inflammatory thyroid disorder classically characterized by anterior neck pain, an enlarged tender thyroid, fever, fatigue, malaise, elevated inflammatory markers and a triphasic course from thyrotoxicosis through hypothyroidism to recovery. It can cause substantial morbidity and remains a frequent diagnostic challenge because it must be distinguished from acute suppurative thyroiditis, Graves' disease, painless thyroiditis, haemorrhage into a nodule and, rarely, malignant 'pseudothyroiditis' (rapidly growing carcinoma). In recent years, the recognized spectrum of triggers has expanded beyond the classical post-viral setting to include SARS-CoV-2 infection or vaccination. This review summarizes current understanding of SAT pathogenesis, including viral and post-viral mechanisms, and HLA-linked susceptibility. We outline the typical and variant clinical phenotypes, emphasising painful classical SAT, painless presentations, pregnancy-associated disease and therapy-related destructive thyroiditis. We then present a practical diagnostic framework based on clinical features, inflammatory markers, thyroid function tests, radionuclide imaging, ultrasound and fine-needle aspiration, when indicated. Management is discussed in a stepwise fashion, including NSAIDs and glucocorticoids for pain and inflammation, β-blockers for symptomatic thyrotoxicosis, selective levothyroxine replacement during the hypothyroid phase, and structured follow-up to detect recurrence and permanent hypothyroidism. Special attention is given to pregnancy and SARS-CoV-2-related SAT cases. Finally, we review long-term outcomes, recurrence risk and future research priorities. The aim is to provide a concise, clinically oriented guide to the contemporary management of SAT and to support rational, evidence-informed decision-making in routine endocrine practice.},
}
@article {pmid42741870,
year = {2026},
author = {Feige, J and Hauer, L and Sellner, J},
title = {SARS-CoV-2 management strategies in B-Cell-depleted people with multiple sclerosis: from prevention to antiviral treatment.},
journal = {Expert review of clinical immunology},
volume = {},
number = {},
pages = {1-19},
doi = {10.1080/1744666X.2026.2731966},
pmid = {42741870},
issn = {1744-8409},
abstract = {INTRODUCTION: Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, necessitating early high-efficacy disease-modifying therapies (DMTs). Monoclonal antibodies targeting the CD20 antigen are a cornerstone of effective disease control, but depletion of peripheral B-cells blunts the humoral immune response. This review synthesizes current evidence on COVID-19 risk, prevention and treatment in anti-CD20-treated people with multiple sclerosis (pwMS).<br><br>AREAS COVERED: A PubMed literature search through June 2026 identified relevant studies on anti-CD20 therapies and COVID-19 in pwMS. While MS itself does not increase COVID-19 susceptibility, anti-CD20-induced immunosuppression predisposes patients to severe COVID-19 outcomes and protracted or relapsing infections. Furthermore, B-cell depletion severely impairs vaccine efficacy, leaving patients with markedly diminished or absent neutralizing antibody responses.<br><br>EXPERT OPINION: To mitigate COVID-19 risks, future strategies should focus on three pillars. First, strategic switching among anti-CD20 antibodies to improve vaccine efficacy. Second, variant-targeted monoclonal antibodies for pre- and post-exposure prophylaxis in patients lacking robust humoral responses. Finally, early administration of direct-acting small-molecule antivirals to halt viral replication before hyperinflammation. Moving forward, integrating real-world data, identifying immunogenetic risk biomarkers, and evaluating long-term combinations of vaccine-passive immunizations will help safely sustain high-efficacy MS treatments.},
}
@article {pmid42743107,
year = {2026},
author = {Valença-Pereira, F and Johnson, B and DeGregori, J and Rincon, M},
title = {Does acute inflammation triggered by infection promote cancer progression?.},
journal = {PLoS biology},
volume = {24},
number = {9},
pages = {e3003962},
pmid = {42743107},
issn = {1545-7885},
mesh = {Humans ; *Inflammation/immunology/virology/pathology/complications ; *Neoplasms/immunology/pathology/virology ; Disease Progression ; Animals ; COVID-19 ; SARS-CoV-2 ; Acute Disease ; Tumor Microenvironment/immunology ; *Coronavirus Infections/complications/immunology ; *Pneumonia, Viral/complications/immunology ; Betacoronavirus ; },
abstract = {Chronic infections are associated with cancer incidence and progression in human epidemiological data, but less is known about how such infections might promote cancer progression. Recent data implicate acute infection with common respiratory viruses, such as influenza and SARS-CoV-2, in cancer progression, providing evidence that infection-driven inflammation can promote tumor expansion and dissemination in experimental systems. The resulting acute inflammatory cascade and dynamic immune cell reprogramming can rapidly remodel the tissue microenvironment to favor cancer cell survival, growth, and evasion of immune elimination. However, acute infections can also elicit anti-tumor immune responses. Defining how infections differentially skew immune programs to promote or restrain cancer progression will therefore be essential for developing future strategies to target this disease.},
}
@article {pmid42744113,
year = {2026},
author = {Persoff, J and Devereaux, A and Maves, R and Mehta, AB and Burry, L and Chakravarti, A and Levy, D and Feldman, HJ and Baez, AA and Felzer, JR and Baum, KD and Dries, DJ and Mukherjee, V and Persson, D and Conrad, TS and Hossain, T and Ghazipura, M and Anesi, GL and Ornoff, D and Freels, N and Sprung, CL and Dichter, JR},
title = {Social Media and Crisis Care Principles During Pandemics and Disasters: A Consensus Report From a Subgroup of the Task Force for Mass Critical Care.},
journal = {Chest},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.chest.2026.08.049},
pmid = {42744113},
issn = {1931-3543},
abstract = {BACKGROUND: Effective communication and coordination are fundamental determinants of the healthcare system's performance during disasters. Failures in these domains during COVID-19 contributed to disrupted care delivery, strained staff, resource shortages, and adverse patient outcomes.<br><br>RESEARCH QUESTION: Drawing on pandemic lessons, the Task Force for Mass Critical Care (TFMCC) conducted a comprehensive assessment of peer-reviewed literature, gray sources, and firsthand experience using a modified Delphi process to develop consensus-based suggestions to strengthen communication strategies and operational coordination.<br><br>STUDY DESIGN AND METHODS: Methodological frameworks from the World Health Organization and Guidelines International Network-McMaster Guideline Development Checklist for rapid guidelines were merged to establish a consensus development process, integrating evidence synthesized from the literature with expert opinions. The previously described process used a three-round modified Delphi approach to synthesize published evidence, collect anecdotal evidence, and develop suggestions.<br><br>RESULTS: A total of 147 evidence statements were evaluated, resulting in 22 suggestions substantiated by other supporting literature and anecdotal experiences. The TFMCC identified transparent, timely, and scientifically grounded public communication with proactive engagement through social media as indispensable for information dissemination and misinformation mitigation. Planning and coordination across federal, state, regional, and hospital systems are critical for effective disaster response, which depends on standardized crisis care frameworks, Medical Operations Coordination Centers, and interoperable health information systems enabling real-time situational awareness. Important findings include community engagement, equitable resource allocation, accessible communication strategies, and processes to avoid restrictive visitation policies that can impede surrogate decision-making. Finally, integrating emergency department expertise into hospital incident command and strengthening the "last mile" of supply-chain distribution are necessary to sustain clinical operations.<br><br>INTERPRETATION: Communication and coordination are core operational priorities during disaster response, emphasizing their impact on patient outcomes, system performance, and public trust. Communication and coordination systems require sustained investments in interorganizational relationships and public engagement.},
}
@article {pmid42744165,
year = {2026},
author = {Aashaq, S and Rakhshan, R and Rafiq, A and Ali, M and Beigh, MA},
title = {Multifaceted signaling of the cell surface receptor neuropilin-1 (NRP1): pathophysiological roles and therapeutic potential.},
journal = {Gene},
volume = {},
number = {},
pages = {150400},
doi = {10.1016/j.gene.2026.150400},
pmid = {42744165},
issn = {1879-0038},
abstract = {Neuropilin-1 (NRP1) is a developmentally conserved cell surface receptor that functionally acts to bind various ligands like class 3 semaphorins and several members of the VEGF family to engage in different signaling pathways that control cell migration and motility. Due to its widespread expression, NRP1 is implicated in immune function, axonal guidance, viral entry, tumor progression and angiogenesis. NRP1 is dysregulated across multiple cancer types and promotes tumor progression in a context-dependent manner in tumor cells and the tumor microenvironment, including endothelial, stromal, and immune-cell compartments. NRP1 is also involved in different autoimmune disorders, anosmia, and cardiovascular disorders. Phage display studies revealed that peptides containing C-terminal CendR motifs engage NRP1 for tissue penetration. Apart from cell-penetrating peptides, monoclonal antibodies against NRP1 also present a promising target for cancer therapeutics. Importantly, NRP1 in SARS-CoV-2 infection act as an auxiliary host factor, and furin cleavage of the viral spike protein exposes a C-terminal CendR motif that can bind NRP1, thereby facilitating viral entry. However, NRP1 is not an independent receptor comparable to ACE2, thus, NRP1-targeted antiviral strategies need further investigations. Given the above, the review provides comprehensive narrative of different signaling mechanisms of NRP1 in different diseases and how this cell surface receptor can be utilized in various therapeutic approaches to combat these diseases.},
}
@article {pmid42744480,
year = {2026},
author = {Lehmann, K and Wang, YF and Mamri, A and Brown, TG and Vanlaar, W and Batomen, B and Ouimet, MC and Nazif-Munoz, JI},
title = {Enhancing crisis resilience for future emergencies: A rapid review of road safety outcomes and reported measures during the COVID-19 pandemic.},
journal = {Journal of safety research},
volume = {98},
number = {},
pages = {265-275},
doi = {10.1016/j.jsr.2026.07.007},
pmid = {42744480},
issn = {1879-1247},
mesh = {Humans ; *Accidents, Traffic/prevention &amp; control/statistics &amp; numerical data ; *COVID-19/epidemiology ; Emergencies ; Pandemics ; *Safety ; },
abstract = {BACKGROUND AND OBJECTIVES: The COVID-19 pandemic disrupted mobility patterns and road usage, raising significant road safety concerns. It remains unclear whether governments worldwide implemented effective road safety measures (RSMs) to address the resulting fluctuations in traffic collisions, injuries, and fatalities. This study aims to: (a) identify global RSMs implemented, discussed or proposed during the pandemic to mitigate traffic-related incidents, and (b) explore their relevance, precision, and applicability in future crises.<br><br>METHODS: A systematic search of public health, transportation, and multidisciplinary databases (PubMed and Scopus) was conducted for studies published between 2019 and the present. This rapid review followed PRISMA and Cochrane Collaboration rapid review guidelines and was registered with PROSPERO (CRD420250599564). Inclusion criteria encompassed observational and quasi-experimental studies examining road safety measures implemented or proposed during the COVID-19 pandemic to address traffic-related incidents. Study selection and data extraction were conducted systematically, and findings were synthesized narratively.<br><br>RESULTS: Twenty-nine studies (published between 2020 and 2024) were included in the review. Findings highlight five key research clusters: (1) changes in crash frequency and severity, (2) risky driving behaviors, (3) regional variation in RSMs, (4) innovative measurement methods, and (5) crisis-responsive interventions. RSMs identified during the pandemic include speed control, traffic flow management, and protection of vulnerable road users, with a strong focus on data-driven approaches. However, some measures, especially behavioral interventions, remain underdeveloped and need further evaluation.<br><br>CONCLUSION: This review highlights the need for a comprehensive, crisis-resilient road safety approach integrating enforcement, behavioral interventions, and infrastructure improvements. This approach should not only address immediate crises but also support long-term road safety enhancements and preparedness for future public health emergencies.},
}
@article {pmid42745337,
year = {2026},
author = {Rossanese, A and Tomasi, A},
title = {Travel vaccination in senior travelers: current evidence, challenges, and prevention.},
journal = {Tropical diseases, travel medicine and vaccines},
volume = {12},
number = {1},
pages = {},
pmid = {42745337},
issn = {2055-0936},
abstract = {The substantial number of older adults undertaking international travel has increased the relevance of pre-travel prevention in this population. However, vaccination strategies in this group require consideration of immune aging, baseline status, medication use, and travel-related exposure. This narrative review summarizes the current evidence on vaccination in senior travelers, with particular attention to the vaccines most relevant to this population, the differences in the strength of evidence across vaccines, and the clinical factors that should guide pre-travel decision-making. Routine vaccines, including influenza, COVID-19, pneumococcal, respiratory syncytial virus, herpes zoster, and tetanus-diphtheria vaccines, constitute an essential part of pre-travel assessment, whereas travel-specific vaccines, such as hepatitis A, hepatitis B, typhoid, rabies, Japanese encephalitis, tick-borne encephalitis, and cholera, should be considered according to the destination, itinerary, expected exposure, and time before departure. Yellow fever vaccination represents a particular clinical challenge because advancing age is associated with a greater risk of serious vaccine-associated adverse events, making individualized risk‒benefit assessment essential. Recently introduced dengue and chikungunya vaccines should also be considered on an individualized basis, taking into account exposure risk, potential benefits, comorbidities, and the current limitations of the available evidence. The review also highlights the importance of integrating vaccination with non-vaccine preventive strategies, including food and water precautions, vector avoidance, and hygiene measures. Although the evidence base has expanded, important uncertainties remain, particularly because age-specific data are limited and frail older adults remain underrepresented in clinical studies. Overall, pre-travel care for senior travelers should be comprehensive, exposure-based, and individualized according to the clinical profile and travel characteristics of each traveler.},
}
@article {pmid42745812,
year = {2026},
author = {Tieu, KDB and Agyapong-Opoku, F and Agyapong, B},
title = {The use of chatbots as interventions for mental health conditions: scoping review of systematic reviews and meta-analyses.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1789599},
pmid = {42745812},
issn = {2673-253X},
abstract = {BACKGROUND: During the COVID-19 pandemic, the use of mental health chatbots received potential attention as a means of addressing the increase in demand for mental healthcare, which has become inaccessible due to a shortage of healthcare workers and lockdown. Even after the pandemic, chatbot versatility holds the potential to address the ongoing limited accessibility of mental healthcare due to a shortage of professionals, geographical challenges, cost, or stigma.<br><br>OBJECTIVE: This review examines the scope and nature of the systematic review and meta-analysis evidence on chatbot interventions for mental health.<br><br>METHOD: This scoping review follows Arksey and O'Malley's five-step guide and was reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for scoping reviews (PRISMA-ScR). The following databases were used to conduct all systematic literature searches: PubMed, Scopus, Medline, and Web of Science. Inclusion criteria include systematic reviews and meta-analyses, written in English, that focus on the use of chatbots as an intervention for mental conditions, with all primary articles being relevant. A total of 14 articles were relevant and included in the data extraction and analysis.<br><br>RESULTS: It was found that although current review-level evidence suggests potential short-term benefits, there was a discrepancy regarding the specific conditions under which chatbots are effective. Moreover, the use of chatbots for symptom improvement is still inconclusive, since there are issues with important aspects such as unclear risk of bias, lack of longitudinal studies, and lack of comparison with traditional therapy.<br><br>CONCLUSION: There is potential for chatbot implementation as an intervention for mental conditions. However, this is still at its early stages of development and requires more research to improve communication quality and ensure safety, which is paramount when communicating with vulnerable patients. The findings of the review provide a useful foundation for informing clinical practice, policy, and future research.},
}
@article {pmid42746222,
year = {2026},
author = {Mundlia, P and Singh, SP and Pothal, P and Thakur, T and Kathuria, R and Maurya, S and Sharma, A and Goel, H and Pandey, A and Ranawat, P and Singh, G and Barnwal, RP},
title = {Target, silence, replace: a review on RNA-based drugs in modern medicine.},
journal = {Frontiers in cell and developmental biology},
volume = {14},
number = {},
pages = {1879681},
pmid = {42746222},
issn = {2296-634X},
abstract = {RNA therapies have evolved into a revolutionary approach in contemporary medicine for treating various diseases by directly targeting RNA molecules engaged in disease pathogenesis. These therapeutic agents regulate biological processes through diverse mechanisms, including modulation of RNA function and gene expression. Medical applications of RNA are greatly enhanced by its structure, adaptability, and capacity for targeted binding. Among these traits is its ability to bind to certain molecules unique to those chemicals. RNA-based treatments have emerged from advancements in the production, modification, and cellular transport of RNA molecules. Several RNA drugs have been approved whereas some are under trial for few diseases. RNA therapeutics can function at the level of RNAs, DNAs and proteins. The evolution of mRNA vaccines during the COVID-19 epidemic emphasizes the exciting potential of RNA therapies in the treatment of diseases. This article provides a comprehensive overview of the several forms of RNA therapies, including small-interfering RNA (siRNA), messenger RNA (mRNA), and antisense-oligonucleotides (ASOs), together with information on their action mechanisms and delivery strategies that improve cellular absorption and shield RNA molecules from degradation. Further, CRISPR-based editing of the genome can be employed for modification of target RNA sequences for various disorders. Development of RNA aptamers have also been identified as pivotal RNA-therapeutic candidate. Additionally, we have explained mechanistic details and examples of drugs approved for RNA therapy. Emphasizing their potential to enhance patient outcomes and fulfil unmet medical requirements, we also highlight the clinical development of RNA therapies in treating cancer and other infectious diseases.},
}
@article {pmid42748865,
year = {2026},
author = {Cho, E and Lee, S and Yang, M and Cho, J and Hwang, S and Kim, E},
title = {Controlling respiratory infections in long-term care facilities: A systematic review.},
journal = {International journal of nursing studies},
volume = {184},
number = {},
pages = {105684},
doi = {10.1016/j.ijnurstu.2026.105684},
pmid = {42748865},
issn = {1873-491X},
abstract = {BACKGROUND: Residents of long-term care facilities are vulnerable to respiratory infections, yet infection prevention and control strategies for these settings remain limited. While extensive infection control guidelines for hospitals are well established, few address long-term care facilities, where prevention efforts have largely prioritized pharmacological over non-pharmacological measures. Non-pharmacological strategies are therefore essential to prevent respiratory infection transmission, particularly during early outbreak stages or in settings where pathogen-specific treatments are limited, such as long-term care facilities.<br><br>OBJECTIVE: To systematically review and synthesize non-pharmacological interventions used to prevent and control respiratory infections in long-term care facilities.<br><br>INFORMATION SOURCES: Experimental and quasi-experimental studies sourced from PubMed, CINAHL, EMBASE, and Cochrane databases.<br><br>METHODS: Systematic search for studies published in English between January 2008 and October 2025 was conducted. Eligible studies included those that implemented non-pharmacological interventions to prevent and control respiratory infections in long-term care facilities. The quality of included studies was assessed using the Cochrane Risk-of-Bias tool for Randomized control trials and the Risk of Bias in Non-randomized Studies of Interventions tool. Study characteristics and findings were extracted, and the World Health Organization's Infection Prevention and Control Assessment Framework was applied for analysis to classify interventions and identify evidence gaps across its core components. For data synthesis, a narrative synthesis with vote counting was performed across each component of the framework.<br><br>RESULTS: Of the 12,203 retrieved studies, 18 met the inclusion criteria. Nine studies broadly examined respiratory tract infections overall, whereas five focused exclusively on coronavirus disease. Based on the framework, interventions related to provision of materials and equipment necessary for infection control, built environments, education, and multimodal strategies were most frequently studied, whereas those addressing guidelines, surveillance methods, and workload, staffing, and bed occupancy received limited attention. Multimodal strategies combining environmental cleaning and education showed the most positive impact, while monitoring and feedback showed promising effectiveness in reducing the incidence of infection. Notably, no studies have addressed all eight components of the framework or fully accounted for the unique characteristics and needs of long-term care facilities.<br><br>CONCLUSIONS: The included studies had limited methodological quality and varied widely in study design, interventions, and outcome measures. However, by employing a globally recognized framework, this study provides a foundation for strengthening infection prevention and control measures in long-term care facilities and outlines key areas for future research. These findings emphasize the need for integrated, system-level multimodal strategies tailored to long-term care facilities to effectively control respiratory infections in vulnerable populations.<br><br>REGISTRATION: International Prospective Register of Systematic Reviews CRD42024544560, registered 08/05/2024.},
}
@article {pmid42749151,
year = {2026},
author = {Bloch, EM and Drews, SJ and Jacobs, JW},
title = {Infectious risks of transfusion: a 10-year look back and perspectives.},
journal = {Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.tracli.2026.09.004},
pmid = {42749151},
issn = {1953-8022},
abstract = {Almost 50 years following the advent -and ensuing tragedy- of transfusion-transmitted HIV, infectious diseases continue to shape blood transfusion practice and policy. Over the past decade alone, a myriad of changes span innovation in donor selection, testing and pathogen reduction, to emergence and re-emergence pathogens that have required evaluation and, in some cases, active intervention. Major developments include refined bacterial testing, novel findings on cold storage of platelets along with the expanded use of pathogen reduction to address the risk of bacterial contamination. Notable pathogens include Zika virus, Plasmodium (malaria), Babesia (babesiosis) and SARS-CoV-2 (COVID-19), the latter spurring a historic pandemic. SARS-CoV-2 highlighted the potential for emerging infectious diseases to impact the blood supply, independent of whether transfusion transmissible. The pandemic afforded new insight into convalescent plasma and how passive immunotherapy can be used to treat infectious diseases. Other favorable developments include a transition to individualized risk assessment and the relaxation of longstanding donor deferral policies (e.g. variant Creutzfeldt-Jacob disease), which have helped to alleviate the transfusion deficit. Progress in artificial intelligence and machine learning has yielded novel tools for surveillance and horizon scanning that enable early recognition of threats and opportunities for transfusion services to contend with infectious diseases. Nonetheless, many of the favorable developments do not extend to low and low-middle income countries, where replacement donation, suboptimal laboratory-based screening with limited molecular testing, and near-absent post-transfusion surveillance, continue to contribute to transfusion transmitted infection. We reflect on the impact of infectious diseases on transfusion services over the last ten years (2016-2026).},
}
@article {pmid42749230,
year = {2026},
author = {He, R and Wang, J and Lin, M and Su, Y and Li, Z and Dong, W and Zhang, D and Yu, X},
title = {RNF5: an emerging therapeutic target for modulating immunity and metabolism.},
journal = {Biochemical pharmacology},
volume = {},
number = {},
pages = {118481},
doi = {10.1016/j.bcp.2026.118481},
pmid = {42749230},
issn = {1873-2968},
abstract = {Ring finger protein 5 (RNF5), a membrane-associated RING-type E3 ubiquitin ligase, serves as a critical regulator of cellular homeostasis by controlling protein stability, metabolic adaptation, and immune signaling. This review provides a comprehensive overview of the multifaceted functions of RNF5, with particular emphasis on its context-dependent roles in cancer progression, antiviral immunity, and non-neoplastic diseases. In cancer, RNF5 exhibits highly context-dependent and sometimes paradoxical functions that are influenced by cellular environments, disease stages, and substrate availability. RNF5 regulates tumor-associated metabolic reprogramming by targeting glutamine transporters and key regulators of lipid metabolism. Moreover, through interactions with autophagy-related proteins and Ephrin receptors, RNF5 modulates tumor growth, therapeutic resistance, and antitumor immune responses. These findings highlight RNF5 as a complex regulator of tumor biology with both oncogenic and tumor-suppressive potential. During viral infections, RNF5 demonstrates dual regulatory activities in host-pathogen interactions. On one hand, RNF5 can suppress antiviral innate immune signaling by promoting the ubiquitination and degradation of key immune adaptors, including STING and MAVS. On the other hand, RNF5 may restrict viral replication by directly targeting viral components, such as the SARS-CoV-2 envelope protein and foot-and-mouth disease virus VP1, for ubiquitination and degradation. Thus, RNF5 functions as a versatile modulator of antiviral defense, with effects determined by the specific viral context and host signaling landscape. Beyond cancer and viral infection, emerging evidence implicates RNF5 in a variety of non-neoplastic disorders. RNF5 contributes to protein quality control in neurodegenerative diseases by facilitating the clearance of pathological tau through the ERAD pathway. In addition, genetic inhibition of RNF5 ameliorates intestinal pathological phenotypes in a mouse model of cystic fibrosis, while RNF5 has also been associated with hepatic and cardiovascular injury responses through regulation of cellular stress pathways. From a therapeutic perspective, RNF5-targeting strategies, including small-molecule inhibitors and pathway modulators, have emerged as potential approaches for manipulating RNF5-associated biological processes. However, substantial challenges remain, including achieving target specificity, understanding the context-dependent consequences of RNF5 modulation, minimizing potential disruptions to proteostasis and innate immune regulation, and developing clinically feasible therapeutic interventions. This review summarizes the complex regulatory network governed by RNF5 and discusses future opportunities and challenges in translating mechanistic insights into therapeutic applications while carefully considering potential risks associated with RNF5 targeting.},
}
@article {pmid42749398,
year = {2026},
author = {Wehbe, I and Tlili, A},
title = {mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.},
journal = {Journal, genetic engineering &amp; biotechnology},
volume = {24},
number = {3},
pages = {100717},
doi = {10.1016/j.jgeb.2026.100717},
pmid = {42749398},
issn = {2090-5920},
abstract = {Lung cancer remains one of the most prevalent and lethal malignancies worldwide owing to late diagnosis, molecular heterogeneity, and development of therapeutic resistance. Recent global cancer statistics indicate that it accounts for approximately 2.5 million new cases and 1.8 million deaths annually. The rise of messenger RNA (mRNA) technology has become a highly effective approach in the fight against infectious diseases, particularly highlighted by its successful use in COVID-19 vaccines. Accordingly, mRNA-based therapeutics have emerged as a versatile and adaptable approach with a high potential to address the limitations of conventional cancer treatments. This review aims to provide a comprehensive overview of the available cancer treatments and their limitations, summarize the molecular and cellular mechanisms involved in lung cancer progression, and introduce the mRNA-based approach and its application in lung cancer, including mRNA vaccines, targeted protein therapy, immune-modulating therapy, gene editing, and cellular reprogramming approaches. Furthermore, we discuss the main mechanisms underlying mRNA-based therapies, address current applications, and evaluate approaches to overcome the limitations and challenges associated with mRNA-based therapies. Overall, mRNA-based therapy represents a flexible and rapidly evolving approach that, with further research and development, will reshape precision treatment of lung cancer.},
}
@article {pmid41320299,
year = {2026},
author = {Inouye, S},
title = {Hypothesis: Transmission of COVID-19 through the Air from Asymptomatic Individuals by Speaking.},
journal = {Japanese journal of infectious diseases},
volume = {79},
number = {5},
pages = {218-221},
doi = {10.7883/yoken.JJID.2025.169},
pmid = {41320299},
issn = {1884-2836},
mesh = {Humans ; *COVID-19/transmission ; SARS-CoV-2 ; Pandemics ; Aerosols ; *Asymptomatic Infections/epidemiology ; *Respiratory Aerosols and Droplets/virology ; *Speech ; *Coronavirus Infections/transmission/epidemiology ; *Pneumonia, Viral/transmission/epidemiology ; Betacoronavirus ; Air Microbiology ; },
abstract = {COVID-19 mortality seems to be higher in high-income, hygienic countries, but this is contrary to conventional communicable diseases, which usually occur in low-income countries. Another characteristic of COVID-19 is that a proportion of infected individuals had no symptoms but transmitted the virus to others. In this paper, the author proposes a hypothesis that infected but asymptomatic individuals produce two kinds of infectious respiratory particles by speaking: large droplets and small aerosols. The large droplets are produced from the saliva by pronouncing a plosive, /p/ or /t/, whereas the small aerosols are produced from the laryngeal secretion by the vibration of vocal cords during the voicing of vowels. The heavy droplets collide with other people's faces in conversation, resulting in droplet infection. In contrast, the lighter aerosols float in the air, accumulate inside a non-ventilated room after prolonged conversation, and cause airborne infection in other people in the same room. Then, the author discusses the global epidemiology of COVID-19, which may have depended on 1) climate and housing structure, 2) cultural behaviors, and 3) languages among different countries.},
}
@article {pmid42275568,
year = {2026},
author = {Chang, E and Mostafa, J},
title = {Use of SNOMED CT, 2020-2025: literature review.},
journal = {Journal of the American Medical Informatics Association : JAMIA},
volume = {33},
number = {9},
pages = {1798-1810},
doi = {10.1093/jamia/ocag094},
pmid = {42275568},
issn = {1527-974X},
mesh = {*Systematized Nomenclature of Medicine ; Humans ; *COVID-19/epidemiology ; *Artificial Intelligence ; },
abstract = {OBJECTIVE: To examine the evolving role and application of SNOMED CT (SCT) during 2020-2025, a period marked by the COVID-19 pandemic and accelerated adoption of artificial intelligence (AI) in healthcare.<br><br>MATERIALS AND METHODS: We searched PubMed and Embase for articles published from October 2020 to June 2025. Included articles were classified into focus categories by implementation maturity (Theoretical, Predevelopment, Implementation, Evaluation/Commodity, and Non-operational) and usage categories. We compared trends with our previous review covering January 2015-September 2020.<br><br>RESULTS: Following exclusion criteria, 651 articles were included for final review. The United States (n&#x2009;=&#x2009;188) and United Kingdom (n&#x2009;=&#x2009;92) were the largest contributors. COVID-19 emerged as the second most-investigated domain. The 2020-2025 period witnessed a dramatic shift toward mature implementation stages: Implementation (26.4%) and Evaluation/Commodity (32.0%) categories expanded, while Theoretical and Predevelopment categories decreased. SCT was increasingly used for knowledge graph construction, machine learning model validation, and patient data retrieval from registries. The most prominent use case involved retrieving patient data from national and commercial registries (n&#x2009;=&#x2009;186).<br><br>DISCUSSION: SCT's role evolved from a clinical terminology to a machine-interpretable biomedical knowledge base, supporting explainable AI. However, coding consistency remains challenging, and evidence demonstrating improved patient outcomes is lacking.<br><br>CONCLUSION: SCT use has matured significantly, with widespread implementation in data repositories and emerging applications in AI. Future research must demonstrate clinical and operational benefits to ensure continued adoption.},
}
@article {pmid42734220,
year = {2026},
author = {Ammar, IM and Panja, SK and Geng, J},
title = {FRET-based nanoprobes for nucleic acid sensing and disease diagnosis: materials, probe architectures, and analytical trends.},
journal = {Journal of materials chemistry. B},
volume = {},
number = {},
pages = {},
doi = {10.1039/d6tb01546h},
pmid = {42734220},
issn = {2050-7518},
abstract = {Förster resonance energy transfer (FRET) translates nanometre-scale changes in donor-acceptor separation into ratiometric fluorescence signals, enabling homogeneous and isothermal detection of nucleic acid biomarkers. In this review, we critically survey FRET-based nanoprobes for nucleic acid sensing and disease diagnosis, spanning organic dyes and cationic conjugated polymers to metallic nanoparticles, quantum dots, upconversion nanoparticles, carbon nanostructures, MXenes and polymeric nanoantennae. We organise probe designs by architectures, including sandwich hybridisation, disassembly hairpins, molecular beacons, dynamic junction sensors and enzyme-free DNA circuits, and analyse how these platforms achieve attomolar limits of detection, single-nucleotide discrimination and multiplexing in complex matrices. Representative case studies highlight applications in viral (e.g. SARS-CoV-2), bacterial and fungal pathogens, circulating cancer-related miRNAs and mRNAs, and neurodegenerative disease markers, as well as integration of FRET readouts with PCR and isothermal amplification workflows. We then compare FRET nanoprobes with established nucleic-acid assays in terms of analytical figures of merit, instrumentation, and compatibility with point-of-care (POC) formats. Remaining challenges, including photobleaching, spectral crowding, matrix autofluorescence, nanocarrier toxicity, and inter-laboratory reproducibility, are discussed in the context of emerging solutions such as near-infrared and lifetime-based FRET, CRISPR-coupled assays, DNA-origami nanoantennas, and microfluidic or smartphone-enabled devices. Finally, we outline key trends that could drive translation of FRET-based nucleic acid nanoprobes from proof-of-concept demonstrations to clinically actionable diagnostics.},
}
@article {pmid42736748,
year = {2026},
author = {Dirican, N and Yardibi, F},
title = {Scientific research dynamics on community-acquired pneumonia: Bibliometric analysis and future perspectives.},
journal = {Medicine},
volume = {105},
number = {37},
pages = {e50602},
pmid = {42736748},
issn = {1536-5964},
mesh = {Humans ; *Bibliometrics ; *Biomedical Research/trends ; *Community-Acquired Pneumonia/epidemiology ; COVID-19/epidemiology ; },
abstract = {BACKGROUND: Community-acquired pneumonia (CAP) is a leading cause of morbidity, mortality, and hospitalization worldwide. This study aimed to provide physicians and researchers with a comprehensive overview of the most influential publications and research trends in CAP.<br><br>METHODS: Research articles and reviews on CAP published in English and indexed in the Web of Science from 1978 to 2023 were analyzed. Network visualization and comprehensive bibliometric analyses of publication output, countries, journals, authors, cited references, and keywords were performed using CiteSpace and VOSviewer software.<br><br>RESULTS: A total of 4141 publications, including 3665 original research articles and 476 reviews, were included in the analysis. Publication output increased after 1991 and showed an overall upward trend, particularly after 2000. The United States, Spain, and China were the most productive countries. Chest published the most articles, whereas Clinical Infectious Diseases received the highest number of citations. Torres A was the most prolific author, whereas Fine MJ was the most cited. The most cited clinical studies published in the past 5 years focused on COVID-19, severe CAP (sCAP), and corticosteroid therapy. Co-citation analysis identified sCAP, healthcare-associated pneumonia, prospective cohort studies, and metagenomic next-generation sequencing as active research clusters. Keyword co-occurrence analysis identified sCAP as the largest and most prominent cluster, whereas the other current clusters included atypical pathogens, antibiotic resistance, chronic obstructive pulmonary disease, and &#x3b2;-lactam monotherapy.<br><br>CONCLUSIONS: This bibliometric analysis highlights the evolving research landscape of CAP and suggests that future research will increasingly focus on sCAP and its treatment, the identification of rare or emerging pathogens, rapid diagnostic technologies, appropriate initial treatment selection, personalized therapeutic strategies, and vaccination. These findings provide valuable insights into the current research hotspots on CAP and future priorities for researchers and clinicians.},
}
@article {pmid42736961,
year = {2026},
author = {Bengoa-Urrengoechea, I and Malo, S and Rabanaque, MJ and Sánchez-Calavera, MA and Aguilar-Palacio, I},
title = {Exploring the Impact of the COVID-19 Pandemic on Patients with Type 2 Diabetes and Primary Care Utilisation: A Scoping Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {17},
pages = {},
pmid = {42736961},
issn = {2227-9032},
support = {PI22/01193//Institute of Health Carlos III/ ; //European Union/ ; B09-26R//Research Group in Health Services in Arag&#xf3;n (GRISSA)/ ; },
abstract = {Background: During the coronavirus disease 2019 (COVID-19) pandemic, changes in healthcare organisation may have affected the management of patients with chronic conditions, such as those with type 2 diabetes (T2D), who require close monitoring. Although there are studies that have analysed the access and management of patients with T2D in primary care (PC) during the pandemic, there is no synthesis of the results that inform us about the care provided and their effect. The aim of this study is to summarise the existing evidence on the care provided in PC settings to patients with T2D during the COVID-19 pandemic, as well as their follow-up care and outcomes, in order to understand the impact of the pandemic on their management. Methods: A scoping review was conducted according to the approach described by Arksey and O'Malley. Structured search strategies were developed for each of the selected databases (PubMed, EMBASE and Web of Science). We included articles published in English and Spanish up to 24 March 2026 on access to care for patients with T2D in PC during the pandemic. Two independent reviewers screened titles and abstracts to select studies related to the population, intervention, and outcomes of interest. In cases of disagreement, a third reviewer resolved the discrepancy. One of the reviewers extracted data and summarised them. Results: After duplicate removal, 535 records were identified, with 116 articles screened in full text and 26 included. Most studies were conducted in Europe and North America using retrospective designs and electronic health records. During the pandemic period, face-to-face visits and routine screenings generally declined, while telemedicine expanded and may have partially mitigated disruptions in patient contact, although inequalities in access were reported. Disease monitoring and complication screening also declined in several settings. Clinical outcomes such as HbA1c and blood pressure (BP) showed heterogeneous trends, with some studies reporting deterioration and others reporting stability. Some studies also highlighted increased adverse events and greater attention to mental health during care. Conclusions: Although telemedicine helped maintain patient follow-up, it could not fully replace face-to-face assessments and was implemented alongside some gaps in clinical monitoring, patient safety, and health equity. These findings underscore the need to maintain structured chronic disease management and to develop safe and inclusive telehealth models.},
}
@article {pmid42737413,
year = {2026},
author = {Muñoz-Almaguer, ML and Flores-Salas, EY and Bancalari-Organista, C and Escutia-Gutierrez, R and Virgen-Montelongo, M and Avalos-Salgado, FA and Franco-Torres, EM and Corona-España, AM},
title = {Vitamin D and COVID-19: Inmunomodulatory Effects and the Mexican Public Health Perspectives.},
journal = {International journal of molecular sciences},
volume = {27},
number = {17},
pages = {},
pmid = {42737413},
issn = {1422-0067},
mesh = {Humans ; COVID-19/epidemiology ; *Vitamin D/therapeutic use ; Mexico/epidemiology ; *Vitamin D Deficiency/epidemiology/complications/immunology ; SARS-CoV-2 ; Public Health ; Dietary Supplements ; *Coronavirus Infections/epidemiology/immunology/drug therapy ; Pandemics ; *Pneumonia, Viral/epidemiology/immunology/drug therapy ; Pregnancy ; Female ; },
abstract = {Vitamin D is a fat-soluble vitamin, considered a prohormone, that plays a fundamental role in calcium absorption and reabsorption, as well as the modulation of inflammatory response in infectious conditions such as COVID-19. A literature search was conducted in scientific databases and official sources, selecting studies published in the last 10 years in Spanish and English related to vitamin D and COVID-19; studies unrelated to the nutritional approach were excluded to reduce bias and ensure a rigorous and reproducible analysis. It was observed that the probability of contracting COVID-19 increases as the D3 hypovitaminosis prevalence increases. In Mexico, the relevance of vitamin D deficiency or supplementation in this disease has been controversial. Some studies claim that vitamin D supplementation could be a protective factor. According to the National Health Survey in Mexico (Ensanut), the Mexican population has significant deficiencies in this vitamin, contributing to an unfavorable diagnosis, particularly for children and pregnant women, as it is considered a deficiency in the blood when it is below 30 ng/mL and insufficiency when below 20 ng/mL, making these deficiencies important risk factors in the development of COVID-19 severe cases. Nevertheless, the use of vitamin D as an adjuvant agent in the treatment of COVID-19 can represent one of the main options for public health, providing therapeutic properties and health benefits.},
}
@article {pmid42739074,
year = {2026},
author = {Grant, WB and Wimalawansa, SJ},
title = {Vitamin D and Health: Establishing Causal Relationships Through Observational Evidence and Hill's Criteria in a Biological Framework.},
journal = {Nutrients},
volume = {18},
number = {17},
pages = {},
pmid = {42739074},
issn = {2072-6643},
mesh = {Humans ; *Vitamin D/blood/analogs &amp; derivatives/administration &amp; dosage ; Observational Studies as Topic ; COVID-19/epidemiology ; Dietary Supplements ; Cardiovascular Diseases/prevention &amp; control ; *Vitamin D Deficiency/blood ; Neoplasms/prevention &amp; control ; SARS-CoV-2 ; },
abstract = {Vitamin D has been linked to beneficial effects across more than 100 health outcomes, generating substantial interest in its extraskeletal functions. However, because nutrients differ fundamentally from pharmaceuticals in biology and mechanisms of action, conventional pharmaceutical-style randomized controlled trials (RCTs) are often inappropriate for evaluating nutrient efficacy. Instead, well-designed observational studies that have assessed serum 25-hydroxyvitamin D [25(OH)D] concentrations and correlated them with biologically relevant clinical outcomes provide evidence of effectiveness and establish causality. Since vitamin D primarily acts as a preventive agent for chronic diseases, the strongest evidence is derived from large, long-term, ecological and prospective cohort studies. In contrast, many RCTs have failed to demonstrate significant benefits because of methodological limitations, including enrollment of vitamin D-sufficient participants, inadequate dosing regimens, vitamin D supplementation in control groups, short intervention periods, and analyses based on assigned dose rather than serum 25(OH)D concentrations achieved, which determine biological responses. Early ecological studies demonstrated inverse associations between solar ultraviolet B doses and the risks of cancer, cardiovascular disease (CVD), and infectious diseases. These findings have been consistently supported by numerous prospective larger cohort studies linking higher serum 25(OH)D concentrations with improved health outcomes. Observational studies also offer important advantages, including being large and covering diverse populations, wide variations in vitamin D status, longer follow-up, and adjustment for multiple confounding factors. When interpreted within a biological framework using Bradford Hill's criteria for causality-including consistency, strength and temporality of associations, dose-response relationships, biological plausibility, mechanistic evidence, coherence, and experimental support-the accumulated evidence strongly supports causal relationships that vitamin D sufficiency reduces risks of several diseases. This narrative review critically evaluates the evidence for cancer, CVD, blood pressure, COVID-19, type 1 and type 2 diabetes, periodontal disease, multiple sclerosis, and dementia. For these diseases, the authors concluded that the evidence satisfies Hill's criteria for causality and aligns with current understanding of vitamin D biology and nutrient-health relationships.},
}
@article {pmid42739654,
year = {2026},
author = {Suzuki-Inoue, K and Ueda, M and Shirai, T and Tsukiji, N and Sasaki, T},
title = {Soluble CLEC-2 as an Emerging Biomarker of In Vivo Platelet Activation.},
journal = {Journal of clinical medicine},
volume = {15},
number = {17},
pages = {},
pmid = {42739654},
issn = {2077-0383},
support = {LS052//Japan Society for the Promotion of Science/ ; },
abstract = {Platelet activation plays a central role in arterial thrombosis, thromboinflammation, and microvascular injury. Conventional platelet function tests evaluate platelet responsiveness to exogenous agonists ex vivo but do not directly reflect in vivo platelet activation. Although several soluble platelet-derived molecules, including platelet factor 4 (PF4), β-thromboglobulin (β-TG), soluble P-selectin, soluble CD40 ligand, glycocalicin, and soluble glycoprotein (GP) VI, have been investigated as in vivo platelet activation markers, their clinical use is limited by preanalytical instability, lack of platelet specificity, constitutive shedding, or uncertain disease specificity. Soluble C-type lectin-like receptor 2 (sCLEC-2) has recently emerged as a promising biomarker of in vivo platelet activation. CLEC-2 is expressed predominantly in platelets and megakaryocytes, and its soluble form is released from activated platelets as both a shed molecule and a microparticle-associated form. Compared with PF4 and β-TG, sCLEC-2 is less susceptible to artifactual release during routine blood collection, making it more suitable for clinical laboratory testing. Elevated sCLEC-2 levels have been reported in acute coronary syndrome, acute ischemic stroke, disseminated intravascular coagulation, thrombotic microangiopathy, antiphospholipid antibody syndrome, and coronavirus disease 2019 (COVID-19). In thrombocytopenic disorders, indices incorporating platelet count, such as the C2PAC index, sCLEC-2/D-dimer ratio, and sCLEC-2 × D-dimer/platelet count, may better reflect platelet activation and disease status than sCLEC-2 concentration alone. However, preanalytical standardization, assay harmonization, reference interval validation, and disease-specific cutoff values remain essential. This review summarizes the biological basis, assay systems, clinical evidence, and future perspectives of sCLEC-2 as an emerging laboratory marker of in vivo platelet activation.},
}
@article {pmid42739690,
year = {2026},
author = {Mostberger, S and Glisic, M and Gamba, MR and Perret, C and Mueller, G},
title = {Early Versus Late Tracheostomy: An Umbrella Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {17},
pages = {},
pmid = {42739690},
issn = {2077-0383},
abstract = {Background: Optimal tracheostomy timing remains controversial due to conflicting evidence across published systematic reviews. To clarify this ambiguity within specific patient populations (critically ill, traumatic brain injury, stroke, trauma, COVID-19, and spinal cord injury), an umbrella review of systematic reviews was conducted comparing early versus late tracheostomy or prolonged intubation. Additionally, potential benefits in clinical outcomes were evaluated across a mixed-etiology cohort of mechanically ventilated patients. Methods: MEDLINE, Embase, Cochrane Library, and Web of Science were searched from inception through July 2024. Systematic reviews evaluating the impact of tracheostomy timing on mechanical ventilation duration, ventilator-associated pneumonia risk, ICU/hospital length of stay, and mortality were included. Two authors independently extracted data using a standardized form. Methodological quality was assessed via AMSTAR 2 and certainty of evidence via GRADE. Random-effects meta-analyses were conducted for each outcome, stratified by study design (RCTs vs. non-RCTs), with subgroup analyses exploring patient subpopulations. Results: Evidence was synthesized from 9 systematic reviews (24 unique RCTs, 54 non-RCTs). In RCTs, moderate certainty evidence suggests that early tracheostomy reduces ventilator-associated pneumonia (OR 0.66, 95% CI 0.46 to 0.94, p = 0.02) and mechanical ventilation duration (MD -3.76 days, 95% CI -6.01 to -1.52, p < 0.001) compared to late tracheostomy or prolonged intubation. Early tracheostomy may reduce ICU length of stay (MD -6.64 days, 95% CI -9.92 to -3.35, p < 0.001, low certainty). The effect of early tracheostomy on hospital length of stay and mortality remains uncertain. Conclusions: Early tracheostomy shows potential to reduce ventilator-associated pneumonia and mechanical ventilation duration in mixed-etiology cohorts. It may also be associated with shorter ICU length of stay, while its effect on mortality and hospital stay remains uncertain. Future research should establish standardized definitions of tracheostomy timing and prioritize high-quality, etiology-specific RCTs in underrepresented cohorts (e.g., traumatic brain injury, stroke, spinal cord injury).},
}
@article {pmid42037238,
year = {2026},
author = {Ruhrländer, J and Schieffer, E and Schieffer, B},
title = {Regulatory cycles of orexin and glucagon-Like peptide-1 in postviral syndromes.},
journal = {Endocrine reviews},
volume = {47},
number = {5},
pages = {535-564},
doi = {10.1210/endrev/bnag009},
pmid = {42037238},
issn = {1945-7189},
mesh = {Humans ; *Orexins/metabolism/physiology ; *COVID-19/complications/metabolism ; *Glucagon-Like Peptide 1/metabolism ; Animals ; *Fatigue Syndrome, Chronic/metabolism/etiology ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Post-Infectious Disorders ; },
abstract = {Postviral syndromes are heterogeneous multisystem diseases without a uniform etiology that occur as a result of acute viral infections. During the COVID-19 pandemic, the number of patients increased dramatically due to infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is known as postacute sequelae of COVID-19 (PASC), with many cases also meeting the criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the most severe form of a postviral disease, characterized by severe fatigue, postexertional malaise (PEM), unrefreshing sleep, neurocognitive impairment, and autonomic and immune dysregulation. Orexin (OX) neuropeptides, which regulate arousal, metabolism, and neuroendocrine functions, may serve as a central link among stress, immune activation, and metabolic changes in these syndromes. Notable phenotypic similarities between OX system dysfunction and core features of PASC and ME/CFS, including fatigue, sleep issues, impaired glucose metabolism, and neuropsychiatric symptoms, support a mechanistic model in which impaired OX signaling contributes to postviral endocrine and metabolic dysfunction. This review examines the role of OX in regulating glucose metabolism, HPA axis activity, and systemic homeostasis, with a specific focus on sexually dimorphic expression and function in relation to postviral syndromes. We also highlight the effect of glucagon-like peptide-1 (GLP-1), another key player in metabolism, which also has neuroprotective, anti-inflammatory, vasoprotective, and immunomodulatory effects. We further emphasize emerging therapeutic strategies, such as GLP-1 receptor agonists (GLP-1RAs) and drugs targeting the OX system. Together, these insights provide an integrated framework for understanding and targeting the neuroendocrine-metabolic underpinnings of PASC, ME/CFS, and other postviral syndromes.},
}
@article {pmid42402151,
year = {2026},
author = {Monreal-Escalante, E and León-Montoya, H and Ramos-Vega, A and Trujillo, E and Angulo, M and Guerra, K and Reyes-Becerril, M and Angulo, C},
title = {Rickettsial Diseases and Vaccines: Is There an Opportunity for Plant-Made Vaccine Technology?.},
journal = {Biotechnology and bioengineering},
volume = {123},
number = {10},
pages = {2587-2604},
pmid = {42402151},
issn = {1097-0290},
support = {PAZA-2026//Centro de Investigaciones Biol&#xf3;gicas del Noroeste/ ; },
mesh = {*Plants, Genetically Modified/genetics/metabolism ; Animals ; Vaccines, Synthetic/immunology/genetics/biosynthesis ; Humans ; *Rickettsia Infections/prevention &amp; control/immunology ; *Rickettsia/immunology/genetics ; *Rickettsial Vaccines/genetics/immunology/biosynthesis ; Genetic Engineering ; },
abstract = {Rickettsiosis is a zoonotic disease caused by obligate intracellular bacteria of the family Rickettsiae, transmitted by arthropods. No commercial vaccine exists, despite the efficacy of experimental prototypes based on whole cells, DNAs, nanosystems, and recombinant antigens. Plants have been used as a platform for producing and delivering recombinant antigens, allowing the commercial vaccines for COVID-19 and Influenza. This technology can be used for recombinant Rickettsia vaccines for the target host, potentially for vector arthropods. These aspects are reviewed in this work, considering a brief immunobiology of Rickettsiae, experimental vaccines against Rickettsiosis, step-by-step genetic engineering in plants for recombinant antigen production and immunological assessment, representative successful examples of plant-made vaccines, and the analysis of the potential of plant-made vaccines to control arthropod-transmitted Rickettsiae. Perspectives in this field are offered, highlighting hurdles and opportunities.},
}
@article {pmid42720236,
year = {2026},
author = {Laparidou, D and Willis, S and Howe, L and Ramachandran, A},
title = {Discovery Research on the Success Factors for Schools-Based Multiple Model Speech and Language Placements: A Rapid Scoping Review.},
journal = {International journal of language &amp; communication disorders},
volume = {61},
number = {5},
pages = {e70331},
pmid = {42720236},
issn = {1460-6984},
support = {0008293-1060//NHS England/ ; },
mesh = {Humans ; *Speech Therapy/organization &amp; administration/education ; *Language Therapy/organization &amp; administration/education ; Child ; *COVID-19/epidemiology ; Schools ; *School Health Services/organization &amp; administration ; },
abstract = {BACKGROUND: Demand for children's speech and language therapy (SLT) services has surged globally, exacerbated by the COVID-19 pandemic and workforce shortages. In England, waiting lists remain extensive, with over 66 000 children awaiting intervention in early 2025. Delayed access to SLT services is linked to poorer academic, social, and health outcomes. Innovative approaches are urgently needed to address these challenges. Embedding SLT student placements within schools offers a potential solution, simultaneously enhancing service capacity and providing authentic learning experiences. International evidence, such as the Broken Hill model in Australia, supports this approach, particularly for rural and remote communities.<br><br>AIMS: This rapid scoping review aimed to identify success factors, barriers, and enablers of school-based SLT placement models, and to assess their potential for scalability and sustainability. The review sought to inform policy and practice by synthesising evidence on supervision models and implementation strategies.<br><br>METHODS: Following PRISMA-ScR guidelines and Arksey &amp; O'Malley's framework, a comprehensive search was conducted across eight databases (e.g., Web of Science, ERIC, CINAHL, Medline) and supplemented by grey literature searches. Inclusion criteria focused on SLT student placements in schools, particularly in underserved areas. Fourteen studies published between 2011 and 2024 were included, predominantly from Australia (57%), with others from the USA and UK. Data were extracted and synthesised narratively around barriers, facilitators, and model characteristics.<br><br>MAIN CONTRIBUTION: Findings indicate that school-based SLT placements can increase service capacity, improve student confidence and employability, and foster interprofessional collaboration. Successful models share key principles: Integration into policy frameworks, dedicated funding, strong cross-sector partnerships, cultural responsiveness, and structured supervision. Barriers include insufficient funding, infrastructure limitations in rural areas, student preparedness, and challenges with technology during remote delivery. Facilitators include early stakeholder engagement, flexible supervision approaches, and orientation training. Evidence suggests that positive placement experiences may influence graduates' willingness to work in underserved areas, addressing workforce shortages.<br><br>CONCLUSIONS: School-based SLT placements represent a promising strategy to alleviate service pressures and enhance workforce development. Greater alignment with health and education policy, sustainable funding, and approaches tailored to diverse contexts may support successful implementation. Scaling effective models could reduce waiting lists, improve equitable access to SLT services, and provide high-quality experiential learning for future practitioners.<br><br>WHAT THIS PAPER ADDS: What is already known on this subject School-based SLT placements have been implemented internationally, particularly in rural and underserved areas, to address workforce shortages and improve access to services. Evidence suggests these models can enhance student learning and service capacity, but there is limited synthesis of success factors, barriers, and scalability in the UK context. What this study adds to the existing knowledge This review identifies key principles for successful school-based SLT placements, including integration into policy frameworks, dedicated funding, cross-sector partnerships, and cultural responsiveness. It highlights barriers such as infrastructure limitations and student preparedness, and demonstrates that positive placement experiences may influence future workforce distribution. These findings provide an evidence-informed foundation for scaling models to reduce waiting lists and improve equitable access. What are the clinical implications of this study? Embedding SLT student placements in schools can increase service capacity, reduce waiting times, and support early intervention for children with speech and language needs. Structured supervision and orientation, alongside policy alignment and appropriate funding, may support sustainability and workforce readiness across diverse clinical contexts.},
}
@article {pmid42721896,
year = {2026},
author = {González-Madrid, E and Andrade, CA and Muñoz, JT and Ariztía, VF and Riedel, CA and González, PA and Kalergis, AM},
title = {Mechanistic analysis of immune communication during respiratory viral infections via the placenta-brain axis.},
journal = {Cytokine &amp; growth factor reviews},
volume = {92},
number = {},
pages = {101526},
doi = {10.1016/j.cytogfr.2026.08.006},
pmid = {42721896},
issn = {1879-0305},
abstract = {Respiratory viral infections during pregnancy can disrupt maternal immune homeostasis, thereby altering placental function and fetal neurodevelopment through cytokine-mediated immune communication. Accumulating evidence suggests that the placenta functions as an active immunological interface, integrating maternal inflammatory signals and shaping fetal neuroimmune development, supporting the concept of the "placenta-brain axis". This review synthesizes current evidence on the cytokine, chemokine, interferon, and complement networks that mediate maternal-fetal immune communication and examines how these pathways are engaged during infections. It addresses four prevalent RNA respiratory viruses for which evidence is available at one or more biological levels of the placenta-brain axis, namely influenza virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human respiratory syncytial virus (hRSV), and human metapneumovirus (hMPV). We highlight substantial differences in the depth of mechanistic evidence across these pathogens, with influenza virus and SARS-CoV-2 supported by comparatively robust experimental evidence, whereas hRSV and hMPV remain biologically plausible but mechanistically underexplored models of maternal-fetal immune communication. Hence, we propose a framework that grades mechanistic evidence across the placenta-brain axis against four explicit criteria and identify gestational timing, fetal sex, and maternal background inflammation as variables that modulate the transmission of inflammatory signals between levels. This structured approach identifies knowledge gaps and guides future mechanistic and translational research.},
}
@article {pmid42723126,
year = {2026},
author = {Ahmad, I and Ahmad Khan, S and Nabi, G and Urano, T and Morita, K and Ngwe Tun, MM},
title = {A comprehensive overview of monkeypox virus disease.},
journal = {Tropical medicine and health},
volume = {54},
number = {1},
pages = {},
pmid = {42723126},
issn = {1348-8945},
abstract = {BACKGROUND: Monkeypox (mpox), caused by monkeypox virus (MPXV), re-emerged as a major global public health concern in 2022, resulting in widespread transmission beyond traditionally endemic regions. As of March 2026, 181,164 confirmed cases and 492 deaths had been reported across 144 countries globally. The unprecedented geographic spread of the outbreak highlighted important knowledge gaps in disease surveillance, prevention, and control. Given the ongoing global circulation of MPXV and the risk of future outbreaks, this review provides a comprehensive synthesis of current evidence on MPXV and mpox.<br><br>METHODS: The literature, surveillance data, and public health reports available up to March 2026 were systematically reviewed and synthesized. The review comprehensively assesses viral biology, genetic diversity, epidemiology, transmission dynamics, clinical manifestations, pathogenesis, laboratory diagnosis, infection during pregnancy, host immune responses, immune evasion mechanisms, therapeutic interventions, and prevention strategies.<br><br>FINDINGS AND CONCLUSIONS: Globally, the decline in public immunity following the cessation of routine smallpox vaccination, together with ongoing viral evolution, may have contributed to the resurgence of mpox. Advances in genomic surveillance, diagnostics, and public health preparedness have strengthened outbreak response; however, important gaps remain in understanding long-term immunity and optimal treatment strategies. This review summarizes current evidence on MPXV and mpox and highlights priorities for future research and public health interventions.},
}
@article {pmid42724928,
year = {2026},
author = {Zhang, G and Lai, Y and Zhao, Y},
title = {The inflammation-immunosuppression loop as a driver of immune dysfunction and secondary infections in severe COVID-19.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1934930},
pmid = {42724928},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology ; *SARS-CoV-2/immunology ; *Inflammation/immunology ; Signal Transduction/immunology ; *Immune Tolerance ; *Coronavirus Infections/immunology ; Animals ; *Betacoronavirus/immunology ; Cytokines/immunology ; *Pneumonia, Viral/immunology ; Pandemics ; Cytokine Release Syndrome/immunology ; },
abstract = {Severe COVID-19 is strongly associated with a high incidence of secondary bacterial, fungal, and viral infections, which substantially contribute to prolonged hospitalization and increased mortality. Although cytokine storm characterized by elevated levels of IL-6, TNF-α, and IL-1β has long dominated the understanding of the immunopathology of severe COVID-19, accumulating clinical and mechanistic evidence indicates that persistent immunosuppression and impaired antimicrobial immunity are equally critical determinants of disease outcomes. The coexistence of excessive inflammatory activation and profound immune paralysis within the same patient represents a major unresolved paradox in COVID-19 immunology. In this review, we systematically summarize recent advances in the mechanisms underlying SARS-CoV-2-induced immune remodeling and propose an integrated signaling network model that links inflammatory amplification with immunosuppressive reprogramming. We highlight the central roles of the GM-CSF, MAPK, TNF-α-NF-κB, and IL-6-JAK-STAT3 signaling networks in sustaining inflammatory activation, driving myeloid cell reprogramming, impairing antigen presentation, and promoting T-cell dysfunction and exhaustion. Furthermore, we propose an "inflammation-immunosuppression loop" model, in which persistent inflammatory signaling actively induces immunosuppressive states through STAT3-dependent transcriptional programs, while impaired antimicrobial immunity facilitates secondary infections. Infection-associated activation of pattern recognition receptors subsequently reinforces inflammatory signaling, establishing a self-amplifying positive feedback loop that accelerates disease progression. This model provides a mechanistic explanation for the paradoxical coexistence of hyperinflammation and immune paralysis in severe COVID-19 and redefines secondary infections as active drivers of disease deterioration rather than merely downstream complications. Finally, we evaluate current and emerging host-directed therapeutic strategies and propose that future immunotherapeutic approaches should shift from single cytokine blockade toward precision restoration of immune homeostasis guided by dynamic monitoring of immune network states.},
}
@article {pmid42725043,
year = {2026},
author = {Lee, JM and Kim, HO and Kim, YJ and Singh, MK and Kim, SS and Yeo, SG},
title = {Respiratory pandemic risk in the Anthropocene: A One Health framework and GISRS+ agenda.},
journal = {One health (Amsterdam, Netherlands)},
volume = {23},
number = {},
pages = {101553},
pmid = {42725043},
issn = {2352-7714},
abstract = {Recent epidemics and pandemics caused by respiratory viruses, alongside the animal panzootic spread of highly pathogenic avian influenza A(H5Nx), have become a structural feature of the Anthropocene, yet responses remain largely reactive. This review integrates findings from WHO's Global Influenza Surveillance and Response System (GISRS) and related surveillance data (2000-2024), epidemiological studies of influenza A virus, SARS-CoV, MERS-CoV, SARS-CoV-2, and H5Nx, and One Health literature. We examine major groups of respiratory viruses and identify mismatches between risk and surveillance by focusing on spillover potential from animal hosts, human-to-human transmission and its controllability, and Anthropocene characteristics that increase epidemic risk. The analysis indicated that SARS-related coronaviruses and influenza A viruses, particularly H5Nx, are among the leading candidates based on currently available evidence because they have large reservoirs in animal hosts and spillover to humans is highly probable. The previous presymptomatic spread of SARS-CoV-2 and recent mammalian adaptation in H5N1 clade 2.3.4.4b highlight limitations of the traditional symptom-based and pathogen-specific surveillance system. Spillover events tend to occur in tropical and subtropical regions in low- and middle-income countries, but most genomic surveillance is in high-income countries. We propose interventions that address the upstream, midstream, downstream processes of epidemics. Upstream interventions are primary prevention measures related to land use, livestock, wildlife, and urban environments; midstream interventions are GISRS+-based pathogen-agnostic genomic and metagenomic early warning systems triggered by One Health; and downstream interventions include vaccines, antivirals, non-pharmaceutical interventions, and engineering with equity-centred global governance and sustainable financing.},
}
@article {pmid42726158,
year = {2026},
author = {Burgess, IF},
title = {Head Lice: A Revised View of the Impact of the COVID-19 Pandemic on Transmission and Prevalence.},
journal = {Acta parasitologica},
volume = {71},
number = {5},
pages = {},
pmid = {42726158},
issn = {1896-1851},
mesh = {*Lice Infestations/epidemiology/transmission/prevention &amp; control ; *Pediculus/virology ; Animals ; *COVID-19/epidemiology ; Humans ; Prevalence ; Child ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Head louse transmission is a regular occurrence among children when coming into close contact with others during social activities. During the Covid-19 pandemic most countries instituted lockdown periods resulting in isolation of children away from regular contacts, potentially restricting opportunities for louse transmission. Subsequently there were reports of reduced infestations in children at schools, compared with before the pandemic, with a parallel fall in sales of pediculicidal treatments in several countries beyond the longer-term decline in product sales observed over several years before the pandemic.<br><br>METHODS: For this narrative review all literature linking Covid-19 and head lice were revisited and re-evaluated.<br><br>RESULTS: Despite the increased opportunity for elimination of infestations, some households with no outside contacts reported persistent incidence of head louse infestation and a review of the various studies suggests that most reported changes in head louse prevalence were relatively short lived or even illusory and in countries with low or middle incomes there was little or no difference in prevalence as a result of lockdowns.<br><br>CONCLUSIONS: Some aspects of the social distancing imposed in several countries during the pandemic appear to have continued to have some effect on social interactions of children, particularly in Western countries, with a commensurate slower recovery of head louse prevalence in some communities.},
}
@article {pmid42726480,
year = {2026},
author = {Fazio, M and Haas, B and Bahreinian, S and Andrei, S and Brown, HK and Raveendran, T and Saunders, N},
title = {Risk of Injury Among Children and Youths Whose Mothers Experienced Violent Injury: A Systematic Review and Meta-Analysis.},
journal = {JAMA network open},
volume = {9},
number = {9},
pages = {e2633054},
pmid = {42726480},
issn = {2574-3805},
mesh = {Humans ; Female ; Child ; *Wounds and Injuries/epidemiology/etiology ; Adolescent ; *Mothers/psychology/statistics &amp; numerical data ; Child, Preschool ; *Violence/statistics &amp; numerical data ; Male ; Prevalence ; Risk Factors ; *Exposure to Violence/statistics &amp; numerical data ; },
abstract = {IMPORTANCE: Maternal exposure to violent injury is a sentinel event with implications for child health and safety. Quantifying the risk of injury in children whose mothers have experienced violent injury is essential for trauma-informed pediatric care.<br><br>OBJECTIVE: To review and synthesize evidence on the risk of physical and sexual injury among children whose mothers have experienced violent injury.<br><br>DATA SOURCES: MEDLINE, Embase, Cochrane, and Web of Science were searched from inception to August 7, 2024.<br><br>STUDY SELECTION: Observational cohort, cross-sectional, and case-control studies and secondary analyses of randomized clinical trials that reported comparative risk estimates or prevalence of child injury following maternal violent injury were included. Children were required to be younger than 25 years at both exposure and outcome assessment.<br><br>DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies and extracted data, with disagreements resolved by a third reviewer. Risk of bias was assessed using Joanna Briggs Institute tools. Random-effects meta-analyses pooled prevalence ratios, odds ratios, and prevalence estimates. Comparative meta-analyses focused on physical injury outcomes. Sexual injury outcomes were synthesized descriptively because of sparse and heterogeneous comparative data. Prespecified subgroup analyses examined corporal punishment vs other physical injuries.<br><br>MAIN OUTCOMES AND MEASURES: The primary outcome was the risk of physical injury in children exposed to maternal violent injury compared with unexposed children. Sexual injury was a secondary outcome.<br><br>RESULTS: Of 6218 unique records identified, 48 (7 666 786 unique participants) met inclusion criteria. Children exposed to maternal violent injury had a higher risk of physical injury compared with unexposed children (pooled prevalence ratio, 1.65 [95% CI, 1.36-2.01]; pooled odds ratio, 2.53 [95% CI, 1.60-4.00]), with substantial heterogeneity. Among exposed children, the pooled prevalence of physical injury was 42.4% (95% CI, 30.6%-54.6%). Sexual injury prevalence among exposed children was 17.0% (95% CI, 12.3%-22.3%); comparative estimates were insufficient for pooling. Subgroup and sensitivity analyses yielded similar findings across injury types.<br><br>CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of children exposed to maternal violent injury, these children were at substantially increased risk for physical injury and experienced a high burden of sexual injury, underscoring the need for trauma-informed integrated family supports following maternal assault.},
}
@article {pmid42728430,
year = {2026},
author = {Xue, L and Ang, MJY and Swingle, KL and Fitzgerald, E and Chalom, O and Gu, N and Mitchell, MJ},
title = {Structural evolution of ionizable lipids for nucleic acid delivery.},
journal = {Nature reviews. Chemistry},
volume = {},
number = {},
pages = {},
pmid = {42728430},
issn = {2397-3358},
abstract = {Ionizable lipid nanoparticles have emerged as a potent non-viral delivery platform for nucleic acid therapeutics, achieving clinical breakthroughs ranging from the FDA-approved small interfering RNA therapeutic to mRNA vaccines against coronavirus disease 2019 and respiratory syncytial virus. Their success stems from the ability of ionizable lipids to remain neutral in physiological environments, yet protonate in acidic endosomes, enabling the efficient release of genetic cargo. Over the last several decades, their structures have evolved extensively through the application of combinatorial chemistry, rational design, incorporation of functional elements and, most recently, machine learning and artificial intelligence-guided strategies. These innovations have expanded ionizable lipids from passive carriers into multifunctional materials capable of organ-specific targeting, responsiveness, immunomodulation and theranostics. In this Review, we highlight the development, synthesis and structural evolution of ionizable lipids as well as their emerging on-demand design functionalities and next-generation biomedical applications. We provide insights into the challenges and gaps for translation, manufacturing and expansion of lipid nanoparticle-mediated nucleic acid therapeutics for precision RNA medicine.},
}
@article {pmid42729498,
year = {2026},
author = {Rasmussen, EB and Alvarado, AY},
title = {A Behavioral Economic Characterization of the Impact of the COVID-19 Quarantine on Reinforcer Diversity, Behavior, and Health.},
journal = {Perspectives on behavior science},
volume = {49},
number = {3},
pages = {569-611},
pmid = {42729498},
issn = {2520-8977},
abstract = {In 2020, the U.S. government, like other countries, instated a nationwide quarantine to reduce the spread of COVID-19, which had reached pandemic status. Though challenging on a number of levels, the quarantine also provided a unique opportunity to examine the effects of a cultural phenomenon that reduced access to many sources of reinforcement and the potential impact on behavior and health. From a behavioral economic standpoint, the quarantine likely resulted in greater consumption of reinforcers that were highly available in the home, such as social media, sleep, substances, and food, while lowering consumption of reinforcers that were restricted by quarantine policies. These two trends likely combined into a net reduction in the diversity of reinforcers that were available to individuals during the quarantine. For some individuals, these shifts in consumption also predicted changes in health and mental health status, especially those involving consumption of social media, sleep, substances, and food. We discuss the implications for health and mental health associated with these trends and end by offering suggestions on how a more careful programming of available reinforcers during times of low reinforcer diversity may prevent excessive consumption of reinforcers that may affect health or mental health risks.},
}
@article {pmid42731987,
year = {2026},
author = {Chiang, HL and Chien, YL and Gau, SS},
title = {Young minds in distress: Exploring the global rise in youth mental health diagnoses.},
journal = {Molecular psychiatry},
volume = {},
number = {},
pages = {},
pmid = {42731987},
issn = {1476-5578},
abstract = {Adolescence represents a critical neurobiological period marked by a developmental "mismatch" between early-maturing limbic systems and the later-maturing prefrontal cortex, conferring heightened vulnerability to the onset of psychiatric disorders. This review synthesizes global epidemiological trends, differentiates true increases in morbidity from diagnostic inflation, and integrates evidence-based intervention strategies. In high-income countries, youth depression, suicide mortality, and self-harm have risen substantially, supported by objective indicators of illness severity that extend beyond changes in diagnostic practices. Key environmental drivers include pervasive digital engagement, cyberbullying, sleep disruption, and academic pressure, with sleep disturbances emerging as a central transdiagnostic risk factor. The COVID-19 pandemic accelerated these pre-existing trajectories of mental health deterioration, with particularly marked effects on eating-disorder incidence and social-emotional development. To address these challenges, we suggest a three-tiered intervention framework. Universal approaches should emphasize regulation of digital environments, implementation of Social-Emotional Learning, and institutional support for regular physical activity. Selective interventions should target high-risk youth by proactively monitoring sleep health and mitigating achievement-related stress in academically competitive settings. Indicated care requires integrated delivery of evidence-based psychotherapies alongside structured return-to-learn protocols following psychiatric hospitalization. Ultimately, translating epidemiological risk into effective prevention demands a shift from reactive, diagnosis-centered models to proactive frameworks that prioritize early risk reduction and the reinforcement of protective factors. By fostering environments that promote circadian stability, physical activity, emotional regulation, and peer connectedness, youth mental health can be strengthened as a foundation for societal well-being, resilience, and adaptive functioning in an increasingly complex world.},
}
@article {pmid42732100,
year = {2026},
author = {Simon, Y and Hadju, V and Dahlan, C and Chaeroel Ansar, M},
title = {Trends and Research Frontiers on Exclusive Breastfeeding Policy: A Bibliometric Analysis.},
journal = {F1000Research},
volume = {15},
number = {},
pages = {792},
pmid = {42732100},
issn = {2046-1402},
mesh = {*Breast Feeding/trends ; Humans ; *Bibliometrics ; *Health Policy/trends ; COVID-19/epidemiology ; },
abstract = {BACKGROUND: Exclusive breastfeeding (EBF) is vital for child survival, growth, and development, yet its promotion and protection remain challenging across diverse policy and health system contexts. Over the past decade, research on EBF policy has increased alongside global health priorities and emerging crises. This study examines publication trends, key sources and authors, collaboration patterns, and thematic evolution in EBF policy research from 2016 to 2025 using bibliometric analysis.<br><br>METHODS: A bibliometric analysis was conducted using Scopus data retrieved with the query "exclusive breastfeeding" and "policy" for publications from 2016-2025. A total of 449 documents were analyzed based on publication trends, influential journals and authors, citation impact, collaboration networks, keyword co-occurrence, and thematic evolution.<br><br>RESULTS: EBF policy research showed a consistent annual growth rate of 18.57%, with publication peaks in 2020 and 2023, partly linked to the COVID-19 pandemic. The International Breastfeeding Journal and Maternal and Child Nutrition were the leading journals, while P&#xe9;rez-Escamilla, Agho, and Ogbo were among the most influential authors. International collaboration increased, although contributions from low- and middle-income countries remained limited. Research themes evolved from child health and biomedical determinants (2016-2019) to broader issues, including maternal factors, workplace support, nutrition policy, and health system resilience, with COVID-19-related challenges emerging after 2020.<br><br>CONCLUSIONS: EBF policy research has shifted toward a more holistic and system-oriented perspective. Strengthening policy frameworks, health systems, and equitable support mechanisms is essential to sustain progress in EBF promotion and protection.},
}
@article {pmid42732429,
year = {2026},
author = {Mousavi, S and Ardekani, MB and Feizi, A},
title = {Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options.},
journal = {Journal of research in pharmacy practice},
volume = {15},
number = {1},
pages = {29},
pmid = {42732429},
issn = {2319-9644},
abstract = {To assess the efficacy and safety of each therapeutic options in the treatment of COVID-19 by assessing the evidence from existing systematic reviews and meta-analyses, and to carry out an umbrella meta-analysis of all meta-analysis studies to assess the efficacy of each drug. A comprehensive search was carried out in electronic databases for systematic reviews and meta-analyses which compared the efficacy and/or safety of therapeutic options in the treatment of COVID-19. Findings from the reviews were synthesized using tables and forest plots and the pooled estimate of effect size using the DerSimonian and Laird method was used for the updated meta-analysis. The main outcome was mortality. 285 reviews with 152 meta-analyses were included, The analysis of systematic reviews contents indicated that most reviewed drugs were as follows: chroquine/hydroxychloroquine (n = 48), tocilizumab (n = 39), remdesivir (n = 25), corticosteroids (n = 25), JAK inhibitors (n = 12), colchicine (n = 11), ivermectin (n = 8), anakinra (n = 7), favipravir (n = 7), lopinavir/ritonavir (n = 6), ACEI/ARB (n = 6), azithromycin (n = 4), sofosbuvir (n = 4), and Vitamin D (n = 4). Findings from the included reviews suggested that tocilizumab, remdesivir, corticosteroids, JAKI, anakinra, colchicine, ivermectin, and sofosbuvir decreased the rate of mortality significantly in those taking the drugs; otherwise hydroxylchroquine increased the risk of mortality significantly, while Lopinavir/Ritonavir had no benefit and ACEI and azithromycin decreased mortality rate not significantly. lower requirement for mechanical ventilation and intensive care unit admission and a shorter hospital length of stay was observed with the tocilizumab, JAKIs, anakinra, corticosteroids and sofosbuvir Only one third of the included reviews had 70% quality based on the AMSTAR scale assessment. The results of this study have the potential to be a useful tool for the translation of health evidence and for designing the decision support systems for evidence synthesis.},
}
@article {pmid42733405,
year = {2026},
author = {Millan, MJ},
title = {From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.},
journal = {Neuroscience applied},
volume = {5},
number = {},
pages = {107024},
pmid = {42733405},
issn = {2772-4085},
abstract = {In 2020, a novel Coronavirus, Severe Acute Respiratory Syndrome-Covid-2 (SARS-CoV-2), spread globally to provoke a pandemic that infected over 750 million people. The associated disorder, Coronavirus-19 (COVID-19), has caused at least 7 million deaths and around a hundred million people have developed a variable yet sometimes incapacitating condition called Long Covid. This multi-organ syndrome, often referred to as "Brain Fog", encompasses symptoms of extreme fatigue, anxiety, poor sleep and, most prominently, cognitive impairment. Long Covid emerges three or more months after SARS-CoV-2 infection and bears a marked resemblance to the suite of neurological symptoms that evolves several years after infection with Human Immunodeficiency Virus (HIV). Accordingly, by analogy to "HIV Associated Neurological Disorder" (HAND), the acronym," SAND" is proposed for SARS-CoV-2 Associated Neurological Disorder. Mimicking HIV infection/HAND, SARS-CoV-2 infection/SAND is on a collision course with aging, leading to their mutual aggravation and an increased risk of disorders like Alzheimer's and Parkinson's disease. In contrast to HIV, where the virus crosses the blood-brain-barrier in T-lymphocytes and monocytes to infect microglia and other cell types, there is little evidence that SARS-CoV-2 enters the brain. Nonetheless, in addition to the indirect effects of a somatic hyper-inflammation ("cytokine storm") and the disruption of blood- and CSF-brain barriers, SARS-CoV-2-encoded S1 Spike protein and other virally-encoded proteins enter the brain to directly interfere with cerebral function. Microglia and astrocytes adopt a pro-inflammatory phenotype, neurotoxic proteins accumulate, mitochondrial energy generation declines, and synaptic transmission is perturbed. These findings for SAND mirror observations seen with aging and dementia. A broad-based programme of "R and D", healthcare and social support would appear desirable to better understand the complex set of interacting mechanisms underlying SAND, to prevent its onset, to alleviate the debilitating symptoms, and to improve our readiness for countering the impact of those novel, brain-damaging viruses that will inevitably arise in the future.},
}
@article {pmid41102952,
year = {2026},
author = {Eltaib, L and Alanazi, MN and Khan, Y and Hanbashi, A and Khan, G and Rikabi, HA and Maqbool, M and Hussain, MS},
title = {PANoptosis in Cytokine Release Syndrome: Bridging the Gap between Inflammation and Cell Death.},
journal = {Current pharmaceutical design},
volume = {32},
number = {29},
pages = {2355-2364},
pmid = {41102952},
issn = {1873-4286},
mesh = {Humans ; *Cytokine Release Syndrome/immunology/pathology/drug therapy ; *Inflammation/immunology/pathology ; *Cell Death/immunology/drug effects ; Animals ; COVID-19/immunology ; Cytokines/metabolism ; Immunotherapy/adverse effects ; },
abstract = {Cytokine Release Syndrome (CRS) is a hyperinflammatory condition triggered by infections, immunotherapies, and systemic immune dysregulation. PANoptosis, a unique form of programmed inflammatory cell death that integrates pyroptosis, apoptosis, and necroptosis, has emerged as a key contributor to CRS pathogenesis. This review explores the mechanistic role of PANoptosis in CRS, with particular emphasis on immunotherapy-induced toxicity and viral infections such as SARS-CoV-2 and influenza. PANoptosis exacerbates cytokine storms through ZBP1, NLRP3, and CASP8-mediated pathways, creating a pathological feedback loop that intensifies inflammation and promotes multi-organ damage. Current evidence suggests that modulating PANoptotic pathways, including targeting TNF-α, IFN-γ, and inflammasome components, may mitigate cytokine-driven tissue injury. Despite growing interest, the therapeutic potential of PANoptosis remains underexplored. Advancing our understanding of PANoptosis and its interaction with cytokine signaling will be critical for developing effective interventions for CRS and improving outcomes in patients undergoing immunotherapy or battling severe infections.},
}
@article {pmid42714194,
year = {2027},
author = {Michou, V and Tsamos, D and Itziou, A and Tsanaktsidis, C},
title = {Breathing in harm: current insights into the effects of air pollution on cardiorespiratory health.},
journal = {Medical gas research},
volume = {17},
number = {1},
pages = {268-284},
pmid = {42714194},
issn = {2045-9912},
mesh = {Humans ; *Air Pollution/adverse effects ; *Cardiovascular Diseases/etiology ; Air Pollutants ; COVID-19 ; *Respiratory Tract Diseases/etiology ; Environmental Exposure/adverse effects ; },
abstract = {Air pollution significantly contributes to cardiovascular and respiratory diseases, leading to increased morbidity and mortality. This review critically examines the mechanisms linking air pollution to higher cardiometabolic risk and cardiovascular death. It examines the impact of air pollution on respiratory health, specifically its role in exacerbating conditions such as heart failure, chronic obstructive pulmonary disease, and asthma. Special attention is given to vulnerable groups, including pregnant individuals, neonates, children, and patients with pre-existing cardiovascular or respiratory conditions, who are particularly susceptible and experience more severe health effects. Emerging evidence regarding the interactions between air pollution and coronavirus disease 2019 is also presented, showing how reductions in pollution levels during pandemic lockdowns were associated with improved cardiopulmonary health. Furthermore, the review discusses international differences in air quality standards and recent updates to exposure limits for air pollutants, as well as their implications for public health. It evaluates various mitigation strategies, including policy interventions, technological solutions, and approaches to reduce risk-based exposure. Lastly, the review emphasizes the need for comprehensive, evidence-based frameworks to minimize exposure and prevent diseases associated with pollution. Strengthening air quality management is essential for reducing the global burden of cardiovascular and respiratory diseases.},
}
@article {pmid42719526,
year = {2026},
author = {Hashmi, MN and Almarzouk, S and Hejaili, F and Raza, H},
title = {Disaster Management in Hemodialysis Centers: Ensuring Continuity of Lifesaving Care.},
journal = {Avicenna journal of medicine},
volume = {16},
number = {3},
pages = {107-115},
pmid = {42719526},
issn = {2231-0770},
abstract = {Hemodialysis is a life-sustaining therapy that depends on uninterrupted access to electricity, clean water, medical supplies, and trained staff. This dependence makes hemodialysis units uniquely vulnerable to disasters such as natural catastrophes, power failures, pandemics, or civil emergencies. The COVID-19 pandemic, major earthquakes, and large-scale floods have highlighted the fragility of dialysis infrastructure worldwide. This review synthesizes available evidence on disaster preparedness, response, and recovery in hemodialysis centers. Drawing on international experiences and existing guidelines, it proposes a framework to enhance resilience and ensure continuity of dialysis care during crises. Key strategies include structured risk assessment, patient and staff education, backup systems for power and water, coordinated regional response networks, and incorporation of disaster readiness into routine dialysis operations. Strengthening preparedness at every level-from the individual center to national health systems-is vital to prevent avoidable morbidity and mortality among this highly vulnerable population.},
}
@article {pmid42719575,
year = {2026},
author = {Schäfer, C and Blamey, C and Balbiano, R and Mena, J and Acuña-Castillo, C and Sandino, AM},
title = {SARS-CoV-2 ORF8: an accessory protein at the interface of immune evasion and inflammation.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1826664},
pmid = {42719575},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/virology ; *SARS-CoV-2/immunology ; *Immune Evasion/immunology ; *Viral Proteins/immunology/metabolism ; *Inflammation/immunology ; Animals ; },
abstract = {SARS-CoV-2 ORF8 is a rapidly evolving accessory protein that modulates host immunity through both intracellular and extracellular mechanisms. Intracellularly, ORF8 disrupts antigen presentation by reducing cell-surface MHC-I and is linked to endoplasmic reticulum remodeling and altered stress responses. Extracellularly, secreted ORF8 behaves as a virokine that can amplify inflammatory programs in myeloid and dendritic cells, with potential implications for acute severity and tissue-specific pathology. ORF8 is also reported to antagonize type I interferon induction through effects on IRF3-dependent pathways. Clinically, circulating ORF8 has been associated with disease severity, and persistent detection of ORF8 after viral RNA becomes undetectable has been reported in some individuals with post-acute symptoms. However, whether this persistence reflects a direct pathogenic role or instead marks ongoing viral burden and immune activation remains unresolved. In this review, we summarize recent findings on the pleiotropic effects of ORF8 and outline key priorities to clarify when ORF8 acts primarily as an immune-evasion factor, an inflammatory amplifier, or both. Collectively, the evidence reviewed here identifies ORF8 as a promising candidate for further mechanistic studies, whose biomarker potential and therapeutic relevance warrant rigorous evaluation in acute and post-acute COVID-19.},
}
@article {pmid42717452,
year = {2026},
author = {Toboltoc, PC and Vekony, A and Gagiu, I},
title = {SARS-CoV-2-related immune dysregulation and biologically plausible pathways to lymphomagenesis: a PRISMA-ScR-based scoping review.},
journal = {Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie},
volume = {67},
number = {2},
pages = {213-224},
doi = {10.47162/RJME.67.2.02},
pmid = {42717452},
issn = {2066-8279},
mesh = {Humans ; *Lymphoma/immunology/pathology/virology ; *COVID-19/immunology/complications/pathology/virology ; *SARS-CoV-2/immunology ; },
abstract = {BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related immune dysregulation has generated interest in diagnostic pathology because infection-related inflammation, long coronavirus disease (COVID)-related immune disturbance, and post-vaccination lymphoid reactions may overlap with lymphoid-biological mechanisms and complicate the distinction between reactive lymphoid proliferations and lymphoid neoplasia.<br><br>AIM: This scoping review aimed to map biologically plausible pathways through which SARS-CoV-2-associated immune perturbation may intersect with lymphomagenesis-related mechanisms, emphasizing diagnostic implications rather than causality.<br><br>MATERIALS AND METHODS: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PubMed&#x2215;MEDLINE, Scopus, and Web of Science were searched from January 2020 to March 2026, with selected pre-2020 sources retained for mechanistic or diagnostic relevance. Sources were charted across mechanistic, immunological, virological, clinicopathological, and diagnostic domains.<br><br>RESULTS: After screening and eligibility assessment, 63 sources were retained for thematic synthesis. Evidence clustered around lymphoma-relevant but non-specific mechanisms, including inflammatory signaling, impaired immune surveillance, latent oncogenic viral reactivation, prolonged germinal-center activity with activation-induced cytidine deaminase (AID)-related genomic vulnerability, and lymphoid microenvironment remodeling. These mechanisms appear most relevant in predisposed hosts with chronic immune dysregulation, latent viral infection, defective deoxyribonucleic acid (DNA) repair, or occult abnormal lymphoid clones. Infection and vaccination are distinct contexts, because infection may produce broader immune disruption, whereas most post-vaccination nodal events are reactive and self-limited.<br><br>CONCLUSIONS: Current evidence supports biological plausibility rather than a direct or generalizable causal relationship. The main diagnostic implication is careful clinicopathological correlation and distinction between reactive lymphoid proliferations and lymphoid neoplasia in post-COVID-19 and post-vaccination settings.},
}
@article {pmid42717903,
year = {2026},
author = {Walldorf, JA and Patel, JC and Cibrelus, L and Fernandez, K and Bouhenia, M and Harutyunyan, V and Pezzoli, L and Staples, JE and Nguyen, T and Costa, A},
title = {Evolution of the global emergency vaccine stockpile system.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2715858},
doi = {10.1080/14760584.2026.2715858},
pmid = {42717903},
issn = {1744-8395},
mesh = {Humans ; Global Health ; *Vaccines/supply &amp; distribution/administration &amp; dosage ; *Strategic Stockpile ; Disease Outbreaks/prevention &amp; control ; Vaccine Development ; },
abstract = {INTRODUCTION: The emergence of epidemic-prone diseases continues to pose a threat to global health. Vaccine stockpiles allow effective and timely response to outbreaks. Global stockpiles have been established for multiple vaccines, but stockpile management has evolved in recent years, both in the number of globally managed stockpiles and in stockpile strategy, from a reactive to a more integrated approach bridging with preventive strategies.<br><br>AREAS COVERED: We conducted a review of published and gray literature to provide an update on the evolution of stockpile management in recent years (2014-2025), specifically for cholera, yellow fever, polio, meningococcus, COVID-19, Ebola, and mpox.<br><br>EXPERT OPINION: The benefit of accelerated development of new vaccines and medical countermeasures to fight epidemic-prone diseases cannot be achieved without efficient and transparent stockpile management and distribution mechanisms, to ensure equitable and needs-based allocation.},
}
@article {pmid42718950,
year = {2026},
author = {Combrink, HMVE and Mkungeka, P and Bhengu, C and Katarya, R and Smart, B},
title = {Managing an infodemic in the global south: a systematic evidence synthesis from COVID-19 social listening reports.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1787026},
pmid = {42718950},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology/prevention &amp; control ; South Africa/epidemiology ; *Infodemic ; *Communication ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic was accompanied by a widespread infodemic characterised by rapidly evolving information, misinformation, and uncertainty, particularly within low- and middle-income country contexts. Social listening emerged as a critical tool for risk communication and community engagement by enabling real-time monitoring of public concerns, misinformation, and information gaps. This study presents a systematic evidence synthesis of national COVID-19 social listening reports produced in South Africa between 2021 and 2023 to inform infodemic management in the Global South. A total of 91 publicly available social listening reports were identified through coordinated national repositories and screened according to predefined inclusion and exclusion criteria. Following PRISMA 2020 guidance for transparent reporting, misinformation signals and corresponding recommended actions were extracted, thematically coded, and synthesised. The synthesis identified 964 instances of misinformation across 12 thematic categories, with dominant themes relating to COVID-19 disease management, vaccine safety, side effects, and conspiracy narratives. In parallel, 573 recommended action items were consolidated into eight thematic response domains, emphasising community-based engagement, targeted health education, communication strategy development, political and public figure credibility, and continuous monitoring and research. Building on these findings, the study proposes a circular social listening health priority nexus that operationalises the translation of misinformation signals into adaptive public health communication responses. While this synthesis does not evaluate the effectiveness of implemented interventions, it provides structured evidence to support decision-making and priority setting for infodemic management. The findings highlight the importance of context-sensitive, adaptive communication strategies and sustained social listening systems to strengthen public health responses to future infodemics in the Global South.},
}
@article {pmid42719002,
year = {2026},
author = {Cabanillas-Lazo, M and Alegre-Cordero, I and Mera-Lojano, LD and Luna-Peralta, G and Cruzalegui-Bazan, C and Castro-Suárez, P and Quispe-Vicuña, C and Mayta-Tovalino, F},
title = {Neutrophil-to-lymphocyte ratio for the clinical management of dengue: a systematic review and meta-analysis.},
journal = {Frontiers in epidemiology},
volume = {6},
number = {},
pages = {1877646},
pmid = {42719002},
issn = {2674-1199},
abstract = {INTRODUCTION: Dengue fever (DF) remains a major global public health concern, especially in tropical and low-resource settings. The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an accessible biomarker for diagnosis and severity assessment, but the existing evidence is heterogeneous. To summarize the current evidence on the behavior of the NLR in DF.<br><br>METHODS: This study conducted a systematic search in five databases for observational studies published until April 2024. Inclusion and exclusion criteria were based on predefined eligibility criteria, and quality and methodological assessment were expressed using the Newcastle-Ottawa Scale. Data was pooled using a random-effects model and results generalized as applicable, when pooling could not be carried out. A summary receiver operating characteristic curve (sROC) was obtained to assess the diagnostic accuracy of NLR for distinguishing DF from COVID-19. The certainty of evidence was graded using the GRADE system.<br><br>RESULT: A total of 6,166 participants from 15 observational studies were included, all with low risk of bias. A single study showed a higher NLR in dengue vs. healthy controls (Bhattarai, 2023; MD: 1.29; 95% CI: 0.87 to 1.71), with moderate certainty. The SROC curve for dengue vs. COVID-19 (2 studies, n&#x2009;=&#x2009;226) showed sensitivity and specificity of 83.9% and an AUC of 0.907, indicating high diagnostic accuracy, with moderate certainty.<br><br>CONCLUSION: For prognosis, severe dengue showed a small, but significant NLR decrease compared with dengue with warning signs (MD: -0.54; 95% CI: -0.91 to -0.17, I2&#x2009;=&#x2009;0%), with very low certainty. NLR may serve as a supportive diagnostic biomarker for dengue. However, its prognostic value remains uncertain, highlighting the need for large, prospective studies to validate cutoff points and clinical utility.},
}
@article {pmid41654320,
year = {2026},
author = {Roth-Walter, F and Adcock, IM and Benito-Villalvilla, C and Bianchini, R and Bjermer, L and Caramori, G and Cari, L and Chung, KF and Diamant, Z and Eguiluz-Gracia, I and Knol, EF and Jesenak, M and Levi-Schaffer, F and Nocentini, G and O'Mahony, L and Palomares, O and Redegeld, F and Sokolowska, M and Van Esch, B and Zurlo, M and Stellato, C},
title = {Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper.},
journal = {Allergy},
volume = {81},
number = {9},
pages = {3039-3070},
doi = {10.1111/all.70235},
pmid = {41654320},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology/ ; },
mesh = {Humans ; *Precision Medicine/methods ; *Inflammation/drug therapy/therapy ; Chronic Disease ; *RNA/therapeutic use ; Animals ; SARS-CoV-2 ; COVID-19 ; COVID-19 Drug Treatment ; },
abstract = {In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way-through the clinical use of monoclonal antibodies-a deeper understanding of how inflammatory and immune pathways are configured in disease-specific patterns. In this biomarker-driven approach, synthetic small molecule drugs (SMDs) were perceived as lagging behind in innovation for their relative lack of specificity. This was, however, mostly due to a shift in focus towards biologics rather than true obsolescence of SMDs. In the same timeframe, in fact, advances in structural biology and medicinal chemistry, bioinformatics and artificial intelligence held steadily SMDs' innovation and relevance. The use of kinase inhibitors, well established in the treatment of cancer and rheumatological diseases, is now approved for some allergic skin diseases and is approaching asthma and COPD with several clinical trials; moreover, new therapeutics targeting mast cell receptors and molecules involved in innate immunity are entering preclinical and clinical testing. Alongside, the portfolio of biologics is harboring the expansion of RNA therapeutics, which gained global recognition during the COVID-19 pandemic due to RNA vaccines. Different types of RNA therapeutics, including those based on different non-coding RNAs, are advancing to agency approval and market, thanks to improvements in molecule stability and delivery systems. In summary, the evidence presented in this position paper illustrates that precision medicine is becoming a goal shared between synthetic SMDs and biologics, both protein/antibody-based and RNA therapeutics. We review the current state, unmet needs and opportunities within this evolving landscape, highlighting how small molecular species, both synthetic as SMDs and biologic in nature as RNA, can contribute to the precision medicine approach along with protein and antibody-based biologics and cell therapies.},
}
@article {pmid42314574,
year = {2026},
author = {Christen, P and Ahmed, MHA and Chua, BWB and Chaowanasawat, P and Chapman-Banks, E and Ozkan, Y and van Elsland, SL and Cori, A and K C, S and Whitaker, MD and Chadeau-Hyam, M and Dabak, SV and Jit, M},
title = {Measuring the growth of infectious disease modelling publications and their impact on policymaking: A large language model-assisted bibliometric review.},
journal = {Epidemics},
volume = {56},
number = {},
pages = {100926},
doi = {10.1016/j.epidem.2026.100926},
pmid = {42314574},
issn = {1878-0067},
mesh = {Humans ; *Bibliometrics ; Large Language Models ; *Policy Making ; *Communicable Diseases/epidemiology ; *Health Policy ; COVID-19/epidemiology ; *Publications/statistics &amp; numerical data ; },
abstract = {BACKGROUND: Infectious disease modelling (IDM) is increasingly used to understand disease transmission and inform public health policy. Its growth and influence on policy have not been quantified, partly due to the large volume of literature. Using a large language model (LLM)-assisted review, we quantified the expansion of IDM publications, trends in policy citations, and regional disparities in research contributions and uptake.<br><br>METHODS: An LLM-assisted bibliometric review was conducted in Embase, Medline, and Scopus, identifying IDM publications to December 2024 via GPT-4o (OpenAI). Eligible studies employed mathematical, statistical, or mechanistic models for infectious disease outcomes. LLM accuracy was iteratively refined through human review. We extracted publication metadata, geographic scope, and policy citations via Overton, a global database of policy documents. Growth trends were analysed using negative binomial regression; geographic disparities were assessed by World Bank income classifications.<br><br>RESULTS: We identified 33,255 IDM publications over 44 years, with distinct growth phases. Publication volume rose with the emergence of HIV/AIDS, expanded through successive outbreaks (Ebola, SARS, H1N1, MERS, Zika), surged just before COVID-19, then declined after 2021. Policy citations accounted for 1.7% of IDM publications, mirroring overall growth and peaking during periods of heightened public health attention. Citations largely reflected national research outputs, with some cross-regional adoption of IDM evidence.<br><br>CONCLUSION: Strengthening IDM's policy impact may require fostering collaboration pu and improving uptake mechanisms. Post-COVID-19, policy citations declined despite continued IDM growth, suggesting a lag or shift in priorities.},
}
@article {pmid42717339,
year = {2026},
author = {He, Y and Mao, Y and Wang, X},
title = {Machine learning-assisted mRNA vaccine pharmacovigilance: a systematic review of multi-source real-world data.},
journal = {BMC medical informatics and decision making},
volume = {26},
number = {1},
pages = {},
pmid = {42717339},
issn = {1472-6947},
support = {23C0169//Scientific Research Project of the Hunan Provincial Department of Education/ ; 2024XJZC016//School-level research project of Hunan University of Traditional Chinese Medicine/ ; 2023BKS050//Hunan University of Traditional Chinese Medicine Undergraduate Research Innovation Fund Project/ ; },
mesh = {*Pharmacovigilance ; Humans ; *Machine Learning ; *COVID-19 Vaccines/adverse effects ; Predictive Learning Models ; COVID-19/prevention &amp; control ; *Adverse Drug Reaction Reporting Systems ; *mRNA Vaccines/adverse effects ; },
abstract = {BACKGROUND: The rapid deployment of mRNA vaccines during the COVID-19 pandemic exposed limitations in traditional pharmacovigilance systems, including delayed reporting, high underreporting rates, and inability to calculate true incidence. Machine learning (ML) offers new pathways to overcome these challenges by integrating multi-source real-world data.<br><br>METHODS: We systematically reviewed English-language studies from database inception to June 2026. Searches were performed in PubMed, Embase, and Web of Science. Two reviewers independently screened records. Given substantial heterogeneity across ML tasks (signal detection, text extraction, risk prediction, prognosis stratification), algorithms, data sources, and metrics, we performed narrative synthesis. Risk of bias was assessed using adapted QUADAS-2.<br><br>RESULTS: We identified 43 studies. For adverse-event prediction, tree-based models reported AUCs of 0.85-0.87, though estimates derive from heterogeneous settings. NLP reduced redundant signals by 17% in vaccine reporting systems. For myocarditis, ML models reached AUCs up to 0.899 in cardiovascular cohorts, but direct mRNA vaccine applications remain limited and retrospective. Emerging platforms (self-amplifying and tumor mRNA vaccines) lack post-marketing data, rendering ML applications largely conceptual.<br><br>CONCLUSION: ML-assisted pharmacovigilance enables a shift from passive to active, intelligent monitoring. Despite challenges in data quality, model interpretability, and regulatory approval, intelligent pharmacovigilance systems will become essential infrastructure for safeguarding public health.},
}
@article {pmid42717375,
year = {2026},
author = {Cano-Cevallos, L and Patiño-Aveiga, G and Gaibor-Pazmiño, A and Ortiz-Prado, E and Izquierdo-Condoy, JS},
title = {Microbiome dysbiosis in long COVID: a scoping review of mechanistic insights, symptom associations, and therapeutic targets.},
journal = {Gut pathogens},
volume = {18},
number = {1},
pages = {},
pmid = {42717375},
issn = {1757-4749},
abstract = {BACKGROUND: The human microbiome, particularly the gut microbiome, plays a critical role in host immunity, metabolism, and barrier function. Emerging evidence suggests that persistent alterations in microbiome composition-termed dysbiosis-may contribute to the development and symptom persistence of Long COVID.<br><br>AIMS: To map the available literature on microbiome dysbiosis in relation to Long COVID, identify key microbial alterations, associated symptoms, and evaluate potential microbiome-targeted interventions.<br><br>MATERIALS AND METHODS: The scoping review followed Joanna Briggs Institute (JBI) methodological guidance and was reported according to PRISMA-ScR. A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Library databases was conducted for studies published from January 2000 to May 2025. Eligible studies included human subjects with a clinical diagnosis of Long COVID and microbiome-related outcomes. Data was charted using a standardized form and synthesized narratively and descriptively.<br><br>RESULTS: A total of 62 sources were included, most of which were narrative, conceptual, or descriptive in nature. The available literature most frequently discussed gut microbiome dysbiosis in relation to Long COVID, including reduced abundance of beneficial taxa such as Faecalibacterium prausnitzii and Bifidobacterium adolescentis, and increased abundance of opportunistic or pro-inflammatory taxa such as Ruminococcus gnavus and Clostridium innocuum. Reported or proposed associations involved fatigue, gastrointestinal symptoms, neuropsychiatric manifestations, and immune dysregulation. Evidence from respiratory and oral microbiomes was more limited. Microbiome-targeted interventions, including probiotics, prebiotics, synbiotics, diet, and fecal microbiota transplantation (FMT), were mainly proposed or discussed, with limited direct interventional evidence.<br><br>CONCLUSIONS: Current evidence suggests that microbiome alterations may be associated with Long COVID, but the available literature remains largely descriptive, observational, and hypothesis-generating. Further longitudinal and interventional studies are needed to clarify causality and determine whether microbiome-targeted strategies have therapeutic value.},
}
@article {pmid41770710,
year = {2026},
author = {Wang, Z and Li, X and Zhang, J},
title = {Research Progress of Sepsis Immunotherapy: A Bibliometric Analysis.},
journal = {Shock (Augusta, Ga.)},
volume = {66},
number = {4},
pages = {892-911},
doi = {10.1097/SHK.0000000000002826},
pmid = {41770710},
issn = {1540-0514},
mesh = {*Bibliometrics ; *Immunotherapy/methods ; Humans ; *Sepsis/therapy/immunology ; },
abstract = {BACKGROUND: Sepsis results in critical organ failure, considerable global mortality, and poses treatment obstacles. The primary issue with its pathophysiology is the improper functioning of the immune system in two phases: initially, there is excessive inflammation, followed by insufficient inflammation. This has generated interest in immunotherapy to restore the immune system to its normal state. This bibliometric analysis mapped the evolving research landscape of sepsis immunotherapy.<br><br>METHODS: Articles and reviews related to sepsis immunotherapy, published between January 1, 2000, and December 31, 2025, in the Web of Science Core Collection, were retrieved, and bibliometric visualization analysis was performed using tools such as VOSviewer, CiteSpace, Scimago Graphica, Charticulator, and the R package bibliometrix.<br><br>RESULTS: A bibliometric analysis of 768 papers (2000-2025) indicates that the domain of sepsis immunotherapy research is seeing rapid expansion and dynamism. The annual publication rate is increasing exponentially, from an average of 11.3 per year (2000-2015) to 69.4 per year (2021-2025), reaching a peak of 79 in 2024. The United States tops the list with 246 articles and an H-index of 55, while China ranks second with 174 publications but exhibits a significantly lower citation impact. The analysis of collaborative networks reveals that the United States serves as a global hub with strong connections to China and European nations, while the European clusters maintain significant interconnections as well. The evolution of keywords delineates four distinct research phases: 2000-2005: focus on anti-inflammatory strategies targeting pivotal mediators such as tumor necrosis factor and cytokines; 2006-2012: shift toward acknowledging clinical complexity and immunosuppression while broadening research at the cellular level; 2013-2018: 2019-2025: in the context of the coronavirus disease 2019 pandemic, a phase of integration and response to emerging challenges marked by diverse clinically oriented advancements in immunomodulation, diagnosis, and integrated management. Journals like Frontiers in Immunology published the most number of articles (58), while the 2016 Sepsis-3 Consensus by Singer et al. was the most cited reference, underscoring its considerable influence. Joint citation analysis revealed that the Global Burden Study 2020 and the Sepsis-3 Consensus by Rudd et al. were the pivotal publications with the highest citation counts and prevalence intensity, respectively, highlighting their significance as foundational sources of information.<br><br>CONCLUSIONS: This bibliometric analysis shows how quickly research on immunotherapy for sepsis is moving forward. It has gone from focusing on anti-inflammatory strategies to precision treatment methods based on biomarkers. The US is still the best at research results and influence, but the lack of coordination in international cooperation has made research move more slowly. Recent research domains, including immune checkpoint inhibitors and multiomics integration, suggest a progression towards personalized algorithms. To accomplish the best clinical results, the future focus must go beyond borders, strengthen translational research, and use drugs based on biomarkers.},
}
@article {pmid42612464,
year = {2026},
author = {Hermann, E and Krammer, F},
title = {The return of H1N1: Reemergence of the influenza virus A subtype H1N1 in 1977.},
journal = {Vaccine},
volume = {91},
number = {},
pages = {128963},
doi = {10.1016/j.vaccine.2026.128963},
pmid = {42612464},
issn = {1873-2518},
mesh = {*Influenza A Virus, H1N1 Subtype/isolation &amp; purification ; Humans ; *Influenza, Human/epidemiology/prevention &amp; control/virology/history ; History, 20th Century ; Influenza Vaccines/immunology/administration &amp; dosage ; United States/epidemiology ; *Disease Outbreaks ; *Pandemics ; *Communicable Diseases, Emerging/epidemiology/virology ; },
abstract = {Four major influenza pandemics and two notable outbreaks have been recorded since 1900. This paper discusses the history of the 1977 influenza virus A H1N1 outbreak and re-emergence, often referred to as the "Russian flu" or the "red flu". We describe the likely events leading to the outbreak, including a brief history of the 1976 H1N1 outbreak in a military base in the United States. We reconstruct the spread of the H1N1 virus across the globe in 1977-1978 and discuss the epidemiology of the outbreak. We describe the likely origins of this unusual outbreak mainly affecting young people, including opinions and evidence pointing towards an unnatural origin. Finally, we outline the vaccines developed and vaccination campaigns that were carried out to combat the outbreak.},
}
@article {pmid42713642,
year = {2026},
author = {Reed, SD and Russell, LB and Kim, DD and Bellows, BK and Hager, K and Wright, DR and Volpp, KG},
title = {Assessing Value of Behavioral Interventions: Designing Cost-Effectiveness Analyses for Food-Is-Medicine Interventions.},
journal = {Circulation. Population health and outcomes},
volume = {},
number = {},
pages = {e013570},
doi = {10.1161/CIRCOUTCOMES.126.013570},
pmid = {42713642},
issn = {3068-563X},
abstract = {Food-is-Medicine (FIM) interventions, including medically tailored meals, medically tailored groceries, and produce prescriptions, represent a promising approach to prevent, manage, and treat diet-related diseases. As the evidence base for FIM interventions expands through large-scale randomized trials, standardized value assessment frameworks will be essential to inform coverage and reimbursement decisions. Using FIM interventions as examples, this article provides guidance on economic evaluation methods, particularly cost-effectiveness analysis. We further discuss emerging methodological approaches in cost-effectiveness analysis for capturing broader nonhealth impacts of FIM interventions, such as productivity, spillover effects on others, and health equity. We offer methodological and reporting recommendations to improve comparability across economic evaluations of FIM interventions. Finally, we examine coverage challenges in the United States health system to underscore the importance of collaboration among providers, patients, researchers, and policymakers to generate rigorous, decision-relevant evidence on the value of FIM interventions.},
}
@article {pmid42714459,
year = {2026},
author = {Şöhret, T and Gürçayir, D},
title = {Burnout in a high-risk environment: A bibliometric analysis of worldwide burnout research in the operating room.},
journal = {Work (Reading, Mass.)},
volume = {},
number = {},
pages = {10519815261485999},
doi = {10.1177/10519815261485999},
pmid = {42714459},
issn = {1875-9270},
abstract = {BackgroundOperating rooms expose healthcare professionals to a high risk of burnout, yet the scientific literature on this topic has not been comprehensively analyzed from a bibliometric perspective.ObjectiveThis study aimed to conduct a bibliometric analysis of research on burnout in the operating room setting indexed in the Web of Science Core Collection to identify research trends, thematic focuses, and patterns of scientific production.MethodsA bibliometric analysis of Web of Science-indexed literature was conducted using the search terms ("operating room" OR "operating theatre") AND "burnout". A total of 290 English-language articles and reviews published up to January 2026 were analyzed using bibliometrix/biblioshiny in R to assess publication trends, authorship and collaboration patterns, leading countries and journals, and research themes.ResultsThe analyzed publications spanned from 1995 to 2026, with a marked increase after 2020, comprising 290 documents and an annual growth rate of 3.61%. The most frequent keywords were "burnout" (6.91%) and "operating room" (5.18%). Research articles accounted for most publications (84.14%), and the United States was the leading contributor (37.93%). Keyword co-occurrence and thematic analyses showed that burnout, operating room, nursing, patient safety, and teamwork were the principal research themes, whereas resilience and well-being represented specialized themes, and ergonomics and COVID-19 emerged as developing research topics.ConclusionsBurnout in the operating room has become an important research focus with implications for patient safety and care quality. This study highlights research gaps and informs future research and policy development.},
}
@article {pmid42715931,
year = {2026},
author = {Ouédraogo, AM and Laprise, C and Blair, DL and Richter, S and Ishola, F and Pollock, NJ and Tonmyr, L},
title = {Child maltreatment and harsh parenting in Canada during the COVID-19 pandemic: a scoping review of the epidemiological evidence, methodological and data gaps, and recommendations for strengthening public health data.},
journal = {Child abuse &amp; neglect},
volume = {181},
number = {},
pages = {108304},
doi = {10.1016/j.chiabu.2026.108304},
pmid = {42715931},
issn = {1873-7757},
abstract = {BACKGROUND: The COVID-19 pandemic caused widespread disruptions to social relationships and caregiving responsibilities, potentially modifying risks for child maltreatment (CM) and harsh parenting (HP). However, the impact of the pandemic on the epidemiology of CM and HP is unclear.<br><br>OBJECTIVE: The objectives of this scoping review were to summarize evidence on the epidemiology of CM and HP in Canada during the COVID-19 pandemic, assess the quality of the included evidence to support the interpretation of the findings, and synthesize published recommendations to strengthen data.<br><br>METHODS: We conducted a systematic search of five bibliographic databases and Statistics Canada's website for relevant Canadian studies published between January 1, 2020 and July 4, 2024. We summarized the findings with descriptive statistics and a narrative review, and assessed study quality using an adapted version of the Evidence-Based Social Services Critical Thinking Tool.<br><br>RESULTS: Twenty-seven studies were included; 81.5% reported on CM. Administrative data indicated fewer referrals to child protection services and hospital visits, but increases in police-reported family violence against children. The quality of studies was negatively impacted by non-representative samples, unstandardized measures, and limited use of pre-pandemic baseline data.<br><br>CONCLUSIONS: Due to the lack of reliable and continuous data about CM/HP, governments and researchers in Canada collaborated to improve data infrastructure and better understand the pandemic's impact on the health and wellbeing of children and youth. New data sources were developed to enhance the quality of CM/HP measures and support ongoing public health surveillance. Sustained collaboration among interest-holders and continued efforts to strengthen existing data are necessary to assess the pandemic's long-term effects and prepare to monitor the impacts of future public health emergencies.},
}
@article {pmid42716325,
year = {2026},
author = {Sakellaropoulos, SG and Spedicato, V and Pfister, O},
title = {Exercise Lactate in Post-COVID-19 Condition: Pathophysiological Signal, Phenotyping Tool, or Candidate Biomarker? A Narrative Review with a Hypothesis-Generating Clinical Observation.},
journal = {Current problems in cardiology},
volume = {},
number = {},
pages = {103453},
doi = {10.1016/j.cpcardiol.2026.103453},
pmid = {42716325},
issn = {1535-6280},
abstract = {Post-COVID-19 condition (PCC), commonly termed long COVID, is a heterogeneous multisystem disorder in which fatigue, exertional dyspnoea, post-exertional symptom exacerbation, and reduced exercise tolerance are prominent. No single laboratory measurement currently confirms or excludes PCC. Because lactate integrates glycolytic flux, pyruvate oxidation, muscle recruitment, oxygen delivery and extraction, adrenergic drive, and clearance by the liver and other tissues, exercise-associated lactate has attracted interest as a potential marker of impaired bioenergetics in PCC. This narrative review evaluates the physiological rationale and clinical evidence for lactate assessment at rest and during exercise in adults with PCC and places a descriptive observation from 22 patients assessed in our clinic into that context. Cardiopulmonary exercise testing studies demonstrate reduced peak oxygen uptake in many symptomatic individuals, although reported mechanisms include deconditioning, dysfunctional breathing, chronotropic incompetence, preload failure, impaired systemic oxygen extraction, autonomic dysfunction, and peripheral or mitochondrial abnormalities. Small mechanistic studies have reported higher exercise lactate, reduced calculated fat oxidation, altered skeletal-muscle metabolism, or more importantly impaired mitochondrial function. In our uncontrolled clinical series, mean arterial lactate increased from 1.23 ± 0.40 mmol/L at rest to 7.11 ± 2.98 mmol/L at peak exercise; the marked difference between testing protocols underscores the methodological dependence of peak values. Overall findings are heterogeneous, populations are selected, and lactate is strongly dependent on achieved work rate, exercise duration, phenotype, medications, nutritional state, and sampling time. Peak lactate alone therefore lacks the specificity, standardization, and validated thresholds required for diagnosis. Its most promising role is as one component of a standardized metabolic exercise phenotype, interpreted alongside work rate, oxygen uptake, ventilatory thresholds, respiratory exchange ratio, symptoms, and recovery kinetics. Controlled prospective studies are required before clinical implementation.},
}
@article {pmid41588895,
year = {2026},
author = {Deshpande, NA and Shaikh, SA and Khode, A},
title = {A Patent Review on the Use of Thymosin Peptides Against Viruses.},
journal = {Recent advances in anti-infective drug discovery},
volume = {21},
number = {2},
pages = {79-90},
doi = {10.2174/0127724344411797251205091136},
pmid = {41588895},
issn = {2772-4352},
mesh = {Humans ; *Thymosin/therapeutic use/pharmacology/administration &amp; dosage ; *Patents as Topic ; *Antiviral Agents/therapeutic use/pharmacology/administration &amp; dosage ; *COVID-19 Drug Treatment ; Animals ; *SARS-CoV-2/drug effects ; Peptides ; },
abstract = {Thymosins are a group of immunomodulatory peptides secreted by the thymus. They play an important role in immune function by inducing T-cell expression and inhibiting viral replication. In light of the COVID-19 pandemic caused by coronavirus, there has been renewed interest in their activity, resulting in a revival of patents claiming the use of thymosin to combat coronavirus. This article reviews patents on the therapeutic application of thymosin peptides against viruses. Conventionally, thymosin is administered via injection or infusion; however, recent research has explored alternative routes, including oral formulations. Thymosin administration is used to complement antiviral drug treatments. Similarly, recent antiviral regimens against SARS-CoV-2 may be supplemented with thymosin based on its proven immunopotentiating activity.},
}
@article {pmid42709284,
year = {2026},
author = {Grattoni, A and Paci, MM and Arnold, N and Aryal, S and Artzi, N and Bao, G and Barcena, AJR and Bentov-Arava, E and Blanco, E and Chua, CYX and Corradetti, B and Cryer, AM and Decuzzi, P and De Giorgi, M and Fell, C and Gao, W and Govindaswamy, B and Jiang, W and Kara, G and King, MR and Krishnan, S and Lagor, WR and Lammers, T and Larsen, J and Manfredi, F and Manickam, DS and Margulis, K and Melancon, MP and Meeuwissen, S and Miller, MA and Mitchell, MJ and Mitragotri, S and Mojiri, A and Cooke, JP and Palanki, R and Phukan, I and Sun, X and Stayton, PS and Tanifum, EA and Veiseh, O and Villapol, S and Wang, J and Williams, R and Arancibia, RY and Zhang, L and Kabanov, A and Godin, B},
title = {Nanomedicine beyond carriers - devices, cells &amp; living therapeutics.},
journal = {Biomedical microdevices},
volume = {28},
number = {3},
pages = {},
pmid = {42709284},
issn = {1572-8781},
mesh = {Humans ; *Nanomedicine/methods ; Animals ; Drug Carriers/chemistry ; Drug Delivery Systems ; Immunotherapy ; SARS-CoV-2 ; Nanoparticles/chemistry ; COVID-19 ; },
abstract = {Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox and today stands as a clinically validated enabling technology. Liposomal formulations and albumin-bound nanoparticles have transformed cancer therapy, while lipid nanoparticle (LNP) platforms accelerated the rapid development and global deployment of SARS-CoV-2 mRNA vaccines-demonstrating how nanoscale engineering can reshape therapeutic response, manufacturing speed, and public health impact. With these successes as foundation, the field is rapidly expanding into more sophisticated delivery systems including cell-hitchhiking nanoparticles, biomimetic multivalent vaccines, implantable immunotherapy depots, high-loading polymeric micelles, organ-targeted gene and RNA carriers, and bio-hybrid extracellular vesicle and mitochondrial therapies. These platforms aim not only to transport drugs, but to modulate immunity, direct regeneration, and enable precision intervention at the cellular and molecular scale. This perspective summarizes the current landscape of biomedical nanotechnologies and outlines how their continued evolution positions nanomedicine as an enabling science driving the next generation of therapeutics.},
}
@article {pmid42711057,
year = {2026},
author = {Pickering, A and Wise, PH and Maldonado, YB},
title = {Pediatric Vaccination and Pandemic Preparedness in Humanitarian Settings.},
journal = {Pediatric clinics of North America},
volume = {73},
number = {5},
pages = {953-964},
doi = {10.1016/j.pcl.2026.04.006},
pmid = {42711057},
issn = {1557-8240},
mesh = {Humans ; *Pandemic Preparedness ; *Pandemics/prevention &amp; control ; *COVID-19/epidemiology/prevention &amp; control ; *Vaccination ; Child ; Global Health ; SARS-CoV-2 ; },
abstract = {Disease outbreaks are increasing in frequency and complexity, disproportionately affecting children in humanitarian settings. Large numbers of zero-dose children live in conflict-affected contexts, heightening vulnerability to vaccine-preventable and emerging viral diseases. Effective pediatric vaccination and pandemic preparedness require integrated, context-adapted strategies encompassing community engagement, infodemic management, resilient delivery systems, service integration, and reliable surveillance. Innovations such as mobile teams, novel financing, and improved data coordination offer promise but require stronger evidence. Lessons from coronavirus disease of 2019 (COVID-19) underscore persistent inequities and the need for ethical, data-driven, and One Health-informed approaches to protect children's right to health and strengthen global health security.},
}
@article {pmid42711060,
year = {2026},
author = {Merrick, MT and Klika, JB},
title = {Child Abuse and Neglect Risk in Times of Crisis.},
journal = {Pediatric clinics of North America},
volume = {73},
number = {5},
pages = {997-1006},
doi = {10.1016/j.pcl.2026.04.009},
pmid = {42711060},
issn = {1557-8240},
mesh = {Humans ; *Child Abuse/prevention &amp; control/statistics &amp; numerical data ; Child ; Medical Neglect ; Risk Factors ; *Economic Recession ; *COVID-19/epidemiology ; },
abstract = {Child abuse and neglect impacts millions of children each year, and the many detrimental impacts on health, well-being, and the economy persist across the lifespan and intergenerationally. Risk and protective factors make child abuse and neglect more or less likely, but during humanitarian crises like economic downturns and health crises, the context and conditions are ripe for increased risk of perpetration and victimization. Prevention is possible when we take a public health approach, and every sector assures the conditions that bolster families, like concrete and economic supports, access to mental health services, and coordinated, aligned ecosystems.},
}
@article {pmid42711184,
year = {2026},
author = {Martín-Noguerol, T and Escartín, J and Vidal-Cameán, C and Díaz-Carreño, JR and López-Úbeda, P and Luna, A},
title = {Are Radiology Departments Ready for the Current Underlying Obesity Pandemic? A Narrative Review.},
journal = {Academic radiology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.acra.2026.08.109},
pmid = {42711184},
issn = {1878-4046},
abstract = {RATIONALE AND OBJECTIVES: The COVID-19 pandemic exposed critical vulnerabilities in healthcare systems, forcing radiology departments to rapidly adapt their infrastructure, workflows, and diagnostic practices. In contrast, obesity represents a chronic and growing global pandemic affecting more than one billion people worldwide. This review examines whether radiology departments are adequately prepared to meet the technical, operational, and safety challenges associated with imaging patients with obesity.<br><br>MATERIALS AND METHODS: A narrative review of the literature was conducted to evaluate the impact of obesity on diagnostic imaging and interventional radiology. Key topics included equipment limitations, image quality, radiation dose optimization, patient and staff safety, workflow efficiency, and procedural challenges.<br><br>RESULTS: Obesity affects virtually every stage of the radiological workflow. Technical limitations include gantry size restrictions, table weight limits, and difficulties in patient positioning. Increased tissue attenuation frequently requires higher radiation exposures and can reduce image quality through increased noise, photon starvation, truncation artifacts, and decreased contrast resolution. MRI examinations are further constrained by bore dimensions and specific absorption rate limits. In interventional radiology, obesity is associated with more challenging vascular access, longer procedure times, increased operator radiation exposure, and higher complication rates. Operationally, these patients often require extended appointment slots, specialized transfer equipment, and trained personnel, placing additional demands on departmental resources and potentially contributing to inequities in access to imaging services.<br><br>CONCLUSION: The obesity pandemic poses substantial technical, safety, diagnostic, and operational challenges for radiology departments. Addressing these issues requires investment in obesity-adapted equipment, optimized imaging protocols, specialized staff training, and workflow redesign to ensure safe, effective, and equitable imaging care for this rapidly expanding patient population.},
}
@article {pmid42711203,
year = {2026},
author = {Zeichner, EH and Familusi, OO and Flook, E and Scribano, P},
title = {Pediatric tele-behavioral health: history, evidence, barriers, and emerging directions.},
journal = {Current problems in pediatric and adolescent health care},
volume = {},
number = {},
pages = {101974},
doi = {10.1016/j.cppeds.2026.101974},
pmid = {42711203},
issn = {1538-3199},
abstract = {There has been an increasing prevalence of mental and behavioral health conditions in children and adolescents in the United States, which has been exacerbated by the COVID-19 pandemic. However, many youth struggle to access behavioral health care. Tele-behavioral health, the delivery of mental health services through videoconferencing and other digital technologies, has emerged as a strategy to facilitate access. There is broad evidence supporting clinical effectiveness of tele-behavioral health across multiple psychiatric and behavioral health conditions. Multiple established care models exist for the delivery of tele-behavioral health. Here, we discuss key facilitators and barriers to implementation of tele-behavioral health, with important considerations including clinical appropriateness, provider training, and organizational support, in addition to essential safety and confidentiality considerations in care delivery with children and adolescents. There are also health equity implications in the use of tele-behavioral health, which can potentially reduce disparities in access to behavioral health care. However, important considerations remain to ensure that telehealth use is accessible and does not exacerbate inequities. Finally, there are emerging directions in the field of tele-behavioral health, particularly in the integration of artificial intelligence (AI).},
}
@article {pmid42712262,
year = {2026},
author = {Hayes, AW and Marini, AM and Pressman, P},
title = {The New Battlefield: Food, Water, and the Evolution of Asymmetric Terror.},
journal = {International journal of toxicology},
volume = {},
number = {},
pages = {10915818261474825},
doi = {10.1177/10915818261474825},
pmid = {42712262},
issn = {1092-874X},
abstract = {This review examines the historical development of biological warfare from premodern contamination practices to twentieth-century state programs, post-9/11 bioterrorism, and the renewed prominence of biological risk in the COVID-19 era. Drawing on historical, policy, and public-health scholarship, it shows how disease came to be understood not only as a natural threat but also as a strategic instrument shaped by scientific knowledge, military organization, and administrative secrecy. The review traces the transition from empirical uses of contamination in siege warfare and colonial settings to laboratory-based weaponization in the 20th century, including German sabotage during the First World War, Imperial Japan's Unit 731, British anthrax trials on Gruinard Island, and the expansion of United States and Soviet biological warfare programs during the Cold War. It also evaluates the limits of international restraint through the 1925 Geneva Protocol and the 1972 Biological Weapons Convention, emphasizing the persistent problem of verification illustrated by the 1979 Sverdlovsk anthrax outbreak. The analysis then follows the shift from state arsenals to public fear through Aum Shinrikyo and the 2001 anthrax letters before situating epidemic and pandemic disease within the broader politics of biological vulnerability. COVID-19 and gain-of-function research are treated as cases of intensified scrutiny of biosafety, uncertainty, and public mistrust, rather than evidence for any single-origin hypothesis. The review concludes that biological warfare is best understood not solely as the deliberate use of pathogens but as a broader political and institutional phenomenon emerging where scientific capacity, strategic fear, concealment, and social vulnerability converge.},
}
@article {pmid42712409,
year = {2026},
author = {Mirza, KM and Rao, A and Baker, JA and Parker, RK and Quinonez, SC and Njenga, P and Saleh, M and Balis, UG and Waljee, AK and Sayed, S},
title = {Bridging the digital pathology divide: reciprocal learning between high-resource and low-resource settings.},
journal = {BMJ digital health &amp; AI},
volume = {2},
number = {1},
pages = {e000026},
pmid = {42712409},
issn = {3049-575X},
abstract = {Digital pathology (DP) represents a major advance in global health, integrating digital whole-slide imaging, telepathology and clinical-grade artificial intelligence into cohesive workflows that can improve diagnostic accuracy and educational access. Realising these gains, however, depends on local infrastructure, governance, reimbursement and workforce capacity. The COVID-19 pandemic accelerated DP uptake in some settings, but adoption remains highly uneven between high-resource settings (HRS) and low-resource settings (LRS), reflecting unequal infrastructure, workforce, policy and financing. This analysis contends that reciprocal innovation, a model of ongoing two-way learning between HRS and LRS that is distinct from one-way technology transfer, can accelerate DP adoption by leveraging the strengths of each environment. Drawing on examples from HRS and LRS, we examine use cases in education and clinical practice, the adoption barriers that persist and policy mechanisms required for sustainable scaling. While HRS contribute regulatory frameworks, validation standards and mentorship, LRS offer innovations in cost efficiency, workflow resilience and open-source adaptation that can inform more sustainable models globally. Neither HRS nor LRS are homogeneous entities. Resource availability also varies substantially within each category: HRS may contain poorly resourced institutions, while some institutions in LRS may have comparatively greater resources but still face broader system-level infrastructure constraints. Ensuring access to those in LRS requires targeted investment, harmonised standards and mutual learning across resource levels. DP has the potential to foster bidirectional partnerships to democratise access to timely, accurate and patient-centred pathology services across all resource settings.},
}
@article {pmid42713005,
year = {2026},
author = {Belaidi, AA and Furtado, DL and Alves, F and Nisbet, RM and Ayton, S and Bush, AI},
title = {Engineering mRNA-LNP Medicines for the Ageing Brain: Opportunities and Challenges for Neurodegenerative Diseases.},
journal = {Exploration (Beijing, China)},
volume = {},
number = {},
pages = {70223},
pmid = {42713005},
issn = {2766-2098},
abstract = {Messenger RNA (mRNA) therapeutics delivered by lipid nanoparticles (LNPs) have advanced from concept to clinic at unprecedented speed, yet their promise for neurodegenerative diseases remains largely untapped. Currently intractable age-related proteinopathies such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis demand new therapies that combine molecular precision with scalable manufacturing. This review surveys recent advances in engineering LNPs that traverse the blood-brain barrier (BBB), evade innate immune surveillance, and achieve cell-selective expression in the ageing brain. We highlight emerging chemistries, including BBB-shuttling ionizable lipids, peptide-functionalized shells, and liver-detargeted formulations that enable systemic or minimally invasive delivery to the central nervous system (CNS) in animal models. Although no CNS-directed mRNA-LNP has yet reached clinical trials, first-in-human studies for rare metabolic disorders demonstrate favourable safety, manufacturability, and durable protein replacement. Drawing lessons from COVID-19 mRNA vaccines and ongoing liver-targeted programmes, we outline a translational roadmap for brain applications. Major hurdles that are critically assessed include efficient endosomal escape in aged neurons, heterogeneity of the senescent BBB, chronic-dose immunogenicity, and large-scale synthesis of next-generation lipids. Finally, we propose design rules and analytical standards to address outstanding knowledge gaps in expression durability and age-related BBB alterations. Together, these insights chart a path for engineering mRNA-LNP therapeutics capable of meeting the rising burden of neurodegenerative diseases in an ageing global population.},
}
@article {pmid42713225,
year = {2026},
author = {Wu, H and Weng, R and Gu, S and Wang, J and Ma, X and Li, J and Tie, X and Huang, C and Chen, K},
title = {Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1916788},
pmid = {42713225},
issn = {1664-3224},
mesh = {Humans ; *Tumor Microenvironment/immunology ; *Lung Neoplasms/immunology/therapy ; *Cancer Vaccines/immunology/therapeutic use ; *mRNA Vaccines/immunology ; Animals ; Immunotherapy/methods ; Antigens, Neoplasm/immunology/genetics ; },
abstract = {Traditional treatments for lung cancer include surgery, radiotherapy, chemotherapy, and targeted therapies (such as Erlotinib, Gefitinib, and Crizotinib), as well as immunotherapy (such as Nivolumab and Pembrolizumab). However, these approaches face challenges such as drug resistance, limited efficacy, and significant side effects, making it difficult to improve long-term prognosis. Therefore, tumor vaccines, as a novel immunotherapy strategy, have become a focus of research, aiming to precisely activate anti-tumor immune responses and address the shortcomings of existing treatments. In recent years, mRNA vaccine technology has developed rapidly, especially following the successful application of COVID-19 vaccines, demonstrating its immense potential for rapid development and large-scale production. mRNA cancer vaccines induce durable anti-tumor immune responses and reshape the tumor microenvironment by delivering mRNA encoding tumor-specific antigens, enabling targeted therapy. Through the dual synergistic pathways of direct local modulation by the vector/encoded factors and secondary effects mediated by antigen-specific T-cell activation, the tumor microenvironment is reshaped, thereby inducing durable antitumor immune responses. Against this background, this review systematically evaluates the current status and prospects of mRNA vaccines in lung cancer treatment, with a focus on their progress in precisely modulating the tumor microenvironment, identifying novel tumor antigens, discovering immune biomarkers, and related clinical studies. Additionally, the review discusses the process optimization of lipid nanoparticle (LNP) delivery systems, aiming to provide theoretical support and practical guidance for the development of safe and effective therapeutic vaccine platforms for lung cancer.},
}
@article {pmid42274978,
year = {2026},
author = {Shadman, M and Munir, T and Xu, S and Yang, K and Mohseninejad, L and Guthrie, G and Hirata, J and Lefebure, M and Williams, R and Tam, CS},
title = {Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.},
journal = {Advances in therapy},
volume = {43},
number = {9},
pages = {4042-4059},
pmid = {42274978},
issn = {1865-8652},
mesh = {Aged ; Female ; Humans ; Male ; Middle Aged ; *Adenine/analogs &amp; derivatives/therapeutic use/analogs &amp; derivatives ; Antineoplastic Agents/therapeutic use ; *Benzamides/therapeutic use ; Follow-Up Studies ; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/mortality ; *Piperidines/therapeutic use ; *Pyrazines/therapeutic use ; Pyrazoles/therapeutic use ; *Pyrimidines/therapeutic use ; Clinical Trials, Phase III as Topic ; },
abstract = {INTRODUCTION: Zanubrutinib, acalabrutinib, and ibrutinib each demonstrated improved investigator-assessed progression-free survival (PFS-INV) and overall survival (OS) versus chemotherapy-based regimens in treatment-naive chronic lymphocytic leukemia (CLL) in the phase 3 trials SEQUOIA (NCT03336333), ELEVATE-TN (NCT02475681), and RESONATE-2 (NCT01722487), respectively. In the absence of head-to-head studies, this analysis compared the efficacy of zanubrutinib vs ibrutinib and vs acalabrutinib in treatment-naive CLL via indirect naive comparisons.<br><br>METHODS: Eligibility criteria were aligned to improve cross-trial comparability. The zanubrutinib vs ibrutinib comparison included COVID-19-adjusted PFS-INV and OS in arm A of SEQUOIA (n = 241; median follow-up, 73.4 months) and the ibrutinib arm of RESONATE-2 (n = 136; median follow-up, 88.5 months). The zanubrutinib vs acalabrutinib comparison included PFS-INV and OS in subgroups of patients without del(17p) and/or TP53 mutations from arm A of SEQUOIA (n = 215; median follow-up, 73.6 months) and the acalabrutinib arm of ELEVATE-TN (n = 156; median follow-up, 74.5 months).<br><br>RESULTS: Baseline characteristics were similar for each comparison. Zanubrutinib significantly prolonged PFS-INV (hazard ratio [HR], 0.65; 95% CI, 0.44-0.97; P = 0.0330) and showed a trend toward improved OS (HR, 0.60; 95% CI, 0.36-1.01; P = 0.0532) vs ibrutinib. At the 72-month landmark, PFS-INV and OS rates were significantly higher with zanubrutinib vs ibrutinib, with a risk difference of 15.3% (95% CI, 8.3-22.2%) for PFS and 9.9% (95% CI, 3.0-16.7%) for OS. Compared with acalabrutinib, zanubrutinib trended toward improved PFS-INV (HR, 0.76; 95% CI, 0.52-1.11; P = 0.1553) and OS (HR, 0.66; 95% CI, 0.41-1.06; P = 0.0836). The 72-month landmark PFS-INV and OS rates were significantly higher with zanubrutinib vs acalabrutinib, with a risk difference of 9.9% (95% CI, 3.0-16.9%) for PFS-INV and 8.8% (95% CI, 2.0-15.5%) for OS.<br><br>CONCLUSION: These findings inform the long-term comparative efficacy of Bruton tyrosine kinase inhibitors and suggest that zanubrutinib may confer sustained PFS and OS benefits compared with ibrutinib and acalabrutinib in similar treatment-naive CLL populations. Graphical abstract and video available for this article. Overview of the Comparative Efficacy of Covalent BTK Inhibitors in Treatment-Na&#xef;ve CLL/SLL With Six-Year Follow-Up (MP4 345006 kb).},
}
@article {pmid42351103,
year = {2026},
author = {De Vita, E and Arzilli, G and Gesualdo, F and Casigliani, V and Pasquale, M and Cruschelli, G and Tecchio, F and Tosi, F and Porretta, AD and Romersi, D and Buquicchio, C and Rizzo, C},
title = {Mapping risk communication practices in public health emergencies: a scoping review and comparison with Italian regional pandemic plans.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42351103},
issn = {1471-2458},
support = {CUP I57G22000460005//Ministero della Salute/ ; },
mesh = {Humans ; Italy/epidemiology ; *COVID-19/epidemiology/prevention &amp; control ; *Public Health ; *Emergencies ; *Communication ; Pandemic Preparedness ; *Pandemics ; *Disaster Planning ; },
abstract = {BACKGROUND: Effective risk communication is a cornerstone of public health emergency preparedness and response. The COVID-19 pandemic and other recent crises have highlighted both the centrality of communication in sustaining trust and compliance, and the persistent gap between theoretical frameworks and operational practice.<br><br>METHODS: Within the framework of the CreSP project (Comunicare il Rischio nelle Emergenze per la Sanit&#xe0; Pubblica), we conducted a scoping review to map international evidence on risk communication in public health emergencies, comparing it with Italian regional pandemic preparedness plans. Following PRISMA-ScR guidelines, we searched PubMed, Scopus, and Web of Science (1 January 2019-16 May 2024). Peer-reviewed studies addressing health risk communication in emergencies were included. In parallel, 18 Italian regional pandemic plans were identified and analysed using a structured checklist derived from inductive thematic analyses.<br><br>RESULTS: Of the 12,479 records identified, 173 studies were included. Most publications originated from high-income countries and focused on COVID-19 pandemic response. Mass communication strategies, especially via social media, predominated, while targeted and participatory approaches were less frequent. The emergency response phase was far more represented than the preparedness or post-emergency phases. Key principles such as timeliness, transparency, and trust were widely discussed across studies, whereas equity, citizen engagement, and infodemic management were less consistently operationalised. Analysis of Italian regional pandemic plans revealed substantial heterogeneity. Although communication was universally acknowledged as important, it was often framed as top-down information dissemination. Structured mechanisms for monitoring, evaluation, citizen participation, and infodemic management were inconsistently addressed.<br><br>CONCLUSIONS: Although the concept of emergency risk communication is well-developed, its implementation varies across different levels of governance. The misalignment between scientific evidence and institutional frameworks-particularly regarding inclusivity, participatory models, and infodemic management-underscores the need for a more integrated and standardised national approach. Incorporating communication into preparedness infrastructures, supported by measurable indicators and workforce capacity building, is essential to strengthen resilience, equity, and public trust in the event of future emergencies.},
}
@article {pmid42703345,
year = {2026},
author = {He, X and Xie, J and Yang, X and Zhou, Y},
title = {The effects of virtual reality interventions on depression and anxiety in older adults during and after the COVID-19 pandemic: A meta-analysis.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076261487229},
pmid = {42703345},
issn = {2055-2076},
abstract = {OBJECTIVES: This study aims to systematically evaluate, through a meta-analysis, the effects of Virtual Reality (VR) interventions on depression and anxiety levels among older adults during and after the COVID-19 pandemic, and to explore variations in the effectiveness of VR interventions under different conditions.<br><br>METHOD: Databases including PubMed, Embase, Web of Science, the Cochrane Library, CINAHL, PsycINFO, CNKI, and Wanfang Data were searched. Studies were screened according to predefined inclusion criteria, and data on study characteristics and intervention outcomes were extracted. The quality of the included studies was assessed using the appropriate risk of bias tools, and meta-analysis was performed using Review Manager (RevMan) version 5.4.1 and Comprehensive Meta-Analysis (CMA) software.<br><br>RESULTS: A total of 12 studies involving 724 older adults aged 60 years and above were included. Compared with control conditions, VR interventions significantly reduced symptoms of depression and anxiety among older adults. Exploratory subgroup analyses indicated that fully immersive VR was associated with a more pronounced pooled effect than semi- and low-immersive VR. Both shorter (<6 weeks) and longer (&#x2265;6 weeks) VR interventions were associated with significant improvements in anxiety and depressive symptoms, with no statistically significant difference between the duration subgroups.<br><br>CONCLUSION: During and after the COVID-19 pandemic, VR interventions may represent a promising complementary non-pharmacological approach for improving depressive and anxiety symptoms among older adults. Exploratory findings suggest that immersion level may contribute to variability in intervention effects; however, these findings should be interpreted cautiously given the limited available evidence. Further high-quality, large-sample randomized controlled trials (RCTs) are needed to clarify the potential influence of intervention characteristics on VR efficacy.},
}
@article {pmid42703559,
year = {2026},
author = {Li, S and Liu, Y and Liu, C},
title = {Global Research Landscape and Clinical Hotspots in COPD-OSA Overlap Syndrome: A Bibliometric and Visualization Analysis.},
journal = {International journal of chronic obstructive pulmonary disease},
volume = {21},
number = {},
pages = {636134},
pmid = {42703559},
issn = {1178-2005},
mesh = {*Bibliometrics ; *Pulmonary Disease, Chronic Obstructive/therapy/epidemiology/physiopathology/diagnosis ; Humans ; *Sleep Apnea, Obstructive/therapy/epidemiology/physiopathology/diagnosis ; *Biomedical Research/trends ; Syndrome ; },
abstract = {BACKGROUND: This study systematically depicts the global research landscape, knowledge base, and thematic evolution of chronic obstructive pulmonary disease combined with obstructive sleep apnea overlap syndrome (COPD-OSA overlap syndrome), providing a reference for subsequent research and clinical translation.<br><br>METHODS: Relevant literature published between 2000 and 2025 was retrieved from the Web of Science Core Collection, Scopus, and PubMed databases. Records from Web of Science and Scopus were merged and deduplicated to construct the primary bibliometric dataset, while PubMed was analyzed separately as a supplementary source for cross-database comparison using keywords and MeSH terms. Bibliometrix, VOSviewer, and CiteSpace were used to analyze research output, collaboration networks, core sources, co-citation structure, and research hotspots. A latent Dirichlet allocation (LDA) model was applied to identify latent topics and their temporal trends.<br><br>RESULTS: The primary dataset included 1239 publications, with an average annual growth rate of 20.62%; publication volume increased markedly after 2017. The United States, China, and Italy ranked highest in publication count, yet the overall international co-authorship rate was only 6.3%. The field's knowledge base centers on nocturnal hypoxemia, cardiovascular outcomes, acute exacerbations, and positive airway pressure therapy. The LDA model identified 10 latent topics, with two showing significant upward trends (COVID-19 with OSA; acute cardiovascular events and adipose tissue) and one showing a downward trend (anthropometry and lung function parameters). The 274 PubMed-included articles complemented cross-database comparisons and indicated growing attention to cognitive function, oxygen saturation, and digital screening.<br><br>CONCLUSION: Research on COPD-OSA overlap syndrome is shifting from describing disease coexistence toward complex multimorbidity, risk stratification, and individualized management. However, international collaboration and high-level clinical evidence remain insufficient. Future work should standardize case definitions, establish multicenter longitudinal cohorts, and conduct phenotype-based treatment studies.},
}
@article {pmid42704107,
year = {2026},
author = {Song, A and Jia, P and Luo, J and Pang, X and He, Y and Tang, YW},
title = {Machine learning-enabled wastewater-based surveillance for emerging pathogen detection and monitoring: current applications, challenges, and future prospects.},
journal = {Emerging microbes &amp; infections},
volume = {},
number = {},
pages = {2731499},
doi = {10.1080/22221751.2026.2731499},
pmid = {42704107},
issn = {2222-1751},
abstract = {AbstractWastewater-based surveillance (WBS) has become an important public-health tool for tracking community-level circulation of emerging and re-emerging pathogens, but wastewater measurements are not directly interpretable public-health indicators. Signals recovered from sewer systems are shaped by sampling variability, environmental and laboratory noise, population-dependent bias, and high-dimensional molecular complexity. Machine learning (ML) is increasingly used to extract predictive and decision-relevant information from these data, but the strength of the supporting evidence varies substantially. This narrative review examines how strongly current applications are supported by published evidence. Sources were identified through iterative searches of three literature-search sources updated to June 2026 and classified by role, analytical task, and strength of evidence. To keep the analytical scope consistent, we use a pragmatic four-layer classification: classical statistical models, conventional machine learning, deep learning, and hybrid or mechanistically informed approaches. Applications are reviewed across five analytical tasks: predictive modeling and forecasting, anomaly and fluctuation detection, data harmonization and normalization, high-dimensional interpretation, and integrated decision support. Among 35 sources reporting analytical or modeling work, 25 analyzed SARS-CoV-2 alone; demonstrated early-warning evidence came predominantly from L1 methods, and most target-task combinations remain prospective. Even within SARS-CoV-2 surveillance, reported performance was context-dependent. We examine the data-quality, methodological, and implementation barriers that limit broader application and validation. Future priorities include standardized and collaborative frameworks, multimodal data fusion, mechanistic and digital-twin modeling with explicit uncertainty assessment, and transparent and actionable analytics, with broader surveillance applications constrained by governance and public acceptability.},
}
@article {pmid42705167,
year = {2026},
author = {Ugwu, OP and Okon, MB and Ogenyi, FC and Ugwu, JN and Ugwu, CN},
title = {Digital twins and explainable AI across the vaccine life cycle: from mRNA manufacturing to thermostability, cold-chain logistics, and immunisation services.},
journal = {Vaccine},
volume = {92},
number = {},
pages = {129131},
doi = {10.1016/j.vaccine.2026.129131},
pmid = {42705167},
issn = {1873-2518},
abstract = {The COVID-19 era accelerated the deployment of mRNA vaccines while exposing persistent weaknesses in manufacturing, thermostability and cold-chain systems, particularly in low- and middle-income countries (LMICs). This narrative review, informed by an explicit search of PubMed, Web of Science, Scopus, IEEE Xplore and the ACM Digital Library (2019-2025), synthesises over 50 studies of digital twins (DTs) and explainable artificial intelligence (XAI) across the vaccine life cycle. The evidence indicates that DTs are progressing from static simulations to operational twins for plasmid-to-mRNA production, supporting virtual commissioning, rapid scale-up and real-time optimisation. In parallel, XAI-enabled approaches improve stability prediction, and artificial intelligence of things (AIoT) architectures strengthen cold-chain monitoring and route planning. At the service level, twins of mass vaccination centres and primary-care immunisation services can improve throughput and temperature management; however, current implementations are often siloed, weakly validated and rarely designed with equity considerations. Priorities for the field include integrated, multi-scale 'vaccine system twins', rigorous validation, effective human-AI collaboration and deployment strategies tailored to LMIC contexts.},
}
@article {pmid42706908,
year = {2026},
author = {Matoshi, H and Billings, J and Janse Van Rensburg, M and Tekin, S},
title = {Exploring the experiences, views, and needs of family members of emergency response workers: a systematic review and meta-synthesis.},
journal = {European journal of psychotraumatology},
volume = {17},
number = {1},
pages = {2713266},
doi = {10.1080/20008066.2026.2713266},
pmid = {42706908},
issn = {2000-8066},
mesh = {Humans ; *Family/psychology ; *Emergency Responders/psychology ; Paramedics ; Adaptation, Psychological ; Mental Health ; },
abstract = {Background: Emergency responders, including firefighters, police officers, and paramedics, face workplace challenges that may harm their well-being. They typically rely on family members for support, which may have damaging effects on the family system. While the experiences of emergency responders are well established, their families' subsequent struggles are less well explored.Objective: This review explores the experiences, views, and needs of family members, through determining the mental health and well-being issues that they face, and establishing ways in which family members could be supported.Method: We searched five databases (MEDLINE, Embase, PsychINFO, Scopus, and ProQuest) for qualitative papers exploring experiences of family members of emergency responders. Seventeen studies met the inclusion criteria, and data were meta-synthesized using thematic analysis.Results: Six themes and two subthemes were identified from the meta-synthesis. 'Experiences of emotional strain' reflected worry over safety and coping with volatile moods. 'Increased responsibilities' involved safeguarding emergency responders' well-being and managing household duties, at the expense of family members' own needs. Families felt 'devoted yet invisible', with sacrifices overlooked by both emergency responders and society. 'Impacts on the family dynamic' included relational detachment and frustration. 'Support for emergency responder families' from fellow emergency responder families was valued, but organizational support was limited. 'Media portrayal and societal perceptions' varied, as police families faced hostility, while firefighter and paramedic families garnered respect, particularly during the COVID-19 pandemic.Conclusions: This review highlights that family members play a central role in maintaining the well-being of emergency responders, yet simultaneously face hardships associated with their family member's work and feel undervalued despite their support. This lack of recognition extends to limited professional support. There is a critical need for targeted mental health interventions to support family members, alongside family support measures from emergency responder organizations to assist with the practical difficulties faced by families.},
}
@article {pmid42707764,
year = {2026},
author = {Mao, L and Wang, S and Bai, Y and Cheng, S and Gao, K and Chang, Y and Li, L and Guo, Y and Gao, M},
title = {IFITM3 at the viral fusion-pore checkpoint: membrane energetics and entry-route-dependent outcomes.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1928879},
pmid = {42707764},
issn = {1664-3224},
mesh = {*Virus Internalization ; Humans ; Animals ; *Membrane Proteins/metabolism/genetics ; *RNA-Binding Proteins/metabolism/genetics ; Influenza A virus/physiology ; Host-Pathogen Interactions ; },
abstract = {Interferon-induced transmembrane proteins (IFITMs) are small interferon-stimulated membrane proteins that can limit viral entry, but their effects depend on the virus, entry route, and experimental context. This Mini Review focuses on IFITM3 at the viral fusion-pore checkpoint, defined here as the transition at which hemifusion either proceeds to fusion-pore opening and viral-content release or stalls before productive entry. Work on influenza virus supports a model in which IFITM3 remodels late-endosomal membranes, prolongs or kinetically stabilizes hemifusion-like intermediates, and raises the activation-energy barrier to fusion-pore formation. Type I interferon signaling, host biological variation, IFITM3 polymorphisms, and post-translational regulation shape IFITM3 abundance and localization, whereas endolysosomal cholesterol homeostasis modifies the membrane environment encountered by incoming virions; whether altered sterol handling also changes IFITM3 turnover remains unresolved. The fusion-pore checkpoint is presented as a working model supported most directly by mechanistic studies of influenza A virus. Coronavirus studies and a Nipah virus entry model illustrate how IFITM phenotypes can shift among restriction, neutrality, and context-dependent support. We therefore interpret IFITM activity as an entry-route-dependent membrane phenotype and outline practical criteria for assigning these outcomes in viral entry studies.},
}
@article {pmid42707957,
year = {2026},
author = {Zhang, C and Zheng, Y and Jiang, C and Zhang, Y},
title = {Herbal medicines against avian infectious bronchitis virus: shared host-directed and multi-stage antiviral pathways.},
journal = {Frontiers in veterinary science},
volume = {13},
number = {},
pages = {1812050},
pmid = {42707957},
issn = {2297-1769},
abstract = {Avian infectious bronchitis virus (IBV) is a highly contagious and genetically diverse coronavirus that continues to pose a major threat to poultry production worldwide. Although vaccination remains the primary control strategy, the frequent emergence of viral variants and incomplete cross-protection among antigenically distinct strains necessitate complementary approaches for effective IBV management. Accumulating evidence suggests that traditional Chinese medicine (TCM) and herbal-derived compounds may provide protective benefits against IBV infection. Although certain herbal compounds directly target viral particles or life-cycle stages, many protective effects appear to involve host-directed regulatory mechanisms. Recurrent mechanisms include modulation of innate immune responses, particularly type I interferon signaling, together with regulation of inflammation, oxidative stress, apoptosis, autophagy, and stress-adaptive processes such as stress granule formation. In this narrative review, we searched PubMed, Web of Science, Scopus, Google Scholar, and major Chinese databases for studies related to IBV, herbal medicines, natural compounds, antiviral activity, and host-directed mechanisms. Direct IBV-specific evidence is available for only a subset of the interventions reviewed; findings from SARS-CoV, SARS-CoV-2, other non-IBV systems, and in silico analyses are treated as indirect and hypothesis-generating, and interventions supported solely by such findings are presented as candidates for IBV-specific validation rather than as established anti-IBV agents. We synthesize in vitro and in vivo evidence to identify recurrent host-response pathways and shared regulatory hubs, and propose a multi-target, multi-stage framework for the adjunctive use of herbal interventions in IBV control.},
}
@article {pmid41047691,
year = {2026},
author = {Agouridis, AP and Makris, A and Ellina, D and Vougiouklakis, G and Alexakis, K and Toulkeridis, G and Ierodiakonou, D and Tsioutis, C and Spernovasilis, N},
title = {Risk of Autoimmune Rheumatic Diseases following COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Current rheumatology reviews},
volume = {22},
number = {3},
pages = {1-10},
doi = {10.2174/0115733971382167250921213314},
pmid = {41047691},
issn = {1875-6360},
mesh = {Humans ; *Rheumatic Diseases/epidemiology/immunology ; *Autoimmune Diseases/epidemiology/immunology ; *COVID-19/complications/epidemiology ; Incidence ; Risk Factors ; },
abstract = {INTRODUCTION: Multiple cases of autoimmune rheumatic diseases following COVID-19 have been reported in the literature. This study aims to systematically determine whether COVID- 19 affects the incidence of autoimmune rheumatic diseases.<br><br>METHODS: We searched MEDLINE (PubMed), Global Index Medicus, and Cochrane Library databases up to March 30, 2024, for studies evaluating the incidence of systemic autoimmune diseases following SARS-CoV-2 infection in adult populations.<br><br>RESULTS: Eight cohort studies with 5,537,742 COVID-19 and 18,433,129 non-COVID-19 patients were included in our pooled analysis. The risk of developing mixed connective tissue disease and Beh&#xe7;et's disease in COVID-19 patients was increased by 168% (RR: 2.68, 95% CI (1.14 to 6.34), I&#xb2;=94%) and 101% (RR: 2.01, 95% CI (1.4 to 2.87), I&#xb2;=6%), respectively, compared to uninfected subjects. A 45% increase in the risk of both rheumatoid arthritis (RR: 1.45, 95% CI (1.02 to 2.06), I&#xb2;=99%) and psoriasis (RR: 1.45, 95% CI (1.10 to 1.92), I&#xb2;=98%) after SARS-CoV-2 infection was noted. The risk of dermatopolymyositis was 40% higher (RR: 1.40, 95% CI (1.10 to 1.79), I&#xb2;=68%) in the COVID-19 group. Non-significant increases in risk were observed in the pooled analysis for ankylosing spondylitis (RR: 1.39, 95% CI (0.94 to 2.05), I&#xb2;=93%), systemic lupus erythematosus (RR: 1.21, 95% CI (0.70 to 2.07), I&#xb2;=98%), systemic sclerosis (RR: 1.23, 95% CI (0.73 to 2.04), I&#xb2;=89%), Sj&#xf6;gren's syndrome (RR: 1.28, 95% CI (0.91 to 1.80), I&#xb2;=95%), and polymyalgia rheumatica (RR: 1.45, 95% CI (0.94 to 2.25), I&#xb2;=94%).<br><br>DISCUSSION: Since the onset of COVID-19, several cases of new-onset autoimmune rheumatic diseases following SARS-CoV-2 infection have been reported. To the best of our knowledge, this is the first systematic review and meta-analysis assessing the impact of COVID-19 on the risk of developing autoimmune rheumatic diseases. Overall, COVID-19 increases the risk of autoimmune rheumatic diseases, especially during the first year after infection.<br><br>CONCLUSION: COVID-19 is associated with an increased risk of several autoimmune rheumatic diseases, including mixed connective tissue disease, Beh&#xe7;et's disease, rheumatoid arthritis, psoriasis, and dermatopolymyositis. However, our results must be interpreted with caution due to high inter-study heterogeneity.},
}
@article {pmid42699167,
year = {2026},
author = {Garnier, N and Ossi, J and Marconi, VC and Schinazi, RF and Titanji, BK},
title = {Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1887876},
pmid = {42699167},
issn = {1664-3224},
support = {P30 AI050409/AI/NIAID NIH HHS/United States ; R01 AG085873/AG/NIA NIH HHS/United States ; R01 MH128158/MH/NIMH NIH HHS/United States ; R01 MH128872/MH/NIMH NIH HHS/United States ; },
mesh = {Humans ; *STAT Transcription Factors/metabolism/immunology/antagonists &amp; inhibitors ; Signal Transduction/drug effects/immunology ; *Janus Kinases/metabolism/immunology ; SARS-CoV-2 ; COVID-19/immunology ; *Janus Kinase Inhibitors/therapeutic use ; *Virus Diseases/drug therapy/immunology ; Immunomodulation/drug effects ; Animals ; Chronic Disease ; COVID-19 Drug Treatment ; Host-Directed Therapy ; *Coronavirus Infections/drug therapy/immunology ; Antiviral Agents/therapeutic use ; Azetidines/therapeutic use ; Purines ; Pyrazoles ; Sulfonamides ; },
abstract = {The discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway as a key regulator of immune function and inflammation led to the development of JAK inhibitors (JAK-i), several of which are now approved for autoimmune and chronic inflammatory conditions. Recently, JAK-i have been repurposed for infectious diseases, most notably with baricitinib, a United States Food and Drug Administration (FDA)-approved JAK1/2 inhibitor for individuals hospitalized for COVID-19, demonstrating a survival benefit by dampening cytokine-mediated hyperinflammation. This has generated increased interest in leveraging JAK-i for treating people with viral infections associated with chronic immune activation, inflammation or viral persistence. This review summarizes JAK/STAT signaling in viral infections characterized by latency or chronic sequelae. We explore how modulation of this pathway may alter immune responses, impact viral control, and mitigate the consequences of chronic inflammation. We also critically examine the therapeutic potential and limitations of JAK-i in these contexts. Finally, we outline key gaps in the field and propose future directions for research into JAK/STAT targeted immunomodulation in chronic viral infections.},
}
@article {pmid42699954,
year = {2026},
author = {Yadav, A and Singh, R and Sinha, P},
title = {Strengthening Tobacco Control during the COVID-19 Pandemic in India: A Secondary Policy Review and Analysis.},
journal = {Indian journal of community medicine : official publication of Indian Association of Preventive &amp; Social Medicine},
volume = {51},
number = {Suppl 4},
pages = {S612-S617},
pmid = {42699954},
issn = {0970-0218},
abstract = {India's response to the COVID-19 crisis involved invoking a combination of emergency and penal laws and regulations to prevent tobacco use, especially in public places to prevent transmission of COVID-19 in the country. This paper presents a review of the laws, policies, and administrative actions undertaken for strengthening and advancing tobacco control during the COVID-19 pandemic in India. All possible pre- and post-independence legislation were used to strengthen, advance, and implement effective tobacco control measures during the COVID-19 pandemic to prevent its transmission. Most restrictions were imposed under the Epidemic Diseases and Disaster Management Acts, in conjunction with laws under the penal code, food safety regulations, and tobacco control statutes. The restrictions were issued in the form of official orders and notifications, primarily aimed at prohibiting the use of tobacco products and spitting in public spaces. Advisories and orders were issued from the national level, the state governments, and district administration in taking these initiatives. Judicial decisions also supported this approach. More than 90% of the reviewed directives specified the type of tobacco products subject to restrictions, 85% cited COVID-19 as the rationale for these measures, and 90% designated enforcement authorities to ensure compliance with the directives. India's longstanding history of tobacco control legislation played a pivotal role in addressing tobacco use as a preventive strategy during the COVID-19 pandemic. The experience of India's pandemic response suggests that a judicious use of existing legislation may offer a pragmatic solution for effectively addressing public health emergencies.},
}
@article {pmid42700361,
year = {2026},
author = {Memariani, M and Memariani, H},
title = {Scorpion Peptides in Antiviral Drug Discovery: An In-depth Review.},
journal = {Probiotics and antimicrobial proteins},
volume = {},
number = {},
pages = {},
pmid = {42700361},
issn = {1867-1314},
abstract = {Despite remarkable progress in the fields of vaccinology and antiviral therapy, viral infections persist as a leading cause of morbidity and mortality worldwide. Therefore, it is crucial to identify new and effective antiviral drug candidates. Scorpion venoms are viewed as a rich source of structurally diverse and biologically active peptides, which may present opportunities for diagnostic, preventive, and therapeutic applications. This review intends to provide a contemporary and detailed analysis of scorpion-derived peptides, with a particular focus on their structural diversity, cytotoxic effects, antiviral properties, and mechanisms of action. Additionally, this paper highlights several potential fruitful areas for future studies. Current evidence indicates that scorpion-derived peptides are effective against a wide array of medically important viral pathogens such as chikungunya virus, dengue virus, enterovirus 71, hepatitis B virus (HBV), herpes simplex virus 1, human immunodeficiency virus 1, influenza A virus (IAV), severe acute respiratory syndrome coronavirus-2, and Zika virus. Nevertheless, the majority of these findings have been obtained from in vitro studies, whereas evidence from animal models remains limited and clinical evaluation in humans is currently unavailable. Available studies suggest that these peptides may act through diverse mechanisms of action, including direct virucidal activity, inhibition of viral entry, immune system modulation, reduction of virus-induced cytopathic effects, and suppression of viral gene expression. Emerging evidence also demonstrates the efficacy of certain scorpion-derived peptides in animal models of HBV, IAV, and Newcastle disease virus infection. Overall, such peptides appear to inaugurate new avenues for the treatment of viral infections.},
}
@article {pmid42700674,
year = {2026},
author = {Berikopoulou, MM and Giavasoglou, DK and Konstantopoulou, A and Gountas, I and Siahanidou, T and Michos, A},
title = {The epidemiology of respiratory syncytial virus (RSV) in hospitalized children in Europe before the widespread implementation of new RSV prophylactic strategies: A systematic review and meta-analysis.},
journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
volume = {186},
number = {},
pages = {105996},
doi = {10.1016/j.jcv.2026.105996},
pmid = {42700674},
issn = {1873-5967},
abstract = {Respiratory syncytial virus (RSV) is a leading cause of pediatric respiratory infections. This systematic review and meta-analysis aims to estimate the in-hospital positivity among children in Europe post-COVID-19 and prior to the implementation of the recent RSV prophylactic strategies. A systematic search was conducted across three databases: PubMed, Scopus and Web of Science from 01/01/2021-31/12/2025. Studies enrolling children aged 0-18 years who were hospitalized with respiratory infection and detected positive for RSV were eligible for inclusion. A random-effect model was applied and heterogeneity was assessed using I[2] statistics. Thirty-eight studies met the inclusion criteria, encompasing 66,065 children. The overall pooled RSV in-hospital positivity was 48% (95%CI: 41%-56%). Positivity estimates per year were: 53% (95%CI:49%-56%) for 2021-2022, 49% (95%CI:36%-62%) for 2022-2023, and 62% (95%CI:51%-73%) for 2023-2024 (p = 0.308). RSV positivity in studies with infants (<12-months-old) was 69% vs 30% in studies including older children (0-18 years). Among RSV-positive patients, co-infections were detected in 17%, respiratory support was required in 62% and ICU/NICU admission in 11%. RSV-B predominated over RSV-A during the study period. A substantial burden of RSV-related hospitalizations was detected, especially in infants < 12-months-old; however, the overall pooled positivity estimate should be interpreted with caution. These findings provide an important pre-immunization baseline for evaluating the impact of maternal RSV vaccination and monoclonal antibodies and support the need for continued RSV surveillance across Europe.},
}
@article {pmid42702237,
year = {2026},
author = {Stasi, C and Voller, F},
title = {Hepatitis C Virus Infection in Africa: Current Burden, Clinical Challenges, Gaps and Perspectives Toward Elimination.},
journal = {Clinics and research in hepatology and gastroenterology},
volume = {},
number = {},
pages = {102917},
doi = {10.1016/j.clinre.2026.102917},
pmid = {42702237},
issn = {2210-741X},
abstract = {One of the main objectives of the WHO is the elimination of viral hepatitis by 2030 (with targets of a 90% reduction in new infections and a 65% reduction in mortality). Globally, an estimated 50 million people are infected with HCV. Several reports demonstrate that the COVID-19 pandemic has reduced HCV diagnoses and treatments in most countries, with few countries on track to meet the 2030 HCV elimination targets, underscoring the need to scale up interventions to achieve viral hepatitis elimination. Based on these premises, this review evaluates the burden of HCV infection in Africa, disparities among population groups, and clinical outcomes observed over the past four years, based on a comprehensive search of the Scopus, Web of Science, PubMed, and African Index Medicus databases from 1 May 2022 to 1 May 2026. Recent studies are concentrated in a limited number of countries, while in many others, they appear to be confined to blood donors and specific clinical populations. The findings of clinical epidemiology studies show that chronic HCV infection continues to be a cause of liver-related morbidity and mortality in Africa, with notable differences across regions. A heavier disease burden appears in high‑risk groups, such as people with HIV infection, people who practice high‑risk sexual behaviours and people who inject drugs. These findings confirm the need to focus on interventions by policymakers and clinicians, including barrier reduction, screening, prevention, and linkage to care for at‑risk populations to reduce HCV transmission and its effects.},
}
@article {pmid42702352,
year = {2026},
author = {Łojko, P and Tomasikiewicz, A},
title = {Red blood cell-directed immune responses in COVID-19: Mechanisms, clinical evidence and implications for transfusion medicine.},
journal = {Transfusion medicine (Oxford, England)},
volume = {},
number = {},
pages = {},
doi = {10.1111/tme.70114},
pmid = {42702352},
issn = {1365-3148},
abstract = {SARS-CoV-2 infection is associated with a broad spectrum of red blood cell (RBC)-directed immune responses, ranging from isolated direct antiglobulin test (DAT) positivity to autoimmune hemolytic anemia (AIHA) and transfusion-related diagnostic challenges. This narrative review integrates current evidence on the mechanisms underlying these abnormalities, their clinical manifestations, and their implications for transfusion medicine. Molecular mimicry, bystander B-cell activation, complement dysregulation, oxidative membrane injury, and structural erythrocyte remodeling appear to represent interconnected mechanisms promoting immune recognition and altered function of RBCs. DAT positivity is frequently observed in hospitalized patients with COVID-19, often in the absence of clinically significant hemolysis, emphasizing that a positive DAT should not be considered synonymous with AIHA. Autoantibodies, complement deposition, and occasional alloimmune responses may complicate antibody identification, compatibility testing, and selection of appropriate blood components. Available evidence remains limited by heterogeneous study designs and the predominance of observational studies and case reports. Recognition of RBC-directed immune responses as part of COVID-19-associated immune dysregulation may improve interpretation of immunohematological findings, facilitate appropriate transfusion support, and help distinguish clinically significant immune hemolysis from isolated serological abnormalities.},
}
@article {pmid42703182,
year = {2026},
author = {Mansour, MA and Wahid, M and El Molla, MAS and Helmy, MH and Adel, TM and Mostafa, HN},
title = {Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update).},
journal = {Mycoses},
volume = {69},
number = {9},
pages = {e70214},
pmid = {42703182},
issn = {1439-0507},
mesh = {Humans ; *Antifungal Agents/therapeutic use/pharmacokinetics ; *Neuroaspergillosis/diagnosis/drug therapy ; Voriconazole/therapeutic use ; *Central Nervous System Fungal Infections/diagnosis/drug therapy ; },
abstract = {BACKGROUND: Central nervous system (CNS) aspergillosis is a life-threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics.<br><br>OBJECTIVE: This comprehensive review aims to synthesize pivotal advances in the management of CNS aspergillosis from 2020 to 2026 and to provide a multidisciplinary framework for addressing these ongoing challenges.<br><br>METHODS: We conducted a comprehensive evaluation of the latest clinical data, pharmacokinetic studies, and expert recommendations from the specified period. The review critically appraises evidence on pharmacological therapies, diagnostic technologies, and adjunctive treatment strategies.<br><br>FINDINGS: Key findings include: Pharmacotherapy: Voriconazole remains the cornerstone of therapy due to its superior CNS penetration (CSF:Plasma ratio ~50%). The roles of alternatives like isavuconazole, salvage combination regimens, and novel agents (e.g., olorofim, fosmanogepix) are evolving.<br><br>DIAGNOSTICS: Cutting-edge tools such as AI-assisted imaging, metagenomic next-generation sequencing (mNGS), and MR spectroscopy for trehalose detection show significant potential for enabling earlier and more accurate diagnosis. Adjunctive Strategies: Neurosurgical intervention, immunomodulation, and therapeutic drug monitoring (TDM) are critical for optimizing outcomes. Emerging strategies like nanoparticle-based drug delivery and host-directed therapies (e.g., PD-1/PD-L1 blockade) offer promising avenues to overcome the blood-brain barrier.<br><br>CONCLUSION: This review integrates the latest evidence to provide a timely and actionable resource for clinicians. It bridges gaps in existing guidelines by offering a multidisciplinary approach that addresses the complex management of CNS aspergillosis, with particular relevance for high-risk populations such as COVID-19 and immunocompromised patients.},
}
@article {pmid38902143,
year = {2026},
author = {Altan, E and Barmak, E and Tatar, E&#xc7; and Saylam, G and Korkmaz, MH},
title = {Which Mask, N95 or Surgical Mask, Causes Hoarseness in Healthcare Workers?.},
journal = {Journal of voice : official journal of the Voice Foundation},
volume = {40},
number = {5},
pages = {1531.e1-1531.e7},
doi = {10.1016/j.jvoice.2024.05.003},
pmid = {38902143},
issn = {1873-4588},
mesh = {Humans ; *Voice Quality ; Adult ; Female ; Male ; *Hoarseness/etiology/diagnosis/physiopathology ; *N95 Respirators/adverse effects ; Time Factors ; Middle Aged ; Laryngoscopy ; Speech Acoustics ; *Laryngeal Masks/adverse effects ; *COVID-19/prevention &amp; control/transmission ; *Health Personnel ; *Occupational Diseases/etiology/diagnosis/physiopathology ; *Masks/adverse effects ; *Occupational Health ; Equipment Design ; Risk Factors ; Phonation ; },
abstract = {OBJECTIVES: This study aimed to determine the impact of different types of masks on the voices of healthcare professionals who had to wear masks for an extended amount of time during the pandemic period and had a healthy voice.<br><br>METHODS: Our research included 41 healthcare workers. The participants were separated into two groups: surgical (n&#xa0;=&#xa0;21) and N95 mask users (n&#xa0;=&#xa0;20). Healthcare workers evaluated masks before and after wearing them for at least 8&#xa0;hours throughout the workday. All subjects had a videolaryngoscopic examination; the Voice Handicap Index-10 (VHI-10), GRBAS, acoustic voice analysis (F0, jitter%, shimmer%, noise/harmonic ratio, relative average perturbation [RAP]), aerodynamic measures (maximum phonation time, MPT), and blood oxygen saturation were evaluated.<br><br>RESULTS: Although both groups' VHI-10 scores increased after using the mask, this rise was not statistically significant in our research. According to the GRBAS classification, voice quality deterioration was identified in 9.6% (mild-moderate) of the group using surgical masks and 15% (mild) of the group wearing N95. Only the jitter and RAP values of individuals wearing both surgical and N95 masks were determined to be statistically significant. There was no significant change in MPT following mask wear in either group. Both the surgical and N95 mask-using groups showed a substantial drop in blood oxygen saturation before and after mask usage.<br><br>CONCLUSION: There was no change in voice quality between healthcare workers wearing surgical and N95 masks. It has been noticed that voice perception and quality are affected by the mask's barrier effect rather than the kind of mask.},
}
@article {pmid41843047,
year = {2026},
author = {Walter, M and Adorjan, K and Bajbouj, M and Deckert, J and Köhler, S and Lieb, K and Priller, J and Schillig, C and Schomburg, AK and Schomerus, G and Schouler-Ocak, M and Meyer-Lindenberg, A},
title = {[The importance of psychiatry in the care and research of Post-COVID].},
journal = {Der Nervenarzt},
volume = {97},
number = {5},
pages = {479-484},
pmid = {41843047},
issn = {1433-0407},
mesh = {Humans ; *COVID-19/psychology/therapy/complications/diagnosis ; *Mental Disorders/therapy/diagnosis/psychology ; Post-Acute COVID-19 Syndrome ; *Psychiatry ; *Biomedical Research ; },
}
@article {pmid42202908,
year = {2026},
author = {Lang, A and Grammatikos, A and Ballow, M and Otani, I and Barmettler, S},
title = {Risk Factors for Secondary Immunodeficiency in the Aged.},
journal = {The journal of allergy and clinical immunology. In practice},
volume = {14},
number = {9},
pages = {2000-2009},
pmid = {42202908},
issn = {2213-2201},
support = {K23 AI163350/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; Risk Factors ; *Immunologic Deficiency Syndromes/immunology/epidemiology/etiology ; Immunosenescence ; Malnutrition/immunology/epidemiology ; *Aging/immunology ; SARS-CoV-2 ; COVID-19/immunology ; Immunosuppressive Agents/therapeutic use ; Vaccination ; },
abstract = {Secondary immune deficiencies, in which the immune system is weakened or compromised by another factor, have become prevalent. Secondary immune deficiencies are particularly pertinent in aged people because numerous etiologies cause immune dysfunction in this population. Immunosenescence is characterized by inflammaging, cellular senescence, thymic involution, reduced naive T- and B-cell output, restricted antigen receptor diversity, and impaired innate immune cell function, leading to increased susceptibility to infection and diminished vaccine responsiveness. Malnutrition is common in aged people and exacerbates immune dysfunction through impaired cell-mediated immunity, micronutrient deficiencies, and weakened mucosal barriers. Immunosuppressive therapies are also frequently used in older adults, such as corticosteroids, cytotoxic agents, purine analogs, and biologics. Other comorbidities such as chronic kidney and liver disease, diabetes, cardiovascular disease, chronic lung disease, and persistent viral infections also contribute to immune dysregulation. Given these cumulative risks, vaccination remains a cornerstone of prevention. Updated immunization strategies targeting COVID-19, influenza, respiratory syncytial virus, herpes zoster, and pneumococcal disease are critical to reducing morbidity and mortality in this vulnerable population.},
}
@article {pmid42418812,
year = {2026},
author = {Tse, WC and Ajluni, T and Chene, C and Leach, D and Leech, M},
title = {Safeguarding medical empathy and cultivating compassion in contemporary medicine.},
journal = {Internal medicine journal},
volume = {56},
number = {9},
pages = {1660-1663},
doi = {10.1111/imj.70484},
pmid = {42418812},
issn = {1445-5994},
mesh = {Humans ; *Empathy ; *COVID-19/psychology/epidemiology ; Burnout, Professional/prevention &amp; control/psychology ; *Students, Medical/psychology ; *Education, Medical ; Physician-Patient Relations ; Compassion Fatigue/prevention &amp; control ; },
abstract = {Empathy and compassion are both fundamental to patient-centred care, enhancing satisfaction, adherence and outcomes while improving clinician well-being. However, certain aspects of medical culture may put these emotional qualities at risk. The preclinical-to-clinical transition exposes students to hierarchical structures, time constraints and performance expectations prioritising technical competence over interpersonal skills. Negative role modelling, rushed consultations and inadequate emotional support normalise emotional detachment. The COVID-19 pandemic intensified burnout and moral injury, while societal desensitisation through social media compounds these effects. Although medical humanities programmes show promise, meaningful change requires addressing both curricula and clinical environments through structured reflection, compassion-focused training and recognising empathy fatigue as an occupational hazard, reaffirming medicine's ethical foundations.},
}
@article {pmid42556209,
year = {2026},
author = {Sehouli, J and Bookman, MA and Harter, P and Oza, A and Brand, A and Fidalgo, JA and Sur, DB and Lee, MM and Louwen, F and Zeimet, A and Mukhopadhyay, A and O'Donnell, J and Pothuri, B and , },
title = {Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting.},
journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
volume = {36},
number = {9},
pages = {104830},
doi = {10.1016/j.ijgc.2026.104830},
pmid = {42556209},
issn = {1525-1438},
mesh = {Humans ; Female ; *Genital Neoplasms, Female/therapy/ethnology ; *Clinical Trials as Topic/standards ; Workforce Diversity ; Diversity, Equity, Inclusion ; Gynecology/standards ; },
abstract = {OBJECTIVE: Under-representation of key population groups limits the generalizability, applicability, and equity of evidence generated by gynecologic oncology trials. Building on the Gynecologic Cancer InterGroup Barcelona consensus, this initiative aimed to translate the principles of diversity into a structured, practice-oriented Code of Conduct spanning all phases of clinical research.<br><br>METHODS: As the third step in an iterative Gynecologic Cancer InterGroup consensus process, a Code of Conduct was developed and formally adopted at the Gynecologic Cancer InterGroup Berlin Meeting. All 33 Gynecologic Cancer InterGroup member groups appointed delegates. Preparatory work included a comprehensive literature review, structured meetings of an interdisciplinary scientific committee, and the NOGGO-GCIG-IDEA survey on equity, diversity, and inclusion. A plenary session included individuals with lived experience, clinicians, and researchers from multiple continents. Statements were drafted in focused working groups and refined to consensus.<br><br>RESULTS: The resulting Code of Conduct provides actionable guidance across 12 domains: transparent inclusion criteria; standardized data collection, analysis, and reporting; ethnicity considerations; patient-centered communication and consent; reducing the burden of participation; ethics and scientific integrity; data and biospecimen sharing; governance, accountability, and oversight; global collaboration and capacity building; post-trial responsibilities; authorship, acknowledgment, and dissemination; and implementation and continuous improvement. Harmonized collection of diversity variables is recommended to enable international comparison.<br><br>CONCLUSION: Diversity is a prerequisite for scientific validity and clinical relevance rather than an optional consideration. By embedding diversity into every phase of research, the Gynecologic Cancer InterGroup Code of Conduct provides a framework to generate robust, generalizable, and inclusive evidence for the global gynecologic oncology community. The Code is endorsed by the European Society of Gynaecological Oncology and the International Federation of Gynecology and Obstetrics and will be reviewed biennially.},
}
@article {pmid42692313,
year = {2026},
author = {Coelho, FDA and Morgan, R and Campos, LC},
title = {Pharmaceuticals and illicit drugs in environmental waters: A systematic review and quantitative analysis of global trends 2004-2021. Part 1.},
journal = {Environmental toxicology and pharmacology},
volume = {127},
number = {},
pages = {105163},
doi = {10.1016/j.etap.2026.105163},
pmid = {42692313},
issn = {1872-7077},
abstract = {Pharmaceuticals and illicit drugs are increasingly recognised as hazardous environmental contaminants, yet global-scale temporal analyses remain limited. This systematic review and quantitative analysis of research published between 2008 and 2021, examines the occurrence of substances across wastewaters and impacted surface waters across six continents and whether temporal patterns coincided with anthropogenic activities and major global events. Significant temporal variations were observed, particularly in Europe and Asia, with notably fluctuations in antibiotics, anti-inflammatories, cardiovascular system medications, cocaine and derivatives, painkillers, and anti-depressants and psychiatric drugs. Higher concentrations of anti-depressants and cardiovascular medications occurred during periods associated with the 2008 Global Financial Crisis, whilst increases in antibiotics and anti-depressants coincided with the SARS-CoV-2 pandemic period. These findings highlight associations between environmental substance occurrence and periods of socioeconomic and public-health disruption and support continuous, geographically inclusive monitoring to improve understanding of long-term temporal patterns.},
}
@article {pmid42693283,
year = {2026},
author = {Kapetanovic, MC},
title = {Vaccination considerations in autoimmune rheumatic diseases.},
journal = {Nature reviews. Rheumatology},
volume = {},
number = {},
pages = {},
pmid = {42693283},
issn = {1759-4804},
abstract = {Patients with autoimmune rheumatic diseases (ARDs) are at increased risk of numerous vaccine-preventable infections owing to a combination of disease-related immune dysregulation, immunosuppressive therapies - including glucocorticoids - and comorbidities. Age-related immunosenescence further increases this susceptibility in older patients. The SARS-CoV-2 (COVID-19) pandemic and measles outbreaks have underscored the importance of optimizing vaccination strategies and improving adherence to recommendations. Nevertheless, coverage for routinely recommended vaccines, including influenza and pneumococcal vaccines, remains suboptimal in this population. Vaccine hesitancy is an important barrier driven by concerns regarding safety, tolerability, disease flares and the potential induction of new autoimmune phenomena. Advanced therapies - including B cell-depleting agents, chimeric antigen receptor T cell therapy and bispecific T cell engagers - can substantially impair vaccine-induced immune responses, highlighting the importance of optimizing vaccination timing in relation to treatment. Although most studies focus on humoral and cellular immune responses, evidence on the long-term durability of vaccine-induced immunity, the need for booster doses and real-world vaccine effectiveness in patients with ARDs remains limited. Ethical considerations are important. Although vaccination in adults is generally not mandatory, improving vaccine uptake reduces the burden of infections in patients with ARDs, contributes to herd immunity and provides indirect protection for other vulnerable populations.},
}
@article {pmid42696051,
year = {2026},
author = {Kajal, and Pandey, A and Yadav, R and Shukla, R and Mishra, S},
title = {PTBP1 at the host-virus interface: mechanistic roles in viral RNA translation, replication, and immune modulation.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {42696051},
issn = {1573-4978},
mesh = {*Polypyrimidine Tract-Binding Protein/metabolism/genetics ; Humans ; *RNA, Viral/genetics/metabolism ; *Virus Replication/genetics ; *Heterogeneous-Nuclear Ribonucleoproteins/metabolism/genetics ; *Host-Pathogen Interactions ; Animals ; Protein Biosynthesis ; Immunity, Innate ; RNA-Binding Proteins/metabolism ; Immunomodulation ; RNA Stability ; },
abstract = {Viruses require the involvement of host RNA binding proteins for completion of important steps of their life cycle. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein found ubiquitously which performs important regulatory functions like alternative splicing, RNA stability, RNA localization, and translation by virtue of its four RRMs and shuttling between nucleus and cytoplasm. There is increasing evidence showing that many viruses make use of such regulatory roles of PTBP1 to facilitate their gene expression and replication. This review describes the existing mechanistic knowledge about the PTBP1 functions during viral infection, paying attention to the role of PTBP1 in viral RNA translation, viral RNA genome replication, and regulation of host antiviral response. Special attention is paid to the regulation by PTBP1 of IRES-dependent translation of enteroviruses and hepatitis C virus, as well as to the PTBP1 contribution to RNA stabilization, long-distance RNA interactions, and genome cyclization of flaviviruses such as dengue virus and Japanese encephalitis virus. Recent data on the PTBP1 function in coronavirus RNA metabolism are discussed as well. Furthermore, the role of PTBP1 in being both proviral and antiviral is reviewed in terms of innate immunity signalling pathways, stress granule biology, and virus-host interaction. Finally, we will explore the possibility of PTBP1 being used as a host-directed antiviral drug target despite the hurdles in doing so considering its multifunctionality as an essential cellular RNA-binding protein.},
}
@article {pmid42698821,
year = {2026},
author = {Jia, Y and Chen, Y and Liao, J and Qu, F and Lu, Y and Niu, C and Chen, F},
title = {Immune-endothelial-coagulation crosstalk as a driver of multi-organ dysfunction in severe viral pneumonia.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1878054},
pmid = {42698821},
issn = {1664-3224},
mesh = {Humans ; *Multiple Organ Failure/immunology/etiology ; *Blood Coagulation/immunology ; Animals ; *Pneumonia, Viral/immunology/blood ; *Endothelium, Vascular/immunology ; SARS-CoV-2 ; Lung/immunology ; },
abstract = {Viral burden or pathogen identity alone cannot adequately explain the progression of severe viral pneumonia from a compartmentalized respiratory infection to acute respiratory distress syndrome, multi-organ failure, and death. Maladaptive immunity, endothelial damage, and coagulation dysregulation are all functionally integrated in a host-driven pathological mechanism that mediates disease escalation. Systemic microvascular damage and pulmonary inflammation are linked by immune-endothelial-coagulation interaction. This review investigates the ways in which immunothrombosis and microcirculatory dysfunction are propagated by defective antiviral immunity, alveolar-capillary barrier failure, damage-associated molecular pattern and neutrophil extracellular trap release, endothelial glycocalyx degradation, complement-platelet interactions, coagulation cascade activation, and impaired fibrinolysis. Lung-derived inflammatory signals cause endothelial activation and procoagulant reprogramming in distal organs following systemic dissemination, resulting in organ-specific phenotypes such as acute kidney injury, secondary myocardial injury, ARDS in the lung, neurovascular unit dysfunction, and barrier-disruption-associated inflammatory amplification along the liver-gut axis. This framework may provide a rationale for exploring stage-adapted and phenotype-guided approaches to severe viral pneumonia, including early antiviral therapy, immunomodulation during disease progression, endothelial-coagulation axis targeting, and host-directed strategies. Further longitudinal cohorts, multi-omics analyses, mechanism-based stratification studies, and mechanism-embedded clinical trials will be needed to determine whether immune-endothelial-coagulation coupling can be translated from a mechanistic model into a clinically actionable framework for precision intervention.},
}
@article {pmid42691821,
year = {2026},
author = {Dudley, MZ and Ali, H and Villaescusa, MR and Law, B},
title = {Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review.},
journal = {Vaccine},
volume = {92},
number = {},
pages = {129120},
doi = {10.1016/j.vaccine.2026.129120},
pmid = {42691821},
issn = {1873-2518},
abstract = {BACKGROUND: The Brighton Collaboration published its standard harmonized case definition for thrombocytopenia in 2007 to facilitate collection of valid and reproducible vaccine safety evidence and enable valid comparisons across studies. A companion guide to this case definition (including background incidence, risk factors, evidence for or against an association with vaccination, medical codes, data collection forms, and algorithms to support level of diagnostic certainty assessment) was initially published in 2021 and updated in 2025 based on a formal scoping review. This article reports the results of this scoping review, summarizing current evidence regarding the background incidence of and risk factors for thrombocytopenia, including immune thrombocytopenia (ITP) and its potential association with vaccination.<br><br>METHODS: Two PubMed searches were conducted in July 2024: one for background incidence and non-vaccine risk factors, and one for vaccine associations. Search results were screened and relevant data were extracted and added to the corresponding companion guide tables.<br><br>FINDINGS: Twenty-two articles contributed to the updated summary of background incidence, 36 articles contributed to the updated summary of non-vaccine risk factors, and 93 articles contributed to the updated summary of vaccine associations. Estimates of the background incidence of thrombocytopenia range between 1.6 and 92.1 per 100,000 person-years, depending on the study, region, and age range. Non-vaccine risk factors for thrombocytopenia include age, sex, genetics, season, geography, comorbidities, iatrogenesis, infection, medication, and food. While studies have consistently found an increased risk of ITP with measles-containing vaccines, and multiple studies found an increased risk following adenoviral COVID-19 vaccination, studies of other vaccines (including mRNA and inactivated COVID-19 vaccines) have largely found no association.<br><br>CONCLUSION: Though rare, thrombocytopenia has many risk factors, including vaccination against measles. This review should be useful to stakeholders attempting to assess the occurrence of thrombocytopenia across a variety of settings, including as an adverse event following immunization.},
}
@article {pmid42692089,
year = {2026},
author = {Cossarizza, A and Poli, G and Clerici, M},
title = {The Silent Infection Load: How Lifelong Asymptomatic Infections May Contribute to Inflammaging as an Evolutionary Trade-off of Longevity.},
journal = {Ageing research reviews},
volume = {},
number = {},
pages = {103340},
doi = {10.1016/j.arr.2026.103340},
pmid = {42692089},
issn = {1872-9649},
abstract = {Asymptomatic infections are traditionally considered harmless, reflecting effective immune control and the absence of clinical disease. Yet growing evidence shows that these silent encounters with microbes are far from being immunologically neutral. Throughout life, humans are challenged by a remarkably broad spectrum of viruses and bacteria, including latent pathogens that persist, fluctuate, or periodically reactivate without producing significant symptoms. From an evolutionary standpoint, this represents a fundamental trade-off. Long-lived hosts benefit from maintaining diverse commensal, latent, and low-grade persistent microbes that enhance immune readiness, promote cross-protective immunity, and reduce vulnerability to severe infections. However, this adaptive advantage is counterbalanced by the continuous burden of chronic, almost undetectable immune activation and inflammation, and by the energetic cost of sustaining such mechanisms of surveillance. In this regard, retroviral integrations provide a striking illustration of how persistent viral presence has shaped the evolution of complex organisms by introducing new regulatory elements, immune modulators, and developmental programs. These ancient viral imprints demonstrate that clinically-silent host-microbe interactions can exert long-term selective pressures and influence species-specific biological trajectories. At the individual level, repeated asymptomatic infections trigger transient waves of immune activation, endothelial perturbation, mitochondrial stress, and complement engagement. Although each episode is mild and self-limited, their cumulative burden generates micro-damage that accelerates immunosenescence, perturbs metabolic and vascular homeostasis, and contributes to the progressive rise in systemic inflammation characteristic of aging. Notably, in the context of the recent pandemics of SARS-CoV-2 infection, the emergence of Long COVID has highlighted how even clinically mild or initially asymptomatic infections can leave durable immunological, metabolic, and neurological traces, reinforcing the concept that "silent" infections may have lasting consequences.},
}
@article {pmid40188869,
year = {2026},
author = {Berche, P},
title = {Laboratory-associated infections and biosafety.},
journal = {Presse medicale (Paris, France : 1983)},
volume = {55},
number = {3},
pages = {104277},
doi = {10.1016/j.lpm.2025.104277},
pmid = {40188869},
issn = {2213-0276},
mesh = {Humans ; *Laboratory Infection/epidemiology/prevention &amp; control/microbiology/etiology ; Animals ; *Containment of Biohazards ; *Laboratories/standards ; Occupational Exposure/prevention &amp; control ; Virus Diseases ; },
abstract = {The occurrence of laboratory-associated infections, which are caused by the handling of human or animal pathogens, represents a significant threat to the health and safety of laboratory workers and the general population. Such risks are present in clinical diagnostic and research laboratories, including those utilizing biotechnology on pathogenic organisms and industrial laboratories engaged in vaccine production. The investigation of these incidents is based on a retrospective analysis of published reports and voluntary questionnaires. The precise level of risk is challenging to ascertain, given the lack of a mandatory reporting system in the majority of countries. This indicates that many event involving exposure to contamination are not reported. The pathogens encountered in the primary published series include bacteria (e.g., Brucella spp., Mycobacterium tuberculosis, Salmonella spp., Shigella spp., Neisseria meningitidis, Coxiella burnetii), viruses (e.g., HBV, HCV, HIV, SARS-CoV-1, VEEV), and particularly dangerous viruses (e.g., hantavirus, filovirus, arenavirus), and less frequently fungi, parasites, and prions. Approximately 70% of these incidents are attributable to human errors. The primary modes of contamination are inhalation of aerosols and accidental parenteral injections. Additionally, contamination may occur during the handling of pathogens and the decontamination of waste, as well as during the inactivation processes of mass cultures utilized in vaccine production. It is therefore imperative that any incident or accident linked to contact with pathogens in laboratories be made compulsory to report. This will facilitate the systematic monitoring of these infections and data analysis for educational purposes, thereby enhancing prevention of laboratory accidents and leaks.},
}
@article {pmid42687186,
year = {2026},
author = {Kand, U and Kabudula, C and Choudhari, B and Mohanty, TK and Bhujbal, S and Gondhali, A and Bashingwa, JJH and Tippett Barr, BA and Tollman, S and Juvekar, S and Kawade, A and Agarwal, D},
title = {Excess mortality and associated sociodemographic factors during the COVID-19 pandemic in rural Pune Maharashtra, India: a retrospective data analysis from the Vadu health and demographic surveillance system.},
journal = {Population health metrics},
volume = {23},
number = {Suppl 2},
pages = {},
pmid = {42687186},
issn = {1478-7954},
mesh = {Humans ; India/epidemiology ; *COVID-19/mortality/epidemiology ; Female ; *Rural Population/statistics &amp; numerical data ; Male ; Retrospective Studies ; Middle Aged ; Adult ; *Sociodemographic Factors ; Socioeconomic Factors ; Young Adult ; Adolescent ; Aged ; SARS-CoV-2 ; Population Surveillance ; Socioeconomic Disparities in Health ; Pandemics ; Risk Factors ; *Mortality/trends ; Child ; Child, Preschool ; },
abstract = {BACKGROUND: Between January 2020 and August 2023, India documented over 450 million confirmed cases of COVID-19 and nearly 0.5 million COVID-19 deaths. While reported mortality rates in India appeared lower than expected, the actual mortality may be higher due to underreporting and disparities in healthcare access. This study aimed to compare mortality before and during the COVID-19 pandemic and identify associated socio-demographic factors in rural Pune, Maharashtra, India using longitudinal population-based data from the Vadu Health and Demographic Surveillance System.<br><br>METHODS: Individual and mortality data from the Vadu HDSS, India were collected from 2018 to 2021. Descriptive analyses were conducted to examine the variation in mortality by sociodemographic factors during pre-COVID-19 [2018-2019] and COVID-19 [2020-2021] periods. Cox regression with hazard ratios [HR] and 95% confidence intervals [CI] were used to measure the association between socio-demographic factors and mortality.<br><br>RESULTS: There were 2039 deaths that occurred between 2018 and 2021, of which 40.6% [828/2039] were female. The overall risk of mortality increased during COVID-19 [HR1.2,95%CI:1.1-1.3], but this varied by sociodemographic characteristics. The risk of death was greater [HR1.8,95%CI:1.5-2.2] among individuals living in single-person households compared to those living in 2-5 member households, and there was a strong trend of increased mortality risk with older age. Widowed individuals had a greater risk of mortality than those who were married [HR2.1,95%CI:1.9-2.4]. Education was strongly protective against mortality; those who had any level of education had a lower risk of dying than those with no education [HR0.4,95%CI:0.3-0.5].<br><br>CONCLUSION: Increased COVID-19 mortality in India was associated with older age, widowhood, and living alone. These findings highlight the need for targeted vaccination, early clinical care, and community outreach for vulnerable populations during future pandemics.},
}
@article {pmid42688262,
year = {2026},
author = {Ohno, T},
title = {Time in tight range (TITR): emerging evidence and clinical perspectives.},
journal = {Diabetology international},
volume = {17},
number = {4},
pages = {72},
pmid = {42688262},
issn = {2190-1678},
abstract = {Continuous glucose monitoring (CGM) has enabled increasingly stringent assessment of glycemic control beyond conventional time in range (TIR; 70-180 mg/dL). Time in tight range (TITR), defined as the percentage of time with glucose levels between 70 and 140 mg/dL, was proposed in 2023 as a more stringent CGM-derived metric. This review summarizes current evidence regarding the clinical significance and limitations of TITR. TITR correlates strongly with HbA1c and TIR, and may be more sensitive than TIR to changes in mean glucose when glycemia approaches the normal range. Recent cohort studies suggest that lower TITR is linearly associated with higher risks of all-cause and cardiovascular mortality, while higher TITR is associated with lower incidence of diabetic retinopathy. TITR has also shown associations with favorable outcomes in COVID-19 pneumonia. However, its interpretation requires caution because glycemic variability can influence TITR differently according to mean glucose levels. In individuals with type 1 diabetes treated with multiple daily injections, higher TITR may be accompanied by increased time below range, suggesting that indiscriminate pursuit of higher TITR could increase hypoglycemia risk. Further prospective studies are needed to establish optimal TITR targets and determine whether TITR provides prognostic value beyond established CGM metrics across diverse populations.},
}
@article {pmid42688493,
year = {2026},
author = {Huang, ZY and Wu, W and Luo, G and Huang, H and Liu, XL},
title = {Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1848518},
pmid = {42688493},
issn = {1664-3224},
mesh = {Humans ; *Multiple Myeloma/drug therapy/immunology ; *Antibodies, Bispecific/adverse effects/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects ; *Infections/etiology/epidemiology ; *Antineoplastic Agents, Immunological/adverse effects/therapeutic use ; Risk Factors ; },
abstract = {BACKGROUND: Talquetamab, a first-in-class G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, demonstrates substantial clinical activity in relapsed/refractory multiple myeloma (RRMM). However, immune dysfunction associated with advanced disease, extensive prior therapies, and bispecific antibody-mediated immune modulation may increase susceptibility to infections. This systematic review and meta-analysis aimed to characterize infection risk associated with talquetamab, with separate evaluation of monotherapy and combination therapy settings.<br><br>METHODS: PubMed, Embase, Web of Science Core Collection, and Cochrane Library databases were searched from inception to July 1, 2026. Studies reporting infection outcomes among RRMM patients treated with talquetamab-containing regimens were eligible. Outcomes included any-grade infections, grade &#x2265;3 infections, infection-related mortality, reported pathogens, and preventive strategies when available. Because talquetamab monotherapy and combination regimens represent clinically distinct treatment strategies, quantitative analyses were restricted to monotherapy cohorts, whereas combination therapy studies were summarized descriptively. A random-effects model was used to estimate pooled infection incidence. Methodological quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Series.<br><br>RESULTS: Six studies were included in the qualitative synthesis, including four talquetamab monotherapy cohorts and two talquetamab-based combination therapy cohorts. Quantitative meta-analysis included four monotherapy cohorts comprising 735 patients for any-grade infections and three cohorts comprising 584 patients for grade &#x2265;3 infections. The pooled incidence of any-grade infections was 51% (95% CI, 34%-67%; I&#xb2; = 94.2%), while the pooled incidence of grade &#x2265;3 infections was 22% (95% CI, 17%-28%; I&#xb2; = 59.6%). Given the limited number of available studies and substantial heterogeneity, these pooled estimates should be interpreted as exploratory and hypothesis-generating. Combination therapy cohorts, including talquetamab plus teclistamab and talquetamab-based regimens from MonumenTAL-3, demonstrated substantial infection burdens and were characterized descriptively rather than quantitatively. Infection-related mortality ranged from 0% to 3.2%. Frequently reported infections included viral infections (particularly SARS-CoV-2 and cytomegalovirus), bacterial pneumonia, and opportunistic infections such as Pneumocystis jirovecii pneumonia.<br><br>CONCLUSIONS: Talquetamab monotherapy in heavily pretreated RRMM patients is associated with a clinically meaningful risk of infections, including severe infections. The substantial heterogeneity observed across studies likely reflects differences in patient characteristics, prior therapies, treatment settings, infection definitions, and supportive care strategies. Combination bispecific antibody regimens may represent a potentially higher infection burden requiring enhanced infection surveillance and preventive approaches. Further prospective studies are warranted to better define infection risk factors and optimal prevention and management strategies during talquetamab therapy.<br><br>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261357352, identifier CRD420261357352.},
}
@article {pmid42688769,
year = {2026},
author = {Wang, Y and Zhuo, H and Wang, L},
title = {Advances in the clinical application of stellate ganglion block for non-pain indications.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1840174},
pmid = {42688769},
issn = {2296-858X},
abstract = {BACKGROUND: Stellate ganglion block (SGB) is a peripheral nerve block technique involving injection of local anesthetics and/or steroids near the stellate ganglion. Traditionally used for pain-related syndromes, SGB has recently expanded into non-pain fields with the advancement of ultrasound guidance, showing therapeutic potential in arrhythmias, menopausal hot flashes, psychiatric disorders, cerebrovascular diseases, insomnia, and COVID-19 sequelae.<br><br>OBJECTIVE: To review the current evidence on SGB applications in non-pain conditions, evaluate its therapeutic efficacy and safety across different diseases, elucidate underlying mechanisms, and identify research gaps and future directions.<br><br>METHODS: This narrative review synthesized data from published literature including case reports, cohort studies, and randomized controlled trials (RCTs) on SGB in non-pain conditions. Studies were analyzed based on disease categories, with focus on mechanism of action, clinical outcomes, and safety profiles.<br><br>RESULTS: Stellate ganglion block demonstrates therapeutic effects across six domains: (1) Ventricular arrhythmias: In a multicenter observational study of 131 patients (the STAR study), 92% (106/115) of patients with treatable arrhythmic episodes achieved a &#x2265;50% reduction in arrhythmia burden within 12 h via sympathetic blockade and QT dispersion reduction; (2) Menopausal hot flashes: Significant reduction in frequency through modulation of thermoregulatory pathways; (3) Insomnia: Improved sleep quality via autonomic balance restoration; (4) Cerebrovascular diseases: Enhanced cerebral perfusion and cognitive function; (5) Post-Traumatic Stress Disorder (PTSD): Case series have reported response rates of 70%-75% via inhibition of locus coeruleus-norepinephrine circuits; randomized evidence is mixed-a small early trial found no benefit over sham, whereas the subsequent multicenter randomized controlled trial (n = 113) demonstrated a statistically significant reduction in PTSD symptom severity (P = 0.01)-and adequately powered confirmatory trials are still needed; (6) COVID-19: Retrospective cohort studies suggest symptom relief in the majority of patients through autonomic reset.<br><br>CONCLUSION: Stellate ganglion block has become an important intervention for autonomic dysfunction in non-pain conditions through sympathetic blockade, neuroendocrine modulation, and anti-inflammatory effects. Although ultrasound guidance has improved safety, evidence remains limited by small RCTs, heterogeneous protocols, and observational designs. Rigorous multicenter RCTs are needed to confirm efficacy, define patient selection, and standardize protocols. Further research should investigate central regulatory mechanisms and long-term neuroplasticity to advance SGB from empirical therapy to precision intervention.},
}
@article {pmid42689122,
year = {2026},
author = {Bonna, K and Alshawaf, A and Abusharkh, F and Alenazi, M and Aljehany, J and Bazerbashi, A and Alshaykhi, MMM and Ajam, D and Hasanoğlu, G},
title = {The multifaceted impact of the COVID-19 pandemic on colorectal cancer care: a systematic review of management disruptions, stage migration, and survival outcomes.},
journal = {Frontiers in oncology},
volume = {16},
number = {},
pages = {1828760},
pmid = {42689122},
issn = {2234-943X},
abstract = {BACKGROUND: The COVID-19 pandemic caused a catastrophic disruption to global healthcare systems. For colorectal cancer (CRC), the world's third most prevalent cancer, the suspension of screening programs and reallocation of resources threatened to severely impact timely diagnosis and treatment, with pre-existing models predicting significant excess mortality from even short delays.<br><br>OBJECTIVE: This systematic review aimed to assess the impact of the COVID-19 pandemic on the management strategies, treatment outcomes, and survival rates of patients with colorectal cancer.<br><br>METHODS: A systematic review was conducted following PRISMA guidelines. A comprehensive search of PubMed was performed for studies published from 2020 onwards. Eligible studies included those focusing on adult CRC patients and reporting on changes in care pathways or outcomes due to the pandemic. Data on diagnostic delays, treatment modifications, stage at presentation, and survival were extracted and synthesized narratively.<br><br>RESULTS: The synthesis of results from the included studies revealed a cascade of negative consequences. There was a severe global reduction in CRC screening, with participation declining by 30-80% and colonoscopy volumes falling by up to 92%, leading to a pool of "missing" diagnoses. This resulted in a significant stage shift, with a higher proportion of patients presenting with advanced stage (e.g., Stage IV) and locally advanced tumors. Treatment protocols were modified, including reduced elective surgical volumes and increased use of neoadjuvant therapy. Consequently, patients diagnosed during the pandemic faced a significantly higher mortality risk, a trend exacerbated by COVID-19 co-infection, which was associated with dramatically worse survival. The pandemic also exacerbated health disparities and imposed a profound psychosocial burden on patients.<br><br>CONCLUSION: The COVID-19 pandemic had a detrimental impact on every facet of colorectal cancer care, from screening and diagnosis to treatment and outcomes, leading to more advanced disease at presentation and worsening survival. These findings underscore the critical need to develop resilient cancer care systems that can maintain essential services during future public health crises.<br><br>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42025638100.},
}
@article {pmid41400415,
year = {2026},
author = {Miranda Mayo, LCDRJJ and Pérez-Cárceles, MC and Fernández-Valera, MM},
title = {Occupational Mental Health in the Military through the Adler-Castro Model: A Comparative Documentary Review (2020-2025).},
journal = {Military medicine},
volume = {191},
number = {9-10},
pages = {e1843-e1848},
doi = {10.1093/milmed/usaf596},
pmid = {41400415},
issn = {1930-613X},
mesh = {Humans ; *Military Personnel/psychology ; *Mental Health ; COVID-19/psychology/epidemiology ; Leadership ; *Occupational Health ; },
abstract = {OBJECTIVE: To evaluate how research published from 2020 to 2025 operationalizes and tests key dimensions of the Adler-Castro occupational mental health model for the military-linking operational demands, organizational resources, and mental health outcomes.<br><br>METHODS: The authors conducted a comparative documentary review following IMRaD conventions and PRISMA guidance for search/selection reporting, 1242 screening indexed literature (PubMed/MEDLINE, Scopus, Google Scholar) within 2020-2025 and extracting study design, context, model variables (leadership, cohesion, identity/culture, system capacity), outcomes (symptoms, functioning, utilization), and reported effect sizes to compare the direction and magnitude of associations across the corpus.<br><br>RESULTS: Twenty studies met inclusion criteria. Supportive, well&#x2011;being-oriented leader behaviors were associated with substantially lower odds of depression and anxiety; a cluster trial of platoon&#x2011;leader training reduced problematic anger. Soldiers' COVID&#x2011;19 concerns tracked with poorer mental health. Increased psychiatry capacity at military installations corresponded to higher probabilities of mental health visits. Across sociocultural domains, moral injury and facets of military identity were linked to post-traumatic stress disorder, depression, and functional impairment.<br><br>CONCLUSIONS: Contemporary evidence largely aligns with the Adler-Castro model although indicating a needed extension to incorporate contextual demands (e.g., pandemic, housing) as a distinct construct influencing risk and access. Several leader-focused interventions, strengthened clinical capacity in military installations, and programs attentive to identity and moral injury are recommended, with rigorous evaluation.},
}
@article {pmid42686296,
year = {2026},
author = {Russell, CD and Westgeest, AC},
title = {Principles of Immunotherapeutic Drug Discovery for Severe Infections Using Extreme Phenotypes.},
journal = {Critical care clinics},
volume = {42},
number = {4},
pages = {763-775},
doi = {10.1016/j.ccc.2026.05.004},
pmid = {42686296},
issn = {1557-8232},
mesh = {Humans ; Phenotype ; *Drug Discovery/methods ; Host-Directed Therapy ; HIV Infections/immunology/drug therapy ; SARS-CoV-2 ; *Immunotherapy/methods ; *COVID-19/immunology ; Critical Illness/therapy ; *COVID-19 Drug Treatment ; },
abstract = {Therapeutically modifying host responses in severe infection is an unmet need in critical care, either to augment pathogen clearance or limit immunopathology. Drug discovery in this space is impeded by the complexity of immune responses during infection. Identifying and studying extreme infection phenotypes is an emerging approach to negotiate this problem: by amplifying biological signal over noise, this can expedite the discovery of host determinants of severe disease or protection. Examples discussed in this article include critical Covid-19, HIV elite controllers, inborn errors of interferon gamma immunity, hypervirulent pathogen variants, and sepsis hyper-inflammatory and immunoparalysis subphenotypes.},
}
@article {pmid42686548,
year = {2026},
author = {Katsuki, H},
title = {[Practical training of pharmacology in School of Pharmaceutical Sciences: the present and the future].},
journal = {Nihon yakurigaku zasshi. Folia pharmacologica Japonica},
volume = {161},
number = {5},
pages = {320-325},
doi = {10.1254/fpj.26006},
pmid = {42686548},
issn = {0015-5691},
mesh = {Animals ; Humans ; *Pharmacology/education ; *Education, Pharmacy/trends ; Academia ; Mice ; },
abstract = {Pharmacology is one of the fundamental academic disciplines in the educational courses of Schools of Pharmaceutical Sciences, and practical training of pharmacology provides profound educational effects. On the other hand, the contents of practical training are increasingly forced to make several changes, which is motivated by several factors such as limitation in budget, concerns on animal welfare and experience of COVID-19 crisis. In Kumamoto University School of Pharmacy, the content of practical training of pharmacology and anatomy has been changed recently to diminish the usage of experimental animals to minimum necessary. For example, experiments on the effects of drugs on blood pressure in rats have been replaced by practical training with software-based simulations. Experiments on the effects of drugs on contraction responses of small intestines have also incorporated software-based simulations, but in addition, students have a chance to observe contraction of mouse small intestines in Magnus preparations. Several movies of pharmacological experiments using animals and isolated organs are provided to students via e-learning system. The other sets of experiments involve drug treatments and surgical operations in mice, and students are encouraged to handle mice by themselves in these experiments. We should continue efforts for improving the contents of practical training, while considering several factors including educational effects benefited from animal experiments and a purpose of Schools of Pharmaceutical Sciences in developing human resources for basic research of pharmaceutical sciences and life sciences.},
}
@article {pmid41649968,
year = {2026},
author = {Paswal, CM and Gupta, N and Satpathy, SK and Kumar, H and Choudhary, SK and Saini, L and Singh, AK and Tiwari, S},
title = {COVID-19 and Neonatal Guillain-Barré Syndrome: Exploring a Possible Causal Link With Review of Literature.},
journal = {Journal of child neurology},
volume = {41},
number = {9},
pages = {1293-1300},
doi = {10.1177/08830738251413670},
pmid = {41649968},
issn = {1708-8283},
mesh = {Humans ; Male ; *Guillain-Barre Syndrome/etiology/diagnosis ; *COVID-19/complications ; Infant, Newborn ; Immunoglobulins, Intravenous/therapeutic use ; SARS-CoV-2 ; *Coronavirus Infections/complications ; Pandemics ; Betacoronavirus ; },
abstract = {IntroductionGuillain-Barré Syndrome (GBS) is an immune-mediated polyneuropathy that is rare in neonates. It may be acquired congenitally via maternal antibody transfer or postnatally after infection. We report a case of postnatally acquired neonatal GBS potentially triggered by SARS-CoV-2 with a review of the literature.PatientA 24-day-old term male presented with progressive hypotonia, a weak cry, and respiratory distress. He had a preceding febrile illness with gastrointestinal symptoms. Examination revealed areflexia, cranial nerve involvement, and generalised weakness.ResultsInvestigations showed albuminocytologic dissociation in cerebrospinal fluid, cauda equina enhancement on magnetic resonance imaging, and motor-sensory polyneuropathy on nerve conduction studies. The infant had high anti-SARS-CoV-2 IgG (>4000 IU/mL) with negative maternal titres. After 2 courses of intravenous immunoglobulin (IVIg), he recovered fully and remained developmentally normal at 2-year follow-up.ConclusionGBS should be considered in floppy neonates with a postinfectious presentation. This case highlights the possibility of SARS-CoV-2 as a postnatal trigger and the importance of early recognition and treatment with IVIg.},
}
@article {pmid42568228,
year = {2026},
author = {Tyldesley-Marshall, N and Chen, YF and Buendia, J and Brown, A and Matthews, T and Parr, J and Chockalingam, S and Elfeky, A and Grove, A and Andronis, L and Coles, SR and Zanganeh, M and Hayee, B and Dhar, A and Sebastian, S and Arasaradnam, R},
title = {Diagnostic and Clinical Performance of Single-Use Versus Reusable Gastrointestinal Endoscopes: A Systematic Review and Meta-Analyses.},
journal = {Journal of gastroenterology and hepatology},
volume = {41},
number = {9},
pages = {2571-2587},
pmid = {42568228},
issn = {1440-1746},
support = {ESI-2021-001//Evidence Synthesis Ireland/ ; NIHR152311//National Institute for Health and Care Research/ ; },
mesh = {Humans ; *Equipment Reuse ; *Endoscopes, Gastrointestinal/adverse effects/microbiology ; *Disposable Equipment ; Cholangiopancreatography, Endoscopic Retrograde/instrumentation/adverse effects ; *Gastrointestinal Diseases/diagnosis ; Equipment Contamination/prevention &amp; control ; },
abstract = {BACKGROUND: Endoscopic procedures are fundamental in the diagnosis and management of gastrointestinal disorders. However, concerns over pathogen transmission have driven the development of single-use and partially single-use endoscopes (reusable endoscopes with disposable components). A comprehensive synthesis of comparative evidence is essential to inform decisions regarding clinical adoption.<br><br>METHODS: We systematically searched MEDLINE, EMBASE, Web of Science, Cochrane Library, and trial registries for randomized controlled trials, non-randomized comparative studies, diagnostic accuracy studies, and case series. Outcomes assessed included technical performance, diagnostic accuracy, infection risk, and adverse events. We also included systematic reviews estimating infection risk associated with exogenous pathogens for reusable gastrointestinal endoscopes. Summary data were pooled using a random-effects model where appropriate, and other findings synthesized narratively. The protocol was registered prospectively on PROSPERO (CRD42024496913).<br><br>RESULTS: Of 6979 records screened, 50 studies (965&#x2009;960 patients) were included. Our meta-analyses demonstrated that in endoscopic retrograde cholangiopancreatography (ERCP), crossover from single-use (EXALT Model D) to reusable duodenoscopes occurred in 7% of cases (95% CI 6-9). Across endoscope types, single-use and partially single-use devices demonstrated similar or slightly reduced technical performance and diagnostic accuracy compared with reusable counterparts. Estimated infection risks from contaminated reusable endoscopes ranged from 0.01% to 0.8%, although these figures are limited by high risk of detection and reporting bias.<br><br>CONCLUSIONS: The current evidence does not support wholesale replacement of reusable gastrointestinal endoscopes with single-use or partially single-use models. More robust and standardized data are needed to quantify infection risks from reusable endoscopes and inform evidence-based policy and procurement decisions.},
}
@article {pmid42682883,
year = {2026},
author = {El-Kafrawy, SA and Othman, NA and Zeyadi, M and El-Daly, MM and Azhar, EI},
title = {Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1904701},
pmid = {42682883},
issn = {2235-2988},
mesh = {Humans ; *Antiviral Agents/pharmacology/therapeutic use ; *Virus Internalization/drug effects ; Animals ; *Receptors, Virus/metabolism ; Dipeptidyl Peptidase 4/metabolism ; Host-Directed Therapy ; Angiotensin-Converting Enzyme 2/metabolism ; Serine Endopeptidases/metabolism ; SARS-CoV-2/drug effects ; *Respiratory Tract Infections/drug therapy/virology ; Respiratory Syncytial Virus Infections/drug therapy ; Middle East Respiratory Syndrome Coronavirus/drug effects ; Host-Pathogen Interactions/drug effects ; Influenza, Human/drug therapy ; Coronavirus Infections/drug therapy ; },
abstract = {Respiratory viral infections caused by seasonal influenza, respiratory syncytial virus (RSV), and pandemic-potential coronaviruses are responsible for several million hospitalisations and an estimated several hundred thousand deaths each year, a burden underscored by the severe 2024-2025 influenza season and the continued emergence of zoonotic threats such as clade 2.3.4.4b H5N1. This review critically examines the pharmacological basis for targeting host cell-surface receptors as a strategy for the treatment and prophylaxis of respiratory viral infections, evaluates the current evidence for each major receptor axis, and identifies the key translational gaps that must be addressed. Respiratory viruses, including influenza, RSV, SARS-CoV-2, and MERS-CoV, collectively cause millions of hospitalisations annually, and the persistent challenges of antigenic drift, zoonotic emergence, and antiviral resistance highlight the need for mechanistically distinct strategies. Host-directed therapies (HDTs) targeting conserved receptors (ACE2, DPP4, sialic acids, TMPRSS2) exploit genetically stable host factors required for viral entry. Across the receptor axes reviewed here, we appraise more than a dozen candidate agents spanning preclinical development through Phase III evaluation, including TMPRSS2 inhibitors, soluble ACE2 decoys, anti-CD147 and receptor-blocking monoclonal antibodies, the sialidase fusion protein DAS181, and avian IgY preparations. This evidence reveals a consistent gap between robust preclinical activity and as-yet-limited clinical efficacy. We conclude that host receptor targeting is a mechanistically rational but still clinically unproven component of the respiratory antiviral landscape; its value is most plausibly realised in defined niches-prophylaxis, early outpatient treatment, and combination with direct-acting antivirals-and within pandemic preparedness frameworks, provided that the safety, delivery, and trial-design challenges identified here are resolved.},
}
@article {pmid42683631,
year = {2026},
author = {Puente, H and Arguello, H and Rubio, P and Carvajal, A},
title = {Porcine Enteric Coronaviruses: Origins, Global Spread, Transmission Pathways and Pathogenesis.},
journal = {Transboundary and emerging diseases},
volume = {2026},
number = {1},
pages = {e6796680},
pmid = {42683631},
issn = {1865-1682},
support = {PID2024-160714OB-I00//Ministerio de Ciencia, Innovaci&#xf3;n y Universidades/ ; LE088P23//Junta de Castilla y Le&#xf3;n/ ; },
mesh = {Animals ; Swine ; *Coronavirus Infections/veterinary/transmission/virology/epidemiology ; *Swine Diseases/virology/transmission/epidemiology ; *Coronavirus/pathogenicity/classification ; Deltacoronavirus/pathogenicity ; },
abstract = {Porcine enteric coronaviruses (CoVs) constitute a persistent and evolving threat to global pig production due to their high transmissibility, environmental stability and capacity for rapid international dissemination. Historically, transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhoea virus (PEDV) have been the most significant enteric CoVs in swine, causing acute outbreaks with severe diarrhoea and high neonatal mortality. In the past decade, additional pathogens have expanded this epidemiological landscape of porcine enteric CoVs. Swine enteric CoV (SeCoV), porcine deltacoronavirus (PDCoV), and swine acute diarrhoea syndrome CoV (SADS-CoV) illustrate the remarkable genetic plasticity, recombination capacity and interspecies transmission potential of this viral group. To address these challenges, this review provides a comprehensive synthesis of the main scope regarding the origins, global spread, transmission pathways, and pathogenesis of these viruses. We emphasise the critical differences among them, particularly concerning transboundary dissemination, host range, and zoonotic potential. In conclusion, the repeated emergence and host adaptation of these agents underscore the urgent need to address surveillance gaps through continuous molecular tracking, improved biosecurity protocols, and the development of coordinated global control strategies to mitigate their impact on animal health and modern production systems.},
}
@article {pmid42684387,
year = {2026},
author = {Helmsdal, G and Petersen, MS and Kristiansen, MF},
title = {Pandemic research in a small island society-a narrative review of research contributions during the SARS-CoV-2 pandemic in the Faroe Islands.},
journal = {International journal of circumpolar health},
volume = {85},
number = {1},
pages = {2727219},
doi = {10.1080/22423982.2026.2727219},
pmid = {42684387},
issn = {2242-3982},
mesh = {Humans ; *COVID-19/epidemiology ; *Pandemics ; SARS-CoV-2 ; Denmark/epidemiology ; *Coronavirus Infections/epidemiology/psychology ; *Pneumonia, Viral/epidemiology/psychology ; Betacoronavirus ; },
abstract = {Small and geographically isolated societies face distinct challenges during a pandemic but may also possess advantages. This narrative literature review presents epidemiological, immunological and psychological studies conducted in the Faroe Islands during the SARS-CoV-2 pandemic, examining its effects on individuals in the Faroe Islands. The COVID-19 pandemic hit the Faroe Islands early in March 2020. With only around 55,000 inhabitants, the Faroe Islands' isolated, well-documented population enabled extensive epidemiological research and close monitoring of infection patterns. This resulted in studies on transmission, immunity, mental health and long COVID. Overall, the Faroese studies demonstrate how small, cohesive societies with robust infrastructure can conduct high-quality research during a crisis, contributing to both local and global knowledge.},
}
@article {pmid42684522,
year = {2026},
author = {Kutuva, AR and Ribeiro, HA and Lima, FT and Schaller, MA and Mehrad, B and Laubenbacher, R},
title = {mTORC1 Promotes SARS-CoV-2 Replication and Attenuates Type I Interferon Responses in the Alveolar Epithelium: A Computational and Experimental Study.},
journal = {Bulletin of mathematical biology},
volume = {88},
number = {10},
pages = {},
pmid = {42684522},
issn = {1522-9602},
support = {R01AI135128//Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases/ ; R01 HL169974-01//NIH (US)/ ; },
mesh = {*Mechanistic Target of Rapamycin Complex 1/antagonists &amp; inhibitors/physiology/immunology ; Humans ; Virus Replication/drug effects/immunology ; *SARS-CoV-2/physiology/pathogenicity ; *Models, Biological ; *Interferon Type I/immunology/antagonists &amp; inhibitors/metabolism ; Sirolimus/pharmacology ; Signal Transduction/immunology ; COVID-19/immunology/virology/metabolism ; Mathematical Concepts ; Computer Simulation ; Alveolar Epithelial Cells/virology/immunology ; Computational Biology ; DEAD Box Protein 58 ; },
abstract = {The mechanistic target of rapamycin complex 1 (mTORC1) has been implicated in coronavirus pathogenesis, yet its precise role in shaping antiviral defenses in pneumocytes remains unresolved. This study combines ex vivo human lung tissue assays with a literature-curated, logic-based (Boolean) signaling model to study how mTORC1 influences SARS-CoV-2 replication and type-I interferon (IFN) responses. Our in-vitro data showed that pharmacologic inhibition of mTORC1 with sirolimus was associated with reduced viral replication and increased IFN- β expression across donor samples. To interpret these data, we constructed a network integrating inflammation, stress, apoptosis, and RIG-I-IFN signaling, and evaluated four mechanistic hypotheses for explaining our experiments in which mTORC1 either promotes replication, inhibits IFN, both, or neither. The model was constructed according to the best evidence in the literature and evaluated against 56 independent protein/phosphoprotein readouts from 26 studies not used for model construction; the model achieved high qualitative accuracy overall (F1 ≳ 0.75) and on live-virus experiments (F1 ≳ 0.9). We found that the hypotheses where mTORC1 promotes viral replication, inhibits IFN, or both were able to qualitatively reproduce the empirical data, i.e., mTORC1 inhibition by sirolimus leads to lower viral replication and higher IFN expression. We queried the robustness of those predictions through a systematic edge knock-in/knockout screen generating 6,328 network variants per scenario (25,312 total). We found that the scenario where mTORC1 enhances viral replication is the more plausible, due to parsimony (this mechanism is also observed in other viral infections), higher robustness (more variants still reproduce the result), and stronger inhibition that is more likely to be observed in biological experiments with low statistical power. This scenario supports the idea that the mTORC1 effects on IFN expression are indirectly mediated by viral replication itself.},
}
@article {pmid42684861,
year = {2026},
author = {Velez-Brochero, M and Rivera, A},
title = {Interferon crosstalk at the lung barrier in viral and fungal infection.},
journal = {Infection and immunity},
volume = {},
number = {},
pages = {e0029526},
doi = {10.1128/iai.00295-26},
pmid = {42684861},
issn = {1098-5522},
abstract = {Interferons (IFNs) coordinate host defense at the lung barrier by linking pathogen recognition to epithelial and immune-cell responses. Their effects are highly context-dependent and can be protective or pathological according to IFN class and ligand, cellular source and target, and the timing and duration of signaling. In this minireview, we compare the induction of type I, II, and III IFNs during respiratory viral infection and pulmonary Aspergillus fumigatus infection, highlighting epithelial-led antiviral sensing and predominantly myeloid-centered antifungal sensing. We then examine how receptor distribution, ligand identity, JAK-STAT complex assembly, and integration with inflammatory pathways generate cell type-specific transcriptional and functional programs. Finally, we discuss three interconnected consequences of IFN crosstalk at the respiratory barrier: regulation of epithelial permeability and repair, licensing or pathological reprogramming of immune effector cells during primary infection, and loss of coordination during viral-fungal coinfection, including influenza-associated and COVID-19-associated pulmonary aspergillosis. Collectively, the available evidence supports a model in which spatially restricted and appropriately timed IFN responses promote pathogen control and preserve barrier function, whereas excessive, prolonged, or mistimed signaling impairs epithelial recovery, disrupts phagocyte activity, and increases susceptibility to secondary fungal invasion. Defining these context-dependent circuits may guide therapeutic strategies that modulate IFN signaling with greater temporal and cell type specificity.},
}
@article {pmid42685247,
year = {2026},
author = {Elias, KM and Mitchell, A and Stadler, E and Schlub, TE and Khan, SR and Xue, C and Kent, SJ and Cromer, D and Davenport, MP and Khoury, DS},
title = {Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis.},
journal = {PLoS medicine},
volume = {23},
number = {9},
pages = {e1005230},
doi = {10.1371/journal.pmed.1005230},
pmid = {42685247},
issn = {1549-1676},
mesh = {Humans ; *Antibodies, Neutralizing/immunology ; *COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; *Antibodies, Viral/immunology/blood ; Disease Progression ; *COVID-19 Vaccines/immunology ; Pandemics/prevention &amp; control ; *Betacoronavirus/immunology ; Vaccination ; },
abstract = {BACKGROUND: Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development.<br><br>METHODS AND FINDINGS: Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64], p&#x2009;<&#x2009;0.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding.<br><br>CONCLUSIONS: Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role.},
}
@article {pmid42686268,
year = {2026},
author = {Hruza, GJ},
title = {Leadership During Times of Crisis.},
journal = {Dermatologic clinics},
volume = {44},
number = {4},
pages = {607-612},
doi = {10.1016/j.det.2026.05.004},
pmid = {42686268},
issn = {1558-0520},
mesh = {Humans ; COVID-19 ; *Leadership ; *Pandemics/prevention &amp; control ; *Dermatology/organization &amp; administration ; United States ; SARS-CoV-2 ; *Pneumonia, Viral/epidemiology ; *Coronavirus Infections/epidemiology ; *Societies, Medical ; *Betacoronavirus ; },
abstract = {In early 2020, as President of the American Academy of Dermatology (AAD), AAD faced the emerging COVID-19 crisis days before the Annual Meeting in Denver. After listening to members' concerns, gathering critical data on health risks, finances, and insurance coverage, and consulting peers, we recommended canceling the meeting 2 weeks in advance. The AAD provided timely guidance on safe office practices, telemedicine, and government relief programs. The author credits servant-leadership principles, rooted in empathy, data-driven decisions, and focus on members, with successfully guiding dermatologists and patients through the pandemic. He later applied similar attributes to the Missouri State House.},
}
@article {pmid42675001,
year = {2026},
author = {Sehabi, WY and Muray, M and Ngwaka, N and Bouraleh, S and Kalay, AL and Chomienne, MH},
title = {[Not Available].},
journal = {Sante publique (Vandoeuvre-les-Nancy, France)},
volume = {38},
number = {HS1},
pages = {63-82},
doi = {10.3917/spub.hs1.2026.0063},
pmid = {42675001},
issn = {0995-3914},
mesh = {Humans ; *Emigrants and Immigrants/psychology/statistics &amp; numerical data ; *COVID-19/psychology/epidemiology ; United Kingdom/epidemiology ; Canada/epidemiology ; *Mental Health/ethnology ; *Black People/psychology ; Health Services Accessibility ; *Mental Disorders/epidemiology/ethnology ; Racism ; Social Stigma ; },
abstract = {INTRODUCTION: Black immigrant communities in Canada and Europe have faced disproportionate mental health challenges, further exacerbated by the COVID-19 pandemic. Structural racism, social isolation, and cultural stigma are among the key factors contributing to mental health distress in these populations. This scoping review aims to explore the mental health outcomes, experiences, and access to care among Black African immigrants in Canada and Europe after the COVID-19 pandemic, using an intersectional lens that considers the combined impact of race, migration, and minority status.<br><br>METHODOLOGY: A total of 19 peer-reviewed studies published during the post-COVID-19 period (2021&#8211;2024) were included. These studies employed qualitative, quantitative, or mixed methods and focused on adult Black immigrants in Canada or the UK. Data were extracted on mental health prevalence, perceptions, and barriers and facilitators to care.<br><br>RESULTS: Findings reveal high rates of depression, anxiety, and psychosis among Black immigrants, often linked to systemic racism, cultural stigma, and poor living conditions. Major barriers to care include mistrust of Eurocentric services, lack of culturally competent providers, financial constraints, and language barriers. Facilitators included strong community ties, religious support, and access to culturally sensitive professionals.<br><br>CONCLUSION: The review highlights a critical need for culturally appropriate mental health services and community-based interventions. It also underscores the importance of policy changes and future research, particularly in underrepresented European regions and among groups experiencing intersectional marginalization.},
}
@article {pmid42675553,
year = {2026},
author = {Gambescia, SF and Tran, V and Almoayad, F and Aboul-Enein, BH},
title = {Examining determinants of COVID-19 vaccine hesitancy and acceptance among Arab university students: A regional scoping review.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2726688},
pmid = {42675553},
issn = {2164-554X},
mesh = {Humans ; Young Adult ; *Arabs/psychology ; *COVID-19/ethnology/prevention &amp; control/psychology ; *COVID-19 Vaccines/administration &amp; dosage ; Health Knowledge, Attitudes, Practice ; Middle East ; *Patient Acceptance of Health Care/ethnology/psychology/statistics &amp; numerical data ; SARS-CoV-2/immunology ; *Students/psychology/statistics &amp; numerical data ; Surveys and Questionnaires ; Universities ; Vaccination/psychology ; *Vaccination Hesitancy/ethnology/psychology/statistics &amp; numerical data ; },
abstract = {This scoping review consolidates survey research conducted among university students across the League of Arab States to understand the nature and extent of COVID-19 vaccine hesitancy and acceptance. Using PRISMA-ScR guidelines, a search was conducted across 10 databases covering publications from 2020 to 2024. Fifty-three studies met the inclusion criteria. Reported determinants of vaccine acceptance and hesitancy aligned with key constructs of the Health Belief Model, including perceived susceptibility, perceived severity, perceived benefits, and perceived barriers. Concerns regarding vaccine safety, effectiveness, and side effects were among the most frequently reported reasons for hesitancy, while perceived protection of self and others, trust in health authorities, and institutional requirements were associated with vaccine acceptance. Findings suggest that vaccine decision-making among university students was influenced by an interaction of individual, familial, social, and informational factors. These results help inform future vaccination communication, education, and public health strategies in university settings across the region.},
}
@article {pmid42676198,
year = {2026},
author = {Shirolapov, IV and Zakharov, AV and Kurmaev, DP and Bulgakova, SV},
title = {[Molecular and systemic mechanisms of cognitive impairment associated with coronavirus infection].},
journal = {Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova},
volume = {126},
number = {8},
pages = {40-50},
doi = {10.17116/jnevro202612608140},
pmid = {42676198},
issn = {1997-7298},
mesh = {Humans ; *COVID-19/complications/physiopathology/metabolism ; *Cognitive Dysfunction/etiology/virology/physiopathology/metabolism ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Blood-Brain Barrier ; Neuroinflammatory Diseases ; },
abstract = {Cognitive dysfunction represents a prevalent and long-lasting non-respiratory symptom following a protracted course of coronavirus infection, yet its molecular basis remains inadequately characterized. This review aims to present a comprehensive and systematic examination of the pathogenic mechanisms underlying cognitive impairment associated with COVID-19 and to consolidate current evidence on the critical processes linking SARS-CoV-2 infection to long-term neurological outcomes. Evidence indicates that cognitive deficits resulting from COVID-19 arise from a multifaceted interplay, including the virus's direct neurotropic effects, the emergence of neuroinflammation characterized by microglial and astrogliosis activation, disruption of the blood-brain barrier, and cerebrovascular complications. Additionally, systemic neuroendocrine alterations - including dysfunctions of the autonomic nervous system, hypothalamic-pituitary-adrenal axis, and monoamine metabolism - as well as diminished glymphatic clearance, are significant in the pathogenesis and are intricately associated with neuropsychiatric symptoms, thereby perpetuating the pathological processes. The notable molecular similarities with the early stages of neurodegenerative diseases suggest a potential risk for long-term acceleration of neurodegenerative processes in individuals experiencing post-COVID syndrome. Future research should focus on developing integrative diagnostic algorithms that combine biomarkers representative of various pathogenic processes with advanced neuroimaging techniques, organizing longitudinal studies to assess the time course of cognitive disorders, and formulating personalized therapeutic strategies to address key components of the identified pathogenic mechanisms.},
}
@article {pmid42676574,
year = {2026},
author = {Wu, W and Sun, Z and Liu, M and Huang, Y and Liu, T and Qiu, X and Wang, Y},
title = {Bibliometric analysis of research on pediatric hypothyroidism treatment: a global perspective on trends and emerging fronts (2018-2026).},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1908940},
pmid = {42676574},
issn = {2296-2360},
abstract = {BACKGROUND: Pediatric hypothyroidism is among the most prevalent endocrine disorders in childhood, yet no bibliometric analysis has systematically mapped the research landscape of its treatment.<br><br>OBJECTIVE: This study aimed to characterize the publication trends, geographic distribution, research hotspots, and emerging fronts in pediatric hypothyroidism treatment research from 2018 to 2026.<br><br>METHODS: A comprehensive search was conducted in the Web of Science Core Collection (WoSCC) as the primary database, with external data validation performed via PubMed. Bibliometric indicators were analyzed using CiteSpace, Python and R. Keyword co-occurrence networks were constructed with Louvain community detection, and burst detection was performed to identify emerging research fronts.<br><br>RESULTS: A total of 1,302 publications were included. Annual output grew from 138 (2018) to a peak of 183 (2022). The United States (n&#x2009;=&#x2009;263, 20.2%), China (n&#x2009;=&#x2009;203, 15.6%), and Italy (n &#x2009;=&#x2009;137, 10.5%) were the leading contributors. Five thematic clusters were identified: (1) congenital hypothyroidism and neonatal screening; (2) subclinical hypothyroidism; (3) pregnancy-related thyroid disorders; (4) autoimmune thyroid disease; and (5) comorbidities and genetic syndromes. Burst detection revealed "obesity" (burst strength&#x2009;=&#x2009;7.2), "COVID-19" (4.0), and "thyroid dyshormonogenesis" (3.2) as emerging fronts.<br><br>CONCLUSIONS: The field is shifting focus from congenital hypothyroidism screening optimization toward subclinical hypothyroidism management and the recognition of obesity-related TSH elevation as a distinct physiological entity. Future research should prioritize prospective trials on watchful-waiting strategies and obesity-specific TSH reference ranges.},
}
@article {pmid42676997,
year = {2026},
author = {Rathee, P and Khatkar, S and Sehrawat, R and Rathee, P and Khatkar, A and Küpeli, E},
title = {Face mask littering: environmental impacts, regulatory challenges, and AI-driven waste management strategies for the postpandemic era.},
journal = {Turkish journal of medical sciences},
volume = {56},
number = {4},
pages = {909-930},
pmid = {42676997},
issn = {1303-6165},
mesh = {Humans ; *Masks/adverse effects ; *Waste Management/methods/legislation &amp; jurisprudence ; *COVID-19/prevention &amp; control ; Pandemics/prevention &amp; control ; *Artificial Intelligence ; SARS-CoV-2 ; *Environmental Pollution ; Public Health ; Microplastics ; },
abstract = {The widespread use of polypropylene-based face masks during the COVID-19 pandemic created a significant and persistent source of plastic pollution. This review aims to provide an integrative assessment of the environmental, toxicological, and public health implications of face mask litter and evaluate current waste management challenges and emerging technological solutions in the postpandemic context. A narrative review approach was employed, synthesizing literature published between 2020 and 2025 and indexed in major scientific databases including Web of Science, Scopus, and PubMed. Studies were selected based on their relevance to the issues of environmental contamination, microplastic generation, toxicological effects, regulatory frameworks, and artificial intelligence (AI)-based waste management strategies. The findings indicate that discarded face masks are a major source of microplastics and hazardous chemical additives, contributing to environmental contamination across terrestrial, aquatic, and atmospheric systems. These materials may enter human exposure pathways through inhalation, ingestion, and dermal contact, with potential implications for respiratory health, systemic toxicity, and endocrine disruption. In addition, current waste management systems are shown to be insufficient for handling personal protective equipment-related waste, particularly under pandemic conditions. While AI-driven technologies can improve waste detection, sorting, and monitoring efficiency, their real-world scalability remains constrained by data limitations, infrastructure requirements, and environmental trade-offs. Overall, this review emphasizes that face mask pollution constitutes a multidimensional environmental and public health challenge requiring integrated responses. Strengthening regulatory frameworks, advancing sustainable material design, and combining AI-based tools with robust waste management systems are essential for mitigating long-term risks and improving preparedness for future global health crises.},
}
@article {pmid42677895,
year = {2026},
author = {Houghton, C and Meskell, P and Delaney, H and Sheehan, S and O Donoghue, C and Glenton, C and Booth, A and Jorem, G and Chan, XHS and Devane, D and Biesty, LM},
title = {Factors that impact on healthcare workers' adherence with infection prevention and control (IPC) guidelines for COVID-19: a qualitative evidence synthesis.},
journal = {The Cochrane database of systematic reviews},
volume = {9},
number = {9},
pages = {CD016384},
pmid = {42677895},
issn = {1469-493X},
mesh = {Humans ; *Guideline Adherence/statistics &amp; numerical data ; *COVID-19/prevention &amp; control/transmission/epidemiology ; *Health Personnel/statistics &amp; numerical data ; *Infection Control/standards ; Personal Protective Equipment ; Practice Guidelines as Topic ; SARS-CoV-2 ; Pandemics/prevention &amp; control ; Qualitative Research ; },
abstract = {BACKGROUND: The COVID-19 pandemic, declared in 2020, brought unprecedented challenges to our healthcare services in relation to the prevention and treatment of the disease. Additionally, preventing transmission within healthcare settings was critical. Infection Prevention and Control (IPC) guidelines are important for providing strategies on the use of personal protective equipment (PPE), the separation of patients with respiratory infections from others, and stricter cleaning routines. It is important to examine how the context of the pandemic impacts healthcare workers' (HCW) ability to adhere to IPC guidance in pandemic situations in the future. This is an update of an earlier review version, published in 2020, titled 'Barriers and facilitators to healthcare workers' adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: a rapid qualitative evidence synthesis'. We built on available evidence for infectious respiratory diseases, but also importantly, given the unprecedented global scale of COVID-19 and its unique challenges for healthcare systems, explored additional factors influencing IPC adherence specific to respiratory diseases with pandemic potential, i.e. infectious respiratory pathogens (such as novel influenza subtypes or coronaviruses) judged capable of causing a pandemic.<br><br>OBJECTIVES: Our primary objective is to identify the factors that impact on HCWs' adherence to IPC guidelines for COVID-19. A second objective is to update an existing rapid review, published in 2020, to identify similarities, differences, and novel insights specific to COVID-19 compared with other respiratory infectious diseases.<br><br>SEARCH METHODS: We searched MEDLINE (Ovid), CINAHL (EBSCO), Scopus, Ovid PsycINFO (EBSCO), and Epistemonikos. We did not apply any language limits but only searched from 2020 to the present (last search 5 April 2024). In the interest of timeliness and relevance, we only included studies published from 2020. We chose this as it marks the year when the COVID-19 pandemic was declared.<br><br>SELECTION CRITERIA: We included qualitative and mixed methods studies that focused on the experiences and perceptions of HCWs towards factors that impact on their ability to adhere to IPC guidelines for COVID-19. We included studies of any type of healthcare worker with responsibility for patient care. We included studies that focused on IPC guidelines (local, national, or international) for COVID-19 in any healthcare setting. We excluded studies that collected data using qualitative methods (e.g. open-ended survey questions) in which the response data were analysed only with descriptive statistics.<br><br>DATA COLLECTION AND ANALYSIS: We used a purposive sampling frame to identify data-rich studies that represented a range of HCWs, healthcare settings, and geographical spread. We assessed methodological strengths and limitations in the same studies using an adapted version of the Critical Skills Appraisal Programme (CASP) tool for qualitative studies. We used the 'best-fit framework approach' to analyse and synthesise the evidence from our included studies. We used the GRADE-CERQual (Confidence in the Evidence from Reviews of Qualitative research) approach to assess our confidence in each finding. We examined each review finding to identify factors that may influence guideline adherence and developed implications for practice.<br><br>MAIN RESULTS: We found 170 studies eligible for inclusion; of these, 26 were sampled for analysis using a purposive sampling frame for a balance of variation and richness of data. Seven of the 26 sampled studies were from high-income countries. Of the 15 middle-income countries, seven were upper middle-income countries, and eight were lower middle-income countries. There were four low-income countries included in the sample. In terms of geographical spread, ten were from Asia, eight from Africa, three were from North America, one from South America, one from Oceania, and three from Europe. Most of the studies included nurses (15 studies) or doctors (11 studies). Other types of healthcare workers included in the studies were other clinical staff (11 studies), such as midwives, allied health professionals, medical and radiologic technologists, dental professionals, neonatologists, radiographers, pharmacists, and support staff (7 studies), such as hospital cleaners, clerical staff, technicians, and hospital attendants. Healthcare settings ranged across and within studies, including hospitals, long-term care settings, and community healthcare settings. Specific units such as maternity, intensive care, emergency care, critical care, and operating rooms were identified in five of the sampled studies. We identified 27 findings that outline the factors that impact on HCWs' adherence to IPC guidelines. We have low (n = 3), moderate (n = 12), and high (n = 12) confidence in these findings. HCWs found it easier to follow IPC guidelines with managerial support, and when IPC guidelines were communicated in a clear, structured, and accessible way. They found it more difficult to follow guidelines if they were busy, short-staffed, or when patients and visitors refused to wear masks and maintain social distancing. Training was considered very important, but not all HCWs had the opportunity to attend IPC training. In terms of the working environment, HCWs need adequate space, hand-washing stations, and showers to follow the IPC guidelines. HCWs worried about infecting other people, but some worried less once people started being vaccinated. It was very important that all HCWs had sufficient and equitable access to PPE and other supplies to follow guidelines. If PPE did not fit properly or was not of good quality, it was more difficult for HCWs to practice IPC. Many factors affect HCWs' willingness and ability to follow IPC guidelines. Our review includes a set of questions based on our findings to help healthcare providers plan, implement, or manage IPC strategies to help their workers follow IPC guidelines for pandemic diseases like COVID-19. It is worth noting that our included studies were conducted primarily during the earlier phase of the pandemic, based on practical considerations to not update the search after April 2024.<br><br>AUTHORS' CONCLUSIONS: We identified several factors that influence the ability of healthcare workers to adhere to IPC guidelines. Practical implications, such as communication strategies and the provision of training and supplies, should guide policymakers and decision-makers in disease outbreaks and future pandemics.<br><br>FUNDING: This Cochrane review had no dedicated funding.<br><br>REGISTRATION: This Cochrane review extends the work by a published rapid review, available via DOI: 10.1002/14651858.CD013582.},
}
@article {pmid42678573,
year = {2026},
author = {Stylianakis, D and Martella, S and Pearce, J and Tomara, A and Porcu, M and Tsagkaris, C and Stylianakis, I and Denaro, N and Lambertini, M and Saba, L and Scartozzi, M and Solinas, C and Soddu, M},
title = {Tele-Oncology in the Post-Pandemic Era: Clinical Integration, Access Disparities and Medico-Legal Accountability.},
journal = {Current oncology reports},
volume = {28},
number = {1},
pages = {},
pmid = {42678573},
issn = {1534-6269},
mesh = {Humans ; *Telemedicine/legislation &amp; jurisprudence ; *COVID-19/epidemiology ; *Medical Oncology/legislation &amp; jurisprudence/methods ; *Health Services Accessibility/legislation &amp; jurisprudence ; *Healthcare Disparities ; *Neoplasms/therapy ; SARS-CoV-2 ; Pandemics ; Digital Health ; Liability, Legal ; },
abstract = {PURPOSE OF THE REVIEW: Tele-health has evolved from a marginal tool confined to rural populations and selected follow-up programs into a structurally integrated component of modern cancer care. Prior to COVID-19, its adoption was constrained by regulatory fragmentation, non-uniform reimbursement, and licensure barriers. This narrative review evaluates the evolutionary integration of tele-health in oncology post-COVID-19, examines digital disparities across patient populations, and addresses the medico-legal implications of this integration, with the objective of providing a comprehensive and clinically actionable framework for the governance of virtual oncology care.<br><br>RECENT FINDINGS: The pandemic acted as a global catalyst, driving telehealth to over 50% of oncology outpatient encounters in some settings, before stabilising post-pandemic at approximately 10-20% of consultations within hybrid care models. Evidence supports meaningful clinical benefits - improved access to specialist services, reduced travel burden, and sustained continuity of care - with outcomes comparable to in-person care in postoperative follow-up, symptom monitoring, and survivorship. However, persistent disparities in device availability, connectivity, and digital literacy disproportionately affect older, rural, and socioeconomically disadvantaged patients, raising the risk that geographic inequalities are replaced by technological ones. From a medico-legal standpoint, the remote modality does not modify the applicable standard of care, yet restricted physical examination and reliance on patient-reported data introduce risks of diagnostic delay and incomplete clinical assessment, with direct implications for professional liability, data protection under HIPAA and GDPR, cross-border licensure, and multi-party accountability across physicians, institutions, and technology providers. Tele-oncology has become a permanent structural feature of modern cancer care, offering demonstrable benefits in access, continuity, and patient satisfaction. Yet its integration has been uneven, its governance remains fragmented, and its medico-legal landscape is still evolving. Realising the full potential of virtual oncology care - equitably and safely - requires coherent regulatory frameworks, sustained investment in digital infrastructure, and explicit attention to the populations at greatest risk of being left behind.},
}
@article {pmid42678586,
year = {2026},
author = {Solari-Hernández, S and González-Madrid, E and González, PA and Bueno, SM and Kalergis, AM},
title = {Immune Dysregulation in Down Syndrome: Implications for Infectious Susceptibility and Vaccine Response.},
journal = {Journal of clinical immunology},
volume = {46},
number = {1},
pages = {},
pmid = {42678586},
issn = {1573-2592},
support = {ICN 2021_045//Millennium Institute on Immunology and Immunotherapy/ ; ICN 2021_045//Millennium Institute on Immunology and Immunotherapy/ ; ICN 2021_045//Millennium Institute on Immunology and Immunotherapy/ ; 1240971//Agencia Nacional de Investigaci&#xf3;n y Desarrollo/ ; 1231905//Agencia Nacional de Investigaci&#xf3;n y Desarrollo/ ; 1231851//Agencia Nacional de Investigaci&#xf3;n y Desarrollo/ ; 23CTEC-250091-P2//Corporaci&#xf3;n de Fomento de la Producci&#xf3;n (INNOVA-CORFO)/ ; },
mesh = {Humans ; *Down Syndrome/immunology ; Disease Susceptibility/immunology ; Vaccination ; Immunity, Innate ; SARS-CoV-2/immunology ; Animals ; Adaptive Immunity ; *COVID-19/immunology/prevention &amp; control ; },
abstract = {Down syndrome (DS), caused by trisomy 21, is characterized by complex immune dysregulation that increases susceptibility to infections and alters vaccine responsiveness. Gene dosage effects involving interferon receptor loci on chromosome 21 contribute to chronic type I interferon hyperactivation, sustained JAK-STAT signaling, and persistent expression of interferon-stimulated genes. This baseline inflammatory state is accompanied by quantitative and functional defects in both innate and adaptive immunity, including impaired neutrophil chemotaxis, pro-inflammatory monocyte polarization, reduced naïve T- and B-cell compartments, restricted antigen receptor diversity, diminished class-switched memory B cells, and features of accelerated immunosenescence. Clinically, these immune alterations are associated with an increased risk of severe respiratory viral infections, such as respiratory syncytial virus, influenza, and SARS-CoV-2, as well as reduced magnitude and durability of vaccine-induced immunity. Cohort studies in both pediatric and adult populations have reported higher rates of hospitalization and mortality, along with lower peak antibody titers and more rapid waning of immunity following vaccination. This review integrates molecular, cellular, and clinical evidence to define the interferon-driven immune phenotype in DS and its implications for susceptibility to infection and vaccination response. A mechanistic understanding of this immune landscape provides a framework for developing tailored preventive strategies and optimizing vaccination approaches in this vulnerable population.},
}
@article {pmid42679935,
year = {2026},
author = {Szabó, M and Perl, A and Nagy, G and Majnik, J},
title = {The renaissance of hydroxychloroquine: bridging antimicrobial immunity and autoimmunity in rheumatic diseases.},
journal = {Autoimmunity reviews},
volume = {},
number = {},
pages = {104175},
doi = {10.1016/j.autrev.2026.104175},
pmid = {42679935},
issn = {1873-0183},
abstract = {Hydroxychloroquine (HCQ) has been a cornerstone of rheumatic disease therapy for more than half a century. Its best-established immunomodulatory actions arise from endosomal and lysosomal alkalinization, with inhibition of endosomal Toll-like receptor 7/9 signaling and attenuation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) activation. Apart from these well-established mechanisms we also discuss a proposed model in which HCQ might influence CD3ζ/CD4 endocytic turnover. A structured narrative search of PubMed/MEDLINE, Scopus, and Web of Science was performed between July and November 2025. Clinically, HCQ remains foundational in systemic lupus erythematosus (SLE), whereas evidence for antiphospholipid syndrome, primary Sjögren's syndrome, lichen planus, and chronic spontaneous urticaria is limited and does not support routine use outside selected off-label settings. Randomized trials demonstrated no clinical benefit in COVID-19. Retinopathy remains the principal dose- and duration-dependent toxicity. Limiting the daily dose to ≤5 mg/kg actual body weight and following current ophthalmic screening recommendations are the main preventive measures. HCQ blood-level monitoring may support adherence assessment and exposure-informed care, but therapeutic thresholds and laboratory interpretation are not yet universally standardized. This review integrates mechanistic, clinical, and safety evidence while explicitly distinguishing established findings from hypotheses and lower-certainty observations.},
}
@article {pmid42681073,
year = {2026},
author = {Shahzad, S and Cetinkaya, A and Ozkan, SA},
title = {Recent advances in MXene-molecularly imprinted polymer hybrid nanocomposites for electrochemical detection of pandemic-related biomarkers.},
journal = {Analytical and bioanalytical chemistry},
volume = {},
number = {},
pages = {},
pmid = {42681073},
issn = {1618-2650},
abstract = {The COVID-19 outbreak highlighted the critical demand for rapid, ultra-sensitive, and selective biosensing platforms to support early diagnosis, point-of-care testing, and large-scale surveillance. Among the various sensing strategies being explored, electrochemical biosensors have attracted considerable interest due to their inherent sensitivity, simplicity, and potential for miniaturization. In this context, hybrid materials combining molecularly imprinted polymers (MIPs) with two-dimensional MXenes have recently emerged as promising platforms for biosensing applications. MXenes offer excellent electrical conductivity, hydrophilic surfaces, and abundant functional groups. At the same time, MIPs provide binding sites that recognize targets, similar to those of natural receptors, yet exhibit enhanced thermal and chemical stability. When these materials are integrated, they can provide a sensing interface that benefits from both efficient electron transfer and highly selective molecular recognition. This review highlights recent advances in MXene-MIP composite materials applied in electrochemical biosensing, with particular emphasis on their potential for pandemic diagnostics. Various fabrication approaches are discussed, including in situ polymerization on MXene sheets, electropolymerization-based surface imprinting, and layer-by-layer (LbL) or covalent grafting strategies. Such strategies allow better control of the sensing interface. Additionally, the influence of various electrochemical transduction techniques and device configurations on sensor performance is also examined. Recent reports on the detection of pandemic-associated biomarkers, such as C-reactive protein, interleukin-6, ferritin, D-dimer, and cardiac troponins, are reviewed to highlight the analytical capabilities of these hybrid systems. Finally, the main challenges that still limit practical applications, such as MXene oxidation, reproducibility of the imprinting process, and device integration, are discussed, along with possible future research directions. Overall, MXene-MIP hybrid materials appear to offer a versatile and promising route toward next-generation electrochemical biosensors for rapid and sensitive diagnostic applications.},
}
@article {pmid39899304,
year = {2025},
author = {Hanlon, P and Butterly, E and Wei, L and Wightman, H and Almazam, SAM and Alsallumi, K and Crowther, J and McChrystal, R and Rennison, H and Hughes, K and Lewsey, J and Lindsay, R and McGurnaghan, S and Petrie, J and Tomlinson, LA and Wild, S and Adler, A and Sattar, N and Phillippo, DM and Dias, S and Welton, NJ and McAllister, DA},
title = {Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.},
journal = {JAMA},
volume = {333},
number = {12},
pages = {1062-1073},
pmid = {39899304},
issn = {1538-3598},
support = {MR/W016648/1/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Aged ; Female ; Humans ; Male ; Middle Aged ; Age Factors ; Cardiovascular Diseases/epidemiology/etiology/prevention &amp; control ; *Diabetes Mellitus, Type 2/blood/complications/drug therapy ; *Dipeptidyl-Peptidase IV Inhibitors/administration &amp; dosage/adverse effects ; *Glucagon-Like Peptide-1 Receptor Agonists/administration &amp; dosage/adverse effects ; Glycated Hemoglobin/analysis ; Randomized Controlled Trials as Topic ; Sex Factors ; *Sodium-Glucose Transporter 2 Inhibitors/administration &amp; dosage/adverse effects ; Treatment Outcome ; Glycemic Control/adverse effects/methods/statistics &amp; numerical data ; Adult ; Aged, 80 and over ; Drug Therapy, Combination/adverse effects/methods ; Incidence ; },
abstract = {IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex.<br><br>OBJECTIVE: To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors.<br><br>The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes.<br><br>DATA EXTRACTION AND SYNTHESIS: Individual participant data and aggregate data were used to estimate age&#x2009;&#xd7;&#x2009;treatment interactions and sex&#x2009;&#xd7;&#x2009;treatment interactions in multilevel network meta-regression models.<br><br>MAIN OUTCOME AND MEASURES: Hemoglobin A1c (HbA1c) and MACEs.<br><br>RESULTS: Of the 601 eligible trials identified (592 trials with 309&#x202f;503 participants reported HbA1c; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168&#x202f;489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI},
0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA1c lowering with increasing age for monotherapy (AR, -0.18% [95% CrI, -0.31% to -0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, -0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per 30-year increment in age), but not for monotherapy (AR, -0.08% [95% CrI, -0.18% to 0.01%]) or triple therapy (AR, -0.01% [95% CrI, -0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex&#x2009;&#xd7;&#x2009;treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists.<br><br>CONCLUSIONS AND RELEVANCE: The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age&#x2009;&#xd7;&#x2009;treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA1c; GLP-1 receptor agonists were more cardioprotective in younger people.},
}
@article {pmid42502260,
year = {2026},
author = {Halabi, KC},
title = {The return of measles: a dangerous comeback.},
journal = {Current opinion in infectious diseases},
volume = {39},
number = {5},
pages = {500-504},
doi = {10.1097/QCO.0000000000001222},
pmid = {42502260},
issn = {1473-6527},
mesh = {Humans ; *Measles/epidemiology/prevention &amp; control ; *Disease Outbreaks/prevention &amp; control ; *Measles Vaccine/administration &amp; dosage ; Global Health ; Vaccination Hesitancy ; Vaccination/statistics &amp; numerical data ; Disease Eradication ; },
abstract = {PURPOSE OF REVIEW: Measles has reemerged as a significant global public health threat, with increasing morbidity and mortality associated with declining vaccination rates. This review summarizes current global outbreaks, history of measles, vaccination and elimination status, vaccine hesitancy, and outbreak response and lessons learned highlighting different novel digital epidemiological tools.<br><br>RECENT FINDINGS: Measles continues to surge worldwide with an estimated 11 million infections in 2024, which is more than prepandemic levels. Developing and developed countries are both facing measles outbreaks, with the United States at risk of losing measles elimination status. Recent studies have showed that worldwide percentages of two-dose measles vaccination were lower than 95% that is required to interrupt measles transmission in all WHO regions. Novel epidemiological tools such as interactive simulators, real-time use of dynamic models, serosurveillance, and others are transforming measles outbreak response and enable earlier outbreak detection, tracking, and targeted public health interventions.<br><br>SUMMARY: Vaccine hesitancy is one of the top global health threats and developing a tailored evidence-based approach is necessary to establish and maintain measles elimination.},
}
@article {pmid42578562,
year = {2026},
author = {Ramakrishna, BS},
title = {Tropical sprue: a forgotten entity.},
journal = {Current opinion in infectious diseases},
volume = {39},
number = {5},
pages = {444-449},
doi = {10.1097/QCO.0000000000001227},
pmid = {42578562},
issn = {1473-6527},
mesh = {Humans ; Diagnosis, Differential ; *Sprue, Tropical/diagnosis/epidemiology ; COVID-19/complications ; SARS-CoV-2 ; Pandemics ; Malabsorption Syndromes/diagnosis ; Irritable Bowel Syndrome/diagnosis ; Coronavirus Infections/complications ; Betacoronavirus ; },
abstract = {PURPOSE OF REVIEW: Tropical sprue, once a major cause of malabsorption syndromes, is declining in prevalence. As a consequence of its rarity, and the absence of specific diagnostic tests, diagnosis of this condition is often delayed or missed. The purpose of this review is to draw attention again to this condition and to its overlap with postinfectious irritable bowel syndrome.<br><br>RECENT FINDINGS: Sporadic case reports of diagnosis in travelers to endemic countries as well as reports of its continuing occurrence in endemic countries indicate the need for continuing diagnosis of the disease. Most recently, the COVID pandemic saw a large number of patients with postinfection gastrointestinal symptoms that lasted longer than 6&#x200a;months and were accompanied by malnutrition. These events deserve deeper investigation and resurrect coronaviruses as one possible cause of tropical sprue. Diagnosis of the disease is another evolving area and the original diagnostic criteria have to be modified in view of the lack of access to formal tests of absorption in most laboratories.<br><br>SUMMARY: Sporadic reports of nonceliac enteropathy with response to antibiotic treatment indicate that the disease needs to be considered in the differential diagnosis of malabsorption in the appropriate clinical context.},
}
@article {pmid42599129,
year = {2026},
author = {De Jesús-González, LA and Santos-Mena, AO and Farfán-Morales, CN and León-Juárez, M and Reyes-Ruiz, JM and Osuna-Ramos, JF and Cordero-Rivera, CD and Palacios-Rápalo, SN and Lira-Hernández, FI and Del Ángel, RM},
title = {A network-driven antiviral discovery pipeline for emerging RNA viruses: a critical perspective from the Red Mexicana de Desarrollo de Antivirales (RMDA).},
journal = {Expert opinion on drug discovery},
volume = {21},
number = {9},
pages = {931-951},
doi = {10.1080/17460441.2026.2716137},
pmid = {42599129},
issn = {1746-045X},
mesh = {*Antiviral Agents/pharmacology ; Humans ; *Drug Discovery/methods ; *RNA Viruses/drug effects/isolation &amp; purification ; Animals ; *RNA Virus Infections/drug therapy/virology ; Mexico ; Host-Directed Therapy ; *Communicable Diseases, Emerging/drug therapy/virology ; },
abstract = {INTRODUCTION: RNA viruses impose a disproportionate burden of emerging and reemerging infectious diseases in Latin America, yet antiviral discovery in the region remains fragmented, target-limited, and frequently disconnected from translational pathways. This perspective discusses the Red Mexicana de Desarrollo de Antivirales (RMDA) as a network-driven model to organize antiviral discovery against clinically relevant RNA viruses.<br><br>AREAS COVERED: The authors describe the conceptual architecture of RMDA, a multi-institutional Mexican initiative that integrates computational prioritization, cell-based antiviral evaluation under BSL-2/BSL-3 conditions, mechanistic virology, assessment of pharmacological synergy, in vivo validation, and clinical linkage through healthcare systems such as the Instituto Mexicano del Seguro Social. The framework is supported by prior work from participating groups on host-directed and virus-directed candidates, including metabolic modulators, lipid-lowering agents, nuclear transport inhibitors, natural products, polyphenols, melatonin, and rational drug combinations evaluated against dengue virus, Zika virus, SARS-CoV-2, respiratory syncytial virus, and related RNA viruses.<br><br>EXPERT OPINION: RMDA provides a scalable and regionally adaptable model for antiviral drug discovery in low- and middle-income settings. By aligning distributed expertise, standardized workflows, and translational decision points, this framework may accelerate candidate prioritization, reduce duplication, and strengthen preparedness against RNA virus threats in Mexico and Latin America.},
}
@article {pmid42669194,
year = {2026},
author = {Almushawah, R and Davis, D and Khan, E},
title = {Tracing the Roots of Inquiry: A Historical Review of Nursing Research Through Professionalisation Theory.},
journal = {Nursing inquiry},
volume = {33},
number = {4},
pages = {e70160},
pmid = {42669194},
issn = {1440-1800},
mesh = {Humans ; History, 20th Century ; *Nursing Research/history ; History, 21st Century ; *History of Nursing ; *Professionalism/history ; *Nursing Theory ; History, 19th Century ; },
abstract = {Nursing research has developed unevenly across history, shaped by shifting institutional structures, professional aspirations and societal demands. Yet existing historical reviews have largely adopted descriptive approaches, while few have applied an explicit theoretical lens to explain why this unevenness persists. This paper addresses that gap by examining the historical development of nursing research through Greenwood's trait-based professionalisation framework. Drawing on a narrative historical review spanning seven chronological periods, the analysis reveals a recurring pattern of partial professionalisation; nursing has consistently generated specialised knowledge yet has struggled to secure organisational infrastructure to embed and control that knowledge within clinical practice. The historical analysis suggests that knowledge production alone within a profession does not guarantee epistemic control.},
}
@article {pmid42669514,
year = {2026},
author = {Kawamoto, H and Kawase, T and Nagano, S},
title = {[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].},
journal = {[Rinsho ketsueki] The Japanese journal of clinical hematology},
volume = {67},
number = {8},
pages = {974-985},
doi = {10.11406/rinketsu.67.974},
pmid = {42669514},
issn = {0485-1439},
mesh = {Humans ; COVID-19 ; *T-Lymphocytes/transplantation/immunology ; SARS-CoV-2 ; *Immunotherapy, Adoptive/methods ; *Induced Pluripotent Stem Cells ; *Embryonic Stem Cells/cytology ; Receptors, Antigen, T-Cell/genetics ; Pandemics ; *Pneumonia, Viral/therapy/immunology ; *Leukemia/therapy ; },
abstract = {Cancer immunotherapy using patient-derived T cells genetically modified in vitro has been demonstrated to be effective. However, issues such as cost, time, and unstable quality must be resolved. To overcome these barriers, we developed the TCR-PS cell method, in which a specific TCR gene is introduced into pluripotent stem cells (PS cells), such as ES cells or iPS cells, and T cells are generated from those PS cells. We are currently preparing for a clinical trial in acute myeloid leukemia, targeting the WT1 antigen, with iPS cells provided by the CiRA Foundation as the starting material. In parallel, we are also investigating this approach for viral infections and preparing for clinical trials in COVID-19, with HLA-deficient ES cells as the starting material. This method should enable stockpiling of T cell therapies against known viruses such as SARS or avian influenza. Even for outbreaks caused by unknown viruses, it should be possible to produce T cell therapies within 100 days after the virus genome is defined.},
}
@article {pmid42670459,
year = {2026},
author = {Komada, K and Sakamoto, H and Nakatani, H},
title = {Late release of World Health Organization governing body documents: Trends in documentation timing at the World Health Assembly and Executive Board and considerations for Member State engagement.},
journal = {Global health &amp; medicine},
volume = {8},
number = {4},
pages = {248-252},
pmid = {42670459},
issn = {2434-9194},
abstract = {Timely access to documentation is essential for meaningful participation in global health governance. At the World Health Organization (WHO), governing body documents for the World Health Assembly (WHA) and the Executive Board (EB) provide the basis on which Member States assess agenda items, consult domestically, and prepare their negotiating positions. In this sense, the timing of document release directly affects transparency, accountability, and quality of decision-making. This study examines trends in documentation timing between 2016 and 2026 using data from the WHO governing body documentation portal. The findings show a clear and sustained shortening of the interval between document release and opening of WHA sessions since 2021, reaching the lowest level observed during the study period. By contrast, timelines for the EB, which were affected during the COVID-19 period, have largely recovered, suggesting that earlier circulation remains feasible in practice. Although this analysis does not directly measure downstream effects, shorter preparation periods may constrain Member States' ability to review materials carefully, coordinate across institutions, and develop negotiation strategies. These constraints may be felt most strongly by countries with limited participation capacities, potentially widening existing disparities in participation. A recent case further illustrates how late document release can affect not only meeting procedures but also depth and coherence of discussions. Despite ongoing WHO governance reforms, the timeliness of documentation has received limited attention. Ensuring earlier circulation and closer adherence to existing timelines would be a practical step toward strengthening transparency, equity, and effectiveness in global health governance.},
}
@article {pmid42670603,
year = {2026},
author = {Lu, S and Wen, J and Wang, D and Xu, M and Dai, Y and Chen, L and Li, H and Pang, D and Li, J and Li, W},
title = {From Occupational Hazard to Public Health Concern: A Bibliometric and Knowledge-Mapping Analysis of Sleep Disorders Among Nurses Worldwide (1985-2025).},
journal = {Journal of nursing management},
volume = {2026},
number = {1},
pages = {e7621317},
pmid = {42670603},
issn = {1365-2834},
support = {2024-DF-03//Nanjing Drum Tower Hospital/ ; 2026ZD1805104//National Science and Technology Major Project/ ; },
mesh = {Humans ; *Bibliometrics ; *Sleep Wake Disorders/epidemiology ; *Nurses/psychology/statistics &amp; numerical data ; COVID-19/epidemiology ; *Public Health ; },
abstract = {PURPOSE: Sleep disorders among nurses are highly prevalent, affecting well-being, clinical performance, and patient safety. A comprehensive mapping of global research trends is lacking. This study evaluates the evolution and focal points of research on sleep disorders among nurses over the last 4 decades, utilizing bibliometric analyses.<br><br>METHODS: We performed a bibliometric analysis of 1553 English-language publications retrieved from the Web of Science Core Collection (WoSCC) (1985-2025). Publication trends, country and institutional contributions, collaboration networks, cocitation, and keyword co-occurrence were analyzed.<br><br>RESULTS: Research output increased steadily, with a sharp surge after 2020, reflecting the impact of COVID-19. The United States and China were leading contributors, but international collaboration was sparse. Core themes included insomnia and sleep quality, shift work and circadian misalignment, and psychological sequelae such as stress, depression, and burnout. Recent hotspots emphasized patient safety, measurement validation, and intervention trials.<br><br>CONCLUSION: The field is expanding rapidly yet remains fragmented. Harmonized measurement, system-level interventions, and stronger international collaboration are required to translate research into sustainable improvements in nurse health and patient safety.},
}
@article {pmid42671478,
year = {2026},
author = {Basile, C and Monzo, L and Farmakis, D and Keramida, K and Liori, S and Kapelios, CJ and Sverdlov, AL and Grupper, A and Ambrosy, AP and Canonico, ME},
title = {Trials and tribulations of spironolactone in heart failure with preserved ejection fraction: Insights from the SPIRIT-HF trial.},
journal = {Heart failure reviews},
volume = {31},
number = {1},
pages = {},
pmid = {42671478},
issn = {1573-7322},
mesh = {Humans ; *Heart Failure/drug therapy/physiopathology ; *Spironolactone/therapeutic use ; *Stroke Volume/drug effects/physiology ; *Mineralocorticoid Receptor Antagonists/therapeutic use ; Randomized Controlled Trials as Topic ; },
abstract = {Heart failure with preserved ejection fraction represents a clinical challenge, accounting for at least 50% of heart failure (HF) cases globally, with a historical lack of efficacious and disease-modifying therapies. Mineralocorticoid receptor antagonists, specifically the steroidal agent spironolactone, have a strong theoretical potential to mitigate systemic inflammation, microvascular endothelial dysfunction, and myocardial fibrosis, which commonly affect patients with HF. However, the clinical validation of spironolactone has been influenced by methodological inconsistencies and safety concerns. The pivotal TOPCAT trial yielded neutral primary outcome results globally, confounded by significant geographical disparities. To provide further evidence the SPIRIT-HF trial evaluated spironolactone in a population with HF and mildly reduced or preserved ejection fraction. This trial was affected by critical operational issues related to the COVID-19 pandemic, resulting in an underpowered study population with a very high study drug discontinuation rate. The trial ultimately failed to demonstrate a cardiovascular benefit on any of the evaluated outcomes. The ongoing SPIRRIT-HFpEF trial represents a pragmatic, registry-based study to overcome traditional enrollment barriers, while evidence from the FINEARTS-HF trial on finerenone, a novel non-steroidal antagonist, has finally highlighted a major role for mineralocorticoid receptor antagonism in patients with HF and mildly reduced or preserved ejection fraction. This meeting report examines the SPIRIT-HF trial and place its results within the broader evidence on steroidal and nonsteroidal MRA in patients with HFpEF.},
}
@article {pmid42674298,
year = {2026},
author = {Loubet, P and Roubille, F and Launay, O and Fourati, S and Peretz, F and Rojido, C and Bricout, H and Touron, C and Martyn, O},
title = {Cardiovascular Outcomes and Acute Human Metapneumovirus Infection in Adults: A Systematic Literature Review.},
journal = {The Journal of infection},
volume = {},
number = {},
pages = {106843},
doi = {10.1016/j.jinf.2026.106843},
pmid = {42674298},
issn = {1532-2742},
abstract = {OBJECTIVES: Acute respiratory viral infections, including influenza, RSV, and SARS-CoV-2, are well-recognized as being associated with cardiovascular events (CVEs). In contrast, the cardiovascular impact of human metapneumovirus (HMPV) remains poorly characterized. We aimed to describe the prevalence of pre-existing cardiovascular diseases (CVDs) and the incidence of acute CVEs in adults with laboratory-confirmed HMPV infection.<br><br>METHODS: PRISMA-guided systematic literature review of MEDLINE, Embase, and Google Scholar (Jan.-2000/Sept.-2025). Observational studies and clinical trials reporting pre-existing CVDs and/or CVEs in adults (&#x2265;18 years) were included.<br><br>RESULTS: Eighteen studies met the inclusion criteria, of which nine underwent critical appraisal. Most involved hospitalized older adults. Pre-existing CVD was reported in 10%-80% of HMPV-infected patients, with chronic heart failure and coronary artery disease being the most common conditions. Acute CVEs, particularly heart failure exacerbations, occurred in 5%-25% of hospitalized patients. Underlying CVD was consistently linked to increased severity of HMPV illness, including higher rates of ICU admission and mortality.<br><br>CONCLUSIONS: Acute HMPV infection frequently occurs in adults with pre-existing CVD and may be associated with CVEs in older hospitalized populations. However, evidence remains limited and largely observational. These findings highlight the need to increase awareness of the potential CV complications associated with HMPV infection.<br><br>TRIAL REGISTRATION: PROSPERO [CRD420251164583].},
}
@article {pmid42674773,
year = {2026},
author = {Sankar, J and K H, PP and Ranjit, S},
title = {The evolution of paediatric dengue management over the past three decades-a historical perspective.},
journal = {Journal of tropical pediatrics},
volume = {72},
number = {5},
pages = {},
doi = {10.1093/tropej/fmag058},
pmid = {42674773},
issn = {1465-3664},
mesh = {Humans ; Child ; *Dengue/therapy/diagnosis/history ; History, 20th Century ; *Severe Dengue/therapy/diagnosis/history ; History, 21st Century ; COVID-19/epidemiology ; Dengue Virus ; World Health Organization ; SARS-CoV-2 ; },
abstract = {Over the past three decades, the recognition and management of dengue fever (DF) and severe dengue (SD) in children have undergone significant transformation. In the 1990s, limited understanding of dengue pathophysiology led to delayed recognition, with aggressive fluid resuscitation, invasive ventilation, and frequent blood product use, often resulting in adverse outcomes. The 1997 World Health Organisation (WHO) Guidelines introduced a structured classification and emphasized cautious fluid management, improving survival. Advances in diagnostics, particularly non-structural (NS) protein antigen testing, enabled earlier detection in the 2000s. The revised WHO 2009 classification and recognition of Expanded Dengue Syndrome (EDS) in 2012 broadened the understanding of severe organ involvement beyond plasma leakage. In the 2020s, improved intensive care unit (ICU) technologies enabled advanced organ support, and the coronavirus disease of 2019 (COVID-19) pandemic highlighted potential viral interactions. Ongoing controversy remains regarding the role of immunomodulation for dengue-associated hyperinflammation. Continued clinical research is essential to refine management strategies and optimize outcomes in severe dengue.},
}
@article {pmid42203176,
year = {2026},
author = {St-Jean, A and Moriello, C and Yu, OHY and Suissa, S and Filion, KB},
title = {A systematic review of observational studies of sodium-glucose cotransporter 2 inhibitors and COVID-19 outcomes: a methodological assessment.},
journal = {Journal of clinical epidemiology},
volume = {197},
number = {},
pages = {112347},
doi = {10.1016/j.jclinepi.2026.112347},
pmid = {42203176},
issn = {1878-5921},
mesh = {Humans ; *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; *Diabetes Mellitus, Type 2/drug therapy/mortality ; *COVID-19/mortality ; Observational Studies as Topic ; *Hospitalization/statistics &amp; numerical data ; *Hypoglycemic Agents/therapeutic use ; SARS-CoV-2 ; },
abstract = {OBJECTIVES: To conduct a systematic review of observational studies examining the association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of mortality and of hospitalization compared with the use of other antidiabetic medications in patients with type two diabetes and COVID-19, with a focus on the methodological quality. We also describe how such studies can be improved when addressing a public health emergency.<br><br>STUDY DESIGN AND SETTING: We conducted a systematic review by searching Embase, MEDLINE, and the WHO COVID-19 research article databases up to March 2025. Observational studies reporting on the risk of mortality and of hospitalization with the use of SGLT2 inhibitors among patients with type two diabetes and COVID-19 were included and study quality was assessed using the ROBINS-I tool. Our systematic review focused on the methodological assessment of the literature.<br><br>RESULTS: We included 20 cohort studies, with 18 reporting on all-cause mortality and eight on COVID-19-related hospitalization. Five studies reported a decreased risk of all-cause mortality (range of effects estimates: 0.25 to 0.82), compared with nonuse or use of other drugs, and four studies reported a decreased risk of hospitalization (range: 0.79 to 0.92); the others reported no association. Overall, 14 studies were at serious risk of bias and six were at critical risk. We identified several methodological issues related to the selection of participants, inadequate control of confounding, and assessment of exposure and outcomes. No meta-analysis was conducted due to the low quality and heterogeneity of the included studies.<br><br>CONCLUSIONS: The observational studies examining the effectiveness of SGLT2 inhibitors among patients with type two diabetes and COVID-19 outcomes have important methodological issues that limit the conclusions that can be drawn from this knowledge base. Although public health emergencies require rapid responses, methodological rigor remains essential to generate actionable evidence.},
}
@article {pmid42309365,
year = {2026},
author = {Bidonde, J and González-Teshima, LY and Moreno López, SM and Avendaño Capriles, CA and Hernández Woodbine, MJ and Ramírez Varela, A and Meneses-Echavez, JF and Gaviria Valencia, S and Siemieniuk, RAC and Zeraatkar, D and Bartoszko, JJ and Brignardello-Petersen, R and Honarmand, K and Rochwerg, B and Guyatt, G and Yepes-Nuñez, JJ},
title = {Patient-important outcomes reported as primary outcomes in clinical studies of treatments for COVID-19: a meta-epidemiological study.},
journal = {Journal of clinical epidemiology},
volume = {197},
number = {},
pages = {112382},
doi = {10.1016/j.jclinepi.2026.112382},
pmid = {42309365},
issn = {1878-5921},
mesh = {Humans ; COVID-19/therapy ; Randomized Controlled Trials as Topic ; *Patient Reported Outcome Measures ; SARS-CoV-2 ; Pandemics ; Treatment Outcome ; *Coronavirus Infections/therapy/mortality/epidemiology ; *Pneumonia, Viral/therapy/mortality ; Epidemiologic Studies ; Severity of Illness Index ; },
abstract = {OBJECTIVES: The reporting of patient-important outcomes (PIOs) in randomized controlled trials (RCTs) for COVID-19 varies widely, limiting their application in clinical decision-making. We evaluated how often PIOs were reported as primary outcomes in RCTs of COVID-19 treatments and identified trial characteristics associated with their reporting.<br><br>STUDY DESIGN AND SETTING: This meta-epidemiological study analyzed primary outcome data from 102 RCTs evaluating COVID-19 treatments.<br><br>RESULTS: Mortality outcomes were more frequently reported in trials with 15- to 28-day follow-up than in trials with &#x2264;14-day follow-up (OR: 3.53, 95% CI: 1.10-11.38), and less frequently in trials enrolling participants with moderate-severity COVID-19 compared with trials not enrolling such participants (odds ratio [OR]: 0.22, 95% confidence interval [CI]: 0.07-0.64). Morbidity outcomes were less frequently reported in trials enrolling severe-COVID-19 participants compared with trials not enrolling them (OR: 0.19, 95% CI: 0.05-0.78), and more frequently reported in trials conducted in Europe (OR: 12.78, 95% CI: 1.01-161.76), Asia (OR: 11.03, 95% CI: 1.50-81.03) and the Americas (OR: 8.92, 95% CI: 1.08-73.89), each compared with multicontinental trials. Trials with more than 200 participants were also more likely to report morbidity outcomes than trials with &#x2264;50 participants (OR: 11.43, 95% CI: 1.37-95.55). Quality of life and functional status outcomes were not associated with any of the predictors examined.<br><br>CONCLUSIONS: Reporting of PIOs as primary outcomes in COVID-19 RCTs is inconsistent and influenced by region, disease severity, and sample size. Quality of life and functional recovery remain overlooked. The implementation of core outcome sets) is required to ensure that PIOs are routinely and consistently incorporated into trial designs.<br><br>PLAIN LANGUAGE SUMMARY: Clinical trials should measure outcomes that matter most to patients, such as survival and quality of life. We investigated whether COVID-19 trials prioritized these outcomes as their main goals. We analyzed 102 COVID-19 trials and found that while survival and clinical complications were frequently measured, quality of life and long-term recovery were rarely used as primary goals. The choice of what to measure was often influenced by the trial's location or size rather than patient needs. The lack of focus on quality of life limits the ability of trials to inform decisions that reflect what patients truly value. Future research should use standardized "patient-important outcomes" to ensure clinical trials remain relevant to the people they intend to help.},
}
@article {pmid42664754,
year = {2026},
author = {Atoom, AM and Rizaev, J and Polatova, D and Patel, PN and Jamuna, KV and Maharana, L and Bainsal, N and Singhal, D},
title = {Acute respiratory viral inflammation and metastatic dormancy: direct evidence, mechanistic convergence, and research priorities.},
journal = {Cancer treatment and research communications},
volume = {49},
number = {},
pages = {101403},
doi = {10.1016/j.ctarc.2026.101403},
pmid = {42664754},
issn = {2468-2942},
abstract = {Metastatic relapse can arise years after apparently successful treatment because disseminated cancer cells (DCCs) persist in reversible states of cellular, angiogenic, or immune-mediated dormancy. The strongest direct evidence that acute viral inflammation can disturb this equilibrium currently comes from experimental breast-cancer lung-dormancy models in which influenza A virus or SARS-CoV-2 promoted DCC cell-cycle re-entry and metastatic expansion, with interleukin-6 (IL-6) required for the initial awakening phenotype. Human findings reported in the same study are observational and do not establish that respiratory viral infection causes metastatic relapse. This hypothesis-generating Perspective therefore separates direct viral-dormancy evidence from direct inflammation-dormancy evidence, established metastatic-niche biology, mechanistic extrapolation, and unvalidated clinical hypotheses. We critically evaluate IL-6/JAK/STAT3 signaling, the time-dependent balance between antiviral and antitumor immunity, neutrophil extracellular trap-mediated matrix remodeling, epithelial RNA sensing, endothelial and perivascular responses, and selected extracellular-vesicle mechanisms. The evidence does not establish a universal infection-to-niche-to-relapse pathway across cancers or organs. Instead, it supports a context-dependent model in which respiratory infection may transiently perturb the DCC-niche equilibrium in susceptible settings. Priority studies should independently replicate the pulmonary phenotype, define causal timing, distinguish local lung injury from systemic effects, test cross-cancer and cross-organ generalizability, and prospectively evaluate human associations. No post-viral biomarker panel, intensified imaging strategy, or pathway-directed intervention is currently validated for routine clinical use.},
}
@article {pmid42664981,
year = {2026},
author = {Chalmers, J and Bansal, K and Scott, R and Hamilton, F and Payne, R and Lim, WS and Waterer, G and Shaw, J and Kagima, J and Bibby, A and Maskell, N and Arnold, D},
title = {Community-acquired pneumonia in adults: acute and long-term complications.},
journal = {The lancet. Healthy longevity},
volume = {},
number = {},
pages = {100872},
doi = {10.1016/j.lanhl.2026.100872},
pmid = {42664981},
issn = {2666-7568},
abstract = {Annually, community-acquired pneumonia (CAP) affects millions of individuals worldwide, resulting in more than 200 000 hospital admissions in England alone. CAP is a major cause of morbidity and mortality. Previous studies have explored the causes, risk factors, and the clinical course of CAP in detail. Sepsis and respiratory failure are important well-recognised consequences of progressive infection and have been researched extensively. In this Review, we focus on complications of CAP beyond the natural history of the condition. These sequelae of CAP often have long-term implications for patients and encompass a wide range of physical, functional, and psychosocial impairments, including reduced functional ability and persistent symptoms that adversely affect quality of life. Research on complications after CAP has increased since the COVID-19 pandemic. A growing body of literature informs clinical trials and guides clinical management. We explore the recovery trajectory and discuss updates in the management of post-CAP pleural infection, the established risk of cardiovascular events after CAP, and association of CAP with cognitive impairment and lung cancer. Finally, we conclude that improved long-term data, standardisation, and targeted research are needed to understand, prevent, and manage these outcomes effectively.},
}
@article {pmid42665337,
year = {2026},
author = {Richards, DP and Fink, C and Granieri, M and Kobow, K and Lane, T and Lillie, D and Mitchell, K and Munro, C and Smith, M and Walz, M and Marlin, S},
title = {Partnering with patients and the public in the clinical trials ecosystem: a decade of lessons learned and shared.},
journal = {BMJ open},
volume = {16},
number = {8},
pages = {e099469},
doi = {10.1136/bmjopen-2025-099469},
pmid = {42665337},
issn = {2044-6055},
mesh = {Humans ; *Clinical Trials as Topic/organization &amp; administration ; *Patient Participation ; Ontario ; COVID-19/epidemiology ; *Community Participation ; },
abstract = {BACKGROUND: In the health research space, it is becoming more common to see patient and public partners as members of teams and contributing to various initiatives rather than solely as participants in research. We use the term patient and public engagement (PPE) to describe this approach. While reporting mechanisms such as the Guidance for Reporting Involvement of Patients and the Public, Version 2 (GRIPP2), are being used to share teams' PPE efforts related to specific research projects, to date we have seen less about how organisations have collaborated with patient and public partners on a broader scale. Clinical Trials Ontario (CTO) is a not-for-profit organisation in the clinical trials space that has been set up to improve the environment for trials rather than conduct trials. We share CTO's PPE processes, how they have evolved over the past decade, outputs related to this work, and lessons learned.<br><br>METHODS: Patient and public partners and team members from CTO used a co-production model. We have co-developed PPE processes to guide and carry out the work under CTO's strategic pillar of Engage. The Patient and Public Engagement Evaluation Tool has played a role in helping ensure CTO's approaches to co-production are on track. Feedback and insights provided in the evaluation tool after engagements have resulted in iterative changes to this work.<br><br>RESULTS: CTO has engaged patient and public partners in its work since its inception in 2014. Gradually, this work has evolved based on both the needs of CTO and the patient and public partners with whom it collaborates. Originally, a small group called the patient and public advisory group was created, which met quarterly in person and provided guidance related to specific products (eg, CTO's website about clinical trials, a clinical trial finder). Based on lessons learned with that group and the abilities of people to participate, the group was expanded to become CTO's College of Lived Experience. The College of Lived Experience includes more perspectives and meets more frequently and predominantly virtually, having been formed just before the COVID-19 pandemic was declared. Working with the College has resulted in: members being embedded in a range of CTO projects, a number of public-facing outputs and generating a research idea and carrying out a project that resulted in a patient partner co-authored, peer-reviewed publication. The College is also available to and has provided input and insights into projects and initiatives outside of CTO. We share lessons learned from organisational perspectives and from those College members who are co-authors of this work.<br><br>CONCLUSIONS: CTO's work in PPE has resulted in a co-production model that is critical to efforts in CTO's Engage strategic pillar and beyond. We provide templates and outputs of this co-production work and lessons learned. We hope our work helps other clinical trials organisations across the globe to include patient and public partners in their operational efforts.},
}
@article {pmid42666214,
year = {2026},
author = {Kassymbek, S and Abduldayeva, A and Safonov, N and Doszhanova, G},
title = {Risk factors for post-COVID-19 condition among previously hospitalized COVID-19 patients: a systematic review and meta-analysis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1911482},
pmid = {42666214},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology/complications/therapy ; Risk Factors ; *Hospitalization/statistics &amp; numerical data ; Post-Acute COVID-19 Syndrome ; Female ; },
abstract = {BACKGROUND: Post-COVID-19 condition is a major source of long-term morbidity after SARS-CoV-2 infection. Patients hospitalized for COVID-19 may be at particularly high risk because hospitalization often reflects greater acute disease severity and comorbidity burden. However, evidence on risk factors in previously hospitalized populations remains inconsistent due to differences in outcome definitions, follow-up periods, and analytical approaches. This systematic review and meta-analysis aimed to identify risk factors associated with post-COVID outcomes among patients previously hospitalized for COVID-19.<br><br>METHODS: A systematic review and meta-analysis was conducted following PRISMA 2020 principles. PubMed/MEDLINE, Scopus, Web of Science Core Collection, and the WHO COVID-19 Global Literature Database were searched for studies published between 1 January 2020 and 24 February 2026. Eligible studies included hospitalized patients with confirmed or probable COVID-19, assessed post-acute outcomes at least 4 weeks after acute infection, hospitalization, recovery, or discharge, and evaluated at least one candidate risk factor. Adjusted effect estimates were prioritized, and random-effects meta-analyses were performed when at least two comparable estimates were available.<br><br>RESULTS: Eleven studies were included in the qualitative synthesis, and seven contributed to quantitative meta-analysis. Five risk-factor groups were pooled: female sex, acute disease severity or respiratory support, intensive care unit (ICU) admission, vaccination status, and hypertension. Female sex was associated with higher odds of post-COVID outcomes (OR 1.94, 95% CI 1.60-2.35; I [2] = 6.9%). The strongest association was observed for greater acute disease severity or advanced respiratory support (OR 2.55, 95% CI 1.77-3.68; I [2] = 13.0%). ICU admission (OR 1.88, 95% CI 1.24-2.83), no or incomplete vaccination (OR 1.90, 95% CI 1.33-2.72), and hypertension (OR 1.60, 95% CI 1.16-2.20) were also associated with increased odds. Additional predictors, including obesity, age, smoking, dysgeusia, symptom burden, and neurological or psychiatric comorbidity, were summarized narratively.<br><br>CONCLUSION: Among previously hospitalized COVID-19 patients, the most consistent risk factors for post-COVID outcomes were female sex, greater acute disease severity or respiratory support, ICU admission, no or incomplete vaccination, and hypertension. These findings support risk-based post-discharge follow-up, although the evidence remains limited by heterogeneous outcome definitions and the small number of studies available for several risk factors.},
}
@article {pmid42666419,
year = {2026},
author = {Aguillon, R and Dufourcq, P and Batut, J},
title = {Mechanical constraints on cell plasticity: insights from the olfactory epithelium.},
journal = {Frontiers in cell and developmental biology},
volume = {14},
number = {},
pages = {1841670},
pmid = {42666419},
issn = {2296-634X},
abstract = {The olfactory epithelium (OE) is a unique model to study how mechanical forces and tissue architecture regulate stem cell plasticity. In vertebrate, its lifelong neurogenesis and regenerative capacity depend on horizontal basal cells and globose basal cells, whose plasticity is gated by niche architecture and morphogenetic cues. While molecular pathways in OE development and regeneration are well-characterized, the role of physical forces, from basal niche stiffness to lamellar folding, remains unexplored. This review integrates single-cell analyses, developmental studies, and mechanobiology to propose that the unique structure of the OE (pseudostratified epithelium, spatial compartmentalization) and conserved pathways (YAP, CXCR4, retinoic acid) coordinate plasticity across ontogeny. We discuss how disrupted mechanoregulation might drive olfactory deficits in aging, infection (COVID-19), congenital disorders (Kallmann syndrome), cancer, and outline key questions and processes to decode the mechanobiological rules governing stem cell and progenitor plasticity. A table summarising the tools available at the cellular and tissue levels for manipulating forces and visualising their effects is provided.},
}
@article {pmid42667567,
year = {2026},
author = {Vekety, B and Takacs, ZK and Kói, T and Protzko, J and Whalley, HC and Logemann, HNA},
title = {Kids These Days! A Cross-Temporal Meta-Analysis of Changes in Emotional and Behavioral Problems of Population-Based Samples Over the Past Decades.},
journal = {Clinical child and family psychology review},
volume = {},
number = {},
pages = {},
pmid = {42667567},
issn = {1573-2827},
support = {&#xda;NKP-22-4//National Research, Development and Innovation Fund/ ; },
abstract = {There is a general belief that mental health problems are increasing in younger generations, though little objective comparisons exist. The current meta-analysis examines changes in subclinical mean-level overall symptom burden and shifts in specific domains among population-based samples of youth (1-18 years) globally over the last four decades. We search systematically in PubMed, Web of Science, Scopus, EBSCO and Google Scholar with pre-registered criteria. Included studies (k = 175, N = 418,528) use the standardized and cross-culturally validated Child Behavior Checklist with parent-, teacher-, and self-report. A cross-temporal meta-analysis is conducted with data points between 1981 to 2019. Age, sex, response rate, and geographic continent, used as moderators. Meta-regression analyses, with year of data collection as a predictor, shows overall symptom burden did not change in the past 40 years except for some decreases in early childhood (parent report), middle childhood (self-report) and teenage boys (self-report). There is evidence of change in specific symptom domains. We find strong, multi-informant evidence for decreased externalizing problems (parent report and self-report in girls) including aggression in middle childhood over time (parent report and self-report), and internalizing problems (parent and teacher report of boys and girls) in middle childhood. Single-informant changes show varying patterns in subscales of internalizing problems with increases in anxiety/depression in teens (parent report) and somatic complaints in teenage boys (self-report) next to a decrease in withdrawn/depressed symptoms (self-report of children and youth overall and parent report in middle childhood). Further single-informant changes suggest an increase in social problems in European teens (self-report) and a decrease in rule-breaking behavior (parent report). Finally, contradicting results were found for attention problems (an increase based on parent report and a decrease in middle childhood boys based on teacher report) and thought problems (an increase based on parent report and decrease in teenage boys based on self-report). However, the finding regarding attention problems should be interpreted cautiously given declining reliability of the subscale over time and evidence suggesting potential measurement non-invariance. In sum, our results do not support concerns that young people today have more overall symptom burden than previous generations, rather, they show a different composition of symptom profiles. However, an important limitation of the study is that post COVID-19 changes were not studied.},
}
@article {pmid42664121,
year = {2026},
author = {Del Parco, F},
title = {Beyond Exposure: A Comprehensive Vision for Healthcare Worker Protection.},
journal = {La Clinica terapeutica},
volume = {177},
number = {5},
pages = {1025-1027},
doi = {10.7417/CT.2026.2101},
pmid = {42664121},
issn = {1972-6007},
mesh = {Humans ; *COVID-19/prevention &amp; control ; *Health Personnel/psychology ; *Occupational Health ; Burnout, Professional/prevention &amp; control ; Working Conditions ; *Pandemics/prevention &amp; control ; SARS-CoV-2 ; *Coronavirus Infections/prevention &amp; control/epidemiology/transmission ; Health Promotion ; *Pneumonia, Viral/prevention &amp; control/epidemiology/transmission ; Occupational Stress/prevention &amp; control ; *Betacoronavirus ; Frontline Workers ; },
abstract = {The protection of healthcare workers (HCWs) requires an integrated approach addressing both traditional occupational hazards and psychosocial challenges. The COVID-19 pandemic demonstrated that HCW safety cannot rely solely on infection prevention but must also consider work-related stress, burnout, and organisational determinants of well-being. Contact tracing supported the prevention of SARS-CoV-2 transmission, while validated tools such as the Mini-Z questionnaire enabled the assessment of stress and burnout. Evidence highlights the association between occupational stress and poorer health-related quality of life, supporting the need for comprehensive strategies. The Total Worker Health® framework integrates occupational safety, health promotion, and organisational well-being, combining individual interventions with organisational measures. A multidimensional approach based on surveillance, assessment, and evidence-based interventions is essential to promote resilient healthcare systems and sustainable working conditions.},
}
@article {pmid42664145,
year = {2026},
author = {Naddeo, N and Faraci, G},
title = {From Infection Control to Healthcare System Resilience: Lessons Learned from SARS-CoV-2 Research in Healthcare Workers.},
journal = {La Clinica terapeutica},
volume = {177},
number = {5},
pages = {1234-1237},
doi = {10.7417/CT.2026.2125},
pmid = {42664145},
issn = {1972-6007},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *Health Personnel/psychology ; *Infection Control/organization &amp; administration ; SARS-CoV-2 ; *Pandemics/prevention &amp; control ; *Delivery of Health Care/organization &amp; administration ; Public Health Infrastructure ; *Pneumonia, Viral/prevention &amp; control/epidemiology/transmission ; *Coronavirus Infections/prevention &amp; control/epidemiology/transmission ; *Betacoronavirus ; Occupational Health ; Contact Tracing ; Frontline Workers ; Working Conditions ; Vaccination ; },
abstract = {The COVID-19 pandemic placed unprecedented pressure on healthcare systems and exposed healthcare workers (HCWs) to biological hazards, organizational pressures, and psychological strain. Evidence generated during the emergency shows that HCW protection cannot rely on isolated measures, but requires an integrated framework combining epidemiological surveillance, contact tracing, infection prevention and control, vaccination, occupational health, and workforce support. Contact tracing helped identify occupational exposures and clarify how duration, proximity, and inadequate use of personal protective equipment jointly shaped infection risk. Subsequent studies of reinfection showed that susceptibility reflected the interaction of viral circulation, individual immunity, and vaccination status. Vaccination reduced the clinical impact of SARS-CoV-2 and supported service continuity, although uptake depended on trust, communication, and management of adverse event concerns. The pandemic also highlighted substantial economic consequences and a high burden of psychological distress and burnout among HCWs. Building on this evidence, future preparedness should translate these lessons into permanent, adaptable infrastructure rather than temporary emergency arrangements, integrating interoperable, AI-assisted surveillance capable of combining occupational, diagnostic, vaccination, and genomic data to detect emerging risks early, while ensuring robust data governance and human oversight. Equally central is the need to address long-term workforce vulnerabilities, including Long COVID, attrition, and burnout, through early identification, rehabilitation, flexible return-to-work models, and sustained psychosocial support. Achieving this requires structured multidisciplinary collaboration among occupational medicine, infection control, epidemiology, mental health, and digital health specialists, moving from fragmented infection-control protocols to an integrated, proactive, and learning-oriented preparedness strategy. Protecting HCWs is therefore not only an occupational safety priority but a foundational prerequisite for safe, equitable, and sustainable healthcare delivery during future infectious threats.},
}
@article {pmid42661818,
year = {2026},
author = {Khan, S and Mehmood, A and Rehman, N and Khitab, U and Wang, X},
title = {Recombinase polymerase amplification: transforming rapid detection of infectious diseases.},
journal = {Virusdisease},
volume = {37},
number = {2},
pages = {106-125},
pmid = {42661818},
issn = {2347-3584},
abstract = {UNLABELLED: Pathogens are the agents responsible for these infections, and they use various mechanisms to invade and evade host defenses, emphasizing the importance of early detection. Molecular techniques such as polymerase chain reaction (PCR) have become the gold standard for detecting viral and bacterial pathogens due to their high sensitivity, specificity, and well-established validation. However, PCR requires thermal cycling equipment, a stable power supply, and trained personnel, which may limit its accessibility in resource-constrained settings. Isothermal amplification techniques are promising alternatives to PCR by providing simplicity, speed, and portability. Among these, recombinase polymerase amplification is particularly notable for its versatility, rapidity, and efficiency in amplifying nucleic acids at constant temperatures. This review discusses pathogen invasion mechanisms and recent advances in molecular diagnostics, with particular emphasis on RPA. The principles of RPA are compared with PCR, highlighting key advantages such as rapid amplification (typically within 20 min), low-temperature operation, minimal instrumentation, and compatibility with point-of-care (POC) platforms. At the same time, limitations of RPA, including primer design complexity, potential non-specific amplification, and current cost considerations, are addressed. RPA represents a versatile and promising tool that complements existing molecular methods and holds significant potential for expanding early infectious disease detection, particularly in decentralized and low-resource environments. By enabling timely and accessible diagnostics, RPA contributes substantially to improved disease surveillance, control, and patient outcomes.<br><br>GRAPHICAL ABSTRACT: Traditional detection methodologies, such as culturing, PCR, and isothermal amplification techniques, with a focus on RPA. Due to its simple procedure, short detection time, high sensitivity and specificity, and suitability for point-of-care testing in remote areas, RPA can be the best alternative for the detection of infectious diseases.},
}
@article {pmid42662919,
year = {2026},
author = {Zhang, Y and Krupinsky, KC and Lauring, AS and Marr, LC},
title = {Heterogeneity of Airborne Virus Transmission in the Built Environment: A Narrative Review.},
journal = {Pathogens &amp; immunity},
volume = {11},
number = {2},
pages = {66-95},
pmid = {42662919},
issn = {2469-2964},
abstract = {The COVID-19 pandemic accelerated recognition of airborne transmission of respiratory infections. Despite improved mechanistic understanding, our ability to predict the risk of infection in a given scenario remains limited, owing, in part, to high heterogeneity in factors involved in transmission. The goal of this work is to quantify variability in factors that control risk of airborne virus transmission in the built environment. Using SARS-CoV-2 as a model, we conducted a narrative review on transmission via inhalable respiratory particles (≤100 μm). We divided transmission into 3 key processes: emissions of virus in respiratory particles from an infected individual (the source) into the air; transport and decay of virus in the environment; and deposition and infection in a new host (the receiver). Among the source-related factors, we found large variabilities spanning 7 or more orders of magnitude. For example, the rate of respiratory emissions from an infected individual ranges from ~1 to > 10[7] particles per second, depending in part on the type of respiratory activity and individual physiological factors. Unexplained inter-individual variations, such as those defining "superemitters," introduce additional uncertainties. We also found considerable variability in the physical and biological decay of virus-laden particles as they move from the source to the receiver. The air exchange rate, which controls physical loss of particles by ventilation, ranges from ~0.01 to > 20 air changes per hour in typical buildings. Lastly, upon inhalation, the efficiency and site of virus deposition vary with the physiological state of the receiver, whose immunological status further influences whether infection is established. Overall, we found the largest variability in the rate of respiratory particle production and viral load of respiratory fluid. These 2 factors determine the amount of virus released into the air by an infected person, which is a critical indicator of the potential for onward transmission. Predicting the risk of infection in a specific scenario remains challenging due to the combined effects of variability in key determinants.},
}
@article {pmid42663308,
year = {2026},
author = {Ali, M and Brady, MC and Campbell, P and Rooney, S and Williams, L and Paul, L and Mason, H and Manoukian, S and Chung, C and Barber, M and McGoldrick, C and Smith, A and Basu, N and Patel, M and VandenBerg, K and Papadopoulou, A and Abdelaal, A and Abraham, SJ and Abu Sayf, A and Agergaard, J and Alawna, M and Albu, S and Alric, L and Andino, P and Antczak, J and Arutyunov, A and Ayyıldız, A and Badrick, E and Yalcin Bahat, P and Ballouz, T and Balsano, C and Bassetti, M and Bendersky, M and Berton, D and Biancari, F and Blomberg, B and Boari, GE and Bonetti, S and Bosaeed, M and Bouteleux, B and Brugaletta, S and Bychinin, M and Callebaut, I and Carter, SJ and Chudzik, M and Coelho, J and Cornejo-Giraldo, M and Costi, S and Darcis, G and Darley, DR and Di Baigio, A and Di Stadio, A and Dreher, M and Enikeev, D and Evans, R and Falcão, LFM and Fehrmann, C and Fugazzaro, S and Gamberini, L and Gencer, FK and Alberto Gonzalez, C and Hamilton, F and Harrison, C and Hayden, MC and Hedlin, H and Heijenbrok-Kal, M and Hellemons, ME and Ingadottir, B and Jagannathan, P and Khokhlov, R and Khokhlov, L and Knight, D and Kollum, M and Kolstad, H and Kopittke, L and Ashman Kröönström, L and Langeland, N and Lawlor, C and Levitt, ML and Santos Lira, F and Loffler-Ragg, J and Lui, DT and Mahmud, R and Małek, &#x141; and Margalit, I and Marti-Beltran, S and Martineau, A and Masia, M and Mathew, P and Mautner, G and Mazeraud, A and Menges, D and Meyhoff, CS and Milne, A and Sadat Mirfazeli, F and Moein, ST and Mohamed-Hussein, AA and Monteleone, G and Murai, IH and Niklassen, AS and Nune, A and Nunez, MNS and Ortega-Paz, L and Ouellette, D and Paranhos, ACM and Pehlivan, E and Pelà, G and Pereira, FA and Persson, HC and Piva, S and Plasse, TF and Platteel, T and Porcelli, S and Prediletto, I and Raday, G and Raghavan, K and Reetz, K and Rizzoni, D and Salinas, M and Santorelli, G and Sarker, HN and P, S and Sayed, IG and Sekine, L and Shapiro, S and Shinjo, SK and Simonovich, V and Sinatti, G and Sonnweber, T and Stavrou, VT and Stessel, B and Sunnerhagen, KS and Vallejos, J and van den Berg-Emons, RJ and Visvabharathy, L and Wan, YI and Wilkinson, J and Yasuda, CL and Yuan, Z and Zavascki, AP and Zeron, MDPB and Zoëga, S and Zoni, C},
title = {Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database.},
journal = {Health and social care delivery research},
volume = {14},
number = {29},
pages = {1-160},
doi = {10.3310/GJMA0602},
pmid = {42663308},
issn = {2755-0079},
mesh = {Humans ; *COVID-19/epidemiology/psychology/mortality ; Quality of Life ; *Databases, Factual ; Female ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Identifying and addressing long-term health and societal challenges after COVID-19 is a research priority.<br><br>OBJECTIVES: To create an international, multidisciplinary COVID-19 database, and synthesise long-term outcomes, predictors and costs.<br><br>DESIGN: Systematic identification of COVID-19 data sets and meta-analysis of individual participant data on long-term outcomes after COVID-19.<br><br>SETTING: Contributed data were collected in clinical, community and research settings.<br><br>INTERVENTIONS: Interventions from original studies were included as covariates in models.<br><br>DATA SOURCES: MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, Web of Science, PsycInfo[&#xae;] (American Psychological Association, Washington, DC, USA), Cumulative Index to Nursing and Allied Health Literature, World Health Organization Global Index Medicus, Epistemonikos, LitCOVID; World Health Organization International Clinical Trials Registry Platform; ClinicalTrials.gov and supplementary searches for studies (November 2019-November 2021) were searched for studies on >&#x2005;10 people from cohort, case-control, survey or randomised controlled trial studies, across any setting, describing validated assessment instruments, symptoms, hospitalisation, discharge destination or mortality beyond 28-days after COVID-19 onset. Data were extracted by two independent reviewers.<br><br>METHODS: Principal investigators contributed fully anonymised individual participant data. Demography, equity and symptoms were described. Assessment instruments were mapped to the International Classification of Functioning, Disability and Health. Factors associated with outcomes at 3-6 months, 9-12 months and beyond 12 months of index infection, for n&#x2005;>&#x2005;500 individual participant data and >&#x2005;1 data set were described using ratio of difference, point estimates, odds ratio and 95% confidence interval, as appropriate. The Mixed Methods Appraisal Tool described study quality; models were appraised using a Grading of Recommendations Assessment, Development and Evaluation-informed approach; heterogeneity was described using I[2].<br><br>OUTCOME MEASURES: Included overall perception of health, multidomain cognitive function, anxiety, depression, stress, post-traumatic stress disorder, fatigue, strength, walking ability, mobility, coping with daily life, breathlessness, mortality, later hospitalisation and health-related quality of life.<br><br>RESULTS: PRECIOUS collated 116 data sets from 40 countries (individual participant data&#x2005;=&#x2005;62,849), comprising 20 randomised controlled trials, 13 case-control, 60 cohort 2 longitudinal, 1 survey and 20 other study types. Participants' median age was 58 years interquartile range (45-68); 34,185 (54.4%) were female; 158 unique symptoms and 137 unique assessment instruments were captured, predominantly describing International Classification of Function, Disability and Health-body functions. Women had poorer outcomes across 30/37 models, compared with men. In 15/37 models, pre-existing lung disease and increasing age were associated with poorer outcomes; hospitalisation, diabetes and chronic kidney disease were each associated with poorer outcomes in 8/37 models. Initial hospitalisation resulted in lower health-related quality of life that did not recover for up to 2 years after initial infection. Heterogeneity was low in 34/37 models; 22/37 models were of moderate and 11/37 were of low quality.<br><br>LIMITATIONS: Use of secondary data limits available covariates, outcomes and time points to those included in primary data sets; evidence was primarily based on high-income countries. There was a lack of data on longer-term healthcare resource use to estimate the costs to the healthcare system.<br><br>CONCLUSIONS: PRECIOUS contributes to the overall picture of long-term COVID-19 outcomes beyond the long-COVID condition and highlights poorer long-term outcomes in women and people with pre-existing comorbidities.<br><br>FUTURE WORK: Evidence gaps included healthcare resource use, isolation, loneliness, societal participation and return to work outcomes. Data are needed on the role of health inequity on long-term outcomes.<br><br>STUDY REGISTRATION: This study is registered as PROSPERO (CRD42020224323, IRAS ID: 293578).<br><br>FUNDING: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: NIHR132895) and is published in full in Health and Social Care Delivery Research; Vol. 14, No. 29. See the NIHR Funding and Awards website for further award information.},
}
@article {pmid42654497,
year = {2026},
author = {Wase, H and Nichlani, M and Shaikh, A and Mahanti, S and Kar, SS and Sadhu, S and Dube, R and Bellary Kuruba, MG},
title = {Post-COVID Multisystem Inflammatory Syndrome in Children with Kawasaki-like Features: A Scoping Review of Middle Eastern Evidence.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {8},
pages = {},
pmid = {42654497},
issn = {1648-9144},
mesh = {Humans ; *Systemic Inflammatory Response Syndrome/etiology/physiopathology/epidemiology/diagnosis/therapy ; Child ; *COVID-19/complications ; Middle East/epidemiology ; *Mucocutaneous Lymph Node Syndrome ; Child, Preschool ; SARS-CoV-2 ; },
abstract = {Background: Multisystem inflammatory syndrome in children (MIS-C) was recognized in 2020 as a post-infectious hyperinflammatory condition occurring 2-6 weeks after SARS-CoV-2 infection. While large studies from Europe and North America have described its clinical spectrum and outcomes, evidence from the Middle East remains limited. MIS-C shares features with Kawasaki disease (KD), including persistent fever, mucocutaneous manifestations, and cardiac involvement, but differs in age distribution, gastrointestinal involvement, and patterns of cardiac injury. Objective: To map the reported Middle Eastern evidence on the clinical and laboratory phenotype, Kawasaki-like manifestations, cardiovascular involvement, management, short-term outcomes, and evidence gaps in children with MIS-C. Methods: A scoping review was conducted using the Arksey and O'Malley framework, guided by Joanna Briggs Institute methodology and reported according to PRISMA-ScR. PubMed/MEDLINE, Scopus, Web of Science, and the WHO COVID-19 database were searched for studies published from 1 December 2020 through 30 September 2025. Two reviewers independently screened records in Rayyan and charted data using standardized forms. Findings were synthesized descriptively; numerical ranges reflect values reported across selected contributing studies and are not pooled regional estimates. Results: Twenty-seven original clinical studies met the eligibility criteria, including case reports, case series, and observational cohorts from the UAE, Saudi Arabia, Qatar, Jordan, and multinational Middle Eastern collaborations. Across the included reports, affected children were generally older than the typical classic Kawasaki disease population. Gastrointestinal symptoms were commonly reported, and myocardial dysfunction was reported more frequently than coronary artery abnormalities. Most patients received intravenous immunoglobulin, often combined with corticosteroids. Short-term outcomes were generally favorable, but the evidence was heterogeneous and follow-up was limited. No meta-analysis was performed. Conclusions: The available Middle Eastern literature suggests that MIS-C commonly presents in school-aged children with gastrointestinal, mucocutaneous, and myocardial involvement. These patterns are descriptive rather than definitive because the evidence is predominantly retrospective, geographically uneven, and methodologically heterogeneous. The principal contribution of this review is to map the regional literature and identify priorities for prospective, standardized, multicenter studies and long-term follow-up.},
}
@article {pmid42654500,
year = {2026},
author = {Christou, EE and Ashworth, JL and Soliman, NM and Kiraly, P and Aslam, T},
title = {Effect of COVID-19 on Retinal and Choroidal Microvasculature in the Pediatric Population: A Literature Review.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {8},
pages = {},
pmid = {42654500},
issn = {1648-9144},
mesh = {Humans ; Child ; *COVID-19/complications/physiopathology ; *Retinal Vessels/diagnostic imaging/physiopathology/pathology ; *Choroid/blood supply/diagnostic imaging ; Tomography, Optical Coherence/methods ; *Microvessels/diagnostic imaging ; Microcirculation ; *Systemic Inflammatory Response Syndrome/physiopathology ; SARS-CoV-2 ; },
abstract = {Backgroundand Objectives: Retinal microcirculation may serve as a surrogate marker of systemic vascular status and can be non-invasively assessed using optical coherence tomography angiography (OCTA). Emerging evidence suggests that retinal and choroidal microvascular alterations may occur following coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C), potentially reflecting systemic vascular and inflammatory processes. This review summarizes the current evidence regarding retinal and choroidal microvascular changes detected by OCTA in pediatric patients with COVID-19 and MIS-C. Materials and Methods: A structured literature search of the National Center for Biotechnology Information (NCBI) PubMed database was conducted from inception until April 2026. Original English-language studies evaluating retinal and choroidal microcirculation using OCTA in pediatric patients with COVID-19 or MIS-C were identified and reviewed. Results: Available studies suggest variable retinal and choroidal microvascular alterations following COVID-19 and MIS-C, including changes in vessel density, perfusion, and foveal avascular zone parameters. Several investigations reported reduced vessel density, particularly within the deep capillary plexus, whereas others demonstrated increased peripapillary vascular parameters or no significant differences during the observation period. Differences in patient characteristics, disease severity, timing of imaging, OCTA protocols, and study design likely contribute to the heterogeneity of the reported findings. Conclusions: OCTA represents a promising research tool for investigating retinal and choroidal microvascular alterations associated with pediatric COVID-19 and MIS-C. However, the available evidence remains limited by small observational studies, methodological heterogeneity and inconsistent findings. Larger prospective longitudinal studies using standardized imaging protocols are needed to determine the clinical significance and reproducibility of OCTA-derived parameters and to establish whether they may have potential as biomarkers of ocular or systemic vascular involvement.},
}
@article {pmid42655159,
year = {2026},
author = {Zhao, Y and Guo, R and Yang, Y and Liu, C},
title = {Structural and Mechanistic Perspectives on SARS-CoV-2 Nonstructural Protein 14-Mediated Cap Formation and Drug Discovery.},
journal = {Microorganisms},
volume = {14},
number = {8},
pages = {},
pmid = {42655159},
issn = {2076-2607},
support = {5R35GM150607-03/NH/NIH HHS/United States ; 5DP2AI177906-03/NH/NIH HHS/United States ; SSP-2024-106//Searle Scholars Program/ ; },
abstract = {SARS-CoV-2 relies on a virus-encoded RNA capping pathway to produce 5' cap structures that are essential for mRNA stability, efficient translation, and evasion of host innate immune surveillance. Within this pathway, nonstructural protein 14 (nsp14) catalyzes N7 methylation of the guanine cap, a key step that converts the cap core into a functional Cap-0 structure and enables subsequent maturation. Owing to its essential role in viral replication and its high conservation across coronaviruses, nsp14 has emerged as an attractive antiviral target. Recent structural and biochemical studies have elucidated the architecture of the nsp14 N7-methyltransferase domain, revealing an S-adenosyl-L-methionine (SAM)-dependent fold with a defined cofactor-binding site and an adjacent cap-binding pocket that orients the RNA substrate for methyl transfer. These insights have guided the development of diverse inhibitor classes, including SAM-competitive analogs, bisubstrate-like compounds, and non-nucleoside inhibitors identified through screening approaches. While early SAM-like inhibitors demonstrated target tractability, their therapeutic potential has been limited by challenges in selectivity and cellular permeability. More recent inhibitors that target the cap-binding pocket or exploit product-assisted ternary complex mechanisms highlight alternative strategies for achieving improved potency and specificity. Despite these advances, current structural models rely on truncated RNA substrates and isolated protein constructs, which may not fully capture the native catalytic environment. Future efforts to resolve nsp14 within the replication-transcription complex and develop novel inhibition strategies will be critical for advancing mechanistic understanding and antiviral development.},
}
@article {pmid42655688,
year = {2026},
author = {Dai, Y and Xia, L and Yang, Y and Qiao, G and Jin, X and Mao, X},
title = {Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics.},
journal = {Viruses},
volume = {18},
number = {8},
pages = {},
pmid = {42655688},
issn = {1999-4915},
support = {HB2023111//Xuhua Mao/ ; },
mesh = {*CRISPR-Cas Systems ; Humans ; *Respiratory Tract Infections/diagnosis/microbiology/virology ; Bacteria/genetics/isolation &amp; purification ; *Molecular Diagnostic Techniques/methods ; Viruses/genetics/isolation &amp; purification ; Nucleic Acid Amplification Techniques/methods ; Rapid Diagnostic Tests ; Fungi/genetics/isolation &amp; purification ; },
abstract = {Early, rapid, and accurate detection is essential for clinical management and epidemiological control of acute respiratory infections caused by pathogens. Traditional testing methods such as microbial culture, serological testing, and PCR are restrictive in terms of operation and logistics and are therefore not easily used in point-of-care settings. The CRISPR/Cas system is an adaptive prokaryotic immune system composed of clustered regularly interspaced short palindromic repeats and their associated proteins, which has been used as a nucleic acid diagnostic platform with programmable sequence-specific target recognition and signal-amplifying collateral cleavage activity. Existing reviews have mostly focused on the classification of Cas enzymes or amplification strategies; in this review, a pathogen-centric approach was taken, covering viral pathogens (SARS-CoV-2, influenza virus, RSV, HAdV and VZV), bacterial pathogens (Mycobacterium tuberculosis, Streptococcus pneumoniae, Mycoplasma pneumoniae and Staphylococcus aureus) and fungal pathogens (Aspergillus fumigatus and Pneumocystis jirovecii). Key technological advances, such as isothermal amplification coupling, single-vessel integrated reaction designs, amplification-free digital detection, and electrochemical biosensor integration, are evaluated for Cas9-, Cas12-, and Cas13-based systems, with their mechanistic bases outlined. The current challenges that hinder clinical translation, such as sample matrix interference, multiple signal cross-talk, crRNA off-target effects, and the lack of large-scale validation studies, are critically assessed. At the same time, future pathways for portable, integrated, and inexpensive diagnostic platforms are suggested.},
}
@article {pmid42655726,
year = {2026},
author = {Wang, D and Zhang, W and Nie, Z and Wang, X and Liu, J and Zhang, Y and Lu, Y and Mai, Z and He, X and Li, J and Gong, C and Guo, Q},
title = {A Review: Bovine Coronavirus Evolution, Molecular Epidemiology, and Genetic Variation.},
journal = {Viruses},
volume = {18},
number = {8},
pages = {},
pmid = {42655726},
issn = {1999-4915},
support = {Funded by the Xinjiang Talent Development Fund (Grant No. XJRC-2025-KJ-PY-KJLJ-032)//Xinjiang Agricultural University/ ; Funded by the Xinjiang Talent Development Fund (Grant No. XJRC-2025-KJ-KJQY-002).//Xinjiang Agricultural University/ ; Supported by the earmarked fund for XJARS (Grant No. XJARS-11-14)//Xinjiang Agricultural University/ ; Science and Technology Department of Xinjiang Uygur Autonomous Region (Grant No. 2023A02007-2-2)//Xinjiang Agricultural University/ ; },
mesh = {Animals ; *Coronavirus, Bovine/genetics/classification/immunology ; Cattle ; *Genetic Variation ; *Evolution, Molecular ; Molecular Epidemiology ; *Coronavirus Infections/veterinary/epidemiology/virology ; *Cattle Diseases/virology/epidemiology ; Phylogeny ; Genome, Viral ; Spike Glycoprotein, Coronavirus/genetics ; },
abstract = {Bovine coronavirus (BCoV) is a key pathogen causing calf diarrhea and bovine respiratory diseases, bringing sustained economic losses to the cattle industry. As an RNA virus, BCoV possesses high mutation and recombination capacities, leading to prominent genomic genetic diversity. The genome contains hypervariable and conserved regions, with the S (especially S1), HE and Open Reading Frame (ORF4) genes serving as major variation hotspots linked to viral antigenicity, tissue tropism shift and immune evasion. Host immune pressure drives strong positive selection on S protein antigenic variation. This review discusses existing research limitations and proposes future directions including genomic surveillance, reverse genetics verification and broad-spectrum vaccine development to support BCoV prevention and control.},
}
@article {pmid42655729,
year = {2026},
author = {Krnjić, H and Hrapović, A and Galijatović, A and Tipura, A and Hajdarpašić, M and Kozarić, S and Berilo, A and Odobašić, N and Hromić-Jahjefendić, A and Šutković, J},
title = {Molecular Insights into High-Pathogenicity RNA Viruses.},
journal = {Viruses},
volume = {18},
number = {8},
pages = {},
pmid = {42655729},
issn = {1999-4915},
mesh = {Humans ; *RNA Viruses/pathogenicity/genetics/drug effects/physiology ; Antiviral Agents/pharmacology/therapeutic use ; Animals ; *RNA Virus Infections/virology/drug therapy ; SARS-CoV-2 ; Host-Pathogen Interactions ; DNA-Directed RNA Polymerases/metabolism/chemistry ; Virus Replication ; Viral Proteins/metabolism/chemistry/genetics ; RNA Replication ; },
abstract = {Highly pathogenic RNA viruses, such as Ebola, SARS-CoV-2, and influenza, cause severe disease in humans. High mutation rates, which enable RNA viruses to evade immunity and escape antivirals, and their ability to spread from animals to humans and cause pandemics and outbreaks, make RNA viruses significant threats to public health. Diseases caused by Ebola, SARS-CoV-2, and influenza are prevented and treated with only a limited number of approved antiviral drugs, the effectiveness of which is limited by mutations in the viral targets. It is crucial to understand the structural determinants, molecular mechanisms, and host interactions of pathogenic RNA viruses to develop effective antiviral strategies. In this review, we discuss selected RNA viruses, focusing on the structure of their RNA polymerases and interactions with host factors during the different stages of the viral lifecycle, as well as the traditional antivirals targeting these structures and pathways. Furthermore, emerging concepts such as liquid-liquid phase separation and biomolecular condensates, and novel promising antiviral strategies are discussed. Understanding shared and distinct structures, molecular mechanisms, and host interactions across highly pathogenic RNA viruses enables the discovery of new and more effective antiviral strategies, ultimately improving clinical outcomes against evolving RNA viruses.},
}
@article {pmid42656073,
year = {2026},
author = {Geerts, JWHJ and Bosman, B and Papenhuijzen, MHG and Ferreira, J and van Meenen, D and Paulus, F and Schultz, MJ and Sodhi, K and Urlings-Strop, L and Buiteman-Kruizinga, LA},
title = {The effect of the respiratory rate on mechanical power and patient outcomes - a systematic review.},
journal = {Expert review of respiratory medicine},
volume = {},
number = {},
pages = {1-11},
doi = {10.1080/17476348.2026.2724585},
pmid = {42656073},
issn = {1747-6356},
abstract = {INTRODUCTION: Mechanical power (MP) is associated with worse clinical outcomes. Respiratory rate (RR) is a key component of MP. The aim of this systematic review was to assess whether, among mechanically ventilated adult ICU patients, a low versus high RR is associated with differences in MP, clinical outcomes and ventilation parameters.<br><br>METHODS: A comprehensive systematic search in PubMed, Embase, Cochrane Central Register of Controlled Trials and Google Scholar was performed in January 2026. Studies were included if they reported on invasively ventilated adult patients in the ICU and evaluated RR in relation to MP or patient outcomes.<br><br>RESULTS: 12 studies were included. Most studies involved patients with ARDS or COVID-19. Lower RR was associated with reduced MP across most studies. Studies using automated ventilation or protocolized RR adjustments showed the largest reductions in MP. Higher RR was associated with increased mortality in three studies. Reducing RR did not lead to significant changes in other ventilation parameters or gas exchange.<br><br>CONCLUSION: Lowering RR is a promising strategy to reduce MP with minimal effects on gas exchange over short durations. RR may represent an underrecognized setting in lung-protective ventilation, but prospective studies are needed to confirm effects on clinical outcomes.<br><br>STUDY REGISTRATION: The search strategy was registered at PROSPERO (registration number CRD420251240779).},
}
@article {pmid42658874,
year = {2026},
author = {Sharma, S and Elhassan, H and Anderson, KK and Heisel, MJ and Wilk, P and Gagnier, J},
title = {Changes in mental health outcomes of middle-aged and older adults during the COVID-19 pandemic: A scoping review.},
journal = {PloS one},
volume = {21},
number = {8},
pages = {e0342140},
pmid = {42658874},
issn = {1932-6203},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Mental Health/statistics &amp; numerical data ; Middle Aged ; Aged ; Pandemics ; Anxiety/epidemiology/psychology ; Depression/epidemiology/psychology ; SARS-CoV-2/isolation &amp; purification ; Female ; Stress, Psychological/epidemiology ; },
abstract = {The COVID-19 pandemic negatively impacted mental health, particularly among middle-aged and older adults, who have emerged as especially vulnerable. This scoping review synthesizes findings from 44 population-based studies retrieved from six databases, aiming to map changes in mental health outcomes during the pandemic and identify associated factors. During the global spread and response phase of the pandemic (May 2020-December 2021), a notable rise in depressive symptoms, anxiety symptoms, stress, distress, loneliness, and poor well-being was documented, highlighting a decrease in overall mental health of middle-aged and older adults. Whereas some studies from the transition period toward the endemic phase of the pandemic (2022-2023), began reporting signs of stabilization or improvement, particularly in depressive symptoms, anxiety symptoms and stress. Factors influencing these negative mental health outcomes were multidimensional (demographic, socioeconomic, health-related, behavioral, and COVID-19-related factors). Female sex, old age, being married, unemployment, lower education status, higher income, poor physical health, limited physical activity, perceived threat of COVID-19, social isolation, and lack of support were mainly associated with worsening mental health changes during the pandemic among middle-aged and older adults. However, there is little research highlighting population-level factors (COVID-19 cases, deaths, vaccination status, etc.) associated with these changes. Also, the evidence remains limited regarding mental health changes during the transition to the endemic phase, possibly due to shifts in research priorities, but it is essential to continue monitoring mental health outcomes to track long-term changes and to prepare for future public health emergencies.},
}
@article {pmid42661284,
year = {2026},
author = {Jang, S and Pyo, SI and Kim, EJ and Lee, W and Kwon, SS},
title = {Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2720955},
doi = {10.1080/14760584.2026.2720955},
pmid = {42661284},
issn = {1744-8395},
mesh = {Humans ; *Stroke/epidemiology/etiology ; *BNT162 Vaccine/adverse effects/administration &amp; dosage ; *Vaccination/adverse effects ; Incidence ; },
abstract = {INTRODUCTION: Whether BNT162b2 (Pfizer-BioNTech) vaccination increases stroke risk remains a public health concern. This is the first meta-analysis to synthesize self-controlled case series (SCCS)-derived stroke risk estimates specifically for BNT162b2 vaccination.<br><br>METHODS: PubMed and Embase were searched from inception through 9 May 2026, following PRISMA 2020 guidelines. Eight eligible SCCS studies were pooled using a random-effects model with restricted maximum likelihood (REML) estimation and the Knapp-Hartung adjustment.<br><br>RESULTS: Eight studies across six countries encompassing several million vaccinated individuals were included. The pooled incidence rate ratio (IRR) was 0.967 (95% CI 0.892-1.049; I[2]&#x2009;=&#x2009;69.2%), indicating no statistically significant increase in stroke risk. Subgroup analyses showed no evidence of effect modification across continent, risk-window length, dose category, SCCS variant, or age group.<br><br>CONCLUSIONS: These findings provide no evidence of increased short-term stroke risk following BNT162b2 vaccination at the population level. The observed heterogeneity appeared to be partly driven by methodological differences rather than true biological variation in vaccine effect.},
}
@article {pmid42661384,
year = {2026},
author = {Mousa, AM and Mohammed, HA},
title = {A Comprehensive Review on Cardioprotective Biological Properties of Crataegus orientalis in Post-COVID-19 Pandemic Cardiovascular Disorders.},
journal = {Molecular nutrition &amp; food research},
volume = {70},
number = {17},
pages = {e70590},
doi = {10.1002/mnfr.70590},
pmid = {42661384},
issn = {1613-4133},
support = {PRI01-2401-QU008-46530391//Saudi National Institute of Health [Saudi NIH]/ ; },
mesh = {*Crataegus/chemistry ; Humans ; *Cardiovascular Diseases/drug therapy/prevention &amp; control ; *Cardiotonic Agents/pharmacology/therapeutic use ; *COVID-19/complications ; *Plant Extracts/pharmacology/chemistry/therapeutic use ; Antioxidants/pharmacology ; SARS-CoV-2 ; Phytochemicals/pharmacology ; Animals ; COVID-19 Drug Treatment ; Anti-Inflammatory Agents/pharmacology ; Phytotherapy ; Pandemics ; },
abstract = {The growing use of herbal medicinal plants like hawthorn is recognized globally as a way to meet the demand for new natural pharmaceuticals with health benefits. The current review provides a comprehensive overview of the phytochemical constituents and heart-protective therapeutic properties of Crataegus orientalis. Despite numerous reviews on the biological properties of the Crataegus genus. C. orientalis has emerged as a promising therapeutic agent in managing the increasing cardiovascular complications that have followed the COVID-19 pandemic. This review highlights the primary cardioprotective biological effects of C. orientalis, including antioxidant, anti-inflammatory, hypolipidemic, antihyperglycemic, antihypertensive, anticoagulant, anti-ischemic, diuretic, and cardiotonic properties, supported by numerous scientific studies in Web of Science, Google Scholar, and PubMed. This updated review provides an overview of the bioactive molecular components of C. orientalis and their cardioprotective mechanisms in cardiac muscle cell biology following the post-COVID-19 Pandemic, exploring its potential as an innovative functional food dietary supplement to enhance plant-derived cardioprotective formulations and its possible health benefits. This study presents a significant challenge for analyzing the active constituents of C. orientalis, which require further research, as they are expected to be promising candidates for developing new approaches to prevent and treat various post-pandemic cardiovascular diseases (CVD).},
}
@article {pmid42647143,
year = {2026},
author = {Pattyn, J and Jindal, S and Hendrickx, G and Bechini, A and Boccalini, S and Del Riccio, M and Noehrenberg, E and Van Damme, P and Bonanni, P and Nohynek, H and Kontio, M and Järvinen, A and Salo, H and Palmu, AA},
title = {Overview of adult immunization in Finland: Successes, lessons learned and the way forward.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2715930},
doi = {10.1080/21645515.2026.2715930},
pmid = {42647143},
issn = {2164-554X},
mesh = {Humans ; Finland ; *Immunization Programs/organization &amp; administration/economics ; *Vaccination ; Health Policy ; *Vaccines/administration &amp; dosage/economics ; Adult ; *Vaccination Coverage ; },
abstract = {The exchange of knowledge and best practices is essential for improving adult vaccination strategies across the European region. Finland serves as a valuable example, with a centralized, publicly funded National Vaccination Program (NVP) supported by national evaluation for decision-making based on comprehensive population-based registers. These registers enable assessment of disease burden, facilitate the identification of high-risk groups, and enable evaluating vaccination coverage, impact, and safety during the implementation. The NVP allows a centralized tender with lower vaccine prices, centralized vaccine procurement, and uniform processes for vaccine administration by public health care. Despite these strengths, Finland faces challenges in adult vaccination similar to other EU countries, including budgetary constraints, as well as the need for improved implementation, especially for high-risk groups. The complex evaluation, decision, funding, and procurement process causes delays in vaccine introduction into the NVP. This review describes Finland's adult vaccination system, from policy to implementation, drawing on a structured search of PubMed/MEDLINE, gray literature (2009-2024) and expert input. While there are areas for further improvement, Finland's commitment to provide cost-effective, equitable, evidence-based vaccination programs with high coverage, including for at-risk subpopulations, ensures continued progress.},
}
@article {pmid42647384,
year = {2026},
author = {Welfringer-Morin, A and Leclerc-Mercier, S},
title = {Cutaneous Pediatric Vasculitis: A Clinico-Histopathological Overview of Common and Novel Entities.},
journal = {Dermatopathology (Basel, Switzerland)},
volume = {13},
number = {3},
pages = {},
pmid = {42647384},
issn = {2296-3529},
abstract = {Vasculitis encompasses a heterogeneous group of diseases characterized by the inflammation of blood vessels. In children, the diagnosis of vasculitis with cutaneous involvement relies on a combination of clinical evaluation, histopathological examination, and, in some cases, genetic investigations. Diagnosing pediatric vasculitis remains particularly challenging due to overlapping clinical manifestations, variable disease courses, and the evolving nature of histological features. Histopathological assessment aims to confirm inflammation of the vessel walls-either readily visible at low magnification or requiring serial sections-and to characterize the inflammatory infiltrate and other key features that aid in classifying the vasculitis subtype. Accurate diagnosis requires ongoing dialog and collaboration among multiple specialists. In this article, we present the clinical and histopathological features of the most common pediatric vasculitides-including IgA vasculitis and polyarteritis nodosa-as well as newly recognized entities such as COVID-19-associated vasculitis and monogenic vasculitides.},
}
@article {pmid42648101,
year = {2026},
author = {Zhang, X},
title = {What does the internet mean to older adults? Evidence from research on health information behavior.},
journal = {Geriatric nursing (New York, N.Y.)},
volume = {73},
number = {},
pages = {104328},
doi = {10.1016/j.gerinurse.2026.104328},
pmid = {42648101},
issn = {1528-3984},
abstract = {As the amount of health information available on the Internet continues to expand (such as digital health records, online consultation services, and support groups), people have more opportunities to enhance their daily well-being. Meanwhile, the Internet became integral to accessing health information and services during and after COVID-19. The evidence regarding the Internet's impact on improving the well-being of older adults, however, is mixed and inconsistent in academic research. To address these inconsistencies and better understand the Internet's role, this integrative review synthesized literature on the health information behaviour of older adults. Six databases were searched for English-language studies published from the earliest records available in each database through September 2025. After screening, 87 studies were included in the synthesis. This review identifies and explains three major themes: health information needs, health information seeking, and health information use. It demonstrates that although the Internet can be a valuable health information resource for older adults, its usefulness is shaped by age, digital and health literacy, social support, trust, Internet design, and the availability of interpersonal and professional sources. Overall, the Internet is best understood as a supplementary health information source for older adults. These findings can help healthcare providers and web designers develop more accessible, trustworthy, and supportive online tools for older adults in the post-pandemic era.},
}
@article {pmid42648114,
year = {2026},
author = {Takano, T},
title = {FECV and FIPV: What biotype labels can, and cannot, tell us about feline coronavirus biology.},
journal = {Veterinary microbiology},
volume = {321},
number = {},
pages = {111207},
doi = {10.1016/j.vetmic.2026.111207},
pmid = {42648114},
issn = {1873-2542},
abstract = {The distinction between feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV) has long provided a practical framework for understanding how common feline coronavirus (FCoV) infection can give rise to feline infectious peritonitis (FIP). The internal mutation hypothesis remains central to explaining many cases. However, the two biotype labels are often used to imply genetic, anatomical, cellular, clinical, and epidemiological properties simultaneously, although these properties are neither synonymous nor invariably linked. Longitudinal observations made possible by effective antiviral treatment and the emergence of the recombinant lineage FCoV-23 have made these interpretive limitations particularly apparent. Clinical remission after treatment does not necessarily coincide with clearance of viral RNA, cessation of faecal shedding, or normalisation of all host-response measures, and post-treatment RNA detection does not by itself establish persistence of replication-competent virus or treatment failure. FCoV-23 combines between-cat transmission of a viral lineage with heterogeneous, cat-specific spike domain 0 deletions consistent with within-host emergence or selection. In this review, we reassess the FECV/FIPV dichotomy by separating five levels of description: genetic background, anatomical compartment, cell tropism, host clinical state, and transmissibility. These levels are analytically distinct but biologically interconnected, and experimentally measurable viral properties can provide mechanistic links between genetic variation and downstream biological outcomes. We examine how molecular markers, PCR findings, faecal shedding, experimental phenotypes, and post-antiviral observations should be interpreted in relation to the biological processes they directly reflect. We argue that FECV and FIPV remain useful terms, but should not be treated as fixed viral entities or used as substitutes for direct evidence. Matching the level of inference to the level of observation will improve interpretation of FCoV studies, diagnostic reporting, and the design of future work on within-host evolution, transmission, and treatment response.},
}
@article {pmid42648240,
year = {2026},
author = {Nadarajah, N and Amanda, LXM and Dempsey, K and Ling, JOE and Lim, S and Seah, B},
title = {Education programs on emerging and reemerging infectious disease outbreak management for pre-registration Nursing and Medical Students: A scoping review.},
journal = {Nurse education today},
volume = {168},
number = {},
pages = {107368},
doi = {10.1016/j.nedt.2026.107368},
pmid = {42648240},
issn = {1532-2793},
abstract = {INTRODUCTION: Preparing the future healthcare workforce in managing emerging and reemerging infectious disease (ERID) outbreaks is critical. However, knowledge gaps remain in education programs for ERID outbreaks for pre-registration nursing and medical students.<br><br>AIM: To comprehensively identify existing ERID outbreak education programs for medical and nursing students, summarizing evidence on program design, curriculum content, learning outcomes, and student experiences.<br><br>METHODS: A scoping review was conducted using the Arksey and O'Malley framework. Eligible studies were searched from inception to 1st November 2025 across nine databases (Cochrane, CINAHL, Embase, MedNar, PubMed, PsycINFO, Scopus, Web of Science, ProQuest). Two reviewers screened for eligible studies and appraised the quality of included studies independently. This was followed by data charting and narrative synthesis of findings.<br><br>RESULTS: Among the 38 included studies, ERID outbreak management programs for medical (n&#xa0;=&#xa0;16) and nursing (n&#xa0;=&#xa0;22) students predominantly targeted COVID-19 and involved short-duration (1 to 5&#xa0;h) online or simulation-based methods. Curriculum content of these programs included fundamentals of infectious diseases, epidemiology and surveillance, clinical management of infected persons, infection prevention and control and public health and pandemic preparedness. Nursing curricula emphasised infection prevention and control while medical programs prioritised epidemiology and clinical patient management. Most programs reported improvements in knowledge and clinical procedural skills, particularly via simulation. Non-procedural skills (e.g., critical thinking) and psycho-emotional outcomes (e.g., anxiety, fear and preparedness) yield inconsistent results. Students favour experiential learning but highlighted gaps in interdisciplinary collaboration and stress management.<br><br>CONCLUSION: This review identified curriculum design gaps in ERID outbreak management education programs and provided future pedagogical directions to prepare a pandemic-ready healthcare workforce. Key strategies include scaffolding ERID content across pre-registration training, incorporating interprofessional education, and leveraging blended pedagogies to balance theoretical and experiential learning. Future programs should integrate realistic scenarios to simulate emotional stressors, foster resilience, and evaluate knowledge and skill retention.},
}
@article {pmid42648641,
year = {2026},
author = {Song, M and Wang, S and Fei, X and Guo, G},
title = {Viral manipulation of DNA damage response signaling: molecular mechanisms and therapeutic implications.},
journal = {Virologica Sinica},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.virs.2026.08.014},
pmid = {42648641},
issn = {1995-820X},
abstract = {The DNA damage response (DDR) network maintains genomic integrity, functions as a signaling hub that viruses exploit to drive pathogenesis, and constitutes a central interface between viral infection and host cell fate. This review discusses the molecular mechanisms by which viruses subvert host DDR pathways, with an emphasis on viral replication, latency, immune evasion, and host genomic instability. Representative examples include PARP1-dependent cccDNA stabilization by hepatitis B virus (HBV), MRN complex sequestration by herpes simplex virus type 1 (HSV-1) for immune evasion, ATM signaling modulation by human immunodeficiency virus (HIV) to maintain viral latency, and DDR activation triggered by RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika virus (ZIKV), and influenza A virus (IAV) via oxidative stress. We evaluate emerging DDR-targeted antiviral strategies, including restoring intrinsic host restriction, exploiting synthetic lethality of dysregulated DDR kinases, and therapeutically modulating DDR-innate immune crosstalk to restore antiviral surveillance (e.g., by stabilizing MRE11 or inhibiting PARP7). Bridging molecular insights with clinical translation, this review positions DDR targeting as a mechanism-driven, host-directed antiviral paradigm.},
}
@article {pmid42648991,
year = {2026},
author = {da Luz Goulart, C and Meyer, GMB and Santos-de-Araújo, AD and Valente, J and Bellon Dos Santos, M and Spilimbergo, FB and Fernandes, E and Alves Dos Santos, SV and Arêas, GPT and Almeida-Val, F},
title = {Infectious Diseases and Pulmonary Arterial Hypertension: A Review.},
journal = {Heart, lung &amp; circulation},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.hlc.2026.06.015},
pmid = {42648991},
issn = {1444-2892},
abstract = {BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease characterised by increased pulmonary vascular resistance, leading to right heart failure and premature death. Although classically linked to idiopathic and autoimmune disorders, infectious diseases are increasingly recognised as contributors to PAH pathogenesis.<br><br>METHOD: This scoping review mapped current evidence on associations between infectious diseases and PAH, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines. PubMed, Scopus, and Web of Science were searched for studies addressing epidemiology, mechanisms and clinical implications.<br><br>RESULTS: Evidence shows robust associations for human immunodeficiency virus and schistosomiasis (Tier 1); hepatitis C virus and hepatitis B virus (Tier 2); and coronavirus disease 2019 (Tier 3). Common mechanisms include chronic inflammation, endothelial dysfunction and vascular remodelling.<br><br>CONCLUSIONS: Infection-associated PAH remains underrecognised in diagnostic frameworks and clinical practice, particularly in low- and middle-income countries where these infections are endemic. Integrating PAH screening and management into existing infectious disease programs could improve early diagnosis and outcomes. Addressing this neglected interface is crucial to reducing morbidity and advancing health equity for affected populations worldwide.},
}
@article {pmid42649322,
year = {2026},
author = {Gowda, N and Harish, S and Joy, J and Tej, G},
title = {Post-Infectious Cerebellitis: A Systematic Review of Aetiology, Clinical Presentation, Treatment, and Outcomes.},
journal = {Cerebellum (London, England)},
volume = {25},
number = {5},
pages = {},
pmid = {42649322},
issn = {1473-4230},
mesh = {Humans ; *Cerebellar Diseases/etiology/therapy ; *COVID-19/complications ; Male ; Treatment Outcome ; Child ; Female ; Post-Infectious Disorders ; SARS-CoV-2 ; *Coronavirus Infections/complications ; Child, Preschool ; Adult ; Adolescent ; Aged ; },
abstract = {Post-infectious cerebellitis is an immune-mediated cerebellar inflammatory syndrome that follows a preceding infection (or, rarely, vaccination) after a latent interval. It spans a spectrum from benign post-infectious/acute cerebellar ataxia (ACA) through more severe acute cerebellitis (AC) with leptomeningeal enhancement and mass effect, to rare, life-threatening acute fulminant cerebellitis (AFC) with hydrocephalus risk. Evidence is largely limited to individual case reports and small case series, and no prior review has systematically pooled patient-level data across etiologies. A PRISMA-guided systematic review screened 899 records identified through electronic database searches, citation tracking, and supplementary bibliography searches. After duplicate removal and eligibility assessment, 47 studies (case reports, case series, and cohort studies) were included in the qualitative synthesis. Patient-level data from 73 individuals were extracted for quantitative pooling. Pooled patients had a mean age of 24.5 years (range 7 months-74 years; 40 pediatric, 28 adult); of 70 patients with sex reported, 51 (72.9%) were male. Based on neuroimaging findings and the presence of life-threatening features, 34 patients (46.6%) were classified as acute cerebellar ataxia (ACA), 26 (35.6%) as acute cerebellitis (AC), and 13 (17.8%) as acute fulminant cerebellitis (AFC), with complete recovery in 58.8%, 69.2%, and 69.2% of each subtype, respectively, and the cohort's only death occurring in the AFC subgroup. SARS-CoV-2 (n = 24, 32.9%) was the most frequently identified trigger, followed by patients with no pathogen identified (n = 18, 24.7%), varicella-zoster virus (n = 8, 11.0%), Epstein-Barr virus (n = 5, 6.8%), and influenza (n = 5, 6.8%). Corticosteroids were the most common treatment (54/73, 74.0%), followed by antivirals (35/73, 47.9%) and IVIG (19/73, 26.0%); plasma exchange was given for refractory cases. Complete recovery occurred in 47/73 patients (64.4%), partial recovery/residual deficit in 15/73 (20.5%), outcome was not stated for 10/73 (13.7%), and one death (1.4%) was recorded (COVID-19-associated necrotizing encephalopathy) - the only fatality, occurring in an adult. Post-infectious cerebellitis is a heterogeneous, largely immune-mediated syndrome with a generally favorable prognosis after corticosteroid-based immunotherapy, though outcomes and evidence quality vary by etiology and severity subgroup.},
}
@article {pmid42649609,
year = {2026},
author = {Ghasemi, SA and SalarSadeghi, M and Miri, M and Khamesan, A},
title = {Psychoeducational Challenges of Dyslexic Children During the COVID-19 Pandemic: A Systematic Review.},
journal = {Dyslexia (Chichester, England)},
volume = {32},
number = {4},
pages = {e70047},
doi = {10.1002/dys.70047},
pmid = {42649609},
issn = {1099-0909},
mesh = {Humans ; *COVID-19/psychology ; *Dyslexia/psychology ; Child ; Pandemics ; },
abstract = {Dyslexic students faced psychological and educational challenges during the COVID-19 pandemic and online learning, including increased anxiety, low self-esteem, reduced reading interest, limited access to educational technologies, insufficient teacher support, and difficulties with reading fluency and concentration. Examining these challenges is crucial for implementing effective measures and enhancing post-pandemic learning. This study investigates the psycho-educational challenges of dyslexic children during the pandemic, highlighting the need for targeted interventions to support them in current and future contexts. This systematic review identified relevant articles through electronic searches of PubMed, Wiley, Scopus, Web of Science, Google Scholar, and ScienceDirect, supplemented by the snowballing technique, which involved examining the bibliographies of retrieved references. The study identified two main categories of challenges for dyslexic children: psychological (mental health, emotional well-being, behavioural issues, parental stress) and educational (socioeconomic status, technology access, special educational needs, teacher support, remote learning difficulties) affecting children with learning disabilities. The research results show that dyslexic children faced various psychological and educational difficulties identified in this review during the COVID-19 pandemic. Therefore, targeted, evidence-based strategies-such as teacher training, family-school collaboration, adaptive learning technologies, and psychological support-are needed to mitigate these challenges in the post-pandemic period.},
}
@article {pmid42650868,
year = {2026},
author = {Rakhimbayeva, Z and Mussayev, A and Oshibayeva, A and Nuskabayeva, G and Kyrykbayeva, S and Begimbekova, L and Khudaibergenova, S and Sadykova, K and Zhagiparova, Z and Aljofan, M},
title = {Mare's Milk for Gut Microbiome Restoration and Immune Recovery After COVID-19 in Children and Pregnant Women: A Hypothesis-Generating Systematic Review.},
journal = {Biomolecules},
volume = {16},
number = {8},
pages = {},
doi = {10.3390/biom16081203},
pmid = {42650868},
issn = {2218-273X},
support = {BR24992814//Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan/ ; },
mesh = {Female ; Animals ; Humans ; Horses ; *COVID-19/immunology/microbiology ; Pregnancy ; *Gastrointestinal Microbiome/immunology ; *Milk ; SARS-CoV-2 ; Child ; Dysbiosis ; },
abstract = {BACKGROUND: Mare's milk has gained attention as a functional food due to its bioactive compounds and potential microbiome-modulating properties. This systematic review evaluated the evidence on its potential role in gut microbiome restoration and immune modulation following COVID-19, particularly in pediatric and maternal populations.<br><br>METHODS: PubMed/MEDLINE, Scopus, Web of Science, and Embase were systematically searched for studies investigating mare's milk or koumiss and their effects on gut microbiota, immune responses, inflammatory markers, or gastrointestinal outcomes.<br><br>RESULTS: Eight studies were included: five examined COVID-19-associated gut microbiome alterations, and three investigated the biological effects of mare's milk or fermented mare's milk. COVID-19 was consistently associated with reduced microbial diversity, depletion of beneficial bacteria, and enrichment of opportunistic pathogens, with some changes persisting after recovery.<br><br>CONCLUSIONS: Koumiss demonstrates biologically plausible microbiome-modulating and immunoregulatory properties that may support recovery from COVID-19-associated gut dysbiosis. However, current evidence remains indirect, and clinical studies are needed before recommendations can be made.},
}
@article {pmid42651310,
year = {2026},
author = {Kaya, E and Ekinci, N and Aslan, I and Gómez-Salgado, J and Fekih-Romdhane, F and Laranjeira, C and Yıldırım, M},
title = {The Association Between Job Stress and Intention to Leave in Healthcare Institutions: A Systematic Review and Meta-Analysis.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {16},
pages = {},
doi = {10.3390/healthcare14162541},
pmid = {42651310},
issn = {2227-9032},
abstract = {Background: Job stress is a pervasive issue in modern workplaces and is associated with numerous adverse outcomes, including employees' turnover intention when stress levels are high. Objective: This study aimed to examine the association between job stress and turnover intention among employees working in healthcare institutions through meta-analysis. Methods: A systematic literature review and meta-analysis were performed following PRISMA guidelines. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO; ID: CRD42024581906). Considering variations in sample sizes, publication years, and measurement scales, a random-effects model was employed. Effect sizes were illustrated with a forest plot, and publication bias analyses were performed. Subgroup analyses were conducted by occupational group, COVID-19 period, and geographic region, while meta-regression tested the moderating effects of publication year. Study quality was assessed using the AXIS tool. Results: Based on predefined inclusion criteria, 38 independent studies were included. Findings revealed a moderate-to-high, positive, and statistically significant relationship (r = 0.441; 95% CI [0.389, 0.490]) between job stress and turnover intention among healthcare workers. Moreover, although between-study heterogeneity was substantial (I[2] = 95.5%), the direction and statistical significance of the association remained consistent across different countries and healthcare systems. Conclusions: This meta-analysis demonstrated a statistically significant positive association between job stress and turnover intention among healthcare workers (r = 0.441). Although substantial heterogeneity was observed across studies, the relationship remained consistent across occupational groups, regions, and study contexts. Addressing job stress may therefore play an important role in supporting workforce retention in healthcare organizations.},
}
@article {pmid42651351,
year = {2026},
author = {Pérez-Jiménez, JM and Feria Dávila, A and Torrado Val, E},
title = {Adolescent Suicide During the COVID-19 Pandemic: Bullying Dynamics, Risk Factors, and Prevention Strategies-A Systematic Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {16},
pages = {},
doi = {10.3390/healthcare14162582},
pmid = {42651351},
issn = {2227-9032},
abstract = {Objectives: To analyze adolescent suicide rates during the COVID-19 pandemic, examine the relationship between bullying, cyberbullying, and suicidal behavior, and identify evidence-based prevention strategies. Methods: A systematic review of 26 peer-reviewed articles (published between 2020 and 2025) was conducted across five databases. Studies were appraised for quality using STROBE and SRQR guidelines. Results: The pandemic significantly impacted adolescent mental health, increasing depression, anxiety, and suicidal ideation, particularly among females and vulnerable populations. Notably, while traditional bullying decreased during school closures (78.2% reduction), cyberbullying reports saw a substantial increase (with a 264.4% spike documented in national helpline data). Key risk factors included social isolation, excessive social media use, pre-existing mental health conditions, and low socioeconomic status. Protective factors included family support and access to mental health services. Conclusions: COVID-19 created a significant adolescent mental health crisis. The shift to cyberbullying represents a critical emerging threat. Effective prevention requires a multitiered approach including universal screening, telehealth, and social-emotional learning programs while addressing the persistent shortage of mental health professionals.},
}
@article {pmid42651374,
year = {2026},
author = {Shaikh, ZH and Yadav, S and Sahoo, BP and Sharma, JS and Meero, A},
title = {Applications of Artificial Intelligence in the Health Sector: A PRISMA-Based Systematic Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {16},
pages = {},
doi = {10.3390/healthcare14162604},
pmid = {42651374},
issn = {2227-9032},
support = {KU-2025-26-02//Kingdom University/ ; },
abstract = {Background: The health sector is getting transformed with the usage of AI, be it diagnosis, treatment planning, disease prediction, and or health system management. Research in this field has picked up in the last few years, which was made possible with the emergence of machine learning, natural language processing and the increasing number of e-health records. Objectives: The study aims to investigate the current trends in the implementation of artificial intelligence (AI) applications in medical settings by investigating the global scientific output/landscape on this theme, such as the annual publication trends, country-wise contributions, and publishing patterns. Methods: The current study is based on systematic review by combining bibliometric analysis and cluster analysis using VOSviewer version 1.6.20, R software version 4.5.0, and Biblioshiny (Bibliometrix package in R) along with preferred reporting items for systematic reviews and meta analyses (PRISMA), 2020 which provides transparency and rigorous visualization to examine the articles published in English on the use of AI in healthcare, after the onset of COVID-19 till date i.e., from 2020 to 2026 on the Scopus database. Results: Using the relevant search string, 5940 documents were identified between 2020 and 2026, 1434 were included for analysis after screening and relevant filters. The publications have increased remarkably after 2020 on this theme and more than half of the publications have their roots in the discipline of Medicine. The USA, China, and the United Kingdom have contributed the most to the volume of research. Natural language processing and diagnosis are the emerging themes. The Journal of Medical Internet Research, BMC Medical Informatics and Decision Making, Computers in Biology and Medicine, IEEE Journal of Biomedical and Health Informatics, Frontiers in Public Health, and Digital Health are some of the most influential sources in the field. Li J and Liu X are among the authors with remarkable local impact. Conclusions: The work aims to assist investigators, health care professionals, and policymakers to learn about modern trends and focus on critical areas of future research and collaboration in AI-enhanced health care. The limitation of the study is that it considered only the Scopus database but it has opened up opportunities for researchers for analysis using other databases such as Dimensions, Lens, and PubMed. Also, this review is considering the publication record since the onset of COVID-19 but a comparative analysis of pre and post-pandemic studies can also be conducted to get a holistic view of drastic collaboration of research in this field. Discussions: The findings suggest that the role of artificial intelligence in health care has paramount over recent years, with other supporting technologies but a technologically hesitant population as well as low acceptance of AI due to ethical issues, cannot be ignored for ensuring efficiency in the health sector.},
}
@article {pmid42652112,
year = {2026},
author = {Jash, S and Sedivy, JM},
title = {Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations.},
journal = {Biomedicines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/biomedicines14081729},
pmid = {42652112},
issn = {2227-9059},
abstract = {The human placenta is a temporary organ structured to optimize exchange between the maternal and fetal circulatory systems. Its fetal component consists of highly branched chorionic villi, which are anchored to the maternal uterine wall and project into the intervillous space. The outer surface of these villi is lined by a multinucleated, continuous layer called the syncytiotrophoblast, which is supported by an underlying layer of proliferative cytotrophoblast cells and the invasive extravillous trophoblast (EVT). This cellular bilayer forms a selective barrier that directly bathes in maternal blood, allowing for the efficient transfer of oxygen and nutrients while structurally preventing the direct mixing of maternal and fetal blood cells. Human placental studies have been stymied by ethical and accessibility constraints. Stem cell biology has now revolutionized the capacity to model human placental development, in particular with the derivation of human trophoblast stem cells (hTSCs) and organoids. Authentic, self-renewing human trophoblast stem cells (hTSCs) were first derived not from pluripotent stem cells but from primary tissue-first-trimester villous cytotrophoblasts and blastocysts. Derivation from human pluripotent stem cells (PSCs) followed only subsequently, along two principal routes: conversion of naive PSCs, which retain extraembryonic competence, and induction from primed PSCs, as well as by direct reprogramming of somatic cells to induced hTSCs. An important advance underlying these improvements is the mapping of a global reprogramming roadmap. Multi-omic and lineage-tracing experiments have mapped the stepwise transcriptional and epigenetic conversions of fibroblasts to hTSCs, including sequential chromatin reconfiguration, trophoblast gene network activation, and repression of somatic signatures. These results identify major regulatory bottlenecks and intermediate states, improving reprogramming fidelity. The derivation of stem-cell-based trophoblast organoids now enables complex modeling of placental architecture, function, and disease susceptibility in vitro. These organoids accurately recapitulate placental barrier functions and immunological features, allowing for examinations of maternal-fetal health, pregnancy disorders, and placental infection response to viruses like cytomegalovirus and SARS-CoV-2. Looking ahead, the integration of reprogramming and organoid technologies will propel patient-specific and tailor-made models for personalized diagnostics, drug screening, and mechanism studies. As we unravel the molecular ballet of trophoblast induction, such discoveries have the potential to bridge basic translational gaps in reproductive biology and maternal-fetal medicine.},
}
@article {pmid42652287,
year = {2026},
author = {Kuwayama, T and Kotani, K},
title = {Themes of Reported Rural Healthcare Challenges Related to Non-Communicable Diseases Before and After the COVID-19 Pandemic: A Scoping Review.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {8},
pages = {},
doi = {10.3390/ijerph23080971},
pmid = {42652287},
issn = {1660-4601},
mesh = {*COVID-19/epidemiology ; Humans ; *Noncommunicable Diseases/therapy/epidemiology ; Pandemics ; SARS-CoV-2 ; *Rural Health Services ; Socioeconomic Disparities in Health ; },
abstract = {Non-communicable diseases (NCDs), including cardiovascular disease, cancer, and chronic respiratory disease, are major causes of death worldwide; addressing NCDs is thus essential. NCDs may contribute to health disparities between rural and urban areas. The COVID-19 pandemic has altered medical and social environments, and NCD management approaches may have changed accordingly. This scoping review aimed to examine themes of reported rural healthcare challenges related to NCD management before and after the COVID-19 pandemic. A literature search of original articles was conducted via PubMed. A thematic analysis was applied to compare the content of studies classified as pre-pandemic and post-pandemic. A total of 23 articles were identified, including 12 studies classified as pre-pandemic and 11 studies classified as post-pandemic. Before the pandemic, commonly reported challenges included low management rates of hypertension and diabetes, instability in pharmaceutical supply, and insufficient training of healthcare personnel. We integrated these into a theme related to "healthcare". After the pandemic, in addition to the low management rates, studies increasingly addressed mental and nutritional health, multimorbidity, and socioeconomic disparities. We integrated there into a theme related to "society". Namely, studies classified as pre-pandemic primarily reported healthcare-related aspects, whereas studies classified as post-pandemic more frequently reported broader societal aspects in addition to healthcare-related aspects. These findings may reflect changes in how rural healthcare challenges related to NCDs have been recognized and discussed following the COVID-19 pandemic. Further research is needed to clarify the significance and implications of these reported themes.},
}
@article {pmid42652316,
year = {2026},
author = {Eigenheer Mühlbauer, J and Ribeiro, AP and B de-Salles Andrade, J and F Testoni de Faro, L and Moreira-de-Oliveira, ME and Hühne, V and Félix-da-Silva, C and B de Menezes, G and Fontenelle, LF},
title = {Assessing Adherence to Preventive Behaviors Among Patients with Mental Illness in the Context of the COVID-19 Pandemic: A Scoping Review.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {8},
pages = {},
doi = {10.3390/ijerph23081001},
pmid = {42652316},
issn = {1660-4601},
support = {#313162/2023-9//National Council for Scientific and Technological Development/ ; #E 26/200.261/2026(314721)//Funda&#xe7;&#xe3;o Carlos Chagas Filho de Amparo &#xe0; Pesquisa do Estado do Rio de Janeiro/ ; no grant number//D'Or Institute for Research and Education/ ; //Coordena&#xe7;&#xe3;o de Aperfei&#xe7;oamento de Pessoal de N&#xed;vel Superior (CAPES)-Brazil/ ; },
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology/psychology ; *Mental Disorders/psychology ; *Patient Compliance/statistics &amp; numerical data ; Vaccination/statistics &amp; numerical data ; Pandemics ; SARS-CoV-2 ; *Health Behavior ; },
abstract = {BACKGROUND: The COVID-19 pandemic has become a global public health emergency, causing substantial disruptions in societal norms and behaviors. Among the affected population, individuals with mental health disorders are particularly vulnerable, facing heightened infection rates and worse outcomes. These challenges can be linked to factors such as insufficient adherence to vaccination and other preventive measures.<br><br>OBJECTIVE: This study aims to investigate the literature on the adherence of individuals with mental disorders to vaccination and other preventive behaviors such as social distancing, use of face masks, and hygiene practices during the COVID-19 pandemic.<br><br>METHODS: This scoping review was performed following the methodological guidelines outlined by the Joanna Briggs Institute and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. A comprehensive search for published research containing original data was conducted in four databases (Embase, Medline, PsycINFO, and Web of Science).<br><br>RESULTS: The search yielded 2778 records, and 10 additional relevant papers were identified through handsearching, resulting in a total of 50 studies meeting all inclusion criteria. Most of them focused on vaccination adherence, with approximately half reporting lower adherence in the patient group, particularly among individuals with severe mental illnesses (SMIs), compared to the general population or to other control groups. However, some studies reported comparable-or, in specific psychiatric populations, even higher-levels of adherence to preventive behaviors. Out of the fifty selected studies, only four employed an interventional approach aimed at increasing preventative behaviors, but they were effective in most of the studies.<br><br>CONCLUSIONS: This review underscores a noticeable lack of intervention studies employing psychoeducational strategies to mitigate risky behaviors among individuals with mental disorders. This gap emphasizes the urgent need for increased research focus in this area, as it holds promise for reshaping future approaches and strategies to address other crises within this vulnerable population.},
}
@article {pmid42652374,
year = {2026},
author = {Triantafyllou, C and Ntikoudi, A and Papachristou, A and Psiakis, V and Fonseca, VR and Breda, J},
title = {Mapping the Public Health Landscape in Greece: Governance, Stakeholders, Data Systems, and Policy Frameworks.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {8},
pages = {},
doi = {10.3390/ijerph23081059},
pmid = {42652374},
issn = {1660-4601},
support = {//Ministry of Health of the Hellenic Republic/ ; },
mesh = {Greece/epidemiology ; Humans ; *Public Health ; Public Health Infrastructure ; *Health Policy ; *COVID-19/epidemiology ; Stakeholder Participation ; },
abstract = {BACKGROUND: Public health in Greece has undergone substantial changes since the COVID-19 pandemic, while challenges related to governance, workforce distribution, regional inequalities and service organization remain. This study aimed to map the current public health landscape in Greece by examining its institutional frameworks, stakeholder roles, policy implementation and public health data systems.<br><br>METHODS: A structured situation analysis combining a review of peer-reviewed and gray literature, policy analysis, and stakeholder mapping was conducted. PubMed, EMBASE, and CINAHL were searched for English- and Greek-language publications issued between 2005 and 2026, supplemented by reports, legislation, and policy documents from the Greek Ministry of Health, the World Health Organization, the Organisation for Economic Co-operation and Development, the European Commission, and other relevant institutions.<br><br>RESULTS: Public health responsibilities were distributed across multiple national, regional, and local institutions, creating challenges concerning coordination and accountability. Regional and socioeconomic inequalities continued to affect access to services, while workforce shortages and skill-mix imbalances constrained public health capacity. Public health information was dispersed across different institutions and data systems, with limitations concerning standardization, accessibility, and interoperability. Recent legislation, prevention programs, and digital-health initiatives indicated increased policy attention to prevention and population health, although publicly available evidence regarding their implementation and outcomes remained limited.<br><br>CONCLUSIONS: Strengthening public health in Greece requires clearer institutional responsibilities, improved coordination across governance levels, sustainable workforce planning and interoperable data systems that support routine monitoring of program coverage, equity, and population-level outcomes.},
}
@article {pmid42652397,
year = {2026},
author = {Ruggiero, RM and Patel, HJ and North, CS and Adams, TN},
title = {Interventions to Support the Mental Health of Frontline Healthcare Workers During the COVID-19 Pandemic: A Systematic Review.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {8},
pages = {},
doi = {10.3390/ijerph23081082},
pmid = {42652397},
issn = {1660-4601},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Frontline Workers/psychology ; *Mental Health ; *Health Personnel/psychology ; SARS-CoV-2 ; Pandemics ; Mental Health Services ; Mental Disorders/therapy ; },
abstract = {The COVID-19 pandemic led to distress and an increased prevalence of psychopathology among front-line (FL) healthcare workers (HCWs). A synthesis of the available data on the effectiveness of MH interventions among FL HCWs is essential to inform an MH plan for FL HCWs in future pandemics. The objective of this systematic review is to examine interventions used to support the MH of FL HCWs during the COVID-19 pandemic. All studies published between 1 January 2020 and 1 March 2026 that reported on MH interventions among FL HCWs during the COVID-19 pandemic were identified using PubMed, PsycINFO, Scopus, EMBASE, Cochrane Database of Systematic Reviews, Google Scholar, Medline, and Web of Science. Studies published in peer-reviewed journals that reported data on interventions to support the MH of FL HCWs were included. The study was conducted using the approach by the PRISMA guidelines. The search generated 1450 records, of which 309 were reviewed at length, and 153 studies (N = 153) were included. Interventions in these studies included identification of risk for psychopathology and linkage to mental health care (n = 3), PE/PFA (n = 44), psychotherapy (n = 26), mindfulness programs (n = 58), medications (n = 5), and multiple/combined psychosocial support interventions (n = 17). The majority of studies found their interventions to be beneficial, largely based on user satisfaction scores and symptom screening scores. Importantly, symptoms in the vast majority of control arms also improved over time, though not to the degree that symptoms in intervention arms improved. This systematic review suggests that an established disaster MH response framework may be useful in directing the design of MH responses to FL HCWs in future pandemics, offering screening for psychopathology and connection with formal psychiatric services for full evaluation and provision of MH care, as well as supportive care with mindfulness interventions, crisis-oriented counseling, PE, and PFA.},
}
@article {pmid42652757,
year = {2026},
author = {Maghiar, L and Iftode, A and Maghiar, TA and Chioibas, R and Grecu, T and Neamțu, C and Ioan, SM and Dehelean, CA and Dumitrescu, C and Neamțu, AA},
title = {Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management.},
journal = {Journal of clinical medicine},
volume = {15},
number = {16},
pages = {},
doi = {10.3390/jcm15166353},
pmid = {42652757},
issn = {2077-0383},
abstract = {Background/Objectives: Occupational contact dermatitis (OCD) is the most common work-related skin disease, accounting for roughly 90-95% of occupational dermatoses and falling predominantly on the hands. It is rarely dangerous yet imposes a substantial burden through impaired quality of life, lost productivity, and premature exit from affected trades. The COVID-19 pandemic intensified this burden among healthcare workers, in whom the pooled one-year prevalence of self-reported hand eczema reaches around 27%; meta-analytic data link the increased risk principally to frequent handwashing and wet work rather than to alcohol-based hand rub. Methods: This narrative review, which follows a non-systematic, thematically organised search strategy rather than PRISMA methodology, integrates current evidence on the epidemiology, pathophysiology, diagnosis, prevention, and management of OCD, with particular emphasis on the self-reinforcing cycle linking skin barrier disruption, microbiome dysbiosis, and antimicrobial-peptide dysregulation to inflammation. Results: We critically appraise the prevention evidence, foregrounding the low certainty of the existing trial base and the tension between the randomised trials of primary and secondary prevention, which have been null, and the encouraging but uncontrolled results of structured tertiary-prevention programmes. We summarise recent therapeutic advances, including topical delgocitinib, and situate the field within the World Health Organisation's 2025 recognition of skin diseases as a global public health priority. Established evidence and hypotheses are kept separate throughout: we additionally advance, explicitly as a conjecture rather than as a demonstrated mechanism, a conceptual trans-kingdom dialogue model in which protease-generated LL-37 fragments may modulate staphylococcal quorum sensing, and each step of that model is labelled according to whether the supporting evidence is direct, extrapolated, or as yet untested. Conclusions: We argue that the prevention failure is less one of biology than of trial design and measurement, and outline the research needed to close the gap.},
}
@article {pmid42652878,
year = {2026},
author = {Palamim, CVC and Camargo, TM and Marson, FAL},
title = {Mechanical Power as a Predictor of Outcomes During Mechanical Ventilation in Coronavirus Disease 2019 (COVID-19): An Updated Systematic Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {16},
pages = {},
doi = {10.3390/jcm15166476},
pmid = {42652878},
issn = {2077-0383},
support = {305906/2024-0//Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico/ ; },
abstract = {Background/Objectives: Mechanical power (MP) quantifies the energy delivered to the respiratory system during ventilation and serves as a promising marker for ventilator-induced lung injury (VILI). According to its original definition by Gattinoni, MP reflects the energy transferred from the ventilator to the respiratory system under conditions of deep sedation, passive breathing, neuromuscular blockade, and volume-controlled ventilation. Its role in coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) remains under investigation. This systematic review aimed to synthesize the available evidence on the association between MP and VILI, complications related to mechanical ventilation (MV), and mortality in adult patients with COVID-19 undergoing invasive mechanical ventilation (IMV). Methods: A systematic review was conducted using PubMed-MEDLINE (Medical Literature Analysis and Retrieval System Online) for studies published in recent years, focusing on adult COVID-19 patients undergoing IMV. Inclusion criteria centered on studies reporting MP and its association with VILI, complications, or mortality. Ten studies met eligibility criteria after screening 356 retrieved articles. Results: Most included studies were retrospective and observational, encompassing critically ill COVID-19 patients. Elevated MP was correlated with more severe outcomes, including increased 28-day mortality, prolonged MV, and weaning failure. Franck et al. demonstrated strong correlations between MP and driving pressure, elastance, and positive end-expiratory pressure, emphasizing the importance of calculation methods. González-Castro et al. identified a threshold of 17 J/min, above which mortality risk increased. Stalla et al. highlighted that dynamic MP reductions during prone positioning were associated with survival. Registry-based analyses confirmed that both magnitude and cumulative exposure above 18 J/min increased intensive care unit mortality. Novel indices combining MP with oxygenation parameters improved prognostic accuracy. While absolute MP at initiation provided limited predictive value, temporal trends and individual components were strongly linked to VILI. Conclusions: Higher MP has been associated with adverse clinical outcomes in patients with COVID-19 receiving invasive mechanical ventilation, supporting its potential role as a prognostic indicator. Its dynamic assessment, thresholds, and integration with ventilatory strategies such as prone positioning enhance risk stratification and may guide individualized, lung-protective ventilation. Continuous monitoring and standardized calculation are recommended to optimize clinical decision-making.},
}
@article {pmid42652915,
year = {2026},
author = {Chagas-Sena, M and Lau, WL and Lane, TE and Resende, PC and Nunes, ACF},
title = {Blood-Brain Barrier Changes and Related Microvascular Outcomes in Long-COVID: A Comprehensive Review.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {8},
pages = {},
doi = {10.3390/life16081227},
pmid = {42652915},
issn = {2075-1729},
abstract = {UNLABELLED: Caused by the SARS-CoV-2 virus, the COVID-19 pandemic is still considered a complex challenge, with manifestations not only of respiratory issues, but also conditions related to chronic cerebrovascular damage. Endothelial biomarkers, neuropathological and neuroimaging findings indicate endothelial dysfunction, microthrombosis, and disruption of the blood-brain barrier (BBB) are central mechanisms for acute and chronic ischemic and hemorrhagic cerebral events. Understanding these mechanisms is vital to reducing their impact on population health, whether through treatment or prevention of adverse outcomes. The objective of this study is to perform a review of the scientific literature on the post-infection effects of SARS-CoV-2 affecting the cerebral endothelium and the BBB, correlating them with potential clinical outcomes.<br><br>MATERIAL AND METHODS: Analysis of studies extracted from the PubMed database using the following terms: Long-COVID "AND" SARS-CoV-2 "AND" blood-brain barrier.<br><br>INCLUSION CRITERIA: keywords, publications related to the topic, and primary studies published after peer review.<br><br>EXCLUSION CRITERIA: preprint studies, publication outside of the timeframe 2020-2025, study design not compatible with this research, and full text not available.<br><br>RESULTS: An initial 121 studies were identified, of which 105 were excluded due to not meeting all inclusion criteria and 6 studies were inaccessible due to not being in the English language and full-text access limitations. Fifteen articles were included in the analysis, for topics as expression of viral receptors in the endothelium, markers of their activation, cerebral microvascular injury and coagulopathies. To clarify the pathogenic cascade, the evidence was stratified by biological model where in vitro evidence demonstrates that the Spike protein induces direct endothelial toxicity and platelet aggregation, establishing the primary molecular insult. Animal models confirm the translation of this insult into structural degradation of the BBB and pericyte loss. Clinically, infection-phase findings, characterized by multifocal microthrombosis and permeability spikes, act as the determining event that predisposes to the persistent neuroinflammatory environment. Biomarkers of BBB disruption and neuronal damage were consistently reported, with persistence of BBB dysfunction modifying risk stratification and rehabilitation efforts. Reported cases of Long-COVID demonstrated normalization of BBB markers without correlation with long-term symptoms, suggesting that other mechanisms are involved in Long-COVID.<br><br>CONCLUSION: Cerebral endotheliopathies and BBB dysfunction in patients with COVID-19 continue to impact the health of the population. The scientific literature indicates that SARS-CoV-2 induces cerebral endothelial injury, BBB disruption, and an increased risk of vascular events related to endotheliopathy, inflammation, and hypercoagulability. Understanding the impact of COVID-19 pathology on the population and developing prospective studies is essential to quantify the prevalence and mechanisms of brain injury. The identification of molecular targets and infection pathways are promising toward defining both preventive and therapeutic strategies to improve outcomes in the Long-COVID population.},
}
@article {pmid42653008,
year = {2026},
author = {Trasca, ET and Radulescu, D and Ciupeanu-Calugaru, ED and Mercut, R and Baleanu, VD and Caluianu, EI and Vieru, AM and Radulescu, PM},
title = {Interpreting Abdominal Surgical-Site Infection Trends Across the COVID-19 Shock: A Critical Narrative Review and the SSI Signal-Validity Framework.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {8},
pages = {},
doi = {10.3390/life16081320},
pmid = {42653008},
issn = {2075-1729},
abstract = {Background/Objectives: Comparisons of abdominal Surgical-Site Infection (SSI) rates during COVID-19 often treat recorded incidence as a direct measure of biological risk, although the pandemic altered operative volume and case mix, prevention practices, and post-discharge detection. This review examines when reported SSI changes are interpretable. Methods: We conducted a critical narrative review, informed by SANRA and critical interpretive synthesis, of MEDLINE/PubMed, Embase, Scopus, and Europe PMC (January 2018-25 June 2026). Comparative SSI studies formed the core evidence set, supported by contextual studies on emergency presentation, biological risk, prevention, and surveillance. Results: Studies reported lower, unchanged, non-monotonic, and higher SSI rates. These differences became more coherent when the recorded rate was separated into operative composition, true infection probability, and detection probability. No core study measured all domains required to isolate a biological pandemic effect. Evidence from acute pancreatitis and abdominal trauma showed that disease severity, care access, inflammatory status, and prognostic relationships varied with health-system context. Conclusions: We propose the Surgical-Site Infection Signal-Validity Framework (SSI-SVF). It classifies findings as probable true improvement, apparent improvement, masked deterioration, mixed deterioration, or indeterminate and requires joint assessment of operative composition, true infection risk, and detection probability before interpreting a calendar-period change as altered surgical safety.},
}
@article {pmid42653089,
year = {2026},
author = {Tsvetkova, V and Todorova, K},
title = {β-Cell Dysfunction in COVID-19 and Post-COVID Syndrome: Molecular Mechanisms Linking Inflammation, Oxidative Stress, and Insulin Secretion.},
journal = {International journal of molecular sciences},
volume = {27},
number = {16},
pages = {},
doi = {10.3390/ijms27167083},
pmid = {42653089},
issn = {1422-0067},
mesh = {Humans ; *Oxidative Stress ; *COVID-19/complications/metabolism ; *Insulin-Secreting Cells/metabolism/pathology ; SARS-CoV-2 ; *Inflammation/metabolism/pathology ; Insulin Secretion ; Insulin/metabolism ; Post-Acute COVID-19 Syndrome ; Insulin Resistance ; },
abstract = {Coronavirus disease 2019 (COVID-19) is increasingly recognized as a multisystem disorder associated with persistent metabolic complications extending beyond the acute phase of infection. Accumulating evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may disrupt glucose homeostasis through mechanisms involving pancreatic β-cell dysfunction, insulin resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction, and hypoxia-related signalling. This review summarizes current evidence regarding the molecular and cellular mechanisms linking SARS-CoV-2 infection to impaired insulin secretion and post-COVID metabolic disturbances. Particular emphasis is placed on the regulation of insulin secretion, β-cell compensation and failure, oxidative stress, inflammatory signalling, mitochondrial dysfunction, and the development of the post-COVID metabolic phenotype. Emerging evidence indicates that persistent metabolic abnormalities after COVID-19 may range from transient dysglycaemia to new-onset diabetes mellitus and metabolic syndrome. The review also discusses clinical implications, biomarkers, therapeutic perspectives, and unresolved questions regarding the reversibility of post-COVID β-cell dysfunction. A better understanding of the mechanisms underlying post-COVID metabolic dysfunction may improve risk stratification, facilitate early intervention, and support development of targeted therapeutic strategies aimed at preserving β-cell function and long-term metabolic health.},
}
@article {pmid42653382,
year = {2026},
author = {Paracchini, V and Petrillo, M and Fornara, L and Gioria, S and Leoni, G and Guerrini, G and Geiss, O and Marchini, A and Calzolai, L},
title = {Critical Evaluation of Key Methods for RNA Quantification.},
journal = {International journal of molecular sciences},
volume = {27},
number = {16},
pages = {},
doi = {10.3390/ijms27167379},
pmid = {42653382},
issn = {1422-0067},
mesh = {Humans ; *RNA, Messenger/analysis/genetics ; Chromatography, High Pressure Liquid/methods ; Electrophoresis, Capillary/methods ; SARS-CoV-2/genetics ; Nanoparticles/chemistry ; Polymerase Chain Reaction/methods ; COVID-19/prevention &amp; control/virology ; Spectrophotometry, Ultraviolet/methods ; mRNA Vaccines ; *COVID-19 Vaccines/genetics ; Liposomes ; },
abstract = {The approval of safe and effective lipid nanoparticles-encapsulated mRNA (LNP-mRNA) vaccines during the SARS-CoV-2 pandemic is catalysing the development of the next generation of mRNA therapeutics. Accurate characterisation methods are crucial for assessing the quality and efficacy of these complex formulations. Several analytical techniques exist for the quantification of the mRNA drug substance, including UV spectroscopy, capillary electrophoresis, high-performance liquid chromatography (HPLC), and digital PCR (dPCR). Here, we compare these methods, highlight their limitations, and discuss critical considerations for experimental design to improve the agreement between different analytical methods.},
}
@article {pmid42653735,
year = {2026},
author = {Șolea, R and Șerban, E and Călugăr-Solea, SF and Mathe, E and Blebea, NM and Hancu, G and Serban, G},
title = {Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders.},
journal = {Pharmaceuticals (Basel, Switzerland)},
volume = {19},
number = {8},
pages = {},
doi = {10.3390/ph19081238},
pmid = {42653735},
issn = {1424-8247},
support = {//University of Oradea/ ; },
abstract = {Background/Objectives: Mental and neurological disorders contribute substantially to the global burden of disease, affecting people of all ages and backgrounds. As their prevalence increases with age, their overall impact is expected to grow in the coming decades. Although psychological and pharmacological treatments are available, many patients fail to achieve satisfactory outcomes, underscoring the need for improved therapeutic strategies. Cannabis sativa L. has been used for medicinal purposes for centuries, and cannabidiol (CBD) has attracted increasing attention because of its broad therapeutic potential. Scientific studies indicate that CBD may be beneficial in several mental and neurological disorders. Methods: A comprehensive literature search was conducted to identify articles investigating the therapeutic potential of CBD and cannabis in selected disorders. Results: Evidence from preclinical and clinical studies, together with findings from the broader cannabis literature, indicates that CBD may offer therapeutic benefits in a range of conditions, including Alzheimer's and Parkinson's disease, anxiety disorders, and epilepsy. Emerging data also support its potential use as an adjunctive therapy for COVID-19. Current research has improved understanding of the neurobiological mechanisms underlying these disorders and the molecular pathways through which CBD may exert its effects. CBD has demonstrated good tolerability, with predominantly mild adverse effects and a favorable safety profile. Conclusions: Despite promising findings, many available studies are preclinical or involve small patient cohorts, and the mechanisms underlying the therapeutic effects of CBD remain incompletely understood. Further well-designed, randomized, controlled, multicenter trials are needed to establish the efficacy and safety of CBD and support its integration into clinical practice.},
}
@article {pmid42653958,
year = {2026},
author = {Nodola, P and Molefe, PSS and Tseki, PF and Gumede, NJ},
title = {Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {16},
pages = {},
doi = {10.3390/molecules31162877},
pmid = {42653958},
issn = {1420-3049},
support = {CPRR23031081848//National Research Foundation/ ; },
mesh = {*Virus Internalization/drug effects ; *Antiviral Agents/pharmacology/chemistry/therapeutic use ; Humans ; *SARS-CoV-2/drug effects/physiology ; *Virus Replication/drug effects ; Molecular Dynamics Simulation ; Quantitative Structure-Activity Relationship ; *Drug Design ; Molecular Docking Simulation ; Computer Simulation ; COVID-19/virology ; Pandemics ; *Betacoronavirus/drug effects/physiology ; },
abstract = {The SARS-CoV-2 pandemic has significantly impacted global health, politics, medicine, finance, and society. Since 2020, various mutations have been reported, leading to drug resistance in current treatments against different SARS-CoV-2 strains and a drastic increase in cases of long-COVID. This situation underscores the urgent need to develop targeted and effective drugs to combat the spread of SARS-CoV-2 strains and their mutants, manage long-COVID symptoms and prepare for future pandemics. Currently, the treatment of SARS-CoV-2 focuses on targeting the virus's entry and replication mechanisms to disrupt its life cycle. This review examines approved drugs, clinical candidates, and inhibitors under development, along with their bioassay data, while highlighting associated challenges. It illustrates how inhibitors bind to active sites, providing insights and emphasizing the importance of in silico studies, such as molecular docking, molecular dynamics simulation, FEP+, WaterMap, and quantitative structure-activity relationship (QSAR) analyses, and their correlation with experimental studies in expediting the drug discovery process. The review aims to provide researchers with insights into the gaps that need to be addressed concerning mutations affecting viral entry and to prepare for future pandemics.},
}
@article {pmid42654058,
year = {2026},
author = {Niazi, SK},
title = {Two Classes of Protein Therapeutics: Why Dose-Response Architecture Defines the Boundary of mRNA Medicines.},
journal = {Pharmaceutics},
volume = {18},
number = {8},
pages = {},
doi = {10.3390/pharmaceutics18080941},
pmid = {42654058},
issn = {1999-4923},
abstract = {Messenger RNA (mRNA) entered clinical medicine through vaccines, where the innate immune reactivity that complicates protein therapeutics acts as a built-in adjuvant. The success of the coronavirus disease 2019 (COVID-19) mRNA vaccines inspired an expansive vision of an mRNA 2.0 era extending the modality to rare and common diseases, with delivery framed as the principal challenge. This review accepts much of that vision but argues it rests on an unstated assumption: that all protein therapeutics form a single pharmacological class. They do not. We propose a taxonomy, the Dose-Response Architecture Classification, separating two classes. Exposure-controlled therapeutics require a specific quantity of active protein on a defined regimen, as outcomes depend on reproducible exposure; examples include insulin, erythropoietin, growth hormone, coagulation factors, and narrow-therapeutic-index biologics. Threshold-response therapeutics depend on surpassing a functional threshold rather than maintaining a precise concentration; these include vaccines, many enzyme-replacement therapies, genome editing, receptor-saturating antibodies, and immune-cell reprogramming. Because an mRNA drug is dosed as an instruction, and a single message is translated into a variable number of proteins through a multiplicative, stochastic intracellular chain, the dose-to-effect relationship is inherently variable. Our central, deliberately falsifiable proposition is that mRNA is suitable for threshold-response therapeutics but unsuitable for exposure-controlled therapeutics unless a construct or delivery system demonstrates validated post-delivery output control within predefined pharmacokinetic and pharmacodynamic limits. This is a pharmacological boundary, not a delivery obstacle. We conclude that the greatest advances in mRNA 2.0 will come not from delivery alone but from disciplined indication triage by class.},
}
@article {pmid42654139,
year = {2026},
author = {Nguyen, HX and Ho, MP},
title = {Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.},
journal = {Pharmaceutics},
volume = {18},
number = {8},
pages = {},
doi = {10.3390/pharmaceutics18081022},
pmid = {42654139},
issn = {1999-4923},
abstract = {Vaccination ranks among the most consequential interventions in medicine, yet cold-chain dependence, sharps hazards, needle phobia, and reliance on trained vaccinators limit coverage where vaccine-preventable mortality is highest. Microneedle patches deposit antigen into the antigen-presenting-cell-rich epidermis and upper dermis through projections that penetrate the stratum corneum without reaching dermal nociceptors. Such targeting yields immunogenicity matching or exceeding intramuscular injection at a fraction of the antigen mass, with dose-sparing up to six-fold recorded for influenza, polio, and SARS-CoV-2 antigens. Solid-state formulation converts that immunological advantage into a logistical one, since polymeric matrices preserve potency for as long as two years at ambient temperature, removing the refrigeration infrastructure that consumes significant delivery cost. Six microneedle types have reached preclinical or clinical maturity, with dissolving microneedle patches the most advanced. Two trials provide the clinical evidence: a Phase I influenza study showing non-inferior antibody responses and successful self-application, and a Phase I/II measles-rubella trial in The Gambia reaching 93% measles and 100% rubella seroconversion in infants without related serious adverse events. Engineering advances currently include an automated printer producing thermostable mRNA-lipid nanoparticle patches that retain bioactivity for six months at ambient temperature, the first intradermal self-amplifying RNA patch, and quantum-dot on-body immunization records. Sterility assurance, dose uniformity, nucleic acid integrity within solid matrices, and fragmented regulatory guidance remain the challenging obstacles, alongside a clinical pipeline concentrated on few antigens. This review integrates the mechanistic, materials, manufacturing, clinical, regulatory, and global health dimensions of the field to guide translation and equitable deployment.},
}
@article {pmid42654231,
year = {2026},
author = {Praet, SFE},
title = {Targeting Bioenergetic, Redox and Prostaglandin Pathways in Long COVID-Associated Post-Exertional Malaise and Brain Fog: A Nutraceutical Translational Hypothesis.},
journal = {Nutrients},
volume = {18},
number = {16},
pages = {},
doi = {10.3390/nu18162650},
pmid = {42654231},
issn = {2072-6643},
mesh = {Humans ; *Dietary Supplements ; *COVID-19/complications ; Post-Acute COVID-19 Syndrome ; *Energy Metabolism/drug effects ; Oxidation-Reduction/drug effects ; SARS-CoV-2 ; *Prostaglandins/metabolism ; Ubiquinone/analogs &amp; derivatives ; Mitochondria/metabolism ; Brain/metabolism ; },
abstract = {Post-exertional malaise (PEM) and cognitive dysfunction (hereafter "cognitive dysfunction", including the patient-reported syndrome often described as "brain fog") are among the most disabling features of Long COVID; yet, approved disease-modifying treatments remain lacking. Emerging evidence implicates interacting disturbances in mitochondrial bioenergetics, redox regulation and neurovascular inflammation, although much of the supporting evidence remains indirect and derives from acute COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), primary mitochondrial disease, inflammatory biology and mechanistic pharmacology rather than from direct Long COVID intervention trials. This hypothesis-generating narrative review develops a mechanism-based translational framework: that a pathway-targeted nutraceutical programme may modulate selected elements of these three axes, subject to prior demonstration of formulation quality, pharmacokinetic feasibility, target engagement and safety. Candidate modules comprise coenzyme Q10 and alpha-lipoic acid for bioenergetic/redox support; selenium, sulforaphane and resveratrol for Nrf2-thioredoxin-related redox regulation; and Boswellia serrata, luteolin and eicosapentaenoic acid for putative prostaglandin/resolution-pathway modulation. Sonlicromanol provides a conceptual mechanistic precedent for combined redox and prostaglandin-directed pharmacology, but it is not considered pharmacologically equivalent to an eight-agent nutraceutical combination. We summarise the mechanistic rationale, distinguish direct from indirect evidence, define qualitative evidence-grading criteria, outline safety and interaction considerations, and propose a staged translational research programme. This framework is intended to generate falsifiable hypotheses for future Long COVID studies, not to imply established clinical efficacy.},
}
@article {pmid42474420,
year = {2026},
author = {Czepiel, D and van der Ven, E and Sijbrandij, M and Hoek, HW},
title = {Rethinking mental disorders in COVID-19: evidence from prepandemic longitudinal data.},
journal = {Current opinion in psychiatry},
volume = {39},
number = {5},
pages = {375-384},
doi = {10.1097/YCO.0000000000001103},
pmid = {42474420},
issn = {1473-6578},
mesh = {Humans ; *Mental Disorders/epidemiology/psychology ; *COVID-19/psychology/epidemiology ; Longitudinal Studies ; },
abstract = {PURPOSE OF REVIEW: To synthesize longitudinal evidence of mental health outcomes, including prepandemic symptom measurements, among individuals with preexisting mental disorders during the COVID-19 pandemic.<br><br>RECENT FINDINGS: Symptom exacerbation commonly occurred in bulimia nervosa, binge-eating disorder, substance use disorders and in obsessive-compulsive psychopathology related to contamination, while symptom improvement was consistently observed in bipolar disorders. In autism spectrum, schizophrenia spectrum and posttraumatic stress disorders, contrasting symptom patterns were reported, possibly reflecting differences in preexisting demographic and clinical profiles and contextual influences. Symptoms in depressive and anxiety disorders, anorexia nervosa and obsessive-compulsive psychopathology unrelated to contamination remained largely stable. Across most disorders, individuals with chronic mental disorders&#xa0;or higher prepandemic symptom levels more frequently showed stable or improving trajectories than those with milder presentations or recent-onset disorders.<br><br>SUMMARY: Given the small number of methodologically diverse studies, definitive statements regarding differential impact of the pandemic across disorders or underlying mechanisms remain premature. Nevertheless, current evidence does not indicate a generalised deterioration in individuals with preexisting mental disorders, including those with the highest prepandemic symptom burden. While some disorder-specific differences emerged, likely reflecting interactions between contextual changes and preexisting disorder processes, the overall picture is more nuanced than frequently portrayed in pandemic-related literature.},
}
@article {pmid42484844,
year = {2026},
author = {Fette, F and Roll, F and Kranke, P and Koscielny, J and Zacharowski, K and Weber, CF and Lindner, ML},
title = {[Hereditary disorders of hemostasis in obstetrics 2/2-Anesthesiological aspects of secondary hemostasis].},
journal = {Die Anaesthesiologie},
volume = {75},
number = {9},
pages = {667-680},
pmid = {42484844},
issn = {2731-6866},
mesh = {Humans ; Female ; Pregnancy ; *Pregnancy Complications, Hematologic/therapy/genetics ; *Hemostasis/physiology/genetics ; *Anesthesia, Obstetrical/methods ; *Blood Coagulation Disorders, Inherited/therapy/genetics/complications ; },
abstract = {Hemophilia A and B as well as von Willebrand diseases account for 95-97% of all congenital blood coagulation disorders and the rare factor deficiency conditions (factors I, II, V, VII, X, XI, XIII) account for the remaining 3-5%. The clinical presentation varies considerably, whereby the correlation between factor activity and bleeding phenotype is only insufficiently expressed, especially for factor VII deficiency. Pregnancy represents a special challenge as the physiological alterations of hemostasis can compensate for the underlying defect to different extents. These heterogeneous dynamics require an individualized monitoring, which also includes the individual history of bleeding as the central instrument of risk stratification, in addition to factor activities. From an anesthesiological perspective two core aspects are prioritized, the safe performance of neuraxial anesthesia procedures and the management of peripartum hemorrhage.},
}
@article {pmid42594644,
year = {2026},
author = {Kazi, F and Shapland, CY and Spiga, F and Villanueva, G and Cornish, RP and Henschke, N and Cogo, E and Sebastianski, M and Aarabi, M and Bergman, H and Buckley, B and Clayton, GL and French, CE and Liu, J and Madley-Dowd, P and Pelone, F and Petkovic, J and Probyn, K and Saulle, R and Savović, J and Wilson, R and Beck, CR and Higgins, JPT},
title = {Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.},
journal = {Vaccine},
volume = {90},
number = {},
pages = {128993},
doi = {10.1016/j.vaccine.2026.128993},
pmid = {42594644},
issn = {1873-2518},
mesh = {Humans ; *COVID-19 Vaccines/immunology/administration &amp; dosage ; *Vaccine Efficacy ; *COVID-19/prevention &amp; control/epidemiology/immunology ; *SARS-CoV-2/immunology ; *Pandemics/prevention &amp; control ; Vaccination ; Observational Studies as Topic ; 2019-nCoV Vaccine mRNA-1273 ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Vaccines, Inactivated/immunology ; },
abstract = {Reliable evidence on COVID-19 vaccine effectiveness during the period of Omicron variant predominance was essential to inform global vaccination strategies. Our living systematic review, commissioned by the World Health Organization (WHO), was established to provide an ongoing synthesis and critical appraisal of comparative observational studies evaluating the effectiveness of vaccines against COVID-19/SARS-CoV-2 infection caused by the Omicron variant. Weekly searches covering seven databases up to 31 December 2022 sought evidence for WHO-approved vaccine platforms, including mRNA vaccines (BNT162b2, mRNA-1273), adenoviral vector vaccines (ChAdOx1-S, SII-ChAdOx1 nCoV-19, Ad26.COV2·S, Gam-COVID-Vac) and inactivated virus vaccines (CoronaVac, BBV-152). We used the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool to assess the validity of estimates of vaccine effectiveness. The review included 79 studies of over 53 million individuals, contributing 2032 estimates of vaccine effectiveness against asymptomatic SARS-CoV-2 infection (36; 45.6%), symptomatic COVID-19 (31; 39.2%), severe or critical COVID-19 (53; 67.1%) and all-cause mortality (2; 2.5%). Structured comparisons of vaccine performance across platforms, dosing schedules and populations, focussed on severe or critical COVID-19 disease. Vaccination was observed to be strongly protective against severe or critical disease caused by the Omicron variant, particularly for mRNA vaccines. Most results were judged to be at moderate risk of bias (361, 18%) or at serious risk of bias (1591, 78%) with the principal concern being confounding. We discuss implications for future pandemic preparedness, including the importance of standardized study protocols; robust data linkage between vaccination, testing and outcomes; and validated risk-of-bias frameworks for diverse observational designs.},
}
@article {pmid42638763,
year = {2024},
author = {Kudryavtsev, I and Starshinova, A and Rubinstein, A and Kulpina, A and Ling, H and Zhuang, M and Kudlay, D},
title = {The role of the immune response in developing tuberculosis infection: from latent infection to active tuberculosis.},
journal = {Frontiers in tuberculosis},
volume = {2},
number = {},
pages = {1438406},
pmid = {42638763},
issn = {2813-7868},
abstract = {Despite advancements in modern medicine, tuberculosis continues to be one of the leading causes of death globally. Findings indicate that COVID-19 may trigger the activation of tuberculosis infection (TB), leading to its spread. Despite the development of new immunological diagnostic methods for latent tuberculosis infection (LTBI), it is still unclear how the infection transitions to an active TB state. The goal of the study is to provide insights into the progression of tuberculosis infection from a latent to an active state. This article presents recent research data focused on investigating the pathogenesis of LTBI, particularly the immune responses in the interaction between Mycobacteria tuberculosis (Mtb) and the host. It describes the mechanisms of T-cell immunity and cytokine activation, supporting the concept of type 1, type 2, and type 3 immune responses. According to the conducted studies, Th17 cells have a significant role in the development of type 3 antigen-specific responses. The cytokines IL-6 and IL-23 activate STAT3, which is necessary to trigger the expression of Th17. Future research on the role of Th17 cells and cytokines, particularly IL-6 and IL-21, may be beneficial in understanding the shift from LTBI to active TB.},
}
@article {pmid42638777,
year = {2024},
author = {Salgame, P and Pentakota, SR and Malabad, JCM and Narasimhan, PB and Verma, S and Prakash Babu, S and Sharma, V and Sarkar, S and Alejandria, MM and Ellner, JJ},
title = {Diverse interactions of Mycobacterium tuberculosis infection and of BCG vaccination with SARS-CoV-2.},
journal = {Frontiers in tuberculosis},
volume = {2},
number = {},
pages = {1378068},
pmid = {42638777},
issn = {2813-7868},
abstract = {The COVID pandemic and tuberculosis (TB) endemicity is double trouble to much of the world. SARS-CoV-2 and Mycobacterium tuberculosis (Mtb), causative agents of COVID and TB, respectively, are both infectious respiratory pathogens involving close communities and individuals. Both pathogens can cause lung disease, involving unbalanced inflammatory cell immune responses that can lead to a syndemic impact. Moreover, dual infection is common in certain settings. In low- and middle- income countries, most individuals with SARS-CoV-2 infection or COVID-19, in fact, will have been exposed to or infected with Mtb and some will develop active TB. Here we review the literature examining the diverse interactions of M. tuberculosis infection and of BCG vaccination with SARS-CoV-2. We discuss areas in which contradictory results have been published and conclude that there are still several unresolved issues that warrant further study on the co-pathogenesis of SARS-CoV-2 and Mtb and BCG- mediated heterologous protection against COVID-19.},
}
@article {pmid42640425,
year = {2026},
author = {Ürem Nokay, M and Dinckol, HA and Sert, G},
title = {The compensation issue for covid-19 vaccines in Türkiye: ethical and legal assessment.},
journal = {Monash bioethics review},
volume = {},
number = {},
pages = {},
pmid = {42640425},
issn = {1836-6716},
}
@article {pmid42641158,
year = {2026},
author = {Karipidis, YK and Karipidis, KY},
title = {eNOS Uncoupling, Shear-Stress Tolerance, and the Two-Threshold Model of Post-Exertional Malaise in Long COVID: A Mechanistic Hypothesis With Implications for Physiotherapy and Recovery Protocols.},
journal = {Microcirculation (New York, N.Y. : 1994)},
volume = {33},
number = {6},
pages = {e70082},
doi = {10.1111/micc.70082},
pmid = {42641158},
issn = {1549-8719},
mesh = {Humans ; *Nitric Oxide Synthase Type III/metabolism ; Post-Acute COVID-19 Syndrome ; *COVID-19/physiopathology/complications/therapy ; Biopterins/analogs &amp; derivatives/metabolism ; SARS-CoV-2 ; *Physical Therapy Modalities ; Nitric Oxide/metabolism ; Stress, Mechanical ; Endothelium, Vascular/physiopathology ; },
abstract = {OBJECTIVE: To propose and make testable a mechanistic hypothesis for post-exertional malaise (PEM) in a clinically distinct subset of Long COVID patients, in whom delayed exertional symptoms coexist with consistently normal macrovascular investigations.<br><br>METHODS: Established vascular-biology literature is synthesized into an integrated, falsifiable model centered on endothelial nitric oxide synthase (eNOS) uncoupling, from which mechanism-specific predictions and a dynamic pre-/post-exertion biomarker validation framework are derived.<br><br>RESULTS: We propose that SARS-CoV-2-induced endotheliitis activates inducible nitric oxide synthase and silently depletes the tetrahydrobiopterin (BH4) pool on return to activity, shear-stress activation of structurally intact eNOS against a depleted BH4 background yields superoxide rather than nitric oxide, generating peroxynitrite that sustains a self-amplifying nitro-oxidative cycle. The Two-Threshold Model distinguishes a PEM threshold from a shear-stress-tolerance threshold and predicts that prolonged immobility may paradoxically erode endothelial function. eNOS uncoupling is positioned as one node among alternative microvascular pathways, and autonomic findings are proposed to be secondary within this phenotype.<br><br>CONCLUSIONS: This phenotype-specific, falsifiable hypothesis yields mechanism-derived predictions and rehabilitation implications consistent with symptom-contingent pacing guidance; it does not claim to explain all Long COVID presentations.},
}
@article {pmid42641338,
year = {2026},
author = {Fanelli, M and Petrone, V and Chirico, R and Matteucci, C and Minutolo, A},
title = {Extracellular vesicles in COVID-19 and long COVID: Structural mediators of viral persistence and immune dysfunction.},
journal = {Current opinion in structural biology},
volume = {101},
number = {},
pages = {103375},
doi = {10.1016/j.sbi.2026.103375},
pmid = {42641338},
issn = {1879-033X},
abstract = {Extracellular vesicles (EVs) have emerged as pivotal structural mediators of immune dysregulation and viral antigen persistence in long COVID. Rather than passive biological carriers, EVs released during SARS-CoV-2 infection function as highly organized lipid nanostructures that preserve the native conformational integrity of viral proteins, including the spike glycoprotein, thereby facilitating chronic signaling and systemic inflammation. Recent advancements in single-particle analytical techniques, such as cryo-electron tomography and atomic force microscopy, are now overcoming the limitations of bulk analysis, enabling the visualization of EV heterogeneity and the quantitative profiling of their nanomechanical properties. This review synthesizes current insights into how EV-associated viral remnants and host-derived inflammatory cargo propagate neuro-immune crosstalk and vascular injury. We conclude by evaluating the potential of EVs as precision biomarkers and bioengineered therapeutic platforms, emphasizing the need for standardized structural characterization to transition these nanovesicles from physiological mediators to clinical diagnostic and regenerative tools.},
}
@article {pmid42641532,
year = {2026},
author = {Spasenoska, D and Araya, N and de Swart, M and Harriss, E and Moetlediwa, M and Ndlovu, M and Ntamo, Y and Probyn, K and Villanueva, G and Henschke, N and Cheng, V and Moldokmatova, A and Saylors, K and Bahkali, K and Aden, J and Moallim Abdi, QM and Al-Abdullah, N and Patel, E and Al-Tawfiq, JA and Azhar, EI and El-Masry, L and Gobat, N and Al-Sayafi, A and Simniceanu, A and von Dobschuetz, S and Van Kerkhove, MD and Ndwandwe, D and Norton, A and Sigfrid, L and , },
title = {Risk factors and mitigation strategies for spillover of MERS-CoV and other infections at the camel-human-interface: Rapid research needs appraisal.},
journal = {Journal of infection and public health},
volume = {19},
number = {10},
pages = {103327},
doi = {10.1016/j.jiph.2026.103327},
pmid = {42641532},
issn = {1876-035X},
abstract = {Middle East respiratory syndrome (MERS), caused by MERS coronavirus (MERS-CoV), is a zoonotic disease transmitted from camels-to-humans. We applied a targeted rapid research needs appraisal (RRNA) to review evidence and gaps on spill-over risk, mitigation measures, associated social and behavioural research. We systematically searched PubMed, Ovid, Scopus, Web of Science and WHO Global Index Medicus up to November 2024, studies on MERS and other zoonoses at the camel-to-human interface. The protocol and interpretation were informed by a WHO-coordinated MERS expert reference group and Secretariat. Of 82 records, 92.7% (76/82) were observational and 74.4% (61/82) focused on MERS. Most were set in the Eastern Mediterranean (69.5%, 57/82) region. Most studies explored spillover risk activities (n = 50), and host and occupational risk factors (n = 36). Current evidence overlooks social and cultural contexts of camel-to-human interactions, highlighting the need for multidisciplinary research and engagement with at-risk populations to inform mitigation strategies applicable to diverse contexts.},
}
@article {pmid42642645,
year = {2026},
author = {Grašo, M and Aquino, K and Baral, S and Berg, N and Clark, CJ and Conway, LG and Dolan, P and Grover, S and Fousiani, K and Kitz, CC and Krpan, D},
title = {Refining the role of behavioural and social sciences in pandemic response post-COVID-19.},
journal = {Nature human behaviour},
volume = {},
number = {},
pages = {},
pmid = {42642645},
issn = {2397-3374},
abstract = {With the acute stage of COVID-19 behind us, reflection can inform future preparedness. During the pandemic, behavioural and social sciences often studied human behaviour through the lens of alignment with public health recommendations, implicitly treating concern and compliance as desirable and rational. While understandable, this emphasis was relatively narrow. Uncertainty, uneven risk distribution and competing values could have led to heterogeneous appraisals of risk and intervention benefit, even with the evidence available at the time. We show that engaging with the possibility that people could have been heterogeneously rational can broaden understanding of behaviour during COVID-19. Our aim is not to revisit the legitimacy of the response but to encourage reflection on the role of behavioural and social sciences in knowledge generation and highlight opportunities to examine pandemic salience and risk calibration. We outline research directions to guide the field and strengthen decision-making, trust and adaptability in future crises, promoting short-term compliance and long-term trust.},
}
@article {pmid42642733,
year = {2026},
author = {Ha, NX and Nguyen, A and Trang, HNM and Abdul Aziz, JM and Dhouibi, N and Le, BD and Altom, A and Amin, MA and Anh, PDT and Said, H and Vadduri, VV and Tam, DNH and Okubayashi, S and Makram, AM and Huy, NT},
title = {The filtration performance of fabrics against particles of viral size: a systematic review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {42642733},
issn = {1471-2334},
mesh = {*Filtration/instrumentation/methods ; Humans ; *Textiles/virology ; SARS-CoV-2 ; *Masks/virology ; COVID-19/prevention &amp; control/transmission ; Particle Size ; Aerosols ; Pandemics/prevention &amp; control ; Respiratory Aerosols and Droplets/virology ; },
abstract = {INTRODUCTION: Wearing a mask is part of the comprehensive strategy to suppress transmission of the SARS-CoV-2 virus and respiratory tract infections. Despite available COVID-19 vaccines, wearing a mask has remained one of the simplest and most effective ways. There was, however, little data available regarding the filtration of fabrics in masks against infectious aerosols or particles of viral size. This study reviewed the filtration performance of fabrics against virus-sized particles.<br><br>METHODS: The systematic review was conducted according to the PRISMA 2020 statement. The literature search started with seven electronic databases (PubMed, Google Scholar, Scopus, Institute of Science Index, EMBASE, Cochrane Library, SciFinder) and two preprints, then manual search. Quality assessment was performed on all included studies using an adaptive tool for in vitro studies.<br><br>RESULTS: Eighteen studies were finally included. Cotton was most commonly investigated, followed by polymers and nanofibers. A study reported filtration performance as droplet blocking efficiency (%), and materials with the highest blocking efficiency comprised polypropylene (99.7 [95.2-99.9]), cotton (98.9 [96.8-99.8]), silk (98.7 [81.1-99.8]), and polyester/polyamide (98.2 [90-99.8]). Other studies reported filtration efficiency (%). Fabrics showing highest filtration efficiency were polymers (polypropylene, polyethylene, spunbond/meltblown/spunbond) (100, 94.4, 93.9, respectively), nanofibers (nanofiber-fabric-layered composite, polyvinyl alcohol/nylon-taffeta composite) (99.8&#x2009;&#xb1;&#x2009;0.24, 97.3, respectively), cotton (cotton/chiffon, cotton quilt, cotton/flannel, cotton/silk) (97&#x2009;&#xb1;&#x2009;2, 96&#x2009;&#xb1;&#x2009;2, 95&#x2009;&#xb1;&#x2009;2, 94&#x2009;&#xb1;&#x2009;2, respectively). Quality assessment showed that most of the studies were adequate to evaluate the filtration performance against aerosol or virus particles.<br><br>CONCLUSION: Some fabrics showed effectiveness in protective applications for respiratory infections; particularly nanofibers and polymers were promising materials for specialized masks or respirators.},
}
@article {pmid42642758,
year = {2026},
author = {Devarshi, R and Myers, C},
title = {Factors influencing implementation of telemedicine in rural dementia care services in high-income countries: a scoping review.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {42642758},
issn = {1472-6963},
mesh = {Humans ; *Dementia/therapy ; *Telemedicine/organization &amp; administration ; *Developed Countries ; *Rural Health Services/organization &amp; administration ; COVID-19/epidemiology ; SARS-CoV-2 ; Digital Health ; },
abstract = {BACKGROUND: Dementia care presents unique challenges in rural areas in high-income countries (HICs) due to limited access to specialised healthcare, fragmented services, and geographical isolation. Telemedicine has emerged as a promising solution, particularly accelerated by the coronavirus disease (COVID-19) pandemic. However, there remains a critical gap in understanding how telemedicine is operationalised within existing dementia care systems, particularly in rural contexts. The aim of this scoping review is to map and analyse existing evidence on the integration of telemedicine into dementia care systems in rural areas in HICs, with a specific focus on identifying barriers, facilitators, and strategies that shape effective implementation.<br><br>METHODS: This scoping review followed Arksey and O'Malley's framework, refined by Levac et al. and reported in accordance with PRISMA-ScR guidelines. Searches covered MEDLINE, Embase, Web of Science and CINAHL for studies published from January 2014 to March 2025. Records were screened against predefined eligibility criteria. Studies were included only where telemedicine involved synchronous, real-time, video-mediated clinical interaction. Data were extracted using a standardised form and analysed through thematic analysis. Themes were subsequently mapped to the Consolidated Framework for Implementation Research 2.0 (CFIR 2.0) to structure interpretation across implementation levels.<br><br>RESULTS: Nine studies met the inclusion criteria across rural settings in the USA, Australia, Canada, Greece, and the United Kingdom. Telemedicine was delivered across home, facility, and community settings, with several studies using blended delivery models. Key barriers included limited connectivity, digital literacy, health impairments, and caregiver capacity. Key facilitators included trust and continuity in provider relationships, perceived practical advantages, and organisational support. Key strategies included training and capacity building, dedicated coordination roles, and co-design with caregivers and patients.<br><br>CONCLUSION: The integration of telemedicine in rural dementia care systems in HICs is shaped by complex interdependencies between technological, organisational, and relational factors. Strengthening health system readiness requires investment in infrastructure, policy alignment, and inclusive design approaches that centre the needs of older adults with dementia, caregivers, and rural health systems.},
}
@article {pmid42642760,
year = {2026},
author = {Alabdulaali, M and Alharthi, A and Siemers, O and Alsuwaidan, D and Alruwaili, A and Almutairi, A and Alharbi, M},
title = {Systems thinking in public health interventions: a systematic review of barriers and facilitators.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {42642760},
issn = {1472-6963},
support = {ORF-2026-1868//Ongoing Research Funding program/ ; },
mesh = {Humans ; *Systems Analysis ; Public Health Infrastructure ; *Public Health ; Saudi Arabia ; },
abstract = {BACKGROUND: Systems thinking has been promoted to address complex public health challenges involving fragmented systems, multi-sectoral governance, and interacting social determinants of health. However, its application in real-world public health interventions and the conditions influencing implementation remain understudied. This systematic review examines how systems thinking has been operationalized in public health interventions, identifies key facilitators and barriers to implementation, and interprets these findings in relation to broader public health practice and ongoing health system reforms in Saudi Arabia.<br><br>METHODS: We conducted a systematic review (2013-2025; final search November 2025) using PubMed, Scopus, Web of Science, CINAHL, and PsycINFO. Studies applying systems thinking in population- or community-level public health interventions with implementation findings were included; conceptual and non-intervention studies were excluded. Data on approaches, frameworks, facilitators, and barriers were extracted and narratively synthesized. Quality was appraised using the MMAT (2018). The review was registered (PROSPERO; registration number CRD420251267775).<br><br>FINDINGS: Of 948 records identified, fifteen studies met the inclusion criteria, spanning communicable and non-communicable disease interventions across high-, middle-, and low-income countries. Systems thinking approaches included learning health systems, systems analysis and improvement approaches, community-based system dynamics, causal loop diagramming, and whole-system or multi-sectoral designs. Systems thinking was embedded within implementation processes, including iterative learning cycles, participatory system mapping, and quality improvement mechanisms. Key facilitators included stakeholder engagement and co-production, integration within existing health system structures, incremental capacity building, and leadership support. Barriers included challenges translating systems concepts into actionable interventions, workforce constraints, fragmented or non-interoperable data systems, rigid governance arrangements, and external disruptions such as COVID-19. Study designs were predominantly qualitative or mixed methods, with heterogeneity in evaluation approaches and limited long-term outcome assessment.<br><br>INTERPRETATION: Systems thinking in public health is applied mainly as an implementation-embedded practice rather than an analytical tool. Its effectiveness depends on participatory processes, adaptive learning, and supportive governance and data systems. These findings provide practical insights for health system reform contexts, including Saudi Arabia, where systems thinking can support integrated and adaptive public health interventions.},
}
@article {pmid42643544,
year = {2026},
author = {Alshahrani, NZ and AlQahtani, M and Alshahrani, AM and Alanazi, A and Alharthy, N and Albalawi, N and Khawaji, T and Qutub, W and Alnamakani, MA and Okmi, EA and Alotaibi, AM and Bafakih, W and Assiri, M},
title = {Speeding up respiratory diagnosis: clinical drivers, barriers, and system readiness for rapid molecular point-of-care testing in Saudi Arabia.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1871669},
pmid = {42643544},
issn = {2296-2565},
mesh = {Saudi Arabia ; Humans ; *Point-of-Care Testing ; *Respiratory Tract Infections/diagnosis ; Male ; Rapid Diagnostic Tests ; Surveys and Questionnaires ; Female ; Time Factors ; },
abstract = {BACKGROUND: Acute respiratory tract infections place substantial strain on healthcare systems, particularly during seasonal respiratory surges and mass-gathering events. Delayed confirmation of respiratory pathogens contributes to diagnostic uncertainty, unnecessary antimicrobial use, delayed infection prevention decisions, and inefficient patient flow. Rapid molecular point-of-care testing (mPOCT) offers near-PCR-level diagnostic accuracy with turnaround times compatible with real-time clinical decision-making; however, implementation and integration into routine clinical pathways remain variable across healthcare systems.<br><br>METHODS: We conducted an implementation-focused mixed-methods descriptive study integrating a synthesis of published evidence with structured stakeholder engagement in Saudi Arabia. Primary data were collected through three multidisciplinary scientific meetings and a stakeholder survey (N&#x202f;=&#x202f;35) involving physicians, point-of-care experts, and laboratory professionals from Ministry of Health (MOH), institutional, and private healthcare settings. Quantitative survey data were analyzed descriptively using R version 4.3.3, including exploratory descriptive subgroup summaries by workplace sector and stakeholder role. Qualitative findings from expert discussions were synthesized thematically and integrated with survey findings and published evidence through methodological triangulation.<br><br>RESULTS: Physicians represented 48.6% of respondents, with most participants working in MOH facilities (60.0%). Rapid mPOCT was reported to be routinely used during respiratory seasons, with 68.6% indicating daily use. Immediate treatment decision-making (74.3%) and patient management activities, including bed designation (57.1%), were the most frequently reported indications for testing. Nearly half of respondents preferred results within 15&#x202f;min (45.7%), while most preferred turnaround times of 30&#x202f;min or less (85.7%). Participants reported generally moderate-to-high implementation of rapid mPOCT (mean implementation score 7.69/10; range 2-10), although variability remained in guideline integration, standard operating procedures, and institutional implementation. Frequently reported implementation barriers included limited education or guidance (31.4%), perceived availability of alternative diagnostic approaches (28.6%), and financial or reimbursement constraints (28.6%).<br><br>CONCLUSION: Saudi healthcare stakeholders perceived rapid mPOCT as a valuable diagnostic tool for respiratory infections, particularly in emergency and acute care settings where timely results may support clinical decision-making. Wider implementation will require standardized diagnostic pathways, workforce education, supportive governance, and sustainable reimbursement strategies to facilitate consistent integration into routine clinical practice.},
}
@article {pmid42644874,
year = {2026},
author = {Ziaka, M and Exadaktylos, A},
title = {Awake Prone Positioning in Non-Intubated Non-COVID-19 ARDS: A Comprehensive Review.},
journal = {Advances in respiratory medicine},
volume = {94},
number = {4},
pages = {},
doi = {10.3390/arm94040053},
pmid = {42644874},
issn = {2543-6031},
mesh = {Humans ; Prone Position/physiology ; COVID-19 ; *Respiratory Distress Syndrome/therapy/physiopathology ; *Patient Positioning/methods ; Pandemics ; Wakefulness ; *Respiratory Insufficiency/therapy/physiopathology ; SARS-CoV-2 ; Respiration, Artificial ; },
abstract = {Despite advances in the understanding of the pathophysiology of acute respiratory distress syndrome (ARDS), treatment options remain limited and are mainly supportive, while mortality remains high. Prone positioning (PP) has been shown to improve oxygenation and lung mechanics in ARDS by reducing the imbalance in ventilation distribution between ventral and dorsal lung regions, altering pulmonary blood flow distribution, modifying the density distribution of edematous lung tissue, and limiting areas with low ventilation-perfusion ratios. During the coronavirus disease 2019 (COVID-19) pandemic, the use of PP, referred to as awake prone positioning (APP), was extended to non-intubated patients with severe hypoxemic respiratory failure. However, several concerns remain, including worsening oxygenation following the transition from prone to supine position, the potential development of patient self-inflicted lung injury (P-SILI), and delays in endotracheal intubation and initiation of invasive mechanical ventilation. Evidence regarding the use of APP in non-COVID-19 ARDS is scarce and consists mainly of small case series and a limited number of prospective studies with small and heterogeneous populations. Therefore, in the present work, we aim to summarize the existing evidence on APP in non-COVID-19 ARDS and acute hypoxemic respiratory failure (AHRF), describe the underlying pathophysiological mechanisms, and highlight areas for future research.},
}
@article {pmid42645038,
year = {2026},
author = {Yin, Y and Yi, Y and Yu, Y and Khrustaleva, TA and Zhai, L and Yu, J and Zhao, W and Shen, C},
title = {Paper-Based Biosensors for Monitoring Binding, Blocking, and Surrogate Neutralizing Antibody Responses Against Viral Infections.},
journal = {Biosensors},
volume = {16},
number = {8},
pages = {},
doi = {10.3390/bios16080420},
pmid = {42645038},
issn = {2079-6374},
support = {2025A0505020047//Department of Science and Technology of Guangdong Province/ ; },
mesh = {*Biosensing Techniques/methods/instrumentation ; Humans ; *Antibodies, Neutralizing/immunology ; *Antibodies, Viral/immunology ; *Virus Diseases/immunology ; Enzyme-Linked Immunosorbent Assay ; },
abstract = {Virus-specific antibody responses, including binding antibodies and neutralizing antibodies (nAbs), are important indicators of antiviral immune status after infection or immunization. They provide complementary information on antiviral humoral immunity after infection or vaccination. Antigen-binding antibodies indicate previous exposure and the magnitude of the immune response, whereas receptor-blocking and functional neutralization assays assess whether antibodies interfere with viral entry or infection. Conventional neutralization assays, such as plaque reduction neutralization tests and pseudovirus neutralization tests, provide functional information but are labor-intensive, time-consuming, biosafety-restricted, and difficult to deploy for large-scale or decentralized monitoring. Paper-based biosensors, including lateral flow assays (LFAs), microfluidic paper-based analytical devices (μPADs), and paper-based ELISA, have emerged as promising point-of-care tools owing to their low cost, portability, simple operation, and compatibility with visual or digital readouts. This review critically evaluates these platforms according to whether they measure antigen-binding antibodies, receptor-blocking activity, surrogate neutralization, or functional neutralization and summarizes the applications of these three platforms for monitoring antibody responses against SARS-CoV-2, influenza, dengue, Zika, and monkeypox viruses. Unlike previous reviews that mainly focus on general paper-based biosensor design or conventional nAb assays, this review emphasizes the distinction between antigen-binding, receptor-blocking, and surrogate neutralization readouts, and critically discusses how paper-based signals should be interpreted in relation to functional immunity. We further analyze key translational challenges, including quantitative accuracy, antigen cross-reactivity, standardization, clinical validation, regulatory positioning, and real-world implementation. Future development should combine multiplex detection, standardized calibration, digital and AI-assisted interpretation, and clinically validated assay formats. Paper-based biosensors have considerable potential for decentralized antibody monitoring and public health surveillance, but their clinical utility depends on clear assay positioning and validation against appropriate functional or reference methods.},
}
@article {pmid42645149,
year = {2026},
author = {Takahashi, K and Minami, N and Horie, K and Sudo, T and Yamada, N and Iwanaga, T and Sakuma, T and Kamezaki, H},
title = {Interventional Endoscopic Ultrasound in Gastroenterology: A Comprehensive Bibliometric Analysis (2001-2024).},
journal = {Clinics and practice},
volume = {16},
number = {8},
pages = {},
doi = {10.3390/clinpract16080153},
pmid = {42645149},
issn = {2039-7275},
support = {//Godo Shigen/ ; },
abstract = {Background/Objectives: Interventional endoscopic ultrasound (I-EUS) has evolved from a diagnostic imaging modality into a transformative therapeutic platform encompassing biliary drainage, pancreatic interventions, luminal bypass, pain management, and ablative therapies. Despite the rapid proliferation of I-EUS research, a comprehensive bibliometric analysis characterizing the global intellectual architecture of this field is lacking. Methods: A Web of Science Core Collection search identified 4340 records, of which 2237 were included (2001-2024), analyzed with R bibliometrix (version 5.0) and VOSviewer (version 1.6.20). Results: Publication output demonstrated three distinct phases with pronounced acceleration from 2017. The United States led global output (n = 625, 27.9%), followed by Japan (n = 435, 19.4%) and Italy (n = 166, 7.42%). At the continental level, Asia collectively produced the largest share of output (n = 884, 39.5% of the total corpus), exceeding the Americas (n = 687, 30.7%) and Europe (n = 492, 22.0%). Gastrointestinal Endoscopy was the most productive journal (n = 173). Tokyo Medical University was the most productive institution (n = 93, 4.16%). Four thematic clusters were identified: EUS-guided biliary and pancreatic ductal drainage; diagnostic, ablative, and injection EUS for pancreatic tumors; LAMS-enabled luminal bypass and gallbladder drainage; and pancreatic fluid collections and necrotizing pancreatitis. Temporal overlay confirmed EUS-guided gastroenterostomy, EUS-guided gallbladder drainage, and EUS-guided radiofrequency ablation as the leading research frontiers. Annual output showed no discernible contraction during the COVID-19 pandemic period (2020-2021). Conclusions: The United States led global I-EUS research output with higher rates of international collaboration compared with East Asian nations, although Asia as a continent generated the largest aggregate volume of publications. EUS-guided biliary drainage and pancreatic fluid collection management constitute the established, high-volume core of the field, while EUS-guided gastroenterostomy and novel ablative technologies represent the most dynamic investigative frontiers.},
}
@article {pmid42645624,
year = {2026},
author = {Rahim, A and Khan, MN and Mehan, S and Khan, Z and Ahamad, M and Haque, I},
title = {Chandipura virus encephalitis: an emerging pediatric neurotropic threat in india-virology, epidemiology, pathogenesis, and public health challenges.},
journal = {Journal of neurovirology},
volume = {32},
number = {5},
pages = {},
pmid = {42645624},
issn = {1538-2443},
mesh = {Humans ; India/epidemiology ; Animals ; *Vesiculovirus/pathogenicity/genetics ; *Encephalitis, Viral/epidemiology/virology/transmission/pathology ; *Rhabdoviridae Infections/epidemiology/transmission/virology ; Child ; Public Health ; Disease Outbreaks ; *Communicable Diseases, Emerging/epidemiology/virology/transmission ; },
abstract = {Chandipura virus (CHPV) is an emerging neurotropic RNA virus and member of the Rhabdoviridae family, causing outbreaks of acute encephalitis in India, mostly in children under 15 years of age. The manuscript reviews in detail the virology, genetics, clinical features, epidemiology, transmission, immunopathogenesis, and treatment of CHPV. CHPV rapidly infects neuronal tissue and activates the extrinsic pathways of neuronal apoptosis through Fas-mediated apoptosis, resulting in rapid neuronal degeneration within 24-48 h. The recent re-emergence of CHPV is another significant re-emergence in Gujarat in 2024, with the distribution of cases by space and time further suggesting CHPV is seasonal, adds new districts, and is still a threat to children. Outbreaks of CHPV typically coincide with monsoonal flooding, and Phlebotomus sandflies primarily spread the disease. The monsoonal flooding and environmental degradation that occurred during the breeding season, rendering sandflies more susceptible to outbreaks, are remarkable. Differentiation of other encephalitic viruses, such as Japanese encephalitis, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and dengue, is important for clinical diagnosis and also because of the rapid progression of CHPV. Several points to consider are low CSF pleocytosis and the neuroimaging characteristics that are identifiable. The immune response after infection is marked by a cytokine storm, followed by lymphocyte apoptosis and reduction in CNS viral clearance. Over the past decade, laboratories in India have developed in the realm of diagnosis and treatment of CHPV with the advent of molecular diagnostics such as real-time RT-PCR and IgM ELISA. However, a lack of a licensed vaccine and antivirals would make this new infectious disease more difficult to manage. This review highlights the critical importance of further surveillance, vector control, public health preparedness, and vaccine development/therapeutics for CHPV.},
}
@article {pmid42645719,
year = {2026},
author = {Dolci, M and Signorini, L and Perego, F and Passerini, S and Giannasi, C and Camurri, F and Berni, A and Messina, S and Pietropaolo, V and Baj, A and Cavalcante, P and Delbue, S},
title = {Possible involvement of viral infection in the pathogenesis of myasthenia gravis.},
journal = {Journal of neurovirology},
volume = {32},
number = {5},
pages = {},
pmid = {42645719},
issn = {1538-2443},
mesh = {Humans ; *Myasthenia Gravis/immunology/virology/pathology/genetics ; B-Lymphocytes/immunology/virology/pathology ; SARS-CoV-2/pathogenicity/immunology ; Receptors, Cholinergic/immunology/genetics ; Herpesvirus 4, Human/immunology/pathogenicity ; *COVID-19/immunology/complications/virology/pathology ; Parvovirus B19, Human/pathogenicity/immunology ; Thymus Gland/virology/immunology/pathology ; Autoantibodies/immunology ; Animals ; *Epstein-Barr Virus Infections/immunology/virology/complications/pathology ; Immunity, Innate ; Toll-Like Receptors/immunology/genetics ; Molecular Mimicry ; Thymoma/virology/immunology/pathology ; },
abstract = {Myasthenia gravis (MG) is a chronic autoimmune disorder that involves the targeting of neuromuscular junctions and is primarily driven by autoantibodies against the acetylcholine receptor (AChR). While genetic susceptibility is a factor, environmental triggers, particularly viral infections, are being increasingly investigated as potential contributors to MG pathogenesis. This review examines the complex interplay between viral pathogens and MG, highlighting mechanisms such as molecular mimicry, bystander activation, and the aberrant stimulation of innate immune pathways via Toll-like receptors (TLRs). Key DNA viruses, including Epstein‒Barr virus (EBV) and parvovirus B19, have been detected within hyperplastic thymic tissues and thymomas, suggesting that they may sustain local autoreactive B-cell activation. Furthermore, recent clinical data emphasize the role of RNA viruses, most notably SARS-CoV-2, as significant triggers of new-onset MG and myasthenic crises. Despite substantial evidence linking viral infections to MG, further mechanistic research and large-scale observational studies are needed to definitively establish causality and refine therapeutic strategies targeting these virus-induced immune responses.},
}
@article {pmid42645813,
year = {2026},
author = {Guarino, P and Chiari, F and La Via, L and Marino, A and Lechien, JR and Lentini, M and Lavalle, S and Nunnari, G and Maira, S and Botto, CG and Ferlito, S and Maniaci, A},
title = {Global Burden of Upper Airway Infections: Epidemiology, Current Challenges and Future Perspectives.},
journal = {Infectious disease reports},
volume = {18},
number = {4},
pages = {},
doi = {10.3390/idr18040089},
pmid = {42645813},
issn = {2036-7430},
abstract = {BACKGROUND: Upper airway tract infections (UATIs) are among the most common infectious diseases worldwide, accounting for an estimated 12.8 billion episodes annually and more than 8 million disability-adjusted life years (DALYs). Despite their generally self-limiting nature, their cumulative clinical, socioeconomic, and public health burden remains substantial, particularly in children, older adults, and low- and middle-income countries (LMICs).<br><br>METHODS: We performed a structured narrative review of the peer-reviewed literature and reports from major international health organizations to summarize the current evidence on the epidemiology, etiology, clinical impact, socioeconomic burden, prevention strategies, and future challenges associated with UATIs. Particular attention was given to the influence of antimicrobial resistance, vaccination policies, and lessons learned from the COVID-19 pandemic.<br><br>RESULTS: UATIs remain one of the leading causes of healthcare utilization worldwide. Children experience the highest incidence, averaging 6-8 episodes annually, whereas vulnerable populations are at increased risk of complications and hospitalization. Marked geographical disparities persist, with LMICs experiencing a disproportionate burden due to limited healthcare access, lower vaccination coverage, and higher complication rates. Inappropriate antibiotic prescribing continues to accelerate antimicrobial resistance, while the COVID-19 pandemic profoundly altered the epidemiology of respiratory infections and demonstrated the effectiveness of non-pharmaceutical interventions. Advances in vaccination, antimicrobial stewardship, rapid diagnostics, and novel therapeutic strategies offer promising opportunities to reduce disease burden.<br><br>CONCLUSIONS: Reducing the global burden of UATIs requires integrated public health strategies combining equitable vaccine access, effective antimicrobial stewardship, strengthened healthcare systems, and sustained surveillance. Lessons learned from the COVID-19 pandemic provide a unique opportunity to improve preparedness for future respiratory outbreaks while addressing persistent regional inequalities in prevention and care.},
}
@article {pmid42646577,
year = {2026},
author = {Oiegar, VF and Călărașu, C and Postolache, P and Ghimuș, C and Bălteanu, MA and Pătru, S and Caimac, D and Bumbea, AM and Roșu, SM and Croitoru, IA},
title = {The Impact of Pulmonary Rehabilitation in Patients with Post-COVID-19 Syndrome: A Systematic Review.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
doi = {10.3390/medsci14040443},
pmid = {42646577},
issn = {2076-3271},
mesh = {Humans ; *COVID-19/rehabilitation/physiopathology/complications ; Quality of Life ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Randomized Controlled Trials as Topic ; Muscle Strength ; Exercise Tolerance ; },
abstract = {BACKGROUND: Post-COVID-19 syndrome represents a global health problem, manifesting with persistent multiple organ symptoms, including respiratory ones. This review aimed to evaluate the efficacy of different pulmonary rehabilitation interventions in the management of the disease, including its particularities.<br><br>METHODS: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) statement and prospectively registered in the PROSPERO database (CRD420261292824). PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from January 2021 to January 2026. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Cochrane Risk of Bias 2 (RoB 2) tool. Twenty randomized controlled trials involving 2101 adult patients with post-COVID-19 syndrome met the eligibility criteria and were included in the qualitative synthesis.<br><br>RESULTS: Pulmonary rehabilitation (PR) demonstrated significant improvements in exercise capacity, with notable increases in 6MWT and VO2max. Respiratory and peripheral muscle strength significantly increased. The quality of life, dyspnea and fatigue consistently improved. The results for intrinsic pulmonary function, anxiety, and depression were heterogeneous, suggesting benefits more related to reconditioning.<br><br>CONCLUSIONS: Pulmonary rehabilitation is an essential and efficient component in post-COVID-19 syndrome, improving physical function, respiratory and peripheral muscle strength, the quality of life, fatigue and dyspnea. Telerehabilitation is a viable alternative. Adapting protocols is crucial, recognizing that most benefits derive from physical reconditioning and muscle training, not necessarily from major structural pulmonary changes.},
}
@article {pmid42646667,
year = {2026},
author = {Alkhidir, M and Sridharan, K},
title = {Seroconversion Rates Following COVID-19 Vaccination in People Living with HIV: A Systematic Review and Meta-Analysis.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080648},
pmid = {42646667},
issn = {2076-393X},
abstract = {Background: People living with human immunodeficiency virus (HIV) (PLWH) remain at increased risk of severe COVID-19 outcomes; however, conflicting evidence exists regarding the seroconversion rates of COVID-19 vaccines in this population. Methods: A systematic review and meta-analysis were conducted on studies reporting seroconversion outcomes following COVID-19 vaccination in PLWH. Results: Forty-four studies (5391 PLWH) were included in the meta-analysis. The overall pooled seroconversion proportion was 93.5%. Bootstrap analysis confirmed robustness (92.8%). Subgroup analyses revealed significantly higher seroconversion rates for mRNA vaccines (98.2%) compared to non-mRNA vaccines (80.5%). CD4 count demonstrated a graded association: <200 cells/mm[3] (53.8%), 200-500 cells/mm[3] (86.2%), and >500 cells/mm[3] (93.5%). Prior COVID-19 infection (99.1% vs. 89.5%) and antiretroviral therapy (ART) status (93.5% vs. 49.6%) were significant determinants. Safety data demonstrated a favorable profile, with predominantly mild-to-moderate local (injection-site pain: 23.8%) and systemic (headache: 12.95%, fatigue: 6.4%) adverse events; serious adverse events were rare and no consistent association with HIV disease progression was observed. Conclusions: COVID-19 vaccination induces high seroconversion rates in PLWH, particularly among those receiving mRNA vaccines, with preserved CD4 counts, on ART, or with prior infection.},
}
@article {pmid42646682,
year = {2026},
author = {Khatiwada, M and Chen, YT and Dochez, C and Delputte, P},
title = {Mapping the Global Landscape of Vaccine Acceptance Among the General Population from 2009 to 2024: A Systematic Review Across COVID-19 Pandemic Phases, Vaccine Categories, and Economic Strata.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080663},
pmid = {42646682},
issn = {2076-393X},
abstract = {Background: Vaccine acceptance is a fundamental prerequisite for uptake, which may vary over time in response to contextual and vaccine-specific factors and major global disruption. This systematic review and meta-analysis evaluated global trends and determinants of vaccine acceptance between 2009 and 2024. Methods: A comprehensive literature search was conducted using pre-defined keywords and controlled vocabulary related to vaccination, vaccine acceptance or hesitancy, with a broad search strategy designed to capture global evidence across multiple vaccine categories and geographic settings. Studies restricted to high-risk groups or other specific sub-populations (e.g., healthcare workers) were excluded. Studies reporting vaccine acceptance outcomes were systematically identified and pooled estimates were calculated across vaccine categories, WHO regions, income groups, and pandemic periods. Temporal trends and interaction effects were assessed to evaluate changes in vaccine acceptance among different vaccines and before, during, and after the COVID-19 pandemic. Results: A total of 264 publications, including 650,772 participants from 97 countries, were included. Overall, pooled vaccine acceptance was 70.63% and remained relatively stable throughout the study period. Most studies originated from high-income countries, whereas low-income countries and the African region were underrepresented. Childhood vaccines demonstrated the highest pooled acceptance (80.26%), followed by HPV vaccines (66.48%), while influenza vaccines showed the lowest acceptance (52.00%). Childhood vaccine acceptance increased over time and during the COVID-19 period, whereas significant negative interaction trends were observed for HPV and influenza vaccines. Higher vaccine acceptance was observed in African and South-East Asian regions compared with Western Pacific and European regions. Acceptance also varied across income groups, with greater hesitancy generally observed in higher-income settings. Conclusions: Vaccine acceptance among the general population remained relatively stable globally between 2009 and 2024 but varied substantially by vaccine categories, geographic regions, and economic settings. These findings highlight the context-specific nature of vaccine acceptance and the need for harmonized measurement tools and stronger evidence from underrepresented regions to support equitable immunization strategies.},
}
@article {pmid42646719,
year = {2026},
author = {Park, GS and Park, M and Lee, S and Kim, C and Seo, BJ},
title = {The Vaccine-Field Strain Gap in Bovine Neonatal Diarrhea: Molecular Epidemiology of Rotavirus, Coronavirus, and Enterotoxigenic Escherichia coli and Priorities for Vaccine Updating.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080702},
pmid = {42646719},
issn = {2076-393X},
support = {RS-2025-02310124//Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries/ ; 2024_IK-A_1//Jeonbuk Technopark/ ; },
abstract = {Bovine neonatal diarrhea (BND) is a leading cause of morbidity and mortality in pre-weaned calves. Commercial maternal vaccines targeting bovine rotavirus (BRV), bovine coronavirus (BCoV), and enterotoxigenic Escherichia coli (ETEC) have been available for decades, yet field outbreaks continue in vaccinated herds. This review examined peer-reviewed literature published between January 2019 and March 2026, identified through a structured PubMed search supplemented by reference-list screening. For BRV, a field strain sharing its VP7 genotype with a vaccine component was not neutralized by vaccine-induced antiserum, indicating that genotype concordance does not predict serologic coverage. For BCoV, hemagglutinin-esterase variation and regional lineage divergence indicate surface-protein evolution, although data linking these changes to reduced efficacy are not available. For ETEC, adhesin diversity and antimicrobial resistance affect both vaccination strategy and case management. Maternal vaccination retains biological value, but field performance is constrained by colostral variability, incomplete passive transfer, and product-to-product immunogenic differences. For all three pathogens, antigenic divergence from vaccine strains is located at individual epitopes, receptor-binding domains, or adhesins rather than at the level of whole-pathogen identity. Subunit and multi-epitope antigen designs, for which proof-of-concept constructs have been reported, operate at this level, and their selection requires characterization of candidate antigens for efficacy, diversity, polymorphism, and cross-protective breadth. Such antigen improvements address the pathogen-side gap but not the passive-transfer and mucosal constraints. Functional surveillance to guide antigen updating, field trials that measure passive-transfer efficiency, and adjunctive strategies are identified as priorities for BND control.},
}
@article {pmid42646722,
year = {2026},
author = {Ding, L and Chen, S and Yu, FY and Chan, KH and Fang, Y and Mo, PKH and Wang, Z},
title = {Determinants of the Seasonal Influenza Vaccination Uptake Among People Aged 50 Years or Above During and After the Pandemic: A Systematic Review.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080705},
pmid = {42646722},
issn = {2076-393X},
support = {14611325//General Research Fund/ ; },
abstract = {Background/Objectives: Seasonal influenza vaccination (SIV) coverage remains suboptimal among adults aged ≥50 years, and the COVID-19 pandemic might influence the determinants of SIV uptake. This systematic review aimed to identify determinants of SIV uptake among adults aged ≥50 years during and after the COVID-19 pandemic. Methods: We searched PubMed, MEDLINE, Embase, Web of Science, Global Health, CINAHL, Cochrane Library, APA PsycINFO, and APA PsycArticles for studies published between 1 December 2019 and 1 January 2026. The pooled prevalence of SIV uptake was synthesized using random-effects models in meta-analysis. Results: A total of 50 studies were included in the systematic review. COVID-19-related factors, such as perceived risk of co-infection with SARS-CoV-2 and seasonal influenza and concerns about potential interactions between COVID-19 vaccines and SIV, were determinants of SIV uptake. Other modifiable determinants included those that existed before the pandemic (e.g., knowledge and perceptions of seasonal influenza and SIV). Subgroup analysis showed that cost and inaccessibility were barriers to receiving SIV in places without a fully subsidized SIV, and perceived susceptibility and vaccine safety concerns were commonly identified as facilitators and barriers in studies with data collected after the pandemic. The pooled prevalence of SIV uptake among adults aged 50 years or above was 53% (95% confidence interval: 44-62%). Such uptake appeared lower among adults aged 50-64 years, in regions without a fully subsidized SIV, and after the COVID-19 pandemic. Conclusions: These findings could inform service planning and interventions promoting SIV uptake among adults aged ≥50 years in the post-pandemic era. More studies are needed to explore determinants specific to people aged 50-64 years to inform health promotion tailored to their needs.},
}
@article {pmid42646723,
year = {2026},
author = {Pinte, L and Balanescu, P and Dima, A and Mandescu, AM and Simion-Stanciu, ME and Dumitru, AC and Baicus, C},
title = {Comparator-Dependent Safety Signals for Incident Systemic Autoimmune Rheumatic Diseases After mRNA COVID-19 Vaccination: A Systematic Review.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080706},
pmid = {42646723},
issn = {2076-393X},
abstract = {BACKGROUND: Pharmacovigilance systems have flagged possible associations between mRNA COVID-19 vaccination and systemic autoimmune inflammatory rheumatic diseases (AIRDs), generating uncertainty for rheumatologists counselling patients. As the first population-scale deployment of an mRNA vaccine platform, COVID-19 vaccination provides a unique setting to examine whether autoimmune safety signals detected in spontaneous reporting systems correspond to measurable disease risk. We synthesised pharmacovigilance and population-based evidence on incident EULAR-defined systemic AIRDs after mRNA COVID-19 vaccination and assessed whether disproportionality signals were corroborated by analytical studies.<br><br>METHODS: We conducted a PRISMA 2020-compliant systematic review searching MEDLINE, Web of Science, Scopus, Embase, and the Cochrane Library from 2019 to April 2026, supplemented by medRxiv and trial registries. Eligible studies included pharmacovigilance disproportionality analyses and analytical studies, including cohorts and randomised controlled trials, evaluating BNT162b2 or mRNA-1273 in adults without known pre-existing autoimmune disease. Risk of bias was assessed using READUS-PV, ROBINS-I, and RoB 2. Meta-analysis was not performed because of substantial heterogeneity.<br><br>RESULTS: Fourteen studies were included: seven pharmacovigilance studies and seven analytical studies. Disproportionality analyses suggested increased reporting of selected AIRDs, most consistently polymyalgia rheumatica and giant cell arteritis, mainly when all other adverse-event reports served as comparators. These signals were largely neutral when influenza vaccines were the reference. Across analytical studies, associations were inconsistent; modest increases in systemic lupus erythematosus appeared only in selected analyses. Long-term evidence was scarce: only four studies, from three countries (South Korea, Israel, and Norway), followed participants for up to approximately one year, and three of these reported at least one positive association-systemic lupus erythematosus, post-booster rheumatoid arthritis, and polymyalgia rheumatica in older adults-whereas studies restricted to risk windows of three months or less reported no increase.<br><br>CONCLUSIONS: The available evidence does not indicate a consistent increase in incident systemic AIRDs after mRNA COVID-19 vaccination. Although pharmacovigilance studies identified comparator-dependent signals for selected diseases, particularly polymyalgia rheumatica and giant cell arteritis, these findings were generally not confirmed in comparative population-based studies and should be considered hypothesis-generating. Delayed-onset disease remains poorly characterised, and studies with at least one year of follow-up are needed.},
}
@article {pmid42646738,
year = {2026},
author = {Egelkrout, E},
title = {Plant-Produced Vaccines for Protection from Human and Veterinary Coronaviruses.},
journal = {Vaccines},
volume = {14},
number = {8},
pages = {},
doi = {10.3390/vaccines14080721},
pmid = {42646738},
issn = {2076-393X},
abstract = {Coronaviruses are responsible for numerous diseases causing substantial morbidity and mortality to both humans and animals. In particular, they have caused three significant outbreaks in humans including severe acute respiratory syndrome 1 (SARS-CoV-1), Middle East respiratory syndrome (MERS-CoV), and, most recently, the severe acute respiratory syndrome 2 (SARS-CoV-2) pandemic. Two relevant veterinary diseases are porcine transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV), which cause severe losses in the pork industry. While efficacious vaccines were developed in an unprecedented timeframe for COVID-19, vaccines have not been commercialized for other human coronaviruses and vaccines against animal coronaviruses have limited efficacy and logistical challenges in administration. There is a clear need for more efficacious vaccines with simpler methods of delivery and administration for both human and veterinary use. The production of subunit vaccines in plant systems holds great promise in addressing the current challenges and facilitate the preparation for future potential outbreaks and new viruses. This review will summarize the state of development of vaccines in plant systems including tobacco, rice, maize, and others.},
}
@article {pmid42632492,
year = {2026},
author = {Gentile, G and Agostinetto, E and Arecco, L and Gerosa, R and Buonaiuto, R and Lobo-Martins, S and Lambertini, M and Botticelli, A and Piccart-Gebhart, M and de Azambuja, E},
title = {From Site-Centered to Patient-Centered: Promises and Challenges of Decentralized Clinical Trials in Oncology.},
journal = {Critical reviews in oncology/hematology},
volume = {},
number = {},
pages = {105545},
doi = {10.1016/j.critrevonc.2026.105545},
pmid = {42632492},
issn = {1879-0461},
abstract = {Decentralized clinical trials (DCTs) are an innovative model of clinical trials in which some or all activities take place at, or near, participants' homes rather than at traditional clinical sites. DCTs represent a shift from a traditional site-centered approach to a more patient-centered one, leveraging digital tools, home-based services, and local healthcare networks. While DCTs can broaden participation and improve equity, they remain underutilized worldwide. The COVID-19 pandemic demonstrated their practicality, but also highlighted challenges such as uneven regulations, logistical complexity, digital literacy gaps, and data-privacy concerns. The objective of this narrative review is to critically evaluate the implementation of DCTs in oncology, examining their potential benefits and limitations and how decentralization may reshape key trial activities, including recruitment, informed consent, investigational drug delivery, monitoring, and data collection. We further assess the organizational, regulatory, technological, and equity-related conditions required for sustainable implementation and discuss the role of hybrid models. Rather than representing a universal alternative to conventional trials, DCTs should be viewed as a flexible model whose value depends on the clinical context, trial design, patient population, and healthcare infrastructure.},
}
@article {pmid42633715,
year = {2026},
author = {Kordyukova, LV and Serebryakova, MV and Panina, IS and Veit, M},
title = {Differential S-Acylation of Viral and Cellular Proteins: Structural Determinants, Enzymes, and Putative Functional Implications.},
journal = {Biochemistry. Biokhimiia},
volume = {91},
number = {7},
pages = {1157-1173},
doi = {10.1134/S0006297926601905},
pmid = {42633715},
issn = {1608-3040},
mesh = {Acylation ; Humans ; Animals ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; *Viral Proteins/metabolism/chemistry ; Protein Processing, Post-Translational ; Acyltransferases/metabolism/chemistry ; },
abstract = {S-acylation is post-translational attachment of fatty acid residues, mostly palmitoyl-groups to cysteines. This lipid modification could influence protein oligomerization, localization, and topology within the membrane, and could play a regulatory role in cellular signaling. Improvements in the experimental techniques, specifically, MALDI-TOF MS, have elevated the study of S-acylation to a level of refined detail. It was possible to conclusively show that, beyond palmitate, other types of fatty acids, such as stearate and oleate could be attached to the specific binding sites. For example, fusion proteins of the enveloped viruses have been shown to attach stearates exclusively to the cysteine located at the C-terminal end of the transmembrane domain, while cysteines in the cytoplasmic domain have been modified with palmitates. In addition, emerging evidence suggests that the covalently linked fatty acids in the viral fusion proteins could recruit cholesterol into the viral membrane. We termed this preferential attachment of fatty acid residues of different types to the specific sites, depending on their localization, as "differential" S-acylation. Furthermore, MALDI-TOF MS detected attachment of unsaturated fatty acids (oleates) to the GNAI protein in response to stearate supplementation, shifting this regulatory protein out of the detergent-resistant membranes (lipid rafts) and, consequently, exerting antitumor effect. Solving the first 3D-structures of DHHC acyltransferases allowed proposing a mechanism of different fatty acids selection. However, it remains unclear whether preference for the acyl chain length is determined by the structure of the enzyme, protein substrate, or by the lipid composition of the membrane. In this review, we summarize the latest advances in the study of protein S-acylation with different types of fatty acids and substantiate significance of this post-translational modification from both fundamental and practical perspectives.},
}
@article {pmid42634361,
year = {2026},
author = {Saghafi, F and Heydari, B and Motevali Haghighi, S and Salehi-Abargouei, A and Hoseini, SM and Akrami, A and Sahebnasagh, A},
title = {Effectiveness of Pentoxifylline in Adult Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.},
journal = {Current medicinal chemistry},
volume = {},
number = {},
pages = {},
doi = {10.2174/0109298673495369260729070918},
pmid = {42634361},
issn = {1875-533X},
abstract = {BACKGROUND: COVID-19 is characterized by immune dysregulation, endothelial dysfunction, and thrombo-inflammation. Pentoxifylline (PTX) has been proposed as an adjunctive modality for COVID-19. Regarding the inconsistent results of earlier trials, this systematic review was conducted to evaluate the efficacy of PTX in COVID-19 patients.<br><br>METHODS: For the study literature up to 16 September 2025 was systematically searched for randomized controlled trials evaluating pentoxifylline in COVID-19. Continuous outcomes were expressed as Mean Differences (MDs) or Standardized Mean Differences (SMDs), whereas dichotomous outcomes were expressed as Odds Ratios (ORs) with 95% confidence intervals. Risk of bias was assessed using the Cochrane RoB 2.0 tool.<br><br>RESULTS: Seven randomized trials (551 participants) were included. Pentoxifylline significantly improved oxygen saturation (SMD = 0.215; 95% CI: 0.016 to 0.415; P = 0.034) and was associated with reduced ICU admission (OR = 0.454; 95% CI: 0.224 to 0.917; P = 0.028). It also significantly reduced inflammatory markers, including CRP and ESR. Effects on mortality, mechanical ventilation requirement, and hospital length of stay were not statistically significant. Risk-of-bias assessments indicated generally low methodological concerns, with minor issues related to blinding. Publication bias could not be reliably assessed for several outcomes because of the small number of included studies.<br><br>CONCLUSION: The results of the present study suggest that pentoxifylline may reduce systemic inflammation and improve oxygenation in hospitalized adults with COVID-19. It may also be associated with reduced ICU admission; however, its effects on mortality, mechanical ventilation requirement, and hospital length of stay remain uncertain. Larger, rigorously designed randomized trials are needed to confirm these findings.},
}
@article {pmid42635737,
year = {2026},
author = {Mól, N and Kwinta, P},
title = {Cardiovascular Sequelae After SARS-CoV-2 in Children: From Myocardial Injury to Dysautonomia and Implications for Phenotype-Guided Follow-Up.},
journal = {Pediatric cardiology},
volume = {},
number = {},
pages = {},
pmid = {42635737},
issn = {1432-1971},
abstract = {To summarise current paediatric evidence on long-term cardiovascular sequelae after SARS-CoV-2 infection, with particular emphasis on the place of multisystem inflammatory syndrome in children (MIS-C), persistent subclinical myocardial abnormalities and autonomic dysfunction. A comprehensive literature search of PubMed and Scopus was conducted for studies published online or in print between January 2020 and 30 May 2026. Eligible studies included original research reporting cardiovascular, autonomic, or exercise-related outcomes in children after SARS-CoV-2 infection or MIS-C, with a minimum follow-up of four weeks. Studies across the full spectrum of acute disease severity were considered. Owing to substantial heterogeneity in study design, patient populations, and outcome definitions, a narrative rather than systematic review approach was adopted. Across paediatric cohorts, overt cardiac dysfunction after MIS-C usually resolves and conventional medium-term outcomes are generally reassuring. However, a subset of children show persistent abnormalities on strain imaging or cardiac magnetic resonance despite normalisation of standard echocardiographic findings, and the clinical significance of these abnormalities remains uncertain. In parallel, growing evidence indicates that autonomic dysfunction contributes to persistent symptoms such as palpitations, orthostatic complaints, fatigue, and exercise intolerance, particularly when structural cardiac evaluation is unremarkable. Current studies are limited by heterogeneity in phenotype, timing of follow-up and diagnostic protocols. Across paediatric cohorts spanning mild acute SARS-CoV-2 infection to severe MIS-C, overt cardiac dysfunction generally resolved and conventional medium-term outcomes were reassuring. However, selected cohorts reported persistent abnormalities on strain imaging or CMR, while their prognostic significance remained uncertain.},
}
@article {pmid42635834,
year = {2026},
author = {Gul, A and Sahoo, OS and Kashyap, N and Singh, S and Rana, A and Gupta, L and Ajmeriya, S and Mukherjee, I and Dhar, R and Nayak, NR and Karmakar, S},
title = {Evolutionary co-option of endogenous retroviruses: syncytins as regulators of placental development and disease.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {42635834},
issn = {1573-4978},
mesh = {Humans ; Female ; *Pregnancy Proteins/genetics/metabolism/physiology ; *Endogenous Retroviruses/genetics/metabolism ; *Gene Products, env/genetics/metabolism ; Pregnancy ; *Placentation/genetics ; Placenta/metabolism ; Trophoblasts/metabolism ; Animals ; Evolution, Molecular ; },
abstract = {Syncytins are envelope proteins of retroviral origin that have been evolutionarily co-opted to play essential roles in placental biology. Primarily recognized for mediating the fusion of cytotrophoblasts into the syncytiotrophoblast, a multinucleated epithelium, critical for nutrient transport and maternal-fetal immune tolerance. Syncytins also contribute to broader aspects of placental development through diverse mechanistic pathways. This review focuses on the evolutionary origins and functional mechanisms of Syncytin-1 (encoded by HERV-W) and Syncytin-2 (encoded by HERV-FRD) in orchestrating placental morphogenesis and homeostasis. We further discuss the clinical significance of aberrant syncytin expression, which is associated with adverse pregnancy outcomes including preeclampsia, intrauterine growth restriction, gestational diabetes mellitus, and trophoblastic disease. Additionally, we examine how exogenous viral infections, such as cytomegalovirus and SARS-CoV-2, may disrupt syncytin transcriptional regulation and compromise placental integrity. Collectively, syncytins represent a paradigm of evolutionary viral domestication, wherein pathogenic genetic elements have been repurposed into indispensable mediators of human reproduction. Their precise spatiotemporal regulation is paramount for optimal placental function and maternal-fetal health. Future research leveraging advanced omics technologies and placental organoid systems will be instrumental in elucidating underlying molecular mechanisms and developing targeted therapeutic interventions for pregnancy-related disorders.},
}
@article {pmid42636028,
year = {2026},
author = {Gaevert, JA and van de Sandt, CE},
title = {The ageing immune system and its battle with viruses.},
journal = {The Journal of general virology},
volume = {107},
number = {8},
pages = {},
doi = {10.1099/jgv.0.002320},
pmid = {42636028},
issn = {1465-2099},
mesh = {Humans ; CD8-Positive T-Lymphocytes/immunology ; *Virus Diseases/immunology/virology ; *Aging/immunology ; Animals ; Immunosenescence ; *Viruses/immunology ; Immunologic Memory ; *Immune System/immunology ; Receptors, Antigen, T-Cell/immunology ; },
abstract = {The global increase in life expectancy has resulted in a growing proportion of older individuals at increased risk of severe disease outcomes following viral infections. CD8[+] T cells play a vital role in controlling viral infections and provide protection against severe disease by eliminating virus-infected cells. Furthermore, CD8[+] T cells recognize conserved internal viral proteins, enabling cross-reactivity and the formation of long-term immunological memory. However, a lifetime of exposures to acute and persistent latent viruses, vaccinations and the age-associated decline in immune functions (immunosenescence and inflammaging) have a profound impact on virus-specific CD8[+] T cell populations. The age-associated progressive decline of naïve CD8[+] T cells, reduced T cell receptor (TCR) diversity, the accumulation of highly differentiated memory and/or exhausted CD8[+] T cells and low-level chronic inflammation directly affect virus-specific immunity. These age-associated changes impair both primary and recall CD8[+] T cell responses to infections and vaccinations in older individuals. Both ageing and exposure history impact the CD8[+] T cell correlates of protection, including frequency, phenotype, TCR diversity, polyfunctionality, cytotoxic potential and proliferation capacity. The implications of these changes are discussed in the context of acute (influenza and respiratory syncytial virus), persistent latent (cytomegalovirus, Epstein-Barr virus and varicella-zoster virus) and novel (severe acute respiratory syndrome coronavirus 2) viruses. An in-depth understanding of how lifelong viral exposures intersect with immunosenescence will elucidate how virus-specific CD8[+] T cells change with age. These insights will aid vaccine strategies to effectively harness CD8[+] T cells and induce long-lasting, broadly reactive virus-specific immunity.},
}
@article {pmid42638128,
year = {2026},
author = {Khoshnam Rad, N and Lakzaei, T and Nakhostin, M and Soltanmohammadi, S},
title = {A clinician's guide to corticosteroid therapy in pneumonia and critical illness: agent selection, dosing, monitoring, and interactions.},
journal = {Pneumonia (Nathan Qld.)},
volume = {18},
number = {1},
pages = {},
pmid = {42638128},
issn = {2200-6133},
abstract = {Corticosteroids are cornerstone therapies in critically ill patients with severe pneumonia, acute respiratory distress syndrome (ARDS), and septic shock. However, their optimal application requires nuanced, syndrome-specific decision-making rather than a "one-size-fits-all" approach. This review provides a practical, evidence-based framework tailored specifically for adult patients in the ICU, defining a clear target audience of intensivists, pulmonologists, infectious disease specialists, and critical care pharmacists. We focus on six pillars: (1) the pathophysiology of critical illness-related corticosteroid insufficiency (CIRCI); (2) syndrome-specific agent selection supported by landmark trials; (3) precise dosing, administration, and tapering strategies; (4) structured safety monitoring; (5) management of high-risk drug-drug interactions; and (6) a comparative analysis of efficacy across agents. By synthesizing data from the CAPE COD, RECOVERY, DEXA-ARDS, APROCCHSS, and ADRENAL trials alongside the 2024 SCCM/ESICM focused guidelines, this guide offers a bedside roadmap for optimizing corticosteroid therapy in the ICU. Important distinctions are made between viral etiologies (benefit in COVID-19, systematic harm in influenza), and clinical exceptions are clearly defined. A dedicated section addresses the unique challenges of corticosteroid use in immunocompromised hosts, a population systematically excluded from landmark trials but increasingly encountered in ICU practice. Practical algorithms, monitoring tables, and drug interaction checklists are provided to support real-time clinical decision-making.},
}
@article {pmid42638446,
year = {2026},
author = {Choi, I and Zander, A and Chan, B and Syedmoradi, L and Trivedi, D and Kaczor-Urbanowicz, KE and Wei, F and Swarup, N and Chan, T and Romandini, M and Wong, DTW},
title = {Saliva Liquid Biopsy for Detection of Oral and Systemic Diseases.},
journal = {Journal of periodontal research},
volume = {},
number = {},
pages = {},
doi = {10.1111/jre.70152},
pmid = {42638446},
issn = {1600-0765},
support = {U01 CA233370/NH/NIH HHS/United States ; PASD-RSG-23-1142089-01-PASD//American Cancer Society/ ; },
abstract = {Saliva has emerged as a compelling liquid biopsy for the non-invasive diagnosis and monitoring of both oral and systemic diseases. Secreted by major and minor salivary glands and enriched by gingival crevicular fluid, epithelial turnover, immune mediators, microbial products, and plasma-derived constituents, saliva reflects a biologically integrated interface between local oral environments and systemic physiology. This dual origin enables detection of disease-associated signals across multiple molecular layers, including extracellular RNA, cell-free DNA, genomic and epigenetic material, proteins, metabolites, microbial signatures, and hormones. Advances in high-throughput sequencing, mass spectrometry, and ultrasensitive immunoassays have revealed that salivary analytes can capture dynamic pathological processes ranging from periodontal inflammation and dental caries to oral and head and neck cancers, as well as systemic conditions such as non-oral cancers and autoimmune, cardiometabolic, infectious, endocrine, and neurodegenerative diseases. In particular, extracellular vesicle-encapsulated RNA, cfDNA fragmentomics, and methylation patterns have expanded the diagnostic reach of saliva beyond conventional protein-based biomarkers, while integrated multi-omics approaches increasingly improve diagnostic performance. Despite this progress, clinical translation remains constrained by biological complexity, including variable glandular contributions, oral microbiome interactions, and pre-analytical variability in collection and processing. Emerging point-of-care technologies, microfluidic platforms, and artificial intelligence-driven multi-omic integration are beginning to address these limitations, enabling higher analytical sensitivity and improved disease stratification. Regulatory pathways, including in vitro diagnostic frameworks and laboratory-developed test structures, are progressively accommodating salivary assays, as demonstrated during the COVID-19 pandemic. However, widespread clinical adoption will require rigorous standardization, large-scale validation, and demonstration of clinical utility. Together, saliva-based liquid biopsy represents a rapidly evolving diagnostic paradigm with the potential to shift disease detection towards earlier, minimally invasive, and data-rich precision medicine approaches across dentistry and systemic healthcare.},
}
@article {pmid42638715,
year = {2026},
author = {Wu, F and He, Q and Zhang, F and Zhang, X and Zhang, W},
title = {MicroRNA regulation in pulmonary fibrosis: a bibliometric analysis of global research trends, collaborative networks, and emerging frontiers.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1914903},
pmid = {42638715},
issn = {2296-858X},
abstract = {BACKGROUND: Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a progressive and fatal interstitial lung disease with limited treatment options. MicroRNAs (miRNAs) have emerged as critical regulators of fibrotic processes, yet a systematic overview of the research landscape in this rapidly growing field is lacking.<br><br>METHODS: We performed a comprehensive bibliometric analysis of publications on miRNA regulation in pulmonary fibrosis from January 1, 2000, to December 31, 2025, using the Web of Science Core Collection and Scopus databases. After deduplication, a total of 2,093 valid documents (articles and reviews) were analyzed. Multiple analytical tools-VOSviewer (v1.6.20), CiteSpace (v6.4R1), and the bibliometrix R package (v3.2.1)-were employed to examine annual publication trends, collaborative networks (countries, institutions, authors), co-citation clusters, citation bursts, journal dual-map overlays, and keyword evolution.<br><br>RESULTS: The annual publication output increased steadily from 2007 to 2021, peaking at 229 papers, then stabilized at 150-193 papers per year (2022-2025). China (889 papers, 38.4%) and the United States (477 papers, 20.6%) were the most productive countries, although United States and European papers exhibited higher average citation impact (United States: 74.79; Germany: 86.49) compared to China (29.28). Nanjing Medical University (43 papers) and the University of Pittsburgh (28 papers) were leading institutions. Author productivity followed Lotka's Law, with 89.6% of authors publishing only one paper. Co-citation network analysis (1,108 nodes, Q&#x202f;=&#x202f;0.8242, S&#x202f;=&#x202f;0.9284) revealed well-defined clusters centered on non-coding RNAs, extracellular vesicles, and cellular senescence. Citation burst detection identified 25 key references, with the Raghu G (2022) clinical guideline showing the most sustained influence. Keyword co-occurrence analysis generated six clusters, with the newest frontier (exosomes, extracellular vesicles, mesenchymal stem cells, COVID-19) having average publication years of 2022-2023. Recent keyword bursts included "systematic review" (2021-2023), "immunofluorescence" (2022-2025), and "circular ribonucleic acid" (2023-2025).<br><br>CONCLUSION: This bibliometric analysis provides a systematic mapping of the global research landscape on miRNA regulation in pulmonary fibrosis over the past 26&#x202f;years. The field has evolved from basic molecular mechanisms toward emerging frontiers including extracellular vesicle-based communication, circular RNAs, and cellular senescence. These findings serve as a valuable resource for researchers seeking to understand current trends, collaborative networks, and future directions in miRNA-targeted pulmonary fibrosis research.},
}
@article {pmid39400062,
year = {2026},
author = {Keřková, B and Kolenič, M and Knížková, K and Hrubý, A and Večeřová, M and Šustová, P and Španiel, F and Rodriguez, M},
title = {Exploring the effects of COVID-19 on verbal memory function in schizophrenia: Multiple case study and brief literature review.},
journal = {Applied neuropsychology. Adult},
volume = {33},
number = {3},
pages = {867-878},
doi = {10.1080/23279095.2024.2416061},
pmid = {39400062},
issn = {2327-9109},
mesh = {Humans ; *Schizophrenia/complications/pathology/diagnostic imaging/physiopathology ; Male ; *Hippocampus/pathology/diagnostic imaging ; *COVID-19/complications/diagnostic imaging ; Adult ; *Memory Disorders/etiology/diagnostic imaging/physiopathology/pathology ; *Verbal Learning/physiology ; Female ; Magnetic Resonance Imaging ; Middle Aged ; Neuropsychological Tests ; *Schizophrenic Psychology ; },
abstract = {Individuals recovering from COVID-19 may experience persistent impairment in verbal memory performance, potentially due to illness-related hippocampal injury. Although verbal memory dysfunction is central to schizophrenia, the interactions between this vulnerability and COVID-19 remain unclear, with no imaging studies addressing the issue to-date. To explore this gap and generate hypotheses for future research, we adopted a multiple case study approach. Two pairs of individuals with an ICD-10 diagnosis of schizophrenia were selected, each consisting of one case with a positive COVID-19 anamnesis and one without. We calculated the Reliable Change Index to estimate the clinical significance of verbal memory performance changes, with annualized change rates in hippocampal volumes assessed against normative data. Compared to their matches, COVID-19 positive cases did not show mutually consistent changes in verbal memory performance: one case experienced a significant decline in verbal memory and learning, while the other showed a general normalization of test scores. Left hippocampal volumes showed a comparatively slowed increase, while the right hippocampi decreased in volume, although these atrophy rates did not exceed those expected in general population samples. Based on these findings, we hypothesize that COVID-19 alone does not lead to verbal memory decline in schizophrenia. Instead, the relationship between the diseases may depend on additional factors. Our case pairs differed in body mass index, systolic blood pressure, sex, phase of illness, and whole grey matter volume trajectories, leading us to hypothesize that these variables represent additional predictors or moderators of this relationship.},
}
@article {pmid41414903,
year = {2026},
author = {Trautner, BW and Cortés-Penfield, NW and Gupta, K and Hirsch, EB and Horstman, M and Moran, GJ and Colgan, R and O'Horo, JC and Ashraf, MS and Connolly, S and Drekonja, D and Grigoryan, L and Huttner, A and Lazenby, GB and Nicolle, L and Schaeffer, A and Yawetz, S and Lavergne, V},
title = {Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections - Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i68-i78},
doi = {10.1093/cid/ciaf461},
pmid = {41414903},
issn = {1537-6591},
mesh = {Humans ; *Anti-Bacterial Agents/administration &amp; dosage/therapeutic use ; *Urinary Tract Infections/drug therapy/microbiology/complications ; Administration, Oral ; Administration, Intravenous ; Bacteremia/drug therapy ; Gram-Negative Bacterial Infections/drug therapy ; },
abstract = {BACKGROUND: These recommendations provide guidance on the optimal timing for transitioning from intravenous to oral antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia.<br><br>METHODS: The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of transitioning to oral therapy versus continuing parenteral therapy of the total duration of treatment, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.<br><br>RESULTS: The guidelines panel suggests transitioning to oral antibiotics in patients with cUTI who are clinically improving, able to take medication, and for whom an effective oral option is available, rather than continuing parenteral therapy for the remaining treatment duration, regardless of the presence of associated Gram-negative bacteremia. An effective oral option needs to be active against the causative pathogen and achieve therapeutic levels in the urine and relevant tissue.<br><br>CONCLUSIONS: Parenteral and oral antibiotics used to complete treatment courses for cUTI provide similar efficacy and adverse events, especially in the context of shorter duration of therapy. This recommendation places a high value on reducing avoidable intravenous catheter-related adverse events, costs, and resources, as well as taking into account practical aspects of antibiotic administration.},
}
@article {pmid41419213,
year = {2026},
author = {Trautner, BW and Cortés-Penfield, NW and Gupta, K and Hirsch, EB and Horstman, M and Moran, GJ and Colgan, R and O'Horo, JC and Ashraf, MS and Connolly, S and Drekonja, D and Grigoryan, L and Huttner, A and Lazenby, GB and Nicolle, L and Schaeffer, A and Yawetz, S and Lavergne, V},
title = {Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i36-i67},
doi = {10.1093/cid/ciaf460},
pmid = {41419213},
issn = {1537-6591},
mesh = {Humans ; *Urinary Tract Infections/drug therapy/microbiology/complications ; *Anti-Bacterial Agents/therapeutic use ; Antimicrobial Stewardship ; Drug Resistance, Bacterial ; },
abstract = {BACKGROUND: These recommendations address the empiric choice of antibiotics in suspected complicated urinary tract infection (cUTI). Issues to balance include the need for appropriate initial empiric antimicrobial therapy, the patient's severity of illness, and antimicrobial stewardship concerns.<br><br>METHODS: The panel's recommendations are based upon evidence derived from systematic literature reviews that focused on comparative benefits and harms of classes of antibiotics approved for cUTI, starting with publications from 2008 onwards, and our review of predictors of resistance in uropathogens included references identified since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.<br><br>RESULTS: The guidelines panel suggests initially selecting among preferred empiric antibiotic choices rather than alternative options, stratified for the patient's severity of illness and antimicrobial stewardship considerations. When choosing among these antibiotics for a specific patient, the guideline panel suggests a 4-step process to account for changing resistance patterns and individualized patient needs. The steps are: (1) assess the severity of illness (for initial prioritization of antibiotics), (2) consider patient-specific risk factors for resistant uropathogens (for optimization of coverage), (3) evaluate other patient-specific considerations (to reduce the risk of adverse events), and (4) for patients with sepsis, consult a relevant local antibiogram if available (to further improve the likelihood of giving appropriate empiric therapy). Lastly, the guideline panel suggests selecting definitive effective therapy with a targeted spectrum based on the result of the urine culture.<br><br>CONCLUSIONS: Many of the classes of antibiotics approved to treat cUTI demonstrate similar efficacy as other classes of antibiotics in randomized controlled trials. Bacterial resistance prevalence is always changing, and new antibiotics will be developed. In this context, the guidelines panel provides recommendations for choosing empiric antibiotic therapy for cUTI that will help clinicians decide among available antibiotic options at the point of care.},
}
@article {pmid41739597,
year = {2026},
author = {Nellore, A and Bajema, K and Belden, K and Blumberg, D and York, E and Falck-Ytter, Y and Baden, L},
title = {IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i111-i116},
doi = {10.1093/cid/ciag115},
pmid = {41739597},
issn = {1537-6591},
support = {//Infectious Diseases Society of America/ ; },
mesh = {Humans ; *Immunocompromised Host ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/administration &amp; dosage/immunology ; Vaccine Efficacy ; Seasons ; SARS-CoV-2/immunology ; Vaccination ; Child ; Adult ; },
abstract = {Immunocompromised individuals face elevated risks of severe COVID-19, yet vaccination guidance for these populations continues to evolve. To support evidence-based decision-making for the 2025-2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary panel to develop rapid guidelines on the use of US-licensed COVID-19 vaccines in adults and children with hematologic malignancies, primary immunodeficiency, autoimmune disease on immunosuppressive therapy, HIV with severe immunosuppression, solid organ transplantation, hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell therapy (CAR-T), or solid tumor chemotherapy. A systematic evidence review of studies published from June 2024 to July 2025 identified comparative data on vaccine effectiveness and safety. Using the GRADE framework, the panel evaluated 7 observational effectiveness studies and 4 safety-focused studies. Across studies, COVID-19 vaccination was associated with reduced hospitalization (33%-56% effectiveness), critical illness, mortality, and COVID-19-related outpatient or emergency care visits. Serious adverse events were rare, and available evidence did not show consistent increases in exacerbations of underlying immunocompromising conditions. Most studies had short follow-up durations, likely reflecting higher-end estimates of vaccine effectiveness. Given moderate certainty of benefit and low certainty of harm, the panel strongly recommends the 2025-2026 COVID-19 vaccine for all immunocompromised individuals aged ≥6 months, with timing tailored to immunosuppressive therapy, clinical stability, and community transmission levels. Adjunct strategies-including vaccination of household contacts and early antiviral access-remain essential. Research priorities include defining immunologic correlates of protection, evaluating durability, optimizing vaccine timing, and improving real-world effectiveness and safety data.},
}
@article {pmid41766454,
year = {2026},
author = {Nellore, A and Goepfert, P and Tan, CS and Bajema, K and Belden, K and Blumberg, D and Katz, MJ and Kaul, D and Sharma, T and Anjan, S and Ariza-Heredia, EJ and Magana, F and Minniear, T and Loveless, J and Kaur, D and York, E and Falck-Ytter, Y and Baden, L},
title = {IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i105-i110},
doi = {10.1093/cid/ciag114},
pmid = {41766454},
issn = {1537-6591},
support = {//Infectious Diseases Society of America/ ; },
mesh = {Humans ; *Immunocompromised Host ; *Influenza, Human/prevention &amp; control ; *Respiratory Syncytial Virus Infections/prevention &amp; control ; *Influenza Vaccines/administration &amp; dosage/immunology ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/administration &amp; dosage ; Child ; Adult ; Vaccination ; SARS-CoV-2/immunology ; },
abstract = {Respiratory viruses-including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19), respiratory syncytial virus (RSV), and influenza-pose significant risks to immunocompromised patients, who experience attenuated vaccine responses and higher morbidity. To address evolving vaccine recommendations for the 2025-2026 season, the Infectious Diseases Society of America (IDSA), in collaboration with the Vaccine Integrity Project (VIP) and partner organizations, developed rapid guidelines for US-licensed vaccines targeting these viruses. The guideline applies to adults and children with compromised immunity due to hematologic malignancy, solid organ or hematopoietic cell transplantation, autoimmune disease on immunosuppressants, human immunodeficienty virus with severe immunosuppression, and similar conditions. Strong recommendations, supported by moderate certainty evidence, endorse timely administration of age-appropriate COVID-19, RSV, and influenza vaccines, with guidance on optimal timing relative to immunosuppressive therapy and transplantation. Coadministration of these vaccines is considered appropriate. Research gaps remain in immunogenicity, durability, and clinical effectiveness, particularly for patients receiving B-cell-depleting therapies or early post-transplant. Priority areas include defining correlates of protection, optimizing vaccine schedules, evaluating high-dose or adjuvanted formulations, and improving real-world effectiveness and safety data. Equity and access strategies are essential to ensure uptake among vulnerable populations. These guidelines aim to support evidence-based decision-making and highlight the need for harmonized, multi-virus research to inform tailored vaccination strategies for immunocompromised individuals.},
}
@article {pmid41766598,
year = {2026},
author = {Tan, CS and Anjan, S and Ariza-Heredia, EJ and Magana, F and Minniear, TD and Kaur, D and Falck-Ytter, Y and Baden, L},
title = {IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i123-i128},
doi = {10.1093/cid/ciag117},
pmid = {41766598},
issn = {1537-6591},
support = {//Infectious Diseases Society of America/ ; },
mesh = {Humans ; *Immunocompromised Host ; *Respiratory Syncytial Virus Infections/prevention &amp; control ; *Respiratory Syncytial Virus Vaccines/administration &amp; dosage/adverse effects/immunology ; Vaccination ; Child ; Adult ; Seasons ; Respiratory Syncytial Virus, Human/immunology ; },
abstract = {Immunocompromised individuals experience disproportionately severe outcomes from respiratory syncytial virus (RSV) infection, yet direct evidence to guide vaccination in this population remains limited. To support clinical and shared decision-making for the 2025-2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary expert panel to develop rapid, evidence-based recommendations on RSV vaccination among immunocompromised adults and children. The panel conducted a systematic review of comparative effectiveness and harms data published between August 2024 and July 2025, supplemented by additional evidence from the Vaccine Integrity Project. Certainty of evidence and recommendation strength were assessed using the GRADE approach. Two test-negative case-control studies in immunocompromised adults showed vaccination reduced RSV-associated hospitalization by 70% (95% CI: 66%-73%). Indirect evidence from older-adult populations demonstrated 81% effectiveness (95% CI: 52%-92%) against critical illness. Across three randomized trials, serious adverse events were comparable between vaccinated and unvaccinated groups. Guillain-Barré syndrome was rare, with an estimated 11 excess cases per million doses. Given substantial reduction in severe disease and low likelihood of serious harm, the panel issued a strong recommendation for age-appropriate RSV vaccination in adults and adolescents with compromised immunity. For immunocompromised patients <18 years, shared decision-making is advised. Timing should be individualized by subgroups, considering treatment cycles, transplant status, and B-cell-depleting therapies. Household members should remain up to date when eligible, and coadministration with influenza and coronavirus disease 2019 vaccines is acceptable. Research priorities include correlates of protection, durability of immunity, subgroup safety, and the role of booster doses.},
}
@article {pmid41920901,
year = {2026},
author = {Nadig, N and Bhimraj, A and Cawcutt, K and Chiotos, K and Dzierba, AL and Kim, AY and Martin, GS and Pearson, JC and Shumaker, AH and Baden, LR and Bedimo, R and Cheng, VC and Chew, KW and Daar, ES and Glidden, DV and Hardy, EJ and Johnson, S and MacBrayne, C and Nakamura, MM and Oliveira, CR and Riley, L and Shafer, RW and Shoham, S and Tebas, P and Tien, PC and Willis, Z and Wolf, J and Loveless, J and Falck-Ytter, Y and Morgan, RL and Gandhi, RT},
title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i18-i23},
doi = {10.1093/cid/ciaf681},
pmid = {41920901},
issn = {1537-6591},
support = {//Infectious Diseases Society of America/ ; /CA/NCI NIH HHS/United States ; 75N91019D00024/NH/NIH HHS/United States ; /CA/NCI NIH HHS/United States ; 75N91019D00024/NH/NIH HHS/United States ; },
mesh = {Humans ; *Antibodies, Monoclonal, Humanized/therapeutic use ; *Azetidines/therapeutic use ; *Pyrazoles/therapeutic use ; *Purines/therapeutic use ; *Sulfonamides/therapeutic use ; *COVID-19 Drug Treatment ; SARS-CoV-2 ; COVID-19 ; *Antiviral Agents/therapeutic use ; },
abstract = {This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.},
}
@article {pmid41920902,
year = {2026},
author = {Shumaker, AH and Bhimraj, A and Bedimo, R and Cheng, VC and Chew, KW and Daar, ES and Glidden, DV and Shafer, RW and Tien, PC and Baden, LR and Cawcutt, K and Chiotos, K and Dzierba, AL and Hardy, EJ and Johnson, S and Kim, AY and MacBrayne, C and Martin, GS and Nadig, N and Nakamura, MM and Oliveira, CR and Pearson, JC and Riley, L and Shoham, S and Tebas, P and Willis, Z and Wolf, J and Loveless, J and Morgan, RL and Falck-Ytter, Y and Gandhi, RT},
title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.},
journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
volume = {82},
number = {Supplement_3},
pages = {i1-i17},
doi = {10.1093/cid/ciaf680},
pmid = {41920902},
issn = {1537-6591},
support = {//Infectious Diseases Society of America/ ; /CA/NCI NIH HHS/United States ; 75N91019D00024/NH/NIH HHS/United States ; /HH/HHS/United States ; /CA/NCI NIH HHS/United States ; 75N91019D00024/NH/NIH HHS/United States ; /HH/HHS/United States ; },
mesh = {Humans ; *Antiviral Agents/therapeutic use ; *COVID-19 Drug Treatment ; Adenosine Monophosphate/analogs &amp; derivatives/therapeutic use ; Alanine/analogs &amp; derivatives/therapeutic use ; COVID-19 ; SARS-CoV-2 ; Ritonavir/therapeutic use ; Adult ; Proline/analogs &amp; derivatives/therapeutic use ; Hydroxylamines/therapeutic use ; Cytidine/analogs &amp; derivatives ; },
abstract = {This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.},
}
@article {pmid42248467,
year = {2026},
author = {Ci, Q and Bian, Y and Meng, XJ and Zhang, C},
title = {Engineering next-generation nanovaccines for maternal immunization and piglet protection against porcine epidemic diarrhea virus.},
journal = {Journal of controlled release : official journal of the Controlled Release Society},
volume = {396},
number = {},
pages = {115070},
doi = {10.1016/j.jconrel.2026.115070},
pmid = {42248467},
issn = {1873-4995},
mesh = {Animals ; *Porcine epidemic diarrhea virus/immunology ; *Nanovaccines/administration &amp; dosage ; *Coronavirus Infections/prevention &amp; control/veterinary/immunology ; Swine ; *Viral Vaccines/administration &amp; dosage/immunology ; *Swine Diseases/prevention &amp; control/immunology/virology ; Female ; Nanoparticles ; },
abstract = {Porcine epidemic diarrhea virus (PEDV) remains a major threat to the global swine industry, causing severe disease with high morbidity and mortality in neonatal piglets. Current vaccine strategies are challenged by the need for rapid, local protection at the intestinal mucosa in newborn piglets, and emerging PEDV variants can partially evade vaccine immunity. Nanoplatforms can help address these challenges. Across recent PEDV nanovaccine studies, a consistent theme emerges in that vaccine platform architecture and immunization route are not only delivery parameters but also the primary determinants of neutralizing activity, mucosal IgA induction, and lactogenic immunity transfer. Here in this critical review, we synthesize important design perspectives from the PEDV nanoparticle vaccine literature spanning self-assembling protein scaffolds such as ferritin and mi3, bacteriophage and virus-like particles including AP205 and HBcAg, polymeric carriers such as PLGA, chitosan, and alginate-chitosan microcapsules, and inorganic particles including silica and layered double hydroxide. All PEDV vaccine design considerations are organized into three interlocking layers including antigen choice and display, adjuvant-carrier integration, and maternal-mucosal vaccination strategy. Concurrently, mechanistic patterns are observed across models. For instance, multivalent display strengthens protective breadth, and mucoadhesive or M-cell-targeted approaches improve antigen retention and epithelial transport. Practical vaccine design principles are derived throughout this review to support translation of PEDV nanoparticle vaccines into maternal immunization strategies focused on protecting piglets against PEDV variants.},
}
@article {pmid42630301,
year = {2026},
author = {Deverakonda, A and Ricotta, EE and Kubale, JT},
title = {Mapping the Surveillance Data Infrastructure in the U.S. for SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.},
journal = {Current epidemiology reports},
volume = {13},
number = {1},
pages = {24},
pmid = {42630301},
issn = {2196-2995},
abstract = {PURPOSE OF REVIEW: Infectious disease surveillance forms the epidemiological bedrock of public health, supporting the continuous and systematic collection, and analysis of health data. However, these data are collected by a fragmented network of systems and entities which complicate their accessibility and efficient use. This review describes the key surveillance systems tracking three important respiratory viruses: influenza, respiratory syncytial virus (RSV), and SARS-CoV-2; highlights these systems' limitations; and identifies opportunities for improvement.<br><br>RECENT FINDINGS: High quality surveillance data are vital for effective public health interventions. The decentralized nature of the U.S. public health infrastructure and the subsequent patchwork of surveillance networks create a formidable challenge for epidemiologists seeking to mobilize these data for outbreak response, policy evaluation, or population-based research. Greater clarity on these key surveillance systems, the data they collect, and the populations they represent could support their more effective use to support public health research and emergency response.<br><br>SUMMARY: We identified thirteen surveillance data sources monitoring influenza, RSV, and SARS-CoV-2 in the U.S; all but one were governmental. Most (9) were case-based systems, 2 were syndromic surveillance systems (that monitor for increases in illness-associated symptoms in a population rather than the disease itself), and 2 were classified as "non-traditional" sources like wastewater surveillance systems. We also assessed the relative accessibility of data from these systems and of data from state and local entities which often feed into these systems, and collated this information to improve its findability and accessibility.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40471-026-00405-w.},
}
@article {pmid42630366,
year = {2026},
author = {Francis, DL and Reddy, SSP},
title = {From fragmented to integrated surveillance in LMICs: digital pathways for outbreak detection and vaccine intelligence.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1843782},
pmid = {42630366},
issn = {2296-2565},
mesh = {Humans ; *Disease Outbreaks/prevention &amp; control ; *Developing Countries ; Digital Health ; *Artificial Intelligence ; *COVID-19/epidemiology/prevention &amp; control ; Public Health Infrastructure ; *COVID-19 Vaccines ; Resource-Limited Settings ; },
abstract = {BACKGROUND: Low- and middle-income countries (LMICs) often rely on fragmented, disease-specific surveillance systems that produce delayed and incomplete data. Recent outbreaks, including COVID-19, have highlighted the urgent need for integrated, real-time digital surveillance to improve early outbreak detection and optimize vaccine deployment.<br><br>METHODS: A structured narrative review was conducted following SANRA recommendations on the literature published between 2019 and 2025 on digital health, artificial intelligence (AI), genomic surveillance, and vaccine-information systems in LMIC infectious disease surveillance. PubMed, Scopus, WHO IRIS, and regional CDC repositories were searched using pre-specified Boolean strings. Over 312 records were screened; 46 unique references were selected for final synthesis.<br><br>RESULTS: Traditional indicator-based systems in LMICs suffer from siloed reporting, poor connectivity, and workforce shortages. Digital platforms (DHIS2, mobile reporting, cloud dashboards) can unify multi-sector data and accelerate outbreak signals. AI tools offer predictive capabilities, though LMIC-specific external validation remains limited in only 14% of published models. Electronic immunization registries demonstrate measurable improvements: stockout reductions of up to 76%, coverage gains of 12.3%, and median reporting delays cut from 28 to 3 days. Key barriers include non-standardized data formats, intermittent connectivity, algorithmic bias, and data governance gaps.<br><br>CONCLUSIONS: Achieving integrated surveillance in LMICs requires adherence to interoperability standards, robust digital infrastructure, One Health data integration, and equitable data governance. A four-layer conceptual framework is presented. Investment in local capacity, supportive policy, and ethical AI frameworks is critical for sustainable innovation.},
}
@article {pmid42631903,
year = {2026},
author = {Ahmadi, P and Mozaffari-Jovin, S and Faraj, TA and Razavi, FT and Javanmardi, Z and Fadaee, A and Doulabi, H and Esmaeili, SA},
title = {"IL-40: A novel immunoregulatory axis at the crossroads of inflammation, tissue remodeling, and cancer immunity".},
journal = {Immunologic research},
volume = {74},
number = {1},
pages = {},
pmid = {42631903},
issn = {1559-0755},
mesh = {Humans ; *Neoplasms/immunology ; Animals ; *Inflammation/immunology ; Autoimmune Diseases/immunology ; *Interleukin-1/immunology/metabolism ; },
abstract = {Interleukin-40 (IL-40), encoded by the C17orf99 gene, is a recently identified B cell-associated cytokine that bridges innate and adaptive immune responses. Since its discovery in 2017, IL-40 has emerged as a pleiotropic immunoregulatory factor with broad implications in human diseases. Elevated IL-40 levels are consistently reported across systemic and organ-specific autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, and autoimmune thyroid diseases. In these conditions, IL-40 correlates with disease activity, inflammatory burden, and adverse outcomes. Mechanistically, beyond B-cell differentiation and IgA production, IL-40 induces neutrophil extracellular trap (NET) formation (NETosis), triggering extracellular release of peptidylarginine deiminase 4. PAD4 catalyzes citrullination of intracellular proteins, converting arginine to citrulline residues, generating neoepitopes that break immune tolerance and drive anti-citrullinated protein antibody (ACPA) production-a hallmark of rheumatoid arthritis and related autoimmunities. Beyond autoimmunity, dysregulated IL-40 is observed in viral infections (COVID-19, Epstein-Barr virus), sepsis, and pneumonia, suggesting roles in host defense, systemic inflammation, and immunopathology. IL-40 deficiency impairs IgA homeostasis and alters gut microbiota, implicating it in mucosal immunity and microbiome crosstalk. In oncology, aberrant IL-40 expression is reported in solid tumors (breast cancer, hepatocellular carcinoma) and hematologic malignancies (acute/chronic myeloid leukemias, Hodgkin lymphoma), indicating context-dependent functions in tumor biology. Elevated IL-40 in obesity, metabolic syndrome, type 2 diabetes, and allergic diseases further implicates this cytokine in low-grade chronic inflammation and hypersensitivity. Overall, IL-40 represents a promising immunoregulatory cytokine with diagnostic and therapeutic potential across immune-mediated diseases and cancer. However, current evidence remains largely observational and animal-based, while mechanistic and clinical investigations are scarce. Future research should prioritize identifying IL-40 receptor(s) and downstream signaling pathways through well-designed cellular and molecular studies, alongside large-scale multicenter trials, to fully elucidate its biological functions and clinical utility.},
}
@article {pmid42632426,
year = {2026},
author = {Kumar, D and Avery, R and Danziger-Isakov, L and Hall, VG and Hanisch, B and Harris, CE and Kates, OS and Nam, HH and Rolfe, RJ and Kotton, CN and , },
title = {Vaccination and Safe Living Strategies for Solid Organ Transplant Candidates and Recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.},
journal = {American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.ajt.2026.07.033},
pmid = {42632426},
issn = {1600-6143},
abstract = {These updated guidelines of the AST IDCOP review safe living practices including routine vaccinations, travel vaccinations including general travel advice, as well as non-pharmacological strategies for safe living. General principles of vaccination as well as the use of specific vaccines in this population are discussed. Vaccination status should be reviewed and updated in the pre-transplant setting and when travel is planned. The optimal timing of vaccination post-transplant should be taken into account. There are accumulating data that live-attenuated vaccines can also be given to select post-transplant pediatric and young adult patients. Since the last update of the guidelines in 2019, several new vaccines are recommended such as those for COVID-19 and RSV. In addition, newer formulations of pneumococcal, meningococcal, and hepatitis B vaccinations are available. There are expanded age indications for recombinant zoster vaccine. Close contacts of transplant patients can receive most routine live and inactivated vaccines. For travel, location, duration, and activity during the trip determines the vaccine requirements as well as the need for malaria chemoprophylaxis. Other strategies for safe living include considerations for food, water, pets, and sexual activity. Detailed recommendations surrounding these are included in these guidelines.},
}
@article {pmid42629733,
year = {2026},
author = {Zhang, N and Fan, Y and Ge, W and Lin, Z},
title = {Familial acute necrotizing encephalopathy temporally associated with SARS-CoV-2 infection: Two case reports and literature review.},
journal = {Medicine},
volume = {105},
number = {34},
pages = {e50329},
doi = {10.1097/MD.0000000000050329},
pmid = {42629733},
issn = {1536-5964},
support = {YKK20189//Nanjing Science and technology Development Project/ ; },
mesh = {Humans ; Female ; *COVID-19/complications ; *Leukoencephalitis, Acute Hemorrhagic/diagnostic imaging/etiology/virology/genetics ; Adolescent ; Magnetic Resonance Imaging ; Young Adult ; SARS-CoV-2 ; Male ; Brain/diagnostic imaging ; Genetic Predisposition to Disease ; Retrospective Studies ; Nuclear Pore Complex Proteins/genetics ; Siblings ; },
abstract = {RATIONALE: Acute necrotizing encephalopathy (ANE) is a rare but life-threatening parainfectious encephalopathy characterized by rapid neurological deterioration following viral infections. Although most cases occur sporadically, familial clustering is uncommon and suggests the involvement of genetic susceptibility factors. The emergence of coronavirus disease 2019 (COVID-19) has broadened the spectrum of viral triggers associated with ANE; however, familial COVID-19-associated ANE remains rarely reported.<br><br>PATIENT CONCERNS: We retrospectively reviewed 2 siblings who developed ANE following laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in December 2022. The first patient was an 18-year-old woman who presented with seizures and progressive impairment of consciousness 2 days after COVID-19 infection. Her 24-year-old brother developed a similar neurological syndrome after SARS-CoV-2 infection, characterized by altered mental status and rapid clinical deterioration.<br><br>DIAGNOSE: Brain magnetic resonance imaging (MRI) of the female patient demonstrated typical bilateral symmetrical lesions involving the thalami, basal ganglia, corpus callosum, cerebellum, and cerebral white matter. MRI of her brother revealed bilateral symmetrical lesions predominantly affecting the lenticular and caudate nuclei. Genetic analysis showed no pathogenic variants in the RANBP2 gene. After comprehensive exclusion of alternative diagnoses, including other infectious encephalitis, metabolic disorders, autoimmune encephalitis, and toxic encephalopathy, both patients were diagnosed with COVID-19-associated ANE.<br><br>INTERVENTIONS: Both patients received immunomodulatory therapy, including high-dose corticosteroids and intravenous immunoglobulin. Supportive treatments and intensive neurological monitoring were also provided according to clinical conditions.<br><br>OUTCOMES: Following treatment, both patients achieved partial neurological recovery; however, residual neurological impairment remained during short-term follow-up. The clinical course and neuroimaging findings were consistent with previously reported characteristics of ANE.<br><br>LESSONS: These familial cases highlight a potential association between SARS-CoV-2 infection and the development of ANE and suggest that genetic susceptibility factors other than RANBP2 mutations may contribute to disease pathogenesis. Early recognition of neurological deterioration, prompt brain MRI evaluation, and timely initiation of immunomodulatory therapy may improve clinical outcomes. Further genetic and mechanistic studies are warranted to identify additional susceptibility genes involved in COVID-19-associated ANE.},
}
@article {pmid42625915,
year = {2026},
author = {Estupiñán-Pérez, VH and Jiménez-Urrego, &#xc1;M and Botero Carvajal, A},
title = {Clinical and environmental risk factors for childhood developmental disabilities: A narrative review (1990-2025).},
journal = {World journal of clinical pediatrics},
volume = {15},
number = {3},
pages = {119109},
pmid = {42625915},
issn = {2219-2808},
abstract = {Developmental disabilities (DD) affect millions of children worldwide and disproportionately burden low- and middle-income countries. Modifiable risks include early-life clinical procedures and environmental/psychosocial exposures, but syntheses spanning 1990-2025, including the coronavirus disease 2019, remain limited. To narratively review evidence on clinical and environmental risk factors for DD in children < 18 years. PubMed (1990-2025) was searched using SPIDER. Clinical trials, cohorts, and population-based studies were thematically synthesized across clinical procedural and environmental/psychosocial domains. Thirty-two studies were included (19 clinical/procedural; 13 environmental/psychosocial/early intervention), enrolling > 100000 participants; registry studies added > 1.8 million. Cardiac surgery for congenital heart disease was associated with below-average cognitive and motor scores, driven mainly by perioperative complexity, low birth weight, and prolonged intensive care rather than surgical technique. Maternal mental illness was linked to adverse neurodevelopmental outcomes (adjusted odds ratio: Approximately 3-4). Multidomain, family-centered interventions - including telehealth - improved developmental outcomes and reduced delay. Several cohorts reported increased developmental concerns during and after coronavirus disease 2019, particularly in communication and social-emotional domains. Clinical and environmental/psychosocial factors are major, potentially modifiable determinants of DD; priorities include strengthened developmental surveillance, caregiver mental health assessment, and equitable access to early intervention.},
}
@article {pmid42626062,
year = {2026},
author = {Müller, L and Di Benedetto, S and Müller, V},
title = {Host-virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1896480},
pmid = {42626062},
issn = {2235-2988},
mesh = {Humans ; *Aging/immunology ; Virus Latency/immunology ; *Cytomegalovirus/physiology/immunology ; *COVID-19/immunology/virology ; *Cytomegalovirus Infections/immunology/virology ; Virus Activation/immunology ; Inflammation/immunology/virology ; SARS-CoV-2/immunology ; *Host-Pathogen Interactions/immunology ; Post-Acute COVID-19 Syndrome ; },
abstract = {Aging and long COVID are increasingly recognized as states of disrupted host homeostasis characterized by chronic inflammation, immune remodeling, metabolic dysfunction, and impaired stress adaptation. These alterations may compromise the mechanisms that normally maintain viral latency, thereby increasing susceptibility to reactivation of persistent viruses such as Cytomegalovirus (CMV). In this mini-review, we propose a systems-level framework in which latent viral reactivation emerges as a manifestation of declining organismal resilience rather than an isolated virological event. We introduce the concept of host-virus resilience networks, encompassing interconnected immune, metabolic, epigenetic, and cellular stress-response pathways that collectively preserve CMV latency across the lifespan. Age-associated immunosenescence, inflammaging, mitochondrial dysfunction, and epigenetic drift may progressively destabilize these networks, weakening antiviral surveillance and facilitating viral reactivation. We further propose the concept of viral inflammaging circuits, defined as self-reinforcing feedback loops in which chronic inflammation promotes viral reactivation, while viral activity further amplifies immune dysregulation, tissue stress, and inflammatory signaling. Within this framework, CMV is considered both a marker and a potential driver of immune aging through persistent antigenic stimulation, T-cell remodeling, and chronic inflammatory activation. Long COVID may represent a convergent resilience failure state in which persistent immune perturbation and metabolic stress intersect with latent herpesvirus biology. By integrating concepts from geroscience, immunology, and systems virology, this review aims to provide a conceptual model linking CMV persistence to network-level dysregulation in ageing and post-viral syndromes and highlights the importance of resilience-based approaches for understanding chronic inflammatory disease progression across the lifespan.},
}
@article {pmid42626188,
year = {2026},
author = {Jain, P and Wu, HHL and Ali, W and Mamidi, V and Chinnadurai, R},
title = {Shadows of infection: Post-coronavirus disease condition and outcome patterns in patients receiving dialysis and kidney transplant recipients.},
journal = {World journal of nephrology},
volume = {15},
number = {3},
pages = {118018},
pmid = {42626188},
issn = {2220-6124},
abstract = {Post-coronavirus disease 2019 (COVID-19) condition describes a constellation of persistent or fluctuating symptoms and organ dysfunction following severe acute respiratory syndrome coronavirus 2 infection. Patients with end-stage kidney disease (ESKD) on dialysis and kidney transplant recipients (KTR) inhabit a landscape of immune dysfunction, multimorbidity, and high healthcare interaction, which may amplify both the risk and consequences of post-COVID condition (PCC). In this article, we aimed to review current evidence on PCC and related post-acute sequelae in dialysis patients and KTR-focusing on symptom burden, risk factors, functional outcomes, health-related quality of life (HRQoL), kidney and graft outcomes, and recovery trajectories. It was found that dialysis patients and KTR experience a substantial burden of PCC superimposed on already complex symptoms and risk profiles. Long COVID in these groups encompasses not only fatigue, dyspnea and a "brain fog" phenomenon but also impaired HRQoL, reduced functional recovery, and potential acceleration of kidney and graft decline. Harmonized PCC definitions, kidney-specific outcome measures, and prospective multicentre studies in ESKD and kidney transplant populations are urgently required to inform prevention and management strategies embedded within the dialysis and kidney transplantation pathways.},
}
@article {pmid42626440,
year = {2026},
author = {Geerdink, TH and Dijkgraaf, MGW and van Veen, RN and Salentijn, DA},
title = {Trends and patterns in hand injuries during the a pandemic.},
journal = {Journal of orthopaedic reports},
volume = {5},
number = {4},
pages = {None},
pmid = {42626440},
issn = {2773-157X},
abstract = {PURPOSE: A significant portion of the musculoskeletal extremity injuries are hand and finger injuries. Strict government measures during the COVID-19 pandemic led to changes in incidence, types and mechanisms of hand injuries. Data is needed to develop targeted strategies for management and treatment of these injuries effectively in case of future pandemics.<br><br>METHODS: In this retrospective study, data were gathered during calendar weeks 11-18 in the years 2019 (pre-pandemic) and 2020 (pandemic). Patients were categorized into adults and children (<18 years). Type of hand injury was further categorized into: carpal injuries or dislocations, metacarpal injuries or dislocations, phalangeal fractures, finger dislocations and mallet fingers.<br><br>RESULTS: During the pandemic the absolute number of hand injuries decreased by 55%, the decrease was larger in children (73%) then in adults (48%). In children, sports as underlying trauma mechanism decreased from 50% to 16%, metacarpal injuries due to physical interactions doubled proportionally from 33% to 70%. In adults, hand injuries caused by sports decreased while injuries resulting from physical interactions increased from 9% to 20%, more patients were operated on (13% versus 7%; p&#xa0;=&#xa0;0.018). Metacarpal injuries proportionally increased and experienced a higher operation rate (20% versus 7%; p&#xa0;=&#xa0;0.026), mallet patients were more often female (50% versus 13%; p&#xa0;=&#xa0;0.031).<br><br>CONCLUSIONS: Restrictions during a pandemic lead to an absolute decrease in number of patients with hand and finger injuries, cause a shift in underlying trauma mechanisms from sport to physical interactions, result in a significantly higher probability of needing operative treatment when being an adult patient.<br><br>LEVEL OF EVIDENCE: IV.},
}
@article {pmid42627775,
year = {2026},
author = {La Via, L and Cuttone, G and Misseri, G and Senussi Testa, T and Paternò, DS and Pappalardo, F and Patroniti, N},
title = {Contemporary Sedation Strategies for Mechanical Ventilation: Balancing Patient Outcomes, Delirium Prevention, and Early Recovery.},
journal = {Respiration; international review of thoracic diseases},
volume = {},
number = {},
pages = {1-15},
doi = {10.1159/000550984},
pmid = {42627775},
issn = {1423-0356},
abstract = {BACKGROUND: The traditional deep sedation approach has been linked to prolonged ventilation, increased delirium incidence, and long-term cognitive impairment. Modern evidence now supports lighter sedation protocols with daily interruptions and spontaneous breathing trials.<br><br>SUMMARY: The authors explore the pathophysiology of sedation-related complications including delirium, ventilator-induced diaphragmatic dysfunction, and ICU-acquired weakness. They analyze clinical assessment tools ranging from validated scales to emerging objective monitoring technologies (processed electroencephalography, automated pupillometry). The pharmacological discussion contrasts traditional benzodiazepines with newer alternatives (propofol, dexmedetomidine, remifentanil) that show improved outcomes regarding delirium, ventilation duration, and cognitive function. Critical examination of sedation-ventilator mode interactions and comparison of analgosedation versus traditional sedation-first paradigms addresses unresolved clinical questions in integrating these therapeutic domains. Structured approaches including goal-oriented protocols and the ABCDEF bundle are presented as implementation frameworks. The review highlights non-pharmacologic interventions as essential complements to drug therapy: sleep promotion, early mobilization, family engagement, and environmental modifications. Special consideration is given to unique populations requiring tailored approaches, including geriatric, neurologic, cardiac, and COVID-19 patients.<br><br>KEY MESSAGES: The authors conclude by addressing future directions in sedation practice, emphasizing cost-effectiveness analysis, quality improvement initiatives, and research priorities that will guide the next phase of sedation management in mechanical ventilation.},
}
@article {pmid42628298,
year = {2026},
author = {Espinoza Díaz, CI and Barreto Espinoza, ME},
title = {[Polypharmacy and mortality in hospitalized older adults: Systematic review with exploratory meta-analysis].},
journal = {Revista espanola de geriatria y gerontologia},
volume = {61},
number = {6},
pages = {101835},
doi = {10.1016/j.regg.2026.101835},
pmid = {42628298},
issn = {1578-1747},
abstract = {Polypharmacy is common in hospitalized older adults, but its independent relationship with mortality remains uncertain. We conducted a PRISMA 2020 systematic review, prospectively registered in PROSPERO (CRD420261398125), of observational studies assessing polypharmacy, excessive polypharmacy, or potentially inappropriate medication and mortality in hospitalized older patients. PubMed/MEDLINE, Scopus, Web of Science, Embase, and LILACS were searched. Of 134 records, seven studies entered the qualitative synthesis and three the exploratory meta-analysis. The pooled estimate showed substantial statistical uncertainty and high heterogeneity (OR=2.23; 95%CI: 0.77-6.43; I[2]=87.2%). After excluding the COVID-19 study, the magnitude of the association decreased (OR=1.20; 95%CI: 0.77-1.88; I[2]=11.7%). Polypharmacy appears to function mainly as a marker of multimorbidity, frailty, and clinical severity. These findings are hypothesis-generating and do not support causal inference. Excessive polypharmacy and potentially inappropriate prescribing may discriminate risk better than the isolated five-medication threshold.},
}
@article {pmid42629673,
year = {2026},
author = {Wu, C and Yu, Y and Wu, Z and Zhu, W},
title = {Exploring the research progression and evolutionary trends of medical adverse events: A bibliometric analysis over the period from 2014 to 2024.},
journal = {Medicine},
volume = {105},
number = {34},
pages = {e50094},
doi = {10.1097/MD.0000000000050094},
pmid = {42629673},
issn = {1536-5964},
mesh = {*Bibliometrics ; Humans ; *Drug-Related Side Effects and Adverse Reactions/epidemiology ; *Biomedical Research/trends ; },
abstract = {BACKGROUND: Medical adverse events pose a major global health challenge that affects millions of patients. Despite growing research interest, bibliometric analysis in this area is lacking. This study seeks to map the current landscape of medical adverse events and identify the relevant knowledge domains and trends through a bibliometric approach.<br><br>METHODS: We comprehensively reviewed the research on medical adverse events using the Web of Science Core Collection database and summarized the findings. Our analysis encompassed data ranging from 2014 to 2024, utilizing the topic keywords "medical" and "adverse events." We employed the R package "Bibliometrix" to compute key bibliometric characteristics, and a three-field plot was generated to illustrate the interrelationships among authors, institutions, and countries. Using CiteSpace, we developed knowledge maps and conducted co-occurrence analyses, clustering analyses, timeline evaluations and burst term detections.<br><br>RESULTS: A total of 2539 articles on medical adverse events were published, with a steady annual increase that peaked in 2022. The U.S. led with 862 articles (34%), followed by China with 253 (10%). The top 10 countries contributed 1782 articles, or 70% of the total. The leading 5 institutions were all US-based, and the Journal of Patient Safety had the most publications. The focus of recent research has been placed on "immune checkpoint inhibitors," "COVID-19 vaccines," "public health," and 'maternal mortality', indicating that these are emerging popular topics. COVID-19 vaccines and immune checkpoint inhibitors have become prominent research areas, with strengths of 4.71 and 4.38, respectively.<br><br>CONCLUSION: In summary, this study systematically depicted the knowledge structure and evolution pattern of the medical adverse event research field from 2014 to 2024. The United States leads in publication output and institutional influence, while the developing countries relatively lacked the global research network. Traditional drug safety research remains central, with immune checkpoint inhibitor-related adverse events and COVID-19 vaccine safety emerging as new hotspots. These findings provide valuable references for researchers and empirical evidence for the formulation of global patient safety strategies.},
}
@article {pmid42621510,
year = {2026},
author = {He, H and Hu, M and Li, S and Yue, F},
title = {The historical and contemporary aspects of cognitive behavioral therapy for insomnia in recent 30 years: a bibliometric study.},
journal = {Frontiers in psychiatry},
volume = {17},
number = {},
pages = {1878379},
pmid = {42621510},
issn = {1664-0640},
abstract = {OBJECTIVE: Cognitive Behavioral Therapy for Insomnia (CBT-I) has become the leading intervention for insomnia over the past two decades, with well-established efficacy. Yet, no systematic approach exists to rapidly capture its intellectual foundations, research frontiers and research hotspots. This study addresses this gap through bibliometric analysis.<br><br>METHOD: Using a comprehensive set of synonyms and related terms for CBT-I as search keywords, a methodical literature search was carried out. The search was restricted to review papers and articles published in peer-reviewed journals between the years 1996 and 2025. This resulted in 6996 records from Scopus and 4595 records from the Web of Science(WoS) Core Collection. CiteSpace was applied to analyze cited references and terms. VOSviewer was applied to analyze the co-authorship in authors, organizations and countries/regions.<br><br>RESULTS: (a)Eight primary knowledge bases were identified, encompassing management guidelines and reference books on insomnia; face-to-face CBT-I interventions for individuals with insomnia; self-help or digital CBT-I interventions for insomnia; CBT-I applications in mental disorders comorbid insomnia; CBT-I interventions for insomnia comorbid with medical conditions; the overview of information about insomnia; sleep assessment tools; and other related topics. (b)Three emerging research frontiers in the CBT-I domain over the past 5 years include: digital delivery of CBT-I interventions, the practice of CBT-I in sleep apnea, and CBT-I among cancer populations. (c)Morin CM is the leading researcher in the field; University of California has emerged as the leading institution in CBT-I research; the United States collectively produces the highest volume of CBT-I related research globally. (d)Current research hotspots in CBT-I include: adding CBT-I applications to obstructive sleep apnea (OSA), the practice of CBT-I during the COVID-19 epidemic, population-specific modifications of CBT-I for at-risk teenagers, new studies on CBT-I's digital delivery methods, assessing CBT-I's effectiveness and adaptation in comorbid psychiatric diseases (especially anxiety-related conditions).<br><br>CONCLUSION: This study delineates the intellectual base and evolving trends of CBTI research. The results help beginners quickly grasp the field's development, improve practice accuracy and consistency, and provide researchers with a comprehensive overview to inform future innovations.},
}
@article {pmid42621656,
year = {2026},
author = {Barry, M and Al-Tawfiq, JA and Farahat, F and Alzunitan, M and Almaziad, S and Alshamrani, M and Memish, ZA},
title = {Pre-Travel Consultation for the Prevention of Infectious Diseases among International Travelers from GCC Countries: Travel Medicine Recommendations for Clinicians.},
journal = {Saudi journal of medicine &amp; medical sciences},
volume = {14},
number = {3},
pages = {183-196},
pmid = {42621656},
issn = {2321-4856},
abstract = {Travel has been increasing globally since the COVID-19 pandemic ended, including travel from the Gulf Cooperation Council (GCC) countries to international destinations. This creates unique risks for travelers, who may return with various infectious diseases. Travel medicine is a well-established medical specialty worldwide; however, it has only recently been introduced within the GCC, with limited healthcare and public awareness of the importance of these services in preventing infectious diseases among international travelers. This document presents travel medicine recommendations for practicing clinicians in the GCC to help prevent these diseases through pre-travel consultation.},
}
@article {pmid42621909,
year = {2026},
author = {Li, X and Cheng, S and Wang, S and Gao, K and Bai, Y and Li, S and Gao, M and Guo, Y},
title = {Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1904565},
pmid = {42621909},
issn = {2235-2988},
mesh = {Humans ; *Virus Activation/immunology ; *Virus Latency/immunology ; *Herpesvirus 3, Human/physiology/immunology ; *COVID-19/immunology/complications/virology ; *Herpes Zoster/immunology/virology ; SARS-CoV-2/immunology ; Post-Acute COVID-19 Syndrome ; Immunity, Cellular ; },
abstract = {Herpes zoster (HZ) is the clinically apparent manifestation of latent varicella-zoster virus (VZV) reactivation. Aging and immunosuppression are established risk contexts. SARS-CoV-2 infection has prompted renewed attention to whether acute or post-acute immune changes can reduce the reserve needed to maintain VZV latency. Large observational studies report a modest increase in HZ after COVID-19, most consistently after severe disease or hospitalization and within early post-infection windows. These associations do not establish direct causation or a population-wide shift of HZ toward younger adults. A threshold-lowering interpretation is more consistent with the available evidence: SARS-CoV-2 infection may narrow latency-control reserve through cellular immune disruption, interferon dysregulation, and inflammation, particularly in hosts already affected by comorbidity or treatment-related immunosuppression. Long COVID provides a setting in which persistent immune dysregulation can be studied, but it is not yet a proven causal framework for VZV disease. Post-COVID HZ may therefore represent a clinically visible manifestation of disrupted host-virus homeostasis in susceptible individuals. Prospective studies that combine clinical phenotyping with VZV-specific cellular immune measurements are needed to test this model.},
}
@article {pmid42623015,
year = {2026},
author = {Cénat, JM and Moshirian Farahi, SMM and Darius, WP and Ouattara, MM and Ben Messaoud, S and Ahmadzai, Z and Kibret, TC and Labelle, PR and Dalexis, RD},
title = {Prevalence and Correlates of Depressive Symptoms in Canada During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis Based on 144 Studies Including 406,043 Participants: Prévalence et corrélats des symptômes dépressifs au Canada pendant la pandémie de COVID-19 : revue systématique et méta-analyse de 144 études comprenant 406 043 participants.},
journal = {Canadian journal of psychiatry. Revue canadienne de psychiatrie},
volume = {},
number = {},
pages = {7067437261477556},
doi = {10.1177/07067437261477556},
pmid = {42623015},
issn = {1497-0015},
abstract = {BackgroundThe COVID-19 pandemic and associated public health measures, including lockdowns, school closures, quarantine, and social restrictions, substantially disrupted social and economic life in Canada. These conditions intensified risk factors for depressive symptoms. However, reported prevalence estimates vary widely across studies, highlighting the need for comprehensive syntheses of evidence specific to the Canadian context. The present study aimed to estimate the pooled prevalence of depressive symptoms and examine key demographic, geographic, and methodological sources of variability.MethodsA systematic review and meta-analysis were conducted following a PROSPERO-registered protocol (CRD42024552536). Five databases were searched for studies published since 2020 assessing depressive symptoms in Canada during COVID-19. Methodological quality was evaluated using Joanna Briggs Institute (JBI) appraisal checklists. Random-effects meta-analyses estimated pooled prevalence, with subgroup analyses and meta-regressions.ResultsA total of 144 studies including 406,043 participants were analysed. The pooled prevalence of depressive symptoms in Canada during the COVID-19 pandemic was 31.1% (95% confidence interval [CI], 28.4%-33.9%), with substantial heterogeneity (I[2] = 99.71). Prevalence was higher among women (29.2% [95% CI, 25.8%-32.7%]) than men (21.1% [95% CI, 18.5%-23.8%]) (p = .0003) and varied significantly across provinces (p = .0001), measurement tools (p < .0001), evaluation periods (p = .017), and study designs (p = .041). No significant publication bias was detected (Egger's test: z = 1.05, p = .295).ConclusionsThese findings underscore the critical need for a comprehensive and coordinated national mental health strategy in Canada. Such a strategy should expand the mental health workforce, implement large-scale promotion and early intervention program across schools, workplaces, and community settings, and provide gender-responsive support. Future research should focus on standardizing depressive assessment measurements and prioritizing studies and interventions targeting healthcare workers, as well as racialized and Indigenous populations, to promote equitable access, strengthen resilience, and enhance preparedness for future public health crises.},
}
@article {pmid42623829,
year = {2026},
author = {Weiner, AA and Chang, L and Dance, MJ and Sud, S and Wright, JL},
title = {Contingency Plans in a Radiation Oncology Department in a Pandemic Outbreak.},
journal = {Seminars in radiation oncology},
volume = {39},
number = {},
pages = {151054},
doi = {10.1016/j.semradonc.2026.151054},
pmid = {42623829},
issn = {1532-9461},
abstract = {The COVID-19 pandemic dramatically impacted radiation oncology departments as efforts were made to maintain high-quality, timely oncologic care in the setting of multiple competing factors. By close collaborations with public health organizations, institutions, and within individual departments, innovative workflows and strategies were created to evolve the field with sustainable programs impacting all aspects of radiation oncology. This manuscript details the response of radiation oncology in a pandemic, the transformation of current radiation oncology practice and education, and the generation of preparedness for a future pandemic.},
}
@article {pmid42624820,
year = {2026},
author = {Garkisch, M and Popp, S},
title = {Lessons learned from crises in blood donation services: A systematic review of operational practices.},
journal = {Vox sanguinis},
volume = {},
number = {},
pages = {},
doi = {10.1111/vox.70337},
pmid = {42624820},
issn = {1423-0410},
abstract = {BACKGROUND AND OBJECTIVES: Blood donation services are vital to healthcare delivery, ensuring the continuous availability of safe and adequate blood products, particularly during periods of disruption and crisis. Disruptive events such as pandemics, mass-casualty incidents, (natural) disasters, pandemics, armed conflicts and blood shortages can affect donor availability, logistics, workforce capacity, communication and operational continuity. This study systematically identifies and synthesizes lessons learned from crises affecting blood donation and translates them into a structured framework of operational practices.<br><br>MATERIALS AND METHODS: A systematic literature review between 2010 and 2025 was conducted using four databases. Study selection followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 142 included publications were analysed using qualitative content analysis with MAXQDA and organized using an analytical framework adapted from the International Society of Blood Transfusion (ISBT) COVID-19 Operational Recommendations Framework.<br><br>RESULTS: The analysis identified six overarching dimensions of operational practice in blood donation services: collaboration, coordination and standards; blood supply chain design and management; resource management; disaster preparedness and risk management; communication; and operations. Three overarching operational practice themes emerged: coordinated governance and communication, operational continuity and organizational resilience.<br><br>CONCLUSION: Crises affecting blood donation services generate transferable lessons for maintaining safe and reliable blood supply operations under disruptive conditions. This review provides a structured synthesis of cross-crisis operational practices and offers an evidence-based foundation for blood services.},
}
@article {pmid42391691,
year = {2026},
author = {Halwe, NJ and Krammer, F},
title = {Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.},
journal = {Vaccine},
volume = {89},
number = {},
pages = {128877},
doi = {10.1016/j.vaccine.2026.128877},
pmid = {42391691},
issn = {1873-2518},
mesh = {Humans ; *Influenza A Virus, H3N2 Subtype/immunology ; *Influenza Vaccines/immunology ; *Influenza, Human/prevention &amp; control/epidemiology/immunology ; *Pandemics/prevention &amp; control ; *Vaccine Development/methods ; Animals ; COVID-19/prevention &amp; control/epidemiology ; Vaccination ; SARS-CoV-2 ; },
abstract = {Nearly 60 years ago, in 1968, the global population was confronted with the emerging pandemic influenza A virus (IAV) subtype H3N2 (1968 H3N2pdm). An estimate of up to two million fatalities have been linked to 1968 H3N2pdm, and the H3N2 subtype continues to circulate as seasonal IAV among humans until today. The last IAV pandemic dates back to the year 2009 but concerns about a new IAV pandemic in the near future are increasing. The global spread of H5N1 highly pathogenic avian influenza virus and its spill-over into new mammalian hosts, discovery of novel influenza A virus with zoonotic or even pandemic potential, as well as seasonal influenza viruses undergoing antigenic changes necessitate constant vigilance. Here, we highlight the proactive actions, precautionary measures and vaccination strategies used during the 1968 H3N2 IAV pandemic. Our review highlights the emergence and spread of 1968 H3N2pdm over the course of the pandemic, alongside a delineation of vaccine development before, during and after the 1968 pandemic. Updating these strategies in the context of new findings combined with our experiences during the coronavirus disease 2019 (COVID-19) pandemic is necessary to improve preparedness for the next pandemic. Influenza viruses with zoonotic potential will remain a constant threat to public health, and improving countermeasures and communication to the public is key to limit the pandemic ramifications.},
}
@article {pmid42391692,
year = {2026},
author = {Brown, J and Brennan, H and Levine, CB and Gwynn, L},
title = {A historical overview of the anti-vaccine movement and its public health implications.},
journal = {Vaccine},
volume = {89},
number = {},
pages = {128903},
doi = {10.1016/j.vaccine.2026.128903},
pmid = {42391692},
issn = {1873-2518},
mesh = {Humans ; History, 20th Century ; *Public Health/history ; *COVID-19/prevention &amp; control/epidemiology ; History, 21st Century ; *Vaccination Hesitancy/psychology/history ; *Anti-Vaccination Movement/history/psychology/trends ; History, 18th Century ; History, 19th Century ; *Vaccination/psychology/history ; SARS-CoV-2 ; COVID-19 Vaccines ; Smallpox/prevention &amp; control ; Vaccines ; Pandemics ; United States ; },
abstract = {Vaccination is one of the most effective public health interventions in history, yet resistance to vaccines has persisted across centuries. This narrative historical review examines the evolution of vaccine hesitancy and anti-vaccine sentiment from the smallpox era to the COVID-19 pandemic. Sources were identified through PubMed and major public health organizations, including the World Health Organization and the U.S. Centers for Disease Control and Prevention, spanning the early 18th century through 2025. Across distinct historical periods, including early smallpox vaccination, mid-20th-century vaccine controversies, the 1998 Wakefield publication, and the COVID-19 pandemic, recurring themes emerge. Concerns regarding vaccine safety, distrust of institutions, and objections grounded in personal liberty have consistently shaped resistance. While these core arguments have remained stable, the mechanisms of dissemination have transformed dramatically. Modern digital platforms enable rapid, large-scale spread of misinformation, often amplified by algorithms that prioritize emotionally engaging content. The COVID-19 pandemic marked a critical inflection point, with vaccine hesitancy becoming increasingly politicized and, in some cases, economically incentivized through monetized online content. Historical examples demonstrate that both genuine safety events and misinformation can produce long-lasting effects on public trust, even after scientific refutation. This review highlights that vaccine resistance is not solely a deficit of scientific knowledge but a complex interplay of social, political, and cultural factors. Effective public health strategies must therefore extend beyond evidence dissemination to include trust-building, transparent communication, and engagement within modern information ecosystems. Sustaining vaccine confidence will require addressing both the historical roots and contemporary drivers of hesitancy.},
}
@article {pmid42612603,
year = {2026},
author = {Mujica-Coopman, MF and Cordero, M and Corvalán, C},
title = {Triple Harm of Malnutrition and Mental Health in Low- and- Middle Income Countries: After COVID-19.},
journal = {Archives of medical research},
volume = {57},
number = {7},
pages = {103501},
doi = {10.1016/j.arcmed.2026.103501},
pmid = {42612603},
issn = {1873-5487},
abstract = {Low- and- middle income countries (LMICs), particularly in Latin America, face a growing double burden of malnutrition, characterized by the coexistence of obesity and micronutrient deficiencies alongside high rates of mental health disorders. From the Developmental Origins of Health and Disease (DOHaD) perspective, maternal nutrition and mental health are critical determinants of offspring growth, neurodevelopment, and long-term health. The COVID-19 pandemic and subsequent global food crisis have exacerbated food insecurity, unhealthy diets, and symptoms of depression and anxiety, increasing the risk of maternal malnutrition in all its forms. Although most evidence on the interaction between maternal nutrition and mental health during early development comes from Asian and European populations, Latin America presents a particularly vulnerable context due to its high prevalence of obesity, micronutrient deficiencies, and perinatal mental health disorders. This work discusses the potential consequences of disruptions in maternal nutrition and mental health during early life on obesity and neurodevelopmental programming, with a focus on the role of micronutrient deficiencies in Latin America. We conclude that urgent action is needed to prevent and mitigate the long-term consequences of the COVID-19 pandemic on maternal nutrition and mental health in LMICs. Special attention should be given to children conceived and developing during and after the pandemic, as early-life exposure to maternal malnutrition, and poor mental health may adversely affect growth and future health outcomes. Strengthening food security programs, improving access to maternal mental health services, and implementing early-life interventions are essential strategies to reduce the potential intergenerational impacts of the pandemic on the offspring.},
}
@article {pmid42613076,
year = {2026},
author = {Yoshida, M and Araya, J},
title = {Ageing-associated regenerative failure in the lung: stem cell senescence and transitional cell persistence in idiopathic pulmonary fibrosis.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {181},
pages = {},
pmid = {42613076},
issn = {1600-0617},
mesh = {Humans ; *Idiopathic Pulmonary Fibrosis/pathology/physiopathology/metabolism ; *Cellular Senescence ; *Regeneration ; Animals ; *Aging/pathology ; *Stem Cells/pathology/metabolism ; *Lung/pathology/physiopathology ; *Alveolar Epithelial Cells/pathology/metabolism ; Signal Transduction ; Cell Differentiation ; *Pulmonary Alveoli/pathology/physiopathology ; },
abstract = {Alveolar regeneration failure due to alveolar stem cell senescence is a defining feature of idiopathic pulmonary fibrosis (IPF), yet the epithelial mechanisms underlying this dysfunction remain incompletely understood. Recent single-cell and lineage-tracing studies have identified distinct transitional epithelial states, such as pre-alveolar type-1 transitional cells, damage-associated transient progenitors, and alveolar-basal intermediates, which normally serve as intermediates during type 2 alveolar cell (AT2) to type 1 alveolar cell (AT1) differentiation. While these states are transient and successfully resolved during acute lung injury, these populations persist abnormally in IPF lungs, exhibiting features of senescence, cell-cycle arrest, and impaired differentiation.We review recent evidence showing how premature alveolar epithelial senescence, suppression of developmental regenerative programmes, and sustained transforming growth factor-β signalling within the fibrotic niche contribute to this disruption. These factors promote the accumulation of dysfunctional transitional cells, such as cytokeratin (KRT)8[+]/KRT17[+] basaloid cells, which fail to regenerate alveolar epithelium and instead contribute to fibrosis and bronchiolisation through pathological crosstalk with macrophages and fibroblasts. Notably, similar transitional states appear in COVID-19-associated acute respiratory distress syndrome, but they typically exhibit minimal features of senescence and resolve during regeneration, underscoring the pathological importance of accelerated epithelial senescence in IPF.Understanding the molecular checkpoints that regulate transitional cell fate may offer novel strategies to restore regenerative capacity in fibrosing lung diseases.},
}
@article {pmid42613077,
year = {2026},
author = {Franco, G and Zanini, U and Peri, G and Galbardi, I and Promi, S and Mazzotta, SM and Faverio, P and Borie, R and Luppi, F and Crestani, B},
title = {Vaccinations in patients with interstitial lung diseases: a narrative review.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {181},
pages = {},
pmid = {42613077},
issn = {1600-0617},
mesh = {Humans ; *Lung Diseases, Interstitial/immunology/drug therapy/diagnosis ; *Vaccination/adverse effects ; Immunocompromised Host ; Immunosuppressive Agents/adverse effects ; Risk Factors ; *Respiratory Tract Infections/prevention &amp; control/immunology/virology/diagnosis ; Influenza Vaccines ; COVID-19 Vaccines ; },
abstract = {Interstitial lung diseases (ILDs) comprise a heterogeneous group of lung disorders marked by progressive fibrosis and increased vulnerability to respiratory infections, which can trigger sudden outbreaks and worsen outcomes. Vaccination is a key preventive strategy in ILD patients to reduce infection-related morbidity and mortality. This review examines the importance of immunisation in individuals with ILDs, with particular emphasis on influenza, pneumococcal and severe acute respiratory syndrome coronavirus 2 vaccines endorsed by major health organisations. Despite evidence of their effectiveness, vaccination rates among patients with ILD remain low. Tailored vaccine strategies may enhance protection in this group. Additionally, although data are limited, immunisations against respiratory syncytial virus, Haemophilus influenzae, varicella-zoster virus, and pertussis may provide additional protection, particularly in older adults and those receiving immunosuppressive therapy. Hepatitis B vaccination should also be considered for patients on immunosuppressive therapies to prevent infection. Healthcare providers should actively encourage vaccination and address obstacles to immunisation in ILD patients. More research is necessary to assess the safety, effectiveness and optimal vaccination approaches for this vulnerable group. Ultimately, implementing systematic vaccination programmes and clear clinical guidelines is essential to improve preventive care and health outcomes for those with ILDs.},
}
@article {pmid42614300,
year = {2026},
author = {Ugwu, OP and Ugwu, CN and Anyanwu, GE and Basajja, M},
title = {From pathogen defence to precision health infrastructure: mRNA vaccines beyond infectious disease in preventive health, chronic disease management, and population wellbeing.},
journal = {Frontiers in bioengineering and biotechnology},
volume = {14},
number = {},
pages = {1869761},
pmid = {42614300},
issn = {2296-4185},
abstract = {Messenger RNA (mRNA) vaccine technology is often portrayed as a pandemic-era innovation for infectious disease control, but this perspective no longer reflects its expanding clinical and societal significance. Although global attention intensified during the SARS-CoV-2 pandemic, mRNA platforms are founded on more than three decades of pre-pandemic research in cancer immunotherapy and experimental vaccinology. Emerging evidence demonstrates that programmable RNA technologies can extend beyond pathogen prevention into oncology, immune modulation, protein replacement, cardiovascular risk reduction, and population-level preventive medicine. Nevertheless, existing literature remains fragmented across disciplines and lacks a unifying framework explaining how a single platform can simultaneously support prevention, therapy, and health-system resilience. This narrative review addresses this gap by synthesising literature from PubMed, Scopus, and Web of Science, emphasising studies published between 2018 and 2025 while retaining seminal pre-2018 mechanistic contributions. We integrate mechanistic, translational, and policy evidence to propose that mRNA vaccines should be reconceptualised as adaptive health infrastructure rather than single-purpose biologics. We introduce the Adaptive Preventive Therapeutics Continuum (APTC), a framework positioning mRNA intervention along a spectrum from anticipatory prevention to chronic disease management and precision restoration of physiological function. The central innovation of mRNA technology lies not only in rapid manufacturing but also in its programmable temporality the capacity to generate transient, titratable, and updateable biological responses tailored to disease stage and population need, thereby supporting resilient and adaptable healthcare systems.},
}
@article {pmid42614454,
year = {2026},
author = {Ataguba, JE and Muriithi, GN and Achala, DM and Adote, ENA and Nwosu, CO and Beshah, SA and Zegeye, EA and Yaya Bocoum, FIK and Sumboh, J and Setshegetso, N and Yakhelef, N and Muhwava, W},
title = {Vaccine equity in Africa: a rapid review of policy, legal and governance frameworks to improve research and development.},
journal = {Frontiers in health services},
volume = {6},
number = {},
pages = {1678143},
pmid = {42614454},
issn = {2813-0146},
abstract = {BACKGROUND: Vaccines are instrumental in promoting preventive health and improving health outcomes globally. However, stark inequities in vaccine production, distribution, and access disproportionately burden low and middle-income countries (LMICs), which suffer significantly from these disparities. The COVID-19 pandemic further reinforced these existing inequities, prompting renewed debates on scaling up Africa's research and development (R&amp;D) capacity as a proactive approach to enhance very limited domestic vaccine production and counter persistent inequities. However, there has been no consolidated review of the policy, legal, and governance frameworks that shape this capacity and their implications for vaccine equity. This rapid review asked which policy, legal, governance, and investment frameworks influence vaccine R&amp;D and manufacturing capacity in African countries, and how they affect the continent's ability to secure equitable access to vaccines.<br><br>METHODS: We conducted a PRISMA guided rapid review of peer-reviewed and grey literature. Searches were conducted in Academic Search Premier, Business Source Premier, CINAHL via EBSCOhost, EconLit, Embase, and Ovid Medline via OVID Platform, as well as Google Scholar databases. Eligible documents reported on African vaccine R&amp;D, manufacturing, or related policy, legal, governance, or investment frameworks. Grey literature was identified from the WHO, the World Bank, the Africa CDC, government organizations, private institutions, and policy think tanks. Data was extracted using a structured template and synthesized narratively into thematic areas that aligned with the study objectives.<br><br>FINDINGS: From 18,038 records, 68 publications met the inclusion criteria. We identified twelve active vaccine manufacturers in Africa and eleven additional initiatives in development, with the majority focusing on fill-and-finish operations and relatively few investing in upstream R&amp;D and drug substance manufacturing. Persistent under-investment in vaccine R&amp;D, fragmented and weak regulatory systems, and dependence on external financing constrain sustainable local manufacturing. Global and regional instruments, including the TRIPS Agreement, the Doha Declaration, ACT-A/COVAX, and the Pandemic Influenza Preparedness (PIP) Framework, create opportunities for technology transfer and impose intellectual property and supply-chain barriers that limit expansion of African vaccine R&amp;D.<br><br>CONCLUSION: Africa has the capacity to produce vaccines and related health products. However, this potential is undermined by structural under-investment in R&amp;D, constrained access to technologies and inputs, and weak coordination of policy and regulatory frameworks. Strengthening domestic R&amp;D financing, enhancing regional regulatory and policy harmonization, and proactively engaging in IP and trade negotiations, alongside strategic public-private and product development partnerships, are critical to achieving vaccine equity for African populations.},
}
@article {pmid42616003,
year = {2026},
author = {Chong, EH and Wee, IJY and Low, JGH and Tambyah, PA and Ng, DHL},
title = {Post-Acute Sequelae of Non-COVID-19 Respiratory Viral Infections: A Systematic Review.},
journal = {Respirology (Carlton, Vic.)},
volume = {},
number = {},
pages = {},
doi = {10.1002/resp.70302},
pmid = {42616003},
issn = {1440-1843},
support = {LCG/MOH-000505-05//Singapore National Medical Research Council Open-Fund Large Collaborative/ ; },
abstract = {Respiratory viral infections (RVIs) affect millions annually, yet long-term consequences outside COVID-19 are poorly defined. Post-acute sequelae, encompassing persistent or new physical, cognitive, and mental health impairments, are increasingly recognised as clinically important. We systematically reviewed evidence on post-acute outcomes in adults following non-COVID RVIs to characterise pathogen-specific patterns and highlight areas for future research. Major databases were searched from January 2004 to August 2025 for observational studies reporting symptoms, functional impairment, or new diagnoses ≥ 4 weeks after RVIs. Study characteristics, pathogens, follow-up duration, and organ-specific outcomes were extracted. Risk of bias was evaluated using ROBINS-I, and certainty of evidence was determined with the GRADE approach. Narrative synthesis was performed owing to heterogeneity. Thirteen studies (n = 631,863) met eligibility criteria. Influenza was the most studied pathogen and consistently associated with long-term pulmonary dysfunction, reduced diffusion capacity, dyspnoea, fatigue, and poorer quality of life. Large cohorts corroborated substantial pulmonary morbidity and less frequent cardiovascular and neuropsychiatric burdens. Two RSV cohorts (n = 1553 and n = 471) showed a predominance of cardiovascular sequelae; respiratory and neurological outcomes were less frequent. A single HMPV cohort (n = 92) reported persistent symptoms in 55% of adults at 90-270 days, most commonly dyspnoea, fatigue, and cough. Overall, the available evidence suggests that non-COVID RVIs are associated with post-acute multi-organ sequelae, particularly following severe infection. Nevertheless, evidence remains fragmented due to inconsistent study designs, limited pathogen coverage, and low certainty. Standardised, prospective, pathogen-specific studies are required to refine these preliminary signals and inform clinical follow-up and prevention strategies.},
}
@article {pmid42618809,
year = {2026},
author = {Bindel, LJ and Seifert, R},
title = {Repurposing of colchicine: critical examination of clinical trials and scoping review.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {9},
pages = {},
pmid = {42618809},
issn = {1432-1041},
mesh = {*Colchicine/therapeutic use/adverse effects ; Humans ; *Drug Repositioning ; *COVID-19 Drug Treatment ; Clinical Trials as Topic ; *Cardiovascular Diseases/drug therapy ; },
abstract = {PURPOSE: Drug repurposing represents a cost-effective and time-efficient strategy to expand therapeutic treatment options. Colchicine, traditionally used for gout and familial Mediterranean fever, has gained attention as a candidate for diverse conditions. This study aimed to provide a comprehensive and critical overview of clinical trials on colchicine repurposing, with particular focus on reliability, significance, and safety outcomes.<br><br>METHODS: A structured search of clinicaltrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) was completed on July 07 2026. Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guideline, PubMed and Scopus were searched using the term "colchicine AND repurposing".<br><br>RESULTS: 40 clinical trials were included. Nine addressed COVID-19, 26 cardiovascular conditions or related interventions, and five with other indications. Evidence in COVID-19 was inconsistent. Cardiovascular evidence was strong for chronic coronary artery disease and prevention after myocardial infarction. Findings in acute coronary syndromes, percutaneous coronary intervention, surgery and heart failure were mixed and often limited to surrogate endpoints. Other indications did not observe a significant benefit. Most frequent adverse effects were gastrointestinal, particularly diarrhoea. Increased non-cardiovascular mortality in individual trials highlights toxicity potential.<br><br>CONCLUSION: Current evidence most consistently supports colchicine for secondary cardiovascular prevention in established coronary disease. No reliable evidence is found for benefit across broader cardiovascular conditions, COVID-19 or other indications. A narrow therapeutic index and high drug-interaction potential necessitate careful patient selection and monitoring. Well-powered and methodologically robust clinical trials are required to investigate and confirm potential benefits.},
}
@article {pmid42621134,
year = {2026},
author = {Varghese, T and Ramesh, RM and Dhinagar, MJ and Gnanaselvam, NA and Kompithra, RZ and Varughese, DT and Kang, G},
title = {Universal immunization program in India: a review of childhood vaccine updates over the last decade (2014-2024).},
journal = {IJID regions},
volume = {20},
number = {},
pages = {100957},
pmid = {42621134},
issn = {2772-7076},
abstract = {OBJECTIVES: Immunization is a cornerstone of public health, protecting children from life-threatening, yet preventable diseases. Established as the Expanded Programme on Immunization in 1978, India's Universal Immunization Programme is the largest in the world and has undergone major transformations over the decades. This narrative review provides an overview of key developments in childhood immunization in India during the last decade (2014-2024).<br><br>METHODS: A literature search of PubMed, Scopus, and Google Scholar was conducted to identify relevant English-language publications from January 2014 to December 2024.<br><br>RESULTS: The review examines four major dimensions: the introduction of new childhood vaccines under the Universal Immunization Programme; trends in vaccination coverage and persistent inequities in access; the implications of the coronavirus disease 2019 pandemic on routine immunization; and recent advances in childhood vaccination within the Indian context.<br><br>CONCLUSION: Collectively, these findings highlight India's substantial progress toward universal immunization, while underscoring the continuing challenges in achieving equitable, resilient, and sustainable vaccine delivery systems.},
}
@article {pmid42621359,
year = {2026},
author = {Milliken, E},
title = {Treatment of acute COVID-19 in the community.},
journal = {Australian prescriber},
volume = {49},
number = {4},
pages = {116-123},
pmid = {42621359},
issn = {0312-8008},
abstract = {COVID-19 infection in an otherwise healthy person is usually a mild to moderate self-limiting illness, but certain populations are at higher risk of severe disease (e.g. older age, severe immunocompromise, certain comorbidities). Adults with acute COVID-19 should be assessed for disease severity and underlying risk factors to guide appropriate management. Infection control, including case isolation, is important to reduce spread. Antiviral therapy is reserved for patients most likely to benefit, given its high cost, potential adverse effects and uncertain clinical benefit. Patients showing signs of severe or critical disease should be referred to hospital. Antiviral therapies are most effective when started within 5 days of symptom onset. Nirmatrelvir with ritonavir is the first-line antiviral for patients without contraindications, but it has extensive drug interactions. Molnupiravir is used when nirmatrelvir with ritonavir is unsuitable. Inhaled and oral glucocorticoids and immune therapies have no role in routine community treatment of mild to moderate COVID-19. Vaccination remains the single most effective intervention for reducing the risk of severe disease and should be actively encouraged, particularly in unvaccinated or vaccine-hesitant individuals.},
}
@article {pmid42621395,
year = {2026},
author = {Liu, X and Xu, X and Duan, LL and Zhang, JZH},
title = {Computational alanine scanning with GBSA and interaction entropy: a review of methodologies and applications in protein-protein and protein-ligand binding.},
journal = {Chemical science},
volume = {},
number = {},
pages = {},
pmid = {42621395},
issn = {2041-6520},
abstract = {Computational alanine scanning (CAS) has emerged as a powerful in silico strategy for identifying binding hot spots in protein-protein and protein-ligand complexes, addressing the limitations of experimental alanine scanning mutagenesis. This review provides a comprehensive overview of CAS methodologies, with particular focus on the integration of GBSA (molecular mechanics/generalized born surface area) and the Interaction Entropy (IE) method. Traditional CAS approaches have been hampered by the systematic neglect of entropic contributions or computationally prohibitive entropy calculations via normal-mode analysis. The IE method overcomes this bottleneck by enabling efficient and rigorous entropy calculation directly from a single molecular dynamics trajectory, using only fluctuations of intermolecular interaction energies. We present the theoretical foundations of the ASGBIE (Alanine Scanning with Generalized Born and Interaction Entropy) framework, which combines GBSA with IE to accurately compute residue-specific binding free energies. The methodology is systematically described for both protein-protein and protein-ligand systems, including practical considerations such as residue type-specific dielectric constants and the single-trajectory approximation. We survey diverse applications across biologically and pharmacologically relevant systems, including the p53/MDM2 complex, PD-1/PD-L1 immune checkpoint, SARS-CoV-2 variant escape from monoclonal antibodies, Nipah virus antibody synergy, and drug resistance mechanisms in kinase inhibitors. These case studies demonstrate the practical utility of ASGBIE across diverse protein-binding systems of biological and pharmaceutical relevance.},
}
@article {pmid42277822,
year = {2026},
author = {Ulbrichtová, R and Baška, T and Tatarková, M and Malobická, E and Štekláčová, N and Kelčíková, S and Hudečková, H and Švihrová, V},
title = {Physician burnout assessed by the Copenhagen Burnout Inventory - the impact of the Covid-19 pandemic: meta-analysis.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {42277822},
issn = {1472-6963},
mesh = {*Burnout, Professional/epidemiology ; Humans ; *Physicians/psychology/statistics &amp; numerical data ; *COVID-19/epidemiology/psychology ; Prevalence ; Cross-Sectional Studies ; },
abstract = {BACKGROUND: The aim of our meta-analysis was to determine the global prevalence of burnout among physicians measured by the Copenhagen Burnout Inventory (CBI).<br><br>METHODS: A meta-analysis performed following the PRISMA guidelines. PubMed, Scopus, and Web of Science were searched for trials on the prevalence of physician's burnout syndrome. A literature search (October-November 2025) was performed, and pooled prevalence was estimated using a random-effects model. Joanna's Briggs Institute (JBI) quality assessment tool was used to evaluate the risk of bias. Cochrane I-squared test was used to evaluate the heterogeneity among studies. The meta-analysis was performed using IBM SPSS Statistics software (version 29.0.2.0.).<br><br>RESULTS: Thirty-nine cross-sectional studies containing 17,963 physicians were finally included in the analysis. The global prevalence of burnout was 52% (95% CI: 46%-57%). Pre-pandemic studies from Europe yielded a pooled prevalence of 34% (95% CI: 23%-46%), compared with 47% (95% CI: 34%-61%) during the COVID-19 era. In Asia, the pooled prevalence increased from 55% (95% CI: 46%-64%) before the pandemic to 66% (95% CI: 57%-74%) during the pandemic.<br><br>CONCLUSIONS: A large number of physicians were identified as having moderate-high burnout levels. The findings of this analysis highlight the need for policy measures aimed at enhancing the working environment of healthcare professionals and mitigating burnout.<br><br>TRIAL REGISTRATION: The protocol was registered on PROSPERO (CRD420251177705).<br><br>CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid42610181,
year = {2026},
author = {Dorri, S and Shariatpanahi, S and Hosseini, L and Seyedhasani, SN and Mahdizadeh, A and Farahani, MA},
title = {Investigating Factors Affecting the Nursing Shortage During the First and Acute Phase of COVID-19: A Systematic Review.},
journal = {Iranian journal of nursing and midwifery research},
volume = {31},
number = {4},
pages = {555-568},
pmid = {42610181},
issn = {1735-9066},
abstract = {BACKGROUND: The COVID-19 pandemic has resulted in a severe shortage of nurses in health care systems worldwide. The first and acute phase of COVID-19 was challenging for health systems due to the unknown nature and complexity of the disease. This study aimed to extract the factors that influenced the shortage of nurses during the first and the acute phase of COVID-19.<br><br>MATERIALS AND METHODS: Based on the PRISMA guidelines, a systematic search was conducted in PubMed, ScienceDirect, Cochrane, Scopus, and Web of Science databases from the start of the COVID-19 outbreak to 2021. Studies were screened separately; the inclusion criteria were applied. The risk of bias was assessed with the Hoy tool, and data extraction was conducted. Factors were extracted and categorized by thematic analysis.<br><br>RESULTS: In total, 1035 studies were found. Finally, 11 original papers met the eligibility criteria. Most studies (seven) were cross-sectional. After thematic analysis, the results showed that the nursing shortage during the COVID-19 outbreak can be attributed to three main categories: 1) The pandemic perceived threat, 2) Internal and External Factors, and 3) Professional and Psychosocial Support.<br><br>CONCLUSIONS: This study highlighted the need for the healthcare system to switch from reactive crisis management to proactive and resilient strategies. To prevent nurse burnout and attrition and guarantee the continuity of care in future emergencies, it is essential to plan to address perceived threats and strengthen support systems in addition to implementing multilevel interventions in organizational and psychological domains. This integrated strategy will convert vulnerability into readiness and resilience.},
}
@article {pmid42610315,
year = {2026},
author = {An, X and Liu, N and Liu, J},
title = {Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.},
journal = {Reviews in medical virology},
volume = {36},
number = {5},
pages = {e70167},
pmid = {42610315},
issn = {1099-1654},
support = {2025-MSLH-772//The Natural Science Foundation of Liaoning Province/ ; },
mesh = {*Oncolytic Virotherapy/methods ; Humans ; *Oncolytic Viruses/genetics/physiology ; *Neoplasms/therapy/virology ; Animals ; SARS-CoV-2/genetics/pathogenicity ; Zika Virus/genetics/pathogenicity ; West Nile virus/genetics ; Dengue Virus/genetics/pathogenicity ; },
abstract = {Oncolytic virotherapy has recently emerged as a promising immuno-oncological strategy, utilising the natural cytolytic potentials of viral pathogens to selectively target and destroy malignant cells. Although various engineered viruses, such as adenoviruses, vaccinia virus, and herpes simplex virus, are currently in clinical evaluation, emerging and re-emerging viruses with intrinsic oncolytic potential, including Zika virus (ZIKV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dengue virus (DENV), and West Nile virus (WNV), have also shown promising results. These emerging and re-emerging viral pathogens show specific tumour tropism, immune evasion strategies, and immunogenic cell death mechanisms that could be harnessed for next-generation therapeutic platforms. Nonetheless, concerns related to safety, viral pathogenicity, host immune responses, and the risk of uncontrolled viral dissemination present significant translational challenges. The present review provides a comprehensive overview of novel viral candidates, including ZIKV, SARS-CoV-2, DENV, and WNV, in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety. Moreover, this review describes clinical perspectives, regulatory considerations, and future directions in integrating emerging virotherapeutic agents into precision oncology.},
}
@article {pmid42611889,
year = {2026},
author = {Khatkar, P and Batrakova, EV and Branscome, H and Kashanchi, F},
title = {Brain Organoids as Emerging Platforms for Modeling CNS Infections: Neuropathogenesis, Therapeutic Discovery, and Drug Delivery.},
journal = {Journal of visualized experiments : JoVE},
volume = {},
number = {234},
pages = {},
doi = {10.3791/70757},
pmid = {42611889},
issn = {1940-087X},
mesh = {Humans ; *Organoids/virology/pathology ; *Brain/virology/pathology/cytology ; Drug Delivery Systems/methods ; Antiviral Agents/administration &amp; dosage/pharmacology ; *Central Nervous System Infections/drug therapy/pathology/virology ; Animals ; *Models, Biological ; COVID-19/pathology/virology ; Zika Virus Infection/pathology/drug therapy ; },
abstract = {Neurotropic viruses remain a persistent global health challenge, and the mechanisms by which they damage the human brain are not yet fully understood. Animal models are often limited by human-specific aspects of CNS biology, whereas two-dimensional (2D) cell cultures cannot recapitulate the complex three-dimensional (3D) cellular interactions that occur during viral infection of the brain. Over the past decade, brain organoids derived from human stem cells have emerged as physiologically relevant models that address these limitations. These 3D cultures self-assemble into structures containing neurons, astrocytes, and progenitor cells arranged in patterns that resemble early brain development. This review examines the application of brain organoids to the study of infections caused by Zika virus (ZIKV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), herpes simplex virus (HSV), and human immunodeficiency virus type 1 (HIV-1). Studies were screened from PubMed and shortlisted based on their relevance to organoid-based CNS infection modeling, antiviral drug screening, CNS-targeted drug delivery, and neuroinflammation. Organoid-based antiviral screening has identified promising compounds from libraries containing more than 1,000 candidates. Drug delivery strategies are also discussed, with particular emphasis on nanoparticles, polymer-based carriers, and extracellular vesicles (EVs) evaluated in organoid and spheroid models for their ability to cross the blood-brain barrier (BBB) and deliver therapeutic cargo to neural cells. The roles of damage-associated and pathogen-associated molecular patterns (DAMPs and PAMPs) in neuroinflammation, complement evasion, and chronic post-infection damage, including long COVID, are also examined. Current limitations, including the lack of functional vasculature, incomplete BBB components, and reproducibility challenges, are discussed. Despite these limitations, CNS organoids bridge the gap between basic research and clinical application, advancing the development of effective therapies for viral infections of the brain.},
}
@article {pmid41232562,
year = {2026},
author = {Noone, D and Preston, RJS and Leon, G},
title = {Adaptive Immunity in Immunothrombosis.},
journal = {Seminars in thrombosis and hemostasis},
volume = {52},
number = {6},
pages = {667-682},
doi = {10.1055/a-2722-7189},
pmid = {41232562},
issn = {1098-9064},
mesh = {Humans ; *Adaptive Immunity/immunology ; *Thrombosis/immunology/blood ; COVID-19/immunology/blood ; *Autoimmune Diseases/immunology/blood ; Animals ; SARS-CoV-2/immunology ; },
abstract = {Thrombosis is a comorbidity associated with autoimmune, allergic, and infectious conditions; however, the mechanistic basis for this elevated risk is poorly understood. The simultaneous activation of the immune and coagulation systems to assist in response to injury and efficient pathogen clearance, termed immunothrombosis, is typically described as a bidirectional interaction between the innate immune and coagulation systems. More recently, however, data have emerged highlighting the involvement of adaptive immune cells in this process. In this review, we discuss the role of adaptive immune cells in clot formation and resolution, and explore how the adaptive immune system modulates procoagulant activity in autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, and graft versus host disease; allergic disorders, such as dermatitis and asthma; infectious diseases, such as coronavirus disease 2019 (COVID-19) and human immunodeficiency virus (HIV); and ischemic conditions such as myocardial infarction and stroke.},
}
@article {pmid42485161,
year = {2026},
author = {Camilleri, M},
title = {Gastroparesis: A Review.},
journal = {JAMA},
volume = {336},
number = {7},
pages = {587-602},
doi = {10.1001/jama.2026.12181},
pmid = {42485161},
issn = {1538-3598},
mesh = {Humans ; *Gastroparesis/etiology/therapy/diagnosis/epidemiology ; Male ; Female ; Risk Factors ; Prevalence ; },
abstract = {IMPORTANCE: Gastroparesis is a condition of delayed gastric emptying in the absence of gastric outlet obstruction. Based on a 2018 US administrative health insurance claims database study, prevalence of definite gastroparesis (with documented delayed gastric emptying) was 21.5 per 100 000 persons.<br><br>OBSERVATIONS: Gastroparesis, which is caused by reduced contractions of the distal stomach or abnormal pyloric relaxation, is more common among females than males (ratio, 2:1-4:1) and typically causes nausea, vomiting, early satiety, bloating, and abdominal pain or discomfort. In a large US epidemiological study involving 82.6 million patients, the most common causes of gastroparesis were type 2 diabetes (51.7%), postsurgical effects (15%), medication-induced (11.8%), idiopathic (11.3%), type 1 diabetes (5.7%), and other (4.5%). Other risk factors include neurological disorders (eg, Parkinson disease), hypothyroidism, amyloidosis, connective tissue disorders (eg, scleroderma), and viral infections (eg, norovirus, cytomegalovirus, Epstein-Barr virus, SARS-CoV-2). The 2022 American College of Gastroenterology and the 2025 American Gastroenterological Association (AGA) guidelines define the criterion standard diagnostic test for gastroparesis as gastric emptying scintigraphy with more than 10% gastric retention at 4 hours in patients with symptoms of gastroparesis without mechanical obstruction based on upper endoscopy or abdominal imaging such as computed tomographic (CT) scan. The carbon 13 spirulina stable isotope breath test is also approved for diagnosing gastroparesis by the US Food and Drug Administration. Based on the percentage of gastric retention at 4 hours, gastroparesis is categorized in the 2022 AGA clinical practice update as mild (10%-15%), moderate (16%-35%), or severe (>35%). Treatment includes discontinuation of medications that delay gastric emptying such as opioids, cannabis, anticholinergics, and glucagon-like peptide-1 receptor agonists and for patients with diabetes, optimizing glycemic control. First-line therapies according to the AGA 2022 clinical practice update are a small particle diet (food that is blended or chopped into small pieces) that is low in fat and nondigestible fiber and antiemetics (eg, serotonin 5-hydroxytryptamine 3 [5-HT3] receptor antagonists, histamine H1 receptor antagonists) for mild gastroparesis; antiemetics and prokinetics (metoclopramide, erythromycin) for moderate gastroparesis, and liquid diet or jejunal enteral feeding for severe gastroparesis. Severe refractory gastroparesis may be treated with gastric peroral endoscopic myotomy (G-POEM), which involves endoscopic-guided incision of the pylorus sphincter muscle, or gastric electrical simulation, in which an implanted neurostimulator sends electrical pulses to the stomach muscle.<br><br>CONCLUSIONS AND RELEVANCE: Gastroparesis is a condition of delayed gastric emptying without gastric outlet obstruction that is diagnosed based on a gastric emptying study. First-line treatments include a small particle diet and antiemetics and prokinetics. Severe refractory gastroparesis may be treated with procedures such as G-POEM or gastric electrical simulation.},
}
@article {pmid42604060,
year = {2026},
author = {Wells, CR and Pandey, A and Bawden, C and Ye, Y and Bilori, B and Potter-Schwartz, L and Ayaz, L and Moghadas, SM and Townsend, JP and Fitzpatrick, MC and Galvani, AP},
title = {Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.},
journal = {Lancet regional health. Americas},
volume = {62},
number = {},
pages = {101596},
pmid = {42604060},
issn = {2667-193X},
abstract = {Messenger RNA (mRNA) technology helped prevent millions of deaths during the COVID-19 pandemic and is emerging as a promising cancer treatment modality. Early-phase trials suggest mRNA immunotherapies can improve overall and recurrence-free survival. However, the U.S. Department of Health and Human Services has terminated investment in this transformative platform. Although the funding cuts target infectious-disease vaccines, they could also slow broader research across the platform, with implications for cancer applications. To assess the potential public health and economic value of mRNA immunotherapies as cancer treatments, we combined early clinical trial evidence with incidence- and demographic-adjusted survival estimates from the National Cancer Institute's SEER program to project outcomes for non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, and metastatic melanoma. We then applied the U.S. Department of Health and Human Services' Value of a Statistical Life Year ($604,246; 3% discount rate) to quantify the economic value associated with survival gains. Among U.S. patients diagnosed with these cancers in a single year, mRNA immunotherapies could avert an estimated 49,415 (95% CrI: 28,233-71,085) deaths. The corresponding economic value is estimated at $75.55 (95% CrI: $44.20-$103.43) billion, substantially exceeding the funding cut and highlighting the long-term value of continued innovation in mRNA-based therapeutics.},
}
@article {pmid42604281,
year = {2026},
author = {Ajmani, TS and Pareek, S and Padmavathy, K and Upadhayay, P and Patel, D and Mukherjee, B},
title = {Bridging the Digital Prevention Gap: A Systematic Literature Review of Digital Health Literacy and Preventive Health Behaviors in Low-Income Communities.},
journal = {Cureus},
volume = {18},
number = {7},
pages = {e112767},
pmid = {42604281},
issn = {2168-8184},
abstract = {Digital health literacy is increasingly central to preventive healthcare, particularly in low-income and socioeconomically vulnerable communities where limited internet access, lower health literacy, and digital exclusion may restrict engagement with prevention services. Although digital health tools are expanding, evidence remains fragmented on how digital health literacy is associated with preventive behaviors in disadvantaged populations. This systematic literature review examined the association between digital health literacy and preventive health behaviors, including COVID-19 prevention, vaccination intention, online health information seeking, screening-related decision support, and chronic disease self-management. A structured search of electronic databases was conducted using terms related to digital health literacy, eHealth literacy, preventive health behavior, socioeconomic vulnerability, and the digital divide. Eligible primary studies assessed digital or eHealth literacy or online health information-related skills and reported prevention-related outcomes. One measurement-support study was retained only to contextualize the digital health literacy assessment and was not included in the preventive outcome synthesis. Findings were synthesized narratively because of heterogeneity in study design, populations, measures, and outcomes. Higher digital health literacy was generally associated with better prevention-related outcomes, especially COVID-19 preventive behaviors, vaccination intention, and online health information use. Education, income, internet access, computer literacy, employment, and general health literacy repeatedly influenced digital health literacy. The evidence also suggested that vulnerable users can benefit from digital prevention tools when interventions include accessible design, low-literacy content, privacy safeguards, and user support. The digital prevention gap is multidimensional, reflecting both individual skill differences and structural barriers. Strengthening digital health literacy should be treated as a core strategy for equitable prevention, not merely as a technology-access issue.},
}
@article {pmid42606181,
year = {2026},
author = {Zhou, Y and Ying, Z and Kondo, A},
title = {Burnout Levels and Associated Factors Among Newly Graduated Nurses: A Systematic Review and Meta-Analysis.},
journal = {Journal of nursing management},
volume = {2026},
number = {1},
pages = {e4994782},
pmid = {42606181},
issn = {1365-2834},
support = {//International Nursing Development's field cost of the Institute of Science, Tokyo/ ; },
mesh = {Humans ; *Burnout, Professional/epidemiology/psychology ; *Nurses/psychology/statistics &amp; numerical data ; Prevalence ; Emotional Exhaustion ; COVID-19/epidemiology ; Workplace/psychology ; },
abstract = {BACKGROUND: The transition into the workplace exposes newly graduated nurses to significant stressors and challenges that enhance their vulnerability to burnout. However, evidence on the level of burnout and its related factors in newly graduated nurses remains limited.<br><br>OBJECTIVES: To determine the prevalence and severity of burnout among newly graduated nurses, identify its associated factors, and examine differences across geographic regions and before versus during the COVID-19 pandemic.<br><br>METHODS: A systematic search of PubMed, CINAHL, MEDLINE, Web of Science, Japan Medical Abstracts Society, and China National Knowledge Infrastructure databases was performed from inception to July 2024. Pooled mean scores for three subscales of the 22-item Maslach Burnout Inventory were calculated using R software (Version 4.4.1) to assess burnout levels. Publication bias tests, sensitivity analyses, and subgroup analyses were performed. Burnout prevalence and associated factors were summarized using narrative synthesis.<br><br>RESULTS: Forty-five studies involving 18,203 newly graduated nurses were included. The reported rates of high-level burnout ranged widely from 1.0% to 78.3%. The pooled mean scores were 28.39 (95% CI: 26.17-30.61) for Emotional Exhaustion, 11.48 (95% CI: 9.40-13.55) for Depersonalization, and 24.99 (95% CI: 21.22-28.76) for Personal Accomplishment. Subgroup analyses showed that newly graduated nurses in Asia had higher depersonalization (12.48 vs. 8.24) and lower personal accomplishment scores (22.34 vs. 32.99) than non-Asian counterparts (both p < 0.01). Factors associated with burnout included personal traits and competencies (such as coping strategies and psychological capital), work-related factors (such as work environment and workplace bullying and incivility), and other factors such as social support; however, evidence regarding sociodemographic factors was mixed.<br><br>CONCLUSIONS: Newly graduated nurses experienced severe burnout, especially in Asia. Factors related to burnout among newly graduated nurses are multifaceted, highlighting the need for nursing managers to prioritize targeted strategies to facilitate their transition to professional roles. Structured orientation, effective preceptorship, supportive work environments, and accessible psychological support may help reduce burnout among newly graduated nurses.},
}
@article {pmid42606349,
year = {2026},
author = {Teng, F and Li, X and Zhao, H and Ma, Y and Wang, Y and Chen, M and Wu, W and Xiao, T and Wei, Y and Gao, S and Li, X and Zhu, C and Li, G and Jiang, Y and Li, J and Cui, W and Qiao, X},
title = {Epidemiological characteristics and structural-functional implications of spike protein variations in a bovine coronavirus isolate from diarrheic calves.},
journal = {Virulence},
volume = {17},
number = {1},
pages = {2712736},
doi = {10.1080/21505594.2026.2712736},
pmid = {42606349},
issn = {2150-5608},
mesh = {Animals ; *Coronavirus, Bovine/genetics/isolation &amp; purification/chemistry ; Cattle ; *Spike Glycoprotein, Coronavirus/genetics/chemistry/metabolism ; *Cattle Diseases/virology/epidemiology ; *Coronavirus Infections/veterinary/epidemiology/virology ; *Diarrhea/veterinary/virology/epidemiology ; Phylogeny ; China/epidemiology ; Genome, Viral ; Feces/virology ; },
abstract = {Bovine coronavirus (BCoV) is an important pathogen associated with enteric disease in calves, contributing to significant economic losses worldwide. To provide an updated overview of BCoV epidemiology, we conducted a systematic review and meta-analysis of studies published up to October 2025. Seventy-two eligible studies comprising 29,045 samples from nine countries were included, yielding a pooled global prevalence of 20.39% (95% CI: 15.07-26.99). Substantial heterogeneity was observed, reflecting variations in geographic regions, detection methods, and study populations. To complement the epidemiological analysis, 298 fecal samples from diarrheic calves in northeastern China were screened by RT-PCR, identifying 36 BCoV-positive samples (12.08%). Co-infection analysis revealed that most positive samples contained additional enteric viruses, indicating complex viral interactions in calf diarrhea. A novel BCoV strain was isolated in MDBK cells and designated DDFX98. Viral identity was confirmed by PCR, transmission electron microscopy, and immunofluorescence assay. Complete genome sequencing demonstrated that DDFX98 belongs to the GIIb subtype and shares high nucleotide identity with contemporary circulating strains. Comparative analysis of the spike (S) protein revealed multiple amino acid substitutions predominantly located within the S1 subunit. Structural modeling suggested localized conformational variations, particularly in surface-exposed and flexible regions, while preserving the overall spike architecture. In silico predictions further indicated minor alterations in glycosylation potential and epitope-associated regions. Collectively, this study integrates global epidemiological evidence with molecular and structural characterization of a contemporary BCoV isolate, providing insights into S protein variability and its potential structural - functional implications.},
}
@article {pmid42606512,
year = {2026},
author = {Green, EW},
title = {Hepatitis Overview: Alcohol-Associated Liver Disease and Drug-Induced Liver Injury.},
journal = {FP essentials},
volume = {566},
number = {},
pages = {25-36},
pmid = {42606512},
issn = {2159-3000},
mesh = {Humans ; *Chemical and Drug Induced Liver Injury/diagnosis/epidemiology/etiology/therapy ; *Hepatitis, Alcoholic/diagnosis/epidemiology ; *Liver Diseases, Alcoholic/diagnosis/epidemiology/therapy ; Liver Transplantation ; United States/epidemiology ; },
abstract = {Alcohol-associated liver disease is the leading cause of cirrhosis in the United States and has become the top indication for liver transplantation since direct-acting antivirals allowed for cure of hepatitis C. The COVID-19 pandemic compounded existing concerns about a rising prevalence of alcohol-associated hepatitis, with a notable increase in women in their 30s and 40s. Insufficient access to health care continues to exacerbate socioeconomic disparities in screening and treatment. People identifying as American Indian or Alaska Native have had the greatest increase in mortality due to alcohol-associated liver disease. Alcohol use screening is essential for all adults. Abstinence from alcohol remains the cornerstone intervention for alcohol-associated liver disease, although pharmacotherapies are under evaluation. Noninvasive liver disease assessment, including serum and imaging modalities, is expanding access to advanced liver disease evaluation in primary care settings. Other causes of substance-based liver injury include prescription and nonprescription medications, herbal products, and dietary supplements.},
}
@article {pmid42607899,
year = {2026},
author = {Mehra, S and Phadnis, S and Ravi Kumar, YS and Singh, A and Verma, B},
title = {Epitranscriptomic regulation of host-virus interactions.},
journal = {Biochimica et biophysica acta. Molecular basis of disease},
volume = {},
number = {},
pages = {168423},
doi = {10.1016/j.bbadis.2026.168423},
pmid = {42607899},
issn = {1879-260X},
abstract = {RNA chemical modifications, collectively termed the epitranscriptome, are now recognized as critical regulators of gene expression that influence host antiviral responses. These modifications are frequently co-opted by both RNA and DNA viruses to enhance their replication and evade immune detection. This review explores key RNA modifications, principal modifying enzymes, emphasizing how these modifications regulate mRNA stability, translation, and innate immune recognition of both host and viral RNAs. Furthermore, this review examines how viruses, including DENV, SARS-CoV-2, HIV-1, HCV, RSV, and HSV, manipulate host RNA modification systems. Overall, this review highlights the epitranscriptome as a dynamic interface in host-virus interactions and underscores its potential as a target for antiviral therapeutic development.},
}
@article {pmid42608690,
year = {2026},
author = {Aktner, I and Forsman, H and Straatmann, VS},
title = {The COVID-19 pandemic's impact on psychotropic medication prescriptions for children and adolescents: a scoping review of quantitative longitudinal studies.},
journal = {Annals of general psychiatry},
volume = {25},
number = {1},
pages = {},
pmid = {42608690},
issn = {1744-859X},
abstract = {Global evidence shows a deterioration in the mental health of children and adolescents during the COVID-19 pandemic, raising questions about how mental health care, including psychotropic medication prescriptions, has adapted. However, it remains unclear how this deterioration affected prescription trends. This scoping review examined quantitative longitudinal studies comparing psychotropic drug prescriptions before and during the pandemic. A search of five databases, PubMed, CINAHL, Web of Science, Scopus, and PsycINFO, yielded 14 studies from 11 OECD countries (Austria, Australia, Canada, Denmark, Israel, Italy, the United States, Portugal, Sweden, Norway, and New Zealand). Included studies were quantitative, longitudinal, in English, and focused on individuals aged 0-19. Most used national health registers or clinical data covering pre-pandemic (2013-2019) and pandemic years (2020-2022). Six studies focused exclusively on adolescents (10-19 or 12-18 years), while others included larger age ranges (0-17/18/19 years). Ten studies reported increases in antidepressant and antipsychotic prescriptions during the pandemic, with two showing initial declines followed by rises; four reported overall decreases. Notable gender and age differences emerged, with girls showing the largest rise in antidepressant use and adolescents exhibiting higher usage than younger children. Stimulant prescription trends varied across countries. Socioeconomic disparities and national policy responses, including school closures and healthcare access, also influenced prescribing patterns. Two studies found higher prescription rates among children from more advantaged backgrounds. Twelve studies focused on the early pandemic period, limiting time generalisability, while only two extended into 2022. This review highlights the need for enhanced monitoring and extended longitudinal research to assess the long-term impact of crises like COVID-19 on youth mental health care. It also emphasises the importance of health system preparedness for managing psychiatric treatment in future public health emergencies. Although an overall shift in psychotropic prescribing among children and adolescents is suggested, the limited number of studies and short follow-up periods restrict conclusions about long-term trends.},
}
@article {pmid42609149,
year = {2026},
author = {Nakane, S},
title = {[Autoimmune Autonomic Ganglionopathy].},
journal = {Brain and nerve = Shinkei kenkyu no shinpo},
volume = {78},
number = {8},
pages = {905-912},
doi = {10.11477/mf.188160960780080905},
pmid = {42609149},
issn = {1881-6096},
mesh = {Humans ; *Ganglia, Autonomic/immunology ; Autoantibodies/blood ; Receptors, Nicotinic/immunology ; COVID-19/immunology/complications ; Immunotherapy/adverse effects ; *Autoimmune Diseases/immunology/therapy ; *Autoimmune Diseases of the Nervous System/immunology/therapy ; *Autonomic Nervous System Diseases/immunology/therapy ; },
abstract = {Autoimmune autonomic ganglionopathy (AAG) is a peripheral neuropathy caused by immune-mediated synaptic transmission dysfunction in autonomic ganglia. Autoantibodies against the nicotinic ganglionic acetylcholine receptor (gAChR) have been detected in the sera of patients with AAG, and gAChR antibodies are considered pathogenic autoantibodies in AAG. In this review, we discuss recent clinical and research developments in AAG, focusing on the following: (1)reports on the clinical features of AAG and immunotherapy; (2)the association between COVID-19, COVID-19 vaccination, and autonomic dysfunction; (3)autonomic dysfunction as an immune-related adverse effect of immune checkpoint inhibitors in cancer treatment; and (4)new methods for measuring gAChR antibodies.},
}
@article {pmid42609807,
year = {2026},
author = {Casanova, G and Fattorini, G and Santini, S and Balietti, M and Barboni, I and Giacconi, R and Lamura, G},
title = {Loneliness among community-dwelling older adults across biological, clinical and psychosocial domains before and during the COVID-19 pandemic: a systematic review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1831731},
pmid = {42609807},
issn = {2296-2565},
mesh = {Humans ; *Loneliness/psychology ; *COVID-19/psychology/epidemiology ; Aged ; *Independent Living/psychology ; Aged, 80 and over ; Female ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Loneliness is a subjective and distressing experience resulting from a discrepancy between desired and actual social relationships and represents an important public health concern among community-dwelling older adults. Although it can occur throughout the life course, older adults are particularly vulnerable because of age-related conditions such as multimorbidity, mobility limitations, sensory impairments, widowhood, and retirement. These factors highlight the need to understand loneliness as a multifactorial phenomenon requiring a multidimensional perspective considering biological, clinical, and psychosocial determinants and consequences.<br><br>OBJECTIVES: This systematic literature review aims to investigate the extent to which the available literature on loneliness in older age adopts a multidisciplinary approach.<br><br>RESEARCH DESIGN AND METHODS: Multiple databases were searched and papers in biological, clinical and socio-psychological areas were selected according to predefined inclusion criteria and the PRISMA guidelines. Study characteristics (author, year of publication, methodology, and sample size) and contents (keywords, loneliness as primary or secondary outcome, multidisciplinary) were analysed.<br><br>RESULTS: One hundred thirty-one articles were selected: 22 biological; 51 clinical and 58 socio-psychological. Eighty-nine studies adopted quantitative methods, mostly concentrated in the biological area, while qualitative and mixed-method approaches are more common in the other two areas. In biological papers, loneliness is treated as an etiopathological factor or pathological condition, thus underestimating or denying its social significance. Clinical papers often associate loneliness with depression and socio-psychological ones do not investigate loneliness biological and clinical implications.<br><br>DISCUSSION AND CONCLUSION: Although the COVID-19 was associated with a growing number of multidisciplinary studies, research on loneliness among older adults remains largely fragmented across disciplinary boundaries. Strengthening collaboration across biological, clinical, and psychosocial domains could contribute to a more comprehensive understanding of loneliness and support the development of more effective prevention and intervention strategies.},
}
@article {pmid42609898,
year = {2026},
author = {Delpino, MV and Quarleri, J},
title = {The effects of SARS-CoV-2 on bone homeostasis.},
journal = {Frontiers in endocrinology},
volume = {17},
number = {},
pages = {1897220},
pmid = {42609898},
issn = {1664-2392},
mesh = {Humans ; *COVID-19 ; *SARS-CoV-2 ; *Homeostasis ; Animals ; Osteoclasts/virology/metabolism ; *Bone Remodeling ; *Bone and Bones/virology/metabolism ; Osteoblasts/virology/metabolism ; Bone Resorption/virology ; },
abstract = {Accumulating evidence suggests that SARS-CoV-2 is associated with disruptions in skeletal homeostasis through both direct viral effects on bone-remodeling cells and indirect inflammatory mechanisms, contributing to bone loss and increased skeletal fragility. The maintenance of healthy bone structure depends on the coordinated activities of bone-resorbing osteoclasts and bone-forming osteoblasts. Recent studies demonstrate that differentiated human osteoblasts support productive SARS-CoV-2 infection, whereas MSC and osteoclast precursors undergo abortive infection. These interactions impair osteoblast differentiation, increase IL-6 and receptor activator of nuclear factor κB Ligand (RANKL) expression, and promote osteoclastogenesis, shifting bone remodeling toward pathological resorption. Additional virus-associated mediators, including Spike protein, ORF8, and miR-4485-3p, further amplify inflammatory and pro-osteoclastogenic signaling. Clinical studies report associations between acute and persistent reductions in bone mineral density, increased vertebral fracture prevalence, and alterations in musculoskeletal (MSK) imaging biomarkers associated with worse COVID-19 outcomes, while animal models confirm osteoclast-driven trabecular bone loss. This review integrates emerging evidence of productive and abortive SARS-CoV-2 infection of human bone cells with recent clinical and experimental findings, providing an updated osteoimmunological perspective on COVID-19-associated bone remodeling. Prospective longitudinal studies and clinical trials are needed to determine the long-term skeletal consequences of COVID-19 and evaluate targeted strategies to prevent infection-associated bone loss.},
}
@article {pmid42610170,
year = {2026},
author = {Poodineh Moghadam, M and Nasiri, A and Mahmoudirad, G},
title = {The Challenges Experienced by Oncology Nurses during the COVID-19 Pandemic: A Systematic Review.},
journal = {Iranian journal of nursing and midwifery research},
volume = {31},
number = {4},
pages = {569-575},
pmid = {42610170},
issn = {1735-9066},
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has introduced a range of obstacles for healthcare workers, including oncology nurses. These frontline workers have had to adjust to updated procedures and protocols while providing care for patients with cancer during times of increased stress and uncertainty. This systematic review aimed to examine the difficulties faced by oncology nurses during the COVID-19 pandemic.<br><br>MATERIALS AND METHODS: A systematic review was performed on the literature using databases, including Web of Science, Scopus, and PubMed, to find related studies published between January 2019 and July 2024. The quality of the articles was evaluated using the Critical Appraisal Skills Program (CASP) tool.<br><br>RESULTS: This systematic review was performed in international databases, resulting in eight eligible studies. The studies highlighted several difficulties experienced by oncology nurses during the COVID-19 pandemic, including heightened workload, lack of personal protective equipment, emotional distress, and challenges in communicating with patients and families.<br><br>CONCLUSIONS: This research revealed that oncology nurses faced numerous challenges during the COVID-19 pandemic, which impacted their well-being and their ability to provide quality care for patients with cancer. Healthcare organizations should provide support and resources to help oncology nurses cope with these difficulties and continue to deliver high-quality care.},
}
@article {pmid41553607,
year = {2026},
author = {Orogun, D},
title = {Anti-COVID-19 Vaccine Narratives Among African and North American Neo-Pentecostals (Part 1): Evidence, Causes and Lessons.},
journal = {Journal of religion and health},
volume = {65},
number = {4},
pages = {3953-3977},
pmid = {41553607},
issn = {1573-6571},
mesh = {Humans ; *COVID-19/prevention &amp; control ; North America ; *COVID-19 Vaccines/administration &amp; dosage ; Narration ; Leadership ; Vaccination Hesitancy/psychology ; Africa ; },
abstract = {The gap in the worldview of spiritual leaders regarding public health and safety became apparent during the COVID-19 pandemic. It engendered narratives and health behaviors that led to the deaths of many. This interdisciplinary study examines the relationship between religious beliefs, practices, and health behavior. In two parts, this empirical research, through a literature review, secondary data analysis, and available narratives in academic and media spaces, deconstructs the activities of some African and North American Neo-Pentecostals during the pandemic. Part 1, presented here, provides evidence of the narratives and discusses the causes of misinformation and hesitancy. Part 2 addressed the public health implications, the ideal theological response, leadership gaps, and lessons learned. Three fundamental points are evident in both parts. The first is a poor "theology of medicine" in health crises. The second is the poor leadership approach to crisis management. The third is the long-term tension and a lack of synergy between health professionals, health policymakers, and spiritual leaders. The outcome of Part 1 revealed that the causes of anti-vaccination narratives are rooted in theological, social, and economic factors. Part 1 concludes with a summary of the lessons and an overview of what to expect in Part 2 of the exercise.},
}
@article {pmid42603085,
year = {2026},
author = {Foti Randazzese, S and Barberi, S and Castagnoli, R and Catamerò, F and Cosmi, L and Guiducci, S and Lodi, L and Mori, F and Taietti, I and Manti, S and Giovannini, M},
title = {Exploring the potential benefits of allergen immunotherapy beyond respiratory allergy.},
journal = {Expert opinion on biological therapy},
volume = {},
number = {},
pages = {},
doi = {10.1080/14712598.2026.2718367},
pmid = {42603085},
issn = {1744-7682},
abstract = {INTRODUCTION: Allergen immunotherapy (AIT) is the only disease-modifying treatment for IgE-mediated allergic disorders, including allergic rhinitis and asthma, with established long-term clinical efficacy and immunological tolerance induction.<br><br>AREAS COVERED: This review synthesizes current evidence on the potential extra-allergic effects of AIT, focusing on respiratory tract infections (RTIs), SARS-CoV-2 outcomes, and selected immune-mediated conditions. AIT modulates key immunopathological pathways by promoting regulatory T and B cell responses, increasing allergen-specific IgG4, and rebalancing Th1/Th2 immunity. Emerging data suggest that these effects may extend beyond allergy control, with observational and limited clinical studies indicating reduced RTIs burden, decreased medication use, and enhanced antiviral responses, including improved interferon-mediated epithelial immunity. Preliminary findings also suggest an association between AIT and milder COVID-19 outcomes. Evidence regarding autoimmune conditions, such as alopecia areata, remains limited and largely anecdotal.<br><br>EXPERT OPINION: Although AIT demonstrates promising immunomodulatory properties beyond allergic disease, current evidence is heterogeneous and primarily observational, precluding causal inference. The broader clinical relevance of these effects remains to be established. Well-designed prospective studies integrating clinical and mechanistic endpoints are required to clarify the extent and clinical significance of AIT-induced systemic immune modulation.},
}
@article {pmid42603329,
year = {2026},
author = {Kozeratska, O and Gutnitska, A and Vdovichenko, O and Spivak, V and Kabesheva, A},
title = {MENTAL HEALTH IN THE MODERN WORLD: THE PROBLEM AND SOLUTIONS.},
journal = {Georgian medical news},
volume = {},
number = {375},
pages = {153-160},
pmid = {42603329},
issn = {1512-0112},
mesh = {Humans ; *Mental Disorders/epidemiology/therapy/psychology ; *Mental Health/statistics &amp; numerical data ; *Mental Health Services ; Ukraine/epidemiology ; *COVID-19/psychology/epidemiology ; Global Health ; Quality of Life ; Health Services Accessibility ; SARS-CoV-2 ; Prevalence ; },
abstract = {AIM OF THE STUDY: To analyze current mental health problems, assess the prevalence of mental disorders, identify key determinants, and evaluate access to mental health care in different countries.<br><br>MATERIAL AND METHODS: A narrative analytical review with a comparative synthesis of international and national data on mental health for 2019-2025 was conducted, including scientific publications, reports and estimates from the World Health Organization, Global Burden of Disease, World Mental Health, the Organization for Economic Co-operation and Development, and national data from Ukraine.<br><br>RESULTS: Mental health significantly affects quality of life, productivity, and social stability. The COVID-19 pandemic, military conflicts, and economic instability have increased the prevalence of depressive, anxiety, and stress-related disorders worldwide. A high global burden of mental disorders and major regional differences were identified. The treatment gap remains especially high in low- and middle-income countries, where less than 10% of the population receives adequate care. In developed countries, coverage reaches 20-40%, although inequalities, long waiting times, and stigmatization persist. In Ukraine, the prevalence of mental disorders is estimated at 31-36% due to socio-economic instability and military conflict.<br><br>CONCLUSIONS: The findings highlight the need to integrate mental health services into primary health care, expand community-based support models, and implement comprehensive policies to reduce the global burden of mental disorders.},
}
@article {pmid42603685,
year = {2026},
author = {Azhar, EI and Alqahtani, M and Assiri, AM and Al-Abri, SS and Traore, T and Ntoumi, F and Bockarie, M and Petersen, E and Ippolito, G and Hui, DS and McCloskey, B and Perlman, S and Zumla, A},
title = {MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.},
journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
volume = {},
number = {},
pages = {109046},
doi = {10.1016/j.ijid.2026.109046},
pmid = {42603685},
issn = {1878-3511},
abstract = {Middle East respiratory syndrome coronavirus (MERS-CoV) remains a low-incidence but high-consequence zoonotic coronavirus threat. Since its identification in Saudi Arabia in 2012, more than 2600 laboratory-confirmed cases have been reported from 27 countries, most from the Arabian Peninsula; the reported case fatality ratio is high but probably overestimates infection fatality because mild and asymptomatic infections are under-detected. Dromedary camels across the Middle East, North Africa, East Africa, the Horn of Africa, and parts of the Sahel show extensive evidence of MERS-CoV infection or exposure, yet PCR-confirmed human disease has rarely been reported from Africa. This "Africa paradox" is one of the most important unresolved issues in MERS-CoV epidemiology. We propose a dromedary camel-centred One Health framework for the connected Middle East-Africa dromedary belt. The framework is organised around two linked barriers: an upstream barrier that detects and reduces zoonotic spillover at the camel-human interface, and a downstream healthcare barrier that prevents amplification after human infection occurs. Preparedness should include sentinel surveillance for severe acute respiratory infection and atypical pneumonia in camel-exposed populations, linked animal-human genomic surveillance, culturally respectful and occupationally practical risk reduction, rapid diagnostic pathways, healthcare infection prevention and control, mass-gathering and travel preparedness, and pre-approved research platforms. A Middle East-Africa preparedness compact aligned with the International Health Regulations, One Health governance, and equitable pathogen access and benefit sharing could transform fragmented surveillance into a standing transregional system for early detection, prevention, and research-ready response.},
}
@article {pmid42604059,
year = {2026},
author = {Dollfus, H and Arzimanoglou, A and Evangelista, T and Graessner, H and Mosca, M and Sangiorgi, L and Blay, JY and Bodemer, C and Fenaux, P and Hernández, F and Jondeau, G and Ligtenberg, MJL and Lohse, AW and Mathijssen, IMJ and Mulders, P and Pereira, AM and Schaefer, F and Swart, JF and Verloes, A and Wagner, TOF and Wijnen, RMH and Wilde, AAM and Pereira, MDMM and Ladenstein, R and Scarpa, M},
title = {Crisis readiness for rare disease populations: learnings and recommendations by the European Reference Networks.},
journal = {The Lancet regional health. Europe},
volume = {69},
number = {},
pages = {101801},
pmid = {42604059},
issn = {2666-7762},
abstract = {Patients with rare diseases are particularly vulnerable during emergencies due to dependence on specialised care pathways, medicines, and expertise. European Reference Networks (ERNs) for rare and complex diseases have operated since 2017 and were confronted with two major crises: the COVID-19 pandemic and the war in Ukraine. To assess ERN experiences, responses, and preparedness for crisis and disaster situations, we conducted a cross-sectional survey of all 24 ERN coordinators between July and September 2025. Only 2 (8·3%) ERNs reported pre-existing preparedness plans, while 70% lack structured frameworks. Major bottlenecks included patient access to healthcare facilities, drug and device shortages, bed shortage, staff unavailability, and diagnostic service interruption. Our findings highlight the need to formally integrate and mandate ERNs into European health emergency preparedness and response mechanisms. We propose a 10-point global crisis preparedness plan for rare diseases emphasizing cross-border coordination, digital infrastructure, patient education, and integration with national emergency services and non-governmental organizations.},
}
@article {pmid42599088,
year = {2026},
author = {Wang, T and Qu, X and Si, J and Meng, J and Zhang, T and Niu, S},
title = {Liver Organoids: From Disease Modelling to Regenerative Medicine.},
journal = {Cell proliferation},
volume = {},
number = {},
pages = {e70268},
pmid = {42599088},
issn = {1365-2184},
support = {81460202//National Natural Science Foundation of China/ ; XJEDU2026Z018//Fundamental Research Funds for Universities in Xinjiang/ ; 2025BA0090//Karamay Key R&amp;D Program Projects/ ; XGGK2025-02//High-Level Talent Research Startup Program of Xinjiang Second Medical College/ ; KT202603//Xinjiang Second Med Coll Res Innov Team Program/ ; 202513560001//Undergraduate Innovation and Entrepreneurship Training Program of Xinjiang Second Medical College/ ; },
abstract = {Liver organoids are three-dimensional miniature liver models that recapitulate the complex architecture and key functions of the human liver in vitro, offering powerful platforms for both fundamental research and translational applications. This review systematically summarises current fabrication strategies, disease-modelling utilities and regenerative potentials of liver organoids, alongside the major challenges and future directions. In recent years, the field has witnessed several breakthroughs. Through endothelial co-culture approaches, vascularised and metabolically zonated liver organoids have been successfully generated, achieving endothelial coverage exceeding 85%. Prime editing enables precise correction of pathogenic mutations in patient-derived organoids, with no off-target effects detected at the genome-wide level. In disease modelling, iPSC-derived liver organoids faithfully recapitulate the pathological progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and verify the lipid-lowering efficacy of semaglutide. Macrophage-integrated organoid models support the full life cycles of HEV, SARS-CoV-2 and dengue virus, providing new tools for antiviral drug screening. Large-scale patient-derived tumour organoid biobanks successfully preserve the heterogeneity and clinical drug-resistance signatures of liver cancers. In regenerative medicine, encapsulated hepatocyte organoids and the UTOpiA bioartificial liver system have effectively rescued acute liver failure in animal models, while gene-edited autologous organoids offer potential curative strategies for genetic disorders such as Wilson disease. Nevertheless, insufficient hepatocyte functional maturity, difficulties in constructing vascular networks, and the lack of standardised culture protocols remain major obstacles to clinical translation. By bridging fundamental liver biology and clinical practice, liver organoid technology lays a solid foundation for precision hepatology and regenerative therapies. Continued interdisciplinary efforts are still required to overcome current limitations and facilitate its clinical adoption.},
}
@article {pmid42599394,
year = {2026},
author = {Sloan, JP and Rong, L and Moore, TW},
title = {Deadbolt Drug Discovery: Locking the Door to Class 1 Viral Entry by Small Molecules.},
journal = {ACS infectious diseases},
volume = {12},
number = {8},
pages = {2485-2504},
doi = {10.1021/acsinfecdis.6c00302},
pmid = {42599394},
issn = {2373-8227},
support = {R01 AI168362//National Institute of Allergy and Infectious Diseases/ ; },
mesh = {*Virus Internalization/drug effects ; *Drug Discovery ; Humans ; *Antiviral Agents/pharmacology/chemistry ; *Small Molecule Libraries/pharmacology/chemistry ; Viral Fusion Proteins/metabolism/antagonists &amp; inhibitors ; Animals ; *Viruses/drug effects ; },
abstract = {The continued emergence of viral pathogens underscores the need for novel antiviral therapeutics with improved efficacy. Small-molecule inhibitors of viral entry are attractive antiviral agents because they block the virus at its earliest step, preventing the virus from entering host cells and causing downstream damage. Some of the viruses of greatest concern for human health, such as human immunodeficiency virus, respiratory syncytial virus, influenza virus, Ebola virus, severe acute respiratory syndrome coronavirus 2, and Lassa virus, encode Class 1 fusion proteins which mediate membrane fusion and viral entry. In this review, we highlight recent advances in the discovery and development of small-molecule entry inhibitors reported over the past five years that target viruses encoding Class 1 fusion proteins.},
}
@article {pmid42600351,
year = {2026},
author = {Wilson, C and Hanson, S and Flannery, L and Warncken, K and Steel, N},
title = {Socioeconomic adversity and child health following the COVID-19 pandemic: A convergent integrated mixed-methods review of household and neighbourhood inequalities.},
journal = {Social science &amp; medicine (1982)},
volume = {407},
number = {},
pages = {119680},
doi = {10.1016/j.socscimed.2026.119680},
pmid = {42600351},
issn = {1873-5347},
abstract = {Children experience inequalities in health at household and neighbourhood level, even in wealthy countries. Measures to contain the COVID-19 pandemic such as school closures, followed by the cost-of-living crisis, did not affect all children equally. This review aimed to understand the impact of socioeconomic adversity on child health and development following the COVID-19 pandemic. Systematic literature searches used the SPIDER tool to identify studies, and a convergent integrated approach to combine and synthesise quantitative and qualitative data. A mixed methods appraisal tool was used to appraise for risk of bias. Three integrated findings were identified from 125 studies: 1. Socioeconomic adversity and unequal exposure to risk; 2. Community support and professional input as protective influences. 3. Structural and system-level requirements to address socioeconomic adversity. COVID-19 restriction measures were associated with worsening family finances and health of disadvantaged children who experienced cramped living conditions and insecure food and housing. COVID-19 amplified existing health inequalities. These inequalities could potentially be reduced through public health interventions such as improved availability of community services, greater consideration of sociodemographic factors in healthcare settings, and by professionals using their collective voice to influence policy development, for example through improved data sharing to help public-sector services make the best use of available data to support vulnerable families.},
}
@article {pmid42322969,
year = {2026},
author = {Abouhend, AS and Hanafy, WA and Watt, C and Nnachi, RC and Shenoy, P and Butler, CS},
title = {Making waves: toward systems-level interpretation of hormonal and endogenous biomarkers in wastewater-based epidemiology.},
journal = {Water research},
volume = {304},
number = {},
pages = {126269},
doi = {10.1016/j.watres.2026.126269},
pmid = {42322969},
issn = {1879-2448},
mesh = {*Biomarkers/analysis ; *Wastewater/chemistry ; *Hormones/analysis ; Humans ; *Wastewater-Based Epidemiological Monitoring ; Environmental Monitoring ; COVID-19/epidemiology ; },
abstract = {Wastewater-based epidemiology (WBE) has proven invaluable for population health monitoring, most notably during the COVID-19 pandemic. Yet current WBE largely relies on exogenous markers such as drugs, pathogens, and their metabolites, limiting surveillance to what communities are exposed to. We argue for expanding WBE towards endogenous biomarkers, particularly hormones, which provide insights into physiological stress, metabolic function, and endocrine activity. Hormone-based WBE offers new opportunities to capture population-level biological responses to societal and environmental stressors, disasters, and chronic disease burdens at the community scale. This perspective outlines a systems-level framework for integrating hormonal signals in wastewater with clinical data, behavioral indicators, environmental factors, and digital markers to support more robust and context-aware public health surveillance. We highlight key technical considerations, interpretive challenges, and opportunities for translational pilot studies. By moving beyond exposure tracking toward more integrated interpretation of biological responses, hormone-informed WBE may contribute to more resilient, inclusive, and actionable public health infrastructure.},
}
@article {pmid42598066,
year = {2026},
author = {Azhar, LE and Alsaieedi, AA and AlEissa, MM and Baroom, HA and Alghoraibi, AH and Alzahrani, KS and Azhar, EI},
title = {Durability of COVID-19 vaccine-induced immunity in Saudi Arabia: evidence, gaps, and implications for Hajj and mass-gathering preparedness.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1853635},
pmid = {42598066},
issn = {2296-2565},
mesh = {Humans ; Saudi Arabia/epidemiology ; *COVID-19/prevention &amp; control/epidemiology/immunology ; *COVID-19 Vaccines/immunology/administration &amp; dosage ; *Mass Gatherings ; SARS-CoV-2/immunology ; *Islam ; Vaccination ; Immunization, Secondary ; Antibodies, Viral ; },
abstract = {The policy question for COVID-19 vaccination has shifted from whether vaccines induce protection to how long clinically meaningful protection persists and how immune information should guide preparedness. This question is especially relevant to Saudi Arabia, where Hajj and Umrah create predictable periods of dense population mixing among pilgrims with diverse vaccination histories, prior infection exposures, ages, and comorbidity profiles. This structured narrative review synthesizes evidence on durability of COVID-19 vaccine-induced immunity, Saudi epidemiological and serological data, heterologous booster strategies, hybrid immunity, and operational implications for mass-gathering preparedness. A structured search of biomedical databases and public-health sources was undertaken for evidence published from January 2020 to May 2026. The review highlights those circulating antibodies and neutralizing activity decline after vaccination, particularly against antigenically divergent variants, whereas memory B-cell responses and CD4+ and CD8+ T-cell immunity generally provide more durable protection against severe disease. Saudi evidence remains limited but informative: national seroprevalence studies, vaccine-rollout data, clinical-effectiveness analyses, and recent serological work indicate substantial prior exposure, strong post-vaccination antibody responses, and meaningful protection against hospitalization and intensive-care admission, particularly after booster dosing. Heterologous schedules and hybrid immunity appear to broaden immune protection, but their policy relevance lies in flexible risk-based planning rather than in promoting infection as a strategy. For Hajj and Umrah, the main implication is a shift from simple dose counting toward immune durability, risk stratification, booster timing, vaccination documentation, genomic surveillance, and integrated respiratory-virus monitoring.},
}
@article {pmid42598440,
year = {2026},
author = {Mallal, S and Asiaee, A},
title = {Keystone Epitope Theory: An Ecological Perspective on RNA Viruses, Tumor Immunoediting, and Vaccine Design.},
journal = {Pathogens &amp; immunity},
volume = {11},
number = {2},
pages = {39-65},
pmid = {42598440},
issn = {2469-2964},
abstract = {We propose that persistent, human-adapted DNA organisms shape postnatal immunity by focusing responses on functionally constrained epitopes within tissue niches. Here, we examine rapidly evolving RNA viruses and tumors through that lens. We propose that their persistence is promoted by 2 coupled mechanisms: (i) immunodominance steering toward mutable "decoy" epitopes that contribute little to durable control, and (ii) antigen display control that reduces cytotoxic T lymphocyte (CTL) recognition while preserving inhibitory natural killer (NK) receptor engagement, for example via HIV Nef/Vpu effects on HLA-A and HLA-B and through HLA-E/NKG2A pathways. Tumors show analogous vulnerabilities through altered class I expression and reinforcement of inhibitory signaling. Using HIV as the primary model, we distinguish HLA-associated viral adaptation mechanisms and highlight evidence consistent with a subset of adaptations that preserve detectable T-cell recognition while being associated with reduced antiviral effector function. We then consider the degree to which this framework can be extended to hepatitis C virus (HCV), influenza, SARS-CoV-2, and tumor immunoediting. We conclude with 3 vaccine design principles: prioritize epitopes where substitutions carry measurable fitness costs, avoid immunogens dominated by mutable targets, and account for antigen presentation context and inhibitory NK signaling when evaluating epitope choice. We distinguish established observations from testable predictions and outline experiments needed to evaluate the framework. We frame the analysis conditionally on the keystone-imprinting premise, which is developed in companion work.},
}
@article {pmid42598757,
year = {2026},
author = {Jamshidi, N and Hampton, I and Theodore, K and Tadakamadla, S and McGrath, R and Kangutkar, T},
title = {Prevalence of Work-Related Hazards Impacting Health and Well-Being Among Australian Dental Practitioners: A Scoping Review.},
journal = {Australian dental journal},
volume = {},
number = {},
pages = {},
doi = {10.1111/adj.70061},
pmid = {42598757},
issn = {1834-7819},
support = {//PSA insurance/ ; //ADA victorian branch/ ; },
abstract = {This scoping review explored the prevalence of work-related psychological and physical health issues among Australian dental practitioners, mapped across key occupational hazard domains (psychosocial/organisational, physical/ergonomic and environmental/infection-related) and summarised reported impacts on practitioner well-being and workforce outcomes. Databases including Embase, PsycINFO and PubMed were systematically searched from 2015 to March 2025 to capture contemporary practice and COVID-19 pandemic period. Eligible studies focused on Australian dental practitioners and reported the prevalence of psychological or musculoskeletal outcomes, and risk or protective factors. Data were synthesised narratively in line with a hazard-outcome framework. Sixteen studies met inclusion criteria (nine pandemic-era, seven pre-pandemic). Across these studies, dental practitioners frequently reported psychological outcomes (distress, burnout, anxiety, depression, suicidal ideation) and musculoskeletal symptoms related to awkward postures and repetitive tasks, particularly when exposed to high workload pressures, emotional demands and limited support. Pandemic-related infection-control and workload pressures were associated with additional stress and fatigue. Reported protective factors included resilience, emotional regulation and supportive workplace or peer environments. This scoping review indicates persistent and overlapping psychosocial, ergonomic and infection-related hazards that may place Australian dental practitioners at risk of mental and physical health challenges, emphasising need for integrated, multi-level strategies and tailored workplace interventions to foster psychologically safe workplaces.},
}
@article {pmid41848188,
year = {2026},
author = {Ayoade, OF and Caturegli, G and Palis, B and McCabe, R and Weigel, RJ and Canavan, ME and Boughey, JC and Boffa, DJ},
title = {Updated Review: Using the National Cancer Database for Outcomes-Based Research.},
journal = {Journal of the American College of Surgeons},
volume = {243},
number = {3},
pages = {696-707},
doi = {10.1097/XCS.0000000000001924},
pmid = {41848188},
issn = {1879-1190},
mesh = {Humans ; United States/epidemiology ; *Databases, Factual ; *Neoplasms/therapy/epidemiology/diagnosis ; *Outcome Assessment, Health Care ; },
abstract = {BACKGROUND: The National Cancer Database (NCDB) captures 73.7% of newly diagnosed cancers in the USs and underpins thousands of outcomes studies informing oncologic practice. To remain relevant amid rapid therapeutic and policy changes, the NCDB has undergone substantial structural and variable-level revisions. We characterized major updates during the past decade and their implications for research.<br><br>STUDY DESIGN: We performed a narrative review of annual NCDB data dictionary revisions, American College of Surgeons bulletins, and internal program updates in collaboration with NCDB leadership. Structural modifications, variable additions, and policy changes affecting data capture, follow-up, staging, and accessibility were systematically summarized.<br><br>RESULTS: The NCDB now includes data from 1,413 Commission on Cancer-accredited hospitals and more than 55 million records. Since 2020, the Rapid Cancer Reporting System enables near-real-time monthly submissions. Embargo periods were reduced from 5 to 3 years for survival data and 2 years for other variables, increasing analytic timeliness. Follow-up was limited to 15 years beginning January 1, 2022. Variable refinements include continuous tumor size in millimeters (since 2016), separation of tumor grade into clinical, pathologic, and posttherapy fields (since 2018), phased radiation treatment reporting (since 2018), and American Joint Committee on Cancer eighth edition staging implementation in January 2018 with nineth edition rollout ongoing. New data elements include Medicaid expansion status (2020), COVID-19 variables (2020 to 2021; 12.4% reduction in cases in 2020), smoking status (2023), and planned programmed death-ligand 1 reporting for non-small cell lung cancer beginning in 2025.<br><br>CONCLUSIONS: The NCDB has evolved toward more granular, contemporary, and policy-relevant data capture while maintaining broad national coverage. Investigators must account for staging transitions, variable maturation, follow-up limits, and registry-specific biases to ensure valid interpretation of NCDB-based research.},
}
@article {pmid42260236,
year = {2026},
author = {Hill, R and Luintel, A and Mutengesa, E and Fink, DL},
title = {Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.},
journal = {Journal of clinical immunology},
volume = {46},
number = {1},
pages = {},
pmid = {42260236},
issn = {1573-2592},
mesh = {Humans ; *Autoantibodies/immunology/blood ; *COVID-19/immunology/epidemiology ; *SARS-CoV-2/immunology ; Seroepidemiologic Studies ; *Communicable Diseases/immunology/epidemiology ; *Interferons/immunology ; Antibodies, Neutralizing/blood/immunology ; },
abstract = {PURPOSE: To perform a systematic review and meta-analysis of prevalence and function of anti-interferon auto-antibodies in acute infectious diseases.<br><br>METHODS: We performed a search on the following electronic bibliographic databases: Medline, Embase, Web of Science and Cochrane. Eligible studies generated a systematic review and random effects model meta-analysis of pooled seroprevalence and neutralisation status of anti-interferon auto-antibodies in acute infectious diseases.<br><br>RESULTS: Thirty-seven studies including 12,629 individuals with SARS-CoV-2 infection were analysed. There are insufficient data for meta-analyses of auto-antibodies in non-SARS-CoV-2 infectious diseases, with crude seroprevalence of auto-antibodies varying widely (0.0-77.0%). The pooled seroprevalence of anti-IFN&#x251; and/or anti-IFN&#x2375; auto-antibodies in individuals with SARS-CoV-2 infection was 14% (95%CI 9-18%, I[2]&#x2009;=&#x2009;92%, [Formula: see text][2]&#x2009;=&#x2009;0.0151, p&#x2009;<&#x2009;0.01). Pooled prevalence of neutralising auto-antibodies were slightly lower (12%; 95%CI 8-17%, I[2]&#x2009;=&#x2009;77%, [Formula: see text][2]&#x2009;=&#x2009;0.0027, p&#x2009;<&#x2009;0.01). The high heterogeneity may reflect divergent SARS-CoV-2 disease severity across studies, and methodological diversity for measurement and definition of auto-antibody binding and neutralisation. Pooled seroprevalence for anti-IFN&#x251; auto-antibodies in uninfected healthy controls were <&#x2009;1% (95%CI 0-1%, I[2]&#x2009;=&#x2009;90%, [Formula: see text][2]&#x2009;=&#x2009;0.0028, p&#x2009;<&#x2009;0.01).<br><br>CONCLUSION: Anti-interferon auto-antibodies may impair immune responses to diverse infections leading to life-threatening disease. These auto-antibodies have not been studied at all in most infectious diseases, most notably for bacterial infection. This study illustrates the urgent need to standardise methodology and reporting of auto-antibodies in the setting of infectious diseases so that the immunopathology and translational impact of these novel biomarkers can be realised.},
}
@article {pmid42556091,
year = {2026},
author = {Kaur, M and Promi, TJ and Gopali, L and Lee, J and Ward, K and Jackson, TM and Lau, AYS},
title = {Virtual hospital services for adult patients: A scoping review.},
journal = {International journal of medical informatics},
volume = {220},
number = {},
pages = {106611},
doi = {10.1016/j.ijmedinf.2026.106611},
pmid = {42556091},
issn = {1872-8243},
mesh = {Humans ; *COVID-19/epidemiology/therapy ; Adult ; *Telemedicine/organization &amp; administration ; Digital Health ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND AND OBJECTIVES: The COVID-19 pandemic expedited the use of virtual hospital services (VHS) and hybrid hospital-in-the-home (HITH) models. However, the current evidence base remains fragmented and heterogeneous in care model designs, terminology, and reported outcome measures. This scoping review maps the published literature on VHS models implemented or evaluated for adults aged 18 to 65 during and after the COVID-19 period.<br><br>METHODS: Following the Joanna Briggs Institute (JBI) methodology and Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, a comprehensive literature search of four online databases was conducted, identifying articles published between March 2021 and July 2025, followed by screening of reference lists of included studies by two authors.<br><br>RESULTS: Of 1624 records identified, 28 studies met the eligibility criteria. Most studies were published in the last two years, reflecting accelerated interest in sustaining VHS models beyond the pandemic. Of these, 16 studies reported on fully virtual models, while 12 studies described hybrid HITH models. Most models utilised mixed synchronous and asynchronous communication, while mobile applications and wearables were uncommon. Respiratory conditions were the most common diagnostic group (n&#xa0;=&#xa0;17/28), and heart failure exacerbation was the most frequently reported specific condition (n&#xa0;=&#xa0;6/28). Patient satisfaction and experience were most frequently reported outcome measures (n&#xa0;=&#xa0;17/28); qualitative evidence on clinician and caregiver experience was limited.<br><br>CONCLUSIONS: This review provides a structured map of VHS model components in the adult non-geriatric population, revealing substantial heterogeneity and inconsistent reporting amongst different care models. The evidence base remains dominated by pilot and single-site studies. Future research should prioritise standardised taxonomy and clear model descriptions to inform future effectiveness and implementation research.},
}
@article {pmid42593604,
year = {2026},
author = {Goulart, CDL and Franzoni, LT and Ferrari, F and Cardoso, AS and Bittencourt, N and Stein, R},
title = {Exercise and Cardiovascular Risk Modulation in Post-COVID Syndrome.},
journal = {Current atherosclerosis reports},
volume = {28},
number = {1},
pages = {},
pmid = {42593604},
issn = {1534-6242},
mesh = {Humans ; *COVID-19/complications/physiopathology ; Post-Acute COVID-19 Syndrome ; *Cardiovascular Diseases/physiopathology/prevention &amp; control/etiology ; *Exercise/physiology ; Endothelium, Vascular/physiopathology ; *Exercise Therapy/methods ; SARS-CoV-2 ; Vascular Stiffness ; Heart Disease Risk Factors ; },
abstract = {PURPOSE OF REVIEW: Post-COVID syndrome (PASC) has emerged as a multisystem condition associated with persistent cardiovascular abnormalities, including endothelial dysfunction, arterial stiffness, chronic inflammation, metabolic disturbances, autonomic imbalance, and increased atherosclerotic risk. This review summarizes the current evidence regarding the pathophysiological mechanisms linking PASC to cardiovascular disease and discusses the potential role of exercise training as a strategy to mitigate vascular dysfunction and cardiovascular risk.<br><br>RECENT FINDINGS: Recent studies demonstrate that individuals with PASC exhibit persistent low-grade inflammation, impaired endothelial function, accelerated vascular aging, platelet hyperreactivity, insulin resistance, sarcopenia, and autonomic dysfunction. These alterations contribute to a pro-atherogenic phenotype that may persist months to years after SARS-CoV-2 infection. Emerging evidence indicates that exercise training improves inflammatory status, endothelial function, arterial stiffness, metabolic health, autonomic regulation, and functional capacity in post-COVID patients, potentially attenuating mechanisms involved in atherosclerotic progression. Post-COVID syndrome is associated with multiple interconnected biological pathways that increase long-term cardiovascular risk. Exercise training appears to be a promising non-pharmacological intervention capable of targeting several of these mechanisms simultaneously. Although further randomized controlled trials are needed, current evidence supports the integration of individualized exercise-based rehabilitation into the management of patients with PASC to promote vascular recovery and reduce cardiovascular risk.},
}
@article {pmid42593790,
year = {2026},
author = {Pita-Martínez, C and Sepúlveda-Crespo, D and Bermejo-Martín, JF and Martínez, I and Resino, S},
title = {CCL5 Levels, Disease Progression, and Mortality in Respiratory Viral Infections: A Systematic Review and Meta-Analysis.},
journal = {JAMA network open},
volume = {9},
number = {8},
pages = {e2628987},
doi = {10.1001/jamanetworkopen.2026.28987},
pmid = {42593790},
issn = {2574-3805},
mesh = {Humans ; *Chemokine CCL5/blood ; Disease Progression ; *Respiratory Tract Infections/mortality/blood/virology ; Male ; *Virus Diseases/mortality/blood ; Female ; Biomarkers/blood ; Middle Aged ; },
abstract = {IMPORTANCE: The role of chemokine C-C motif ligand 5 (CCL5) in respiratory viral infections remains controversial; although essential for viral clearance, it is also implicated in pathogenic hyperinflammation.<br><br>OBJECTIVE: To quantify associations between CCL5 levels and unfavorable disease progression and mortality in respiratory viral infections.<br><br>DATA SOURCES: Medline and PubMed, Embase, Scopus, Web of Science, the Cochrane Library, CABI Digital Library, and Global Health (Ovid) were searched from inception to October 1, 2025.<br><br>STUDY SELECTION: Observational studies evaluating the association of CCL5 levels with clinical severity or survival in patients with confirmed respiratory viral infections.<br><br>DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data and assessed risk of bias (Newcastle-Ottawa Scale) and certainty of evidence (GRADE). Data were pooled using a random-effects model following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analysis was performed from September 2025 to December 2025.<br><br>MAIN OUTCOMES AND MEASURES: Unfavorable disease progression (severity) and all-cause mortality.<br><br>RESULTS: The meta-analysis included 18 studies (2376 patients; median age, 58.2 [range, 0.08-65.0] years; 1278 of 2126 male [60.1%]); 12 studies (67%) were of high methodological quality. Eleven studies (1214 patients) evaluated disease progression and 7 (1162 patients) evaluated mortality. Elevated CCL5 levels were associated with reduced odds of unfavorable disease progression (OR, 0.78; 95% CI, 0.71-0.85; I2&#x2009;=&#x2009;0%) and mortality (OR, 0.65; 95% CI, 0.55-0.76; I2&#x2009;=&#x2009;23.1%). The protective association had significantly larger effect sizes for mortality than for disease progression (P&#x2009;=&#x2009;.047 for interaction). Subgroup analyses for disease progression demonstrated consistent protective associations without significant interaction by virus type (coronavirus: OR, 0.80 [95% CI, 0.70-0.90] vs noncoronavirus: OR, 0.74 [95% CI, 0.63-0.87]) or age group (pediatric: OR, 0.79 [95% CI, 0.69-0.90] vs adult: OR, 0.75 [95% CI, 0.63-0.88]). Results remained consistent in sensitivity analyses.<br><br>CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of 18 observational studies, elevated CCL5 levels were associated with favorable outcomes and survival in respiratory viral infections, reflecting a competent antiviral immune response rather than pathogenic hyperinflammation. These findings suggest that CCL5 may serve as a prognostic biomarker for risk stratification.},
}
@article {pmid42593939,
year = {2026},
author = {Hu, X and Hu, T and Loregian, A and Yang, H and Gao, S and Zhan, P},
title = {Recent Advances in Antiviral Medicinal Chemistry against Flaviviruses Driven by Multistrategic Approaches.},
journal = {Journal of medicinal chemistry},
volume = {69},
number = {15},
pages = {17561-17583},
doi = {10.1021/acs.jmedchem.6c00626},
pmid = {42593939},
issn = {1520-4804},
support = {55777 2020.0162 - ARREST-COV//Fondazione Cassa di Risparmio di Padova e Rovigo/ ; PE00000007//NextGenerationEU/ ; 22307067//National Natural Science Foundation of China/ ; 20223RYYFC//Ministero dell?Istruzione, dell?Universit? e della Ricerca/ ; P20222YKP8//Ministero dell?Istruzione, dell?Universit? e della Ricerca/ ; IG 2021 - ID. 25899//Associazione Italiana per la Ricerca sul Cancro/ ; 2023YFC2606500//Jiangsu Provincial Key Research and Development Program/ ; 2024KJJ063//Young Innovation Team of Colleges and Universities in Shandong Province/ ; NA//Young Talent of Lifting Engineering for Science and Technology in Shandong/ ; TQ052025001//Independent Project of Shandong Basic Research Special Zone/ ; ZD2021CY001//Shanghai Municipal Science and Technology Major Project/ ; },
mesh = {*Antiviral Agents/pharmacology/chemistry/therapeutic use ; Humans ; *Flavivirus/drug effects/metabolism ; Viral Nonstructural Proteins/antagonists &amp; inhibitors/metabolism ; Chemistry, Pharmaceutical ; Animals ; Drug Discovery ; },
abstract = {Flaviviruses constitute a global health threat, mainly because of the increasing geographical spread of vectors and the suboptimal efficacy of existing prophylactic vaccines. Despite the substantial clinical burden imposed by these pathogens, a critical gap remains in the approved specific antiviral therapies. This Perspective critically evaluates recent advances in antiflaviviral drug discovery, focusing on viral nonstructural proteins (NSs), host-targeted therapeutic targets, and emerging targeted protein degradation (TPD) technologies. We highlight direct-acting antivirals (DAAs) against NS2B-NS3, NS5, and NS4B, host-targeted antivirals (HTAs) that modulate virus-dependent cellular pathways, and the transformative potential of TPD, thereby filling the gap of insufficient systematic summaries in this field. By integrating rational drug design strategies and dissecting the pharmacological profiles of agents with different scaffolds, this Perspective aims to provide a panoramic snapshot of the current landscape and a conceptual roadmap for accelerating the development of next-generation, broad-spectrum antiflaviviral drugs.},
}
@article {pmid42594551,
year = {2026},
author = {Silva-Miranda, M and Lara-Espinosa, JV and Gordillo-Marroquín, C and Sánchez-Pérez, HJ and Hernández Pando, R},
title = {The burden of tuberculosis in Latin America: Immunogenetic and socioepidemiological determinants.},
journal = {Seminars in immunology},
volume = {83},
number = {},
pages = {102054},
doi = {10.1016/j.smim.2026.102054},
pmid = {42594551},
issn = {1096-3618},
abstract = {Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health challenge and the leading cause of death from a single infectious agent. Despite diagnostic and therapeutic advances, the COVID-19 pandemic reversed progress in TB control, with a notable rise in incidence across Latin America. This region bears a disproportionate burden of the disease due to socioeconomic inequality, limited access to healthcare, and high rates of multidrug-resistant TB. Interactions among pathogen genetics, host susceptibility, immune response, and environmental determinants critically shape disease outcomes. Several key questions remain about the higher incidence of TB in the Americas, including the roles of genetic predisposition, environmental factors, and social determinants such as poverty and migration. Addressing these issues is essential to refining control strategies. Accordingly, this review provides an updated overview of TB in Latin America, integrating immunological, genetic, and socio-epidemiological perspectives that could be useful for future research and policy discussions toward more region-specific interventions against Mtb.},
}
@article {pmid42595311,
year = {2026},
author = {Araujo, AQC},
title = {Lost in translation: why pharmacological trials keep failing in acute spinal cord injury.},
journal = {Arquivos de neuro-psiquiatria},
volume = {84},
number = {8},
pages = {1-9},
doi = {10.1055/s-0046-1827054},
pmid = {42595311},
issn = {1678-4227},
mesh = {Humans ; *Spinal Cord Injuries/drug therapy ; *Translational Research, Biomedical ; *Neuroprotective Agents/therapeutic use ; Clinical Trials as Topic ; },
abstract = {Despite four decades of translational research, no pharmacological agent has been approved for acute traumatic spinal cord injury (SCI) based on class-I evidence. The current narrative review critically examines the seven agents evaluated in phase-II to -III clinical trials-methylprednisolone (MPSS), GM-1 monosialotetrahexosylganglioside, minocycline, riluzole, anti-Nogo-A antibody NG101, VX-210, and granulocyte colony-stimulating factor (G-CSF)-with emphasis on quantitative effect estimates, confidence intervals, and mechanisms of translational failure. Polylaminin, under phase-I evaluation approved by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA, in Portuguese), is discussed in the context of disproportionate public communication relative to the stage of evidence; available human data are limited to a small, uncontrolled, unreviewed pilot study insufficient for efficacy inferences. High-dose MPSS conferred no motor recovery benefit in a meta-analysis of 1,863 participants and was significantly associated with gastrointestinal hemorrhage (odds ratio [OR] = 2.07; 95%CI: 1.02-4.20) and respiratory infections (OR = 1.73; 95%CI: 1.12-2.68). Furthermore, GM-1 ganglioside, G-CSF, and VX-210 failed to meet the prespecified primary endpoints. Minocycline produced inconclusive results in an underpowered phase-II study. Riluzole (Riluzole in Spinal Cord Injury Study [RISCIS]), which was prematurely terminated at 55% of enrollment due to the coronavirus disease 2019 (COVID-19) pandemic, showed a significant motor benefit in patients classified as grade C according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) (+8.0 points; 95%CI: 1.5-14.4; 2-tailed p = 0.034). The Nogo Inhibition in Spinal Cord Injury (NISCI) trial (2025), the most methodologically rigorous SCI trial to date, demonstrated no primary endpoint benefit but identified functional signals in motor-incomplete injuries. In total, six structural domains of translational failure are identified and methodological solutions proposed.},
}
@article {pmid42595776,
year = {2026},
author = {Khalid, K and Ahmed Abd El-Aal, AA and Lee, MF},
title = {Prevalence of hypertension in severe vs. non-severe COVID-19: a systematic review and meta-analysis.},
journal = {Journal of human hypertension},
volume = {},
number = {},
pages = {},
pmid = {42595776},
issn = {1476-5527},
abstract = {Although numerous studies have investigated the association between hypertension and coronavirus disease 2019 (COVID-19) severity, differences in study characteristics have limited the consistency and generalizability of the available evidence. This systematic review and meta-analysis systematically evaluated the association between hypertension and COVID-19 severity by synthesizing evidence from 30 studies involving 15,549 participants comparing the prevalence of hypertension in non-severe and severe COVID-19 patients. Pooled odds ratios (ORs) were calculated using a random-effects model. Heterogeneity was assessed using I[2] and τ[2] statistics, while subgroup analyses and meta-regression examined the effects of region, sample size, study quality, age, and gender. Publication bias was evaluated using funnel plots and Egger's test. Hypertension was more frequently observed in severe COVID-19 cases across the included studies with a pooled odds ratio (OR) of 2.73 (95% CI: 1.85-4.02, p < 0.00001), However, substantial heterogeneity was observed (I[2] = 88%), limiting the precision of the pooled estimate. Subgroup analysis showed that sample size, NOS scores, and age did not significantly explain heterogeneity, with gender composition also not significantly associated with effect size (β = 0.021, p = 0.38). Funnel plot analysis and Egger's test showed no significant publication bias. Overall, hypertension was associated with an increased likelihood of severe COVID-19, although the high level of heterogeneity suggests that the findings should be interpreted with caution. These findings contribute to the understanding of the association between hypertension and COVID-19 severity and may inform clinical risk stratification and public health decision-making.},
}
@article {pmid42596759,
year = {2026},
author = {Cintra, O and Alsharef, Z and Phansalkar, A and Anzueto, A and Loeb, M},
title = {Consensus based expert recommendations for management and prevention of RSV infections in older adults in emerging market countries: results from an expert panel structured survey.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2715855},
doi = {10.1080/14760584.2026.2715855},
pmid = {42596759},
issn = {1744-8395},
mesh = {Humans ; *Respiratory Syncytial Virus Infections/prevention &amp; control/diagnosis/epidemiology ; Surveys and Questionnaires ; *Respiratory Syncytial Virus Vaccines/administration &amp; dosage ; Aged ; Middle Aged ; Vaccination/methods ; Delphi Technique ; Immunization Programs ; *Respiratory Tract Infections/prevention &amp; control/virology/epidemiology ; Consensus ; },
abstract = {BACKGROUND: Respiratory syncytial virus (RSV) can cause serious disease in older adults (OAs), particularly those with comorbidities. It is a leading cause of acute respiratory illness and lower respiratory tract infections in adults ≥60 years. Its impact on morbidity, mortality, and healthcare systems is becoming evident. Questions about the burden of disease (BoD) are raised due to underdiagnosis and the similarity with other respiratory illnesses. First opportunities for prevention came in 2023 and 2024, with vaccines approved for ≥60 years, expanding eligibility to additional age groups.<br><br>RESEARCH DESIGN AND METHODS: A modified Delphi approach through a questionnaire survey and virtual consensus workshop with 27 experts in respiratory and infectious diseases from 12 emerging market countries was done to reach consensus on diagnosis, prevention, and treatment of RSV in OAs.<br><br>RESULTS: The panel recommends the introduction of a universal vaccination program for all adults aged&#x2009;&#x2265;70&#x2009;years, and vaccination for all adults aged&#x2009;&#x2265;60&#x2009;years with comorbidities. The need for increased awareness, better testing, and national and international guidelines was also agreed.<br><br>CONCLUSION: The agreements highlight that RSV vaccination for OAs should be prioritized. Educating clinicians and patients, improving surveillance, and integrating RSV vaccination into health policies are key to reducing BoD in OAs.},
}
@article {pmid42597254,
year = {2026},
author = {Gambadauro, A and Piedimonte, GA and Manti, S and Piedimonte, G},
title = {Insights Into monoclonal antibodies and vaccines targeting respiratory viruses.},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1864969},
pmid = {42597254},
issn = {2296-2360},
abstract = {INTRODUCTION: Viral respiratory infections are a leading cause of morbidity and mortality in children worldwide, with lower respiratory tract infections (LRTIs) a major contributor to hospitalizations and healthcare utilization. Among respiratory pathogens, respiratory syncytial virus (RSV) is the leading cause of severe disease in early life and has driven major advances in preventive strategies. Increasing evidence also suggests that early-life viral infections may influence long-term respiratory outcomes, including recurrent wheezing and asthma.<br><br>AIM OF THE STUDY: This article provides a comprehensive overview of the epidemiological burden, risk factors, and long-term consequences of pediatric viral infections. It also examines RSV as a case study in the evolution of preventive strategies and explores knowledge that can be translated from RSV management to other major respiratory viruses, including influenza, SARS-CoV-2, rhinovirus, human metapneumovirus (HMPV), and parainfluenza.<br><br>DISCUSSION: RSV has reshaped pediatric respiratory prevention through the development of monoclonal antibodies and maternal vaccination strategies, enabling a shift from high-risk-based approaches to broader population-level protection. Advances in structural virology have enabled targeting of conserved viral epitopes, thereby improving efficacy and the duration of protection. Similar strategies are being explored for other respiratory viruses. However, antigenic variability, limited pediatric data, and incomplete vaccine effectiveness remain significant barriers.<br><br>CONCLUSION: RSV experience provides a robust foundation for preventing viral respiratory infections. Integrating passive and active immunization strategies, targeting conserved viral structures, and improving global access are essential to reduce the disease burden of pediatric respiratory infections.},
}
@article {pmid42597518,
year = {2026},
author = {Liu, Y and Chen, S and Wu, Y and Zhou, W and Shang, H and Chen, X and Ou, R},
title = {Isolated orofacial dystonia and facial pain as the inaugural manifestation of anti-NMDAR encephalitis: a case report and literature review.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1885984},
pmid = {42597518},
issn = {1664-3224},
mesh = {Humans ; Female ; *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/complications/drug therapy ; Adult ; *Facial Pain/etiology/diagnosis/drug therapy ; *Dystonia/etiology/diagnosis ; Immunoglobulins, Intravenous/therapeutic use ; Autoantibodies/blood/cerebrospinal fluid ; },
abstract = {Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis typically presents with psychiatric symptoms, seizures, and cognitive dysfunction. Movement disorders, when present, usually coexist with these features. We report a rare case of anti-NMDAR encephalitis in a 30-year-old female who presented with isolated left temporomandibular joint (TMJ) dystonia, jaw tremor, and facial pain as the sole manifestations for seven months, without clinically significant psychiatric, cognitive, or seizure symptoms. The patient was repeatedly misdiagnosed with TMJ disorder and muscular dysfunction before anti-NMDAR IgG antibodies were detected by cell-based assay (CBA) in serum (1:32) and cerebrospinal fluid (CSF, 1:1). First-line immunotherapy with intravenous immunoglobulin (IVIG) achieved remission. However, she relapsed five months later following COVID-19 infection, with antibody titers rising to 1:100 in both serum and CSF. High-dose corticosteroid pulse therapy and maintenance mycophenolate mofetil were administered, achieving sustained clinical improvement over four years of follow-up, although mild residual focal dystonia persisted. Whole-exome sequencing and hereditary ataxia screening excluded genetic causes. This case broadens the clinical spectrum of anti-NMDAR encephalitis and underscores the importance of early antibody testing in young patients with treatment-refractory orofacial movement disorders.},
}
@article {pmid42597676,
year = {2026},
author = {Cao, YL and Shan, J and Bao, XY and Jin, M and Huai, W and Jin, YC and Jin, YX and Zhang, ZN and Kuang, JQ},
title = {Rethinking preventive medicine education after COVID-19: bridging training gaps in public health practice.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1852914},
pmid = {42597676},
issn = {2296-858X},
abstract = {The COVID-19 pandemic exposed persistent structural weaknesses in public health systems worldwide, particularly in relation to workforce preparedness and the translation of training into practice. These shortcomings have renewed attention to the role of preventive medicine education, which is increasingly expected to respond to complex and rapidly evolving health challenges. Drawing on literature published since the COVID-19 pandemic and recent reforms in China, particularly within the framework of the "Healthy China 2030" initiative, and considering broader international developments, this mini-review examines how preventive medicine training is being reshaped. Recent shifts include a greater emphasis on competency-oriented approaches, expanded practice-based learning, and the integration of interdisciplinary perspectives. However, graduates of preventive medicine programs frequently perceived gaps between academic training and practical public health competencies, particularly in field epidemiology and emergency response preparedness. Building on these observations, we outline a forward-looking perspective that highlights the potential role of systems thinking, adaptive training models, and emerging forms of agentic learning. While these approaches appear promising, their practical implementation and long-term impact have yet to be fully established. Overall, this review seeks to contribute to ongoing discussions on how preventive medicine education can better support the development of a responsive and resilient public health workforce in the post-pandemic context.},
}
@article {pmid42597999,
year = {2026},
author = {Natarajan, C and Harshini, G and Priyadharsini, GT and Maheswaran, T and Naveenraj, NS and Venkat, M},
title = {Scope, Prospects, and Limitations of Living Systematic Reviews in Medical Literature: A Narrative Overview.},
journal = {Cureus},
volume = {18},
number = {7},
pages = {e112631},
pmid = {42597999},
issn = {2168-8184},
abstract = {Living systematic reviews (LSRs) have emerged as a response to the persistent lag between the publication of primary research and its incorporation into systematic reviews, a delay that has historically spanned several years and can render a meaningful proportion of reviews outdated within two years of publication. Since their formal introduction in 2014, LSRs have evolved from a single conceptual proposal into a maturing methodological field, supported by a dedicated PRISMA reporting extension, decision frameworks for determining when a living approach is warranted, and demonstrated applications in COVID-19 therapeutics, vaccine effectiveness, long COVID, and the development of formal clinical guidelines. Uptake accelerated markedly during the COVID-19 pandemic, and automation, ranging from human-machine collaborative workflows to large language models, has become central to sustaining the frequency of updates required by the living model, with reported gains in screening and extraction efficiency. However, methodological guidance for reporting and appraising LSRs remains underdeveloped relative to the pace of adoption, statistical methods for repeated meta-analytic updating are heterogeneous and imperfectly matched to network meta-analyses, and operational surveys consistently document inconsistent update schedules, limited communication of living status, and resource constraints that threaten their long-term sustainability. Realizing the full clinical and policy value of LSRs will require coordinated progress across methodological guidance, automation, and institutional support. Hence, this narrative review aims to examine the above concerns related to LSR.},
}
@article {pmid42598025,
year = {2026},
author = {Bashir, SG and Khalif, IA and Hubow, YA and Omar, AM and Mohamed, NO and Mohammed, AA and Mohamed, HH and Dahir, NA and Abdi, AM and Abdi, AN and Abdullahi, YB and Abdi, MS and Ahmed, NI and Abdi, YH and Abdulle, AA},
title = {Nipah virus and the lessons of COVID-19: are we prepared for the next pandemic threat?.},
journal = {Infectious medicine},
volume = {5},
number = {3},
pages = {100269},
pmid = {42598025},
issn = {2772-431X},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has exposed profound and persistent weaknesses in global preparedness, including fragmented surveillance systems, governance failures, inequitable access to countermeasures, and erosion of public trust. Although SARS-CoV-2 has dominated global attention, other high-consequence zoonotic pathogens with pandemic potential have remained comparatively neglected. Among these, the Nipah virus (NiV) represents a particularly serious threat, characterized by high case-fatality rates, zoonotic spillover from wildlife reservoirs, documented human-to-human transmission, and the absence of licensed vaccines or specific antiviral therapies. This narrative review synthesizes and contextualizes existing evidence on the NiV through the lens of lessons learned during the COVID-19 pandemic. Drawing on epidemiological data, outbreak experience, and global health policy literature, this review examines the key dimensions of preparedness, including surveillance and diagnostics, laboratory and health-system capacity, vaccine and therapeutic development, emergency governance, ethical decision-making, and the operationalization of One Health approaches, with particular attention to low- and middle-income and fragile settings. The review highlights that despite scientific advances achieved during COVID-19, preparedness for the NiV remains limited and uneven. Persistent gaps in integrated surveillance at human-animal-environment interfaces, constrained laboratory capacity, insufficient investment in countermeasures, fragmented governance, and enduring global inequities threaten timely detection and containment. The NiV should therefore be understood not as an isolated regional concern, but as a warning signal for future "Disease X" scenarios, underscoring the urgent need to translate COVID-19 lessons into sustained, equitable, and multisectoral pandemic preparedness.},
}
@article {pmid42598046,
year = {2026},
author = {Hamilton, A and Prihartono, I and Okura, Y and Rankin, N and Saiyed, S and Ratcliff, J and Oladimeji, A and Igusa, T and Gardner, L and Morgan, R},
title = {Gender-responsive infectious disease models: Guidelines and systematic scoping review.},
journal = {Dialogues in health},
volume = {9},
number = {},
pages = {100329},
pmid = {42598046},
issn = {2772-6533},
abstract = {BACKGROUND: Sex and gender influence infectious disease outcomes through biological and social mechanisms. Gender norms, roles, and behaviors affect exposure, care-seeking, and service access, yet many infectious disease models overlook these factors.<br><br>METHODS: To provide guidance to researchers considering sex/gender in epidemiological models, we propose structured guidelines for developing gender-responsive infectious disease models, adapted from an established monitoring and evaluation framework. Recommendations include: 1) using sex/gender-disaggregated or sex/gender-specific populations; 2) incorporating an additional social stratifier (e.g., age, race/ethnicity); 3) maintaining stratification in results; 4) addressing the needs, rights, and preferences of gender groups; and 5) grounding models in context with participation from target groups. To provide examples, we conducted a scoping review using these criteria, drawing from HIV, COVID-19, and malaria literature.<br><br>FINDINGS: Of 7303 studies screened, 45 met inclusion criteria. Most modeled HIV (96%), used compartmental (73%) or agent-based (22%) approaches, and included sexual orientation or occupation as an additional stratifier. Studies contextualized their models by discussing local healthcare systems, unequal access to care, stigma, gender norms in partnership dynamics, and occupational risk.<br><br>INTERPRETATION: Gender-responsive modeling is feasible but uncommon beyond sexually transmitted infections. Applying intersectional, context-specific approaches can reveal disparities and inform equitable, efficient interventions. These guidelines can be adapted to address other health disparities.},
}
@article {pmid42454876,
year = {2026},
author = {Albini, TA and Yeh, S and Regillo, CD and Schwartz, R and Ferrone, PJ and Baumal, CR and Wykoff, CC},
title = {Expert Opinion: Management of Intraocular Inflammation and Vasculitis After Intravitreal Pegcetacoplan for Geographic Atrophy.},
journal = {Ophthalmic surgery, lasers &amp; imaging retina},
volume = {57},
number = {8},
pages = {492-498},
doi = {10.3928/23258160-20260521-03},
pmid = {42454876},
issn = {2325-8179},
mesh = {Humans ; Intravitreal Injections ; *Geographic Atrophy/drug therapy ; Female ; Visual Acuity ; *Retinal Vasculitis/diagnosis/drug therapy/chemically induced ; Glucocorticoids/therapeutic use ; Aged ; *Angiogenesis Inhibitors/adverse effects ; Male ; *Vasculitis/drug therapy/diagnosis/chemically induced ; },
abstract = {BACKGROUND AND OBJECTIVE: This expert opinion review is intended to provide guidelines for diagnosis and management of intraocular inflammation (IOI) and vasculitis following pegcetacoplan.<br><br>PATIENTS AND METHODS: A case series of all post-marketing reports classified by experts as definite or suspected vasculitis over an 18-month period was assessed.<br><br>RESULTS: A total of 306,000 pegcetacoplan intravitreal injections were given in the real world between March 1, 2023, and August 31, 2024. Twenty-four eyes from 22 patients (mean age 76 years, 59% female) with definite or suspected vasculitis were evaluated. Comorbidities included hypertension (55%), hypothyroidism (27%), and recent COVID-19 infection (14%). Twelve eyes were classified as vasculitis with occlusion, seven as vasculitis without occlusion, and five as suspected vasculitis. Median time from intravitreal injection to symptoms was 10 days and 88% (n = 21) occurred after the first injection. Symptoms included reduced vision (71%), eye pain (33%), and elevated intraocular pressure (50%). All patients received corticosteroids and 29% received antibiotics. At last follow-up, six eyes recovered visual acuity to within one line of baseline, seven lost between 2 to 5 lines, and 11 lost 6 lines or more.<br><br>CONCLUSION: While IOI and vasculitis are rare, patients can be educated to call a retina specialist promptly if symptoms or any vision loss develop, especially within the 2 weeks following the first injection. In addition to excluding an infectious etiology, individualized management with multiroute corticosteroids can be considered.},
}
@article {pmid42582094,
year = {2026},
author = {Zhao, J and Chang, J and Qu, J and Li, F and Zhang, S and Yang, Y and Zhao, T},
title = {Efficacy of supplementation with nutrients and dietary supplements on recovery and inflammatory response among patients with COVID-19: a network meta-analysis.},
journal = {Frontiers in nutrition},
volume = {13},
number = {},
pages = {1825539},
pmid = {42582094},
issn = {2296-861X},
abstract = {BACKGROUND: At present, the clinical course of COVID-19 is synergistically influenced by the systemic inflammatory storm and nutritional deterioration triggered by COVID-19. Nutrition interventions have demonstrated potential clinical value.<br><br>OBJECTIVE: This study aims to systematically compare the relative efficacy of different dietary patterns and nutritional supplements on key outcomes among adult patients with COVID-19, and to identify the optimal regimen of nutrition intervention.<br><br>METHODS: PubMed, Embase, Cochrane Library, and Web of Science, were systematically searched. Randomized controlled trials (RCTs) were independently screened. The risk of bias was assessed using the Cochrane Risk of Bias 2.0 (RoB 2.0) tool. The inflammation status of patients was measured by alterations in indicators such as interleukin-6 (IL-6) and neutrophil-to-lymphocyte ratio (NLR), while recovery was evaluated based on changes in the number of patients with adverse complications, including cough and death. Statistical analysis was performed in R (version 4.5.1). A random-effects model under the Bayesian framework was adopted to pool mean differences (MDs) or risk ratios (RRs) alongside their corresponding 95% credible intervals (CrIs). Additionally, regression analyses were performed for sample size, treatment duration, and disease severity of patients. The confidence in the evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA).<br><br>RESULTS: The efficacy of interventions varied for different immune and clinical outcomes among patients with COVID-19. Compared with standard of care (SoC) alone, vitamin C&#x202f;+&#x202f;SoC significantly decreased IL-6(vitamin C&#x202f;+&#x202f;SoC vs. SoC alone: MD&#x202f;=&#x202f;-88.77, 95% CrI: -139.02, -38.66, CINeMA: low certainty). Compared with SoC, COVID-19 patients supplemented with nanocurcumin+SoC showed a significant increase in lymphocyte count (nanocurcumin + SoC vs. SoC: MD&#x202f;=&#x202f;4.76, 95% CrI: 2.91, 6.62, CINeMA: NA). In comparison with SoC, COVID-19 patients supplemented with pomegranate juice exhibited a marked increase in NLR (pomegranate juice + SoC vs. Placebo: MD&#x202f;=&#x202f;1.04, 95% CrI: 0.21, 1.88, CINeMA: very low certainty).<br><br>CONCLUSION: Compared with SoC alone, significant changes were observed in IL-6, NLR, and lymphocyte count among patients suffering from COVID-19 following supplementation with nutrients and dietary supplements.<br><br>PROSPERO (CRD420251110943).},
}
@article {pmid42584103,
year = {2026},
author = {Yang, Y and Zhao, Y},
title = {Surface-Enhanced Raman Spectroscopy for Viral Diagnostics: Principles, Strategies, Clinical Challenges, and Future Directions.},
journal = {Chemical reviews},
volume = {126},
number = {15},
pages = {8694-8742},
doi = {10.1021/acs.chemrev.6c00201},
pmid = {42584103},
issn = {1520-6890},
support = {AP230A000000C009//U.S. Department of Agriculture/ ; 2023-67015-39237//National Institute of Food and Agriculture/ ; },
mesh = {*Spectrum Analysis, Raman/methods ; Humans ; *COVID-19/diagnosis/virology ; *SARS-CoV-2/isolation &amp; purification ; *Viruses/isolation &amp; purification ; Rapid Diagnostic Tests ; },
abstract = {Viral outbreaks such as SARS-CoV, MERS-CoV, and COVID-19 underscore the urgent need for rapid, sensitive, and scalable diagnostic technologies. Current standard methods, including nucleic acid amplification tests and immunoassays, offer complementary strengths but face limitations in cost, turnaround time, and early-stage detection. Surface-enhanced Raman spectroscopy (SERS) has emerged as a promising alternative, leveraging plasmonic nanostructures to amplify weak Raman signals and provide molecular "fingerprints" of viral components with single-molecule sensitivity. This review provides a comprehensive overview of SERS-based virus detection, highlighting the fundamental principles of Raman enhancement, the role of substrates and hotspots, and analyte-specific challenges. We categorize sensing strategies into direct detection of intact viruses and components, affinity-based approaches using antibodies, aptamers, or viral receptors, and labeled methods that amplify specificity and multiplexing. Advances in nanofabrication, receptor engineering, and machine learning have significantly improved sensitivity, reproducibility, and classification accuracy, with detection limits reaching down to a few viral particles per milliliter. Despite these advances, challenges remain in handling biological complexity, ensuring reproducibility, and translating assays into clinical practice. We conclude by outlining opportunities for integrating SERS with portable devices, standardized spectral libraries, and artificial intelligence, paving the way toward rapid, robust, and deployable viral diagnostics for future pandemic preparedness.},
}
@article {pmid42585098,
year = {2026},
author = {Bayat, A and Pavakopethan, A and Kashmar, N and Yousuf, I and Saab, A and Salem Sokhn, E and El-Lahib, Y and El Morr, C},
title = {AI-based epidemic early warning using social media and search engine signals: A scoping review.},
journal = {Health informatics journal},
volume = {32},
number = {3},
pages = {14604582261479106},
doi = {10.1177/14604582261479106},
pmid = {42585098},
issn = {1741-2811},
mesh = {Humans ; *Artificial Intelligence/trends ; *Social Media/statistics &amp; numerical data ; *Search Engine/methods ; Disease Outbreaks/prevention &amp; control ; COVID-19/epidemiology ; Digital Media ; },
abstract = {BackgroundEarly detection of infectious disease outbreaks is essential for timely public health response. Artificial intelligence (AI) combined with digital traces from social media and search engines may strengthen epidemic early warning systems (EWS).ObjectiveTo map how AI-based EWS use social media and search engine signals for outbreak detection/forecasting, and to characterize whether studies integrate clinical and climate/environmental data.MethodsFollowing PRISMA-ScR, we reviewed 38 studies (past five years) across six databases. We extracted study characteristics, data sources, target diseases, prediction tasks, validation practices, and performance metrics. For cross-tabulated evidence maps, each study was coded once using its primary data-source category and primary modeling approach to avoid double-counting.ResultsDeep learning and ensemble approaches were the most common methods. COVID-19 and influenza-like illness dominated the literature. Few studies combined social media and search engine signals. Clinical and climate/environmental data were rarely integrated. No study reported prospective, real-time evaluation. Geographic coverage was skewed toward high-income settings.ConclusionAI-based epidemic early warning systems using digital signals show promise for outbreak detection and forecasting. However, the evidence remains largely retrospective, fragmented, and geographically uneven. Future research should prioritize multi-stream data integration, equity-aware design, and prospective validation to support real-world global applicability.},
}
@article {pmid42585558,
year = {2026},
author = {Huang, S and Zhang, M and Ruan, C and Song, Y and Hu, X and Liu, N and Ye, J and Chen, D and Zhang, Y and Zhou, J and Li, Q and Wang, L and Shi, X and Yu, W and Luo, S},
title = {Determinants and mitigation strategies of vaccine hesitancy toward routine immunisations recommended for older adults: a systematic review.},
journal = {Age and ageing},
volume = {55},
number = {8},
pages = {},
doi = {10.1093/ageing/afag233},
pmid = {42585558},
issn = {1468-2834},
mesh = {Humans ; *Vaccination Hesitancy/psychology ; Aged ; *Vaccination/psychology ; Health Knowledge, Attitudes, Practice ; *COVID-19/prevention &amp; control/epidemiology ; },
abstract = {BACKGROUND: Vaccine hesitancy among older adults has increasingly raised public concern and warrants global actions in the post-COVID-19 era. This systematic review aimed to synthesise determinants of vaccine hesitancy and related mitigation strategies toward routine vaccinations recommended for older adults (influenza, pneumococcal and shingles vaccines), which is important for promoting healthy ageing and fighting against infectious diseases during both pandemic and non-pandemic periods.<br><br>METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic literature search was conducted between November 2024 and June 2025 across Web of Science, PubMed and MEDLINE. The data were analysed by narrative synthesis guided by two theoretical frameworks.<br><br>RESULTS: A total of 72 studies were included. Most of them were conducted in developed countries, with a surge since the COVID-19 pandemic. Determinants of vaccine hesitancy were summarised from 49 studies into 3 levels, 8 themes and 24 sub-themes: individual level (sociodemographics, personal perceptions, previous experiences), group and social level (interpersonal influence, community influence, media/cultural influence) and practical issues level (willingness to pay, convenience of access). The intervention strategies were categorised from 23 studies into five types, including dialogue-based intervention, reminder/recall-based intervention, incentive-based intervention, passive intervention and multi-component intervention. Notably, this review identified a lack of conceptual clarity in distinguishing vaccine hesitancy from actual vaccination behaviours and a shortage of comprehensive interventions tailored to older adults.<br><br>CONCLUSION: Vaccine hesitancy toward routine immunisations among older adults is driven by multilayer determinants, underscoring the need for comprehensive, theory-informed and tailored interventions that address the diverse determinants.},
}
@article {pmid42585811,
year = {2026},
author = {Koonin, LM and Velez, SD and Bresee, JS},
title = {Expanding adult immunization in low- and middle-income countries through pharmacist-provided vaccination.},
journal = {Vaccine},
volume = {90},
number = {},
pages = {129004},
doi = {10.1016/j.vaccine.2026.129004},
pmid = {42585811},
issn = {1873-2518},
abstract = {Adult immunization is increasingly recognized as an essential component of life-course vaccination strategies that improve population health, promote healthy aging, and strengthen pandemic preparedness. Despite recommendations from the World Health Organization (WHO) to expand seasonal influenza vaccination and other adult immunization programs, vaccine coverage among adults in low- and middle-income countries (LMICs) remains substantially below global targets. This shortfall is largely due to insufficient healthcare infrastructure, shortages of trained immunization providers, inadequate financing, and barriers to accessing healthcare services. Community pharmacists represent an underutilized health workforce that could substantially expand adult vaccination capacity in many LMICs. Evidence from high-income countries consistently demonstrates that pharmacist-provided vaccination improves vaccine uptake, expands access, and reduces pressure on overstretched healthcare systems. Emerging evidence from LMICs similarly suggests that pharmacist-provided vaccination is feasible, acceptable, and supported by pharmacists when appropriate regulatory frameworks, training, and operational systems are established. Pharmacists played a critical role during the COVID-19 pandemic by expanding access to vaccination, testing, treatment, and public health education, demonstrating their value as health system force multipliers during public health emergencies. This review synthesizes current evidence supporting pharmacist-provided vaccination for adults in LMICs, summarizes emerging implementation experience, and discusses policy, regulatory, workforce, and operational considerations for integrating pharmacists into national immunization programs. Expanding pharmacists' role in vaccine delivery represents a practical, scalable strategy for improving adult vaccination coverage, advancing life-course immunization, and strengthening preparedness for future epidemics and pandemics.},
}
@article {pmid42587639,
year = {2026},
author = {Hetta, HF and Ahmed, R and Haseeb, A and Bukhari, SQ and Alatawi, Z and Mahrous, AJ and Elrggal, ME and Masri, MA and Kotb, AA},
title = {SARS-CoV-2 Point-of-Care Testing Modalities: Integrating Molecular, Immunological, Biosensor, and AI Approaches.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {15},
pages = {},
doi = {10.3390/diagnostics16152402},
pmid = {42587639},
issn = {2075-4418},
support = {26UQU4320605GSSR03//Umm al-Qura University/ ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic highlighted the critical need for rapid, accessible, and accurate diagnostic tools to support timely clinical decision-making, outbreak control, and public health surveillance. Point-of-care testing (POCT) has emerged as an essential component of decentralized healthcare by enabling diagnostic testing outside conventional laboratory settings. This review was based on a structured literature search of PubMed, Scopus, and Web of Science databases covering studies published between January 2020 and January 2026. The review evaluates current advances in COVID-19 POCT technologies, including molecular assays, antigen-based tests, antibody-based assays, biosensor platforms, and artificial intelligence (AI)-assisted diagnostic approaches. Molecular POCT methods, including rapid reverse transcription polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), and CRISPR-based technologies, provide high analytical sensitivity and specificity and are increasingly suitable for decentralized diagnostic applications. Antigen-based assays offer rapid and cost-effective screening solutions, although diagnostic performance may vary depending on viral load, symptom onset, and circulating variants. Antibody-based POCT remains valuable for seroprevalence studies, retrospective diagnosis, and immune-response monitoring rather than acute infection detection. Emerging biosensor technologies and AI-enabled diagnostic systems demonstrate promising analytical capabilities and operational advantages; however, many remain at the prototype or early-validation stage and require further clinical evaluation before widespread implementation. The findings indicate that no single POCT modality is optimal for all clinical scenarios. Instead, molecular, antigen, antibody, biosensor, and AI-assisted approaches provide complementary strengths that support different diagnostic and public health objectives. Continued advances in assay design, digital connectivity, multiplex testing, and variant-resilient detection strategies are expected to further enhance the role of POCT in COVID-19 management and future infectious disease preparedness.},
}
@article {pmid42588324,
year = {2026},
author = {Donisa, E and Roșu, ST and Roșu, VE and Cărăușu, EM},
title = {Global Trends, Inequalities, and Citation Dynamics in Burnout Research Among Healthcare Professionals: A Bibliometric Analysis (1987-2024).},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {15},
pages = {},
doi = {10.3390/healthcare14152356},
pmid = {42588324},
issn = {2227-9032},
abstract = {Background/Objectives: Burnout among healthcare professionals has emerged as a major occupational and organizational challenge with important implications for workforce sustainability, patient safety, and healthcare system performance. Although the scientific literature on burnout has expanded substantially, an integrated understanding of its global development, research structure, and scientific impact remains limited. This study aimed to examine the evolution, thematic development, and citation dynamics of burnout research among healthcare professionals through an integrated bibliometric approach combining science mapping, multilevel citation modelling, and critical literature synthesis. Methods: A bibliometric analysis was conducted using publications indexed in the Web of Science Core Collection between 1987 and 2024. Science mapping techniques were applied using Bibliometrix and VOSviewer to evaluate publication trends, collaboration networks, thematic development, and citation patterns. In addition, a multilevel negative binomial regression model was used to identify publication characteristics associated with citation impact. Results: A total of 1232 publications were included in the analysis. Scientific production increased markedly after 2020, temporally coinciding with the COVID-19 pandemic and growing scientific interest in healthcare workforce wellbeing. Research output was concentrated in high-income countries, particularly the United States, China, the United Kingdom, Canada, and Australia. Physicians and nurses dominated the literature, while non-clinical healthcare workers remained underrepresented. The thematic analysis indicated an increasing emphasis on organizational and system-level determinants of burnout alongside the continued presence of individual-centered perspectives. The multilevel negative binomial model identified longer title length and a greater number of author-provided keywords as being associated with lower expected citation counts, whereas a greater number of Keywords Plus terms was associated with higher expected citation counts. Conclusions: Burnout research has evolved into a rapidly expanding and increasingly interdisciplinary field. However, important gaps persist regarding geographic representation, workforce diversity, methodological standardization, and organizational intervention research. Future studies should move beyond descriptive approaches and further evaluate organizational interventions and workforce-related strategies to strengthen the evidence base that may inform healthcare policy and organizational practice.},
}
@article {pmid42588503,
year = {2026},
author = {Bai, X and Ye, B and Gao, S and Zhan, P and Liu, X},
title = {Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {15},
pages = {},
doi = {10.3390/molecules31152655},
pmid = {42588503},
issn = {1420-3049},
mesh = {Humans ; *Drug Resistance, Viral/genetics/drug effects ; *Antiviral Agents/pharmacology/chemistry/therapeutic use ; *SARS-CoV-2/drug effects/genetics ; Drug Design ; Mutation ; Coronavirus 3C Proteases/genetics/chemistry/antagonists &amp; inhibitors ; Viral Nonstructural Proteins/genetics/chemistry/antagonists &amp; inhibitors/metabolism ; Exoribonucleases/metabolism/genetics ; COVID-19 Drug Treatment ; *Betacoronavirus/drug effects ; },
abstract = {Antiviral drug resistance in SARS-CoV-2 is increasingly limiting treatment efficacy. Four recent studies have revealed two key resistance mechanisms: (1) Mutations in the main protease (M[pro])-including E166V, E166A, and S144-series variants-disrupt drug binding or active-site conformation, reducing nirmatrelvir efficacy. (2) The proofreading exoribonuclease (ExoN) removes incorporated nucleoside analogues (e.g., bemnifosbuvir, sofosbuvir), conferring resistance. Guided by structural and pharmacological insights, three effective countermeasures have been established: structure-based optimization of M[pro] inhibitors, rational design of ExoN-evading nucleoside analogues, and synergistic combination therapies. These advances provide a solid framework for developing next-generation antivirals to combat emerging resistant SARS-CoV-2 variants.},
}
@article {pmid42589418,
year = {2026},
author = {Łętocha, A and Miastkowska, M and Sikora, E},
title = {Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.},
journal = {International journal of molecular sciences},
volume = {27},
number = {15},
pages = {},
doi = {10.3390/ijms27156763},
pmid = {42589418},
issn = {1422-0067},
mesh = {Humans ; *Skin Microbiome ; *Dysbiosis/microbiology/therapy ; Probiotics/therapeutic use ; Prebiotics/administration &amp; dosage ; *Skin Diseases/microbiology/therapy ; Animals ; *Skin/microbiology ; COVID-19 ; Microbiota ; },
abstract = {The skin functions primarily as a protective physical shield, defending the body against harmful external factors such as invading microorganisms and toxic agents. When this barrier becomes impaired and skin microbiome homeostasis is disturbed, exacerbation of chronic skin diseases may occur, including atopic dermatitis, psoriasis, and acne. This issue became particularly important during the coronavirus pandemic, when it turned out that handwashing and disinfection removed not only impurities and pathogenic microorganisms but also beneficial components of the skin microbiome. This review provides a critical overview of recent advances in understanding the skin microbiome and its influence on skin health, as well as supportive therapies for the treatment of dermatoses. Contemporary therapeutic approaches focus not only on suppressing inflammatory symptoms but also on modulating the skin microbiome as part of a causal treatment strategy, in which prebiotics and probiotics play a significant role. Moreover, probiotics are also considered a valuable component of anti-aging approaches, as they may help counteract the detrimental effects of ultraviolet (UV) radiation on the skin. By reducing oxidative stress, strengthening the epidermal barrier, and exerting immunomodulatory effects, they may complement traditional photoprotection methods. Nevertheless, further research-particularly into their long-term efficacy and safety-is essential to support their broader clinical and consumer application.},
}
@article {pmid42589484,
year = {2026},
author = {Mitev, V},
title = {Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza.},
journal = {International journal of molecular sciences},
volume = {27},
number = {15},
pages = {},
doi = {10.3390/ijms27156827},
pmid = {42589484},
issn = {1422-0067},
support = {BG-RRP-2.004-0004-C01//Bulgarian National Science Fund/ ; },
mesh = {Humans ; *Colchicine/therapeutic use/pharmacokinetics/pharmacology/adverse effects/administration &amp; dosage ; *NLR Family, Pyrin Domain-Containing 3 Protein/antagonists &amp; inhibitors/metabolism ; *Inflammasomes/metabolism/antagonists &amp; inhibitors ; COVID-19 ; *Influenza, Human/drug therapy/immunology ; SARS-CoV-2 ; COVID-19 Drug Treatment ; *Coronavirus Infections/drug therapy/immunology ; *Pneumonia, Viral/drug therapy/immunology ; Animals ; Pandemics ; Betacoronavirus ; Cytokine Release Syndrome ; },
abstract = {Coronavirus disease 2019 (COVID-19) and influenza share key pathogenic mechanisms, including viral invasion, dysregulated innate immune activation, and the development of severe systemic complications. A central mediator of disease progression in both infections is the hyperactivation of the NLRP3 inflammasome, which drives excessive production of pro-inflammatory cytokines, immunothrombosis, multiorgan injury, and increased mortality. Colchicine possesses a unique pharmacokinetic property of preferential accumulation within myeloid cells, where sufficiently high intracellular concentrations inhibit NLRP3 inflammasome activation. This mechanism provides a biological rationale for preventing the cytokine storm and its downstream consequences when colchicine is administered early during infection. Available pharmacokinetic, toxicological, and clinical evidence suggests that loading doses of colchicine up to approximately 0.05 mg/kg body weight can be administered safely in appropriately selected patients, provided that clinically significant drug-drug interactions and hepatic or renal impairment are carefully excluded. The widely accepted belief that total doses of 7-7.5 mg are inherently lethal appears to reflect historical cases complicated by drug interactions and/or hepatic or renal impairment, rather than toxicity attributable to colchicine dose alone. These observations support reconsideration of current guideline recommendations regarding colchicine dosing. In particular, cumulative doses below 0.1 mg/kg appear to be consistently safe, whereas doses between 0.1 and 0.2 mg/kg are associated with only a low risk of toxicity and rarely with severe intoxication. Reassessment of colchicine dosing strategies may therefore be warranted to optimize NLRP3 inflammasome inhibition and improve outcomes in patients with COVID-19 and influenza.},
}
@article {pmid42589551,
year = {2026},
author = {Marek-Józefowicz, L and Borkowska, A and Nedoszytko, B and Cubała, WJ and Purzycka-Bohdan, D and Bohdan, M},
title = {Neurodegenerative and Cognitive Consequences of Long COVID.},
journal = {International journal of molecular sciences},
volume = {27},
number = {15},
pages = {},
doi = {10.3390/ijms27156897},
pmid = {42589551},
issn = {1422-0067},
mesh = {Humans ; *COVID-19/complications/pathology/virology ; *Neurodegenerative Diseases/etiology/virology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2/isolation &amp; purification ; *Cognitive Dysfunction/etiology/virology ; Blood-Brain Barrier ; },
abstract = {The SARS-CoV-2 virus has infected approximately 778 million people worldwide since the pandemic. Patients who have survived coronavirus disease (COVID-19) may experience long-term symptoms related to cognitive deficits, mood changes, and depressive disorders. The mechanisms underlying the long-term effects of COVID-19 on the brain are being actively investigated. SARS-CoV-2 infection triggers various mechanisms, such as hyperstimulation of the immune response, which may lead to changes in the central nervous system. In this article, we review the evidence linking COVID-19 to neurodegenerative disorders and cognitive impairment. Current research indicates that patients with pre-existing cognitive and neuropsychiatric deficits have a poorer prognosis after SARS-CoV-2 infection, and patients who have survived COVID-19 may be at increased risk of developing dementia and mood disorders. We analyse the available evidence regarding SARS-CoV-2 brain infection, induction of inflammation, coagulopathy, and blood-brain barrier (BBB) dysfunction as possible mechanisms underlying the disorders in the acute phase of COVID-19 disease and contributing to the development of neurodegenerative disorders in long COVID. Viral infection can trigger inflammation of the central nervous system (CNS), leading to damage and contributing to the development of cognitive dysfunction.},
}
@article {pmid42591297,
year = {2026},
author = {Luque-Bolivar, A and Ruiz-Araujo, K and Aristizábal-Pachón, AF and González, J},
title = {Integrated meta-analysis of human astrocytes transcriptomes reveals a candidate recurrent inflammatory signature in response to inflammatory and immune stimuli.},
journal = {Frontiers in cellular neuroscience},
volume = {20},
number = {},
pages = {1870142},
pmid = {42591297},
issn = {1662-5102},
abstract = {Astrocytes are key regulators of inflammatory and immune responses in the central nervous system, particularly under pathological conditions. We conducted a systematic search of the NCBI GEO and ENA databases to identify transcriptomic studies of stimulated astrocytes. This meta-analysis integrates 11 RNA-Seq datasets, encompassing a total of 153 samples (91 stimulated, and 62 controls) exposed to pro-inflammatory stimuli such as cytokines (TNF-α, IL-6, and IL-1β), palmitic acid, and pathogens like SARS-CoV-2 and Borrelia burgdorferi. Through robust rank aggregation (RRA), we identified 130 differentially expressed genes (DEGs), including 125 upregulated and 5 downregulated. Functional enrichment analyses revealed that these DEGs are primarily involved in immune and inflammatory pathways, such as cytokine signaling, interferon responses, and NF-κB activation. Network analysis revealed five hub nodes, CXCL10, DDX58, IFIH1, IL-1β, and TLR3, underscoring their importance in astrocytic inflammatory signaling. These findings emphasize the ability of astrocytes to act as immunocompetent cells that coordinate inflammatory responses through mechanisms such as the NOD-like receptor and NF-κB pathways. Although chronic activation of NF-κB has been linked to inflammation, this pathway also plays essential roles in synaptic plasticity. Moreover, the consistent upregulation of DDX58 and IFIH1 across varied inflammatory stimuli suggests that astrocytes transition into a common 'reactive' state that may contribute to chronic neuroinflammation. This study identifies a candidate gene signature and underscores the dual protective and pathological roles of astrocytes in inflammatory processes.},
}
@article {pmid42592512,
year = {2026},
author = {Patel, R and Nguyen, AT and Malone, J and Aguirre, JE and Gopalakrishna, H},
title = {Secondary sclerosing cholangitis: contemporary etiologies, diagnostic pathways, and treatment strategies for clinicians: a narrative review.},
journal = {Translational gastroenterology and hepatology},
volume = {11},
number = {},
pages = {92},
pmid = {42592512},
issn = {2415-1289},
abstract = {BACKGROUND AND OBJECTIVE: Secondary sclerosing cholangitis (SSC) comprises a heterogeneous group of identifiable etiologies causing inflammation and fibrosis of the bile ducts. Given that SSC often progresses more rapidly than primary sclerosing cholangitis and treatment is frequently etiology-directed, early recognition is critical. In this narrative review, we summarize contemporary causes of SSC and propose a diagnostic and management approach for clinicians.<br><br>METHODS: We performed a narrative literature review using PubMed search with medical subject headings (MeSH) and free text terms for SSC and key etiologies, including critical illness/ischemic cholangiopathy, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), infectious, coronavirus disease 2019 (COVID-19)-associated cholangiopathy, immunoglobulin G4 (IgG4)-related/eosinophilic cholangitis, drug-induced cholangiopathy, including immune checkpoint inhibitors and ketamine, malignancy-associated, and post-procedural ischemic injury. The search included randomized trials, observation studies, case reports, case series, and practice guidelines. Two reviewers independently screened studies, reviewed full texts, and synthesized findings by etiology.<br><br>KEY CONTENT AND FINDINGS: SSC following ischemic injury in critically ill patients (SSC-CIP) accounted for a significant portion of the recent literature, which presents with persistent cholestatic liver injury after intensive care unit (ICU) recovery. Infectious causes include recurrent pyogenic cholangitis, parasitic disease, HIV-related, and, most notably, given the recent pandemic, post-COVID-19 cholangiopathy. Infectious etiologies mirror SSC-CIP and may often progress to liver failure. Immune-related SSC [IgG4-related sclerosing cholangitis (IgG4-SC) and eosinophilic cholangitis] requires targeted serologies, tissue confirmation with biopsy, and typically responds briskly to corticosteroids. Drug-induced SSC is increasingly linked to immune checkpoint inhibitors, given their rise in use, as well as ketamine, and may be steroid refractory. SSC associated with malignancy requires cross-sectional imaging and tissue diagnosis. Endoscopic therapy may palliate obstruction, but liver transplantation is the definitive option for advanced disease.<br><br>CONCLUSIONS: Given its diverse etiologies, SSC requires a structured evaluation that integrates exposure history, laboratory investigations, magnetic resonance cholangiopancreatography (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) patterns, and histology for diagnosis. Etiology-specific therapy may slow progression, but early transplant referral is critical for rapidly progressive phenotypes.},
}
@article {pmid42592525,
year = {2026},
author = {Roy, A and Yang, Y and Du, L},
title = {Nanobodies targeting SARS-CoV-2 variants.},
journal = {Acta pharmaceutica Sinica. B},
volume = {16},
number = {8},
pages = {4978-4997},
pmid = {42592525},
issn = {2211-3835},
abstract = {Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a beta-coronavirus, caused the recent global Coronavirus Disease 2019 (COVID-19) pandemic. Among the virus-encoded proteins, the surface spike (S) protein is critical for viral entry, membrane fusion, and pathogenesis, and its receptor-binding domain (RBD) initiates viral entry by binding to a cellular receptor. This makes the S an important therapeutic target for COVID-19. SARS-CoV-2 mutates frequently, giving rise to five major variants of concern, among which the Omicron variant and its subvariants are less sensitive to current therapeutic antibodies. The first part of this review describes the main protein constituents of SARS-CoV-2 and their functions, the S protein-mediated viral entry and fusion processes, and the main SARS-CoV-2 variants. Nanobodies are single-domain antibodies with high target-binding affinity, strong stability, and low production costs, whose small size facilitates their access to protein regions that are inaccessible to conventional antibodies. Thus, in the second part, we comprehensively review SARS-CoV-2-targeting nanobodies, including those that bind specifically to the RBDs of the S proteins, non-RBD S proteins, and non-S proteins of variants and subvariants of SARS-CoV-2, with the hope that this information will be valuable for the generation of novel SARS-CoV-2-targeting nanobodies with improved potency against COVID-19.},
}
@article {pmid42592984,
year = {2026},
author = {Doka, G and Aliçka, Y and Tahiraj, D and Elezi, B and Gega, V and Sula, E},
title = {The role of telehealth in autism spectrum disorder management: a scoping review.},
journal = {Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina},
volume = {23},
number = {2},
pages = {},
doi = {10.17392/medglas-2179-23-2},
pmid = {42592984},
issn = {1840-2445},
mesh = {Humans ; *Telemedicine ; *Autism Spectrum Disorder/therapy/diagnosis ; Digital Health ; },
abstract = {AIM: To map and summarise evidence on the role, benefits and challenges of telehealth in autism spectrum disorder (ASD) management, including assessment and intervention.<br><br>METHODS: This scoping review searched PubMed and Scopus for English-language studies published from 2015 to 2025; the search was last updated on 14 April 2026. Nine studies met the eligibility criteria, comprising randomised controlled trials and observational, mixed-methods, descriptive, pilot, and qualitative studies.<br><br>RESULTS: Available findings suggest that telehealth-based assessment may achieve high diagnostic concordance with in-person evaluation, and that telehealth-delivered interventions may yield similar outcomes in selected domains. Several studies reported high caregiver and clinician satisfaction. Key challenges included technological access barriers, variability in caregiver engagement, and concerns regarding reliability and equity in under-resourced settings.<br><br>CONCLUSION: Telehealth may be a valuable complement to, rather than a replacement for, in-person care. Future primary studies should use rigorous designs and standardised outcome measures and should prioritise linguistically diverse and low-resource populations; future evidence syntheses should include formal risk-of-bias assessment.},
}
@article {pmid42593075,
year = {2026},
author = {Pfefferbaum, B and Newman, E and Nitiema, P and Slaughter, A},
title = {Practice Elements in Targeted and Universal Child Mass Trauma Interventions.},
journal = {Trauma, violence &amp; abuse},
volume = {},
number = {},
pages = {15248380261473929},
doi = {10.1177/15248380261473929},
pmid = {42593075},
issn = {1552-8324},
abstract = {Many child mass trauma interventions are a composite of multiple practice elements which commonly are not well identified or assessed in the treatment outcome research. Understanding the practice elements used for targeted (samples of children with direct exposure, intense experiences, and/or serious reactions) and universal (general samples without consideration of exposure or reactions) populations can help clarify future directions for intervention development and delivery. A systematic review of 84 randomized controlled trials (RCTs) and cluster RCTs identified 131 psychosocial interventions addressing mass trauma. The current analysis compared frequently used elements delivered to targeted and universal populations and examined the populations served across context (country income), event types (including the COVID-19 epidemic), delivery modes, and delivery settings. Reflecting the importance of accessible interventions for those with the greatest need, most child mass trauma interventions overall were administered to targeted populations in group applications delivered in schools or other community settings. Psychoeducation for the child, affect modulation, and relaxation were the most frequently offered elements for both targeted and universal populations. Exposure, narrative, and psychoeducation for the caregiver were administered more often in targeted than universal populations while social skills training, mindfulness, self-praise, and communication skills training were administered more often in universal populations. Future evaluation research should identify, describe, and evaluate specific practice elements included in interventions in the two populations and should address concerns related to certain groups of children receiving interventions and to aspects of intervention delivery.},
}
@article {pmid42593538,
year = {2026},
author = {Daoud, T and Villar, J and Annane, D},
title = {Corticosteroids in ARDS: old controversies, new insights, and future directions.},
journal = {Intensive care medicine},
volume = {},
number = {},
pages = {},
pmid = {42593538},
issn = {1432-1238},
support = {ANR-18-RHUS-0004//Agence Nationale de la Recherche/ ; ANR-23-IAHU-0004//Agence Nationale de la Recherche/ ; iRECORDS JTC_2021//EraPerMed/ ; },
abstract = {Corticosteroids modulate key inflammatory and fibroproliferative pathways involved in ARDS through genomic and non-genomic glucocorticoid receptor signaling. Advances in ARDS pathophysiology have highlighted the importance of timing, inflammatory burden, and host response in determining treatment efficacy. Clinical evidence supports corticosteroid use in moderate-to-severe ARDS, particularly in COVID-19 ARDS and severe community-acquired pneumonia, with reductions in mortality and duration of mechanical ventilation. However, treatment effects remain heterogeneous across etiologies and biological subphenotypes. Recent identification of hyperinflammatory and hypoinflammatory ARDS phenotypes suggests that corticosteroid responsiveness is not uniform. Hyperinflammatory phenotypes and septic ARDS appear more likely to benefit, whereas evidence remains limited or conflicting in influenza-associated and non-septic ARDS. Long-term effects and adverse outcomes, including metabolic complications and ICU-acquired weakness, remain insufficiently characterized. Future research is increasingly focused on precision medicine approaches integrating biomarkers, adaptive platform trials, and phenotype-guided strategies. Emerging developments include lung-targeted corticosteroid delivery systems and selective glucocorticoid receptor modulators designed to improve efficacy while reducing systemic toxicity. Corticosteroids should therefore be considered a context-dependent therapy whose benefit is influenced by etiology, disease stage, inflammatory phenotype, and timing of administration.},
}
@article {pmid41623157,
year = {2026},
author = {Klimek, L and Mullol, J and Hummel, T and Del Giacco, S and Georgalas, C and Rondon, C and Schiappoli, M and Gevaert, P and Bozkurt, B and Chaker, A and Reitsma, S and van Gerven, L and Maza-Solano, J and Lundberg, M and Becker, S and Bärhold, F and Karavelia, A and Cuevas, M and Gröger, M and Huber, P and Arasi, S and Cingi, C and Rojas-Lechuga, MJ and Izquierdo-Domínguez, A and Agache, I and Gawlik, R and Sokolowska, M and Adcock, I and Celik, G and Escribese, M and Walusiak-Skorupa, J and Betz, C and Palomares, O and Moreira, A and Bonadonna, P and Shamji, M and Torres Jaen, MJ and Akdis, CA and Hagemann, J and Hox, V and Toppila-Salmi, S},
title = {The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.},
journal = {Allergy},
volume = {81},
number = {8},
pages = {2633-2655},
pmid = {41623157},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology/ ; },
mesh = {Humans ; *Olfaction Disorders/diagnosis/etiology/epidemiology ; COVID-19 ; SARS-CoV-2 ; Smell ; Anosmia/diagnosis ; *Respiratory Tract Infections/complications ; Pandemics ; },
abstract = {The sense of smell, with its extensive evolutionary history, is highly prone to disorders that can have a profound impact on daily life. Anosmia affects approximately 5% of the population, with an additional 15% exhibiting reduced olfactory function. The prevalence of olfactory dysfunction (OD) varies by population and age group, and standardized testing reveals a broad range of impacts. OD includes various causes, most commonly aging, inflammation of the olfactory epithelium, upper respiratory tract infections (URTI), traumatic brain injury, and neurological conditions. The recent COVID-19 pandemic has highlighted the association between viral infections and olfactory dysfunction, with severe hyposmia/anosmia being an early marker of infection. Despite its importance, the assessment of olfactory function remains inconsistent across clinical practices. Psychophysical smell tests, while vital for diagnosis and patient management, are underutilized, especially outside of specialized centers. Standardized testing methods are crucial for objective diagnosis, but significant challenges, including test variability, lack of comparability, and healthcare reimbursement issues, persist. The European Academy of Allergy and Immunology (EAACI) advocates for improvements in the quality and standardization of chemosensory assessments. Future efforts must prioritize education, incentives for better testing, and the integration of digital tools to expand access to olfactory testing and diagnosis in remote or quarantine situations. However, office-based testing remains irreplaceable, even with advancements in telemedicine.},
}
@article {pmid41823158,
year = {2026},
author = {Batarfi, M and Alraddadi, A},
title = {Adaptations and innovations in histology and embryology education during the COVID-19 pandemic: a systematic review.},
journal = {Folia morphologica},
volume = {85},
number = {},
pages = {e01726122},
doi = {10.5603/fm.106914},
pmid = {41823158},
issn = {1644-3284},
mesh = {*Embryology/education ; *COVID-19/epidemiology ; Humans ; *Education, Distance ; *Histology/education ; *Pandemics ; SARS-CoV-2 ; *Coronavirus Infections/epidemiology ; },
abstract = {BACKGROUND: As an alternative to traditional teaching, online education enabled the continuity of histology and embryology learning during the COVID-19 pandemic. This systematic review explores the new tools adopted for histology and embryology education during the pandemic and examines students' perceptions, acceptance, and engagement with e-learning.<br><br>MATERIALS AND METHODS: This systematic review followed the PRISMA guidelines by searching six databases: PubMed, Cochrane Reviews, MEDLINE, Web of Science, Scopus, and Google Scholar. We used the Joanna Briggs Institute (JBI) Critical Appraisal Checklist to assess the quality of the included studies.<br><br>RESULTS: Of the 338 studies initially identified, 26 met the inclusion criteria. Most studies reported positive perceptions, with the availability of technology, the pedagogical setup of the online course, and schedule autonomy being the most common reasons. However, the negative views identified concerned limited face-to-face interaction with instructors, interruptions in internet connectivity, and technical issues. Students' perception, acceptance, attendance, and engagement in online education were favorable, as reflected in positive findings on their performance.<br><br>CONCLUSIONS: Overall, students' perception of online histology and embryology courses during the COVID-19 lockdown was positive, with some areas identified for further improvement. Additional research is needed to assess educators' perceptions of histology and embryology education during the pandemic.},
}
@article {pmid42320559,
year = {2026},
author = {Thomas, N and Huang, K and Schneider-Futschik, EK and Pollack, B and Tal, MC and Fineberg, D and Wang, X and Gurvich, C and Pretorius, R and Bergquist, J and Armstrong, CW},
title = {Systems neuroendocrinology in ME/CFS and long COVID: a chronobiological framework for hormone-based research.},
journal = {Frontiers in neuroendocrinology},
volume = {82},
number = {},
pages = {101268},
doi = {10.1016/j.yfrne.2026.101268},
pmid = {42320559},
issn = {1095-6808},
mesh = {Humans ; Post-Acute COVID-19 Syndrome ; *Circadian Rhythm/physiology ; *Fatigue Syndrome, Chronic/physiopathology/metabolism ; Neuroendocrinology ; Female ; *Neurosecretory Systems/physiopathology/metabolism ; *Hypothalamo-Hypophyseal System/physiopathology/metabolism ; *Hormones/metabolism ; Hypothalamic-Pituitary-Gonadal Axis ; Menstrual Cycle/physiology ; },
abstract = {Hormonal dysregulation is increasingly reported in ME/CFS and Long COVID, yet the broader role of neuroendocrine disruption in these conditions remains underexplored. While changes in steroid, peptide, and neuropeptide hormones have been identified, these findings are often considered in isolation and without attention to their timing or integration within broader physiological systems. The hypothalamic-pituitary axes regulate endocrine, immune, autonomic, nervous, and metabolic functions, systems commonly affected in both conditions, yet their circadian and menstrual dynamics are rarely investigated. In this review, we examine the evidence for neuroendocrine dysfunction in ME/CFS and Long COVID, focusing on hormone output, functional assays, receptor expression, and the coordination of endocrine biorhythms. Sex hormone signalling emerges as a key area of vulnerability, particularly given the female predominance in both conditions and the complexity of reproductive hormone regulation. We argue that accurate hormone measurement and time-structured sampling, including circadian and menstrual rhythms, are essential for detecting meaningful biological differences. By embedding chronobiology-aware, dense-sampling strategies and integrating multi-omic analyses into multi-system study designs, we outline a framework for investigating dynamic endocrine mechanisms underlying symptom variability and multisystem dysfunction, which may ultimately support the development of more targeted, personalised interventions.},
}
@article {pmid42335758,
year = {2026},
author = {Liu, Z and Wang, X and Hu, Y and Duan, X and Xu, S and Ge, Q and Zhu, W and Zhao, J and Yao, Y and Wang, W},
title = {Burden of infection and hospitalization from respiratory syncytial virus-associated acute lower respiratory tract infections in Chinese children: Modeling of national, regional, and provincial estimates.},
journal = {Vaccine},
volume = {88},
number = {},
pages = {128875},
doi = {10.1016/j.vaccine.2026.128875},
pmid = {42335758},
issn = {1873-2518},
mesh = {Child, Preschool ; Humans ; Infant ; Infant, Newborn ; China/epidemiology ; Cost of Illness ; COVID-19/epidemiology ; *Hospitalization/statistics &amp; numerical data ; Incidence ; *Respiratory Syncytial Virus Infections/epidemiology ; Respiratory Syncytial Virus, Human ; *Respiratory Tract Infections/epidemiology/virology ; Risk Factors ; Seasons ; },
abstract = {BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infections (ALRIs) in children. To guide policymaking on controlling RSV-associated ALRIs (RSV-ALRIs) in China, we estimated the national, regional, and provincial burdens of RSV-ALRIs and associated hospitalizations for children under 5 years old.<br><br>METHODS: We systematically identified publications about RSV-ALRIs in China with epidemiological data before 2020. We compared seasonality data from this period with data during the COVID-19 epidemic. We built a dataset to assess RSV-ALRI burden by age and region, using a generalized linear mixed-effects model and a conceptual proportionality framework to assess hospitalization rates. A risk factor-based model were used to estimate regional and provincial RSV-ALRI incidence.<br><br>FINDINGS: Children aged 0 to 12&#xa0;months had the highest risk of RSV-ALRI and associated hospitalization. Provincial variations existed, with some southern provinces exhibiting higher incidence and some western provinces higher hospitalization rates. The COVID-19 epidemic shifted RSV hospitalization peaks to early autumn (Guangdong, Shanghai), whereas Hubei and Shandong demonstrated delayed peak onset compared with the pre-pandemic period.<br><br>INTERPRETATION: Our study of the burden RSV-ALRIs in China identified obvious heterogeneity by age and region. These findings highlight the need for targeted RSV vaccination strategies and resource allocation prioritizing high-risk groups and areas.<br><br>FUNDING: This work was supported by the Shanghai Municipal Science and Technology Major Project (Grant No. ZD2021CY001), the National Natural Science Foundation of China (Grant No. 82073612), and Shanghai New Three-year Action Plan for Public Health (GWVI-1, GWVI-11.1-03 and GWVI-11.1-01).},
}
@article {pmid42341950,
year = {2026},
author = {Giunta, S and Sabbatinelli, J and Olivieri, F and Giuliani, A},
title = {Aging-related autonomic nervous system imbalance and adrenergic regulation of immunity: Implications for inflammaging, autoimmunity, and long COVID.},
journal = {Frontiers in neuroendocrinology},
volume = {82},
number = {},
pages = {101269},
doi = {10.1016/j.yfrne.2026.101269},
pmid = {42341950},
issn = {1095-6808},
mesh = {Humans ; Post-Acute COVID-19 Syndrome ; *Aging/immunology ; *Autoimmunity/immunology/physiology ; *COVID-19/immunology/physiopathology ; *Autonomic Nervous System/immunology/physiopathology ; *Inflammation/immunology/physiopathology ; Animals ; SARS-CoV-2 ; *Coronavirus Infections/immunology/physiopathology ; Th17 Cells/immunology ; },
abstract = {The autonomic nervous system (ANS) plays a central role in immune homeostasis by integrating sympathetic and parasympathetic signals that regulate inflammation, immune cell trafficking, and tolerance. Aging is associated with a progressive autonomic imbalance characterized by sympathetic overactivation, reduced parasympathetic tone, and impaired β-adrenergic signaling in immune cells, which together contribute to inflammaging and immune dysregulation. In this review, we discuss how aging-related alterations in adrenergic pathways affect immune cell differentiation and cytokine networks, with particular emphasis on β2-adrenergic control of the Th17/regulatory T cell balance through cAMP-dependent mechanisms interacting with cytokine-driven STAT signaling. Chronic sympathetic stimulation and β-adrenergic desensitization weaken these regulatory constraints, favoring pro-inflammatory immune trajectories and loss of immune tolerance. Finally, we propose Long COVID as a paradigmatic condition in which pre-existing inflammaging and autonomic vulnerability are amplified by viral infection, leading to persistent inflammation, impaired immune regulation, and increased susceptibility to autoimmune manifestations.},
}
@article {pmid42577662,
year = {2026},
author = {Mohee, K and Antoun, I and Ambrogetti, R and Eldesouky, M and Somani, R and Ng, A and Bhandari, SS},
title = {Myocarditis in the Modern Era: Navigating Diagnosis, Innovative Treatments, the COVID-19 Challenge and the Role of Artificial Intelligence.},
journal = {Cardiology research and practice},
volume = {2026},
number = {},
pages = {5956965},
pmid = {42577662},
issn = {2090-8016},
abstract = {Myocarditis is an inflammatory disease of the myocardium with diverse aetiologies, ranging from infections and autoimmune processes to drug-induced reactions. Clinical manifestations vary widely from mild chest discomfort to life-threatening complications such as acute heart failure, cardiogenic shock and sudden cardiac death. Although the diagnosis of myocarditis historically relied heavily on invasive biopsy, recent advances in noninvasive imaging modalities, notably cardiac magnetic resonance (CMR) imaging, have transformed clinical practice. The Lake Louise Criteria (LLC), supplemented by parametric imaging techniques, have significantly enhanced diagnostic accuracy. Furthermore, the emergence of COVID-19 has renewed interest in myocarditis due to its association with viral-induced myocardial injury. This review synthesises the current understanding of myocarditis, including epidemiological insights, its diverse aetiologies, diagnostic innovations including the importance of viral load quantification and contemporary management strategies.},
}
@article {pmid42578412,
year = {2026},
author = {Soultanopoulos, GC and Idzenga, JJ and Kamperman, AM and van Pampus, MG and Ket, JCF and Henrichs, J and Verhoeven, CJM},
title = {Psychological interventions to improve maternal mental health and resilience during pregnancy in the COVID-19 pandemic: a systematic review.},
journal = {Journal of psychosomatic obstetrics and gynaecology},
volume = {47},
number = {1},
pages = {2714888},
doi = {10.1080/0167482X.2026.2714888},
pmid = {42578412},
issn = {1743-8942},
mesh = {Humans ; Female ; Pregnancy ; *COVID-19/psychology ; *Resilience, Psychological ; *Psychosocial Intervention/methods ; Mental Health ; *Pregnant People/psychology ; *Pregnancy Complications/therapy/psychology ; *Stress, Psychological/therapy ; },
abstract = {BACKGROUND: During the COVID-19 pandemic, pregnant women experienced increased psychological distress, while access to routine mental health care was often disrupted. Psychological interventions may provide an effective strategy to support maternal mental health under these circumstances.<br><br>OBJECTIVE: This systematic review aimed to provide an overview of psychological interventions for pregnant women during the COVID-19 pandemic and to evaluate their effectiveness in reducing distress and enhancing resilience.<br><br>METHODS: A systematic search of four databases was conducted up to 3 September 2025. Randomised and non-randomised studies evaluating psychological interventions during pregnancy were included.<br><br>RESULTS: Sixteen studies met the inclusion criteria. Interventions included cognitive behavioural therapy, mindfulness-based interventions, psychoeducation, and other psychological approaches delivered through individual, group, digital, or hybrid formats. Most studies reported reductions in depression, anxiety, or stress, and some found improvements in resilience-related factors. However, the methodological quality was modest; with heterogeneous outcome measures and limited follow-up.<br><br>CONCLUSIONS: Overall, psychological interventions adapted for digital or hybrid delivery show promise for improving maternal emotional well-being in times of crises. The findings suggest that accessible and scalable psychological interventions may support maternal mental health during crisis situations when routine care is disrupted. Future research should prioritize larger, methodologically rigorous trials with standardized outcomes, and longer follow-up periods.},
}
@article {pmid42579217,
year = {2026},
author = {Jawaid, I and Lanca, C},
title = {Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.},
journal = {Ophthalmology and therapy},
volume = {},
number = {},
pages = {},
pmid = {42579217},
issn = {2193-8245},
abstract = {We conducted a narrative review of peer-reviewed randomized controlled trials (RCTs) investigating low-concentration atropine for myopia management. Studies were identified using the terms "myopia" AND "atropine" and supplemented through reference searches. Key data on spherical equivalent refraction (SER), axial length (AL) progression, participant demographics, and ethnicity were extracted and qualitatively compared across trials. In addition, observed AL progression was contextualized against expected age-matched myopic axial elongation and physiological emmetropic eye growth derived from previously published normative models. Evidence from pivotal trials such as ATOM and LAMP, mainly conducted in Asian populations, demonstrated dose-dependent efficacy of atropine, with 0.05% showing superior outcomes compared with 0.01%. However, more recent studies in non-Asian populations, including STAR, MOSAIC, WA-ATOM, and MTS, have reported more modest treatment effects with 0.01% atropine. Differences in efficacy appear influenced by factors including age, ethnicity, baseline progression rates, environmental exposures, and placebo-group axial elongation rates. The coronavirus disease 2019 (COVID-19) pandemic also impacted outcomes in several trials, highlighting environmental influences on myopia progression. In addition, off-protocol use of myopia-control interventions in studies such as CHAMP further complicates interpretation of atropine efficacy. While low-concentration atropine remains a promising option for myopia management, rebound progression after cessation remains a concern. Emerging evidence suggests that future research should look at higher atropine concentrations, individualized treatment strategies, and comparisons against normative ocular growth trajectories rather than placebo alone. Licensed atropine formulations, particularly within Europe, are anticipated to improve treatment standardization, support regulatory oversight, and help refine future clinical guidelines for myopia management.},
}
@article {pmid42580608,
year = {2026},
author = {Napolitano, F and Montuori, N},
title = {suPAR as a circulating inflammatory biomarker: time for translation into clinical practice - A systematic review.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {},
number = {},
pages = {121260},
doi = {10.1016/j.cca.2026.121260},
pmid = {42580608},
issn = {1873-3492},
abstract = {Urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored cell surface receptor composed of three homologous domains (DI, DII, and DIII), forming a flexible structure that mediates interactions with multiple ligands. Through these interactions, uPAR plays a key role in extracellular matrix (ECM) remodeling, cell invasion, proliferation, and migration, making it a promising therapeutic target in various diseases. In addition to its membrane-bound form, uPAR can be released into circulation following cleavage of its GPI anchor, generating soluble uPAR (suPAR), which is detectable in blood, serum, plasma, urine, and other biological fluids. Proteolytic cleavage within the linker region between domains I and II produces three main isoforms: full-length suPAR (suPARI-III), suPAR domain I (suPARDI), and suPAR domains II-III (suPARDII-III). suPAR has been extensively investigated as a biomarker of systemic chronic inflammation across multiple conditions. During COVID-19 pandemic, suPAR gained attention as a predictor of disease severity and mortality in acute patients, reinforcing its role as a marker of sepsis. Elevated suPAR levels have also been reported in diseases such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and various malignancies, supporting its diagnostic and prognostic value. Several analytical methods are currently available for suPAR quantification, including ELISA, turbidimetric immunoassays, and chemiluminescence immunoassays. However, these assays differ in their ability to detect specific isoforms, which may vary in biological and clinical significance. This review summarizes the clinical relevance of suPAR, examines the functional roles of its isoforms, and evaluates current detection methods and their implications for clinical practice.},
}
@article {pmid42580773,
year = {2026},
author = {van Susante-Oost, LJ and Mastebroek, M and Koks-Leensen, MCJ and Timen, A and Leusink, GL and Cuypers, M},
title = {Disease burden of viral respiratory infections in people with intellectual disabilities: a scoping review.},
journal = {BMJ open respiratory research},
volume = {13},
number = {1},
pages = {},
doi = {10.1136/bmjresp-2025-004082},
pmid = {42580773},
issn = {2052-4439},
mesh = {Humans ; *Intellectual Disability/epidemiology/complications ; *Respiratory Tract Infections/epidemiology/virology ; *COVID-19/epidemiology ; *Cost of Illness ; *Influenza, Human/epidemiology ; Quality of Life ; Comorbidity ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Viral respiratory infections are highly contagious and associated with an increased risk of serious adverse health outcomes in vulnerable populations, including people with intellectual disabilities. However, little is known about the overall disease burden of viral respiratory infections among people with intellectual disabilities.<br><br>AIM: This scoping review aims to provide an overview of the existing literature on the disease burden of viral respiratory infections among people with intellectual disabilities.<br><br>METHODS: Studies published between 1999 and 10 July 2024, were identified through PubMed, MEDLINE, Embase and Web of Science, and included if focused on adults with intellectual disabilities, viral respiratory infections and relevant health outcomes such as infection rate, mortality, hospitalisation, functional impairments or quality of life.<br><br>RESULTS: 58 articles were included, of which the majority focused on COVID-19 (42/58) or influenza (13/58). Studies varied in their methodology and outcome measures. Evidence on COVID-19 and influenza showed that people with intellectual disabilities experience a higher disease burden from these infections compared with the general population. Particularly disproportionate effects were evident among people with Down syndrome, who had higher mortality estimates and an increased burden of comorbidities associated with severe disease and death.<br><br>CONCLUSION: Although available evidence appeared limited and diverse, this scoping review shows a higher disease burden in people with intellectual disabilities, in particular for COVID-19 and influenza-type viruses, which can be indicative of the impact of other viral respiratory infections as well. This highlights the importance of measures to prevent and control the spread of respiratory pathogens among this group.},
}
@article {pmid42581338,
year = {2026},
author = {Omer, SH and Mahmood, MK and Gul, SS and Amin, YMM and Lan, R},
title = {Association Between Periodontitis and Respiratory Diseases: A Systematic Umbrella Meta-Analysis.},
journal = {Oral diseases},
volume = {},
number = {},
pages = {},
doi = {10.1111/odi.70448},
pmid = {42581338},
issn = {1601-0825},
abstract = {AIM: This study aimed to evaluate the association between periodontitis and respiratory diseases using an umbrella meta-analysis.<br><br>METHODS: Meta-analyses (MAs) reporting odds ratios (OR) and mean differences (MD) for the association between periodontitis and respiratory diseases of COVID-19, chronic obstructive pulmonary disease (COPD), asthma, and pneumonia were included. Random-effects meta-analysis was performed. Egger's test and trim-and-fill method were used to assess publication bias.<br><br>RESULTS: Fourteen MAs encompassing more than 500,000 participants were included. A significant association was found between periodontitis and respiratory disease (OR 2.45, 95% CI 2.06-2.92, p&#x2009;<&#x2009;0.0001), with substantial heterogeneity (I[2]&#x2009;=&#x2009;82%). The pooled OR for the association between periodontitis with COVID-19, COPD, asthma, and pneumonia was 2.75, 1.42, 3.42, and 2.73, respectively. The association remained consistent even after adjustment for publication bias and among different study qualities and sample sizes. Notably, the association with COPD may not be independent of smoking. The GRADE assessment rated the certainty of evidence of the outcomes as "low" due to high heterogeneity and publication bias.<br><br>CONCLUSIONS: The results suggest a statistical association between periodontitis and most of the studied respiratory diseases. However, these results should be interpreted with caution and be seen as exploratory and hypothesis-generating, rather than definitive effect sizes.<br><br>PROSPERO REGISTRATION: CRD420251250830.},
}
@article {pmid40849756,
year = {2026},
author = {Voltan, G and Graziani, A and Torchio, M and Mian, C and Betterle, C and Sabbadin, C},
title = {An Intriguing Case Report of Type 2 Autoimmune Polyendocrine Syndrome Post-SARS-CoV-2: Cause or Coincidence?.},
journal = {Endocrine, metabolic &amp; immune disorders drug targets},
volume = {26},
number = {},
pages = {e18715303407830},
doi = {10.2174/0118715303407830250807114958},
pmid = {40849756},
issn = {2212-3873},
mesh = {Humans ; *Polyendocrinopathies, Autoimmune/diagnosis/etiology/drug therapy/immunology ; Male ; Adult ; *COVID-19/complications/diagnosis ; SARS-CoV-2 ; Addison Disease ; },
abstract = {INTRODUCTION: SARS-CoV-2, the virus responsible for COVID-19, is primarily associated with respiratory illness but can also affect multiple organ systems, including the endocrine system. Viral entry into endocrine tissues may lead to immune activation and trigger or unmask autoimmune conditions in individuals who are genetically predisposed. Autoimmune Polyendocrine Syndrome type 2 (APS-2), a rare disorder characterized by autoimmune Addison’s disease (AAD) and autoimmune thyroid disease (AITD), may represent one such manifestation.<br><br>CASE PRESENTATION: We report the case of a 36-year-old male who developed APS-2 following a mild SARS-CoV-2 infection. Two months post-infection, the patient experienced asthenia, hypotension, gastrointestinal symptoms, and weight loss. Laboratory investigations revealed undetectable morning cortisol, positive 21-hydroxylase and thyroid-peroxidase autoantibodies, elevated ACTH and renin, and subclinical hypothyroidism&#x2014;consistent with a diagnosis of APS-2 (AAD and Hashimoto&#x2019;s thyroiditis). Treatment with cortisone acetate and fludrocortisone led to clinical improvement. No previous history of autoimmune disease was reported. A review of the literature identified only four similar case reports, with varying timelines between SARS-CoV-2 infection and APS-2 diagnosis, suggesting that the infection may act as a trigger in predisposed individuals.<br><br>CONCLUSION: This case adds to limited evidence suggesting a possible link between SARS-CoV-2 infection and the onset or unmasking of APS-2. While a direct causal role of the virus remains uncertain, SARS-CoV-2 may function as an environmental trigger, accelerating the transition from subclinical to clinical autoimmunity in genetically susceptible patients. This observation supports the need for clinical vigilance in post-COVID-19 patients presenting with nonspecific but suggestive endocrine symptoms.},
}
@article {pmid42237329,
year = {2026},
author = {Zeniecki, P and Kamens, R and Kilpatrick, J and Papanagnou, D and Zhang, XC},
title = {Screen-based simulation assessment for emergency medicine learners: a rapid review.},
journal = {BMC medical education},
volume = {26},
number = {1},
pages = {},
pmid = {42237329},
issn = {1472-6920},
mesh = {*Emergency Medicine/education ; Humans ; *Clinical Competence ; *Simulation Training/methods ; *Educational Measurement/methods ; COVID-19/epidemiology ; *Computer Simulation ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Simulation has played a vital role in training medical professionals. The COVID-19 Pandemic has highlighted the need for physically distant educational assessment methods. Screen-based simulation (SBS) demonstrates one alternative to traditional in-person simulation methods to assess learners clinical reasoning and communication skills. This study aims to compare in-person simulation to SBS as assessment methods in Emergency Medicine (EM).<br><br>METHODS: A rapid review literature search methodology of an electronic database (PubMed) was performed in February 2022 with search terms such as "Computer Simulation," "Patient Simulation," "Simulation Training," "Education, Distance," "Virtual OSCE," "Academic Performance," or "Emergency Medicine." Reference lists of relevant articles were manually analyzed for additional studies. Studies were manually reviewed by multiple authors following strict inclusion/exclusion criteria.<br><br>RESULTS: 751 articles were identified based on title and abstract. Sixty articles were selected for retrieval, of which seven pilot and small population studies were included. Study participants varied based on experience level. Three key findings were derived from these studies. First, SBS is comparable to in-person simulation as a clinical competence and communication skill assessment method when evaluated by independent raters and mock EM oral board examination scores. Second, SBS is capable of discerning EM learners by educational level given SBS/serious game mean clinical score clustering. Lastly, various SBS software demonstrated strong participant interest across the EM learner spectrum through subjective exit questionaries.<br><br>CONCLUSION: Current research regarding SBS as an assessment method for EM learners is severely limited as demonstrated by low number of included studies and small populations. Even so, SBS shows promise as a possible alternative and/or supplement to traditional in-person simulation to assess clinical reasoning/communication skills and discern learners by educational level. Further large-scale studies are required to establish the validity of SBS as an assessment method.},
}
@article {pmid42249377,
year = {2026},
author = {Berry, R and Wilkinson, A and Turk, A and Ng, BY and Pinkney, S and Halai, B and Emoche, A and Thornley, T and Ashiru-Oredope, D},
title = {The role of pharmacists and pharmacy team members in the prevention, preparedness, response and recovery of outbreaks - a global rapid systematic review.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42249377},
issn = {1471-2458},
mesh = {Humans ; *Professional Role ; *Disease Outbreaks/prevention &amp; control ; *Pharmacists ; Pandemic Preparedness ; World Health Organization ; },
abstract = {BACKGROUND: Pharmacists and their teams can undertake pharmaceutical public health roles during outbreaks within the World Health Organization (WHO) emergency cycle of prevention, preparedness, response, and recovery. These may be at micro- (individual), meso- (regional or organisational) or macro- (national) levels. The primary outcome was to identify pharmacy team members' roles in outbreaks (excluding COVID-19) and classify by WHO emergency cycle phase and intervention level.<br><br>METHODS: We conducted a rapid systematic review (PROSPERO: CRD42024617152) in Embase, Medline, and SCOPUS databases including articles published from 2014 to Feb 2025. After duplicate removal, titles/abstracts and full texts were screened, extracted and assessed for bias by one reviewer, with 10% second-checked. Thematic synthesis was used and described narratively to reflect variability in the studies.<br><br>RESULTS: From 161 articles across all WHO regions, 145 distinct thematically derived role categories were identified. Most were in the response phase (46%), followed by prevention (29%), preparedness (15%), and recovery (10%). Roles were primarily at meso-level (37%) and micro-level (35%), with fewer at macro-level (28%). 34% of the articles reported contributions related to health inequalities. Reported barriers were clustered into five themes: knowledge/training gaps, regulatory restrictions, resource and infrastructure constraints, communication, and cultural factors.<br><br>CONCLUSION: Pharmacy team members have roles during non-COVID outbreaks across all stages of the WHO emergency cycle at all levels. However, their contributions are less well documented in recovery and at macro-level. Integrating pharmacy roles into emergency frameworks, supported by regulatory reform, funding, and training, may support health-system resilience, and reduce health inequalities.},
}
@article {pmid42486051,
year = {2026},
author = {Okoli, GN and Sullivan, SG and Harper, DM and Tsang, TK and Cowling, BJ},
title = {A systematic meta-analytic comparative evaluation of seasonal influenza vaccine effectiveness from test-negative design studies in the Northern Hemisphere pre/post COVID-19 pandemic.},
journal = {Vaccine},
volume = {88},
number = {},
pages = {128956},
doi = {10.1016/j.vaccine.2026.128956},
pmid = {42486051},
issn = {1873-2518},
mesh = {Humans ; *Influenza Vaccines/immunology/administration &amp; dosage ; *Influenza, Human/prevention &amp; control/immunology/epidemiology ; *Vaccine Efficacy ; Adolescent ; Influenza A Virus, H3N2 Subtype/immunology ; Influenza B virus/immunology ; *COVID-19/epidemiology/prevention &amp; control/immunology ; Influenza A Virus, H1N1 Subtype/immunology ; Seasons ; Child, Preschool ; Middle Aged ; Adult ; Child ; Young Adult ; Infant ; Pandemics ; Aged ; },
abstract = {BACKGROUND: Influenza circulation was substantially reduced during the COVID-19 pandemic. The consequent reduction in population immunity may have resulted in increased influenza vaccine effectiveness (VE) after the pandemic via reduced immunity in unvaccinated individuals compared to the pre-pandemic period.<br><br>METHODS: We systematically reviewed published peer-reviewed test-negative design (TND) studies of seasonal influenza VE against medically-attended, laboratory-confirmed influenza in the Northern Hemisphere. We compared pooled VE estimates before (2010/11-2019/20) and after (2022/23-2024/25) the COVID-19 pandemic (defined as 2020/21-2021/22). Pooled VE against A(H1N1)pdm09, A(H3N2), influenza B, and B/Victoria was calculated for three age groups (6&#xa0;months-17&#xa0;years, 18-64&#xa0;years, &#x2265;65&#xa0;years) using inverse-variance random-effects meta-analysis. Heterogeneity was quantified with the I[2] statistic, and differences between pooled VE estimates pre- and post-pandemic periods were tested with the &#x3c7;[2] statistic.<br><br>RESULTS: Eighty-five publications were included. Post-pandemic VE against A(H3N2) was significantly higher than pre-pandemic VE in 6-month-17-year-olds (53% [42-64%] vs 37% [30-45%]) and 18-64-year-olds (35% [25-45%] vs 21% [13-29%]). Similarly, VE against influenza B was higher post-pandemic in both age groups (85% [78-93%] vs 52% [45-60%] and 73% [59-87%] vs 49% [41-57%], respectively). Conversely, VE against A(H1N1)pdm09 was lower post-pandemic in 18-64-year-olds (37% [27-46%] vs 55% [47-62%]). No significant differences were observed for &#x2265;65-year-olds, and data for B/Victoria were limited.<br><br>CONCLUSIONS: The evidence suggests slightly higher VE against seasonal influenza after the COVID-19 pandemic although there may be factors other than population immunity that may explain our observations.},
}
@article {pmid42571535,
year = {2026},
author = {Khawaja, I and Khan, N and Kannangara, L and Panangala Liyanage, SN and Gomez Canales, E and Sahedra, SS},
title = {The Association Between COVID-19 and Herpes Zoster in Adult Populations: A Systematic Review.},
journal = {Cureus},
volume = {18},
number = {7},
pages = {e112344},
pmid = {42571535},
issn = {2168-8184},
abstract = {Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), has been associated with a wide range of dermatological manifestations. Herpes zoster (HZ), also known as shingles, has been increasingly reported in adults with COVID‑19 infection. Several reports suggest that SARS‑CoV‑2-associated immune dysregulation, particularly lymphopenia and impaired T-cell-mediated immunity, may contribute to varicella-zoster virus (VZV) reactivation. This systematic review aimed to evaluate the temporal relationship between COVID‑19 infection and shingles rash, including the onset, clinical outcomes, prognostic implications, recovery, and relationship with lymphopenia. This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic literature review was conducted using PubMed, MEDLINE and Cochrane databases for studies published within the last five years. Search terms included "COVID‑19", "SARS-CoV-2", "herpes zoster" and "shingles rash". Inclusion criteria consisted of case reports, case series, cohort studies, systematic reviews, and research studies. Studies included were in the English language. Studies not relevant to the research question, paediatric cohorts, or commenting on vaccination were excluded. Fifty-seven studies (N=57) were initially identified through database search, with 35 studies (N=35) deemed relevant to the research question following screening. Twenty-five studies (N=25) were excluded due to data not being relevant to the research question, paediatric cohort data, or vaccination-related data. After exclusion, 10 studies (N=10) were included in the review for qualitative analysis. Most studies demonstrated a temporal association between COVID‑19 infection and HZ occurrence. HZ rash developed from two days before COVID‑19 symptoms and up to 70 days after infection, with an average onset approximately 17 days after COVID‑19 diagnosis. Several studies reported that HZ preceded or coincided with COVID‑19 symptoms, suggesting that shingles may serve as an early indicator of SARS‑CoV‑2 infection. Associated lymphopenia was noted, suggesting that COVID-19-induced immune dysregulation contributes to VZV reactivation. Most patients recovered from HZ rash following antiviral therapy, although severe complications and prolonged hospitalisation were observed in cases involving co-infection and systemic disease. Overlooking this possible association may result in an undiagnosed COVID-19 infection in those presenting with shingles rash and a higher risk of developing long COVID. The reviewed studies indicate that COVID-19 may be associated with HZ reactivation in the general adult population, although causality remains unproven. This detailed data analysis and systematic review demonstrate that evidence is scarce in this domain, which warrants larger epidemiological and immunological studies as well as further meta-analyses to determine the prognostic significance of shingles rash in COVID‑19 infection, in particular long COVID.},
}
@article {pmid42572688,
year = {2026},
author = {Aly, S and Grundmann, O},
title = {A Review of Kratom Product Evolution and Its Associated Health Outcomes.},
journal = {Substance abuse and rehabilitation},
volume = {17},
number = {},
pages = {606821},
pmid = {42572688},
issn = {1179-8467},
abstract = {PURPOSE OF REVIEW: Kratom (Mitragyna speciosa Korth) is a tree that belongs to the coffee family (Rubiaceae) and is native to Southeast Asia. This review article focuses on the diversification of kratom products, differentiating between native leaf, extracts and isolates based on use patterns and conceptualization of kratom for self-treatment of disorders.<br><br>FINDINGS: The dried powdered native leaf and its extract derivatives are primarily used as kratom products in the US and Europe. Diversification of kratom products has increased since 2021 following the global COVID-19 pandemic. There has been a rise in chemically altered kratom products, including enriched extracts, edibles, resins, and isolates. Most prominent among them is the oxidative metabolite of mitragynine, 7-hydroxymitragynine.<br><br>SUMMARY: The total alkaloid content is lowest in native kratom leaf products (2-5% by weight) which is associated with a lower potential for adverse effects and dependence compared to concentrated products, where extracts can contain five to 50 times the alkaloid content of the native leaf. Purified compounds, predominantly mitragynine and semi-synthetic 7-hydroxymitragynine, are likely to be associated with a higher risk for dependence and overdose potential.},
}
@article {pmid42574721,
year = {2026},
author = {Liu, Y and Zhu, Y and Luo, G},
title = {A narrative review of the epidemiological and mechanistic associations between ABO blood groups and diseases: focusing on cardiovascular diseases, cancers, diabetes, malaria, COVID-19 and rheumatic diseases.},
journal = {Annals of medicine},
volume = {58},
number = {1},
pages = {2710922},
doi = {10.1080/07853890.2026.2710922},
pmid = {42574721},
issn = {1365-2060},
mesh = {Humans ; *ABO Blood-Group System/genetics ; *COVID-19/epidemiology/blood ; *Cardiovascular Diseases/epidemiology/blood/genetics ; *Rheumatic Diseases/epidemiology/blood/genetics ; *Diabetes Mellitus/epidemiology/blood/genetics ; *Neoplasms/epidemiology/blood/genetics ; *Malaria/epidemiology/blood ; SARS-CoV-2 ; Malaria, Falciparum/epidemiology/blood ; Risk Factors ; Genetic Predisposition to Disease ; },
abstract = {BACKGROUND: The ABO blood group system is one of the most clinically significant human blood group systems and is closely associated with pathogenesis, progression, and prognosis of numerous diseases. This narrative review synthesizes recent epidemiological evidence and explores potential mechanisms linking ABO to cardiovascular diseases, malignancies, diabetes, Plasmodium falciparum malaria, COVID‑19, and rheumatic diseases.<br><br>METHODS: We searched PubMed and CNKI up to September 2025.<br><br>RESULTS: Epidemiological studies consistently show non&#x2011;O blood groups have significantly elevated cardiovascular risk, with venous thromboembolism risk about two to four times higher than in type O. In oncology, ABO influences susceptibility and prognosis in various cancers, with type A linked to increased gastric cancer risk (pooled OR&#x2248;1.2). Type O individuals show relative resistance to severe malaria. During COVID&#x2011;19, type A was linked to higher susceptibility and severity, whereas type O appeared mildly protective, though associations exhibited substantial heterogeneity across populations, viral variants, and vaccination contexts. ABO polymorphisms may also modulate risk and manifestations of rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis.<br><br>CONCLUSION: Accumulating evidence suggests ABO status is associated with susceptibility and outcomes for a range of diseases. These findings are primarily hypothesis&#x2011;generating and underscore the need for further research to elucidate causal mechanisms. The potential of ABO typing as a biomarker for risk stratification in personalized medicine warrants investigation in large, multi&#x2011;ethnic prospective studies.},
}
@article {pmid42574892,
year = {2026},
author = {Bansal, P and Khan, NA and Singh, H and Siddiqui, M and Schram, J and Patel, S and Karri, S and Constantakos, A and Sundararajan, N and Saldanha, IJ},
title = {Timeliness of publication of randomized controlled trials in rheumatology: A systematic review.},
journal = {Seminars in arthritis and rheumatism},
volume = {80},
number = {},
pages = {153052},
doi = {10.1016/j.semarthrit.2026.153052},
pmid = {42574892},
issn = {1532-866X},
abstract = {OBJECTIVE: To systematically review the (1) timeliness of publication of randomized controlled trials (RCTs) in rheumatology, (2) impact of the COVID-19 pandemic on time to publication, and (3) factors associated with publication delays.<br><br>METHODS: We searched Medline, Embase, EBM Reviews, Cochrane Central Register of Controlled Trials, and Scopus from January 1, 2018, to June 30, 2023 for Phase 3, superiority, parallel-design RCTs that evaluated any treatment for a rheumatologic illness or a rheumatologic treatment for COVID-19 and reported clinical primary efficacy outcome. Outcomes of interest were time to publication after trial completion and publication delay of >2 years after trial completion.<br><br>RESULTS: 448 RCTs were included in this systematic review. Median time from completion to publication was 549 days and 65.9 % RCTs were published within 2 years of completion. Compared with RCTs on rheumatologic diseases, RCTs on COVID-19 were published sooner (253 vs. 549 days; p < 0.001) and were more likely to be published within 2 years (adjusted OR 9.49, 95 % CI 2.07 to 43.61). Compared with RCTs completed before March 1, 2020, RCTs completed after March 1, 2020, were published sooner (327 vs. 724 days; p < 0.001) and were more likely to be published within 2 years (adjusted OR 9.40, 95 % CI 5.14 to 17.21). Time from RCT completion to submission accounted for most (67 %) of the time to publication.<br><br>CONCLUSIONS: Publication delay continues to be an important concern in dissemination of clinical research. Most of the delays in publication were attributable to delays in submission to journals after trial completion.},
}
@article {pmid42576855,
year = {2024},
author = {Brüssow, H},
title = {Pandemic preparedness-political perspectives.},
journal = {Sustainable microbiology},
volume = {1},
number = {1},
pages = {qvae018},
pmid = {42576855},
issn = {2755-1970},
abstract = {Pandemic preparedness is explored for the antibiotic resistance crisis and the threat of a next viral pandemic. Bacterial pathogens escaping from control by antibiotics are well defined, and resistance develops over decades while a next viral pandemic occurs suddenly with a novel virus. The death toll for resistant bacterial infections is reviewed, and the scientific and economic hurdles to the development of new antibiotics are discussed. Regulatory adaptations and financial push and pull programs to restimulate new antibiotic development are explored. The COVID-19 pandemic caused not only millions of deaths, but also economic losses in excess of 10 trillion US dollars. Coronaviruses and influenza viruses remain usual suspects for new viral pandemics, followed by paramyxoviruses. Viral infections at the animal-human interface in wet markets and in disturbed environments need active virus surveillance programs. Learning lessons from the COVID-19 for non-pharmaceutical interventions is difficult to draw since measures were frequently applied in combination against different variant viruses and against changing population immunity levels. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) clinical trials demonstrated that even under emergency situations clinical trials can rapidly provide solid treatment data. Various novel vaccine approaches were the most efficient control measures for the COVID-19 pandemic. Pandemic preparedness also requires a fact-based discussion both in the public and in parliaments to settle the conflict between individual freedom and necessary restrictions during a pandemic. Mature and educated citizens are needed not only for coping with pandemics but also for creating stress-resistant democratic societies. Learned scientific societies should contribute to this discussion.},
}
@article {pmid42576971,
year = {2026},
author = {Contreras, S and Dönges, P and Müller, L and Mallick, P and Paltra, S and Hvid, U and Kettlitz, RJN and Reitenbach, A and Lind, RA and Aguiar, M and Bechtle, P and Valdez, AC and Gronemeyer, R and Harries, M and Jaeger, VK and Karch, A and Klett-Tammen, CJ and Klimek, P and Kretzschmar, ME and Nagel, K and Nielsen, BF and Prainsack, B and Radhuber, IM and Simonsen, L and Sneppen, K and Suer, J and Priesemann, V},
title = {Mechanics of pandemics.},
journal = {EClinicalMedicine},
volume = {98},
number = {},
pages = {104101},
pmid = {42576971},
issn = {2589-5370},
abstract = {COVID-19 and previous pandemics have shown how diseases can disrupt, threaten, and transform daily life. Since pathogens and societies are continuously evolving, every pandemic is different. However, certain fundamental principles of disease transmission appear to hold true across different outbreaks. These "mechanisms" are grounded in natural laws or the very structure of our biology and societies. This paper compiles ten fundamental mechanisms, curated by a multidisciplinary team with backgrounds spanning public health, medicine, epidemiology, political science, mathematics, physics, and psychology. These mechanisms, although perhaps underappreciated, substantially shape how pandemics unfold and are controlled. The better we succeed in understanding these mechanisms and establishing this knowledge in our societies, the better we will be able to prepare for future pandemics and respond appropriately when they occur.},
}
@article {pmid42576972,
year = {2026},
author = {Mohamed Omer, SO and Eltahir, R and Osman Elsayed, SB and Eldyasty Ahmed Eid, MA and Hassan Khattab, RA and Elfaki Omer, EO and Gomaa Abdelfattah, MK and Mustafa Alsalhi, AS and Elawad Ahmed, NF},
title = {Autoimmune Manifestations Following COVID-19 Infection: A Systematic Review.},
journal = {Cureus},
volume = {18},
number = {7},
pages = {e112421},
pmid = {42576972},
issn = {2168-8184},
abstract = {Coronavirus disease 2019 (COVID-19) has been linked to immune dysregulation and autoantibody formation, raising concern that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may precipitate new-onset autoimmune disease. This systematic review synthesises controlled observational evidence on the incidence and risk of autoimmune manifestations following confirmed COVID-19. Following the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 2020 guidelines, electronic databases were searched from inception upto the search date for original cohort or case-control studies comparing incident autoimmune disease in individuals with versus without confirmed COVID-19. Eligibility was structured using the PICOS (Population, Intervention/Exposure, Comparator, Outcome, and Study design) framework. Methodological quality was appraised using the Newcastle-Ottawa Scale and certainty of evidence using the GRADE approach. Findings were synthesised narratively. Eight large cohort studies, drawn from multiple national health systems and collectively encompassing tens of millions of individuals, met the inclusion criteria. Confirmed SARS-CoV-2 infection was consistently associated with an increased risk of incident autoimmune disease spanning rheumatological, dermatological, vasculitic, endocrine, gastrointestinal, haematological, and neurological domains, with adjusted hazard ratios ranging from approximately 1.3 to 3.0. Connective tissue, vasculitic, and antibody-mediated disorders were most frequently implicated. Several studies demonstrated a severity-dependent gradient and attenuation of risk over time, and one cohort reported a reduced risk among vaccinated individuals. The overall certainty of evidence was low to moderate. Confirmed COVID-19 is associated with an increased, though in absolute terms modest, risk of new-onset autoimmune disease, most reproducibly affecting connective tissue, vasculitic, and antibody-mediated conditions. The observational evidence supports clinical vigilance, particularly after severe infection, while prospective studies with validated outcomes and infection comparators are needed to confirm causality.},
}
@article {pmid42577597,
year = {2026},
author = {Huang, K and Liang, X and Pi, R and Dai, J and Lei, X and Fang, J},
title = {Advances in AI for detecting pulmonary inflammation and perioperative medicine: a mini-review.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1865505},
pmid = {42577597},
issn = {2296-858X},
abstract = {With increasing human longevity, early recognition and treatment of pneumonia in the elderly are crucial to prevent disease progression. Artificial intelligence (AI) is rapidly transforming the detection and management of pulmonary inflammation (pneumonia, COVID-19 lung damage). Accurate preoperative assessment of pneumonia contributes to improved perioperative surgical and anesthesia management. This mini-review highlights key advances: (1) Hybrid deep learning models achieve high accuracy (>96%) in analyzing ultrasound videos for disease differentiation. (2) Self-supervised learning enables expert-level X-ray interpretation without extensive annotations. (3) Multimodal integration combines imaging (CT/X-ray) with clinical data, enhancing lesion visibility and pathogen-specific diagnosis (viral vs. bacterial AUC: 0.95). Clinically, AI demonstrates high efficacy in COVID-19 detection (AUC: 0.992), pediatric pneumonia diagnosis (89-96% accuracy), and identifying post-COVID complications. Despite this promise, challenges remain, including data bias, limited pediatric datasets, "black-box" model interpretability, and ethical concerns. Future progress depends on expanding diverse training data (e.g., via federated learning), integrating explainable AI (XAI), and ensuring equitable access. In conclusion, AI offers accurate, scalable solutions for pulmonary inflammation diagnostics, with significant potential to augment clinical decision-making and extend into proactive areas like perioperative medicine for complication screening and prevention.},
}
@article {pmid42569481,
year = {2026},
author = {Shin, H},
title = {U.S. Public Health Policy Shifts Under the Second Trump Administration and Implications for the Republic of Korea's Health Security.},
journal = {Public health weekly report},
volume = {19},
number = {30},
pages = {1251-1280},
pmid = {42569481},
issn = {3092-491X},
abstract = {OBJECTIVES: This report evaluates the U.S. public health policy shifts enacted by the 2025 Trump administration and assesses their implications for global health cooperation, evidence-based policymaking, and the Republic of Korea's health security strategy.<br><br>METHODS: This study employed a narrative review and policy analysis based on documents published between January 2025 and May 2026. Data were collected from official U.S. federal agency sources and major media outlets using specific search terms, including "Trump administration" and "public health policy." After screening for policy relevance and reliability, the reviewed literature was synthesized and qualitatively analyzed into four main topics: agency reorganization and budget cuts, immunization policy adjustments, data-driven research environments, and global health cooperation.<br><br>RESULTS: To improve efficiency and realign priorities, the U.S. federal government restructured public health governance by streamlining U.S. Department of Health and Human Services agencies from 28 to 15 and reducing staff. Immunization policy shifted toward emphasizing individual choice, reducing the number of routine recommended vaccines from 17 to 11 by excluding rotavirus, hepatitis A and B, meningococcal, coronavirus disease 2019, and influenza vaccines. Multilateral cooperation also declined as the Centers for Disease Control and Prevention decentralized data management, the U.S. withdrew from the World Health Organization, and the United States Agency for International Development was dissolved, shifting the focus toward bilateral memoranda of understanding. However, these swift transformations triggered sharp institutional resistance, including judicial injunctions, government shutdowns, and state-level policy fragmentation.<br><br>CONCLUSIONS: Alterations to these frameworks and guidelines may reduce the predictability of global infectious disease surveillance and cooperation. Consequently, the Korea Disease Control and Prevention Agency must enhance independent global surveillance, develop science-based communication to sustain vaccine confidence, and diversify multi- and bilateral cooperation networks to keep pace with evolving global health dynamics.},
}
@article {pmid42570952,
year = {2026},
author = {Brock, J and Lux, H and Bauer, M and Dickmann, P},
title = {Inter-hospital ICU-to-ICU transfer of critically ill COVID-19 patients is not associated with increased mortality: a systematic review with exploratory meta-analysis.},
journal = {Scientific reports},
volume = {16},
number = {1},
pages = {},
pmid = {42570952},
issn = {2045-2322},
mesh = {Humans ; *Intensive Care Units ; *Critical Illness/mortality ; *Patient Transfer/statistics &amp; numerical data ; *COVID-19/mortality ; SARS-CoV-2 ; Pandemics ; Hospital Mortality ; },
abstract = {During the COVID-19 pandemic, inter-hospital transfer of critically ill patients between intensive care units was widely used to manage capacity shortages. While several individual studies have compared outcomes of transferred and non-transferred patients, no systematic synthesis of this evidence exists. This systematic review aims to determine whether inter-hospital ICU-to-ICU transfer of adult COVID-19 patients is associated with increased mortality or other adverse clinical outcomes. We systematically searched PubMed, Web of Science, and Scopus for observational studies comparing clinical outcomes of adult COVID-19 patients who underwent inter-hospital ICU-to-ICU transfer with non-transferred ICU patients. Two reviewers screened, selected, and extracted data independently and in duplicate. Risk of bias was assessed using the Newcastle-Ottawa Scale and ROBINS-I, and certainty of evidence using GRADE. Exploratory random-effects meta-analyses were performed separately for each effect measure, with Hartung-Knapp and crude-effect sensitivity analyses. Nine observational studies from seven countries were included (approximately 6,100 transferred and 29,200 non-transferred ICU patients). None of the adjusted effect estimates showed a statistically significant mortality disadvantage for transferred patients. Pooled adjusted subgroup estimates were an odds ratio of 1.29 (95% CI 0.84 to 1.98; k = 3) and a hazard ratio of 0.71 (95% CI 0.34 to 1.46; k = 2). Length of stay was longer in transferred patients in most studies. The available observational evidence did not show a clear increase in mortality among transferred compared with non-transferred COVID-19 ICU patients. These findings support the use of inter-hospital transfer as a safe strategy for managing ICU surge capacity. PROSPERO CRD420261356915.},
}
@article {pmid42571046,
year = {2026},
author = {Gravenstein, S and Cooke, CE and Verdi, D and Fedele, MJ and Ganguli, S and Martin, S and Draica, F},
title = {Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature Review.},
journal = {The Senior care pharmacist},
volume = {41},
number = {5},
pages = {167-186},
doi = {10.4140/TCP.n.2026.167},
pmid = {42571046},
issn = {2639-9636},
mesh = {Humans ; *COVID-19/epidemiology/mortality ; United States/epidemiology ; *Long-Term Care/statistics &amp; numerical data ; *Nursing Homes/statistics &amp; numerical data ; Nursing Home Residents ; SARS-CoV-2 ; Aged ; Hospitalization/statistics &amp; numerical data ; },
abstract = {Background: COVID-19 disproportionately affects older adults, placing residents of closed-community settings, such as long-term care facilities (LTCFs), at increased risk for severe illness and death. Objective: To describe the epidemiology and healthcare resource utilization associated with acute COVID-19 in LTCFs in the United States during Omicron variant predominance. Data Sources: MEDLINE and Embase databases were searched on January 15, 2025 for full-text citations published on or after January 1, 2022. Conference abstracts from long-term care conferences in 2023 and 2024 were hand-searched. Records were included if they described acute COVID-19 in LTCFs (nursing homes, assisted living facilities, or Veterans Affairs Community Living Centers). Records were excluded if they were conducted outside the United States, published in languages other than English, focused on long COVID, did not include data from the Omicron predominance period (beginning November 1, 2021), or were clinical trials, case reports/case series, narrative reviews, editorials, or commentaries. Data Synthesis: Forty-three articles met the inclusion criteria, most of which reported COVID-19 cases (20 studies), mortality (18 studies), and/or healthcare resource utilization (11 studies). Although all studies included COVID-19 data during the Omicron period, most also included earlier periods during which other COVID-19 variants were predominant. In the United States, weekly incidence rates for COVID-19 infections and hospitalizations among nursing home residents ranged from 614 to 1338 and from 38 to 71 per 1,000 residents, respectively. Approximately 1 in 6 COVID-19 hospitalizations occurred among LTCF residents. Compared with community-dwelling individuals, mortality was 4.6-fold higher among LTCF residents. Conclusion: COVID-19 in LTCFs was associated with high rates of hospitalization and mortality among residents, including vaccinated individuals, during the study period.},
}
@article {pmid42565313,
year = {2026},
author = {SeyedAlinaghi, S and Mehraeen, E and Rad, FF and Siami, H and Javaherian, M and Rasheed, MA and Bagheri, A and Zand, A and Emamgholizadeh Baboli, E and Rostami, K and Yarmohammadi, S},
title = {Risk Factors of the Spread of COVID-19 in Prisoners: A Systematic Review and Meta-Analysis.},
journal = {Disaster medicine and public health preparedness},
volume = {20},
number = {},
pages = {e141},
doi = {10.1017/dmp.2026.10392},
pmid = {42565313},
issn = {1938-744X},
mesh = {Humans ; *COVID-19/epidemiology/transmission/prevention &amp; control ; *Prisoners/statistics &amp; numerical data ; Risk Factors ; SARS-CoV-2/pathogenicity ; Vaccination/statistics &amp; numerical data ; },
abstract = {OBJECTIVES: This systematic review and meta-analysis aimed to identify and synthesize evidence on risk factors for COVID-19 in incarcerated populations.<br><br>METHODS: A systematic search of PubMed, Scopus, and Google Scholar was conducted for English articles until October 2025. Study quality was assessed using the PRISMA checklist and NOS tool. Meta-analysis was performed in Stata 17 using a random-effects model, with odds ratios as the primary effect measure and statistical significance set at P < 0.05. Heterogeneity was evaluated via I[2] statistics.<br><br>RESULTS: Twelve articles were ultimately included in the study. For the meta-analysis, only 5 articles were considered, which evaluated sex, age, and vaccination status as the risk factors of COVID-19. The total sample size was 176169, consisting of 169117 males and 7,726 females. In most studies, the average age was reported to be around 40 years. Fully vaccinated prisoners were less likely to contract COVID-19 than unvaccinated ones (OR: 0.38; 95% CI: 0.22, 0.67; P = 0.001), while no significant relationships were found regarding sex and age.<br><br>CONCLUSIONS: Our findings confirm that full vaccination significantly protects against COVID-19 in prisons. Prioritizing vaccination campaigns, along with measures like mask use and hand hygiene, is essential to protect incarcerated individuals and the wider community.},
}
@article {pmid42568381,
year = {2026},
author = {Cebeci, F},
title = {The rise of hikikomori research: a bibliometric analysis of an emerging global phenomenon.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1862953},
pmid = {42568381},
issn = {1664-1078},
abstract = {INTRODUCTION: Hikikomori, characterized by prolonged and severe social withdrawal, has attracted growing international attention as research has extended beyond its original Japanese context. This study examines the growth dynamics, citation impact, productivity patterns, collaboration structure, and conceptual and intellectual development of the hikikomori literature.<br><br>METHODS: Data have been retrieved from the Web of Science Core Collection and Scopus databases. Following screening and deduplication, 348 unique publications from 2002 to 2025 have been included. Performance analysis and science mapping techniques have been applied using the bibliometrix R package, Biblioshiny, and VOSviewer.<br><br>RESULTS: Publication output has remained limited during the early years, has become more visible after 2010, and has increased markedly after 2018, with the highest annual output recorded in 2025 (n&#x202f;=&#x202f;62). Highly cited publications have included both core hikikomori studies and research related to internet addiction, digital behaviors, youth social withdrawal, and measurement. Scientific production has been concentrated among a limited group of authors and institutions, while 14 journals have formed the Bradford core. Japan has remained the dominant contributor, although substantial research activity has also been recorded in Italy, China, the United States, and other regions. International collaboration has been unevenly distributed and has remained less prominent than nationally based research production. Keyword analyses have revealed strong connections among hikikomori, social withdrawal, social isolation, depression, loneliness, mental health, and anxiety. Bibliographic coupling has revealed substantial overlap in shared reference bases, while thematic evolution has shown continuity around hikikomori and social isolation together with the later prominence of mental health, COVID-19, depression, and adolescent-related themes.<br><br>CONCLUSION: The findings have indicated that hikikomori research has developed into a broader and increasingly international field in which clinical, psychosocial, developmental, cultural, and digital perspectives have been represented. Greater interdisciplinary and cross-cultural engagement has therefore been identified as an important direction for future research.},
}
@article {pmid40314137,
year = {2026},
author = {Lam, BJW and Loh, MCS and Yew, YW},
title = {Telemedicine in the Care of Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis.},
journal = {Dermatitis : contact, atopic, occupational, drug},
volume = {37},
number = {4},
pages = {632-639},
doi = {10.1089/derm.2024.0173},
pmid = {40314137},
issn = {2162-5220},
mesh = {Humans ; *Dermatitis, Atopic/therapy ; *Telemedicine ; Severity of Illness Index ; Quality of Life ; COVID-19 ; },
abstract = {Importance: More patients are opting for telemedicine because of its convenience and potential cost savings, especially post-COVID-19. This is also applicable to atopic dermatitis (AD).Objective: To investigate telemedicine's impact on the care of patients with AD.Methods: Relevant articles from five databases-namely, MEDLINE, Embase, Scopus, CINAHL, and the Cochrane Library-were searched up to August 1, 2023. Controlled prospective clinical trials, long-term follow-up studies, retrospective studies, and observational studies that assessed the effectiveness of telemedicine in terms of patient- and physician-reported outcomes of AD were included. A random-effects model was chosen to estimate all pooled data, with results presented in forest plots.Results: Regarding teleconsultation, four studies reported decreases in Patient-Oriented Eczema Measure (POEM), Investigator Global Assessment, Scoring Atopic Dermatitis, and Dermatology Life Quality Index (DLQI), which were comparable with the control arm. For electronic interventions, POEM and Hand Eczema Severity Index significantly decreased from baseline in favor of telemedicine (P = 0.0003 and P < 0.00001, respectively), while no difference was observed for Eczema Area and Severity Index and DLQI.Conclusions: Telemedicine can be a useful adjunct to traditional face-to-face consultations in AD but with potential cost savings and convenience for patients.},
}
@article {pmid42349233,
year = {2026},
author = {Lv, F and Chen, Y and Xia, Y},
title = {Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.},
journal = {Journal of neuroimmunology},
volume = {419},
number = {},
pages = {579010},
doi = {10.1016/j.jneuroim.2026.579010},
pmid = {42349233},
issn = {1872-8421},
mesh = {Humans ; *COVID-19/complications/physiopathology/therapy/psychology/immunology ; Post-Acute COVID-19 Syndrome ; *Nervous System Diseases/diagnosis/therapy/etiology/physiopathology ; Animals ; },
abstract = {SARS-CoV-2 infection may result in persistent neuropsychiatric symptoms beyond the acute phase, often discussed under the umbrella term "Long COVID". These manifestations commonly include mood disturbances, post-traumatic stress symptoms, cognitive impairment, sleep disturbances, and fatigue, with substantial effects on daily functioning and quality of life. Despite these concerns, the pathophysiological mechanisms underlying these sequelae remain poorly understood, and the lack of specific biomarkers hampers the development of targeted interventions. This review synthesizes recent advances in the clinical presentation, underlying mechanisms, diagnostic approaches, and therapeutic strategies for neuropsychiatric sequelae of Long COVID. We also discuss current challenges and outline future research priorities to facilitate the establishment of standardized diagnostic criteria and the development of effective, mechanism-based therapies.},
}
@article {pmid42564287,
year = {2026},
author = {Mensah, C and Bodunrin, S},
title = {Injustice unmasked: a systematic review of social justice struggles during the COVID pandemic in Canada.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1856009},
pmid = {42564287},
issn = {2296-2565},
mesh = {*COVID-19/epidemiology ; Humans ; *Social Justice ; Canada/epidemiology ; *Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: The COVID-19 pandemic amplified social injustices through institutional system disruption among marginalized communities in Canada. This study fills an important literature gap by providing the first holistic systematic review with a theoretically grounded framework to anticipate and mitigate social injustices in future public health crises.<br><br>METHOD: Using PRISMA 2020 framework and the databases of Web of Science, Scopus, and PubMed (n&#x202f;=&#x202f;58, 2020-2023), the study analyzed the pandemic-induced inequities through the PEO framework.<br><br>RESULTS: Discrimination was identified as the most pervasive social injustice during the pandemic. Immigrants, Refugees, and Women were identified as the most vulnerable group impacted with various forms of social injustices due to the intersection between different social identities.<br><br>DISCUSSION: The novel PISIIM framework was developed to equip policy makers, social workers, and other stakeholders in anticipating and mitigating injustices in future public health crises.<br><br>https://www.prisma-statement.org/prisma-2020-flow-diagram.},
}
@article {pmid42564508,
year = {2026},
author = {Bösenberg, LH and Ueckermann, V},
title = {Pandem-ethics: Post-mortem reflection on healthcare worker ethics during the time of coronavirus disease 2019 pandemonium.},
journal = {Southern African journal of infectious diseases},
volume = {41},
number = {1},
pages = {798},
pmid = {42564508},
issn = {2313-1810},
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic created ethical and legal tension for healthcare workers (HCWs), who had to balance professional obligations with personal safety, family responsibilities and resource limitations. The concept of 'duty to care' re-emerged as a contested ethical construct during periods of workforce vulnerability and healthcare scarcity.<br><br>AIM: This article examines the ethical and juridical dimensions of HCWs' duty of care during the COVID-19 pandemic, focusing on the South African constitutional framework, occupational health obligations and professional regulation, and whether this duty is absolute or subject to reasonable limits.<br><br>SETTING: The discussion is situated within South Africa's healthcare response to the COVID-19 pandemic and the ethical expectations placed on clinicians in high-risk and emergency settings.<br><br>METHOD: A narrative review was conducted using PubMed, Google Scholar and grey literature. Sources included peer-reviewed ethical analyses, legal frameworks and policy documents. A thematic synthesis analysed moral theory, legal duty, reciprocity and public health ethics.<br><br>RESULTS: The duty of care is substantial but not limited. South African law supports coexistence of rights rather than hierarchical obligations. Ethical analysis shows that proportionality, reciprocity and reasonable risk mitigation conditions professional duty. Employers must ensure adequate protection, transparent triage systems and psychosocial support. Failure to ensure reciprocity risks moral coercion and workforce attrition. The pandemic highlighted the need to define the thresholds where professional obligation yields to legitimate self-protection.<br><br>CONCLUSION: The duty of care should be reconceptualised as a conditional, relational obligation grounded in constitutional values and public health ethics, with clear risk thresholds and enforceable reciprocal protections.<br><br>CONTRIBUTION: This article contributes to post-COVID-19 pandemic ethics literature by clarifying between the duty to treat, care and serve, proposing a Decatrad of operational reforms, reframing the duties as conditional, reciprocal and legally bounded.},
}
@article {pmid42564512,
year = {2026},
author = {Dawood, F and Singaram, VS and Cassim, B},
title = {An exploratory evaluation of the acceptability of revised physician examinations in South Africa initiated during the coronavirus disease 2019 pandemic.},
journal = {Journal of the colleges of medicine of South Africa},
volume = {4},
number = {1},
pages = {388},
pmid = {42564512},
issn = {2960-110X},
abstract = {BACKGROUND: This study explored the acceptability of the decentralised assessment of clinical competency (AOCC) and digital structured oral examination (SOE), introduced in South Africa (SA) during the coronavirus disease 2019 (COVID-19) pandemic, with a view to informing their potential continuation and refinement in post-pandemic contexts.<br><br>METHODS: A mixed-methods study was conducted with candidates and examiners from SA training centres who participated in the AOCC and SOE in 2020-2021. Quantitative data explored perceptions regarding the credibility of the revised formats. For deeper insights, focus group discussions were held. Data were analysed using descriptive statistics and thematic analysis.<br><br>RESULTS: Forty candidates completed the questionnaires with at least one representative from each SA training centre. Twelve examiners responded to the AOCC and 13 to the SOE questionnaires. Both groups viewed the revised formats broadly positively, highlighting the AOCC's fairness, relevance and acceptability. Analysis highlighted advantages such as logistical benefits, and challenges, including the need for standardisation of registrar training. The SOE was endorsed by more than 70% of participants for its standardisation, objectivity and breadth of content coverage. Both groups expressed concerns about limited examiner-candidate interaction, while candidates reported uncertainty regarding the depth of responses required.<br><br>CONCLUSION: The revised formats were broadly acceptable and perceived as valid alternatives to the previous format of the examination. These findings support the continuation of hybrid, decentralised formats for future assessments.<br><br>CONTRIBUTION: This study provides insight into the benefits and drawbacks of the amended Fellowship of the College of Physicians (SA) examination format, offering guidance for future reforms in medical assessment in SA and comparable resource-constrained contexts.},
}
@article {pmid42274123,
year = {2026},
author = {Saleem, S and Hussain, A and Haroon, M and Raza, A and Afzal, U and Anwar, MF and Imran, S and Iqbal, MU and Hajj, F},
title = {Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.},
journal = {Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis},
volume = {37},
number = {6},
pages = {288-295},
doi = {10.1097/MBC.0000000000001439},
pmid = {42274123},
issn = {1473-5733},
mesh = {Humans ; *Thrombelastography/methods ; *Fatigue Syndrome, Chronic/blood/diagnosis ; *COVID-19/blood/complications/diagnosis ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Pandemics ; *Betacoronavirus ; *Pneumonia, Viral/blood/diagnosis ; *Coronavirus Infections/blood/diagnosis ; Anticoagulants/therapeutic use ; },
abstract = {Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) share overlapping symptoms, and emerging evidence implicates persistent fibrinoid microclots in their pathophysiology, contributing to impaired microcirculation. This review explores the role of microclots and evaluates thromboelastography (TEG) as a potential diagnostic tool. A comprehensive literature review was conducted using major biomedical databases. Studies indicate microclots are prevalent in both conditions. Long COVID patients demonstrate a TEG profile of increased clot strength (maximum amplitude) and reduced fibrinolysis (LY30), suggesting a persistent hypercoagulable state. Despite its advantages in real-time assessment, TEG interpretation faces challenges from preanalytical variability and a lack of standardized protocols. Promising therapeutic trials, including anticoagulants (e.g., apixaban) and fibrinolytics (e.g., lumbrokinase), require further validation. Technological advancements like AI-driven TEG analysis and portable devices could improve diagnostic precision. In conclusion, persistent microclots are a key pathophysiological feature. TEG provides a promising, novel approach for detecting coagulation abnormalities and could guide treatment, but requires standardization in future clinical trials. Future research should integrate multiomics biomarkers for precision therapeutics to improve patient outcomes.},
}
@article {pmid42411507,
year = {2026},
author = {Kumar, V and Qadri, SH and Nardelli da Silva, AB and Malaj, A and Qadri, SF and Wajeeha, F and Kasina, P and Jumani, MM and Muhammad, H},
title = {Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.},
journal = {Journal of cardiovascular pharmacology},
volume = {88},
number = {2},
pages = {115-122},
pmid = {42411507},
issn = {1533-4023},
mesh = {Humans ; *Ivabradine/therapeutic use/adverse effects ; *Postural Orthostatic Tachycardia Syndrome/drug therapy/physiopathology/diagnosis/epidemiology ; *COVID-19/epidemiology ; Heart Rate/drug effects ; Treatment Outcome ; *Cardiovascular Agents/therapeutic use/adverse effects ; Female ; Male ; Adult ; },
abstract = {Postural orthostatic tachycardia syndrome (POTS) is a debilitating autonomic disorder characterized by excessive orthostatic tachycardia and significant functional impairment. Conventional therapies, including beta-blockers, often provide incomplete relief or are poorly tolerated. Ivabradine, a selective If channel inhibitor, reduces heart rate without affecting blood pressure or myocardial contractility, making it a promising option, particularly in post-COVID-19 POTS. This systematic review and meta-analysis evaluated the efficacy and safety of ivabradine in patients with POTS. PubMed, Embase, and the Cochrane Library were searched through August 2025 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420251073600). Eligible studies included randomized controlled trials, observational studies, and case series reporting ivabradine outcomes in POTS. Primary outcomes were changes in standing and supine heart rate; secondary outcomes included symptom burden, quality of life, and adverse events. A random-effects model was used, heterogeneity was assessed through sensitivity analyses, and certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation. Nine studies involving 245 patients were included. Ivabradine significantly reduced standing heart rate (-18.5 bpm; 95% confidence interval -23.3 to -13.8) and supine heart rate (-9.7 bpm; 95% confidence interval -13.4 to -6.1). Symptom improvement particularly palpitations, lightheadedness, and exercise intolerance was consistently reported across classic, pediatric, hyperadrenergic, and post-COVID-19 subgroups. Adverse events were infrequent and mild, most commonly transient visual disturbances, with no reports of severe bradycardia or hypotension. Heterogeneity was high, largely driven by pediatric and post-COVID-19 cohorts. In conclusion, ivabradine seems to provide meaningful heart rate reduction and symptomatic improvement in POTS with a favorable safety profile. However, evidence is limited by small, heterogeneous, predominantly observational studies, underscoring the need for large, multicenter randomized controlled trials.},
}
@article {pmid42556322,
year = {2026},
author = {Pizzato, HA and Bhattacharya, D},
title = {Guiding pluripotent stem cell therapies past the immune system.},
journal = {Stem cells translational medicine},
volume = {15},
number = {8},
pages = {},
pmid = {42556322},
issn = {2157-6580},
support = {R41AI191979/NH/NIH HHS/United States ; R41AI192172/NH/NIH HHS/United States ; },
mesh = {Humans ; *Pluripotent Stem Cells/immunology/transplantation ; Animals ; *Diabetes Mellitus, Type 1/therapy/immunology ; *Stem Cell Transplantation/methods ; *Graft Rejection/immunology/prevention &amp; control ; *Immune System ; },
abstract = {Pluripotent stem cell (PSC)-based therapies hold the potential to unlock cures for numerous diseases, including, but not limited to, Parkinson's disease, macular degeneration, heart failure, type 1 diabetes, and cancer. Yet as protocols to differentiate PSCs into therapeutically useful cell types have progressed rapidly, immunological rejection remains a major barrier that may limit the widespread use of such PSC-based therapies. In recent years, strategies to genetically modify PSCs to prevent immunological rejection of the downstream cell product have become a point of emphasis. Here, we provide an immunological perspective on these strategies, discussing the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms. We focus in particular on how these strategies apply to the treatment of type 1 diabetes.},
}
@article {pmid42560049,
year = {2026},
author = {Liu, Y and Ye, Q},
title = {From decline to resurgence: current perspectives on Mycoplasma pneumoniae.},
journal = {Clinical microbiology reviews},
volume = {},
number = {},
pages = {e0005126},
doi = {10.1128/cmr.00051-26},
pmid = {42560049},
issn = {1098-6618},
abstract = {SUMMARYMycoplasma pneumoniae pneumonia (MPP) is an acute respiratory infection caused by Mycoplasma pneumoniae (MP) and constitutes the primary cause of community-acquired pneumonia (CAP) among children aged 5 years and older in China. The clinical manifestations of MP-associated respiratory disease in children are diverse, ranging from mild upper respiratory symptoms to life-threatening pneumonia. Notably, during the implementation of nonpharmaceutical interventions (NPIs) aimed at curbing SARS-CoV-2 transmission, there was a significant decline in MP infection rates. However, a pronounced global resurgence of MP infections was documented in 2023-2024. The increasing global prevalence of macrolide resistance, particularly in China, coupled with limited alternative antibiotic options for children, increasing rates of coinfections, and the absence of a preventive vaccine, collectively exacerbate treatment challenges and increase the disease burden. Furthermore, the insufficient availability of MP nucleic acid testing and antimicrobial resistance surveillance in primary healthcare settings, coupled with the absence of a comprehensive epidemiological monitoring network, results in a vicious public health cycle. Recent advances and emerging genomic data have provided new insights into its pathogenesis and clinical management. Therefore, in this narrative review, we aim to (i) synthesize the current understanding of the etiological characteristics of MP and the present status of MPP diagnosis and treatment; (ii) analyze recent advances and drivers behind the global resurgence of MP infections; and (iii) propose integrated prevention and control strategies to increase the recognition of MPP and prevent unanticipated outbreaks.},
}
@article {pmid42560673,
year = {2026},
author = {Sung, GCY and Wu, Y and Fan, S and Dal Santo, T and González-Domínguez, NP and Sun, Y and Li, L and Li, K and Jiang, X and Tasleem, A and Wang, Y and Boruff, JT and Desai, P and Tougas, B and D'Onofrio, M and Krishnan, A and Adams, C and He, C and Henry, RS and Alkan, A and Rice, DB and Markham, S and Azar, M and Nassar, EL and Hu, S and Cañedo-Ayala, M and Neupane, D and Benedetti, A and Thombs, BD},
title = {Mental Health Symptom Changes by Sex or Gender Before and During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.},
journal = {JAMA network open},
volume = {9},
number = {8},
pages = {e2627595},
doi = {10.1001/jamanetworkopen.2026.27595},
pmid = {42560673},
issn = {2574-3805},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; Female ; Male ; *Anxiety/epidemiology ; *Depression/epidemiology ; Sex Factors ; Pandemics ; *Mental Health/statistics &amp; numerical data ; SARS-CoV-2 ; *Stress, Psychological/epidemiology ; },
abstract = {IMPORTANCE: A previous systematic review reported that general mental health and anxiety symptoms, but not depression or stress, worsened more for females or women than for males or men from before to during the COVID-19 pandemic based on 12 studies published up to August 2021.<br><br>OBJECTIVE: To update a systematic review on sex or gender differences in mental health symptom changes from before to during the COVID-19 pandemic.<br><br>DATA SOURCES: Medline, PsycINFO, CINAHL, Embase, Web of Science, China National Knowledge Infrastructure, Wanfang, medRxiv, and Open Science Framework Preprints were searched from December 31, 2019, to August 31, 2023.<br><br>STUDY SELECTION: Eligible studies included data to calculate changes in general mental health, anxiety symptoms, depression symptoms, or stress from before to during the COVID-19 pandemic by sex or gender.<br><br>DATA EXTRACTION AND SYNTHESIS: Standardized mean differences (SMDs) for continuous changes and proportions for dichotomous changes were used. Two independent reviewers extracted data and evaluated risk of bias. Data were pooled via random-effects models on March 21, 2024.<br><br>MAIN OUTCOMES AND MEASURES: The main outcome was the differences in SMD changes and proportions between women or females and men or males of mental health symptoms from before the COVID-19 pandemic to during the COVID-19 pandemic.<br><br>RESULTS: The study included 27 unique cohorts from 14 countries (n&#x2009;=&#x2009;102-18&#x202f;127; 31&#x202f;155 women or females and 30&#x202f;737 men or males). Differences in SMD change between men and women were minimal and not statistically significant for continuous outcomes of general mental health (0.01 [95% CI, -0.07 to 0.10 and 95% prediction interval (PI), -0.23 to 0.25]; 8 cohorts; 21&#x202f;762 participants; heterogeneity [I2] =&#x2009;81.4%), anxiety (0.09 [95% CI, -0.04 to 0.22 and 95% PI, -0.27 to 0.45]; 7 cohorts; 6039 participants; I2&#x2009;=&#x2009;68.7%), depression (0.10 [95% CI, -0.00 to 0.20 and 95% PI, -0.23 to 0.43]; 12 cohorts; 9750 participants; I2&#x2009;=&#x2009;65.4%), and stress (-0.08 [95% CI, -0.16 to 0.01 and 95% PI, -0.18 to 0.02]; 8 cohorts; 2994 participants; I2&#x2009;=&#x2009;0%). Substantial heterogeneity, high risk of bias, or both were present across analyses. No studies reported changes for gender minority groups (eg, transgender, nonbinary).<br><br>CONCLUSION AND RELEVANCE: In this systematic review and meta-analysis of sex or gender differences in mental health changes from before to during the COVID-19 pandemic, no significant differences were found. However, findings should be interpreted cautiously and may not apply in all settings due to heterogeneity and methodological limitations of included studies.},
}
@article {pmid42563962,
year = {2026},
author = {Chen, R},
title = {Human interferon-ω: an underappreciated type I interferon.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1891351},
pmid = {42563962},
issn = {1664-3224},
mesh = {Humans ; *Interferon Type I/immunology/genetics ; Autoantibodies/immunology ; Autoimmunity ; Animals ; Immune Tolerance ; Virus Diseases/immunology ; },
abstract = {Interferon-ω (IFN-ω) is a member of the human type I interferon family that has historically been overshadowed by IFN-α and IFN-β. Recent human "natural perturbations", most notably selective neutralization of IFN-ω by autoantibodies in life-threatening viral infections, have renewed interest in this comparatively understudied cytokine and indicate that its antiviral activity may not always be fully compensated in defined clinical settings. This renewed focus has prompted reassessment of its single-gene organization, distinct antigenicity, intermediate receptor-binding kinetics, cellular sources, and regulatory mechanisms. In parallel, thymus-centered tolerance disorders, including autoimmune regulator (AIRE) deficiency, additional inborn errors of immune tolerance, and acquired "sick thymus" states, establish anti-IFN-ω autoantibodies as a stable, high-penetrance immunophenotype linking tolerance failure to durable cytokine-directed autoimmunity. Beyond antiviral defense, multi-omic studies in lupus-spectrum disease suggest tissue- and compartment-specific IFN-ω signals within broader type I interferon programs, yet endogenous IFN-ω remains rarely quantified with ligand-level resolution. This Review integrates current knowledge of IFN-ω from molecular regulation to human disease. Further progress will require subtype-resolved measurement, direct comparison with other type I interferons under matched conditions, and human genetic studies testing whether rare IFNW1 variants contribute to severe viral disease.},
}
@article {pmid37231727,
year = {2024},
author = {Mishra, R and Chaudhary, K and Mishra, I},
title = {Weapons and Strategies against COVID-19: A Perspective.},
journal = {Current pharmaceutical biotechnology},
volume = {25},
number = {2},
pages = {144-158},
doi = {10.2174/1389201024666230525161432},
pmid = {37231727},
issn = {1873-4316},
mesh = {Humans ; *Drug Repositioning/methods ; *Antiviral Agents/therapeutic use/pharmacology ; COVID-19 ; SARS-CoV-2/drug effects ; *COVID-19 Drug Treatment ; Pandemics ; *Coronavirus Infections/drug therapy ; *Pneumonia, Viral/drug therapy ; *Betacoronavirus/drug effects ; Virus Replication/drug effects ; },
abstract = {Currently, there are no approved treatments for the fatal infectious coronavirus disease. The process of identifying new applications for approved pharmaceuticals is called drug repurposing. It is a very successful strategy for drug development as it takes less time and cost to uncover a therapeutic agent than the de novo procedure. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the seventh coronavirus that has been identified as a causative agent in humans. SARS-CoV-2 has been recorded in 213 countries, with over 31 million confirmed cases and an estimated death rate of 3%. Medication repositioning may indeed be regarded as a unique therapeutic option for COVID-19 in the present situation. There are various drugs and techniques, which are being used to treat the symptoms of COVID-19. These agents are directed against the viral replication cycle, viral entrance, and viral translocation to the nucleus. Additionally, some can boost the innate antiviral immune response. Drug repurposing is a sensible method and could be a vital approach to treat COVID-19. Combining some of the drugs or supplements with an immunomodulatory diet, psychological assistance, and adherence to standards can ultimately act against COVID-19. A better knowledge of the virus itself and its enzymes will enable the development of more precise and efficient direct-acting antivirals. The primary aim of this review is to present the various aspects of this disease, including various strategies against COVID-19.},
}
@article {pmid42555410,
year = {2026},
author = {Mashhadi Abolghasem Shirazi, M},
title = {Comparative innate immune responses across major RNA and DNA viral infections: Mechanisms, immunopathology, and therapeutic perspectives.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2714657},
doi = {10.1080/21645515.2026.2714657},
pmid = {42555410},
issn = {2164-554X},
mesh = {Humans ; *Immunity, Innate/immunology ; *DNA Virus Infections/immunology/pathology/drug therapy/therapy ; Innate Immunity Recognition ; *RNA Virus Infections/immunology/pathology/drug therapy ; Antiviral Agents/therapeutic use ; Animals ; cGAS-STING Signaling Pathway ; *RNA Viruses/immunology ; Receptors, Pattern Recognition/immunology ; *DNA Viruses/immunology ; Host-Directed Therapy ; Immune Evasion ; },
abstract = {Innate immunity is the first defense against viral infections, limiting viral replication and initiating adaptive immunity. Viral pathogens are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), (RIG-I-like receptors) RLRs, and the (cyclic GMP-AMP synthase) cGAS-STING pathway, which trigger interferon production and antiviral responses. This review compares innate immune responses to major RNA viruses (influenza, SARS-CoV-2, HIV) and DNA viruses (HSV, HBV, CMV). While these viruses activate similar pathways, they differ in interferon dynamics, inflammatory responses, immune cell activation, and immune evasion mechanisms. RNA viruses often induce rapid and strong innate responses, whereas many DNA viruses establish persistence through immune modulation. Dysregulated innate immunity can contribute to cytokine storms, chronic inflammation, and tissue damage. Therapeutic strategies targeting innate immunity, such as interferons, cytokine inhibitors, PRR agonists, and host-directed antivirals, may improve outcomes. Infection severity depends on the timing, magnitude, and regulation of innate immune responses.},
}
@article {pmid42555953,
year = {2026},
author = {Shankar, R and Wang, L and Ho, SH and Liew, MF and Kumar Gollamudi, SP and Wong, TC and Wong, S},
title = {Cost-Effectiveness of Virtual Emergency Care Models: Systematic Review.},
journal = {JMIR mHealth and uHealth},
volume = {14},
number = {},
pages = {e82143},
doi = {10.2196/82143},
pmid = {42555953},
issn = {2291-5222},
mesh = {Humans ; *Cost-Benefit Analysis ; Cost-Effectiveness Analysis ; *Telemedicine/economics ; *Emergency Medical Services/economics/methods ; *COVID-19/epidemiology ; },
abstract = {BACKGROUND: Virtual care technologies have rapidly expanded in emergency medicine, particularly following the COVID-19 pandemic. However, comprehensive economic evaluations of their cost-effectiveness remain fragmented across different clinical applications and health care settings, creating uncertainty for policymakers and health care administrators considering implementation.<br><br>OBJECTIVE: This study aimed to systematically review and synthesize evidence on the cost-effectiveness of virtual emergency care models compared to traditional in-person emergency care across diverse clinical conditions, populations, and health care settings.<br><br>METHODS: We conducted a systematic review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, searching 8 electronic databases (PubMed, Embase, Scopus, Web of Science, CINAHL, Cochrane Library, MEDLINE, and PsycINFO) from inception to February 2025. We included full economic evaluations comparing virtual emergency care interventions with usual care. Two reviewers independently screened studies, extracted data, and assessed quality using the Drummond checklist and Consensus Health Economic Criteria (CHEC) list. Evidence certainty was evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. Given heterogeneity in interventions and methods, we conducted a narrative synthesis by virtual care modality and clinical application.<br><br>RESULTS: From 5817 identified references, 13 studies met inclusion criteria, representing diverse virtual care modalities across 6 countries (United States, Australia, Italy, Canada, Haiti, and Belgium). All included studies reported favorable economic outcomes for virtual emergency care. Video consultation was the most common modality (11/13 studies), achieving 31% to 73% reduction in patient transfers and cost savings of US $73 (AUD $105) to US $5118 per encounter. A total of 6 (46%) studies found virtual care to be dominant (both less costly and more effective). Incremental cost-effectiveness ratios ranged from US $1273 (&#x20ac;990) to US $108,363 per quality-adjusted life year, with most below accepted willingness-to-pay thresholds. Transfer avoidance was the primary economic driver, particularly in rural settings. Quality assessment revealed high methodological rigor (mean Drummond score 92.3%, SD 6.0%; mean CHEC score 95%, SD 4.2%). Using GRADE, evidence certainty was rated high for cost-effectiveness, moderate for transfer reduction and quality of life improvements, and low for emergency department length of stay and mortality benefits.<br><br>CONCLUSIONS: Virtual emergency care demonstrates strong and consistent cost-effectiveness across diverse clinical conditions, populations, and health care settings. The evidence particularly supports implementation for stroke care, pediatric emergencies, and rural/remote populations where transfer avoidance drives substantial economic benefits. All evaluated modalities achieved favorable economic outcomes, suggesting technology should match context rather than maximize sophistication. These findings provide robust economic justification for expanding virtual emergency care access and removing regulatory barriers. As health care systems face mounting pressures from aging populations, workforce shortages, and budget constraints, virtual emergency care offers a proven strategy for improving access and quality while reducing costs.<br><br>TRIAL REGISTRATION: PROSPERO CRD42025648218; https://www.crd.york.ac.uk/PROSPERO/view/CRD42025648218.},
}
@article {pmid42556039,
year = {2026},
author = {Li, H and Du, H and Xu, R and Xue, H and Liu, Y and Cao, Y and Guo, Z and Pan, J and Liu, Y},
title = {Point-of-care detection for respiratory diseases: From samples and biomarkers to principles and applications.},
journal = {Talanta},
volume = {312},
number = {Pt A},
pages = {130377},
doi = {10.1016/j.talanta.2026.130377},
pmid = {42556039},
issn = {1873-3573},
abstract = {Early screening can significantly reduce the severe morbidity and mortality of respiratory diseases and alleviate the burden on public healthcare systems. Point-of-care (POC) devices refer to portable instruments that meet the REASSURED criteria and can be conveniently used near the patient without professional laboratory conditions. POC devices played an important role in patient initiated early diagnosis during the COVID-19 pandemic, demonstrating great potential. From a macro-to-micro perspective, this review first comprehensively introduces clinically relevant sample types, including blood, respiratory tract and oral samples, and exhaled breath, along with the clinical significance of corresponding biomarkers (nucleic acids, proteins, gaseous molecules, extracellular vesicles, circulating tumor cells, and pathogen particles) and pre-processing methods. Subsequently, it summarizes the test principles and promising bioreceptors including base pairing-based systems (PCR, isothermal amplification, CRISPR/Cas), antibodies and antibody mimetics, and other affinity-based recognition elements, and innovatively presents portable integration platforms of biosensors from the perspective of bioreceptor compatibility. It then evaluates the application performance of transducers and corresponding optical or electrochemical portable detection devices, including SERS, e-nose, nanopore sensors, and portable GC-MS. Finally, the latest applications of computer technology and artificial intelligence tools in POC detection for respiratory diseases, spanning device design, bioreceptor screening, biomarker discovery, and diagnostic data processing, are presented by functional category. This review aims to provide a reference for the research and application of multiplex biomarker/sample/disease POC testing in respiratory diseases, and to offer perspectives on future directions for technological innovation, intelligentization, and commercial translation.},
}
@article {pmid42556934,
year = {2026},
author = {Donskey, CJ},
title = {Carbon dioxide monitoring and other practical tools to investigate infection prevention issues associated with heating, ventilation, and air conditioning systems: You can't improve what you don't measure.},
journal = {American journal of infection control},
volume = {54},
number = {9S},
pages = {S34-S41},
doi = {10.1016/j.ajic.2026.02.008},
pmid = {42556934},
issn = {1527-3296},
mesh = {Humans ; *Ventilation/methods/standards ; *Carbon Dioxide/analysis ; *Air Conditioning/methods ; *Infection Control/methods ; *Heating/methods ; *Environmental Monitoring/methods ; Aerosols/analysis ; COVID-19/prevention &amp; control ; *Cross Infection/prevention &amp; control ; },
abstract = {BACKGROUND: Heating, ventilation, and air conditioning (HVAC) systems play an essential role in minimizing the risk for transmission of airborne pathogens. A basic understanding of how HVAC systems work and of tools that are available to assess their performance is essential for infection prevention.<br><br>METHODS: The published English literature was searched for articles on use of practical tools to assess ventilation and airflow and their application to address infection prevention issues related to health care HVAC systems.<br><br>RESULTS: Carbon dioxide monitoring is an inexpensive, easy-to-use tool that provides rapid information on the quality of ventilation and the efficacy of interventions. Clearance of aerosol particles provides supplemental information on ventilation and devices that emit smoke or condensed moisture show patterns of airflow. Multiple publications have demonstrated the use of these tools to evaluate ventilation and airflow patterns and assess the impact of interventions.<br><br>CONCLUSIONS: Several practical tools are available to assess ventilation and patterns of airflow. These tools can be used to develop effective interventions to reduce the risk for airborne transmission of pathogens.},
}
@article {pmid42556949,
year = {2026},
author = {Bondzi-Simpson, A and Hallet, J},
title = {What Do Population-based Studies Tell Us about the Ideal Timing of Surgical Resection for Colorectal Cancer?.},
journal = {Advances in surgery},
volume = {60},
number = {1},
pages = {149-167},
doi = {10.1016/j.yasu.2026.03.014},
pmid = {42556949},
issn = {1878-0555},
mesh = {Humans ; *Colorectal Neoplasms/surgery ; Treatment Delay ; *Time-to-Treatment ; COVID-19/epidemiology ; Colorectal Surgical Procedures ; },
abstract = {Timely access to curative-intent colorectal cancer (CRC) surgery is a central component of surgical quality. Yet contemporary evidence challenges historical assumptions that shorter wait times always confer better outcomes. Drawing on population-based studies which offer the most robust and generalizable data this article synthesizes what is known about the relationship between surgical delay and oncologic outcomes in CRC. We outline key conceptual considerations in defining wait-time intervals, discuss lessons from the coronavirus disease 2019 pandemic, and identify gaps for future research. Ultimately, wait times should be applied as flexible, evidence-informed quality indicators that support patient-centered, biologically sound, and operationally feasible cancer care.},
}
@article {pmid42557465,
year = {2026},
author = {Bai, X and Dong, S},
title = {Clinical outcomes of neurosurgical patients during the COVID-19 pandemic: a systematic review and meta-analysis of global data.},
journal = {Acta neurologica Belgica},
volume = {},
number = {},
pages = {},
pmid = {42557465},
issn = {2240-2993},
abstract = {BACKGROUND: COVID-19 pandemic has substantially affected neurosurgical care globally through service reorganizations, delayed presentation, alterations in case selection, and limited perioperative resources. However, overall impact of these changes on clinical outcomes in neurosurgical patients remains unclear. Hence, this review evaluated clinical outcomes of neurosurgical patients managed during COVID-19 era compared with pre-pandemic era.<br><br>METHODS: Systematic search of PubMed, Embase, Scopus, Web of Science was conducted from inception of database till March 2026. Pooled effect estimates were calculated using random-effects meta-analysis. Odds ratios (ORs) were used for dichotomous outcomes and weighted mean differences (WMDs) for continuous outcomes. Heterogeneity was assessed using I&#xb2; statistic.<br><br>RESULTS: Twenty studies were included. In the primary pre-pandemic comparison, mortality was significantly higher during the COVID-19 era across 18 studies including 35,639 patients (OR&#x2009;=&#x2009;1.49, 95%CI 1.20-1.85; I&#xb2; = 44.7%). Postoperative complications were also increased across 13 studies including 12,174 patients (OR&#x2009;=&#x2009;1.44, 95%CI 1.04-1.98; I&#xb2; = 78.5%). No significant difference was observed for requirement of mechanical ventilation (OR&#x2009;=&#x2009;1.20, 95%CI 0.81-1.76; I&#xb2; = 0.0%), whereas length-of-stay findings were inconclusive because of high heterogeneity (WMD = -1.46 days, 95%CI -3.19 to 0.28; I&#xb2; = 85.8%).<br><br>CONCLUSIONS: Neurosurgical patients managed during the COVID-19 era had higher mortality and postoperative complication rates than those treated before the pandemic. These findings highlight the vulnerability of neurosurgical care systems to large-scale health-system disruption and underscore the need for resilient strategies to ensure timely and safer neurosurgical care during future disruptions.<br><br>CLINICAL TRIAL REGISTRATION: Not applicable.},
}
@article {pmid42557823,
year = {2026},
author = {Lituma-González, WD and Casella, C and Ballaz, SJ},
title = {Resolution-Oriented Immunopharmacological Potential of the Lipid Matrix of Rhynchophorus palmarum Larvae in Viral Respiratory Infections: A Perspective Review.},
journal = {Lipids},
volume = {},
number = {},
pages = {},
doi = {10.1002/lipd.70077},
pmid = {42557823},
issn = {1558-9307},
abstract = {This review explores how the fatty acid (FA) profile of the Amazonian Rhynchophorus palmarum larva (Chontacuro), traditionally eaten for respiratory ailments, might biochemically mitigate viral respiratory infections. During metamorphosis, this insect utilizes its unique FA matrix to survive severe, self-inflicted oxidative and inflammatory tissue stress. The authors hypothesize that when consumed by humans, these insect lipids undergo chylomicron-mediated lymphatic transport. This pathway bypasses initial liver metabolism, delivering unsaturated FAs directly to the pulmonary microvasculature and alveolar macrophages in the lungs. Once there, the FAs are proposed to act via two main mechanisms: One is inflammation resolution, where the ω-3 fraction is hypothesized to be metabolized via the 15-LOX enzyme pathway into Specialized Pro-Resolving Mediators (SPMs) and activate PPAR-α, potentially shifting the immune response from chronic inflammation toward active tissue repair. The other is viral sabotage: The highly unsaturated fats increase cell membrane fluidity, destabilizing the "lipid rafts" that viruses rely on for cellular entry and assembly. While in vitro and in silico models suggest a synergistic "cocktail effect" that primes and then resolves the immune response, the authors note that direct human clinical evidence is currently lacking.},
}
@article {pmid42558130,
year = {2025},
author = {Real, FJ and Meisman, A and Wijesooriya, J and Crosby, LE and Rosen, BL},
title = {Using Intervention Mapping to Develop a Virtual Reality Intervention to Support COVID-19 Vaccination Among Black Families.},
journal = {Journal of medical extended reality},
volume = {2},
number = {1},
pages = {230-243},
pmid = {42558130},
issn = {2994-1520},
abstract = {Pediatric uptake of COVID-19 vaccines is low, particularly among Black children. There is a critical need for pediatric clinicians to address COVID-19 vaccine concerns through community-centered, culturally appropriate communication strategies. Virtual reality (VR) may provide a modality to support clinicians' relational skills related to COVID-19 vaccine by providing a safe, realistic environment to practice preferred communication behaviors. The aim of this project was to use Intervention mapping (IM), a six-step framework, to cocreate a VR intervention with Black families to support COVID-19 vaccine uptake. For IM, step 1 (develop a logic model of the problem) and step 2 (identify program objectives and outcomes), our team used quantitative and qualitative methods to identify caregiver, adolescent, and young adult factors associated with intention and decisions to vaccinate against COVID-19. IM step 3 (program design) consisted of assembling planning board sessions with the Black community stakeholders including adolescents, young adults, and caregivers, along with primary care pediatric clinicians. A modified Delphi technique was used to build consensus for salient COVID-19 vaccine concerns and communication preferences. During IM step 4 (program production), the VR intervention (Virtual Immersive Communication Training on Recommending Immunization COVID-19) and accompanying simulation flowsheets were developed. An implementation plan was developed for IM step 5 (program implementation) and an evaluation plan for IM step 6 (evaluation). Through IM, an intervention centered on the needs and preferences of Black families was successfully developed. Lessons learned using IM included: (1) the importance of collaborating with patients and families on clinical topics where there is limited data, (2) the use of rigorous methods such as the modified Delphi approach to help build consensus, and (3) community relationships are critical to drive culturally informed technology-based interventions, especially when urgency is required.},
}
@article {pmid42558223,
year = {2025},
author = {Pan, A and Moreau, S and Rafeeh, G and Ahsan, N and Robinson, CL and Lang, M and Paul, M and Khan, J and Thérond, A},
title = {The Role of Virtual Reality in Chronic Pain and Loneliness: Narrative Review.},
journal = {Journal of medical extended reality},
volume = {2},
number = {1},
pages = {142-159},
pmid = {42558223},
issn = {2994-1520},
abstract = {Chronic pain and loneliness are significant public health challenges that often intersect, leading to a cyclical cycle of physical, emotional, and social distress. The COVID-19 pandemic has further exacerbated these issues, highlighting the need for innovative solutions. Virtual reality (VR) has emerged as a promising tool for managing chronic pain and alleviating loneliness, but its potential to address the complex interplay between these conditions remains underexplored. This narrative review aims to synthesize current evidence on the effectiveness of VR interventions in managing chronic pain and loneliness, identify key themes and knowledge gaps, and provide recommendations for future research and clinical applications. A literature search was conducted, focusing on randomized controlled trials, cohort studies, and case-control studies published between January 2020 and December 2024 that investigated VR interventions for chronic pain and loneliness in adult populations. Studies were analyzed for recurring themes, trends, applications, and implications. VR interventions demonstrate the potential to reduce pain intensity, improve mood, and foster social connectedness through immersive, interactive experiences. Several key themes emerged, including the importance of multisensory stimulation, personalization, and social presence in enhancing VR's therapeutic effects. However, challenges related to accessibility, user experience, and long-term efficacy remain. VR offers a promising approach to managing chronic pain and loneliness, with the potential to improve patient outcomes and quality of life. Future research should address identified barriers, develop culturally adaptive interventions, leverage artificial intelligence for personalization, and conduct longitudinal studies to assess long-term benefits and potential side effects. Integrating VR into collaborative health care teams and comprehensive treatment plans has the potential to maximize its impact and help with cost efficiencies. Advancing VR technology will require continued research to maximize its potential to enhance physical, emotional, and social well-being for those experiencing chronic pain and loneliness.},
}
@article {pmid42559013,
year = {2026},
author = {Asim, M and Abuhelaiqa, EA and Malki, HAA},
title = {Breaking barriers: A decade-long institutional journey to sustain mandated living kidney-donor follow-up in Qatar.},
journal = {Qatar medical journal},
volume = {2026},
number = {2},
pages = {39},
pmid = {42559013},
issn = {0253-8253},
abstract = {INTRODUCTION: Living kidney donation is essential for expanding transplant opportunities, given the worldwide scarcity of deceased donor organs. Kidney donors experience a slight but detectable long-term increase in risks such as hypertension, diabetes, and end-stage kidney disease, making sustained follow-up essential. However, adherence to post-donation surveillance remains inconsistent worldwide.<br><br>METHODS: This descriptive evaluation included living kidney donors enrolled in Qatar's national follow-up program at Hamad Medical Corporation, implemented in January 2017. The program mandates nephrology follow-up at 1 and 6 months post-donation and annually thereafter, with standardized clinical and laboratory monitoring. Adherence rates from 2017 to 2024 were assessed against institutional benchmarks (>90%).<br><br>RESULTS: Of 349 registered donors nationwide, 233 donated after program implementation. Despite a fourfold increase in eligible donors between 2017 and 2024, 1- and 6-month follow-up rates remained near 100%, and annual adherence consistently exceeded 90% from 2020 onward. Compliance with the nephrologist-led review of clinical and laboratory data approached 100% among attendees. Sustained performance was temporally associated with system-level interventions, including coordinator-led outreach, structured process redesign, enhanced donor education, and continuous quality improvement initiatives. Follow-up rates also remained robust during the COVID-19 pandemic despite the transition to telephone-based consultations.<br><br>CONCLUSION: A centralized, quality-driven national framework can achieve durable, high-level adherence to long-term follow-up among living kidney donors, even amid rapid program expansion. This scalable model provides a strong foundation for registry-based outcome monitoring and evidence-informed donor care.},
}
@article {pmid37723634,
year = {2025},
author = {Hajihasani, MM and Farkhad, NK and Mahmoudi, A and Sahebkar, A},
title = {How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery.},
journal = {Current medicinal chemistry},
volume = {32},
number = {8},
pages = {1575-1588},
pmid = {37723634},
issn = {1875-533X},
mesh = {Humans ; *COVID-19/immunology/therapy ; SARS-CoV-2/immunology ; *Immunotherapy/methods ; Immunity, Innate ; Pandemics ; Adaptive Immunity ; Killer Cells, Natural/immunology ; *Coronavirus Infections/immunology/therapy ; },
abstract = {The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2) is one of the biggest unsolved global problems of the 21[st] century for which there has been no definitive cure yet. Like other respiratory viruses, SARS-COV-2 triggers the host immunity dramatically, causing dysfunction in the immune system, both innate and adaptive, which is a common feature of COVID-19 patients. Evidence shows that in the early stages of COVID-19, the immune system is suppressed while it is overactive in severe patients characterized by excessive and prolonged inflammatory responses called "Cytokine Storm". There are many elements in the immune system that undergo alterations as the disease progresses. Some significant changes in the innate immune system following infection with SARS-COV-2 include delayed or inhibited interferon type 1 production by the infected cells leading to elevated virus replication, excessive recruitment of activated monocytes and macrophages, decrease in eosinophil population (eosinopenia), consequent decrease in CD[8+]T lymphocyte proliferation, natural killer (NK) cell dysfunction, and increase in neutrophil infiltration (neutrophilia) and neutrophil extracellular trap (NET) formation. Moreover, hallmark alterations in the adaptive immune system in this process cause an overall decrease in the T lymphocyte number (lymphopenia) and changes in the activity of some lymphocyte subsets and a number of B cells. This review delves into the mentioned changes in the immune system following SARS-COV-2 infection and the implications thereof to guide the development of immunotherapies for patients with COVID-19.},
}
@article {pmid42500896,
year = {2026},
author = {Blasi, F and Casiraghi, M and Morello, M and Arnò, C and Golino, M and Franceschi, E and Alicandro, G and Vicenzi, M and De Ponti, R},
title = {Bradyarrhythmia in Hospitalized Patients With SARS-CoV-2 Infection: A Systematic Scoping Review and Clustering Analyses.},
journal = {Journal of the American Heart Association},
volume = {15},
number = {15},
pages = {e047934},
doi = {10.1161/JAHA.125.047934},
pmid = {42500896},
issn = {2047-9980},
mesh = {Humans ; *Bradycardia/therapy/epidemiology/diagnosis/etiology/mortality ; *COVID-19/complications/therapy/epidemiology/mortality ; Female ; Cluster Analysis ; Middle Aged ; Male ; Hospitalization ; Aged ; SARS-CoV-2 ; Clustering Algorithms ; Adult ; },
abstract = {BACKGROUND: Among arrhythmias observed in SARS-CoV-2 infection, bradyarrhythmia poses the dilemma of urgent pacing. In this population, data on patients' characteristics and clinical outcomes are lacking.<br><br>METHODS: A systematic literature search was conducted for bradyarrhythmia associated with COVID-19 from inception to December 2024 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines; quality assessment was performed using the Joanna Briggs Institute critical appraisal tool. From each report, the type of bradyarrhythmia, relevant clinical variables, and outcomes were extracted. Comparison between groups with different bradyarrhythmias was performed for the variables available in all cases. Cluster analyses were performed using both the k-means and hierarchical methods.<br><br>RESULTS: Overall, 103 case series/case reports were identified reporting data on 151 patients: 76 with sinus node dysfunction and 75 with atrioventricular block (AVB). Median age was 54.5&#x2009;years; 10.6% were pediatric patients. Despite few comorbidities, 24.5% required mechanical ventilation and 11.3% died. Sinus node dysfunction was more frequently associated with antiviral therapy, while patients with permanent AVB were significantly older (58 versus 48.5&#x2009;years; P=0.011) and showed a significant trend toward a higher mortality rate (23.1% versus 5.6%; P=0.048) than those with transient AVB. Cluster analyses showed a higher inflammatory profile in younger patients associated with left ventricular dysfunction and AVB.<br><br>CONCLUSIONS: COVID-19 can be associated with sinus node dysfunction or AVB even in a young patient population exhibiting a high inflammatory profile. The need for mechanical ventilation and the mortality rate was not negligible. Sinus node dysfunction was associated with the use of antiviral therapy, and permanent AVB was associated with a higher mortality rate.},
}
@article {pmid41972671,
year = {2026},
author = {Asaba, CN and Gwanyama, BN and Ayuk, HS and Odo, TI and Bitazar, R and Noumi, T and Labonté, P and Bukong, TN},
title = {Neutrophil Extracellular Traps in Viral Infections: Regulation, Immune Consequences, and Pathogenic Outcomes.},
journal = {Cells},
volume = {15},
number = {7},
pages = {},
pmid = {41972671},
issn = {2073-4409},
support = {Relance 2024//The INRS-Armand-Frappier Sant&#xe9; Biotechnologie Research Centre/ ; 363424//A doctoral scholarship from the Fonds de Recherche du Qu&#xe9;bec./ ; },
mesh = {*Extracellular Traps/immunology ; Humans ; *Neutrophils/immunology ; *Virus Diseases/immunology ; Immunity, Innate ; COVID-19/immunology ; Animals ; SARS-CoV-2/immunology ; },
abstract = {Neutrophils are among the early responders of the innate immune system and play a key role in host defense against viral infections. Beyond their classical antimicrobial functions, neutrophils can engage in a specialized defense mechanism by releasing web-like extracellular DNA known as neutrophil extracellular traps (NETs). These extracellular traps are a mesh-like network of chromatin DNA decorated with cellular components, including histones, proteases, and antimicrobial enzymes, that function to contain and limit the spread of pathogens. While NET formation contributes to antiviral immunity, accumulating evidence indicates that excessive or dysregulated NET formation can significantly contribute to immunopathology during viral infections. Thus, depending on the context and outcome, NET formation may be viewed as a double-edged sword. Therefore, understanding the regulatory mechanisms governing NET formation and its harmful effects is critical for developing therapeutic strategies that enhance antiviral defense while minimizing tissue damage. In this review, we provide a comprehensive overview of the molecular mechanisms that drive NET formation and clearance, with a particular focus on how viruses modulate these processes to influence disease outcome. We also discuss the pathways underlying NET formation and subsequent neutrophil cell death (NETosis), including canonical and non-canonical pathways, and highlight key signaling axes involving SYK, MAPKs, and NF-κB. Using SARS-CoV-2 and hepatitis B virus as representative models, we examine how different viral components trigger, exploit, or evade NET targeting and how persistent accumulation of NETs can contribute to hyperinflammation, progressive tissue injury, and post-viral syndromes. We further explore emerging evidence linking impaired NET clearance and neutrophil heterogeneity, particularly low-density neutrophils (LDNs), to chronic inflammation and post-viral sequelae such as long COVID and autoimmune hepatitis. Finally, we summarize current and emerging therapeutic strategies aimed at modulating NET formation or enhancing NET clearance. Altogether, this review underscores the dual nature of NETs in viral infections, highlighting their potential roles in antiviral defense and tissue injury, and provides a framework for the development of targeted interventions to limit virus-induced immunopathology.},
}
@article {pmid41972882,
year = {2026},
author = {Wang, Z and Chen, B and Gao, Y and Wu, C and Shuai, Q and Yan, Y},
title = {Redox-responsive nanoparticles for enhanced mRNA delivery: a comprehensive review.},
journal = {Journal of materials chemistry. B},
volume = {14},
number = {15},
pages = {4546-4570},
doi = {10.1039/d6tb00186f},
pmid = {41972882},
issn = {2050-7518},
mesh = {Oxidation-Reduction ; Humans ; *Nanoparticles/chemistry ; *RNA, Messenger/chemistry/metabolism/administration &amp; dosage ; Animals ; COVID-19/prevention &amp; control ; },
abstract = {The clinical success of mRNA vaccines during the COVID-19 pandemic highlighted the therapeutic potential of mRNA while exposing persistent delivery barriers, including intrinsic instability, poor cellular uptake, and inefficient intracellular trafficking. Redox-responsive nanoparticles (NPs) provide a promising strategy to improve mRNA delivery by undergoing stimulus-triggered disassembly in the reductive cytosol, facilitating efficient mRNA release, endosomal escape, and enhanced translation. This review elucidates emerging structure-function relationships by systematically linking redox-labile chemistries (e.g., disulfide, diselenide, and polysulfide), carrier type, and NP architecture to key biological outcomes, including endosomal escape, redox responsiveness, transfection efficiency, and biodistribution. We further identify critical translational challenges-such as tumor redox heterogeneity, insufficient systematic preclinical evaluation, and manufacturing constraints-and propose actionable strategies, including multi-stimulus-responsive systems, microfluidic and process-analytical manufacturing, and formulation approaches to improve efficacy, reproducibility, and stability. Collectively, these insights provide a practical framework to guide the rational design and clinical translation of next-generation redox-responsive mRNA delivery platforms.},
}
@article {pmid41973314,
year = {2026},
author = {Peddireddy, S and VanWingerden, N and Patel, P and Howard, G and Berger, J},
title = {Stellate Ganglion Block in the Treatment of Long COVID: A Systematic Review.},
journal = {Current pain and headache reports},
volume = {30},
number = {1},
pages = {},
pmid = {41973314},
issn = {1534-3081},
mesh = {Humans ; *Autonomic Nerve Block/methods ; *Post-Acute COVID-19 Syndrome/therapy ; *Stellate Ganglion/drug effects ; Treatment Outcome ; },
abstract = {OBJECTIVES: This review evaluates stellate ganglion block as a treatment for long COVID, seeking to evaluate the treatment's efficacy by various symptoms and the limitations of the current literature.<br><br>STUDY DESIGN: Systematic Review.<br><br>SETTING: Ambulatory or Outpatient Setting.<br><br>METHODS, SUBJECTS: A systematic review of the current literature regarding use of stellate ganglion block in patients with long COVID was conducted. 2 databases were searched on August 28th, 2025. Search terms were "long COVID" and "stellate ganglion block", yielding 45 results. Studies examining patient outcomes after stellate ganglion block were included. Case reports, case series, basic science studies and previous reviews were excluded. Seven studies met inclusion criteria.<br><br>RESULTS: Patients received a single stellate ganglion block in some studies and multiple stellate ganglion blocks in others. All studies reported symptomatic improvement without control groups. Response rates ranged from 55.8% to 100%. The most robust improvements (>&#x2009;80% patients reporting relief) were seen in cough, dyspnea, headache, joint pain, pain interference/intensity, pins/needles, subjective relief.<br><br>CONCLUSION: Stellate ganglion block is a promising treatment that appears to generate substantive benefit for many of the symptoms seen in long COVID. However, the current literature has small, uncontrolled studies with heterogenous study designs and follow-up periods. Standardized research with larger sample sizes, control groups, and longer-term follow up is necessary to elucidate the degree of benefit. IRB approval and clinical trial registration not required.},
}
@article {pmid41973527,
year = {2026},
author = {Hudnall, SR and Jacobs, BC and Fields, KB},
title = {Functional Testing for Return to Activity with COVID-19.},
journal = {Current sports medicine reports},
volume = {25},
number = {4},
pages = {118-122},
doi = {10.1249/JSR.0000000000001330},
pmid = {41973527},
issn = {1537-8918},
mesh = {Humans ; *Return to Sport ; *COVID-19 ; *Exercise Test/methods ; SARS-CoV-2 ; Pandemics ; Post-Acute COVID-19 Syndrome ; Recovery of Function ; },
abstract = {Return-to-play decisions following COVID-19 infection remain challenging due to persistent variability in cardiopulmonary and functional recovery. This review examines four validated functional tests: the Timed Up and Go, 6-Minute Walk Test, Kasch Pulse Step Recovery Test, and 1-Minute Sit-to-Stand Test and their potential roles in assessing readiness for physical activity and sport after COVID-19 infection. These office-based assessments are simple, reproducible, and sensitive to impairments in cardiovascular, pulmonary, and musculoskeletal function. Evidence suggests that post-COVID-19 individuals may demonstrate significant deficits in performance across functional tests, supporting their integration into return-to-play evaluations. The 6-Minute Walk Test is recommended as the primary measure of functional capacity, with the 1-Minute Sit-to-Stand Test as a validated alternative. Incorporating functional testing into return-to-play protocols can enhance clinical decision-making, guide rehabilitation, and promote safe resumption of physical activity.},
}
@article {pmid41973776,
year = {2026},
author = {Fam, JY and Männikkö, N},
title = {Can the Bergen Facebook Addiction Scale be adapted across contexts? Evidence from a COnsensus-based Standards for the selection of health Measurement INstruments systematic review.},
journal = {Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors},
volume = {40},
number = {4},
pages = {484-497},
doi = {10.1037/adb0001149},
pmid = {41973776},
issn = {1939-1501},
mesh = {Humans ; *Psychometrics ; *Social Media ; COVID-19 ; Reproducibility of Results ; *Internet Addiction Disorder/diagnosis ; *Behavior, Addictive/diagnosis ; Pandemics ; *Psychiatric Status Rating Scales/standards ; Consensus ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: The Bergen Facebook Addiction Scale (BFAS) has served as a foundation for a series of adapted measures designed to assess social media-related behavioral addictions. Despite widespread application of these instruments, a systematic evaluation of their psychometric properties is lacking. This review aimed to evaluate the measurement properties of the BFAS and its adaptations using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology.<br><br>METHOD: A systematic search was conducted to identify psychometric studies of the BFAS and its adapted versions, including the BFAS-18, Bergen Social Media Addiction Scale (BSMAS), Bergen Mukbang Addiction Scale, Social Media Addiction during COVID-19 Pandemic scale, and Social Networks Addiction Scale-6 Symptoms. Eligible studies were assessed using the COSMIN Risk of Bias checklist, and the quality of evidence was graded according to the COSMIN-Grading of Recommendations Assessment, Development and Evaluation approach.<br><br>RESULTS: A total of 55 studies were included. The BFAS and BSMAS demonstrated strong evidence for structural validity, internal consistency, measurement invariance, and hypothesis testing, with high-quality evidence across multiple domains. The BFAS-18 and Bergen Mukbang Addiction Scale received more limited and inconsistent support, while the Social Media Addiction during COVID-19 Pandemic scale and Social Networks Addiction Scale-6 Symptoms remain underexplored with very low-quality evidence. Across all scales, evidence for content validity, reliability, measurement error, and responsiveness was sparse, highlighting important gaps.<br><br>CONCLUSIONS: The BFAS and BSMAS currently represent the most robust instruments for assessing Facebook and social media addiction, respectively. However, additional research is required to strengthen evidence for other adaptations, particularly in relation to content validity, measurement error, and responsiveness, as well as to evaluate linguistic and cultural invariance. (PsycInfo Database Record (c) 2026 APA, all rights reserved).},
}
@article {pmid41974008,
year = {2026},
author = {Albaloul, H and Nemer, A and Saini, N and Schuster, MG},
title = {Infectious Diseases: What You May Have Missed in 2025.},
journal = {Annals of internal medicine},
volume = {179},
number = {5_Supplement},
pages = {e2600983},
doi = {10.7326/ANNALS-26-00983},
pmid = {41974008},
issn = {1539-3704},
mesh = {Female ; Humans ; Anti-Bacterial Agents/therapeutic use ; COVID-19/prevention &amp; control ; HIV Infections/drug therapy ; Influenza Vaccines/therapeutic use ; *Clinical Trials as Topic ; *Communicable Diseases ; },
abstract = {This article highlights clinical trials on infectious diseases published in 2025 that we believe are highly relevant to internal medicine physicians who are not infectious diseases specialists. Selected studies address prevention and treatment strategies across infectious diseases. We highlight 2 studies of sexually transmitted infections (STIs): one examining the effectiveness of treating male partners to reduce recurrence of bacterial vaginosis and another study of doxycycline as postexposure prophylaxis against bacterial STI. A strategy for using methanamine hippurate to prevent recurrent urinary tract infections (UTIs) in older women is included in our review. We review the updated evidence supporting the effectiveness of COVID-19, respiratory syncytial virus, and influenza vaccines for the 2025-2026 season, and a modified messenger RNA influenza vaccine, which showed superior efficacy with an acceptable safety profile. In HIV care, a study of dual antiretroviral maintenance therapy showed that dolutegravir and lamivudine was noninferior to triple therapy at 48 weeks. A meta-analysis supporting shorter antibiotic courses for pyelonephritis and complicated UTIs provides important information for antibiotic stewardship strategies. In serious infections, dalbavancin was noninferior to standard therapy for Staphylococcus aureus bacteremia, whereas cefiderocol expanded treatment options for gram-negative bloodstream infections without clear superiority, particularly in carbapenem-resistant pathogens. Finally, a study found that elevated C-reactive protein identifies patients most likely to benefit from adjunctive corticosteroids in community-acquired pneumonia.},
}
@article {pmid41974432,
year = {2026},
author = {Watanabe, H and Nagao, R and Kawabata, K and Mizutani, Y},
title = {[Olfactory Nerve: The Vulnerability Inherent in its Unique System and Neurological Diseases].},
journal = {Brain and nerve = Shinkei kenkyu no shinpo},
volume = {78},
number = {4},
pages = {303-311},
doi = {10.11477/mf.188160960780040303},
pmid = {41974432},
issn = {1881-6096},
mesh = {Humans ; *Olfactory Nerve/pathology/physiopathology ; *Parkinson Disease/complications ; *COVID-19/complications ; *Nervous System Diseases ; Animals ; },
abstract = {The olfactory nerve possesses unique anatomical features, including direct central nervous system (CNS) projection and continuous regeneration. Scientific advances have elucidated mechanisms such as combinatorial receptor coding and signal amplification. This review summarizes these foundations and examines olfactory dysfunction in COVID-19 and Parkinson's disease (PD). In COVID-19, evidence suggests that SARS-CoV-2 targets sustentacular cells rather than olfactory neurons, causing gene downregulation and parosmia attributed to incomplete peripheral filtering, while direct CNS invasion remains rare. In PD, olfactory loss is a prodromal feature. However, seed amplification assays reveal that alpha-synuclein aggregation in the nasal mucosa does not fully correlate with olfactory dysfunction, as reflected by differences between PD and Multiple System Atrophy. This, together with correlations with cardiac sympathetic denervation, challenges simple pathogen propagation hypotheses. We propose that PD-related hyposmia reflects a systemic vulnerability involving deficits in energy metabolism and neural network organization, rather than solely peripheral protein aggregation. Understanding these pathologies requires a multifaceted approach beyond anatomical lesions.},
}
@article {pmid41975034,
year = {2026},
author = {Matthews, R and Alam, A and Bullmore, E and Michael, BD},
title = {Understanding the long-term neurological effects of SARS-CoV-2 infection.},
journal = {Nature reviews. Neurology},
volume = {22},
number = {6},
pages = {351-365},
pmid = {41975034},
issn = {1759-4766},
mesh = {Humans ; *COVID-19/complications ; *Nervous System Diseases/etiology ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Pandemics ; Cognitive Dysfunction/etiology/physiopathology ; },
abstract = {Post-COVID-19 condition (PCC), also known as long COVID, is a heterogeneous condition marked by persistent symptoms following acute SARS-CoV-2 infection. As approximately 6% of people who have experienced acute COVID-19 are estimated to develop PCC, the potential population is vast. Many of the key symptoms of PCC reflect involvement of the nervous system, ranging from cognitive impairment ('brain fog'), headaches and fatigue to anxiety and depression. This Review summarizes the spectrum of neurological and psychological symptoms that occur following acute SARS-CoV-2 infection, with a particular focus on the international consensus-based core outcome set for PCC. We also explore the proposed underlying mechanisms, including evidence for immune system dysregulation, microvascular dysfunction and volumetric changes on neuroimaging. In addition, we review ongoing and completed large-scale treatment trials. Growing evidence suggests a bidirectional interaction between symptoms traditionally considered neurobiological in origin, such as cognitive deficits and headache, and those within the purview of psychiatry, such as anxiety and depression. PCC represents an opportunity to better understand the long-term consequences of acute infection and improve management strategies and outcomes, not only for people with the condition but also for those with other post-viral syndromes that affect brain health.},
}
@article {pmid41975314,
year = {2026},
author = {Alhumaid, S and Alkhars, O and Algrafi, AS and Dossary, NA and Elhaj, N and Majzoub, RA and Turkistani, JA and Alhumaid, SM and Shaikh, HAA and Aldiaram, A and Alahmed, AH and Alomran, SA and AlQatifi, MB and Alkolib, MJ and Almubarak, MS and Al-Helal, H and Alhaddad, AJ and Alsouaib, HA and Albahrani, AA and Aldera, AH and Alnasser, FM and Alhmeed, N and Alsulaiman, MS and Al Alawi, Z and Alghazal, HA},
title = {Vaccine effectiveness across the Omicron evolutionary spectrum (BA.2, BA.5, XBB, JN.1, KP.3): a systematic review of studies published 2022-2025.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {41975314},
issn = {1471-2334},
mesh = {*Vaccine Efficacy ; Humans ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/immunology/epidemiology/virology ; *SARS-CoV-2/immunology/genetics ; },
abstract = {BACKGROUND: Since late 2021, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone rapid evolutionary diversification, giving rise to successive subvariants with increasing immune escape. In response, coronavirus disease 2019 (COVID-19) vaccination strategies transitioned from ancestral-strain vaccines to variant-adapted formulations. Real-world evidence on the effectiveness and durability of these updated vaccines across the full Omicron evolutionary spectrum remains fragmented. OBJECTIVES: To synthesise real-world evidence on the effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe clinical outcomes across successive Omicron subvariants from 2022 to 2025, with particular emphasis on variant-adapted vaccine formulations and waning immunity over time. METHODS: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and registered in PROSPERO. MEDLINE (via PubMed), Embase, CINAHL, Scopus, and Web of Science Core Collection were systematically searched for peer-reviewed observational studies published between January 2022 and December 2025. Eligible studies assessed vaccine effectiveness during periods dominated by Omicron subvariants including BA.2, BA.5, XBB, BA.2.86/JN.1, and KP lineages. Findings were synthesised narratively due to substantial heterogeneity. RESULTS: Thirty observational studies from North America, Europe, and East Asia were included. Across Omicron subvariants, vaccine effectiveness against SARS-CoV-2 infection was generally modest and short-lived, with rapid waning within months after vaccination and estimates frequently approaching null during later subvariant periods. In contrast, updated and variant-adapted vaccines consistently provided meaningful protection against severe COVID-19 outcomes, including hospitalization and death. Protection was highest during BA.4/BA.5 and early XBB-dominant periods and declined with increasing time since vaccination, especially during JN.1- and KP-predominant periods and among the oldest age groups. Importantly, substantial protection against severe outcomes persisted within the first 1–3 months following vaccination, with effectiveness against hospitalization and death generally ≥ 50%, although effectiveness declined over time during later Omicron subvariant periods. CONCLUSION: Updated and variant-adapted COVID-19 vaccines continue to confer substantial protection against severe COVID-19 outcomes across successive Omicron subvariants, despite limited and rapidly waning effectiveness against SARS-CoV-2 infection. These findings support prioritisation of periodic booster vaccination for older adults and other high-risk populations, with vaccine performance primarily evaluated using protection against severe clinical outcomes. CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid41975359,
year = {2026},
author = {Porter, AV and Joseph-Williams, N and Leighton, C and Gal, M and Edwards, A and Cooper, A},
title = {Barriers and facilitators to knowledge translation at the science-policy interface during the COVID-19 pandemic public health emergency: a rapid review and theoretical analysis to inform development of a logic model.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {41975359},
issn = {1471-2458},
mesh = {Humans ; *COVID-19/epidemiology/prevention &amp; control ; *Health Policy ; Models, Theoretical ; *Pandemics ; Policy Making ; *Public Health ; SARS-CoV-2 ; *Translational Research, Biomedical ; *Translational Science, Biomedical/organization &amp; administration ; },
abstract = {BACKGROUND: The COVID-19 pandemic necessitated the rapid production, synthesis, and translation of best available evidence to inform public health policy and practice decisions. This presents a unique learning opportunity to understand the interventions and strategies used to promote evidence-informed decision-making at the science-policy interface during this public health emergency and to explore what hindered or facilitated these processes. OBJECTIVES: To describe the interventions at the science-policy interface used to support knowledge translation during the COVID-19 pandemic, explore the barriers and facilitators to such interventions, and apply findings to formal knowledge translation principles to inform the development of a logic model. METHODS: A systematic literature search of Medline via OVID, Scopus, and Web of Science was conducted. Studies were assessed for eligibility and critically appraised. A narrative synthesis was conducted. Knowledge translation models and frameworks were identified via Google Scholar and analysed for their applicability to a public health emergency context. RESULTS: We included 18 articles. The most common interventions at the science-policy interface were advisory committees, knowledge translation platforms and hubs, knowledge translation activities (knowledge brokering, priority-setting, workshops) and products (data visualisation and summaries). Barriers included: data availability and accessibility, time constraints, underrepresentation in advisory committees, political influence, and lack of transparency. Facilitators included: research coordination, interdisciplinary collaboration, transparency in research methods, and actionable and accessible evidence. We identified 11 knowledge translation models that contributed to the logic model. CONCLUSIONS: Our findings, developed from empirical findings and theoretical principles, offer valuable insights into how knowledge translation infrastructures and processes could be strengthened in preparation for future public health emergencies.},
}
@article {pmid41975387,
year = {2026},
author = {Rák, T and Ormai, E and Pandur, E and Horváth, G and Adrienne, C},
title = {Exploring the interplay between olfaction and vision: neuroplasticity, rehabilitation, and the therapeutic potential of herbal ingredients.},
journal = {BMC complementary medicine and therapies},
volume = {26},
number = {1},
pages = {},
pmid = {41975387},
issn = {2662-7671},
support = {PTE GYTK-KK Kollab 2025, Dr. Gy&#xf6;rgyi Horv&#xe1;th//University of P&#xe9;cs, Faculty of Pharmacy-Clinical Centre Collaboration Funding/ ; },
mesh = {Humans ; *Neuronal Plasticity ; Olfactory Training ; Oils, Volatile/therapeutic use ; *Vision Disorders/rehabilitation/drug therapy ; *Smell/physiology ; *Vision, Ocular/physiology ; },
abstract = {Post-COVID-19, olfactory and visual training have demonstrated health benefits, particularly for individuals with visual impairments and neurodegenerative conditions such as Parkinson’s and glaucoma. Integrating olfactory training with essential oils and developing multisensory technologies could improve the quality of life for those with sensory deficits, underscoring the brain’s adaptability and the therapeutic potential of herbal ingredients. This short review commentary proposes that the neuroplastic interplay between the olfactory and visual pathways, including their demonstrated anatomical and functional convergence, may provide a conceptual foundation for integrating olfactory stimulation into future visual rehabilitation strategies.},
}
@article {pmid41975908,
year = {2026},
author = {Noh, W and Ko, Y},
title = {Resilience-Enhancing Programs for Nurses in the Era of COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {7},
pages = {},
pmid = {41975908},
issn = {2227-9032},
abstract = {Background/Objectives: In the post-pandemic era, growing concern about the mental health of healthcare professionals has led to the development of various resilience-enhancing programs. Although such programs are not new, having been implemented before the pandemic, it is important to investigate how post-pandemic programs differ from earlier ones. This review aimed to analyze resilience-enhancing programs for nurses and evaluate their effectiveness. Methods: This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A search was performed in the Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, and EMBASE. Six studies met the inclusion criteria. The meta-analysis was conducted using Stata version 16.0 (StataCorp LLC., College Station, TX, USA). Results: Six studies were included in the systematic review and meta-analysis. The characteristics of the included studies, such as country, study design, setting, population, outcome variables, and resilience-enhancing programs for nurses, were analyzed. The random-effects meta-analysis indicated a statistically significant positive effect on nurses' resilience (SMD = 0.58, 95% CI 0.10 to 1.07, Z = 2.35, p = 0.019). Conclusions: This study provides foundational evidence for understanding resilience-enhancing programs for nurses and highlights their potential value in post-pandemic healthcare settings.},
}
@article {pmid41976966,
year = {2026},
author = {Mihai, AM and Marc, M and Lucaciu, F and Sima, A},
title = {Incident Heart Failure Risk Following COVID-19 Recovery: A Systematic Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {7},
pages = {},
pmid = {41976966},
issn = {2077-0383},
support = {We would like to acknowledge the Victor Babes University of Medicine and Pharmacy, Timisoara, for paying the APC. The funder had no role in study design, data collection/analysis, decision to publish, or manuscript preparation//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
abstract = {Background/Objectives: While acute cardiac injury during COVID-19 is well-documented, the long-term risk of new-onset heart failure (HF) in survivors remains a critical clinical concern. This study aims to quantify the risk of new-onset heart failure during a 25 months prognostic follow-up period following recovery from SARS-CoV-2. Methods: We conducted a systematic review and meta-analysis of nine high-quality studies (n > 400,000 survivors) in accordance with PRISMA 2020 guidelines. Databases including PubMed/MEDLINE and Scopus were searched through January 2026. A quantitative meta-analysis was performed on six studies using a random-effects model to pool adjusted hazard ratios (aHR). Results: The pooled analysis revealed a significant 35% increased risk of new-onset heart failure following COVID-19 recovery (aHR 1.35; 95% CI: 1.14-1.60; p = 0.001). Significant heterogeneity was observed (I[2] = 92.62%), reflecting diverse risk profiles among survivors. The risk was most pronounced in immunocompromised kidney transplant recipients (aHR 2.32) and younger adults under the age of 65 (aHR 1.53). Subclinical myocardial damage, characterized by reduced left ventricular longitudinal strain, was identified even in survivors who experienced mild initial infections. Conclusions: COVID-19 recovery serves as a significant independent risk factor for chronic heart failure, emphasizing that cardiovascular impact extends far beyond the acute phase. These findings necessitate the implementation of structured cardiovascular monitoring and biomarker screening for at least one year post-infection to address this emerging chronic disease burden.},
}
@article {pmid41977035,
year = {2026},
author = {Mastrangelo, H and Sacco, MA and Gualtieri, S and Grimaldi, G and Monterossi, MD and Neri, G and Aquila, I},
title = {Placental Vascular Malperfusion, Perinatal Death and Neonatal Brain Injury: A Mechanism-Based Narrative Review with Medico-Legal Implications.},
journal = {Journal of clinical medicine},
volume = {15},
number = {7},
pages = {},
pmid = {41977035},
issn = {2077-0383},
abstract = {Background/Objectives: Placental vascular malperfusion, on both the maternal (MVM) and fetal (FVM) side, is a key mechanism linking hypertensive disorders of pregnancy, fetal growth restriction (FGR), stillbirth, preterm neonatal death and neonatal encephalopathy. Nevertheless, clinical use and medico-legal interpretation of placental findings remain inconsistent. To summarize recent evidence on the relationship between placental vascular malperfusion, perinatal mortality and neonatal brain injury, integrating standardized placental pathology with Doppler and angiogenic biomarkers, and to outline the main medico-legal implications. Methods: A PubMed search using the string "((placenta OR placental pathology) AND (stillbirth OR fetal death) AND (maternal vascular malperfusion OR fetal vascular malperfusion))" yielded 118 records. After excluding reviews, meta-analyses, case reports (except one illustrative SARS-CoV-2 placentitis case), non-human studies and papers without original histopathology, 33 studies were included: observational cohorts and case-control studies with standardized placental assessment, autopsy series, biomarker/Doppler cohorts, mechanistic work, one randomized trial protocol and a small number of focused clinical commentaries. Results: Across these studies, MVM emerges as the dominant placental lesion in pre-eclampsia, FGR and a large proportion of stillbirths, especially in early-onset disease and in association with maternal hypertension. FVM is strongly linked to stillbirth and term neonatal encephalopathy, and specific combinations of MVM, FVM and inflammatory lesions correspond to distinct patterns of brain injury. Large population-based cohorts confirm that maternal hypertensive disorders and placental malperfusion are major upstream causes of intrauterine hypoxia and preterm neonatal death. Doppler velocimetry and angiogenic biomarkers (PlGF, sFlt-1 and their ratio) are strongly associated with an increased likelihood of underlying MVM and adverse neonatal outcomes, although their predictive performance remains probabilistic and context-dependent rather than diagnostic. Mechanistic studies suggest roles for placental genomic instability and altered decidual immunity in defective placentation. Conclusions: Maternal and fetal vascular malperfusion represent converging pathways to FGR, stillbirth, preterm neonatal death and neonatal encephalopathy. Routine, standardized placental examination, interpreted together with Doppler and biomarker data, substantially improves causal attribution and timing of injury, with direct consequences for counselling, prevention and medico-legal assessment.},
}
@article {pmid41978842,
year = {2026},
author = {Ganji, V and Kamble, B and Mustafa, F and Ravi, N and Madhusudhan, U and Archana, G and Kalpana, M and Taranikanti, M and John, NA},
title = {The Dual Burden: Long-Term Impact of COVID-19 on Tuberculosis Incidence - Presentation and Outcomes.},
journal = {Maedica},
volume = {21},
number = {1},
pages = {198-206},
pmid = {41978842},
issn = {1841-9038},
abstract = {INTRODUCTION: Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major public health concern globally ranking as the second leading infectious disease and the 13th leading cause of death worldwide. The global healthcare systems have experienced unprecedented challenges in recent years due to COVID-19 pandemic causing widespread disruptions. Delaying TB diagnosis and treatment led to lower reported incidence but could increase mortality, hindering efforts to eradicate TB. Although a few studies have focused on COVID-19 and TB cases to date, most of them are case reports. Since it is unclear whether patients with COVID-TB co-infection have a worse prognosis or more likely to develop severe disease, we believed that doing this study was a necessity. The present systematic review investigates the long-term effects of COVID-19 on TB incidence, reporting follow-up and treatment outcomes.<br><br>OBJECTIVES: The present study aimed to explore the long-term impact of COVID-19 on TB incidence, presentation and outcome.<br><br>METHODS: We conducted our systematic review following PRISMA (Preferred reporting in systematic reviews and meta-analysis) guidelines. We performed a comprehensive literature search of EMBASE, PubMed, Scopus, The Lancet, Web of Science and Cochrane Central Register of Controlled Trials. The search items included "Corona virus disease 19", "impact of COVID-19", "SARS-CoV-2", "Tuberculosis", "TB and COVID-19 co-infection", "comorbidities", "prognosis", "incidence", "outcomes" and "risk factors" for articles published between the 1st of January 2020 and the 31st of June 2024. Searches were limited to English language only. We included articles with primary outcomes including studies which reported TB incidence or notification rates, clinical presentation, treatment interruption or outcomes of TB due to COVID-19 and TB-COVID-19 co-infection. Cohort studies, case-control studies, cross-sectional studies and surveillance or registry-based studies were included.<br><br>RESULTS: Information regarding COVID-19 and TB was collected from the databases, and out of 1973 articles, 41 articles were included. COVID-19 has had a negative impact on TB control programs leading to decrease in reporting of TB cases. As per the global tuberculosis report by WHO 2025, there has been approximately one-third reduction in incidence rates with TB case notifications declining by 21% of TB cases notification in 2020 compared to 2019. The reports indicated that the number of people diagnosed with TB was 7.5 million in 2022 above the baseline of 7.1 million in 2019 and 5.8 million in 2020.<br><br>CONCLUSION: COVID-19 has affected TB diagnosis and control, with a significant decline in TB case notifications leaving many undiagnosed cases, thereby reversing years of progress in TB control. The high-TB burden countries like India should tackle the havoc caused by the COVID-19 pandemic by addressing the needs of the poor and having a concrete agenda and perpetual TB strategy to reach the target by 2030.},
}
@article {pmid41979291,
year = {2026},
author = {Abid, S and Jannath, H},
title = {Cardiac Effects in Post-COVID-19 Heart Failure: A Systematic Review of Longitudinal Imaging- and Biomarker-Based Structural and Functional Remodeling.},
journal = {Annals of cardiac anaesthesia},
volume = {29},
number = {2},
pages = {157-168},
pmid = {41979291},
issn = {0974-5181},
mesh = {Humans ; *COVID-19/complications ; Biomarkers/blood ; *Heart Failure/diagnostic imaging/physiopathology/etiology/blood ; *Ventricular Remodeling/physiology ; Echocardiography ; Post-Acute COVID-19 Syndrome ; Global Longitudinal Strain ; Magnetic Resonance Imaging ; },
abstract = {COVID-19 has been linked to persistent cardiovascular sequelae, yet the trajectory of structural and functional cardiac changes beyond the acute phase remains unclear. This systematic review synthesizes longitudinal evidence on post-COVID cardiac remodeling assessed by imaging and biomarkers. Following PRISMA guidelines, we searched PubMed and Cochrane Library (January 2020-April 2025) for peer-reviewed studies enrolling adults (≥18 years) with polymerase chain reaction (PCR)/antigen-confirmed SARS-CoV-2 infection and reporting cardiac outcomes ≥ 12 weeks post-infection. Eligible outcomes included imaging-based abnormalities (cardiac magnetic resonance [CMR]: T1/T2 mapping, late gadolinium enhancement [LGE]; echocardiography: left ventricular ejection fraction [LVEF], LV/RV strain). Longitudinal trends of biomarkers (troponin, NT-proBNP, C-reactive protein [CRP]) were also studied. Risk of bias was assessed using joanna briggs institute (JBI) tools; synthesis followed synthesis without metaanalysis (SWiM) principles. Fifteen studies (n ≈ 166,000; 14 cohorts, 1 case report) were included. Across CMR cohorts, global systolic function was largely preserved, but tissue abnormalities were frequent early and improved over time: edema indices normalized by ~ 12 months, while LGE prevalence declined (e.g. 50%→19% in paired scans). However, residual non-ischemic scars and elevated T1/T2 persisted in symptomatic subgroups. Echocardiography showed normal LVEF, but subtle left ventricular global longitudinal strain (LV-GLS) impairment versus controls (e.g. -18.5% vs - 19.3%). Biomarker trends were heterogeneous: natriuretic peptide positivity persisted in patients with prior cardiovascular disease (CVD), while troponin and CRP generally normalized. Large population-based cohorts demonstrated sustained 12-month risk for heart failure, myocarditis, and major cardiovascular events, graded by acute severity. Most patients recover gross systolic function, yet subclinical myocardial changes and elevated population-level cardiovascular risk persist up to 1 year. These findings support risk-stratified follow-up, judicious use of advanced imaging, and preventive cardiology strategies.},
}
@article {pmid41979592,
year = {2026},
author = {Rosińska, M and Czarkowski, MP and Sadkowska-Todys, M},
title = {Infectious diseases in Poland in 2023.},
journal = {Przeglad epidemiologiczny},
volume = {79},
number = {4},
pages = {730-749},
doi = {10.32394/pe/218649},
pmid = {41979592},
issn = {0033-2100},
mesh = {Humans ; Poland/epidemiology ; *COVID-19/epidemiology/mortality ; *Communicable Diseases/epidemiology ; Incidence ; Adult ; Female ; Male ; Ukraine ; Middle Aged ; Infant ; Adolescent ; Child ; Registries ; Young Adult ; Aged ; Child, Preschool ; SARS-CoV-2 ; Pandemics ; Infant, Newborn ; *Refugees/statistics &amp; numerical data ; },
abstract = {OBJECTIVE. The aim of this study was to summarize the epidemiological situation of infectious diseases in Poland in 2023. The ongoing impact of the COVID-19 pandemic and the effects of the influx of refugees to Ukraine were taken into account. MATERIAL AND METHODS. We performed a narrative review of studies published in Epidemiological Chronicle, along with data from the national infectious disease registry, Epibaza, which collects data from epidemiological investigations conducted by the State Sanitary Inspectorate. Mortality data were obtained from reports of the Statistics Poland Office. RESULTS. In 2023, 381,244 cases of COVID-19 and 4,329 deaths due to this disease were recorded. The COVID-19 mortality rate in 2023 was several times lower than in 2022, although COVID-19 still accounted for more deaths than other infectious diseases. An "immunity gap" effect was observed following the COVID-19 pandemic, resulting in a significant increase in the incidence of pertussis (2.5 times compared to 2022), influenza and influenza-like illnesses, and intestinal infections (enteric salmonellosis +57.9%, campylobacteriosis +64.1%, yersiniosis +74.5%, norovirus +27.8%). A reduction in the incidence was observed for rotavirus infections, for which routine infant vaccinations were introduced in 2021. The increase in pneumococcal disease incidence occurred mainly in the adult and senior population. While the number of new HIV diagnoses among Polish nationals is increasing, the number of cases among migrants has declined, although they still account for 25% of all new diagnoses. The incidence of other sexually transmitted infections also continues to increase (compared to 2022, gonorrhoea +110.6%, syphilis +89.6%). CONCLUSIONS. For many diseases, incidence increased compared to previous years, for a variety of reasons, including the persistent "immunity gap" following the pandemic and the specific nature of the vaccination program. The impact of the influx of refugees from Ukraine was minor.},
}
@article {pmid41981625,
year = {2026},
author = {Graessner, H and Ripp, S and Pereira, AM and Schaefer, F and Mathijssen, I and Blay, JY and Mulders, PFA and Evangelista, T and Ligtenberg, MJL and Wilde, AAM and Ladenstein, R and Lohse, AW and Mosca, M and Swart, JF and Hernández, F and Fenaux, P and Dollfus, H and Verloes, A and Wagner, T and Bodemer, C and Wijnen, R and Scarpa, M and Jondeau, G and Tumienė, B and Gallina, S and Arzimanoglou, A and Sangiorgi, L},
title = {European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.},
journal = {Orphanet journal of rare diseases},
volume = {21},
number = {1},
pages = {},
pmid = {41981625},
issn = {1750-1172},
mesh = {Humans ; *Rare Diseases/epidemiology ; European Union ; Europe ; },
abstract = {BACKGROUND: Although individual rare and complex diseases (RDs) affect small patient populations, together they impact an estimated 27–36 million people across the European Union. Addressing this major public health challenge has been a long-term priority for the European Union, leading to the establishment of the European Reference Networks (ERNs) in 2017. MAIN BODY: ERNs are cross-border networks connecting clinical expert centres to share knowledge, improve and harmonise diagnosis and care for patients with rare and complex diseases. Since their inception, 24 ERNs have united 1,606 expert centres across 375 hospitals in all EU Member States and Norway. Their activities span multidisciplinary clinical collaboration, patient-centred governance, education and training, and the development of clinical guidelines. Over 4900 extremely rare or difficult cases have been discussed among experts without requiring the patients to travel abroad when expertise was not available in their own countries. A key factor for this success is the cross-border IT platform - known as the Clinical Patient Management System 2.0 - provided by the European Commission for medical discussions, which enables experts to share patient data, including medical images and lab results, in a secure and protected environment that is fully compliant with all relevant security and data privacy requirements. ERNs have demonstrated resilience in crises such as the COVID-19 pandemic and the war in Ukraine, providing rapid, coordinated responses to sustain care for vulnerable patient groups. The first formal evaluation in 2023 confirmed that more than 95% of member centres met quality standards, underscoring the networks’ maturity and effectiveness. Moving into the next phase, the Joint Action JARDIN (2024–2027) aims to integrate ERNs into national healthcare systems to ensure sustainability and equitable access to high-quality RD care. CONCLUSIONS: ERNs exemplify European solidarity and innovation in healthcare, transforming how rare disease expertise is shared and applied across borders. Their continued integration into national systems will be pivotal to achieving a truly cohesive European Health Union that delivers improved outcomes for all patients with rare and complex diseases.},
}
@article {pmid41981814,
year = {2026},
author = {Sjauw, DJT and Janssen, ML and Türk, Y and Reep, CAT and Heunks, L and Baart, SJ and Wils, EJ and , and , },
title = {Predicting Failure at Initiation of High-Flow Nasal Oxygen in Patients With COVID-19: Literature Review, Development and Internal Validation of a Prediction Model.},
journal = {Respirology (Carlton, Vic.)},
volume = {31},
number = {8},
pages = {798-807},
pmid = {41981814},
issn = {1440-1843},
support = {10430102110007/ZONMW_/ZonMw/Netherlands ; },
mesh = {Humans ; *Oxygen Inhalation Therapy/methods ; *COVID-19/therapy/complications ; *Respiratory Insufficiency/therapy/etiology ; Female ; Male ; Middle Aged ; Prospective Studies ; Netherlands/epidemiology ; SARS-CoV-2 ; Aged ; Treatment Failure ; *Hypoxia/therapy/etiology ; },
abstract = {BACKGROUND AND OBJECTIVE: High-Flow Nasal Oxygen (HFNO) can reduce the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF) from viral pneumonias, like COVID-19. Early prediction of HFNO failure is useful for timely decision-making at HFNO initiation. This study aimed to develop a prediction model for HFNO failure using predictors available just prior to HFNO initiation in patients with COVID-19 AHRF and compare its performance to existing models.<br><br>METHODS: This multicenter, prospective observational cohort study included hospitalized patients from 10 centers in the Netherlands between December 2020 and July 2021. Adults who tested positive for SARS-CoV-2, had no treatment limitations, and initiated HFNO for hypoxemia were included. The primary outcome was HFNO failure, defined as the event of endotracheal intubation. Pre-defined candidate predictors were selected by multivariable logistic regression for prediction model development. Internal validation was conducted using bootstrapping.<br><br>RESULTS: Out of 608 patients, 277 (46%) experienced HFNO failure. Independent predictors of HFNO failure included (odds ratio [95% CI]): age (1.02 [1.00-1.03]), urea (1.04 [1.00-1.08]), platelet count (0.94 [0.92-0.97]), respiratory rate (1.05 [1.02-1.08]), oxygen saturation (0.89 [0.84-0.94]), and FiO2 (conventional oxygen 10-15&#x2009;L/min vs. <&#x2009;10&#x2009;L/min: 3.00 [1.71-5.29], 15&#x2009;L/min vs. <&#x2009;10&#x2009;L/min: 4.95 [3.19-7.70]) prior to HFNO initiation. The model C-statistic was 0.767; 95% CI [0.727-0.803], with excellent calibration (intercept: -0.005, slope: 1.001), and stable performance after internal validation.<br><br>CONCLUSIONS: This newly developed model, using variables available at HFNO initiation, effectively predicted HFNO failure in hospitalized hypoxemic patients due to COVID-19 pneumonia with good performance.<br><br>Dutch Trial Registry: DTR, NL9067.},
}
@article {pmid41981866,
year = {2026},
author = {Sepúlveda, MD and Cardona Maya, WD and Zapata-Builes, W and Velilla, PA},
title = {Decoding NK Cell Subset Dysregulation in SARS-CoV-2 Infection: Phenotypic, Functional, and Transcriptomic Insights Into COVID-19 Pathogenesis.},
journal = {Scandinavian journal of immunology},
volume = {103},
number = {4},
pages = {e70115},
doi = {10.1111/sji.70115},
pmid = {41981866},
issn = {1365-3083},
support = {//Universidad de Antioquia/ ; //Universidad Cooperativa de Colombia/ ; },
mesh = {Humans ; *Killer Cells, Natural/immunology ; *COVID-19/immunology ; *SARS-CoV-2/immunology ; Transcriptome ; Phenotype ; Immunity, Innate ; CD56 Antigen ; *Lymphocyte Subsets/immunology ; Immune System Exhaustion ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly affects innate immune responses, particularly those of natural killer (NK) cells, which play an important role in antiviral defence. This review combines phenotypic, functional, and transcriptomic findings to explain the disruption of NK cell subsets in COVID-19. Flow cytometry studies have shown generalised lymphopenia and a significant reduction in the CD56bright and CD56[dim]CD16[+] subsets. This change is linked to an increase in the CD56[dim]CD16[-] and CD56[-]CD16[+] populations, which correlate with disease severity. At the molecular level, there is an imbalance between activating and inhibitory receptors. This includes increases in NKG2A, PD-1, and LAG-3, along with decreases in NKp30, NKp46, and NKG2D. These findings are consistent with an exhausted phenotype and weakened cytotoxicity. Single-cell RNA sequencing (scRNA-seq) studies have identified an increase in proliferative, cytotoxic, and platelet-associated CD56[dim] NK subpopulations in severe cases and a reduction of CD56[bright] cells. Transcriptomic profiling showed that upregulation of interferon-stimulated genes (ISGs) and inflammatory pathways driven by STAT1/3, NF-κB activation, and transforming growth factor-beta (TGF-β) signalling suppresses NK effector functions. Collectively, these findings suggest a model in which progressive NK cell dysfunction may be associated with the immunopathogenesis of COVID-19. The integration of multi-omic and phenotypic approaches provides a comprehensive view of NK cell responses to SARS-CoV-2 and suggests potential biomarkers and therapeutic targets to restore NK cell antiviral activity.},
}
@article {pmid41981907,
year = {2026},
author = {Bechini, A and Salvati, C and Del Riccio, M and Bonito, B and Stancanelli, E and Bruschi, M and Ionita, G and Iamarino, J and Bentivegna, D and Buscemi, P and Ciardi, G and Cosma, C and Stacchini, L and Bega, M and Schirripa, A and Bertizzolo, L and Muzii, B and Azzi, MV and Parisi, S and Trippi, F and Bonanni, P and Boccalini, S},
title = {Burden and Characteristics of Respiratory Syncytial Virus-Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review.},
journal = {Immunity, inflammation and disease},
volume = {14},
number = {4},
pages = {e70420},
pmid = {41981907},
issn = {2050-4527},
support = {//Sanofi and AstraZeneca/ ; },
mesh = {Humans ; Italy/epidemiology ; *Respiratory Syncytial Virus Infections/epidemiology/virology ; Infant ; *Hospitalization/statistics &amp; numerical data ; *Respiratory Syncytial Virus, Human/genetics ; Infant, Newborn ; *Bronchiolitis/epidemiology/virology ; Coinfection/epidemiology/virology ; COVID-19/epidemiology ; Seasons ; Prevalence ; Child, Preschool ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Respiratory syncytial virus (RSV) is the main cause of bronchiolitis in infants. This systematic review aimed to evaluate the burden of RSV-associated bronchiolitis among hospitalized Italian infants between 2000 and 2023.<br><br>METHODS: A comprehensive literature search identified studies examining RSV-related hospitalizations for bronchiolitis in children aged 0-59 months. Eligible studies met the following criteria: conducted in Italy, focused on children, reported on RSV prevalence, co-infections, genotype distribution (RSV-A, RSV-B), and seasonal trends, and published in English or Italian. Data extraction focused on study design, infant characteristics (e.g., age, preterm birth), and RSV detection methods.<br><br>RESULTS: Twenty-four studies were included. Infants under 12 months were most affected. RSV was the primary pathogen identified, though co-infections with other respiratory viruses, such as human rhinovirus, were common. RSV infections typically peaked in late autumn and winter, but the COVID-19 pandemic altered these patterns. This review highlights the significant burden of RSV-associated bronchiolitis in Italian infants. While RSV remains the primary pathogen, co-infections and pandemic related factors have altered its epidemiological trends.<br><br>CONCLUSIONS: Nationwide RSV immunization programmes and improved diagnostics are crucial to ease the strain on pediatric intensive care units. Recent recommendations for widespread RSV long-acting monoclonal antibody use in infants offer promising solutions to address this challenge.},
}
@article {pmid41981982,
year = {2026},
author = {Gou, H and Zhai, Y and Yu, Q and Liu, Y and Zhou, H and Zhao, Q},
title = {Epidemiological Changes in Mycoplasma pneumoniae Infections in Children and Adolescents Before and After COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Reviews in medical virology},
volume = {36},
number = {3},
pages = {e70151},
doi = {10.1002/rmv.70151},
pmid = {41981982},
issn = {1099-1654},
support = {2024YFC3506000//National Key Research and Development Program of China/ ; },
mesh = {Humans ; *COVID-19/epidemiology ; *Pneumonia, Mycoplasma/epidemiology/microbiology ; Child ; *Mycoplasma pneumoniae/pathogenicity ; Adolescent ; Prevalence ; SARS-CoV-2 ; Child, Preschool ; },
abstract = {Mycoplasma pneumoniae (M. pneumoniae) is a major cause of respiratory tract infections in children and adolescents, yet its epidemiological burden before, during, and after the COVID-19 pandemic remains unclear. This meta-analysis, which searched Web of Science, Embase, PubMed, and Cochrane Library for reports published up to December 25, 2025, aimed to evaluate trends in the prevalence of M. pneumoniae infections across these three periods to guide clinical practice and public health responses. A total of 70 studies were included, and methodological quality was assessed using the Joanna Briggs Institute criteria. The pooled prevalence of M. pneumoniae infections before, during, and after COVID-19 was calculated in R 4.5.0, with Freeman-Tukey double arcsine transformation for extreme proportions. The prevalence of M. pneumoniae infections before COVID-19, during COVID-19, and after COVID-19 was 21.72% (95% CI: 17.09, 26.73), 10.73% (95% CI: 7.57, 14.35), and 28.64% (95% CI: 22.74, 34.93), respectively. Age-stratified analysis revealed the highest prevalence consistently in children > 6 years (pre-pandemic: 46.35%; during-pandemic: 27.32%; post-pandemic: 41.36%) and the lowest in infants < 1 year (8.21%, 4.87%, and 7.81%, respectively). Seasonally, pre-pandemic prevalence peaked in summer (33.34%) and autumn (31.00%). During the pandemic, overall rates declined but remained highest in autumn (15.51%). Post-pandemic, prevalence rebounded broadly, peaking in autumn (37.97%). In conclusion, this study summarises M. pneumoniae trends in children and adolescents before and after COVID-19, indicating a delayed resurgence following the pandemic, and highlights the need for further research to explain these patterns and improve future pandemic preparedness.},
}
@article {pmid41982246,
year = {2026},
author = {Welberry Smith, M and Wrigley, A and Kojro, A and Emmanouilidou, A and O'Callaghan, J and Woywodt, A},
title = {No more waiting: 10 tips to turn kidney transplantation green.},
journal = {Clinical kidney journal},
volume = {19},
number = {4},
pages = {sfag073},
pmid = {41982246},
issn = {2048-8505},
abstract = {To date, the environmental impact of kidney transplantation has received much less attention than that of dialysis. Facilitating a pre-emptive transplant is probably one of the most environmentally friendly interventions available in kidney care, as it avoids dialysis, with its requirements for water and energy. However, transplant assessment also requires scrutiny, as it involves a multitude of tests, often with duplication of tests and sometimes with little, if any, evidence (e.g. cardiac testing of asymptomatic patients). Organ retrieval often involves air travel of either the organ or a surgical team, although more innovative approaches, such as drone transport, are being tested. Transplant anaesthesia also has an environmental footprint linked to volatile substances. Surgical tray optimization is well established in other surgical specialties to reduce the effects of repeatedly sterilizing instruments that are only rarely used. Post-transplant patients have a lot of regular blood tests, and it is time we scrutinise those and find a better balance between safe care and environmental footprint. Virtual appointments have become much more common since the COVID-19 pandemic and we should use them where appropriate, for example in long-term care of stable transplant patients. Transplantation is a very research-oriented specialty, and this also has an environmental footprint that is amenable to intervention. In addition, our congresses and conferences have an environmental footprint, and it is for us to promote meetings with just as much learning and interaction but less travel, waste and energy use. The opportunities are there for us to take and our tips provide ideas for clinical teams to turn kidney transplantation into a showcase for excellent, safe and environmentally friendly care in nephrology.},
}
@article {pmid41982635,
year = {2026},
author = {Khezri, M and Holm, J and Dahlen, A and Johnson, C and Agyabeng, K and Lei, F and Pagán, JA and Healton, C and Farhat, T},
title = {Illicit drug supply, naloxone availability, and overdose mortality in the fentanyl era: a systematic review.},
journal = {Health affairs scholar},
volume = {4},
number = {4},
pages = {qxag074},
pmid = {41982635},
issn = {2976-5390},
abstract = {BACKGROUND: The overdose crisis is shaped by increasing synthetic opioids and expanding access to naloxone. We synthesized evidence on associations between illicit drug supply, naloxone availability/distribution, and overdose mortality.<br><br>METHODS: Following PRISMA, we searched 4 databases for studies between 2015 and 2025. Eligible studies examined associations of drug supply indicators or naloxone interventions, and overdose mortality. Data were extracted and synthesized narratively.<br><br>RESULTS: Forty-seven studies met inclusion criteria. Eighteen studies assessed drug supply changes and all but 2 found significant positive associations between increased fentanyl reports in drug seizures and overdose mortality. Drug seizure data were interpreted as indicators of supply trends or as enforcement disruptions. Thirty-one studies assessed naloxone availability. Thirteen studies reported naloxone access laws, take-home naloxone programs, and/or community interventions were associated with reductions in overdose deaths. Nine studies reported null effects, particularly during the COVID-19 pandemic.<br><br>CONCLUSIONS: Fentanyl reports in drug seizures and drug potency are key drivers of overdose mortality. This review highlights variability in interpreting drug seizure data and the need for clearer conceptualization in future research. Naloxone interventions show promise but depend on consistent implementation and effective targeting of high-risk populations. Coordinated public health strategies are needed to monitor the drug market and strengthen overdose prevention.},
}
@article {pmid41983114,
year = {2025},
author = {Gushansky, KY and Sutinen, P and Jeon, S and Tuuminen, R},
title = {Exploring the Association Between Lipid-Lowering Medications and Dry Eye Disease in COVID-19 Patients.},
journal = {Romanian journal of ophthalmology},
volume = {69},
number = {4},
pages = {536-543},
pmid = {41983114},
issn = {2501-2533},
mesh = {Humans ; *Dry Eye Syndromes/epidemiology/diagnosis/etiology/prevention &amp; control ; Retrospective Studies ; Female ; *COVID-19/epidemiology/complications ; Male ; Middle Aged ; *SARS-CoV-2 ; *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Aged ; *Hypolipidemic Agents/therapeutic use ; Risk Factors ; },
abstract = {PURPOSE: To explore the associations between systemic lipid-lowering medications and dry eye disease (DED) in patients hospitalized for SARS-CoV-2.<br><br>METHODS: This retrospective cohort study analyzed electronic medical records of SARS-CoV-2 patients hospitalized at Shaare Zedek Medical Center from April 1, 2020, to December 31, 2024. Adults without a previous DED diagnosis who had an ophthalmologic examination confirming no DED within the year preceding hospitalization were included. Exclusions included ICU admissions, specific systemic conditions, ocular surgeries, and systemic medications known to induce DED. Patients were categorized into those who developed DED within six months post-hospitalization and those who did not.<br><br>RESULTS: Among the 1,165 patients, 167 (14.3%) developed DED post-hospitalization. After adjusting for age, gender, and SARS-CoV-2 vaccination status, an inverse association between statins and dry eye disease was evident. Treatment with any statin was associated with reduced odds of developing dry eye disease (OR 0.289, p<0.001), particularly with atorvastatin (OR 0.374, p<0.001) and simvastatin (OR 0.297, p<0.001).<br><br>DISCUSSION: The inverse association observed in this study supports a potential protective effect of statins, consistent with their known anti-inflammatory properties and their ability to reduce cholesterol-driven Meibomian gland dysfunction.<br><br>CONCLUSION: Statin use is inversely associated with the development of DED in SARS-CoV-2 hospitalized patients. The anti-inflammatory and cholesterol-lowering effects of statins provide a robust framework for understanding the underlying pathophysiological mechanisms.},
}
@article {pmid41983631,
year = {2026},
author = {El-Kafrawy, SA and Abbas, AT and Abdel-Dayem, UA and El-Kafrawy, MS and Azhar, EI},
title = {IgY passive immunotherapy for pandemic preparedness: a One Health platform approach against pathogen X.},
journal = {Clinical microbiology reviews},
volume = {39},
number = {2},
pages = {e0024925},
pmid = {41983631},
issn = {1098-6618},
mesh = {*Immunoglobulins/therapeutic use/immunology ; Humans ; Animals ; *Immunization, Passive/methods ; Zoonoses/prevention &amp; control ; Pandemic Preparedness ; One Health ; COVID-19/prevention &amp; control ; SARS-CoV-2/immunology ; *Pandemics/prevention &amp; control ; Chickens ; },
abstract = {SUMMARYThe rising threat of emerging infectious diseases, especially zoonotic pathogens crossing species barriers, highlights the urgent global need for scalable, rapid-response passive immunotherapy platforms. Chicken egg yolk-derived immunoglobulin Y (IgY) antibodies offer unique conceptual and practical advantages. This review critically evaluates IgY antibodies (IgY-Abs) as a One Health immunotherapeutic strategy with strong potential for mitigating zoonotic spillover risks. Drawing on insights from SARS-CoV-2, we highlight the advantages of IgY-Abs over traditional approaches in specific scenarios while emphasizing their role as a complementary rather than replacement platform within the broader passive immunotherapy landscape. We discuss key strategic considerations, regulatory challenges, and essential knowledge gaps. Finally, we propose a forward-looking research and development roadmap that emphasizes interdisciplinary collaboration, optimized production methods, targeted regulatory frameworks, and integrated One Health strategies to facilitate the rapid deployment of IgY-based countermeasures against WHO-priority zoonotic pathogens.},
}
@article {pmid41983640,
year = {2026},
author = {Qu, Y and Xiao, Y and Liu, L and Qu, J},
title = {Diagnosis of Mucormycosis: Current Situation, Challenges and Future Prospects.},
journal = {Mycoses},
volume = {69},
number = {4},
pages = {e70175},
pmid = {41983640},
issn = {1439-0507},
mesh = {*Mucormycosis/diagnosis/microbiology ; Humans ; *Mucorales/isolation &amp; purification ; Early Diagnosis ; Immunocompromised Host ; Biomarkers ; Artificial Intelligence ; COVID-19/complications ; },
abstract = {Mucormycosis, an aggressive fungal infection caused by members of the order Mucorales, progresses rapidly and is associated with high mortality, particularly in immunocompromised hosts such as patients with uncontrolled diabetes, transplant recipients or those with COVID-19-associated immunosuppression. Early diagnosis remains challenging with current clinical methods, yet it is essential to reduce mortality. This review examines the evolution of diagnostic strategies for mucormycosis, ranging from conventional techniques such as histopathology, culture and microscopy to advanced and emerging methods including molecular assays, serological testing, imaging and metabolomics. We also explore the ongoing transition towards integrated, rapid and non-invasive diagnostic platforms that leverage novel biomarkers, portable devices and artificial intelligence. These new technologies have the potential to facilitate early diagnosis, thereby enabling early treatment and reducing the mortality rate of mucormycosis.},
}
@article {pmid41984151,
year = {2026},
author = {Myatra, SN and Nasa, P and Chanchalani, GP and Zimmerman, JL and Venkatesh, B and Machado, FR and Ostermann, M and Leeies, M and Coopersmith, CM and Sorce, LR and Weiss, B and Kuberkar, D and Abbenbroek, B and Acharya, SP and Akech, S and Akinci, SB and Al Duhailib, Z and Berger-Estilita, J and Branson, RD and De Waele, J and Derde, LPG and Divatia, MJ and Dzierba, AL and Elhoufy, AM and Fiest, KM and Fillipescu, D and Fox-Robichaud, AE and Freires, FJC and Fujii, T and Galarza, L and Gopalan, DP and Hamzaoui, O and Hidalgo, JL and Jayasinghe, AS and Kanoore Edul, VS and Lubis, AP and Matot, I and Mehta, S and Milic, V and Monnet, X and Morrow, BM and Nadkarni, VM and Needham, DM and Osinaike, BB and Patil, VP and Pérez Cornejo, MS and Perez-Fernandez, J and Ray, S and Robba, C and Rodriguez-Vega, GM and Rubulotta, F and Seifelnasr, O and Turnbull, AE and Ugarte, S and Vincent, JL and Wendon, J and Xie, J and Zabaleta Polo, YM and Burns, KEA},
title = {Gender equality and equity in intensive care: an international Delphi consensus study.},
journal = {Intensive care medicine},
volume = {52},
number = {5},
pages = {1035-1050},
pmid = {41984151},
issn = {1432-1238},
mesh = {Humans ; Delphi Technique ; Female ; *Gender Equity ; *Critical Care/standards ; Male ; *Consensus ; Middle Aged ; Adult ; Aged ; Surveys and Questionnaires ; },
abstract = {PURPOSE: We used Delphi methodology to provide guidance on gender equality and equity issues in professional life in intensive care, where information is evolving and no clear standard exists.<br><br>METHODS: A 12-member Steering Committee (7 women, 5 men) from 7 countries and 46 international panelists [(23 women, 21 men, 2 preferred not to disclose; median age 52 (33-75) years] from 32 countries (43% low- and middle-income) including intensive care practitioners, scientists, researchers, and trainees voted on 57 statements addressing issues related to gender equality and equity in 10 domains of professional life. Delphi rounds were conducted using online surveys. Consensus (at least 75% of panelists voting for a response option) and stability (consistent responses on iterative rounds) were assessed.<br><br>RESULTS: Six Delphi rounds were conducted between May and July 2025. A 100% response rate was achieved in each round. Consensus and stability were achieved on 43 (75%) of 57 statements from which 37 professional practice guidance statements were developed. Across domains, greater consensus was achieved on equality [23/27 (85.2%)] versus equity [12/18 (66.7%)] statements. Discordant equity statements primarily pertained to academia and engagement in multiprofessional meetings and the workplace.<br><br>CONCLUSION: Using a Delphi method, international experts reached consensus to generate 37 professional practice guidance statements. The consensus statements provide needed guidance for professional engagement and highlight areas for policy development to advance gender equity and equality for healthcare workers in intensive care. The discordant statements highlight areas for future research.},
}
@article {pmid41984738,
year = {2026},
author = {Oliveira, TT and Medeiros, VPB and Freitas, JF and Melo Martins Silva, G and Xavier, TJDS and Fassarella Agnez-Lima, L},
title = {COVID-19 severity biomarkers identified by transcriptomics: a scoping review.},
journal = {Infectious diseases (London, England)},
volume = {58},
number = {7},
pages = {661-679},
doi = {10.1080/23744235.2026.2651977},
pmid = {41984738},
issn = {2374-4243},
mesh = {Humans ; Biomarkers/analysis ; *COVID-19/diagnosis/genetics/immunology ; Cytokines/genetics ; Gene Expression Profiling ; Severity of Illness Index ; *Transcriptome ; },
abstract = {BACKGROUND: Omics technologies, particularly transcriptomics, were widely used during the COVID-19 pandemic to investigate host and viral gene expression. Given the substantial number of studies published during this period, systematic reviews are essential for synthesising findings and identifying consistent patterns.<br><br>OBJECTIVES: This scoping review aimed to identify and evaluate transcriptomic studies of SARS-CoV-2 infection in humans published between 2020 and January 2023, with a focus on genes and pathways affected by the virus.<br><br>METHODS: A comprehensive literature search was conducted using PubMed and Scopus, employing predefined keywords. Studies were screened using established inclusion and exclusion criteria, and only articles published in journals affiliated with the Committee on Publication Ethics (COPE) or Directory of Open Access Journals (DOAJ) were included. Data extraction followed a two-step process, collecting detailed information on sample and patient characteristics, transcriptomic methods, and main findings.<br><br>RESULTS: Despite methodological differences and varying time points of sample collection, several immune-related genes and pathways were recurrently reported. These included cytokines and chemokines (e.g. CXCL8, TNF-&#x3b1;, CCL2, CXCL10, and IL-1B), interferon-stimulated genes (e.g. MX1, IFI27, IRF7, and ISG15), and neutrophil degranulation markers (e.g. S100A8 and S100A9).<br><br>CONCLUSIONS: The recurrent identification of these genes underscores their potential as prognostic biomarkers and therapeutic targets, thereby contributing to a deeper understanding of immunopathological mechanisms and supporting the development of improved diagnostic tools and early intervention strategies. However, limited reproducibility across studies poses challenges for robust meta-analyses, underscoring the urgent need for standardised guidelines and protocols to improve consistency and reliability in future research.},
}
@article {pmid41985440,
year = {2026},
author = {Crotty, S},
title = {Immunological memory to vaccines.},
journal = {Immunity},
volume = {59},
number = {4},
pages = {813-832},
pmid = {41985440},
issn = {1097-4180},
support = {U19 AI142742/AI/NIAID NIH HHS/United States ; UM1 AI144462/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; *Immunologic Memory/immunology ; *Vaccines/immunology ; Animals ; CD8-Positive T-Lymphocytes/immunology ; B-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/immunology ; *SARS-CoV-2/immunology ; Adaptive Immunity ; *COVID-19/immunology/prevention &amp; control ; },
abstract = {The extraordinary success of vaccines saving lives and improving human health is predicated on immune memory. Within the armamentarium of adaptive immunity, a holistic view of the different components contributing to immune protection is important for understanding the myriad benefits of vaccines. This review presents the current understanding of vaccine-generated memory, integrating layers of immunity including B cells, CD8+ T cells, CD4+ T cells, and antibody responses, with emphasis on human vaccine data. Functions and durability of distinct memory types are considered, including those of tissue-resident and circulating cells as well as hybrid immunity, and within this context, common misconceptions and important next questions are discussed. Understanding the multifaceted layers that underlie protective immunity can guide future vaccines and broader immune-focused interventions. A video lecture accompanies this review (https://youtu.be/8DeZJ6V7nuI). VIDEO ABSTRACT.},
}
@article {pmid41985441,
year = {2026},
author = {Fields, CA and Bhattacharya, D},
title = {Plasma cell ontogenies, functions, and lifespans.},
journal = {Immunity},
volume = {59},
number = {4},
pages = {833-846},
doi = {10.1016/j.immuni.2026.01.030},
pmid = {41985441},
issn = {1097-4180},
mesh = {*Plasma Cells/immunology/cytology ; Animals ; Humans ; *B-Lymphocytes/immunology ; Cell Differentiation/immunology ; Germinal Center/immunology ; Immunologic Memory ; },
abstract = {B cell development is one of the best-understood processes within the immune system. Coordination between transcriptional programs and antigen receptor assembly determines B cell fate, diversifies the antibody repertoire, and allocates specificities to the best-suited subsets. This enables B cells to respond to a wide variety of challenges, which, when encountered, can lead B cells to seemingly converge upon a common fate: the antibody-secreting plasma cell. Yet, as we discuss in this review, this convergence is not complete. Developmental origins, anatomical sites, the nature of the challenge, and other factors all leave their marks on plasma cells in ways that diversify their functions and longevity. Looking forward, these marks may provide targets to engineer vaccines that provide durable antibody-mediated immunity.},
}
@article {pmid41985976,
year = {2026},
author = {Davies, SR and Davies, AL and Higgins, JPT and Caldwell, DM and Thornton, ZA and Aiton, E and Ali, I and Dawson, S and McGrath, C and Parkhouse, T and Yardley, L and Yates, J and Letley, L and Ismail, SA and Christensen, H and French, CE},
title = {Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.},
journal = {BMJ (Clinical research ed.)},
volume = {393},
number = {},
pages = {e087578},
pmid = {41985976},
issn = {1756-1833},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *COVID-19 Vaccines/administration &amp; dosage ; SARS-CoV-2 ; *Vaccination/statistics &amp; numerical data ; Randomized Controlled Trials as Topic ; Adherence Interventions ; Pandemics/prevention &amp; control ; *Immunization Programs ; Bayes Theorem ; },
abstract = {OBJECTIVES: To identify the effective components of interventions to increase vaccine uptake and to explore variations in effectiveness by population group and in relation to the covid-19 pandemic.<br><br>DESIGN: Component network meta-analysis.<br><br>SETTING: Systematic review of randomised controlled trials in high and upper middle income countries.<br><br>PARTICIPANTS: 237 studies with 570 intervention arms and 4&#x2009;361&#x2009;717 participants.<br><br>INTERVENTIONS: Any intervention targeting vaccine recipients or their caregivers aiming to increase demand for, or access to, vaccinations on the UK immunisation schedule. Key content and delivery features of interventions were identified using a bespoke coding framework co-developed with stakeholders.<br><br>MAIN OUTCOME MEASURES: The outcome of interest was vaccine uptake. Bayesian component level meta-regression estimated relative effects of intervention components as ratios of odds ratios with 95% credible intervals (CrIs).<br><br>RESULTS: Of the included studies, 110 were at low risk of bias, 96 had some concerns, and 31 were at high risk. 40% (n=1&#x2009;744&#x2009;686) of the participants were male. For children, there was evidence of beneficial effects for payments to cover costs (ratio of odds ratios 3.01, 95% CrI 1.49 to 6.06) and decision aids (2.73, 1.14 to 7.06), and some evidence for extended opportunities (1.37, 0.98 to 1.95) and social factors (1.27, 0.99 to 1.65). For adolescents and young adults, there were beneficial effects for personal delivery formats (2.13, 1.09 to 4.40), delivery by community members alongside healthcare professionals (6.42, 1.94 to 25.62), and social factors (2.62, 1.45 to 5.04), and negative effects for decision aids (0.43, 0.18 to 0.98) and human versus non-human interaction (0.47, 0.21 to 1.02). For adults, beneficial effects were shown for human interaction (1.86, 1.42 to 2.45), extended opportunities (1.63, 1.35 to 2.00), help with appointment scheduling (1.38, 1.06 to 1.78), payments to cover costs (1.47, 1.03 to 2.16), and motivational interviewing (1.79, 1.21 to 2.64), and there was some evidence for financial incentives (1.15, 0.99 to 1.35) and information on vaccine safety and/or efficacy (1.15, 0.99 to 1.32). For adults, evidence also showed a negative effect of non-human interaction versus no interaction (0.72, 0.57 to 0.92). Subgroup analyses showed variation for underserved populations and in relation to the covid-19 pandemic (before 2020 and 2020 onwards).<br><br>CONCLUSION: Overall, extended opportunities, appointment scheduling help, financial incentives, payments to cover costs, and motivational interviewing were effective content components of interventions to increase vaccine uptake. Effective delivery components overall were human interaction and delivery by community members alongside healthcare professionals. However, effective components varied by age group, for underserved populations, and in analyses investigating the impact of the covid-19 pandemic. These findings have important implications for designing, optimising, and implementing targeted interventions, highlighting which components are effective across different populations and contexts. Consideration of the economic data on interventions should further support resource informed decision making.},
}
@article {pmid41986256,
year = {2026},
author = {Andrés, C and Prats-Méndez, I and Midgley, S and Berginc, N and González-Sánchez, A and Johannesen, CK and Antón, A and Nadal-Barón, P and Fischer, TK and Harvala, H and Benschop, KSM},
title = {Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.},
journal = {Emerging infectious diseases},
volume = {32},
number = {4},
pages = {491-499},
pmid = {41986256},
issn = {1080-6059},
mesh = {Humans ; Europe/epidemiology ; *Enterovirus Infections/epidemiology/virology ; *Genetic Variation ; *Enterovirus D, Human/genetics/classification ; Public Health ; Phylogeny ; COVID-19/epidemiology ; },
abstract = {Enterovirus D68 (EV-D68) represents a continuing public health concern, given its association with severe respiratory illness and neurologic complications. In this study, we analyzed EV-D68 circulation and genetic evolution during 2014-2024 using data from 18 countries in Europe. Of 61,297 enterovirus-positive specimens, molecular detection and viral protein 1 sequencing identified 3,541 (6%) EV-D68 cases. A biennial circulation pattern was observed; detection rates ranged from 9% in 2014 to 0.9% in 2019. The pattern was disrupted in 2020 because of measures implemented in response to the COVID-19 pandemic, but then notable increases occurred in 2021 (14%), 2022 (10.7%), and 2024 (20.6%). Subgenogroups B3 (59.8%) and A2/D (28.0%) were predominant; A2/D reemerged as dominant in 2024. Mutation analyses revealed changes in antigenic regions. Our findings underscore the persistent adaptation and resurgence of EV-D68 after COVID-19. Continued genomic surveillance is essential to monitor transmission patterns caused by antigenic changes.},
}
@article {pmid41987025,
year = {2026},
author = {Mora Castaño, I and Hasbun, R},
title = {Neurological manifestations of respiratory viral infections.},
journal = {Current opinion in infectious diseases},
volume = {39},
number = {3},
pages = {218-226},
doi = {10.1097/QCO.0000000000001189},
pmid = {41987025},
issn = {1473-6527},
mesh = {Humans ; *Respiratory Tract Infections/complications/virology/epidemiology ; *Nervous System Diseases/virology/etiology/diagnosis/epidemiology ; *Virus Diseases/complications ; *COVID-19/complications/epidemiology ; SARS-CoV-2 ; },
abstract = {PURPOSE OF REVIEW: This review summarizes current evidence on the general epidemiology, routes of central nervous system (CNS) invasion, clinical manifestations, diagnostic approaches, and treatment considerations associated with neurological complications of respiratory viral infections. Greater awareness of the neurological impact of respiratory viral infections is crucial to improving patient outcomes and mitigating long-term burden of these diseases.<br><br>RECENT FINDINGS: Recent studies have reinforced the association between respiratory viral infections and a broad spectrum of neurological complications. Evidence accumulated during and after the coronavirus disease 2019 (COVID-19) pandemic has expanded this awareness, and emerging data suggest that immune-mediated mechanisms such as glial cell activation, rather than direct viral neurotropism alone, play a central role in CNS injury. Although diagnostic limitations still exist, some advances have been made to increase specificity of resources available for clinicians, particularly PCR and immunologic profiling. Furthermore, vaccination against certain respiratory viruses may reduce the risk of subsequent neurodegenerative disease, highlighting the potential impact of preventive strategies on long-term neurological burden.<br><br>SUMMARY: Establishing causality between respiratory viral infections and subsequent neurological dysfunction remains challenging given the ubiquitous nature of many respiratory viruses and their capacity to cause lifelong latent or persistent infection. Even though some efforts have been made to optimize diagnosis and treatment, addressing these challenges will require further coordinated efforts across clinicians, researchers and healthcare policymakers.},
}
@article {pmid41987085,
year = {2026},
author = {Burton, K and Best, J and DeCoster, J and Ritchwood, TD},
title = {Pandemic ready or playing catch-up? A scoping review of public health training programs for pandemic preparedness and response efforts.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {41987085},
issn = {1471-2458},
mesh = {Humans ; *Pandemic Preparedness ; *COVID-19/epidemiology/prevention &amp; control ; *Public Health/education ; Public Health Infrastructure ; *Pandemics ; *Education, Public Health Professional/organization &amp; administration ; },
abstract = {BACKGROUND: The COVID-19 pandemic underscored the urgent need for scalable, adaptable training programs to support public health preparedness and response. While many training initiatives emerged globally, their effectiveness, sustainability, and relevance to community needs remain uneven. This scoping review characterizes the landscape of pandemic-related training programs and identifies barriers, facilitators, and gaps in preparedness education for public health professionals, community-based organizations (CBOs), and frontline responders. METHODS: We conducted a scoping review of English-language peer-reviewed articles published between 2005 and 2023. Using the Consolidated Framework for Implementation Research (CFIR) to guide data extraction and thematic synthesis, we examined training programs focused on pandemic preparedness, including design, delivery, implementation processes, and evaluation strategies. RESULTS: Thirty-eight studies met inclusion criteria. Training programs varied in scope, format, and target populations, with most focused on COVID-19 and conducted in low- and middle-income countries. Programs commonly emphasized contact tracing, epidemiology, surveillance, and community engagement. While virtual formats increased accessibility, participants often preferred in-person, interactive learning. Facilitators were associated with perceived success included strong partnerships, culturally tailored materials, and improvement through feedback, while barriers were associated with program challenges included limited infrastructure, unclear learning objectives, lack of sustained funding, and inadequate evaluation. Most programs were reactive and short-term, with minimal input from community stakeholders. Trust, equity, and cultural responsiveness emerged as central themes. CONCLUSIONS: Preparedness training programs remain fragmented and overly reliant on crisis-driven implementation. Future programs would benefit from prioritizing sustained investment, co-design with community partners, and use of validated frameworks like CFIR to guide development and evaluation. Strengthening the capacity of CBOs and embedding preparedness within trusted community networks are essential to building equitable and resilient public health systems.},
}
@article {pmid41987119,
year = {2026},
author = {Oshinubi, K and Chen, Y and Doerry, E and Gel, ES and Hepp, C and Lant, T and Mehrotra, S and Sabo, S and Mihaljevic, J},
title = {A systematic review of spatial epidemiological modeling approaches applied during the COVID-19 pandemic.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {41987119},
issn = {1471-2458},
support = {R01 AI168144/AI/NIAID NIH HHS/United States ; R01AI168144//National Institute of Allergy and Infectious Diseases of the National Institutes of Health/ ; },
mesh = {Humans ; *COVID-19/epidemiology ; *Epidemiological Models ; *Spatial Analysis ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: A wide range of epidemiological modeling approaches have been applied to the SARS-CoV-2 pandemic, which presents an opportunity to assess common approaches applied to specific research questions. Spatial models interrogate how heterogeneities and host movement dynamics influence local and regional patterns of disease, issues that were of great interest for understanding and controlling SARS-CoV-2. OBJECTIVE: Here, we present a systematic review of spatial epidemiological modeling approaches of SARS-CoV-2. We describe common themes and highlight unique strategies, providing a foundation for researchers to devise spatial models most appropriate for future pathogens and epidemics. Our review also categorizes the research questions that were addressed with spatial models, highlights parameter estimation techniques, and describes the cyber infrastructure used for model development. METHODS: We conducted a systematic review using Web of Science and a standardized set of keywords, followed by thorough examination of abstracts and full texts to determine which studies met our inclusion criteria. To guide our description and comparisons of models, we developed a Geography, Population, Movement (GPM) framework that conceptualizes the interactions between three distinct subcomponents of any spatial model. The geographic model represents the physical arena in which the model is implemented, the intra-population model describes the transmission and disease processes that occur within distinct spatial units of the geography, and the movement model describes the algorithms that dictate how hosts move among spatial units within the geography. RESULTS: The search identified a total of 193 articles, of which 109 were included in our review. The most abundant intra-population modeling methods were agent-based (47.7%) and compartmental modeling (29.4%) approaches. Movement models ranged in complexity, with the most complex models implementing commuter movement among many points of interest in the geographic arena, which were sometimes parameterized by fine-scale mobility data. Geographic models ranged from describing microcosms, such as single classrooms, all the way up to multi-country models. Of the 63.3% of models studies that specified the programming language used, we detected ten different languages, with Matlab and Python being the most frequent, although only 30.6% of studies provided open-access code for their models. We also described eight specialized software systems that were used to construct agent-based or compartment models of COVID-19. CONCLUSIONS: Our review identified and characterized a variety of spatial modeling strategies and software that were usefully employed to address many relevant epidemiological questions for COVID-19. Future research is needed to quantitatively assess which modeling approaches are most appropriate in specific situations, to answer specific questions, or to apply to certain disease systems. Moreover, future cyber-infrastructure could help to modularize and standardize modeling approaches, which would increase transparency and reproducibility, and which would facilitate a detailed examination of which model attributes relate to model performance in a variety of contexts.},
}
@article {pmid41987698,
year = {2026},
author = {Bucharová, M and Hořejší, B and Kantor, J and Perimal-Lewis, L and Klugar, M},
title = {Virtual music therapy during the COVID-19 pandemic: an updated scoping review.},
journal = {JBI evidence synthesis},
volume = {24},
number = {7},
pages = {1368-1430},
pmid = {41987698},
issn = {2689-8381},
mesh = {Humans ; *COVID-19 ; *Music Therapy/methods ; SARS-CoV-2 ; Pandemics ; Telemedicine ; },
abstract = {OBJECTIVE: The objective of this update to a previously published scoping review was to map how music therapists used virtual music therapy during the COVID-19 pandemic.<br><br>INTRODUCTION: Virtual music therapy underwent significant development during the COVID-19 pandemic. Consequently, the number of publications increased dramatically compared to early 2021, when only 10 records were available. An update to the previous scoping review was necessary to explore the current state of this emerging music therapy discipline and provide important information for health care practitioners, scholars, and researchers.<br><br>ELIGIBILITY CRITERIA: This scoping review included studies examining how music therapists (population) delivered virtual, remote, or online music therapy (concept) across all client groups during the COVID-19 pandemic (context). All types of evidence were included except for literature reviews, newspaper articles, essays, editorials, letters to the editor, and bachelor's theses. The search strategy was conducted in English across relevant databases and journals.<br><br>METHODS: Following the JBI methodology for scoping reviews, we updated a scoping review published in 2021. Available evidence was searched for in databases, including searches for unpublished studies, gray literature, and relevant journal archives, along with manual searches of reference lists. The search was limited from October 2020 (the date of the previous search) until December 2024. Two independent reviewers screened all reports against the eligibility criteria and performed the data extraction.<br><br>RESULTS: The global music therapy community adapted to the restrictions resulting from the COVID-19 pandemic through a significant expansion of virtual music therapy. A total of 145 new records, along with 5 records from the original review, were included in this scoping review. The papers were from North America (n=63), Europe (n=34), Asia (n=19), and Oceania (n=16), with the rest developed through international cooperation (n=18). Most texts described virtual music therapy in the form of synchronous video calls. We reported the characteristics of the records, the types of texts, the client groups to which virtual music therapy was delivered, and the platforms and equipment used. We identified research papers (n=103), other texts (n=44), study protocols, and an evidence implementation report. We also described the challenges, facilitators, and barriers, along with the music therapy methods. Most frequently, a combination of active and receptive methods was used, with an emphasis on listening, singing, and music-based relaxation or imagery methods. Virtual music therapy was delivered to a wide range of clients, including those with various medical diagnoses and mental health issues; caregivers; and health care workers. Virtual music therapy took place in clients' homes, hospitals, or educational settings.<br><br>CONCLUSIONS: The virtual music therapy field experienced significant growth during the COVID-19 pandemic and developed into a distinct area of music therapy. This scoping review reports on a substantial body of relevant evidence, providing detailed insights into the nuances of virtual music therapy practice, which may remain useful even beyond pandemic restrictions. Future research is needed to examine the impact of virtual music therapy in the post-COVID-19 era and its potential as a complementary approach to face-to-face therapy.<br><br>REVIEW REGISTRATION: OSF https://osf.io/tnw3c/.<br><br>SUPPLEMENTAL DIGITAL CONTENT: A Czech-language version of the abstract of this review is available: http://links.lww.com/SRX/A189.},
}
@article {pmid41988578,
year = {2026},
author = {Vargas-Veliz, SR and Izquierdo-Cevallos, DR and Fajardo-Vargas, JE and Solórzano-Rezabala, DK and Peralta-Gamboa, DA},
title = {Psychosocial risks in Latin America: trends and research gaps.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1788232},
pmid = {41988578},
issn = {2296-2565},
mesh = {Latin America/epidemiology ; Humans ; *COVID-19/epidemiology/psychology ; *Mental Health ; Bibliometrics ; Evidence Gaps ; *Stress, Psychological/epidemiology ; Working Conditions ; Burnout, Professional/epidemiology ; },
abstract = {This study analyzes the scientific evolution of psychosocial risks in Latin America through a bibliometric analysis of 1,866 articles indexed in Scopus and Web of Science between 1963 and 2026. The results show sustained growth in academic production, particularly during the last decade, accompanied by an increase in impact measured by citations. The international collaboration network reveals a structure articulated in South-South and South-North patterns, with Brazil as a regional node and the United States as a transnational bridge. The keyword co-occurrence analysis identifies three main thematic clusters: (1) mental health and psychological distress-including anxiety, depression, and stress-; (2) labor and organizational factors, including burnout, working conditions, workplace violence, and job satisfaction; and (3) the disruptive effects of the COVID-19 pandemic, which reorganized the recent scientific agenda. The findings demonstrate that psychosocial risks in Latin America constitute a field in consolidation, characterized by the convergence of clinical, labor, and structural dimensions, and by growing regional visibility in the international literature. However, limitations persist, associated with the predominance of cross-sectional studies, the underrepresentation of informal and precarious sectors, and geographical asymmetries in scientific infrastructure. It is suggested to advance toward comparative, longitudinal, and interdisciplinary approaches that integrate mental health, work organization, and regional socioeconomic contexts. This study provides an empirical basis for understanding the investigative configuration of the field and guiding future research agendas, public policies, and interventions aimed at psychosocial well-being in the region.},
}
@article {pmid41989511,
year = {2026},
author = {Sun, S and Guo, X and Liu, S and Wu, S and Ma, L and Yang, H},
title = {Probiotics and Bacteriocins Against SARS-CoV-2: Therapeutic Frontiers and Mechanistic Insights.},
journal = {Probiotics and antimicrobial proteins},
volume = {},
number = {},
pages = {},
pmid = {41989511},
issn = {1867-1314},
support = {No. C2023201049//Natural Science Foundation of Hebei Province/ ; No. C20230309//Funding Program for Introducing Overseas Scholars of Hebei Province/ ; },
abstract = {The COVID-19 pandemic has posed significant challenges to global public health. The continuous mutations of its pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have further complicated containment efforts. As functional foods, probiotics and their metabolites, particularly bacteriocins, are recognized for their safety and potential antiviral roles in infection prevention and health management. This review summarizes the current research status, mechanisms, and potential applications of probiotics and bacteriocins against SARS-CoV-2. Clinical and preclinical evidence indicates that specific probiotic strains, such as Lactiplantibacillus plantarum GUANKE, Lactococcus lactis strain Plasma, and Lactiplantibacillus plantarum MPL16/CRL1506, can effectively alleviate clinical symptoms, shorten disease duration, and reduce the risk of severe illness by modulating the gut microbiota, strengthening the mucosal barrier, and enhancing innate immune responses. Representative bacteriocins, including nisin, pediocin PA-1, plantaricin W, glycocin F, and lactococcine G, can mitigate cytokine storms and gut dysbiosis by modulating host immunity, for example, by inhibiting inflammatory factor release as observed in cellular and animal models. Furthermore, molecular docking and dynamics simulations suggest that these bacteriocins may inhibit viral entry and replication by competitively binding to the SARS-CoV-2 Spike (S) protein or the angiotensin-converting enzyme 2 (ACE2) receptor and by interfering with key viral enzyme activities. However, translating these promising findings—supported by clinical observations, animal studies, and computational predictions—into practical applications requires overcoming major bottlenecks, from mechanistic elucidation and in vivo validation to formulation development. Therefore, future research should focus on more in-depth studies to bridge the gap between experimental evidence and clinical translation.},
}
@article {pmid41990021,
year = {2026},
author = {Wandrekar, J and Ranade, K and Chakrapani, V and Lakshmi, P},
title = {Mental Health of Transgender and Gender-Diverse Persons in India: A Scoping Review of Literature Since Legal Recognition of Self-Affirmed Gender Identity, 2014-2024.},
journal = {LGBT health},
volume = {13},
number = {4},
pages = {195-214},
pmid = {41990021},
issn = {2325-8306},
mesh = {Humans ; India/epidemiology ; *Transgender Persons/psychology ; Male ; Female ; *Mental Health ; Gender Identity ; Gender-Nonconforming Persons ; *Sexual and Gender Minorities/psychology ; },
abstract = {PURPOSE: India's 2014 Supreme Court ruling in National Legal Services Authority v. Union of India affirmed transgender and gender-diverse (TGD) persons as equal citizens with a right to self-identified gender. This scoping review (2014-2024) sought to map TGD mental health research in India, characterize study details and themes, and identify gaps to guide future research and interventions.<br><br>METHODS: Following Joanna Briggs Institute methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic search of peer-reviewed literature (PubMed, PsycINFO, Web of Science, Google Scholar, specific journal search, hand search) and grey literature (Google Scholar, websites of LGBTQ organizations, and digital thesis repositories Shodh Ganga and Shodh Gangotri). All publications between April 2014 and December 2024 that focused on the mental health of the Indian transgender population were included.<br><br>RESULTS: From 246 initial sources, 124 were included in the review. The reviewed studies described prevalence rates of common mental disorders, transgender-specific psychosocial stressors, positive psychology variables, role of mental health professionals, mental health interventions and guidelines, forced gender "correction" practices, mental health impact of gender-affirming surgeries, links between sexual health and mental health, and experiences during the COVID-19 pandemic.<br><br>CONCLUSIONS: This review demonstrates substantial mental health needs among TGD communities in India but a narrow, uneven evidence base. Several articles revealed researcher misconceptions indicating ethical and epistemic harm. Priority next steps are adequately powered, intersectional longitudinal studies and rigorously evaluated, community-partnered interventions (including family support and mental health professional training) to advance gender-affirming, evidence-based care.},
}
@article {pmid41991389,
year = {2026},
author = {de Oliveira, LMC and de Araújo, ANB and Soares, TSL and Ferreira, LP and Queiroga, BAM and de Lima, MLLT and de Arruda, RG and Lucena, JA},
title = {The Relationship Between Teachers' Vocal Production Conditions, Interpersonal Communication Competence, and Mental Health After the Pandemic in Brazil.},
journal = {Journal of voice : official journal of the Voice Foundation},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jvoice.2026.03.003},
pmid = {41991389},
issn = {1873-4588},
abstract = {OBJECTIVE: To determine whether teachers' vocal production conditions and interpersonal communication competence are associated with mental health after the COVID-19 pandemic in Brazil.<br><br>STUDY DESIGN: Cross-sectional study with an analytical approach.<br><br>METHOD: The sample comprised 361 middle and high school teachers from Pernambuco state schools. Data were collected using the following instruments: Teacher Vocal Production Condition (VPC-T) and Screening Index for Voice Disorder (SIVD), which characterized teachers' vocal profiles and working conditions; the Interpersonal Communication Competence Scale (ICCS), which assessed interpersonal communication competence; the State-Trait Anxiety Inventory (STAI), which assessed trait and state anxiety; and the Self-Reported Questionnaire (SRQ-20), which suggests the level of suspicion (presence/absence) of a common mental disorder. Pearson's correlation test, multiple linear regression analysis, chi-square test, and the ANOVA test were performed for comparison analysis between variables.<br><br>RESULTS: Higher levels of anxiety and common mental distress were associated with the presence of self-reported voice disorders and less-developed interpersonal communication skills. Voice disorders were self-reported by 44.41% of teachers, while 40.44% presented high anxiety on the STAI-S and 38.78% on the STAI-T. There was an indication that 25% of teachers had common mental distress. The data also indicated that participants had good interpersonal communication skills, particularly in the domains of environmental control, self-disclosure, and immediacy.<br><br>CONCLUSION: Self-reported voice disorders and trait and state anxiety are notably present in teachers. Their vocal production conditions and interpersonal communication skills were associated with anxiety and common mental distress after the COVID-19 pandemic.},
}
@article {pmid41991875,
year = {2026},
author = {Hensel, O and Pfrommer, L and Furch, P and Strutz, N and Wohlgemuth, WA and Posa, A},
title = {[Post-COVID: An inventory focusing on the key complaints PEM and POTS].},
journal = {MMW Fortschritte der Medizin},
volume = {168},
number = {Suppl 3},
pages = {3-10},
doi = {10.1007/s15006-026-5691-7},
pmid = {41991875},
issn = {1613-3560},
mesh = {Humans ; *COVID-19/complications/therapy ; *Postural Orthostatic Tachycardia Syndrome/therapy/etiology/diagnosis ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND: More than five years after the start of the COVID-19 pandemic, its long-term effects are increasingly coming into focus. Post-COVID disease poses a significant challenge, - not only for the individuals affected, but also for healthcare providers and society as a whole. In order to improve care for post-COVID patients, the current state of research should be reviewed and the frequent and characteristic complaints post-exertional malaise and postural tachycardia syndrome should be presented.<br><br>METHOD: The literature search for this narrative review was conducted in the PubMed and Semantic Scholar databases.<br><br>RESULTS: Post-COVID symptoms are often nonspecific, diverse, and fluctuating. However, post-exertional malaise and postural tachycardia syndrome are characteristic of post-COVID when they occur newly after COVID-19 disease. Post-exertional malaise is an intensification of symptoms after exertion that occurs in about 86% of post-COVID patients. Pacing is a promising treatment approach here. Postural tachycardia syndrome manifests as autonomic, tachycardic, orthostatic dysregulation and affects up to 82% of post-COVID patients. Symptomatic therapy includes pharmacological and non-pharmacological measures.<br><br>CONCLUSIONS: Post-exertional malaise and postural tachycardia syndrome are typical and characteristic post-COVID symptoms. Current scientific findings underscore the SARS-CoV-2-related organic origin of post-COVID symptoms.},
}
@article {pmid41992382,
year = {2026},
author = {Cuteri, V and Preziuso, S and Li, Y and Laus, F},
title = {Fecal virome at the human-animal interface: a one health perspective on an uncharted frontier.},
journal = {Animal microbiome},
volume = {8},
number = {1},
pages = {},
pmid = {41992382},
issn = {2524-4671},
abstract = {The exponential growth of the human population and associated intensifications in animal farming, pet ownership, and habitat anthropisation have dramatically increased human-animal interactions. Global livestock production now exceeds 24 billion animals annually, and pet ownership has risen to over 70% of households in many developed nations, creating unprecedented interfaces for viral exchange. This heightened contact has multiplied opportunities for zoonotic and reverse-zoonotic transmission, as tragically exemplified by the SARS-CoV-2 pandemic. The fecal virome—defined as the totality of viral nucleic acids in the gastrointestinal tract—represents a crucial, yet largely unexplored, pathway for such exchanges. While the bacterial microbiome’s role is increasingly recognized, the virome’s composition, dynamics, and transmissibility between co-habiting humans and animals remain poorly characterized. This review compiles current evidence on the fecal virome of key domestic animals (equines, livestock, pets) and their human contacts under the “One Health” framework. We critically evaluate methodological approaches—from targeted PCR to viral metagenomics—and highlight the discovery of novel viruses and identification of zoonotic agents through metagenomic approaches. Critically, we identify significant knowledge gaps, including the absence of definitive evidence for contemporary cross-species transmission versus shared ancestry or convergent evolution. We propose a strategic research agenda focused on longitudinal studies of human-animal cohorts, standardized metagenomic methodologies, and functional analyses of the virome. Elucidating the fecal virome at this interface is paramount for developing proactive surveillance strategies to predict and prevent the next emerging viral disease.},
}
@article {pmid41992508,
year = {2026},
author = {Alsaqer, K and Alhmoud, SH and Khamis, S},
title = {Healthcare Providers' Attitudes and Willingness Toward Monkeypox Vaccination in Jordan: A National Cross-Sectional Survey.},
journal = {Public health nursing (Boston, Mass.)},
volume = {43},
number = {4},
pages = {957-964},
doi = {10.1111/phn.70126},
pmid = {41992508},
issn = {1525-1446},
mesh = {Humans ; Cross-Sectional Studies ; Jordan ; Female ; Male ; Adult ; Surveys and Questionnaires ; *Attitude of Health Personnel ; *Vaccination/psychology/statistics &amp; numerical data ; *Health Personnel/psychology/statistics &amp; numerical data ; *Mpox, Monkeypox/prevention &amp; control ; Middle Aged ; COVID-19/prevention &amp; control ; },
abstract = {BACKGROUND: Despite their crucial role, research shows that healthcare professionals are not well-informed about or adequately equipped to handle newly emerging infectious diseases like monkeypox.<br><br>AIM: This study aims to assess attitudes and willingness toward monkeypox among Jordanian healthcare providers.<br><br>METHOD: This was an analytical cross-sectional survey conducted among healthcare providers in Jordan. Data were collected using a self-administered questionnaire (online and paper-based, as needed) over a defined 4-8-week period.<br><br>RESULTS: A total of 638 healthcare providers participated in the study. The mean age was 35.8 &#xb1; 8.4 years. Composite measures showed moderate willingness (mean = 3.56 &#xb1; 0.78) but high concern levels (mean = 3.98 &#xb1; 0.61). Willingness did not differ significantly across most demographic variables; however, concerns were higher among single participants and those with 5-10 years of experience. A moderate positive correlation was found between willingness and concerns (r = 0.42, p < 0.001). Logistic regression identified COVID-19 vaccination history (OR = 2.22, p = 0.019), trust in health agencies (OR = 1.21, p = 0.028), and greater willingness scores (OR = 1.41, p = 0.006) as significant predictors of acceptance. Concerns did not significantly reduce the likelihood of willingness.<br><br>CONCLUSION: Jordanian Healthcare providers demonstrated relatively low immediate willingness to vaccinate, driven by substantial concerns about safety, effectiveness, and vaccine defects. Confidence in public health agencies and prior vaccination history significantly improved acceptance.},
}
@article {pmid41993129,
year = {2026},
author = {Ugwu, OP and Ogenyi, FC and Basajja, M and Ugwu, CN and Mustafa, MM and Okon, MB},
title = {Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review.},
journal = {Frontiers in drug delivery},
volume = {6},
number = {},
pages = {1793322},
pmid = {41993129},
issn = {2674-0850},
abstract = {INTRODUCTION: Messenger RNA (mRNA) therapeutics have advanced from experimental platforms to clinical application, driven largely by the success of lipid nanoparticle (LNP)-based COVID-19 vaccines. Building on this progress, nanoparticle-mediated mRNA delivery is being extended to non-infectious indications, including oncology, autoimmune disorders, and inherited diseases. However, challenges such as extrahepatic targeting, endosomal escape, repeat-dose immunogenicity, thermostability, and scalable manufacturing remain significant barriers to translation.<br><br>METHODS: A rapid review of peer-reviewed studies and registered clinical trials published between January 2020 and October 2025 was conducted. Searches were performed in PubMed, Scopus, Web of Science Core Collection, and ClinicalTrials.gov using combined terms related to RNA modality and nanoparticle delivery. Eligible studies focused on non-viral nanoparticle platforms for therapeutic, non-infectious mRNA delivery, including applications in protein replacement, genome editing, and immune modulation. Screening yielded 15 studies for inclusion.<br><br>RESULTS: LNPs remain the most clinically advanced platform for therapeutic mRNA delivery. At the same time, polymeric, peptide-based, exosome-inspired, and hybrid nanoparticle systems are expanding the delivery landscape. Emerging RNA formats, including self-amplifying RNA and circular RNA, show potential to prolong expression at lower doses. Clinically, individualized mRNA neoantigen therapy (mRNA-4157/V940) combined with pembrolizumab reduced recurrence risk by approximately 49% in high-risk melanoma in the KEYNOTE-942 phase 2b trial, supporting phase 3 development. In cystic fibrosis, inhaled CFTR mRNA (ARCT-032) advanced to phase 2 after early phase 1 data demonstrated safety and tolerability.<br><br>DISCUSSION: Evidence for non-viral nanoparticle-mediated mRNA therapeutics is strong in preclinical research and increasingly promising in clinical applications beyond vaccinology. While LNPs dominate current translation, alternative carriers and improved RNA formats may broaden tissue targeting and therapeutic durability. Advances in biodegradable ionisable lipids, organ-selective LNPs, and lyophilised or solid formulations are being developed to address persistent delivery and manufacturing constraints. As the field matures, regulatory and policy frameworks will need to align with therapeutic endpoints and support long-term safety monitoring.},
}
@article {pmid41993174,
year = {2026},
author = {Mohiuddin, N and Shah, Y and Subramaniam, S},
title = {Regulation of histones in thromboinflammation.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1791619},
pmid = {41993174},
issn = {1664-3224},
mesh = {Humans ; *Histones/metabolism/immunology ; *Thromboinflammation/immunology/metabolism ; Animals ; Extracellular Traps/immunology/metabolism ; Protein Processing, Post-Translational ; COVID-19/immunology ; Alarmins/metabolism ; *SARS-CoV-2 ; Nucleosomes/metabolism ; Inflammation/immunology ; },
abstract = {Extracellular histones, once regarded solely as nuclear structural proteins, are now recognized as potent mediators of thrombo-inflammation which is the pathological interface of coagulation and immunity. Released during necrosis, apoptosis, and neutrophil extracellular trap (NET) formation, histones act as damage-associated molecular patterns (DAMPs), engaging receptors such as Toll-like receptors (TLR2, TLR4, TLR9) to trigger endothelial dysfunction, platelet activation, and cytokine release. Post-translational modifications (PTMs), including citrullination, acetylation, and methylation, further modulate histone immunogenicity, cytotoxicity, and procoagulant potential. These mechanisms amplify thrombin generation, impair anticoagulant pathways, and promote vascular permeability, positioning histones as central drivers of immunothrombosis in sepsis, stroke, ARDS, COVID-19, and autoimmune disorders. Circulating histones and nucleosomes are emerging as biomarkers for disease severity and prognosis. Therapeutic strategies targeting histones, such as neutralizing antibodies, heparin derivatives, PAD inhibitors, and activated protein C, show promise in mitigating histone-driven pathology. This review highlights mechanistic insights into histone biology and explores translational opportunities for targeted interventions at the intersection of inflammation and thrombosis.},
}
@article {pmid41993206,
year = {2026},
author = {Manu, GP and Bonney, JHK and Bawa, FK and Quashie, PK and Kusi, KA and Amoah, LE},
title = {Reduced COVID-19 severity in Africa: a systematic review of host genetic and immunological responses to SARS-CoV-2 infection.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1782808},
pmid = {41993206},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/genetics/epidemiology ; *SARS-CoV-2/immunology ; Africa/epidemiology ; Severity of Illness Index ; Cytokines ; African People ; T-Lymphocytes/immunology ; },
abstract = {BACKGROUND: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had immense global consequences, leading to widespread illness, deaths, and devastated economies. Despite this, Africa has experienced a high prevalence of asymptomatic coronavirus disease 2019 (COVID-19) and mild cases. While reported cases and deaths have been lower, limited testing and undiagnosed infections make it difficult to determine the true burden of the disease. Understanding the unique immune response and the variations in genetics affect COVID-19 outcomes in African populations is important for shaping future public health responses. This review examines key immune factors and genetic variations in key host proteins that may help explain why COVID-19 was less severe in Africa.<br><br>METHODOLOGY: A systematic review was conducted following PRISMA guidelines to identify studies published between 2019 and January 2026 that investigated immunological responses and genetic variations associated with COVID-19 in African populations. Literature searches were performed in PubMed, Scopus, and African Journals Online (AJOL). Inclusion criteria focused on studies reporting responses from cytokines, T-cells, antibodies or host genetic factors. After screening 4,170 records and removing duplicates, 420 studies were assessed for abstracts, and 240 full texts were reviewed. A total of 40 studies were included, and data synthesized narratively due to heterogeneity in study designs and outcomes.<br><br>RESULTS: Of the 40 studies analyzed from 19 African populations, 26 focused on immunological responses and 9 on host genetic factors. Immune studies revealed widespread pre-existing immunity, including cross-reactive antibodies (especially to the N proteins) and polyfunctional T-cell responses, likely shaped by exposure to malaria, helminths, and other coronaviruses. Severe COVID-19 cases showed elevated IL-6, TNF-&#x3b1;, and IFN-&#x3b3;, while asymptomatic individuals had broader, milder cytokine profiles. Antibody responses were robust across disease severities, with long-lasting IgG activity. Genetic studies identified HLA-B41, B42, C16, and C17 as risk alleles, while HLA-DQB106, DQB103, and B*15 conferred protection. ACE2 polymorphisms including rs2285666, rs73635825 were reportedly prevalent in Africans and were linked to varied ACE2 expression, viral load, and disease severity.<br><br>CONCLUSION: The findings suggest that immune and genetic adaptations in African populations may have modulated susceptibility and severity of SARS-CoV-2 infection outcomes in Africans.<br><br>https://www.crd.york.ac.uk/PROSPERO/view, identifier CRD420251121731.},
}
@article {pmid41993579,
year = {2026},
author = {Song, JH and Shim, SR and Shin, J and Choe, WH and Park, J and Lee, TH and Kang, S and Rhee, TG and Huh, KC},
title = {Clinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose-response meta-analysis.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1719144},
pmid = {41993579},
issn = {1663-9812},
abstract = {OBJECTIVES: Previous studies have shown that ursodeoxycholic acid (UDCA) reduces COVID-19 infection by inhibiting farnesoid X receptor activity, a direct regulator of ACE2. Even though UDCA, an easily accessible medication with few side effects, could be considered for administration to prevent infection and relieve symptoms for COVID-19 infection, there are limited supporting studies with a high-level of evidence and recommendations for the exact dosage of UDCA. We conducted a systematic review and dose-response meta-analysis to evaluate the clinical effect of UDCA in COVID-19 infection.<br><br>METHODS: Studies were identified through a literature search: PubMed, Embase, and Cochrane from inception to March 2025. We included research related to COVID-19 infection and UDCA. Primary outcomes were COVID-19 infection rate, mortality rate, COVID-19 severe infection risk, ventilator use, hospitalization, ICU hospitalization, and recovery time between UDCA group and controls. The secondary outcome was UDCA dose-response association regarding infection risk. We analyzed for odds ratios (ORs), including infection rate, mortality rate, severe infection risk, ventilator use, hospitalization, and intensive care unit hospitalization, and for standardized mean difference (SMD), including recovery time between UDCA groups and controls. Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) was used to evaluate bias risk.<br><br>RESULTS: Of 188 articles, 15 cohort studies with 716,310 participants (control = 495,276; UDCA treatment = 221,034) were included. The level of risk of bias was seven studies at low, four at moderate, and four at serious. UDCA showed association with a lower risk of infection (OR, 0.69; 95% CI, 0.55-0.86), lower severe infection risk (OR, 0.75; 95% CI, 0.64-0.89), and ventilator use (OR, 0.75; 95% CI, 0.62-0.90) compared to controls.<br><br>CONCLUSION: The findings support evidence for the clinical effects of UDCA for COVID-19 infection. There is a need for randomized trials to evaluate UDCA as a potential prophylactic agent against COVID-19.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251019195, identifier #CRD420251019195.},
}
@article {pmid41995128,
year = {2026},
author = {Gonah, L and Ginindza, TG and Hlongwana, KW},
title = {Mapping global evidence on compassion fatigue among healthcare workers during COVID-19: insights and implications for future preparedness - a scoping review.},
journal = {Journal of global health},
volume = {16},
number = {},
pages = {04130},
pmid = {41995128},
issn = {2047-2986},
mesh = {Humans ; *Compassion Fatigue/epidemiology ; *COVID-19/epidemiology/psychology ; *Health Personnel/psychology ; Risk Factors ; Frontline Workers ; Prevalence ; },
abstract = {BACKGROUND: Compassion fatigue (CF) is a critical occupational hazard for healthcare workers (HCWs), intensified by the COVID-19 pandemic, with implications for well-being, retention, and quality of care. We aimed to map the global evidence on CF prevalence, risk factors, effects, interventions, and research gaps among HCWs during the COVID-19 pandemic.<br><br>METHODS: A scoping review of 56 studies from 21 countries (2020-2025) was conducted following PRISMA-ScR guidelines. Seven databases were searched, and findings were synthesised narratively with attention to occupational, demographic, and systemic determinants of CF.<br><br>RESULTS: Compassion fatigue prevalence ranged from 20 to 87%. It was most pronounced among nurses, women, frontline staff, early-career professionals, and those in under-resourced or rural settings. Key risk factors included high workload, long shifts, repeated exposure to death, moral distress, and limited organisational support. Symptoms encompassed emotional exhaustion, depersonalisation, diminished empathy, and co-occurring anxiety, depression, or secondary traumatic stress. Interventions (resilience and peer-support programmes, self-compassion training, motivational messaging, and mobile psychoeducation) showed small-to-moderate benefits but were limited by methodological heterogeneity and scarce robust evaluation. Temporally, CF peaked during early pandemic surges and persisted among frontline staff and in resource-constrained or long-COVID contexts.<br><br>CONCLUSIONS: Compassion fatigue is a multifactorial, context-dependent hazard disproportionately affecting vulnerable HCWs. Effective mitigation requires longitudinal research, inclusive global representation, and multi-level strategies linking individual resilience with organisational reform and policy action to safeguard HCW well-being in current and future crises.},
}
@article {pmid41995349,
year = {2026},
author = {Schiffer, JT and Reeves, DB and Mayer, B and Rodriguez, LR and Duke, ER and Haddock, B and Avila-Ponce de Leon, U and Iwami, S and Owens, K and Esmaeili-Wellman, S},
title = {Clinical trial simulation of antiviral drugs.},
journal = {Journal of virology},
volume = {100},
number = {5},
pages = {e0181424},
pmid = {41995349},
issn = {1098-5514},
support = {R01AI77512//National Institute of Allergy and Infectious Diseases/ ; R01 AI186721/AI/NIAID NIH HHS/United States ; R01 AI150500/AI/NIAID NIH HHS/United States ; },
mesh = {*Antiviral Agents/pharmacokinetics/pharmacology/therapeutic use ; Humans ; *Clinical Trials as Topic ; Computer Simulation ; Viral Load/drug effects ; Models, Theoretical ; *Virus Diseases/drug therapy/virology ; Models, Biological ; },
abstract = {Antiviral clinical trial simulation (CTS) is a type of mathematical modeling that couples viral- immune dynamics (VID) unique to each human viral pathogen, with mechanistic, pharmacokinetic (PK), and pharmacodynamic (PD) drug characteristics. Validation is achieved by matching model output to detailed viral load trajectories from trials. Antiviral CTS can be applied at all stages of drug development to viruses with distinct shedding patterns. Models can capture the activity of small molecules, neutralizing antibodies, and cellular therapies, as well as combination strategies to enhance potency and avoid drug resistance. Several principles are observed across antiviral CTS models. First, PK and PD models that recapitulate drug levels and concentration-dependent antiviral activity are often necessary, but never sufficient to predict trial results. VID equations are also required to guide optimal treatment timing because expanding immune responses synergistically eliminate infection but are deleterious if too sustained or intense. Therefore, equivalent antiviral doses may have different efficacy if given during different infection stages. Second, antiviral CTS models identify effective plasma drug concentrations in humans, which are often poorly predicted by in vitro assays. Finally, models that do not consider drug mechanisms lead to incorrect efficacy estimates. Data-validated CTS is increasingly used to inform drug dose and dosing interval, treatment timing and duration, virologic endpoint selection, and sample size, particularly when applied to detailed phase 1 and 2 trial data. Given the high expense of antiviral licensure trials, CTS models are vital to optimize trial efficacy and de-risk the drug development process.},
}
@article {pmid41995633,
year = {2026},
author = {Kruger, EC and Fataar, A and Kengne, AP and Erasmus, RT and Zemlin, AE},
title = {Mapping the evidence: a scoping review of the impact of COVID-19 on non-communicable disease care in Sub-Saharan Africa.},
journal = {Critical reviews in clinical laboratory sciences},
volume = {},
number = {},
pages = {1-13},
doi = {10.1080/10408363.2026.2651301},
pmid = {41995633},
issn = {1549-781X},
abstract = {Non-communicable diseases (NCDs) are the leading cause of mortality globally and account for a growing proportion of the disease burden in sub-Saharan Africa (SSA), where health systems face significant resource constraints. The COVID-19 pandemic disrupted healthcare delivery globally, raising concerns that interruptions to routine NCD care could lead to higher morbidity and mortality among populations requiring ongoing care. Although evidence of the pandemic's impact on NCD care has been documented in high-income settings, the experience of SSA health systems, which entered the pandemic with preexisting infrastructure and workforce limitations, remains incompletely understood. This scoping review aimed to systematically map the evidence on COVID-19's impact on NCD care in SSA and to identify service adaptations implemented to maintain care continuity during the pandemic. Studies examining the COVID-19 pandemic and disruptions in NCD screening, diagnosis, or monitoring among adults in SSA were identified from four electronic databases: PubMed/Medline, Scopus, EBSCOhost, and Web of Science. The search strategy combined Medical Subject Headings (MeSH) terms and keywords related to geographic location (SSA), exposure (COVID-19 pandemic and related public health measures), and outcomes (screening, diagnosis, and monitoring of NCDs). Inclusion was limited to original research published between March 2020 and December 2023, written in English, French, or German, and reporting observational data on pandemic-related disruptions to NCD care. Two reviewers independently screened titles, abstracts, and full texts, with data extraction conducted using a standardized form capturing study characteristics, NCD types examined, nature of documented disruptions, and reported innovations. Twenty-eight studies were eligible for inclusion across seven countries in SSA, with the majority of evidence originating from South Africa and Ethiopia. Included studies were mainly retrospective and cross-sectional, with some using mixed-methods and time-series designs, and examined various NCDs, including diabetes mellitus, hypertension, and cancers. Sample sizes ranged from fewer than 100 participants to datasets exceeding 9 million records. Due to the heterogeneity of study designs, populations, and outcomes, findings were synthesized narratively. Six major themes emerged: disrupted access to routine care, interruptions to diagnostics and monitoring, medicine supply chain challenges, adoption of remote care models, health equity impacts, and clinical outcome implications. The pandemic was associated with widespread barriers to healthcare access, diagnostic delays, and medication shortages, with the implementation of innovations such as telemedicine and community-based delivery often hindered by technological and resource limitations. COVID-19 significantly disrupted NCD care across SSA, though health systems demonstrated notable capacity for adaptation, emphasizing the need for resilient service delivery models and equity-focused monitoring to safeguard care during future health emergencies.},
}
@article {pmid41996417,
year = {2026},
author = {Byrd, W and Salehi, N and Henderson, C},
title = {Covid-19 testing, sick-pay and public health outbreak management of respiratory infections in care homes: three rapid reviews of the literature.},
journal = {Journal of public health (Oxford, England)},
volume = {48},
number = {2},
pages = {539-542},
pmid = {41996417},
issn = {1741-3850},
support = {NIHR154310//UK National Institute for Health Research Health and Social Care Delivery Research/ ; },
mesh = {Humans ; *Clinical Laboratory Techniques ; COVID-19 ; *COVID-19 Testing ; *Disease Outbreaks/prevention &amp; control ; *Nursing Homes ; Pandemics ; *Public Health ; *Respiratory Tract Infections/epidemiology/diagnosis/therapy ; },
abstract = {BACKGROUND: Credible and costed plans for managing future outbreaks of Covid-19 and other respiratory infections depend on the availability of good quality evidence. Methods: Three rapid reviews (RRs) examined evidence on: Bibliographic database searches for each RR and supplementary grey literature searches of Google for RR1 and RR3.<br><br>RESULTS: RR1 included 1 study, RR2 none, and RR3, 1 report. RR1: a study of testing undertaken during an outbreak of Covid-19 in one care home. RR3: a report briefly described recommended inputs of one local authority's public health service into managing outbreaks of respiratory infections in settings including care homes.<br><br>CONCLUSION: The reviews found little-to-no recent evidence on care home providers' policy and practice on asymptomatic Covid-19 testing, care home sick pay and/or shift backfill, and the incidence of Covid-19 and other respiratory infections, nor on costs of public health teams' outbreak management.},
}
@article {pmid41996892,
year = {2026},
author = {Liu, C and Yuan, X},
title = {Respiratory viruses as key drivers of pulmonary fibrosis: integrated pathways from barrier injury to immune-fibrotic crosstalk.},
journal = {Virology},
volume = {620},
number = {},
pages = {110913},
doi = {10.1016/j.virol.2026.110913},
pmid = {41996892},
issn = {1096-0341},
mesh = {Humans ; *Pulmonary Fibrosis/virology/immunology/pathology ; Signal Transduction ; Animals ; Transforming Growth Factor beta/metabolism ; Macrophages, Alveolar/immunology ; SARS-CoV-2/pathogenicity ; COVID-19/complications/virology/immunology ; Lung/virology/pathology/immunology ; },
abstract = {Pulmonary fibrosis (PF), a highly heterogeneous form of interstitial lung disease, presents substantial challenges for both basic research and clinical management due to its complex pathogenesis and poor clinical outcomes. In recent years, PF induced by respiratory viral infections has emerged as a forefront topic in respiratory medicine. However, the dynamic regulatory network linking virus-mediated alveolar epithelial injury, aberrant tissue repair, and fibroblast activation remains incompletely understood. This review focuses on representative respiratory viruses-including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), seasonal influenza viruses, and highly pathogenic avian influenza viruses-and analyzes, from multiple mechanistic dimensions, how viral infection drives the development of PF. The article analyzes how viral infections contribute to tissue damage and functional loss in the lungs via direct host-cell injury, dysregulated immune responses, and disturbances in epigenetic regulation. In particular, the review highlights the aberrant activation of the transforming growth factor-β (TGF-β)/Smad signaling pathway and virus-induced polarization of alveolar macrophages as key processes in the progression of fibrosis. Furthermore, this review systematically summarizes the shared molecular pathways triggered by viral infections in the development of PF and their potential biomarkers, providing a theoretical basis for targeted therapies. In conclusion, respiratory viruses are not only significant etiological factors in PF, but also accelerate the fibrotic process through immune-fibrotic interactions. This review provides a theoretical framework for a deeper understanding of virus-induced PF and outlines directions for the development of targeted therapies and clinical intervention strategies.},
}
@article {pmid41998470,
year = {2026},
author = {Ho, JKY and Brewster, A and Kienzler, H and Brown, JSL},
title = {Perceived Discrimination and Mental Health Among First-Generation East Asian Immigrants: A Systematic Review.},
journal = {Journal of racial and ethnic health disparities},
volume = {},
number = {},
pages = {},
pmid = {41998470},
issn = {2196-8837},
abstract = {BACKGROUND: Research has found that first-generation immigrants often experience poorer mental health outcomes than later-generation immigrants and native-born individuals. Perceived discrimination is a key factor, exacerbated by recent global events such as COVID-19. However, much of the literature aggregates immigrants of different Asian ethnicities and generational statuses, despite documented disparities in mental health outcomes. This review aims to address this gap in literature by systematically reviewing empirical studies that explore the relationship between perceived discrimination and mental health outcomes of first-generation immigrants from East Asia only. METHODS: This review was registered on the PROSPERO international registry for systematic review protocols (Registration Number: CRD42024505188). Five databases (Embase, PsycINFO, Medline, Web of Science and Scopus) were searched for quantitative, English-language studies that explored the relationship between perceived discrimination and validated measures of mental health outcomes among first-generation East Asian immigrants. Studies were appraised for methodological quality using The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Analytical Cross-Sectional Studies tool [1]. Findings were synthesised narratively due to heterogeneity in methodology across studies. RESULTS: Out of 1,061 screened articles, 10 studies met the inclusion criteria. All included studies explored perceived discrimination, through racial discrimination. Only studies of Korean or Chinese first-generation immigrants were found. Ten studies reported a significant association between perceived racial discrimination and poorer mental health outcomes, particularly depressive symptoms. A range of variables that influenced this relationship were also identified, with degree of social support emerging as a consistent factor. Methodological limitations included inconsistent control for relevant sociodemographic or immigrant-related variables and differences in in exclusion or inclusion criteria used in the different studies. CONCLUSION: Overall, the findings highlight that experiences of perceived racial discrimination have a detrimental impact on the mental health of first-generation Korean and Chinese immigrants. However, inconsistencies in the measurement and study design presented challenges for synthesising the results and drawing firm conclusions, particularly regarding the role of influencing variables. Future research should use more consistent measures of perceived discrimination and mental health to better quantify the outcomes and understand the mental health implications. Research should also continue to disaggregate data by both generational status and specific East Asian ethnic groups, particularly those underrepresented in the current review, such as Japanese, Taiwanese, and Mongolian immigrants.},
}
@article {pmid41998754,
year = {2026},
author = {Amanat, N and Hosseini, SH and Habibisaravi, R and Omrani, MG},
title = {COVID-19 vaccination hesitancy in pediatrics: a systematic review.},
journal = {Systematic reviews},
volume = {15},
number = {1},
pages = {},
pmid = {41998754},
issn = {2046-4053},
mesh = {Humans ; *Vaccination Hesitancy/psychology ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/administration &amp; dosage ; *Parents/psychology ; Child ; Pediatrics ; SARS-CoV-2 ; *Vaccination/psychology ; Health Knowledge, Attitudes, Practice ; Infant ; },
abstract = {BACKGROUND: Vaccine-preventable diseases remain among the top ten global health threats. These findings indicate an important link between health and vaccine literacy. Children are less affected by COVID-19 than adults are but can be particularly vulnerable in communities with inadequate and weak infrastructure. One in five parents was skeptical about the COVID-19 vaccine. The present study combined the findings of previous studies to identify the reasons for parental hesitancy related to children's COVID-19 vaccination.<br><br>METHODS: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to investigate vaccine hesitancy among parents of children aged 0-18 years in the context of COVID-19. We searched PubMed, Scopus, Web of Science, and Google Scholar using the keywords "vaccine hesitancy," "pediatrics," and "COVID-19" for studies published between January 2019 and August 2024. Eligible studies were published in English and focused on parental perspectives. Two independent reviewers screened 2950 records, extracted data, and assessed study quality using the Joanna Briggs Institute (JBI) critical appraisal checklists. Thematic analysis identified key drivers of vaccine hesitancy.<br><br>RESULTS: Of the 48 full-text articles screened, 22 studies met the eligibility criteria. The included studies took place in 11 different countries. The thematic analysis resulted in two main headings: (1) vaccine-related concerns, which included safety/trust concerns (100% of studies) and accessibility barriers (13.6%), and (2) user-related concerns: risk perception (31.8%), lack of knowledge (50%), cultural manifestation (13.6%), and previous medical conditions (31.8%). Universal concerns about safety and trust were evident in all studies, while cultural and accessibility barriers were context-specific and fluctuated by region and population.<br><br>CONCLUSION: The study points to interventions for reversing parental hesitation towards pediatric COVID-19 vaccination, like tailored education programs, streamlining distribution procedures, creating public acceptance through local community opinion leaders, and appropriate risk communication by public health institutions. All of these can contribute to making sound policies and making future immunization planning easier.},
}
@article {pmid41999993,
year = {2026},
author = {Farsiu, N and Khodadadpour Mahani, F and Arefinia, N and Charostad, J and Pardeshenas, M and Mirzaei, H and Nakhaie, M and Hassandarvish, P and AbuBakar, S},
title = {From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.},
journal = {Virus research},
volume = {368},
number = {},
pages = {199730},
pmid = {41999993},
issn = {1872-7492},
mesh = {Humans ; *Virus Diseases/prevention &amp; control/immunology ; Vaccines, Virus-Like Particle/immunology ; *Vaccine Development/methods ; *Viral Vaccines/immunology ; Animals ; Vaccines, DNA/immunology ; Vaccination/methods ; COVID-19/prevention &amp; control/immunology ; COVID-19 Vaccines/immunology ; Vaccines, Subunit/immunology ; Vaccines, Attenuated/immunology ; Vaccine Efficacy ; },
abstract = {Viral infections continue to pose a substantial global health concern, resulting in extensive morbidity and mortality among various populations. Although conventional vaccinations have been pivotal in managing and eliminating certain viral infections, the introduction of new viruses and the resurgence of existing ones underscore the ongoing necessity for creative immunization techniques. This review offers an extensive examination of both conventional and novel vaccine platforms for preventing viral diseases. It analyzes traditional approaches such as inactivated and attenuated vaccines in conjunction with innovative technologies, including subunit, viral vector-based, DNA, mRNA, and virus-like particle (VLP) vaccines. Furthermore, novel strategies to enhance vaccination efficacy, including nanoparticle-based and plant-derived vaccines, are examined. Each platform is evaluated according to its mode of action, immunogenicity, safety, scalability, and adaptation to novel threats. Empirical instances, especially observations from the COVID-19 pandemic, are employed to underscore the achievements, obstacles, and pragmatic utilization of these tools. By reviewing the scientific foundations and developmental pathways of diverse vaccine strategies, this paper offers a more profound understanding of the evolving landscape of viral vaccine development. Finally, this review emphasizes the critical role of innovation in strengthening global readiness for current and future outbreaks.},
}
@article {pmid42000530,
year = {2026},
author = {Yoshii, K and Kunisawa, J},
title = {Alcaligenes lipid A: a unique TLR4 agonist mucosal adjuvant inducing secretory IgA and Th17 responses.},
journal = {Current opinion in virology},
volume = {76},
number = {},
pages = {101533},
doi = {10.1016/j.coviro.2026.101533},
pmid = {42000530},
issn = {1879-6265},
abstract = {The COVID-19 pandemic has underscored the importance of infectious disease control. In this context, intensive efforts are underway to develop novel vaccine modalities that will enable the production of effective and safe vaccines in preparation for future pandemics caused by emerging and re-emerging infectious diseases. To maximize the performance of these new modalities, adjuvants tailored to the characteristics of each platform are indispensable. In particular, the ability to elicit appropriate immune responses with minimal amounts of antigen is a critical determinant of both vaccine efficacy and safety in the development of mucosal vaccines that confer protection against infection by inducing immune responses in mucosal tissues - the primary sites of pathogen entry. Consequently, the development of superior adjuvants is a key factor for the practical implementation of mucosal vaccines. In this article, we focus on adjuvant development aimed at the creation of mucosal vaccines and introduce our efforts to apply Alcaligenes-derived lipid A to mucosal vaccine platforms.},
}
@article {pmid42000586,
year = {2026},
author = {Gulati, RR and Yaqub, F and Goodman, AL},
title = {Enhancing uptake of respiratory vaccinations in asthma and chronic obstructive pulmonary disease (COPD) patients: a systematic review.},
journal = {Vaccine},
volume = {81},
number = {},
pages = {128560},
doi = {10.1016/j.vaccine.2026.128560},
pmid = {42000586},
issn = {1873-2518},
mesh = {Humans ; *Pulmonary Disease, Chronic Obstructive/immunology ; *Asthma/immunology ; Pneumococcal Vaccines/administration &amp; dosage ; *Vaccination/statistics &amp; numerical data ; Influenza Vaccines/administration &amp; dosage ; COVID-19 Vaccines/administration &amp; dosage ; COVID-19/prevention &amp; control ; Influenza, Human/prevention &amp; control ; Patient Education as Topic ; Randomized Controlled Trials as Topic ; },
abstract = {INTRODUCTION: Despite influenza, pneumococcal and COVID vaccines being widely recommended for patients with chronic respiratory disease, vaccination rates in this cohort remain low. The aim of this systematic review is to identify interventions which are effective in increasing respiratory vaccination rates in adults with chronic obstructive pulmonary disease (COPD) or asthma.<br><br>METHODS: The inclusion and exclusion criteria for the study can be found in the PROSPERO protocol (PROSPERO registration no: CRD42025588565). A search was run across four databases (MEDLINE, Embase, CENTRAL and ClinicalTrials.gov) in February 2025, which returned 2537 studies. Eleven studies were deemed to meet the study inclusion/exclusion criteria and these were narratively synthesised: four randomised clinical trials (RCTs), six longitudinal studies and one observational cohort study. Risk of bias was assessed using the Cochrane's Risk of Bias (RoB-V2) and ROBIN-I-V2 tools. Studies were categorised according to the COM-B model of behaviour change.<br><br>RESULTS: All 11 studies consisted of COPD populations, with four studies also including asthma patients. Interventions focused on patient education, with/without involvement of a healthcare professional (HCP). Nine of the eleven studies showed a statistically significant improvement in influenza and/or pneumococcal vaccination rate with an intervention. No studies assessing COVID vaccine uptake in this population were suitable for inclusion. Most studies targeted patients' capability to get vaccinated through improving patients' and HCPs' knowledge. Fewer studies focused on social opportunity (e.g. support from other patients/HCPs) or automatic motivation (e.g. reminders).<br><br>DISCUSSION: The published literature in this area is currently limited. Most studies are non-randomised and are at high-risk of bias, making meta-analysis not possible. Further research should assess the practicalities (physical opportunity) of vaccination, especially in low-income economies (where most respiratory patients reside) and standardising research methods to allow for future meta-analysis.<br><br>OTHER: There is no funding for this review.},
}
@article {pmid42000938,
year = {2026},
author = {Ramirez Campos, MS and Barati, K and Samavi, R and Pires, P and Duncan, L and Sassi, RB and Noseworthy, MD and Gadsden, SA and Doyle, TE},
title = {Multimodal artificial intelligence and online learning in youth mental health: a scoping review.},
journal = {Npj mental health research},
volume = {5},
number = {1},
pages = {},
pmid = {42000938},
issn = {2731-4251},
abstract = {Youth mental health-related problems and disorders have garnered increased attention due to global prevalence estimates that have, in some cases, increased following the COVID-19 pandemic. Various methodologies have been proposed to leverage artificial intelligence (AI) for detecting mental health problems in the general population; however, research specifically focused on AI methods for youth remains limited. Shortcomings in modern AI include limited training data modalities (i.e., types of input data used for model training), reliance on offline training, and the use of static models. This scoping review provides an overview of evidence that uses AI methods applied to youth mental health (YMH) and provides an assessment of the current state of research that integrates multimodal AI (i.e., models that incorporate multiple data modalities) and/or online learning (i.e., incremental or continual model training from streaming data) for the diagnosis, monitoring, and treatment of YMH-related problems. The findings indicate that research in AI applied to YMH is limited in the areas of multimodal AI and online learning. The number of studies in this field is steadily growing. Studies incorporating online learning demonstrate that this approach enhances model performance and adaptability, which is crucial for developing translational models capable of addressing real-world challenges effectively. Despite these advances, key challenges remain, including the availability and long-term validity of multimodal data, the lack of participant-related information in certain databases and studies, the ethical and logistical difficulties of collecting data from minors, and the computational costs of training robust AI models.},
}
@article {pmid42001013,
year = {2026},
author = {Marks, Y and Cunningham, J and Jiang, A and Li, L and Lin, YS and McGrory, A and Ouyang, Y and Tran, NA and Wang, Y and Heath, A},
title = {A systematic review of sample size determination in Bayesian randomized clinical trials: full Bayesian methods are rarely used.},
journal = {BMC medical research methodology},
volume = {26},
number = {1},
pages = {},
pmid = {42001013},
issn = {1471-2288},
support = {463252//Canadian Institutes for Health Research Grant/ ; CIHR Grant #184898//CANSSI-CRT award; CIHR CANTRAIN program/ ; RGPIN-2021-03366//Canada Research Chair in Statistical Trial Design; Natural Sciences and Engineering Research Council of Canada/ ; },
mesh = {Bayes Theorem ; Humans ; Sample Size ; *Randomized Controlled Trials as Topic/methods/statistics &amp; numerical data ; *Research Design ; COVID-19/epidemiology ; },
abstract = {BACKGROUND: Utilizing Bayesian methods in clinical trials has become increasingly popular, as they can incorporate prior information into the design, and allow for smaller sample sizes while providing reliable and robust statistical results. Various Bayesian methods for sample size determination are available, and while these methods are well justified and understood, it is unclear how they are being used in practice. This study aims to understand how sample sizes for Bayesian efficacy randomized clinical trials (RCTs) are determined and inform future designs of Bayesian trials. METHODS: A systematic literature review was conducted in May 2023 and updated in July 2025. We included completed RCTs which (a) assessed the efficacy of interventions in humans; (b) utilized a Bayesian framework for the primary data analysis; (c) published in English; and (d) enrolled participants between December 2009 – July 2025. RESULTS: The literature search produced 74,833 records, of which 27,890 were duplicates, and 46,943 were screened using manual and automated screening. 283 full texts were screened and 164 studies moved to extraction. Our findings demonstrate a slow increase in RCTs using Bayesian methods to analyse primary efficacy data from 2012 onwards, with a sharp increase during the COVID-19 pandemic (42%). The most common method for sample size determination in Bayesian RCTs was a hybrid approach (58%) in which elements of Bayesian and frequentist theory are combined. Bayesian RCTs predominantly took place in North America (34%) and mainly focused on adult study populations (85%). Bayesian trials were used in a variety of disease areas; the most common being COVID-19 (31%). CONCLUSION: Fully Bayesian methods for sample size determination are rarely used in practice, despite significant theoretical development. Our review revealed a lack of standardized reporting across Bayesian RCTs, making it challenging to review the sample size determination. The CONSORT statement indicates that RCTs must report sample size calculations; adhered to by only 84% of included RCTs. Among RCTs that reported sample size determination, relevant information was frequently omitted from reports and discussed in poorly structured supplementary materials. Thus, there is a critical need for greater transparency, standardization and translation of relevant methodology in Bayesian RCTs.},
}
@article {pmid42001977,
year = {2026},
author = {Nilius, H and Kuster, L and Boss, R and Boschetti, L and Mihalek, N and Soares Ferreira Junior, A and Naas, S and Jegerlehner, S and Largiader, CR and Nakas, C and Nagler, M},
title = {Dissemination in diagnostic accuracy studies is not associated with methodological quality: a systematic review and meta-epidemiological analysis.},
journal = {Journal of clinical epidemiology},
volume = {195},
number = {},
pages = {112270},
doi = {10.1016/j.jclinepi.2026.112270},
pmid = {42001977},
issn = {1878-5921},
mesh = {Humans ; *COVID-19/diagnosis/epidemiology ; Journal Impact Factor ; SARS-CoV-2 ; *Information Dissemination ; Pandemics ; },
abstract = {OBJECTIVES: To evaluate associations between methodological characteristics and dissemination measures in diagnostic accuracy studies. The COVID-19 pandemic generated a large body of studies addressing a single diagnostic question, allowing assessment of how study characteristics relate to dissemination.<br><br>STUDY DESIGN AND SETTING: Using a preregistered systematic review (PROSPERO CRD42023343656), we identified studies evaluating the diagnostic performance of SARS-CoV-2 serological tests through Medline, Embase, and the iSearch Portfolio. Risk of bias and applicability were assessed using QUADAS-2. Study characteristics were linked to dissemination measures, including journal impact factor, citation counts, network-based scientific influence (PageRank), and policy and guideline citations, using multivariable regression models.<br><br>RESULTS: Among 18,092 screened records, 782 studies met the inclusion criteria. QUADAS-2 assessments varied substantially, with 772 of 782 studies (98.7%) exhibiting high or unclear risk of bias in at least one domain. Dissemination measures were positively associated with journal impact factor, earlier publication year, reporting of extreme diagnostic accuracy estimates, and higher last author H-index. In contrast, the number of domains rated as low risk of bias or high applicability was not positively associated with citation counts, network-based scientific influence, or policy citations.<br><br>CONCLUSION: Dissemination was primarily associated with structural and authorship characteristics rather than QUADAS-2 ratings. These findings suggest that dissemination in diagnostic research is more closely linked to structural factors than assessed methodological quality and support strengthening diagnostic-specific approaches to evidence appraisal.<br><br>PLAIN LANGUAGE SUMMARY: We examined whether high-quality diagnostic studies receive more attention in science and clinical practice. Using a large set of studies on COVID-19 antibody tests, we found that attention was mainly linked to factors such as the journal, publication timing, and authorship, rather than to methodological quality. Studies reporting very high accuracy also received more attention. This suggests that widely cited or highly visible studies are not necessarily the most reliable. Our findings highlight the need for careful evaluation of diagnostic studies and stronger emphasis on study quality when interpreting and using research results.},
}
@article {pmid42005246,
year = {2026},
author = {Lala, A and Vysochyn, M and Shyshkova, K},
title = {COVID-19-Associated Cardiovascular Complications: A Narrative Literature Review.},
journal = {Cureus},
volume = {18},
number = {3},
pages = {e105394},
pmid = {42005246},
issn = {2168-8184},
abstract = {Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, coronavirus disease 2019 (COVID-19) has caused significant global morbidity and mortality. Although initially recognized as a respiratory illness, COVID-19 is now understood to be a systemic disease with substantial cardiovascular involvement. Both patients with pre-existing cardiovascular disease and those without prior cardiac conditions may develop a wide range of cardiovascular complications during and after acute infection. Reported complications include myocardial injury, myocarditis, heart failure, arrhythmias, and thromboembolic events, all of which contribute to increased disease severity and mortality. This narrative review summarizes current evidence on cardiovascular complications associated with COVID-19 among adult patients in the United States, with particular attention to differences between individuals with pre-existing cardiovascular disease and those who develop new cardiovascular pathology following SARS-CoV-2 infection. This review discusses proposed mechanisms of cardiovascular injury, clinical manifestations, diagnostic approaches, and current management strategies. By summarizing current knowledge, this review aimed to increase awareness of COVID-19-related cardiovascular complications, support timely recognition in emergency and inpatient settings, and assist clinicians in improving patient outcomes.},
}
@article {pmid42005429,
year = {2026},
author = {Rukundo, G and Moore, M and Semukunzi, H and Chatterjee, S and Musabyimana, JP and Mambo Muvunyi, C and Green, CA},
title = {Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases.},
journal = {BMJ medicine},
volume = {5},
number = {1},
pages = {e001835},
pmid = {42005429},
issn = {2754-0413},
abstract = {Vaccines have saved an estimated 154 million lives in the past 50 years and support 15 of the 17 United Nations sustainable development goals. Vaccines are also an important tool in the control of new outbreaks of infectious diseases. The vaccine cold chain, however, is key in enabling and empowering implementation of vaccine policy and societal protection from all vaccine preventable diseases, and is especially relevant in low and middle income countries in sub-Saharan Africa. The vaccine cold chain is a complex, highly specialised, temperature controlled supply chain network that extends from the point of vaccine manufacture to dose administration, and has multiple points of vulnerability. Large quantities of vaccines are lost because of excess heat or accidental freezing, resulting in missed opportunities for vaccination. Disruption to the provision of routine vaccines during the covid-19 pandemic resulted in millions of children not being vaccinated. The vaccine cold chain needs strategic prioritisation for investment and innovation so that the next generation of vaccine cold chains for low and middle income countries can be designed towards providing reliable and sustainable vaccine security in an uncertain world of climate change, managing the advent of new vaccine technologies, and narrowing inequalities in global health for resource poor communities. This review focuses on the vaccine cold chain in African low and middle income countries, and how new and emerging advances in vaccine science and challenges will affect the readiness to control the burden of vaccine preventable disease on the continent.},
}
@article {pmid42005985,
year = {2026},
author = {Msobo, A and Maphari, PW and Koorsen, G and Singab, ANB and Mhlongo, MI},
title = {Modernising antiviral drug discovery: harnessing medicinal plants through machine learning and metabolomics to target the SARS-CoV-2 main protease.},
journal = {In silico pharmacology},
volume = {14},
number = {2},
pages = {120},
pmid = {42005985},
issn = {2193-9616},
abstract = {The COVID-19 pandemic highlighted critical limitations in the speed, scalability and translational efficiency of conventional antiviral drug discovery. Although vaccines and repurposed antivirals have reduced disease severity, the continued emergence of SARS-CoV-2 variants and breakthrough infections underscores the need for sustained discovery of novel therapeutics. The main protease (Mpro), an essential and highly conserved enzyme required for viral replication remains a validated and attractive antiviral target. Medicinal plants represent a vast and underexplored source of structurally diverse bioactive compounds with antiviral potential; however, traditional plant-based drug discovery approaches are often constrained by reliance on ethnobotanical knowledge and fragmented screening workflows. This review critically examines emerging strategies that integrate machine learning, LC-MS-based metabolomics and network pharmacology to modernise medicinal plant-based antiviral discovery. We highlight how machine learning enables data-driven prioritisation of candidate compounds and plant species beyond well-studied taxa, while metabolomics provides experimental validation through comprehensive chemical profiling and dereplication. Molecular docking and molecular dynamics further refine candidate selection by evaluating binding modes and stability, whereas network pharmacology offers systems-level insight into multitarget and multipathway effects. Importantly, we discuss key limitations of these approaches, including data bias, model interpretability, and gaps between in silico prediction and experimental validation. By synthesising these methodologies into a unified computational-experimental pipeline, this review provides a critical framework for accelerating the discovery of plant-derived Mpro inhibitors and supports the development of resilient antiviral strategies for current and future pandemics.},
}
@article {pmid42007740,
year = {2026},
author = {Almaraz-De-Santiago, J and Solís-Torres, N and Escudero-Lourdes, C and Méndez-Frausto, G and Gonzalez-Curiel, I and Rivas-Santiago, B and Rivas-Santiago, C},
title = {Particulate Matter and Innate Airway Immunity: Mechanisms of Disruption and Impact on Respiratory Infections.},
journal = {Immunological investigations},
volume = {55},
number = {5},
pages = {1029-1053},
doi = {10.1080/08820139.2026.2655720},
pmid = {42007740},
issn = {1532-4311},
mesh = {Humans ; *Immunity, Innate ; *Particulate Matter/adverse effects/immunology ; Animals ; *Respiratory Tract Infections/immunology ; SARS-CoV-2/immunology ; *Respiratory System/immunology ; Disease Susceptibility ; Respiratory Mucosa/immunology ; },
abstract = {BACKGROUND: Air pollution is a major global public health challenge, with particulate matter (PM) as a leading environmental risk factor for increased morbidity and premature mortality worldwide. The respiratory tract is the primary interface for PM exposure, where airway epithelial cells and innate immune systems coordinate frontline host defense. Chronic PM-exposure disrupts this system, impairing airway immune homeostasis and increasing susceptibility to respiratory infections.<br><br>OBJECTIVE: This review aims to integrate current molecular and cellular evidence describing how PM affects airway innate immunity, focusing on its impact on host defense mechanisms and its role in increasing susceptibility to respiratory infections.<br><br>METHODS: A comprehensive literature review was conducted focusing on PM interactions with the respiratory tract and their effects on airway epithelial and innate immune functions, emphasizing mechanisms of immune dysregulation.<br><br>RESULTS: PM-exposure induces innate immune dysregulation characterized by oxidative imbalance, altered cytokine and chemokine signaling, reduced phagocytic capacity, and decreased production of host defense peptides, resulting in impaired epithelial barrier integrity, persistent inflammation, defective pathogen clearance, and increased susceptibility and severity of respiratory infections, including tuberculosis, bacterial pneumonia, and viral respiratory diseases such as COVID-19.<br><br>CONCLUSION: PM is a key driver of airway innate immune dysfunction and increased susceptibility to respiratory infections by disrupting epithelial and immune defense pathways, weakening host resistance, and exacerbating disease burden. Further studies are needed to elucidate PM-immune interactions and support the development of preventive and therapeutic strategies.},
}
@article {pmid42009524,
year = {2026},
author = {Mao, M and He, Z and Wang, J and Li, M and Hao, X},
title = {[Research progress in mRNA vaccines for animal disease prevention and control].},
journal = {Sheng wu gong cheng xue bao = Chinese journal of biotechnology},
volume = {42},
number = {4},
pages = {1458-1469},
doi = {10.13345/j.cjb.250738},
pmid = {42009524},
issn = {1872-2075},
support = {2025BBF02009//the Key Research and Development Program of Ningxia Hui Autonomous Region/ ; 32360877 and 32370198//the National Natural Science Foundation of China/ ; 2023AAC02016//the Ningxia Hui Autonomous Region Natural Science Foundation/ ; },
mesh = {Animals ; *mRNA Vaccines/immunology ; *Vaccines, Synthetic/immunology ; SARS-CoV-2/immunology ; COVID-19/prevention &amp; control ; Vaccine Development ; RNA, Messenger/immunology/genetics ; },
abstract = {mRNA vaccines, as an emerging preventive measure, have gained widespread recognition due to their high efficacy, favorable safety profile, substantial research potential, and short development cycle. In recent years, the global pandemic of COVID-19 has greatly promoted the development of mRNA vaccines, and the research process in mRNA vaccines for animal disease prevention. This paper briefly reviews the structural and functional characteristics of mRNA vaccines, as well as the latest research progress in mRNA vaccines for animal diseases caused by viruses, bacteria, and parasites, with the aim of providing a reference for future research on mRNA vaccines for animal diseases.},
}
@article {pmid42009582,
year = {2026},
author = {Dutta, S},
title = {International collaborations in neonatal and fetal medicine - Low-and-middle income countries have the patients and high-income countries have the technology: Consensus, conundrums and controversies.},
journal = {Seminars in fetal &amp; neonatal medicine},
volume = {31},
number = {3},
pages = {101737},
doi = {10.1016/j.siny.2026.101737},
pmid = {42009582},
issn = {1878-0946},
mesh = {Humans ; *Developing Countries ; *International Cooperation ; Developed Countries ; *Neonatology ; COVID-19/epidemiology ; },
abstract = {International collaborations between investigators in low-and-middle-income countries (LMICs) and high-income countries (HICs) in neonatal and fetal medicine have expanded over the past decade. This narrative review documents a rise in HIC-LMIC publications since 2014, with a plateau and transient dip during the COVID-19 pandemic. It analyses leadership, patient recruitment, and how HIC-based technologies and laboratory platforms shape research agendas. Many influential trials are conceived and sponsored by HIC institutions, with recruitment concentrated in LMICs because of higher disease burden, larger eligible populations and lower costs. Meanwhile, LMIC centers report growing readiness to support randomized controlled trials, and LMIC-conceived, led and completed multicentre studies are increasingly reported. Ongoing concerns include misalignment between donor priorities and national agendas, inequities in authorship and leadership, and ethical challenges related to standards of care, post-trial access, consent and compensation. The review compares regulatory, consent and insurance processes in India and the United States, and highlights enabling factors such as harmonised guidelines, global registries, political goodwill and professional networks. It anticipates a doubling of HIC-LMIC collaborative studies over the next decade, rapid growth of South-South partnerships, and gradual, though incomplete, correction of authorship and leadership imbalances in global neonatal and fetal medicine.},
}
@article {pmid42009999,
year = {2026},
author = {Ashique, S and Mondal, M and Hussain, MS and Islam, A and Tariq, M and Chellappan, DK and Yasmin, S and Malik, T and Attar, JR and Ansari, MY},
title = {Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review.},
journal = {Inflammopharmacology},
volume = {34},
number = {5},
pages = {2873-2888},
pmid = {42009999},
issn = {1568-5608},
mesh = {Humans ; Female ; Pregnancy ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage/immunology ; *Lactation/immunology ; *COVID-19/prevention &amp; control/immunology ; Breast Feeding ; *Pregnancy Complications, Infectious/prevention &amp; control ; SARS-CoV-2/immunology ; Vaccine Efficacy ; Vaccination ; },
abstract = {Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant's life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations.},
}
@article {pmid42010035,
year = {2026},
author = {Elalouf, A and Maoz, H},
title = {Immunomodulatory Strategies for Managing Viral Infections in Solid Organ Transplantation: Progress and Challenges.},
journal = {Current microbiology},
volume = {83},
number = {6},
pages = {},
pmid = {42010035},
issn = {1432-0991},
mesh = {Humans ; *Organ Transplantation/adverse effects ; *Virus Diseases/immunology/therapy/prevention &amp; control ; *Immunomodulation ; Antiviral Agents/therapeutic use ; Immunosuppression Therapy/adverse effects ; Immunosuppressive Agents/therapeutic use ; },
abstract = {Solid organ transplantation (SOT) is a critical treatment for end-stage organ failure. Still, lifelong immunosuppression leaves recipients vulnerable to opportunistic viral infections, which can lead to severe complications such as graft dysfunction and post-transplant lymphoproliferative disorder. With emerging viral threats such as SARS-CoV-2 and arboviruses, alongside persistent challenges posed by CMV, EBV, and BKV, this review is timely in addressing the evolving landscape of post-transplant viral infections and their management. Recent studies highlight how immunosuppression impairs both innate and adaptive antiviral defenses, including diminished toll-like receptor signaling, dysfunction of NK cells, and disrupted T- and B-cell responses. Viruses exploit these deficits through immune evasion strategies, such as MHC-I downregulation and the production of immunosuppressive microRNA. Advances in management include antiviral prophylaxis, adoptive T-cell therapy, and immune monitoring, with emerging therapies like virus-specific T-cell infusions and complement inhibition showing promise. The findings underscore the need for personalized, organ-specific approaches to post-transplant care. Enhanced surveillance, vaccination strategies, and novel immunotherapies are critical in mitigating viral risks. Future research should focus on immune-risk stratification and the development of an adaptable therapeutic approach to enhance transplant outcomes in the face of evolving viral threats.},
}
@article {pmid42010704,
year = {2026},
author = {Wang, RY and Zheng, Y and Ge, Y and Xu, YF and Ding, Y},
title = {Electrophysiological features and outcomes of post-infectious myoclonus-ataxia syndrome: a case report and literature review.},
journal = {Journal of medical case reports},
volume = {20},
number = {1},
pages = {},
pmid = {42010704},
issn = {1752-1947},
support = {LY24H090004//Natural Science Foundation of Zhejiang Province/ ; 82201607//National Natural Science Foundation of China/ ; },
mesh = {Female ; Humans ; Middle Aged ; *Ataxia/physiopathology/drug therapy/virology/diagnosis/etiology ; *COVID-19/complications ; Electroencephalography ; Electromyography ; Methylprednisolone/therapeutic use/administration &amp; dosage ; *Myoclonus/physiopathology/drug therapy/etiology/diagnosis/virology ; Pandemics ; *Post-Infectious Disorders/diagnosis/therapy ; SARS-CoV-2 ; Syndrome ; Treatment Outcome ; },
abstract = {BACKGROUND: Myoclonus has become one of the neurological manifestations associated with coronavirus disease 2019 (COVID-19); however, the origin and pathophysiological mechanism remained uncertain.<br><br>CASE PRESENTATION: A rare case of myoclonus-ataxia syndrome associated with COVID-19 was presented. A 52-year-old Asian woman exhibited generalized myoclonus, ataxia, nystagmus, and dysarthria two weeks after a fever episode, which deteriorated rapidly within a few days. Electromyography (EMG) revealed synchronized bursts in both hands concurrent with myoclonic jerks. The absence of somatosensory evoked potential and lack of correlation between electromyography (EEG) and EMG suggested a subcortical origin of the myoclonus. A post-infectious immune-mediated process was considered the most likely mechanism, given the latency from fever to myoclonus onset, and the absence of other possible etiologies. Treatment with intravenous methylprednisolone led to notable improvement and a good outcome at the two-month follow-up.<br><br>CONCLUSION: Myoclonus arising from subcortical structures can be associated with COVID-19. Early aggressive immunotherapy is important for a favorable outcome. Review of similar cases along with our report suggests COVID-19-associated myoclonus-ataxia as a distinct syndrome warranting prompt diagnosis and treatment.},
}
@article {pmid42011141,
year = {2026},
author = {Lloyd-Jones, G and Santamarina, MG and Alcock, R and Oudkerk, M},
title = {Acute COVID-19 lung disease and long COVID vascular pathophysiology modelling: the relevance of medical imaging in building multidisciplinary understanding.},
journal = {The British journal of radiology},
volume = {99},
number = {1182},
pages = {1009-1023},
doi = {10.1093/bjr/tqag056},
pmid = {42011141},
issn = {1748-880X},
mesh = {*COVID-19/diagnostic imaging/epidemiology/physiopathology ; *Post-Acute COVID-19 Syndrome/diagnostic imaging/epidemiology/physiopathology ; *Diagnostic Imaging/methods ; *Lung/blood supply/diagnostic imaging ; SARS-CoV-2 ; Acute Disease ; Models, Theoretical ; Interdisciplinary Research/methods ; Guidelines as Topic ; Humans ; },
abstract = {Radiologists have a central role in building understanding of many diseases. In multidisciplinary settings, medical imaging has a role in diagnosing, assessing severity, monitoring progress and delineating anatomical structures involved in diseases. Imaging also helps to elucidate models of disease pathogenesis. In this review, imaging features of COVID-19 lung disease are analysed in the context of pathophysiological processes in different phases of the disease. Radiological evidence is presented for the central role of vasculopathic phenomena in both the acute and post-acute phases of COVID-19. From the outset of the COVID-19 pandemic, a lack of formal collaborative interdisciplinary systems to build models of pathophysiology led to widespread misunderstanding of the lung disease. Specifically, the lack of a systematic multidisciplinary approach to share concepts relating to radiological evidence with collaborators from other medical and scientific fields led to the use of terminology which was, and remains, potentially inappropriate or misleading. In conclusion, imaging is essential to multidisciplinary understanding of COVID-19 vascular pathophysiology. Current evidence should lead to adapted diagnostic guidelines for long COVID. Formation of collaborative systems to build interdisciplinary understanding of disease pathogenesis across all medical and scientific specialties should be a priority at the outset of any future pandemic.},
}
@article {pmid42011734,
year = {2026},
author = {Santos, MLK and Schmidt, CR and Dalcól, CX and Malkiewiez, MM and Alvarez, AG and Fabrizzio, GC and de Melo Lanzoni, GM and Lorenzini, E},
title = {Care Transition Strategies, Opportunities, and Challenges for Patients Following COVID-19 Hospitalization: An Integrative Review.},
journal = {Clinical nursing research},
volume = {35},
number = {5},
pages = {235-247},
doi = {10.1177/10547738261429358},
pmid = {42011734},
issn = {1552-3799},
mesh = {Humans ; *Continuity of Patient Care/organization &amp; administration ; *COVID-19/therapy ; *Hospitalization ; Pandemics ; Patient Discharge ; SARS-CoV-2 ; Telemedicine ; *Transitional Care/organization &amp; administration ; },
abstract = {Care transition is a strategy that aims to overcome the fragmentation of healthcare services, ensuring continuity of care. The review question was: What scientific evidence is available on care transition strategies for patients after hospitalization for COVID-19 and what are the opportunities and challenges of their implementation? Integrative literature review was guided by Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines and carried out between March and June 2024 in the Medical Literature Analysis and Retrieval System Online, Web of Science, Excerpta Medica Database, Cumulative Index to Nursing and Allied Health Literature, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Cochrane Library, Scientific Electronic Library Online and Scopus databases, using Medical Subject Headings, Health Sciences Descriptors, and Entry Terms. Fourteen articles published between 2020 and 2023 were included, with 57% originating from the Americas, 28.6% using a qualitative approach, 78.6% addressing the transition from hospital to home, and 78.6% involving patients. The results were organized into four thematic categories: virtual care transition; patients' and healthcare professionals' experiences in care environments; patients' needs after hospital discharge; and care transition assessment through Care Transition Measure (CTM-15). Care transition strategies, including teleconsultations, videoconferencing, telerehabilitation, and discharge guidance, can reduce complications and readmissions and improve patient satisfaction, but challenges such as early discharge, poor communication, lack of protocols, variability in care transition strategies, and discontinuity of care still persist. The results of this review highlight the importance of structured, patient-centered transition planning, integration of telehealth and remote monitoring, and the use of systematic assessment tools, such as the CTM-15, to optimize post-hospital care for COVID-19 survivors.},
}
@article {pmid42012187,
year = {2026},
author = {Salisch, F and Müller-Ruttloff, C},
title = {Behind the membranous curtain-lipid dynamics and functions in coronaviral replication.},
journal = {Journal of virology},
volume = {100},
number = {5},
pages = {e0175325},
pmid = {42012187},
issn = {1098-5514},
support = {06/2023//University Medical Center Giessen-Marburg/ ; project 71_0016//Von-Behring-R&#xf6;ntgen-Stiftung/ ; project 530813989//Deutsche Forschungsgemeinschaft/ ; //Hessisches Ministerium f&#xfc;r Wissenschaft und Kunst/ ; //Research Campus of Central Hesse/ ; },
mesh = {*Virus Replication/physiology ; Humans ; *SARS-CoV-2/physiology ; *Lipid Metabolism ; COVID-19/virology/metabolism ; Animals ; Host-Pathogen Interactions ; *Lipids/chemistry ; Cell Membrane/metabolism ; },
abstract = {Lipids are naturally occurring hydrophobic biomolecules characterized by remarkable structural diversity. This includes various types of head groups, varying fatty acid chain lengths, degrees of unsaturation, and stereochemical configurations. Such variability enables lipids to serve multiple biological functions, such as forming membranes, storing energy, and facilitating signaling. Given their diverse roles, it is not surprising that approximately 5% of genes in eukaryotic cells are involved in lipid biosynthesis pathways. The multifunctional nature of lipids also makes them attractive targets for pathogens, including viruses, as cellular lipids are involved in and manipulated throughout every stage of viral replication. In the initial phase of replication, viruses exploit existing cellular lipids for entry and trafficking. After the replication is established and viral proteins are processed, extensive reprogramming of lipid synthesis and redistribution supports viral replication, assembly, and other processes. This review focuses on how coronaviruses, especially severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), utilize different lipid species and related cellular enzymes to interfere with lipid dynamics and functions and how this affects the different stages of coronaviral replication in vitro. Besides illuminating virus-host lipid interactions, this review identifies remaining open questions and promising new avenues for future mechanistic research.},
}
@article {pmid42012503,
year = {2026},
author = {Gödecke, V},
title = {[Immune complex- and complement-mediated glomerulonephritides].},
journal = {Innere Medizin (Heidelberg, Germany)},
volume = {67},
number = {5},
pages = {506-514},
pmid = {42012503},
issn = {2731-7099},
mesh = {Humans ; *Glomerulonephritis/immunology/pathology/diagnosis/therapy ; *Antigen-Antibody Complex/immunology ; Lupus Nephritis/immunology/pathology/diagnosis/therapy ; Kidney Glomerulus/pathology/immunology ; Complement C3/immunology ; *Immune Complex Diseases/immunology/pathology/diagnosis/therapy ; Glomerulonephritis, Membranoproliferative/immunology/pathology ; Complement Pathway, Alternative/immunology ; *Complement System Proteins/immunology ; Biopsy ; Cryoglobulinemia/immunology/pathology ; },
abstract = {Glomerulonephritis represents a heterogeneous group of kidney diseases characterized by inflammation of the glomeruli and capable of leading to acute or chronic kidney failure. In addition to the primary glomerulonephritides described elsewhere in this issue, there is a group of diseases in which immune complex deposition or disturbances in complement regulation play a central pathogenic role. Among the most important and clinically relevant forms of these immune complex- and complement-mediated glomerulonephritides are postinfectious glomerulonephritis (PIGN), lupus nephritis (LN), cryoglobulinemic glomerulonephritis, and C3 glomerulopathy (C3G). While PIGN, LN, and cryoglobulinemic glomerulonephritis are characterized by glomerular immune complex deposits, C3 glomerulopathy is primarily based on a dysregulation of the alternative complement pathway. These diseases require specialized treatment in university outpatient clinics in collaboration with nephrology practices. Renal biopsy is a key diagnostic tool, and histologically, a membranoproliferative pattern is frequently observed. This article provides a systematic overview of immune complex- and complement-mediated glomerulonephritis and compares their pathogenesis, clinical presentation, immunoserological profiles, histology, and available therapies.},
}
@article {pmid42013593,
year = {2026},
author = {Sarnaik, AY and Khan, ZU and Rajeswaran, T and Majoe, A and Zeng, J and Ponrajah, L and Kastura, Z and Iftikhar, L and Islam, MA and Basharat, N and Hassan, M and Kaur, J and Torres, DL and Bhattacharyya, DS and AlShurman, BA and Namiha, N and Butt, ZA},
title = {The role of misinformation in COVID-19 vaccine hesitancy in low- &amp; middle-income countries.},
journal = {Vaccine},
volume = {82},
number = {},
pages = {128595},
doi = {10.1016/j.vaccine.2026.128595},
pmid = {42013593},
issn = {1873-2518},
mesh = {*Vaccination Hesitancy/psychology ; Humans ; *COVID-19/prevention &amp; control ; Developing Countries ; *COVID-19 Vaccines/administration &amp; dosage ; *Communication ; Social Media ; Pandemics/prevention &amp; control ; SARS-CoV-2 ; Vaccination/psychology ; },
abstract = {BACKGROUND: During the COVID-19 pandemic, timely vaccination was crucial in acquiring herd immunity. While high-income countries typically had better access to vaccines, interventions were implemented to improve accessibility for low and middle-income countries (LMICs). Vaccine uptake presented major barriers to achieving herd immunity globally and was more significant in LMICs. Vaccine hesitancy was amplified by misinformation, including but not limited to social media misinformation. This scoping review aims to: (1) explore the role of misinformation in COVID-19 vaccine hesitancy in LMICs and (2) identify primary sources, key themes, and dissemination channels of this misinformation, encompassing all relevant sources but with an emphasis on social media, given the infodemic context which proved to be particularly significant during the COVID-19 pandemic.<br><br>METHODS: This scoping review was conducted using the Arksey and O'Malley framework and PRISMA-ScR guidelines. Five databases (Scopus, Embase, PubMed, CINAHL, and PsycINFO) were searched using predefined search terms. All identified articles underwent a rigorous screening process, and if eligible, proceeded to data extraction.<br><br>RESULTS: In total, 119 studies were included in this review. Primary dissemination platforms included Facebook, WhatsApp, X, YouTube, Instagram, TikTok, Telegram, Pinterest, LinkedIn, and Zalo. Key themes of misinformation identified included (1) malicious intent, (2) fear of side effects, (3) concerns about vaccine development and safety, (4) religious and cultural beliefs, and (5) natural immunity.<br><br>CONCLUSION: Overall, this scoping review addresses the literature gap in the role of misinformation pertaining to COVID-19 vaccine hesitancy and suggests investing in misinformation-mitigation interventions to reduce public harms and disruptions.},
}
@article {pmid42013745,
year = {2026},
author = {Previti, S and Calcaterra, E and González, FV and Di Chio, C and Calabrò, ML and Ettari, R and Zappalà, M},
title = {Macrocycles and stapled-peptides in the fight against SARS-CoV-2: a review.},
journal = {European journal of medicinal chemistry},
volume = {312},
number = {},
pages = {118828},
doi = {10.1016/j.ejmech.2026.118828},
pmid = {42013745},
issn = {1768-3254},
mesh = {*Antiviral Agents/chemistry/pharmacology/therapeutic use ; Humans ; *SARS-CoV-2/drug effects ; *Macrocyclic Compounds/chemistry/pharmacology/therapeutic use ; *Peptides/chemistry/pharmacology/therapeutic use ; Structure-Activity Relationship ; *COVID-19 Drug Treatment ; COVID-19/virology ; Animals ; },
abstract = {The development of innovative therapeutic strategies for challenging biological targets has led to a resurgence of interest in macrocyclic and peptide-stapled compounds. The conformationally constrained architectures of these compounds enable high affinity, selectivity, and improved pharmacokinetic profiles compared with linear analogues. These properties position macrocycles and stapled-peptides as promising platforms for the development of next-generation therapeutics, including antiviral agents addressing emerging diseases such as COVID-19. In six years, the scientific community has provided several structure-activity relationship studies in which the anti-SARS-CoV-2 effects of macrocycles and stapled-peptides have been reported. The present review aims to discuss macrocycles and stapled-peptides with inhibitory properties against SARS-CoV-2 infection. A particular focus has been addressed to the design of cyclic entities, effect of ring size, presence of unnatural amino acids, stapling position, stereochemistry, role of linkers, pan-antiviral effects, metabolic stability assessment, and selectivity profile, among others. Comparisons with linear counterparts were discussed, wherever applicable, to elucidate the differences in terms of biological properties towards the target, antiviral effects in cell-based assays, molecular architecture, and proteolytic resistance. Overall, the development of macrocycles and stapled-peptides against SARS-CoV-2 was found to be a productive strategy for the identification of novel and effective antiviral agents. Furthermore, future challenges and perspectives have been discussed.},
}
@article {pmid42015364,
year = {2026},
author = {Page, R and Carter, G},
title = {Unsteady Foundations: The Effects of Environmental Instability on Nurses and Implications for Nursing Management-An Integrative Review.},
journal = {Journal of nursing management},
volume = {2026},
number = {1},
pages = {e9920089},
pmid = {42015364},
issn = {1365-2834},
mesh = {Humans ; Working Conditions ; *Workplace/psychology/standards ; COVID-19/epidemiology ; *Nurses/psychology ; Personnel Turnover ; Leadership ; Organizational Culture ; },
abstract = {AIM: To determine the state of the science of how instability in the nursing practice environment affects nurses.<br><br>BACKGROUND: The COVID-19 pandemic, workforce shortages, and an aging population have highlighted the critical need to build and maintain stable nursing practice environments. Factors such as staffing inconsistencies, fluctuating workloads, and workplace violence create instability. While research has explored nursing practice environments broadly, limited research has been conducted on how instability affects nurses.<br><br>METHODS: An integrative review was conducted using CINAHL, PsycINFO, and PubMed, with search terms related to instability and fluctuations in the nursing practice environment. Articles from 2014 to 2026 were included if they addressed instability in the nursing practice environment and its impact on nurses in hospital settings. Fifteen studies were included in this integrative review.<br><br>FINDINGS: Instability in the nursing practice environment has many sources. Organizational support plays a significant role in determining the magnitude and management of environmental instability. Adverse nurse outcomes from instability in the nursing practice environment include decreased well-being, increased turnover, and workplace violence.<br><br>Effective leadership and management are necessary to create and maintain positive nursing practice environments, manage environmental instability, and improve nurse well-being and retention. Targeted strategies such as collaborating with policymakers, strengthening the nursing workforce pipeline, and supporting nurses in their practice environments can mitigate environmental instability and its adverse effects on nurses.<br><br>CONCLUSIONS: Instability is a common feature of nursing practice environments. Excessive instability can cause adverse nurse outcomes. Nurse leaders are optimally situated to mitigate environmental instability and provide leadership support to improve nurse outcomes.},
}
@article {pmid42015917,
year = {2026},
author = {Okechukwu Paul-Chima, U and Michael Ben, O and Fabian C, O and Jovita Nnenna, U and Chinyere N, U},
title = {Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: Progress, evidence gaps, and translational pathways for durable and scalable immunization.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2661120},
pmid = {42015917},
issn = {2164-554X},
mesh = {Humans ; *RNA, Circular/immunology/genetics ; Animals ; *COVID-19 Vaccines/immunology/administration &amp; dosage/genetics ; *COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology/genetics ; *RNA/immunology ; },
abstract = {Self-amplifying RNA (saRNA) and circular RNA (circRNA) are emerging vaccine modalities that extend conventional, non-replicating mRNA platforms. Self-amplifying RNA encodes a replicase that amplifies intracellular RNA templates, enabling high antigen expression at substantially lower doses than non-replicating mRNA. Circular RNA has a covalently closed topology that confers resistance to exonucleases and supports sustained translation through cap-independent initiation. The evidence base remains asymmetric: saRNA has progressed through multiple human studies, including phase 3 evaluations of COVID-19 vaccines, and has received regulatory authorization in several jurisdictions, whereas circRNA vaccines remain largely preclinical, with limited publicly available human data. This review integrates clinical, animal, and mechanistic evidence, proposes a '3D' framework (durability, dose-sparing, and deployability) and identifies key barriers to robust cross-platform comparison, encompassing delivery systems, innate immune sensing, and chemistry, manufacturing and controls (CMC).},
}
@article {pmid42017651,
year = {2026},
author = {Bing, J and Li, S and Ji, L and Du, H and Shamoon, NM and Nobile, CJ and Huang, G},
title = {Global emergence and rapid spread of Candidozyma auris (syn. Candida auris): epidemiology, biology, and antifungal resistance.},
journal = {Clinical microbiology reviews},
volume = {39},
number = {2},
pages = {e0039425},
pmid = {42017651},
issn = {1098-6618},
support = {2025YFE0205500//National Key Research and Development Program of China/ ; 32530005 and 82272359//National Natural Science Foundation of China/ ; 32570226//National Natural Science Foundation of China/ ; 82172290//National Natural Science Foundation of China/ ; 23JC1404200//Science and Technology Innovation Plan Of Shanghai Science and Technology Commission/ ; R35GM156045/GM/NIGMS NIH HHS/United States ; //The Kamangar family/ ; },
mesh = {Humans ; *Antifungal Agents/pharmacology ; *Drug Resistance, Fungal ; *Candida auris/drug effects/pathogenicity/genetics ; Global Health ; *Communicable Diseases, Emerging/epidemiology/microbiology ; COVID-19/epidemiology ; *Candidiasis/epidemiology/microbiology/transmission ; Drug Resistance, Multiple, Fungal ; },
abstract = {SUMMARYThe emerging fungal pathogen Candidozyma auris (syn. Candida auris; C. auris) has attracted considerable attention from the scientific, clinical, and public health communities due to its multidrug resistance, environmental persistence, and high transmissibility. Since its first description in Japan in 2009, C. auris has spread rapidly worldwide, with a marked acceleration following the coronavirus disease 2019 (COVID-19) pandemic. As of December 2025, 84,941 colonization or infection cases have been reported across 82 countries spanning 6 continents. In this review, we summarize the current knowledge of the biology and global epidemiology of C. auris. We first examine its taxonomy, proposed origins, and key biological, genetic, and phenotypic characteristics, with particular emphasis on factors underlying environmental persistence, transmission dynamics, antifungal resistance, and virulence. Drawing on published literature and publicly available surveillance data from national public health authorities worldwide, we provide an updated overview of the global epidemiological landscape and evolving transmission patterns of C. auris. Finally, we discuss potential strategies to mitigate the continued and escalating global spread of this emerging multidrug-resistant fungal pathogen.},
}
@article {pmid42018659,
year = {2026},
author = {Wu, CJ and Caligaris-Cappio, F and Chiorazzi, N and Gribben, JG and Hallek, M and Wierda, WG and Kipps, TJ},
title = {Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.},
journal = {Blood},
volume = {148},
number = {2},
pages = {175-186},
pmid = {42018659},
issn = {1528-0020},
mesh = {Humans ; *Leukemia, Lymphocytic, Chronic, B-Cell/therapy/immunology/genetics ; Translational Research, Biomedical ; COVID-19/epidemiology ; SARS-CoV-2 ; },
abstract = {Remarkable progress in the understanding of disease pathogenesis and treatment across hematologic malignancies has been achieved in the past 2 decades. Nevertheless, the reliable elimination of disease remains elusive for many cancers. Chronic lymphocytic leukemia (CLL) exemplifies the needs that must be addressed to close the gap between discovery science and the remaining clinical challenges. In CLL, targeted therapies have substantially prolonged survival and enabled long-term disease control for many patients. However, curative outcomes remain exceptional, particularly in high-risk groups such as those with TP53 disruption, dual resistance to Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, or transformation to aggressive lymphoma. Recent insights into the interconnection between cancer and immunity have positioned CLL as a model example of cancer-associated immunodeficiency, a realization brought into sharp focus by the severe acute respiratory syndrome coronavirus 2 pandemic during which patients with CLL were at extremely high-risk for infection and poor outcomes. Therefore, complications related to infections, autoimmunity, and secondary cancers continue to contribute substantially to morbidity and mortality, underscoring the need for research on immune dysfunction in CLL. Furthermore, pronounced heterogeneity in disease progression and therapeutic resistance highlight the need for mechanistic studies to clarify these distinct biological patterns. Advances in these areas not only hold the promise of curative therapy for broader patient subgroups in CLL but will also inform innovation in research on other cancers, particularly in establishing a molecular definition of disease and defining those interactions with the underlying and resultant immune deficiencies.},
}
@article {pmid42018766,
year = {2026},
author = {Straus, W},
title = {From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2653369},
pmid = {42018766},
issn = {2164-554X},
mesh = {Humans ; 2019-nCoV Vaccine mRNA-1273/adverse effects ; *COVID-19/prevention &amp; control ; Emergency Use Authorization ; *COVID-19 Vaccines/adverse effects ; SARS-CoV-2/immunology ; Adverse Drug Reaction Reporting Systems ; Vaccine Development ; },
abstract = {The COVID-19 pandemic created an urgent need to develop preventive vaccines to blunt the impact of the greatest global health crisis in a century. Two vaccines, both employing mRNA technology, were developed from bench to bedside in under one year - a milestone considered nearly impossible. This paper examines the evolving safety profile of mRNA-1273, from development under Operation Warp Speed through Emergency Use Authorization, and subsequent deployment at nearly unprecedented scale. Vaccine safety was characterized during clinical development and refined through well-established safety monitoring systems (e.g. Vaccine Adverse Event Reporting System [VAERS]), as well as newly introduced systems such as V-Safe. Key safety findings, such as myocarditis, are reviewed as well as safety findings in special populations. The complementary contributions of public, private, and academic sectors highlight how collaboration and rigorous monitoring supported timely and comprehensive safety assessment of a new vaccine in the extraordinary setting of a global pandemic.},
}
@article {pmid42018905,
year = {2026},
author = {Silva, JAD and Barbosa, MEJDP and Sena, MM and Sousa, VMF and Vieira, NFC},
title = {[Implications of the COVID-19 pandemic on the health behaviors of adolescent and young parents: integrative review].},
journal = {Ciencia &amp; saude coletiva},
volume = {31},
number = {3},
pages = {e12012024},
doi = {10.1590/1413-81232026313.12012024},
pmid = {42018905},
issn = {1678-4561},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; Adolescent ; *Health Behavior ; *Parents/psychology ; Mental Health ; Socioeconomic Factors ; Health Services Accessibility ; Risk-Taking ; },
abstract = {The study aims to identify the implications of the COVID-19 pandemic on the health behaviors of adolescent and young parents, highlighting parenthood and their impacts on the health and well-being. This is an integrative literature review, carried out by searching for scientific publications indexed in the following databases: Virtual Health Library (BVS), Medical Literature Analysis and Retrieval System Online (MedLine/PubMed), Scopus and Web of Science (WOS). As a result, after reading 137 titles and abstracts and 69 full articles, 7 articles were selected for the final sample. The results of the included articles were grouped into two analytical categories: cross-cutting themes, which contemplate the implications resulting from COVID-19, such as impacts on mental and emotional health, socioeconomic aspects and access to health and education services. The second category was composed of specific themes addressed individually in each study, such as immunization, maternal and child health and food insecurity. From the analysis, a significant increase in risk behaviors and vulnerabilities suffered by young parents and adolescents was identified, with future implications for health and well-being, in addition to economic, emotional and social challenges.},
}
@article {pmid42018907,
year = {2026},
author = {Mangas, GM and Rodriguez, JGV and Santos, JARBD and Souza, FNB and Silva, LFLD and Azevedo Junior, GL and Chivaca, A and Jessen, NPJ and Oliveira, &#xc2; and Mesquita, ET},
title = {Fundamentals of Acute Pericarditis: State of the Art.},
journal = {Arquivos brasileiros de cardiologia},
volume = {123},
number = {2},
pages = {e20240572},
pmid = {42018907},
issn = {1678-4170},
mesh = {Humans ; *Pericarditis/etiology/diagnosis/therapy/physiopathology ; Acute Disease ; COVID-19/complications ; },
abstract = {Acute pericarditis is an inflammation of the pericardium, the lining that surrounds the heart. It is the most common inflammatory heart condition. The disease frequently affects young adults and can manifest with varying severity. Pericarditis can have diverse causes, including viral infections, autoimmune diseases, post-infarction conditions, and, more recently, SARS-CoV-2 infections or COVID-19 vaccines. In developing countries, especially in Africa, tuberculosis is the leading cause of pericarditis, often associated with HIV. Diagnosis is based on clinical criteria, such as chest pain and electrocardiographic changes, and it can be supported by imaging studies such as echocardiography, cardiac magnetic resonance imaging, and computed tomography. Identification of etiology is crucial to personalized treatment, although the specific cause is often unidentified. New research has highlighted the role of the NLRP3 inflammasome in the pathophysiology of pericarditis, which may pave the way for new therapies. Furthermore, technological advancements and artificial intelligence are discussed as promising tools to improve the management of pericarditis.},
}
@article {pmid42019647,
year = {2026},
author = {Nieuwland, JM and Scaramuzza, A and Bugiani, M and van de Berg, WDJ and Middeldorp, J},
title = {Human brain matters: Navigating the neuropathology of COVID-19.},
journal = {Brain pathology (Zurich, Switzerland)},
volume = {},
number = {},
pages = {e70101},
doi = {10.1111/bpa.70101},
pmid = {42019647},
issn = {1750-3639},
support = {//European research project NEUROCOV, funded by Horizon Europe (EU)/ ; },
abstract = {Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of deaths worldwide. Although the incidence of severe acute cases has declined, the prevalence of long COVID, also known as post-acute sequelae of COVID-19 (PASC), is rising. The pathological mechanisms underlying severe COVID-19, along with the relationship to neurological disorders and potential risk for neurodegeneration, remain poorly understood. The aim of this narrative review is to summarize neuropathological features described in postmortem human COVID-19 brains (n = 352). Furthermore, analysis of biofluids and neuroimaging from PASC patients underline long-term changes in the proteome and CNS response following the infection. Postmortem brain studies from severe COVID-19 patients highlight disruption of the fluid-brain barriers and vascular dysregulation defined by endothelial inflammation and disruption, hemorrhages, and hypoxic-ischemic damage. Neuroinflammation, including astrogliosis, microglia nodules and infiltration of adaptive immune cells, has been reported in the olfactory bulb, medulla oblongata, midbrain and cerebellum. Neuronal damage was demonstrated in the hippocampus, midbrain and cerebellum in severe COVID-19 and protein aggregation was observed in the midbrain and entorhinal cortex. Neuropathological burden and elevated blood and/or cerebrospinal fluid (CSF) levels of proinflammatory cytokines (e.g. IL-6) and neuro-axonal proteins (e.g. NfL) correlated with severity of anosmia, memory deficits, and cerebellar ataxia. Elderly patients and/or patients with underlying neurological diseases were more susceptible and had worsened symptoms. Potential disease mechanisms underlying neurological symptoms observed in severe COVID-19 are vascular and fluid-brain barrier abnormalities, chronic neuroinflammation, persistent axonal damage and protein aggregation. In PASC patients, an altered biofluid proteome with increased neuronal proteins and pro-inflammatory cytokines was observed. The pathological burden in affected brain regions may contribute to manifestations such as anosmia, memory deficits, and cerebellar ataxia.},
}
@article {pmid42021240,
year = {2026},
author = {Moufawad, M and DeLapp, S and Rhodes, ST and Rose, KL and Domoff, SE and Kells, M and Hunger, JM and Wallace, L and Brewer, S and Coleman, A and Rakowski, A and Aguilar, N and Hahn, SL},
title = {A systematic review of social media use among rural US adolescents and associated health outcomes.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42021240},
issn = {1471-2458},
mesh = {Humans ; *Social Media/statistics &amp; numerical data ; Adolescent ; *Rural Population/statistics &amp; numerical data ; United States/epidemiology ; COVID-19/epidemiology ; *Adolescent Behavior/psychology ; Media Exposure ; Digital Media ; },
abstract = {BACKGROUND: Understanding social media use among rural adolescents is important because they are a geographically and socially isolated population which may impact how they use social media and affect the impacts of use. The goal of this study was to systematically review and evaluate the literature on rural US adolescent social media use. Specifically, what is known about their social media use, amount and type of use, and the associations between social media use and health outcomes. METHODS: A systematic search was conducted on seven databases: PubMed, CINAHL, SCOPUS, PsycINFO (ProQuest), Web of Science, Embase, and Google Scholar. Studies were eligible for inclusion if they sampled rural US populations, sampled adolescents (ages 10–19), and had at least one of the following as an outcome: how much adolescents use social media, how adolescents are using social media including content, and/or whether social media use was associated with a health outcome. RESULTS: A total of 34 articles matched the inclusion criteria and were included in analysis (N = 22,315). Results suggest that rural US adolescents use social media to the same extent as non-rural adolescents. Rural adolescents with marginalized identities rely on social media to form connections with those with shared identities outside of their geographic area. Social media also fostered an environment for harmful connections, as numerous studies reported cyberbullying. In respect to mental health, using social media was found to be an avenue for coping with anxiety during the COVID-19 pandemic; however, increased time spent on social media did not reduce existing feelings of nervousness, anxiety, depression, or stress in the pandemic. Interventional studies indicated that social media was successfully used as a tool to disseminate health information and provide support to marginalized groups amongst the already hard-to-reach population of rural adolescents. CONCLUSIONS: This systematic review highlights the lack of research dedicated to social media use amongst rural US adolescents, despite high prevalence of use. More research on the specific popularity of platforms and content consumed is needed to understand the nuanced effects of social media and to further investigate social media usage as a potential intervention target for this geographically and socially isolated population.},
}
@article {pmid42021332,
year = {2026},
author = {Halder, P and Debnath, A and Achary, T and Mondal, A and Dhandapani, G and Mandal, I and Saha, S and Nongkynrih, B and Thakur, JS},
title = {Systematic review and meta-analysis on depression burden among Type 2 diabetes patients in India.},
journal = {Diabetology &amp; metabolic syndrome},
volume = {18},
number = {1},
pages = {},
pmid = {42021332},
issn = {1758-5996},
abstract = {BACKGROUND: Depression and Type 2 Diabetes Mellitus (T2DM) are closely linked health challenges in India, which currently has more than 101 million people living with diabetes. This systematic review and meta-analysis aimed to determine the pooled prevalence of depression among Indian T2DM patients, highlight regional differences, and identify associated risk factors. METHODS: Following PRISMA guidelines, a thorough search was conducted across PubMed, Embase, Scopus, and Web of Science for studies published until February 3, 2025. Random-effects models were applied to calculate pooled prevalence, while subgroup analyses assessed variations by geographic region, diagnostic tool, and study setting. Heterogeneity was quantified using I[2] statistics. Publication bias was evaluated using funnel plots and Egger’s regression, with trim-and-fill analysis performed when bias was detected. Meta-regression examined the impact of covariates such as sample size, mean age, diabetes duration, hypertension, and urban residence. RESULTS: A total of 59 studies with 24,073 participants were included. The pooled prevalence of depression among T2DM patients was 38% (95% CI: 33–42%), derived using a random-effects model to account for the substantial heterogeneity observed across studies (I[2] = 98.28%). This estimate reflects a statistical synthesis across studies with widely varying diagnostic tools, cutoff thresholds, and clinical settings, and should be interpreted as an approximation of the burden rather than a precise national prevalence figure. Mild, moderate, and severe depression accounted for 24%, 14%, and 14% of cases respectively. Regional variation was observed, with Western India showing the highest prevalence (48%) and multicenter studies the lowest (27%). Prevalence differed by diagnostic tool: CIDI-SF (20%), PHQ-9 (34%), and BDI (72% with lenient cutoffs). Hospital-based studies reported higher prevalence (42%) compared to community-based ones (28%). Females had a greater burden (39%) than males (31%). No significant differences were found between pre- and post-COVID-19 studies. Sensitivity analyses confirmed robustness of estimates. Meta-regression identified diabetes duration as a significant predictor (p = 0.026). CONCLUSION: Nearly two in five Indian T2DM patients experience depression, emphasizing the urgent need for standardized screening and integration of mental health care into India’s National Program for Non-Communicable Diseases.},
}
@article {pmid42021395,
year = {2026},
author = {Chen, Y and Zheng, J and Wang, H and Wu, Z},
title = {Advance in the Kawasaki disease related coronary artery aneurysms: knowledge mapping, trends, and research frontiers.},
journal = {Journal of cardiothoracic surgery},
volume = {21},
number = {1},
pages = {},
pmid = {42021395},
issn = {1749-8090},
mesh = {*Mucocutaneous Lymph Node Syndrome/complications ; Humans ; *Coronary Aneurysm/etiology ; Bibliometrics ; *Biomedical Research/trends ; },
abstract = {BACKGROUND: Kawasaki disease (KD) is the leading cause of acquired heart disease in children. In untreated cases, coronary artery aneurysms (CAAs) may develop in up to 25% of patients. As the most significant long-term sequelae of KD, Kawasaki disease-related coronary artery aneurysms (KD-CAAs) contribute substantially to long-term cardiac morbidity and mortality. To date, few bibliometric study has specifically focused on this area.<br><br>METHODS: We conducted a search in the Web of Science Core Collection (WOSCC) for papers related to KD-CAAs published between 2005 and 2024, and performed visual analysis using CiteSpace, VOSviewer, and the "biblioshiny" web interface from the "bibliometrix" package in R. A total of 1018 publications were retrieved, which collectively received 25,068 citations, averaging 24.62 citations per paper.<br><br>RESULTS: A steady increase was shown in the cumulative number of publications. The highest productivity was observed in the United States of America (USA), followed by Japan, China, and Canada. The University of California system was identified as the most productive institution, and Pediatric Cardiology was recognized as the journal with the most publications. Burns Jane C, Tremoulet Adriana H, and McCrindle Brian W were found to be the most prolific authors, while Newburger Jane W was identified as the most co-cited author. It was revealed by keyword cluster analysis that KD-CAAs research was organized into ten distinct clusters, and three major research hotspots were highlighted: molecular pathogenesis and therapeutic resistance pathways, long-term vascular sequelae and management, and the impact of coronavirus disease 2019 (COVID-19). A shift in research focus from fundamental disease mechanisms toward long-term patient follow-up and multidisciplinary clinical collaboration was indicated by keyword burst detection, and this shift was reflected in terms such as "long-term management" and "health professionals".<br><br>CONCLUSIONS: Research on KD-CAAs requires further breakthroughs in molecular mechanisms and enhanced interdisciplinary integration. The resulting visualizations offer an efficient framework for identifying emerging trends and critical advances in KD-CAAs research.},
}
@article {pmid42022217,
year = {2026},
author = {Carissa Aurelia, L and Selva, KJ and Chung, AW},
title = {Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.},
journal = {PNAS nexus},
volume = {5},
number = {4},
pages = {pgag110},
pmid = {42022217},
issn = {2752-6542},
abstract = {Antibodies are critical for protection against a range of viral respiratory diseases, including SARS-CoV-2, but the induction of durable and potent antibody responses continues to be a challenge. Beyond neutralization, there is growing appreciation for the potential protective role of Fc-mediated functions, especially against immune-evasive variants. Induction of polyfunctional antibody responses is a complex multifactorial process that is shaped by interactions between various antibody features, viral properties, and host factors. Here, we review lessons learned from the COVID-19 pandemic regarding how prior infection and different vaccination strategies can modulate plasma and mucosal antibody profiles, including isotypes, immunoglobulin G subclasses, Fc glycosylation, and consequently, antibody functions. Additionally, we discuss the challenges of immune imprinting and its effects upon antibody responses to viral variants. This review provides insights into optimizing antibody-based strategies for COVID-19 prevention and treatment, emphasizing the need for further research to understand the mechanisms behind effective antibody responses and their impact upon clinical outcomes.},
}
@article {pmid42022434,
year = {2026},
author = {Julius, N and John, M and Emmanuel, N},
title = {Public Health Achievements in Rwanda: A 21st Century Transformation.},
journal = {Public health challenges},
volume = {5},
number = {2},
pages = {e70225},
pmid = {42022434},
issn = {2769-2450},
abstract = {This narrative review documents how Rwanda has transformed in public health extraordinarily post the 1994 Genocide against the Tutsi, placing it as an exemplary model for health care systems resilience in low-income countries. The review is based on the World Health Organization building blocks to look at the strategic changes that have led to measurable gains in the health of Rwandan people. Good centralized leadership and control have been key to this accomplishment. This made it possible to decentralize service delivery, build excellent health information systems, and invest money in the health workforce. A key part of the transformation is universal health coverage (UHC), especially mutuelle de santé, which increased coverage from 27% in 2004 to more than 85%, hence cutting down out of pocket costs, which improved equity. Integration and use of community health workers (CHWs) have been instrumental in expansion of primary care to the population mostly in rural settings, improving maternal and child life, tuberculosis (TB) treatment through direct observed therapy (DOT), and disease surveillance. These coordinated actions have resulted in substantial reductions in mortality from infectious diseases (HIV/AIDS, TB, and malaria), maternal and child health indicators, and the gradual integration of services for noncommunicable diseases and mental health. Rwanda's health system was stress tested and proved its effectiveness in the COVID-19 and Marburg outbreaks, proving exceptional planning and rapid response capacities. Despite Rwanda's achievement, obstacles still persist, such as reliance on foreign funds, limited human resources lowering the quality-of-service delivery, and mental health challenges still in existence. Rwanda's experience illustrates that a proactive government, citizen participation, and research-based innovation may produce rapid and significant overall health gains, providing a valuable model for similar situations to other countries.},
}
@article {pmid42024317,
year = {2026},
author = {Brunner, M and Preckel, F and Götz, T and Lüdtke, O and Keller, L},
title = {High math anxiety is associated with lower math achievement across 90 countries: An individual participant data meta-analysis of representative student and adult samples.},
journal = {Psychological bulletin},
volume = {152},
number = {2},
pages = {207-253},
doi = {10.1037/bul0000514},
pmid = {42024317},
issn = {1939-1455},
support = {//German Research Foundation/ ; },
mesh = {Humans ; *Mathematics ; *Anxiety/psychology/epidemiology ; Adult ; Female ; *Academic Success ; *Students/psychology/statistics &amp; numerical data ; Male ; *COVID-19 ; },
abstract = {Math anxiety and math achievement are reciprocally related, which likely impacts individuals' agency; their educational and career trajectories in science, technology, engineering, and mathematics fields; and countries' economic growth in these areas. Previous meta-analyses on this relationship have faced limitations from studies by using small convenience samples and have encountered methodological issues, such as variance restriction, low statistical power, and ecological bias. To address these challenges, the present research synthesis is the first to use a comprehensive collection of representative individual participant data from international large-scale assessments. This analysis incorporated cumulative evidence from 1980 to 2022, including 452 probability samples from 90 countries, and covered student and adult populations. The meta-analytic average correlation between math anxiety and math achievement was r = -.26. Moderator analyses revealed novel evidence that this relationship is sensitive to both construct characteristics and individual and contextual factors. Specifically, the negative relationship was weaker for the worry facet of math anxiety compared to its affective and cognitive interference facets, and it was weaker following the onset of the COVID-19 pandemic in 2020. Additionally, the negative relationship was stronger for individuals with average and high levels of math achievement and in countries with higher gross domestic product per capita. Gender differences in the relationship were largely negligible after 2010, although female individuals exhibited a stronger negative relationship in the 1980s and 1990s than male individuals. In summary, synthesizing individual participant data from international large-scale assessments provided novel, nuanced, and robust evidence for research, practice, and policy. (PsycInfo Database Record (c) 2026 APA, all rights reserved).},
}
@article {pmid42024896,
year = {2026},
author = {Raina, SK},
title = {Methodological considerations regarding comparison group verification in maternal COVID-19 research.},
journal = {The Indian journal of medical research},
volume = {163},
number = {3},
pages = {420},
pmid = {42024896},
issn = {0971-5916},
}
@article {pmid42025371,
year = {2026},
author = {Imai, Y},
title = {Viral infection and establishing new therapeutic platforms- On the occasion of receiving the 16th Setsuro Ebashi award.},
journal = {Journal of pharmacological sciences},
volume = {161},
number = {2},
pages = {25-27},
doi = {10.1016/j.jphs.2026.03.002},
pmid = {42025371},
issn = {1347-8648},
mesh = {Humans ; *Awards and Prizes ; COVID-19 ; SARS-CoV-2 ; Pandemics ; Angiotensin-Converting Enzyme 2 ; Animals ; Immunity, Innate ; Influenza, Human/immunology ; },
abstract = {During the past quarter century, a series of global pandemics-caused by coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2) and influenza A (H1N1, H5N1)-has underscored that viral infection is not merely a transient invasion but a systemic and temporal perturbation of the host life system. My research has sought to elucidate the principles by which the host organism senses, integrates, and regulates responses to viral stress, spanning molecular to organismal levels. Key discoveries include the identification of ACE2 as the functional receptor for SARS-CoV and a critical regulator of disease severity; elucidation of innate-immune overactivation ("cytokine storm") as a driver of fatal pathology; identification of lipid-mediated RNA regulation that restrains excessive inflammation; and discovery of neuro-immune and epigenetic mechanisms linking acute infection to long-term dysfunction. These findings reveal infection as a multi-layered biological reprogramming process involving immunity, metabolism, the nervous system, and chromatin architecture. Building on this mechanistic foundation, we established data-driven infrastructures-AI-assisted predictive models and Medical MLOps systems-that integrate clinical and molecular data for personalized infection medicine. This perspective summarizes the evolution of this integrative research and discusses future directions toward precision therapeutics for acute and post-infectious syndromes.},
}
@article {pmid42025580,
year = {2026},
author = {Shukla, SK and Singh, A and Yadav, R and Kumar, A},
title = {Advances in molecular diagnostic strategies during the SARS-CoV-2 pandemic.},
journal = {Expert review of molecular diagnostics},
volume = {26},
number = {4},
pages = {293-308},
doi = {10.1080/14737159.2026.2665263},
pmid = {42025580},
issn = {1744-8352},
mesh = {Humans ; *COVID-19/diagnosis/epidemiology/virology ; *SARS-CoV-2/genetics/isolation &amp; purification ; *Molecular Diagnostic Techniques/methods ; Pandemics ; COVID-19 Testing/methods ; COVID-19 Nucleic Acid Testing/methods ; Rapid Diagnostic Tests ; Pandemic Preparedness ; CRISPR-Cas Systems ; },
abstract = {INTRODUCTION: The SARS-CoV-2 pandemic provided critical insights into pandemic preparedness. The community spread can be slowed down or contained through effective, rapid, and robust diagnosis of infected individuals.<br><br>AREA COVERED: During the pandemic, substantial advances were made in developing rapid and cost-effective diagnostic approaches. Self-collected gargle samples offer clear advantages over conventional NSP/OPS methods by reducing reliance on trained personnel and personal protective equipment. Colorimetric assays further improve accessibility, enabling rapid, instrument-free, and visually interpretable detection at low cost. CRISPR-based diagnostics present a promising alternative to RT-PCR, facilitating scalable mass screening with reduced technical dependence. Concurrently, optimization of RT-PCR workflows-particularly through minimization of pre-PCR steps-can enhance speed and affordability. The integration of digital technologies and artificial intelligence further leverages diagnostic capabilities. Despite this, improved regulatory frameworks and resilient supply chains are critical for ensuring scalable, equitable access, and effective pandemic preparedness.<br><br>EXPERT OPINION: Global efforts were made to develop sensitive, rapid, cost-effective, and noninvasive technologies to identify the pandemic virus; however, variations in sensitivity/specificity and limited sample size validation hampered their utility in routine diagnostics. The COVID-19 pandemic has ended, but global efforts are still needed to combat the early infection of subsequent waves or similar disease waves.},
}
@article {pmid42027925,
year = {2026},
author = {Mullen, L and Kobokovich Mui, A and Watson, C and Heymann, D and McCloskey, B and Hughes, G and Bonell, C},
title = {Effectiveness of public health measures and strategies to reduce risk of spread of respiratory pathogens at sporting mass gatherings: systematic literature review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1789413},
pmid = {42027925},
issn = {2296-2565},
mesh = {Humans ; *Sports ; *Respiratory Tract Infections/prevention &amp; control ; *Public Health ; *Mass Gatherings ; *COVID-19/prevention &amp; control ; },
abstract = {OBJECTIVES: To determine the type and effectiveness of public health interventions implemented at sporting mass gatherings to mitigate respiratory infectious disease spread and understand how feasible and acceptable the interventions were to implement.<br><br>DESIGN: Systematic review.<br><br>DATA SOURCES: Medline, EMBASE, Cochrane Library, Scopus, Web of Science, Global Health, Epistemonikos, Global Index Medicus, WHO Library, WHO IRIS, IOC and FIFA were search in June 2023 and July 2025.<br><br>Studies that assessed public health strategies for sporting mass gatherings aiming to reduced respiratory infections were included. Publications prior to 2000, predictive modeling studies, commentaries, editorials, literature reviews, pre-prints and studies that did not retrospectively discuss official sporting events were excluded.<br><br>RESULTS: Thirty-four articles assessing 37 sporting MGs were included. The most common MGs assessed were the Olympic Games (n = 10). Almost all articles described multi-layered intervention packages including bubble approaches, routine testing, country entry screening, masking, physical distancing and/or isolation and quarantine. Based on an effectiveness framework developed for this study, 23 articles described effective intervention packages, three described non-effective packages and six were indeterminate. Feasibility concerns appeared a challenge for MGs with many spectators and linked to scalability issues. Acceptability factors were likely influenced by perceptions of increased work burden, compliance levels and stakeholder engagement.<br><br>CONCLUSION: This systematic review provides the first opportunity to comprehensively map pre-pandemic and pandemic-era planning for sporting MGs and underscores the importance of multilayered, context-specific intervention packages which may meaningfully reduce the risk of respiratory disease spread.<br><br>CRD42023433619.},
}
@article {pmid42027972,
year = {2025},
author = {Amiri-Dashatan, N and Koushki, M and Parsamanesh, N and Ahmadi, N and Chiti, H and Rezaei, M and Razzaghi, Z and Robati, RM},
title = {COVID-19: A Systematic Review of Metabolomics Data and Predicting Potential Biomarkers Based on Pathway Analysis.},
journal = {Tanaffos},
volume = {24},
number = {1},
pages = {9-29},
pmid = {42027972},
issn = {1735-0344},
abstract = {The COVID-19 pandemic is a worldwide disaster in medicine, public health, and the economy. Many details of COVID-19 are currently unknown. This study aims to offer dysregulated metabolic profiles as potential biomarkers for SARS-CoV-2 infection by analyzing identified COVID-19 metabolites. We searched PubMed, Web of Science, EMBASE, and Scopus for metabolomics studies on COVID-19 patients. Studies investigating COVID-19 metabolite changes and utilizing mass spectrometry-based techniques are included. Two reviewers separately retrieved pertinent data for each selected publication. Differences of opinion among the reviewers were settled via conversation, and a final judgment was obtained. The online MetaboAnalyst 3.0 was used to conduct the pathway analysis of COVID-19. This study comprised 31 investigations with QUADOMICS quality evaluation. We isolated modified metabolites that have been found in at least three other investigations. The metabolomics data in response to SARS-CoV-2 alter at the metabolite expression level, leading to dysregulation of major metabolic pathways, including carbohydrates, amino acids, and lipids associated with COVID-19. The pathway analysis of metabolic reprogramming across different biological samples demonstrated a significant role in amino acid metabolism, including phenylalanine, tyrosine, and tryptophan production, in the severity of COVID-19. This review showed dysregulated metabolic profiling for identifying individuals with high severity of COVID-19. These results provide an understanding of metabolic pathways and how dysregulated metabolic profiling reflects the severity of COVID-19 in the general population. The high frequency of changed metabolites might be used as COVID-19 biomarkers for early detection, and significant metabolic routes could reveal new information about pathogenesis and lead to potential treatment targets.},
}
@article {pmid42028925,
year = {2026},
author = {Silva, LI and Gonzalez-Zambrano, CM and Ferreira, VCMP and Corrêa, FC and Dias-Melicio, LA},
title = {MicroRNAs in Acute COVID-19 and Long COVID: Dysregulation, Pathogenic Roles, and Clinical Implications.},
journal = {Journal of immunology research},
volume = {2026},
number = {1},
pages = {e5862241},
pmid = {42028925},
issn = {2314-7156},
support = {001//Coordena&#xe7;&#xe3;o de Aperfei&#xe7;oamento de Pessoal de N&#xed;vel Superior/ ; },
mesh = {Humans ; *COVID-19/genetics/immunology ; *MicroRNAs/genetics/immunology ; *SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Biomarkers ; Extracellular Vesicles ; Gene Expression Regulation ; Inflammation/genetics ; Pandemics ; *Betacoronavirus ; },
abstract = {MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression with central roles in immune responses, inflammation, and viral pathogenesis. Increasing evidence indicates that severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection induces marked dysregulation of host and viral miRNAs (v-miRNAs), contributing to disease severity during acute COVID-19 and to the persistent manifestations observed in long COVID (LC). This narrative review critically synthesizes current evidence on miRNA dysregulation across the acute and post-acute phases of COVID-19, highlighting their pathogenic roles, clinical relevance, and existing knowledge gaps. During acute infection, altered miRNA profiles-including those associated with immune activation, endothelial dysfunction, and immunothrombosis-reflect both host responses and viral strategies of immune modulation, including miRNAs carried by extracellular vesicles (EVs) and SARS-CoV-2-derived v-miRNAs. In LC, emerging data suggest that persistent miRNA alterations are associated with unresolved inflammation, pulmonary dysfunction, neurological symptoms, and vascular injury, although available studies remain limited and heterogeneous. Overall, miRNAs represent promising biomarkers and potential therapeutic targets in COVID-19; however, robust longitudinal and mechanistic studies are urgently needed to clarify their causal roles and translational utility in post-acute disease.},
}
@article {pmid42033452,
year = {2026},
author = {Mok, TC and Mok, CC},
title = {Vaccination in systemic lupus erythematosus.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2663637},
pmid = {42033452},
issn = {2164-554X},
mesh = {Humans ; *Lupus Erythematosus, Systemic/immunology/complications/drug therapy ; *Vaccination/methods ; COVID-19 Vaccines/immunology/administration &amp; dosage ; Pneumococcal Vaccines/immunology/administration &amp; dosage ; Influenza Vaccines/immunology/administration &amp; dosage ; Immunosuppressive Agents/therapeutic use ; },
abstract = {Despite advancement in anti-microbial therapies, infection remains the leading cause of mortality in systemic lupus erythematosus (SLE). Vaccination is a major strategy in reducing infection risk. Recent studies suggest most SLE patients are able to mount an adequate immune response to the SARS-CoV2 vaccines but lower immunogenicity is observed with influenza and pneumococcal vaccination. Current evidence does not indicate an increased risk of SLE flares after administration of common vaccines. Live vaccines are less preferred to inactivated or recombinant vaccines in SLE patients receiving immunosuppression. However, the decision to vaccinate should be individualized according to risk and benefit evaluation. Vaccination in patients with SLE should best be performed during periods of low disease activity or remission. In patients receiving intense immunosuppression or biologic/targeted therapies, particularly B-cell depletion, vaccine responses are expected to be attenuated. Adjunctive measures such as booster dose of vaccines, passive immunization and microbial prophylaxis may be considered.},
}
@article {pmid42033494,
year = {2026},
author = {Chakraborty, B and Singh, T},
title = {mRNA vaccines for viral diseases: mechanism, advances, and future perspective.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {42033494},
issn = {1573-4978},
mesh = {Humans ; COVID-19 Vaccines/immunology ; mRNA Vaccines/immunology ; *Virus Diseases/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; *COVID-19/prevention &amp; control/immunology ; *Viral Vaccines/immunology ; Animals ; Vaccine Development ; *RNA, Messenger/immunology/genetics ; Vaccines, Synthetic/immunology ; },
abstract = {The rapid development and global distribution of messenger ribonucleic acid (mRNA) vaccines against Coronavirus Disease 2019 (COVID-19) indicated an important shift in vaccine science and public health response. Unlike traditional vaccines that rely on live-attenuated or inactivated pathogens, mRNA vaccines use synthetic mRNA encoding the antigen, allowing host cells to produce the antigen and elicit strong immune responses. The success of mRNA vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has gradually increased global curiosity in applying this technology to treat other diseases. This review discusses the scientific basis of mRNA vaccines, including their mechanism of action, advantages in antigen design, expandable manufacturing, and modern delivery systems such as organic, inorganic, and hybrid. Beyond COVID-19, mRNA vaccines are being studied for other viral diseases, including influenza, Human Immunodeficiency Virus (HIV), Zika, and dengue. The intrinsic flexibility and speed of mRNA technology make it a valuable platform for next-generation pandemic preparedness and new therapeutic development. Despite these advantages, many challenges exist, including mRNA instability, cold-chain storage requirements, regulatory issues, and concerns regarding global vaccine availability and acceptance. Overcoming these will be critical for the full long-term potential of mRNA vaccines as a sustainable and transformative platform for global health. This review highlights recent advances, current challenges, and future perspectives of mRNA vaccine technology for viral diseases.},
}
@article {pmid42034588,
year = {2026},
author = {Shang, J and Cui, H and Shu, C and Zheng, L and Liu, F and Peng, Y and Wei, Z and Ni, X and Liu, J},
title = {Comprehensive overview of triclosan neurotoxicity and construction of adverse outcome pathways using a systems toxicology approach: Triclosan-induced attention-deficit hyperactivity disorder as an example.},
journal = {Ecotoxicology and environmental safety},
volume = {316},
number = {},
pages = {120169},
doi = {10.1016/j.ecoenv.2026.120169},
pmid = {42034588},
issn = {1090-2414},
mesh = {*Triclosan/toxicity ; *Attention Deficit Disorder with Hyperactivity/chemically induced ; Humans ; Animals ; *Adverse Outcome Pathways ; *Neurotoxicity Syndromes/etiology ; *Anti-Infective Agents, Local/toxicity ; Risk Assessment ; *Environmental Pollutants/toxicity ; },
abstract = {Triclosan (TCS) is widely applied to daily necessities as a chemical bacteriostatic agent. Environmental TCS levels have increased significantly following the coronavirus disease 2019 pandemic, posing a potential threat to humans and ecosystems. Epidemiological investigations and toxicological studies have shown that long-term TCS exposure can damage human tissues and organs and induce neurodevelopmental disorders in offspring. However, studies on the mechanisms underlying its neurotoxicity and toxicity risk assessments are limited. This review summarizes the status of environmental and human TCS exposure and systematically outlines its neurotoxic effects. To further elucidate the mechanisms underlying TCS neurotoxicity, using TCS-induced attention-deficit hyperactivity disorder (ADHD) as an example, we constructed an adverse outcome pathway (AOP) framework based on a systematic toxicology approach. We found that TCS increased the expression of cannabinoid receptor 1, which activates the "neuroactive ligand-receptor interaction" pathway, leading to ADHD-like behaviors, including cognitive, learning, and memory deficits, by modulating chemical synaptic transmission and neurotransmitter levels. The AOP framework was further used to assess the associated neurodevelopmental toxicity risks of TCS, contributing to a better understanding of its characteristics and safety. Thus, future research on the mechanisms underlying TCS toxicity and issues related to its detection and regulation should be emphasized.},
}
@article {pmid42034797,
year = {2026},
author = {Balak, N and Broekman, M and Samprón, N and Tsianaka, E and Sandvik, U and Bolger, C and Soleman, J and Visocchi, M and Agboola, KM and Syrmos, N and Vulekovic, P and Mathiesen, T and Ganau, M and , },
title = {Ethical aspects of waiting lists in neurosurgery.},
journal = {Acta neurochirurgica},
volume = {168},
number = {1},
pages = {},
pmid = {42034797},
issn = {0942-0940},
mesh = {Humans ; *Waiting Lists ; *Elective Surgical Procedures/ethics ; *Neurosurgical Procedures/ethics ; COVID-19 ; *Health Services Accessibility/ethics ; Ethical Dilemmas ; Pandemics ; SARS-CoV-2 ; },
abstract = {PURPOSE: Long waiting times for elective surgery have been a persistent problem in many countries since well before the COVID-19 pandemic. This study aims to describe the extent of waiting lists&amp;times for elective neurosurgery and discuss the potential ethical dilemmas they pose.<br><br>METHODS: A narrative review was conducted on waiting lists&#xa0;&amp;&#xa0;times in neurosurgery using PubMed and the Web of Science Core Collection.<br><br>RESULTS: The majority of the available data on elective surgery waiting times and lists are based on analyses of non-neurosurgical interventions. These are generally high-volume surgical procedures, such as cataract surgery, hip replacement, and knee replacement. Elective surgery waiting times challenge the clinical application of the bioethical principles of beneficence, nonmaleficence, autonomy, and justice. Extensive waiting may prolong time to benefit or even lead to harm. Moreover, failure to receive timely care runs counter to patients' autonomous wishes to be treated without delay. Finally, different principles of distributive justice are likely to contradict each other under the conditions of restrained access to care that exist when patients must wait for care. It is essential to ensure that patients on waiting lists receive fair access to health care services.<br><br>CONCLUSION: This analysis indicates that long waiting lists potentially violate three of the four basic biomedical principles proposed by Beauchamp and Childress. The fourth principle, justice, is also challenged and remains to be analyzed in reference to underlying ethical principles. From an ethical perspective, waiting lists create accountability at the governmental, institutional, and physician levels, although not to an equal degree.},
}
@article {pmid42035205,
year = {2026},
author = {Yuan, MQ and Pan, YF and Zhang, ZY and Wu, YX and Zhu, KD and Wang, ZR and Zhang, ZY and Xiong, JQ and Xu, Z and Huang, L and Wang, FS and Shi, L},
title = {Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.},
journal = {Stem cell research &amp; therapy},
volume = {17},
number = {1},
pages = {},
pmid = {42035205},
issn = {1757-6512},
support = {No. 2022YFA1105604//National Key Research and Development Program of China/ ; },
mesh = {Humans ; *COVID-19/therapy/mortality/epidemiology ; *Mesenchymal Stem Cell Transplantation/methods ; *Mesenchymal Stem Cells/cytology ; *SARS-CoV-2 ; Clinical Trials as Topic ; Pandemics ; Treatment Outcome ; },
abstract = {BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can induce immune dysregulation and multi-organ injury; mesenchymal stromal cell (MSC) therapy has shown promise in clinical trials for COVID-19 and may have broader applicability to pneumonia induced by respiratory viruses (e.g., the influenza virus). This meta-analysis synthesized the available comparative clinical evidence on the safety and efficacy of MSCs in patients with moderate to critical COVID-19 and examined the reported outcomes relevant to Long-COVID.<br><br>METHODS: We searched the PubMed, Embase, and CNKI databases for original, comparative studies in moderate, severe, or critical COVID-19 published up to September 2, 2024. Twenty-four eligible studies (13 RCTs and 11 non-randomized controlled trials; n&#x2009;=&#x2009;1080) were included in the mortality meta-analysis. Patients were assigned to either the intervention group (MSC therapy plus standard care) or the control group (standard care with or without placebo). The primary efficacy outcome was all-cause mortality, while the primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs). Secondary outcomes included clinical recovery, hospitalization metrics, chest imaging, and inflammatory biomarkers. We performed a pooled meta-analysis on mortality with subgroup analyses (by disease severity, administration route, dosing frequency, and study design), assessment of publication bias (using funnel plots and Egger's test), and evaluation of the quality of evidence via the GRADE approach. AEs/SAEs were analyzed using meta-analysis and descriptive statistics, while other secondary outcomes were summarized descriptively.<br><br>RESULTS: MSC therapy significantly reduced all-cause mortality (MSC: 26.4% vs control: 31.9%; fixed-effect OR&#x2009;=&#x2009;0.74, 95% CI 0.55-0.99), with low heterogeneity (I[2]&#x2009;=&#x2009;2.8%, P&#x2009;=0.422[Q-test]) and no publication bias. The quality of evidence was moderate (according to the GRADE assessment). The subgroup analysis revealed a significant survival benefit in severe/critical patients (OR&#x2009;=&#x2009;0.73, 95% CI 0.54-0.98) but not in studies that included moderate cases (OR&#x2009;=&#x2009;0.91, 95% CI 0.23-3.65). No significant heterogeneity was found across study designs, administration routes, or dosing frequencies, which confirmed the robustness of the primary findings while indicating insufficient evidence to determine the optimal regimen. The secondary outcomes suggested improvements in clinical recovery, pulmonary function, and pro-/anti-inflammatory cytokine balance in patients that received MSC therapy. Limited studies with long-term follow-up indicated potential benefits for Long-COVID outcomes (e.g., fatigue, quality of life, residual CT abnormalities, and exercise tolerance). No significant differences were observed in AEs or SAEs post-MSC infusion, which suggested that MSC therapy was well tolerated.<br><br>CONCLUSION: This meta-analysis indicated that MSC therapy may reduce mortality in patients with severe or critical COVID-19, demonstrating a favorable safety profile and potential benefits for Long-COVID and other viral pneumonias. Further large-scale, rigorous RCTs and mechanistic studies are warranted to strengthen the evidence base and standardize MSC administration regimens (source, dosing, frequency, and intervals) for managing COVID-19, Long-COVID, and other viral pneumonias.},
}
@article {pmid42035616,
year = {2026},
author = {Kimura, R and Hayashi, Y and Fujimoto-Sato, Y and Ishii, H and Suzuki, Y and Katayama, K and Mizukoshi, F and Ryo, A and Kimura, H},
title = {Decoding viral evolution through integrative bioinformatics: From genomes to global health.},
journal = {Virology},
volume = {620},
number = {},
pages = {110920},
doi = {10.1016/j.virol.2026.110920},
pmid = {42035616},
issn = {1096-0341},
mesh = {*Computational Biology/methods ; Humans ; *Evolution, Molecular ; *Genome, Viral ; Phylogeny ; Global Health ; *Viruses/genetics/classification ; SARS-CoV-2/genetics ; Animals ; },
abstract = {Bioinformatics has transformed modern virology by linking genomic variation to epidemiology, protein structure, and public health action. This review integrates core analytical frameworks-sequence alignment and genome annotation; maximum-likelihood and Bayesian phylogenetic/phylodynamic inference; codon-based selection and recombination analyses; and AI-assisted structural prediction combined with deep mutational scanning (DMS)-to convert viral sequences into mechanistic and predictive insight. We emphasize how global surveillance ecosystems (GISRS, GISAID, and Nextstrain) and sustained regional programs reveal genotype turnover, antigenic drift, and seasonality in RSV, HPIV, norovirus, and SARS-CoV-2, enabling near real-time lineage tracking and vaccine-strain deliberation. Mapping positively selected residues and recombination breakpoints onto three-dimensional protein structures clarifies immune escape in key surface glycoproteins (e.g., RSV F/G, HPIV HN/F, norovirus VP1) and strengthens genotype-phenotype interpretation. Comparative reinfection patterns-lifelong immunity in measles versus recurrent RSV/HPIV infections-illustrate how evolutionary rate and antigenic constraint shape population immunity and control strategies. Despite major advances, progress remains constrained by geographic sampling bias, incomplete metadata, uneven computational capacity, and uncertainties in molecular clocks, recombination inference, and machine-learning predictions. The field is now moving toward predictive virology, integrating AI-enabled structural modeling, mutational fitness landscapes, and clinical-immunological metadata within real-time analytical platforms to anticipate immune-escape trajectories. Prioritizing pediatric respiratory pathogens alongside influenza and coronaviruses, and reinforcing equitable data-sharing and governance, will be essential for globally inclusive, forward-looking viral surveillance and intervention.},
}
@article {pmid42038565,
year = {2026},
author = {Baldo, KAT and King, RAN and San Juan, FGF and Dungog, CC and Solidum, JGN and Ceriales, JA and Dela Cruz, MCP and Ho, FDV and Picart, N and Plantado, ANR and Perez, J and Garcia, JP and Lapeña, JFF and Paz-Pacheco, E and Tantengco, OAG},
title = {Epidemiology, Diagnosis, and Management of Thyroid Cancer in the Philippines.},
journal = {Indian journal of surgical oncology},
volume = {17},
number = {3},
pages = {484-498},
pmid = {42038565},
issn = {0975-7651},
abstract = {Thyroid cancer incidence is rising in the Philippines, warranting attention due to unique risk factors and growing economic implications. This review examines the epidemiological trends, diagnosis, treatment, impact of COVID-19, and economic burden associated with thyroid cancer in the Philippines. We conducted a literature search in Scopus and HERDIN to synthesize the existing data on the epidemiology, diagnosis, and management of thyroid cancer in the Philippines. Filipinos exhibit a higher prevalence of BRAFV600E mutations, and thyroid cancer is more common among females and older individuals. Diagnostic procedures include risk assessment, family history evaluation, neck examination, hormone tests, neck ultrasonograms, thyroid scans, and biopsies guided by the Bethesda System. Treatment primarily involves surgery, which is determined by risk classification and disease extent. Total or near-total thyroidectomy is recommended for most cases, followed by postoperative management tailored to individual patient factors. Anaplastic thyroid cancer may require multimodal approaches. The COVID-19 pandemic disrupted healthcare access, leading to delays in thyroid cancer treatment and challenges in monitoring, prompting the adoption of telemedicine. However, the pandemic's psychological impact on thyroid cancer survivors is concerning. The economic burden remains substantial despite health insurance programs. In conclusion, thyroid cancer in the Philippines necessitates enhanced prevention, early detection, determination of risk factors, risk stratification, and treatment strategies. The COVID-19 pandemic emphasized the need for adaptable healthcare systems. This study summarized the epidemiology, diagnosis, and management of thyroid cancer in the Philippines. Implementation of existing policies and further research on the Filipino population is vital to address this growing health concern and ensure improved outcomes for thyroid cancer patients.},
}
@article {pmid42038922,
year = {2025},
author = {Kiran, MA and Saeed, S and Bin Nafisah, A and Alqarni, A and Alotaibi, AH and Alqahtan, AS and Aljadaan, H and Osayl, HB and Alsane, M and Alsuhail, N and Alrawaf, N and Albalawi, RS and Alanazi, SA and Aloufi, R},
title = {Impact of The COVID-19 Pandemic on Salivary Gland-related Healthcare Interventions; A Systematic Review And Meta-analysis :.},
journal = {Galen medical journal},
volume = {14},
number = {},
pages = {e3970},
pmid = {42038922},
issn = {2322-2379},
abstract = {BACKGROUND: The emergence of SARS-CoV-2 variants has raised concerns regarding their potential impact on perioperative outcomes. Its effect on patients undergoing surgery for salivary gland diseases remains unclear. This systematic review and meta-analysis aimed to evaluate the impact of the COVID-19 pandemic on salivary gland-related healthcare interventions, including cancer treatments, sialendoscopy procedures, and parotid surgery outcomes.<br><br>MATERIALS AND METHODS: Following PRISMA guidelines, a systematic search was conducted in PubMed, Embase, and Web of Science (2019-2025) for studies reporting pre- and during-COVID data. Two reviewers independently screened records, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed to pool odds ratios (ORs) for intervention outcomes.<br><br>RESULTS: Four studies (n=7,740 participants) were included. The pooled OR for salivary gland interventions during versus pre-COVID was 1.08 (95% CI: 0.88-1.33, P=0.45), indicating no significant change, with moderate heterogeneity (I&#xb2;=46%). Subgroup analyses revealed increased odds of wound dehiscence post-parotid surgery (OR=4.40, 95% CI: 1.18-16.40) but no significant differences in delayed cancer diagnosis or urgent sialendoscopy.<br><br>CONCLUSION: The COVID-19 pandemic did not significantly alter overall salivary gland intervention rates or adverse events, though some procedural complications increased non-significantly. Limited evidence underscores the need for larger, standardized studies. While this shows that surgeons maintained quality of practice in this era during the COVID-19.},
}
@article {pmid42039182,
year = {2026},
author = {Lap, CR and van Houten, M and Bogaert, D and Biesbroek, G},
title = {A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1794596},
pmid = {42039182},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications ; *SARS-CoV-2/immunology ; Child ; Post-Acute COVID-19 Syndrome ; Immunity, Innate ; Dysbiosis/immunology ; Adolescent ; },
abstract = {Pediatric Post-COVID Condition (PPCC) represents a significant and complex long-term sequela of SARS-CoV-2 infection, affecting a subset of children and adolescents even after mild acute disease. While acute COVID-19 is generally milder in children due to a more robust innate immune response, the mechanisms driving the persistence of symptoms in PPCC remain incompletely understood and likely multifactorial. This narrative review synthesizes current epidemiological data and explores the "perfect storm" of immunological and pathophysiological alterations underpinning the condition. We examine critical hypotheses including a dysregulated immune response characterized by altered T-cell subsets, monocyte activation, and autoantibody production. We discuss the potential role of persistent SARS-CoV-2 viral reservoirs in "sanctuary sites" like the gastrointestinal tract and the reactivation of latent viruses such as Epstein-Barr virus (EBV). Furthermore, the review details downstream pathogenic pathways, including vascular endothelial inflammation (thrombo-inflammation), neuroinflammation, and metabolic dysfunctions affecting the mitochondria and tryptophan-kynurenine pathway. Finally, we address the role of microbiome dysbiosis in perpetuating systemic inflammation and the gut-lung axis dysfunction. Given the heterogeneity of clinical presentations, we conclude that PPCC is likely a syndrome of overlapping biological phenotypes. Future research must prioritize identifying these specific biological endotypes to develop targeted diagnostic and therapeutic strategies for the pediatric population.},
}
@article {pmid42041273,
year = {2026},
author = {Silveira, JM and Nakaishi, APM and da Silva, MG and Dos Santos, DO and Gastaldi, AC},
title = {Effects of Exercise-Based Pulmonary Rehabilitation in Patients with Long COVID: A Systematic Review and Meta-Analysis.},
journal = {Advances in respiratory medicine},
volume = {94},
number = {2},
pages = {},
pmid = {42041273},
issn = {2543-6031},
mesh = {Humans ; *COVID-19/rehabilitation/complications/physiopathology ; *Exercise Therapy/methods ; Quality of Life ; Post-Acute COVID-19 Syndrome ; Exercise Tolerance ; SARS-CoV-2 ; Randomized Controlled Trials as Topic ; },
abstract = {Background/Objective: A substantial proportion of infected individuals develop persistent symptoms after the acute phase of COVID-19, regardless of initial disease severity. Long COVID (LC) remains a public health challenge characterized by impaired functional exercise capacity (FEC) and quality of life (QoL). We systematically synthesized evidence on the effects of in-person outpatient pulmonary rehabilitation (OPR) with individualized and supervised exercise in adults with LC. Methods: Following PROSPERO (CRD42023389365), this study reviewed randomized controlled trials (RCTs) and observational cohort studies (OCSs) published between November 2019 and January 2026 in MEDLINE/PubMed, Web of Science, PEDro, and EMBASE. Results: Fifteen studies (n = 803) were included. OPR improved FEC (6MWT; MD: 53.72 m, 95% CI 43.69-63.75) and 30″SST (MD: 4.68, 95% CI 3.59-5.77) and reduced exertional dyspnea. RCTs showed benefits in physical (MD: 8.04, 95% CI 3.02-13.05) and mental QoL (MD: 6.60, 95% CI 2.01-11.18) and dyspnea impact, with inconsistent PF findings. Fatigue showed a trend toward improvement but was measured using heterogeneous patient-reported tools in RCTs and OCSs. Conclusions: Supervised PR improves FEC, QoL, and dyspnea in individuals with LC. In patients with fatigue/PEM, systematic assessment and continuous symptom monitoring are essential. High-quality controlled studies are needed to strengthen evidence and clinical guide.},
}
@article {pmid42041392,
year = {2026},
author = {Markwitz, M and Welc, N and Kępińska, K and Bowszyc-Dmochowska, M and Dmochowski, M},
title = {Non-COVID-19 Vaccinations and the Induction of Autoantibodies in Pemphigus Diseases: A Review of the Speculative Issue and Our Clinical-Laboratory Experience.},
journal = {Antibodies (Basel, Switzerland)},
volume = {15},
number = {2},
pages = {},
pmid = {42041392},
issn = {2073-4468},
abstract = {Background: Pemphigus diseases are rare autoimmune blistering disorders mediated by pathogenic autoantibodies directed mainly against desmoglein 1 and desmoglein 3. Although most cases are considered idiopathic, external triggers that can disrupt immune tolerance have been described. Vaccination has been discussed as a potential precipitating factor in autoimmune skin diseases. However, the relationship between vaccination and the induction of pemphigus-related autoantibodies has not been comprehensively summarized. Methods: We conducted a narrative review of all available studies published in the last 25 years identified through medical databases, excluding studies on COVID-19 vaccinations. Reports describing either new-onset pemphigus or exacerbation of preexisting pemphigus with a temporal association to vaccination were included. Clinical characteristics, vaccine type, latency period, direct immunofluorescence findings, and ELISA results for desmoglein autoantibodies were analyzed. In addition, we present our own clinical-laboratory experience illustrating this issue. Results: The current evidence consists predominantly of case reports and small case series. Published cases describe pemphigus vulgaris and pemphigus foliaceus occurring after vaccinations against influenza, hepatitis B, tetanus, diphtheria, pertussis, rabies, and other routinely administered immunizations. The latency period most often ranged from several days to a few weeks. Immunopathological findings were consistent with classical pemphigus diseases, including intercellular IgG deposits in the epidermis and circulating autoantibodies against desmoglein 1 and/or desmoglein 3. Our patient was a 78-year-old woman who developed cutaneous form of pemphigus vulgaris, diagnosed with direct immunofluorescence (DIF) and multiplex ELISA, 10 days after diphtheria-tetanus-pertussis vaccination. The patient had a positive family history of autoimmune blistering disease, namely mucous membrane pemphigoid. Conclusions: Based on the currently available evidence, a direct causal relationship between vaccination and pemphigus diseases cannot be established. Nevertheless, accumulated clinical and serological observations suggest that vaccination may act as a triggering factor in genetically or immunologically predisposed individuals, possibly by amplifying pre-existing subclinical autoreactive immune responses. Further population-based and mechanistic studies are required to clarify this association, while the overall benefits of vaccination remain substantial.},
}
@article {pmid42041609,
year = {2026},
author = {Breaux, AM and Miller, GR and Cooper, HD and Bembenick, KN and Reddy, A and Ahmadzadeh, S and Shekoohi, S and Kaye, AD},
title = {Critical Care Sedation: Emerging Clinical Considerations and Risks of Volatile Anesthetics for Sedation: A Narrative Review.},
journal = {Diseases (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
pmid = {42041609},
issn = {2079-9721},
abstract = {Volatile anesthetics have steadily become more popular in intensive care units for sedation for reasons related to their beneficial pharmacokinetic and pharmacodynamic properties. Common anesthetics such as isoflurane and sevoflurane rapidly reach sedative levels in the body, but they are also rapidly eliminated, allowing for quick recovery. These agents have minimal impact on the liver and kidneys, which makes them attractive options when compared to other agents including opioids, benzodiazepines, ketamine, and propofol. Use of delivery systems like AnaConDa[®] (Anaesthetic Conserving Device; Sedana Medical AB, Danderyd, Sweden) has enabled providers to easily use these agents in the Intensive Care Unit (ICU). In this regard, they have recently provided additional beneficial consideration during intravenous drug shortages seen during the COVID-19 pandemic and at other times. These agents have shown organ-protective effects in the kidneys and lungs, which may even reduce the total time spent in the ICU. Pharmacodynamically, these anesthetics mediate their effects through central nervous system ion channels to exert analgesic and anxiolytic actions, thereby minimizing effects in the kidneys and lungs. These agents are primarily eliminated via exhalation, which makes them potential options for those with liver or kidney failure. This narrative review examines current efficacy and risks of using volatile anesthetics for sedation in the ICU setting and clinical roles for the future.},
}
@article {pmid42041712,
year = {2026},
author = {Vo, AH and Libmann, M and Carson, D and Wang, K and Puri, S and Butowski, N and Winters-Stone, K},
title = {A Scoping Review of Exercise Oncology in the Primary Brain Tumor Patient-Caregiver Dyad.},
journal = {Current oncology (Toronto, Ont.)},
volume = {33},
number = {4},
pages = {},
pmid = {42041712},
issn = {1718-7729},
mesh = {Humans ; *Brain Neoplasms/therapy/psychology ; *Caregivers/psychology ; *Exercise Therapy/methods ; Quality of Life ; Exercise ; },
abstract = {BACKGROUND: Primary malignant brain tumors (PBT) impose substantial burdens on patients and caregivers. Caregivers are essential in the delivery of outpatient care for patients with PBT but experience high levels of fatigue, distress, and health decline. Although exercise is known to improve outcomes in cancer patients, interventions tailored specifically to the PBT patient-caregiver dyad remain limited. Dyadic intervention, as well as exercise oncology, are emerging areas of active research in neuro-oncology. This scoping review incorporates both principles to evaluate the existing literature on exercise interventions on primary brain tumor patient-caregiver dyads.<br><br>METHODS: We conducted a comprehensive search of MEDLINE (PubMed), Embase, CINAHL (EBSCO), Rehabilitation &amp; Sports Medicine (EBSCO), and Cochrane Central (Ovid) in December 2025 for studies involving exercise interventions that included adult PBT patients and caregivers.<br><br>RESULTS: Of the 1126 records screened, eight studies were included: four yoga-based interventions (three feasibility trials and one ongoing multicenter RCT), one pilot ski-based intervention, and three aerobic and resistance training-based interventions (two qualitative and one ongoing trial). The interventions were safe and feasible, with high adherence and retention. The preliminary reported benefits included improvements in fatigue, sleep, quality of life, and caregiver distress for the dyads. Videoconference delivery was effective, particularly during the COVID-19 pandemic. The eight included studies comprised 5-67 dyads, with four being single-arm feasibility studies.<br><br>CONCLUSIONS: Current literature on dyadic exercise intervention in neuro-oncology consists primarily of small-scale feasibility and pilot studies. Initial findings have demonstrated that such interventions are safe. However, preliminary efficacy remains limited due to the risk of bias and lack of statistical power. Larger randomized clinical trials with objective endpoints are needed to define efficacy and guide evidence-based protocols.},
}
@article {pmid42041941,
year = {2026},
author = {Ramos-Nino, ME},
title = {Triple Latency as a Driver of Chronic Inflammation: An Integrative View of HSV, EBV, and CMV Persistence in Immunocompetent Hosts.},
journal = {Clinics and practice},
volume = {16},
number = {4},
pages = {},
pmid = {42041941},
issn = {2039-7275},
abstract = {Background: Herpes simplex virus (HSV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) establish lifelong latency in sensory neurons, lymphoid tissue, and myeloid-endothelial cells, respectively. A substantial proportion of adults worldwide are infected with all three viruses and may experience concurrent herpesvirus latency, yet they have largely been studied independently. This review examined whether latent and intermittently reactivating herpesviruses share overlapping inflammatory signatures and whether their combined presence contributes to chronic inflammatory burden. Methods: A narrative integrative review was conducted using MEDLINE, Embase, and Google Scholar (inception-October 2025). Evidence from thirty-one cohort studies and mechanistic investigations spanning virology, immunology, neurology, and clinical medicine was synthesized. Results: Herpesvirus reactivation rates ranged from 23% in general Intensive Care Unit (ICU) populations to 85% in severe COVID-19. Concurrent reactivation of multiple viruses occurred in 34-63% of critically ill patients and was associated with worse clinical outcomes. Notably, simultaneous CMV and EBV reactivation independently predicted mortality (adjusted hazard ratio, 3.17; 95% CI, 1.41-7.13). Across infections, overlapping inflammatory biomarkers, including IL-6, TNF-α, CRP, and PGE2, were consistently elevated, reflecting convergent activation of IFN and NF-κB signaling pathways. Mechanistic studies suggest cross-compartment immune priming, where CMV-driven T-cell exhaustion facilitates EBV reactivation, and viral cytokine signaling enhances HSV-associated neuroinflammation. Conclusions: HSV, EBV, and CMV triple latency may represent an underrecognized contributor to chronic inflammation in immunocompetent hosts. Understanding this multi-virus inflammatory network may inform mechanistic research, biomarker-guided risk stratification, and therapeutic strategies targeting convergent inflammatory pathways. Prospective interventional studies incorporating concurrent multi-virus monitoring are needed to clarify causal relationships.},
}
@article {pmid42041954,
year = {2026},
author = {Liu, Y and Khatchadourian, C and Sanders, L and Eweroke, Q and Warner-McCutcheon, C and Lewis, J and Santos, J and Venketaraman, V},
title = {Systematic Review: The Impact of COVID-19 Vaccination on Myocarditis Risk and Recovery.},
journal = {Clinics and practice},
volume = {16},
number = {4},
pages = {},
pmid = {42041954},
issn = {2039-7275},
support = {R15 HL143545/HL/NHLBI NIH HHS/United States ; },
abstract = {Background: Myocarditis is an uncommon but recognized adverse event following mRNA COVID-19 vaccination, with risk varying by age, sex, dose number, and vaccine product. Clarifying the magnitude of risk, clinical course, and recovery-relative to myocarditis following SARS-CoV-2 infection-is essential for risk-benefit assessment and public health guidance. Methods: We performed a systematic PubMed and Embase search (January 2020-December 2024) and synthesized cohort, registry, and surveillance data on myocarditis incidence and outcomes following mRNA COVID-19 vaccination. Outcomes included incidence, observed-to-expected (OE) or incidence rate (IRRs) ratios, hospitalization, and short-term recovery. Study selection followed PRISMA 2020 systematic review guidelines. Results: Myocarditis following mRNA COVID-19 vaccination was identified as a rare adverse event, most commonly occurring after the second dose and in younger male individuals. Across multiple cohort and registry-based studies, cases were generally mild and self-limited, with most patients recovering without complication. In contrast, myocarditis following SARS-CoV-2 infection was consistently associated with more severe outcomes, including higher rates of hospitalization and mortality. Conclusions: Vaccine-associated myocarditis is rare, typically mild, and self-limited, with excellent short-term recovery; vaccinated individuals also exhibit lower odds of in-hospital death and intubation. In contrast, infection-associated myocarditis is more frequent and severe. Overall, the benefit-risk profile of mRNA vaccination remains strongly favorable.},
}
@article {pmid42042039,
year = {2026},
author = {Chang, H and Wu, CS and Yeh, TY and Ko, WC},
title = {Tea Polyphenols in the COVID-19 Era: Mechanistic Insights and Translational Challenges.},
journal = {Current issues in molecular biology},
volume = {48},
number = {4},
pages = {},
pmid = {42042039},
issn = {1467-3045},
support = {Not applicable//Renal Care Research and Health Promotion Association, New Taipei City/ ; },
abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has driven the global COVID-19 pandemic, imposing a tremendous burden on public health. As the virus continually evolves through rapid mutations, the pandemic has transitioned into a prolonged endemic phase. Despite the development of novel drugs and vaccines, clinical outcomes remain suboptimal for vulnerable populations, including the elderly and those with comorbidities or compromised immunity. Tea polyphenols, a class of structurally diverse and bioactive nutraceuticals, may modulate viral entry, replication, and host inflammatory pathways implicated in disease progression through pleiotropic effects on viral attachment, membrane fusion, intracellular replication, and proteolytic processing. Here, we provide an updated chemo-biological perspective on the antiviral and immunomodulatory mechanisms of tea polyphenols against SARS-CoV-2. Current evidence highlights their potential to serve as promising candidates for further mechanistic and translational investigation as adjunctive strategies and nutraceuticals for COVID-19 management. Importantly, no large-scale randomized controlled trials have yet demonstrated clinical benefit of tea polyphenols in COVID-19.},
}
@article {pmid42042775,
year = {2026},
author = {Damnjanović, K and Djurov, K and Galic, M and Lisul, B and Mocanu, IV and Shukla, S and Enstone, A and Dai, L and Vrdelja, M and Batselova, H and Drăgănescu, A and Tešović, G},
title = {Vaccine Confidence and Vaccine Hesitancy in Several Countries in Southeastern Europe in Past 10 Years: A Structured Review of Published Literature.},
journal = {Vaccines},
volume = {14},
number = {4},
pages = {},
pmid = {42042775},
issn = {2076-393X},
support = {N/A//Merck Sharp &amp; Dohme LLC/ ; },
abstract = {OBJECTIVES: Despite vaccination being the most effective way of preventing infections and vaccination rates recovering worldwide after the COVID-19 pandemic, vaccine hesitancy persists. Some factors, such as psychological and social barriers, can negatively impact views on vaccines and can contribute to vaccine hesitancy. The primary objective of this structured literature review is to investigate the available evidence relating to factors affecting vaccine hesitancy within several countries in Southeastern Europe.<br><br>METHODS: An electronic database search was conducted to identify studies assessing the public and healthcare professionals' (HCPs) attitudes towards vaccination in Southeastern Europe. These searches were supplemented with grey literature searches. Included studies were conducted in Bulgaria, Croatia, Romania, Serbia, and Slovenia between 1 January 2012 and 31 December 2022.<br><br>RESULTS: Of the 35 studies identified from the database searches, the most prominent theme observed across Romania, Croatia, and Bulgaria was low confidence in COVID-19 vaccines. Across all age groups, COVID-19 vaccine confidence in these regions was highly dependent on whether individuals thought vaccines were safe and effective, as well as their general trust in vaccines. Confidence in COVID-19 vaccines was seen as relatively high, with attitudes towards routine and elective vaccines being generally positive amongst the general public and HCPs, in Romania, Croatia, Serbia and Slovenia. However, uncertainty around the effectiveness of the vaccine still exists. In Bulgaria, trust in routine and elective vaccines remained low in the general public. Complacency and financial constraints were also identified as underlying causes of vaccine hesitancy.<br><br>CONCLUSIONS: The main cause behind vaccine hesitancy in several countries in Southeastern Europe is distrust in vaccine effectiveness and safety. These key findings can be utilised to support evidence-based decisions regarding where to focus resources to improve public and HCP perception of vaccines in Southeastern Europe.},
}
@article {pmid42042784,
year = {2026},
author = {Runzer-Colmenares, FM and Cahuapaza-Gutierrez, NL and Calderon-Hernandez, CC and Umeres-Bravo, MM},
title = {Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review.},
journal = {Vaccines},
volume = {14},
number = {4},
pages = {},
pmid = {42042784},
issn = {2076-393X},
abstract = {Background/Objectives: Vaccination against respiratory viruses-such as respiratory syncytial virus (RSV), pneumococcal disease, influenza, and COVID-19-may reduce the risk of adverse outcomes in older adults with cardiovascular disease. This study conducted a scoping review of the effects of respiratory vaccines in older adults with cardiovascular disease. Methods: We included studies evaluating adults aged ≥ 60 years with cardiovascular disease who received different types of respiratory vaccines. Eligible designs comprised clinical trials, observational cohort studies, and other relevant studies. Editorials, commentaries, and non-original publications were excluded. A comprehensive and targeted literature search was conducted in PubMed, Scopus, EMBASE, and Web of Science from database inception through January 2026. Results: A total of 25 studies were included, encompassing 1,782,787 adults aged ≥ 60 years with cardiovascular disease who received various respiratory vaccines. RSV vaccines were associated with a lower incidence of cardiorespiratory hospitalization and stroke among vaccinated individuals. Pneumococcal vaccines showed that sequential dual vaccination strategies were associated with a lower risk of cardiovascular events. Influenza vaccination was associated with improved cardiovascular outcomes, lower mortality, and reduced adverse events. COVID-19 vaccines were associated with reductions in mortality and hospitalizations. These benefits are particularly relevant in an older population with a high burden of comorbidities; therefore, complete vaccination schedules, including booster doses, should be considered a central strategy for prevention and comprehensive management in this high-risk group. Conclusions: Vaccination against respiratory viruses in older adults with cardiovascular disease demonstrates an overall favorable/acceptable profile of efficacy and safety, with reductions in mortality, hospitalizations, and cardiovascular events, without a significant increase in serious adverse events.},
}
@article {pmid42042800,
year = {2026},
author = {Lopes de Abreu, AJ and Mpande, CAM and Song, Y and Nicholson, MW and Nannei, C and Friede, M},
title = {Unpacking the mRNA Supply Chain: Challenges and Opportunities for Global Health.},
journal = {Vaccines},
volume = {14},
number = {4},
pages = {},
pmid = {42042800},
issn = {2076-393X},
abstract = {The COVID-19 pandemic highlighted both the transformative potential of mRNA vaccines and the structural challenges associated with their supply chains. Unlike traditional vaccine platforms, mRNA vaccines depend on highly specialized raw materials, including plasmid DNA (pDNA), nucleotides, enzymes, and lipid nanoparticles (LNP), that are produced by a limited number of global suppliers. These dependencies, combined with platform-specific manufacturing processes and stringent cold chain requirements, introduce vulnerabilities across production, distribution, and regulatory oversight. This narrative review examines the distinctive features of mRNA vaccine supply chains and identifies key challenges and opportunities across three interconnected domains: manufacturing systems, logistics and distribution, and regulatory governance. Drawing on literature published between January 2021 and March 2026, the review synthesizes evidence on supply chain bottlenecks revealed during the COVID-19 pandemic, including upstream raw-material dependencies, limitations in manufacturing scale-up, cold chain constraints, and regulatory fragmentation. Particular attention is given to the implications of these challenges for low- and middle-income countries, where infrastructure, technical capacity, and regulatory resources may limit participation in mRNA vaccine production and deployment. The review also highlights emerging strategies to strengthen supply chain resilience, including diversification of input suppliers, development of regional manufacturing hubs, improvements in vaccine thermostability, regulatory harmonization initiatives, and the use of digital technologies for supply chain management. By integrating insights from manufacturing, logistics, and regulatory perspectives, this study contributes to a better understanding of the structural characteristics shaping mRNA vaccine supply chains and identifies priority areas for strengthening global preparedness for future health emergencies.},
}
@article {pmid42042827,
year = {2026},
author = {Aljohani, M},
title = {Seasonal Influenza Vaccine Uptake, Acceptance and Willingness to Vaccinate in Post-COVID-19 Vaccine Era Among Adult High-Risk Groups in Gulf Cooperation Council Countries (GCC): A Narrative Review of the Literature.},
journal = {Vaccines},
volume = {14},
number = {4},
pages = {},
pmid = {42042827},
issn = {2076-393X},
abstract = {BACKGROUND/OBJECTIVES: Reports on seasonal influenza vaccine (SIV) coverage in Gulf Cooperation Council (GCC) countries showed lower than targeted coverage among high-risk populations both before and after the COVID-19 pandemic and subsequent COVID-19 vaccine release. This narrative review aims to synthesise SIV coverage following the introduction of COVID-19 vaccines among at-risk groups in the GCC region.<br><br>METHODS: Database searches included PubMed and Google Scholar for articles assessing SIV uptake, acceptance, hesitancy, and intention to vaccinate among adults in high-risk groups in GCC countries, with data collected after the introduction of COVID-19 vaccines.<br><br>RESULTS: SIV uptake ranged from 1.8% among pregnant women to 64.1% among dialysis patients in Saudi Arabia. Healthcare workers (HCWs) demonstrated the highest overall coverage, reaching 64.5% for annual uptake in Bahrain, with 79% of HCWs in Saudi Arabia intending to vaccinate. Prevalent barriers included low risk perception and consideration of influenza as a mild disease not necessitating SIV uptake, as well as vaccine effectiveness and safety concerns. Previous vaccination, physician advice, and policy or mandates for HCWs were identified as frequent facilitators of uptake.<br><br>CONCLUSION: Suboptimal uptake was reported among most high-risk groups in GCC countries. Health Belief Model components and physician involvement appear to have a significant impact on vaccine uptake among the intended population. More emphasis should be directed toward effective risk communication and action cues methods to enhance uptake among high-risk groups. Future research is needed to cover understudied areas like the elderly aged &#x2265; 65 years, cancer and other high-risk groups, in addition to further studies for GCC countries other than Saudi Arabia in the post-COVID-19 vaccine period.},
}
@article {pmid42042830,
year = {2026},
author = {Bellavite, P and Di Fede, G and Mantovani, M and Zanolin, E},
title = {Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin-Angiotensin System.},
journal = {Vaccines},
volume = {14},
number = {4},
pages = {},
pmid = {42042830},
issn = {2076-393X},
abstract = {One of the most critical aspects of post-acute COVID-19 syndrome (PACS) and post-acute COVID-19 vaccination syndrome (PACVS) is the presence of autoantibodies. These autoantibodies are directed against various receptors in the autonomic and cardiovascular systems, including those targeting proteins of the renin-angiotensin system (RAS). The RAS plays a central role in regulating vascular homeostasis, inflammation, and endothelial function. During SARS-CoV-2 infection, the interaction of the spike (S) protein with angiotensin-converting enzyme 2 (ACE2) can alter the balance of the RAS, favoring an imbalance towards the ACE/Angiotensin II/AT1R axis, known for its pro-inflammatory, pro-thrombotic, and vasoconstrictive properties. Similar pathological mechanisms also come into play in response to vaccinations that use the S protein as an antigen. Studies conducted by other groups and us on patients with PACS and PACVS have revealed the presence of autoantibodies directed against these RAS components and the mechanisms by which these antibodies can worsen the clinical situation. In particular, anti-ACE2, presumably formed by the anti-idiotype network or molecular mimicry, is correlated with PACVS symptoms in many patients. Furthermore, the presence of anti-MAS1 antibodies can reduce the efficiency of the ACE2/Angiotensin-(1-7)/MAS1 axis, which normally acts as a counter-regulator. Considering this evidence, an analysis of RAS molecules and the autoantibodies implicated in reactions to them may be useful for evaluating a state of persistent dysregulation associated with post-vaccination symptoms such as asthenia, headache, skin edema and bruising, cardiovascular alterations, and neurovegetative manifestations. Finally, we offer insights into diagnosing these multifaceted syndromes and working hypotheses to guide research into possible therapeutic approaches.},
}
@article {pmid42043214,
year = {2026},
author = {Natarajan, M and Jayashankar, B and Nataraj, R},
title = {Placental Vulnerability to SARS-CoV-2: Viral Entry Pathways and Immune Activation.},
journal = {Viruses},
volume = {18},
number = {4},
pages = {},
pmid = {42043214},
issn = {1999-4915},
mesh = {Humans ; Female ; Pregnancy ; *Virus Internalization ; *Placenta/virology/immunology ; *SARS-CoV-2/physiology ; *COVID-19/immunology/virology ; *Pregnancy Complications, Infectious/immunology/virology ; Angiotensin-Converting Enzyme 2 ; Infectious Disease Transmission, Vertical ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {Pregnancy represents a distinct immunological and physiological state that modifies maternal susceptibility to SARS-CoV-2 and influences the clinical and biological course of COVID-19. Accumulating evidence indicates that the interaction between viral entry determinants, gestation-specific immune modulation, placental endocrine-angiogenic pathways, and systemic inflammatory responses underlies the characteristic manifestations of SARS-CoV-2 infection during pregnancy. This review consolidates current understanding of SARS-CoV-2 viral structure, receptor biology, and the gestational regulation of key entry cofactors, including ACE2, TMPRSS2, NRP1, CTSL and FURIN, within reproductive and placental tissues. The review further integrates documented mechanisms of cytokine-mediated immune dysregulation, endothelial injury, thrombo-inflammation, and steroidogenic alteration observed in affected pregnancies, and examines their contribution to placental malperfusion, preeclampsia-like presentations, fetal growth abnormalities and preterm birth. Published molecular and computational studies characterising trophoblast antiviral defenses, receptor expression patterns, and structural determinants of Spike-ACE2 affinity are synthesised to contextualise the biological basis of placental susceptibility and the rarity of confirmed transplacental transmission. Current evidence on maternal clinical outcomes, fetal and neonatal consequences, vaccination efficacy, therapeutic considerations and contemporary management guidelines is also critically reviewed. By integrating molecular, immunological, pathological and clinical insights, this article provides a comprehensive framework for understanding the interaction between SARS-CoV-2 infection and pregnancy-specific physiology, with implications for risk assessment, preventive strategies and maternal-fetal care.},
}
@article {pmid42043241,
year = {2026},
author = {Tasker, S and Spiri, AM and Hartmann, K and Addie, DD and Belák, S and Bergmann, M and Egberink, H and Frymus, T and Hofmann-Lehmann, R and Marsilio, F and Pennisi, MG and Thiry, E and Truyen, U and Boucraut-Baralon, C and Möstl, K and Hosie, MJ},
title = {Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines.},
journal = {Viruses},
volume = {18},
number = {4},
pages = {},
pmid = {42043241},
issn = {1999-4915},
mesh = {Animals ; Cats ; *Feline Infectious Peritonitis/drug therapy/diagnosis/virology ; *Antiviral Agents/therapeutic use/administration &amp; dosage ; Adenosine Monophosphate/analogs &amp; derivatives/therapeutic use ; Alanine/analogs &amp; derivatives/therapeutic use ; Europe ; Coronavirus, Feline/drug effects ; Adenosine/analogs &amp; derivatives ; Cytidine/analogs &amp; derivatives ; Hydroxylamines ; },
abstract = {Feline infectious peritonitis (FIP) is a disease arising as a result of feline coronavirus infection. It used to be regarded a fatal disease, with euthanasia commonly recommended following diagnosis due to its very poor prognosis. The availability of effective antiviral therapies, particularly nucleoside analogues such as oral GS-441524, has fundamentally changed the outlook for cats with FIP. FIP is now a treatable and frequently curable disease. In these revised guidelines, the European Advisory Board on Cat Diseases (ABCD) presents an update on the treatment of FIP, incorporating the findings of new studies including the range of available treatments (such as GS-441524, remdesivir and molnupiravir (EIDD-2801) and its active metabolite EIDD-1931), which varies globally, as well as suggestions for monitoring and prognostic indicators. Tables are used to present easy-to-find information on antiviral and supportive treatments for cats with FIP. GS-441524 is the most extensively studied antiviral for FIP with treatment success rates often exceeding 90%. Remdesivir is primarily reserved as an injectable antiviral for severely affected cats unable to tolerate oral medication; it is usually replaced by oral medication as soon as, and when, possible. Although 84-day treatment courses have historically been used, emerging evidence suggests that shorter regimens of 42 days can be equally effective.},
}
@article {pmid42043247,
year = {2026},
author = {Mahajan, S and Mahajan, S and Kaushik, N},
title = {Integrative Insights into the Immunopathogenesis and Organ-Specific Immunological Mechanisms of Long COVID: A Narrative Review.},
journal = {Viruses},
volume = {18},
number = {4},
pages = {},
pmid = {42043247},
issn = {1999-4915},
mesh = {Humans ; *COVID-19/immunology/pathology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2/immunology ; Immunity, Innate ; Adaptive Immunity ; },
abstract = {Long COVID (LC), also referred to as post-acute sequelae of SARS-CoV-2 infection, is characterized by persistent symptoms originating 3 months following acute COVID-19, lasting for at least two months and frequently affecting individuals who initially experienced mild to moderate disease. The clinical spectrum is heterogeneous, involving respiratory, cardiovascular, neurological, renal, gastrointestinal, and endocrine systems, thereby posing substantial diagnostic and therapeutic challenges. Despite extensive investigation, the precise immunopathogenic mechanisms underlying LC remain incompletely defined. Accumulating evidence suggests that LC is driven by a multifactorial interplay of persistent viral antigen reservoirs, chronic immune activation, dysregulated innate and adaptive immune responses, autoimmunity, endothelial dysfunction, microvascular injury, and aberrant tissue repair. These systemic immune perturbations manifest variably across different organs, contributing to the diverse clinical phenotypes observed. However, mechanistic clarity is hindered by heterogeneity in study designs, limited longitudinal data, and the absence of standardized immunological profiling. This narrative review provides integrative insights into the immunopathogenesis of LC, synthesizing current evidence on systemic immune dysregulation and organ-specific immunological mechanisms. A conceptual framework is proposed to facilitate a structured understanding of this complex syndrome and to guide future research toward targeted immunomodulatory strategies.},
}
@article {pmid42043661,
year = {2026},
author = {Pashapour, H and Nikfarjam, A and Ghaffari, M and Kavousi, A and Aslani, N and Karami, M},
title = {Good Practices for Managing Acute Respiratory Viral Infections at Aerial Entry Points: A Scoping Review.},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {},
pmid = {42043661},
issn = {2210-6014},
support = {43013183//Shahid Beheshti University of Medical Sciences/ ; },
mesh = {Humans ; *Quarantine/methods ; *Contact Tracing/methods ; *COVID-19/prevention &amp; control/epidemiology ; *Respiratory Tract Infections/prevention &amp; control ; Disease Outbreaks/prevention &amp; control ; *Virus Diseases/prevention &amp; control ; },
abstract = {BACKGROUND: Aerial entry points are critical in the international spread of infectious diseases, underscoring the need for effective management of acute respiratory viral infections (ARVIs). Recent global outbreaks, including COVID‑19, have highlighted the importance of strengthened public health measures at air borders. However, evidence on ARVI management strategies at these points remains fragmented. This scoping review mapped and synthesized existing approaches to quarantine protocols, contact‑tracing methods, and advanced or innovative technologies used at aerial entry points. METHODS: We conducted a scoping review following the Arksey and O’Malley framework, refined by Levac et al., and reported in accordance with PRISMA ScR guidelines. Scientific databases were systematically searched for English language studies published between 2003 and 2024 that described the management of ARVIs at air borders. Data from eligible studies were charted and analyzed using thematic analysis to identify and categorize quarantine approaches, contact tracing strategies, and advanced or innovative technologies applied in these settings. RESULTS: A total of 80 studies were included in the review, addressing diseases such as COVID 19, influenza, SARS, and Ebola. Most studies were conducted in high income countries and in regions of Southeast Asia and the Western Pacific. Various quarantine approaches were identified, including mandatory quarantine, risk based quarantine, and home based isolation strategies. Contact tracing methods ranged from traditional manual approaches using passenger information to technology supported systems that improved the speed of identifying exposed individuals. Several studies reported the use of advanced digital technologies such as digital health passports, geofencing monitoring systems, and electronic reporting platforms to support monitoring, compliance, and data management during public health responses at air borders. CONCLUSION: The findings highlight the diverse range of quarantine protocols, contact tracing approaches, and emerging technological tools used to manage ARVIs at air borders. Despite these developments, evidence regarding the effectiveness and long term implementation of these strategies remains limited. Further research is needed to strengthen the evidence base and support evidence informed policies for managing respiratory infectious diseases at international points of entry.},
}
@article {pmid42044369,
year = {2026},
author = {Banerjee, P and Holly, L},
title = {Everyday Digital Technology Use and Youth Health: Scoping Review of Longitudinal Studies.},
journal = {JMIR public health and surveillance},
volume = {12},
number = {},
pages = {e85094},
pmid = {42044369},
issn = {2369-2960},
mesh = {Humans ; Adolescent ; Longitudinal Studies ; *Digital Technology/statistics &amp; numerical data ; Digital Media ; *Adolescent Health/statistics &amp; numerical data ; Social Media/statistics &amp; numerical data ; Child ; Young Adult ; COVID-19/epidemiology ; Digital Health ; },
abstract = {BACKGROUND: Everyday digital technologies such as social media, gaming, and internet use are deeply integrated into the lives of children, adolescents, and young adults. While these platforms can foster connection, learning, and entertainment, concerns have grown about their potential to influence mental, physical, and social well-being. Research on this topic has expanded rapidly over the past decade, yet much of it remains cross-sectional, limiting insights into long-term outcomes. Longitudinal studies are essential to capture evolving patterns of digital engagement, identify causal relationships, and guide effective policies and interventions that support youth in navigating digital environments. In particular, evidence is needed to distinguish between beneficial and harmful forms of digital engagement, such as social connection versus problematic use, and to understand how these impacts differ across diverse populations and contexts. The COVID-19 pandemic further accelerated young people's technology use, underscoring the urgency of examining both risks and opportunities. This review, therefore, synthesizes longitudinal research to map trends, identify knowledge gaps, and inform future directions.<br><br>OBJECTIVE: The study aimed to systematically identify and map longitudinal studies examining associations between everyday digital technology use (eg, social media, gaming, and internet use) and the health and well-being of youth (25 years or younger) and to chart the types of evidence available by technology category, outcomes, and geographical setting in order to highlight key gaps for future research.<br><br>METHODS: A systematic search of PubMed, Embase, and PsycArticles (2014-2024) was conducted and reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Data extraction covered demographics, digital technology categories, and health outcomes. Studies were grouped into 6 key themes: social media use and mental health, digital addiction and behavioral outcomes, physical activity and digital technology, digital health technologies and cognitive development, parental influence and digital technology, and digital well-being and risk behaviors.<br><br>RESULTS: Of the 456 studies identified, 267 were longitudinal studies relevant to our research aims. Internet use (n=201 studies), social media (n=140 studies), and gaming (n=83 studies) dominated the themes. Mental health was the most frequently assessed outcome, with a focus on anxiety and depression. Geographically, 15% (40/267) of studies originated from low- and middle-income countries, with the majority from high-income settings such as the United States (n=76 studies) and Australia (n=15 studies). Nearly half (131/267, 49%) were published post 2020, reflecting heightened interest during the COVID-19 pandemic.<br><br>CONCLUSIONS: Longitudinal evidence on everyday digital technology use and youth health is growing but remains concentrated in mental health outcomes and high-income settings, with notable gaps in physical health, educational outcomes, and equity-focused research. These findings highlight the need for more diverse, methodologically robust longitudinal studies to inform context-sensitive policies and interventions that balance the risks and benefits of digital engagement for young people.},
}
@article {pmid42044651,
year = {2026},
author = {Agyemang, C and Tetteh, J and Mbaye, MN and Lamptey, R and Seidu, S and Khunti, K and Kengne, AP},
title = {Burden and determinants of diabetes in sub-Saharan Africa.},
journal = {The lancet. Diabetes &amp; endocrinology},
volume = {14},
number = {6},
pages = {498-511},
doi = {10.1016/S2213-8587(26)00065-3},
pmid = {42044651},
issn = {2213-8595},
mesh = {Humans ; Africa South of the Sahara/epidemiology ; *Cost of Illness ; COVID-19/epidemiology ; *Diabetes Mellitus, Type 2/epidemiology/etiology ; Prevalence ; },
abstract = {The prevalence of type 2 diabetes is rising rapidly across sub-Saharan Africa; however, its epidemiology, clinical phenotypes, and underlying mechanisms remain insufficiently characterised. This first paper in a Series on diabetes in sub-Saharan Africa synthesises current evidence on the burden, distribution, and determinants of diabetes, including emerging phenotypes and the roles of early life adversity, psychosocial stress, and interactions with infectious disease. We also identify major gaps in surveillance systems, research capacity, prevention, and clinical management across the region. Sub-Saharan Africa is experiencing one of the fastest global increases in diabetes, with the highest proportion of undiagnosed cases and a projected steep rise in intermediate hyperglycaemia and diabetes by 2050. Urbanisation, ageing, obesity, and lifestyle transitions are major contributors; however, a substantial proportion of type 2 diabetes occurs in lean individuals (BMI <25 kg/m[2]), particularly in rural settings, suggesting distinct metabolic and developmental pathways not captured by models derived from high-income countries. Bidirectional interactions between diabetes and malaria, tuberculosis, HIV, or COVID-19 make disease trajectories complex. Persistent gaps in surveillance, a reliance on modelled estimates, low genomic representation, and constrained access to modern diabetes medications hinder progress. Strengthening health system capacity, improving data infrastructure, and investing in regionally driven research are essential to develop effective, context-specific interventions and advance precision medicine tailored to sub-Saharan African populations.},
}
@article {pmid42045685,
year = {2026},
author = {Mehdizadeh, M and Zhang, FW and Yu, LC and Li, JH and Posso, AN and Mustoe, AK and Escobar-Domingo, MJ and Foppiani, J and Karinja, S and Lee, BT},
title = {Telemedicine in Plastic Surgery: A Systematic Review and Meta-analysis of Utilization and Outcomes Pre- and Post-pandemic.},
journal = {Aesthetic plastic surgery},
volume = {50},
number = {13},
pages = {5712-5720},
pmid = {42045685},
issn = {1432-5241},
mesh = {Humans ; *Telemedicine/statistics &amp; numerical data ; *COVID-19/epidemiology/prevention &amp; control ; Patient Satisfaction/statistics &amp; numerical data ; *Surgery, Plastic/methods ; *Plastic Surgery Procedures/methods ; Health Services Accessibility ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Telemedicine revolutionized healthcare post-COVID-19 by expanding virtual care across consultations, post-operative care, and inter-physician collaboration. However, its impact on adoption and effectiveness in plastic surgery remains underexplored. This study systematically compares pre- and post-pandemic telemedicine in plastic surgery, focusing on outcomes, accessibility, and patient satisfaction to inform best practices.<br><br>METHODS: A systematic review was conducted using PubMed, Medline, and Web of Science, following PRISMA guidelines, for articles published through November 2024. Extracted data included author, year, country, subspecialty, pandemic classification, sample size, demographics, utilization, barriers, travel time/distance, satisfaction, complications, and appointment duration. Meta-analyses calculated pooled estimates with 95% confidence intervals. Meta-regression and Welch's t-test assessed pre- versus post-pandemic differences. Analyses were performed in R 4.4.1.<br><br>RESULTS: Of 450 identified publications, 72 met inclusion criteria, encompassing 9435 subjects (mean age: 47.99). 89.3% (95% CI 59.3-96.2%) of patients reported willingness to reuse telemedicine, and the pooled satisfaction rate was 83.9% (95% CI 79.4-88.5; p&#x2009;<&#x2009;0.05). Meta-analysis showed significant reductions in travel time (120&#xa0;min; p&#x2009;<&#x2009;0.05) and distance (187.1&#xa0;km; p&#x2009;<&#x2009;0.05). Five studies reported a mean appointment duration of 16.07&#xa0;min. Complications were rare (7.7%; 95% CI 2.9-18.6%; p&#x2009;<&#x2009;0.05). Post-pandemic satisfaction score was lower (81.1 vs. 91.2; p&#x2009;=&#x2009;0.0315), likely reflecting increased utilization and technological barriers. Other outcomes, including complication rates and willingness to reuse telemedicine, showed no significant difference (p&#x2009;>&#x2009;0.05).<br><br>CONCLUSION: Telemedicine plays an evolving role in plastic surgery, reducing travel burden and maintaining safety. However, lower post-pandemic satisfaction highlights the need to improve accessibility and technology to optimize outcomes.<br><br>LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .},
}
@article {pmid42046671,
year = {2026},
author = {Hudu, SA and Jimoh, AO},
title = {Operational zoonotic containment of Middle East respiratory syndrome coronavirus in Saudi Arabia: An implementation-oriented One Health genomic framework.},
journal = {Veterinary world},
volume = {19},
number = {3},
pages = {1322-1341},
pmid = {42046671},
issn = {0972-8988},
abstract = {Middle East respiratory syndrome coronavirus (MERS-CoV) remains a persistent zoonotic threat more than a decade after its first detection, with Saudi Arabia continuing to be the global epicenter of human infections and the main reservoir interface through dromedary camels. Despite ongoing surveillance, advances in molecular diagnostics, and research on vaccines and therapeutics, sporadic zoonotic spillovers and healthcare-associated outbreaks still occur, showing that current prevention strategies are still not enough. This review compiles current evidence from epidemiological studies, camel reservoir research, genomic monitoring, and public health reports published between 2012 and April 2025 to identify the key gaps preventing effective containment. Special focus is given to recent genomic discoveries, including post-2022 clade B sublineages, recombination events, and spike protein changes that might affect transmission and the effectiveness of countermeasures. Available data suggest that MERS-CoV epidemiology is driven by repeated camel-to-human transmission, followed by occasional amplification in healthcare settings rather than sustained community spread. High seroprevalence and frequent detection of viral RNA in juvenile camels, seasonal gathering in markets, and extensive animal movement networks contribute to ongoing viral circulation at the animal-human interface. Genomic studies consistently show close phylogenetic relationships between camel and human isolates, confirming recurrent zoonotic transmissions. However, fragmented surveillance systems, delayed genomic data integration, inconsistent biosecurity practices, and limited field evidence for camel vaccination pose major barriers to control. Additionally, hospital outbreaks continue to occur due to delayed diagnosis, overcrowding, and incomplete adherence to infection-prevention protocols, underscoring the need for improved clinical preparedness. Based on the integrated synthesis of epidemiological, veterinary, and genomic evidence, this review proposes an implementation-focused One Health genomic framework tailored to the Saudi context. The proposed roadmap highlights real-time connection of human and camel surveillance, expands genomic sequencing capacity, targets vaccination strategies in camels and high-risk human populations, standardizes biosecurity measures in markets and abattoirs, and strengthens infection control systems in healthcare facilities. Alignment with national governance structures and Saudi Vision 2030 offers a practical pathway for coordinated multi-sectoral action. This review concludes that MERS-CoV is unlikely to be eradicated soon, but it can be effectively managed through a genomics-enabled, operational One Health approach that combines surveillance, vaccination, clinical preparedness, and policy coordination. The model outlined here provides a scalable way to reduce zoonotic spillover risk and strengthen readiness against future coronavirus and emerging zoonotic threats.},
}
@article {pmid42046765,
year = {2026},
author = {Matenga-Ikihele, A and Asafo, F and Tuesday, R and Netzler, N and Puliuvea, C and Percival, T},
title = {Pacific-Led Responses to COVID-19: Lessons for Future Pandemic Preparedness.},
journal = {Journal of the Royal Society of New Zealand},
volume = {56},
number = {2},
pages = {e70049},
pmid = {42046765},
issn = {1175-8899},
abstract = {The COVID-19 pandemic exposed deep inequities in health systems globally and in Aotearoa New Zealand, with Pacific communities experiencing a disproportionate burden of illness, economic hardship, and social disruption. Despite these challenges, Pacific communities demonstrated resilience, culturally grounded leadership, and the ability to meet community needs through collective action. This qualitative review of peer-reviewed literature, government reports, and community-led research identified five interconnected themes: (1) community partnerships; (2) Pacific-centred approaches; (3) clear and trusted communication; (4) digital inclusion and literacy skills; and (5) economic support and sustainability. From these themes, key enablers were identified, which included community leadership, trusted communication strategies, and agile local systems, alongside barriers such as underinvestment, digital exclusion, reliance on unpaid labour, and limited inclusion of Pacific leadership in early planning. The findings highlight that Pacific-led systems are not supplementary but an essential public health infrastructure. Embedding these approaches within national emergency planning, through sustainable funding, formal governance roles, and strengthened digital inclusion, offers a pathway to a more equitable, trusted, and resilient pandemic response.},
}
@article {pmid42047168,
year = {2026},
author = {Uzer, F and Erendor, F and Sanlioglu, S},
title = {SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.},
journal = {Reviews in medical virology},
volume = {36},
number = {3},
pages = {e70157},
pmid = {42047168},
issn = {1099-1654},
mesh = {Humans ; *Immune Evasion ; *SARS-CoV-2/immunology/genetics ; *Spike Glycoprotein, Coronavirus/immunology/genetics/chemistry ; *COVID-19/immunology/prevention &amp; control/virology ; *COVID-19 Vaccines/immunology ; Vaccine Development ; Evolution, Molecular ; Mutation ; Animals ; },
abstract = {The evolutionary trajectory of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has progressed through several distinct phases since its zoonotic emergence, transitioning from initial human adaptation to an era of rapid antigenic drift and complex immune evasion. As of early 2026, the global landscape is dominated by highly evolved sublineages of the Omicron (B.1.1.529) variant, including the JN.1-descendent subvariants NB.1.8.1 and XFG. This review provides a comprehensive overview of the molecular mechanisms driving viral fitness, with a primary focus on the structural transformations within the spike (S) protein's receptor-binding domain (RBD), N-terminal domain (NTD), and S2 subunit. We examine the biophysical impacts of pivotal mutations, such as E484 K, K417 N, and F486P, alongside the phenomenon of convergent evolution and epistatic compensation. Furthermore, we provide an integrated analysis of current knowledge regarding the evolving dynamics of humoral and cellular immunity, exploring the challenges posed by immune imprinting and the decline of neutralizing antibody titers against antigenically distant strains. A comparative discussion of SARS-CoV-2 and seasonal influenza highlights divergent evolutionary paces but converging regulatory frameworks for annual vaccine updates. Finally, the current status of next-generation vaccine platforms is evaluated, specifically mosaic nanoparticles and mucosal delivery systems, which aim to provide pan-sarbecovirus protection and interrupt transmission. These insights are integrated into a policy framework focused on annual strain selection and enhanced genomic surveillance for sustainable long-term pandemic management.},
}
@article {pmid42047233,
year = {2026},
author = {Bashir, HM and Ciftci, D},
title = {Impact of COVID-19 on female reproductive health and communication post-pandemic: A scoping review.},
journal = {African journal of reproductive health},
volume = {30},
number = {8},
pages = {102-118},
doi = {10.29063/ajrh2026/v30i8.10},
pmid = {42047233},
issn = {1118-4841},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; Female ; *Reproductive Health ; SARS-CoV-2 ; *Health Communication ; Pandemics ; },
abstract = {The COVID-19 pandemic significantly affected Female Reproductive Health (FRH), intensifying physiological and psychological conditions such as amenorrhea and postpartum related issues. While clinical studies have well-documented these impacts on FRH, no studies empirically tested health communication interventions, revealing a significant research gap. This scoping review bridges this gap, mapping evidence on the impact of COVID-19 on FRH and probing the untapped potential of communication strategies to mitigate these impacts. Following PRISMA-ScR guidelines, we systematically searched PubMed, PsycINFO, BMJ Global Health, and Frontiers (2021-2024) for peer-reviewed studies. The 13 included studies documented menstrual irregularities in 50-67% of women post-infection/vaccination, fertility rate declines of 18 per 100,000 women, and postpartum depression prevalence of 25.27%. Eligibility criteria included Women of reproductive age (15-49 years) affected by COVID-19's impact and implemented strategies addressing these impacts post-pandemic. We proposed integrating robust trauma-informed communication road map such as digital health literacy programs and community-led strategic initiatives.},
}
@article {pmid42047332,
year = {2026},
author = {Paik, S and Um, S and Kim, IS and Park, EJ and Kim, KT and Basu, J and Oh, DC and Jo, EK},
title = {Exploiting autophagy-targeting natural compounds for potential antimicrobial actions.},
journal = {Autophagy},
volume = {22},
number = {8},
pages = {1762-1787},
doi = {10.1080/15548627.2026.2662426},
pmid = {42047332},
issn = {1554-8635},
mesh = {*Autophagy/drug effects ; Humans ; Animals ; *Anti-Infective Agents/pharmacology ; *Biological Products/pharmacology ; Host-Directed Therapy ; Signal Transduction/drug effects ; },
abstract = {Natural products are biologically active compounds used for therapeutic interventions for various diseases, particularly infections. Autophagy is an intracellular catabolic pathway involving lysosomal degradation and is closely associated with immunological pathways, effectively combating bacterial, viral, fungal, and parasitic infections. Accumulating evidence suggests that autophagy activation or inhibition by natural products promotes antimicrobial responses against various pathogens. Numerous natural products can modulate autophagy through diverse signaling pathways, suggesting their potential as a host-directed therapeutic strategy that may complement conventional drug regimens or help mitigate drug resistance in various infectious diseases. However, it remains largely unclear whether these effects are mediated by direct modulation of autophagy or indirectly through associated mechanisms, including enhanced immune defense, attenuation of pathological inflammation, or crosstalk with other organelle functions. Additionally, multiple pathogens can evade host responses; thus, autophagy activation may inadvertently create favorable conditions for certain pathogens. This review discusses the current knowledge of natural products in terms of their antimicrobial actions through autophagy regulation, particularly the roles of distinct natural product classes, such as polyphenols, alkaloids, terpenoids, quinones, peptides, and macrolides in modulating autophagy for potentially contributing to control various infectious diseases. Exploring the intricate molecular interplay between natural products and autophagy in limiting infections may provide valuable insights that could inform the development of innovative host-directed antimicrobial treatments based on autophagy regulation.Abbreviations: 3-MA: 3-methyladenine; AM: alveolar macrophages; AMP: antimicrobial peptides; AMPK: 5' adenosine monophosphate-activated protein kinase; ARDS: acute respiratory distress syndrome; ART: artemisinin; ASFV: African swine fever virus; ATG: autophagy related; AZM: azithromycin; BafA1: bafilomycin A1; BECN1: beclin 1; BMDM: bone marrow-derived macrophage; BNIP3: BCL2 interacting protein 3; BNIP3L: BCL2 interacting protein 3 like; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CAMKK2: calcium/calmodulin-dependent protein kinase kinase 2; CBD: cannabidiol; CF: cystic fibrosis; CGA: chlorogenic acid; CGAS: cyclic GMP-AMP synthase; CHUK/IKKα: component of inhibitor of nuclear factor kappa B kinase complex; CLP: cecal ligation and puncture; CLR: clarithromycin; CMA: chaperone-mediated autophagy; CoV: coronavirus; DHT: dihydrotanshinone I; EGCG: epigallocatechin-3-gallate; EIF2A: eukaryotic translation initiation factor 2A; EIF2AK2: eukaryotic translation initiation factor 2 alpha kinase 2; ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.; ESRRA: estrogen related receptor alpha; FOXO1: forkhead box O1; FUNDC1: FUN14 domain containing 1; HBV: hepatitis B virus; HCV: hepatitis C virus; HDT: host-directed therapy; HIV: human immunodeficiency virus; HMGB1: high mobility group box 1; HSV: herpes simplex virus; IAV: influenza A virus; ICT: isocryptotanshinone; IFN: interferon; IKBKB/IKKβ: inhibitor of nuclear factor kappa B kinase subunit beta; IL: interleukin; INH: isoniazid; IRF3: IFN regulatory factor 3; KEAP1: kelch like ECH associated protein 1; LAMP: lysosomal associated membrane protein; LAP: LC3-associated phagocytosis; LPS: lipopolysaccharide; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPK: mitogen-activated protein kinase; MDM: monocyte-derived macrophage; MDR: multidrug-resistant; MON: monotropein; Mtb: Mycobacterium tuberculosis; MTOR: mechanistic target of rapamycin kinase; mtROS: mitochondrial ROS; NET: neutrophil extracellular trap; NFE2L2/Nrf2: NFE2 like bZIP transcription factor 2; NFKB/NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain containing 3; NLRX1: NLR family member X1; NOTCH1: notch receptor 1; NTM: nontuberculous mycobacteria; OMS: ohmyungsamycin; PAK1: p21 (RAC1) activated kinase 1; PINK1: PTEN induced kinase 1; PKM/PKM2: pyruvate kinase M1/2; PLD: phospholipase D; PM: peritoneal macrophage; PPM1A: protein phosphatase, Mg2+/Mn2+ dependent 1A; PRKN/parkin: parkin RBR E3 ubiquitin protein ligase; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; PTEN: phosphatase and tensin homolog; RB1CC1/FIP200: RB1 inducible coiled-coil 1; RELA/p65: RELA proto-oncogene, NF-kB subunit; RIF: rifampicin; ROS: reactive oxygen species; RSV: resveratrol; RUBCN/rubicon: rubicon autophagy regulator; SAR: selective autophagy receptor; SIRT: sirtuin; STING1: stimulator of interferon response cGAMP interactor 1; STX17: syntaxin 17; Tat: trans-activator of transcription; TB: tuberculosis; TBK1: TANK binding kinase 1; TFEB: transcription factor EB; TLR: toll like receptor; TNA: tanshinone IIA; TNF: tumor necrosis factor; UA: ursolic acid; ULK1/Atg1: unc-51 like autophagy activating kinase 1; UPR: unfolded protein response; UVRAG: UV radiation resistance associated; VAMP8: vesicle associated membrane protein 8; VDR: vitamin D receptor; WIPI2: WD repeat domain, phosphoinositide interacting 2; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1; ZIKV: Zika virus.},
}
@article {pmid42048372,
year = {2026},
author = {Braga, A and Fialho, SCAV and Martins, CAO and Duvivier, KM and Callado, GY and Araujo Júnior, E and de Rezende-Filho, J},
title = {Maternal vaccination in the immunization era: implementation, uptake, and emerging vaccines.},
journal = {Journal of perinatal medicine},
volume = {54},
number = {6},
pages = {962-973},
pmid = {42048372},
issn = {1619-3997},
mesh = {Humans ; Female ; Pregnancy ; *Vaccination/methods ; *Pregnancy Complications, Infectious/prevention &amp; control ; *Immunization Programs ; *Vaccines ; },
abstract = {Maternal immunization has ascended as a cornerstone of contemporary strategies aimed at safeguarding pregnant women, fetuses, and children in early childhood against vaccine-preventable diseases. The profound physiological and immunological adaptations inherent to gestation heighten maternal susceptibility to infectious morbidity, while several pathogens, including influenza, pertussis, COVID-19, rubella, and respiratory syncytial virus (RSV), pose significant risks of adverse maternal, fetal, and neonatal outcomes. Although an extensive body of evidence attests to the safety and effectiveness of maternal vaccines, global uptake among pregnant people remains markedly uneven and, in many settings, critically suboptimal. A nuanced understanding of national and international immunization programs, along with their structural and sociocultural challenges, is imperative to strengthen perinatal health protection. This narrative review synthesizes evidence drawn from peer-reviewed scientific literature, global health agency publications, and official national immunization guidelines. Extracted data were complemented by analyses of the immunological landscape of pregnancy, current vaccine recommendations, established safety profiles, and maternal immunization schedules across high-, middle-, and low-income countries. Particular emphasis was placed on the vaccines most consistently recommended during pregnancy, namely influenza, Tdap, COVID-19, and RSV, as well as on contextual determinants influencing vaccine hesitancy, access barriers, and global disparities in coverage.},
}
@article {pmid42048529,
year = {2026},
author = {Ventriglio, A and Torales, J and Castaldelli-Maia, JM and Caycho-Rodríguez, T and Hualparuca-Olivera, L and Bhugra, D},
title = {The past, present and future of Social Psychiatry.},
journal = {International review of psychiatry (Abingdon, England)},
volume = {38},
number = {1-3},
pages = {6-16},
doi = {10.1080/09540261.2025.2523454},
pmid = {42048529},
issn = {1369-1627},
mesh = {Humans ; *Community Psychiatry/trends/history ; *Models, Biopsychosocial ; History, 20th Century ; History, 21st Century ; *Social Determinants of Health ; COVID-19 ; *Mental Disorders/therapy ; },
abstract = {In psychiatry, tensions have often arisen between biological and social approaches, despite their interconnection. Social psychiatry has evolved alongside changing understandings of mental health and its ties to broader social and geopolitical determinants. Global factors such as economic inequality, migration, and social exclusion are increasingly recognized as key influences on mental health outcomes. Nonetheless, challenges like stigma, lack of access, and resource limitations persist. The Biopsychosocial Model remains central to social psychiatry, offering an integrated framework that considers biological, psychological, and social dimensions. This comprehensive perspective ensures that interventions target not only symptoms but also contextual factors contributing to mental illness. The future of social psychiatry will be shaped by heightened awareness of social determinants, particularly amid global crises like war or COVID-19. Consistent application of the biopsychosocial model in clinical settings is essential. Policy advocacy focused on housing, employment, and inclusive care-alongside cultural sensitivity and the use of digital tools-will be vital. Moreover, enhancing psychiatric education and fostering interdisciplinary collaboration will be key to addressing social determinants across all levels of mental health care.},
}
@article {pmid42048993,
year = {2026},
author = {Amiral, J and Seghatchian, J},
title = {An in-depth synthetic wrap on the immune-hemostatic axis in human disease.},
journal = {Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis},
volume = {65},
number = {3},
pages = {104441},
doi = {10.1016/j.transci.2026.104441},
pmid = {42048993},
issn = {1473-0502},
mesh = {Humans ; *COVID-19/immunology/blood ; *Hemostasis/immunology ; *SARS-CoV-2 ; Inflammation/immunology ; Renin-Angiotensin System/immunology ; },
abstract = {Human defense systems (immunity, inflammation, hemostasis, fibrinolysis, and the renin-angiotensin-aldosterone system) have co-evolved to provide multilayered protection against infections, trauma, malignancies, and metabolic disturbances. In humans, these systems reach exceptional regulatory sophistication and are coordinated through integrated immunological and hemostatic mechanisms forming the frontline of defense. While highly efficient under physiological conditions, these networks can become dysregulated when challenged by overwhelming pathological stimuli. The COVID-19 pandemic exemplified these vulnerabilities, revealing profound inter-individual variability in immune activation that shaped susceptibility, disease progression, and outcomes. Similar variability extends to autoimmune disorders, cancer, and neurodegenerative diseases, where immunity and hemostasis govern detection, response, and chronicity. Artificial-intelligence models now propose an "immunological age," reflecting cumulative immune behavior and predictive disease risk. Nevertheless, pathologies may escape immune-hemostatic control and become refractory to therapy, leading to severe complications or fatal outcomes, as emphasized previously. This review synthesizes current understanding of the molecular, cellular, and systemic interplays linking immunity, inflammation, hemostasis, fibrinolysis, and RAAS. We highlight how these interdependent pathways shape disease expression across infections, autoimmunity, sepsis, malignancy, and cardiometabolic syndromes. In addition, we examine emerging laboratory biomarkers, such as NETs, Annexin A1, micro-RNAs, sACE2, and procoagulant platelets, that now provide unprecedented insights into immunothrombosis and thrombo-inflammation. By integrating mechanistic biology with diagnostic innovation, this narrative presents a unified perspective on immune-hemostatic interactions and outlines how these insights may reshape therapeutic strategies and precision medicine.},
}
@article {pmid42049130,
year = {2026},
author = {de la Mota, S and Suchet, L and van Wijk, M and Stibbs, DJ and Silva Couto, P and Rafiq, QA},
title = {On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors.},
journal = {Biotechnology advances},
volume = {90},
number = {},
pages = {108907},
doi = {10.1016/j.biotechadv.2026.108907},
pmid = {42049130},
issn = {1873-1899},
mesh = {Humans ; *Immunotherapy, Adoptive/methods ; *Genetic Vectors/genetics ; *Receptors, Chimeric Antigen/genetics/immunology/therapeutic use ; Animals ; Genetic Therapy/methods ; Nanoparticles ; Gene Transfer Techniques ; Viruses/genetics ; Lentivirus/genetics ; },
abstract = {Chimeric antigen receptor (CAR)-T-cell therapies have demonstrated substantial efficacy in haematological malignancies, with multiple products approved for clinical use. However, broader application remains limited by severe toxicities, reduced efficacy toward solid tumours, and the high cost and complexity of ex vivo manufacturing. The autologous nature of most current therapies contributes to variable product quality, lengthy vein-to-vein times, and restricted patient access. In vivo CAR-T therapy has emerged as a potential solution, aiming to generate functional CAR-T-cells within the patient, with several platforms progressing into early Phase I clinical trials. This approach eliminates reliance on patient-derived starting material, reduces manufacturing failure rates, and offers the prospect of off-the-shelf availability at lower cost. Central to in vivo CAR-T development is selecting an appropriate gene delivery platform. Viral vectors, including lentiviral, adenoviral, and adeno-associated viral systems, have an established role in ex vivo CAR-T manufacturing and in vivo gene therapies. Non-viral vectors, such as lipid nanoparticles (LNP) and polyplexes, have garnered increasing attention due to their high packaging capacity, potential for redosing, and validation in large-scale production, as exemplified by mRNA-LNP vaccines against COVID-19. Recently, the in vivo CAR-T engineering toolbox has expanded with DNA-based LNP platforms capable of stably integrating CAR transgenes via transposon systems, fourth-generation T-cell-targeted lentiviral systems that minimise CAR display on vector particles and aberrant splicing, and emerging genome-editing technologies. This review compares viral and non-viral vectors for in vivo CAR-T therapy, evaluating their relative advantages and limitations in terms of safety, efficacy, scalability, analytical methods, regulatory implementation and commercial feasibility.},
}
@article {pmid42050447,
year = {2026},
author = {El-Saed, A and Al-Fayez, S and AlAmeer, K and Zunitan, MA and Othman, F and Farahat, F and Fletcher, T and Okwor, T and Mahamed, H and Hurwitz, HH and Willet, V and Alshamrani, MM and Baller, A},
title = {Secondary attack rates after mpox exposure in multiple settings during the 2022-2024 pandemic: a systematic review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {42050447},
issn = {1471-2334},
mesh = {Humans ; *SARS-CoV-2/genetics ; *COVID-19/epidemiology/transmission/virology ; *Pandemics ; },
abstract = {BACKGROUND: Estimating secondary attack rates is essential for assessing the spread potential of mpox during an outbreak. The objective of the study was to assess secondary attack rates after mpox exposure in multiple settings worldwide.<br><br>METHODS: A systematic review was conducted for studies published between May 2022 and September 2024 and reporting mpox exposure data. The levels and types of exposure were defined as per the study description.<br><br>RESULTS: A total of 62 studies including 8712 mpox exposures were included. Out of 8712 exposures, 239 were associated with mpox infection (secondary attack rate of 2.74%). The rates were highest in household setting (4.02%), intermediate in congregate/community setting (2.50%), and lowest in healthcare setting (0.81%). The rates were highest in the African region (8.00%), intermediate in the European region (4.23%), and lowest in the American region (1.10%). Clade data were available in 17 (27.42%) studies; mainly clade IIb (15 studies) and to less extent clades Ia and Ib (one study each). Secondary attack rates were higher among individuals reporting sexual contact (11.35%) compared with non-sexual contact (1.34%, p&#x2009;<&#x2009;0.001). Non-sexual contact exposures (83.17%) were more frequent (p&#x2009;<&#x2009;0.001) than sexual contact exposures (13.66%, p&#x2009;<&#x2009;0.001).<br><br>CONCLUSIONS: The overall mpox secondary attack rate in the published data from the 2022-2024 multi-country outbreak is relatively low (<&#x2009;3%). While exposures involving non-sexual contact were more prevalent in all settings, sexual contact was responsible for the majority of secondary infections in household and congregate/community settings. The findings may guide mpox preventive and control activities in different settings.<br><br>CLINICAL TRIAL: Not applicable.},
}
@article {pmid42050591,
year = {2026},
author = {Tan, E and Loveys, K and Ali, W and McKinlay, CJD and Dalziel, SR},
title = {Digital tools for recruitment and retention of participants in paediatric clinical research: a scoping review.},
journal = {Trials},
volume = {27},
number = {1},
pages = {},
pmid = {42050591},
issn = {1745-6215},
support = {19/003//Health Research Council of New Zealand/ ; 17/614//Health Research Council of New Zealand/ ; },
mesh = {Adolescent ; Child ; Child, Preschool ; Humans ; Biomedical Research/methods ; COVID-19/epidemiology ; *Digital Health ; *Digital Media ; Pandemics ; *Patient Selection ; *Pediatrics/methods ; SARS-CoV-2 ; Social Media ; *Clinical Trials as Topic ; },
abstract = {BACKGROUND: Digital tools are increasingly used to support recruitment and retention of participants in paediatric research, particularly since the COVID-19 pandemic. However, the extent of the evidence supporting this method in paediatric populations has yet to be evaluated. This scoping review aimed to review the literature on digital tools for recruitment and/or retention of participants in paediatric research, including emerging evidence following the pandemic.<br><br>METHODS: A scoping review was conducted following Joanna Briggs Institute methodology. We included peer-reviewed quantitative, qualitative, and mixed-method studies evaluating a digital tool for recruitment or retention in paediatric research in any patient population aged <13 years. Records were identified from systematic database searches with a librarian (EMBASE, MEDLINE, CINAHL), limited to English, from 2013 onwards (last search 03/07/2024), and manual searches. Records were screened and extracted independently in duplicate. The data were charted and narratively summarised.<br><br>RESULTS: Sixty-one out of 4988 records were included. Most evaluations used an observational design; only 5 (8%) involved a randomised experiment. The host studies were mostly aiming to recruit children aged 5-12 years (n&#x2009;=&#x2009;42; 69%), with a predominantly health promotion (n&#x2009;=&#x2009;18; 30%), developmental (n&#x2009;=&#x2009;12; 20%), or oncology (n&#x2009;=&#x2009;9; 15%) focus. Most studies used multi-component digital interventions for recruitment (n&#x2009;=&#x2009;39/53; 74%) or retention (n&#x2009;=&#x2009;17/31; 55%). Social media (n&#x2009;=&#x2009;33/52; 62%) and websites (n&#x2009;=&#x2009;19/53; 36%) were most commonly used for recruitment, whereas text/instant messaging (n&#x2009;=&#x2009;17/31; 55%) and email (n&#x2009;=&#x2009;11/31; 36%) were the most common retention strategies. The estimates of recruitment and retention rates, and reach per digital tool varied widely between studies. Strategies in underserved populations reflected those used most commonly overall. Multi-component digital strategies were found to support a high rate of retention (84.1-90.7%) during pandemic restrictions.<br><br>CONCLUSIONS: This scoping review highlights the broad array of digital tools that have been used to support recruitment and retention in studies of infants and children, including in subgroups of underserved populations and in response to the COVID-19 pandemic. Most evaluations were observational and examined&#xa0;multi-component digital interventions. The lack of studies with a robust analytical design in the literature signals a need for further high-quality, randomised, within-study evaluations following standardised reporting criteria.<br><br>REGISTRATION: The protocol was registered on the Open Science Framework (OSF) at https://osf.io/ybfhr/ . Registered on&#xa0;July 5 2024.},
}
@article {pmid42051502,
year = {2026},
author = {Huang, S and Zhang, X and Luo, W and Yao, Y and Hu, J and Wang, X and Xin, H},
title = {Drugs against broad-spectrum of coronaviruses.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1728474},
pmid = {42051502},
issn = {1664-3224},
mesh = {Humans ; *Antiviral Agents/therapeutic use/pharmacology ; *SARS-CoV-2/drug effects ; *COVID-19 Drug Treatment ; Medicine, Chinese Traditional ; Animals ; Coronavirus/drug effects ; COVID-19/virology ; },
abstract = {The continuous emergence of severe acute respiratory type 2 coronavirus (SARS-CoV-2) variants (e.g., Omicron) and the threat of future emerging coronavirus pandemics highlight the urgent need for broad-spectrum antiviral strategies. While various therapeutics exist, a systematic integration of diverse treatment modalities remains lacking. This review introduces a comprehensive conceptual framework that compares and integrates four major therapeutic categories: small-molecule drugs (targeting viral enzymes), macromolecular drugs (including peptides and polymers), Traditional Chinese Medicine (TCM, focusing on holistic regulation and active ingredients), and carrier vector vaccines. Beyond traditional pharmacology, we further incorporate the emerging role of Artificial Intelligence (AI) and computational screening in accelerating the discovery of broad-spectrum inhibitors. The primary goal of this article is to: (1) critically analyze the distinct antiviral mechanisms, advantages, and limitations of each category; (2) explore synergistic combination therapies (e.g., combining antiviral drugs with immunomodulators or TCM) to overcome drug resistance; and (3) provide a strategic reference for developing "pan-coronavirus" therapeutics that are resilient against viral mutations.},
}
@article {pmid42051540,
year = {2026},
author = {Jin, H and An, Y and Huang, J and Luo, T and Wu, X},
title = {Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1774310},
pmid = {42051540},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications/metabolism ; Post-Acute COVID-19 Syndrome ; Mitochondria/metabolism ; *Fatigue Syndrome, Chronic/immunology/physiopathology/metabolism ; *SARS-CoV-2/immunology ; Neuroimmunomodulation ; Animals ; Exercise ; Reactive Oxygen Species/metabolism ; Energy Metabolism ; },
abstract = {Post-exertional malaise (PEM) is a common core symptom in various chronic debilitating conditions, such as Post COVID-19 Condition (PCC, also known as Long COVID) and Chronic Fatigue Syndrome (CFS). It is characterized by the delayed and persistent exacerbation of symptoms following even mild physical or cognitive activities. This review presents a systematic review of the pathophysiological mechanisms involved in PEM, proposing a dynamic framework of multi-system interactions that may lead to homeostatic imbalance. The etiology of PEM is multifactorial, potentially involving factors such as the persistent presence of pathogens, exposure to environmental toxins, and genetic predisposition. Collectively, these factors may establish a vulnerable baseline that heightens the body's physiological response to stressors, such as exercise, potentially triggering a pathological reaction. First, mitochondrial dysfunction and metabolic abnormalities may act as potential initiating factors in PEM, manifesting as impaired ATP synthesis, overproduction of reactive oxygen species (ROS), and the accumulation of metabolic byproducts. It is crucial to emphasize that exercise itself induces a 'toxic excitatory effect,' whereby healthy individuals enhance mitochondrial function and antioxidant defenses through physical activity. However, in individuals predisposed to PEM, due to underlying pathological conditions (e.g., sequelae of viral infections), this adaptive process is disrupted, preventing effective restoration of mitochondrial homeostasis and may initiate a potential vicious cycle of dysfunction. Second, ROS and mitochondrial DNA (mtDNA), as damage-associated molecular patterns (DAMPs), along with pathogen-associated molecular patterns (PAMPs), may activate the NLRP3 inflammasome and induce the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, potentially transforming localized metabolic stress into a systemic inflammatory response. Subsequently, peripheral inflammation may be transmitted to the central nervous system through disruption of the blood-brain barrier and vagal nerve pathways, activating glial cells and initiating neuroinflammation. This process may ultimately affect the brain's interoceptive network, particularly the insular cortex, resulting in altered perception and processing of signals related to fatigue and pain. Furthermore, mitochondrial dysfunction in neurons may contribute to central energy depletion, which may impair synaptic plasticity and induce cognitive deficits and brain fatigue. Ultimately, this review proposes that PEM may arise from a complex interplay among mitochondrial dysfunction, immune activation, and neuroinflammation, which together form a self-perpetuating loop of "energy exhaustion - inflammation amplification," potentially contributing to the chronic and multi-system nature of PEM symptoms. The integrated "metabolism-immune-neuro" interaction model presented in this article may provide a potential comprehensive framework for understanding PEM and highlights the need for a multi-target, collaborative intervention approach that may help disrupt the pathological cycle.},
}
@article {pmid42051939,
year = {2026},
author = {do Nascimento, BB and Silva, BGB and de Souza, LA and Andrade, JCBN and de Sá Del Fiol, F},
title = {From Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID-19 Pandemic-A Systematic Review and Meta-Analysis.},
journal = {International journal of microbiology},
volume = {2026},
number = {},
pages = {8643896},
pmid = {42051939},
issn = {1687-918X},
abstract = {OBJECTIVES: We are aimed at evaluating whether the widespread use of azithromycin during the COVID-19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta-analysis.<br><br>METHODS: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID-19 pandemic were identified. Odds ratios (ORs) were pooled using a random-effects model. Methodological quality was assessed using the Newcastle-Ottawa scale.<br><br>RESULTS: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta-analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04-3.59). Substantial heterogeneity was observed (I [2] = 73.5%), justifying the use of a random-effects model.<br><br>CONCLUSIONS: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID-19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.},
}
@article {pmid42051949,
year = {2026},
author = {Mugundan, UM and Saravanan, V and Rajanandh, MG},
title = {Could excessive zinc supplementation during pregnancy cause menkes disease? A hypothesis worth investigating.},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1734361},
pmid = {42051949},
issn = {2296-2360},
abstract = {BACKGROUND: Copper is an essential micronutrient critical for fetal neurodevelopment, haematopoiesis, angiogenesis, and immune function, with maternal transfer-particularly in the third trimester-playing a key role in establishing fetal copper stores. Disruption of this process, due to genetic defects or micronutrient imbalance, can lead to significant neonatal complications.<br><br>OBJECTIVE: This review examines the potential role of excessive maternal zinc supplementation as an underrecognized environmental modifier in Menkes disease (MD), an X-linked disorder caused by mutations in the ATP7A copper transporter. We hypothesize that in fetuses with ATP7A dysfunction, elevated maternal zinc intake may further impair copper absorption and placental transfer through competitive antagonism, thereby exacerbating fetal copper deficiency and influencing disease severity or onset.<br><br>EVIDENCE: Limited clinical data in pregnant women demonstrate that zinc supplementation can reduce maternal and fetal copper levels, supported by consistent findings from animal models and case reports indicating disrupted copper homeostasis. However, no large-scale or disease-specific studies have evaluated this interaction in relation to Menkes disease or neonatal outcomes.<br><br>CONCLUSION: Given the widespread use of zinc supplementation, particularly during the COVID-19 era, its impact on fetal copper status in genetically susceptible populations warrants urgent investigation. Targeted retrospective analyses and well-designed prospective studies are needed to validate this hypothesis. A re-evaluation of prenatal micronutrient strategies with emphasis on trace element balance may improve risk stratification and optimize maternal-fetal health outcomes.},
}
@article {pmid42052276,
year = {2026},
author = {Han, S and Qin, T and Feng, Z},
title = {Artificial intelligence and synthetic biology in traditional Chinese medicine: revolutionizing public health applications.},
journal = {Frontiers in plant science},
volume = {17},
number = {},
pages = {1789960},
pmid = {42052276},
issn = {1664-462X},
abstract = {Traditional Chinese Medicine (TCM) has played a vital role in public health throughout history, particularly evidenced during the COVID-19 pandemic, where it demonstrated both accessibility and clinical efficacy. However, TCM faces critical challenges, including unsustainable medicinal resources, ambiguous multi-target mechanisms, and a lack of standardized clinical evaluation systems. Addressing these issues requires interdisciplinary integration, particularly between synthetic biology and artificial intelligence (AI). Synthetic biology offers solutions to resource scarcity and production standardization by enabling the sustainable biosynthesis of active compounds. Meanwhile, AI enhances TCM research through bioinformatics-driven compound prediction, machine learning-assisted quality control, and network pharmacology-based mechanism elucidation. AI also improves diagnostic reproducibility, aligning with synthetic biology's precision-driven framework. Together, these technologies facilitate the transformation of TCM from an experience-based practice into a standardized, evidence-based public health intervention. This review highlights the synergistic potential of AI and synthetic biology in overcoming TCM's modernization barriers. By leveraging AI for data-driven drug discovery and synthetic biology for scalable production, TCM can achieve sustainable development while retaining its therapeutic value. Future efforts should focus on enhancing AI interpretability, expanding biological databases, and optimizing cross-disciplinary collaboration to fully realize this integration.},
}
@article {pmid42052932,
year = {2024},
author = {Williams, TR and Bass, JE and Swain, M and Jennings, D and Wyatt, WN and Foster, S},
title = {Unpacking the stress of 2020: Black Americans cope with systemic trauma.},
journal = {Clinical psychology &amp; psychotherapy},
volume = {31},
number = {1},
pages = {e2944},
doi = {10.1002/cpp.2944},
pmid = {42052932},
issn = {1099-0879},
support = {//American Association of University Women/ ; },
mesh = {Humans ; *Black or African American/psychology ; *COVID-19/psychology/ethnology ; United States ; *Adaptation, Psychological ; *Psychological Trauma/psychology/ethnology/therapy ; *Stress, Psychological/psychology/ethnology ; Racism/psychology ; Grief ; Posttraumatic Growth, Psychological ; },
abstract = {The year 2020 was a challenging and traumatic year for Americans, especially Black Americans. Many Black people quickly succumbed to Coronavirus Disease 2019 (COVID-19). This paper describes systemic trauma as a lens to conceptualize the effects of COVID-19, racial stress and trauma, and grief. A recount of the events during the year 2020 is reviewed. Racism towards Black people was at an all-time high. Complicated and collective grief was ever-present. As a by-product of COVID-19, economic and health disparities resurfaced to further complicate Black people's well-being. Systemic trauma is described as a comprehensive and inclusive framework that captures the intensity and depth of the trauma Black Americans experienced. We argue that culturally appropriate interventions are needed to help Black people continue to heal from the distress of 2020. Race-informed trauma treatment is a culturally appropriate intervention that facilitates healing, improves the quality of life, and fosters posttraumatic growth for Black Americans. We offer race-informed treatment as a theoretical orientation that can facilitate healing and posttraumatic growth for Black people.},
}
@article {pmid42053299,
year = {2026},
author = {Darko, E and Akortia, D and Nkrumah, G and Opoku Agyapong, F and Twumasi-Ankrah, S and Owusu-Ansah, M and Glazik, R and Shaw, A and Grassly, N and Owusu-Dabo, E and Adu-Sarkodie, Y and Owusu, M},
title = {Environmental surveillance of pathogens in Africa.},
journal = {Applied and environmental microbiology},
volume = {92},
number = {5},
pages = {e0193225},
pmid = {42053299},
issn = {1098-5336},
support = {INV-INV-076273//Bill and Melinda Gates Foundation/ ; },
mesh = {Africa/epidemiology ; *Environmental Monitoring/methods ; Viruses/isolation &amp; purification ; Bacteria/isolation &amp; purification ; Humans ; Fungi/isolation &amp; purification ; },
abstract = {The control of infectious diseases depends on effective diagnostics and interventions. In Africa, resource limitations hinder clinical surveillance. Environmental surveillance (ES), particularly wastewater surveillance, offers a cost-effective alternative. While globally expanding, its application in Africa remains limited. This review aimed to describe published studies in Africa that have utilized ES for the detection of infectious pathogens of public health importance in Africa. The study employed a rapid review approach to synthesize evidence on ES of infectious pathogens in Africa, following guidance from the Cochrane Rapid Reviews Methods. Articles from major databases, including Scopus, PubMed, Science Direct, and Cochrane, were screened using Catchii.org. Duplicates were removed, and data were extracted into Excel, and study quality was appraised using the AXIS tool and a modified Newcastle-Ottawa Scale. The search strategy identified 2,189 articles, of which 90 were found to be eligible. We identified 47 microbial species that have been reported across studies. These consisted of 46.8% bacteria (n = 22), 36.2% viruses (n = 17), 4.3% fungi (n = 2), and 12.7% parasites (n = 6). Among viruses identified, SARS-CoV-2 was the most common, followed by rotaviruses and polioviruses. Vibrio cholerae was mostly reported among bacterial pathogens. The most common sampling method was grab sampling (n = 85, 94.4%), while two-phase separation (n = 22, 37.3%) and filtration (n = 11, 39.3%) were the most frequently used concentration methods for viral and bacterial detection, respectively. ES of infectious pathogens in Africa remains limited. There is a need to expand this to enhance pathogen monitoring, transmission insights, and preparedness for emerging variants.},
}
@article {pmid42053373,
year = {2026},
author = {Pfannschmidt, V and Röhren, F and Stollenwerk, A and Leonhardt, S},
title = {A systematic review of pandemic ventilator designs.},
journal = {Biomedizinische Technik. Biomedical engineering},
volume = {},
number = {},
pages = {},
pmid = {42053373},
issn = {1862-278X},
abstract = {This paper presents a systematic literature research and review of ventilator systems developed during the COVID-19 pandemic. Peer-reviewed journal and conference articles published through January 16th, 2025 were screened, and eligible systems were classified by actuation principle. Performance criteria were derived from Emergency Use Authorization requirements and used to generate a score-based ranking for each class. Performance was analyzed within and across classes to identify the situations in which each actuation principle is most advantageous. As an indicator of study quality, we evaluated the testing modalities reported for each device. Valve-based ventilators emerged as the most mature class in terms of ventilation functionality and testing. An emerging class of bag-based systems performed remarkably well compared with established valve- and blower-based designs. Across all three classes, the most frequent shortcomings concerned oxygen dosage of the inspired gas and the implementation of monitoring and alarm functions. Finally, we provide recommendations on development processes, testing procedures, and mitigation of supply-chain vulnerabilities that may support ventilator development in future pandemics.},
}
@article {pmid42053725,
year = {2026},
author = {Ardizzone, A and Agoy, CA and Carota, G and Altruda, I and Erba, I and Del Re, M and Esposito, E and Caruso, G},
title = {Assessing the Risk of Myocarditis Post-COVID-19 Vaccination: A Systematic Review of Case Reports from 2023 to 2025.},
journal = {Cardiovascular toxicology},
volume = {26},
number = {5},
pages = {},
pmid = {42053725},
issn = {1559-0259},
mesh = {Humans ; *Myocarditis/chemically induced/therapy/diagnosis/epidemiology ; *COVID-19 Vaccines/adverse effects ; Male ; Adolescent ; Risk Factors ; Risk Assessment ; Young Adult ; Female ; *Vaccination/adverse effects ; *COVID-19/prevention &amp; control ; Child ; Adult ; Case Reports as Topic ; Middle Aged ; },
abstract = {COVID-19 vaccines covered a crucial role in mitigating the pandemic; however, rare adverse events such as myocarditis continue to raise safety concerns. This systematic review evaluated whether the clinical profile and outcomes of COVID-19 vaccine–associated myocarditis (CVAM) have changed in the post-2022 era. Following PRISMA guidelines, case reports published between 2023 and 2025 were identified through Web of Science, Embase, and PubMed (MEDLINE). Twenty-eight articles describing 35 patients were included. CVAM predominantly affected males, with the highest frequency among adolescents aged 10–19 years, and most cases occurred after the second vaccine dose, typically within two weeks. Chest pain was the most common presenting symptom, followed by tachycardia, fever, and dyspnea. Elevated cardiac biomarkers, electrocardiographic abnormalities, and myocardial edema on cardiac magnetic resonance imaging were frequently observed, with reduced left ventricular ejection fraction in a subset of patients. Management ranged from nonsteroidal anti-inflammatory drugs and colchicine to immunosuppressive therapy and mechanical circulatory support in severe cases. Although many patients experienced clinical improvement, fatal cases were documented, and follow-up revealed persistent late gadolinium enhancement and recurrent arrhythmias in several individuals, indicating incomplete myocardial recovery. Unlike earlier reviews reporting largely mild and self-limiting disease, this 2023–2025 case series documents fatal outcomes, persistent myocardial fibrosis, and recurrent arrhythmias, suggesting that CVAM may lead to long-term cardiac sequelae in a subset of patient. These findings indicate that contemporary clinical spectrum of CVAM may be broader and more severe than previously recognized, underscoring the need for prolonged surveillance and updated management strategies.},
}
@article {pmid42054706,
year = {2026},
author = {Vilaseca, A and Toledano, M and Flanagan, EP},
title = {Complexities in evaluation and management of infectious myelopathies.},
journal = {Current opinion in infectious diseases},
volume = {39},
number = {3},
pages = {227-239},
doi = {10.1097/QCO.0000000000001204},
pmid = {42054706},
issn = {1473-6527},
mesh = {Humans ; Myelitis/diagnosis/virology ; *COVID-19/complications/epidemiology ; *Spinal Cord Diseases/diagnosis/virology ; SARS-CoV-2 ; Magnetic Resonance Imaging ; Neuromuscular Diseases ; Central Nervous System Viral Diseases ; },
abstract = {PURPOSE OF REVIEW: To review recent advances in infectious myelopathies and integrate them into a practical, syndrome-based approach that supports early recognition, guides testing, and avoids pitfalls.<br><br>RECENT FINDINGS: Advances in MRI pattern recognition and pathogen-specific diagnostics have refined the evaluation of infectious myelopathies, with strategies tailored to geographic epidemiology, host susceptibility, and distinction from immune-mediated causes. During the COVID-19 pandemic, SARS-CoV-2-associated myelopathy emerged as a rare para- or postinfectious cause of myelitis. The pandemic coincided with a decline in enterovirus outbreaks and acute flaccid myelitis, which are now re-emerging, underscoring the importance of epidemiologic surveillance. Metagenomic next-generation sequencing is useful in suspected infectious myelopathy because it can identify unexpected pathogens from cerebrospinal fluid, but its imperfect sensitivity and contamination risk mean it should complement rather than replace conventional testing. Growing recognition of compartmentalized central nervous system inflammation and cerebrospinal fluid viral escape in HIV myelopathy has shifted management toward antiretroviral resistance patterns and treatment optimization. Therapeutic advances remain limited and largely pathogen-specific, although targeted approaches such as mogamulizumab for HTLV-1-associated myelopathy are promising.<br><br>SUMMARY: Recent progress in infectious myelopathies has been driven by improved pathogen detection and more tailored diagnostic strategies, although treatment advances are beginning to emerge.},
}
@article {pmid42055480,
year = {2026},
author = {Lu, X and Shi, Y and Chen, L and Jiang, X and Wang, Z and Tu, Y},
title = {Recombinant human interleukin-7 for patients with infection-associated lymphopenia: a systematic review and meta-analysis.},
journal = {Respiratory medicine},
volume = {257},
number = {},
pages = {108858},
doi = {10.1016/j.rmed.2026.108858},
pmid = {42055480},
issn = {1532-3064},
mesh = {Humans ; *Interleukin-7/therapeutic use ; *Lymphopenia/drug therapy/etiology/mortality ; *COVID-19/complications/mortality ; *Sepsis/complications ; Recombinant Proteins/therapeutic use ; Lymphocyte Count ; Randomized Controlled Trials as Topic ; Length of Stay ; SARS-CoV-2 ; Intensive Care Units ; *COVID-19 Drug Treatment ; },
abstract = {PURPOSE: This study aims to evaluate the efficacy of recombinant human interleukin-7 (rhIL-7) in treating lymphopenia and related clinical outcomes in patients with infection-associated lymphopenia through a meta-analysis.<br><br>METHODS: A Literature retrieval was conducted across databases, including the Cochrane Library, Web of Science, PubMed, Embase, SinoMed, CNKI, Wanfang, and VIP from the inception until October 2025. Randomized controlled trials of rhIL-7 for the treatment of lymphopenia were screened and identified for eligibility. Primary outcomes included absolute lymphocyte counts (ALC), mortality, intensive care unit (ICU) length of stay, and incidence of secondary infections.<br><br>RESULTS: Four studies were included, covering sepsis and COVID-19. In septic patients, rhIL-7 significantly increased ALC (MD&#x202f;=&#x202f;1.33&#x202f;at 3 weeks; 95% CI [0.29, 2.38]; MD&#x202f;=&#x202f;1.14&#x202f;at 4 weeks; 95% CI [0.02, 2.25]), CD4[+] T-cell counts (MD&#x202f;=&#x202f;0.56&#x202f;at 3 weeks; 95% CI [0.08, 1.05]) and CD8[+] T-cell counts (MD&#x202f;=&#x202f;0.40&#x202f;at 2 weeks; 95% CI [0.05, 0.76]). However, rhIL-7 failed to reduce mortality (RR&#x202f;=&#x202f;1.01; 95% CI [0.36, 2.81]) or the incidence of secondary infections (RR&#x202f;=&#x202f;1.05; 95% CI [0.48, 2.30]) in patients with sepsis. In patients with COVID-19, rhIL-7 did not significantly increase ALC at 30 days (MD&#x202f;=&#x202f;0.46; 95% CI [-0.15, 1.08]) or reduce mortality (RR&#x202f;=&#x202f;0.85; 95% CI [0.55, 1.33]), but it did significantly reduce the incidence of secondary infections (RR&#x202f;=&#x202f;0.58; 95% CI [0.46, 0.74]; p&#x202f;<&#x202f;0.0001). A combined analysis revealed that rhIL-7 significantly increased ALC (MD&#x202f;=&#x202f;1.15&#x202f;at 3 weeks; 95% CI [0.47, 1.84]; MD&#x202f;=&#x202f;0.80&#x202f;at 4 weeks; 95% CI [0.24, 1.36]) and reduced the risk of secondary infections (RR&#x202f;=&#x202f;0.64; 95% CI [0.50, 0.81]), but had no effect on mortality or ICU length of stay.<br><br>CONCLUSION: RhIL-7 effectively ameliorates sepsis-associated lymphopenia but does not improve prognosis. Although rhIL-7 reduces the incidence of secondary infections in COVID-19 patients, confounding factors related to the pandemic context must be taken into account.},
}
@article {pmid42055829,
year = {2026},
author = {Shammout, M and Abdullah, J and Shammout, A and Williams, R and Mcmillan, K},
title = {A call for fixed standards: a decade of orthognathic surgery, biting into revision rates and metalwork removal.},
journal = {The British journal of oral &amp; maxillofacial surgery},
volume = {64},
number = {6},
pages = {457-463},
doi = {10.1016/j.bjoms.2026.03.011},
pmid = {42055829},
issn = {1532-1940},
mesh = {Humans ; *Hardware Removal/statistics &amp; numerical data ; *Bone Plates ; *Orthognathic Surgical Procedures/instrumentation/standards ; Retrospective Studies ; *Reoperation/statistics &amp; numerical data ; Female ; Male ; Titanium ; Adult ; *Device Removal/statistics &amp; numerical data ; Benchmarking ; },
abstract = {The removal rate of titanium miniplates following orthognathic surgery varies widely (3.2-27.5%) due to inconsistent study designs and mixed samples. Plate removal is not routinely conducted in the UK. A 2019-2020 meta-analysis reported a 13.4% removal rate, though regular audits are uncommon. This study evaluates whether audit of local plate removal rates against established benchmarks merits encouragement. A retrospective review was conducted of orthognathic surgery at a tertiary centre (2014-2024). Procedures included Le Fort osteotomy, bilateral sagittal split osteotomy (BSSO), bimaxillary osteotomy (BIMAX), genioplasty, and other mandibular osteotomies. All patients received two postoperative doses of dexamethasone and intravenous antibiotics. Data collected included demographics, smoking status, surgical site, re-plating, and antibiotic use. The primary outcome was return to theatre (RTT) for plate removal or replacement. Chi squared, Fisher's exact, and binomial tests were used to assess statistical significance. Over 10 years, 417 patients underwent 429 orthognathic procedures, including 12 revisions to achieve the desired skeletal and orthodontic outcome. Overall, metalwork removal/adjustment occurred in 46 cases, predominantly within the first year, with infection identified as the leading cause. The removal rate was 10.7% (46/429), consistent with the 13.4% benchmark (p = 0.12). Yearly rates generally aligned with the benchmark, except in 2021, when deviations were likely to have been influenced by COVID-19-related disruptions. Smoking (p = 1.0) and oral antibiotics on discharge (p = 0.09) were not significantly associated with plate removal rates. These findings validate the 13.4% benchmark for metalwork removal. Routine audit and inter-unit collaboration are vital for refining benchmarks and improving patient care.},
}
@article {pmid42056917,
year = {2026},
author = {Bergqvist, E and Valerio-Shewmaker, M and Swartz, M and Patel, J and Padilla, L and Amavisca, XF and Gandhi, H and Messiah, SE},
title = {Association of race, ethnicity, and pediatric long COVID and MIS-C: a systematic review and meta-analysis.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {42056917},
issn = {1471-2334},
mesh = {Humans ; *COVID-19/ethnology/epidemiology/complications ; Post-Acute COVID-19 Syndrome ; Child ; *Systemic Inflammatory Response Syndrome/ethnology/epidemiology ; SARS-CoV-2 ; *Ethnicity/statistics &amp; numerical data ; Socioeconomic Disparities in Health ; *Racial Groups ; White ; },
abstract = {BACKGROUND: Pediatric long COVID and other post-COVID conditions, particularly in relation to racial, ethnic, and household social determinants, are not yet well understood. This study aims to synthesize evidence on racial and ethnic disparities in pediatric long COVID and related conditions like MIS-C.<br><br>METHODS: A systematic review and meta-analysis were performed on studies reporting post-COVID conditions and outcomes by race and ethnicity. Studies were identified through comprehensive database searches, screened for relevance, and assessed for quality. Data on race, ethnicity, and social determinants were extracted and analyzed using random-effects models to estimate pooled odds ratios. Sensitivity analyses were performed to address potential publication bias.<br><br>RESULTS: Non-Hispanic Black children had significantly higher odds of ICU admission (OR 1.89, 95% CI 1.01-3.28), MIS-C development (OR 2.37, 95% CI 1.43-3.90), and PIMS-TS (OR 16.28, 95% CI 9.24-28.70) compared to Non-Hispanic White children. Although Hispanic children showed a protective effect against severe MIS-C (OR 0.77, 95% CI 0.64-0.93), their MIS-C incidence remained higher (OR 2.70, 95% CI 1.10-6.65). Elevated risks of MIS-C death were observed for Asian/Pacific Islander (OR 6.79, 95% CI 1.2-38.52) and Alaskan Indian/Native American children (OR 4.07, 95% CI 3.4-44.53). Additionally, Asian children had increased odds of PIMS-TS (OR 6.42, 95% CI 2.70-15.27), while groups labeled as 'Other' were at higher odds for both PIMS-TS (OR 9.75, 95% CI 3.04-31.30) and MIS-C (OR 2.36, 95% CI 1.18-4.71).<br><br>CONCLUSIONS: Significant racial and ethnic disparities in pediatric long COVID, and MIS-C outcomes emphasize the need for targeted interventions addressing social and healthcare inequities.<br><br>CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid42057724,
year = {2026},
author = {Hay, JA and Larremore, DB and Aatresh, AV and Kissler, S},
title = {Integrating viral kinetics into routine outbreak surveillance: challenges, opportunities and lessons from COVID-19.},
journal = {Philosophical transactions of the Royal Society of London. Series B, Biological sciences},
volume = {381},
number = {1949},
pages = {},
doi = {10.1098/rstb.2024.0347},
pmid = {42057724},
issn = {1471-2970},
support = {//National Science Foundation/ ; /WT_/Wellcome Trust/United Kingdom ; },
mesh = {*COVID-19/virology/epidemiology ; Humans ; *SARS-CoV-2/physiology ; Pandemics ; Kinetics ; },
abstract = {Viral kinetics provide crucial insights into the biology and epidemiology of infections, with direct implications for basic science, therapeutics development and policy. The COVID-19 pandemic showcased the power of viral kinetics surveillance and modelling; however, our understanding of viral kinetics has been limited to retrospective analyses, convenience samples and bespoke models. To strengthen responses to ongoing and emerging outbreaks, we argue that viral kinetics should be a core component of pathogen surveillance. Building upon insights gained during the COVID-19 pandemic, we review ways that continuous viral kinetic surveillance supports infectious disease response by informing epidemiological parameters, development and deployment of therapeutics, and adaptive policy design. To achieve this, various challenges must be addressed regarding data standards, study design and communication. We advocate for the creation of a global, living library of viral kinetics data, with associated data sharing standards, modelling toolkits and on-demand epidemiological reports. Successfully integrating viral kinetics into active disease surveillance efforts will support both active outbreak response and improve the knowledge base vital for pandemic preparedness. This article is part of the Theo Murphy meeting issue 'Evaluating anti-infective drugs'.},
}
@article {pmid42057741,
year = {2026},
author = {Mtei, M and Hien Trang, TP and Navarro-Torné, A and Douglas, IJ and Schultze, A},
title = {Approaches to observational study designs and analytical options to evaluate the safety of multi-dose vaccines: a systematic review.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2667740},
doi = {10.1080/14760584.2026.2667740},
pmid = {42057741},
issn = {1744-8395},
mesh = {Humans ; *Observational Studies as Topic/methods ; *Research Design ; *Vaccines/administration &amp; dosage/adverse effects ; *COVID-19 Vaccines/administration &amp; dosage/adverse effects ; *Vaccination/adverse effects/methods ; },
abstract = {INTRODUCTION: Observational studies require careful considerations when evaluating the safety of multidose vaccines. We reviewed design and analytical approaches in observational studies evaluating the safety of multidose vaccines in the post-licensure phase.<br><br>METHODS: EMBASE, MEDLINE, Web of Science, and Scopus (2018-2022) were searched for hypothesis-testing studies evaluating the safety of multidose vaccines. Key features from frequently used designs were extracted.<br><br>RESULTS: Among 123 eligible studies, cohort (46%) and self-controlled case series (SCCS)/self-controlled risk interval (SCRI) (40%) followed by case-control (12%) were the most common designs, and 15% of studies used multiple designs. Among cohort studies evaluating multiple doses, vaccination date (36%) and cohort entry with time-updated exposure status (32%) were frequent approaches used to define time zero. Twenty-eight percent of cohort studies did not report time zero; all but one evaluated COVID-19 vaccine effect on post-delivery and fertility-related outcomes. For SCCS/SCRI, 64% of studies accounted for event-dependent exposures, mainly by including pre-exposure periods (53%) and modified SCCS model (48%), while 20% employed multiple correction strategies. Among studies using multiple designs, 68% reached consistent conclusions.<br><br>CONCLUSIONS: SCCS/SCRI and cohort designs dominate multidose vaccine safety studies. Clear reporting on time zero in pregnancy and fertility-related cohort studies, and on addressing event-dependent exposures in SCCS/SCRI studies is needed, along with guidance on interpreting results from multiple designs.},
}
@article {pmid42058503,
year = {2026},
author = {Dimnjaković, J and Buble, T and Brborović, O},
title = {Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review.},
journal = {Frontiers in clinical diabetes and healthcare},
volume = {7},
number = {},
pages = {1760695},
pmid = {42058503},
issn = {2673-6616},
abstract = {At the start of the COVID-19 pandemic, there were concerns that some antidiabetic medications might worsen outcomes, though anti-inflammatory properties suggested possible benefits. Many observational studies examined antidiabetic medications use and COVID-19 outcomes. Meta-analyses showed that insulin was linked to worse outcomes, while metformin, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists were associated with better outcomes. Findings on dipeptidyl peptidase-4 (DPP-4) inhibitors, pioglitazone, and sulfonylureas were mixed-showing neutral, beneficial, or negative effects. However, randomized controlled trials (RCTs) testing these medications after SARS-CoV-2 infection found no effect on COVID-19 outcomes, implying that their anti-inflammatory effects do not translate into meaningful clinical benefits during acute infection. This discrepancy prompts questioning what observational studies actually measured. Given that many studies applied robust statistical methods, their results are unlikely solely due to confounding or indication bias. We hypothesize that these studies reveal broader cardiovascular effects and illuminate diabetes management more than they inform COVID-19 pathology. Their findings align with current 2022 American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) consensus guidelines for the management of type 2 diabetes mellitus endorsing metformin, SGLT-2 inhibitors, and GLP-1 agonists as first-line therapies, recommending cautious early insulin use, and reserving DPP-4 inhibitors, sulfonylureas, and pioglitazone for selective cases. This is applicable regardless of COVID-19 status. Further research should determine whether infection-related clinical endpoints, such as mortality or hospitalization from COVID-19 or other infections, might serve as valid surrogate markers for cardiovascular outcomes.},
}
@article {pmid42058812,
year = {2026},
author = {Ibrahim, Y and Qureshi, A and Jackson, M and Zovich, B and Freeland, C and Flomo, M and Alik, K and Yakubov, R and Chen, LH and Yeboah, PK and Cohen, C},
title = {Why does hepatitis B remain underprioritized? A view through lived experience.},
journal = {World journal of methodology},
volume = {16},
number = {2},
pages = {114604},
pmid = {42058812},
issn = {2222-0682},
abstract = {Nearly 259 million people are living with chronic hepatitis B globally, with just 7 million of them receiving life-saving treatment. In 2022, 83% of all viral hepatitis deaths were attributed to hepatitis B. Despite the availability of effective vaccines, diagnostics, and treatments, hepatitis B continues to be underprioritized on the global health agenda. Stigma and discrimination have been pervasive and entrenched in numerous countries, resulting in economic and social setbacks for people living with hepatitis B. Through the personal stories of several individuals living with hepatitis B worldwide, this article explores the question: Why does hepatitis B remain underprioritized? It walks through the roadblocks hindering the progress towards hepatitis B elimination efforts and draws lessons from other diseases - such as human immunodeficiency virus, coronavirus disease 2019, and Ebola, where advocacy, political commitment, and sustained funding led to meaningful progress in prevention, diagnosis, and treatment. This evidence-backed perspective is based on decades-long efforts of the Hepatitis B Foundation, collaborating with international partners to prevent new infections, documenting the lived experiences of those living with hepatitis B and supporting them, and advocating for better care and policies affecting those impacted by the disease. Beyond identifying persistent challenges to eliminating hepatitis B, the article succinctly issues a call to action for greater investment, cross-sector collaboration, integration of disease programs to improve efficiency, and inclusion of patient-reported outcomes in hepatitis B management and evaluation, to better support those living with hepatitis B.},
}
@article {pmid42059835,
year = {2026},
author = {Ávila-Aguero, ML and Brenes-Chacon, H and Falleiros-Arlant, LH and Brea-Del Castillo, J and Soriano-Fallas, A and Naranjo-Zúñiga, G and Sáez-Llorens, X and Gentile, A and Lopez-Medina, E and Muñoz, FM},
title = {COVID-19 in pediatrics in Latin America: six years later.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2667741},
doi = {10.1080/14760584.2026.2667741},
pmid = {42059835},
issn = {1744-8395},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; Latin America/epidemiology ; *Immunization Programs ; Child ; Pandemics/prevention &amp; control ; Vaccination Coverage ; Vaccination/statistics &amp; numerical data ; SARS-CoV-2 ; COVID-19 Vaccines/administration &amp; dosage ; Child Health ; Infant ; },
abstract = {INTRODUCTION: Six years later, the impact of the COVID-19 pandemic on children in Latin America remains profound. Even though they were considered less susceptible to the disease, infants have emerged as one of the most affected populations, with the pandemic exposing deep inequities and magnifying vulnerabilities. This paper is presented as a perspective from SLIPE on COVID-19, providing expert insight into the current epidemiological situation in the region.<br><br>AREAS COVERED: This review analyzes the effects of the COVID-19 pandemic on children's health and wellbeing, education, and immunization efforts. Vaccination coverage against COVID-19 in children is suboptimal, particularly among those with high-risk underlying conditions, and the disruption of routine immunization programs has led to outbreaks of vaccine preventable diseases in the region.<br><br>EXPERT OPINION: Addressing these challenges requires strengthening both COVID-19 vaccination strategies for high-risk pediatric populations and routine childhood immunization programs, along with effective communication to combat misinformation, prioritization of educational recovery, social protection, and resilient health systems. Recovery must focus on closing inequity gaps and placing children at the center of public policy to safeguard their future.},
}
@article {pmid42059914,
year = {2026},
author = {Lobaina, D and Llorens, C and Eldawy, N and Kosseifi, G and Puvvala, A and Srivastav, M and Miron, E and Frishman, M and Nasr, M and Jhumkhawala, V and Jimenez, S and Etzel, M and Knecht, M and Mejia, M and Sacca, L},
title = {The Role of Telehealth in Decreasing Barriers in Accessing Primary and Specialized Care Services in U.S. Rural and Underserved Communities: A Scoping Review.},
journal = {Telemedicine journal and e-health : the official journal of the American Telemedicine Association},
volume = {32},
number = {8},
pages = {811-826},
doi = {10.1177/15305627261443159},
pmid = {42059914},
issn = {1556-3669},
mesh = {Humans ; *Telemedicine/organization &amp; administration ; *Health Services Accessibility/organization &amp; administration ; United States ; COVID-19/epidemiology ; Access to Primary Care ; *Medically Underserved Area ; Social Determinants of Health ; *Primary Health Care/organization &amp; administration ; Rural Population ; SARS-CoV-2 ; Pandemics ; Digital Health ; *Rural Health Services/organization &amp; administration ; },
abstract = {BACKGROUND: Telehealth has emerged as a promising strategy to mitigate access barriers, particularly following rapid expansion during the COVID-19 pandemic; however, evidence on its role across care settings and populations remains fragmented. This scoping review synthesizes United States (U.S.)-based evidence on the role of telehealth in improving access to primary and specialized medical care for underserved, rural, and hard-to-reach adult populations.<br><br>METHODS: Guided by the Arksey and O'Malley framework and PRISMA-ScR guidelines, peer-reviewed studies were identified through PubMed, Embase, and the Cochrane Library. Eligible studies examined telehealth use in adult U.S. populations and reported outcomes related to health care access, social determinants of health (SDoH), or implementation strategies. Data were charted and synthesized narratively, with implementation approaches categorized using the ERIC framework.<br><br>RESULTS: Of 9,212 records identified, 242 studies met inclusion criteria. Telehealth was associated with comparable or improved access and clinical outcomes across primary care, specialty care, behavioral health, palliative care, and perioperative settings. Commonly addressed SDoH and demographic characteristics included age, race/ethnicity, socioeconomic status, insurance coverage, geography, and digital access. While telehealth reduced barriers related to transportation, travel burden, and scheduling flexibility, disparities persisted for older adults, individuals with limited English proficiency, and those with low digital literacy or broadband access. Implementation strategies most frequently involved adapting interventions to local context, iterative evaluation, and clinician support, whereas financial and infrastructure-level strategies were less commonly reported.<br><br>CONCLUSIONS: Extant literature suggests that telehealth has broad and firm support for its role in reducing access barriers and improving health outcomes across a wide range of conditions and populations. Therefore, future community-based approaches should focus on integrating telehealth into existing care delivery systems, tailoring interventions to the needs and preferences of different populations, and addressing structural barriers such as digital access, health literacy, and reimbursement to ensure sustained implementation.},
}
@article {pmid42060541,
year = {2026},
author = {Sanchez Villalobos, N and van Loenen, T and Ngongalah, L and Connolly, MA and Stein, ML and Rovers, CP and Timen, A},
title = {Hybrid Care Modifications in the Delivery of Nonpandemic Care During the COVID-19 Pandemic: Scoping Review.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e84756},
pmid = {42060541},
issn = {1438-8871},
mesh = {Humans ; COVID-19/epidemiology ; Europe/epidemiology ; Pandemics ; *Delivery of Health Care/organization &amp; administration ; *Telemedicine/organization &amp; administration ; Digital Health/organization &amp; administration ; },
abstract = {BACKGROUND: The COVID-19 pandemic had an unprecedented impact on the delivery of health care, with digital interventions accelerating more than ever before. However, evidence of how hybrid care models, combining digital health interventions with in-person care, were implemented during the pandemic remains scattered. Understanding hybrid care models is imperative to build resilient health systems that can ensure access to care during crisis situations.<br><br>OBJECTIVE: The study aimed to examine the implementation of hybrid care modifications to support the delivery of nonpandemic health care services in Europe during the COVID-19 pandemic.<br><br>METHODS: A scoping review was conducted following PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. Systematic searches were conducted in PubMed or MEDLINE, Embase, CINAHL, Web of Science, and PsycINFO on May 22, 2024, and updated on January 14, 2026. Studies were eligible if they included primary data on the use of digital care modifications implemented or scaled up during the COVID-19 pandemic for the delivery of nonpandemic health care services in Europe. Non-peer-reviewed publications and studies with a primary focus on mental health or pediatric care were excluded. Quality appraisal was conducted using the Mixed Methods Appraisal Tool. Descriptions of digital care modifications were inductively analyzed and used to create digital flows, combining telehealth systems, digital interventions, and care functions. Digital care modifications were categorized according to their hybrid care implementation (digital-only or hybrid). Study evaluations were extracted using the Kirkpatrick model.<br><br>RESULTS: A total of 189 studies were included for analysis. Studies covered evidence from 2020 to 2024, a total of 23 countries, and 37 health care disciplines. Hybrid care implementation was reported in over 60% (115/189) of the studies, describing various forms of digital and in-person care. Care modifications incorporating in-person and digital care components were more commonly described in specialty care contexts. A total of 68 distinct digital flows were identified, with a limited number of telehealth systems allowing substantial variety in both interventions and care functions. Prominent digital flows included the use of online platforms to support video and messaging for follow-up care. Over half of the studies did not describe any kind of evaluation.<br><br>CONCLUSIONS: This review has shown how few telehealth systems were able to support a variety of care functions in the delivery of nonpandemic care throughout the COVID-19 pandemic, underscoring their practical versatility. Integrating digital health as part of hybrid care models is essential in designing care pathways that can adapt to different contexts, including future health crises. Although a comprehensive search was conducted, the heterogeneous reporting of care modifications may have influenced the interpretation of the findings. In the future, research may expand the application of hybrid care models to innovative strategies for effective crisis management.},
}
@article {pmid42060826,
year = {2026},
author = {Bawne, G and Coenen, L and Nutma, E and Middeldorp, J and Lorenowicz, MJ},
title = {When Viruses Talk through Extracellular Vesicles: a New Perspective on Sars-Cov-2-Induced Neurodegeneration.},
journal = {Journal of extracellular vesicles},
volume = {15},
number = {5},
pages = {e70272},
pmid = {42060826},
issn = {2001-3078},
mesh = {Humans ; *Extracellular Vesicles/metabolism/virology ; *COVID-19/complications/metabolism/virology ; *Neurodegenerative Diseases/virology/metabolism/etiology ; *SARS-CoV-2 ; MicroRNAs/metabolism/genetics ; Animals ; Alzheimer Disease/metabolism/virology ; },
abstract = {SARS-CoV-2 infection is linked to persistent neurological symptoms Post-Acute Sequelae SARS-CoV-2 (neuro-PASC) and elevated risk of neurodegenerative disease, but molecular events connecting acute viral injury to long-term CNS dysfunction remain unclear. Here, we advance a perspective that Extracellular Vesicles (EVs) act as active mediators bridging SARS-CoV-2 infection and neurodegenerative processes. As nanoscale messengers capable of crossing the blood-brain barrier, EVs can transmit post-viral signals and orchestrate multi-target gene regulation in recipient cells through their microRNA (EV-miRNA) cargo. Our integrative analysis suggests that EV-miRNAs dysregulated in acute COVID-19, Alzheimer's Disease (AD), and Parkinson's Disease (PD) converge on pathways governing neurovascular integrity, redox and metabolic homeostasis, and neuronal proteostasis. We propose that sustained dysregulation of these interconnected modules-driven by EV-mediated signalling-may underlie the perpetuation of neuro-PASC and accelerate neurodegeneration in susceptible individuals. Viewing EVs as mechanistic agents that both transmit and amplify pathogenic cues reframes them as actionable targets for intervention and risk stratification. This perspective calls for translational frameworks that leverage EVs to illuminate, predict, and modify the trajectory of post-viral neurodegeneration.},
}
@article {pmid42061613,
year = {2026},
author = {Kaur, H and Gupta, P and Dhaliwal, M and Chakrabarti, A},
title = {Fungal infections in diabetes mellitus.},
journal = {Indian journal of medical microbiology},
volume = {61},
number = {},
pages = {101130},
doi = {10.1016/j.ijmmb.2026.101130},
pmid = {42061613},
issn = {1998-3646},
mesh = {Humans ; Antifungal Agents/therapeutic use ; *Mycoses/diagnosis/drug therapy ; *Diabetes Complications/microbiology ; *Diabetes Mellitus/microbiology/immunology ; Mucormycosis ; Risk Factors ; COVID-19 ; },
abstract = {PURPOSE: Diabetes mellitus is recognised as a global health problem and has increasingly been associated with fungal infections, as an independent risk factor. Diabetic patients are predisposed to both superficial as well as invasive fungal disease, and account for substantial morbidity and mortality. Recent pandemic of COVID-19 underlined the global problem of mucormycosis, however, the burden of fungal infections among diabetics has a much broader horizon. This review aims to summarise the spectrum of fungal infections encountered among diabetic patients, along with elucidating immunopathogenesis and clinical challenges encountered in diagnosis and management of such infections.<br><br>METHODS: We conducted a narrative review of all published literature focusing on spectrum of fungal infections, immunopathogenesis and clinical challenges encountered in diagnosis and management, among diabetic patients.<br><br>RESULTS: Diabetes mellitus facilitates the acquisition and progression of fungal infections via multiple coordinated mechanisms viz. hyperglycemia, impaired immune (innate and adaptive) response, altered microenvironment and endothelial dysfunction. These changes in the milieu contribute to pervasive clinical presentations, ranging from cutaneous and oral candidiasis to invasive fungal diseases like mucormycosis, aspergillosis and cryptococcosis. Besides predisposing to fungal infections, diabetes also serves as a prognostic factor and has been noted to worsen the outcome. Furthermore, the altered microenvironment affects the pharmacokinetics of antifungal drugs and can also reduce the efficacy of antifungal regime, further convoluting and worsening the progression of disease.<br><br>CONCLUSION: Early diagnosis and management of fungal infections is necessary to mitigate the associated morbidity and mortality among diabetic patients. A multidisciplinary approach is imperative as diabetes hampers the effectiveness of conventional antifungal regimens and facilitates antifungal resistance. Regular monitoring of glycaemic index and compliance for drugs, along with lifestyle modifications desired for optimal levels, is pre-requisite for antifungal therapy to exhibit desired action.},
}
@article {pmid42061662,
year = {2026},
author = {Mahooti, M and Safaei, F and Abdolalipour, E and Ahmadbeigi, G and Shokouhi, H and Fallah, T and Zare, D},
title = {Short-chain fatty acid-producing probiotics: an effective approach for modulating gut dysbiosis and mitigating inflammatory responses.},
journal = {Microbial pathogenesis},
volume = {216},
number = {},
pages = {108520},
doi = {10.1016/j.micpath.2026.108520},
pmid = {42061662},
issn = {1096-1208},
mesh = {*Probiotics/therapeutic use ; Humans ; *Fatty Acids, Volatile/metabolism/biosynthesis ; *Inflammation/prevention &amp; control ; *Dysbiosis/therapy/microbiology ; *Gastrointestinal Microbiome/drug effects ; Animals ; COVID-19 ; Diabetes Mellitus, Type 2 ; Neoplasms ; Obesity ; Cardiovascular Diseases ; },
abstract = {Alterations in the intestinal microbiome participate with inflammatory responses and associate with pathological outcomes, along with changing the production of myriad metabolites such as short-chain fatty acids. A growing body of evidences have indicated that different dietary components, like polyphenols, may also increase short-chain fatty acids production by gut microbiota, playing a preventative role against various diseases, such as type 2 diabetes (T2D), obesity, cardiovascular diseases (CVD), and even mitigate inflammation attributed to disorders like those observed in COVID-19 and even cancer. Some infectious illnesses alter the microbiome, resulting in a decrease in the production of fermentative products, such as short-chain fatty acids. Managing the microbiome with probiotics to compensate the changes caused by these diseases leads to improvements in the microbiome and a reduction in inflammation. This reduction may even have positive effects in managing cancer. In this review, we compile cutting-edge discoveries on probiotic-derived SCFAs, highlighting their mechanisms associated with their prophylactic and therapeutic potential and their impact across infectious and non-infectious diseases, particularly in mitigating inflammation. Therefore, this review seeks to facilitate the development, evaluation, and clinical implementation of SCFAs-based interventions in future studies, particularly in preventive and therapeutic clinical settings.},
}
@article {pmid42061834,
year = {2026},
author = {Leonforte, F and Nicosia, V and Comite, P and Morlino, G and Mistretta, A},
title = {Media Exposure and Its Association With Vaccine Attitudes, Intentions, and Hesitancy: Systematic Review.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e74280},
pmid = {42061834},
issn = {1438-8871},
mesh = {Humans ; Media Exposure ; *Vaccination Hesitancy/psychology ; *COVID-19/prevention &amp; control ; *Intention ; Vaccination ; SARS-CoV-2 ; Female ; *Health Knowledge, Attitudes, Practice ; Adult ; COVID-19 Vaccines ; },
abstract = {BACKGROUND: Vaccine hesitancy, amplified by the COVID-19 "infodemic," has emerged as a pressing public health challenge. Communication strategies are pivotal for enhancing vaccine literacy, countering misinformation, and sustaining immunization programs.<br><br>OBJECTIVE: This systematic review evaluates the association between communication channels and vaccine hesitancy and adherence, while examining the moderating role of sociodemographic factors.<br><br>METHODS: A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)-compliant search was conducted across PubMed, Scopus, and Web of Science, yielding 17,407 records screened according to predefined eligibility criteria (peer-reviewed studies with N>1000 adults assessing communication media targeting vaccine hesitancy and adherence, excluding pediatric, health care-specific, and non-English research). After full-text assessment, studies were appraised using the Modified Medical Education Research Study Quality Instrument for methodological quality and the Joanna Briggs Institute Critical Appraisal Checklist, ROBIN-I (Risk of Bias in Nonrandomized Studies of Interventions), or RoB 2.0 (Risk-of-Bias 2.0 tool for randomized trials) tools for risk of bias.<br><br>RESULTS: Thirty-six studies were included (26 cross-sectional, 4 quasi-experimental, 4 randomized controlled trials, 1 cohort, and 1 global analysis). Randomized and nonrandomized experimental studies demonstrated that tailored communication strategies delivered via radio, web platforms, and social media significantly improved vaccine acceptance. Adaptive public health campaigns achieved up to an 8% weekly increase in uptake in Madagascar (relative risk 1.08; 95% CI 1.01-1.15) and a 7.8% higher vaccination rate among Nigerian adults at first follow-up compared with controls. Digital and social media campaigns effectively reduced hesitancy and enhanced trust among hesitant pregnant women in the United States. Sociodemographic factors significantly moderated communication outcomes: a COVID-19 chatbot proved most effective among individuals with lower education and minority backgrounds, while religiosity (b=0.17; 95% CI 0.05-0.30; t810=2.80; P=.005) and cultural congruence (odds ratio 1.89; P<.01) influenced message credibility and engagement, respectively. The persuasive effect of online memes on COVID-19 vaccine intentions was not significantly influenced by gender (P=.83), age (P=.60), or political orientation (P=.44). Age-specific effects were observed, with greater responsiveness to a social media campaign among adults aged 25-34 years and reduced hesitancy among older groups. Multiple cross-sectional studies indicated higher adherence among audiences exposed to traditional media (television, radio, newspapers) and lower trust among social media users. Other studies suggested significant influences of gender, age, socioeconomic status, education level, and political orientation.<br><br>CONCLUSIONS: By synthesizing fragmented evidence, this review provides a systematic examination of the interplay between multichannel media and vaccine acceptance. It diverges from existing literature by integrating both traditional and digital media perspectives through the lens of sociodemographic moderation. This work offers a critical framework for public health interventions, advocating for rigorous longitudinal research to establish definitive causal links between communication and behavior. Consequently, these findings support a "precision" communication model, enabling the development of culturally congruent strategies tailored to specific recipient profiles to bolster vaccine adherence.<br><br>TRIAL REGISTRATION: PROSPERO CRD42025637441; https://tinyurl.com/4r9w83kw.},
}
@article {pmid42065140,
year = {2026},
author = {Thompson, CR and Adams, ER and Fletcher, TE},
title = {Diagnostics and the 100-day mission: why preparedness cannot wait.},
journal = {Transactions of the Royal Society of Tropical Medicine and Hygiene},
volume = {120},
number = {8},
pages = {898-900},
doi = {10.1093/trstmh/trag052},
pmid = {42065140},
issn = {1878-3503},
support = {//University of Liverpool/ ; //Liverpool School of Tropical Medicine/ ; //Liverpool John Moores University/ ; //Liverpool City Council/ ; //Liverpool City Region Combined Authority/ ; //Liverpool University Hospital Foundation/ ; //Trust and Knowledge Quarter Liverpool/ ; },
mesh = {Humans ; Global Health ; Pandemic Preparedness ; *Pandemics/prevention &amp; control ; *COVID-19/diagnosis ; Public Health Infrastructure ; },
abstract = {The 2025 International Panel for Pandemic Surveillance Report and the G7 100-day mission emphasise rapid deployment of diagnostics, but preparatory infrastructure is vital to achieve this goal. Drawing on lateral flow development and haemorrhagic fever case studies, we highlight the requirement for pre-established diagnostic building blocks, including monoclonal antibodies, antigens, biological reference materials and regulatory pathways. Persistent funding imbalances and inequitable global investment threaten timely outbreak response. Sustained preparedness investment, strengthened biobanking and equitable access frameworks will ensure that diagnostics can be delivered within meaningful response timelines.},
}
@article {pmid42066776,
year = {2026},
author = {Akil, H and Maras, PM and Turner, CA},
title = {Stress fitness: A neuroscientific approach to building emotional resilience.},
journal = {Neuron},
volume = {114},
number = {13},
pages = {2298-2314},
doi = {10.1016/j.neuron.2026.03.032},
pmid = {42066776},
issn = {1097-4199},
mesh = {Humans ; *Resilience, Psychological ; *Stress, Psychological/psychology/physiopathology ; *COVID-19/psychology ; *Emotions/physiology ; Animals ; *Anxiety Disorders/psychology ; },
abstract = {Across the globe, rates of mood and anxiety disorders have been increasing steadily, a trend accelerated by the COVID-19 pandemic. Stress triggers these disorders, precipitating initial episodes and provoking relapses. In this perspective, we argue that the stress system is not merely a threat mechanism but also an ongoing and active monitor of the environment and that resilience is not simply the lack of sensitivity to stress but an active function with an intrinsic neurobiology. Through the interplay of genetic, developmental, and experiential mechanisms, individuals evolve their own "stress-resilience algorithm" that determines their stress reactivity and the resulting adaptive or maladaptive consequences. This algorithm represents a dynamic, lifelong process that is often self-reinforcing. We underscore the importance of focusing on prevention by assessing and enhancing an individual's "stress fitness." This perspective offers a new conceptualization of the neurobiology of stress and resilience as a framework for basic and translational neuroscience research aimed at confronting the challenges of stress disorders.},
}
@article {pmid42067236,
year = {2026},
author = {Tolchard, J and Le Marchand, T and Aspers, RLEG and Batta, G and Bechinger, B and Brath, U and Chasapi, SA and Čikoš, A and Ecsedi, K and Favier, A and Ferreira, ASD and Fiala, R and Georgiopoulou, PD and Gómez, JS and Jaudzems, K and Karlsson, G and Kentgens, APM and Lambregts, SFH and Morelli, F and Mulder, FAA and Natarajan, SV and Persson, C and Pierattelli, R and Pons, M and Raya, J and Redfield, C and Smrečki, V and Spyroulias, GA and Trébosc, J and Vallet, A and van Heijenoort, C and van Ingen, H and Vosegaard, T and Wirmer-Bartoschek, J and Schwalbe, H and Lesage, A and Pintacuda, G},
title = {Moving NMR infrastructures to remote access capabilities.},
journal = {Progress in nuclear magnetic resonance spectroscopy},
volume = {152-153},
number = {},
pages = {101595},
doi = {10.1016/j.pnmrs.2026.101595},
pmid = {42067236},
issn = {1873-3301},
abstract = {Traditionally, Nuclear Magnetic Resonance (NMR) infrastructures have relied on in-person access, requiring researchers to travel to centralized facilities to conduct experiments. However, recent advancements in remote access technologies, accelerated by the constraints imposed by the COVID-19 pandemic, have demonstrated the feasibility and strategic benefits of transitioning NMR operations toward remote accessibility. This review examines the key challenges and opportunities associated with remote access to NMR instrumentation, including standardized protocols for sample handling, secure authentication mechanisms, real-time instrument control, and data management. By establishing a unified framework for remote access, we aim to enhance the sustainability and accessibility of NMR facilities. Our findings highlight the necessity for collaborative efforts to develop best practices that ensure reproducibility, high-quality data acquisition, and equitable access to NMR infrastructure on a global scale.},
}
@article {pmid42067749,
year = {2026},
author = {Sharma, B and Smith, R and E Pennell, C},
title = {Global Trends in Maternal Mortality and Efforts to Improve Maternal Outcomes Through Sociomedical Interventions.},
journal = {Reproductive sciences (Thousand Oaks, Calif.)},
volume = {33},
number = {5},
pages = {950-960},
pmid = {42067749},
issn = {1933-7205},
mesh = {*Maternal Mortality/trends ; Humans ; Female ; Pregnancy ; COVID-19 ; Developing Countries ; *Global Health ; },
abstract = {Maternal mortality continues to be a major global health concern that disproportionately affects low- and middle-income countries (LMICs), with the World Health Organisation (WHO) estimating a maternal death occurring every two minutes. The data-sparse LMICs employ a multitude of estimation approaches to gauge maternal mortality ratios (MMR); however, their classification of deaths and reproducibility of estimates remain open to discussion. Despite a considerable reduction of MMR levels since 2000, more recently, the MMR levels in countries including the US have resurged due to the sociomedical crises brought about by the COVID-19 pandemic. The United Nations' Sustainable Development Goal (SDG) 3.1 aims to achieve global maternal mortality ratios of less than 70 per 100,000 live births and below 140 per 100,000 live births at the national level by 2030. However, recent projections indicate it will remain unmet by a margin of a million maternal deaths. Many LMICs apply the three-delays framework of maternal deaths that requires verbal autopsy to be used in tandem with the identification of maternal deaths. The three-delays model devised in the mid-1990s allows LMICs to gear their resources towards specific intervention points. A significant portion of the existing literature has focused on the description of the magnitude of the issue and the factors precipitating maternal deaths. Innovative solutions have recently been implemented, such as repurposing military helicopters to reduce the delays in managing obstetric complications. Similarly, prospective studies are required to devise ways to address the sociomedical mechanisms underlying maternal deaths.},
}
@article {pmid42067830,
year = {2026},
author = {Youssef, DM and Al-Shehabi, H and Johann, S and Kitts, J and Bauer, M and Montt-Maray, E and Bcheraoui, CE},
title = {Public health emergency response through field epidemiology training and rapid response teams - a scoping review.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42067830},
issn = {1471-2458},
mesh = {Humans ; *Epidemiology/education ; *Public Health/education ; Public Health Infrastructure ; },
abstract = {BACKGROUND: Public Health Emergency Workforce (PHEW) plays a significant role in the detection and rapid response to emerging diseases, thus helping countries manage global threats. In line with the International Health Regulations' call for strengthening national capacities, field epidemiology training programs (FETPs) and rapid response teams (RRTs) have been developed to enhance countries' preparedness and response capacities. This scoping review synthesizes the evidence on available FETPs and RRTs and on their effectiveness as well as the challenges they face.<br><br>METHODS: A scoping review was conducted using EMBASE, Ovid Medline and Scopus databases in addition to the grey literature for studies published after year 2000, in the English language. Studies were selected by two independent reviewers and data were extracted into an excel sheet. Included manuscripts were analyzed through a narrative synthesis.<br><br>RESULTS: Four thousand one hundred ten studies were identified from the three peer-reviewed databases and six articles from the grey literature. Finally, 67 studies were included in the review comprising 47 identified through our search and 20 sourced from the references. The studies on PHEW training included FETPs encompassing those with laboratory and veterinary focus, and training on rapid response. Enhancement in learning acquired, course satisfaction, application of skills in workplace and engagements in key emergency response activities were found. However, lack of funding and a standardized curriculum were still among the most common challenges facing FETPs and RRTs.<br><br>CONCLUSION: While PHEW training including FETPs and RRTs are essential for building resilience against health threats, financial challenges, lack of standardized curricula and operating procedures hinders their effectiveness. Integrating One Health and laboratory skills into FETPs are vital, as seen during the COVID-19 pandemic response. Governments should work towards increasing funding and incentivizing graduate retention. They should also collaborate with organizations such as the International Association of National Public Health Institutes (IANPHI) and the Global Field Epidemiology Partnership (GFEP) to establish standardized curricula for FETP and RRT.},
}
@article {pmid42068116,
year = {2026},
author = {Peart, SR and Haj-Yahya, R and Nugent, M and Ganbold, O and Harbinson, L and Jly, C and Manley, BJ and Whitehead, CL},
title = {Preterm Birth and Perinatal Mortality During the COVID-19 Pandemic Period: A Systematic Review and Meta-Analysis.},
journal = {Journal of paediatrics and child health},
volume = {62},
number = {6},
pages = {924-935},
pmid = {42068116},
issn = {1440-1754},
mesh = {Humans ; *Premature Birth/epidemiology ; *COVID-19/epidemiology ; Pregnancy ; *Perinatal Mortality/trends ; Female ; Infant, Newborn ; Stillbirth/epidemiology ; Pandemics ; },
abstract = {BACKGROUND: Preterm birth rates may have been affected during the COVID-19 pandemic but the impact of this on perinatal morbidity is unknown.<br><br>AIM: To review the impact of the COVID-19 pandemic on rates of preterm birth and perinatal mortality.<br><br>METHODS: Medline, Embase, and online pre-prints were searched from Jan 2020 to Oct 2022. Case-control, cohort studies and reports comparing rates of preterm birth, stillbirth and neonatal death before and during the COVID-19 pandemic period were included. The pooled odds ratio (OR) for preterm birth, stillbirth and neonatal death was calculated using a random effects model. The primary outcome was the rate of preterm birth, stillbirth and neonatal death in the pre-pandemic and pandemic periods.<br><br>RESULTS: 100 studies were included. Compared with pre-pandemic periods, there was a decrease in preterm births during the pandemic period: OR 0.95 (95% CI 0.94-0.97) I [2] &#x2009;=&#x2009;0.93, with the greatest reduction for births <&#x2009;28&#x2009;weeks' gestation in high-income countries: OR 0.92 (95% CI 0.88-0.96), I [2] &#x2009;=&#x2009;0.46. There was a reduction in neonatal deaths in high-income countries: OR 0.78 (95% CI 0.64-0.95), I [2] &#x2009;=&#x2009;0.4. In low- and middle-income countries the stillbirth rate increased during the pandemic compared with the pre-pandemic period: OR 1.18 (95% CI 1.02-1.36), I [2] &#x2009;=&#x2009;0.86.<br><br>CONCLUSION: The COVID-19 pandemic was associated with a reduction in preterm births and neonatal deaths. Further research is needed to investigate the mechanisms underlying these findings. Stillbirth rates increased in low- and middle-income countries where access to healthcare may have been restricted and strategies to address this in future pandemics are warranted.},
}
@article {pmid42068729,
year = {2026},
author = {Menin, IBF and Dias, ADC and da Rosa, MI and Colonetti, T and Grande, AJ},
title = {COVID-19 vaccine hesitancy among people with epilepsy: an updated systematic review and meta-analysis.},
journal = {Seizure},
volume = {138},
number = {},
pages = {198-211},
doi = {10.1016/j.seizure.2026.04.007},
pmid = {42068729},
issn = {1532-2688},
mesh = {Humans ; *Epilepsy/psychology ; *Vaccination Hesitancy/psychology ; *COVID-19 Vaccines ; *COVID-19/prevention &amp; control ; Vaccination/psychology ; },
abstract = {OBJECTIVE: To systematically review and meta-analyze COVID-19 vaccine hesitancy among individuals with epilepsy.<br><br>METHODS: Following PRISMA 2020 guidelines, we searched Cochrane CENTRAL, MEDLINE, EMBASE, CINAHL, LILACS, PsycINFO databases, and grey literature through February 6, 2026. We included studies addressing COVID-19 vaccination hesitancy in adults with epilepsy, with no date or language restrictions. Two reviewers independently screened articles, extracted data, and assessed quality using the Newcastle-Ottawa Scale (NOS). Meta-analyses were conducted using random-effects models, with heterogeneity assessed using I&#xb2; statistics. The certainty of evidence was evaluated using the GRADE criteria.<br><br>RESULTS: Fourteen studies comprising 4230 participants were included. Overall vaccination willingness was 51.7% (95% CI: 36.6-68.8%, I&#xb2;=98%). Among unvaccinated individuals, 44.2% (95% CI: 26.6-61.8%, I&#xb2;=95%) expressed willingness to be vaccinated. Well-controlled epilepsy was associated with higher vaccination rates (OR 1.91, 95% CI: 1.49-2.46, I&#xb2;=0%). Conversely, frequent seizures (daily/weekly) were associated with lower vaccination likelihood (OR 0.52, 95% CI: 0.35-0.76, I&#xb2;=0%). The primary reasons for vaccine hesitancy were fear of seizure worsening (23.8-88.5% across studies) and concerns about side effects (13.0-53.0%). Methodological quality was generally poor, with only one study rated as "satisfactory" using NOS criteria. GRADE assessment indicated very low certainty of evidence due to serious risk of bias, inconsistency, and imprecision.<br><br>CONCLUSIONS: COVID-19 vaccine hesitancy remains present in people with epilepsy, primarily driven by concerns about seizure exacerbation. Individuals with well-controlled epilepsy show higher vaccination acceptance. Healthcare providers should address specific concerns about seizure control while emphasizing vaccine safety data. High-quality prospective studies using validated instruments are recommended.},
}
@article {pmid42068781,
year = {2026},
author = {Chang, SY and Hsieh, CY and Lee, WY and Hung, HM and Lee, HF and Hsu, HC},
title = {The career choices of nursing students after the COVID-19 pandemic: A scoping review.},
journal = {International journal of nursing studies},
volume = {180},
number = {},
pages = {105547},
doi = {10.1016/j.ijnurstu.2026.105547},
pmid = {42068781},
issn = {1873-491X},
mesh = {Humans ; *Career Choice ; *Coronavirus Infections/epidemiology ; *COVID-19/epidemiology ; Pandemics ; *Pneumonia, Viral/epidemiology ; *Students, Nursing/psychology ; },
abstract = {BACKGROUND: The COVID-19 pandemic disrupted nursing education worldwide, limiting clinical learning opportunities and increasing psychological stress. These challenges forced nursing students to make career decisions in uncertain, risky, and changing social environments.<br><br>OBJECTIVE: To explore the scope, influencing factors, and strategies related to nursing students' career choices after the pandemic.<br><br>DESIGN: A scoping review following Arksey and O'Malley's framework.<br><br>METHODS: Six databases were searched without restrictions on language or publication date. Seventeen studies involving 5167 nursing students from Asia, Europe, and the Middle East were included. Data were analyzed thematically to identify career intentions, influencing factors, and development strategies.<br><br>RESULTS: Most nursing students intended to remain in the profession, although their intentions varied by country and over time. Key positive influences included strengthened professional identity, societal recognition, and supportive learning environments. Negative influences included perceived occupational risk, inadequate compensation, and reduced clinical experience. Recommended strategies included flexible teaching approaches, enhanced clinical preparation, psychological support, and policy measures to improve working conditions and enhance professional image.<br><br>CONCLUSIONS: Despite these significant challenges, many nursing students showed resilience and a willingness to remain in nursing. Investment in education, mentorship, and workforce policy is vital to sustain the nursing workforce and strengthen healthcare resilience in the face of future crises.},
}
@article {pmid42069208,
year = {2026},
author = {Singh, Y and Gupta, A and Gupta, S and Goud, P and Pandey, SN and Goyal, K and Kumbhar, PS and Singh, SK and Dua, K and Gupta, G},
title = {Pentraxin-3 as a diagnostic and prognostic biomarker in inflammatory lung diseases.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {589},
number = {},
pages = {121044},
doi = {10.1016/j.cca.2026.121044},
pmid = {42069208},
issn = {1873-3492},
mesh = {Humans ; Pentraxins ; *Serum Amyloid P-Component/analysis/metabolism ; *C-Reactive Protein/analysis/metabolism ; Biomarkers/blood/analysis ; Prognosis ; COVID-19 ; SARS-CoV-2 ; *Pneumonia, Viral/diagnosis/blood ; Pandemics ; },
abstract = {Inflammatory lung diseases, including community-acquired pneumonia, acute respiratory distress syndrome (ARDS), severe viral pneumonia (including COVID-19), ventilator-associated pneumonia, and exacerbations of chronic obstructive pulmonary disease (COPD), necessitate prompt diagnostic and prognostic assessments accompanied by microbiological confirmation of the causative pathogen. Conventional biomarkers, including C-reactive protein and procalcitonin, are insufficient to distinguish between localized pulmonary and systemic inflammation. This narrative review summarizes the studies on Pentraxin-3 (PTX3), a locally synthesized, extrahepatic acute-phase protein secreted by endothelial cells, epithelial cells, and myeloid leukocytes at sites of inflammation, as a diagnostic and prognostic biomarker in the continuum of inflammatory lung diseases. Plasma PTX3 indicates systemic endothelial activation and disease severity, whereas bronchoalveolar lavage PTX3 concentrations provide compartment-specific diagnostic data, identify follow-up infections, and allow therapeutic escalation in relation to the disease phenotype. Nevertheless, clinical laboratory implementation involves matrix-specific reference levels, analytical validation containing limits of detection/quantification, precision, linearity, and interfering studies according to CLSI, commutable calibrators, and traceability hierarchies. The pre-analytical procedure is standardized, and platform-independent decision limits through harmonized assays, preparation of external quality assessment, and compatibility of acute-care turnaround times are required to implement multicenter PTX3 in routine clinical laboratory diagnostics.},
}
@article {pmid42069590,
year = {2026},
author = {Yeh, CF and Ianalieva, L and Wong, HK and Wu, CC and Yang, KC},
title = {Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.},
journal = {Journal of biomedical science},
volume = {33},
number = {1},
pages = {},
pmid = {42069590},
issn = {1423-0127},
support = {111-2314-B-002-069 MY3, 112-2314-B-002-277 MY3, 112-2918-I-002-002, 112-2926-I-002-511-G (KCY)//National Science and Technology Council/ ; NHRI-EX113-11213BI (KCY)//National Health Research Institutes/ ; IBMS-CRC111-P01 (KCY), AS-TM-113-01-02 (KCY), AS-GC-110-L06 (KCY, SYC)//Academia Sinica/ ; VN112-06, VN-113-03, 112-S0307, 112-S0311, 113-S0196, 113-IF0002, 113-E0008 (KCY)//National Taiwan University Hospital/ ; 110F005-112-M2 (KCY)//National Taiwan University College of Medicine, National Taiwan University Hospital and Min-Sheng General Hospital/ ; NSCCMOH-131-41, 111C101-051, 112C101-031 (KCY)//of National Taiwan University College of Medicine and National Taiwan University Hospital/ ; 112L7849, 113L7832 (KCY)//National Taiwan University/ ; NTU ABRC TCE//NTU Advanced Biomedical Research Center, Taiwan Centers of Excellence/ ; },
mesh = {Humans ; *Theranostic Nanomedicine/methods ; *Atherosclerosis/therapy/diagnosis ; COVID-19/prevention &amp; control ; *Nanomedicine ; Animals ; SARS-CoV-2 ; *Cardiovascular Diseases/therapy ; },
abstract = {Current treatment for atherosclerotic cardiovascular diseases (ASCVD) mainly focuses on the modification of systemic risk factors, such as hyperglycemia and hyperlipidemia. Despite significant efforts and expanse, achieving early and proper diagnosis of ASCVD to improve clinical outcomes remains challenging, and vascular-targeted therapies or genetic editing, while ideal, are still limited. The development of nanomedicine-based mRNA vaccines for SARS-CoV-2 has demonstrated the potential of nanotechnology to target previously inaccessible molecules. Precision therapies by nanomedicine targeting specific tissues/molecules hold potential for new treatment paradigms by precisely modulating disease-causing molecular pathways within diseased tissues, including dysfunctional vasculature. By leveraging insights into the pathogenic contributors of atherogenesis, researchers have optimized nanoplatforms' composition, synthesis strategies, and surface design to enhance therapeutic efficacy and enable early diagnosis. Herein, we present an updated overview of therapeutic and diagnostic strategies using nanomedicine for ASCVD, and explore future research directions and innovative approaches for nanomedicine-driven theranostics in cardiovascular care.},
}
@article {pmid42070118,
year = {2026},
author = {Kusuma, NHS and Irnandi, DF and Pakpahan, C and An Nguyen, TT},
title = {Masturbation as a sexual and psychological coping strategy in long-distance relationships: a systematic review.},
journal = {The journal of sexual medicine},
volume = {23},
number = {5},
pages = {},
doi = {10.1093/jsxmed/qdag121},
pmid = {42070118},
issn = {1743-6109},
mesh = {Humans ; *Masturbation/psychology ; *Adaptation, Psychological ; Female ; Personal Satisfaction ; Male ; *Sexual Behavior/psychology ; COVID-19/psychology ; *Sexual Partners/psychology ; *Interpersonal Relations ; Coping Skills ; },
abstract = {INTRODUCTION: Long-distance relationships (LDRs) reduce opportunities for physical intimacy, often prompting individuals to seek alternative sexual activities such as masturbation. Although common, its influence on sexual satisfaction, sexual health, psychological well-being, and relational stability in LDRs remains understudied. Moreover, cultural and population differences shape diverse meanings and perspectives on masturbation.<br><br>OBJECTIVES: We employed a systematic review approach to explore the role of masturbation within long-distance relationships. Specifically, this review aims to examine how masturbation is associated with sexual, relational, and psychological outcomes and how these perspectives vary across cultural contexts.<br><br>METHODS: A systematic review was conducted following the PRISMA guidelines, compiling both quantitative and qualitative studies on masturbation as an alternative sexual activity in LDRs as well as its implications for sexual satisfaction, relationship satisfaction, and psychological well-being.<br><br>RESULTS: Fourteen studies were eligible for further analysis in which men reported higher frequencies of masturbation compared to women, with significant increases observed in the context of long-distance relationships and during COVID-19 quarantine periods. Men were mainly motivated by biological release, orgasm, and stress reduction, often with pornography, whereas women reported broader motives such as relaxation, better sleep, stress relief, and emotional closeness. The effects on sexual satisfaction were mixed: masturbation was reported to be associated with greater body awareness, self-esteem, and relational harmony, yet excessive frequency was linked to lower satisfaction and arousal. Mutual, technology-mediated practices helped maintain intimacy, while excessive solitary use undermined relationship quality. From a sexual health perspective, moderate masturbation may be associated with indirect benefits through improved body awareness, whereas frequent use was linked to poorer experiences. Psychologically, it served as a coping strategy for sleep and stress, but excessive engagement increased anxiety and reduced emotional well-being.<br><br>CONCLUSION: Masturbation appears to be a common and potentially adaptive alternative sexual activity in the context of LDRs and during the COVID-19 pandemic. However, in Eastern contexts, its meaning and impact are strongly shaped by sociocultural and religious norms.},
}
@article {pmid42070964,
year = {2026},
author = {Kamel, EM and Khadrawy, SM and Allam, AA and Ahmed, NA and Aba Alkhayl, FF and Lamsabhi, AM},
title = {Targeting the Elongin BC-BC-Box Interface: Structural Insights, Peptidic Disruptors and Emerging Small-Molecule Strategies.},
journal = {Chemical biology &amp; drug design},
volume = {107},
number = {5},
pages = {e70307},
doi = {10.1111/cbdd.70307},
pmid = {42070964},
issn = {1747-0285},
support = {IMSIU-DDRSP2601//Imam Mohammad Ibn Saud Islamic University (IMSIU)/ ; },
mesh = {Humans ; *Elongin/metabolism/chemistry/antagonists &amp; inhibitors ; *Peptides/chemistry/pharmacology/metabolism ; *Small Molecule Libraries/chemistry/pharmacology/metabolism ; Protein Binding/drug effects ; },
abstract = {Protein-protein interactions (PPIs) that orchestrate ubiquitin-dependent signaling have long challenged drug discovery because their interfaces are typically large and hydrophobic. The heterodimeric adaptor Elongin BC (ELOB/ELOC) defies this stereotype: its BC-box-binding groove is a deep, rigid pocket that anchors dozens of cellular and viral partners to cullin-RING ligases and to transcriptional machinery. Recent structural and chemical-biology breakthroughs have converted this once "undruggable" site into a tractable target. A sub-nanomolar peptide derived from the chromatin factor EPOP has been shown to displace native BC-box proteins, trigger apoptosis in multiple cancer lines, and unveil a transcriptomic signature that converges on MYC and cell-cycle control. Parallel fragment screens and crystallography have mapped adjacent hot spots suitable for small-molecule growth, while functional genomics highlights Elongin BC as a pan-cancer dependency and an unexpected regulator of the SARS-CoV-2 co-receptor TMPRSS2. This review synthesizes the structural principles of BC-box recognition, the current state of peptide and fragment-based inhibitors, and the biological consequences of disrupting the Elongin BC hub. We discuss therapeutic prospects in oncology and virology, outline key challenges-delivery, selectivity, and resistance-and propose future directions ranging from stapled-peptide optimization to covalent fragment tethering and PROTAC strategies. Together, these advances position Elongin BC inhibition at the forefront of next-generation PPI drug discovery, offering a unified approach to modulate ubiquitin signaling, epigenetic regulation, and viral entry through a single conserved pocket.},
}
@article {pmid42071153,
year = {2026},
author = {Gomes, JP},
title = {Genome Sequencing in Infectious Disease Outbreaks.},
journal = {Advances in experimental medicine and biology},
volume = {1504},
number = {},
pages = {357-371},
pmid = {42071153},
issn = {0065-2598},
mesh = {Humans ; *Disease Outbreaks ; *Whole Genome Sequencing/methods ; *Genome, Viral ; *COVID-19/epidemiology/virology/transmission ; *SARS-CoV-2/genetics/pathogenicity ; *Genome, Bacterial ; *Communicable Diseases/epidemiology/genetics/transmission ; Animals ; High-Throughput Nucleotide Sequencing/methods ; },
abstract = {Genome sequencing has become a crucial tool in the management and understanding of infectious disease outbreaks. By decoding the entire genetic material of pathogens, this technology allows scientists to track the spread and evolution of infectious agents with unprecedented precision. During an outbreak, one of the key applications of genome sequencing is in tracing the transmission pathways of the disease. By comparing the genetic sequences of pathogens from different patients and sources, epidemiologists can determine the source of the outbreak and how the disease is spreading through populations. In addition, genome sequencing has the potential to identify mutations that may affect transmissibility, virulence, or resistance to treatment, providing critical insights for public health responses, for instance enabling targeted interventions, such as specific treatments or vaccines. During the last years, this was particularly evident for multiple internationally occurring severe outbreaks caused by either bacteria or virus, with special emphasis during the COVID-19 pandemic, where genome sequencing played a vital role in monitoring the emergence of new variants and informing vaccine strategies. As sequencing technologies continue to advance and associated costs decline, their integration into public health strategies will be essential for more effective control and prevention of infectious disease outbreaks in the future.},
}
@article {pmid42072232,
year = {2026},
author = {Franco, A and Angelone, F and Calderone, D and Ponsiglione, AM and Romano, M and Ricciardi, C and Amato, F},
title = {Telemedicine and 5G Technologies: A Systematic Global Review of Applications over the Past Decade.},
journal = {Bioengineering (Basel, Switzerland)},
volume = {13},
number = {4},
pages = {},
pmid = {42072232},
issn = {2306-5354},
support = {E63C22002040007//RESTART - RESearch and innovation on future Telecommunications systems and networks, to make Italy more smART/ ; },
abstract = {This systematic review analyzes how the introduction and progressive deployment of 5G networks have influenced the evolution of telemedicine between 2014 and 2024, focusing on their impact on performance, accessibility, and the feasibility of advanced clinical applications across the pre-COVID-19, COVID-19, and post-COVID-19 periods. The review was conducted in accordance with PRISMA guidelines and included publications retrieved from SCOPUS, PubMed, and Web of Science using a PICO-based search strategy. Studies were selected based on predefined inclusion and exclusion criteria, and extracted data included clinical parameters, network characteristics such as bandwidth and latency, geographic setting, and type of telemedicine service. A total of 45 studies met the inclusion criteria, with most published between 2020 and 2024. The most frequently reported applications were telediagnosis, particularly robotic ultrasound, followed by telesurgery and teleconsultation. The low latency enabled by 5G networks supported complex telesurgical procedures over distances exceeding 5000 km, while in ultra-remote areas, hybrid solutions combining 5G and fiber-optic networks were often adopted to ensure stable connections. The integration of robotic platforms and AI-based tools further enhanced the precision and reliability of remote procedures. Overall, 5G technology has significantly advanced telemedicine by enabling real-time, high-quality care over long distances, improving access to specialist services and supporting more equitable and efficient digital healthcare delivery, particularly in underserved regions.},
}
@article {pmid42074180,
year = {2026},
author = {Mosteanu, IM and Parliteanu, OA and Mahler, B and Mitrea, A and Clenciu, D and Stefan, AG and Timofticiuc, DCP and Stoichita, A and Popoviciu, MS and Reurean Pintilei, DV and Rosu, MM and Radu Gheonea, TC and Vladu, BE and Boldeanu, L and Mota, E and Efrem, IC and Vladu, IM and Mota, M},
title = {Diabetes Mellitus and COVID-19 in Adults: A Systematic Review of Pathophysiological Connections, Clinical Outcomes, and Therapeutic Considerations.},
journal = {International journal of molecular sciences},
volume = {27},
number = {8},
pages = {},
pmid = {42074180},
issn = {1422-0067},
support = {NA//University of Medicine and Pharmacy of Craiova/ ; },
mesh = {Humans ; *COVID-19/complications/epidemiology/therapy/physiopathology ; SARS-CoV-2/isolation &amp; purification ; Adult ; *Diabetes Mellitus/physiopathology ; Hyperglycemia ; *Diabetes Mellitus, Type 2/complications ; },
abstract = {The disproportionately severe disease course of diabetic patients with SARS-CoV-2 infection was repeatedly observed by clinicians during the COVID-19 pandemic. The overlap between metabolic impairment, viral pathophysiology, and chronic inflammation created a pattern that urged deeper examination. The aim of this paper was to review and synthesize evidence regarding the interaction between diabetes mellitus and COVID-19. We synthesized evidence across mechanistic pathways (immune dysregulation, chronic inflammation, ACE2/DPP-4-related signaling, endothelial dysfunction, and pancreatic involvement) and key clinical outcomes (severity, intensive care unit (ICU) admission, mortality, dysglycaemia/new-onset diabetes, and DKA). This systematic search was conducted in PubMed, Clinical Key, and Google Scholar. The eligibility criteria included papers on adults (≥18 years) with pre-existing diabetes mellitus (type 1 or type 2) or newly diagnosed diabetes/hyperglycemia and confirmed SARS-CoV-2 infection, published between January 2020 and October 2025, in English language. The PRISMA guidelines were used for data extraction. We identified 412 articles, out of which only 30 met all the inclusion criteria. Diabetes was consistently evoked as a major risk factor for severe COVID-19, being associated with higher susceptibility to pneumonia, respiratory failure, ICU admission, and mortality. The explanation lies in the impaired immune system, endothelial dysfunction, and metabolic repercussions imposed by hyperglycemia. Several antidiabetic drugs appeared protective in multiple cohorts. In conclusion, the accumulated evidence underscores the tight interplay between metabolic disease and COVID-19. Essentially, the clinical management of these patients would be a thoughtful selection of antidiabetic therapy and close metabolic monitoring.},
}
@article {pmid42074269,
year = {2026},
author = {Rangel, K and Villas-Bôas, MHS and De-Simone, SG},
title = {Advances in Ozone-Based Inactivation of SARS-CoV-2: An Updated Review.},
journal = {International journal of molecular sciences},
volume = {27},
number = {8},
pages = {},
pmid = {42074269},
issn = {1422-0067},
support = {#200.960-2022//Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)/ ; #30515- 2020-5//Brazilian Council for Scientific Research (CNPq)/ ; },
mesh = {*Ozone/pharmacology ; Humans ; *SARS-CoV-2/drug effects ; COVID-19/prevention &amp; control/virology ; Disinfection/methods ; *Disinfectants/pharmacology ; Pandemics/prevention &amp; control ; *Virus Inactivation/drug effects ; *Betacoronavirus/drug effects ; },
abstract = {The onset of the COVID-19 pandemic prompted the rapid development and deployment of novel strategies and methodologies to manage the dissemination of microorganisms. Understanding the crucial role that contaminated surfaces play in the spread of viruses highlights the importance of having effective cleaning and disinfection protocols in place for inanimate objects. A variety of antimicrobial agents have shown strong effectiveness against the SARS-CoV-2 virus. Various factors can impact on the performance of these agents. As a result, technologies utilizing ozone's microbicidal effects have been developed or improved for cleaning indoor areas, surfaces, and materials, despite ozone's diverse uses being known for years. Ozone offers the advantage of adaptability for both gaseous and aqueous use, depending on the nature of the decontaminated surfaces. Moreover, ozone-infused water is ecologically benign, possesses microbial-fighting capabilities, and synergistically reinforces the biocidal action of other chemical disinfectants. This review aims to summarize the efforts dedicated to harnessing gaseous and aqueous ozone as a valuable means to eliminate the SARS-CoV-2 virus from environments, surfaces, clinical equipment, and office supplies. This review sourced evidence-based articles from electronic databases, including MEDLINE (via PubMed), EMBASE, the Cochrane Library (CENTRAL), and preprint repositories. The findings illustrated that ozone could serve as an additional tool for curbing the proliferation of COVID-19 and other viral infections. Additionally, we elucidated the operational attributes of ozone, the variables that influence its disinfection potency, and the mechanisms of its virucidal action. Notably, this review does not encompass the disinfection of the COVID-19 virus in wastewater.},
}
@article {pmid42074690,
year = {2026},
author = {Lucaciu, FC and Wellmann, N and Mihai, AM and Sima, A and Rosca, O and Suba, MI and Tarau, A and Bosoanca, A and Marc, M},
title = {Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up.},
journal = {Journal of clinical medicine},
volume = {15},
number = {8},
pages = {},
pmid = {42074690},
issn = {2077-0383},
abstract = {Context/Objectives: In patients with COPD (chronic obstructive pulmonary disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection represents an overlap of viral injury on a lung already affected by pathological mucus, altered mucociliary clearance, chronic inflammation, and impaired antiviral immunity. Methods: A focused narrative review (2020-2025) was conducted using clinical, experimental, and consensus evidence. The evidence was synthesized qualitatively, with priority given to cohort studies, meta-analyses, and mechanism-focused studies with clinical relevance. Results: Mucus obstruction ("mucus plugs") is frequent in COPD (41-67%) and is associated with unfavorable outcomes. COPD also increases the risk of post-COVID respiratory sequelae. Bacterial coinfection at presentation is uncommon (3-5%), whereas secondary bacterial infections are more frequent (14-18%), especially in severe disease requiring intensive care, where VA-LRTI/VAP (ventilator-associated lower respiratory tract infection/ventilator-associated pneumonia) become predominant. Sepsis, whether viral or mixed, reflects disease severity and may contribute to functional decline and susceptibility to reinfections; however, the concept of a post-acute "sepsis legacy" in COPD after COVID-19 should currently be regarded as a clinically plausible but still emerging hypothesis rather than an established COPD-specific outcome. During recovery, acute exacerbation risk rises to 5.6% versus 3.9%, peaking in the first 30 days after severe disease (aHR ≈ 8.14). Persistent dyspnea and reduced DLCO (diffusing capacity for carbon monoxide) suggest ARDS-related injury, tissue remodeling, and microvascular dysfunction. Conclusions: In COPD, post-COVID respiratory sequelae result from the interaction of mucus, immunity, and infectious/sepsis-related complications. The first post-discharge month is a critical period requiring careful risk stratification and targeted follow-up.},
}
@article {pmid42075512,
year = {2026},
author = {Alexandru, GC and Gligor, LN and Chioran, D and Roi, CI and Riviș, M and Pricop, MO and Urîtu, A and Pacnejer, AM and Manea, HC and Olariu, TR},
title = {Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {4},
pages = {},
pmid = {42075512},
issn = {1648-9144},
mesh = {Humans ; *COVID-19/complications ; *Osteonecrosis/etiology/therapy ; Risk Factors ; *Jaw Diseases/etiology/therapy ; SARS-CoV-2 ; Mucormycosis/complications ; Bisphosphonate-Associated Osteonecrosis of the Jaw ; },
abstract = {Background and Objectives: Osteonecrosis of the jaw (ONJ) occurring after infection with SARS-CoV-2 has emerged as an increasingly reported complication in the post-COVID-19 era. Post-COVID-19 osteonecrosis of the jaw (PC-ONJ) has been described in association with both COVID-19-associated mucormycosis (CAM) and non-fungal phenotypes. This narrative review aims to synthesize and critically analyze the available evidence regarding terminology and classification, epidemiology and risk factors, pathophysiological mechanisms, clinical and imaging characteristics, diagnostic challenges, and management strategies relevant to oral and maxillofacial surgery practice. Materials and Methods: An extensive literature search was conducted in the PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and Google Scholar databases. The search targeted peer-reviewed publications published between 2020 and 2025, reflecting the post-pandemic emergence of this clinical spectrum. Original studies, systematic and narrative reviews, multicenter case series, consensus guidelines, and well-documented case reports were considered. Results: Available data, largely derived from case reports and small series, demonstrate a predominance of maxillary involvement and frequent association with diabetes mellitus and systemic corticosteroid therapy. Proposed mechanisms include COVID-19-associated endothelial dysfunction, microvascular thrombosis, immune dysregulation, metabolic imbalance, and treatment-related effects. Clinically, patients may present with persistent orofacial pain, tooth mobility, exposed or probeable bone, and frequent sinonasal extension, with symptoms sometimes preceding bone exposure. Diagnostic challenges arise from the overlap with medication-related osteonecrosis of the jaw (MRONJ), osteoradionecrosis (ORN), and chronic osteomyelitis. Imaging is essential for assessing disease extent but remains insufficient for etiologic differentiation, making histopathological examination and targeted microbiological investigations necessary, particularly to exclude invasive fungal infection. Conclusions: Management must be etiology-driven. CAM requires urgent antifungal therapy combined with surgical debridement, whereas non-fungal forms are generally managed with conservative surgery and appropriate antimicrobial stewardship. Standardized diagnostic criteria and prospective multicenter studies are needed to reduce nosological ambiguity and optimize clinical decision-making in this emerging post-viral condition.},
}
@article {pmid42075521,
year = {2026},
author = {Balan, A and Graham, G and Sorin, H and Marcu, M and Gheorghe, N and Gabriela, M and Florescu, AR and Popa, AM and Lascu, A and Mot, CI and Mihaicuta, S and Frent, SM},
title = {Efficacy and Safety of Vagus Nerve Stimulation for Hospitalized COVID-19 Patients: A Systematic Review and Methodological Evaluation of Randomized Controlled Trials.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {4},
pages = {},
pmid = {42075521},
issn = {1648-9144},
mesh = {Humans ; Randomized Controlled Trials as Topic ; *Vagus Nerve Stimulation/methods/adverse effects ; *COVID-19/therapy ; Hospitalization ; Treatment Outcome ; SARS-CoV-2 ; },
abstract = {Background and Objectives: Coronavirus disease 2019 (COVID-19) is characterized by excessive inflammatory responses, including the so-called cytokine storm, which contributes substantially to morbidity and mortality in hospitalized patients. The vagus nerve, through the cholinergic anti-inflammatory pathway, represents a theoretically attractive therapeutic target for modulating systemic inflammation. Vagus nerve stimulation (VNS) has emerged as a potential adjunctive treatment for COVID-19, with several randomized controlled trials (RCTs) investigating its efficacy on inflammatory biomarkers and clinical outcomes. The quality of this evidence base has not been rigorously evaluated. This systematic review critically appraises all available RCT evidence for VNS in hospitalized COVID-19 patients. Materials and Methods: We systematically searched PubMed, Scopus, Cochrane (CENTRAL), and Web of Science from database inception to January 2026, for RCTs evaluating any form of VNS (invasive, non-invasive, cervical, or auricular) in hospitalized patients with confirmed acute COVID-19. Two reviewers independently screened titles, abstracts, and full texts according to pre-specified eligibility criteria. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, with assessments initially performed using multiple artificial intelligence tools and subsequently validated by the authors in accordance with PRISMA 2020 guidelines. Given substantial heterogeneity and high risk of bias, narrative synthesis was performed rather than meta-analysis. Also, GRADE assessment was performed. Results: From 437 records identified, six RCTs comprising 221 patients met the inclusion criteria. Five trials (83%) were rated as high risk of bias, primarily due to inadequate blinding, substantial baseline imbalances, significant missing data and extensive multiple testing without statistical correction. The single double-blind trial with a credible sham control (Rangon et al.) found null results across all outcomes, including clinical progression, ICU transfer, and mortality, while the five "high" risk-of-bias trials generally reported positive findings on various inflammatory markers and clinical outcomes. One trial (Corrêa et al.) measured heart rate variability as a direct indicator of vagal activation and found no change despite claiming anti-inflammatory effects, contradicting the proposed mechanism of action. Significant cognitive findings from an interim analysis (Uehara et al., n = 21) disappeared in the larger completed trial (Corrêa et al., n = 52), providing empirical demonstration of false positive findings in small, underpowered studies. Conclusions: Currently available evidence supporting the use of VNS for acute COVID-19 remains scarce; however, the physiological rationale remains sound, although the absence of reliable target engagement markers in the included studies limits confidence in this treatment method. Large-scale, double-blind, sham-controlled trials are required before VNS can be firmly recommended for COVID-19 management.},
}
@article {pmid42075693,
year = {2026},
author = {Amusan, OT and Guo, H},
title = {CMGC Kinases in Viral Infection and Human Disease.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {4},
pages = {},
pmid = {42075693},
issn = {2076-0817},
support = {R21CA303392//National Institute of Health/ ; P20GM134974//National Institute of Health/ ; },
mesh = {Animals ; Humans ; Host-Pathogen Interactions ; Receptor Cross-Talk ; *Signal Transduction ; *Virus Diseases/enzymology ; Phosphorylation ; *Protein Serine-Threonine Kinases/metabolism ; },
abstract = {Cellular processes rely heavily on protein phosphorylation, a mechanism essential for organismal physiology and pathology. The CMGC family comprises a large group of serine/threonine kinases defined by a conserved catalytic core and closely related kinase domains. While several CMGC members have been extensively studied, others, including the RCK and CDKL subfamilies, remain less studied. Here, we synthesize current knowledge of CMGC kinases, emphasizing their structural organization, mechanisms of activation, and roles in infection and disease. CMGC kinases such as CDKs and DYRKs are activated downstream of growth factor signaling to drive proliferative programs. In contrast, other CMGC members respond to cellular stress signals, including stress cytokines, and function during quiescence or adverse conditions to regulate antiproliferative and pro-survival pathways. Through these context-dependent activities, CMGCs govern fundamental cellular processes, including growth, metabolism, transcription, and genome integrity. Although individual CMGC kinases operate within distinct signaling cascades, substantial crosstalk exists among their pathways. Both DNA and RNA viruses exploit host CMGC networks to reprogram the intracellular environment and enhance replication. While CMGC-virus interactions are often proviral, specific CMGC-mediated antiviral responses have been described, notably in SARS-CoV-2 infection. Collectively, CMGC kinases occupy a central position in cellular homeostasis and disease.},
}
@article {pmid42075711,
year = {2026},
author = {Khan, MA and Khan, MH and Allemailem, KS},
title = {Mitogen-Activated Protein Kinases: Therapeutic Signaling Catalysts in Viral Immune Evasion.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {4},
pages = {},
pmid = {42075711},
issn = {2076-0817},
mesh = {Humans ; *Immune Evasion ; *Mitogen-Activated Protein Kinases/metabolism/immunology ; *Virus Diseases/immunology/drug therapy/virology ; SARS-CoV-2/immunology ; Signal Transduction ; Antiviral Agents/therapeutic use/pharmacology ; Animals ; *MAP Kinase Signaling System/immunology ; COVID-19/immunology ; Host-Pathogen Interactions/immunology ; },
abstract = {The mitogen-activated protein kinase (MAPK) pathways, ERK, JNK, and p38, are key regulators of immune responses during viral infections. These signaling cascades control cytokine production, T cell activity, and antigen presentation. However, many viruses can hijack MAPK pathways to avoid immune detection, promote their replication, and establish chronic infection. In this review, we discuss how different viruses, including HSV-1, HBV, HCMV, and SARS-CoV-2, manipulate MAPK signaling to alter host cell functions. A particular focus is given to the CD1d-iNKT cell axis, which plays a critical role in early antiviral responses but is often disrupted through MAPK-dependent mechanisms. We explore how changes in MAPK signaling affect antigen-presenting cells, drive T cell exhaustion, and reprogram immune cell metabolism, factors that contribute to viral immune evasion. The review also examines therapeutic strategies aimed at targeting MAPKs to improve antiviral immunity. These include small-molecule inhibitors and immune modulators that may enhance antiviral responses while limiting side effects. We emphasize the importance of context, as MAPK-targeted therapies must be carefully timed and tailored to avoid suppressing protective immunity or triggering unwanted inflammation. Overall, this review highlights the therapeutic potential and challenges of targeting MAPK pathways in viral infections and encourages further research into selective, host-directed antiviral strategies.},
}
@article {pmid42075977,
year = {2026},
author = {Büyüker, SM and Khan, KA and Khalil, AQK and Khan, I and Jahan, S and Adil, M and Al-Rohily, KM and Al-Khamees, AH and Khalil, AAK},
title = {Elaeocarpus sylvestris (Lour.) Poir.: Phytochemistry and Pharmacological Potential-A Review.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {8},
pages = {},
pmid = {42075977},
issn = {1420-3049},
mesh = {Humans ; *Plant Extracts/chemistry/pharmacology ; *Phytochemicals/chemistry/pharmacology ; Antiviral Agents/chemistry/pharmacology ; *Elaeocarpaceae/chemistry ; Antioxidants/chemistry/pharmacology ; Animals ; Anti-Inflammatory Agents/chemistry/pharmacology ; Flavonoids/chemistry/pharmacology ; COVID-19 Drug Treatment ; Antineoplastic Agents, Phytogenic/chemistry/pharmacology ; },
abstract = {Elaeocarpus sylvestris (Lour.) Poir., an evergreen tree native to East and Southeast Asia, has gained increasing scientific attention owing to its broad pharmacological properties. Traditionally used in East Asian medicine to treat inflammation, fever, and infectious diseases, modern research has revealed diverse bioactivities, including potent antioxidant, anti-inflammatory, antiviral, anticancer, antidiabetic, and immunomodulatory effects. This therapeutic potential is primarily attributed to its rich phytochemical composition, particularly polyphenols such as geraniin, 1,2,3,4,6-penta-O-galloyl-β-D-glucose and quercetin. This review particularly focuses on the chemistry of E. sylvestris, summarizing structurally elucidated compounds, including hydrolysable tannins, flavonoids, and triterpenoids, along with recent insights into the structure-activity relationships that underpin these antiviral, antioxidant, and anticancer activities. Recent studies have demonstrated substantial antiviral efficacy of E. sylvestris extracts and isolated compounds against major human pathogens, including herpesviruses, influenza A virus, and SARS-CoV-2, supported by in silico, in vitro, in vivo, and early-phase clinical evaluations. Its cosmeceutical applications, including antioxidant, skin-whitening, and blue-light protective effects, further highlight its multifunctional potential. To our knowledge, this is the first comprehensive review summarizing the phytochemistry, pharmacological activities, therapeutic potential, and cosmeceutical applications of E. sylvestris. Despite these promising findings, challenges remain in elucidating precise molecular mechanisms, pharmacokinetics, and clinical validation. This review identifies current research gaps and future directions necessary to advance E. sylvestris as a scientifically validated natural therapeutic resource.},
}
@article {pmid42076082,
year = {2026},
author = {Generalov, E and Shevelev, A and Romanov, D and Tarasova, O and Pozdniakova, N},
title = {RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review.},
journal = {Pharmaceutics},
volume = {18},
number = {4},
pages = {},
pmid = {42076082},
issn = {1999-4923},
support = {25-24-01206//Russian Science Foundation/ ; },
abstract = {Background: RNA therapeutics represent a rapidly advancing field with significant potential for treating viral infections and cancer. This review examines the current landscape of RNA-based strategies, including siRNA, miRNA mimics, and antisense oligonucleotides. For viral infections, the focus is on hepatitis B (HBV) and C (HCV), HIV, and SARS-CoV-2. Approaches include targeting viral transcripts directly (e.g., siRNAs against HBV surface antigen) or host factors critical for viral replication (e.g., anti-miR-122 miravirsen for HCV). The successful development of mRNA vaccines for COVID-19 is highlighted as a major breakthrough, demonstrating the feasibility of rapid RNA vaccine deployment. The manuscript reviews several RNA therapeutics in oncology that have reached clinical trials. These include TargomiR (a miR-16 mimic for mesothelioma), cobomarsen (an anti-miR-155 for lymphomas), and MRX34 (a miR-34a mimic for various solid tumours). The review also covers emerging candidates like an miR-221 inhibitor and various strategies for breast cancer, such as targeting Bcl-2, KRAS, and specific miRNAs. A critical challenge across both fields is developing efficient and safe delivery systems, including lipid nanoparticles, GalNAc conjugates, and bacterial minicells. Despite promising preclinical results, clinical translation has been hampered by issues like insufficient delivery efficiency to human tumours, toxicity, and the complex, interconnected regulatory networks of miRNAs, which can lead to unpredictable off-target effects. Conclusions: While RNA therapeutics hold immense promise, overcoming delivery barriers and enhancing understanding of RNA regulatory networks are essential for future success.},
}
@article {pmid42076446,
year = {2026},
author = {Al-Halawani, R and Qassem, M and Kyriacou, PA},
title = {Modelling Skin Pigmentation Using the Monte Carlo Technique: A Review.},
journal = {Sensors (Basel, Switzerland)},
volume = {26},
number = {8},
pages = {},
pmid = {42076446},
issn = {1424-8220},
mesh = {Monte Carlo Method ; *Skin Pigmentation/physiology ; Melanins/metabolism ; Humans ; COVID-19/epidemiology/virology ; *Models, Biological ; Computer Simulation ; SARS-CoV-2 ; },
abstract = {The impact of skin pigmentation on the accuracy of optical biomedical devices has gained increased attention since the COVID-19 pandemic, particularly following evidence of oximetry measurement bias in dark-skinned individuals. Meanwhile, many computational models utilising the Monte Carlo (MC) technique have been developed as a cost-effective and scalable method for investigating these effects. Hence, this review explores the application of the MC technique in modelling skin pigmentation, focusing specifically on how melanin in the epidermis is represented across different studies. First, the biological mechanisms of pigmentation and current stratification methods are outlined to contextualise the variability in skin tone, followed by the principles of MC modelling, including photon scattering, absorption, reflection, and detection. Following a screening and exclusion process, 50 studies were evaluated in terms of how melanin concentration and distribution are incorporated into MC models and their applications, revealing a range of approaches that include analytical equations, experimental optical property measurements, or hybrid methods. The benefits and limitations of each approach is discussed, in addition to emerging advancements such as heterogeneous melanin distribution and the relation between optical properties and skin colour classification scales. Overall, the review outlines the current methodological approaches utilised for skin pigmentation modelling and offers a reference framework for researchers seeking to improve the representation of skin pigmentation in MC-based optical simulations.},
}
@article {pmid42077021,
year = {2026},
author = {Maunder, RG and Strudwick, G and Heeney, ND and Lawson, A and Chaukos, D and Margolese, N},
title = {What Nurse Leaders Can Learn From the Pre-Pandemic Literature Regarding Occupational Stress in Hospital-Based Healthcare Workers.},
journal = {Nursing leadership (Toronto, Ont.)},
volume = {38},
number = {4},
pages = {79-91},
doi = {10.12927/cjnl.2026.27822},
pmid = {42077021},
issn = {1929-6355},
mesh = {Humans ; *Occupational Stress/psychology ; COVID-19 ; *Leadership ; *Nurse Administrators/psychology ; Pandemics ; Frontline Workers ; },
abstract = {The purpose of this paper is to identify studies of hospital-based occupational stress prior to the COVID-19 pandemic that can offer lessons to nurse leaders in our current post-pandemic environment. A scoping review was conducted based on the Joanna Briggs Institute framework, including key phases and principles identified by Arksey and O'Malley. Evidence from different disciplines and settings has been relatively siloed. Nurses and doctors have tended to be studied separately using different constructs. Progress in developing more effective interventions to mitigate occupational stress in healthcare may require greater cross-disciplinary collaboration in which nurse leaders are well poised to lead.},
}
@article {pmid42077335,
year = {2025},
author = {Tian, V and Ramlee, F and Hamzah, H and Ng, TS},
title = {Exploring Sleep and Physical Activity among Young Adults Across Asia: A Systematic Literature Review.},
journal = {The Malaysian journal of medical sciences : MJMS},
volume = {32},
number = {4},
pages = {106-128},
pmid = {42077335},
issn = {1394-195X},
abstract = {Previous studies have examined the association between sleep and physical activity; however, few have systematically reviewed the studies on young adults in Asia. Therefore, the present study aimed to systematically summarise the research on sleep and physical activity among young adults in Asia and critically assess the methodological quality of existing studies. The review process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, beginning with research question formulation and systematic searches through identification, screening, and eligibility in the Scopus, PubMed, and ScienceDirect databases. Subsequently, the studies underwent quality appraisal, data extraction, and analysis. Thematic analysis organised the findings into three main themes: i) the prevalence of sleep quality and physical activity in Asia; ii) the association between sleep quality and physical activity; and iii) sleep quality and physical activity during the COVID-19 outbreak. These findings reveal a high prevalence of sleep deprivation and poor sleep quality among young adults in Asia, whereas the prevalence of physical activity varies. Moreover, the COVID-19 outbreak negatively affected sleep quality and physical activity. Therefore, proactive measures should be implemented to improve sleep quality and promote physical activity, thereby improving physical and mental health.},
}
@article {pmid42077952,
year = {2026},
author = {He, J and Rameli, MRM},
title = {A systematic review of predictors of college students' subjective well-being: evidence from pre- and post-pandemic literature.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1793063},
pmid = {42077952},
issn = {2296-2565},
mesh = {Humans ; *Students/psychology ; Psychological Well-Being ; Universities ; *COVID-19/psychology/epidemiology ; *Mental Health ; Social Support ; Adaptation, Psychological ; China/epidemiology ; Coping Skills ; Exercise ; },
abstract = {BACKGROUND: The COVID-19 pandemic significantly affected the mental health of university populations, necessitating a systematic synthesis of the predictors of subjective well-being among Chinese college students.<br><br>METHODS: Following PRISMA 2020 guidelines, the researchers searched PubMed, Web of Science, and Scopus for peer-reviewed studies published between 2018 and 2024, completing the final search on December 30, 2024. Methodological quality was evaluated using design-specific JBI appraisal tools to accommodate the diverse longitudinal, quasi-experimental, qualitative, and cross-sectional methodologies within the sample. The analytic process utilized a two-stage thematic synthesis involving deductive data extraction followed by inductive theme generation to maintain methodological precision.<br><br>RESULTS: The final sample included 34 studies comprising 15,301 participants and revealed six primary predictive clusters for well-being, including social support, interpersonal dynamics, physical activity, and individual resilience. Longitudinal and quasi-experimental findings indicate that familial cohesion, leisure crafting, and adaptive coping strategies are sustained predictors of happiness during the post-pandemic recovery phase. Qualitative data further elucidate subjective challenges regarding digital temperance and the construction of self-identity in virtual environments.<br><br>CONCLUSION: This study provides an empirical framework to guide higher education administrators and policymakers in developing targeted mental health interventions tailored to evolving academic environments.},
}
@article {pmid42079577,
year = {2026},
author = {Xi, H and Li, M and Shen, J and Lin, Y and Wang, B and Yu, Q and Wang, H and Zhao, Y},
title = {COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors therapy in cancer patients: a meta-analysis of real-world studies.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1807267},
pmid = {42079577},
issn = {1664-3224},
mesh = {Humans ; *Immune Checkpoint Inhibitors/therapeutic use ; *Neoplasms/drug therapy/mortality/immunology ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology/therapeutic use/administration &amp; dosage ; *SARS-CoV-2/immunology ; Treatment Outcome ; Observational Studies as Topic ; Vaccination ; },
abstract = {BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet treatment responses remain heterogeneous. With the widespread implementation of coronavirus disease 2019 (COVID-19) vaccination, uncertainty persists regarding its impact on antitumor efficacy in patients receiving ICIs. While vaccine safety has been extensively studied, the association between COVID-19 vaccination and ICI therapeutic outcomes has not been systematically evaluated.<br><br>METHODS: We conducted a systematic review and meta-analysis of observational studies examining the association between COVID-19 vaccination and oncologic outcomes in patients treated with ICIs. PubMed, Embase, and Scopus were searched from 2020 to December 31, 2025. Primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes included objective response rate (ORR) and disease control rate (DCR). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using random-effects models.<br><br>RESULTS: Ten observational studies comprising 4,929 patients receiving ICIs were included. COVID-19 vaccination was associated with significantly improved PFS (pooled HR&#xa0;=&#xa0;0.66, 95% CI 0.48-0.90) and OS (pooled HR&#xa0;=&#xa0;0.51, 95% CI 0.39-0.66) compared with no vaccination. Vaccinated patients showed numerically higher ORR (pooled OR&#xa0;=&#xa0;1.74, 95% CI 0.89-3.41) and DCR (pooled OR&#xa0;=&#xa0;1.74, 95% CI 0.83-3.46), although these differences were not statistically significant. Subgroup analyses by vaccine platform and cancer type yielded consistent associations.<br><br>CONCLUSIONS: COVID-19 vaccination is associated with improved survival outcomes in patients receiving ICIs. Although the observational nature of available data warrants cautious interpretation, the consistency of findings and their biological plausibility support the clinical compatibility of vaccination with ICI therapy, but causal or synergistic effects cannot be established from these data. These results reinforce current vaccination recommendations and highlight the need for prospective studies to further elucidate underlying mechanisms and optimize integration with cancer immunotherapy.<br><br>https://www.crd.york.ac.uk/prospero/, identifier CRD420261277938.},
}
@article {pmid42079584,
year = {2026},
author = {Liu, X and Mai, Z and Sun, L and Deng, L and Tang, M and Li, G and Yang, X},
title = {Respiratory epithelial cells as central mediators of immune crosstalk in SARS-CoV-2 infection.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1799580},
pmid = {42079584},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/pathology ; *SARS-CoV-2/immunology ; *Epithelial Cells/immunology/virology ; *Respiratory Mucosa/immunology/virology ; Angiotensin-Converting Enzyme 2 ; Renin-Angiotensin System/immunology ; Animals ; Signal Transduction ; Cytokines/immunology ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces life-threatening acute lung injury (ALI) and disrupts immune homeostasis, however, the role of epithelial-immune cell crosstalk in driving this pathology remains incompletely elucidated. Respiratory epithelial cells (RECs) as the primary targets of SARS-CoV-2 via the ACE2 receptor, act as central mediators of immune crosstalk that balances antiviral defense and immunopathology in COVID-19. Beyond forming a physical barrier against pathogen invasion, RECs regulate bidirectional crosstalk with immune cells (including alveolar macrophages, dendritic cells, neutrophils, and lymphocytes) through multiple mechanisms, such as cytokine signaling, antigen presentation, PD-L1 checkpoint modulation, and renin-angiotensin-aldosterone system (RAAS) dysregulation. Under physiological conditions, these interactions promote viral clearance and epithelial repair; In contrast, dysregulation of such crosstalk leads to excessive inflammatory responses like cytokine storm and impaires tissue regeneration. Elucidating the molecular dynamics underlying REC-immune crosstalk is crucial for gaining insights into the development of targeted therapies (e.g., modulating cytokine signaling, restoring RAAS balance) to mitigate the severity of COVID-19. This review summarized recent findings to clarify how REC-mediated immune crosstalk dictates antiviral responses and pathological outcomes, thereby providing a theoretical basis for optimizing therapeutic strategies that strengthen antiviral immunity while minimizing immunopathology.},
}
@article {pmid42080553,
year = {2026},
author = {Zhang, L and Hoffmann, M and Pöhlmann, S},
title = {Lock out: targeting TMPRSS2 to block influenza and coronaviruses.},
journal = {Journal of virology},
volume = {100},
number = {6},
pages = {e0080725},
pmid = {42080553},
issn = {1098-5514},
support = {101057100//HORIZON EUROPE Health/ ; COFONI 14-76403-184//Nieders&#xe4;chsisches Ministerium f&#xfc;r Wissenschaft und Kultur/ ; VIGILANT (101041799)//HORIZON EUROPE Health/ ; TTU 01.829//German Center for Infection Research/ ; },
mesh = {Humans ; *Serine Endopeptidases/metabolism/genetics ; SARS-CoV-2 ; *Influenza, Human/drug therapy/virology ; *Influenza A virus/drug effects ; *Antiviral Agents/pharmacology/therapeutic use ; COVID-19 ; Animals ; Pandemics ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {Coronaviruses and influenza A viruses (IAV) can cause severe respiratory disease and have pandemic potential. Both viruses depend on priming of their glycoproteins by host cell proteases for the acquisition of infectivity, and the responsible enzymes represent potential targets for intervention. Initial studies suggested that these viruses may exploit redundant proteolytic systems. However, research conducted over the last two decades has pointed to a key role for a single enzyme in coronavirus and IAV priming, the transmembrane protease serine 2 (TMPRSS2). Interest in TMPRSS2 as a host dependency factor and therapeutic target intensified during the COVID-19 pandemic, prompting extensive investigation into its biology, substrate specificity, and pharmacological inhibition. Here, we review recent efforts to define the role of TMPRSS2 in coronavirus infection and to target this protease for antiviral intervention.},
}
@article {pmid42081038,
year = {2026},
author = {McGrath, H and Brennan, E and Harmon, D},
title = {The assessment of clinical competence in medical students during the COVID-19 pandemic: a scoping review.},
journal = {Irish journal of medical science},
volume = {},
number = {},
pages = {},
pmid = {42081038},
issn = {1863-4362},
abstract = {BACKGROUND: The COVID-19 pandemic necessitated unprecedented changes to clinical education and assessment. Restrictions on in-person clinical encounters led to rapid adoption of digital assessment modalities, raising concerns about graduate preparedness and the validity of pandemic-adapted assessment approaches. Wojniusz, [40].<br><br>OBJECTIVES: This scoping review aimed to: (1) map approaches to assessing clinical competence in medical students during COVID-19; and (2) evaluate the validity, reliability, feasibility, and acceptability of pandemic-adapted assessments.<br><br>METHODS: Following Arksey and O'Malley's framework, we systematically searched six databases (PubMed/MEDLINE, Scopus, Web of Science, EMBASE, ERIC, Google Scholar) for peer-reviewed empirical studies published March 2020-March 2023 examining clinical competence assessment in final-year medical students. Studies were analyzed using Van der Vleuten's utility framework (validity, reliability, feasibility, acceptability) and Miller's Pyramid to categorize competency levels assessed.<br><br>RESULTS: From 1,247 references, 13 studies met inclusion criteria, representing 8 countries. Virtual OSCEs were the predominant assessment method (n&#x2009;=&#x2009;8, 62%). Study designs were predominantly weak: surveys (n&#x2009;=&#x2009;6), evaluative case studies (n&#x2009;=&#x2009;4), and observational studies (n&#x2009;=&#x2009;2), with only three cohort studies providing stronger evidence. Most studies (92%) focused on feasibility and acceptability rather than validity or psychometric properties. Physical examination and procedural skills assessment remained a critical unresolved limitation across all digital modalities. No studies employed generalizability theory or Kane's validity framework.<br><br>CONCLUSIONS: A paucity of rigorous research on pandemic-adapted assessment validity exists. Published studies employed weak designs producing non-generalizable findings focused on feasibility over validity. Urgent research priorities include: longitudinal cohort studies comparing pandemic-trained graduates to pre-pandemic cohorts; psychometric validation of hybrid assessment models now institutionalized; application of contemporary validity frameworks to digital assessments; and equity analysis of differential impacts across student populations. The field requires systematic validity evidence before permanently adopting pandemic-adapted approaches.},
}
@article {pmid42081931,
year = {2026},
author = {Basil, B and Eze, OE},
title = {Strengthening laboratory quality through risk-based thinking: Implementation challenges and opportunities in Nigeria.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {589},
number = {},
pages = {121041},
doi = {10.1016/j.cca.2026.121041},
pmid = {42081931},
issn = {1873-3492},
mesh = {Nigeria ; Humans ; Quality Control ; *Laboratories, Clinical/standards ; *Laboratories/standards ; },
abstract = {BACKGROUND: Medical laboratories in Nigeria are pivotal for national health security but operate under severe infrastructural deficits and a high disease burden. Traditional Quality Control (QC) methods are prevalent but reactive and fail to address the high proportion of errors occurring in pre- and post-analytical phases. This necessitates a strategic shift toward Risk-Based Thinking (RBT) as mandated by the new ISO 15189:2022 standard to bridge the gap between international requirements and local environmental volatility.<br><br>OBJECTIVES: This review assesses the current state of laboratory quality in Nigeria and evaluates the applicability of RBT frameworks (ISO 15189:2022 and CLSI EP23) in resource-limited settings. It aims to identify structural and cultural implementation barriers and propose actionable mitigation strategies.<br><br>METHODS: This comprehensive narrative review utilized a systematic search strategy across PubMed, Scopus, and AJOL covering 2010-2025. Data from 85 identified sources, including 66 studies selected using a defined criticality matrix, were synthesized using the Plan-Do-Check-Act (PDCA) framework operationalized with specific quality indicators to contrast regulatory expectations with operational realities.<br><br>MAIN TEXT: The sector is polarized, with elite private and donor-funded public laboratories driving accreditation (representing only 26 facilities or&#xa0;<&#xa0;0.5% of the sector), while the majority struggle with a punitive blame culture, the "Japa" syndrome workforce crisis, and erratic power supply. RBT frameworks like Parvin's Risk Management Index offer tools to quantify these unique environmental risks and enable targeted resource allocation. Case studies from EL-LAB and HVL, alongside adaptive lessons from the COVID-19 pandemic, demonstrate that RBT facilitates resilience by scientifically validating investments in solar energy and staff competence to mitigate local hazards.<br><br>CONCLUSION: Transitioning to RBT is critical for Nigerian laboratories to move from reactive compliance to proactive resilience. By managing risks like power instability and supply chain volatility, laboratories can effectively optimize scarce resources through data-driven mitigation to ensure patient safety.},
}
@article {pmid42083745,
year = {2026},
author = {Hussain, SR and El Sahly, HM},
title = {Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2667742},
doi = {10.1080/14760584.2026.2667742},
pmid = {42083745},
issn = {1744-8395},
mesh = {Humans ; *Vaccine Development ; *Respiratory Syncytial Virus Infections/prevention &amp; control/immunology ; Respiratory Syncytial Virus Vaccines/immunology/administration &amp; dosage ; COVID-19 Vaccines/immunology/administration &amp; dosage ; Animals ; *COVID-19/prevention &amp; control/immunology ; *Viral Vaccines/immunology/administration &amp; dosage ; *Respiratory Tract Infections/prevention &amp; control/immunology ; Vaccines, Synthetic/immunology ; Influenza Vaccines/immunology/administration &amp; dosage ; Adenoviridae/genetics ; },
abstract = {INTRODUCTION: Respiratory infections with influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 are a major cause of global mortality. Vaccination is a cornerstone of disease prevention, though traditional platforms face challenges. Recently, several vaccines utilizing mRNA and adenovirus platforms were brought to the market, with additional vaccines undergoing Phase 3 clinical testing.<br><br>AREAS COVERED: This review assesses vaccine literature primarily from 2020 to the present, using National Library of Medicine databases. The rapidity of mRNA technology was tested and implemented successfully during the COVID-19 pandemic. Since then, the mRNA RSV vaccine has been licensed as well. mRNA platforms also offer the ability of combining antigens for multivalent vaccines against multiple pathogens. Several combination products have been used in phase III clinical trials. Adenovirus-vectored vaccines for respiratory viruses have the added advantage of mucosal-based delivery and inducing a potentially stronger local immune response. However, both of these platforms have immunogenicity and safety shortcomings.<br><br>EXPERT OPINION: Novel respiratory virus vaccine platforms have demonstrated their importance with both endemic and pandemic pathogens, because of decades of concerted efforts and investment in research. Expediting future vaccine development requires a continuation of these efforts with a focus on pre-clinical models and a better understanding of correlates of protection.},
}
@article {pmid42083839,
year = {2026},
author = {Godart, N and Cruanès, T and Hirot, F and Huas, C},
title = {[Eating disorders].},
journal = {La Revue du praticien},
volume = {76},
number = {4},
pages = {433-440},
pmid = {42083839},
issn = {2101-017X},
mesh = {Humans ; *Feeding and Eating Disorders/therapy/diagnosis/epidemiology ; COVID-19/epidemiology ; Anorexia Nervosa/diagnosis/therapy/epidemiology ; },
abstract = {Eating disorders (EDs) are very frequent and are increasing since the Covid-19 pandemic. They include anorexia nervosa, bulimia nervosa, binge eating disorder, avoidance and restriction disorders and their subsyndromic forms. EDs affect people of all ages, they generate somatic, psychiatric and social complications. Early diagnosis and appropriate care can considerably improve the prognosis. Unfortunately, these disorders steel underdiagnosed and the specialized care pathway available are not well known. After describing eating disorders, the article outlines elements for identification and initial assessment, and discusses the main lines of treatment, which must be multidisciplinary, coordinated, gradual and tailored to each individual.},
}
@article {pmid42084832,
year = {2026},
author = {Venkataraman, A and Joseph, NH and Sadanandan, G and Balasubramanian, S},
title = {Navigating the Challenges of Implementing Tuberculosis Research During COVID-19 Pandemic: Insights from the Pediatric Tuberculosis-Moderate Acute Malnutrition Study.},
journal = {Indian pediatrics},
volume = {},
number = {},
pages = {},
pmid = {42084832},
issn = {0974-7559},
support = {BT/RLF/Re-entry/69/2017//Department of Biotechnology, Ministry of Science and Technology, India/ ; },
abstract = {Clinical research involving children presents significant challenges due to physiological, ethical, regulatory, and practical considerations unique to this vulnerable population. These intrinsic challenges were amplified during the COVID-19 pandemic, which substantially disrupted pediatric research and child health services. The pandemic exposed critical ethical, operational, and communicative tensions, especially with respect to informed consent, caregiver trust, and safe research implementation. Examining these intersecting challenges can improve and strengthen pediatric research to remain ethically robust and child-centred in the event of future public health crises.},
}
@article {pmid42085748,
year = {2026},
author = {Tuite, AR and Forbes, N and Salvadori, MI and Tunis, M},
title = {Cost-effectiveness of ongoing COVID-19 vaccination in the context of high population immunity: A structured review of international economic evidence.},
journal = {Vaccine},
volume = {83},
number = {},
pages = {128660},
doi = {10.1016/j.vaccine.2026.128660},
pmid = {42085748},
issn = {1873-2518},
mesh = {Humans ; *Cost-Benefit Analysis ; *COVID-19/prevention &amp; control/economics/immunology/epidemiology ; *COVID-19 Vaccines/economics/administration &amp; dosage/immunology ; Cost-Effectiveness Analysis ; *Vaccination/economics ; SARS-CoV-2/immunology ; Quality-Adjusted Life Years ; Disability-Adjusted Life Years ; Middle Aged ; Aged ; Female ; Child ; Adult ; },
abstract = {BACKGROUND: In the context of ongoing SARS-CoV-2 circulation and high population immunity, jurisdictions face decisions about which population groups should receive ongoing annual vaccination. Economic evaluations are increasingly central to these deliberations but the growing body of global cost-effectiveness evidence has not been synthesized.<br><br>OBJECTIVE: To summarize cost-effectiveness evidence for COVID-19 vaccination from 2023 onwards, organized by population groups of policy relevance.<br><br>METHODS: We conducted a structured literature search in December 2025 across MEDLINE, Embase, and EconLit, supplemented by grey literature searches of National Immunization Technical Advisory Group (NITAG) websites. From 644 screened references, 21 studies met inclusion criteria: economic evaluations of COVID-19 vaccination from 2023 onwards reporting cost-effectiveness of annual vaccination compared to no additional vaccination in quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Results were synthesized by population group.<br><br>RESULTS: Annual COVID-19 vaccination was economically favourable for older adults (&#x2265;60-65&#xa0;years) across all 18 contributing studies spanning 12 countries and using diverse analytic approaches. For individuals with underlying conditions or comorbidities, results were more variable, with cost-effectiveness depending on age, specific conditions, and vaccine price. Vaccination of healthy working-age adults (3 of 4 studies) and children (2 of 3 studies) was generally unfavourable at standard cost-effectiveness thresholds. Limited evidence was identified for healthcare workers and no economic evaluations from 2023 onwards were identified for pregnancy. The evidence base was geographically concentrated in high-income countries, with approximately half of included studies reporting industry funding. Sequential US economic evaluations demonstrated progressive declines in cost-effectiveness as disease burden decreased over time.<br><br>CONCLUSIONS: The economic evidence supports a risk-stratified approach to COVID-19 vaccination, with the strongest economic value observed for older adults and individuals with comorbidities. Cost-effectiveness is dynamic, sensitive to disease burden, vaccine price, and population characteristics, and should be reassessed regularly as epidemiological conditions evolve.},
}
@article {pmid42085825,
year = {2026},
author = {Ambade, PN and Zimmerman, C and Haddad, C and Koperski, C and Rashid, G and Kafri, A and Yazdani, F and Renirie, RH and Pruitt, D and MacKinnon, NJ},
title = {Updating knowledge on existing approaches on advanced care planning interventions: An umbrella review.},
journal = {Archives of gerontology and geriatrics},
volume = {148},
number = {},
pages = {106255},
doi = {10.1016/j.archger.2026.106255},
pmid = {42085825},
issn = {1872-6976},
mesh = {Humans ; *Advance Care Planning/organization &amp; administration ; *Terminal Care ; *COVID-19/epidemiology ; Aged ; Palliative Care ; SARS-CoV-2 ; Quality of Life ; },
abstract = {CONTEXT: Advanced care planning (ACP) can reduce hospitalizations, increase quality of life, and align treatment with patient wishes, while lowering healthcare costs. However, healthcare providers' discomfort, lack of training, and patient anxiety may hinder ACP. Furthermore, disparities exist among minority and low-income groups. Growing research highlights the need for standardized definitions and broader implementation, especially post-COVID-19, incorporating digital tools, economic impacts, ethics, and family roles to improve ACP worldwide.<br><br>OBJECTIVES: This study aims to update and synthesize knowledge from all published systematic reviews from the past ten years, focusing on ACP-related interventions.<br><br>METHODS: We conducted a comprehensive search across PubMed, Cochrane, and Scopus, including only English-language, peer-reviewed systematic reviews published between 2015 and 2025. We employed rigorous screening, dual-reviewer validation, and quality-assessment tools, and synthesized evidence on intervention effectiveness across diverse populations and settings to identify effective ACP strategies.<br><br>RESULTS: Of the deduplicated 7513 records, 61 reviews met the inclusion criteria. For older adult patients, structured conversations reduce unnecessary aggressive treatments and align end-of-life care with preferences. Among racial groups, peer support and palliative consultations boost ACP completion. Patient-centric interventions include video decision aids and web tools, whereas provider-centric interventions include conversation guides, reminder systems, electronic coordination platforms, and facilitator training.<br><br>CONCLUSION: ACP is an ongoing process tailored to patient preferences, requiring efforts to address stigmatized conversations, especially in minority communities and severe illnesses. Emphasis on research into digital tools, policy incentives, infrastructure, and family support is essential. Bridging research and practice will improve outcomes and patient-centered end-of-life care.<br><br>KEY MESSAGE: This article describes an umbrella review of 61 systematic reviews on advanced care planning-related interventions. The analysis indicates that the reviews covered interventions focusing on both facility and community-based individuals and had a specific population or disease focus. The articles covered both patient and provider-centric interventions.},
}
@article {pmid42086298,
year = {2026},
author = {Stark, L and Noble, DJ and Meinhart, M and Erhardt-Ohren, B and Karmin, S and Poulton, C and Sarraf, D and Bustreo, F and Seff, I},
title = {A systematic review of infectious disease outbreaks and violence against women and girls: changes in magnitude, mechanisms and lessons for the future.},
journal = {BMJ global health},
volume = {11},
number = {5},
pages = {},
pmid = {42086298},
issn = {2059-7908},
mesh = {Humans ; Female ; COVID-19/epidemiology ; *Disease Outbreaks ; Pandemics ; SARS-CoV-2 ; *Gender-Based Violence/statistics &amp; numerical data ; *Violence/statistics &amp; numerical data ; },
abstract = {Infectious disease outbreaks (outbreaks) are increasing across the globe due to climate change, urbanisation and changes in land use, and many of their response measures impact risk factors for violence against women and girls (VAWG). We conducted a systematic review to consolidate existing evidence on the impact of any outbreaks, and their public health responses, on the change in magnitude of VAWG and mechanisms facilitating violence among women and girls in low-income and middle-income countries. Though our search strategy aimed to capture studies from any outbreak since 2014, all quantitative evidence on VAWG impacts, and all but one qualitative study, focused on the COVID-19 pandemic, and only three studies disaggregated outcomes for women versus girls. Overall, our synthesis of the evidence points to increased VAWG during the first year of the COVID-19 pandemic compared with pre-pandemic levels. We identified five broad mechanisms through which violence occurred against women and girls: (1) income loss due to economic shutdown, financial insecurity, and/or job loss, (2) movement restrictions, (3) changes in access to public services, (4) fear of exposure to infectious disease, and (5) a legacy of mistrust in health systems from previous outbreaks. Our study demonstrates the novelty of VAWG monitoring during outbreaks, the need for increased surveillance and the known mechanisms to date through which VAWG may be perpetrated during outbreaks. By implementing both short-term protective measures and long-term structural reforms, outbreak responses may not only break the cycle of VAWG exacerbated by public health emergencies but build resilient systems that protect women, girls and marginalised populations before, during and after crises.},
}
@article {pmid42086867,
year = {2026},
author = {Elahi, S},
title = {Immune regulation by erythroid cells: how erythroid progenitor cells and mature red blood cells shape immunity.},
journal = {Nature reviews. Immunology},
volume = {},
number = {},
pages = {},
pmid = {42086867},
issn = {1474-1741},
abstract = {Once considered to be passive oxygen carriers, erythroid cells are now recognized as dynamic modulators of immune responses. Erythroid progenitors and precursors, collectively known as CD71[+] erythroid cells, can suppress innate and adaptive immune responses in neonates, in mothers during pregnancy, in chronic conditions such as cancer and autoimmunity, and during infection with viruses, including SARS-CoV-2 and HIV. Mature red blood cells engage pathogens directly, scavenge chemokines, cytokines and nucleic acids, and modulate immune functions through redox buffering and receptor-mediated interactions. The immune effects of red blood cells are highly context dependent, ranging from suppression to activation. This Review highlights the emerging field of erythroid-immune crosstalk and its translational potential in the settings of infection, cancer, pregnancy and chronic inflammatory conditions.},
}
@article {pmid42087099,
year = {2026},
author = {Varmazyar, S},
title = {Smartphone use and related factors with hand pain among university students: a systematic review.},
journal = {BMC musculoskeletal disorders},
volume = {27},
number = {1},
pages = {},
pmid = {42087099},
issn = {1471-2474},
mesh = {Humans ; *Smartphone ; *Students ; Universities ; *Hand/physiopathology ; Risk Factors ; *Musculoskeletal Pain/epidemiology/etiology ; },
abstract = {BACKGROUND: University students often use smartphones for daily tasks, which can lead to awkward posture and musculoskeletal pain in the hand, wrist, and fingers due to prolonged use. This review aims to investigate the relationship between smartphone use and hand pain among university students.<br><br>METHODS: For this review, we collected and analyzed original English-language articles published between 2014 and 2024. Keywords were selected from the MeSH database. We excluded review articles, books, letters, reports, and other non-original sources, as well as studies that focused on mobile phones or populations other than university students and smartphone users. Additionally, articles addressing pain in other body parts, injuries, and complications from smartphone use, as well as those published during the COVID-19 pandemic, were also omitted. We utilized various keyword combinations related to "university", "students", "smartphone use", "addiction", "overuse", "hand", "pain", "musculoskeletal pain", "wrist", "fingers", "thumb", "risk factors", "characteristics", and "posture" in the search, along with the use of "AND", "OR", or no conjunctions, and the use of quotation marks for one, two, or a few keywords. Literature was obtained from databases such as Web of Science, ScienceDirect, Scopus, PubMed, and ProQuest. A total of 18 studies were selected from 390 primary literature sources, following the PRISMA framework.<br><br>RESULTS: A total of 393 articles were found in the initial search. Duplicate articles were removed, leaving 259 that were examined according to inclusion and exclusion criteria. After assessing the relevance of titles and abstracts, screening, and qualitatively evaluating journals, 18 articles were included in the study. Brazil, Saudi Arabia, and Turkey had the highest number of articles (n&#x2009;=&#x2009;3 or 16.6% of articles). The age group investigated was 18 to 26 years old. Based on the identified risk factors, the articles were discussed in three groups: (1) role of smartphone duration, addiction, and hand pain (83.3% of studies investigated the duration of smartphone use, while 38.8% surveyed smartphone addiction), (2) the effect of smartphone holding posture on the hand and hand pain (38.8% of studies), and (3) the relation of smartphone physical characteristics to hand pain (27.7% of studies). Daily usage duration ranged from less than or equal to 4&#xa0;h/day (53.2%) to 7&#xa0;h or more (73.9%). The reported range of smartphone addiction among students was between 15.9% and 66.6%. The reported prevalence of wrist, hand, and thumb pain was 19.2% to 68.7%. Between 14.75% and 41% of students use their right hand to hold smartphones and type with their right thumb, while 24% to 77.79% use both hands and both thumbs. The size and weight of smartphones can predict hand pain.<br><br>CONCLUSIONS: The amount of time spent using a smartphone, how it is held, how long it has been owned, smartphone addiction, holding posture, frequent thumb movements, preferred hand position, screen size, weight of the smartphone, and smartphone -related the purpose of usage are all risk factors that can lead to pain in the hand, wrist, palm, thumb, and other fingers.},
}
@article {pmid42087263,
year = {2026},
author = {Wogick, L and Goyal, SM},
title = {Porcine epidemic diarrhea virus: a model for coronavirus persistence and immune escape in intensive livestock systems.},
journal = {Porcine health management},
volume = {12},
number = {1},
pages = {},
pmid = {42087263},
issn = {2055-5660},
abstract = {Porcine epidemic diarrhea virus (PEDV) is an enteric alphacoronavirus that has shifted from a sporadic regional pathogen to a worldwide, persistent virus, despite years of vaccination, biosecurity measures, and monitoring. Since the early 1970s, PEDV has shown strong genetic flexibility, the ability to evade immunity, survive in the environment, and spread quickly through connected livestock networks. Major outbreaks in Asia, Europe, and North America, especially the 2013-2014 outbreak in the United States, have revealed key weaknesses in traditional control methods for enteric coronaviruses, especially those that depend on systemic immunization. In this review, we bring together over fifty years of PEDV research to look at how viral evolution, mucosal immune responses, and livestock production systems work together to keep the virus circulating. We point out that changes in the spike gene, including recombination and deletions, along with changes in other viral genes, affect disease severity, immune system recognition of the virus, and the inability of vaccines to provide protection. We also stress the key role of lactogenic immunity and the gut-mammary-secretory IgA system in protecting newborn animals, which helps explain why vaccine inoculations have not been effective in stopping the spread of enteric coronaviruses. By combining evidence from molecular, immune, epidemiological, and systems research, we suggest that PEDV is a strong example for studying how coronaviruses persist under immune pressure in managed animal groups. Using a One Health approach, this review encourages moving away from only reacting to outbreaks and instead focusing on ongoing, genome-based management of coronaviruses in livestock operations.},
}
@article {pmid42087622,
year = {2026},
author = {Lorusso, R and De Piero, ME and Mariani, S and Ravaux, JM and Nardelli, P and Jacobs, JP and Guarracino, F and Patroniti, N and van Bussel, BCT and van der Horst, ICC and Taccone, FS and Heinsar, S and Shekar, K and Yamashita, MH and Obonyo, NG and Ciullo, AL and Riera, J and Dalton, H and Wang, A and Zaaqoq, AM and MacLaren, G and Ramanathan, K and Suen, JY and Li Bassi, G and Sato, K and Fraser, JF and Peek, GJ and Arora, RC and , },
title = {Hemodynamic monitoring during veno-venous extracorporeal membrane oxygenation: A scoping review.},
journal = {Perfusion},
volume = {41},
number = {1_suppl},
pages = {95S-109S},
doi = {10.1177/02676591261429826},
pmid = {42087622},
issn = {1477-111X},
support = {//The Bill and Melinda Gate Foundation/ ; },
mesh = {Humans ; *Extracorporeal Membrane Oxygenation/methods ; *Hemodynamic Monitoring/methods ; *Hemodynamics ; },
abstract = {BackgroundIn adult patients receiving veno-venous Extracorporeal Membrane Oxygenation (VV ECMO), cardiovascular performance plays a critical role in determining oxygen delivery, organ perfusion and safe titration of extracorporeal support. Despite the increasing VV ECMO use, contemporary guidance on hemodynamic monitoring remains limited and largely experience-based. This scoping review aimed to map available basic and advanced monitoring approaches and to identify current evidence gaps.MethodsPubMed, EMBASE, and Cochrane CENTRAL were searched from inception until September 2025, along with reference lists of relevant articles. We included studies of any design reporting techniques, targets, or protocols for hemodynamic monitoring during VV ECMO.ResultsOf 465 records screened, 106 met inclusion criteria. No protocolized, evidence-based hemodynamic monitoring protocol specific to VV ECMO was identified. The available evidence was heterogeneous and mostly derived from physiologic studies or single-center observational cohorts. Findings were narratively synthesized across three domains: basic bedside monitoring, diagnostic/prognostic tools and advanced assessment of cardiopulmonary interaction. Across studies, no monitoring strategy consistently reduced time-to-wean or mortality. Observational data suggested that care bundles and multidisciplinary approaches may reduce complications. However, the risk of bias limits causal inference.ConclusionsDespite the complex interaction between native cardiovascular function and extracorporeal circulation, VV ECMO lacks consensus on evidence-based hemodynamic monitoring pathways. A pragmatic core monitoring bundle with tiered triggers for escalation is necessary. Future priorities include implementation models based on multidisciplinary teams, specific training, standardized bundles, and multicenter studies aimed to define right ventricular-centered targets to improve safety and clinical decision-making.},
}
@article {pmid42087798,
year = {2026},
author = {Rosca, EC and Oke, J and Jefferson, T and Brassey, J and Onakpoya, I and Plüddemann, A and Gandini, S and Maltoni, S and Evans, D and Conly, J and Heneghan, C},
title = {Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.},
journal = {Epidemiology and infection},
volume = {154},
number = {},
pages = {e89},
pmid = {42087798},
issn = {1469-4409},
support = {//University of Calgary/ ; },
mesh = {Humans ; *SARS-CoV-2/genetics/isolation &amp; purification/pathogenicity ; *COVID-19/diagnosis/transmission/virology/epidemiology ; },
abstract = {We sought to assess predictive factors for SARS-CoV-2 infectiousness using a meta-analytic approach. We searched LitCovid, medRxiv, Google Scholar, and the WHO COVID-19 database until June 30 2025, including studies which cultured SARS-CoV-2, relating them to clinico-epidemiologic and laboratory variables and RT-PCR cycle threshold (Ct) values. Using linear mixed-effects regression models, we tested for independent associations with Ct values with 95%CIs and adjusted P-values in a multivariable model. We used a modified QUADAS criteria to assess risk-of-bias. We included 50 studies, with 39 in quantitative synthesis. The percentage of culture-positive specimens decreased with increasing Ct values (subgroup test difference Q = 96.71;P < 0.001) and time since the first PCR test (Q = 26.95;P = 0.0026). Presence of symptoms (Q = 20.1;P < 0.01), gene platform used (Q = 14.89;P = 0.002), being a cancer patient (Q = 24.9;P < 0.0001), and vaccination status (Q = 8.80;P = 0.012) were associated with increased culture-positivity, whereas a rising Ct (adjusted Ct change -6.58[95%CI] -5.30, -7.86;P < 0.001) was strongly associated with culture-negativity. Analysing 186 immunocompetent patients with 1,393 Ct values, 2 consecutive Cts ≥ 30 or a rising Ct value on serial testing demonstrated a sensitivity of 87.5% and specificity of 96.3% using culture positivity as the outcome. Serial Ct monitoring, integrated with clinico-epidemiologic data is a valuable tool for assessing infectiousness, providing objective criteria for discontinuing isolation and guiding clinical decisions.},
}
@article {pmid42088248,
year = {2026},
author = {Biscaldi, V and Guerini, J and Ghelfi, M and Velasco, V},
title = {Instruments used to measure well-being, ill-being, and health-related lifestyle behaviors in students attending Italian universities: a systematic review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1787567},
pmid = {42088248},
issn = {2296-2565},
mesh = {Humans ; *Students/psychology/statistics &amp; numerical data ; Italy ; Universities ; Psychological Well-Being ; *Life Style ; *Health Behavior ; Female ; *Health Status ; Surveys and Questionnaires ; Male ; },
abstract = {BACKGROUND: The well-being of university students is increasingly recognized as a critical public health issue, influenced by complex interactions among psychological, behavioral, and contextual factors. Despite growing research, measurement tools often lack standardization and contextual specificity, limiting the understanding of students' health. This review aimed to map and critically analyze instruments assessing well-being, ill-being, and health-related lifestyle behaviors among Italian university students, as well as the associated variables, including risk and protective factors.<br><br>METHODS: The systematic review followed PRISMA guidelines and included peer-reviewed studies published from 2010 onward, identified across five databases: Scopus, APA PsycInfo, PubMed, ERIC, and Web of Science. A structured data extraction process was applied to collect information on sample characteristics, health-related outcomes, and associated variables (protective and risk factors). Descriptive statistics were used to synthesize frequencies, proportions, and distributions of measurement instruments and constructs across the included studies.<br><br>RESULTS: A total of 223 studies were included. Samples were largely non-probabilistic and female-biased. Ill-being measures appeared exclusively in 66.3% of the studies, while 7.9% focused on well-being, and 25.8% included both. A total of 159 instruments assessing well-being and ill-being were identified. Of these, the majority measured ill-being (118 instruments), followed by instruments assessing well-being (28), and a smaller number addressing both constructs (13). In addition, 154 instruments measuring lifestyle were identified. Lifestyle behaviors were measured in a fragmented, health-risk-oriented manner, often lacking contextual influences. Individual predictors (130) were prioritized over relational and environmental factors (53). Few instruments were tailored specifically to university students, and many studies used non-validated or ad hoc tools, especially those developed during the COVID-19 pandemic.<br><br>DISCUSSION: Findings highlight the need for standardized, validated, and context-sensitive instruments to assess student health holistically.},
}
@article {pmid42088258,
year = {2026},
author = {Huang, H and Chen, S and Fang, Z and Ma, Y and Xu, Y and Dong, G},
title = {The "two-hit" storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia-a mechanistic review and clinical implications.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1782871},
pmid = {42088258},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/immunology/complications ; Post-Acute COVID-19 Syndrome ; *Pneumonia, Bacterial/immunology ; Child ; SARS-CoV-2 ; *Inflammation/immunology ; Community-Acquired Pneumonia ; Severity of Illness Index ; },
abstract = {Following the COVID-19 pandemic, the clinical patterns of pediatric respiratory infections have undergone significant changes, with increasing attention on the immunological imprint left by Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. A perplexing clinical phenomenon has been observed: some children with a history of Long COVID exhibit a disproportionately severe inflammatory response and extensive lung injury when encountering common community-acquired pneumonia, such as that caused by Mycoplasma pneumoniae or Streptococcus pneumoniae, inconsistent with their pathogen load. This review aims to dissect this phenomenon and proposes the "Immune Priming and Two-Hit" model as its core pathophysiological framework. This model posits that the Long COVID state constitutes the "first hit," establishing a "primed" or "hyper-reactive" immune baseline through viral persistence, trained immunity-induced monocyte reprogramming, and sustained endothelial dysfunction. Upon the "second hit" of a bacterial infection, this primed immune system triggers a dysregulated, synergistically amplified inflammatory cascade. The mechanisms involve the exponential release of cytokines such as Interleukin-6 (IL-6), IL-1β, and Tumor Necrosis Factor-α (TNF-α), inflammation-mediated immunothrombosis, and excessive activation of Neutrophil Extracellular Trap formation (NETosis), ultimately leading to severe outcomes like Acute Respiratory Distress Syndrome (ARDS) and necrotizing pneumonia. Consequently, identifying and defining this "Hyper-inflammatory endotype" is of critical clinical importance. We define it as an "endotype" to emphasize the distinct, host-determined pathophysiological mechanisms underlying it, rather than merely a collection of clinical manifestations. By monitoring biomarkers such as ferritin, D-dimer, lactate dehydrogenase (LDH), and lymphocyte counts, clinicians may be able to perform early risk stratification of these children. This approach not only facilitates a shift in therapeutic strategy from purely antimicrobial therapy to "host-directed therapy"-emphasizing the necessity of early, adequate corticosteroid use and consideration of anticoagulation-but also provides a new theoretical basis and intervention window for preventing long-term sequelae such as pulmonary fibrosis.},
}
@article {pmid42088527,
year = {2026},
author = {Focosi, D and Franchini, M and Casadevall, A},
title = {On the Use of Immunoglobulins for Pre-exposure Prophylaxis Against COVID-19 in Immunocompromised Patients.},
journal = {Infection and drug resistance},
volume = {19},
number = {},
pages = {540925},
pmid = {42088527},
issn = {1178-6973},
abstract = {COVID-19 remains a cause of significant mortality and morbidity for immunocompromised patients. In the current absence of effective monoclonal antibodies to SARS-CoV-2, standard commercial intravenous/subcutaneous immunoglobulin (IVIG/SCIG) lots provide an option for passive immunotherapy since these now consistently contain SARS-CoV-2-reactive antibodies. Strong mechanistic considerations and emerging observational data support the use of IVIG/SCIG as a biologically plausible option for COVID-19 pre-exposure prophylaxis (PreEP) in immunocompromised patients. In this review, we summarize the supporting evidence available and consider optimal use cases. Neutralization capacity against Omicron lineages is consistently reduced and highly variable between lots, and there is an intrinsic several-month lag between donor immunity and product infusion. The available information in literature sources consistently reflects the use of standard replacement dosing of IVIG/SCIG and does not systematically analyze COVID-19-specific safety or outcomes with dose intensification. While the available evidence suggests that IVIG/SCIG may be effective in PreEP, without dedicated randomized or well-controlled human trials, the magnitude of clinical benefit from this intervention remains uncertain, especially against contemporary Omicron sublineages.},
}
@article {pmid42091413,
year = {2026},
author = {Abbehausen, C},
title = {"Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies".},
journal = {Journal of inorganic biochemistry},
volume = {281},
number = {},
pages = {113341},
doi = {10.1016/j.jinorgbio.2026.113341},
pmid = {42091413},
issn = {1873-3344},
mesh = {Humans ; *Leishmaniasis/drug therapy ; *gag Gene Products, Human Immunodeficiency Virus/metabolism/antagonists &amp; inhibitors/chemistry ; *Antiparasitic Agents/chemistry/pharmacology/therapeutic use ; *HIV-1/drug effects ; *Antiviral Agents/chemistry/pharmacology/therapeutic use ; *HIV Infections/drug therapy ; Animals ; Zinc Fingers ; *Coordination Complexes/chemistry/pharmacology/therapeutic use ; },
abstract = {Metallodrugs have long occupied a significant position in medicinal chemistry, yet their application to infectious diseases has historically lagged the extensive development observed in cancer therapy. The COVID-19 pandemic, together with the increased spread of parasitic diseases driven by climate change and human migration, has renewed interest in metal-based compounds as antiviral and antiparasitic agents. These efforts have been further enabled by advances in computational modeling and mechanistic analysis, allowing rational design strategies that extend beyond in vitro drug screening. This focused review traces a coherent body of work, including studies developed by our research group, illustrating how fundamental coordination chemistry principles can be progressively integrated to address infectious disease challenges. Viral molecular targets, exemplified by the HIV-1 nucleocapsid protein NCp7, a zinc finger protein essential for multiple stages of retroviral replication, demonstrate how combined spectroscopic, mass-spectrometric, and computational approaches enable molecular-level understanding of metal-mediated zinc finger inhibition. Similar principles have been extended to neglected and emerging viral pathogens, including arboviruses such as Zika and chikungunya, where metal-based compounds can be modulated to interfere with different steps of replication cycle. In contrast, kinetoplastids such as Leishmania spp. present a complex intracellular environment in which the biological activity of metal complexes is governed predominantly by redox perturbation, disruption of thiol-dependent metabolism, and mitochondrial dysfunction. By following a continuous methodological and conceptual progression from drug-screening to mechanistic approach and in vivo models, this review highlights this transition and underscores the potential of metallodrugs in infectious disease agents.},
}
@article {pmid42091717,
year = {2026},
author = {Amal, HM and Mohamed, AMG and Abdel-Halim, MO and Hassan, MS and Khorshid, OA and Osman, WA},
title = {Exploring the long-term hydroxychloroquine's effects on COVID-19 outcomes in patients with autoimmune diseases: a systematic review and meta-analysis.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {6},
pages = {},
pmid = {42091717},
issn = {1432-1041},
mesh = {Humans ; *Hydroxychloroquine/therapeutic use/administration &amp; dosage ; *Autoimmune Diseases/drug therapy/mortality/complications ; COVID-19/mortality ; *COVID-19 Drug Treatment ; SARS-CoV-2 ; Treatment Outcome ; Pandemics ; Observational Studies as Topic ; },
abstract = {BACKGROUND: Hydroxychloroquine (HCQ) usage in COVID patients was a popular topic of study, especially during the first wave of the pandemic. However, the long-term impact of HCQ therapy on infected COVID-19 patients remains unclear.<br><br>OBJECTIVES: Holding a PROSPERO registration (CRD42025113906), this study aimed to investigate the impact of long-term treatment with HCQ in patients with autoimmune diseases on mortality, as well as on the development of disease-related complications.<br><br>METHODS: A comprehensive search was conducted across multiple databases. Full-text reports were included for clinical trials and observational studies on adult patients with autoimmune disease and confirmed COVID-19 infection subjected to HCQ therapy.<br><br>RESULTS: The search process has identified 1,126 studies, of which 17 observational studies were included.No randomized controlled trials meeting the inclusion criteria were found. Eligible studies involved 229,142 autoimmune patients treated with HCQ, of which 197,118 patients were diagnosed with COVID-19. In 14 observational studies (196,965 patients), HCQ use was associated with a lower overall mortality rate by 21%&#xa0;in patients with autoimmune diseases and COVID-19 (RR 0.79; 95% CI: 0.64-0.97, p = 0.02). This association may reflect a potential survival benefit; however, given the observational nature of the studies included,&#xa0;causal inference cannot be established, and the findings should be interpreted cautiously. There was no significant difference between HCQ-treated patients and untreated patients regarding hospitalization (12 studies with 2,238 patients included), ICU admission (8 studies with 527 patients included), mechanical ventilation (8 studies with 546 patients included), sepsis (2 studies with 132 patients included), or thrombo-embolic events rates (2 studies with 195 patients included) (RR 0.92, 95% CI 0.75- 1.14; p = 0.46), (RR 1.45; 95% CI; 0.82- 2.56, p = 0.2) and (RR 1.28; 95% CI; 0.68- 2.4, p = 0.44), (RR 1.44; 95% CI; 0.57 - 3.65, p = 0.44), (RR 0.89; 95% CI; 0.16-4.97, p = 0.89), respectively. Nonetheless, the incidence of Acute Kidney Injury (AKI) in 2 studies (136 patients) was higher in HCQ-treated groups compared to the untreated groups (RR 2.31; 95% CI; 1.29-4.12, p = 0.0047).<br><br>CONCLUSION: HCQ was associated with a significantly lower overall mortality rate in patients with autoimmune diseases and COVID-19; this association is consistent with its known immunomodulatory properties. On the other hand, it does not prevent COVID-19-related complications and could be associated with an increased risk for developing AKI. However, given the observational nature of all included studies, causal inference cannot be established. Future research is needed to confirm these observed survival benefits and to establish clear safety parameters regarding renal toxicity.},
}
@article {pmid42091820,
year = {2026},
author = {Syed, P and Schembri, MA and McCann, AJ and Meunier, FA},
title = {Case Study: Illuminating the Nanoscale World of Microbiology.},
journal = {Methods in molecular biology (Clifton, N.J.)},
volume = {3034},
number = {},
pages = {303-327},
pmid = {42091820},
issn = {1940-6029},
mesh = {*Microscopy/methods ; *Bacteria/ultrastructure/metabolism ; Single Molecule Imaging/methods ; Microscopy, Fluorescence/methods ; Host-Pathogen Interactions ; Nanotechnology/methods ; Software ; },
abstract = {Super-resolution microscopy has emerged as a groundbreaking tool in microbiology, enabling the visualization of structures and molecules far below the diffraction limit of light. We provide an overview of the various techniques employed in super-resolution microscopy, including deterministic (scanning and structured illumination) and stochastic (single-molecule localization microscopy and fluctuation-based computation) methods, summarizing their respective advantages and limitations. Applications in microbiology are presented, including investigations of cellular processes, physiology, cell wall biology, and elucidation of bacterial toxin pathogenesis mechanisms at nanoscale resolution. New and emerging uses of super-resolution microscopy are also explored, focusing on addressing critical challenges in the field: pathogen-host interactions, antibiotic resistance, mode of action of bacterial toxins, and nanoscale detail of bacterial secretion systems and their translocated effectors. With the expanding accessibility of resources and increasing availability of open-source software to democratize data analysis, super-resolution microscopy is poised to revolutionize our understanding of the nanoscale world in microbiology, paving the way for new discoveries.},
}
@article {pmid42091825,
year = {2026},
author = {Gerdes, R and Roberts, R and Jackson, TD and Premji, R and Deibert, D and Choi, C and Steer, KJD and Bani-Fatemi, A and Dennett, L and Lytvyak, E and Ferguson-Pell, M and Tsuyuki, R and Durand-Moreau, Q and Gross, DP and Hagtvedt, R and Vandermeer, B and Nowrouzi-Kia, B and Straube, S},
title = {Telehealth Treatments of Common Psychological Disorders: An Overview and Meta-analysis.},
journal = {Journal of occupational rehabilitation},
volume = {},
number = {},
pages = {},
pmid = {42091825},
issn = {1573-3688},
abstract = {PURPOSE: The evidence base for telehealth treatments for mental health has grown substantially in the years following the COVID-19 pandemic. We conducted a narrative synthesis and meta-analysis of reviews investigating the efficacy of live, one-to-one telehealth interventions for common mental disorders.<br><br>METHODS: We conducted a search for systematic reviews of randomized controlled trials or controlled before-and-after studies. Two independent reviewers screened potentially eligible references and extracted data from all eligible reviews. A meta-regression was conducted with reviews containing data suitable for quantitative analysis. A narrative synthesis of results was undertaken for included reviews that did not contain suitable quantitative data.<br><br>RESULTS: The search yielded 4180 references, from which 11 eligible reviews were identified. Seven systematic reviews with meta-analyses were included in the meta-regression. Only telehealth interventions for depression and anxiety disorders were identified in the eligible literature. A small significant effect was observed for interventions targeting depression and comparing to active control, where SMD&#x2009;=&#x2009;- 0.316, and p&#x2009;=&#x2009;0.003.<br><br>CONCLUSIONS: The results of the meta-regression and narrative synthesis indicate that live one-to-one telehealth produces similar reductions in symptom severity across diagnoses and comparator groups. We identified that most of the research on telehealth for common mental disorders includes low-intensity, self-help tools with reduced clinician involvement, highlighting that much of the research conducted in this area aims at providing care at reduced cost, despite the importance of therapeutic alliance in the provision of mental health care. Investigations of telehealth interventions targeting posttraumatic stress disorder in non-military populations are also needed.},
}
@article {pmid42093970,
year = {2026},
author = {Qiu, W and Wang, S and Huang, Y and Xu, N and Yang, J and Wu, H},
title = {Global research trends and future frontiers in the immunology of spontaneous abortion: a 25-year scientometric analysis.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1753732},
pmid = {42093970},
issn = {1664-3224},
mesh = {Humans ; Female ; *Abortion, Spontaneous/immunology ; Pregnancy ; *Bibliometrics ; *Allergy and Immunology/trends ; *Biomedical Research/trends ; },
abstract = {BACKGROUND: The intricate role of the immune system in spontaneous abortion is a critical and rapidly evolving field of reproductive medicine.<br><br>METHODS: We conducted a scientometric analysis of 4,495 publications on the immunology of spontaneous abortion retrieved from the Web of Science Core Collection for the period 2000-2025. Bibliometric tools, including CiteSpace and HistCite, were used to analyze publication trends, collaboration networks, co-citation patterns, and keyword evolution to identify the intellectual structure and research frontiers.<br><br>RESULTS: The annual publication output experienced rapid growth from 2008, peaking in 2022. The American Journal of Reproductive Immunology was the most prolific journal, while China and the USA were the leading countries in scientific collaboration. Co-citation analysis identified foundational works by authors such as Atik RB (2018) and Quenby S (2021). Burst detection analysis revealed a dynamic shift in research hotspots over time, with recent high-strength keywords including "recurrent implantation failure" (strength: 15.87), "chronic endometritis" (13.4), and "maternal-fetal interface" (10.35). Timeline and cluster analyses further pinpointed the field's evolution from foundational topics like "tolerance" and "antiphospholipid syndrome" to current emerging frontiers. These new frontiers are concentrated in distinct clusters, prominently including #0 recurrent pregnancy loss, #2 maternal-fetal interface, #11 chronic endometritis, and #12 COVID-19. Alluvial flow visualization confirmed that themes related to "regulatory_t_cells" and therapeutic interventions at the "maternal-fetal_interface" represent major developing research streams.<br><br>CONCLUSION: This study comprehensively maps the historical landscape and dynamic evolution of research on immunology in spontaneous abortion, identifying key emerging frontiers that may represent important directions for future investigation in the field.},
}
@article {pmid42094618,
year = {2026},
author = {Amegashie, EA and Sikeola, RO and Kwayisi-Darkwah, CK and Atampugbire, G and Tagoe, EA and Paintsil, E and Torpey, K and Quaye, O},
title = {Viral Mechanisms and Drug Influences on Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Human Coronaviruses Infection: A Systematic Review.},
journal = {Health science reports},
volume = {9},
number = {5},
pages = {e72474},
pmid = {42094618},
issn = {2398-8835},
abstract = {BACKGROUND AND AIM: Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway is crucial for various stages of immunity, from innate to adaptive responses. Type 1 IFNs activate JAK/STAT pathway by binding to receptors on JAK, phosphorylating STAT and upregulating interferon-stimulated genes (ISGs) leading to cytokines production. Viruses, however, have developed mechanisms to prevent antiviral type I IFNs induction, resulting in active viral replication. This study seeks to review viral mechanisms, drug influences, and vitamin D supplements affecting the JAK/STAT pathway in human coronavirus infection.<br><br>METHODS: Literature searches were conducted across Google Scholar, Scopus, PubMed, and ScienceDirect in accordance with the PRISMA guidelines. The study included all publications that satisfied the PRISMA criteria, were written in English, and fell within a 10-year window from July 2014 to June 2024. Forty-seven (47) studies satisfied the requirement for selection, out of which 31 studies were on viral mechanism, 12 were on drug interaction, and 2 were on vitamin D supplements.<br><br>RESULTS: There is consistent evidence of viral proteins, including ORF6, ORF8, spike, NSP14, NSP 1, and N of human coronaviruses disrupting the JAK/STAT pathway. Ruxolitinib, baricitinib, and Liantua Qingwen capsules have, however, been shown to stabilize the pathway by attacking viral proteins, inhibiting some pro-inflammatory cytokines, and downregulating STAT components to lessen cytokine storm, during hyperinflammation.<br><br>CONCLUSION: This finding emphasizes the need for controlled regulation of JAK/STAT pathway to address coronavirus infections and immune disruptions, with continued research essential in developing targeted treatment against present and future viral threats.},
}
@article {pmid42094979,
year = {2026},
author = {Huang, Y and Zhang, X and Miao, R and Wang, J and Xi, X and Pan, H and Lu, Y and Li, D},
title = {Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1828887},
pmid = {42094979},
issn = {2296-858X},
abstract = {The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization. Hybrid immunity, shaped by the combination of natural infection and vaccination, induces more potent, broad-spectrum, and durable protective immunity. This review proposes that heterologous vaccination - the sequential use of vaccines based on different technological platforms - can serve as an active public health strategy to simulate and optimize hybrid immunity. We systematically elaborate on the synergistic advantages of hybrid immunity at both the humoral and cellular levels, citing evidence from multiple clinical trials that for both convalescent individuals and infection-naïve populations, heterologous vaccination regimens outperform homologous regimens in enhancing the breadth of neutralizing antibodies, strengthening cross-protection, and establishing robust immune memory. By mimicking the antigenic distance effect, heterologous vaccination safely replicates the immunological benefits of natural infection without the associated risks, positioning it as a key strategic tool to counter persistent viral evolution and build a resilient population-wide immune barrier.},
}
@article {pmid42095491,
year = {2026},
author = {Hu, R and Dou, Y and Li, C and Mu, Y and Ouyang, H and Shen, W and Zhang, J},
title = {Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
volume = {13},
number = {33},
pages = {e75548},
pmid = {42095491},
issn = {2198-3844},
support = {CQYC20220303706//Chongqing Innovation Leading Talent Project/ ; CSTB2022TIAD-KPX0156//Key Program for Technological Innovation &amp; Application Development of Chongqing/ ; 2023GGXM005//Key Medical Program Integrated by Chongqing Science and Technology Bureau and Chongqing Health Commission/ ; CSTB2024NSCQ-QCXMX0005//New Chongqing Youth Innovative Talent Program/ ; },
mesh = {Humans ; *Nanoparticles/chemistry/adverse effects/administration &amp; dosage ; *Lipids/chemistry/immunology ; *Inflammation/immunology ; Animals ; *Nucleic Acids/administration &amp; dosage ; *COVID-19 Vaccines/immunology/administration &amp; dosage ; *COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; Liposomes ; },
abstract = {Lipid nanoparticles (LNPs) are transformative vectors for nucleic acid delivery, proven safe and effective in COVID-19 mRNA vaccines, and enabling advances in cancer immunotherapy and gene editing. However, their inherent immunogenicity presents a double-edged sword: beneficial adjuvant effects in vaccination can become detrimental inflammatory responses in applications like treating inflammatory/fibrotic diseases or gene editing-based therapies. This review comprehensively evaluates LNP-associated inflammation and mitigation strategies. We begin with an in-depth analysis of molecular mechanisms, detailing how specific lipid components, endocytic pathway activation, and nucleic acid sensing drive immune stimulation. Key modulatory factors, including LNP structural characteristics, administration routes, and biodistribution, are examined. We then explore cutting-edge engineering approaches to circumvent immunogenicity, encompassing structure-guided design of ionizable lipids, sophisticated biomimetic strategies using natural membrane coatings, innovative co-delivery systems incorporating anti-inflammatory agents, and emerging technologies for immune-evasive LNPs. By elucidating the intricate relationship between nanocarrier physicochemical properties and host immune recognition, while addressing translational hurdles, this review provides critical insights for developing safer, next-generation LNPs tailored for diverse therapeutic applications.},
}
@article {pmid42095944,
year = {2026},
author = {Azi, AO and Lim, HS and Yohanna, E},
title = {Air pollution in Malaysia: current understanding and future directions.},
journal = {Environmental geochemistry and health},
volume = {48},
number = {7},
pages = {},
pmid = {42095944},
issn = {1573-2983},
support = {FRGS/1/2021/STG08/USM/02/2//Ministry of Higher Education (MOHE)/ ; },
mesh = {Malaysia/epidemiology ; *Air Pollution/analysis/adverse effects ; Particulate Matter/analysis ; *Air Pollutants/analysis ; Humans ; Environmental Monitoring/methods ; COVID-19/epidemiology ; },
abstract = {Air pollution remains a significant environmental and public health issue in Malaysia, with notable effects on the economy and climate. Despite long-standing monitoring systems and regulations, comprehensive assessments that combine multiple data sources with health impact analysis are still lacking. This study reviews peer-reviewed studies, haze events from 1983 to 2024, regulatory documents from the Department of Environment, Malaysia, and data from air quality monitoring stations across regions. and presents an integrated assessment of air quality across strategic and important urban, industrial, coastal, and residential areas. It analyses trends in the Air Pollutant Index and PM2.5 levels from 2013 to 2024, and uses exposure-response models to estimate related deaths and economic impacts. Satellite data (MODIS and AERONET) help understand spatial variation and cross-border pollution. Average PM2.5 levels ranged from 8.66-16.77 µg/m[3], consistently above WHO guidelines from 2021. In 2020, PM2.5 exposure was linked to 1.419 early deaths in four urban areas, costing about MYR 2.46 billion (USD 524 million). Population-attributable fractions ranged from 2.6-7.1%, with risk rising by 2.7-7.6% per 10 µg/m[3] increase. The study identified 12 major haze events, notably in 1997 and 2015. COVID-19 restrictions temporarily reduced emissions, but levels quickly rebounded afterward. Conclusively, Malaysia's air quality issues are mainly due to transport, industry, dust, and recurring transboundary haze. Solutions include better source tracking, enhanced secondary pollutant monitoring, integrating health data more effectively, adopting advanced technologies, and aligning policies with WHO standards. Pollution effects are more pronounced in metropolitan regions due to proximity to dense sources.},
}
@article {pmid42096655,
year = {2026},
author = {Ren, J and Qiu, J and Cai, J and Li, Y and Huang, L and Li, X},
title = {Effectiveness of digital health interventions in reducing loneliness among older adults: a systematic review and meta-analysis.},
journal = {Age and ageing},
volume = {55},
number = {5},
pages = {},
doi = {10.1093/ageing/afag122},
pmid = {42096655},
issn = {1468-2834},
support = {2023AH040086//Anhui Province University Scientific Research Projects/ ; YJS20240069//Anhui Province University Scientific Research Projects/ ; },
mesh = {*Loneliness ; *Digital Health ; Humans ; Aged ; Randomized Controlled Trials as Topic ; Middle Aged ; Internet-Based Intervention ; *Cognitive Training ; },
abstract = {BACKGROUND: Loneliness affects 12% of older adults globally, with concerns exacerbated by the COVID-19 pandemic. While digital health interventions (DHIs) show promise, evidence of their effectiveness remains mixed.<br><br>METHODOLOGY: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted in the PubMed, Cochrane, Web of Science and Embase databases (2010-25). Inclusion criteria were adults aged 60&#xa0;years, with loneliness as the primary or secondary outcome. Study quality was assessed using GRADE and Cochrane risk of bias tools. Subgroup analyses explored intervention type, measurement scales, national development level, pandemic timing and some secondary outcomes.<br><br>RESULTS: Seventeen studies (n&#x2009;=&#x2009;2423) showed DHIs significantly reduced loneliness scores (standardized mean difference [SMD]&#x2009;=&#x2009;-0.39, 95% CI -0.77 to -0.01). Subgroup analyses revealed significant reductions for social cognitive training (SMD&#x2009;=&#x2009;-0.82, 95% CI -1.47 to -0.16). Greater effectiveness was observed in developed countries (SMD&#x2009;=&#x2009;-0.30, 95% CI: -0.51 to -0.09) and during the pandemic period (SMD&#x2009;=&#x2009;-0.54, 95% CI: -1.03 to -0.06). DHIs also improved mental health (SMD&#x2009;=&#x2009;0.98, 95% CI: 0.12 to 1.84) and marginally reduced depressive symptoms (SMD&#x2009;=&#x2009;-0.73, 95% CI: -1.45 to 0.00).<br><br>CONCLUSION: DHIs show promise in reducing loneliness scores among older adults, particularly through cognitive-focused interventions in supportive digital environments. However, the overall effect is modest and highly heterogeneous, with benefits that appear context-dependent and short-lived. Future research should prioritise standardised measurement, diverse populations and long-term follow-up to optimise DHI design.},
}
@article {pmid42096888,
year = {2026},
author = {Unger, M and Munro, JB},
title = {Control of viral envelope glycoprotein function revealed by single-molecule imaging.},
journal = {Current opinion in structural biology},
volume = {98},
number = {},
pages = {103275},
pmid = {42096888},
issn = {1879-033X},
support = {R01 AI150322/AI/NIAID NIH HHS/United States ; R01 AI174645/AI/NIAID NIH HHS/United States ; R01 GM143773/GM/NIGMS NIH HHS/United States ; },
mesh = {*Viral Envelope Proteins/chemistry/metabolism ; *Single Molecule Imaging/methods ; Fluorescence Resonance Energy Transfer ; Virus Internalization ; Humans ; Protein Conformation ; },
abstract = {Viral envelope glycoproteins catalyze membrane fusion during entry into cells. Envelope glycoprotein function has traditionally been viewed through the lens of kinetic control, where environmental cues like pH trigger irreversible refolding from the pre-fusion conformation to the post-fusion conformation. Single-molecule Förster resonance energy transfer (smFRET) imaging has revealed an additional layer of thermodynamic control that governs the conformational dynamics of envelope glycoproteins in their pre-fusion form. smFRET studies of the envelope glycoproteins from HIV-1, SARS-CoV-2, MERS-CoV, Ebola virus, and influenza A virus demonstrate that these glycoproteins dynamically sample an ensemble of pre-fusion conformations whose relative stabilities respond to pH, receptor binding, ions, and host proteases. This thermodynamic tuning precedes the kinetically controlled transition that promotes membrane fusion. Collectively, smFRET imaging has transformed our understanding of viral entry, illustrating how the pre-fusion energy landscape of envelope glycoproteins is tuned by the host environment to maintain viral fitness.},
}
@article {pmid42096990,
year = {2026},
author = {Auckburally, A and Grubb, TL and Perchiazzi, G and Högman, M and Nyman, G},
title = {Nitric oxide and its role in the management of hypoxaemia in the anaesthetised horse-a narrative review.},
journal = {Veterinary anaesthesia and analgesia},
volume = {53},
number = {4},
pages = {101227},
doi = {10.1016/j.vaa.2026.101227},
pmid = {42096990},
issn = {1467-2995},
mesh = {Animals ; Horses ; *Hypoxia/veterinary/drug therapy ; *Nitric Oxide/administration &amp; dosage/therapeutic use ; *Horse Diseases/drug therapy ; *Anesthesia, General/veterinary/adverse effects ; },
abstract = {OBJECTIVE: To outline historical aspects of nitric oxide, including its discovery and biological effects, to describe the current use of inhaled nitric oxide (iNO) in human healthcare, and to review the available evidence on the use of pulsed iNO (PiNO) for the management of hypoxaemia in anaesthetised horses.<br><br>DATABASES USED: Google Scholar and PubMed databases were searched using the search terms nitric oxide, PiNO, environment, discovery, acute respiratory distress syndrome, COVID-19, SARS-CoV-2, horse, pony, hypoxaemia, and anaesthesia.<br><br>CONCLUSIONS: Inhaled NO is licensed in the management of hypoxic respiratory failure in human neonates and has also been used to treat refractory hypoxaemia in humans fulfilling certain criteria. There is now a substantial body of evidence demonstrating that PiNO is an effective treatment option for managing hypoxaemia during general anaesthesia in horses. The administration of PiNO to well-ventilated alveoli leads to a redistribution of pulmonary blood flow from dependent, nonventilated regions to nondependent, better ventilated regions of the lung. This reduces intrapulmonary shunting and improves indices of oxygenation and oxygen delivery. Whilst much of the evidence is experimental, there are some descriptions of its successful use in client-owned horses undergoing surgery for colic and arthroscopic procedures. As the prototypical delivery device (the NOrse, Datex-Ohmeda Research Department, Helsinki, Finland) has been redeveloped, the use of PiNO in clinical equine anaesthesia may offer a realistic treatment option for the management of hypoxaemia in anaesthetised horses in the near future.},
}
@article {pmid42097077,
year = {2026},
author = {Baldry, K and Koekemoer, E and Olckers, C},
title = {Structural constraints and psychological need satisfaction among platform-based delivery riders in South Africa.},
journal = {Acta psychologica},
volume = {266},
number = {},
pages = {106989},
doi = {10.1016/j.actpsy.2026.106989},
pmid = {42097077},
issn = {1873-6297},
mesh = {Humans ; South Africa ; Female ; Adult ; Male ; *Employment/psychology ; *Personal Satisfaction ; Personal Autonomy ; Qualitative Research ; *COVID-19/psychology ; },
abstract = {Platform-based motorbike delivery riders have become an essential part of the urban labour force, especially since the COVID-19 pandemic increased online shopping. This qualitative study used Self-Determination Theory and the Psychology of Working Theory to explore how motorbike delivery work promotes or undermines riders' psychological needs of competence, relatedness and autonomy. Ten motorbike delivery riders in Johannesburg, Gauteng, participated in twenty semi-structured interviews (two per participant). Hybrid thematic analyses were employed to analyse the data. Findings indicated that, amidst high unemployment and limited job opportunities in South Africa, platform-based motorbike delivery work partially satisfies riders' psychological needs. Relatedness was supported in interactions with customers and co-workers but limited by experiences of social stigmatisation. As independent contractors, riders enjoyed greater labour market flexibility and often earned more than in previous jobs, both of which promoted their autonomy. However, constant concerns regarding personal safety severely undermined this need. Challenges such as limited training and procedural injustice also restricted their need for competence. This study extends the Psychology of Working Theory by demonstrating how structural constraints not only influence the attainment of decent work but also shape the outcomes of decent work, specifically the fulfilment of psychological needs in precarious labour contexts.},
}
@article {pmid42097153,
year = {2026},
author = {Zumla, A and Hui, DS and Peiris, M and Perlman, S},
title = {Respiratory infections due to human common cold coronaviruses, SARS-CoV, MERS-CoV, and SARS-CoV-2: epidemiology, pathogenesis, clinical features, diagnostics, therapeutics, and vaccine landscapes.},
journal = {The Lancet. Respiratory medicine},
volume = {14},
number = {6},
pages = {545-566},
doi = {10.1016/S2213-2600(26)00049-4},
pmid = {42097153},
issn = {2213-2619},
mesh = {Humans ; Middle East Respiratory Syndrome Coronavirus/pathogenicity ; SARS-CoV-2 ; COVID-19 ; *Severe Acute Respiratory Syndrome/epidemiology/diagnosis/therapy/prevention &amp; control ; Viral Vaccines ; Severe acute respiratory syndrome-related coronavirus/pathogenicity ; Pandemics/prevention &amp; control ; Animals ; *Common Cold/epidemiology/diagnosis/therapy ; COVID-19 Vaccines ; *Respiratory Tract Infections/epidemiology/diagnosis/therapy/virology ; },
abstract = {Over the past half-century, perceptions of human coronaviruses have evolved from their initial characterisation as causes of the common cold to recognition of their capacity to trigger severe disease and global epidemics. The emergence of three zoonotic coronaviruses-severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, and SARS-CoV-2 in 2019, has had profound health, economic, and societal consequences and continues to influence global epidemic-preparedness strategies. All three viruses remain on the WHO Blueprint of priority pathogens for research and development. This Review summarises current knowledge on human coronaviruses, drawing lessons from the past 25 years of epidemic outbreaks. The shared and divergent features of SARS-CoV, MERS-CoV, and SARS-CoV-2, including their origins, evolution, transmission determinants, zoonotic transmission, viral entry pathways, pathogenesis, spectrum of clinical manifestations, long-term sequelae, and case-fatality profiles are highlighted. The full range of clinical manifestations, from asymptomatic or atypical presentations to severe acute respiratory and multisystem disease, are outlined together with risk factors for progression and populations with the greatest susceptibility. Diagnostic approaches, including molecular assays, antigen-based tests, and imaging modalities are described alongside current therapeutics, antiviral strategies, immunomodulators, supportive care principles, and evidence from clinical trials. Advances in diagnostics, vaccines, therapeutics, and infection-control practices are examined together with persistent challenges in early recognition, particularly in resource-limited settings. Strengthening multinational clinical trial capacity, leveraging digital innovations, and embedding One Health approaches are essential to mitigating spillover risks and improving global readiness. We review the latest data, identify gaps and opportunities, and outline forward-looking strategies to anticipate and prepare for the threat of future coronaviruses, and other existing or new respiratory pathogens with epidemic potential. Clinicians and other health-care workers play a central role in detecting and reporting possible lethal coronavirus infection including atypical presentations, enabling rapid, coordinated infection control and management responses.},
}
@article {pmid42097990,
year = {2026},
author = {Bruffaerts, R},
title = {Mental Health in College Students: From Epidemiological Findings to Sustainable Policies.},
journal = {Annual review of clinical psychology},
volume = {22},
number = {1},
pages = {533-557},
doi = {10.1146/annurev-clinpsy-061724-084303},
pmid = {42097990},
issn = {1548-5951},
mesh = {Humans ; *Students/psychology/statistics &amp; numerical data ; Universities/statistics &amp; numerical data ; *Mental Disorders/epidemiology ; *COVID-19 ; *Mental Health ; *Mental Health Services/statistics &amp; numerical data ; Young Adult ; },
abstract = {Higher education has seen rising enrollment, mobility, and diversity; there are approximately 254 million students globally, a figure that has doubled since the early 2000s. The college years (roughly the age range between 18 and 30) coincide with key developmental phases marked by personal, social, and academic stressors like leaving home and adjusting to new environments. This period is high-risk for mental health issues such as anxiety and depression, which negatively affect academic success and future quality of life. The COVID-19 pandemic challenged students' mental health due to isolation, online learning, and fears of infection. Despite growing emotional problems, many students do not seek help, and this avoidance results in inadequate treatment and fragmented mental health services. These issues present significant challenges in addressing mental health within higher education and beyond. The goal of this article is to offer a thorough, critical review of the existing research on college mental health, including key data-driven epidemiological findings on mental disorders, theory-driven approaches to challenges faced during college, and prospects for future research.},
}
@article {pmid42098872,
year = {2026},
author = {Donglin, W and Xuewei, W and Syed Jaapar, SZ and Ab Razak, A},
title = {Cultural background and pandemic context as moderators of the association between expressive suppression and sleep quality in healthy adults: a systematic review and meta‑analysis.},
journal = {BMC psychology},
volume = {14},
number = {1},
pages = {},
pmid = {42098872},
issn = {2050-7283},
mesh = {Humans ; *Sleep Quality ; *COVID-19/psychology ; *Emotional Regulation ; Pandemics ; Adult ; },
abstract = {BACKGROUND: Expressive suppression is a widely used emotion regulation strategy, but studies have reported mixed findings regarding its association with sleep quality in healthy adults. This meta-analysis aimed to synthesize the evidence on the association between expressive suppression and sleep quality in non-clinical adult samples and examine the moderating effect of cultural background and pandemic context.<br><br>METHODS: Electronic databases including PubMed, EBSCO, and Web of Science were systematically searched from database inception to May 2025 using predefined search terms related to emotion regulation and sleep quality. Studies were included if they: (1) involved non-clinical adult samples; (2) assessed expressive suppression with the Emotion Regulation Questionnaire (ERQ); (3) used standardized self-report measures of sleep quality (e.g., PSQI, ISI); and (4) reported zero-order Pearson correlations. A total of twenty-three independent samples (N&#x2009;=&#x2009;13,636) met the inclusion criteria. A random-effects model was used to estimate the pooled effect size, and pre-specified subgroup and moderation analyses were conducted.<br><br>RESULTS: Expressive suppression showed a small but significant positive association with poorer sleep quality (r = .14, 95% CI [0.12, 0.16], p < .0001). Between-study heterogeneity was low (I&#xb2; = 28.21%). The association was stronger in studies explicitly focused on COVID-19-related stress than in studies conducted in general contexts, whereas cultural background, type of sleep measure, study design, and publication period did not significantly moderate the effect.<br><br>CONCLUSION: Habitual use of expressive suppression appears to be associated with poorer sleep quality in healthy adults, and this association may be stronger under conditions of major psychosocial stress such as the COVID-19 pandemic. Interventions that reduce reliance on suppression or promote more flexible emotion regulation may help support sleep health, particularly during periods of widespread stress.<br><br>TRIAL REGISTRATION: This study has been registered with the PROSPERO (registration number: CRD420251059053).},
}
@article {pmid42099599,
year = {2026},
author = {Liu, Y and Zhong, R and Wu, X and Wang, Y and Zhang, J and Kou, Z},
title = {Global trends and research hotspots in autoimmune encephalitis: insights from a bibliometric and visualized analysis: 1971-2025.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1798782},
pmid = {42099599},
issn = {1664-3224},
mesh = {*Bibliometrics ; Humans ; *Encephalitis/immunology/therapy ; *Hashimoto Disease/immunology/epidemiology/therapy ; History, 21st Century ; History, 20th Century ; *Biomedical Research/trends ; },
abstract = {BACKGROUND: Autoimmune encephalitis (AE) encompasses a highly heterogeneous spectrum of severe immune-mediated neurological disorders. Over the past 50 years, research has expanded rapidly, yet a quantitative synthesis of its evolution, key contributors, and thematic trends is lacking. Here, we provide a comprehensive 50-year, multi-database bibliometric study that systematically maps the full trajectory of AE research-from early descriptions to the current era of mechanism-driven therapeutics-using advanced analytical tools.<br><br>METHODS: We systematically retrieved AE-related publications from 1971 to May 24, 2025 from PubMed, Web of Science, and Scopus. After deduplication, records were analyzed using bibliometric tools (CiteSpace, VOSviewer, Bibliometrix). Analyses included publication trends, national/institutional contributions, author networks, journal distributions, co-citation patterns, keyword co-occurrence, and thematic evolution.<br><br>RESULTS: Annual publications surged after 2007, coinciding with the discovery of anti-NMDA receptor encephalitis (anti-NMDAR AE), reaching a peak in 2022. The USA and China were the leading contributors by volume, while Spain had the highest average citation impact. The University of Pennsylvania and the University of Oxford emerged as the most productive institutions. Dr. Josep Dalmau is the most prolific author in the field, leading a major collaborative cluster. Frontiers in Neurology published the most papers, while Neurology had the highest H-index. Keyword and thematic analyses confirmed anti-NMDAR AE as the dominant research focus, with intense scholarly interest in its pathogenesis, diagnosis, and immunotherapy. Recent trends highlight emerging topics like COVID-19-associated AE, anti-IGLON5 disease.<br><br>CONCLUSIONS: This study outlines the development, collaboration patterns, and research hotspots in AE. Research continues to center on anti-NMDAR encephalitis, with a growing focus on clinical and therapeutic applications. Future directions include mechanistic studies, biomarker discovery, and advanced immunotherapies.},
}
@article {pmid42099707,
year = {2026},
author = {Lokonon, BE and Houetohossou, SCA and Tchede, BA and Yapi, RB and Cailleau, A and Haydon, DT and Bonfoh, B},
title = {The use of artificial intelligence based modelling techniques in One Health-related infectious disease studies in Sub-Saharan Africa: a review.},
journal = {Frontiers in artificial intelligence},
volume = {9},
number = {},
pages = {1778800},
pmid = {42099707},
issn = {2624-8212},
abstract = {BACKGROUND: Sub-Saharan Africa continues to face a substantial burden of infectious diseases, many of which are zoonotic and shaped by complex interactions across human, animal, and environmental systems. Artificial Intelligence (AI), encompassing machine learning (ML) and deep-learning (DL) techniques, has emerged as a powerful tool for enhancing disease prediction, surveillance, diagnosis, and decision-making within a One Health (OH) framework.<br><br>METHOD: This systematic review synthesizes evidence from 62 peer-reviewed studies to assess how AI-based modelling techniques have been applied to infectious disease research across Sub-Saharan Africa.<br><br>RESULTS: Results show that AI adoption has grown rapidly since 2019, with a pronounced surge in publications between 2021 and 2024. However, research leadership and implementation capacity remain geographically uneven, with South Africa, Ethiopia, Kenya, and Tanzania dominating the landscape. Across studies, AI tools were used primarily for classification and prediction tasks, with ensemble models and deep-learning architectures showing the strongest performance (with median accuracy close to 100% for Convolutional Neural Network model). Malaria (24%), HIV (12%), COVID-19 (12%), and Tuberculosis (6.7%) were the most frequently targeted diseases, while zoonotic and environmentally linked infections were comparatively underrepresented. Most studies relied exclusively on human data, revealing a persistent gap in the integration of animal and environmental components critical to the OH paradigm.<br><br>CONCLUSION: Despite promising applications, including image-based parasite detection, IoT-enabled surveillance, ecological risk modelling, and smartphone-assisted diagnostics, AI deployment remains constrained by limited computational infrastructure, inadequate digital connectivity, data-governance weaknesses, and shortages of AI-trained specialists. Conversely, expanding mobile connectivity, cloud-based analytics, and advancements in multilingual AI tools could create new opportunities to strengthen surveillance systems, empower health workers, and improve community engagement.},
}
@article {pmid42100527,
year = {2026},
author = {Alghamdi, B and Albedah, N and Almalki, T and Almudarra, S and Penttinen, P and Wang, C and Hong, PY},
title = {Wastewater-based surveillance of microbial pathogens in GCC countries (2015-2025): a scoping review and questionnaire survey with stakeholders.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1786753},
pmid = {42100527},
issn = {2296-2565},
mesh = {*Wastewater/microbiology ; Surveys and Questionnaires ; Humans ; },
abstract = {BACKGROUND: Wastewater-based surveillance (WBS) of microbial pathogens has become an increasingly useful approach to monitor public health at the population level. However, these efforts varied widely in scope, methodology and focus within the GCC region. It remains unclear how WBS is being used across the region, and to what extent it can inform decision-making or contribute to long-term surveillance infrastructure within the GCC. This review aimed to critically assess WBS studies conducted across GCC and to provide perspective on how to further strengthen the ability of WBS to inform and provide early detection on the emergence of health concerns arising from microbial contaminants that are circulating in the community.<br><br>METHODS: This review was conducted following the PRISMA extension for scoping reviews guidance, aiming to identify and critically evaluate peer-reviewed studies that applied WBS across GCC between January 2015 and October 2025. A structured English-language literature search was carried out on the Web of Science, Scopus, and Google Scholar. Search results were screened against predefined inclusion and exclusion criteria. A survey was conducted with GCC stakeholders involved in the execution of wastewater surveillance, and their responses were studied to align actual WBS activities against that reported in the literature.<br><br>RESULTS: A total of 26 studies met the inclusion criteria for this review, with uneven distribution of studies published across the GCC countries (n = 6). The main targets reported in the WBS studies are antimicrobial resistance (AMR) and SARS-CoV-2. Majority of the studies report qualitative presence of microbial targets and lack quantitative measurements that are required to facilitate decision-making and intervention measures. Emerging methods and technology that can enable WBS were discussed to facilitate future WBS effort in GCC.<br><br>CONCLUSION: Although WBS holds significant promises to enhance public health surveillance in the GCC, its potential remains underutilized. Moving forward, addressing capacity training and providing sustainable long-term funding mechanisms, standardizing methodological differences and/or providing a guideline that detail the best practices, promoting a consortium-based surveillance system and initiating research that can facilitate the utilization of WBS data to inform decision-making processes would be crucial for the successful integration of WBS into the region's public health framework.},
}
@article {pmid42100531,
year = {2026},
author = {Carbajal, C and Dasgupta, T and Russell, E and Latt, SM and Horgan, G and Peterson, L and Mistry, HD and Kitchen, K and Wilson, M and Smith, V and Boulding, H and Sheen, KS and Van Citters, AD and Nelson, EC and Duncan, EL and von Dadelszen, P and , and Silverio, SA and Magee, LA},
title = {Women's experiences of maternity care in high-income countries during the pandemic health system shock: a follow-up systematic review and qualitative evidence synthesis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1715725},
pmid = {42100531},
issn = {2296-2565},
mesh = {Humans ; Female ; *COVID-19/epidemiology ; *Maternal Health Services/organization &amp; administration ; Pregnancy ; *Developed Countries ; Qualitative Research ; SARS-CoV-2 ; Pandemics ; },
abstract = {INTRODUCTION: COVID-19 disrupted healthcare systems globally, particularly challenging maternity services which continued to be operated as an essential service. Reconfigurations were implemented to continue providing care in a safe manner and in line with infection control restrictions. This systematic review of women's experiences of maternity care during the COVID-19 pandemic in high-income countries (HICs), aimed to synthesize published literature and inform future responses to global disasters.<br><br>MATERIAL AND METHODS: Electronic database of Scopus, MEDLINE, EMBASE, CINAHL PsychINFO, and the Cochrane COVID Study Register, were searched from June 2021- June 2024 to identify eligible records. Thematic synthesis was used to synthesise the data.<br><br>RESULTS: 79 studies were included with data from over 20,000 perinatal women, most were of moderate to high methodological quality. Data synthesis showed 11 themes across five main concepts related to maternity service reconfigurations, namely: (1) Care-seeking and care experience, (2) Virtual care, (3) Self-monitoring, (4) Vaccination, and (5) Ethical future of maternity care.<br><br>CONCLUSIONS: Women predominantly viewed changes to maternity care negatively. Future strategies to ensure safeguarding of mothers and infants during crises should include enhancing service accessibility, emphasizing women-centered care, and prioritizing support systems for mothers and infants.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD42022355948, identifier: CRD42022355948.},
}
@article {pmid42100538,
year = {2026},
author = {Muturiki, M and Mapukata, NO and Chauke, L and Jewett, S},
title = {Mental health patterns and associated social determinants among university and college students in sub-Saharan Africa during the COVID-19 pandemic era: a scoping review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1800724},
pmid = {42100538},
issn = {2296-2565},
mesh = {Humans ; *Social Determinants of Health ; *COVID-19/epidemiology/psychology ; *Students/psychology/statistics &amp; numerical data ; Universities ; *Mental Health/statistics &amp; numerical data ; Africa South of the Sahara/epidemiology ; Sub-Saharan African People ; Pandemics ; *Mental Disorders/epidemiology ; },
abstract = {BACKGROUND: Evidence on student mental health in sub-Saharan Africa (SSA) remains limited, particularly studies examining how mental health patterns intersect with social determinants within higher education institutions (HEIs). This scoping review identifies gaps in the literature documenting student mental health and associated social determinants during the COVID-19 period and highlights priorities for future research in SSA.<br><br>METHODS: Eight databases (MEDLINE, PsycInfo, Open Access Journals, CINAHL, Google Scholar, Cochrane Library, ProQuest, Scopus) and grey literature were searched for English-language studies from 2020 to 2023. Sixty-seven studies from 214 full-text articles screened met the inclusion criteria.<br><br>RESULTS: The included studies varied widely in their examination of student mental health and its links to social determinants of health (SDOH). Mental health was most frequently assessed in terms of depression, anxiety, suicidality, substance use disorders, and psychological distress. Mood disorders were the most commonly reported outcomes. Few studies explored help-seeking behavior. Reported social determinants aligned with structural factors (socioeconomic and political contexts, cultural norms, gender disparities) and intermediary factors such as academic stress, service access, and behavioral patterns including substance use, physical activity, sleep, and diet.<br><br>CONCLUSION: Although many studies addressed social determinants of student mental health in SSA, none provided comparable, multi-country data across HEIs. Most research focused on undergraduate particularly medical students, with limited attention to postgraduate populations. Future work should prioritize multi-country comparative studies and context-specific approaches that strengthen help-seeking and support for at-risk students across diverse SSA settings.},
}
@article {pmid42101066,
year = {2026},
author = {Boufleuer, E and Vieira, TW and Sakamoto, VTM and Anschau, F and Tavares, JP and Filho, FFD and Pai, DD},
title = {Psychological and Cognitive Sequelae of COVID-19: Systematic Review and Meta-Analysis.},
journal = {Journal of psychiatric and mental health nursing},
volume = {33},
number = {4},
pages = {653-666},
pmid = {42101066},
issn = {1365-2850},
support = {312850/2025-5//Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico/ ; },
mesh = {Humans ; *Anxiety/epidemiology/etiology ; *Cognitive Dysfunction/epidemiology/etiology ; *Depression/epidemiology/etiology ; *Post-Acute COVID-19 Syndrome/complications/epidemiology/physiopathology/psychology ; *Sleep Wake Disorders/epidemiology/etiology ; },
abstract = {INTRODUCTION: COVID-19 pandemic has exacerbated global mental health problems with the development of persistent symptoms.<br><br>AIM: To conduct a prevalence meta-analysis of persistent psychological and cognitive sequelae of COVID-19 based on cohort studies.<br><br>METHOD: This study followed PRISMA. Cohort studies that followed individuals for at least 12&#x2009;weeks post-COVID-19 were included and pediatric studies were excluded. The databases Embase, Lilacs/BVS, PubMed, SciELO and Scopus were searched in November 2023. Meta-analyses were performed with subgroup analyses conducted. Results were presented with forest plot graphs and tables. Risk of bias and methodological quality were assessed using Eggers's Test and the Newcastle-Ottawa Scale.<br><br>RESULTS: 2,456 studies were identified and screened. Forty-seven articles were included in the systematic review, and 46 in the meta-analysis (192,158 participants). The most prevalent psychological outcome was anxiety (0.17; 95% CI 0.11-0.27, 19 studies), followed by cognitive impairments (0.15; 95% CI 0.11-0.20, 35 studies), sleep disturbances (0.14; 95% CI 0.09-0.19, 33 studies) and depression (0.11; 95% CI 0.06-0.19, 16 studies).<br><br>DISCUSSION: The mental health consequences of COVID-19 highlight the need for long-term monitoring and represent a significant public health challenge. The limitation is the heterogeneity among the studies.<br><br>These findings represent a public health issue emphasizing the need for public policies and support strategies to mitigate consequences.<br><br>CONCLUSION: Although high prevalence rates were identified, the prediction intervals were wide and heterogeneity remained high-common characteristics of studies conducted during the pandemic.<br><br>REGISTRATION: Registered in the international Prospective Register of Ongoing Systematic Reviews (PROSPERO) under number CRD42023460632, on&#xa0;September 5, 2023.},
}
@article {pmid42101598,
year = {2026},
author = {Coles, S},
title = {Vaccine Adverse Effects: An Overview.},
journal = {American family physician},
volume = {113},
number = {4},
pages = {339-348},
pmid = {42101598},
issn = {1532-0650},
mesh = {Humans ; *Vaccines/adverse effects ; Measles-Mumps-Rubella Vaccine/adverse effects ; COVID-19 Vaccines/adverse effects ; *Vaccination/adverse effects ; Thimerosal/adverse effects ; Female ; Pregnancy ; },
abstract = {Vaccines are one of the most successful medical advances in modern times. Patients are increasingly questioning the necessity of immunizing themselves and their families, and family physicians should be aware of the risks and benefits of recommended immunizations to accurately counsel about adverse effects and address vaccine hesitancy. Vaccines are associated with local adverse reactions, such as pain and redness. Thimerosal is currently used only in multidose vials of influenza vaccine; exposure to thimerosal through vaccines is not associated with adverse neurologic outcomes. The measles-mumps-rubella vaccine is not associated with autism spectrum disorder. The respiratory syncytial virus vaccine does not increase the risk of stillbirth, infant death, birth defects, or growth restriction when administered during pregnancy. COVID-19 vaccine minimally increases the risk of myocarditis and pericarditis. Physicians should counsel patients and guide them to credible resources if patients are considering vaccine refusal. The Vaccine Adverse Event Reporting System and National Vaccine Injury Compensation Program track adverse events from vaccines; the National Vaccine Injury Compensation Program provides compensation for documented harms from vaccinations.},
}
@article {pmid42103644,
year = {2026},
author = {Liu, LY and Xu, YS},
title = {[Research progress on laryngitis in children infected with the Omicron variant of the Novel Coronavirus].},
journal = {Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery},
volume = {61},
number = {4},
pages = {487-492},
doi = {10.3760/cma.j.cn115330-20251102-00580},
pmid = {42103644},
issn = {1673-0860},
support = {TJYXZDXK-3-016B//Tianjin Key Medical Discipline(Specialist)Construction Project/ ; CMANKUA202401//Research and Application of Influenza Early Warning Technology for Children Based on Multi-Source Big Data/ ; },
mesh = {Humans ; *Laryngitis/epidemiology/virology/diagnosis/therapy ; *COVID-19 ; SARS-CoV-2 ; Child ; Pandemics ; Child, Preschool ; },
}
@article {pmid42104283,
year = {2026},
author = {Bates, J and Moon, JR and Gaisser, S and Nikiforov, A and Ryan, JG and Chekar, CK and Meurant, R and Vignola-Gagné, E and Iwuji, C and Grapsa, E and Barbéra-Tomás, D and Meseguer, E and Davey, G and Hopkins, MM},
title = {Policy challenges in the provision of COVID-19 border screening: evidence from eight countries.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42104283},
issn = {1471-2458},
support = {ES/W00156X/1//Economic and Social Research Council/ ; },
mesh = {Humans ; *COVID-19/diagnosis/epidemiology/prevention &amp; control ; Private Sector ; Australia/epidemiology ; *Health Policy ; Canada/epidemiology ; *Mass Screening/organization &amp; administration ; United Kingdom ; South Africa/epidemiology ; Spain/epidemiology ; *COVID-19 Testing ; Germany/epidemiology ; Republic of Korea/epidemiology ; },
abstract = {BACKGROUND: While border screening measures were widely adopted by countries during the COVID-19 pandemic, a lack of consensus on the utility of border screening created a gap in best practice for its implementation. As such, countries adopted a diversity of approaches, providing an opportunity to evaluate the configuration and evolution of border screening systems. The article addresses three questions: (i) how did countries configure their border screening systems for COVID-19? (ii) In what contexts did countries rely on public or private providers of these services? (iii) what do policies and narratives reveal about the perceived role of border screening in global public health? The article contributes to long-standing debates over the private sector's role in public health and the perceived value of border screening measures.<br><br>METHODS: This article presents results from an international comparative study based on tracking the organisation of border screening in eight countries. Secondary data was collected between July 2021 - June 2022 from official government websites and policy publications, private sector sources where relevant, and trusted media sources in each study country. The countries included are Australia, Canada, Germany, Ireland, South Africa, South Korea, Spain, and the United Kingdom.<br><br>RESULTS: All study countries used private provision for pre-departure diagnostic testing for international travellers. In contrast, screening of arriving travellers was more diverse. Countries that opted for private sector post-arrival screening saw governance challenges around accreditation and monitoring of providers, while public service provision saw challenges in capacity and high resource costs. Travel was often framed as a 'luxury,' allowing states to shift responsibility for obtaining tests onto individuals; especially in the context of individuals travelling from low income to high income countries.<br><br>CONCLUSIONS: The different approaches countries followed for screening of departing and incoming travellers suggests wealthy countries were more oriented towards defending their populations against disease importation, rather protecting the international community from disease exportation. These findings provide an opportunity to reflect on the purpose and implementation of border screening. We emphasise a need for further discussion on the efficacy of border screening from both perspectives, given the tendency for countries to rely on these measures.},
}
@article {pmid42104831,
year = {2026},
author = {Widyaningrum, R and Ambarwati, K and Kuntari, T and Putri, TA and Kusumaninrum, PD},
title = {Mothers' and Health Care Professionals' Experiences of Remote Provision of One-to-One Synchronous Breastfeeding Support: A Qualitative Systematic Review.},
journal = {Asia-Pacific journal of public health},
volume = {38},
number = {5},
pages = {351-358},
doi = {10.1177/10105395261437273},
pmid = {42104831},
issn = {1941-2479},
mesh = {Humans ; *Breast Feeding ; Female ; *Mothers/psychology/statistics &amp; numerical data ; *COVID-19/epidemiology ; *Telemedicine ; Qualitative Research ; *Social Support ; *Health Personnel/psychology ; *Attitude of Health Personnel ; },
abstract = {Breastfeeding has been shown to provide numerous benefits for mothers and babies in the short and long term. During the COVID-19 pandemic, breastfeeding support, which was traditionally provided offline, shifted to online platforms. Although these remote services were available before the pandemic began, online interventions emerged as an alternative and proved effective in helping mothers breastfeed during that period. We aimed to explore the existing literature on the experiences of mothers and health care professionals with remote one-to-one synchronous breastfeeding support and to identify the unmet support needs of mothers regarding this type of support. We systematically searched seven literature databases: MEDLINE, CINAHL Plus, MIDIRS, Web of Science, ASSIA, WHO Global Index, and Google Search. Articles published before 2010 and in languages other than English and Indonesian language were excluded. A thematic approach was used to synthesise the data. Twenty-one studies were included in this review. Three themes generated from the synthesis: (1) mothers' acceptance of one-to-one synchronous telelactation, (2) benefit of one-to-one synchronous telelactation, and (3) challenges faced in one-to-one synchronous telelactation. In conclusion, mothers generally accepted one-to-one synchronous breastfeeding support as an alternative to in-person sessions, although some challenges remain. Further improvements are needed to address accessibility and scheduling issues.},
}
@article {pmid42105055,
year = {2026},
author = {Nolan, B and O'Connor, C},
title = {Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives.},
journal = {Dermatology and therapy},
volume = {16},
number = {5},
pages = {2363-2376},
pmid = {42105055},
issn = {2193-8210},
support = {223047/Z/21/Z/WT_/Wellcome Trust/United Kingdom ; },
abstract = {Infantile haemangiomas (IH) are the most common vascular tumours of infancy, characterised by a predictable trajectory of rapid proliferation, plateau, and slow spontaneous involution. Although most regress uneventfully, a significant minority risk ulceration, functional compromise, or disfigurement, and therefore require timely intervention. The therapeutic landscape was once dominated by corticosteroids, interferon, and cytotoxic chemotherapeutics of modest efficacy and considerable toxicity. Management was revolutionized in 2008 by the discovery that the beta-blocker propranolol induced prompt and sustained regression. Propranolol has since become the established first-line therapy for IH, with efficacy and safety confirmed by randomized controlled trials and corroborated by observational cohorts. Mechanistically there are multiple temporally stratified actions: immediate vasoconstriction, suppression of angiogenic signalling pathways, induction of endothelial apoptosis, and ultimately the promotion of adipogenic differentiation in keeping with natural involution. Safety is favourable under expert supervision, though hypoglycemia remains the principal preventable hazard, necessitating caregiver education on feeding regimens and "sick day" rules. Rebound growth, encountered in roughly one-fifth of cases, usually responds to re-treatment. Alternative beta-blockers such as atenolol and nadolol provide comparable efficacy with potential advantages in tolerability or dosing convenience. Topical timolol has limited effectiveness for small superficial lesions, while sirolimus, becaplermin gel, laser devices, and surgery may have circumscribed adjunctive roles. Corticosteroids and cytotoxic agents are now confined to salvage use. Contemporary perspectives extend beyond pharmacology to encompass caregiver experience and health-system burden. Recent work highlights the low burden of treatment with propranolol, while digital innovations such as photo-triage during the COVID-19 pandemic illustrate opportunities to reduce healthcare exposure and improve equity of access. This review describes the evolution of drug therapy for IH and integrates mechanistic insights, clinical pragmatism, and patient-centred innovations to chart the current trajectory of care.},
}
@article {pmid42105073,
year = {2026},
author = {Schultz, T and Rosenthal, S},
title = {Telemedicine in Pediatric Headache in a Post-COVID-19 World: A Narrative Review and Practical Implementation.},
journal = {Current pain and headache reports},
volume = {30},
number = {1},
pages = {},
pmid = {42105073},
issn = {1534-3081},
mesh = {Humans ; *Telemedicine ; Child ; *Headache/therapy ; *COVID-19/epidemiology ; *Migraine Disorders/therapy ; Pediatrics/methods ; },
abstract = {PURPOSE OF REVIEW: Pediatric migraine is a leading cause of disability worldwide, yet access to pediatric headache specialists remains limited due to workforce scarcities and geographic disparities. This review examines the evolution of telemedicine in headache care, evaluates current evidence for safety and efficacy, and explores its role in improving access and multidisciplinary management.<br><br>RECENT FINDINGS: Randomized trials and observational studies demonstrate that telemedicine provides clinical outcomes comparable to in-person visits with high patient satisfaction and reduced logistical burden. Emerging data support its safety in non-acute headache evaluation as well as benefit of supporting multidisciplinary care. Professional societies, including the American Headache Society and the American Academy of Pediatrics, endorse telemedicine as an appropriate modality for headache management. Telemedicine has matured into a sustainable, evidence-based approach for pediatric headache care. When implemented thoughtfully, it expands access, supports multidisciplinary treatment, and maintains safety, positioning it as an essential component of future headache care delivery models.},
}
@article {pmid42105110,
year = {2026},
author = {Savorgnan, F and Prabhu, J and Pilla, P and Flores, S and Loomba, RS and Acosta, S},
title = {Pulse Oximetry, Skin Pigmentation, and Occult Hypoxemia in Pediatric Cardiac Critical Care.},
journal = {Pediatric cardiology},
volume = {},
number = {},
pages = {},
pmid = {42105110},
issn = {1432-1971},
abstract = {Pulse oximetry (SpO2) is central to oxygenation assessment in pediatric and cardiac intensive care. Increasing evidence demonstrates that SpO2 may systematically overestimate arterial oxygen saturation (SaO2), particularly in individuals with darker skin pigmentation, thereby increasing the risk of occult hypoxemia-arterial hypoxemia not detected by pulse oximetry. We sought to synthesize current evidence and define implications for pediatric and congenital heart disease populations. We performed a narrative review of experimental physiology studies; observational adult and pediatric cohorts; pediatric COVID-19, ICU, and cardiac ICU investigations; device-comparison analyses; systematic reviews; and regulatory evaluations reporting paired SpO2-SaO2 measurements or validated reference standards stratified by race, ethnicity, or objectively measured skin pigmentation. Data sources included PubMed, MEDLINE, and bibliographies of relevant studies. Experimental data demonstrate directional SpO2 overestimation that increases during hypoxemia. Large adult cohorts confirm higher rates of occult hypoxemia in patients with darker skin pigmentation, findings subsequently replicated in hospitalized children. Emerging pediatric cardiac ICU data suggest that physiologic complexity may further amplify SpO2-SaO2 discordance. Device-comparison studies reveal variability across manufacturers, influenced by calibration datasets and signal-processing algorithms. Across populations, misclassification is most clinically relevant near commonly used escalation thresholds. SpO2 frequently overestimates SaO2 in darker skin pigmentation and during hypoxemia, increasing vulnerability to occult hypoxemia in hospitalized and critically ill children. In pediatric cardiac populations-where narrow saturation thresholds guide management-contextual, bias-aware interpretation of pulse oximetry is essential to support accurate decision-making and equitable care.},
}
@article {pmid42105330,
year = {2026},
author = {Callens, S and Dambre, C and De Schryver, A and Desmet, S and Flamaing, J and Peeters, M and Vigneron, L and Van Laethem, Y},
title = {Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.},
journal = {Acta clinica Belgica},
volume = {},
number = {},
pages = {1-11},
doi = {10.1080/17843286.2026.2671079},
pmid = {42105330},
issn = {2295-3337},
abstract = {BACKGROUND: Pneumococcal disease remains a significant burden in Belgian adults, with 2,120 cases of invasive pneumococcal disease (IPD) reported in 2024, the highest in a decade. Despite clear indications, vaccination uptake remains unacceptably low (13-24% in risk groups). Complex sequential vaccination schedules involving pneumococcal conjugate vaccines followed by the 23-valent polysaccharide vaccine (PPV23), combined with limited awareness among healthcare providers and the public, and incomplete reimbursement policies, have contributed to implementation barriers and poor adherence.<br><br>METHODS: This review provides a practice-oriented translation of the 2025 Superior Health Council of Belgium guidelines on adult pneumococcal vaccination. We analysed Belgian National Reference Centre 2024 serotype surveillance data to support age-stratified vaccine selection recommendations.<br><br>KEY RECOMMENDATIONS: A single-dose conjugate vaccine approach now replaces all prior sequential regimens. Vaccine selection is age-stratified based on Belgian serotype epidemiology: PCV20 for adults 18-49&#x2009;years with risk conditions (serotype 4 coverage critical); PCV20 or PCV21 for ages 50-84&#x2009;years; and PCV21 preferred for adults&#x2009;&#x2265;&#x2009;85&#x2009;years (15% coverage advantage). PPV23 is eliminated from routine recommendations. Co-administration with influenza, RSV, and COVID-19 vaccines is supported, enabling maximal respiratory protection in a single visit.<br><br>CONCLUSION: One conjugate vaccine dose, selected by age, provides maximal pneumococcal protection. The challenge is implementation to increase vaccination coverage: every clinical encounter with an at-risk adult is a vaccination opportunity.},
}
@article {pmid42106620,
year = {2026},
author = {Zakaria, AM and El Shahidy, SM and Diab, AM},
title = {Epidemiology and genetic variation of acute viral gastroenteritis in children under five years in the Middle East (2020-2025): a systematic review and meta-analysis.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {42106620},
issn = {1471-2334},
mesh = {Humans ; *Gastroenteritis/epidemiology/virology ; Middle East/epidemiology ; *Genetic Variation ; Infant ; Child, Preschool ; Prevalence ; Infant, Newborn ; Coinfection/epidemiology/virology ; Rotavirus/genetics ; Rotavirus Infections/epidemiology/virology ; *Virus Diseases/epidemiology/virology ; Acute Disease ; },
abstract = {BACKGROUND: Acute viral gastroenteritis remains a major cause of morbidity and hospitalization among children under five years worldwide. In the Middle East, epidemiological and molecular evidence remains fragmented, particularly in the post-COVID-19 period. This systematic review and meta-analysis aimed to synthesize recent data (2020-2025) on the prevalence, genetic diversity, and co-infection patterns of enteric viruses among children aged 0-59 months in the region.<br><br>METHODS: A comprehensive search of PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and the WHO Global Index Medicus identified eligible observational and molecular studies published between 1 January 2020 and 31 May 2025. Study selection, data extraction, and risk-of-bias assessment were independently conducted by two reviewers according to PRISMA 2020 guidelines. The protocol was prospectively registered in PROSPERO (CRD420251064184). Pooled prevalence estimates were calculated using a random-effects model with Freeman-Tukey double arcsine transformation.<br><br>RESULTS: Forty-three studies, including 22,021 children tested for acute gastroenteritis (AGE) from nine Middle Eastern countries, met the inclusion criteria. Rotavirus (28 studies) was the most prevalent pathogen, with a pooled prevalence of 30.4% (95% CI: 24.3-35.8; I&#xb2; = 96%, p&#x2009;<&#x2009;0.001), followed by norovirus (12 studies) at 23.5% (95% CI: 11.4-29), adenovirus (13 studies) at 11.3% (95% CI: 8.6-17.6), and astrovirus (10 studies) at 6.0% (95% CI: 1.3-12.7). Predominant rotavirus genotypes included G1, G2, G3, and G9, commonly combined with P[8], P[4], and P[6], with G3P[8] and G1P[8] as dominant constellations. Norovirus GII.4 and recombinant GII.4[P16] strains were frequently detected. Viral co-infections were also reported, particularly involving rotavirus and other enteric viruses.<br><br>CONCLUSION: Rotavirus and norovirus remain the principal viral causes of pediatric acute gastroenteritis in the Middle East and exhibit substantial genetic diversity with frequent co-infection patterns. However, marked inter-study heterogeneity and uneven geographic representation limit regional generalizability. Strengthened molecular surveillance, standardized diagnostic approaches, and continuous genotype monitoring are essential to optimize prevention strategies and vaccination policies across the region.},
}
@article {pmid42106756,
year = {2026},
author = {Saito, H and Tartari, E and Garlasco, J and Pittet, D and Allegranzi, B},
title = {Global landscape of locally produced alcohol-based handrub in health care settings: a scoping review.},
journal = {Antimicrobial resistance and infection control},
volume = {15},
number = {1},
pages = {},
pmid = {42106756},
issn = {2047-2994},
mesh = {Humans ; *COVID-19/prevention &amp; control ; Developing Countries ; *Ethanol ; *Hand Disinfection/methods ; Health Personnel ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Reliable access to alcohol-based handrub (ABHR) is essential for hand hygiene and infection prevention, yet many low- and middle-income countries (LMICs) continue to face supply constraints. A 2011 WHO global assessment demonstrated that WHO-recommended ABHR formulations produced locally at low cost, were well accepted by healthcare workers, but also highlighted persistent barriers, including challenges in procuring ingredients and dispensers and in ensuring adequate quality control. This review aimed to provide an updated global synthesis of evidence on local ABHR production in healthcare settings.<br><br>METHODS: Following the Joanna Briggs Institute framework and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, we systematically searched Embase, Medline, and CINAHL from inception to 19 March 2025. Two reviewers independently conducted title-abstract screening, full-text screening and data extraction. Primary research articles reporting local ABHR production in healthcare settings in LMICs were eligible for data extraction and descriptive synthesis.<br><br>RESULTS: Of 2343 articles screened, 31 studies from 19 countries were included (2006-2023). Over half (n&#x2009;=&#x2009;18, 58%) were conducted during the COVID-19 pandemic; 22 described health-facility production and 9 described factory-level manufacturing. Of the 22 health-facility production studies, 12 (55%) used WHO Formulation 1 (ethanol-based) or modifications thereof. Pharmacists most commonly led production at the health-facility level. Only 6% (two articles) reported the source of alcohol, and less than half evaluated efficacy or organoleptic properties (13 and 12, respectively). Most funded studies relied on high-income-country (HIC) grants (17 of 24, 71%).<br><br>CONCLUSIONS: Local ABHR production remains infrequently reported in the literature, although publications increased during the COVID-19 pandemic. Heavy reliance on short-term, HIC-funded initiatives raises concerns about the long-term scalability and sustainability of local ABHR production in LMICs. Strengthening national regulatory capacity, quality-control laboratories, and sustainable financing is critical to maintain safe ABHR access beyond pandemic contexts, for resilient national supply chains and in-country quality control capacity.},
}
@article {pmid42106840,
year = {2026},
author = {Hu, H and Jin, G and Zhang, X},
title = {Older adults and online health misinformation: a systematic literature review.},
journal = {BMC psychology},
volume = {14},
number = {1},
pages = {},
pmid = {42106840},
issn = {2050-7283},
support = {No. 24CXW053//National Social Science Fund Youth Project/ ; No. 12625311//Fundamental Research Funds for the Central Universities/ ; },
mesh = {Humans ; Digital Media ; *Communication ; Aged ; *Internet ; *Health Literacy ; COVID-19 ; *Social Media ; *Health Communication ; },
abstract = {As older adults increasingly rely on the internet for health-related information, concerns about their vulnerability to online health misinformation have intensified. This systematic literature review synthesizes findings from 26 empirical studies published between 2000 and 2024 to examine how older adults interact with health misinformation in digital contexts. The review identifies a complex interplay of factors contributing to their susceptibility, including cognitive decline, gaps in digital and health literacy, emotional and psychological influences, and the role of social relationships. However, most studies lack theoretical grounding, platform-specific analysis, and geographical diversity. Conceptual inconsistencies and a COVID-19 research bias further limit generalizability. The review calls for clearer definitions, interdisciplinary approaches, and targeted interventions to address this urgent public health issue and provide a foundation for designing more targeted and effective interventions.},
}
@article {pmid42106851,
year = {2026},
author = {Zhu, S and Li, X and Chen, R and Wu, S and Jiang, L and Li, M and Huang, L and Cui, N},
title = {Rare pediatric multi-system thrombosis post-COVID-19: a three-year follow-up case report and narrative review on rivaroxaban for long-term management.},
journal = {Orphanet journal of rare diseases},
volume = {21},
number = {1},
pages = {},
pmid = {42106851},
issn = {1750-1172},
support = {SZXK202106//Key Laboratory in Science and Technology Development Project of Suzhou/ ; SS202067//Key Laboratory in Science and Technology Development Project of Suzhou/ ; },
mesh = {Child ; Humans ; Male ; Anticoagulants/therapeutic use ; *COVID-19/complications ; *Factor Xa Inhibitors/therapeutic use ; Follow-Up Studies ; Pulmonary Embolism/drug therapy/etiology ; Retrospective Studies ; *Rivaroxaban/therapeutic use ; SARS-CoV-2/physiology ; *Thrombosis/drug therapy/etiology ; *Venous Thromboembolism/drug therapy/etiology ; },
abstract = {This retrospective study presents a 10-year-old male with multi-systemic venous thromboembolism (VTE) secondary to COVID-19, including right ventricular thrombus(40 mm × 18 mm), bilateral iliac vein thrombosis, pulmonary embolism, and renal vein thrombosis. The child presented with fever, abdominal pain, and elevated inflammatory markers (CRP 222.72 mg/L, WBC 22.41 × 10[[9]]/L). Imaging confirmed extensive thrombi in the right ventricle, pulmonary arteries, and lower extremities. Anticoagulation with rivaroxaban (10 mg QD) was initiated alongside anti-infective and anti-inflammatory therapies. Over a 3-year follow-up, thrombus burden significantly regressed, with D-dimer decreasing from 73 430 µg/L to 290 µg/L, and no recurrence or bleeding complications were observed. Coagulation parameters (PT, APTT) stabilized within therapeutic ranges. This case suggests the efficacy and safety of rivaroxaban in long-term management of multi-system VTE in pediatric patient, especially in cases of COVID-19-associated hypercoagulability. The primary clinical outcomes were the resolution of thrombus burden as evidenced by imaging and the absence of bleeding complications or recurrence during the follow-up period. The findings align with emerging evidence supporting direct oral anticoagulants (DOACs) in children, emphasizing individualized dosing and long-term management. Further studies are warranted to validate DOACs' role in pediatric thrombosis, especially in the context of viral infections.},
}
@article {pmid42107172,
year = {2026},
author = {Alenzi, TK and Alhussaini, NT and Alhazmi, OA and Althuwaiqeb, MS and Alotaibi, RF and Alqahtani, SM and Badroun, DK and Alotaibi, SA and Almehayawi, SS and Basamih, K and Al-Otaibi, WA and Allemailem, KS},
title = {Association of ABO blood groups with SARS-CoV-2 infection in Saudi Arabia based on a systematic review and meta-analysis.},
journal = {Journal of infection and public health},
volume = {19},
number = {6},
pages = {103240},
doi = {10.1016/j.jiph.2026.103240},
pmid = {42107172},
issn = {1876-035X},
mesh = {Humans ; Saudi Arabia/epidemiology ; *ABO Blood-Group System ; *COVID-19/epidemiology/blood ; SARS-CoV-2 ; Female ; Disease Susceptibility ; },
abstract = {Although previous studies and meta-analyses have suggested modest and population-dependent associations between ABO blood groups and susceptibility to SARS-CoV-2 infection, findings have remained inconsistent across different geographic regions. We synthesized data from nine studies conducted in Saudi Arabia between 2020 and 2024 to define national patterns. Eight datasets with extractable data contributed 7650 laboratory-confirmed cases to quantitative analyses. Group O accounted for the largest proportion of infections (random effects estimate 41.7%, 95% CI 38.0-45.6), followed by group A (27.8%, 95% CI 25.6-29.9) and group B (21.2%, 95% CI 18.0-24.6). Group AB represented the smallest fraction (6.4%, 95% CI 3.7-9.9). Substantial heterogeneity was observed across all blood groups (I[2] 72.1-96.5%) yet leave-one-out analyses confirmed stable pooled estimates. Statistical assessments provided no evidence of publication bias. The pooled distributions closely mirrored background ABO frequencies in the Saudi population, indicating that ABO-related differences in infection susceptibility are modest relative to epidemiologic and demographic factors.},
}
@article {pmid42107305,
year = {2026},
author = {Ching, LY and Kunnath, AP},
title = {The resurgent threat: human metapneumovirus in a post-pandemic landscape.},
journal = {Diagnostic microbiology and infectious disease},
volume = {116},
number = {1},
pages = {117445},
doi = {10.1016/j.diagmicrobio.2026.117445},
pmid = {42107305},
issn = {1879-0070},
mesh = {Humans ; *Metapneumovirus ; *Paramyxoviridae Infections/epidemiology/prevention &amp; control/diagnosis/virology ; COVID-19/epidemiology ; Pandemics ; Seasons ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic profoundly disrupted global respiratory virus transmission. Widespread nonpharmaceutical interventions (NPIs) sharply suppressed common pathogens, including human metapneumovirus (HMPV). However, as these measures were lifted, HMPV re-emerged with unexpected intensity-a resurgence driven primarily by population-wide "immunity debt" accrued during years of reduced viral exposure. Unlike influenza or RSV, HMPV's post-pandemic behavior has challenged long-held assumptions about seasonal respiratory virus dynamics. Traditional late-winter peaks have given way to out-of-season surges, year-round co-circulation with other viruses has become commonplace, and existing surveillance systems designed for a pre-pandemic world have proven inadequate. This review examines HMPV's renewed clinical and public health significance, focusing on epidemiological shifts, health system pressures, diagnostic gaps, and the critical need for coordinated, multi-pathogen preparedness. We argue that HMPV is no longer a minor seasonal pathogen but a persistent stressor requiring targeted countermeasures, including accelerated vaccine development, integrated surveillance, and healthcare system redesign.},
}
@article {pmid42107387,
year = {2026},
author = {Goode, JR and Rothholz, MC and Foster, SL and Brody, ER and Gräbenstein, JD},
title = {Pharmacy-Based Immunization Delivery: A Comprehensive History and Current Challenges.},
journal = {Journal of the American College of Clinical Pharmacy : JACCP},
volume = {9},
number = {6},
pages = {e70219},
doi = {10.1002/jac5.70219},
pmid = {42107387},
issn = {2574-9870},
mesh = {Humans ; United States ; *Pharmacists/organization &amp; administration ; COVID-19/prevention &amp; control/epidemiology ; History, 20th Century ; COVID-19 Vaccines/administration &amp; dosage ; History, 21st Century ; History, 19th Century ; *Immunization/history ; *Immunization Programs/history ; Professional Role ; Vaccines/administration &amp; dosage ; },
abstract = {Pharmacists and their teams have a long history of involvement with vaccines. This paper describes the contributions of pharmacy-based immunization delivery in the United States from the 1800's to date. Early activities centered around storage and distribution of antitoxins and vaccines. From the 1950s through the early 1990s, pharmacists were facilitating administration of vaccines by other health care providers. In the early 1990s, efforts began to allow pharmacists to administer vaccines, with the first pharmacist immunization training in 1994. By 2009, all 50 states allowed pharmacists to administer vaccines. From the 1990s onward, pharmacists increasingly contributed to national vaccine policies and guidelines, and states expanded their authority to a broader range of patient ages and vaccines. The coronavirus disease 2019 (COVID-19) pandemic opened more opportunities for pharmacy-based involvement, including federal expansion of immunizing authority to children aged 3 years and older, and the authority for pharmacy technicians and student pharmacists to administer vaccines. Pharmacists and their teams administered more than 50% of the COVID-19 vaccines. Today, the majority of adult vaccines are administered in pharmacy-based settings. Even with pharmacy's substantial contributions to immunization delivery in the United States, challenges persist for providers and patients, including inconsistent state-to-state immunizing authority by age and disease and payor payment. Pharmacy-based immunization delivery has become a significant contributor to improving public health by protecting against vaccine-preventable diseases.},
}
@article {pmid42107644,
year = {2026},
author = {Maio, N and Rouault, TA},
title = {Iron-sulfur cofactors in nucleic acid metabolism and protein synthesis: Assembly, delivery, and putative roles in cellular and viral systems.},
journal = {The Journal of biological chemistry},
volume = {302},
number = {6},
pages = {113129},
pmid = {42107644},
issn = {1083-351X},
mesh = {*Iron-Sulfur Proteins/metabolism ; Humans ; *Iron/metabolism ; *Sulfur/metabolism ; *Protein Biosynthesis ; *Nucleic Acids/metabolism ; Animals ; Viral Proteins/metabolism ; SARS-CoV-2/metabolism ; DNA Replication ; Virus Replication ; *Coenzymes/metabolism ; },
abstract = {Composed of iron (Fe) and inorganic sulfur (S), iron-sulfur clusters (ISCs) are ancient cofactors present across all domains of life and in some viruses. Over the past 3 decades, cytosolic and nuclear Fe-S proteins have emerged as integral components of DNA replication and repair machineries, telomere maintenance pathways, transcriptional processes, cell cycle regulation, and protein synthesis. More recently, ISCs were identified in viral proteins, including multiple components of the SARS-CoV-2 replication and transcription complex (RTC), which collectively host seven experimentally verified Fe-S cofactors. The coexistence of multiple ISC-dependent enzymes within both cellular and viral replication machineries raises fundamental questions about how these metal cofactors coordinate genome maintenance, replication, and host-virus interactions. Here, we provide an inventory of known mammalian nucleocytoplasmic Fe-S proteins, discuss mechanisms of ISC acquisition, explore the potential roles of ISCs within cellular and viral replication complexes, and highlight critical gaps in our understanding of ISC delivery, coordination, and function among Fe-S proteins in large multi-subunit assemblies.},
}
@article {pmid42108283,
year = {2026},
author = {Azadinia, F and Shamsi, F and Ebrahimi-Takamjani, I and Rasouli, O},
title = {Changes in Quadriceps Force Control and Torque Quality Following Anterior Cruciate Ligament Injury and Reconstruction: Associations with Functional Performance-A Systematic Review and Meta-Analysis.},
journal = {Sports medicine - open},
volume = {12},
number = {1},
pages = {},
pmid = {42108283},
issn = {2199-1170},
abstract = {BACKGROUND: Consistent force output is a critical indicator of the neuromuscular system's effectiveness. Although force signals inherently fluctuate, the ability of skeletal muscles to generate accurate and steady force offers insights into the system's adaptability and its ability to adjust motor control strategies to meet task demands. This systematic review and meta-analysis aimed to synthesize evidence on quadriceps force control in individuals with anterior cruciate ligament (ACL) injury and/or surgical reconstruction (ACLR). Additionally, it sought to explore the relationship between force control measures and physical function outcomes.<br><br>METHODS: A literature search was conducted across several databases, including PubMed, EMBASE, Scopus, Web of Science, and SPORTDiscus. Risk of bias was assessed using the adapted Newcastle-Ottawa tool. The study included individuals with unilateral ACL injury and/or ACLR, with comparisons to uninjured controls or unaffected contralateral limbs. Primary outcomes included torque quality, force accuracy, and force/torque steadiness, while secondary outcomes included function-related clinical questionnaires and performance tests. Eligible studies consisted of observational studies and baseline data from interventional studies published in English. Standardized mean differences (SMDs) were calculated using a random effects meta-analysis.<br><br>RESULTS: A total of 33 studies were included, comprising 20 individuals with ACLR, 12 with ACL injuries, and one with both. The meta-analysis showed significant effects of ACL injury (SMD&#x2009;=&#x2009;0.84) and ACLR (SMD&#x2009;=&#x2009;1.57) on quadriceps torque frequency content. Individuals with ACLR had a greater root mean squared error (RMSE) or absolute error (AE) in force output compared to healthy controls (SMD&#x2009;=&#x2009;0.35) and exhibited a significant difference in the coefficient of variation (CoV) of the force signal (SMD&#x2009;=&#x2009;0.22), indicating impaired force control in those with ACLR.<br><br>CONCLUSIONS: ACL injury impairs quadriceps force control in the injured limb, as shown by torque frequency content analysis. While ACL reconstruction is the gold standard for joint stability, it may not fully restore neuromuscular function, potentially compromising physical functioning. However, the limited number of high-quality studies may weaken these conclusions.<br><br>REGISTRATION: The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42024571495).},
}
@article {pmid42109487,
year = {2026},
author = {Hu, Y and Li, J and Zheng, Y and Cheng, Y and Li, W and Wang, X and Sun, Y},
title = {Epidemiology and clinical impact of pediatric RSV co-infections after the COVID-19 pandemic: a narrative review.},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1787312},
pmid = {42109487},
issn = {2296-2360},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic profoundly disrupted the global epidemiology of respiratory syncytial virus (RSV), leading to atypical off-season surges and altering infection dynamics across different climatic zones. This review synthesizes evidence on the landscape of pediatric RSV co-infections in this transformed post-pandemic context. RSV co-infection is frequent, with human rhinovirus (HRV) being the most common viral co-pathogen and Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hi) predominating as bacterial co-infections. Critically, these co-infections are significantly associated with heightened disease severity, including more intense clinical presentations, prolonged hospitalizations, increased intensive care unit (ICU) admission rates, and greater therapeutic complexity. The relaxation of non-pharmaceutical interventions has been linked to a rebound in co-infection rates. While advances in molecular diagnostics have improved detection, and new prophylactics like nirsevimab offer promise, significant challenges remain. These include gaps in understanding pathogenic synergies, inequities in access to novel interventions, and the need for strategies to manage the ongoing evolution of RSV epidemiology. This underscores the necessity for enhanced surveillance, equitable prevention, and targeted research to mitigate the substantial burden of pediatric RSV co-infections.},
}
@article {pmid42111388,
year = {2026},
author = {Bongiovanni, G and Polelli, V and Stainer, A and Russo, M and Gatti, R and Aliberti, S and Amati, F},
title = {Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature.},
journal = {ERJ open research},
volume = {12},
number = {2},
pages = {},
pmid = {42111388},
issn = {2312-0541},
abstract = {BACKGROUND: Rehabilitation represents a key nonpharmacological treatment for patients with interstitial lung diseases (ILDs). As a consequence of improvement in technologies and social distancing in the SARS-CoV-2 era, a growing body of evidence demonstrated the effectiveness of tele-rehabilitation programmes for chronic respiratory diseases.<br><br>METHODS: We conducted a systematic review to identify randomised controlled trials (RCTs) on tele-rehabilitation in ILD and extended the search to ongoing trials.<br><br>RESULTS: Throughout our research, we identified four RCTs describing home rehabilitation in ILD. All RCTs were heterogenous small trials. Thus, a meta-analysis could not be performed, and data were reported in a descriptive way. The primary outcomes of the RCTs analysed included both physical and functional measures. We also identified through ClinicalTrials.gov four ongoing clinical trials investigating pulmonary rehabilitation in ILD with a considerable degree of heterogeneity regarding the populations included. In our systematic review, we also highlighted the key pillars for future trials in the field.<br><br>CONCLUSION: Potential treatment trajectories on outcomes of ILD patients related to the implementation of tele-rehabilitation are also discussed.},
}
@article {pmid42111593,
year = {2026},
author = {Zhao, J and Wang, J and Jiang, L and Li, F and Ji, L and Jin, H},
title = {Pandemic fatigue and associated factors: a meta-analysis using the COM-B model.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1765375},
pmid = {42111593},
issn = {1664-1078},
abstract = {BACKGROUND: Pandemic fatigue during the prolonged COVID-19 crisis undermines sustained engagement with protective measures and public health messaging. Existing studies provide heterogeneous prevalence estimates and disparate lists of correlates but lack a unified, theory-driven synthesis.<br><br>METHODS: Searches were conducted in six databases up until March 2026. This study synthesized the prevalence of pandemic fatigue and factors associated with it during COVID-19 using the COM-B model and TDF theory.<br><br>RESULTS: Twenty-three cross-sectional studies (n&#x202f;=&#x202f;49,285) were included. The pooled prevalence of pandemic fatigue was 51% (95%CI: 0.38, 0.65), with substantial heterogeneity. Health literacy (Capability) was inversely associated with fatigue (&#x3b2;&#x202f;=&#x202f;-0.257, 95%CI: -0.404, -0.110). Opportunity-related stressors-including bereavement due to COVID-19 (&#x3b2;&#x202f;=&#x202f;0.281, 95%CI: 0.124, 0.437), daily troubles (&#x3b2;&#x202f;=&#x202f;0.296, 95%CI:0.211, 0.380), and working student status (&#x3b2;&#x202f;=&#x202f;0.232, 95%CI: 0.122, 0.341)-were positively associated with pandemic fatigue. Motivation-related factors showed mixed associations, whereas negative emotional states were associated with higher odds of pandemic fatigue.<br><br>CONCLUSION: Pandemic fatigue is common and was associated with diverse capability-, opportunity-, and motivation-related factors. A COM-B-informed interpretation suggests multi-level strategies that combine skills building, supportive environments, and psychosocial support.},
}
@article {pmid42112438,
year = {2026},
author = {Liu, Y and Zhang, Y and Liang, L and Zhang, H and Zhang, T and Rong, X and Tan, J and Mi, Y},
title = {Engineering strategies and decision frameworks for virus-like particle-based vaccines against infectious diseases.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1795711},
pmid = {42112438},
issn = {1664-302X},
abstract = {Virus-like particles (VLPs) have emerged as a versatile and clinically validated platform for developing safe, effective vaccines against infectious diseases. However, the expanding toolkit of VLP engineering strategies-spanning genetic fusion, modular conjugation, and nucleic acid encapsulation-creates a critical need for a rational selection framework to match technological strengths with specific vaccine objectives. This review addresses this gap by constructing a comparative decision-making framework centered on four core engineering dimensions: cargo flexibility, loading specificity, functional efficiency, and manufacturability. We systematically juxtapose two principal technology streams: (1) the display of protein antigens (through genetic, chemical, and bio-conjugation) and (2) the encapsulation of nucleic acid cargo (via physical, electrostatic, and programmable packaging mechanisms), evaluating each within this unified framework. This technological dissection is directly linked to the development landscape of VLP-based vaccines against major pathogens-including HBV, HPV, malaria, influenza, and SARS-CoV-2-illustrating how strategic choices at the engineering level fundamentally underpin immunogenic potency and translational success. By sequentially considering immunological objectives, antigen compatibility, surface display modality, interior cargo integration, and manufacturing constraints, this framework facilitates rational, stepwise VLP vaccine design. Looking forward, we discuss emerging trends toward modular and computationally guided platforms for antigen placement and scaffold design. By integrating a structured technology assessment with translational insights, this review aims to provide a practical roadmap for the rational design and accelerated development of next-generation, broadly protective VLP-based vaccines.},
}
@article {pmid42113367,
year = {2026},
author = {Shukla, S and Sharma, MP and Rashmi, R and Misra, G},
title = {Long non-coding RNAs as modulators of endocrine therapy response in hormone receptor-positive breast cancer.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {42113367},
issn = {1573-4978},
mesh = {Humans ; *Breast Neoplasms/genetics/drug therapy/metabolism ; Female ; *RNA, Long Noncoding/genetics/metabolism ; Drug Resistance, Neoplasm/genetics ; Receptors, Estrogen/metabolism/genetics ; *Antineoplastic Agents, Hormonal/therapeutic use/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects ; Tumor Microenvironment/genetics/drug effects ; Signal Transduction/drug effects ; },
abstract = {Breast cancer is a major cause of cancer-related mortality among women, with hormone receptor-positive (HR+) breast cancer accounting for 70-80% of diagnosed cases. The current treatment approaches include both endocrine monotherapy and combinational strategies incorporating targeted signaling pathway inhibitors. Despite recent therapeutic advances that have significantly improved patient outcomes, the development of resistance to endocrine therapies leads to relapses and treatment failure. Emerging evidence has shown that long non-coding RNAs (lncRNAs) are therapeutic modulators; however, their involvement in clinical studies has not been much explored. In HR+ breast cancer, lncRNAs influence both sensitivity and resistance to endocrine therapy by modulating estrogen receptor (ER) function, switching between alternative survival pathways, and altering tumor epigenetics and tumor microenvironment. The major focus of this comprehensive review is to understand the role of lncRNAs in overcoming the endocrine resistance issues in the treatment of HR+ breast cancer. It presents a comprehensive approach focused on endocrine therapy mechanisms, resistance, and adaptive escape pathways of HR+ tumor cells. By mapping these mechanisms of endocrine therapy, the review reveals novel therapeutic targets for the treatment of HR+ breast cancer. Lastly, it highlights the specialized lncRNA-based therapeutics for bone metastatic niches in HR+ breast cancer and current approaches of therapeutic targeting of lncRNAs for disease treatment.},
}
@article {pmid42114091,
year = {2026},
author = {Johnson, D and Quinn, S and Algase, LF and Watkins, C and , },
title = {Telemedicine Policy and Practice: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {179},
number = {7},
pages = {1030-1032},
doi = {10.7326/ANNALS-25-04194},
pmid = {42114091},
issn = {1539-3704},
mesh = {Humans ; COVID-19 ; *Telemedicine/legislation &amp; jurisprudence/economics/organization &amp; administration ; United States ; SARS-CoV-2 ; Pandemics ; *Health Policy ; Licensure, Medical ; Health Services Accessibility ; Patient Safety ; Practice Patterns, Physicians' ; },
abstract = {In response to the COVID-19 pandemic, federal policymakers temporarily lifted long-standing restrictions on telemedicine, resulting in an unprecedented and rapid expansion of virtual care across video, audio, and asynchronous modalities. When integrated into longitudinal care relationships, telemedicine can increase access, reduce patient burden, and support continuity for people facing geographic, mobility, or socioeconomic barriers. However, telemedicine also introduces new clinical, regulatory, equity, and safety challenges that require deliberate policy design. Beyond its clinical considerations, telehealth offers environmental and logistical benefits, including reduced travel time and cost, decreased fuel consumption, lower transportation expenses, and lower greenhouse gas emissions. In this position paper, the American College of Physicians updates its previous policy paper on telemedicine to reflect changes in payment policy, licensure, prescribing authority, and utilization patterns that have occurred over the past decade and accelerated during the COVID-19 public health emergency. This paper focuses on access, payment policy, licensure, prescribing practices, equity, and patient safety across federal and state programs and private payers and emphasizes the conditions under which telemedicine should be integrated into clinical practice. Key developments addressed include the expansion and partial lapse of Medicare telemedicine waivers, evolving U.S. Drug Enforcement Administration rules governing prescribing, increased reliance on interstate practice, and normalization of telemedicine by private payers.},
}
@article {pmid42115141,
year = {2026},
author = {Yang, MJ and Bohnet-Joschko, S},
title = {Thematic Mapping and Evolution of Social Media Mining in Health Research: Hybrid Bibliometric Synthesis.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e86200},
pmid = {42115141},
issn = {1438-8871},
mesh = {*Bibliometrics ; *Data Mining/methods ; *Social Media ; Humans ; Machine Learning ; PubMed ; },
abstract = {BACKGROUND: Social media platforms offer extensive data, as they are widely used globally. Social media mining (SMM) enables real-time monitoring of user-reported health information and serves as a supplement to traditional health data analytics. However, the rapid proliferation of literature has produced fragmentation, and a comprehensive knowledge map regarding SMM is lacking. Further, existing bibliometric reviews in health fields are easily undermined by synonym fragmentation and parameter settings, reducing their robustness. Thus, a more robust, reproducible, and decision-oriented bibliometric framework is required.<br><br>OBJECTIVE: This study aimed to (1) outline key thematic clusters in health-related SMM and map their dynamic evolution, and (2) methodologically demonstrate how machine learning-based bibliometric analysis can strengthen the robustness, transparency, and foresight capacity of evidence synthesis.<br><br>METHODS: This study designed a fully automated and reproducible bibliometric analysis of PubMed journal articles published from 2015 to 2025 (n=250) and analyzed records with both abstracts and keywords (n=189). We performed cleaning and standardization for titles, abstracts, author keywords, and MeSH terms, and carried out an exploratory descriptive analysis to obtain preliminary insights into publication patterns. Subsequently, we used SPECTER2 and PubMedBERT embeddings with keywords and abstracts to construct a hybrid similarity matrix. Then, we applied Uniform Manifold Approximation and Projection for dimensionality reduction, followed by Hierarchical Density-Based Spatial Clustering of Applications with Noise for thematic clustering, and visualized the results in a 3D strategic coordinate system (maturity, influence, and recency). We performed intercluster relationship analysis and time-slice analysis to examine thematic intersections and evolution. To ensure robustness and enhance interpretability, we implemented dual-level validation.<br><br>RESULTS: We identified 6 thematic clusters: cluster 1 (candidate incubator pool of peripheral cross-cutting topics in health-related SMM), cluster 2 (computational methods in health informatics), cluster 3 (public attitudes and sociopsychological determinants), cluster 4 (infodemiology and the COVID-19 information ecosystem), cluster 5 (health communication and public health engagement), and cluster 6 (social media analysis and network methods). Strategic 3D mapping revealed that methodological clusters (clusters 2 and 6) occupied high-maturity and high-influence positions, while application-driven clusters (clusters 3 and 4) occupied high-influence and high-recency positions, representing rapidly expanding frontiers. Clusters 1 and 5 demonstrated strong potential for further growth. Temporal slicing confirmed a trajectory moving from methodological consolidation and thematic diversification to a renewed focus on convergence and problem-solving. Validation showed strong semantic coherence and robustness of the methods and findings.<br><br>CONCLUSIONS: We developed a semantic-structural hybrid bibliometric framework with dual-level validation, reducing synonym fragmentation and parameter sensitivity inherent in traditional approaches. The resulting decision-oriented knowledge map offers strategic guidance for infodemiology-informed and audience-segmented public health communication, research priority settings, and the deployment and evaluation of real-world surveillance and pharmacovigilance workflows while supporting evidence-driven and patient-centered decision-making in public health and health care.},
}
@article {pmid42115792,
year = {2026},
author = {Manti, S and Licari, A and Del Giudice, MM and Tosca, MA and Ciprandi, G and Marseglia, G},
title = {Pragmatic management of acute cough in children and adolescents: an updated position paper by the Italian Society of Pediatric Allergy and Immunology (SIAIP).},
journal = {Allergologia et immunopathologia},
volume = {54},
number = {3},
pages = {31-41},
pmid = {42115792},
issn = {1578-1267},
support = {//The publication was supported by the Italian Society of Pediatric Allergy and Immunology (SIAIP)./ ; },
mesh = {Humans ; Adolescent ; Child ; *Cough/therapy/diagnosis/etiology ; Acute Disease ; Italy ; Antitussive Agents/therapeutic use ; SARS-CoV-2 ; Allergy and Immunology ; Societies, Medical ; Quality of Life ; },
abstract = {BACKGROUND: Cough is one of the most common and distressing symptoms in pediatric practice and represents a major cause of medical consultation, parental anxiety, and inappropriate medication use. Although most acute cough episodes are benign and self-limiting, they can significantly affect child's sleep, school performance, and quality of life. The COVID-19 pandemic and subsequent changes in infection patterns and immune responses have further highlighted the need to update the existing clinical guidance.<br><br>OBJECTIVE: This joint position paper by the Italian Society of Pediatric Allergy and Immunology (SIAIP) aims to provide a pragmatic, evidence-based update on the management of acute and post-viral cough in children and adolescents, integrating recent scientific advances and real-world clinical experiences.<br><br>METHODS: A multidisciplinary board of experts from SIAIP critically reviewed the literature published from 2019 to 2025 and updated the previous 2019 SIAIP document. The group achieved consensus on diagnostic and therapeutic recommendations through structured discussion and iterative revision.<br><br>RESULTS: The document emphasizes a stepwise approach to pediatric acute cough, starting with careful history-taking, clinical evaluation, and reassurance. Non-pharmacological measures-hydration, nasal saline irrigation, and avoidance of irritants-remain the first-line management. Pharmacological therapy may be considered in selected cases where cough is particularly distressing or significantly interferes with sleep; peripherally acting, nonsedative antitussives represent a reasonable option in terms of efficacy and safety. Centrally acting antitussives and unnecessary antibiotics should be avoided. Standardized, high-quality natural medical devices-with appropriate supporting evidence-represent a valid option. Honey-based preparations can be considered as complementary options. The paper also discusses new insights into cough pathophysiology, particularly the role of airway sensory hypersensitivity and neurogenic inflammation, which are paving the way for mechanism-based treatments.<br><br>CONCLUSIONS: This position paper provides an updated, pragmatic framework for the management of acute and post-viral cough in children and adolescents. It promotes rational drug use, integration of non-pharmacological and complementary measures, and awareness of emerging therapeutic targets. A mechanism-driven, individualized, and family-centered approach is advocated to improve clinical outcomes and quality of life for pediatric patients.},
}
@article {pmid42116176,
year = {2026},
author = {Soliman, AR and Abouzeid, A and Ahmed, HH},
title = {Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications.},
journal = {Diabetology &amp; metabolic syndrome},
volume = {18},
number = {1},
pages = {},
pmid = {42116176},
issn = {1758-5996},
abstract = {BACKGROUND: Obesity has emerged as a global pandemic with profound implications for respiratory health. The complex interplay between excessive adiposity and pulmonary function encompasses mechanical, metabolic, and inflammatory pathways that significantly impact morbidity and mortality.<br><br>OBJECTIVES: This comprehensive review synthesizes current evidence on obesity-related respiratory disorders, examining pathophysiological mechanisms, clinical phenotypes, epidemiological trends, and therapeutic considerations across the spectrum of respiratory diseases. This review provides a novel integrative framework unifying mechanical, inflammatory, and metabolic mechanisms across all major obesity-related respiratory conditions, with emphasis on clinically actionable phenotyping and emerging pharmacological therapies.<br><br>METHODS: We conducted a narrative review of peer-reviewed literature (PubMed/MEDLINE, Embase, and Cochrane Database, January 2000 - December 2024, using pre-specified MeSH terms; study selection and quality assessment followed SANRA guidelines focusing on the relationship between obesity and respiratory disorders including asthma, obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), chronic obstructive pulmonary disease (COPD), respiratory infections, and lung cancer.<br><br>RESULTS: Obesity profoundly affects respiratory mechanics through a right-shift of the static volume-pressure relationship of the chest wall, reducing FRC and ERV without a true restrictive pattern, altered respiratory muscle function, and systemic inflammation. Asthma prevalence increases with body mass index, demonstrating distinct phenotypes including atopic, insulin-resistant, dyslipidemic, and non-Th2 neutrophilic subtypes. OSA affects 22% of men and 17% of women, with obesity being the principal modifiable risk factor. OHS occurs in 8-20% of obese patients with sleep-disordered breathing, characterized by daytime hypercapnia (arising from impaired neuromuscular ventilatory drive and progressive nocturnal hypoventilation) and increased cardiovascular mortality. Paradoxically, obesity appears protective in advanced COPD by reducing FRC, thereby increasing inspiratory capacity and limiting dynamic pulmonary hyperinflation, and ARDS-the so-called obesity paradox-while conferring increased risk in COVID-19 pneumonitis. In lung cancer, obesity demonstrates complex relationships with risk and prognosis that vary by sex, smoking status, and disease stage.<br><br>CONCLUSIONS: Obesity-related respiratory disorders represent a multifaceted clinical challenge requiring integrated multidisciplinary approaches. Understanding distinct phenotypes and pathophysiological mechanisms is essential for personalized therapeutic strategies addressing both weight management and respiratory-specific interventions. Emerging pharmacological therapies including GLP-1 receptor agonists and dual GIP/GLP-1 agonists show particular promise in improving OSA severity and airway inflammation.},
}
@article {pmid42116640,
year = {2026},
author = {Verryt, C and Gray, P and McNaughton, P and Peake, J and Wong, M and Aho, G and Best, E and Brewerton, M and Lutui, F and Tulifau, LE and Qin, R and Viali, S and White, P and Wood, A and Woon, ST and Cole, T and Charry, AP and Hsiao, KC},
title = {Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania.},
journal = {Journal of paediatrics and child health},
volume = {62},
number = {7},
pages = {1113-1120},
pmid = {42116640},
issn = {1440-1754},
mesh = {Humans ; *Receptor, Interferon alpha-beta/deficiency/genetics ; Oceania ; Australia ; *Virus Diseases ; Practice Guidelines as Topic ; },
abstract = {Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life-threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due to being homozygous for or having two copies of the regionally relevant pathogenic IFNAR1 variant c.1156G>T, p.Glu386*. IFNAR1 deficiency confers an increased risk of severe and life-threatening infections caused by naturally circulating viruses including influenza, SARS-CoV-2, herpes simplex virus, respiratory syncytial virus (RSV), arboviruses and viruses in live attenuated vaccines (LAVs) including measles-mumps-rubella (MMR) and yellow fever. Complications including virus induced systemic hyperinflammation (VISH) are associated with significant mortality. This document outlines expert consensus regarding early identification, diagnostic workup and management of IFNAR1 deficiency in Australia, Aotearoa New Zealand and Western Pacific nations.},
}
@article {pmid42117022,
year = {2026},
author = {Yousefi, M and Sheydaee, F and Khoshnoodifar, M},
title = {E-learning Challenges among Healthcare Students: A Scoping Review.},
journal = {Journal of advances in medical education &amp; professionalism},
volume = {14},
number = {2},
pages = {129-147},
pmid = {42117022},
issn = {2322-2220},
abstract = {INTRODUCTION: Despite the growing reliance on e-learning and the paradigm-shifting impact of the COVID-19 pandemic on educational systems, there is a lack of up-to-date evidence on the specific challenges that healthcare students confront in practical courses. Thus, this scoping review aims to address the challenges of E-learning among healthcare students post-pandemic and to provide possible solutions.<br><br>METHODS: This study was undertaken using the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist. A search of English-language materials and peer-reviewed articles was performed from January 2020 to November 18, 2023, across five databases: PubMed, Web of Science, Scopus, ERIC, and EMBASE. Quality appraisal was done using JBI checklists.<br><br>RESULTS: Of the 4,559 potential records, 95 articles were included in this study. Using thematic analysis, 12 themes were identified, including Rapid progression and obligatory shift, Physical and mental problems of learners, Low digital literacy, Technical problems, Financial burden, Challenges of designing a practical course, Omission of learners' feedback in Designing, Learning contents and adopted strategy challenges, Unpreparedness of users, Lack of engagement and distracting learning environment, Lack of users' security and support, and Summative evaluation challenges.<br><br>CONCLUSION: Although a vast majority of literature highlights the effectiveness of E-learning courses, weaknesses such as engagement, interaction, development of practical skills, and evaluation of challenges are mentioned in literature. Thus, the use of blended learning in the LMICs in conjunction with instructional models, like the ADDIE model, is strongly recommended throughout the entire learning process to forecast upcoming challenges and prevent them, thereby boosting the quality of an E-learning course.},
}
@article {pmid42117444,
year = {2026},
author = {Iannizzi, C and Chai, KL and Piechotta, V and Monsef, I and Wood, EM and Lamikanra, AA and Roberts, DJ and McQuilten, Z and So-Osman, C and Jindal, A and Estcourt, LJ and Skoetz, N and Kreuzberger, N},
title = {Convalescent plasma for people with COVID-19.},
journal = {The Cochrane database of systematic reviews},
volume = {5},
number = {5},
pages = {CD013600},
pmid = {42117444},
issn = {1469-493X},
support = {101015756/ERC_/European Research Council/International ; },
mesh = {Humans ; Randomized Controlled Trials as Topic ; COVID-19 Serotherapy ; *COVID-19/therapy/mortality ; Immunization, Passive/methods/adverse effects ; SARS-CoV-2 ; Quality of Life ; Betacoronavirus ; },
abstract = {RATIONALE: Convalescent plasma (CP) may reduce mortality in people with viral respiratory diseases, and is being investigated as a potential therapy for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding the benefits and risks of this intervention is required.<br><br>OBJECTIVES: To assess the effectiveness and safety of convalescent plasma transfusion in the treatment of people with COVID-19.<br><br>SEARCH METHODS: To identify completed and ongoing studies, we searched CENTRAL, MEDLINE, Embase, the Epistemonikos COVID-19 L*OVE Platform, and clinical trial registries to October 2024.<br><br>ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) evaluating convalescent plasma for people with COVID-19, irrespective of disease severity, age, gender, or ethnicity. We excluded studies investigating other coronavirus diseases or standard immunoglobulin.<br><br>OUTCOMES: We used the GRADE approach to rate the certainty of evidence for the following outcomes: all-cause mortality (up to day 28), worsening and improvement of clinical status (for individuals with moderate to severe disease), hospital admission or death, COVID-19 symptoms resolution (for individuals with mild disease), quality of life (QoL), grade 3/4 adverse events, and serious adverse events.<br><br>RISK OF BIAS: We used RoB 2 to assess bias in included studies.<br><br>SYNTHESIS METHODS: We followed standard Cochrane methodology.<br><br>INCLUDED STUDIES: We included 48 RCTs (24,518 participants), 15 of which were added in this update. We also identified 36 new ongoing studies and 33 completed studies awaiting classification.<br><br>SYNTHESIS OF RESULTS: Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Forty-two RCTs investigated the use of CP for 21,393 participants with moderate to severe disease. Of these, 36 RCTs (20,798 participants) compared CP to placebo or standard care, five (604 participants) to standard plasma, and one (190 participants) to human immunoglobulin. In the full review, we performed subgroup analyses by antibody detection, time since symptom onset, country income level, and key comorbidities. Convalescent plasma versus placebo or standard care alone CP does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.90 to 1.03; 31 RCTs, 20,798 participants; high-certainty evidence). It has little to no impact on the need for invasive mechanical ventilation, or death (RR 1.03, 95% CI 0.98 to 1.08; 8 RCTs, 15,189 participants; high-certainty evidence) and has no impact on whether participants are discharged from hospital (RR 1.00, 95% CI 0.97 to 1.02; 9 RCTs, 13,930 participants; high-certainty evidence). CP may have little to no impact on QoL (MD 1.00, 95% CI -2.14 to 4.14; 1 RCT, 483 participants; low-certainty evidence). CP may have little to no impact on the risk of grade 3/4 adverse events (RR 1.17, 95% CI 0.96 to 1.42; 6 RCTs, 2392 participants; low-certainty evidence). It probably has little to no effect on the risk of serious adverse events (RR 1.19, 95% CI 1.02 to 1.38; 11 studies, 5298 participants; moderate-certainty evidence). Convalescent plasma versus standard plasma The evidence is uncertain about whether CP reduces all-cause mortality at up to day 28 (RR 0.77, 95% CI 0.53 to 1.10; 5 RCTs, 604 participants; very low-certainty evidence) and whether it increases the need for invasive mechanical ventilation, or death (RR 5.59, 95% CI 0.29 to 108.38; 1 study, 34 participants; very low-certainty evidence). The evidence is uncertain about whether convalescent plasma reduces or increases the risk of grade 3/4 adverse events (1 RCT, 248 participants). The evidence is also uncertain about whether CP reduces the risk of serious adverse events (RR 0.82, 95% CI 0.57 to 1.17; 4 RCTs, 447 participants; very low-certainty evidence). No studies in this comparison reported clinical improvement or QoL. Individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease Six RCTs investigated the use of CP for 2761 participants with mild disease. Four RCTs (1164 participants) compared CP to placebo or standard care alone, and two (1597 participants) to standard plasma. Convalescent plasma versus placebo or standard care alone The evidence is uncertain about whether CP reduces all-cause mortality at up to day 28 (odds ratio (OR) 1.24, 95% CI 0.33 to 4.60; 3 RCTs, 1004 participants; very low-certainty evidence) and admission to hospital or death within 28 days (RR 0.45, 95% CI 0.04 to 4.81; 2 RCTs, 493 participants; very low-certainty evidence). It may have little to no impact on time to COVID-19 symptom resolution (hazard ratio (HR) 1.05, 95% CI 0.85 to 1.30; 1 RCT, 376 participants) and on the risk of grade 3/4 adverse events (RR 1.29, 95% CI 0.75 to 2.19; 1 RCT, 376 participants), both with low-certainty evidence. The evidence is uncertain about whether CP has an impact on the risk of serious adverse events (RR 0.84, 95% CI 0.56 to 1.26; 2 RCTs, 494 participants; very low-certainty evidence). No studies in this comparison reported other critical outcomes. Convalescent plasma versus standard plasma The evidence is uncertain about whether CP reduces all-cause mortality at up to day 28 (RR 0.41, 95% CI 0.05 to 3.06; 2 RCTs, 1597 participants; very low-certainty evidence). It probably reduces admission to hospital or death within 28 days (RR 0.50, 95% CI 0.32 to 0.78; 2 RCTs, 1597 participants; moderate-certainty evidence). CP may have little to no effect on initial symptom resolution at up to day 28 (RR 1.12, 95% CI 0.82 to 1.54; 1 RCT, 416 participants; low-certainty evidence). Neither study in this comparison reported other critical outcomes.<br><br>AUTHORS' CONCLUSIONS: Compared with placebo or standard care, high-certainty evidence shows that CP does not reduce mortality in individuals with moderate to severe disease and has little to no effect on clinical improvement or worsening. CP probably has little to no effect on serious adverse events. Publication of ongoing studies might resolve some of the uncertainties around CP therapy for people with asymptomatic or mild disease. This review was previously a living systematic review, from the first version published in 2020 until our last search in October 2024. The research question is no longer a priority for decision-making, new studies are less frequently published, and research that might impact the conclusions of the review is no longer emerging.<br><br>FUNDING: The European Commission, Belgium SUPorting high quality evaluation of COVID-19 convalescent plasma thrOughouT Europe (SUPPORT-E, grant number 101015756) supported this review.<br><br>REGISTRATION: Protocol registered with the Center for Open Science on 17 April 2020 (DOI: 10.17605/OSF.IO/DWF53). Access the 2023 version of this review here: DOI: 10.1002/14651858.CD013600.pub6.},
}
@article {pmid42117901,
year = {2026},
author = {Scaglione, F and Ciprandi, G},
title = {Corticosteroids or NSAIDs in Managing Acute Respiratory Infections: Valuable Differences.},
journal = {Journal of immunology research},
volume = {2026},
number = {1},
pages = {e9991040},
pmid = {42117901},
issn = {2314-7156},
mesh = {Humans ; *Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; *Adrenal Cortex Hormones/therapeutic use ; *Respiratory Tract Infections/drug therapy ; Oxidative Stress/drug effects ; COVID-19 ; SARS-CoV-2 ; Pandemics ; COVID-19 Drug Treatment ; Acute Disease ; },
abstract = {Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for respiratory infections. These drugs work by blocking two enzymes, COX-1 and COX-2, which regulate the production of prostaglandins, mediators involved in pain, fever, and inflammation. Corticosteroids (CSs) are commonly used in outpatient settings for anti-inflammatory purposes in the treatment of infectious diseases. However, their potential side effects, such as immunosuppression and increased metabolism, can be overlooked, even at low doses. Their use is clearly defined for severe conditions. Other infections, such as community-acquired pneumonia, pharyngotonsillitis, or otitis, do not have supportive data for the use of systemic CSs. For COVID-19, CSs are beneficial for severe cases that require ventilation, while they may not be helpful in mild cases. Infection-induced inflammation is associated with oxidative stress, a condition that arises from an imbalance between reactive oxygen species (ROS) and inadequate antioxidant responses. This stress worsens inflammatory reactions and can lead to severe respiratory infections and tissue damage. Managing oxidative stress is crucial in treating respiratory infections, and both CSs and NSAIDs can help reduce it. NSAIDs are preferred for treating symptoms such as fever and pain during the early phases of infections, especially viral ones, without hindering the immune response. CSs are powerful anti-inflammatory medications that are useful for treating infections in patients with asthma or allergies. However, CSs are not recommended for relieving pain and fever and can weaken the immune response. Both NSAIDs and steroids can mask serious infections, so doctors must be cautious in their use.},
}
@article {pmid42118190,
year = {2026},
author = {Ebell, M and Kurotschka, P},
title = {Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis.},
journal = {Journal of general internal medicine},
volume = {},
number = {},
pages = {},
pmid = {42118190},
issn = {1525-1497},
abstract = {BACKGROUND: Since the benefit of nirmatrelvir-ritonavir (N-R) may have changed in contemporary patients, we assessed the effectiveness of N-R for preventing hospitalization and death among outpatients with COVID-19 in the Omicron era.<br><br>METHODS: This was a meta-analysis of cohort studies comparing rates of hospitalization and/or mortality in outpatients treated with N-R compared with untreated patients. Analysis was limited to studies conducted since December 2021 that performed an adjusted multivariate analysis. Quality was assessed using the Newcastle-Ottawa Scale. Summary estimates of adjusted relative risks (aRR) with 95% confidence intervals (CI) and prediction intervals (PI) were calculated overall and for prespecified subgroups. Heterogeneity was summarized visually and with &#x3c4; and 95% PIs. Absolute effects were estimated by applying pooled aRRs to baseline risks to obtain absolute risk reductions (ARRs) and numbers needed to treat (NNTs).<br><br>RESULTS: Forty-seven studies (10,791,211 patients) were included. Pooled aRRs were 0.54 (95% CI, 0.43-0.68) for all-cause hospitalization and 0.45 (0.36-0.56) for COVID-19 hospitalization. Pooled RRs were 0.30 (0.23-0.39) for all-cause mortality and 0.43 (0.32-0.59) for COVID-19 mortality. PIs were&#x2009;<&#x2009;1.0 for COVID-19 hospitalization (0.21-0.96), all-cause mortality (0.11-0.83), and any mortality (0.13-0.88), indicating likely benefit in future studies in similar settings. Subgroup analyses showed larger effects earlier in the Omicron period for hospitalization (RR 0.46 vs 0.68; p&#x2009;=&#x2009;0.0049) and the composite outcome (0.45 vs 0.68; p&#x2009;=&#x2009;0.0078), and a smaller mortality reduction among immunocompromised patients (RR 0.26 vs 0.11; p&#x2009;=&#x2009;0.034). The estimated NNT to prevent a COVID-19 hospitalization for patients at low risk (0.16%), moderate risk (2.2%), and high risk (8.9%) of hospitalization based on a validated risk score were 1148, 84, and 20 respectively.<br><br>DISCUSSION: N-R is associated with reduced hospitalization and death. Absolute risk reductions of hospitalization are small in low-risk patients but clinically meaningful in moderate- and high-risk patients.},
}
@article {pmid42119693,
year = {2026},
author = {Schomerus, G and Nicolas, ML and Fritz, F and Schneider, D and Büchner, R},
title = {What is the Role of "the Psyche"? Long COVID and ME/CFS as Test Cases for Evidence-Based and Patient-Centered Psychiatry and Psychotherapy.},
journal = {Psychiatrische Praxis},
volume = {53},
number = {5},
pages = {263-269},
pmid = {42119693},
issn = {1439-0876},
mesh = {Humans ; *Fatigue Syndrome, Chronic/psychology/therapy ; *Psychotherapy ; Post-Acute COVID-19 Syndrome ; *Evidence-Based Medicine ; *Patient-Centered Care ; *COVID-19/psychology ; Psychiatry ; },
abstract = {The role of psychological factors in the development and course of Long Covid (LC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) remains a subject of controversial debate. We argue that psychologizing LC and ME/CFS carries significant risks: it leads to potentially harmful therapies, invalidates the patients' experience of illness, hinders effective interventions such as pacing, diverts focus from necessary physical diagnostics and treatment, disadvantages patients in medical assessments, and places a considerable additional burden on the families of affected children or other relatives. We show that many of the arguments presented for a psychological contribution are nonspecific or insufficiently supported by empirical evidence. Our essay therefore advocates for extreme caution in attributing psychological factors to these conditions, in the interest of a specific, evidence-based, and patient-centered psychiatry and psychotherapy.},
}
@article {pmid42120165,
year = {2026},
author = {Lot, L and DePietro, R and Tosh, AK},
title = {Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.},
journal = {Primary care},
volume = {53},
number = {2},
pages = {295-310},
doi = {10.1016/j.pop.2026.01.011},
pmid = {42120165},
issn = {1558-299X},
mesh = {Humans ; *Feeding and Eating Disorders/diagnosis/therapy/epidemiology ; Adolescent ; Young Adult ; COVID-19/epidemiology ; Anorexia Nervosa/diagnosis/therapy ; Mass Screening ; United States/epidemiology ; },
abstract = {Eating disorders (EDs) are characterized by persistent disturbance of eating behavior that impairs health or psychosocial functioning. ED can persist for decades resulting in substantial burdens and psychosocial impairments. An increased prevalence of anorexia nervosa was noted during the COVID-19 pandemic. Despite a worsening trend in risky eating behavior among US college students, only 22% of colleges report offering year-round ED screening opportunities with 45% offering ED screenings once per year or semester. Furthermore, 20% or less of those who screened positive, received treatment.},
}
@article {pmid42121619,
year = {2026},
author = {Kész, A and Balatoni, I},
title = {Globalization in the Healthcare Industry: Drivers, Risks, and Adaptation.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {9},
pages = {},
pmid = {42121619},
issn = {2227-9032},
abstract = {Globalization refers to the increasing density of economic, social, and technological interconnections on a global scale. In the healthcare industry, it simultaneously accelerates innovation and increases systemic vulnerabilities. This study aims to review and conceptually synthesise the main channels of impact: (1) pharmaceuticals, clinical development, and regulation; (2) supply chains and resilience; (3) service mobility (health tourism); (4) human resources and competencies; (5) digitalization, artificial intelligence (AI), and data governance; (6) ethics, law, and public policy; and (7) sustainability and climate change. The COVID-19 pandemic highlighted the risks associated with global interdependencies, particularly in supply chains, while also demonstrating the innovation-accelerating effects of knowledge sharing and international cooperation. Particular attention is given to artificial intelligence and digital health, which open up new potential for efficiency and quality improvement from research and development through diagnostics to healthcare organization, while simultaneously intensifying concerns related to data protection, cyber security, and liability. Telemedicine, platform-based systems, and real-world data may contribute to addressing the care needs of ageing societies, but only when supported by appropriate competencies and sound data governance. As global data flows intensify, the importance of data protection, bias mitigation, transparency, and accountability correspondingly increases. Through the cultural channels of globalization, health-conscious lifestyles and complementary approaches are also spreading, which we address in a brief, separate subsection. The guidelines of international organizations foster standardization; however, due to differences in local capacities and institutional environments, the effects are not homogeneous. In conclusion, the study emphasises the dual nature of globalization; it expands access and accelerates innovation, while at the same time creating new vulnerabilities-in supply chains, labour mobility, and data security-and, together with climate-related risks, generating complex adaptive pressures for the healthcare industry.},
}
@article {pmid42121847,
year = {2026},
author = {Vezzoli, M and Dieci, G and Ferrari, R},
title = {The Viral Immunoshadow: Early Adenovirus Strategies for Cloaking Innate Immunity with E1A, E4orf1, and Beyond.},
journal = {Cells},
volume = {15},
number = {9},
pages = {},
pmid = {42121847},
issn = {2073-4409},
support = {IG2022-27712//Italian Association for Cancer Research (AIRC)/ ; },
mesh = {Humans ; *Immunity, Innate/immunology ; *Adenoviruses, Human/immunology/pathogenicity ; *Adenovirus E1A Proteins/immunology/metabolism ; *Adenovirus E4 Proteins/immunology/metabolism ; Animals ; Virus Replication ; },
abstract = {Human adenovirus (HAdV), a double-stranded DNA virus, targets terminally differentiated cells in the upper respiratory tract. As a key platform for gene therapy vectors, elucidating HAdV's virulence factors is vital for optimizing therapeutic applications and mitigating risks. To achieve productive replication, HAdV strategically neutralizes host immune defenses and induces S-phase pathways essential for viral propagation. This review synthesizes the latest insights into the key pathways through which HAdVs harness these early proteins to enhance virulence, skilfully evading and counteracting host defense mechanisms while propelling viral replication. As foundational platforms for gene therapy vectors (e.g., in oncology and rare disease treatments) and vaccine backbones (e.g., COVID-19 vaccines like ChAdOx1), understanding HAdV's immunoshadowing-the multifaceted strategies used to cloak innate and adaptive immunity-is crucial for enhancing vector safety and efficacy. Recent insights unveil how early viral proteins-including E1A, E1B-55K, E4orf1, E4orf3, E4orf6, and the E3 complex-participate in these processes. This review critically synthesizes these pathways, evaluating study limitations such as reliance on immortalized cell lines that underestimate the role of these proteins in immunological competent cells, and addresses unresolved controversies, including differential immunoshadowing efficacy across HAdV species that impacts vaccine design.},
}
@article {pmid42121889,
year = {2026},
author = {Kopańska, M and Trojniak, J and Góral-Półrola, J and Pąchalska, M},
title = {Alterations in Cortical Oscillatory Dynamics Following SARS-CoV-2 Infection: QEEG Biomarkers of Vulnerability to Attention and Seizure-Related Symptoms.},
journal = {Cells},
volume = {15},
number = {9},
pages = {},
pmid = {42121889},
issn = {2073-4409},
mesh = {Humans ; *COVID-19/physiopathology/complications ; *Electroencephalography/methods ; *Attention/physiology ; Biomarkers/metabolism ; *Seizures/physiopathology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; *Cerebral Cortex/physiopathology ; },
abstract = {SARS-CoV-2 infection is associated with not only acute respiratory symptoms but is also characterized by strong neurotropism which may contribute to the development of the multisystem post-COVID syndrome (PASC). Patients frequently report chronic neurocognitive disorders such as brain fog, significant attention deficits and increased susceptibility to epileptiform discharges. The aim of this review is to systematize the knowledge regarding deviations in quantitative electroencephalography (QEEG) recordings in convalescents and to evaluate the utility of this method as an objective biomarker. This work constitutes a comprehensive literature review integrating the latest data on neuroinflammation, blood-brain barrier damage and changes in cortical oscillatory dynamics induced by the infection. The literature analysis indicates that the virus may induce a pathological excitation and inhibition imbalance (E/I imbalance) in neuronal networks. In QEEG studies this manifests as excessive activity of slow bands (Theta, Delta), a deficit of rhythms responsible for attention and sensorimotor integration (SMR) and a pathologically elevated Theta to Beta ratio (TBR). In conclusion, QEEG can serve as an objective and highly sensitive tool supporting the diagnosis and stratification of patients with neurocognitive complications of Long COVID. The integration of precise electrophysiological phenotyping with targeted behavioral neuromodulation (e.g., EEG-Biofeedback) fits into the paradigm of personalized medicine and offers a prospective strategy for mitigating long-term neurological burdens.},
}
@article {pmid42122974,
year = {2026},
author = {Baiasu, AF and Rotaru-Zavaleanu, AD and Boldea, AM and Ruscu, MA and Serbanescu, MS and Radu, L},
title = {Bridging Traditional Modeling and Artificial Intelligence in Measles Epidemiology: Methods, Applications, and Future Directions-A Narrative Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {9},
pages = {},
pmid = {42122974},
issn = {2077-0383},
abstract = {Measles remains one of the most contagious infectious diseases globally and continues to pose substantial public health risks despite decades of effective vaccination. This narrative review examines both classical and contemporary computational approaches used for measles monitoring, prediction, and control, with particular attention given to the emerging role of artificial intelligence (AI). We synthesized findings from 46 studies; 31 focused directly on measles and 15 on methodologically relevant studies from related infectious diseases (COVID-19, influenza, malaria), selected through searches of PubMed, Scopus, Web of Science, IEEE Xplore, and preprint servers, conducted between June and December 2025. Traditional compartmental models (SIR, SEIR, MSEIR), statistical tools (ARIMA, SARIMA), and seroepidemiological analysis provide transparent, well-characterized frameworks for estimating transmission dynamics and simulating intervention scenarios. Spatial modeling, network analysis, and Monte Carlo simulations have added geographic granularity to outbreak characterization. More recently, AI and machine learning (ML) methods, including supervised algorithms (Random Forest, XGBoost, SVM), deep learning architectures (CNN, LSTM), and hybrid mechanistic ML models, have shown improved predictive performance by integrating multiple data sources: epidemiological records, demographic profiles, mobility patterns, and behavioral indicators. AI-based approaches appear most valuable for high-dimensional risk prediction and image-based diagnostic tasks, while classical models retain clear advantages for policy-oriented scenario analysis. However, no AI-based or hybrid model identified in this review has been adopted into routine national measles surveillance or used for vaccination policy decisions at scale. Important challenges remain: data quality varies across settings, model generalizability cannot be assumed, and computational infrastructure disparities limit deployment in high-burden regions. Explainable AI, federated learning, workforce training for model interpretation, and integration of vaccination registries with mobility and genomic surveillance data represent concrete future directions for strengthening computational support for measles elimination.},
}
@article {pmid42123618,
year = {2026},
author = {Wirth, KJ and Scheibenbogen, C},
title = {Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {International journal of molecular sciences},
volume = {27},
number = {9},
pages = {},
pmid = {42123618},
issn = {1422-0067},
mesh = {Humans ; *Fatigue Syndrome, Chronic/metabolism/physiopathology/pathology ; *Neurotransmitter Agents/metabolism ; Post-Acute COVID-19 Syndrome ; Animals ; SARS-CoV-2 ; },
abstract = {Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and post-COVID-19 syndrome share a symptom profile, including severe fatigue, cognitive dysfunction, exertional intolerance, sleep disturbances, hypervigilance, and the paradoxical state of being "wired but tired." A well-established finding is sympathetic hyperactivity with reduced vagal tone, typically interpreted as autonomic nervous system dysfunction. Emerging evidence, however, suggests a broader disturbance across multiple neurotransmitter systems. This paper reviews current knowledge on neurotransmitter systems implicated in ME/CFS and Long COVID, focusing on potential mechanisms of dysregulation and their roles in disease pathology and symptom generation, as well as implications for treatment. In addition to abnormalities of the noradrenergic system, disturbances in serotonergic, GABAergic, and glutamatergic signaling have been reported. Contributing factors may include autoimmunity, neuroinflammation, gut dysbiosis, epigenetic influences, and stressors such as orthostatic intolerance, metabolic strain, and pain. A shift favoring excitatory over inhibitory neurotransmission can lead to excessive neural activation, autonomic dysfunction, sensory hypersensitivities, sleep disturbances, and cognitive impairment. Reduced GABAergic tone combined with increased glutamatergic and noradrenergic activity may elevate skeletal muscle tone, contributing to calcium overload, mitochondrial dysfunction, exertional intolerance, and post-exertional malaise. Various pharmacological treatments may partially rebalance these neurotransmitter systems, but limited efficacy highlights the need for systematic investigation and individualized strategies.},
}
@article {pmid42126095,
year = {2025},
author = {Pourshaban, M and Allahbakhshian, A and Purabdollah, M},
title = {Mapping the Contributing Factors to Missed Nursing Care in Hospital Settings During a Global Health Crisis: A Systematic Scoping Review.},
journal = {Journal of nursing management},
volume = {2025},
number = {1},
pages = {e7343469},
doi = {10.1155/jonm/7343469},
pmid = {42126095},
issn = {1365-2834},
support = {75775//Student Research Committee, Tabriz University of Medical Sciences/ ; },
mesh = {Humans ; *COVID-19/nursing/epidemiology ; *Nursing Care/standards ; Global Health ; },
abstract = {BACKGROUND: Little foreknowledge and preparation exist for health-related crises, and they do not match the magnitude of the problem. During the COVID-19 pandemic, nursing care in some countries faced more challenges. One of these challenges was missed nursing care. This scoping review aims to identify and map the factors influencing missed nursing care in hospital settings during the COVID-19 pandemic in studies conducted in developed and developing countries.<br><br>METHODS: A scoping review was conducted according to methodology recommended by the Joanna Briggs Institute (JBI). We searched five databases-PubMed, Scopus, CINAHL, ProQuest, and Web of Science-as well as the Google Scholar search engine, from December 2019 to July 2025. Keywords of the study were selected according to the Medical Subject Headings (MeSH) and previous research. We included studies in hospital wards that examined missed nursing care and related concepts, specifically those whose data collection periods occurred during the COVID-19 pandemic. Language restrictions were not applied. The factors were derived inductively, considering conceptual similarities, relevance to the core themes, and similarities in meaning, including aspects related to the missed nursing care model, the developed model derived from it related to the factors considered for missed nursing care, and emerging challenges introduced by COVID-19. Findings were reported following the PRISMA-ScR.<br><br>FINDINGS: From the 1966 studies, we included 57 articles in the final review. Among them, 50 were cross-sectional, four were qualitative, two were mixed, and one was quasiexperimental. They were conducted mainly in Iran and the hospital units. Four main themes and nine subthemes emerged (1) work environment (structure, work climate), (2) nurse characteristics (individual and professional, personal), (3) workflow characteristics (intensity, predictability, risk), (4) country (developed, developing). Although the lack of human resources was reported in most studies, it was not the most significant contributing factor.<br><br>CONCLUSION: These findings can inform the development of strategies to address underlying factors affecting workflow, such as nurses' attitudes and the work environment, thereby enhancing adaptability to future global health crises and serving as a crucial policy foundation for mitigating the missed nursing care during health emergencies.<br><br>PRACTICAL IMPLICATIONS: These findings not only complement other global research exploring the reasons behind missed cares in nursing but also offer a framework for understanding and anticipating reported instances of missed care, enabling targeted interventions to address them effectively.},
}
@article {pmid42126431,
year = {2026},
author = {Brosnan, C and Rossi, A and van der Hoorn, A and Due-Tønnessen, P and Looby, S and , },
title = {Choosing wisely in neuroradiology: evaluating CT and MR utilization trends in Europe.},
journal = {European radiology},
volume = {36},
number = {8},
pages = {6589-6598},
pmid = {42126431},
issn = {1432-1084},
mesh = {Europe ; *Tomography, X-Ray Computed/statistics &amp; numerical data/trends ; *Magnetic Resonance Imaging/statistics &amp; numerical data/trends ; Humans ; *Neuroimaging/trends/statistics &amp; numerical data ; },
abstract = {OBJECTIVES: To assess trends in volume and utilization of neuroimaging (CT and MR) across Europe over the last decade, within the context of evolving clinical practice on behalf of the European Society of Neuroradiology's Choosing Wisely committee.<br><br>MATERIALS AND METHODS: A systematic search of PubMed was performed (following PRISMA 2020 guidelines) to identify studies reporting European neuroimaging volumes. As no eligible studies were identified, descriptive analysis of Eurostat and OECD data was performed for 29 European countries from 2015 to 2022, covering CT and MR examination volumes and scanner availability per 100,000 population across four geographic regions (Northern, Southern, Eastern, and Western Europe). Total CT/MR volumes served as neuroimaging surrogates.<br><br>RESULTS: 316 publications were identified (with none meeting predefined inclusion criteria). Eurostat data from 29 countries revealed substantial growth in imaging from 2015 to 2022. Per capita CT exam rates increased 40.8% (10,872 to 15,312 per 100,000 population), and MR scan rates increased 43.5% (5746 to 8244 per 100,000 population). Scanner availability also increased (CT scanners from 2.3 to 2.68, MR scanners from 1.43 to 2.11 per 100,000 population). Regional variations were evident: Western Europe showed the highest utilization rates, Eastern Europe demonstrated the largest relative growth despite lower absolute numbers. All regions experienced consistent growth except during the 2020 COVID-19 disruptions.<br><br>CONCLUSION: Neuroimaging utilization has substantially increased across Europe from 2015 to 2022, with disproportionate growth in scan volumes relative to scanner availability. These findings highlight regional disparities in utilization and underscore the need for coordinated evidence-based appropriateness initiatives to support sustainable neuroimaging practice.<br><br>KEY POINTS: Question Have CT and MR neuroimaging utilization rates changed across Europe over the last decade compared to scanner availability? Findings CT and MR scan rates increased 40.8% and 43.5%, respectively, from 2015 to 2022, reflecting increased per-scanner utilization across the continent. Clinical relevance Neuroimaging examination volumes increased substantially across Europe from 2015 to 2022. This highlights the value of evidence-based imaging appropriateness initiatives to ensure sustainable healthcare resource utilization.},
}
@article {pmid42127260,
year = {2026},
author = {Antar, AAR},
title = {CROI 2026: Acute and Postacute COVID-19.},
journal = {Topics in antiviral medicine},
volume = {34},
number = {2},
pages = {494-500},
pmid = {42127260},
issn = {2161-5853},
mesh = {Humans ; *COVID-19/immunology/complications/therapy ; Post-Acute COVID-19 Syndrome ; *SARS-CoV-2/immunology ; *COVID-19 Drug Treatment ; Acute Disease ; },
abstract = {The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) furthered our understanding of acute COVID-19, long COVID, postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viral immunity, and SARS-CoV-2 therapeutics. Results of a first-in-human validation study of DNA-encoded monoclonal antibody (DMAb) technology demonstrated safety and robust and durable monoclonal antibody (mAb) production, giving the green light to further develop the DMAb platform. Pemivibart administration to people with advanced HIV was well tolerated and associated with good levels of neutralizing antibodies. A new pan-coronavirus 3C-like protease inhibitor was shown to have similar pharmacokinetics and a similar safety profile in people with renal impairment and people with hepatic impairment. A study of SARS-CoV-2 infections in 2023 demonstrated continued risk for new incident diagnoses and worsening of prior comorbidities in the year after infection. SARS-CoV-2 infection in people with HIV is associated with discernible decline in estimated glomerular filtration rate in the 2 years after infection. A blinded study of circulating SARS-CoV-2 antigen found no association between the presence of antigen and the likelihood of having long COVID. Most people with long COVID in a cohort study have experienced stigma or feeling dismissed in interactions with their clinicians.},
}
@article {pmid42127571,
year = {2026},
author = {Obilor, HN and Oluwole, O and Ross-White, A and Premji, SS and , and , },
title = {Mental health and mental health care of South and East Asian immigrant pregnant women residing in five OECD Countries: A systematic review.},
journal = {Midwifery},
volume = {159},
number = {},
pages = {104818},
doi = {10.1016/j.midw.2026.104818},
pmid = {42127571},
issn = {1532-3099},
mesh = {Female ; Humans ; Pregnancy ; Asia, Southern/ethnology ; Australia/epidemiology ; Canada/epidemiology ; East Asian People ; *Emigrants and Immigrants/psychology/statistics &amp; numerical data ; *Mental Health/ethnology ; *Mental Health Services/statistics &amp; numerical data/standards ; New Zealand/epidemiology ; Organisation for Economic Co-Operation and Development/organization &amp; administration ; *Pregnant People/psychology/ethnology ; South Asian People ; United Kingdom/epidemiology ; United States/epidemiology ; Asia, Eastern/ethnology ; },
abstract = {BACKGROUND: South and East Asian immigrant pregnant women across Organisation for Economic Co-Operation and Development (OECD) countries face barriers to accessing perinatal mental health care. This review examined the prevalence of common mental health conditions and experiences with perinatal mental health services among South and East Asian immigrant pregnant women in five OECD countries (Canada, the United Kingdom, the United States, Australia, and New Zealand).<br><br>METHODS: A systematic review was conducted using a comprehensive search strategy developed by an expert librarian for five databases (CINAHL, MEDLINE, EMBASE, PsycINFO, and MIDIRS) from inception to February 2026. Quantitative, qualitative, and mixed-methods studies and published abstracts were considered.<br><br>RESULTS: The review comprised six studies (five quantitative and one qualitative) conducted in Canada, the United Kingdom and the United States. The point prevalence of depression and state anxiety among participants was 16.3% and 19.7%, respectively, based on studies published mostly between 2012 and 2016. The qualitative study suggested that the utilization of mental health services was poor due to a lack of understanding of mental health issues, stigma, language barriers, cultural taboos, and distrust of mental health professionals.<br><br>CONCLUSIONS: The review highlights the magnitude of antenatal depression and anxiety among South and East Asian immigrants, mainly before the COVID-19 pandemic. More research is required to understand the current demand for perinatal mental health services among immigrant South and East Asian pregnant women. Evaluating how effectively each OECD country is prioritizing the mental health needs of this population post-COVID-19 will inform practice and policy reform.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD42023440054 PROSPERO Identifier: CRD42023440054.},
}
@article {pmid42128596,
year = {2026},
author = {De Sousa-De Sousa, L and Espinosa, HG and Maté-Muñoz, JL and Ramón Heredia-Elvar, J and Martín, L and Solís-Mencía, C and García-Fernández, P},
title = {A decade of concussion in rugby: a 2014-2024 systematic review and meta-analysis update.},
journal = {British journal of sports medicine},
volume = {60},
number = {11},
pages = {811-826},
doi = {10.1136/bjsports-2025-110774},
pmid = {42128596},
issn = {1473-0480},
mesh = {Humans ; *Brain Concussion/epidemiology/diagnosis ; *Football/injuries ; Incidence ; *Athletic Injuries/epidemiology/diagnosis ; Male ; Female ; },
abstract = {OBJECTIVE: To quantify the incidence of concussions identified through clinical assessments or diagnostic protocols in rugby union (RU) (sevens and XVs) and rugby league (RL) over the past decade and analyse differences by sex, playing level, match versus training exposure and concussion assessment protocols (Head Injury Assessment (HIA) vs non-HIA).<br><br>DESIGN: Systematic review and meta-analysis.<br><br>DATA SOURCES: PubMed, Web of Science, Scopus, Embase, SPORTDiscus, PsycINFO and CINAHL were searched in February 2025 for studies published between 2014 and 2025.<br><br>Studies were eligible if they reported concussions identified through clinical assessment or diagnostic protocols in rugby with extractable exposure data (match-player-hours and/or training-player-hours) and incidence rates per 1000 player-hours.<br><br>RESULTS: 98 studies, comprising 10&#x2009;591 concussions across 3&#x2009;275&#x2009;130 player-hours, met the inclusion criteria. Studies included data from 2003 to 2023. The pooled overall concussion incidence was 9.74 per 1000 player-hours (95%&#x2009;CI 8.54 to 10.95) in RU and 9.20 (95% CI 7.38 to 11.02) in RL, with no significant difference between codes (p=0.891). When analysed by subgroups, no statistically significant overall sex-based differences in concussion incidence were observed in either RU or RL; however, post hoc analyses identified higher concussion incidence among female youth players (<18 years) compared with males. Match play showed a markedly higher incidence than training (RU: 10.98 per 1000 match-player-hours vs 0.34 per 1000 training-player-hours; RL: 10.45 per 1000 match-player-hours vs 0.32 per 1000 training-player-hours; p<0.001). Studies using HIA protocols reported nearly double the incidence compared with non-HIA protocols (RU: 15.35 vs 7.72; rate ratio=1.83; p<0.001). Concussion trends reflected external factors, including COVID-19 disruptions and policy changes.<br><br>CONCLUSION: Concussion incidence in rugby appears to be strongly influenced by match intensity and assessment protocol. Structured diagnostic approaches, such as the HIA protocol, are associated with higher reported concussion incidence, likely reflecting improved detection.<br><br>PROSPERO REGISTRATION: CRD42023480774.},
}
@article {pmid42128720,
year = {2026},
author = {Cantor-Cutiva, LC and Ramirez Ardila, MDP and Hunter, EJ},
title = {Gaps and Future Directions in the Research About Masking and Voice Production: Bibliometric Analysis, Systematic Literature Review, and Meta-analysis.},
journal = {Journal of voice : official journal of the Voice Foundation},
volume = {},
number = {},
pages = {},
pmid = {42128720},
issn = {1873-4588},
support = {R01 DC012315/DC/NIDCD NIH HHS/United States ; },
abstract = {BACKGROUND: While facemasks have played a vital role in mitigating the spread of infectious diseases, their prolonged use has raised questions about their potential effects on voice production and communication.<br><br>METHODS: The present study integrated three complementary methodological approaches with three specific aims. First, to identify trends in research on facemasks and voice production, including thematic clusters and patterns, using bibliometric methods. Second, critically appraise and synthesize findings from primary research studies on the effects of facemask use on voice-related outcomes through a systematic literature review. Third, to determine the pooled effects of facemask use on selected vocal outcomes, where data allow, using meta-analysis.<br><br>RESULTS: In total, 48 publications were included in this review. The term co-occurrence network map generated with VOSviewer showed three clusters: voice-related consequences of mask use during the COVID-19 pandemic,&#xa0;the impact of protective equipment on speech acoustics and intelligibility,&#xa0;and acoustic markers of voice quality in healthy speakers. The overlay visualization map showed that earlier studies emphasized the subjective assessment of the relationship between facemasks and voice production. In contrast, more recent publications reflect a growing interest in the instrumental assessment of the relationship. Most studies based their results on voice acoustic analysis, followed by questionnaires and aerodynamic assessment. The results suggested no significant differences in fundamental frequency, jitter, shimmer, harmonics-to-noise ratio, and maximum phonation time. The results on vocal effort and sound pressure levels are inconsistent. The meta-analysis suggested that facemasks cause a small increase in SPL, but the effect was not statistically significant.<br><br>CONCLUSION: Facemasks create complex communication challenges that extend beyond acoustic changes to encompass multimodal perception disruption and disproportionate impacts on vulnerable populations. While acoustic measurements show minimal direct effects, the elimination of visual speech cues and facial expression recognition may create substantial barriers for individuals with hearing impairments, developmental disabilities, and age-related communication difficulties.},
}
@article {pmid42129070,
year = {2026},
author = {Veenstra, TD},
title = {Basic Virology.},
journal = {Advances in experimental medicine and biology},
volume = {1511},
number = {},
pages = {29-49},
pmid = {42129070},
issn = {0065-2598},
mesh = {Humans ; *SARS-CoV-2/genetics/physiology ; *Virology/methods ; *Proteomics/methods ; *COVID-19/virology/epidemiology ; Genome, Viral ; Viral Proteins/metabolism/genetics ; Animals ; },
abstract = {Current generations are living through a historical event in virology: the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. If you asked people when the last major pandemic was, many would probably say the Spanish flu of 1918-1920. Pandemics happen more frequently than most people think (Sampath et al., Cureus 13:e18136-18144, 2021). There have been at least five recorded pandemics between the Spanish flu and the recent SARS-CoV-2 pandemic. While the SARS-CoV-2 pandemic has brought with it indescribable sorrow and pain, it has also increased people's awareness of the impact viruses can have on life on Earth. Terms such as hygiene, modes of infection, community spread, quarantine, vaccines, etc. have become part of our daily conversations. As this book's first chapter provided a basic review of proteomic technologies for virologists, this chapter provides a basic review of virology for proteomic scientists. While virologist may find this chapter unsatisfying, hopefully proteomic scientists will learn enough to be able to understand how proteomic technology can be used to further detail the structure, function, and life cycle of viruses. This chapter will provide both generic and specific examples of viral structures, how they infect cells, and their effects on both the infected cell and the entire organism.},
}
@article {pmid42129072,
year = {2026},
author = {Veenstra, TD},
title = {Viral Prognosis Using Proteomics.},
journal = {Advances in experimental medicine and biology},
volume = {1511},
number = {},
pages = {75-102},
pmid = {42129072},
issn = {0065-2598},
mesh = {Humans ; *Proteomics/methods ; *COVID-19/diagnosis/virology/metabolism ; *SARS-CoV-2/genetics/metabolism/pathogenicity ; Prognosis ; },
abstract = {So much was learned during the COVID-19 pandemic of 2020-2023. Some of the things that were learned were obvious. Many people in the public learned about social distancing, personal hygiene, and how to conduct a COVID-19 diagnostic test. Pharmaceutical companies and government organizations learned to efficiently work together to produce and distribute vaccines in record time. Although it may have generated controversy, the value in getting vaccinated was revalidated. There were other things that the world learned, although it was not as obvious. The effect of vaccination rate on preventing virus mutation became evident during the pandemic. The original SARS-CoV-2 virus that started the pandemic mutated several times over the course of the pandemic. One thing that became clear during the pandemic was the lack of knowledge on how SARS-CoV-2 infection would affect individuals during the course of the disease. This inability to accurately prognose the disease made it difficult to personalize treatments for specific individuals and the distribution of resources to protect the most vulnerable populations challenging. What is required to increase the accuracy of prognosis is more knowledge about how dynamic changes occur within the host cell during viral infection. Since many proteins become dysregulated during infection, proteomics is a prime technology for gaining this knowledge to increase prognostic capabilities and enable personalized treatments that alleviate the suffering viruses cause on humanity.},
}
@article {pmid42129074,
year = {2026},
author = {Veenstra, TD},
title = {The Pathology of Viral Infections.},
journal = {Advances in experimental medicine and biology},
volume = {1511},
number = {},
pages = {127-158},
pmid = {42129074},
issn = {0065-2598},
mesh = {Humans ; *Virus Diseases/pathology/virology ; Viruses/pathogenicity ; Microbiota ; Animals ; Host-Pathogen Interactions/physiology ; },
abstract = {If you were to ask, "Biologically speaking, what are humans made of?", almost everyone would reply "Human cells and molecules, of course." This seemingly logical answer, however, does not truly capture the diversity of the human organism. Over the past couple of decades scientists have discovered that humans are a collective of cohabitating human, bacteria, and fungi cells along with countless numbers of viruses. Collectively, these microorganisms are referred to as the microbiome (Lederberg and McCray, The Scientist 15:8, 2001). The most recent estimates suggest the biological material from these microorganisms makes up as much as half of every human. Considering the size of the microbiome, it is not surprising that humans share an intimate relationship with viruses since they will be found wherever life exists.},
}
@article {pmid42129077,
year = {2026},
author = {Veenstra, TD},
title = {Proteomic Analysis of Influenza.},
journal = {Advances in experimental medicine and biology},
volume = {1511},
number = {},
pages = {223-258},
pmid = {42129077},
issn = {0065-2598},
mesh = {Humans ; *Influenza, Human/metabolism/virology/epidemiology ; *Proteomics/methods ; Animals ; Pandemics ; *Proteome ; *Viral Proteins/metabolism/genetics ; },
abstract = {The past several years have increased the public's knowledge of various terms related to virology. Besides learning about messenger RNA (mRNA) vaccines, N95 masks, and coronaviruses (CoVs), we became familiar with the term pandemic. Pandemics are not novel. There have been approximately 250 pandemics recorded throughout history since 1200 B.C. with approximately 20 of these resulting in the deaths of more than one million people (https://study.com/learn/lesson/pandemics-in-history.html ; Sampath S et al., Cureus 13:e18136, 2021). The earliest recorded pandemic for which there is detailed information is the Justinian plague (Drancourt M and Raoult D, Clin Microbiol Infect 22:911-915, 2016). This pandemic began in 540 A.D., lasted for two centuries, and was a major factor that hastened the fall of the Roman Empire. So what exactly is a pandemic? At its most basic a pandemic is a disease that is simultaneously occurring worldwide, affecting many individuals. This definition does not include anything about the severity of the disease or the population's immunity. While most people would say that pandemics and epidemics are extremely rare, there have been six just in the last two decades (Bhadoria P et al., J Family Med Prim Care 10:2745-2750, 2021). These include the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), swine flu, Middle Eastern respiratory syndrome CoV infection, Ebola virus, Zika virus, and the most recent SARS-CoV-2 pandemic (see Table 9.1).},
}
@article {pmid42129712,
year = {2026},
author = {Mahmoudi, S and Mohammadpour, M and Olfat, M},
title = {Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis.},
journal = {BMC pulmonary medicine},
volume = {26},
number = {1},
pages = {},
pmid = {42129712},
issn = {1471-2466},
mesh = {Child ; Child, Preschool ; Humans ; Infant ; *Adenosine Monophosphate/analogs &amp; derivatives/therapeutic use/adverse effects/analogs &amp; derivatives ; *Alanine/analogs &amp; derivatives/therapeutic use/adverse effects/analogs &amp; derivatives ; *Antiviral Agents/therapeutic use/adverse effects ; COVID-19/therapy ; *COVID-19 Drug Treatment ; Hospital Mortality ; Hospitalization ; Pandemics ; *Pneumonia, Viral/drug therapy/mortality ; Respiration, Artificial/statistics &amp; numerical data ; SARS-CoV-2 ; Treatment Outcome ; },
abstract = {INTRODUCTION: Remdesivir (RDV) is an FDA-approved drug for the treatment of COVID-19 in children weighing at least 3.5 kg. While its safety and efficacy are well established in adults, data in pediatric populations remain limited and are largely extrapolated from adult studies. Therefore, we aimed to assess the clinical outcomes and safety of RDV in pediatric patients.<br><br>METHODS: We performed a systematic review and meta-analysis of studies evaluating RDV in hospitalized children under 18 years with COVID-19. The primary outcomes were in-hospital mortality and the level of respiratory support (baseline and highest). The secondary outcome was the safety profile of RDV identified by adverse events and treatment discontinuation. Meta-analysis was performed only on patients who received RDV.<br><br>RESULTS: From 1298 records, 16 studies were included. A total of 722 patients who received remdesivir were included in this study. Pooled analysis at admission showed that 28% of patients required no oxygen, 23% needed low-flow oxygen, 21% needed high-flow oxygen, 11% required non-invasive ventilation (NIV), and 9% were treated with mechanical ventilation (MV). During hospitalization, the highest respiratory support required was no oxygen in 27%, low-flow oxygen in 33%, high-flow oxygen in 32%, NIV in 5%, and MV in 19%. Overall mortality was 2% (95% CI: 0.00, 0.04, I[2]&#x2009;=&#x2009;59.81%, p&#x2009;<&#x2009;0.001). The most frequent RDV-related adverse events were elevated ALT in 11% (95% CI: 0.00, 0.42, I[2]&#x2009;=&#x2009;94.02%, p&#x2009;<&#x2009;0.001), increased AST in 10% (95% CI: 0.00, 0.41, I[2]&#x2009;=&#x2009;94.56%, p&#x2009;=&#x2009;<&#x2009;0.001), unspecified liver enzymes elevation in 8% (95% CI: 0.01, 0.20, I[2]&#x2009;=&#x2009;81.84%, p&#x2009;<&#x2009;0.001), and hypertension in 10% (95% CI: 0.00, 0.58, I[2]&#x2009;=&#x2009;97.16%, p&#x2009;<&#x2009;0.001). Bradycardia (3%) and increased creatinine (2%) were also reported. Almost all studies reported no drug-related serious adverse events.<br><br>CONCLUSION: This meta-analysis suggests that RDV has an acceptable safety profile in pediatric patients with COVID-19. The most commonly reported adverse events were elevated hepatic enzymes and hypertension, with occasional reports of bradycardia and increased creatinine. The pooled results should be interpreted with caution due to study heterogeneity and possible publication bias.},
}
@article {pmid42129716,
year = {2026},
author = {Farah, MM},
title = {The impact of telehealth services on healthcare access in rural areas.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42129716},
issn = {1471-2458},
mesh = {*Telemedicine/organization &amp; administration ; Humans ; *Health Services Accessibility ; *Rural Health Services/organization &amp; administration ; COVID-19/epidemiology ; *Rural Population ; Pandemics ; Digital Health ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: This review aims to elucidate the role, advantages, and limitations of telehealth in enhancing healthcare access in rural regions globally.<br><br>METHODS: A comprehensive literature search was conducted across Google Scholar, PubMed, Web of Science, and specific national databases (including those from Turkey, Australia, and India) for studies published between 2000 and 2024. A PRISMA-style flow approach was used to document the study selection process. Relevant articles, reviews, and reports were analyzed using thematic synthesis.<br><br>FINDINGS: The review identified a range of telehealth services that effectively mitigate geographical and socioeconomic barriers by facilitating specialist consultations, enabling chronic disease management, and offering cost-effective solutions. Evidence from multiple studies indicates a reduction in emergency department visits and hospitalization rates. For instance, (Eze, P., Health Serv Insights 15, 2020) demonstrated that telehealth implementation can significantly reduce missed appointments, generating substantial cost savings for clinics. Nevertheless, the review found that significant challenges remain across the literature, including inadequate digital infrastructure, low technological literacy, data security concerns, and regulatory gaps (Butzner, M., &amp; Cuffee, Y&#xa0;J Med Int Res 23:(8) e29575, 2020). The COVID-19 pandemic has markedly accelerated the adoption of telehealth practices worldwide (Bashshur, Telemedicine and e-Health 26(5):571-573, 2020).<br><br>CONCLUSION: Telehealth serves as a transformative tool for improving accessibility and equity in rural healthcare. Sustainable implementation requires prioritized investments in infrastructure, digital literacy programs, comprehensive legal frameworks, and robust cybersecurity measures. Hybrid models that integrate traditional services with telehealth, along with culturally adapted and patient-centered solutions, are crucial for developing inclusive and resilient future health systems.},
}
@article {pmid42131658,
year = {2026},
author = {Joy, P and Kunthavai, R and Sahu, S and Routray, S},
title = {COVID-19 and Congenital Cleft Lip and Palate: A Systematic Review Focusing on Nonsyndromic Neonatal Outcomes.},
journal = {Cureus},
volume = {18},
number = {4},
pages = {e106878},
pmid = {42131658},
issn = {2168-8184},
abstract = {Craniofacial anomalies (CFAs), such as cleft lip and palate, are among the most frequent birth defects, often necessitating multidisciplinary care. The COVID-19 pandemic raised concerns that maternal SARS-CoV-2 infection and associated factors, such as fever, inflammation, and psychosocial stress, might elevate teratogenic risk. This systematic review aims to synthesize the evidence on the association between maternal COVID-19 exposure and nonsyndromic CFAs in neonates. We conducted a systematic review in accordance with the PRISMA 2020 guidelines. Major electronic databases (PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, and the WHO COVID-19 Database) were searched from their inception until February 2025. We included studies examining the association between documented maternal COVID-19 infection (before or during pregnancy) and the incidence, type, or severity of CFAs, with a focus on nonsyndromic orofacial clefts (NSOFC). Risk of bias of the studies was assessed using the ROBINS-I tool. Findings were synthesized narratively, and bibliometric analyses, including geo-mapping and conceptual structure mapping, were performed. Eleven studies met the inclusion criteria. The evidence was mixed: smaller regional studies suggested a possible link, particularly with first-trimester infection, which aligns with the critical timing of craniofacial development. However, large-scale, robust epidemiological and registry-based studies from the USA and Nordic countries consistently found no significant association between maternal COVID-19 infection and congenital anomalies. A meta-analysis could not be performed due to study heterogeneity. Maternal stress and fear of COVID-19 were repeatedly highlighted as potential factors, in some cases showing stronger or even paradoxical associations than the infection itself. Research activity was concentrated primarily in Saudi Arabia and the United States. Robust population-level evidence does not currently support a direct, major causal link between maternal SARS-CoV-2 infection and NSOFC. While a modest or context-specific association cannot be entirely excluded, the effects of maternal psychosocial stressors and restricted healthcare access during the pandemic appear to be important explanatory factors that warrant further investigation, independent of the viral infection itself.},
}
@article {pmid42132825,
year = {2026},
author = {Wong, LP and Megat Hashim, MMAA and Huang, Z and Zhao, Q and Lee, HY},
title = {Navigating acceptance: challenges and barriers to Nipah virus vaccine uptake in Malaysia's muslim-majority context.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2674683},
doi = {10.1080/14760584.2026.2674683},
pmid = {42132825},
issn = {1744-8395},
mesh = {Humans ; Malaysia/epidemiology ; *Nipah Virus/immunology ; *Henipavirus Infections/prevention &amp; control ; *Patient Acceptance of Health Care/psychology ; *Islam/psychology ; *Vaccination Hesitancy/psychology ; *Vaccination/psychology ; Health Knowledge, Attitudes, Practice ; COVID-19/prevention &amp; control ; *Viral Vaccines/administration &amp; dosage/immunology ; },
abstract = {INTRODUCTION: The development of Nipah virus (NiV) vaccine offers a vital opportunity for pandemic preparedness in Southeast Asia, especially in Malaysia, where the first outbreak occurred. However, vaccine acceptance must be understood within diverse cultural, religious, and social contexts.<br><br>AREAS COVERED: This review explores key challenges and barriers to NiV vaccine uptake among Malaysia's Muslim-majority population, drawing insights from past rollouts such as COVID-19 and HPV vaccines. Key issues include religious concerns, misinformation, historical hesitancy, lack of trust in health authorities, and gaps in knowledge, attitudes, and perceptions, which collectively hinder vaccine acceptance and uptake. The paper also highlights enablers namely religious endorsements, transparent communication, and culturally sensitive engagement with trusted healthcare and community leaders. Evidence-based strategies, like motivational interviewing, narrative communication, and tailored outreach, are discussed. Finally, the 7C model is introduced as a structured framework to address behavioral and psychological barriers to vaccination.<br><br>EXPERT OPINION: Research gaps remain in understanding local psychological drivers, religious governance dynamics, and misinformation patterns. Future efforts should prioritize nationwide KAP studies, validation of behavioral frameworks such as the 7C model, and interventional research on culturally tailored communication. Integrating early halal certification and coordinated religious engagement will be essential for effective and equitable uptake.},
}
@article {pmid42133579,
year = {2026},
author = {Lai, X and Gao, Q and Wu, L},
title = {A 56-Year-Old Male Farmer From China With Severe Fever With Thrombocytopenia Syndrome and Pulmonary Aspergillosis: A Case Report and Review of Literature.},
journal = {The American journal of case reports},
volume = {27},
number = {},
pages = {e951798},
pmid = {42133579},
issn = {1941-5923},
mesh = {Male ; Humans ; Middle Aged ; *Severe Fever with Thrombocytopenia Syndrome/diagnosis/complications ; *Pulmonary Aspergillosis/diagnosis/complications ; China ; Phlebovirus ; Aspergillus fumigatus/isolation &amp; purification ; Antifungal Agents/therapeutic use ; },
abstract = {BACKGROUND Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by the Dabie bandavirus (commonly known as SFTS virus, or SFTSV). SFTSV-induced immunosuppression during infection renders patients highly susceptible to invasive pulmonary aspergillosis. SFTS-associated pulmonary aspergillosis (SAPA) presents major therapeutic challenges and is linked to drastically worsened outcomes, including high mortality. This report aims to highlight the diagnostic and therapeutic challenges of SAPA and emphasize the value of early diagnosis using metagenomic next-generation sequencing (mNGS). CASE REPORT We report a case of a previously healthy 56-year-old male farmer admitted with SFTS. On hospital day 3, when only mild cough had begun, mNGS of both blood and sputum concurrently detected Aspergillus fumigatus alongside SFTSV. This very early, pre-radiographic diagnosis prompted immediate targeted therapy with voriconazole and favipiravir. Despite this, imaging showed progressive pulmonary infiltrates with cavitation. The clinical course was further complicated by severe acute respiratory syndrome coronavirus 2 co-infection, but the patient recovered with intensive care and was discharged on day 24. A review of 13 literature-reported SAPA cases revealed a mortality rate of 30.77% (4/13). CONCLUSIONS SAPA is a severe, rapidly progressive complication of SFTS with high mortality, typically emerging 1-2 weeks after onset. This case highlights the importance of early diagnosis using rapid methods such as mNGS and the need for timely antifungal intervention to improve patient outcomes. Early antifungal therapy in high-risk patients is crucial.},
}
@article {pmid42134908,
year = {2026},
author = {Herlinda, O and Jundullah, SM and Saminarsih, DS},
title = {Reaching the margins: examining equity in Indonesia's COVID-19 vaccination strategy.},
journal = {BMJ global health},
volume = {11},
number = {5},
pages = {},
pmid = {42134908},
issn = {2059-7908},
mesh = {Humans ; Indonesia/epidemiology ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/supply &amp; distribution ; *Pandemics/prevention &amp; control ; SARS-CoV-2 ; *Vaccination ; },
abstract = {The COVID-19 pandemic profoundly affected health, social and economic systems worldwide. In less than a year, COVID-19 vaccines were developed and distributed. However, global and national distribution efforts faced significant challenges in ensuring equitable access, particularly for vulnerable populations. Despite WHO guidelines for national vaccine allocation, governments encountered difficulties in vaccine allocation and prioritisation. While Indonesia's COVID-19 primary dose coverage surpassed 70%, disparities persisted both across and within provinces as well as among different population groups. Discussion about the definition of vulnerable population and who should be prioritised remains critical to preparing for future pandemics. This paper argues for the establishment of clear guidelines for national governments on the allocation of vaccines, enabling timely action in future pandemics to prevent avoidable deaths and disabilities. Robust governance and data also remain a key area to improve. Drawing on Indonesia's experience with COVID-19, this paper offers recommendations for vaccine allocation during a respiratory pathogen pandemic.},
}
@article {pmid42134950,
year = {2026},
author = {Tebay, Z and McNamara, P},
title = {GP burnout post-COVID-19 pandemic: a narrative review on burnout with consideration towards Deep End practices.},
journal = {The British journal of general practice : the journal of the Royal College of General Practitioners},
volume = {76},
number = {suppl 1},
pages = {},
doi = {10.3399/bjgp26X745485},
pmid = {42134950},
issn = {1478-5242},
mesh = {Humans ; *Burnout, Professional/epidemiology/psychology ; *COVID-19/epidemiology/psychology ; Workload/psychology ; United Kingdom/epidemiology ; SARS-CoV-2 ; *General Practitioners/psychology ; Pandemics ; },
abstract = {BACKGROUND: Recent data suggest that GP burnout is of significant concern, particularly post-pandemic. Burnout is defined as a syndrome of fatigue and apathy resulting from chronic workplace stress; as many as 75% of GP trainees recently reported these symptoms. Increased workload and demand coupled with workforce shortages and systemic strain are contributing factors. GP burnout impacts continuity of care and threatens patient safety. These pressures significantly impact deprived Deep End practices.<br><br>AIM: To review recent evidence on GP burnout in the UK over the pandemic period, with consideration of its impact on deprived practices.<br><br>METHOD: Narrative review of 2019-2023 UK-based studies exploring GP burnout, synthesising findings from peer-reviewed literature, policy reports, and national surveys. The review focused on trends, potential drivers, and interventions.<br><br>RESULTS: Evidence indicates a sustained rise in GP burnout, accelerated over the pandemic. Contributing factors include workload intensity, administrative burden, consulting pressures, and moral failure. Studies revealed that Deep End GPs experience disproportionate burnout rates due to complex patient needs, unprecedented demand, and limited resources. Interventions involving institutional and systemic changes to improve workflow and expand the multidisciplinary team must be assessed. A meta-analysis of UK-based GP data would be invaluable to evaluate preventative interventions across different practices.<br><br>CONCLUSION: GP burnout is a growing problem, complicated by COVID-19. Future research should examine long-term trajectories and appraise protective factors, given the limitation of this review capturing small studies. UK policy should prioritise retention, resource allocation, and offer targeted support for practices, particularly Deep End, to not only protect practitioner wellbeing but service sustainability for patients.},
}
@article {pmid42135534,
year = {2026},
author = {Della Rosa, G and Raffo, M and Tammaro, S and Morelli, M and Arcaniolo, D and Pandolfo, SD and Sciorio, C and Romano, L and Manfredi, C and Cindolo, L and De Sio, M and Spirito, L},
title = {The impact of COVID-19 on sexual behavior, male sexual function, and reproductive health: an interdisciplinary narrative review from a urological perspective.},
journal = {International urology and nephrology},
volume = {},
number = {},
pages = {},
pmid = {42135534},
issn = {1573-2584},
abstract = {The COVID-19 pandemic profoundly modified daily life and interpersonal relationships, with relevant consequences on sexual health, which integrates biological, psychological, and social components. This narrative review summarizes current evidence regarding the impact of the pandemic on sexual behavior, sexual function, and male reproductive health. A comprehensive literature search of recent studies and clinical reports was performed focusing on psychosexual wellbeing, erectile function, fertility, and healthcare access during and after infection or lockdown periods. Current evidence indicates that lockdown-related stress, anxiety, and depression were consistently associated with reduced sexual desire and frequency of sexual activity, as reported in predominantly cross-sectional, questionnaire-based studies conducted during lockdown periods, particularly among couples with children and non-cohabiting partners, whereas alternative sexual practices increased. Sexual activity generally recovered after restrictions were lifted. Emerging data suggest a possible association between COVID-19 and erectile dysfunction mediated by endothelial damage, hypogonadism, and psychological distress, while long-COVID symptoms may further worsen sexual function. Male fertility alterations related to inflammatory and oxidative stress pathways have also been reported. Overall, the pandemic primarily affected sexuality through psychosocial mechanisms, although potential organic effects of SARS-CoV-2 infection on erectile function and fertility cannot be excluded. This review provides an interdisciplinary synthesis of current evidence with a specific focus on clinically relevant urological implications, including erectile dysfunction and male reproductive health, which remain incompletely addressed in the existing literature.},
}
@article {pmid42135711,
year = {2026},
author = {Wang, M and Liu, H and Zhu, W and Li, Z and Li, C and Jin, L},
title = {Factors affecting loneliness in pregnant women: A scoping review.},
journal = {BMC pregnancy and childbirth},
volume = {26},
number = {1},
pages = {},
pmid = {42135711},
issn = {1471-2393},
mesh = {Female ; Humans ; Pregnancy ; *Loneliness/psychology ; *Pregnant People/psychology ; COVID-19/psychology ; *Pregnancy Complications/psychology ; },
abstract = {BACKGROUND: Loneliness during pregnancy is a critical yet overlooked determinant of maternal health, distinct from postpartum depression. While the COVID-19 pandemic highlighted this vulnerability, the mechanisms and typologies of prenatal loneliness remain under-researched.<br><br>METHODS: A scoping review was conducted following PRISMA-ScR guidelines. Seven databases were searched up to March 15, 2025. Influencing factors were first screened according to the Social-Ecological Model (SEM) framework, followed by thematic analysis.<br><br>RESULTS: Twenty-three studies were included. Alongside emotional and social loneliness, a context-specific form tied to role transition during matrescence was identified ('transitional loneliness'). The reported prevalence of loneliness varied substantially, ranging from 26.26% to 55.40%. This wide variation likely reflects methodological heterogeneity (e.g., sampling and assessment tools) and population characteristics. Determinants were categorized into individual, interpersonal, community, and societal levels.<br><br>CONCLUSIONS: Current generic instruments fail to capture the unique transitional nature of prenatal loneliness. Addressing this issue requires developing pregnancy-specific assessment tools and implementing multi-level interventions targeting multi-level socio-ecological factors.},
}
@article {pmid42135872,
year = {2025},
author = {Mäki, K and Llewellyn-Zaidi, A and St Louis, D and Ralsky, M and O'Neill, DG and Hedhammar, &#xc5; and Packer, RMA and Ekenstedt, KJ and Bell, JS and Murphy, B and Seath, IJ and Courtin, A and Montonen, M and Nygård, A and Reunanen, V},
title = {Moving from information and collaboration to action: report from the 5th International Dog Health Workshop in Helsinki, June 2024.},
journal = {Companion animal health and genetics},
volume = {12},
number = {1},
pages = {},
pmid = {42135872},
issn = {3059-3255},
abstract = {BACKGROUND: The International Partnership for Dogs, together with a rotating national host organisation, holds approximately biennial meetings called the International Dog Health Workshop (IDHW). These workshops bring together a broad range of stakeholders in dog health and welfare, including scientists and veterinary practitioners, to improve the international sharing of information and resources, to provide a forum for ongoing collaboration, and to identify and agree on specific needs and actions to improve canine health and welfare.<br><br>WORKSHOP PRESENTATION: 5th International Dog Health Workshop was hosted by the Finnish Kennel Club in Helsinki, Finland, in June 2024. The workshop was structured around four key issues facing those working to improve dog health: 'Supply and Demand', 'Breeding for Health and Well-Being', 'Big Data', and 'Does the Colour Matter? Defining Breed vs. Variety'. The workshop provided an opportunity for participants to meet face-to-face after a five-year hiatus due to COVID-19, on the 10[th] anniversary of the International Partnership for Dogs. Among the 106 decision-makers from 16 countries who attended the workshop, there was broad agreement on several issues during the discussions, such as following the scientific evidence on canine genetics and health, moving away from extreme conformation, and using all available tools, including crossbreeding, to maintain and increase genetic variation within dog breeds. It was agreed that these principles should become priorities for welfare-minded organisations at the national and international levels. Better education of puppy buyers, breeders, show judges, and other relevant parties was recurringly identified as a priority across all four themes of the workshop.<br><br>CONCLUSIONS: In summary, key agreements from the 5th IDHW were that organisations must comply fully with relevant national animal welfare legislation, that organisations must work to eliminate extreme conformations from all dogs and to improve and maintain genetic diversity within subpopulations of dogs, and that organisations should recognise and support crossbreeding as an accepted and valuable tool for modern dog breeding.},
}
@article {pmid42138330,
year = {2026},
author = {Gardner, J},
title = {The immunogenicity and safety of adenoviral-based vaccines.},
journal = {Current opinion in allergy and clinical immunology},
volume = {26},
number = {4},
pages = {264-273},
pmid = {42138330},
issn = {1473-6322},
mesh = {Humans ; *SARS-CoV-2/immunology ; *Genetic Vectors/immunology/genetics ; *COVID-19/immunology/prevention &amp; control ; *T-Lymphocytes/immunology ; *COVID-19 Vaccines/immunology ; Animals ; *Adenoviridae/immunology/genetics ; *Adenoviruses, Human/immunology/genetics ; *Immunogenicity, Vaccine ; Cross Reactions ; },
abstract = {PURPOSE OF REVIEW: Human adenoviruses (HAdVs) have shown promise as versatile and effective delivery vectors for vaccine development. This was highlighted during the COVID-19 pandemic, which demonstrated the importance of effective vaccines but also provided scope to explore potential limitations of current viral-vector based strategies. This review summarizes the current applications of adenoviral vectors, in addition to discussing the immunological mechanisms underpinning immunogenicity and safety of viral vector-based vaccines.<br><br>RECENT FINDINGS: Clinical trials involving HAdVs have been undertaken to combat a range of infectious diseases, such as SARS-CoV-2, Ebola and HIV-1. However, empirical evidence indicates that preexisting T-cell immunity to adenoviruses may occur independent of serological exposure, predominantly arising from the conserved nature of immunogenic hexon proteins. As a result, T-cell responses are frequently detectable and often demonstrate broad cross-reactivity between human and nonhuman adenovirus (AdV) serotypes. Adverse events to vaccination are rare, although thrombotic events and severe cutaneous adverse reactions have been reported.<br><br>SUMMARY: Antivector T-cell immunogenicity arising from preexisting viral exposure or T-cell cross-reactivity may influence vaccine-specific immune responses. Continuous iterative refinement within the development of new vaccine vector technologies is therefore essential to circumvent limitations associated with vector-specific T-cell responses. However, mechanistic insight on the role of T-cells within pathomechanisms of adverse events remains unclear.},
}
@article {pmid42138647,
year = {2026},
author = {Bu, GL and Chen, LN and Wu, PH and Zeng, MS and Zhong, Q},
title = {Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research.},
journal = {Journal of medical virology},
volume = {98},
number = {5},
pages = {e70961},
doi = {10.1002/jmv.70961},
pmid = {42138647},
issn = {1096-9071},
support = {U24A20743//National Natural Science Foundation of China/ ; 32441094//National Natural Science Foundation of China/ ; 82030046//National Natural Science Foundation of China/ ; 82572641//National Natural Science Foundation of China/ ; 2022YFC3400900//National Key Research and Development Program of China/ ; 2023ZD0501000//Noncommunicable Chronic Diseases-National Science and Technology Major Project/ ; 2025M781430//China Postdoctoral Science Foundation/ ; },
mesh = {Humans ; *Epstein-Barr Virus Infections/prevention &amp; control/immunology ; *Herpesvirus 4, Human/immunology ; Vaccine Development ; *Herpesvirus Vaccines/immunology ; *Viral Vaccines/immunology ; },
abstract = {Epstein-Barr Virus (EBV), the first identified human oncovirus, is associated with a variety of human malignancies. It is estimated that more than 90% of the adults worldwide are infected with EBV. In 2020, EBV-attributable cancers accounted for approximately 1.3%-1.9% of the global cancer burden. Currently, no licensed vaccine against EBV is available for clinical use. The success of COVID-19 vaccines has provided a framework and momentum for novel efforts against EBV, accelerating vaccine research and yielding several promising candidates, some of which have entered clinical trials. These advances are expected to contribute substantially to preventing EBV infection and managing EBV-associated diseases. In this review, we assess the current landscape and recent advances in EBV vaccine research, summarizing progress across different vaccine platforms. This overview intends to provide a theoretical foundation for the future development and translational application of EBV vaccines.},
}
@article {pmid42138851,
year = {2026},
author = {Silva, AS and Dornelas, R and Silva, JRLE},
title = {COVID-19-related voice disorders: a scoping review.},
journal = {CoDAS},
volume = {38},
number = {3},
pages = {e20250243},
pmid = {42138851},
issn = {2317-1782},
mesh = {Humans ; *Voice Disorders/virology/etiology ; *COVID-19/complications ; SARS-CoV-2 ; Adult ; Voice Quality ; },
abstract = {PURPOSE: To map the available evidence on voice changes in non-intubated adults diagnosed with mild to moderate COVID-19.<br><br>RESEARCH STRATEGIES: Scoping review conducted according to PRISMA-ScR guidelines, including studies published between 2019 and 2025. Systematic searches were performed in the MEDLINE (PubMed), EMBASE, LILACS, Scopus, Web of Science, and Cochrane Library databases and in grey literature sources (Google Scholar, MedRxiv, and ProQuest). Controlled descriptors and free terms related to COVID-19 and voice disorders were combined using Boolean operators.<br><br>SELECTION CRITERIA: The review included studies with adults (18-65 years) with a confirmed diagnosis of mild to moderate COVID-19 and excluded studies with individuals undergoing endotracheal intubation and with a previous history of voice disorders or respiratory comorbidities. The selection was performed by two independent reviewers.<br><br>DATA ANALYSIS: The data were extracted and analyzed descriptively and quantitatively, considering study characteristics, vocal assessment methods, and main outcomes.<br><br>RESULTS: Of the 35,497 records identified, 19 studies met the inclusion criteria. The most frequent voice disorders were dysphonia, hoarseness, reduction in maximum phonation time, and changes in acoustic measures such as jitter, shimmer, and harmonic-to-noise ratio. Associated symptoms included vocal fatigue, cough, dyspnea, and laryngeal discomfort, as well as a negative impact on voice-related quality of life.<br><br>CONCLUSION: Mild to moderate COVID-19 can lead to clinically relevant vocal impairments, reinforcing the need for speech-language-hearing follow-up and research to support vocal assessment and rehabilitation protocols in the post-infection period.},
}
@article {pmid42139088,
year = {2026},
author = {Esa, N and Matsuda, S and Kuwabara, H and Oe, K and Okazaki, A and Suzuka, T and Wada, Y and Shoda, T and Kotani, T and Takeuchi, T},
title = {Microscopic polyangiitis-associated interstitial lung disease with acute exacerbation after SARS-CoV-2 infection: a case report and literature review.},
journal = {Modern rheumatology case reports},
volume = {10},
number = {1},
pages = {},
doi = {10.1093/mrcr/rxag035},
pmid = {42139088},
issn = {2472-5625},
mesh = {Humans ; Male ; *Lung Diseases, Interstitial/etiology/diagnostic imaging ; *Microscopic Polyangiitis/complications ; Aged, 80 and over ; *COVID-19/complications ; Fatal Outcome ; SARS-CoV-2 ; Tomography, X-Ray Computed ; Disease Progression ; Pandemics ; },
abstract = {Microscopic polyangiitis (MPA) is a type of systemic inflammatory small vessel vasculitis that is frequently accompanied by interstitial lung disease (ILD). Acute exacerbations (AE) of ILD are fatal complications in patients with MPA and can be triggered by various factors, including infections. We report a case of AE of MPA-ILD following severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection. An 81-year-old male with MPA during remission maintenance therapy was hospitalised for Coronavirus disease 2019 pneumonia. Treatment for SARS-CoV-2 infection improved his respiratory symptoms and radiological findings, but his respiratory condition suddenly deteriorated with a high fever on hospital Day 52. Chest high-resolution computed tomography showed diffuse bilateral ground glass opacity, and we diagnosed AE of MPA-ILD. He was refractory to steroid pulse therapy and died on the second day after the onset of AE. Pathologic autopsy revealed hyaline membrane formation over the entire bilateral lobes, consistent with the exudative phase of the diffuse alveolar damage pattern. Our case suggests that persistent immune activation during the post-acute phase of SARS-CoV-2 infection may contribute to delayed AE of MPA-ILD with a diffuse alveolar damage pattern through macrophage-driven lung injury, given that ILD exacerbation occurred approximately 2 months after the onset of Coronavirus disease 2019 pneumonia.},
}
@article {pmid42139648,
year = {2026},
author = {Meza, N and Lizana, FJ and Velásquez, M and Hormazábal, J and Morgado, B and Osses-González, PI and Silva, CE and Villalobos, SV and Bachelet, VC},
title = {Quality of reporting of systematic reviews with meta-analysis of diagnostic test accuracy of rapid antigen tests for SARS-CoV-2 according to PRISMA-DTA: A meta-epidemiological survey.},
journal = {Medwave},
volume = {26},
number = {4},
pages = {e3219},
doi = {10.5867/medwave.2026.04.3219},
pmid = {42139648},
issn = {0717-6384},
mesh = {Humans ; *COVID-19/diagnosis/epidemiology ; *Systematic Reviews as Topic ; Rapid Diagnostic Tests ; Sensitivity and Specificity ; *COVID-19 Serological Testing ; *SARS-CoV-2/isolation &amp; purification/immunology ; Meta-Analysis as Topic ; *Research Design/standards ; Antigens, Viral ; },
abstract = {INTRODUCTION: Systematic reviews are crucial for informing health decisions and supporting evidence-based policymaking. Reporting guidelines aim to reduce ambiguity and confusion while promoting clarity, completeness, and transparency in reporting. Our study aimed to assess the completeness of reporting of diagnostic test accuracy systematic reviews with meta-analysis on rapid antigen tests for SARS-CoV-2 deployed during the COVID-19 pandemic using the PRISMA-DTA guideline.<br><br>METHODS: We conducted a meta-epidemiological survey of systematic reviews with meta-analysis of rapid antigen tests for SARS-CoV-2. We searched MEDLINE/PubMed, EMBASE, L&#xb7;OVE Covid-19, and Web of Science Clarivate, covering the period from inception to April 3, 2025, with no language restrictions. We included reviews that used explicit systematic review methodologies with summary estimates of test sensitivity and specificity. We assessed compliance with the 27 PRISMA-DTA items.<br><br>RESULTS: After screening 5252 publications, we included 38 reviews. We found no PRISMA-DTA item with a low reporting frequency. Regarding the number of items reported, 23 (60%) of the included studies reported over 66%, and 15 (40%) reported between 33% and 66%, with none reporting fewer than 33%. None of the included reviews complied with the full PRISMA-DTA checklist.<br><br>CONCLUSIONS: Our meta-epidemiological survey reveals persistent shortcomings in the reporting quality of systematic reviews evaluating rapid antigen test accuracy for SARS-CoV-2. While some items were consistently addressed, numerous critical domains requiring a deeper understanding of the specific diagnostic test accuracy assessment methods showed low reporting adherence.},
}
@article {pmid42140392,
year = {2026},
author = {Streiber, M and Schubert, US and Traeger, A},
title = {Innovative lipid nanoparticle formulations: Bridging the gap toward decentralized personalized gene therapies.},
journal = {Journal of controlled release : official journal of the Controlled Release Society},
volume = {395},
number = {},
pages = {115023},
doi = {10.1016/j.jconrel.2026.115023},
pmid = {42140392},
issn = {1873-4995},
mesh = {Humans ; *Nanoparticles/chemistry/administration &amp; dosage ; *Lipids/chemistry ; *Precision Medicine/methods ; *Genetic Therapy/methods ; Animals ; Liposomes ; },
abstract = {Lipid nanoparticles (LNPs) have become a key technology for delivering nucleic acids, playing a critical role in the success of mRNA vaccines and RNA-based therapeutics. Established manufacturing methods, including microfluidic mixing and impingement jet mixing, have exhibited excellent scalability, reproducibility, and clinical relevance, most notably during the development of vaccines for SARS-CoV-2. Nevertheless, these techniques are accompanied by challenges related to the handling of organic solvents (ethanol), scalability for personalized medicine, and environmental considerations. This review draws attention to recent innovations in LNP formulation that seek to address these challenges through alternative and complementary approaches. One central focus of this review highlights post-formation encapsulation strategies, utilizing preformed vesicles or other nanostructures. These strategies facilitate modular, on-demand loading of nucleic acids. In addition, organic solvent-free techniques, including thermocycling, calcium-mediated DNA encapsulation, and aqueous sonication, offer new opportunities for biocompatible, streamlined manufacturing. In line with these formulation strategies, the review discusses recent progress in continuous manufacturing platforms, which enable end-to-end process control, real-time analytics, and increased production efficiency. By comparing conventional and emerging techniques, this review provides an overview of the evolving LNP formulation landscape and identifies key opportunities for integrating innovation into conventional production pipelines.},
}
@article {pmid42140539,
year = {2026},
author = {Tamariz, L and Shehadeh, LA and Bast, E and Klimas, N and Palacio, A},
title = {The role of the endothelium in long COVID.},
journal = {Vascular pharmacology},
volume = {163},
number = {},
pages = {107654},
doi = {10.1016/j.vph.2026.107654},
pmid = {42140539},
issn = {1879-3649},
mesh = {Animals ; Humans ; *Cardiovascular Diseases/physiopathology/virology/drug therapy ; *Endothelium, Vascular/physiopathology/drug effects/metabolism/virology ; Pandemics ; *Pneumonia, Viral/physiopathology/drug therapy/virology ; *Post-Acute COVID-19 Syndrome/physiopathology ; SARS-CoV-2 ; Vasodilation/drug effects ; },
abstract = {SARS-CoV2 infection significantly increases the risk of cardiovascular events through multiple interconnected mechanisms including systemic inflammation, dysautonomia, endothelial dysfunction, and prothrombotic states. The endothelium plays a critical role in this increase in risk together with dysautonomia and mast cell activation. SARS-CoV2 activates endothelial cells creating a pro-inflammatory, and pro-thrombotic phenotype. This phenotype could lead to microcirculatory changes that decrease oxygen delivery to tissues because of loss of laminar flow, lack of nitric oxide dependent vasodilation, increased viscosity and abnormal constriction of vascular smooth muscle cells due to neuropathy. There are several ways of identifying patients with endothelial dysfunction and the most used is flow mediated dilation. Many randomized trials have already found significant treatments for endothelial dysfunction and include antihypertensives, statins, beta-blockers, supplements and lifestyle interventions. Only two studies using vitamin C and L-arginine demonstrated improvements in flow mediated dilation in patients with long COVID.},
}
@article {pmid42140729,
year = {2026},
author = {El Kardoudi, A and Ouzir, M and Chetoui, A and Kaoutar, K and Ghandour, EK and Chigr, F},
title = {[Mental health symptoms during the Covid-19 pandemic and hypertension in Morocco].},
journal = {Soins; la revue de reference infirmiere},
volume = {71},
number = {905},
pages = {10-17},
doi = {10.1016/j.soin.2026.03.002},
pmid = {42140729},
issn = {0038-0814},
mesh = {Humans ; Morocco/epidemiology ; COVID-19/psychology ; *Hypertension/psychology/epidemiology ; *Depression/epidemiology/etiology ; *Anxiety/epidemiology/etiology ; Pandemics ; *Stress, Psychological/epidemiology/etiology ; Male ; Female ; Middle Aged ; SARS-CoV-2 ; *Mental Health ; Adult ; },
abstract = {The Covid-19 pandemic has had well-established effects on mental health. However, few studies have examined its specific impact on people with hypertension. To address this gap, a study was conducted in the Beni Mellal province, Morocco, to assess the psychological repercussions of Covid-19 in hypertensive patients compared to normotensive controls. Symptoms of depression, anxiety, and stress were measured using the DASS-21 scale.},
}
@article {pmid42141948,
year = {2026},
author = {Lamikanra, OK and Venigalla, M and Olowofeso, AM and Aneni, EC and Osondu, CU and Otite, FO},
title = {COVID-19 and the ICU: Redesigning Critical Care Services for a New Era.},
journal = {Journal of intensive care medicine},
volume = {},
number = {},
pages = {8850666261451793},
doi = {10.1177/08850666261451793},
pmid = {42141948},
issn = {1525-1489},
abstract = {BackgroundCoronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, was first identified in late 2019 and went on to profoundly disrupt health care systems worldwide. The pandemic led to unprecedented increases in healthcare delivery costs, widespread disruption in medical supply chains, workforce instability, and a loss of typical inpatient caregiver support. These challenges affected all levels of care, from primary health services to highly specialized intensive care units (ICUs). Before vaccines were available, ICUs were overwhelmed by critically ill patients requiring mechanical ventilation, saturating capacity and straining staff.ObjectivesThis article seeks to examine the effect that COVID-19 had on ICUs globally, acknowledging its impact with an aim to identify solutions that can be used to help mitigate the overburdening of this limited resource in future pandemics.MethodsA narrative review approach was used, drawing on published literature, observational data, and institutional responses from 2020 to 2025, to analyze structural, operational, and clinical adjustments in ICU design and function.ResultsKey adaptations included physical redesigns, rapid infection-control upgrades, the use of negative pressure rooms, expansion of tele-ICU systems, and virtual family engagement strategies. These interventions were implemented to address ICU crowding, equipment shortages, and staff burnout, and helped to maintain continuity of care during surge conditions.ConclusionsThe COVID-19 pandemic demonstrated the need for ICUs to be more agile, scalable, and future-facing. Lessons learned highlight the importance of preparedness strategies that strengthen ICU resilience and support critical care delivery in future public health emergencies.},
}
@article {pmid42142180,
year = {2026},
author = {Mapindra, MP and Mahindra, MP and McNamara, P and Kartasasmita, C and Semple, MG and Clark, H and Madsen, J},
title = {Prevalence of common respiratory viruses of infants with respiratory tract infections in European countries in the past decade: a systematic review and meta-analysis comparing between the pre-COVID-19, pandemic, and post-COVID-19 periods.},
journal = {European journal of pediatrics},
volume = {185},
number = {6},
pages = {},
pmid = {42142180},
issn = {1432-1076},
mesh = {Humans ; *Respiratory Tract Infections/virology/epidemiology ; Europe/epidemiology ; *COVID-19/epidemiology ; Prevalence ; Infant ; Infant, Newborn ; Pandemics ; SARS-CoV-2 ; Respiratory Syncytial Virus Infections/epidemiology ; },
abstract = {UNLABELLED: The purpose of this study is. to determine the leading cause of respiratory tract infections over the decade; this review examined the proportions of airway viruses in infants with respiratory tract infections in Europe before, during, and after the COVID-19 pandemic. The protocol for this systematic review was registered in the PROSPERO database (CRD42024497097). Literature searches in PubMed, Embase, Scopus, and Web of Science (WoS) identified 20,453 studies reporting respiratory viral testing in Europe over the past decade (2012/13-2022/23). Eligible studies were English-language full-text or grey articles with low risk of bias and complete data, and reports that explicitly provided the number of positive airway virus cases (n, virus) and the total infant population (N). Risk of bias was assessed using the Hoy et al. scoring system. Pooled prevalence estimates (pooled proportion [95% CI]) were calculated for pre-, during-, and post-COVID-19 periods using proportional meta-analysis with the MetaProp package in R. Fifty studies before, ten studies during, and 18 studies after the COVID-19 pandemic were eligible for proportional meta-analyses of viral testing in infants. Before the pandemic, the predominant viruses in infants with respiratory infections were Respiratory Syncytial Virus (RSV) (0.48 [0.41-0.56]), Human rhinovirus (HRV) (0.24 [0.18-0.29]), and Influenza virus (IV) (0.08 [0.04-0.12]). Post-pandemic, the leading viruses were RSV (0.63 [0.51-0.75]), HRV (0.25 [0.11-0.40]), and IV (0.10 [0.00-0.20]) again.<br><br>CONCLUSIONS: &#xa0;RSV and HRV remained the two most identified viruses in infants with respiratory infections, pre- and post-COVID-19 pandemic. Interestingly, both RSV and IV were suppressed during the pandemic. The trajectory dynamics of respiratory viruses were divergent, with resilient viruses (RSV, HRV, and IV) regaining dominance more rapidly than persistently suppressed viruses.<br><br>WHAT IS KNOWN: &#x2022; The COVID-19 pandemic induced an infection precautions policy, which reduced the spread of respiratory infectious diseases. &#x2022; Respiratory Syncytial Virus (RSV) was estimated as one of the most common causes of respiratory infections in infants. Still, there are no reports summarising the geographical distributions of the various viral agents of infant respiratory diseases.<br><br>WHAT IS NEW: &#x2022; This meta-analysis shows that the prevalence of RSV and HRV infections in infants remains high in Europe following the COVID-19 pandemic and the associated precautionary policy.&#xa0;Furthermore, RSV proportionally experienced a marked reduction during COVID-19 pandemic (lockdown periods). However, the immunological debt may have led to a re-emergence in RSV positivity after the lockdown periods. &#x2022; Our proportional meta-analysis indicates the heterogeneous post-pandemic recovery patterns of each respiratory virus commonly identified in infants, where HRV was shown to be resilient whilst RSV was rapidly rebound.},
}
@article {pmid42142525,
year = {2026},
author = {Trang, TPH and Bazelier, MT and Klungel, OH and Bots, SH},
title = {Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.},
journal = {Vaccine},
volume = {85},
number = {},
pages = {128722},
doi = {10.1016/j.vaccine.2026.128722},
pmid = {42142525},
issn = {1873-2518},
mesh = {Humans ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage ; *Myocarditis/etiology/epidemiology/chemically induced ; *COVID-19/prevention &amp; control ; SARS-CoV-2/immunology ; Observational Studies as Topic ; Vaccination/adverse effects ; },
abstract = {BACKGROUND: The risk of myocarditis following COVID-19 vaccines has been widely investigated, yielding highly variable effect estimates. It remains unclear how much of this variation can be explained by methodological differences and study quality. This study aimed to evaluate the methodology of observational studies on myocarditis risk post-COVID-19 vaccination and identify sources of heterogeneity.<br><br>METHODS: We systematically searched PubMed and EMBASE for observational studies reporting relative risks of myocarditis after COVID-19 vaccination published between December 2020 and October 2023. Risk of Bias (RoB) was assessed using the ROBINS-I tool. Meta-analysis and multivariable meta-regression were conducted for studies addressing comparable population-intervention-comparator-outcome (PICO) questions.<br><br>RESULTS: We included 30 studies, comprising 35 design-specific analyses. We identified considerable variability in design elements including risk window length (7-288&#xa0;days), reference period timing (three different ways), and control for COVID-19 disease (five different approaches). Thirteen (37%) design-specific analyses had serious or critical overall RoB. We observed strongest heterogeneity between studies in general population for dose 2 of BNT162b2 and mRNA-1273 compared to unvaccinated individuals/reference period (I[2]&#xa0;=&#xa0;96%, prediction interval (PI) of relative risk 0.40-20.20; I[2]&#xa0;=&#xa0;92%, PI 1.23-88.63, respectively). Meta-regression for the former PICO indicated that after adjusting for age and sex, effect estimates of samples with 28-day risk window were 0.56 times (95% CI 0.43-0.72) lower than those with 7-day risk window, but its overall effect was not significant. The effect of study design, outcome definition, approaches to handle COVID-19 infection and overall RoB were not significant in the meta-regression.<br><br>CONCLUSIONS: There is substantial variation in study design specifications and corresponding heterogeneity in reported effect estimates. Design choices like risk window length may explain some of this heterogeneity, although evidence remains inconclusive. Future vaccine safety studies should include sensitivity analyses to explore the effect of design choices on their findings.},
}
@article {pmid42143870,
year = {2026},
author = {Wang, B and Cheah, KSL and Beh, WF},
title = {Fostering collaborative creativity and ensemble skills through virtual ensembles in hybrid music education: A systematic literature review.},
journal = {Acta psychologica},
volume = {267},
number = {},
pages = {107060},
doi = {10.1016/j.actpsy.2026.107060},
pmid = {42143870},
issn = {1873-6297},
mesh = {Humans ; *Music ; *Creativity ; *Cooperative Behavior ; *COVID-19 ; Virtual Reality ; },
abstract = {The sudden change of music education to a hybrid form during the COVID-19 pandemic has made virtual ensembles the primary way of learning together. The authors aim through this review to understand how much digital platforms such as JackTrip, Jamulus, Zoom, and Soundtrap have affected the student engagement in musical ensemble practice. The paper emphasizes virtually choreographed concerts not only as a method for being able to continue training when difficulties arise but also to develop creative cooperation, self-management, and more advanced group playing skills. Seventeen peer-reviewed articles from 2020 to 2025 show that low latency platforms such as JackTrip and Jamulus are instrumental in facilitating musical engagement in real-time. Along with this, by using constructivist pedagogical methods like project-based learning, flipped classrooms, and DIY/DIWO, students become relentlessly more creative with music. Tools like Soundtrap help students create ideas asynchronously, while real-time platforms support timing and listening skills. However, there are still problems besides these advantages. Latency, audio compression, the difference in the equipment, and complicated user interfaces make it difficult for everyone to participate equally and for the group to stay together. The review points out that the success of virtual ensemble learning depends on instruction supported by well-aligned technology, which means planning, scaffolding, and technical support as well as flexible roles. This study provides a framework for educators, curriculum developers, and institutions seeking to improve hybrid music education. The right technology with inclusive, reflective teaching, virtual ensembles can become great ways to work together creatively and perform well.},
}
@article {pmid42144508,
year = {2026},
author = {Malhotra, D and Nepal, RM and Zografaki, I and Kyaw, MH and Nikolopoulou, P and de Almeida, RS and Lopez, SMC and Wiblin, S and Williams, F and Pope, S and Whittle, I and Pearson, F and Curcio, D},
title = {Severity of COVID-19 Omicron Variants: A Global Systematic Review.},
journal = {Infectious diseases and therapy},
volume = {15},
number = {7},
pages = {1827-1849},
pmid = {42144508},
issn = {2193-8229},
abstract = {INTRODUCTION: The continual emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants drives the need to update evidence on coronavirus disease 2019 (COVID-19) severity and disease burden, and better understand the impact on prevention, treatment, and healthcare systems.<br><br>METHODS: This systematic review aimed to determine relative disease severity, through comparative measures of hospitalization, intensive care unit admission and mortality, between SARS-CoV-2 variants of concern emerging since Omicron was first identified. A protocol was registered a priori (PROSPERO ID: CRD42024619193). Systematic searches of MEDLINE and EMBASE databases were conducted in November 2024 and supplemented by conference searches from 2022-2024. Population, Exposure, Comparisons, Outcomes (PECO) criteria were used to screen publications for inclusion. Critical appraisal tools published in the Joanna Briggs Institute (JBI) Handbook for Evidence Synthesis were used to assess the risk of bias of the primary studies included. The outcomes associated with Omicron variants, identified by sequencing or predominance periods, included hospitalization, admission to intensive care, death, and various composite endpoints.<br><br>RESULTS: Thirty-two studies fulfilled the eligibility criteria, most reported on relative disease severity for early Omicron BA.5 (n&#x2009;=&#x2009;23) and XBB (n&#x2009;=&#x2009;24) variants. Overall, COVID-19 severity appeared largely comparable across the various Omicron subvariants. Among the subset of studies that directly compared various severity outcomes to earlier SARS-CoV-2 variants (n&#x2009;=&#x2009;7), some reported modest increases or decreases in severity. However, these differences were generally not statistically significant. Five studies stratifying outcomes by the presence of comorbid conditions noted that comorbidities were predictors of significantly worse COVID-19 disease outcomes (p&#x2009;=&#x2009;0.000-0.027).<br><br>CONCLUSIONS: Overall, this systematic review found the severity of COVID-19 disease to be comparable among Omicron subvariants. As SARS-CoV-2 subvariants continue to emerge, these results highlight the continuing need for vaccination against SARS-CoV-2 infection alongside early antiviral intervention to support short-term management and long-term reduction of COVID-19-associated morbidity and mortality.},
}
@article {pmid42144551,
year = {2026},
author = {Chehade, M and Meyers, S and McCright-Gill, T and Gifford, R and Sahin, M and Shy, ME and Manion, M and Campbell, D and Rothenberg, ME and Macaluso, M},
title = {Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network.},
journal = {Clinical and translational science},
volume = {19},
number = {6},
pages = {e70585},
pmid = {42144551},
issn = {1752-8062},
mesh = {*Rare Diseases/therapy/diagnosis ; Humans ; *Biomedical Research/organization &amp; administration ; United States ; Information Dissemination ; COVID-19/epidemiology ; *Translational Research, Biomedical/organization &amp; administration ; Cooperative Behavior ; National Institutes of Health (U.S.) ; *Intersectoral Collaboration ; Patient Advocacy ; },
abstract = {The Rare Diseases Clinical Research Network (RDCRN) was established to improve diagnosis, treatment, and research collaboration across rare diseases through collaborative, multi-site, translational, and clinical research. Its governance framework promotes efficient data sharing and collaboration among research consortia, NIH representatives, and patient advocacy groups (PAGs). This infrastructure facilitates coordinated efforts to advance rare disease research through shared resources and communication. Prompted by the COVID-19 pandemic's impact on rare disease patients, the RDCRN recognized cross-consortia collaboration as a priority. Its policies promote data sharing while protecting participant confidentiality. PAGs participate in governance, study design, and regulatory discussions, helping to identify patient-relevant priorities, improve recruitment and retention, and strengthen trust between researchers and patients. Cross-consortia efforts have addressed challenges like biomarker identification and harmonization of clinical measures, leading to new methods and standardized data collection that benefit multiple rare diseases. Studies by teams focusing on different diseases have led to improved diagnostic tools by addressing overlapping disease presentations. The RDCRN offers scholars cross-consortia opportunities for presentations, competitions, and NIH training collaborations, fostering growth and networking. Network meetings promote exchange and process standardization; pilot projects facilitate independent grant submissions, forming a pipeline of skilled investigators. The RDCRN fosters trust, shared vision, and open communication by cultivating a culture of mutual respect, shared learning, and collective problem solving. By engaging a wide range of stakeholders, it has aligned its research with patient needs, advancing innovation. Its high-impact publications, effective mentoring programs, and pioneering cross-consortia initiatives underscore the value of collaboration in rare disease research.},
}
@article {pmid42144754,
year = {2026},
author = {Cho, JY and Kim, KH},
title = {Current Challenges and Emerging Therapeutic Strategies in Acute Myocarditis.},
journal = {Korean circulation journal},
volume = {},
number = {},
pages = {},
doi = {10.4070/kcj.2026.0006},
pmid = {42144754},
issn = {1738-5520},
abstract = {Acute myocarditis encompasses a heterogeneous group of inflammatory myocardial disorders with clinical presentations ranging from self-limited chest pain to fulminant cardiogenic shock. Despite advances in cardiac magnetic resonance imaging and molecular diagnostics, substantial uncertainty persists regarding early diagnosis, etiologic classification, and optimal therapeutic strategies. Current management relies largely on supportive care, as robust randomized evidence guiding immunomodulatory therapy remains limited and confined to selected virus-negative or autoimmune phenotypes. This review synthesizes contemporary evidence on the pathophysiology, diagnostic challenges, and treatment paradigms of acute myocarditis, with a particular focus on the critical distinction between virus-positive and virus-negative disease. We discuss established supportive and guideline-directed therapies, emerging immunomodulatory approaches-including corticosteroids, biologics targeting interleukin-1, complement, and mammalian target of rapamycin pathways-and the evolving role of mechanical circulatory support in fulminant myocarditis. COVID-19 vaccination-related myocarditis is highlighted as a modern example of immune-triggered, predominantly virus-negative myocarditis, illustrating both the generally favorable prognosis and the potential for severe clinical courses. Finally, this review outlines future directions toward precision immunocardiology, emphasizing the integration of endomyocardial biopsy, molecular virology, multi-omics profiling, and artificial intelligence-guided phenotyping to enable mechanism-driven, individualized therapy. Advancing from empirical management to precision-based intervention will be essential to improving outcomes in acute myocarditis.},
}
@article {pmid42146723,
year = {2026},
author = {Shipton, A and Mcbain, K and Wake, M and Goldfeld, S and Mensah, F},
title = {Policy Responses to the COVID-19 Pandemic in High-Income Countries and the Associated Maternal-Infant Health Outcomes: A Systematic Literature and Policy Review.},
journal = {Health science reports},
volume = {9},
number = {5},
pages = {e71523},
pmid = {42146723},
issn = {2398-8835},
abstract = {BACKGROUND: Foreseeing how policy impacts pregnant women and infants is limited by ethical challenges of experimental research within these groups. The COVID-19 pandemic generated natural experiments, offering rare opportunities to explore associations between specific policy responses and maternal-infant health outcomes. These insights are useful for informing policy design aligned with the 2030 Sustainable Development Goals.<br><br>AIMS: To systematically review evidence of associations between COVID-19 policies, OxCGRT Stringency Index (a University of Oxford tool for comparing the stringency of policies) and maternal-infant health outcomes during pregnancy, birth, and the first 12 months postpartum from 2020-2022 in high-income countries.<br><br>METHODS: Following PRISMA guidelines, Embase, MEDLINE, PubMed, and Web of Science were searched (January 1 2020-July 9 2022) using subject headings, keywords, and variants for "COVID-19", "policies", "perinatal", and "randomized", and "non-randomized" study designs. Eligible studies were from high-income countries, published in English, and used comparison groups. Two reviewers independently extracted and analyzed data. Heterogeneity and risk of bias made meta-analysis inappropriate. Outcomes were instead reported using tables and visuals of effect sizes, ratio estimates, and 95% confidence intervals.<br><br>RESULTS: Of 3143 citations, 35 studies met inclusion criteria. All reported high OxCGRT Stringency Index during exposure, validating the fidelity of adhering to defined policy exposure periods. Lockdown was associated with reductions in preterm and low birthweight births, infant emergency admissions, and breast feeding women, and increases in hypertensive disorders of pregnancy and gestational diabetes mellitus. Telehealth was associated with earlier gestational age at antenatal visits and less breast feeding women. Maternal mental health and stillbirth results were mixed.<br><br>CONCLUSION: High stringency policies, including lockdowns and telehealth, were associated with both favorable and adverse maternal-infant outcomes. Findings inform avenues for future causal inference research and areas for mitigation planning should high stringency policies be reintroduced, supporting progress towards the 2030 Sustainable Development Goals.},
}
@article {pmid42146922,
year = {2026},
author = {Ravi, N and Bamgbose, MO and Abdelkhalek, YY and Parkar, S and Alnasser, Y},
title = {Telemedicine for new immigrant children in the US: a tool for equity or another layer of disparity?.},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1814069},
pmid = {42146922},
issn = {2296-2360},
abstract = {Telemedicine refers to the use of digital communication tools to deliver healthcare services. In pediatrics care in the United States (US), it has become an important approach to expand access to primary and subspecialty care while reducing travel demands and improving continuity of care, particularly for children in remote and underserved communities. Evidence consistently shows that telemedicine can supplement in-person visits while maintaining high levels of family satisfaction and clinical effectiveness among American families. This narrative review was developed to assess the applicability of telemedicine for new immigrant families in the US using a structured literature search across PubMed, Scopus, Google Scholar, and Cochrane of published English literature. Peer-reviewed studies were included if they were conducted in the last 50 years and focused on pediatric patients from birth to 21 years of age. Findings were synthesized to evaluate the acceptance, accessibility, feasibility, and applicability of telemedicine for new immigrant children in the US. Across the reviewed literature, telemedicine has meaningful potential in narrowing health disparities faced by new immigrant families such as transportation, specialist shortages, scheduling delays, limited English proficiency, and difficulty navigating the complex healthcare system. Furthermore, telemedicine can connect families with providers who share similar cultural and linguistic backgrounds, thereby strengthening cultural sensitivity and trust. Still, it comes with several obstacles limiting its use among new immigrant families. From digital divide, poor network coverage, low health literacy, privacy concerns, immigration-related concerns, to mistrust, the challenges are numerous. Studies during the COVID-19 pandemic found low acceptance and infeasibility of telemedicine for new immigrant families. However, telemedicine offers multiple opportunities and future directions to better serve immigrant children and their families. Expanding multilingual telehealth platforms and integrating telemedicine access points into schools, community centers, and immigrant resource hubs can enhance accessibility, usability, and acceptance. Pairing telemedicine with artificial intelligence can have huge future potential and might be a tool for inclusive care at lower cost. Furthermore, policy amendments, particularly broader Medicaid telemedicine coverage and mandates for interpreter integration into telemedicine workflows, are essential for promoting more equitable access with higher acceptance and more applicability for new immigrant children in the US.},
}
@article {pmid42147457,
year = {2026},
author = {Zhang, Y and Sun, Y and Wang, J and Wang, L and Fang, R and Wu, X and Yang, X and Guo, Y and Li, S},
title = {A Scoping Review of Machine Learning Applications Across Epidemiological Stages of Zoonotic Disease.},
journal = {Transboundary and emerging diseases},
volume = {2026},
number = {},
pages = {2215823},
pmid = {42147457},
issn = {1865-1682},
mesh = {*Zoonoses/epidemiology/prevention &amp; control ; Animals ; *Machine Learning ; Humans ; Communicable Diseases, Emerging/epidemiology ; COVID-19/epidemiology ; },
abstract = {Emerging zoonotic diseases represent a significant threat to global health. While machine learning (ML) holds promise for their management, a comprehensive understanding of how these technologies are applied across the entire animal-to-human transmission pathway is lacking. This scoping review systematically maps ML applications in zoonotic disease management to identify research trends, methodological approaches, and critical gaps across different epidemiological stages and functional domains. We organize the literature along two dimensions: epidemiological stages, from animal hosts to human populations, and functional domain, including diagnosis, epidemiology, and intervention. We searched PubMed and Web of Science for studies on 14 preselected high-priority zoonotic diseases. The search string combined keywords for the selected diseases, ML techniques, and functional applications (diagnosis, epidemiology, and intervention). A total of 966 studies were included in the final analysis, of which 72.8% focused on COVID-19. Our analysis shows robust ML performance in clinical diagnostics, epidemic forecasting, and intervention optimization within human populations. However, critical gaps persist, only 1.96% of studies examined the animal-human interface, no ML models explicitly targeted spillover prevention, and studies on animal-reservoir surveillance remain limited. All spillover studies originated from high-income or upper-middle-income countries (UMICs), in contrast with low- and lower-middle-income countries (LMICs) contributing 21.4% of human-stage studies. These findings reveal a pronounced mismatch between research investment and spillover risk and highlight the need for greater emphasis on spillover mechanisms, enhanced integration of cross-species transmission dynamics, and methods suitable for surveillance in resource-limited settings. Addressing these imbalances is essential for advancing a shift from reactive outbreak response to proactive spillover prevention within a One Health framework.},
}
@article {pmid42148087,
year = {2026},
author = {Huang, ZY and Chen, J and Zhu, B and Liu, XL},
title = {Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1804838},
pmid = {42148087},
issn = {1664-3224},
mesh = {Humans ; *Multiple Myeloma/drug therapy/immunology ; *Antibodies, Bispecific/adverse effects/therapeutic use ; *Infections/epidemiology/etiology ; B-Cell Maturation Antigen/immunology ; Clinical Trials as Topic ; },
abstract = {BACKGROUND: Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody (BsAb), has shown remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). However, its mechanism leads to profound hypogammaglobulinemia, making infection a critical concern. This systematic review and meta-analysis aimed to quantify the infectious burden and contrast outcomes between clinical trial and real-world evidence (RWE).<br><br>METHODS: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for studies reporting infection outcomes in RRMM patients treated with teclistamab. Pooled incidences of any-grade and grade &#x2265;3 infections were calculated using a random-effects model. Subgroup analysis compared the pivotal MajesTEC-1 trial with multi-institutional RWE cohorts.<br><br>RESULTS: Five studies encompassing 714 patients were included. The overall pooled incidence was 56.5% (95% CI: 43.1%-69.9%) for any-grade infections and 27.6% (95% CI: 21.0%-34.3%) for grade &#x2265;3 infections. Subgroup analysis revealed a significantly higher risk in the clinical trial compared to RWE (Any-grade: 76.4% vs. 45.4%, p< 0.01; Grade &#x2265;3: 44.8% vs. 22.8%, p<0.01). Infection-related mortality was reported in all cohorts, ranging from 0.9% to 7.3%, with COVID-19 and opportunistic pathogens (for example, Pneumocystis jirovecii) being prevalent. Significant heterogeneity was driven by variations in follow-up duration and intravenous immunoglobulin (IVIG) prophylaxis rates (range: 41.8%-81.3%).<br><br>CONCLUSIONS: Teclistamab is associated with a substantial and cumulative infectious burden. The lower infection rates in RWE may reflect shorter follow-up and evolving prophylactic strategies. Standardized infection surveillance, including regular IgG monitoring and consideration of IVIG replacement in patients with low IgG levels, may help optimize the safety of BCMA-directed bispecific therapies.<br><br>https://www.crd.york.ac.uk/prospero/, identifier CRD420261297645.},
}
@article {pmid42148106,
year = {2026},
author = {Guo, H and Wang, H and Wu, S and Lin, H and Wang, G and Pu, Q},
title = {Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1818721},
pmid = {42148106},
issn = {1664-3224},
mesh = {Humans ; *Respiratory Syncytial Virus Infections/immunology/therapy ; *SARS-CoV-2/immunology ; *Antibodies, Viral/immunology/therapeutic use ; *Antibodies, Neutralizing/immunology/therapeutic use ; *COVID-19/immunology/therapy ; *Respiratory Syncytial Virus, Human/immunology ; Animals ; Antibodies, Monoclonal/therapeutic use/immunology ; Epitopes/immunology ; Spike Glycoprotein, Coronavirus/immunology ; },
abstract = {Respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent two extremes in the outcome of antibody-based interventions. The long-acting monoclonal antibody nirsevimab has achieved durable, population-level protection against RSV in infants, reducing hospitalizations by 70-90% with no evidence of antigenic escape. In contrast, all neutralizing monoclonal antibodies against SARS-CoV-2 became obsolete within three years due to rapid viral evolution, particularly in the spike receptor-binding domain. This review dissects the mechanistic determinants underlying this divergence. We propose four key principles that govern antibody efficacy against respiratory viruses: (i) targeting a structurally conserved epitope with high fitness cost for escape; (ii) achieving sufficient antibody concentrations in the airway epithelial lining fluid; (iii) the vulnerability of single-epitope strategies against mutable viral targets; and (iv) the auxiliary but non-substitutable role of Fc effector functions. By comparing RSV and SARS-CoV-2, we illustrate how these principles align in successful interventions and fail in others. Finally, we discuss emerging strategies-particularly inhaled delivery and mRNA-encoded antibodies-that may overcome current limitations and enable durable protection against antigenically variable respiratory pathogens.},
}
@article {pmid42148664,
year = {2026},
author = {Arnaboldi, PM and Becker, J and Nath, A and Coyle, PK and Handel, A and Sellati, TJ and Gomes-Solecki, M and Garcet, S and Henderson, MK and Mullins, P and Cowan, E and McCombie, WR and Wellins, AM and Allegretta, M and Bergquist, J and Schutzer, SE},
title = {Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.},
journal = {Brain : a journal of neurology},
volume = {149},
number = {6},
pages = {1842-1859},
pmid = {42148664},
issn = {1460-2156},
support = {//Banbury Center of Cold Spring Harbor Laboratory/ ; },
mesh = {Humans ; *Fatigue Syndrome, Chronic/diagnosis/therapy ; *Lyme Disease/diagnosis/therapy ; Post-Lyme Disease Syndrome/diagnosis ; Chronic Disease ; *Multiple Sclerosis/diagnosis/therapy ; *Research Design ; COVID-19/therapy/diagnosis ; },
abstract = {Infection-associated chronic illnesses (IACIs) encompass a spectrum of poorly understood syndromes often marked by significant neurologic and multisystem symptoms following an infectious event. This review focuses on several diseases representative of the IACI spectrum. These are post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS). Their clinical and biological complexity, combined with a lack of clear diagnostic criteria and objective available laboratory biomarkers, makes them difficult to distinguish from conditions with overlapping features. This presents challenges for research studies, as well as diagnosis and clinical management. This diagnostic ambiguity, coupled with heterogeneous patient presentations, has led to challenges in research, including misclassification of study participants and inconsistent or irreproducible findings. Some PTLDS research exemplifies these issues, which also extend to other IACIs. To advance the field, we highlight key methodological refinements and approaches for studying IACIs, including rigorous participant selection, standardized sample collection protocols, and the use of appropriate control groups, including those with microbiologic proof of the initial infection when known and technologically feasible. We also address broader influences on research quality, such as stigma, historical neglect, and the urgency to find treatments, which have contributed to the proliferation of poorly controlled studies and questionable practices. Drawing lessons from past challenges, we propose a path forward grounded in fit-for-purpose methodological rigour to improve scientific understanding and support evidence-based therapeutic development for IACIs.},
}
@article {pmid42148826,
year = {2026},
author = {Fresilli, S and Belletti, A and Labanca, R and Monti, G and Schultz, MJ and Corbo, F and Luciano, AP and Ferrara, B and Turi, S and Landoni, G and , },
title = {Nebulized Heparin in Adults With Acute Respiratory Failure: A Meta-Analysis of Randomized Trials.},
journal = {Critical care medicine},
volume = {54},
number = {7},
pages = {1755-1766},
doi = {10.1097/CCM.0000000000007161},
pmid = {42148826},
issn = {1530-0293},
mesh = {Humans ; *Heparin/administration &amp; dosage/therapeutic use ; Randomized Controlled Trials as Topic ; *Respiratory Insufficiency/drug therapy/mortality ; *Anticoagulants/administration &amp; dosage ; Nebulizers and Vaporizers ; Administration, Inhalation ; Adult ; COVID-19/complications ; },
abstract = {OBJECTIVES: Dysregulated pulmonary coagulation and inflammation is a hallmark of respiratory failure in various etiologies. Excessive fibrin deposition contributes to alveolar collapse, impaired gas exchange, and progression to pulmonary fibrosis. Nebulized heparin can mitigate these coagulation and inflammation disturbances. Although several randomized controlled trials have explored its effects, results remain inconsistent and limited by small patient populations. We conducted a random-effects meta-analysis to calculate the risk ratio (RR) and 95% CIs.<br><br>DATA SOURCES: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled trials comparing nebulized unfractionated heparin to standard care or placebo in adult patients with respiratory failure either invasively mechanical ventilated or not. The primary outcome was all-cause mortality at the longest follow-up.<br><br>STUDY SELECTION: We included randomized clinical trials enrolling adult patients with respiratory failure, comparing nebulized heparin vs. standard care or placebo, and reporting at least one clinical outcome, including all-cause mortality.<br><br>DATA EXTRACTION: Two independent investigators extracted data on trial design, setting, etiology of respiratory failure, heparin dosing regimens, follow-up duration, and outcomes. Discrepancies were resolved by consensus.<br><br>DATA SYNTHESIS: We identified 16 studies (787 receiving nebulized heparin, 833 control). Six (38%) were multicenter, five focused on COVID-19, 12 enrolled ICU patients, and dosing clustered around 25,000 international units (IUs) three times a day (~75,000 IU/d for ~10 d). At the longest follow-up, nebulized heparin reduced all-cause mortality vs. control (110/645 [17.1%] vs. 157/711 [22.1%]; RR, 0.79; 95% CI, 0.66-0.95; with ten studies included). Nebulized heparin was also associated with more ventilation-free days by day 28 (mean difference, +4.85; 95% CI, 1.47-8.24). Major bleeding was rare (1.1 vs. 0.7%; RR, 1.48; 95% CI, 0.42-5.18), while no minor bleeding or heparin-induced thrombocytopenia was reported.<br><br>CONCLUSIONS: Nebulized unfractionated heparin may improve survival in patients with respiratory failure without increasing adverse events.},
}
@article {pmid42149126,
year = {2026},
author = {Akinbolade, S and Potter, R and Inskip, A and Nesworthy, J and Brock, K and Norman, G},
title = {Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan.},
journal = {Pharmacology research &amp; perspectives},
volume = {14},
number = {3},
pages = {e70271},
pmid = {42149126},
issn = {2052-1707},
support = {HSRIC-2016-10&#x2009;009//National Institute for Health and Care Research/ ; },
mesh = {Humans ; *Drug Repositioning/methods ; *Antiviral Agents/therapeutic use/pharmacology ; SARS-CoV-2 ; Pandemics ; Animals ; COVID-19 ; COVID-19 Drug Treatment ; },
abstract = {Viruses such as Ebola, Marburg, influenza, mpox, MERS-CoV, SARS-CoV, and SARS-CoV-2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time-consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost-effective strategy to expand treatment options during public health emergencies. This scan aimed to map current investigational activity involving repurposed medicines for these viruses. A horizon scanning approach was employed, starting with a targeted search in Embase followed by a systematic search of ClinicalTrials.gov to identify developmental stages of relevant technologies. Eligible technologies included UK- or EU-licensed medicines being investigated for antiviral use, while vaccines, unlicensed medicines, and treatments already approved for the target viruses were excluded. From the literature, 196 repurposed technologies were identified, and the expanded search on the clinical trials registry revealed 58 technologies in active clinical development. Interventional trial activity was limited to influenza and SARS-CoV-2, with 29 technologies for SARS-CoV-2 and two influenza technologies advancing to phase III evaluation. For other viruses, candidate repurposed technologies were identified only at preclinical or exploratory stages. Frequently investigated pharmacological classes included direct-acting antivirals, immunomodulators, and anti-inflammatory agents. While repurposing represents a potentially rapid strategy for therapeutic deployment, inclusion in this horizon scan does not imply clinical efficacy. Rigorous preclinical validation, pharmacokinetic feasibility assessment, and mechanistic confirmation remain essential before clinical translation.},
}
@article {pmid42149279,
year = {2026},
author = {Abu-Qatouseh, L and Al-Kubaisi, K and Laham, NA and Al-Adham, I and Collier, PJ},
title = {Pandemic Preparedness and Health System Resilience: Lessons from Jordan's COVID-19 Response.},
journal = {Journal of community health},
volume = {51},
number = {4},
pages = {637-647},
pmid = {42149279},
issn = {1573-3610},
mesh = {Humans ; Jordan/epidemiology ; *COVID-19/epidemiology ; *Pandemic Preparedness ; *Delivery of Health Care/organization &amp; administration ; Public Health Infrastructure ; SARS-CoV-2 ; },
abstract = {This review article provides a comprehensive analysis of Jordan's health sector preparedness and response to the COVID-19 pandemic from 2020 to 2025. It critically examines the national response framework, the capacity and challenges of frontline healthcare workers, and the systemic strengths and weaknesses of the healthcare system. The article further explores the multifaceted economic and social impacts of the pandemic on Jordanian society, including the effects on the economy, education, and mental health. Finally, it discusses the post-pandemic improvements and long-term strategies being implemented to strengthen the resilience of Jordan's healthcare system. The findings indicate that while Jordan's initial response was robust and well-coordinated, the prolonged nature of the pandemic exposed significant vulnerabilities in resource availability, practical training, and the psychological well-being of healthcare workers. By 2025, Jordan has made substantial progress in institutional reforms and health system strengthening, although challenges remain in sustaining these improvements. This review synthesizes the key lessons learned [1] and offers evidence-based recommendations for enhancing institutional preparedness and resilience for future public health emergencies. The experience of Jordan provides valuable insights for other resource-constrained settings facing similar health security challenges.},
}
@article {pmid42149692,
year = {2026},
author = {Amahong, K and Liu, Y and Zhang, Z and Tao, L and Sarshad, AA and Zhu, F},
title = {An integrative meta-analysis of SARS-CoV-2 RNA-protein interactomes identifies conserved host factors shared with other RNA viruses.},
journal = {Briefings in functional genomics},
volume = {25},
number = {},
pages = {},
pmid = {42149692},
issn = {2041-2657},
mesh = {Humans ; *SARS-CoV-2/metabolism/genetics ; *RNA, Viral/metabolism/genetics ; *Host-Pathogen Interactions ; *RNA-Binding Proteins/metabolism ; *RNA Viruses/metabolism/genetics ; Influenza A virus/metabolism/genetics ; Dengue Virus/metabolism/genetics ; COVID-19/virology/metabolism ; Zika Virus/metabolism/genetics ; },
abstract = {RNA viruses cause substantial global disease burden and depend on host RNA-binding proteins and translation machinery. However, it remains unclear which host factors are robustly engaged across independent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA interactome studies and to what extent these factors are shared with other RNA viruses. Here, we perform an integrative meta-analysis of eight published SARS-CoV-2 RNA-protein interactomes and compare them with corresponding Influenza A virus, Zika virus, and Dengue virus datasets to define conserved host networks and prioritize candidate host-directed antiviral targets. By integrating multiple datasets and applying ClusterProfiler together with curated pathway resources (KEGG, Reactome, WikiPathways, and Gene Ontology), we systematically characterize the functional landscape of SARS-CoV-2 RNA-protein interactions. The consensus SARS-CoV-2 interactome is enriched for mRNA processing, translation, RNA surveillance and innate immune functions. Cross-viral comparison identifies 275 host proteins shared across all four RNA viruses, forming interconnected modules that include key translation factors (EEF1A1, EIF4A1, EIF3H) and RNA-binding proteins (Nucleolin, ILF3). Drug-target annotation prioritizes 21 proteins with 35 approved or investigational modulators for host-directed antiviral repurposing. Together, these findings generate a consensus map of conserved host dependencies and highlight prioritized targets for future mechanistic and translational studies. Research Highlights Integrated SARS-CoV-2 datasets and compared with, Influenza A virus, Zika virus, Dengue virus. Identified 275 host proteins shared across these four pathogens. Conserved proteins were enriched in translation, RNA processing, and innate immune pathways. Prioritized 21 host targets and 35 drugs for antiviral repurposing.},
}
@article {pmid42151636,
year = {2026},
author = {Khateb, AM},
title = {Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {},
pmid = {42151636},
issn = {2210-6014},
mesh = {Humans ; *Coinfection/microbiology/diagnosis ; *Respiratory Tract Infections/microbiology/diagnosis ; *Mycoses/diagnosis/microbiology ; Risk Factors ; },
abstract = {BACKGROUND: This review examines the increasing clinical challenge of mixed respiratory fungal infections (MRFIs), emphasizing interkingdom interactions and their impact on disease progression and patient outcomes.<br><br>MAIN BODY: We critically analyze current literature on the clinical implications, risk factors, and diagnostic complexities of MRFIs, with a primary focus on fungal-bacterial, fungal-viral, and fungal-parasitic co-infections. Fungal-bacterial co-infections, often involving Candida spp. and Pseudomonas aeruginosa, significantly worsen disease severity. Fungal-viral co-infections, particularly in COVID-19 patients with Candida albicans and Aspergillus fumigatus, represent a major threat. While rare, fungal-parasitic co-infections pose risks for immunocompromised individuals. The review highlights diagnostic difficulties due to non-specific symptoms and the vital need to distinguish colonization from true infection. It also explores the complex symbiotic, synergistic, and antagonistic relationships between fungi and other microorganisms, alongside the immune-modulating role of commensal fungi.<br><br>CONCLUSION: Ultimately, this review seeks to enhance understanding of MRFIs to improve diagnostic and therapeutic strategies and patient care.},
}
@article {pmid42151642,
year = {2026},
author = {Cirovic, A and Brankovic, N and Antelj, G and Cirovic, A},
title = {Iron Deficiency as an Important Predictor of Arterial and Venous Thrombosis, Myocarditis, and Atrial Fibrillation in COVID-19 and Influenza.},
journal = {Cardiovascular toxicology},
volume = {26},
number = {6},
pages = {},
pmid = {42151642},
issn = {1559-0259},
mesh = {Humans ; *COVID-19 ; *Myocarditis/virology/epidemiology/diagnosis ; *Influenza, Human/epidemiology/complications/diagnosis/virology ; *Atrial Fibrillation/epidemiology/diagnosis/virology/etiology ; *Thrombosis/epidemiology/diagnosis/etiology/virology ; SARS-CoV-2 ; Animals ; Risk Factors ; *Iron Deficiencies ; Pandemics ; *Anemia, Iron-Deficiency/epidemiology/diagnosis/blood ; },
abstract = {Arterial and venous thrombosis, atrial fibrillation, and viral myocarditis are potentially life-threatening conditions and well-documented complications of both COVID-19 and influenza. Therefore, clinicians should be aware of all factors that may promote their occurrence, particularly those related to common viral infections such as influenza and SARS-CoV-2. Both influenza and SARS-CoV-2 utilize transferrin receptor 1 (TfR1) to enter host cells; notably, SARS-CoV-2 has been detected in tissues that do not express ACE2. TfR1 is highly expressed on cardiomyocytes, as well as on endothelial cells. Iron deficiency -a common disorder in the general population- promotes overexpression of TfR1, thereby facilitating the entry of SARS-CoV-2 and influenza viruses into cardiomyocytes and endothelial cells. Therefore, an increased expression of the TfR1 on cardiomyocytes may consequently contribute to the development of viral myocarditis, and atrial fibrillation. Finally, TfR1 is involved in viral uptake by endothelial cells and in molecular pathways implicated in thrombus formation. Clinicians should recognize that individuals with iron deficiency and concomitant SARS-CoV-2 or influenza infection may be at increased risk of arterial and venous thrombosis, atrial fibrillation, and viral myocarditis. Given that approximately two billion people worldwide have some degree of iron deficiency-especially older adults and young children-appropriate preventive strategies should be considered.},
}
@article {pmid42151979,
year = {2026},
author = {Bergsträsser, J and Schmahl, T and Steinhäuser, J and Goetz, K},
title = {Interventions against loneliness and social isolation in older adults- a systematic review.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42151979},
issn = {1471-2458},
mesh = {Humans ; *Loneliness/psychology ; *Social Isolation/psychology ; *COVID-19/psychology ; Aged ; Pandemics ; Middle Aged ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Loneliness is a growing health and social challenge. The COVID-19 pandemic boosted feelings of loneliness for many people. To combat loneliness, a wide range of interventions have been developed and evaluated for their efficacy and effectiveness. As a result, many new interventions to alleviate loneliness have been developed, especially technological interventions. Therefore, the objective of this study was to conduct a comprehensive and up-to-date systematic review to identify interventions aimed at loneliness and social isolation among adults, 60 years and older published during or post-pandemic.<br><br>METHODS: A comprehensive literature search was conducted for studies between 2020 and 2024 across five online databases: MEDLINE via PubMed, Web of Science, Scopus, Cochrane Library, and CINAHL. Title and abstract screening, critical appraisal of the studies, and data extraction were performed by two independent reviewers. A narrative approach was adopted to assess and integrate the diverse findings from the research.<br><br>RESULTS: Ultimately, 79 studies were included in this systematic review. The results are structured based on the categorization of the interventions, which includes differentiation between analogue interventions, technological interventions and multicomponent (analogue and technological) interventions. The effectiveness of analogue interventions, particularly community-based interventions such as group meetings, social participation programs, and educational or psychological interventions, tended to be superior to that of technological interventions.<br><br>CONCLUSIONS: The combination of analogue and technological interventions in particular produced promising results regarding a decrease of loneliness. Specific interventions must be tailored to the target group and setting and regularly reevaluated. The aim now should be to implement these interventions comprehensively and monitor their effectiveness over several years. Future research should focus on differentiating the circumstances under which various forms of intervention are effective.<br><br>TRIAL REGISTRATION: PROSPERO systematic review registration: CRD42024538755.},
}
@article {pmid42152524,
year = {2026},
author = {Kim, J and Lee, H and Jang, YS},
title = {Macrophage Immune Responses in Viral Infections: Functional Plasticity and Therapeutic Targeting.},
journal = {Journal of microbiology and biotechnology},
volume = {36},
number = {},
pages = {e2602035},
pmid = {42152524},
issn = {1738-8872},
mesh = {Humans ; *Macrophages/immunology ; *Virus Diseases/immunology/therapy ; Immunity, Innate ; Animals ; Host-Directed Therapy ; COVID-19/immunology/virology/therapy ; SARS-CoV-2/immunology ; Macrophage Activation ; Antiviral Agents/therapeutic use ; Cytokines/immunology ; Cell Plasticity ; },
abstract = {Macrophages play dual roles, contributing to both protection and disease progression during viral infections. As crucial immune cells against pathogens, they activate innate immunity by releasing antiviral agents and inflammatory cytokines. At the same time, they serve as targets for infection and as carriers of viruses, thereby contributing to viral dissemination. This review emphasizes macrophage plasticity and the functional shifts it undergoes during M1/M2 polarization. It also explores mechanisms that maintain persistent viral reservoirs in chronic infections such as SARS-CoV-2 and discusses the impact of macrophage dysregulation on the immune microenvironment. Furthermore, it highlights recent advances in macrophage-targeted therapies, including reprogramming macrophages for homeostasis, eliminating pathogenic macrophages, and boosting antiviral responses.},
}
@article {pmid42153918,
year = {2026},
author = {Thain, BK},
title = {Syndemic Effects of Covid-19 Lockdown on Chemsex and HIV Among MSM in Malaysia: A Narrative Review.},
journal = {Journal of the International Association of Providers of AIDS Care},
volume = {25},
number = {},
pages = {23259582261447929},
pmid = {42153918},
issn = {2325-9582},
mesh = {Humans ; *Chemsex/psychology ; Malaysia/epidemiology ; Male ; *HIV Infections/epidemiology/psychology/transmission/diagnosis ; *Homosexuality, Male/psychology/statistics &amp; numerical data ; *COVID-19/epidemiology/psychology/prevention &amp; control ; *Substance-Related Disorders/epidemiology ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Chemsex, sexual activity under the influence of psychoactive substances, remains a major public health concern for men who have sex with men (MSM) globally. In Malaysia's conservative context, the convergence of chemsex and HIV transmission presents complex challenges. This narrative review examines how the Covid-19 pandemic and extended lockdown disrupted HIV services and intensified psychosocial stressors, amplifying chemsex, HIV, and mental health issues among Malaysian MSM.<br><br>METHODS: A systematic search of international databases (2018-2025) identified relevant studies through keyword screening of articles, abstracts, and full texts.<br><br>KEY FINDINGS: The Covid-19 lockdown exacerbated psychosocial stressors such as isolation and minority stress, altered chemsex patterns, and increased drug use. Disruption of HIV testing and treatment delayed diagnoses and potentially heightened transmission, while PrEP uptake remained low (18.3%) despite awareness.<br><br>CONCLUSION: The pandemic intensified syndemic interactions concerning chemsex, HIV, and mental health. Urgent, integrated, person-centered intervention is needed to address this multifaceted crisis.},
}
@article {pmid42154963,
year = {2026},
author = {Clarke, C and Esposito, D and Urdaneta, V and Mukherjee, P and Buttery, AK},
title = {Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2662118},
pmid = {42154963},
issn = {2164-554X},
mesh = {Humans ; *2019-nCoV Vaccine mRNA-1273/adverse effects/administration &amp; dosage ; Asia/epidemiology ; Asian People ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage ; *Immunization, Secondary/adverse effects/methods ; Observational Studies as Topic ; Product Surveillance, Postmarketing ; },
abstract = {Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data. PubMed and EMBASE were searched on June 30, 2025, for studies meeting the following predefined criteria: observational design, adverse events (AEs), mRNA-1273 boosters (dose 3+), and population data from the South-East Asia and Western-Pacific regions. Data on study characteristics, and AE incidence and severity, were extracted. Of 886 records screened, 27 studies from eight countries (Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore) met the inclusion criteria. Across studies, mRNA-1273 boosters were well tolerated, with severe AEs occurring at low frequency. Based on the included observational studies, these findings support the favorable safety profile of mRNA-1273 boosters in Asian populations. Long-term safety monitoring is needed to guide public-health responses to evolving SARS-CoV-2 variants.},
}
@article {pmid42155083,
year = {2026},
author = {Alnaeem, MM and Alshamlan, MJ},
title = {Medical Device-Related Pressure Injuries: A Systematic Review for Prevalence, Causes, and Risk Factors Since the COVID-19 Pandemic.},
journal = {Advances in skin &amp; wound care},
volume = {39},
number = {6},
pages = {E286-E294},
doi = {10.1097/ASW.0000000000000468},
pmid = {42155083},
issn = {1538-8654},
mesh = {Humans ; *Pressure Ulcer/epidemiology/etiology ; *COVID-19/epidemiology ; Risk Factors ; Prevalence ; *Equipment and Supplies/adverse effects ; Intensive Care Units ; Pandemics ; Female ; },
abstract = {OBJECTIVE: The intensive care unit (ICU) is a critical environment where patients are at risk for developing medical device-related pressure injuries (MDRPIs). This review aims to synthesize the literature and assess the prevalence, causes, and risk factors of MDRPIs, particularly in the context of the COVID-19 pandemic.<br><br>DATA SOURCES: A systematic review was conducted to guide this study. A comprehensive search strategy was used across multiple databases, including PubMed, EMBASE, Web of Science, Scopus, and CINAHL.<br><br>STUDY SELECTION: The search focused on studies published between 2019 and 2024, specifically targeting adult patients in the ICU. Studies focusing on pediatric populations, patients with mental illnesses, or those investigating ulcers unrelated to MDRPIs were excluded.<br><br>DATA EXTRACTION: After screening and selecting relevant studies, data were extracted and analyzed in numerical data.<br><br>DATA SYNTHESIS: The review included 35 studies, revealing a high prevalence of MDRPIs in ICU settings, ranging from 5.01% to 62.4% across various countries. The prevalence was related to several factors, such as patient demographics (age and comorbidities), ICU practices, and the type and duration of medical device usage. Mechanical ventilation, nasogastric tubes, and endotracheal tubes were among the most common devices associated with MDRPIs.<br><br>CONCLUSIONS: Tailored interventions, such as regular skin assessments and pressure-redistributing devices, are crucial for preventing MDRPIs and improving patient outcomes. The COVID-19 pandemic experience emphasizes the need for vigilant monitoring and evidence-based preventive measures in critical care environments.},
}
@article {pmid42156022,
year = {2026},
author = {Murai, H},
title = {[Imported Infectious Diseases of the Nervous System].},
journal = {Brain and nerve = Shinkei kenkyu no shinpo},
volume = {78},
number = {5},
pages = {432-436},
doi = {10.11477/mf.188160960780050432},
pmid = {42156022},
issn = {1881-6096},
mesh = {Humans ; Animals ; Rabies/epidemiology/transmission ; Japan/epidemiology ; Dengue/epidemiology/transmission ; Dogs ; },
abstract = {Although sanitary conditions in Japan are generally favorable, pathogens may be introduced by patients who acquire the infections overseas. Dengue fever has a high global incidence, with nearly 200 cases occurring annually in Japan. Most of these infections are acquired in Southeast Asia. As dengue fever is transmitted by mosquitoes, preventive measures against insect bites are important. The incidence of Japanese encephalitis has markedly decreased in Japan owing to widespread vaccination. This disease is mosquito-borne, and only approximately 1% of infected individuals develop symptoms. However, once symptoms appear, the mortality rate is 20-30%. A characteristic clinical feature of this condition is the presence of extrapyramidal symptoms. Rabies is a representative disease transmitted through dog bites. In Japan, its incidence has dramatically declined owing to canine vaccination and the control of stray dogs. Once rabies develops, the fulminant form accounts for 70-80% of cases. Measles is a representative disease that is transmitted between humans. It is highly contagious and requires careful monitoring. During the coronavirus disease-19 pandemic, the number of measles cases decreased. Recently, the trend has reversed, with many patients believed to have been infected in Vietnam.},
}
@article {pmid42156048,
year = {2026},
author = {Shimohata, T},
title = {[COVID-19-Associated Encephalitis and Encephalopathy: Current Status].},
journal = {Brain and nerve = Shinkei kenkyu no shinpo},
volume = {78},
number = {5},
pages = {567-572},
doi = {10.11477/mf.188160960780050567},
pmid = {42156048},
issn = {1881-6096},
mesh = {Humans ; COVID-19/complications ; *Brain Diseases/therapy/etiology ; Pandemics ; *Encephalitis, Viral/therapy ; SARS-CoV-2 ; },
abstract = {In recent years, the incidence of COVID-19-associated encephalitis and encephalopathy has decreased due to viral mutations and the acquisition of population immunity. The underlying mechanisms are now thought to involve immune-mediated pathology and cerebral microvascular injury, rather than direct viral invasion. In adults, encephalitis and encephalopathy are independent predictors of disease severity and mortality. In children, acute necrotizing encephalopathy is associated with high mortality rates and long-term neurological sequelae. Regarding treatment, correction of reversible factors and timely immunotherapy are essential, and favorable responses to high-dose corticosteroids and interleukin-6 receptor blockade have been reported.},
}
@article {pmid42156133,
year = {2026},
author = {Richter, ML and Ditmore, MH and de Vries, J},
title = {Demanding solidarity, not salvation: sex work and global health.},
journal = {BMJ global health},
volume = {11},
number = {5},
pages = {},
pmid = {42156133},
issn = {2059-7908},
support = {225230/Z/22/Z/WT_/Wellcome Trust/United Kingdom ; },
mesh = {Humans ; *Global Health ; *Human Rights ; *Sex Work ; COVID-19/epidemiology ; *International Cooperation ; },
abstract = {There is increasing attention paid to solidarity in global health, but its substance and definitions remain contested. We explore the tensions between global health institutions' historic approaches to sex work, their commitment to health and human rights and how these are connected to or disconnected from solidarity. We foreground the protracted and incomplete evolution from international health approaches to sex workers as spreaders of pathogens that should be punished, to sex work health programmes that are situated within human rights principles. Thus, substantial resources and material changes to laws, policies and programmes are required to action claims of 'standing in solidarity' with sex workers. We argue that the drastic cuts to global health funding initiated by the Trump Administration in January 2025 require careful consideration of what 'solidarity' with the most marginalised entails and bold action.},
}
@article {pmid42157493,
year = {2026},
author = {Portillo-Ledesma, S and Lee, S and Laederach, A and Schlick, T},
title = {Open questions on viral frameshifting: Exploiting the structural plasticity of the frameshifting element for therapeutic intervention.},
journal = {Biophysical journal},
volume = {},
number = {},
pages = {},
pmid = {42157493},
issn = {1542-0086},
support = {R35 GM122562/GM/NIGMS NIH HHS/United States ; },
abstract = {Programmed ribosomal frameshifting (PRF) is a specialized controlled-slippage genetic mechanism that viruses such as SARS-CoV-2 and HIV-1 use to shift the reading frame during translation. This process is used in compact viral genomes to enhance their protein repertoire, maintain a precise balance of viral proteins necessary for successful replication, and enhance survival within a host. Because this mechanism is vital to the viral life cycle and remains consistent across strains, frameshifting has emerged as a promising therapeutic target for new antiviral therapeutic strategies. However, the complexity of the frameshifting process has posed many challenges that need to be addressed so that the relationship between cellular mechanisms and viral replication can be exploited for novel therapeutics. In this review, we introduce frameshifting mechanisms, define open questions being explored by many modeling and experimental studies, and illustrate how coarse-grained graphs have been used in our lab to study frameshifting mechanisms. Specifically, we describe how conformational landscapes, mutation designs of frameshifting elements, all-atom molecular dynamics, and enhanced sampling simulations have been combined with chemical mapping and functional experiments to advance studies of three viral systems employing -1 PRF: SARS-CoV-2, HIV-1, and chikungunya.},
}
@article {pmid42158631,
year = {2026},
author = {Dai, CL and Guo, Y and Sharma, M and Chen, CC and Rodriguez, J},
title = {Evidence-based Review of Yoga Interventions for Adolescent Health and Well-being in US Schools.},
journal = {International journal of yoga},
volume = {19},
number = {1},
pages = {10-20},
pmid = {42158631},
issn = {0973-6131},
abstract = {The adolescent behavioral health crisis has intensified pressures to foster both physical health and mental well-being, particularly in the post-COVID-19. Yoga, as a holistic approach, has been integrated into existing curricula and positive behavioral interventions. This review examines the implementation and impact of yoga interventions in the U.S., with a focus on adolescent students in secondary schools, to identify effective strategies and provide recommendations to ensure the sustainable integration of yoga into school-based behavioral health initiatives. The articles were systematically searched from EBSCOhost, PubMed, and Web of Science databases. Inclusion criteria were: yoga component with physical elements, implemented in U.S. secondary schools as part of PE curricular or school interventions, and published in English in peer-reviewed journals. This review synthesizes findings from 17 studies on yoga interventions, highlighting notable benefits across physical and psychosocial outcomes. While most interventions are integrated into the school day, some alterations, including the afterschool and virtual formats, have emerged, providing insight into accessibility to school health promotion. The review suggests that ongoing research to refine intervention designs, address implementation barriers, and expand the reach of yoga interventions to racially and ethnically diverse populations is warranted. Overall, this review advocates for integrating yoga into health promotion initiatives, which provide adolescents with practical tools to enhance their well-being in the educational setting.},
}
@article {pmid42158816,
year = {2026},
author = {Zhang, W and Li, X and Ma, H and Li, Y and Xi, Y and Wang, W and Liu, Y and Han, P},
title = {The Adjunctive Role of Hyperbaric Oxygen Therapy in Microbial Infection-Related Conditions.},
journal = {International journal of medical sciences},
volume = {23},
number = {6},
pages = {2154-2165},
pmid = {42158816},
issn = {1449-1907},
mesh = {Humans ; *Hyperbaric Oxygenation/methods ; *COVID-19/therapy/immunology ; Diabetic Foot/therapy ; Mucormycosis/therapy ; SARS-CoV-2 ; Soft Tissue Infections/therapy ; Combined Modality Therapy ; *Bacterial Infections/therapy ; Diving and Hyperbaric Medicine ; },
abstract = {Hyperbaric oxygen therapy (HBOT) demonstrates expanding applications in infectious diseases through its multimodal mechanisms. As an adjunctive treatment, HBOT directly exerts antimicrobial effects through oxygen toxicity and reactive oxygen species generation, while indirectly enhances host immunity by improving neutrophil function and promoting tissue repair. Clinical evidence supports its adjunctive use in complex infections including diabetic foot wounds, necrotizing soft tissue infections, COVID-19, and mucormycosis, particularly in hypoxic wounds where conventional therapies show limited efficacy. While current studies are promising, further randomized trials are needed to standardize protocols and confirm efficacy.},
}
@article {pmid42159324,
year = {2026},
author = {Imani, D and Dashti, N and Peymani, A and Soltani, A and Hassanzadeh Makoui, M},
title = {Effect of Pentoxifylline on Inflammatory Markers in COVID-19: A Meta-Analysis of Randomized Controlled Trials.},
journal = {Viral immunology},
volume = {39},
number = {6},
pages = {223-231},
doi = {10.1177/08828245261445782},
pmid = {42159324},
issn = {1557-8976},
mesh = {Humans ; *Pentoxifylline/therapeutic use ; Interleukin-6/blood ; Randomized Controlled Trials as Topic ; C-Reactive Protein/analysis ; *COVID-19 Drug Treatment ; Biomarkers/blood ; *COVID-19/immunology/blood ; SARS-CoV-2 ; *Inflammation/drug therapy ; },
abstract = {The hyperinflammatory response in COVID-19 is a major factor contributing to morbidity. Pentoxifylline, a methylxanthine derivative, has immunomodulatory properties, but its effects on inflammatory markers in COVID-19 remain unclear. This meta-analysis aims to evaluate the efficacy of pentoxifylline supplementation on CRP and interleukin-6 (IL-6) levels in these patients. A systematic search was conducted across multiple databases for randomized controlled trials (RCTs) published up to September 2025. Four RCTs, including 178 cases and 321 controls for CRP, and two RCTs, including 70 cases and 70 controls for IL-6, were included. Two reviewers independently performed data extraction and assessed the risk of bias using the Cochrane tool. Pooled standardized mean differences (SMDs) were calculated using a random-effects model. Heterogeneity was analyzed through meta-regression, and the conclusiveness of the evidence was evaluated using Trial Sequential Analysis (TSA). Pentoxifylline did not significantly reduce C-reactive protein (CRP) levels compared to the control group (SMD = -0.89; 95% CI: -1.85 to 0.07; p = 0.07). However, substantial heterogeneity was noted across the studies (I[2] = 95.3%). Similarly, a nonsignificant trend toward reduction was observed for IL-6 (SMD = -0.22; 95% CI: -0.96 to 0.52; p = 0.55), accompanied by significant heterogeneity (I[2] = 79.1%). Given the limited number of studies included, the results are inherently fragile, and one additional trial could substantially shift the pooled estimate. Meta-regression analysis indicated that patient age and publication year did not account for the heterogeneity, although there was a nonsignificant trend suggesting that a longer treatment duration might be associated with greater CRP reduction. TSA for CRP showed that cumulative evidence suggested futility and a lack of meaningful effect, confirming a significant lack of effect. The included studies generally had a low risk of attrition and reporting bias. Current evidence does not support the use of pentoxifylline for significantly reducing CRP or IL-6 levels in COVID-19 patients. The findings regarding CRP are considered conclusive, but the limited number of studies suggests that further trials on this outcome may alter this conclusion.},
}
@article {pmid42159817,
year = {2026},
author = {Ali, S and Shafiq, M and Aziz, A and Rahman, NU and Bakky, MAH},
title = {The Prevalence of Methicillin-resistant Staphylococcus aureus in Clinical Settings of Pakistan: A Systematic Review and Meta-Analysis.},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {},
pmid = {42159817},
issn = {2210-6014},
mesh = {Humans ; *Methicillin-Resistant Staphylococcus aureus/isolation &amp; purification ; Pakistan/epidemiology ; Prevalence ; *Staphylococcal Infections/epidemiology/microbiology ; },
abstract = {BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) represents a significant and growing public health challenge in Pakistan, due to antibiotic misuse, weak infection control measures and rapid bacterial evolution. Determining the overall prevalence of MRSA in the country is crucial for informing targeted treatment protocols and effective management strategies. This study conducted a systematic review and meta-analysis to establish the pooled prevalence of MRSA in Pakistan.<br><br>METHODS: We searched electronic databases (Google Scholar, PubMed, Embase) for studies published between 2015 and 2025. The PRISMA guidelines were followed to conduct this systematic review. Meta-analyses were performed using R Studio software, applying both fixed- and random-effects models to calculate pooled prevalence. The heterogeneity was assessed using the I&#xb2; statistics. Publication bias was assessed using Begg's and Egger's tests. Most studies used cefoxitin disk diffusion to characterize MRSA, while some studies used PCR to detect the mecA gene.<br><br>RESULTS: Sixty-eight studies meeting the inclusion criteria were analyzed. The overall pooled MRSA prevalence was estimated at 50% (95% CI: 45-54%), with I&#xb2; = 98.9). Year-wise subgroup analysis revealed significant variation from 2015 to 2025, with estimates ranging from 64% (95% CI: 26-90%), with I&#xb2; = 96.68 in 2022 to a low of 34% (95% CI: 17-56%), with I&#xb2; = 99.16 in 2020, which may be due to reduced healthcare access and infection control measures implemented during the COVID-19 lockdowns. The pooled estimate among general patients and healthcare personnel was 50% (95% CI: 44-57%), with I&#xb2; = 98.5 and 44% (95% CI: 30-60%), with I&#xb2; = 95.4, respectively. The subgroup differences test (p&#x2009;=&#x2009;0.54) for population type revealed no statistically significant difference. The Begg's test (p&#x2009;=&#x2009;0.2378) and Egger's test (p&#x2009;=&#x2009;0.8893) showed no significant evidence of bias. The significant variation between the two diagnostic methods (p&#x2009;=&#x2009;0.03) showed that the observed heterogeneity may be due to diagnostic methods used across the studies.<br><br>CONCLUSION: The high pooled prevalence of MRSA in Pakistan highlights an urgent need for strengthened antimicrobial stewardship, standardized surveillance systems, and integrated infection prevention strategies.},
}
@article {pmid42160264,
year = {2026},
author = {Romoff, M and Chandekar, A and Beyer, R and Kim, MS and Baz, S and Mills, ES and Park, DY and Lee, YP and Bhatia, N and Hashmi, S and Wu, HH},
title = {Evaluating Virtual and Hybrid Mentorship in Orthopaedic Surgery: Perceived Benefits, Challenges, and Impacts in the Post-COVID Era.},
journal = {JBJS reviews},
volume = {14},
number = {5},
pages = {},
pmid = {42160264},
issn = {2329-9185},
mesh = {Humans ; COVID-19 ; *Mentors ; *Orthopedics/education ; Pandemics ; SARS-CoV-2 ; },
abstract = {» Virtual and hybrid mentorship models have transitioned from temporary coronavirus disease 2019 pandemic responses to durable, scalable components of the orthopaedic training curriculum. » Despite high trainee satisfaction, most orthopaedic virtual mentorship programs rely on short-term, self-reported metrics and lack the objective, longitudinal tracking of research productivity or career advancement seen in other specialties. » While virtual pipelines demonstrate the potential to broaden access for underrepresented groups, inconsistent collection of detailed demographic and socioeconomic data limits the assessment of their true impact on diversity. » Neurosurgery and plastic surgery provide instructive models for virtual collaboratives that successfully use standardized expectations and longitudinal outcome tracking to measure success. » To ensure these programs drive equitable change rather than just broader participation, future orthopaedic virtual mentorship programs should incorporate standardized outcome frameworks, mentor perspectives, and longitudinal, multi-institutional follow-up.},
}
@article {pmid42161577,
year = {2026},
author = {O'Donovan, CJ and Ramanan, AV},
title = {Infection, inflammation and immune dysregulation: evolving perspectives on the host response.},
journal = {Archives of disease in childhood},
volume = {},
number = {},
pages = {},
doi = {10.1136/archdischild-2025-330158},
pmid = {42161577},
issn = {1468-2044},
abstract = {Host inflammatory responses contribute substantially to infection-related morbidity, and in severe cases such as sepsis, acute respiratory distress syndrome (ARDS) and haemophagocytic lymphohistiocytosis, immune-mediated tissue injury may exceed the direct effects of pathogens themselves. Although traditional wisdom has considered immunosuppression risky when antimicrobial therapy is required, modern insights into immune biology reveal a more nuanced landscape in which targeted immunomodulators can attenuate harmful inflammation without broadly compromising host defence. This evolution is particularly relevant in paediatrics, influenced by developmental stage, distinct exposure history and patterns of host response. The COVID-19 pandemic catalysed wider acceptance of immunomodulation in infection management, including corticosteroids in children and highlighted safe use of agents such as baricitinib. Platform trials of the hyperinflammatory syndrome (paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2) also identified benefits of methylprednisolone and tocilizumab in select groups. For other paediatric infections, including dengue, influenza and Epstein-Barr virus, the evidence remains sparse, with emerging mechanistic and early-phase clinical studies exploring interleukin (IL)-1 blockade, corticosteroids, immunoglobulin and anticytokine biologics. In paediatric sepsis, immunophenotype-guided trials represent a major conceptual advance. Adaptive studies, such as TRIPS and GRACE-2, aim to tailor immunomodulation to hyperinflammation or immunoparalysis, though definitive efficacy data are awaited. Parallel efforts in ARDS explore statins, IL-6 blockade and cell-based therapies, but robust paediatric evidence is still lacking. Collectively, evolving insights and trial designs offer renewed opportunities to use targeted immunomodulation in the management of paediatric infection. Large-scale, collaborative paediatric research networks will be essential to translate these advances and better integrate infection research into everyday paediatric practice.},
}
@article {pmid42162612,
year = {2026},
author = {Stiefel, P and Muñoz-García, J and Pino-Mejías, R},
title = {Blood pressure variability: a still underestimated topic.},
journal = {Revista clinica espanola},
volume = {226},
number = {7},
pages = {502580},
doi = {10.1016/j.rceng.2026.502580},
pmid = {42162612},
issn = {2254-8874},
mesh = {Humans ; *Blood Pressure/physiology ; Blood Pressure Monitoring, Ambulatory/methods ; *Hypertension/physiopathology/diagnosis ; *Blood Pressure Determination/methods ; COVID-19/physiopathology ; Pregnancy ; },
abstract = {The importance of blood pressure variability has grown exponentially over the past two to three years. In this review, we aim to discuss the reasons underlying this increasing interest. First, we describe the different methods used to assess blood pressure variability, including very short-term (beat-to-beat), short-term (24-h ambulatory blood pressure monitoring), mid-term (home self-measurements), and long-term (visit-to-visit measurements), as well as the mathematical indices used to quantify it. We then address the clinical relevance of blood pressure variability. First, increased variability is more prevalent in several health conditions not necessarily related to vascular disease, such as mental illness, severity of COVID-19 infection, bone fractures, and various forms of cognitive impairment. Second, blood pressure variability appears to be involved in the progression from prehypertensive states to established hypertension and, once hypertension is present, in the development of target organ damage. It has also been associated with an increased risk of gestational hypertension, preeclampsia, and adverse neonatal outcomes. Furthermore, blood pressure variability, even independently of mean arterial blood pressure, influences the development, prognosis, and complications of coronary and cerebrovascular disease. Finally, we discuss evidence suggesting that blood pressure variability is associated with both vascular and all-cause mortality.},
}
@article {pmid42163819,
year = {2026},
author = {McDonnell, R and Chauhan, A and Adams, C and Cardenas, A and Moscova, M and Walsan, R and Sina, M and Munro, A and Manias, E and Mitchell, R and Gust, A and Sabesan, S and Harrison, R},
title = {Applying Change Models and Methods During a Period of Vast Digital Transformation: A Systematic Review of Practice in Healthcare.},
journal = {The International journal of health planning and management},
volume = {},
number = {},
pages = {},
doi = {10.1002/hpm.70092},
pmid = {42163819},
issn = {1099-1751},
support = {//National Health and Medical Research Council/ ; //Western Sydney Local Health District/ ; //University of New South Wales/ ; //Western Health Foundation/ ; //Townsville Hospital and Health Service/ ; //Monash University/ ; },
abstract = {INTRODUCTION: Reflection and learning about the use of virtual care in healthcare delivery has become a central goal for health systems internationally. Insights drawn in the aftermath of the COVID-19 pandemic have led to vast changes to embed virtual care in health care delivery. This study explored the methodologies used to manage change that encompasses virtual care and factors contributing to success.<br><br>METHODS: A systematic review and narrative synthesis was undertaken. Eligible articles were those reporting structured change management processes in the context of virtual care published between 1st January 2019-31st December 2023, identified by searching four electronic databases (Scopus, MedLine, PsycInfo and Business Source Premier). Data were extracted and synthesised from the eligible studies.<br><br>RESULTS: Seventeen studies met inclusion criteria describing changes occurring within hospital settings or in community health centres. Kotter's 8-Step Model was the most frequently applied change framework, often combined with other approaches. Commonly enablers included high quality communication among all parties involved and strong leadership. Common barriers included overemphasis on technology at the expense of people and processes, linear application of models, and lack of mechanisms to monitor change progress.<br><br>DISCUSSION: Structured change methodologies were often integrated in a strategic change framework with process improvement methods utilised to support the change process. Managing change relating to the technology with attention to the clinical and people aspects of change was considered a key gap and challenge in the context of virtual care change. Change leadership and the integration of technical and clinical teams were identified as key enablers.},
}
@article {pmid42163826,
year = {2026},
author = {Guan, Z and Li, X and Zhu, X},
title = {Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.},
journal = {Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis},
volume = {32},
number = {},
pages = {10760296261454788},
pmid = {42163826},
issn = {1938-2723},
mesh = {Humans ; *Venous Thromboembolism/etiology/drug therapy ; *Neoplasms/complications ; *Anticoagulants/therapeutic use/adverse effects ; Female ; Risk Factors ; },
abstract = {Cancer -associated thrombosis (CAT), particularly venous thromboembolism (VTE), is a major contributor to mortality in cancer patients and is widely recognized as a leading cause of death after the direct effects of cancer progression. Cancer patients have significantly higher VTE risk than the general population, due to hypercoagulable states and anticancer therapies, with those with advanced malignancies carrying the highest risk. Primary thromboprophylaxis and anticoagulation are pivotal for CAT management. Despite advances, key challenges include different thrombotic and bleeding risks across cancers and how recurrent VTE affects anticoagulation duration. Low-molecular-weight heparin (LMWH) has largely replaced warfarin, and direct oral anticoagulants (DOACs) are challenging LMWH's first-line role with proven efficacy. However, the key dilemma is balancing thromboprophylaxis and treatment against anticoagulant-induced bleeding, particularly in the context of recurrent VTE. Current CAT guidelines show discrepancies and gaps in clinical coverage; some conclusions derived from meta-analyses need validation via more randomized controlled trials. This review synthesizes recent CAT research (focused on VTE) across epidemiology, pathophysiology, laboratory assessments, and management. It analyzes how cancer type, patient conditions, and drug-drug interactions influence anticoagulant selection, supported by a review of the corresponding experimental evidence. Additionally, the article addresses key clinical scenarios (e.g., intracerebral hemorrhage, pregnancy, pediatric and adolescent patients, and COVID-19) to aid clinical decision-making, delineates unresolved clinical controversies, and integrates high-quality cohort/subgroup data to guide meta-analysis validation. By summarizing risk-benefit consideration, this article provides a framework for complex cases and informs future RCT design.},
}
@article {pmid42163969,
year = {2026},
author = {Hendriks, S and Grady, C and Fitzgerald, ML and Gross, RS and Maughan, C and Peluso, MJ and Varma, S and Nath, A and Rid, A},
title = {The next phase in Long COVID research: addressing the ethical challenges in trials of disease-modifying treatments.},
journal = {EClinicalMedicine},
volume = {95},
number = {},
pages = {103918},
pmid = {42163969},
issn = {2589-5370},
abstract = {Almost five years after COVID-19 emerged, multiple scientific uncertainties remain about why some people experience ongoing symptoms long after being infected with SARS-CoV-2 (Long COVID). The pathophysiology underlying Long COVID and its potential to represent several endotypes are still under investigation. These scientific uncertainties around Long COVID have been cited as a reason to delay treatment trials until the disease is better understood. In this paper, a group of bioethicists, clinician-scientists and people with lived experience with Long COVID argue that it is ethically imperative to conduct trials of disease-modifying treatments for Long COVID now. Furthermore, we argue that although conducting such trials can pose ethical challenges, these challenges can be overcome through careful research priority-setting, rigorous trial design, fair participant selection, and ensuring that the risk-benefit profile is favorable.},
}
@article {pmid42164546,
year = {2026},
author = {Petrovan, A and Puiu, L and Pop, CM},
title = {COVID-19, the disease that changed the world.},
journal = {Medicine and pharmacy reports},
volume = {99},
number = {2},
pages = {91-105},
pmid = {42164546},
issn = {2668-0572},
abstract = {Five years ago, the COVID-19 coronavirus emerged as an invisible threat that profoundly disrupted the world, becoming a public health challenge. The COVID-19 pandemic has shown us how important it is to have health systems that can quickly find and track new viruses as they spread and has ushered in a new era of genomic surveillance, allowing scientists to track the evolution of the coronavirus, providing public health strategies. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been associated with very important global morbidity and mortality. The discovery of SARS-CoV-2 in bats and pangolins in South Asian countries indicates that SARS-CoV-2 likely originated from wildlife being the third highly pathogenic human coronavirus. The increased contagiousness of SARS-CoV-2 virus was due to the spike glycoprotein (S) that favors the attachment of the virus to the cell surface. SARS-CoV-2 infection triggers a damaging triad of oxidative stress, intense inflammation with cytokine storm, and endothelial dysfunction, leading to widespread cellular damage, blood clotting with thrombosis, and organ failure by overwhelming the body's antioxidant defenses, damaging blood vessel linings, and promoting hyperinflammation, all crucial factors in severe COVID disease. The purpose of the review is to make a synthesis of the data known so far about SARS-CoV-2 virus etiology, the complex interactions between the virus and the host, imbalanced immune response and cytokine storm, molecular mechanisms by which the spike protein drives endothelial dysfunction and, multisystemic pulmonary, cardiovascular, neurological, renal involvement.},
}
@article {pmid42164657,
year = {2026},
author = {Li, K and Cao, R and Li, M and Tian, Z and Fan, H and Hong, B and Liu, X},
title = {Organoids: From Bench to Bedside Applications.},
journal = {MedComm},
volume = {7},
number = {6},
pages = {e70768},
pmid = {42164657},
issn = {2688-2663},
abstract = {Organoids are three-dimensiona(3D) models derived from stem cells that closely replicate the structure and cellular complexity of human tissues, providing physiologically relevant platforms for biomedical research. This technology addresses the limitations of two-dimensional (2D) cultures, reduces species-specific discrepancies, and is particularly valuable for investigating virus-host interactions and pathogenic mechanisms under near-physiological conditions. This review systematically outlines key advancements in organoid-based virology, including the propagation of hard-to-culture pathogens such as human rhinovirus C (HRV-C) and norovirus (NoV), as well as novel insights into viral pathogenesis, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Zika virus (ZIKV) infection, and the translational utility of organoids for antiviral drug screening and preclinical assessment. It further examines the use of organoids in modeling cancer and neurological diseases, compares the strengths and limitations of different cellular sources, and discusses their potential integration with emerging technologies such as CRISPR gene editing and 3D bioprinting. In addition, it maps a translational pathway from molecular mechanisms to clinical practice to facilitate the study of disease mechanisms and accelerate drug and vaccine development. Finally, holistic strategies are proposed to address existing challenges, such as the lack of immune components and inadequate vascularization. Together, these efforts aim to promote the broader adoption of organoid technology across the life sciences and translational medicine.},
}
@article {pmid42165098,
year = {2026},
author = {Li, S and Qiu, L and Li, Y and Liu, X and Luo, Z and Liu, J and Ma, X},
title = {Global prevalence of prolonged grief disorder during the COVID-19 pandemic under standardized diagnostic frameworks: A systematic review and meta-analysis.},
journal = {Psychological medicine},
volume = {56},
number = {},
pages = {e160},
pmid = {42165098},
issn = {1469-8978},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; Prevalence ; *Prolonged Grief Disorder/epidemiology/diagnosis ; Pandemics ; Global Health ; },
abstract = {Prolonged grief disorder (PGD), recently classified in ICD-11 and DSM-5-TR, is characterized by persistent and functionally impairing grief lasting beyond 6-12 months. The COVID-19 pandemic was accompanied by widespread mortality, social isolation, disrupted mourning rituals, and social disconnection, raising concerns about a potentially high burden of PGD during the pandemic period. We conducted a systematic review and meta-analysis, following PRISMA guidelines and PROSPERO registration (CRD42023463720), to estimate PGD prevalence under standardized ICD-11 and DSM-5-TR diagnostic frameworks and to examine potential moderators during the COVID-19 pandemic. PubMed, EMBASE, and the Cochrane Library were searched from inception to October 2024. Eligible studies included adults who experienced bereavement during the pandemic and were assessed using validated PGD instruments (PG-13-R, ICG, BGQ). Random-effects models were applied to pool prevalence estimates, with subgroup and meta-regression analyses. Thirteen studies comprising 5,766 participants were included. The pooled prevalence of PGD during the pandemic period was 24% (95% CI: 13%-36%), with the highest estimates observed in China (43%, 95% CI: 33%-54%). In the overall pooled analysis, studies applying DSM-5-TR criteria yielded lower prevalence estimates than those using ICD-11 criteria (18% vs.26%, p = 0.41). Digital interventions showed no statistically significant pooled effects (Hedges' g = -0.38, 95% CI: -0.90 to 0.14). The high and geographically heterogeneous prevalence of PGD observed during the COVID-19 pandemic underscores the need to strengthen mental health surveillance, standardized assessment, and service accessibility in large-scale public health emergencies, and provides important evidence to inform population-level interventions and resource allocation strategies.},
}
@article {pmid42165724,
year = {2026},
author = {Dhar, RR and Reshmi, B and Holla, R},
title = {Barriers to help-seeking for cancer in India: A scoping review.},
journal = {The Indian journal of medical research},
volume = {163},
number = {4},
pages = {534-540},
pmid = {42165724},
issn = {0971-5916},
mesh = {Humans ; India/epidemiology ; *Neoplasms/epidemiology/therapy/diagnosis/psychology ; *Health Services Accessibility ; *Patient Acceptance of Health Care ; *Help-Seeking Behavior ; },
abstract = {Background and objectives Cancer is a leading cause of death in India, with delays in diagnosis and treatment contributing to poor outcomes. Although several studies document these delays, most focus on single cancer types or specific regions. This review aimed to synthesise evidence across cancers to identify barriers to help-seeking and their implications for cancer control in India. Methods A scoping review was conducted using Arksey and O'Malley and Levac frameworks, guided by the PRISMA-ScR checklist. The protocol was registered on the Open Science Framework. Systematic searches were carried out in PubMed, EMBASE, and Scopus for studies published in English between January 2010 and December 2024. Eligible studies included empirical research on barriers to help-seeking among individuals with cancer in India. Titles and abstracts were screened using Rayyan, followed by full-text review. Data were charted and synthesised thematically. Results Of 349 records screened, 30 studies met the inclusion criteria. Barriers were categorised as: financial and economic, lack of awareness/knowledge, cultural stigma and embarrassment, reliance on alternative medicine, systemic and health system inefficiencies, psychological fear and distrust, family and gender bias, and COVID-19-related disruptions. These factors collectively led to delays in presentation, diagnosis, and treatment of cancer in India. Interpretation and conclusions Delays in cancer care in India arise from intersecting socio-economic, cultural, systemic, and gendered barriers. Strengthening insurance coverage, patient navigation, awareness initiatives, gender-sensitive services, and long-term investments in rural infrastructure and psychosocial support are critical to improving timely cancer care.},
}
@article {pmid42166076,
year = {2026},
author = {Haimi, M},
title = {Addressing the silent epidemic: a narrative review and evidence synthesis of digital health and telehealth interventions for loneliness in older adults.},
journal = {Aging clinical and experimental research},
volume = {38},
number = {1},
pages = {},
pmid = {42166076},
issn = {1720-8319},
mesh = {Humans ; *Loneliness/psychology ; Digital Health ; *Telemedicine ; *COVID-19/epidemiology/psychology ; Social Isolation/psychology ; Aged ; SARS-CoV-2 ; Depression ; },
abstract = {BACKGROUND: Loneliness and social isolation represent major threats to the health and well-being of older adults, conferring elevated risks for depression, cognitive decline, cardiovascular disease, and premature mortality. The rapid proliferation of digital health technologies and telehealth services-accelerated by the COVID-19 pandemic-has opened new pathways for addressing these challenges at scale.<br><br>OBJECTIVE: This narrative review synthesizes the current evidence on the effectiveness of digital health and telehealth interventions in reducing loneliness and social isolation among older adults, examines the diverse modalities employed, identifies barriers to equitable adoption, and proposes directions for future research.<br><br>METHODS: A narrative synthesis was conducted drawing on systematic reviews, meta-analyses, randomized controlled trials, and observational studies identified through PubMed, PsycINFO, CINAHL, Cochrane Library, and Web of Science, primarily spanning 2020-2025. Interventions examined include telehealth video visits, empathy-focused telephone programs, group videoconferencing, digital mental health platforms, mobile health applications, social robots, and AI-enabled companions.<br><br>RESULTS: Telehealth video visits, empathy-focused telephone programs, and group-based videoconferencing demonstrate meaningful reductions in loneliness, depression, and anxiety in several RCTs and pilot studies. Digital mental health platforms incorporating cognitive behavioral therapy and mindfulness show promise, as do AI-enabled social robots in institutional and community settings. However, meta-analytic evidence reveals considerable heterogeneity: some pooled analyses report modest to null overall effects, while others find medium effect sizes (d = -&#x2009;0.47). Intervention effectiveness appears contingent on design features, population characteristics, training support, and integration with existing social networks. The digital divide-limited digital literacy, technology access, usability challenges, and preference for in-person care-remains a challenging barrier to equitable implementation.<br><br>CONCLUSIONS: Digital health and telehealth interventions hold considerable promise for mitigating loneliness among older adults. However, their benefits cannot be realized without systematically addressing the digital divide. Large-scale, well-powered RCTs with standardized outcome measures and longer follow-up periods are urgently needed, alongside implementation science research to translate evidence into scalable practice.},
}
@article {pmid42166945,
year = {2026},
author = {Duy, NBP},
title = {What are the intellectual foundations and thematic structures shaping flow experience research in tourism?.},
journal = {Acta psychologica},
volume = {267},
number = {},
pages = {107104},
doi = {10.1016/j.actpsy.2026.107104},
pmid = {42166945},
issn = {1873-6297},
mesh = {Humans ; *Tourism ; *Virtual Reality ; *COVID-19 ; },
abstract = {This study addresses the fragmented state of research on flow experience in the tourism sector, an increasingly important concept in the modern experience economy. The main objective was to systematize and map the intellectual structure, development, and future trajectory of this field. Applying a hybrid bibliometric-systematic literature review method, the paper analyzed 118 articles from the Scopus database (2011-2025) using VOSviewer and Bibliometrix. The study's conclusions were further reinforced and validated through a comparative analysis with data extracted from the Web of Science database. Key findings revealed two distinct research phases, with a significant boom after 2020 driven by the impact of the COVID-19 pandemic and the rise of virtual reality (VR) tourism. Thematic analysis revealed a clear knowledge structure, with basic themes serving as the theoretical basis, while motor themes (authenticity and tourism live streaming) drove the current research. This landscape was divided into a psychological core, focused on exploring the nature of the experience, and a managerial core, centered on applying the flow experience for strategic goals. This study contributes a new conceptual framework that organizes the research field into antecedents, flow state, and outcomes, while also providing practical guidance for managers to design engaging experiences.},
}
@article {pmid42167127,
year = {2026},
author = {Boamah, SA and Sedzro, MT and Alexander, A and Ramirez, K and Shams, S and Rugole, D and Zhou, F and Belita, E},
title = {Harnessing leadership experiences for improved healthcare delivery: A scoping review of the experiences of healthcare leaders in navigating crisis.},
journal = {International journal of nursing studies},
volume = {181},
number = {},
pages = {105577},
doi = {10.1016/j.ijnurstu.2026.105577},
pmid = {42167127},
issn = {1873-491X},
mesh = {*Leadership ; Humans ; *COVID-19/epidemiology ; *Delivery of Health Care/organization &amp; administration ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: The COVID-19 pandemic placed unprecedented strain on health care systems worldwide, exposing and amplifying longstanding vulnerabilities in leadership and management structures. Although the roles of frontline healthcare workers have been widely documented, the experiences of healthcare leaders remain understudied.<br><br>OBJECTIVE: To systematically synthesize global evidence on healthcare leaders' experiences in navigating crises, with a particular focus on the pandemic; and to derive actionable strategies to strengthen crisis preparedness, response capacity, and health system resilience.<br><br>DESIGN: A scoping review was conducted following Arksey and O'Malley's framework. The reporting of the review adhered to the recommendations outlined in the PRISMA-ScR checklist.<br><br>METHODS: Peer-reviewed articles published in English from 2020 to 2026 that reported on the experiences of healthcare leaders were included. Gray literature, review articles, and studies that did not explicitly focus on managerial experiences were excluded. Databases including EMBASE, Emcare, CINAHL, MEDLINE (Ovid), PsycINFO, Scopus and Web of Science were searched. A total of 20,107 records were identified, of which 10,203 were screened after deduplication. After full-text review, 277 articles were extracted for analysis. Data extraction followed a structured approach, capturing study characteristics, healthcare settings, and key findings. Thematic analysis was conducted using Delve software, with systematic coding applied to ensure analytical rigor.<br><br>RESULTS: Three interrelated themes with 16 sub-themes emerged: (1) navigating leadership challenges during crisis, (2) leadership strategies and adaptive responses, and (3) implications for future crisis leadership and resilient health systems. The findings illuminate how adaptive leadership, judicious resource allocation, transparent communication, digital transformation, and attention to workforce mental health function as critical mechanisms for navigating complex health crises.<br><br>CONCLUSIONS: This study demonstrates that effective healthcare crisis leadership extends beyond operational competence to require adaptability, clear communication, and sustained commitment to workforce well-being. Strengthening leadership capacity, investing in interoperable digital infrastructure, and embedding mental health supports within crisis preparedness frameworks will be critical to enhancing health system responsiveness and sustaining resilient care delivery during future global disruptions.<br><br>SOCIAL MEDIA ABSTRACT: Healthcare leaders showed great adaptability during COVID-19, but lasting system resilience requires more than individual effort. It demands investment in equitable, well-resourced systems, ethical leadership, integrated digital infrastructure, and cultures that support leader and staff well-being. [A scoping review | @SABoamah].},
}
@article {pmid42167688,
year = {2026},
author = {Valenzuela-Fuenzalida, JJ and Valarezo, LM and Silva, V and Delgado, F and Nazar-Izquierdo, D and Bruna-Mejias, A and Nova-Baeza, P and Donoso, MO and Amaro, GO and Cifuentes-Suazo, G and Moya, MP and Gimeno, JS and Konschake, M and Loaiza-Giraldo, JP},
title = {Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.},
journal = {Virus research},
volume = {369},
number = {},
pages = {199748},
pmid = {42167688},
issn = {1872-7492},
mesh = {Humans ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage ; *Myocarditis/epidemiology/etiology ; SARS-CoV-2/immunology ; Vaccination/adverse effects ; },
abstract = {BACKGROUND: Myocarditis has emerged as a rare but clinically relevant adverse event reported after COVID-19 vaccination, particularly following widespread use of vaccines based on novel molecular platforms. Given variability in vaccine technologies, population characteristics, and surveillance methodologies, a comprehensive quantitative synthesis is required to better characterize the occurrence of post-vaccination myocarditis. This study aimed to characterize the distribution of reported myocarditis cases among individuals receiving COVID-19 vaccines, including mRNA, viral vector, and protein-subunit platforms, and to synthesize available evidence on reported post-vaccination myocarditis across different demographic and geographic subgroups.<br><br>METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD420251118332). MEDLINE, Web of Science, Scopus, CINAHL, Google Scholar, and LILACS were searched from inception to January 2024 for observational studies reporting myocarditis following COVID-19 vaccination. Cohort, case-control, cross-sectional studies, and case series were eligible. Study quality was assessed using the ROBINS-I tool. Random-effects models were applied to estimate pooled proportions with 95% confidence intervals (CIs). Statistical heterogeneity was quantified using the I&#xb2; statistic, and prespecified subgroup analyses were performed by sex, age, geographic region, and vaccine platform. Publication bias was explored using funnel plot analysis.<br><br>RESULTS: Fifty-nine studies comprising 196,478,861 vaccinated individuals and 13,348 reported myocarditis cases were included. Due to substantial heterogeneity in study designs and denominators, pooled estimates represent the proportion of myocarditis cases within reported samples rather than population-level incidence or risk. Across all included studies, the pooled proportion of myocarditis cases within reported study samples was 34% (95% CI: 19-50%), with considerable heterogeneity (I&#xb2; = 100%). These estimates should not be interpreted as population-level incidence or risk. Reported myocarditis cases were more frequently observed among males (72%, 95% CI: 58-86%) than females (56%, 95% CI: 35-77%) and were predominantly identified in individuals younger than 40 years. Subgroup analyses by region and vaccine platform should be interpreted cautiously due to methodological variability and potential selection bias. Funnel plot asymmetry suggested possible small-study effects.<br><br>CONCLUSIONS: This systematic review and meta-analysis aimed to characterize the distribution of reported myocarditis cases following COVID-19 vaccination rather than to estimate population-level incidence or risk. Although pooled proportions within reported samples were substantial, these estimates do not reflect population-level incidence. Available evidence suggests that myocarditis following COVID-19 vaccination remains uncommon at the population level, predominantly affecting younger males and more commonly reported after mRNA-based vaccines. Most reported cases appear to follow a benign and self-limited clinical course. These findings support the overall favorable benefit-risk profile of COVID-19 vaccines while underscoring the need for continued pharmacovigilance and more robust epidemiological studies to better characterize the epidemiology of vaccine-associated myocarditis.},
}
@article {pmid42168400,
year = {2026},
author = {Si, Y and Zhu, X and Zhang, Y and Zhou, Z and Liu, Y and Ma, H},
title = {PANoptosis as a Therapeutic Target for COVID-19.},
journal = {Current microbiology},
volume = {83},
number = {7},
pages = {},
pmid = {42168400},
issn = {1432-0991},
support = {No.2023-CX-TD-66//the Innovation Capability Support Program of Shaanxi/ ; 82202367//the National Natural Science Foundation of China/ ; },
mesh = {Humans ; *COVID-19/immunology/virology/pathology ; *SARS-CoV-2/drug effects/physiology ; *Apoptosis/drug effects ; Pyroptosis/drug effects ; *Necroptosis/drug effects ; Cytokine Release Syndrome/immunology ; *COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use/pharmacology ; Post-Acute COVID-19 Syndrome ; Animals ; },
abstract = {Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has sparked a global pandemic with extensive spread, posing a severe threat to public health due to its high mortality rate in severe cases. The continuous emergence of variants with enhanced immune evasion capabilities, coupled with the prolonged and debilitating symptoms of Long Coronavirus Disease (Long COVID) such as intermittent dyspnea, persistent fatigue, and cognitive impairment (brain fog), has become a major global concern. The pathogenesis of COVID-19 is a complex interplay of direct viral cytotoxicity and an overwhelming secondary inflammatory response in the host, with the latter being a key driver of immune homeostasis disruption. Accumulating evidence indicates that PANoptosis, an integrated programmed cell death process involving the crosstalk and coordinated activation of apoptosis, pyroptosis, and necroptosis, is closely linked to the cytokine storm syndrome triggered by SARS-CoV-2 infection. As a critical mediator of various infectious diseases, PANoptosis plays a pivotal role in regulating the balance between viral clearance and pathological inflammation. This review specifically targets SARS-CoV-2, adopting a "basic mechanism-molecular regulation-therapeutic target-clinical translation" framework. We elaborate on SARS-CoV-2-induced PANoptosis mechanisms, including its constituent cell death pathways and contributions to cytokine storms. By dissecting the intricate regulatory networks between PANoptosis and interferon (IFN) signaling during viral infection, this work aims to identify potential therapeutic targets and provide novel insights for the development of effective strategies to mitigate severe COVID-19 and its long-term sequelae.},
}
@article {pmid42168956,
year = {2026},
author = {Ottiger, M and Poppele, I and Seefen Soliman, AS and Schlesinger, T and Müller, K},
title = {Factors influencing work ability and return-to-work in individuals affected by post-COVID: a systematic review.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42168956},
issn = {1471-2458},
mesh = {Humans ; *Return to Work/statistics &amp; numerical data ; *COVID-19/psychology ; Post-Acute COVID-19 Syndrome ; Working Conditions ; Work Capacity Evaluation ; },
abstract = {BACKGROUND: Post-COVID is associated with prolonged impairments in work ability and return-to-work (RTW). The heterogeneity and complexity of post-COVID symptoms present major obstacles to a sustainable RTW. This systematic review aims to identify facilitators and obstacles affecting work ability and RTW.<br><br>METHODS: Eligible studies examined factors affecting work ability or RTW in post-COVID patients. Systematic search of literature was performed up to March 2025 using MEDLINE, CENTRAL, PsycINFO, Scopus, and Web of Science. Study selection followed the Preferred Reporting Items for Systematic Review and Meta-analysis Statement. Risk of bias was evaluated with the "Joanna Briggs Institute Critical Appraisal Tools".<br><br>RESULTS: 31 studies published between 2021 and 2025 were included in the analysis. Most originated from Europe and North America with sample sizes reaching from small qualitative studies to large registry-based cohort studies. The identified factors (N&#x2009;=&#x2009;59; facilitators: n&#x2009;=&#x2009;25, obstacles: n&#x2009;=&#x2009;34) could be grouped into four domains: Disease-related factors associated with SARS-CoV-2 infection (n&#x2009;=&#x2009;8), Individual biopsychosocial factors (n&#x2009;=&#x2009;35), Contextual workplace factors (n&#x2009;=&#x2009;10), Healthcare system and service-related factors (n&#x2009;=&#x2009;6). The most frequently reported obstacles were fatigue and neurocognitive impairments, stigmatization, lack of managerial support, and rigid RTW policies. Adequate workplace adjustments, interprofessional therapeutic interventions, and self-management strategies facilitate work ability and RTW.<br><br>CONCLUSIONS: Work ability and RTW with post-COVID is determined by complex multilevel interactions of biopsychosocial, workplace-related, and systemic factors. Findings suggest that coordinated care and workplace adaptations may help to bridge the gap between medical recovery and occupational participation. Future research should aim to better understand how multiple factors interact in individual cases to develop targeted, evidence-based interventions and policy frameworks.<br><br>PROSPERO REGISTRATION NUMBER: CRD420251010826.},
}
@article {pmid42168998,
year = {2026},
author = {Meshref, M and Hussein, AS and Allam, SA and Moghib, K and Younis, H and Shalaby, N},
title = {Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications.},
journal = {Virology journal},
volume = {23},
number = {1},
pages = {},
pmid = {42168998},
issn = {1743-422X},
mesh = {Humans ; *Multiple Sclerosis/virology/immunology/therapy/etiology ; *Virus Diseases/complications/virology/immunology ; Animals ; Herpesviridae/pathogenicity ; },
abstract = {Multiple sclerosis (MS) is a neurological inflammatory disease with a complex etiology involving the dysregulated immune system, chronic inflammation, and genetic susceptibility. Although the precise cause of MS is unknown, previous studies have found a strong link between MS and certain viral infections, leading researchers to speculate that viruses may play a role in MS pathogenesis by acting as environmental triggers. We present a comprehensive review of viral associations with MS, focusing on viruses with strong evidence for involvement in disease development, including members of the Herpesviridae family-such as Epstein-Barr virus, human herpesvirus 6, varicella-zoster virus, herpes simplex virus 1, cytomegalovirus, and SARS-CoV-2. Those viruses appear to modulate the neuro-immunological system in genetically susceptible individuals, leading to immune-mediated demyelination. Viral exposure is thought to represent an early initiating or permissive event that triggers downstream immune dysregulation, ultimately leading to MS onset in predisposed hosts. Additionally, they can cause latent infections with episodes of reactivation, which might be associated with relapsing presentation of MS. Several theories have been proposed to explain the viral etiology of MS, including molecular mimicry, virus-induced inflammatory response, autoreactive T- and B-cell activation, and increased susceptibility to antigenic exposure. Besides addressing the current knowledge gap, we also highlight future research directions for effective MS management, including developing experimental models and conducting clinical trials, identifying specific biomarkers, and investigating novel antiviral agents. An improved understanding of MS etiology and the role of viruses in its physiopathology may enable more targeted interventions and better treatment outcomes.},
}
@article {pmid42169206,
year = {2026},
author = {Ropeter, J and Overhageböck, N and Dreier, M and Meyerdierks, D and Imran, A and Heinsohn, T and Steinmann, M and Kuhlmann, A and Jahn, B and Lange, B and Klett-Tammen, CJ and Harries, M},
title = {Impact of the COVID-19 pandemic on diagnosis, and healthcare utilization, among patients with cancer (lung, breast, and pancreas) and cardiovascular diseases (HF, AF, hypertensive, and chronic ischemic heart disease) in Germany: two systematic reviews.},
journal = {Systematic reviews},
volume = {15},
number = {1},
pages = {},
pmid = {42169206},
issn = {2046-4053},
support = {031L0299H//Bundesministerium f&#xfc;r Forschung, Technologie und Raumfahrt/ ; },
mesh = {Female ; Humans ; *Cardiovascular Diseases/diagnosis/therapy/epidemiology ; *COVID-19/epidemiology ; Germany/epidemiology ; Hospitalization/statistics &amp; numerical data ; *Neoplasms/diagnosis/therapy/epidemiology ; Pandemics ; *Patient Acceptance of Health Care/statistics &amp; numerical data ; },
abstract = {BACKGROUND: The COVID-19 pandemic and related non-pharmaceutical interventions (NPIs) (e.g., lockdowns and contact restrictions) disrupted routine healthcare delivery. In Germany, these measures affected diagnostic and treatment services for people with cancer and cardiovascular diseases, potentially delaying diagnosis and adversely influencing outcomes. We assessed whether and to what extent diagnosis, health utilization and health outcome among patients with selected cancer and cardiovascular conditions changed in Germany during the pandemic.<br><br>METHODS: We conducted two systematic reviews of studies from Germany on selected cancers (breast, lung and pancreatic) and cardiovascular conditions (atrial fibrillation/flutter, heart failure, hypertensive and chronic ischemic heart disease). Protocols were registered in PROSPERO and the reviews were reported in accordance with PRISMA. We searched PubMed, Web of Science, Cochrane Library, Scopus, and Embase and screened grey literature. Outcomes included changes in new diagnoses, healthcare utilization, treatment, and disease-specific mortality during the pandemic (2020-2023) compared with the pre-pandemic period (2018-2019). Two reviewers independently screened records, extracted data, and assessed risk of bias using an adapted ROBINS-E tool. Owing to heterogeneity, we synthesized findings narratively.<br><br>RESULTS: We screened 1991 records for cancer and 4,981 records for cardiovascular diseases, and included 9 cancer studies and 10 cardiovascular studies. For cancer, several studies reported a relative reduction in new breast and lung cancer diagnoses of up to 25% during lockdown periods; hospital admissions decreased by up to 9%. For cardiovascular conditions, hospital admissions for atrial fibrillation/flutter and heart failure decreased by up to 20%, particularly during pandemic peaks. Evidence on treatment delays, changes in treatment, and mortality was limited, and outcomes for other included diagnoses were often not reported.<br><br>DISCUSSION: The available evidence indicates substantial reductions in hospital admissions and new diagnoses among patients with cancer and cardiovascular disease in Germany during the pandemic, suggesting major disruptions to care delivery. However, heterogeneity and gaps in the evidence base limit a comprehensive assessment of downstream outcomes. More comprehensive, linked data and further research are needed to quantify the full pandemic's impact and to strengthen health-system resilience for future crises.},
}
@article {pmid42169472,
year = {2026},
author = {Das, HK and Amudhan, S and Bhaskarapillai, B and Sasi, S and Sridhar, R and Prasad, NN and Kanmani, TR},
title = {Prevalence of Common Mental Health Problems Among Transgender and Non-Binary Individuals During the COVID-19 Pandemic: A Systematic Review &amp; Meta-Analysis.},
journal = {The International journal of social psychiatry},
volume = {},
number = {},
pages = {207640261453025},
doi = {10.1177/00207640261453025},
pmid = {42169472},
issn = {1741-2854},
abstract = {INTRODUCTION: The COVID-19 pandemic has exacerbated the mental health challenges globally and adversely affected the marginalised populations, including transgender and non-binary (TNB) individuals. Despite evidence, there is a lacuna of a systematic synthesis explicitly focussing on the prevalence of screen-positive common mental health problems, as prior reviews either examined sexual and gender minority populations as a whole or overlooked the full scope of pandemic-related mental health challenges, which the current review seeks to address through systematic review and meta-analysis.<br><br>METHODOLOGY: A comprehensive literature search was conducted across PubMed, Scopus, PsycINFO, and Web of Science, applying the PRISMA 2020 guidelines between March and August 2025. Eligible studies reporting the mental health outcomes of TNB individuals during the pandemic were screened, extracted, and critically appraised with the help of the COVIDENCE and JBI checklists for analytical cross-sectional studies. Meta-analyses were performed using a DerSimonian-Laird random effects model with the Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment to estimate pooled prevalence with 95% confidence intervals. Heterogeneity was quantified with I[2] statistics.<br><br>RESULTS: For depression (n&#x2009;=&#x2009;4,832), the screen-positive pooled prevalence was estimated as 0.59 (95% CI [0.47, 0.70]; I[2]&#x2009;=&#x2009;98.23%). The pooled prevalence for screen-positive anxiety (n&#x2009;=&#x2009;2,833) and substance (n&#x2009;=&#x2009;1,632) use was 0.50(95% CI [0.37, 0.63]; I[2]&#x2009;=&#x2009;94.04%) and 0.47 (95% CI [0.16, 0.79]; I[2]&#x2009;=&#x2009;98.58%), respectively. It is identified that the pandemic reinforced existing healthcare disparities, with disrupted gender-affirming care (e.g. hormone therapy, surgeries) significantly associated with increased psychological distress and gender dysphoria among transgender and gender diverse individuals.<br><br>CONCLUSION: Mental health problems among TNB individuals were markedly elevated during the COVID-19 pandemic, highlighting the urgent need for tailored mental health interventions, uninterrupted gender-affirming care, and policies that address systemic social stigma and discrimination. Strengthening telehealth, community-based supports, and inclusive public health strategies are essential to mitigate disparities and promote resilience in this population.},
}
@article {pmid42170790,
year = {2026},
author = {Carretero Rey, M},
title = {[Epidemiological surveillance of Andes virus: have we really learned anything after COVID-19?].},
journal = {Revista espanola de salud publica},
volume = {100},
number = {},
pages = {},
pmid = {42170790},
issn = {2173-9110},
mesh = {Animals ; Humans ; *Communicable Diseases, Emerging/epidemiology ; COVID-19 ; Disease Outbreaks ; *Epidemiological Monitoring ; *Hantavirus Infections/epidemiology/transmission/prevention &amp; control ; *Orthohantavirus ; *Pandemics ; Spain/epidemiology ; Viral Zoonoses/epidemiology ; },
abstract = {Recent Andes virus outbreaks have reignited international debate regarding Public Health preparedness for hantaviruses with documented interpersonal transmission capacity. Unlike other orthohantaviruses, Andes virus has demonstrated person-to-person transmission in specific epidemiological settings, including household and nosocomial environments. The recent emergence of cases linked to multinational outbreaks has prompted renewed assessments and recommendations from international public health organizations. This manuscript presents an epidemiological reflection on current surveillance challenges associated with emerging hantaviruses following the experience gained during the COVID-19 pandemic. It also reviews aspects related to zoonotic surveillance, molecular monitoring, early detection, and integrated One Health approaches applied to preparedness against future emerging threats. Available evidence highlights the need to strengthen multidisciplinary surveillance systems capable of integrating human, environmental, and zoonotic information in order to improve responses to complex epidemiological scenarios associated with emerging hantaviruses.},
}
@article {pmid42171504,
year = {2026},
author = {Brüssow, H},
title = {Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.},
journal = {Microbial biotechnology},
volume = {19},
number = {5},
pages = {e70376},
pmid = {42171504},
issn = {1751-7915},
mesh = {*Antiviral Agents/pharmacology/therapeutic use ; Humans ; SARS-CoV-2/drug effects ; COVID-19 Drug Treatment ; Animals ; Spike Glycoprotein, Coronavirus/metabolism/antagonists &amp; inhibitors ; Drug Evaluation, Preclinical ; COVID-19 ; Viral Nonstructural Proteins/antagonists &amp; inhibitors/metabolism ; Pandemics ; },
abstract = {Antiviral drugs have been approved for the treatment of COVID-19. However, they present pharmacological limitations, a mixed efficacy profile and target just two coronavirus proteins. To extend the range of druggable coronavirus proteins, researchers explored small molecule N-glycan binders as inhibitors of SARS-CoV-2 spike protein interaction with the cell receptor. Other groups investigated lipopeptides as inhibitors of cell fusion by viral spikes. High throughput screening of chemical libraries yielded viral maturation inhibitors that targeted the viral M protein. Massive screening led to inhibitors of the non-structural coronavirus protein NSP14, a methyltransferase involved in viral mRNA cap synthesis. Machine learning-driven scans of chemical space revealed inhibitors of non-structural coronavirus protein NSP3, a papain-like protease subverting innate immune response to viral infection. A chimera of a nucleotide analogue coupled to an RNase L attractor bound the RNA-dependent RNA polymerase NSP12 and mediated degradation of the viral RNA. Several of these compounds showed comparable or even superior antiviral efficacy as approved COVID-19 drugs in preclinical animal tests. Parallel efforts were made to develop chemical compounds targeting host proteins needed for viral multiplication. Peptidomimetic tetrapeptides acted as inhibitors of the host protease TMPRSS2 involved in cell fusion by the viral spike protein. A repurposed TMPRSS2 inhibitor was tested in COVID-19 patients without demonstrating efficacy. A genetic screen demonstrated an enzyme involved in sphingomyelin synthesis and its inhibitor which impaired SARS-CoV-2 replication. A viral-cell protein interactome study showed 332 cellular proteins interacting with 26 coronaviral proteins. A chemoinformatic search found inhibitors for the interaction of NSP9 with host elongation factor eIF4A and for NSP13 with elongation factor eEF1A. Plitidepsin, a clinically used eEF1A inhibitor, was tested in human clinical trials with COVID-19 patients demonstrating in vivo antiviral activity and a trend for clinical amelioration in an underpowered phase 3 clinical trial.},
}
@article {pmid42171849,
year = {2026},
author = {Simon, MR and Nussbaum, JM and Goodson, K and Allen, BL and Smith, M and Yalif, IU and Cohen, AK},
title = {Industrial Pollution and Health in Louisiana: A Systematic Review of Quantitative and Qualitative Studies.},
journal = {Current environmental health reports},
volume = {13},
number = {1},
pages = {},
pmid = {42171849},
issn = {2196-5412},
support = {P30-ES030284/ES/NIEHS NIH HHS/United States ; 2318237, 2318238, 2318239//National Science Foundation/ ; },
mesh = {Humans ; Louisiana/epidemiology ; *Environmental Exposure/adverse effects ; *Air Pollution/adverse effects ; COVID-19/epidemiology ; *Environmental Pollution/adverse effects ; Oil and Gas Industry ; },
abstract = {PURPOSE OF REVIEW: Louisiana has one of the largest concentrations of petrochemical industry in the USA. Many studies have assessed patterns of industrial pollution and health in Louisiana; we aim to systematically review this evidence. We systematically searched PubMed, Web of Science, Embase, APA PsycInfo, and GreenFILE for peer-reviewed papers published 1999-2024 that reported geographical variation in health or industrial pollution, and/or tested for an association between the two in Louisiana. We used Covidence to support standardized review and extraction.<br><br>RECENT FINDINGS: We identified 2485 non-duplicate papers in our search; 53 met the inclusion criteria. Most reported quantitative findings. All studies of industrial pollution described air pollution (some also described other pollution). Studies described various health outcomes, including cancer, respiratory health, mortality, and COVID-19. Overall, people who lived closer to industrial activity had higher pollution exposure and worse health. Black and lower-income residents were exposed to more industrial activity than white and higher-income residents. Twenty-one studies assessed statistical associations between industrial pollution and health; many found an association. Twenty-one studies were quantitative and adjusted for confounding, 29 studies did not adjust for confounding (including qualitative studies), and three studies did not adjust for confounding and had authors with industry ties. Evidence suggests that there is a higher burden of air pollution and worse health outcomes in industrialized areas of Louisiana. While there was some evidence of significant associations between industrial pollution and health outcomes, research with larger sample sizes and improved pollution exposure measurements could be informative.},
}
@article {pmid42172294,
year = {2026},
author = {Swartwood, NA and Singh, N and Mortazavi, SA and Can, MH and Cui, H and Ryuk, DK and MacPherson, P and Horton, KC and Menzies, NA},
title = {Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993-2025: A systematic review and meta-analysis.},
journal = {PLoS medicine},
volume = {23},
number = {5},
pages = {e1005114},
pmid = {42172294},
issn = {1549-1676},
mesh = {Humans ; Prevalence ; Male ; Female ; *Developing Countries/economics ; Sex Factors ; *Tuberculosis/epidemiology ; Risk Factors ; },
abstract = {BACKGROUND: Global and national initiatives to combat tuberculosis (TB) have expanded over recent years. Despite this, the TB burden remains high in some population groups, with men recognized as having elevated TB risks. Summary measures of sex differences in TB prevalence were last estimated in 2016. Since then, many additional prevalence surveys have been conducted, including in the highest TB burden countries. We conducted a systematic review of sex-stratified TB prevalence survey data published over 1993-2025, to provide updated estimates of male-to-female (M:F) TB prevalence ratios and determine whether sex-related disparities in TB burden have closed over time.<br><br>METHODS AND FINDINGS: We identified surveys reporting community-representative, sex-stratified estimates of pulmonary TB prevalence in low- and middle-income countries (LMICs), including surveys from an earlier review (covering January 1993-March 2016) and a new systematic review (covering 1st December 2015-13th October 2025). This review was prospectively registered with PROSPERO (CRD42024503853) and included searches of PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO. We extracted data on bacteriologically confirmed and smear-positive TB prevalence among adults (aged&#x2009;&#x2265;&#x2009;15 years), stratified by sex. Risk of bias was evaluated using eight criteria specific to prevalence surveys. We fit multi-level Bayesian regression models with study- and country-level random effects to estimate the M:F ratio of TB prevalence (male prevalence divided by female prevalence), overall and for key subgroups. In meta-regression analyses, we estimated how prevalence ratios varied over time and according to known TB risk factors and TB case definitions. We identified 10,124 publications and extracted data from 100 eligible studies representing 102 unique prevalence surveys and 4,658,310 participants (45.6% male) in 33 LMICs. TB prevalence was higher in men than women in 90/102 of the included surveys, with a pooled M:F prevalence ratio of 2.02 (95% credible interval (CrI): 1.71, 2.34) for bacteriologically confirmed TB and 2.38 (95% CrI: 1.91, 2.90) for smear-positive TB. Time trend analyses showed a 2.0% (95% CrI: -0.2, 4.5%) average annual change in the M:F ratio of bacteriologically confirmed TB over the study period. The M:F prevalence ratio was estimated to be higher for countries with greater excess HIV prevalence among men, and countries with greater gender equity (as measured by the United Nation's Gender Development Index). The estimated M:F prevalence ratio was also higher for surveys that did not restrict testing to individuals reporting TB symptoms. Study limitations include heterogeneity in survey methods and definitions, as well as limited data from the Americas, Eastern Mediterranean, and Europe WHO world regions and post-COVID-19 period.<br><br>CONCLUSIONS: Men in LMICs consistently experience TB at a higher prevalence than women. Time trend estimates are uncertain, but consistent with widening sex differences in TB prevalence over the last three decades, despite efforts to address the risk factors underlying this excess TB burden.},
}
@article {pmid42172568,
year = {2026},
author = {Santos, C and Da Ponte, G},
title = {Moral Distress, Work Engagement, and Meaningful Work in Healthcare: A Narrative Review.},
journal = {Acta medica portuguesa},
volume = {},
number = {},
pages = {},
doi = {10.20344/amp.24197},
pmid = {42172568},
issn = {1646-0758},
abstract = {The psychological well-being of healthcare professionals is increasingly recognized as a critical determinant of patient safety, quality of care, and healthcare system sustainability. Among the constructs most relevant to this domain are moral distress, work engagement, and meaningful work. This narrative review aimed to synthesize conceptual and empirical evidence on these three constructs and to examine their interrelations and implications for healthcare practice. A selective narrative review of the literature was conducted, integrating theoretical frameworks, systematic and integrative reviews, and empirical studies, resulting in a final synthesis of 41 articles. Moral distress arises when clinicians are prevented from acting in accordance with their ethical convictions, often due to institutional or systemic constraints, and has been consistently associated with burnout, turnover, and compromised quality of care. In contrast, work engagement - characterized by vigor, dedication, and absorption - and meaningful work - reflecting the perception that professional activities have meaning and purpose - function as protective factors that enhance resilience and sustain intrinsic motivation. Evidence highlights the central role of organizational climate, leadership, resource availability, and ethical culture in shaping experiences of distress, engagement, and meaningfulness, a dynamic further intensified during the COVID-19 pandemic. The synthesis emphasizes that organizational and systemic interventions, including ethics consultation, supportive leadership, workflow redesign, and resilience-building programs, are essential to mitigate moral distress and promote engagement and meaningful work. The integration of these constructs aligns with the Quadruple Aim, reinforcing the premise that caring for healthcare professionals is indispensable to caring for patients.},
}
@article {pmid42172606,
year = {2026},
author = {Vagg, T and Doherty, R and Ranganathan, SC and Plant, BJ},
title = {Reporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e86194},
pmid = {42172606},
issn = {1438-8871},
mesh = {*Cystic Fibrosis/therapy ; *Telemedicine ; Humans ; Digital Health ; },
abstract = {BACKGROUND: Many inductive reviews exploring telehealth and its application in health care have identified missing or inconsistently reported implementation data, calling for a standardized approach to telehealth research.<br><br>OBJECTIVE: Using cystic fibrosis (CF) as a case exemplar, this study evaluated the adherence of telehealth research to standardized reporting frameworks through a theory-based evaluation lens to assess implementation reporting quality and identify knowledge gaps and strengths across the literature.<br><br>METHODS: We conducted an updated systematic review of the PubMed, Scopus, and Web of Science databases using a novel deductive approach to identify relevant scientific papers available in English and focusing on the delivery of telehealth interventions to CF populations as part of or alongside routine CF care. Two relevant reporting checklists were identified in the Equator Network database (Guidelines and Checklist for the Reporting on Digital Health Implementations [iCHECK-DH] and Template for Intervention Description and Replication for Telehealth [TIDiER-telehealth]) to extract data from the papers. Each checklist category was described as being "fully reported" (score=2), "partially reported" (score=1), and "did not report" (score=0) for each paper. An overall score was calculated for adherence to the checklists.<br><br>RESULTS: In total, 98 studies published between 2006 and May 2025 were included in this review, with the majority appearing during the COVID-19 pandemic (2021-2022). Most studies were conducted in a single country, predominantly the United States, Australia, and the United Kingdom, and were published in medical journals. Telehealth was variably described, with video call-based models in combination with remote monitoring being most common. The median score was 22/40 (range 11-29, 55.0% adherent) for iCHECK and 15/24 (range 6-23, 62.5% adherent) for TIDiER, demonstrating moderate overall reporting quality. For iCHECK, &#x2265;50% of studies fully reported 6/20 categories, partially reported 9/20 categories, and did not report 3/20 categories. For TIDiER, &#x2265;50% of studies fully reported 4/12 categories, partially reported 6/12 categories, and did not report 1/12 categories, indicating persistent gaps in intervention description despite improved partial reporting.<br><br>CONCLUSIONS: Key areas, such as justification for telehealth, target populations, and outcomes, are well documented, offering valuable insights into the rationale for and outcomes associated with telehealth. However, implementation processes remain underreported, partly due to the more recent adoption of frameworks like iCHECK and TIDiER. The clinical implications of the current evidence limit the implementation of telehealth in terms of the ability to assess feasibility and readiness for adoption; understand financial implications and plan sustainably; ensure patient safety, data protection, and equity; interpret outcome data in context; and share, replicate, or scale evidence-based models of care. Strengthening the commitment to standardized telehealth reporting will ultimately support clinical decision-making and improve the effective and equitable integration of telehealth into care.},
}
@article {pmid42172709,
year = {2026},
author = {Jing, W and Zheng, M and Yang, X and He, B and Zhang, X and Cui, W},
title = {Micro- and nanoplastics in the central nervous system: Transport pathways, neurotoxicity, and implications for brain disorders.},
journal = {Ecotoxicology and environmental safety},
volume = {319},
number = {},
pages = {120278},
doi = {10.1016/j.ecoenv.2026.120278},
pmid = {42172709},
issn = {1090-2414},
mesh = {Humans ; Animals ; *Central Nervous System/drug effects/metabolism ; *Microplastics/toxicity/pharmacokinetics ; *Brain Diseases/chemically induced ; Blood-Brain Barrier/metabolism ; *Nanoparticles/toxicity ; *Neurotoxicity Syndromes/etiology ; Environmental Pollutants/toxicity ; },
abstract = {Micro- and nano-plastics (MNPs) are widely distributed across global ecosystems and have been extensively detected in human tissues, including the brain. The levels of MNPs are highly correlated with the occurrence of various brain disorders, suggesting the potential central nervous system (CNS) toxicity of MNPs. In this review, we summarize the major circuits by which MNPs may transport into and out of the CNS, including blood-brain barrier crossing, nasal-to-brain routes, and glymphatic system transport. Small-sized MNPs are difficult to eliminate from the brain, which may explain why MNPs may accumulate in the brain. We further discuss the potential neurotoxic effects of MNPs, such as inducing synaptic and neuronal injury, promoting neuroinflammation, dysregulating the neuroendocrine system, and modulating the gut-brain axis. MNP-induced CNS toxicity follows a pattern in which increased susceptibility occurs before direct toxicity. We also review evidence that MNPs, together with environmental and genetic factors, may synergistically contribute to cognitive impairment in Alzheimer's disease, motor dysfunction in Parkinson's disease, and depression- and anxiety-like behaviors. Prenatal exposure to MNPs might induce autism spectrum disorder-related phenotypes in offspring. MNPs could also obstruct cerebral vessels and trigger acute cerebrovascular diseases, as well as promote the entry of viruses such as SARS-CoV-2 into the CNS, thereby increasing the occurrence of neurological symptoms. Finally, this review discusses physical, pharmacological, and plastics substitution interventions designed to regulate MNPs transport in the brain and enhance neuroprotection, thereby reducing CNS toxicity of MNPs.},
}
@article {pmid42173631,
year = {2026},
author = {Vaidya, H and Kumar, M},
title = {AI in multi-omics analysis in viral diseases.},
journal = {Progress in molecular biology and translational science},
volume = {222},
number = {},
pages = {229-240},
doi = {10.1016/bs.pmbts.2026.02.005},
pmid = {42173631},
issn = {1878-0814},
mesh = {*Multiomics ; Humans ; *Artificial Intelligence ; *Virus Diseases/genetics/metabolism/virology ; Machine Learning ; Genomics ; Metabolomics ; Proteomics ; },
abstract = {Viral diseases are a serious threat to human health worldwide, and are known to cause long-term health complications as well as epidemics and pandemics. Yet it is difficult to understand how they spread, persist, and damage the body, which requires advanced methods. Multi-omics datasets, including genomics, transcriptomics, epigenomics, proteomics and metabolomics provide a complete view of virus-host interactions. However, the integration and interpretation of these high dimensional datasets remain a major challenge. To overcome this, artificial Intelligence (AI), including machine learning (ML) and network-based approaches, has proven to be a powerful tool to analyze, integrate, and interpret multi-omics data. This chapter discusses examples from studies on SARS-CoV-2, HIV, influenza, EBV and others, where AI has been applied to multi-omics research. These studies show how AI-assisted multi-omics approaches are helping in the advancement of viral disease research by providing better understanding of virus induced cellular changes, identifying biomarkers, designing targeted therapies etc. Therefore, integrating multi-omics with AI enables improved diagnosis, treatment, and prevention of viral diseases. We have also discussed challenges faced in combining multi-omics with AI and highlighted future directions that would help in enhancing AI assisted multi-omics research.},
}
@article {pmid42173633,
year = {2026},
author = {Agrawal, P},
title = {AI in multi-omics analysis of COVID-19 patient data.},
journal = {Progress in molecular biology and translational science},
volume = {222},
number = {},
pages = {261-293},
doi = {10.1016/bs.pmbts.2026.01.017},
pmid = {42173633},
issn = {1878-0814},
support = {//Non-US Government Research Support type/ ; },
mesh = {Humans ; *Multiomics ; *COVID-19/genetics/virology/metabolism ; *Artificial Intelligence ; *SARS-CoV-2 ; Genomics ; Proteomics ; Pandemics ; Metabolomics ; Machine Learning ; },
abstract = {The COVID-19 pandemic has led to an unprecedented increase in the volume of biological data generation, demonstrating the importance of developing an integrative and intelligent analytical framework. In the last few years, advancements in the artificial intelligence (AI) approaches have completely transformed the biological research landscape. Researchers have integrated the AI approaches with the multi-omics data generated from the COVID-19 patients to have a systems-level understanding of underlying disease mechanisms, predicting new variants and their spread rate, disease severity, immune response, and therapeutic opportunities. In this chapter, we have explored the utility of AI on multi-omics data. We started with an introduction to different kinds of omics data, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Next, we elaborated on what AI is and discussed its types, which include conventional machine learning methods (supervised and unsupervised), deep learning methods (autoencoders and convolutional neural networks), and network-based methods (graph neural networks, network propagation, and knowledge graphs). Next, we discussed different types of integration methods (early, intermediate, and late) used for integrating AI and multi-omics data. Moving ahead, we mentioned several applications of AI, such as biomarker discovery, host-pathogen interaction, drug repurposing, and predicting long COVID. Lastly, we mentioned several important projects and consortia and discussed several important case studies highlighting the usefulness of integrating AI with multi-omics data for personalized medicine.},
}
@article {pmid42173646,
year = {2026},
author = {Decker, BK and O'Donnell, M},
title = {Infection Prevention and Control in the Intensive Care Unit.},
journal = {Critical care clinics},
volume = {42},
number = {3},
pages = {611-634},
doi = {10.1016/j.ccc.2025.12.010},
pmid = {42173646},
issn = {1557-8232},
mesh = {Humans ; *Intensive Care Units ; *Cross Infection/prevention &amp; control ; *Infection Control/methods/standards ; *COVID-19/prevention &amp; control/epidemiology ; Risk Factors ; SARS-CoV-2 ; },
abstract = {Health care-associated infections are common and burdensome in intensive care units, contributing to increased costs, morbidity, and mortality. The coronavirus disease 2019 (COVID-19) pandemic led to an increase in the incidence of intensive care unit (ICU)-acquired infections and multidrug-resistant organisms (MDROs), highlighting the urgent need for effective prevention strategies. This article summarizes core infection prevention practices in the ICU, examines risk factors, reviews approaches to limit the spread of MDROs and explores innovations in infection prevention.},
}
@article {pmid42173648,
year = {2026},
author = {Sweeney, DA and Wittebole, X and Kalil, AC},
title = {The Respiratory Triple Pandemic in the Intensive Care Unit: Epidemiology, Clinical Features and Management of COVID-19, Influenza and Respiratory Syncytial Virus.},
journal = {Critical care clinics},
volume = {42},
number = {3},
pages = {651-667},
doi = {10.1016/j.ccc.2026.01.007},
pmid = {42173648},
issn = {1557-8232},
mesh = {Humans ; *Respiratory Syncytial Virus Infections/epidemiology/therapy/diagnosis ; *Influenza, Human/epidemiology/therapy/diagnosis ; *COVID-19/epidemiology/therapy/diagnosis ; *Intensive Care Units ; Antiviral Agents/therapeutic use ; SARS-CoV-2 ; Pandemics ; },
abstract = {The anticipated "tripledemic" during the 2023-2024 season-in which simultaneous epidemics of SARS‑CoV‑2, influenza, and respiratory syncytial virus were projected-ultimately fell short of early forecasts. Nevertheless, each virus remains a significant public health concern in its own right. This article reviews the microbiology, diagnosis, and treatment of these three pathogens (including the role of immunomodulatory therapies), as well as key considerations for hospital infection prevention in the care of critically ill patients. The piece highlights the clinical indistinguishability of these viral infections and acknowledges the evolving public health discourse surrounding the role of vaccination in preventing disease.},
}
@article {pmid42174572,
year = {2026},
author = {Hunting, G and Hankivsky, O and Christoffersen, A},
title = {Taking stock of intersectionality-informed policy guidance for post-pandemic recovery: a scoping review.},
journal = {International journal for equity in health},
volume = {25},
number = {1},
pages = {},
pmid = {42174572},
issn = {1475-9276},
mesh = {*COVID-19/epidemiology ; Humans ; *Pandemics ; SARS-CoV-2 ; *Health Policy ; *Public Policy ; *Health Equity ; },
abstract = {BACKGROUND: COVID-19 was a catalyst for popularizing intersectionality, an approach now recognized as central to understanding the inequitable consequences of COVID-19 and as a necessary lens for recovery. Yet, a key question remains: Did the pandemic provide the stimulus for improving or advancing operational policy-relevant guidance for intersectionality? Answering this is critical, given persistent calls for practical policy guidance for operationalizing intersectionality. This article explores this question by first providing a brief overview of intersectionality, including its value-added in relation to equity-promoting public policies. We then summarise how intersectionality was taken up during and post-pandemic, situating these trends within the broader field of intersectionality-informed research and policy. Following this, we present findings derived from a review of guidance for applying intersectionality in the context of COVID-19.<br><br>METHODS: The literature reviewed derives from a larger scoping review (conducted by the authors) of guidance (including tools, guides, and frameworks) intended to facilitate the application or operationalization of intersectionality as relevant to public policy. Inclusion criteria for the scoping review included English language, any date (to end of 2023), presents user-friendly guidance, mentions policy, and contains intersectional* in the title.<br><br>RESULTS: Our findings show that despite much discussion on intersectionality in relation to COVID-19 and the increase in intersectionality guidance since the outbreak, little guidance was developed on how to conduct intersectionality-informed analysis in relation to COVID-19 or post-pandemic recovery. Yet, our analysis also shows that the guidance focused on COVID-19 stands out as more robust than the majority of intersectionality guidance produced to date. Specifically, the COVID-19 guidance reflects the foundational tenets of intersectional analysis and action, boosting its potential to capture and address inequities. This is in contrast to the broader scoping review which indicates that most existing intersectionality guidance has failed to do this.<br><br>CONCLUSION: It is pressing that researchers, policy actors and practitioners who seek to take up intersectionality in their work critically take stock of promising practices in intersectionality guidance - exemplified by the COVID-19 guidance reviewed in this article - to strengthen how inequities are captured and addressed.},
}
@article {pmid42174645,
year = {2026},
author = {Plaut, S},
title = {A systematic scoping review and conceptual analysis of new-onset fibromyalgia manifestations after non-hospitalized COVID-19: empirics, definitions, methodologies, pathophysiology, mapping of literature, and knowledge gaps.},
journal = {Journal of translational medicine},
volume = {24},
number = {1},
pages = {},
pmid = {42174645},
issn = {1479-5876},
mesh = {Humans ; *Fibromyalgia/physiopathology/etiology/epidemiology/diagnosis ; *COVID-19/complications ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Pandemics ; Fatigue Syndrome, Chronic ; },
abstract = {BACKGROUND: The global coronavirus pandemic has led to a quiet wave of a chronic illness referred to as 'Long/Post Covid-19 syndrome' (LC) which bears a notable resemblance to functional-somatic or 'fibromyalgia-type' syndromes, and whose pathophysiology is undetermined. The lack of effective therapies for LC is straining healthcare systems worldwide and causing widespread public health and socioeconomic concerns. "Fibromyalgia" is a controversial chronic pain condition of unknown etiology largely attributed to generalized sensory hypersensitivity due to dysregulated central pain processing pathways (i.e. neuroplasting central sensitization). Despite intense research and growing attention in the scientific community, the clinical overlap of fibromyalgia, somatic symptom disorder, and post-viral chronic fatigue, is a medical puzzle yet to be solved, especially when occurring in non-severe infections and previously healthy individuals.<br><br>METHODS: This systematic scoping review covers the empirical findings on new-onset fibromyalgia manifestations after non-hospitalized covid-19. MEDLINE, Web of Science, and APA PsycINFO were searched in a systematic scoping approach for empirical studies on new-onset fibromyalgia after non-severe non-hospitalized covid-19, charting study characteristics and outcome data. A total of 228 records were included.<br><br>FINDINGS: Various types of methods, tools, and study designs are being used for LC research, with inconsistency in key concepts and definitions. This leads to a fragmented understanding of the relationship between SARS-CoV-2 infection and LC. Prevalence studies of post-Covid fibromyalgia are ongoing and susceptible to bias. The empirical evidence supports an overlap between LC, chronic fatigue syndrome, and fibromyalgia but the molecular mechanisms still remain unclear. There are conflicting findings regarding presence of viral particles, central sensitization, autoantibodies, and more.<br><br>DISCUSSION: This review highlights the need for standardized definitions and rigorous methodologies in research on LC. Future research should focus on epidemiological population-based studies with representative sampling and improving methodology, refining evolving definitions, harmonization of research, elucidating neurological mechanisms in hypothesis driven studies, and developing effective therapeutic strategies. The discussion synthesizes findings and offers an integrative mechanism for the pathophysiology of fibromyalgia and multisystem medically unexplained manifestations of LC as a non-autoimmune connective tissue disease. It helps explain neuropsychiatric and psychosomatic manifestations and is used to make testable theory-based predictions for future hypothesis-driven investigations.},
}
@article {pmid42175870,
year = {2026},
author = {Allgoewer, K and Lavenia, A and Secco, L and Schaller, T and Fitzek, A and Kriebel, C and Azeke, AT and Kondo, T and Tse, R and Chui, P and Schmiedel, S and Ondruschka, B},
title = {Autopsy practices for high-consequence infectious diseases: global guidelines, alternatives, and the BSL-4 gap.},
journal = {Emerging microbes &amp; infections},
volume = {15},
number = {1},
pages = {2678656},
pmid = {42175870},
issn = {2222-1751},
mesh = {*Autopsy/instrumentation/methods/standards ; Humans ; *Containment of Biohazards/methods ; Communicable Disease Control ; *Hemorrhagic Fevers, Viral/pathology/prevention &amp; control/transmission/virology ; Resource-Limited Settings ; Tomography, X-Ray Computed ; Robotics ; COVID-19/pathology/prevention &amp; control/virology ; Pandemics ; Practice Guidelines as Topic ; },
abstract = {Autopsies play a critical role in elucidating the pathogenesis of emerging infectious diseases, particularly in cases involving high-consequence pathogens such as viral haemorrhagic fevers (VHFs). While biosafety concerns have restricted post-mortem examinations in such contexts, the COVID-19 pandemic has renewed interest in autopsy-based research and highlighted both the potential and the gaps in current biosafety protocols. This narrative review outlines autopsy practices in the context of high-consequence infectious diseases (HCIDs) with a focus on VHFs, summarizes reported autopsy cases, explores alternative post-mortem methods, and examines the evolution of legal and institutional frameworks in response to the pandemic. A comparison of official international guidelines shows that while detailed autopsy protocols have been published for pathogens requiring BSL-3 containment - particularly in the United States (US) and United Kingdom (UK) - no official procedural guidance seems to be available for performing autopsies under BSL-4 conditions. Instead, current recommendations at this level are limited to post-mortem handling and disposal of the deceased. This regulatory and procedural gap underscores the urgent need for harmonized, high-containment autopsy protocols that balance biosafety with scientific value. Developing such frameworks will be essential to improve outbreak preparedness and enable evidence-based responses to future pandemics globally. Accordingly, we propose a structured, system-based approach to BSL-4 autopsy practice as a foundation for discussion and future guideline development.},
}
@article {pmid42176005,
year = {2026},
author = {Walia, HK and Choudhary, K and Kumar, N},
title = {Aptamer-conjugated nanoparticles: emerging nano-enabled platforms for rapid and sensitive detection of viral infections.},
journal = {Archives of microbiology},
volume = {208},
number = {8},
pages = {},
pmid = {42176005},
issn = {1432-072X},
mesh = {Humans ; *Nanoparticles/chemistry ; *Aptamers, Nucleotide/chemistry ; *COVID-19/diagnosis ; Biosensing Techniques/methods ; SARS-CoV-2/isolation &amp; purification ; *Virus Diseases/diagnosis ; Rapid Diagnostic Tests ; Nanotechnology/methods ; },
abstract = {During the recent outbreak of SARS-CoV-2, the global healthcare system experienced firsthand the importance of accurate and rapid detection techniques in the containment of pandemic situations. Conventional viral detection techniques, although highly specific, often suffer from slow, labour-intensive workflows that limit their applicability for rapid diagnosis. Moreover, their reliability can be compromised by factors such as inadequate technical expertise and improper sample handling, potentially leading to erroneous results. When the global public health system is continuously struggling to control viral diseases like dengue, influenza, hepatitis B, and acquired immunodeficiency syndrome, cutting-edge nanotechnology and biosensor-enabled next-generation diagnostic platforms have shown improved analytical performances. Among these, aptamer-conjugated nanoparticles (ACNPs) have emerged as a promising nanosystem that integrates the high molecular recognition capability of aptamers with the unique physicochemical and optical properties of nanoparticles. Aptamers are short, single-stranded DNA, RNA, or peptide sequences that offer remarkable affinity and selectivity toward diverse viral biomarkers, including proteins, nucleic acids, and intact virions. Their conjugation with nanoparticles imparts superior stability, signal amplification, and biofunctional versatility under physiological conditions. These hybrid systems demonstrate substantial potential in biosensing, bioimaging, and providing enhanced diagnostic precision. This review aims to present the fundamental design principles of ACNP-based detection strategies and to highlight recent advances in viral diagnostics. Additionally, it underscores the underlying sensing mechanisms and analytical advantages, and discusses the current challenges associated with ACNP-enabled diagnostic platforms.},
}
@article {pmid42176257,
year = {2026},
author = {Abdelhady, E and Abdo Khalafallah, M and Alkajah, HA and Reda Elmahadi, R and Willer, BL and Tobias, JD},
title = {Telemedicine-Enabled Surgical Outreach across the Surgical Continuum to Bridge the Gap in Low- and Middle-Income Countries: Lessons from the COVID-19 Era and Applications Beyond.},
journal = {Telemedicine journal and e-health : the official journal of the American Telemedicine Association},
volume = {},
number = {},
pages = {15305627261453274},
doi = {10.1177/15305627261453274},
pmid = {42176257},
issn = {1556-3669},
abstract = {INTRODUCTION: Telemedicine has revolutionized health care delivery globally, reducing health care costs, increasing patient satisfaction, and improving surgical outcomes. Innovation is often born out of necessity, and during the Coronavirus disease 2019 (COVID-19) pandemic, there was a surge of telemedicine initiatives both in surgical education and surgical care delivery. This has been well documented in high-income countries, but there has been less evaluation of the use and potential application of telemedicine in low- and middle-income countries (LMICs) to support surgical outreach efforts. This review seeks to describe telemedicine-enabled surgical outreach across the surgical continuum that emerged from the COVID-19 era in LMICs and provide recommendations for future practices.<br><br>METHODS: A scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines. Identified studies on telemedicine indexed in PubMed, Web of Science, Scopus, and Embase from January 2020 to February 2025 were aggregated. The search terms included "telemedicine," "surgery," "COVID-19," "SARS-CoV-2," "e-learning," "remote," "tele-simulation," and "LMICs." Of 713 papers, 15 eligible studies were found. Data were summarized by study type, intervention type, and outcomes. Themes of accessibility, efficacy, and user satisfaction were analyzed. Key implementation challenges were reviewed. Summary recommendations for future directions are provided.<br><br>RESULTS: The 15 studies identified provide evidence for the feasibility and effectiveness of a variety of surgical teleinterventions within LMICs. The majority of the qualifying research consisted of prospective cohort studies that involved physicians, surgical residents, and patients. The primary findings include improvements in surgical skills, positive perception by participants, and high satisfaction with tele-simulation and e-learning. Key implementation challenges identified were technical issues, insufficient infrastructure, and unreliable internet.<br><br>CONCLUSION: Preliminary experience suggests that telemedicine applications during the COVID-19 pandemic proved to be effective tools for both surgical education and patient care. These initiatives may hold promise for augmenting surgical outreach efforts in a more sustainable fashion to facilitate both surgeon training and improved care delivery for underserved communities in LMICs. However, numerous challenges must be addressed to ensure long-term effectiveness and sustainability.},
}
@article {pmid42176585,
year = {2026},
author = {Wang, Q and Wang, XN and Liu, XQ and Zhao, LG and Jing, ZT and Tian, T and Zhang, JT and Zhao, YX and Li, JM and Diao, NC and Shi, K and Du, R},
title = {Prevalence and risk factors of bovine tuberculosis in dairy cattle, 2020-2025: A systematic review and meta-analysis of available literature.},
journal = {Preventive veterinary medicine},
volume = {254},
number = {},
pages = {106920},
doi = {10.1016/j.prevetmed.2026.106920},
pmid = {42176585},
issn = {1873-1716},
mesh = {Animals ; Cattle ; *Tuberculosis, Bovine/epidemiology/microbiology ; Risk Factors ; Prevalence ; Dairying ; Female ; },
abstract = {BACKGROUND: Bovine tuberculosis (bTB) is a zoonotic disease caused by members of the Mycobacterium tuberculosis complex (MTBC), with Mycobacterium bovis being the primary agent responsible for infections in cattle, posing a significant threat to the global dairy industry. Although the COVID-19 pandemic during the 2020-2025 period may have disrupted its epidemiology, a comprehensive global meta-analysis of bTB prevalence and risk factors in dairy cattle for this period is currently lacking.<br><br>METHODS: We conducted an extensive literature search across multiple databases, including CNKI, PubMed, ScienceDirect, VIP, and Wan Fang. A total of 4783 records were initially identified, of which 45 studies met the inclusion criteria, encompassing 468,769 dairy cattle across 10 countries.<br><br>RESULTS: The global pooled bTB prevalence was 6.9% (95% CI: 4.4-9.9). Africa had the highest regional prevalence (12.4%, 95% CI: 6.6-19.7), and Ethiopia the highest among countries (16.6%, 95% CI: 7.8-27.9). Low-income countries showed higher prevalence (16.7%, 95% CI: 8.9-26.3) than others. Rapid antibody tests yielded significantly higher infection rates (24.8%, 95% CI: 9.7-44.1) than other diagnostic methods. Prevalence differed significantly between lactating and non-lactating cows (p&#x202f;<&#x202f;0.05). Other risk factors assessed included breed, sex, age, farming mode, sampling time, sample type, and tuberculin type.<br><br>CONCLUSIONS: bTB remains a significant challenge in dairy production, demanding tailored control strategies adapted to regional contexts. However, the geographic distribution of available studies was heavily skewed, with the majority originating from China and Africa, while regions with advanced control programs were underrepresented. This geographic limitation should be carefully considered when interpreting the global estimates. Surveillance efforts should prioritize high-risk populations, particularly hybrid cattle, aging animals, and lactating cows, through the combined use of interferon&#x2011;&#x3b3; release assays and tuberculin tests. Effective control hinges on integrated approaches including veterinary capacity building, genetic selection for disease resistance, and management at the wildlife-livestock interface. Sustainable prevalence reduction requires evidence-based measures designed for local production systems.},
}
@article {pmid42176717,
year = {2026},
author = {Farsiu, N and Charostad, J and Khodadadpour Mahani, F and Mir, Y and Rezaei Zadeh Rukerd, M and Zeinali Nezhad, N and Shahpar, A and Pardeshenas, M and Nakhaie, M},
title = {An extensive overview on MicroRNAs and pandemic-prone viral diseases: The next frontier in predicting and mitigating pandemics.},
journal = {Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases},
volume = {142},
number = {},
pages = {105963},
doi = {10.1016/j.meegid.2026.105963},
pmid = {42176717},
issn = {1567-7257},
mesh = {*MicroRNAs/genetics/metabolism ; Humans ; *Pandemics/prevention &amp; control ; SARS-CoV-2 ; *Virus Diseases/genetics/epidemiology ; Host-Pathogen Interactions/genetics ; COVID-19 ; Biomarkers ; Middle East Respiratory Syndrome Coronavirus/genetics ; Influenza, Human/genetics/epidemiology/virology ; },
abstract = {MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play important roles in host-virus interactions. Increasing evidence indicates that viral infections can alter host miRNA expression profiles, influencing viral replication, immune responses, and disease severity. In this review, we summarize current knowledge on miRNA dysregulation in major pandemic-prone viral infections, including severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, (middle east respiratory syndrome coronavirus) MERS-CoV, and influenza viruses. We also discuss how specific miRNAs may function as antiviral or proviral regulators by targeting viral genomes or key host signaling pathways involved in immune responses and inflammation. Particular attention is given to the potential role of circulating miRNAs as diagnostic or prognostic biomarkers, as well as the emerging concept of miRNA-based therapeutics. While numerous studies report associations between altered miRNA expression and infection outcomes, most findings are derived from relatively small and heterogeneous cohorts and require further validation. Consequently, many proposed miRNA applications remain at an exploratory stage. Nevertheless, advances in high-throughput sequencing, integrative omics approaches, and functional validation studies are expected to improve our understanding of miRNA-mediated regulatory networks during viral infections. These developments may ultimately support the development of host-response biomarkers and therapeutic strategies that contribute to improved surveillance and preparedness for future viral outbreaks.},
}
@article {pmid42176857,
year = {2026},
author = {Shaban, RZ and Curtis, K and Fry, M and McCormack, B and Parker, D and Macbeth, D and Mitchell, BG and Russo, PL and Friedman, ND and Bennett, N and Thompson, L and Dalton, JA and Dempsey, K and Henderson, B and Considine, J and Bowes, R and Powell, M and Battaglini, E and Dodson, N and El-Assad, K and McKay, K and Viengkham, C},
title = {Professional practice requirements and competency standards for infection prevention and control professionals in residential aged care: A scoping review.},
journal = {American journal of infection control},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.ajic.2026.05.013},
pmid = {42176857},
issn = {1527-3296},
abstract = {BACKGROUND: Healthcare-associated infections are a major health issue for older adults in residential aged care homes (RACHs). Events like the COVID-19 pandemic have increased focus on the practice of infection prevention and control professionals (ICPs) in RACHs.<br><br>AIM: To synthesise evidence on practice requirements and competency standards for ICPs in RACHs globally.<br><br>METHODS: This scoping review examined&#xa0;literature from electronic bibliographic databases and gray literature via citation chaining and manual searching limited to English from 1980 to 2025. Studies were screened against eligibility criteria. Data were analyzed using descriptive statistics and framework analysis.<br><br>RESULTS: Forty-nine articles were included. Key practice requirements in the white literature included surveillance, staff education, resident care, and employee health; and directing IPC activities, standard precautions, and resident care in the gray literature. Training and credentialing featured less frequently, identifying a need for specialized training. Only 2 formal competency certifications were noted as a requirement or expectation for ICPs.<br><br>CONCLUSION: Several key elements of practice have been identified, but there is limited detail and consistency regarding qualifications, competency standards, and credentialing.<br><br>IMPACT: This work reviewed the literature regarding ICP practice requirements, qualifications, and credentialing. Gaps in this literature indicate a need for formal, evidence-based guidelines for ICPs in RACHs.},
}
@article {pmid42177562,
year = {2026},
author = {Bagaforo, RJ and Dupas, MC and Abrams, S and Dellicour, S and Hens, N},
title = {A scoping review of COVID-19 modelling studies in Belgium 2020-2024: incorporation of behaviour and lessons learned.},
journal = {Archives of public health = Archives belges de sante publique},
volume = {84},
number = {1},
pages = {},
pmid = {42177562},
issn = {0778-7367},
support = {G0A4624N//Fonds Wetenschappelijk Onderzoek/ ; TD/231/BE-PIN//Belgian Federal Science Policy Office/ ; },
abstract = {BACKGROUND: The COVID-19 pandemic underscored the importance of integrating human behaviour in infectious disease modelling approaches, yet an in-depth assessment of how behavioural components are incorporated remains limited. We conducted a scoping review of COVID-19 models applied to Belgian data to examine how behavioural dynamics, both voluntary and policy-driven, were represented within model structures. Our aim was to identify current practices, highlight methodological gaps, and provide recommendations for the development of behaviourally integrated epidemiological models.<br><br>METHODS: Using Scopus and PubMed, we identified 98 studies published between March 2020 and October 2024, describing 105 models in total. Models were classified by model class (mathematical, statistical, or ensemble), objectives, approaches used to incorporate behavioural factors, and types of behaviour data employed.<br><br>RESULTS: Behavioural integration was confined to specific modelling contexts, with only half of the 105 models incorporating behavioural components. Mechanistic models, particularly compartmental models, were the most likely to include behavioural features, especially in studies assessing non-pharmaceutical interventions or conducting long-term forecasts and scenario analyses. Behavioural change was most commonly represented through modifications to transmission parameters or contact matrices. These adjustments were frequently informed by social contact surveys or mobility data derived from various sources.<br><br>CONCLUSIONS: In contrast to previous reviews that focused exclusively on behavioural models, this study evaluates the full landscape of Belgian COVID-19 models, offering a comprehensive perspective on how behavioural representation varies across modelling approaches. Our findings recommend that effective behavioural integration relies on timely, routine, and disaggregated surveillance and behaviour data, alongside the use of flexible mechanistic models.},
}
@article {pmid42178124,
year = {2026},
author = {Saad, MH and Taha, TH and Alhudhaibi, AM and Albatli, SA and El-Sayed, MH and Sidkey, NM and El-Fakharany, EM},
title = {Insights into prospective antiviral activities of algal polysaccharides along with their properties, extraction, and characterization: A review.},
journal = {International journal of biological macromolecules},
volume = {368},
number = {},
pages = {152675},
doi = {10.1016/j.ijbiomac.2026.152675},
pmid = {42178124},
issn = {1879-0003},
mesh = {*Antiviral Agents/pharmacology/chemistry/isolation &amp; purification/therapeutic use ; *Polysaccharides/pharmacology/chemistry/isolation &amp; purification ; Humans ; SARS-CoV-2/drug effects ; *COVID-19 Drug Treatment ; Animals ; },
abstract = {The global escalation of viral outbreaks, particularly the COVID-19 pandemic caused by SARS-CoV-2, highlights the urgent need for effective antiviral agents against emerging infections. Despite their importance, quarantine and vaccination alone are insufficient, necessitating advanced approaches for effective viral infection control. One such strategy involves investigating efficacious antiviral agents that don't induce toxicity. Algal polysaccharides represent a significant frontier in pharmacological research for the development of novel antiviral therapeutics. Unlike other sources, marine algae offer an underexploited reservoir of unique metabolites with potent, broad-spectrum antiviral properties. A multitude of studies have recognized numerous algal polysaccharides exhibiting antiviral characteristics, including laminaran, alginate, carrageenan, fucan, and naviculan. Moreover, these polysaccharides exert antiviral effects through diverse mechanisms, including blocking viral attachment and entry into host cells, as well as inhibiting viral genome replication and protein synthesis. The shift towards treatment with polysaccharides derived from marine algae represents a step towards more flexible and resistance-resistant antiviral strategies. By leveraging the gradual evolution of algal metabolites, researchers can develop agents that are not only effective against current threats but also adaptable to changes in the antigenic composition of future viral outbreaks. This review summarizes recent advances in the current understanding of algal polysaccharides, including their production, extraction methods, structural characterization, and applications in gene delivery. It also provides a critical discussion of structure-activity relationships, antiviral mechanisms, and comparative evaluation of different classes of algal polysaccharides to support their advancement as promising natural antiviral agents for future research and therapeutic development.},
}
@article {pmid42178216,
year = {2026},
author = {Chadha, U and Kushnirenko, A and Fernandes, DC and Patel, KB and Crothers, NJ and Singh, H and Isiksalan, M and Nasir, I and Armstrong, S and Behdinan, K},
title = {Augmenting healthcare systems for pandemic preparedness: a Lean Six Sigma perspective.},
journal = {International journal for quality in health care : journal of the International Society for Quality in Health Care},
volume = {38},
number = {2},
pages = {},
pmid = {42178216},
issn = {1464-3677},
mesh = {Humans ; Pandemic Preparedness/organization &amp; administration ; *COVID-19 ; *Pandemics/prevention &amp; control ; *Total Quality Management/organization &amp; administration ; Efficiency, Organizational ; Public Health Infrastructure ; SARS-CoV-2 ; *Delivery of Health Care/organization &amp; administration ; Hospital Administration ; },
abstract = {BACKGROUND: Past global healthcare crises have exposed vulnerabilities in healthcare systems, including inefficiencies in hospital operations, delayed response times, and overburdened infrastructure. Traditional hospital systems built for routine care were sometimes not resilient or adaptable in the face of such crises, resulting in global failures. This narrative review examines how Lean Six Sigma (LSS) principles can be incorporated into conventional hospital operations to enhance pandemic preparedness by building the resilience of hospital infrastructure, streamlining processes during time-sensitive situations, and improving waste reduction, all while being adaptable and sustainable.<br><br>METHODS: This narrative review synthesizes literature using Coronavirus Disease 2019 (COVID-19)&#xa0;as a benchmark to evaluate hospital response strategies, failures, and factors contributing to failure, including the critical assessment of ethical disruptions, operational weaknesses, and healthcare business models. LSS principle applications, i.e. DMAIC, Value Stream Mapping, SIPOC, FMEA, and Control Charts, were explored for facilitating efficient care, crisis response, and policy integration. Various case studies were used to support the comparative analysis and insights.<br><br>RESULTS: The literature indicates that adoption of LSS tools in the most vulnerable aspects of healthcare, including patient triage, supply chain optimization, and controlling and reducing mortality, has been associated with measurable improvements. Most importantly, integrating data-driven LSS resulted in enhanced surge responsiveness and ethical compliance within national healthcare frameworks and policies. However, despite its efficacy, there are institutional barriers like capital constraints, resistance to change, data inconsistencies, and a lack of legislative frameworks that impede widespread LSS adoption.<br><br>CONCLUSION: LSS offers an adaptable and scalable methodology to re-engineer conventional hospital operations and pandemic preparedness. The emphasis on 'kaizen' (continuous improvement), data-informed decision making, and focus on precision aligns with the needs of healthcare systems as revealed by recent crises. To unlock the potential for preparedness, healthcare systems and legislation must focus on institutionalizing LSS across public and private sectors through strategic investment, education, and cross-sector collaborations. This review provides a comprehensive framework for policymakers, governments, epidemiologists, doctors, and hospital business managers for building resilient, efficient, and pandemic-ready hospitals.},
}
@article {pmid42178593,
year = {2026},
author = {Esperatti, M and Olmos, M and Fuentes, N},
title = {ARDS and corticosteroids: beyond COVID-19.},
journal = {Pneumonia (Nathan Qld.)},
volume = {18},
number = {1},
pages = {},
pmid = {42178593},
issn = {2200-6133},
abstract = {Acute respiratory distress syndrome (ARDS) remains a high‑mortality condition despite major advances in ventilatory and supportive care. Because lung injury is driven by uncontrolled inflammation and disruption of the alveolar–capillary barrier, corticosteroids have long been considered a biologically plausible therapy. Over several decades, randomized trials have evaluated different corticosteroid types, doses, durations, and initiation timings in heterogeneous populations, including patients with primary ARDS and those with sepsis or pneumonia complicated by ARDS. The COVID‑19 pandemic provided a unique opportunity to study a more homogeneous cause of ARDS, generating additional evidence supporting corticosteroid efficacy in virus‑related respiratory failure. Despite these advances, clinical practice remains variable worldwide. Evolving definitions, diverse trial designs, and etiologic variability have led to uncertainty regarding indication, optimal dosing, drug selection, and treatment duration. The new global definition of ARDS now includes patients supported with noninvasive ventilation or high‑flow nasal oxygen, raising questions about how evidence derived from invasively ventilated populations applies to these groups. Parallel research identifying inflammatory subphenotypes with potentially divergent treatment responses further underscores the need for individualized, evidence‑based strategies. In this review, we examine conceptual, biological, and clinical considerations and synthesize the available evidence to inform decision‑making. We propose a pragmatic, context‑based framework to guide corticosteroid use in ARDS according to etiology and patient characteristics, emphasizing early initiation—ideally within 24–48 hours—and regimens equivalent to ≥80 mg/day of methylprednisolone or ≥400 mg/day of hydrocortisone for at least seven days, which have demonstrated efficacy with an acceptable safety profile. Research priorities include optimizing dose and duration, evaluating non‑ventilated and underrepresented subgroups, and clarifying phenotype‑specific effects and long‑term safety.},
}
@article {pmid42179466,
year = {2026},
author = {Von Rekowski, CP and Fonseca, TAH and Araújo, R and Calado, CRC and Bento, L and Pinto, I},
title = {Blood biomarker trajectories in ICU-directed prediction models - A scoping review.},
journal = {The EPMA journal},
volume = {17},
number = {2},
pages = {427-455},
pmid = {42179466},
issn = {1878-5077},
abstract = {BACKGROUND: Despite advanced analytical methods and increasing data availability, most intensive care unit (ICU) prediction models rely on static measurements. However, longitudinal monitoring of biomarkers may better capture disease progression and support timely, individualized interventions within the framework of predictive, preventive, and personalized medicine (PPPM). Since the COVID-19 pandemic, interest in both static and dynamic modelling has expanded. Therefore, this review aimed to summarize current evidence on the use of longitudinal blood biomarker data in ICU prediction models, assess how the pandemic shaped this research, and report validation strategies.<br><br>METHODS: This scoping review followed the PRISMA-ScR guidelines. PubMed and Google Scholar were searched for studies on blood biomarker trajectory analysis in the ICU published between 2014 and 2025, covering five years before and after the onset of the COVID-19 pandemic.<br><br>RESULTS: Forty-seven studies were included, mainly from North America (47%), Europe (45%), and Asia (34%). ICU and hospital mortality were the predominant outcomes. Although 53% of studies used pre-pandemic data, 94% were published afterwards. The most frequent biomarker categories were immune response (74.5%) and metabolic/organ function (66.0%). Common biomarkers included platelets and lactate (n&#x2009;=&#x2009;9), lymphocytes and mHLA-DR (n&#x2009;=&#x2009;6), and creatinine and interleukin-6 (n&#x2009;=&#x2009;5). Modelling approaches integrated longitudinal regression-based models (31.9%), latent class-based models (44.7%), and machine-learning/data-driven clustering (27.7%). Trajectory patterns varied depending on both biomarker type and modelling technique. Cox regression, Kaplan-Meier, and logistic regression were commonly applied to assess associations with outcomes. Notably, only 21% of studies reported any form of validation, highlighting a major limitation for clinical applicability.<br><br>CONCLUSION: Blood biomarker trajectories have potential to improve dynamic risk prediction and stratification, supporting targeted prevention through early identification of high-risk patterns, and enable more personalized treatment via adaptive, patient-specific approaches. Nevertheless, substantial methodological heterogeneity and the low proportion of validated models limit clinical applicability. Greater standardization and robust validation are essential to facilitate translation into PPPM-oriented intensive care.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13167-026-00456-5.},
}
@article {pmid42181019,
year = {2026},
author = {Koehler, SM and Ayhan, E},
title = {What's New in Wide-Awake Local Anesthesia No Tourniquet (WALANT) Hand Surgery?.},
journal = {Journal of hand surgery global online},
volume = {8},
number = {4},
pages = {101033},
pmid = {42181019},
issn = {2589-5141},
abstract = {Wide-awake local anesthesia no tourniquet (WALANT) has evolved from a novel technique to an increasingly adopted anesthetic strategy in hand surgery. In the post-coronavirus disease (COVID)-19 era, there has been a marked expansion in WALANT-related literature, necessitating synthesis of contemporary evidence to guide clinical practice. This narrative review examines recent WALANT studies organized into six thematic domains: comparative trials versus traditional anesthesia, use in the pediatric population, patient satisfaction and experience, environmental impact, cost comparison and value-based care, and applications beyond the hand and wrist. Comparative studies consistently demonstrate that WALANT provides noninferior functional outcomes and complication rates relative to regional and general anesthesia, with improved intraoperative pain and similar early postoperative pain. Pediatric data support feasibility and high satisfaction in appropriately selected patients, particularly adolescents. Patient satisfaction is uniformly high, with strong willingness to repeat WALANT procedures. WALANT pathways also reduce solid waste and carbon emissions, particularly when procedures are performed outside the main operating room. Cost analyses demonstrate substantial savings driven by decreased anesthesia use and site-of-service optimization. Expanding indications now include proximal upper extremity procedures and select nonupper extremity surgeries, reflecting increasing surgeon experience and confidence. WALANT represents a mature, evidence-supported care pathway that aligns clinical outcomes with patient-centered experience, environmental sustainability, and cost efficiency. Its greatest impact is realized when integrated into procedure room-based workflows with careful patient selection and standardized technique. Future efforts should focus on refining indications, optimizing patient experience, and expanding scalable implementation across diverse practice settings.},
}
@article {pmid42181087,
year = {2026},
author = {Kaushik, R and Re, S},
title = {Artificial intelligence directed computational protein design: lessons from COVID-19 for pandemic-ready vaccines and antibody therapeutics.},
journal = {Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques},
volume = {29},
number = {},
pages = {16146},
pmid = {42181087},
issn = {1482-1826},
mesh = {*Artificial Intelligence ; Humans ; *COVID-19 Vaccines/chemistry ; *COVID-19/prevention &amp; control ; *Drug Design ; SARS-CoV-2/drug effects ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Pandemic Preparedness ; },
abstract = {Artificial intelligence (AI) directed computational protein design has emerged as a transformative force in modern therapeutic discovery, reshaping how vaccines and antibody-based interventions are conceived, optimized, and deployed against emerging infectious diseases. The COVID-19 pandemic served as an unprecedented real-world stress test for these technologies, highlighting their potential to accelerate antigen design, guide antibody optimization, and anticipate viral evolution in near real time. AI driven approaches contributed to faster characterization of viral variants, supported vaccine and broadly neutralizing antibodies developments. Despite the significant contributions, the pandemic also revealed important limitations that must be addressed before such approaches can be relied upon as cornerstones of global preparedness. Challenges related to data bias, model interpretability, experimental validation bottlenecks, and integration with existing regulatory frameworks became increasingly apparent. In several cases, the gap between computational promise and translational readiness underscored the need for closer coupling between in silico design, laboratory experimentation, and clinical evaluation. Moreover, the rapid pace of AI innovation often outstripped established regulatory pathways, raising questions about standardization, validation, and long-term safety. This mini review provides a focused overview of recent advances in AI enabled computational protein design, with an emphasis on applications relevant to pandemic response. Drawing on lessons from COVID-19 case studies, it examines translational and regulatory considerations, highlights unresolved controversies, and identifies critical research gaps. Collectively, these insights outline a path toward transitioning AI designed vaccines and antibody therapeutics from reactive emergency tools into proactive, scalable infrastructures for future pandemic preparedness.},
}
@article {pmid42181627,
year = {2026},
author = {Maurya, N and Le, A and Melbourne, G and Chow, JSF},
title = {Long-term cardiovascular impact of COVID-19 among hospitalised and non-hospitalised populations: a narrative synthesis review.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1741293},
pmid = {42181627},
issn = {2297-055X},
abstract = {INTRODUCTION: COVID-19, initially recognised as a respiratory illness, affects multiple organ systems, including the cardiovascular system. Both hospitalised and non-hospitalised patients may experience persistent cardiac complications; however, the long-term impact across different levels of disease severity remains unclear. This review aims to summarise the existing evidence on the long-term cardiovascular impact of COVID-19, with a particular focus on differences between hospitalised and non-hospitalised patients.<br><br>METHOD: PubMed, MEDLINE, CINAHL, and Embase databases were searched for studies published between December 2019 and January 2024 that investigated cardiovascular outcomes in long COVID. Studies were screened for eligibility, and data were extracted using a standardised form. Due to heterogeneity across the included studies, a narrative synthesis was performed.<br><br>RESULTS: Seventy-one studies were included, most of which were observational and conducted in Europe and Asia, with follow-up periods ranging from <1 to >24 months. Hospitalised patients reported more frequent cardiovascular symptoms; however, echocardiographic abnormalities were observed across all groups. Reporting of symptom severity was inconsistent. Common cardiovascular manifestations included palpitations, chest pain, fatigue, and arrhythmias. Persistent cardiac dysfunction and dysautonomia were observed regardless of hospitalisation status.<br><br>CONCLUSION: Hospitalised patients are at higher risk of long-term cardiovascular complications, including myocardial injury, arrhythmias, and heart failure, while non-hospitalised individuals may experience subclinical cardiac changes. Vaccination appears to have a protective effect. Standardised, prospective studies are needed to clarify long-term cardiovascular risks and to guide follow-up care.},
}
@article {pmid42183922,
year = {2026},
author = {Kavak, S},
title = {Biomechanics and Oxidative Stress: An Integrative Review of the Redox-Mechanobiological Axis and the Role of Trace Elements in Disease.},
journal = {Biological trace element research},
volume = {204},
number = {9},
pages = {6961-6970},
pmid = {42183922},
issn = {1559-0720},
mesh = {Humans ; *Oxidative Stress/physiology ; Oxidation-Reduction ; *Trace Elements/metabolism ; Biomechanical Phenomena ; Animals ; *Mechanotransduction, Cellular ; *COVID-19/metabolism ; *Cardiovascular Diseases/metabolism ; Neoplasms/metabolism ; Reactive Oxygen Species/metabolism ; },
abstract = {Oxidative stress and mechanobiological signaling are increasingly recognized as interconnected determinants of cellular and systemic homeostasis. Reactive oxygen species (ROS), traditionally associated with molecular damage, are now understood to directly regulate cytoskeletal remodeling, membrane viscoelasticity, mitochondrial dynamics, and mechanotransduction pathways including focal adhesion kinase (FAK), integrins, and Yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ). Conversely, biomechanical forces such as extracellular matrix stiffness, cyclic stretch, and disturbed shear stress modulate intracellular redox signaling through mitochondrial dysfunction, NADPH oxidase activation, and inflammatory pathways. This bidirectional interaction forms a self-amplifying "redox-mechanobiological axis" that contributes to endothelial dysfunction, fibrosis, thrombosis, tumor progression, and viral pathophysiology.Trace elements, particularly selenium, zinc, and iron, emerge as critical modulators of this axis by influencing antioxidant defense systems, cytoskeletal integrity, membrane stability, ferroptosis, and cellular stiffness. Selenium-dependent selenoproteins regulate mitochondrial redox balance and actin organization; zinc stabilizes membrane architecture and mechanosensitive proteins; and iron-mediated Fenton chemistry promotes oxidative injury, ferroptosis, and biomechanical alterations.This review integrates molecular mechanisms, mechanobiological principles, and recent clinical findings-particularly from cardiovascular disease, cancer biology, and COVID-19-to propose a unified framework linking oxidative stress to biomechanical dysfunction. In addition, current controversies, methodological limitations, and future therapeutic directions targeting the redox-mechanobiological axis are critically discussed.},
}
@article {pmid42184107,
year = {2026},
author = {Khoo, LY and Dhillon, SK},
title = {Comparative review of artificial intelligence for transcriptomic biomarker discovery in coronavirus disease 2019 (COVID-19).},
journal = {Briefings in bioinformatics},
volume = {27},
number = {3},
pages = {},
pmid = {42184107},
issn = {1477-4054},
support = {//Ministry of Higher Education, Malaysia/ ; FP019-2022//Fundamental Research Grant Scheme/ ; },
mesh = {*Artificial Intelligence ; *COVID-19/genetics/virology/metabolism ; Humans ; *SARS-CoV-2/genetics ; Biomarkers/metabolism ; *Transcriptome ; Gene Expression Profiling ; },
abstract = {The Coronavirus Disease 2019 (COVID-19) pandemic has highlighted the significance of reliable molecular biomarkers in clinical use. Despite the popularity of traditional statistical approaches, the high dimensionality of transcriptomic data presents challenges for these conventional methods. While artificial intelligence (AI) algorithms have emerged as highly advantageous for handling these complex datasets, there is a lack of evaluation of these approaches in COVID-19 transcriptomic studies. This review aims to provide an evaluation of these studies employed for transcriptomic biomarker discovery in COVID-19 using AI, assessing their study designs, methodologies, and outcomes. Based on a comprehensive search for literature across five databases including Web of Science Core Collection, Scopus, PubMed/MEDLINE, IEEE Xplore Digital Library, and LitCovid from December 2019 to March 2025, this review selected 63 studies for a narrative synthesis of four key sections: (i) The Landscape of AI-Driven COVID-19 Transcriptomics, (ii) Limitations of Studies, (iii) A Proposed AI-Driven Transcriptomics Framework, and (iv) Clinical Translation Challenges, Opportunities, and Future Directions. Our analysis revealed limitations in data quality, sample size, and heterogeneity, as well as methodologies regarding validation and interpretability. Thus, we proposed an evidence-informed workflow that addresses these current limitations in study design, while acknowledging real-world constraints. We further discuss the emerging potential of agentic AI systems as a promising solution to current limitations. By bridging methodological gaps with translation considerations, this review can enhance pandemic response strategies for future emerging infectious diseases. Key Points Applications observed in reviewed studies mainly included applications in diagnosis and severity stratification of COVID-19 patients. The limitations of current studies included small sample sizes, the reliance on public datasets lacking detailed metadata, batch effects and data heterogeneity reducing model robustness, the lack of external validation, risks of data leakage and circular validation leading to inflated performance metrics, and challenges in model interpretability. An evidence-informed AI-driven framework is proposed, acknowledging real-world constraints including small pandemic cohort sizes, domain shift from viral evolution, and resource-limited settings, with emerging agentic AI systems offering potential solutions.},
}
@article {pmid42185895,
year = {2026},
author = {Petakh, P and Ravlo, E and Pan, Q and Bruzzone, R and Oksenych, V and Vähä-Koskela, M and Kamyshnyi, O and Kainov, DE},
title = {Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections.},
journal = {Virology journal},
volume = {23},
number = {1},
pages = {},
pmid = {42185895},
issn = {1743-422X},
mesh = {*Antiviral Agents/therapeutic use/pharmacology ; Humans ; Drug Therapy, Combination ; *Virus Diseases/drug therapy ; Drug Resistance, Viral ; SARS-CoV-2/drug effects ; COVID-19 ; Pandemics ; Microbial Sensitivity Tests/standards ; Animals ; *COVID-19 Drug Treatment ; },
abstract = {The COVID-19 pandemic showed that heterogeneous antiviral assay designs, endpoints and reporting practices can obscure which candidate drugs and combinations are genuinely promising. As antiviral discovery expands from acute infections to chronic and latent viral diseases, the field needs a compact, reproducible and biologically interpretable set of response metrics. In this Personal View, we argue that EC50 and the selectivity index should be retained for pharmacological interpretation but systematically complemented by drug sensitivity scores (DSS), which integrate potency and efficacy across the tested concentration range, and by ΔDSS, calculated as DSS_antiviral minus DSS_toxicity from matched efficacy and viability curves. We propose standardized modules for resistance passaging, sequencing and host-side-effect profiling so that monotherapies are assessed not only for antiviral potency but also for durability and host-cell perturbation. For combinations, we discuss Bliss, ZIP, HSA and Loewe models as complementary tools for identifying additive or synergistic regimens while accounting for toxicity, resistance suppression and drug-drug interactions. Finally, we outline how harmonized metrics can support organoid, animal and clinical prioritization, improve machine-learning datasets and guide pandemic response, including rapid monotherapy testing for some DNA viruses and early combination testing for RNA and reverse-transcribing viruses.},
}
@article {pmid42188759,
year = {2026},
author = {Wiysonge, CS and Adamu, AA and Bwaka, AM and Wiysonge, CN and Ticha, JM and Katsande, R and Bita Fouda, AA and Safdar, N and Teka Bekele, A and Iwu-Jaja, C and Bathondoli, B and Ndiaye, S and Amani, A and Demanou, M and Ainan, S and Gunaratna, MP and Diop, A and Han, Y and Kfutwah, A and Mukaro, R and Doshi, RH and Lukoya, CO and Nyarko, K and Mwenda, JM and Masresha, BG},
title = {Vaccine-Preventable Disease Control in the WHO African Region After the COVID-19 Public Health Emergency of International Concern: Implications for Recovery, Resilience, and System Transformation.},
journal = {Vaccines},
volume = {14},
number = {5},
pages = {},
pmid = {42188759},
issn = {2076-393X},
abstract = {BACKGROUND: The end of the COVID-19 public health emergency of international concern (PHEIC) in May 2023 marked a transition from disruption to recovery and rebuilding of health systems. The WHO African Region entered this period with declining routine immunization coverage, widening inequities, and fragile surveillance systems. We conducted a critical narrative synthesis of post-PHEIC recovery and the transformation of immunization systems in the region from 2023 to 2025.<br><br>METHODS: We thematically analyzed publicly available data from the WHO and other sources using a systems-oriented framework covering immunization coverage, equity, vaccine introductions, disease control, governance, financing, and data systems.<br><br>RESULTS: Regional coverage for most antigens was restored to 2019 pre-pandemic levels by 2024, e.g., three doses of diphtheria-tetanus-pertussis-containing vaccines at 76%. However, progress remains insufficient to meet the Immunization Agenda 2030 (IA2030) target of 90% coverage. In addition, there were 6.7 million zero-dose children in the 2024 birth cohort (6.3% higher than the 6.3 million in 2019), concentrated in a few countries. The IA2030 target is a 50% reduction in the number of zero-dose children by 2030, compared to 2019. Recovery initiatives have restored services, while accelerated introductions (e.g., malaria vaccines introduced in 20 new countries in 2024-2025) signal renewed system momentum. Yet, progress has plateaued at pre-pandemic levels, reflecting structural constraints rather than sustained transformation. Concurrently, recurrent outbreaks of measles, yellow fever, and other vaccine-preventable diseases highlight persistent immunity gaps and surveillance limitations. Structural constraints (including financing fragility, subnational inequities, and system fragmentation) continue to limit sustained progress.<br><br>CONCLUSION: This study offers important insights that can inform immunization policymaking in the WHO African Region and beyond. Current post-PHEIC trends reflect recovery without transformation. Achieving IA2030 targets will require a shift from broad coverage expansion to precision delivery approaches that prioritize zero-dose and underserved populations. Immunization must be positioned as a central pillar of primary health care and health security systems.},
}
@article {pmid42188768,
year = {2026},
author = {Xue, H and Haynesworth, K and Hempel, HA and Kemp, TJ and Pinto, LA},
title = {Measuring Humoral Immune Responses to SARS-CoV-2: A Comprehensive Review of Serological Assays.},
journal = {Vaccines},
volume = {14},
number = {5},
pages = {},
pmid = {42188768},
issn = {2076-393X},
support = {Contract No. 75N91019D00024/CA/NCI NIH HHS/United States ; },
abstract = {The COVID-19 pandemic highlighted the critical role of serological assays in understanding antiviral immune responses, monitoring vaccine efficacy, and informing public health strategies. This review provides a comprehensive overview of commonly used SARS-CoV-2 antibody detection methods, focusing on binding and neutralization assays. Antibody binding assays, including enzyme-linked immunosorbent assays (ELISAs), chemiluminescence immunoassays (CLIAs), lateral flow immunoassays (LFAs), and multiplex platforms, enable the rapid and high-throughput detection of immunoglobulin isotypes against various viral antigens. Neutralization assays, including live-virus, pseudovirus (PsV), and surrogate assays, offer functional insights into the ability of antibodies to prevent viral entry, though they often require higher biosafety levels and optimization. Serological assays, primarily antibody binding assays and several surrogate neutralization assays, received Emergency Use Authorization (EUA) during the pandemic, supporting seroprevalence efforts. Antibody binding assays and neutralization assays were also widely used in vaccine immunogenicity studies. Despite many standardization initiatives, assay standardization and data harmonization remain challenging and require further efforts. The choice of assay should be guided by study goals: antibody binding assays are preferred for high-throughput monitoring and epidemiological studies, while neutralization assays are essential for assessing functional immunity and variant-specific neutralization and protection.},
}
@article {pmid42188804,
year = {2026},
author = {Omondi, J and Ambogo, R and Ochieng, C and Farag, M and Mutwiri, G},
title = {Impact of the COVID-19 Pandemic on HPV Vaccination in Low- and Middle-Income Countries: A Scoping Review.},
journal = {Vaccines},
volume = {14},
number = {5},
pages = {},
pmid = {42188804},
issn = {2076-393X},
support = {345526//University of Saskatchewan, OPVPA/ ; },
abstract = {Background: The COVID-19 pandemic caused disruptions in HPV vaccination and may have severely undermined global cervical cancer prevention, posing long-term risks to controlling cervical cancer and other HPV-related diseases. Objective: We conducted a scoping review to map and synthesize available evidence on how the COVID-19 pandemic has affected human papillomavirus (HPV) vaccination programs in low- and middle-income countries (LMICs) focusing on changes in vaccine delivery and coverage, determinants of uptake, economic and programmatic consequences and vaccine hesitancy. Methods: Inclusion criteria were limited to studies published in the English language between January 2020 to May 2025, and followed JBI and Arksey &amp; O'Malley's scoping review guidelines. The review proceeded through three stages: database searches, gray literature and citation tracking and used a PRISMA-ScR checklist to guide narrative and tabular synthesis. Results: A total of 1063 records, 57 studies were included in the final analysis, and these were spread out across 37 low- and middle-income countries (LMICs) mainly in Africa, Asia, and Latin America. Our analysis revealed that HPV vaccination coverage declined substantially during the COVID-19 pandemic, with reductions of up to 90% reported across the included studies, in the context of school closures, workforce redeployment, and supply-chain disruptions. Recovery efforts also faced major barriers including vaccine hesitancy, misinformation about COVID-19 vaccines, and travel restrictions. Strategies like digital tools, mobile clinics, and community health workers showed promise alongside integrated school- and facility-based approaches, although there is limited evidence on cost-effectiveness and long-term sustainability of these strategies. Conclusions: HPV vaccination in LMICs was significantly disrupted by the COVID-19 pandemic due to unreliable vaccine supply chains, health-worker shortages, and challenges tied to school-based vaccine delivery. Although recovery methods show potential, longer observation periods are needed to determine their full effectiveness.},
}
@article {pmid42188806,
year = {2026},
author = {Lee, HM},
title = {Immune Cell Signaling in Feline Infectious Peritonitis Virus Infection and Implications for Vaccine Design.},
journal = {Vaccines},
volume = {14},
number = {5},
pages = {},
pmid = {42188806},
issn = {2076-393X},
support = {Research Grant, 2024//Chungnam National University/ ; },
abstract = {Feline infectious peritonitis virus (FIPV) remains one of the most challenging viral diseases in veterinary medicine, largely owing to the absence of a consistently effective and safe vaccine. Despite widespread feline coronavirus infection, only a subset of infected cats progresses to feline infectious peritonitis, indicating that host immune responses are key determinants of disease outcomes. Accumulating evidence indicates that disease severity is driven not only by viral replication but also by macrophage- and monocyte-centered immune signaling, leading to excessive inflammation and systemic immunopathology in the host. Previous vaccine approaches against FIPV have failed to provide consistent protection and, in some cases, have been associated with enhanced disease. These outcomes suggest that vaccine-induced immune responses that recapitulate pathogenic signaling patterns may exacerbate disease rather than confer protection. In this review, we discuss the current knowledge of immune cell signaling pathways implicated in FIPV infection, including innate sensing through Toll-like receptors, downstream mitogen-activated protein kinases and NF-κB signaling, cytokine production profiles, Fc receptor-associated processes, and intracellular pathways such as autophagy, and how these mechanisms shape vaccine-induced immunity. By integrating insights from immune signaling kinetics, antibody functionality, adjuvant-driven pathway engagement, and platform-specific immune signatures, this review emphasizes the need to reframe FIPV vaccine development strategies that actively shape host immune responses. Rather than maximizing immunogenicity, successful vaccine design is likely to depend on limiting sustained macrophage activation and pro-inflammatory cytokine amplification while supporting antiviral immune functions, thereby reducing the risk of antibody-dependent enhancement and immunopathology. Beyond feline diseases, these considerations provide broader lessons for vaccine design in settings where immune-mediated pathology contributes to disease severity.},
}
@article {pmid42188810,
year = {2026},
author = {Park, SH and Son, YM},
title = {Bacterial Membrane Vesicles as Versatile Platforms for Systemic and Mucosal Vaccines.},
journal = {Vaccines},
volume = {14},
number = {5},
pages = {},
pmid = {42188810},
issn = {2076-393X},
support = {RS-2024-00438990//Korea Health Industry Development Institute/Republic of Korea ; RS-2025-16066763//National Research Foundation of Korea/ ; },
abstract = {Bacterial membrane vesicles (BMVs), encompassing outer membrane vesicles (OMVs) released from Gram-negative bacteria and extracellular vesicles (EVs) released from Gram-positive bacteria, have emerged as promising vaccine platforms owing to their intrinsic immunostimulatory properties and capacity to deliver a wide range of antigens. Although conventional vaccines effectively prevent infectious diseases, their long-term efficacy is often limited by antigenic variation and reliance on a restricted number of licensed adjuvants. BMVs, as self-adjuvanting systems, enable both antigen delivery and innate immune activation. BMVs are nanoscale lipid bilayer structures enriched with pathogen-associated molecular patterns (PAMPs), facilitating their recognition and uptake by antigen-presenting cells. This leads to the activation of pattern recognition receptors and the induction of pro-inflammatory cytokines, type I interferons, and adaptive immune responses, including antibody production and Th1- and Th17-biased cellular immunity. Recent studies highlight the versatility of BMVs as vaccine platforms across bacterial, fungal, and viral infection models. BMVs induce protective immunity by promoting both systemic and mucosal immune responses, thereby reducing bacterial burden and limiting pathogen colonization across diverse infection models. These properties have supported their application in viral vaccine development, including influenza and SARS-CoV-2, with the potential to enhance mucosal immunity. Despite these advantages, challenges remain in standardization, safety, and antigen-loading efficiency. Engineered BMVs incorporating protein or mRNA antigens may further enhance antigen presentation and CD8[+] T cell responses. This review summarizes the biological features, immunological mechanisms, and future potential of BMVs in vaccine development.},
}
@article {pmid42189412,
year = {2026},
author = {Minari, TP},
title = {Modernization of Nutritional Assessment in Population Surveys: Integrating Anthropometry, Body Composition, and Biomarkers in the Digital Era.},
journal = {Current nutrition reports},
volume = {15},
number = {1},
pages = {},
pmid = {42189412},
issn = {2161-3311},
mesh = {Humans ; *Body Composition ; *Nutrition Assessment ; *Anthropometry/methods ; Biomarkers/analysis ; Nutritional Status ; COVID-19/epidemiology ; Digital Health ; *Nutrition Surveys/methods ; Malnutrition/diagnosis ; SARS-CoV-2 ; Public Health ; },
abstract = {PURPOSE OF REVIEW: This narrative review examines current approaches to nutritional status assessment in population-based surveys, emphasizing the complementary roles of anthropometric measurements, body composition analysis, and biochemical indicators. It aims to critically analyze methodological advances, operational constraints, and emerging strategies to improve the quality and applicability of nutritional surveillance in public health.<br><br>RECENT FINDINGS: Anthropometry remains the most widely used method due to its feasibility and scalability, although its diagnostic capacity is limited. Body composition techniques provide more detailed insights into tissue distribution but are constrained by cost and infrastructure requirements. Biochemical indicators offer high sensitivity for detecting metabolic and micronutrient alterations, yet their use in large-scale surveys is restricted by logistical and ethical challenges. The COVID-19 pandemic exposed vulnerabilities in data collection systems and highlighted the need for more resilient surveillance approaches. In parallel, digital technologies have expanded possibilities for data integration and analysis, although their implementation remains uneven across settings. A comprehensive approach to nutritional assessment requires the integration of complementary methods to address the multidimensional nature of malnutrition and chronic disease monitoring. Strengthening population-based surveys depends on balancing methodological rigor with operational feasibility, alongside investments in infrastructure, workforce capacity, and data governance. Advances in digital health may enhance surveillance systems, but their impact will depend on equitable implementation and alignment with public health priorities and equity-oriented strategies.},
}
@article {pmid42189856,
year = {2026},
author = {Malieuze Nanfah, MD and Binam Nkot, VM and Yop Kite, MM and Beack Bayengue, SS and Tchamba, GB and Tandja, AG and Koloko, BL and Ngo Malabo, ET and Ekwe Priso, JGLF and Embolo Enyegue, EL and Koanga Mogtomo, ML and Kojom Foko, LP},
title = {Burden and clinical impact of 'neglected' transfusion-transmitted infections in Cameroon: A systematic review and meta-analysis.},
journal = {PLoS neglected tropical diseases},
volume = {20},
number = {5},
pages = {e0014378},
pmid = {42189856},
issn = {1935-2735},
mesh = {Humans ; Cameroon/epidemiology ; *Transfusion Reaction/epidemiology ; Blood Donors ; *Blood-Borne Infections/epidemiology ; Prevalence ; Blood Banks ; Blood Safety ; },
abstract = {BACKGROUND: Blood supply is a public health challenge in African countries. In Cameroon, blood selection guidelines focus on four viral and bacterial pathogens (HIV, hepatitis B and C viruses, Treponema pallidum) associated with transfusion-transmitted infections (TTIs). Other pathogens, often endemic (e.g., Plasmodium spp.), are not routinely screened in blood banks and are not included in blood safety guidelines or surveillance, despite their potential for transfusion transmission.<br><br>MATERIALS AND METHODS: Here, we conducted a systematic review and meta-analysis of prevalence, determinants, and clinical impact of 'neglected' pathogens, defined as pathogens not included in national blood safety guidelines (e.g., filaria, dengue virus, Toxoplasma gondii), in blood banks. Additionally, we identified the most urgent challenges and proposed actionable solutions to guide blood safety guidelines in the country.<br><br>RESULTS: A total of 18 studies, covering ~12,500 donations, were included, with the bulk coming from donors living in three regions (Littoral, Northwest, Centre). Plasmodium parasite (68.4%) was the major studied pathogen, even though an evident publication bias was found (p&#x2009;=&#x2009;0.004). The other pathogens included dengue virus (5.3%), T. gondii (5.3%), and HTLV-1 (5.3%). The filarial parasite Loa loa was consistently accidentally found. Even though there is no evidence of SARS-CoV-2-associated TTIs till now, the pooled proportion of this virus was 17.7%. The pooled proportions of infection in blood donors were 16.6% for Plasmodium spp. and 0.5% for Loa loa. There is a paucity of clinical impact studies on these 'neglected' TTIs, and the available literature suggests impaired levels of immunoglobulin E and albumin. We identified urgent challenges, including awareness among healthcare providers and policymakers, diagnostic and logistical constraints, and low microbial density infections, associated with neglected pathogen-related blood safety.<br><br>CONCLUSION: We opine that providing more epidemiological evidence is crucial to address the above-mentioned challenges for guiding and guaranteeing blood safety in Cameroon.},
}
@article {pmid42191274,
year = {2026},
author = {Parikesit, AA and Ansori, ANM and Kharisma, VD and Purnobasuki, H and Nugraha, Y},
title = {Advances in bioinformatics: Integration of biomolecular simulations and virtual reality for revolutionizing disease mechanism elucidation and therapeutic development.},
journal = {International review of cell and molecular biology},
volume = {402},
number = {},
pages = {211-236},
doi = {10.1016/bs.ircmb.2025.11.004},
pmid = {42191274},
issn = {1937-6448},
mesh = {Humans ; *Molecular Dynamics Simulation ; *Virtual Reality ; *Computational Biology/methods ; COVID-19/virology ; SARS-CoV-2 ; },
abstract = {Virtual reality and biomolecular simulations currently lie at the leading edge in dissecting the molecular pathways underlying the disease. This chapter will discuss how the integrations of various technologies will extend knowledge about complex biological processes and their contribution to disease pathophysiology. Advances in molecular dynamics (MD) simulations currently make it possible to record the behavior of proteins and other biomolecules with accurate temporal resolution and full atom detail. Such simulations include information on critical structural changes related to diseases, interactions with possible medication, and functionality of proteins. With recently improved speed, accuracy, and accessibility, MD. has become a basic research and drug development tool. From the researcher's point of view, virtual reality has revolutionized how one can conceptualize and interact with molecular structures. Virtual reality (VR) is a method that uses the three-dimensional presentation of biomolecules as manipulable virtual objects for intuitive insight into molecular interactions and structural connections. In this way, virtual technology can be very helpful in investigating complex chemical systems and creating new theories. It facilitates the Cloud-based co-creation of environments in cloud systems for molecular modeling. The same technologies allow real-time research collaboration by sharing and changing virtual molecules. These cooperative situations reward the generation of new ideas and information, which might provide novel discoveries that more direct approaches could not realize. This chapter will discuss the range of computational methods applied to elucidate molecular recognition mechanisms and will cover improved sampling methods and in silico screening. It will also describe how such techniques may be applied to investigate viral proteins and help develop vaccines and drugs during the COVID-19 pandemic. The combination of the predictive power of MD. Simulations with intuitive visualization capabilities from VR would allow researchers to achieve an unprecedented understanding of the molecular origin of many diseases. This should inspire innovation in therapeutic intervention and accelerate discovery in molecular biology.},
}
@article {pmid42191709,
year = {2026},
author = {Fleming, D and Smith, E and Ostrowsky, J and Ulrich, A and Leighton, T and Vestin, N and Mehr, AJ and Furst, R and Norton, A and Lackritz, E},
title = {Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats.},
journal = {NPJ vaccines},
volume = {},
number = {},
pages = {},
doi = {10.1038/s41541-026-01493-x},
pmid = {42191709},
issn = {2059-0105},
support = {226543/WT_/Wellcome Trust/United Kingdom ; 226543/WT_/Wellcome Trust/United Kingdom ; },
abstract = {The COVID-19 pandemic triggered unprecedented investment in coronavirus vaccine R&amp;D, but the long-term trajectory of this funding remains unclear. We mapped coronavirus vaccine grant support from 2020 through 2025, and found an early surge focused on ancestral SARS-CoV-2, a pivot toward broadly protective coronavirus vaccines (BPCV), and then a steep decline in publicly available funding overall, especially in the United States. Reduced sustained investment may weaken future preparedness and response globally to emergent coronavirus threats.},
}
@article {pmid42192748,
year = {2026},
author = {Ramos Marichal, AI and Brady, SP and Ho, HH and Tarullo, AR and Gill, SV},
title = {Physical Activity, Sleep, and Cognition in Preschool-Aged Children: A Scoping Review.},
journal = {Brain sciences},
volume = {16},
number = {5},
pages = {},
pmid = {42192748},
issn = {2076-3425},
abstract = {BACKGROUND/OBJECTIVES: Early childhood is a critical period for executive function and broader cognitive development. Physical activity and sleep are modifiable health behaviors that support neurobiological processes underlying learning. While each has been widely examined, research investigating their combined or interactive relationships with learning remains fragmented. This scoping review synthesizes the literature on associations among physical activity, sleep, and cognition in preschool-aged children (3-5 years) and identifies gaps in the integration of these domains.<br><br>METHODS: Electronic databases were searched for peer-reviewed studies published within the past 10 years. Eligible studies included typically developing children aged 3-5 years and examined overlaps between at least two domains: physical activity, sleep, and cognition. Cross-sectional and longitudinal observational studies were included; intervention and review studies, and those conducted during the COVID-19 pandemic, were excluded.<br><br>RESULTS: Thirty-eight studies met the inclusion criteria. Evidence examining physical activity and sleep was limited and inconsistent. Sleep quality indicators (e.g., sleep efficiency and bedtime regularity) were more often reported to be associated with executive function and broader cognitive outcomes than total sleep duration, which showed variable relationships. Findings linking physical activity and cognition were heterogeneous; however, moderate-intensity and cognitively engaging activities were more often reported in association with executive function than total activity or intensity alone.<br><br>CONCLUSIONS: Findings suggest that sleep quality and characteristics of physical activity may be relevant for preschool cognitive outcomes. Greater integration of these domains is needed, and future research should examine physical activity, sleep, and cognition within a single integrated framework to clarify potential interactive pathways linking these behaviors within this evidence base and to inform physical activity recommendations for early childhood development.},
}
@article {pmid42193193,
year = {2026},
author = {Lee, J and Hwang, H and Hyun, DH},
title = {Plasma Membrane Redox Failure Links COVID-19 Metabolic Stress to Ferroptotic Neurodegeneration.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {5},
pages = {},
pmid = {42193193},
issn = {2076-3921},
support = {RS-2026-25470627//National Research Foundation (NRF) of the Korean government (Ministry of Science and ICT)/ ; },
abstract = {Oxidative stress and redox imbalance are central features of both age-related neurodegenerative disorders and the persistent neurological sequelae of coronavirus disease 2019. Increasing evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disrupts neuronal redox homeostasis via mitochondrial dysfunction, iron dysregulation, inflammatory signaling, and the depletion of pyridine nucleotide pools. In that context, ferroptosis provides a unifying mechanistic framework linking lipid peroxidation to progressive neuronal injury. This review proposes that neuronal vulnerability might depend not only on the oxidative burden itself but also on the failure of membrane-localized antioxidant defenses. Particular emphasis is placed on the plasma membrane redox system (PMRS), a membrane-associated quinone-reducing network that can support coenzyme Q redox cycling and constrain lipid radical propagation at the plasma membrane. Unlike canonical ferroptosis defense systems that rely predominantly on NADPH, components of the PMRS, particularly cytochrome b5 reductase, can also use NADH, conferring partial metabolic flexibility in conditions of redox stress. We further discuss how SARS-CoV-2-induced NAD[+] depletion might progressively destabilize this membrane-proximal defense architecture, potentially lowering the ferroptotic threshold of vulnerable neurons. Finally, we outline therapeutic strategies that might reinforce PMRS-dependent membrane redox control through NRF2 activation, NAD[+] restoration, coenzyme Q-centered interventions, and modulation of iron-catalyzed lipid oxidation.},
}
@article {pmid42193385,
year = {2026},
author = {Lee, WH and Kim, E},
title = {Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies.},
journal = {Biomedicines},
volume = {14},
number = {5},
pages = {},
pmid = {42193385},
issn = {2227-9059},
support = {RS-2026-25479119//National Research Foundation of Korea/ ; 2022R1F1A1074797//National Research Foundation of Korea/ ; },
abstract = {Most infectious pathogens enter the host through mucosal surfaces, yet conventional injectable vaccines primarily induce systemic immunity without eliciting robust secretory immunoglobulin A (SIgA) responses at mucosal sites. The COVID-19 pandemic highlighted this limitation, as intramuscular mRNA vaccines failed to establish durable mucosal immunity in the upper respiratory tract. This review covers recent progress in mucosal vaccine development. We first discuss the organization of the mucosal immune system, focusing on SIgA induction, tissue-resident memory T (TRM) cells, and resident memory B (BRM) cells. We then examine mucosal adjuvants, from cholera toxin and heat-labile enterotoxin derivatives to stimulator of interferon gene (STING) agonists and a strategy to enhance alum adjuvanticity through neutrophil elastase inhibition. Delivery routes including intranasal, oral, and sublingual administration are reviewed alongside viral vectors, nanoparticles, mRNA-lipid nanoparticles, virus-like particles, and engineered bacterial platforms. The roles of innate immune cells, T helper cell subsets, and the microbiota in shaping vaccine responses are discussed. Finally, we survey licensed mucosal vaccines and the COVID-19 mucosal vaccine pipeline, analyze persistent barriers to clinical translation including the absence of validated mucosal correlates of protection, and outline future directions for thermostable formulations and systems biology-driven vaccine design.},
}
@article {pmid42193881,
year = {2026},
author = {Chidanand, D and Cheruku, R and Perla, NS and Darapaneni, A and Panguluri, SK},
title = {Impact of Supplemental Oxygen on Cardiovascular Physiology.},
journal = {Cells},
volume = {15},
number = {10},
pages = {},
pmid = {42193881},
issn = {2073-4409},
mesh = {Humans ; *Oxygen ; Oxidative Stress/drug effects ; Reactive Oxygen Species/metabolism ; Animals ; *Cardiovascular Physiological Phenomena/drug effects ; Hyperoxia/physiopathology ; Lung/physiopathology ; *Oxygen Inhalation Therapy/adverse effects ; COVID-19/therapy ; Respiration, Artificial ; },
abstract = {Supplemental oxygen is a cornerstone intervention in modern clinical practice, widely used to correct hypoxemia in emergency, perioperative, and critical care settings. While oxygen therapy is lifesaving, accumulating evidence indicates that excessive oxygen exposure can induce significant pathophysiological disturbances, particularly within the cardiovascular and pulmonary systems. Hyperoxia (PaO2 > 100 mm Hg) promotes the generation of reactive oxygen species (ROS), leading to oxidative stress, mitochondrial dysfunction, and the activation of pro-fibrotic pathways. When combined with mechanical ventilation, these effects are further amplified through alterations in intrathoracic pressure, reduced venous return, and increased pulmonary vascular resistance, collectively imposing hemodynamic stress on the myocardium. These mechanical and biochemical perturbations converge to drive structural, functional, and electrical remodeling of the heart, including conduction abnormalities and arrhythmogenesis. Emerging clinical insights, particularly from critically ill and COVID-19 populations, underscore the importance of titrated oxygen strategies that balance adequate tissue oxygenation with minimization of hyperoxic injury. This review synthesizes current evidence on hyperoxia-induced oxidative stress, heart-lung interactions, and mechanisms underlying myocardial remodeling to provide a comprehensive framework for optimizing oxygen therapy.},
}
@article {pmid42193931,
year = {2026},
author = {Farooqui, SA and Santerre, M and Shcherbik, N and Sawaya, BE},
title = {Memory Impairments: Type, Causes, and Molecular Players-Memory Dysfunction Across Neurologic Insults.},
journal = {Cells},
volume = {15},
number = {10},
pages = {},
pmid = {42193931},
issn = {2073-4409},
mesh = {Humans ; *Memory Disorders/virology/etiology/pathology/metabolism ; Animals ; Hippocampus/virology/pathology/metabolism ; },
abstract = {Viral infections of the central nervous system produce memory impairment through mechanisms that extend beyond acute neuronal injury. Herpes simplex virus type 1, human immunodeficiency virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, influenza, SARS-CoV-2, West Nile virus, and Zika virus each enter or engage the brain through distinct routes, yet converge on four shared molecular pathways that selectively damage hippocampal circuits: mitochondria-associated membrane (MAM) dysfunction, chronic neuroinflammation, blood-brain barrier (BBB) disruption, and impaired CREB-BDNF signaling. These pathways specifically compromise the dentate gyrus, CA3, and CA1 subfields, producing predictable deficits in pattern separation, associative retrieval, and temporal memory binding. Antiretroviral and antiviral therapies suppress viral replication but fail to reverse organelle-level dysfunction, leaving most hippocampal injury unaddressed. Emerging plasma biomarkers, p-tau217, neurofilament light chain, and GFAP, combined with hippocampal subfield MRI, now enable mechanistic stratification before irreversible circuit loss occurs. This review proposes, as a unifying hypothesis, that virus-associated memory impairment represents a convergent hippocampal syndrome driven by shared downstream pathways, and that combination therapies targeting these pathways simultaneously offer greater therapeutic promise than pathogen-specific approaches alone. The evidentiary basis for this framework varies across pathogens and conditions; direct mechanistic evidence, mechanistic analogy, and preclinical data are distinguished throughout.},
}
@article {pmid42193949,
year = {2026},
author = {Abdelhakim, M and Miyata, T},
title = {Plasminogen Activator Inhibitor-1 as a Therapeutic Target for Healthy Longevity, Immunosenescence, and Age-Related Disease: Translational Development of the Small-Molecule Inhibitor TM5614.},
journal = {Cells},
volume = {15},
number = {10},
pages = {},
pmid = {42193949},
issn = {2073-4409},
mesh = {Humans ; *Plasminogen Activator Inhibitor 1/metabolism ; Animals ; *Longevity/drug effects ; *Immunosenescence/drug effects ; Translational Research, Biomedical ; *Aging/drug effects ; *para-Aminobenzoates/pharmacology/therapeutic use ; Piperazines ; },
abstract = {Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is the principal physiological inhibitor of tissue-type and urokinase-type plasminogen activators and a central regulator of fibrinolysis. Beyond its canonical hemostatic role, PAI-1 has emerged as a pleiotropic mediator of tissue remodeling, fibrosis, metabolic dysfunction, cancer progression, cellular senescence, and age-associated immune dysregulation. A central argument of this review is that PAI-1 should be understood not only as a downstream biomarker of aging-associated pathology, but also as an active effector linking senescence-associated secretory phenotype (SASP) signaling, chronic low-grade inflammation, impaired immune surveillance, fibrotic extracellular matrix remodeling, and a prothrombotic state. In this framework, PAI-1 may function as an immune-aging checkpoint: a molecular node through which senescent, stromal, malignant, and inflammatory cells reinforce immune evasion and tissue dysfunction. Structure-guided drug discovery has enabled the development of small-molecule PAI-1 inhibitors, including TM5275, TM5441, TM5509, and TM5614. Among these, TM5614 is an orally available investigational compound that has progressed to clinical evaluation. Preclinical studies support anti-thrombotic, anti-fibrotic, anti-inflammatory, anti-senescent, and tumor-microenvironment-modulating effects of PAI-1 inhibition, while early clinical studies have evaluated TM5614 in chronic myeloid leukemia, immune-checkpoint-refractory malignant melanoma, non-small-cell lung cancer, and COVID-19-associated pneumonia. This review summarizes the biology of PAI-1, expands the discussion of immunoaging, reviews representative preclinical and clinical data, compares available PAI-1 inhibitors, and discusses the translational opportunities and safety considerations for TM5614 and related compounds.},
}
@article {pmid42194913,
year = {2026},
author = {Almulhem, MM and Siraj, RA},
title = {Mental Health in Cystic Fibrosis in the Modulator Era: Epidemiology, Prognostic Significance, and Therapeutic Implications.},
journal = {Journal of clinical medicine},
volume = {15},
number = {10},
pages = {},
pmid = {42194913},
issn = {2077-0383},
abstract = {Individuals with cystic fibrosis (CF) face significant treatment burdens, and as life expectancy has increased, there is growing emphasis on their psychosocial well-being. Prevalence data indicate that approximately one-quarter to one-third of individuals with CF and their caregivers experience clinically significant anxiety or depression. Specifically, pooled global estimates report an anxiety prevalence of 24.9% (95% CI: 20.8-28.9%) and depression prevalence of 13-33% in adults with CF, with caregivers experiencing even higher rates (anxiety: 35-38%; depression: 20-35%). Depression is independently associated with a nearly twofold increase in mortality risk and substantially higher healthcare costs, underscoring its prognostic significance. These mental health comorbidities are consistently associated with reduced treatment adherence, diminished quality of life, increased healthcare utilisation, and decreased survival. Accordingly, psychological well-being has emerged as a key patient outcome that directly shapes engagement with care and the effectiveness of long-term CF management. International CF guidelines now recommend routine mental health screening within multidisciplinary care frameworks. Evidence-based interventions include cognitive-behavioural therapy (CBT), which is endorsed as a primary treatment, although access remains limited, and stepped-care pharmacotherapy, primarily selective serotonin reuptake inhibitors (SSRIs), for moderate to severe symptoms. Telemedicine and other digital health approaches have expanded access to psychological support, with remote CBT and online programmes demonstrating feasibility and symptom improvement during the COVID-19 pandemic and beyond. The advent of CFTR modulator therapies has significantly altered clinical outcomes, enabling many patients to achieve improved lung function and daily functioning. Nevertheless, mental health challenges persist, as individuals navigate new identity shifts and anxieties despite enhanced physical health. The implementation of mental healthcare remains inconsistent; while screening rates have increased, timely follow-up and integrated psychosocial support are frequently insufficient across care centres. This narrative review highlights the ongoing need to integrate mental health management into CF care to optimise adherence, patient outcomes, and long-term survival in the current therapeutic landscape.},
}
@article {pmid42195058,
year = {2026},
author = {Groff, P and De Vuono, S},
title = {Non-Invasive Respiratory Support in "De Novo" Acute Hypoxemic Respiratory Failure: Which Technique Is Best?.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {5},
pages = {},
pmid = {42195058},
issn = {1648-9144},
mesh = {Humans ; *Respiratory Insufficiency/therapy ; *Hypoxia/therapy ; COVID-19/complications ; *Noninvasive Ventilation/methods ; Practice Guidelines as Topic ; Acute Disease ; },
abstract = {Background: One of the most debated scientific topics in recent years is the role of non-invasive respiratory support techniques in the treatment of de novo acute hypoxemic respiratory failure. Until pre-COVID-19, the most accredited guidelines did not make recommendations for or against the use of these techniques in this clinical condition, and the increased risk of adverse events for patients who failed the non-invasive approach was widely reported in the literature. The most recent guidelines recommend the use of HFNC as a first-line technique in the treatment of de novo acute hypoxemic respiratory failure to avoid the need for tracheal intubation. However, the strength of these recommendations remains weak, the quality of the underlying evidence is poor, and their usefulness in deciding which technique to apply to an individual patient is questionable. Aim: The aim of this review was to provide the reader with some critical tools to interpret the different indications regarding the choice of the best non-invasive support technique to be used in this setting. Methods: To this end, we analyzed the available literature on this topic, privileging the works that are most useful in correlating the practical indications to the pathophysiological assumptions. Results and Conclusions: The notable heterogeneity of the studies on which the current recommendations are based, as well as the affirmation of the concept of patient self-induced lung injury (P-SILI), highlights the importance of assessing each patient's risk of developing this complication, individualizing treatment to the patient's specific needs, and monitoring the patient during treatment.},
}
@article {pmid42196353,
year = {2026},
author = {Jarończyk, M and Walory, J},
title = {Mortality Assessment in Patients with Cardiovascular Disease and COVID-19: A Systematic Review and Meta-Analysis.},
journal = {International journal of molecular sciences},
volume = {27},
number = {10},
pages = {},
pmid = {42196353},
issn = {1422-0067},
mesh = {Humans ; *Cardiovascular Diseases/mortality/complications/epidemiology ; *COVID-19/mortality/epidemiology/complications ; Comorbidity ; Hypertension/mortality/epidemiology ; Diabetes Mellitus/mortality/epidemiology ; SARS-CoV-2/isolation &amp; purification ; Renal Insufficiency, Chronic/mortality/epidemiology ; },
abstract = {The COVID-19 pandemic has had a profound impact on global health, especially among patients with cardiovascular disease (CVD) and the existence of additional conditions such as diabetes (DM), hypertension (HT), and chronic kidney disease (CKD) can have a significant impact on survival rates. The aim of this study was to determine the mortality rate in patients with CVD and the impact of other comorbidities on the death of patients with COVID-19. This systematic review was conducted using PubMed, EMBASE, and Google Scholar databases from August 2020 to June 2025. Inclusion criteria were patients with cardiovascular disease and associated comorbidities during the COVID-19 pandemic. Article selection was limited to articles published in English and Polish. Statistical analysis using a random-effects model was performed using STATA software. Heterogeneity between studies was examined, and a funnel plot for publication bias was generated. The higher mortality rates (OR = 3.00, 95% CI: 2.06-4.38) for patients with cardiovascular disease were observed. In the group of patients with comorbidities such as hypertension and diabetes mellitus the risk of death was also determined and for HT was OR = 1.94, 95% CI, 1.50-2.52 and for DM OR = 2.17, 95% CI: 1.64-2.86. The mortality in the chronic kidney disease group was higher than for HT and DM (OR = 3.91, 95% CI: 2.50-6.10). The risk of death is three times higher for patients with COVID-19 and CVD. High mortality risk is also linked to diabetes and hypertension but for chronic kidney disease patients increased up to four times.},
}
@article {pmid42196720,
year = {2026},
author = {Norlund, P and Arsanjani, JJ and Paasch, JM},
title = {Spatio-Temporal COVID-19 Modeling: A Global Systematic Review of Data Integration, Equity, and Lessons for Pandemic Preparedness.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {5},
pages = {},
pmid = {42196720},
issn = {1660-4601},
mesh = {*COVID-19/epidemiology ; Pandemic Preparedness ; Humans ; Spatio-Temporal Analysis ; Bayes Theorem ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic generated an unprecedented volume of spatially and temporally resolved data, enabling rapid development of spatio-temporal models for surveillance, forecasting, and policy support. However, the evolution, geographic distribution, and equity implications of these models remain insufficiently synthesized. This study presents a global systematic review of 363 peer-reviewed studies published between January 2020 and August 2025 using publicly available data. Following PRISMA 2020 guidelines, studies were classified by geographic scale, modeling approach, data streams, and analytical purpose. The results indicate that Bayesian and compartmental models remained dominant throughout the pandemic, although methodological diversity increased over time with the growing use of machine learning and hybrid frameworks integrating mobility, environmental, and socio-demographic data. Data integration was more common than previously reported. Approximately 30% of studies relied on a single data stream, while 70% incorporated multiple sources, although most multi-source approaches combined only two data types and relatively few studies integrated three or more. Geographic coverage was uneven, with a strong concentration of studies in high-income regions and persistent underrepresentation of low- and middle-income contexts. Models incorporating finer spatial scales and socio-demographic variables more frequently supported geographically targeted interpretation of risk, vulnerability, testing access, and intervention needs. Overall, the findings highlight the importance of multi-source data integration, improved geographic representativeness, and transparent uncertainty communication, alongside the need for FAIR-aligned and equity-aware data infrastructures to strengthen future pandemic preparedness.},
}
@article {pmid42196842,
year = {2026},
author = {Oksentowicz, MA and Sztachelska, M and Dymicka-Piekarska, V},
title = {Platelet-to-Lymphocyte Ratio-A Real or Fake Bridge Between Inflammation and Coagulation in COVID-19 Patients: A Scoping Review.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {10},
pages = {},
pmid = {42196842},
issn = {2075-4418},
support = {SUB/1/DN/22/005/2209//Medical University of Bia&#x142;ystok/ ; },
abstract = {Background: Patients with COVID-19 often develop COVID-19-Associated Coagulopathy (CAC)-an imbalance between procoagulant and anticoagulant pathways resulting from the uncontrolled inflammatory response triggered by SARS-CoV-2 infection. This study aims to investigate the impact of a hematological and inflammatory parameter-the platelet-to-lymphocyte ratio (PLR)-on the severity and mortality of COVID-19. Methods: We conducted a comprehensive search of the PubMed database and yielded 75 articles published in the period of 2020-2025, of which 20 studies that evaluated the prognostic value of PLR on hospital admission in COVID-19 patients were included. The review particularly focuses on ROC analyses and reported AUC values. Results: A total of 20 studies were analyzed, including 13 studies assessing disease severity and 14 studies evaluating mortality. Higher PLR values have been observed in patients with a more severe course of COVID-19 compared to those with milder disease, and in non-survivors compared to survivors. However, the literature shows inconsistency regarding the diagnostic utility of PLR based on ROC curve analysis. The reported AUC values ranged from 0.559 to 0.811 for disease severity differentiation and from 0.474 to 0.758 for mortality, which may be related to the heterogeneity of the study populations included in the analysis. Conclusions: PLR may not serve as a direct bridge between inflammation and coagulation in COVID-19-Associated Coagulopathy, but it is indirectly linked to disease severity and mortality, as it reflects changes in both platelet and lymphocyte counts. It is a complementary marker that may assist clinicians in assessing COVID-19 patients but still requires further investigation.},
}
@article {pmid42198337,
year = {2026},
author = {Akkineni, S and Gulani, M and Kouzi, SA and D'Souza, MJ and Uddin, MN},
title = {Delivery of mRNA Therapeutics Beyond Infectious Diseases: Design Innovations and Applications in Oncology, Cardiovascular, and Rare Genetic Diseases.},
journal = {Pharmaceuticals (Basel, Switzerland)},
volume = {19},
number = {5},
pages = {},
pmid = {42198337},
issn = {1424-8247},
abstract = {Empowered by nanotechnology, messenger RNA (mRNA) therapeutics have shown a rapid evolution post COVID-19 from a conceptual platform to a clinically validated modality, and they diversified into oncology, cardiovascular diseases, and rare disorders. As a template for in situ protein production, it offers several advantages over traditional proteins and DNA drugs. The intrinsic stability of mRNA and its sensitivity to innate immune sensing hinder its capacity for immediate cellular entry, necessitating its need for a delivery system to obtain optimal therapeutic potential. This review explores the innovations in nanocarrier engineering, design principles for lipid nanoparticles-mRNA (LNPs) platforms, and their clinical translation across the prominent indications. It also addresses their safety, immunogenicity, and scalability while addressing the key limitations and manufacturing scalability through comparative platform analysis. Although LNPs usually dominate their delivery through encapsulation and manufacturability, their limitations, like repeat dose reactogenicity and liver tropism, require next-generation designs like SORT lipids, stimuli-responsive hybrids for extrahepatic targeting. In oncology, LNP-mRNA drives the neoantigen vaccines, and rare diseases leverage the transient enzyme replacement. While the safety profiles highlight the innate immune tuning through nucleoside mods and lipid biodegradability, chronic administration risks are still persistent. While there are novel scalability options like microfluidic mixing to support the production gaps in organ selectivity and durability, their adoption is hindered. We outline the future directions to perceive mRNA's full potential as a broader therapeutic class.},
}
@article {pmid42198624,
year = {2026},
author = {Vashishat, I and Han, SE and Assogba, BD},
title = {COVID-19 in Space: Possible Health Risks and Preparedness Guidelines.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {5},
pages = {},
pmid = {42198624},
issn = {2076-0817},
support = {SRIG104486.//Kwantlen Polytechnic University/ ; },
mesh = {Humans ; Astronauts ; *COVID-19/transmission/epidemiology/prevention &amp; control/virology ; Pandemic Preparedness ; Pandemics/prevention &amp; control ; SARS-CoV-2 ; *Space Flight ; Weightlessness ; },
abstract = {BACKGROUND: The COVID-19 pandemic resulted in over 705 million infections and 7 million deaths, underscoring the importance of understanding disease behavior across diverse environments. As NASA, SpaceX, and ISRO prepare for more frequent missions, managing health risks for astronauts and space tourists is essential.<br><br>OBJECTIVE: This study reviews the literature on airborne infections in space, identifies research gaps, and establishes preparedness strategies for potential COVID-19 outbreaks during space missions.<br><br>METHODS: A systematic literature review was conducted to identify studies examining airborne infectious diseases in space. To compare these findings with Earth-based data, pathogen safety data sheets were used. A separate systematic review was conducted to explore similarities between COVID-19 and the identified airborne infectious diseases. A comparative approach was used to predict COVID-19's potential behavior in microgravity. Existing guidelines for managing airborne diseases in space and on Earth were reviewed and compared to develop a set of preparedness recommendations for COVID-19 in space.<br><br>RESULTS: Nine airborne infectious diseases occurring in space were identified. Six tentative effects of COVID-19 in a microgravity environment were theorized in this study. We propose recommendations to improve current space travel health guidelines and address the identified risks.<br><br>CONCLUSIONS: The results of this study will change the course of human space exploration by assisting in the protection of space travelers and guiding the development of new protocols that include comprehensive safety features.},
}
@article {pmid42198648,
year = {2026},
author = {Alanazi, A and Ibrahim, MN and Alenezi, MA and Albalawi, WO},
title = {Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {5},
pages = {},
pmid = {42198648},
issn = {2076-0817},
mesh = {Humans ; *Mucormycosis/immunology/microbiology/pathology ; *Immune Evasion ; *Host-Pathogen Interactions/immunology ; *Mucorales/pathogenicity/immunology ; Endoplasmic Reticulum Chaperone BiP ; COVID-19/immunology/complications ; Animals ; Virulence Factors/metabolism ; Immunity, Innate ; SARS-CoV-2 ; },
abstract = {Mucormycosis, triggered by fungi of the order Mucorales, represents a potentially fatal invasive mycosis, with death rates over 50% despite intensive therapy. The COVID-19 pandemic brought a sharp increase in cases, especially in individuals with diabetes mellitus and those undergoing immunosuppressive treatment, emphasizing significant gaps in our comprehension of disease pathogenesis. Emerging molecular studies have highlighted key virulence factors, such as the CotH family of invasins that facilitate endothelial invasion via interaction with glucose-regulated protein 78 (GRP78), complex iron acquisition systems necessary for fungal growth, and the release of mucoricin, a ricin-like toxin that impairs vascular integrity. Host defense depends mainly on innate immunity, with neutrophils and macrophages working as critical effector cells, while adaptive Th1 and Th17 responses aid in the fungal removal. Mucorales use a variety of immune evasion techniques, such as pathogen-associated molecular pattern (PAMP) masking via cell wall transformations, resistance to phagocytic death, and metabolic utilization of host factors including hyperglycemia and increased free iron in diabetic ketoacidosis (DKA). This review summarizes current evidence of the molecular processes underlying mucormycosis pathogenesis, underscoring host-pathogen interactions at the cellular and molecular levels, immune evasion tactics, and translational potential for new diagnostic and therapeutic approaches. Comprehending these molecular processes is crucial for creating efficient therapies against mucormycosis in an era of growing immunocompromised patients and expanding infectious disease synergies.},
}
@article {pmid42198669,
year = {2026},
author = {Bahmad, HF and Ghssein, G and Bahmad, M and Elajami, TK and Forghani, I and Tuda, C and Ruiz-Cordero, R},
title = {Paleopathology Meets Public Health: Deep-Time Syndemics and the Ecology of Emerging Infections.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {5},
pages = {},
pmid = {42198669},
issn = {2076-0817},
mesh = {Humans ; *Public Health ; *Paleopathology/methods ; SARS-CoV-2 ; COVID-19/epidemiology ; Pandemics ; *Communicable Diseases, Emerging/epidemiology ; DNA, Ancient/analysis ; },
abstract = {Why do pandemics keep emerging despite decades of surveillance and response? Paleopathology, the study of disease traces in ancient remains, has been revolutionized by ancient DNA (aDNA) analysis and next-generation sequencing (NGS). Reconstructing pathogen genomes from archaeological material enables the identification of extinct lineages, the refinement of disease chronologies, and the characterization of long-term host-pathogen co-evolution. This provides context for public health challenges, including the emergence of pandemics and antimicrobial resistance (AMR). Infectious diseases are increasingly understood as complex phenomena arising from biological, ecological, and sociopolitical forces. Integrating paleopathology, aDNA, and paleomicrobiology supports a deep-time syndemic framework, revealing how recurring biosocial drivers have structured infectious disease risk throughout history. Ancient resistome studies demonstrate that AMR predates modern antibiotic use, reframing resistance as an intrinsic ecological feature rather than solely a modern phenomenon. Coronavirus disease 2019 (COVID-19) reaffirmed how infection intersects with chronic disease, health system fragility, and social inequities. This review highlights how integrating evolutionary perspectives into One Health shifts surveillance from a reactive approach to upstream risk mitigation and spillover prevention.},
}
@article {pmid42198712,
year = {2026},
author = {Shalaby, L and Al-Haneedi, Y and Abdelhamid, A and Yassine, H and Emara, MM},
title = {Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2.},
journal = {Viruses},
volume = {18},
number = {5},
pages = {},
pmid = {42198712},
issn = {1999-4915},
support = {ARG01-0521-230249//Qatar Research, Development and Innovation Council, Academic Research/ ; },
mesh = {Humans ; *Furin/antagonists &amp; inhibitors/metabolism ; *Antiviral Agents/pharmacology/therapeutic use ; *Dengue Virus/drug effects/physiology ; *SARS-CoV-2/drug effects/physiology ; Virus Internalization/drug effects ; *Dengue/drug therapy/virology ; COVID-19/virology ; *COVID-19 Drug Treatment ; Animals ; Host-Directed Therapy ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {Dengue virus (DENV) and SARS-CoV-2 are emerging viral pathogens that share overlapping clinical features, including fever, fatigue, and respiratory symptoms, complicating differential diagnosis in endemic regions. Their co-circulation has increased the risk of co-infections, which may result in unpredictable disease progression, increased morbidity, and mortality. This overlap presents a significant challenge in managing outbreaks, as both viruses pose a major public health threat. Vaccines and direct-acting antivirals may be rendered ineffective by viral mutations, making it difficult to address evolving strains. Host-directed antivirals offer a promising alternative, potentially maintaining efficacy against a multitude of variants. Both DENV and SARS-CoV-2 rely on host proteases for viral maturation and entry, with furin playing a crucial role in viral glycoprotein cleavage. In DENV, furin cleaves the prM protein, facilitating virion maturation, while in SARS-CoV-2, the polybasic furin cleavage site in the spike protein enhances viral entry. This makes furin a compelling pan-viral target, where inhibiting furin could reduce viral fitness without relying on viral mutations. This review highlights the therapeutic rationale for targeting furin and discusses luteolin, a furin inhibitor showing antiviral activity against both viruses. Furin-targeted therapies may offer a durable antiviral strategy effective across DENV serotypes, SARS-CoV-2 variants, and co-infection settings.},
}
@article {pmid42198723,
year = {2026},
author = {Griffith, LD and Dervisevic, S and Powell, PP},
title = {Development and Evaluation of Molecular Diagnostic Tests for SARS-CoV-2 at English NHS Sites Throughout the COVID-19 Pandemic.},
journal = {Viruses},
volume = {18},
number = {5},
pages = {},
pmid = {42198723},
issn = {1999-4915},
support = {MR/R015937/1/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Humans ; *SARS-CoV-2/genetics/isolation &amp; purification ; *COVID-19/diagnosis/epidemiology ; *Molecular Diagnostic Techniques/methods ; Pandemics ; Sensitivity and Specificity ; United Kingdom/epidemiology ; Nucleic Acid Amplification Techniques/methods ; State Medicine ; COVID-19 Nucleic Acid Testing/methods ; COVID-19 Testing/methods ; Retrospective Studies ; England/epidemiology ; },
abstract = {The COVID-19 pandemic placed unprecedented pressure on diagnostic services worldwide. The first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the UK were confirmed on 31 January 2020, prompting National Health Service (NHS) laboratories to scale diagnostic procedures. The demand for testing rapidly exceeded historical norms for respiratory virus diagnostics, necessitating substantial government investment in consumables, assay development, and workforce expansion. This review presents a retrospective evaluation of SARS-CoV-2 diagnostic platforms deployed within the Norfolk and Norwich University Hospital (NNUH) trust and compares them with those implemented by other regional laboratories during the pandemic. It examines the molecular mechanisms, performance, scalability, and specificity of the multiple molecular testing approaches to optimise workflow based on the evolving technology. The integration of complementary platforms through a stratified testing strategy enabled high-throughput population screening while preserving diagnostic resolution for complex respiratory cases, substantially improving laboratory efficiency and resilience. The emerging diagnostic methodologies, RT-LAMP and CRISPR-based assays, are described, and we discuss their potential roles in future outbreaks. We critically evaluate the overall preparedness of UK health services for the COVID-19 pandemic and highlight key priorities for future pandemic preparedness at both local and national levels.},
}
@article {pmid42198738,
year = {2026},
author = {Skowron, K and Bauza-Kaszewska, J and Budzyńska, A and Wiktorczyk-Kapischke, N and Czuba, J and Wałecka-Zacharska, E and Wnuk, K and Zapadka, M and Kasprzyk, K and Grudlewska-Buda, K},
title = {Bat-Borne Viruses and Pandemic Risk: Could Europe Be an Emergence Hotspot?.},
journal = {Viruses},
volume = {18},
number = {5},
pages = {},
pmid = {42198738},
issn = {1999-4915},
mesh = {*RNA Viruses/isolation &amp; purification ; *Zoonoses/epidemiology/transmission/virology ; *Viral Zoonoses/epidemiology/transmission/virology ; *Disease Reservoirs/virology ; Virus Diseases/epidemiology/transmission/virology ; Pandemics ; Chiroptera/virology ; Europe/epidemiology ; *SARS-CoV-2 ; *Middle East Respiratory Syndrome Coronavirus ; Animals ; },
abstract = {The recent SARS-CoV-2 pandemic-which had significant worldwide health, economic, and other effects-indicated the need to monitor zoonotic viruses with pandemic potential. The aim of this review is to assess bat-borne viruses as a potential pandemic risk, with a particular focus on Europe. The presence and activity of bats, as well as diseases emerging in humans in various regions of the world, point to their importance in the context of a possible outbreak of future epidemics. The rate of genetic change observed among viruses requires constant scrutiny on all continents, including Europe. Bats are a considerable source of many zoonotic viruses, including coronaviruses, filoviruses and paramyxoviruses. Among viruses associated with bats, RNA viruses are the dominant ones, characterized by high pathogenicity and often leading to interspecies transmission. The majority (about 80%) of RNA viruses were identified in bats from three families: Vespertilionidae, Rhinolophidae and Pteropodidae. Understanding how viruses are transmitted in the environment and the role of reservoir organisms and intermediate hosts is crucial to determining the level of epidemic risk. This review discuses viruses identified in bats globally, with a special focus on Europe, and evaluates their potential to cause epidemics.},
}
@article {pmid42198749,
year = {2026},
author = {Hou, S and Shen, X and Sun, D and An, Y and Zhou, Y and Sun, X and Wang, S and Liu, X and Zhu, M and Zhao, S and Liu, Z and Wu, X and Liu, R},
title = {NLR Inflammasomes in Viral Infections: From Molecular Mechanisms to Therapeutic Interventions.},
journal = {Viruses},
volume = {18},
number = {5},
pages = {},
pmid = {42198749},
issn = {1999-4915},
support = {No.82272330//National Natural Science Foundation of China/ ; 2024JC-ZDXM-42//Shaanxi Provincial Natural Science Basic Research Program Key Project/ ; },
mesh = {*Inflammasomes/immunology/metabolism ; Humans ; *Virus Diseases/immunology/virology/drug therapy ; Immune Evasion ; Innate Immunity Recognition ; Animals ; *NLR Proteins/immunology/metabolism ; Immunity, Innate ; Pyroptosis ; Host-Pathogen Interactions ; },
abstract = {The innate immune system serves as the primary barrier against viral invasion, utilizing pattern recognition receptors (PRRs) to orchestrate a rapid defense. Among these, the nucleotide-binding domain and leucine-rich repeat (NLR) containing proteins function as central signaling scaffolds, assembling into multiprotein complexes known as inflammasomes. These complexes drive the maturation of pro-inflammatory cytokines IL-1β and IL-18, and initiate gasdermin D (GSDMD)-mediated pyroptosis, a lytic cell death pathway that eliminates intracellular replication niches. This comprehensive review synthesizes the diversified landscape of inflammasome activation during viral infections, extending beyond the canonical NLRP3 inflammasome to include specialized sensors such as NLRP6, NLRP9, NLRP1, NLRP12, and NLRC4. We critically evaluate the evolutionary "arms race" between host defenses and viral pathogens, detailing the sophisticated immune evasion strategies employed by viruses-ranging from the expression of decoy proteins and direct proteolytic cleavage of immune sensors to the manipulation of post-translational modifications (PTMs). Furthermore, we discuss the dual nature of inflammasome activation, which balances protective viral clearance against pathological hyperinflammation, and provide an exhaustive analysis of novel therapeutic strategies, including direct NLR inhibitors and downstream cytokine blockers, currently navigating clinical transition.},
}
@article {pmid42198768,
year = {2026},
author = {Ambasta, RK and Das, SR},
title = {Viral Comorbidities Remodel Host Transcriptome and Redox Signaling in an NADPH Oxidase Isoform-Specific Manner.},
journal = {Viruses},
volume = {18},
number = {5},
pages = {},
pmid = {42198768},
issn = {1999-4915},
support = {U24OD035523//National Institutes of Health Clinical Center/ ; },
mesh = {Humans ; Oxidation-Reduction ; *Signal Transduction ; *NADPH Oxidases/metabolism/genetics ; Reactive Oxygen Species/metabolism ; *Transcriptome ; *Virus Diseases/metabolism/genetics/virology ; MicroRNAs/genetics/metabolism ; Animals ; Host-Pathogen Interactions ; },
abstract = {Viral comorbidities elicit complex host responses by activating redox-sensitive signaling pathways, prominently those regulated by NADPH oxidase (Nox) enzymes. Nox are critical components of host defense, generating reactive oxygen species (ROS) that modulate key cellular signaling cascades. Under normal physiological conditions, Nox activity is tightly controlled; however, viral infections frequently disrupt this regulation, leading to aberrant upregulation of specific Nox isoforms. Elevated expression of individual Nox enzymes has been observed in infections such as influenza A and hepatitis C virus, while simultaneous activation of multiple Nox isoforms occurs in HIV and SARS-CoV infections. Similar patterns of dual or multi-isoform Nox activation are also reported in complex disease states, including diabetes, thrombosis, and fibrosis. MicroRNAs play a crucial role in this process by selectively regulating Nox isoform expression during viral infection, thereby remodeling the host redox environment. Nox-derived ROS influence multiple downstream signaling pathways, including SMAD, MAPK, CXCR-mediated signaling, and the JNK/ERK axis, promoting inflammation and fibrosis that worsen viral disease outcomes. Additionally, several FDA-approved drugs, investigational agents, and microRNA-based therapeutics show promise in modulating Nox activity. Therefore, this article substantiates how viral infections reprogram host transcriptomic and redox signaling networks, contributing to viral pathogenesis and offering potential therapeutic intervention strategies.},
}
@article {pmid42199010,
year = {2026},
author = {Kim, YJ and Lee, SJ and Lee, W and Kim, SJ and Ahn, DG},
title = {Modulation of Host Innate Immune Response by Highly Pathogenic Human Coronaviruses during Viral Infection.},
journal = {Journal of microbiology and biotechnology},
volume = {36},
number = {},
pages = {e2602038},
pmid = {42199010},
issn = {1738-8872},
mesh = {Humans ; *Immunity, Innate ; SARS-CoV-2/immunology ; Immune Evasion ; COVID-19/immunology ; *Coronavirus/immunology/pathogenicity ; Severe acute respiratory syndrome-related coronavirus/immunology/pathogenicity ; Middle East Respiratory Syndrome Coronavirus/immunology/pathogenicity ; Pandemics ; Innate Immunity Recognition ; Host-Pathogen Interactions/immunology ; Animals ; },
abstract = {Highly pathogenic human coronaviruses, including SARS-CoV, SARS-CoV-2, and MERS-CoV have emerged as significant public health threats due to their ability to cause widespread outbreaks and pandemics. These viruses induce dysregulated inflammatory responses, typified by cytokine storms that drive extensive tissue damage in pulmonary and extrapulmonary systems, leading to acute respiratory distress syndrome (ARDS) and multi-organ failure. These pathological outcomes are driven by sophisticated mechanisms that manipulate host immune pathways and evade innate and adaptive immune surveillance. The innate immune system plays a pivotal role in the early detection and control of viral infections through mechanisms such as cytoplasmic RNA sensors, Toll-like receptors, interferon signaling, and inflammasome activation. However, these coronaviruses effectively exploit and subvert these processes, suppressing antiviral defenses while amplifying inflammatory cascades. This review delineates the molecular and cellular strategies employed by these pathogens to evade immune recognition and exacerbate immune-mediated tissue injury. Understanding these processes is fundamental for guiding the development of targeted antiviral interventions, immunomodulatory therapeutics, and robust strategies to mitigate the impact of future coronavirus pandemics.},
}
@article {pmid42199422,
year = {2026},
author = {Zhang, J and Li, C and Wu, Y and Wang, L and Yu, J and Wang, A and Kong, W and Ning, M and Chen, J and Chen, Y},
title = {Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1772257},
pmid = {42199422},
issn = {1664-3224},
mesh = {Humans ; Animals ; *Immunoglobulin Fc Fragments/immunology ; *Viral Vaccines/immunology ; *Receptors, Fc/immunology ; Antibody-Dependent Cell Cytotoxicity ; *Antibodies, Viral/immunology ; Antibodies, Neutralizing/immunology ; *RNA Virus Infections/immunology/prevention &amp; control ; Vaccine Development ; Antibody-Dependent Enhancement ; },
abstract = {Neutralizing antibodies (NAbs) have long been the principal correlate of antiviral protection. Evidence now indicates that antibody Fc-mediated effector functions play indispensable and context-dependent roles in antiviral immunity. Through interactions between the fragment crystallizable (Fc) domain and Fc receptors (FcRs) or complement components, antibodies mediate a broad spectrum of effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular and neutrophil phagocytosis (ADCP and ADNP), and complement activation, contributing to viral control beyond direct neutralization. In this review, we integrate recent evidence on Fc effector biology across major viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus, human immunodeficiency virus (HIV), Ebola virus (EBOV), and dengue virus (DENV). We discuss how Fc-FcR interactions shape antiviral immune outcomes, modulate vaccine efficacy, and influence the balance between protective immunity and immunopathology, including antibody-dependent enhancement (ADE). We focus on the experimental strategies used to assess Fc-mediated functions and on the inherent limitations of in vitro assays and animal models in defining their physiological relevance in humans. We explore how different vaccine platforms and immunization strategies shape Fc effector profiles, specifically through antibody subclass selection, Fc glycosylation patterns, and engagement with Fcγ receptors. We also summarize emerging approaches to Fc engineering and glycan modification that aim to enhance antibody efficacy while limiting adverse immune activation. This review summarizes current understanding of Fc effector functions in antiviral immunity and discusses their relevance for the design of next-generation vaccines and antibody-based therapies.},
}
@article {pmid42199444,
year = {2026},
author = {Okezie, CW and Badru, OA and Ibitoye, FA and Edeh, JC and Adeagbo, OA},
title = {Perspective of People Living With HIV and Healthcare Workers on the Uptake, Barriers, and Benefits of Multimonth Dispensing: A Qualitative Systematic Review.},
journal = {AIDS research and treatment},
volume = {2026},
number = {},
pages = {1392259},
pmid = {42199444},
issn = {2090-1240},
abstract = {INTRODUCTION: Multimonth dispensing (MMD) is a strategy in the HIV care continuum for people living with HIV (PLWH), especially for those who are virally suppressed. With the increase in MMD following the COVID-19 pandemic, there is a dearth of data on its impact on HIV care outcomes, such as viral suppression. Therefore, we conducted a qualitative systematic review to explore how PLWH and healthcare workers (HCWs) perceive the uptake, barriers, challenges, and benefits of MMD, as well as its effects on viral suppression.<br><br>METHODS: In January 2025, following the PRISMA approach, we searched CINAHL, Embase, PubMed, and Scopus databases for articles. Two reviewers independently performed the screen, extraction, and appraisal processes. We descriptively reported the findings in line with our objectives.<br><br>RESULTS: Of the 3521 studies found, only 15 were included in this review, and most were from sub-Saharan Africa. HCWs initiated PLWH on MMD because of the COVID-19 pandemic, particularly to reduce clinic traffic, even when they did not meet the criteria for MMD. The barriers to PLWH initiating MMD, confirmed by HCWs, include privacy concerns and the stigma associated with having multiple antiretroviral therapy (ART) medication bottles and the stockout of ART medications in clinics. Furthermore, some PLWH refused MMD because plenty of ART bottles can increase the risk of unintended HIV disclosure. Confirmed by HCWs, PLWH share their medication with others and, at times, misuse it. Regarding MMD benefits, PLWH reported job stability as a benefit because of reduced permission from work to refill ART medication and waiting time in the clinics, a decrease in stigma and discrimination, and a generally improved HIV care experience; all confirmed by HCWs. Furthermore, HCWs reported benefits, including reduced workload and burnout. Interestingly, unlike PLWH's claim that MMD improved adherence and viral suppression, HCWs reported the opposite.<br><br>CONCLUSION: The COVID-19 pandemic increased MMD rollout to those who met and those who did not meet its criteria, leading to shorter waiting times, job stability, and reduced HCWs' burnout. However, HIV clinics should initiate MMD for PLWH who meet the criteria, which allows for closer monitoring of the unsuppressed PLWH.},
}
@article {pmid42199803,
year = {2026},
author = {Liu, Y and Yang, M and Liao, Y and Hu, Z},
title = {Global research trends, reporting and handling of missing data in observational studies of type 2 diabetes mellitus with mild cognitive impairment from 2020 to 2025: a systematic review.},
journal = {Frontiers in endocrinology},
volume = {17},
number = {},
pages = {1649881},
pmid = {42199803},
issn = {1664-2392},
mesh = {*Diabetes Mellitus, Type 2/complications/epidemiology ; *Cognitive Dysfunction/epidemiology/complications ; Humans ; *Observational Studies as Topic ; Bibliometrics ; },
abstract = {BACKGROUND: Missing data is common in observational studies, and even more so in type 2 diabetes mellitus with mild cognitive impairment(T2DM-MCI), which limits the completion of assessments. We evaluated the extent, current reporting, and handling of missing data, as well as the prevailing research trends in observational studies related to T2DM-MCI.<br><br>METHODS: A systematic search of PubMed, Embase, and Cochrane Library was conducted from January 2020 to April 2025 to identify observational studies related to T2DM-MCI. Bibliometrics was performed using VOSviewer and CiteSpace to evaluate publishing trends, authors, journals, and keywords. The reporting and handling of missing data were assessed according to the guidelines recommended by STROBE and Sterne et&#xa0;al., with a focus on the recording, causes, mechanisms, processing methods, and sensitivity analysis of missing data. Data analysis was conducted using SPSS 26, and visualization was performed using Origin Pro 2024.<br><br>RESULTS: Among the 4,471 screened records, 88 studies (78 in English and 10 in Chinese) were included in this analysis. Among the 78 English articles, the annual publication volume exhibited fluctuations, peaking in 2024. Chinese institutions and authors led in research output. Diabetes, Metabolic Syndrome, and Obesity had the highest publication volume (7, 8.97%). Keyword identified five clusters: 1) resting-state functional magnetic resonance imaging, 2) metabolic disorders, 3) clinical assessment tools, 4) molecular mechanisms, and 5) emerging fields such as the gut microbiome.<br><br>MISSING DATA: Only 22.7% (n = 20) of the studies quantified the missing data, with an average of 9.1%. Among studies with missing data (n = 23), 52.2% (n = 12) provided reasons for missing data, primarily citing poor quality of data collection (41.7%) and loss to follow-up (41.7%). Complete case analysis was the predominant method for addressing missing data (93.3%). No study articulated the hypothesized mechanisms underlying the missing data, and only 4.4% (n = 1) performed a sensitivity analysis.<br><br>CONCLUSION: In the domain of T2DM-MCI, research outcomes post-COVID-19 pandemic indicate a rebound, with China maintaining a leading position in scientific research output. However, the reporting of missing data remains ambiguous, and the methods employed to handle such data are insufficient, which may potentially introduce bias.<br><br>https://doi.org/10.17605/OSF.IO/EZDXM.},
}
@article {pmid42201010,
year = {2026},
author = {Ceasovschih, A and Kounis, NG and Markos, S and Ejubovic, M and Cherska, M and Barkas, F and Ristovski, V and Corlateanu, A and Sivapalan, P and Kotlyarov, S and Sorodoc, V and Sorodoc, L},
title = {Kounis Syndrome Features in Special Populations.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {2},
pages = {},
pmid = {42201010},
issn = {2076-3271},
mesh = {Humans ; *Kounis Syndrome/epidemiology/diagnosis/immunology/etiology ; Female ; Pregnancy ; },
abstract = {Kounis syndrome (KS) describes the occurrence of acute coronary syndromes precipitated by allergic, hypersensitivity, or anaphylactic reactions and represents a unique intersection between immunologic activation and cardiovascular disease. The epidemiology of KS is likely underestimated due to diagnostic overlap with other cardiac and allergic conditions and limited awareness across medical specialties. This narrative review focuses on the distinctive features of KS in special populations, emphasizing how patients' age, comorbidities, immune status, and vascular substrate modify presentation, diagnosis, and outcomes. In elderly patients, polypharmacy, increased plaque vulnerability, and endothelial dysfunction favor Type II and III KS. Pediatric cases, although rare, are predominantly Type I and strongly associated with food allergies, insect stings, vaccines, and antibiotics, with under-recognition driven by diagnostic bias and ethical concerns surrounding invasive testing. Patients with coronary stents, cardiac devices, chronic kidney disease, and those receiving dialysis exhibit heightened susceptibility due to chronic inflammation, foreign-body hypersensitivity, and prothrombotic states. Pregnancy and the peripartum period represent a unique immuno-hemodynamic milieu in which Th2 immune shift, increased coronary vasoreactivity, and obstetric triggers can compromise both maternal and fetal perfusion. Additional risk modulation is observed in atopic individuals, asthmatics, patients with autoimmune, inflammatory, oncologic, psychiatric, and neurodevelopmental conditions, as well as in COVID-19 and post-infectious states. We propose a host-modified framework for KS that complements traditional classification by integrating immune phenotype and vascular substrate, enabling improved risk stratification and personalized preventive strategies.},
}
@article {pmid42201879,
year = {2026},
author = {Oliveira, GM and Ferreira, MCFLA and Filho, SS and Netto, OM and Cade, JR},
title = {Effectiveness of Telemedicine-Based Interventions in Primary Health Care: A Systematic Review in a Universal Health System.},
journal = {Telemedicine journal and e-health : the official journal of the American Telemedicine Association},
volume = {},
number = {},
pages = {15305627261453270},
doi = {10.1177/15305627261453270},
pmid = {42201879},
issn = {1556-3669},
abstract = {INTRODUCTION: Telemedicine has increasingly been adopted as a digital care strategy to support access, continuity, and care coordination in primary health care (PHC). While its use accelerated during the COVID-19 pandemic, evidence regarding the effectiveness of telemedicine-based interventions in routine primary care remains heterogeneous and highly context-dependent. The objective of this review was to critically assess the effectiveness of telemedicine-based interventions in PHC, focusing on their effects on access, continuity, and care coordination, and to identify implementation-related barriers and facilitators based on empirical evidence from a universal health system context.<br><br>METHODS: A systematic review was conducted in accordance with PRISMA 2020 and registered in PROSPERO (CRD420251005446). Searches were performed in PubMed/MEDLINE, SciELO, and BVS/LILACS for studies published between 2015 and 2025. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using RoB 2.0 and ROBINS-I. Due to methodological heterogeneity, findings were synthesized through a structured narrative approach (SWiM), and certainty of evidence was interpreted qualitatively based on study design, risk of bias, and consistency of findings.<br><br>RESULTS: Twenty-two studies were included, evaluating teleconsultations, telemonitoring, telediagnosis, tele-regulation, and tele-education in PHC settings. Telemedicine-based interventions were associated with improved access, reduced waiting times, and enhanced care coordination, particularly when embedded within primary care teams and integrated with information systems. Telemonitoring showed more consistent benefits for chronic disease management and continuity of care. User and provider acceptability was generally high, although technical limitations, workload concerns, and digital inequities were frequently reported. Certainty of evidence ranged from low to moderate.<br><br>CONCLUSIONS: Telemedicine-based interventions can strengthen core PHC functions when implemented as integrated organizational components of routine care delivery rather than as standalone technologies. Their effectiveness is strongly shaped by implementation context, digital infrastructure, and workforce readiness, highlighting the need for pragmatic and implementation-focused evaluations to inform sustainable telemedicine integration in primary care systems.},
}
@article {pmid42202423,
year = {2026},
author = {Liu, R and Fan, Y and Xiong, S and Lin, J and Patel, A and Du, X and Di Tanna, GL and Liu, H},
title = {Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.},
journal = {Vaccine},
volume = {86},
number = {},
pages = {128761},
doi = {10.1016/j.vaccine.2026.128761},
pmid = {42202423},
issn = {1873-2518},
mesh = {Humans ; *Influenza Vaccines/administration &amp; dosage ; *Influenza, Human/prevention &amp; control/epidemiology ; China/epidemiology ; *Cardiovascular Diseases/epidemiology ; *Vaccination/statistics &amp; numerical data ; Vaccination Hesitancy ; Vaccination Coverage ; COVID-19/epidemiology/prevention &amp; control ; Immunization Programs ; },
abstract = {INTRODUCTION: Understanding the drivers of influenza vaccine hesitancy, acceptance, demand, and uptake especially in low- and middle-income countries is a priority in preventing seasonal influenza as outlined in the World Health Organization (WHO) global influenza strategy. Individuals with cardiovascular disease (CVD) are a key target group recommended by WHO, yet influenza vaccine coverage in China is reported to be extremely low. We aim to explore drivers of this and implementation strategies used to increase the influenza vaccine coverage among CVD populations in China.<br><br>METHODS: We conducted a scoping review using academic databases, the Chinese Clinical Trial Registry, and Chinese grey literature repositories from database inception till August 2025, based on predetermined inclusion criteria. Data on potential determinants of vaccine uptake and intervention details were extracted and analyzed using a narrative synthesis. Implementation strategies were mapped to the Availability, Accessibility, Acceptability, and Quality (AAAQ) health service delivery framework.<br><br>FINDINGS: Thirteen publications published between 2009 and 2024 were included, with an increase in outputs since the COVID-19 pandemic. Lower vaccine uptake appeared to be associated with lower socioeconomic status and poorer health literacy. Physician recommendations, accessible vaccine clinics, and adequate vaccine supply appeared to be health system related facilitators to vaccination. Four studies reported implementation strategies comprising provider education and recommendations, public funding, and follow-up on vaccination status. Incorporating strategies that addressed a greater number of AAAQ domains appeared to result in higher influenza vaccine uptake.<br><br>CONCLUSION: Drivers and implementation strategies of influenza vaccination have not been widely studied among CVD populations in China. Available information suggests that higher patient sociodemographic status, greater health literacy, presence of physician recommendations, accessible vaccine clinics, and affordable vaccines may positively drive influenza vaccination. Addressing gaps in the AAAQ domains through targeted implementation strategies could improve influenza vaccination. Future strategies should undergo rigorous evaluation.<br><br>REGISTRATION DETAILS: Our protocol is registered at Open Science Foundation (OSF) with registration DOI https://doi.org/10.17605/OSF.IO/XDMBT.},
}
@article {pmid42203050,
year = {2026},
author = {Zhao, X and Wang, Y and Yi, Y and Zhan, H and Chen, H and Song, Q},
title = {Association between adherence to 24-hour movement guidelines and anxiety and depression: A systematic review and meta-analysis of observational studies.},
journal = {Journal of affective disorders},
volume = {411},
number = {},
pages = {121998},
doi = {10.1016/j.jad.2026.121998},
pmid = {42203050},
issn = {1573-2517},
mesh = {Humans ; *Anxiety/prevention &amp; control/psychology/epidemiology ; *Depression/prevention &amp; control/psychology/epidemiology ; Observational Studies as Topic ; *Exercise/psychology ; Sedentary Behavior ; *COVID-19/psychology ; *Guideline Adherence ; },
abstract = {BACKGROUND: Depression and anxiety constitute a global health crisis, with prevalence increasing by 27.6% during the COVID-19 pandemic. The 24-Hour Movement Guidelines, integrating physical activity, sedentary behavior, and sleep, have been linked to improved mental health, yet no meta-analysis has quantified these associations.<br><br>METHODS: Following PRISMA guidelines, PubMed, Embase, Cochrane Library, and Web of Science were searched through January 1, 2026. Observational studies examining adherence to the 24-Hour Movement Guidelines and anxiety or depression were included. Cross-sectional and cohort studies were assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tools, with the 8-item checklist for cross-sectional studies and the 11-item checklist for cohort studies. Random-effects models generated pooled odds ratios (ORs) with 95% confidence intervals (CIs).<br><br>RESULTS: Twenty studies (17 cross-sectional, 3 cohort) involving 323,440 participants from seven countries were included, with the majority being adolescents (n = 210,394, 65%). Adherence to the 24-Hour Movement Guidelines was significantly associated with lower odds of anxiety and depression symptoms. Meeting one, two, or three guideline components was consistently linked to lower odds of anxiety (ORs = 0.74, 0.59, and 0.43, respectively) and depression (ORs = 0.73, 0.55, and 0.41, respectively). Among individual components, adherence to sleep recommendations demonstrated the strongest associations for both anxiety (OR = 0.72) and depression (OR = 0.69), followed by sedentary behavior and physical activity. Sensitivity and publication bias analyses confirmed robustness.<br><br>CONCLUSIONS: Adherence to the 24-Hour Movement Guidelines is significantly associated with lower risks of anxiety and depression, supporting their integration into mental health prevention strategies.},
}
@article {pmid42203413,
year = {2026},
author = {Baker, JM and Dickson, RP},
title = {The Role of the Respiratory Microbiome in Pneumonia.},
journal = {Clinics in chest medicine},
volume = {47},
number = {2},
pages = {199-213},
doi = {10.1016/j.ccm.2025.12.004},
pmid = {42203413},
issn = {1557-8216},
mesh = {Humans ; *Microbiota ; COVID-19 ; *Lung/microbiology ; SARS-CoV-2 ; *Pneumonia, Viral/microbiology ; Pandemics ; *Pneumonia/microbiology ; Betacoronavirus ; },
abstract = {The lung microbiome field has matured into a promising area of translational research. Emerging evidence from the past decade, including studies of COVID pneumonia, indicates a role for respiratory microbiota in pneumonia pathogenesis. Here, the authors discuss areas of investigation that will be essential to refine an ecology-based conceptual framework of pneumonia pathogenesis, which will ultimately guide the development of microbiome-targeted diagnostics and therapeutics for pneumonia management.},
}
@article {pmid42203415,
year = {2026},
author = {Naghshtabrizi, N and Robinson, KM},
title = {Respiratory Viral and Bacterial Superinfection.},
journal = {Clinics in chest medicine},
volume = {47},
number = {2},
pages = {225-235},
doi = {10.1016/j.ccm.2025.12.006},
pmid = {42203415},
issn = {1557-8216},
mesh = {Humans ; *Superinfection/immunology ; Coinfection ; *Pneumonia, Bacterial/immunology ; COVID-19/complications ; Influenza, Human/complications/immunology ; *Respiratory Tract Infections/immunology/virology/complications ; Immunity, Innate ; },
abstract = {Respiratory viral infections are major predisposing factors for secondary bacterial pneumonia, a complication associated with increased disease severity, prolonged hospitalizations, and higher mortality. This review discusses the key mechanisms by which viral infections disrupt lung physiology, impair innate and adaptive immune defenses, and dysregulate cytokine signaling, creating a permissive environment for bacterial superinfection. Common pathogenic processes across different respiratory viruses are highlighted to provide a comprehensive understanding of how viral infections alter host susceptibility to bacterial pneumonia.},
}
@article {pmid42203428,
year = {2026},
author = {Renzetti, M and Losier, A},
title = {Vaccines Against Pneumonia: Current Updates.},
journal = {Clinics in chest medicine},
volume = {47},
number = {2},
pages = {399-417},
doi = {10.1016/j.ccm.2025.12.019},
pmid = {42203428},
issn = {1557-8216},
mesh = {Humans ; Pneumococcal Vaccines/therapeutic use ; Pertussis Vaccine/therapeutic use ; COVID-19 Vaccines ; COVID-19/prevention &amp; control ; Influenza Vaccines/therapeutic use ; Vaccination ; Pneumonia, Pneumococcal/prevention &amp; control ; Respiratory Syncytial Virus Vaccines/therapeutic use ; *Pneumonia/prevention &amp; control ; SARS-CoV-2 ; Haemophilus Vaccines/therapeutic use ; },
abstract = {Pneumonia is one of the global leading causes of mortality and impacts all age groups. Both viruses and bacteria can contribute to the development of lower respiratory tract infections and incidences of each vary in different age groups and immune statuses. Vaccines exist to target many of the pathogens associated with pneumonia including influenza, COVID-19, respiratory syncytial virus, pneumococcal pneumonia, pertussis, and Haemophilus influenzae type b. Vaccinations have demonstrated positive effects at reducing rates of infection and hospitalizations related to pneumonia. However, vaccination rates remain low and barriers including vaccine hesitancy exist among the general population.},
}
@article {pmid42205352,
year = {2026},
author = {Soriano, JB and Miravitlles, M and López-Campos, JL and García-Río, F and Ancochea, J},
title = {[2027: A new year for a new epidemiological study of chronic obstructive pulmonary disease in Spain].},
journal = {Open respiratory archives},
volume = {8},
number = {3},
pages = {100628},
pmid = {42205352},
issn = {2659-6636},
abstract = {A real opportunity exists to conduct a fourth epidemiological study of COPD in Spain by 2027, continuing the trilogy begun with IBERPOC (1997), EPISCAN (2007), and EPISCAN II (2017). These previous studies have been fundamental to understanding the evolution of COPD, showing a relative reduction in prevalence but a persistently high underdiagnosis rate (around 75%). The need for a new study is justified by six key reasons: 1) Monitoring the secular evolution of the disease. 2) Evaluating the impact of new exposures (pollution, vaping, etc.) and phenotypes (COPD in non-smokers, pre-COPD, etc.). 3) Integrating novel tests such as low-dose CT scans or biomarkers for earlier and more accurate diagnosis. 4) Validating new screening tools. 5) Evaluating the quality of care and the burden of disease in the post-COVID-19 era. 6) Creation of a prospective cohort for translational research. Novel funding models, such as final contributions, should be explored. This review argues that a study in 2027 would not be a mere repetition, but an opportunity to make a qualitative leap toward a multidimensional and precise characterization of COPD in Spain today.},
}
@article {pmid42205482,
year = {2026},
author = {Albelasi, A},
title = {Symptoms, mechanisms, and management of long COVID: understanding its prevalence, characteristics, and healthcare challenges in Saudi Arabia.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1747443},
pmid = {42205482},
issn = {2235-2988},
mesh = {Humans ; *COVID-19/epidemiology/therapy ; Saudi Arabia/epidemiology ; Post-Acute COVID-19 Syndrome ; Prevalence ; SARS-CoV-2 ; Pandemics ; },
abstract = {Long COVID is a prolonged health condition wherein patients continue to experience symptoms long after recovering from infection, so it presents a significant global health challenge with multi-organ involvement. This review provides evidence from several studies to elucidate the prevalence, symptom clusters, and underlying mechanisms of Long COVID. Key findings highlight fatigue (25-73%), cognitive dysfunction, respiratory symptoms (dyspnea: 6.9-47%), cardiovascular symptoms (49.37/1,000), and reproductive symptoms (menstrual irregularities, erectile dysfunction) as predominant manifestations. Mechanistic insights include viral persistence, immune dysregulation, and endothelial dysfunction. The review gives detailed information about prevalence and immunological studies carried out in Saudi Arabia on Long COVID and underscores the importance of longitudinal immune studies, multidisciplinary approaches, biobanks, and global collaborations to improve patient outcomes. Recommendations emphasize tailored therapies, psychological support, and large-scale cohort studies to address heterogeneity and optimize care for Long COVID patients in Saudi Arabia.},
}
@article {pmid42205661,
year = {2026},
author = {Shrivastava, M and Suri, I},
title = {Day-of-Surgery Cancellations in NHS and Independent-Sector Elective Surgery in England: A Narrative Review of Publicly Available Data.},
journal = {Cureus},
volume = {18},
number = {4},
pages = {e107720},
pmid = {42205661},
issn = {2168-8184},
abstract = {Day-of-surgery cancellation of elective surgery causes patient harm, wastes theatre capacity, and reflects wider perioperative system pressure. In England, the principal public source for routine surveillance is the NHS England Quarterly Monitoring of Cancelled Operations (QMCO) collection, but direct comparison between NHS trusts and independent-sector providers remains methodologically difficult. This revised narrative review synthesised 10 publicly available NHS England datasets/documents and 13 supporting peer-reviewed or policy sources relevant to elective surgery cancellation and independent-sector provision. Publicly available national time-series data show that last-minute non-clinical cancellation rates have generally remained around 1% of elective admissions since the early 2000s, whereas the proportion of cancelled patients not treated within 28 days increased substantially after the COVID-19 pause in data collection. In the latest official commentary, 21,456 operations were cancelled at the last minute in the third quarter (Q3) 2025/26, and 4,821 patients (22.5%) breached the 28-day standard. Recent provider files identify only a small number of independent-sector organisations. Across the public extracts reviewed from 2021/22 to 2025/26 (Q1-Q3), identifiable independent-sector providers accounted for 296 cancellations versus 337,004 in NHS organisations, contributing under 0.2% of recorded cancellations in each year examined. However, the public files do not provide matched provider-level denominators or case-mix adjustment, and the reporting scope has changed over time. The main conclusion is therefore methodological: current public English data are suitable for surveillance of NHS-funded last-minute cancellations, but they do not permit a fair denominator-matched comparison of day-of-surgery cancellation rates between NHS trusts and private providers. Future comparative work will require linked activity denominators, transparent provider classification, and standardised sector-wide reporting.},
}
@article {pmid42207935,
year = {2026},
author = {Boulton, AJ and Elfeky, A and Court, R and Grove, A and Wilson, A and Auguste, P and Clayton, D and Gallacher, D and Goligher, EC and MacLeod Hall, C and McAuley, DF and Perkins, GD and Scholefield, BR and Thompson, M and Yeung, J and Chen, YF and Couper, K},
title = {Technology-Enhanced Strategies to Optimize Positive End-Expiratory Pressure in Patients Receiving Invasive Mechanical Ventilation: A Systematic Review and Meta-Analysis.},
journal = {Critical care medicine},
volume = {54},
number = {7},
pages = {1767-1778},
pmid = {42207935},
issn = {1530-0293},
mesh = {Humans ; *Positive-Pressure Respiration/methods ; *Respiration, Artificial/methods ; Cost-Benefit Analysis ; Intensive Care Units ; },
abstract = {OBJECTIVES: To undertake a systematic review evaluating the clinical and cost-effectiveness of technology-enhanced positive end-expiratory pressure (PEEP) optimization strategies in adults and children receiving invasive mechanical ventilation on an ICU.<br><br>DATA SOURCES: We searched key electronic databases (including MEDLINE and Embase) from inception to July 2024.<br><br>STUDY SELECTION: We included randomized studies examining clinical or cost-effectiveness of technology-enhanced PEEP optimization strategies compared with standard care or an alternative PEEP optimization strategy in adults and children. The primary outcome was duration of mechanical ventilation and secondary outcomes were clinical effectiveness (e.g., mortality) and efficacy (e.g., PEEP).<br><br>DATA EXTRACTION: Two reviewers independently assessed eligibility, extracted data, assessed risk of bias (Revised Cochrane tool) and performed Grading of Recommendations Assessment, Development and Evaluation evidence certainty assessments.<br><br>DATA SYNTHESIS: Our database and trial register search retrieved 8845 results, of which 34 studies (2951 patients) were included. Eight studies were at low risk of bias. Across studies, 7 technologies were evaluated, most commonly esophageal balloon measurement of transpulmonary pressure (10 studies), electrical impedance tomography (7 studies), pressure-volume curve analysis (6 studies), and fully automated closed-loop ventilation (5 studies). Meta-analysis used random-effects models. Duration of mechanical ventilation was reported in only three studies (172 patients, two technologies) and there was no effect compared with standard care (mean difference -0.06 d; 95% CI, -0.20 to 0.09; very low-certainty evidence).For 28-day mortality (10 studies; 1,719 patients; six technologies), technology-enhanced PEEP optimization reduced 28-day mortality (risk ratio 0.69; 95% CI, 0.52-0.93; very low-certainty evidence). No significant differences were found for other clinical-effectiveness outcomes. We identified no evidence in children or on cost-effectiveness.<br><br>CONCLUSIONS: Technology-enhanced PEEP optimization strategies did not reduce duration of mechanical ventilation, but these technologies may reduce mortality. Evidence certainty was low or very low, highlighting the urgent need for adequately powered randomized trials.<br><br>REGISTRATION: PROSPERO (CRD42024555390).},
}
@article {pmid42208954,
year = {2026},
author = {Baker, B and Baz Lomba, JA and Bitilinyu-Bangoh, J and Berglöf, A and Bombaywala, S and Calvert-Joshua, T and Kaboré, B and Kingpriest, P and Lang, T and Levy, JI and Lompo, P and Lyimo, E and Martens, L and Mavoko, HM and Mesuere, B and Moremi, N and Mulder, N and Ndure, SL and Rameto, MA and Rinke de Wit, TF and Sebukoto, H and Smith, E and Tahita, MC and Tevuzula, VM and Tippett Barr, BA and Tiwari, A and Tran, T and Ubomba-Jaswa, E and Van Den Bossche, T and Wolday, D and Krolicka, A and Baraka, V and Pitkänen, T and Lood, R},
title = {Project ODIN: advancing environmental genomic surveillance for public health across sub-Saharan Africa.},
journal = {The Lancet. Microbe},
volume = {},
number = {},
pages = {101426},
doi = {10.1016/j.lanmic.2026.101426},
pmid = {42208954},
issn = {2666-5247},
abstract = {Persistent SARS-CoV-2 transmission, ongoing mpox outbreaks, and the continued spread of endemic diseases such as typhoid fever and cholera underscore the urgent need for global, multiomics surveillance. In this Personal View, we present Project ODIN, a consortium of European and African partners launched in 2023 that aims to meet this challenge by deploying innovative systems for near real-time pathogen detection and actionable public health insights. The project is a collaboration between high-income and low-income countries in northern Europe and sub-Saharan Africa. Focusing on low-income and middle-income countries, ODIN integrates metagenomics with mobile laboratory systems for comprehensive pathogen monitoring across diverse environments. ODIN emphasises standardised sampling, bioinformatics pipelines, and data-sharing protocols to ensure reliable, interoperable results while addressing infrastructure and resource limitations. By bridging gaps in genomic surveillance, these initiatives seek to strengthen outbreak preparedness, improve pathogen detection, monitor antimicrobial resistance, and provide a holistic approach to One Health challenges. Together, these innovations could advance global surveillance capacity-particularly in under-resourced regions-paving the way for effective disease control and evidence-based policy making.},
}
@article {pmid42210098,
year = {2026},
author = {Alsarayreh, M and Moawad, MHED and Barham, H and Abdelkarim, OY and Al-Janabi, DRF and Alkhawaldeh, IM and Abdul-Hafez, HA},
title = {Awake prone positioning reduces mortality, intubation, and hospital stay in acute hypoxemic respiratory failure: a systematic review and meta-analysis of 6,164 patients.},
journal = {BMC anesthesiology},
volume = {26},
number = {1},
pages = {},
pmid = {42210098},
issn = {1471-2253},
mesh = {Humans ; *Respiratory Insufficiency/mortality/therapy ; Prone Position ; *Length of Stay/statistics &amp; numerical data ; *Intubation, Intratracheal/statistics &amp; numerical data ; Wakefulness ; *Hypoxia/therapy/mortality ; Respiration, Artificial ; Randomized Controlled Trials as Topic ; *Patient Positioning/methods ; },
abstract = {BACKGROUND: Acute hypoxemic respiratory failure (AHRF) is a major cause of morbidity and mortality and often requires advanced respiratory support. Awake prone positioning (APP) has emerged as a simple, low-cost intervention to improve oxygenation in non-intubated patients; however, its clinical effectiveness and safety remain uncertain.<br><br>AIM: This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of awake prone positioning in non-intubated adult patients with acute hypoxemic respiratory failure.<br><br>METHODS: A systematic search of PubMed, Scopus, and Web of Science was conducted from database inception to February 2026. Randomized controlled trials and observational comparative studies evaluating APP versus usual care were included. Primary outcomes were mortality, intubation, and length of hospital stay. Secondary outcomes included ICU stay, invasive mechanical ventilation, ICU admission, escalation of respiratory support, time to invasive ventilation, and adverse events. Risk of bias was assessed using ROB 2 for randomized trials and the Newcastle-Ottawa Scale for observational studies. Meta-analysis was performed using a random-effects model.<br><br>RESULTS: Twenty-four studies involving 6,164 patients were included. APP significantly reduced mortality (OR&#x2009;=&#x2009;0.60, 95% CI 0.42-0.86, p&#x2009;=&#x2009;0.005), intubation (OR&#x2009;=&#x2009;0.69, 95% CI 0.60-0.79, p&#x2009;<&#x2009;0.00001), length of hospital stay (MD&#x2009;=&#x2009;-&#x2009;0.70 days, 95% CI&#x2009;-&#x2009;1.07 to -&#x2009;0.32, p&#x2009;=&#x2009;0.0003), ICU stay (MD&#x2009;=&#x2009;-&#x2009;2.84 days, 95% CI&#x2009;-&#x2009;5.44 to -&#x2009;0.24, p&#x2009;=&#x2009;0.03), and invasive mechanical ventilation (OR&#x2009;=&#x2009;0.42, 95% CI 0.31-0.58, p&#x2009;<&#x2009;0.00001). No significant differences were observed in ICU admission, escalation of respiratory support, or adverse events.<br><br>CONCLUSION: Awake prone positioning was associated with improved clinical outcomes, including reduced mortality, intubation, and hospital stay, without an apparent increase in adverse events. However, these findings should be interpreted cautiously given the observed heterogeneity and potential publication bias. Further high-quality randomized trials are needed to confirm these results.},
}
@article {pmid42210183,
year = {2026},
author = {Li, K and Johar, ER and Zheng, J},
title = {Prevalence, associated factors, and outcomes of workplace violence against doctors in China: a systematic review and meta-analysis.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {42210183},
issn = {1471-2458},
mesh = {Humans ; *Workplace Violence/statistics &amp; numerical data ; China/epidemiology ; Prevalence ; *Physicians/statistics &amp; numerical data/psychology ; Risk Factors ; Working Conditions ; Male ; Female ; },
abstract = {BACKGROUND: Workplace violence is a major occupational and public health concern in healthcare settings. Although doctors are a high-risk group, existing research has primarily focused on healthcare workers in general or on nurses, with less attention to doctors. This systematic review and meta-analysis synthesized evidence on the prevalence, types, associated factors, outcomes, and perceived impacts of workplace violence against doctors in China.<br><br>METHODS: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Web of Science, Scopus, and China National Knowledge Infrastructure were systematically searched from database inception to 31 December 2025. Eligible studies were Chinese- or English-language cross-sectional or mixed-methods studies with extractable cross-sectional data that reported the 12-month prevalence of overall workplace violence among doctors in China. Data were synthesized using random-effects meta-analysis in R, and heterogeneity was assessed using Cochran's Q and I[2] statistics.<br><br>RESULTS: Nineteen studies involving 114,270 doctors were included. The pooled 12-month prevalence of workplace violence against doctors in China was 60.85% (95% CI: 49.16%-71.42%; range: 14.26%-90.40%). Verbal violence was the most common type, with a pooled prevalence of 49.56% (95% CI: 29.69%-69.57%), followed by threats (28.08%; 95% CI: 15.90%-44.64%), physical violence (14.36%; 95% CI: 7.77%-25.02%), sexual harassment (11.81%; 95% CI: 5.75%-22.73%), and sexual assault (4.66%; 95% CI: 2.19%-9.62%). Patients and their family members or relatives were the main perpetrators. Workplace violence was associated with demographic factors, professional characteristics, workload-related factors, and clinical setting and organizational factors, including male sex, higher educational attainment, professional title or level, longer working hours, and high-risk clinical settings. Subgroup analyses showed a significantly lower pooled prevalence during the COVID-19 pandemic than before the pandemic. Workplace violence was also associated with adverse psychological, occupational, and organizational outcomes; perceived impacts included emotional distress, reduced work efficiency, decreased patient trust, and thoughts of leaving the profession.<br><br>CONCLUSIONS: Workplace violence against doctors in China remains highly prevalent, with verbal violence as the dominant form. The findings suggest that workplace violence may be more likely in high-demand clinical contexts characterized by heavy workloads, frequent doctor-patient interactions, and unmet patient expectations. Structural, organizational, and policy measures are needed to reduce service pressure, strengthen prevention and reporting systems, and protect doctors' well-being and retention.<br><br>PROSPERO REGISTRATION NUMBER: CRD420251088438.},
}
@article {pmid42210267,
year = {2026},
author = {Caffe, S and Bautista, EG and Roman-Orozco, OS and Sanhueza, A},
title = {COVID-19 morbidity and mortality in young people in selected countries of the Americas.},
journal = {International journal for equity in health},
volume = {25},
number = {1},
pages = {},
pmid = {42210267},
issn = {1475-9276},
mesh = {Humans ; Adolescent ; *COVID-19/mortality/epidemiology ; Female ; Child ; Young Adult ; Male ; Americas/epidemiology ; Incidence ; SARS-CoV-2 ; Comorbidity ; Morbidity ; },
abstract = {BACKGROUND: While COVID-19 primarily affected adults, the epidemiology among adolescents and young adults has been less explored. This study describes the burden, outcomes, and correlates of COVID-19 among people aged 10-24 years in selected countries in the Americas during the acute pandemic phase (2020-mid-2022).<br><br>METHODS: We analyzed case-based surveillance data reported by 32 countries and territories to the Pan American Health Organization between January 2020 and July 2022. Confirmed and probable SARS-CoV-2 infections were included following WHO definitions. We described age, sex, and temporal distributions, estimated cumulative incidence, and assessed associations between recovery status, comorbidities, and treatment modalities using logistic regression models adjusted for age and sex.<br><br>RESULTS: A total of 17,031,217 COVID-19 cases were reported among young people (72% aged 10-19; 28% aged 20-24). Females accounted for 53% of cases. The pooled cumulative incidence was 7.7 per 100 population aged 10-24, ranging from 0.1 in Cuba to 52.0 in Bonaire, Sint Eustatius, and Saba. Recovery was documented in 88.9% of adolescents and 87.0% of young adults. The odds of recovery were lower among those aged 20-24 years (aOR 0.84, 95% CI 0.83-0.84), those with &#x2265;&#x2009;1 comorbidity (aOR 0.17, 95% CI 0.16-0.18), and those requiring ventilatory support (aOR 0.28, 95% CI 0.25-0.31). Females and hospitalized patients had slightly higher recovery odds. Cardiovascular, kidney, and diabetic comorbidities were significantly associated with increased mortality.<br><br>CONCLUSIONS: Young people in the Americas represented a substantial proportion of COVID-19 cases, though with low overall mortality. However, chronic conditions markedly increased the risk of poor outcomes. Strengthening surveillance, ensuring continuity of care for young people with chronic diseases, and tailoring risk communication are essential components of future pandemic preparedness and life-course health strategies.},
}
@article {pmid42210365,
year = {2026},
author = {Murunga, AA and Ngoye, B and Wafula, FP},
title = {Short-term health system responses to epidemics across hard-to-reach areas in sub-Saharan Africa: a scoping review.},
journal = {Infectious diseases of poverty},
volume = {15},
number = {1},
pages = {},
pmid = {42210365},
issn = {2049-9957},
support = {MR/T022078/1.//the Wellcome Trust (UKAid), the Economic and Social Research Council, and the Medical Research Council/ ; },
mesh = {Humans ; Africa South of the Sahara/epidemiology ; *Epidemics/prevention &amp; control ; Public Health Infrastructure ; *Delivery of Health Care/organization &amp; administration ; *COVID-19/epidemiology/prevention &amp; control ; Resource-Limited Settings ; Hemorrhagic Fever, Ebola/epidemiology/prevention &amp; control ; SARS-CoV-2 ; Evidence Gaps ; },
abstract = {BACKGROUND: Epidemics and disease outbreaks continue to threaten public health security in sub-Saharan Africa (SSA), disproportionately impacting impoverished and hard-to-reach populations. Although many country-specific studies exist, few syntheses have examined short-term health system responses to epidemics in hard-to-reach areas of SSA and their effects on health equity and resilience. This scoping review consolidates regional evidence on structural and policy-relevant lessons for enhancing health system preparedness and epidemic management in resource-limited settings.<br><br>METHODS: A scoping review was conducted in accordance with the PRISMA-ScR guidelines. Four electronic databases (PubMed, Cochrane Library, CAB Direct, and Google scholar) and grey literature sources for studies published between 2012 and 2022. Eligible studies reported short-term (immediate or early-phase) health system responses to epidemic-prone infectious diseases in SSA. Data were extracted thematically using Excel and analysed using a modified Donabedian framework encompassing structures, processes, and outcomes.<br><br>RESULTS: Fifteen studies met the inclusion criteria and examined responses to Coronavirus 2019 (COVID-19), Ebola Virus Disease (EVD), and other epidemic-prone infections. Common weaknesses identified included shortages of trained healthcare workers, limited financial resources, poor leadership and coordination, and weak information systems. However, countries such as Rwanda, Ethiopia, Nigeria, and Uganda demonstrated adaptive governance, decentralised coordination, and the use of digital tools to improve surveillance, communication, and service delivery. Strong community engagement helped reduce stigma and increased adherence to control measures, especially in rural and underserved areas. Countries that incorporated epidemic response into existing primary healthcare and routine services achieved better equity and system resilience.<br><br>CONCLUSION: The scoping review underscores strong evidence for incorporating epidemic preparedness into the broader health system. Policy focus areas include enhancing leadership and governance, establishing swift response mechanisms at subnational levels, and utilising technology for real-time data and coordination. Regional collaborations like those facilitated by the Africa CDC can improve collective resilience. Going forward, policies should prioritise not just emergency response but also ongoing investment in flexible, learning health systems that can withstand shocks while consistently providing essential services.},
}
@article {pmid42210924,
year = {2026},
author = {Zhu, Y and Chen, Y and Izumoji, G and Qu, S and Wu, D and Chu, H and Wang, Y and Sun, H and Li, X},
title = {Neurobiological mechanisms of olfactory dysfunction: a ten-year bibliometric and visualization analysis.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1812327},
pmid = {42210924},
issn = {2296-858X},
abstract = {BACKGROUND: Olfactory dysfunction (OD) has gained prominence in neurodegenerative diseases and COVID-19 sequelae in recent years. Its mechanisms have also attracted increasing research interest. However, there is currently a scarcity of bibliometric analyses in this field.<br><br>METHODS: Articles related to OD mechanisms were searched in the Web of Science Core Collection (WoSCC) and Scopus. Data merging and bibliometric analysis were conducted using CiteSpace, VOSviewer, Excel, Scimago Graphica, and the bibliometrix in R package. Simultaneously, PubMed was used to search and summarize interventional clinical trials in this field, and their protocols were tracked through trial registration information and ethical approval records.<br><br>RESULTS: A total of 7,915 articles met the inclusion criteria in WoSCC and Scopus. Overall, the number of articles published annually on the mechanisms of OD is on the rise. The USA (2635 publications), University of California System (143 publications), and Thomas Hummel (174 publications) are the most productive country, institution, and author, respectively. Keyword analysis shows that "COVID-19," "Parkinson's disease," "inflammation," "odorant receptor," and other related topics are hot topics and trends in research. PubMed retrieved and included 14 interventional clinical trials. These trials mainly focus on pharmacological interventions, non-pharmacological interventions, surgical interventions, and mechanistic studies.<br><br>CONCLUSION: Mechanistic research on OD is advancing from macroscopic observations to precise molecular mechanisms. This review synthesizes evidence on how distinct etiologies, ranging from post-viral and inflammatory damage to neurodegeneration and metabolic imbalances, contribute to OD. Notably, the dysregulation of the inflammatory NF-&#x3ba;B, signal-transducing cAMP, and neuroregenerative Wnt/&#x3b2;-catenin pathways may collectively contribute to the development of OD. By integrating bibliometric trends with clinical trial evaluations, this study delineates a clear translational pipeline from mechanism exploration to clinical interventions.},
}
@article {pmid42211274,
year = {2026},
author = {Okungu, V and Mulupi, S and Muriithi, GN and Achala, DM and Adote, E and Mbachu, CO and Beshaha, SA and Nwosu, CO and Ataguba, JE},
title = {Scoping review of COVID-19 vaccines access, equity, hesitancy, and uptake in Kenya: lessons for the next pandemic.},
journal = {Frontiers in health services},
volume = {6},
number = {},
pages = {1648814},
pmid = {42211274},
issn = {2813-0146},
abstract = {INTRODUCTION: The global rollout of COVID-19 vaccines was hampered by hesitancy, even as the pandemic intensified, underscoring the urgent need to strengthen vaccination efforts to reach most of the population. The primary objective of this review was to identify the critical barriers to equitable and timely access to and uptake of vaccines in Kenya with a view to mitigating the impacts of future pandemics, such as COVID-19.<br><br>METHODS: A digital search was conducted between February and March 17, 2024, and between December 2025 and February 2026, using four databases: PUBMED, Google Scholar, Cochrane Library, and Africa Journals Online. The search was limited to peer-reviewed articles only. The keywords used in the search were: COVID-19 vaccine&#x2009;+&#x2009;Access +Kenya; COVID-19 vaccine +Uptake+ Kenya; COVID-19 vaccine +Equity+ Kenya; COVID-19 vaccine +Hesitancy+ Kenya. The search was restricted to studies published from 2020, when the first vaccines were rolled out. Three researchers independently reviewed articles for inclusion and exclusion.<br><br>RESULTS: A total of 60 articles were included in the review. The main themes identified include geographic access, socio-demographic factors, economic and political determinants, and distrust in government systems. Among the critical determinants of COVID-19 vaccine uptake, confidence in the vaccine's efficacy and safety was a significant consideration. Geographic access to vaccination sites hindered uptake; for example, only 9.7% were vaccinated in a hard-to-reach county, compared to 53% in an urban county. Sociodemographic factors, including age, gender, level of education, occupation, and co-morbidity, significantly influenced vaccine uptake in Kenya. Above all, the Ministry of Health's failure to mount a convincing response to myths and misconceptions about the COVID-19 vaccine ultimately affected vaccination coverage nationwide.<br><br>CONCLUSION: Future preparedness must ensure inclusive vaccine strategies led by governments with clear policies and tailored outreach. Communication should address vulnerable groups and reduce hesitancy. Improving access and engaging communities are key to equity. Social workers help build trust and local relevance.},
}
@article {pmid42211665,
year = {2026},
author = {Jia, Y and Wang, Y},
title = {Comparative progress on the mechanisms of airway mucosal injury induced by different pathogens: SARS-CoV-2, influenza A virus, and Mycoplasma pneumoniae.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1777403},
pmid = {42211665},
issn = {2235-2988},
mesh = {Humans ; *SARS-CoV-2/pathogenicity ; *COVID-19/pathology/virology/immunology ; *Influenza, Human/pathology/virology ; *Mycoplasma pneumoniae/pathogenicity ; *Respiratory Mucosa/microbiology/pathology/virology/immunology ; *Influenza A virus/pathogenicity ; *Pneumonia, Mycoplasma/pathology/microbiology/immunology ; Animals ; Angiotensin-Converting Enzyme 2/metabolism ; },
abstract = {Respiratory infectious diseases remain a major global public health challenge. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A Virus (IAV), and Mycoplasma pneumoniae (MP), as three representative respiratory pathogens, all clinically cause airway epithelial shedding, ciliary dysfunction, and Acute Respiratory Distress Syndrome (ARDS). Notably, they are the common triggers of acute respiratory infections characterized by persistent and severe cough, a clinical hallmark rooted in the structural disintegration of the airway mucosal barrier. However, the molecular mechanisms by which they compromise the airway mucosal barrier exhibit significant heterogeneity. Currently, there is a paucity of systematic reviews offering a comparative analysis between these viral and atypical bacterial pathogens. This review comprehensively examines the pathogenic mechanisms of these three agents across four dimensions: receptor recognition, direct cytotoxicity, immunopathology, and abnormal tissue repair. Studies indicate that during the invasion phase, SARS-CoV-2 relies on the Angiotensin-converting enzyme 2 (ACE2) receptor and Transmembrane protease, serine 2 (TMPRSS2) -mediated membrane fusion; IAV identifies sialic acid receptors via hemagglutinin, whereas MP utilizes specialized attachment organelles for "gliding" colonization. Regarding cellular injury mechanisms, SARS-CoV-2 primarily hijacks the endoplasmic reticulum (ER) to induce stress responses and promote syncytium formation; IAV predominantly targets mitochondria to trigger apoptosis and cellular necrosis; while MP utilizes hydrogen peroxide and Community-Acquired Respiratory Distress Syndrome (CARDS) toxin to implement oxidative damage and vacuolating toxicity. At the immunopathological level, SARS-CoV-2-induced delayed interferon response and cytokine storm, IAV-triggered excessive formation of neutrophil extracellular traps (NETs), and MP-mediated activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome are key drivers exacerbating airway injury. Furthermore, distinct acute injury mechanisms determine differentiated long-term prognoses, such as pulmonary fibrosis, airway hyperresponsiveness, and airway remodeling. In summary, elucidating the commonalities and specificities of these mechanisms has significant clinical guidance value for precisely distinguishing clinical phenotypes, predicting disease progression, and developing host-directed therapies targeting specific injury pathways.},
}
@article {pmid42211706,
year = {2026},
author = {Shin, HY and Ki, M},
title = {COVID-19 legislative response and challenges in Republic of Korea.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1800597},
pmid = {42211706},
issn = {2296-2565},
mesh = {Republic of Korea/epidemiology ; Humans ; *COVID-19/epidemiology/prevention &amp; control ; Pandemic Preparedness ; SARS-CoV-2 ; *Pandemics ; *Health Policy/legislation &amp; jurisprudence ; *Communicable Disease Control/legislation &amp; jurisprudence ; },
abstract = {This narrative review systematically analyzes the longitudinal evolution of South Korea's legal and institutional frameworks from the 2015 MERS outbreak through the COVID-19 pandemic. The study introduces the "Pandemic Response Pentad," an original conceptual model positioning Legislation as the foundational core, mediated by Governance, to drive three interconnected field operations. Based on this framework, Korea's infectious disease control system is evaluated across four operational domains: (1) governance reform and personnel structure enhancement, (2) epidemiological response capabilities and data utilization, (3) medical response system, including vaccination programs and supply stockpiling, and (4) social response mechanisms, encompassing social distancing and the protection of vulnerable populations. While rapid legislative enactments enabled effective disease control, they also generated profound ethical tensions regarding fundamental human rights. To mitigate these unintended socioeconomic consequences, Korea institutionalized extensive statutory compensation mechanisms for healthcare facilities, small business owners, and vaccine injuries. The findings highlight that advancing national research infrastructure and establishing policy-oriented think tanks for future pandemic preparedness strictly require proactive legislative backing. Ultimately, this study provides valuable insights into the critical interplay between legal mandates and institutional resilience in global health crisis management.},
}
@article {pmid42213226,
year = {2026},
author = {Zorina, O and Beiki, O and Holt, M and Buisker, J and Ferber, P and Fermont, JM and Kelly, RJ},
title = {Global Epidemiology of Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {},
pmid = {42213226},
issn = {2210-6014},
mesh = {*Hemoglobinuria, Paroxysmal/epidemiology ; Humans ; *Global Health/statistics &amp; numerical data ; Incidence ; Prevalence ; },
abstract = {BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disorder characterized by chronic intravascular hemolysis and an increased risk of thrombosis. A systematic synthesis of disease epidemiology is essential to understand disease patterns, improve timely diagnosis, and guide healthcare policies. This review aims to consolidate contemporary estimates of PNH incidence and prevalence globally and describe any observed trends in these epidemiological parameters.<br><br>METHODS: A systematic search of electronic databases was performed in November 2024 and identified 27 studies published between 2006 and 2024 following PRISMA guidelines. All population-based observational studies reporting incidence or prevalence measures of PNH were included, with no restrictions on age or geography; the synthesis of results focused on studies evaluated as medium or high-quality based on a structured assessment.<br><br>RESULTS: The annual incidence of patients diagnosed with PNH ranged from 0.17 to 0.35 per 100,000 population between 2002 and 2022 in the majority of high-quality studies. Regional variability emerged: studies from countries with high healthcare system quality scores consistently reported higher incidence estimates than those from countries with low scores. Yearly prevalence estimates in 2010-2021 ranged from 1.1 to 2.1 per 100,000 population, while longer-period prevalence (10-17 years) ranged from 1.5 to 6.4 per 100,000 population.<br><br>DISCUSSION: The prevalence of diagnosed PNH has been steadily growing since 2006 across all regions, possibly reflecting improved survival rates following the introduction of effective therapies or improved diagnostic practices. Despite disruptions observed during the COVID-19 pandemic (2020-2021), this upward trend is expected to continue as treatment access improves globally. The lower incidence reported in the regions with lower healthcare quality scores reflects potential underdiagnosis of PNH or unequal access to healthcare, highlighting the need for strengthening healthcare systems to ensure timely diagnosis and access to treatment of PNH.<br><br>CONCLUSIONS: This review provides updated global estimates of the incidence and prevalence of PNH, offers new insights into epidemiological trends, and highlights potential regional inequities in diagnosis and treatment. The results aim to support future research initiatives and inform healthcare strategies to improve outcomes for patients with PNH.},
}
@article {pmid42213322,
year = {2026},
author = {Ahmad, T and Alhammadi, BA and Almaazmi, SY and Arafa, S and Blatch, GL and Dutta, T and Gestwicki, JE and Keyzers, RA and Meskiri, A and Sharafeldin, A and Shonhai, A and Singh, H},
title = {Malaria Public Health Status: Global Context and Update on Gulf Cooperation Council Countries.},
journal = {Advances in experimental medicine and biology},
volume = {1507},
number = {},
pages = {35-53},
pmid = {42213322},
issn = {0065-2598},
mesh = {Humans ; Antimalarials/therapeutic use ; *Malaria/epidemiology/prevention &amp; control/drug therapy/transmission ; Animals ; *Public Health ; Middle East/epidemiology ; Drug Resistance ; Plasmodium falciparum/drug effects/pathogenicity ; Malaria Vaccines/therapeutic use ; Global Health ; },
abstract = {From 2000 to 2019, the global malaria death toll fell from 864,000 to 576,000 deaths; however, progress on reducing this toll has since slowed, with the COVID-19 pandemic contributing to an increase in the mortality rate since 2020. The emergence of widespread resistance in the major malaria parasite (Plasmodium falciparum) to first-line treatment drugs has highlighted the need for new antimalarials and smarter drug delivery strategies. Nevertheless, recent successes of the first malaria vaccines (RTS,S/AS01 and R21/MM) have renewed the promise of widely applicable vaccines in the future. Since 2015, the Eastern Mediterranean Region has experienced an overall increase in malaria cases and deaths. In the Arabian Peninsula, while most of the Gulf Cooperation Council (GCC) countries have been declared free of indigenous malaria (Bahrain, Kuwait, Qatar, and the United Arab Emirates), malaria is still endemic in two GCC countries (Saudi Arabia and Oman) and their neighbors (Yemen). Furthermore, a number of factors threaten malaria control in this region, especially antimalarial drug resistance, the emergence of highly invasive mosquito species, increasing average temperatures, and imported malaria. In this review, we assess the current worldwide status of malaria before providing a critical evaluation of the malaria situation in the GCC countries.},
}
@article {pmid42215147,
year = {2026},
author = {Petropoulou, D and Karampela, I and Christodoulatos, GS and Kounatidis, D and Vallianou, NG and Dalamaga, M},
title = {Hormonal, metabolic and metabolomic biomarkers in long COVID.},
journal = {Advances in clinical chemistry},
volume = {133},
number = {},
pages = {217-283},
doi = {10.1016/bs.acc.2026.01.002},
pmid = {42215147},
issn = {2162-9471},
mesh = {*SARS-CoV-2 ; *COVID-19/complications/metabolism ; Metabolomics ; *Hormones/metabolism ; },
abstract = {Long COVID (LC), a complex syndrome affecting approximately 6-12 % of individuals post infection, is characterized by persistent, fluctuating, or progressive symptoms lasting at least three months. Its pathogenic mechanisms involve viral persistence, chronic inflammation, immune dysregulation, endothelial dysfunction, and endocrine/metabolic abnormalities. Currently, no specific diagnostic tests exist for LC, highlighting the need for reliable biomarkers. This review synthesizes current evidence on hormonal, metabolic, and metabolite biomarkers in LC. While vitamin D deficiency is prevalent in LC, being associated with neurocognitive symptoms, delayed recovery and poor physical performance, particularly in older adults, its lack of specificity reduces diagnostic utility. Insulin resistance markers consistently correlate with fatigue, mood disturbances, and myalgia, suggesting a distinct metabolic LC phenotype. Lower cortisol frequently correlates with fatigue, sensory disturbances, and neurocognitive symptoms. Alterations in cortisol/adrenocorticotropic hormone, growth hormone, prolactin, and gonadotropins suggest a potential hypothalamic-pituitary axis involvement; however, these abnormalities are often transient, dynamic or nonsignificant. While some patients may exhibit low free triiodothyronine associated with fatigue, no significant incidence of thyroid dysfunction and autoimmunity was associated with LC. Despite the absence of a distinct and consistent metabolomic signature, LC is characterized by the activation of the kynurenine pathway, including increased kynurenine and quinolinic acid, being associated with fatigue, neurocognitive and depressive symptoms. Emerging metabolites of mitochondrial dysfunction and lipid metabolism alterations require further validation. Despite promising findings, evidence remains scattered, hindered by small sample sizes and methodological limitations. Future research should prioritize standardization of biomarker assessment, validation in diverse populations, and exploration of targeted therapeutic interventions.},
}
@article {pmid42215223,
year = {2026},
author = {Li, T and Li, X and Liu, M and Shahbaz, Z and You, J and Quan, Z and Li, J and Liu, Y and Xu, Y and Wang, L},
title = {Analysis of foodborne disease outbreak surveillance in the China Mainland 2014-2023.},
journal = {Food microbiology},
volume = {139},
number = {},
pages = {105143},
doi = {10.1016/j.fm.2026.105143},
pmid = {42215223},
issn = {1095-9998},
mesh = {China/epidemiology ; Humans ; *Disease Outbreaks/statistics &amp; numerical data ; *Foodborne Diseases/epidemiology/microbiology/mortality ; Seasons ; Mushroom Poisoning/epidemiology ; Agaricales/pathogenicity ; COVID-19/epidemiology ; Salmonella/isolation &amp; purification ; Vibrio parahaemolyticus/isolation &amp; purification ; },
abstract = {Foodborne diseases pose a significant public health and economic burden worldwide. This study systematically analyzed a decade (2014-2023) of national surveillance data from mainland China, encompassing 50,434 outbreaks, 311,672 illnesses, and 1330 fatalities. The results revealed pronounced geographical disparities, with five provinces (Shandong, Yunnan, Hunan, Guizhou, and Sichuan) collectively accounting for 59.27% of outbreaks. A distinct seasonal peak was observed from June to August, correlated with high temperature and humidity. Poisonous mushrooms were the predominant causative agent, responsible for 50.65% of outbreaks with identified etiology and the highest case fatality. Microbial pathogens, notably Vibrio parahaemolyticus and Salmonella spp., were also major contributors. Most outbreaks and fatalities occurred in household settings, with a notable surge during the COVID-19 pandemic. Our findings underscore the critical need for targeted interventions, enhanced public education on toxic mushrooms, and strengthened surveillance systems to reduce the burden of foodborne diseases in China.},
}
@article {pmid42215915,
year = {2026},
author = {Khorram-Manesh, A and Carlström, E},
title = {Patient-centered care for patients requiring dialysis during disasters and public health emergencies: a scoping review.},
journal = {International journal of emergency medicine},
volume = {19},
number = {1},
pages = {},
pmid = {42215915},
issn = {1865-1372},
abstract = {BACKGROUND: Disasters and public health emergencies disrupt health systems, threaten continuity of care, and disproportionately affect medically vulnerable populations. Patients requiring dialysis are especially at risk because their survival depends on regular access to complex, resource-intensive treatment. While disaster nephrology literature increasingly addresses preparedness and resilience, it remains unclear how explicitly this literature addresses patient-centered care.<br><br>OBJECTIVE: To map the literature on patient-centered care for patients requiring dialysis during disasters and public health emergencies, with attention to preparedness, continuity of care, communication, access, and vulnerable populations.<br><br>METHODS: A scoping review was conducted using searches in Web of Science, Scopus, and PubMed. Search terms combined concepts related to disaster, emergency, patient-centered care, vulnerability, dialysis, and alternative care facilities. Records were screened for relevance to dialysis care in disasters or public health emergencies, or for conceptual relevance to patient-centered dialysis care in disrupted settings. Both authors conducted screening, eligibility assessment, and data charting, using a predefined set of inclusion criteria and a consistent conceptual framework. The search was intentionally focused to prioritize literature most directly relevant to dialysis-dependent patients in disaster and public health emergency contexts. Forty-three studies were included.<br><br>RESULTS: The included studies comprised reviews, scoping reviews, observational studies, qualitative studies, case studies, program reports, pilot studies, trials, and conceptual papers. The literature clustered around six themes: preparedness for dialysis patients and providers; continuity of care and treatment access; infrastructure, logistics, and resilience; patient awareness, communication, and lived experience; public health emergency adaptations, particularly during COVID-19; and broader frameworks for disaster risk reduction in kidney care. Although relatively few studies explicitly used the term patient-centered care, many addressed closely related domains, including communication, care planning, family involvement, psychosocial support, access, and continuity. Taken together, the findings suggest that patient-centered dialysis care in emergencies is shaped by broader health system factors, including preparedness, coordination, service design, and equity.<br><br>CONCLUSIONS: Patients requiring dialysis are among the most vulnerable groups during disasters and public health emergencies. Existing literature provides a strong foundation in preparedness and continuity of treatment but addresses patient-centered care more often implicitly than explicitly. Future research should develop and test patient-centered indicators for dialysis care in emergencies, including communication, shared planning, caregiver involvement, psychosocial support, and the role of alternative care facilities.},
}
@article {pmid42215997,
year = {2026},
author = {Harmouch, J and Green, R and Mayilsamy, K and Tosi, K and Mohapatra, S and Mohapatra, SS},
title = {Convergence of neuroinflammation across major neurotropic viral exposomes in AD and ADRD.},
journal = {Journal of neuroinflammation},
volume = {23},
number = {1},
pages = {},
pmid = {42215997},
issn = {1742-2094},
support = {AG086245, IK6BX004212, BX006456//National Institute of Health USA and Dept of Vet Affairs, USA/ ; AG086245, IK6BX006032, BX005757//National Institute of Health,USA and Dept of Veteran Affairs USA/ ; },
mesh = {Humans ; *Alzheimer Disease/virology/immunology/metabolism/epidemiology ; *Neuroinflammatory Diseases/virology/immunology ; Animals ; *Virus Diseases/complications ; },
abstract = {BACKGROUND: Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) are multifactorial neurodegenerative disorders driven by complex interactions among genetic susceptibility, aging, and environmental exposures. Growing epidemiological and mechanistic evidence implicates neurotropic viral exposomes, defined as cumulative lifetime viral infections, as significant contributors to AD risk. Viral encephalitis and common viral infections, including herpes simplex virus type 1 (HSV-1), human immunodeficiency virus (HIV), cytomegalovirus (CMV), SARS-CoV-2, and influenza, have been associated with an increased incidence of AD/ADRD; however, the molecular mechanisms underlying these associations remain incompletely understood.<br><br>METHODS: A systematic literature review was conducted using PubMed, Web of Science, Scopus, and Google Scholar (1990-2025) to identify epidemiological, experimental, and mechanistic studies linking viral infections to AD-related pathology. Systems biology approaches were applied using Cytoscape, STRING, KEGG, WikiPathways, and Ingenuity Pathway Analysis to construct protein-protein interaction networks and identify convergent biological processes shared between AD and viral host-response pathways. Functional enrichment analyses focused on neuroinflammation, amyloid-&#x3b2; (A&#x3b2;) metabolism, tau pathology, autophagy, and blood-brain barrier (BBB) integrity.<br><br>RESULTS: Across diverse viral infections, strong convergence was observed in innate immune activation pathways, including microglial priming and NLRP3 inflammasome signaling, accompanied by chronic production of proinflammatory cytokines (IL-1&#x3b2;, TNF-&#x3b1;, IFN-&#x3b3;). Multiple viruses modulated amyloidogenic APP processing, impaired A&#x3b2; clearance, promoted tau hyperphosphorylation, disrupted autophagy-lysosomal systems, and compromised BBB integrity. Systems-level analyses revealed overlapping signaling hubs, including NF-&#x3ba;B, MAPK, PI3K-Akt, and cGAS-STING that amplify neurodegenerative cascades, with effects most pronounced in genetically susceptible populations such as APOE4 carriers.<br><br>CONCLUSIONS: Collectively, current evidence supports a mechanistic link between viral exposomes and AD/ADRD mediated through convergent neuroinflammatory, and proteostatic pathways. Although viral infections alone are unlikely to be sufficient to cause AD, recurrent or persistent viral exposures may act as potent disease modifiers that accelerate neurodegenerative processes. Integrating viral biomarkers, genetic risk stratification, and systems biology approaches offers promising opportunities for early diagnosis, prevention, and development of mechanism-guided therapeutic strategies.},
}
@article {pmid42216226,
year = {2026},
author = {, },
title = {Bridging the gap: the Pasteur Network's approach to equitable vaccine development and manufacturing.},
journal = {BMC global and public health},
volume = {4},
number = {1},
pages = {},
pmid = {42216226},
issn = {2731-913X},
abstract = {Equitable access to vaccines remains a cornerstone of global health security, yet persistent gaps in regional manufacturing capacity continue to undermine timely and fair distribution. The COVID-19 pandemic exposed the risks of highly concentrated production systems and underscored the need for locally anchored manufacturing models capable of responding rapidly to public health emergencies. The Pasteur Network (PN)-a global consortium of 32 public health and research institutes across Africa, Asia, Europe, and the Americas-offers an operational example of decentralized vaccine manufacturing embedded in national public health systems linking regional manufacturing capacity with public health priorities. Here, we examine the contributions and challenges of members within the PN engaged in vaccine manufacturing. Twelve members currently produce more than 525 million doses annually, covering a broad range of human and veterinary vaccines. Embedded within national health systems, the PN members combine research, development, and partial or end-to-end manufacturing capacities, ensuring close alignment with national public health priorities. Several members within the PN also contribute to global initiatives, including the Coalition for Epidemic Preparedness Innovations (CEPI) manufacturing network, reinforcing their role in global preparedness efforts. Despite these strengths, common barriers persist across the PN, including workforce retention challenges, limited sustainable core funding, supply chain vulnerabilities, fragmented regulatory pathways, and insufficient coordination. We argue that the PN illustrates a scalable, public-health-embedded manufacturing model that complements existing industrial and technology-transfer approaches and should inform future global financing and governance.},
}
@article {pmid42216347,
year = {2026},
author = {Faseeh, A and Rida, M and Karim, NE and Zafar, A and Shah, A and Perveen, A},
title = {Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.},
journal = {Medicine},
volume = {105},
number = {22},
pages = {e49022},
pmid = {42216347},
issn = {1536-5964},
mesh = {Humans ; *Cognitive Dysfunction/epidemiology/etiology ; Prevalence ; *COVID-19/complications/epidemiology ; Post-Acute COVID-19 Syndrome ; Female ; Male ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Long COVID is increasingly recognized as a complex multisystem condition, with brain fog and cognitive impairment emerging as some of its manifestations. Despite growing literature, the pooled prevalence, subgroup differences, and underlying mechanisms remain incompletely understood.<br><br>METHODS: We systematically reviewed 47 studies (2000-2025) encompassing over 25,000 patients to evaluate the prevalence of brain fog and cognitive impairment among long COVID populations. Data were extracted on study design, patient demographics, follow-up duration, and subgroup variables including gender, hospitalization, vaccination, and geographic region. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS v9.0) and JBI checklists. Quantitative synthesis was performed with subgroup and temporal analyses, presented in forest plots and summary figures.<br><br>RESULTS: The pooled prevalence of brain fog was 30% (95% CI: 28-32), while cognitive impairment was 25% (95% CI: 23-27). Female patients consistently showed higher rates compared to males (34% vs 23% for brain fog; 29% vs 21% for cognitive impairment). Community-managed patients demonstrated higher prevalence compared to hospitalized cohorts, and unvaccinated individuals had a greater burden than vaccinated ones. Temporal analyses indicated that prevalence increased with longer follow-up, suggesting symptom persistence or late manifestation. Pathophysiological explanations include neuroinflammation, microvascular injury, immune dysregulation, and psychosocial stressors.<br><br>CONCLUSION: Brain fog and cognitive impairment are common, persistent, and clinically significant features of long COVID. Gender differences, vaccination status, and follow-up duration influence prevalence. Future studies should focus on mechanisms, preventive strategies, and targeted interventions to mitigate long-term cognitive sequelae.},
}
@article {pmid42219104,
year = {2026},
author = {Maiti, S and Joseph, J},
title = {From systemic disease to the eye: Why senescence deserves attention in ocular infections.},
journal = {Experimental eye research},
volume = {270},
number = {},
pages = {111095},
doi = {10.1016/j.exer.2026.111095},
pmid = {42219104},
issn = {1096-0007},
mesh = {Humans ; *Cellular Senescence/physiology ; *Aging/physiology ; *Eye Infections/physiopathology ; Senescence-Associated Secretory Phenotype/physiology ; Animals ; Immunity, Innate/physiology ; Adaptive Immunity/physiology ; },
abstract = {The global increase in life expectancy has led to a growing elderly population, bringing new challenges in managing infectious diseases. Advancing age is accompanied by progressive dysfunction of both innate and adaptive immunity, resulting in impaired responses to pathogens and elevated morbidity and mortality. Cellular senescence, a state of permanent cell-cycle arrest with extensive molecular and phenotypic changes, including chromatin remodelling and the senescence-associated secretory phenotype (SASP), has emerged as a key factor in this process. Though initially protective as a tumor-suppressive mechanism, senescence becomes maladaptive with age, contributing to inflammaging, immune dysregulation, and heightened susceptibility to infection. In ocular diseases, such as age-related macular degeneration and chronic keratitis, senescent cells in retinal pigment epithelium and corneal tissues drive persistent inflammation and fibrosis, exacerbating vulnerability to opportunistic pathogens. Pathogens can exploit senescent cells through virulence factors and persistent inflammatory responses, thereby promoting chronic infection and even age-related diseases. Conversely, senescent cells and their SASP can intensify infection severity, as shown in viral infections such as SARS-CoV-2 and bacterial pathogens including Streptococcus pneumoniae and Mycobacterium tuberculosis. This reciprocal relationship illustrates how infection accelerates cellular aging while aging predisposes individuals to more severe infections. Emerging therapeutic strategies targeting senescence, including senolytics and senomorphics, hold promise for mitigating infection-related pathology. In parallel, vaccines and immunotherapies tailored to the aging immune system will be crucial for reducing infection burden in older populations. This review integrates current evidence on the bidirectional interplay between senescence and infection, emphasizing its clinical relevance and potential for translational intervention.},
}
@article {pmid42221305,
year = {2026},
author = {Flisiak, R and Frankova, S and Jindal, S and Aster, V and Hunyady, B and Makara, M and Kristian, P and Stanekova, DV and Zarębska-Michaluk, D and Valckx, S and Hendrickx, G and Van Damme, P and Maticic, M},
title = {Towards elimination of viral hepatitis in the Czech Republic, Hungary, Poland and Slovakia: insights from the Viral Hepatitis Prevention Board (VHPB).},
journal = {Clinical and experimental hepatology},
volume = {12},
number = {1},
pages = {1-10},
pmid = {42221305},
issn = {2392-1099},
abstract = {The Visegrad Group - the Czech Republic, Hungary, Poland and Slovakia - face shared challenges in preventing and controlling viral hepatitis. A regional meeting convened by the Viral Hepatitis Prevention Board evaluated health systems, epidemiology, and national policies, revealing accomplishments and needs for prevention, screening, diagnosis, and linkage to care of viral hepatitis. Universal hepatitis B (HBV) vaccination exists, yet vaccine hesitancy and incomplete coverage threaten progress, while surveillance and registries remain fragmented. Access to hepatitis C (HCV) treatment has improved recently, but remains centralized, with limited engagement of marginalized populations. Elimination of HCV by 2030 is unlikely due to insufficient screening, COVID-19-related healthcare disruptions, and weak political commitment, whereas HBV control depends on maintaining high vaccination coverage and robust monitoring. Participants called for harmonized national guidelines, strengthened regional collaboration, and sustainable action plans backed up by political commitment. Urgent, coordinated efforts are needed to achieve the WHO 2030 elimination goals.},
}
@article {pmid42221476,
year = {2026},
author = {Passerini, I and Pereira, EG and Galvão Fernandes Alves, I and Padoveze, MC},
title = {Simulation of healthcare professional teams in infection prevention and control: A scoping review.},
journal = {Journal of infection prevention},
volume = {},
number = {},
pages = {17571774261456671},
pmid = {42221476},
issn = {1757-1774},
abstract = {BACKGROUND: Healthcare-associated infections (HAIs) are a major public health concern. Although interprofessional education (IPE) is recognized as a promising strategy, there is limited robust evidence demonstrating its effectiveness in reducing infection rates in healthcare settings.<br><br>AIM/OBJECTIVE: To identify studies on interprofessional simulation for healthcare teams focused on infection prevention and control (IPC).<br><br>METHODS: This scoping review followed the PRISMA-ScR checklist and was registered on the OSF platform (https://osf.io/bj6uc/). Six databases (MEDLINE, Embase, Web of Science, CINAHL, ERIC, Scopus) were searched, yielding 632 citations. After screening and applying exclusion criteria, 11 studies were included.<br><br>FINDING/RESULTS: Among the selected studies, four (36.4%) originated from the United States. Five studies (45.5%) employed simulation practices based on evidence or expert consensus. Seven studies (63.6%) involved teams comprising three or more professional categories. All studies addressed infectious diseases requiring rapid response, mainly COVID-19 (55%) and Ebola (45%). Most (81.8%) used patient simulators. The most frequently addressed IPE competencies were teamwork (90.9%), roles and responsibilities (81.8%), and interprofessional communication (72.7%).<br><br>DISCUSSION: Findings indicate a reliance on expert-driven simulation practices and a concentration on emergency contexts. There is a lack of studies evaluating interprofessional simulation in routine care environments, such as primary health care and long-term care. Additionally, the absence of medium- and long-term outcome assessments limits our understanding of the sustained impact of interprofessional simulation on IPC. Further research is needed to support evidence-based implementation in diverse healthcare settings.},
}
@article {pmid42221597,
year = {2026},
author = {Kebe, AT and Diarra, B and Kalossi, I and Traore, BM and Savadogo, L and Sangho, H},
title = {[Associated factors with vaccine hesitancy in sub-Saharan Africa: a literature review].},
journal = {The Pan African medical journal},
volume = {53},
number = {},
pages = {143},
pmid = {42221597},
issn = {1937-8688},
mesh = {Humans ; Africa South of the Sahara ; COVID-19 Vaccines/administration &amp; dosage ; Immunization Programs ; *Patient Acceptance of Health Care/statistics &amp; numerical data ; *Vaccination/psychology/statistics &amp; numerical data ; *Vaccination Hesitancy/statistics &amp; numerical data/psychology ; *Vaccines/administration &amp; dosage ; },
abstract = {Vaccination is a key intervention for reducing infant and child morbidity and mortality. Its success depends largely on public acceptance. This study aims to understand the determinants of vaccine hesitancy in sub-Saharan Africa. The methodological approach consisted of a systematic review of the literature, conducted through consultation of PubMed and grey literature, according to Population/Patient, Intervention, Comparison, and Outcome (PICO) criteria and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Of the 32 studies included, 28 were peer-reviewed, while the others were taken from dissertations and theses by master's and doctoral students in health sciences. The main factors contributing to hesitancy include young age, rural location, low educational attainment, doubts about the safety and efficacy of vaccines, and fear of possible side effects. Mistrust of governments and the influence of social media also play a role. This review identifies these barriers and proposes solutions to improve vaccine uptake, particularly for the Expanded Programme on Immunisation and COVID-19 vaccines.},
}
@article {pmid42221881,
year = {2026},
author = {Asadigandomani, H and Tahmasebi, A and Jalilzadeh, M and Arab Bafrani, M and Mahmoudi, F and Daneshvar, K and Zonouzi, SK and Riazi-Esfahani, H and Khalili Pour, E},
title = {Impact of COVID-19 pandemic on surgical volume, clinical presentations, and management of rhegmatogenous retinal detachment: A systematic review and meta-analysis.},
journal = {SAGE open medicine},
volume = {14},
number = {},
pages = {20503121261456478},
pmid = {42221881},
issn = {2050-3121},
abstract = {PURPOSE: To systematically evaluate the impact of the COVID-19 pandemic, particularly lockdown (LD) periods, on the incidence, clinical presentations, surgical management, and outcomes of rhegmatogenous retinal detachment (RRD).<br><br>METHODS: A systematic literature search was conducted in PubMed, Embase, and Web of Science up to June 2025. Observational studies comparing RRD patients during COVID-19 LDs or pandemic periods with pre-pandemic controls were included. Outcomes assessed included RRD incidence, baseline clinical characteristics, intervals from symptom onset to first visit and surgery, surgical interventions, and anatomical and visual outcomes. Meta-analyses were performed for comparable outcomes using random- or fixed-effects models based on heterogeneity.<br><br>RESULTS: Twenty-nine observational studies involving more than 116,000 eyes were included. COVID-19-related restrictions were associated with a significant reduction in RRD surgical volume (rate ratio 0.71; 95% CI: 0.60-0.84), although marked regional heterogeneity was observed. Marked heterogeneity across studies appeared to be partly related to differences in LD severity, duration, and regional healthcare system burden. Patients presenting during LD periods were significantly less likely to have macula-on RRD (OR = 0.61; 95% CI: 0.46-0.83) and more likely to exhibit moderate-to-severe proliferative vitreoretinopathy (PVR) (OR = 2.58; 95% CI: 1.37-4.87) compared with pre-LD periods. Time from symptom onset to surgery increased during LD periods, while presentation-to-surgery intervals decreased. Surgical practice shifted toward greater use of pars plana vitrectomy (PPV), often combined with longer-acting gas tamponades or silicone oil. Despite increased disease severity, single-surgery retinal attachment rates and postoperative visual outcomes remained largely unchanged across periods.<br><br>CONCLUSIONS: The COVID-19 pandemic had substantial and region-specific effects on RRD management, influencing patient presentation patterns, disease severity, and surgical strategies. Nevertheless, adaptive healthcare responses helped preserve overall anatomical and visual outcomes.},
}
@article {pmid42222230,
year = {2026},
author = {Al-Bar, MH},
title = {Sudden sensorineural olfactory loss: a structured narrative review and proposal for a standardised terminological framework.},
journal = {Frontiers in surgery},
volume = {13},
number = {},
pages = {1838659},
pmid = {42222230},
issn = {2296-875X},
abstract = {BACKGROUND: Sudden loss of smell - particularly when sensorineural in origin - is a clinically disabling condition that the medical community has never adequately named. Patients presenting with acute olfactory loss encounter a field without shared definitions, dedicated ICD codes, or guidelines built around their specific presentation. The consequence is diagnostic delay, terminological inconsistency in the literature, and a research base that cannot be meaningfully synthesised.<br><br>OBJECTIVE: This paper reviews the evidence on sudden sensorineural olfactory loss, demonstrates that existing terminology is inadequate, and proposes a single new clinical term: Sudden Sensorineural Olfactory Loss (SSNOL). Two descriptive aetiological categories are introduced solely to guide future research, not as additional terminology.<br><br>METHODS: A structured narrative review was conducted using PubMed, Embase, and Scopus databases. Studies were selected based on relevance to sudden olfactory dysfunction, neural pathway mechanisms, diagnostic imaging, and clinical management. Both primary research articles and systematic reviews published between 2000 and 2024 were considered.<br><br>RESULTS: The evidence describes a condition with serious, sometimes permanent neural consequences. Post-viral olfactory loss - which received relatively limited specialist attention before the COVID-19 pandemic - was suddenly experienced by hundreds of millions of people, exposing how poorly the field was equipped to respond. Diagnostic tools are blunt. Treatment options are thin. Olfactory training is the only intervention with consistent evidence behind it. None of this will improve without better terminology to organise research around.<br><br>CONCLUSION: We propose the term "Sudden Sensorineural Olfactory Loss" (SSNOL) as the sole terminological contribution of this paper, modelled on the established precedent of sudden sensorineural hearing loss (SSNHL). To guide future research, two descriptive aetiological categories are described - SSNOL-Viral and SSNOL-Idiopathic - presented as hypothesis-generating models to support future research design. Traumatic olfactory loss is explicitly excluded from the SSNOL definition and should be managed under existing post-traumatic frameworks.},
}
@article {pmid42223244,
year = {2026},
author = {Akhavan, M and Khodavaisy, S and Akbarzadeh, S and Mojtahedi, SS and Xu, J and Aala, F and Shafaati, M and Salehi, M},
title = {Post-Viral Aspergillosis: A Systematic Review of Incidence, Clinical Manifestations, and Outcomes.},
journal = {Reviews in medical virology},
volume = {36},
number = {3},
pages = {e70163},
doi = {10.1002/rmv.70163},
pmid = {42223244},
issn = {1099-1654},
support = {//Association Canadienne d'Anthropologie Physique/ ; },
mesh = {Humans ; Incidence ; *COVID-19/complications/virology/epidemiology ; Antifungal Agents/therapeutic use ; Immunocompromised Host ; *Aspergillosis/epidemiology/drug therapy/diagnosis ; SARS-CoV-2/pathogenicity ; *Virus Diseases/complications ; },
abstract = {Invasive aspergillosis (IA) has traditionally been associated with immunocompromised individuals. Post-viral aspergillosis (PVA) has emerged as a significant secondary complication among patients with viral infections, particularly during the COVID-19 pandemic. This systematic review aimed to summarise the patients' clinical characteristics, diagnostic approaches, treatment options, and outcomes of PVA across various respiratory viral infections. This study was registered in PROSPERO (No. CRD420250652078) and followed the PRISMA 2020 guidelines. We systematically searched PubMed, Embase, Scopus, and Web of Science for publications without a time limitation up to the end of May 2025 reporting clinical data on PVA in patients following infections by respiratory viruses, including SARS-CoV-2, influenza, respiratory syncytial virus (RSV), metapneumovirus, parainfluenza, rhinovirus, adenovirus, and cytomegalovirus (CMV). Overall, the reports highlighted PVA occurrence after infections by SARS-CoV-2, influenza, and CMV. Our analyses revealed that PVA is a clinically heterogeneous but frequently deadly infection in patients who are critically ill, immunocompromised patients, or those receiving corticosteroids, following respiratory viral infections. Among critically ill patients, PVA is a clinically important complication of respiratory viral infections, and timely diagnosis and early initiation of appropriate antifungal therapy- considering that Aspergillus is an aerobic fungus requiring specific culture conditions-play a key role in improving patient outcomes.},
}
@article {pmid42225335,
year = {2026},
author = {Chen, M and Wei, S and Sun, J and Zhang, C},
title = {Compassion fatigue and associated factors among palliative care nurses: A systematic review and meta-analysis.},
journal = {Applied nursing research : ANR},
volume = {89},
number = {},
pages = {152070},
doi = {10.1016/j.apnr.2026.152070},
pmid = {42225335},
issn = {1532-8201},
mesh = {Humans ; *Burnout, Professional/psychology ; *Compassion Fatigue/psychology ; Cross-Sectional Studies ; *Hospice and Palliative Care Nursing ; *Palliative Care/psychology ; },
abstract = {BACKGROUND: Palliative care nurses face a high risk of compassion fatigue due to chronic exposure to suffering and death. However, synthesized evidence regarding its prevalence and key determinants remains scarce. This meta-analysis aims to inform targeted support strategies for safeguarding the well-being of nurses and maintaining the quality of care.<br><br>PURPOSE: To systematically quantify the levels of compassion fatigue among palliative care nurses and synthesize the key influencing factors.<br><br>METHODS: We systematically searched 11 electronic databases from their inception to April 2025. Studies were included if they met the following criteria: (1) cross-sectional design; (2) palliative care nurses as participants; (3) assessment of compassion fatigue levels or associated factors; (4) publication in Chinese or English. Random-effects meta-analyses and pre-specified subgroup analyses were conducted in Stata.<br><br>RESULTS: Twelve cross-sectional studies involving 3515 palliative care nurses from high- and middle-income countries were included (no eligible low-income country studies). Pooled analysis showed moderate mean scores of compassion satisfaction (34.64), burnout (25.24), and secondary traumatic stress (26.76). Subgroup analyses indicated that nurses in high-income countries reported significantly better outcomes than their counterparts in middle-income countries. Secondary traumatic stress increased in post-2020 (COVID-19 pandemic) studies. Key influencing factors spanned demographic, work-related, psychological, and social domains, with psychological resilience and strong social support being the most prominent protective factors for nurse well-being.<br><br>CONCLUSIONS: This meta-analysis indicates that palliative care nurses encounter moderate compassion fatigue, and secondary traumatic stress has deteriorated in recent years. Multilevel interventions (which prioritize resilience training, strengthening support systems, and optimizing the work environment) are recommended to alleviate compassion fatigue and protect the well-being of palliative care nurses.},
}
@article {pmid42226636,
year = {2026},
author = {Xiao, Y and Bai, L and Zhan, Z and Fang, L and Liu, R and Fan, W},
title = {The role and mechanism of ZBP1 in the occurrence and development of systemic inflammation.},
journal = {Histology and histopathology},
volume = {},
number = {},
pages = {25102},
doi = {10.14670/HH-25-102},
pmid = {42226636},
issn = {1699-5848},
support = {82270968//National Natural Science Foundation of China/ ; },
abstract = {This review aims to comprehensively summarize the roles and underlying mechanisms of Z-DNA-binding protein 1 (ZBP1) in the onset and progression of systemic inflammation. As a critical initiator of PANoptosis and a sensor of Z-nucleic acids (e.g., viral RNA replication intermediates), ZBP1 has garnered growing attention in recent years for its critical involvement in various inflammatory diseases. By integrating current research progress, this review further explores the functional roles of ZBP1 in distinct inflammatory diseases and its potential value as a novel therapeutic target. Through systematic collation and analysis of recent studies on the regulatory mechanisms of ZBP1 in systemic inflammation, this review covers a broad range of disease areas, including neuroinflammation, diseases of the digestive, musculoskeletal, circulatory, and endocrine systems, as well as autoimmune diseases, sepsis, and bone marrow failure. Comprehensive analysis of these studies further elucidates the common regulatory mechanisms and disease-specific roles of ZBP1 in diverse inflammatory diseases. ZBP1 exerts diverse functions in inflammatory diseases across multiple organ systems. In the nervous system, it exacerbates brain injury and neuroinflammation by activating the RIPK3 (receptor-interacting protein kinase 3)-MLKL (mixed lineage kinase domain-like protein)-dependent necroptosis pathway. In digestive system diseases, it contributes to the pathological processes of periodontal disease and non-alcoholic steatohepatitis by regulating pyroptosis and inflammatory responses. In the musculoskeletal system, it accelerates the progression of osteoarthritis by facilitating chondrocyte damage and inflammation. In the circulatory system, it mitigates inflammatory responses in myocarditis and heart failure by inhibiting the activation of RIPK3 and NF-κB signaling pathways. In the endocrine system, it is implicated in the development of type 2 diabetes by regulating inflammatory responses and insulin resistance. In the respiratory system, it mediates programmed cell death and inflammatory responses by activating pathways such as ZBP1-RIPK3-MLKL, thereby participating in lung injury processes in diseases such as asthma, ARDS, and COVID-19. In the immune system, it aggravates the pathological progression of systemic lupus erythematosus and rheumatoid arthritis by triggering inflammatory cell death and related signaling pathways. ZBP1 exerts a pivotal role in the onset and progression of systemic inflammation by regulating inflammatory responses and tissue damage through multiple cell death and inflammatory signaling pathways. These findings not only offer novel insights into the mechanistic underpinnings of ZBP1 in systemic inflammation but also lay a theoretical basis for developing ZBP1-targeted therapeutic strategies. Future research should further elucidate the disease-specific mechanisms of ZBP1 in distinct inflammatory disorders and assess its therapeutic potential, thereby providing novel directions and strategies for the management of systemic inflammation- associated diseases.},
}
@article {pmid42226661,
year = {2026},
author = {Guo, A and Bell, AG and Myhrvold, C},
title = {Towards deployable CRISPR-based nucleic acid detection.},
journal = {Progress in biomedical engineering (Bristol, England)},
volume = {8},
number = {2},
pages = {},
pmid = {42226661},
issn = {2516-1091},
support = {R01 AI182281/AI/NIAID NIH HHS/United States ; T32 GM148739/GM/NIGMS NIH HHS/United States ; T32 GM007388/GM/NIGMS NIH HHS/United States ; },
mesh = {Humans ; Nucleic Acid Amplification Techniques/methods ; SARS-CoV-2/genetics/isolation &amp; purification ; *COVID-19/diagnosis/virology ; *CRISPR-Cas Systems ; Molecular Diagnostic Techniques/methods ; Point-of-Care Systems ; *COVID-19 Nucleic Acid Testing/methods ; *Clustered Regularly Interspaced Short Palindromic Repeats ; Rapid Diagnostic Tests ; },
abstract = {Deployable diagnostics are necessary for the control and treatment of infectious diseases, with significant unmet needs revealed during the COVID-19 pandemic. Nucleic acid diagnostics remain among the most sensitive and specific forms of detection, yet their reliance on laboratory equipment and trained personnel limits their deployment in resource limited settings. CRISPR-based diagnostics are uniquely positioned to enable rapid, affordable, and highly accurate nucleic acid testing at both the point-of-care and the point-of-need. In this review, we discuss advances toward deployable CRISPR-based diagnostics. We begin by examining innovations in sample processing methods, emphasizing strategies that reduce equipment requirements and enhance compatibility across diverse sample types and pathogens. We then explore developments in one-pot isothermal and amplification-free approaches, comparing the benefits and tradeoffs associated with each, as well as multiplexing strategies for simultaneous detection of multiple pathogens. Finally, we consider additional factors that impact assay deployability, including reagent lyophilization to minimize cold chain dependence and readout technologies that enable detection in resource-limited settings. We conclude by outlining remaining challenges and opportunities for future progress.},
}
@article {pmid42227017,
year = {2026},
author = {Sheerah, HA and Alzaaqi, SM and Arafa, A and Banjar, WM and Liu, K and Withers, M and El-Jardali, F and Penttinen, P and Al-Jedai, AH and Selbie, D},
title = {Evolution of the Healthcare System in Saudi Arabia Over the Last Century: A Historical and Policy Analysis.},
journal = {Journal of healthcare leadership},
volume = {18},
number = {},
pages = {598238},
pmid = {42227017},
issn = {1179-3201},
abstract = {This article presents a narrative historical review of the development of the Saudi healthcare system from the establishment of the Public Health Directorate in 1925 to the ongoing reforms under Vision 2030. Saudi Arabia's healthcare journey has included major milestones, including the founding of the Ministry of Health in 1951, national immunization programs, the expansion of hospital infrastructure, and the introduction of primary healthcare services. Each era of national development contributed to shaping a system that today serves a rapidly growing and diverse population. Major reforms under the reigns of King Khalid, King Fahd, and King Abdullah significantly improved healthcare access, quality, and health outcomes. These reforms were supported by evolving governance mechanisms, including centralized administration through the Ministry of Health, national development planning, expanded public financing, and regulatory frameworks guiding healthcare delivery. In the contemporary period, under Vision 2030, healthcare transformation has accelerated through initiatives emphasizing public-private partnerships and sustainable financing. Digital health has expanded through national electronic health records, telemedicine platforms, integrated health information systems, and emerging artificial intelligence applications. The healthcare system has also demonstrated resilience in responding to challenges such as the MERS-CoV and COVID-19 pandemics, as well as the health demands of the Hajj pilgrimage. Despite substantial progress, challenges remain, including regional disparities, rising non-communicable diseases, and workforce sustainability. The Saudi experience offers important policy and leadership lessons for countries pursuing large-scale health system reform.},
}
@article {pmid42228279,
year = {2026},
author = {Terra, C and Terrier, O and Le Gouellec, A},
title = {Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts.},
journal = {Metabolomics : Official journal of the Metabolomic Society},
volume = {22},
number = {3},
pages = {},
pmid = {42228279},
issn = {1573-3890},
support = {IDIVIA-MET//Fondation Air Liquide/ ; IDIVIA-MET//Fondation Air Liquide/ ; AO#15-11//Fondation Innovations en Infectiologie/ ; },
mesh = {Humans ; *SARS-CoV-2 ; *Influenza, Human/metabolism/virology ; *COVID-19/metabolism/virology ; *Host-Pathogen Interactions ; *Orthomyxoviridae/physiology/metabolism ; Virus Replication ; Citric Acid Cycle ; Metabolic Reprogramming ; },
abstract = {BACKGROUND: SARS-CoV-2 and Influenza virus are two major respiratory viruses, responsible for the COVID-19 and the flu respectively. To achieve their replication, these viruses do not merely hijack host cells; they reprogram them, and the host's metabolism is no exception.<br><br>AIM OF THE REVIEW: This review explores how two major respiratory pathogens, SARS-CoV-2 and influenza virus, manipulate host metabolism to fuel their replication and drive disease.<br><br>Despite differences in their genome organization and replication strategies, both viruses disrupt central metabolic pathways, including glucose processing, the Krebs cycle, amino acid and nucleotide synthesis. Common effects include enhanced anaerobic glycolysis, depletion of key amino acids, activation of the kynurenine pathway, and disruption of purine signaling. However, each virus leaves a distinct metabolic fingerprint. SARS-CoV-2 infection leads to glucose accumulation, alters late-stage Krebs cycle metabolites, and significantly disrupts nucleotide production. In contrast, influenza viral infection depletes glucose and dampens Krebs cycle activity, with a less consistent impact on nucleotide pathways. Viral proteins, such as SARS-CoV-2 ORF3a and influenza virus NS1, play a crucial role in these metabolic shifts. These changes not only reflect viral strategies but also correlate with disease severity. As metabolomics technologies advance, understanding these virus-specific and shared metabolic changes could unlock new diagnostic tools, prognostic markers, and treatment strategies.},
}
@article {pmid42229123,
year = {2026},
author = {Al-Rifai, RH and Taher, S and Amoodi, H and Alshamma, D and Rasheed, L and Alhammadi, W and Alhosani, S and Meslamani, AA},
title = {Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) research in the Gulf Cooperation Council Countries: A mapping scoping review of epidemiology, clade, and research priority gaps.},
journal = {Journal of infection and public health},
volume = {19},
number = {7},
pages = {103272},
doi = {10.1016/j.jiph.2026.103272},
pmid = {42229123},
issn = {1876-035X},
mesh = {Humans ; *Middle East Respiratory Syndrome Coronavirus/genetics/classification ; *Coronavirus Infections/epidemiology/virology ; Animals ; Evidence Gaps ; Middle East/epidemiology ; Saudi Arabia/epidemiology ; },
abstract = {Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to pose a substantial public health challenge within Gulf Cooperation Council (GCC) countries. This scoping review systematically examines geographic distribution, methodological characteristics, and thematic priorities of published research, while identifying critical evidence gaps. A total of 171 peer-reviewed studies on human MERS-CoV were included, with a marked predominance from Saudi Arabia (88.3%). Research output peaked in 2016 and 2019, followed by a decline coinciding with the COVID-19 pandemic. Cross-sectional designs were most common (43.3%), with widespread reliance on non-probability sampling (95.3%). Epidemiology and surveillance constituted the primary research focus (∼24%), with case fatality rate being the most frequently reported metric (43.9%). Limited genomic investigations were identified, with Clade B representing 71.4% of characterized strains. Overall, the evidence base reflects geographic concentration, methodological heterogeneity, and thematic limitations, underscoring the need for expanded research scope and enhanced regional collaboration.},
}
@article {pmid42229246,
year = {2026},
author = {Kontogiannis, G and Tzamalis, P and Giannikopoulos, A and Nikoletseas, S},
title = {On-device cough detection and respiratory disease classification enhanced by generative data augmentation.},
journal = {Computers in biology and medicine},
volume = {213},
number = {},
pages = {111784},
doi = {10.1016/j.compbiomed.2026.111784},
pmid = {42229246},
issn = {1879-0534},
mesh = {*Cough/diagnosis/classification/physiopathology ; Humans ; Autoencoder ; Generative Artificial Intelligence ; *Smartphone ; Support Vector Machine ; *Signal Processing, Computer-Assisted ; },
abstract = {BACKGROUND: Cough sounds are accessible, non-invasive biomarkers for respiratory disease assessment and can be captured using consumer-grade smartphones. Existing approaches typically focus solely on cough detection or rely on server-based deep learning for disease classification, which limits deployability and raises privacy concerns. Small, imbalanced cough datasets further hinder model generalization.<br><br>OBJECTIVE: To develop a multilayer, smartphone-compatible AI framework for automated cough detection and respiratory disease classification, and to propose a pioneering generative augmentation strategy utilizing a suite of five Variational Autoencoder (VAE) variants and a probabilistic cough-level fusion mechanism to improve disease classification under severe data scarcity and the limitations of conventional audio augmentation techniques.<br><br>METHODS: The proposed framework consists of three AI modules: (1) A Cough Detection Module (CDM) that performs real-time cough event detection and segmentation from continuous audio using lightweight models optimized for on-device execution. (2) A Disease Analysis Module (DAM) that classifies cough events into asthma, COVID-19, or healthy classes using parallel Support Vector Machine classifiers and a probabilistic cough-level fusion strategy. (3) A Generative Augmentation Module (GAM) employing five distinct VAE architectures. This module uniquely operates across the time-frequency domain for latent feature optimization while reconstructing samples in the time-domain to ensure acoustic verifiability.<br><br>RESULTS: The CDM provides reliable segmentation across heterogeneous recording conditions. The DAM achieves strong discriminability between asthma, COVID-19, and healthy coughs using compact cepstral and spectral features. The multi-variant GAM framework demonstrates superior efficacy in alleviating class imbalance specifically, the cross-domain (time-frequency to time-domain) reconstruction allows for the clinical verification of synthetic biomarkers. All system components operate in real time on commodity Android hardware.<br><br>CONCLUSION: This integrated framework addresses key limitations in dataset availability, model generalizability, and deployability, introducing an interpretable generative approach that demonstrates the feasibility of smartphone-based acoustic sensing as a scalable and privacy-preserving tool for respiratory health monitoring.},
}
@article {pmid42231138,
year = {2026},
author = {Raps, SJ and Phillips, AK and McGinnis, LJ and Heyne, RE and Tilbury, ME and Patrician, PA},
title = {Patient Outcomes Associated With Continuous Remote Patient Monitoring: A Scoping Review.},
journal = {Worldviews on evidence-based nursing},
volume = {23},
number = {3},
pages = {e70134},
doi = {10.1111/wvn.70134},
pmid = {42231138},
issn = {1741-6787},
mesh = {Humans ; *Remote Patient Monitoring ; COVID-19/nursing ; Pandemics ; Digital Health ; Telemedicine ; },
abstract = {BACKGROUND: The COVID-19 pandemic highlighted the need for alternative healthcare delivery models, leading to the development of Continuous Remote Patient Monitoring (CRPM). CRPM allows for real-time monitoring of high-risk patients, reducing the burden on hospital resources. The integration of virtual nursing into CRPM has enhanced remote care capabilities, though it has also introduced new challenges related to patient safety and staffing, that is, nurse-to-patient ratios.<br><br>OBJECTIVE: This scoping review aims to explore the current evidence on virtual nursing using CRPM and identify challenges or barriers that help further future research and healthcare practices.<br><br>METHODS: This scoping review followed the PRISMA-ScR guidelines. Eligible studies focused on virtual nursing with physiological monitoring in either remote hospital or home-based care settings, with explicit examination of nursing care and its impact on patient and nursing outcomes. Peer-reviewed articles published in the past 10&#x2009;years in English were included. Four databases (Ovid, PubMed, CINAHL, and Medline) were searched with support from a medical librarian. After screening 207 records using Covidence, 17 studies met the inclusion criteria. Two reviewers independently screened all records, with a third resolving discrepancies. Data was charted using a standardized extraction template.<br><br>RESULTS: Seventeen studies were included in this review. CRPM was associated with reported benefits in managing chronic conditions, extending acute care into home settings, and enhancing healthcare system adaptability, particularly during the COVID-19 pandemic. Clinical benefits included early detection of health deterioration, reduced hospital readmissions, and improved patient satisfaction. Nurses played a pivotal role in physiologic data interpretation and intervention, highlighting the importance of continuous oversight in achieving favorable outcomes. However, implementation challenges, such as alert fatigue, data overload, user interface complexity, and financial sustainability were consistently reported. These findings underscore the need for improved data management systems, targeted nurse training, and sustainable funding models to support broader CRPM adoption.<br><br>LINKING EVIDENCE TO ACTION: Virtual nursing within CRPM demonstrates strong potential to improve patient outcomes and reduce hospitalizations by extending inpatient-level physiologic surveillance into home-based and hospital-at-home settings through continuous, nurse-led monitoring. Successful integration of this model into routine practice will require addressing challenges related to data management, clinician workload associated with 24/7 surveillance, and sustainable funding mechanisms to support continuous virtual nursing coverage.},
}
@article {pmid42231687,
year = {2026},
author = {Verma, A},
title = {Common and Rare Emerging and Re-Emerging Infectious Diseases in Pediatric Transplant Recipients: A Comprehensive Review.},
journal = {Pediatric transplantation},
volume = {30},
number = {6},
pages = {e70365},
doi = {10.1111/petr.70365},
pmid = {42231687},
issn = {1399-3046},
mesh = {Humans ; *Communicable Diseases, Emerging/epidemiology/diagnosis ; Child ; *Organ Transplantation ; Immunocompromised Host ; *Postoperative Complications/epidemiology ; *Transplant Recipients ; },
abstract = {The established pathogens, including cytomegalovirus, Epstein-Barr virus, and bacterial bloodstream infections, remain leading causes of morbidity and mortality in pediatric transplant recipients (PTR). However, over the past two decades, the landscape of infectious diseases in this population has evolved substantially, marked by an increasing burden of emerging and re-emerging pathogens. The global rise in multidrug-resistant bacteria and fungi has complicated antimicrobial management and limited therapeutic options. Concurrently, novel and re-emerging viral threats, most notably severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and other opportunistic viruses have been associated with severe disease, graft dysfunction, and prolonged hospitalization in immunocompromised children. Declining vaccination coverage has further contributed to the resurgence of vaccine-preventable infections such as measles and pertussis, which often present a more aggressive clinical course in PTR. Rare but consequential emerging pathogens, including arboviruses, hepatitis E virus, polyomaviruses, lymphocytic choriomeningitis virus, Enterovirus D68, Mpox (monkeypox virus), avian influenza A(H5N1), and emerging fungi, pose additional risks through both donor-derived transmission and community exposure, particularly in endemic and resource-limited settings. Broader global factors, including climate change, increased travel, and population displacement, have expanded pathogen distribution and exposure risk. Simultaneously, advances in molecular and syndromic diagnostics have improved pathogen detection, identifying infections previously under-recognized in transplant populations. These evolving epidemiological trends highlight the importance of ongoing surveillance, improved vaccination strategies, antimicrobial stewardship, and individualized prevention and treatment approaches. This comprehensive review synthesizes current evidence on most encountered and rare emerging and re-emerging bacterial, viral, and fungal infectious diseases affecting PTR.},
}
@article {pmid42231938,
year = {2026},
author = {Okwei, ANN},
title = {Artificial intelligence and digital health equity: a post-pandemic evidence synthesis and implementation safeguards framework.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1785700},
pmid = {42231938},
issn = {2673-253X},
abstract = {INTRODUCTION: The rapid expansion of AI-enabled digital health after COVID-19 created new possibilities for extending care while raising concerns about unequal access, subgroup underperformance, and weak accountability. These effects remain difficult to interpret because telehealth infrastructure, predictive analytics, clinical decision support, and generative AI operate through different equity mechanisms.<br><br>METHODS: A transparent narrative evidence synthesis was conducted using peer-reviewed literature and selected governance documents. Structured searches of PubMed, Scopus, Web of Science, and IEEE Xplore were refreshed on March 5, 2026, for English-language sources published between January 1, 2020, and December 31, 2025. A second reviewer independently assessed a sample of 12 full-text inclusion and exclusion decisions using the same pre-specified criteria, with 100% agreement. The final corpus included 29 sources.<br><br>RESULTS: Evidence was strongest for digital access barriers, subgroup underperformance, and implementation-related governance concerns. AI-assisted screening and digitally mediated remote support showed conditional benefits in targeted settings when high-touch support was built into implementation. Evidence on generative AI and language-support tools was comparatively smaller, newer, and concentrated in representational-bias applications, with limited evidence of sustained downstream equity gains.<br><br>CONCLUSION: AI-enabled digital health may reduce selected barriers to care when supported by equitable access conditions, subgroup validation, accountable governance, and implementation oversight. Equity gains were conditional rather than automatic, and evidentiary depth varied substantially across modalities. The review distills recurring patterns into a synthesis-derived operational roadmap for procurement, validation, implementation, and post-deployment monitoring.},
}
@article {pmid42232574,
year = {2026},
author = {Pan, C and Wang, S and Yang, Y and Hu, J and Pan, Y},
title = {Curcumin-piperine supplementation modulates inflammation, oxidative stress, and cardiometabolic risk: a systematic review of randomized controlled trials.},
journal = {Frontiers in nutrition},
volume = {13},
number = {},
pages = {1814168},
pmid = {42232574},
issn = {2296-861X},
abstract = {BACKGROUND: Although curcumin has well-established anti-inflammatory and antioxidant qualities, its low bioavailability limits its therapeutic applicability. Piperine improves systemic exposure and absorption of curcumin. This systematic study aimed to examine the effectiveness and safety of curcumin-piperine supplementation in relation to inflammatory, metabolic, cardiovascular, autoimmune, infectious, and pulmonary disorders.<br><br>METHODS: From 2026, a comprehensive search of randomised controlled trials (RCTs) was conducted across the main electronic databases. Studies that assessed oral curcumin in combination with piperine and reported results related to oxidative stress, inflammation, metabolism, cardiovascular disease, or clinical symptoms were considered eligible. Using accepted methodological standards, the risk of bias was evaluated.<br><br>RESULTS: There were 20 RCTs with sample sizes ranging from 8 to 117 individuals and durations ranging from 1 to 12&#x202f;weeks. Doses of piperine (5-15&#x202f;mg/day) and curcumin (500-1,500&#x202f;mg/day) varied. Fifteen out of twenty trials indicated significant decreases in inflammatory biomarkers [C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), and interleukin-6 (IL-6)]. Of 15 studies evaluating these outcomes, 12 showed improvements in oxidative stress markers, including superoxide dismutase (SOD), total antioxidant capacity (TAC), and malondialdehyde (MDA). Supplementation dramatically decreased fasting blood glucose (FBS), glycated haemoglobin (HbA1C), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) in individuals with metabolic syndrome (MetS) and type 2 diabetes. At the same time, 14 out of 18 trials showed reductions in lipid markers (triglycerides (TG), LDL-C, total cholesterol, and HDL-C). After coronary artery bypass grafting and acute myocardial infarction (AMI), cardiovascular populations showed decreases in cardiac damage biomarkers (CK-MB, AST, and ALT). COVID-19, premenstrual syndrome (PMS), dysmenorrhea, and chronic pulmonary illness all showed symptom-based improvements. No significant adverse effects were noted. None of the trials was high risk; 13 had low risk of bias, and 6 had moderate issues.<br><br>CONCLUSION: In a variety of clinical populations, curcumin-piperine supplementation consistently demonstrates anti-inflammatory, antioxidant, metabolic, and cardioprotective effects, with a good safety profile. Its utility as an adjuvant in metabolic and cardiometabolic illnesses is most strongly supported by evidence. To verify clinical efficacy and improve dosing techniques, larger, longer-term RCTs with standardized objectives are necessary.},
}
@article {pmid42233731,
year = {2026},
author = {Shaver, N and Dahroug, L and Vyas, N and McGuire, M and Tahsin, A and Adedunye, D and Gauthier, S and Sterling, E and Collins, E and Hughes, SE and Rafferty, AM and Rafferty, E and Groot, G and Laframboise, W and Mann, C and Bhereur, A and Edwards, J and McQuillan, R and Theodoratou, E and Edjoc, R and Little, J},
title = {Barriers and facilitators for return-to-work following post-COVID-19 condition: A scoping review.},
journal = {Work (Reading, Mass.)},
volume = {},
number = {},
pages = {10519815261454982},
doi = {10.1177/10519815261454982},
pmid = {42233731},
issn = {1875-9270},
abstract = {BackgroundSupporting workers with post-COVID condition in returning to work is critical. Qualitative evidence may provide insight into the complex factors shaping this process and inform intervention and policy development.ObjectiveTo identify and synthesize qualitative evidence on barriers and facilitators influencing return to work following post-COVID condition.MethodsWe conducted a scoping review using the Arksey and O'Malley framework, refined by Levac et al. MEDLINE, EMBASE, CINAHL, and Scopus were searched from inception to July 2025. Eligible qualitative and mixed-methods studies examined barriers and facilitators to returning to work among working-age adults with post-COVID condition or healthcare professionals involved in their care. Data were synthesized using critical interpretive synthesis, informed by the International Classification of Functioning, Disability and Health framework.ResultsTwenty-nine qualitative or mixed-methods studies (n=1902 participants) were included. Barriers and facilitators operated across domains within broader organizational and systemic contexts. Fluctuating, unpredictable symptoms were major barriers, while gradual rehabilitation and energy management facilitated return to work. Mismatches between work capacity and job demands limited work participation. Environmental barriers included stigma, inflexible policies, limited accommodations, and financial or compensation pressures, while facilitators included flexible work arrangements, supportive leadership, and collaborative planning. Guilt and fear of underperformance were personal barriers, while acceptance and motivation facilitated return to work. Specialists identified fragmented services and limitations of current care models as systemic concerns.ConclusionsPost-COVID condition necessitates flexible, multidisciplinary return-to-work models that accommodate symptom variability and address psychosocial needs. Improved coordination across healthcare, workplace, and social systems is essential for sustainable workforce participation.RegistrationThe review protocol was publicly registered on the Open Science Framework prior to screening and was approved by all team members (https://osf.io/nrbu5/).},
}
@article {pmid42233803,
year = {2026},
author = {Ferreira, APR and Silva, ENXD and Molina, MDCB and Assis, SG},
title = {Childhood obesity and food insecurity: scoping review - 2020 to 2023.},
journal = {Ciencia &amp; saude coletiva},
volume = {31},
number = {4},
pages = {e22732024},
doi = {10.1590/1413-81232026314.22732024},
pmid = {42233803},
issn = {1678-4561},
mesh = {Humans ; *Food Insecurity ; *Pediatric Obesity/epidemiology ; *COVID-19/epidemiology ; Child ; Socioeconomic Factors ; Socioeconomic Disparities in Health ; Pandemics ; Food Supply ; Cross-Sectional Studies ; },
abstract = {This study conducted a scoping review to examine the relationship between food insecurity and childhood obesity, analyzing 47 articles with empirical data published between 2020 and 2023. The studies were categorized by income level of the countries of origin and included cross-sectional surveys, cohorts, and ecological approaches. Most of the research focused on low- and middle-income countries, where food insecurity is more prevalent, but articles from high-income countries were also analyzed. The principal factors evaluated were the household's socioeconomic status, the children's age group and gender, and the COVID-19 pandemic's impact. The results point to a significant association between food insecurity and childhood obesity, especially in low-income households and in regions with insufficient policies on both issues. The COVID-19 pandemic has deteriorated inequalities, reducing access to healthy foods and increasing childhood obesity rates. Thus, the two problems are interconnected and multifactorial and require interventions tailored to local contexts. An integrated and contextualized approach is essential to promote child health.},
}
@article {pmid42235797,
year = {2026},
author = {Manzoor, S},
title = {Pan-pathogen vaccine approaches: Toward broad-spectrum immunity in a One Health era.},
journal = {Journal of microbiological methods},
volume = {247},
number = {},
pages = {107563},
doi = {10.1016/j.mimet.2026.107563},
pmid = {42235797},
issn = {1872-8359},
mesh = {Humans ; Animals ; *Vaccine Development/methods ; Vaccinology/methods ; *Communicable Diseases, Emerging/prevention &amp; control/immunology ; *Viral Vaccines/immunology ; *Vaccines/immunology ; Global Health ; SARS-CoV-2/immunology ; Immunoinformatics ; Pandemic Preparedness ; Epitopes/immunology ; COVID-19/prevention &amp; control ; },
abstract = {Emerging and re-emerging infectious diseases (EIDs) represent an escalating threat to global public health, as exemplified by outbreaks of COVID-19, Ebola, Zika, and other zoonotic viruses. Traditional pathogen-specific vaccines, although effective for individual diseases, face significant limitations in addressing EIDs due to long development timelines, resource intensity, and restricted adaptability to novel pathogens or variants. Pan-pathogen vaccines-designed to provide broad-spectrum immunity across multiple related or unrelated pathogens-offer a transformative approach to pandemic preparedness. This review presents a comprehensive overview of pan-pathogen vaccinology within the One Health framework, emphasizing the integration of human, animal, and environmental health for proactive disease prevention. We provide explicit definitions for "universal", "broad-spectrum", and "pan-pathogen" vaccines and embed the One Health principle into the full vaccine development lifecycle through real-world case studies, including Nipah virus and rVSV-Ebola. The review highlights strategies for epitope discovery using comparative genomics, evolutionary biology, and immunoinformatics to identify conserved antigenic regions, and details mechanisms of cross-protective immunity mediated by T cells, broadly neutralizing antibodies, mucosal responses, and trained innate immunity with emphasis on their interplay. Advanced vaccine platforms-mRNA, viral vectors, protein subunits, and nanoparticle-based systems-are evaluated for their capacity to deliver multivalent, chimeric, and mosaic antigens. Preclinical and clinical advances against influenza, coronaviruses, flaviviruses, filoviruses, and critically, bacterial, fungal, parasitic, and DNA virus targets are summarized. Ethical, regulatory, and global health considerations for equitable vaccine distribution are discussed, with expanded safety analysis addressing pan-pathogen-specific hazards such as antigenic competition, autoimmunity, and regulatory adaptation. Persistent gaps, including antigenic variability, immune imprinting, safety concerns, and challenges in clinical validation, are identified, alongside controversies surrounding the balance between broad coverage and potential immune escape. Integrating genomic surveillance, predictive modeling, and emerging technologies such as artificial intelligence, systems biology, and synthetic vaccinology is essential to optimize vaccine design and accelerate translational implementation. Collectively, pan-pathogen vaccines represent a proactive, adaptive, and globally coordinated strategy to mitigate future pandemics and strengthen long-term health security.},
}
@article {pmid42238204,
year = {2026},
author = {Mahallawi, WH},
title = {Artificial Intelligence in Dialysis Therapies: Applications in Hemodialysis and Peritoneal Dialysis for Managing Infectious Diseases and Complications.},
journal = {Saudi medical journal},
volume = {47},
number = {6},
pages = {998-1007},
pmid = {42238204},
issn = {1658-3175},
mesh = {Humans ; *Artificial Intelligence ; Peritoneal Dialysis/methods ; *Renal Dialysis/methods ; Sepsis/mortality ; },
abstract = {This narrative review synthesizes evidence from a systematic literature search (2019-2025) on artificial intelligence (AI) applications in hemodialysis and peritoneal dialysis for managing infections and complications. Dialysis patients face infection rates 100-fold higher than the general population and sepsis mortality exceeding 35%. The AI, utilizing machine learning algorithms such as XGBoost, deep neural networks, and explainable AI tools, revolutionizes care through precise diagnostics, prognostics, and therapeutics. Key models demonstrate high accuracy in predicting bloodstream infections (area under the curve [AUC] 0.914), classifying peritonitis (F1 0.93), detecting SARS-CoV-2 (AUROC 0.82), and forecasting mortality (AUC 0.979). Therapeutically, AI guides antibiotic stewardship, reducing inappropriate use by 18-67%, and mitigates intradialytic hypotension via ultrafiltration adjustments, reducing incidence by 25-40%. Despite promising results, challenges include data scarcity, algorithmic bias, and the integration of these tools into clinical workflows. Future directions involve diverse datasets, explainable AI, and real-time decision support systems. The AI holds transformative potential for personalizing dialysis management and improving patient outcomes.},
}
@article {pmid42238848,
year = {2026},
author = {Yaghobi, M and Jalilian, M},
title = {The potential role of indomethacin in COVID-19 management: A systematic review of therapeutic and mechanistic evidence.},
journal = {New microbes and new infections},
volume = {72},
number = {},
pages = {101771},
pmid = {42238848},
issn = {2052-2975},
abstract = {BACKGROUND: Indomethacin has been proposed as a repurposed agent for COVID-19 due to its anti-inflammatory and potential antiviral effects against coronaviruses. However, the available evidence is limited, heterogeneous, and largely indirect, with a large observational NSAID study dominating the sample size without evaluating indomethacin-specific efficacy.<br><br>METHODS: We conducted a PRISMA 2020-compliant systematic review registered in PROSPERO (CRD420251272994). Major databases and trial registries were searched from January 2019 to July 2025 using reproducible strategies. Eligible studies included randomized trials, observational studies, case series, and experimental investigations. Clinical and mechanistic evidence were synthesized separately, and risk of bias was assessed using RoB 2 and ROBINS-I tools.<br><br>RESULTS: Eight studies were included: two randomized trials, three observational studies, one case series, one in vitro study, and one pharmacokinetic/pharmacodynamic modeling study. The largest dataset (n&#x202f;=&#x202f;536,423) provided indirect safety data only. Small clinical studies suggested faster symptom resolution and shorter hospitalization in mild-to-moderate cases, but findings were inconsistent and at risk of bias. Experimental studies supported antiviral mechanisms, including inhibition of viral RNA synthesis and host translation pathways. No study evaluated prophylactic use.<br><br>CONCLUSION: Evidence for indomethacin in COVID-19 remains limited and low certainty. Safety conclusions should be cautious given incomplete reporting and known NSAID risks. Larger, well-designed randomized trials are required.},
}
@article {pmid42239536,
year = {2026},
author = {Singh, P and Saravanan, A and Seitz, J and Alkarzon, N and Medugu, N},
title = {A one health perspective on the intestinal microbiome's role in COVID-19 outcomes and recovery.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1763844},
pmid = {42239536},
issn = {2235-2988},
mesh = {Humans ; *COVID-19/microbiology/therapy ; Dysbiosis/microbiology ; *Gastrointestinal Microbiome/physiology ; SARS-CoV-2 ; Animals ; Fecal Microbiota Transplantation ; Probiotics/therapeutic use ; Prebiotics ; Pandemics ; },
abstract = {Emerging infectious diseases, particularly zoonotic ones, remain major global health concerns. The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), highlights the interconnectedness of human, animal, and environmental health within the One Health framework. The intestinal microbiome plays a central role in host immunity and systemic homeostasis, and its disruption has been linked to altered disease severity and recovery patterns in COVID-19. Evidence suggests that SARS-CoV-2 infection induces intestinal dysbiosis, modifies immune signaling, and affects the microbiota-gut-brain axis (MGBA), contributing to neuropsychiatric and metabolic complications. This review synthesizes current findings on the intestinal microbiome's role in COVID-19 pathophysiology and recovery, explores emerging therapeutic strategies including probiotics, prebiotics, and fecal microbiota transplantation, and emphasizes the importance of integrating microbiome research into pandemic preparedness through a One Health approach.},
}
@article {pmid42239667,
year = {2026},
author = {Trejo-Castro, AI and Marín-Obispo, LM and Carrion-Alvarez, D and Mora-Godínez, S and Martinez-Torteya, A and Hernández-Brenes, C and Martinez-Ledesma, E},
title = {A bibliometric and text-mining analysis of lipidomics and metabolomics in human disease.},
journal = {Frontiers in physiology},
volume = {17},
number = {},
pages = {1727465},
pmid = {42239667},
issn = {1664-042X},
abstract = {INTRODUCTION: Lipidomics and metabolomics have become key approaches for understanding and diagnosing human diseases, including type 2 diabetes, Alzheimer's disease, cancer, and kidney dysfunction. This study provides a comprehensive overview of the evolution of these disciplines through a bibliometric and text-mining analysis of scientific production from 2004 to 2024, based on data from Scopus and validated through a multi-database comparative approach.<br><br>METHODS: A total of 9,628 articles were harmonized and analyzed using Bibliometrix, Scimago Graphica, OpenRefine, and custom R scripts to identify the most productive journals, authors, countries, and institutions, and to map thematic structures and keyword dynamics. Beyond traditional bibliometric indicators, our integrative approach combined quantitative trends with semantic and conceptual mapping to trace the methodological and translational evolution of the field. To ensure robustness and generalizability, equivalent searches were conducted in the Web of Science Core Collection and PubMed, and cross-database validation assessed concordance in journal and country rankings, as well as temporal and thematic trends.<br><br>RESULTS: The field shows rapid expansion, with an annual growth rate of 32.6%. The United States and China lead global output, followed by major European contributors. Core topics include Alzheimer's disease, obesity, and breast cancer, while emerging areas focus on artificial intelligence, multi-omics integration, and Mendelian randomization. Analytical methodologies such as liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, and nuclear magnetic resonance, together with metabolic diseases, remain central to the field. In contrast, niche themes such as microbiota-COVID-19 interactions and oxidative stress-cancer associations represent emerging interdisciplinary bridges.<br><br>DISCUSSION: Overall, lipidomics and metabolomics are evolving toward integrative and computational frameworks with strong diagnostic potential, underscoring the need for validated biomarkers, standardized data pipelines, and open repositories to enable clinical translation.},
}
@article {pmid42240857,
year = {2026},
author = {Desai, M and Malik, S and Singh, A and Kukreti, R and Kukreti, S and Grewal, GK},
title = {Targeting oxidative stress pathways in epilepsy: mechanistic insights into the role of ascorbic acid.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {42240857},
issn = {1573-4978},
support = {TAR/2022/000636//Department of Science and Technology, Ministry of Science and Technology, India/ ; },
mesh = {*Ascorbic Acid/pharmacology/therapeutic use/metabolism ; Humans ; *Epilepsy/drug therapy/metabolism ; *Oxidative Stress/drug effects ; Animals ; Antioxidants/pharmacology/therapeutic use ; Signal Transduction/drug effects ; Anticonvulsants/pharmacology/therapeutic use ; Reactive Oxygen Species/metabolism ; NF-E2-Related Factor 2/metabolism ; NF-kappa B/metabolism ; },
abstract = {Epilepsy, a neurological disease, is linked to oxidative stress generated due to the synchronous firing of neurons during seizures and use of antiseizure medications (ASMs). Among commonly prescribed ASMs, carbamazepine, valproate, and levetiracetam have been implicated in modulating oxidative stress-related signaling pathways, including Nrf2, NF-κB, and MAPK. Ascorbic acid, a potent antioxidant capable of crossing the blood-brain barrier, has emerged as a promising therapeutic candidate. This review examines the molecular mechanisms underlying ASM-associated oxidative stress in clinical, non-kindled/kindled preclinical, as well as non-epilepsy models, and highlights evidence demonstrating the ability of ascorbic acid to attenuate ROS accumulation, enhance endogenous antioxidant defenses, and modulate redox-sensitive signaling pathways implicated in epileptogenesis and ASM-induced toxicity. Collectively, the available evidence suggests that ascorbic acid has the potential to confer neuroprotection and reduce oxidative injury in epilepsy. Insights presented in this review aim to initiate research focusing on ascorbic acid as an adjuvant in epilepsy. Further studies are warranted to clarify its interactions with ASM metabolism, to optimize dosing strategies, and to establish its translational potential as an adjuvant therapy in clinical epilepsy management.},
}
@article {pmid42241918,
year = {2026},
author = {Sierra, NM and Hernández Rincón, EH and Bejarano, VN and Ghotme, KA},
title = {Unlocking global neurosurgery: how telemedicine addresses unmet needs and future prospects - a scoping review.},
journal = {Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia},
volume = {152},
number = {},
pages = {112121},
doi = {10.1016/j.jocn.2026.112121},
pmid = {42241918},
issn = {1532-2653},
mesh = {Humans ; *Telemedicine/trends ; *COVID-19 ; *Neurosurgery/trends/methods ; *Neurosurgical Procedures/trends/methods ; Pandemics ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: Telemedicine, as defined by the WHO, utilizes information and communication technologies for disease diagnosis, treatment, and prevention, enabling remote healthcare delivery. While its adoption accelerated during the COVID-19 pandemic, its role in global neurosurgery remains underexplored and presents unique challenges.<br><br>OBJECTIVE: This scoping review examines the implementation of telemedicine in neurosurgery and its subspecialties across different global contexts-before, during, and after the COVID-19 pandemic.<br><br>METHODS: We scoped the scientific literature published in English, Spanish, and Portuguese from 2014 to 2024. We analyzed primary and secondary studies, excluding gray literature. Initial searches yielded 3,622 articles, with 67 studies meeting the eligibility criteria for final review.<br><br>RESULTS: Telemedicine has been implemented in various neurosurgical subspecialties, including general neurosurgery, perioperative assessment, traumatic brain injury, stroke, neurosurgical oncology, spine surgery, neurocritical care, functional neurosurgery, and pediatric neurosurgery. Reported outcomes encompass patient and neurosurgeon satisfaction and perceptions regarding telemedicine's role during and beyond the COVID-19 pandemic.<br><br>CONCLUSIONS: Telemedicine holds promise in addressing unmet needs in global neurosurgical care, offering benefits such as enhanced clinical effectiveness, patient satisfaction, cost-effectiveness, and reduced hospital readmissions. It extends access to specialized care, improving the overall quality of life and proving indispensable in contemporary neurosurgery, especially within a global context. Continued research and optimization of telemedicine implementation are essential for ensuring safe and effective healthcare delivery, particularly within the global neurosurgical landscape.},
}
@article {pmid42243031,
year = {2026},
author = {Savvidou, P and Iosifidis, E and Roilides, E and Gika, H and Antachopoulos, C},
title = {Viral respiratory infections in children and metabolomics: a review of literature.},
journal = {Paediatric respiratory reviews},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.prrv.2026.05.007},
pmid = {42243031},
issn = {1526-0550},
abstract = {Acute respiratory infections (ARIs) are the most common infectious diseases during childhood, responsible for significant morbidity and mortality in the pediatric population worldwide. Metabolomics, the global analysis of small metabolites, is a novel tool that offers insights into diagnostics and prognostics of viral respiratory infections. This review summarizes the existing literature on metabolomic studies in viral acute respiratory infections (ARIs) within the pediatric population. Metabolomic research on patients with bronchiolitis has addressed several clinical questions, such as discrimination by causative agent, i.e. respiratory syncytial virus or rhinovirus, and most importantly prognosis, predicting disease severity and long-term outcomes. In pneumonia, studies have focused on discriminating viral from bacterial etiology and from healthy controls but also predicting disease severity. There is a growing number of studies on metabolomics in ARIs providing a strong foundation for addressing remaining challenges and allowing for more comparable results and greater impact on clinical practice.},
}
@article {pmid42243943,
year = {2026},
author = {Kayda, I and Lechiile, K and Kinshella, MW and Bone, JN and Lavoie, PM and Goldfarb, DM},
title = {Sensitivity of gargle samples compared to swabs for SARS-CoV-2 detection with nucleic acid amplification testing: a systematic review and meta-analysis.},
journal = {Virology journal},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12985-026-03206-1},
pmid = {42243943},
issn = {1743-422X},
abstract = {BACKGROUND: Gargle sampling emerged as a novel method for diagnostic testing during the coronavirus disease 2019 (COVID-19) pandemic, yet uncertainty remained about its performance when compared with conventional sampling methods.<br><br>OBJECTIVE: To evaluate the performance of self-collected gargle samples compared to traditional healthcare worker (HCW)-collected upper respiratory tract swabs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection with nucleic acid amplification testing (NAAT).<br><br>METHODS: We conducted a systematic review (PROSPERO registration: CRD42022312628) to (1) estimate sensitivity of gargle sampling, (2) estimate the difference in sensitivity between gargle and swab methods, and (3) understand how various testing contexts may impact gargle sensitivity. MEDLINE, EMBASE, Web of Science, Global Index Medicus, and preprint servers were searched. Studies reporting primary data and investigating COVID-19 diagnostic performance of self-collected gargle samples compared to HCW-collected swabs tested using NAAT were included. Quality assessment was performed, and random effects meta-analysis was conducted to estimate the pooled gargle sensitivity and mean difference in sensitivity between gargle and swab methods.<br><br>RESULTS: Searches identified 1453 results with 32 studies included. Meta-analysis pooled 34 gargle-swab comparisons. Gargle sensitivity was estimated to be 92.2% (95% confidence interval: 89.6% to 94.2%), and 3.3% (0.4% to 6.3%) less sensitive than swab collection. Gargle sensitivity was greater than 87.0% across diverse patient characteristics, settings, type or volume of gargle liquid, length of gargling time, wait time prior to gargling, and reference swab type used. Greatest sensitivities were observed when gargle sampling for 30&#xa0;s or greater using 5-9 mL of saline. Gargle sensitivity of 93.0% (87.8% to 96.1%) was observed when there was no required wait time, and 90.1% (87.0% to 92.5%) when compared to combined nasopharyngeal and oropharyngeal swabs.<br><br>CONCLUSION: Gargle sampling may be a sensitive, alternative method for SARS-CoV-2 detection across various testing contexts, and its implementation has potential to reduce barriers associated with HCW-collected swabs, that may be challenging to collect.},
}
@article {pmid42245362,
year = {2026},
author = {Alrossies, AS},
title = {Post-COVID syndrome in Pakistan, India, and Bangladesh: a systematic narrative review of epidemiology, clinical manifestations, and healthcare system responses.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1714880},
pmid = {42245362},
issn = {2296-2565},
mesh = {Humans ; Post-Acute COVID-19 Syndrome ; *COVID-19/epidemiology/complications ; India/epidemiology ; Bangladesh/epidemiology ; Pakistan/epidemiology ; Female ; Prevalence ; *Delivery of Health Care ; },
abstract = {BACKGROUND: Post-COVID syndrome, defined by the WHO as persistent multisystem symptoms extending beyond 4 weeks post-infection, has emerged as a critical public health concern in South Asia, a region home to approximately 1. 9 billion individuals across Pakistan, India and Bangladesh. Despite the disproportionate burden affecting an estimated 54.3 million individuals in this region, no prior systematic synthesis has integrated evidence across all three major South Asian countries, creating a significant gap in the evidence-based policy development.<br><br>METHODS: This systematic narrative review, conducted following the PRISMA-ScR guidelines, synthesized evidence from 388 peer-reviewed publications identified through PubMed, Scopus, and Google Scholar databases (January 2020-December 2023). Study quality was assessed using the JBI Critical Appraisal Checklist and the GRADE framework. Two independent reviewers performed the screening (inter-rater reliability: 87.3%) and data extraction (concordance: 94.1%).<br><br>RESULTS: The prevalence of post-COVID syndrome varied geographically: 15.8%-18.3% in Pakistan, 9.4%-22.5% to 11.2%-16.8% in India, Females consistently demonstrated higher prevalence across all countries, with ratios ranging from 1.41:1 to 1.81:1. The peak burden occurred in the 35-54 age group. Urban areas reported a higher prevalence than rural areas, with disparities correlating with healthcare infrastructure metrics. Fatigue (58.3%), brain fog (52.1%), and memory problems (48.7%) were the most prevalent symptoms. The prevalence declined across successive pandemic waves, with vaccination associated with substantial reductions in later waves.<br><br>CONCLUSION: Post-COVID syndrome poses a substantial and ongoing public health challenge in South Asia, disproportionately affecting women and adults of working age. Urban-rural disparities in prevalence reflect underlying healthcare access inequities rather than true epidemiological differences. Urgent priorities include establishing dedicated post-COVID clinics, strengthening rehabilitation infrastructure, and conducting region-specific genetic and long-term outcome research to inform evidence-based interventions for this vulnerable population.},
}
@article {pmid42245628,
year = {2026},
author = {Yuan, H and Zhang, T and Du, M and Liang, Z},
title = {Progressive cerebral infarction as the presenting feature of ANCA-associated vasculitis with concurrent Evans syndrome: a case report and literature review.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1764226},
pmid = {42245628},
issn = {1664-3224},
mesh = {Humans ; Female ; *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications/diagnosis/therapy/immunology ; Aged ; *Cerebral Infarction/etiology/diagnosis/therapy ; *Anemia, Hemolytic, Autoimmune/complications/therapy/diagnosis/immunology ; *Thrombocytopenia/complications/diagnosis/therapy/immunology ; Plasma Exchange ; Antibodies, Antineutrophil Cytoplasmic/blood/immunology ; *COVID-19/complications/therapy ; SARS-CoV-2 ; Cyclophosphamide/therapeutic use ; },
abstract = {Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease, and central nervous system involvement, though uncommon, can be a severe manifestation. The co-occurrence of AAV and Evans syndrome (ES) is exceptionally rare and may reflect broader immune dysregulation. A 72-year-old female presented with progressive right-sided hemiplegia and mixed aphasia. Imaging revealed multiple acute cerebral infarcts. Laboratory findings showed anemia, thrombocytopenia, acute kidney injury, and elevated inflammatory markers. Serology confirmed myeloperoxidase (MPO)-ANCA positivity, supporting a diagnosis of AAV, most consistent with microscopic polyangiitis. Subsequent hematological workup supported concurrent autoimmune cytopenias consistent with probable ES. Despite corticosteroids and intravenous immunoglobulin, her condition deteriorated with left middle cerebral artery occlusion; during hospitalization, this deterioration coincided with a SARS-CoV-2 infection. Management was escalated to therapeutic plasma exchange and cyclophosphamide. This regimen stabilized renal and hematological parameters, although severe neurological deficits and thrombocytopenia persisted. This case highlights that stroke may be a catastrophic presenting feature of AAV and that concurrent autoimmune cytopenias may add substantial diagnostic and therapeutic complexity. Early ANCA testing in cryptogenic or progressive stroke with systemic involvement is vital, and management requires careful balance between immunosuppression and infection risk.},
}
@article {pmid42246405,
year = {2026},
author = {Zheng, Z and Yousefi, M and Marks, M and Dixit, A and Wahid, R and Viscidi, E and Anderson, EJ},
title = {A narrative review of COVID-19 epidemiology and mRNA vaccine impact in children &lt;12 years during the omicron era (November 2021 - December 2025).},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2684961},
doi = {10.1080/14760584.2026.2684961},
pmid = {42246405},
issn = {1744-8395},
mesh = {Child ; Child, Preschool ; Humans ; Infant ; *COVID-19/epidemiology/prevention &amp; control/immunology ; *COVID-19 Vaccines/administration &amp; dosage/immunology ; Hospitalization/statistics &amp; numerical data ; mRNA Vaccines/administration &amp; dosage/immunology ; Post-Acute COVID-19 Syndrome/epidemiology ; *SARS-CoV-2/immunology ; Vaccination/statistics &amp; numerical data ; Vaccine Efficacy/statistics &amp; numerical data ; },
abstract = {INTRODUCTION: COVID-19 continues to pose a burden in children under 12 years of age during the Omicron era (November 2021 - December 2025). Following Omicron's emergence, SARS-CoV-2 seroprevalence increased rapidly, with most children infected by ages 2-4 years. Pediatric hospitalization rates declined after the initial Omicron wave but remained elevated in children under 2 years and in those with underlying conditions. While healthy children typically experience mild illnesses, severe outcomes-including hospitalization, admission to an intensive care unit, death, and multisystem inflammatory syndrome-can occur, particularly in unvaccinated children.<br><br>AREAS COVERED: This narrative review summarizes current evidence on pediatric COVID-19 epidemiology and vaccine impact, including infection rates, severe outcomes, post-acute COVID-19 syndrome (Long COVID), and mRNA vaccine effectiveness and uptake in high-income regions. A literature search included peer-reviewed publications, surveillance data, and reports from health agencies during the Omicron era.<br><br>EXPERT OPINION: mRNA vaccines are effective in reducing pediatric COVID-19-related morbidity, but uptake remains low globally. Addressing parental concerns, improving vaccine accessibility, and promoting evidence-based communication are critical to increasing uptake. Given the continued disease burden and the potential for severe outcomes, ensuring access to mRNA COVID-19 vaccines for children at higher risk and for families who wish to vaccinate their children is beneficial.},
}
@article {pmid42247671,
year = {2026},
author = {Datta, B and Jaremski, JE and Wilkins, AS and Hoffman, Z},
title = {Assessing income heterogeneity of female sex as risk factor for long COVID: a meta-analytic investigation.},
journal = {Biodemography and social biology},
volume = {71},
number = {2},
pages = {125-136},
doi = {10.1080/19485565.2026.2684735},
pmid = {42247671},
issn = {1948-5573},
mesh = {Humans ; Female ; *Income/statistics &amp; numerical data ; *COVID-19/epidemiology/economics ; Middle Aged ; Risk Factors ; United States/epidemiology ; Adult ; Post-Acute COVID-19 Syndrome ; Adolescent ; Sex Factors ; Aged ; Young Adult ; SARS-CoV-2 ; Age Factors ; Behavioral Risk Factor Surveillance System ; },
abstract = {Women have a higher risk of Long COVID, defined as symptoms persisting for three or more months after SARS-CoV-2 infection. This study examines whether the elevated risk of Long COVID among women varies across income subgroups in a nationally representative sample of the U.S. population. Using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), we estimated adjusted odds ratios for Long COVID associated with female sex, stratified by four age categories and 11 income groups. We conducted random-effects meta-analyses of income subgroup estimates within each age category and assessed heterogeneity using Cochran's Q, I[2] statistics, prediction intervals, and Galbraith plots. Among younger age groups (18-34, 35-49, and 50-64 years), Cochran's Q ranged from 7.70 to 10.98 (p > 0.10), and I[2] was 0.00%, indicating no significant heterogeneity across income groups. In the ≥65 age group, Cochran's Q was 18.35 (p = 0.0494), and I[2] was 21.96%, suggesting modest heterogeneity. The 95% prediction interval for the ≥65 group (1.121-1.978) was wider than those for younger groups: 1.437-1.975 (18-34 years), 1.551-2.019 (35-49 years), and 1.355-1.766 (50-64 years).},
}
@article {pmid42247713,
year = {2026},
author = {Käufer, C and Kotzur, R and Lau, K and Richter, F},
title = {Beyond brain fog: viral proteins as convergent drivers of neuroinflammation and proteinopathy.},
journal = {Current opinion in virology},
volume = {76},
number = {},
pages = {101559},
doi = {10.1016/j.coviro.2026.101559},
pmid = {42247713},
issn = {1879-6265},
abstract = {Post-viral neurological syndromes, such as post-acute sequelae of COVID-19, present a paradox of severe symptoms despite minimal CNS viral replication. The 'protein-as-pathogen' model, where shed viral proteins act as soluble neurotoxins, is now central to understanding this phenomenon. This review presents the opinion that the most critical recent developments are not that these proteins are toxic, but how their mechanisms converge. We synthesize evidence from the last two years showing that proteins from diverse, highly infectious virus families with zoonotic potential (e.g. Coronaviridae, Flaviviridae, Orthomyxoviridae) engage shared host pathways. We focus on two convergent mechanisms: (1) the activation of glial Toll-like receptor (TLR)4/TLR2 signaling, which initiates a chronic neuroinflammatory cascade, and (2) the disruption of host proteostasis, which seeds neurodegenerative proteinopathies like alpha-synuclein and tau aggregation. This framework positions post-viral syndromes as mechanistically related disorders and identifies pan-viral therapeutic targets, such as TLR inhibitors and autophagy activators.},
}
@article {pmid42247732,
year = {2026},
author = {Bykerk, VP and Bartlett, SJ and Schieir, O and Boire, G and Hitchon, CA and Thorne, C and Tin, D and Haraoui, B and Bessette, L and Hazlewood, G and Allard-Chamard, H and Kuriya, B and Valois, MF and Pope, JE and , },
title = {Lessons from an early rheumatoid arthritis incident cohort.},
journal = {Seminars in arthritis and rheumatism},
volume = {79},
number = {},
pages = {152992},
doi = {10.1016/j.semarthrit.2026.152992},
pmid = {42247732},
issn = {1532-866X},
mesh = {Humans ; *Arthritis, Rheumatoid/drug therapy/diagnosis/epidemiology ; *Registries ; *Antirheumatic Agents/therapeutic use ; Canada/epidemiology ; Cohort Studies ; Female ; Methotrexate/therapeutic use ; Early Diagnosis ; Patient Reported Outcome Measures ; },
abstract = {BACKGROUND: The Canadian Early Arthritis Cohort (CATCH) study, a pioneering national registry established in 2007, has generated robust real-world evidence that has significantly advanced early rheumatoid arthritis (ERA) care in Canada and internationally.<br><br>METHODS: Data have been collected from over 3800 patients across 25 sites and >35,000 study visits.<br><br>RESULTS: This paper synthesizes 15 key learnings from CATCH that span early diagnosis, treatment strategies, patient-reported outcomes, and health equity. Findings underscore the importance of standardized data collection, early methotrexate use, and treat-to-target approaches, while also highlighting challenges such as persistent disease activity, treatment adherence, and disparities linked to sex, comorbidities, and social determinants of health. CATCH has contributed to the development and validation of novel outcome measures, supported the training of future rheumatology leaders, and informed national and international guidelines. Its infrastructure enabled continuity of research during the COVID-19 pandemic and supports pragmatic trials and innovations in care delivery.<br><br>CONCLUSIONS: As real-world incident cohort, CATCH has helped to answer questions that impact clinical and policy decisions, and CATCH exemplifies the enduring value of well-curated patient registries in generating actionable insights to improve outcomes for people living with ERA.},
}
@article {pmid42248032,
year = {2026},
author = {Rajalingam, A and Ganjiwale, A},
title = {Viral-induced autoimmune disorders: Mechanistic insights and emerging concepts.},
journal = {Human immunology},
volume = {87},
number = {8},
pages = {111765},
doi = {10.1016/j.humimm.2026.111765},
pmid = {42248032},
issn = {1879-1166},
mesh = {Humans ; *Autoimmune Diseases/immunology/virology/etiology ; Molecular Mimicry ; *Virus Diseases/immunology/complications/virology ; Dysbiosis/immunology ; *SARS-CoV-2/immunology ; *COVID-19/immunology/complications ; Gastrointestinal Microbiome/immunology ; Autoimmunity ; Animals ; Trained Immunity ; Cytokine Release Syndrome/immunology/virology ; Herpesvirus 4, Human/immunology ; },
abstract = {Autoimmune disorders (ADs) result from a complex interaction of genetic predisposition and environmental triggers, with viral infections identified as primary causes. This review summarizes current evidence on how viruses-including Epstein-Barr Virus (EBV), Enteroviruses, and SARS-CoV-2-initiate and worsen autoimmunity. We explore established mechanisms such as molecular mimicry, bystander activation, and epitope spreading, while highlighting the emerging roles of maladaptive trained immunity and cytokine storms in chronic inflammation. Additionally, we discuss the bidirectional relationship between gut microbiota dysbiosis and virus-induced immune failure. Understanding these layered interactions is crucial for developing biomarker-driven diagnostic and treatment strategies.},
}
@article {pmid42249389,
year = {2026},
author = {Thompson, C and Fonseca-Cuevas, A and Frimpong, KJE and Martin, W},
title = {Facilitators and barriers to childhood immunization in Canada: a scoping review.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-27858-4},
pmid = {42249389},
issn = {1471-2458},
support = {Establishment Grant 2024-2025//Saskatchewan Health Research Foundation/ ; },
abstract = {BACKGROUND: Immunization is a primary prevention public health strategy that has saved more lives than any other health service. Achieving the recommended 95% childhood immunization coverage rate remains a challenge in Canada, especially post-COVID-19. This challenge highlights the need to better understand current immunization facilitators and barriers to improve coverage rates. This study aimed to determine: (1) Factors that support and create barriers to childhood immunization for families with children 0-6 years of age in Canada (2) If childhood immunization facilitators and barriers changed from pre-to-post-COVID-19.<br><br>METHODS: Using Arksey and O'Malley scoping review framework informed by Levac et al. and JBI Scoping Review Guidelines, seven databases were searched: MedLine (OVID), EMBASE (OVID), Web of Science (Clarivate), CINAHL (EBSCOhost), Cochrane Library (Wiley), APA PsycArticles (OVID), ProQuest Dissertations and Theses (Clarivate) for peer-reviewed literature. Articles were screened against inclusion/exclusion criteria, data extracted and thematically analyzed using the Braun and Clarke framework.<br><br>RESULTS: Thirty-one studies were included. Five identified themes had a dual role supporting and creating barriers to childhood immunization and included: access to healthcare services, cognitive reasoning, affective influences on decision-making, external influences, and information. Two standalone barriers included: use of alternative medicine and colonial institutional practices. Differences pre-to-post-COVID-19 in factors supporting immunization included: cognitive reasoning and access to healthcare services; barriers included cognitive reasoning, information, access to healthcare services, and colonial institutional practices.<br><br>CONCLUSIONS: This scoping review highlighted factors from caregiver perspectives that support and create barriers to childhood immunization including cognitive reasoning, affective influences on decision-making, and information. Post-COVID-19 considerations noted in our findings were affective influences on decision-making - trust and relationships and access to healthcare services. There appears an immunization information time gap in the prenatal period. Colonial institutional practices create access challenges for Indigenous families. To better understand these gaps, additional research is needed to understand current immunization information practices in the prenatal period, the contextual nuances of immunization service delivery, and Indigenous Peoples' experiences with immunization services. Further exploration of these areas may help to inform strategies to address identified barriers, strengthen immunization services, and improve immunization coverage rates.},
}
@article {pmid42250263,
year = {2026},
author = {Tahir, T and Siddique, MA and Ijaz, K and Nadeem, H and Rehman, A and Khan, S and Tarar, AH and Lajwanti, and Zafar, MAS and Raja, F and Jafar, U and Alsubari, AMA and Ehsan, M and Ikram, J},
title = {Metformin for COVID-19: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.},
journal = {Reviews in medical virology},
volume = {36},
number = {4},
pages = {e70172},
doi = {10.1002/rmv.70172},
pmid = {42250263},
issn = {1099-1654},
mesh = {*Metformin/therapeutic use/adverse effects ; Humans ; Randomized Controlled Trials as Topic ; *COVID-19 Drug Treatment ; Hospitalization/statistics &amp; numerical data ; *Hypoglycemic Agents/therapeutic use ; SARS-CoV-2/drug effects ; COVID-19/mortality ; Treatment Outcome ; },
abstract = {Metformin has been shown to reduce hospitalisation and symptom duration among adults with COVID-19, but the effect has not been studied. We conducted this meta-analysis to assess the efficacy and safety of metformin in patients with COVID-19. Randomized controlled trials (RCTs) comparing metformin with placebo in COVID-19 were identified through major databases through November 2025. We performed statistical analyses using RevMan 5.4, employing the random-effects model, along with Risk Ratio (RR) and Mean Difference (MD) as the effect measures. Our meta-analysis of four RCTs showed that metformin did not significantly reduce the composite outcome of hospitalisation, emergency department (ED) visits, or death, compared with placebo (RR 0.60, 95% CI 0.40-0.90.21). The incidence of all-cause mortality (RR 1.00; 95% CI 0.06-15.91) and serious adverse events (RR 2.86; 95% CI 0.76-10.76) was also comparable between the two groups. Our meta-analysis, with low to moderate certainty, found that metformin may provide modest benefit in reducing hospitalisation, ED visits, or mortality in patients with COVID-19 without an association with increased serious adverse events. However, these findings should be interpreted cautiously, given the limited number of trials, low event rates, and clinical heterogeneity across studies. Further large RCTs are needed before metformin can be considered for use in COVID-19.},
}
@article {pmid42250934,
year = {2026},
author = {Ferguson, M and Englund, HM and Habeck, J},
title = {Virtual learning modalities and clinical competence in baccalaureate nursing education: An integrative review.},
journal = {Journal of professional nursing : official journal of the American Association of Colleges of Nursing},
volume = {64},
number = {},
pages = {34-41},
doi = {10.1016/j.profnurs.2026.02.012},
pmid = {42250934},
issn = {1532-8481},
mesh = {Humans ; *Education, Nursing, Baccalaureate/methods ; *Clinical Competence ; *Virtual Reality ; *Students, Nursing/psychology ; *Education, Distance/methods ; COVID-19/epidemiology ; },
abstract = {BACKGROUND: The COVID-19 pandemic accelerated the use of digital education in nursing, including simulation, virtual reality (VR), telehealth, and AI-supported tools. Despite increased access and engagement, concerns remain about preparation for clinical practice.<br><br>AIM: To examine associations between virtual learning modalities and clinical competence and workforce readiness among undergraduate nursing students.<br><br>METHODS: The authors conducted an integrative review guided by PRISMA and SWiM and used Whittemore and Knafl's five-step methodology to synthesize evidence from diverse study designs.<br><br>RESULTS: Five themes were identified: foundational skill development, perceived clinical readiness, communication and psychosocial competency, instructional design and faculty capacity, and equity and access. Virtual learning was generally associated with cognitive and affective outcomes, while evidence related to psychomotor skill development and readiness for hands-on care was mixed. Perceived preparedness differed across studies and was commonly described in relation to instructional quality, faculty support, and access to technology.<br><br>CONCLUSIONS: Virtual learning supports clinical education but does not replace hands-on experiences. Blended models integrating virtual and in-person learning, supported by faculty development and equitable access, are recommended to promote clinical competence and workforce readiness.},
}
@article {pmid42250978,
year = {2026},
author = {Luján, M and Heili-Frades, S and Abad, A and López-Padilla, D and Sayas, J and Cebrià, MA and Sánchez-Zaballos, M and Alonso, P and Pardo, A and Ussetti, P and Landete, P and Ramírez, MT},
title = {SEPAR Position Paper on Infrastructure, Technology, Staffing, Quality Standards, and Management of Intermediate Respiratory Care Units in Spain.},
journal = {Archivos de bronconeumologia},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.arbres.2026.05.007},
pmid = {42250978},
issn = {1579-2129},
abstract = {Intermediate Respiratory Care Units (IRCUs) play an increasingly important role in the management of patients with acute or acute-on-chronic respiratory failure who require more advanced monitoring and respiratory support than can be provided on conventional hospital wards but do not require admission to an Intensive Care Unit (ICU). Their development has been driven by the widespread adoption of noninvasive ventilation, high-flow nasal cannula (HFNC) therapy, and continuous respiratory monitoring, and their strategic value was clearly demonstrated during the COVID-19 pandemic. This position paper from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) provides evidence-informed recommendations regarding the infrastructure, technology, staffing, organization, and quality standards necessary for the optimal functioning of IRCUs in Spain. A multidisciplinary panel of experts developed consensus-based guidance drawing on available scientific evidence and clinical experience, addressing architectural design, technological resources, professional roles, training pathways, clinical care models, and quality indicators. IRCUs have emerged as a key component in the management of acute and chronic respiratory failure, contributing to improved clinical outcomes and more efficient use of critical care resources. This document highlights the importance of standardized admission criteria, structured care processes, multidisciplinary coordination, and continuous performance evaluation using validated indicators to support the consolidation of IRCUs as high-value, sustainable components of modern respiratory care systems.},
}
@article {pmid42251316,
year = {2026},
author = {Bannout, AA and Hussein, FH and Haddad, LR},
title = {Management of Bell's palsy in a 2-month-old following COVID-19 infection: a case report and review of the literature.},
journal = {BMC neurology},
volume = {26},
number = {1},
pages = {},
pmid = {42251316},
issn = {1471-2377},
mesh = {Humans ; *Bell Palsy/etiology/drug therapy/therapy/diagnosis ; Female ; Infant ; *COVID-19/complications ; *Prednisolone/therapeutic use ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Bell's palsy (idiopathic peripheral facial nerve paralysis) is uncommon in children and is particularly rare in infants younger than one year of age. Its occurrence following viral infections, including coronavirus disease 2019 (COVID-19), is exceedingly rare. We report a case of Bell's palsy in an infant following COVID-19 infection and provide a review of the relevant pediatric literature.<br><br>CASE PRESENTATION: We report the case of a 2-month-old female infant who developed left-sided facial weakness shortly after a COVID-19 infection. She had previously been healthy, except for a COVID-19-positive upper respiratory infection at the age of 4 weeks. Three weeks after her infection resolved, her parents noticed the sudden onset of left facial drooping, which progressed over the following three days. A diagnosis of peripheral facial nerve palsy following COVID-19 infection was proposed. Given the absence of clear treatment guidelines for infants, management options were carefully considered. The patient was ultimately started on oral prednisolone in addition to protective eye care. She demonstrated gradual clinical improvement during treatment, and at follow-up several weeks later, complete recovery of normal facial movement was observed.<br><br>CONCLUSIONS: This case highlights that Bell's palsy, although extremely rare in infancy, may occur following a viral infection such as COVID-19. A prompt and thorough evaluation is essential to exclude alternative causes of facial paralysis. Despite no clear guidelines or recommendations favoring corticosteroid treatment vs conservative management in this age category, a decision of pharmacologic treatment was taken. In this case, corticosteroid treatment was well tolerated, and no adverse events were observed. Further studies are needed to evaluate the correlation between COVID-19 infection and facial palsy in infants, and to further assess the efficacy and safety of oral prednisolone in this age group.},
}
@article {pmid42251625,
year = {2026},
author = {Thoburn, E and Giannakoulis, VG and Hu, T and Goebe, H and Raina, S and Moran, MM and Perreault, B and Val-Maranes, L and Millar, EB and Whittle, I and Pearson, F and Lopez, SMC},
title = {Safety of BNT162b2 COVID-19 Vaccine in Pregnancy: A Systematic Review.},
journal = {Infectious diseases and therapy},
volume = {15},
number = {8},
pages = {2087-2101},
pmid = {42251625},
issn = {2193-8229},
abstract = {INTRODUCTION: Since COVID-19 vaccine introduction in December 2020, > 13 billion doses have been distributed globally, including > 5 billion Pfizer-BioNTech (BNT162b2) doses. Real-world evidence in pregnancy remains heterogenous in design and outcome definitions, with limited analysis by dose timing or variant period. Most reviews evaluated COVID-19 vaccines as a class without focus on individual products, limiting product-specific interpretation. Given expanding evidence and public concern around safety of vaccines during pregnancy, an updated, pregnancy-focused systematic review of BNT162b2 safety is warranted. This study aimed to review and synthesize evidence on the safety of Pfizer-BioNTech COVID-19 vaccine in pregnant women, including pregnancy-related outcomes.<br><br>METHODS: A systematic literature review (PROSPERO registered) was conducted in accordance with Cochrane methodology and reported following PRISMA guidelines. Medline and Embase were searched from December 2020 to June 2025, supplemented by regulatory reports and conference searches. Eligible randomized and observational studies reporting obstetric or neonatal outcomes after&#x2009;&#x2265;&#x2009;1 dose of BNT162b2 were included. Quality appraisal was conducted using NICE checklists. Results were narratively synthesized and reported following SWiM guidance.<br><br>RESULTS: Across 25 studies, comprising&#x2009;>&#x2009;450,000 BNT162b2-vaccinated pregnant women, no increased risk was observed for miscarriage, congenital anomalies, preterm birth, hypertensive disorders, small for gestational age, low birth weight, or neonatal death, with effect estimates broadly consistent and centered around the null across available trimester-stratified analyses, dose numbers, and study design. However, trimester-specific data, particularly for first-trimester exposure, were limited.<br><br>CONCLUSION: The cumulative evidence demonstrates a reassuring safety profile for Pfizer-BioNTech (BNT162b2) COVID-19 vaccination with no indication of increased pregnancy-related or neonatal risk. The evidence is mainly observational and heterogeneous, with limited precision for rare outcomes, but the results align with findings from international registry, surveillance, and population-based evidence and support BNT162b2 vaccination in pregnancy as an effective and safe means to reduce preventable maternal morbidity, although evidence remains limited for first-trimester-specific exposure.<br><br>TRIAL REGISTRATION: The review protocol was prospectively registered with PROSPERO [CRD420251080193] [1].},
}
@article {pmid42253106,
year = {2026},
author = {Khalil, A},
title = {Antiviral nucleoside mimics: the development and future perspective of Molnupiravir.},
journal = {Future medicinal chemistry},
volume = {18},
number = {14},
pages = {1895-1906},
doi = {10.1080/17568919.2026.2684621},
pmid = {42253106},
issn = {1756-8927},
mesh = {*Antiviral Agents/chemistry/pharmacology/chemical synthesis ; Humans ; *Nucleosides/chemistry/pharmacology ; *Hydroxylamines/chemistry/pharmacology/chemical synthesis ; *Cytidine/analogs &amp; derivatives/pharmacology/chemistry/chemical synthesis ; SARS-CoV-2/drug effects ; RNA-Dependent RNA Polymerase/antagonists &amp; inhibitors/metabolism ; COVID-19 Drug Treatment ; *Uridine/analogs &amp; derivatives/chemistry/pharmacology ; Bioisosterism ; },
abstract = {In 2021, the U.S. Food and Drug Administration (FDA) authorized the oral prodrug molnupiravir, the β-D-N4-hydroxycytidine precursor, for emergency use as an antiviral agent against SARS-CoV-2. Molnupiravir (MK-4482, EIDD-2801) was originally developed at Emory University, where its design leveraged the bioisosteric replacement of the carbonyl group in the pyrimidine base of endogenous uridine with an oxime (NHOH) functionality. This modification enabled effective mimicking of natural nucleosides and enhanced antiviral activity by targeting the viral RNA-dependent RNA polymerase (RdRp). In this review, the collective advancements in the synthesis of molnupiravir aimed at achieving scalable, cost-effective, and efficient manufacturing are discussed, along with an exploration of oxime bioisosterism within medicinal chemistry.},
}
@article {pmid42253600,
year = {2026},
author = {Kraselnik, A and McGowan, H and Amiali, IA and Gibson, I and Joshi, S and Magero, N and Miller, CH and Oulousian, S and Sharma, A and Sonyuy, MF and Kulnik, ST and Shah, NS},
title = {Factors Influencing the Uptake of Digital Health Interventions for Cardiovascular Disease Prevention Among Healthcare Providers: A Systematic Review.},
journal = {Global heart},
volume = {21},
number = {1},
pages = {45},
pmid = {42253600},
issn = {2211-8179},
mesh = {Humans ; Digital Health ; *Cardiovascular Diseases/prevention &amp; control ; *Health Personnel ; *Secondary Prevention/methods ; Telemedicine ; Attitude of Health Personnel ; *Primary Prevention/methods ; },
abstract = {BACKGROUND: Digital health interventions (DHIs) offer major potential for improving cardiovascular disease (CVD) primary and secondary prevention, but their adoption by healthcare providers (HCPs) remains inconsistent.<br><br>OBJECTIVE: To identify barriers and facilitators to DHI uptake in CVD primary and secondary prevention from HCPs' perspectives.<br><br>METHODS: We conducted a systematic review of studies published between 2020 and 2024 that investigated HCPs' perceptions of DHI implementation for CVD primary and secondary prevention. We appraised individual study quality using a validated tool. We performed a qualitative synthesis of reported barriers and facilitators, categorized according to country income level and according to the World Heart Federation Roadmap domains: HCPs, patients, technology, and health systems.<br><br>RESULTS: We included 125 primary studies (101 qualitative, 15 quantitative, 9 mixed methods). The most frequently cited barrier was excessive workload, both from existing responsibilities and additional tasks introduced by DHIs. The leading facilitator was the perceived positive clinical impact of DHIs-such as improved adherence, reduced hospital readmissions, and better outcomes. HCP motivation, adequate training, and system integration also facilitated adoption. Many factors-like effects on HCP-patient relationships and workflow-functioned as either barriers or facilitators, depending on the setting. Patient-related barriers included limited digital access and literacy; facilitators included perceived gains in patient-centered care. Health system factors such as organizational structure, financing, and policy support were commonly mentioned, with mixed views. Technology-related facilitators included usability, adaptability, and integration with electronic records; instability was a key barrier.<br><br>CONCLUSIONS: This is the first systematic review to synthesize post-COVID-19 literature on HCPs' perceptions of DHIs in CVD primary and secondary prevention. While offering a rich, global overview, limitations include a predominance of qualitative studies and lack of data from low-income countries. Effective implementation must address workload, align with workflows, and build trust through training and leadership.<br><br>LAY SUMMARY: This research analyzed 125 studies from 33 countries to understand the factors that influence healthcare professionals' uptake of digital health tools, such as apps and wearable devices, for preventing cardiovascular disease.The leading facilitator for adoption is the perceived positive clinical impact; doctors and nurses are highly motivated to use digital tools when they help patients follow treatments better, reduce hospital readmission rates, and improve overall heart health.The most significant barrier is the perceived excessive workload. While some digital health tools can be time-saving, many providers feel that they add burdensome technical tasks to their already busy schedules, which undermines their acceptance.Uptake is also influenced by patient-related factors, such as digital literacy and internet access, as well as technological factors like how easily a tool integrates into existing hospital computer systems.To improve the future of cardiovascular care, digital tools should be co-designed with clinicians to ensure they fit seamlessly into daily work routines and are supported by proper training and strong institutional leadership.},
}
@article {pmid42253757,
year = {2026},
author = {Maharjan, R and Shin, CY and Lee, SK and Ha, ES and Park, H and Kim, JS and Kim, KH and Kim, NA and Kim, MS and Jeong, SH},
title = {Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals.},
journal = {International journal of pharmaceutics: X},
volume = {11},
number = {},
pages = {100575},
pmid = {42253757},
issn = {2590-1567},
abstract = {The success of mRNA-lipid nanoparticles (LNPs) vaccines during the COVID-19 pandemic has significantly increased global demand for stable, thermo-resistant biologicals. Lyophilization remains a cornerstone technology for enhancing the stability of these formulations; however, the freezing and drying processes impose major stresses that can compromise the integrity of fragile LNPs. This review systematically explores the molecular mechanisms by which lyoprotectants, including sugars, polyols, amino acids, and polymers, mitigate challenges such as ice-induced denaturation, dehydration-driven aggregation, and interfacial destabilization. This review emphasizes the importance of optimized sucrose-trehalose combinations and effective ice-nucleation control in preserving encapsulation efficiency and maintaining particle integrity. Furthermore, the review discusses advanced process optimization tools, including digital twin modeling and in-line Raman spectroscopy, which enhance lyophilization efficiency by reducing primary drying times by up to 40% while ensuring critical quality attributes are preserved. Additionally, emerging applications utilizing novel excipient combinations are highlighted, showcasing their potential to enable refrigerated storage of viral vectors. With 85% of commercial conjugates relying on lyophilization, recent advancements in continuous freeze-drying technology, such as spin-freeze approaches, have achieved cycle times that are three-fold faster. These developments provide a comprehensive roadmap for overcoming cold chain limitations while addressing the stabilization needs of next-generation biologicals, CRISPR-based systems, and personalized medicines.},
}
@article {pmid42253906,
year = {2026},
author = {Bukhari, OM},
title = {Perception, Acceptance, and Utilization of Teledentistry by the Public: A Literature Review.},
journal = {Journal of International Society of Preventive &amp; Community Dentistry},
volume = {16},
number = {2},
pages = {107-115},
pmid = {42253906},
issn = {2231-0762},
abstract = {OBJECTIVES: Teledentistry demonstrates significant potential in enhancing access to, reducing costs of, and improving oral healthcare delivery, particularly in under-resourced areas and during crises, like the coronavirus disease 2019 (COVID-19) pandemic. Despite its high acceptance rate among dental professionals, the perspectives of patients and the public remain less explored. This narrative review synthesizes evidence on public perception, acceptance, utilization, and satisfaction of teledentistry globally.<br><br>METHODS: A comprehensive search was conducted across PubMed, Scopus, EMBASE, Web of Science, Cochrane Database, and Google Scholar for peer-reviewed English articles (2010-2025) using keywords like "teledentistry," "patients," and "public." Included studies assessed patient and public perspectives on teledentistry benefits, barriers, satisfaction, and utilization. Exclusions comprised non-patient or non-English articles. Data from 21 selected studies were narratively synthesized.<br><br>RESULTS: Awareness of teledentistry varied widely (e.g., 64% aware in one Saudi Arabian study vs. 87.3% unaware of teledentistry in a study in Jeddah). Attitudes were generally positive, as seen with 82.4% of the cohort in a Malaysian study, where the convenience of tele-orthodontics and increased safety during COVID-19 were observed, although older adults across the studies and those with lower levels of education reported technological barriers. Acceptance rates of teledentistry were high among patients (70%-87% in Saudi Arabia, the United Kingdom, and Malaysia), particularly when used for triage and follow-ups, but lower for complex treatments (e.g., 35.3% of patients in a Qatar study noted unresolved issues following teledentistry consultations, like pulpitis). Satisfaction was favorable across the cohorts (reaching between 72% and 94% across multiple studies) due to the benefits of reduced treatment time and lower financial cost; however, patient satisfaction declined when they faced dental conditions requiring physical intervention. Key barriers faced by patients and the public to teledentistry included limited awareness, patient concerns with diagnostic accuracy, and technical access issues.<br><br>CONCLUSION: Public perception of teledentistry is moderate, attitudes are broadly positive, and teledentistry is being increasingly accepted with high satisfaction rates for convenient, non-urgent care. However, demographic factors, such as age, education, and location, and clinical limitations for hands-on treatments limit its utilization. Teledentistry is best positioned as a complement to traditional care through hybrid models. Future efforts should prioritize targeted education, improved accessibility, and standardized teledentistry protocols to optimize equitable implementation.},
}
@article {pmid42254411,
year = {2026},
author = {Chen, S and Wen, Z and Wang, C and Li, J and Zou, K},
title = {High-flow nasal cannula for acute respiratory failure: a bibliometric analysis of current trends and future directions.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1811474},
pmid = {42254411},
issn = {2296-858X},
abstract = {BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy has emerged as a pivotal non-invasive respiratory support modality for acute respiratory failure (ARF), fundamentally transforming critical care practice. Despite substantial growth in HFNC research and clinical significance, no comprehensive bibliometric analysis has systematically examined the knowledge structure, research trends, and emerging frontiers in this rapidly evolving field.<br><br>METHODS: A comprehensive bibliometric analysis was conducted using the Web of Science Core Collection (WOSCC), supplemented by PubMed and Scopus for literature retrieval, covering publications from January 2015 to December 2025. Search terms included combinations of "acute respiratory failure," "respiratory failure," "ARF," "high-flow nasal oxygen," "high-flow oxygen," and "HFNC" in titles and abstracts. Data were analyzed using three visualization tools: CiteSpace (version 6.4.R1), VOSviewer (version 1.6.20), and Bibliometrix in R (version 4.5.1) to examine publication trends, country collaborations, author networks, journal distributions, co-citation patterns, and keyword evolution.<br><br>RESULTS: A total of 1,477 publications were identified, with annual output peaking at 256 in 2022, reflecting intensified research during the COVID-19 pandemic. The United States led in productivity (n = 139), while France achieved the highest citation impact (TC = 7,726). Keyword and co-citation clustering revealed evolving research foci from foundational respiratory support (2015-2017) to pandemic-driven applications (2019-2021) and emerging artificial intelligence (AI) integration (2022-2025). Nine distinct research clusters were identified, with recent emphasis on chronic obstructive pulmonary disease, reintubation, and advanced respiratory technologies.<br><br>CONCLUSION: The findings highlight HFNC's successful transition from experimental therapy to evidence-based standard care, with future trends indicating movement toward personalized medicine approaches and technology-enhanced respiratory care delivery systems.},
}
@article {pmid42254753,
year = {2026},
author = {Yen, PS and Huang, JJ and Lu, JC and Chang, TN},
title = {International Microsurgery Club for 10 Years-A New Online Education Platform and Beyond.},
journal = {Seminars in plastic surgery},
volume = {40},
number = {2},
pages = {183-192},
pmid = {42254753},
issn = {1535-2188},
abstract = {The rapid evolution of digital communication has transformed medical education, a shift accelerated by the COVID-19 pandemic. The International Microsurgery Club (IMC), founded in 2016 as a private Facebook group for verified professionals, exemplifies how social media can democratize microsurgical education on a global scale. By the end of 2025, IMC Facebook group had grown to over 22,600 members from more than 70 countries, facilitating case sharing, peer consultation, and professional recognition beyond geographic and institutional boundaries. Analysis of IMC activity between 2019 and 2025 identified 2,124 unique case-related posts contributed by 526 authors, with wide geographic diversity and high engagement independent of posting frequency. During the pandemic, IMC expanded into a sustained weekly webinar series, delivering nearly 600 sessions featuring international experts. Complemented by an open-access journal, a digital educational Web site, and multi-platform social media integration, IMC has evolved into a comprehensive, sustainable ecosystem for global microsurgical education, offering an effective model that complements traditional academic pathways.},
}
@article {pmid42255427,
year = {2026},
author = {Lawal, B and Saidu Musa, S and Soe Thu, M and Ondee, T and Chatsirisakul, O and Pongpirul, K},
title = {Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.},
journal = {Frontiers in endocrinology},
volume = {17},
number = {},
pages = {1835180},
pmid = {42255427},
issn = {1664-2392},
mesh = {Humans ; Blood Glucose/metabolism ; *COVID-19/complications/metabolism ; *Diabetes Mellitus/etiology/metabolism ; Glycated Hemoglobin/metabolism ; Insulin Resistance ; Post-Acute COVID-19 Syndrome/complications/metabolism ; Risk Factors ; },
abstract = {BACKGROUND: COVID-19 has been associated with persistent metabolic disturbances; however, the magnitude, consistency, and underlying mechanisms of post-infection alterations in glucose regulation remain incompletely characterized.<br><br>METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed and Embase were searched on December 18, 2024, for studies published from 2020 onward. Eligible studies included observational cohort and cross-sectional designs assessing metabolic outcomes at least three months after recovery from COVID-19.<br><br>RESULTS: Sixteen studies met inclusion criteria. Pooled analysis suggested a 41% increased risk of new-onset diabetes among COVID-19 survivors compared with non-infected individuals (RR 1.41, 95% CI: 1.38-1.44); however, this estimate was predominantly driven by a single large-scale study. Quantitative synthesis demonstrated higher HbA1c (SMD 1.44, 95% CI: 0.36-2.52) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (SMD 0.96, 95% CI: 0.33-1.58), consistent with impaired glycemic control and increased insulin resistance. In contrast, fasting blood glucose (FBG) findings were inconsistent and highly heterogeneous (SMD 0.77, 95% CI: -0.40-1.94). Substantial heterogeneity was observed across outcomes.<br><br>CONCLUSION: COVID-19 may be associated with an increased risk of incident diabetes and persistent metabolic dysregulation. However, the limited number of studies contributing to pooled risk estimates and the influence of large registry-based data warrant cautious interpretation. These findings support consideration of metabolic monitoring and longitudinal follow-up in post-COVID care, particularly among individuals at elevated cardiometabolic risk.<br><br>https://www.crd.york.ac.uk/prospero/, identifier CRD42025630971.},
}
@article {pmid42255944,
year = {2026},
author = {Abdul Khalek, J and Al Hajjar, M and Al-Khalil, Z and Salem, J and Zareef, R and Bitar, F and Arabi, M},
title = {Unveiling the Link Between COVID-19 and Pulmonary Hypertension.},
journal = {The Canadian journal of infectious diseases &amp; medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale},
volume = {2026},
number = {},
pages = {9352258},
pmid = {42255944},
issn = {1712-9532},
abstract = {INTRODUCTION: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, was first identified in Wuhan, China, in December 2019 and has had a significant impact on global health. The virus uncovered multifaceted complications across various organ systems, including the cardiovascular system. Pulmonary hypertension, often exacerbated in settings of severe or prolonged viral infections, presents unique challenges in the context of COVID-19 due to its complex pathophysiology involving vascular inflammation and thrombotic events.<br><br>METHODS: This narrative review aims to delineate the emerging relationship between COVID-19 and pulmonary hypertension, focusing on pathophysiological insights, clinical implications, and evolving therapeutic strategies, enriching clinical practice and guiding future research of this complex interaction. We conducted a comprehensive literature review using databases such as MEDLINE, PubMed, and Google Scholar with keywords related to pulmonary hypertension and COVID-19, covering studies published between December 2019 and February 2025.<br><br>RESULTS: COVID-19 has been linked to an increased incidence of pulmonary hypertension due to direct viral effects on pulmonary vasculature and secondary inflammatory responses. Clinical manifestations of pulmonary hypertension in COVID-19 include typical symptoms such as dyspnea and chest pain. Effective management strategies include the use of vasodilators, anticoagulants, and tailored experimental treatments. The review also emphasizes the importance of long-term follow-up and monitoring to evaluate disease progression and treatment response.<br><br>CONCLUSION: The intersection of COVID-19 and pulmonary hypertension presents a significant challenge in cardiovascular medicine, necessitating advanced diagnostic and therapeutic approaches. The insights gained from the current pandemic will likely influence broader public health strategies and clinical protocols, improving outcomes for patients with pulmonary hypertension and those at risk of severe viral infections. Future research should focus on personalized medicine approaches and the development of innovative treatments to manage the unique aspects of pulmonary hypertension in the context of COVID-19.},
}
@article {pmid42256552,
year = {2026},
author = {Huang, F and Zhan, P and Shi, X and Sun, Y and Song, X and Sun, P and Liu, B},
title = {Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib.},
journal = {Pharmaceutical science advances},
volume = {4},
number = {},
pages = {100125},
pmid = {42256552},
issn = {2773-2169},
abstract = {Opaganib is a proprietary, host-directed, potentially broadly potent, first-in-class oral sphingosine kinase 2 (SphK2) selective inhibitor developed by RedHill Biopharma Tel Aviv, Israel. It is currently the most widely used selective SphK2 inhibitor. It simultaneously inhibits three sphingolipid-metabolizing enzymes in human cells-SphK2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS)-leading to depletion of sphingosine 1-phosphate (S1P), accumulation of ceramides and dihydroceramides, and suppression of key pro-survival pathways including pERK, pAKT, and NF-κB. These events promote autophagy, apoptosis, and disruption of viral replication. A large body of evidence indicates that SphK plays an important role in health and disease. This study reviews the role and mechanisms of opaganib effects as anticancer, anti-inflammatory, and antiviral agent. The latest research directions for opaganib are described as gastrointestinal acute radiation syndrome (GI-ARS), chemical exposure indications, and COVID-19, Ebola, and other viruses, providing new therapeutic ideas and considerations for future research and clinical trials.},
}
@article {pmid42256623,
year = {2026},
author = {Hattingh, A and Joubert, J and Viljoen, M},
title = {Transitioning regulatory authorities in South Africa: a comparative review of the organisational structure and management practices.},
journal = {Journal of pharmaceutical policy and practice},
volume = {19},
number = {1},
pages = {2673693},
pmid = {42256623},
issn = {2052-3211},
abstract = {BACKGROUND: South Africa's transition from the Medicines Control Council (MCC) to the South African Health Products Regulatory Authority (SAHPRA) in 2018 marked a critical shift in the regulatory landscape. The MCC faced prolonged timelines, inadequate resources and a growing application backlog. This review comparatively examines how organisational, governance, managerial and procedural reforms introduced under SAHPRA (2018-2022) addressed these structural and performance limitations, and assesses their implications for regulatory policy and future system strengthening.<br><br>METHOD: A mixed-method literature review combining qualitative thematic synthesis and quantitative descriptive analysis was conducted, drawing on publicly available sources, including government reports, academic journal articles, and organisational websites. Quantitative data (e.g. median approval timelines, backlog volumes and approval numbers) were systematically extracted from included studies and official reports without primary statistical modelling. Keywords included 'SAHPRA', 'MCC', 'management structures', 'organisational structures', 'regulatory review process', 'approval timelines', 'medicine approval', and 'regulatory authorities'. Screening followed predefined inclusion and exclusion criteria, and data extraction captured governance structures, funding models, quality systems, reliance pathways, review timelines and backlog metrics.<br><br>RESULTS: SAHPRA's implementation of reliance-based review pathways and risk-based assessments, alongside streamlined operations, reduced median approval times from 2,124 in 2018 to 783 days in 2020, and increased new chemical entity registrations from 15 to 155 over the same period. The inherited backlog (8,220 new applications in 2018) was cleared by 2022. The transition improved financial independence, enhanced institutional autonomy and reduced administrative bottlenecks. SAHPRA also demonstrated responsiveness during the COVID-19 pandemic through expedited review pathways.<br><br>CONCLUSION: The transition from MCC to SAHPRA represents a structural and procedural modernisation of South Africa's regulatory framework. While improving efficiency and access to essential medicines, findings should be interpreted cautiously due to reliance on secondary data and variation across sources. Continued digital reform, capacity development and strengthening post-marketing surveillance remain key priorities.},
}
@article {pmid42256699,
year = {2026},
author = {Mussi, M and Zengarini, C and Corrà, A and Brunetti, T and Natale, A and La Placa, M and Piraccini, BM and Guglielmo, A and Pileri, A},
title = {Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review.},
journal = {Journal of skin cancer},
volume = {2026},
number = {},
pages = {4893577},
pmid = {42256699},
issn = {2090-2905},
abstract = {BACKGROUND: Cutaneous lymphomas (CLs) are rare neoplastic skin disorders, primarily of T-cell origin. Since the widespread rollout of SARS-CoV-2 vaccines, several cases of CLs and non-neoplastic lymphoproliferative disorders (nn-LPDs) temporally associated with vaccination have been reported, raising concerns about a potential immunologic link.<br><br>OBJECTIVE: To systematically review the literature on cases of CLs and related nn-LPDs occurring after COVID-19 vaccination, focusing on clinical features, subtype distribution, latency to onset, and proposed pathophysiological mechanisms.<br><br>METHODS: A systematic review was conducted according to PRISMA guidelines. Case reports and series describing new-onset or relapsed CLs or nn-LPDs temporally following SARS-CoV-2 vaccination were included. Demographic, clinical, histological, therapeutic and temporal data were extracted and analysed.<br><br>RESULTS: Fifteen manuscripts encompassing 35 cases met the inclusion criteria. Eighteen (51.4%) were histologically confirmed CLs, most commonly lymphomatoid papulosis (n&#x2009;=&#x2009;9), followed by S&#xe9;zary syndrome (n&#x2009;=&#x2009;3) and mycosis fungoides (n&#x2009;=&#x2009;2). The remaining 17 cases (48.6%) were classified as nn-LPDs, including cutaneous lymphoid hyperplasia, lymphomatoid reactions and CD4+ small/medium T-cell lymphoproliferative disorders. CD30 positivity was noted in 76.2% of the cases with available immunophenotyping. Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine. In the 17 new-onset CLs, time to onset ranged from 3 to 42&#x2009;days, with most cases clustering within 14&#x2009;days.<br><br>CONCLUSIONS: Most of the cases were low-grade T-cell CLs and nn-LPDs. Although a causal relationship cannot be established, the short latency observed in many new-onset cases raises the possibility that some patients may have harboured an undiagnosed disease, with vaccination acting as a trigger for clinical manifestation or for raised awareness. These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.},
}
@article {pmid42256801,
year = {2026},
author = {Whalley, R and Primdal, A and Hardie, I and Xiao, Z and Auyeung, B},
title = {Maternal SARS-CoV-2 infection during pregnancy and child neurodevelopmental outcomes: A systematic review and meta-analysis of observational studies.},
journal = {Preventive medicine reports},
volume = {67},
number = {},
pages = {103508},
pmid = {42256801},
issn = {2211-3355},
abstract = {OBJECTIVE: To assess: (a) associations between prenatal SARS-CoV-2 exposure and early childhood neurodevelopmental outcomes, and (b) whether these varied by infection trimester.<br><br>METHODS: We conducted a systematic review and meta-analysis of observational studies modelling the neurodevelopmental outcomes of children prenatally exposed to SARS-CoV-2 compared to unexposed children. PubMed and PsychInfo were systematically searched from inception to March 2025. Primary analysis was random-effects modelling of overall associations. Secondary analysis assessed variation by trimester via standardised mean differences (SMD).<br><br>RESULTS: 11 observational studies were included. Overall, there was no statistically significant association between prenatal SARS-CoV-2 exposure and early childhood neurodevelopmental outcomes, both before (odds ratio: 1.08; 95% confidence intervals: 0.82, 1.42) and after (odds ratio: 0.98; 95% CI: 0.81, 1.17) excluding high variance studies. First trimester prenatal SARS-CoV-2 exposure was associated with poorer neurodevelopmental scores (3.87; 95% CI: 3.19, 4.55) than prenatal exposure in the second trimester (6.07; 95% CI: 5.11, 7.03) or third trimester (6.31; 95% CI: 5.54, 7.09). However, this analysis was limited to three studies only, with high heterogeneity between studies.<br><br>CONCLUSIONS: Prenatal SARS-CoV-2 exposure is not associated with early childhood neurodevelopmental outcomes. Future research should keep monitoring associations as more data becomes available. More robust research is required on trimester-specific associations.},
}
@article {pmid42256874,
year = {2026},
author = {Jalilian, S and Bastani, MN and Afsharzadeh, F},
title = {Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".},
journal = {Biomarker insights},
volume = {21},
number = {},
pages = {11772719261452224},
pmid = {42256874},
issn = {1177-2719},
abstract = {In the context of COVID-19, a range of neglected biomarkers provide critical insights into the mechanisms of the disease and potential therapeutic targets. This review aims to address this gap by systematically analyzing the diagnostic and prognostic potential of these neglected biomarkers, with particular emphasis on their mechanistic connections to COVID-19 pathophysiology. Reduced levels of adiponectin and prostacyclin (PGI2) and elevated level of endothelin are associated with endothelial dysfunction, whereas elevated levels of endocan and endoglin are indicative of elevated vascular inflammation. Increased concentrations of markers such as angiopoietin, E-selectin, P-selectin, ICAM-1, and VCAM-1 suggest endothelial activation, while higher levels of fractalkine, galectin, HMGB1, and osteopontin reflect an ongoing inflammatory state. Immunological markers, including HMGB1, neopterin, and serum amyloid A, are significantly elevated, underscoring prolonged immune activation associated with severe COVID-19. Elevated levels of matrix metalloproteinases (MMPs) and soluble urokinase plasminogen activator receptor (SuPAR) highlight tissue remodeling and fibrinolytic imbalance related to vascular injury. Additionally, increases in soluble fms-like tyrosine kinase-1 (sFlt-1) and pentraxin reflect inflammatory pathways that exacerbate endothelial dysfunction. Elevated levels of syndecan-1 reflect endothelial glycocalyx degradation and impaired endothelial barrier integrity. Increased von Willebrand factor (vWF) indicates endothelial activation and injury with a prothrombotic shift. Elevated surfactant protein D (SP-D) is a marker of pulmonary epithelial injury and disruption of the alveolar-capillary interface. Other biomarkers, such as the receptor for advanced glycation end products (RAGE) and MR-proADM, signal oxidative stress and endothelial damage. Collectively, these biomarkers emphasize the extensive vascular and endothelial impairment in COVID-19, suggesting their utility as diagnostic tools and potential targets for therapeutic intervention against the systemic effects of the disease. This review advocates for the integration of these biomarkers into standard monitoring and treatment protocols for COVID-19, thereby enhancing personalized care. Furthermore, our analysis underscores the necessity for additional research into the roles of these biomarkers in other endothelial disorders, ultimately contributing to a more nuanced approach to managing viral infections characterized by vascular complications.},
}
@article {pmid42257651,
year = {2026},
author = {Vicente, C and Froes, F and Lopalco, PL and Heffernan, C and Nilforooshan, R and Martin, F and Leroux-Roels, I and Nesher, L and Déplanque, T and Dani, N and Coelho, A and Pinto de Castro, N and Tayarani-Binazir, K},
title = {From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2684962},
doi = {10.1080/14760584.2026.2684962},
pmid = {42257651},
issn = {1744-8395},
mesh = {Humans ; *Respiratory Syncytial Virus Infections/prevention &amp; control/epidemiology ; *Respiratory Syncytial Virus Vaccines/administration &amp; dosage/immunology/adverse effects ; *Vaccination/statistics &amp; numerical data/methods ; Adult ; Vaccine Efficacy ; Respiratory Syncytial Virus, Human/immunology ; },
abstract = {INTRODUCTION: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection, with substantial morbidity and mortality in older adults, yet its impact in this population remains underrecognized compared with childhood RSV. Despite the availability of effective vaccines, RSV immunization in adults is underutilized, as observed for other vaccines.<br><br>AREAS COVERED: We summarize the RSV burden in adult populations and present clinical and real-world evidence supporting efficacy/effectiveness and safety of three approved RSV vaccines. We explore barriers to adult vaccine uptake - including limited awareness, lack of reimbursement, mistrust, misinformation, and inconsistent guidance - and highlight broader benefits of adult immunization, including reducing antimicrobial resistance and promoting healthy aging. We conclude that to improve uptake, communication strategies should include messages that emphasize how vaccination prevents severe illness, preserves independence, and supports everyday well-being. We highlight that a life-course immunization strategy, built on trust, is essential to achieve equitable protection across populations.<br><br>EXPERT OPINION: Adult vaccines remain undervalued despite their proven safety and benefits, which extend beyond infection prevention to support healthy aging and reduce antimicrobial resistance. To maximize their impact, strategies such as harmonizing recommendations, improving reimbursement, leveraging digital tools, and addressing vaccine hesitancy through better communication and research are essential.},
}
@article {pmid42257882,
year = {2026},
author = {Meybohm, P and Baron, DM and Fries, D and Lasocki, S and Vlaar, APJ and Zacharowski, K and Choorapoikayil, S},
title = {Patient blood management in general intensive care patients.},
journal = {Intensive care medicine},
volume = {52},
number = {6},
pages = {1290-1305},
pmid = {42257882},
issn = {1432-1238},
mesh = {Humans ; *Critical Care/methods ; *Anemia/therapy ; Critical Illness/therapy ; Intensive Care Units/organization &amp; administration ; *Blood Transfusion/methods ; Erythropoietin/therapeutic use ; Platelet Transfusion/methods ; },
abstract = {PURPOSE: Critically ill and high-risk perioperative patients requiring intensive care are often multimorbid and depend on rapid, highly specialized management. While most comorbidities are difficult to modify in the acute setting, anemia, particularly iron-defi ciency anemia, represents a potentially modifiable risk factor. Clinicians are also often confronted with complex alterations in hemostasis that require rapid assessment and targeted therapeutic interventions, including the optimal use of blood products. This narrative review summarizes the current evidence on Patient Blood Management strategies, including anemia management, the use of small-volume tubes, and the appropriate use of blood products in intensive care unit patients.<br><br>RESULTS: Intravenous iron supplementation can safely raise hemoglobin to a clinically meaningful degree. Erythropoietin therapy may also raise hemoglobin, but its use should remain selective given uncertain thromboembolic risk. Small-volume blood collection tubes and closed blood-conservation systems should be routinely used to reduce iatrogenic anemia. Current evidence supports restrictive red blood cell transfusion strategies in most clinical settings, particularly in patients with gastrointestinal bleeding. Similarly, a restrictive platelet transfusion strategy is supported by current evidence. Prophylactic platelet transfusion should be reserved for high-risk hematologic malignancies. In other critically ill patients with severe thrombocytopenia, a therapeutic (bleeding-driven) approach is preferred. Finally, current evidence does not support prophylactic fresh frozen plasma transfusion in non-bleeding patients.<br><br>CONCLUSIONS: Overall, these findings support the implementation of Patient Blood Management strategies that optimize blood health and promote safer, more individualized care in critically ill patients.},
}
@article {pmid42258511,
year = {2026},
author = {Bolshov, O and Chumachenko, D},
title = {Reinforcement learning for policymaking in epidemic control: A scoping review.},
journal = {PloS one},
volume = {21},
number = {6},
pages = {e0351176},
pmid = {42258511},
issn = {1932-6203},
mesh = {*Reinforcement Machine Learning ; Humans ; *Policy Making ; *Epidemics/prevention &amp; control ; *COVID-19/epidemiology/prevention &amp; control ; Algorithms ; },
abstract = {BACKGROUND: Managing an epidemic demands policies that respond at the pace of the outbreak. Conventional rule‑based interventions struggle to keep up, prompting interest in reinforcement learning (RL) for designing non‑pharmaceutical interventions (NPIs). However, current evidence is fragmented across diverse models and reporting styles.<br><br>OBJECTIVES: To systematically map how RL is applied for epidemic NPI design, describe modeling choices, algorithm architectures, evaluation practices, and identify trends and research gaps.<br><br>METHODS: Peer-reviewed studies (2014-2025, English) that applied deep RL to select NPIs were retrieved from IEEE Xplore, ACM Digital Library, ScienceDirect, and Scopus, searched on December 23, 2025. Reference list scanning supplemented database results. Predefined data items (bibliographic details, epidemic and RL model characteristics, experiments, validation methods, outcomes) were charted and summarized descriptively.<br><br>RESULTS: Of 512 retrieved records, 10 met the inclusion criteria, and three additional studies were identified via reference-list scanning, yielding 13. Five employed value&#x2011;based methods, four policy&#x2011;gradient, and four hybrid; one study additionally incorporated model-based planning. Six simulations relied on compartmental models, six on agent&#x2011;based models, and one on a hybrid model. Action spaces were predominantly discrete restriction levels. Five studies incorporated sequence-modeling techniques to include temporal context into a state space. Eleven studies designed reward functions as a trade-off between pandemic severity and socio-economic cost. According to the reviewed studies, RL policies across various settings outperform heuristic, rule-based, and historical baselines in reducing infections, deaths, or lockdown duration while limiting economic loss.<br><br>CONCLUSIONS: RL shows promise for adaptive epidemic control. Comparison is hampered by simplified economic costs, inconsistent calibration rigor, varied evaluation metrics, and limited uncertainty or policy robustness analysis. Future work should establish common benchmark environments and reporting standards, incorporate empirically grounded economic and behavioral models, adopt uncertainty-aware and probabilistic RL, develop more sophisticated control spaces, investigate more advanced algorithms, and validate learned policies prospectively to enable real-world deployment.},
}
@article {pmid42258788,
year = {2026},
author = {León-Herrera, S and Sánchez-Castro, M and Luisa Neves, A and Rodríguez-Pérez, MP and Jobim Fischer, V and Hutmacher, D and Aldakhil, R and Vaillancourt de Dios, M and Anjos de Almeida, V and Oliván-Blázquez, B and Magallón-Botaya, R and Benoy, C and Gómez-Bravo, R},
title = {Digital Interventions Addressing Cognitive and Psychological Symptoms in Long COVID: Scoping Review of Multicomponent Approaches.},
journal = {Interactive journal of medical research},
volume = {15},
number = {},
pages = {e80616},
pmid = {42258788},
issn = {1929-073X},
abstract = {BACKGROUND: Long COVID, or postacute COVID-19 syndrome, presents with persistent cognitive and psychological symptoms such as brain fog, anxiety, depression, and fatigue, significantly impacting quality of life and daily functioning. Digital health interventions offer a scalable, accessible solution to bridge care gaps, especially where conventional neuropsychological support is limited. However, evidence regarding their effectiveness for neuropsychiatric symptoms in long COVID remains fragmented.<br><br>OBJECTIVE: This scoping review aimed to systematically identify and map the existing evidence on digital interventions targeting cognitive and psychological symptoms in individuals with long COVID. The review also sought to categorize intervention types, assess reported outcomes, and identify methodological gaps to inform future clinical and research priorities.<br><br>METHODS: The review followed the Arksey and O'Malley framework and adhered to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. Comprehensive searches were conducted in 4 databases (PubMed, Scopus, Web of Science, and ScienceDirect) from December 2024 to February 2025. Eligible studies included peer-reviewed and gray literature published in English or Spanish since 2020. Studies were screened and selected based on predefined inclusion and exclusion criteria. Data were extracted using a standardized charting form and synthesized narratively, with thematic grouping by intervention type.<br><br>RESULTS: Of 888 records identified, 25 (2.82%) were included. Intervention types encompassed telehealth platforms, mobile health apps, virtual reality, online cognitive and psychological therapies, game-based cognitive training, neuromodulation (transcranial direct current stimulation), and multicomponent programs. Most studies reported improvements in psychological well-being, emotional regulation, and cognitive domains such as attention and memory. However, findings varied, with some interventions showing no significant cognitive gains or sustained effects. Common limitations included small sample sizes, lack of control groups, heterogeneity in outcomes and intervention protocols, and short follow-up durations. The underrepresentation of older adults and underserved populations was also noted.<br><br>CONCLUSIONS: Digital interventions show promise for addressing cognitive and psychological symptoms in long COVID, particularly when delivered as multicomponent programs. Nonetheless, the evidence base remains preliminary. Future research should prioritize high-quality randomized trials with standardized outcome measures, long-term follow-up, and diverse participant samples. Addressing barriers related to digital literacy and access will be essential to ensure equity and real-world effectiveness.},
}
@article {pmid42260222,
year = {2026},
author = {Bravo-Hernández, Z and Márquez-Domínguez, L and Domínguez-Ramírez, L and Martínez-de la Peña, CF and Santos-López, G},
title = {Programmed -1 ribosomal frameshifting in SARS-CoV-2: molecular mechanisms and implications for antiviral targeting.},
journal = {Virus genes},
volume = {},
number = {},
pages = {},
pmid = {42260222},
issn = {1572-994X},
support = {R-2020-785-085//Instituto Mexicano del Seguro Social/ ; },
abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome is organized into two functional regions. The 5' region comprises an open reading frame (ORF1a) that encodes the polyprotein pp1a and, through a programmed frameshifting event, enables the production of the extended polyprotein pp1ab. These polyproteins are processed by the viral proteases 3CLpro and PLpro into 16 nonstructural proteins (nsps). Nsps 1-11 participate in polyprotein processing, formation, and regulation of the replication-transcription complex, and modulation of host immune responses. Nsps 12-16 form the core of the viral RNA synthesis machinery and are primarily associated with RNA-dependent RNA polymerase activity, proofreading, capping, and RNA modification, while also functioning in coordination with additional nsps. The 3' functional region of the genome encodes structural (S, E, M, and N) and accessory proteins (e.g., 3a, 6, 7a, 8, and 9b) that contribute to viral assembly, replication efficiency, and pathogenicity. Synthesis of pp1ab depends on a programmed -1 ribosomal frameshifting (-1 PRF) event mediated by cis-acting RNA elements that induce a one-nucleotide shift in the 5' direction of the ribosome. This mechanism is critical for maintaining the stoichiometric balance of replication proteins. Here, we review recent current insights into the molecular mechanisms and structural dynamics of -1 PRF in SARS-CoV-2 and discuss its potential as a therapeutic target for antiviral intervention across clinically relevant coronaviruses.},
}
@article {pmid42261850,
year = {2026},
author = {Choi, K and Choi, S and Joe, D and Seo, YS and Ham, J and Chung, H and Ramadan, Y and Park, YS},
title = {Myocarditis After mRNA Vaccination: A Metabolic-Innate Immune Cascade Centered on Lipid Nanoparticles.},
journal = {Mediators of inflammation},
volume = {2026},
number = {1},
pages = {e8991922},
pmid = {42261850},
issn = {1466-1861},
support = {RS-2024-00346434//Ministry of Science, ICT and Future Planning/ ; 2020R1I1A1A01067800//Ministry of Education/ ; },
mesh = {*Myocarditis/immunology/metabolism/etiology ; Humans ; Animals ; *Nanoparticles/chemistry ; *Immunity, Innate/physiology ; *Lipids/chemistry ; Inflammasomes/metabolism ; *Vaccination/adverse effects ; *mRNA Vaccines/adverse effects ; 2019-nCoV Vaccine mRNA-1273 ; *RNA, Messenger ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Liposomes ; },
abstract = {mRNA vaccine-associated myocarditis is a rare but clinically important adverse event whose pathogenesis remains incompletely understood. Initial hypotheses focused primarily on the spike protein antigen, with growing preclinical evidence implicating the lipid nanoparticle (LNP) delivery system as an additional and potentially important contributor to myocardial inflammation. Here, we propose a multi-hit model that integrates LNP-driven mechanisms as a central pathogenic axis, initiated by the systemic distribution and accumulation of LNPs in the heart. While the mRNA payload is cleared within days, the synthetic ionizable lipids -ALC-0315 (BNT162b2) and SM-102 (mRNA-1273) persist significantly longer than the mRNA payload itself. These two lipids differ in biodegradability and pharmacokinetic distinctions, together with differences in lipid dose and formulation, they may contribute to the divergent myocarditis rates observed between the two vaccine products. In this suggesting review, the first hit" involves the disruption of myocardial energy metabolism by these lipids, which can integrate into cellular membranes and impair mitochondrial fatty acid oxidation. This is compounded by a second hit of direct innate immune activation, preclinical studies demonstrate that LNPs engage pattern-recognition receptors (PRRs) like toll-like receptors (TLRs) and the NLRP3 inflammasome, leading to the release of pro-inflammatory cytokines such as IL-1β and IL-18. Inflammation is then amplified via Damage-associated molecular patterns (DAMPs) released from stressed cardiomyocytes. The clinical outcome-ranging from self-limited mild myocarditis to fulminant disease with diverse histopathological patterns-is likely shaped by host susceptibility factors, including sex hormones, genetic predisposition, and prior immune priming, that modulate the intensity of this pathogenic cascade.},
}
@article {pmid42262130,
year = {2026},
author = {Yu, H-M and Zhu, M-L and Zhao, Y-L and Tan, J-X and Luo, S-C and Pang, P-P and Zheng, C-B},
title = {Research progress on the association between viruses and cardiac diseases.},
journal = {Journal of virology},
volume = {100},
number = {7},
pages = {e0038326},
pmid = {42262130},
issn = {1098-5514},
support = {202105AG070012//Yunnan Science and Technology Talent and Platform Program/ ; 202401AY070001-303//Yunnan Provincial Science and Technology Department/ ; 202303AC100026, 202403AC100033//Yunnan Key Research and Development Program/ ; CXTD202202//Program Innovative Research Team in Science and Technology in Kunming Medical University/ ; FWCY-BSPY2025074//Science and Technology Projects of Yunnan Universities Serving Key Industries/ ; 2024XKTDPY12, 2024XKTDTS12//First-Class Discipline Team of Kunming Medical University/ ; 202505AS350006//Yunnan Talent Suppot Plant/ ; 2025S185//Graduate Student Innovation Foundation of Kunming Medical University/ ; 2025Y0411//Yunnan Provincial Department of Education Scientific Research Fund Project/ ; 82460105, 82570588//National Natural Science Foundation of China/ ; 202301AT070270//Yunnan Provincial Science and Technology Department/ ; },
mesh = {Humans ; *Heart Diseases/virology ; *Virus Diseases/complications/virology/drug therapy ; Antiviral Agents/therapeutic use ; SARS-CoV-2 ; COVID-19 ; Myocarditis/virology ; Animals ; },
abstract = {Virus-related cardiac diseases encompass a diverse spectrum of cardiovascular pathologies caused by direct viral infection and indirect immune-mediated injury. Major cardiotropic and cardioactive viruses-including severe acute respiratory syndrome coronavirus 2, influenza virus, human immunodeficiency virus, arboviruses (dengue virus, chikungunya virus, Zika virus), enteroviruses (coxsackievirus B3), and human cytomegalovirus-contribute to myocardial injury manifesting as myocarditis, pericarditis, arrhythmias, acute and chronic heart failure, and thromboembolic complications. Mechanisms of cardiac involvement are multifactorial, involving direct infection of cardiac cells leading to cytopathic effects and innate immune activation, dysregulated adaptive immune responses promoting myocardial inflammation and fibrosis, electrophysiological disturbances, and systemic effects such as endothelial dysfunction and prothrombotic states that precipitate ischemic events. Clinical manifestations range from subclinical injury to fulminant myocardial inflammation and may also include long-term sequelae, such as post-acute cardiovascular symptoms, as observed in long COVID cases. Therapeutic strategies emphasize early antiviral treatment when effective agents exist, judicious immunomodulation based on viral replication status, and supportive management of cardiac dysfunction and arrhythmias. Prevention through vaccination, personal protective measures, vector control, and optimization of cardiovascular risk factors remains pivotal to reduce the burden of virus-associated cardiovascular diseases. Future research requires improved diagnostic precision, mechanistic elucidation, and randomized trials to optimize antiviral and immunomodulatory interventions and to develop vaccines for currently unmet viral targets. An integrated, mechanism-informed approach across prevention, acute management, and long-term care is essential to mitigate the cardiovascular morbidity and mortality attributable to viral infections.},
}
@article {pmid42262134,
year = {2026},
author = {Artusa, V and Limanaqi, F and Santacroce, E and Clerici, M and Cossarizza, A and Biasin, M and Gibellini, L and Trabattoni, D},
title = {Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.},
journal = {Journal of virology},
volume = {100},
number = {7},
pages = {e0019126},
pmid = {42262134},
issn = {1098-5514},
support = {2022-PNRR-P2022ALFEK//European Union - Next Generation EU under the National Recovery and Resilience Plan/ ; },
mesh = {*alpha-Synuclein/metabolism/immunology/genetics ; Humans ; *Host-Pathogen Interactions/immunology ; Animals ; Immunity, Innate ; Nervous System/immunology/virology/metabolism ; Parkinson Disease/immunology ; Proteostasis ; },
abstract = {Alpha-synuclein (α-syn) is best known as a presynaptic protein that supports synaptic vesicle dynamics and neurotransmission. Conversely, misfolded or aggregated α-syn represents a hallmark of synucleinopathies, including Parkinson's disease. Beyond the nervous system, α-syn has been detected in peripheral compartments, including blood cells and selected epithelial tissues, although the robustness and context dependence of expression outside neuronal and erythroid lineages remain under active investigation. Also, it can be released extracellularly through unconventional secretion or cell damage. These observations have reframed α-syn as an immune-relevant molecule positioned at host-pathogen interfaces, endowed with antimicrobial peptide-like and damage-associated molecular pattern-like properties that enable shaping of both innate and adaptive immunity. Increasing evidence indicates that viral challenge alters α-syn expression, localization, and conformational states in central and peripheral settings, in part through interferon-dependent programs that couple antiviral immunity with cellular homeostasis. A plethora of RNA viruses, such as influenza virus, flavivirus, enterovirus, and coronavirus, perturb α-syn abundance, post-translational modifications, trafficking, secretion, and aggregation propensity. These effects converge on shared mechanisms that include altered proteostasis, autophagy-lysosomal dysfunction, oxidative and mitochondrial injury, and inflammatory signaling. Importantly, outcomes are highly context dependent, ranging from cell-intrinsic antiviral restriction to aggregation-prone states that may fuel chronic inflammation and neurodegeneration. Collectively, the evidence discussed herein supports a dual framework in which α-syn contributes to antiviral defense; yet, under conditions of sustained inflammation or impaired clearance, it may undergo pathological transformation that promotes neuronal damage. Defining when virus-induced α-syn responses are protective versus pathogenic, and clarifying their relevance to human disease, will be critical for developing strategies that target host-virus interactions, neuroinflammation, and α-syn proteostasis in infection-associated synucleinopathies.},
}
@article {pmid42262426,
year = {2026},
author = {Sivasubramaniam, P and Alagarsamy, K and Michael, MM and Arumugam, TU and Antonysamy, M},
title = {IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.},
journal = {Archives of microbiology},
volume = {208},
number = {9},
pages = {},
pmid = {42262426},
issn = {1432-072X},
mesh = {*Immunoglobulins/immunology/therapeutic use ; Humans ; Animals ; Immunization, Passive/methods ; *Egg Yolk/immunology ; COVID-19 ; SARS-CoV-2/immunology ; *Respiratory Tract Infections/immunology/therapy ; Pandemics ; Chickens ; },
abstract = {The respiratory system is under strain due to rising infections and diseases affecting millions globally, with antimicrobial resistance, allergens, and the recent pandemic further burdening public health. These challenges emphasize the critical need for support-based adjunct or combination biologics as essential measures for combating disease pathogenesis and optimizing the rational use of antimicrobials and steroids. Passive immunization represents an encouraging approach, with immunoglobulin Y (IgY) derived from hyperimmunized hen egg yolk emerging as a promising, cost-effective, and ethical alternative to conventional mammalian-derived antibodies. IgY technology addresses challenges including stability, process complexity, and antimicrobial resistance, offering practical advantages for human and animal applications. This review examines the application of IgY technology against majorly evolving respiratory pathogens and conditions - influenza virus, SARS-CoV-2, respiratory syncytial virus, Mycobacterium tuberculosis, Streptococcus pneumoniae, and respiratory allergens - highlighting IgY technology's significance as biologics across viral, bacterial, and allergen-driven respiratory diseases. Evidence from the IgY literature is broadly encouraging, demonstrating efficacy in pathogen neutralization, virulence attenuation, and hypersensitivity suppression, particularly through intranasal and oral delivery routes. IgY technology represents an affordable and scalable tool for low- and middle-income countries (LMICs) and beyond. Future priorities should include standardized antibody production protocols, optimized formulations and dosing strategies, rational point-of-care diagnostic integration, and well-designed prospective trials in high-burden settings to bring forth IgY technology's translational potential against prevailing and forthcoming respiratory afflictions.},
}
@article {pmid42263302,
year = {2026},
author = {Tyagi, A and Singh, K and Singh, PM and Gerges, FJ},
title = {Sympathetic and Parasympathetic Ganglion Blocks for Treatment of Long COVID-19 Symptoms: A Scoping Review.},
journal = {Pain physician},
volume = {29},
number = {3},
pages = {E151-E161},
pmid = {42263302},
issn = {2150-1149},
mesh = {Humans ; *Autonomic Nerve Block/methods ; *Ganglia, Parasympathetic/drug effects ; *Ganglia, Sympathetic/drug effects ; Pandemics ; *Post-Acute COVID-19 Syndrome/therapy ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Long COVID-19 affects approximately 10-30% of individuals who are infected with SARS-CoV-2 and is associated with persistent functional impairment and reduced quality of life. The heterogeneous, multisystemic nature and nonspecific symptomatology of long COVID-19 makes its treatment challenging. This scoping review evaluates existing evidence on sympathetic and parasympathetic ganglion blocks as potential interventions for patients suffering from long COVID-19.<br><br>OBJECTIVE: Our primary objective was to assess the effectiveness of sympathetic and parasympathetic ganglion blocks in treating patients with long COVID-19 by identifying the most commonly reported symptoms, symptom response to different block regimens, and any adverse effects associated with these interventions.<br><br>STUDY DESIGN: A scoping review.<br><br>SETTING: Outpatient clinics where patients received sympathetic blocks or parasympathetic blocks.<br><br>METHODS: A comprehensive search was conducted across PubMed, Embase, Cochrane CENTRAL, Web of Science, Google Scholar, and ClinicalTrials.gov using MeSH and free-text terms related to "long COVID-19," "post-COVID-19 syndrome," and "sympathetic ganglion blocks" and "parasympathetic blocks." Only English-language articles were included. Pre-print repositories and reference lists were also manually screened.<br><br>RESULTS: A total of 22 articles covering 505 patients were included in this review. The most frequently studied symptoms were olfactory dysfunction, fatigue, headache, and cognitive disturbances. The most commonly utilized intervention was the stellate ganglion block. The available evidence suggests that the stellate ganglion block could be an effective treatment for dysautonomia symptoms and cognitive dysfunction related to long COVID-19. Sphenopalatine ganglion block may be an effective option to treat headaches in long COVID-19 patients who are refractory to other treatments.<br><br>LIMITATIONS: The significant existing variations in treatment regimens precluded our ability to do a quantitative analysis. Reporting bias from case reports and small observational studies should also be considered.<br><br>CONCLUSIONS: Stellate ganglion blocks may offer therapeutic benefit for the dysautonomia and cognitive dysfunction associated with long COVID-19. Sphenopalatine ganglion blocks have shown promise in managing refractory headache symptoms in this population. Further well-designed, placebo-controlled randomized studies that employ validated outcome measures are required to establish the efficacy of sympathetic ganglion blocks in the treatment of long COVID-19.},
}
@article {pmid42263636,
year = {2026},
author = {Mohd Pakri, MA and Khalid, NA and Shah, JA and Mohamed Shaffril, HA},
title = {Factors influencing farmer's adaptation potential towards post COVID-19 impacts: A systematic literature review.},
journal = {Journal of environmental management},
volume = {411},
number = {},
pages = {130134},
doi = {10.1016/j.jenvman.2026.130134},
pmid = {42263636},
issn = {1095-8630},
mesh = {*Farmers/psychology ; *COVID-19 ; Humans ; *Agriculture ; *Adaptation, Psychological ; Pandemics ; SARS-CoV-2 ; Coping Skills ; },
abstract = {The COVID-19 pandemic has had a profound impact on the global agricultural sector, affecting all stages of the food system, from production to consumption. This study aims to comprehensively explore the factors influencing farmers' coping potential to adapt to the challenges posed by the COVID-19 crisis. A systematic literature review (SLR) was conducted, adhering to the ROSES (Reporting Standards for Systematic Evidence Syntheses) methodology. Publications were selected from two major academic databases, Scopus and Web of Science. Through thematic analysis, seven key themes emerged: (1) resource management and input accessibility, (2) diversification of activities and strategic planning, (3) community networks and cooperation, (4) digital transformation in agriculture, (5) individual farmer behaviors and capabilities, (6) market chain resilience and adaptation, and (7) policy support and government initiatives. These themes were further refined into 19 sub-themes, shedding light on the multifaceted nature of farmers' coping potential during crises. This review not only synthesizes existing research but also offers novel insights into the adaptation strategies of farmers, highlighting critical areas for policy intervention, capacity building, and future research to enhance agricultural resilience in the face of global disruptions.},
}
@article {pmid42263803,
year = {2026},
author = {Rambabu, I and Baskar, G and Suliman, M and Saeed, M and Radhakrishnan, M and Balu, R and Palaniyandi, T},
title = {Engineered CRISPR-Cas systems for transcriptional regulation and precision molecular diagnostics: advances, challenges, and emerging microfluidic integration.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {591},
number = {},
pages = {121145},
doi = {10.1016/j.cca.2026.121145},
pmid = {42263803},
issn = {1873-3492},
abstract = {CRISPR-Cas technology has evolved rapidly from a bacterial adaptive immune system to transformative use in molecular diagnostic and genomic engineering. Beyond traditional genome-editing capabilities, newly engineered versions of CRISPR/Cas can be used for programmable transcriptional regulation, epigenetic modification, molecular imaging, and ultrasensitive nucleic acid detection. Specifically, catalytic-inactive Cas proteins like dCas9 and dCas12 retain their ability to bind specific sequences on DNA but do not cleave it. Therefore, these proteins can be reversibly regulated by either CRISPRi or CRISPRa to alter gene expression. Thus, they represent powerful tools for both functional genomic studies and synthetic biological applications. Advances in CRISPR engineering have recently greatly increased the diagnostic potential of Cas12 and Cas13 enzymes. For example, collateral cleavage activity allowed the creation of CRISPR-based diagnostic platforms (SHERLOCK, DETECTR and FELUDA), which can detect target DNA/RNA sequences at high sensitivity and specificity. Moreover, they were demonstrated to work in detecting several infectious pathogens (SARS-CoV-2, Zika virus, and M. tuberculosis) and thus have significant value in point-of-care testing, especially when there is limited availability of resources. CRISPR systems are also being combined with increasing frequency with epigenetic regulators, fluorescence microscopy methods, biosensors, and lab-on-a-chip platforms that incorporate microfluidics to provide improved molecular analysis and automated diagnosis. The purpose of this review is to describe how engineered CRISPR-Cas systems have been developed from primarily genome editing tools into multi-functional platforms for transcriptional regulation, epigenetic engineering, diagnostics, imaging, and emerging microfluidic integrations. Additionally, this review will address some of the current challenges that exist with using CRISPR-based technologies, including off-target effects, delivery efficiency, diagnostic standardization, scaling up production, and translating these technologies clinically.},
}
@article {pmid42266820,
year = {2026},
author = {Xing, K and Wen, J and Xing, D and Liang, B},
title = {Digital first primary care in NHS England: evaluating alignment with patient-centered care and implications for future practice.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1723805},
pmid = {42266820},
issn = {2673-253X},
abstract = {The Digital First Primary Care (DFPC) model, introduced by NHS England, aims to enhance healthcare accessibility and efficiency by leveraging digital tools such as telemedicine, digital triage, and virtual consultations. In this structured narrative review, we synthesized UK-focused empirical, policy, and implementation literature to examine DFPC through the patient-centered care (PCC) domains of access, autonomy, shared decision-making, continuity, relational quality, and equity. The available evidence suggests that DFPC can improve convenience, flexibility, and timeliness of first contact for some patients, but these gains are unevenly distributed and depend heavily on system design, workflow integration, and patient capability. Evidence generated during the COVID-19 emergency should not be conflated with the evaluation of routine, policy-driven post-pandemic DFPC, because the goals, constraints, and patient expectations differ across these contexts. We therefore argue that DFPC aligns with PCC only when implemented within a flexible hybrid model that preserves modality choice, supports continuity, provides safe escalation to in-person care, and actively mitigates digital exclusion. Future research should prioritize patient-reported experience, continuity, safety, and equity outcomes under routine post-pandemic conditions.},
}
@article {pmid42267299,
year = {2026},
author = {Zu, Y and Wang, H and Wu, J and Tang, C and Han, R and Fang, F},
title = {Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review.},
journal = {Frontiers in endocrinology},
volume = {17},
number = {},
pages = {1712510},
pmid = {42267299},
issn = {1664-2392},
mesh = {Adult ; Female ; Humans ; Betacoronavirus ; Calcium/therapeutic use ; *COVID-19/complications ; Follow-Up Studies ; Hashimoto Disease/complications ; Hypocalcemia/etiology ; *Hypoparathyroidism/blood/diagnosis/virology ; Pandemics ; Parathyroid Hormone/blood ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; },
abstract = {Beyond its predominant respiratory involvement, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has also been implicated in endocrine dysfunction. Hypocalcemia is common in Coronavirus Disease 2019 (COVID-19), yet the insufficient compensatory rise in parathyroid hormone (PTH) and its long-term outcomes remain poorly characterized. We describe a young adult Chinese woman with no history of neck surgery who developed severe symptomatic hypocalcemia shortly after acute SARS-CoV-2 infection. Laboratory evaluation revealed inappropriately low PTH levels with concomitant hyperphosphatemia, consistent with hypoparathyroidism (HypoPT). Although baseline calcium/PTH data prior to infection were unavailable, the regular calcium and vitamin D supplementation, along with serial monitoring over more than two years, demonstrated persistently suppressed PTH secretion, supporting a diagnosis of permanent HypoPT. Thyroid imaging and antibody testing confirmed coexistent Hashimoto's thyroiditis, raising the possibility of an autoimmune contribution. To contextualize this case, we reviewed 14 previously published reports of COVID-19-associated HypoPT, among which no cases originating from China were identified. Based on available data, it cannot be ruled out that SARS-CoV-2 infection may contribute to the development of new-onset HypoPT in addition to worsening pre-existing conditions. Young-onset patients without a history of surgery-particularly those whose hypocalcemia severity does not clearly parallel the severity of infection-appear to have a higher likelihood of subsequent persistent dysfunction, though this observation remains preliminary. This case, together with the literature, underscores the need for extended follow-up in patients presenting with hypocalcemia and blunted PTH responses after COVID-19. Comprehensive autoimmune evaluation and, where appropriate, genetic testing should be considered to clarify etiology and guide long-term management.},
}
@article {pmid42267411,
year = {2026},
author = {Jung, J and Cho, I and Moon, J},
title = {Factors Associated With Work Productivity Loss Among Workers During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis of Correlations.},
journal = {Workplace health &amp; safety},
volume = {},
number = {},
pages = {21650799261454290},
doi = {10.1177/21650799261454290},
pmid = {42267411},
issn = {2165-0969},
abstract = {Background:The COVID-19 pandemic disrupted work environments worldwide, increasing productivity loss through absenteeism and presenteeism. Identifying key associated factors is essential for informing workplace health strategies during public health crises. Methods/Project: A systematic review and meta-analysis were conducted following PRISMA guidelines, using comprehensive searches of seven electronic databases from inception through January 2024. Studies were systematically selected based on predefined eligibility criteria, and 24 studies examining individual and work-related factors associated with work productivity loss were included. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tools. Correlation coefficients were synthesized using a random-effects meta-analysis of correlations in STATA 17.0, and heterogeneity was evaluated using the I[2] statistic and Cochran's Q test. Findings: Twenty-one factors were analyzed. Job stress, fear of COVID-19, mental health problems, job insecurity, turnover intention, exhaustion, and job demands exhibited moderate positive correlations with productivity loss during the COVID-19 pandemic. Fear of COVID-19 and mental health problems showed relatively large positive correlations with presenteeism. General health status was the factor most strongly associated with absenteeism, exhibiting a moderate negative correlation. Conclusions/Application to Practice: These findings identify key individual and work-related determinants of productivity loss during pandemics. The results support the development of targeted workplace health promotion, mental health support, and preparedness strategies to mitigate productivity loss during future public health emergencies.},
}
@article {pmid42267834,
year = {2026},
author = {Yu, J and Li, W and Xu, Y and Tang, J},
title = {Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections.},
journal = {Clinical microbiology reviews},
volume = {},
number = {},
pages = {e0036825},
doi = {10.1128/cmr.00368-25},
pmid = {42267834},
issn = {1098-6618},
abstract = {SUMMARYThe human gut microbiotas constitute a complex microecosystem essential for host homeostasis. Among its metabolites, short-chain fatty acids (SCFAs) act as key signaling molecules linking microbial activity to host immunity and barrier function. Based on existing literature, we conducted a comprehensive analysis of the interaction between SCFAs and 11 key gut pathogens. These pathogens include bacteria (i.e., Staphylococcus aureus, Clostridioides difficile, Salmonella spp., Campylobacter jejuni, Klebsiella pneumoniae, Vibrio cholerae), fungi (i.e., Candida albicans), and viruses (i.e., SARS-CoV-2, influenza virus, respiratory syncytial virus, rotavirus). In terms of antibacterial effects, SCFAs exhibit antibacterial activity against most gut microorganisms, but they support the colonization of a few species (i.e., Campylobacter jejuni). Given the complex interactions between SCFAs and the gut microbiota, as well as their regulatory roles in infection, further investigation of the microbiota-SCFA axis is essential for developing effective strategies to prevent and treat infectious diseases. This review systematically summarizes the mechanism and clinical evidence of SCFAs in microbial infections to provide novel ideas for infectious disease management.},
}
@article {pmid42268693,
year = {2026},
author = {Zhao, V and Gutman, G},
title = {Navigating Identification and Management of Substance Use in Adolescents.},
journal = {Pediatric annals},
volume = {55},
number = {6},
pages = {e229-e233},
doi = {10.3928/19382359-20260223-05},
pmid = {42268693},
issn = {1938-2359},
mesh = {Humans ; *Substance-Related Disorders/diagnosis/therapy/epidemiology ; Adolescent ; Motivational Interviewing ; Adolescent Behavior ; COVID-19/epidemiology ; Physician's Role ; },
abstract = {Substance use in adolescents is an important public health topic. It can affect cognitive development and is associated with negative outcomes, such as school truancy, low graduation rates, and increased high-risk behaviors (eg, unprotected sex, dangerous driving), as well as high rates of suicide, substance abuse, dependence in adulthood, and death by overdose. Substance use among adolescents declined during the coronavirus 2019 pandemic and has continued to do so, resulting in the lowest rates of substance use in decades. Despite this decrease, physicians and nonphysician practitioners still need to be prepared to navigate this issue in teenagers and young adults. The role of primary care physicians and other practitioners includes promotion of abstinence from substances, using validated screening questionnaires, and treatment through motivational interviewing and harm reduction, as well as referring to specialists, higher levels of care, and rehabilitation centers as needed.},
}
@article {pmid42269323,
year = {2026},
author = {Lequipe Mamani, C and Salazar, MDT and Poma Plata, GL and Camacho Garnica, RA and Sandi Lora, F},
title = {Clinical characteristics and factors associated with mortality in critically ill COVID-19 patients at high altitude.},
journal = {Journal of critical care},
volume = {95},
number = {},
pages = {155650},
doi = {10.1016/j.jcrc.2026.155650},
pmid = {42269323},
issn = {1557-8615},
mesh = {Humans ; *Altitude ; *Critical Illness/mortality ; *COVID-19/mortality ; Retrospective Studies ; Bolivia/epidemiology ; Middle Aged ; Female ; Male ; SARS-CoV-2 ; *Polycythemia/mortality/etiology ; APACHE ; Risk Factors ; Aged ; Pandemics ; Intensive Care Units ; Hematocrit ; Fibrin Fibrinogen Degradation Products/analysis ; Blood Viscosity ; },
abstract = {OBJECTIVE: To investigate factors associated with mortality in critically ill COVID-19 patients at 3640 m above sea level (m.a.s.l.), focusing on the interaction between altitude-induced secondary erythrocytosis and virus-induced hyperviscosity.<br><br>METHODS: We conducted a retrospective cohort study of 59 adult patients with severe ARDS admitted to the ICU in La Paz, Bolivia. Severe ARDS was defined using altitude-adapted criteria.<br><br>RESULTS: Non-survivors exhibited significantly higher median hematocrit (53.4% vs 49.7%; p&#xa0;=&#xa0;0.0001) and D-dimer (29,729 vs 16,521&#xa0;ng/mL; p&#xa0;=&#xa0;0.0001) compared to survivors. An "APACHE II paradox" was observed, as survivors had significantly higher admission scores than non-survivors (24 vs 17; p&#xa0;=&#xa0;0.01). While initial ventilatory mechanics were comparable (14.3 vs 14.1&#xa0;cm H&#x2082;O; p&#xa0;=&#xa0;0.81), non-survivors experienced exclusive complications, including pneumothorax (24.2%) and pulmonary embolism (18.2%).<br><br>CONCLUSIONS: Hyperviscosity, exacerbated by altitude-induced erythrocytosis, is a primary factor associated with mortality in this environment. Traditional severity scores may not adequately stratify risk in high-altitude contexts, highlighting the need for altitude-specific protocols focusing on rheological control.},
}
@article {pmid42269957,
year = {2026},
author = {Salehinejad, MA and Fathi Jouzdani, A and Bandeira, ID and Bender, S and Bikson, M and Castelo-Branco, M and Cohen Kadosh, R and Costanzo, F and Croarkin, PE and Desarkar, P and Dyke, K and Eickhoff, S and Fitzgerald, PB and Hartwigsen, G and Koenig, J and Martino, D and Menghini, D and Mirfazeli, FS and Moliadze, V and Nitsche, MA and Oberman, LM and Siniatchkin, M and Vaziri, Z and Vicario, CM and Vöckel, J and Wischnewski, M and Wolters, CH and Zangen, A and Zaehle, T and Zomorrodi, R and Brunoni, AR},
title = {Global prevalence and disability burden of brain disorders: Impact of neurological, mental, and substance use disorders.},
journal = {Neuroscience and biobehavioral reviews},
volume = {188},
number = {},
pages = {106808},
doi = {10.1016/j.neubiorev.2026.106808},
pmid = {42269957},
issn = {1873-7528},
mesh = {Humans ; *Mental Disorders/epidemiology ; *Substance-Related Disorders/epidemiology ; Prevalence ; *Nervous System Diseases/epidemiology ; *COVID-19/epidemiology ; *Brain Diseases/epidemiology ; *Global Burden of Disease ; Disability-Adjusted Life Years ; *Persons with Disabilities/statistics &amp; numerical data ; Cost of Illness ; },
abstract = {Brain disorders-encompassing neurological, mental, and substance use disorders-account for 10 of the top 25 causes of disability worldwide according to the Global Burden of Disease (GBD) 2021 study. Despite such an impact, they have not been centrally analyzed in prior GBD studies. This paper synthesizes the latest disability-focused GBD study to quantify the prevalence and disability burden of 35 conditions from 2010 to 2021, a period marking the first decline in global health outcomes in three decades. It further incorporates disability metrics from 2021 to 2023 to contextualize post-pandemic trends. The paper covers the prevalence and disability burden of neurological, mental, and substance use disorders along with COVID-19 using disability-adjusted life-years (DALYs) and years lived with disability (YLDs) metrics. From 2010-2021, Parkinson's, Alzheimer's, and migraine (in neurological disorders), major depressive, anxiety, and eating disorders (in mental disorders), and opioid and drug use disorders (in substance use disorders) showed the greatest increases in age-adjusted prevalence rates across both sexes. In 2021, neurological disorders were the largest contributor to DALYs among brain-disorder categories, while depressive and anxiety disorders ranked as the 2nd and 6th leading causes of global YLDs. Alzheimer's disease/dementias, Parkinson's disease, autism spectrum disorder (ASD), depressive and anxiety disorders, and opioid and drug use disorders showed the largest increases in burden within their respective categories between 2010 and 2021. In both 2021 and 2023, females had higher prevalence rates of overall neurological disorders, headache/migraine, multiple sclerosis, depressive/anxiety disorders, and anorexia nervosa, while males had higher rates of stroke, Parkinson's disease, ASD/ADHD, and substance use disorders. In DALY/YLD metrics, females showed higher rates for anorexia nervosa and multiple sclerosis, and males for ASD, certain neurological disorders, COVID-19, and substance use disorders. In the 2021-2023 extension analysis, disability data showed increases in prevalence and disability of several brain disorders, mostly anxiety disorders, while the COVID-19 disability burden declined markedly by 2023. Further sex-specific disability burden metrics, key insights from each disorder, and limitations/confounds are discussed.},
}
@article {pmid42270545,
year = {2026},
author = {Louvet, A and Ntandja Wandji, LC and Mathurin, P},
title = {Updates in clinical science: Alcohol-related hepatitis.},
journal = {Journal of hepatology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jhep.2026.04.016},
pmid = {42270545},
issn = {1600-0641},
abstract = {Alcohol-related hepatitis (AH) is a complex disease associated with numerous unmet needs, particularly in diagnosis and treatment. The epidemiology of AH has evolved in recent years, reflecting changes in alcohol consumption during the COVID-19 pandemic and the increasing incidence of AH following bariatric surgery. Advances have also been made in the non-invasive diagnosis of AH, helping to reduce the need for liver biopsy, as well as in the management of infection. Several novel therapeutic strategies have been evaluated, including faecal microbiota transplantation, IL-1 receptor antagonists, oxysterols, and reduced exposure to corticosteroids or antibiotics. Although the results of these trials have been relatively disappointing, they have helped identify promising directions for future research. In patients with the most severe form of AH, particularly those who do not respond to corticosteroids, several studies have suggested that the indications for early liver transplantation could be expanded. Overall, developments over recent years have generated increased optimism regarding the management of patients with severe AH.},
}
@article {pmid42270928,
year = {2026},
author = {Sanyal, D and Chaubey, B},
title = {SARS-CoV-2 3CL protease interaction with host factors - identifying novel drug targets.},
journal = {Archives of virology},
volume = {171},
number = {7},
pages = {},
pmid = {42270928},
issn = {1432-8798},
mesh = {Humans ; *SARS-CoV-2/enzymology ; *Coronavirus 3C Proteases/metabolism ; *Host-Pathogen Interactions ; COVID-19/virology ; Immunity, Innate ; },
abstract = {SARS-CoV-2 3CL protease (3CL[Pro]) plays crucial role in the viral life cycle by releasing different non-structural proteins from viral polyproteins. It also interacts with several host factors and orchestrates different host cell pathways by cleaving key cellular factors involved in immune modulation, cellular metabolism and cell death. Several host factors have been identified as high confidence substrates of 3CL[Pro] which regulates host cellular environment both in an enzyme-dependent and enzyme-independent manner. Degradation of RIG-I, TRIM25 and NLRP12 by 3CL[Pro] downregulates the innate immune response while enzyme-independent interaction with host factors like MAVS promote both its degradation and upregulation. Cellular transcription and translation are altered by interaction of 3CL[Pro] with host proteins. It affects cell-death by interacting with factors like Gal-8, NDP52 and GSDMD. Post-COVID neurodegenerative disorders have been observed due to the downregulation of neuronal factors like NEMO and UBE3A. The spectrum of 3CL[Pro] interaction with the key host factors indicates the alternate role of viral protease that modulates host response during infection. Several 3CL[Pro] targets and their cleavage sites on the target proteins have been identified. This review highlights the crosstalk between 3CL[Pro] and different host factors as possible alternate therapeutic targets to inhibit the viral propagation as well as address the post COVID clinical issues.},
}
@article {pmid42271099,
year = {2026},
author = {Kuai, M and Li, B and Shi, Z and Huang, Q and Pan, Y and Tang, M and Gao, X and Fang, J and Lü, P},
title = {Molecular Insights Into Endometriosis for Early Detection and Therapeutic Targets.},
journal = {Reproductive sciences (Thousand Oaks, Calif.)},
volume = {33},
number = {7},
pages = {1228-1248},
pmid = {42271099},
issn = {1933-7205},
support = {Grant No. K2024018//Medical Scientific Research Foundation of Jiangsu Commission of Health/ ; KYCX24_3922//Postgraduate Research &amp; Practice Innovation Program of Jiangsu Province/ ; Grant No. Jdfyxgzx004//COVID-19 Special Fund of the Affiliated Hospital of Jiangsu University/ ; },
mesh = {Humans ; *Endometriosis/diagnosis/metabolism/therapy/drug therapy ; Female ; Early Diagnosis ; Biomarkers/metabolism ; Animals ; Signal Transduction ; *Endometrium/metabolism/pathology/drug effects ; Molecular Targeted Therapy ; },
abstract = {Endometriosis is a hormone-dependent chronic inflammatory disease associated with pain and infertility, remains diagnostically and therapeutically challenging due to its multifactorial nature. Molecular mechanisms of the dynamic changes during disease pathogenesis may help identify potential diagnostic biomarkers and therapeutic targets. This paper reviews the molecular pathological alterations in endometriosis, focusing on the regulation of sex hormones, the endometrial microenvironment, immune dysregulation, and relevant signaling pathways. The lack of reliable early detection biomarkers significantly contributes to diagnostic delays. We summarize the research progress on biomarkers for endometriosis, providing the latest information on early diagnosis. We also review the therapeutic strategies targeting anti-proliferative/pro-apoptotic pathways and inflammatory responses. Although challenges persist in translating mechanistic discoveries into clinical applications, preclinical evidence suggests that addressing diagnostic delays and advancing innovative therapies may hold potential for yielding targeted management strategies for this complex disease.},
}
@article {pmid42271357,
year = {2026},
author = {Javed, MN and Khan, SM and Hussain, JM and Alam, H and Sheikh, M and Saleem, Z and Parkash, S and Rani, M and Khan, M and Saleem, H and Asif, MA and Zayed, A},
title = {Effectiveness of telerehabilitation in patients with post-COVID-19: an updated systematic review and meta-analysis of randomized controlled trials.},
journal = {BMC pulmonary medicine},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12890-026-04377-x},
pmid = {42271357},
issn = {1471-2466},
abstract = {INTRODUCTION: Post-COVID-19 syndrome affects 10-15% of survivors, causing multisystem complications and significant economic burden. Telerehabilitation (TR) has emerged as a scalable solution to deliver care remotely. This study aims to re-evaluate the effectiveness of TR in improving physical and psychological outcomes in post-COVID-19 patients.<br><br>METHODS: Registered on PROSPERO (CRD420251082578) under PRISMA guidelines, we searched PubMed, Cochrane, and Scopus from April 2024 till July 2025 for randomized trials. Primary outcomes included clinical symptoms (Borg score, dyspnea) and physical function (30-s sit-to-stand test, 6-min walking distance). A random-effects model assessed pooled outcomes with heterogeneity (I[2]) and sensitivity analyses along with subgroup analysis. Additionally, publication bias and certainty of evidence using Gradepro was performed. Risk of bias was evaluated using the Cochrane ROB2 tool.<br><br>RESULTS: Twenty-eight randomized controlled trials (RCT's) comprising approximately 1,400 participants were included. TR significantly improved physical function, including the 30&#xa0;s-STS (MD&#x2009;=&#x2009;2.07; 95% CI: 1.24 to 2.90; p&#x2009;<&#x2009;0.00001) and 6MWD (MD&#x2009;=&#x2009;85.83&#xa0;m; 95% CI: 67.14 to 104.52; p&#x2009;<&#x2009;0.00001). Significant reductions were observed in dyspnea (Borg overall MD&#x2009;=&#x2009;-3.74, p&#x2009;=&#x2009;0.003) and fatigue (VASF MD&#x2009;=&#x2009;-1.83, p&#x2009;<&#x2009;0.0001). However, no significant differences were found for HADS-Anxiety (p&#x2009;=&#x2009;0.27) or HADS-Depression (p&#x2009;=&#x2009;0.11). Pulmonary function showed significant gains only in FEV1 change scores (p&#x2009;=&#x2009;0.008). Preliminary data suggests a favorable safety profile; while no serious adverse events were reported across the trials, safety was infrequently listed as a primary outcome.<br><br>CONCLUSION: TR appears to be a promising and well-tolerated modality for enhancing physical capacity and alleviating fatigue in post-COVID-19 patients, though further large-scale studies with safety as a primary endpoint are warranted to definitively establish its safety profile. While physical gains are robust, additional targeted interventions may be necessary to address psychological and pulmonary sequelae.},
}
@article {pmid42272086,
year = {2026},
author = {Jan, A and Waheed, B and Hussein, GA and Pandey, P and Sultana, H and Kumar, S and Dagnaw, M},
title = {Prevalence, Comparative Risk, and Predictors of Shock in Children With Multisystem Inflammatory Syndrome Associated With COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Journal of paediatrics and child health},
volume = {},
number = {},
pages = {},
doi = {10.1111/jpc.70470},
pmid = {42272086},
issn = {1440-1754},
abstract = {BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition associated with SARS-CoV-2 infection and is frequently complicated by cardiovascular dysfunction, particularly shock. Early recognition of shock in MIS-C is critical to reduce morbidity and mortality.<br><br>OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the prevalence, comparative risk, and predictors of shock among children with MIS-C, enhancing clinical management and informing future research.<br><br>METHODS: A systematic search of PubMed, Embase and Web of Science was conducted from database inception to 15 July 2025. Observational studies reporting prevalence, comparative risk or predictors of shock in children with MIS-C were included. Random-effects meta-analysis with Freeman-Tukey double arcsine transformation was used to estimate pooled prevalence with 95% confidence intervals (CI). Relative risks (RR) were pooled for comparative analyses. Subgroup analyses, sensitivity analyses and meta-regression were performed to explore heterogeneity. Publication bias was assessed using funnel plots and Egger's regression test.<br><br>RESULTS: Seventy studies involving 13&#x2009;263 children with MIS-C were included. The pooled prevalence of shock was 56% (95% CI: 49%-63%), although substantial heterogeneity was observed (I[2]&#x2009;=&#x2009;98.4%). Sensitivity analyses excluding studies with sample sizes <&#x2009;50 and <&#x2009;100 participants yielded pooled prevalence estimates of 50% (95% CI: 40%-59%) and 46% (95% CI: 33%-59%), respectively. Subgroup analyses demonstrated variation according to publication year and diagnostic criteria. Children with MIS-C had a significantly increased risk of shock compared with Kawasaki disease cohorts (RR&#x2009;=&#x2009;8.52, 95% CI: 1.24-58.41; p&#x2009;<&#x2009;0.05) and acute/severe COVID-19 cohorts without MIS-C (RR&#x2009;=&#x2009;4.42, 95% CI: 2.44-8.02; p&#x2009;<&#x2009;0.001). Echocardiographic abnormalities, myocardial dysfunction, elevated inflammatory markers and acute kidney injury were consistently associated with shock.<br><br>CONCLUSION: The certainty of evidence ranged from very low to low because of substantial heterogeneity, imprecision and methodological variability across studies. Despite these limitations, shock remains a frequent and serious complication of MIS-C, highlighting the importance of early cardiovascular assessment and timely recognition of high-risk children.},
}
@article {pmid42273166,
year = {2026},
author = {Alhumaid, S and Alshehri, SM and Sabr, Z and Aborshaid, FA and Noorsaeed, S and Alsaidalani, AA and Banjar, SS and Aljasem, K and AlQahtani, FA and Baltyour, SA and Bu Subaih, AJ and Alwesaibi, AA and Alghanim, AH and Al Alawi, Z and Alsaadoun, DS},
title = {Persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults: a systematic review.},
journal = {Frontiers in allergy},
volume = {7},
number = {},
pages = {1847423},
pmid = {42273166},
issn = {2673-6101},
abstract = {BACKGROUND: Viral infections are recognized triggers of acute urticaria; however, the long-term outcomes of infection-associated urticaria, including persistence, recurrence, and progression to chronic disease, remain incompletely characterized.<br><br>OBJECTIVE: To systematically review the available evidence on the persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults.<br><br>METHODS: A systematic review was conducted in accordance with PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420261319656). Electronic databases (PubMed, Embase, CINAHL, Scopus, and Web of Science) were searched from inception to 17 March 2026. Observational studies reporting long-term outcomes of infection-associated urticaria following viral infection were included. Data extraction and risk of bias assessment using the Newcastle-Ottawa Scale were performed independently by two reviewers. Due to substantial heterogeneity, findings were synthesized narratively.<br><br>RESULTS: Five studies involving 596 participants were included. Most cases of infection-associated urticaria occurred during the acute phase of infection and resolved within weeks to months. However, persistence beyond 6 months was reported in up to 9.5% of cases, and a small proportion demonstrated persistent symptoms extending beyond 1 year. Reported recurrence and chronicity rates ranged from approximately 7% to 30%, although several estimates were derived from mixed-etiology cohorts in which infection-related cases were not analyzed separately. Delayed-onset urticaria, particularly following SARS-CoV-2 infection, was associated with an increased likelihood of progression to chronic spontaneous urticaria. However, interpretation is limited by the inclusion of mixed-etiology cohorts in which viral infection was not always laboratory-confirmed or analyzed separately.<br><br>CONCLUSION: Infection-associated urticaria is typically self-limiting; however, a small but potentially clinically relevant subset of patients may develop persistent or chronic symptoms. Recognition of potential risk patterns, particularly delayed-onset urticaria in the context of SARS-CoV-2 infection, may support improved patient counselling and follow-up. Current evidence remains limited by heterogeneous study designs, mixed aetiologies, and inconsistent pathogen-specific reporting. Further prospective studies with standardized definitions and pathogen-specific analyses are needed.<br><br>https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1319656, identifier CRD420261319656.},
}
@article {pmid42273265,
year = {2026},
author = {Shi, P and Zhang, Z and He, W and Duan, Y and He, Y and Feng, H and Shu, J},
title = {Leveraging single B cell antibody platforms to develop countermeasures against animal viral diseases: recent advances and future perspectives.},
journal = {Frontiers in veterinary science},
volume = {13},
number = {},
pages = {1854176},
pmid = {42273265},
issn = {2297-1769},
abstract = {The discovery and application of monoclonal antibodies (mAbs) have fundamentally revolutionized clinical medicine, driving significant paradigm shifts in disease prevention, precise diagnosis and targeted treatment. The demand for high-affinity antibodies continues to surge, yet traditional discovery platforms such as hybridoma and phage display suffer from low efficiency, disrupted native pairing, and time-consuming workflows. Single B cell antibody technology overcomes these limitations by directly retrieving naturally paired heavy and light chain sequences from antigen-specific B cells, thereby preserving authentic affinity and specificity. Following its remarkable success in combating human emergencies like COVID-19, this platform is now being rapidly adapted to veterinary viral diseases, a critical effort under the "One Health" framework to safeguard both animal and public health. This review systematically outlines the core principles and workflows of single B cell-based mAb discovery. It then summarizes recent advances in applying this technology to viruses that infect animals and zoonotic viruses, emphasizing how native antibody repertoires have been harnessed to generate high-affinity mAbs. Ultimately, the article concludes with a discussion of current technical challenges, proposing future research directions to improve both the accessibility and efficacy of veterinary immunotherapeutics.},
}
@article {pmid42275913,
year = {2026},
author = {Mhade, S and Bhosekar, U and Hill, MD and Sinclair, S and Agrawal, S and Guerrini, J and Pletz, K and Zou, L and Koebcke, A and Kummer, AG and Ventura, PC and Del Valle, SY and Chinazzi, M and Litvinova, M and Vespignani, A and Ajelli, M},
title = {Mapping the landscape of individual-based models for respiratory pathogen transmission in the pandemic and post-pandemic era (2020-2024): A systematic review.},
journal = {Epidemics},
volume = {56},
number = {},
pages = {100924},
doi = {10.1016/j.epidem.2026.100924},
pmid = {42275913},
issn = {1878-0067},
abstract = {Individual-based models (IBMs) provide a mechanistic framework in which population-level outcomes emerge from interactions between individuals. We conducted a systematic review on IBMs for respiratory pathogens published in 2020-2024. We identified 855 eligible studies. Publications peaked in 2021, with a geographical distribution positively correlated with national GDP, leaving regions understudied. Most studies focused on SARS-CoV-2 and assessed public health interventions. Research priorities evolved over time, shifting from social distancing to vaccination. Age was included in 72.4% of studies; other sociodemographic factors (e.g., race/ethnicity) were rarely considered. This review maps the IBM landscape, offering a framework to guide future modeling efforts.},
}
@article {pmid42276971,
year = {2026},
author = {Farquhar, H},
title = {AI-Enhanced Point-of-Care Diagnostics for Infectious Diseases in Resource-Limited Settings: A Scoping Review.},
journal = {Tropical medicine &amp; international health : TM &amp; IH},
volume = {31},
number = {8},
pages = {966-996},
pmid = {42276971},
issn = {1365-3156},
mesh = {Humans ; Resource-Limited Settings ; *Communicable Diseases/diagnosis ; *Point-of-Care Systems ; *Artificial Intelligence ; COVID-19/diagnosis ; Rapid Diagnostic Tests ; Evidence Gaps ; *Point-of-Care Testing ; },
abstract = {OBJECTIVES: To systematically map the extent and nature of research on AI-enhanced point-of-care (POC) and rapid diagnostic technologies for infectious diseases in resource-limited settings, and to identify gaps in disease coverage, geographic representation and validation rigour.<br><br>METHODS: This scoping review followed JBI methodology and PRISMA-ScR guidelines. The protocol was registered on OSF (https://doi.org/10.17605/OSF.IO/KV8MP). Five databases (PubMed, Embase, Scopus, Web of Science and IEEE Xplore) were searched for studies published from January 2015 to March 2026. Title/abstract and full-text screening used rule-based keyword screening with manual validation (Cohen's kappa&#x2009;=&#x2009;0.856). Data were extracted using a 19-variable charting form and enriched with PubMed Central full texts.<br><br>RESULTS: From 1072 records, 551 remained after deduplication and 237 studies were included. Publication volume grew exponentially, with 44% published in 2025-2026. COVID-19 (32%), malaria (27%) and tuberculosis (14%) dominated; neglected tropical diseases accounted for fewer than 8%. Microscopy (21%), molecular diagnostics (17%), biosensors (14%) and rapid diagnostic tests (14%) were the most common modalities. Convolutional neural networks predominated (26%), followed by random forests (10%) and support vector machines (8%). Only 7% of studies reported prospective field validation, while 62% did not report validation level. Geographic analysis revealed concentration in East Africa and South Asia, with underrepresentation of West Africa and Latin America.<br><br>CONCLUSIONS: AI-enhanced POC diagnostics for infectious diseases in resource-limited settings is a rapidly growing field facing critical gaps in validation rigour, disease equity and geographic representation. Only 16 of 237 studies (6.8%) report prospective field validation. Future research should prioritise field validation, expand beyond the COVID-19/malaria/TB triad and involve end-user communities from the design stage.},
}
@article {pmid42277518,
year = {2026},
author = {Frühwein, M},
title = {[Focus on respiratory vaccinations].},
journal = {MMW Fortschritte der Medizin},
volume = {168},
number = {11},
pages = {38-41},
doi = {10.1007/s15006-026-5953-4},
pmid = {42277518},
issn = {1613-3560},
}
@article {pmid42277912,
year = {2026},
author = {Chang, L and Xu, W and Wang, X and Xue, Y and Zhang, Y and Zhu, X and Zhang, Y and Liang, T and Liu, W},
title = {CRISPR diagnostics: from trans-nuclease activity to cancer diagnosis.},
journal = {Cell &amp; bioscience},
volume = {},
number = {},
pages = {},
doi = {10.1186/s13578-026-01603-1},
pmid = {42277912},
issn = {2045-3701},
support = {2019YFC1316000//National Key Research and Development Program of China/ ; 81830089//National Natural Science Foundation of China/ ; 82188102//National Natural Science Foundation of China/ ; LQ23H200004//Natural Science Foundation of Zhejiang Province/ ; },
abstract = {The field of nucleic acid-based testing experienced a decade-long stagnation since the development of quantitative polymerase chain reaction (qPCR) in 1992 and isothermal amplification methods in the early 2000s. However, in 2016, the discovery of trans-nuclease activity in CRISPR-Cas systems revolutionized the molecular diagnostics for nucleic acids. A typical CRISPR diagnostic workflow comprises three phases: (1) target recognition through CRISPR RNA (crRNA)-guided hybridization; (2) signal transduction via trans-cleavage of engineered reporters (e.g., fluorophore-quencher oligonucleotides), and (3) signal readout using fluorescence, electrochemical, or colorimetric platforms. Emerging shortly prior to the COVID-19 pandemic, CRISPR diagnostics quickly gained prominence as a field-deployable alternative to qPCR due to its rapidity (< 1 h), minimal equipment requirements, and field adaptability. This technological paradigm underwent rigorous validation and refinement alongside the rapid evolution of SARS-CoV-2 detection, which facilitated its adaptation for cancer diagnosis. Recent advancements in sensitivity (attomolar-level detection) and specificity (single-nucleotide discrimination) have enabled transformative applications in cancer diagnostics, including: (1) identification of nucleic acid biomarkers, such as high-frequency somatic mutations, circulating nucleic acids and miRNAs; and (2) detection of non-nucleic acid biomarkers, including epigenetic aberrations, proteins, small molecules and metabolite biomarkers. This review chronicles the decadal evolution of CRISPR diagnostics, with particular emphasis on recent advancements of its application in cancer diagnosis. We critically evaluate persistent technical limitations, including PAM sequence restriction, suboptimal sensitivity and specificity, quantitative constraints, and unmet point-of-care testing (POCT) in complex biological matrices. Additionally, we discuss prospective solutions to address these challenges.},
}
@article {pmid42278622,
year = {2026},
author = {Zhao, YY and Evans, CE},
title = {Contemporary Endothelial Genome Editing Technologies: Towards Precision Genetic Medicine for Vascular Diseases.},
journal = {International journal of molecular sciences},
volume = {27},
number = {11},
pages = {},
pmid = {42278622},
issn = {1422-0067},
support = {1R01HL133951-21/NH/NIH HHS/United States ; 2R01HL164014-22/NH/NIH HHS/United States ; 3R01HL162299-22/NH/NIH HHS/United States ; 4R01HL172447-23/NH/NIH HHS/United States ; 24TPA1285575//American Heart Association/ ; 23SCEFIA1155876//American Heart Association/ ; 5P20GM103499-23/NH/NIH HHS/United States ; },
mesh = {Humans ; *Gene Editing/methods ; CRISPR-Cas Systems ; *Vascular Diseases/genetics/therapy ; *Endothelial Cells/metabolism ; Animals ; *Precision Medicine/methods ; *Genetic Therapy/methods ; Endothelium, Vascular/metabolism ; },
abstract = {Endothelial dysfunction is a key characteristic of many diseases, including atherosclerosis, hypertension, heart failure, stroke, cancer, acute respiratory distress syndrome (ARDS), peripheral vascular disease, coronavirus 2019 (COVID-19), and pulmonary arterial hypertension (PAH). To improve understanding of the roles of endothelial cells (ECs) in health and disease, EC-specific genome editing technologies have been developed in recent years. Therapeutic strategies that aim to restore a healthy endothelial monolayer include the inhibition of endothelial genes that cause EC injury and dysfunction and the induction or activation of endothelial genes that drive EC repair and regeneration. In this review, we describe established recombinase-mediated genetic modification technologies and emerging EC-specific genome editing technologies including viral and non-viral delivery of the CRISPR/Cas9 genome editing system, and we summarize the strengths and limitations of each technology. We then discuss possible avenues for future research, including the development of organ-specific EC genome editing technologies. In short, EC-specific genome editing technologies can be used to modulate gene expression selectively in ECs and even within a specific vascular bed and/or distinctive EC subtype, and, in doing so, greatly improve the understanding of vascular biology and help develop precision genetic medicine targeting the disease-causing vascular bed(s) to effectively treat diseases caused by vascular endothelial dysfunction.},
}
@article {pmid42278781,
year = {2026},
author = {Karanikola, M and Middleton, N},
title = {Suicide Prevention as a Pillar of Sustainable Mental Health: A Focused Comparative Narrative Review of the Republic of Cyprus and Selected European Countries in the Post-COVID-19 Era.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {11},
pages = {},
pmid = {42278781},
issn = {2227-9032},
abstract = {Background/Objectives: Mental health and suicide prevention are increasingly recognized as critical components of sustainable development in the European Union (EU), particularly in light of the broader mental health challenges highlighted during the COVID-19 pandemic. This review aimed to explore suicide prevention policies and mental health strategies across selected European countries through a focused comparative analysis centered on the Republic of Cyprus. Methods: A narrative review design was applied. A purposive literature search focused on national strategies, epidemiological trends, policy papers, and peer-reviewed articles published from 2000 to January 2026 was followed. Databases searched included PubMed, Scopus, PsychInfo, Embase and Google Scholar, supplemented by grey literature from the World Health Organization (WHO), European Commission, and national health authorities. The review focused on selected European countries, i.e., the United Kingdom, Sweden, Finland, Greece, and the Republic of Cyprus, chosen to illustrate variation in suicide prevention policies, health system structures, and implementation frameworks. Evidence was critically appraised and synthesized thematically to identify commonalities and contrasts in policy, implementation and emerging challenges. Results: The review identified substantial variation in national suicide prevention strategies, monitoring systems, and policy implementation across the selected countries. Persistent gender- and age-related disparities in suicide patterns were observed, alongside the influence of socio-economic determinants, and the broader mental health effects associated with the COVID-19 pandemic. The findings also underscored the need for robust, gender-sensitive, and data-driven national strategies that are contextually grounded and equitably resourced. Conclusions: This review concludes with recommendations for enhancing mental health sustainability across Europe, emphasizing cross-sectoral coordination, improved surveillance systems, and future research priorities.},
}
@article {pmid42278883,
year = {2026},
author = {Scocca, V and Lauda, L and Nocini, R and Dell'Aversana Orabona, G},
title = {Nasal Epithelial Organoids as Translational Platforms in Inflammatory, Infectious, and Precision Medicine Applications: A Systematic Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {11},
pages = {},
pmid = {42278883},
issn = {2077-0383},
abstract = {Background/Objectives: The airway epithelium plays a central role in host defense, inflammatory signaling, and disease progression across infectious, inflammatory, and genetic respiratory disorders. Human nasal epithelial organoids have emerged as accessible and patient-specific in vitro platforms with increasing translational relevance. This systematic review aimed to critically evaluate the current evidence on nasal epithelial organoid models, focusing on donor characteristics, culture methodologies, differentiation strategies, and translational applications. Methods: A systematic search of PubMed/MEDLINE, Embase, Scopus, Ovid MEDLINE, and Cochrane Library was conducted for studies published between 1990 and April 2026. The review followed PRISMA guidelines and was structured according to the PICOTS framework. Eligible studies included in vitro experimental investigations using human-derived nasal epithelial organoids in infectious, inflammatory, or precision medicine contexts. Risk of bias was assessed using the QUIN tool. Results: Seventeen studies met the inclusion criteria. Applications clustered into three principal domains: infectious disease modeling, inflammatory and epithelial remodeling research, and cystic fibrosis precision medicine. Most studies employed expandable three-dimensional Matrigel-embedded organoids or organoid-derived air-liquid interface systems. Infection-focused studies demonstrated variant-specific viral replication dynamics and epithelial immune responses, while inflammatory models reproduced disease-associated differentiation and remodeling phenotypes. Cystic fibrosis oriented studies showed that organoid swelling and electrophysiological assays correlate with CFTR functional rescue and, in selected cases, clinical response. Methodological heterogeneity across protocols and outcome reporting precluded quantitative synthesis. Conclusions: Human nasal epithelial organoids represent versatile translational platforms bridging accessible patient-derived tissue and advanced airway disease modeling. Although variability in culture protocols and functional benchmarks limits standardization, these models hold significant promise for mechanistic investigation, therapeutic stratification, and precision medicine applications.},
}
@article {pmid42279108,
year = {2026},
author = {Balan, A and Graham, G and Herban, S and Marcu, M and Gheorghe, N and Mara, G and Rasinar, FC and Lascu, A and Mot, CI and Dan, TF and Mihaicuta, S and Frent, SM},
title = {Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence.},
journal = {Journal of clinical medicine},
volume = {15},
number = {11},
pages = {},
pmid = {42279108},
issn = {2077-0383},
abstract = {Background: Long COVID, or post-COVID-19 condition (PCC), affects around 36% of individuals following SARS-CoV-2 infection, manifesting as persistent fatigue, cognitive dysfunction, and dysautonomia among its hallmark features. Affecting an estimated 400 million individuals globally, it imposes an annual economic burden exceeding $1 trillion, yet no pharmacological therapy has demonstrated consistent efficacy in adequately powered randomized controlled trials. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a candidate intervention targeting the autonomic dysfunction and neuroinflammation responsible for PCC pathophysiology. Methods: We conducted a PRISMA 2020-compliant systematic review (PROSPERO: CRD420261287286) searching PubMed, Scopus, Cochrane, and Web of Science databases from inception to January 2026 for studies evaluating any form of VNS in adults with Long COVID. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, the JADAD scale, and the PEDro scale. Certainty of evidence was evaluated using the GRADE framework. Narrative synthesis followed SWiM guidelines. Results: Five studies (n = 154 participants) (three randomized controlled trials (RCTs) and two single-arm studies) met inclusion criteria. Three of five studies (60%) were rated high overall risk of bias; only two RCTs achieved "some concerns." The only adequately double-blinded RCT found no significant between-group differences across all outcomes. Paradoxically, in the best-powered RCT (Percin et al.), sham stimulation produced significantly greater fatigue improvement than active taVNS, despite active taVNS producing significant HRV increases consistent with cardiac autonomic modulation. All efficacy outcomes were rated "very low" certainty (GRADE); safety was rated "low" certainty. Conclusions: Currently available evidence supporting the use of taVNS for Long COVID remains limited, and the absence of reliable target engagement markers in the included studies constrains confidence in this approach. Nonetheless, the physiological rationale remains sound, and the favorable safety profile across all included studies supports the feasibility of future investigation. However, given that positive findings were confined to inadequately controlled studies, enthusiasm for further research should be directed first toward mechanistic clarification and rigorous dose-finding work. Large-scale, double-blind, sham-controlled trials incorporating validated markers of vagal engagement are required before taVNS can be firmly recommended for COVID-19 sequelae management.},
}
@article {pmid42280324,
year = {2026},
author = {Morales-Juárez, A and Reed, JB and Romanovich-Brown, O and Tooze, JA and Eicher-Miller, HA},
title = {How Is U.S. Food-Insecurity Related to Dietary Quality? A Scoping Review to Inform Nutrition Security Across the Lifespan.},
journal = {Nutrients},
volume = {18},
number = {11},
pages = {},
pmid = {42280324},
issn = {2072-6643},
support = {Elevating the Visibility of Research: Seed Funding for Academic Books and Monographs//Purdue University System/ ; Hatch Project IND90005789//United States Department of Agriculture/ ; Danone International Prize for Alimentation//Fondation pour la Recherche M&#xe9;dicale/ ; },
mesh = {Humans ; United States ; *Food Security ; *Food Insecurity ; *Diet ; Child ; Adult ; Nutritive Value ; Female ; Adolescent ; Infant ; Child, Preschool ; },
abstract = {Background/Objectives: This review examined how different levels of U.S. food-security (FS) relate to dietary markers, informing the concept of nutrition security over the lifespan. Methods: The authors followed PRISMA-ScR guidelines. PubMed, CINAHL, Scopus, Embase, and CAB Abstracts were searched for eligible U.S.-based, English-language studies examining FS and dietary markers in free-living, disease-free populations, excluding COVID-19-era research. Two reviewers independently screened records in Covidence, with discrepancies resolved by a third reviewer. The percentage of studies evaluating >2 FS levels was determined. Dietary markers were classified into three domains: food and beverage (9 components), nutrient (16 components) and bioactive (2 components) markers. The percentages of studies with significant differences were estimated for each dietary domain. Results: Of 1069 records, 78 met full-text eligibility. Among these, 15% evaluated dietary markers across >2 FS levels. Among adults, differences by FS status were observed in 67% of assessed food and beverage components (6 out of 9), 50% of nutrient components (8 out of 16), and all evaluated bioactives (100%; 2 out of 2). Children exhibited differences in all assessed food and beverage components (100%; 9 out of 9) and 29% (2 out of 7) of nutrients by FS level. Adolescents had fewer dietary marker differences than children and adults. Findings among infants, pregnant women and older adults were limited, with no studies for lactating women. Conclusions: Low FS level is associated with poorer dietary markers across the lifespan compared with FS. Age-specific differences highlight the need for targeted interventions and nutrition security measures.},
}
@article {pmid42280413,
year = {2026},
author = {Lesgards, JF},
title = {Whey Proteins and Immunity: Mechanisms Underlying Immune System Reinforcement and Protection Against Viral and Bacterial Infections.},
journal = {Nutrients},
volume = {18},
number = {11},
pages = {},
pmid = {42280413},
issn = {2072-6643},
mesh = {Animals ; Humans ; *Bacterial Infections/prevention &amp; control/immunology ; Bioactive Peptides, Dietary ; COVID-19/immunology/prevention &amp; control ; Immunity, Innate ; Lactalbumin/administration &amp; dosage ; Lactoferrin/administration &amp; dosage ; Milk Proteins ; *Virus Diseases/prevention &amp; control/immunology ; *Whey Proteins/administration &amp; dosage/immunology ; Dietary Supplements ; },
abstract = {This review aims to examine the immunological, anti-inflammatory, antiviral, and antibacterial activities of key whey and milk proteins, specifically lactoferrin, glycomacropeptide, β-lactoglobulin, α-lactalbumin and their derived peptides, particularly lactoferricin and lactoferrampin, highlighting their potential as preventive or therapeutic agents. Whey and dairy products represent complex biological matrices that, beyond their high nutritional value, serve as reservoirs of bioactive proteins and peptides with documented health-promoting properties. It has been reported that certain whey proteins (WPs) and whey-derived peptides may contribute to improvements in both innate and adaptive immunity, exert direct antiviral and antibacterial effects while also modulating host defenses through immunoregulatory, antioxidant, and anti-inflammatory activities. These mechanisms contribute not only to enhanced resistance against viral pathogens but also to maintaining intestinal homeostasis and microbiota balance, both of which are critical during infection. In recent years, particularly in the context of the COVID-19 pandemic, natural bioactive compounds derived from whey, and, more broadly, milk, have attracted increasing attention as potential adjuncts or alternatives to conventional antivirals, with reported activity not only against SARS-CoV-2, influenza but also other viral and microbial infections. Despite encouraging in vitro and in vivo evidence, clinical validation remains limited, and the antiviral and immunomodulatory effects of WPs still require deeper mechanistic clarification. Future research should focus on identifying molecular targets, as well as characterizing the pharmacokinetics and safety profiles of WPs and WP peptides across diverse clinical settings. At the same time, attention should be given to optimizing their application as nutraceuticals or functional dairy ingredients.},
}
@article {pmid42281865,
year = {2026},
author = {Papic, N and Kosuta, I and Ljubas, D and Vrsaljko, N and Sesa, V and Domislovic, V and Ahsan, S and Mrzljak, A},
title = {Not just another shot: Tailoring vaccination in the era of modern liver transplantation.},
journal = {World journal of transplantation},
volume = {16},
number = {2},
pages = {118012},
pmid = {42281865},
issn = {2220-3230},
abstract = {Infections remain a leading cause of morbidity and mortality in patients with cirrhosis and liver transplantation (LT). Vaccination is underutilized despite proven benefits, and responses are often blunted by cirrhosis-associated immune dysfunction and post-transplant immunosuppression. This review synthesizes current evidence and recent advances in vaccination strategies for adult LT recipients, emphasizing optimal timing, novel vaccine platforms, and precision vaccinology. We discuss emerging data on coronavirus disease 2019, respiratory syncytial virus, and new pneumococcal and hepatitis B vaccines, highlight strategies to overcome immunogenicity gaps, and address implementation barriers. A practical roadmap and clinician-focused algorithms are proposed to integrate vaccination into the continuum of LT care.},
}
@article {pmid42285439,
year = {2026},
author = {Michas, G and Trikas, G and Trikas, A},
title = {Cardiovascular risk factors in Greece: looking beyond the classics. A narrative review.},
journal = {Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.hjc.2026.06.002},
pmid = {42285439},
issn = {2241-5955},
abstract = {Cardiovascular disease is the leading cause of death in Greece, despite substantial reductions in age-standardized mortality over recent decades. These improvements have been largely confined to older populations, while the burden of cardiometabolic risk remains high. The Greek cardiovascular landscape has also evolved under the combined influence of population aging, the COVID-19 pandemic, persistent socioeconomic pressures, and increasingly stringent European Society of Cardiology targets for lipid and blood pressure control. Traditional determinants, particularly dyslipidemia, hypertension, diabetes, obesity, unhealthy dietary patterns, smoking, and physical inactivity, remain prevalent and frequently suboptimally controlled. Against this background, residual risk and emerging determinants of disease are increasingly recognized as clinically relevant contributors to cardiovascular burden. This narrative review summarizes recent evidence on the role of non-traditional risk factors in the Greek population, including lipoprotein(a), inflammation, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, chronic obstructive pulmonary disease, sleep disturbances, infections and vaccination, environmental exposures, mental health, and social determinants of health. Overall, the available evidence supports a broader cardiovascular prevention framework that extends beyond conventional risk-factor assessment. Integrating selected non-traditional determinants into clinical practice and prevention policy may improve risk stratification, support individualized care, and help address the evolving cardiovascular burden in Greece.},
}
@article {pmid42285845,
year = {2026},
author = {Chen, PC and Hsu, YL and Wu, LS and Liu, XL and Tsai, HJ and Wang, JY and , },
title = {Pediatric post-acute sequelae of SARS-CoV-2 infection in Taiwan: Insights from the DISCOVER cohort.},
journal = {Pediatrics and neonatology},
volume = {67},
number = {4},
pages = {343-349},
doi = {10.1016/j.pedneo.2026.03.007},
pmid = {42285845},
issn = {2212-1692},
mesh = {Humans ; Taiwan/epidemiology ; *COVID-19/complications/diagnosis/epidemiology ; Post-Acute COVID-19 Syndrome ; Child ; Cohort Studies ; SARS-CoV-2 ; },
abstract = {The post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID, represent a multifaceted challenge in pediatric populations, characterized by symptoms persisting beyond the acute phase. In Taiwan, where early public health measures initially contained the pandemic, the 2022 Omicron surge prompted focused investigation into pediatric PASC, highlighting the critical need for longitudinal data in this specific demographic. To address this challenge, the Diagnosis and Support for COVID Children to Enhance Recovery (DISCOVER) study was established as a prospective, multidisciplinary cohort. By employing a multimodal approach, this study characterizes the clinical landscape of pediatric PASC in Taiwan through validated screening instruments, AI-driven diagnostics, and pulmonary assessments, while concurrently evaluating immune biomarkers, vaccination protection, and vitamin D intervention. This review synthesizes comprehensive findings from the cohort. While the acute phase of infection was predominantly mild, a substantial proportion of children experienced persistent multisystem symptoms, with fatigue, respiratory issues, and somatic complaints being most prevalent. Vaccination was found to significantly modify the disease trajectory, offering protection against subsequent gastrointestinal sequelae and preserving pulmonary function by mitigating small airway resistance. Furthermore, advanced diagnostic modalities, including impulse oscillometry and deep learning-assisted echocardiography, successfully unmasked subclinical organ dysfunction that conventional methods often failed to detect. Mechanistic investigations revealed that symptom severity was closely linked to elevated anti-nucleocapsid antibody titers, while markers of T-cell exhaustion evidenced persistent immune dysregulation, rather than ongoing viral replication. Notably, a preliminary single-center randomized controlled trial within this cohort provided early evidence that vitamin D supplementation may reduce the overall symptom burden and modulate pro-inflammatory cytokine profiles in children with PASC. Collectively, these findings underscore the multisystem nature and immune-driven mechanism of pediatric PASC, while highlighting the role of vaccination, advanced diagnostics, and targeted nutritional interventions in improving recovery. CLINICAL TRIAL REGISTRATION: NCT05426291 (ClinicalTrials.gov).},
}
@article {pmid42286395,
year = {2026},
author = {Jia, Y and Han, X and Ma, Y and Wang, X and Yang, Y and Zhang, A and Ding, K and Chen, S},
title = {Reverse genetics strategies for coronaviruses: platform construction and applications in vaccine development.},
journal = {Virus genes},
volume = {},
number = {},
pages = {},
pmid = {42286395},
issn = {1572-994X},
support = {ZDYF202605//Xinxiang Major Science and Technology Special Project/ ; 252102111004//the Science and Technology Research Project of Henan Province/ ; },
abstract = {The continuous emergence of novel coronaviruses, characterized by high mutation rates and frequent recombination events, poses severe threats to global "One Health." Notably, the recent outbreak of the recombinant feline coronavirus (FCoV-23) and the persistence of SARS-CoV-2 variants underscore the urgent need to understand viral pathogenesis and cross-species transmission mechanisms. Reverse genetics technology serves as a critical platform for bridging genomic sequencing to functional virology, enabling targeted mutagenesis and the generation of recombinant viruses. However, the construction of reverse genetics systems for coronaviruses is often hampered by their exceptionally large genomes and the instability of viral cDNA sequences in bacterial hosts due to cytotoxicity. This review moves beyond a simple enumeration of methods to systematically compare current reverse genetics strategies-including in vitro ligation, bacterial artificial chromosome (BAC) systems, and transformation-associated recombination (TAR)-across different viral genera. Furthermore, we critically evaluate the application of these platforms in deciphering pathogenic mechanisms and developing next-generation vaccines, with a specific focus on overcoming technical bottlenecks and designing broad-spectrum countermeasures against emerging cross-species threats.},
}
@article {pmid42286517,
year = {2026},
author = {Adnyanaschah, R and Abdulah, R and Oktora, MP},
title = {Clinical manifestations and laboratory findings in patients coinfected with dengue virus and SARS-CoV-2: a systematic review.},
journal = {BMC infectious diseases},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12879-026-13752-2},
pmid = {42286517},
issn = {1471-2334},
abstract = {BACKGROUND: Dengue Hemorrhagic Fever and Coronavirus disease 2019 (COVID-19) are infectious diseases caused by dengue virus (DENV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While DENV remains endemic in many tropical regions, SARS-CoV-2 spread globally beginning in 2020. Reports of coinfection have emerged from several countries. This systematic review describes the clinical manifestations and laboratory findings reported in patients coinfected with DENV and SARS-CoV-2.<br><br>METHODS: This review followed the PRISMA guidelines and collecting data from PubMed for articles published between 2020 and 2025 that discussed DENV and SARS-CoV-2 coinfection. Eligible study designs included theoretical articles, case reports, case series, and cohort studies. Data were synthesized descriptively due to heterogeneity and the absence of comparator groups.<br><br>RESULTS: Fifteen studies met the inclusion criteria, identifying 65 patients with SARS-CoV-2 and DENV coinfection. Reported symptoms included fever (69%), vomiting (57%), abdominal pain (55%), rash (54%), and shock (51%). Laboratory findings also showed hematological and physiological alterations including hypotension (57.14%), tachypnea (50%), fever (62.5%), neutropenia (33.33%), neutrophilia (50%), lymphopenia (42.86%), and lymphocytosis (28.57%). These percentages represent descriptive counts across heterogeneous case reports and do not reflect prevalence estimates.<br><br>CONCLUSIONS: Patients with DENV and SARS-CoV-2 coinfection exhibit a range of clinical and laboratory abnormalities, but the available evidence-primarily case reports and case series without comparator groups-does not allow conclusions about disease severity or prognosis relative to monoinfection. The findings should therefore be interpreted as descriptive and hypothesis-generating. Careful diagnostic evaluation and clinical monitoring remain essential in suspected coinfection cases.<br><br>CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid42288770,
year = {2026},
author = {Lamadrid, A and Leiva-Escobar, I and Soza, A and Quentin, W},
title = {Impact of the COVID-19 pandemic on hepatitis C care across the cascade of care: a scoping review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {42288770},
issn = {1471-2334},
mesh = {Humans ; *COVID-19/epidemiology ; *Hepatitis C/therapy/diagnosis/epidemiology ; SARS-CoV-2 ; Pandemics ; Europe/epidemiology ; Hepacivirus ; },
abstract = {BACKGROUND: The COVID-19 pandemic was associated with widespread health services disruption, including challenges in the management of chronic infectious diseases. However, evidence regarding reported changes in hepatitis C virus (HCV) care during this period remains limited and fragmented. We aimed to map the available evidence on reported changes in HCV care during the COVID-19 pandemic across the HCV cascade of care.<br><br>METHOD: We conducted a scoping review following the Arksey and O'Malley methodological framework. Searches of Medline (PubMed), Cochrane Library, Embase, Scopus, Web of Science, and grey literature identified studies reporting pandemic-related changes in HCV diagnosis, linkage to care, treatment, or cure from; March 2020 to March 2025. Data were extracted on the study setting, stage of the cascade of care, and observed changes in HCV care, and synthesized narratively.<br><br>RESULTS: Twenty-eight studies met the inclusion criteria. Eighteen were conducted in Europe and North America. Most studies found declines in HCV care across all stages of the cascade of care: diagnosis (15 of 21 studies), linkage to care (9 of 10), treatment initiation or completion (18 of 27), and cure (6 of 13). Among the included studies, linkage to care was the stage most consistently reported as disrupted.<br><br>CONCLUSION: Evidence on reported changes in the HCV cascade of care during the COVID-19 pandemic is limited and geographically skewed toward high-income countries. Available data suggest service reductions across all stages, with linkage to care being the stage most frequently reported as disrupted among the studies that assessed it. Strengthening surveillance, ensuring routine monitoring at all stages of the cascade of care, and building resilient HCV services are critical to safeguarding progress toward the 2030 hepatitis elimination goal.},
}
@article {pmid42290783,
year = {2026},
author = {Shah, SFA and Tharwat, M and Rehman, A and Alshanbari, FA},
title = {The impact of bacterial and viral diseases on dromedary camel (Camelus dromedarius) welfare: a comprehensive review.},
journal = {Frontiers in veterinary science},
volume = {13},
number = {},
pages = {1795334},
pmid = {42290783},
issn = {2297-1769},
abstract = {Dromedary camels (Camelus dromedarius) are vital to food security, livelihoods and cultural identity in arid and semi-arid regions of Africa, the Middle East and South Asia, with global populations exceeding 35-40 million and continuing to rise as climate change favors livestock adapted to harsh environments. Despite their expanding roles in meat and milk production, transport, tourism and racing, camel health and welfare remain comparatively underexplored, particularly regarding infectious diseases. This review synthesizes current knowledge on major bacterial infections, including brucellosis, tuberculosis, mastitis, suppurative infections, salmonellosis, and clostridial diseases, as well as important viral diseases such as Middle East respiratory syndrome coronavirus, camel pox, Rift Valley fever, rabies, contagious ecthyma, and peste des petits ruminants, with a focus on their implications for animal welfare. These diseases commonly lead to acute and chronic pain, fever, respiratory compromise, reproductive failure, debilitation, and mortality, and are associated with physiological stress responses such as activation of the hypothalamic-pituitary-adrenal axis and increased acute-phase proteins, alongside behavioral changes including lethargy, reduced grooming, altered social interactions, and impaired maternal and working behaviors. Using the Five Freedoms and the Five Domains Model frameworks, this review demonstrates how infectious diseases undermine multiple dimensions of camel welfare, including nutrition, physical comfort, health, behavior, and mental state. Beyond individual animals, camel diseases have significant socioeconomic and ethical implications. Several pathogens are zoonotic, posing risks to pastoralists, veterinarians, and other stakeholders, and influencing trade regulations, disease control strategies, and culling practices, which may further exacerbate welfare compromise. Key knowledge gaps remain, including the lack of validated camel-specific welfare assessment tools, limited longitudinal data on welfare trajectories during disease outbreaks, and insufficient integration of welfare indicators into surveillance and control programs. The review highlights priority research and policy needs, including the development of field-adapted welfare scoring systems, evaluation of welfare impacts of interventions such as vaccination and movement restrictions, and stronger integration of animal welfare into One Health and One Welfare frameworks to support sustainable camel production and resilient dryland livelihoods.},
}
@article {pmid42291020,
year = {2026},
author = {Khani, E and Afsharirad, H and Yadegari, AT and Zarezadeh, M and Asham, H and Bannazadeh-Baghi, H and Entezari-Maleki, T},
title = {Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis.},
journal = {Journal of research in pharmacy practice},
volume = {15},
number = {1},
pages = {20},
pmid = {42291020},
issn = {2319-9644},
abstract = {The high mutations of the Omicron variant of severe acute respiratory syndrome coronavirus 2 raised concerns regarding the efficacy of antivirals. This meta-analysis aimed to determine the impact of nirmatrelvir/ritonavir on the outcomes of immunocompetent patients with confirmed Omicron variant. Three reviewers systemically searched PubMed (Medline), Cochrane Library, and Embase databases up to June 9, 2025. Randomized clinical trials (RCTs) and observational studies with a control group were screened for eligibility to extract data. Studies that included only patients with immunosuppression, malignancy, or renal failure, severe disease, or assessed nirmatrelvir/ritonavir efficacy on variants other than Omicron were excluded. Forty-six observational studies, including 6,099,805 participants, were involved in the meta-analysis. Our findings revealed that nirmatrelvir/ritonavir significantly decreases death (risk ratio [RR] =0.31; 95% confidence interval [CI]: 0.23-0.40), disease progression (RR = 0.57; 95% CI: 0.42-0.71), hospitalization (RR = 0.45; 95% CI: 0.35-0.56), composite outcome of hospitalization and death (RR = 0.58; 95% CI: 0.44-0.71), ventilation (RR = 0.46; 95% CI: 0.19-0.72), and intensive care unit admission (RR = 0.56; 95% CI: 0.38-0.73) compared to the control group. However, no significant difference was shown across the two groups regarding hospitalization duration (mean difference = -2.34; 95% CI: -5.60-0.93). The current updated meta-analysis supported the efficacy of nirmatrelvir/ritonavir on the Omicron variant. However, further RCTs are recommended for accurate results.},
}
@article {pmid42291037,
year = {2026},
author = {Seboka, BT and Ma, L and Magliano, DJ and Talic, S and Junior, ADSM and Borlotti, A and Brears, HT and Dennis, A and Banerjee, A and Marwick, TH and Huynh, Q},
title = {The impact of post-acute sequelae of COVID-19 on cardiac function and structure: A systematic review and a hybrid individual participant data meta-analysis.},
journal = {American journal of preventive cardiology},
volume = {27},
number = {},
pages = {101457},
pmid = {42291037},
issn = {2666-6677},
abstract = {BACKGROUND: Post-acute sequelae of SARS-CoV-2 infection (PASC), also referred to as Long COVID, affect a significant proportion of COVID-19 survivors, with evidence suggesting cardiovascular involvement. However, the nature, extent, and clinical significance of these alterations remain uncertain.<br><br>AIM: To synthesize evidence on structural and functional cardiac alterations in individuals with PASC compared with those without PASC.<br><br>METHOD: We systematically searched seven databases. Random-effects meta-analyses were performed and supplemented by individual participant data (IPD) analyses from three studies. Univariable and multivariable meta-regressions examined associations with study-level characteristics. Publication bias and evidence certainty were assessed using standard methods (funnel plots, Egger's test, trim-and-fill, and GRADE).<br><br>RESULTS: From 3580 records, 17 studies with 4852 participants (3173 PASC, 1679 controls) met the inclusion criteria. IPD analysis revealed an impairment in global longitudinal strain (GLS) (mean difference (MD) = 3.63 %) in individuals with PASC. When using categorical thresholds, 58 % of individuals with PASC had GLS < 16 %, indicating a significant prevalence of subclinical left ventricular dysfunction. Meta-analysis supported these findings, showing impaired GLS (MD = 1.07 %), along with reductions in left ventricular ejection fraction (MD = -1.30 %) and left ventricular end-diastolic volume (MD=-3.98 mL). Meta-regression showed that cardiac dysfunction was more frequently observed in individuals with older age, diabetes, and hypertension.<br><br>CONCLUSION: This review indicates that PASC is associated with modest, subclinical alterations in cardiac function. These alterations appear more pronounced in older adults and those with cardiometabolic comorbidities, highlighting the potential value of risk-stratified cardiovascular surveillance in individuals with PASC. The long-term clinical relevance of these changes remains unclear and warrants further study.},
}
@article {pmid42291464,
year = {2026},
author = {Nwokocha, C and Palacios, J and Kolawole, T and Nwokocha, M and Anyaorah, C and Chiroma, JH and McGrowder, D and Orie, N and Husaini, DC},
title = {Toward Precision in Myocardial Injury Management: A Critical Synthesis and the C.A.L.I.B.R.A.T.E. Framework for Biomarker Integration.},
journal = {Clinical Medicine Insights. Cardiology},
volume = {20},
number = {},
pages = {11795468261454738},
pmid = {42291464},
issn = {1179-5468},
abstract = {Cardiovascular diseases remain the leading cause of global mortality, necessitating precise strategies for diagnosing and managing myocardial injury. This review critically synthesizes the current biomarker landscape and proposes an integrative framework to address the significant translational gaps between biomarker science and clinical practice. We conducted a comprehensive critical review, analyzing established and emerging biomarkers, including cardiac troponins, natriuretic peptides, and inflammatory and fibrotic markers, within the context of biological confounders, etiology-specific challenges, and clinical implementation barriers. Through thematic synthesis, we developed the novel C.A.L.I.B.R.A.T.E. framework to structure biomarker integration. While high-sensitivity assays have improved detection, they reveal chronic elevations in conditions like renal dysfunction, aging, and heart failure, reducing specificity and complicating acute diagnosis. Emerging biomarkers (eg, sST2, galectin-3) offer prognostic insight but lack therapeutic guidance and specificity. Etiology-specific puzzles (eg, myocarditis, COVID-19, MINOCA) highlight the limitations of isolated biomarker interpretation. The C.A.L.I.B.R.A.T.E. framework addresses these gaps by integrating Clinical context, Assay characteristics, Likelihood, Injury mechanism, Biomarker profiles, Rule-out/in thresholds, Adjunctive tests, Time kinetics, and Etiologies &amp; comorbidities. The future of myocardial injury management depends on shifting from isolated biomarker measurement to integrated, algorithm-driven interpretation. The C.A.L.I.B.R.A.T.E. framework provides a structured pathway for personalized diagnostic reasoning, bridging the translational chasm and advancing precision cardiology through context-dependent, multi-modal data synthesis.},
}
@article {pmid42291864,
year = {2026},
author = {Vipler, BS and Arnet, C and Keniston, A and Mardo, M and King, CJ},
title = {Balancing the Positives and Negatives: A Bibliometric Analysis of Positive and Negative Study Publication Patterns in High-Impact General Medical Journals.},
journal = {Cureus},
volume = {18},
number = {5},
pages = {e108720},
pmid = {42291864},
issn = {2168-8184},
abstract = {Despite calls to publish negative studies in prominent medical journals, greater submission and acceptance of positive results remains an issue. We aimed to quantify the degree to which high-impact general medical journals publish negative study results. We searched MEDLINE/PubMed for all randomized controlled trials published in five high-impact general medicine journals: Annals of Internal Medicine, the British Medical Journal (BMJ), the Journal of the American Medical Association (JAMA), the Lancet, and the New England Journal of Medicine (NEJM). Our search spanned a 10-year period from 2014 to 2023, which included data from before and after the emergence of the COVID-19 global pandemic. We performed single-author data extraction via abstract review to determine study positivity, defined as statistical significance for the primary outcome, flagging abstracts for secondary review if positivity was not clear. Two authors reviewed all flagged abstracts. We calculated the proportion of negative studies (i.e., not meeting statistical significance for the primary outcome) overall, by journal, and by publication year. We used logistic regression to model the odds of a study reporting a negative result by journal and year. Our search yielded 3722 individual citations, with screening resulting in 3600 randomized controlled trials for review, with 31% of studies reporting negative results. The proportion of negative studies varied, ranging from 22% in the Lancet to 51% in BMJ and JAMA. The proportion of negative studies remained consistent over time. High-impact general medical journals vary widely in the percentage of negative studies that they publish but did not change over time, even during and after a global pandemic. Further study is needed to determine factors influencing this phenomenon and what can be done to minimize publication bias.},
}
@article {pmid42292375,
year = {2026},
author = {Salvador Ibarra, IJ and Mora Guzmán, Z and Borrás Enríquez, AJ and Alpuche, J and Castañeda-Hernández, G and Pérez-Campos, E and Hernández-Huerta, MT and Cabrera-Fuentes, HA},
title = {Proteomic signals are not equal clinical phenotypes: redefining evidence standards in arbovirus-SARS-CoV-2 cross-reactivity.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1849848},
pmid = {42292375},
issn = {1664-3224},
mesh = {Humans ; *Proteomics/methods ; Cross Reactions/immunology ; *SARS-CoV-2/immunology ; *Dengue Virus/immunology ; *COVID-19/immunology ; Phenotype ; *Dengue/immunology/virology ; },
abstract = {The interaction between SARS-CoV-2 and dengue virus represents a biologically plausible yet clinically unresolved challenge in regions where both pathogens co-circulate. Emerging omics-based studies propose that prior SARS-CoV-2 exposure may shape a distinct dengue phenotype through immune imprinting and antibody-dependent mechanisms. However, whether these molecular signals translate into clinically meaningful outcomes remains unclear. This Perspective argues that current evidence remains preliminary and insufficient for clinically actionable interpretation, particularly regarding the conflation of group-level proteomic signals with patient-level clinical phenotypes. Using a recent pilot proteomic study as an illustrative example, we highlight key methodological constraints, including pooled sampling, limited sample size, inadequate control of confounding, and absence of longitudinal and clinical validation. We propose a framework for advancing from exploratory omics observations to clinically interpretable evidence, emphasizing patient-level resolution, temporal dynamics, statistical rigor, functional validation, and integration with standardized clinical endpoints. We also examine the clinical and public health consequences of premature inference, including the potential for premature clinical interpretation, overestimation of disease associations, and challenges in translational interpretation. We conclude that proteomic signals should be regarded as hypothesis-generating rather than predictive until supported by robust, reproducible, and clinically anchored evidence.},
}
@article {pmid42292490,
year = {2026},
author = {Lu, J and Ahmad, A and Chomont, N and Costiniuk, CT},
title = {Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1829485},
pmid = {42292490},
issn = {1664-3224},
mesh = {Humans ; *HIV Infections/immunology/virology ; *SARS-CoV-2/immunology/physiology ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology ; Virus Latency ; Vaccination ; CD4-Positive T-Lymphocytes/immunology/virology ; *HIV-1/physiology ; Disease Reservoirs/virology ; Virus Activation ; },
abstract = {Due to persistent immune dysfunction, People with HIV (PWH) are at increased risk of more severe infections with SARS-CoV-2 and hospitalizations. In several countries, they were listed as a priority group for receiving anti-SARS-CoV-2 vaccines when these vaccines were in scarce supply. These prophylactic vaccines do not completely prevent infections in vaccinated individuals, especially with a heterologous vaccine strain. However, they persistently reduce the severity of breakthrough infections, hospitalization rates and deaths. Although antiretroviral therapy (ART) suppresses HIV replication below the levels detectable by the assays used routinely in clinical care, it does not eliminate viral reservoirs; a small pool of infected cells carrying HIV proviruses integrated into the genomes of CD4[+] T cells and a subset of myeloid cells. Since vaccines work by stimulating these cells, they may theoretically reactivate latent HIV, increase plasma viremia and modulate the size of the HIV reservoir. The apprehension of HIV reactivation in PWH on ART prompted several studies in the past five years to investigate the impact of anti-SARS-CoV-2 vaccination on the markers of HIV persistence. Collectively, these studies have shown that the vaccination is generally safe in PWH on ART and induces only transient increases in viremia with no measurable impact on the size of the reservoir. However, in PWH with unsuppressed viremia, the vaccination was accompanied by more prolonged increases in viremia and in the frequencies of HIV-infected cells. In this review, we discuss these studies, their outcomes, their implications for HIV cure and propose topics for further research.},
}
@article {pmid42292740,
year = {2026},
author = {Lora, D and Lalueza Blanco, A and Maestro de la Calle, G and García Reyne, A and Ruíz-Ruigómez, M and Calderón, EJ and Menéndez-Orenga, M},
title = {A visual framework for classifying adaptive design clinical trials using the GATE frame and PICO terminology.},
journal = {Dialogues in health},
volume = {8},
number = {},
pages = {100315},
pmid = {42292740},
issn = {2772-6533},
abstract = {An adaptive design of a clinical trial is a trial design that offers pre-planned opportunities to use accumulating trial data to modify aspects of an ongoing trial while preserving the validity and integrity of that trial. The Consolidated Standards Of Reporting Trials (CONSORT) 2025 statements show the minimum information that should be included in the reporting of trials to ensure that trial protocols and trials reports are clear and transparent. Pre-planned interim analysis of adaptive clinical trials can modify the study population, the randomization, the intervention arms, the primary outcome or the clinical trial phase. Such key aspects can be reported using the Adaptive designs CONSORT Extension (ACE) statement, and additionally, conceptualised and represented using the Graphic Appraisal Tool for Epidemiological (GATE) and the PICO terminology (Population, Intervention, Comparison and Outcome). The main purpose of this article is to show how the GATE frame can complement the ACE guidelines by serving as a teaching tool to explain adaptive design clinical trials to a clinical or nonspecialist audience using examples of clinical trials for the prevention and treatment of COVID-19.},
}
@article {pmid42292916,
year = {2026},
author = {Otani, K and Kinoshita, T and Shindo, R and Kurushima, S},
title = {Digital harassment and its mental health impact among healthcare professionals: A scoping review.},
journal = {PCN reports : psychiatry and clinical neurosciences},
volume = {5},
number = {2},
pages = {e70362},
pmid = {42292916},
issn = {2769-2558},
abstract = {Digital harassment, including workplace cyberbullying, online defamation, and social media attacks, has been reported among healthcare professionals. This scoping review systematically maps existing evidence on digital harassment and its mental health consequences among healthcare professionals. Following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, we searched MEDLINE, Google Scholar, and Ichushi-Web through December 2025. Twenty-four studies from 12 countries were included. Workplace cyberbullying prevalence ranged from 1.5% to 46.6%. Across studies, digital harassment was reported in association with depression, anxiety, burnout, post-traumatic stress disorder (PTSD) symptoms, and moral injury-related experiences, although causal relationships could not be established. Seven included studies (28%) addressed pandemic-related digital harassment, including online abuse and stigmatization of healthcare workers during the COVID-19 period. Within the English- and Japanese-language literature identified in this review, Japanese studies were limited (three studies). From a consultation-liaison psychiatry perspective, harassment following ethically mandated actions may relate to moral injury-related experiences and may warrant further attention to institutional support. Evidence for effective interventions remains scarce. This review suggests that digital harassment may represent an emerging occupational concern with potential mental health implications. The evidence base was predominantly cross-sectional and methodologically heterogeneous, and findings should therefore be interpreted cautiously. Important needs include institutional policies, legal protections, psychological support systems, and further research on intervention effectiveness and cross-cultural patterns.},
}
@article {pmid42294056,
year = {2026},
author = {Baumann, H and Thomas, G and Alley, S and Duncan, MJ and Browne, M and Wollesen, B and Vandelanotte, C and Gilson, N},
title = {The past, present and future use of technology-enabled physical activity interventions in clinical and non-clinical populations: a bibliometric trend analysis across four decades.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1801405},
pmid = {42294056},
issn = {2673-253X},
abstract = {BACKGROUND: Physical inactivity remains a persistent global health challenge despite long-standing evidence that regular physical activity (PA) reduces chronic disease risk, cognitive decline and premature mortality. In parallel, digital health technologies have expanded rapidly, yet it remains unclear how distinct platform types have emerged, diffused and been differentially adopted in clinical vs. non-clinical populations.<br><br>METHODS: We conducted a large-scale bibliometric trend analysis of technology-supported PA interventions indexed in Scopus and SportDiscus, covering records published from 1953 to 2025. Using an active-learning screening workflow with title/abstract screening, sensitivity checks and consensus adjudication, we identified 2,981 eligible studies published between 1988 and 2025 across 757 journals and 63 countries. Studies were coded by population (clinical vs. non-clinical), platform cluster, and author-reported PA outcome direction abstracted from the publication record.<br><br>RESULTS: Publications increased markedly after 2008, with smartphone/mHealth and wearable sensors becoming the dominant platform clusters in the 2010s and early 2020s. In the smoothed overall trajectories, publication activity reached its highest level around 2022, followed by a contraction concentrated mainly in mature clinical platform clusters. Non-clinical studies generally adopted newer platforms earlier, whereas clinical studies showed a recurrent lag before converging for more established, accessible technologies. A distinct population-level reversal was visible in mature platforms: non-clinical studies led early smartphone, wearable and web-based uptake, clinical studies became more prominent around the COVID-19 period, and non-clinical studies again predominated by 2025 for smartphone/mHealth, wearable sensors and web applications. Multi-component designs were common, with the strongest network backbone centred on smartphone, wearable and web-based combinations. Reported PA improvement signals were common across both population strata, but these findings reflect patterns in published study reporting rather than comparative effectiveness.<br><br>CONCLUSIONS: By providing a platform-centred, cross-population and temporally resolved map of technology-enabled PA interventions, this study identifies mature technology backbones, emerging areas of experimentation, and recurrent translational gaps between clinical and non-clinical contexts. The findings support more theory-informed and implementation-aware intervention design while underscoring that bibliometric prominence should not be equated with real-world efficacy.},
}
@article {pmid42294358,
year = {2026},
author = {Chetty, L and Reddy, P and Ramdin, S and Govender, N},
title = {Long term cardiometabolic outcomes in COVID positive patients.},
journal = {Journal of public health research},
volume = {15},
number = {2},
pages = {22799036261445801},
pmid = {42294358},
issn = {2279-9028},
abstract = {In South Africa, approximately 4.5 million confirmed COVID-19 cases and 103,000 deaths have been noted. Symptoms range from being asymptomatic, mild respiratory issues to severe multi-organ failure and consequent death. Cardiometabolic risk factors, viz., type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), atherosclerosis, chronic kidney disease, hypertension, heart failure, and obesity, are flagged as the most prevalent comorbidities associated with the risk of severe COVID-19 and death. Many who have recovered from hospitalization continue to experience lingering symptoms known as long COVID, which have been linked to new-onset cardiometabolic disorders (CMD). This narrative review thus focusses on the clinical factors and the patient burden of diabetes mellitus and hypertension as two of the most commonly observed CMD, and aims to raise awareness regarding possible cardiometabolic complications. The findings expand the existing literature on the cardiometabolic effects of COVID-19, concentrating on outcomes observed more than three months after the acute phase of the illness.},
}
@article {pmid42298083,
year = {2026},
author = {Al-Shami, AS and Anwar, MM},
title = {The lung-brain axis in neurodegeneration: inflammatory, immune, and vascular mechanisms with therapeutic implications.},
journal = {Inflammopharmacology},
volume = {34},
number = {7},
pages = {4483-4513},
pmid = {42298083},
issn = {1568-5608},
mesh = {Humans ; *Neurodegenerative Diseases/immunology/physiopathology ; *Brain/metabolism/immunology ; Animals ; COVID-19 ; Inflammation/immunology ; *Lung/immunology/metabolism ; Blood-Brain Barrier ; SARS-CoV-2 ; Oxidative Stress ; },
abstract = {Neurodegenerative and chronic pulmonary diseases represent major global health challenges and have widely been investigated separately. Emerging evidence indicates the existence of a lung-brain axis, through which pulmonary pathology and environmental exposures can influence neurological health. The current review highlights the mechanistic and clinical evidence linking chronic lung inflammation, air pollution, and immune dysregulation to the onset and progression of Alzheimer's disease (AD), Parkinson's disease (PD), Multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). A pathway-based framework is presented in which lung inflammation, systemic cytokine release, oxidative stress, blood-brain barrier disruption, immune priming, and protein misfolding mediate lung-to-brain communication. Associations between chronic obstructive pulmonary disease, asthma, particulate matter exposure, and adverse neurological outcomes including cognitive decline, brain atrophy, disease progression, and elevated neurodegenerative risk are emphasized. Specific mechanisms are addressed, including immune-mediated effects in multiple sclerosis, inhalation-driven protein aggregation in Parkinson's disease, and vascular and oxidative injury contributing to dementia and amyotrophic lateral sclerosis. COVID-19 is considered a clinical model of acute lung-brain axis disruption, demonstrating inflammation-driven neurocognitive consequences, and its role in this context was also highlighted. Additionally, potential preventive and therapeutic strategies are discussed, highlighting pulmonary health and environmental exposure reduction as modifiable factors that may help mitigate neurological disease. This integrative review underscores the clinical relevance of the lung-brain axis and calls for interdisciplinary strategies to improve neurological outcomes through pulmonary and environmental interventions.},
}
@article {pmid42298693,
year = {2026},
author = {Meng, X and Wang, L and Tian, X},
title = {MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.},
journal = {Stem cell research &amp; therapy},
volume = {},
number = {},
pages = {},
doi = {10.1186/s13287-026-05115-0},
pmid = {42298693},
issn = {1757-6512},
abstract = {Diffuse alveolar damage (DAD) is the core pathological process of acute lung injury, characterized by dual injury to alveolar epithelial and capillary endothelial cells, initiation of an inflammatory storm, and subsequent fibrotic remodeling, with persistently high clinical mortality. This pathological change is not restricted to a single disease but widely exists in critical pulmonary disorders such as acute respiratory distress syndrome (ARDS), severe COVID-19, and rapidly progressive interstitial lung disease (RP-ILD), acting as a key driver of disease progression. In recent years, mesenchymal stromal cells (MSCs) and their derived extracellular vesicles (EVs) have become research hotspots for their superior immunomodulatory, anti-apoptotic, tissue-repair, and anti-fibrotic properties. Based on the DAD pathological framework, this article systematically correlates epithelial barrier injury, inflammatory cascade amplification and pulmonary fibrotic remodeling with the therapeutic mechanisms of MSCs and their derived EVs in ARDS, COVID-19 and RP-ILD. It aims to provide a solid basis for the clinical translation of MSCs- and EVs-based therapies and promote their development into a mechanism-driven therapeutic paradigm targeting DAD, with great clinical value and academic innovation.},
}
@article {pmid42299918,
year = {2026},
author = {Martyn, O and Devos, J and Bourron, P and AbouElwafa, D and Vitoux, O and Fougerolles, TR},
title = {A Cross-Country Evaluation of Respiratory Syncytial Virus and Human Metapneumovirus Surveillance Systems: Identifying Gaps and Best Practices for Improved Disease Monitoring.},
journal = {Reviews in medical virology},
volume = {36},
number = {4},
pages = {e70175},
pmid = {42299918},
issn = {1099-1654},
support = {//Sanofi/ ; },
mesh = {Humans ; *Metapneumovirus/pathogenicity/isolation &amp; purification ; *Respiratory Syncytial Virus Infections/epidemiology/virology ; *Paramyxoviridae Infections/epidemiology/virology ; *Respiratory Syncytial Virus, Human/pathogenicity/isolation &amp; purification ; United States/epidemiology ; *Epidemiological Monitoring ; Japan/epidemiology ; United Kingdom/epidemiology ; Germany/epidemiology ; France/epidemiology ; Spain/epidemiology ; Italy/epidemiology ; Population Surveillance ; },
abstract = {Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are seasonal respiratory viruses that can cause severe outcomes, particularly in older adults; however, their burden remains under-captured. The World Health Organisation (WHO) recommends expanding surveillance over pathogens, such as RSV and hMPV, through the Mosaic Respiratory Surveillance Framework. Although COVID-19 accelerated RSV surveillance, similar advancements for hMPV are lacking. This study evaluated and compared RSV and hMPV surveillance across multiple countries. A comparative qualitative analysis of RSV and hMPV surveillance was conducted in France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States using a framework based on the WHO guidance. Surveillance systems were mapped across seven modules: non-medically attended community, virological, community, outbreak, primary care, hospital, and mortality surveillance. Each was assessed using five criteria: granularity, timing, representativeness, sampling strategy, and communication. Sources included public health institution webpages, surveillance subsystems, and peer-reviewed publications. Most countries have dedicated RSV surveillance frameworks, with the United States and Spain having the most comprehensive systems. Key areas for potential improvement included limited adult-centric data and severe outcome reporting. No country had robust surveillance for hMPV (Germany reported hMPV-specific hospital data, whereas France, Germany, and the United Kingdom published sentinel positivity rates), and detection was mainly through influenza or COVID-19 virological surveillance. The absence of hMPV reporting from active sentinel surveillance, year-round monitoring, demographic and severity data, and restricted public information dissemination are common limitations. Significant limitations persist in RSV and particularly hMPV surveillance, highlighting the need for more robust, comprehensive systems.},
}
@article {pmid42300346,
year = {2026},
author = {N, SR and Jin, GW and Choy, JH},
title = {Nanochemical modulation of ECM-driven pseudo-resistance: convergent microenvironmental pathways in COVID-19 and cancer.},
journal = {Chemical communications (Cambridge, England)},
volume = {62},
number = {49},
pages = {12205-12215},
doi = {10.1039/d5cc07234d},
pmid = {42300346},
issn = {1364-548X},
mesh = {Humans ; *Extracellular Matrix/metabolism/drug effects ; *COVID-19/pathology ; SARS-CoV-2 ; *Neoplasms/pathology/drug therapy/metabolism ; Tumor Microenvironment/drug effects ; Pulmonary Fibrosis/pathology ; Animals ; },
abstract = {Extracellular matrix (ECM) remodeling is increasingly recognized as a central determinant of inflammation, fibrosis, and therapeutic response across chronic diseases. This Perspective examines how post-COVID-19 pulmonary fibrosis and stromal-driven resistance in solid tumors converge on a shared phenomenon, ECM-driven pseudo-resistance, an extrinsic and reversible microenvironmental state in which pathological matrix architecture, fibro-inflammatory signaling, and immune exclusion transiently limit therapeutic efficacy without conferring stable, mutation-driven cellular resistance. We highlight how nanochemical strategies, including ECM-penetrating and ECM-modulating nanohybrids, can dismantle these physical and signaling barriers by reprogramming matrix stiffness, mechanotransduction, and immune accessibility. By integrating evidence from virology, oncology, and materials science, this review proposes that targeting conserved ECM pathways through advanced nanochemistry offers a cross-disease therapeutic paradigm for overcoming pseudo-resistance in fibrotic and malignant pathologies.},
}
@article {pmid42300867,
year = {2026},
author = {Debbag, R and Avila-Agüero, ML and Gentile, A and Torres, J and Torres, C and Vazquez, L and Beltran, C and Brea-Del Castillo, J and Dagan, R},
title = {Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2689604},
doi = {10.1080/14760584.2026.2689604},
pmid = {42300867},
issn = {1744-8395},
mesh = {Humans ; *Pneumococcal Infections/epidemiology/prevention &amp; control ; *Pneumococcal Vaccines/administration &amp; dosage/immunology ; Latin America/epidemiology ; Immunization Programs ; *COVID-19/epidemiology ; Streptococcus pneumoniae/immunology ; Caribbean Region/epidemiology ; Vaccines, Conjugate/administration &amp; dosage ; Child ; Vaccination Coverage ; Vaccination ; Incidence ; },
abstract = {INTRODUCTION: The Latin American Society of Pediatric Infectious Diseases (SLIPE) convened a multidisciplinary expert panel to assess the post-pandemic epidemiology of invasive pneumococcal disease (IPD) in Latin America and the Caribbean. The COVID-19 pandemic initially reduced IPD incidence due to non-pharmaceutical interventions, but subsequent relaxation of restrictions, coupled with immunization gaps, led to a resurgence of pneumococcal infections. The consensus statement reviews literature and regional surveillance data to analyze how disrupted vaccination programs, socioeconomic inequities, and weakened healthcare systems amplified the regional vulnerability to vaccine-preventable diseases.<br><br>AREAS COVERED: This document addresses epidemiologic changes in IPD following the pandemic, the interplay between respiratory viral infections and pneumococcal disease, trends in pneumococcal conjugate vaccine (PCV) coverage and related barriers, and the emergence of non-vaccine serotypes causing IPD.<br><br>EXPERT OPINION: Sustaining herd protection in the region requires strengthening vaccination infrastructure, restoring confidence through effective communication, and ensuring the completion of booster doses in the second year of life. Despite limited serotype data, countries should prioritize the timely adoption of higher-valency PCVs in feasible schedules to mitigate the growing burden of pneumococcal disease and prevent further setbacks in child health.},
}
@article {pmid42302976,
year = {2026},
author = {Xie, L and Wu, LH and Ni, XC and Zhang, JN},
title = {Beyond proteostasis: LONP1 as an immunometabolic checkpoint in health and disease.},
journal = {Biochemical pharmacology},
volume = {251},
number = {Pt 2},
pages = {118170},
doi = {10.1016/j.bcp.2026.118170},
pmid = {42302976},
issn = {1873-2968},
mesh = {Humans ; *ATP-Dependent Proteases/metabolism/chemistry/genetics/immunology ; Animals ; *Mitochondrial Proteins/metabolism/chemistry/genetics/immunology ; *Proteostasis/physiology ; Mitochondria/metabolism/immunology ; Metabolic Reprogramming ; DNA, Mitochondrial/metabolism/genetics ; },
abstract = {Mitochondrial Lon protease 1 (LONP1) is an ATP-dependent protease involved in mitochondrial protein quality control, mitochondrial DNA (mtDNA) maintenance, and stress adaptation. Beyond this canonical role, accumulating evidence links LONP1 to metabolic rewiring, inflammatory signaling, immune-cell polarization, and disease-associated mitochondrial dysfunction. Recent human LONP1 cryo-electron microscopy (cryo-EM) structures have revealed nucleotide- and substrate-dependent conformational states, including fold-sensing intermediates, pore-loop rearrangements, and catalytic-site organization, providing a structural framework for substrate processing and state-dependent ligandability. Functionally, LONP1 regulates the turnover or stability of metabolic enzymes such as pyruvate dehydrogenase kinase 4 (PDK4), 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), and aconitase 2 (ACO2), thereby influencing carbon flux, epigenetic regulation, and immune-related metabolic programs. LONP1 deficiency or dysfunction can promote mitochondrial stress responses, including mtDNA release and cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING)-dependent inflammation, with implications for aging, pulmonary fibrosis, developmental disorders such as cerebral, ocular, dental, auricular, and skeletal anomalies (CODAS) syndrome, and organ injury. Conversely, increased LONP1 activity or expression has been associated with tumor progression, desmoplastic remodeling, ferroptosis resistance, and viral pathogenesis in selected models, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coxsackievirus B3 (CVB3). Pharmacological studies, including activators, dual-target inhibitors, and bortezomib-bound structural complexes, support the potential ligandability of LONP1 but also highlight unresolved issues in selectivity, target engagement, mitochondrial toxicity, and context-dependent therapeutic windows. This review summarizes current structural, mechanistic, and pharmacological evidence for LONP1 as a context-dependent immunometabolic regulatory node and discusses limitations and open questions that must be addressed before clinical translation.},
}
@article {pmid42302999,
year = {2026},
author = {de Victoria Carazo, JM and Guirao Arrabal, E and Montero-Alonso, M&#xc1; and Yuste Ossorio, ME and García García, F and Hernández Quero, J},
title = {Incidence, mortality and risk factors in COVID-19-associated pulmonary aspergillosis (CAPA): an umbrella review and meta-meta-analyses (2020-2025).},
journal = {Respiratory medicine},
volume = {260},
number = {},
pages = {108960},
doi = {10.1016/j.rmed.2026.108960},
pmid = {42302999},
issn = {1532-3064},
mesh = {Humans ; *COVID-19/complications/epidemiology/mortality ; Critical Illness ; Incidence ; *Pulmonary Aspergillosis/mortality/epidemiology ; Risk Factors ; SARS-CoV-2/physiology ; },
abstract = {INTRODUCTION: COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a severe and potentially underrecognised complication in patients with SARS-CoV-2 infection, particularly in intensive care units (ICUs). Existing reviews show substantial heterogeneity in diagnostic criteria, incidence estimates, and reported risk factors, limiting reliable interpretation of the overall evidence base.<br><br>MATERIALS AND METHODS: this umbrella review synthesised systematic reviews and meta-analyses published between 2020 and 2025 to clarify the incidence, mortality, and risk factors associated with CAPA. Searches were conducted in PubMed and Scopus. Eligibility was restricted to articles published in English and Spanish. Pooled estimates were re-calculated through a dedicated meta-metaanalysis.<br><br>RESULTS: sixteen reviews met the inclusion criteria, nine of them with meta-analysis. The pooled incidence among critically ill patients was 11.3% (95% CI 9.2-13.9), strongly influenced by diagnostic variability and the limited use of bronchoalveolar lavage during the pandemic. Overall mortality reached 51.6% (IQR 48.3-54.5), and CAPA tripled the risk of death compared with non-CAPA patients (OR 3.08; 95% CI 2.73-3.49). Consistent risk factors identified across meta-analyses included advanced age (OR 1.05 per year), chronic obstructive pulmonary disease (OR 1.98), type 2 diabetes mellitus (OR 1.25), systemic corticosteroid exposure (OR 1.72), and IL-6 inhibitors (OR 2.32).<br><br>DISCUSSION AND CONCLUSIONS: the marked heterogeneity observed across studies highlights the urgent need for harmonised and clinically applicable diagnostic criteria. CAPA remains an underdiagnosed condition associated with substantial mortality, underscoring the importance of early recognition strategies and improved diagnostic availability to guide timely management in high-risk patients.},
}
@article {pmid42303108,
year = {2026},
author = {Zhang, T and Zhang, H and Huang, S and Nong, T and Mo, X and Huang, J and Zheng, H and Liu, Y},
title = {Worldwide prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes: A systematic review and meta-analysis.},
journal = {Preventive medicine},
volume = {210},
number = {},
pages = {108625},
doi = {10.1016/j.ypmed.2026.108625},
pmid = {42303108},
issn = {1096-0260},
mesh = {Humans ; *Diabetic Ketoacidosis/epidemiology ; *Diabetes Mellitus, Type 1/complications/epidemiology/diagnosis ; Prevalence ; *Global Health/statistics &amp; numerical data ; Female ; Delayed Diagnosis ; COVID-19/epidemiology ; },
abstract = {OBJECTIVE: Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 diabetes (T1D) and a marker of delayed diagnosis, associated with significant morbidity, mortality, and healthcare costs. Global estimates of DKA at T1D onset remain inconsistent.<br><br>METHODS: We conducted a systematic review and meta-analysis, searching PubMed (1996), Web of Science (1966), Embase (1947), and Scopus (1980), each from its inception to October 2025, without restrictions. Studies reporting DKA prevalence at diagnosis in individuals <19&#xa0;years with newly diagnosed T1D were included. Pooled prevalence was calculated using random-effects meta-analysis. Subgroup analyses explored variations by country, region, World Bank income level, and pre- versus post-COVID-19 period; meta-regression examined continuous moderators.<br><br>RESULTS: A total of 233 studies from 58 countries (380,191 participants) were included. The pooled global prevalence was 41.9% (CI&#xa0;=&#xa0;39.7, 44.0; I[2]&#xa0;=&#xa0;99.3%; prediction interval: 12.9, 74.3), ranging from 15.6% (Sweden) to 78.5% (Thailand). Rates were lower in high-income (38.6%) countries (p&#xa0;<&#xa0;0.001). Younger age and higher female proportion were independently associated with higher prevalence.<br><br>CONCLUSIONS: Approximately two in five children with new-onset T1D present in DKA. The rising trend is indicative of ongoing challenges in achieving timely diagnosis, demanding urgent public health strategies encompassing clinical vigilance and innovative early detection approaches.},
}
@article {pmid42304269,
year = {2026},
author = {Conway-Moore, K and Birch, JM and McKinlay, AR and Graham, F and Oliver, EJ and Bambra, C and Kelly, MP and Bonell, C},
title = {The association between populist-aligned views and engagement with public health interventions: a systematic review of longitudinal studies.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-28020-w},
pmid = {42304269},
issn = {1471-2458},
support = {NIHR206124//National Institute for Health and Care Research/ ; },
abstract = {BACKGROUND: Population-level engagement with public health interventions is needed to achieve impact. Recently, however, there has been evidence of increasing resistance to government-led public health interventions in areas such as vaccination, climate change mitigation, sexual and reproductive healthcare, and non-pharmaceutical-based infection control measures. The rise in populist attitudes that has taken place in many countries over the last two decades may be one potential explanation for this phenomenon, given the importance placed on individual freedom and national sovereignty, and a distrust of scientific, government and other elites within much populist discourse.<br><br>METHODS: To understand how populist-aligned views might subsequently influence the receipt of public health interventions, we systematically reviewed quantitative, longitudinal evidence across thirteen bibliographic databases and relevant websites, published between 2008 and 2024. All studies were set in Organisation for Economic Co-operation and Development (OECD) countries and results were synthesised narratively.<br><br>RESULTS: Across 16 included studies, much of the evidence focused on COVID-19. We found evidence that prior populist-aligned attitudes have a negative impact on subsequent receipt of public health interventions, such as the COVID-19 vaccine and non-pharmaceutical-based prevention measures against COVID-19 (i.e., engaging in masking and social distancing) through both existing and increasing distrust in elite institutions and actors over time. We also found preliminary evidence about the potentially negative role of populist-aligned attitudes on the receipt of other vaccinations before and during the COVID-19 pandemic.<br><br>CONCLUSIONS: From a policy perspective, the findings from this review suggest the need for proactive efforts by political, scientific and medical establishments to build and maintain trust, thereby strengthening the reputation of both the public health leaders and institutions that engage with those more likely to be resistant to public health interventions to increase overall acceptance and uptake.<br><br>TRIAL REGISTRATION: PROSPERO registration number CRD4202451312.},
}
@article {pmid42305755,
year = {2026},
author = {Sharif, N and Chen, W and Niu, M},
title = {Mental health problems among ethnic minorities during public crises: a systematic review of coping strategies during the COVID-19 pandemic.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1822085},
pmid = {42305755},
issn = {2296-2565},
mesh = {*COVID-19/psychology ; Humans ; *Minority Groups/psychology ; Coping Skills ; *Adaptation, Psychological ; *Ethnicity/psychology ; *Mental Health/ethnology ; Pandemics ; *Mental Disorders/psychology ; SARS-CoV-2 ; },
abstract = {Public health crises exert a disproportionate psychological burden on ethnic minority populations, exacerbating pre-existing health disparities. Drawing upon the COVID-19 pandemic as a focal case, this systematic review synthesizes the coping strategies employed by ethnic minority communities, organized through the lens of ecological systems theory. Adhering to PRISMA guidelines, 65 peer-reviewed studies published between 2020 and 2023 were analyzed. The synthesis identified a multi-tiered coping response: (1) individual-level cognitive-emotional regulation and faith-based practices; (2) microsystem-level familial and communal support and digital mediation; (3) exosystem-level community governance and health policy; and (4) macrosystem-level cultural values and systemic belief structures. The analysis revealed a pronounced research emphasis on individual and microsystemic adaptations, exposing a critical empirical gap concerning structural and policy-driven interventions. While culturally tailored individual support is essential, these findings underscore the need for future research and policy to prioritize integrated, multilevel frameworks capable of effectively mitigating mental health inequities during future public health emergencies.},
}
@article {pmid42307131,
year = {2026},
author = {Specchia, ML and Zaçe, D and Cacciuttolo, MG and La Gatta, E and Petrella, L and Messina, R and Beccia, F and Capriolo, A and Turati, G and Di Pietro, ML},
title = {Addressing food and nutrition insecurity in European countries: a scoping review of strategies and policies.},
journal = {Annali dell'Istituto superiore di sanita},
volume = {62},
number = {2},
pages = {163-178},
doi = {10.4415/ANN_26_02_09},
pmid = {42307131},
issn = {2384-8553},
mesh = {Europe ; Humans ; *Food Insecurity ; *Food Supply ; *Nutrition Policy ; Agriculture ; COVID-19/epidemiology ; Food Security ; },
abstract = {BACKGROUND: Food and nutrition insecurity (FNI) is a major public health concern, due to its association with a variety of adverse health outcomes.<br><br>OBJECTIVE: The aim of this article is to provide a description of the strategies and policies to mitigate FNI in European countries, with a particular focus on economic, agriculture and social macro-areas.<br><br>METHODS: A scoping review, following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA) guidelines, was performed to map any study design, reporting policies and strategies that tackle FNI through food and nutrition security (FNS), access, utilization, or stability.<br><br>RESULTS: The review identified 13 documents from institutional websites and 6 scientific articles, published from 2005 to 2022. The included papers highlight a multifaceted approach to addressing food insecurity, with policies covering several dimensions. The policies identified can be categorized into several key themes: agriculture and fisheries, nutrition, environment, sustainability, economy, stakeholder's views, COVID-19 pandemic and other crisis, vulnerable populations (women, children, migrants) and information campaigns. The review describes in detail several policies, examining their effectiveness and the challenges faced in ensuring that these initiatives result in tangible improvements in food access, affordability, and nutritional quality, particularly for vulnerable populations.<br><br>CONCLUSIONS: The results show a current lack of a specific and coherent policy framework on FNI at a European level. Policy fragmentation is mainly due to the multidimensional nature of FNI, which has interconnections with many different areas of the food system. The findings suggest a comprehensive approach, incorporating several policy measures and involving multiple stakeholders to ensure sustainable and equitable access to nutritious food.},
}
@article {pmid42307996,
year = {2026},
author = {Chang, TMS},
title = {Artificial Cells: Perspective on Reconstructing Biological Cells and "Out of the Box" Innovations.},
journal = {Chembiochem : a European journal of chemical biology},
volume = {27},
number = {12},
pages = {e202500933},
pmid = {42307996},
issn = {1439-7633},
support = {271810//Virage Centre of Excellence in High Technology award, McGill University Advancement Program/ ; },
mesh = {Humans ; *Artificial Cells/metabolism/chemistry ; *Erythrocytes/cytology/metabolism ; Oxygen/metabolism ; COVID-19/prevention &amp; control ; },
abstract = {The first artificial cell (Chang 1957, 1964) was in the form of artificial red blood cells (RBCs), one of the most important cells because all cells, tissues, organs, and indeed the human being need it for survival. I first reconstructed artificial RBCs in vitro. This is made of cellular dimensions with ultrathin membranes of polymer, crosslinked protein, protein-lipid, or lipid. The next step in this work is to develop this for actual use to replace RBCs in the body. This is a more complex task requiring modifying the configuration and dimensions. Instead of starting with all three functions, a bottom-up approach is used. First, one with only oxygen transport function shows promising results in clinical trials with patients. A future direction is the development of artificial cells that have all three red blood cell functions including antioxidant, oxygen, and CO2 transport. My research group has also been doing innovative research going outside the box of RBCs. This way, extensive variations in contents, membranes, dimensions, and configurations are possible. This allows for worldwide and innovative applications that encompass hemoperfusion, delivery systems, COVID-19 vaccines, cancer therapy, therapy for hereditary enzyme defects like phenylketonuria, cell/stem cell therapy, microbes, nanomedicine, biotherapeutics, gene therapy, regenerative medicine, agricultural applications, aquatic culture, fermentation, nanorobotics, and other areas.},
}
@article {pmid42309184,
year = {2026},
author = {Zhou, W and Xu, P},
title = {Deciphering viral infections at single-cell resolution: From immune dynamics to host-pathogen interactions.},
journal = {Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases},
volume = {143},
number = {},
pages = {105969},
doi = {10.1016/j.meegid.2026.105969},
pmid = {42309184},
issn = {1567-7257},
mesh = {*Host-Pathogen Interactions/immunology/genetics ; Humans ; *Virus Diseases/immunology/virology/genetics ; *Single-Cell Analysis/methods ; Animals ; Single-Cell Gene Expression Analysis ; },
abstract = {Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology in infectious disease research, enabling high-resolution characterization of cellular heterogeneity, immune dynamics, and host-pathogen interactions at the single-cell level. In the context of viral infections-including SARS-CoV-2, hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza virus, and respiratory syncytial virus (RSV)-scRNA-seq has provided critical insights into immune-cell heterogeneity, immune landscape remodeling, and the emergence of previously unrecognized cellular states. Beyond immune profiling, scRNA-seq enables direct detection of viral transcripts within infected cells. This allows discrimination between productively infected and bystander cells and reveals virus-induced transcriptional reprogramming within target tissues. Additionally, single-cell approaches facilitate the analysis of adaptive immune repertoires through integrated integrated T-cell receptor (TCR) and B-cell receptor (BCR) sequencing sequencing and uncover intra-host viral diversity and evolutionary dynamics at unprecedented resolution. This review summarizes recent advances in the application of scRNA-seq in viral infection research, with a focus on immune regulation, host-pathogen co-transcriptomics, inflammatory signaling pathways, biomarker discovery, and translational implications. Comparative single-cell studies across acute and chronic viral infections have further revealed both shared antiviral programs and virus-specific immune adaptations.We further discuss current technical limitations and emerging computational strategies, as well as future integration with spatial transcriptomics and multi-omics platforms. Collectively, these developments highlight the potential of single-cell technologies to advance mechanistic understanding and guide precision diagnostics and therapeutic strategies in viral diseases.},
}
@article {pmid42309909,
year = {2026},
author = {Guedj, E and Horowitz, T and Verger, A},
title = {Brain [18F]FDG PET in Encephalitis and Postinfectious Neurocognitive Syndromes.},
journal = {PET clinics},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.cpet.2026.05.003},
pmid = {42309909},
issn = {1879-9809},
abstract = {Brain [18F]FDG PET can reveal metabolic abnormalities that precede, exceed, or clarify structural MR imaging findings. Among inflammatory brain diseases, the strongest clinical rationale is currently in autoimmune encephalitis, where fluorodeoxyglucose (FDG) PET increases diagnostic sensitivity, supports syndrome-oriented metabolic pattern recognition, and may contribute to selected follow-up. In viral encephalitis, use is selective rather than routine. In post-coronavirus infectious disease (COVID) condition and related postinfectious syndromes, FDG PET may support biological stratification and differential diagnosis in a subset of patients. Interpretation remains highly dependent on clinical context and methods. Translocator protein (TSPO) PET adds mechanistic information on neuroimmune activation but belongs mainly to the research domain.},
}
@article {pmid42310647,
year = {2026},
author = {Al-Marwani, S and Murang, Z and Tuah, NA},
title = {Integration technology into health care: a scoping review of digital interventions for adult obesity management.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-27904-1},
pmid = {42310647},
issn = {1471-2458},
abstract = {BACKGROUND: Digital health interventions are emerging as an approach to support obesity management through self-management and remote care. However, utilization, impact, and practicality remain unclear. This study aims to map research on digital health interventions for obesity management among adults, describing their characteristics, uses, and outcomes, and identifying gaps.<br><br>METHODS: A comprehensive scoping review following Arksey and O'Malley's methodological framework, in accordance with the Joanna Briggs Institute's guidelines and reported in line with the PRISMA-ScR guidelines, examined studies published between 2015 and 2025 across four databases: PubMed, Google Scholar, Scopus, and APA PsycNet.<br><br>RESULTS: A total of 43 studies met the eligibility criteria. Digital health interventions for obesity encompassed consultations and education on healthy lifestyle, behavioral change strategies, physical activity, dietary management, weight goal setting, intermittent fasting, gamification, and psychological support. Digital health interventions were delivered through telehealth, mobile apps, web-based programs, multicomponent digital approaches integrating several digital tools, and hybrid models combining digital delivery with face-to-face communication. These interventions often supported by devices such as digital scales, wearable trackers, and telemonitoring units to enhance self-monitoring, adherence, and engagement. The interventions were implemented across clinical, workplace, and community settings, including adaptations developed during the COVID-19 pandemic. The included studies showed varying and inconsistently reported outcomes, with some showing significant weight loss, improvements in metabolic markers and behavioral outcomes, including dietary adherence, physical activity, and self-monitoring, as well as favorable feasibility outcomes and the potential to maintain continuity of service delivery during the COVID-19 outbreak.<br><br>CONCLUSIONS: Digital health interventions used telehealth, mobile applications, web-based, multicomponent, and hybrid models across different settings, including healthcare settings (e.g., clinical and primary care) and community settings. Digital devices, such as scales, wearables, and activity trackers, were often incorporated to support self-tracking, adherence, and engagement. Reported outcomes included weight loss, improved self-monitoring, and behavioral changes such as enhanced dietary adherence and increased physical activity, and a favorable feasibility outcome; however, these outcomes were not consistently reported across all studies. Key gaps included short follow-up periods and limited evidence from LMICs. Future research should prioritize sustainable, equitable, scalable, culturally adapted, and cost-effective digital interventions.},
}
@article {pmid42310689,
year = {2026},
author = {Cornil, A and Roussel, S and Vander Haegen, M and Grenier, C and Vanpee, D and Van den Broucke, S},
title = {Key factors for promoting protective behaviours in future pandemics: an umbrella review.},
journal = {Archives of public health = Archives belges de sante publique},
volume = {},
number = {},
pages = {},
doi = {10.1186/s13690-026-01948-6},
pmid = {42310689},
issn = {0778-7367},
abstract = {BACKGROUND: The COVID-19 pandemic highlighted the critical importance of protective behaviours-such as mask-wearing, hand hygiene, and physical distancing-in managing public health crises. Understanding the factors that influence these behaviours is essential for improving preparedness and response in future health crises. This umbrella review aimed to synthesize evidence on determinants of protective behaviours during pandemics and to provide recommendations for policy and practice.<br><br>METHODS: Following PRISMA 2020 guidelines, we conducted an umbrella review of peer-reviewed literature reviews and meta-analyses published up to June 2025. Searches in Epistemonikos, MEDLINE, and Scopus targeted reviews on "protective behaviours" and "COVID-19", including other infectious diseases. Eligibility criteria followed the Population-Concept-Context framework: general population, multifactorial determinants of protective behaviours, and pandemic contexts. Data extraction was performed in a table that included review characteristics, behavioural domains (general compliance, medical interventions, open dialogue promotion, information handling, hygiene, physical distancing, and other behaviours), and factor valence. We conducted a narrative synthesis organizing factors by sociodemographic, personal, and social-environmental categories, with valence classification based on consistency of findings across reviews. Quality appraisal used the Joanna Briggs Institute checklist.<br><br>RESULTS: From 86 records identified, 11 met inclusion criteria, covering COVID-19 and other diseases (e.g., H1N1, SARS, MERS, Ebola). Quality scores averaged 8.8/10. Protective behaviours were influenced by three categories of factors: (1) sociodemographic (age, gender, education, socio-economic status) (2), personal (perceptions, beliefs, trust in authorities and science, political orientation) and (3) social/environmental (access to protective materials, social norms, community support, health education and communication, policies). Enabling factors included trust in credible sources, perceived effectiveness of measures, and multimodal communication. Barriers comprised misinformation, conspiracy beliefs, and resource inaccessibility. Some factors (e.g., age, gender, education) showed inconsistent effects across behaviours. Findings underscore the need for culturally sensitive messaging, transparent communication, and targeted interventions for vulnerable populations.<br><br>CONCLUSIONS: This umbrella review identifies multi-level determinants of protective behaviours to inform pandemic preparedness. It highlights the need for transparent communication through trusted channels, culturally adapted messaging, equitable access to protective resources, and targeted interventions for low-engagement groups. Integrating these determinants early may enhance population-level adherence.<br><br>REGISTRATION: PROSPERO registration number: CRD42023467236.},
}
@article {pmid42311945,
year = {2026},
author = {Vasileiou, E and Nena, E and Ntolios, P and Zissimopoulos, A and Constantinides, T},
title = {Vitamin D levels, general health status, and work productivity among healthcare workers-a scoping review of published literature (2010-2025).},
journal = {Frontiers in nutrition},
volume = {13},
number = {},
pages = {1816046},
pmid = {42311945},
issn = {2296-861X},
abstract = {INTRODUCTION: The risk for Vitamin D deficiency has been reported to be elevated among healthcare workers (HCWs), a fact that raises concerns about their health, resilience, and work performance. The objective of the study is to review published literature on Vitamin D deficiency among HCWs, reported health implications as well as the association with productivity.<br><br>METHODS: A comprehensive search of two databases (2010-2025), PubMed and Scopus was conducted with Google Scholar used as a supplementary source following PRISMA-ScR guidelines. The inclusion criteria were full-text studies in English enrolling HCWs per WHO definition, measuring serum 25(OH)D, and reporting health or work-related outcomes.<br><br>RESULTS: Thirty-six studies met the criteria 30 cross-sectional, 2 prospective, 4 interventional studies, 2 of which were Randomized Controlled Trials (RCTs). Vitamin D deficiency was highly prevalent across studies with reported prevalence ranging from 30% to over 90% varying by geographic region, season, professional role, deficiency threshold and assay method, particularly among nurses and shift workers. Key determinants included indoor work, long shifts, night duties, limited sun exposure, female sex, younger age, higher Body Mass Index (BMI), veiling, and lack of supplementation. Seasonal variation was confirmed. Deficiency was linked to immune vulnerability (higher SARS-CoV-2 infection), musculoskeletal issues, and mixed evidence for mental health outcomes. Limited data suggest higher Vitamin D levels may reduce presenteeism. RCTs demonstrated that high-dose supplementation improved serum levels and reduced respiratory infections.<br><br>CONCLUSION: Existing literature points that Vitamin D inadequacy among HCWs represents significant occupational health concern highlighting important evidence gaps and future research priorities.},
}
@article {pmid42311972,
year = {2026},
author = {Al Sabbah, H and Bani Hani, A and Bessadet, N and Aremu, O},
title = {A semantic FAIRness framework for epidemiological analysis of COVID-19 data in the UAE.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1759032},
pmid = {42311972},
issn = {2296-2565},
mesh = {*COVID-19/epidemiology ; Humans ; United Arab Emirates/epidemiology ; *Semantics ; SARS-CoV-2 ; *Information Dissemination/methods ; Data Analytics ; },
abstract = {The increasing availability of Coronavirus disease 2019 (COVID-19)-related data has highlighted the need for robust epidemiological analysis to support public health decision-making, particularly in contexts where data are heterogeneous and fragmented. In the United Arab Emirates (UAE), COVID-19 research has generated diverse genomic, clinical, and epidemiological datasets, yet their integration and reuse remain challenging due to inconsistencies in data representation, semantics, and interoperability. This study aimed to review key genomic and epidemiological studies related to COVID-19 in the UAE and, informed by identified gaps, proposes a semantic FAIRness framework for epidemiological data integration and analysis. The framework leverages the FAIR data principles and semantic technologies to provide a conceptual architecture for aggregating heterogeneous data sources, transforming data using ontological models, and enabling semantic linkage and reasoning across datasets. At a conceptual level, the framework is intended to support comparative analysis across studies, facilitate transparent representation of uncertainty, and promote semantically interoperable data sharing among diverse stakeholders. While selected components of the framework build on prior proof-of-concept implementations, the framework as a whole has not yet been fully implemented or empirically evaluated. The proposed approach is therefore positioned as a foundation for future development and evaluation, with the potential to enhance evidence-informed epidemiological analysis and public health decision-making in the UAE and similar contexts.},
}
@article {pmid42313357,
year = {2026},
author = {Chhokar, JK and Antonipillai, V},
title = {Prescription Medication Access Among Immigrant and Refugee Populations in Canada: A Scoping Review.},
journal = {Journal of immigrant and minority health},
volume = {},
number = {},
pages = {},
pmid = {42313357},
issn = {1557-1920},
abstract = {Access to prescription medication is a critical component of healthcare; however, immigrant and refugee populations in Canada face barriers that contribute to inequities in access to these essential treatments, which may subsequently influence health outcomes. This scoping review examines the existing literature on prescription medication access among immigrant and refugee populations in Canada, identifying key barriers and addressing knowledge gaps affecting medication access and related health outcomes. The Joanna Briggs Institute scoping review methodology was employed, including 21 peer-reviewed studies and 6 grey literature reports. Using the Socio-Ecological Model of Health (SEM), the findings were synthesized across individual, interpersonal, organizational, community, and societal levels to examine factors influencing prescription medication access among immigrant and refugee populations. Barriers to prescription medication access were identified across multiple SEM levels. At the individual level, language barriers, cultural beliefs regarding medications, and limited health system literacy affected medication access. Interpersonal barriers included challenges in patient-provider communication and concerns regarding privacy. Organizational barriers included structural characteristics of the healthcare system, including the gatekeeper model and limited availability of interpreter services. Community-level barriers included socioeconomic constraints affecting the ability to obtain medications. Societal level barriers included variation in provincial prescription drug coverage, reliance on private insurance, and disruptions associated with the COVID-19 pandemic. Addressing inequities in prescription medication access among immigrant and refugee populations will require coordinated multi-level strategies that improve health system navigation, communication supports, and medication coverage.},
}
@article {pmid42314718,
year = {2026},
author = {Abubakar, I and Tellez, D and Aldridge, RW and Altare, C and Barreto, ML and Boukari, Y and Burns, R and Cabieses, B and Devakumar, D and Fouad, F and Hargreaves, S and Knipper, M and Kumar, BN and Langella, R and Lau, K and Madise, N and Miranda, JJ and Mosca, D and Parikh, K and Pocock, N and Rast, E and Romanello, M and Rubenstein, L and Sheikh, K and Stevenson, K and Trummer, U and Zimmerman, C and Spiegel, PB},
title = {The UCL-Lancet Commission on Migration and Health: review of the state of progress.},
journal = {Lancet (London, England)},
volume = {407},
number = {10547},
pages = {2554-2576},
doi = {10.1016/S0140-6736(26)00494-0},
pmid = {42314718},
issn = {1474-547X},
mesh = {Humans ; *Emigration and Immigration/trends ; Health Policy ; *Health Services Accessibility ; *Refugees ; *Transients and Migrants ; },
abstract = {Although progress towards implementation of international agreements since publication of the UCL-Lancet Commission on Migration and Health in December, 2018, has been slow, global trends in migration and forced displacement have continued to rise. However, the COVID-19 pandemic showed that reaching refugees and migrants with health interventions is feasible with political will. The benefits of refugee-inclusive and migrant-inclusive health-care systems during emergencies (eg, COVID-19 and the war in Ukraine) are apparent, with numerous examples of inclusive policy making being rapidly introduced and innovative models developed to support health-care access, including preventive measures such as vaccination. Lessons from these successes should be learned and incorporated into future policy and practice. However, global political and financial uncertainty and disruption-combined with multiple conflicts and natural disasters-have increased individuals' need to move, which will continue to be exacerbated by the climate crisis. Although new conflicts and exacerbations of existing ones have led to a rise in forced displacement within and across national borders, labour migration has also risen dramatically, with the pandemic highlighting the health and social needs of these groups globally. The need for strong leadership and accountability, engagement of policy makers in the highest-level fora, and improved access to quality health services for refugees and migrants has never been greater. In this Review, nearly 8 years after the UCL-Lancet Commission on Migration and Health was published, we renew our call for action to: (1) improve health-care access and optimise outcomes for refugees and migrants by emphasising health in all migration and forced displacement policies; (2) establish data systems to monitor progress, together with appropriate use of new technologies to improve access, prevent harm, and safeguard privacy; (3) support research on adaptation to and mitigation of the health consequences of climate change on refugees and migrants; and (4) renew focus on the political determinants of health outcomes for people on the move. At this pivotal moment, with geopolitical, sociodemographic, and environmental turmoil, political leaders and societies can shape a better future by leveraging the human capital of migrants and upholding the human rights and dignity of all.},
}
@article {pmid42316311,
year = {2026},
author = {Wang, A and Hussain, N and Mudhar, A and Robbins, J and Friessen, J and Hicks, A and Satyapriya, S and Whitson, B and Bhandary, S and Khorsandi, M and Awad, H},
title = {Recent perioperative challenges in anesthesia during expansion of heart transplantation.},
journal = {Journal of cardiothoracic surgery},
volume = {},
number = {},
pages = {},
doi = {10.1186/s13019-026-04365-6},
pmid = {42316311},
issn = {1749-8090},
abstract = {The evolving landscape of heart transplantation requires cardiac anesthesiologists to adapt to new paradigms aimed at expanding donor and recipient pools such as utilizing more donor hearts from older donors, those with higher BMI, left ventricular hypertrophy (LVH), or coronary artery disease, as well as grafts obtained through long-distance procurement and from donors with infectious conditions such as hepatitis C, COVID-19, and HIV. The promising use of devices such as Organ Care System (OCS), Paragonix SherpaPak (SCTS), and Hypothermic Oxygenated Machine Perfusion (HOPE) for preservation of donor hearts, as well as recent increases in donation after circulatory death (DCD) transplants, exemplifies these advancements. In particular, the introduction of beating heart DCD transplants offers the opportunity to minimize ischemic times. However, perioperative complications such as catecholamine-sensitive and resistant vasoplegia, acute right-sided heart dysfunction, primary graft dysfunction (PGD), surgical bleeding, and coagulopathy complicate the picture. The expansion of donor and recipient pools increases the risk of ischemia and reperfusion injury. Despite these challenges, cardiac anesthesiologists must be vigilant in recognizing and managing these complications to ensure the best short and long-term outcomes. For example, novel prediction tools for PGD such as RADIAL and PREDICTA may assist in facilitating earlier intervention in high-risk patients. Finally, the interplay between surgical bleeding, vasoplegia, acute RV dysfunction/failure, and PGD immediately post-transplant provides a significant challenge to cardiac anesthesiologists. By addressing these challenges, they can improve outcomes and play a pivotal role in advancing heart transplantation. Their efforts will make the expansion worthwhile, increasing the availability of donor hearts and enhancing patient care.},
}
@article {pmid42316411,
year = {2026},
author = {Nikpour, J and Bouvier, M and Razmpour, O and Leslie, SL and Cimiotti, JP},
title = {Virtual Nursing Programs in Acute Care Settings: A Scoping Review of Patient, Nurse, and System-Level Outcomes.},
journal = {The Journal of nursing administration},
volume = {56},
number = {7},
pages = {390-396},
doi = {10.1097/NNA.0000000000001753},
pmid = {42316411},
issn = {1539-0721},
mesh = {Humans ; Patient Satisfaction ; *COVID-19/nursing/epidemiology ; *Nursing Staff, Hospital/organization &amp; administration ; *Telenursing/organization &amp; administration ; },
abstract = {OBJECTIVE: To synthesize the literature on the influence of virtual nursing (VN) on patient, nurse, and system-level outcomes in acute care.<br><br>BACKGROUND: Persistent nursing workforce challenges, including staff shortages and turnover, have been intensified by the COVID-19 pandemic, rising patient acuity, and increasing documentation demands. Many health systems have adopted VN programs, where remote nurses support bedside staff using audiovisual technology. Although these programs are rapidly expanding, evidence of their effectiveness remains limited.<br><br>METHODS: These authors conducted a scoping review following PRISMA guidelines. Eleven studies reporting patient, nurse, or system-level outcomes were included.<br><br>RESULTS: Most studies were cross-sectional pilots. Evidence was strongest for nurse and patient satisfaction, with reports of improved discharge efficiency, reduced administrative burden, and higher patient satisfaction. Findings for other outcomes, including safety indicators and financial metrics, were inconsistently reported.<br><br>CONCLUSIONS: Virtual nursing shows promise for enhancing patient satisfaction and workflow efficiency, but cannot replace investments in sufficient bedside staff and resources.},
}
@article {pmid42316413,
year = {2026},
author = {Crossen, EM and Murphy, J},
title = {Elements of Effective Professional Governance: An Integrative Review.},
journal = {The Journal of nursing administration},
volume = {56},
number = {7},
pages = {403-408},
doi = {10.1097/NNA.0000000000001755},
pmid = {42316413},
issn = {1539-0721},
mesh = {Humans ; *Leadership ; *COVID-19/nursing/epidemiology ; *Decision Making ; *Clinical Governance/organization &amp; administration ; *Nurse's Role ; },
abstract = {OBJECTIVE: This review synthesizes literature on elements of professional governance structures that support effective nurse-led decision-making and sustained engagement.<br><br>BACKGROUND: Professional governance has been demonstrated to enhance nursing engagement and improve patient outcomes. However, it remains unclear which elements of governance structures are most effective in a complex post-COVID-19 healthcare environment.<br><br>METHODS: A systematic search and critical appraisal were conducted to identify relevant literature. Data were extracted and analyzed to identify key themes.<br><br>RESULTS: Eight articles met the inclusion criteria. Thematic analysis revealed 4 key elements influencing nurse-led decision-making and engagement: council structure, leadership engagement, clinical nurse accessibility, and education and training. Several barriers to engagement were also noted.<br><br>CONCLUSIONS: Effective professional governance structures are crucial for fostering nurse-led decision-making and engagement. Future research should focus on empirical evaluations of professional governance structures and protocols to guide best practices in a rapidly changing healthcare landscape.},
}
@article {pmid42317109,
year = {2026},
author = {Davoodi, Z and Laurie, C and Tingley, K and Skidmore, B and Shaver, N and Sundaram, ME and Fell, DB and Brouwers, M and Sulis, G},
title = {Risk-of-bias assessment of vaccine effectiveness studies: a scoping review of systematic reviews.},
journal = {Epidemiology and infection},
volume = {154},
number = {},
pages = {e95},
pmid = {42317109},
issn = {1469-4409},
mesh = {Humans ; Bias ; COVID-19/prevention &amp; control ; *COVID-19 Vaccines ; Systematic Reviews as Topic ; *Vaccine Efficacy ; },
abstract = {Observational vaccine effectiveness (VE) studies provide essential real-world evidence but are prone to bias. Valid synthesis relies on rigorous risk-of-bias (RoB) assessment in systematic reviews of VE studies. Following JBI guidance, we mapped and described RoB assessment methodologies in systematic reviews of VE studies. We searched MEDLINE, Embase, and Web of Science from 1 January 2013 to 17 May 2023 and the grey literature from 1 January 2018 to 15 August 2023. Of 367 identified reviews, 38 lacked any RoB assessment, yielding 203 systematic reviews. Of these, 190 used existing tools (NOS (85/190, 44.7%), ROBINS-I (46/190, 24.2%), and JBI (11/190, 5.8%)) and 13 used an author-developed tool (13/203, 6.4%). Tools were adapted in 16.7% (34/203) of reviews and 7.2% (14/203) used multiple tools. Reviews included 20 (±25.7) observational studies, commonly cohorts (175/203, 86.2%), with COVID-19 (66/203, 32.5%) and seasonal influenza (62/203, 30.5%) frequently studied. VE was reported descriptively in 25.1% (51/203) of reviews, while 74.9% (152/203) provided meta-analyzed estimates primarily based on laboratory-confirmed infection (137/203, 67.5%) and symptomatic disease (130/203, 64.0%). Our findings indicate heterogeneous RoB assessment, reflected by use of different/multiple tools, frequent adaptations, author-developed methods, and absence of RoB assessment, highlighting the need for clearer guidance or tailored tools.},
}
@article {pmid42317372,
year = {2026},
author = {Pan, Y and Liu, G and Wang, H and Zhu, J and Tong, J and Li, Z and Yang, Q},
title = {From immunological mechanisms to targeted therapies: a bibliometric analysis in the domain of research concerning neutrophil extracellular traps and pulmonary diseases (2006-2025).},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1837492},
pmid = {42317372},
issn = {1664-3224},
mesh = {*Extracellular Traps/immunology ; *Bibliometrics ; Humans ; *Neutrophils/immunology ; *COVID-19/immunology ; *Lung Diseases/immunology/therapy ; *SARS-CoV-2/immunology ; Animals ; },
abstract = {OBJECTIVES: Neutrophil extracellular traps (NETs) are a crucial mechanism of the neutrophil immune response and exhibit complex dual pathological and physiological effects in pulmonary diseases. In recent years, this research domain has increased significantly, yet systematic bibliometric research remains absent. Therefore, this study utilizes bibliometric methods to thoroughly examine the research landscape and development sequence of this domain, aiming to provide theoretical references for future research.<br><br>METHODS: In this study, VOSviewer and CiteSpace were used to conduct a visualization analysis of the article concerning NETs and pulmonary diseases indexed in the Web of Science Core Collection (WoSCC) and Scopus databases from January 1st, 2006, to December 31st, 2025. Additionally, we utilized the R package bibliometric and Origin 2025b to optimize the data and visualization charts, ensuring that the analytical results were presented with greater clarity and intuitiveness.<br><br>RESULTS: This study covered 1, 539 articles from 561 journals. The results indicate that since 2006, this domain has seen a phased growth trend. The phase from 2010 to 2018 was a stable growth phase; After 2019, propelled by the COVID-19 virus infection (COVID-19), it entered a significant development phase, and reached its peak in 2022. In terms of influence, China and the United States are leading contributors. Mark R. Looney of the University of California is the core author, and "Frontiers in Immunology" is the most frequently cited journal. Through the visualization analysis of topic categories, keywords, and references indicates that research focal points in this domain have progressively transitioned from initial fundamental mechanisms and pathological descriptions to concerns regarding pulmonary inflammation, immune thrombosis, COVID-19, and biomarkers, subsequently extending to frontiers such as the NLRP3 inflammasome, interstitial lung disease (ILD), and tumor microenvironment (TME).<br><br>CONCLUSIONS: This study is the first application of bibliometric methods to visually present research domains related to NETs and pulmonary diseases, revealing the correlation between NETs and ILD, lung cancer (LC), and respiratory infections, along with the underlying mechanisms, continues to be a hot topic in research. However, the predominant function of NETs in specific diseases and their potential utility as therapeutic targets still necessitate further systematic elaboration.},
}
@article {pmid42317536,
year = {2026},
author = {Arzanani, KG and Rashidian Vaziri, MR and Sharif, S and Mollaee, M},
title = {A review on applications and safety of 222 nm far UVC light for surface and air disinfection.},
journal = {Biophysical reviews},
volume = {18},
number = {2},
pages = {545-561},
pmid = {42317536},
issn = {1867-2450},
abstract = {The emergence of the COVID-19 pandemic has highlighted the critical need for disinfecting methods that are effective to control and reduce the fast spread of infectious diseases. Among these methods, 222 nm UVC light has garnered noteworthy attention due to its unique properties and promising applications. In this paper, the importance, applications, safety considerations, and generation of 222-nm UVC light for disinfection are explored. The various UVC wavelengths commonly employed for disinfection purposes, emphasizing the distinct advantages of 222 nm are reviewed. It is discussed how 222 nm UVC light effectively inactivates pathogens on surfaces, making it a valuable tool for healthcare facilities, public spaces, and residential areas. The use of 222 nm UVC light in food processing, storage, and agricultural settings is explored. Its role in purifying indoor air, particularly in crowded environments, is examined. Specifically, its efficacy against viral pathogens, including SARS-CoV-2, is focused on. The studies on the impact of 222 nm UVC light on human skin and eyes considering both acute and long-term effects are discussed. The technological aspects of generating 222-nm UVC light are also explored.},
}
@article {pmid42317701,
year = {2026},
author = {Chen, S and Vermol, VV and Yu, J and Jiang, H},
title = {Immersive metaverse art as a psychological intervention for depression and anxiety: a narrative review and multilevel model integrating engagement, cultural identity, and neurocognitive mechanisms.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1829947},
pmid = {42317701},
issn = {1664-1078},
abstract = {Depression and anxiety rank among the leading causes of global disability, yet traditional treatments reach only a minority of affected individuals. The COVID-19 pandemic further exacerbated this crisis, triggering a ~ 25% worldwide surge in anxiety and depression prevalence. In parallel, immersive digital environments (the "metaverse") are maturing as platforms for creative expression and social connection. This review proposes that immersive metaverse art - interactive art experiences in VR/AR - can act as a multilevel psychobehavioral modulator. We integrate recent evidence showing that such experiences enhance engagement (flow, presence), enable identity exploration (customizable avatars, cultural narratives), and engage neurocognitive systems (reward, attention, regulation). Empirical studies of VR art interventions report acute mood improvements, stress reduction, and greater social connectedness. We synthesize these findings into a conceptual model linking core components (immersion, creative agency, social avatar, cultural symbolism) to mediating processes (flow, meaning-making, belonging) and outcomes (symptom relief, emotional regulation, behavioral activation). Rather than examining these domains as separate interdisciplinary themes, the review integrates them within a unified clinical framework focused on transdiagnostic mechanisms relevant to depression and anxiety. We compare immersive art therapy with traditional art therapy, noting unique advantages (scalability, personalization) and novel risks (overdependence, identity diffusion). Finally, we outline translational pathways - e.g. integrating VR art with cognitive therapies and highlight the need for rigorous trials and cross-cultural validation. Overall, immersive metaverse art emerges as a promising, if nascent, approach to mental health intervention, warranting further empirical and ethical scrutiny.},
}
@article {pmid42318393,
year = {2026},
author = {Xu, J and Liu, F and Yuan, HY and Pan, H and Xi, X and Chen, C and Li, DH and Lu, Y},
title = {COVID-19 vaccination in pregnancy: efficacy of second-generation vaccines, maternal-neonatal safety, and strategies to address vaccine hesitancy.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1835847},
pmid = {42318393},
issn = {2296-858X},
abstract = {The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound impact on global public health. The Omicron variant, marked by high transmissibility and pronounced immune evasion capabilities, poses a particularly severe threat. Pregnant women undergo physiological immune modulation during pregnancy, which increases their susceptibility to severe disease following SARS-CoV-2 infection. This heightened risk is evidenced by elevated rates of intensive care unit (ICU) admission and increased maternal mortality. Additional pregnancy-related physiological changes-including heightened oxygen consumption and reduced respiratory reserve-further compromise respiratory function and worsen clinical outcomes in infected individuals. Although robust evidence confirms the efficacy and safety of COVID-19 vaccines, vaccine hesitancy remains prevalent among pregnant women due to concerns about potential adverse effects and fetal safety. This review evaluates current vaccination strategies for pregnant women using second-generation COVID-19 vaccines, with particular emphasis on maternal and neonatal health outcomes. It also analyzes barriers to vaccine uptake and underscores the need for further research to refine vaccination protocols, support equitable access, and ensure the safe and effective deployment of vaccines-ultimately mitigating the risks of SARS-CoV-2 infection during pregnancy.},
}
@article {pmid42318873,
year = {2026},
author = {Liao, R and Luo, M and Yang, F and Xu, L and Zhang, J and Zhang, W and Guan, S and Zhang, Y and Luo, P and Cheng, P and Yang, J and Li, Y and Wang, Q},
title = {Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance.},
journal = {Drug development research},
volume = {87},
number = {5},
pages = {e70335},
pmid = {42318873},
issn = {1098-2299},
support = {32370993//National Natural Science Foundation of China/ ; 82173764//National Natural Science Foundation of China/ ; 2025ZD01903302//National Science and Technology Major Project/ ; 2021YFC2302500//National Science and Technology Major Project/ ; 2024YFC2310804//National Science and Technology Major Project/ ; CSTB2025NSCQ-GPX0624//Natural Science Foundation of Chongqing/ ; },
mesh = {Humans ; Animals ; *Drug Resistance, Bacterial/immunology ; *Bacterial Vaccines/immunology/administration &amp; dosage ; *RNA, Messenger/immunology/administration &amp; dosage ; *mRNA Vaccines/immunology ; Antigens, Bacterial/immunology ; Nanoparticles ; Vaccines, Synthetic/immunology ; Vaccine Development ; },
abstract = {The relentless rise of antimicrobial resistance poses a critical threat to global health, urgently demanding the development of antibacterial vaccines. Messenger RNA (mRNA) technology, validated during the COVID-19 pandemic, offers a powerful platform of fast development and flexibility. However, its application against bacterial pathogens remains an emerging frontier due to the structural complexity of bacterial antigens, challenges in achieving effective mucosal and cellular delivery, and the need to elicit balanced Th1/Th17-dominated immune responses for durable protection. Progress in antigen design, mRNA engineering, and lipid nanoparticle (LNP) delivery has enabled early preclinical success against Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Streptococcus pneumoniae. Yet, challenges such as complex antigen expression, mucosal targeting, and immune durability persist. This review provides a brief overview of recent advances in bacterial mRNA vaccine design, including antigen selection, mRNA engineering, and delivery platform optimization. Additionally, we summarize current preclinical progress across key bacterial pathogens and highlight emerging strategies that integrate AI-guided antigen discovery, synthetic biology, and next-generation delivery systems to accelerate clinical translation. Finally, we highlight the prospects of bacterial mRNA vaccines by integrating synthetic biology, AI-driven antigen prediction, and advanced delivery systems. These cutting-edge technologies hold the promise of overcoming existing barriers, ultimately establishing mRNA vaccines as a viable and powerful strategy to curb the tide of antibiotic-resistant infections.},
}
@article {pmid42319502,
year = {2026},
author = {Ahmad, R and Ullah, Z and Li, M and Tong, Y},
title = {Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.},
journal = {Archives of microbiology},
volume = {208},
number = {9},
pages = {},
pmid = {42319502},
issn = {1432-072X},
mesh = {Humans ; Animals ; *Anti-Bacterial Agents/pharmacology/therapeutic use ; *Drug Resistance, Bacterial/genetics ; *One Health ; *Bacteria/drug effects/genetics ; Global Health ; Gene Transfer, Horizontal ; Bacterial Infections/microbiology/drug therapy ; Drug Resistance, Multiple, Bacterial ; },
abstract = {Antimicrobial resistance (AMR) is a critical global health threat that undermines the treatment of infections and compromises medical interventions. AMR develops when microorganisms evolve mechanisms to survive antimicrobial exposure, a process accelerated by misuse and overuse of antibiotics in human medicine, agriculture, and veterinary settings. Bacterial resistance poses the greatest immediate concern, contributing to an estimated 1.27 million deaths in 2019 and nearly 5 million deaths associated with resistant infections worldwide. Without urgent intervention, Projections suggest that AMR could cause up to 10 million deaths annually by 2050, potentially surpassing cancer as a leading cause of mortality although these estimates remain subject to uncertainty. This review examines key biological mechanisms of resistance, including enzymatic degradation, target modification, efflux pumps, porin loss, and horizontal gene transfer. It highlights global hotspots and emerging resistance determinants such as NDM-1 and mcr-1, as well as antibiotic usage trends across human and animal sectors. Unlike acute pandemics such as COVID-19, AMR progresses silently but persistently, earning recognition as a "slow pandemic." Its spread involves interconnected human, animal, and environmental reservoirs, necessitating a One Health approach. The review also summarizes current global responses, including the WHO Global Action Plan, surveillance platforms such as GLASS, and ECDC, and research initiatives like CARB-X and GARDP. Despite progress, significant gaps remain in policy, surveillance, and antimicrobial stewardship, particularly in low- and middle-income countries, underscoring the urgent need for coordinated multisectoral action. However, the conclusions drawn are limited by variability in global surveillance data, differences in reporting standards, and reliance on previously published studies, which may not fully capture regional disparities.},
}
@article {pmid42320154,
year = {2026},
author = {Reeves, J and Daynes, E and Janaudis-Ferreira, T and Agarwal, K and Spencer, L and Tsai, LL and Alison, JA},
title = {Physiotherapy management of Long-COVID: an evidence-based approach.},
journal = {Brazilian journal of physical therapy},
volume = {30},
number = {4},
pages = {101609},
pmid = {42320154},
issn = {1809-9246},
mesh = {Humans ; *COVID-19 ; *Physical Therapy Modalities ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Long-COVID is a heterogenous, episodic, and multisystemic condition which can result following infection with a novel pathogen, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Whilst a precise pathophysiological cause is unknown, several mechanisms are hypothesised, each with plausible scientific rationale. Most people experiencing persistent symptoms following COVID-19 infection recover, yet some experience severe and debilitating illness for years after infection. Strategies to manage the sequelae of Long-COVID can improve the lives of sufferers.<br><br>OBJECTIVE: To describe the physiotherapy management of Long-COVID based on current evidence.<br><br>CONTENT: Those with 'invisible illness' (illness without outwardly visible signs), such as Long-COVID, often report stigmatisation and scepticism from healthcare systems. Validation of the experience of those with Long-COVID is therefore crucial to ensure patient-centred care. Thorough patient assessment is required to provide tailored management approaches given the diversity of Long-COVID presentations. Red flags that may contraindicate certain rehabilitation approaches (particularly exercise-based interventions) or that warrant further investigation should be considered. Assessments of fatigue, post-exertional malaise, respiratory symptoms, neurocognitive symptoms (i.e., brain fog), physical function, and orthostatic intolerance are strongly recommended. Management strategies may involve pacing and energy conservation techniques, pulmonary rehabilitation, inspiratory muscle training, dysfunctional breathing retraining, lifestyle and dietary strategies to manage orthostatic intolerance, and return-to-work planning.<br><br>CONCLUSION: Physiotherapists are well positioned to deliver individualised, patient-centred, and validating care based on best available evidence.},
}
@article {pmid42320893,
year = {2026},
author = {Koo, BS and Nederlof, RA and Jeon, E and Bae, GS and Kim, DS and Hong, JJ and Bakker, J},
title = {Machine Learning in Nonhuman Primate Models of Infectious Diseases: Current Applications and Future Perspectives.},
journal = {Journal of the American Association for Laboratory Animal Science : JAALAS},
volume = {},
number = {},
pages = {1-10},
doi = {10.30802/AALAS-JAALAS-26-043},
pmid = {42320893},
issn = {2769-6677},
abstract = {The amount of biologic data produced by biomedical research has increased significantly in both volume and complexity in recent years. Advances in computational power have increasingly enabled the use of machine learning (ML) to analyze and predict patterns from large-scale, complex biologic datasets. In nonhuman primate (NHP) infectious disease models, such high-dimensional datasets containing a large number of features are often obtained by next-generation sequencing-based multiomics and immunologic analyses. As a result, ML is particularly valuable for effective analysis and predictive modeling in this context. This review demonstrates that the application of ML in NHP infectious disease models has increased over time. Ensemble methods, particularly random forest, have emerged as the most frequently used algorithms, followed by regression and clustering approaches. Logistic regression and hierarchical clustering were the most commonly applied regression and clustering methods, respectively. These techniques are primarily used for vaccine response prediction, biomarker discovery, disease progression analysis, gene and pathway identification, and immune response characterization. Despite this increasing trend, the overall adoption of ML in NHP infectious disease models remains limited, which may reflect gaps in familiarity and computational expertise among researchers. Recent advances in generative artificial intelligence and user-friendly analytical platforms are expected to improve accessibility and promote broader adoption. This review aims to support understanding and facilitate wider application of ML in NHP infectious disease models.},
}
@article {pmid42322485,
year = {2026},
author = {Domingo-Del-Val, D and Lozano-Berges, G and Moradell, A and Gómez-Bruton, A and Matute-Llorente, &#xc1; and Casajús, JA},
title = {Temporal Trends in Health-Related Components of Physical Fitness of European Children and Adolescents from 1965 to 2025: A Systematic Review of Data on 417,362 Participants from 20 Countries.},
journal = {Sports medicine - open},
volume = {12},
number = {1},
pages = {},
pmid = {42322485},
issn = {2199-1170},
support = {CUS/621/2023//Gobierno de Arag&#xf3;n/ ; },
abstract = {BACKGROUND: Physical fitness is an important indicator of health during childhood and adolescence. Several components of physical fitness showed declining trends, with periods of acceleration or stabilisation depending on the component. Although Europe is the most studied continent, existing reviews have largely relied on single-test approaches or descriptive summaries, without simultaneously examining all health-related components, accounting for between-study variability analyses, or extending monitoring beyond 2014 to include the COVID-19 pandemic. This systematic review aims to analyse temporal trends of health-related components of physical fitness in European children and adolescents aged 6-16 years, examining differences by sex and age groups.<br><br>METHODS: A systematic search was conducted in PubMed, Web of Science, SPORTDiscus and Scopus up to December 2025. Eligible studies were conducted in European countries and included children and adolescents aged 6-16&#xa0;years, using repeated cross-sectional designs and reporting physical fitness components at two or more time points including sample sizes, means and standard deviations. Study quality was assessed with a modified Downs and Black checklist. Data were standardised into z scores based on sample-weighted means and standard deviations, considering the study, physical fitness component, sex and age. Linear mixed models were developed for each physical fitness component to estimate trends (linear, quadratic or cubic) and interactions by sex or age group.<br><br>RESULTS: Thirty-eight studies were included, representing 417,362 children and adolescents, from 20 European countries between 1965 and 2023. Cardiorespiratory endurance increased until the 1980s, then declined with a deceleration between 2015 and 2023. Body composition decreased linearly up to 2022, more markedly among males. Upper-body strength declined from the 1970s to 2020s, stabilising between the 1980s and 2000s. Lower-body strength increased until the 1980s and declined until 2023. Flexibility declined continuously, with an accelerated decrease after the 2000s.<br><br>CONCLUSIONS: Health-related components of physical fitness showed persistent declines among European children and adolescents, with differences in the shape and magnitude of trends. These findings highlight the heterogeneity of the available evidence and the need for a standardised, valid and feasible European fitness test battery. Public initiatives should continue to promote adherence to physical activity guidelines, particularly muscle-strengthening recommendations.<br><br>REGISTRATION: PROSPERO ID: CRD42024609888.},
}
@article {pmid42323274,
year = {2026},
author = {Wu, G and Jiang, S and Zhang, J},
title = {Lessons from warfarin management during the COVID-19 pandemic: from crisis to an opportunity to revolutionize telemedicine for chronic disease care.},
journal = {Expert review of hematology},
volume = {},
number = {},
pages = {1-7},
doi = {10.1080/17474086.2026.2692435},
pmid = {42323274},
issn = {1747-4094},
abstract = {INTRODUCTION: Corona virus disease 2019 (COVID-19) had a dramatic impact on the daily management of warfarin. To improve the quality of warfarin anticoagulation management in the outbreak setting while reducing the risk of patient exposure to COVID-19, researchers around the world have conducted many explorations and practices on warfarin management models.<br><br>AREAS COVERED: This review analyzes the factors affecting the management of warfarin by COVID-19, summarizes the current situation of warfarin management in the epidemic environment, introduces the characteristics and limitations of feasible warfarin management strategies, and provides a reference for the selection of warfarin management plans in clinical practice. From before 31 May 2025, we conducted a literature search using the PubMed database to identify relevant studies.<br><br>EXPERT OPINION: Warfarin management faced major challenges during the epidemic, exposing the vulnerability of its management system. At the same time, this state of affairs has driven improvements and innovations in related programs, facilitating the use of telemedicine technology in anticoagulation therapy. More importantly, this change is expected to inspire legislators and policy makers to introduce policies to extend telemedicine to a wider range of chronic disease management areas, thereby improving the overall quality and efficiency of healthcare services.},
}
@article {pmid42323682,
year = {2026},
author = {Hussain, BM and Hannigan, M and Conklin, D and Gordon, M and Huckins, A and Beauvais, A},
title = {Disordered eating behaviors, food insecurity and the COVID-19 pandemic among undergraduate students in the United States: a systematic review.},
journal = {Journal of eating disorders},
volume = {},
number = {},
pages = {},
doi = {10.1186/s40337-026-01604-y},
pmid = {42323682},
issn = {2050-2974},
abstract = {BACKGROUND: Eating disorders are highly prevalent among undergraduate students at colleges and universities in the United States (US). These behaviors may be associated with food insecurity and the COVID-19 pandemic, as both represent stressors that may be difficult for young adults to independently manage and cope with, turning to maladaptive coping strategies that are characteristic of disordered eating. The aim of this systematic review was to understand the relationship between eating disorders, defined by DSM-5 criteria, and food insecurity among undergraduate college students in the US, with additional consideration for the effects of the COVID-19 pandemic.<br><br>METHODS: PubMed, Cochrane Library, Scopus, Global Health (Ovid), PsycInfo, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Psychology Database were searched from 2014 to 2024 to capture eating disorders as defined by the DSM-5 criteria, searching terms representing eating disorders, food insecurity, and COVID-19. Articles were screened independently by 2 researchers using inclusion criteria agreed upon by all authors.<br><br>RESULTS: Disordered eating was associated with food insecurity and changes in behavior due to the COVID-19 pandemic. All studies were cross sectional with the number of participants ranging from 98 to 1996. Due to heterogeneity in assessment tools used in studies pooling of data and direct comparison of findings was limited. While no study measured eating disorders, food insecurity, and COVID-19 together, studies did reveal that food insecurity and COVID-19 were both associated with emotional eating that may indicate a greater risk for binge eating disorder.<br><br>CONCLUSIONS: While the overall data is limited, studies examining the effect of food insecurity or COVID-19 on undergraduate eating behaviors found that students experienced a significant increase in depressive and anxious symptoms contributing to disordered eating patterns. This may have a long-term impact on academic and health outcomes for young adults.<br><br>PROSPERO registration number CRD42024577588.},
}
@article {pmid42324038,
year = {2026},
author = {Ikrar, T and Muchsin, W and Sophian, A},
title = {Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development.},
journal = {Journal of virological methods},
volume = {345},
number = {},
pages = {115432},
doi = {10.1016/j.jviromet.2026.115432},
pmid = {42324038},
issn = {1879-0984},
mesh = {Humans ; *Vaccine Development/methods ; *Influenza Vaccines/immunology ; *Influenza, Human/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/immunology ; Epitopes/immunology ; SARS-CoV-2/immunology ; *Antigens, Viral/immunology ; Animals ; Coronavirus/immunology ; Pandemic Preparedness ; },
abstract = {BACKGROUND: The global burden of respiratory viral disease is shaped by two enduring threats: influenza, responsible for 290,000-650,000 annual deaths, and coronaviruses, exemplified by the catastrophic SARS-CoV-2 pandemic that caused over 7 million confirmed fatalities and profound socioeconomic disruption. Current strain-specific vaccines remain inherently reactive, incapable of anticipating antigenic drift, reassortment, or zoonotic emergence. A paradigm shift toward universal vaccines-designed to target evolutionarily conserved viral epitopes and confer durable, broad-spectrum protection across strains, subtypes, and viral genera-represents the most strategically consequential frontier in contemporary vaccinology and pandemic preparedness.<br><br>OBJECTIVE: This comparative narrative review provides an integrated synthesis of universal influenza vaccine (UIV) and pan-coronavirus vaccine (UCV) development, critically evaluating conserved immunological targets, advanced platform technologies, Phase I-III clinical pipeline status, and key translational barriers. By juxtaposing both developmental trajectories in a single analytical framework, we identify convergent scientific principles and divergent challenges to inform a unified pandemic preparedness strategy-an approach not previously addressed in the literature.<br><br>METHODS: A structured narrative review was conducted via systematic literature search of PubMed, EMBASE, and ClinicalTrials.gov covering 2015-June 2026, supplemented by hand-searching reference lists of landmark studies. MeSH and free-text terms encompassed universal influenza vaccines, pan-coronavirus vaccines, mRNA vaccine platforms, hemagglutinin stalk, neuraminidase, M2e, receptor-binding domain (RBD), fusion peptide, S2 subunit, and broadly neutralizing antibodies. Peer-reviewed original research articles, Phase I-III clinical trial reports, and authoritative reviews were included; non-English publications and preclinical-only studies lacking translational immunogenicity data were excluded.<br><br>RESULTS: Conserved viral epitopes-principally the hemagglutinin (HA) stalk domain, neuraminidase (NA) ectodomain, and M2e protein for influenza, and the receptor-binding domain (RBD) Class 4 epitope, fusion peptide, and S2 subunit for coronaviruses-have been validated as targets for broadly neutralizing antibodies (bnAbs). Multiple advanced platforms, including lipid nanoparticle-encapsulated mRNA, adenoviral vectors, computationally designed self-assembling nanoparticles (Mosaic-8 RBD-I53-50, SpFN), and structure-guided protein antigens, are progressing through early-phase clinical trials with promising cross-reactive immunogenicity profiles. Comparative analysis reveals that UIV development benefits from well-characterised bnAb epitopes and established animal challenge models, while UCV development is accelerated by unprecedented mRNA manufacturing infrastructure and genomic surveillance networks built during the COVID-19 response. Shared translational obstacles include antigenic imprinting, the absence of validated correlates of protection for cross-strain immunity, and inequitable manufacturing scalability.<br><br>CONCLUSIONS: Cross-strain protective vaccines against influenza and coronaviruses are scientifically achievable, supported by converging immunological principles and advancing clinical evidence across both fields. Accelerating translation to population-level protection requires coordinated investment in epitope-focused antigen engineering, correlate-of-protection validation, adaptive regulatory frameworks, and equitable global manufacturing capacity. Crucially, the scientific and policy lessons of COVID-19-both the remarkable speed enabled by prior platform investments and the inequities exposed in global vaccine distribution-must be integrated into universal respiratory virus vaccine programmes now, before the next pandemic forces another reactive response.},
}
@article {pmid42325158,
year = {2026},
author = {Ivers, N and Yogasingam, S and Lacroix, M and Brown, KA and Antony, J and Soobiah, C and Simeoni, M and Willis, TA and Crawshaw, J and Antonopoulou, V and Meyer, C and Solbak, NM and Murray, BJ and Butler, EA and Lepage, S and Giltenane, M and Carter, MD and Fontaine, G and Sykes, M and Halasy, M and Bazazo, A and Seaton, S and Canavan, T and Alderson, S and Reis, C and Linklater, S and Lalor, A and Fletcher, A and Gearon, E and Jenkins, H and Wallis, JA and Grobler, L and Beccaria, L and Cyril, S and Rozbroj, T and Han, JX and Xu, AX and Wu, K and Rouleau, G and Shah, M and Konnyu, K and Colquhoun, H and Presseau, J and O'Connor, D and Lorencatto, F and Grimshaw, JM},
title = {Audit and feedback: effects on professional practice.},
journal = {The Cochrane database of systematic reviews},
volume = {6},
number = {6},
pages = {CD000259},
pmid = {42325158},
issn = {1469-493X},
mesh = {Humans ; *Professional Practice/standards/statistics &amp; numerical data ; *Feedback ; Randomized Controlled Trials as Topic ; },
abstract = {BACKGROUND: Audit and feedback (A&amp;F) is a widely used strategy to improve professional practice. This is supported by prior Cochrane reviews and behavioural theories describing how healthcare professionals are prompted to modify their practice when given data showing that their clinical practice is inconsistent with a desirable target. Yet there remains uncertainty regarding the effects of A&amp;F on improving healthcare practice and the characteristics of A&amp;F that lead to a greater impact.<br><br>OBJECTIVES: To assess the effects of A&amp;F on the practice of healthcare professionals and to examine factors that may explain variation in the effectiveness of A&amp;F.<br><br>SEARCH METHODS: With the Cochrane Effective Practice and Organisation of Care (EPOC) group information scientist, we updated our search strategy to include studies published from 2010 to June 2020. Search updates were performed on 28 February 2019 and 11 June 2020. We searched MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), the Cochrane Library, clinicaltrials.gov (all dates to June 2020), WHO ICTRP (all dates to February Week 3 2019, no information available in 2020 due to COVID-19 pandemic). An updated search and duplicate screen was completed on February 14, 2022; studies that met inclusion criteria are included in the 'Studies awaiting classification' section.<br><br>SELECTION CRITERIA: Randomised trials, including cluster-trials and cross-over and factorial designs, featuring A&amp;F (defined as measurement of clinical performance over a specified period of time (audit) and provision of the resulting data to clinicians or clinical teams (feedback)) in any trial arm that reported objectively measured health professional practice outcomes.<br><br>DATA COLLECTION AND ANALYSIS: For this updated review, we re-extracted data for each study arm, including theory-informed variables regarding how the A&amp;F was conducted and behaviour change techniques for each intervention, as well as study-level characteristics including risk of bias. For each study, we extracted outcome data for every healthcare professional practice targeted by A&amp;F. All data were extracted by a minimum of two independent review authors. For studies with dichotomous outcomes that included arms with and without A&amp;F, we calculated risk differences (RDs) (absolute difference between arms in proportion of desired practice completed) and also odds ratios (ORs). We synthesised the median RDs and interquartile ranges (IQRs) across all trials. We then conducted meta-analyses, accounting for multiple outcomes from a given study and weighted by effective sample size, using reported (or imputed, when necessary) intra-cluster correlation coefficients. Next, we explored the role of baseline performance, co-interventions, targeted behaviour, and study design factors on the estimated effects of A&amp;F. Finally, we conducted exploratory meta-regressions to test preselected variables that might be associated with A&amp;F effect size: characteristics of the audit (number of indicators, aggregation of data); delivery of the feedback (multi-modal format, local champion, nature of comparator, repeated delivery); and components supporting action (facilitation, provision of specific plans for improvement, co-development of action plans).<br><br>MAIN RESULTS: We included 292 studies with 678 arms; 133 (46%) had a low risk of bias, 41 (14%) unclear, and 113 (39%) had a high risk of bias. There were 26 (9%) studies conducted in low- or middle-income countries. In most studies (237, 81%), the recipients of A&amp;F were physicians. Professional practices most commonly targeted in the studies were prescribing (138 studies, 47%) and test-ordering (103 studies, 35%). Most studies featured multifaceted interventions: the most common co-interventions were clinician education (377 study arms, 56%) and reminders (100 study arms, 15%). Forty-eight unique behaviour change techniques were identified within the study arms (mean 5.2, standard deviation 2.8, range 1 to 29). Synthesis of 558 dichotomous outcomes measuring professional practices from 177 studies testing A&amp;F versus control revealed a median absolute improvement in desired practice of 2.7%, with an IQR of 0.0 to 8.6. Meta-analyses of these studies, accounting for multiple outcomes from the same study and weighting by effective sample size accounting for clustering, found a mean absolute increase in desired practice of 6.2% (95% confidence interval (CI) 4.1 to 8.2; moderate-certainty evidence) and an OR of 1.47 (95% CI 1.31 to 1.64; moderate-certainty evidence). Effects were similar for pre-planned subgroup analyses focused on prescribing and test-ordering outcomes. Lower baseline performance and increased number of co-interventions were both associated with larger intervention effects. Meta-regressions comparing the presence versus absence of specific A&amp;F components to explore heterogeneity, accounting for baseline performance and number of co-interventions, suggested that A&amp;F effects were greater with individual-recipient-level data rather than team-level data, comparing performance to top-peers or a benchmark, involving a local champion with whom the recipient had a relationship, using interactive modalities rather than just didactic or just written format, and with facilitation to support engagement, and action plans to improve performance. The meta-regressions did not find significant effects with the number of indicators in the audit, comparison to average performance of all peers, or co-development of action plans. Contrary to expectations, repeated delivery was associated with lower effect size. Direct comparisons from head-to-head trials support the use of peer-comparisons versus no comparison at all and the use of design elements in feedback that facilitate the identification and action of high-priority clinical items.<br><br>AUTHORS' CONCLUSIONS: A&amp;F can be effective in improving professional practice, but effects vary in size. A&amp;F is most often delivered along with co-interventions which can contribute additive effects. A&amp;F may be most effective when designed to help recipients prioritise and take action on high-priority clinical issues and with the following characteristics: 1. targets important performance metrics where health professionals have substantial room for improvement (audit); 2. measures the individual recipient's practice, rather than their team or organisation (audit); 3. involves a local champion with an existing relationship with the recipient (feedback); 4. includes multiple, interactive modalities such as verbal and written (feedback); 5. compares performance to top peers or a benchmark (feedback); 6. facilitates engagement with the feedback (action); 7. features an actionable plan with specific advice for improvement (action). These conclusions require further confirmatory research; future research should focus on discerning ways to optimise the effectiveness of A&amp;F interventions.},
}
@article {pmid42325292,
year = {2024},
author = {Muruganantham, JK and Veerabathiran, R},
title = {Genetic Basis for Mucormycosis Progression in COVID-19 Patients: From Susceptibility to Severity.},
journal = {Infectious diseases &amp; immunity},
volume = {4},
number = {2},
pages = {86-92},
pmid = {42325292},
issn = {2693-8839},
abstract = {The dynamics of COVID-19 and mucormycosis reveal a complex interplay of genetic factors that influence the susceptibility, severity, and immune responses. COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits an increased incidence of mucormycosis, particularly in individuals with comorbidities or corticosteroid therapy. Mucormycosis is a fungal infection that affects the sinuses, orbits, and lungs and demands timely intervention with antifungal medications and surgery because of its life-threatening nature. Research on the genetic underpinnings of this intersection has unveiled key insights into the pathogenicity of Mucorales. Breakthroughs in genetic tools have exposed virulence factors, such as the CotH protein family and high-affinity iron-uptake mechanisms. Genetic susceptibility is a pivotal element in identifying individuals at risk of developing COVID-19, facilitating early detection, and allowing for personalized treatment strategies. DPP9, MIF, and TYK2 are among the genes implicated in COVID-19 severity, emphasizing the intricate relationship between genetic makeup and viral response. The genetic landscape extends to viral entry mechanisms, thereby affecting infection efficiency. Specific polymorphisms in genes such as IFNAR2, OAS3, and TYK2 are associated with COVID-19 severity, indicating shared genetic bases between severe and hospitalized cases. Mucormycosis is genetically predisposed, particularly in immunocompromised individuals. The challenge lies in understanding the genetic factors influencing susceptibility and offering insights into pathogenesis and potential therapeutic avenues. Organ transplantation adds another layer, increasing susceptibility to infections such as COVID-19 and mucormycosis. The impact of immunosuppression on COVID-19 severity remains elusive, necessitating ongoing research on the immunological mechanisms. Despite the challenges posed by emerging SARS-CoV-2 variants, the intricate connection between genetic factors and the interplay of COVID-19 and mucormycosis presents an opportunity for personalized treatment, targeted interventions, and refined public health strategies.},
}
@article {pmid42325367,
year = {2025},
author = {Zhang, R and Gu, X and Zhang, H and Guo, Y and Cao, B},
title = {Long COVID: current research and future directions.},
journal = {Infectious diseases &amp; immunity},
volume = {5},
number = {4},
pages = {260-271},
pmid = {42325367},
issn = {2693-8839},
abstract = {Long coronavirus disease (COVID) is defined as the continuation or development of new symptoms three months after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and that last for at least two months, with no other explanation for their cause. This disease includes various clinical manifestations that affect multiple organ systems, such as complications in respiratory, cardiovascular, neurological, and musculoskeletal systems. The most commonly reported symptoms include fatigue, cognitive dysfunction, dyspnea, and chest pain; however, the prevalence and severity of these symptoms vary greatly among individuals. The underlying mechanisms of long COVID are complex and multifaceted, encompassing viral persistence, immune system dysfunction, mitochondrial abnormalities, endothelial impairment, and alterations in the microbiome. Further, long COVID has imposed a significant burden on individuals, healthcare systems, and the economy by impairing an individual's quality of life and functional capacity, thereby increasing costs and demand for care and rehabilitation services. This review summarizes the definition, phenotypes, mechanisms, and current treatment advancements of long COVID and highlights specific research directions for future investigation.},
}
@article {pmid42325370,
year = {2025},
author = {Liu, S and Guo, Y and Wang, FS},
title = {Viral persistence in long COVID: Research advances and treatment strategies.},
journal = {Infectious diseases &amp; immunity},
volume = {5},
number = {4},
pages = {272-288},
pmid = {42325370},
issn = {2693-8839},
abstract = {Although the coronavirus disease 2019 (COVID-19) pandemic has ended, the enduring health impacts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continue to garner global attention, as approximately 10% of patients develop long COVID (post COVID-19 condition). The epidemiological characteristics and symptoms of long COVID have been reported, and various pathogenic hypotheses have been proposed. Recent evidence suggests that SARS-CoV-2 nucleic acids or fragments persist in some patients post-infection and that these are correlated with long COVID symptoms. This review focuses on clinical studies linking SARS-CoV-2 persistence to long COVID symptoms, and explores the relationship between viral persistence and other etiological hypotheses, such as immune dysregulation, vascular issues, coagulation dysfunction, microbiome dysbiosis, brainstem/vagus nerve signaling dysfunction, and latent virus reactivation. Futhermore, treatment strategies for long COVID are proposed based on current clinical trials of antiviral and immune modulation therapies. Understanding the role of viral persistence in long COVID pathogenesis is critical for developing targeted therapies and improving clinical management of this debilitating condition.},
}
@article {pmid42325371,
year = {2025},
author = {Jin, X and Ren, L and Ren, X and Wang, J},
title = {A survey of SARS-CoV-2 tropism.},
journal = {Infectious diseases &amp; immunity},
volume = {5},
number = {4},
pages = {289-302},
pmid = {42325371},
issn = {2693-8839},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly burdened global public health. However, the tropism of SARS-CoV-2 within the human body remains not fully understood. In this review, we overview the literature on SARS-CoV-2 infection across various human organs and tissues. We summarize the relevant specimen types, techniques for examining SARS-CoV-2 tropism, and findings at both organ/tissue and cellular levels. To systematically evaluate the evidence supporting SARS-CoV-2 tissue tropism, we establish a hierarchical classification system based on two key criteria: (1) specimen origin and (2) detection methodology. Clinical specimens obtained directly from COVID-19 patients provide the most definitive evidence, whereas organoid-derived specimens and animal models indicate potential infectivity under artificial conditions. In terms of detection methods, we prioritize viral particle identification over viral protein or RNA detection, as the latter requires further confirmation to establish productive infection. Our findings indicate that SARS-CoV-2 potentially targets multiple human organ systems, including the respiratory tract, lungs, kidneys, heart, blood vessels, pancreas, small intestine, liver, and salivary glands. By contrast, viral tropism for the central nervous system and the reproductive system remains uncertain and requires further validation. At the cellular level, we identify specific target cell types vulnerable to infection, including ciliated epithelial cells, alveolar type II pneumocytes, enterocytes, cardiomyocytes, vascular endothelial cells, renal tubular epithelial cells, and pancreatic acinar cells. Furthermore, we analyze the correlation between angiotensin-converting enzyme 2 receptor distribution patterns and viral tropism, as well as potential variations in tissue specificity among different viral variants. We expect this review to provide a comprehensive landscape of SARS-CoV-2 tropism and enhance our understanding of the life cycle and consequences of SARS-CoV-2 infection within the human body.},
}
@article {pmid42325459,
year = {2026},
author = {Ravindhiran, R and Chidambaram, K and Subramanian, A and Velayutham, S and Ramar, M and Dhandapani, K},
title = {Uncovering the Predisposing Factors of Mucormycosis: Insights from Systematic Review.},
journal = {Indian journal of microbiology},
volume = {66},
number = {3},
pages = {522-535},
pmid = {42325459},
issn = {0046-8991},
abstract = {Mucormycosis is a life-threatening fungal infection with high morbidity and mortality, particularly affecting immunocompromised individuals. Despite its growing clinical significance, its true global prevalence remains unclear. This systematic review identifies the key risk factors, epidemiological trends, and clinical challenges associated with mucormycosis. A comprehensive literature search was conducted to analyze global case reports, underlying predisposing conditions, and regional variations in disease manifestation. The leading risk factor in developed nations is hematological malignancies, while uncontrolled diabetes mellitus dominates in regions like India. Environmental and climatic factors influence fungal exposure and disease progression. Diagnosis remains challenging due to nonspecific symptoms, contributing to delayed treatment and poor outcomes. Early recognition of risk factors and improved diagnostic strategies are critical to reducing mucormycosis-related mortality. Public health initiatives must prioritise awareness, especially in high-risk populations. Further research is needed to address gaps in treatment and prevention.},
}
@article {pmid42325681,
year = {2026},
author = {Sheng, J and Song, Y and Zhang, A and Wang, M and Li, T and Ji, J},
title = {Unraveling the cardiovascular burden of long COVID: symptom profiles, underlying mechanisms, and clinical management insights.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1786633},
pmid = {42325681},
issn = {2297-055X},
abstract = {BACKGROUND: Long COVID refers to multisystem symptoms that begin within 3 months of COVID-19 infection and persist for at least 2 months. To this day, Long COVID remains a challenging clinical entity and a substantial global health burden, with cardiovascular sequelae representing a prominent component. Patients frequently report a range of symptoms including chest pain, palpitations, fatigue, and exercise intolerance.<br><br>OBJECTIVE: This mini review aims to synthesize current evidence on the symptom profiles, underlying mechanisms, and clinical management of Long COVID-related cardiovascular complications.<br><br>METHODS: We conducted a targeted narrative literature search of PubMed/MEDLINE, Web of Science, Scopus, Embase, and Google Scholar for articles published up to January 2026 using combinations of "Long COVID," "post-acute sequelae of SARS-CoV-2 infection," "cardiovascular," "myocarditis," "endothelial dysfunction," "microvascular injury," "dysautonomia," "vaccination," and "SARS-CoV-2 variants." Original studies, systematic reviews, meta-analyses, clinical guidance documents, and selected mechanistic studies were prioritized, whereas non-peer-reviewed preprints and single case reports were included only when they provided unique mechanistic or hypothesis-generating information. Eligibility was based on cardiovascular relevance to Long COVID; studies without post-acute or cardiovascular relevance were excluded.<br><br>RESULTS: The evidence indicates that cardiovascular Long COVID is heterogeneous and multifactorial, involving viral persistence, immune dysregulation, endothelial dysfunction, microvascular injury with hypercoagulability, autonomic nervous system dysregulation, and risk modification by acute disease severity, vaccination status, and SARS-CoV-2 variant period. Current management strategies remain primarily symptom-based, with emphasis on cardiovascular risk assessment, mechanism-informed phenotyping, graded rehabilitation, dysautonomia-directed treatment, and multidisciplinary follow-up.<br><br>CONCLUSIONS: Cardiovascular Long COVID is a heterogeneous burden driven by interacting mechanisms. Current evidence supports subgroup-based risk stratification and mechanism-informed management, while future studies should standardize endpoints and evaluate mechanism-targeted interventions.},
}
@article {pmid42326053,
year = {2026},
author = {Fernàndez-López, L},
title = {Community-Based Rapid Testing for HIV in Europe and Central Asia: A Narrative Review of Models, Effectiveness, and Implementation Challenges.},
journal = {Infection and drug resistance},
volume = {19},
number = {},
pages = {541591},
pmid = {42326053},
issn = {1178-6973},
abstract = {This narrative review examines the evolution, implementation, and impact of Community-Based HIV Testing (CBT) across Europe and Central Asia (ECA), a region where late diagnosis remains a persistent challenge and key populations continue to face substantial structural, legal, and social barriers to accessing conventional healthcare. This review synthesises evidence from academic studies, surveillance reports, and European initiatives to describe the diverse modalities of CBT, as well as their contribution to earlier diagnosis, improved case-finding among first-time testers, and more timely linkage to care. Across the region, CBT showed higher acceptability and positivity yields than facility-based testing, reaching populations disproportionately affected by HIV, such as men who have sex with men, people who inject drugs, migrants, and sex workers, and supports differentiated, person-centred service delivery aligned with World Health Organization and European Centre for Disease Prevention and Control guidance. Despite clear progress, major implementation gaps persist, driven by restrictive regulatory frameworks, uneven adoption of innovations such as lay provider testing and HIV self-testing, limited integration of community-generated data into national surveillance systems, and structural inequities including stigma, criminalisation, and lack of universal healthcare entitlements. This review also notes the resilience and adaptability of community-based models during recent crises, including COVID-19 and the war in Ukraine. Overall, the evidence demonstrates that CBT is a fundamental component of HIV prevention and diagnosis in ECA. Fully realising its potential requires updated policies that enable task-sharing, integration of multi-disease testing, strong referral pathways, sustainable financing, and formal incorporation of community-generated data into national monitoring frameworks. Strengthening these components is essential to accelerate progress toward the 2030 goal of ending AIDS as a public health threat.},
}
@article {pmid42326550,
year = {2024},
author = {Halma, M},
title = {Alterations of SARS-CoV-2 Evolutionary Dynamics by Pharmaceutical Factors.},
journal = {Infectious diseases &amp; immunity},
volume = {4},
number = {1},
pages = {35-40},
pmid = {42326550},
issn = {2693-8839},
abstract = {The outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has been influenced by the human response to the virus. These responses have undoubtedly impacted the evolutionary dynamics of the virus in ways distinct from a scenario lacking a widespread response. Two important pharmaceutical interventions, vaccination and the utilization of medications, particularly molnupiravir, known to have mutagenic properties, were the focus of this article. The impact of molnupiravir on human health was evaluated through 3 mechanisms: viral resistance, mutagenesis of SARS-CoV-2, and mutagenesis occurring in patients undergoing treatment with molnupiravir. These mechanisms, as well as the impact of vaccination, have inadvertently given rise to unforeseen challenges in the management of the COVID-19 crisis. Taking a systems view in future pandemic responses, and taking into account the evolution of the pandemic virus, may be critical to ending the pandemic at an earlier date.},
}
@article {pmid42326936,
year = {2026},
author = {Xiang, Y and Sun, G and Xiang, P and Hu, J and Tian, L and Zhang, Q and Wang, J and Xie, C},
title = {Confronting the known unknown: historical lessons and future strategies for Disease X.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1833807},
pmid = {42326936},
issn = {2296-2565},
mesh = {Animals ; Humans ; *COVID-19/epidemiology/prevention &amp; control ; *Henipavirus Infections/epidemiology/prevention &amp; control ; India/epidemiology ; Nipah Virus ; One Health ; *Pandemic Preparedness/methods ; Pandemics/prevention &amp; control ; SARS-CoV-2 ; },
abstract = {The 2026 outbreak of Nipah virus in West Bengal, India, a known WHO priority pathogen, serves as a timely reminder of the constant threat from high-consequence emerging diseases and underscores the critical relevance of Disease X-a future pandemic caused by an unknown pathogen. The profound global health and economic impact of COVID-19 has made the potential devastation of Disease X tangible. However, despite the insights gained from COVID-19, significant gaps remain in translating this awareness into an effective, coordinated, and pre-emptive preparedness strategy. This review advances an integrated response framework built around a One Health surveillance diagnostic therapeutic continuum. This foundational system enables real-time pathogen tracking and host immune profiling across human, animal, and environmental interfaces. Insights generated through this continuum directly inform the timely activation of non-pharmaceutical interventions, guide dynamic modeling, and enable the precise deployment of rapid medical countermeasures. Furthermore, these measures should be supported by resilient health infrastructure and equitable data sharing mechanisms, and be embedded within a governance model that prioritizes global collaboration and equity. Ultimately, mitigating Disease X requires a unified strategy that seamlessly integrates continuous monitoring, diagnostics, and treatment within a resilient and equitable operational architecture, thereby transforming pandemic preparedness from concept into reality.},
}
@article {pmid42327608,
year = {2026},
author = {Mostafa, MEA and Ahmed, AE and Abdulqader, MN and Abdel-Karim, SAM and Elgebaly, AS and Hagras, SAA},
title = {Antiviral Properties of Green-Synthesized Silver and Zinc Oxide Nanoparticles Against Coronaviruses: A Review.},
journal = {International journal of microbiology},
volume = {2026},
number = {},
pages = {7207868},
pmid = {42327608},
issn = {1687-918X},
abstract = {It is acknowledged that COVID-19 pandemic triggered by SARS-CoV-2 outbreak demands the development of efficient antiviral modalities independent of traditional vaccines and antiviral reagents. Metallic nanoparticles, such as silver nanoparticles (Ag-NPs) and zinc oxide nanoparticles (ZnO-NPs), have attracted considerable attention as promising antiviral agents due to their distinctive physicochemical properties and universal antimicrobial activity. This article examines the progress made between (2021 and 2025) in the green synthesis and the antiviral applications of Ag-NPs and ZnO-NPs against Coronavirus. The environmental friendly synthesis protocols using natural plant juices have been highlighted in this article due to their lower toxicity and greater biocompatibility. Various characterization methods, such as scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray diffraction (XRD), and UV-Vis spectrophotometry, have been used to examine nanoparticle morphology, stability, and surface characteristics. The findings reveald that Ag-NPs can suppress the viral replication by interacting strongly with S proteins, thereby hindering the cellular entry of the targeted Coronavirus. In contrast, ZnO-NPs showed that they have dual purposes: direct antiviral effects and immunomodulatory effects that involve cytokine regulation. The antiviral properties and the limitations of the individual nanoparticles are significantly modified by hybrid nanocomposites. In closing, the significance of using green-synthesized Ag-NPs and ZnO-NPs as antiviral materials is tremendous and warrants further exploration for antiviral applications. Nonetheless, there are still some unaddressed areas concerning the standardization of synthesis techniques and the validation of prolonged safety. Finally, it has been proven that there is a need for collaboration between nanotechnology and green technology in the development of environmentally benign, and universal antiviral medications against any future coronavirus pandemics.},
}
@article {pmid42327741,
year = {2026},
author = {Ma, J and Chen, H and He, Y and Huang, Y and Duan, X and Liu, Q and Liu, Z and Liu, H},
title = {COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1757291},
pmid = {42327741},
issn = {1664-3224},
mesh = {Humans ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/immunology ; *SARS-CoV-2/immunology ; Vaccine Development ; Vaccines, Synthetic/immunology ; mRNA Vaccines/immunology ; Nanoparticles ; Animals ; Vaccination ; Antibodies, Viral/immunology ; Nanovaccines ; Antibodies, Neutralizing/immunology ; Liposomes ; },
abstract = {The COVID-19 pandemic established mRNA vaccines as a clinically validated platform for rapid vaccine development and deployment. This review summarizes recent progress in COVID-19 mRNA vaccine technology, clinical performance, immunological mechanisms, and translational applications. First-generation nucleoside-modified mRNA vaccines formulated in lipid nanoparticles demonstrated strong protection against symptomatic disease and, more durably, against severe outcomes, while variant-driven immune escape, waning protection against infection, limited mucosal immunity, and heterogeneous responses in special populations revealed important constraints. The review compares mRNA vaccines with other COVID-19 vaccine platforms and clarifies endpoint-specific correlates of protection, emphasizing the distinct roles of neutralizing antibodies, memory B cells, T-cell responses, and non-neutralizing antibody functions. It further examines unresolved issues associated with repeated vaccination, including immune imprinting and IgG4 class switching, and evaluates technological strategies designed to improve durability, breadth, delivery, and immune programming. Key innovations include optimized RNA chemistry, structure-guided antigen design, advanced lipid nanoparticle formulations, alternative delivery systems, immune-shaping adjuvant approaches, and next-generation RNA formats such as self-amplifying RNA and circular RNA. Finally, the review discusses vaccination strategies for immunocompromised individuals, pregnant and lactating women, older adults, and children, as well as the expansion of mRNA technology into respiratory virus vaccines, cancer immunotherapy, and therapeutic protein expression. These developments define mRNA technology as a modular platform whose clinical impact depends on aligning RNA architecture, delivery system, antigen design, and target population.},
}
@article {pmid42327772,
year = {2026},
author = {Wang, S and Chen, T and Liu, S and Du, Z and Kong, Y and Yuan, Y and Ding, T and Wang, Q},
title = {Idiopathic multiple castleman disease case combined with severe neuropathy, Sjogren's syndrome and membrane nephropathy treated by rituximab: a case report and literature review.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1804654},
pmid = {42327772},
issn = {1664-3224},
mesh = {Humans ; Female ; *Castleman Disease/drug therapy/diagnosis/complications ; *Rituximab/therapeutic use ; *Sjogren's Syndrome/drug therapy/complications/diagnosis ; Aged ; *Glomerulonephritis, Membranous/drug therapy/complications/diagnosis ; *Immunologic Factors/therapeutic use ; Treatment Outcome ; },
abstract = {BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder characterized by dysregulated systemic immunity. Multiple cytokines had been found involved in the disease pathogenesis. Hence, involvement of multiple systems in iMCD complicates diagnosis and efficacy assessments. Although guidelines recommend anti-interleukin-6 (IL-6) agents as the primary treatment, options for second-line therapy remain indeterminate.<br><br>CASE PRESENTATION: A 65-year-old woman presented with progressive polyneuropathy and nephrotic-range proteinuria ten days after COVID-19 vaccination. Evaluation revealed multicentric lymphadenopathy, elevated IL-6, and plasmacytic-variant CD histopathology (HHV-8 negative). Concurrent Sj&#xf6;gren's syndrome and anti-PLA2R-negative membranous nephropathy were confirmed. After exclusion of POEMS syndrome, iMCD-NOS with intermediate severity was diagnosed. Initial rituximab-cyclophosphamide-dexamethasone therapy resulted in paradoxical neurological worsening despite declining VEGF levels. Anti-IL-6 therapy was inaccessible due to economic constraints. Single-agent rituximab was initiated and continued for nine cycles over 24 months, achieving clinical remission by January 2024 with near-normalization of inflammatory markers, resolution of proteinuria, and neurological recovery.<br><br>CONCLUSIONS: This case demonstrates that rituximab monotherapy can achieve clinical remission in iMCD-NOS with concurrent autoimmune manifestations when anti-IL-6 therapy is unavailable. The delayed response pattern-with biomarker improvement preceding clinical recovery-highlights the importance of serial VEGF monitoring and persistence with B-cell-directed therapy before concluding treatment failure.},
}
@article {pmid42327821,
year = {2026},
author = {Diago-Navarro, E and García-Vaz, C and Fanjul, G and Naniche, D and Almuedo-Riera, A and Bassat, Q},
title = {From Ebola to Hantavirus: Spain's Preparedness for High-Consequence Infectious Diseases.},
journal = {The Lancet regional health. Europe},
volume = {66},
number = {},
pages = {101749},
pmid = {42327821},
issn = {2666-7762},
abstract = {The hantavirus outbreak linked to the MV Hondius cruise ship, managed by Spanish authorities in May 2026, provides a timely opportunity to examine how Spain prepares and responds to imported high-consequence infectious diseases (HCID). This crisis bears greater resemblance to Spain's 2014 Ebola response than to the early stages of the COVID-19 pandemic. A decade after Ebola, Spain has built substantially stronger HCID capacities: a network of High Level Isolation and Treatment Units, improved clinical protocols, diagnostic capacity, and more consistent technical communication. Coordination with international partners functioned effectively. However, structural challenges persist: political tensions between central and regional authorities complicated real-time operational coordination and spilled into public communication, undermining the perception of a unified, technically-led response. Finalisation of a National Preparedness and Response Plan and full operationalisation of the National Public Health Agency (AESAP) remain urgent priorities. These domestic challenges sit within a deteriorating global health financing environment, directly eroding the surveillance and response capacities that HCID containment depends upon globally. Spain's Estrategia Española de Salud Global 2025-2030, its seat on the WHO Executive Board and its commitment to increasing ODA, position it well to advocate for stronger HCID-specific frameworks internationally, building on the genuine progress this response demonstrated.},
}
@article {pmid42328006,
year = {2025},
author = {Sekar, PKC and Veerabathiran, R},
title = {COVID-19 associated acute kidney injury.},
journal = {Infectious diseases &amp; immunity},
volume = {5},
number = {3},
pages = {190-197},
pmid = {42328006},
issn = {2693-8839},
abstract = {Acute kidney injury (AKI) associated with Coronavirus Disease 2019 (COVID-19) is a notable complication of COVID-19 that is difficult to diagnose and treat. This review summarizes the prevalence, pathophysiology, clinical presentation, and management of COVID-19-associated AKI (hereafter COVID-19 AKI). COVID-19 AKI is linked to a multisystem inflammatory syndrome and presents symptoms similar to those of AKI, which is associated with increased morbidity and death rates. The pathophysiological mechanisms of AKI include direct viral injury, cytokine storms, and systemic effects on the renin-angiotensin-aldosterone system. The diagnostic assessment of patients at risk for AKI involves screening for symptoms such as decreased urine output, fluid retention, and fatigue. In contrast, biomarkers like serum creatinine and blood urea nitrogen are used for early detection. The management strategies for COVID-19 AKI, such as avoiding nephrotoxic medications, are similar to those for AKI of other causes. Renal replacement therapy may be considered as a treatment option for severe COVID-19 AKI, particularly in cases of fluid overload, or electrolyte imbalances that cannot be managed with conservative treatments. Future research is essential to elucidate the pathophysiology, optimize diagnostic criteria, and develop targeted therapies for COVID-19 AKI. A multidisciplinary approach focusing on physical and mental health is crucial for comprehensive patient care. Addressing these gaps will necessitate substantial funding support to propel research efforts and improve patient outcomes.},
}
@article {pmid42328007,
year = {2025},
author = {Bassetti, M and Giacobbe, DR and Sepulcri, C and Labate, L},
title = {Epidemiology, clinical overview, and potential risk of a new pandemic of measles virus.},
journal = {Infectious diseases &amp; immunity},
volume = {5},
number = {3},
pages = {198-205},
pmid = {42328007},
issn = {2693-8839},
abstract = {Measles outbreaks are increasingly being reported worldwide, posing a global health problem of pandemic potential. Europe was particularly affected in 2024, with a surge in cases linked to a decrease in herd immunity caused by reduced vaccination rates. COVID-19 has worsened the already alarming situation due to the disruption of surveillance systems and access to vaccinations. Here, we discuss the issue of the global surge of measles, its clinical picture, and the role of vaccination, focusing in particular on the European region and describing the underlying causes and potential of a measles pandemic. The purpose of this review is to address current measles epidemiology, highlighting the risks of a potential measles pandemic and exploring possible strategies to address it.},
}
@article {pmid42328241,
year = {2024},
author = {Wang, M and Guo, H and Ju, B and Zhang, Z},
title = {Original Antigenic Sin on Antibody Response in SARS-CoV-2 Infection.},
journal = {Infectious diseases &amp; immunity},
volume = {4},
number = {3},
pages = {132-137},
pmid = {42328241},
issn = {2693-8839},
abstract = {Infection and vaccination can provide protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the emergence of SARS-CoV-2 variants has persisted, leading to breakthrough infections. Owing to the original antigenic sin (OAS), variant breakthrough infection or vaccination potentially induces a stronger antibody response against the ancestral strain than to subsequent variants, as in the case of influenza. Thus, overcoming OAS is important for the development of future vaccine designs. This review summarizes the recent findings on OAS in the antibody response to SARS-CoV-2 and its variants, with an emphasis on future vaccine designs.},
}
@article {pmid42328981,
year = {2026},
author = {Ortiz-Mateu, J and Martinez-Gil, L},
title = {Role of TMDs in Class I viral fusion proteins.},
journal = {Microbiology and molecular biology reviews : MMBR},
volume = {},
number = {},
pages = {e0000626},
doi = {10.1128/mmbr.00006-26},
pmid = {42328981},
issn = {1098-5557},
abstract = {SUMMARYClass I fusion proteins are trimeric viral membrane proteins that mediate fusion between the virion and cellular membranes. In their prefusion state, they comprise three domains: a globular "head" domain that binds the target cell receptor, a helical "stalk" domain, and a transmembrane domain (TMD) at the carboxy-terminal end that anchors the protein in the viral membrane. However, it is now evident that the role of the TMD extends beyond simple membrane anchoring. This review explores the dynamic and regulatory functions of the TMD throughout the viral life cycle. TMDs contribute to intracellular trafficking and modulate membrane fusion activity and receptor binding. During virion assembly, they facilitate the incorporation of fusion proteins into budding particles, and influence virion formation and release. Furthermore, TMDs mediate interactions between viral and host proteins, shaping the structural organization of viral complexes, and impacting cellular responses to infection. Collectively, these findings highlight the TMD as a critical determinant of viral fitness and infectivity, underscoring its potential as a novel therapeutic target.},
}
@article {pmid42329435,
year = {2026},
author = {Kareem, RA and Sameer, HN and Athab, ZH and Adil, M and Yaseen, A and Allela, OQB},
title = {Review: natural compounds as PCSK9 inhibitors for antiviral therapy.},
journal = {Archives of microbiology},
volume = {208},
number = {9},
pages = {},
pmid = {42329435},
issn = {1432-072X},
mesh = {Humans ; *PCSK9 Inhibitors ; *Antiviral Agents/pharmacology/therapeutic use ; Proprotein Convertase 9/metabolism ; *Biological Products/pharmacology/therapeutic use ; Animals ; SARS-CoV-2/drug effects ; Antibodies, Monoclonal, Humanized/pharmacology ; *Virus Diseases/drug therapy ; },
abstract = {From the perspective of both the host cell and the virus, cholesterol (CHO) plays a critical role during viral infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases the risk of cardiovascular disease by regulating plasma levels of lipoprotein(a), triglyceride-rich lipoproteins, and low-density lipoprotein cholesterol (LDL-C), and by promoting the degradation of the LDL receptor (LDLR). Emerging evidence implicates PCSK9 in the pathophysiology of several viral diseases, including human immunodeficiency virus (HIV), SARS-CoV-2, dengue virus (DENV), and hepatitis viruses. Two monoclonal antibody PCSK9 inhibitors (PCSK9i), evolocumab (Repatha[®]) and alirocumab (Praluent[®]), are approved by the Food and Drug Administration (FDA) for managing atherosclerotic risk. However, despite preclinical studies suggesting that these inhibitors and other CHO-lowering medications may interfere with viral replication, their therapeutic application as antivirals remains limited due to various restrictions. Naturally occurring compounds such as curcumin, berberine, quercetin, and polyphenols have demonstrated PCSK9-modulating and antiviral properties in preclinical models against viruses including HIV, hepatitis viruses, SARS-CoV-2, DENV, herpes simplex virus, human cytomegalovirus, and Epstein-Barr virus. Crucially, the majority of evidence for these natural substances remains preclinical, derived from in vitro and animal studies. The contribution of PCSK9 inhibition to the reported antiviral effects remains unclear, as pleiotropic mechanisms may be involved. Therefore, rather than being clinically proven substitutes for licensed PCSK9-targeted treatments, these molecules should be considered experimental or maybe supplementary medicines. This review examines the current preclinical evidence for natural inhibitors of PCSK9 and their antiviral properties, discusses clinical assessments to date, and considers the potential future role of naturally occurring PCSK9i in antiviral development, acknowledging the substantial research gaps that remain.},
}
@article {pmid42329791,
year = {2026},
author = {Jhandai, P and Vaddadi, K and Liu, L},
title = {NAD[+] metabolism at the host-virus interface.},
journal = {The Journal of general virology},
volume = {107},
number = {6},
pages = {},
pmid = {42329791},
issn = {1465-2099},
mesh = {*NAD/metabolism ; Humans ; Sirtuins/metabolism ; Poly(ADP-ribose) Polymerases/metabolism ; *Host-Pathogen Interactions ; Animals ; ADP-ribosyl Cyclase 1/metabolism ; Virus Replication ; *Virus Diseases/metabolism/virology ; *Viruses/metabolism ; SARS-CoV-2/metabolism ; },
abstract = {Nicotinamide adenine dinucleotide (NAD[+]) is one of the most important metabolic coenzymes that not only drives redox reactions and energy production but also acts as a critical substrate for several enzymes involved in immune signalling, DNA repair and epigenetic regulation. Viral infections are known as potent modulators of NAD[+] metabolism, with pathogens such as SARS-CoV-2, influenza A virus, Zika virus, herpes simplex virus and human immunodeficiency virus altering NAD[+] biosynthesis and consumption to benefit their persistence and replication. In this review, we summarize the current understanding of NAD[+] metabolism and its regulatory enzymes: sirtuins, poly (ADP-ribose) polymerases and CD38/CD157. We then discuss the interplay between NAD[+] homeostasis and virus infection. Understanding how diverse viruses manipulate NAD[+] metabolism could lead to broad-spectrum antiviral strategies grounded in metabolic resilience.},
}
@article {pmid42331642,
year = {2026},
author = {Guedj, E and Verger, A and Horowitz, T},
title = {Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.},
journal = {PET clinics},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.cpet.2026.05.004},
pmid = {42331642},
issn = {1879-9809},
abstract = {Subjective cognitive complaints are heterogeneous and may occur with normal, subtle, or objectively abnormal cognitive testing. Fluorodeoxyglucose (FDG) PET can help explore their metabolic substrate, particularly in subjective cognitive decline within the Alzheimer's disease continuum. In mild traumatic brain injury and long coronavirus disease (COVID), available studies suggest possible metabolic-network abnormalities but involve more heterogeneous populations and should be interpreted cautiously within multimodal, clinically characterized frameworks.},
}
@article {pmid42332867,
year = {2026},
author = {Barash, JA and Madden, J and Kofke, WA},
title = {Opioid-Associated Hippocampal Injury: Past, Present, and Future Directions.},
journal = {Hippocampus},
volume = {36},
number = {4},
pages = {e70111},
doi = {10.1002/hipo.70111},
pmid = {42332867},
issn = {1098-1063},
support = {1R21DA051737-01A1/DA/NIDA NIH HHS/United States ; },
mesh = {Humans ; *Hippocampus/drug effects/pathology/injuries ; Animals ; *Analgesics, Opioid/adverse effects ; *Opioid-Related Disorders/complications/pathology/epidemiology ; Amnesia/chemically induced ; },
abstract = {Three of the great public health challenges of our time converge at the hippocampus. The first, dementia, most commonly in the form of Alzheimer's disease, is well known to cause progressive hippocampal damage, resulting in the memory loss associated with the illness. The second, COVID-19 infection, has thus far been linked to hippocampal alterations across multiple studies. Lastly, the third, opioids-especially in the setting of misuse-have been associated with acute and persistent hippocampal injury; this review focuses on the collection of pre-clinical, clinical, and epidemiologic observations supporting this final relationship. Basic science work dating back decades has demonstrated a hypermetabolic response to opioids and associated damage to the hippocampus. The earliest cases recognized as opioid-associated amnestic syndrome (OAS) were subsequently identified in 2012 and reported as part of larger case series several years later. In 2019, a related but more fulminant syndrome involving cerebellar, hippocampal, and basal nuclei transient edema with restricted diffusion (CHANTER) was first described. From these investigations, a growing body of data has since emerged to suggest that regular opioid use, particularly at higher doses or potency, may be connected to a reduction in hippocampal volume and greater risk of dementia. This review begins with a synthesis of data supporting the underlying pathological mechanisms of opioid-associated hippocampal injury (OAHI), then covers the clinical spectrum of this phenomenon. Lastly, we will close with implications of OAHI that warrant further study, including the future epidemiologic impact on related cognitive disorders in the wake of the opioid epidemic and potential therapeutic applications of opioid antagonism for mild cognitive impairment.},
}
@article {pmid42333972,
year = {2026},
author = {Pizarro Andrade, RLN and Enriquez Canto, Y and Angulo Salas, RJ and Cahui Ramirez, CR and Díaz Gervasi, GM},
title = {Mental health outcomes and physical activity during the COVID-19 pandemic: A systematic review and meta-analysis of observational studies.},
journal = {Journal of health psychology},
volume = {},
number = {},
pages = {13591053261460700},
doi = {10.1177/13591053261460700},
pmid = {42333972},
issn = {1461-7277},
abstract = {The COVID-19 pandemic disrupted physical activity behaviors and worsened mental health worldwide. This study synthesized observational evidence on relationships between physical activity and depression, anxiety, and stress in adults during COVID-19. A systematic review and multilevel random-effects meta-analysis (PROSPERO CRD42023491651) of observational studies published January 2020-May 2023 included 38 studies with 140,915 adults using validated measures. Physical activity showed significant inverse associations with depression (r = -0.18; p < 0.001) and stress (r = -0.14; p = 0.043), but not anxiety (p = 0.340). Heterogeneity was substantial. Findings suggest physical activity can serve as a low-risk adjunct to mitigate depressive symptoms and perceived stress during public health crises, though interpretation should be cautious given observational design and high heterogeneity. Clinically, brief assessment and promotion of regular physical activity-tailored to context and delivered in-person or remotely-may support psychological well-being, while anxiety may require combined approaches during emergencies.},
}
@article {pmid42334213,
year = {2026},
author = {Bermejo-Jambrina, M and Paužuolis, M and Kimpel, J and Gerold, G},
title = {Double trouble: how co- and superinfections shape viral dynamics and host responses.},
journal = {Journal of virology},
volume = {100},
number = {7},
pages = {e0205525},
pmid = {42334213},
issn = {1098-5514},
mesh = {*Superinfection/virology/immunology ; *Coinfection/virology/immunology ; Humans ; *Host-Pathogen Interactions/immunology ; Virus Replication ; *Virus Diseases/virology/immunology ; Animals ; },
abstract = {Concurrent infection of humans by multiple distinct viruses is a common biological phenomenon with important consequences for virus-host interactions. While coinfection refers to the simultaneous infection of an individual or cell with two or more viruses, superinfection denotes the establishment of a secondary infection following a primary one, in which the initial infection influences the susceptibility, replication, or outcome of the secondary infection. Virus-virus interactions can be antagonistic, facilitative, dependent/assisted, or neutral. Antagonistic interactions include superinfection exclusion, whereby a primary virus prevents or restricts secondary infection of the same cell, securing access to host resources and stabilizing replication while limiting genetic and viral diversity. In contrast, facilitative viral interactions arise when one virus disrupts tissue barriers, suppresses immune responses, or remodels cellular pathways, thereby increasing susceptibility to additional viral infections. These interactions intersect with fundamental viral strategies, including the generation of genetically diverse RNA virus quasispecies that promote rapid adaptation and the deployment of DNA virus immunoevasins that interfere with antigen presentation and host immune recognition. While each of these processes has been extensively studied individually, their combined impact during coinfection remains poorly defined. In this review, we synthesize current knowledge on virus-virus interactions, viral diversity, and immune evasion in the context of multi-viral infections. We focus on how interactions at cellular and tissue levels shape infection outcomes, influence viral evolution, and contribute to virus-host coevolution. Finally, we also highlight key gaps in our understanding of viral interference and cooperation and discuss emerging approaches needed to define the spatiotemporal dynamics of coinfection in vivo.},
}
@article {pmid42334562,
year = {2026},
author = {Khudair, M and Swift, SL and Dienes, K and Kannan, YA and Vedhara, K},
title = {Factors associated with vaccination intentions and uptake among pregnant women in the UK: A scoping review.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2687220},
pmid = {42334562},
issn = {2164-554X},
mesh = {Humans ; Female ; Pregnancy ; United Kingdom ; *Vaccination/psychology/statistics &amp; numerical data ; *Pregnant People/psychology ; *Vaccination Hesitancy/psychology/statistics &amp; numerical data ; *Health Knowledge, Attitudes, Practice ; *Patient Acceptance of Health Care/psychology ; *Intention ; },
abstract = {This scoping review aimed to identify factors associated with vaccination decisions among pregnant women in the UK, guided by the SAGE matrix on vaccine hesitancy, and explored differences between qualitative and quantitative findings and between vaccine intentions (attitudes) and actual uptake (behaviors). Embase®, MEDLINE®, PsycInfo, Web of Science, and Cochrane were searched; rapid review methodologies were applied. From 2,326 records, 49 primary studies were included (published 2010-2025). We identified 222 qualitative factors from 32 studies, and 114 quantitative factors from 30 studies. Qualitative studies frequently reported individual and group influences, particularly beliefs and attitudes about vaccine effectiveness and safety, and the role of healthcare professionals in decision-making. Quantitative studies highlighted sociodemographic influences, including older age, ethnicity, and lower social/economic deprivation. Factors found to be associated with vaccination intention vs. uptake were inconsistent, though these findings should be interpreted cautiously given the modest number of studies addressing this issue.},
}
@article {pmid42336668,
year = {2026},
author = {Hasmee, N and Joshi, H and Gurung, M and Singh, B and Naseema, S},
title = {Optimising ICU supply chains: Evidence-based strategies for efficiency, resilience and patient safety-a structured narrative review.},
journal = {BMJ open quality},
volume = {15},
number = {2},
pages = {},
pmid = {42336668},
issn = {2399-6641},
mesh = {Humans ; *Intensive Care Units/organization &amp; administration ; *Patient Safety/standards ; COVID-19/epidemiology ; *Efficiency, Organizational ; SARS-CoV-2 ; Evidence-Based Practice ; },
abstract = {Inventory management in intensive care units (ICUs) plays a critical role in ensuring uninterrupted patient care, yet it remains an underprioritised component of healthcare operations. This narrative review explores current challenges and evidence-based strategies for optimising ICU supply chains. Issues such as unpredictable demand, manual stock tracking, procurement inefficiencies and limited staff training often contribute to stockouts, expired supplies and delayed interventions. The COVID-19 pandemic further exposed systemic vulnerabilities, emphasising the need for resilient, technology-driven supply systems. A comprehensive literature search (2004-2025) was conducted across PubMed, Scopus, Web of Science and Google Scholar using keywords related to ICU inventory, artificial intelligence (AI) forecasting, radio frequency identification (RFID), procurement and digital health logistics. Findings were synthesised into thematic categories addressing core problems and interventions. Key strategies include implementing automated tracking systems, adopting AI-driven demand forecasting, standardising procurement policies, training ICU staff in inventory best practices and establishing emergency buffer stock. Emerging technologies such as digital twins and blockchain are highlighted for their potential to enhance transparency, responsiveness and planning accuracy. Additionally, fostering multisourcing supplier partnerships and optimising ICU storage space can further enhance system agility and reduce waste. In conclusion, ICU supply chains must evolve from reactive, manual systems to proactive, data-driven frameworks. Hospitals should invest in digital infrastructure, staff training and ethical procurement models to build resilient, cost-effective and patient-centred supply chains.},
}
@article {pmid42337147,
year = {2026},
author = {Lansayan, J and Chin, KL and AbuBakar, S and Zainal, N},
title = {Clinical Manifestations and Immunological Impacts in Co-Infections and Sequential Infections of SARS-CoV-2 and Arboviruses.},
journal = {Current microbiology},
volume = {83},
number = {8},
pages = {},
pmid = {42337147},
issn = {1432-0991},
support = {MO002D-2021//Ministry of Higher Education, Malaysia/ ; MO002D-2021//Ministry of Higher Education, Malaysia/ ; MO002D-2021//Ministry of Higher Education, Malaysia/ ; MO002D-2021//Ministry of Higher Education, Malaysia/ ; },
mesh = {Humans ; *Coinfection/immunology/virology ; *COVID-19/immunology ; *Arbovirus Infections/immunology/pathology/virology/diagnosis ; SARS-CoV-2/immunology ; Arboviruses/immunology ; Cross Reactions ; Antibody-Dependent Enhancement ; Pandemics ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and arboviruses represent major global public health threats, each with distinct epidemiological and pathogenic profiles that often overlap in endemic regions. Reports of co-infection and cross-reactivity between these viruses highlight the need for deeper understanding of their interactions. Co-infections pose diagnostic challenges due to overlapping clinical symptoms and immune modulation, which may exacerbate disease severity. Moreover, antibodies generated from prior virus infections may influence the outcome of subsequent infections through mechanisms such as cross-reactivity and antibody-dependent enhancement (ADE). This review summarises current knowledge on the clinical manifestations and immunological consequences of co- and subsequent infections involving SARS-CoV-2 and arboviruses. Emphasis is placed on underlying pathophysiological mechanisms, including cross-reactivity and ADE, that shape host immune responses. Understanding these interactions is essential for improving diagnostic accuracy and guiding public health strategies to mitigate the risks associated with co-infections and sequential viral infections.},
}
@article {pmid42338490,
year = {2026},
author = {Nirala, S and Huang, C and Mu, Q},
title = {TORCH infections at the maternal-fetal placental transmission: an overview of multi-omics, pathogenesis and innate immune defense.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1817189},
pmid = {42338490},
issn = {2235-2988},
mesh = {Humans ; Female ; Pregnancy ; *Infectious Disease Transmission, Vertical ; *Immunity, Innate ; *Placenta/virology/immunology/parasitology ; *Pregnancy Complications, Infectious/immunology/virology ; Multiomics ; Host-Pathogen Interactions/immunology ; Toxoplasmosis/transmission/immunology ; Rubella/transmission/immunology ; Toxoplasma/immunology/pathogenicity ; Animals ; Proteomics ; Zika Virus Infection/transmission/immunology ; SARS-CoV-2/immunology ; Maternal-Fetal Exchange/immunology ; },
abstract = {The maternal-fetal interface represents a dynamic immunological frontier where pregnancy outcomes are determined by the delicate balance between host defense and microbial pathogenesis. Vertical transmission of pathogens across the placental barrier can lead to devastating consequences including fetal loss, stillbirth, prematurity, and congenital anomalies. The classic TORCH acronym encompasses Toxoplasma gondii, Other agents, Rubella virus, Cytomegalovirus, and Herpes simplex virus, though emerging viruses including Zika virus and SARS-CoV-2 have expanded this spectrum. This review synthesizes current understanding of molecular mechanisms underlying vertical transmission, emphasizing the placenta's multi-layered defense system encompassing the syncytiotrophoblast physical barrier, specialized decidual immune cell populations including decidual natural killer cells and macrophages, and constitutive antimicrobial signaling pathways focusing on the placenta's multi-layered defense system encompassing the syncytiotrophoblast physical barrier, specialized decidual immune cell populations including decidual natural killer cells and macrophages, and constitutive antimicrobial signaling pathways. Concurrently, we examine pathogen strategies to subvert these defenses through receptor manipulation, immune evasion, and intracellular replication niches. A major focus is dedicated to the impact of proteomics and single-cell multi-omics in deconvoluting the host-pathogen interactome and identifying biomarkers of fetal injury. Recent seroprevalence studies demonstrate that younger women represent the most susceptible population to acute TORCH infections, highlighting the need for targeted screening programs. This synthesis provides a framework for developing precision diagnostics and targeted interventions to prevent vertical transmission and reduce the global burden of congenital infections.},
}
@article {pmid42339932,
year = {2026},
author = {Theodoro, EL and Prediger, KM and Damacena, MA and Silva, CVD and Cano, RDN and Uehara, SCDSA},
title = {Oral manifestations associated with long COVID: a scoping review.},
journal = {Revista brasileira de enfermagem},
volume = {79},
number = {},
pages = {e20250198},
pmid = {42339932},
issn = {1984-0446},
mesh = {Humans ; Post-Acute COVID-19 Syndrome ; *COVID-19/complications ; *Mouth Diseases/etiology/epidemiology ; Quality of Life ; SARS-CoV-2 ; Female ; },
abstract = {OBJECTIVES: to map scientific evidence on oral manifestations originating during long COVID.<br><br>METHODS: this is a scoping review based on the method described by JBI. Primary articles published in Portuguese, English, and Spanish between March 2020 and December 2024 were included from the PubMed, Web of Science, Virtual Health Library, Scopus, Excerpta Medica dataBASE, and Scientific Electronic Library Online databases, and a descriptive analysis was performed.<br><br>RESULTS: of the 15 studies analyzed, the most frequent oral manifestations of long COVID were taste alterations, xerostomia, difficulty chewing, gingival bleeding, periodontitis, and changes in the teeth.<br><br>CONCLUSIONS: an association between long COVID and various oral manifestations was evidenced, impacting the quality of life of patients. Factors such as age, comorbidities, and social inequalities influence the persistence of these manifestations, with a higher prevalence in women. Multiprofessional collaboration and clearer guidelines are essential to improve dental care.},
}
@article {pmid42340118,
year = {2026},
author = {Poder, TG and Camara, MA and Bouchard, PA and Lellouche, F},
title = {Pricing Policy for Medical Oxygen and Potential Savings.},
journal = {Journal of evaluation in clinical practice},
volume = {32},
number = {4},
pages = {e70510},
pmid = {42340118},
issn = {1365-2753},
mesh = {Humans ; Quebec ; *Oxygen Inhalation Therapy/economics ; *Cost Savings ; *Oxygen/economics/therapeutic use ; *COVID-19/epidemiology ; *Costs and Cost Analysis ; },
abstract = {BACKGROUND: Medical oxygen is essential in modern medicine.<br><br>AIMS: This study analyzes the pricing policies and costs of medical oxygen in Quebec, provides elements of international comparison, and explores the potential savings through the optimization of oxygen therapy practices.<br><br>MATERIALS AND METHODS: It combines a narrative literature review, an analysis of administrative and financial documents, as well as administrative data obtained from representatives of the healthcare sector in Quebec.<br><br>RESULTS: The literature review highlights the challenges of producing, storing, and distributing medical oxygen, which have been accentuated by the COVID-19 pandemic. A very large disparity in pricing policies is also noted among healthcare systems, especially when cylinders are predominantly used. In Quebec, costs vary according to production methods, logistics, and contractual clauses. Optimizing oxygen therapy practices would allow significant savings, particularly by reducing oxygen consumption through various strategies.<br><br>DISCUSSION: The study shows the complexity of managing medical oxygen costs, amplified by limited competition and rigid contractual clauses. International comparison highlights the importance of infrastructure, while optimizing oxygen therapy practices offers significant savings potential. To reduce costs, it is recommended to improve distribution management, adopt more flexible contractual clauses, and strengthen competition.<br><br>CONCLUSION: To optimize medical oxygen use, actions to undertake from managers and clinicians are highlighted.},
}
@article {pmid42340456,
year = {2026},
author = {Tahmtan, A and Nissapatorn, V and Saravanabhavan, SS and Taherkhani, S and Aghcheli, B},
title = {Viral Infections and Neurodegenerative Diseases: Reinterpreting the Crosstalk Through a Dual-Role Lens.},
journal = {Current microbiology},
volume = {83},
number = {8},
pages = {},
pmid = {42340456},
issn = {1432-0991},
mesh = {Humans ; *Neurodegenerative Diseases/virology/therapy ; Genetic Vectors/genetics ; *Virus Diseases/complications/virology/therapy ; Genetic Therapy/methods ; Animals ; Gene Therapy Agents ; },
abstract = {Neurodegenerative diseases (NDDs) are multifactorial disorders with increasing evidence implicating viral infections in their pathogenesis. However, current reviews often catalog virus-disease associations without integrating this evidence into a unified conceptual model that also accounts for the therapeutic potential of viral platforms. This review investigates recent literature to propose a "dual-role" model for viruses in NDDs. We analyze how diverse viruses (e.g., HSV-1, HIV, EBV, and SARS-CoV-2) converge on shared pathogenic pathways, including protein misfolding, chronic neuroinflammation, and mitochondrial dysfunction, across different NDDs. Paradoxically, engineered viral vectors derived from neurotropic viruses are being investigated as tools for targeted gene therapy. To address these therapeutic applications of viruses, this review also provides an in-depth report of the various viral vector technologies developed. The approaches involved in designing rationally engineered viral vectors based on various adeno-associated virus serotypes through rational design, directed evolution and machine learning strategies, as well as the lentiviral and herpes simplex virus-based platform are described. Different strategies that have been used to incorporate large and/or small payloads such as gene replacement, RNA interference, microRNA cassettes, CRISPR-based gene editing (base editing, prime editing, CRISPRa and CRISPRi) and the double AAV systems to deliver larger transgene cassette have also been reviewed. This review further includes various routes of administration including intrathecal, intracerebroventricular and convection-enhanced delivery with the use of Focused Ultrasound. The constraints imposed by the Blood-Brain Barrier are discussed, especially the approach using receptor-mediated transcytosis for crossing. The review also critically evaluates obstacles toward clinical translation of viral vectors due to various factors including immunogenicity, the presence of pre-existing neutralising antibodies and dose-dependent toxicity, illustrated by the fatal outcome of ASPIRO and DMD trials. Finally, this review concludes with other promising non-viral approaches such as lipid nanoparticle and extracellular vesicles. Future research needs include long-term studies to investigate causality and extensive safety optimization of viral vectors.},
}
@article {pmid42340792,
year = {2026},
author = {Elgazzar, YA and Abdelrazek, M and Ghozzy, OAM and Mashhour, K and Elhady, MA and Amro, OAEA and Mokhtar, HM and Abdellatif, KAK and Mohamed, MM and Alsharif, MB and Mawkili, H and Hendi, AM and Dhayihi, TM and Adawy, Z and Ali, RF},
title = {CT-Assessed Sarcopenia Combined with Laboratory Inflammatory Markers for Outcome Prediction in Critically Ill, Pulmonary, and Geriatric Patients: A Systematic Review and Meta-Analysis.},
journal = {La Clinica terapeutica},
volume = {177},
number = {4},
pages = {903-915},
doi = {10.7417/CT.2026.2085},
pmid = {42340792},
issn = {1972-6007},
mesh = {Humans ; *Sarcopenia/diagnostic imaging/blood/mortality ; *Tomography, X-Ray Computed ; *Critical Illness ; Biomarkers/blood ; Prognosis ; Aged ; C-Reactive Protein/analysis ; *Lung Diseases/blood/complications/mortality ; Length of Stay ; Respiration, Artificial/statistics &amp; numerical data ; Predictive Value of Tests ; *Inflammation/blood ; },
abstract = {BACKGROUND: Sarcopenia, assessed via computed tomography (CT), is an emerging prognostic tool in critically ill, pulmonary, and geriatric patients. Laboratory inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) are routinely obtained in these populations. Whether CT-assessed sarcopenia combined with laboratory markers offers superior prognostic accuracy over either measure alone remains unclear.<br><br>OBJECTIVES: To systematically evaluate the prognostic value of CT-assessed sarcopenia, alone or combined with laboratory inflammatory/nutritional markers, for predicting mortality, mechanical ventilation duration, and ICU length of stay in critically ill, pulmonary, and geriatric patients.<br><br>METHODS: MEDLINE/PubMed, Scopus, Embase, and Cochrane Library were searched from inception to December 2024. Observational studies (prospective or retrospective cohorts, case-control) that reported CT-based sarcopenia assessment alongside at least one laboratory inflammatory marker and at least one clinical outcome were included. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale (NOS). Random-effects meta-analysis was performed; heterogeneity was assessed using the I&#xb2; statistic.<br><br>RESULTS: Twenty-five studies encompassing 12,347 patients were identified. The pooled odds ratio for mortality in sarcopenic versus non-sarcopenic patients was 2.28 (95% CI: 1.83-2.83; I&#xb2; = 22.1%) across critically ill ICU cohorts. In COVID-19 pulmonary populations, pooled OR for in-hospital mortality with low skeletal muscle mass was 5.84 (95% CI: 1.07-31.83). CT-derived muscle measurements correlated inversely with CRP (r = -0.315), fibrinogen (r = -0.392), D-dimers (r = -0.363), and WBC count (r = -0.287). Combined CT-sarcopenia and inflammatory marker models outperformed conventional scoring systems (APACHE II, SOFA, CURB-65, PSI).<br><br>CONCLUSIONS: CT-assessed sarcopenia, when integrated with laboratory inflammatory markers, provides a robust, mechanistically grounded, and clinically accessible multimodal prognostic framework across critically ill, pulmonary, and geriatric populations.},
}
@article {pmid42342266,
year = {2026},
author = {Xu, J and Kathiresan, T and Siddiqui, A and Mazzone, SB and Vogel, A},
title = {Cough biomarkers for diagnosis and monitoring of respiratory disease: a systematic review.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {180},
pages = {},
pmid = {42342266},
issn = {1600-0617},
mesh = {Humans ; *Cough/diagnosis/physiopathology/etiology ; Biomarkers ; Predictive Value of Tests ; *Respiratory Tract Diseases/diagnosis/physiopathology ; *Acoustics ; Prognosis ; },
abstract = {Cough is a common and physiologically informative component of respiratory morbidity, but its potential for diagnosing and monitoring disease is not thoroughly investigated. This systematic review synthesised the literature on algorithmic and statistical models analysing cough acoustics for diagnosing or monitoring respiratory conditions. Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, five databases (PubMed, Embase, Scopus, Web of Science and CENTRAL) were systematically searched for studies published from January 2010 to June 2025. Eligible studies performed quantitative acoustic feature analysis of human coughs using statistical, machine learning or deep learning models and reported diagnostic or prognostic performance. 89 studies from 34 countries were assessed, covering cough detection (n=31), disease classification (n=55) and disease severity prediction (n=3), reflecting potential applications in disease monitoring. Deep learning approaches, especially convolutional and recurrent networks, were predominant (n=56) and tended to achieve the higher accuracies, although machine learning ensemble methods and logistic regression also demonstrated strong performance, particularly with well-engineered features. Across different diseases, sensitivities and specificities were often reported to be ≥90%, notably for tuberculosis, asthma and COVID-19. However, methodological weaknesses were common, with only 11.2% of studies introducing external validation, 71.1-87.6% demonstrating high risk of bias (according to PROBAST-AI) and most based on small, homogeneous or crowdsourced cohorts with limited generalisability. These limitations contribute to inflated internal performance and uncertainty about real-world applicability. Cough acoustic biomarkers hold promise as an adjunctive tool for screening and longitudinal monitoring in low-resource environments. Nevertheless, widespread implementation will require large, multicentre validation, standardised calibration, bias control and incorporation into privacy-preserving workflows.},
}
@article {pmid42342297,
year = {2026},
author = {Yasam, SK and Vignesh, N and Rajagopal, S},
title = {Advances in ferroptosis research and applications.},
journal = {International review of cell and molecular biology},
volume = {405},
number = {},
pages = {149-186},
doi = {10.1016/bs.ircmb.2025.12.004},
pmid = {42342297},
issn = {1937-6448},
mesh = {*Ferroptosis/drug effects/physiology ; Humans ; Animals ; COVID-19/metabolism/pathology/virology ; Iron/metabolism ; Lipid Peroxidation ; SARS-CoV-2 ; Neoplasms/pathology/metabolism ; Neurodegenerative Diseases/pathology/metabolism ; Pulmonary Fibrosis/pathology/metabolism ; Renal Insufficiency, Chronic/metabolism/pathology ; },
abstract = {Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and redox imbalance. It has emerged as a pivotal mechanism implicated in various diseases, including cancer, chronic kidney diseases (CKD), neurodegenerative disorders, pulmonary fibrosis, chronic wounds, and viral infections such as COVID-19. This chapter presents a comprehensive overview of the molecular underpinnings of ferroptosis, emphasizing its key regulators-iron metabolism, lipid peroxidation pathways, and antioxidant defenses such as GPX4 and system Xc[-]. We explore recent advances highlighting the therapeutic potential of ferroptosis modulation across multiple pathological contexts. In cancer, ferroptosis inducers have shown efficacy in overcoming drug resistance and enhancing immunotherapy. In contrast, inhibition of ferroptosis offers protective effects in neurodegenerative diseases, ischemia-reperfusion injury, and chronic inflammatory conditions. Applications in nanomedicine have further enabled targeted delivery of ferroptosis modulators, expanding their clinical relevance. The chapter also discusses emerging roles of ferroptosis in wound healing, CKD and pulmonary fibrosis, with particular attention to COVID-19-related lung injury. Finally, we evaluate current therapeutic strategies, safety considerations, and potential clinical applications, along with future directions including biomarker development and personalized medicine. Our aim is to provide a unified perspective on ferroptosis as a disease-modifying mechanism and to highlight its growing importance as a therapeutic target across diverse clinical disciplines.},
}
@article {pmid42342836,
year = {2026},
author = {Schuele, L and Nzoyikorera, N and Udahemuka, JC and Cassidy, H and Murhula Masirika, L and Nieuwenhuijse, DF and Nduwimana, C and Molenkamp, R and Nyandwi, J and Boter, M and Minega Ndoli, J and Zaeck, LM and Musabyimana, JP and de Vries, RD and Mbiribindi, JB and Siangoli, FB and Otani, S and Aarestrup, FM and Koopmans, M and Ndishimye, P and Oude Munnink, BB},
title = {Capacity building for genomic surveillance of mpox and other emerging diseases in resource-limited settings within the African Great Lakes region.},
journal = {Communications medicine},
volume = {6},
number = {1},
pages = {},
pmid = {42342836},
issn = {2730-664X},
abstract = {Genomic surveillance has become an indispensable tool for the identification of pathogens and tracking of transmission chains. Building upon the global sequencing and surveillance infrastructure developed and expanded during the COVID-19 pandemic, these capacities are now being adapted to track other pathogens in low- and middle-income countries which remain disproportionately affected by infectious diseases. This is evident in the recent and unprecedented spread of mpox virus in regions experiencing multiple concurrent infectious disease outbreaks, highlighting the need for broad, adaptable diagnostic detection and sequencing capacity. In this Perspective, we describe the applications, insights, and challenges encountered during ongoing capacity building efforts for the characterization of the mpox outbreak and other emerging pathogens in the African Great Lakes Region.},
}
@article {pmid42342874,
year = {2026},
author = {Locci, M and Pardi, N},
title = {Immunological mechanisms of mRNA vaccines for infectious diseases.},
journal = {Nature},
volume = {654},
number = {8120},
pages = {892-901},
pmid = {42342874},
issn = {1476-4687},
mesh = {Animals ; Humans ; Adaptive Immunity ; Adjuvants, Immunologic ; *Communicable Diseases/immunology ; COVID-19/prevention &amp; control/immunology ; COVID-19 Vaccines/immunology ; Immunity, Innate ; Immunogenicity, Vaccine ; *mRNA Vaccines/immunology ; Nanoparticles/chemistry ; *RNA, Messenger/immunology/chemistry/genetics ; Vaccines, Synthetic/immunology/chemistry ; Liposomes ; },
abstract = {Nucleoside-modified mRNA-lipid-nanoparticle (mRNA-LNP) vaccines confer a high level of protection against severe COVID-19 and, since their first authorization for human use in 2020, have saved millions of lives. The efficacy of this vaccine platform relies on the induction of powerful and coordinated innate and adaptive immune responses. A deep understanding of the mechanisms of action by which mRNA-LNP vaccines drive protective immunity is crucial for advancing the development of next-generation mRNA vaccines with improved immunogenicity and tolerability. A flurry of recent studies has shed light on aspects of this vaccine modality's modus operandi. Nonetheless, key gaps in knowledge remain, including understanding how LNPs are sensed by the immune system and exert their adjuvant activity, identifying the specific signals and cellular pathways critical for eliciting protective immune responses and determining whether it is feasible to uncouple vaccine immunogenicity and reactogenicity. Here we review the known and unknown features of the immunological mechanisms of mRNA-LNP vaccines for infectious diseases. Furthermore, we discuss how the components of this vaccine platform can be modified to fine-tune immune responses against challenging pathogens for which effective vaccines do not exist or need improvement.},
}
@article {pmid42342927,
year = {2026},
author = {Li, X and Kang, M and Jiao, XY and Merits, A and Veit, M and Rey, FA and Dai, H and Wang, XY and He, WT and Holmes, EC and Varjak, M and Mahalingam, S and Wang, D and Jiang, Z and Wang, S and Li, X and Peng, Z and He, N and Su, S},
title = {Addressing the zoonotic threat of merbecoviruses.},
journal = {Nature microbiology},
volume = {11},
number = {7},
pages = {1774-1785},
pmid = {42342927},
issn = {2058-5276},
mesh = {Animals ; Humans ; Receptors, Virus/metabolism ; *Zoonoses/virology/transmission ; Virus Internalization ; *Coronavirus Infections/virology/prevention &amp; control/transmission/epidemiology/diagnosis ; *Viral Zoonoses/virology/prevention &amp; control/transmission ; *Coronavirus/genetics/classification/physiology/pathogenicity ; Angiotensin-Converting Enzyme 2/metabolism ; },
abstract = {Merbecovirus is a subgenus of betacoronaviruses and exhibits high genetic diversity with a capacity for cross-species transmission. However, beyond Middle East respiratory syndrome coronavirus (MERS-CoV), our knowledge of the ecology and pathogenic potential of these viruses remains limited. Merbecoviruses were once thought to rely exclusively on dipeptidyl peptidase 4 for cell entry, but recent discoveries have revealed that several members can also engage with angiotensin-converting enzyme 2 or aminopeptidase N, expanding their receptor repertoire and potential host range. Here we summarize recent advances in understanding of the receptor usage of merbecoviruses and examine how these insights inform pandemic preparedness and risk assessment. We discuss the development of targeted diagnostics, broad-spectrum antivirals and vaccines, including pan-coronavirus strategies. Together, these advances provide a foundation for predictive surveillance and rational countermeasure design, enabling earlier detection and more effective containment of future merbecovirus spillover events before they escalate into epidemics.},
}
@article {pmid42344053,
year = {2026},
author = {Nichols, E and Arhin-Wiredu, K and Bratton, S and Cercone, E and Longa Chanda, S and Cobos Muñoz, D and Ebonwu, J and Espinosa-Bode, A and Handzel, E and Kapombe, P and Martin, D and Moolenaar, R and Muhwava, W and Atuheire, EB},
title = {Integrating mortality surveillance as a routine component of national essential public health functions: a blueprint for action.},
journal = {BMJ public health},
volume = {4},
number = {2},
pages = {e003392},
pmid = {42344053},
issn = {2753-4294},
abstract = {The COVID-19 pandemic and other recent public health responses have highlighted significant challenges in global mortality data collection, with approximately 40% of deaths unregistered and fragmented reporting systems hampering public health responses. This paper supports the establishment of routine mortality surveillance as a core function of essential public health services, emphasising the need for integration with civil registration and vital statistics (CRVS) systems. By leveraging existing frameworks and proposing a Theory of Change (ToC), we outline critical linkages between CRVS and mortality surveillance that enhance data accuracy, timeliness and utility for public health decision-making. The paper provides examples across key enablers-policies, agreements and legislation; infrastructure; governance, funding and resources; and people and organisational culture-that facilitate these linkages. We also present examples from initiatives like the Africa CDC's Mortality Surveillance Programme to illustrate effective strategies in low- and middle-income countries (LMICs). The ToC serves as a blueprint for stakeholders to implement strategic interventions aimed at overcoming barriers to linking systems and data integration and utilisation. Ultimately, this paper underscores the importance of coordinated efforts among national public health agencies, civil registration authorities and other stakeholders to improve mortality data systems globally. By addressing these systemic challenges through enhanced collaboration and technological innovation, we can significantly advance public health outcomes and policy formulation in response to future health crises.},
}
@article {pmid42344113,
year = {2026},
author = {Mohamed, RA and Huitao, S and Si, M and Jinguan, Z and Mabrouk, MS},
title = {An End-to-End Modular Blueprint for Rapid mRNA Vaccine Development, Computational Design, Functional Validation, and Scalable Delivery Against Evolving Pathogens.},
journal = {In silico pharmacology},
volume = {14},
number = {2},
pages = {173},
pmid = {42344113},
issn = {2193-9616},
abstract = {The rapid emergence of new pathogens evolving viral variants. Underscores the need for agile vaccine platforms capable of outpacing infectious threats. Building on the success of mRNA vaccine technology during the COVID-19 pandemic. We integrated computational precision tool to help the young Scientifics map the vaccine design. It is not a validated lab protocol nor does it report experimental results. Instead, it offers a stepwise conceptual roadmap to guide future wet-lab research. We also outline in silico workflow encompassing antigen selection, consensus sequence generation. The first step in the workflow is to check the conserved antigenic domains and epitopes. Bioinformatic analysis supported antigen identifying and its targets using appropriate tools, followed by consensus sequence creation through multiple sequence alignment using specific platforms. mRNA constructs were optimized via codon adaptation, GC content balancing, and secondary structure analysis. Delivery strategies also were briefly assessed between the FDA approved systems. Lipid nanoparticle formulation, were incorporated into the design to theoretically enhance stability and cellular uptake. Robust protein expression both in vitro and in vivo assessments further suggested the immunogenic potential along with providing a computational basis for future preclinical evaluation. This study review provides a step-by-step protocol that clarifies and simplifies the design process for linear mRNA constructs. The framework translates complex design considerations into actionable, sequential guidelines, enabling researchers to rationally design vaccine candidates in silico. Certainly, we support accelerated design efforts against current threats, while also serving as a preparedness blueprint for future pandemics.},
}
@article {pmid42344246,
year = {2026},
author = {Birhman, N and Kharkwal, G and Roy, S and Shaikh, N and Velamuri, PS and Lata, H and Saxena, A and Satija, A and Singh, KJ and Madan, T and Kishore, J and Kanti, P and Anand, T},
title = {Occupational health and safety in the wake of COVID-19: insights from India's workforce.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1807940},
pmid = {42344246},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology/prevention &amp; control ; *Occupational Health ; India/epidemiology ; Working Conditions ; *Health Personnel/psychology ; SARS-CoV-2 ; Occupational Exposure/prevention &amp; control ; Frontline Workers ; Pandemics ; Workplace ; },
abstract = {INTRODUCTION: Occupational health and safety (OHS) practices witnessed profound changes worldwide during the COVID-19 pandemic. The pandemic exposed critical vulnerabilities in workplace preparedness, particularly among workers in high-exposure and essential service sectors.<br><br>METHODS: A systematic review was conducted following PRISMA guidelines using PubMed, Google Scholar, DOAJ, ResearchGate, and gray literature sources. Studies published between January 2020 and December 2024 focusing on occupational exposure, workplace transmission, OHS guidelines, and workforce health during COVID-19 were included.<br><br>RESULTS: Healthcare workers experienced the highest occupational risk due to sustained patient contact and aerosol-generating procedures, accompanied by significant psychological distress and burnout. Essential workers, manufacturing sectors, retail workers, educators, and informal sector workers also faced substantial occupational and socioeconomic challenges. Workplace interventions including engineering controls, administrative controls, PPE use, vaccination strategies, and digital surveillance tools reduced workplace transmission. Remote-enabled sectors demonstrated lower infection risk but increased mental health concerns.<br><br>DISCUSSION: The COVID-19 pandemic transformed traditional OHS frameworks by integrating infectious disease preparedness, vaccination strategies, mental health support, and workplace surveillance into occupational safety systems. The findings emphasize the need for integrated, adaptive, and equitable OHS frameworks aligned with public health preparedness to strengthen workforce resilience against future pandemics.},
}
@article {pmid42344751,
year = {2026},
author = {Toboltoc, PC and Gagiu, I and Lukusa, AL and Vekony, A},
title = {Hemato-Oncology Care During and After the COVID-19 Pandemic: Changes in Treatment Pathways, Patient Flow, and Durable Organizational Adaptations.},
journal = {Cureus},
volume = {18},
number = {6},
pages = {e111331},
pmid = {42344751},
issn = {2168-8184},
abstract = {The COVID-19 pandemic disrupted cancer care at every level of the clinical pathway, but its effect on hemato-oncology was distinctive because patients with hematologic malignancies often require urgent diagnosis, frequent hospital visits, transfusion support, intensive therapy, transplantation, cellular therapy, and infection-sensitive follow-up. This narrative review examines the pandemic as a disruption of hemato-oncology care delivery rather than only as a source of excess infection-related morbidity. It synthesizes evidence on diagnostic access, patient flow, treatment prioritization, infection-control circuits, day-hospital organization, inpatient access, telemedicine and hybrid follow-up, supportive care, vaccination, antiviral pathways, and high-complexity care delivery. The review distinguishes between temporary crisis restrictions, harmful diagnostic and therapeutic delays, and durable organizational adaptations that may remain relevant after the acute pandemic period. Evidence from cancer-service disruption studies, hemato-oncology outcome registries, telemedicine cohorts, and European hematopoietic cell transplantation activity surveys indicates that hemato-oncology care pathways were reorganized and selectively redirected during the pandemic, while selected components recovered through structured triage, protected circuits, remote review of stable patients, and individualized timing of transplantation and cellular therapy. The post-pandemic priority is not to preserve restrictive crisis practice, but to retain the organizational discipline generated by the crisis: protected diagnostic capacity, risk-stratified access, selective hybrid care, rapid infectious-risk assessment pathways, disciplined day-hospital scheduling, and reserved in-person capacity for unstable, procedure-dependent, or curative-intent patients. These adaptations should be maintained only insofar as they improve access, safety, and continuity of care without normalizing delayed diagnosis or undertreatment of aggressive disease.},
}
@article {pmid42344914,
year = {2026},
author = {Batool, R},
title = {From Jenner to genomics: the unfolding future of vaccinology.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1860464},
pmid = {42344914},
issn = {1664-3224},
mesh = {Humans ; *Vaccinology/trends/methods ; Genomics ; *COVID-19/immunology/prevention &amp; control ; Animals ; COVID-19 Vaccines/immunology ; *SARS-CoV-2/immunology ; Vaccine Development ; History, 20th Century ; Vaccines/immunology ; Vaccines, DNA/immunology ; History, 21st Century ; },
abstract = {The development of the smallpox vaccine two centuries ago laid the foundation for modern vaccinology. Smallpox, once a major killer in human history, was eradicated globally in 1980. This breakthrough encouraged the development of contemporary vaccine technologies, including inactivated, recombinant, viral vector, and mRNA platforms. Owing to developments in genetics, bioinformatics, and molecular biology, personalised vaccines have been made possible. Advances in the field of immunology facilitated an accelerated response to the COVID-19 pandemic. This perspective synthesises key developments and technological advances in the field of global immunisation. The author sheds light on emerging tools, transformative platforms, and long-term directions in vaccine science research.},
}
@article {pmid42345054,
year = {2026},
author = {Calcaterra, G and Oreto, L and Perrone, M and Chessa, M and Bianco, F and Borrelli, N and Leonardi, B and Moscatelli, S and Ciliberti, P and Sabatino, J and Guccione, P and Martino, F and Thiene, G and Di Salvo, G and Bassareo, PP},
title = {[Kawasaki disease: the update of American Heart Association guidelines. What adult cardiologists need to know].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {27},
number = {7},
pages = {479-488},
doi = {10.1714/4722.47387},
pmid = {42345054},
issn = {1972-6481},
mesh = {Adult ; Child ; Child, Preschool ; Humans ; American Heart Association ; Cardiologists ; Diagnosis, Differential ; Immunoglobulins, Intravenous/therapeutic use ; *Mucocutaneous Lymph Node Syndrome/diagnosis/therapy/complications/physiopathology ; Practice Guidelines as Topic ; United States ; },
abstract = {The recent document from the American Heart Association updates the guidelines on the diagnosis and management of Kawasaki disease (KD), a severe acute systemic inflammatory and febrile illness with mucocutaneous manifestations and lymph node involvement primarily affecting children under 5 years of age. Coronary artery involvement, with dilation and aneurysms in approximately 25% of patients, and cardiovascular system involvement make KD the most common systemic vasculitides and the leading cause of acquired heart disease in pre-school children living in developed countries. Classic KD is diagnosed based on established clinical and laboratory criteria, which exclude other similar conditions. The etiology and pathogenesis of KD remain unknown, with the disease affecting genetically susceptible children through an immune-mediated mechanism. The leading theory is that an unidentified trigger initiates a multi-organ inflammatory pathological cascade, sometimes resulting in incomplete or atypical forms in younger patients. For this reason, the American guidelines review KD diagnostic criteria, cardiac imaging techniques (echocardiography, coronary computed tomography, magnetic resonance imaging), specific therapies (intravenous immunoglobulin, aspirin, and additional treatments for resistant cases), management of myocardial infarctions, and the transition of care from pediatric to adult age. This review article also highlights future research areas, the role of inflammation, the development of differential diagnostic algorithms for multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection, and the use of new oral anticoagulants. Lastly, the most recent data on the long-term course of the disease and the regression of coronary aneurysms are revisited.},
}
@article {pmid42345733,
year = {2026},
author = {Ionescu, A and Mihăilescu, A and Dumache, R and Capcelea, A and Turceanu, AD and Albulescu, N and Săndesc, MA},
title = {Perioperative Anemia, Transfusion Practices, and Patient Blood Management: Lessons from the COVID-19 Pandemic.},
journal = {Hematology reports},
volume = {18},
number = {3},
pages = {},
pmid = {42345733},
issn = {2038-8322},
abstract = {The COVID-19 pandemic exposed vulnerabilities in global blood supply systems and accelerated the adoption of patient blood management (PBM) strategies aimed at optimizing transfusion practices in surgical care. Perioperative anemia is a key contributor to adverse outcomes and is frequently treated with allogeneic blood transfusion (ABT), which carries infectious and immunologic risks. Iron deficiency remains the most common and potentially correctable cause of perioperative anemia. This narrative review examines various approaches to perioperative anemia, strategies to minimize reliance on ABT, and alternatives within the PBM paradigm. Evidence supports the use of iron therapy, erythropoiesis-stimulating agents, antifibrinolytic strategies, and blood conservation techniques to reduce transfusion requirements and improve clinical outcomes. Lessons from the COVID-19 pandemic highlight PBM as a framework to enhance transfusion safety and sustainability. Broader implementation of PBM may improve patient outcomes, reduce unnecessary transfusions, and preserve scarce blood resources.},
}
@article {pmid42345852,
year = {2026},
author = {Ferrara, F and De Berardinis, F and Scognamiglio, M and Zovi, A},
title = {The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives.},
journal = {Antibodies (Basel, Switzerland)},
volume = {15},
number = {3},
pages = {},
pmid = {42345852},
issn = {2073-4468},
abstract = {BACKGROUND: Monoclonal antibodies (mAbs) initially played a major role in outpatient COVID-19 management by providing rapid passive immunity and reducing progression to severe disease. However, continuous SARS-CoV-2 evolution progressively compromised the effectiveness of several anti-spike products. This narrative review summarizes the trajectory of COVID-19 mAbs across three phases: early clinical efficacy, loss of efficacy due to immune escape, and future directions.<br><br>METHODS: We conducted a narrative review focusing on mechanisms of action, pivotal clinical trials, and real-world effectiveness of neutralizing anti-spike mAbs and host-directed immunomodulatory mAbs. Emphasis was placed on the impact of variants-especially Omicron-on susceptibility and clinical use, as well as on emerging next-generation platforms.<br><br>RESULTS: First-generation neutralizing mAbs substantially reduced the hospitalization rates during the Alpha and Delta waves, while immunomodulatory mAbs became standard options for the hyperinflammatory phase in hospitalized patients. With the emergence of Omicron and its sub-lineages, extensive immune escape led to marked reductions in neutralization for many earlier anti-spike agents and consequent restrictions in use. Later-generation approaches targeting more conserved epitopes provided temporary solutions but were also challenged by ongoing antigenic drift. Host-directed immunomodulators retained clinical relevance because their mechanism is independent of viral spike mutations.<br><br>CONCLUSIONS: The clinical role of monoclonal antibodies in COVID-19 has been dynamic and increasingly constrained by viral evolution. Future strategies should prioritize broadly neutralizing antibodies targeting conserved epitopes, innovative delivery platforms, and integration with real-time surveillance to preserve clinical utility in the endemic phase and improve preparedness for future outbreaks.},
}
@article {pmid42345854,
year = {2026},
author = {Lim, XR and Teo, RXW and Par, RYX and Leung, BPL},
title = {Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review.},
journal = {Antibodies (Basel, Switzerland)},
volume = {15},
number = {3},
pages = {},
pmid = {42345854},
issn = {2073-4468},
abstract = {Type I interferons (IFN-I), including IFN-α, IFN-β, and IFN-ω, are central to antiviral defence and immune regulation. Autoantibodies targeting IFN-I (anti-IFN-I AAbs) have emerged as key pathogenic factors in severe coronavirus disease 2019 (COVID-19) and are detectable in systemic lupus erythematosus (SLE), a prototypic IFN-driven autoimmune disease. Here we compare the prevalence and clinical impact of anti-IFN-I autoantibodies (Aabs) in COVID-19 and SLE based on a structured review of 53 studies from 2014 to 2025 and highlight the clinical associations and therapeutic opportunities presented by these autoantibodies. In COVID-19, neutralising anti-IFN-α and/or anti-IFN-ω AAbs were consistently associated with severe disease and impaired antiviral responses, particularly in older male populations. In SLE, anti-IFN-α AAbs were variably detected; neutralising antibodies were associated with reduced interferon gene signatures in some cohorts but inconsistent correlations with disease activity. Therapeutically, anti-IFN-I AAbs in COVID-19 may inform risk stratification and early antiviral strategies, whereas in SLE, IFN-α blockade, including IFN-α kinoid vaccination, demonstrates modulation of IFN signatures but variable clinical benefit. Notably, these findings reveal an immunological paradox: the same neutralising mechanism that impairs antiviral defence in COVID-19 may attenuate chronic IFN-driven inflammation in SLE. Taken together, anti-IFN-I AAbs exert context-dependent effects: pathogenic in acute viral infection yet potentially modulatory in chronic IFN-driven autoimmunity. Prospective longitudinal studies are required to further clarify their translational utility and long-term clinical impact.},
}
@article {pmid42346165,
year = {2026},
author = {Ntais, C and Chatziprodromidou, IP},
title = {COVID-19 and Interacting Public Health Threats in Europe During 2020-2025: A Narrative Review.},
journal = {Epidemiologia (Basel, Switzerland)},
volume = {7},
number = {3},
pages = {},
pmid = {42346165},
issn = {2673-3986},
abstract = {Between 2020 and 2025, Europe has faced multiple interacting public health threats shaped by and following the COVID-19 pandemic. Alongside COVID-19, the region experienced other infectious disease events, including monkeypox, measles resurgence, legionellosis and acute hepatitis of unknown origin in children. At the same time, non-communicable disease burdens, including obesity, type II diabetes mellitus, disruption of chronic disease care, mental health disorders and increased problematic digital use, intensified during and after the pandemic period. Antimicrobial resistance (AMR) remained a major cross-cutting threat because it undermines the effective treatment of infections and weakens emergency preparedness. This narrative review synthesizes peer-reviewed articles and selected reports from international organizations for the 2020-2025 period, using COVID-19 as the organizing context for examining interconnected infectious, chronic and system-level threats. Across these topics, recurring themes included vaccination gaps, fragmented surveillance, disruption of routine care, health system inequities, misinformation and insufficient preparedness for cross-border threats. The review supports integrated surveillance, continuity plans for essential services, stronger vaccination and risk-communication strategies and sustained AMR stewardship within a One Health framework. Coordinated action across public health, primary care, mental health and chronic disease policy is essential for future resilience.},
}
@article {pmid42346828,
year = {2026},
author = {Cacciatore, S and Abbatecola, G and Calvani, R and Veronese, N},
title = {Effectiveness and Safety of Ozone Therapy in Humans: An Umbrella Review of Systematic Reviews with Meta-Analyses of Randomized Clinical Trials.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {2},
pages = {},
pmid = {42346828},
issn = {2076-3271},
mesh = {Humans ; *Ozone/therapeutic use/adverse effects ; Randomized Controlled Trials as Topic ; COVID-19/therapy ; Systematic Reviews as Topic ; *Chronic Periodontitis/therapy/drug therapy ; Treatment Outcome ; Meta-Analysis as Topic ; Diabetic Foot/therapy ; SARS-CoV-2 ; },
abstract = {BACKGROUND/OBJECTIVES: Ozone therapy has been proposed across multiple clinical conditions based on hormetic, antioxidant, and immunomodulatory effects, but its efficacy and safety remain controversial. We conducted an umbrella review to appraise the effectiveness and safety of ozone therapy using evidence from meta-analyses of randomized controlled trials (RCTs).<br><br>METHODS: We searched MEDLINE, Web of Science, Embase, and the Cochrane Library from inception to 14 February 2025, with an updated search performed on 9 May 2026. Eligible studies were systematic reviews with meta-analyses comparing ozone therapy with non-active controls, including placebo, sham, saline, or standard care. Methodological quality was evaluated with AMSTAR-2 and certainty of evidence with GRADE.<br><br>RESULTS: Of 1243 records identified, seven meta-analyses representing four clinical indications (chronic periodontitis, COVID-19, diabetic foot ulcers, and impacted mandibular third-molar surgery) were included. In chronic periodontitis, evidence was mixed: one meta-analysis found no significant adjunctive benefit, whereas a more recent meta-analysis reported improvements in probing depth and gingival index, but not in bleeding on probing, plaque index, or clinical attachment level. For COVID-19, ozone therapy reduced PCR positivity at follow-up (RR 0.07; 95% CI 0.01-0.34), although this was considered a clinically non-important surrogate endpoint, and showed no significant benefit for hospital stay, intensive care unit admission, or mortality. For diabetic foot ulcers, ozone therapy was not superior to control treatment for ulcer healing (RR 1.69; 95% CI 0.90-3.17) or reduction in ulcer area. In third-molar surgery, ozone therapy did not reduce swelling or improve mouth opening, but was associated with improved short-term quality of life and reduced analgesic use. Safety outcomes were inconsistently reported, and available data did not allow firm conclusions regarding adverse events. The certainty of evidence was low or very low for all outcomes.<br><br>CONCLUSIONS: Despite mechanistic plausibility, current meta-analytic evidence from RCTs remains inconsistent, methodologically fragile, and largely based on low- or very low-certainty findings. Routine clinical use is not justified pending adequately powered, blinded RCTs with standardized dosing and delivery, patient-centered endpoints, and rigorous safety monitoring.},
}
@article {pmid42347188,
year = {2026},
author = {Bambara, S and Isingizwe, MC and Adegboyega, TT and Mutesa, L},
title = {A Systematic Review of Gastrointestinal and Respiratory Pathogen Detection in Wastewater in Africa, with Focus on Rwanda: Implications for Early Warning and Public Health Surveillance.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {6},
pages = {},
pmid = {42347188},
issn = {2076-0817},
mesh = {Humans ; Rwanda/epidemiology ; *Wastewater/virology/microbiology ; *Respiratory Tract Infections/epidemiology/virology/microbiology ; *Public Health Surveillance ; Public Health ; Wastewater-Based Epidemiological Monitoring ; },
abstract = {In Africa, the disease burden of diarrheal and respiratory diseases is amplified by limited surveillance capacity, diagnostic limitations, and socioeconomic inequalities. In rapidly urbanizing settings such as Kigali (Rwanda), integrating wastewater-based epidemiology (WBE) into existing surveillance systems offers a promising strategy for generating real-time epidemiological intelligence, identifying community-level hotspots, and addressing gaps in traditional reporting systems. Gastrointestinal and respiratory infections remain major causes of morbidity and mortality globally, particularly in low- and middle-income countries (LMICs), where traditional clinical surveillance systems frequently underreport the true disease burden. This systematic review synthesizes current evidence on the detection of gastrointestinal and respiratory pathogens in wastewater and evaluates the utility of WBE for early warning and public health action. A narrative review approach was used to identify peer-reviewed literature, global health reports, and surveillance studies focusing on the wastewater detection of gastrointestinal and respiratory pathogens. Databases including PubMed, Scopus, and Google Scholar were searched for studies published between 2000 and 2026. The search yielded 1247 records, of which 312 duplicates were removed. After title/abstract screening, 228 full-text articles were retrieved and assessed for eligibility. After a detailed evaluation, 108 studies were excluded for the following reasons: absence of pathogen-specific wastewater data (n = 46), a focus on environmental monitoring without public health relevance (n = 25), insufficient methodological description (n = 21), or other eligibility limitations such as a lack of primary data (n = 16). WBE provides a non-invasive, cost-effective approach for monitoring symptomatic and asymptomatic infections. Challenges involve variability in sampling, environmental factors affecting viral decay, and differences in laboratory workflows. WBE is a powerful complement to traditional infectious disease surveillance, offering early warning capabilities, population-level coverage, and real-time insights into pathogen circulation. Integrating WBE into surveillance programs, especially in LMICs such as Rwanda, can significantly strengthen epidemic preparedness, guide resource allocation, and improve outbreak response. Sustained investment in laboratory capacity, standardized protocols, and multisector collaboration is essential to fully leverage WBE for public health protection.},
}
@article {pmid42347608,
year = {2026},
author = {Jang, HY and Ko, Y and Han, SY},
title = {Understanding Healthcare Workers' COVID-19 Vaccination Decision-Making as a Dynamic Process: A Qualitative Meta-Synthesis.},
journal = {Vaccines},
volume = {14},
number = {6},
pages = {},
pmid = {42347608},
issn = {2076-393X},
support = {HY- 202200000003466//Hanyang University/ ; },
abstract = {Background/Objectives: Healthcare workers play a critical role in vaccination programs, yet vaccine hesitancy has been widely reported even among this group during the Coronavirus disease 2019 (COVID-19) pandemic. Previous studies have primarily focused on identifying factors associated with vaccine acceptance, offering limited insight into the processes underlying decision-making. This study aimed to synthesize qualitative studies on healthcare workers' COVID-19 vaccination experiences to develop a comprehensive understanding of their decision-making processes. Methods: A qualitative meta-synthesis was conducted using the thematic synthesis approach proposed by Thomas and Harden. Electronic databases including PubMed, Embase, and CINAHL were searched for qualitative studies published up to February 2026. Thirteen studies were included following PRISMA guidelines. Data were analyzed through line-by-line coding, followed by the development of descriptive and analytical themes. Results: Four analytical themes were identified: (1) vaccination as a dynamic risk-benefit negotiation process, (2) trust as a central mechanism shaping information interpretation, (3) socially embedded and relationally negotiated decision-making, and (4) moral identity as a driver of vaccination behavior. Healthcare workers' vaccination decision-making was not a static choice but an evolving process shaped by continuous appraisal of risks and benefits, filtered through trust in information and institutions, influenced by social interactions, and guided by professional identity and ethical responsibility. Conclusions: Healthcare workers' vaccination decision-making is a multidimensional process embedded in cognitive, social, and ethical contexts. Interventions should move beyond individual-level approaches and instead focus on building trust, leveraging social networks, and reinforcing professional identity with implications for future public health crises.},
}
@article {pmid42347619,
year = {2026},
author = {Kong, F and Wu, N and Liang, S and Yan, Y},
title = {Next-Generation Vaccine Design for Porcine Enteric Coronaviruses: Aligning Antigenic Breadth, Mucosal Immunity, and Translational Evaluation.},
journal = {Vaccines},
volume = {14},
number = {6},
pages = {},
pmid = {42347619},
issn = {2076-393X},
support = {LH2022C070//Heilongjiang Provincial Natural Science Foundation of China/ ; },
abstract = {Porcine enteric coronaviruses (PECs), including porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), porcine deltacoronavirus (PDCoV), and swine acute diarrhea syndrome coronavirus (SADS-CoV), remain major causes of neonatal diarrhea, dehydration, mortality, and economic loss in swine production. Despite substantial progress in vaccine development, durable field protection is still inconsistent. In this narrative review, this narrative review synthesizes current knowledge on PEC vaccine design from three connected perspectives: antigenic breadth, mucosal immunity, and translational evaluation. The economic and virological context of PEC vaccine development is first summarized, including the recurrent production burden of PECs, coronavirus genome organization, structural proteins, and the central role of the spike protein in receptor engagement, membrane fusion, and neutralizing antibody induction. Key issues are then discussed, including how spike diversity, conformational stability, epitope accessibility, glycan shielding, and antigen matching influence protective breadth; why intestinal secretory IgA, mucosal immune-cell trafficking, local memory responses, and lactogenic immunity should be prioritized as biologically relevant endpoints; and how delivery route, adjuvant selection, and platform design shape response quality. Current evidence on recombinant protein, viral-vectored, nanoparticle, virus-like particle, probiotic, plant-derived, and mRNA-based approaches is compared with attention to both promise and current evidentiary and translational limitations. The available literature suggests that future progress in PEC vaccinology is likely to depend less on platform novelty alone than on integrated vaccine designs that align antigen selection, mucosal delivery, maternal-neonatal protection, heterologous challenge, manufacturability, and field applicability.},
}
@article {pmid42347657,
year = {2026},
author = {Frączek, B and Pieniawska-Śmiech, K and Babicki, M and Balcer, B and Dolata, N and Pokorna-Kałwak, D and Kłoda, K},
title = {Maternal Vaccine Acceptance and Attitudes Before and After the COVID-19 Pandemic: A Narrative Literature Review.},
journal = {Vaccines},
volume = {14},
number = {6},
pages = {},
pmid = {42347657},
issn = {2076-393X},
abstract = {OBJECTIVES: This study aims to assess the acceptance of vaccinations among pregnant women, particularly against influenza, pertussis, COVID-19, and RSV, and to identify factors influencing their willingness to get vaccinated. It also seeks to evaluate the impact of the COVID-19 pandemic on maternal attitudes and behaviors regarding vaccination.<br><br>METHODS: The analysis involved a review of existing literature and studies to evaluate the level of vaccine acceptance among pregnant women before and after the COVID-19 pandemic. Factors contributing to vaccine hesitancy, including misinformation, lack of knowledge, and the influence of healthcare professionals, were examined.<br><br>RESULTS: The findings indicated that, despite scientific evidence supporting the safety and efficacy of vaccines during pregnancy, public concerns remain about their impact on the developing fetus. The outbreak of the COVID-19 pandemic has increased awareness of the risk of infectious diseases, but at the same time, its impact on vaccination rates among pregnant women is ambiguous and geographically diverse. Misinformation and decreased access to healthcare during the pandemic negatively affected vaccine uptake. Trustworthy information provided by healthcare professionals emerged as a key factor in promoting vaccine acceptance.<br><br>CONCLUSIONS: To improve vaccination rates among pregnant women, it is essential to provide clear, evidence-based information through healthcare professionals, particularly those directly caring for pregnant women. Educational campaigns should address concerns calmly and without judgment, emphasizing the safety and benefits of vaccinations. Enhanced access to healthcare and vaccinations, along with strategic information dissemination, can significantly improve vaccine acceptance during pregnancy. Lessons learned from past pandemics should be incorporated into the development of healthcare strategies aimed at implementing recommended vaccinations for pregnant women in the future.},
}
@article {pmid42347672,
year = {2026},
author = {Aljadeeah, S and Payedimarri, AB and Dochez, C and Kielmann, K and Wirtz, VJ and Hargreaves, S and Ravinetto, R},
title = {Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.},
journal = {Vaccines},
volume = {14},
number = {6},
pages = {},
pmid = {42347672},
issn = {2076-393X},
abstract = {Introduction: Inequities in access to medicines persist for asylum seekers, refugees, and undocumented migrants in Europe. For vaccines, access gaps not only exist for these groups in childhood routine immunization, but also for life-course and catch-up vaccinations. As part of a broader project examining access to medicines and vaccines for migrants across all stages of the migration cycle, this scoping review synthesizes evidence on the determinants of access to vaccines. Methods: We conducted a scoping review across PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Database of Systematic Reviews, Scopus, and grey literature sources, covering the period 2000-2024. Sources were eligible if they addressed access to vaccines among migrants. We examined access to vaccines along the life course, and across phases of the migratory cycle, including departure, transit, reception and settlement, and return or deportation. Results: A total of 47 research studies and grey literature reports were included. Most studies focused on migrants in reception and settlement (destination) settings, with only twelve sources addressing other phases of the migratory cycle. Across European countries, migrants were frequently reported to have lower uptake of routine vaccines (e.g., measles-mumps-rubella (MMR), polio, diphtheria-tetanus-pertussis (DTP), and human papillomavirus (HPV)) and COVID-19 vaccines than host populations. The most frequently reported barriers were related to migrants' legal status, administrative requirements, and lack of documentation, alongside poor affordability of vaccination, limited awareness of their rights, and mistrust in the health system. Conclusions: Health systems need to adopt innovative approaches to expand vaccine access for migrant populations. Further, protecting confidentiality is essential for building trust and reducing ethical and legal risks. Flexible and coordinated vaccination strategies are required to address migrants' mobility across the different migration stages and settings. Our findings appeal for sustained improvements in access to vaccines among migrants in Europe, contingent on strong policy commitments to equity, data protection, and the adoption of life-course and catch-up vaccination strategies.},
}
@article {pmid42348970,
year = {2026},
author = {Zhang, W and Yuan, W and Yuan, C and Cheng, Y and Zhang, D and Cao, X and Ding, C},
title = {Shared and context-specific mechanisms of T cell exhaustion in chronic viral infections and cancer: Transcriptional, metabolic, epigenetic, and therapeutic perspectives.},
journal = {Cytokine &amp; growth factor reviews},
volume = {90},
number = {},
pages = {88-106},
doi = {10.1016/j.cytogfr.2026.06.004},
pmid = {42348970},
issn = {1879-0305},
mesh = {Humans ; *T-Cell Exhaustion ; *Neoplasms/immunology/therapy/genetics/metabolism ; Epigenesis, Genetic ; *Virus Diseases/immunology/genetics/therapy ; Animals ; Transcription, Genetic ; *T-Lymphocytes/immunology ; *COVID-19/immunology/genetics/therapy ; SARS-CoV-2/immunology ; },
abstract = {T cells are crucial for defending against viral infection and cancer by eliminating infected or transformed cells and establishing immune memory. However, persistent antigenic stimulation in chronic infections or tumors drives T cells into a dysfunctional state known as exhaustion. This state is characterized by reduced proliferation and effector functions, upregulation of inhibitory receptors like PD-1, LAG-3, and CTLA-4, and alterations in transcriptional, epigenetic, and metabolic programs. T cell exhaustion is driven by both intrinsic factors, including changes in transcription factor networks and metabolic dysfunction, and extrinsic factors, such as continuous antigen exposure and an immunosuppressive microenvironment. Key molecules like PD-1, TOX, and TCF-1 are central to this process, though the complex interactions between intrinsic and extrinsic signals in chronic viral infections and cancers remain poorly understood. This review summarized T cell exhaustion in chronic viral infections, such as HIV, HBV, and SARS-CoV-2, as well as in tumors, emphasizing shared mechanisms and context-specific differences. We focused on the roles of transcriptional networks, metabolic changes, immune checkpoints, and exhaustion-related signaling. Additionally, we discussed emerging therapeutic strategies, such as immune checkpoint inhibitors, CAR-T cell therapies, cytokine supplementation, and metabolic interventions, based on recent high-impact studies. By integrating insights from both chronic infection and cancer, this review aims to identify common principles of T cell exhaustion and propose strategies to improve clinical outcomes in chronic viral diseases and cancer immunotherapy.},
}
@article {pmid42349034,
year = {2026},
author = {Abdel-Moneim, AS and Al-Balushi, MS and Al-Jabri, AA},
title = {Post-COVID-19 immune dysregulation and autoimmune sequelae.},
journal = {Virology},
volume = {623},
number = {},
pages = {111017},
doi = {10.1016/j.virol.2026.111017},
pmid = {42349034},
issn = {1096-0341},
mesh = {Humans ; *COVID-19/immunology/complications ; *SARS-CoV-2/immunology ; *Autoimmunity ; *Autoimmune Diseases/immunology/virology/etiology ; Post-Acute COVID-19 Syndrome ; Autoantibodies/immunology ; Gastrointestinal Microbiome/immunology ; Dysbiosis/immunology ; Molecular Mimicry ; },
abstract = {SARS-CoV-2 infection induces profound immune dysregulation, including hyperinflammation, lymphopenia, and innate/adaptive immune imbalance. In some individuals, these responses persist beyond viral clearance, creating conditions that may disrupt immunological self-tolerance and precipitate autoimmune phenomena. We critically review mechanistic and clinical evidence linking SARS-CoV-2 infection to autoimmunity. Viral entry via ACE2/TMPRSS2, endothelial injury, and renin-angiotensin system dysregulation generates a pro-inflammatory milieu. Immune pathways, including molecular mimicry, bystander activation, epitope spreading, and persistent antigenic stimulation, can trigger the activation of autoreactive lymphocytes. Emerging evidence further implicates SARS-CoV-2-associated oral-gut microbiome dysbiosis and alterations in tryptophan and arginine metabolic checkpoints as contributors to chronic inflammatory signaling and impaired tolerance maintenance. We propose a mechanistic cascade from viral infection to dysbiosis to metabolic perturbation to loss of tolerance to autoantibody generation. Clinical manifestations encompass neurological, hematological, endocrine, and systemic autoimmune syndromes, with evidence of autoantibody emergence and post-COVID-19 immune sequelae. SARS-CoV-2 acts as an amplifier of autoimmune reaction in genetically susceptible hosts. Understanding these mechanisms is critical for identifying at-risk individuals and informing preventive and therapeutic strategies for post-COVID-19 autoimmune sequelae.},
}
@article {pmid42349528,
year = {2026},
author = {Elgendi, MM and Stewart, SH and Sherry, S and Deacon, SH},
title = {Did COVID-19 change the trajectory of children's internalising symptoms? A meta-analysis of longitudinal studies and moderating factors.},
journal = {Journal of affective disorders},
volume = {413},
number = {},
pages = {122168},
doi = {10.1016/j.jad.2026.122168},
pmid = {42349528},
issn = {1573-2517},
mesh = {Humans ; *COVID-19/psychology ; Longitudinal Studies ; Child ; *Anxiety/psychology/epidemiology ; Adolescent ; *Depression/psychology/epidemiology ; Child, Preschool ; Female ; Male ; },
abstract = {The COVID-19 pandemic disrupted children's and adolescents' daily lives worldwide, raising concerns about changes in internalising symptoms. Prior reviews have documented elevated depression and anxiety symptoms during the pandemic, but cross-sectional designs have limited conclusions about within-person change and its moderators. To address this gap, we conducted a meta-analysis of longitudinal studies assessing internalising symptoms before and during the COVID-19 pandemic. Eighty peer-reviewed studies (187 effect sizes) contributed data from youth aged 5-17 years across 20 countries. Standardized mean change (SMC) effect sizes were synthesised using random-effects models with robust variance estimation. Guided by Bronfenbrenner's ecological systems theory, we examined moderators spanning individual, family/school, contextual, and temporal domains. Overall, internalising symptoms increased modestly from pre- to peri-pandemic assessments (SMC = 0.32, 95% CI [0.11, 0.53]; multilevel SMC = 0.34, 95% CI [0.15, 0.53]). Effects varied widely across studies (I[2] = 97.9%), indicating highly heterogeneous symptom trajectories, and suggesting that pooled estimates should be interpreted cautiously. Larger increases were observed in studies including parent-report measures and in contexts of full school closures and highly stringent government responses. Age, gender/sex, region, COVID prevalence, and assessment timing were not significant moderators. Although there were larger increases for composite scores across broad internalising and depressive symptoms than for anxiety or stress, there were no statistically robust between-domain differences. Together, these results indicate that internalising symptoms increased modestly during the COVID-19 pandemic, but that youth experiences were highly context-dependent, underscoring the importance of considering ecological conditions-such as school closures and policy responses-when evaluating pandemic-related mental health change.},
}
@article {pmid42350210,
year = {2026},
author = {Marchesi, F and Girmenia, C and Trecarichi, EM and Piciocchi, A and Busca, A and Candoni, A and Cattaneo, C and Delia, M and Del Principe, MI and Fianchi, L and Gentile, G and Fracchiolla, NS and Tumbarello, M and Vignetti, M and Venditti, A and Pagano, L},
title = {Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.},
journal = {Blood reviews},
volume = {},
number = {},
pages = {101412},
doi = {10.1016/j.blre.2026.101412},
pmid = {42350210},
issn = {1532-1681},
abstract = {Infections are a leading cause of morbidity, mortality, and treatment delays in AML and APL. While international guidelines emphasize intensive chemotherapy, they often overlook less intensive regimens, rely on outdated data, and ignore rising MDR infections. A GIMEMA survey across Italian centers revealed significant heterogeneity in antimicrobial prophylaxis, and vaccination practices. An expert panel reviewed 2012-2025 English literature with focus on infections via Delphi/nominal group methods, achieving ≥70% consensus. Prophylaxis with fluoroquinolones showed low agreement (28%) for intensive chemotherapy and venetoclax-based regimens due to no survival benefit, MDR pressure and microbiota disruption; not recommended for low-intensity/palliative care. Posaconazole is advised for intensive chemotherapy with or without FLT3 inhibitors, venetoclax-based regimens, HMA with or without ivosidenib (first 4 cycles), but not APL/palliative care. Antiviral prophylaxis is recommended for APL receiving arsenic trioxide; limited evidence elsewhere. The panel supports universal pneumococcal, influenza, SARS-CoV-2 and herpes zoster vaccination. Overall, these consensus statements aim to harmonize practice and highlight key areas requiring specifically designed prospective studies.},
}
@article {pmid42350880,
year = {2026},
author = {Filippatos, F and Kakleas, K and Michos, A},
title = {Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.},
journal = {Clinical reviews in allergy &amp; immunology},
volume = {69},
number = {1},
pages = {},
pmid = {42350880},
issn = {1559-0267},
mesh = {Humans ; *Cytokines/metabolism/immunology ; Child ; *Mucositis/immunology/diagnosis ; Immunity, Innate ; Signal Transduction ; Innate Immunity Recognition ; },
abstract = {Reactive infectious mucocutaneous eruption (RIME) is increasingly recognized as a pediatric syndrome in which severe mucositis follows a recent infection and cutaneous involvement is usually limited. Although Mycoplasma pneumoniae remains the prototype trigger, influenza, SARS-CoV-2, adenovirus, respiratory syncytial virus, and other respiratory pathogens can produce a similar clinical phenotype. This narrative review summarizes pediatric RIME/MIRM literature and selected adult or comparator-disease evidence when direct pediatric data are unavailable, explicitly distinguishing direct RIME evidence from extrapolated mechanisms. This review synthesizes current evidence on the immunopathogenesis of RIME in children, with emphasis on how pathogen-specific factors intersect with innate and adaptive immune pathways to drive mucosal injury. We discuss the central roles of epithelial sensing, inflammasome activation, cytokine amplification, neutrophil recruitment, and T-cell polarization, and we relate these mechanisms to the severe oral, ocular, and anogenital disease that often defines pediatric presentations. We also integrate emerging proteomic data showing recurring molecular programs, including acute-phase and complement activation, neutrophil-associated epithelial injury, and interferon-inducible antiviral responses. In addition, we review the possible contribution of genetic susceptibility, especially variation in innate immune sensors and cytokine signaling pathways, to disease severity and recurrence. Finally, we address the main diagnostic challenges, histopathologic and imaging findings, differential diagnosis from Stevens-Johnson syndrome, erythema multiforme, and Kawasaki disease, and the implications of these insights for risk stratification and treatment. Taken together, current evidence supports RIME as a pathogen-triggered, mucosa-predominant inflammatory syndrome in which exaggerated host responses, rather than pathogen presence alone, shape the clinical phenotype.},
}
@article {pmid42351066,
year = {2026},
author = {Tolera, ST and Zerihun, E and Hunduma, G and Letta, S},
title = {Application of health belief model (HBM) in health sciences and medical researches: systematic review on African and Asian countries.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-28281-5},
pmid = {42351066},
issn = {1471-2458},
abstract = {BACKGROUND: The Health Belief Model (HBM) is a widely used psychological framework for explaining and predicting individual's health related attitudes, belief, and behaviors. Although the model has been applied across various fields of health and medical sciences, the extent of its global use, particularly across African and Asian countries has not been well documented.<br><br>OBJECTIVE: This systematic review aimed to assess the application of HBM in health sciences and medical research conducted between 2010 and 2025 in Africa and Asian countries.<br><br>METHODS: The review followed the updated Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted using keywords "Health Belief Model" combined with Boolean operators (AND, OR) across major databases, including PubMed, CINAHL, Web of Science, Scopus, Cochrane Library and PsycINFO. Eligible studies included peer-reviewed research articles applying the HBM within African and Asian contexts.<br><br>RESULT: From a total of 1,421 identified records, 77 studies met the inclusion criteria. Of these, 61% (n&#x2009;=&#x2009;47) were conducted in Africa countries and 39% (n&#x2009;=&#x2009;30) in Asian countries. Most studies (64.94%) employed cross-sectional quantitative design, while 12% used mixed-methods approaches. Random controlled trial account for 9.11% of studies, quasi-experimental design for 7%, and qualitative approaches (including focus groups and in-depth interviews) for 6%. Overall, 85.71% of the studies applied all core components of HBM. Fifteen studies examined COVID-19 vaccine acceptance, nine focused on HIV/AIDS testing, counseling and prevention, and eleven studies explored non-communicable diseases prevention. Additionally, six studies assessed women's adherence to breast cancer screening, and four studies examined cervical cancer screening behaviours using HBM.<br><br>CONCLUSION: A current systematic review demonstrates that the HBM remain a valuable framework for understanding and influencing health behaviors across diverse settings. Its application in Africa and Asian research highlights its usefulness in guiding targeted interventions that address perceived susceptibility, severity, benefits, barriers, and cues to action, ultimately contributing to improved health outcomes.},
}
@article {pmid42351227,
year = {2026},
author = {Kumar, N and Khandavalli, N and Avedissian, SN and Chand, HS and Acharya, A and Byrareddy, SN},
title = {Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.},
journal = {Journal of neuroinflammation},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12974-026-03928-7},
pmid = {42351227},
issn = {1742-2094},
support = {DA052845, DA059874, DA061678/NH/NIH HHS/United States ; },
abstract = {Long-COVID, also referred to as post-acute sequelae of COVID-19 (PASC), is a heterogeneous disorder encompassing more than 200 reported symptoms that commonly affect the respiratory and nervous systems. Emerging clinical evidence indicates that unresolved lung inflammation, vascular injury, and immune dysregulation drive sustained neuroinflammation and impaired neurocognitive function in Long-COVID patients. Given the ethical and logistical constraints of human studies, biologically relevant animal models are essential for understanding the mechanisms and for evaluating therapeutic strategies against Long-COVID. In this review, we synthesize current evidence from preclinical animal models of Long-COVID, with a particular emphasis on the Golden Syrian Hamsters. Golden Syrian Hamsters are naturally susceptible to SARS-CoV-2 infection without the need for genetic modification and recapitulate key features of human disease, including robust viral replication, pulmonary pathology, and inflammatory response during acute infection. Importantly, accumulating evidence demonstrates that Golden Syrian Hamsters develop persistent post-acute abnormalities along the lung-brain-immune axis, including impaired alveolar repair, fibrotic lung remodeling, neuroinflammation, viral or antigen persistence, and behavioral alterations that parallel core features of Long-COVID. We compare the strengths and limitations of Golden Syrian Hamsters with other commonly used pre-clinical animal models including mice, and non-human primates, highlighting differences in translational relevance, feasibility, and ability to model chronic lung-brain-immune axis dysfunction. While there are limitations, particularly regarding limited availability of immunological reagents and validated cognitive and behavioral assays, the Golden Syrian Hamsters offers a balanced and accessible platform for mechanistic studies of PASC. Overall, this review positions Golden Syrian Hamster as a robust translational model for investigating lung-brain-immune axis pathology in Long-COVID and for advancing the development of targeted therapeutic interventions.},
}
@article {pmid42351549,
year = {2026},
author = {Shati, A and Abdulmutaali, A and Alsaeed, N},
title = {Respiratory Disease Detection: A Systematic Review of AI-Based Approaches, from Audio and Visual Unimodal Methods to Multimodal Integration.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {12},
pages = {},
pmid = {42351549},
issn = {2075-4418},
support = {RA.KKU/2/46/1446H//The Deanship of Research and Graduate Studies at King Khalid University/ ; },
abstract = {Background: Respiratory diseases (RDs), including asthma, COVID-19, chronic obstructive pulmonary disease (COPD), and pneumonia, remain a major global health challenge, contributing substantially to global morbidity and mortality. Conventional diagnosis relies heavily on clinicians' expertise to interpret respiratory sounds and radiographic images, a process that can be subjective, time-consuming, and prone to inter-observer variability. Recent advances in artificial intelligence (AI) and machine learning (ML) have enabled automated diagnostic approaches that can improve the efficiency, consistency, and scalability of respiratory disease detection. However, existing research remains fragmented across different data modalities. Methods: This review systematically analyzes recent studies on AI-based respiratory disease detection using both visual modalities (e.g., chest X-rays, computed tomography (CT) scans, and ultrasound) and audio modalities (e.g., cough and breath sounds). To provide a comprehensive perspective, the reviewed literature is organized using a unified taxonomy that categorizes existing approaches into three main groups: audio-based, visual-based, and audio-visual-based methods. In addition, two conceptual frameworks are proposed to illustrate representative pipelines for audio-based and visual-based respiratory disease classification. Results: The analysis reveals that most existing studies focus on single-modality approaches, while multimodal integration remains relatively underexplored. Only a limited number of studies combine audio and visual data within unified frameworks, primarily due to the scarcity of synchronized multimodal datasets collected from the same patients. The proposed taxonomy and conceptual frameworks provide a structured basis for comparing existing methods, identifying methodological trends, and highlighting key research gaps in multimodal respiratory disease detection. Conclusions: Future research should prioritize the development of multimodal datasets, robust evaluation protocols, and interpretable and lightweight AI models suitable for real-world clinical deployment. Advancing multimodal integration has the potential to significantly enhance the accuracy, reliability, and clinical applicability of AI-driven respiratory disease diagnosis systems.},
}
@article {pmid42351791,
year = {2026},
author = {Zdrobe, Z and Tornyi, I and Sárközi, AT and Horváth, I},
title = {The Complement System and Its Role in Eosinophilic Inflammation in Respiratory Diseases.},
journal = {Biomedicines},
volume = {14},
number = {6},
pages = {},
pmid = {42351791},
issn = {2227-9059},
abstract = {The complement system is a key link between innate and adaptive immunity, contributing to pathogen elimination, immune regulation, and tissue homeostasis. Its activation is not only crucial in infections, such as COVID-19, but also plays a major role in the pathomechanism of several non-infectious respiratory diseases, such as asthma, COPD, sarcoidosis and lung cancer. Complement components can modulate the quality of the adaptive immune responses, including through the regulation of T2 immunity and eosinophilic inflammation, thereby linking natural defense to complex immune processes. In recent years, it has become increasingly clear that dysregulated complement activity contributes to inflammation, thrombosis and tissue damage in a wide range of respiratory diseases. The study of the various components of this cascade system may therefore be promising from both a diagnostic and therapeutic point of view. Some of its components may serve as biomarkers for distinguishing between different phenotypes of certain lung diseases, while their targeted inhibition or modulation may open the way towards new treatment options. A better understanding of the complement system's integrative and regulatory role not only allows for a deeper insight into immunological interactions but may also bring us closer to phenotype-oriented, immunology-based pulmonology, which may have real clinical benefits in the future.},
}
@article {pmid42352300,
year = {2026},
author = {Beyoğlu, D and Idle, JR},
title = {The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.},
journal = {Biomolecules},
volume = {16},
number = {6},
pages = {},
pmid = {42352300},
issn = {2218-273X},
mesh = {Humans ; *Lung/microbiology/metabolism ; *Gastrointestinal Microbiome ; *Lung Diseases/microbiology/metabolism ; Animals ; COVID-19/microbiology ; *Microbiota ; Dysbiosis ; },
abstract = {Both the gut and the lungs possess a microbiome, a community of commensal bacteria, archaea, fungi, and viruses that perform important housekeeping functions in those organs. The colonic microbiome primarily ferments indigestible dietary fibers into essential short-chain fatty acids, synthesizes essential vitamins, regulates the mucosal immune system, and forms a protective barrier against pathogenic colonization. The lung microbiome maintains respiratory health primarily by regulating mucosal immunity, providing a physical barrier against invading pathogens, and producing beneficial metabolites. Several colonic microbiota metabolites, including the short-chain fatty acids acetate, propionate, and butyrate, together with the tryptophan metabolites indole-3-acetate and indole-3-propionate, secondary bile acids, and the polyamines spermidine and putrescine, are transported to the lungs via the gut-lung axis. These colonic microbiota biomolecules suppress lung inflammation, strengthen immune homeostasis, and reduce the severity of respiratory diseases. In contrast, lung microorganisms and their metabolites can travel to the gut via the gut-lung axis, influencing intestinal immune responses and potentially leading to an imbalance of gut microorganisms or dysbiosis. This means that respiratory diseases may lead to digestive issues, intestinal inflammation and chronic diseases. Here, we have reviewed this crosstalk and its impact on the principal pulmonary diseases: asthma, chronic obstructive pulmonary disease, cystic fibrosis, bronchogenic carcinoma, COVID-19, interstitial lung diseases, pneumonia, and tuberculosis. It is concluded that the gut microbiome plays a significant part in lung health and disease. Diet, tobacco smoking and electronic cigarette vaping all impact both the gut and lung microbiomes.},
}
@article {pmid42353563,
year = {2026},
author = {Liu, J and Mao, N and Cui, Y and Bao, Y and Tang, C},
title = {Research Progress on Coronary Artery Injury and Myocardial Ischemia in Multisystem Inflammatory Syndrome in Children.},
journal = {Current issues in molecular biology},
volume = {48},
number = {6},
pages = {},
pmid = {42353563},
issn = {1467-3045},
abstract = {Multisystem inflammatory syndrome in children (MIS-C) is a severe systemic inflammatory complication triggered by prior SARS-CoV-2 infection. It predominantly affects the cardiovascular system, and coronary artery injury, myocardial dysfunction, and myocardial ischemia are closely associated with disease severity and clinical outcomes. This article reviews the immunopathological characteristics and clinical manifestations of MIS-C-related coronary artery lesions, including coronary artery dilation and aneurysm formation, as well as the key pathophysiological mechanisms leading to myocardial ischemia. Based on recent clinical and translational research, we summarize current approaches to diagnosis, risk stratification, acute medical management, and long-term follow-up strategies. By synthesizing updated evidence, this review aims to provide theoretical support and practical clinical guidance for the early identification, timely intervention, and optimized management of affected children, ultimately improving their long-term cardiovascular prognosis.},
}
@article {pmid42353688,
year = {2026},
author = {Wahnou, H and El Kebbaj, R and Demoré, B and Limami, Y and Duval, RE},
title = {Current State of the Fight Against Antimicrobial Resistance: What Are the Different Strategies for Tomorrow?.},
journal = {Antibiotics (Basel, Switzerland)},
volume = {15},
number = {6},
pages = {},
pmid = {42353688},
issn = {2079-6382},
abstract = {Antimicrobial resistance (AMR) is a leading global cause of death, with recent World Health Organization (WHO) data revealing that one in six laboratory-confirmed bacterial infections shows resistance to at least one antibiotic treatment. This review comprehensively analyzes the AMR landscape in 2026, detailing its evolution, mechanisms, and the innovative strategies being deployed to combat it. Driven by Darwinian selection and accelerated by factors like antibiotic overuse during the Coronavirus Disease 2019 (COVID-19) pandemic (predominantly in hospitalized patients with suspected bacterial co-infection), AMR is propelled by a diverse molecular arsenal in bacteria. Key mechanisms include enzymatic drug inactivation (e.g., the diversifying β-lactamase superfamily), target site modification (e.g., mcr genes conferring colistin resistance), efflux pumps, and biofilm formation. The rapid global spread of these traits is facilitated by a dynamic "mobilome", a network of plasmids and transposons that shuttle resistance genes between species. This crisis has sparked a major scientific mobilization. Advances include the discovery of novel antibiotic scaffolds like lariocidin and the regulatory approval of critical new antibiotic/inhibitor combinations such as sulbactam/durlobactam and aztreonam/avibactam, which target highly resistant Gram-negative bacteria. Moreover, the first-in-class antibiotic gepotidacin offers a new option for urinary tract infections. Beyond traditional drugs, the pipeline is diversifying to include phage therapy, antivirulence strategies, and artificial intelligence-guided drug discovery. This diversification is critical as it helps preserve the effectiveness of existing Medically Important Antimicrobials (MIAs), those deemed essential for human medicine, by providing alternative or adjunctive treatment options. However, scientific innovation alone is insufficient. This review argues that lasting success requires parallel progress in global policy and infrastructure. Strategic priorities beyond 2026 must include finalizing and funding updated global action plans, strengthening real-time surveillance and diagnostic capacity, especially in low-resource settings, and implementing new economic models to de-risk antibiotic development. Embedding effective antimicrobial stewardship within universal health coverage and pandemic preparedness plans is crucial. Ultimately, defeating AMR demands an unprecedented, coordinated global effort that outpaces the relentless adaptability of bacterial pathogens.},
}
@article {pmid42354127,
year = {2026},
author = {Piva, M and Martelossi-Cebinelli, G and Mendes-Pierotti, S and Chinen, WH and Cardines, PHF and Martinez, RM and Georgetti, SR and Baracat, MM and Vicentini, FTMC and Verri, WA and Casagrande, R},
title = {Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems.},
journal = {Foods (Basel, Switzerland)},
volume = {15},
number = {12},
pages = {},
pmid = {42354127},
issn = {2304-8158},
support = {Grant call #067/2024//Funda&#xe7;&#xe3;o Arauc&#xe1;ria/ ; #309633/2021-4, #405027/2021-4, #307852/2019-9; #481049/2012-6; #427946/2018-2 and # 405848/2025-0//Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico/ ; finance code 001//Coordena&#xe7;&#xe3;o de Aperfeicoamento de Pessoal de N&#xed;vel Superior/ ; n/a//Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa do Estado de S&#xe3;o Paulo/ ; dota&#xe7;&#xe3;o or&#xe7;ament&#xe1;ria #4560.19.571.06.6153; eprotocolo 21.234.745-0//Secretaria de Estado da Ci&#xea;ncia, Tecnologia, e Ensino Superior (SETI)/ ; },
abstract = {The immune response is essential in the protection of our body against pathogens; however, the inflammatory response caused by the immune system can become a disease itself. In fact, anti-inflammatory and immune-suppressive drugs are applied to limit the immune response to treat inflammatory diseases. Flavonoids are plant-derived polyphenols extensively investigated for their anti-inflammatory and antioxidant properties in inflammatory diseases. Studies applying isolated compounds as well as using supplements as nutraceuticals based on flavonoids have been conducted. Our review systematically analyzed the top five studied flavonoids between 2020 and 2025: quercetin (1742 articles), kaempferol (642), luteolin (589), apigenin (419), and epicatechin (354), highlighting their major therapeutic applications in diseases affecting the liver (12%), nervous system (11%), and lungs (10%). Mechanistically, these compounds act as multi-target agents mainly by inhibiting NF-κB and inducing Nrf2-dependent antioxidant programs. Application of advanced delivery systems, which increase oral bioavailability by up to 20-fold, overcomes pharmacokinetic bottlenecks. Clinical highlights demonstrated promising therapeutic effects, including reduced intrahepatic lipid accumulation in non-alcoholic fatty liver disease patients following quercetin supplementation (11.5% to 9.6%) and accelerated SARS-CoV-2 clearance after quercetin phytosome administration. The translation of flavonoids into standardized clinical therapies remains limited by the lack of large-scale, well-controlled clinical trials.},
}
@article {pmid42354220,
year = {2026},
author = {Messova, AM and Ganiyeva, I and Abdrakhmanova, ST and Tuleubayeva, A and Sanbayev, M and Makibayeva, MG and Tamadon, A},
title = {Autoimmune Thyroid Diseases After COVID-19 Infection: A Systematic Review of Clinical Manifestation and Outcomes.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {6},
pages = {},
pmid = {42354220},
issn = {1660-4601},
mesh = {Humans ; *COVID-19/complications ; *Graves Disease/etiology ; *Hashimoto Disease/etiology ; SARS-CoV-2 ; *Thyroiditis, Autoimmune/etiology ; },
abstract = {Background: Increasing evidence suggests that COVID-19 can induce or exacerbate autoimmune disorders, including immune-mediated thyroid dysfunction. The most common autoimmune thyroid diseases are Graves' disease and Hashimoto's thyroiditis; the mechanisms by which viral infections like SARS-CoV-2 trigger these diseases are not fully understood. Objectives: This study aims to systematically review published clinical evidence on the presentation, laboratory characteristics, and outcomes of autoimmune thyroid diseases after COVID-19 infection. Methods: The review followed the PRISMA 2020 framework. Scopus, Web of Science, and PubMed were searched for English-language studies between January 2020 and December 2025 using the terms COVID-19, SARS-CoV-2, autoimmune thyroiditis, Graves' disease, Hashimoto's thyroiditis, and autoimmune thyroid disease. Results: In total, 46 studies (five cohort studies and 41 case reports/series) involving 3856 patients were analyzed. The findings indicate that a significant increase in TPOAb prevalence occurs post-COVID-19 infection (15.7% vs. 7.7% in controls). New-onset Graves' disease (GD) post-COVID-19 presented with higher fT3/fT4 ratios and more aggressive thyrotoxicosis compared to non-viral cases. Rare but severe manifestations included thyrotoxic periodic paralysis, Hashimoto's encephalopathy, and dilated cardiomyopathy. Conclusions: SARS-CoV-2 may act as a trigger for autoimmune thyroid diseases, particularly in moderate-to-severe infections; however, the strength of this association warrants further investigation with controlled prospective data. Standard therapy remains effective, but thyroid function monitoring is advisable during post-COVID-19 recovery. An interdisciplinary approach is essential for early diagnosis and management of systemic complications.},
}
@article {pmid42354473,
year = {2026},
author = {De Micco, F and Di Palma, G and Ferorelli, D and Giacomobono, F and Lima Arrais Ribeiro, I and Nóbrega, JBMD and Scendoni, R},
title = {Patient Safety Implications of Opportunistic Pathogens and Healthcare-Associated Infections in COVID-19 Patients: A Narrative Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {12},
pages = {},
pmid = {42354473},
issn = {2227-9032},
abstract = {The COVID-19 pandemic has highlighted the increased vulnerability of hospitalized patients to healthcare-associated infections (HAIs), which significantly impact patient safety and clinical outcomes. This narrative review summarizes the main opportunistic pathogens associated with HAIs in COVID-19 patients, with particular focus on multidrug-resistant organisms such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, and Candida spp. The review also examines key aspects of antimicrobial resistance, prevention and control strategies, and medico-legal implications. The evidence supports the need for a multifaceted approach based on antibiotic stewardship, infection prevention guidelines, and multidisciplinary clinical risk management.},
}
@article {pmid42354881,
year = {2026},
author = {Precup, CV and Mateescu, DM and Enache, A and Buhas, CL and Muresan, CO},
title = {SARS-CoV-2 Persistence and Cardiovascular Sequelae in the Post-COVID Era: A Public Health Microbiology Perspective on Sudden Cardiac Death and Pulmonary Thromboembolism.},
journal = {Microorganisms},
volume = {14},
number = {6},
pages = {},
pmid = {42354881},
issn = {2076-2607},
support = {Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
abstract = {Post-acute sequelae of SARS-CoV-2 infection (PASC) extend well beyond the acute respiratory phase, with accumulating virological evidence that SARS-CoV-2 RNA, viral antigens, and proteolytic fragments may persist in cardiovascular and other extrapulmonary tissues, although the extent to which such detection represents replication-competent reservoirs versus residual viral material with uncertain pathological relevance remains under active investigation. Sudden cardiac death (SCD) and fatal pulmonary thromboembolism (PTE) have emerged as forensically and epidemiologically significant outcomes in individuals with prior infection, situated at the intersection of microbiology, public health, and forensic medicine. To synthesize current evidence on the virological mechanisms by which SARS-CoV-2 may contribute to post-acute sudden cardiac death (SCD) and pulmonary thromboembolism (PTE), the population-level epidemiology of these outcomes, and their implications for public health surveillance and forensic practice, we conducted a narrative review of PubMed (MEDLINE), Scopus, and Web of Science Core Collection. The search covered publications from January 2020 to December 2025 and focused on SARS-CoV-2 cellular tropism and tissue persistence, immune-mediated and thromboinflammatory mechanisms, excess cardiovascular and thromboembolic mortality, and autopsy-based pathological findings. After de-duplication of 1837 initially identified records (412 duplicates removed) and screening of 1425 unique records, 78 studies were retained for final synthesis based on virological, epidemiological, and forensic relevance. SARS-CoV-2 enters cardiomyocytes, pericytes, and vascular endothelial cells through ACE2-dependent mechanisms, with cathepsin L compensating for the limited cardiac expression of TMPRSS2. Viral RNA and antigen have been detected in cardiovascular and other extrapulmonary tissues months after symptom onset in selected autopsy series, although persistent detection of viral components does not necessarily indicate ongoing productive infection or direct tissue injury. Endothelial dysfunction, neutrophil extracellular trap (NET) formation, complement activation, and persistent thromboinflammation have been proposed as plausible mechanistic substrates for arrhythmogenic remodelling and thromboembolic events, although definitive causal pathways remain incompletely understood. Population-based studies document persistent excess cardiovascular mortality across multiple jurisdictions, with hazard ratios for pulmonary embolism remaining elevated months after acute infection, particularly in unvaccinated individuals. Autopsy series identify mixed pathological patterns including focal lymphocytic infiltrates, microvascular thrombosis, contraction-band necrosis, and cardiomyocyte vacuolation, although fulminant lymphocytic myocarditis fulfilling Dallas criteria remains uncommon. A microbiology-informed framework uniting tissue-based viral detection, standardized cardiac and pulmonary sampling protocols, and prospective post-mortem registries is needed to better characterize the potential contribution of SARS-CoV-2 to post-acute cardiovascular mortality and to support cause-of-death certification, public health surveillance, and medicolegal practice in the post-pandemic era. Many of the proposed mechanisms remain under active investigation, and definitive causal relationships between viral persistence and adverse cardiovascular outcomes have not yet been conclusively established.},
}
@article {pmid42354940,
year = {2026},
author = {Mpakosi, A and Cholevas, V and Lianou, A and Tziraki, F and Vogiatzis, I and Cholevas, S and Tzouvelekis, I and Mironidou-Tzouveleki, M and Tsante, KA and Tsakri, D and Petrakis, V and Ioannou, P and Bonovas, S and Sokou, R and Tsantes, AG},
title = {Targeting Zoonotic Spillover Drivers for Global Pandemic Prevention: A Narrative Review.},
journal = {Microorganisms},
volume = {14},
number = {6},
pages = {},
pmid = {42354940},
issn = {2076-2607},
abstract = {Zoonoses account for the majority of recognized mammalian viral spillover events, primarily originating from bats, rodents, and primates. Human activities have significantly accelerated these transmissions. This narrative review synthesizes the evolutionary, ecological, pathogen-related, and anthropogenic drivers of viral zoonotic spillover to identify critical leverage points for pandemic prevention. A narrative literature review was conducted. The analysis focused on factors enabling animal pathogens to transform into human pathogens, examining host species, pathogen traits, human-animal interactions, and environmental impacts. Pathogen transformation depends on host traits, contact frequency, and viral characteristics. Anthropogenic drivers-including livestock expansion, the bushmeat trade, wet markets, and the exotic pet industry-significantly elevate spillover risks. Effective pandemic prevention requires targeted interventions at the wildlife-livestock-human interfaces. A holistic, multidisciplinary collaboration between national governments and international organizations is essential to mitigate future risks.},
}
@article {pmid42355811,
year = {2026},
author = {Khawandi, J and Choaib, A and Azzam, M and Oudit, GY and Patel, K and Nazzal, J and Khader, AA and Kawtharany, H and Al Zabibi, MA and Ahmad, J and Kivan, H and Al Hussein, S and Rehman, AU and Piché, A and Vasquez Camargo, A and McNaughton, C and Lam, GY and Kamrul, R and Afzal, S and Schunemann, HJ and Wiercioch, W and Nieuwlaat, R and Brignardello-Petersen, R and Falcone, EL and Mustafa, RA},
title = {Echocardiogram Testing in Patients with Post-COVID-19 Condition: A Systematic Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {12},
pages = {},
pmid = {42355811},
issn = {2077-0383},
support = {2223-HQ-000415//Public Health Agency of Canada/ ; },
abstract = {Background: Post-COVID-19 condition (PCC) is a complication following acute COVID-19 infection, which may lead to long-term cardiac abnormalities. This review aimed to assess the prevalence of structural/functional deviations in echocardiography in individuals with PCC compared to patients without PCC. Methods: We searched three databases. Two reviewers independently screened articles using LASER Al and extracted relevant data using a piloted Excel sheet. We performed meta-analysis using OpenMeta and RevManWeb and a subgroup analysis based on patients' settings during acute COVID-19. We assessed the risk of bias using the Hoy et al. tool and the certainty using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: We included 16 studies that reported on differences in echocardiographic findings in patients with or without PCC. Individuals with PCC were more likely to have structural/functional deviations in echocardiographic readings of unclear clinical significance, particularly those who were hospitalized during acute COVID-19. The overall certainty of the evidence was very low due to the high risk of bias, indirectness, and imprecision. Conclusions: This review provides insight into the use of echocardiograms and the frequency of test deviations in individuals with PCC. Despite existing evidence, there is a need for future studies to assess the diagnostic test accuracy of echocardiograms in PCC.},
}
@article {pmid42356418,
year = {2026},
author = {Posta, E and Gyarmati, E and Majoros, L and Fekete, I and Varkonyi, I and Zold, E and Barta, Z},
title = {Across Kingdoms: The Bacteriome, Mycobiome, and Virome in Autoimmune Diseases: Mechanistic Insights, Therapeutic Perspectives, and the Emerging Role of COVID-19.},
journal = {Nutrients},
volume = {18},
number = {12},
pages = {},
pmid = {42356418},
issn = {2072-6643},
mesh = {Humans ; *COVID-19/immunology ; *Autoimmune Diseases/microbiology/immunology/virology/therapy ; SARS-CoV-2 ; *Virome ; Dysbiosis/immunology ; *Gastrointestinal Microbiome/immunology ; },
abstract = {Autoimmune and immune-mediated inflammatory diseases (IMIDs) develop when genetically and environmentally susceptible hosts lose stable immune tolerance. The gut ecosystem is increasingly recognized as a biologically active interface in this process. Its bacterial, fungal, and viral components may shape mucosal and systemic immunity through antigenic stimulation, barrier regulation, and metabolite-dependent signaling, although the strength of evidence is uneven: bacteriome data are currently the most mature, whereas mycobiome, virome, and phageome findings remain more disease-specific and emerging. Dysbiosis may influence autoimmunity through overlapping routes, including epithelial barrier failure, altered short-chain fatty acid, bile acid, and tryptophan metabolism, molecular mimicry, and cross-kingdom microbial interactions. Nutrition is central to this network because dietary substrates determine microbial growth, metabolic output, epithelial integrity, and immune-cell differentiation. In this narrative review, we integrate evidence on disease-associated bacteriome, mycobiome, and virome patterns in systemic autoimmune diseases, with emphasis on rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, spondyloarthritis, vasculitides, and idiopathic inflammatory myopathies. COVID-19 is considered not as a proven causal driver of autoimmunity, but as an example of an environmental and infectious insult capable of perturbing microbiome-barrier-immune communication. Finally, we discuss diet-based and microbiome-targeted approaches, including probiotics, prebiotics, synbiotics, and postbiotics, as adjunctive strategies that may help restore microbial resilience and immune balance. A better understanding of the diet-microbiome-host immunity axis may support more personalized preventive and therapeutic concepts in autoimmune disease.},
}
@article {pmid42356487,
year = {2026},
author = {Chiririwa, H},
title = {Selected Cannabinoids, Cannabimimetic Agents and Artemisia Combinations as Theoretical Adjunct Strategies Against COVID-19.},
journal = {Pharmaceuticals (Basel, Switzerland)},
volume = {19},
number = {6},
pages = {},
pmid = {42356487},
issn = {1424-8247},
abstract = {COVID-19 has spurred much interest in complementary and alternative agents for therapeutic purposes having antiviral and immunomodulatory effects. In these, natural products and bioactive compounds from plants have been at the center of attention due to their easy access, relatively low risk and long history of use in traditional medicine. This paper reviews in detail and critically assesses the scientific data that presently proposes the use of certain cannabinoids, cannabimimetic compounds and Artemisia species in the treatment and prevention of COVID-19. It gives an account of medicinal approaches to cannabinoids like cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) alongside other minor cannabinoids and synthetic and naturally-occurring cannabimimetics. The paper reports the potential of Artemisia annua and other species as treatments, especially focusing on their antiviral, anti-regulatory, anti-inflammatory and immunomodulating properties. It highlights the molecular interactions with SARS-CoV-2 targets as well as cytokine regulation and modulation of oxidative stress pathways, with special emphasis on these areas. The paper raises multiple issues like preclinical and clinical studies, safety aspects, regulatory hurdles and drawbacks related to the use of these natural compounds. After analyzing all the available data, the article entertains the idea of a cannabinoid-Artemisia combination as a supportive or adjunct therapy in COVID-19 treatment. It also points out that the clinical trials are insufficient concerning the establishment of effectiveness, determination of the appropriate dosage and assurance of the long-term safety of the treatment.},
}
@article {pmid42357296,
year = {2026},
author = {Dos Santos, RPN and Betancourt Roldan, DC and Guven, M and Leite, LC and Furlan, FJM and da Silva, GRM and de Oliveira, VAP and Capriglione, CDS and da Silva, JP and Pinto, JC and Eş, I and Balbino, TA},
title = {Microfluidic-Driven Assembly of RNA Nanocomplexes: Design, Process Control and Translational Perspectives in Oncology.},
journal = {Pharmaceutics},
volume = {18},
number = {6},
pages = {},
pmid = {42357296},
issn = {1999-4923},
support = {124C536//Scientific and Technological Research Council of Turkey/ ; YTB//Presidency for Turks Abroad and Related Communities/ ; },
abstract = {RNA-based therapeutics are becoming increasingly important in oncology, particularly following the rapid development of mRNA technologies during the COVID-19 pandemic, but their success strongly depends on how efficiently they can be delivered to target cells. Microfluidic technologies have redefined the design and manufacturing of RNA-based nanocomplexes, as they enable precise control over physicochemical features that are critical for clinical translation in oncology. This review examines recent developments in microfluidic-assisted synthesis of RNA nanocarriers, with a focus on cancer applications. Through a detailed analysis of material systems, device architectures, and formulation strategies, we explore how laminar flow environments enable reproducible encapsulation, tunable particle size, and improved payload stability. We examine the microfluidic assembly of lipid nanoparticles and polymeric carriers for RNA delivery, highlighting strategies to enhance durability, bioavailability, and cellular uptake. Advancements in process optimization, including flow parameter refinement and inline monitoring, are discussed alongside the influence of device geometries on mixing dynamics and nucleation. Beyond formulation, we explore the integration of microfluidics with tumor-on-chip platforms to evaluate transport, penetration, and therapeutic response in physiologically relevant cancer models. By connecting technological innovation with preclinical application, this work outlines the trajectory toward next-generation, personalized RNA nanomedicines enabled by microfluidic precision.},
}
@article {pmid42357309,
year = {2026},
author = {Porta, EOJ and AlKharboush, DF and Jackson, L and Pang, F and Darin, A and Louka, J and Quamruzzaman, M and Shi, X and Wells, G and Kozielski, F},
title = {Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.},
journal = {Pharmaceutics},
volume = {18},
number = {6},
pages = {},
pmid = {42357309},
issn = {1999-4923},
support = {MR/X013995/1/MRC_/Medical Research Council/United Kingdom ; },
abstract = {The SARS-CoV-2 non-structural proteome remains the most clinically validated and strategically important landscape for direct-acting small-molecule antiviral drug discovery. The success of inhibitors targeting the main protease (M[pro], Nsp5) and RNA-dependent RNA polymerase (RdRp, Nsp12) has firmly established viral replication enzymes as tractable, druggable, and therapeutically relevant targets, while setting clear benchmarks for translational antiviral development. Building on this foundation, a second wave of non-structural protein (Nsp) targets has emerged with increasing translational promise, including the papain-like protease (PL[pro]), the bifunctional Nsp14 proofreading and capping machinery, Nsp16 2'-O-methyltransferase, Nsp13 helicase, and Nsp15 endoribonuclease. In parallel, additional components such as Nsp1 and the Mac1 domain of Nsp3 continue to expand the antiviral design space, although they remain at earlier stages of chemical validation. In this review, we comprehensively assess SARS-CoV-2 non-structural proteins through a medicinal chemistry and translational lens, with an emphasis on structural tractability, mechanism of action, quality of chemical matter, cellular and in vivo antiviral evidence, evolutionary conservation, resistance liabilities, and developability. Particular attention is given to the features that distinguish tool compounds from genuinely actionable leads and to the opportunities for rational combination regimens that extend beyond first-generation protease- and polymerase-centred therapy. Collectively, the non-structural proteome offers the strongest foundation for next-generation and potentially broader-spectrum coronavirus antivirals with improved resilience to viral evolution.},
}
@article {pmid42357322,
year = {2026},
author = {Porta, EOJ and AlKharboush, DF and Jackson, L and Pang, F and Darin, A and Louka, J and Shi, X and Wells, G and Kozielski, F},
title = {Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.},
journal = {Pharmaceutics},
volume = {18},
number = {6},
pages = {},
pmid = {42357322},
issn = {1999-4923},
support = {MR/X013995/1/MRC_/Medical Research Council/United Kingdom ; },
abstract = {Although antiviral development against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been dominated by replication-directed strategies, structural and accessory proteins offer a complementary and increasingly important opportunity for small-molecule intervention. These proteins control key processes outside the core replication machinery, including viral entry, membrane remodelling, virion assembly, egress, and host immune modulation, thereby expanding the mechanistic scope of antiviral design. However, many of these targets are membrane-associated, oligomeric, conformationally dynamic, or function through protein-protein interactions, creating distinct challenges in target validation, assay design, and chemical optimisation. In this review, we comprehensively and critically evaluate the structural and accessory proteomes of SARS-CoV-2, with a strict focus on small-molecule tractability and translational relevance. We highlight the most credible direct-acting opportunities, focusing on the membrane (M), envelope (E), and nucleocapsid (N) structural proteins, together with the accessory protein open reading frame 3a (ORF3a), for which emerging chemical matter strengthens confidence in druggability. In contrast, Spike (S) and several host-interface accessory proteins, including ORF6, ORF8, ORF9b, and ORF10, are best viewed as more selective or earlier-stage opportunities that require stronger on-target chemical validation. Emphasis is placed on structural accessibility, mechanism-based assay systems, evidence quality, cellular and in vivo activity, and developability constraints relevant to exposure at the infection site. Rather than replacing replication-directed antivirals, these non-canonical targets are best considered adjunctive or complementary components of future combination strategies designed to broaden antiviral coverage, enhance robustness, and improve pandemic preparedness.},
}
@article {pmid42357443,
year = {2026},
author = {Zhao, S and Lin, Z and Wang, M},
title = {Positive-Strand RNA Viral RdRps: From Structure Conservation and Activity Assay to Drug Development.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {12},
pages = {},
pmid = {42357443},
issn = {1420-3049},
mesh = {*RNA-Dependent RNA Polymerase/chemistry/antagonists &amp; inhibitors/metabolism/genetics ; *Antiviral Agents/pharmacology/chemistry/therapeutic use ; Humans ; *Drug Development ; *Positive-Strand RNA Viruses/enzymology/drug effects/genetics ; RNA Replication/drug effects ; Virus Replication/drug effects ; SARS-CoV-2/enzymology/drug effects ; },
abstract = {Positive-strand RNA viruses represented by SARS-CoV-2 and DENV spread globally with high infectivity and frequent mutations, posing a severe threat to human health. However, specific and effective antiviral drugs remain limited. RNA-dependent RNA polymerase (RdRp) plays a critical role in the genome replication of RNA viruses and shows high structural conservation. No homologous protein exists in human cells, making RdRp an effective, safe, and broad-spectrum antiviral target. Therefore, establishing an RdRp activity assay for drug development based on its mechanism is of great significance. This paper summarizes the structural characteristics of RdRp and the methods for constructing RdRp activity assay, especially for cell-free activity assay. In addition, several reported RdRp inhibitors and their pharmaceutical progress are also reviewed, aiming to provide a reference for the development of novel antiviral drugs targeting RdRp.},
}
@article {pmid42357608,
year = {2026},
author = {Domingo, JL},
title = {Toxicants, Exposome, and Hantavirus Disease: A One Health Perspective.},
journal = {Viruses},
volume = {18},
number = {6},
pages = {},
pmid = {42357608},
issn = {1999-4915},
mesh = {Humans ; *Hantavirus Infections/transmission/epidemiology/virology ; Orthohantavirus ; Animals ; Climate Change ; *One Health ; *Environmental Exposure/adverse effects ; *Exposome ; SARS-CoV-2 ; COVID-19 ; Zoonoses/virology ; },
abstract = {Although hantaviruses have traditionally been considered geographically restricted rodent-borne pathogens, globalization, climate change, ecosystem disruption, and environmental contamination may collectively favor novel transmission scenarios and altered epidemiological patterns. The experience gained during the SARS-CoV-2 pandemic showed the importance of environmental determinants, airborne exposure, and host susceptibility factors in emerging viral diseases. In this context, increasing but still indirect evidence suggests that environmental toxicants and the exposome may modulate susceptibility to hantavirus infection and influence disease severity. The proposed mechanisms include oxidative stress, endothelial dysfunction, pulmonary inflammation, and immune dysregulation, rather than direct causal effects of toxicants on infection itself. This article discusses current knowledge regarding interactions among toxic environmental exposures, climate change, and hantavirus disease, with special emphasis on Andes orthohantavirus (ANDV), the principal hantavirus known to exhibit person-to-person transmission. The article integrates recent evidence within the One Health framework and highlights future research priorities linking environmental toxicology, zoonotic disease ecology, and global environmental change.},
}
@article {pmid42357652,
year = {2026},
author = {Jia, T and Huang, Z and Xia, N and Yuan, Q},
title = {Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.},
journal = {Viruses},
volume = {18},
number = {6},
pages = {},
pmid = {42357652},
issn = {1999-4915},
support = {824B2066//National Natural Science Foundation of China/ ; 92369110//National Natural Science Foundation of China/ ; 82272305//National Natural Science Foundation of China/ ; },
mesh = {*Antibodies, Neutralizing/immunology/therapeutic use ; Humans ; *SARS-CoV-2/immunology/genetics ; *Antibodies, Viral/immunology/therapeutic use ; *COVID-19/immunology/prevention &amp; control ; Spike Glycoprotein, Coronavirus/immunology/genetics ; Animals ; Epitopes/immunology ; Single-Domain Antibodies/immunology ; Protein Engineering ; Mutation ; },
abstract = {The high-frequency mutation characteristics of SARS-CoV-2 have posed formidable challenges to the development of vaccines and therapeutic agents. Neutralizing antibodies, which serve as effective tools for prevention and control, have undergone continuous updates and iterations in response to viral mutations. This article provides a comprehensive review of researchers' efforts to achieve both high neutralizing potency and high mutation tolerance in SARS-CoV-2-targeting neutralizing antibodies. Building on the characteristics of conventional antibodies directed against distinct epitopes on the S protein, it further discusses the research on nanobodies, antibody cocktails, multi-specific antibodies, and other antibody formats and engineering approaches, including artificial intelligence-enabled optimization. Each antibody-based strategy targeting SARS-CoV-2 has its own distinctive advantages and potential applications, providing an integrated perspective to support the continued development of antiviral neutralizing antibodies.},
}
@article {pmid42359054,
year = {2026},
author = {Dinç, H&#xd6; and Saribaş, S and Kocazeybek, B},
title = {The immunopathological spectrum of COVID-19: from cytokine storm to autoimmunity-a systematic review.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1864452},
pmid = {42359054},
issn = {2296-858X},
abstract = {INTRODUCTION: This systematic review aimed to provide a comprehensive evaluation of the immunopathological mechanisms associated with SARS-CoV-2 infection and COVID-19 vaccination based on current evidence. Particular emphasis was placed on cytokine storm, endothelial dysfunction, complement activation, and autoimmune processes in COVID-19 pathogenesis.<br><br>METHODS: The study was conducted as a systematic literature review in accordance with PRISMA guidelines. English-language research articles published between 2020 and 2026 were identified through a structured search of the Scopus database. A total of 1,331 records were screened, and 53 studies were included based on predefined inclusion and exclusion criteria. The findings were systematically categorized according to major immunopathological mechanisms.<br><br>RESULTS: The included studies indicate that endothelial dysfunction (24.5%) and cytokine dysregulation (18.9%) are the most frequently reported mechanisms in COVID-19 immunopathogenesis. Autoimmune responses (15.1%), complement activation (17%), and immune complex-mediated inflammation also play significant roles. Elevated levels of proinflammatory cytokines, lymphopenia, and markers of vascular injury were consistently associated with increased disease severity and mortality. In addition, persistent immunological alterations and autoantibody production were observed in a subset of patients during the post-COVID period.<br><br>CONCLUSION: COVID-19 pathogenesis is driven by complex and interconnected immunopathological mechanisms rather than viral effects alone. Hyperinflammation, endothelial dysfunction, complement activation, and autoimmune processes are key determinants of disease severity and clinical outcomes. These findings underscore the importance of targeted immunomodulatory strategies and provide a comprehensive framework for future research.},
}
@article {pmid42359168,
year = {2026},
author = {Mundt, B and Kant, R and Grzybek, M},
title = {Viral pathogens in urban rats: A one health systematic review of global surveillance evidence.},
journal = {One health (Amsterdam, Netherlands)},
volume = {23},
number = {},
pages = {101468},
pmid = {42359168},
issn = {2352-7714},
abstract = {BACKGROUND: Commensal rats (Rattus norvegicus and Rattus rattus) thrive in urban environments worldwide, where they live near humans and may act as reservoirs for viral pathogens of public health relevance. Although rats are increasingly recognised as sentinels of urban environmental health, the diversity and distribution of viral infections circulating in urban rat populations remain incompletely characterised within a One Health framework.<br><br>OBJECTIVES: This systematic review synthesises global evidence on viral pathogens detected in urban rats, focusing on rat hepatitis E virus/Rocahepevirus ratti and human-associated hepatitis E virus/Paslahepevirus balayani where distinguishable, Seoul virus (SEOV), SARS-CoV-2, and additional viral taxa identified through targeted surveillance or, in rare cases, metagenomic approaches.<br><br>METHODS: Following PRISMA 2020 guidelines, five electronic databases were searched for primary studies reporting viral detection in urban Rattus spp. Eligible studies underwent screening, structured data extraction and quality appraisal. Viral prevalence was summarised descriptively by pathogen and geographic region.<br><br>RESULTS: A total of 70 studies met the inclusion criteria, spanning Europe, Asia, North America, South America and the Caribbean. HEV and SEOV were the most frequently reported viruses, with prevalence varying widely between regions. HEV prevalence ranged from low levels in parts of Europe and Asia to high levels in North America. SEOV was detected across all regions, with particularly high prevalence in parts of Asia and the Americas. SARS-CoV-2 was not detected in European rats but was reported at low to moderate prevalence in the Americas. Numerous additional viral pathogens were identified.<br><br>CONCLUSIONS: Urban rats globally harbour diverse viral communities, including pathogens with zoonotic potential. Surveillance remains uneven and methodologically heterogeneous. Integrating rat biomonitoring into coordinated One Health surveillance systems is critical to strengthen early warning capacity and mitigate zoonotic risk.},
}
@article {pmid42361431,
year = {2026},
author = {Bourgon, C and Moseman, EA},
title = {On or within: spatial determinants of antigen handling in the nasal turbinates.},
journal = {Current opinion in immunology},
volume = {101},
number = {},
pages = {102808},
pmid = {42361431},
issn = {1879-0372},
support = {R01 AI179729/AI/NIAID NIH HHS/United States ; R01 NS121067/NS/NINDS NIH HHS/United States ; R21 DC021260/DC/NIDCD NIH HHS/United States ; },
mesh = {Humans ; Animals ; *Turbinates/immunology ; *Nasal Mucosa/immunology ; *SARS-CoV-2/immunology ; *COVID-19/immunology/prevention &amp; control ; *Antigens/immunology ; Lymph Nodes/immunology ; *COVID-19 Vaccines/immunology ; Immunity, Mucosal ; },
abstract = {The SARS-CoV-2 pandemic has renewed interest in mucosal vaccines, yet these approaches have long struggled to generate durable protection against airway pathogens. A key limitation is the incomplete understanding of how upper airway antigens are handled to shape immune response quality and durability. Antigens located within the airspace or on the mucosal surface can be directly sampled by mucosal-associated lymphoid tissues (MALTs), such as Nasal-associated lymphoid tissue (NALT) in mice, or tonsils in humans. Because MALTs lack afferent lymphatics, antigen entry occurs primarily across a specialized epithelium. In contrast, antigens that arise within the mucosa following barrier breach are captured by immune cells and lymphatics for delivery to draining lymph nodes. This framework suggests that 'on the mucosa' antigens preferentially engage MALTs, whereas 'within the mucosa' antigens are handled by lymph nodes. However, the rules governing antigen handling within the nasal cavity remain poorly defined, limiting rational mucosal vaccine design.},
}
@article {pmid42361718,
year = {2026},
author = {Sanga, NA and Oranzie, M and January, JL and Cox, M and Januarie, KC and Cupido, C and Tovide, OO and Pokpas, K and Douman, SF and Iwuoha, EI},
title = {Bioelectrochemical Sensing Dynamics of SARS-CoV-2 Biomarkers.},
journal = {Bioelectrochemistry (Amsterdam, Netherlands)},
volume = {172},
number = {},
pages = {109368},
doi = {10.1016/j.bioelechem.2026.109368},
pmid = {42361718},
issn = {1878-562X},
mesh = {*Biosensing Techniques/methods ; Humans ; *Electrochemical Techniques/methods ; *SARS-CoV-2/isolation &amp; purification/genetics/immunology ; Spike Glycoprotein, Coronavirus/analysis ; Biomarkers/analysis ; *COVID-19/diagnosis/virology ; RNA, Viral/analysis ; Phosphoproteins/analysis ; Coronavirus Nucleocapsid Proteins/analysis ; },
abstract = {The SARS-CoV-2 outbreak has underscored the urgent need for rapid, sensitive and accessible diagnostic technologies. This review provides a comprehensive overview of recent advances in nucleic acid- and antibody-based bioelectrochemical detection strategies for SARS-CoV-2, targeting the nucleocapsid (N) protein, spike (S) protein, the receptor binding domain (RBD) antigens and the viral RNA genome. Particular emphasis is placed on aptasensor, immunosensor and genosensor, highlighting biosensor design strategies and associated advantages and limitations. Key analytical parameters, such as sensitivity, detection limit, response time, transduction mechanisms and integrated nanomaterials are compared and discussed. Future perspectives on the innovative nucleic acid- and antibody-based point-of-care biosensors for SARS-CoV-2 are presented.},
}
@article {pmid42362025,
year = {2026},
author = {Liaw, PC and Zarychanski, R and Lawler, PR and Lother, SA and Mendelson, AA},
title = {The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis.},
journal = {Journal of thrombosis and haemostasis : JTH},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jtha.2026.06.017},
pmid = {42362025},
issn = {1538-7836},
abstract = {Sepsis is a life-threatening syndrome caused by a dysregulated host response to infection and remains a leading cause of global morbidity and mortality. Despite decades of research, most biologically targeted therapies have failed to improve survival, highlighting the need for new treatment strategies that address the complex pathophysiology of sepsis. A defining feature of sepsis is immunothrombosis, characterized by widespread activation of inflammation and coagulation, endothelial injury, platelet activation, and neutrophil extracellular trap (NET) formation, resulting in both macrovascular thrombosis and microvascular occlusion. Heparin is commonly used as an anticoagulant and has re-emerged as a potential therapeutic agent for sepsis due to its pleiotropic properties that extend beyond anticoagulant effects. Heparin exhibits anti-inflammatory and antimicrobial activities, inhibits immune activation, neutralizes damage-associated molecular patterns, and modulates NET-mediated pathology. Clinical evidence for efficacy in sepsis remains limited, and no adequately powered randomized trials have confirmed a net survival benefit of therapeutic-dose heparin. This may reflect historical challenges with trial methodology and the heterogeneous nature of human sepsis. Data from COVID-19-associated sepsis suggest that severity may influence outcomes, with potential benefits in earlier disease stages and possible harm in advanced stages. Emerging interest in nonanticoagulant heparin derivatives and biomarker-guided patient selection may offer scientific opportunities to optimize therapeutic benefit while minimizing bleeding, but these approaches remain investigational. This review synthesized current mechanistic, preclinical, and clinical evidence supporting heparin-based strategies in sepsis and emphasizes that therapeutic use beyond standard thromboprophylaxis should be evaluated in clinical trials before being applied in practice.},
}
@article {pmid42362430,
year = {2026},
author = {Wei, HY and Lin, CY and Lin, YJ and Huang, SC and Shih, YL and Lin, FT and Yang, CH},
title = {Evolution of COVID-19 antiviral interventions in Taiwan, 2022-2025: Insights from public health policy.},
journal = {Journal of the Formosan Medical Association = Taiwan yi zhi},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jfma.2026.06.042},
pmid = {42362430},
issn = {0929-6646},
abstract = {This study reviewed the use of COVID-19 antiviral agents in Taiwan (2022-2025), focusing on how policy changes influenced drug deployment, and explored trends in outpatient visits, hospitalizations, emergency department visits, and mortality. Policy changes and usage patterns of Remdesivir, Molnupiravir, and Nirmatrelvir/Ritonavir, were tracked using the Stockpile Management Information System (SMIS). As policies shifted to focus on the treatment of mild-to-severe cases in high-risk groups, the percentages of both oral antivirals and Remdesivir use increased. Remdesivir use (among hospitalized patients and emergency departments visits) rose from 10% in 2022 to 20% during COVID resurgence in 2025. Among adults aged ≥65 years, the oral antiviral utilization percentage remained stable at 53-54% after March 2023 based on total healthcare visits, and reached 65-69% when using outpatient visits as the denominator. As vaccine coverage expanded and herd immunity increased through 2022-2024, Taiwan's population developed robust hybrid immunity, hospitalizations and deaths declined substantially in subsequent epidemic waves. This analysis of the utilization percentages of COVID-19 antiviral drugs may serve as a valuable reference for future drug procurement and resource allocation. Timely, and adaptive deployment of antiviral agents remains critical for mitigating public health and healthcare system burdens during large-scale epidemics.},
}
@article {pmid42362970,
year = {2026},
author = {Said, N and Jones, I and Anderson-Baucum, EK and Evans-Molina, C},
title = {SARS-CoV-2 and diabetes: a post-pandemic reappraisal.},
journal = {Diabetologia},
volume = {69},
number = {9},
pages = {2396-2407},
pmid = {42362970},
issn = {1432-0428},
support = {I01BX001733//U.S. Department of Veterans Affairs/ ; P30DK097512/DK/NIDDK NIH HHS/United States ; R01DK093954/DK/NIDDK NIH HHS/United States ; R01DK127308/DK/NIDDK NIH HHS/United States ; P30DK097512/DK/NIDDK NIH HHS/United States ; R01DK093954/DK/NIDDK NIH HHS/United States ; R01DK127308/DK/NIDDK NIH HHS/United States ; },
mesh = {Humans ; *COVID-19/epidemiology/complications ; SARS-CoV-2 ; *Diabetes Mellitus, Type 2/epidemiology ; *Diabetes Mellitus, Type 1/epidemiology ; Pandemics ; *Coronavirus Infections/epidemiology/complications ; Betacoronavirus ; *Diabetes Mellitus/epidemiology ; },
abstract = {The COVID-19 pandemic was a dynamic and often confusing period for clinical and biomedical research. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread globally, knowledge accumulated rapidly through publications that were frequently based on preliminary or sometimes conflicting evidence, yet these papers played a critical role in shaping evolving medical, research and societal responses. Early in the pandemic, diabetes emerged as one of the strongest predictors of severe COVID-19 outcomes and mortality, placing it at the centre of early risk-stratification and therapeutic frameworks and prompting urgent efforts to understand the biological basis of these associations. As the pandemic progressed, reports of new-onset diabetes following COVID-19 infection raised the possibility of a bidirectional relationship between SARS-CoV-2 infection and diabetes. In this review, we provide a post-pandemic reappraisal of the clinical and experimental literature examining the intersection of COVID-19 and diabetes. We summarise proposed pathophysiological mechanisms, including the effects of SARS-CoV-2 infection in the pancreas and on peripheral insulin-sensitive tissues. We review key meta-analyses assessing the association between COVID-19 and incident type 1 and type 2 diabetes and highlight strengths and weaknesses of the epidemiologic studies underpinning these findings. We highlight the highest-quality evidence from prospective cohorts, as well as relevant clinical trials and registry-based studies that emerged from this collective experience. We discuss emerging relationships between long COVID and diabetes and the effect of vaccination on diabetes risk following SARS-CoV-2 infection. Finally, we identify critical knowledge gaps and outline priorities for ongoing and future studies needed to resolve remaining uncertainties.},
}
@article {pmid42363391,
year = {2026},
author = {Kazmi, SM and Khan, MO and Safdar, SN and Ahmad, S and Ghazi, KR and Bakhshi, SK},
title = {The Evolution of Patient Safety Practices Over the Last Two Decades.},
journal = {JPMA. The Journal of the Pakistan Medical Association},
volume = {76(Suppl 1)},
number = {3},
pages = {S131-S135},
doi = {10.47391/JPMA.AKU-10Surg-24},
pmid = {42363391},
issn = {0030-9982},
mesh = {Humans ; *Patient Safety/standards ; COVID-19 ; Pandemics ; SARS-CoV-2 ; Artificial Intelligence ; Electronic Health Records ; Digital Health ; Telemedicine ; },
abstract = {Patient safety has undergone significant evolution over the past two decades, driven by a shift towards systemsbased approaches, the adoption of technological solutions, and a growing global commitment to improving healthcare outcomes. Early milestones (2000- 2010) saw the establishment of key safety protocols, including the "To Err is Human" report and the World Health Organisation's global initiatives. The following decade (2011-2020) marked the widespread integration of electronic health records and simulation-based training. The coronavirus disease-2019 pandemic presented unique challenges, including healthcare resource shortages and increased errors, but also accelerated innovations, such as telehealth and clinical decision-support tools. More recently, artificial intelligence has emerged as a powerful tool for enhancing patient safety, offering predictive capabilities and personalised care. However, barriers such as organisational resistance, resource constraints and inconsistent data-collection remain. Looking ahead, fostering a culture of safety, collaboration and continuous innovation is essential to address systemic gaps, and to ensure safer healthcare practices globally.},
}
@article {pmid42364134,
year = {2026},
author = {Vacaru, RP and Didilescu, AC and Scannapieco, FA},
title = {Oral Health, Periodontitis, and Respiratory Diseases: Biological Pathways.},
journal = {Journal of periodontal research},
volume = {},
number = {},
pages = {},
doi = {10.1111/jre.70126},
pmid = {42364134},
issn = {1600-0765},
abstract = {Poor oral hygiene and periodontitis influence lung diseases such as pneumonia, chronic obstructive pulmonary disease (COPD), COVID-19, and asthma. The normal lung is not sterile, with a distinct microbial ecosystem that is spatially varied along the respiratory tract. The biogeography of the lung microbiome is balanced between microbial microaspiration from the oral-pharynx and clearance. The mouth is an important reservoir for respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, and Staphylococcus aureus, as well as oral microbes (Porphyromonas, Prevotella, Fusobacterium, etc.). Poor oral hygiene and periodontitis increase the bacterial load that can be aspirated, and the host produces pro-inflammatory components that enhance microbial virulence and compromize epithelial integrity. Both poor oral hygiene and periodontitis have been associated with pneumonia, particularly in hospitals and nursing home settings. Periodontitis may also facilitate viral pneumonia (including COVID-19) by altering receptor expression and immune function. Periodontitis correlates with COPD severity and exacerbation frequency through pathways involving matrix metalloproteinases and cytokines. Periodontitis also is associated with asthma and acute exacerbations. Inflammation shapes the lung microbiome by impacting microbial nutrient availability through vascular leakage, inducing changes to epithelial cells which facilitate bacterial adherence, and inducing the production of cytokines, leading to mucus overproduction, inhibition of phagocytosis, and enhancement of microbial pathogen virulence. Multiple biological pathways have been examined in vitro that suggest how "the oral-lung axis" influences pneumonia, COPD, and asthma. Periodontal treatment and effective oral hygiene should be well integrated into medical care to prevent and manage respiratory diseases.},
}
@article {pmid42364372,
year = {2026},
author = {Tomassini, L and Onofri, M and Gambelunghe, C and Fedeli, P and Scendoni, R and Pini, N and Lancia, M},
title = {Toward methodological standardization in forensic immunohistochemistry: a critical appraisal of 144 post-mortem studies and a proposed evaluative framework.},
journal = {Legal medicine (Tokyo, Japan)},
volume = {84},
number = {},
pages = {102894},
doi = {10.1016/j.legalmed.2026.102894},
pmid = {42364372},
issn = {1873-4162},
mesh = {Humans ; *Immunohistochemistry/standards/methods ; *Forensic Pathology/methods/standards ; Autopsy/methods ; Quality Control ; },
abstract = {Immunohistochemistry (IHC) is widely applied in post-mortem forensic investigations. Its evidentiary value depends critically on methodological standardization. Following PRISMA guidelines and PROSPERO registration (CRD420251063965), we systematically searched PubMed, Scopus, and Web of Science for original IHC studies on human autopsy material. A total of 144 studies were included and evaluated against six predefined methodological criteria (M1-M6) addressing slide interpretation metrics, multi-reader assessment, observer blinding, concordance reporting, quality control, and predefined positivity thresholds. IHC was applied across diverse forensic domains, most frequently in traumatic brain injury (16%), sudden cardiac death (14%), COVID-19-related death (13%), and wound vitality/wound dating (11%). Quantitative or semi-quantitative slide reading (M1) was adopted in 75.7% of studies, and quality control measures (M5) in 52.8%. By contrast, blinded reading (M3) was implemented in only 40% of applicable studies, inter-observer concordance (M4) in 10%, and predefined positivity thresholds (M6) in only 4.2% of studies. Only 38.9% of studies met three or more methodological criteria, and a single study satisfied all six criteria. Forensic IHC demonstrates broad application and considerable inferential ambition, but its methodological foundations remain inconsistently consolidated. We propose that future forensic IHC studies place greater emphasis on analytical validation, standardized interpretation criteria, assessment of observer agreement, and systematic reporting of relevant pre-analytical variables in order to improve reproducibility and comparability.},
}
@article {pmid42364454,
year = {2026},
author = {Madia, VN and Patacchini, E and Saccoliti, F and Zarbo, L and Arpacioglu, M and Costi, R and Di Santo, R},
title = {Twin engines of viral replication: Medicinal chemistry insights on SARS-CoV-2 nsp12 and nsp13.},
journal = {European journal of medicinal chemistry},
volume = {317},
number = {},
pages = {119083},
doi = {10.1016/j.ejmech.2026.119083},
pmid = {42364454},
issn = {1768-3254},
abstract = {The SARS-CoV-2 pandemic highlighted the urgent need for antivirals targeting essential viral enzymes. Herein, we critically examine the current landscape of small molecule inhibitors targeting the highly conserved non-structural protein 12 (nsp12), the RNA-dependent RNA polymerase, and non-structural protein 13 (nsp13), the helicase, both critical for viral genome replication. Structural and mechanistic features that inform rational inhibitor design, including active sites and cofactor interactions, are discussed. For nsp12, nucleoside analogues derived from a drug repurposing strategy, as well as emerging non-nucleoside inhibitors targeting allosteric sites, are evaluated. Development of ATPase and helicase inhibitors for nsp13 is at an earlier stage, but promising scaffolds have been revealed through high-throughput and structure-based screening. An in-depth analysis of small molecule inhibitors from synthetic and natural sources is presented for both enzymes, highlighting key limitations and strategic directions to advance the development of next-generation antivirals against SARS-CoV-2 through targeted modulation of nsp12 and nsp13.},
}
@article {pmid42366006,
year = {2026},
author = {Bush, SH and Kabir, M and French Merkley, V and Sikora, L and Agar, M and Hosie, A and Featherstone, I and Isenberg, S and Lawlor, P},
title = {Clinical checklists of multicomponent non-pharmacological interventions for delirium management in adult patients in non-ICU inpatient healthcare settings: a rapid review.},
journal = {BMJ open},
volume = {16},
number = {6},
pages = {e105740},
pmid = {42366006},
issn = {2044-6055},
mesh = {Humans ; *Delirium/therapy/prevention &amp; control ; *Checklist ; Inpatients ; Adult ; },
abstract = {OBJECTIVES: To identify clinical checklists of multicomponent non-pharmacological interventions for the prevention and treatment of delirium used in non-intensive care unit inpatient healthcare settings, their content and reported implementation.<br><br>DESIGN: Rapid review.<br><br>DATA SOURCES: Medline, Embase, PsycINFO, CINAHL and Cochrane CENTRAL were searched from 1 January 1999 to 31 March 2022 and updated on 16 January 2025. A comprehensive grey literature search, including websites of guideline development groups and international delirium organisations, was conducted on 26 and 27 February 2024.<br><br>ELIGIBILITY CRITERIA: We included records reporting the use of a 'clinical checklist' used by the healthcare team, family carers or adult patient (&#x2265;18 years) to prompt and document multicomponent non-pharmacological interventions for the prevention or treatment of delirium. Publication language was restricted to English and French.<br><br>DATA EXTRACTION AND SYNTHESIS: Using rapid review methodology, two independent reviewers screened the included records. A single reviewer undertook the data extraction, with a third independent reviewer verifying the data extraction for completeness. All included studies were assessed using the JBI critical appraisal tools according to the study design. A narrative synthesis was used to summarise the findings.<br><br>RESULTS: From the database searches, 4796 records were identified. After the removal of duplicates, 3513 records underwent title and abstract screening, with 344 records undergoing full-text screening. A final 32 records were included. From the grey literature search, 6593 records were reviewed for relevance, from which 62 records were included in full-text screening. No grey literature records were of high enough quality to be included. All studies were published in English, with most studies conducted in the USA, n=12/32 (37.5%). The 32 studies were quasi-experimental (n=18), randomised controlled trials (n=8), qualitative (n=4), expert opinion (n=1) and policy/consensus guidelines (n=1). Clinical checklists included structured protocols, algorithms and order sets, which were paper-based or part of electronic delirium order sets. People with dementia participated as key stakeholders for a guidance document during the COVID-19 pandemic, but the target population was not included in the development phase of other checklists. Target users of clinical checklists were usually healthcare staff and trained volunteers and rarely family carers and study intervention nurses. Four of the 32 studies included all 10 National Institute for Health and Care Excellence clinical factors/preventive strategies for non-pharmacological interventions. For the remaining 28 studies, missing domains varied and included: therapeutic/cognitive activity, hydration, nutrition, constipation, urinary catheterisation, hypoxia, infection, pain and medication review. Only two studies involved family carers as active partners in patient care. Reported formal economic analysis was limited.<br><br>CONCLUSIONS: Codesign of future clinical checklists should involve patients and family carers. Further research is needed on the feasibility of using clinical checklists by all members of the interprofessional team and family carers, the factors needed to ensure high levels of adherence and sustainability of multicomponent non-pharmacological interventions for delirium management, in addition to economic evaluations.<br><br>PROSPERO REGISTRATION: CRD42022342328.},
}
@article {pmid42366185,
year = {2026},
author = {Benson, B and Taheri, M and Suleman, S and Paslawski, T and O'Brien, JM and Cruz, M and Sullivan, P and Khan, S and Boden, C and Abramyk, C and Reimche, E and Valiani, S and McIlduff, C and , },
title = {Patient- and Family-Centered Care, Communication, and Relationship Development Along a Technological Continuum in the ICU: A Scoping Review.},
journal = {Critical care explorations},
volume = {8},
number = {7},
pages = {e1429},
pmid = {42366185},
issn = {2639-8028},
mesh = {Humans ; *Intensive Care Units/organization &amp; administration ; *Patient-Centered Care/organization &amp; administration ; *Communication ; *COVID-19 ; *Professional-Family Relations ; SARS-CoV-2 ; Pandemics ; },
abstract = {OBJECTIVES: Effective multidirectional and longitudinal communication is essential to patient- and family-centered care (PFCC) in the ICU. While communication technologies have the potential to facilitate effective communication, their utilization, especially during the COVID-19 pandemic, has been variable. This scoping review answers the following research questions: What communication tools, strategies, and programs have been used in ICUs? What are their reported effects on PFCC and multidirectional communication? To what extent do these studies consider equity, diversity, and inclusion principles?<br><br>DATA SOURCES: The scoping review followed Arksey and O'Malley's (2005) framework and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. We conducted a search covering the period from 2007 to 2024, focusing on the concepts of communication, ICU, and PFCC in OVID Medline, EBSCO CINAHL, and OVID Embase. Relevant studies were screened and reported in this review.<br><br>STUDY SELECTION: Searches identified 3280 unique sources, which were screened at a three-stage asynchronous review. A total of 131 articles were included in this review.<br><br>DATA EXTRACTION: Communication tools, strategies, and programs were categorized into technology-based and non-technology-based interventions. Technology-based interventions included eight subcategories such as data-enabled devices, electrolarynx, and eye trackers. Non-technology-based strategies included 13 subcategories such as family meetings, diaries, and dedicated personnel.<br><br>DATA SYNTHESIS: Positive outcomes were reported in 82% of studies for both technology-based and non-technology-based communication tools, strategies, and programs on PFCC.<br><br>CONCLUSION: Most technology and non-technology communication tools, strategies, and programs positively impact communication and PFCC in the ICU. However, only 4% of studies focused on equity, diversity, and inclusion in the evaluation, design, or development of their intervention, indicating a need for further research in this area.},
}
@article {pmid42366188,
year = {2026},
author = {Ralethoko, N and Letumanyane, K},
title = {A comparative assessment of road traffic injury patterns in KwaZulu-Natal and the Western Cape before, during and after COVID-19 (2019-2023).},
journal = {International journal of injury control and safety promotion},
volume = {},
number = {},
pages = {1-16},
doi = {10.1080/17457300.2026.2691909},
pmid = {42366188},
issn = {1745-7319},
abstract = {Road traffic injuries (RTIs) are a significant cause of death in South Africa; however, the effects of the COVID-19 pandemic on provincial RTI patterns remain insufficiently explored. This systematic review compared RTI patterns in KwaZulu-Natal and the Western Cape across pre-COVID-19 (2019), during-COVID-19 (2020-2021), and post-COVID-19 (2022-2023) periods. A systematic search of five electronic databases and grey literature sources was conducted, with 90 sources included following an adapted PRISMA 2020 framework. Findings were analysed using a descriptive comparative approach and synthesised through narrative synthesis guided by the framework proposed by Popay et al. (2006). In KwaZulu-Natal, fatalities declined from 2,331 in 2019 to 2,031 in 2020 before returning to slightly below baseline levels (2,229) in 2023. In contrast, fatalities in the Western Cape increased from 1,013 in 2019 to 1,158 in 2020, declined slightly in 2021, and increased further to 1,371 in 2023. Males aged 25-39 years and pedestrians remained the most affected groups across all study periods. The findings suggest that both pandemic-related behavioural changes and persistent structural and system-level factors may have contributed to the observed provincial differences in RTI patterns.},
}
@article {pmid42366377,
year = {2026},
author = {Antón-Ruiz, JA and Bernabé, M and Heredia-Oliva, E},
title = {Prevalence of depression, anxiety, and stress among university students in the post-COVID-19 period: a systematic review and meta-analysis.},
journal = {BMC psychology},
volume = {},
number = {},
pages = {},
doi = {10.1186/s40359-026-05066-4},
pmid = {42366377},
issn = {2050-7283},
abstract = {BACKGROUND: The COVID-19 pandemic has had lasting effects on university students' mental health. While numerous studies have examined depression, anxiety, and stress during the pandemic, the post-pandemic burden of these conditions remains unclear. This systematic review and meta-analysis aimed to estimate the pooled prevalence of depression, anxiety, and stress among university students during the post-COVID-19 period.<br><br>METHODS: A systematic search of PubMed, Web of Science, MEDLINE, and Scopus was conducted from inception to August 2025 following PRISMA guidelines (OSF: 10.17605/OSF.IO/S3R2E). Cross-sectional studies published between 2022 and 2025 reporting the prevalence of depression, anxiety, and/or stress among university students using validated assessment tools were included. Study quality was assessed using the Joanna Briggs Institute checklist. Single-arm meta-analyses of proportions were performed using logit transformation. Subgroup analyses by geographic region, meta-regression, sensitivity analyses, and publication bias assessments were conducted.<br><br>RESULTS: Sixty-three studies involving more than 255,000 university students across multiple global regions were included. The pooled prevalence of overall depression was 45.1% (95% CI: 38.5% to 51.8%), with prevalence estimates of 21.9% for mild, 12.8% for moderate, and 4.1% for severe depression. The pooled prevalence of overall anxiety was 43.6% (95% CI: 35.3% to 52.3%), with 23.1% mild, 13.7% moderate, and 6.1% severe anxiety. Overall stress prevalence was 45.6% (95% CI: 32.9% to 58.8%), while high perceived stress affected 14.5% of students. Significant regional variations were observed for depression and anxiety. Meta-regression indicated no consistent temporal trends, although prevalence varied by sample size and, for moderate and severe anxiety, by publication year. Sensitivity analyses confirmed robust findings. Publication bias was detected in mild depression, mild anxiety, and severe anxiety subgroups.<br><br>CONCLUSIONS: Depression, anxiety, and stress remain highly prevalent among university students in the post-pandemic period, highlighting a sustained mental health burden. Most studies were cross-sectional and relied on self-reported measures, with variability in sample sizes and sociocultural contexts, hindering comparability and generalizability. Despite these constraints, these findings highlight the urgent need for targeted mental health screening, preventive strategies, and accessible psychological support services within higher education settings.},
}
@article {pmid42367802,
year = {2026},
author = {Fu, J and Mi, Z and Li, Z},
title = {SARS-CoV-2-host and interactions: the dual roles of E3 ubiquitin ligases and ubiquitin-like modification mechanisms in viral infection.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1796416},
pmid = {42367802},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/enzymology/immunology/virology ; *SARS-CoV-2/enzymology/pathogenicity/physiology ; *Ubiquitin-Protein Ligases/immunology/metabolism ; *Ubiquitins/immunology/metabolism ; *Host-Pathogen Interactions/immunology ; Virus Replication/immunology ; Immune Evasion/immunology ; Ubiquitination/immunology ; Animals ; Apoptosis/immunology ; },
abstract = {Following the global outbreak of the COVID-19 pandemic, the interactions between SARS-CoV-2 and host cells have attracted widespread attention. As crucial intracellular enzymes, E3 ubiquitin ligases are involved in numerous physiological processes, including protein degradation, cell cycle regulation, and immune responses. Recent studies have demonstrated that E3 ubiquitin ligases play a pivotal role in the interplay between SARS-CoV-2 and the host. Through interactions with host E3 enzymes, SARS-CoV-2 regulates key processes such as viral replication, immune evasion, and apoptosis. For instance, viral proteins can bind to E3 enzymes to modulate host immune responses and inhibit interferon production, thereby promoting persistent infection. Conversely, E3 enzymes can also regulate the viral life cycle and host cell survival by mediating targeted protein degradation. This mini-review summarizes the roles of E3 ubiquitin ligases in SARS-CoV-2 infection, introduces E3 ligase-mediated ubiquitin-like modifications, and discusses their underlying mechanisms at the virus-host interface. Furthermore, we highlight future research directions and potential therapeutic strategies. Understanding the functions of E3 ubiquitin ligases not only provides novel insights into the pathogenesis of SARS-CoV-2 but also offers promising targets for the development of antiviral therapeutics.},
}
@article {pmid42368852,
year = {2026},
author = {Endara-Mina, J and Escudero, CJ and Intriago, C and Coloma-Ramirez, L and Cabrera, W and Gonzaga, R and Fuentes, S and Chicaiza, D and Carvajal, C and Lopez-Carrera, R and Baño-Jimenez, B and Ruilova, J and Atahualpa, E and Aldaz, J and Quishpe, M and Simbaña-Rivera, K},
title = {Associated thromboembolic events to the post COVID syndrome: a systematic review and meta-analysis.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1742868},
pmid = {42368852},
issn = {2297-055X},
abstract = {BACKGROUND: The COVID-19 pandemic has imposed a substantial worldwide health burden; a fraction of people develops post-COVID syndrome, in which symptoms persist long after the initial phase of infection. Although these individuals may be more susceptible to developing thromboembolic events, the extent and significance of this link remain uncertain. This systematic review and meta-analysis sought to explore the prevalence of thromboembolic events in people with post-COVID syndrome, therefore addressing knowledge gaps and providing critical information for therapeutic management.<br><br>METHODS: Following PRISMA principles, a thorough search across numerous databases-including Medline, Web of Science, Scopus, Dimensions, the Virtual Health Library, the British Library, and Google Scholars-was performed. Analytical cross-sectional, case-control, and cohort studies on individuals with post-COVID syndrome were considered eligible research. Meta-analysis was performed using Review Manager 5.4.1, with a random-effects model providing hazard ratios (HR) and 95% confidence intervals (CI) for specific thromboembolic events.<br><br>RESULTS: The initial database search yielded 1,617 publications, 1,021 of which passed title and abstract screening after duplicates were removed. Following a full-text analysis of 83 publications, 20 met the inclusion criteria, with 5 included in the quantitative synthesis and 15 in the qualitative synthesis.<br><br>CONCLUSION: Emphasizing ramifications for clinical therapy, particularly among vascular surgeons, this thorough review and meta-analysis exposes a significant thromboembolic risk among patients with post-COVID syndrome. The outcomes highlight the need for early detection, proactive monitoring, and tailored preventive treatments, including anticoagulant drugs.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD42023441556, PROSPERO CRD42023441556.},
}
@article {pmid42368930,
year = {2026},
author = {Miao, R and Wang, J and Huang, Y and Zhang, X and Lei, P and Li, D and Chen, C and Lu, Y},
title = {Optimizing COVID-19 vaccination strategies for high-risk populations: potential and challenges of combining heterologous boosting with respiratory mucosal delivery.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1849650},
pmid = {42368930},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/administration &amp; dosage/immunology ; SARS-CoV-2/immunology ; Immunity, Mucosal ; *Immunization, Secondary/methods ; *Respiratory Mucosa/immunology ; *Vaccination/methods ; },
abstract = {Despite the decline of the global peak of COVID-19, SARS-CoV-2 continues to circulate, evolve, and undergo immune escape, posing persistent threats, particularly to older adults, individuals with comorbidities, and immunocompromised populations. Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time. Current heterologous booster strategies still rely largely on combinations of different parenteral vaccine platforms. Although these regimens can enhance systemic humoral and cellular immunity, they are insufficient to robustly induce upper respiratory mucosal immunity, thereby limiting their role in early infection control and interruption of transmission. Because respiratory mucosal vaccines target the natural entry site of SARS-CoV-2, they have the potential to induce secretory IgA, tissue-resident memory immune cells, and local immune memory, offering distinct advantages in compensating for the shortcomings of conventional heterologous boosting. Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission while preserving systemic immunity, thereby providing more comprehensive immune protection for high-risk populations. However, this strategy still faces challenges related to mucosal barriers, delivery efficiency, adjuvant safety, manufacturing scale-up, and incomplete clinical evaluation frameworks. Future high-quality studies focusing on high-risk populations are needed to clarify its value in preventing infection, protecting against severe disease, and providing long-term protection.},
}
@article {pmid42369559,
year = {2026},
author = {Xu, W and Wang, J and Liu, X and Lu, M and Zhang, Z and Li, L},
title = {mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1821852},
pmid = {42369559},
issn = {1664-302X},
abstract = {As a next-generation vaccine technology, mRNA vaccines mark a transformative advancement in vaccinology research. Their key strengths lie in rapid development cycles, high-efficiency manufacturing processes, robust immunogenic properties, and adaptable design frameworks. For infectious disease prevention, mRNA-based immunizations targeting SARS-CoV-2, such as the mRNA-1273 vaccine, have shown promising results in clinical evaluations. Validated efficacy metrics and safety profiles have supported their regulatory approval for public use. Additionally, mRNA platforms have shown substantial therapeutic potential against respiratory syncytial virus. However, this technology still faces multiple challenges, including poor stability, limited delivery efficiency, high production costs, unclear mechanisms of adverse reactions. Distinct from existing literature that primarily focuses on COVID-19 or specific delivery technologies, this review provides a comprehensive, integrated framework covering molecular design, delivery systems, and clinical translation across multiple viral pathogens, while also critically analyzing current controversies and future directions. This review aims to provide a comprehensive reference for researchers and clinicians in related fields.},
}
@article {pmid42369668,
year = {2026},
author = {Peter, S and Mohana, T and Anandhi, D and Priya, VS and Sleeba, RK and Haridas, HP and Mohanan, MT and Thoduvayil, S and Mathew, S and Santhamma, DM and Divakaran, DR},
title = {ACE/ACE2 axis in cardiovascular disease and COVID-19: Molecular insights and therapeutic perspectives.},
journal = {Journal of cardiovascular and thoracic research},
volume = {18},
number = {1},
pages = {15-25},
pmid = {42369668},
issn = {2008-5117},
abstract = {The renin-angiotensin system (RAS) plays a central role in regulating blood pressure and cardiovascular health. Angiotensin-converting enzyme (ACE) facilitates the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that contributes to hypertension and heart failure. Conversely, ACE2 converts angiotensin II into angiotensin-(1-7), a vasodilator with protective cardiovascular effects. An imbalance between ACE and ACE2 activities has been increasingly associated with the progression of cardiovascular diseases and complications related to COVID-19. This review analyzed 100 relevant studies published up to May 2024, identified through a comprehensive literature search on PubMed and Scopus. The findings highlighted that dysregulation of the ACE/ACE2 axis exacerbates cardiovascular dysfunction. The interaction of SARS-CoV-2 with ACE2 reduces its protective function, intensifying inflammatory responses and leading to complications such as lung injury and heart failure. Additionally, genetic polymorphisms in ACE and ACE2 influence individual susceptibility and severity of COVID-19. Promising therapeutic strategies, including ACE2-based peptides and angiotensin II receptor modulators, are under investigation but require further clinical validation. Targeting the ACE/ACE2 axis could provide effective treatment options for cardiovascular disease and COVID-19-related complications, warranting further in-depth research.},
}
@article {pmid42370216,
year = {2026},
author = {Karasneh, D and Patel, M and Hasan, SS and Conway, BR and Sadeq, AA and Aldeyab, MA},
title = {Impact of the COVID-19 pandemic on systemic anti-cancer therapy in patients with breast cancer: a systematic review and meta-analysis.},
journal = {Journal of pharmaceutical policy and practice},
volume = {19},
number = {1},
pages = {2684148},
pmid = {42370216},
issn = {2052-3211},
abstract = {BACKGROUND: The COVID-19 pandemic caused significant disruptions in oncology services worldwide. Breast cancer care depends on timely and coordinated treatment pathways. This review assessed changes in systemic anti-cancer therapy, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Secondary outcomes included treatment delays, short-term mortality, and hospital admissions.<br><br>METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines. The protocol was registered with PROSPERO (CRD42024542702). We searched PubMed, Scopus, Web of Science, and CINAHL for studies published between March 2020 and August 2024. We included original studies comparing adult breast cancer patients treated before and during the pandemic. Patients of any stage and sex were eligible. We assessed risk of bias and used a random-effects model to present pooled proportions and odds ratios (ORs) with 95% confidence intervals (CIs).<br><br>RESULTS: Forty-eight studies were included in the review, and 35 in the meta-analysis. Chemotherapy use increased from 35% before the pandemic to 42% during the pandemic. This rise was driven by an increase in neoadjuvant chemotherapy, from 18% to 22%, while adjuvant chemotherapy remained stable. Endocrine therapy increased from 35% to 42%. Neoadjuvant endocrine therapy rose from 2% to 10%, whereas adjuvant endocrine therapy declined from 46% to 43%. Targeted therapy and immunotherapy showed minimal change. The pooled OR for short-term mortality was 0.81 (95% CI: 0.56-1.15). Hospital admission estimates showed wide confidence intervals, reflecting heterogeneity.<br><br>CONCLUSION: The pandemic led to notable shifts in systemic treatment patterns, particularly an increase in the use of neoadjuvant strategies. Short-term mortality did not significantly differ between periods. The study findings should be interpreted with caution due to variability in studies. Health systems require robust pharmaceutical policies and resilient triage frameworks to ensure continuity of cancer treatment during future crises.},
}
@article {pmid42370424,
year = {2026},
author = {Ratautas, D and Serapinas, S and Stakelytė, D and Guobužaitė, S and Danytė, A and Dagys, M},
title = {Quo Vadis, Electrochemical DNA Biosensor? Lessons from Three Decades of SNP Sensing.},
journal = {ACS sensors},
volume = {},
number = {},
pages = {},
doi = {10.1021/acssensors.6c01221},
pmid = {42370424},
issn = {2379-3694},
abstract = {Electrochemical DNA biosensors have been studied for over three decades, producing thousands of publications and a sophisticated engineering toolkit. However, a broad clinical adoption remains limited. The COVID-19 pandemic served as a stress test-global demand, unprecedented funding, accelerated regulatory pathways, and a clearly defined genomic target-yet electrochemical nucleic acid biosensors played no meaningful role in the diagnostic response, indicating that the barriers to translation are structural. Here, rather than cataloguing sensing formats, we analyze the field framing progress through three interacting constraints focusing on single-nucleotide polymorphism (SNP) sensing: the biological realities of nucleic acid targets, the physical limits of surface-based hybridization, and the clinical/market environment that governs adoption. We find that many advances optimize analytical performance under laboratory conditions while leaving application complexity largely unresolved. Yet, viable niches emerge at the intersection of low information complexity and operational urgency-rapid pharmacogenomic genotyping, now driven by directive clinical guidelines, and infection diagnostics, where simplicity matters more than sophistication. A broader redirection emerges when DNA acts not as the analyte but as a functional tool: Electrochemical aptamer-based sensors are entering commercial markets; nuclease and enzymatic activity profiling exploits the regime where these sensors perform best; and therapeutic oligonucleotides-invisible to standard sequencing workflows-map naturally onto the platform's strengths. The field's most transferable contribution may not be DNA detection itself, but the programmable molecular interfaces it has developed.},
}
@article {pmid42370758,
year = {2026},
author = {Ogungbite, AB and Sibiya, M},
title = {A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).},
journal = {CPT: pharmacometrics &amp; systems pharmacology},
volume = {15},
number = {7},
pages = {e70272},
pmid = {42370758},
issn = {2163-8306},
mesh = {*Drug Repositioning/methods/trends ; Humans ; *Artificial Intelligence/trends ; COVID-19 ; SARS-CoV-2 ; Machine Learning ; *COVID-19 Drug Treatment ; Antineoplastic Agents/therapeutic use ; Deep Learning ; *Neoplasms/drug therapy ; Medical Oncology/methods/trends ; Natural Language Processing ; },
abstract = {Drug repurposing presents a cost-effective and time-efficient strategy to identify new therapeutic applications for existing drugs. Recent advances in artificial intelligence, including machine learning, deep learning, knowledge graphs, and natural language processing, have revolutionized this field by enabling automated discovery of drug-disease associations. This review examines the role of artificial intelligence in drug repurposing, drawing insights from two critical case areas: Coronavirus disease 2019 and oncology. We explore current trends, methodological frameworks, and technological innovations in artificial intelligence-driven drug repurposing, as well as challenges and emerging future directions. The findings of this paper underscore the transformative potential of artificial intelligence in biomedical research and justify its continued integration in pharmaceutical pipelines.},
}
@article {pmid42371105,
year = {2026},
author = {Nofal, S and Al-Said, O and Alnimer, K and Sarah, JM and Alam, TA and Ali, O and Abuquteish, D},
title = {Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {7},
pages = {},
pmid = {42371105},
issn = {1432-1041},
mesh = {Humans ; *COVID-19 Drug Treatment ; *Antiviral Agents/therapeutic use/adverse effects/administration &amp; dosage ; RNA, Viral/blood ; SARS-CoV-2/drug effects ; Randomized Controlled Trials as Topic ; COVID-19/virology ; Treatment Outcome ; Indazoles ; Triazines ; Triazoles ; },
abstract = {BACKGROUND: Coronavirus Disease (COVID-19), which is caused by SARS-CoV-2 virus, led to a worldwide pandemic in late 2019, thus challenged the healthcare infrastructure across the world, creating an urgent need for the development of effective antiviral medications to handle its spread and evolving strains.<br><br>OBJECTIVE: This Meta-Analysis aims to investigate the overall efficacy and safety of Ensitrelvir.<br><br>METHODS: We conducted a systematic review and meta-analysis, according to PRISMA guidelines, searching web databases for relevant literature. We limited our eligibility to randomized clinical trials involving mild-to-moderate COVID-19 patients.<br><br>RESULTS: Our study included four randomized controlled trials involving a total of 2,890 patients. For patients with mild-to-moderate Covid-19, treatment with Ensitrelvir (125&#xa0;mg or 250&#xa0;mg) was associated with significantly improved outcomes compared to placebo across several metrics: higher viral clearance was observed for 125&#xa0;mg [MD&#x2009;= -&#x2009;37.74, P&#x2009;<&#x2009;0.00001] and 250&#xa0;mg [MD&#x2009;= -&#x2009;35.02, P&#x2009;<&#x2009;0.00001]; greater reductions in viral RNA were achieved by 125&#xa0;mg [MD&#x2009;=&#x2009;-1.41, P&#x2009;<&#x2009;0.00001] and 250&#xa0;mg [MD&#x2009;=&#x2009;-1.37, P&#x2009;<&#x2009;0.00001]; and a significantly lower proportion of patients maintained a positive viral titer at 125&#xa0;mg [RR 0.08, P&#x2009;<&#x2009;0.00001, I[2]&#x2009;=&#x2009;82%] and 250&#xa0;mg [RR 0.10, P&#x2009;<&#x2009;0.00001, I[2]&#x2009;=&#x2009;16%]. Ultimately, there were no significant differences in reported outcomes between the 125&#xa0;mg and 250&#xa0;mg Ensitrelvir dosage groups.<br><br>CONCLUSION: This systematic review and meta-analysis support Ensitrelvir efficacy and safety in promoting rapid viral clearance and greater reduction in viral RNA in mild-to-moderate or asymptomatic COVID-19 patients, justifying its integration into outpatient treatment protocols while emphasizing the need for further large-scale, variant-inclusive studies to validate and extend these findings.<br><br>REGISTRATION: PROSPERO (CRD420251030953).},
}
@article {pmid42371512,
year = {2026},
author = {Cezar da Cruz, D and Haertl, K and Tomlin, GS and Yu, CH and Hernández-Lanas, O and Haigh, J},
title = {Mapping the occupational therapy process in response to COVID-19 and long COVID: A scoping review.},
journal = {The British journal of occupational therapy},
volume = {89},
number = {7},
pages = {435-448},
pmid = {42371512},
issn = {1477-6006},
abstract = {BACKGROUND: COVID-19 and long COVID have had an impact worldwide on people's participation in occupations. Occupational therapists play a role in supporting individuals' recovery and participation in daily life.<br><br>OBJECTIVE: This present study undertook a scoping review of research on COVID-19 and long COVID to map the occupational therapy process with this population, including evaluation, intervention and outcomes.<br><br>METHODOLOGY: Three online databases were searched to identify research papers published between 2020 and 2023 from all countries, published in English, Portuguese, or Spanish. From 455 texts, 25 studies were selected for this review.<br><br>RESULTS: Studies were conducted across varied healthcare settings, mainly inpatient hospitals. Participants ranged from children to older adults, with adults being the most represented group. Standardised assessments included occupational history, activities, body functions, cognition and emotional regulation. Interventions were educational, compensatory, restorative or acquisitional, with outcomes focused on daily living activities, performance skills and client factors.<br><br>CONCLUSION: Our review underscores the need for more comprehensive documentation of occupational therapy effectiveness, particularly in unpredictable circumstances such as COVID.},
}
@article {pmid42374300,
year = {2026},
author = {Kennard, A and Kılıç, A and Alsugeir, D and Hamada, Y and Rangaka, MX},
title = {A systematic review of the determinants of vaccine hesitancy in the UK: Implications for future TB vaccine adoption.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-28299-9},
pmid = {42374300},
issn = {1471-2458},
abstract = {BACKGROUND: Tuberculosis (TB) is a deadly yet vaccine-preventable disease mostly affecting adolescents and adults. Novel TB vaccines are now emerging, particularly for these populations; however, vaccine hesitancy, characterised by delays, doubts or refusal to seek or accept vaccines, poses a challenge for sufficient adoption once these vaccines become available. Thus, this review systematically explored system- and individual-level determinants of vaccine hesitancy among adults in the UK, interpreting implications for the adoption of novel TB vaccines.<br><br>METHODS: Five databases systematically searched for studies from 2020 - 2024 reporting qualitative outcomes on determinants of vaccine hesitancy among people living in the UK. Thematic analysis mapped extracted data onto a framework combining the Strategic Advisory Group of Experts (SAGE) model to explore system-level factors (e.g., vaccine-specific influences) and the Perceptions and Practicalities Approach (PaPA) to explore individual-level factors (e.g., perceptual influences) of vaccine hesitancy. The Mixed Methods Appraisal Tool was used to assess study quality.<br><br>RESULTS: 29 qualitative and 21 mixed methods studies; 87.5% investigated hesitancy to COVID-19 vaccines. All SAGE themes were identified at the system level, most notably vaccine novelty, the media environment and health system experiences. At individual-level, all PaPA themes emerged, with vaccine-specific beliefs and knowledge most frequently identified. Overall, themes varied across the lifespan, with adolescents influenced mainly by media and social norms, and older adults by safety concerns and trust in health professionals.<br><br>CONCLUSIONS: Vaccine hesitancy determinants interacted and were compounded in vulnerable subgroups, while post-pandemic disruptions to TB services may undermine adoption of novel TB vaccines. Addressing these challenges requires multi-level strategies centred on trusted, culturally sensitive communication. Delivery through routine, school and community-based programs aligns with evidence from high-incidence settings and highlights the need for coordinated action by policymakers and healthcare providers.},
}
@article {pmid42374517,
year = {2026},
author = {Harvey, E and Van Brussel, K and Holmes, EC},
title = {Empowering One Health with metagenomics.},
journal = {One health outlook},
volume = {},
number = {},
pages = {},
doi = {10.1186/s42522-026-00225-4},
pmid = {42374517},
issn = {2524-4655},
support = {GNT2017197//National Health and Medical Research Council/ ; },
abstract = {In an increasingly connected world a global One Health approach to the management of human, animal and ecosystem health will be critical to effective infectious disease responses. The emergence and rapid global spread of several emerging and re-emerging pathogens in the past decade has highlighted the need for rapid, sensitive and accurate diagnostics. Metagenomics, while commonly used for research purposes for almost two decades, entered the global spotlight during the COVID-19 pandemic. In this review we discuss the impacts that metagenomic studies have had on our understanding of origins, aetiology and ecology of infectious diseases within a One Health context. We also discuss the role of metagenomics in the future of diagnostics and disease surveillance, and outline the challenges and limitations of current metagenomic methods.},
}
@article {pmid42374546,
year = {2026},
author = {Stroobants, T and Willemart, C and Walravens, M and Veeckmans, G and Ligthart, S and Hoste, E and Benoit, DD and Berghe, TV and Jorens, PG},
title = {Clinical implications of ferroptosis in critical illness: a narrative review.},
journal = {Journal of intensive care},
volume = {},
number = {},
pages = {},
doi = {10.1186/s40560-026-00899-y},
pmid = {42374546},
issn = {2052-0492},
support = {BOF-IMPULS//University of Antwerp/ ; 1SH9524N//Fund for Scientific Research (FWO) Flanders/ ; },
abstract = {Despite major advances in care for patients admitted to the intensive care unit (ICU), mortality remains high and functional outcomes for ICU survivors are often poor. The persistent burden underscores the need for innovative, mechanism-based approaches. Precision medicine has emerged as a promising paradigm in critical illness, and regulated cell death (RCD) may offer a novel entry point for targeted interventions. Among the various RCD pathways, ferroptosis, an iron-dependent form of RCD driven by excessive lipid peroxidation within cellular membranes, has gained increasing attention. Its mechanistic distinctiveness from other RCDs and potential reversibility make it particularly relevant in acute, dynamic disease states. In this narrative review, we explore the role of ferroptosis in critical care, focusing on high-impact conditions such as sepsis, COVID-19, ischaemia-reperfusion injury, and neurological emergencies. We outline the molecular mechanisms of ferroptosis and discuss how it may contribute to organ dysfunction across systems. While most insights to date stem from preclinical models, emerging clinical data suggest translational potential. We highlight key studies, discuss current limitations in detection and therapeutic targeting, and consider how the evaluation of ferroptosis could help shape the future of precision medicine in the ICU.},
}
@article {pmid42374888,
year = {2026},
author = {Talabani, B and Hanif, S and Ramzan, K and Mohammed, F and Naseem, A and Alauddin, E},
title = {Improving COVID-19 Vaccine Uptake Among Ethnic Minority Communities in Wales: A Community-Based Approach.},
journal = {Immunology and cell biology},
volume = {104},
number = {7},
pages = {700-707},
pmid = {42374888},
issn = {1440-1711},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; Wales/epidemiology ; *COVID-19 Vaccines/administration &amp; dosage ; *Minority Groups ; *Ethnicity ; SARS-CoV-2 ; Islam ; Vaccination Hesitancy ; Vaccination ; Pandemics ; },
abstract = {During the COVID-19 pandemic, misinformation and vaccine hesitancy disproportionately affected ethnic minority communities across the United Kingdom, including in Wales. Muslim Doctors Cymru (MDC), a grassroots coalition of Muslim healthcare professionals, played a pivotal role in countering this challenge. This paper describes the strategies and impact of MDC's work in addressing health misinformation, building trust, and promoting vaccine uptake among ethnic minority communities in Wales. Through culturally sensitive engagement, multilingual public health messaging, and close collaboration with mosques, community leaders, and local media, MDC delivered targeted outreach that bridged gaps between public health authorities and underserved populations. This case study draws on a grassroots-efforts approach to tackling vaccine inequity using community-based approaches. Findings highlight the importance of culturally competent healthcare communication and the value of community-led initiatives in improving public health outcomes during crises. MDC's model offers a replicable framework for addressing health inequalities and misinformation in diverse populations.},
}
@article {pmid42376297,
year = {2026},
author = {Mao, X and Cai, M and Fan, B},
title = {Lung organoids for respiratory diseases: overcoming translational hurdles in drug discovery and safety assessment.},
journal = {Frontiers in bioengineering and biotechnology},
volume = {14},
number = {},
pages = {1859058},
pmid = {42376297},
issn = {2296-4185},
abstract = {Respiratory diseases, encompassing chronic inflammatory conditions, interstitial fibrotic disorders, acute infectious diseases, and pulmonary malignancies, represent a profound global health burden with unacceptably high morbidity and mortality rates. Historically, the pharmaceutical pipeline for respiratory therapeutics has suffered staggering attrition rates during clinical development. This is primarily due to the fundamental inability of conventional two-dimensional cell cultures and in vivo animal models to faithfully recapitulate the complex three-dimensional architecture, multicellular heterogeneity, and human-specific physiological dynamics of the pulmonary system. To bridge this critical translational gap, lung organoids-self-organizing, three-dimensional microphysiological constructs derived from pluripotent or adult stem cells-have emerged as a useful human-cell-based platform. This comprehensive review critically evaluates current lung organoid technologies, elucidating their derivation pathways and capacity for high-fidelity disease modeling. We analyze their application in dissecting the pathogenesis of chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, viral infections including SARS-CoV-2, and non-small cell lung cancer. Furthermore, we highlight their important role in predictive toxicology for assessing environmental inhalation hazards, cosmetic safety, and drug-induced lung injury, aligning with evolving regulations prioritizing alternatives to animal testing. Despite their immense potential, widespread clinical and industrial translation is currently impeded by biological bottlenecks: the absence of functional vascularization, incomplete immune integration, and reliance on undefined xenogeneic matrices. We systematically examine bioengineering strategies addressing these limitations-including synthetic hydrogels, microfluidic organ-on-a-chip platforms, and 3D bioprinting-to overcome translational hurdles, accelerate precision medicine, and improve respiratory pharmacology.},
}
@article {pmid42376726,
year = {2026},
author = {Abdul Rahman, H and Zahari, NH},
title = {The Silent Crisis: Loneliness in Older Adults-A Critical Review of Impacts, Strategies and Path Forward.},
journal = {Scandinavian journal of caring sciences},
volume = {40},
number = {3},
pages = {e70292},
doi = {10.1111/scs.70292},
pmid = {42376726},
issn = {1471-6712},
mesh = {Humans ; *Loneliness/psychology ; Aged ; *COVID-19/psychology ; Aged, 80 and over ; Middle Aged ; Male ; Female ; *Social Isolation/psychology ; },
abstract = {BACKGROUND: Loneliness, distinct from social isolation, is a subjective sense of social disconnection exacerbating a public health crisis among older adults. Affecting ~33% of community-dwelling individuals aged 50-80 years post-COVID-19, it rivals smoking in mortality risk and drives cognitive, cardiovascular, and mental health declines. This review synthesises evidence to inform clinical strategies.<br><br>METHODS: A critical review of per-reviewed meta-analyses, RCTs, and prospective cohorts literature (2019-2025) was conducted for adults aged 50&#x2009;years and above. Studies were selected using validated loneliness or social isolation measures, with quality appraised via AMSTAR-2, Cochrane RoB 2, and Newcastle-Ottawa Scale; 34 studies met eligibility criteria from an initial yield of 1,847 records.<br><br>RESULTS: Prevalence of loneliness stands at 29% isolation by 2024, highest among those with poor health (53%-75%), unemployment (52%), solitary living, and ages 50-64. Loneliness elevates all-cause mortality (32%), dementia (50%-59%), cardiovascular events (29%-32%), depression (40%), and anxiety (35%). Mechanisms include increased inflammation (&#x2191;CRP, IL-6), HPA dysregulation, immune compromise, hippocampal atrophy, and behavioural lapses. Interventions like CBT/reminiscence therapy, multicomponent programs, animal therapy, exercise, and digital platforms have been shown to reduce loneliness, though primary care implementation lags due to screening/referral barriers. Tools such as the UCLA Loneliness Scale enable feasible assessment.<br><br>CONCLUSIONS: Loneliness as a geriatric syndrome demands mandated screening, provider education, and reimbursement reforms. Coordinated healthcare-community efforts could avert substantial morbidity/mortality, addressing gaps in long-term outcomes and cost-effectiveness research.},
}
@article {pmid42376837,
year = {2026},
author = {Tafazoli, A and Dowran, R},
title = {Syncytia Formation in the Pathogenesis of SARS-CoV-2 Infection: Lessons from Viral Infections.},
journal = {Viral immunology},
volume = {39},
number = {6},
pages = {232-240},
doi = {10.1177/08828245261433819},
pmid = {42376837},
issn = {1557-8976},
mesh = {Humans ; *Giant Cells/virology/immunology ; *COVID-19/virology/immunology/pathology ; Spike Glycoprotein, Coronavirus/genetics/immunology/metabolism ; *SARS-CoV-2/pathogenicity/genetics/immunology/physiology ; Virus Internalization ; Immunity, Innate ; Mutation ; Animals ; },
abstract = {It is widely known that numerous enveloped viruses can produce multinucleated cells (syncytia) as a result of viral entry-related membrane fusion events. By protecting the virus from the host's immune reaction, these syncytia are thought to promote viral reproduction. Syncytia are collections of merged cells. A viral spike protein (S) on the surface of an infected cell interacts with receptors on nearby cells to cause the syncytia response. The innate immune system's response to viruses affects how syncytia form. Some interferon-stimulated genes change the membrane in a way that reduces the likelihood of fusion. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus is quickly changing; also, several mutations occurred in its S protein. Individually and together, the Alpha, Beta, Gamma, and Delta variants carry mutations that significantly affect S function and syncytia formation. The function of syncytia in newly emerging variant diseases is still unknown, though. Syncytia could cause disease through promoting viral transmission, cytopathicity, immunological evasion, and inflammatory responses. The SARS-CoV-2 S protein variations include several changes that improve receptor interactions, fusogenicity, and antibody reactivity. A wide range of clinical symptoms, including moderate febrile sickness, severe respiratory distress, and occasionally deadly lung damage, can be brought on by an infection with SARS-CoV-2. Several of these lung illnesses (MERS-CoV) are linked to both the Middle East Respiratory Syndrome (MERS) and the severe acute respiratory syndrome coronavirus (SARS-CoV). Compared to acute respiratory syndromes, the lung thrombosis brought on by Coronavirus disease 2019 (COVID-19) is incredibly severe. In this review we focused on innate immunological elements that prevent syncytia from forming and the molecular triggers of S-mediated fusion.},
}
@article {pmid42377214,
year = {2026},
author = {Tanriover, MD and Forsyth, K and He, Q and Diavatopoulos, DA and Orozco Fernández, R and Hozbor, DF and Middleton, DB and Muloiwa, R and Muñoz, FM and Ong-Lim, A and Tan, TQ and Heininger, U},
title = {Immunological insights into why pertussis continues to be endemic.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2692306},
pmid = {42377214},
issn = {2164-554X},
mesh = {*Whooping Cough/epidemiology/immunology/prevention &amp; control ; Humans ; *Bordetella pertussis/immunology/genetics ; *Pertussis Vaccine/immunology/administration &amp; dosage ; *Endemic Diseases/prevention &amp; control ; Th1 Cells/immunology ; Th17 Cells/immunology ; Vaccines, Acellular/immunology ; Th2 Cells/immunology ; },
abstract = {Pertussis (whooping cough) is a vaccine-preventable bacterial disease caused by Bordetella pertussis. Despite widespread vaccination, cases have increased globally since the 1990s, with notable outbreaks in 2012, 2016, and following the COVID-19 pandemic. Persistent endemicity and periodic epidemics are driven by limited prevention of nasal colonization, waning immunity after vaccination or natural infection, and pathogen adaptation. Differences between acellular (aP) and whole-cell (wP) vaccines reflect distinct immune profiles, with aP vaccines favoring Th2 responses and wP vaccines inducing Th1/Th17 responses and tissue-resident memory T cells. Circulating strains have evolved under vaccine pressure, including shifts in ptxP, ptxA and prn alleles, increasing pertussis toxin production, emergence of pertactin-deficient variants, and rising macrolide resistance linked to 23S rRNA mutations. Optimizing current vaccine strategies and developing next-generation vaccines that improve durable, Th1/Th17-polarized immunity and reduce transmission are essential for enhanced pertussis control.},
}
@article {pmid42377340,
year = {2026},
author = {Rodríguez-Rodríguez, E and Rodríguez-Rodríguez, P and Jiménez-Ortega, AI and Aparicio, A},
title = {[Nutrition, microbiota and respiratory infections: key aspects of their interaction].},
journal = {Nutricion hospitalaria},
volume = {43},
number = {Spec No4},
pages = {54-57},
doi = {10.20960/nh.06966},
pmid = {42377340},
issn = {1699-5198},
mesh = {Humans ; *Respiratory Tract Infections/immunology/microbiology/prevention &amp; control ; *Nutritional Status ; Probiotics ; *Diet ; COVID-19/immunology ; Prebiotics ; *Gastrointestinal Microbiome ; *Microbiota ; },
abstract = {Introduction: respiratory infections (RI) have experienced a rebound following the lifting of COVID-19 restrictions, constituting a major public health problem. Diet and nutritional status are determining factors in the competence of the immune system, where the gut-lung axis has been identified as a key mechanism in regulating the immune response against these processes. Objectives: to analyze the scientific evidence on the role of diet and microbiota in the prevention and evolution of respiratory infections. Methods: narrative review of recent scientific literature on nutrients, dietary patterns, gut microbiota, and their relationship with respiratory immunity. Results: various nutrients such as fiber, n-3 polyunsaturated fatty acids, vitamins, minerals, and polyphenols, as well as the use of probiotics, modulate the gut microbiota and promote the production of metabolites, especially short-chain fatty acids (SCFAs), with immunomodulatory effects. These mechanisms contribute to improving the pulmonary immune response and reducing the incidence and severity of RI. Conclusions: a balanced and high-nutrient-density diet, rich in prebiotic and probiotic compounds, can contribute to strengthening the immune response and decreasing vulnerability to respiratory infections.},
}
@article {pmid42378128,
year = {2026},
author = {Escobar, M and Arenas, &#xc1; and Perdomo-Luna, C and Londoño, D and Molano, JC and Nieto, M and Borrero, E and Vanegas, E},
title = {Is mental health in Colombia a right or a privilege?.},
journal = {Biomedica : revista del Instituto Nacional de Salud},
volume = {46},
number = {2},
pages = {219-227},
doi = {10.7705/biomedica.7429},
pmid = {42378128},
issn = {2590-7379},
mesh = {Colombia/epidemiology ; Humans ; *COVID-19/epidemiology/psychology ; *Mental Disorders/epidemiology/therapy ; *Mental Health ; *Mental Health Services/organization &amp; administration ; Health Services Accessibility ; Armed Conflicts ; Social Stigma ; Healthcare Disparities ; SARS-CoV-2 ; Right to Health ; Pandemics ; },
abstract = {This article offers a vision of the mental health situation in Colombia, highlighting its growing relevance in the public sphere and the specific challenges facing the country. It analyzes the impact of the armed conflict and the COVID-19 pandemic on the mental health of the Colombian population, focusing on how these situations have exacerbated pre-existing problems. Additionally, the existence of significant barriers to accessing specialized services is highlighted, such as stigma, lack of trained personnel, and high costs associated with the treatment of mental disorders. Therefore, the need to address inequalities in mental health care is raised, both nationally and internationally. Finally, recommendations are proposed to improve prevention, community care and access to mental health services in Colombia.},
}
@article {pmid42378358,
year = {2026},
author = {Atencio, MA and Luini, JA and Cappella, RB and Mattei, L and Giuffre, CV and Pereyra Huertas, J and Scherñuk Schroh, MP and Davit Baridón, NS and Boscardin, C and Esandi, ME and Duran, LG},
title = {Effectiveness of strategies to prevent burnout syndrome in hospital-based healthcare personnel: an overview of systematic reviews.},
journal = {Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)},
volume = {83},
number = {2},
pages = {e49503},
pmid = {42378358},
issn = {1853-0605},
mesh = {Humans ; *Burnout, Professional/prevention &amp; control ; *Personnel, Hospital/psychology ; *COVID-19/psychology ; *Health Personnel/psychology ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: Burnout syndrome (BO) significantly affects healthcare personnel, especially in hospital settings. The COVID-19 pandemic has intensified this issue, highlighting the need for effective preventive strategies.<br><br>OBJECTIVES: To synthesize available evidence on the effectiveness of individual, organizational, and combined strategies to prevent or reduce BO in hospital-based healthcare personnel.<br><br>MATERIALS AND METHODS: A systematic search was conducted in PubMed, Cochrane Library, Epistemonikos, and the Virtual Health Library for systematic reviews published between January 1, 2014, and January 15, 2024. Reviews with or without meta-analyses were included if they evaluated preventive interventions for BO and contained at least one primary study. Reviews focused solely on stress, well-being, or anxiety without specific BO outcomes were excluded. Two reviewers independently extracted data on study characteristics, types of interventions, measurement tools, and outcomes. A de novo extraction of 107 primary studies was also performed.<br><br>RESULTS: Twenty-seven systematic reviews were included. The most frequently evaluated interventions were mindfulness, cognitive-behavioral therapy, workload reduction, and professional coaching. Structured, in-person interventions generally showed greater effectiveness. Organizational strategies yielded mixed results.<br><br>CONCLUSION: Both individual and organizational interventions can reduce BO in healthcare professionals. Structured, face-to-face, and multifaceted approaches appear to be more effective. High-quality research is needed, with emphasis on implementation strategies tailored to clinical contexts.},
}
@article {pmid42379196,
year = {2026},
author = {Blakney, AK and Top, KA and Cowling, BJ and Larson, HJ and Shattock, RJ and Sadarangani, M},
title = {Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.},
journal = {Lancet (London, England)},
volume = {408},
number = {10551},
pages = {275-288},
doi = {10.1016/S0140-6736(26)00512-X},
pmid = {42379196},
issn = {1474-547X},
mesh = {Humans ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/adverse effects/immunology ; *mRNA Vaccines/adverse effects/immunology ; Public Health ; *Vaccine Efficacy ; *Vaccines, Synthetic/adverse effects/immunology ; },
abstract = {mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global deployment of mRNA vaccines during the COVID-19 pandemic provided an unprecedented real-world evaluation of this platform, with billions of doses administered across diverse populations. In this Review, we critically examine the safety and efficacy of mRNA vaccines from mechanistic, preclinical, clinical, and public health perspectives. We outline the biological basis of mRNA vaccines, including their transient cytoplasmic expression, lack of genomic integration, and rapid clearance, distinguishing them clearly from other gene therapies. We synthesise evidence on vaccine components, manufacturing quality controls, and regulatory standards that underpin safety, alongside data from randomised trials, post-authorisation surveillance, and active pharmacovigilance systems. We also review real-world effectiveness across age groups, pregnancy, and populations that are immunocompromised, along with the effects on transmission. Last, we address public perception and vaccine confidence, and discuss implications for next-generation mRNA vaccines, including strategies to reduce reactogenicity, improve breadth and durability of immunity, enhance global access, and support sustainable public trust. Together, the accumulated evidence affirms mRNA vaccines as a safe, effective, and adaptable platform with enduring relevance for future infectious disease prevention and public health preparedness, and for the treatment of cancer and autoimmunity.},
}
@article {pmid42379531,
year = {2026},
author = {Alsulami, AS and Al-Kuraishy, HM and Al-Gareeb, AI and Abdelnaby, MA and Haggag, MM and El-Saber Batiha, G},
title = {Pathophysiology of silent hypoxia in COVID-19: Truth and mystery.},
journal = {Respiratory medicine},
volume = {261},
number = {},
pages = {109013},
doi = {10.1016/j.rmed.2026.109013},
pmid = {42379531},
issn = {1532-3064},
abstract = {Coronavirus disease 2019 (COVID-19) is a highly infectious viral disease caused by the SARS-CoV-2. COVID-19 commonly leads to mild flu-like illness in most of cases. However, severe COVID-19-induced pneumonia and associated acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) may lead to ventilation-perfusion mismatch and the development of silent hypoxia. Silent hypoxemia is observed in critically COVID-19 patients without signs of subjective dyspnea that is often linked with poor clinical outcomes. Proposed mechanisms include impairment of peripheral carotid chemoreceptors, attenuation of the sensitivity of the respiratory center, and the development of acute vascular distress syndrome (AVDS). However, it should be noted that while AVDS is supported by imaging and pathological evidence, the roles of carotid body dysfunction and other proposed mechanisms remain incompletely validated and require further investigation. The pathophysiology of silent hypoxia in COVID-19 and other viral infections is a complex condition. Accordingly, this review aims to explain and discuss the pathophysiology of silent hypoxia, and its critical role in COVID-19.},
}
@article {pmid42380588,
year = {2026},
author = {Singh, A and Tekade, M and Nagaraja, S and Bharti, A and Tekade, RK},
title = {Advancements in RNA-based therapies from bench to bedside.},
journal = {npj drug discovery},
volume = {3},
number = {1},
pages = {},
pmid = {42380588},
issn = {3005-1452},
abstract = {RNA research has advanced rapidly, becoming a key component of modern therapeutics. This review outlines key milestones and innovations from antisense oligonucleotides and RNA interference to mRNA therapies and aptamers that have enabled targeted treatments for diverse diseases. The success of COVID-19 mRNA vaccines highlighted the remarkable clinical potential of RNA-based technologies. Emphasis is placed on delivery technologies, landmark approvals, and ongoing trials shaping the future of RNA-based medicine.},
}
@article {pmid42380995,
year = {2026},
author = {Delano, P and Serra-Suton, V and Benavides, FG and Utzet, M},
title = {Prolonged return to work and hampered work ability: insights from a scoping review on the impact of long COVID on healthcare workers job performance.},
journal = {BMC health services research},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12913-026-15032-w},
pmid = {42380995},
issn = {1472-6963},
abstract = {BACKGROUND: Healthcare workers (HCWs) may have a higher risk of developing long COVID due to greater exposure to COVID-19, with symptoms extending beyond the acute phase impacting their daily living activities and job performance.<br><br>AIMS: To systematically map the existing literature on the impact of long COVID on HCWs' job performance, focusing on their time to return to work and work ability.<br><br>METHODS: A scoping review following PRISMA-ScR guidance included peer-reviewed studies in English or Spanish (January 2020-December 2024). Four databases were searched. Experimental, epidemiological and qualitative studies were eligible. Two reviewers independently screened records. Methodological quality was appraised using the Mixed-Methods Appraisal tool (MMAT).<br><br>RESULTS: Nineteen studies were included, mainly European and predominantly cross-sectional. Long COVID was most often defined as symptoms lasting&#x2009;&#x2265;&#x2009;3&#x2009;months. Among HCWs with prior infection or whole-staff samples, prevalence ranged from 10% to 74%, with multiple reports above 50%. Thirteen studies evaluated RTW, with 19-63% resumed work within six months, commonly with restrictions, while around one in five remained unable to work in some cohorts. Full-time employment decreased markedly (e.g., 57% pre-infection vs 31% at follow-up). Between 16% and 40% required workplace adjustments such as reduced hours, reassignment, or avoidance of night shifts. Sixteen studies reported diminished work ability compared with pre-infection or unaffected peers. Greater symptom burden, particularly cognitive impairment and fatigue, consistently predicted poorer outcomes. One study estimated a mean of 223&#x2009;days to reach current work-ability levels. Older age, depression, comorbidity, and acute disease severity were recurrent associated factors while evidence for gender and job category was inconsistent.<br><br>CONCLUSIONS: Long COVID delays RTW and reduces work ability in HCWs. Health services should plan long-term occupational follow-up, flexible reintegration pathways, and targeted accommodations while higher-quality longitudinal research refines risk and prognosis.},
}
@article {pmid42381166,
year = {2026},
author = {Yang, Y and Weng, J and Tao, Y and Luo, B and Lian, D and Li, F and Yan, J and Chen, Y},
title = {Cost-Effectiveness of Vaccination Strategies for COVID-19: A Systematic Review.},
journal = {Journal of evidence-based medicine},
volume = {19},
number = {2},
pages = {e70136},
doi = {10.1111/jebm.70136},
pmid = {42381166},
issn = {1756-5391},
mesh = {Humans ; *Cost-Benefit Analysis ; Cost-Effectiveness Analysis ; *COVID-19/prevention &amp; control/economics ; *COVID-19 Vaccines/economics/administration &amp; dosage ; *Vaccination/economics/methods ; SARS-CoV-2 ; },
abstract = {OBJECTIVES: This study aims to provide a comprehensive overview of the cost-effectiveness of COVID-19 vaccination strategies and examine the reporting quality of the included studies.<br><br>METHODS: A systematic search was performed across PubMed, Web of Science, Embase, Cochrane Library, the International Network of Agencies for Health Technology Assessment, and Chinese databases (CNKI, WanFang, VIP, and SinoMed). Health economic evaluations published from inception to December 19, 2024, considering both costs and effects of vaccination strategies for COVID-19 were included. The reporting quality of the included studies was comprehensively assessed according to the Consolidated Health Economic Evaluation Reporting Standards Checklist (CHEERS) 2022. A narrative synthesis was employed to summarize and present the findings across diverse vaccination strategies. To ensure transparency, the study protocol was registered prospectively in the Prospective Register of Systematic Reviews (CRD42025629706).<br><br>RESULTS: A total of 68 studies were included. These studies were heterogeneous concerning reporting quality, vaccination strategies, adopted perspective, applied models, and outcome indicator used. The CHEERS quality scoring rate of 68 studies ranged from 23% to 88%, with a median of 71%. Vaccination was consistently found more cost-effective or cost-saving than no vaccination. Prioritizing high-risk populations, particularly older adults, delivered even higher economic benefits across diverse settings.<br><br>CONCLUSION: COVID-19 vaccination remains cost-effective globally. While rapid deployment and high risk prioritization maximize economic benefits, optimal strategies are sensitive to epidemiological and methodological factors, placing substantial demands on policymakers. Future research should integrate long-term impacts, health equity, and reporting standards to strengthen evidence based vaccination policies.},
}
@article {pmid42381225,
year = {2026},
author = {Shakerdi, AL and Drda, J and Dutta, JA and Vockley, J},
title = {Immune Dysregulation in Branched Chain Organic Acidemias.},
journal = {Journal of inherited metabolic disease},
volume = {49},
number = {4},
pages = {e70203},
pmid = {42381225},
issn = {1573-2665},
support = {1U54HD121579-01//Foundation for the National Institutes of Health/ ; },
mesh = {Humans ; *Amino Acid Metabolism, Inborn Errors/immunology ; Cytopenia ; Animals ; Adaptive Immunity ; },
abstract = {Organic acidemias (OAs) are a group of inherited disorders, most commonly caused by defects in mitochondrial enzymes involved in amino acid and fatty acid metabolism. While they characteristically present with metabolic and neurological crises, growing evidence reveals a significant burden of chronic immune dysregulation in some disorders and patients. This review provides a synthesis of clinical and mechanistic evidence discussing immune dysregulation in OAs. Cytopenia can occur in OAs and predispose patients to recurrent and severe infections. Adaptive immune deficits, such as hypogammaglobulinemia, reduced B and T cell populations, and impaired vaccine-specific antibody responses, including to diphtheria and tetanus in MSUD and to the inactivated COVID-19 vaccine in propionic acidemia, have also been reported. Additionally, some case series note hyperinflammatory conditions, such as hemophagocytic lymphohistiocytosis. Mechanistic studies indicate that accumulated metabolites disrupt innate and adaptive hematopoietic progenitor function, mitochondrial homeostasis, and inflammatory signaling. Emerging therapeutic avenues, such as gene and mRNA-based therapies, hold the potential to improve or normalize the biochemical phenotype in OAs. While their impact on immune abnormalities remains largely unexplored, future clinical trials offer an opportunity to systematically assess potential effects on immune parameters. OAs are increasingly recognized as disorders with intrinsic immune dysregulation, extending beyond their well-characterized metabolic and neurological manifestations. Future clinical trials will benefit from including immunological endpoints to evaluate immunological recovery for novel therapies.},
}
@article {pmid42381868,
year = {2026},
author = {Wang, Z and Wang, J and Wu, Q and Wang, B},
title = {Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.},
journal = {Frontiers in endocrinology},
volume = {17},
number = {},
pages = {1846640},
pmid = {42381868},
issn = {1664-2392},
mesh = {Humans ; *COVID-19/mortality/blood ; Hospitalization ; *Blood Glucose/metabolism/analysis ; SARS-CoV-2 ; Hospital Mortality ; Pandemics ; },
abstract = {BACKGROUND: Glucose variability (GV) reflects fluctuations in blood glucose and may better capture metabolic instability than static glycemic measures in patients with Coronavirus disease 2019 (COVID-19). However, its association with mortality remains uncertain due to heterogeneous study designs and inconsistent findings. This meta-analysis was performed to evaluate the association between GV and short-term all-cause mortality in adult patients hospitalized with COVID-19.<br><br>METHODS: PubMed, Embase, and Web of Science were systematically searched for longitudinal observational studies reporting the association between GV and mortality in patients hospitalized with COVID-19. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model accounting for the possible influence of heterogeneity.<br><br>RESULTS: Ten cohort studies comprising 11 datasets and 77,395 patients were included, with 8,189 deaths. High GV was associated with a significantly increased risk of all-cause mortality (RR&#xa0;=&#xa0;2.10, 95% CI: 1.69-2.59; I&#xb2; = 45%). The association was stronger in studies with a mean age &#x2265; 62 years (RR&#xa0;=&#xa0;2.79) compared with < 62 years (RR&#xa0;=&#xa0;1.78; p for subgroup difference = 0.03). Results were consistent across GV metrics, analytic models, adjustment for diabetes status, and study quality (all p > 0.05). Meta-regression analysis showed that mean age demonstrated a borderline association with the effect estimate (coefficient = 0.020, p&#xa0;=&#xa0;0.07), explaining a moderate proportion of heterogeneity (adjusted R&#xb2; = 49.2%).<br><br>CONCLUSIONS: Higher GV is associated with increased short-term mortality in hospitalized patients with COVID-19, supporting its role as a potential prognostic marker.<br><br>https://www.crd.york.ac.uk/prospero/, identifier CRD420261358246.},
}
@article {pmid42382219,
year = {2026},
author = {Renukappa, S and Subbarao, C and Suresh, S and Pillai, P and Fernando, K and Rangaswamy, C and Shetty, J and Krishnadas, R and Veenith, T},
title = {An assessment of cyber security and resilience of the National Digital Health Mission of India.},
journal = {Oxford open digital health},
volume = {4},
number = {},
pages = {oqag012},
pmid = {42382219},
issn = {2754-4591},
abstract = {The healthcare sector has undergone a transformation driven by the adoption of digital technology. Digital strategies have become the principal mechanism for delivering high-quality, cost-effective healthcare at scale. The Indian Government is also rapidly deploying the Ayushman Bharat Digital Mission (ABDM), launched in September 2021. ABDM is the flagship programme of the Indian Government, which has become the standard platform for healthcare delivery and allied services, including insurance management. The COVID-19 pandemic further accelerated digital adoption, making dependence on digital infrastructure both pervasive and unavoidable. Ensuring cybersecurity and resilience is therefore fundamental to uninterrupted healthcare delivery. This paper examines cyber resilience and cybersecurity within ABDM, with specific reference to its architecture and governing policies. A rigorous assessment of cyber resilience and cybersecurity, encompassing potential threats and attack vectors, is essential to the programme&amp;#×2019;s long-term success. We conclude that ABDM&amp;#×2019;s success is intrinsically linked to robust cybersecurity and resilience. Further work is required to develop a comprehensive framework for ABDM cyber resilience and security that is applicable across all ecosystem partners.},
}
@article {pmid42384225,
year = {2026},
author = {Miranda, M and Brown, M and van Haren, FMP and Brown, B and Page, CP},
title = {Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.},
journal = {Lung},
volume = {204},
number = {1},
pages = {},
pmid = {42384225},
issn = {1432-1750},
mesh = {Humans ; *Heparin/administration &amp; dosage/chemistry ; Administration, Inhalation ; Nebulizers and Vaporizers ; *COVID-19 Drug Treatment ; *Drug Delivery Systems ; *Lung Diseases/drug therapy ; *Anticoagulants/administration &amp; dosage ; COVID-19 ; SARS-CoV-2 ; Drug Compounding ; Aerosols ; },
abstract = {The COVID-19 pandemic further emphasized the global demand for heparin and its expanding clinical relevance, indicating that even one of the oldest drugs in medicine continues to reveal new therapeutic horizons. Traditionally recognized for its anticoagulant and antithrombotic activities, heparin is increasingly being explored for its versatile therapeutic potential in the treatment of a range of pulmonary diseases, including respiratory infections (e.g. COVID-19), Acute Respiratory Distress Syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. In all of these diseases, inhaled unfractionated heparin (UFH) therapy has been investigated in a number of clinical trials that have demonstrated promise for this drug when administered directly to the lungs. However, using heparin by this "off label" route of administration, poses a number of technical challenges: the physicochemical properties of heparin at therapeutic doses often results in highly viscous formulations, causing device blockage and drug sorption during nebulization. These limitations underscore the need for innovative formulation strategies to improve aerosol flow, reduce dosing inefficiencies, and enable reliable pulmonary administration. Advancing heparin formulations for delivery to the lung could therefore unlock significant benefits for a wide spectrum of respiratory disorders, marking a new chapter in the long medical history of this drug as discussed below.},
}
@article {pmid42384642,
year = {2026},
author = {Kagbadouno, M and Camara, O and Diallo, BM and Camara, AD and Soumah, A and Leno, M and Béavogui, F and Gassama, MD and Camara, I and Coulibaly, B and Kaba, D and Camara, A and Boiro, S and Ilboudo, H and Rayaisse, JB and MacLeod, A and Ndungu, J and Bieler, S and Bessell, P and Ott, D and Lejon, V and Ravel, S and Courtin, F and Solano, P and Jamonneau, V and Bart, JM and Rotureau, B and Bucheton, B and Camara, M},
title = {Elimination of gambiense human African trypanosomiasis as a public health problem in Republic of Guinea: Paving the way for zero transmission.},
journal = {PLoS neglected tropical diseases},
volume = {20},
number = {7},
pages = {e0014469},
pmid = {42384642},
issn = {1935-2735},
mesh = {Humans ; *Trypanosomiasis, African/prevention &amp; control/epidemiology/transmission ; Animals ; Guinea/epidemiology ; *Trypanosoma brucei gambiense/physiology ; *Disease Eradication ; Public Health ; Insect Vectors/parasitology ; Tsetse Flies/parasitology ; },
abstract = {The Republic of Guinea has faced an important challenge with human African trypanosomiasis (HAT), which was endemic over the last century. After initial control in the 1960s-1970s, HAT resurged in the 1990s along the Guinean coast, driven by economic and demographic pressures on the mangrove ecosystem. In response, the Guinean government established a national control program in 2002, focusing on medical mass screenings. In 2012, vector control using tiny targets was introduced in the East Boffa focus to reduce fly density and human-vector contact. However, the Ebola epidemic from 2013 to 2016 disrupted these efforts, leading to a reliance on passive screening. Resuming screenings in 2016-2017 revealed increased cases in all foci except the East Boffa area, where vector control had been effective. Vector control continued during the SARS-CoV2 pandemic and at the same time targeted door-to-door screenings were introduced to target high-risk individuals. Since 2018, around 30,000 at-risk individuals have been screened annually. These strategies reduced the total number of new cases below 1 per 10,000 inhabitants in endemic areas over the period 2019-2023, allowing to validate the elimination of HAT as a public health problem. The Guinean team and partners then focused on systematic spatial monitoring of patients and community engagement in vector control. The program also integrates control of other neglected tropical diseases and addresses new research questions, especially about anatomical and animal reservoirs for parasites. These efforts, combined with implementation of improved diagnostic tests and new oral treatments, through active involvement in multiple clinical trials and studies, now aim to interrupt HAT transmission by 2030.},
}
@article {pmid42385584,
year = {2026},
author = {Kiprov, DD and Green, AP and Boyinapalli, P},
title = {Technological advances in selective plasma adsorption: The MTx.100 column and the emergence of subtractive precision medicine.},
journal = {Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis},
volume = {65},
number = {4},
pages = {104484},
doi = {10.1016/j.transci.2026.104484},
pmid = {42385584},
issn = {1473-0502},
mesh = {Humans ; *Precision Medicine/methods ; Adsorption ; *Plasma Exchange/methods/instrumentation ; },
abstract = {Therapeutic plasma exchange (TPE) is well-established for autoimmune, hematological, and neurological disease but is intrinsically non-selective: protective immunoglobulins, coagulation factors, and albumin are depleted alongside pathogenic substances, and reliance on donor-derived replacement fluid carries logistical and immunological costs. The MTx.100 column (Marker Therapeutics AG) is a selective plasma adsorption device that addresses these limitations through hydrophobic-affinity adsorption. It targets pro-inflammatory cytokines, protein-bound metabolic waste, hydrophobic environmental contaminants, and microparticulates while preserving immunoglobulins, coagulation factors, electrolytes, and the patient's own signaling proteins. Plasma is treated and conserved, eliminating replacement-fluid dependency. Clinical experience encompasses approximately 1000 procedures globally. A prospective single-arm multicenter trial in 107 critically ill COVID-19 patients (424 procedures) demonstrated 28-day mortality of 37.4% against an FDA-agreed performance goal of 88.1% (p < 0.0001); propensity-matched analysis showed approximately three-fold higher survival odds versus standard of care (OR 3.0; 95% CI 1.56-5.85; p = 0.0008), with significant reductions in inflammatory and metabolic markers and no serious adverse events attributable to the column or procedure. Hospital case reports across polytrauma, post-LVAD implantation, and toxin-induced hepatitis demonstrated hemodynamic and electrolyte stability and favorable clinical trajectories. Across 114 elective outpatient procedures, vital signs and electrolytes remained stable throughout treatment, and third-party laboratory analyses confirmed measurable reduction of PFAS, microplastics, and persistent organic pollutants in treated patients. Within the emerging framework of subtractive precision medicine, selective plasma adsorption offers a complementary paradigm to additive pharmacotherapy for conditions characterized by inflammatory and toxic burden. A pilot trial in Alzheimer's disease is underway.},
}
@article {pmid42386620,
year = {2026},
author = {Kishikawa, JI},
title = {[Structural Analysis Using Cryo-electron Microscopy for Protein-based Drug Design].},
journal = {Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan},
volume = {146},
number = {7},
pages = {631-639},
doi = {10.1248/yakushi.25-00183-3},
pmid = {42386620},
issn = {1347-5231},
mesh = {*Cryoelectron Microscopy/methods ; *Drug Design ; Angiotensin-Converting Enzyme 2 ; SARS-CoV-2 ; Protein Conformation ; Spike Glycoprotein, Coronavirus/chemistry/metabolism ; Humans ; Vibrio cholerae/enzymology ; Peptidyl-Dipeptidase A/chemistry ; Protein Binding ; Betacoronavirus ; },
abstract = {Structure-based drug design (SBDD) plays a crucial role in modern drug discovery. SBDD is a methodology that utilizes the three-dimensional (3D) structural information of a target protein to computationally search for compounds that bind to it and/or to optimize the binding of known compounds. This article provides an overview of recent advances in SBDD. Furthermore, we introduce 2 case studies conducted by the authors using single-particle analysis via Cryo-electron microscopy (Cryo-EM), a powerful technique for obtaining protein structures. The first example is the sodium ion (Na[+])-translocating NADH-quinone oxidoreductase derived from Vibrio cholerae. This enzyme is suggested to undergo large conformational changes during the reaction cycle. By performing classification in single-particle analysis, we successfully captured a partial view of these conformational dynamics. The second example involves the angiotensin-converting enzyme 2 (ACE2) decoy, which binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and inhibits infection. Focusing on ACE2, which is critical for SARS-CoV-2 infection, an ACE2 decoy was developed to achieve higher binding affinity than the wild-type ACE2. We successfully elucidated how this ACE2 decoy binds to the spike protein.},
}
@article {pmid42387249,
year = {2026},
author = {Frischhut, M and Gamba, S and Magazzini, L and Pertile, P},
title = {The Price of National Pharmaceutical Pricing in the EU: A Proposal for "Common Procurement".},
journal = {Applied health economics and health policy},
volume = {},
number = {},
pages = {},
pmid = {42387249},
issn = {1179-1896},
abstract = {Within the European Union (EU), pricing and reimbursement decisions for new medicines are the responsibility of individual Member States. The presence of many regulated prices for medicines within the EU single market drives strategic decisions by payers and manufacturers, resulting, among other things, in launch delays and unequal patient access across European countries. To increase equity in patient access, we propose strengthening collaboration on medicines procurement among Member States beyond emergency situations. Joint initiatives undertaken by groups of countries have demonstrated their potential to deliver benefits, and the need for common procurement initiatives has become apparent during the coronavirus disease 2019 (COVID-19) pandemic. We present our proposal within the context of the current European regulatory framework and the recently proposed "Critical Medicines Act", emphasising the key legislative provisions that can be invoked to support a common procurement initiative. We also provide relevant, actionable options for designing such initiatives. Strong political commitment and agreement on equity and solidarity principles would be needed for the successful implementation of the proposal.},
}
@article {pmid42388294,
year = {2026},
author = {Arévalo-Guadalupe, GC and Gamboa-Tama, JE and Mederos-Mollineda, K and Peralta-Gamboa, DA},
title = {Digital epidemiology and public health surveillance: scientometric mapping of emerging technologies and challenges (2000-2025).},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1789164},
pmid = {42388294},
issn = {2673-253X},
abstract = {The rapid advancement of digital technologies has transformed traditional mechanisms of epidemiological surveillance and response, giving rise to an interdisciplinary field known as digital epidemiology. This study presents a scientometric mapping of the main trends, collaboration networks, and thematic foci linked to the use of emerging technologies-such as artificial intelligence, machine learning, big data, the Internet of Things (IoT), and social media mining-in global public health surveillance from 2000 to 2025. The methodology combines bibliometric and social network analysis on documents indexed in Scopus and Web of Science, complemented by a qualitative examination of the fifty most cited studies. The results reveal an exponential growth in scientific output starting from 2010, with an inflection point during the COVID-19 pandemic. The United States, the United Kingdom, and China stand out as the primary centers of production and international collaboration. However, significant gaps persist in digital equity, interoperability, and ethical governance, particularly in regions with lower technological infrastructure. This work contributes to understanding the evolution and challenges of digital epidemiology, proposing a future research agenda centered on algorithmic ethics, transparency, international cooperation, and technological inclusion in vulnerable contexts.},
}
@article {pmid42388544,
year = {2026},
author = {Simon, AK and Bhatt, S and Thakkar, VP and Sajjanshetty, M and Bano, S and Maheswaran, T and Sivaguru, K},
title = {A Narrative Review of Teledentistry in the AI Era: Scope, Opportunities, and Future Prospects in India.},
journal = {Cureus},
volume = {18},
number = {5},
pages = {e110008},
pmid = {42388544},
issn = {2168-8184},
abstract = {Teledentistry has evolved from pilot programs and COVID-19 adaptations into a clinically validated component of modern oral healthcare. In India, where access to dental care remains severely limited in rural populations, the convergence of teledentistry with artificial intelligence (AI) offers an urgent opportunity to reduce the burden of oral diseases. This narrative review examines the modalities and clinical evidence for teledentistry; awareness profiles and adoption barriers among Indian dental professionals and students; the diagnostic capabilities and readiness landscape for AI in dentistry; and the prospects, challenges, and implementation frameworks for AI-teledentistry integration in India. Evidence supports the diagnostic validity of synchronous and asynchronous teledental platforms for caries screening, oral lesion triage, and community surveillance. AI tools, including convolutional neural networks, large language models, and AI-generated educational content, enhance diagnostic accuracy, patient education, and resource optimization. However, formal training deficits, rural infrastructure gaps, limited oral health digital initiatives, and the absence of national regulatory frameworks remain critical barriers. A coordinated policy response that integrates AI into the dental curriculum and is supported by equity-centered implementation research is required.},
}
@article {pmid42388548,
year = {2026},
author = {Koul, PA and Vora, A and Tiwaskar, M and Bhargava, R and Dhar, R and Ramasubramanian, VR and Kher, V and Nangia, V and Jha, V and Dutta, T and Mahajan, M},
title = {Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India.},
journal = {Cureus},
volume = {18},
number = {5},
pages = {e110007},
pmid = {42388548},
issn = {2168-8184},
abstract = {India's immunization program focuses predominantly on children, leaving adults vulnerable to vaccine-preventable diseases (VPDs). The COVID-19 pandemic further disrupted routine vaccination. A life course approach (LCA) is needed to address these gaps. However, implementation of adult vaccination programs in low- and middle-income countries (LMICs) remains challenged by inequities in healthcare access, infrastructural limitations, and variable awareness regarding adult immunization. A 16-member expert panel from pulmonology, geriatrics, oncology, obstetrics, nephrology, diabetology, and life sciences reviewed literature (2014-2023) from MEDLINE, Scopus, and Cochrane databases. Using a structured, evidence-based grading approach, the panel formulated consensus recommendations for adult vaccination in India. The Life Course Vaccination Continuum (LCVAC) proposes three target groups: adults aged 18-59 years with comorbidities; elderly ≥60 years with or without comorbidities; and healthy adults aged 18-60 years. Key recommended vaccines include Tdap (every 10 years), influenza (annual), pneumococcal (PCV13/PPSV23 series), zoster (for ≥50 years), hepatitis B, meningococcal, and hepatitis A (risk-based). Major barriers identified include vaccine hesitancy, cost, access limitations, and inadequate provider prioritization. Life Course Vaccination Continuum provides the first comprehensive expert consensus on life course vaccination in India. The framework is intended to complement broader public health strengthening efforts, and its successful implementation will require vaccine awareness campaigns, healthcare professional education, equitable access strategies, and the establishment of dedicated adult vaccination centers nationwide.},
}
@article {pmid42388750,
year = {2026},
author = {Luo, X and Deng, JS and Chen, JN and Ye, T and Chen, SJ and Su, HL and Tung, TH and Zhu, JS},
title = {Bidirectional associations between influenza and COVID-19 vaccination: a systematic review and meta-analysis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1756985},
pmid = {42388750},
issn = {2296-2565},
mesh = {Humans ; *COVID-19 Vaccines/administration &amp; dosage ; *Influenza, Human/prevention &amp; control ; *Influenza Vaccines/administration &amp; dosage ; *Vaccination/statistics &amp; numerical data/psychology ; *COVID-19/prevention &amp; control ; *Patient Acceptance of Health Care/statistics &amp; numerical data ; },
abstract = {PURPOSE: This study aimed to investigate the effect of vaccination history on future willingness or behavior to receive vaccinations for influenza and COVID-19.<br><br>METHODS: In this systematic review and meta-analysis, the PubMed, Embase, Web of Science, Cochrane Library, APA PsycInfo, CINAHL and Scopus databases were searched up to February 28, 2026, to identify relevant studies in accordance with the inclusion and exclusion criteria. The analysis ultimately included 145 population-based studies conducted in the United States, China, Thailand, the United Arab Emirates, Egypt, and other countries.<br><br>RESULTS: Prior vaccination histories for influenza and COVID-19 interacted with each other and were associated with an increased willingness and likelihood to receive future vaccines. Specifically, having received the influenza vaccine was associated with an increased willingness to receive the COVID-19 vaccine(odds ratio [OR]&#x202f;=&#x202f;2.73, 95% confidence interval [CI]: 2.34-3.19, 95% prediction interval:[PI] 0.66-11.07), as well as with an increased likelihood of actually receiving the COVID-19 vaccine (OR&#x202f;=&#x202f;2.76, 95% CI: 2.32-3.29, 95%PI: 0.90-8.52). Receiving a COVID-19 vaccine was associated with an increased willingness to receive a influenza vaccine (OR&#x202f;=&#x202f;3.04, 95% CI: 1.25-7.39), and was also associated with an increased likelihood of actually receiving the influenza vaccine (OR&#x202f;=&#x202f;3.91, 95% CI: 2.45-6.24, 95%PI: 0.81-18.81).<br><br>CONCLUSION: In conclusion, prior vaccination history was associated with higher odds of future vaccination, and influenza and COVID-19 vaccination experiences influenced each other. Influenza and COVID-19 vaccine promotion strategies can likely be combined to increase overall vaccination rates.<br><br>PROSPERO identifier CRD42024594174.},
}
@article {pmid42389412,
year = {2026},
author = {El-Annan, RJ and Safi, D and Arabi, M},
title = {Point-of-care Cardiac Ultrasound in Coronavirus Disease 2019: Indications and Potentials.},
journal = {Journal of cardiovascular echography},
volume = {36},
number = {2},
pages = {101-110},
pmid = {42389412},
issn = {2211-4122},
abstract = {Coronavirus disease 2019 (COVID-19) strained health systems worldwide and underscored the need for rapid, safe, and efficient bedside imaging. This narrative review synthesizes forty studies, largely from the United States and Europe, on the role of point-of-care ultrasound (POCUS) in the care of patients with COVID-19, with emphasis on cardiology. Compared with full transthoracic echocardiography and computed tomography, POCUS is faster, less costly, and free of ionizing radiation. Several reports document a reduction in staff exposure time by up to seventy-one percent, lowering infection risk and conserving personal protective equipment. In critically ill patients, POCUS frequently identifies right ventricular dysfunction and pulmonary abnormalities, including vertical reverberation artifacts and subpleural consolidations, which support timely clinical decisions; some series observed management changes in as many as seventy percent of cases. Limitations include operator dependence, variable image quality, and a restricted field of view that can necessitate complementary imaging. Overall, POCUS shows strong promise as an integral element of COVID-19 pathways and routine cardiovascular care. Broader training, competency assessment, and standardized protocols are needed to ensure consistent, high-quality implementation at the bedside.},
}
@article {pmid42389926,
year = {2026},
author = {Öztürk, K and Haslak, F and Yıldız, M and Adrovic, A and Kasapçopur, &#xd6;},
title = {Nailfold Videocapillaroscopy in Pediatric Rheumatology: Established Roles, Emerging Applications, and Future Perspectives.},
journal = {Balkan medical journal},
volume = {43},
number = {7},
pages = {360-371},
pmid = {42389926},
issn = {2146-3131},
mesh = {Humans ; *Microscopic Angioscopy/methods/trends ; Child ; Raynaud Disease/diagnosis/physiopathology ; *Rheumatology/methods/trends/instrumentation ; *Nails/blood supply/physiopathology ; Scleroderma, Systemic/diagnosis/physiopathology ; *Pediatrics/methods/trends ; Capillaries/physiopathology ; },
abstract = {Nailfold videocapillaroscopy (NVC) provides direct, non-invasive access to the peripheral microcirculation and has become a central tool in adult rheumatology. Its primary clinical value lies in the evaluation of patients presenting with signs of Raynaud phenomenon (RP) and scleroderma-spectrum disorders. In particular, NVC facilitates the differentiation between primary and secondary (scleroderma-related) RP. The characteristic scleroderma pattern observed on NVC, including giant capillaries, capillary loss, microhemorrhages, and architectural disorganization, supports the diagnosis of scleroderma-spectrum disorders. International standardization efforts have further improved the reliability and interpretability of these findings, particularly in adult populations with RP and systemic sclerosis (SSc). In children, the clinical utility of NVC is now well established for similar indications; however, interpretation requires age-specific reference data. Pediatric capillary density, diameter, and length vary throughout childhood, and minor findings such as tortuosity, crossing, and isolated microhemorrhages may also be observed in healthy individuals. Without normative pediatric data, these features may be overinterpreted as pathological findings. Beyond RP and juvenile SSc, evidence supporting the use of NVC is accumulating across a range of pediatric rheumatic diseases. NVC abnormalities have been reported in juvenile dermatomyositis (JDM), mixed connective tissue disease, childhood-onset systemic lupus erythematosus, juvenile Sjögren disease, and juvenile localized scleroderma. Among these conditions, JDM demonstrates the strongest association between NVC abnormalities-including reduced capillary density, dilatation, abnormal morphology, and microhemorrhages-and disease activity. In contrast, findings in juvenile idiopathic arthritis remain non-specific. More recent studies involving pediatric patients with Behçet disease, psoriatic arthritis, and certain autoinflammatory and vasculitic disorders suggest that NVC may detect subtle microvascular alterations; however, disease-specific patterns have not been established outside the scleroderma spectrum. Selected non-rheumatologic conditions, particularly diabetes mellitus, severe acute respiratory syndrome coronavirus 2 infection, multisystem inflammatory syndrome in children, and long coronavirus disease, further highlight the potential of NVC to reflect systemic endothelial dysfunction and non-specific microvascular injury, although these applications remain exploratory. Despite its promise, several limitations continue to restrict the broader clinical application of NVC. Pediatric reference data remain heterogeneous, scoring systems are largely adapted from adult protocols, and longitudinal evidence linking capillaroscopic changes to disease progression, treatment response, or long-term outcomes remains limited. Standardized image acquisition and reporting, multicenter cohort studies, and validation of automated image-analysis techniques are essential next steps for translating descriptive observations into clinically actionable information. This review summarizes the contribution of NVC to pediatric rheumatology and explores potential areas for future expansion. The strongest indications remain RP and scleroderma-spectrum disorders, whereas the most promising emerging application is in JDM, where microvascular changes correlate with disease activity. Across other pediatric rheumatic diseases, NVC currently serves as a complementary descriptive tool for vascular phenotyping rather than a standalone diagnostic modality. With the development of age-specific reference standards, harmonized protocols, and longitudinal validation studies, NVC has the potential to evolve from a descriptive imaging technique into an integral component of risk stratification and disease monitoring in pediatric rheumatology.},
}
@article {pmid42390108,
year = {2026},
author = {Marie, SE},
title = {Examining the state of telehealth for mental health and substance use care after the coronavirus disease 2019 pandemic: An integrative review.},
journal = {The Journal of international medical research},
volume = {54},
number = {7},
pages = {3000605261459841},
pmid = {42390108},
issn = {1473-2300},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Substance-Related Disorders/therapy/psychology ; *Telemedicine ; *Mental Disorders/therapy/psychology ; Pandemics ; SARS-CoV-2 ; Mental Health ; Mental Health Teletherapy ; Health Services Accessibility ; Mental Health Services ; Patient Satisfaction ; Digital Health ; },
abstract = {ObjectiveThe objective of this integrative review was to synthesize literature and provide implications for clinical practice on telehealth use among patients with serious mental illness and substance use disorders following the coronavirus disease 2019 pandemic.MethodsAn integrative review guided by Socio-Technical Systems Theory was applied. The PubMed, Cumulative Index to Nursing and Allied Health Literature, PsycINFO, Medline, Academic Search Complete, and Gale Health and Wellness databases were searched for publications from 1 January 2019 to 1 December 2024. Articles selected according to the established inclusion and exclusion criteria were evaluated using a rapid critical appraisal checklist developed by Fineout-Overholt and Melnyk.ResultsAmong the 172 articles reviewed, 16 peer-reviewed and 2 government publications were included. Four themes were identified: (a) treatment adherence; (b) satisfaction reported by patients and providers; (c) telehealth policy developments; and (d) access to services. Telehealth supported continuity of care, improved satisfaction, and improved access. Technological and financial barriers restricted equitable access. Policy changes enabled broader adoption; however, regulatory approaches varied across jurisdictions.ConclusionTelehealth remains an integral method for delivering mental health and substance use care following the coronavirus disease 2019 pandemic. Greater focus is needed on long-term effectiveness and limitations of telehealth.},
}
@article {pmid42390310,
year = {2026},
author = {Bidhendi-Yarandi, R and Nosrati Nejad, F and Biglarian, A and Roshnfekr, P and Behboudi-Gandevani, S},
title = {Global prevalence of domestic violence against adults during COVID-19 and its determinants: A systematic review, meta-analysis, and meta-regression analysis.},
journal = {Women's health (London, England)},
volume = {22},
number = {},
pages = {17455057261465474},
pmid = {42390310},
issn = {1745-5065},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; Prevalence ; *Domestic Violence/statistics &amp; numerical data ; Female ; Adult ; Global Health/statistics &amp; numerical data ; SARS-CoV-2 ; Regression Analysis ; Male ; },
abstract = {BackgroundDomestic violence (DV) is a pressing public health issue with worldwide implications. Crises like the COVID-19 pandemic can exacerbate this problem, as social and personal challenges intersect with the disruptive effects of health measures.ObjectiveThis study aimed to determine the prevalence of DV during the COVID-19 pandemic and identify its associated determinants.DesignSystematic review and meta-analysis.Data sources and methodsA comprehensive review of the literature in PubMed/Medline, EMBASE, PsycINFO and Cochrane Covid-19 register up to July 2024 were conducted. Pooled prevalence of DV during COVID-19, including overall and subtype prevalence were assessed, while also extracting associated factors and determinants. Meta-regression analyzed the impact of determinants on heterogeneity. A random effects model estimated the pooled prevalence using the meta-prop method, applying Freeman-Tukey double arcsine transformation for variance stabilization.ResultsA total of 37 qualifying studies were included in our final analysis with a total sample size of 160,701 individuals. The overall pooled prevalence of DV, regardless of subtypes, was 13% (95% CI: 12-14%). Among the different subtypes, psychological violence had the highest pooled prevalence of 24% (95% CI: 19-28%), while financial violence had the lowest pooled prevalence of 7% (95% CI: 6-9%). Sexual violence (11%, 95% CI: 9-12%), physical violence (10%, 95% CI: 9-12%), and violence involving threats and controlling behaviors 11% (95% CI: 8-13%) had approximately similar prevalence rates. Meta-regression analyses showed the risk of overall DV was significantly higher among younger women Risk Difference (RD) =15% (P<0.001), 40 years and younger individuals RD=12% (P<0.001), and those living in developing countries RD=14% (P<0.001) compared to their counterparts. On average, women had a higher risk of overall DV than the elderly and men RD=9% (P<0.001).ConclusionThe study revealed a concerning global prevalence of DV at 13% during the COVID-19 pandemic, with psychological violence being the most common subtype. Women and young adults were identified as particularly vulnerable, with risk differentials of 15% and 12%, respectively, notably higher in developing countries (14%). This comprehensive assessment of DV prevalence and determinants offers valuable insights for future research and public health strategies.RegistrationPROSPERO CRD42022351634.},
}
@article {pmid42391723,
year = {2026},
author = {Husein, A and Jamal, A and Ali, R and Kamal, MA and Alqurashi, YE and Nasim, A and Hussain, SA and Hattiwale, HM},
title = {Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications.},
journal = {Pathology, research and practice},
volume = {286},
number = {},
pages = {156609},
doi = {10.1016/j.prp.2026.156609},
pmid = {42391723},
issn = {1618-0631},
abstract = {Ras signalling is an important regulator of cell proliferation, survival, differentiation, and immune responses. Although Ras pathways have been extensively studied in cancer biology, increasing evidence suggests that many pathogens also manipulate Ras-associated signalling networks to support infection, persistence, and immune evasion. Viruses, bacteria, and parasites can alter Ras activity either directly or indirectly through downstream pathways such as MAPK/ERK and PI3K/AKT. However, activation of ERK or AKT does not always indicate direct Ras involvement, and this distinction remains important in infectious disease research. Recent studies show that pathogens including SARS-CoV-2, Epstein-Barr virus, hepatitis B virus, Helicobacter pylori, Pseudomonas aeruginosa, Mycobacterium tuberculosis, and Leishmania species regulate Ras-associated signalling in ways that contribute not only to pathogen survival but also to inflammation, tissue injury, and disease progression. In several infections, isoform-specific regulation of H-Ras, K-Ras, and N-Ras has also been observed, suggesting distinct roles in immune modulation and pathological outcomes. Dysregulated Ras-associated signalling has been linked to lung injury, liver fibrosis, gastric epithelial damage, granuloma formation, and systemic dissemination of infection. This review summarizes current evidence on the role of Ras signalling in infectious disease pathology, focusing on host-pathogen interactions, isoform-specific regulation, tissue damage, and therapeutic implications. Although Ras signalling represents a promising host-directed target, much of the current evidence remains indirect and requires further pathogen-specific validation.},
}
@article {pmid42391726,
year = {2026},
author = {Kaplan, G},
title = {Therapeutic plasma exchange and immunomodulatory strategies in post-infectious syndromes: A review of immune dysregulation in PTLDS, long COVID, ME/CFS, and PANS/PANDAS.},
journal = {Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis},
volume = {65},
number = {4},
pages = {104482},
doi = {10.1016/j.transci.2026.104482},
pmid = {42391726},
issn = {1473-0502},
mesh = {Humans ; *COVID-19/therapy/immunology/complications ; *Plasma Exchange/methods ; *Fatigue Syndrome, Chronic/therapy/immunology ; Post-Acute COVID-19 Syndrome ; *Post-Lyme Disease Syndrome/therapy/immunology ; *Streptococcal Infections/therapy/immunology ; *Autoimmune Diseases of the Nervous System/therapy/immunology ; *Autoimmune Diseases/therapy/immunology ; Post-Infectious Disorders ; Child ; Obsessive-Compulsive Disorder ; },
abstract = {Post-infectious syndromes including post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and pediatric acute-onset neuropsychiatric syndrome (PANS)/pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) share overlapping clinical phenotypes characterized by fatigue, cognitive dysfunction, sleep disturbance, and neuropsychiatric symptoms. Increasing evidence suggests that immune dysregulation-including persistent inflammation, autoantibody production, and cellular immune dysfunction-may underlie these conditions. This narrative review synthesizes peer-reviewed literature describing immune abnormalities across these syndromes and evaluates the rationale for immunomodulatory therapies, including intravenous immunoglobulin (IVIG), rituximab, and therapeutic plasma exchange (TPE). Evidence supporting immune-targeted treatment strategies is strongest in subsets of patients with identifiable immunologic abnormalities. Notably, the phase III RituxME trial in ME/CFS and a phase II trial of TPE in post-COVID condition both failed to demonstrate efficacy in unselected populations, reinforcing the importance of biomarker-guided patient stratification. TPE functions by removing circulating immune complexes, autoantibodies, and inflammatory mediators, and observational data suggest benefit in patients with demonstrable autoantibody burden. Further controlled studies incorporating immunologic phenotyping and early intervention are needed to define the therapeutic role of immune-directed interventions across these conditions.},
}
@article {pmid42392062,
year = {2026},
author = {Leichtle, A and Bruchhage, KL and Hoffmann, TK and Leffers, D},
title = {[Otitis media - update on clinical presentation, diagnosis and therapy].},
journal = {Laryngo- rhino- otologie},
volume = {105},
number = {7},
pages = {450-460},
doi = {10.1055/a-2606-8101},
pmid = {42392062},
issn = {1438-8685},
mesh = {Humans ; *Otitis Media/diagnosis/therapy/epidemiology/etiology ; Risk Factors ; COVID-19/epidemiology ; Chronic Disease ; Acute Disease ; },
abstract = {Otitis media is a complex disease. The pathogenesis of both acute and chronic otitis media results from a complex interplay of anatomical, microbiological, and immunological factors. Identified risk factors include patient-related aspects such as nutrition, allergies, ethnicity, and genetic predisposition, as well as environmental factors such as socioeconomic status, tobacco use, attendance at daycare centers and recurrent respiratory infections. During the COVID-19 pandemic, strict measures led to a significant decline in the incidence of acute otitis media. However, infections with variants such as Omicron showed an increased rate of secretory otitis media. In the post-COVID phase, complication rates due to middle ear infections rose again, with prevalence returning to pre-lockdown levels. Preventive measures focus on ensuring adequate Eustachian tube function, treating allergies, and consistently administering pneumococcal vaccinations. In contrast, surgical treatment remains the gold standard for chronic middle ear infections and cholesteatoma. However, radical removal can be associated with high morbidity rates, underscoring the need for innovative approaches. These include optical coherence tomography (OCT) and minimally invasive laser surgery. Furthermore, new insights into the role of the immune system in the pathogenesis of both acute and chronic otitis media could open up new therapeutic possibilities for the future. This article discusses the current state of knowledge on the pathophysiological mechanisms, classification, diagnosis, and treatment of otitis media, as well as new treatment models and their implications.},
}
@article {pmid42392626,
year = {2026},
author = {Beulen, V and Noben, C and Smits, M and Mertens, H and Paulus, A and Van Mook, W},
title = {Workforce shortages and supported access to medical care for hospital employees: a scoping review.},
journal = {BMJ open},
volume = {16},
number = {7},
pages = {e117423},
pmid = {42392626},
issn = {2044-6055},
mesh = {Humans ; *Health Services Accessibility ; COVID-19 ; SARS-CoV-2 ; *Personnel, Hospital ; Pandemics ; },
abstract = {OBJECTIVES: This scoping review synthesises peer-reviewed and grey literature on supported access to medical care for hospital employees with existing physical health complaints to understand how it may reduce sickness absenteeism by promoting sustainable employability and to identify gaps and opportunities to inform the design and implementation of organisational supported care frameworks.<br><br>DESIGN: We conducted this scoping review following the Arksey and O'Malley framework and Levac et al's methodological recommendations, reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extensions for Scoping Reviews (PRISMA-ScR).<br><br>DATA SOURCES: MEDLINE (Ovid), Embase (Elsevier), CINAHL (EBSCO) and Web of Science were searched from database inception to 8 November 2024. The search was updated on 18 May 2026. This was supplemented by forward and backward citation tracking of included peer-reviewed articles and targeted hand searching of Dutch grey literature in Medisch Contact , a leading Dutch professional journal for the medical profession, focusing on clinical practice, medical policy and professional issues.<br><br>ELIGIBILITY: English-language or Dutch-language peer-reviewed publications and well-argued opinion pieces on healthcare workers' access to care (COVID-19 and beyond) in hospital or transferable settings were included. Sources focused on mental health or health promotion, financial aspects, personal protective equipment, patient access or healthcare worker utilisation, as well as non-English/Dutch sources, webpages and papers without full text, were excluded.<br><br>DATA EXTRACTION: ASReview was used for title and abstract screening following the SAFE procedure and full-text screening was conducted with team consensus.<br><br>RESULTS: 27 publications were included from 36&#x2009;685 identified records. The literature was predominantly qualitative in nature and COVID-19-focused, yielding four themes (ethical considerations, multilevel challenges, target groups and strategies and outcomes). It also highlighted limited evidence on evaluated supported-access interventions and workforce outcomes beyond crises.<br><br>CONCLUSIONS: Although supported access to medical care for hospital employees appears a promising multilevel, system-embedded strategy to reduce sickness absenteeism and promote sustainable employability in general, the evidence to substantiate and justify such strategies beyond acute crises is limited. Moreover, current literature lacks clear conceptualisation, operationalisation as well as robust implementation and evaluation frameworks. Addressing these gaps is a priority for future research to scientifically scaffold policies and frameworks to sustain a healthy and stable future hospital workforce.},
}
@article {pmid42392788,
year = {2026},
author = {Yan, X and Tang, X and Zhang, YZ and Liu, YY and Liu, Y and Pang, WT and Yang, FW and Jin, XY},
title = {[Status analysis of clinical outcome for treatment of long COVID with traditional Chinese and western medicines].},
journal = {Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica},
volume = {51},
number = {7},
pages = {2081-2091},
doi = {10.19540/j.cnki.cjcmm.20251125.501},
pmid = {42392788},
issn = {1001-5302},
mesh = {Humans ; COVID-19 ; *Drugs, Chinese Herbal/therapeutic use ; *Medicine, Chinese Traditional ; Pandemics ; *Post-Acute COVID-19 Syndrome/drug therapy ; SARS-CoV-2/physiology/drug effects ; Treatment Outcome ; },
abstract = {This study sorted out the clinical outcome of traditional Chinese and western medicines in the treatment of long COVID to lay the foundation for the construction of a core indicator set. Search was made on some databases and platforms from their inception to December 2024, which included eight databases of CNKI, Wanfang, SinoMed, VIP, PubMed, Cochrane Library, EMbase, and Web of Science and three clinical research protocol registration platforms, namely the Chinese Clinical Trial Registry(ChiCTR), the International Traditional Medicine Clinical Trial Registry(ITMCTR), and the American Clinical Trial Registry(ClinicalTrials.gov). Two researchers independently extracted the basic information, outcomes, measurement time points, and measurement tools of literature in parallel according to the inclusion and exclusion standards. If there are any differences, a third researcher would make discussions and decisions. A total of 152 studies, including 50 literature studies and 102 protocol studies, were ultimately included. A total of 338 outcomes indicators were reported, with a reporting frequency of 1 633 times. Outcome indicators can be classified into 10 indicator domains based on attributes, including symptoms and signs(694 times, 42.50%), TCM diseases(61 times, 3.74%), security incidents(93 times, 5.70%), etiological detection(23 times, 1.41%), long-term prognosis(72 times, 4.41%), economic indicators(14 times, 0.86%), physical and chemical testing(472 times, 28.90%), quality of life(173 times, 10.59%), major events(16 times, 0.97%), and other indicators(15 times, 0.92%). There were problems in the outcomes indicators of treating long COVID with both traditional Chinese and western medicines, such as significant differences in symptom descriptions, lack of standardization in indicator selection, diverse choices of measurement tools, diverse selection of measurement time, lack of practicality in clinical practice, and non-prominent TCM indicators. These issues led to scattered evidence and the absence of a unified core indicator set to guide clinical research. Further efforts are needed to develop COS of integrated traditional Chinese and western medicine treatments for long COVID, and to enhance the quality of clinical research on long COVID.},
}
@article {pmid42393625,
year = {2026},
author = {Shrivastav, VN and Akurathi, HK and Kalariya, H and Savaj, D},
title = {Anemia burden in tuberculosis patients across Southeast Asia: a systematic review and meta-analysis.},
journal = {BMC pulmonary medicine},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12890-026-04404-x},
pmid = {42393625},
issn = {1471-2466},
abstract = {BACKGROUND: Anemia represents a significant comorbidity in tuberculosis (TB) patients, affecting treatment outcomes and mortality. Despite Southeast Asia accounting for 46% of global TB cases, no comprehensive regional synthesis of anemia burden exists, limiting evidence-based policy development.<br><br>OBJECTIVES: This systematic review and meta-analysis aimed to estimate the pooled prevalence of anemia among tuberculosis patients across Southeast Asia and to examine variations in prevalence by geographic, demographic, and clinical characteristics.<br><br>METHODS: We searched PubMed, Embase, Scopus, and Web of Science for observational studies published from 2000 onwards that reported anemia prevalence in drug-susceptible TB patients from Southeast Asian countries. Random-effects meta-analysis was performed to calculate pooled prevalence estimates with 95% confidence intervals. Subgroup analyses were conducted by country, HIV co-infection status, treatment status, study setting, COVID-19 period, and World Bank income classification. Publication bias was assessed using Egger's and Begg's tests.<br><br>RESULTS: Twenty-one studies comprising 6,090&#xa0;TB patients from five Southeast Asian countries were included. The pooled prevalence of anemia was 72% (95% CI: 68%-76%), with substantial heterogeneity (I&#xb2;=89.9%). These regional prevalence estimates are higher than the global pooled estimate of 53.9% reported by Barzegari et al. (2019), reflecting the distinct epidemiological context of Southeast Asia. Subgroup analysis revealed significantly higher prevalence in HIV-positive patients (88%, 95% CI: 78%-94%) compared to HIV-negative patients (70%, 95% CI: 65%-74%). Studies conducted during COVID-19 showed elevated prevalence (84%, 95% CI: 75%-90%) compared to pre-COVID (72%, 95% CI: 70%-73%) and post-COVID periods (72%, 95% CI: 68%-83%, p&#x2009;=&#x2009;0.03). Lower-middle income countries showed higher prevalence (73%, 95% CI: 69%-77%) than upper-middle income countries (67%, 95% CI: 63%-70%). No significant publication bias was detected (Egger's p&#x2009;=&#x2009;0.721, Begg's p&#x2009;=&#x2009;0.537).<br><br>CONCLUSIONS: This first regional synthesis demonstrates that anemia affects three-quarters of TB patients in Southeast Asia, with significant variation by HIV status, income level, and pandemic period. Unlike previous global estimates (53.9%), our region-specific findings (72%) and documentation of COVID-19 impact (84% during pandemic) provide actionable evidence for Southeast Asian TB programs to integrate anemia screening and management, particularly for vulnerable populations during health system disruptions.},
}
@article {pmid42393859,
year = {2026},
author = {Wickramarathna, EAAM},
title = {Student-authored expressions of gratitude as an alternative approach to ceremonial body donor commemoration: An experience from a New Sri Lankan Medical Faculty.},
journal = {Anatomical sciences education},
volume = {},
number = {},
pages = {},
doi = {10.1002/ase.70298},
pmid = {42393859},
issn = {1935-9780},
abstract = {The sustainability of body donation programs is contingent not only on cultural and religious frameworks that motivate altruistic giving, but also on the institutional practices that honor donors and maintain public trust. In Sri Lanka, Theravada Buddhist principles of dana (generosity) and karuna (compassion) underpin a well-established culture of body donation. The formal memorial ceremonies have served as the conventional expression of institutional gratitude to body donors. The Faculty of Medicine (FOM) at Wayamba University of Sri Lanka (WUSL), however, faced successive and compounding adversities following its inaugural student intake in 2018-including the Easter Sunday terrorist attack (2019), the COVID-19 pandemic (2020-2022), and a national economic crisis (2022-2023)-that rendered formal ceremonial commemoration logistically and practically unfeasible. In response, the corresponding author implemented an alternative commemorative practice in which medical students authored gratitude notes, poems, and artistic tributes addressed to body donors. This discursive article describes that initiative, situates it within the pluralistic society of Sri Lanka, and examines its implications for humanistic medical education. Drawing on the established literature on reflective writing, professional identity formation, and inclusive commemorative practice, student-authored expressions of gratitude are proposed as a pedagogically meaningful, complementary, and mutually reinforcing practice alongside formal ceremony. This experience offers a transferable model for newly established or resource-limited medical institutions navigating institutional constraints while remaining committed to the body donor commemoration.},
}
@article {pmid42393869,
year = {2026},
author = {Marne, O and Jacob Machado, D},
title = {Advancing FAIR phylogenetics for health threats: a systematic review of SARS-CoV-2 research and guidelines for future outbreaks.},
journal = {Cladistics : the international journal of the Willi Hennig Society},
volume = {},
number = {},
pages = {},
doi = {10.1111/cla.70050},
pmid = {42393869},
issn = {1096-0031},
abstract = {During the COVID-19 pandemic, the need for quick public health action often conflicted with the careful methods required in phylogenetics. To explore this, we reviewed 217 SARS-CoV-2 studies published from January 2020 to March 2025 in 121 journals. We found many methodological problems that weaken the reliability and reproducibility of these studies. Key issues include missing outgroup sampling, which affects ingroup topology, tree rooting and how we interpret evolutionary changes and relationships. Another issue is the lack of gene annotations, which can cause characters from one gene to align with those of a different gene. Many studies also misinterpret support or other branch statistics, treating them as proof of clade accuracy instead of as measures of relative evidence. In addition, 91% of the studies do not follow FAIR (Findable, Accessible, Interoperable, and Reusable) data principles, with data and code often unavailable. Finally, we also found a "prestige paradox": journals with higher impact factors do not necessarily have better methods or transparency. Therefore, we offer simple guidelines for authors, reviewers and editors to improve transparency and FAIR data standards in viral phylogenetics, making writing and reviewing papers easier, ensuring published phylogenetic analyses remain a trustworthy resource for future pandemics.},
}
@article {pmid42393993,
year = {2026},
author = {Ito, E and Harris, L and Gold, S and Archer, A},
title = {AI-Enabled Public Health Surveillance: Interim Findings from a Scoping Review of Governance and Implementation Frameworks.},
journal = {Studies in health technology and informatics},
volume = {338},
number = {},
pages = {211-212},
doi = {10.3233/SHTI260831},
pmid = {42393993},
issn = {1879-8365},
mesh = {Humans ; *Artificial Intelligence ; *COVID-19/epidemiology ; *Public Health Surveillance/methods ; SARS-CoV-2 ; },
abstract = {Artificial intelligence (AI)-enabled public health surveillance systems have expanded rapidly following the COVID-19 pandemic, yet governance and implementation structures guiding their deployment remain inconsistently defined. We conducted a scoping review following PRISMA-ScR guidelines to examine governance and regulatory frameworks associated with AI-enabled surveillance systems. A search of three databases yielded 707 unique records after deduplication. Preliminary findings indicate a predominance of centralized governance models and limited explicit articulation of equity safeguards or public oversight mechanisms. Results will provide a typology of centralized, federated, and hybrid governance models characterized by authorization structure, data governance architecture, oversight mechanisms, and equity safeguards, to inform the design of accountable AI surveillance systems.},
}
@article {pmid42395315,
year = {2026},
author = {Turebekova, D and Kosherova, B and Dauletkaliyeva, Z and Shayakhmetova, Y and Marchenko, A and Solyanov, D and Hendrixson, V and Kadyrova, I},
title = {Long COVID and health-related quality of life: a systematic review of immune, inflammatory, and metabolic markers.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1846407},
pmid = {42395315},
issn = {2296-2565},
mesh = {Humans ; *Quality of Life ; Biomarkers/blood ; *COVID-19/immunology ; *Inflammation/immunology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: Long COVID is known to be associated with prolonged multiple organ symptoms and decreased health-related quality of life (HRQoL), but the pathogenesis and relationship between immune, inflammatory, and metabolic biomarkers and HRQoL remains poorly understood. This systematic review aims to synthesize the evidence on the health-related quality of life of patients with Long COVID and to summarize the reported associations between health-related outcomes and biomarkers.<br><br>METHODS: We conducted a systematic search in PubMed, Web of Science, and Scopus in search of studies that evaluated immune, inflammatory, or metabolic biomarkers and HRQoL in patients with Long COVID. This review included case-control and cohort studies with a control group. The Rayyan tool was used to select studies, and full-text articles were evaluated for compliance with the criteria. Information was obtained on biomarkers, analytical methods, tools for assessing the HRQoL, and the relationship between HRQoL and biomarkers. Due to the high heterogeneity of the methods, the results were summarized in a descriptive form.<br><br>RESULTS: Ten studies were included, involving 1,078 patients with Long COVID and 768 healthy controls. Most studies that used various methods to assess HRQoL consistently reported long-term deterioration after COVID, with the greatest deterioration observed in the areas of physical functioning, vitality, fatigue, daily activities, pain, discomfort, and respiratory distress. The most frequently measured markers were related to inflammation and endothelial/coagulation pathways, including CRP, hsCRP, IL-6, TNF-&#x3b1;, D-dimer, and VCAM-1. Autoimmune, metabolic, intestinal barrier, and omics-based markers were measured less frequently, but indicated phenotype-specific biological heterogeneity. Only a few studies have identified a direct link between biomarkers and HRQoL. Lower HRQoL indicators were associated with increased neurotoxicity, decreased calcium levels, systemic inflammation, endothelial dysfunction, and signals from individual autoantibodies.<br><br>CONCLUSION: Our results indicate that Long COVID is consistently associated with a long-term decline in HRQoL, especially in the physical and functional areas. The available data indicate the presence of a strong signal regarding inflammatory processes and endothelial coagulation, while autoimmune, metabolic, and genetic data indicate phenotype-specific heterogeneity.<br><br>Unique identifier: CRD420251239371, URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251239371.},
}
@article {pmid42396427,
year = {2026},
author = {Grover, S and Vaishya, R and Gupta, BM and Mahapatra, N and Chaman, SM and Madhu, S},
title = {A bibliometric assessment of the Indian Journal of Psychiatry: Trends, impact, and collaboration (2009-2024).},
journal = {Indian journal of psychiatry},
volume = {68},
number = {6},
pages = {510-516},
pmid = {42396427},
issn = {0019-5545},
abstract = {BACKGROUND: The Indian Journal of Psychiatry (IJP) serves as a premier repository for psychiatric research in India.<br><br>AIM: This study conducts a comprehensive bibliometric analysis to evaluate the journal's publication trends and citation impact from 2009 to 2024.<br><br>METHODS: Bibliographic data were retrieved from the Scopus database, covering the period from January 2009 to December 2024. A final dataset of 2,357 publications was analyzed for this paper.<br><br>RESULTS: The journal experienced robust growth, registering an average annual publication growth rate of 9.16% over the 16 years. The journal's Impact Factor rose significantly from 0.384 in 2010 to a peak of 3.1 in 2022. Authors from India contributed 88.63% of the total output, anchored by institutions such as the National Institute of Mental Health and Neuro Sciences, Bangalore, and the Post Graduate Institute of Medical Education and Research, Chandigarh, although international contributions from countries like Switzerland (Citation per paper [CPP]: 22.36), Germany (CPP: 17.68), Canada (CPP: 17.68), and Italy (CPP: 17.63) demonstrated a higher citation efficiency compared to those from India (11.6). The authorship pattern revealed a definitive shift from single-author (reduced from 28.65% to 9.9%) to collaborative, multiauthor research. Thematically, research concentrated on core areas such as depression and schizophrenia, while displaying responsiveness to emerging crises like the COVID-19 pandemic.<br><br>CONCLUSION: The IJP has consistently demonstrated a trajectory of upward influence and academic reputation over the past 16 years. While the journal serves as a vibrant ecosystem for domestic research, future strategies should focus on leveraging international collaborations to enhance global visibility and citation impact further.},
}
@article {pmid42396674,
year = {2026},
author = {Charlton, KE and Pickles, SC and Kent, K},
title = {Redistributing power in food systems: how community-led responses move from crisis buffering to systems transformation.},
journal = {The Proceedings of the Nutrition Society},
volume = {},
number = {},
pages = {1-14},
doi = {10.1017/S0029665126105059},
pmid = {42396674},
issn = {1475-2719},
abstract = {Food and nutrition insecurity in high‑income countries is increasingly persistent, driven by intersecting economic, social and environmental disruptions. In Australia, acute shocks such as the COVID‑19 pandemic, floods and bushfires, alongside chronic pressures including rising food prices, housing stress and concentrated corporate power, have exposed structural weaknesses in food access, governance and system resilience. This review examines how community‑led responses to food and nutrition insecurity function during disruption, whether they buffer short-term hardship or contribute to adaptive capacity and redistribution of agency. Guided by the six‑pillar food security framework and a socio-ecological model, responses are examined across household, community, organisational and governance levels. A continuum of responses is identified, ranging from downstream emergency food relief that buffers immediate hardship through to community and organisational food infrastructure that strengthens local resilience and governance‑level responses with greater transformative potential. Drawing on this synthesis, we propose the SEEDS (Socio-Ecological Enablers of Dietary Security) Model, which conceptualises how food system responses across socio-ecological levels and over time can progress from buffering (acute) to adaptation (medium‑term) and ultimately transformation (long‑term). Central to this framework is a shift in decision‑making power, accountability and participation. While many initiatives improve food access and short‑term stability during crises, the greatest potential for transformation lies where responses are embedded within governance structures, enable meaningful community participation and influence policy, procurement and resource allocation. Implications for public health nutrition practice include expanded roles in systems leadership, cross‑sector governance and advocacy for upstream policy reform.},
}
@article {pmid42396845,
year = {2026},
author = {Sagar, K and Mukherjee, D and Savareh, BA and Talibouya Toure, C and Ceruti, A and Ghosh, P and Weidmann, M and Truyen, U and Abd El Wahed, A and Kobialka, RM},
title = {Artificial intelligence in molecular diagnostics for pandemic preparedness.},
journal = {Expert review of molecular diagnostics},
volume = {26},
number = {8},
pages = {709-718},
doi = {10.1080/14737159.2026.2697900},
pmid = {42396845},
issn = {1744-8352},
mesh = {Humans ; *Artificial Intelligence ; *Molecular Diagnostic Techniques/methods ; Pandemic Preparedness ; *COVID-19/diagnosis/epidemiology/virology ; SARS-CoV-2/genetics ; *Pathology, Molecular/methods ; Pandemics ; },
abstract = {INTRODUCTION: Molecular diagnostics focusing on the detection and analysis of nucleic acids are indispensable tools for early pathogen identification, transmission monitoring, and genomic surveillance during pandemics. Recent technological advances have broadened the diagnostic landscape, incorporating PCR-based methods, isothermal amplification, high-CRISPR-based amplification detection, and sequencing. Despite their diagnostic potential, widespread implementation remains limited by high validation costs, time and logistical constraints, the need for specialized professional knowledge, and a lack of adaptability in resource-limited settings. Artificial intelligence (AI) is increasingly recognized as a promising but challenging approach, offering tools that streamline assay development, automate data interpretation, and optimize real-time diagnostic performance.<br><br>AREAS COVERED: This review introduces recently published AI tools with potential to enhance the in-silico design validation process of oligonucleotides for molecular assays. These cover tools for initial assay design and optimization to validation and continuous assay updates. The limitations, including concerns regarding data accuracy, the lack of transparency in data processing ('black box' models), and unresolved licensing and regulatory issues, are highlighted for each tool and as expert opinion.<br><br>EXPERT OPINION: Collectively, these challenges currently confine most AI-based approaches to research settings and prevent their routine implementation in clinical molecular diagnostics. Their widespread adoption depends on addressing remaining technical, regulatory, and practical challenges.},
}
@article {pmid42398834,
year = {2026},
author = {Zhou, J and Li, N and Liu, R and Kabanov, AV and Polacheck, WJ and Nguyen, J and Cao, Y},
title = {New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.},
journal = {Journal of controlled release : official journal of the Controlled Release Society},
volume = {397},
number = {},
pages = {115157},
pmid = {42398834},
issn = {1873-4995},
support = {R35 GM142944/GM/NIGMS NIH HHS/United States ; },
abstract = {Messenger RNA-lipid nanoparticle (mRNA-LNP) therapeutics have emerged as a versatile drug modality, enabling in vivo protein expression for vaccines, cancer immunotherapy, and the treatment of genetic and metabolic diseases. Although mRNA-LNP platforms achieved rapid clinical success during the COVID-19 pandemic, most candidates fail to progress beyond preclinical development, largely due to the limited capacity of conventional animal models to predict human-relevant efficacy, safety, inflammation, biodistribution, and population heterogeneity. New approach methodologies (NAMs), encompassing advanced in vitro and ex vivo human systems and in silico computational models, offer a promising strategy to address these translational gaps while reducing reliance on animal testing. In this review, we evaluate commonly used animal models for mRNA-LNP development and highlight key areas where animal findings have shown poor concordance with human clinical outcomes. We then provide a comprehensive overview of emerging NAM technologies, including in vitro and ex vivo-based platforms such as two-dimensional and three-dimensional cell culture systems and microphysiological platforms; as well as in silico tools, including physiologically based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP), and artificial intelligence (AI) models for formulation design and delivery optimization. Collectively, this review highlights how systematic adoption of NAMs can improve human predictivity, accelerate development timelines, and support more efficient, ethical, and translational robust mRNA-LNP drug development.},
}
@article {pmid42398993,
year = {2026},
author = {Ahmad Nazari, MA and Yaacob, SS and Muzaini, K and Rosely, MF and Md Yazin, NKR and Mohamad, M},
title = {Factors associated with occupational fatigue among healthcare workers in Malaysia: a systematic review.},
journal = {BMJ open},
volume = {16},
number = {7},
pages = {e118439},
pmid = {42398993},
issn = {2044-6055},
mesh = {Humans ; Malaysia/epidemiology ; *Fatigue/epidemiology/etiology ; *Health Personnel/psychology ; *Occupational Diseases/epidemiology ; Risk Factors ; Working Conditions ; },
abstract = {BACKGROUND: Due to the nature of their work, occupational fatigue is an important issue among healthcare workers (HCWs), with implications for workers' health, patient safety and healthcare organisation performance. However, the evidence on factors of work fatigue among HCWs in Malaysia remains fragmented.<br><br>OBJECTIVE: To synthesise the existing evidence on work fatigue among HCWs in Malaysia, with a focus on its associated factors across HCW populations and to examine the types of fatigue instruments used.<br><br>DESIGN: Systematic literature review.<br><br>SETTING: Literature on fatigue among HCWs in Malaysia.<br><br>PARTICIPANT: Studies on occupational fatigue involving HCWs conducted within the Malaysian context.<br><br>METHOD: A systematic literature search was conducted using electronic databases of PubMed, Scopus, Web of Science and Science Direct. Studies must involve HCWs. Studies not in English, focusing on burn-out and different fatigue constructs, such as compassion fatigue, were excluded. Data extracted included study characteristics, setting, fatigue instruments, HCW groups and key findings. Factors associated with fatigue were synthesised thematically. This review followed Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, and the quality of the study was assessed using the Newcastle-Ottawa Scale.<br><br>MAIN OUTCOME MEASURE: Factors associated with work fatigue among HCWs in Malaysia.<br><br>RESULTS: Out of 1699 articles screened, 138 studies were within the Malaysian setting. Nine (n=9) articles were finally included. One study, each was conducted nationwide, in Peninsular zones, in Melaka and Kuala Lumpur, also, three studies in Selangor and two in Sarawak. A total of 4662 HCWs participated, of which 1419 were doctors (30.4%), 1014 nurses (21.8%) and 2229 HCWs of various positions (47.8%). Fatigue instruments used were the Occupational Fatigue/Exhaustion Recovery Scale, the Chalder Fatigue Scale, the Fatigue Assessment Scale, the Zoom Exhaustion and Fatigue Scale, and the postacute COVID syndrome checklist. Two studies used electroencephalogram. Thematic synthesis identified factors such as high job demands (66.67%), high effort (11.11%), sustained strain (11.11%), and an environmental/contextual factor related to the COVID-19 pandemic (11.11%). An integrated conceptual framework is proposed.<br><br>CONCLUSION: Occupational fatigue among HCWs in Malaysia is multifactorial. Limitations include heterogeneity in study design and fatigue assessment tools. Despite the limited number of included studies, the findings provide theory-informed insights into understanding occupational fatigue; however, they should be interpreted cautiously, despite the need for standardised work fatigue surveillance as part of an efficient fatigue management system.<br><br>REGISTRATION: This review was registered under PROSPERO with the ID of CRD420251001576.},
}
@article {pmid42399828,
year = {2026},
author = {Appel, S and Coughtrey, AE and Kyrdalen, A and Takeda, A and Newlands, F and Stephenson, T and Shafran, R and Pereira, SMP},
title = {Understanding heterogeneity in paediatric long COVID research: an overview of reviews and recommendations for future pandemics.},
journal = {BMC pediatrics},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12887-026-07276-6},
pmid = {42399828},
issn = {1471-2431},
abstract = {BACKGROUND: Studies of Long COVID or Post-COVID-19 condition in children and young people have varied considerably in their reported prevalences. We aimed to examine the methodological heterogeneity underlying this variability and explore whether methodological characteristics were correlated with reported Long COVID outcome prevalence, in order to inform recommendations to improve reporting in future pandemic-related epidemiological research.<br><br>METHODS: We conducted an overview of reviews with a narrative synthesis, identifying systematic reviews and meta-analyses and extracting their included primary studies. We identified reviews of Long COVID in children &amp; young people in PubMed and Embase using a systematic search strategy. We extracted key methodological details including study design, sample size, sample and control group characteristics, data collection and reporting methods, as well as time-point(s) of surveying and frequency of follow-up. We explored correlations between these factors and prevalence of Long COVID via Spearman's rank correlation coefficients or the Kruskal-Wallis test.<br><br>RESULTS: 69 studies, from identified reviews, met the inclusion criteria with outcome symptom prevalence varying between 0 and 90% at >&#x2009;3-months post-COVID-19 infection. Only 19% of studies used an established Long COVID definition to guide analyses. There was substantial heterogeneity in the design and outcome reporting of Long COVID studies. We did not find Long COVID prevalence varied by examined methodological factors (p&#x2009;&#x2265;&#x2009;0.08 for all correlations).<br><br>CONCLUSION: While substantial methodological heterogeneity was observed across studies of paediatric Long COVID, no statistically significant correlations were identified between examined methodological factors and reported prevalence. Such variability limits comparability across studies and highlights the need for more standardised definitions, outcome measures, and reporting approaches in future pandemic-related epidemiological research: we discuss reporting guidelines and recommendations for future paediatric epidemiological research during a pandemic.},
}
@article {pmid42402140,
year = {2026},
author = {Fésü, D and Horváth, G and Müller, V},
title = {[Long-COVID syndrome and lung-specific abnormalities following COVID-19].},
journal = {Orvosi hetilap},
volume = {167},
number = {27},
pages = {1051-1058},
doi = {10.1556/650.2026.33584},
pmid = {42402140},
issn = {1788-6120},
mesh = {Humans ; *COVID-19/complications/physiopathology ; *Pulmonary Fibrosis/etiology ; Quality of Life ; Post-Acute COVID-19 Syndrome ; *Lung/diagnostic imaging ; SARS-CoV-2 ; Antiviral Agents/therapeutic use ; Respiratory Function Tests ; },
abstract = {Following the acute phase of a SARS-CoV-2 infection, post-COVID - or long-COVID - syndrome may develop. This condition is characterized by unpleasant, persistent or new-onset symptoms following the acute phase of the infection. It might lead to an impaired health-related quality of life of affected patients and may involve multiple organ systems. It often poses diagnostic and therapeutic challenges for the healthcare system, and its exact course and outcomes are not yet fully understood. A multidisciplinary approach is required for diagnosis, including imaging studies (e.g., chest CT), tests to assess functional status (e.g., 6-minute walk test, pulmonary function tests, cardiopulmonary exercise testing) and the evaluation of parameters reported by patients subjectively (e.g., symptom burden, health-related quality of life). As part of long-COVID, lung parenchymal changes or abnormalities resulting from the viral infection can be detected on imaging studies in some cases, referred as post-COVID pulmonary fibrosis. Currently, therapeutic options are limited and largely based on symptomatic or organ-specific approaches. However, antiviral treatments used in the acute phase, such as remdesivir or nirmatrelvir/ritonavir, may be potentially beneficial regarding the development of late complications. Prevention, particularly COVID-19 vaccination, plays a key role, as it has been shown to reduce the risk of severe acute disease and the later probability of long-COVID syndrome. Further long-term patient follow-up is necessary to better understand the pathomechanisms underlying long-term effects of the virus, such as long-COVID and post-COVID pulmonary fibrosis. This article aims to present an up-to-date, comprehensive review of long-COVID syndrome and post-COVID pulmonary fibrosis. Orv Hetil. 2026; 167(27): 1051-1058.},
}
@article {pmid42402418,
year = {2026},
author = {Ma, S and Chen, H and Wang, J},
title = {Occurrence of antibacterials, antivirals, and anti-inflammatory pharmaceuticals for COVID-19 treatment as emerging contaminants in the Chinese freshwater environment before, during and after the pandemic: the need for dynamic eco-pharmacovigilance.},
journal = {Environmental health and preventive medicine},
volume = {31},
number = {},
pages = {44},
pmid = {42402418},
issn = {1347-4715},
mesh = {China/epidemiology ; *Antiviral Agents/analysis ; Humans ; *Fresh Water/chemistry ; *Pharmacovigilance ; *Anti-Bacterial Agents/analysis ; *COVID-19 Drug Treatment ; *Water Pollutants, Chemical/analysis ; *Anti-Inflammatory Agents/analysis ; COVID-19/epidemiology ; Pandemics ; Environmental Monitoring ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Global epidemic diseases such as COVID-19 have driven both the excessive use of pharmaceuticals and shifts in their usage spectrum. Consequently, the profile of pharmaceuticals in the environment (PiE) may undergo dynamic temporal changes, posing a significant challenge to eco-pharmacovigilance (EPV), a specialized branch of pharmacovigilance focused on detecting, evaluating, understanding, and preventing the adverse environmental effects of pharmaceuticals.<br><br>METHODS: Based on data extracted from 89 studies published between 2014 and 2025, this review conducts a focused comparison of the occurrence patterns of 43 selected typical anti-COVID-19 drugs (20 antibacterials, 11 antivirals, and 12 anti-inflammatory pharmaceuticals) as contaminants in distinct regions across China's seven major river basins before, during, and after the pandemic. The need of dynamic EPV was then analyzed.<br><br>RESULTS: Before the COVID-19 outbreak, erythromycin, ampicillin, roxithromycin, and acetaminophen dominated the PiE profile in terms of reported maximum residual concentrations; during the pandemic lockdown, ciprofloxacin, ofloxacin, azithromycin, and ketoprofen were identified as the top-priority anti-COVID-19 PiE; after the pandemic, azithromycin, norfloxacin, ofloxacin, ciprofloxacin, and roxithromycin remained the dominant PiE. Residual levels of individual PiE at the same location varied noticeably across the three periods.<br><br>CONCLUSIONS: Results revealed highly distinct regional and temporal variations in surface freshwater pollution by these COVID-19-associated PiE across the three periods, with no consistent regularity observed, thereby further highlighting the necessity of implementing EPV in a "dynamic" manner. Drawing on the framework of dynamic pharmacovigilance, the implementation of dynamic EPV can be promoted by establishing a dynamic watch-list mechanism, clarifying stakeholder roles, and advancing supportive policies and technological platforms, so as to enable adaptive interventions for the timely management of event-driven pharmaceutical pollution.},
}
@article {pmid42402538,
year = {2026},
author = {Kumar, K},
title = {Applications of Recombinant DNA Technology in Medicine: A Comprehensive Review.},
journal = {Molecular biotechnology},
volume = {},
number = {},
pages = {},
pmid = {42402538},
issn = {1559-0305},
abstract = {Recombinant DNA (rDNA) technology has revolutionised modern medicine by providing precise genetic manipulation for therapeutic, diagnostic, and preventive uses. By integrating genetic material from multiple sources, rDNA permits the creation of physiologically active compounds and the development of new medical therapies. This study summarises the basics of rDNA technology, including DNA separation, gene cloning, vector design, transformation, and expression systems, emphasising their foundational importance in biotechnology. Recombinant procedures make it possible to produce insulin, growth hormones, interferons, monoclonal antibodies, and enzymes on a large scale with better purity, safety, and scalability in the biopharmaceutical industry. Subunit, DNA, and viral-vector vaccines are examples of recombinant vaccines that have been effectively used to prevent infectious diseases such COVID-19, HPV, and hepatitis B. Gene therapy techniques using viral and non-viral vectors, together with CRISPR-based genome editing, provide targeted repair of genetic diseases. Additionally, recombinant systems promote pharmacogenomics and personalised medicine by improving molecular diagnostics such as PCR, qPCR, DNA probes, and enzyme-based tests. Furthermore, platforms for translational research and disease modelling are provided by genetically modified animal and cell models. The paper further examines ethical, safety, and regulatory considerations, as well as upcoming technologies such as CRISPR 2.0, synthetic biology, mRNA therapies, and designer vaccinations. Together, rDNA technology is still revolutionising healthcare by providing novel approaches to illness diagnosis, treatment, and prevention.},
}
@article {pmid42404849,
year = {2025},
author = {Cairney, P and Intropido, S},
title = {The pursuit of equity in COVID-19 policy and policymaking: A qualitative systematic review.},
journal = {Open research Europe},
volume = {5},
number = {},
pages = {167},
pmid = {42404849},
issn = {2732-5121},
abstract = {BACKGROUND: The COVID-19 pandemic produced a devastating and unequal effect on global population health and wellbeing. Although research demonstrated multiple COVID-19 inequalities, the pursuit of equity (to address unfair inequalities) remained politically contested and overshadowed by higher priority crisis responses. It is essential to learn from these experiences to inform future crisis responses and anticipate the lack of proportionate and sustained attention to inequalities. We seek to understand how COVID-19 equity research defines this policy problem, offers solutions, and considers their feasibility in complex and political policy processes.<br><br>METHODS: We conducted a qualitative systematic review (2024) to identify peer reviewed journal articles on COVID-19, policymaking, and equity in three databases (Web of Science, Scopus, Proquest). We sought articles providing a non-trivial reference to policymaking concepts, including 55 texts that meet the inclusion criteria, and adding 30 texts by snowballing. We used an immersive and inductive approach to identify key themes and show how the use of policy concepts and theories informs an overall narrative of COVID-19 equity research.<br><br>RESULTS: This research documents the unequal impact of the COVID-19 pandemic and policy, then identifies potential policy solutions and some hopes that governments will support them. However, it highlights a major gap between this aspiration for change versus political reality, and identifies barriers to the production and use of lessons for future crises.<br><br>CONCLUSION: Most governments appear to have learned few lessons about inequalities from their COVID-19 experiences. The literature suggests that most governments will contribute to very similar unfair inequalities in their responses to the next crisis.},
}
@article {pmid42404887,
year = {2026},
author = {Ponnachan, P and Dhawlarker, A and Yasmin, H and Shah, A and Malhotra, A and Shastri, A and Al-Ramadi, BK and Kishore, U},
title = {Mechanisms and impact of long COVID: pathophysiology, neuropsychiatric effects and vaccination.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1710777},
pmid = {42404887},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/physiopathology/psychology/complications/prevention &amp; control ; Post-Acute COVID-19 Syndrome ; *SARS-CoV-2/immunology ; *COVID-19 Vaccines/immunology ; Vaccination ; Mental Disorders/etiology ; },
abstract = {Long COVID or post-acute sequelae of COVID-19 is defined as an after-effect of acute COVID-19 infection. Its broad clinical symptoms include brain fog, shortness of breath, fatigue, joint, chest, or muscle pain, dysautonomia and neuropsychiatric symptoms such as anxiety, depression and post-traumatic stress disorder. It is estimated that 1 in every 5 COVID-19 survivors exhibit symptoms within the Long COVID bracket. An array of risk factors such as smoking habit, age, obesity, female sex, and prior hospitalization may increase the probability of a person developing Long COVID. While the underlying mechanisms of Long COVID remain elusive, we examine the various possible pathophysiologies involved in Long COVID. We take up impactful neuropsychiatric issues as another spectrum of Long COVID symptoms and the likely effect of various forms of COVID-19 vaccines. In this review, the focus will be on the main mechanisms associated with the development of long COVID, which include latent Epstein-Barr virus reactivation, molecular mimicry, virus persistence, autoantibodies, and mitochondrial dysfunction. Understanding these mechanisms shed light on the continued persistence of COVID-19 related symptoms long after the resolution of acute infection. For instance, the reactivation of Epstein-Barr virus in the immunocompromised context seen post-acute SARS-CoV-2 infection could lead to the symptoms commonly observed in Long COVID such as fatigue and brain fog. The Epstein-Barr virus could possibly disrupt mitochondrial function, explaining the fatigue commonly observed in Long COVID patients. Other factors such as continued presence of viral particles in specific areas such as the gut may result in continued inflammation, leading to manifestations such as fatigue, cognitive impairment and gastrointestinal dysfunction. Additionally, heightened and persistent presence of autoantibodies post-acute infection results in persistent symptoms and could potentially trigger the onset of autoimmune disorders. We also aim to revisit the diverse and prolonged effects of the COVID-19 pandemic that continue to affect the well-being and quality of human life.},
}
@article {pmid42404899,
year = {2026},
author = {Oh, SJ and Shin, OS and Hur, JY},
title = {From infection to dysfunction: viral triggers and antiviral immune factors in Alzheimer's disease pathology.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1839357},
pmid = {42404899},
issn = {1664-3224},
mesh = {Humans ; *Alzheimer Disease/immunology/pathology/virology ; Animals ; *Virus Diseases/immunology ; Brain/immunology/virology/pathology ; Host-Pathogen Interactions/immunology ; SARS-CoV-2/immunology ; },
abstract = {Neurodegenerative diseases and neurocognitive disorders increasingly appear to share a common and underappreciated contributor: the viral-immune axis in the brain. This review presents current evidence linking neurotropic viruses and host antiviral immunity to the onset and progression of neurodegeneration and neurocognitive dysfunction. We explore how viral infections, particularly by Herpesviruses, Severe Acute Respiratory Syndrome Coronavirus 2, and Human Immunodeficiency Virus, disrupt neural homeostasis through neuroinflammation, amyloidosis, tauopathy, and autophagy dysregulation in neurodegeneration including Alzheimer's disease (AD). Simultaneously, host antiviral mechanisms, including type I interferons and interferon regulatory factors, often amplify neuronal damage when dysregulated. By examining viral and immune interactions within the neurodegenerative diseases, this review aims to broaden our understanding of the viral-immune axis in the brain and inspire novel approaches to prevention and treatment.},
}
@article {pmid42405478,
year = {2026},
author = {Wyszynski, DF and Renz, C and Espinueva, A and Shulman, LP and Lee, E and Fitzgibbon, A and Brown, G},
title = {Remdesivir Use During Pregnancy: Findings From the Prospective COVID-19 International Drug Pregnancy Registry and Narrative Literature Review.},
journal = {Journal of pregnancy},
volume = {2026},
number = {1},
pages = {e8700344},
pmid = {42405478},
issn = {2090-2735},
support = {//Genentech/ ; //Roche/ ; //Merck Sharp and Dohme United Kingdom/ ; //Regeneron Pharmaceuticals/ ; //GlaxoSmithKline/ ; //Gilead Sciences/ ; },
mesh = {Female ; Humans ; Pregnancy ; *Adenosine Monophosphate/analogs &amp; derivatives/adverse effects/therapeutic use ; *COVID-19 Drug Treatment ; *Antiviral Agents/adverse effects/therapeutic use ; *Alanine/analogs &amp; derivatives/adverse effects/therapeutic use ; *Pregnancy Complications, Infectious/drug therapy ; Registries ; Adult ; Prospective Studies ; SARS-CoV-2 ; COVID-19 ; },
abstract = {BACKGROUND AND AIMS: Remdesivir (RDV), an inhibitor of coronavirus replication including SARS-CoV-2, has been approved for the treatment of COVID-19. Nevertheless, its use during pregnancy lacks specific efficacy and safety data due to the exclusion of pregnant patients from clinical trials. Authorization for compassionate use in pregnant women was granted during the conduct of the Phase 3 clinical trials in adult patients hospitalized with moderate or severe COVID-19. Available evidence from prior studies suggests that no consistent safety concern has been identified, although available data remain limited. The most commonly reported adverse event (AE) is transaminitis, which rarely necessitates treatment discontinuation.<br><br>METHODS: Safety data for RDV exposure during pregnancy were collected by the COVID-19 International Drug Pregnancy Registry (COVID-PR) between December 2021 and November 2023. Information was obtained through self-administered online questionnaires completed during pregnancy and up to 1 year after live birth, with medical record corroboration when available.<br><br>RESULTS: Nine women reported a total of 15 AEs, with an additional seven AEs reported in three infants. Ten of these AEs were considered serious and included a life-threatening hypersensitivity episode. No consistent pattern of AEs suggestive of a specific safety concern was identified.<br><br>CONCLUSIONS: This study contributes additional observational safety data regarding RDV use during pregnancy. However, due to the small size of the study population and various study limitations, definitive conclusions about the safety of this treatment in pregnant populations cannot be drawn.<br><br>PLAIN LANGUAGE SUMMARY: RDV is a drug used to treat COVID-19 by blocking the virus from multiplying in the body. However, since pregnant women were not included in early clinical trials, we did not have much information about how safe and effective this drug is for them. During the pandemic, some pregnant women with severe COVID-19 were allowed to receive RDV through compassionate use programs, and our study is aimed at collecting data on their experiences. We looked at 23 pregnant women who took RDV between December 2021 and November 2023. Out of these, eight were followed through the end of their pregnancy, resulting in seven live births and one miscarriage. Some women and their babies experienced side effects, with the most common being temporary increases in liver enzyme levels, and one woman had a serious allergic reaction. Overall, no consistent pattern of adverse pregnancy or infant outcomes was identified. However, because only a small number of pregnancies were available for analysis and many participants were lost to follow-up, larger studies are needed to better understand the safety of RDV use during pregnancy.},
}
@article {pmid42405958,
year = {2026},
author = {Zarrinpanah, T and Mashhadi Abolghasem Shirazi, M and Modarressi, SMH and Haghighat, S},
title = {Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2684345},
pmid = {42405958},
issn = {2164-554X},
mesh = {Humans ; *Vaccinology/methods ; *Adjuvants, Immunologic/administration &amp; dosage ; *Nanotechnology/methods ; *Adjuvants, Vaccine/administration &amp; dosage ; Immunoinformatics ; *Vaccines/immunology ; COVID-19 Vaccines/immunology ; Vaccine Development/methods ; Systems Biology ; Nanoparticles ; Animals ; Immunity, Innate ; },
abstract = {Vaccines based on purified antigens, recombinant proteins, and nucleic acid platforms increasingly depend on adjuvants to induce robust, durable, and appropriately polarized immune responses in humans. While classical adjuvants such as aluminum salts and oil-in-water emulsions have enabled the success of many licensed vaccines, their largely empirical design limits adaptability to emerging pathogens and population-specific needs. This review presents a translational framework for next-generation vaccine adjuvant development by integrating nanotechnology-based delivery systems, innate immune signaling mechanisms, and systems-level computational strategies relevant to human vaccination. We summarize the mechanisms and clinical relevance of licensed and advanced adjuvants, including alum, MF59, AS01/AS04, saponins, toll-like receptor agonists, and lipid nanoparticles, with emphasis on influenza, HPV, herpes zoster, and COVID-19 vaccines. By linking immunological mechanisms with delivery engineering and predictive modeling, this review highlights rational strategies to support safer and more effective human vaccines.},
}
@article {pmid42406005,
year = {2026},
author = {Ahuja, S and Kanwar, D and Silakari, P and Sahu, SK and Kaur, P},
title = {Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.},
journal = {Therapeutic innovation &amp; regulatory science},
volume = {},
number = {},
pages = {},
pmid = {42406005},
issn = {2168-4804},
abstract = {Drug repurposing involves the discovery of new therapeutic uses of existing drugs that have already been approved by the regulatory authorities. It provides an alternative with more efficient approaches to traditional drug discovery, leveraging already known safety profiles, shortened development and financial costs. Current advances in computational biology, artificial intelligence and big-data analytics have expanded the range of opportunities for systematic repurposing, but the successful translation of these opportunities is increasingly dependent on the holistic input of medicinal chemistry. The therapeutic relevance of medicinal chemistry-guided repurposing is being investigated over a range of unmet medical conditions, such as complicated diseases, rare diseases and new health crises, such as the COVID-19 pandemic. In this review, we underscore the critical importance of medicinal chemistry, including structure-activity relationship analysis, molecular optimization, target engagement assay, and ADMET refinement, in supporting the efficacy and safety of repurposed candidates. We further discuss the co-existence of these strategies with in silico predictions of the target, virtual screening, and phenotypic assays to narrow down lead compounds and improve translational success. Additionally, the role of medicinal chemistry in personalized medicine is also taken into account, where special attention is paid to the possibility of modifying pharmacological characteristics to patient-specific molecular and biological phenotypes. The study aims to encourage researchers and clinicians to adopt the revolutionary potential of drug repurposing to enhance treatment decisions and overall health outcomes among a large number of patients. Moreover, in a medical landscape that is becoming more complex, drug repurposing can transform the pharmaceutical industry, accelerate the process of making viable therapy available, and facilitate the delivery of quality healthcare.},
}
@article {pmid42406015,
year = {2026},
author = {Mirchevska, G},
title = {The Emerging Global Threat of Candida auris: A Call for Enhanced Public Health Policy and Regional Coordination.},
journal = {Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)},
volume = {47},
number = {2},
pages = {73-83},
doi = {10.2478/prilozi-2026-0020},
pmid = {42406015},
issn = {1857-8985},
mesh = {Humans ; *Candida auris/drug effects ; *Health Policy ; Antifungal Agents/therapeutic use ; *Cross Infection/prevention &amp; control/epidemiology/microbiology ; Global Health ; *Candidiasis/epidemiology/prevention &amp; control/diagnosis/drug therapy ; Infection Control ; COVID-19/epidemiology ; *Public Health ; Drug Resistance, Fungal ; Candidiasis, Invasive ; },
abstract = {Antimicrobial resistance represents a paramount challenge to global public health in the 21st century. The multidrug-resistant fungal pathogen Candida auris poses a critical and escalating threat to global public health. Characterized by rapid nosocomial transmission, persistent environmental contamination, and resistance to multiple antifungal classes, C. auris challenges healthcare systems worldwide. Its independent emergence across distinct geographic clades and exponential rise in cases, exacerbated by the COVID-19 pandemic, underscore the urgent need for robust, coordinated response. This review synthesizes the current knowledge on C. auris with a focus on its implications for public health policy, particularly in the European and Balkan healthcare settings, where surveillance gaps and cross-border transmission risks remain pronounced. We analyze the key drivers of spread, including diagnostic misidentification, extensive antifungal resistance, and lapses in infection control, and evaluate the strain on surveillance and hospital preparedness. Effective mitigation is fundamentally dependent on implementing comprehensive, multi-faceted infection prevention and control strategies, guided by antifungal stewardship and rapid diagnostics. We conclude that addressing the C. auris threat requires an urgent, coordinated international and regional response focused on strengthening surveillance networks, standardizing diagnostic and infection prevention and control protocols, and fostering data sharing across borders to contain this resilient pathogen.},
}
@article {pmid42406565,
year = {2026},
author = {Mugwagwa, T and Marcano Belisario, J and Hartley, L and Phan, NTN and Mokgokong, R},
title = {Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.},
journal = {Journal of medical economics},
volume = {29},
number = {1},
pages = {1875-1897},
doi = {10.1080/13696998.2026.2695551},
pmid = {42406565},
issn = {1941-837X},
mesh = {*Ritonavir/therapeutic use/economics ; Humans ; *COVID-19 Drug Treatment ; Cost-Benefit Analysis ; Quality-Adjusted Life Years ; *Antiviral Agents/economics/therapeutic use ; Cost-Effectiveness Analysis ; Drug Combinations ; COVID-19 ; SARS-CoV-2 ; Lopinavir ; },
abstract = {AIMS: Nirmatrelvir/ritonavir (NMV/r)[i] is an antiviral drug indicated for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk of progressing to severe disease. We performed an updated economic systematic literature review (eSLR) of NMV/r to build upon evidence reported in our previous eSLR and additionally examine the health-related outcomes associated with NMV/r and any potential effect of long COVID.<br><br>METHODS: A systematic search of Embase, PubMed, Cochrane, and EconLit and of conference and health technology assessment agency websites was performed to identify economic analyses published between January 2022 and October 2025.<br><br>RESULTS: Of the 33 included economic evaluations, most were cost-utility analyses (n&#x2009;=&#x2009;16) and used an analysis of a short-term decision tree with a long-term Markov model (n&#x2009;=&#x2009;11). Several types of health-related endpoints were reported by studies, with most including hospital-related endpoints (n&#x2009;=&#x2009;20), quality-adjusted life-years (QALYs) (n&#x2009;=&#x2009;18), and death-related endpoints (n&#x2009;=&#x2009;18). Positive health-related outcomes were associated with NMV/r treatment, including reductions in hospitalizations and deaths and an increase in QALYs. NMV/r treatment was also associated with a reduced number of patients with long COVID complications.<br><br>LIMITATIONS: Most studies were conducted in high-income countries, were based on different COVID-19 variants, and were limited in data on the long COVID population.<br><br>CONCLUSION: In addition to monetary benefits, NMV/r provides short-term and long-term health-related benefits to patients with mild to moderate COVID-19. This study provides further support for NMV/r as a cost-effective treatment option.},
}
@article {pmid42407372,
year = {2026},
author = {Kachanov, A and Brezgin, S and Kostyusheva, A and Ponomareva, N and Chulanov, V and Parodi, A and Kostyushev, D},
title = {Safeguarding nanovesicles and their payload: A framework for stable storage.},
journal = {Colloids and surfaces. B, Biointerfaces},
volume = {267},
number = {},
pages = {115956},
doi = {10.1016/j.colsurfb.2026.115956},
pmid = {42407372},
issn = {1873-4367},
abstract = {Recent advances in biomedical science have shifted therapeutic strategies toward biologics, nucleic acid-based medicines, and precision gene regulation, demanding equally sophisticated delivery and preservation vehicles. This shift is epitomized by the breakthrough of RNA therapeutics during the COVID-19 pandemic, which are now advancing into oncology, autoimmune disorders, and inflammatory diseases, alongside powerful gene-editing, and gene-regulation tools. Biological nanoparticles and, in particular, (EVs) are uniquely positioned to enable targeted delivery of these advanced strategies. Their favorable biodistribution, biocompatibility, biodegradability, and high loading capacity make them an ideal delivery platform. However, a critical translational gap remains: while experimental innovation accelerates, the practical knowledge of selecting appropriate dosage forms, storage conditions, and necessary stabilizers is lacking. This challenge extends beyond maintaining vehicle integrity to the crucial preservation of the therapeutic payload's activity. This review examines current advancements in EVs storage methods and conditions, highlighting the challenges for preserving functional activity of the payload. By evaluating preservation strategies and their effects on EV integrity and cargo stability, we discuss critical insights to enhance storage, ensuring both structural preservation of EVs and functionality of bioactive cargo.},
}
@article {pmid42410869,
year = {2026},
author = {O'Donnell, J and Fenn, R},
title = {Respiratory Support in the Emergency Department: An Updated Systematic Review and Meta-Analysis.},
journal = {Worldviews on evidence-based nursing},
volume = {23},
number = {4},
pages = {e70165},
pmid = {42410869},
issn = {1741-6787},
mesh = {Humans ; *Emergency Service, Hospital/organization &amp; administration/statistics &amp; numerical data ; Noninvasive Ventilation ; *Oxygen Inhalation Therapy/methods ; *Respiratory Therapy/methods ; },
abstract = {BACKGROUND: An estimated 20% of emergency department (ED) patients require respiratory support (RS). Evidence suggests that nasal high flow (NHF) reduces RS need.<br><br>AIMS: This is an update of a published review comparing NHF to non-invasive ventilation (NIV) or to conventional oxygen therapy (COT) in adult ED patients.<br><br>METHOD: This updated systematic review (SR) and meta-analysis (MA) methods reflect the Cochrane Collaboration's methodology. The search of six databases was first completed in July 2023 and then repeated in November 2025. Databases were searched for randomized controlled trials (RCTs) comparing NHF to COT or NIV in the ED. Three summary estimates were reported: (1) need to escalate care, (2) mortality, and (3) adverse events (AEs).<br><br>RESULTS: The updated search identified three new studies, bringing the total to 21 eligible RCTs (n&#x2009;=&#x2009;2158). One of the six MA conclusions was statistically significant. Compared with COT, NHF showed no SS difference in the risk of escalation (RR 0.65; 95% CI [0.41, 1.04]; p&#x2009;=&#x2009;0.07), mortality (RR 1.05; 95% CI [0.74, 1.51]; p&#x2009;=&#x2009;0.77), and AE (RR was 0.98; 95% CI [0.6, 1.6]; p&#x2009;=&#x2009;0.94) outcomes were found. Compared with NIV, NHF increased the risk of escalation by 86% (RR 1.86; 95% CI [1.26, 2.75]; p&#x2009;=&#x2009;0.001), but mortality risk was not SS (RR 1.33; 95% CI [0.86, 2.06]; p&#x2009;=&#x2009;0.20).<br><br>LINKING EVIDENCE TO ACTION: Evidence suggests NHF therapy may be an alternative to COT in managing RS in EDs. While NHF may not be as effective as NIV at preventing escalation, it does not increase mortality risk, offering a nuanced approach to RS tailored to patient-specific needs. This evidence-informed decision-making can enhance patient outcomes. However, further research is needed, especially given the COVID-19 pandemic's impact on ED research.},
}
@article {pmid42410924,
year = {2026},
author = {Liu, W and Wang, B and Cosco, TD and Cai, Z and Tang, X and Zhou, Z and Ren, Z},
title = {Prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns: a systematic review and meta-analysis.},
journal = {Aging &amp; mental health},
volume = {},
number = {},
pages = {1-14},
doi = {10.1080/13607863.2026.2690401},
pmid = {42410924},
issn = {1364-6915},
abstract = {BACKGROUND: The COVID-19 lockdowns presented an unprecedented challenge to public mental health. The impact of these lockdowns on older adults remains unclear. To quantify the prevalence of anxiety and depressive symptoms among older adults during COVID-19 lockdowns, we conducted this systematic review and meta-analysis.<br><br>METHODS: We systematically searched nine electronic databases for relevant literature published in English or Chinese, covering the period from January 1, 2020, to November 29, 2024. The Joanna Briggs Institute Critical Appraisal tool was used to assess the risk of bias. A random-effects model was used to calculate the overall pooled prevalence.<br><br>RESULTS: A total of 51 articles, encompassing 57 studies, satisfied the inclusion criteria and included data from 26,616 participants across 23 countries. The estimated prevalence of anxiety and depressive symptoms was 12.82% (95% CI: 9.13-17.72) and 15.01% (95% CI:11.61-19.19), respectively. Factors significantly associated with anxiety symptom prevalence included the proportion of females, study quality, lockdown duration, international travel control policies, workplace closure policies, and changes in human mobility across six categories of location. Factors significantly associated with depressive symptom prevalence included study quality, international travel control policies, and public transport closure policies.<br><br>CONCLUSIONS: This study enhances our understanding of anxiety and depression symptoms among older adults during COVID-19 lockdowns, notably revealing the moderating effects of human mobility on anxiety symptoms. The findings offer tentative insights for comprehending and addressing the psychological impact of major public health emergencies on older adults.},
}
@article {pmid42410961,
year = {2026},
author = {Almulla, AF and Zhang, Y and Tunvirachaisakul, C and Carvalho, AF and Maes, M},
title = {Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.},
journal = {Expert reviews in molecular medicine},
volume = {28},
number = {},
pages = {e38},
doi = {10.1017/erm.2026.10064},
pmid = {42410961},
issn = {1462-3994},
mesh = {Humans ; *Insulin Resistance ; *Hyperglycemia/blood/metabolism/virology/etiology ; *COVID-19/complications/metabolism/virology ; Post-Acute COVID-19 Syndrome ; Insulin/blood ; SARS-CoV-2 ; Blood Glucose/analysis/metabolism ; Biomarkers/blood ; Glycated Hemoglobin/metabolism/analysis ; },
abstract = {BACKGROUND: Accumulating evidence suggests that long COVID (LC) is mediated by chronic immune activation, oxidative stress and metabolic dysregulation. These processes may impair glucose homeostasis and promote insulin resistance (IR). However, no prior meta-analysis has systematically and quantitatively evaluated IR indices and related biomarkers in LC compared with normal controls.<br><br>OBJECTIVES: To systematically review and meta-analyse IR indices including HOMA-IR, HOMA-%B, HOMA-%S, insulin, fasting and random blood sugar (FBG, RBS), glycated haemoglobin (HbA1c), C-peptide and adipokine levels in individuals with LC compared with normal controls.<br><br>METHODS: PubMed, SCOPUS, SciFinder and Google Scholar databases were searched for relevant studies from inception to September 2025. Fifty-six eligible studies were included, comprising 9623 participants, 5340 LC patients and 4283 normal controls.<br><br>RESULTS: LC disease is characterized by elevated HOMA-IR (standardized mean difference, SMD&#xa0;=&#xa0;0.539; 95% confidence interval, CI: 0.311; 0.766), insulin (SMD&#xa0;=&#xa0;0.424; 95% CI: 0.113; 0.735), FBG and RBS (SMD&#xa0;=&#xa0;0.734; 95% CI: 0.190; 1.277, SMD&#xa0;=&#xa0;0.325; 95% CI: 0.133; 0.517). Furthermore, reduced HOMA-%S was observed in LC patients versus normal controls. Publication bias was generally low, though evidence of small-study effects was observed for several outcomes. The Immunological Confounder Scale was employed to evaluate study quality, revealing an overall intermediate methodological quality.<br><br>CONCLUSIONS: Our results show that LC is associated with multiple abnormalities in glucose homeostasis, including increased HOMA-IR, hyperglycaemia and impaired insulin sensitivity indices, sustained metabolic disturbances beyond the acute phase.},
}
@article {pmid42411042,
year = {2026},
author = {Zhang, Y and Chen, J and Li, J and Xu, Z and Wang, J and Shang, L},
title = {Advances in Antiviral Drug Development Targeting Viral Proteases.},
journal = {Medicinal research reviews},
volume = {},
number = {},
pages = {},
doi = {10.1002/med.70075},
pmid = {42411042},
issn = {1098-1128},
support = {22177055//National Natural Science Foundation of China/ ; U23A20147//National Natural Science Foundation of China/ ; GZNL2023A01002//R&amp;D Program of Guangzhou Laboratory/ ; 63243133//Fundamental Research Funds for the Central Universities, Nankai University/ ; },
abstract = {Viral proteases are critical targets in antiviral drug development due to their essential role in the viral lifecycle and high conservation across viral strains. This review summarizes the recent progress of antiviral drugs based on protease structures, with a focus on the structural characteristics and inhibitor design strategies targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Enterovirus 71 (EV71), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). Based on the three-dimensional structure of proteases, various types of protease inhibitors such as peptidomimetic, non-peptidic, and natural product-derived inhibitors are discussed. Given the critical challenge of drug resistance in antiviral therapies, we address the mechanisms of protease inhibitor resistance and explore advanced strategies, including allosteric inhibition, dual-target inhibition, and Proteolysis-Targeting Chimeras (PROTAC) to overcome drug resistance. This review also explores the cutting-edge applications of artificial intelligence (AI) for viral protease-based antiviral drug discovery, providing valuable insights for the rational design and development of antiviral drugs.},
}
@article {pmid42412197,
year = {2026},
author = {Goldberg-Bockhorn, E and Reich, A and Vahl, JM and Hoffmann, TK and Hahn, J},
title = {[Otorhinolaryngologic infections in the post-pandemic context: What can we learn from the literature?].},
journal = {HNO},
volume = {},
number = {},
pages = {},
pmid = {42412197},
issn = {1433-0458},
abstract = {BACKGROUND: The epidemiology of various respiratory infections changed due to the impact of the COVID-19 pandemic. Lockdowns and other containment measures (nonpharmacologic interventions, NPI) led to a decline in virus circulation, resulting in fewer cases at hospitals and practices. Once restrictions were eased, a rebound effect was observed worldwide, resulting in an increase in viral and severe invasive bacterial infections.<br><br>OBJECTIVE: Various case series on different ear, nose, and throat (ENT) infections have been conducted in the context of the pandemic in Germany. These studies should be summarized and interpreted in the context of currently available data.<br><br>MATERIALS AND METHODS: The literature review focuses particularly on studies from Germany before, during, and after the pandemic, supplemented by European and international data.<br><br>RESULTS: Following the lifting of NPIs, a&#xa0;general increase in severe bacterial ENT infections was observed worldwide, particularly among children. Evidence from the underlying retrospective data from Germany is limited. For mastoiditis and complicated sinus infections, cohort studies showed no change in the bacterial spectrum or in the complication rate. Microbiological data for peritonsillar abscesses are currently lacking. Necrotizing fasciitis in the head and neck region increased globally. Reliable data from Germany are currently unavailable.<br><br>CONCLUSION: The increased susceptibility due to low exposure to pathogens during the pandemic and the simultaneous surge in post-pandemic virus circulation is believed to be the main cause of the rise in infections. The current data do not prove a&#xa0;direct influence of the severe acute respiratory syndrome coronavirus&#xa0;2 (SARS-CoV-2). Vaccinations, strict hygiene measures, patient education, and monitoring could help to mitigate the severity of such phenomena in the future.},
}
@article {pmid42412629,
year = {2026},
author = {Dai, Y and Li, S and He, X and Lu, K and Tian, J and Huang, Y and Wei, D and He, X and Duan, X and Liu, Y and Zhang, B},
title = {Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.},
journal = {Virulence},
volume = {17},
number = {1},
pages = {2696653},
pmid = {42412629},
issn = {2150-5608},
mesh = {Humans ; *Viral Nonstructural Proteins/metabolism/antagonists &amp; inhibitors/chemistry/genetics ; *Antiviral Agents/pharmacology ; *RNA Helicases/metabolism/antagonists &amp; inhibitors/genetics/chemistry ; Virus Replication/drug effects ; *Coronavirus/enzymology/drug effects/genetics ; G-Quadruplexes ; SARS-CoV-2/enzymology/drug effects/genetics ; COVID-19 Drug Treatment ; Methyltransferases ; },
abstract = {Coronavirus helicase NSP13 is essential for viral replication and transcription and is a promising target for broad-spectrum anti-coronavirus drugs due to its high sequence conservation and structural homology. This review summarizes NSP13 sequence features, structural organization, and functional activities across the seven human-infecting coronaviruses. We outline key enzymatic properties, including duplex RNA/DNA unwinding and NTP hydrolysis, and describe how NSP13 cooperates with other nonstructural proteins to drive replication and transcription. Beyond canonical helicase roles, we discuss the genomic distribution of G-quadruplex (G4) elements in coronaviruses and potential functional connections between G4 structures and NSP13 in regulating the viral life cycle. Finally, we highlight recent progress in developing NSP13-targeting inhibitors and consider their potential utility against COVID-19 and other emerging coronaviruses, providing a rationale for broad-spectrum antiviral design.},
}
@article {pmid42414623,
year = {2026},
author = {Vidal, D and Castro, &#xcd;A and López, CB},
title = {Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.},
journal = {Nature immunology},
volume = {27},
number = {8},
pages = {1553-1562},
pmid = {42414623},
issn = {1529-2916},
mesh = {Humans ; *Inflammation/virology/immunology ; *RNA Viruses/immunology/physiology/genetics ; Animals ; *RNA Virus Infections/immunology/virology/complications ; *Persistent Infection/immunology/virology ; Chronic Disease ; Post-Acute COVID-19 Syndrome ; Genome, Viral ; Host-Pathogen Interactions/immunology ; Virus Replication ; },
abstract = {Viral persistence refers to the ability of a virus to remain in its host for an extended period. Although most non-retroviral RNA viruses are traditionally known for causing acute, self-limiting infections, accumulating evidence of the detection of viral products long after the infectious virus is cleared suggests that RNA viruses can establish persistent infections. Persistent viral products include replication-competent viral genomes, viral proteins, mutated viruses or non-standard viral genomes. The persistence of viral products entails a continuous interaction with the host and is often associated with prolonged tissue inflammation and chronic disease. Here, we discuss emerging evidence of the persistence of viral products from viruses commonly considered to cause acute infections. We explore the known requirements for virus persistence and the implications for the development of post-acute sequelae and predisposition to chronic inflammatory syndromes.},
}
@article {pmid42414952,
year = {2026},
author = {Parent-Lamarche, A and Beauregard, N and Blanc, M&#xc8; and Cadieux, N and Dextras-Gauthier, J and Afota, MC and Merkouche, W and Hamouche, S and R'biaa, O and Garneau, J},
title = {Teleworking and its impact on health and well-being: a systematic review of longitudinal studies considering the psychosocial work environment (2005-2024).},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-28220-4},
pmid = {42414952},
issn = {1471-2458},
support = {IRSST 2024-0004//Institut de Recherche Robert-Sauv&#xe9; en Sant&#xe9; et en S&#xe9;curit&#xe9; du Travail/ ; },
abstract = {BACKGROUND: Teleworking expanded dramatically during the COVID-19 pandemic and is expected to remain widespread. While it offers benefits such as greater autonomy and improved work-life balance, teleworking also poses challenges related to workload, social isolation, and blurred boundaries between work and personal life, shaped by the psychosocial work environment. These contrasting effects raise questions about whether teleworking promotes or undermines workers' health. This systematic review synthesizes longitudinal evidence on the relationship between teleworking and workers' health, with particular attention to the role of the psychosocial work environment as an explanatory framework. Specifically, it addresses two questions: (1) What is the impact of teleworking on health (physical and mental) when psychosocial work environment factors are considered? (2) How have longitudinal studies examined the relationship between teleworking and health, including direct, mediation, and moderation effects, and how the role of teleworking in these relationships has been studied?<br><br>METHODS: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024599518). We searched five electronic databases (Embase, Medline, PsycInfo, Web of Science, CINAHL Plus) and bibliographies for longitudinal studies published between 2005 and 2024 in OECD countries. Eligible studies examined teleworking and workers' health (physical and/or psychological) in combination with psychosocial work environment factors. Study quality was assessed using the National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool. Data from 20 studies published between 2017 and 2024 were extracted and synthesized based on study and psychosocial work environment characteristics, as well as the nature of the association between telework and health outcomes.<br><br>RESULTS: All 20 studies were rated fair or good in methodological quality. Teleworking effects on health were heterogeneous and context-dependent, increasing psychological distress, exhaustion, and anxiety under high psychosocial risk (i.e., adverse work conditions such as high workload or work intensification, low autonomy, limited social support, job insecurity, reduced psychological detachment, and blurred work-nonwork boundaries) or mandatory arrangements, but protective with autonomy, supportive psychosocial conditions, or individual resources. Psychosocial work environment factors such as autonomy, job security, workload, and social support emerged as central determinants of health outcomes. Effects operated through moderation and mediation involving psychosocial work environment factors. Important gaps remain, particularly the limited investigation of physical health outcomes.<br><br>CONCLUSIONS: Teleworking is neither uniformly beneficial nor harmful. Its health impact depends on psychosocial work environment factors, individual characteristics, and contextual conditions. Longitudinal research should expand the range of psychosocial work environment factors examined, consider physical health outcomes, and investigate effects across pre-, during-, and post-pandemic periods. These insights are critical to inform evidence-based workplace interventions and organizational policies that promote employee health.},
}
@article {pmid42415007,
year = {2026},
author = {Tsehay, A and Menkir, S and Hailegebriel, T},
title = {Prevalence and associated risk factors of malaria in Amhara National Regional State: a systematic review and meta-analyses.},
journal = {Malaria journal},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12936-026-06034-4},
pmid = {42415007},
issn = {1475-2875},
abstract = {BACKGROUND: Malaria is a major parasitic infectious disease caused by Plasmodium species and remains a significant public health challenge in sub-Saharan African, including Ethiopia. The Amhara National Regional State is among the most malaria-affected region in Ethiopia. However, comprehensive evidence on the pooled prevalence of malaria and its associated risks in the region has been limited. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of malaria and identify its associated risk factors in Amhara National Regional State.<br><br>METHODS: A systematic search of studies published between 2013 to March 3, 2023, was conducted using PubMed, Springer nature, Science Direct, and Google Scholar. Eligible studies were selected based on predefined inclusion criteria. Data were extracted using Microsoft Excel and analysed with Stata version 17. Heterogeneity among studies was assessed using the inverse variance (I[2]) statistic, while publication bias was evaluated using Egger's regression test and funnel plot.<br><br>RESULTS: Out of 2,743 records initially identified, 43 studies met the inclusion criteria. The pooled prevalence of malaria in the Amhara National Regional State was 14% (95% CI 12.0-17.0%). Subgroup analysis showed that the highest (17%, 95% CI 4.0-30.0%) pooled prevalence was from South and North Gonder Zones, whereas the lowest (8%, 95% CI 5.0-11.0%) prevalence was observed in East Gojjam Zone. Malaria prevalence estimate varied according to the diagnostic methods; with microscopy reporting a prevalence of 16%; 95% CI 13.0-18% and combination of microscopy with RDT reporting 9%; 95% CI 4.0-14.0%. The prevalence increased from 13% (95% CI 10.0-17%) before the onset of COVID-19 pandemic to 15% (95% CI 14.0-10.0%) after the onset. Plasmodium falciparum was the predominant species, accounting 9% (95% CI 6-11%) of the infection followed by P. vivax at 5% (95% CI 4-5%). Significant predictors of malarial infection included, the presence of stagnant water near residences (OR&#x2009;=&#x2009;2.64; 95% CI 2.09-3.34), engagement in outdoor night activities (OR&#x2009;=&#x2009;1.69; 95% CI 1.33-2.16), and lack of insecticide treated net (ITN) utilization (OR&#x2009;=&#x2009;2.05; 95% CI 1.71-2.46).<br><br>CONCLUSION: This systematic review and meta-analysis revealed that malaria remained a considerable public health burden in the Amhara National Regional State with Plasmodium falciparum as the dominant species. Malaria prevalence varied across administrative zones, diagnostic methods, study seasons, and study periods. Environmental and behavioural factors significantly contributed to malaria transmission, highlighting the need for a strengthened and targeted malaria prevention and controlled interventions in the region.},
}
@article {pmid42415124,
year = {2026},
author = {Sewell, PE and Jensen, C},
title = {Clinical rationale for thymic restoration in adult immunosenescence.},
journal = {Immunity &amp; ageing : I &amp; A},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12979-026-00584-6},
pmid = {42415124},
issn = {1742-4933},
abstract = {Age-related thymic involution is a central feature of immunosenescence and intersects with multiple "hallmarks of aging", including genomic instability, telomere attrition, mitochondrial dysfunction, and chronic inflammation. The decline in thymic epithelial integrity and FOXN1-driven thymopoiesis reduces naïve T-cell output, contracts TCR repertoire diversity, and perturbs central tolerance, contributing to increased susceptibility to infection, cancer, and autoimmunity. These changes occur alongside broader immune-aging phenomena such as inflammaging and frailty and are reflected in poorer vaccine responses and altered outcomes to novel pathogens such as SARS-CoV‑2. This review integrates mechanistic, preclinical, and human data to reassess the adult thymus as a therapeutic target. Higher-confidence domains for thymic restoration include cancer immunosurveillance, infectious disease vulnerability, vaccine responsiveness, and post-treatment immune reconstitution, supported by modeling of age-related disease incidence, transplant and HIV cohorts, and new observational links between radiographic thymic health, mortality, and immunotherapy outcomes. High-plausibility but less directly validated domains include autoimmunity, chronic herpesvirus control, HIV immunological non-responders, and post-acute infection syndromes such as long COVID, which share convergent patterns of T-cell dysfunction and persistent immune activation. The translational landscape spans hormonal and somatotropic modulation (sex steroid ablation, growth hormone/ghrelin), cytokine and growth-factor strategies (IL‑7, IL‑22, KGF/BMP4, FGF21), cell- and tissue-engineering approaches leveraging thymic epithelial stem cells and FOXN1-reprogrammed stromal cells, and gene-therapy concepts such as intrathymic AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways. Collectively, these data support the biological plausibility of adult thymus restoration but highlight that robust, domain-specific clinical benefits have not yet been demonstrated in controlled trials. Future work should prioritize harmonized structural and functional biomarkers, domain-focused interventional studies in high-risk populations, and combined strategies that situate thymus-directed interventions within broader efforts to modify immune and organismal aging.},
}
@article {pmid42415281,
year = {2026},
author = {Aldana, BI and Freude, K},
title = {Chemokines in Alzheimer's Disease: Early Defence, Late Damage and the Impact of Sex and Infection.},
journal = {Basic &amp; clinical pharmacology &amp; toxicology},
volume = {139},
number = {2},
pages = {e70273},
pmid = {42415281},
issn = {1742-7843},
support = {R434-2023-242//Lundbeck Foundation/ ; N/A//Alzheimersfonden/ ; },
mesh = {Humans ; *Alzheimer Disease/immunology/metabolism ; *Chemokines/metabolism/immunology ; Animals ; Female ; Male ; Sex Factors ; Signal Transduction ; Virus Diseases/immunology ; Neuroinflammatory Diseases/immunology ; COVID-19/immunology ; Receptors, Chemokine/metabolism ; Brain/immunology/metabolism ; Sex Characteristics ; },
abstract = {Chemokines constitute a versatile signalling network maintaining homeostasis and glia-neuron communication in the healthy brain but become progressively dysregulated during aging and Alzheimer's disease (AD). This review examines how chemokine systems transition from tightly regulated homeostatic signals to drivers of chronic neuroinflammation in AD. We describe the major chemokine families (CC, CXC, CX3C) and their dominant central nervous system (CNS) receptors (CCR2, CXCR3, CX3CR1), which activate canonical inflammatory pathways including NF-κB, JAK/STAT and PI3K-AKT. In AD, chemokine dysregulation occurs in a coordinated manner across multiple functional modules, including recruitment-associated (CCL2, CXCL1), interferon-inducible (CXCL10), loss-of-restraint (CX3CL1) and vascular-associated chemokines. These alterations shift the network from regulated immune communication to self-sustaining inflammatory circuits perpetuating chronic neuroinflammation. These networks reprogram microglia and astrocytes into disease-associated phenotypes, amplify peripheral immune cell infiltration and destabilise synaptic function. Biological sex profoundly influences neuroinflammatory trajectories, with females exhibiting enhanced microglial senescence and interferon signalling, while males show accelerated complement activation. Viral pathogens, particularly neurotropic viruses (HSV-1, HHV-6, VZV) and SARS-CoV-2, actively reprogram chemokine networks, linking infection to amyloid-β accumulation, tau pathology and neurodegeneration. Therapeutically, chemokine axes represent precision targets requiring stage-matched, sex-stratified interventions rather than broad anti-inflammatory approaches. Understanding chemokine network dynamics offers mechanistic insights into AD pathogenesis and could provide pointers for therapeutic strategies.},
}
@article {pmid42415571,
year = {2026},
author = {Kılıç, S},
title = {Effectiveness of manual detorsion in the treatment of testicular torsion: systematic review and meta-analysis.},
journal = {The Canadian journal of urology},
volume = {33},
number = {3},
pages = {505-514},
pmid = {42415571},
issn = {1488-5581},
mesh = {Humans ; Male ; *Spermatic Cord Torsion/therapy/surgery ; Treatment Outcome ; Orchiectomy ; *Musculoskeletal Manipulations/methods ; },
abstract = {OBJECTIVES: Testicular torsion is the most common surgical cause of an acute scrotum. Manuel detorsion renewed attention as a practical initial treatment, particularly in the COVID-19 pandemic. This study aims to systematically review and meta-analyze the current literature to determine whether manual detorsion offers a viable alternative to immediate surgery in improving testicular salvage rates.<br><br>METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and registered with PROSPERO (CRD420251039489). Studies including &#x2265;30 male patients comparing manual detorsion and surgical exploration were included. Searches were performed in PubMed/MEDLINE, Scopus, TR Index, and Web of Science. Risk of bias was assessed using a predefined scoring system based on methodology, sample size, and follow-up objectivity. Data were synthesized using RevMan 5.4 to calculate pooled risk ratios.<br><br>RESULTS: Eight retrospective studies involving a total of 670 patients were included. Patients were divided into a manual detorsion group (G1, n = 394) and a surgical exploration group (G2, n = 316). Success rates of manual detorsion ranged from 15% to 76%, while orchiectomy rates were lower in G1 (0% to 10.3%) compared to G2 (0% to 43.8%). The pooled success rate of manual detorsion was 75.7%. Although orchiectomy rates appeared numerically lower in the manual detorsion group (3.8% vs. 29.2%), the pooled analysis did not demonstrate a statistically significant overall difference between the two groups (risk ratio [RR] = 1.23; 95% CI: 0.82-1.84; p = 0.31).<br><br>CONCLUSION: Manual detorsion appears time-saving and effective maneuver. To our knowledge, this is the first meta-analysis focused exclusively on manual detorsion, and it supports its consideration as an initial management strategy in selected clinical scenarios.},
}
@article {pmid42415773,
year = {2026},
author = {Kusunoki, H and Sakai, R and Watanabe, Y and Kakeya, H},
title = {Persistent excess mortality in post-pandemic Japan: current evidence, methodological limitations, and future directions.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1878166},
pmid = {42415773},
issn = {2296-2565},
mesh = {Japan/epidemiology ; Humans ; *COVID-19/mortality/prevention &amp; control ; *Mortality/trends ; COVID-19 Vaccines/administration &amp; dosage ; Pandemics ; SARS-CoV-2 ; Immunization, Secondary ; },
abstract = {More than six years after the emergence of COVID-19, Japan continues to experience persistently elevated excess mortality despite entering a post-pandemic phase. Excess mortality, defined as the difference between observed and expected deaths, reflects both direct and indirect effects of the pandemic, including healthcare disruption, delayed care, and broader social changes. In Japan, mortality decreased slightly in 2020 but increased markedly from 2022 onward, with annual excess deaths approaching 100,000, despite widespread vaccination and the predominance of the less virulent Omicron variant. Multiple factors may underlie this sustained increase, including population aging, changes in healthcare access, delayed diagnosis and treatment, regional disparities, and psychosocial stress. Some ecological and observational studies have reported a statistical association between repeated COVID-19 booster vaccination and excess mortality in Japan; however, these findings do not establish causality, and a causal relationship cannot currently be concluded. Against this background, this narrative review examines persistent excess mortality in Japan, uses the literature on repeated booster vaccination as an illustrative example to highlight methodological limitations, and discusses the need for nationwide, linked individual-level data infrastructure and appropriate analytical frameworks for more robust future evaluations.},
}
@article {pmid42415774,
year = {2026},
author = {You, Q and Li, J and Yang, L and Zhang, Y and Chen, L},
title = {Prevalence of secondary traumatic stress in nurses: a meta-analysis of observational studies.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1877091},
pmid = {42415774},
issn = {2296-2565},
mesh = {Humans ; *Compassion Fatigue/epidemiology ; COVID-19/epidemiology ; *Nurses/psychology/statistics &amp; numerical data ; Observational Studies as Topic ; Prevalence ; },
abstract = {BACKGROUND: The reported prevalence of secondary traumatic stress (STS) among nurses varies considerably across studies, ranging from 22. 1 to 84.4%. This meta-analysis aimed to estimate the pooled prevalence of STS and identify potential moderating factors among nurses.<br><br>METHODS: From the inception of each target database to April 2026, a comprehensive search was performed across PubMed, Web of Science, Scopus, Embase, Cochrane Library, CINAHL, and PsycINFO. We calculated the pooled prevalence of STS using a random-effects model and assessed heterogeneity using the I[2] statistic. Subgroup analyses and meta-regression were conducted to explore potential sources of heterogeneity.<br><br>RESULTS: A total of 28 studies comprising 7,090 nurses were included. The pooled prevalence of STS in nurses was 57.3% (95% CI: 49.7-64.9%). STS prevalence was significantly associated with mean age (&#x3b2; = -0.064, p = 0.023), work experience (&#x3b2; = -0.080, p = 0.040), publication year (during COVID-19: &#x3b2; = 0.979, p = 0.024; after COVID-19: &#x3b2; = 0.848, p = 0.030), and geographic region (North America: &#x3b2; = -0.881, p = 0.019; Europe: &#x3b2; = -1.031, p = 0.005).<br><br>CONCLUSIONS: Our findings indicated that STS was very prevalent in nurses, and the prevalence is moderated by mean age, work experience, publication year, and geographic region. Regular STS assessments and multi-level support systems, such as early warning, peer support, and mental health training, are recommended to reduce STS risk and enhance the wellbeing of nurses.},
}
@article {pmid42415809,
year = {2026},
author = {Sun, C and Chen, Q and Wang, Y and Yuan, S and Su, Y and Zhang, L},
title = {A visualization analysis of Traditional Chinese Medicine for influenza prevention and treatment: advances, hotspots, and future trends.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1852941},
pmid = {42415809},
issn = {2296-858X},
abstract = {OBJECTIVES: As an acute respiratory infectious disease, influenza continues to impose a substantial public health burden worldwide. This study aims to systematically review the progress of research on the treatment of influenza with Traditional Chinese Medicine (TCM) from 2005 to 2025, identify current research hotspots, and forecast future development trends, in order to provide a clear and systematic reference framework for subsequent research.<br><br>METHODS: A bibliometric and scientometric analysis was conducted using the Web of Science Core Collection (WOSCC), PubMed, and Scopus databases. Following the PRISMA 2020 guidelines, the retrieved records underwent a comprehensive deduplication process and stringent quality control checks. By comprehensively applying CiteSpace, VOSviewer, and the R-based Bibliometrix package, metrics and visualization were performed across multiple dimensions, including publication volume, geographical contribution, annual trends, national/regional influence, core authors and institutions, and keywords.<br><br>RESULTS: A total of 1,527 publications were included in this study. Since 2014, publication output in this field has shown significant growth, with a rapid upward trend emerging after 2020. At the national and institutional level, China ranked first globally in both the number of publications and total citation frequency. Research institutions in China not only serve as the dominant force in this field but also act as hubs for international collaboration. Notable contributions were made by institutions such as the Chinese Academy of Sciences, Beijing University of Chinese Medicine, and the China Academy of Chinese Medical Sciences. Journal analysis revealed that the Journal of Ethnopharmacology is the most influential journal in this domain. In terms of scholarly impact, Yang Zifeng ranked first in both h-index and publication output, establishing them as the most prolific and influential core scholar in the field. Keyword analysis indicated that research focuses on core themes such as "herbal medicine" and "antiviral activity." The evolutionary trajectory demonstrates a shift from traditional clinical practice toward modern mechanistic investigation. Driven by emerging public health events such as COVID-19, the field has rapidly integrated cutting-edge methodologies like network pharmacology, reflecting distinct characteristics of contemporary responsiveness and interdisciplinary convergence.<br><br>CONCLUSION: This analysis confirms that TCM for influenza has matured into a structured and interdisciplinary research field. Substantial evidence supports its multi-component and multi-target therapeutic model as a clinically effective strategy against influenza. Future efforts should prioritize the integration of mechanistic insights with standardized clinical translation to enhance global antiviral preparedness.},
}
@article {pmid42416292,
year = {2026},
author = {Kim, SJ and Choi, KS},
title = {Vaccination-driven evolution of infectious bronchitis virus in Korea: implication for the control of other coronavirus infections.},
journal = {Frontiers in veterinary science},
volume = {13},
number = {},
pages = {1859772},
pmid = {42416292},
issn = {2297-1769},
abstract = {Infectious bronchitis virus (IBV) remains a major pathogen in global poultry production due to its extensive genetic diversity and rapid evolutionary capacity. Antigenic diversification driven by mutation, homologous recombination, and sustained immune selection pressure complicates long-term control and reduces vaccine effectiveness. Increasing evidence suggests that IBV evolution is largely driven by the selective expansion of pre-existing variants under changing ecological and immunological conditions, rather than by the de novo emergence of novel lineages. South Korea provides a valuable model for understanding these processes within intensive poultry systems characterized by high host density, extensive farm connectivity, widespread vaccination, and long-term molecular surveillance. Since its first isolation in 1986, IBV in Korea has undergone repeated cycles of lineage emergence, diversification, and replacement, culminating in the predominance of nephropathogenic GI-19 viruses, including KM91 and QX-like variants. Persistent co-circulation of multiple lineages, together with frequent recombination and regional viral introduction, has shaped a highly dynamic viral population. Within this environment, vaccination plays a central yet paradoxical role. While essential for disease control, widespread vaccination imposes continuous immune selection pressure and may contribute to co-circulation of vaccine-derived and field strains, facilitating recombination and the emergence of immune escape variants. These processes drive lineage turnover and antigenic mismatch between circulating viruses and vaccine strains, forming a vaccination-driven evolutionary cycle. This review integrates global IBV diversity with insights from the Korean system to propose an evolution-centered framework in which viral genetic plasticity, host population dynamics, and vaccination practices interact. These findings have important implications for optimizing vaccination strategies and provide broader insights into the evolutionary dynamics of rapidly evolving RNA viruses under sustained immune pressure.},
}
@article {pmid42417247,
year = {2026},
author = {Gong, H and Cai, C},
title = {Plastic antibodies that see viruses: optical sensing with molecularly imprinted polymers.},
journal = {Chemical communications (Cambridge, England)},
volume = {62},
number = {57},
pages = {14113-14125},
doi = {10.1039/d6cc03116a},
pmid = {42417247},
issn = {1364-548X},
mesh = {*Molecularly Imprinted Polymers/chemistry ; Humans ; *Biosensing Techniques/methods ; *Viruses/isolation &amp; purification/immunology ; *Molecular Imprinting ; Surface Plasmon Resonance ; SARS-CoV-2/isolation &amp; purification/immunology ; Polymers/chemistry ; *Antibodies/immunology/chemistry ; },
abstract = {The need for rapid, sensitive, and selective detection of viral pathogens has never been more apparent. Molecularly imprinted polymers have emerged as robust synthetic receptors that rival biological antibodies in affinity and specificity, while offering superior chemical stability, low cost, and design flexibility. This Feature Article focuses on recent advances in the integration of virus-imprinted polymers with optical transducers, creating powerful platforms for viral diagnostics. We discuss key imprinting strategies including solid-phase synthesis, epitope imprinting, and nanogel approaches that enable precise recognition of whole viruses or their surface proteins. The optical readout mechanisms-fluorescence, resonance light scattering, colorimetric/visual detection, and surface plasmon resonance-are critically reviewed, with emphasis on signal amplification, multiplexing, and point-of-care deployment. Special attention is paid to the work of our group and others in engineering paper-based sensors, ratiometric probes, and smartphone-readable devices that detect viruses from Hepatitis A and B to SARS-CoV-2 and influenza at femtomolar or even attomolar levels. Current challenges and future directions for virus-imprinted optical sensors are discussed, highlighting the road toward commercial and clinical translation.},
}
@article {pmid42417638,
year = {2026},
author = {Bendoumou, M and Langlet, P and Gustot, T},
title = {Auto-immune hepatitis following COVID-19 Vaccination and SARS-COV2 infection : A narrative Review.},
journal = {Acta gastro-enterologica Belgica},
volume = {89},
number = {2},
pages = {341-354},
doi = {10.51821/89.2.15138},
pmid = {42417638},
issn = {1784-3227},
mesh = {Humans ; *Hepatitis, Autoimmune/etiology/immunology/drug therapy/diagnosis ; *COVID-19/prevention &amp; control/epidemiology/immunology ; *COVID-19 Vaccines/adverse effects ; Female ; SARS-CoV-2 ; *Vaccination/adverse effects ; },
abstract = {BACKGROUND AND OBJECTIVES: Since the onset of the COVID-19 pandemic, both SARS-CoV-2 infection and vaccination have been implicated as potential triggers for de novo autoimmune hepatitis (AIH). This review summarizes published cases, outlining clinical and biological features, treatment approaches, and outcomes.<br><br>METHODS: A PubMed search identified reports of new-onset AIH following SARS-CoV-2 infection or COVID-19 vaccination up to February 1, 2025. Inclusion criteria encompassed case reports, series, and reviews. Data were extracted on demographics, vaccine type, onset timing, laboratory findings, histology, treatments, and outcomes.<br><br>RESULTS: A total of 74 post-vaccination AIH cases and 22 post-infection cases were included. Post-vaccination AIH predominantly affected older women (median age 62) and occurred mainly after mRNA vaccines, with a median onset of 14 days. Most patients showed marked transaminase elevation, high IgG, and positive ANA (74.3%). Liver biopsies (performed in 92% of cases) showed features compatible with AIH. A total of 80% of the 50 cases of our study with available serology and liver histology were classified as probable / definite AIH, according to the simplified AIH score. Corticosteroid therapy was effective in most cases (survival 95.9%). Post-infection AIH cases showed similar features but affected younger individuals (median age 47), with uniformly favorable responses to immunosuppression.<br><br>CONCLUSIONS: New-onset AIH can occur following both SARS-CoV-2 infection or vaccination. Although these events remain rare, recognition of this association is essential for timely diagnosis and management.},
}
@article {pmid42417685,
year = {2026},
author = {Hovnanian, A and Mondon, G and Titeux, M},
title = {History and future of RNA medicines.},
journal = {The Journal of investigative dermatology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jid.2026.05.023},
pmid = {42417685},
issn = {1523-1747},
abstract = {RNA therapeutics are a versatile class of medicines that exploit different types of RNA molecules to prevent or treat a wide spectrum of diseases. Compared with traditional small-molecule drugs, protein drugs, or gene therapies, these therapies offer notable advantages, including faster, less expensive development, and simplified manufacturing. The field encompasses multiple modalities, such as antisense oligonucleotides, small interfering RNAs, microRNAs, mRNAs, and aptamers. The success of mRNA vaccines against SARS-CoV-2 has accelerated research and clinical translation of RNA approaches for conditions with limited treatment options, including chronic wounds, aggressive metastatic melanoma, and autoimmune and genetic skin diseases.},
}
@article {pmid42417944,
year = {2026},
author = {Li, Y and Yu, W and Yun, J and Wang, J and Liu, Y and Su, H and Guo, H and Yang, J and Yan, Y and Yan, X and Zhang, S and Yang, H and Wang, Z},
title = {Virus infections and cancers: from mechanisms to therapeutics.},
journal = {Molecular biomedicine},
volume = {7},
number = {1},
pages = {},
pmid = {42417944},
issn = {2662-8651},
support = {202503021211266//The Natural Science Foundation of Shanxi Province/ ; 2021M691995//china postdoctoral foundation committee/ ; },
mesh = {Humans ; *Neoplasms/virology/therapy ; Tumor Microenvironment ; *Oncogenic Viruses/genetics ; *Virus Diseases/therapy/complications/virology ; *Tumor Virus Infections/therapy ; Animals ; },
abstract = {Viral infections are a major contributor to global cancer incidence and mortality. However, integrative reviews that connect viral classification, carcinogenic mechanisms, tumor microenvironment remodeling, and translational strategies remain limited. This review summarizes the classification and epidemiological characteristics of major oncogenic viruses, including human papillomavirus (HPV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Merkel cell polyomavirus (MCPyV), human T-lymphotropic virus type 1 (HTLV-1), Kaposi's sarcoma-associated herpesvirus (KSHV), and human immunodeficiency virus (HIV), as well as emerging viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We then discuss the molecular basis of virus-associated carcinogenesis, including viral oncogenes, viral DNA integration, epigenetic remodeling, aberrant host signaling, and metabolic dysregulation. We further examine how chronic inflammation and fibrosis create oncogenic niches within the tumor microenvironment (TME), how viruses promote tumor progression through immune evasion and immune exhaustion, and how infected cells interact with stromal and immune components of the TME. At the preventive and therapeutic levels, we discuss antiviral therapies, vaccines, biomarker-based precision diagnostics, and prognostic strategies, with particular attention to the synergistic potential of emerging therapeutic approaches such as immune checkpoint inhibitors (ICIs), CAR-T therapy, and oncolytic viruses (OVs). Finally, we highlight how multi-omics approaches, single-cell transcriptomics, spatial transcriptomics, organoid models, and artificial intelligence can advance mechanistic studies and translational innovation in virus-associated cancers. Overall, this review provides an integrated framework for understanding, preventing, and treating virus-associated tumorigenesis.},
}
@article {pmid42420694,
year = {2026},
author = {Mosa, KA and Khare, T and Syed, F and Sirajudeen, F and Afzal, S and Dairi, Z and Younus, K and Chauhan, V and Kumar, A and Shaaban, AM and Katoch, M},
title = {Plant Biofactories for Vaccination: Progress in Edible Vaccine Technologies as a Sustainable Approach to Global Immunization.},
journal = {Plant foods for human nutrition (Dordrecht, Netherlands)},
volume = {81},
number = {3},
pages = {},
pmid = {42420694},
issn = {1573-9104},
support = {24021450161//Office of the Vice Chancellor for Research and Graduate Studies at the University of Sharjah/ ; },
mesh = {*Vaccines, Edible/immunology ; Humans ; Animals ; Plants, Genetically Modified ; *Vaccination/veterinary/methods ; Vaccine Development ; },
abstract = {Globally, the pathogen-driven enteric diseases remain a leading cause of morbidity and mortality, disproportionately affecting populations in low-income regions. While significant strides have been made in vaccine research, challenges such as high production costs, complex manufacturing processes, and inefficient distribution continue to hinder global vaccine accessibility. To overcome these challenges, plant-based edible vaccines have emerged as a promising and innovative alternative, offering advantages such as affordability, ease of administration, and reduced reliance on cold-chain infrastructure. This study presents a comprehensive overview of recent advances in the development of edible plant-derived vaccines, highlighting the strategic evolution from conventional genetic engineering to more refined and scalable biotechnological methods. In the work, various applications targeting diseases such as measles, hepatitis B, rabies, dengue, and norovirus, are discussed as well as veterinary vaccines for livestock and aquaculture. The significant progress in creating vaccines targeting prevalent human pathogens is examined and the discussion is extended to include edible vaccines developed for livestock, underscoring their role in both public and veterinary health. Furthermore, the review emphasizes the transformative potential of 'omics' technologies, such as genomics, proteomics, and metabolomics, as well as artificial intelligence in streamlining vaccine design, improving antigen expression, and accelerating development timelines. This assessment review was conducted by performing a comprehensive literature survey of peer-reviewed articles. By integrating multidisciplinary insights, the work underscores the feasibility and future prospects of edible plant vaccines as a sustainable solution to global immunization challenges, with practical applications in improving vaccine accessibility, enhancing outbreak preparedness, and supporting immunization efforts in resource-limited settings. It aims to inform and inspire continued research and collaborative innovation in this emerging field with significant implications for global public health.},
}
@article {pmid42420701,
year = {2026},
author = {Zeng, Y and Fu, BM and Tarbell, JM},
title = {Endothelial Surface Glycocalyx in Vascular Functions and Diseases.},
journal = {Advances in experimental medicine and biology},
volume = {1512},
number = {},
pages = {1-42},
pmid = {42420701},
issn = {0065-2598},
mesh = {*Glycocalyx/metabolism/ultrastructure/pathology/physiology ; Humans ; *Mechanotransduction, Cellular/physiology ; Animals ; *Endothelium, Vascular/metabolism/pathology ; *Vascular Diseases/metabolism/pathology ; *Endothelial Cells/metabolism/pathology ; },
abstract = {Endothelial cells (ECs), which form the inner lining of the vasculature, are perpetually exposed to mechanical stimuli from blood flow. Their capacity to sense and respond to these forces is essential for vascular homeostasis. A diverse array of mechanosensors operates on the EC surface, within the plasma membrane, and throughout the cytoskeleton. Among these, the endothelial surface glycocalyx (ESG)-uniquely positioned at the blood-endothelium interface and intimately linked to classical mechanosensory complexes-has emerged as a pivotal yet underappreciated regulator. Once viewed merely as a passive barrier, the ESG is now acknowledged as a primary mechanosensor that converts hemodynamic forces into biochemical signals critical for vascular health. This updated chapter from the first edition offers a comprehensive review of the ESG. We begin with its molecular composition, ultrastructural organization, and variable thickness, as elucidated by advanced imaging techniques such as immunolabeling, electron microscopy, and super-resolution microscopy. Next, we examine the ESG's biomechanical properties and its central role in endothelial mechanotransduction and barrier regulation. We then explore its dynamic remodeling in response to physiological and pathological stimuli, with a focus on degradation in major vascular diseases. ESG shedding is not only a hallmark but also a causal driver of pathophysiology in conditions including atherosclerosis, sepsis, diabetes, cancer metastasis, and COVID-19-associated endotheliopathy. Finally, we spotlight emerging diagnostic tools for evaluating ESG integrity and review promising therapeutic strategies to preserve or restore its structure and function.},
}
@article {pmid42421001,
year = {2026},
author = {Nila, FH and Villeneuve, M and Chang, KJ and Subramaniam, P},
title = {Service continuity of community-based health and social care organisations in times of disaster and health emergencies: a mapping review.},
journal = {BMC health services research},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12913-026-15001-3},
pmid = {42421001},
issn = {1472-6963},
abstract = {BACKGROUND: The physical and economic impacts of disaster and health emergencies have become a global concern that continues to generate discussion regarding disaster preparedness, response, and mitigation strategies. Maintaining continuity of services during these challenging and dynamic circumstances requires adequate organisational preparedness. This study aimed to map the existing research on the emergency management capabilities of community-based health and social care organisations and identify the factors that impact service continuity as a critical component of business continuity planning.<br><br>METHOD: This mapping review was carried out in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Eight databases were searched: Medline, PsycINFO, Embase, CINAHL, Scopus, ProQuest, Web of Science, EBSCOhost. Studies written in English and published between January 2000 and August 2022 were included. Eligible studies were primarily focused on business or service continuity of community-based health and social care organisations. Thematic analysis of data was conducted.<br><br>RESULTS: Out of 3,195 articles, 176 met the inclusion criteria, mostly conducted in developed countries. These studies investigated various natural hazard emergencies, disease outbreaks, and pandemics, using different study designs, offering valuable insights into emergency management capabilities of community-based health and social care organisations across the disaster cycle. The findings suggest that several factors can serve as both barriers and enablers to the continuity of care, depending on the context and the specific stage of the disaster cycle at which they are addressed. Limited research was found on organisational preparedness for at-risk clients, including the elderly and individuals with disabilities. Additionally, there is a scarcity of research on the prevention and recovery stages of the emergency management cycle.<br><br>CONCLUSION: This mapping review offers a comprehensive overview of the factors influencing service continuity, highlights existing research gaps and targeted recommendation for service providers and governments to inform effective planning that ensures continuity of service and supports for people whose health, safety and well-being can be compromised in emergency situations. Future research could focus on strengthening organisational resilience during the prevention phase, examine tools and approaches for optimising emergency management efforts, and investigate strategies to improve cross-sector collaboration across all stages of disaster management cycle.},
}
@article {pmid42421498,
year = {2026},
author = {Carnevali, F and Muollo, MC and Biagini, L and Rossi, G},
title = {Xenosialylation as immunological chimerism: a host-centered unifying model for viral and post-vaccination immune complications.},
journal = {European cytokine network},
volume = {37},
number = {2},
pages = {55-77},
pmid = {42421498},
issn = {1952-4005},
mesh = {Humans ; Glycosylation ; *COVID-19/immunology/prevention &amp; control ; *SARS-CoV-2/immunology ; *Vaccination/adverse effects ; *COVID-19 Vaccines/immunology/adverse effects ; Neuraminic Acids/immunology ; *Models, Immunological ; Animals ; },
abstract = {Severe immune-mediated complications following viral infections and vaccinations, including COVID-19 and anti-SARS-CoV-2 immunization, display remarkable clinical overlap despite occurring in distinct biological contexts. In a previous hypothesis-driven work, we proposed that metabolic incorporation of the non-human sialic acid N-glycolylneuraminic acid (Neu5Gc) into human glycoconjugates-defined as xenosialylation-may contribute to post-infectious and post-vaccination immune dysregulation. We further suggest that this phenomenon may represent a form of "immunological chimerism", in which host glycoconjugates incorporate non-self molecular structures that predispose the immune system to varying degrees of immune imbalance. In its most severe manifestation, this process may culminate in a profound state of immune dysregulation characterized by loss of immune tolerance, aberrant antibody responses, cytokine storm, and thrombo-inflammatory pathology, which we define as "immunological marasmus". In the present paper, we extend this conceptual framework by integrating glycobiology, Fc immunoglobulin glycosylation, endothelial biology, and sex-dependent immune regulation into a unified, testable immunopathogenic model. We hypothesize that interindividual differences in the extent, tissue distribution, and persistence of xenosialylation may influence susceptibility to exaggerated innate and adaptive immune responses following antigenic challenge. In this context, immune activation may unmask pre-existing xeno-sialylated self-structures embedded within host glycans, promoting varying degrees of glycan dysregulation, autoantibody production, immunothrombosis and chronic inflammatory sequelae. We further propose circulating anti-Neu5Gc antibodies as functional biomarkers for risk stratification and outline preventive strategies based on dietary modulation of xenosialic acid exposure. Taken together, this expanded model provides a potential mechanistic framework for understanding the shared immunological features of post-viral syndromes and vaccine-related adverse immune reactions, while offering a basis for experimental validation and future approaches to personalized risk mitigation.},
}
@article {pmid42421939,
year = {2026},
author = {Li, E and Shi, M and Huang, S},
title = {New-onset allergic diseases after SARS-CoV-2 infection: mechanistic hypotheses and emerging strategies for risk stratification.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1879430},
pmid = {42421939},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications ; *SARS-CoV-2/immunology ; *Hypersensitivity/immunology/epidemiology ; Animals ; Risk Assessment ; },
abstract = {Multinational cohort studies consistently associate SARS-CoV-2 infection with elevated incidence of allergic diseases, with hazard ratios of 2.25 for asthma and 1.23 for allergic rhinitis persisting beyond six months post-infection; whether this excess risk reflects de novo allergic sensitization or preferential unmasking of pre-existing subclinical atopy remains to be established. Yet mechanisms bridging acute viral illness to delayed allergic phenotypes remain incompletely understood. This review synthesizes recent advances across epithelial biology, immunology, and neuroimmune interactions to propose a unified mechanistic framework organized around three interconnected axes. First, epithelial injury during COVID-19 triggers passive IL-33 release while inducing active TSLP and IL-25 production. These alarmins act through mechanistically distinct pathways to converge on type 2 immune priming, which is established and reinforced by epigenetic memory in group 2 innate lymphoid cells and dendritic cells. Second, regulatory T cell depletion and, hypothetically, hematopoietic stem and progenitor cell epigenetic reprogramming driven by acute interleukin-6 elevation may generate immune cell progeny with persistently altered inflammatory responsiveness, while dendritic cells adopt Th2-polarizing phenotypes that lower the threshold for allergic sensitization; the direct contribution of hematopoietic reprogramming to Th2-skewed allergic outcomes remains to be demonstrated. Third, mast cells undergo direct spike protein-mediated activation via angiotensin-converting enzyme 2 receptors, and alarmin-primed mast cells establish bidirectional crosstalk with sensory neurons that amplifies neuroinflammation and links long COVID symptoms to heightened allergic susceptibility. Together, these axes define a post-infectious vulnerability window during which allergen encounters trigger exaggerated type 2 responses. Risk stratification incorporating disease severity, circulating biomarkers including immunoglobulin E and eosinophil counts, and genetic susceptibility variants may identify individuals requiring targeted surveillance, while mechanistically informed interventions such as low-dose interleukin-2, mast cell stabilizers, and alarmin-targeted biologics warrant prospective evaluation in convalescent cohorts.},
}
@article {pmid42421948,
year = {2026},
author = {Liu, A and Chen, H and Liu, Q and Al-Azab, M and Shaher, F and Li, J and Liu, T and Yang, M},
title = {Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1815269},
pmid = {42421948},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications ; Post-Acute COVID-19 Syndrome ; *Cardiovascular Diseases/immunology/etiology ; *Inflammation/immunology ; Immunity, Innate ; *SARS-CoV-2/immunology ; Animals ; Adaptive Immunity ; },
abstract = {Long coronavirus disease 2019 (Long COVID-19), also referred to as post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has emerged as a major global health challenge. Common manifestations include fatigue, dyspnea, cognitive dysfunction, and exercise intolerance. Beyond these systemic manifestations, the enduring cardiovascular manifestations are increasingly identified as core characteristics of Long COVID-19 syndromes secondary to SARS-CoV-2 infection, encompassing myocarditis, ischemic and non-ischemic heart disease, arrhythmias, heart failure, and thrombotic events. Accumulating evidence suggests that immune dysregulation and persistent inflammation are central drivers of cardiovascular injury in Long COVID. Persistent activation of innate and adaptive immune pathways fosters endothelial injury, thrombo-inflammation, and adverse myocardial remodeling. In this review, we focus on current clinical and experimental evidence to delineate the immune-mediated mechanisms underlying cardiovascular sequelae in Long COVID and explore potential therapeutic strategies targeting persistent inflammation and immune dysregulation.},
}
@article {pmid42421959,
year = {2026},
author = {Bansal, A},
title = {Proteomic landscapes of post-COVID condition: biomarkers and translational pathways.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1783192},
pmid = {42421959},
issn = {1664-3224},
mesh = {Humans ; *Biomarkers/blood/metabolism ; *Proteomics/methods ; *COVID-19/complications/immunology/metabolism ; Post-Acute COVID-19 Syndrome ; *SARS-CoV-2 ; },
abstract = {Post-COVID condition is a heterogeneous, multi-system sequela of SARS-CoV-2 infection that imposes substantial socioeconomic burden and currently needs validated diagnostic biomarkers or established therapeutic pathways. This brief communication synthesises blood-based proteomic and targeted biomarker evidence and organises it into three overlapping pathophysiological domains: persistent immune dysregulation (IL-6, IL-20, MCP-1 and TNF- α), endothelial dysfunction and disordered haemostasis (VEGF-A, P-selectin, vWF, ICAM-1 and D-dimer); and neurological injury (NFL, GFAP, NAAA, LXN, NBL1, HAGH). Across studies, no single protein provides adequate diagnostic performance; phenotype-linked multi-analyte panels show the greatest promise. Researching post-COVID conditions requires harmonised case definitions, cross-platform validation, and the integration of coagulation assays and extracellular vesicle profiling to improve tissue signal detection.},
}
@article {pmid42421968,
year = {2026},
author = {Ramesh, RP and Premraj, A and Yasmin, H and Alkaabi, H and Dodan, S and Almahri, M and Alameri, N and Alyaarbi, YY and Mohteshamuddin, K and Al Aiyan, A and George, AJT and Conca, W and Kishore, U},
title = {Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovation.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1833289},
pmid = {42421968},
issn = {1664-3224},
mesh = {Animals ; *Immunity, Innate ; *Adaptive Immunity ; *Camelidae/immunology/genetics ; *Biological Evolution ; Humans ; *Adaptation, Physiological/immunology ; Camelus/immunology ; },
abstract = {Camelids have evolved to survive some of the most challenging climatic conditions on our planet and are resilient to physiological stress such as temperature extremes, drought, storms, intense ultraviolet radiation, dehydration, and starvation. They exhibit remarkable resistance to several diseases that severely affect other livestock including tetanus, foot-and-mouth disease, and bovine spongiform encephalopathy. The robust nature of the camelid immune system, which maintains functionality under extreme conditions, is remarkable. The special features of the camelid immune system include differences (when compared to ruminants) in the distribution and anatomy of their lymphoid organs. The innate immune system merits further investigation, though potent antimicrobial peptides have been identified in camelid milk. It is in the adaptive immune response that the most distinctive aspects of the camelid immune system are seen, especially, the presence of heavy chain-only antibodies, somatic hypermutation of T cell receptors; in the dromedary, a significant number of γδ T cells. In this review, the interplay between innate and adaptive immunity in camelids is examined, highlighting their functions in systemic and mucosal immune defense. An understanding of these adaptations is important for the development of innovative biomedical applications, such as nanobody-based diagnostics and therapeutics. In addition, dromedary camels are the main likely animal reservoir for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), an emerging zoonotic pathogen with potential for large-scale human spillover. Finally, as climate change is likely to result in increased environmental stress worldwide, a comparison of how the immune system in different species has adapted to their environment will be important.},
}
@article {pmid42422050,
year = {2026},
author = {Ha, KM},
title = {A post-PHEIC review of cultural awareness in the COVID-19 response.},
journal = {Public health reviews},
volume = {47},
number = {},
pages = {1608243},
pmid = {42422050},
issn = {0301-0422},
abstract = {OBJECTIVES: The PHEIC status of COVID-19 was officially lifted by the WHO on May 5, 2023. However, many nations continue to grapple with its impacts, particularly those that have not fully embraced the emergency culture. This study aims to explore ways to enhance emergency culture that rose during the COVID-19 response, ultimately contributing to effective pandemic management.<br><br>METHODS: A systematic literature review, including the PRISMA 2020 flow diagram and checklist, was used to compare cultural unawareness with cultural awareness across six nations: Japan, Sweden, South Africa, the United States, Brazil, and Australia.<br><br>RESULTS: To varying degrees, all six nations exhibited cultural unawareness during their COVID-19 responses, which manifested in issues such as personal responsibilities, herd immunity, inequalities, individualism, economic priorities, language barriers, and other factors.<br><br>CONCLUSION: These six nations must adaptively transform their cultural unawareness into cultural awareness while enhancing leadership, communication, cultural competence, emergency preparedness, and international cooperation. This study offers a comprehensive perspective on the emergency culture surrounding the coronavirus pandemic, emphasizing the critical importance of cultural awareness.},
}
@article {pmid42422161,
year = {2026},
author = {Santis, B and Baldo, F and Vento, G and Nobile, S},
title = {Impact of COVID-19 on Subsequent Lung Function in Childhood: A Systematized Review.},
journal = {Health science reports},
volume = {9},
number = {7},
pages = {e72793},
pmid = {42422161},
issn = {2398-8835},
abstract = {BACKGROUND AND AIMS: The SARS-CoV-2 infection can lead to transiently altered lung function in adults, but data is less clear in children. We aimed to summarize the available evidence about respiratory outcomes after COVID-19 in childhood.<br><br>METHODS: We conducted a literature search on post-COVID-19 lung function tests (LFT) on the Medline and Cochrane databases, including studies published between 2019 and 2025.<br><br>RESULTS: Three hundred forty-seven publications were identified, and 20 were selected. Results are presented in two sections, based on the duration of follow-up. Most studies included spirometry, whereas many of them presented data from diffusing lung capacity for carbon monoxide, multiple breath nitrogen washout, fractional exhaled nitric oxide, impulse oscillometry, 6-minute walking test, and interrupter resistance. Five papers described no association between COVID-19 and respiratory outcomes, nor a link between the persistence of symptoms and the outcomes. Other authors reported a mild obstructive pattern which showed reversibility post bronchodilators, or a restrictive pattern, particularly when long-COVID was evident. Some papers showed that pulmonary function may be influenced by the initial severity of the SARS-CoV-2 infection.<br><br>CONCLUSION: Some studies reported no clear association between lung function impairment and previous history of COVID-19. Other authors reported mild, transient consequences. A small number of papers concluded that severe infection, which is relatively rare in children, might affect pulmonary function. The main limitation of this review was the high heterogeneity of the included studies, especially regarding the COVID-19 severity, the age groups, the LFT details, and the duration of follow-up.},
}
@article {pmid42422237,
year = {2026},
author = {Garzón-Duque, MO and Rodriguez-Ospina, FL and Tobón, ST and Vasquez-Trespalacios, EM and Naranjo, VM},
title = {Food insecurity, habits, and working conditions in subsistence workers during COVID-19 isolation, Medellin, Colombia, 2021.},
journal = {Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT},
volume = {24},
number = {},
pages = {e20261279},
pmid = {42422237},
issn = {1679-4435},
abstract = {INTRODUCTION: Mandatory isolation and quarantine measures implemented between 2020 and 2021 had important repercussions on labor dynamics.<br><br>OBJECTIVES: To identify the characteristics of COVID-19 isolation, as well as the habits and working conditions that characterize food insecurity in subsistence workers in Medellin, Colombia, in 2021.<br><br>METHODS: Cross-sectional study using primary data sources. An interviewer-administered survey was conducted among 656 workers selected through snowball sampling.<br><br>RESULTS: Overall, 56.4% were men and 74.7% were aged &#x2265;45 years. Furthermore, 89.9% of women were the primary household income provider, and 74.8% did not have a partner. Alcohol and tobacco use were more frequent among men, and 43.0% of women consumed two meals a day. Furthermore, 95.6% of participants underwent mandatory quarantine; 73.2% remained isolated > 12 weeks; and 77.0% received support during isolation. The prevalence of moderate/severe food insecurity was 44.1%, increasing to 51.4% among women. Conditions characterizing food insecurity included being female, consuming one meal a day, not having a partner, being the primary household income provider, lacking work permit, not receiving government food assistance, making payment arrangements with landlords, and receiving food assistance from a university.<br><br>CONCLUSIONS: Although food insecurity decreased by 10 percentage points, the conditions characterizing it reveal the subsistence circumstances experienced by workers, particularly women, whose social and occupational disadvantage deepened.},
}
@article {pmid42424026,
year = {2026},
author = {Kianfar, E},
title = {Vitamins impacting mental/physical well-being during viral pandemics: a mechanistic review based on COVID-19: a comprehensive review.},
journal = {Inflammopharmacology},
volume = {},
number = {},
pages = {},
pmid = {42424026},
issn = {1568-5608},
abstract = {The emergence of novel strains of SARS-CoV-2 highlights the pressing need to investigate various strategies for enhancing pandemic resilience. Even though tried-and-true methods like social separation, masks, and vaccinations have proven effective, issues with immunizations make finding a global answer more complex. This paper underscores the pivotal connection between immunological resilience and vitamins, shedding light on the compromised immune response resulting from undernourishment. Vitamins become essential for protecting the body from viral invasion, particularly from SARS-CoV-2. Crucial roles in cellular activities are played by vitamin A, which is necessary for vision, and the B-vitamin complex, which supports energy synthesis and nerve function. In the context of viral infections, the significance of vitamin D, crucial for both immune system function and bone health, along with vitamin C and its ability to combat free radicals, becomes paramount.This research aims to to elucidate the specific effects and mechanisms by which essential vitamins (A, B, C, D, and E) contribute to the mitigation of COVID-19. By investigating the distinct roles of vitamins within the framework of the pandemic, this research seeks to clarify the potential benefits that these micronutrients may offer in mitigating the severity of COVID-19 and bolstering immune responses to combat viral infectons.},
}
@article {pmid42424341,
year = {2026},
author = {Ruan, B and Tian, J and Wang, X and Su, D},
title = {The Association Between eHealth Literacy and Health Behaviors During and Since the COVID-19 Pandemic: Systematic Review and Meta-Analysis.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e94233},
pmid = {42424341},
issn = {1438-8871},
mesh = {Humans ; *COVID-19/epidemiology ; Digital Health ; *Health Behavior ; *Health Literacy ; *Pandemics ; *Telemedicine ; },
abstract = {BACKGROUND: Since COVID-19, health information seeking, service navigation, and routine care have become increasingly digitally mediated. It remains unclear whether the association between eHealth literacy and health behaviors is consistent across behavioral domains, populations, and analytic frameworks.<br><br>OBJECTIVE: This systematic review and meta-analysis synthesized COVID-19 and post-COVID-19 evidence on the association between eHealth literacy and health behaviors and examined variation across study contexts.<br><br>METHODS: We conducted a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020-compliant, PROSPERO-registered review (CRD420251009048). PubMed, Embase, Web of Science Core Collection, CINAHL Ultimate, and Scopus were searched from January 1, 2020, through March 27, 2026. Eligible observational studies assessed eHealth literacy and reported analyzable associations with health behavior outcomes collected in 2020 or later. Health behaviors were classified as health decision-making, health-promoting, or health management behaviors. Correlation coefficients, grouped odds ratios (ORs), and continuous ORs were synthesized separately using random-effects models with Knapp-Hartung adjustment. Certainty was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.<br><br>RESULTS: In total, 19 studies were included: 10 contributed correlation coefficients, 6 grouped ORs, and 3 continuous ORs. In the correlation-based synthesis, higher eHealth literacy was associated with more favorable health behaviors (pooled r=0.43, 95% CI 0.36-0.51; 95% prediction interval 0.22-0.61), with substantial heterogeneity (I2=80.50%). In the grouped OR synthesis, higher eHealth literacy was also associated with more favorable health behaviors (pooled OR 2.12, 95% CI 1.47-3.05; 95% prediction interval 1.11-4.06), with moderate heterogeneity (I2=46.33%). In the continuous OR synthesis, all 3 studies showed positive associations, but the pooled effect was not statistically significant (pooled OR 1.07, 95% CI 0.89-1.30; 95% prediction interval 0.84-1.37), with very high heterogeneity (I2=97.98%). Subgroup analyses showed a significant difference only by geriatric status in the grouped OR synthesis. Certainty was low for the grouped OR synthesis and very low for the other 2 syntheses.<br><br>CONCLUSIONS: Higher eHealth literacy was generally associated with more favorable health behaviors in the correlation-based and grouped OR syntheses, whereas evidence from the continuous OR synthesis was inconclusive. Given the predominantly cross-sectional evidence base, heterogeneity, risk-of-bias concerns, and low to very low certainty, the association should be interpreted as contextual and associative rather than causal or uniform. This review is innovative in synthesizing COVID-19 and post-COVID-19 evidence, applying a functional classification of health behaviors, and analyzing distinct effect measures separately. Unlike previous reviews that summarized the association more broadly, it avoids a single mixed pooled effect and provides a cautious, context-specific interpretation. In practice, interventions should pair eHealth literacy improvement with trustworthy digital services, clinician support, and behavior-specific conditions that help translate digital information into sustained health-related action.},
}
@article {pmid42424858,
year = {2026},
author = {Etemadifar, M and Salari, M and Rezaei, K and Hojjatipour, F},
title = {Multiple sclerosis during an emergency or crisis: A narrative review focused on the effect of war and COVID-19 pandemic.},
journal = {Multiple sclerosis and related disorders},
volume = {113},
number = {},
pages = {107361},
doi = {10.1016/j.msard.2026.107361},
pmid = {42424858},
issn = {2211-0356},
abstract = {BACKGROUND: Armed conflict fractures the systems that multiple sclerosis (MS) care depends on, yet MS-specific guidance for war is scarce. The aim of this study is to synthesize evidence on MS care during armed conflict and other crises, and to develop practical, crisis-ready recommendations to maintain treatment continuity, reduce inequities, and guide clinicians and policymakers.<br><br>METHODS: We reviewed peer-reviewed literature (2000-2025) on MS during conflicts; when MS-war data were scarce, we utilized transferable evidence from COVID-19 MS studies.<br><br>RESULTS AND CONCLUSION: War disrupts disease-modifying therapies (DMT) supply, safety monitoring, rehabilitation, and continuity of care, widening inequities. A key controversy was whether to continue higher-risk DMTs with limited labs/MRI, and which monitoring to prioritize. Our recommendations established a five-action basis: create a single MS crisis hub (information, tele-access, patient passports), safeguard DMTs with lean pharmacovigilance and predefined substitutions, adopt tele-first care with a relapse pathway favoring high-dose oral steroids when appropriate, deliver equity-first outreach via mobile clinics and transport/fee support, and run a minimal data loop (stock, relapses, severe adverse events, hospitalizations, brief fatigue screening) for weekly course correction. Additionally, the basis of recommendations was transformed into a three-stage guideline figure.},
}
@article {pmid42424887,
year = {2026},
author = {Hayes, JE and Hayes, SA and Wilkins, D and Lindley, MR and Stuetz, RM},
title = {Olfaction as a diagnostic instrument - a review of current, and future medical applications.},
journal = {Talanta},
volume = {311},
number = {},
pages = {130256},
doi = {10.1016/j.talanta.2026.130256},
pmid = {42424887},
issn = {1873-3573},
abstract = {The olfactory sense has evolved to provide environmental and physiological cues through the detection of volatile organic compounds. While historically a clinician's sense of smell was used to assist in diagnosing illness, with some notable exceptions, this has fallen out of favour with the advent of analytical tools. Recently, world events have shown that olfactory methodologies can be highly useful for diagnostic purposes. The emergence of the SARS-CoV-2 virus (causing COVID-19) presented a number of logistical issues with regards to establishing fast and accurate diagnosis-while the idea of detection dogs was proposed at the time, little in the way of routine clinical application was accomplished for this disease. The reasons for this are multifactored, but the use of olfaction as a diagnostic tool can be efficacious, provided appropriate methodological considerations are met. Here, the use of olfaction within a medical diagnostic framework is discussed; with olfactory diagnosis having the potential of very high sensitivity and specificity, but with a low diagnostic cost in terms of expense, time, and patient discomfort. This review will also discuss the ways in which olfactory medical diagnosis can be accomplished using humans, dogs, as well as other animals. Finally, this paper will outline recommendations of how future olfactory diagnostic options can be researched and implemented to ensure best practice.},
}
@article {pmid42425738,
year = {2026},
author = {Lac, J and Han, S and Ahmad, M and Starey, H and Ganguly, S and Tett, M and Adeyemi, O and Bray, JJH and Ahmad, MT and Providência, R},
title = {Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.},
journal = {BMJ open respiratory research},
volume = {13},
number = {1},
pages = {},
pmid = {42425738},
issn = {2052-4439},
mesh = {Humans ; Randomized Controlled Trials as Topic ; *Adrenal Cortex Hormones/administration &amp; dosage ; Length of Stay/statistics &amp; numerical data ; Community-Acquired Pneumonia/drug therapy/mortality ; Intensive Care Units ; Respiratory Distress Syndrome/drug therapy/mortality ; COVID-19/mortality ; COVID-19 Drug Treatment ; Pneumonia, Pneumocystis/drug therapy/mortality ; Community-Acquired Infections/drug therapy/mortality ; SARS-CoV-2 ; Sepsis/drug therapy/mortality ; },
abstract = {PURPOSE: Pulmonary infections are one of the leading causes of intensive care unit (ICU) admission and contribute to high mortality rates. This paper aimed to determine the effect of low-dose corticosteroids on outcomes in patients with severe pulmonary infections, including coronavirus disease of 2019, community-acquired pneumonia (CAP), pneumocystis pneumonia, sepsis, septic shock, and acute respiratory distress syndrome.<br><br>METHODS: We systematically reviewed randomised controlled trials (RCTs) comparing low-dose corticosteroids (&#x2264;400&#x2009;mg hydrocortisone-equivalent daily) to placebo or standard care in adults with severe pulmonary infections. The primary outcome was short-term mortality (&#x2264;90 days). Secondary outcomes included 28-day mortality, 30-day mortality, number of patients with at least one serious adverse event, length of hospital stay and ICU stay.<br><br>RESULTS: We analysed twelve RCTs including 4622 patients and 1203 events. The pooled OR showed a short-term mortality benefit: 0.83 (95% CI 0.70 to 0.98; p=0.029; I&#xb2;=2.0%; number needed to treat: 37.84; Grading of Recommendations Assessment, Development and Evaluation (GRADE): low certainty). There was a reduction in length of ICU stay in patients with CAP, with a pooled mean difference of -0.78&#x2009;days (95%&#x2009;CI -1.46 to -0.10, p=0.025). The use of corticosteroids did not significantly affect the length of hospital stay or severe adverse events. A significant difference remained in longer courses of steroids, whereas shorter courses had no significant difference (&#x2264;7&#x2009;days vs >7&#x2009;days; OR: 0.69; 95%&#x2009;CI 0.53 to 0.89; p=0.039&#x2009;vs OR: 0.96; 95%&#x2009;CI 0.813 to 1.14; p=0.67; subgroup differences: p=0.03). Subgroup analyses in patients with CAP showed a significant benefit in short-term mortality (OR: 0.72, 95%&#x2009;CI 0.54 to 0.98; p=0.034; number needed to treat: 28.10).<br><br>CONCLUSION: We found that low-dose corticosteroids significantly reduce 90-day mortality in severe CAP, although evidence for their benefit in other severe pulmonary infections and at shorter follow-up intervals remains inconclusive.<br><br>PROSPERO REGISTRATION NUMBER: CRD42024627881.},
}
@article {pmid42427146,
year = {2026},
author = {Ghosh, AK and Overgaard, JD and Abubeker, I and Rice, EM and Larson, AM and Pagel, EM and Hurt, RT and Gilman, EA},
title = {Consultative General Internal Medicine for Complex Care: The Model, Outcomes, and Lessons Learned.},
journal = {The Permanente journal},
volume = {},
number = {},
pages = {1-7},
doi = {10.7812/TPP/25.212},
pmid = {42427146},
issn = {1552-5775},
abstract = {As the landscape of modern medicine evolves, new health care delivery models are needed to meet the growing complexity of medical care. Primary care clinicians are increasingly managing patients with multiple chronic conditions, a challenge that will intensify as the population ages. Complex medical care involves multiple factors that contribute to difficulties in providing optimal quality of care for patients facing these types of medical problems. To address this need, models of consultative general internal medicine have emerged at various tertiary care institutions across the United States to synthesize prior evaluations, recommend appropriate testing and specialty consultations, and integrate findings into a cohesive care plan for implementation by patients' local care teams. Variability in expertise, patient volume, and structure exists across institutions, but the expansion of multidisciplinary care capabilities during the COVID-19 pandemic has created new opportunities for destination-type practices. This narrative review explores how consultative medicine will be crucial to providing integrative, patient-centric care by enhancing diagnostic accuracy, coordinating multidisciplinary input, and communicating actionable care plans to patients.},
}
@article {pmid42428921,
year = {2026},
author = {Kassymbek, S and Abduldayeva, A and Safonov, N},
title = {Global prevalence of post-COVID-19 condition (Long COVID): a systematic review and meta-analysis of observational studies.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1839646},
pmid = {42428921},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology/complications ; *Global Health/statistics &amp; numerical data ; Observational Studies as Topic ; *Post-Acute COVID-19 Syndrome/complications/epidemiology ; Prevalence ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Long COVID is an umbrella term for persistent, relapsing, or newly developed health problems after SARS-CoV-2 infection, whereas post-COVID-19 condition (PCC) refers more specifically to the World Health Organization clinical case definition. Reported prevalence varies substantially because of differences in terminology, operational definitions, study populations, follow-up duration, hospitalization status, and symptom ascertainment. This systematic review and meta-analysis synthesized global observational evidence on Long COVID/PCC prevalence and examined major sources of variability.<br><br>METHODS: A systematic review and meta-analysis was conducted according to PRISMA 2020 principles. PubMed/MEDLINE, Scopus, Web of Science, and the WHO COVID-19 Global Literature Database were searched for studies published from 1 January 2020 to 23 February 2026. Observational studies were eligible if they included individuals with confirmed or probable SARS-CoV-2 infection, reported Long COVID/PCC or persistent post-COVID symptoms at least 4 weeks after acute infection, and provided numerator and denominator data. Terminology and operational case definitions were extracted separately. Prevalence estimates were pooled using a random-effects model with logit transformation and back-transformation. Heterogeneity was assessed using Cochran's Q, I[2], tau[2], and prediction intervals. Subgroup and sensitivity analyses were performed.<br><br>RESULTS: Twenty-two studies contributing 27 prevalence estimates and more than 200,000 participants were included. The primary estimate-level pooled prevalence was 30.8% (95% CI 26.8-35.0). Heterogeneity was extreme: Q = 8031.9, df = 26, p < 0.001; I[2] = 99.7%; tau[2] = 0.252 on the logit scale. The prediction interval was 14.0-54.8%. Pooled prevalence was higher among hospitalized cohorts (37.9%, 95% CI 29.5-47.1) than among non-hospitalized, community-based, or mixed cohorts (26.2%, 95% CI 22.0-30.9). WHO-defined PCC yielded lower prevalence (22.8%, 95% CI 14.3-34.4) than broader symptom-based definitions (39.7%, 95% CI 30.5-49.5). Cohort-level sensitivity analysis yielded a similar prevalence of 31.0% (95% CI 26.8-35.4).<br><br>CONCLUSION: Long COVID/PCC represents a substantial post-acute public health burden. However, because heterogeneity was extreme, the pooled prevalence should be interpreted as a descriptive summary of heterogeneous observational evidence rather than as a single precise global rate. Standardized definitions, harmonized surveillance, transparent reporting, rehabilitation pathways, and multidisciplinary care models are needed.},
}
@article {pmid42430764,
year = {2026},
author = {Hasenpusch, C and Kuper, P and Skiba, EM and Sprenger, AA and Matterne, U and Kannengießer, L and Grätsch, EI and Shin, J and Li, M and Apfelbacher, CJ},
title = {Interventions to Enhance COVID-19 Pandemic Health Literacy in Health Professionals: Systematic Review.},
journal = {JMIR medical education},
volume = {12},
number = {},
pages = {e70400},
pmid = {42430764},
issn = {2369-3762},
mesh = {Humans ; *COVID-19/epidemiology/prevention &amp; control ; *Health Literacy/methods ; *Health Personnel/education ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: The COVID-19 pandemic has placed a significant burden on health professionals (HPs). They face higher infection risks due to the nature of their work environment and patient care responsibilities. Their ability to access and apply reliable COVID-19 information affects their own preventive behavior and that of those around them. In this context, health literacy (HL) has become increasingly important. Despite extensive research, information to foster COVID-19-related HL in HPs remains limited.<br><br>OBJECTIVE: This systematic review aimed to identify, appraise, and synthesize intervention studies on the effectiveness of COVID-19-related HL interventions in HPs.<br><br>METHODS: Five electronic databases (eg, PubMed (MEDLINE), Embase), six clinical trials registries (eg, ISRCTN registry), one preprint server (MEDRXIV), published conference proceedings, and five gray literature databases (eg, opengrey.eu, ProQuest) were searched in May 2022 and updated in August 2025. Reference lists of included studies were screened manually. Two reviewers independently screened titles, abstracts, and full-texts according to eligibility criteria and extracted data; disagreements were resolved by discussion or consultation with a third reviewer. We included randomized controlled trials (RCTs), nonrandomized studies of interventions, and uncontrolled before-and-after studies evaluating the effectiveness of any COVID-19-related HL intervention. Primary outcomes include COVID-19-related HL, its four facets (access, understand, appraise, and apply COVID-19 information), and indicators (eg, COVID-19-related knowledge), assessed at postintervention and follow-up. When studies were sufficiently similar, random-effects meta-analyses were performed; otherwise, a narrative synthesis was provided. Risk of bias was assessed using validated tools based on study design, and the overall certainty of the evidence was evaluated by the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.<br><br>RESULTS: We included 15 RCTs (2034 participants), 4 nonrandomized studies of interventions (291 participants), 74 uncontrolled before-and-after studies (327,298 participants), 5 ongoing studies, and 1 study with awaiting classification. Interventions targeted a broad range of health occupational groups. Intervention type, delivery mode, methods, settings, and comparator varied widely. No outcome measure explicitly referred to an HL model. Most studies aimed to enhance COVID-19-related knowledge and skills, and had a high risk of bias. COVID-19-related interventions may increase knowledge of vaccines (standardized mean difference 1.00; 95% CI 0.33 to 1.67, I2=24%), and the infection prevention control skills, such as donning and doffing of personal protective equipment (standardized mean difference 1.95; 95% CI 1.82 to 3.09, I2=46%), but the evidence remains very uncertain.<br><br>CONCLUSIONS: COVID-19-related HL interventions may promote HP's short-term competencies in infection control. However, the evidence remains uncertain, primarily due to the low quality of studies, characterized by a high risk of bias. Interventions specifically designed to enhance the full COVID-19 HL operationalized by its four facets are lacking. High-quality RCTs with sufficient statistical power, grounded in HL theoretical principles, are needed to achieve precise understanding.},
}
@article {pmid42430872,
year = {2026},
author = {Hensley, AA and Jiles, KA and Edwards, S and Clinchard, C and Hosig, K},
title = {Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression.},
journal = {Vaccine},
volume = {88},
number = {},
pages = {128910},
pmid = {42430872},
issn = {1873-2518},
support = {UL1 TR003015/TR/NCATS NIH HHS/United States ; },
abstract = {BACKGROUND: Vaccine-preventable diseases continue to burden U.S. population health. Despite the Affordable Care Act (ACA) eliminating cost-sharing for recommended vaccines in 2010, adult vaccination rates persistently fall below Healthy People 2030 targets, signaling that access alone is insufficient.<br><br>OBJECTIVES: To synthesize peer-reviewed literature (2010-2025) on interventions designed to increase vaccine intention or uptake among U.S. adults; characterize strategies, populations, settings, and study quality; and identify predictors of vaccine uptake rate.<br><br>METHODS: Following PRISMA 2020 guidelines, a multi-database search was conducted across PubMed, Web of Science, Ovid/MEDLINE, and EBSCOhost, with a final updated search in December 2025. Dual independent reviewers screened studies in two stages. Quality was assessed using the EPHPP tool and certainty evaluated using GRADE. Strategies were categorized per the WHO Behavioral and Social Drivers of Vaccination (BeSD) Model. A meta-regression was conducted on 79 studies, with narrative synthesis across all 92 included studies.<br><br>RESULTS: Of 11,219 records, 92 studies were included. Study designs were predominantly RCTs; Influenza and COVID-19 vaccines were most commonly studied. In the meta-regression (adjusted R[2] = 0.229), prioritizing a specific population (b=0.121, p=.027), using service quality improvement strategies (b=0.226, p=.040), and recruiting through community-based partner organizations (b=0.585, p=.005) or healthcare organizations (b=0.230, p=.040) were associated with significantly higher vaccine uptake rates. Onsite vaccination was associated with lower uptake rates (b=-0.185, p=.033), an effect confirmed as specific to the COVID-19 pandemic emergency-response context rather than a generalizable effect of the strategy in sensitivity analysis. Narrative synthesis identified message framing and educational campaigns as the most frequently deployed strategies, with multi-component designs and community partnerships showing the most favorable outcomes.<br><br>CONCLUSIONS: Effective adult vaccination strategies were multifactorial. Service quality improvement, priority population focus, and community-based recruitment were the strongest predictors of higher uptake. Findings support the WHO BeSD model's Practical Issues domain: reducing friction outperformed persuasion alone. GRADE certainty remained LOW to MODERATE, emphasizing the need for higher-quality, equity-focused research.<br><br>REGISTRATION: This systematic review was registered at Open Science Framework: 10.17605/OSF.IO/SM7YD.},
}
@article {pmid42432642,
year = {2026},
author = {Jöud, AS and Thorén, H and Spreco, A and Lundh, T and Timpka, T and Gerlee, P},
title = {Computational forecasting using Swedish data in the vaccination phase of the COVID-19 pandemic: a systematic literature review deliberating modelling relevance for public health and healthcare.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {42432642},
issn = {1472-6963},
mesh = {Sweden/epidemiology ; Humans ; *COVID-19/prevention &amp; control/epidemiology ; Forecasting/methods ; *Public Health ; *Vaccination ; *COVID-19 Vaccines ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: The benefits of computational forecasting in the later phase of the COVID-19 pandemic when vaccines and clinical pharmaceutical interventions were available have seldom been assessed. We aimed to evaluate computational forecasting research applied to Swedish populations in the vaccination phase of the pandemic.<br><br>METHODS: A systematic search was performed on March 8, 2024 in the electronic databases PubMed, Scopus, Cochrane library, Embase, Love platform and Epistemikos. An updated version of the Risk of bias Opinion Tool (ROBOT) was used to assess the quality of evidence reported in the papers identified in the search. The articles fulfilling the quality criteria were assessed for suitability for meta-analysis. Data were extracted from the selected articles for synthesis of characteristics, and a thematic analysis was used for a qualitative synthesis of the contents.<br><br>RESULTS: Of 2034 unique publications identified in the database search, 6 articles satisfied the selection and quality criteria. Variability in the reporting of forecasting performance results was found to make a quantitative meta-analysis of forecast performance infeasible. The data synthesis showed that statistical modeling using Bayesian calibration was the most common methodological approach. No external model validation was reported, but 5/6 articles included internal model corroboration data. The primary theme resulting from the qualitative synthesis of article content was design or refinement of computational models with demonstration of model use in health service practice as a secondary theme. None of the articles referred to health service policymaking as the primary research context.<br><br>CONCLUSION: Computational forecasting research using Swedish population data from the vaccination phase of the COVID-19 pandemic was deployed in a model design context. While methodological knowledge was developed, most of the research was not initiated to solve the public health and healthcare problems at hand. Our results indicate that the alignment between computational forecasting research and policymaking needs in the vaccination phase of pandemics can be enhanced.},
}
@article {pmid42432680,
year = {2026},
author = {Sasso, EM and Eaton-Fitch, N and Thapaliya, K and Marshall-Gradisnik, S},
title = {Neurological impairment in long COVID: implications for neurodegenerative disease.},
journal = {Journal of translational medicine},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12967-026-08607-y},
pmid = {42432680},
issn = {1479-5876},
support = {489798//Stafford Fox Medical Research Foundation/ ; 1199502//National Health and Medical Research Council/ ; 47107//Mason Foundation/ ; 49979//McCusker Charitable Foundation/ ; 4676//Ian and Talei Stewart, the Buxton Foundation/ ; 4579//Blake Beckett Trust Foundation/ ; 4570//Alison Hunter Memorial Foundation/ ; 4575//Change for ME Charity/ ; Dr John Hamwood//Dr John Hamwood/ ; 4879//Henty Community/ ; },
abstract = {BACKGROUND: It has been six years since the COVID-19 pandemic and, despite substantial advances in management, the disease sequelae known as long COVID continues to represent a significant medical and societal burden. Long COVID is characterised by persistent neurological and neurocognitive symptoms, including brain fog, memory deficits, attention impairments, and fatigue, lasting for months after acute SARS-CoV-2 infection.<br><br>MAIN BODY: In this review, we collated emerging neurological findings related to long COVID, discussing neurodegenerative processes associated with long COVID, potential clinical implications and research limitations. Neurological and neurocognitive manifestations arise through multiple mechanisms, including direct SARS-CoV-2 invasion of the central nervous system and peripheral lymphocyte infiltration. Additionally, neurovascular damage potentially contributes to neurodegeneration through neuronal injury, impaired neurogenesis, microvascular abnormality and sustained neuroinflammation.<br><br>CONCLUSION: Understanding the mechanisms underlying neurological and neurocognitive symptoms is essential for developing long-term monitoring strategies and targeted interventions to mitigate neurocognitive decline in individuals with long COVID.},
}
@article {pmid42433760,
year = {2026},
author = {Magsi, IA and Advani, A and Alokozay, E and Qutub, Z and Hamid, M and Kharka, M and Kunwar, R and Ahsan, S and Msheik, A and Waqas, SA and Hassan, A and Waseem, N and Patel, T and Ahmed, R and Hemida, MF},
title = {Trends and disparities in HIV before and after COVID-19 from 1999 to 2023.},
journal = {Annals of medicine and surgery (2012)},
volume = {88},
number = {7},
pages = {4306-4313},
pmid = {42433760},
issn = {2049-0801},
abstract = {Despite advances in human immunodeficiency virus (HIV) treatment, disparities in HIV-related mortality persist across demographic groups in the United States. The COVID-19 pandemic disrupted healthcare systems and may have influenced established mortality trends. This study evaluates HIV-related mortality in the U.S. from 1999 to 2023, with emphasis on changes following the onset of COVID-19. Data were obtained from the CDC WONDER database, identifying HIV-related deaths (ICD-10: B20-B24) among adults aged 25 to 85+. Age-adjusted mortality rates (AAMR) per 100 000 were calculated. Trends were analyzed using Joinpoint regression to estimate annual percent changes (APCs) and average annual percent changes (AAPCs). From 1999 to 2023, there were 271 932 HIV-related deaths in the U.S. The overall AAMR declined by an AAPC of -4.34%, with a slower post-COVID decline of -4.19% (P < 0.05) from 2020 to 2023. Gender-stratified analysis showed greater post-COVID declines in women (APC: - .58%) than in men (APC: -3.90%). Older adults (85+) experienced a post-COVID increase in mortality (APC: +12.37%). Urban centers showed an APC increase (+2.33%), while rural areas continued to decline. Racial disparities narrowed modestly. Black and Hispanic populations saw sharper post-COVID declines (APCs: -6.21% and -6.26%, respectively) compared to White populations (-1.33%). The Southern U.S. remained the highest-burdened region across both timeframes. Observed mortality trends were temporally associated with demographic characteristics and urbanization patterns during the COVID-19 period. While HIV mortality continues to decline, the COVID-19 pandemic has disrupted progress, especially among elderly and urban populations. Persistent disparities demand targeted, equitable public health interventions.},
}
@article {pmid42433775,
year = {2026},
author = {Abera, EG and Himbaro, SA and Megersa, SW and Ashine, AH and Tukeni, KN and Gebremichael, EH},
title = {Emerging trends in post-COVID immune dysregulation: a narrative review.},
journal = {Annals of medicine and surgery (2012)},
volume = {88},
number = {7},
pages = {4362-4370},
pmid = {42433775},
issn = {2049-0801},
abstract = {BACKGROUND: Long coronavirus disease (COVID), or post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a multi-system condition associated with persistent immune dysregulation, autoimmunity, and vascular perturbations. Understanding these immunological mechanisms is essential for guiding clinical management and therapeutic strategies.<br><br>METHODS: We conducted a narrative review of peer-reviewed human studies published between January 2020 and August 2025, using PubMed/Medline, Scopus, and Web of Science, supplemented by manual searches. Studies reporting immunological assessments in long COVID patients, recovered individuals, or healthy controls were included. Findings were extracted and synthesized thematically across six domains: humoral and cellular immunity, autoimmune signatures, proteomic/metabolic and vascular dysregulation, viral persistence, complement/coagulation/thromboinflammation, and pediatric long COVID.<br><br>RESULTS: Long COVID is characterized by persistent low-grade inflammation, T- and B-cell dysregulation, and prolonged adaptive immune activation. Humoral responses remain elevated, while T-cell exhaustion and loss of coordination between immune compartments are common. Autoimmune phenomena, including latent and polyautoimmunity targeting cytokines, thyroid antigens, and interferons, are frequently observed. Proteomic, metabolic, and vascular perturbations, complement activation, and thromboinflammatory processes contribute to ongoing symptoms. Viral persistence and early immune biomarkers predict long COVID development. These immune alterations correlate with fatigue, cognitive impairment, respiratory dysfunction, and reduced quality of life in both adults and children.<br><br>CONCLUSION: SARS-CoV-2 infection leaves a lasting immunological footprint marked by chronic inflammation, adaptive immune dysregulation, autoimmunity, and vascular perturbations. Integrating longitudinal immune assessments, biomarker profiling, and early predictive markers is critical for identifying high-risk individuals and informing interventions to reduce long COVID morbidity.},
}
@article {pmid42434515,
year = {2026},
author = {Chen, B and Tao, X and Wang, Y},
title = {Emerging Strategies for Antitumor Immunotherapy and Antiviral Defense Through the cGAS-STING Pathway.},
journal = {International journal of nanomedicine},
volume = {21},
number = {},
pages = {593033},
pmid = {42434515},
issn = {1178-2013},
mesh = {Humans ; cGAS-STING Signaling Pathway ; *Immunotherapy/methods ; *Neoplasms/therapy/immunology ; *Membrane Proteins/metabolism ; *Nucleotidyltransferases/metabolism ; Animals ; STING Protein ; Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase ; Immunity, Innate ; Antiviral Agents/pharmacology ; Signal Transduction ; Virus Diseases/immunology/therapy ; Host-Directed Therapy ; },
abstract = {The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a central regulator of innate immunity and plays a critical role in inducing pro-inflammatory cytokines and type I interferons (IFN-I). This pathway has emerged as a promising target for cancer immunotherapy and antiviral treatments. Despite its promise, the clinical translation of STING agonists is hindered by several challenges, including structural instability, high production costs, and inefficient delivery systems. These barriers underscore the urgent need for further research and innovation to optimize STING-based therapies. This review provides a comprehensive overview of the cGAS-STING pathway, focusing on its activation mechanisms and recent advances aimed at enhancing its therapeutic efficacy. Alternative activators of STING, including metal ions, exogenous DNA, and endogenous DNA, are discussed for their potential to stimulate this pathway. Furthermore, synergistic therapeutic strategies combining cGAS-STING activation with reactive oxygen species (ROS)-based treatments, such as photodynamic therapy, radiotherapy, sonodynamic therapy, and chemodynamic therapy, are highlighted. Finally, recent progress in harnessing STING activation for antiviral defense against emerging pathogens, such as SARS-CoV-2 and influenza viruses, is summarized to provide insights into the future development of cGAS-STING-targeted immunotherapies.},
}
@article {pmid42434765,
year = {2026},
author = {Joshi, A and Ogbemudia, H and Cruess, C and Livinski, AA and Hall, R and Roback, E and Jain, J and Sharma, A and Smith-Davidson, P and Xu, M and Asher, V and Joseph, PV and Levy, JM},
title = {Point-of-care smell testing for evaluation of olfactory function: a narrative review of clinical utility.},
journal = {Frontiers in allergy},
volume = {7},
number = {},
pages = {1882615},
pmid = {42434765},
issn = {2673-6101},
abstract = {IMPORTANCE: Olfactory dysfunction (OD) is increasingly recognized as a clinically relevant biomarker for a wide range of health conditions, including neurodegenerative diseases, respiratory infections such as COVID-19, psychiatric disorders, and age-related sensory decline. Despite its diagnostic value, olfactory testing remains underutilized in routine clinical care due to challenges related to test accessibility, cultural adaptability, cost and practical implementation.<br><br>OBSERVATIONS: This narrative review provides a clinically focused synthesis of olfactory tests suitable for point-of-care (POC), focusing on their diagnostic accuracy, administration methods, user-friendliness, and applicability across diverse clinical populations. Commonly used tests such as the University of Pennsylvania Smell Identification Test (UPSIT&#xae;) and Sniffin' Sticks&#xae; are discussed alongside emerging rapid screening tools, pediatric assessments, and culturally adapted tests. Attention is given to distinguishing screening tools from comprehensive diagnostic batteries and to the role of point-of-care (POC) testing in primary care, neurology, and otorhinolaryngology settings. Practical considerations including assessment time, workflow feasibility, and clinical decision pathways are also examined. This review emphasizes the translation of available psychophysical tests into a practical POC framework for real-world clinical use.<br><br>CONCLUSIONS AND RELEVANCE: Available olfactory tests vary substantially in diagnostic accuracy, feasibility, and clinical applicability, highlighting the importance of selecting tests based on clinical indication and practice setting. Brief POC tests are best positioned as screening tools, while comprehensive batteries remain necessary when diagnostic precision is required. The main contribution of this review is a clinically oriented framework that distinguishes screening from diagnostic testing and aligns test selection with adult and pediatric clinical scenarios, workflow constraints, and referral needs. A tiered clinical approach using rapid screening followed by targeted comprehensive testing may represent the most practical, cost and time effective strategy for integrating olfactory assessment into routine care. Broader implementation of clinically feasible olfactory testing may improve early disease detection, support clinical decision making, and enhance patient care across conditions associated with OD.},
}
@article {pmid42435889,
year = {2026},
author = {Gazda, J and Koky, T and Robinska, A and Bo, N and Bjornsson, ES and Drazilova, S and Janicko, M and Díaz, LA and Rhoads, F and Jarcuska, P and Arab, JP},
title = {Epidemiology of Alcohol-Associated Hepatitis: A Systematic Review of Population-Based Studies.},
journal = {Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.cgh.2026.06.032},
pmid = {42435889},
issn = {1542-7714},
abstract = {BACKGROUND AND AIMS: Alcohol-associated hepatitis (AH) is an acute and severe manifestation of alcohol-related liver injury that can occur at any stage of fibrosis. Despite its high mortality, reliable epidemiological data on AH remain limited. We conducted a systematic review to synthesize available population-based estimates of AH annual incidence and point prevalence from 2000 to 2025.<br><br>METHODS: A comprehensive literature search of MEDLINE (PubMed), Scopus, and the Cochrane Library was performed. Eligible studies reporting population-based rates of AH were included. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data.<br><br>RESULTS: Eleven population-based studies from seven countries were included. Reported annual incidence rates of AH ranged from 1.02 per 100,000 inhabitants in Iceland to 98.5 per 100,000 inhabitants in the United States, with a median incidence rate of 6.8 cases per 100,000 inhabitants (IQR 4.2-19). Among the nine studies reporting at least two estimates over time, seven demonstrated an increasing incidence rate, whereas two reported a decrease. A pre-pandemic sensitivity analysis excluding studies affected by the COVID-19 pandemic showed a similar pattern, with incidence rates increasing in five of the seven studies. Two studies reported a surge in incidence during the COVID-19 pandemic, while one of them extended follow-up beyond the pandemic period and observed a gradual return toward pre-pandemic levels. No studies reported prevalence data.<br><br>CONCLUSION: The global burden of AH remains poorly characterized. Existing population-based estimates are highly heterogeneous, reflecting differences in case definitions as well as probable true epidemiological variation across countries, and collectively suggest an increasing trend over the past 25 years. These findings underscore the urgent need for prospective studies employing standardized and harmonized methodologies to more accurately define the burden of this condition.},
}
@article {pmid42436688,
year = {2026},
author = {Hernandez, J and Delgado, S and McCarthy, M and Nelson, F and Rammohan, K},
title = {The Impact of COVID-19 Infection and Vaccination on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody Disease: A Narrative Review.},
journal = {Journal of central nervous system disease},
volume = {18},
number = {},
pages = {11795735261467600},
pmid = {42436688},
issn = {1179-5735},
abstract = {Despite the estimated 776 million coronavirus disease 2019 (COVID-19) cases globally, little is known about its impact on immune-mediated neurological disorders such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD). Scattered case reports, and reviews address this association, but none have collectively examined the impact of COVID-19 infection or vaccination on established and new-onset NMOSD and MOGAD. Reviewing all published reports of COVID-19 infection and vaccination in NMOSD and MOGAD from December 2019 to October 2024, this report examined the effects of infection and vaccination on patients with established disease and the occurrence of new-onset NMOSD and MOGAD. Outcomes associated with COVID-19 infection in NMOSD and MOGAD patients revealed similar hospitalization rates but a notable difference in deaths in NMOSD patients treated with rituximab. Following COVID-19 infection, twice as many patients developed new-onset MOGAD compared to NMOSD, with a similar larger number of patients who developed MOGAD than NMOSD post-COVID-19 vaccination. While the heavy female predominance in NMOSD is well-established, a greater ratio of male to female patients developed MOGAD post-infection and post-vaccination. Clinicians should closely monitor NMOSD patients with COVID-19 infection, particularly those receiving B-cell depleting therapies, among whom mortality was more frequently reported. The rise in NMOSD and MOGAD following COVID-19 infection and vaccination cases warrants further investigation of the underlying immunological mechanisms. Molecular mimicry and a bystander immune-mediated injury likely play a greater role in central nervous system damage than does direct viral injury.},
}
@article {pmid42438709,
year = {2026},
author = {Torres-Pasillas, HA and Luna-García, H and Celaya-Padilla, JM and Espino-Salinas, CH and Acra-Despradel, C and Villalba-Condori, K and Cárdenas Núñez, YM},
title = {Metabolomic datasets in COVID-19 research: a systematic literature review of availability, characteristics, and methodologies.},
journal = {PeerJ},
volume = {14},
number = {},
pages = {e21313},
pmid = {42438709},
issn = {2167-8359},
mesh = {Humans ; *Metabolomics/methods ; *COVID-19/metabolism ; *Biomedical Research ; SARS-CoV-2 ; *Datasets as Topic ; Information Dissemination ; },
abstract = {The COVID-19 pandemic has accelerated the integration of metabolomics and Machine Learning in biomedical research, resulting in the creation of numerous datasets with high potential for reuse. However, information regarding their accessibility, quality, and usability remains scattered and inconsistent. This systematic review aims to identify and evaluate publicly available human metabolomic datasets related to COVID-19, providing detailed information on their main characteristics and how to access them, with the goal to inform their potential for reuse in future research. Following PRISMA guidelines and the Kitchenham methodology, we conducted a comprehensive search of the scientific literature and specialized metabolomics repositories, identifying 110 unique datasets. Each dataset was assessed based on 15 variables related to data availability, accessibility, collection methodologies, sample sizes, and the extent of participant metadata provided. These datasets offer significant value for secondary analyses and ML applications, contributing to insights into disease mechanisms, early diagnosis, and patient stratification. By offering a structured overview of dataset characteristics, this review aims to support researchers in identifying suitable resources, encourages data reuse, and promotes best practices for data sharing and standardization in the context of COVID-19 and metabolomics. Nonetheless, our findings reveal critical limitations, including the underuse of dedicated repositories, frequent unavailability of raw data, lack of standardization in processed data, and insufficient metadata-particularly regarding participant demographics and clinical information. Inconsistencies in data formats and reporting standards further hinder dataset findability, interoperability, and reuse. To enhance the value and impact of future metabolomic research, we recommend adopting standardized reporting guidelines, improving metadata completeness, ensuring the availability of raw data, and promoting the use of interoperable repositories to facilitate reproducibility, integration, and broader application of shared datasets.},
}
@article {pmid42438902,
year = {2026},
author = {Kim, JH},
title = {Use of corticosteroids in sepsis and infectious diseases: a narrative review.},
journal = {The Korean journal of internal medicine},
volume = {41},
number = {4},
pages = {585-596},
pmid = {42438902},
issn = {2005-6648},
mesh = {Humans ; *Adrenal Cortex Hormones/therapeutic use/adverse effects ; *Sepsis/drug therapy ; COVID-19 ; Critical Illness ; SARS-CoV-2 ; COVID-19 Drug Treatment ; Community-Acquired Pneumonia/drug therapy ; *Anti-Inflammatory Agents/therapeutic use/adverse effects ; Shock, Septic/drug therapy ; *Pneumonia, Viral/drug therapy/diagnosis ; Pandemics ; Treatment Outcome ; },
abstract = {Critically ill patients with septic shock exhibit dysregulated host inflammatory responses. Critical illness-related corticosteroid insufficiency (CIRCI) has been recognized as a potential contributor to poor outcomes in critically ill patients. CIRCI is characterized by dysregulation of the hypothalamic-pituitary-adrenal axis, which results in a state of systemic inflammation through altered cortisol metabolism and tissue resistance to corticosteroids, all of which may lead to systemic inflammation. Based on these pathophysiological mechanisms, the beneficial anti-inflammatory effects of corticosteroids have been proposed and evaluated in several clinical trials. However, evidence of the beneficial effects of corticosteroids has been evolving for years. While some studies have demonstrated beneficial outcomes, such as accelerated shock reversal, reduced duration of mechanical ventilation, and reduced mortality, other studies have failed to demonstrate significant mortality benefits. Such disparity in studies suggests the heterogeneity of critical illnesses and the difficulty in identifying optimal indications for corticosteroids. Recent studies demonstrated the beneficial role of corticosteroids in patients with severe COVID-19 and community-acquired pneumonia. Given the evolving body of evidence, this review discusses the utility of corticosteroids in critically ill patients, including those with sepsis, septic shock, COVID-19, and severe community-acquired pneumonia.},
}
@article {pmid42438903,
year = {2026},
author = {Kong, J and Hong, S and Oh, J and Lee, S and Smith, L and Branda, F and Cho, H and Hwang, J and Yon, DK},
title = {Autoimmune diseases in the era of COVID-19: emerging mechanisms, clinical implications, vaccine considerations, and future directions.},
journal = {The Korean journal of internal medicine},
volume = {41},
number = {4},
pages = {597-619},
pmid = {42438903},
issn = {2005-6648},
support = {//Institute of Information &amp; Communications Technology Planning &amp; Evaluation/ ; RS-2024-00509257//Ministry of Science and ICT/ ; },
mesh = {Humans ; *COVID-19/immunology ; *Autoimmune Diseases/immunology/drug therapy/epidemiology ; *COVID-19 Vaccines/adverse effects ; SARS-CoV-2/immunology ; Immunosuppressive Agents/therapeutic use/adverse effects ; Immunocompromised Host ; Pandemics ; Risk Factors ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has highlighted a complex, bidirectional relationship between SARSCoV-2 infection and autoimmune diseases. This review examines how SARS-CoV-2 infection influences the incidence, progression, and outcomes of five major autoimmune conditions: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and Guillain-Barré syndrome. Patients with autoimmune diseases are at increased risk of severe COVID-19 due to intrinsic immune dysregulation and the use of immunosuppressive therapies, both of which impair antiviral host defenses. Conversely, COVID-19 has been implicated in the initiation and exacerbation of autoimmune responses through mechanisms such as molecular mimicry and bystander activation. Concerns have also arisen regarding the safety and efficacy of COVID-19 vaccines in immunocompromised populations. Although vaccines are generally tolerated in these individuals, certain immunosuppressive therapies may attenuate humoral and cellular immune responses. Strategies such as adjusting immunosuppressive regimens and optimizing the timing of vaccination have been proposed to improve vaccine efficacy. Disease-specific considerations are essential to balance infection risk with adequate control of autoimmune activity. Overall, this review underscores the importance of individualized treatment strategies, close clinical monitoring, and interdisciplinary care in managing patients with autoimmune diseases during the COVID-19 pandemic. A deeper understanding of these interactions will be critical for improving patient outcomes and preparing for future pandemics involving immune-mediated diseases.},
}
@article {pmid42441431,
year = {2026},
author = {Warkentin, TE and Greinacher, A},
title = {Platelet-Activating Anti-Platelet Factor 4 Disorders.},
journal = {The New England journal of medicine},
volume = {395},
number = {5},
pages = {478-491},
doi = {10.1056/NEJMra2502459},
pmid = {42441431},
issn = {1533-4406},
mesh = {Humans ; *Autoantibodies/blood/immunology ; COVID-19 Vaccines/adverse effects/immunology ; Heparin/adverse effects/immunology ; Paraproteinemias/blood/diagnosis/drug therapy/immunology ; *Platelet Activation/drug effects/immunology ; *Platelet Factor 4/immunology ; Purpura, Thrombocytopenic, Idiopathic/blood/diagnosis/drug therapy/immunology ; *Thrombocytopenia/blood/diagnosis/drug therapy/immunology ; *Thrombosis/blood/diagnosis/drug therapy/immunology ; Platelet Count ; Adenoviruses, Human/immunology ; Anticoagulants/administration &amp; dosage ; Immunoglobulins, Intravenous/administration &amp; dosage ; Tyrosine Kinase Inhibitors/administration &amp; dosage ; Agammaglobulinaemia Tyrosine Kinase/antagonists &amp; inhibitors ; },
abstract = {Platelet-activating antibodies against platelet factor 4 (PF4) cause highly prothrombotic disorders with reduced platelet counts. In heparin-induced thrombocytopenia (HIT), these antibodies bind PF4-heparin complexes, causing heparin-dependent platelet activation. Less common autoimmune and spontaneous HIT variants that are triggered by heparin and nonpharmacologic polyanions, respectively, have atypical clinical features and antibodies with additional heparin-independent platelet-activating properties. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) antibodies directly target PF4. Initially, VITT was linked to adenoviral vector-based coronavirus disease 2019 vaccines, but in rare cases, an immune thrombocytopenia and thrombosis disorder that is clinically nearly identical to VITT can be caused by infection resulting from natural exposure to viruses, especially adenovirus. In persons with the IGLV3-21*02/*03 gene, anti-adenovirus protein VII antibody specificity shifts to PF4 by way of a specific somatic hypermutation (K31E) that creates VITT antibodies. In VITT-like monoclonal gammopathy of thrombotic significance, monoclonal anti-PF4 antibodies cause chronic prothrombotic conditions. Accurate diagnosis relies on distinct assays for HIT and VITT antibodies. Beyond anticoagulation, inhibition of FcγIIa receptor-mediated platelet activation may be needed for anti-PF4 disorders with heparin-independent reactivity (e.g., high-dose immune globulin in acute disease manifestations and Bruton's tyrosine kinase inhibitors in chronic manifestations).},
}
@article {pmid42441648,
year = {2026},
author = {Capodici, A and Filippeschi, A and Noci, F and Michelucci, A and El Motarajji, S and Benedetto, V and Vandelli, A and Passino, C and Emdin, M and Nuti, S and Avizzano, CA and Bellè, N and Giannoni, A},
title = {Mapping global inequities in telemedicine implementation: An umbrella review of barriers and facilitators.},
journal = {PloS one},
volume = {21},
number = {7},
pages = {e0351885},
pmid = {42441648},
issn = {1932-6203},
mesh = {Humans ; *Telemedicine ; *COVID-19/epidemiology ; SARS-CoV-2/isolation &amp; purification ; Digital Health ; Global Health ; *Healthcare Disparities ; Evidence Gaps ; },
abstract = {Telemedicine expanded rapidly during the COVID-19 pandemic, yet its diffusion has remained uneven across health systems. Whether implementation challenges differ systematically across economic contexts, and what implications these differences hold for global digital health equity, has not been comprehensively characterized. This study presents an umbrella review (PROSPERO CRD42024615998) of systematic reviews and meta-analyses indexed in PubMed and Scopus through December 2025 that reported barriers and/or facilitators to telemedicine implementation. Methodological quality was appraised using R-AMSTAR. Reported items were extracted verbatim, embedded with the Universal Sentence Encoder, and grouped into thematic clusters using HDBSCAN density-based clustering, with parameters optimized by SLSQP for cluster cohesion (median intra-cluster similarity ≥ 0.5). Analyses were stratified by World Bank country income group to characterize context-specific implementation profiles, identify evidence gaps, and detect orphaned barriers, defined as challenges lacking any corresponding documented facilitator. A total of 161 systematic reviews were included, yielding 1,333 barriers and 504 facilitators (corresponding to a barrier-to-facilitator ratio of 2.6:1). Across all settings, the most frequently reported barriers were high costs (n = 106), technical issues (n = 94), and training and knowledge (n = 91). Thematic profiles differed markedly by income group: high-income countries reported predominantly second-generation challenges centered on workflow integration, interoperability, and user experience, whereas lower-middle-income countries reported foundational barriers centered on infrastructures and costs. Evidence produced from low-income countries was entirely absent. Several high-frequency barriers lacked corresponding facilitator clusters, indicating challenges for which the published literature provides no documented solutions. The global telemedicine evidence base is itself inequitably distributed and risks reinforcing the disparities it is intended to reduce. High-income settings require implementation research focused on human and organizational factors, whereas lower-income settings require foundational research and investment in basic infrastructures before workflow-level optimization becomes meaningful. Without context-specific, equity-oriented strategies, telemedicine risks widening rather than narrowing the global digital health divide.},
}
@article {pmid42442307,
year = {2026},
author = {Alaka, M and Tuaillon, E and Desnues, B},
title = {Intravenous immunoglobulin therapy in viral infections: Lessons learned from COVID-19.},
journal = {Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie},
volume = {201},
number = {},
pages = {119762},
doi = {10.1016/j.biopha.2026.119762},
pmid = {42442307},
issn = {1950-6007},
mesh = {Humans ; *Immunoglobulins, Intravenous/therapeutic use/pharmacology ; *COVID-19/immunology ; *COVID-19 Drug Treatment ; *Virus Diseases/drug therapy/immunology ; SARS-CoV-2/immunology ; Animals ; Antiviral Agents/therapeutic use ; Immunologic Factors/therapeutic use ; },
abstract = {OBJECTIVES: Intravenous immunoglobulin (IVIg) exerts both antiviral and immunomodulatory effects, but its role in viral infections remains incompletely defined. This review aims to provide an integrated overview of IVIg mechanisms of action and to evaluate its clinical relevance in viral diseases, with particular emphasis on coronavirus disease 2019 (COVID-19).<br><br>METHODS: A structured narrative literature review was conducted using PubMed (MEDLINE) and complemented by manual screening of the reference lists of relevant publications. The search included studies available through early 2026 addressing the mechanisms of action of IVIg and its clinical application in viral infections. Records were screened by title, abstract, and full-text evaluation according to predefined eligibility criteria, and the evidence was synthesized qualitatively.<br><br>RESULTS: IVIg acts through multiple mechanisms, including fragment antigen binding (Fab)-mediated neutralization, fragment crystallizable (Fc) receptor modulation, complement inhibition, cytokine regulation, and neonatal Fc receptor (FcRn)-mediated immunoglobulin G clearance. In immunodeficient patients, IVIg provides passive antiviral immunity and improves viral control. In contrast, in severe viral infections such as COVID-19, disease severity is largely driven by immune dysregulation. In this context, IVIg may exert benefit primarily through immunomodulatory effects rather than direct antiviral activity. Clinical studies in COVID-19 have shown heterogeneous results, influenced by treatment timing, patient selection, dosing strategies, and concomitant therapies.<br><br>CONCLUSIONS: IVIg should be considered a context-dependent immunomodulatory therapy rather than a universal antiviral strategy. Its clinical efficacy likely depends on alignment between its mechanisms and disease-specific immunopathology, highlighting the need for biomarker-guided and stage-specific therapeutic approaches.},
}
@article {pmid42442360,
year = {2026},
author = {Kazer, SW and Walsh, JML and Juttukonda, LJ and Ordovas-Montanes, J},
title = {Nasal immunity in respiratory viral infection, transmission, and protection.},
journal = {Immunity},
volume = {},
number = {},
pages = {},
pmid = {42442360},
issn = {1097-4180},
support = {R01 HL162642/HL/NHLBI NIH HHS/United States ; },
abstract = {The nasal mucosa plays key roles in protecting against airborne pathogens as the major barrier to the airway. Catalyzed by the COVID-19 pandemic, recent studies focusing on nasal immunity have begun to elucidate how epithelial and immune cells work in concert to fight viral infection, reduce spread to the lower airways, and limit onward transmission. Technologies such as single-cell RNA sequencing and air-liquid interface models are enabling high-resolution views of the cell states and responses that dictate infection resolution and memory formation. Here, we review our current understanding of the cells of the nasal mucosa at homeostasis and their responses during and following viral infection in mice and humans. We discuss emerging correlates of protection before and after exposure, noting the differences between infection and intramuscular vaccination. Finally, we examine novel intranasal vaccination strategies and propose approaches to program tissue-scale memory into the nose to prevent disease and viral spread.},
}
@article {pmid42442743,
year = {2026},
author = {Lee, DH and Hideki, K},
title = {Reassessing Early COVID-19 Strategies in East Asia: Insights from Japan and South Korea.},
journal = {Journal of preventive medicine and public health = Yebang Uihakhoe chi},
volume = {},
number = {},
pages = {},
doi = {10.3961/jpmph.26.274},
pmid = {42442743},
issn = {2233-4521},
abstract = {East Asian countries had remarkably low COVID-19 mortality in 2020, a pattern widely cited as evidence of effective public health interventions. However, Japan and South Korea-often classified as having followed similar early intervention strategies-adopted substantially different approaches. These differences are largely obscured by commonly used stringency indices and policy score analyses. While neither country implemented a lockdown, South Korea pursued an aggressive, government-mandated strategy based on extensive testing, isolation, quarantine, and compulsory data collection. In contrast, Japan relied on a voluntary model with limited mass testing, a policy that drew strong criticism during the early phase of the pandemic. Because asymptomatic COVID-19 infection was highly prevalent, these divergent testing policies were particularly important in shaping patterns of community transmission. Using excess mortality as a comprehensive outcome metric, Japan's outcomes were as favorable as South Korea's through the pre-Omicron period, despite Japan's limited testing. In 2020, excess mortality was negligible in both countries (-1.7% in Japan vs. +0.3% to +2.1% in South Korea). In 2021, excess mortality increased modestly (+2.2% vs. +4.0% to +5.6%). However, in 2022, after both countries had achieved approximately 80% vaccination coverage, excess mortality rose substantially (+7.6% vs. +19.6% to +21.0%), threefold higher in South Korea. These similar patterns of excess mortality in 2 countries with contrasting testing strategies challenge the view that East Asia's early success stemmed primarily from stringent virus suppression measures. They also highlight the need to consider alternative explanations, including the possibility that pre-existing immunity differed substantially across geographical regions.},
}
@article {pmid42445051,
year = {2026},
author = {Balcha, WF and Kassahun, EA and Nega, AT and Abie, A and Demsie, DG and Negesse, CT and Feyisa, K and Mekonnen, BA and Biadigilign, TM and Addisu, ZD and Ayenew, W and Siraj, EA and Zewdie, S and Anagaw, YK and Alene, GM and Yismaw, MB and Yehualaw, A and Kebede, SY and Mihiretie, EA and Awoke, AM and Bante, SA and Tesfu, AA and Sendeku, FW and Demissie, BA and Shiferaw, WG and Megule, SM and Abebe, YM and Tessema, LW and Chekole, FA},
title = {Labor Pain Management Practices and Associated Factors Among Licensed Obstetric Care Providers in Ethiopia: A Systematic Review and Meta-Analysis.},
journal = {Health science reports},
volume = {9},
number = {7},
pages = {e72770},
pmid = {42445051},
issn = {2398-8835},
abstract = {BACKGROUND AND AIMS: Labor pain is a multidimensional experience influenced by emotional, cognitive, and cultural factors. It can be managed using pharmacological, non-pharmacological, or combined approaches. Licensed obstetric care providers (OCPs) are ethically obligated to ensure maternal comfort while safeguarding fetal safety. Evidence on labor pain management practices (LPMP) in Ethiopia remains inconsistent, as prior studies often included students or had unclear inclusion criteria. This systematic review and meta-analysis estimated the pooled prevalence of LPMP among licensed OCPs, identified associated factors, and examined trends before and during the COVID-19 pandemic.<br><br>METHODS: We searched major databases and repositories for studies published between January 1, 2018 and October 3, 2025. Risk of bias was assessed using the Joanna Briggs Institute checklist and modified Newcastle-Ottawa Scale, with inter-rater reliability analyses. Meta-analysis was conducted in STATA 17 using random or fixed-effects models. Heterogeneity was assessed using Cochran's Q test and quantified with I[2] statistic. Certainty of evidence rated using GRADE.<br><br>RESULTS: Twenty studies involving 7,202 participants were included. LPMP prevalence varied substantially across studies and settings. The pooled prevalence of overall LPMP was 46.9% (95% CI: 42.7-51.1; I[2] = 92.4%). Non-pharmacological practice was 42.8% (95% CI: 36.6-49.1), whereas pharmacological practice was 21.1% (95% CI: 12.5-29.7), decreasing to 15.2% after adjustment for publication bias. Pharmacological practice was modestly higher during COVID-19 (23.7% vs. 18.0%). Factors positively associated with LPMP included provider knowledge, attitudes, training, drug/protocol availability, supportive environments, higher education, longer experience, positive perceptions, being a midwife, and female sex. Certainty of evidence ranged from low to moderate.<br><br>CONCLUSION: LPMP prevalence varied considerably across studies and settings. While the pooled estimate suggests that fewer than half of Ethiopian OCPs practiced LPMP, substantial unexplained heterogeneity warrants cautious interpretation. Non-pharmacological methods were more commonly used than pharmacological approaches, highlighting opportunities to strengthen provider training, institutional support, and resource availability.},
}
@article {pmid42445255,
year = {2026},
author = {Jha, S and Chaliha, LB and Pandey, K and Patel, R},
title = {Reimagining tuberculosis elimination in India: diagnostics, drug resistance, and digital health strategies.},
journal = {Frontiers in epidemiology},
volume = {6},
number = {},
pages = {1868261},
pmid = {42445255},
issn = {2674-1199},
abstract = {Tuberculosis (TB) remains a major global public health challenge and one of the leading infectious causes of mortality worldwide, with India contributing approximately 26% of the global TB burden. Despite substantial progress under the National Tuberculosis Elimination Programme (NTEP), India's efforts to achieve the ambitious 2025 TB elimination target continue to face major challenges due to the COVID-19 pandemic, multidrug-resistant tuberculosis (MDR-TB), healthcare disparities, and limitations in surveillance and reporting systems. This review provides a comprehensive overview of the epidemiology of TB in India and critically evaluates the impact of COVID-19, drug resistance, healthcare accessibility, and emerging diagnostic technologies on TB control efforts. A structured literature search was conducted using PubMed, Scopus, and Google Scholar, along with reports from the World Health Organization and the Government of India. The reviewed evidence indicates that the COVID-19 pandemic significantly disrupted TB diagnosis, treatment, surveillance, and healthcare accessibility, leading to declines in case notification and the possible accumulation of undiagnosed TB cases. In addition, the increasing burden of MDR/RR-TB, fragmented private healthcare systems, underreporting, and unequal access to diagnostics and treatment continue to hinder progress toward TB elimination. Although advancements including molecular diagnostics, digital surveillance platforms such as Nikshay, AI-assisted screening, and patient-support programmes have strengthened TB control strategies, important challenges related to implementation, infrastructure, scalability, and antimicrobial stewardship remain unresolved. This review highlights the need for integrated and patient-centred TB control strategies that combine rapid diagnostics, strengthened surveillance, public-private healthcare integration, health systems strengthening, and interventions addressing broader socioeconomic determinants such as poverty, malnutrition, and healthcare inequity. Coordinated multisectoral approaches will be essential for accelerating TB elimination efforts in India in the post-COVID era.},
}
@article {pmid42446912,
year = {2026},
author = {Li, N and Yan, Y and Li, Y and Ni, J and Gao, J and Piao, X and Hou, X},
title = {The effect of high-dose of vitamin C on mortality among aged patients with severe COVID-19: A systematic review and meta-analysis.},
journal = {Clinical and investigative medicine. Medecine clinique et experimentale},
volume = {49},
number = {2},
pages = {31-42},
doi = {10.3138/CIM-2024-0302},
pmid = {42446912},
issn = {1488-2353},
mesh = {Humans ; *Ascorbic Acid/administration &amp; dosage/therapeutic use ; *COVID-19/mortality ; Aged ; Critical Illness/mortality ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; Randomized Controlled Trials as Topic ; },
abstract = {BACKGROUND: Critically ill patients are frequently deficient in vitamin C. Given the significant mortality rates in the elderly population associated with COVID-19, we aimed to systematically review the literature and evaluate whether high-dose vitamin C can reduce COVID-19 mortality in this population.<br><br>METHODS: Multiple data sources (PubMed, Web of Science, ScienceDirect, and medRxiv) were searched using the keywords "COVID-19" AND "vitamin C" up to November 2024. Randomized controlled trials (RCTs) involving COVID-19 patients with relevant data were collected. We used a random or fixed effects meta-analysis to calculate the pooling effect.<br><br>RESULTS: Eight RCTs comprising 2,104 patients were ultimately included in the meta-analysis. The pooling effect (odds ratio [OR] 0.97[95% CI 0.80-1.18, P = 0.76) suggested no significant difference in mortality rates between patients treated with high-dose vitamin C and those who were not.<br><br>CONCLUSIONS: Vitamin C supplementation might reduce the risk of COVID-19 mortality in critically ill patients; however, this effect varied by study. Additional research is necessary to arrive at a definitive conclusion on this subject.},
}
@article {pmid42447883,
year = {2026},
author = {Naidoo, T and Morgenstern, C and Doohan, P and Earl, R and Rawson, T and Sheppard, RJ and Hicks, JT and Radhakrishnan, S and Johnson, R and Hartner, AM and Cattarino, L and McCain, K and Vicco, A and Imai-Eaton, N and Elsland, SV and Cori, A and McCabe, R and Bhatia, S and , },
title = {A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models.},
journal = {The Lancet. Infectious diseases},
volume = {},
number = {},
pages = {},
doi = {10.1016/S1473-3099(26)00239-2},
pmid = {42447883},
issn = {1474-4457},
abstract = {Our systematic review, based on PRISMA guidelines (PROSPERO CRD42023393345), characterised the epidemiology, outbreaks, and mathematical models of Nipah virus, an important public health threat in south and southeast Asia. We searched PubMed and Web of Science from database inception to March 14, 2025, and extracted 243 parameters, 89 risk factors, 39 models, and 23 distinct outbreaks from 119 papers. IgG seroprevalence estimates in the general population ranged from 0% to 12·5%. Nipah virus causes severe disease, with pooled case-fatality ratio estimates ranging widely from 9·1% (95% CI 0·2-41·3) in Singapore to 81·9% (95% CI 71·9-88·9) in Bangladesh. The infection timeline and clinical course of Nipah virus remain poorly characterised; we estimated a median incubation period of 8·77 days (165, 95% CI 7·53-10·02) from eight estimates in seven articles with sufficient information. Transmission parameter estimates were scarce, and all but one of five central estimates of the basic reproduction number were less than one. Nipah virus mathematical models (39) were rarely fitted to data (eight). All extracted information is accessible via our R package, epireview.},
}
@article {pmid42448011,
year = {2026},
author = {Thapa, N and Jin, Y and Han, JH},
title = {Innate immune surveillance and nucleic acid sensing: Gatekeepers of inflammatory cell death in respiratory infectious diseases.},
journal = {Pharmacological research},
volume = {231},
number = {},
pages = {108340},
doi = {10.1016/j.phrs.2026.108340},
pmid = {42448011},
issn = {1096-1186},
abstract = {Respiratory infections caused by viral pathogens, including influenza A virus, respiratory syncytial virus, and SARS-CoV-2, as well as bacterial pathogens, remain major contributors to global morbidity and mortality. The outcomes of these infections are largely determined by how the host innate immune system detects pathogen-derived nucleic acids and regulates subsequent inflammatory responses. Pattern recognition receptors (PRRs) located in endosomal and cytosolic compartments, including toll-like receptors, RIG-I-like receptors, absent in melanoma 2, and Z-DNA-binding protein 1, as well as the cyclic GMP-AMP synthase-stimulator of interferon genes pathway, recognize viral and bacterial nucleic acids and initiate signaling cascades that promote cytokine production and antimicrobial defense. However, dysregulated PRR activation can trigger inflammatory programmed cell death, including apoptosis, pyroptosis, necroptosis, and PANoptosis. This review summarizes recent advances in understanding how nucleic acid sensing orchestrates inflammatory cell death during respiratory infections, with particular emphasis on pathogen- and cell type-specific mechanisms that shape disease outcomes. We further highlight the dual nature of these pathways, which are essential for pathogen clearance but can drive immunopathology when excessively activated. Defining how nucleic acid-sensing pathways shape inflammatory cell death in respiratory infections may guide host-directed therapies that enhance pathogen clearance while preserving lung function. Overall, the field remains constrained by the predominance of virus-focused and murine preclinical studies, whereas bacterial nucleic acid sensing during respiratory infections remains poorly defined. Future studies should integrate major bacterial infection models with human-relevant respiratory epithelial systems to better translate PRR-mediated immune mechanisms into host-directed therapeutic strategies.},
}
@article {pmid42448413,
year = {2026},
author = {Viknesh, K and Vijayalakshmi, P and Alex, AM and Muthumani, LN and Muthupandian, S and Desai, D and Ramanathan, S and Likson, A and Selvaraj, C},
title = {Energetic landscapes and fuzzy complexes: Computational targeting of viral intrinsically disordered proteins.},
journal = {Advances in protein chemistry and structural biology},
volume = {153},
number = {},
pages = {351-407},
doi = {10.1016/bs.apcsb.2026.04.009},
pmid = {42448413},
issn = {1876-1631},
mesh = {Humans ; *Intrinsically Disordered Proteins/chemistry/metabolism/antagonists &amp; inhibitors ; *Viral Proteins/chemistry/metabolism/antagonists &amp; inhibitors ; *Antiviral Agents/chemistry/pharmacology ; SARS-CoV-2 ; Machine Learning ; },
abstract = {The increased recognition of intrinsically disordered proteins (IDPs) as critical mediators in viral infections has shifted attention toward fuzzy drug targets, challenging the conventional structure-based paradigms of drug discovery due to their inherent conformational flexibility. The binding of viral IDPs and IDRs to host factors occurs in dynamic, multivalent, and context-dependent interactions and constitute flexible complexes, which form the basis of pathogenicity and immune evasion. In this review, the disordered proteins of viruses are considered with a combination of molecular, computational, and translational insights to assess the next-generation antiviral targets. In this, we have discuss about the energetic landscapes that control the disorder, functional disorder order transitions and the fuzzy interfaces as centers of the networks of virus-host interactions. Special focus is kept on the new lines of computational and AI-directed technologies such as ensemble-based docking, machine-learning computational models of IDP ligand recognition, and multi-omics-driven target prioritization. The experimental approaches that are modified to characterize disordered systems, including NMR spectroscopy and hybrid structural biology, are also reviewed. The translational applicability of the targeting of viral fuzziness is highlighted by case studies of HIV-1, influenza, SARS-CoV-2, and emerging viral pathogens. We also provide directions about the future involving adaptive pharmacophores, customized antiviral approaches, and AI-driven ensemble targeting making disordered viral proteins a paradigm shift in antiviral drug discovery.},
}
@article {pmid42449828,
year = {2026},
author = {Hetta, HF and Haseeb, A and Bukhari, SQ and Alatawi, Z and Mahrous, AJ and Elrggal, ME and Masri, MA and Kotb, AA},
title = {Emerging Multimodal Point-of-Care Diagnostic Strategies for Rapid Detection and Management of Respiratory Viruses: A State-of-the-Art Review.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {13},
pages = {},
pmid = {42449828},
issn = {2075-4418},
support = {26UQU4310470GSSR02//Umm al-Qura University/ ; 26UQU4310470GSSR03//Umm al-Qura University/ ; },
abstract = {The co-circulation of respiratory viruses, including SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV), represents a significant global health challenge that requires rapid, accurate, and differential diagnosis to support infection control and appropriate clinical decision-making. This narrative review summarizes emerging multimodal point-of-care testing (POCT) strategies for the detection and management of these respiratory viruses. Relevant studies were identified through literature searches of major scientific databases, including PubMed, Scopus, and Web of Science, focusing on recent advances in molecular diagnostics, biosensors, microfluidics, and digital health technologies. To improve clinical interpretation and comparative assessment, current POCT platforms were organized into four operational tiers based on infrastructure dependence, degree of portability, and level of decentralization of testing. Tier 1 (Professional Clinical Systems) includes fully integrated automated molecular diagnostic platforms designed for use in hospital and emergency care settings. Tier 2 (Field-Deployable Systems) comprises portable molecular and isothermal amplification technologies designed for use in decentralized or resource-limited environments. Tier 3 (Hardware-Lite Assays) includes simplified diagnostic approaches that minimize instrument requirements and are suitable for near-patient or low-infrastructure settings. Tier 4 (Consumer-Digital Diagnostics) encompasses emerging smartphone- and IoT-integrated diagnostic platforms that support user-driven testing and digital health connectivity. This tier-based framework reflects a proposed stratification of POCT technologies along a decentralization continuum and aims to facilitate comparison and selection of diagnostic strategies across diverse healthcare settings.},
}
@article {pmid42450061,
year = {2026},
author = {Lim, S and Martina, B},
title = {Immune Mechanisms and Translational Study Design in Viral Vaccine Development.},
journal = {International journal of molecular sciences},
volume = {27},
number = {13},
pages = {},
pmid = {42450061},
issn = {1422-0067},
mesh = {Humans ; Animals ; *Translational Research, Biomedical ; *Viral Vaccines/immunology ; *Vaccine Development/methods ; COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; Adaptive Immunity ; Immunity, Innate ; COVID-19 Vaccines/immunology ; },
abstract = {Viral vaccine development requires both mechanistic understanding of protective immunity and translational study designs that connect preclinical data with human outcomes. Animal models remain important for early assessment of safety, immunogenicity and protective efficacy, but their predictive value depends on the question being asked, the pathophysiology of infection, the immune mechanisms expected to mediate protection, and the biomarkers chosen to bridge animal and human data. This review focuses on viral vaccines and examines innate and adaptive mechanisms of vaccine-induced protection, including B cell and antibody responses, Fc-mediated functions, Fc glycosylation, T cell memory and CD8+ cytotoxic responses. We discuss common reasons for clinical failure and show how preclinical endpoints can be classified as human-counterpart, surrogate or comparative/mechanistic readouts. Influenza and COVID-19 examples illustrate how different models can be combined across discovery, challenge, transmission and late-stage bridging studies. Emerging tools such as systems serology, omics, AI/ML and new approach methods can improve candidate prioritization, but their value depends on assay standardization, biological validation and cautious interpretation. A mechanism-driven model cascade, paired with human-relevant immunological readouts, can improve preclinical interpretation and reduce the risk of advancing candidates that are unlikely to succeed in clinical trials.},
}
@article {pmid42450077,
year = {2026},
author = {Russjan, E and Zając, D and Kaczyńska, K},
title = {Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.},
journal = {International journal of molecular sciences},
volume = {27},
number = {13},
pages = {},
pmid = {42450077},
issn = {1422-0067},
mesh = {Humans ; *Glucagon-Like Peptide-1 Receptor Agonists ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Glucagon-Like Peptide-1 Receptor/metabolism ; Glucagon-Like Peptide 1/metabolism ; Animals ; COVID-19/metabolism ; Asthma/drug therapy ; Pulmonary Fibrosis/drug therapy ; Sleep Apnea, Obstructive/drug therapy ; SARS-CoV-2 ; },
abstract = {Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted in response to food intake that acts biologically by binding to GLP-1 receptors. The primary function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion, which helps limit after-meal spikes in blood glucose. GLP-1 reduces intestinal contractility, slows down gastrointestinal motility and emptying, and also acts directly on the hypothalamus, thereby regulating appetite and food intake. Due to its metabolic effects, GLP-1 forms the basis of medications currently used to treat type 2 diabetes (T2DM) and obesity. However, it has also been observed that the use of GLP-1 agonists in the treatment of obesity or diabetes has a beneficial effect on comorbid respiratory conditions. This narrative review analyzes the scientific literature and describes the most recent information on the impact of GLP-1 receptor agonist (GLP-1 RA) therapies on the most common respiratory disorders-both the beneficial and undesirable effects. We discuss evidence that acute lung injury, COVID-19, pulmonary fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea can benefit from therapies with various GLP-1 RAs. They can complement existing lung-targeted treatments, but as research progresses, they are likely to play an ever more important role in the treatment of respiratory diseases.},
}
@article {pmid42450260,
year = {2026},
author = {Angamarca-Iguago, J and Parise-Vasco, JM and Reytor-González, C and Cagua-Ordoñez, J and Simancas-Racines, D},
title = {Temporal Dynamics of Innate Immune Activation and Viral Interference During Sequential Co-Infection with Influenza A Virus and SARS-CoV-2: Molecular Mechanisms, Clinical Evidence, and Therapeutic Implications.},
journal = {International journal of molecular sciences},
volume = {27},
number = {13},
pages = {},
pmid = {42450260},
issn = {1422-0067},
mesh = {Humans ; *Immunity, Innate ; Animals ; *Influenza A virus/immunology ; *Influenza, Human/immunology/virology/drug therapy ; *SARS-CoV-2/immunology/physiology ; *COVID-19/immunology/virology ; *Coinfection/immunology/virology ; *Viral Interference ; Host-Pathogen Interactions/immunology ; Interferons ; Antiviral Agents/therapeutic use ; },
abstract = {The concurrent circulation of influenza A virus (IAV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unveiled complex host-pathogen interactions governed by temporal dynamics of innate immune activation. This narrative review synthesizes evidence from human air-liquid interface (ALI) epithelial models, animal studies (hamster, ferret), clinical cohorts, and randomized controlled trials (2015-2026) to delineate the molecular mechanisms underlying viral interference between these two major respiratory pathogens. Prior IAV infection induces a robust type I/III interferon (IFN) response and broad interferon-stimulated gene (ISG) upregulation that restricts subsequent SARS-CoV-2 replication within a critical 24-72 h temporal window. Conversely, SARS-CoV-2 employs a multi-layered immune evasion strategy that blunts IFN induction, providing minimal heterologous protection. Simultaneous co-infection tends to exacerbate disease severity. Host genetic determinants, including OAS1 and TLR7 variants, modulate interference capacity. Therapeutically, early pegylated IFN-λ shows clinical benefit, while experimental evidence from in vitro and animal models suggests oseltamivir may paradoxically reduce IAV-induced interference. These findings underscore the need for multi-pathogen diagnostics, temporally informed clinical decision-making, and IFN-based therapeutic strategies during co-circulation periods.},
}
@article {pmid42450302,
year = {2026},
author = {Basu, S and Adhikary, D and Ghosh, K and Chattopadhyay, S and Deb, S and Mondal, R and Roy, J and Chowdhury, A and Benito-León, J},
title = {Machine Learning and Deep Learning Frameworks for Human-Virus Protein-Protein Interaction Prediction: Emerging Architectures, Methods, Benchmarks, and Challenges.},
journal = {International journal of molecular sciences},
volume = {27},
number = {13},
pages = {},
pmid = {42450302},
issn = {1422-0067},
mesh = {Humans ; *Deep Learning ; *Machine Learning ; SARS-CoV-2 ; COVID-19/virology ; *Viral Proteins/metabolism ; Host-Pathogen Interactions ; *Protein Interaction Mapping/methods ; Protein Interaction Maps ; Prediction Algorithms ; Betacoronavirus/metabolism ; Benchmarking ; },
abstract = {The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as one of the most significant global health crises in recent history. Coronaviruses are a diverse group of RNA viruses classified into alpha, beta, gamma, and delta genera, with SARS-CoV-2 belonging to the beta-coronavirus family. The virus exhibits high transmissibility and causes a wide spectrum of clinical manifestations ranging from mild respiratory symptoms to severe complications such as acute respiratory distress syndrome, multi-organ failure, and death, particularly among elderly and immunocompromised individuals. Structurally, SARS-CoV-2 possesses a large single-stranded RNA genome encoding major structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, which play critical roles in host-cell recognition and viral infection. Understanding the molecular mechanisms of virus-host interactions, especially protein-protein interactions (PPIs), is essential for uncovering viral pathogenesis and identifying potential therapeutic targets. Traditional experimental techniques for PPI detection, such as yeast two-hybrid and affinity purification methods, are often expensive, labor-intensive, and prone to inaccuracies. Consequently, computational approaches based on machine learning (ML) and deep learning (DL) have gained significant attention for efficient and scalable PPI prediction. These methods use diverse biological information, including protein sequences, structural features, genomic data, Gene Ontology annotations, and interaction networks, to model complex biological relationships. This survey reviews computational approaches to PPI prediction, highlighting ML- and DL-based techniques, methodological advances, performance evaluation practices, and limitations that affect benchmark comparability. It also discusses biological databases and data sources commonly used in PPI studies and explicitly considers how models trained in coronavirus-centered settings may generalize to other viral families with different mechanisms of host interaction.},
}
@article {pmid42450918,
year = {2026},
author = {Latzer, Y and Stein, D},
title = {The Impact of Recent Collective Trauma in Israel on Eating Disorders and Disordered Eating: An Overview and Clinical Perspective.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {13},
pages = {},
pmid = {42450918},
issn = {2227-9032},
abstract = {Background: Periods of collective crises are associated with substantial deterioration in mental health. Whereas trauma-related psychopathology has received considerable clinical and policy attention during such periods, eating disorders (EDs) and disordered eating (DE) remain comparatively under-recognized. EDs and DE are well recognized in the Israeli context; however, accumulating evidence indicates a significant increase in their prevalence during periods of collective crisis. Objective: We sought to synthesize empirical findings and clinical observations in Israel about the impact of the COVID-19 pandemic and the October 2023 War on the emergence and exacerbation of DE and EDs, and to examine the implications for clinical practice and mental health policy. Methods: We conducted a narrative review integrating epidemiological data, findings from Israeli healthcare organizations, scientific studies, and clinical insights from specialized ED services. Results: Across both crises, Israel experienced a marked increase in the full spectrum of eating-related disturbances, ranging from emotional eating and subclinical DE to severe full-blown EDs. Adolescents and young adults were particularly affected, but increased ED-related disturbance was also observed among adults and individuals with pre-existing EDs. These findings coincide with a prolonged duration period before receiving treatment and with limited service capacity. In response, the mental health system attempted to implement rapid adaptations, including expanded telemedicine, short-term targeted interventions, and new ambulatory and day treatment programs. Conclusions: Our findings indicate that DE and EDs constitute a significant and escalating mental health burden during periods of collective crises that is comparable to other trauma-related conditions. Just as comprehensive short- and long-term intervention frameworks have been developed for trauma-related conditions, similar models are urgently required for EDs.},
}
@article {pmid42452468,
year = {2026},
author = {Rada, M and Petculescu, IM and Pah, AM and Avram, A and Velimirovici, DE and Velciov, AB and Tudoran, C and Iurciuc, S and Utu, D and Gheorghe, DR and Craciun, ML},
title = {Valvular Heart Disease and Heart Failure in the Post-COVID-19 Era: A Narrative Review of Mechanisms, Diagnosis, Differential Assessment, and Clinical Outcomes.},
journal = {Journal of clinical medicine},
volume = {15},
number = {13},
pages = {},
pmid = {42452468},
issn = {2077-0383},
support = {Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
abstract = {Background/Objectives: Cardiovascular involvement is among the most consequential sequelae of SARS-CoV-2 infection. Myocardial injury, arrhythmia, and thromboembolic disease have been characterized in depth, yet the relationship between COVID-19 and valvular heart disease (VHD), and its interplay with heart failure (HF), has received comparatively limited synthesis. This narrative review consolidates current evidence on the mechanisms, diagnosis, differential assessment, and clinical outcomes linking acute and post-acute COVID-19 to valvular dysfunction and to incident or worsening heart failure, with emphasis on practical implications for cardiologists and internists. Methods: We searched PubMed, Scopus, and Web of Science (January 2020-January 2026) for studies on valvular dysfunction, heart failure, myocardial injury, and endothelial pathology in SARS-CoV-2 infection, and synthesized findings narratively. Results: Convergent pathways-endothelial injury, systemic hyperinflammation, micro- and macrovascular thrombosis, and pressure-volume overload-contribute to functional and, less frequently, structural valvular changes. Available evidence suggests that clinically relevant post-COVID valvular abnormalities are more often secondary/functional (mitral and tricuspid regurgitation) than primary structural lesions, although dedicated prospective valvular studies remain scarce. Pre-existing severe VHD markedly worsens acute COVID-19 prognosis. Elevated NT-proBNP, troponin, and interleukin-6 consistently predict decompensation and mortality, and a substantial minority of survivors show persistent fibrotic pulmonary changes and restrictive ventilatory defects on follow-up (pulmonary rather than cardiac findings). Conclusions: Post-COVID valvular dysfunction appears, on currently available but largely indirect evidence, predominantly functional and inflammation-related, and may overlap with HFpEF phenotypes in selected patients when objective diagnostic criteria are fulfilled. Biomarker-guided, multimodality follow-up is reasonable in high-risk survivors, and prospective longitudinal studies with standardized valvular endpoints remain a priority. Dedicated longitudinal evidence on valvular outcomes specifically remains very limited.},
}
@article {pmid42452593,
year = {2026},
author = {Kasiak, P and Procyk, G},
title = {COACH Study: COVID-19 Influence on Cardiorespiratory Fitness in Athletes-A Systematic Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {13},
pages = {},
pmid = {42452593},
issn = {2077-0383},
abstract = {Objectives: We aimed to systematically review and meta-analyze the impact of COVID-19 infection on cardiorespiratory fitness (CRF): (1) within-athlete (the same participants before and after infection), and (2) between-athlete (infected vs. healthy reference participants). Methods: In this systematic review (PROSPERO Registry: CRD42024540430) we included observational studies enrolling recreational or competitive athletes ≥18 years old with laboratory confirmation of SARS-CoV-2 infection. The primary outcome was change in relative maximal oxygen uptake (VO2max). Secondary outcomes included changes in absolute VO2max, maximal ventilation (VEmax), and maximal heart rate (HRmax). We searched Embase, PubMed, Medline, Scopus, and Web of Science up to August 9th, 2025. Risk of bias was assessed with the JBI critical appraisal tool. Meta-analyses were performed with a random-effects model. Results: Twelve studies enrolling a total of 1595 participants met the eligibility criteria. COVID-19 infection was associated with lower relative VO2max (MD = -1.83 mL·kg[-1]·min[-1]; 95%CI [-3.16, -0.49]; p = 0.007; I[2] = 54%) and absolute VO2max (MD = -0.15 L·min[-1]; 95%CI [-0.29, -0.01]; p = 0.03; I[2] = 0%). COVID-19 infection was associated with lower VEmax (MD = -7.99 L·min[-1]; 95%CI [-12.94, -3.04]; p = 0.002; I[2] = 0%) but not with HRmax (MD = -0.34 bpm; 95%CI [-1.54, 0.86]; p = 0.58; I[2] = 0%). High heterogeneity of included studies was addressed with subgroup analyses. The risk of bias in most studies was high. The certainty of evidence was very low for each outcome. Conclusions: COVID-19 infection in athletes was associated with reduced VO2max and VEmax. The relationships were highly dependent on the quality of the studies. CRF and athlete profile should be considered when making shared decisions regarding safe return to sport after infection.},
}
@article {pmid42452704,
year = {2026},
author = {Olarewaju, A and Adebowale, A and Odutola, P and Arnold, A},
title = {Use of Natriuretic Peptides in Critically Ill Patients: A Narrative Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {13},
pages = {},
pmid = {42452704},
issn = {2077-0383},
abstract = {Background: Natriuretic peptides, including B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), are established biomarkers of myocardial stress and circulatory overload. Although originally validated for diagnosis and exclusion of heart failure, their diagnostic and prognostic applications have expanded significantly in the context of critical illness. However, interpretation in critically ill patients is complicated by confounding factors such as systemic inflammation and renal dysfunction. Objective: This review synthesizes current evidence on the diagnostic, monitoring, and prognostic applications of natriuretic peptides in critically ill adults. It further outlines practical considerations, confounding variables, and emerging complementary biomarkers pertinent to clinical decision-making. Methods: A structured search of PubMed, Embase, and the Cochrane Library (January 2000 to October 2025) identified studies evaluating BNP, NT-proBNP, and atrial natriuretic peptide (ANP) in intensive care unit (ICU) patients. Eligible studies and review articles assessed diagnostic utility, volume status, hemodynamic monitoring, and prognostic performance. Narrative synthesis was employed using information obtained from eligible studies. Results: Twenty-four studies met the inclusion criteria. BNP and NT-proBNP facilitate differentiation between cardiogenic and noncardiogenic respiratory failure, identification of mixed shock states, and assessment of volume status when used in association with other modalities such as echocardiography and ultrasonography. Elevated natriuretic peptide concentrations consistently predict mortality, acute kidney injury, prolonged mechanical ventilation, and adverse outcomes in several disease states, including sepsis, acute respiratory distress syndrome [ARDS], postoperative cardiac dysfunction, and COVID-19-related critical illness. However, interpretation remains limited by confounders, including renal impairment, age, systemic inflammation, brain injury, mechanical ventilation, and right-ventricular strain/dysfunction. Conclusions: Natriuretic peptides serve as valuable adjuncts for diagnostic assessment, hemodynamic monitoring, and risk stratification in the ICU. When interpreted with attention to biological kinetics and clinical context, these biomarkers enhance multimodal monitoring and support individualized management. Future research should refine ICU-specific cutoffs and assess natriuretic peptide-guided therapeutic strategies in prospective multicenter trials.},
}
@article {pmid42453219,
year = {2026},
author = {Neogi, SB and Saroha, E and Mishra, SS and Tolani, H and Samtani, R},
title = {Telemedicine: An exploration of global impact and Indian perspectives on healthcare delivery, effectiveness, and challenges.},
journal = {Journal of family medicine and primary care},
volume = {15},
number = {4},
pages = {1473-1478},
pmid = {42453219},
issn = {2249-4863},
abstract = {Telemedicine represents a transformative approach to healthcare delivery, leveraging information and communication technologies to bridge geographical barriers between patients and healthcare providers. This paper explores telemedicine's historical development, global applications, and specific relevance in India, particularly focusing on the eSanjeevani program. Despite its potential, telemedicine faces challenges, such as the digital divide, regulatory frameworks, patient acceptance, and technical limitations. Addressing these challenges requires collaborative efforts among stakeholders to ensure equitable access, data security, and interoperability of telemedicine platforms. Telemedicine has demonstrated its efficacy in enhancing access to healthcare services, particularly in underserved regions, and has emerged as a vital tool during the COVID-19 pandemic. The eSanjeevani program in India serves as a prominent example of successful telemedicine implementation, facilitating millions of consultations and bridging the urban-rural healthcare divide. Looking ahead, telemedicine holds promise in revolutionizing healthcare delivery, fostering ecological responsibility, and advancing toward universal health coverage. Embracing telemedicine represents a significant step toward a healthier, greener, and more sustainable future for healthcare systems worldwide.},
}
@article {pmid42453257,
year = {2026},
author = {Rajeh, DA and Amer, KA and Alasmari, R and Brema, I and Aljumah, M and Aljuaid, S},
title = {Diabetic ketoacidosis after COVID-19 infection in newly diagnosed patients with diabetes in the Middle East and African countries: A systematic review and meta-analysis.},
journal = {Journal of family medicine and primary care},
volume = {15},
number = {4},
pages = {1527-1539},
pmid = {42453257},
issn = {2249-4863},
abstract = {INTRODUCTION: The risk of diabetic ketoacidosis (DKA) is increased following the severe acute respiratory syndrome coronavirus 2 infection, "COVID-19," however, little evidence is available regarding the prevalence and outcomes of DKA in newly diagnosed patients with diabetes in the Middle East and African countries. Our objective was to conduct a systematic review of case reports detailing the prevalence and outcomes of DKA in COVID-19 infected in the above referenced countries.<br><br>METHODS AND SUBJECTS: Our search encompassed Medline (via PubMed), Embase (via OVID), Web of Science, Scopus, grey literature sources such as Open Access Theses and Dissertations (OATD), and the reference lists of the included studies.<br><br>RESULTS: The results of the current meta-analysis study showed that 17 studies met the search criteria and a total of 22 patients (15 patients with newly type 1 diabetes and seven patients with newly diagnosed type 2 diabetes). About 69.5% of the patients were of Arabian ethnicity. Body mass index (BMI) was reported only for seven patients, with a mean of 25.04 k g/m[2]. Two patients died in patients with newly diagnosed type 2 diabetes, giving a mortality rate of 14.3%, while all patients were in type 1 diabetes, who had DKA survived.<br><br>CONCLUSIONS: Covid 19 infection in patients with new diabetes from the Middle East and African countries was associated with increased risk of DKA with high mortality in patients with newly diagnosed type 2 diabetes.},
}
@article {pmid42453521,
year = {2026},
author = {Hsu, PC and Tsai, CC and Chu, TY and Kuo, CY},
title = {Jing-Si Herbal Tea as a multitargeted complementary therapy: Evidence from preclinical and clinical studies.},
journal = {Tzu chi medical journal},
volume = {38},
number = {3},
pages = {289-299},
pmid = {42453521},
issn = {2223-8956},
abstract = {Jing-Si Herbal Tea (JSHT) is a traditional multi-herbal preparation composed of flavonoids, polyphenols, triterpenoid saponins, glycyrrhizin, and other bioactive constituents that collectively contribute to a wide spectrum of biological activities. Emerging laboratory and clinical studies indicate that JSHT is associated with modulation of oxidative stress, inflammatory responses, and immune-related pathways, with reported antiviral and cytoprotective effects primarily observed in experimental models and exploratory clinical settings. This review synthesizes current evidence describing the diverse pharmacological actions of JSHT and its potential applications across oncologic, inflammatory, metabolic, and infectious disease contexts. Experimental findings suggest that JSHT may be associated with modulation of tumor progression-related processes, including epithelial-mesenchymal transition and aberrant nuclear factor kappa B activity, while being associated with intracellular oxidative stress-related activation of apoptosis- and ferroptosis-related pathways in cancer cell models. Its immunoregulatory capacity is reflected in the attenuation of pro-inflammatory cytokines and the promotion of anti-inflammatory macrophage phenotypes. In respiratory and infectious diseases such as coronavirus disease 2019 and chronic obstructive pulmonary disease, JSHT has been reported to attenuate hyperinflammatory responses and preserve cellular or organ function and has been associated with clinical improvement in selected observational studies, which should be interpreted cautiously. Early clinical data, including results from a randomized study in functional dyspepsia, suggest benefits for gastrointestinal symptoms and anxiety, accompanied by increases in serum butyrate that may indicate involvement of the gut-brain axis. Across available studies, JSHT has shown good tolerability with few reported adverse effects. Overall, the accumulating evidence suggests that JSHT may have potential relevance as a multitarget complementary approach, pending confirmation through well-controlled clinical studies. Nonetheless, more extensive, well-controlled clinical investigations are warranted to validate its efficacy and clarify its mechanistic pathways.},
}
@article {pmid42454043,
year = {2026},
author = {Wendt, K and Schieck, M and Gille, C and Marschollek, M and Illig, T and Wolff, D and Nee, S},
title = {Biomarkers of post-acute infection syndrome: a systematic literature review.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1741761},
pmid = {42454043},
issn = {1664-3224},
mesh = {Humans ; *Biomarkers/metabolism ; Post-Acute COVID-19 Syndrome ; *COVID-19/complications ; *SARS-CoV-2 ; *Fatigue Syndrome, Chronic/diagnosis ; },
abstract = {BACKGROUND: Post-acute infection syndrome (PAIS) remained underrecognized before the COVID-19 pandemic, which further increased exposure by introducing a novel global cause. The global burden of post-acute COVID syndrome (PACS) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) alone is estimated at several tens of millions affected worldwide. Biomarker discovery is central to improving PAIS diagnosis and may provide therapeutic targets. This review summarizes current knowledge on biomarkers for PAIS, including PACS and ME/CFS.<br><br>METHODS: A systematic literature search was conducted in PubMed and Web of Science. Inclusion criteria were: (1) studies including PAIS patients; (2) reporting laboratory or omics biomarkers; and (3) investigating biomarkers or pathomechanisms of PAIS. Although Guillain-Barr&#xe9; syndrome (GBS) is not PAIS, we have included it as a separate mechanistic comparator due to its prevalence in search results and its clinical and immunological similarities to PAIS.<br><br>RESULTS: A total of 142 studies analyzing PAIS biomarkers were included. GBS was analyzed separately and later compared with the other results. Overall, the reviewed studies employed heterogeneous approaches. While similar types of data were frequently investigated, analytical methods varied and often focused only on a subset of molecules. The results indicate that amino acid, energy, and lipid metabolism, microbiome, mitochondrial stress, and miRNA networks are affected. All pathways are connected via NF-&#x3ba;B.<br><br>DISCUSSION: PAIS is a multisystem disorder rooted in persistent immune activation, metabolic reprogramming, and systemic inflammation, driven not by active viral infection, but by dysregulated host responses. The NF-&#x3ba;B pathway serves as a unifying hub, connecting molecular, cellular, and clinical phenotypes. Our framework enables a shift from symptom-based to mechanism-based classification, paving the way for biologically grounded interventions.<br><br>CONCLUSION: This review synthesizes a broad spectrum of biomarkers in PAIS, integrating findings across pathogens and molecular levels rather than restricting to individual conditions or symptom clusters. This study highlights the differences and commonalities among pathogens and diseases that lead to post-acute sequelae, fills a critical knowledge gap, and provides a foundation for future research and clinical practice. Future studies incorporating multi-omics approaches, longitudinal designs, and larger patient cohorts are needed to validate specific biomarkers and advance the understanding of PAIS.},
}
@article {pmid42454050,
year = {2026},
author = {Sanz-Muñoz, I and Farre-Avella, M and Barroso-Santos, PJ and Eiros, JM},
title = {State-of-the-art of the high dose influenza vaccine in Spain.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1843611},
pmid = {42454050},
issn = {1664-3224},
mesh = {Humans ; *Influenza Vaccines/administration &amp; dosage/immunology ; Spain/epidemiology ; *Influenza, Human/prevention &amp; control/immunology/epidemiology ; Vaccination ; Aged ; *COVID-19/prevention &amp; control/epidemiology ; Middle Aged ; SARS-CoV-2 ; },
abstract = {High-dose (HD) influenza vaccines have demonstrated robust effectiveness in preventing severe influenza-related outcomes, including pneumonia, cardiorespiratory complications, and mortality, with evidence from randomized clinical trials, meta-analyses, and real-world studies consistently showing superiority over standard-dose (SD) vaccines and supporting international recommendations for adults aged ≥60 years. This is increasingly relevant in the context of global aging and immunosenescence, which weakens vaccine-induced immune responses and heightens biological frailty, functional decline, and the risk of severe complications in older adults, especially those with comorbidities. The objective of this work is to describe the introduction, uptake, and current use of HD influenza vaccines in Spain and to summarize the evidence supporting their broader adoption in adults ≥60 years of age. Methods include a narrative synthesis of clinical evidence and an analysis of vaccination strategies implemented across Spanish autonomous communities since the introduction of HD vaccines during the COVID-19 pandemic. Available evidence supports extending HD vaccine use as a population-based strategy to enhance protection and promote equitable access. The results show that the incorporation of HD influenza vaccines marked a significant shift in national vaccination strategies, with heterogeneous uptake across regions: while some prioritized institutionalized or dependent populations, others implemented mixed approaches that also included community-dwelling adults aged ≥60 years. In conclusion, a clear trend toward wider adoption is emerging, with an increasing number of autonomous communities incorporating HD vaccines into their programs and progressively lowering the recommended age threshold, in alignment with international guidance and the biological rationale for strengthened protection in older adults.},
}
@article {pmid42456241,
year = {2026},
author = {Dietrich, N and Stubbert, B},
title = {Artificial intelligence for chest imaging in hantavirus pulmonary syndrome: A review of practical considerations for rare-disease imaging.},
journal = {Clinical imaging},
volume = {138},
number = {},
pages = {110895},
doi = {10.1016/j.clinimag.2026.110895},
pmid = {42456241},
issn = {1873-4499},
abstract = {Hantavirus pulmonary syndrome (HPS) is an uncommon zoonotic respiratory illness with a high case fatality rate. Recent travel-associated Andes orthohantavirus clusters have renewed interest in early radiographic recognition of the disease outside its usual geographic range. Artificial intelligence (AI) tools developed during the COVID-19 pandemic now inform several radiology workflows, but the application of AI to HPS chest imaging remains largely unexplored. This narrative review summarises the imaging features of HPS across modalities, considers lessons from AI applications in COVID-19 and viral pneumonia imaging, and discusses practical development considerations for HPS-aware imaging AI, including dataset development, label standardisation, realistic comparator inclusion, candidate modelling approaches, external validation, and clinical workflow integration. The review also considers challenges to HPS-aware imaging AI, including data scarcity, low pretest probability in non-endemic settings, overlapping imaging findings, and translational pitfalls from recent AI literature. As HPS is unlikely to support conventional disease-specific model development without coordinated data collection, future work will likely require multi-institutional datasets, prevalence-aware evaluation, and multimodal workflow integration that combines imaging with clinical, laboratory, and epidemiologic context.},
}
@article {pmid42459265,
year = {2026},
author = {Vera, E and Galanis, P and Mangoulia, P and Pesiridis, T},
title = {Factors affecting nurses' professional quality of life in Europe - A systematic review.},
journal = {AIMS public health},
volume = {13},
number = {2},
pages = {485-512},
pmid = {42459265},
issn = {2327-8994},
abstract = {BACKGROUND: Nursing care involves both cognitive and emotional aspects, significantly impacting nurses' professional quality of life (ProQOL). This systematic review investigated the factors affecting nurses' professional quality of life in Europe.<br><br>METHODS: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting framework and was registered in the International Prospective Register of Systematic Reviews (registration number: CRD420251133948). Searches were conducted in PubMed, Scopus, CINAHL, ScienceDirect, and EBSCOhost from inception to August 2025. Eligible peer-reviewed quantitative studies from European Union countries utilized the ProQOL instrument, reporting on all three dimensions: compassion satisfaction, burnout, and secondary traumatic stress. Two reviewers independently screened records, extracted data, and appraised methodological quality using the Joanna Briggs Institute critical appraisal tool.<br><br>RESULTS: A total of 3407 records were initially identified, and 35 studies were ultimately included, comprising 8580 nursing staff across diverse clinical settings, predominantly hospitals, with 13 studies conducted during the coronavirus disease period in 2019. Most studies reported moderate levels of compassion satisfaction and moderate levels of burnout and secondary traumatic stress. Higher compassion satisfaction was generally associated with greater age and professional experience, relevant education and training, work engagement, supportive work environments, better perceived control over workload, and stronger psychosocial resources, including resilience, psychological flexibility, self-compassion, mindfulness, and social support. Higher burnout and secondary traumatic stress related to indirect exposure were consistently linked to a high workload, overtime, rotating schedules, job stress, workplace violence, employment in high-intensity clinical areas, and adverse psychological states, including persistent stress, fear related to the coronavirus disease, and moral distress.<br><br>CONCLUSIONS: Professional quality of life among European nursing staff is influenced by a combination of demographic, occupational, and psychosocial factors. Multilevel strategies addressing organizational stressors while strengthening individual and team-based resources are warranted to improve compassion satisfaction and reduce burnout and secondary traumatic stress.},
}
@article {pmid42459266,
year = {2026},
author = {Du, D and Sun, G and Yuan, L and Yao, Y and Yang, T and Gao, J and Zhang, L},
title = {Internet healthcare in Chinese public hospitals: Towards high-quality development (1986-present).},
journal = {AIMS public health},
volume = {13},
number = {2},
pages = {598-621},
pmid = {42459266},
issn = {2327-8994},
abstract = {BACKGROUND: Internet healthcare has become a key part of China's hospital-centered health system. Driven by "Internet Plus Healthcare", Healthy China 2030, and public-hospital high-quality development policies, it has evolved from remote consultation experiments into regulated online-offline care pathways. This review traces its development from the first documented remote medical practice in 1986 to the present, focusing on policy, institutional models, clinical evidence, governance challenges, and reform.<br><br>METHODS: We conducted a structured narrative review of English- and Chinese-language sources on internet healthcare in Chinese public hospitals. PubMed/MEDLINE, Web of Science Core Collection, China National Knowledge Infrastructure (CNKI), and official policy sources were searched. Eligible sources addressed internet hospitals, telemedicine, online follow-ups, remote monitoring, e-prescriptions, insurance payments, digital governance, clinical outcomes, patient safety, equity, or implementation barriers in mainland China.<br><br>RESULTS: Internet healthcare progressed through early telemedicine, institutional network expansion, internet-hospital development, and pandemic-driven normalization. The 2018 regulatory framework positioned internet hospitals as extensions of licensed physical medical institutions, thereby permitting online follow-ups for common and chronic diseases while preserving offline accountability. During COVID-19, online consultation, e-prescriptions, drug delivery, and insurance payments rapidly expanded. Evidence suggests benefits for chronic disease management, medication adherence, cardiovascular secondary prevention, and reduced travel burden. However, evidence remains limited for diagnostic accuracy, adverse events, emergency escalation, and long-term outcomes. Persistent barriers include quality variation, workload, cybersecurity, data fragmentation, artificial intelligence (AI) accountability, reimbursement design, regional inequity, and digital exclusion among older adults.<br><br>CONCLUSION: China's model may be understood as a hospital-centered extension of public-hospital functions rather than a stand-alone virtual-care system. Future development should prioritize outcome-based evaluations, safety governance, equitable access, data interoperability, and accountability for internet-based and AI-assisted care.},
}
@article {pmid42459503,
year = {2026},
author = {Larrain, D and Parker, CM},
title = {Beyond Prison Walls: A Scoping Review of Incarceration's Public Health Impacts in Latin America.},
journal = {Wellcome open research},
volume = {11},
number = {},
pages = {193},
pmid = {42459503},
issn = {2398-502X},
abstract = {BACKGROUND: Incarceration has vast and unequal impacts on public health beyond prison walls. Research from the United States documents these collateral consequences, including elevated mental illness and morbidity for the children and partners of incarcerated individuals, alongside community-level effects such as increased rates of teenage pregnancy and multidrug-resistant tuberculosis. In Latin America, however, these broader health impacts remain critically understudied. A significant barrier is the absence of data collection efforts or theoretical frameworks for mapping how Latin America's prisons affect the health of families and surrounding communities.<br><br>OBJECTIVE: This scoping review synthesises existing evidence on the collateral health consequences of incarceration in Latin America by conducting a comprehensive search in 2025 that included English, Spanish and Portuguese language peer-reviewed studies.<br><br>RESULTS: From 17 included documents, prisons emerge as epicentres for tuberculosis transmission to visiting families and surrounding communities. The evidence reveals significant mental and physical health burdens on families. Women with incarcerated partners experience depression and anxiety whilst managing economic strain and expanded caregiving responsibilities, often neglecting their own health. Children of incarcerated parents show marked emotional distress, and incarcerated mothers alongside their young children face severely inadequate healthcare access within detention spaces.<br><br>CONCLUSIONS: Despite collecting demographic data, most studies overlook how these burdens fall unequally across racialised populations. Future research must centre ethnoracial disparities and situated knowledge.},
}
@article {pmid42460684,
year = {2026},
author = {Foláyan, MO and Arobo, A and Oyeyemi, E and Bhayat, A and Tantawi, ME},
title = {Integrating Oral Health Into Pandemic Preparedness and Response: Missed Opportunities and Strategic Imperatives for Global Health System Resilience and Security.},
journal = {Community dentistry and oral epidemiology},
volume = {},
number = {},
pages = {},
doi = {10.1111/cdoe.70092},
pmid = {42460684},
issn = {1600-0528},
abstract = {BACKGROUND: Despite evidence linking oral health to severe COVID-19 outcomes and its potential role in surveillance and service delivery, integration remained absent. This study enquired about: (1) representation of oral health in national COVID-19 taskforces and funding; (2) policy-level barriers to inclusion; (3) lessons from maintaining essential services; and (4) strategies for mobilizing oral health professionals in future emergencies.<br><br>METHODS: We conducted a scoping review guided by the PRISMA-ScR framework. Systematic searches were performed in PubMed/MEDLINE and Scopus (2000-2025) using tailored search strings combining key terms: oral health, pandemic preparedness, COVID-19, dentistry, health systems and related MeSH terms. Eligible evidence included peer-reviewed studies, reviews, policy documents and commentaries in English. Non-human studies were excluded. Data were charted using the WHO Health System Building Blocks framework.<br><br>RESULTS: After dual-reviewer screening, 2569-3860 records were screened, yielding 5-8 eligible studies per question (26 studies total). The evidence revealed a consistent narrative of systemic exclusion yet operational resilience. For representation, oral health professionals were almost universally absent from national COVID-19 task forces, with dedicated financial support entirely lacking. Regarding barriers, policy integration was hindered by the framing of oral care as non-essential, its omission from global health security architectures like the International Health Regulations, and limited professional advocacy. In contrast, lessons from service adaptation demonstrated that essential care was maintained through the rapid adoption of triage, teledentistry, robust infection control and effective communication. On workforce mobilization, while consensus existed on the potential for OHPs to expand into roles such as vaccination and surveillance, implementation was obstructed by a lack of pre-emergency training, formal deployment mechanisms and regulatory frameworks with minimal linkage to international instruments.<br><br>CONCLUSION: The review reflects systemic neglect of oral health, with the literature dominated by descriptions of clinical and operational adaptations rather than formal policy integration. We identify missed opportunities in leveraging OHPs for pandemic response and propose embedding oral health within One Health governance, financing, surveillance and emergency response structures to build more resilient health systems.},
}
@article {pmid42461048,
year = {2026},
author = {Översti, S and Lytras, S and Kawakubo, S and Ito, J and Ghafari, M},
title = {From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.},
journal = {Journal of virology},
volume = {},
number = {},
pages = {e0168725},
doi = {10.1128/jvi.01687-25},
pmid = {42461048},
issn = {1098-5514},
abstract = {The genomic deluge has pushed viral molecular evolution into a site-resolved era. For antigenically evolving viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), dense genomic sampling now supports mutation-annotated phylogenies and per-site estimates of mutation and substitution processes. These data highlight strong effects of sequence context, genomic region, RNA structure, and protein-level constraints that are blurred by classic uniform substitution models. In parallel, accurate structure prediction and emerging structure-aware phylogenetic and machine-learning approaches provide practical ways to map mutations onto three-dimensional constraints, identify structurally plausible escape routes, and interpret evolutionary rate variation through solvent exposure, packing, stability, glycosylation, receptor-binding interfaces, and epitope geometry. Finally, antigenic cartography translates some forms of genetic change into an epidemiologically meaningful phenotype-antigenic distance-while predictive modeling increasingly enables sequence-to-antigenicity inference for variants that have not yet been tested experimentally. Here, we outline a practical framework linking sites, structure, and serology for viruses in which antigenic evolution is a major component of immune escape and lineage turnover; highlight why genetic and antigenic "clocks" can diverge; and discuss how integrating genomic surveillance data, phylogenetics, structural analysis, and predictive modeling could support more prospective variant assessment and improved vaccine and therapeutic design.},
}
@article {pmid42461075,
year = {2026},
author = {Hashemi, S and Pati, D},
title = {Healthcare Design for Pandemic Resilience: A Systems Thinking Approach.},
journal = {HERD},
volume = {},
number = {},
pages = {19375867261466289},
doi = {10.1177/19375867261466289},
pmid = {42461075},
issn = {2167-5112},
abstract = {BackgroundThe COVID-19 pandemic created unprecedented operational challenges (such as surge-capacity demands and infection-control requirements) that disturbed the equilibrium of healthcare work systems worldwide. Physical environments can play a pivotal role in mitigating or exacerbating these challenges.PurposeThis article aims to strengthen healthcare-system resilience in future pandemics by synthesizing the findings of existing literature to identify environmental factors that supported or hindered healthcare work systems during the COVID-19 pandemic.MethodsWe conducted a systematic search of the CINAHL, MEDLINE, PubMed, and ScienceDirect databases and complemented this search with handsearching. We included studies if they addressed the COVID-19 pandemic, focused on physical healthcare environments, and were published in English in peer-reviewed journals. With a focus on environmental influences, we deductively coded the findings using components of the Systems Engineering Initiative for Patient Safety (SEIPS) model.ResultsForty-two studies met the inclusion criteria. The analysis revealed six major operational challenges: (1) surge capacity, (2) infection control, (3) increased risk of errors, (4) rethinking of care models, (5) financial losses, and (6) the pandemic's adverse psychological impacts on staff and patients. The article documents environmental factors that influenced either the overall healthcare work system or its individual components during the COVID-19 pandemic. We identified three overarching roles for these environmental factors: they served as barriers, solutions, or facilitators.ConclusionsUsing the SEIPS framework can enable well-orchestrated pandemic-response planning by guiding the creation of design strategies that will strengthen resilience, flexibility, and safety in future health crises.},
}
@article {pmid42461270,
year = {2026},
author = {Farrag, MA},
title = {The Role of Artificial Intelligence and Machine Learning in Predictive Virology: Forecasting, Tracking, and Combating Viral Threats.},
journal = {Vector borne and zoonotic diseases (Larchmont, N.Y.)},
volume = {},
number = {},
pages = {15303667261469037},
doi = {10.1177/15303667261469037},
pmid = {42461270},
issn = {1557-7759},
abstract = {The escalating threat of viral pandemics, dramatically illustrated by the COVID-19 crisis, has exposed the critical shortcomings of conventional reactive virology in addressing rapidly evolving pathogens. This review introduces predictive virology (PV) as an artificial intelligence (AI)-driven discipline within broader epidemic intelligence and public health surveillance that uses advanced computational tools to forecast viral threats and accelerate countermeasure design. The current review systematically examines how AI-driven approaches (e.g., machine learning and deep learning) are reshaping virology by integrating vast genomic datasets, multimodal surveillance signals, and advanced computational models to anticipate viral emergence and evolution before widespread transmission occurs. Core pillars of PV discussed include zero-shot mutational fitness and antigenic escape prediction using large protein language models; multimodal early-warning systems that fuse wastewater monitoring, digital epidemiology, mobility data, and social media; neural differential equation-based transmission modeling; generative AI for de novo design of broad-spectrum antivirals and vaccines; and ecological risk assessment of zoonotic spillovers. In retrospective benchmarks against deep mutational scanning experiments and real-world epidemiological outcomes (SARS-CoV-2 variants, influenza, and other outbreaks), several AI-powered tools have demonstrated performance comparable to or exceeding traditional methods, although prospective validation at scale remains limited. Despite remarkable progress, significant challenges persist, including data bias, overfitting to historical patterns, lack of prospective validation, and limited generalizability across settings. In addition, there are concerns about mechanistic interpretability, equitable global data integration, and responsible deployment. This review also critically addresses the ethical, governance, and equity implications of deploying predictive capabilities at a global scale. By consolidating cutting-edge AI methodologies with virological insights and acknowledging current limitations, this work provides a comprehensive framework for transitioning virology from a reactive to a truly predictive discipline, ultimately strengthening global health security and pandemic preparedness.},
}
@article {pmid42461676,
year = {2026},
author = {Mace, SE and Doyle, CJ and Biddinger, PD and Bradin, S and Burdash, S and Lefort, R and Noll, S and Moriber, MR and Cornelius, A},
title = {Disaster preparedness for vulnerable populations during a pandemic: Part 1: Pandemics: Overview, history, and vulnerability for a pandemic.},
journal = {American journal of disaster medicine},
volume = {21},
number = {2},
pages = {109-118},
doi = {10.5055/ajdm.0531},
pmid = {42461676},
issn = {1932-149X},
mesh = {Humans ; *Vulnerable Populations ; *Pandemics/history ; COVID-19/epidemiology ; *Disaster Planning/organization &amp; administration ; Pandemic Preparedness ; SARS-CoV-2 ; *Surge Capacity/organization &amp; administration ; United States ; },
abstract = {OBJECTIVE: To provide an overview of the literature on disaster preparedness regarding surge capacity, with a particular focus on vulnerable populations during a pandemic.<br><br>DESIGN: The Disaster Preparedness and Response Committee of the American College of Emergency Physicians addressed the topic of vulnerable populations during a pandemic. A workgroup of nine physicians with academic and/or disaster deployment experience was formed. A literature review focused on individuals with access and functional needs, also referred to as special healthcare needs (SHCNs) or vulnerable individuals, was performed. Search terms included pandemic, public health emergency of international concern, disaster, COVID-19, vulnerable population, individuals with access and functional needs, special healthcare needs (SHCN), surge capacity, and CMIST (communications, medical care, independence, supervision, and transportation). Search strategies included medical sources such as PubMed, Medline, Google Scholar, ScienceDirect, Scopus, and the Cochrane Database of Systematic Reviews. Reviews were performed by a librarian. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members were included. The workgroup evaluated the literature and identified issues regarding surge capacity occurring during a pandemic that particularly impacted the SHCN population. Potential solutions were identified.<br><br>RESULTS: Vulnerable individuals are at greater risk during a pandemic than the general population, although potential solutions to mitigate the impact of a pandemic on vulnerable individuals are possible.<br><br>CONCLUSIONS: Although pandemics can have significant adverse effects on the general population, vulnerable individuals have the greatest morbidity and mortality and are at greatest risk. Efforts are warranted to better address the negative impact of a pandemic, not just for the general population, but also for individuals with access and functional needs, and to find solutions that can help mitigate the consequences of a pandemic.},
}
@article {pmid42461677,
year = {2026},
author = {Mace, SE and Doyle, CJ and Biddinger, PD and Bradin, S and Burdash, S and Lefort, R and Noll, S and Moriber, MR and Cornelius, A},
title = {Disaster preparedness for vulnerable populations during a pandemic: Part 2: The origins of a pandemic: Emerging infectious diseases, bioterrorism, and laboratory accidents.},
journal = {American journal of disaster medicine},
volume = {21},
number = {2},
pages = {119-131},
doi = {10.5055/ajdm.0527},
pmid = {42461677},
issn = {1932-149X},
mesh = {Humans ; *Vulnerable Populations ; *Pandemics ; *Bioterrorism ; *Disaster Planning/organization &amp; administration ; COVID-19 ; *Communicable Diseases, Emerging/epidemiology ; Surge Capacity/organization &amp; administration ; Pandemic Preparedness ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: To provide an overview of the literature on disaster preparedness regarding surge capacity with a particular focus on vulnerable populations during a pandemic.<br><br>DESIGN: The Disaster Preparedness and Response Committee of the American College of Emergency Physicians addressed the topic of vulnerable populations during a pandemic. A workgroup of nine physicians with academic and/or disaster deployment experience was formed. A literature review focused on individuals with access and functional needs, also referred to as special healthcare needs (SHCN) or vulnerable individuals, was performed. Search terms included pandemic, public health emergency of international concern (PHEIC), disaster, COVID-19, vulnerable population, individuals with access and functional needs, special health care needs (SHCN), surge capacity, and CMIST (communications, medical care, independence, supervision, and transportation). Search strategies included medical sources such as PubMed, Medline, Google Scholar, ScienceDirect, Scopus, and the Cochrane Database of Systematic Reviews. Reviews were performed by a librarian. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members were included. The workgroup evaluated the literature and identified issues regarding surge capacity occurring during a pandemic that particularly impacted the SHCN population. Potential solutions were identified.<br><br>RESULTS: Vulnerable individuals are at greater risk during a pandemic than the general population, although potential solutions to mitigate the impact of a pandemic on vulnerable individuals are -possible.<br><br>CONCLUSIONS: Although pandemics can have significant adverse effects on the general population, vulnerable individuals have the greatest morbidity and mortality and are at the greatest risk. Efforts are warranted to better address the negative impact of a pandemic, not just for the general population but also for individuals with access and functional needs, and to find solutions that can help mitigate the consequences of a pandemic.},
}
@article {pmid42461678,
year = {2026},
author = {Mace, SE and Doyle, CJ and Biddinger, PD and Bradin, S and Burdash, S and Lefort, R and Noll, S and Moriber, MR and Cornelius, A},
title = {Disaster preparedness for vulnerable populations during a pandemic: Part 3: Surge capacity and communications in a pandemic.},
journal = {American journal of disaster medicine},
volume = {21},
number = {2},
pages = {133-148},
doi = {10.5055/ajdm.0525},
pmid = {42461678},
issn = {1932-149X},
mesh = {Humans ; *Vulnerable Populations ; *Pandemics ; *Surge Capacity/organization &amp; administration ; COVID-19/epidemiology ; *Disaster Planning/organization &amp; administration ; Pandemic Preparedness ; SARS-CoV-2 ; United States ; },
abstract = {OBJECTIVE: To provide an overview of the literature on disaster preparedness regarding surge capacity with a particular focus on vulnerable populations during a pandemic.<br><br>DESIGN: The Disaster Preparedness and Response Committee of the American College of Emergency Physicians addressed the topic of vulnerable populations during a pandemic. A workgroup of nine physicians with academic and/or disaster deployment experience was formed. A literature review focused on individuals with access and functional needs, also referred to as special healthcare needs (SHCN) or vulnerable individuals, was performed. Search terms included pandemic, public health emergency of international concern (PHEIC), disaster, COVID-19, vulnerable population, individuals with access and functional needs, special health care needs (SHCN), surge capacity, and communications, medical care, independence, supervision, and transportation (CMIST). Search strategies included medical sources such as PubMed, Medline, Google Scholar, ScienceDirect, Scopus, and the Cochrane Database of Systematic Reviews. Reviews were performed by a librarian. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members were included. The workgroup evaluated the literature and identified issues regarding surge capacity occurring during a pandemic that particularly impacted the SHCN population. Potential solutions were identified.<br><br>RESULTS: Vulnerable individuals are at greater risk during a pandemic than the general population, although potential solutions to mitigate the impact of a pandemic on vulnerable individuals are possible.<br><br>CONCLUSIONS: Although pandemics can have significant adverse effects on the general population, vulnerable individuals have the greatest morbidity and mortality and are at the greatest risk. Efforts are warranted to better address the negative impact of a pandemic, not just for the general population but also for individuals with access and functional needs, and to find solutions that can help mitigate the consequences of a pandemic.},
}
@article {pmid42461679,
year = {2026},
author = {Mace, SE and Doyle, CJ and Biddinger, PD and Bradin, S and Burdash, S and Lefort, R and Noll, S and Moriber, MR and Cornelius, A},
title = {Disaster preparedness for vulnerable populations during a pandemic: Part 4: Pandemics: Planning for those with access and functional needs in a pandemic.},
journal = {American journal of disaster medicine},
volume = {21},
number = {2},
pages = {149-159},
doi = {10.5055/ajdm.0526},
pmid = {42461679},
issn = {1932-149X},
mesh = {Humans ; *Vulnerable Populations ; *Disaster Planning/organization &amp; administration ; *Pandemics ; *Surge Capacity/organization &amp; administration ; *Health Services Accessibility ; Pandemic Preparedness ; COVID-19/epidemiology ; Health Services Needs and Demand ; },
abstract = {OBJECTIVE: To provide an overview of the literature on disaster preparedness regarding surge capacity with a particular focus on vulnerable populations during a pandemic.<br><br>DESIGN: The Disaster Preparedness and Response Committee of the American College of Emergency Physicians addressed the topic of vulnerable populations during a pandemic. A workgroup of nine physicians with academic and/or disaster deployment experience was formed. A literature review focused on individuals with access and functional needs, also referred to as special healthcare needs (SHCN) or vulnerable individuals, was performed. Search terms included pandemic, public health emergency of international concern (PHEIC), disaster, vulnerable population, individuals with access and functional needs, special health care needs (SHCN), surge capacity, and communications, medical care, independence, supervision, and transportation (CMIST). Search strategies included medical sources such as PubMed, Medline, Google Scholar, ScienceDirect, Scopus, and the Cochrane Database of Systematic Reviews. Reviews were performed by a librarian. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members were included. The workgroup evaluated the literature and identified issues regarding surge capacity occurring during a pandemic that particularly impacted the SHCN population. Potential solutions were identified.<br><br>RESULTS: Vulnerable individuals are at greater risk during a pandemic than the general population, although potential solutions to mitigate the impact of a pandemic on vulnerable individuals are possible.<br><br>CONCLUSIONS: Although pandemics can have significant adverse effects on the general population, vulnerable individuals have the greatest morbidity and mortality and are at the greatest risk. Efforts are warranted to better address the negative impact of a pandemic, not just for the general population but also for individuals with access and functional needs, and to find solutions that can help mitigate the consequences of a pandemic.},
}
@article {pmid42461883,
year = {2026},
author = {Sheybani, F and Haddad, M},
title = {Community-Acquired CNS Infections in Western Asia (2010-2025): A Systematic Review.},
journal = {Neuroepidemiology},
volume = {},
number = {},
pages = {1-22},
doi = {10.1159/000553536},
pmid = {42461883},
issn = {1423-0208},
abstract = {UNLABELLED: Background / Objective: This systematic review aimed to summarize the epidemiology, etiology, diagnostic challenges, antimicrobial resistance, and clinical outcomes of community-acquired central nervous system (CNS) infections in Western Asian countries.<br><br>METHODS: A systematic search of PubMed was conducted for studies published from January 2010 to July 2025. Eligible studies included original research and case reports on CNS infections, while unrelated studies or studies outside Western Asia were excluded. Data were extracted and synthesized narratively by pathogen group. Risk of bias was assessed based on study design, sample size, and methodological quality.<br><br>RESULTS: Of 1,790 retrieved articles, 450 studies met the inclusion criteria, including case reports and observational studies across neonates, children, and adults. Streptococcus pneumoniae and Neisseria meningitidis were the most common bacterial pathogens; Listeria monocytogenes and multidrug-resistant Gram-negative organisms were notable. Among viral pathogens, Enteroviruses, herpes simplex virus type 1, and West Nile virus predominated, with increasing reports of post-COVID-19 autoimmune encephalitis. Tuberculous meningitis and neurobrucellosis remained significant causes of chronic CNS infections in endemic areas. Pneumococcal penicillin resistance exceeded 40% in some countries. Molecular diagnostic capacity and surveillance were limited.<br><br>LIMITATIONS: Evidence was limited by heterogeneity in study design, regional data gaps, and variable reporting of antimicrobial resistance, which may affect the comprehensiveness of the review. Conclusions / Interpretation: Community-acquired CNS infections continue to impose a substantial health burden in Western Asia. Expanded vaccination, improved molecular diagnostics, strengthened surveillance, and regional antimicrobial resistance monitoring are essential to reduce preventable mortality and long-term neurological sequelae.},
}
@article {pmid42462434,
year = {2026},
author = {Wołowiec, &#x141; and Wesołowska, W and Skibicka, K and Jaśniak, A and Banach, J and Osiak, J and Wołowiec, A and Skibicki, T and Grześk, G},
title = {Pleiotropic effects of direct oral anticoagulants on the coagulation-inflammation-endothelium axis: A phenotype-stratified narrative review.},
journal = {Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie},
volume = {202},
number = {},
pages = {119768},
doi = {10.1016/j.biopha.2026.119768},
pmid = {42462434},
issn = {1950-6007},
abstract = {AIMS: Direct oral anticoagulants (DOACs) - dabigatran (a thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (factor Xa [FXa] inhibitors) - modify oxidative stress, endothelial inflammation, and barrier integrity beyond anticoagulation. We ask whether this reflects distinct pharmacology or silencing of proteases at protease-activated receptors (PARs), and propose a three-condition framework for when it becomes clinically measurable.<br><br>METHODS: Narrative review (PubMed, Scopus, Web of Science; primary search 2019-2026, with foundational earlier references retained) with claims graded on a six-tier hierarchy; A&#x2021; marks trials formally negative or inconclusive owing to insufficient statistical power.<br><br>RESULTS: DOAC effects largely converge on one node - reduced PAR-1 signalling under thrombin inhibition and dual PAR-1/PAR-2 blockade under FXa inhibition - rather than independent targets; the FXa-PAR-2 axis is cross-validated across macrophages, liver sinusoidal endothelial cells, and neutrophils; and dabigatran plausibly differs qualitatively rather than only in degree - a working hypothesis whose mechanistic linchpin (residual exosite-I signalling) currently rests on a single unreplicated in-vitro study (level D). Clinically the signal sorts by phenotype and disease phase, not class: low-dose rivaroxaban benefits stable atherosclerosis (COMPASS) but not heart failure in sinus rhythm (COMMANDER-HF), and COVID-19 benefit appears only in convalescence (MICHELLE), not acutely or in outpatients (ACTIV-4B, A&#x2021;). A nationwide cohort linked DOACs to lower acute kidney injury and chronic kidney disease progression than vitamin K antagonists, pending separation from their nephrotoxicity.<br><br>CONCLUSIONS: Pleiotropy emerges where three conditions coincide - the protease is available at PARs, its generation is chronic, and PAR signalling is rate-limiting. This supports within-indication molecule selection (selection, not extension) and biomarker co-primary trials, not extension of indications.},
}
@article {pmid42462528,
year = {2026},
author = {Ganesan, K and Chen, J},
title = {Dual-targeting cancer and SARS-CoV-2: The host-directed mechanisms of Spatholobus suberectus Dunn (Jixueteng).},
journal = {Phytomedicine : international journal of phytotherapy and phytopharmacology},
volume = {159},
number = {},
pages = {158560},
doi = {10.1016/j.phymed.2026.158560},
pmid = {42462528},
issn = {1618-095X},
mesh = {Humans ; *SARS-CoV-2/drug effects ; Host-Directed Therapy ; *Fabaceae/chemistry ; *Antiviral Agents/pharmacology ; Animals ; *Drugs, Chinese Herbal/pharmacology/therapeutic use ; *COVID-19 Drug Treatment ; COVID-19 ; *Neoplasms/drug therapy ; *Antineoplastic Agents, Phytogenic/pharmacology ; Antineoplastic Agents/pharmacology ; },
abstract = {BACKGROUND: Spatholobus suberectus Dunn (SSD), known in traditional Chinese medicine as Jixueteng, has historically been used to treat conditions characterized by blood stasis. Modern research has validated its anticancer potential. Recent studies reveal broad-spectrum antiviral activity.<br><br>PURPOSE: This review synthesizes these two research frontiers. It proposes a unified host-directed therapy paradigm as the core mechanism underlying SSD's dual therapeutic capability.<br><br>METHODS: A comprehensive analysis of peer-reviewed literature was conducted. This included phytochemical studies, in vitro and in vivo pharmacological investigations, and computational modeling related to SSD. Emphasis was placed on integrating the latest mechanistic findings on its antiviral action against SARS-CoV-2 with its established anticancer profile.<br><br>RESULTS: SSD contains bioactive flavonoids, such as isoliquiritigenin and procyanidins. These compounds enable multi-target interactions with host proteins. In cancer, SSD acts as a host-directed anticancer agent by inhibiting lactate dehydrogenase A, activating AMP-activated protein kinase, inducing apoptosis and pyroptosis, and arresting the cell cycle at the G2/M checkpoint. Against SARS-CoV-2, SSD functions as a direct inhibitor of the host angiotensin-converting enzyme 2 receptor. It blocks viral entry with pan-variant efficacy validated in vivo. The anticancer evidence for SSD is extensive and derived from multiple independent laboratories. The antiviral data are currently more limited. Published studies have identified SSD as active against SARS-CoV-2 and demonstrated that isoliquiritigenin inhibits viral replication via NRF2 activation. Mechanistic ACE2-targeting data remain preliminary. A comparative synthesis reveals that SSD's efficacy in both oncology and virology converges on the modulation of host protein targets. SSD targets dysregulated host enzymes in cancer and a hijacked host receptor in viral infection. This strategy provides a high barrier to therapeutic resistance.<br><br>CONCLUSION: SSD represents a promising natural host-directed therapeutic platform. Its dual ability to disrupt cancer cell physiology and inhibit SARS-CoV-2 entry via distinct host targets positions it as a potential template for developing resistance-evasive strategies against complex diseases. Future efforts must focus on isolating the precise ACE2-inhibiting compounds, optimizing disease-specific delivery, and advancing translational studies to realize its clinical potential.},
}
@article {pmid42463201,
year = {2026},
author = {Byambasuren, O and Atkins, T and Baptista, S and Glasziou, P and Chakraborty, S},
title = {Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis.},
journal = {BMJ open},
volume = {16},
number = {7},
pages = {e111253},
pmid = {42463201},
issn = {2044-6055},
mesh = {Humans ; *Naltrexone/administration &amp; dosage/therapeutic use ; Post-Acute COVID-19 Syndrome ; *COVID-19 Drug Treatment ; *Narcotic Antagonists/administration &amp; dosage/therapeutic use ; Quality of Life ; Fatigue/drug therapy/etiology ; *COVID-19/complications ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: Long covid is a debilitating chronic condition, and the effect of low-dose naltrexone (LDN) on its symptoms is unclear. We aimed to determine the effectiveness of LDN on symptoms of long covid.<br><br>DESIGN: Systematic review and meta-analysis.<br><br>DATA SOURCES: PubMed, Embase and Cochrane Library for published studies; ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) for registered ongoing studies were searched through 5 May 2026.<br><br>ELIGIBILITY CRITERIA: We included randomised controlled trials and pre-post studies of patients with long covid reporting on fatigue, quality of life, cognitive symptoms or function and other long covid symptoms.<br><br>DATA EXTRACTION AND SYNTHESIS: Two independent reviewers used standardised methods to search, screen and select included studies. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analysis was conducted using random effects models.<br><br>RESULTS: Of 397 titles and abstracts screened, no randomised controlled trials were identified. Four observational pre-post studies from the USA and Ireland (n=155) met inclusion criteria. LDN doses varied from 1 mg/day to 6&#x2009;mg/day. Pooled pre-post analyses showed moderate effects for reducing fatigue (Hedges' g=-0.74; 95%&#x2009;CI -1.11 to -0.37; p<0.001), brain fog (Hedges' g=-0.53; 95%&#x2009;CI -1.01 to -0.05; p=0.03) and improving sleep quality (Hedges' g=-0.60; 95%&#x2009;CI -0.91 to -0.30; p=0.0001), and large effects for pain (Hedges' g=-0.93; 95%&#x2009;CI -1.29 to -0.57; p<0.001) and daily functioning (Hedges' g=-0.93; 95%&#x2009;CI -1.29 to -0.57; p<0.0001) in favour of LDN. Heterogeneity ranged from 0% to 62%. No serious adverse events were reported in the two studies that assessed safety.<br><br>CONCLUSION: Limited evidence from small pre-post studies suggests LDN may improve fatigue, cognition, sleep, pain and functioning in long covid. However, certainty of evidence is low. Well-powered trials are needed to confirm efficacy, determine dosing and duration and identify subgroups most likely to benefit.<br><br>TRIAL REGISTRATION: https://doi.org/10.17605/OSF.IO/C2VKX.},
}
@article {pmid42464199,
year = {2026},
author = {Pham, ANQ and Akram, I and Tiwana, MH and Smith, J},
title = {Waiting times for primary care appointments among older adults: a scoping review.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-026-28406-w},
pmid = {42464199},
issn = {1471-2458},
abstract = {BACKGROUND: Healthcare service waiting times have worsened due to the COVID-19 pandemic, particularly impacting older adults who need timely access to primary care to manage chronic conditions and prevent hospitalizations. This scoping review aims to fill a research gap by examining whether delays in primary care appointments for older adults occurred and, if so, how these delays have affected their access to primary care, with a focus on the role of social determinants of health.<br><br>METHODS: Following PRISMA guidelines, a systematic search was conducted across three health databases-MEDLINE (Ovid), CINAHL, and EMBASE-as well as one AI platform (typeset.io). To be included, articles needed to discuss waiting times for primary care appointments, include older adults in their target population, and be published in English since 2014. Non-English articles were excluded due to language proficiency constraints among the review team. The review also examined the impact of social determinants of health on equity in access to care.<br><br>RESULTS: This review identified a significant lack of research on primary care waiting times for older adults, with only twelve studies addressing the issue. Findings indicate that prolonged wait times act as a major barrier to accessing timely care, resulting in patient frustration, delayed treatment, and increased reliance on emergency services. The COVID-19 pandemic has exacerbated these challenges, particularly through care interruptions and the shift to virtual care, which is understudied regarding its impact on waiting times.<br><br>CONCLUSIONS: Prolonged waiting times for primary care disproportionately affect older adults, exacerbated by age-related health conditions and intersecting social determinants. Healthcare systems must address these barriers and prioritize research into tailored interventions to ensure equitable access to care for older adults.},
}
@article {pmid42465772,
year = {2026},
author = {Feya, Q and Mkhize-Kwitshana, ZL and Milase, RN and Wadee, A and Naidoo, N and Maiga, M and Senzani, S and Nakiyingi, L and Mvubu, NE},
title = {Molecular signaling in coinfection: how M. tuberculosis and respiratory viruses rewire host immunity and alter TB outcomes.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1863302},
pmid = {42465772},
issn = {1664-3224},
mesh = {Humans ; *Coinfection/immunology ; *Mycobacterium tuberculosis/immunology ; Signal Transduction/immunology ; Animals ; *Tuberculosis/immunology ; Immunity, Innate ; Host-Pathogen Interactions/immunology ; *Respiratory Tract Infections/immunology ; },
abstract = {Tuberculosis (TB) caused by Mycobacterium tuberculosis (M. tuberculosis) and respiratory viral infections remain major, intersecting global health challenges, and their co-occurrence imposes a disproportionate burden in high-HIV/high-TB regions such as sub-Saharan Africa. Coinfection biology is heterogeneous and dynamic, driven by viral diversity including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A/B, Respiratory Syncytial Virus (RSV), parainfluenza, metapneumovirus, rhinovirus, adenovirus, and bocavirus, and by the underlying TB stage, from latent and subclinical to active and reactivation disease. Innate sensing pathways, such as Toll-like receptors (TLR), retinoic acid-inducible gene I (RIG-I), and cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING), converge during coinfection, reshaping type I interferon (IFN-I), Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), and AP-1-driven responses and triggering a network of autocrine and paracrine signaling that reprograms macrophages, dendritic cells, and T-cell subsets. This immune rewiring alters granuloma equilibrium through suppressed Th1/IFN-γ coordination, exaggerated Th17/IL-17-driven neutrophilia, and regulatory T-cell or IL-10-mediated dampening, which together destabilize macrophage activation and tissue architecture. Oxidative stress, mitochondrial dysfunction, and Matrix Metalloproteinases (MMP)-driven matrix remodeling further integrate with these pathways, converting inflammatory signals into epithelial damage, cavitation, and fibrosis. Consequently, disease outcomes depend critically on timing, viral burden, pathogen order, host immune endotype, and TB stage, such that the same virus can either preserve containment or drive progression depending on the local immunological context. Importantly, the effects of respiratory viral coinfection vary across the TB disease continuum, influencing early granuloma formation, latent infection, reactivation risk, and established disease through distinct immunological mechanisms. Host-directed therapies (HDT) targeting interferon, IL-1, TNF, inflammasome, or metabolic checkpoints hold mechanistic promise but exhibit variable clinical translation, underscoring the need for precision approaches that integrate stage- and endotype-specific biomarkers. This narrative review proposes an integrated systems framework that links viral sensing, immune rewiring, granuloma biology, and tissue-remodeling to TB-respiratory virus coinfection, and emphasizes how timing-aware, biomarker-guided strategies can refine diagnosis, clinical management, prognosis, and vaccine design in vulnerable populations.},
}
@article {pmid42466633,
year = {2026},
author = {Li, Z and Han, X and Ren, Y},
title = {Global epidemiological and aetiological patterns of hand, foot, and mouth disease: a country-level scoping synthesis.},
journal = {Journal of global health},
volume = {16},
number = {},
pages = {04220},
pmid = {42466633},
issn = {2047-2986},
mesh = {*Hand, Foot and Mouth Disease/epidemiology/etiology/virology ; Humans ; *Global Health/statistics &amp; numerical data ; Incidence ; Disease Outbreaks ; Enterovirus ; COVID-19/epidemiology ; },
abstract = {BACKGROUND: Hand, foot, and mouth disease (HFMD) has historically been predominantly reported in the Asia-Pacific region, while its global epidemiology and aetiology remain fragmented and incompletely characterised. We aimed to synthesise currently available country-level evidence to describe global epidemiological and aetiological patterns of HFMD.<br><br>METHODS: We conducted a country-level scoping synthesis of published studies and publicly available surveillance reports through August 2025. Studies were eligible for inclusion if they reported epidemiological or aetiological data on HFMD at the national or subnational level, including case numbers, incidence, outbreaks, and enterovirus (EV) serotype distributions. We qualitatively synthesised the data, with a focus on surveillance availability, epidemiological trends, and major circulating EV serotypes.<br><br>RESULTS: Reported HFMD incidence declined during the COVID-19 pandemic and subsequently rebounded in many settings, in some settings exceeding pre-pandemic levels. Aetiological evidence suggests an increasing circulation of coxsackievirus A6 in multiple regions, with coxsackievirus A16 and EV A71 continuing to co-circulate in specific settings. However, routine epidemiological and aetiological surveillance remained largely concentrated in the Asia-Pacific region. In many other countries, available data were limited and primarily derived from outbreak-driven or sporadic studies. Heterogeneity was observed in surveillance systems and data availability across countries.<br><br>CONCLUSIONS: Global HFMD epidemiological and aetiological patterns are characterised by disparities in surveillance capacity and data availability. Developing standardised surveillance and aetiological monitoring is essential to further understand the global landscape of HFMD, improve data comparability, support early detection of epidemiological changes, and inform evidence-based prevention and control strategies.},
}
@article {pmid42466786,
year = {2026},
author = {Szynal, D and Olszowski, T},
title = {Nurse burnout as a public health issue and Its impact on patient care quality. A narrative review.},
journal = {Roczniki Panstwowego Zakladu Higieny},
volume = {77},
number = {1},
pages = {21-32},
doi = {10.32394/rpzh/225226},
pmid = {42466786},
issn = {0035-7715},
mesh = {Humans ; *Burnout, Professional/psychology/prevention &amp; control/epidemiology ; *Quality of Health Care ; Quality of Life ; *Nurses/psychology ; Workload/psychology ; Public Health ; Emotional Exhaustion ; },
abstract = {Occupational burnout among nurses is a significant public health issue. It affects both nurses' well-being and the quality of patient care. The aim of this narrative review is to provide a comprehensive synthesis of four key aspects of occupational burnout among nurses, namely its prevalence, determinants, consequences for patient care and mental health, and available prevention strategies. Literature was identified through searches of PubMed and Google Scholar. Articles published in English between 2015 and 2026 were reviewed and selected according to predefined inclusion and exclusion criteria. Burnout develops through the interaction of organizational, psychosocial, and individual factors. The most important contributors include work overload, staffing shortages, low autonomy, psychosocial stress, personality traits, and health status. Higher burnout levels are associated with increased medical errors, patient falls, and missed nursing care. Burnout also contributes to lower patient satisfaction and poorer perceived quality of care. Prolonged stress increases the risk of depression, anxiety, sleep disturbances, reduced psychological resilience, and intentions to leave the profession, negatively impacting nurses' quality of life and social functioning. Effective preventive and therapeutic strategies include mindfulness-based programs, cognitive-behavioral therapy, physical exercise, and resilience training. These interventions may be delivered both in person and digitally. Their effectiveness improves in supportive environments with allocated participation time and leadership engagement. Interventions at individual, team, and system levels reduce emotional exhaustion and depersonalization, enhance staff well-being, and improve patient safety. In the context of a global nursing shortage and increased workloads following the COVID-19 pandemic, multi-level strategies to prevent occupational burnout are essential for protecting nurses' mental health and maintaining high-quality healthcare. The review highlights the importance of multi-level preventive interventions to reduce burnout and improve healthcare outcomes.},
}
@article {pmid42467815,
year = {2026},
author = {Mastrovito, B and Abou Chakra, CN and Mahé, C and Nunes, MC},
title = {How Pandemics Have Reshaped the Respiratory Virus Data Landscape in Europe: Scoping Review.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e92917},
pmid = {42467815},
issn = {1438-8871},
mesh = {Humans ; Europe/epidemiology ; *Respiratory Syncytial Virus Infections/epidemiology ; *Pandemics ; *Influenza, Human/epidemiology ; *COVID-19/epidemiology ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Acute respiratory infections caused by influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 remain a major public health challenge in Europe. Although surveillance systems for these pathogens are well established, the past 2 decades have seen a rapid diversification of data streams supporting surveillance and research. This expanding data landscape, combined with fragmentation across institutions, sectors, and countries, may limit timely evidence synthesis and effective public health decision-making.<br><br>OBJECTIVE: This scoping review aimed to identify and characterize data sources used for surveillance and research on influenza, RSV, and SARS-CoV-2 in Europe over the past 20 years, and to examine their evolution over time, their alignment with research objectives, and geographic variation in data availability and use.<br><br>METHODS: We conducted a scoping review using an objective-driven analytical framework. Empirical reports published between January 2005 and September 2025 were identified in MEDLINE, Web of Science, and Embase. Eligible reports focused on influenza, RSV, or SARS-CoV-2 and included data from 12 European countries. Clinical and interventional studies were excluded. Reports were classified according to 4 research objectives: epidemiological monitoring, evaluation of interventions, assessment of disease burden and health outcomes, and analyses of population adherence and trust toward public health measures. Data sources were grouped into 9 categories, including surveillance systems, electronic health records (EHRs), registries, claims, surveys, digital, environmental, integrated datasets, and others.<br><br>RESULTS: A total of 2564 empirical reports were included. Over time, respiratory virus research relied on an increasingly diverse set of data streams. While surveillance systems remained central, particularly for epidemiological monitoring, their relative dominance declined. From 2020 onward, there was a marked expansion in the use of EHRs, registries, claims data, digital sources, and linked or integrated datasets, alongside increased use of open-access data. Data source use varied by research objective: surveillance data predominated in monitoring and intervention evaluation; EHRs in studies of risk factors and treatment effectiveness; surveys in seroprevalence and public trust analyses; and claims data in assessments of economic burden. Substantial geographic disparities were observed. Northern European countries more frequently used linked and multisource datasets, whereas Southern Europe relied more often on open-access or single-source data.<br><br>CONCLUSIONS: This scoping review provides a multipathogen, cross-country mapping of data sources for respiratory virus surveillance and research in Europe over 2 decades, applying an innovative objective-driven framework. Unlike prior reviews focused on single pathogens or data types, it offers a consolidated, comparative perspective based on 2564 reports to inform public health decision-making. The COVID-19 pandemic accelerated innovation in data generation and access, but progress remained largely centered on SARS-CoV-2, while structural fragmentation continues to limit timely, integrated data across Europe. Strengthening preparedness will require interoperable infrastructures, federated analysis platforms, sustainable funding for surveillance innovations, and cross-sectoral data sharing.},
}
@article {pmid42467983,
year = {2026},
author = {Tholo, N and Markey, G and Harrigan, R and Pandey, P and Prasad, B and Barai, RS and Gibson, DS and Shukla, P},
title = {The critical role of artificial intelligence and bioinformatics in accelerating peptide-based vaccine discovery for tackling global infectious diseases.},
journal = {Briefings in bioinformatics},
volume = {27},
number = {4},
pages = {},
pmid = {42467983},
issn = {1477-4054},
support = {//Department for the Economy/ ; },
mesh = {Humans ; *Artificial Intelligence ; *Computational Biology/methods ; Protein Subunit Vaccines ; Immunoinformatics ; *Vaccines, Subunit/immunology ; *Vaccine Development ; Epitopes, T-Lymphocyte/immunology ; Machine Learning ; COVID-19 Vaccines/immunology ; COVID-19/prevention &amp; control/immunology ; *Communicable Diseases/immunology ; Epitopes, B-Lymphocyte/immunology ; },
abstract = {Peptide-based vaccines, enabled by bioinformatics and machine learning (ML), have emerged as one of the most promising approaches for rapid, safe, and cost-effective vaccine design against infectious diseases. Unlike conventional approaches that depend heavily on whole-pathogen cultures or recombinant protein expression, peptide vaccines can be designed in silico and synthesized quickly. Rational and targeted in silico approaches for the discovery of peptide-based vaccine candidates include B-cell and T-cell epitope prediction, immunogenicity, antigenicity, allergenicity, autoimmunity, population coverage, sequence conservation, molecular docking, molecular dynamics simulation, in silico cloning, and immunological simulation analyses. The combination of these comprehensive computational methods can effectively generate high-quality vaccine candidates for subsequent validation via in vitro and in vivo experiments. This review contextualizes the historical trajectory of peptide-based vaccinology, from early linear epitope discoveries in the 1960s to multi-epitope constructs and clinically tested candidates such as UB-612 and PepGNP-Covid19. It examines critical challenges in immunoinformatics, including performance gaps in epitope prediction tools, complexities in human leucocyte antigen (HLA) mapping, and the need for extensive manual intervention in pipelines. Artificial intelligence-driven approaches, spanning deep learning, and interpretable ML, are positioned to transform epitope prediction, reduce human error, and standardize reproducibility. These advances have the potential to support global outbreak response targets such as the Coalition for Epidemic Preparedness Innovations (CEPI) 100 Days Mission and the World Health Organization (WHO) Research and Development (R&amp;D) Blueprint. However, their performance remains constrained by data quality, dataset imbalance, limited benchmark standardization, and persistent underrepresentation of many HLA alleles and population groups. Key Points Peptide-based vaccines, accelerated by bioinformatics and machine learning, offer a potentially rapid, relatively safe, and cost-effective alternative to traditional vaccine design, enabling in silico development and swift synthetic manufacturing. Computational methods such as B-cell and T-cell epitope prediction, immunogenicity analysis, and molecular simulations allow for rational and targeted vaccine candidate discovery, enhancing quality and efficiency. The field has evolved from early linear epitope discoveries in the 1960s to sophisticated multi-epitope constructs and clinically tested candidates like UB-612 and PepGNP-Covid19. Major challenges in immunoinformatics include performance limitations in epitope prediction tools, complexities in HLA mapping, and the necessity for manual intervention in data pipelines. Artificial intelligence-driven models, including deep learning and interpretable machine learning, promise to overcome these challenges by improving prediction accuracy, reducing errors, and supporting global epidemic response efforts such as CEPI's 100 Days Mission and the WHO R&amp;D Blueprint.},
}
@article {pmid42468359,
year = {2026},
author = {Kelly, JB and Brodie, G and Zeden, MS},
title = {Antisense oligonucleotides: design, implementation and future perspectives in microbiology.},
journal = {Current opinion in microbiology},
volume = {93},
number = {},
pages = {102794},
doi = {10.1016/j.mib.2026.102794},
pmid = {42468359},
issn = {1879-0364},
abstract = {Advances in molecular biology have expanded antimicrobial strategies that traditionally targeted proteins or metabolic pathways to now include RNA, enabling a previously unattainable precision through control of gene expression. The clinical potential of RNA-therapeutics was demonstrated during the COVID-19 pandemic, when mRNA vaccines marked a transformative milestone for RNA-based interventions for viral infections. Increasingly, similar principles are emerging for the treatment of bacterial infections. Antisense oligonucleotides (ASOs) bind complementary mRNA sequences to induce RNase H-mediated degradation or block their translation. Initially developed for genetic and neurodegenerative disorders, ASOs are now emerging as next-generation antibacterials, termed ASOBiotics, designed to silence essential bacterial genes. In this review, we explore the advances of ASO technologies with applications in bacterial pathogens, outlining design considerations while discussing the challenges and opportunities for making precision antibacterial therapeutics.},
}
@article {pmid42469771,
year = {2026},
author = {Kassie, AM and Endalamaw, A and Khatri, RB and Assefa, Y},
title = {Barriers and facilitators to diabetes service uptake and self-care management in Australia: a scoping review.},
journal = {BMC health services research},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12913-026-15150-5},
pmid = {42469771},
issn = {1472-6963},
abstract = {BACKGROUND: Diabetes represents a major and increasing public health burden in Australia. Despite this, there remains limited consolidated evidence on patterns of diabetes-related service uptake and self-management, particularly among priority population groups. This scoping review synthesizes existing evidence on diabetes-related health service utilization and self-management practices in Australia, focusing on key barriers and facilitators that affect access to care and engagement in self-management.<br><br>METHODS: We conducted a scoping review of journal articles published up to 20 October 2025. Major databases: PubMed, Embase, Scopus, and Web of Science, were utilized along with manual reference searches. Articles were screened in two stages, and data were extracted using a piloted template. A descriptive thematic analysis was performed focusing on the three major themes: service uptake, self-care management, and the associated barriers and facilitators. Diabetes service uptake was categorized into three subthemes: practitioner-based primary care, allied health and preventive services, and acute and emergency care. Moreover, the barriers and facilitators were organized using the socioecological framework.<br><br>RESULTS: Thirty-two articles were included in this review. The general population showed consistent engagement with practitioner-based routine diabetic services, with studies reporting up to 92% of adults visiting their general practitioners and having at least one HbA1c test over a six-month period. Aboriginal and Torres Strait Islander people also showed an improvement in primary care engagement despite a historical high dependency in acute care. In contrast, areas containing a higher proportion of overseas-born residents tended to rely more on acute services. The uptake of preventive services and allied health care was inconsistent and generally low. For example, up to 40% of adults had no contact with diabetes educators, dietitians, or podiatrists in some rural populations. One study has also reported that only 55.2% of high-risk adults were screened at least once for diabetes over a three-year period. Key barriers to service uptake and/or self-care management included limited health literacy, fragmented care pathways, financial constraints, cultural and language barriers, geographic remoteness, and variable digital capability. In contrast, coordinated multidisciplinary care, structured management plan, strong patient-provider relationship, social support, and access to digital health services were reported as important facilitators. Telehealth has also emerged as an effective facilitator for maintaining engagement, particularly during the COVID-19 pandemic.<br><br>CONCLUSION: Despite high engagement with routine primary care, significant gaps remain in preventive services and allied health use among people with diabetes in Australia, particularly among younger adults, rural residents, and socioeconomically disadvantaged or culturally diverse populations. Addressing these gaps requires equitable, person-centered, and integrated multidisciplinary care that aligns with patients' cultural values and everyday lives, alongside efforts in improving health literacy.},
}
@article {pmid42469840,
year = {2026},
author = {Riley, A and Doughty, H and Hill, JE and Giebel, C and Harris, M and Williams, NH},
title = {Barriers to and facilitators of the implementation of Community Health Worker programmes in high-income countries: a systematic review.},
journal = {BMC health services research},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12913-026-15114-9},
pmid = {42469840},
issn = {1472-6963},
support = {NIHR200182/ARCNWC161//National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast/ ; },
abstract = {BACKGROUND: Global interest in Community Health Workers (CHWs) is rising as health systems seek to address persistent health inequities and the social determinants of health. However, in high-income countries (HICs), CHW implementation remains fragmented. This systematic review synthesises evidence on the factors that act as barriers and facilitators to the implementation and integration of CHW programmes across HIC primary healthcare settings.<br><br>METHODS: We searched MEDLINE, Scopus, PsycINFO, and CINAHL for studies published between January 2001 and August 2025. Inclusion focused on qualitative, quantitative, and mixed-methods papers regarding CHW implementation in HICs. Methodological quality was appraised using the Mixed Methods Appraisal Tool (MMAT). Data were synthesised using a 'Best Fit' Framework Synthesis and confidence in the findings was assessed via GRADE-CERQual.<br><br>RESULTS: Seventy-two papers were included (US n&#x2009;=&#x2009;64; UK n&#x2009;=&#x2009;4; Australia n&#x2009;=&#x2009;3; Belgium n&#x2009;=&#x2009;1), primarily comprising qualitative and mixed methods designs. Key facilitators included leadership buy-in, the presence of implementation champions, and established community partnerships that enabled resource sharing. Prominent barriers included precarious, short-term funding models that prioritised quantitative outputs over relational labour; hierarchical medical power dynamics; and disconnected IT systems that necessitated redundant data entry. The COVID-19 pandemic acted as a catalyst, elevating the CHW role within public health infrastructure while simultaneously exposing digital divides and structural fragility. GRADE-CERQual ratings indicated high confidence in findings regarding funding sustainability, training, and integration.<br><br>CONCLUSIONS: The evidence synthesised in this review reveals a fundamental misalignment within current health services: while CHWs are valued for their unique relational capacity, they remain systemically undermined by transactional health system designs. Achieving sustainability requires a strategic shift toward long-term, flexible funding models and the workforce development of supportive infrastructure, including reflective supervision and standardised training. Integration must move beyond short-term, project-based initiatives toward a resilient and permanent public health workforce capable of addressing structural health inequities.<br><br>TRIAL REGISTRATION: PROSPERO: CRD42022310789.},
}
@article {pmid42470742,
year = {2026},
author = {N, B and Radhakrishnan, SSR and V, RS and J, PK and Srinivasan, S and Lamech, T and S, RK and Mani, R and Sharma, M and Vasudeva, K and Mahadevan, A and Hb, V},
title = {Emerging importance of bio-bank for precision diagnostics and research in neuroinfections - a narrative review.},
journal = {Diagnostic microbiology and infectious disease},
volume = {116},
number = {3},
pages = {117546},
doi = {10.1016/j.diagmicrobio.2026.117546},
pmid = {42470742},
issn = {1879-0070},
abstract = {The diagnosis of neuroinfectious diseases, including Tuberculous Meningitis (TBM), viral encephalitis, Human Immunodeficiency Virus (HIV), and post COVID-19 neurological syndromes, remains challenging due to limited surveillance, non-specific symptoms, inadequate laboratory sensitivity, and restricted availability of high-quality CSF or tissue specimens. The critical need for early and precise diagnosis and the development of reliable, validated biomarkers highlight the importance of biospecimen-driven approaches that leverage CSF and other biobanked materials, as evidenced by the emerging literature. This review aims to summarize the need for biobanks, discuss sample preservation and tracking, examine quality control frameworks, and evaluate current advances, translational applications, and ongoing challenges of biobanking in neuroinfectious disease research. We extracted evidence from existing neuroinfection biobanks, reviewed global standards governing bio-specimen preservation and storage, and analyzed studies demonstrating how archived CSF, blood, and brain tissue have enabled pathogen characterization, biomarker discovery, and translational research. Our analysis shows that biobanked specimens have facilitated high-resolution pathogen genotyping, immune profiling, and identification of diagnostic and prognostic biomarkers, such as neuro-filament light chain (NfL) and CSF proteomic signatures. Strengthening biobanking infrastructure, harmonized governance, established FAIR-aligned data systems, and the integration of AI and digital analytics will help accelerate biomarker validation, drive diagnostic innovation, and ultimately improve clinical outcomes for patients worldwide.},
}
@article {pmid42471030,
year = {2026},
author = {Kumar, CS and Joe Thomas, M and Thomas, NP and Kotwani, VS},
title = {Domestic robots: recent trends and innovations.},
journal = {Disability and rehabilitation. Assistive technology},
volume = {},
number = {},
pages = {1-27},
doi = {10.1080/17483107.2026.2702778},
pmid = {42471030},
issn = {1748-3115},
abstract = {PURPOSE: Domestic Service Robots (DSRs) are employed to perform personalised tasks in domestic/household environments. Recent times, especially after the COVID-19 pandemic, have shown a rapid increase in demand for household companion bots. Despite the development of several such service robots, there are still potential challenges that need to be addressed. Domestic robots that perform basic household chores such as vacuum cleaning are the most popular and commercially a big hit. It is desirable to have an advanced multipurpose robot that can interact with humans and the surrounding environment in real time.<br><br>METHODS: A comparative analysis of existing DSRs and their corresponding gaps is highlighted in this article. Emphasis is given to the design/appearance, choice of sensors and actuators, cognition, effectiveness in manipulating domestic objects, control and task planning algorithms, safety measures and reliability of DSRs validated in real-world settings.<br><br>RESULTS: This article presents a systematic review of the latest developments in DSR and outlines the future direction of research to tackle the unsolved problems. Key highlights from 83 research articles published after 2020 in reputed journals/platforms are studied and analysed to understand the latest trends in DSR.<br><br>CONCLUSION: This review highlights current progress, identifies existing gaps, and outlines future research directions essential for deploying reliable domestic service robots in real world environments.},
}
@article {pmid42471883,
year = {2025},
author = {Inuwa, U and Bakari, MA and Kaitafi, MT and Kadas, S},
title = {Analysis of Caesarean Deliveries (CD) at a Tertiary Hospital in Northeastern Nigeria: A 5 Year Review.},
journal = {Nigerian medical journal : journal of the Nigeria Medical Association},
volume = {66},
number = {5},
pages = {1768-1776},
pmid = {42471883},
issn = {0300-1652},
abstract = {BACKGROUND: One of the most commonly performed surgical procedures in Obstetrics is caesarean delivery (CD), and certainly the oldest surgical operation. Caesarean delivery is life-saving, especially when there is a failure or contraindication to vaginal delivery. However, the health risk and the cost of the surgery may be quite challenging, especially in low-resource countries like Nigeria. The observed increased prevalence rate in recent times is alarming and has become a major public health concern, calling for regular appraisal of its indications in order to reduce the prevalence. This study was undertaken to determine the prevalence, trend, indications, maternal and foetal outcomes at Modibbo Adama University Teaching Hospital, Yola, Adamawa State. Nigeria.<br><br>METHODOLOGY: It was a hospital-based retrospective study of all the cases of CD undertaken between 1st January 2018 and 31st December 2022. Names and hospital numbers of patients were identified; the case folders were traced and retrieved. Necessary information was obtained and analyzed using SPSS version 17 software. Results were presented in percentages, simple graphs, and ratios.<br><br>RESULTS: During the years under review, there were 8568 deliveries, out of which 2707 had cesarean delivery, giving a cesarean delivery rate of 31.6%. The major maternal indication was prolonged obstructed labor, 627 (23.09%), while that of foetal indication was foetal distress, 418 (15.44%). The trend of caesarean delivery in this study showed a steady increase between 2018 and 2019 and 2021 to 2022, with a drop in 2020. This was due to the lockdown following the COVID-19 pandemic in that year. The maternal mortality ratio was 776/100,000 live births, and case fatality was 0.8%, while perinatal mortality was 41/1000 births.<br><br>CONCLUSION: The caesarean delivery rate in this study was very high when compared to most teaching hospitals in Nigeria. Effort should therefore be made to reverse the ugly trend. Therefore, a thorough and meticulous assessment of patients should be done before a decision is taken for surgery, especially elective caesarean deliveries.},
}
@article {pmid42472491,
year = {2026},
author = {Bijkerk, HJC and Antonis, AFG and Wagenaar, JA and Lam, TJGM and van Doorn, DCK},
title = {Anthelmintic stewardship: An essential step towards sustainable dairy farming.},
journal = {Veterinary parasitology},
volume = {347},
number = {},
pages = {110846},
doi = {10.1016/j.vetpar.2026.110846},
pmid = {42472491},
issn = {1873-2550},
abstract = {Helminth infections in grazing dairy cattle can lead to asymptomatic infections, subclinical- or clinical disease. Whether the course of infection leads to disease depends on various factors, leading to a broad variety of prevalence rates and severity of disease between farms, between groups of cattle in a farm and between individual animals. Production losses related to helminth infections, the difficulty in diagnosing helminth disease and the wide availability and high efficacy of anthelmintics have led to overreliance on these products. Combined with management and other factors, this results in the development of anthelmintic resistance and an environmental hazard of drug residues. To slow down the development of anthelmintic resistance and to reduce the consequences of anthelmintic use on the environment, anthelmintic stewardship (AHS) is urgently needed. We define AHS as a systematic approach to optimize the management of helminth infections with the goal to minimize their negative consequences through minimizing the usage of anthelmintics, reducing the development of anthelmintic resistance and reducing environmental contamination. Implementation of AHS requires an approach that considers the complexity of helminth infections weighing different interests, while transferring them to practical applications. An integrated approach implementing AHS on dairy farms is proposed, consisting of four steps: risk assessment, prevention, diagnostics, and treatment. For each of these steps, implementation possibilities and gaps are reviewed. Although there are knowledge and implementation gaps in each of the steps, enough tools are currently available to implement AHS based on the proposed four step approach on dairy farms.},
}
@article {pmid42472528,
year = {2026},
author = {Dai, T and Wu, W and Wang, B and Feng, G and Wang, J and Hu, T and Lin, Y and Sun, F and Wei, G and Xia, Y and Chen, T and Liu, B},
title = {Advances in lateral flow immunoassays: from technological innovations to diverse applications.},
journal = {Talanta},
volume = {312},
number = {Pt A},
pages = {130269},
doi = {10.1016/j.talanta.2026.130269},
pmid = {42472528},
issn = {1873-3573},
abstract = {Lateral flow immunoassay (LFIA), as a rapid, simple, and cost-effective point-of-care testing (POCT) method, has made remarkable progress over the past few decades, especially demonstrating its unique public health value during the global 2019 coronavirus disease (COVID-19) pandemic. This review aims to systematically introduce the technical principles, core components, technological innovations of LFIA, applications in the field of analytical testing, and to explore the current challenges and future development directions. The review first introduces the basic principle and structural composition of LFIA. Then, it highlights the strategies related to performance improvement in LFIA, including structural engineering, nanomaterial innovations, buffer optimization, signal amplification, smartphone-based image analysis and the integration of artificial intelligence (AI) techniques. Subsequently, the main applications of LFIAs in analytical testing are discussed in detail, including the detection of pathogens, protein markers, and small molecule substances. Finally, this review points out the current status and emerging challenges of LFIAs, and elaborates on their future development trends, aiming to promote further technological advancements and wider application of this technology in the field of POCT.},
}
@article {pmid42473682,
year = {2026},
author = {Bamberg, S and Schulte-Frankenfeld, PM and Kreye, J},
title = {Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.},
journal = {Brain, behavior, &amp; immunity - health},
volume = {56},
number = {},
pages = {101301},
pmid = {42473682},
issn = {2666-3546},
abstract = {BACKGROUND: Autoimmune encephalitis (AIE) comprises a diverse group of neurological disorders characterized by autoantibodies targeting specific antigens of the central nervous system (CNS). While the pathophysiological effects of these autoantibodies have been extensively studied, the principles and immunological triggers underlying their generation remain less well understood. Viral infections and antiviral vaccinations have been reported as potential immunological triggers. However, a systematic overview of their specific associations and frequencies across AIE subtypes is lacking.<br><br>METHODS: Here, we performed a systematic literature review in PubMed to identify published cases of AIE linked to viral infections or antiviral vaccinations, and to test whether herpes simplex virus (HSV)-associated anti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E) represents a disproportionately strong association. We quantified the frequencies of viral infection- or vaccine-related AIE across ten common antibody-defined subtypes, and characterized their epidemiological and clinical features, complemented by data from 23 population-based viral encephalitis cohorts.<br><br>RESULTS: We identified 556 cases, of which 488 were infection-associated and 68 followed vaccination. The most frequent combination was HSV infection in association with NMDAR-E, which outnumbered all other reported virus-AIE associations combined and was almost exclusively attributable to preceding HSV encephalitis (HSE). Other recurrent associations included Japanese encephalitis virus, Epstein-Barr virus (EBV), and SARS-CoV-2 infections, although EBV- and SARS-CoV-2-associated cases were less clearly suggestive of causal post-infectious autoimmunity. Across 23 population-based viral encephalitis cohorts from five continents, HSV was the leading causative pathogen. Despite this high background frequency, HSV was significantly overrepresented among viral CNS infection-associated NMDAR-E cases in our dataset compared with the reference cohorts (P&#x202f;<&#x202f;0.0001), indicating a disproportionate association. Most reported HSE-associated NMDAR-E cases originated from Europe and occurred in young children (median age 6 years), with a balanced sex distribution and a median interval between infection and NMDAR-E onset of 30 days.<br><br>CONCLUSION: Collectively, these findings provide the most comprehensive overview of viral infection- and antiviral vaccination-associated AIE to date and support a pathogen-specific link between HSE and secondary NMDAR-E as the most dominant virus-AIE association in the published literature. They underscore the need to elucidate the underlying immunological mechanisms and to develop biomarkers predictive of secondary NMDAR-E.},
}
@article {pmid42473975,
year = {2026},
author = {Natarajan, RA},
title = {Stage-specific circulating transcriptomic and proteomic biomarkers and regulators in colorectal cancer: bridging affordable diagnostics and translational therapeutics.},
journal = {Critical reviews in clinical laboratory sciences},
volume = {},
number = {},
pages = {1-25},
doi = {10.1080/10408363.2026.2682852},
pmid = {42473975},
issn = {1549-781X},
abstract = {Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, driven largely by pronounced molecular heterogeneity and delayed clinical detection. Although high-throughput sequencing technologies have substantially advanced the understanding of CRC biology, their routine clinical implementation remains constrained by high costs, infrastructural requirements, and limited accessibility. This review addresses these translational barriers by systematically synthesizing circulating transcriptomic and proteomic biomarkers within a clinically scalable framework. Particular emphasis is placed on biomolecules detectable using reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), two widely accessible platforms that underwent extensive global optimization during the COVID-19 pandemic and are readily adaptable to liquid biopsy workflows. Through a stage-resolved analysis, we identify 9 genomic and 7 proteomic biomarkers associated with early-stage (I-II) CRC, alongside 9 genomic and 4 proteomic biomarkers linked to advanced-stage (III-IV) disease progression. Beyond biomarker cataloging, these molecules are integrated with Cancer Hallmark pathways, clinical-stage associations, and available clinical trial evidence to evaluate their biological relevance and translational readiness. In addition, we summarize standardized operating procedure (SOP) considerations and multiplex detection strategies to improve assay reproducibility, scalability, and cross-border clinical implementation. Collectively, this review bridges molecular discovery with clinically deployable laboratory workflows and provides a translational roadmap for the development of affordable, liquid biopsy-based diagnostic strategies aimed at improving CRC detection, patient stratification, longitudinal monitoring, and early therapeutic intervention.},
}
@article {pmid42474726,
year = {2026},
author = {Ehrmann, S and Li, J and Liu, L and Guérin, C},
title = {Prone positioning in ARDS.},
journal = {Intensive care medicine},
volume = {},
number = {},
pages = {},
pmid = {42474726},
issn = {1432-1238},
abstract = {Over the past five decades, prone positioning has evolved from single case reports to an evidence-based intervention. Initially used as a rescue therapy, it is now recognized as an integral component of lung-protective mechanical ventilation strategies, applied early in intubated patients with acute respiratory distress syndrome (ARDS) with a PaO2/FIO2 ratio < 150 mmHg. The COVID-19 pandemic further expanded its use to non-intubated patients, the so-called awake prone position (APP), with promising results. APP requires confirmation in non-COVID patients and in a more routine ICU practice. Improved oxygenation is a consistent and well-recognized effect of prone positioning in both intubated and non-intubated patients with ARDS. Beyond its effects on gas exchange, prone positioning mitigates ventilator-induced lung injury by reducing lung stress and strain and may also confer favorable hemodynamic effects. This article reviews the physiologic rationale for prone positioning, evidence from randomized controlled trials, current guideline recommendations, practical aspects of implementation, and ongoing questions in both intubated and non-intubated patients.},
}
@article {pmid42475596,
year = {2026},
author = {Müller, F and Tomczyk, S and Fiedrich, F},
title = {Analyzing Social Media to Infer Mental Health Status and Affective States for Crisis and Disaster Management: Scoping Review.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e79762},
pmid = {42475596},
issn = {1438-8871},
mesh = {Humans ; *Social Media ; *Mental Health ; *Disasters ; *Affect ; },
abstract = {BACKGROUND: The use of social media (SoMe) during crisis and disaster situations (CaDs) has gained increasing attention across disciplines. However, existing research is highly fragmented and often focused on technical aspects, with a limited understanding of how and which psychosocial information is derived from SoMe in CaDs.<br><br>OBJECTIVE: This scoping review provides an overview of the current research landscape regarding the analysis of SoMe data during CaDs to obtain information about public mental health and psychosocial needs. It identifies key themes, methodological approaches, and research gaps, with a particular focus on relevance for the German context.<br><br>METHODS: Following a scoping review protocol, a structured database search was conducted in PubMed, Web of Science, and Scopus to identify peer-reviewed studies published up to 2025. A method of triangulation combining qualitative and quantitative approaches was applied. The studies were analyzed regarding the type of CaDs, geographical focus, classification systems, methods of analysis used, and inclusion of psychosocial aspects (such as affect and mental health status).<br><br>RESULTS: Overall, we identified 179 studies that examined 267 CaDs. Of the included studies, 76% (136/179) focused on natural disasters, with biological CaDs representing 23% (41/179) of these events. For Germany, 5 studies were found, with only one covering storms, floods, or extreme temperatures, despite these making up most of the disasters in Germany per EM-DAT (Emergency Events Database) data. Most studies used datasets from Asia (especially China), while Africa was examined less often, pointing to differences in geographical representativeness. To infer mental health status or affective state, 47 studies used machine learning, 87 studies used lexicon-based approaches, and 25 studies used a combination; 14 studies used manual coding, and few studies did not explicitly mention their approach. Mental health outcomes ranged from affective valence (positive, negative, or neutral) to specific primary (eg, fear) and secondary (eg, denial) emotions and needs (eg, resources). Yet, few studies were based on theoretical models or included end-user perspectives. No study conducted real-time analysis; instead, all were retrospective. Additionally, current research focuses primarily on deficits (eg, psychological needs, negative affect, or stress), and often neglects positive mental health outcomes (eg, resilience and collective coping).<br><br>CONCLUSIONS: This scoping review underlines the rising popularity of SoMe analysis in CaDs regarding public mental health and needs. Although different techniques were developed and tested, there remain major gaps in real-time application, end-user integration, and contextual adaptation-particularly for underrepresented regions such as Africa, but also in countries such as Germany. As most models were developed or tested retrospectively (eg, using data from the COVID-19 pandemic), future research should examine the validity and tenability of such models in real-time monitoring and data, and emphasize more user-centered design and participatory research, theoretical grounding, and practical utility.},
}
@article {pmid42479201,
year = {2026},
author = {Stathopoulos, P and Kalogerakos, G and Kakoullis, SA and Michaeloudes, C and Falagas, ME},
title = {Pharmacological thromboprophylaxis in hospitalized patients with acute infectious diseases: a meta-analysis.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {8},
pages = {},
pmid = {42479201},
issn = {1432-1041},
mesh = {Humans ; *Venous Thromboembolism/prevention &amp; control/etiology ; *Anticoagulants/therapeutic use/adverse effects ; Acute Disease ; *Communicable Diseases/complications/drug therapy ; Hospitalization ; Randomized Controlled Trials as Topic ; Hemorrhage/chemically induced ; Fondaparinux/therapeutic use ; },
abstract = {INTRODUCTION: Venous thromboembolism (VTE) may be a significant complication in medical patients, and infectious disease has been highlighted as an additional risk factor. Pharmacological thromboprophylaxis can prevent VTE and is recommended in at-risk populations, but not routinely in patients with infectious diseases.<br><br>METHODS: We conducted a systematic review and meta-analysis of studies on the effectiveness of pharmacological thromboprophylaxis in patients with acute infections, excluding those involving COVID-19. The primary outcome was VTE events. Secondary outcomes were mortality and adverse events related to anticoagulant therapy.<br><br>RESULTS: Data from seven studies (four randomized controlled trials and three observational studies) involving 16,994 patients with infectious diseases were analyzed. Pharmacological thromboprophylaxis regimens consisted of unfractionated heparin, low-molecular-weight heparin (enoxaparin or dalteparin), and fondaparinux. The severity of the disease varied from acute infections to sepsis. Six studies reported fewer VTE events with thromboprophylaxis. The meta-analysis yielded a pooled odds ratio of 0.50 [95% CI: 0.37-0.69, I[2]&#x2009;=&#x2009;47%]. Three studies reported bleeding or bruising outcomes: one observational study reported significantly more bleeding with thromboprophylaxis, while two randomized trials reported either no significant difference in severe bleeding or in mild bleeding-related adverse events. Two studies assessed mortality, but neither found a statistically significant difference with or without thromboprophylaxis. One study was at high risk of bias, and another was at critical risk of bias.<br><br>CONCLUSION: This analysis quantifies the effect of thromboprophylaxis in patients with acute infectious diseases. Although available results show that thromboprophylaxis is associated with fewer VTE events, limited data, sparse safety and mortality reporting, and heterogeneity among studies preclude reliable risk-benefit evaluation. Further prospective research is warranted.},
}
@article {pmid42480062,
year = {2026},
author = {Alqarni, AA and Al-Kuraishy, HM and Alqarni, M and Eliwa, D and Al-Gareeb, AI and Bahaa, MM and Batiha, GE},
title = {Adiponectin Signaling as an Immunometabolic Regulator in COVID-19: Mechanistic Insights and Therapeutic Potential.},
journal = {Immunological investigations},
volume = {},
number = {},
pages = {1-24},
doi = {10.1080/08820139.2026.2704902},
pmid = {42480062},
issn = {1532-4311},
abstract = {BACKGROUND: Adiponectin is a pleiotropic adipocytokine with anti-inflammatory, antioxidant, and insulin-sensitizing functions. Its regulatory role in glucose and lipid metabolism, endothelial homeostasis, and immune responses positions it as a key determinant of immunometabolic resilience. Dysregulated adiponectin signaling has been increasingly implicated in adverse COVID-19 outcomes, particularly among individuals with metabolic comorbidities.<br><br>OBJECTIVE: To synthesize mechanistic, preclinical, and translational evidence on adiponectin signaling in COVID-19 and evaluate its potential as a therapeutic and lifestyle-modulated target.<br><br>METHODS: A critical review of published literature on adiponectin biology, AdipoR1/R2 receptor signaling, AMPK and PPAR-&#x3b1; pathways, cytokine regulation, oxidative stress, and infection-induced metabolic reprogramming was conducted.<br><br>RESULTS: COVID-19 is consistently associated with reduced circulating adiponectin, with the greatest declines observed in obesity, diabetes, and metabolic syndrome. Mechanistic and animal studies show that adiponectin activation attenuates hyperinflammation, oxidative stress, endothelial dysfunction, and multi-organ injury. These effects are mediated through AMPK activation, PPAR-&#x3b1; modulation, NF-&#x3ba;B suppression, and restoration of metabolic-immune balance.<br><br>CONCLUSIONS: Adiponectin signaling represents a promising therapeutic target for mitigating COVID-19 severity, especially in metabolically vulnerable populations. Pharmacological agonists and lifestyle interventions that enhance adiponectin pathways warrant further translational investigation.},
}
@article {pmid42481378,
year = {2026},
author = {Raiten, DJ and Bundy, DA and DeBernardo, D and Steiber, AL and Papoutsakis, C and Jimenez, EY and Proaño, GV and Rozga, M and Bremer, AA},
title = {The "Biomarkers of Nutrition for Development: Knowledge Indicating Dietary Sufficiency (BOND-KIDS)" Project-Justification and Conceptual Approach.},
journal = {The Journal of nutrition},
volume = {},
number = {},
pages = {101614},
pmid = {42481378},
issn = {1541-6100},
support = {Z99 OD999999/ImNIH/Intramural NIH HHS/United States ; },
abstract = {The global food and nutrition enterprise is confronted with daunting challenges to all aspects of the food system, from social/economic/political crises to pandemic diseases to climate change, all of which impact our ability to meet the health needs of a growing population. The response has been focused on vulnerable groups and critical periods of human development, starting with the "first 1000 d" (i.e., pregnancy and the first 2 y of life). However, another critical developmental period, the "next 7000 d" (i.e., 2-21 y of age), has received less attention in terms of efforts to inform our understanding of the role of nutrition in the health and development of children and adolescents. Although significant effort has gone into providing nutritional support to school-aged children (particularly via school-based programs), a lack of research (and thus evidence) has constrained our ability to assess the need for and impact of these programs on health and development. The recent impact of the COVID-19 pandemic on our ability to provide services to this vulnerable age group has highlighted not only the need to redouble efforts to address the effects of food and nutrition insecurity on these children but also a daunting lack of evidence to inform the development and evaluation of such programs. When viewed as a complex biological system, we can understand that school-aged children interact with both internal (biological, genetic, and nutritional) and external (social/behavioral/economic/political, home, community, and physical) environments (i.e., an ecology). The "Biomarkers of Nutrition for Development: Knowledge Indicating Dietary Sufficiency (BOND-KIDS)" Project was initiated to apply a transdisciplinary approach to address this ecology and help inform the range of communities involved in providing nutritional support to school-aged children in the United States and globally. This Executive Summary provides an overview of the conceptual approach, goals, objectives, and process of the BOND-KIDS Project.},
}
@article {pmid42481444,
year = {2026},
author = {Martins, D and Beckman, D and Loggia, M and Costanza, A and Borsini, A},
title = {Understanding neuroinflammation in post-COVID-19 syndrome: biological mechanisms, diagnostic biomarkers, and therapeutic prospects.},
journal = {Translational psychiatry},
volume = {},
number = {},
pages = {},
doi = {10.1038/s41398-026-04286-x},
pmid = {42481444},
issn = {2158-3188},
abstract = {Post-COVID-19 syndrome (PCS) is an escalating global health concern, marked by persistent cognitive, neurological, and psychiatric symptoms following acute SARS-CoV-2 infection. Although its underlying mechanisms remain incompletely understood, mounting evidence implicates chronic neuroinflammation as a key driver. Sustained microglial and astrocyte activation, blood-brain barrier disruption, and aberrant cytokine signaling contribute to prolonged immune dysregulation within the central nervous system, promoting long-term brain dysfunction. In this expert review, we synthesize emerging insights into how neuroimmune processes impair brain function in PCS. We explore novel mechanistic pathways - including local sleep intrusions, impaired memory reconsolidation, and astrocyte-mediated destabilization of functional networks - that may underlie the syndrome's fluctuating and heterogeneous presentation. We evaluate fluid biomarkers of neuroinflammation, including glial fibrillary acidic protein (GFAP), soluble TREM2, S100β, and pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-α. In parallel, we highlight converging neuroimaging biomarkers derived from PET and MRI studies. These include increased TSPO-PET binding in limbic and frontal regions, alterations in cerebral blood flow and oxygen metabolism, neurometabolic changes detected via MR spectroscopy (e.g., elevated myo-inositol and choline), and increased free water content on diffusion imaging - each suggestive of glial activation and network-level dysfunction. We propose a multiscale, longitudinal framework that integrates molecular, neuroimaging, and behavioral data to link immune dysregulation with brain network instability and symptom emergence. Such integrative approaches are critical for advancing precision diagnostics and informing the development of targeted, mechanism-based treatments for individuals affected by PCS.},
}
@article {pmid42482056,
year = {2026},
author = {Arthur, SE and Turkson, G and Quarcoo, JA and Cudjoe, MAP and Trotter, C},
title = {From trial site to research emerging research hub: mapping Ghana's vaccine research ecosystem, 1977-2025.},
journal = {Health research policy and systems},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12961-026-01516-y},
pmid = {42482056},
issn = {1478-4505},
abstract = {BACKGROUND: Ghana's vaccine research ecosystem has evolved substantially alongside national and global immunisation efforts. However, the extent and distribution of research activity across the full vaccine development continuum have not been systematically synthesised. This review maps peer-reviewed publications and institutional reports across a nine-stage vaccine development framework from 1977 to 2025, comparing patterns between the pre-pandemic (2000-2020) and post-pandemic (2021-2025) periods.<br><br>MAIN BODY: Before 2020, vaccine-related research in Ghana was concentrated predominantly in downstream domains, including disease surveillance, programme implementation, and Phase II-III clinical trials, with notable contributions to malaria and pneumococcal vaccine development. Following the COVID-19 pandemic, publication output increased more than fivefold and diversified into emerging areas such as genomic surveillance, regulatory science, behavioural research, and digital health systems, accompanied by stronger leadership from domestic institutions. Despite this expansion, engagement in upstream domains, including discovery science, preclinical development, Phase I clinical trials, and local vaccine manufacturing, remains limited, reflecting persistent structural and infrastructure constraints.<br><br>CONCLUSIONS: Ghana has transitioned from a primarily implementation-focused setting to an increasingly active contributor to multidisciplinary vaccine evidence. Sustained investment in upstream research infrastructure, early-phase clinical trial capacity, sustainable financing mechanisms and behavioural intervention research will be essential to strengthen national vaccine sovereignty. The Ghanaian experience offers transferable lessons for other low- and middle-income countries seeking to build resilient and locally driven vaccine research ecosystems.},
}
@article {pmid42482485,
year = {2026},
author = {Ruting, W and Jiale, L and Hongxi, W and Zhenjin, H and Ruohan, Z and Yuanbo, S and Rongxin, Z and Hongzhen, T and Feng, J},
title = {Intestinal Organoids as Models to Study Viruses: Current Application and Future Perspective.},
journal = {Journal of microbiology and biotechnology},
volume = {36},
number = {},
pages = {e2603016},
pmid = {42482485},
issn = {1738-8872},
mesh = {*Organoids/virology ; Humans ; Animals ; *Intestines/virology ; *Viruses/growth &amp; development ; Virology/methods ; Intestinal Mucosa/virology ; Host Microbial Interactions ; Models, Biological ; Microphysiological Systems ; Host-Pathogen Interactions ; Coculture Techniques ; },
abstract = {Intestinal organoids have emerged as a transformative model system in virology, bridging the gap between conventional cell lines and animal models by recapitulating the complex cellular diversity, three-dimensional architecture, and key functions of the human intestinal epithelium. This review highlights how this technology has enabled groundbreaking studies of enteric viruses, including the successful cultivation of previously uncultivable human norovirus, and has provided critical insights into the infection mechanisms of rotavirus, enterovirus A71, and Severe Acute Respiratory Syndrome Coronavirus 2. We discuss how emerging technologies, such as co-culture systems for host-microbiome interactions, vascularization techniques, and CRISPR/Cas9 gene editing, are being integrated with organoids to create more physiologically relevant microphysiological systems. Despite challenges related to immune component integration and model standardization, intestinal organoids offer a promising platform for elucidating virus-host interactions, advancing antiviral drug screening, and promoting personalized infectious disease research.},
}
@article {pmid42483585,
year = {2026},
author = {Hirvonen, A and Pellegrinelli, L and Binda, S and Pariani, E},
title = {Wastewater-Based Epidemiology for Infectious Diseases: A New Trick for an Old Threat.},
journal = {Environment &amp; health (Washington, D.C.)},
volume = {4},
number = {7},
pages = {1309-1316},
pmid = {42483585},
issn = {2833-8278},
abstract = {Wastewater-based epidemiology (WBE) is an innovative approach to epidemiology that offers unique opportunities for public health surveillance. Its potential had been recognized in various applications over the years, but it was the global scale of the response to the SARS-CoV-2 pandemic that truly brought WBE to the fore. In this perspective paper we explore the untapped potential of WBE as a catalyst for infectious disease surveillance and as a One Health epidemiological tool, and the future horizons and innovative applications of WBE. It is clear that WBE will address a growing number of pathogens of concern to human health, such as avian influenza viruses, mpox, enterovirus D68, Candida auris, and antimicrobial resistance. In addition, it will contribute to epidemic intelligence by monitoring mass gathering events, and by predictive modeling and forecasting in combination with artificial intelligence to mitigate and prevent infectious diseases from reaching the highest level of clinical complexity. We believe that the maximum performance and complete institutional integration into public health of WBE is yet to be realized on a global scale.},
}
@article {pmid42486492,
year = {2026},
author = {Kao, CM and Bahakel, H and Heald-Sargent, TA and Minniear, TD and Statler, VA and Thomas, SJ and Weakley, KE and Cao, Q and Ardura, MI and Danziger-Isakov, L and Foca, M and Herold, BC},
title = {Influenza, COVID-19, and RSV Vaccinations for Immunocompromised Children and Household Contacts.},
journal = {Pediatrics},
volume = {158},
number = {2},
pages = {},
doi = {10.1542/peds.2026-075971},
pmid = {42486492},
issn = {1098-4275},
mesh = {Humans ; *Immunocompromised Host ; Child ; *Influenza, Human/prevention &amp; control/immunology ; *Influenza Vaccines/administration &amp; dosage/immunology ; *COVID-19/prevention &amp; control/immunology ; *Respiratory Syncytial Virus Infections/prevention &amp; control/immunology ; *COVID-19 Vaccines/administration &amp; dosage ; *Respiratory Syncytial Virus Vaccines/administration &amp; dosage/immunology ; *Vaccination ; },
abstract = {Immunocompromised pediatric patients, including hematopoietic cell and solid organ transplant recipients, those undergoing chemotherapy for malignancy, and those receiving biologic response modifiers for autoimmune or inflammatory conditions, are at risk for severe disease from vaccine-preventable respiratory viral infections such as influenza, SARS-CoV-2 (COVID-19), and respiratory syncytial virus (RSV). These children face higher rates of hospitalization, intensive care admissions, and mortality, reflecting contributions from an immature immune system, absence of immunologic memory, and/or increased environmental exposures. Immunization recommendations for immunocompromised children are largely extrapolated from studies conducted among healthy children and/or immunocompromised adults due to a paucity of primary data on immunological responses and vaccine efficacy in immunocompromised children. Trends in vaccine hesitancy in the general population, ongoing transmission of respiratory viral infections in the community, and suboptimal vaccination rates among immunocompromised children and their household contacts further compound the risk for this vulnerable population. As the number of children with immunocompromising conditions expands, it is imperative that primary care practitioners and subspecialists who care for immunocompromised children ensure appropriate immunizations are provided to these patients and their household and community contacts. We will review available data supporting the current guidelines regarding vaccine dosing, scheduling, and formulations to prevent influenza, COVID-19, and RSV infections in immunocompromised children. Furthermore, we highlight key knowledge gaps and areas of current investigation aimed at improving respiratory viral vaccine immunogenicity and optimize protection.},
}
@article {pmid42486499,
year = {2026},
author = {Clemén, H and Ramu, S and Uller, L},
title = {The triple-hit hypothesis: exploring pulmonary e-cigarette, PM2.5 and viral polyexposure.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {181},
pages = {},
pmid = {42486499},
issn = {1600-0617},
mesh = {Humans ; *Electronic Nicotine Delivery Systems ; *Vaping/adverse effects ; Animals ; *Particulate Matter/adverse effects ; *Lung/virology/immunology/drug effects/physiopathology/metabolism/pathology ; Risk Factors ; *Respiratory Tract Infections/virology/immunology ; Particle Size ; Host-Pathogen Interactions ; Aerosols ; *Inhalation Exposure/adverse effects ; *E-Cigarette Vapor/adverse effects ; },
abstract = {Exposure to e-cigarette aerosols, particulate matter with aerodynamic diameter ≤2.5 µm (PM2.5) and respiratory viruses rarely occurs in isolation, but rather in complex polyexposure contexts during daily life. On a cellular and molecular level, vaping induces a distinct lipid-laden macrophage phenotype, alters pulmonary neutrophilic infiltration and impairs epithelial differentiation and ciliary function. In contrast, PM2.5 alters the macrophage polarisation equilibrium, temporally favouring an acute pro-inflammatory phenotype and a subsequent chronic tissue-remodelling phenotype, while also driving an oxidative inflammatory epithelial milieu. Both exposures thus impair antiviral defences and enhance susceptibility to respiratory viral infections such as influenza A, rhinovirus and severe acute respiratory syndrome coronavirus 2. The triple-hit hypothesis proposes that concurrent exposure to vaping aerosols, PM2.5 and respiratory viruses may exert additive or synergistic effects on chronic airway inflammation. PM2.5 may amplify vaping-induced macrophage lipid accumulation, thereby reducing the macrophage clearance capacity. Decreased efferocytosis and autophagy may further exacerbate inflammation by increasing secondary necrosis from apoptotic cells and debris. This persistent inflammatory state coupled with epithelial injury and impaired antiviral responses may increase the risk of infection and accelerate the development or progression of chronic respiratory diseases such as asthma and COPD. These insights highlight the crucial need for polyexposure models to accurately reflect real-world environmental and behavioural exposures and evaluate their impact on respiratory health and disease exacerbations. Understanding this exposure triad is also crucial for refining exposure guidelines, updating risk assessments and implementing preventive strategies.},
}
@article {pmid42486943,
year = {2026},
author = {Vaidya, N and Zhang, Z and Agunbiade, K and Keggin, G and Hedi, K and Winterer, J and Bobou, M and Broulidakis, J and King, S and Robinson, L and Zhang, Y and Barker, GJ and Bokde, AL and Brühl, R and Grigis, A and Lemaître, H and Lett, T and Nees, F and Papadopoulos, D and Poustka, L and Schmidt, U and Sinclair, J and Stringaris, A and Whelan, R and Walter, H and Desrivières, S and Schumann, G},
title = {Brain network-based stratification of mental health disorders: design and cohort description of the STRATIFY and ESTRA studies.},
journal = {Molecular psychiatry},
volume = {},
number = {},
pages = {},
pmid = {42486943},
issn = {1476-5578},
support = {695313//EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)/ ; 2023YFE0199700//Chinese Ministry of Science and Technology | Department of S and T for Social Development (Department of S&amp;T for Social Development)/ ; 82150710554//National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)/ ; 675346//Deutsche Forschungsgemeinschaft (German Research Foundation)/ ; MRF-058-0014-F-ZHAN-C0866//RCUK | MRC | Medical Research Foundation/ ; MRF-058-0004-RG-DESRI//RCUK | MRC | Medical Research Foundation/ ; MR/R00465X/1//RCUK | Medical Research Council (MRC)/ ; },
abstract = {The STRATIFY (Brain Network-Based Stratification of Reinforcement-Related Disorders) and ESTRA (Eating Disorders Stratification) studies were established as harmonised "sibling" cohorts to develop a mechanistically informed framework for stratifying psychiatric disorders. Here, we describe the study design, methodology, and cohort characteristics. Both studies investigate how network properties of brain structure and function, together with biological markers derived from blood-based genomics, epigenetics, and proteomics, relate to reinforcement-related behaviours that cut across major depressive disorder, alcohol use disorder, psychosis, and eating disorders. A further objective is to identify discriminative multimodal features that predict disease onset, symptom course, and functional outcomes, thereby supporting the development of targeted interventions. STRATIFY and ESTRA recruited 674 patients and 70 healthy controls aged 18-30 years (76% females), supplemented by 199 age- and sex-matched healthy controls from the population-based IMAGEN cohort assessed at the same sites using harmonised protocols. Multimodal assessment included structured clinical interviews, self-report measures, cognitive testing, biosamples for molecular analyses, and multimodal MRI (structural, diffusion, resting-state, and task-based fMRI). ESTRA participants additionally completed longitudinal follow-up, and all cohorts were assessed during the COVID-19 pandemic. STRATIFY and ESTRA together constitute a large-scale, open-science resource integrating multimodal brain, behavioural, and biological data across transdiagnostic patient cohorts in early adulthood. The anonymised dataset is available to the research community through managed access, supporting international collaboration and accelerating the development of mechanistically informed classification systems and predictive tools in psychiatry.},
}
@article {pmid42488644,
year = {2026},
author = {Yamashita, M and Park, J and Park, S and Kang, HJ and Chung, YS and Lim, SA and Lee, S},
title = {Convergent innate immune and regulated cell-death pathways in selected myopathies.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1871966},
pmid = {42488644},
issn = {1664-3224},
mesh = {Humans ; *Immunity, Innate ; Animals ; *Muscular Diseases/immunology/pathology ; Signal Transduction/immunology ; Muscle, Skeletal/immunology/pathology ; *Regulated Cell Death/immunology ; Innate Immunity Recognition ; Inflammasomes/immunology/metabolism ; Cytokines/metabolism ; },
abstract = {Myopathies are a heterogeneous group of skeletal muscle disorders caused by genetic mutations or acquired insults, including inflammation, infection, endocrine imbalance, and toxic exposure. Myopathies affect a substantial number of individuals worldwide and are a significant cause of chronic muscle weakness and disability. Despite diverse etiologies, progressive myofiber injury and degeneration underlie the functional decline across disease subtypes. Accumulating evidence indicates that innate immune activation and regulated myofiber death pathways, including apoptosis, necroptosis, and pyroptosis, contribute to disease progression in selected genetic and acquired myopathies and may represent increasingly actionable therapeutic targets. This review focuses specifically on the interplay between innate immune signaling and the regulation of cell death pathways in skeletal muscle across diverse myopathies. We discuss pattern recognition receptors, inflammasome activation, and cytokine-driven pathways, such as tumor necrosis factor-alpha (TNF-α), type I interferons (IFNs), and interleukin (IL) family signaling, highlighting how these mechanisms amplify inflammation, impair regeneration, and promote myofiber degeneration. To illustrate category-specific mechanisms, we selected representative disorders from each major myopathy group, including Duchenne muscular dystrophy (DMD) as a prototypical DAMP-driven muscular dystrophy, myotonic dystrophy type 1 (DM1) as a model of secondary innate immune activation associated with RNA toxicity-induced cellular stress, dermatomyositis (DM) as a representative inflammatory myopathy, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated myopathy as a clinically relevant model of virus-related muscle involvement and systemic inflammation-associated muscle injury. By integrating evidence across these disease contexts, this review highlights convergent mechanisms in which innate immune dysregulation and regulated myofiber death drive muscle pathology and provide rational targets for mechanism-based therapeutic strategies.},
}
@article {pmid42488856,
year = {2025},
author = {Attah, FA and Obame-Nkoghe, J and Osayomi, T and Omobowale, OC and Chachage, M and Lakoh, S and Adediji, AO and Ogunmolasuyi, AM and Nsojo, A and Famuyide, IM and Ilesanmi, O and Adenomon, M and Adekanmbi, O and Mohammed, Y and Fowotade, A},
title = {Combating Emerging Zoonotic Diseases Using One Health Strategies To Curb Local, National, Regional And Global Transmission And Mortality: A Scoping Review.},
journal = {Nigerian medical journal : journal of the Nigeria Medical Association},
volume = {66},
number = {6},
pages = {2082-2102},
pmid = {42488856},
issn = {0300-1652},
abstract = {BACKGROUND: Emerging zoonotic diseases account for 75% of new infectious threats worldwide due to increasing human-animal-environment interactions, land-use change, wildlife trade, and climate variability. The COVID-19 pandemic underscored the need for integrated, joint approaches such as One Health to strengthen prevention, early detection, and response to zoonotic risks. The study objective is to synthesize evidence on the burden, drivers, challenges, and One Health strategies for combating emerging zoonotic diseases, and to identify actions to improve implementation at local, national, regional, and global levels.<br><br>METHODOLOGY: A systematic literature search was conducted across PubMed, EMBASE, Scopus, and Google Scholar. Studies were included if they examined zoonotic diseases using a One Health approach and were published in English. Data were synthesized thematically to identify key patterns, intervention strategies, and gaps.<br><br>RESULTS: Zoonotic diseases impose morbidity, mortality, and economic losses. Evidence shows that One Health interventions such as integrated surveillance, joint outbreak investigations, and targeted vaccination have improved detection and control of diseases. However, implementation remains hindered by fragmented communication across sectors, policy inconsistencies, limited laboratory and surveillance capacity, inadequate cross-border cooperation, and limited funding. Vulnerabilities are particularly pronounced in low- and middle-income countries.<br><br>CONCLUSION: Effective implementation needs improved governance, sustainable financing, aligned policies, robust surveillance and laboratory systems, and meaningful community engagement. Investing in interdisciplinary research, early warning systems, and integrated response mechanisms will enhance preparedness and reduce zoonotic disease transmission. A well-resourced One Health framework is essential to protect human, animal, and environmental health.},
}
@article {pmid42488877,
year = {2025},
author = {Stephen, RI and Reyes, JA and Tyndall, J and Zawaya, K and Inyang, V and Rapheal, F and Yunusa, D and Simnawa, SF and Ayogu, S and Nuhu, YB and Dunga, J},
title = {COVID-19's Hidden Impact on Chronic Liver Disease Mortality in Nigeria: Findings from an 18-Year Retrospective Review.},
journal = {Nigerian medical journal : journal of the Nigeria Medical Association},
volume = {66},
number = {6},
pages = {2312-2327},
pmid = {42488877},
issn = {0300-1652},
abstract = {BACKGROUND: The COVID-19 pandemic disrupted healthcare systems globally, disproportionately affecting patients with decompensated chronic liver disease (DCLD) due to interrupted care, resource diversion, and the immunosuppressive state associated with DCLD.In Nigeria, where viral hepatitis is endemic, evidence on the pandemic's indirect impact on DC LD mortality remains scarce. This study examined 18-year mortality trends among patients who died from DCLD in North-eastern Nigeria and evaluated the influence of the COVID-19 pandemic on DCLD-related mortalities.<br><br>METHODOLOGY: A retrospective review of 436 adult decedents with confirmed DCLD (2006-2024) was conducted at Modibbo Adama University Teaching Hospital, Adamawa State. Sociodemographic and clinical data were abstracted from records. Mortality trends were analysed using Poisson regression, changepoint detection, and joinpoint analysis to identify inflection years, focusing on 2020-2022 as the pandemic window.<br><br>RESULTS: The mean age at death was 50.3 &#xb1; 14.4 years; 74.5 % were male, and 76.1 % were from low-income households. Viral Hepatitis B &amp; C infections were linked to 67.8 % of deaths, followed by alcohol use (30.1 %). Common complications included hepatic encephalopathy (83.8 %) and portal hypertension (58.2 %). Mortality rose steadily over 18 years, with an abrupt 8.7 % increase in 2020 (p < 0.01). Joinpoint analysis identified 2013 and 2020 as major inflection points.<br><br>CONCLUSION: Mortality from DCLD in North-eastern Nigeria increased sharply during the COVID-19 pandemic. Viral hepatitis remains the dominant cause, compounded by late presentation and poor access to care. Strengthening hepatitis prevention, integrating CLD management into non-communicable disease programs, and maintaining chronic care continuity during health emergencies are crucial to mitigating future excess deaths.Top of FormBottom of Form.},
}
@article {pmid42489461,
year = {2026},
author = {Beeton, K and Case, JB},
title = {Respiratory mucosal vaccines for emerging viruses: promise and challenges.},
journal = {Journal of virology},
volume = {},
number = {},
pages = {e0174825},
doi = {10.1128/jvi.01748-25},
pmid = {42489461},
issn = {1098-5514},
abstract = {Systemically administered vaccines were instrumental in reducing severe disease, hospitalizations, and deaths during the SARS-CoV-2 pandemic. However, they often failed to consistently elicit robust immunity at mucosal sites. This minireview examines a central role for respiratory mucosal immunity in protection against emerging viral pathogens and highlights key takeaways from the SARS-CoV-2 pandemic. Evidence from SARS-CoV-2 and influenza studies demonstrates that mucosal vaccination uniquely induces secretory IgA, as well as resident memory B and T cells within the upper and lower airways, thereby promoting broader and more potent protection. Accordingly, interest in mucosal vaccination strategies has been recently renewed. However, significant knowledge gaps remain, which include determining optimal vaccination strategies (systemic prime-mucosal boost versus mucosal-only), identifying the underlying mechanisms that cause the relatively rapid decay of mucosal immunity, establishing reproducible and standardized correlates of protection, and developing safe, effective delivery platforms and adjuvants that are compatible with the respiratory environment. These challenges are particularly relevant for high-priority zoonotic threats, such as henipaviruses, hantaviruses, arenaviruses, and emerging influenza strains, for which mucosal immune responses and correlates of protection remain poorly defined. Moreover, advancing mucosal vaccine design through improved viral vectors, nanoparticle systems, and immunomodulatory adjuvants will be critical for achieving durable immunity. Ultimately, leveraging insights gained from the SARS-CoV-2 pandemic may enable breakthroughs in mucosal vaccination strategies that reduce transmission, limit viral evolution, and strengthen preparedness for future respiratory pandemics.},
}
@article {pmid42489894,
year = {2026},
author = {Roll, F and Fette, F and Kranke, P and Koscielny, J and Zacharowski, K and Weber, CF and Lindner, ML},
title = {[Hereditary disorders of hemostasis in obstetrics 1/2-Anesthesiological aspects of primary hemostasis].},
journal = {Die Anaesthesiologie},
volume = {75},
number = {8},
pages = {592-604},
pmid = {42489894},
issn = {2731-6866},
mesh = {Humans ; Female ; Pregnancy ; *Anesthesia, Obstetrical/methods ; Anesthesia, Epidural ; *Pregnancy Complications, Hematologic/therapy/physiopathology/diagnosis/genetics ; Hemostasis/physiology ; Postpartum Hemorrhage/therapy ; von Willebrand Diseases/therapy/genetics ; *Blood Coagulation Disorders, Inherited/therapy/genetics/physiopathology ; Anesthesia, Spinal ; },
abstract = {Disorders of primary hemostasis affect platelet adhesion and aggregation and include von Willebrand disease (vWD), Glanzmann thrombasthenia (GT) and Bernhard-Soulier syndrome (BSS). The safe administration of epidural anesthesia procedures, such as peridural or spinal anesthesia (PDA/SpA) in patients with coagulation disorders requires a thorough weighing-up of the risk of bleeding, especially the risk of spinal epidural hematoma. The adequate management of postpartum hemorrhage (PPH) also requires exact knowledge of the underlying pathophysiology and the available hemostatic treatment options. This article provides an overview of selected hereditary coagulation disorders of primary hemostasis during pregnancy and elucidates the pathophysiological principles, clinical symptoms, diagnostic procedures and treatment strategies.},
}
@article {pmid42491006,
year = {2026},
author = {Zhou, ZP and Chen, ZR and Bandara, RA and Duan, R and Cao, H and Liu, J and Hu, J},
title = {DNA-based vaccines: Advances, applications, and future prospects.},
journal = {Genes &amp; diseases},
volume = {13},
number = {6},
pages = {102025},
pmid = {42491006},
issn = {2352-3042},
abstract = {DNA-based vaccines represent a promising advancement in immunization strategies, offering a novel approach for preventing infectious diseases and treating various conditions, including cancers and autoimmune disorders. These vaccines utilize genetically engineered plasmid or viral vector DNA encoding antigens of interest, which, upon administration, are taken up by host cells to produce the antigen in situ. This endogenous antigen expression elicits both humoral and cellular immune responses, mimicking natural infection pathways. Compared to conventional vaccines, DNA vaccines offer several advantages: they are relatively easy to design and manufacture, relatively stable, and capable of inducing long-lasting immunity without the need for live pathogens. Additionally, their platform is highly adaptable, enabling rapid development against emerging pathogens. Despite their success in animal models and promising results in clinical trials for infectious diseases caused by viruses, such as Zika, HPV, and SARS-CoV-2, DNA vaccines have faced challenges in eliciting robust immunogenicity in humans. Recent innovations-including improved delivery technologies, adjuvant formulations, and optimized plasmid and viral vectors-are addressing these limitations. The approval of DNA vaccines for veterinary use and recent human applications, such as Adenovirus (Ad) DNA-based Ebola vaccines and plasmid DNA-based COVID-19 vaccine, ZyCoV-D, mark significant milestones. Continued research and technological refinement are expected to expand their utility in global health. Overall, DNA-based vaccines hold great potential as a next-generation platform for safe, effective, and rapid-response immunization against a broad spectrum of diseases.},
}
@article {pmid42491141,
year = {2026},
author = {Soltani, S and Choobineh, H and Nabatchian, F and Kord, M and Nikmanesh, B and Razi, F and Firouzian, H and Majidi, Z},
title = {Systematic review of amino acid profiles among COVID-19 patients caused by SARS-CoV-2.},
journal = {Journal of diabetes and metabolic disorders},
volume = {25},
number = {2},
pages = {201},
pmid = {42491141},
issn = {2251-6581},
abstract = {BACKGROUND: Emerging evidence highlights the critical role of amino acid metabolism in the pathogenesis and severity of COVID-19. This review included studies encompassing patients with varying degrees of disease severity, from mild to critical cases.<br><br>METHODS: A systematic review following PRISMA guidelines was conducted, and study quality was appraised using the Newcastle-Ottawa tools to explore the relationship between amino acid profiles and clinical outcomes in COVID-19 patients. A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar (from the start of the pandemic through the most recent data available on December 2024) identified peer-reviewed studies reporting original data on amino acid metabolism in COVID-19 patients.<br><br>RESULTS: Fourteen eligiblestudies involving 1355 confirmed COVID-19 patients (1726 total participants) were included and revealed significant disruptions inamino acid profiles. Key findings included reduced levels of arginine, glutamine, and tryptophan, alongside elevated phenylalanine andbranched-chain amino acids (BCAAs). These changes were associated with disease severity, immune suppression, systemicinflammation, and metabolic reprogramming. Dysregulation of pathways such as the urea cycle and kynurenine pathway were linked toendothelial dysfunction and immune dysregulation.<br><br>CONCLUSIONS: Dysregulated amino acid profiles may serve as potential biomarkers for disease severity and require further validation before clinical application. Restoring amino acid balance or modulating metabolic pathways could improve clinical outcomes. Further research is needed to validate these findings and explore personalized treatment strategies aimed at mitigating the metabolic consequences of SARS-CoV-2 infection.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40200-026-02012-4.},
}
@article {pmid42491406,
year = {2026},
author = {Šalamon, &#x160; and Kruger, A and Lupton, D and Pretorius, E and Ewing, AG and Bar-Yam, Y},
title = {COVID-19 Is Airborne AIDS: Provocative Oversimplification, Emerging Science, or Something in Between?.},
journal = {AJPM focus},
volume = {5},
number = {4},
pages = {100458},
pmid = {42491406},
issn = {2773-0654},
abstract = {Immune dysfunction and systemic effects in HIV and SARS-CoV-2 infections are distinct but share relevant similarities and downstream consequences. The authors compare and contrast observations of the immunological impacts of COVID-19 and HIV infections. By examining shared and distinct mechanisms, such as immune dysfunction, vulnerability to opportunistic infections, accelerated aging, and neurocognitive disorders, the authors highlight critical parallels and their implications. The authors review the extensive scientific evidence showing that SARS-CoV-2 infections result in immune cell depletion, dysfunction, and exhaustion, with impacts on several immune system cell types. Higher rates of individual susceptibility to infections lead to population-wide increases in diverse infectious diseases, including those that are signatures of immunodeficiency. Finally, the authors characterize societal responses to both pandemics, providing insights into public health strategies and lessons for improving current and future research, treatment, preparedness, and mitigation efforts.},
}
@article {pmid42492397,
year = {2026},
author = {Serrão, ASR and do Amaral Teixeira, L and Pereira Serrão, GM and Comarú, MW and Pierini, MF and Mota, FB and Lopes, RM},
title = {Virtual reality in nursing education: Integrating technology, pedagogy, and learning outcomes - A scoping review.},
journal = {Nurse education in practice},
volume = {95},
number = {},
pages = {104905},
doi = {10.1016/j.nepr.2026.104905},
pmid = {42492397},
issn = {1873-5223},
abstract = {AIM: To map and synthesize how VR has been applied in nursing education by integrating technologies, pedagogical strategies, learning outcomes and implementation challenges.<br><br>BACKGROUND: Virtual Reality (VR) has become an increasingly relevant educational tool in nursing education, particularly following the COVID-19 pandemic. However, evidence remains fragmented across technological, pedagogical and learning dimensions.<br><br>METHODS: A scoping review was conducted according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Searches were performed in the Web of Science Core Collection for studies published between 2020 and 2024. Sixty-eight empirical studies met the inclusion criteria, including randomized controlled trials, quasi-experimental, observational, descriptive, mixed-methods and feasibility studies.<br><br>RESULTS: VR applications ranged from immersive head-mounted displays to interactive virtual platforms, supporting the development of technical and socio-emotional competencies. Common pedagogical approaches included simulation-based learning, problem- and scenario-based learning, self-directed learning, feedback and reflective debriefing. Self-confidence and self-efficacy were the most frequently assessed outcomes, followed by satisfaction and engagement, with predominantly positive findings. Improvements in practical performance and knowledge acquisition were also reported, although outcomes were often comparable to traditional educational approaches. Across studies, educational effectiveness was consistently associated with instructional design features, particularly feedback, repeated practice and structured reflection. Technical limitations, physical discomfort and institutional barriers were the main implementation challenges.<br><br>CONCLUSIONS: VR is a complementary pedagogical resource whose effectiveness depends on instructional design and purposeful curricular integration. Future research should prioritize long-term outcomes, transfer to clinical practice and cost-effectiveness analyses.},
}
@article {pmid42492839,
year = {2026},
author = {Typiak, M and Piwkowska, A},
title = {Various effects of ADAM10 and ADAM17 metalloproteases on kidney (dys)function.},
journal = {Biochimica et biophysica acta. Molecular basis of disease},
volume = {1872},
number = {8},
pages = {168380},
doi = {10.1016/j.bbadis.2026.168380},
pmid = {42492839},
issn = {1879-260X},
abstract = {A disintegrin and metalloprotease 10 (ADAM10) and ADAM17 regulate cellular communication by shedding membrane-bound proteins. They participate in numerous physiological processes, e.g. contribute to proper glomerular filtration maintenance. Because of their broad substrate specificity, their activity is tightly regulated and dependent on the local tissue microenvironment, including blood glucose fluctuations. The dysregulation of ADAM10/17-mediated shedding has been associated with the development of several kidney diseases. Increases in ADAM10/17 mRNA, protein levels, and activity have been reported in renal disorders, suggesting their possible application as indicators of renal involvement in systemic diseases. Serum and urinary levels of soluble ADAM10/17 substrates, shed from resident kidney cells, may serve as early biomarkers of renal dysfunction. ADAM10/17 have also emerged as potential therapeutic targets in renal diseases. Thus, the present review summarizes current knowledge of the various roles ADAM10/17 perform in kidney physiology and pathophysiology, with a particular emphasis on diabetic kidney disease.},
}
@article {pmid42493737,
year = {2026},
author = {Lanrewaju, AA and Folami, AM and Sabiu, S and Swalaha, FM},
title = {Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery.},
journal = {Chemical biology &amp; drug design},
volume = {108},
number = {1},
pages = {e70365},
pmid = {42493737},
issn = {1747-0285},
support = {//South African Medical Research Council/ ; SRUG2204193723//National Research Foundation of South Africa/ ; K5/C2020-2021-00181//Water Research Commission/ ; },
mesh = {*Antiviral Agents/chemistry/pharmacology/therapeutic use ; Humans ; *Biological Products/chemistry/pharmacology/therapeutic use ; *Drug Design ; *Drug Delivery Systems ; *COVID-19 Drug Treatment ; SARS-CoV-2/drug effects ; Machine Learning ; Drug Discovery ; },
abstract = {The COVID-19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread, emphasising the necessity for expedited and adaptable antiviral drug discovery and development. Despite ongoing efforts to develop effective, low-toxicity therapeutics, the number of antivirals that have achieved clinical approval remains limited. The shortfall is especially significant in developing countries, where access to new antivirals is limited by high prices, few options, import dependence, unstable supply chains and weak purchasing systems. The challenge is further heightened by the emergence of increasingly drug-resistant variants while vaccines often provide inadequate protection against newly mutated or novel viruses. Consequently, the identification of novel antiviral agents that are both effective and cost-efficient via innovative strategies for antiviral drug discovery is essential to manage and control viral infections. Therefore, this review examines the different challenges associated with conventional antiviral drugs alongside recent strategies in antiviral drug discovery and development, such as the exploitation of plant secondary metabolites with antiviral properties, advanced microscopy technologies, computer-aided drug design, artificial intelligence and machine learning, gene-editing technologies, drug combination therapy and nanotechnology-enhanced drug delivery systems. Additionally, this study proposes a simple decision-focused pathway integrating natural products, computation and targeted delivery to guide candidate prioritisation, optimisation and translation from discovery to implementation. While these emerging strategies offer considerable promise, challenges related to validation, toxicity, scalability and equitable access remain important considerations for successful clinical translation. Future research should therefore integrate complementary technologies to accelerate the development of effective antiviral agents against current and emerging viral threats.},
}
@article {pmid42493748,
year = {2026},
author = {Khubchandani, J and Prabhu, N and Craig, K and Wiblishauser, M and Mustapha, T and Srejon, RR and Batra, K},
title = {COVID-19 Vaccination Refusal and Non-Uptake Among People Living with HIV in the United States.},
journal = {Journal of community health},
volume = {},
number = {},
pages = {},
pmid = {42493748},
issn = {1573-3610},
support = {102066//Merck/ ; },
abstract = {More than a million individuals in the United States are living with HIV and constitute a particularly vulnerable group for morbidity and mortality associated with COVID-19. Despite the early availability and prioritization of this group for COVID-19 vaccination, notable levels of vaccine refusal and non-uptake have been reported among this group. This scoping review aimed to investigate the nature and extent of COVID-19 vaccine refusal and non-uptake among people living with HIV (PLWH) in the USA. A comprehensive literature search was performed utilizing multiple scholarly databases for studies published between December 2020 and May 2026 that reported on COVID-19 vaccine refusal or non-uptake rates among PLWH in the USA. Data extraction focused on sample size, refusal/non-uptake rates, reasons for refusal, and vaccination enablers. A total of 27 studies were included, encompassing 185,430 PLWH from various settings across the U.S. and the COVID-19 vaccination refusal and non-uptake rates varied from 3.8% to 57.9% [average across all studies=21.0% (95% CI=16.2-26.2%)]. Major barriers identified included medical mistrust, apprehensions regarding vaccine safety and side effects, misinformation, structural issues such as poverty and housing instability, and sociodemographic factors (e.g., sexual/ethnic minority status, lower income or education). Conversely, enablers of vaccination included older age, male gender, White race, active engagement in HIV care, previous vaccination history, recommendations from trusted providers, and higher perceived infection risk or belief in vaccination. The refusal and non-uptake rates for COVID-19 vaccines among PLWH in the USA are considerable and influenced by multiple factors. Interventions should focus on addressing systemic mistrust and psychosocial or structural obstacles while utilizing the existing HIV care framework to increase vaccination rates in this population.},
}
@article {pmid42494498,
year = {2026},
author = {Banik, I and Coppé, JP},
title = {CRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine.},
journal = {Molecular therapy. Nucleic acids},
volume = {37},
number = {3},
pages = {103003},
pmid = {42494498},
issn = {2162-2531},
abstract = {Given the plethora of emerging technologies, none have truly captured the minds as CRISPR. From the groundbreaking research, the ultimate battle of the prizes and patents to a number of books, the science of CRISPR continues to be significant in the biomedical field. For many decades now, the emergence of synthetic biology as an intervention to correct diseases has become the foundation of biomedical research. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based genetic editing has become a common place for routine investigation of scientific hypotheses in pre-clinical settings. More recently, CRISPR-based diagnostic testing kits for SARS-CoV-2 have showcased a translational output. Furthermore, a technological landmark was achieved when the Food and Drug Administration (FDA) approved the first CRISPR-based gene therapy (exa-cel) to edit erythroid specific enhancer region of BCL11A in hematopoietic stem cells, introduced in patients suffering from sickle cell anemia to achieve durable remission. In this review, we provide a snapshot into the most important milestones along the journey of CRISPR from its discovery in bacteria to its usage in precision medicine. The intervention of machine learning tools has now intertwined complex biology with high-throughput scalable outputs. Given the vast amount of information on CRISPR, we try to pin down key take-home messages for scientists as well as non-scientist readers. This review article attempts to understand why and how CRISPR remains significant and seamlessly integrates in the emerging era of new technologies.},
}
@article {pmid42494546,
year = {2026},
author = {Billias, N and D'Alessandro, V and Pouliopoulou, DV and Wong, JJ and Miller, E and Hopkins, JP and Boutsikari, EC and Cipriano, LE and da Veiga Pereira, T and Johnstone, J and Stranges, S and Weese, JS and MacDermid, JC and Quinn, KL and Fisman, DN and Bobos, P},
title = {Mapping Reported Modes of Transmission of Highly Pathogenic Avian Influenza A (H5N1) to Humans: A Scoping Review.},
journal = {One health (Amsterdam, Netherlands)},
volume = {23},
number = {},
pages = {101492},
pmid = {42494546},
issn = {2352-7714},
abstract = {BACKGROUND: Highly Pathogenic Avian Influenza A (subtype H5N1) poses a threat to human health, and its pandemic potential emphasizes the need to better understand detailed reported transmission pathways to humans. Existing literature is outdated or lacks detailed, comprehensive analysis of the range of transmission routes and how the virus may enter the human body.<br><br>OBJECTIVE: To comprehensively map all reported H5N1 transmission pathways to humans, as well as viral entry routes.<br><br>METHODS: CINAHL, Embase, MEDLINE, Scopus, PubMed, grey literature, and reference lists (of included studies) were searched up to October 29th, 2025, with no language restrictions. Observational studies and grey literature reporting H5N1 transmission evidence to humans were included. Two reviewers conducted duplicate screening independently (two of three reviewers per record). One reviewer completed data extraction, which was cross-verified for accuracy by a second. Findings were summarized narratively.<br><br>RESULTS: 120 sources met inclusion criteria (70 studies, 50 grey literature). Reported H5N1 transmission pathways were classified into animal-to-human (109 of 120 sources, 90.8%; including poultry-to-human in 100 sources [83.3%] and cattle-to-human in nine sources [7.5%]), environment-to-human (32 of 120 sources, 26.7%), and human-to-human (14 of 120 sources, 11.7%). Reported transmission pathways were further classified as direct or indirect contact, synthesized, and linked to suspected routes of human entry, including mucosal entry (eyes, nose, mouth), inhalation of aerosols or droplets, ingestion, and percutaneous exposure. Entry routes are biologically plausible and do not imply relative likelihood or causal attribution.<br><br>CONCLUSIONS: There are multiple reported pathways of H5N1 exposure, and a single pathway may involve multiple ways to infect humans. Further research is needed to determine causal mechanisms, identify specific risk factors and measures of association, and strengthen evidence-based prevention strategies.},
}
@article {pmid42494828,
year = {2026},
author = {Hadley, L and Ben Miled, S and Clapham, HE and Djaafara, BA and Dyson, L and Funk, S and Gog, JR and Heesterbeek, H and Hill, EM and Howerton, E and Isham, V and Kebir, A and Keeling, M and Kissler, SM and Lessler, J and Leung, K and McBryde, E and McCaw, JM and Mercado, CEG and Mollison, D and Thumbi, SM and Pan-Ngum, W and Pellis, L and Pérez-Reche, FJ and Plank, MJ and Thompson, RN and Tran-Kiem, C},
title = {How understanding the diversity of perspectives and systems in governments can increase the impact of scientific research.},
journal = {Communications health},
volume = {1},
number = {1},
pages = {13},
pmid = {42494828},
issn = {3091-4841},
abstract = {The COVID-19 crisis required scientists worldwide to contribute to complex, hectic, and unfamiliar governmental decision-processes. In this Perspective, we reflect on this intense interaction between science and health policy for pandemic response, drawing from the experience of infectious disease modellers across the world. We highlight the diversity of actors and interests in government, aiming to demystify the elusive 'policy makers'. We present a general taxonomy to help research scientists more effectively support evidence-based policy. We stress the importance of building and maintaining relationships appropriate to the diverse pool of government actors. Not recognising this diversity may lead to miscommunication and reduce the positive impacts of scientific evidence for public policy in crisis and non-crisis situations.},
}
@article {pmid42495546,
year = {2026},
author = {Tsai, TH},
title = {Remdesivir from failed Ebola drug to first FDA-approved COVID-19 antiviral: The medico-legal integration.},
journal = {iScience},
volume = {29},
number = {8},
pages = {116867},
pmid = {42495546},
issn = {2589-0042},
abstract = {Remdesivir became the first antiviral for COVID-19 to receive emergency use authorization (EUA) and, subsequently, full FDA approval. This article provides a statutory analysis of its development life cycle, tracing the contributions of nine US federal statutes from foundational coronavirus science through full approval, using a qualitative regulatory-science method that combines doctrinal and document analysis. Each statute is mapped onto a staged life cycle framework. The National Institute of Allergy and Infectious Diseases, under 42 U.S.C. § 282, designed and ran the pivotal the adaptive COVID-19 treatment trial (ACTT-1), generating EUA-supporting evidence in 14 weeks; Biomedical Advanced Research and Development Authority's (BARDA) Other Transaction Authority enabled at-risk manufacturing before the EUA; the Project BioShield Act addressed the market failure of an intravenous, hospital-only antiviral; and the Defense Production Act supported domestic supply. Together, these interdependent statutes show how an integrated legal architecture compressed development into months. Sustaining this institutional infrastructure is the most consequential investment in pandemic preparedness.},
}
@article {pmid42495643,
year = {2026},
author = {Zhang, W and Caligaris, M and Tiwary, S and Nicolau, D},
title = {The emerging roles of eosinophils in immune regulation in health and disease.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1652583},
pmid = {42495643},
issn = {1664-3224},
mesh = {Humans ; *Eosinophils/immunology ; Animals ; Th2 Cells/immunology ; Cytokines/immunology ; },
abstract = {Eosinophils are evolutionarily conserved granular innate cells that can trace back to 100 million years to the emergence of gnathostomes, which now is involved in regulation of diverse homeostatic conditions and diseases in mammals. They have traditionally been associated with Th2 responses, primarily in eosinophilic allergic asthma and helminth parasitic infections. These Th2 responses are correlated with basic cationic proteins and specific cytokines release from preformed eosinophilic vesicles, associated with tissue damage and remodeling. Consequently, eosinophils have historically been characterized as potent cytotoxic effector cells. In human patients, their high blood count has been linked to clinical concerns and necessary further patient evaluations. However, this reflects only a cursory understanding of eosinophils, as their involvement in a broad and diverse range of disorders has recently emerged. Indeed, eosinophils extend beyond traditionally ascribed Th2 responses, which appear to be both global and pivotal in immune regulation contexts. Its role varies from speculative controlled embryological tissue modeling, to tissue regeneration post-injury, uncontrolled neoplastic development, novel Th2 eosinophilic gastrointestinal disorders, reproductive homeostasis and SARS-CoV-2 in a non-exhaustive list of its emerging association with health and disease. This review evaluates the emerging roles of eosinophils which are both pro- and anti-inflammatory, dependent on disease context and microenvironment. Our knowledge of the novel and diverse roles of eosinophils has been applied to the emergence of targeted, and successful clinical therapies to a range of diseases, opening doors to extend assessment on their potential roles in the original embryological modeling and development. Collectively, diverse modern evidence indicates that eosinophils-an ancient evolutionarily conserved cell lineage-has an imperative function in immune networks.},
}
@article {pmid42496299,
year = {2026},
author = {Lim, ECN and Cheng, NCL and Lim, CED},
title = {Infection-Associated Pediatric Acute-Onset Neuropsychiatric Syndrome: A Review of Immunological Mechanisms, Clinical Phenotypes, and Therapeutic Strategies.},
journal = {Infectious disease reports},
volume = {18},
number = {4},
pages = {},
pmid = {42496299},
issn = {2036-7430},
abstract = {BACKGROUND/OBJECTIVES: Pediatric acute-onset neuropsychiatric syndrome (PANS) describes the rapid onset of obsessive-compulsive symptoms or severe food restriction, accompanied by neuropsychiatric or somatic features that are not better explained by another disorder. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) is a related, more narrowly defined construct in which symptoms are temporally associated with group A Streptococcus infection. This review examines clinical symptoms, infectious associations, proposed immune mechanisms, biomarker limitations, and treatment strategies for infection-associated PANS/PANDAS.<br><br>METHODS: A structured narrative search of PubMed/MEDLINE, Embase, the Cochrane Library, Google Scholar/publisher-indexed literature, ClinicalTrials.gov, and reference lists was performed up to 16 June 2026. Original cohorts, case series, systematic reviews, narrative reviews, consensus guidance, mechanistic studies, and registered prospective studies were prioritized. The review was not designed as a PRISMA-ScR scoping review; however, the methods were expanded to improve transparency and align with SANRA principles.<br><br>RESULTS: Group A Streptococcus remains the best characterized infectious association, although prospective studies have not uniformly demonstrated a consistent temporal relationship between streptococcal infection and neuropsychiatric exacerbations. Parent-reported surveys and case-based literature also describe temporal associations with Mycoplasma pneumoniae, influenza-like illnesses, upper respiratory infections, Borrelia burgdorferi, Epstein-Barr virus, and SARS-CoV-2. Proposed mechanisms include molecular mimicry, anti-D1R and anti-D2R antibodies, other antineuronal antibodies, calcium/calmodulin-dependent protein kinase II signaling, blood-brain barrier vulnerability, cytokine and Th17 effects, neuroinflammatory amplification, basal ganglia/CSTC circuit dysfunction, and gut-oral-brain immune interactions. None currently provides a definitive diagnostic biomarker.<br><br>CONCLUSIONS: Infection-associated PANS is best approached as a clinically defined, heterogeneous neuroimmune presentation that requires rigorous differential diagnosis, multidisciplinary care, cautious treatment escalation, prospective biomarker validation, and large, multicenter treatment trials.},
}
@article {pmid42496488,
year = {2026},
author = {Khalid, H and Istanaksai, A and Abbasi, M},
title = {Screen Time and Myopia-Related Outcomes in European Children: A Systematic Review.},
journal = {Vision (Basel, Switzerland)},
volume = {10},
number = {3},
pages = {},
pmid = {42496488},
issn = {2411-5150},
abstract = {Myopia is an increasingly common refractive disorder in children, with growing concern regarding the potential role of screen time and digital device use in its development and progression. This systematic review assessed the association between screen-related behaviours and myopia in European children and adolescents. A systematic search of Ovid Embase, Ovid MEDLINE, Scopus, Web of Science and Cochrane/CENTRAL was conducted in accordance with PRISMA guidance. Original English-language studies published within the last 10 years were included if they involved participants aged <18 years, were conducted in Europe, and investigated screen time, digital device use, near-work behaviour or related lifestyle exposures in relation to myopia-related outcomes. A total of 1196 records were identified across the databases. After duplicate removal, title and abstract screening, and full-text assessment, 14 studies were included. Overall, the evidence suggested an association between screen-related behaviours, prolonged near work, reduced outdoor exposure and myopia-related outcomes in European children. However, findings were heterogeneous, and screen exposure was often measured using broad or proxy variables, including total screen time, smartphone use, internet data consumption, computer use, handheld near-screen use and COVID-19-related lifestyle change. Outdoor activity appeared to be a protective factor, while parental myopia was an important risk factor and confounder. Most included studies were observational, many were cross-sectional, and several relied on self- or parent-reported exposure measures, limiting causal inference and introducing potential recall bias. Overall, the certainty of evidence was low to very low. Practical advice should therefore be framed around balanced digital device use, regular breaks from prolonged near work, appropriate viewing distances and increased outdoor activity, while further longitudinal studies using objective screen-use measures, cycloplegic refraction and axial length outcomes are needed to clarify causality.},
}
@article {pmid42496967,
year = {2026},
author = {Akinnawo, A and Bécares, L and Pollock, A and Rachet, B},
title = {Has COVID-19 Exacerbated Ethnic-Related Inequalities in Cancer Care in the UK? Findings from a Narrative Review with a Systematic Search.},
journal = {Journal of racial and ethnic health disparities},
volume = {},
number = {},
pages = {},
pmid = {42496967},
issn = {2196-8837},
support = {ES/P00072X/1//Economic and Social Research Council/ ; },
abstract = {Ethnic inequalities in cancer care have long been a concern in the UK, with minoritised populations facing inequalities in access, diagnosis, treatment, and outcomes. The COVID-19 pandemic exacerbated these inequities, worsening barriers to care. This narrative literature review, which incorporates a systematic search, examines the impact of the pandemic on ethnic inequalities in cancer care in the UK. Findings indicate that due to the pandemic, ethnic minority patients experienced lower screening uptake, greater delays in diagnosis, and reduced access to timely treatment. GP referral thresholds were higher for ethnic minority groups, leading to later-stage diagnoses, while emergency presentations and treatment delays were more frequent. Systemic healthcare pressures and communication gaps further contributed to inequalities. Addressing these inequities requires urgent policy interventions, including improved access to screening, equitable referral processes, and culturally sensitive care pathways. Further research is needed to assess post-treatment outcomes and evaluate targeted interventions. As the NHS recovers from the COVID-19 pandemic's disruptions, ensuring equitable access to high-quality cancer care for all ethnic groups must remain a priority.},
}
@article {pmid42497965,
year = {2026},
author = {Bustos, M and Rodríguez-Hernández, M&#xc1;},
title = {IL-6 family cytokines behind acute COVID-19 and Long COVID syndrome: Mechanisms, biomarkers, and intervention strategies.},
journal = {Biochimica et biophysica acta. Molecular cell research},
volume = {1873},
number = {7},
pages = {120198},
doi = {10.1016/j.bbamcr.2026.120198},
pmid = {42497965},
issn = {1879-2596},
abstract = {IL-6 family of cytokines is increasingly recognized as a potential contributor to the immune alterations observed in COVID-19 and its long-term sequelae. Beyond the well-established pro-inflammatory actions of IL-6 itself, members of this family collectively orchestrate a complex network integrating antiviral defence, tissue repair, and maladaptive inflammation. Evidence accumulated over the past five years suggests altered regulation and signalling of those cytokines may help explain the heterogeneity of clinical outcomes, ranging from acute respiratory failure to persistent post-COVID symptoms. Recent advances -including the development of multispecific fusion proteins capable of simultaneously blocking viral entry and selectively modulating IL-6-related inflammatory pathways- highlight the expanding therapeutic potential of targeting this cytokine axis. Effective intervention requires precise knowledge of the cytokines temporal expression patterns to avoid interfering with beneficial immune responses. This review examines the molecular mechanisms involving IL-6 family cytokines, their promise as biomarkers of disease progression, and the current or emerging therapeutic strategies aimed at modulating their signalling pathways.},
}
@article {pmid42498332,
year = {2026},
author = {Youngblood, SR},
title = {Optimizing Care in Respiratory Infections: Advanced Approaches to Mechanical Ventilation.},
journal = {Critical care nursing clinics of North America},
volume = {38},
number = {3},
pages = {327-334},
doi = {10.1016/j.cnc.2026.04.003},
pmid = {42498332},
issn = {1558-3481},
mesh = {Humans ; *Respiration, Artificial/methods ; *COVID-19/therapy/complications ; *Respiratory Distress Syndrome/therapy/etiology ; Patient Positioning ; *Respiratory Tract Infections/therapy ; },
abstract = {Caring for patients with respiratory infection induced acute respiratory distress syndrome (ARDS) is a complex task. During the Covid-19 pandemic, patients with ARDS due to Covid-19 overwhelmed the hospitals and traditional care practices were not as effective leading to a high mortality rate. This caused many providers to seek out other less traditional treatments for these patients in order to save lives. Proper patient positioning, ventilation settings, and ventilation delivery changes were some of the areas explored. As the pandemic has resolved, retrospective studies have looked at the effectiveness of these changes with mixed results.},
}
@article {pmid42498334,
year = {2026},
author = {Smith, LG},
title = {Emerging Viral Infections: Nursing Implications and Management Strategies.},
journal = {Critical care nursing clinics of North America},
volume = {38},
number = {3},
pages = {359-367},
doi = {10.1016/j.cnc.2026.04.005},
pmid = {42498334},
issn = {1558-3481},
mesh = {Humans ; *Communicable Diseases, Emerging/nursing/epidemiology ; COVID-19/epidemiology/nursing ; Pandemics ; SARS-CoV-2 ; },
abstract = {Infectious diseases have circulated the globe since the dawn of time, and new ones are seen often. Emerging infectious diseases (EIDs) are defined as a newly found or an already known infectious disease that is rapidly increasing in incidence. COVID-19 changed the theoretic risk of this to a reality. Frontline providers, particularly nurses, were at the forefront of caring for those with COVID-19. This article discusses the history of EID, how care is and should be provided to patients with infectious disease, and future work that needs to be done.},
}
@article {pmid42499246,
year = {2026},
author = {Orue, A and Cornejo, A and Rangel, HR},
title = {SARS-CoV-2 and Cancer Biology: Exploring the Mechanistic Links.},
journal = {Cancer reports (Hoboken, N.J.)},
volume = {9},
number = {7},
pages = {e70629},
pmid = {42499246},
issn = {2573-8348},
mesh = {Humans ; *COVID-19/immunology/complications/virology ; *Neoplasms/immunology/virology/pathology/genetics ; SARS-CoV-2 ; Animals ; Pandemics ; Post-Acute COVID-19 Syndrome ; Signal Transduction ; MicroRNAs ; },
abstract = {BACKGROUND: Five years after the emergence of SARS-CoV-2 and the declaration of the COVID-19 pandemic, the long-term implications of COVID-19 for cancer biology remain incompletely understood. Beyond the major disruptions in cancer screening, diagnosis, and treatment observed worldwide, increasing attention has focused on whether SARS-CoV-2 infection and post-acute sequelae of COVID-19 (Long COVID) may induce persistent biological alterations relevant to tumor progression or recurrence.<br><br>RECENT FINDINGS: Current evidence does not support SARS-CoV-2 as a classical oncogenic virus or demonstrate direct viral carcinogenesis. However, experimental, transcriptomic, and clinical studies suggest that SARS-CoV-2 infection can induce persistent inflammatory and immune alterations that overlap with pathways implicated in cancer biology. Among the most consistently reported findings are chronic activation of IL-6/STAT3 and NF-&#x3ba;B signaling, immune dysregulation, T-cell exhaustion, oxidative stress, mitochondrial dysfunction, and senescence-associated inflammatory programs. Additional proposed mechanisms include perturbation of tumor suppressor pathways, epigenetic remodeling, and microRNA alterations involving the let-7/LIN28B/STAT3 axis. Experimental models have further suggested that inflammatory remodeling induced by respiratory viral infection may influence dormant tumor cell behavior and tissue microenvironments under defined conditions. However, many of these observations derive from in&#xa0;vitro systems, animal models, or association studies, and their long-term relevance to human oncogenesis remains uncertain.<br><br>CONCLUSION: Collectively, current evidence supports the existence of convergent biological mechanisms between SARS-CoV-2-induced inflammatory stress responses and pathways involved in cancer progression, rather than direct oncogenic transformation. Future longitudinal studies integrating immune profiling, inflammatory biomarkers, transcriptomic and epigenetic analyses, and clinical cancer outcomes will be essential to determine whether persistent post-infectious alterations contribute to tumor progression, recurrence, or susceptibility in selected patient populations.},
}
@article {pmid42500010,
year = {2026},
author = {Hijano, DR},
title = {From data to action: a community-centered framework for translating community health assessment into coordinated public health strategy.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1879850},
pmid = {42500010},
issn = {2296-2565},
mesh = {Humans ; Public Health Infrastructure ; *COVID-19/epidemiology ; Tennessee ; *Public Health ; SARS-CoV-2 ; Health Equity ; Needs Assessment ; },
abstract = {Public health agencies routinely conduct community health assessments, yet many jurisdictions continue to face challenges translating population health data into coordinated action that addresses structural determinants of health, health equity, and public health infrastructure needs. These challenges became increasingly visible during the COVID-19 pandemic and highlight the need for community-centered approaches that align public health, healthcare systems, and community partnerships across sectors. This Policy and Practice Review presents a community-centered framework for translating local population health data into coordinated, equity-oriented population health strategy. Using Shelby County, Tennessee, a large urban county in the southern United States, as an illustrative case, the analysis synthesizes publicly available datasets, community health needs assessments, and institutional reports to align local priorities, governance structures, and cross-sector operational strategies within a unified implementation approach. The framework organizes population health priorities into five domains: chronic disease prevention, maternal and child health equity, HIV and sexual health, behavioral health and substance use, and violence prevention and community safety. Across domains, the framework emphasizes shared measurement, data integration, community partnerships, trust, and cross-sector accountability as foundational components of sustainable population health improvement. Although not an implementation evaluation, this review offers a practical approach for jurisdictions seeking to strengthen public health infrastructure, operationalize equity-centered decision-making, and move from fragmented programs toward coordinated population health action responsive to evolving community needs.},
}
@article {pmid42500652,
year = {2026},
author = {Chen, B and Tao, E},
title = {Immunological mechanisms and prevention strategies for febrile seizures in children.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1833132},
pmid = {42500652},
issn = {1664-3224},
mesh = {Humans ; *Seizures, Febrile/prevention &amp; control/immunology/epidemiology ; *COVID-19/prevention &amp; control/immunology ; Child ; *SARS-CoV-2/immunology ; Vaccination ; },
abstract = {Febrile seizures (FS) affect 2-5% of children globally, causing significant caregiver anxiety and healthcare utilization. Emerging evidence implicates neuroinflammation and T-cell-mediated immunity in FS pathogenesis, suggesting potential targets for future investigation. This Review synthesizes current evidence on FS prevention, emphasizing a paradigm shift from universal pharmacological approaches toward risk-stratified, personalized strategies. The COVID-19 pandemic provided unique insights: non-pharmaceutical interventions reduced FS incidence by 54-70%, while the Omicron variant emerged as a novel trigger associated with complex FS features. Prevention is conceptualized within a three-level framework: primary prevention targets all children through vaccination (MMR, PCV13, COVID-19 vaccines) and infection control; secondary prevention focuses on high-risk children with prior FS, where risk stratification integrates clinical predictors (complex features, young age, low fever), biomarkers (hyponatremia, zinc/vitamin D deficiency, inflammatory indices), and pathogen-specific risks (influenza A, Omicron); tertiary prevention addresses complications and epileptogenesis in children with complex FS or genetic predisposition (SCN1A, PCDH19). Key immunological mechanisms include HMGB1-NLRP3 inflammasome activation, TRPV1-mediated Th17 differentiation, and IL-1β/IL-10 dysregulation. Antipyretics do not prevent FS recurrence during distant febrile episodes, while intermittent benzodiazepines (diazepam, intranasal midazolam) effectively reduce early recurrence in high-risk children (NNT = 6.8), albeit with adverse effects in up to 36%. Emerging frontiers include novel therapeutic targets (HMGB1 inhibitors, TRP channel modulators, TSP-1 pathway inhibitors) and non-pharmacological innovations (wearable sensors, chronotherapy). Crucially, caregiver education underpins all prevention levels, addressing high rates of parental anxiety (58.2%). This integrated framework guides clinical practice toward more individualized, risk-based management.},
}
@article {pmid42501562,
year = {2026},
author = {Zhang, H and Liu, X and Zhao, Y and Fang, H and Wang, Y and Chen, L},
title = {Selinexor as a multi-pathway regulator of the XPO1-inflammation Axis: Mechanisms, evidence in inflammatory diseases, and translational challenges.},
journal = {International immunopharmacology},
volume = {187},
number = {},
pages = {117185},
doi = {10.1016/j.intimp.2026.117185},
pmid = {42501562},
issn = {1878-1705},
abstract = {Selinexor (KPT-330), the first oral selective nuclear export inhibitor, simultaneously modulates key signaling pathways, including NF-κB, JAK/STAT, FOXO, Nrf2, and NLRP3, by blocking XPO1-mediated nuclear export, thereby offering a novel multi-target strategy for treating chronic inflammatory diseases. This review systematically integrates existing preclinical and early clinical evidence within the framework of "cytokine signaling networks", focusing on elucidating the molecular mechanisms and biological effects of selinexor in suppressing proinflammatory factor production, mitigating oxidative stress, and regulating inflammatory tissue-remodeling networks. Recent findings further indicate that SINE compounds can remodel proteostasis, including ankyrin repeat and SOCS box-containing protein 8 (ASB8)/Cullin-RING ligase 5 (CRL5)-associated XPO1 degradation and regulation of the ACE2-TMPRSS2-XPO1 coronavirus-entry network. However, current evidence primarily stems from in vitro and animal studies, and randomized controlled trials in human chronic inflammatory diseases are lacking. Moreover, hematopoietic and gastrointestinal toxicities observed in oncology settings suggest a narrow therapeutic window. This review emphasizes a stepwise translational logic from protein turnover and receptor regulation to next-generation XPO1 inhibitors. At present, selinexor is more suitable as a mechanistic tool for exploring the XPO1-inflammation axis, whereas inflammatory-disease translation will require eltanexor or related agents with more favorable tissue distribution and tolerability, together with precisely stratified clinical studies.},
}
@article {pmid42501745,
year = {2026},
author = {Dutta, T and Kumar, A},
title = {Harnessing Latent Dirichlet Allocation-based topic modeling to unveil the focus areas in Ayush healthcare in India.},
journal = {Journal of Ayurveda and integrative medicine},
volume = {17},
number = {4},
pages = {101356},
pmid = {42501745},
issn = {0975-9476},
abstract = {The exponential growth of unstructured data has presented new opportunities for leveraging computational techniques to uncover meaningful insights in diverse domains, including healthcare. In the context of India's pluralistic medical ecosystem, the Ministry of Ayush plays a central role in shaping policies related to traditional systems such as Ayurveda, Yoga, Naturopathy, Unani, Siddha, and Homeopathy. Despite the increasing prominence of AYUSH, especially post-COVID-19, there has been limited scholarly engagement with its policy evolution through a data-driven lens. This study applies Latent Dirichlet Allocation (LDA), a topic modeling technique, to analyze annual reports published by the Ministry of Ayush from 2012 to 2023. The research aims to (i) identify recent focus areas in alternate healthcare policy, (ii) track temporal shifts in strategic priorities, and (iii) uncover underrepresented themes in institutional discourse. The findings reveal evolving trends such as increased emphasis on research, integration with mainstream health systems, digital initiatives, and global promotion. The study identifies four critical dimensions that remain underrepresented within Ayush policy discourse: the positioning of Ayush philosophy as a frontline public health framework, the articulation of an Ayush-centric health system paradigm, the programmatic integration of mental health, and the systematic incorporation of artificial intelligence beyond foundational digital health initiatives, thereby identifying areas requiring greater strategic attention and reform. By introducing topic modeling into Indian healthcare policy research, this paper fills a key methodological gap and offers empirical insights into the policy trajectory of Ayush. To the best of the authors' knowledge, this is the first application of LDA to Ayush's policy literature.},
}
@article {pmid42503166,
year = {2026},
author = {Palmer, E and Polivka, L and Fekete, M and Pándi, V and Megyaszai, &#xc1; and Rozgonyi, Z and Lukácsovits, J and Komáromi, T and Kováts, Z and Varga, JT},
title = {[Current issues and digital technologies in pulmonary rehabilitation].},
journal = {Orvosi hetilap},
volume = {167},
number = {30},
pages = {1199-1206},
doi = {10.1556/650.2026.33590},
pmid = {42503166},
issn = {1788-6120},
mesh = {Humans ; Digital Health ; Telemedicine ; Pulmonary Disease, Chronic Obstructive/rehabilitation ; *Lung Diseases/rehabilitation ; Quality of Life ; COVID-19 ; Remote Patient Monitoring ; },
abstract = {Chronic respiratory diseases - including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung diseases, lung cancer, and post-COVID conditions - are associated with substantial morbidity and reduced quality of life. In addition to pharmacological therapy, chest physiotherapy and pulmonary rehabilitation play a crucial role in improving functional capacity and patient outcomes. This review aims to summarize contemporary approaches in pulmonary rehabilitation, with particular emphasis on the integration of digital technologies and telerehabilitation strategies. A narrative review of the literature was conducted focusing on the structure of pulmonary rehabilitation programs, training modalities, maintenance strategies, and the clinical applicability of telemedicine-based solutions. Pulmonary rehabilitation, particularly when combined with structured exercise programs, maintenance interventions, and telemonitoring systems, can significantly improve exercise tolerance, symptom control, and health-related quality of life. Modern digital technologies enable real-time monitoring of patient status, facilitate individualized rehabilitation strategies, and support early detection of disease exacerbations. Telemedicine platforms, smart inhalers, and wearable sensors represent promising tools for the management of chronic respiratory diseases. Data generated by these technologies may contribute to improved clinical decision-making and optimization of rehabilitation outcomes. The integration of pulmonary rehabilitation with digital health technologies may play a key role in the future management of chronic respiratory diseases and in maintaining long-term functional stability in affected patients. Orv Hetil. 2026; 167(30): 1199-1206.},
}
@article {pmid42503519,
year = {2026},
author = {Hong, W and Alu, A and Zhang, Z and Zhang, Y and He, X and Xu, L and Li, M and He, W and Wang, J},
title = {Mucosal immunity and vaccine development.},
journal = {Signal transduction and targeted therapy},
volume = {11},
number = {1},
pages = {},
pmid = {42503519},
issn = {2059-3635},
mesh = {Humans ; *Immunity, Mucosal/immunology ; *Vaccine Development ; *SARS-CoV-2/immunology/pathogenicity ; *COVID-19/immunology/prevention &amp; control/virology ; Animals ; *COVID-19 Vaccines/immunology/therapeutic use ; Vaccination/methods ; },
abstract = {The mucosal system, which includes the respiratory, gastrointestinal, and urogenital tracts, serves as a primary entry point for pathogens, with a unique immune microenvironment and specialized defense mechanisms. In recent years, especially following the onset of the COVID-19 pandemic, there has been increasing recognition of the importance of mucosal immunity, motivated by an enhanced comprehension of its fundamental mechanisms. Currently, strategies based on mucosal delivery systems to administer antigens and induce strong mucosal protective immunity have become a key focus in the development of mucosal vaccines. Compared with conventional intramuscular delivery, mucosal vaccination can simultaneously elicit a robust local mucosal response, effectively block pathogen entry into the local mucosa, and generate systemic immune responses to prevent symptomatic infections and severe disease. In addition, mucosal delivery offers advantages such as ease of administration and low invasiveness, making it a more widely acceptable approach to vaccination. In the present study, we conducted a systematic review of the mechanisms of mucosal immunity, the technological platforms for mucosal vaccines, and proposed a perspective on the challenges and future directions for the development of next-generation mucosal vaccines, with the goal of enhancing public knowledge and awareness regarding mucosal immunity and its possible effects on global health.},
}
@article {pmid42504235,
year = {2026},
author = {Amiri, P and Mohammadi, NM and Sharifi, M and Mohammadi, A and Sharifi, H and Galavi, Z and Afsharifard, P},
title = {Mobile Health Interventions to Support Patients With Dementia During the COVID-19 Pandemic: A Systematic Review.},
journal = {Health science reports},
volume = {9},
number = {8},
pages = {e72883},
pmid = {42504235},
issn = {2398-8835},
abstract = {BACKGROUND AND AIMS: During the COVID-19 pandemic, mobile health (mHealth) utilization increased, especially among specific groups such as patients with dementia (PwD). This systematic review aimed to assess mHealth interventions among PwD during the COVID-19 pandemic.<br><br>METHODS: This systematic review followed the PRISMA 2020 guidelines. PubMed, Scopus, and Web of Science were searched for English-language studies published between January 2019 and November 2025. Quantitative, qualitative, and mixed-methods studies reporting mHealth interventions for PwD during the COVID-19 pandemic were eligible. Study selection and data extraction were independently conducted by three reviewers. A thematic synthesis based on the Unified Theory of Acceptance and Use of Technology (UTAUT) framework was conducted using ATLAS.ti version 8.<br><br>RESULTS: Of the 16,691 records identified, 13 studies met the inclusion criteria, including 7 quantitative, 3 qualitative, and 3 mixed-methods studies conducted across 12 countries. The synthesis identified 36 drivers and 21 barriers influencing the adoption of mHealth interventions among PwD. Key drivers included perceived usefulness, ease of use, enhanced caregiver support, improved communication with healthcare professionals, and improved access to care. Major barriers comprised technical limitations, inadequate digital infrastructure, language and accessibility challenges, and limited digital literacy among caregivers.<br><br>CONCLUSION: mHealth interventions represent feasible tools for supporting PwD during public health emergencies by enabling remote monitoring, caregiver support, and continuity of care. In practice, healthcare providers should prioritize user-friendly mHealth solutions tailored to caregivers' digital literacy and dementia severity. At the policy level, investments in digital infrastructure, technical support, and caregiver training programs are essential to reduce adoption barriers and ensure equitable implementation of mHealth interventions.},
}
@article {pmid42504319,
year = {2026},
author = {Pitton Rissardo, J and Katz, M and Byroju, VV and Fornari Caprara, AL and Walker, IM},
title = {Neurodegeneration in Parkinson's Disease: The Role of Environmental Toxins.},
journal = {Journal of central nervous system disease},
volume = {18},
number = {},
pages = {11795735261461554},
pmid = {42504319},
issn = {1179-5735},
abstract = {Parkinson's disease (PD) is a rapidly growing global health challenge, with prevalence projected to reach 13-14 million cases by 2040. While aging and improved diagnostic awareness partly explain this trend, mounting evidence implicates environmental factors as critical contributors. This review synthesizes current literature on exposures such as pesticides, solvents, heavy metals, air pollutants, and infectious agents, emphasizing their mechanistic links to neurodegeneration. These factors interact with genetic susceptibility and aging, supporting the "multiple-hit" hypothesis, which posits that PD arises from cumulative insults rather than a single cause. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired protein clearance emerge as convergent pathways underlying dopaminergic vulnerability. Recent findings highlight viral infections-particularly SARS-CoV-2-as potential triggers or amplifiers of PD pathogenesis, raising concerns about long-term neurological sequelae following pandemics. Beyond individual toxins, the exposome concept underscores the lifelong interplay of physical, chemical, and social exposures in shaping disease risk. Climate-related changes, including increased air pollution and wildfire frequency, further compound these risks, suggesting a systemic dimension to PD etiology. Understanding these complex interactions is essential for developing preventive strategies, refining experimental models, and informing public health policies aimed at mitigating environmental contributions to neurodegeneration. This multifactorial perspective offers a foundation for future research targeting modifiable risk factors and resilience mechanisms in PD.},
}
@article {pmid42504772,
year = {2026},
author = {Saad, C and Sammour, C and Nguyen, T and Asmar, C and Slaiby, N and Asmar, R and Menendez, JP and Rangel, T and Nicolas, G and de Freitas Busnardo, F and Gemperli, R},
title = {Marin-Amat syndrome: a comprehensive review of pathophysiology, clinical presentation, and management.},
journal = {Orbit (Amsterdam, Netherlands)},
volume = {},
number = {},
pages = {1-11},
doi = {10.1080/01676830.2026.2706730},
pmid = {42504772},
issn = {1744-5108},
abstract = {PURPOSE: Marin-Amat syndrome is a rare, acquired facial synkinesis characterized by involuntary eyelid closure upon jaw opening. It is historically confused with other types of synkinesis, despite distinct underlying mechanisms. This scoping review aims to clarify the pathophysiology, clinical presentation, and optimal treatment modalities for Marin-Amat syndrome.<br><br>METHODS: A comprehensive search was conducted on PubMed, Scopus, Embase, and Web of Science databases following PRISMA-ScR guidelines. Studies published from inception to January 2026 were screened. Inclusion criteria were restricted to cases of acquired synkinesis manifesting as eyelid closure triggered by jaw movement. Congenital syndromes were excluded.<br><br>RESULTS: Twenty articles met inclusion criteria, comprising 37 patients. The mean age was 55.8&#x2009;&#xb1;&#x2009;23.3&#x2009;years. Bell's palsy was the most common etiology (73.0%), followed by iatrogenic or surgical injury (8.1%), trauma (8.1%), COVID-19-associated palsy (8.1%), and vascular causes (2.7%); latency to onset ranged from approximately 24&#x2009;days to 40&#x2009;years. Electrophysiologic and clinical descriptions supported active orbicularis oculi co-contraction consistent with post-paralytic synkinesis, with a margin reflex distance-1 reduction of roughly 0.5-2.5&#x2009;mm on jaw opening. Botulinum toxin type A directed at the orbicularis oculi produced effective but transient control. Selective preseptal orbicularis myectomy or resection, frequently combined with levator advancement or plication when concomitant ptosis was present, achieved durable resolution and high satisfaction without reported recurrence.<br><br>CONCLUSION: Marin-Amat syndrome is a distinct clinical entity resulting from aberrant regeneration of the facial nerve. Botulinum toxin is effective for temporary management, while surgical myectomy combined with ptosis correction represents the definitive treatment for long-term functional and aesthetic restoration.},
}
@article {pmid42505458,
year = {2026},
author = {Han, Y and Jo, H and Ju, M and Bae, S and Kim, JY and Yoon, J and Lee, T},
title = {Recent Progress in Artificial Intelligence in Biosensor Development: From Bioprobe Design to Fabrication and Signal Analysis.},
journal = {Biosensors},
volume = {16},
number = {7},
pages = {},
pmid = {42505458},
issn = {2079-6374},
support = {RS-2025-24683337//National Research Foundation of Korea/ ; RS-2024-00416117//National Research Foundation of Korea/ ; KOITA-2026-0002-29//Korea Industrial Technology Association/ ; },
mesh = {*Biosensing Techniques/methods/instrumentation ; *Artificial Intelligence ; Humans ; Machine Learning ; *COVID-19/diagnosis ; SARS-CoV-2 ; Electrochemical Techniques ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic highlighted the need for rapid, accurate, and point-of-care diagnostic technologies, accelerating interest in biosensors as next-generation analytical platforms. However, biosensor performance is governed by a connected sequence of processes, including bioprobe-target recognition, sensor fabrication, structural optimization, and signal interpretation. Because these processes involve multiple interacting variables, conventional empirical approaches often have limitations in efficiently optimizing biosensor performance and interpreting complex analytical signals. Artificial intelligence (AI) and machine learning (ML) provide tools to model these relationships and support prediction-guided biosensor development. This review discusses recent progress in AI-assisted biosensor development in three sequential stages. First, AI-assisted bioprobe design is reviewed, including in silico aptamer discovery, smart-SELEX-based aptamer screening, and peptide receptor design for improving molecular recognition. Second, AI-driven sensor fabrication and structural optimization are discussed, focusing on electrochemical feature extraction, paper-based microfluidic device optimization, and optical biosensor parameter prediction. Third, ML-based signal analysis is examined as a strategy for converting complex electrochemical, colorimetric, and optical responses into quantitative analytical outputs. By organizing these examples as a connected workflow rather than as separate applications, this review highlights how AI can link molecular design, device engineering, and signal interpretation to accelerate the development of next-generation biosensors.},
}
@article {pmid42505558,
year = {2026},
author = {Hudu, SA and Alruwaili, M and Soliman, M and Morad, EA and Alhazimi, GM and Jimoh, AO},
title = {From Pandemic Innovation to Platform Diversification: A Systematic Review of Clinical and Preclinical Development of Non-SARS-CoV-2 mRNA Vaccines.},
journal = {Diseases (Basel, Switzerland)},
volume = {14},
number = {7},
pages = {},
pmid = {42505558},
issn = {2079-9721},
support = {NBU-CRP-2026-3770//Northern Border University/ ; },
abstract = {Background: Messenger RNA (mRNA) vaccines have emerged as a versatile platform beyond SARS-CoV-2, with expanding applications in infectious diseases and oncology. However, comprehensive evidence synthesis of non-SARS-CoV-2 mRNA vaccines remains limited. Methods: This systematic review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420261323500). MEDLINE, Embase, Web of Science, Scopus, ClinicalTrials.gov, and WHO ICTRP were systematically searched for studies published between 1 January 2000 and 28 February 2026. Eligible studies included phase I-III clinical trials and in vivo preclinical studies evaluating non-SARS-CoV-2 mRNA vaccines. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2, ROBINS-I, and SYRCLE tools. Findings were synthesized narratively because of substantial heterogeneity. Results: A total of 40 studies met the eligibility criteria and were included in the review, comprising 20 clinical studies and 20 preclinical studies. Advanced clinical programs targeted influenza and respiratory syncytial virus (RSV), with phase III trials displaying seroconversion rates above 70% with good safety profiles. Preliminary phase I studies for HIV, cytomegalovirus, rabies, and personalized cancer mRNA vaccines showed promising humoral and cellular immune responses. Preclinical studies showed strong antibody and T-cell responses against malaria, tuberculosis, Group B Streptococcus, and Zika virus. Most adverse events were mild to moderate, while serious vaccine-related adverse events were uncommon. Conclusions: Non-SARS-CoV-2 mRNA vaccines demonstrate substantial translational potential across infectious disease and oncology applications. Although the vaccine candidates have demonstrated promising immunogenicity and safety, most are in the early stages of development. This highlights the need for large trials, long-term safety follow-up and better global representation.},
}
@article {pmid42505582,
year = {2026},
author = {Frosolini, A and Benedetti, S and Vaira, LA and Gabriele, G and Gennaro, P},
title = {Oncological Care During a Crisis: A Systematic Review and Meta-Analysis of Non-Melanoma Skin Cancer of the Head and Neck Region in the COVID-19 Pandemic.},
journal = {Diseases (Basel, Switzerland)},
volume = {14},
number = {7},
pages = {},
pmid = {42505582},
issn = {2079-9721},
abstract = {INTRODUCTION: The COVID-19 pandemic profoundly disrupted healthcare, prompting adaptations in oncological practices. This systematic review evaluates the pandemic's impact on the management of non-melanoma skin cancer (NMSC) of the head and neck (H&amp;N) region.<br><br>METHODS: The review was reported according to PRISMA guidelines. Eligible studies compared pre-pandemic and pandemic periods in adult patients treated for head and neck NMSC reporting outcomes related to histological distribution, time to treatment initiation, reconstructive method, and surgical margin status. Risk of bias was assessed using the Newcastle-Ottawa Scale. Random-effects meta-analyses were performed for outcomes with sufficient extractable data.<br><br>RESULTS: The review comprised five studies involving 1318 cases. The relative distribution of basal cell carcinoma and squamous cell carcinoma did not differ significantly between pre-pandemic and pandemic periods. Time to treatment initiation showed no significant overall change, although heterogeneity was high, indicating substantial variability among healthcare settings. Reconstruction shifted significantly toward primary closure compared with flap reconstruction during the pandemic period (OR 1.90; 95% CI: 1.46-2.47; p < 0.0001). Negative surgical margins were reported in 1119 of 1266 excisions/cases with available data (88.4%), with no significant difference between pre-pandemic and pandemic periods (OR 0.77; 95% CI: 0.46-1.32; p = 0.34).<br><br>CONCLUSIONS: The pandemic was associated with a shift toward simpler reconstructive strategies, particularly increased use of primary closure, likely reflecting attempts to reduce operative complexity and resource use. While short-term oncologic outcomes appeared broadly preserved, long-term functional, aesthetic, and patient-reported outcomes remain insufficiently characterized. Future studies should evaluate these outcomes to better inform crisis-adapted oncologic and reconstructive care pathways.},
}
@article {pmid42505617,
year = {2026},
author = {Lucaciu, FC and Rosca, O and Mihai, AM and Sima, A and Suba, MI and Wellmann, N and Rosian, A and Oancea, C and Cialma, M and Tarau, A and Bosoanca, A and Marc, M},
title = {Antibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis.},
journal = {Antibiotics (Basel, Switzerland)},
volume = {15},
number = {7},
pages = {},
pmid = {42505617},
issn = {2079-6382},
support = {5/4270/04.03.2025//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
abstract = {BACKGROUND: Adults hospitalized with COVID-19, influenza A/B, or respiratory syncytial virus (RSV) frequently receive empirical antibiotics, but antibiotic prescribing, confirmed bacterial co-infection, antimicrobial resistance (AMR), and outcomes have not been jointly synthesized across these infections.<br><br>METHODS: We conducted a PRISMA 2020 systematic review and meta-analysis of 39 studies including 839,531 hospitalized adults. Random-effects models with Freeman-Tukey double-arcsine transformation pooled prevalence estimates; sensitivity and publication-bias analyses were performed where appropriate.<br><br>RESULTS: Pooled antibiotic use was 62.56% (95% CI, 53.75-70.97%) for COVID-19, 57.48% (25.76-86.09%) for influenza A/B, and 76.03% (67.62-83.53%) for RSV, with very high heterogeneity. Confirmed bacterial co-infection was lower: 5.31% (3.43-7.56%), 18.66% (9.98-29.30%), and 24.36% (18.53-30.70%), respectively. Prescribing-to-confirmed infection ratios ranged from 3.0 to 46.2. AMR evidence was restricted to COVID-19 studies and was dominated by carbapenem-resistant Gram-negative organisms, mainly in secondary, ICU-associated, or healthcare-associated infections. Confirmed bacterial complications were associated with ICU admission, longer hospitalization, and higher mortality.<br><br>CONCLUSIONS: Antibiotic prescribing exceeded confirmed bacterial infection across all viral groups, but estimates require cautious interpretation due to heterogeneity, diagnostic uncertainty, observational evidence, and the absence of low-risk-of-bias studies. The evidence base was dominated by COVID-19 cohorts, while influenza A/B and RSV data, especially virus-specific AMR evidence, remain limited. COVID-19-specific AMR findings should not be generalized to influenza A/B or RSV. Virus-specific stewardship should prioritize rapid diagnostics, systematic sampling, reassessment, and de-escalation when bacterial infection is not confirmed.},
}
@article {pmid42506036,
year = {2026},
author = {Filipska-Blejder, K and Biercewicz, M and Jabłońska, R and Królikowska, A and Haor, B and Ślusarz, R},
title = {Behind Closed Doors: Elder Abuse as an Overlooked Pandemic of Modern Times.},
journal = {Nursing reports (Pavia, Italy)},
volume = {16},
number = {7},
pages = {},
pmid = {42506036},
issn = {2039-4403},
abstract = {Elder abuse is internationally recognized as a growing problem of the 21st century that requires urgent intervention and action. This review aimed to synthesize evidence on the prevalence and risk factors of elder abuse between 2010 and 2022. A total of 2875 articles were identified through database searches, of which 28 met the inclusion criteria and were included in the final analysis (24 cross-sectional studies, 3 prospective studies, and 1 descriptive study). Reported prevalence rates of elder abuse ranged from 2.2% to 81.2% overall, while studies conducted during the COVID-19 pandemic reported rates ranging from 1.6% to 44.7%. Psychological abuse was the most frequently reported form of violence. The most commonly identified risk factors included low income, low educational level, gender, disability, depression, and-during the COVID-19 pandemic-social isolation. Across most studies, individuals with lower education and women were statistically more likely to experience abuse. The findings indicate substantial variability in the prevalence of elder abuse both before and during the pandemic, with consistently high rates observed. These results highlight the urgent need for improved screening, education, and targeted interventions by healthcare and social service professionals.},
}
@article {pmid42506341,
year = {2026},
author = {Poboży, T and Poboży, K and Domańska-Poboża, J and Konarski, W},
title = {Impact of COVID-19 on the Development of Femoral Head Avascular Necrosis: A Systematic Review.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {3},
pages = {},
pmid = {42506341},
issn = {2076-3271},
mesh = {Humans ; *Femur Head Necrosis/etiology/epidemiology/diagnostic imaging ; *COVID-19/complications ; Adrenal Cortex Hormones/adverse effects/therapeutic use ; SARS-CoV-2 ; Risk Factors ; Pandemics ; },
abstract = {BACKGROUND: COVID-19 has been linked to musculoskeletal complications, including femoral head avascular necrosis (AVN). Both COVID-19-related hypercoagulability and corticosteroid therapy have been proposed as contributing factors. This systematic review synthesizes current evidence on the occurrence, clinical characteristics, timing, and risk factors for femoral head AVN following COVID-19.<br><br>METHODS: A PRISMA-compliant systematic search of PubMed, Embase, and Scopus identified observational studies and case series (&#x2265;10 patients) reporting femoral head AVN in adults or adolescents with confirmed COVID-19. Data on epidemiology, symptom onset, imaging findings, and corticosteroid exposure were narratively synthesized due to heterogeneity.<br><br>RESULTS: Fifteen eligible studies described patients with post-COVID femoral head AVN. Symptom onset ranged from days to >12 months after infection. Early MRI often revealed asymptomatic or low-grade disease. Corticosteroid exposure was common and strongly associated with AVN severity; however, several studies reported AVN in patients without steroid use, whether this reflects an independent contribution of COVID-19 or unrecognized confounding cannot be determined from the available uncontrolled data. Higher cumulative steroid doses, severe pulmonary involvement, and elevated inflammatory markers were consistently linked to more advanced AVN stages.<br><br>CONCLUSIONS: Femoral head AVN is an emerging post-COVID complication with variable timing and presentation. Corticosteroid exposure remains the principal risk factor; whether COVID-19 contributes independently of corticosteroids is unproven, and current evidence supports an association rather than a causal relationship. Awareness of this potential complication is warranted, although the role of early MRI screening remains to be established in prospective studies.},
}
@article {pmid42506369,
year = {2026},
author = {Bajić, D and Andrijević, L and Todorović, N and Lalić-Popović, M and Zarić, B and Dimić, S and Stojčević Maletić, J and Lendak, D and Milijašević, B and Milošević, N},
title = {High-Dose Intravenous Vitamin C in Critical Illness: A Translational Exposure-Response Framework for Biomarker-Guided Precision Therapy.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {3},
pages = {},
pmid = {42506369},
issn = {2076-3271},
mesh = {Humans ; *Ascorbic Acid/administration &amp; dosage/pharmacokinetics/therapeutic use ; *Critical Illness/therapy ; Biomarkers/blood ; COVID-19 ; Sepsis/drug therapy ; *Precision Medicine/methods ; SARS-CoV-2 ; Administration, Intravenous ; Respiratory Distress Syndrome/drug therapy ; COVID-19 Drug Treatment ; Dose-Response Relationship, Drug ; Pandemics ; },
abstract = {High-dose intravenous vitamin C (HDIVC) has been investigated as a potential adjunctive therapy in critical illness, including sepsis, acute respiratory distress syndrome (ARDS), and COVID-19. Despite a strong mechanistic rationale, clinical trials have yielded inconsistent results. From a clinical pharmacology perspective, this variability may reflect, at least in part, differences in pharmacokinetic exposure, timing of administration, and patient selection rather than a lack of biological activity. Intravenous administration enables plasma concentrations in the millimolar range (≈1-5 mM), far exceeding those achievable with oral dosing (<100 µM), thereby reaching thresholds required for pharmacodynamic effects on oxidative stress, immune signaling, and endothelial function. This exposure-dependent transition distinguishes vitamin C as a pharmacological agent rather than a nutritional supplement in critically ill populations. Therapeutic response may be influenced by timing relative to disease progression, with earlier administration representing a biologically plausible strategy that warrants prospective evaluation rather than a clinically established therapeutic window. Interindividual variability in transporter function, redox status, and genetic background may further contribute to heterogeneous responses. Biomarkers such as interleukin-6 (IL-6), C-reactive protein (CRP), D-dimer, and markers of endothelial injury provide a framework for patient stratification and monitoring of pharmacodynamic effects. Integrated with pharmacokinetic principles, these markers support a shift toward biomarker-guided, precision-based therapeutic strategies. This review synthesizes current clinical and mechanistic evidence through an exposure-response conceptual framework, framing HDIVC as a context-dependent pharmacological intervention and advancing a shift toward biomarker-guided, precision-based therapeutic strategies in critical illness.},
}
@article {pmid42506596,
year = {2026},
author = {Mpakosi, A and Moutsopoulou, RA and Cholevas, S and Lianou, A and Samata, A and Tziraki, F and Vogiatzis, I and Cholevas, V and Iliodromiti, Z and Boutsikou, T and Iacovidou, N and Tsantes, AG and Sokou, R},
title = {A Double-Edged Sword: Breast Milk-Derived Maternal Antibodies and Infant Vaccine Responses: A Narrative Review.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506596},
issn = {2076-393X},
abstract = {Neonatal defense against pathogens relies on maternal antibodies transferred both through the placenta (IgG) and through breast milk (primarily secretory IgA). Maternal IgG antibodies are transferred across the placenta to the fetus mainly via the neonatal Fc receptor (FcRn), which is expressed at high levels in placental syncytiotrophoblasts, and results in the acquisition of maternal-fetal IgG. Transplacental transfer via the FcRn pathway can provide therapeutic proteins and protective antibodies following maternal vaccination. However, maternal IgG antibodies can bind to vaccine antigens such as measles, tetanus, and poliovirus, resulting in rapid clearance through FcgRIIB-mediated inhibition and inadequate B cell activation. In this way, they can inhibit de novo immune responses and significantly reduce vaccine response. On the other hand, the interference that breast milk-derived antibodies may have on vaccine-induced immunity is still largely unknown. Vaccination against influenza, pertussis, and COVID-19 during pregnancy or lactation has been shown to induce the production of protective, pathogen-specific, secretory IgA and IgG antibodies in breast milk. Conversely, studies found that breast milk-derived antibodies of vaccinated mothers reduced vaccine-induced immunity in breastfed infants by accelerating the clearance of vaccine antigen, resulting in reduced antigen availability and reduced plasma cell formation after vaccination. Additional factors in middle- and low-income countries, including environmental (increased microbiome diversity, environmental intestinal dysfunction, malnutrition, co-infections) and breastfeeding practices, may exacerbate the interference effect of maternal antibodies. Current evidence supports that breastfeeding is associated with a reduced immunological response exclusively to the rotavirus vaccine. However, the limited evidence base to date precludes definitive conclusions regarding the role of breast milk-derived antibodies in modulating vaccine-induced immunity. Nevertheless, the evidence suggests that although maternal antibodies may theoretically reduce vaccine immunogenicity, the overall protective benefits of breastfeeding outweigh any potential interference with vaccine responses.},
}
@article {pmid42506608,
year = {2026},
author = {Galili, U},
title = {Arming Inactivated Enveloped Virus Vaccines with the GGTA1 Gene: A Potent Method for Amplification of Viral Vaccines Effectiveness and Protection Against Variants.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506608},
issn = {2076-393X},
abstract = {This review describes a novel method for increasing the effectiveness of inactivated enveloped whole-virus vaccines by targeting them for extensive uptake by antigen-presenting cells (APCs). Several inactivated whole-virus vaccines with dense glycan shields display suboptimal effectiveness because the multiple carbohydrate chains (glycans) on the virus mask immunogenic peptides and surround the virus with a negative electrostatic charge that decreases uptake by APCs. It is postulated that engineering such vaccinating viruses to present the carbohydrate antigen "α-gal epitope" on the glycan shields will immunocomplex them with the anti-Gal antibody; thus, it will target them for robust uptake by APCs. Anti-Gal is an abundant natural antibody in humans, constituting ~1% of human circulating immunoglobulins. The ligand of anti-Gal is the α-gal epitope, which is naturally synthesized in non-primate mammals and New World monkeys by the glycosylation enzyme α1,3galactosyltransferase. This enzyme is encoded by the GGTA1-gene. Viral vaccines presenting multiple α-gal epitopes on their glycan shield bind anti-Gal and activate the complement system to produce complement chemotactic cleavage peptides C5a and C3a that induce extensive recruitment of APCs to vaccine injection sites. The virion-bound anti-Gal further targets the viral vaccine for robust uptake by APCs, following binding of its Fc "tail" to Fcγ-receptors on APCs. The efficacy of this method was studied in anti-Gal-producing mice with α-gal presenting inactivated influenza virus vaccine and with gp120 of HIV presenting this epitope. These studies indicated that virus vaccines engineered to present α-gal epitopes increase anti-virus antibody production and virus-specific T-cell activation by 15- to 100-fold in comparison to the same vaccines lacking α-gal epitopes. It is suggested that α-gal presenting inactivated SARS-CoV-2 virus vaccines can induce a similar protective long-term immune memory against S- M-, E-, and N-viral proteins. Furthermore, immune-escaping variants of the mutated S-protein may be destroyed by antibodies to M and E proteins, and cells infected with such variants may be killed by cytotoxic T cells specific to peptides of the N-protein. Such an anti-M-, E-, and N-protein immune protection may prevent expansion of these variants and thus may avoid the need for immunization with COVID-19 vaccines every 6 months or following the appearance of new variants. A similar potent immunization may be achieved with an inactivated Ebolavirus vaccine engineered to present α-gal epitopes on the glycan shield. The resulting immune response to the various Ebolavirus proteins also may contribute to cross-reactive protection against other Ebolavirus species containing proteins with evolutionarily conserved structures. An effective method for the preparation of a whole-virus vaccine presenting α-gal epitopes is by arming it with the GGTA1-gene inserted into the viral genome. Such virions will present multiple α-gal epitopes on their glycan shield, which will amplify their immunogenicity instead of reducing it in the wild-type virus.},
}
@article {pmid42506648,
year = {2026},
author = {Siniscalchi, C and Imbalzano, E and Basaglia, M and Cerundolo, N and Meschi, T and Prati, B and Parise, A and Nouvenne, A and Di Micco, P},
title = {Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506648},
issn = {2076-393X},
abstract = {Six years after the emergence of SARS-CoV-2, COVID-19 remains a dynamic public health challenge shaped by viral evolution, heterogeneous population immunity, changing vaccine strategies, and the long-term consequences of acute infection. Although the transition from pandemic emergency to endemic circulation has reduced the global burden of severe disease, COVID-19 continues to affect vulnerable populations, particularly older adults, frail patients, immunocompromised individuals, and subjects with multiple comorbidities. Vaccination has substantially modified the clinical course of infection, reducing hospitalization, intensive care admission, and mortality, while also reshaping surveillance priorities toward variant monitoring, vaccine effectiveness, waning immunity, breakthrough infections, and long COVID. At the same time, the pandemic has highlighted the need for integrated clinical risk stratification, including age, sex, frailty, inflammatory biomarkers, respiratory support requirements, and thromboembolic risk. Venous and arterial thrombotic complications have represented a key feature of severe COVID-19 and remain relevant for both acute management and post-discharge follow-up. This narrative review summarizes the main lessons learned from six years of COVID-19, focusing on epidemiology, vaccination campaigns, clinical risk assessment, thromboembolic complications, and surveillance strategies. Particular attention is given to the need for multidisciplinary and data-driven approaches capable of integrating virological, epidemiological, clinical, geriatric, and vascular medicine perspectives. Future COVID-19 surveillance should move beyond case counting and incorporate vaccine impact, population vulnerability, thrombotic and bleeding complications, long-term outcomes, and preparedness for emerging variants.},
}
@article {pmid42506651,
year = {2026},
author = {Zuo, N and Zheng, X and Ishaq, R and Ren, D and Hu, A},
title = {The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506651},
issn = {2076-393X},
abstract = {Human viral entry receptor mouse models exist to overcome a fundamental experimental barrier: many clinically important viruses bind their human entry factors far more efficiently than the corresponding murine orthologs, leaving conventional mice unable to support authentic infection, physiological tissue tropism, or meaningful countermeasure evaluation. This review is organized around the receptor-humanization concept rather than around a single coronavirus model. Engineering strategies compared here include random transgenesis, endogenous-locus knock-in, minimal receptor-interface humanization, conditional and inducible expression, and transient vector-mediated delivery. Receptor systems covered span human angiotensin-converting enzyme 2 (hACE2)-dependent sarbecoviruses, human dipeptidyl peptidase 4 (hDPP4)-dependent Middle East respiratory syndrome coronavirus (MERS-CoV), human cluster of differentiation 4/human C-C chemokine receptor type 5 (hCD4/hCCR5)-dependentt human immunodeficiency virus type 1 (HIV-1), adenovirus receptor models, human intercellular adhesion molecule 1 (hICAM-1) rhinovirus systems, hepatitis C virus (HCV), hepatitis B virus (HBV), and hepatitis D virus (HDV) entry-factor models, measles receptor models, poliovirus receptor/CD155 (PVR/CD155) models, human scavenger receptor class B member 2 (hSCARB2) enterovirus systems, and human transferrin receptor 1 (hTfR1) arenavirus models. We then discuss how these platforms support antibody evaluation, Fc-effector analysis, vaccine protection, variant benchmarking, and safety assessment. These models yield the most reliable data when the experimental question is explicitly entry-dependent and when receptor expression level, anatomical distribution, pathology window, and immune context have all been independently validated. They are least informative when receptor expression is non-physiological, when disease readouts are driven by promoter artifacts, or when post-entry species barriers remain the dominant bottleneck. A validation-centered framework is therefore proposed to guide the selection of each model for the specific antiviral antibody or vaccine question it can legitimately answer.},
}
@article {pmid42506659,
year = {2026},
author = {Maria, F and Branda, F and Ceccarelli, G and Scarpa, F and Ciccozzi, M and Russo, A},
title = {From Vaccine Skepticism to Institutional Distrust: The Post-Pandemic Shift.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506659},
issn = {2076-393X},
abstract = {Background: Vaccine hesitancy has traditionally been understood as a multifactorial phenomenon shaped by individual beliefs, risk perceptions, and access barriers. However, the COVID-19 pandemic has fundamentally transformed the relationship between citizens, science, and public institutions, raising the question of whether vaccine hesitancy has evolved into a broader form of institutional distrust. Objective: This narrative review synthesizes evidence on vaccine confidence, trust dynamics, misinformation, and post-pandemic attitudes to propose a new conceptual framework, i.e., institutional hesitancy, that reframes vaccine acceptance within the wider context of institutional credibility, transparency, and legitimacy. Methods: We conducted a narrative synthesis of peer-reviewed literature, surveillance reports, and cross-national surveys published between 2015 and 2026, focusing on trust in science, governments, public health agencies, healthcare systems, and regulatory authorities as determinants of vaccination behavior. Results: The evidence consistently demonstrates that institutional trust is among the strongest predictors of vaccine acceptance, often surpassing traditional demographic and knowledge-based variables. The pandemic exposed and amplified pre-existing fractures in the relationship between citizens and institutions, creating a legacy of institutional skepticism that extends beyond COVID-19 vaccines to routine immunization programs, seasonal vaccination campaigns, and future pandemic preparedness. Traditional information-based approaches, which assume that knowledge deficits drive hesitancy, have proven insufficient when trust is compromised. Instead, rebuilding vaccine confidence requires sustained investment in institutional transparency, community engagement, and accountable governance. Conclusions: The post-pandemic era calls for a fundamental reconceptualization of vaccine hesitancy. We propose the institutional hesitancy framework as a complementary lens that shifts the analytical focus from individual knowledge deficits to relational dynamics between citizens and institutions. Addressing this challenge requires moving beyond communication campaigns toward long-term strategies that restore institutional trust and strengthen the resilience of public health systems.},
}
@article {pmid42506664,
year = {2026},
author = {Ndembi, N and Folayan, MO and Pilorget, A and Ntinginya, NE and Mwesigwa, B and Crowell, TA and Mgodi, NM and Kim, JH},
title = {Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa.},
journal = {Vaccines},
volume = {14},
number = {7},
pages = {},
pmid = {42506664},
issn = {2076-393X},
abstract = {The era of highly effective pre-exposure prophylaxis (PrEP) has transformed HIV prevention, yet global HIV incidence remains unacceptably high, particularly in sub-Saharan Africa. While antiretroviral-based prevention is critical, persistent structural barriers to access and adherence highlight the urgent need for a complementary preventive HIV vaccine. In this narrative review and perspective, we argue that scientific progress toward an HIV vaccine must be matched by equally ambitious preparedness investments across three domains: manufacturing and supply chains, clinical trial and regulatory infrastructure, and delivery systems and community engagement. Drawing on lessons from the global rollout of PrEP, post-exposure prophylaxis (PEP), and the COVID-19 pandemic response, we outline a five-pillar strategic roadmap. This roadmap focuses on ensuring that a future HIV vaccine reaches the people who need it most from the moment of regulatory authorization, calling for co-investment in diverse platforms, binding advance market commitments, logistical simulation, and proactive planning for post-licensure effectiveness trials. Preparedness is not secondary to science; it is its essential partner.},
}
@article {pmid42506782,
year = {2026},
author = {Amare, SN and Choon Yee, K and Leung, M and Naunton, M and Wilson, A and Rooney, A and Gannash, O and Bushell, M},
title = {The Evolution of Pharmacist Administered Vaccinations in Australia: A Narrative Review of Legislation and Regulatory Documents.},
journal = {Pharmacy (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
pmid = {42506782},
issn = {2226-4787},
abstract = {Background: Since 2014, all Australian jurisdictions have progressively amended legislation to authorise pharmacists to administer vaccines, evolving from restricted pilots to an essential public health pillar. Objective: This review analyses the longitudinal evolution of pharmacist-administered vaccinations (PAVs), documenting changes in authorised vaccines, age eligibility, and regulatory frameworks across all Australian jurisdictions. Methods: A retrospective review of Australian jurisdictional legislation, regulations, and policy documents was undertaken. Searches included official legislative registers, Government Gazettes, Health Department protocols, and professional guidance published by Pharmaceutical Society of Australia (PSA) and The Pharmacy Guild of Australia between 2014 to 2026. Documents were independently reviewed by five authors, followed by secondary verification and consensus-based adjudication to resolve discrepancies and confirm findings. Results: PAVs scope was expanded from a single influenza pilot in 2014 to include over 21 vaccine-preventable diseases by 2026. The COVID-19 pandemic catalysed rapid reform, leading to the standardisation of age eligibility (largely ≥5 years). A landmark milestone occurred in 2025 when South Australia enabled pharmacists to administer any vaccine within their professional scope. Conclusion: Legislative reforms have significantly enhanced vaccine accessibility. However, jurisdictional fragmentation persists. National harmonisation, using a competency-based model similar to South Australia, is recommended to streamline delivery and optimise public health outcomes.},
}
@article {pmid42506789,
year = {2026},
author = {Malak, H and Mirza, M and Gambescia, SF and Aboul-Enein, BH},
title = {Pharmacy Students' Perception of E-Learning During the COVID-19 Pandemic Across the League of Arab States: A Regional Scoping Review.},
journal = {Pharmacy (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
pmid = {42506789},
issn = {2226-4787},
abstract = {The COVID-19 pandemic compelled higher education to resort to e-learning, posing new challenges to the teaching/learning of pharmacy students worldwide. While digital learning provided flexibility, diverse technological infrastructure and institutional availability of resources greatly influenced the student experience. This scoping review aims to assess the perceptions relating to the pivot to e-learning among pharmacy students in the League of Arab States due to the COVID-19 pandemic and how the shift affected student engagement, learning outcomes, and institutional preparedness. Following PRISMA-ScR guidelines, a comprehensive search across ten databases was conducted to identify relevant studies published between January 2020 and December 2025. Forty studies satisfied the inclusion criteria. Pharmacy students in this region responded to the transition to e-learning in diverse ways. While most appreciated the convenience of online modalities, several challenges were consistently enumerated. These were limited technological infrastructure, reduced interpersonal interaction, and disruption of hands-on practical training. Blended learning approaches were largely favored, particularly for their ability to marry online theoretical instruction with face-to-face experiential learning. Reliability and validity issues of internet-based tests were felt by both faculty and students. Stress and mental health problems among students surfaced. Student complaints in general depicted pharmacy education's need for pedagogic reform, better infrastructure, and student mental health services during e-learning. Areas identified from this review are instructional technology infrastructure improvement, adopting a blended learning strategy, and the need to consider the mental health of students learning at a distance.},
}
@article {pmid42507119,
year = {2026},
author = {Algothmi, KM and Alwathinani, NF and Sohrab, SS and Azhar, EI},
title = {Human Bocavirus (HBoV): An update on current status and future prospects in Saudi Arabia.},
journal = {The new microbiologica},
volume = {49},
number = {2},
pages = {83-93},
pmid = {42507119},
issn = {1121-7138},
mesh = {Humans ; Saudi Arabia/epidemiology ; *Human bocavirus/genetics/isolation &amp; purification/classification ; *Parvoviridae Infections/epidemiology/diagnosis/virology ; *Respiratory Tract Infections/epidemiology/virology/diagnosis ; Prevalence ; },
abstract = {Viral respiratory tract infections, particularly Human Bocavirus (HBoV) infections, are a significant global health concern. COVID-19 has provided a suitable platform for infectious diseases caused by multiple pathogens. This review highlights key aspects of the current status and future prospects of HBoV research in the Kingdom of Saudi Arabia, including global and local prevalence, clinical impact, and diagnostic challenges. It also emphasizes the need for future research, particularly in Saudi Arabia, to fill knowledge gaps, improve diagnosis, and design and develop future treatment and prevention strategies. HBoV was identified from a ten-year-old infected patient in Sweden from collected nasopharyngeal samples in 2005. It has been classified into four genotypes (1-4), and HBoV-1 causes respiratory infections requiring hospitalization. Co-infections with other viruses are well known, with the most common symptoms being pneumonia, cough, fever, and wheezing. Most studies on HBoV diagnosis have relied primarily on polymerase chain reaction techniques. Even though pediatric HBoV infections are common worldwide, due to limited HBoV research, there is a lack of awareness among healthcare providers, especially in Saudi Arabia and the Middle East &amp; North Africa region. Expanding research and awareness on HBoV is urgently required to address the burden of respiratory infections in these regions, not only to explore long-term effects, potential treatments, and vaccine development, but also to use advanced diagnostic methods to analyze the changing epidemiology of respiratory pathogens and achieve effective infection control measures.},
}
@article {pmid42507165,
year = {2026},
author = {Salimi, S and Amiri, S and Karimi, SA and Babajani, MM and Rezaiemanesh, A},
title = {Effect of glucocorticoids on smell sensation in patients with non-traumatic olfactory disorders: a systematic review and meta-analysis.},
journal = {European journal of clinical pharmacology},
volume = {82},
number = {8},
pages = {},
pmid = {42507165},
issn = {1432-1041},
mesh = {Humans ; *Olfaction Disorders/drug therapy/etiology ; *Glucocorticoids/therapeutic use/pharmacology/administration &amp; dosage ; Rhinosinusitis/drug therapy/complications ; COVID-19/complications ; *Smell/drug effects ; Nasal Polyps/complications/drug therapy ; },
abstract = {BACKGROUND: The efficacy of glucocorticoids (GCs) for treating non-traumatic olfactory disorders (ODs) remains controversial, with existing meta-analyses showing inconsistent results, largely due to variations in included studies and a lack of etiology-specific analysis.<br><br>METHODS: This systematic review and meta-analysis followed a pre-registered protocol (PROSPERO: CRD42022319449). We searched four databases up to December 2025 for studies assessing GCs therapy in adults with non-traumatic ODs. Efficacy was analyzed by etiology, with the primary outcome being the standardized mean difference (SMD) in objective or subjective olfactory score change.<br><br>RESULTS: Thirty-four studies were included. GCs therapy significantly improved olfactory function in patients with COVID-19-related ODs (13 studies, 1538 patients, SMD&#x2009;=&#x2009;0.53, 95% CI: 0.27-0.79), nasal polyposis (9 studies, 2022 patients, SMD&#x2009;=&#x2009;0.56, 95% CI: 0.39-0.72), and chronic rhinosinusitis with nasal polyps (5 studies, 318 patients, SMD&#x2009;=&#x2009;0.89, 95% CI: 0.18-1.59). No significant benefit was found for chronic rhinosinusitis without polyps (4 studies, 464 patients, SMD&#x2009;=&#x2009;0.25, 95% CI: -0.03-0.53) or allergic rhinitis (3 studies, 240 patients, SMD&#x2009;=&#x2009;0.50, 95% CI: -0.02-1.01). Significant heterogeneity was observed for the positive outcomes. Given the significant heterogeneity (I&#xb2; > 50%), subgroup analyses were performed based on the method of olfactory assessment, treatment duration, formulation, and control group type.<br><br>CONCLUSION: The efficacy of GCs in olfactory dysfunction is probably etiology-dependent. They are most beneficial for ODs related to nasal polyps. For COVID-19-related ODs, short-term intranasal GCs may be effective, while evidence for allergic rhinitis remains inconclusive.},
}
@article {pmid42507202,
year = {2026},
author = {Barnawi, AB and Aseeri, IM and Alotaibi, AA and Alasmari, KAS and Alkholaiwi, F},
title = {Navigating the efficacy, safety and outcome of intranasal platelet-rich plasma for persistent olfactory loss: a systematic review and meta-analysis.},
journal = {European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery},
volume = {},
number = {},
pages = {},
pmid = {42507202},
issn = {1434-4726},
support = {grant number IMSIU- DDRSP2601)//Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University/ ; },
abstract = {BACKGROUND: Persistent olfactory dysfunction (OD) poses a significant clinical challenge with limited therapeutic options. Intranasal platelet-rich plasma (PRP), an autologous source of regenerative growth factors, presents a biologically plausible intervention, yet its efficacy across various OD etiologies remains synthetically underexplored.<br><br>METHODS: This systematic review and meta-analysis adhered to PRISMA guidelines. A comprehensive search of PubMed/MEDLINE, Web of Science, and Cochrane Library (2010-2025) identified studies assessing intranasal PRP for persistent OD (>&#x2009;6 months). Random-effects models pooled standardized mean differences (SMD) for objective (e.g., Sniffin' Sticks TDI) and subjective outcomes.<br><br>RESULTS: Seven studies (n&#x2009;=&#x2009;473) were included. Meta-analysis of controlled studies (n&#x2009;=&#x2009;314) demonstrated a moderate, significant improvement in objective olfactory scores favoring PRP over control (SMD 0.61, 95% CI 0.38-0.84). The pooled mean TDI change from baseline was 7.73 points (95% CI 6.59-8.87), exceeding the minimal clinically important difference of 5.5 points. Benefits were observed across post-COVID-19, post-viral, and post-traumatic etiologies. Adverse events were predominantly mild and transient (e.g., epistaxis).<br><br>CONCLUSION: Intranasal PRP appears to be a generally well-tolerated and promising therapeutic strategy, yielding clinically meaningful improvements in persistent OD of diverse origins. However, the evidence remains preliminary and should be interpreted cautiously, as it is based on only two small RCTs plus non-randomized or single-arm studies. Future studies must optimize its protocol and evaluate its potential synergy with standard therapies like olfactory training.},
}
@article {pmid42507660,
year = {2026},
author = {Murtaza, M and Rasool, MM and Ali, SME and Farhan, M and Ilyas, L and Raza, AA and Amjad, H and Kumar, S and Khan, Z and Tahir, S and Samadi, A},
title = {National Trends &amp; Disparities in Ischemic Heart Disease &amp; Cardiac Arrhythmias Related Mortality in the United States From 1999 to 2024: A CDC Wonder Analysis.},
journal = {Clinical cardiology},
volume = {49},
number = {8},
pages = {e70427},
pmid = {42507660},
issn = {1932-8737},
mesh = {Humans ; United States/epidemiology ; Female ; *Myocardial Ischemia/mortality/ethnology ; *Arrhythmias, Cardiac/mortality/ethnology ; Male ; Cross-Sectional Studies ; Retrospective Studies ; Aged ; Middle Aged ; Centers for Disease Control and Prevention, U.S. ; Age Distribution ; Risk Factors ; *Health Status Disparities ; Adult ; },
abstract = {BACKGROUND: Ischemic heart disease and cardiac arrhythmias are major contributors to cardiovascular mortality in the United States. Understanding long-term national trends and demographic disparities is essential for guiding prevention strategies and public health policies.<br><br>METHODS: A retrospective cross-sectional analysis was conducted using mortality data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2024. Deaths in which IHD and a cardiac arrhythmia were both recorded were identified using ICD-10 codes. Crude mortality rates and age-adjusted mortality rates per 100,000 population were calculated. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Mortality patterns were further stratified by sex, race/ethnicity, age group, geographic region, and urbanization status.<br><br>RESULTS: A total of 1&#x2009;885&#x2009;917 deaths were attributed to IHD and cardiac arrhythmias between 1999 and 2024. The overall AAMR declined from 41.97 in 1999 to 31.75 in 2024. Mortality decreased substantially from 1999 to 2009, stabilized through 2018, and increased sharply during 2018-2021 before declining again through 2024. The cumulative AAMR was 45.09 among males and 23.33 among females. Mortality varied across racial and ethnic groups, geographic regions, urbanization levels, and age groups.<br><br>CONCLUSION: Although overall mortality related to IHD and cardiac arrhythmias has declined over the past two decades, demographic and geographic differences persist. The temporary rise during 2018-2021 coincided with the COVID-19 pandemic period and underscores the need for sustained prevention strategies and equitable healthcare access.},
}
@article {pmid42508371,
year = {2026},
author = {Bonanad, C and Alfaro, R and Morán Bayón, &#xc1; and Cainzos-Achirica, M and García-Lledó, A and Raposeiras-Roubín, S and Vivas, D and Freixa-Pamias, R and Mora, J and Martín-Toro, MA and Fernández-Olmo, R and Maidana, D and Barreres-Martín, G and Barrios, V and Redondo, E},
title = {[Comprehensive cardiovascular prevention: the role of vaccination in older adults with cardiovascular disease. Expert consensus document].},
journal = {Semergen},
volume = {52},
number = {7},
pages = {102819},
doi = {10.1016/j.semerg.2026.102819},
pmid = {42508371},
issn = {1578-8865},
abstract = {INTRODUCTION: Respiratory and systemic infections can trigger cardiovascular events by increasing inflammation, atherosclerotic plaque instability, and a prothrombotic state. Given this situation, vaccination is a relevant preventive tool in patients with cardiovascular disease (CVD).<br><br>OBJECTIVE: To review the available evidence on the impact of vaccination in patients with CVD and to propose recommendations to improve vaccination coverage in clinical practice.<br><br>CONTENT: This expert consensus, developed through a structured narrative review and panel discussion rounds, synthesizes the evidence on vaccination against influenza, pneumococcal disease, respiratory syncytial virus (RSV) infection, COVID-19, and herpes zoster in patients with CVD. The influenza vaccine presents the strongest evidence for reducing cardiovascular events, especially after acute episodes and in high-risk patients. For vaccination against pneumococcal disease, COVID-19, RSV infection, and herpes zoster, although direct cardiovascular evidence is more limited, the reduction in infections and hospitalizations supports its recommendation for a comprehensive preventive approach.<br><br>CONCLUSIONS: Vaccination is part of a comprehensive cardiovascular prevention approach. Improved coverage, supported by shared pathways between cardiology and primary care, along with public health services, can result in fewer infectious complications, fewer cardiovascular decompensations, and better clinical outcomes.},
}
@article {pmid42509561,
year = {2026},
author = {Liu, JH and Zang, J and Xu, JR and Ran, XB and Su, M and Zhang, WM and Ge, ZW and Sun, QY and Ding, LW},
title = {The current landscape of mRNA therapy and the strategies for mRNA purification and dsRNA removal.},
journal = {Journal of biomedical science},
volume = {33},
number = {1},
pages = {},
pmid = {42509561},
issn = {1423-0127},
support = {MOH-OFIRG21nov-0007//the Singapore Ministry of Health's NMRC Open Fund-Individual Research Grant/ ; NUHSRO/2023/005/STARTUP/3//National University of Singapore startup grant/ ; },
mesh = {*RNA, Double-Stranded/isolation &amp; purification ; Humans ; *RNA, Messenger/isolation &amp; purification/therapeutic use ; *SARS-CoV-2/genetics ; },
abstract = {Messenger RNA (mRNA) technology has emerged as a cornerstone in vaccine development and therapeutic applications, offering key benefits such as high potency, rapid scalability, and cost-effectiveness. The success of COVID-19 mRNA vaccines has underscored their efficacy and safety. However, residual byproducts generated during mRNA synthesis, such as unincorporated caps, nucleoside triphosphates (NTPs), DNA templates, enzymes, abortive transcripts, and double-stranded RNA (dsRNA), pose significant challenges to the clinical application of the RNA therapy. Among these, dsRNA is particularly problematic as it can activate various innate immune responses, suppress mRNA translation and potentially compromise the therapeutic efficacy of mRNA. Therefore, effectively removing dsRNA from in vitro synthesized mRNA is essential before its used in preclinical or clinical settings. In this review article, we provide a comprehensive overview of current mRNA development pipelines and ongoing clinical trials, and recent advances in mRNA purification techniques. Specifically, we focus on strategies for dsRNA removal, which can be broadly categorized into two approaches: (1) separating or removing dsRNA from in vitro transcription (IVT) mRNA products using methods such as RP-HPLC chromatography and cellulose-based purification; and (2) minimizing dsRNA formation during IVT by employing engineered RNA polymerase mutants, chaotropic agents, and magnetic beads, as well as modifying/optimizing DNA templates or RNA molecules to reduce dsRNA generation. We also discuss the advantages and limitations of these purification methods, the factors influencing the selection of purification strategies, and explore potential future directions for improving dsRNA purification technologies and their applications in mRNA-based therapeutics.},
}
@article {pmid42511473,
year = {2026},
author = {Starek, E and Żak, K and Ostrowska-Leśko, M and Bobiński, M},
title = {The Impact of Long COVID on the Female Reproductive System: A Narrative Review.},
journal = {International journal of molecular sciences},
volume = {27},
number = {14},
pages = {},
pmid = {42511473},
issn = {1422-0067},
mesh = {Humans ; Female ; *COVID-19/complications/pathology/virology ; Post-Acute COVID-19 Syndrome ; Ovarian Reserve ; SARS-CoV-2 ; *Genitalia, Female ; Anti-Mullerian Hormone/metabolism ; Primary Ovarian Insufficiency/etiology ; },
abstract = {Long COVID affects multiple organ systems and disproportionately affects women, raising concerns about reproductive health. This updated narrative review summarizes evidence from PubMed, Scopus, and Web of Science through March 2026 and extends previous reviews by distinguishing Long COVID-specific findings from acute and early post-infection observations and integrating newer evidence on ovarian reserve, follicular-fluid biology, assisted reproduction, and endometrial function. Reported menstrual changes include irregular cycles, heavy or prolonged bleeding, intermenstrual bleeding, and amenorrhea. Evidence regarding ovarian reserve remains inconsistent: some studies reported lower anti-Müllerian hormone (AMH) levels and/or antral follicle count (AFC), whereas others found no significant changes. Case reports describe premature ovarian insufficiency (POI) and possible autoimmune oophoritis but do not establish causality. Proposed mechanisms include immune dysregulation, inflammation, oxidative stress, endothelial dysfunction, and hypothalamic-pituitary-ovarian axis disturbance. Available evidence does not indicate adverse effects of COVID-19 vaccination on ovarian reserve or fertility outcomes. Most studies suggest transient changes. Direct Long COVID-specific evidence for persistent ovarian or endometrial injury remains limited. However, short follow-up precludes conclusions regarding ovarian aging, menopausal timing, lifetime fertility, or long-term endometrial receptivity. Symptom-guided assessment may include menstrual tracking, AMH, early-follicular-phase follicle-stimulating and luteinizing hormones, and pelvic ultrasonography when clinically indicated.},
}
@article {pmid42512089,
year = {2026},
author = {Leyfman, Y and Ikkurthy, N and Dohadwala, TK and Coloma, HS and Ghazal, J and Joshi, M and Cortiana, V and Pasnoor, DS and Menon, GP and Levi, N and Balasubramanian, M and Park, C},
title = {Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Vesicles.},
journal = {Biomedicines},
volume = {14},
number = {7},
pages = {},
pmid = {42512089},
issn = {2227-9059},
abstract = {Patients with multiple myeloma (MM) exhibit profound immune dysregulation, predisposing them to severe outcomes following SARS-CoV-2 infection. Current evidence highlights shared immunopathological mechanisms linking MM and COVID-19, with particular emphasis on the interleukin-6 (IL-6) axis as a shared amplifier of inflammation rather than the sole driver of disease. MM is characterized by a baseline pro-inflammatory milieu, in part mediated by IL-6, which is further amplified during SARS-CoV-2 infection, resulting in cytokine escalation, complement activation, coagulopathy, and multi-organ injury. This amplification operates within a broader, redundant network that also includes T-cell exhaustion, NK-cell dysfunction, checkpoint signaling, complement and endothelial injury, and treatment-induced immune defects. This overlap provides a mechanistic basis for the disproportionately high morbidity and mortality observed in this population. Even with advancements in vaccination, antiviral therapy, and clinical practice, patients with MM who exhibit impaired vaccine responses, active disease, or treatment-related immune dysfunction continue to experience considerable vulnerability to COVID-19. In addition, MM patients demonstrate suboptimal vaccine-induced immune responses, contributing to persistent vulnerability to severe and breakthrough infections. Modern MM therapies, including anti-CD38 antibodies, BCMA-directed agents, and bispecific T-cell redirecting antibodies, further reshape antiviral immunity by reducing NK cells, inducing plasma cell aplasia, causing hypogammaglobulinemia, and impairing T-cell function. Emerging treatment approaches targeting this shared pathway have been explored, with a focus on mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs). EVs exhibit multimodal properties, including suppression of pro-inflammatory cytokines, restoration of immune homeostasis, inhibition of viral entry, and promotion of tissue repair and regeneration. Early clinical experience in severe COVID-19 populations suggests a favorable short-term safety profile; reported efficacy, however, derives from small, largely uncontrolled or early-phase studies, and the single randomized trial reporting a mortality benefit did so only in an exploratory post hoc subgroup, with its pre-specified primary endpoint not met. Overall, EVs constitute a biologically plausible but as yet unproven adjunctive strategy that warrants further investigation. Critically, no MM patient has ever been enrolled in an EV trial; current rationale for EV use in MM is therefore extrapolated entirely from non-MM populations, and no MM-specific data exist. Difficulties such as EV heterogeneity, manufacturing variability, uncertain pharmacokinetics, limited targeting efficiency, and potential prothrombotic effects must be resolved before their application in MM-specific clinical settings.},
}
@article {pmid42512304,
year = {2026},
author = {Savva, A and Christodoulou, P and Michaeloudes, C and Farazi, PA},
title = {Impact of the COVID-19 Pandemic on Lung Cancer Screening and Diagnosis: A Systematic Review.},
journal = {Cancers},
volume = {18},
number = {14},
pages = {},
pmid = {42512304},
issn = {2072-6694},
abstract = {Background/Objectives: The global health crisis of the COVID-19 pandemic in 2020 severely impacted healthcare systems, particularly affecting cancer patients, including those with lung cancer. Understanding the pandemic's effects on lung cancer diagnosis is important for providing guidelines for future similar crises. Methods: A comprehensive search was conducted using the SCOPUS and PubMed databases, including keywords such as 'COVID-19 pandemic,' 'lung cancer,' 'diagnosis,' and 'screening.' In the initial screening phase, studies were selected based on their title and abstract, followed by the removal of duplicates. A second round of full-text screening was then performed using predefined inclusion and exclusion criteria. Specific checklists were applied to ensure methodological quality. Results: Out of 564 articles, 78 met the inclusion criteria and were grouped according to changes in lung cancer incidence, screening and diagnostic procedures, and staging during the COVID-19 pandemic compared to pre-pandemic. Multiple studies reported an average decline of 20% in newly diagnosed lung cancer cases, alongside significant decreases in screenings, follow-ups, and diagnostic procedures. In contrast, only two studies reported an increase in lung cancer incidence, and three studies reported increases in screening or diagnostic activity. Eight studies reported a shift toward more advanced-stage diagnoses and fewer early-stage detections, while four studies observed a decrease in advanced-stage lung cancer during the pandemic compared to pre-pandemic years. Conclusions: Studies show that overall, the COVID-19 pandemic disrupted lung cancer diagnosis in many countries, highlighting the need for stronger healthcare systems that can support crisis response and equitable care.},
}
@article {pmid42512659,
year = {2026},
author = {Hsieh, MC and Lu, MC and Koo, M},
title = {Mapping TriNetX-Based Real-World Evidence Publications by Clinical Domain and Study Purpose, 2018-2025: A Bibliometric Analysis.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {14},
pages = {},
pmid = {42512659},
issn = {2227-9032},
abstract = {Background/Objectives: Federated electronic health record networks are increasingly used for real-world evidence generation, but publication-use patterns for TriNetX remain incompletely characterized. This study mapped Web of Science-indexed articles that explicitly mentioned TriNetX and examined their distribution across clinical domains and study purposes. Methods: We searched the Web of Science Core Collection for articles published during 2018-2025 with "TriNetX" in the title, abstract, or author keywords. Bibliometric indicators, journal sources, citation impact, author-keyword co-occurrence, and trend topics were analyzed using R, bibliometrix, Biblioshiny, and VOSviewer. A reproducible rule-based dictionary classified clinical domains and study purposes, and a supplementary Scopus analysis assessed pattern-level reproducibility. Results: The corpus included 1573 articles. Annual output increased from 1 article in 2018 to 871 in 2025. Corresponding-author output was concentrated in the United States and Taiwan. Highly cited studies were dominated by COVID-19 research. Keyword analyses suggested a shift from pandemic-related topics toward mortality, cardiometabolic disease, and medication-related outcomes. Domain-purpose mapping showed that risk/prognosis studies were most common, whereas effectiveness, health services, and method/validation studies were less frequent. Scopus validation reproduced the main annual, source-level, and domain-purpose patterns. Conclusions: TriNetX-based publications expanded rapidly and diversified across clinical fields. Domain-purpose mapping shows where research has concentrated and where it remains sparse; lower frequency, however, should not be read as a definitive clinical evidence gap, since some areas may be less suited to the platform. Where the network is well suited, future work could give greater attention to comparative effectiveness, long-term safety, care pathways, and phenotype validation.},
}
@article {pmid42513402,
year = {2026},
author = {Bermejo-Pareja, F and Ramo-Tello, C and Benito-León, J},
title = {Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {14},
pages = {},
pmid = {42513402},
issn = {2077-0383},
abstract = {Background: Ischemic stroke has been reported rarely after coronavirus disease 2019 (COVID-19) vaccination, most clearly in association with vaccine-induced immune thrombotic thrombocytopenia (VITT). Nevertheless, temporal proximity alone cannot establish causality, particularly when conventional vascular risk factors are present. We report a case of posterior circulation ischemic stroke occurring 36-48 h after first-dose ChAdOx1 nCoV-19/AZD1222 vaccination without VITT and provide a focused narrative review of the clinical, epidemiological, and mechanistic evidence regarding post-vaccination stroke. Methods: Clinical, laboratory, and neuroimaging data were reviewed retrospectively. A focused narrative literature review was performed to contextualize VITT-related and non-VITT ischemic stroke after COVID-19 vaccination, pharmacovigilance signals, population-based evidence, and proposed biological mechanisms. Results: A 63-year-old man with well-controlled hypertension and a remote history of smoking developed systemic symptoms within 24 h of first-dose ChAdOx1 nCoV-19/AZD1222 vaccination, followed by severe hypertension and acute posterior circulation neurological symptoms 36-48 h after vaccination. Neuroimaging showed an acute left cerebellar infarct extending into the middle cerebellar peduncle, with approximately 50% stenosis of the intradural left vertebral artery. Platelet counts remained normal, D-dimer and anti-PF4 antibody testing were normal, SARS-CoV-2 polymerase chain reaction (PCR) testing was negative, and routine cardiac evaluation did not identify a definite cardioembolic source. Conclusions: This case highlights an early posterior circulation ischemic stroke temporally associated with ChAdOx1 nCoV-19/AZD1222 vaccination in the absence of VITT. Although individual causality cannot be established from a single case, careful reporting of such presentations may improve clinical recognition, etiological evaluation, and pharmacovigilance.},
}
@article {pmid42513511,
year = {2026},
author = {Cioni, G and Calo', GL and Kerpaci, B and Troia, A and Gregori, N and Manzoli, L and Flacco, ME},
title = {The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {14},
pages = {},
pmid = {42513511},
issn = {2077-0383},
abstract = {Background/Objectives: There is wide variability in the available estimates on the burden of Long-COVID (LC), both among adults and children. Preliminary evidence suggests that this inconsistency may be due, at least in part, to the adoption of uneven diagnostic criteria, proposed by several international entities during the course of the pandemic, but no comprehensive evaluation has been performed so far to quantify the extent of variation among children. This systematic review and meta-analysis aims to update the available epidemiological estimates of LC among pediatric subjects, and to systematically appraise the degree of variability that can be attributed to the diagnostic criteria adopted. Methods: A systematic literature search identified cohort studies providing data on LC among children and adolescents with a previous SARS-CoV-2 infection. We computed (a) proportion and (b) head-to-head meta-analyses (a) to quantify the pooled rates of LC and LC-related symptoms, and (b) to assess the likelihood of developing LC based upon selected demographic and/or clinical characteristics, respectively. Results: In total, 52 cohort studies and 960,089 subjects were included. The pooled rate of LC was 18.1% (95% CI: 13.1-23.6), ranging from 16.2% to 21.6%, according to NIH or WHO diagnostic criteria, respectively. Fatigue, respiratory and neurological symptoms were most commonly reported by LC patients. Stratified analyses showed that females, adolescents (vs. children), subjects with comorbidities, and those with a previous severe COVID-19 (as compared to asymptomatic primary infections) were more likely to develop LC (all p < 0.05). In contrast, the likelihood of LC onset did not significantly vary between individuals with ≥1 anti-SARS-CoV-2 vaccine dose, versus the unvaccinated (pooled OR: 0.92; 95% CI: 0.61-1.41). Conclusions: Although the available estimates may largely vary depending on the adopted definition, LC affects a meaningful proportion of the pediatric population; as such, common clinical criteria and diagnostic approaches are urgently needed. Moreover, given the relevant methodological heterogeneity and the generally poor-to-fair quality of a large part of the available literature, high-quality studies adopting standardized methodologies are warranted to identify at-risk populations and guide the implementation of targeted follow-up strategies.},
}
@article {pmid42513914,
year = {2026},
author = {He, Y and Lo, WS and Yuen, PL and Ching, PTY and Sze, EPT and Kwok, KO and Ip, M and Lai, CKC},
title = {Environmental Disinfection in Long-Term Care Facilities-A Scoping Review.},
journal = {Microorganisms},
volume = {14},
number = {7},
pages = {},
pmid = {42513914},
issn = {2076-2607},
abstract = {Background: Long-term care facility (LTCF) residents are highly susceptible to healthcare-associated infections, and prevention is challenging given frailty, dementia, communal living, and resource constraints. Environmental surface and air contamination contribute to transmission. Novel no-touch automated disinfection technologies have been studied in hospitals, but evidence specific to LTCFs is scarce. This scoping review summarizes recent LTCF-focused interventions, their effectiveness, and implementation considerations. Methods: This scoping review was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist. We searched PubMed, Medline, Embase, CINAHL, and Scopus for observational or experimental studies evaluating environmental disinfection in LTCFs/nursing homes, excluding body decolonization, non-LTCF settings, and reviews/protocols. Two reviewers independently screened and extracted data via Covidence. This review has been registered on OSF (Open Science Framework). Results: Of 1491 records, 7 studies met the inclusion criteria (6 from the USA, 1 from Australia): one cluster randomized trial, one interrupted time series studies, three prospective observational studies, and two pre-post designs. Interventions included physical methods (HVAC-integrated UV/UVGI, continuous UVGI) and chemical approaches (dry hydrogen peroxide, room fogging plus chlorine dioxide wipes, hydrogen peroxide wipes). Outcomes were heterogeneous (surface SARS-CoV-2 RNA, COVID-19 attack/case rates, airborne/surface microbial loads, and one clinical endpoint-acute respiratory illness). Several studies reported reductions in environmental or airborne bioburden; however, UV-based studies did not demonstrate statistically significant reductions in clinical infections. Certainty was limited by small numbers, non-randomized designs, and diverse outcome measures. Conclusions: No-touch automated disinfection methods appear promising as supplements to standard infection prevention control bundles for reducing environmental contamination in LTCFs. Nevertheless, consistent clinical benefits are unproven. Rigorous, LTCF-tailored, adequately powered trials with standardized clinical and environmental outcomes, plus implementation and cost-effectiveness evaluations, are needed.},
}
@article {pmid42514077,
year = {2026},
author = {Liu, A and Ran, D and Shen, Z and Rojba, M and Zhang, J},
title = {The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.},
journal = {Microorganisms},
volume = {14},
number = {7},
pages = {},
pmid = {42514077},
issn = {2076-2607},
abstract = {The mammalian respiratory system stands as a frontline barrier, constantly exposed to environmental insults, balancing defensive immunity with gas exchange. Historically considered sterile, the lung harbors a dynamic, low-biomass microbiome that evolves continuously in response to pulmonary pathologies. Accumulating evidence underscores that respiratory health and structural recovery are not autonomous but are critically integrated with distal microbial systems, especially the intestinal tract, through the gut-lung axis (GLA). This review characterizes the GLA as a bidirectional communication highway fueled by immune pathways, microbial metabolites, and direct microbial translocations. During acute or chronic injuries, such as COVID-19, COPD, asthma, idiopathic pulmonary fibrosis (IPF) and lung cancer, the gut microbiota serves as a remote metabolic "rheostat". It delivers pivotal signaling molecules, such as short-chain fatty acids (SCFAs) and tryptophan metabolites (indoles), that could shape the local microenvironment in which the respiratory epithelium undergoes functional repair or maladaptive, fibrotic remodeling. Mechanistically, gut-derived butyrate enhances mitochondrial activity in alveolar epithelial cells, while resident progenitors, such as Alveolar Type 2 (AT2) cells, depend on intact mitochondrial fatty acid oxidation for proper regenerative differentiation. Conversely, critical lung illness disrupts this homeostasis via a "pathological circuit," where severe pulmonary inflammation drives gut permeability, fecal dysbiosis, and the subsequent translocation of pathogen-associated molecular patterns (PAMPs, such as LPS) or gut-associated bacteria back into the pulmonary circulation. This review highlights the systemic nature of lung regeneration, which likely depends heavily on intestinal health through the GLA. Ultimately, leveraging these remote microbial networks through precision postbiotic supplementation, dietary priming, or microbiota transplantation represents a crucial frontier in precision medicine to promote definitive alveolar repair.},
}
@article {pmid42514086,
year = {2026},
author = {Zheng, Y and Ma, N and Zhao, B and Li, Y and Tian, Y and Liu, J and Quan, Y},
title = {Wastewater Metagenomics for Antimicrobial Resistance and Pathogen Surveillance: A Bibliometric Analysis.},
journal = {Microorganisms},
volume = {14},
number = {7},
pages = {},
pmid = {42514086},
issn = {2076-2607},
support = {YDZJ202601ZYTS183//Jilin Province Science and Technology Department/ ; },
abstract = {Wastewater systems are critical reservoirs where antibiotic resistance genes, antibiotic-resistant bacteria, and pathogens converge and disseminate into receiving waters, posing risks to ecosystems and public health. Metagenomics enables culture-independent surveillance of resistome and pathogens in wastewater. After the COVID-19 pandemic, the rapid expansion of wastewater-based epidemiological surveillance, together with growing emphasis on the One Health framework, has further promoted the integration of wastewater metagenomic monitoring with public-health surveillance strategies. However, no bibliometric study has systematically mapped the global research landscape at the intersection of metagenomics, wastewater systems, antimicrobial resistance, and pathogen surveillance. This study retrieved 1161 publications from the Web of Science Core Collection and used CiteSpace to conduct bibliometric analyses. From 2010 to 2025, annual publications increased from 1 to 219, with 72.7% of the total output concentrated between 2021 and 2025. China led in publication output but showed low betweenness centrality, whereas Australia and Sweden served as key intermediaries. Keyword analysis revealed a gradual thematic evolution from the basic detection of antibiotic resistance genes in activated sludge, through studies of dissemination mechanisms, to recent work on One Health and wastewater surveillance. Literature co-citation analysis showed that integration between environmental monitoring and public health literature remains limited, suggesting that the translation of metagenomic surveillance data into health risk assessment frameworks is still at an early stage. By mapping the field's knowledge structure and gaps, this review highlights priorities for advancing wastewater-based Antimicrobial Resistance surveillance, including standardizing analytical methods, developing artificial intelligence-assisted resistome analysis, promoting equitable participation from underrepresented regions, and operationalizing One Health surveillance, thereby supporting the translation of wastewater monitoring into actionable public-health solutions.},
}
@article {pmid42514170,
year = {2026},
author = {Călinoiu, AL and Mincă, A and Popescu, CC and Vodă, IM and Cristea, AM and Mincă, DI},
title = {New-Onset Myasthenia Gravis Associated with SARS-CoV-2 Infection: A Systematic Review.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {7},
pages = {},
pmid = {42514170},
issn = {2075-1729},
abstract = {This systematic literature review synthesizes available data from published case reports and case studies describing de novo myasthenia gravis (MG) following confirmed SARS-CoV-2 infection, focusing on clinical presentation, immunological characteristics, temporal relationship, management, and outcomes. The study addresses the following research question: What are the clinical, immunological, temporal, and outcome characteristics of de novo MG following SARS-CoV-2 infection based on published case reports and case studies? Following the PRISMA 2020 guidelines, the analysis included 44 studies describing 48 patients. The findings suggest that MG temporally associated with COVID-19 typically occurred within a relatively short latency period, with a median interval of 21 days. Most patients presented with generalized onset and were predominantly positive for AChR-Abs, consistent with the established clinical and serological profile of classical MG, in which AChR-Abs represent the most common subtype, particularly in generalized disease. MuSK and LRP4-positive cases were less frequent; ICU admission, myasthenic crisis, and respiratory failure were frequently reported. Importantly, most patients responded well to conventional MG therapies.},
}
@article {pmid42514186,
year = {2026},
author = {Massip Copiz, MM},
title = {Folic Acid and Endothelial Dysfunction in COVID-19.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {7},
pages = {},
pmid = {42514186},
issn = {2075-1729},
abstract = {Since 2020, recurrent waves of SARS-CoV-2 infection have persisted globally. Despite the advancements in vaccines and pharmacological treatments, a subset of patients still exhibits an aggressive form of COVID-19 requiring prolonged stays in the intensive care unit (ICU) or experiences major acute infections (or reinfections) and long-term symptoms. Endothelial dysfunction is one of the key events contributing to both the severity of acute COVID-19 and the development of long COVID (LC)/post-acute sequelae of SARS-CoV-2 infection (PASC) syndrome. Since the beginning of the pandemic, the efficacy of nutraceuticals, particularly essential micronutrients, has been investigated as a complementary treatment to prevent disease onset and improve clinical outcomes. One such bioactive molecule is folate (vitamin B9), a member of the B-vitamin family involved in the pathogenesis of multiple diseases, including viral infections and vascular disorders. This review examines the role of folic acid in COVID-19 and its interaction with homocysteine metabolism, which is frequently dysregulated in inflammatory endothelial diseases. It further discusses the potential benefits of folic acid supplementation for the prevention and treatment of COVID-19 in both the acute and long-term phases of the disease, alongside the therapeutic role of vitamin B12 supplementation in LC syndrome.},
}
@article {pmid42515022,
year = {2026},
author = {Makhoba, XH},
title = {Dual Functions of Polyamines in Shaping Host-Specific Pathogen Dynamics.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {7},
pages = {},
pmid = {42515022},
issn = {2076-0817},
mesh = {Humans ; *Polyamines/metabolism ; COVID-19/metabolism/virology ; *Host-Pathogen Interactions ; *SARS-CoV-2/physiology ; Animals ; Spermine/metabolism ; Plasmodium falciparum/metabolism ; Spermidine/metabolism ; },
abstract = {Polyamines such as putrescine, spermidine, and spermine play essential roles in most living organisms. They regulate fundamental processes, like cell proliferation, differentiation, growth, gene expression (DNA/RNA stability, transcription, and translation), and signal transduction. As important regulators, polyamines influence development, stress responses, and the progression of health and disease, including cancer and aging. These positively charged molecules have been extensively studied for decades. In humans, polyamines are often researched as potential therapeutic targets for diseases such as malaria and, more recently, COVID-19. Obligate parasites, such as Plasmodium falciparum, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rely on host cellular machinery for survival, replication, and growth. Notably, both hosts and pathogens need polyamines to sustain these processes. This review summarizes current advances in understanding the roles of polyamines in humans, viruses, and obligate parasites. It also explores strategies to prevent pathogens from hijacking host polyamine metabolism as a way toward developing novel therapeutic interventions.},
}
@article {pmid42515093,
year = {2026},
author = {Broccolo, F and Sannino, A and Pollini, M and Paladini, F and Mourer, T and Di Nunzio, F},
title = {Hiding in Plain Sight: HIV-1 Membraneless Organelles as Nuclear Hubs-Host Hijacking, Replication, Immune Evasion, and Drug-Access Implications.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {7},
pages = {},
pmid = {42515093},
issn = {2076-0817},
support = {//Institut Pasteur/ ; //PTR-Carnot/ ; B53C20040570005//Italian National Recovery and Resilience Plan &amp; European Union/ ; CODSOG S5.P0005//Tackling Influenza Viruses by Optimized Hemagglutinin (HA) and/or Neuraminidase (NA) Inhibitors/ ; },
mesh = {Humans ; *HIV-1/physiology/drug effects/immunology ; *Immune Evasion ; *Virus Replication ; *HIV Infections/virology/drug therapy/immunology ; *Host-Pathogen Interactions ; *Organelles/virology/metabolism ; mRNA Cleavage and Polyadenylation Factors/metabolism ; Cell Nucleus/virology/metabolism ; cGAS-STING Signaling Pathway ; },
abstract = {Theories on the early steps of the HIV-1 life cycle have been radically revised over the past five years. The long-held assumption that the capsid fully disassembles in the cytoplasm has given way to a more nuanced view: Cytoplasmic disassembly does occur and, in several myeloid systems, is increasingly linked to cytosolic cDNA sensing and to abortive infection. However, a substantial fraction of intact or nearly intact capsid cores instead traverse the nuclear pore complex (NPC) and, upon interacting with the host factor CPSF6, induce liquid-liquid phase separation. This leads to the formation of biomolecular condensates, termed HIV-1 membraneless organelles (HIV-1-MLOs), which subsequently merge with nuclear speckles (NSs). In this Perspective we read these condensates along five interlocking axes. First, the virus drives the host phase separation of cleavage and polyadenylation specificity factor 6 (CPSF6), which quickly fuses with another MLO: the NS composed of the speckle scaffold factors, SON and SRRM2. Second, the resulting condensate behaves as a catalytic site that concentrates the reverse-transcription machinery and thereby promotes integration of the viral DNA into speckle-associated chromatin (SPADs). Third, the same compartment is the final layer of a stratified programme of innate immune evasion, shielding nascent double-stranded DNA from cGAS-STING after cytoplasmic restriction factors and sensors have been outmanoeuvred. Fourth, although demonstrated only in vitro, stable HIV-1-MLOs can maintain the viral RNA genome in the presence of a reverse-transcription inhibitor. Upon removal of the inhibitor, reverse transcription resumes, mirroring, to some extent, the situation in individuals undergoing interruption of antiretroviral therapy and suggesting that these structures may act as a pre-integration reservoir. Fifth, and still largely unexplored, the sanctuary has a pharmacological dimension: anatomical lymphoid compartments, and possibly the condensate itself through selective small-molecule partitioning, may limit antiretroviral drug access. We situate HIV-1-MLOs within the convergent condensate strategies of SARS-CoV-2 and other viruses, and we discuss the clinical, diagnostic, therapeutic, and vaccine implications, including capsid inhibitors as "block-and-expose" tools.},
}
@article {pmid42515573,
year = {2026},
author = {Yu, Y and He, W and Geng, X and He, Y and Feng, H and Chen, J and Shu, J},
title = {A Comprehensive Review of Coronavirus Non-Structure Protein 6 on Structure, Functions, Mechanisms and Its Implications for Antiviral Research.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515573},
issn = {1999-4915},
support = {2025C01138//Pioneer/ ; },
mesh = {Humans ; *Viral Nonstructural Proteins/chemistry/genetics/metabolism ; *Coronavirus/genetics/drug effects/physiology/metabolism ; *Antiviral Agents/pharmacology ; Animals ; Virus Replication ; Immunity, Innate ; Mutation ; Autophagy ; Host-Pathogen Interactions ; Endoplasmic Reticulum/metabolism ; Coronavirus Infections/virology/drug therapy ; },
abstract = {Coronaviruses encode a variety of non-structural proteins (NSPs) that collectively mediate viral genome replication, transcription and remodeling of the host cellular microenvironment. As a highly conserved transmembrane protein, non-structural protein 6 (NSP6) predominantly localizes to the endoplasmic reticulum. Through interactions with other viral proteins and host factors, NSP6 participates in multiple pivotal processes, including the formation and stabilization of double-membrane vesicles (DMVs), reprogramming of lipid metabolism, blockade of autophagic flux, and evasion of innate immunity. Recent advances in structural biology and research on virus-host interactions have further elucidated the essential roles of NSP6 throughout the viral life cycle. Mutations in NSP6 are closely associated with viral adaptability, transmissibility and pathogenicity. Herein, we comprehensively review the latest advances on the molecular structure, biological functions and mutation hotspots of coronavirus NSP6, as well as its implications for antiviral research. This review aims to provide a theoretical basis for further dissecting the pathogenic mechanisms of coronaviruses and developing broad-spectrum antiviral drugs.},
}
@article {pmid42515595,
year = {2026},
author = {Ilsby, CS and Kristensen, TL and Bagge, K and Bukh, J and Lisby, JG and Schneider, UV},
title = {Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515595},
issn = {1999-4915},
support = {Project number: 101102733//The DURABLE project/ ; },
mesh = {Humans ; *RNA Viruses/isolation &amp; purification/genetics/pathogenicity/classification ; *Nucleic Acid Amplification Techniques/methods ; *RNA Virus Infections/diagnosis/virology ; Urine/virology ; RNA, Viral/genetics ; Feces/virology ; Body Fluids/virology ; },
abstract = {Nucleic acid amplification tests (NAATs) are central to modern virology diagnostics. However, evidence supporting alternative specimen types remains uneven across viral families, especially for emerging viruses. This limits diagnostic flexibility in outbreak and clinically complex settings. We conducted a scoping review of NAAT detectability across key body sites for human RNA viruses. PubMed and Embase were systematically searched for studies reporting NAAT results from urine, blood, fecal, cerebrospinal fluid, or respiratory specimens. Data were independently screened and synthesized to summarize specimen-specific detectability for each virus. From 8676 screened records, 321 studies were included, covering 39 viruses across 25 RNA virus families. Detectability across specimen types varied substantially between viruses. Consistent detection across multiple specimens was observed for few viruses, including SARS-CoV-2, Zika virus, and HIV, whereas many emerging viruses were evaluated in a single body compartment with limited comparative data. NAAT performance across specimen types is highly virus-specific and unevenly studied, with reliance on blood or respiratory specimens, potentially overlooking viable, less invasive alternatives. Evidence gaps are particularly pronounced for urine and cerebrospinal fluid, and heterogeneous reporting limits cross-study comparability. Standardized, cross-specimen and longitudinal studies are needed to improve diagnostic strategies, outbreak preparedness, and future assay development.},
}
@article {pmid42515597,
year = {2026},
author = {Lin, S and Zhang, G and Wang, Q and Niu, K and Liu, Q},
title = {Mechanisms Underlying the Induction of Immunological Imprinting by RNA Viruses and Intervention Strategies.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515597},
issn = {1999-4915},
support = {202549CE340077//Yunnan Key Laboratory of Screening and Research on Anti-pathogenic Plant Resources from Western Yunnan/ ; FZ2023ZD029, FZ2024YB004, FZ2025YB056//Dali University/ ; },
mesh = {Humans ; Animals ; *RNA Viruses/immunology/genetics ; Immunologic Memory ; Memory B Cells/immunology ; Orthomyxoviridae/immunology/genetics ; SARS-CoV-2/immunology/genetics ; B-Lymphocytes/immunology ; Dengue Virus/immunology ; *RNA Virus Infections/immunology/virology ; Coronavirus/immunology ; },
abstract = {The inherent genomic plasticity of RNA viruses, particularly influenza viruses and SARS-CoV-2, poses a major obstacle to the establishment of durable herd immunity. This challenge is further compounded by immune imprinting, whereby prior antigenic exposures bias subsequent responses toward previously encountered epitopes at the expense of effective recognition of antigenically drifted variants. In this review, we delineate the mechanistic basis of immune imprinting, with emphasis on the competitive dominance of cross-reactive memory B cells (MBCs). We discuss how the rapid "back-boosting" of these pre-existing clones can limit de novo priming of naïve B cells-through epitope masking and competition for antigen and T follicular helper cell support-thereby diverting germinal center selection and affinity maturation away from variant-specific de novo epitopes and promoting viral immune escape. To address this challenge, this article further reviews the characteristics of immune imprinting responses in influenza viruses, coronaviruses, and dengue virus, as well as corresponding countermeasures, providing a theoretical basis and new avenues for intervention to address immune imprinting induced by rapidly mutating RNA viruses.},
}
@article {pmid42515606,
year = {2026},
author = {Soares, VC and Dias, SSG},
title = {Antiviral Candidates and Vaccine Development for the Neglected Oropouche Virus.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515606},
issn = {1999-4915},
mesh = {*Orthobunyavirus/immunology/drug effects/genetics ; *Bunyaviridae Infections/prevention &amp; control/drug therapy/virology/immunology ; Animals ; *Antiviral Agents/pharmacology ; Humans ; *Viral Vaccines/immunology ; *Vaccine Development ; },
abstract = {The Oropouche virus (OROV), an orthobunyavirus primarily transmitted by the biting midge Culicoides paraensis, is the causative agent of Oropouche fever, a re-emerging arboviral disease associated with significant morbidity in Central and South America. The increasing frequency of outbreaks, including cases of sustained transmission in non-endemic regions and reports of vertical transmission, highlights the growing public health concern posed by OROV. Currently, there are no specific antiviral therapies or licensed vaccines available, underscoring the urgent need for effective therapeutic and preventive strategies. Recent advances in antiviral research have identified promising candidates, including repurposed drugs and bioactive compounds that target key stages of the viral replication cycle. In parallel, vaccine development has progressed through modern platforms, including viral vector-based and nucleic-acid-based technologies, enabling rapid responses to emerging outbreaks. However, major challenges remain, particularly due to the limited understanding of OROV pathogenesis, virus-host interactions, and the correlates of protective immunity. Furthermore, the ongoing evolution of OROV, including the genetic diversity and potential genomic rearrangements observed among circulating strains, represents an additional challenge that may influence viral characteristics and potentially affect the long-term efficacy of antiviral interventions and vaccine-induced protection. This review summarizes recent advances in the discovery of antiviral candidates and the development of vaccine approaches against OROV, both of which are essential for reducing the impact of OROV infections and strengthening preparedness for future outbreaks.},
}
@article {pmid42515632,
year = {2026},
author = {Setar, L and Coates, B},
title = {Age-Dependent Differences in the Antiviral Response of the Respiratory Epithelium.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515632},
issn = {1999-4915},
support = {1T32HL076139/NH/NIH HHS/United States ; R01HL168672//National Heart Lung and Blood Institute/ ; P01HL154998//National Heart Lung and Blood Institute/ ; R01AI177498//National Institute of Allergy and Infectious Diseases/ ; },
mesh = {Humans ; *Respiratory Mucosa/immunology/virology ; Animals ; Age Factors ; Immunity, Innate ; *Respiratory Tract Infections/immunology/virology ; COVID-19/immunology/virology ; Child ; *Virus Diseases/immunology ; SARS-CoV-2/immunology ; Infant ; Adult ; Respiratory Syncytial Virus Infections/immunology ; },
abstract = {Age is an established risk factor for severe viral respiratory infections, yet the mechanisms driving increased severity of illness in infants and older adults remain incompletely understood. The respiratory epithelium is the primary target of viral infection and how it orchestrates the immune response may be a key determinant of clinical outcomes. The profound age-related difference in susceptibility to severe Coronavirus disease 2019 (COVID-19) brought increased attention to the epithelial response to viral infection in children and adults, adding significant data to the preexisting body of work largely focused on influenza and respiratory syncytial virus (RSV). This review synthesizes current knowledge on the structural and functional differences in the respiratory epithelium between children and adults at baseline and during viral infection. We review the variable and heterogenous human studies in addition to in vitro and animal model data to identify key gaps in current knowledge. Here, we advocate for a more complete understanding of age-dependent differences in the respiratory epithelial response to viral infection to uncover therapeutic targets for prevention and treatment of viral-associated respiratory failure.},
}
@article {pmid42515655,
year = {2026},
author = {Du, S and Wang, Y and Liu, C and Han, Y and Zong, R and Wang, S and Du, W and Yu, L and Li, Y},
title = {Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515655},
issn = {1999-4915},
support = {No. 32573409, No. 32172839//National Natural Science Foundation of China/ ; No. 252300423606//Natural Science Foundation of Henan/ ; },
mesh = {Humans ; *Antiviral Agents/pharmacology/therapeutic use ; Animals ; *Drug Repositioning/methods ; *Coronavirus/drug effects ; *Coronavirus Infections/drug therapy/virology ; },
abstract = {Coronaviruses (family Coronaviridae) are enveloped, positive-sense, single-stranded RNA viruses with broad host adaptability. They transmit across species among humans, livestock, companion animals, and wildlife, eliciting a disease spectrum ranging from mild respiratory and gastrointestinal symptoms to fatal multi-organ failure, thereby posing significant challenges to global health. In this context, drug repurposing has emerged as a practical strategy for rapidly identifying broad-spectrum antivirals against emerging and re-emerging coronaviruses. Using coronaviruses as a paradigm, this review systematically summarizes research advances and mechanistic insights into the repurposing of existing drugs against coronaviruses. Simultaneously, we dissect core challenges including species-specific pharmacokinetic disparities, insufficient inter-genera conservation of viral targets, and systemic barriers between human and veterinary drug regulatory frameworks and propose innovative solutions encompassing AI-driven cross-species drug prediction, next-generation cross-species infection models, and a "human-veterinary dual-track" collaborative research and development system. Collectively, this review highlights the promise of drug repurposing as a broad-spectrum antiviral strategy and provides a translational perspective for the development of cross-species anti-coronavirus therapeutics.},
}
@article {pmid42515657,
year = {2026},
author = {Helena, AL and Ozanique, PR and Lima, KHS and Tondato, WN and Baio, VYI and Soares, OHL and Regasini, LO},
title = {Chalcones as a Versatile Antiviral Scaffold: Molecular Targets, ADMET Profiles, and Translational Challenges.},
journal = {Viruses},
volume = {18},
number = {7},
pages = {},
pmid = {42515657},
issn = {1999-4915},
support = {Finance code 001//the Coordena&#xe7;&#xe3;o de Aperfei&#xe7;oamento de Pessoal de N&#xed;vel Superior-Brasil (CAPES)/ ; },
mesh = {*Antiviral Agents/pharmacology/chemistry ; *Chalcones/pharmacology/chemistry/pharmacokinetics ; Humans ; Animals ; Drug Discovery ; Structure-Activity Relationship ; Virus Replication/drug effects ; Molecular Docking Simulation ; Virus Internalization/drug effects ; Virus Diseases/drug therapy ; Plant Viruses/drug effects ; },
abstract = {Chalcones are naturally occurring open-chain flavonoids widely distributed in plants and recognized for their broad spectrum of pharmacological activities. Their versatile scaffold allows for extensive structural modifications, leading to a diverse range of natural and synthetic derivatives with notable biological potential. In the context of viral infections, chalcones have demonstrated remarkable efficacy against a variety of human pathogens, including dengue virus, HIV, HCV, influenza A, SARS-CoV-2, and other emerging viruses. Beyond human health, several chalcones have shown potent activity against plant viruses such as tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV), and animal viruses including porcine reproductive and respiratory syndrome virus (PRRSV) and mammalian reovirus (MRV), underscoring their broad antiviral spectrum. These compounds act through multiple mechanisms, including the inhibition of viral enzymes (e.g., proteases, polymerases, and integrases), interference with viral entry and replication, and the modulation of host-related pathways. Recent advances in molecular docking, structure-activity relationship (SAR) studies, and synthetic optimization have further highlighted chalcones as a promising scaffold for antiviral drug discovery. Accordingly, this review summarizes and categorizes antiviral chalcones reported over the last two decades, emphasizing and critically discussing their molecular targets, mechanisms of action, and pharmacological potential as lead compounds. It also provides a comparative perspective on their pharmacological relevance by correlating their activities against standard therapeutic agents and reference inhibitors. Furthermore, the most recurrent viral targets were critically discussed regarding their conservation, expected genetic barriers to resistance, and the global SAR trends identified for the corresponding antiviral chalcones. Finally, in silico ADMET profiling of the most promising naturally occurring chalcones was performed to evaluate their drug-likeness and pharmacokinetic properties, offering guidance for future structural optimization and translational development. Collectively, these findings highlight the chalcone scaffold as a versatile platform for the development of novel antiviral agents targeting diverse viral and host pathways.},
}
@article {pmid42515812,
year = {2026},
author = {Kozlova, AA and Borokh, VN and Oslovsky, VE and Alexeev, CS and Drenichev, MS},
title = {Chiral-Modified Nucleoside Analogues: From Bioactivity to Therapeutic Applications.},
journal = {Pharmaceuticals (Basel, Switzerland)},
volume = {19},
number = {7},
pages = {},
pmid = {42515812},
issn = {1424-8247},
support = {25-24-01136//Russian Science Foundation/ ; },
abstract = {Nucleosides are extensively employed for the development of pharmaceuticals, chemotherapeutic agents, and bioregulators. Background/Objectives: The introduction of an additional chiral functionality into a carbohydrate or heterocyclic base fragment may increase the selectivity of interactions with nucleos(t)ide-metabolizing enzymes and receptors and, in some cases, lead to more specific physiological activities. Methods: An improvement of the selectivity of nucleoside-based drugs can be achieved either by the chemical modification of a carbohydrate or a base constituent or by a combination of these two approaches. Additionally, stereospecific enzymatic cleavage of nucleos(t)ide prodrugs containing biodegradable substituents can reduce cytotoxicity and enhance bioavailability. Results: A series of enantiomerically pure nucleosides modified at the ribose or heterocyclic base were obtained by chemical and enzymatic methods. Novel antiviral or anticancer active compounds, inhibiting viral or cellular enzymes or activating cellular nucleoside kinases have been found among chemically synthesized derivatives. Some exhibit strengthened "ligand-receptor" interaction, acting on receptors of the purinergic signaling system. During recent extensive structure-activity studies, several drugs and their prototypes have been proposed for the treatment of viral infections: the 2'C-fluoromethyl derivative of sofosbuvir (anti-SARS-CoV, preclinical), VV-261 (SFTSV, phase I clinical), balapiravir (dengue, phase I clinical), mericitabine (approved drug for HCV), and lumicitabine (approved drug for RSV and HMPV). Conclusions: Modern literature data within the scope of the present review suggest that direct modification of nucleosides with various chiral functionalities can be considered as an approach to increase their efficacy, specificity and selectivity.},
}
@article {pmid42515816,
year = {2026},
author = {Chen, X and Ding, S},
title = {Post-COVID-19 rise in central precocious puberty: an integrative Review.},
journal = {Journal of pediatric endocrinology &amp; metabolism : JPEM},
volume = {},
number = {},
pages = {},
pmid = {42515816},
issn = {2191-0251},
abstract = {The COVID-19 pandemic was associated with a marked increase in central precocious puberty (CPP), particularly among girls, with pooled estimates showing higher odds during pandemic than pre-pandemic periods. The available evidence supports a reproducible epidemiological signal, but it does not establish a single causal mechanism. This narrative review synthesizes epidemiological findings, clinical features, and proposed mechanisms, including sedentary behavior, weight gain, increased screen exposure, sleep and melatonin rhythm disruption, psychological stress, altered healthcare-seeking behavior, and environmental endocrine-disrupting chemicals (EDCs). Recent high-throughput toxicology data indicate that selected environmental compounds, including musk ambrette and some quaternary ammonium compounds (QACs), can activate human KISS1R- or GnRHR-related signaling in experimental systems. However, pediatric exposure levels, internal dose, target-tissue concentrations, and disease-level causality remain unproven. We therefore frame these chemical findings as a hypothesis-generating exposomic perspective rather than as an established explanation for pandemic-era CPP. A cautious integrative model may help reconcile the strong female predominance, limited mean BMI shift, and temporal association with lockdown-related exposures, while defining testable priorities for future cohort, exposure, and mechanistic studies.},
}
@article {pmid42515932,
year = {2026},
author = {Vahid, F and Stopa, V and Malisoux, L and Devaux, Y and Lamy, E and Silva, FCE and Forberger, S and de Magistris, T and Sureda, A and Monserrat-Mesquida, M and Pérez-Jiménez, M and Nagrani, R and Onorati, MG and Fontefrancesco, MF and Turner, J and Desai, MS and Tur, J and Bouzas, C and Bonetti, GG and Riedel, O and Ravn-Haren, G and Andersen, R and Bohn, T},
title = {Established and Emerging Biomarkers to Characterize Persons at Risk for Obesity-Paving the Way for Targeted Clinical Intervention Trials-A Comprehensive Position Paper.},
journal = {Obesity reviews : an official journal of the International Association for the Study of Obesity},
volume = {},
number = {},
pages = {e70175},
doi = {10.1111/obr.70175},
pmid = {42515932},
issn = {1467-789X},
support = {n&#xb0;101080645//European Union's Horizon Europe Research and Innovation Programme/ ; CB12/03/30038//CIBEROBN/ ; 101016072//EU Horizon 2020 project COVIRNA/ ; C14/BM/8225223//National Research Fund/ ; C17/BM/11613033//National Research Fund/ ; COVID-19/2020-1/14719577/miRCOVID//National Research Fund/ ; CA17129//COST Association/ ; CA21153//COST Association/ ; //Ministry of Higher Education and Research/ ; //Heart Foundation-Daniel Wagner of Luxembourg/ ; //Co-operative Research Programme (OCDE) (2023): Sustainable Agriculture and Food Systems/ ; },
abstract = {Despite all efforts, obesity remains a major health concern worldwide, with continuously increasing rates, affecting approx. 14% of the total world population, being as high as 43% in some countries. As obesity is related to numerous comorbidities, including type 2 diabetes, cardiovascular diseases, and some types of cancer, the consequences for the individual and society at large are drastic. Therefore, it is crucial to understand and predict who is at risk of developing obesity in order to implement early prevention strategies. Many individual risk factors have been emphasized. However, as obesity is a rather multifactorial complication, single markers/biomarkers have thus far not allowed for an efficient prediction of obesity. In addition to less modifiable parameters, such as environment and socio-demographics, studies have revealed that obesity is related to several interacting aspects, including host factors such as genetics/epigenetics or gut microbiota, and more readily modifiable factors, including nutrition and physical activity, as well as sleep patterns and psychological well-being. It is likely that combining markers from across different domains, that is, multimodal markers, allows for better predictability for the risk of developing obesity. However, it must be considered that not all markers are fully predictive; many are rather reactive or even both. In this review and position paper, we emphasize the state-of-the-art regarding (bio)markers that have successfully been employed for predicting obesity risk. An emphasis will rest on novel, emerging biomarkers, and the need for a more integrative, multimodal assessment of obesity risk for a combined assessment aimed at improving risk prediction.},
}
@article {pmid42516401,
year = {2026},
author = {Theoharides, TC and Papadopoulou, P},
title = {Pathogen effects on the brain: the case of SARS-CoV-2 spike protein and neuro COVID.},
journal = {Frontiers in neurology},
volume = {17},
number = {},
pages = {1853951},
pmid = {42516401},
issn = {1664-2295},
abstract = {Many patients develop cognitive and neuropsychiatric issues after viral infections, but the mechanisms are not well understood. A case in point is Long-COVID syndrome, which may affect as many as 50 percent of patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is characterized by lingering physical and mental fatigue, brain fog and neuropsychiatric symptoms. Meanwhile, emerging evidence suggests the presence of inflammation around blood vessels in the brain due to the Spike protein remaining in "reservoirs" especially in the meninges that contain great numbers of the unique tissue immune cells, mast cells (MCs). In fact, Spike protein has been reported to stimulate MCs and microglia to release pro-inflammatory, neurotoxic and vasoactive mediators leading to Long-COVID and other neurodegenerative disorders. Thus, it is of great urgency to gain insight into how the Spike protein and neuroinflammatory molecules contribute to Long-COVID and how to regulate this response.},
}
@article {pmid42518594,
year = {2026},
author = {Liao, H and Gao, Y},
title = {Experiences of team collaboration among intensive care nurses during COVID-19: a qualitative systematic review and meta-synthesis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1852917},
pmid = {42518594},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/nursing ; *Cooperative Behavior ; Qualitative Research ; *Critical Care Nursing/organization &amp; administration ; *Patient Care Team/organization &amp; administration ; Adaptation, Psychological ; Pandemics ; Intensive Care Units ; SARS-CoV-2 ; *Nursing Staff, Hospital/psychology ; },
abstract = {OBJECTIVE: This study included qualitative studies and employed a meta-synthesis to assess the support, challenges, and coping strategies related to teamwork among Intensive Care Unit (ICU) nurses during the Corona Virus Disease 2019 (COVID-19) pandemic.<br><br>DESIGN: Qualitative meta-synthesis.<br><br>METHODS: A systematic search was conducted across five databases: PubMed, Web of Science, Embase, CINAHL, and PsycINFO. The search period covered from inception to December 11, 2025. The study employed the three-stage thematic synthesis approach by Thomas and Harden, aided by the NVivo 14 software.<br><br>FINDINGS: A total of 48 qualitative studies were included, and six main themes with thirteen sub-themes were identified: (1) the support and understanding received from colleagues, the team, and management; (2) interpersonal unfamiliarity and tension; (3) instability in the team structure; (4) managerial inadequacies; (5) team adaptability; (6) empowered teamwork.<br><br>CONCLUSION: Beyond the need for psychological support from colleagues, the team, and management, it was found that strengthening organizational resilience was key to improving teamwork.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD420261281080, identifier PROSPERO (CRD420261281080).},
}
@article {pmid42518759,
year = {2026},
author = {Lee, J and Almomani, Y and Davis, A and Miller, M and Li, P and Cockayne, D and Premji, S and MacEachen, E},
title = {Home-based telework and worker health and well-being across service occupations: A critical interpretive synthesis.},
journal = {SSM - population health},
volume = {35},
number = {},
pages = {101951},
pmid = {42518759},
issn = {2352-8273},
abstract = {The rapid expansion of home-based telework since COVID-19 has diversified the remote workforce to include service occupations centered on real-time interaction with patients, clients, and customers. Yet the literature on telework and health remains largely oriented toward the experiences of knowledge workers, obscuring how home-based telework shapes the health and well-being of interaction-intensive service workers. We conducted a Critical Interpretive Synthesis of 69 peer-reviewed studies (2000 to 2025) to develop a theoretical account of how home-based telework is experienced across service occupations. The evidence base was profoundly skewed: 64 studies examined healthcare and social work professionals, while only three focused on scripted, routinized, and monitored service roles such as call and contact center work. The synthesis identified two divergent narratives, each reflecting a distinct labor process through which home-based telework shapes worker health and well-being. For healthcare and social work professionals, home-based telework eroded the institutional boundaries that had contained clinical distress within the workplace, transforming the home into a "contaminated sanctuary" as the emotional and psychological demands of care work increasingly spilled into private life. For call and contact center workers, while home-based telework initially appeared to reduce direct physical surveillance, control was reconstituted through digital technologies, producing a "digital panopticon" marked by algorithmic monitoring, enforced immobility, and the collapse of work-home boundaries. These findings suggest that the health consequences of home-based telework are shaped as much by the organization and demands of the work being performed as by the domestic setting.},
}
@article {pmid42518987,
year = {2026},
author = {Gittinger, R and Halper, E and Nur, N and Kennar, A and Thomas, H and Loh, S and Byrd, KM and Ehlman, D and Bustamante, ND},
title = {A scoping review of the available literature on the epidemiologic profile of migrants in-transit through South America, Central America, and Mexico from 2013-2025.},
journal = {Journal of migration and health},
volume = {14},
number = {},
pages = {100422},
pmid = {42518987},
issn = {2666-6235},
abstract = {BACKGROUND: Migration through Latin America has increased, resulting in new routes and greater diversity among migrants. Timely, accurate data on the epidemiologic profiles of migrants in-transit could inform public health surveillance and interventions.<br><br>OBJECTIVE: Provide an overview of the type of data collected on the epidemiologic profiles of migrants in-transit through South America, Central America, and Mexico.<br><br>METHODS: We conducted a scoping review from peer-reviewed and grey literature reporting quantitative health data on selected infectious and non-infectious diseases, vaccination coverage, and causes of mortality migrants in-transit through South America, Central America, and Mexico between 2013 and 2025 by searching Embase, Medline, Global Health, Sociological Abstracts, Scopus, LILACS, NTIS, OpenGrey, and MedRxlv.<br><br>RESULTS: We identified 7,355 publications; 124 met inclusion criteria. Of these, 24% specified a transit migration phase. Cross-sectional methodology was employed in 86%; and 62% were published in the last four years (2022-2025). Sociodemographic variables were inconsistently reported, and migration-related variables were infrequent. Health concepts frequently investigated included HIV (28%), TB (14%) COVID-19 (15%), mental health (33%), food insecurity (14%), mortality (10%) and vaccination (6%). Chronic conditions were frequently reported as comorbidities.<br><br>CONCLUSION: Limited detailed information is available to inform health surveillance and interventions among migrants in-transit. Additional migration-related variables, including time in-transit and transit migration phase, an expansion of data collection to geographical areas experiencing an increase in mobility, and rigorous study designs could yield valuable insights.},
}
@article {pmid42519268,
year = {2026},
author = {Menoudji Djetoyom, P and Ngueilbaye, A and Abakar Hamid, A and Akofala, A},
title = {Mapping COVID-19 Artificial Intelligence (AI) Research in Medical Imaging: A Bibliometric Analysis of Datasets, Trends, and Clinical Challenges.},
journal = {Cureus},
volume = {18},
number = {6},
pages = {e111190},
pmid = {42519268},
issn = {2168-8184},
abstract = {The rapid adoption of artificial intelligence (AI) for COVID-19 pandemic diagnosis has exposed critical gaps in medical imaging datasets. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant bibliometric review of 450 PubMed studies (2020-2024) reveals that only 21.5% of the datasets remain clinically validated, while 55% are unavailable or repurposed from non-COVID-19 sources. We identified persistent issues, such as resolution heterogeneity and radiologist annotation scarcity, that undermine model reliability. Numerous convolutional neural network (CNN) architectures have been developed to enable fast and accurate automated diagnosis of COVID-19 using computed tomography (CT) or X-ray imaging. However, due to the urgency of the pandemic and the rapid demand for solutions, existing computer-aided diagnostic (CAD) systems face several critical limitations, such as imbalanced datasets, insufficient bias assessment in model training, and inconsistent quality control in image acquisition and preprocessing. In this bibliometric analysis, we provide an analysis of PubMed articles on COVID-19 imaging published between January 1, 2020, and November 1, 2024. The research included 1261 publications. VOSviewer was used to generate a visual map of the keyword networks and authors. The journal with the most publications was Elsevier, and the most used dataset was the COVID-19 Radiography Database from Kaggle.},
}
@article {pmid42519317,
year = {2026},
author = {Neelakantan, HJ},
title = {FcγR-ACE2 cooperative antibody-dependent enhancement in human and veterinary coronaviruses: mechanistic insights, comparative immunology, and implications for nano-engineered immunomodulatory platforms.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1859321},
pmid = {42519317},
issn = {1664-3224},
mesh = {Humans ; *Receptors, IgG/immunology/metabolism ; Animals ; *Antibody-Dependent Enhancement/immunology ; SARS-CoV-2/immunology ; *Angiotensin-Converting Enzyme 2/immunology ; COVID-19/immunology ; *Antibodies, Viral/immunology ; *Coronavirus Infections/immunology/veterinary/virology ; *Peptidyl-Dipeptidase A/immunology ; *Coronavirus/immunology ; *Betacoronavirus/immunology ; Virus Internalization ; },
abstract = {Antibody-dependent enhancement (ADE) is a paradoxical immunological phenomenon in which pre-existing antibodies facilitate viral entry into host cells rather than conferring protection. ADE has been extensively characterised in flaviviral systems, most notably dengue virus (DENV), and presents a significant challenge for vaccine development and antibody-based therapeutic design. In coronavirus infections, ADE may operate through both classical Fc gamma receptor (FcγR)-mediated pathways and an intrinsic signalling mechanism involving inhibitory FcγRIIb-mediated suppression of the type I interferon (IFN-I) response. Of critical translational relevance is the functionally demonstrated cooperative FcγR-ACE2 entry model for SARS-CoV-2, wherein virus-antibody immune complexes engage Fcγ receptors and require ACE2 interaction for efficient enhancement. For SARS-CoV-2 specifically, ADE magnitude appears to be determined by an antibody's capacity to block spike-ACE2 interaction rather than its neutralisation potency in vitro-a finding distinct from FIPV and other coronavirus ADE systems where classical FcγR-mediated mechanisms predominate without ACE2 co-receptor dependency. Feline infectious peritonitis virus (FIPV) represents one of the most rigorously documented biological systems in which antibody-mediated macrophage infection directly determines systemic disease outcome. This comprehensive review integrates current knowledge of FcγR biology, IgG subclass dynamics, antibody glycosylation, coronavirus cell entry mechanisms, intracellular signalling cascades, cytokine dysregulation, comparative veterinary immunopathology, and nano-engineered immunomodulatory platforms for ADE-safe vaccine development. No confirmed clinical ADE has been documented to date in mRNA-vaccinated populations, though theoretical risk windows and population-specific vulnerabilities are critically discussed.},
}
@article {pmid42519879,
year = {2026},
author = {Sivel, I and Rief, W and Weise, C},
title = {Psychotherapy Research During the COVID-19 Pandemic: Trends in Treatment Modalities and Digital Therapy Uptake (2019-2023).},
journal = {Clinical psychology &amp; psychotherapy},
volume = {33},
number = {4},
pages = {e70311},
pmid = {42519879},
issn = {1099-0879},
mesh = {Humans ; *COVID-19 ; *Psychotherapy/trends/methods ; *Telemedicine/trends ; Randomized Controlled Trials as Topic ; Pandemics ; Mental Health Teletherapy ; Digital Health ; Cognitive Behavioral Therapy/trends ; SARS-CoV-2 ; Digital Media ; *Mental Disorders/therapy/psychology ; },
abstract = {The COVID-19 pandemic necessitated rapid transitions to digital psychotherapy delivery formats, yet systematic quantification of these developments within psychotherapy research remains limited. This study presents an updated trend analysis of psychotherapy randomized controlled trials (RCTs) from 2019 to 2023. Systematic searches in PubMed, Web of Science and PsycINFO identified RCTs across predefined psychotherapeutic intervention categories. Trials were categorized by treatment approach, region and age group. A total of 1223 psychotherapy RCTs were identified. Despite a temporary decline in 2022 (-13%), the overall number of trials increased by 26.3% across the study period. eHealth interventions constituted the largest psychotherapeutic intervention category (43%), surpassing cognitive behavioural therapy (CBT; 37%). Among eHealth trials, 71% evaluated internet-delivered CBT. Only eHealth and telehealth showed statistically significant increases in proportional representation over time. Other therapeutic approaches each represented < 7% of treatment arms and showed no significant proportional change. Trial activity remained concentrated in high-income countries (73.4%) and predominantly targeted adult populations, with children and adolescents comprising 17.3% of trials. The findings illustrate a dynamic field that remained active during the COVID-19 crisis, with eHealth emerging as the most frequently investigated therapeutic approach accompanied by substantial growth in telehealth interventions. Despite the overall growth in trial activity, research efforts remained heavily concentrated around CBT-derived interventions, adult populations and high-income country settings.},
}
@article {pmid42520549,
year = {2026},
author = {Hülsemann, M and Kniffert, S and Löwa, A and Baumgardt, M and Hönzke, K and Vallone, VF and Drude, NI and Stüdemann, T and Ali, ASM and Arroyo Araujo, M and Bannach-Brown, A and Brunotte, L and Faist, A and Fatykhova, D and Fischer, M and Hellwig, L and Hinse, S and Kessler, M and Carlisle, BG and Khankeh, S and Dhamrait, IS and Klein, C and Koceva, H and Kumar, S and Kurreck, J and Ludwik, KA and Mergenthaler, P and Schmerbeck, SS and Singh, S and Teixeira Alves, LG and Wyler, E and Stachelscheid, H and Hippenstiel, S and Toelch, U and Hocke, AC},
title = {Low reporting quality limits the contribution of human organ models to COVID-19 research: a systematic review.},
journal = {EBioMedicine},
volume = {130},
number = {},
pages = {106392},
doi = {10.1016/j.ebiom.2026.106392},
pmid = {42520549},
issn = {2352-3964},
abstract = {BACKGROUND: The COVID-19 pandemic created a unique situation in which researchers repurposed human models of varying complexity to investigate SARS-CoV-2, providing the opportunity to analyse their contribution across organs.<br><br>METHODS: We conducted a systematic review of 558 studies, divided into pandemic and post-pandemic periods, to assess how human models were applied to investigate host factors, viral replication of SARS-CoV-2, immune responses, and to evaluate reporting quality.<br><br>FINDINGS: Our analysis revealed substantial limitations that were only partially alleviated in post-pandemic studies. These limitations included heterogeneity of outcome measures, incomplete documentation of model characteristics and experimental procedures, and variable reporting quality, which were associated with reduced cross-study comparability, more difficult risk-of-bias assessment, and limited reliability and interpretability of evidence synthesis and meta-analytical results.<br><br>INTERPRETATION: Strengthening community-driven reporting standards and methodological transparency is essential to enable robust evidence synthesis and to fully realise the potential of human organ models in future pandemics and translational research.<br><br>FUNDING: The study was supported by Einstein Foundation Berlin; Federal Ministry of Research, Technology and Space; European Union; Else Kr&#xf6;ner-Fresenius-Stiftung; Volkswagen Foundation; Charit&#xe9; 3R; Foundation Charit&#xe9;.},
}
@article {pmid42522246,
year = {2026},
author = {Kubo, M},
title = {The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity.},
journal = {Immunological reviews},
volume = {341},
number = {1},
pages = {e70148},
pmid = {42522246},
issn = {1600-065X},
support = {19gm1310002//Japan Agency for Medical Research and Development (AMED)/ ; 25K10403//Japan Society for the Promotion of Science/ ; },
mesh = {Humans ; *Immunologic Memory ; Animals ; *SARS-CoV-2/immunology ; *CD4-Positive T-Lymphocytes/immunology ; Vaccination ; *Influenza, Human/immunology ; *COVID-19/immunology/prevention &amp; control ; *COVID-19 Vaccines/immunology ; *Influenza Vaccines/immunology ; Antibodies, Neutralizing/immunology ; Memory T Cells/immunology ; },
abstract = {CD4[+] T cells orchestrate adaptive immunity against respiratory viruses through functionally distinct subsets, yet the qualitative differences between vaccine- and infection-induced responses remain incompletely understood. This review summarizes current evidence on how CD4[+] T cell subsets shape the magnitude, breadth, and durability of immunity to SARS-CoV-2 and influenza virus. mRNA vaccines elicit a potent Th1/Tfh1-biased response that generates high-affinity neutralizing antibodies and cytotoxic CD4[+] T cells (CD4-CTLs) with stem-cell memory properties. However, this strong type I bias may come at the cost of long-term maintenance of humoral memory. Natural infection additionally establishes tissue-resident memory CD4[+] T cells (CD4 TRMs) at respiratory mucosal surfaces, providing a frontline defense that current intramuscular vaccines fail to recapitulate efficiently. Crucially, this T cell immunity proves far more resilient than neutralizing antibodies against Variants of Concern, as many memory T cell epitopes from the ancestral strain are conserved across successive variants, a robustness further reinforced by pre-existing cross-reactive CD4[+] T cells primed through prior seasonal coronavirus exposure or influenza infection. These observations argue for a fundamental shift in vaccine design toward mucosal delivery and conserved-epitope antigens to achieve durable, broadly cross-reactive protection.},
}
@article {pmid42522402,
year = {2026},
author = {Böhler, LI and Koeppel, L and Weber, SF and Gaeddert, M and Thielemann, K and Glaser, K and Ismail, HM and Reinacher, U and Jaeger, VK and Böhnke, J and Bartz, A and Pavic, M and Harries, M and Kuczewski, C and Heinsohn, T and Hovardovska, O and Huei, SY and Xu, C and Gottschick, C and Contreras, S and Filinski, M and Grilli, M and Lange, B and , and Denkinger, CM},
title = {Impact of Non-Pharmaceutical Interventions Targeted at COVID-19 Pandemic on Influenza Burden-A Systematic Review and Meta-Analysis.},
journal = {Influenza and other respiratory viruses},
volume = {20},
number = {8},
pages = {e70301},
pmid = {42522402},
issn = {1750-2659},
support = {031L0298C//Federal Ministry of Education and Research (BMBF)/ ; MV2021-012//Federal Ministry of Education and Research (BMBF)/ ; FKZ031L0298B//Federal Ministry of Education and Research (BMBF)/ ; 031L0298G//Federal Ministry of Education and Research (BMBF)/ ; 031L0298F//Federal Ministry of Education and Research (BMBF)/ ; },
mesh = {Humans ; *Influenza, Human/epidemiology/prevention &amp; control ; *COVID-19/epidemiology/prevention &amp; control ; Incidence ; *Pandemics/prevention &amp; control ; Global Health ; },
abstract = {Seasonal influenza imposes a substantial global health burden. The COVID-19 pandemic, accompanied by widespread non-pharmaceutical interventions (NPIs), profoundly disrupted respiratory virus circulation, offering a unique opportunity to assess their broader epidemiological impact. This study aimed to quantify changes in influenza burden between the pre-pandemic and intra-pandemic periods. Within the RESPINOW project, we conducted a systematic review following PRISMA guidelines. Studies reporting absolute influenza case counts before and during the pandemic were included. Data extraction and quality assessment were performed using a modified NHLBI tool for before-after studies. Influenza cases were normalized by reporting period length, and relative changes were estimated using incidence rate ratios. Subgroup analyses explored age, setting, hemisphere, human development index, influenza transmission zones, WHO regions, and viral strains. Of 20,676 screened records, 115 studies from 98 countries were included. Globally, influenza incidence declined by -92% (95% CI: -94 to -90) following the onset of the pandemic. Reductions varied geographically, ranging from near-elimination in several countries to more modest declines (e.g., South Korea: -61%, 95% CI: -79 to -26). Decreases were observed across all transmission zones and WHO regions, with descriptively larger reductions observed in high-income countries (-96%, 95% CI: -98 to -94) than in low-income settings (-82%, 95% CI: -88 to -73). Age-specific declines appeared smaller among young children (< 6 years: -66%, 95% CI: -79 to -45) compared with adults aged 18-64 years (-80%, 95% CI: -90 to -63). Influenza A appeared to decline more strongly than influenza B. The COVID-19 pandemic was associated with an unprecedented global reduction in influenza incidence. Data limitations and the need for robust epidemiological indicators highlight the importance of strengthened, integrated global surveillance to inform future pandemic responses.},
}
@article {pmid42522596,
year = {2026},
author = {Zhao, Y and Lees, S and Palmer, J and Nyikuri, M and Beckmann, N},
title = {Understanding anthropological contributions to infectious disease outbreak preparedness and response: a scoping review of key trends since 2019.},
journal = {Anthropology &amp; medicine},
volume = {},
number = {},
pages = {1-18},
doi = {10.1080/13648470.2026.2688493},
pmid = {42522596},
issn = {1469-2910},
abstract = {This review explores how anthropology has been applied in outbreak preparedness and response since the onset of COVID-19 in 2019, identifying key trends and providing recommendations to its integration into global health practice. Our search of four databases yielded 68 studies published between 2019 and August 2024. Most studies (71%) focused on COVID-19, followed by Ebola (17%). Nearly half examine African contexts (46%), with fewer studies in Asia (26%), Europe (8%) and North America (4%). Existing studies predominantly address outbreak response rather than preparedness. Key themes include: local knowledge and the governance of outbreaks; the heterogeneity of communities and the vital role of local leaders; power dynamics and mistrust; and growing recognition of multispecies, zoonotic and planetary health dimensions. The review highlights persistent structural inequalities, with anthropological engagement in outbreak preparedness and response deeply shaped by Global North dominance. It calls for more critical and inclusive approaches to local leadership, challenging assumptions about representation, authority and trust. While rapid methods enable timely insights, they also involve trade-offs in depth and long-term engagement. Addressing these challenges requires more equitable partnerships, sustained investment in Global South capacity and participation, and deeper engagement with the structural, cultural and political dimensions of health emergencies.},
}
@article {pmid42524094,
year = {2026},
author = {Mishra, D and Pattnaik, S},
title = {Understanding the biology of mucormycosis using contemporary omics tools: a review.},
journal = {Biotechnologia},
volume = {107},
number = {2},
pages = {205-220},
pmid = {42524094},
issn = {2353-9461},
abstract = {Mucormycosis (the "black fungus infection") is a life-threatening angioinvasive fungal infection caused by opportunistic fungi of the class Mucormycetes. A lot of clinical exercises were made in the post-coronavirus disease 2019 period due to admission of patients suffering from so called "black fungus disease". Many of patients had been operated for excision of their vital organs, colonized with massive fungal mycelia to restrict further invasion. In these circumstances, this apt article endeavour to scrutinize and debate some of the viable factors and prospective mechanisms that can assist to understand and elucidate the enigma of sudden, steep and deadly upsurge of mucormycosis infection. Here we review the specific contribution of high-throughput next-generation sequencing and multi-omics-based approaches to the general knowledge and understanding of Mucormycetes and further detail about the most exciting discoveries pertaining to the recently identified genetic advancements in Mucormycetes and mucormycosis. Through the use of a few genetic study models virulence factors in Mucormycetes that were previously unknown have been identified. Most remarkably, new research has opened up new possibilities for developing novel treatments against mucormycosis by identifying novel genes and process governing the pathogenic potential of Mucormycetes and their interaction with host. Ultimately virulence investigations in Mucormycetes that were previously hindered are now possible with new study models indicating a promising future for the field leading to the development of therapies to treat mucormycosis.},
}
@article {pmid42524579,
year = {2026},
author = {Ludovici, GM and Tassi, PA and Iannotti, A and Russo, C and Quaranta, R and Manenti, G and Malizia, A},
title = {Emerging zoonotic threats: HKU5-CoV-2 and the CBRNE approach to pandemic prevention.},
journal = {Infectious diseases &amp; immunity},
volume = {6},
number = {1},
pages = {72-77},
pmid = {42524579},
issn = {2693-8839},
abstract = {The emergence of HKU5-CoV-2, a novel lineage in the Merbecovirus subgenus, represents a potential zoonotic threat with significant implications for global health. This bat-derived virus, which is phylogenetically similar to the Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus 2, has demonstrated the ability to use the human angiotensin-converting enzyme 2 receptor to enter human cells. Although no human infections have been reported, its zoonotic potential raises the possibility of spillover events, which could lead to widespread transmission and, under certain conditions, pandemics. This study explores the virological characteristics, epidemiological risks, and clinical implications of HKU5-CoV-2, emphasizing its capacity to cross species barriers and cause severe respiratory diseases. To address the potential for a future pandemic, we propose a theoretical response framework based on the Chemical, Biological, Radiological, Nuclear, and Explosive approach traditionally employed for high-consequence biological threats. This strategy integrates early detection through advanced genomic surveillance, rapid containment measures, the development of targeted medical countermeasures, effective risk communication, and international collaboration. By leveraging lessons from previous coronavirus outbreaks, this framework aims to mitigate the impact of a potential HKU5-CoV-2 spillover and to ensure a coordinated and efficient global response. This study underscores the importance of preparedness in the face of emerging zoonotic viruses and provides a roadmap for managing future biological threats of pandemic potential.},
}
@article {pmid42525082,
year = {2026},
author = {Souza, FC and Souza, KP and Scaramello, CBV},
title = {Evaluating the Relationship Between Plasma Cell-Free Mitochondrial DNA (cf-mtDNA) Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis.},
journal = {Anais da Academia Brasileira de Ciencias},
volume = {98},
number = {suppl 1},
pages = {e20251250},
doi = {10.1590/0001-3765202620251250},
pmid = {42525082},
issn = {1678-2690},
mesh = {*DNA, Mitochondrial/blood ; Humans ; *COVID-19/blood ; Severity of Illness Index ; SARS-CoV-2 ; Pandemics ; *Coronavirus Infections/blood ; *Cell-Free Nucleic Acids/blood ; *Pneumonia, Viral/blood ; Biomarkers/blood ; *Betacoronavirus ; Cross-Sectional Studies ; },
abstract = {The objective of the study was to evaluate the convergence between cell-free mitochondrial DNA (cf-mtDNA) and COVID-19. This was a systematic review and meta-analysis of cohort and cross-sectional studies, considering the best level of evidence available and the protocol was registered in PROSPERO (CRD 42024508173). After the criteria were established, the search encompassed three databases (MEDLINE, EMBASE, and Web of Science) to identify studies that evaluated the possible convergence between cf-mtDNA and the development of COVID-19, verifying its relationship with survival and severity. A Microsoft Excel spreadsheet was used for data extraction, and R software for analysis. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklists. After the identification and screening processes, eleven studies were selected for the final analysis, that revealed a convergence between elevated levels of cf-mtDNA and the development of COVID-19 (MD=0.70, IC95% 0.39-1.01, p<0.001) and its relationship with the disease severity (MD=1.08, IC95% 0.35-1.82, p=0.004), but not with survival (MD=0.58, IC95% -0.24-1.41, p=0.16). Conclusions: These findings contribute to a better understanding of cf-mtDNA's role in COVID-19 pathogenesis, its potential as a promising biomarker, and pave the way for the identification of new therapeutic targets.},
}
@article {pmid42525146,
year = {2026},
author = {Majewska, M and Harshkova, D and Aksmann, A},
title = {NSAIDs in the environment: a 2020-2025 review of impacts on plant and algal Physiology.},
journal = {Ecotoxicology (London, England)},
volume = {35},
number = {6},
pages = {},
pmid = {42525146},
issn = {1573-3017},
support = {UMO-2023/49/N/NZ8/02077//National Science Centre, Poland/ ; },
mesh = {*Anti-Inflammatory Agents, Non-Steroidal/toxicity ; *Water Pollutants, Chemical/toxicity ; Oxidative Stress/drug effects ; Photosynthesis/drug effects ; *Plants/drug effects ; },
abstract = {Non-steroidal anti-inflammatory drugs (NSAIDs) belong to the most frequently detected pharmaceutical pollutants in aquatic ecosystems, raising growing concern about their effects on non-target primary producers. Unlike earlier reviews, based mainly on data collected before the year 2020, when environmental exposure levels were substantially lower, this work synthesizes research conducted over the last five years (2020-2025), a period that includes the SARS-CoV-2 pandemic. The pandemic was associated with a sharp global increase in the consumption of NSAIDs, resulting in their markedly elevated environmental loads. Consequently, the studies assessed in this review reflect plant and algal responses under significantly higher contamination pressures than those reported in pre-pandemic decades, offering a new perspective on their phytotoxic potential. A systematic literature search retrieved over 5,000 records, from which the most relevant experimental studies were selected for detailed evaluation. The compiled evidence demonstrates that NSAIDs adversely affect photosynthesis, induce ultrastructural damage to chloroplasts, and compromise mitochondrial respiration, including alterations in membrane potential and ATP production. Exposure to NSAIDs triggers oxidative stress responses, characterized by reactive oxygen species overproduction, lipid peroxidation, and variable changes in antioxidant enzyme activity. Beyond primary metabolism, numerous reports document disruptions in growth patterns, root system architecture, mineral balance, and secondary metabolite biosynthesis. By integrating the most up-to-date findings from a period of exceptionally intense pharmaceutical pollution, this review provides a novel and more realistic assessment of the ecological risks posed by NSAIDs. It underscores the urgency of developing stricter environmental quality standards and highlights key directions for future research under contemporary contamination scenarios.},
}
@article {pmid42526183,
year = {2026},
author = {Kaburu, FM and Zhu, P and Kudiza, A and McDonnell, D and da Veiga, CP and Nie, JB and Xiang, YT and Su, Z},
title = {AI for mental disorders and diabetes comorbidity management: A scoping review.},
journal = {General hospital psychiatry},
volume = {102},
number = {},
pages = {105-114},
doi = {10.1016/j.genhosppsych.2026.06.009},
pmid = {42526183},
issn = {1873-7714},
abstract = {BACKGROUND: The comorbidity of mental disorders and diabetes is on the rise, presenting a significant global public health challenge that gravely impacts the physical and psychological health of patients and presents obstacles to their effective management. The coronavirus disease 2019 (COVID-19) pandemic, in particular, aggravated these challenges owing to restrictions on in-person care. Artificial intelligence (AI) interventions have emerged as a promising solution to alleviate this burden. Thus, we conducted a scoping review to map the current evidence in the literature and provide a clear understanding of AI for mental disorders and comorbid diabetes.<br><br>METHODS: This scoping review utilized the Arksey &amp; O'Malley framework. Five electronic databases were systematically searched for studies published in the post-COVID era, focusing on AI-assisted approaches for individuals with mental disorders and comorbid diabetes.<br><br>RESULTS: Twenty-four studies were reviewed. Supervised learning algorithms were most commonly employed, with studies reporting positive performance metrics, while generative AI was essentially absent. The findings demonstrated promising outcomes in four functional domains: Risk assessment, Prediction, Diagnosis, and Personalised care. AI applications are predominantly at the capability stage of translation maturity, focusing mainly on model development and validation, with limited adoption in existing clinical workflows. Other limitations include little demographic reporting, limited external validation, scarce intervention-focused research, and ethical concerns.<br><br>CONCLUSION: AI shows promise in enhancing support for individuals with mental disorders and diabetes through targeted, data-driven strategies. Future studies should prioritize clinically integrated, patient-centred AI interventions and evaluate their effectiveness in improving functional outcomes, while addressing ethical considerations.},
}
@article {pmid42526994,
year = {2026},
author = {Innes, R and Petrie, JR and Dejgaard, TF},
title = {Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next.},
journal = {Endocrinology and metabolism clinics of North America},
volume = {55},
number = {3},
pages = {421-435},
doi = {10.1016/j.ecl.2026.04.002},
pmid = {42526994},
issn = {1558-4410},
mesh = {Humans ; *Diabetes Mellitus, Type 1/drug therapy/blood ; *Glucagon-Like Peptide-1 Receptor Agonists ; *Hypoglycemic Agents/administration &amp; dosage/therapeutic use/adverse effects ; Continuous Glucose Monitoring ; Glucagon-Like Peptide-1 Receptor ; Peptides/administration &amp; dosage ; },
abstract = {Phase 2 clinical trials using daily injectable glucagon-like peptide-1 receptor agonists as adjunct therapy in type 1 diabetes showed promising signals for efficacy on glycemic control and weight. These effects were confirmed in larger phase 3 trials but accompanied by safety issues including hypoglycemia and ketosis. Of note, these trials were conducted before the availability of widespread continuous glucose monitoring (CGM) and used simple one size fits all rules for insulin dose titration. Attention has moved on to weekly injectable agents at present, with more individualized insulin titration and guided by CGM.},
}
@article {pmid42527933,
year = {2026},
author = {Seabi, T and Barr, BAT and Kabudula, CW and Herbst, K and Ohene-Kwofie, D and Bashingwa, J and Dube, A and Kahn, K and Tollman, S},
title = {Strengthening data, analytic and scientific writing skills: Insights from working with 17 health and demographic surveillance system (HDSS) centres in sub-Saharan Africa and South Asia.},
journal = {Population health metrics},
volume = {23},
number = {Suppl 2},
pages = {},
pmid = {42527933},
issn = {1478-7954},
mesh = {Humans ; COVID-19/epidemiology ; Africa South of the Sahara/epidemiology ; *Population Surveillance/methods ; Asia, Southern ; SARS-CoV-2 ; Pandemics ; Capacity Building ; Public Health Infrastructure ; *Demography ; },
abstract = {In the ever-evolving landscape of global health, Health and Demographic Surveillance Systems (HDSS) generate rare and valuable longitudinal data for understanding health and population dynamics and their determinants in low- and middle-income countries, where vital registration systems are often weak. However, the utility of HDSS centres relies heavily on the capabilities of those responsible for cleaning, describing and analysing the wealth of data they generate. This paper describes our targeted strategy for strengthening the capacity of personnel in HDSS research settings, particularly focusing on data managers and analysts. Additionally, we explore the unique challenges created by the COVID-19 pandemic for HDSS research centres, emphasizing the need for a skilled workforce to navigate complex data dynamics. Our approach involved three in-person workshops dedicated to data preparation, analysis, and scientific writing, supplemented by weekly online check-ins and a 25-week writing program. Each workshop included two representatives from participating sites with skills aligned to the workshops. Following two years of intensive capacity building, this project has yielded 15 original research manuscripts currently under review, forming part of a journal special issue on the impact of COVID-19 on mortality in African and South Asian populations. Open-access aggregated data will complement these papers.},
}
@article {pmid42528790,
year = {2026},
author = {Jabin, MSR and Bi, N and Thomas, S and Ashfaq, A and Nilsson, E},
title = {The impact of training and education programs for healthcare professionals on video- and text-based consultations in ensuring healthcare quality: a scoping review.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1861018},
pmid = {42528790},
issn = {2673-253X},
abstract = {BACKGROUND: The rapid expansion of video- and text-based consultations has transformed healthcare delivery, particularly during and after the COVID-19 pandemic. As virtual care becomes embedded in routine practice, healthcare professionals require appropriate training to deliver safe and effective digital healthcare.<br><br>OBJECTIVE: This scoping review aimed to map and synthesize evidence on training and education programs designed to prepare healthcare professionals for video- and text-based consultations and to examine reported outcomes, facilitators, and barriers.<br><br>METHODS: This review followed Joanna Briggs Institute methodology and was reported in accordance with PRISMA-ScR and PRISMA-S guidelines. Multiple bibliographic databases and grey literature sources were searched for studies published between January 1, 2003, and December 24, 2024. Eligible studies included those involving healthcare professionals receiving training in video consultations or text-based communication. Two reviewers independently conducted study selection and data extraction. Findings were synthesized descriptively.<br><br>RESULTS: Twenty studies were included. Training approaches varied considerably and included workshops, webinars, online modules, simulations, telehealth Objective Structured Clinical Examinations, and hybrid programs. Most studies reported improvements in confidence, perceived competence, and readiness to provide virtual care. However, outcomes were predominantly based on short-term self-reported measures, with limited evidence relating to long-term skill retention, patient outcomes, or organizational impact. Most included studies focused on video-based consultations, while evidence relating specifically to text-based consultation training was limited. Common challenges included virtual physical examinations, technological barriers, and maintaining patient engagement.<br><br>CONCLUSIONS: Telehealth training programs are increasingly used to support healthcare professionals in delivering video- and text-based consultations. The available evidence is concentrated on learner-focused outcomes, whereas patient-level, organizational, and long-term outcomes remain underexplored. To our knowledge, this is the first scoping review to synthesize training approaches across both video- and text-based consultation modalities. Future research should prioritize longitudinal evaluation, patient and organizational outcomes, and modality-specific competency development to support sustainable digital healthcare delivery.},
}
@article {pmid42529082,
year = {2026},
author = {Xi, B and Zhao, Y and Fu, W and Ling, Y and Zhuang, Q and Zhang, D},
title = {High-flow nasal oxygen in perioperative and critical care: a bibliometric analysis.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1856380},
pmid = {42529082},
issn = {2296-858X},
abstract = {BACKGROUND: High-flow nasal oxygen (HFNO), also known as high-flow nasal cannula, is an important noninvasive respiratory support strategy in perioperative and critical care practice. As the literature has expanded across multiple clinical contexts, a structured overview is needed to clarify the development, knowledge base, and emerging priorities of the field.<br><br>METHODS: We conducted a bibliometric and visual analysis of HFNO research using English-language articles and reviews retrieved from the Web of Science Core Collection, Scopus, and PubMed for the period 2000-2025. After screening, merging, and deduplication, 2,314 unique publications were included. Bibliometrix in R was used for performance analysis, thematic mapping, and thematic evolution; VOSviewer for collaboration analysis; and CiteSpace for co-citation analysis, keyword clustering, timeline visualization, burst detection, and dual-map overlay.<br><br>RESULTS: HFNO research showed sustained exponential growth, with marked acceleration after 2018 and especially after 2020. The literature was concentrated in respiratory medicine, critical care, and anesthesiology journals, with Respiratory Care ranking first in publication output. The United States and China were the leading contributors, while several French institutions, particularly Assistance Publique-H&#xf4;pitaux de Paris, were prominent in the institutional network. Co-citation analysis identified major clusters related to acute respiratory failure, perioperative oxygen therapy, preoxygenation strategies, and coronavirus disease. Keyword and thematic analyses indicated a shift from early emphasis on perioperative oxygenation and postoperative respiratory support toward broader critical care application and, more recently, toward context-specific deployment, acute hypoxemic respiratory failure, awake prone positioning, treatment monitoring, and the ROX index.<br><br>CONCLUSION: HFNO research has evolved from a focused literature on oxygenation support into a broader and more clinically differentiated field spanning perioperative and critical care practice. Current hotspots are increasingly centered on context-specific use, monitoring, failure prediction, and escalation decisions. Future research should prioritize clinically actionable patient stratification, standardized outcome definitions, and protocol-based integration of HFNO across different care pathways.},
}
@article {pmid42529130,
year = {2026},
author = {Cao, Z and Song, Y and Li, J and Cao, Y},
title = {The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1837477},
pmid = {42529130},
issn = {2297-055X},
abstract = {SARS-CoV-2 infection not only leads to severe respiratory diseases but also has a significant impact on the cardiovascular system, inducing acute cardiac injury and various long-term cardiovascular complications. Non-coding RNAs (ncRNAs), as key molecules in gene expression regulation, exhibit important regulatory roles in viral infections and cardiovascular pathological processes. Current research indicates that ncRNAs such as miRNA, lncRNA, and circRNA participate in the occurrence and development of cardiac injury related to SARS-CoV-2 infection by regulating apoptosis, metabolic reprogramming, and cell communication. However, there are still many challenges and unresolved mysteries regarding their specific regulatory networks and clinical applications. This review systematically summarizes the expression changes and functional characteristics of ncRNAs in COVID-19-related cardiovascular diseases, focusing on their potential as biomarkers and therapeutic targets, and combining the latest multi-omics data and cutting-edge technologies to anticipate the development direction of precise interventions and personalized treatments.},
}
@article {pmid42529204,
year = {2026},
author = {Li, Y and Liao, W and Liang, Q and Li, Y},
title = {Toll-like receptors in infectious myocarditis: pathogen-specific recognition, spatiotemporal dynamic regulation and clinical translation.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1881939},
pmid = {42529204},
issn = {2297-055X},
abstract = {Infectious myocarditis is a life-threatening cardiovascular inflammatory disorder characterized by high heterogeneity in clinical onset, progression and prognosis. Large-sample clinical data have demonstrated that the in-hospital mortality of COVID-19-associated myocarditis reaches 19.4%, significantly higher than that of influenza-associated myocarditis (10.5%). Additionally, the incidence of adeno-associated virus (AAV) gene therapy-related myocarditis is 6.2%, while the mortality of sepsis-associated myocarditis is as high as 70%-90%. Toll-like receptors (TLRs), the core pattern recognition receptors of innate immunity, dominate the entire pathological cascade, ranging from pathogen recognition and acute inflammatory burst to myocardial injury and chronic fibrous remodeling. Nevertheless, most current studies merely focus on the linear correlation between individual TLR activation and myocardial inflammation, failing to systematically clarify pathogen-TLR matching specificity and the spatiotemporal dynamic regulatory mechanisms of TLR signaling throughout disease progression. This review comprehensively combs the latest epidemiological profiles of infectious myocarditis, characterizes the expression patterns and signaling regulatory features of the TLR family within the cardiac immune microenvironment, analyzes pathogen-specific recognition modes mediated by common pathogens, elaborates the spatiotemporal regulatory rules of TLR signaling across acute inflammation, immune deviation and chronic fibrosis stages, and summarizes pathogen-oriented intervention strategies as well as relevant translational bottlenecks. Cumulative clinical evidence confirms that pathogen-TLR matching determines inflammatory phenotypes and severity of infectious myocarditis, and that the spatiotemporal dynamics of TLR signaling directly govern disease progression. Notably, TLR-targeted therapies must adhere to the core principles of pathogen specificity and staged precise regulation. This review provides a systematic theoretical basis for precise immunodiagnosis and individualized immunotherapy of infectious myocarditis.},
}
@article {pmid42531590,
year = {2026},
author = {Suárez-Moreno, V},
title = {COVID-19 pandemic response in South American countries: lessons learned and recommendations for health strengthening.},
journal = {Revista peruana de medicina experimental y salud publica},
volume = {43},
number = {2},
pages = {260-266},
doi = {10.17843/rpmesp.2026.432.15674},
pmid = {42531590},
issn = {1726-4642},
mesh = {*COVID-19/prevention &amp; control/epidemiology ; Humans ; South America/epidemiology ; Telemedicine/organization &amp; administration ; *Delivery of Health Care/organization &amp; administration ; Pandemics ; Public Health Infrastructure ; },
abstract = {The COVID-19 pandemic represented the greatest health and public management challenge of the 21st century for health systems in South America. Peru was one of the countries with the highest mortality rates globally during 2020 and 2021, a situation that evidenced deep structural gaps in its health system. This special article synthesizes the available scientific evidence on the response and lessons learned in South American countries facing the pandemic, based on a literature review published between 2020 and February 2025. It analyzes non-pharmacological interventions, the functioning of health services, the fight against the infodemic, social support, the use of telehealth, vaccination campaigns, and the innovations applied. Responses varied significantly among countries in terms of timeliness, scope, and effectiveness, allowing for the identification of key areas of intervention and replicable good practices. Among the most relevant lessons, the highlights include the need to strengthen critical health infrastructure, institutionalize telehealth, actively combat the infodemic, and promote research and innovation as strategic components of the response.},
}
@article {pmid42531714,
year = {2026},
author = {Cerri, A and Arcaro, P and Perilli, A and Veneziano, E and D'Agostino, L and Romano, A and Sessa, G and Cicciarella Modica, D and Cecchetti, L and Panà, A and Mete, R and De Vito, C and Maurici, M and Damiani, G},
title = {A scoping review on community health care centers: Evidence in support of Italian policymakers to redesign the Italian primary care system.},
journal = {Health policy (Amsterdam, Netherlands)},
volume = {172},
number = {},
pages = {105690},
doi = {10.1016/j.healthpol.2026.105690},
pmid = {42531714},
issn = {1872-6054},
abstract = {BACKGROUND: The COVID-19 pandemic underscored the central role of primary health care in managing patients with complex and chronic health conditions. In response, the Italian government launched a reform of the National Health Service, introducing Community Health Care Centers ("Case della Comunità") as a key pillar of the new primary care model. Evidence is needed on which organizational features of such centers best support integrated, high-quality care.<br><br>OBJECTIVE: This scoping review synthesized international evidence on community health care centers characterized by integrated care and co-location of professionals, to identify organizational elements relevant to the Italian reform.<br><br>METHODS: We conducted a scoping review of international literature on community health care centers. Included studies were assessed using eight integration domains derived from Valentijn's taxonomy, which were combined into an overall integration score. Additional features, including horizontal collaboration, accessibility, home care, and multiprofessional integration, were also analyzed.<br><br>RESULTS: Statistical analysis showed a positive association between horizontal collaboration, overall level of integration, and multiprofessional integration. Centers with higher integration and stronger horizontal collaboration more often reported improved organization of services and care for people with complex or chronic conditions.<br><br>CONCLUSIONS: These findings support Community Health Care Centers in Italy as integrated, multiprofessional hubs within the primary care network, where strengthened horizontal collaboration may improve quality and continuity of care for complex and chronic patients.},
}
@article {pmid42532101,
year = {2026},
author = {Opsteen, S and Erdmann, N},
title = {COVID-19 treatments: current options and therapies under investigation.},
journal = {Topics in antiviral medicine},
volume = {34},
number = {Ahead of Issue},
pages = {1-10},
pmid = {42532101},
issn = {2161-5853},
mesh = {Humans ; *COVID-19/therapy/complications ; Post-Acute COVID-19 Syndrome ; *Antiviral Agents/therapeutic use ; *COVID-19 Drug Treatment ; SARS-CoV-2/drug effects ; },
abstract = {The COVID-19 pandemic has contributed to more than 7 million deaths globally and has triggered a variety of postacute sequelae, now commonly referred to as long COVID, in millions more. Early efforts during the pandemic resulted in several therapies to mitigate the severity and mortality of acute COVID-19. However, despite effective therapies and accumulated immunity through vaccination and natural infection reducing disease severity, COVID-19 continues to contribute to hospitalizations and mortality. Long COVID encompasses several distinct yet overlapping clinical syndromes, and evidence suggests that these manifestations are mediated by numerous underlying mechanisms. There are currently no approved therapies for the treatment of long COVID, driven in part by its heterogeneity in presentation and etiology. This review will outline the current guidelines for treating acute COVID-19 and summarize information on the mechanistic rationale behind various published and ongoing clinical trials investigating potential long COVID therapeutic agents.},
}
@article {pmid42532773,
year = {2026},
author = {Evans, SJM},
title = {The Shifting Paradigm of Feline Infectious Peritonitis: New Diagnostics and Therapeutics.},
journal = {The Veterinary clinics of North America. Small animal practice},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.cvsm.2026.06.003},
pmid = {42532773},
issn = {1878-1306},
abstract = {Feline infectious peritonitis (FIP) has long represented one of the most devastating and frustrating diseases in feline medicine. Historically regarded as almost universally fatal, the FIP paradigm has shifted dramatically over the past 5 to 10 years. Safe and effective antiviral therapies, including GS-441524 and related compounds, have transformed FIP into a treatable disease with survival rates previously unimaginable. In parallel, advances in molecular diagnostics and immunocytochemical techniques have improved antemortem diagnostic confidence. This review explores the evolving understanding of FIP pathogenesis, diagnostic testing, and antiviral therapy, emphasizing the rapid pace of change and the implications for contemporary clinical practice.},
}
@article {pmid42535035,
year = {2026},
author = {Fahad, N and Sadib, RJ and Sajib, RH and Morol, MK and Nandi, D and Liew, TH},
title = {Responsible artificial intelligence in medical imaging: a systematic review.},
journal = {Frontiers in digital health},
volume = {8},
number = {},
pages = {1884692},
pmid = {42535035},
issn = {2673-253X},
abstract = {INTRODUCTION: Responsible artificial intelligence (AI) in medical imaging requires more than high diagnostic accuracy; it also requires transparent reasoning, equitable performance across patient subgroups, privacy protection, calibrated uncertainty, and clinical trustworthiness.<br><br>METHODS: This PRISMA-informed systematic review synthesized 24 studies published between 2020 and 2025 that used AI or deep learning for disease detection or diagnostic support in X-ray, CT, MRI, mammography, ultrasound, dermoscopy, retinal fundus imaging, optical coherence tomography, and abdominal CT. PubMed, Scopus, Web of Science, IEEE Xplore, ScienceDirect, SpringerLink, and Google Scholar were searched, and extracted evidence was appraised qualitatively using adapted QUADAS-2 and PROBAST-AI domains.<br><br>RESULTS: The included studies covered lung diseases, COVID-19, pneumonia, lung cancer, breast cancer, melanoma and other dermatological disorders, brain tumors, diabetic retinopathy, chest abnormalities, and pancreatic ductal adenocarcinoma. Explainability methods such as Grad-CAM, Grad-CAM++, LIME, SHAP, saliency maps, and layer-wise relevance propagation dominated the evidence base, whereas fairness, privacy-preserving learning, uncertainty estimation, and human-centered clinical trust were represented by fewer studies. Several papers reported accuracy or sensitivity above 90%, but these values should be interpreted cautiously because many studies relied on internal validation, curated public datasets, class-balanced splits, augmentation, or limited demographic reporting.<br><br>DISCUSSION: Responsible medical-imaging AI should be evaluated through multidimensional evidence, including external and subgroup validation, calibration, privacy risk analysis, clinician-centered explanation assessment, workflow integration, regulatory readiness, and post-deployment monitoring.},
}
@article {pmid42535959,
year = {2026},
author = {Liang, X and Chi, X and Deng, X},
title = {Coronavirus Nsp15 endoribonuclease: linking viral RNA regulation to immune evasion and viral fitness.},
journal = {Journal of virology},
volume = {},
number = {},
pages = {e0170025},
doi = {10.1128/jvi.01700-25},
pmid = {42535959},
issn = {1098-5514},
abstract = {Coronavirus nonstructural protein 15 (Nsp15) is a conserved uridine-preferring endoribonuclease (EndoU). Studies using mouse hepatitis virus (MHV), SARS-CoV-2, and other coronaviruses have shown that Nsp15 associates with replication-transcription complexes (RTCs) and contributes to viral immune evasion. Structural studies of alpha- and beta-coronavirus Nsp15 proteins reveal a hexameric enzyme that engages viral RNA substrates and cleaves at unpaired uridines through an RNase A-like, largely metal-independent mechanism stimulated by divalent cations. The Nsp15 hexamer functions as a dynamic, cooperative platform capable of accommodating extended double-stranded and structured RNA substrates. Genetic studies in several coronaviruses indicate that EndoU activity is dispensable for viral RNA synthesis in cell culture, but critical for suppressing host antiviral responses. Loss of EndoU activity promotes accumulation of immunostimulatory RNA species and activation of dsRNA-sensing pathways, including MDA5-dependent interferon signaling, PKR-mediated translational arrest, and the OAS/RNase L system. Mechanistically, Nsp15 is proposed to suppress these responses by selectively processing uridine-rich and structurally accessible regions in viral RNA, including poly(U)-containing negative-strand RNAs, and elements within untranslated regions and transcription regulatory sequences. Beyond catalysis, Nsp15 may contribute to RTC organization and regulate viral RNA recombination or defective viral genome formation, although these roles remain less well-defined and may vary among coronavirus species. Together, these findings support a model in which Nsp15 functions as a regulator of viral RNA composition and immunogenicity rather than solely as a degradative nuclease. This review summarizes recent advances in Nsp15 structure, RNA processing, immune evasion, and antiviral targeting, and highlights key unresolved questions.},
}
@article {pmid42536576,
year = {2026},
author = {Zheng, Q and Chen, J and Wang, N and Hou, M and Xu, X and Liu, Z},
title = {Bibliometric and visualization analysis of exercise interventions for respiratory infectious diseases (2000-2025): Trends, hotspots, and future directions.},
journal = {Medicine},
volume = {105},
number = {31},
pages = {e50013},
pmid = {42536576},
issn = {1536-5964},
mesh = {Humans ; *Bibliometrics ; COVID-19/epidemiology ; SARS-CoV-2 ; *Exercise Therapy/trends/methods ; Pandemics ; *Respiratory Tract Infections/rehabilitation/therapy ; },
abstract = {BACKGROUND: Respiratory infectious diseases impose a heavy burden on global health. Exercise-related interventions have attracted increasing research attention, but the knowledge landscape and emerging trends in this field have not yet been comprehensively mapped. This study aims to address this gap through a bibliometric and visualization analysis of the literature published between 2000 and 2025.<br><br>METHODS: A search was conducted in the Web of Science Core Collection and PubMed databases, incorporating relevant English-language literature published between January 1, 2000, and March 31, 2025. After deduplication and screening, 944 articles were ultimately included. Co-occurrence network, clustering, and emergence analyses were conducted using CiteSpace 6.4.R1 software. Descriptive statistical analyses of publication volume and country, institutional, and author distribution were performed using Microsoft Excel.<br><br>RESULTS: Publication output in this field has increased significantly since 2020, peaking in 2022, a trend highly consistent with the progression of the coronavirus disease 2019 (COVID-19) outbreak. Arena Ross, the University of London (United Kingdom), and the United States emerged as the most prolific author, institution, and country, respectively. Frequent keywords include "Physical activity," "Pulmonary rehabilitation," "Exercise," "COVID-19," "Coronavirus disease," "Rehabilitation," and "Quality of life." Keywords exhibiting high burst strength include "COVID-19 (30.04)," "Coronavirus disease (10.19)," and "respiratory tract infections (7.95)." Emerging research hotspots concentrate primarily on 3 domains: "respiratory function," "Telerehabilitation," and "dyspnea."<br><br>CONCLUSION: Research on physical activity interventions for respiratory infectious diseases has shown sustained growth over the past 25 years, undergoing significant structural shifts during the COVID-19 pandemic. This study provides a broad overview of the knowledge landscape and developmental trajectory in this field.},
}
@article {pmid42536797,
year = {2026},
author = {Khawandi, J and Kivan, H and Al Hussein, S and Azzam, M and Nazzal, J and Vasquez Camargo, A and Kamrul, R and Al Khader, A and Kawtharany, H and Al Zabibi, MA and Ahmad, J and Patel, K and Rehman, AU and Ahmed, Z and Piché, A and McNaughton, CD and Lam, GY and Oudit, GY and Afzal, S and Schunemann, H and Wiercioch, W and Nieuwlaat, R and Brignardello-Petersen, R and Falcone, EL and Mustafa, RA},
title = {The use of patient-reported outcome questionnaires in patients with post-COVID-19 condition: a systematic review and meta-analysis.},
journal = {Family practice},
volume = {43},
number = {5},
pages = {},
doi = {10.1093/fampra/cmag054},
pmid = {42536797},
issn = {1460-2229},
support = {//Public Health Agency of Canada/ ; },
mesh = {Humans ; *COVID-19/complications ; *Patient Reported Outcome Measures ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Surveys and Questionnaires ; Quality of Life ; Pandemics ; },
abstract = {BACKGROUND AND OBJECTIVE: Post-COVID-19 condition (PCC) is a complication of acute COVID-19, which often presents with a variety of symptoms. It can also impact individuals' overall well-being, capacity to carry out daily activities, engage in physical exercise, maintain employment, and their general quality of life. Therefore, this review aimed to examine the role of patient-reported outcome measures (PROMs) questionnaires in assessing patients with PCC through prevalence of abnormal tests.<br><br>METHODS: We searched three databases. Two reviewers independently screened articles using Laser Al and extracted relevant data using a piloted Google Sheets. We performed a meta-analysis using OpenMeta and RevManWeb and conducted a subgroup analysis based on the setting of the patients during their acute COVID-19 infection. We assessed the risk of bias using a modified ROBINS-I tool and the certainty using the Grading of Recommendations Assessment, Development, and Evaluation approach.<br><br>RESULTS: No studies reported diagnostic test accuracy measures for questionnaires in PCC. However, 23 comparative studies reported on the prevalence of abnormal questionnaire results in patients with PCC. Outcomes showed that patients with PCC have higher abnormal results than controls, regardless of their setting during acute COVID-19 infection. The overall certainty of the evidence was low due to the high risk of bias, indirectness, and imprecision.<br><br>CONCLUSION: This review sheds light on the importance of testing PROMs in patients with PCC using these questionnaires and the need for further testing their validity in this condition.},
}
@article {pmid42536815,
year = {2026},
author = {Kuś, A and Makuch, S and Dybko, J and Agrawal, S},
title = {Timing, Titre, and Host Determinants of Convalescent Plasma Efficacy in COVID-19: A Systematic Review With Design-Stratified Narrative Synthesis.},
journal = {Reviews in medical virology},
volume = {36},
number = {5},
pages = {e70189},
pmid = {42536815},
issn = {1099-1654},
mesh = {Humans ; *COVID-19/therapy/immunology ; COVID-19 Serotherapy ; *Antibodies, Viral/blood/immunology ; *SARS-CoV-2/immunology ; *Immunization, Passive/methods ; Treatment Outcome ; Randomized Controlled Trials as Topic ; },
abstract = {The efficacy of convalescent plasma (CP) in COVID-19 has been contested, with large randomized trials producing conflicting results that led to recommendations against routine use. We performed a systematic review with design-stratified narrative synthesis (PRISMA 2020; SWiM; OSF: https://osf.io/tjcuq) to test whether these conflicting outcomes can be reconciled through three interacting determinants-timing, antibody titre, and host characteristics-using a standardized 91-field extraction matrix applied to each study. PubMed, Web of Science, and Scopus were searched through May 2026. Thirty-one studies (20,793 patients; 8 RCTs, 23 observational) were included. The synthesis indicates that CP is effective, but only under a specific convergence of conditions: when administered early in the disease course, with sufficient antibody titre, to seronegative or immunocompromised hosts who have not yet mounted an endogenous antibody response. Among RCTs analysing timing, 4 of 6 found benefit with earlier administration; for titre, 3 of 4 RCTs with explicit comparisons found benefit with higher-titre CP; and two large RCTs (combined n = 12,522) demonstrated preferential benefit in seronegative recipients. This interpretation is consistent with modelling estimates that CP, deployed largely to hospitalised patients, nonetheless saved tens of thousands of lives in the United States during the first pandemic year, an effect attributed to the subset treated early enough to modify disease progression. A second, previously unquantified finding concerns antibody class: characterisation of non-IgG immunoglobulins was nearly absent, with only 2 of 31 studies-both from our group-reporting IgA or IgM data, despite evidence that IgA and IgM are among the most potent neutralising classes against SARS-CoV-2. This hypothesis-generating observation identifies a systematic gap in CP product assessment. These findings reframe CP efficacy from a binary question to a conditional one and provide a template for the precision deployment of passive immunotherapy in future pandemics.},
}
@article {pmid42536824,
year = {2026},
author = {Focosi, D and Aiello, TF and Casadevall, A and Cruciani, M and D'Abramo, A and De Marco, P and Gachoud, D and Garcia-Vidal, C and Glingani, C and Hueso, T and Joyner, MJ and Lacombe, K and Mengoli, C and Nicastri, E and Richier, Q and Rufer, N and Senefeld, JW and Shoham, S and Sullivan, DJ and Tomisti, L and Weinbergerova, B and Zani, M and Zaremba, S and Franchini, M},
title = {Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.},
journal = {Reviews in medical virology},
volume = {36},
number = {5},
pages = {e70185},
pmid = {42536824},
issn = {1099-1654},
mesh = {Humans ; *Immunocompromised Host ; *SARS-CoV-2/immunology ; *Antibodies, Monoclonal/therapeutic use/immunology ; *COVID-19/therapy/immunology/virology ; Immunization, Passive/methods ; COVID-19 Serotherapy ; *Antibodies, Viral/therapeutic use/immunology ; *Spike Glycoprotein, Coronavirus/immunology/antagonists &amp; inhibitors ; },
abstract = {Anti-Spike monoclonal antibodies (mAbs) progressively lost efficacy during the COVID-19 pandemic due to the emergence and predominance of resistant SARS-CoV-2 variants. By contrast, high-titre COVID-19 convalescent plasma (CCP) collected from vaccinated donors recently recovered from infection provides a polyclonal source of antibodies that remains effective in clearing SARS-CoV-2 in immunosuppressed patients, unable to mount an adequate immune response against the virus. We conducted a systematic review and individual participant data meta-analysis to examine the effect of CCP in immunocompromised patients persistently positive for SARS-CoV-2 viraemia following mAb therapy, and to evaluate possible biological factors associated with a favourable outcome. Electronic databases were searched for studies published from January 2020 to January 2026. All studies including eligible cases were considered in the systematic review. Unpublished cases were also collected from investigators of the selected studies. The protocol was registered at PROSPERO (CRD420251142891). Forty-seven cases (30 cases from 12 published studies and 17 unpublished cases) were included. In 33 out of 47 patients (70.2%) with a mAb-resistant infection, SARS-CoV-2 clearance occurred following CCP transfusion, with a mean of 2.7 CCP units administered. In logistic regression, total CCP volume transfused was positively associated with SARS-CoV-2 clearance. In conclusion, CCP transfusion was associated with SARS-CoV-2 clearance in persistently positive immunocompromised patients following failure of anti-Spike mAb therapy.},
}
@article {pmid42538553,
year = {2026},
author = {Li, JJ and Fu, ML and Kong, LF and Zhao, ZY and Ohore, OE and Bergquist, R and Tanner, M and Yang, GJ},
title = {Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.},
journal = {Infectious diseases of poverty},
volume = {15},
number = {1},
pages = {},
pmid = {42538553},
issn = {2049-9957},
support = {Hys2025-466//Hainan Medical University Graduate Innovative Research Project/ ; 82260655//National Natural Science Foundation of China/ ; ZDYF2024SHFZ083//Key Research and Development Program in Hainan Province/ ; },
mesh = {Humans ; *Noncommunicable Diseases/prevention &amp; control/epidemiology/therapy ; *Communicable Diseases/epidemiology/therapy ; Neoplasms ; },
abstract = {BACKGROUND: Evidence increasingly shows close, bidirectional links between infectious diseases (IDs) and non-communicable diseases (NCDs). However, research, health policy, and prevention practices still largely address them in separate frameworks. This scoping review summarises the current evidence on the interconnections between IDs and NCDs and explores integrated strategies for their prevention and management.<br><br>METHODS: This scoping review systematically searched PubMed, Web of Science, and Scopus for English-language systematic reviews and meta-analyses published between Jan 1, 2000, and April 20, 2026.&#xa0;Two reviewers independently screened eligible studies and extracted effect estimates for associations between IDs and NCDs. Evidence was grouped into two themes: associations between infectious agents and cancer, and the effects of NCDs on susceptibility to or severity of IDs.<br><br>RESULTS: From 5799 records identified, 41 meta-analyses or systematic reviews met the inclusion criteria. The included reviews showed associations between pathogen infections and specific cancers, including hepatitis B and C virus infections with liver cancer, human papillomavirus infection with cervical cancer, and Helicobacter pylori infection with gastric cancer. IDs were also associated with an increased risk or burden of NCDs, as illustrated by the association between tuberculosis and chronic obstructive pulmonary disease. Conversely, NCDs could affect susceptibility to and outcomes of IDs; patients with diabetes or cardiovascular disease had higher risks of severe disease&#xa0;or adverse outcomes following tuberculosis, influenza, or COVID-19&#xa0;infection.<br><br>CONCLUSION: IDs and NCDs can interact through shared mechanisms, overlapping risk factors, and bidirectional pathways, underscoring the need for integrated strategies that combine prevention, early detection, treatment, and long-term management. At the public health level, this calls for health policies and financing mechanisms to move beyond disease-specific silos towards systemic frameworks that support integrated prevention and control, coordinated management, and cross-sectoral action.},
}
@article {pmid42541079,
year = {2026},
author = {Zhang, Y and Song, Z and Hong, W and He, X and Wei, X},
title = {Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy.},
journal = {Genes &amp; diseases},
volume = {13},
number = {6},
pages = {102200},
pmid = {42541079},
issn = {2352-3042},
abstract = {Respiratory mucosal (RM) immunity is a highly specialized and dynamic network that safeguards the airways from inhaled pathogens while preserving tissue homeostasis. Acting as the body's first line of defense, RM immunity integrates immune tolerance, barrier protection, immune surveillance, tissue repair, and the establishment of long-term immunological memory. Dysregulation of these processes contributes to a broad spectrum of diseases, including acute viral and bacterial infections, fungal colonization, and chronic inflammatory disorders, highlighting the urgent need for effective preventive strategies targeting the respiratory mucosa. The unprecedented global impact of coronavirus disease 2019 (COVID-19) has further highlighted this need and catalyzed rapid advances in vaccines capable of inducing both local and systemic immunity at the respiratory portal of entry, alongside progress in inhalable antibody therapies. This review first summarizes the principal biological functions of the respiratory mucosa and the underlying mechanisms, followed by an overview of immune dysregulation associated with respiratory diseases. It then highlights recent advances in mucosal intervention strategies, with a particular focus on the development of RM vaccine platforms-including live-attenuated, inactivated, viral vector, protein subunit, and mRNA vaccines. It further discusses next-generation RM vaccine strategies emphasizing upper airway immunity, broadened antigen design and intranasal safety. Together, these advances provide a conceptual and translational framework for advancing RM-based interventions against respiratory pathogens.},
}
@article {pmid42541600,
year = {2026},
author = {Zuccotti, G and Scavone, IAM and Cordaro, E and Rossi, V and Calcaterra, V},
title = {Telemedicine in pediatrics: a critical narrative review of innovations, limitations, and future priorities.},
journal = {European journal of pediatrics},
volume = {185},
number = {8},
pages = {},
pmid = {42541600},
issn = {1432-1076},
mesh = {Humans ; *Telemedicine/trends/organization &amp; administration ; *Pediatrics/trends/methods ; Child ; Digital Health ; },
abstract = {UNLABELLED: This narrative review synthesizes recent technological and organizational developments in pediatric telemedicine, maps their principal clinical applications, and critically discusses implementation, safety, equity, and future priorities. This narrative review used a transparent, non-systematic literature-search approach in PubMed/MEDLINE, Scopus, and Google Scholar, considering publications available through April 2026. Searches were intended to identify and contextualize relevant literature across pediatric settings rather than to provide an exhaustive, reproducible systematic evidence synthesis. No formal risk-of-bias assessment, meta-analysis, or certainty-of-evidence grading was undertaken; therefore, findings are interpreted cautiously and according to the maturity and consistency of the available evidence. Evidence suggests that telemedicine can support follow-up, access to specialist care, and family engagement in several pediatric chronic-care pathways, particularly diabetes and asthma. However, the evidence base is heterogeneous across specialties, frequently relies on observational or implementation studies, and is less mature for acute assessment, neonatal and rehabilitation uses, wearables, and AI-enabled tools.<br><br>CONCLUSION: Telemedicine should be considered a complementary component of pediatric healthcare rather than a replacement for in-person assessment. Hybrid models may support accessibility, continuity, and sustainability when embedded in structured, patient-centered, equitable, and clinically appropriate pathways.<br><br>WHAT IS KNOWN: &#x2022; Telemedicine expanded rapidly in pediatrics during the COVID-19 pandemic and is now used across many specialties. &#x2022; It can improve access, continuity of care, remote monitoring, and family engagement, especially in chronic and complex conditions.<br><br>WHAT IS NEW: &#x2022; This review summarizes recent technological and organizational innovations, including wearables, mHealth, EHR integration, AI, and hybrid care models. &#x2022; It highlights current limits and future requirements for safe, equitable, and sustainable integration into routine pediatric care.},
}
@article {pmid42541646,
year = {2026},
author = {Sadat Larijani, M and Bavand, A and Moradi, L and Ramezani, A},
title = {Past achievements and future perspectives of personalized vaccines and the role of dendritic cells.},
journal = {Immunologic research},
volume = {74},
number = {1},
pages = {},
pmid = {42541646},
issn = {1559-0755},
mesh = {Humans ; *Dendritic Cells/immunology/transplantation ; *Precision Medicine/methods ; *Cancer Vaccines/immunology ; *Neoplasms/immunology/therapy ; Animals ; Antigens, Neoplasm/immunology ; mRNA Vaccines/immunology ; Vaccine Development ; Protein Subunit Vaccines ; *COVID-19/immunology/prevention &amp; control ; },
abstract = {Personalized vaccines provide the advantage of patient-specific antigen selection to optimize immune responses, a strategy extensively explored in oncology through neoantigen-targeted peptide, mRNA, and dendritic cell platforms. Peptide vaccines provide simplicity and stability though often elicit limited cytotoxic T-cell responses. What is more, mRNA vaccines lead to rapid, multiplexed neoantigen delivery, endogenous antigen processing and eventually improved immunogenic coverage. Dendritic cell-based vaccines have the potency to prime potent T-cells although this technology requires labor-intensive manufacturing and extensive production timelines. Integration with immune checkpoint inhibitors, adoptive cell therapies, and oncolytic viruses further enhances efficacy, suggesting that rational combinations may be more effective than single modalities. Recent advances in sequencing, computational epitope prediction, and bioinformatics pipelines have facilitated neoantigen prioritization and DC vaccine design, enabling more rapid and precise personalization. Hybrid vaccination strategies, such as ex-vivo mRNA-electroporated dendritic cells and in-vivo DC-targeted platforms, bridge the gap between manufacturing feasibility and potent immune activation. Emerging technologies, including AI-driven neoepitope prediction, receptor-targeted antigen delivery, biomaterial-based modulation, and distributed mRNA manufacturing, seem to be promising approaches to accelerate personalized vaccine development in future. From another point of view, lessons learned from the COVID-19 pandemic accelerated the development, large-scale deployment, and validation of mRNA vaccine platforms for infectious diseases. Host HLA diversity, prior immune history, and viral evolution create heterogeneity in immune responses, highlighting opportunities for semi-personalized or adaptive strategies. In this review, we provide a landscape of personalized vaccines, with a focus on DC-based platforms, and explore translational lessons for viral pathogens. A conceptual framework linking cancer immunotherapy and infectious disease preparedness is proposed, emphasizing hybrid personalization approaches, rapid manufacturing, and AI-enabled epitope selection. This perspective highlights how convergence of immunology, computational biology, and advanced vaccine technologies could expand the scope of personalized vaccination, from oncology to future epidemic and pandemic scenarios as well as the current challenges.},
}
@article {pmid42543609,
year = {2026},
author = {Tada, M and Aoyama, M and Ishii-Watabe, A},
title = {[Perspectives on the Future of Antibody Therapeutic Use for the Prevention and Treatment of Infectious Diseases].},
journal = {Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan},
volume = {146},
number = {8},
pages = {709-721},
doi = {10.1248/yakushi.26-00014},
pmid = {42543609},
issn = {1347-5231},
mesh = {Humans ; *Antibodies, Monoclonal/therapeutic use ; Emergency Use Authorization ; SARS-CoV-2/immunology ; *COVID-19 Drug Treatment ; Spike Glycoprotein, Coronavirus/immunology ; Drug Development/trends ; *COVID-19/prevention &amp; control ; },
abstract = {Antibodies are endogenous proteins that are involved in humoral immunity. Although various therapeutic monoclonal antibodies (mAbs) targeting cancer and immune diseases have been widely used, the development of mAbs for the treatment of infectious diseases has remained limited. During the coronavirus disease 2019 (COVID-19) pandemic, various mAbs targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed, received Emergency Use Authorization (EUA), and were used for treating and preventing COVID-19. As successive SARS-CoV-2 variants emerged and the pandemic spread, mAbs with high target specificity proved less effective against these variants. Consequently, their EUAs were suspended within a short period, highlighting the limitations of antiviral mAbs developed against emerging infectious diseases. Since 2021, guidance documents on mAbs for prevention and treatment of COVID-19 have been issued by the WHO and US FDA, and efforts to prepare a regulatory environment supportive of drug development for future emerging and re-emerging infectious diseases have accelerated. The EMA published a concept paper on development of guidelines for non-clinical and clinical evaluation of mAbs for COVID-19. These trends indicate that the international regulatory landscape for mAbs against infectious diseases is entering a new era. We here provide an overview of the guidance documents issued by regulatory agencies, based on insights obtained from anti-SARS-CoV-2 mAbs during the COVID-19 pandemic. We also discuss the challenges and future prospects for the development of mAbs against infectious diseases, particularly in situations requiring rapid responses during pandemics.},
}
@article {pmid42544134,
year = {2026},
author = {Ding, Y and Wen, S and Tao, X and Yu, W},
title = {Mapping the global landscape of wearable devices in healthcare: A dual-database bibliometric analysis (2016-2026).},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076261473979},
pmid = {42544134},
issn = {2055-2076},
abstract = {BACKGROUND: The escalating demand for proactive, personalized healthcare, heavily driven by the rising global burden of chronic diseases, necessitates a shift in modern medical management. While wearable devices are central to this transition, a comprehensive, multi-source quantitative mapping of the field's evolutionary trajectory and application domains remains lacking.<br><br>OBJECTIVE: This study systematically visualizes the knowledge structure, spatiotemporal distribution, and developmental trends of wearable healthcare technology over the past decade.<br><br>METHODS: A bibliometric analysis was conducted using integrated data from Web of Science and Scopus (2016-2026). Utilizing CiteSpace and VOSviewer, we performed cooperation network analysis, co-citation clustering, and keyword burst detection to identify global collaboration patterns and research emerging trends.<br><br>RESULTS: Analysis of 12,812 eligible articles identified China and the United States as leading contributors. Ten distinct research clusters emerged: (1) PM2.5; (2) breast milk; (3) chronic wounds; (4) COVID-19 pandemic; (5) Internet of medical things; (6) human activity recognition; (7) cancer survivors; (8) chronic disease; (9) water-soluble composite; (10) personalized health monitoring. Burst detection further highlighted an escalating shift toward telemedicine integration, cost-efficiency, and quality-of-life-focused rehabilitation.<br><br>CONCLUSION: This study presents a comprehensive bibliometric assessment of wearable health technology. By delineating established domains and emerging trajectories in telemedicine and personalized prevention, it provides evidence for researchers and policymakers to optimize resource allocation in digital health innovation.},
}
@article {pmid42544214,
year = {2026},
author = {Omokhua, H and Beauty, O and Favour, E and Blessing, I and Gabriella, O and Onyekachi, C},
title = {Impact of COVID-19 Outbreak on Dental Services Utilisation Among Patients Visiting a Tertiary Health Facility in South-South, Nigeria.},
journal = {Nigerian medical journal : journal of the Nigeria Medical Association},
volume = {67},
number = {1},
pages = {291-299},
pmid = {42544214},
issn = {0300-1652},
abstract = {BACKGROUND: COVID-19 caused significant disruption to dental services worldwide, with Nigeria restricting care to emergencies, which could have worsened existing access barriers. Empirical data from the South-South region remains limited. Objective: To evaluate the impact of COVID-19 on dental service utilisation, barriers, perceived oral health outcomes, and post-pandemic recovery among patients at a tertiary facility in South-South Nigeria.<br><br>METHODOLOGY: A descriptive cross-sectional study of 120 adults attending the University of Benin Teaching Hospital dental clinic from March 2020 to December 2021, using an interviewer-administered questionnaire. Data were analysed with SPSS v25.<br><br>RESULTS: Utilisation sharply declined during the pandemic, with 53.3% not attending the clinic versus 35.8% before the pandemic. Major barriers included fear of infection (29.2%) and lack of information about services (16.7%). Post-pandemic attendance improved but remained slightly below pre-pandemic levels. While 40.8% reported improved oral health due to increased self-care, 17.5% reported deterioration. Most participants were satisfied with current service availability (58.3%) and perceived improved access (60.8%).<br><br>CONCLUSION: COVID-19 significantly reduced dental utilisation due to fear and restricted access. Although recovery is underway, preventive visits remain low. Public education, tele-dentistry, and enhanced emergency preparedness are recommended.},
}
@article {pmid42544246,
year = {2026},
author = {Nnabugwu, II and Okwesili, OR and Anyimba, SK},
title = {A Descriptive National Survey of Post-COVID Experiences of Nigerian Surgical Trainees.},
journal = {Nigerian medical journal : journal of the Nigeria Medical Association},
volume = {67},
number = {1},
pages = {59-73},
pmid = {42544246},
issn = {0300-1652},
abstract = {BACKGROUND: Medical training was disrupted during the COVID-19 pandemic, with an unprecedented reduction in elective, emergency surgical, and clinical procedures. This led to great interest in the use of virtual lectures, virtual conferences, webinars, and other technology-based resources such as telehealth consultations. This trend has introduced changes that have transformed surgical training/fellowship. The study aims to explore the transformation in clinical practice and residency training induced by the COVID-19 pandemic in a low- and middle-income country such as Nigeria, and ways of aligning with global trends.<br><br>METHODOLOGY: This was a quantitative questionnaire-based cross-sectional study. The survey link was distributed through professional WhatsApp&#xae; platforms of the residency associations of diverse surgery training institutions in Nigeria, and via email.<br><br>RESULTS: There were 157 respondents. Urology (26.1%) and orthopaedic surgery (22.3%) had the highest numbers of respondents. The major cases done after the lockdown decreased COMPARED to the period before the lockdown. The residents using the audio form of telemedicine increased from 48% in the pre-COVID period to 61% in the post-COVID period. The video form increased from 4.5% to 21%, and those using internet Apps for clinical consultation increased from 13.4 % to 31.8%. McNemar's test was significant for the differences in responses before and after COVID for audio telemedicine (p = 0.011), video (p = 0.000), and internet App telemedicine (p = 0.000). In the pre-COVID period, lectures, tutorials, and seminars were frequently delivered in-person (96.2%), while in the post-COVID period, they were predominantly done virtually (74.5%). Pearson's chi-square test showed no significant associations between the stage of training and the responses (p > 0.05).<br><br>CONCLUSION: The pandemic affected surgical training for fellowships, hastening the adoption of virtual platforms, simulation technology, remote teaching, and mentorship into many fellowships' curricula, giving rise to a flexible hybrid model of surgical fellowship.},
}
@article {pmid42545007,
year = {2026},
author = {Hanrieder, L and Schreiner, S},
title = {One virus-many strategies: type-specific interactions between human adenoviruses and innate immunity.},
journal = {Journal of virology},
volume = {},
number = {},
pages = {e0020426},
doi = {10.1128/jvi.00204-26},
pmid = {42545007},
issn = {1098-5514},
abstract = {Human adenoviruses (HAdVs) are double-stranded DNA viruses that can cause a wide range of infections, including respiratory, gastrointestinal, and ocular diseases, as well as less common conditions such as hepatitis, hemorrhagic cystitis, and encephalitis. While most infections in immunocompetent individuals remain clinically asymptomatic, immunocompromised patients are at a high risk of developing severe HAdV infections. Due to their exceptional transduction efficiency, HAdVs are also widely used as vaccine vectors, such as in vector-based COVID-19 vaccines. Although HAdVs are present as pathogens and vectors, the interaction between HAdVs and the human immune system remains insufficiently studied. Most adenoviral basic research in this context has focused on HAdV-C5. However, differences in capsid structure and genome organization exist not only between adenovirus species but also among types within the same species. These variations may influence the ability of the virus to evade or counteract the host immune system, ultimately influencing viral infectivity and replication efficiency. Further studies are needed to elucidate these differences. In this review, we summarize the differences in immune responses, with a particular emphasis on triggered IFN responses, across various HAdV species and their influence on infection outcomes, as well as their implications for the use of adenoviral vectors. Future research addressing these differences will be essential to better understand adenovirus pathogenesis and the rational design of adenovirus-based vectors.},
}
@article {pmid42545119,
year = {2026},
author = {Jeena, N and Khan, IA},
title = {Targeting SARS-CoV-2 programmed -1 ribosomal frameshifting: structural dynamics and RNA-directed antiviral strategies.},
journal = {Antimicrobial agents and chemotherapy},
volume = {},
number = {},
pages = {e0068726},
doi = {10.1128/aac.00687-26},
pmid = {42545119},
issn = {1098-6596},
abstract = {Programmed -1 ribosomal frameshifting (-1 PRF) is a translational recoding mechanism used by many RNA viruses to regulate the expression of viral replication proteins. In coronaviruses, including SARS-CoV-2, -1 PRF is controlled by a conserved frameshift stimulation element containing a three-stemmed RNA pseudoknot located downstream of a slippery sequence. Studies have shown that conformational dynamics, mechanical stability, and structural variability of the pseudoknot influence ribosome pausing and frameshifting efficiency, identifying viral RNA structures as potential antiviral targets. This review outlines the structural organization, mechanistic basis, and conformational dynamics of viral frameshifting pseudoknots, with emphasis on the SARS-CoV-2 frameshift stimulation element. Advances in cryo-electron microscopy, single-molecule biophysics, molecular dynamics simulations, and computational modeling have identified multiple pseudoknot conformations involved in translational recoding and ribosome-RNA interactions. RNA-targeted therapeutic approaches used to suppress or modulate -1 PRF are also discussed, including small-molecule RNA binders, antisense oligonucleotides, peptide nucleic acids, and ribonuclease-targeting chimeras. These approaches act on distinct aspects of RNA structure, conformational flexibility, and stability to inhibit viral translation or promote selective RNA degradation. Major challenges include selective targeting of highly dynamic RNA structures, optimization of intracellular delivery, and minimizing off-target effects. Integration of structural biology, computational modeling, and RNA-targeted therapeutic strategies may support the development of next-generation antivirals targeting conserved viral RNA regulatory elements.},
}
@article {pmid42546716,
year = {2026},
author = {Lailach, S and Neudert, M and Zahnert, T},
title = {[Interdisciplinary Management of Acute and Chronic Mastoiditis].},
journal = {Laryngo- rhino- otologie},
volume = {105},
number = {8},
pages = {516-532},
doi = {10.1055/a-2623-3015},
pmid = {42546716},
issn = {1438-8685},
mesh = {Humans ; *Mastoiditis/therapy/diagnosis/etiology ; Acute Disease ; Chronic Disease ; *Patient Care Team ; Child ; Interdisciplinary Communication ; Anti-Bacterial Agents/therapeutic use ; Infant ; Mastoidectomy ; Intersectoral Collaboration ; Combined Modality Therapy ; },
abstract = {Acute mastoiditis represents the most common complication of acute otitis media in childhood and, despite a declining incidence in the era of vaccine prevention, remains a clinically significant entity. Particularly in infants and immunocompromised patients, symptoms may be nonspecific, thereby complicating early diagnosis. The present review provides a structured overview of the etiology, pathophysiology, diagnostic workup, and therapeutic management of acute and chronic mastoiditis, with special emphasis on interdisciplinary aspects.The pathogen spectrum is age-dependent and subject to epidemiological shifts driven by vaccination programs and external factors such as the COVID-19 pandemic. In acute cases, Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes predominate, whereas chronic mastoiditis frequently exhibits a polymicrobial flora including Pseudomonas aeruginosa and anaerobic pathogens. Diagnosis remains primarily clinical and is supported by imaging modalities (CT, MRI).Treatment is stage-dependent and may be conservative (high-dose intravenous antibiotic therapy, with or without ventilation tube placement) or surgical (mastoidectomy). Interdisciplinary management involving otolaryngology, pediatrics, (pediatric) radiology, neuropediatrics, and infectious diseases is of crucial importance-particularly in complicated courses such as abscess formation, labyrinthitis, facial nerve palsy, Gradenigo's syndrome, or intracranial complications.Special consideration is given to high-risk populations, including infants, immunocompromised patients, and children with cochlear implants, in whom atypical clinical courses and biofilm formation necessitate tailored management strategies. Follow-up care includes structured audiological assessment, vaccination counseling, and parental education aimed at preventing recurrence. A coherent, stage-oriented interdisciplinary treatment algorithm combined with close clinical re-evaluation by the surgical team enables effective management while reducing the rate of operative interventions-consistent with current international standards.},
}
@article {pmid42547170,
year = {2026},
author = {Abul, Y and Leeder, C and Gravenstein, S},
title = {Epidemiology and Clinical Presentation of COVID-19 in Older Adults.},
journal = {Clinics in geriatric medicine},
volume = {42},
number = {3},
pages = {399-425},
doi = {10.1016/j.cger.2025.09.007},
pmid = {42547170},
issn = {1879-8853},
mesh = {Humans ; *COVID-19/epidemiology/diagnosis/therapy ; Aged ; SARS-CoV-2 ; Severity of Illness Index ; Age Factors ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains asymptomatic in 33% to 90% of older adults depending on their immune status from prior infection, vaccination, and circulating strain. Older adults symptomatic with SARS-CoV-2 often both present atypically, such as with a blunted fever response, and develop more severe disease. Early and late reports showed that older adults have increased severity of coronavirus disease 2019 (COVID-19) with higher case fatality rates and higher intensive care needs compared with younger adults. Infection and vaccine-induced antibody response and long-term effects of COVID-19 also differ in older adults.},
}
@article {pmid42547171,
year = {2026},
author = {Olagunju, OJ and Oyebanji, OA and Mylonakis, E and Canaday, DH},
title = {Vaccines for the Prevention of COVID-19 in Older Adults.},
journal = {Clinics in geriatric medicine},
volume = {42},
number = {3},
pages = {427-448},
doi = {10.1016/j.cger.2025.09.003},
pmid = {42547171},
issn = {1879-8853},
mesh = {Humans ; *COVID-19 Vaccines ; *COVID-19/prevention &amp; control/epidemiology ; Aged ; SARS-CoV-2 ; *Pandemics/prevention &amp; control ; Vaccine Efficacy ; Vaccination/methods ; },
abstract = {Institutionalized and community-dwelling older adults have been greatly impacted by the COVID-19 pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide will be discussed. Optimizing vaccine usage will remain crucial to maximize protection due to reduced initial immunity, the emergence of variant strains, and the waning of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens where there is minimal to no prior immunity.},
}
@article {pmid42547176,
year = {2026},
author = {Oliver, NT and Skalweit, MJ},
title = {Outpatient Parenteral Antibiotic Therapy in Older Adults.},
journal = {Clinics in geriatric medicine},
volume = {42},
number = {3},
pages = {529-543},
doi = {10.1016/j.cger.2025.09.011},
pmid = {42547176},
issn = {1879-8853},
mesh = {Humans ; *Anti-Bacterial Agents/administration &amp; dosage ; Aged ; *Ambulatory Care/methods ; *COVID-19/epidemiology ; SARS-CoV-2 ; Infusions, Parenteral ; },
abstract = {Outpatient parenteral antimicrobial therapy (OPAT) for older adults is a complex process that involves multiple stakeholders and care coordination, but it is a useful and patient-centered tool with opportunities for the treatment of complicated infections, improved patient satisfaction, and reduced health-care costs. Older age should not be an exclusion for OPAT but rather prompt the OPAT provider to thoroughly evaluate candidacy and safety. Amid the on-going COVID-19 pandemic, innovations in OPAT are needed to shepherd OPAT care into a more patient-centered, thoughtful practice, whereas minimizing harm to older patients from unnecessary health-care exposure and thus health-care associated infections.},
}
@article {pmid42549148,
year = {2026},
author = {Fatima, I and Saif, MA and Messova, AM and Abdrahmanova, ST and Mussin, NM and Tamadon, A},
title = {New-onset adrenal insufficiency in COVID-19 patients without preexisting adrenal disease: A systematic review.},
journal = {Qatar medical journal},
volume = {2026},
number = {2},
pages = {35},
pmid = {42549148},
issn = {0253-8253},
abstract = {INTRODUCTION: Coronavirus disease 2019 (COVID-19) is increasingly recognized as a multisystem disorder with potential endocrine sequelae. Emerging reports suggest that adrenal insufficiency (AI) may occur in patients with COVID-19 without preexisting adrenal disease, but the clinical spectrum and strength of evidence remain unclear. To systematically review the literature on new-onset AI associated with COVID-19 in patients without prior adrenal disorders, focusing on clinical presentation, diagnostic approaches, and underlying mechanisms.<br><br>METHODS: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to December 28, 2025. Eligible studies included observational studies, case reports, and case series reporting AI in COVID-19 patients without known adrenal disease. Risk of bias was assessed using the Newcastle-Ottawa Scale and Joanna Briggs Institute tools. Given the heterogeneity, a qualitative synthesis was conducted.<br><br>RESULTS: Nine primary studies (two observational studies and seven case reports) were included. Four narrative reviews were used solely for contextual discussion. Cases involved adults and children and occurred during acute infection or the post-COVID period. Most reports described biochemically confirmed central AI, while fewer reported primary AI due to adrenal infarction, hemorrhage, or autoimmune adrenalitis. Some presentations based mainly on steroid responsiveness were interpreted as probable critical illness-related corticosteroid insufficiency. Diagnostic thresholds and the use of ACTH stimulation testing varied. Most patients improved with glucocorticoid replacement.<br><br>CONCLUSION: New-onset AI has been reported in temporal association with COVID-19 and may represent an infrequently reported but clinically significant endocrine manifestation. Prospective studies with standardized hormonal assessment are needed to clarify incidence, mechanisms, and screening strategies.<br><br>REGISTRATION: The review was registered with PROSPERO under registration number CRD420251275141.},
}
@article {pmid42549181,
year = {2026},
author = {Wang, Y and Mao, H and Zhang, X and Li, D and Liu, Z and Shang, W and Song, G},
title = {Association between physical activity and depression in university students: a systematic review and meta-analysis with public health implications.},
journal = {Frontiers in psychology},
volume = {17},
number = {},
pages = {1850043},
pmid = {42549181},
issn = {1664-1078},
abstract = {OBJECTIVE: To systematically review and meta-analyze the association between physical activity and depression among university students, quantify the linear correlation between physical activity level and depressive symptoms, and examine the binary association of insufficient physical activity or sedentary behavior with depression risk, thereby providing evidence-based support for mental health promotion and public health interventions in higher education settings.<br><br>METHODS: Following PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Scopus, and PsycINFO from inception to March 31, 2026, for observational studies examining the relationship between physical activity and depression in university students. Two reviewers independently performed study selection, data extraction, and quality assessment. For studies reporting correlation coefficients, separate meta-analyses were conducted for Pearson and Spearman correlations using Fisher's z-transformation under a random-effects model. For studies reporting binary outcomes, adjusted odds ratios (ORs) with 95% confidence intervals were extracted and pooled separately for physical activity and sedentary behavior groups.<br><br>RESULTS: A total of 36 studies were included: 30 in the linear correlation meta-analysis and 6 in the binary association meta-analysis. The linear correlation analysis comprised 31 effect sizes with a total sample of 30,307 individuals. The pooled correlation estimates showed an inverse direction but substantial to extreme heterogeneity (Pearson: r&#x202f;=&#x202f;-0.19, 95% CI: -0.28 to -0.11, I[2]&#x202f;=&#x202f;94.4%; Spearman: r&#x202f;=&#x202f;-0.44, 95% CI: -0.73 to -0.01, I[2]&#x202f;=&#x202f;99.2%), indicating that these pooled estimates should be interpreted as average directional trends rather than precise or universally applicable effect sizes. After trim-and-fill correction, the Pearson correlation remained statistically significant (r&#x202f;=&#x202f;-0.114, 95% CI: -0.209 to -0.016). The binary association analysis showed that the pooled OR for the physical activity group (4 studies) was 0.53 (95% CI: 0.27 to 1.07), suggesting a protective trend of higher physical activity against depression that did not reach statistical significance; the pooled OR for the sedentary behavior group (2 studies) was 1.60 (95% CI: 1.26 to 2.04), indicating a significant association between higher sedentary behavior and increased depression risk. Subgroup analyses revealed a stronger negative association between physical activity and depression during and after the COVID-19 period.<br><br>CONCLUSION: Physical activity promotion and sedentary behavior reduction may be practical components of campus mental health strategies, including brief activity breaks during long lectures, low-threshold exercise opportunities, and active commuting support. However, because most included studies were cross-sectional, geographically skewed toward Chinese samples, and highly heterogeneous, these implications should be interpreted cautiously as public health directions rather than causal or universally generalizable recommendations.},
}
@article {pmid42549744,
year = {2026},
author = {Harris, JC and Holovac, DJ and Marino, GA and Montes, R and Holt, GR and Bowe, SN},
title = {Emerging Ethical Considerations in Otolaryngology-Head and Neck Surgery.},
journal = {Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery},
volume = {},
number = {},
pages = {},
doi = {10.1002/ohn.70376},
pmid = {42549744},
issn = {1097-6817},
abstract = {OBJECTIVES: To perform a scoping review of ethics-based literature published in the last 5 years in otolaryngology-head and neck surgery (OHNS), and to identify and reflect on emerging topics of ethical consideration for otolaryngologists.<br><br>DATA SOURCES: A comprehensive literature search was performed using the PubMed, SCOPUS, and Cochrane databases.<br><br>REVIEW METHODS: A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews protocol. Inclusion criteria included peer-review articles published from 2019 to 2024 that explored at least one foundational bioethical principle in a primary context of OHNS. Original research, literature reviews, editorials, and letters to the editor were included to capture the full extent of the academic ethics conversation. An inductive qualitative content analysis was performed in multi-step process to identify recurrent ethics issues and themes.<br><br>RESULTS: The systematic review identified 1191 unique abstracts, of which 31 met inclusion criteria. This literature emphasized topics including conflicting physician obligations during the coronavirus-19 pandemic, integration of artificial intelligence into clinic practice, diversity and inclusion within OHNS, health equity, ethics education, pediatric autonomy, and considerations for global health programs. These conversations explored conflicting definitions of justice and divergence between personal and institutional ethical obligations.<br><br>CONCLUSION: This scoping review identified salient topics within the current ethics OHNS literature and explores implications for practicing otolaryngologists.},
}
@article {pmid42549821,
year = {2026},
author = {Jafari, A and Manzari-Tavakoli, A and Manzari Tavakoli, M and Hashemian, SM and Jamaati, H and Akhtari, M and Tabarsi, P and Omrani, M},
title = {Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine.},
journal = {Expert review of molecular diagnostics},
volume = {},
number = {},
pages = {},
doi = {10.1080/14737159.2026.2714060},
pmid = {42549821},
issn = {1744-8352},
abstract = {INTRODUCTION: Introduction: Infectious lung diseases, including pneumonia, tuberculosis (TB), COVID-19, influenza, and emerging fungal infections, are major causes of illness and death worldwide. Traditional methods have serious limitations such as diagnostic delays, antimicrobial resistance, and non-targeted therapy. Theranostics offers a transformative precision medicine paradigm for pulmonary infections.<br><br>AREAS COVERED: This review looks closely at how biotechnology and nanotechnology synergistically advance theranostic strategies for infectious lung diseases. We explore biotechnological tools including CRISPR-Cas systems, non-coding RNAs (ncRNAs), and monoclonal antibodies (mAbs) for detecting specific pathogens and intervening directly. We also discuss nanotechnological platforms such as nanosensors, surface-enhanced Raman spectroscopy (SERS), and various nanocarriers (lipid nanoparticles, polymeric nanoparticles, liposomes, metallic nanoparticles, mesoporous silica nanoparticles, and biomimetic systems) for drug, gene, and vaccine delivery with better targeting, controlled release, and imaging capabilities. Integrated case studies across major diseases, including COVID-19, influenza, TB, pneumonia, COPD, and idiopathic pulmonary fibrosis, demonstrate effective theranostic applications. We also address associated challenges like safety, manufacturing, regulatory hurdles, and economic feasibility.<br><br>EXPERT OPINION: The combination of biotechnology and nanotechnology represents a paradigm shift toward personalized pulmonary medicine. Future success needs to develop smart, multi-stimuli-responsive nanoplatforms, integrating artificial intelligence for predictive modeling and treatment optimization, and establishing closed-loop theranostic systems that connect real-time diagnostics with adaptive therapies. Key priorities include standardized preclinical models, clear regulations for combination products, and health economic analyses demonstrating cost-effectiveness. Interdisciplinary collaboration among material scientists, molecular biologists, clinicians, and regulatory specialists will be essential to translate these promising platforms from bench to bedside.},
}
@article {pmid42551545,
year = {2026},
author = {Fontana, A and Chiariello, AM},
title = {Deciphering viral action on host genome structure: a computational physics perspective.},
journal = {Biochimica et biophysica acta. Molecular basis of disease},
volume = {},
number = {},
pages = {168394},
doi = {10.1016/j.bbadis.2026.168394},
pmid = {42551545},
issn = {1879-260X},
abstract = {Recent experimental findings indicate that several viruses are able to substantially re-organize the host cell genome architecture. Since chromatin three-dimensional (3D) organization is tightly linked to vital cellular functions, investigating how viral infections impact physical mechanisms shaping DNA folding provides useful clues about virus action on gene regulation and consequent activation. This review provides an overview of recent advances in the development of computational modelling approaches used to shed light on how host cell chromatin 3D structure is altered following viral infections, including SARS-CoV-2 and avian influenza IAV-H5N1. Given the flexibility of this approach, such models can be adapted to a wide range of pathogens, making them valuable methods for investigating the specificity of distinct infection mechanisms. Overall, we show how such models can be helpful tools that, in tandem with traditional experimental methods, allow to decipher complexity of infection mechanisms at molecular level from a new perspective.},
}
@article {pmid42552557,
year = {2026},
author = {Okesanya, OJ and Oso, TA and Amisu, BO and Abdullahi, YB and Ahmed, MM and Adebayo, UO and Abdi, YH and Ong, CJN and Adigun, OA and Ogaya, JB and Lucero-Prisno, DE},
title = {Advanced statistical approaches in tuberculosis diagnosis and treatment outcomes in Africa: a systematic review.},
journal = {Tropical medicine and health},
volume = {54},
number = {1},
pages = {},
pmid = {42552557},
issn = {1348-8945},
abstract = {BACKGROUND: Tuberculosis (TB) remains a major public health challenge in Africa; however, conventional statistical approaches often fail to capture diagnostic uncertainty, spatial heterogeneity, and complex disease dynamics, limiting evidence-based decision-making. This review synthesizes the application and performance of advanced statistical and computational methods for TB diagnosis and treatment outcomes in Africa.<br><br>METHODS: Following the PRISMA 2020 guidelines, we systematically searched PubMed and Scopus for peer-reviewed studies (2010-2025) conducted in Africa that applied advanced methods, including Bayesian models, machine learning (ML) algorithms, spatiotemporal analyses, time-series models, and multistate or survival frameworks. Study selection, data extraction, and quality appraisal were independently conducted by multiple reviewers using the Joanna Briggs Institute tools. Findings were synthesized narratively because of substantial methodological heterogeneity.<br><br>RESULTS: Twenty-seven studies from nine African countries were included. Bayesian hierarchical, geostatistical, and latent class models improved estimation of TB incidence, mortality, and diagnostic accuracy by accounting for uncertainty, imperfect reference standards, and sparse data. Spatiotemporal analyses consistently identified geographic TB and TB-HIV hotspots linked to low Bacillus Calmette-Gu&#xe9;rin vaccine coverage, illiteracy, and urban crowding as risk factors. Time-series models quantified the significant decline in TB notifications during the COVID-19 disruptions. ML approaches, particularly random forests, outperformed traditional regression in predicting latent TB infection and treatment outcomes. Drug resistance, notably to bedaquiline and levofloxacin, showed clear spatial clustering and dynamic progression patterns.<br><br>CONCLUSIONS: Advanced statistical and computational methods are increasingly improving TB diagnosis, prognosis, and treatment insights in Africa by capturing complex patterns beyond classical models, but their broader impact is limited by data gaps, heterogeneity, and insufficient validation, highlighting the need for high-quality, multi-country research and stronger implementation frameworks.<br><br>PROSPERO ID: CRD420251160248.},
}
@article {pmid42553092,
year = {2026},
author = {Guo, N and Chen, S and Guo, L and Qiu, X and Li, Z},
title = {Metagenomic next-generation sequencing: new horizons in microbiology.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1824160},
doi = {10.3389/fcimb.2026.1824160},
pmid = {42553092},
issn = {2235-2988},
mesh = {Humans ; *High-Throughput Nucleotide Sequencing/methods ; *Metagenomics/methods ; Animals ; COVID-19/diagnosis ; Computational Biology/methods ; Pandemics ; SARS-CoV-2/genetics ; Public Health ; One Health ; },
abstract = {The COVID-19 pandemic has exposed vulnerabilities in global health systems while accelerating the adoption of metagenomic next-generation sequencing (mNGS) as a transformative tool for culture-independent, unbiased microbial detection. In clinical diagnostics, mNGS enables simultaneous detection of diverse pathogens without prior hypothesis, though its yield depends heavily on specimen type and clinical context. In public health, mNGS has demonstrated remarkable utility in outbreak tracing, novel pathogen discovery, antimicrobial resistance (AMR) surveillance, and One Health initiatives. However, massive data volumes pose persistent challenges in bioinformatics, standardization, and computational demands. Future integration of artificial intelligence, automated platforms, and multi-omics approaches will enhance the conversion of raw data into actionable insights. Collectively, mNGS is poised to drive a paradigm shift from reactive responses to proactive, system-level microbial surveillance across human, animal, and environmental health.},
}
@article {pmid42553294,
year = {2026},
author = {Aldrees, T},
title = {Assessing the prevalence of anosmia and taste dysfunction in COVID-19 patients in Saudi Arabia: a systematic review and meta-analysis.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1815114},
doi = {10.3389/fpubh.2026.1815114},
pmid = {42553294},
issn = {2296-2565},
mesh = {Humans ; Saudi Arabia/epidemiology ; *COVID-19/epidemiology/complications ; Prevalence ; *Anosmia/epidemiology ; *Taste Disorders/epidemiology ; Female ; },
abstract = {OBJECTIVES: Patients with coronavirus disease-2019 (COVID-19) frequently report olfactory and gustatory dysfunctions, including anosmia and ageusia. Multiple studies have assessed the prevalence of these symptoms in COVID-19 patients in Saudi Arabia. This systematic review and meta-analysis aimed to estimate the pooled prevalence of anosmia and taste dysfunction in confirmed COVID-19 patients in Saudi Arabia across inpatient, outpatient, and community settings, from March 2020 to March 2023.<br><br>METHODS: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. No review protocol was prospectively registered prior to this review. A comprehensive search was conducted across PubMed, ScienceDirect, CINAHL, MEDLINE, and Google Scholar (supplementary) from 1 March 2020 to 1 March 2023. Data were pooled using a random-effects model. The methodological quality of included studies was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools for prevalence studies.<br><br>RESULTS: Of 230 records identified across all databases, 156 remained after deduplication; 24 met the eligibility criteria, encompassing 26,068 COVID-19 patients (58.2% female). The pooled prevalence of anosmia was 44% (95% CI: 37-52%) and of taste dysfunction was 46% (95% CI: 39-54%). Subgroup analyses comparing validated versus non-validated assessment instruments revealed no statistically significant difference in prevalence estimates.<br><br>CONCLUSION: Anosmia and taste loss are common manifestations of COVID-19 in Saudi Arabia. The findings should be interpreted with caution given the methodological heterogeneity of included studies, reliance on self-reported measures in the majority of studies, and the absence of a prospectively registered protocol. Future studies using objective validated instruments are warranted.},
}
@article {pmid42553309,
year = {2026},
author = {Cong, P and Wang, J and Du, X},
title = {Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1880420},
doi = {10.3389/fimmu.2026.1880420},
pmid = {42553309},
issn = {1664-3224},
mesh = {Humans ; *Glomerulonephritis, Membranous/drug therapy ; *Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects ; Treatment Outcome ; Remission Induction ; },
abstract = {OBJECTIVE: Membranous nephropathy (MN) constitutes an autoimmune glomerular disorder and represents the most frequent etiology of primary nephrotic syndrome in adults. Although obinutuzumab exhibits favorable efficacy in managing refractory MN, outcomes diverge across individual investigations. Consequently, the present meta-analysis is undertaken to systematically evaluate the clinical efficacy and safety of obinutuzumab in individuals with refractory MN.<br><br>METHODS: A systematic search was conducted across the Cochrane Library, Embase, Web of Science, and PubMed to determine relevant clinical investigations published up to November 12, 2025. Treatment effects were quantified employing the pooled proportion rate with 95% confidence interval (CI), mean difference (MD, 95% CI), and standardized mean difference (SMD, 95% CI). Heterogeneity was examined via the I&#xb2; statistic. Subgroup analyses were implemented based on the geographic distribution of the study population and duration of follow-up. All extracted data were subjected to statistical analysis using R (v4.5.2).<br><br>RESULTS: The present meta-analysis ultimately incorporated 12 articles (222 individuals) after applying the eligibility criteria. Concerning remission rates, the overall clinical remission rate reached 86% (95% CI: 80% to 90%), the complete clinical remission rate stood at 31% (25% to 37%), the partial clinical remission rate was 55% (49% to 63%), and the immunologic remission rate achieved 88% (81% to 92%). Obinutuzumab reduced proteinuria (SMD = -1.2, 95%CI -1.37 to -1.03) and raised serum albumin (MD&#xa0;=&#xa0;12.5, 95%CI 9.91-15.08), while eGFR showed no significant change (MD&#xa0;=&#xa0;3.23, 95%CI -3.76-10.21). The pooled adverse event rate was 29% (95%CI 15%-48%), with two fatal pneumonia-related events: severe COVID-19 pneumonia and pneumonia-induced respiratory failure.<br><br>CONCLUSION: Obinutuzumab demonstrates marked efficacy in treating refractory MN, with an overall clinical remission rate of 86% and a low incidence of severe adverse events. This profile signifies a potential therapeutic role for this condition. However, all raw data included in this meta-analysis were derived from uncontrolled retrospective single-arm trials and case series. Given factors such as selection bias, the remission rate may be overestimated. Large-scale, multicenter randomized controlled trials are necessary for verification in future investigations.<br><br>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251231344.},
}
@article {pmid42553313,
year = {2026},
author = {Jiang, G and Buccino, F and Vergani, LM},
title = {Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.},
journal = {Frontiers in bioengineering and biotechnology},
volume = {14},
number = {},
pages = {1812439},
doi = {10.3389/fbioe.2026.1812439},
pmid = {42553313},
issn = {2296-4185},
abstract = {The skeletal consequences of COVID-19 have emerged as an important but still underrecognized component of post-viral systemic disease. Increasing clinical, experimental, and imaging-based evidence indicates that SARS-CoV-2 infection may impair bone health through multiscale mechanisms involving bone remodeling, osteoimmune signaling, vascular regulation, and mechanical adaptation. In this review, we summarize current evidence linking COVID-19 to skeletal deterioration, ranging from changes in bone mineral density, trabecular microarchitecture, and mechanical competence to osteocyte lacunar remodeling and altered bone-cell activity. We discuss both potential direct and indirect mechanisms by which SARS-CoV-2 may affect the skeletal system. Direct effects may involve viral infection-associated inflammatory and oxidative responses that promote osteoclastogenesis and bone resorption. Indirectly, SARS-CoV-2 may disturb bone homeostasis through ACE2 downregulation and renin-angiotensin system imbalance, systemic inflammation, endothelial dysfunction, glucocorticoid exposure, avascular necrosis, prolonged bed rest and mechanical unloading, vitamin D deficiency, and mineral dysregulation. Based on well-characterized mechanisms from other osteotropic viral diseases, we propose possible modes by which SARS-CoV-2 may affect the skeletal system. This review emphasizes key knowledge gaps, including the limited availability of longitudinal human data, the need for advanced imaging and multiscale mechanical modeling, and the potential role of host genetic susceptibility. Overall, COVID-19-related skeletal impairment should be considered a multifactorial and multiscale process. Integrated clinical, molecular, imaging, genetic, and biomechanical approaches will be essential to identify vulnerable individuals, monitor long-term skeletal outcomes, and develop targeted strategies to preserve bone health in COVID-19 survivors.},
}
@article {pmid42553331,
year = {2026},
author = {Onyango, JO},
title = {The growing burden of mental health and the role of digital technologies in the Global South: policies, cultural contexts, and community-based transformations-a systematic review of gray literature evidence.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1875110},
doi = {10.3389/fpubh.2026.1875110},
pmid = {42553331},
issn = {2296-2565},
mesh = {Humans ; Digital Health ; *Digital Technology ; *Mental Health ; *Global Health ; *Health Policy ; COVID-19/epidemiology ; *Mental Disorders/epidemiology ; Digital Media ; Developing Countries ; },
abstract = {BACKGROUND: Mental health conditions are among the fastest growing and most inequitably distributed global disease burdens. Structural determinants- poverty, conflict, climate change, and the COVID-19 pandemic compound a persistent mismatch between internationally developed policy frameworks and the cultural and infrastructural realities of populations in the Global South.<br><br>OBJECTIVE: This systematic review identified, appraised, and synthesized gray literature evidence on (1) the growing mental health burden across Global South regions (2015-2025); (2) digital technology responses in Global South LMIC contexts; and (3) policy, cultural, and community-based factors shaping mental health transformation efforts.<br><br>METHODS: A pre-registered systematic gray literature review spanned five source tiers. Following systematic screening and AACODS quality appraisal, 140 records published between 2015 and 2025 were included.<br><br>RESULTS: Four themes emerged: (1) an accelerating, structurally driven mental health burden across Global South regions; (2) a severe and entrenched treatment gap sustained by chronic underinvestment, workforce shortages, and stigma; (3) a rapidly expanding but uneven digital mental health landscape, in which SMS-based and CHW-mediated platforms achieve substantially greater reach than smartphone-dependent tools; and (4) significant structural, cultural, and policy barriers constraining scale-up. The effectiveness of digital mental health interventions (DMHIs) varies by modality, population, and setting, and is not a single generalizable finding.<br><br>CONCLUSION: The mental health burden in the Global South is growing faster than existing systems can address. Transformative progress requires sustained investment in CHW-mediated digital tools, culturally co-designed platforms, decolonized research partnerships, and mental health policies that center Global South communities as co-producers of their own mental health futures.},
}
@article {pmid42553409,
year = {2026},
author = {Dotan, I and Dubinsky, MC and Siegel, CA and Lindsay, J and McGovern, D and Allez, M and Myrelid, P and Lewis, J and Sands, BE and Peyrin-Biroulet, L and Danese, S and Ahuja, V and Kaplan, GG and Konings, M and Gearry, R and Ng, SC and Jairath, V and Magro, F and Silverberg, MS and Turner, D and Abreu, MT and Hart, A and Dignass, A and Rubin, DT and , },
title = {IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.},
journal = {Therapeutic advances in gastroenterology},
volume = {19},
number = {},
pages = {17562848261470923},
doi = {10.1177/17562848261470923},
pmid = {42553409},
issn = {1756-283X},
abstract = {The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) is an international scientific organization that has shaped the framework for inflammatory bowel disease (IBD) research, clinical management strategy, therapeutic development, and clinical trial methodology for more than four decades. Formally constituted in April 1981 in Lyon, France, IOIBD was created to address fundamental barriers to scientific and clinical progress in IBD, including inconsistent definitions of disease activity and outcomes across studies and countries. Since the establishment of the IOIBD Foundation for Research and Education in 1997, IOIBD has combined a highly engaged global membership of experts with structured governance, continuously active thematic clusters, and an annual rotating international meeting to deliver consensus frameworks and collaborative initiatives that translate directly to clinical practice and regulatory and translational science. Key outputs include studies of global epidemiology of IBD, the Selecting Therapeutic Targets in IBD (Selecting Therapeutic Targets in Inflammatory Bowel Disease, STRIDE) treat-to-target programs; the SPIRIT consensus initiative addressing long-term disease impact and endpoints for disease-modification trials; validated approaches to capturing disability and patient-reported outcomes; consensus guidance on nutrition and diet as modifiable and potentially disease-modifying factors; recommendations to optimize IBD clinical trial design and endpoints; reclassification of IBD initiative; rapid international guidance during the COVID-19 pandemic; and educational initiatives including topic-focused satellite symposia, the Helmsley-IOIBD Clinical Experience Exchange Program, and the Empowering Women in IBD Leadership Program (EMPOWHER). This manuscript reviews IOIBD's history, operational model, selected scientific contributions, educational mission, and evolving strategy as the field moves toward precision medicine, globalization of care, and data-intensive approaches, including artificial intelligence.},
}
@article {pmid42553490,
year = {2026},
author = {Han, X and Zhang, J and Bai, J and Tian, W and Zhou, J and Ding, L and Gao, X},
title = {Engineering Organoid Platforms for Pathogenesis Research.},
journal = {Research (Washington, D.C.)},
volume = {9},
number = {},
pages = {1346},
doi = {10.34133/research.1346},
pmid = {42553490},
issn = {2639-5274},
abstract = {Emerging and re-emerging infectious diseases ranging from the 1918 H1N1 influenza pandemic to the recent SARS-CoV-2 and monkeypox virus outbreaks continue to pose profound threats to global public health. These crises underscore the critical need for high-fidelity and human-relevant infection models. Organoid technology has emerged as a cornerstone platform for pathogen research by faithfully recapitulating the 3-dimensional architecture and physiological microenvironment of native human tissues in vitro. This review systematically examines the development and structural refinement of organoid-based infection models with an emphasis on evidence-based strategies for stem cell source selection, extracellular matrix optimization, and dynamic culture system engineering. Such advancements enable the robust generation of multi-organ models including respiratory, intestinal, and neural organoids tailored for investigating viral tropism, spatiotemporal infection kinetics, and host immune responses. Furthermore, we evaluate the translational utility of organoids in high-throughput antiviral drug screening and preclinical vaccine assessment. To further enhance physiological relevance and functional fidelity, organoid platforms are being increasingly combined with advanced engineering strategies, including coculture approaches, CRISPR-Cas9-mediated genetic perturbation, engineered microphysiological systems (such as organ-on-a-chip), and 3D bioprinting. These integrated technologies improve biomimicry while expanding experimental controllability and scalability. In addition, we critically examine the major bottlenecks limiting clinical translation and discuss emerging frontiers driven by artificial intelligence and synthetic biology. Through iterative technological refinement and cross-disciplinary convergence, organoids have evolved beyond reductionist in vitro surrogates into physiologically informed and mechanism-driven platforms that advance our understanding of host-pathogen interactions while enhancing global preparedness against emerging pathogens.},
}
@article {pmid42553575,
year = {2026},
author = {Bherer, J and Clemenceau, A and Diorio, C and Durocher, F},
title = {Bazedoxifene and Beyond: Identifying This SERM's Targets and Deciphering Its Molecular Mechanisms.},
journal = {Advances in pharmacological and pharmaceutical sciences},
volume = {2026},
number = {},
pages = {3028716},
doi = {10.1155/adpp/3028716},
pmid = {42553575},
issn = {2633-4690},
abstract = {Bazedoxifene (BZA), a third-generation selective estrogen receptor modulator (SERM) approved for osteoporosis treatment, is attracting attention for drug repurposing, especially in cancer research. While designed primarily for estrogen receptors, BZA exhibits in vitro off-target interactions that may explain novel therapeutic benefits or account for potential side effects. This review comprehensively examines both established and newly identified targets of BZA beyond estrogen receptors. To gather relevant data, we reviewed over 1500 articles selecting key studies proposing insights into BZA targets and mechanisms. This review details BZA's roles in estrogen receptor signaling and its interactions with glycoprotein 130, elaborating on vital components of each signaling pathway. It also compiles its potential interactions with cannabinoid receptors, as well as BZA targets related to biotransformation, absorption/transport, DNA cycle, Sars-CoV-2, ferroptosis, ROS production, and cholesterol biosynthesis. For each target, we discuss evidence from computational studies, direct interaction assay, and functional testing. This work provides the most complete overview of BZA's molecular mechanisms to date and suggests new avenues for future research and potential applications beyond osteoporosis.},
}
@article {pmid41482260,
year = {2026},
author = {Ticinesi, A and Zuliani, G and Spaggiari, R and Volpato, S and Maggi, S and Franceschi, C},
title = {The social microbiome of older people.},
journal = {Ageing research reviews},
volume = {115},
number = {},
pages = {103008},
doi = {10.1016/j.arr.2025.103008},
pmid = {41482260},
issn = {1872-9649},
mesh = {Humans ; *Gastrointestinal Microbiome/physiology ; *Dysbiosis/microbiology ; Aged ; *Aging/psychology/physiology ; *COVID-19 ; Animals ; Social Isolation ; Frailty/microbiology ; },
abstract = {The human gut microbiome (GM) is increasingly recognized as one of the main systems influencing the aging trajectory. Age-related dysbiosis, with imbalance between symbionts and pathobionts, can in fact fuel chronic inflammation (inflammaging) and promote frailty. In older individuals, GM composition is characterized by marked inter-individual variability and consistently influenced by environmental exposures. Studies conducted in animals and closed human communities suggest that social contacts are associated with horizontal transmission of commensal bacteria, enhancing biodiversity and preventing dysbiosis. Recent studies also suggest transmission of intestinal commensal bacteria from animals to humans sharing the same household. Bacterial populations residing on environmental surfaces may also have an influence on GM composition. In this framework, impoverishment of social relationships in older individuals may not be only associated with cognitive and emotional disengagement, but also with unfavorable changes in GM composition, driven by isolation and top-down neuromodulation of intestinal function. In fact, studies conducted during forced social distancing in the COVID-19 pandemic suggest GM changes pointing towards dysbiosis. Therefore, the detrimental consequences of social isolation for health outcomes of older individuals, including frailty progression towards disability, could be at least partly mediated by GM dysbiosis. Conversely, interventions aimed at restoring sociality, including animal-assisted activities, could expose older individuals to a range of novel bacterial species helping to counteract GM dysbiosis. This perspective article critically discusses the concept of social microbiome, its possible relevance for maintenance of good health in human beings, and its implications for the care of older patients.},
}
@article {pmid41482689,
year = {2026},
author = {Yang, YJ and Kim, KH and Park, JH and Ro, YS and Song, KJ and Shin, SD},
title = {Impact of the COVID-19 Pandemic on the Mortality of Traumatic Brain Injury Patients Transported by Emergency Medical Services.},
journal = {Asia-Pacific journal of public health},
volume = {38},
number = {1},
pages = {55-64},
doi = {10.1177/10105395251407042},
pmid = {41482689},
issn = {1941-2479},
mesh = {Humans ; *COVID-19/epidemiology ; *Brain Injuries, Traumatic/mortality/therapy ; Male ; Female ; Middle Aged ; *Hospital Mortality/trends ; *Emergency Medical Services/statistics &amp; numerical data ; Adult ; Aged ; Retrospective Studies ; Pandemics ; },
abstract = {The purpose of this study was to investigate the effects of the COVID-19 pandemic on the mortality of traumatic brain injury (TBI) patients transported by emergency medical services (EMS). Adult TBI patients who were assessed and transported by EMS between January 2018 and December 2021 were analyzed. The main exposure was during the COVID-19 pandemic period at the time of the event. The primary outcome was in-hospital mortality. A total of 18 988 patients were analyzed. The in-hospital mortality in the COVID-19 era group was 1812 (20.9%), and that in the non-COVID-19 era group was 2040 (19.8%). Multivariate logistic regression analysis revealed a significantly greater probability of in-hospital mortality in the COVID-19-era group; adjusted odds ratio of 1.16. Compared with non-COVID-19 era patients, TBI patients who were assessed and transported during the COVID-19 era were more likely to have higher in-hospital mortality.},
}
@article {pmid41482705,
year = {2026},
author = {Sabeena, S and Beynon, C},
title = {The Impact of the COVID-19 Pandemic on HPV Vaccination Coverage Among Adolescents From High-Income Countries and Challenges: A Scoping Review.},
journal = {Reviews in medical virology},
volume = {36},
number = {1},
pages = {e70102},
doi = {10.1002/rmv.70102},
pmid = {41482705},
issn = {1099-1654},
mesh = {Humans ; Adolescent ; *COVID-19/epidemiology/virology ; *Papillomavirus Vaccines/administration &amp; dosage ; *Papillomavirus Infections/prevention &amp; control/virology/epidemiology ; Female ; *Vaccination Coverage/statistics &amp; numerical data ; Developed Countries ; Vaccination ; Male ; SARS-CoV-2 ; Patient Acceptance of Health Care ; Uterine Cervical Neoplasms/prevention &amp; control/virology ; Vaccination Hesitancy ; Health Knowledge, Attitudes, Practice ; },
abstract = {Persistent high-risk Human Papillomavirus (HPV) infection causes anogenital and oropharyngeal cancers across all genders. The primary cancer associated with HPV is cervical cancer and the HPV vaccination before sexual exposure is recommended for cervical cancer elimination globally. This scoping review aims to map the preliminary evidence regarding the determinants of adolescent HPV vaccine acceptance and hesitancy during the COVID-19 pandemic in high income countries. A scoping review was conducted as per the updated Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews (PRISMA-ScR) checklist. Using the PCC (Population, Concept, and Context) framework, search keywords and search strategies were developed. Electronic databases were searched using specific search terms and the last search date noted as February 8, 2025. A thematic content analysis was carried out to identify the themes and subthemes by a deductive approach. Fourteen studies were included as the potential sources of evidence in this review. The study population included 493,819 adolescents from Australia, Hong Kong, Italy, Poland, Saudi Arabia, and the USA. The themes identified were inequity, attitude and behaviour, knowledge and communication, and engagement and influence. The COVID-19 pandemic generated a negative parental attitude towards HPV vaccines for a brief period. The adolescent HPV vaccine acceptance mainly depended on strong parental support and appropriate access to healthcare professionals and vaccination services. Travel restrictions, lockdowns, school closures, and social distancing contributed to significant HPV vaccine hesitancy in high income countries.},
}
@article {pmid41482979,
year = {2026},
author = {Hecht, JD and Heitkemper, EM and Danesh, V and Clark, AP and Yoder, LH},
title = {A Concept Analysis of Expertise Associated With Practicing Clinical Nurses in Hospital Settings.},
journal = {Journal of advanced nursing},
volume = {82},
number = {8},
pages = {7803-7814},
pmid = {41482979},
issn = {1365-2648},
mesh = {Humans ; *Clinical Competence/standards ; *Nursing Staff, Hospital/standards ; Female ; *Nurse Clinicians/standards ; Concept Formation ; Male ; },
abstract = {AIM: Analyse the concept of expertise among practicing clinical nurses in hospital settings.<br><br>BACKGROUND: The generational loss of expert clinical nurses was exacerbated globally by the novel coronavirus. This ongoing loss combined with the increased complexity of hospitalised patients has prompted an urgent need to understand expertise among clinical nurses who practice in hospital settings.<br><br>METHODS: Walker and Avant's concept analysis method was used. PubMed, Medline, CINAHL and Access Medicine were searched (1982-2025) for research studies and literature reviews published in English that addressed clinical nursing expertise in hospitals.<br><br>RESULTS: Expertise is the knowledge and skills that are enculturated from immersion in a domain. Common attributes include obtaining salient information from different sources, interpreting patient situations rapidly and holistically, and performing actions that are individualised, immediate and appear instinctive. Common antecedents include deliberate accumulation of relevant experience and contextual connections within the hospital. Facilitating improved outcomes and facilitating improved outcomes are common consequences.<br><br>CONCLUSION: The attributes, antecedents and consequences of clinical nursing expertise are complementary and cross specialties. Experts' apparently instinctive actions are not intuitive but rather related to relevant past experiences, pattern recognition and skilled know-how. The requirements to develop expertise have evolved with the increased volume of available knowledge.<br><br>Expertise requires cultivating relevant experiences through active engagement with patients and creating contextual connections with others regarding hospital systems and processes. Experts should be formally included when developing processes and guidelines. Low-fidelity proxy measures like years of experience should be replaced with psychometrically validated instruments to measure expertise.<br><br>IMPACT: This concept analysis addresses the ambiguity of clinical nursing expertise by synthesising over 40&#x2009;years of literature and provides insights for clinical nurses and researchers regarding the importance of context and the growing complexity of care delivery.<br><br>No patient or public involvement.},
}
@article {pmid41483690,
year = {2026},
author = {Farmer, MS and Herbert, D and Torrisi, C and Zacharjasz, A and Castaneda, G and Schomberg, T and Dardis, M and Montgomery, N and Melvin, ME},
title = {Digital equity in nursing research: A methodological review of nursing studies requiring internet connection.},
journal = {Nursing outlook},
volume = {74},
number = {1},
pages = {102667},
doi = {10.1016/j.outlook.2025.102667},
pmid = {41483690},
issn = {1528-3968},
mesh = {Humans ; *Nursing Research/methods ; *COVID-19/epidemiology ; *Internet ; *Internet Access/statistics &amp; numerical data ; Research Design ; },
abstract = {BACKGROUND: Shifting external factors, including public health emergencies and changes in funding, can prompt nurse scientists to modify study protocols, adopting internet-required methods for recruitment or data collection. Reliance on these methods could exclude populations, with significant implications for nursing, its science, practice, and policy. The onset of the COVID-19 pandemic provides a temporal dividing point to assess the impact on these methodological decisions.<br><br>PURPOSE: This methodological review aimed to (a) quantify the prevalence of internet-required methods in nursing research before and after March 2020, and (b) evaluate their impact on participant inclusivity among digitally disconnected populations.<br><br>METHODS: We analyzed the participant recruitment and data collection methods of a random sample of 232 peer-reviewed nursing studies published in 2021. We assessed whether the methods required internet access or not, then calculated the proportional difference between studies before and after March 2020.<br><br>DISCUSSION: Studies requiring internet access increased from 18.0% pre pandemic to 52.5% post pandemic onset. Internet-required methods also increased for nurses (54.4%), the general population (18.9%), and students (36.3%).<br><br>CONCLUSION: The percentage of internet-required studies in nursing research increased significantly after March 2020. In a shifting research environment, nurse scientists and leaders must proactively address the impact of methodological changes on participant inclusion, ensuring that bridging the digital divide remains a focus of policy and practice.},
}
@article {pmid41484272,
year = {2026},
author = {Liu, X and Zou, Y and Jin, C and Wang, Y and Zhang, J and Yan, M and Xie, Y and Ding, M and Wang, K and Liu, L and Ding, C and Chen, X},
title = {Viral infections are associated with apical periodontitis: A meta-analysis of prevalence, clinical symptoms, and lesion sizes across 31 clinical studies.},
journal = {Clinical oral investigations},
volume = {30},
number = {1},
pages = {37},
pmid = {41484272},
issn = {1436-3771},
support = {HB2023093//Top Talent Support Program for young and middle-aged people of Wuxi Health Committee/ ; A20210056//Health and Science Project of Hangzhou/ ; 2023WJC034//Hangzhou Biological Medicine and Health Industry Development Support Science and Technology Project/ ; 2021WJCY131//Hangzhou Biological Medicine and Health Industry Development Support Science and Technology Project/ ; 2024ZL724//Zhejiang Science and Technology Program of Chinese Medicine/ ; 20211231Y028//Guided Project of Science and Technology of Hangzhou/ ; },
mesh = {Humans ; *Periapical Periodontitis/virology/epidemiology/pathology ; Prevalence ; *Virus Diseases/complications/epidemiology ; },
abstract = {OBJECTIVE: Bacteria and viruses are components of the oral microbiome and are linked to various oral diseases. Clinical observations indicate a higher prevalence of apical periodontitis (AP) during viral epidemics. However, research on this association is limited. This meta-analysis aimed to explore the relationship between viral infections and AP.<br><br>METHODS: This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were identified through systematic database searches, and data were extracted for eligible studies. Three validated quality assessment tools were used to ensure rigor. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to quantify the strength of the association.<br><br>RESULTS: Out of 427 screened records, 31 studies comprising 1,341,636 participants met the inclusion criteria. The meta-analysis revealed that the prevalence of AP was 2.78 times higher in patients with viral infections compared to controls (95% CI&#x2009;=&#x2009;1.88-4.12, p&#x2009;<&#x2009;0.001). Infected individuals demonstrated more severe clinical symptoms (OR&#x2009;=&#x2009;3.49, 95% CI&#x2009;=&#x2009;2.07-5.90, p&#x2009;<&#x2009;0.001) and significantly larger periapical lesions (OR&#x2009;=&#x2009;3.84, 95% CI&#x2009;=&#x2009;1.08-13.67, p&#x2009;<&#x2009;0.05).<br><br>CONCLUSIONS: The evidence suggests a significant association between viral infections and AP, particularly in cases of viral co-infections.<br><br>CLINICAL RELEVANCE: These findings suggest that evaluating viral infections, particularly herpesviruses, could inform the clinical management of AP. However, further research is required to establish causality.},
}
@article {pmid41484399,
year = {2026},
author = {Mols, F and van Cappellen-van Maldegem, S and Hoedjes, M and Horevoorts, N and Oerlemans, S and de Rooij, BH and Ezendam, N and de Theije, C and Hageman, G and Schoormans, D},
title = {Remote blood collection among cancer patients and age- and sex-matched controls for biomarker and genetic analyses using the PROFILES registry.},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
volume = {34},
number = {1},
pages = {61},
pmid = {41484399},
issn = {1433-7339},
mesh = {Humans ; *Neoplasms/blood/genetics ; Registries ; *Blood Specimen Collection/methods ; Male ; Female ; Patient Reported Outcome Measures ; Case-Control Studies ; *Biomarkers, Tumor/blood ; Cohort Studies ; Cancer Survivors ; },
abstract = {Studies on patient-reported outcomes (PROs) among cancer survivors are increasing but are most often limited to PRO and clinical data. To better understand the underlying biological mechanisms that mediate a decline in health after cancer, several PROFILES-registry studies were enriched with biological data. This paper summarizes lessons learned from collecting blood samples to obtain biomarker data among survivors and controls in large-scale ambulatory cohort studies. These lessons address financial challenges, ethical issues, insurance, legal matters, standardization of assessment, recruitment, communication with participants, lab facilities and protocols, transportation, the need for a biobank, and the value of a normative population. We also describe our experiences with collecting remote blood samples in these studies among cancer patient populations and a study in our normative population to illustrate these issues further.},
}
@article {pmid41484775,
year = {2026},
author = {Dhuria, M and VanderEnde, K and Tanwar, S and Vaze, A and Yadav, S and Choudhary, S and Yadav, R and Desai, M and Bahl, A and Jain, SK and Singh, SK and Chauhan, H and Goel, A},
title = {Rapid expansion of the Frontline Field Epidemiology Training Program across 124 districts in India, 2021-2023.},
journal = {Health research policy and systems},
volume = {24},
number = {1},
pages = {11},
pmid = {41484775},
issn = {1478-4505},
mesh = {India/epidemiology ; Humans ; *COVID-19/epidemiology ; *Epidemiology/education ; SARS-CoV-2 ; *Public Health/education ; Pandemics ; Mentors ; },
abstract = {BACKGROUND: India conducts all three tiers of the Field Epidemiology Training Program (FETP). During the coronavirus disease 2019 (COVID-19) pandemic, the country committed to rapid scale-up of its frontline public health workforce capacity through the 3-month in-service Frontline FETP.<br><br>Between January 2021 and May 2023, 300 district-level public health workers and 73 mentors were trained across 124 districts in eight states. Frontline FETP officers successfully completed 236 field assignments, nearly half of which were surveillance systems evaluations or surveillance data analyses and another half of which were case, cluster or outbreak investigations. Acute diarrhoeal disease (ADD) was the most frequently assessed or investigated condition and was one of many diseases exemplifying how FETP officers may need to work across multiple sectors (for example, health, water and sanitation) to help mitigate the public health impact of disease on the affected communities. Challenges (for example, time-consuming process of tailoring learning content, attrition, identification of qualified mentors and task-shifting) and lessons learned (for example, pivoting to a self-paced learning model, using case studies with real-world examples, and a blended learning approach) are described.<br><br>CONCLUSION: This paper portrays the feasibility of not only implementing a 3-month FETP in India's diverse context but, given the complexity of health challenges in an increasingly interconnected environment, its flexibility to be naturally transitioned towards One Health FETP (named SectorConnect in India). It highlights a milestone in India's journey towards realizing the goals set under the One India FETP Roadmap for having at least one trained field epidemiologist per district.},
}
@article {pmid41485125,
year = {2026},
author = {Miao, G and Lu, R and Pipanmekaporn, T and Kacha, S and Supphapipat, A and Phothikun, N and Jewprasertpan, P and Chittawatanarat, K},
title = {Association Between Blood Glucose Variability and Clinical Outcomes in Patients With Sepsis: A Systematic Review and Meta-Analysis.},
journal = {Diabetes/metabolism research and reviews},
volume = {42},
number = {1},
pages = {e70119},
doi = {10.1002/dmrr.70119},
pmid = {41485125},
issn = {1520-7560},
mesh = {Humans ; *Sepsis/mortality/blood ; *Blood Glucose/analysis ; Prognosis ; Hospital Mortality ; },
abstract = {AIMS: Glycaemic variability (GV) has emerged as an important prognostic indicator in critical illness, yet its predictive value among patients with sepsis remains unclear. This systematic review and meta-analysis aimed to evaluate the association between GV metrics and mortality outcomes in adult patients with sepsis.<br><br>METHODS: Cohort studies enrolling septic patients and reporting in-hospital, 28-day, or 30-day mortality in relation to GV were identified through PubMed, Embase, Cochrane Library, Scopus, CNKI, and Wanfang databases. Pooled odds ratios (ORs) were calculated using a random-effects model. Sensitivity analyses were performed to assess the robustness of the findings.<br><br>RESULTS: Ten studies comprising 18,337 patients were included. For categorical analysis, high-GV patients had nearly twice the mortality risk (OR&#xa0;=&#xa0;1.99, 95% CI: 1.66-2.40, p&#xa0;<&#xa0;0.0001; I[2]&#xa0;=&#xa0;45%). For continuous analysis, all 4&#xa0;GV metrics showed significant associations with mortality: CoV (OR&#xa0;=&#xa0;1.050, I[2]&#xa0;=&#xa0;76.6%), SD (OR&#xa0;=&#xa0;1.0037, I[2]&#xa0;=&#xa0;83.5%), GLI (OR&#xa0;=&#xa0;1.0171, I[2]&#xa0;=&#xa0;0.0%), and MAGE (OR&#xa0;=&#xa0;1.0062, I[2]&#xa0;=&#xa0;0.0%). High GV was associated with prolonged ICU stay (0.95&#xa0;days, p&#xa0;=&#xa0;0.0018). Sensitivity analyses confirmed the result robustness.<br><br>CONCLUSIONS: Elevated GV is independently linked to an increased risk of death among patients with sepsis. GLI and MAGE are the most reliable GV metrics for prognostic assessment, whereas CoV and SD are less consistent. Standardised GV measurement and prospective studies are warranted to evaluate whether interventions targeting GV can improve outcomes in this population.},
}
@article {pmid41485706,
year = {2026},
author = {Salmanton-García, J and Nóbrega de Almeida, J and Colombo, AL},
title = {Candidozyma auris (formerly Candida auris): resistant, long lasting, and everywhere.},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {32},
number = {3},
pages = {374-381},
doi = {10.1016/j.cmi.2025.12.022},
pmid = {41485706},
issn = {1469-0691},
mesh = {Humans ; *Candida auris/drug effects/classification ; *Antifungal Agents/pharmacology/therapeutic use ; Cross Infection/epidemiology/microbiology ; *Drug Resistance, Fungal ; Disease Outbreaks ; Global Health ; },
abstract = {BACKGROUND: Invasive fungal diseases represent a significant global health concern, with Candidozyma auris (formerly Candida auris) emerging as a major healthcare-associated pathogen. Its multidrug resistance, environmental persistence, prolonged skin colonization, and efficient nosocomial transmission have driven sustained outbreaks and endemicity worldwide, and recent taxonomic changes have further complicated surveillance and diagnostics.<br><br>OBJECTIVES: This narrative review summarizes current evidence on the taxonomy, epidemiology, clinical impact, antifungal resistance, transmission, and infection prevention and control (IPC) of C. auris, highlighting outbreak drivers, regional endemicity, and key gaps relevant to surveillance and policy.<br><br>SOURCES: We conducted a structured narrative review of peer-reviewed and grey literature published between 2009 and 2025, drawing from PubMed/MEDLINE, Embase, Scopus, Web of Science, and major public health websites, such as the WHO, the CDC, the European Centre for Disease Prevention and Control, the UK Health Security Agency, and national surveillance portals.<br><br>CONTENT: C. auris has rapidly evolved into an endemic healthcare threat across multiple continents, with substantial regional variation in incidence, outbreak dynamics, antifungal resistance, and control capacity. Candidemia mortality averages &#x223c;30% but differs by region and patient population. Azole resistance is widespread in several clades, whereas resistance to amphotericin B and echinocandins is increasingly reported, particularly in high-endemic settings. Outbreaks are sustained by environmental persistence, prolonged skin colonization, and healthcare-associated transmission, amplified by intensive care exposure, antimicrobial pressure, and system strain during the COVID-19 pandemic. Despite broadly aligned IPC guidance, major challenges persist in screening, decolonization, laboratory identification, and long-term outbreak control.<br><br>IMPLICATIONS: The continued global expansion of C. auris has major clinical, economic, and public health implications. Effective control requires sustained investment in laboratory capacity, standardized nomenclature adoption, active surveillance, genomic monitoring, and rigorous IPC measures tailored to the pathogen's unique biology. Without coordinated regional and international responses, C. auris is likely to continue shifting from epidemic emergence to entrenched endemicity in diverse healthcare systems worldwide.},
}
@article {pmid41486189,
year = {2026},
author = {Terrones-Campos, C and Gallardo-Pizarro, A and Martinez-Urrea, A and Castiella, A and Vergara, A and Gonzalez, A and Egri, N and Garcia-Vidal, C},
title = {Invasive pulmonary aspergillosis in the ICU: the corticosteroid link.},
journal = {Pneumonia (Nathan Qld.)},
volume = {18},
number = {1},
pages = {2},
pmid = {41486189},
issn = {2200-6133},
support = {SGR 01324 Q5856414G//Agencia de Gesti&#xf3;n de Ayudas Universitarias y de Investigaci&#xf3;n de Catalunya/ ; },
abstract = {Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection traditionally associated with severely immunocompromised hosts, particularly those with hematologic malignancies. However, its epidemiological profile has shifted in recent years, with a rising incidence among critically ill patients in intensive care units (ICUs), many of whom lack classical risk factors. This change is driven by increased use of corticosteroids and immunomodulatory therapies, the growing prevalence of chronic lung disease, and severe viral pneumonias such as influenza and COVID-19. In these patients, airway epithelial injury, immune dysregulation, and mechanical ventilation facilitate fungal invasion even in the absence of profound immunosuppression. Corticosteroids play a central role in IPA pathogenesis. While they limit hyperinflammation, they simultaneously impair fungal clearance by suppressing NF-κB signaling, downregulating TNF-α production, and promoting IL-10 secretion, resulting in a Th2-skewed immune profile. Neutrophil recruitment persists but becomes dysregulated, contributing to tissue injury rather than effective pathogen elimination. Corticosteroids may also directly enhance Aspergillus growth, further compounding risk. Diagnosis of IPA in ICU patients remain challenging because radiological hallmarks such as the halo sign are uncommon, and distinguishing colonization from invasive disease is difficult. Serum and bronchoalveolar lavage galactomannan, β-D-glucan assays, and PCR can improve early detection, but no single test is definitive in this heterogeneous population. As much as possible, high-quality lower respiratory tract samples should be obtained. Furthermore, effective treatment requires not only timely diagnosis, but also careful selection of antifungal taking into consideration pharmacologic challenges of ICU patients and pharmacodynamics of antifungals. Recognition of high-risk patients such as those receiving corticosteroids, those with chronic lung disease, severe viral pneumonia, or requiring invasive ventilation is critical to improve outcomes. Mortality in this group can exceed that of neutropenic patients, underscoring the need for heightened clinical suspicion and timely antifungal therapy. A deeper understanding of the immunopathogenesis of IPA in non-neutropenic patients, particularly the dual effects of corticosteroids on inflammation and host defense, may inform risk stratification and guide earlier intervention. Enhanced surveillance, prompt diagnostic workup, and judicious use of immunomodulatory therapy represent key strategies to mitigate the rising burden of this devastating infection in ICU settings.},
}
@article {pmid41486437,
year = {2025},
author = {Park, WB and Hwang, YH and Kwon, KT and Noh, JY and Park, SH and Song, JY and Choo, EJ and Choi, MJ and Choi, JY and Heo, JY and Choi, WS and , },
title = {COVID-19 Vaccination Recommendations for 2025-2026 in Korea.},
journal = {Infection &amp; chemotherapy},
volume = {57},
number = {4},
pages = {472-477},
pmid = {41486437},
issn = {2093-2340},
abstract = {The Korean Society of Infectious Diseases has regularly updated its adult immunization guidelines, including the coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023 and the 2024-2025 seasonal update. This article provides a comprehensive update as of September 2025, reflecting the latest evidence and international guidance. Focusing on the 2025-2026 season, it reviews vaccines currently authorized in Korea and their effectiveness against predominant JN.1 sublineage variants, including LP.8.1, NB.1.8.1, and XFG. The updated recommendations prioritize vaccination with LP.8.1-adapted vaccines for high-risk groups-adults aged 65 years and older, individuals aged 6 months and older at increased risk for severe disease, and residents of facilities vulnerable to infection-while vaccination remains available for all individuals aged 6 months and older. A single-dose strategy is generally recommended, although older adults and immunocompromised individuals may consider an additional dose at 6-month intervals in consultation with healthcare professionals. These updates aim to refine Korea's COVID-19 vaccination strategy and sustain protection in high-risk populations, with recommendations remaining subject to revision as new evidence and epidemiological conditions evolve.},
}
@article {pmid41486438,
year = {2025},
author = {Seo, JW and Seo, YB and Kim, SE and Kim, Y and Kim, EJ and Kim, T and Kim, T and Lee, SH and Lee, E and Lee, J and Jeong, YH and Jung, YH and Choi, YJ and Song, JY},
title = {Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19.},
journal = {Infection &amp; chemotherapy},
volume = {57},
number = {4},
pages = {478-521},
pmid = {41486438},
issn = {2093-2340},
support = {HD22C2045//Korea Health Industry Development Institute/Republic of Korea ; },
abstract = {The guidelines presented herewith are based on the "Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 (PASC)" published in Infection &amp; Chemotherapy in March 2024; these guidelines have been refined by incorporating the most recent Korean and international research findings and clinical evidence published since then. In the context of patients experiencing various physical and mental symptoms that persist long after the acute phase of coronavirus disease 2019 (COVID-19) infection, the diagnosis and management of PASC has emerged as a novel public health challenge. These guidelines are intended to provide standardized diagnostic and management recommendations applicable to the Korean healthcare setting and were developed through a comprehensive review of existing guidelines from organizations such as the World Health Organization, the United States National Institutes of Health, the United Kingdom National Institute for Health and Care Excellence, and the European Society of Clinical Microbiology and Infectious Diseases, along with the latest meta-analyses and Korean cohort studies. PASC is defined as the persistent presence of symptoms and signs lasting more than 3 months after COVID-19 diagnosis for which the symptoms cannot be explained by alternative diagnoses. The revised guidelines emphasize the importance of integrated management for patients with PASC, including a multidisciplinary approach considering risk groups, symptom-specific assessment, and rehabilitation and psychological interventions, based on a total of 32 key questions. This revision reflects rapidly evolving research trends regarding the long-term effects of COVID-19 and is expected to serve as an evidence-based standard guideline for future patient care, clinical research, and health policy development in Korea.},
}
@article {pmid41486819,
year = {2026},
author = {Gupta, T and Verma, JK},
title = {Critical appraisal of methodological rigor in a systematic review on post-COVID-19 vaccination-associated olfactory dysfunction.},
journal = {Rhinology},
volume = {64},
number = {2},
pages = {285-286},
doi = {10.4193/Rhin25.440},
pmid = {41486819},
issn = {0300-0729},
mesh = {Humans ; *Olfaction Disorders/etiology ; *COVID-19 Vaccines/adverse effects ; *COVID-19/prevention &amp; control ; SARS-CoV-2 ; *Vaccination/adverse effects ; },
abstract = {We read with keen interest the article by Kawabata et al. titled "Olfactory disorder after COVID-19 vaccination" which explores 16 cases of olfactory dysfunction temporally associated with vaccination. The paper addresses an important and under-recognized topic; however, several methodological aspects warrant clarification to aid accurate interpretation. First, the inclusion of five institutional cases within a review otherwise presented as PRISMA-compliant raises questions regarding methodological consistency. Under PRISMA, all included studies should be identified through transparent and reproducible database searches. Clarifying whether institutional data were processed separately from literature-derived cases would strengthen transparency and avoid confusion about the evidence level.},
}
@article {pmid41487586,
year = {2025},
author = {Fan, H and Wang, L and Zhai, L and Deng, S and Li, Y and Niu, H and Zhao, B and Gao, J and Gao, X},
title = {Mapping three decades of air pollution-lung cancer research: trends, hotspots, and networks (1990-2025).},
journal = {Frontiers in oncology},
volume = {15},
number = {},
pages = {1698246},
pmid = {41487586},
issn = {2234-943X},
abstract = {BACKGROUND: The relationship between air pollution and lung cancer has attracted considerable attention from researchers worldwide. To systematically assess the scholarly landscape and pinpoint research fronts, this study employs bibliometric analysis to delineate global trends, collaborative networks, and key publications within this field.<br><br>METHODS: Publications from 1990 to 2025 were extracted from Web of Science Core Collection and Scopus databases. Bibliometric tools including VOSViewer, Citespace, and Bibliometrix R were used to examine trends, key contributors, research themes, and prominent journals.<br><br>RESULTS: Among 4,238 publications, citation rates rose significantly. China produced the most publications, with leading institutions such as Harvard University and the Chinese Academy of Sciences. Key researchers included Lan Q, Rothman N, and Vermeulen R. Major journals were Environmental Health Perspectives and Atmospheric Environment. Frequently used keywords like "Lung Cancer" and "Particulate Matter" indicate core themes, while emerging terms such as "Covid-19" and "Machine Learning" reflect evolving interests.<br><br>CONCLUSION: Fine particulate matter is an established environmental risk factor for lung cancer, and research on polycyclic aromatic hydrocarbons and asbestos remains active. The field has shifted from exposure assessment to mechanistic investigations focusing on oxidative stress, gene expression, and machine learning applications, defining key future research directions.},
}
@article {pmid41488032,
year = {2026},
author = {Suresh, RR and Abuduani, T and Kasthuri, M and Chen, Z and Tber, Z and Loubidi, M and Zhang, H and Zhou, L and Zhou, S and Li, C and Kumari, A and Tao, S and Wiseman, JM and Hurwitz, SJ and Amblard, F and Schinazi, RF},
title = {Prodrug strategies in developing antiviral nucleoside analogs.},
journal = {RSC medicinal chemistry},
volume = {17},
number = {1},
pages = {105-131},
pmid = {41488032},
issn = {2632-8682},
support = {P30 AI050409/AI/NIAID NIH HHS/United States ; },
abstract = {Prodrug strategies are used to enhance the physicochemical and pharmaceutical properties of drug candidates that may not be suitable for specific delivery or are limited by formulation options. A prodrug derivative is converted into its active pharmaceutical ingredient (drug) through enzymatic or chemical reactions within the body. Antiviral nucleoside prodrugs have garnered considerable interest in drug discovery, leading to the approval of key drugs such as remdesivir (SARS-CoV-2), Sovaldi (hepatitis C virus, HCV), and tenofovir disoproxil fumarate [hepatitis B virus (HBV) and human immunodeficiency viruses (HIV)]. Their success lies in improving the oral bioavailability and delivering the parent drug to the targeted tissues. This review focuses on the prodrugs of antiviral nucleosides evaluated in humans (approved, in development or terminated), providing an overview of the different approaches utilized and discussing their in vitro and in vivo benefits.},
}
@article {pmid41488148,
year = {2025},
author = {Shitaye, G and Getie, M and Mekonnen, Z and D'Abrosca, G and Fattorusso, R and Isernia, C and Amuamuta, A and Malgieri, G},
title = {Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views.},
journal = {Frontiers in endocrinology},
volume = {16},
number = {},
pages = {1737894},
pmid = {41488148},
issn = {1664-2392},
mesh = {Humans ; *COVID-19/complications/metabolism/pathology/epidemiology ; *SARS-CoV-2 ; *Diabetes Mellitus, Type 2/epidemiology/etiology/virology/metabolism/pathology ; *Diabetes Mellitus, Type 1/epidemiology/metabolism/etiology/virology ; Renin-Angiotensin System ; Post-Acute COVID-19 Syndrome ; Insulin Resistance ; },
abstract = {Long COVID, or post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), refers to a range of persistent health effects associated with SARS-CoV-2 infection. Long COVID is a complex, multisystem disorder that can affect nearly every organ system and is strongly linked with the incidence of diabetes and other chronic conditions. Increasing evidence also connects persistent SARS-CoV-2 infection with the development of new-onset diabetes and other metabolic disorders. In this review, we assess the current evidence and discuss the incidence of new-onset diabetes, along with the pathobiological mechanisms by which SARS-CoV-2 may contribute to the progression of both new-onset type 1 and type 2 diabetes mellitus (T1DM and T2DM). We summarize the latest understanding of the molecular and cellular mechanisms underlying SARS-CoV-2-associated new-onset diabetes. Potential mechanisms include direct damage to pancreatic β-cells, inflammation, insulin resistance, and autoimmune responses. Dysregulation of the ACE2/renin-angiotensin system (RAS) pathway has been linked to multiple inter-organ pathologies, and increased inflammatory cytokines together with dysregulation of interferon regulatory factors (IRFs)-such as overexpression of IRF1-appear to represent key mechanistic links to widespread tissue damage and metabolic alterations. Moreover, the presence of viral RNA or viral RNA fragments may directly damage pancreatic islets, contributing to insulin resistance and β-cell dysfunction that, in turn, may promote the development of new-onset diabetes. In light of these findings, this review further examines evidence supporting the persistence of SARS-CoV-2 RNA in PASC reservoir tissues, including the pancreas, and its potential association with the development of new-onset diabetes mellitus.},
}
@article {pmid41488264,
year = {2025},
author = {Kumar, C and Akhileshwar, and Kumar Neeraj, R and Hameed, S and Husain, N and Roy, SS and Mohan, L and Anantsaznam, },
title = {Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barré Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine.},
journal = {Cureus},
volume = {17},
number = {11},
pages = {e98208},
pmid = {41488264},
issn = {2168-8184},
abstract = {This study aimed to evaluate the incidence and risk of rare long-term adverse events, specifically myocarditis and Guillain-Barré syndrome (GBS), in adolescents (12-19 years) following COVID-19 mRNA vaccination. We systematically searched MEDLINE, Embase, Cochrane CENTRAL, and Scopus, supplemented by trial registries and reference lists (PROSPERO: CRD420251045173). Eligible studies included randomized controlled trials (RCTs), cohort studies, case-control studies, self-controlled case series, and pharmacovigilance database analyses reporting myocarditis or GBS outcomes in adolescents receiving BNT162b2 or mRNA-1273. The search was conducted in June 2025, and all published studies were included. Risk of bias was assessed using the Cochrane RoB-2 tool, Newcastle-Ottawa Scale, or adapted criteria for pharmacovigilance studies. Effect measures were expressed as incidence rate or incidence rate ratios (IRRs) with 95% confidence intervals (CIs). Meta-analyses were conducted using random-effects models. Ten studies met the inclusion criteria. Myocarditis incidence was elevated in adolescent and young adult males, particularly after the second dose. Pooled analyses indicated a higher risk with mRNA-1273 compared to BNT162b2 (pooled IRR ≈ 3.9), although heterogeneity was very high (I[2] > 95%). For GBS, global pharmacovigilance data suggested only a modest association with mRNA vaccines (ROR 9.66), substantially weaker than for adenoviral vector or influenza vaccines. COVID-19 mRNA vaccination in adolescents is associated with a small but measurable increased risk of myocarditis, particularly in males, after the second dose, with a higher incidence following mRNA-1273. No consistent evidence of increased GBS risk was observed. Absolute risks remain low, and outcomes are generally favorable compared to SARS-CoV-2 infection. Continued surveillance and long-term follow-up are warranted.},
}
@article {pmid41488437,
year = {2025},
author = {Pluetrattanabha, N and Direksunthorn, T},
title = {Mobile Health Clinics and Telehealth Outreach in Thailand: A Focus on Elderly Care and NCDs.},
journal = {Journal of multidisciplinary healthcare},
volume = {18},
number = {},
pages = {8321-8331},
pmid = {41488437},
issn = {1178-2390},
abstract = {BACKGROUND: Thailand faces a rapidly aging population alongside a high burden of non-communicable diseases (NCDs). Ensuring equitable healthcare access for older adults with NCDs is a pressing challenge. Mobile health clinics and telehealth services have emerged as key strategies to reach underserved elderly populations and maintain continuity of NCD care in remote or resource-limited settings.<br><br>OBJECTIVE: To examine current mobile clinic initiatives and telehealth outreach in Thailand focused on elderly care and NCD management, and to evaluate their impact on healthcare access and outcomes for older adults.<br><br>METHODS: We conducted a narrative review of published literature, policy reports, and program descriptions on mobile health clinics and telehealth interventions in Thailand, with emphasis on applications for older adults and chronic disease care (eg, diabetes, hypertension). A comprehensive search (2010-2025) of PubMed, Google Scholar, and Thai government/organization websites identified relevant sources. Data on intervention models, settings, target populations, and reported outcomes were extracted. In total, 15 key publications and reports were reviewed, from which 8 major mobile clinic or telehealth initiatives were identified.<br><br>RESULTS: Mobile health clinics have expanded primary care access for vulnerable elderly in both urban and rural areas. The Thai Red Cross Society's mobile clinic serves remote mountainous communities and provides primary care, NCD screenings, vaccinations, and medications to about 5,000 underserved people annually. Past mobile outreach programs have uncovered many untreated cases-in one survey, 58% of hypertensive and 75% of diabetic elderly were first diagnosed via a mobile unit. Telehealth services have likewise grown substantially. During the COVID-19 pandemic, telemedicine was rapidly adopted for routine consultations and chronic disease follow-ups. The National Health Security Office (NHSO) introduced a nationwide telemedicine service under the Universal Coverage Scheme, enabling remote consultations and medication deliveries for stable chronic NCD patients, ensuring continuity of care during lockdowns. Numerous telehealth applications emerged (public and private); for example, smartphone apps like MorDee ("Good Doctor") gained wide usage in Thailand. In an urban pilot "Dusit Telemedicine" model, integrating community clinics with a tertiary hospital, over 300 elderly patients received teleconsultations, reducing overcrowding. An acceptance study in this Bangkok pilot found older generations significantly less likely to adopt telemedicine than younger people - perceived ease of use was a strong predictor of acceptance (adjusted OR 3.95 for usability). Community-based telehealth pilots in rural areas, such as a Chiang Mai program using Community Health Leaders, demonstrated high satisfaction (&#x2265;90%) and successful NCD risk screenings, but also highlighted the need for training and support for both health workers and patients.<br><br>CONCLUSION: Mobile clinics and telehealth are complementary strategies for enhancing healthcare delivery to elderly Thais with NCDs. Mobile clinics physically bring essential services to those unable to travel, while telehealth connects patients to providers for continuous care and monitoring. The Thai experience illustrates that integrating these innovations into primary healthcare systems can enhance equity of care for aging populations. Continued support, digital literacy training for seniors, and policy integration of telehealth into the health system are recommended to ensure healthy aging under universal health coverage.},
}
@article {pmid41488438,
year = {2025},
author = {Maulana, I and Shalahuddin, I and Eriyani, T and Pebrianti, S},
title = {"Exploring Psychosocial Interventions to Improve Mental Health Outcomes Among Healthcare Workers": Scoping Review.},
journal = {Journal of multidisciplinary healthcare},
volume = {18},
number = {},
pages = {8293-8303},
pmid = {41488438},
issn = {1178-2390},
abstract = {BACKGROUND: Healthcare workers (HCWs) face heightened risks of stress, anxiety, depression, and burnout, particularly during and after the COVID-19 pandemic. Psychosocial interventions have been increasingly implemented, yet the evidence remains fragmented across diverse settings and modalities. This scoping review aimed to map current psychosocial interventions designed to improve mental health outcomes among HCWs.<br><br>METHODS: Guided by the PRISMA-ScR framework, five databases (PubMed, Scopus, ScienceDirect, EBSCOhost, Google Scholar) were searched from January 2000 to September 2025. Eligible studies involved HCWs, assessed psychosocial interventions, and reported mental health outcomes. The Joanna Briggs Institute (JBI) appraisal tool was applied, and only studies scoring &#x2265;70% were retained. Although multiple designs were eligible, only randomized controlled trials (RCTs) met the quality threshold and were included. Data were synthesized descriptively and thematically.<br><br>RESULTS: Of 312 identified records, 15 RCTs (2021-2025) were included. Interventions were grouped into mindfulness and meditation programs (n=6), digital and mHealth approaches (n=5), and coaching or AI-assisted resilience training (n=4). Specifically, mindfulness interventions reduced stress and anxiety by up to 30% and consistently improved well-being. Notably, digital modalities-including mobile apps and internet-delivered cognitive behavioral therapy (CBT)-were widely used during the pandemic and demonstrated benefits for burnout, sleep quality, and resilience. Across all studies, coaching and AI-assisted interventions improved work engagement and reduced exhaustion, particularly in non-pandemic contexts.<br><br>CONCLUSION: Psychosocial interventions demonstrate strong potential to improve HCWs' mental health. Digital programs offer scalable support, while resilience-based approaches promote long-term well-being. Future research should examine implementation in low-resource settings, compare digital versus in-person modalities, and explore organizational-level strategies to complement individual interventions.},
}
@article {pmid41488474,
year = {2025},
author = {Yamin, M and Alsahafi, N and Abdulal, RH and Asad, M and Bosaeed, M and Zohaib, A},
title = {Non-coding RNAs in the viral host-pathogen interaction: molecular regulation and therapeutic potential.},
journal = {Frontiers in cellular and infection microbiology},
volume = {15},
number = {},
pages = {1734182},
pmid = {41488474},
issn = {2235-2988},
mesh = {Humans ; *Host-Pathogen Interactions/genetics ; *RNA, Untranslated/genetics ; COVID-19/virology ; SARS-CoV-2/genetics ; MicroRNAs/genetics/antagonists &amp; inhibitors ; RNA, Circular/genetics ; Hepacivirus/genetics ; RNA, Long Noncoding/genetics ; Virus Replication ; *Virus Diseases/virology/genetics ; Antiviral Agents/therapeutic use ; Animals ; },
abstract = {Non-coding RNAs (ncRNAs), including microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA), serve as key regulatory molecules in the context of viral infection. They play dual roles by modulating host immune responses and influencing viral replication, persistence, and disease progression. Numerous ncRNAs have been implicated in infections caused by viruses such as HCV, DENV and SARS-CoV. This review highlights the biogenesis and multifaceted functions of both host-encoded and virus-encoded ncRNAs in shaping host-pathogen interactions. It also examines their potential as novel biomarkers and therapeutic agents for viral infections. We discuss translational applications such as Miravirsen, a miRNA inhibitor that reached clinical trials for Hepatitis C Virus (HCV) and diagnostic relevance of lncRNA NEAT1 in SARS-CoV-2 infection. In the end, we have also addressed the current challenges and limitations involved in translating research observations of ncRNAs to clinical outcomes.},
}
@article {pmid41488618,
year = {2025},
author = {Rodrigues, T and Beltrão, GS and Girardi, H and Pinto, AR},
title = {Viral reprogramming of glial metabolism as a driver of neuroinflammation.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1686774},
pmid = {41488618},
issn = {1664-3224},
mesh = {Humans ; *Neuroinflammatory Diseases/metabolism/virology/immunology ; *SARS-CoV-2/immunology ; Animals ; *COVID-19/immunology/metabolism/virology ; *Neuroglia/metabolism/virology/immunology ; Astrocytes/virology/metabolism/immunology ; HIV-1 ; Microglia/metabolism/virology/immunology ; Glycolysis ; Zika Virus/immunology ; },
abstract = {Considerable attention has been recently devoted to the involvement of immune cells in the central nervous system (CNS) during infections with neurotropic viruses, such as SARS-CoV-2, HIV-1, and ZIKV. These viruses are capable of infecting astrocytes and microglia, the main glial cells in the CNS, responsible for regulating neuronal activity. Here, we discuss how viral infections lead to metabolic reprogramming toward aerobic glycolysis in these cells, enhancing pro-inflammatory pathways, such as inflammasome activation, resulting in the secretion of inflammatory cytokines that favor the development of neuroinflammation. In this mini review, we discuss the pivotal interplay between metabolism and immunity towards viral pathogenesis in the CNS, pointing out the relevance of therapeutic strategies targeting both metabolic and immunological pathways to enhance antiviral and neuroprotective responses.},
}
@article {pmid41488628,
year = {2025},
author = {Yin, L and Sun, CY and Chen, GL and Xiang, Z and Hu, BQ and Zhou, F and Wang, Q},
title = {Modular mastery of inflammation: umbilical cord mesenchymal stem cells as a therapeutic frontier.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1721947},
pmid = {41488628},
issn = {1664-3224},
mesh = {Humans ; *Mesenchymal Stem Cells/immunology ; *Umbilical Cord/cytology ; *Mesenchymal Stem Cell Transplantation/methods ; *COVID-19/therapy/immunology ; *Inflammation/therapy/immunology ; SARS-CoV-2 ; *Inflammatory Bowel Diseases/therapy/immunology ; Graft vs Host Disease/therapy/immunology ; Animals ; },
abstract = {Inflammation operates as a dual-edged sword in physiological defense and pathological damage, driving conditions from diabetes to neurodegeneration. Current anti-inflammatory therapies-NSAIDs, corticosteroids, and biologics-face clinical bottlenecks including non-specific toxicity, therapeutic ceiling effects, and drug resistance. Umbilical cord mesenchymal stem cells (UC-MSCs) emerge as a transformative alternative, leveraging three synergistic modules: Immune reprogramming, Inflammasome inhibition, Intercellular communication. Clinical trials demonstrate efficacy in inflammatory bowel disease, COVID-19 ARDS, and graft-versus-host disease. UC-MSCs outperform conventional therapies by multi-pathway modulation and tissue-regenerative capacity, though challenges persist in cell heterogeneity and long-term safety. Future work must standardize dosing protocols and validate scalable production for clinical translation.},
}
@article {pmid41488667,
year = {2025},
author = {Zheng, Y and Liu, C and Li, Y and Wang, W and Dou, Q},
title = {The dual role of thrombospondin-1 in inflammatory regulation during acute respiratory distress syndrome: a mini-review.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1699900},
pmid = {41488667},
issn = {1664-3224},
mesh = {Humans ; *Thrombospondin 1/metabolism/immunology ; *Respiratory Distress Syndrome/immunology/metabolism/pathology ; *COVID-19/immunology ; Animals ; *Inflammation/immunology/metabolism ; *SARS-CoV-2/immunology ; },
abstract = {Inflammation serves as a fundamental defense against tissue injury and infection, yet dysregulation can lead to pathological outcomes. Thrombospondin-1 (Thbs1/TSP1), a multifunctional glycoprotein significantly upregulated during inflammation, exemplifies a dualistic regulator with context-dependent roles. Through modulation of cytokine networks and inflammatory cell activity (notably macrophages), Thbs1 critically governs inflammatory responses. Acute respiratory distress syndrome (ARDS), a life-threatening condition fueled by systemic inflammation secondary to infection or trauma, presents complex pathophysiology requiring elucidation. COVID-19 research highlights elevated Thbs1 expression in severe patients, where it demonstrates protective effects against pulmonary damage primarily via extracellular matrix protection, inhibition of neutrophil serine proteases, and TGF-β-dependent repair pathways. However, paradoxical evidence indicates that dysregulated Thbs1 can also contribute to ARDS pathogenesis, potentially by amplifying inflammation, promoting thromboinflammation, or driving fibrosis. Mechanistic insights reveal Thbs1's influence on ARDS progression through ECM remodeling, serine protease inhibition, and TGF-β activation. While significant progress has been made in understanding Thbs1 signaling, the precise mechanisms dictating its context-dependent switch between protective and pathogenic functions in inflammatory pathways remain a critical area for future investigation.},
}
@article {pmid41488929,
year = {2025},
author = {Du, S and Cui, Z and Xu, X and Liu, T and Ye, J},
title = {Clinical efficacy of exercise in the treatment of post-COVID-19 syndrome: a systematic review and network meta-analysis.},
journal = {Frontiers in physiology},
volume = {16},
number = {},
pages = {1656713},
pmid = {41488929},
issn = {1664-042X},
abstract = {BACKGROUND: Post-COVID-19 syndrome (PCS) describes a constellation of persistent or new symptoms lasting beyond the acute phase of SARS-CoV-2 infection. Emerging evidence suggests that exercise is a cost-effective and accessible intervention that may enhance pulmonary function, improve cardiopulmonary circulation, regulate emotional status, and alleviate symptoms of PCS. However, robust evidence supporting the efficacy of exercise therapy in PCS remains limited. This systematic review and meta-analysis aimed to elucidate the therapeutic potential of exercise therapy in PCS.<br><br>METHOD: A search of the PubMed, Embase, Web of Science, and Ovid databases up to March 25, 2025 yielded 33 randomized controlled trials (with 2,895 participants) for meta-analysis.<br><br>RESULT: The results showed that exercise therapy significantly improved the multi-dimensional outcomes of patients with PCS. Bayesian network meta-analysis indicated that the combination of aerobic exercise and respiratory muscle training had the best effect on lung function. Multimodal exercise significantly improved the results of the six-minute walk test, the dyspnea score, and peak oxygen uptake. Mental Health and Mental Component Summary scores improved significantly in the group that received exercise therapy (P<0.01).<br><br>CONCLUSION: The results of this meta-analysis confirm that exercise can significantly improve quality of life and the emotional state of patients with PCS. They also provide evidence for a treatment strategy in patients with post-COVID-19 sequelae.<br><br>https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier CRD420251034187.},
}
@article {pmid41489056,
year = {2026},
author = {Boesen, K and Hemkens, LG and Janiaud, P and Hirt, J},
title = {Topic-specific living databases of clinical trials: A scoping review of public databases.},
journal = {Clinical trials (London, England)},
volume = {23},
number = {2},
pages = {198-209},
pmid = {41489056},
issn = {1740-7753},
mesh = {Humans ; *Clinical Trials as Topic ; COVID-19 ; *Databases, Factual ; SARS-CoV-2 ; Information Storage and Retrieval ; },
abstract = {INTRODUCTION: Conducting systematic reviews of clinical trials is time-consuming and resource-intensive. One potential solution is to design databases that are continuously and automatically populated with clinical trial data from harmonised and structured datasets. This scoping review aimed to identify and map publicly available, continuously updated, topic-specific databases of clinical trials.<br><br>METHODS: We systematically searched PubMed, Embase, the preprint servers medRxiv, arXiv, Open Science Framework, and Google. We characterised each database using seven predefined features (access model, database type, data input sources, retrieval methods, data-extraction methods, trial presentation, and export options) and narratively summarised the results.<br><br>RESULTS: We identified 14 continuously updated databases of clinical trials, seven related to COVID-19 (initiated in 2020) and seven non-COVID-19 databases (initiated as early as in 2009). All databases, except one, were publicly funded and accessible without restrictions. Most relied on traditional methods used in static article-based systematic reviews sourcing data from journal publications and trial registries. The COVID-19 databases and some non-COVID-19 databases implemented semi-automated features of data import, which combined automated and manual data curation, whereas the non-COVID-19 databases mainly relied on manual workflows. Most reported information was metadata, such as author names, years of publication, and link to publication or trial registry. Only two databases included trial appraisal information (such as risk of bias assessments). Six databases reported aggregate group-level results, but only one database provided individual participant data on request.<br><br>DISCUSSION: Continuously updated topic-specific databases of clinical trials remain limited in number, and existing initiatives mainly employ traditional static systematic review methodologies. A key barrier to developing truly living platforms is the lack of accessible, machine-readable, and standardised clinical trial data.},
}
@article {pmid41490687,
year = {2026},
author = {Sousa Almeida, PR and Sarmento, G and Gruner, H and Veríssimo, R and Duque, S},
title = {[Vaccination of Older Adults in Portugal: Recommendations from the Geriatrics Study Group of the Portuguese Society of Internal Medicine].},
journal = {Acta medica portuguesa},
volume = {39},
number = {3},
pages = {223-234},
doi = {10.20344/amp.23786},
pmid = {41490687},
issn = {1646-0758},
mesh = {Humans ; Aged ; Portugal ; Influenza Vaccines/administration &amp; dosage ; *Vaccination/standards ; Middle Aged ; Pneumococcal Vaccines/administration &amp; dosage ; Geriatrics ; *COVID-19 Vaccines/administration &amp; dosage ; Aged, 80 and over ; COVID-19/prevention &amp; control ; Influenza, Human/prevention &amp; control ; },
abstract = {Older persons are more susceptible to infections and have a higher risk of serious complications, with a worse functional and vital prognosis. Vaccination is an effective strategy with a favorable safety profile for preventing infections and promoting healthy aging. In view of the clinical evidence and the vaccines available in Portugal in the first half of 2025, the Geriatrics Study Group of the Portuguese Society of Internal Medicine presents a proposal for vaccination of adults aged 65 years or older. The experts also point out the need to create a national lifelong vaccination program that includes older people to increase vaccination coverage and reduce the impact of infections in this population. Although the document focuses on people aged 65 years or older, vaccination against some diseases should start earlier. This article outlines five main recommendations: 1) Annual influenza and COVID-19 vaccination for all adults aged 50 years or older, with those aged 65 years or older receiving the high-dose trivalent influenza vaccine; 2) Respiratory syncytial virus vaccination for all adults aged 60 years or older and adults aged 18 - 59 years with risk factors, prioritizing people aged 75 years or older and those aged 50 years or older with risk factors; 3) Pneumococcal vaccination with the 20-valent or 21-valent pneumococcal conjugate vaccine for all adults aged 50 years or older and adults aged 18 - 49 years with risk factors; 4) Herpes zoster vaccination with the recombinant vaccine for all adults aged 50 years or older and adults aged 18 - 49 years at high risk of herpes zoster; 5) From the age of 65 years, booster vaccination against tetanus, diphtheria and pertussis every 10 years.},
}
@article {pmid41491167,
year = {2026},
author = {Liao, Y and Liu, Y and Xu, S and Yang, J and Chen, Y},
title = {Incomplete Kawasaki disease associated with acute icteric hepatitis and Torque teno virus infection: a case report and literature review.},
journal = {BMC pediatrics},
volume = {26},
number = {1},
pages = {14},
pmid = {41491167},
issn = {1471-2431},
support = {0102018005//the 2024 Guangdong Renowned Traditional Chinese Medicine Practitioner Inheritance Studio Construction Project- Xu Youjia/ ; E43729//the State Administration of Traditional Chinese Medicine, under the project "a project for Chinese Medicine on Ying Lv's Renowned Expert Inheritance Studio"/ ; 2023B1111020004//the Department of Science and Technology of Guangdong Province, under the project "Efficacy and safety of the Jianer Jiedu Formula for the treatment of novel coronavirus infections in children- a real-world and randomized controlled study"/ ; 2024A03J0125//Bureau of Science and Technology of Guangzhou Municipality, under the project "Mechanism Study on the Regulation of NLRP3-mediated Pyroptosis by Jianer Jiedu Formula for the Treatment of RSV Pneumonia in Children Based on the Lingnan DampHeat Theory"/ ; },
mesh = {Humans ; Male ; *Mucocutaneous Lymph Node Syndrome/complications/diagnosis ; Infant ; *Torque teno virus/isolation &amp; purification ; *DNA Virus Infections/complications/diagnosis ; *Jaundice/etiology ; Acute Disease ; *Hepatitis/diagnosis/complications ; Immunoglobulins, Intravenous/therapeutic use ; },
abstract = {INTRODUCTION: Kawasaki disease (KD) is an acute, self-limiting vasculitis that primarily affects children under five years of age. Its classic clinical features include prolonged fever, bilateral conjunctival injection, changes in the lips and oral cavity, cervical lymphadenopathy, rash, and extremity changes. Acute jaundice and liver dysfunction are atypical manifestations of KD. Cases in which jaundice is the initial presenting symptom-especially when accompanied by Torque Teno Virus (TTV) infection-are rarely reported.<br><br>CASE PRESENTATION: We describe a 17-month-old boy diagnosed with incomplete Kawasaki disease (IKD), who initially presented with persistent fever, jaundice, and elevated liver enzymes. At disease onset, characteristic mucocutaneous signs of KD were absent. As the illness progressed, the patient developed dorsal foot edema, erythematous lips, and cervical lymphadenopathy. On the ninth day of illness, echocardiography revealed dilation of the left coronary artery, confirming a retrospective diagnosis of IKD. Additionally, high-throughput sequencing of peripheral blood identified TTV type 28. The patient was treated with intravenous immunoglobulin, methylprednisolone, and hepatoprotective agents. Following treatment, his fever resolved, jaundice subsided, liver function normalized, and coronary artery dimensions gradually returned to within the normal range.<br><br>CONCLUSIONS: This case highlights an atypical presentation of IKD, characterized by early-onset jaundice and later development of coronary artery dilation, in a patient also infected with TTV. To our knowledge, this is the first reported case of IKD associated with acute icteric hepatitis and TTV infection. This case may inform clinical evaluation in similar presentations and contribute to future research on the etiology of KD.},
}
@article {pmid41492414,
year = {2026},
author = {Govorchin, A and Leduc, M and Atleo, CG and Hoogeveen, D and Borgos, I and Patrick, L},
title = {The right to health: indigenous data sovereignty in Canada during and beyond the COVID-19 pandemic.},
journal = {Lancet regional health. Americas},
volume = {54},
number = {},
pages = {101335},
pmid = {41492414},
issn = {2667-193X},
abstract = {The COVID-19 pandemic disproportionately impacted Indigenous Peoples in Canada, highlighting preexisting health inequities. These disparities were exacerbated by inadequate data management policies across Canadian governments, which contribute to inaccurate health information and access challenges for Indigenous Nations. Indigenous data sovereignty, which recognizes the right of Indigenous Peoples to govern their own data, has been identified as essential for achieving self-determination and improving health outcomes. We focus on British Columbia (BC) given its unique health and data governance structure with First Nations. This policy paper examines the challenges related to health data management that arose during COVID-19 in BC, and the regulatory barriers hindering Indigenous health equity. We present four policy recommendations that address data issues as a promising avenue to reducing health inequities in Canada. This includes supporting research by and with Indigenous Peoples, promoting ethical responsibilities of non-Indigenous researchers, implementing anti-racism policies, and adopting Indigenous data management frameworks.},
}
@article {pmid41493182,
year = {2026},
author = {Oliveira, T and Naranjo-Zolotov, M and Martins, R and Karatzas, S},
title = {Adoption of Internet of Things in Health Care: Weighted and Meta-Analytical Review of Theoretical Frameworks and Predictors.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e64091},
pmid = {41493182},
issn = {1438-8871},
mesh = {Humans ; COVID-19/epidemiology ; *Delivery of Health Care ; *Internet of Things ; SARS-CoV-2 ; Telemedicine ; *Bibliometrics ; },
abstract = {BACKGROUND: The integration of the Internet of Things (IoT) into health care is transforming the industry by enhancing disease care and management, as well as supporting self-health management. The COVID-19 pandemic has accelerated the adoption of IoT devices, particularly wearable medical devices, which enable real-time health monitoring and advanced remote health management. Globally, the increased adoption of IoT in health care has improved efficiency, enhanced patient care, and generated substantial economic value.<br><br>OBJECTIVE: This review aims to conduct a comprehensive meta- and weight analysis of quantitative studies to identify the most influential predictors and theoretical frameworks explaining the adoption of IoT in health care.<br><br>METHODS: We searched databases, including Web of Science and PubMed, for quantitative studies on IoT health care adoption, with the last search conducted in early July 2025. Inclusion criteria comprised peer-reviewed articles written in English that employed a quantitative approach to IoT health care technology adoption. Studies were excluded if they did not report the significance of relationships, involved technologies without IoT features or were outside the scope, or examined target variables irrelevant to the analysis. The weight analysis identified the pathways with the most significant effects. A meta-analysis using a random-effects model was conducted to estimate combined effect sizes and their statistical significance. The results from both methods were then integrated to visualize the most frequently used theoretical frameworks. Risk of bias and heterogeneity were assessed using a funnel plot, Egger regression test, the I2 statistic, and subgroup analysis, which indicated no strong evidence of publication bias but revealed a high level of heterogeneity.<br><br>RESULTS: Analysis of 115 datasets from 109 papers identified the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology (UTAUT) as the primary frameworks for explaining IoT adoption in health care. Incorporating context-specific variables-such as health consciousness, innovativeness, and trust-into these traditional technology acceptance frameworks enhances the understanding of IoT adoption. Although high heterogeneity suggests a need to refine theoretical models to account for regional contexts, universal adoption drivers such as performance expectancy and effort expectancy remain consistent.<br><br>CONCLUSIONS: Behavioral intention is the most frequently studied variable in IoT health care adoption, whereas attitude, performance expectancy, effort expectancy, and task-technology fit remain underexplored. While adoption theories from the information systems field, such as the TAM, are predominantly used, integrating context-specific constructs and theories-such as trust and innovativeness-can provide deeper insights into IoT adoption in health care. The strongest and most consistent predictors of behavioral intention were attitude, performance expectancy, habit, self-efficacy, functional congruence, and benefits. Additionally, social influence, facilitating conditions, trust, and aesthetic appeal demonstrated promising or strong effects. By contrast, variables such as privacy and security, barriers, vulnerability, severity, compatibility, financial cost, health, and technology anxiety were generally inconsistent or not statistically significant.},
}
@article {pmid41493556,
year = {2026},
author = {Pathak, R and Vandeliwala, M and Patel, P and Patel, N and Patel, K},
title = {Resurgence of human metapneumovirus: an overview of past and current trends.},
journal = {Archives of microbiology},
volume = {208},
number = {2},
pages = {93},
pmid = {41493556},
issn = {1432-072X},
mesh = {*Metapneumovirus/physiology/genetics/pathogenicity ; Humans ; *Paramyxoviridae Infections/epidemiology/virology/diagnosis/drug therapy ; Antiviral Agents/therapeutic use ; *Respiratory Tract Infections/virology/epidemiology ; Host-Pathogen Interactions ; },
abstract = {Human metapneumovirus (HMPV) is a major respiratory pathogen belonging to the Pneumoviridae family that primarily affects children, the elderly, and immunocompromised individuals. Since its discovery in 2001, HMPV has been recognized as a significant cause of acute respiratory infections (ARIs) worldwide, exhibiting seasonal peaks and recurring outbreaks. In recent years, the virus has shown an unusual resurgence, particularly in the post-COVID-19 era, emphasizing the need for renewed clinical and epidemiological attention. This review provides a comprehensive overview of HMPV, encompassing its epidemiology, virion structure, replication mechanisms, host-pathogen interaction, clinical manifestations, diagnostic strategies, and current therapeutic approaches. Special attention is given to recent epidemiological trends, molecular insights derived from structural studies of viral proteins, and the challenges faced in developing vaccines and antiviral agents. Additionally, the review discusses the potential of plant-derived bioactive compounds as alternative or complementary therapeutic options. By consolidating the latest global data and highlighting existing knowledge gaps, the work aims to facilitate a better understanding of HMPV pathogenesis and guide future research directions for improved surveillance, diagnosis, and management of HMPV infections.},
}
@article {pmid41494094,
year = {2026},
author = {Cao-Lei, L and Vrantsidis, D and Giesbrecht, GF},
title = {Epigenetic Insights into the Impact of Disaster-Related Prenatal Stress: A Narrative Review.},
journal = {Harvard review of psychiatry},
volume = {34},
number = {1},
pages = {7-22},
doi = {10.1097/HRP.0000000000000446},
pmid = {41494094},
issn = {1465-7309},
mesh = {Humans ; Pregnancy ; *Prenatal Exposure Delayed Effects/genetics ; *Stress, Psychological/genetics ; Female ; *Epigenesis, Genetic ; *Disasters ; DNA Methylation ; *Pregnancy Complications/genetics ; },
abstract = {Disaster-related prenatal maternal stress, whether due to natural or human-made crises, can have profound effects on offspring health and development. This narrative review synthesizes research findings on the epigenetic mechanisms through which prenatal maternal stress influences long-term offspring health outcomes. Focusing primarily on DNA methylation, we examine how exposure to stress during gestation alters the epigenetic profile and may contribute to mental, cognitive, and physical health vulnerabilities. Studies were categorized based on disaster type, including time-limited events such as hurricanes, floods, and earthquakes, and stressors like the COVID-19 pandemic and famine. Key findings highlight the timing of exposure, sex-specific epigenetic effects, and the potential for epigenetic markers to mediate stress-induced health outcomes. While considerable progress has been made, our review emphasizes the need for further research on how epigenetics may mediate mental health outcomes and the development of interventions that target these molecular mechanisms.},
}
@article {pmid41494304,
year = {2026},
author = {Kung, PJ and Chen, CM and Lin, EC and Shu, BC and Tew, Y and He, J and Fang, CJ and Reynolds, NR and Ornstein, KA},
title = {Ethical challenges around mandatory vaccination among nurses: A systematic review of qualitative and quantitative evidence.},
journal = {International journal of nursing studies},
volume = {175},
number = {},
pages = {105313},
doi = {10.1016/j.ijnurstu.2025.105313},
pmid = {41494304},
issn = {1873-491X},
mesh = {Humans ; *COVID-19/prevention &amp; control ; *Mandatory Vaccination/ethics ; *Nurses/psychology ; Qualitative Research ; *Vaccination/ethics ; },
abstract = {BACKGROUND: Mandatory vaccination policies have sparked global ethical debates, particularly in the context of COVID-19. Among healthcare workers, nurses-the largest segment of the frontline workforce-face distinct tensions between professional responsibilities and personal autonomy. Yet, the ethical challenges these policies pose from nurses' perspectives remain insufficiently examined.<br><br>AIM: This review examines the ethical challenges of mandatory vaccination from nurses' perspectives, informs ethical policymaking, and provides insights to navigate similar future scenarios.<br><br>DESIGN: A mixed-methods systematic review guided by the Joanna Briggs Institute methodology.<br><br>DATA SOURCES: Final searches of five databases-Embase, MEDLINE, CINAHL, Web of Science, and Scopus-were conducted in September 2025. Additional records were identified through citation tracking and supplementary searches.<br><br>METHODS: Empirical studies published from 2019 onward were screened for relevance and assessed for methodological quality using standardized critical appraisal tools. Studies were included if they examined nurses' experiences, attitudes, or ethical perspectives regarding mandatory vaccination. A narrative synthesis approach was applied to integrate qualitative, quantitative, and mixed-methods findings.<br><br>RESULTS: Twenty-eight studies were included (19 quantitative, 5 qualitative, and 4 mixed methods). Four themes emerged: (1) Walking a Tightrope-Between Vaccine Safety and Effectiveness; (2) Silent Burden-Navigating Stigma in the Shadows; (3) Navigating the Fine Line-Balancing Rights and Public Health in Times of Crisis; and (4) Strengthening Leadership and Communication.<br><br>CONCLUSIONS: While mandatory vaccination policies may serve public health goals, they can also generate ethical distress, undermine trust, and increase stigmatization among nurses who remain unvaccinated. Future policies should move beyond enforcement toward fostering ethical alignment through education, open dialog, and respectful engagement.<br><br>REGISTRATION: PROSPERO registration number: CRD42024551112, registered 03/06/2024.},
}
@article {pmid41494305,
year = {2026},
author = {Pupillo, E and Leone, MA and Amato, A and Bianchi, E and Damian, MS and Dyck, J and Garcia-Azorin, D and Giussani, G and Guekht, A and Koike, H and Khadilkar, S and Lehmann, H and Pochigaeva, K and Povolnova, J and Tumurov, D and Vetrov, F and de Visser, M and Winkler, AS and Grisold, W},
title = {Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis.},
journal = {Journal of the neurological sciences},
volume = {481},
number = {},
pages = {125710},
doi = {10.1016/j.jns.2025.125710},
pmid = {41494305},
issn = {1878-5883},
mesh = {Humans ; *COVID-19/complications/epidemiology ; Prevalence ; *Neuromuscular Diseases/epidemiology/etiology ; Guillain-Barre Syndrome/epidemiology ; },
abstract = {INTRODUCTION: Neuromuscular diseases (NMDs) are a significant component of the post-acute sequelae of COVID-19. However, their long-term prevalence and trajectories remain poorly defined. This systematic review and meta-analysis aimed to determine the long-term prevalence in COVID-19 survivors of fourteen specific NMDs and related symptoms: cranial nerve diseases, Guillain-Barré syndrome, small fiber neuropathy, (poly)radiculopathies, (poly)neuropathies, plexopathies, motor neuron disease, myasthenia gravis, Lambert-Eaton syndrome, neuropathic pain, sarcopenia, myalgia, myalgia associated with other symptoms, and of other muscle diseases.<br><br>METHODS: We searched MEDLINE, Embase, and the Cochrane Library (January 2020 through November 2024) for studies with at least 3&#xa0;months of follow-up. Pooled prevalence estimates were calculated at multiple time points (acute phase to 24&#xa0;months) using random effects models.<br><br>RESULTS: Among 180 unique studies representing 15,865,322 cases (54&#xa0;% female, mean age 50.0&#xa0;years), the pooled prevalence for individuals with at least one NMD or related symptoms decreased from 36&#xa0;% in the acute phase to 8&#xa0;% at 24&#xa0;months. Myalgia prevalence steadily declined from 35&#xa0;% to 8&#xa0;% by two years. A trend towards lower prevalences across the time points was observed also for Guillain-Barr&#xe9; syndrome, and other muscle diseases, while other conditions showed a more erratic pattern. The prevalence of neuropathic pain remained high and persisted almost unchanged through the follow-up period (from 31&#xa0;% in the acute phase to 25&#xa0;% at 12&#xa0;months).<br><br>CONCLUSIONS: NMDs and related symptoms are common following COVID-19, but their general prevalence decreases with time. However, trajectories varied depending on the type of NMD or symptom.},
}
@article {pmid41494490,
year = {2026},
author = {Messina, A and Bella, F and Maccarone, G and Avincola, G and Signorelli, MS},
title = {Astrocyte-mediated hippocampal damage in the pathogenesis of dysexecutive syndrome following COVID-19: A narrative review.},
journal = {Journal of psychiatric research},
volume = {194},
number = {},
pages = {164-173},
doi = {10.1016/j.jpsychires.2026.01.007},
pmid = {41494490},
issn = {1879-1379},
mesh = {Humans ; *COVID-19/complications/immunology/pathology ; *Astrocytes/pathology/immunology/metabolism ; *Hippocampus/pathology/physiopathology/metabolism/virology/immunology ; SARS-CoV-2 ; *Neuroinflammatory Diseases ; *Cognitive Dysfunction/etiology ; *Executive Function/physiology ; },
abstract = {SARS-CoV-2 infection has been implicated in hippocampal damage, contributing to the pathogenesis of dysexecutive syndrome observed in post-COVID-19 patients. Given the growing prevalence of long-COVID worldwide, understanding how SARS-CoV-2 affects hippocampal structure and function has become an urgent scientific and clinical priority. The hippocampus-crucial for memory, emotional regulation, and executive functioning-is especially susceptible to viral-driven neuroinflammatory cascades. SARS-CoV-2 triggers astrocyte and microglia activation, disrupts blood-brain barrier integrity, and induces cytokine-mediated neurotoxicity, ultimately impairing neuroplasticity and neurogenesis. These mechanisms converge to produce cognitive and affective disturbances-most notably fatigue, apathy, low mood, and executive dysfunction-that typify dysexecutive syndrome in long-COVID. This review synthesizes current evidence from clinical and experimental studies, integrating findings on viral neurotropism, hippocampal hypometabolism, and astrocyte-mediated neurodegeneration. Distinctions between depressive symptoms driven by neuroinflammation and classical depressive disorders are clarified to improve diagnostic accuracy and guide personalized treatment. Emerging data on the neuroprotective role of COVID-19 vaccination-particularly its capacity to modulate microglial activation and support hippocampal neurogenesis-are also examined. Overall, the findings underscore the need for targeted therapeutic strategies aimed at modulating neuroinflammation and supporting hippocampal plasticity, including cognitive rehabilitation approaches. Longitudinal studies are essential to elucidate the enduring impact of SARS-CoV-2 on hippocampal function and to inform effective clinical interventions.},
}
@article {pmid41496089,
year = {2026},
author = {Lu, YX and Wan, DL},
title = {Burnout in nursing during the COVID-19 pandemic: A bibliometric analysis of global research (2020-2023).},
journal = {Medicine},
volume = {105},
number = {1},
pages = {e46125},
pmid = {41496089},
issn = {1536-5964},
mesh = {*COVID-19/epidemiology/psychology/nursing ; *Bibliometrics ; *Burnout, Professional/epidemiology ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Burnout is an occupational phenomenon characterized by professionals experiencing a complete loss of concern and emotional connection towards the individuals they work with, resulting in their treatment in a detached or dehumanized manner. Extensive research has been conducted on burnout syndrome within the healthcare environment, however, prior to addressing this urgent public health issue, it is crucial to examine the existing literature on burnout among nurses during the COVID-19 pandemic and identify relevant variables explored in recent articles.<br><br>METHODS: An extensive literature search was conducted in the Web of Science Core Collection database to identify all relevant studies on nursing burnout during the COVID-19 pandemic.<br><br>RESULTS: According to the search strategy, a total of 1051 eligible publications were collected from the time of January 01, 2020 to December 31, 2023 in Web of Science Core Collection database. Finally, 946 eligible publications, including 865 articles and 81 reviews, were included in the subsequent analysis. In the inaugural year of the COVID-19 pandemic in 2020, a mere 48 articles were dedicated to examining the correlation between the pandemic and nursing staff burnout. However, this figure surged to 215 publications in 2021 and further escalated to an impressive count of 380 articles in 2022.<br><br>CONCLUSION: In summary, this is the first comprehensive analysis of publications related to nursing burnout in the context of COVID-19 from 2020 to 2023 through bibliometrics. Our results show the COVID-19 pandemic has certainly had a significant impact on the occupational burnout of nurses.},
}
@article {pmid41496808,
year = {2025},
author = {Woods, JA and Hutchinson, NT and Powers, SK and Gomez-Cabrera, MC and Radak, Z and Leeuwenburgh, C and Cacciatore, S and Marzetti, E and Zhang, T and Garza, R and Sidebottom, C and Anderson, E and Durstine, JL and Sun, J and Ji, LL},
title = {Physical activity during COVID-19 pandemic: A 5-year retrospect.},
journal = {Sports medicine and health science},
volume = {7},
number = {6},
pages = {405-418},
pmid = {41496808},
issn = {2666-3376},
abstract = {The purpose of this article is to provide a follow-up review of the impact of the SARS-CoV-2 Disease or Coronavirus Disease 2019 (COVID-19) pandemic on human health and the role of physical activity (PA) during the 5-year pandemic. We aim to cover the immune system, the cardiopulmonary system, the musculoskeletal system, and the central nervous system (brain function), particularly among older adults, college students, and individuals with post-acute sequelae of COVID-19 (Long-COVID). The COVID-19 pandemic has given us many lessons, learned from the death of six million lives and tremendous disturbance to human life. First, we need to continue to investigate cellular and molecular mechanisms that mediate various organistic failures resulting from the viral infection. Such investigations are the only way to completely understand the etiology of the diseases and to develop new drugs and vaccines. The molecular pathways that transmit the signals of viral infection to each organ system are different requiring both basic and clinical research. Available evidence suggests that mitochondrial dysfunction, reduced microcirculation and latent immune activation play a major role, eventually impairing cardiovascular tolerance and peripheral bioenergetics. Second, the COVID-19 pandemic has manifested major disturbances to human lifestyles with reduced PA and exercise standing out as a major factor. Conversely, physical inactivity due to social confinement and mental/psychological stresses has been clearly linked to intensified pathogenic symptoms and amplification of adverse effects on multiple physiological systems. If not intervened, this interaction can lead to Long-COVID, a dangerous futile circle to cause systemic failure. Finally, the COVID-19 pandemic has exerted differential impacts on different populations. Thus, the strategy to develop and conduct to cope with the negativity of pandemic needs to be specific, flexible and tailored to fit different patient populations.},
}
@article {pmid41497070,
year = {2026},
author = {Obeagu, EI},
title = {Immunomodulatory strategies for managing cytokine storms in chronic COVID: mechanisms, therapeutic targets, and clinical advances.},
journal = {Annals of medicine and surgery (2012)},
volume = {88},
number = {1},
pages = {653-659},
pmid = {41497070},
issn = {2049-0801},
abstract = {Chronic COVID, characterized by persistent symptoms following acute SARS-CoV-2 infection, is increasingly linked to sustained immune dysregulation, particularly cytokine storms that drive chronic inflammation and multi-organ complications. Understanding the mechanisms underlying cytokine dysregulation in chronic COVID is essential for developing effective therapeutic strategies aimed at restoring immune balance and mitigating long-term morbidity. This review critically examines current immunomodulatory strategies for managing cytokine storms in chronic COVID, including corticosteroids, cytokine-specific biologics, Janus kinase inhibitors, and emerging cell-based therapies. Additionally, the role of biomarker-guided precision medicine in personalizing treatment to optimize efficacy and safety is discussed. Challenges such as patient heterogeneity, timing and duration of therapy, and potential adverse effects are also addressed. Future research directions emphasize the need for robust clinical trials, novel therapeutic development, and integrated multidisciplinary care to improve patient outcomes. By tailoring immunomodulatory approaches based on individual immune profiles, it is possible to enhance the management of cytokine-driven inflammation in chronic COVID and advance the field toward more effective, personalized treatments.},
}
@article {pmid41497304,
year = {2025},
author = {Fadaei, MR and Fadaei, MS and Kheirieh, AE and Hatami, H and Rahmanian-Devin, P and Tayebi-Khorrami, V and Fathabadi, MF and Baradaran Rahimi, V and Askari, VR},
title = {Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications.},
journal = {International journal of pharmaceutics: X},
volume = {10},
number = {},
pages = {100390},
pmid = {41497304},
issn = {2590-1567},
abstract = {Dendrimers are tree-like polymeric molecules that have three main compartments: the core, branching units, and functional end groups. They are nanosized and monodispersed, with an almost spherical shape. For the past few decades, dendrimers have been evaluated in numerous studies as a promising category of candidates for gene delivery and diagnostic applications. Nowadays, some advanced dendrimers are considered promising anticancer delivery systems due to the vast types and applicable modifications. They also showed their effectiveness as antibacterial and antiviral agents. Smart dendrimers with pH-, redox-, or directly tumor microenvironment-responsive properties are investigated. pH-sensitive dendrimers enhance drug release in the tumor's acidic environment and inhibit release at physiological pH, thereby increasing the hemocompatibility of these chemical agents. Dendrimers have been examined for years to prevent sexually transmitted diseases, such as HIV, HPV, HSV, etc. In this regard, some studies yielded encouraging results and opened new avenues. Following the onset of the COVID-19 pandemic, researchers have shifted their focus toward seeking remedies to prevent and treat this viral disease. Dendrimers have already demonstrated favorable efficacy in protection against COVID-19 and other respiratory viral diseases. Furthermore, they may mitigate the neuroinflammatory manifestations of COVID-19 in individuals experiencing a critical disease state.},
}
@article {pmid41497535,
year = {2025},
author = {Yang, Y and Wang, K and Chen, S},
title = {Effects of Hypoglycemic Agents on Pulmonary Diseases: A Comprehensive Narrative Review.},
journal = {Journal of inflammation research},
volume = {18},
number = {},
pages = {18053-18078},
pmid = {41497535},
issn = {1178-7031},
abstract = {Beyond glycemic control, hypoglycemic agents exhibit multifaceted effects that may influence pulmonary health in patients with diabetes mellitus. This narrative review synthesizes available evidence from preclinical and clinical studies on the impact of major hypoglycemic drug classes-including biguanides, sulfonylureas, thiazolidinediones, α-glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and insulin-on pulmonary diseases. Evidence suggests that these agents exert class-specific, and often conflicting, effects: preclinical studies support their protective potential in acute lung injury, while clinical data indicate variable efficacy in asthma, COPD, and respiratory infections including COVID-19. Conversely, some agents may be associated with increased risks of lung cancer or COPD exacerbations, underscoring the need for context-specific prescribing. Mechanistic insights from animal models primarily involve modulation of inflammatory, oxidative, and immune pathways. This narrative review aims to provide a clinical framework for personalizing hypoglycemic therapy in patients with comorbid pulmonary conditions, while underscoring the need for well-designed prospective studies to resolve existing controversies.},
}
@article {pmid41497729,
year = {2025},
author = {Liu, T and Li, M and Zhu, L and Liang, R and Zhang, P and Liu, X},
title = {Ocular Lesions Related to COVID-19 and Its Vaccines.},
journal = {Journal of ophthalmology},
volume = {2025},
number = {},
pages = {7078264},
pmid = {41497729},
issn = {2090-004X},
abstract = {OBJECTIVE: To review COVID-19 infection and COVID-19 vaccine-related ocular lesions.<br><br>METHODS: We carried out a systematic search in PubMed, Web of Science, Embase, and the Cochrane Library on COVID-19 and ophthalmology and reviewed the incidence, specific manifestations, and risk factors for COVID-19-related eye diseases and the relationship between the detection of COVID-19 in the conjunctiva and tears and eye involvement.<br><br>RESULTS: Conjunctivitis was the most common ocular lesion caused by 2019-nCoV infection, followed by uveitis and retinopathy. Conjunctivitis can be the first manifestation of COVID-19 infection and may be clinically related to the severity of pneumonia caused by COVID-19. In particular, conjunctivitis that occurs after pneumonia suggests that the patient has severe systemic disease. COVID-19 infection can cause uveitis, but the infection rate of COVID-19 in patients with uveitis is similar to that of the general population. Patients with uveitis need to reduce the dosage of systemic hormones and discontinue biological agents after being infected with COVID-19. Retinopathy caused by COVID-19 infection is mainly manifested as retinal microvascular disease, and the prognosis is good. SARS-CoV-2 detection in the conjunctiva and tears has high sensitivity and is of great value for disease diagnosis. Eye lesions caused by the COVID-19 vaccine, similar to other vaccines, have a low incidence and a good prognosis.<br><br>CONCLUSION: COVID-19-related ocular lesions are mainly manifested as conjunctivitis, uveitis, and retinal microvascular changes. These diseases are somewhat self-limiting and have a good prognosis.},
}
@article {pmid41497937,
year = {2025},
author = {Idahor, CO and Ogunfuwa, O and Ogbonna, N and Ogbeide, OA and Abe, O and Oore-Ofe, O},
title = {Transforming Emergency Care Through Telemedicine: A Narrative Review.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e98481},
pmid = {41497937},
issn = {2168-8184},
abstract = {Telemedicine has fleetly evolved from a niche result to a central pillar in modern emergency and critical care systems. This narrative review delves into the multifaceted role of telemedicine in emergency settings, tracing its historical development, present applications, and future possibilities. It examines how telemedicine islands geographical and infrastructural gaps, particularly in underserved communities, by enabling timely access to specialist care similar to telestroke services and remote ferocious care. Substantiation highlights advancements in clinical outcomes, functional effectiveness, and patient satisfaction, with global case studies demonstrating successful perpetration across both high- and low-resource settings. Despite these advances, challenges persist. Technological restrictions, regulatory barriers, digital knowledge gaps, and unlikeness in assent continue to hamper wide relinquishment. This review discusses these obstacles and underscores the significance of strategic investment, cross-sector collaboration, and policy reform. Arising inventions, including artificial intelligence, wearable devices, and scalable telehealth platforms, signal promising directions for perfecting reach and adaptability in emergency systems. Additionally, this paper identifies crucial areas for unborn research, including long-term outgrowth assessment and telemedicine's part in disaster and pandemic response. By synthesizing current substantiation and practical perceptivity, this review aims to inform clinicians, health system leaders, and policymakers about the transformative eventuality and ongoing challenges of telemedicine in emergency care. Eventually, it calls for sustained invention, equity-concentrated perpetration, and cooperative sweats to completely realize telemedicine's pledge in erecting a more accessible, responsive, and flexible emergency care geography.},
}
@article {pmid41498242,
year = {2026},
author = {Kuperwasser, C and El-Deiry, WS},
title = {COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms.},
journal = {Oncotarget},
volume = {17},
number = {},
pages = {1-29},
pmid = {41498242},
issn = {1949-2553},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology/immunology ; *Neoplasms/epidemiology/etiology/immunology ; *COVID-19 Vaccines/adverse effects ; *Vaccination/adverse effects ; SARS-CoV-2/immunology ; Incidence ; },
abstract = {A growing number of peer-reviewed publications have reported diverse cancer types appearing in temporal association with COVID-19 vaccination or infection. To characterize the nature and scope of these reports, a systematic literature search from January 2020 to October 2025 was conducted based on specified eligibility criteria. A total of 69 publications met inclusion criteria: 66 article-level reports describing 333 patients across 27 countries, 2 retrospective population-level investigations (Italy: ~300,000 cohort, and Korea: ~8.4 million cohort) quantified cancer incidence and mortality trends among vaccinated populations, and one longitudinal analysis of ~1.3 million US miliary service members spanning the pre-pandemic through post-pandemic periods. Most of the studies documented hematologic malignancies (non-Hodgkin's lymphomas, cutaneous lymphomas, leukemias), solid tumors (breast, lung, melanoma, sarcoma, pancreatic cancer, and glioblastoma), and virus-associated cancers (Kaposi and Merkel cell carcinoma). Across reports, several recurrent themes emerged: (1) unusually rapid progression, recurrence, or reactivation of preexisting indolent or controlled disease, (2) atypical or localized histopathologic findings, including involvement of vaccine injection sites or regional lymph nodes, and (3) proposed immunologic links between acute infection or vaccination and tumor dormancy, immune escape, or microenvironmental shifts. The predominance of case-level observations and early population-level data demonstrates an early phase of potential safety-signal detection. These findings underscore the need for rigorous epidemiologic, longitudinal, clinical, histopathological, forensic, and mechanistic studies to assess whether and under what conditions COVID-19 vaccination or infection may be linked with cancer.},
}
@article {pmid41498334,
year = {2026},
author = {Azasi, E and Asamoah, PE and Diaconu, K},
title = {Understanding the needs and key determinants of maternal, newborn, and child health among migrants in transit: a scoping review.},
journal = {Global health action},
volume = {19},
number = {1},
pages = {2607905},
pmid = {41498334},
issn = {1654-9880},
mesh = {Humans ; Female ; Pregnancy ; *Transients and Migrants/statistics &amp; numerical data ; Health Services Accessibility ; Infant, Newborn ; *Child Health ; *Maternal Health ; *Health Services Needs and Demand ; Child ; },
abstract = {The global surge in migration has exposed pregnant women and children in transit to heightened risk of maternal and child health (MCH) challenges, driven by systemic barriers and unstable conditions. Evidence on how these transitory factors influence MCH remains limited. This scoping review examined the health needs and key determinants affecting migrant populations in transit, specifically pregnant women and children travelling from their countries of origin to their intended destination countries, with the aim of identifying major barriers and proposing strategies for improved health outcomes. We screened 1202 sources of evidence using five databases (PubMed, Scopus, Europe PMC, CINAHL, and Medline) as well as grey literature. Seven studies met the inclusion criteria. Data were drawn from peer-reviewed literature, charted using a standardized framework, and analysed thematically. Key barriers included financial constraints, language obstacles, and limited access to healthcare services. Although humanitarian organizations offered some support, significant unmet needs remain, including exposure to transactional sex, absence of respectful maternity care, and restricted access to essential health services. These challenges are exacerbated in conflict and crisis settings. The review underscores the importance of addressing key determinants, including location, language, financial capacity, and community support, to improve health outcomes for pregnant women and children under five on the move. This review recommends strengthening community mobilization, leveraging technology, and ensuring equitable access irrespective of users' cultural or financial constraints.},
}
@article {pmid41498391,
year = {2026},
author = {Zhang, X and Han, X and Xu, J and Li, G},
title = {Disease-associated adipose browning: current evidence and perspectives.},
journal = {Adipocyte},
volume = {15},
number = {1},
pages = {2610540},
pmid = {41498391},
issn = {2162-397X},
mesh = {Humans ; *Adipose Tissue, Brown/metabolism/pathology ; Animals ; Energy Metabolism/physiology ; Adipose Tissue, White/metabolism ; Thermogenesis/physiology ; COVID-19/metabolism/pathology ; },
abstract = {Brown and beige adipose tissue represent evolutionary adaptations in mammals, functioning as specialized thermogenic organs to maintain body temperature. Over the past two decades, researches have demonstrated that white adipose tissue (WAT) browning is an effective strategy to enhance energy expenditure. However, a growing body of evidence indicates that the browning process frequently occurs in a variety of chronic disease states, though its pathophysiological significance remains unclear. This review summarized evidence of pathological browning observed in human diseases and animal models, including breast cancer, colorectal cancer (CRC), clear cell renal cell carcinoma (ccRCC), kidney health, burn injury, atherosclerotic, SARS-CoV-2 and sepsis. Despite distinct pathological contexts, adipose tissue browning is consistently observed. This suggests that browning may not simply serve its classical metabolically protective role, but instead reflect an atypical response to pathological stress. It is currently unclear whether this is a compensatory mechanism by the organism in a diseased state or merely a byproduct of the disease process. Whether this response is adaptive or a cause of disease progression remains unresolved. Future research should therefore focus on identifying the triggers and functional outcomes of pathological browning to better understand adipocyte plasticity and its role in disease progression.},
}
@article {pmid41499907,
year = {2026},
author = {Ruan, T and Li, M},
title = {The inverse relationship between post-traumatic growth and job burnout among medical staff during the COVID-19 normalization period: A systematic review.},
journal = {Asian journal of psychiatry},
volume = {116},
number = {},
pages = {104814},
doi = {10.1016/j.ajp.2025.104814},
pmid = {41499907},
issn = {1876-2026},
mesh = {Humans ; *Burnout, Professional/psychology/epidemiology ; *COVID-19 ; *Medical Staff/psychology ; *Posttraumatic Growth, Psychological ; },
abstract = {OBJECTIVE: To synthesize empirical evidence on the association between post-traumatic growth (PTG) and job burnout among medical staff across varied healthcare settings during the COVID-19 normalization period (2022 onward).<br><br>METHODS: Following PRISMA guidelines, a database indexing over 126 million records was searched, yielding 499 records for screening, and 11 studies that measured both PTG and burnout in active healthcare professionals. Data on study design, setting, instruments, sample characteristics, and key findings were extracted.<br><br>RESULTS: Nine quantitative (seven cross-sectional, one longitudinal, one unspecified design) and two qualitative studies met inclusion criteria, encompassing nurses, physicians, psychiatrists, paramedics, and medical rescuers in eight countries. Standardized instruments (e.g., Post-Traumatic Growth Inventory variants; Maslach Burnout Inventory variants) were most common. Eight studies reported a significant inverse correlation between PTG and burnout (e.g., odds ratio=&#x202f;0.653, 95&#x202f;% CI=&#x202f;0.525-0.812, p&#x202f;<&#x202f;0.001; r&#x202f;=&#x202f;-0.276, p&#x202f;=&#x202f;0.034). Five studies identified PTG as a mediator or moderator of stress-burnout pathways. Qualitative analyses described a trajectory from acute stress through cognitive restructuring to growth, with burnout linked to unresolved trauma.<br><br>CONCLUSIONS: Consistent evidence indicates that higher PTG protects against burnout in medical staff post-pandemic peak. Psychological resources-resilience, self-compassion, adaptive coping, meaning in work, and job satisfaction-emerge as key mediators or moderators. Interventions fostering PTG and its correlates may mitigate burnout in healthcare workers.},
}
@article {pmid41499962,
year = {2026},
author = {Wang, B and Fu, Y and Duan, F and Pan, S and Zheng, Y},
title = {Decoding emerging viral sepsis: Molecular crosstalk, dysregulation, and precision strategies.},
journal = {Molecular aspects of medicine},
volume = {107},
number = {},
pages = {101442},
doi = {10.1016/j.mam.2025.101442},
pmid = {41499962},
issn = {1872-9452},
mesh = {Humans ; *Sepsis/virology/immunology/therapy ; SARS-CoV-2/pathogenicity ; *COVID-19/virology/complications/immunology ; Host-Pathogen Interactions ; *Virus Diseases/virology/immunology ; Influenza, Human ; HIV Infections ; Precision Medicine ; Animals ; },
abstract = {Emerging and re-emerging viral pathogens pose a major challenge to global public health systems. One of the most significant complications associated with these viruses is viral sepsis, a severe condition characterized by organ dysfunction resulting from an unregulated host response to a viral infection. The present review comprehensively describes the molecular mechanisms underlying viral sepsis induced by emerging and re-emerging viral pathogens, such as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), influenza virus, dengue virus (DENV), Ebola virus (EBOV), and human immunodeficiency virus (HIV). It discusses the complex molecular interactions between particular viral factors and host cellular pathways, highlighting significant dysregulations in various immune responses, metabolic reprogramming, and endothelial integrity that induce sepsis development. Furthermore, this review thoroughly addresses nascent precision strategies, including advanced diagnostics, targeted therapeutics, and immunomodulatory interventions, carefully tailored to distinct viral etiologies and host endotypes. By shedding light on the intricate molecular landscape of viral sepsis, this review aims to provide a robust framework for future mechanistic research and accelerate the development of effective, personalized interventions to combat this challenging complication.},
}
@article {pmid41501207,
year = {2026},
author = {Murata, A and Tanaka, M and Takayoshi, M and Matsuyama, Y and Sato, R and Ishida, Y and Teragaki, M and Iwanari, S and Ikeda, M and Takeoka, H},
title = {Osmotic nephropathy as a potentially underrecognized cause of acute kidney injury during SGLT2 inhibitor therapy: a case report and literature review.},
journal = {CEN case reports},
volume = {15},
number = {1},
pages = {16},
pmid = {41501207},
issn = {2192-4449},
mesh = {Humans ; Male ; Aged ; *Acute Kidney Injury/etiology/chemically induced/therapy/diagnosis ; *Diabetes Mellitus, Type 2/drug therapy/complications ; *Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use ; *Benzhydryl Compounds/adverse effects ; Glucosides/adverse effects ; Renal Dialysis ; *Renal Insufficiency, Chronic/drug therapy/complications ; Diabetic Nephropathies ; Creatinine/blood ; Kidney Tubules, Proximal/pathology ; },
abstract = {In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors have become essential therapeutic agents in the management of chronic kidney disease (CKD), owing to their established renoprotective effects. Although acute kidney injury (AKI) may occasionally occur during SGLT2 inhibitor therapy, its pathological features remain incompletely understood. Here, we report a case of AKI caused by osmotic nephropathy in a patient with underlying CKD following the initiation of an SGLT2 inhibitor. We also review previously reported cases of SGLT2 inhibitor-associated osmotic nephropathy. A 71-year-old man with type 2 diabetes and CKD developed oliguric AKI, with his serum creatinine level increasing from 2.0 to 8.3 mg/dL, one month after initiating dapagliflozin. During this period, he experienced transient appetite loss associated with a COVID-19 infection. Despite initial management for presumed prerenal AKI, his renal function did not improve with intravenous fluid therapy, and he required hemodialysis. Kidney biopsy revealed characteristic features of osmotic nephropathy, including numerous isometric vacuoles within the epithelial cells of proximal tubules with preserved brush borders. His renal function began to improve approximately two weeks after discontinuation of the SGLT2 inhibitor, and eventually returned to baseline. This case and literature review highlight the potential for osmotic nephropathy as a rare but reversible complication of SGLT2 inhibitor therapy, which may be triggered by volume depletion, particularly in diabetic patients with pre-existing renal dysfunction. Recognition of this underdiagnosed entity is crucial for timely diagnosis and appropriate management.},
}
@article {pmid41502328,
year = {2026},
author = {Gimmon, Y and Gordon, CR},
title = {Neuro-vestibular rehab: new developments.},
journal = {Current opinion in neurology},
volume = {39},
number = {1},
pages = {83-87},
doi = {10.1097/WCO.0000000000001441},
pmid = {41502328},
issn = {1473-6551},
mesh = {Humans ; *Reflex, Vestibulo-Ocular/physiology ; *Vestibular Diseases/rehabilitation/physiopathology ; *Adaptation, Physiological/physiology ; Telemedicine ; *Neurological Rehabilitation/methods/trends ; Digital Health ; Virtual Reality ; },
abstract = {PURPOSE OF REVIEW: This review highlights recent advances in neuro-vestibular rehabilitation, with emphasis on vestibular adaptation and emerging mobile technologies. It summarizes developments in promoting vestibular plasticity and discusses novel tools such as virtual reality, wearable sensors, and telehealth platforms that enhance access, engagement, and outcomes. The scope is broad, focusing on general principles rather than specific populations.<br><br>RECENT FINDINGS: New methods to enhance vestibulo-ocular reflex (VOR) adaptation include incremental adaptation devices and gamified exercises. Inducing VOR gain-down adaptation temporarily increases postural sway, which normalizes via sensory reweighting, demonstrating central compensation. Portable tools like StableEyes show promise in boosting VOR gain with brief sessions. Concurrently, technology-driven approaches are gaining traction. Gamified mobile applications and wearable sensors allow home-based rehabilitation with remote supervision and monitoring, showing promising results in conditions like multiple sclerosis. Virtual reality interventions and telehealth models accelerated during the COVID-19 era, expanding therapy delivery to underserved populations. Adjunctive methods such as vibrotactile feedback and galvanic vestibular stimulation are emerging as complementary therapies.<br><br>SUMMARY: Recent developments are advancing vestibular rehabilitation by refining adaptive training techniques and leveraging digital tools to overcome barriers in access and adherence. These innovations point to a more personalized, technology-enabled approach to optimizing neuro-vestibular recovery.},
}
@article {pmid41502909,
year = {2026},
author = {El Rassi, C and El Darzi, R and Abou Mansour, M and Arabi, M},
title = {MIS-C: Diagnosis, Management, and Outcomes.},
journal = {Open forum infectious diseases},
volume = {13},
number = {1},
pages = {ofaf762},
pmid = {41502909},
issn = {2328-8957},
abstract = {Multisystem inflammatory syndrome in children (MIS-C) is an emergent postinfectious hyperinflammatory disorder predominantly affecting the pediatric population following COVID-19 infection. Clinically, it is characterized by persistent fever, shock, multiorgan involvement, and potentially severe cardiovascular involvement. This comprehensive review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic criteria, with particular emphasis on the management of MIS-C. We also stress on the importance of distinguishing MIS-C from phenotypically similar entities. Acute-phase management centers on supportive care, hemodynamic stabilization, and targeted immunomodulation, with intravenous immunoglobulin, corticosteroids, and biologic forming the therapeutic cornerstone. Thromboprophylaxis is frequently warranted due to the elevated thromboembolic risk, and long-term follow-up is essential to monitor for cardiac, gastrointestinal, and neurologic complications. Additional considerations include postrecovery vaccination protocols and the use of extracorporeal membrane oxygenation in cases of refractory cardiorespiratory failure. Despite advancements in clinical outcomes, diagnostic ambiguity and heterogeneous management guidelines continue to pose significant challenges.},
}
@article {pmid41503324,
year = {2025},
author = {Dameche, K and Shams, S and AlMesallam, MS},
title = {Herpes Zoster (HZ) Over the Past 10 Years: A Systematic Review on Trends, Triggers, and Post-COVID-19 Impact.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e98556},
pmid = {41503324},
issn = {2168-8184},
abstract = {Herpes zoster (HZ) is a reactivation of varicella-zoster virus (VZV), which has been traditionally associated with aging and immunosuppression. However, new data indicate that the coronavirus disease 2019 (COVID-19) pandemic has changed HZ epidemiology, with a higher incidence of HZ in post-COVID-19 patients and vaccinated subjects. This systematic review assesses the trends and triggers of HZ as well as the impact after the pandemic, focusing on the changes in the incidence rate among adult and pediatric patients during the last 10 years. All studies published between the years of 2014 and 2024 were accrued, based on a systematic review conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Relevant articles were identified from searches of databases and other sources. Eligibility criteria of studies were applied, and qualitative and quantitative syntheses of studies were performed. A total of 11 studies were included in the review, which examined the association between COVID-19, vaccination, and HZ risk. Several studies suggested that psychological stress and immune dysfunction could be risk factors for HZ incidence. HZ cases after COVID-19 vaccination have been reported, although causation is not established. Based on countries in which COVID-19 was diagnosed, hospitalizations are estimated at 14.4 per 100,000 inhabitants (0.6 to 32.9 per 100,000), and mortality was 1.3 per 100,000, points in this IR Batch (assuming that these are of all diagnosed cases). The risk of HZ reactivation may be increased following COVID-19 infection and vaccination. Higher hospitalization rates with higher mortality risks and neurological consequences were also observed in some populations. Strengthening HZ vaccination programs and studying post-COVID-19 immune responses further can be essential for reducing long-term health risks.},
}
@article {pmid41504094,
year = {2025},
author = {Galuia, M and Hussain, A and Ahmad, S},
title = {Biosimilars in Gynecologic Cancers: Basic Principles and New Horizons.},
journal = {Frontiers in bioscience (Elite edition)},
volume = {17},
number = {4},
pages = {33415},
doi = {10.31083/FBE33415},
pmid = {41504094},
issn = {1945-0508},
mesh = {Humans ; *Biosimilar Pharmaceuticals/therapeutic use/economics ; Female ; *Genital Neoplasms, Female/drug therapy ; Cost-Benefit Analysis ; *Antineoplastic Agents/therapeutic use ; },
abstract = {Biological therapies have transformed cancer treatment by targeting the molecular mechanisms involved in carcinogenesis. However, higher costs, limited accessibility, and supply chain disruptions-such as those caused by COVID-19 in recent years-underscore the need for cost-effective alternatives. Biosimilars, which are drugs that are highly similar to their reference biologics in terms of safety, efficacy, and quality, offer a viable solution (as these demonstrate clinically meaningful outcomes). This review article examines the role of biosimilars, mainly in gynecological cancers. The primary focus of this article is to compare the efficacy, safety, and cost-effectiveness of biosimilars, as well as to explore the barriers that restrict their widespread adoption. A comprehensive literature review was conducted, analyzing various studies, regulatory guidelines, and the latest data on biosimilars for the treatment of gynecological cancers. Pivotal trials, such as the GOG-0218, ICON7, and RUBY, were reviewed to assess the efficacy, safety, and cost-effectiveness of these biosimilars. This review highlights key oncologic therapies, including bevacizumab, trastuzumab, pembrolizumab, and their biosimilars, mainly for gynecological cancers. Additionally, this review considers the challenges of immunogenicity, interchangeability, and clinician awareness. After reviewing the latest peer-reviewed literature and related online materials, we found that biosimilars demonstrate comparable efficacy and safety to their reference biologics while also being more cost-effective. Recent clinical trials support the role of biosimilars in limiting the progression of disease and improving overall survival while reducing the financial burden of cancer treatments.},
}
@article {pmid41504442,
year = {2026},
author = {Masters, PS},
title = {Coronavirus genome packaging and nucleocapsid assembly.},
journal = {Journal of virology},
volume = {100},
number = {2},
pages = {e0133025},
pmid = {41504442},
issn = {1098-5514},
support = {R01 AI064603/AI/NIAID NIH HHS/United States ; },
mesh = {*Virus Assembly ; *Nucleocapsid/metabolism/genetics ; *Genome, Viral ; *Viral Genome Packaging ; RNA, Viral/genetics/metabolism ; *Coronavirus/genetics/physiology ; Humans ; Phosphorylation ; Nucleocapsid Proteins/metabolism ; SARS-CoV-2/genetics/physiology ; Animals ; },
abstract = {Coronaviruses are a family of positive-strand RNA viruses that exhibit highly selective packaging of their genomic RNA (gRNA) into assembled virions, despite the presence of a large excess of subgenomic viral RNA species and host RNA in infected cells. While this high selectivity is critical to evading host innate immune responses, surprisingly, it is not essential for virion assembly. This review focuses on four main topics: (i) coronavirus genome packaging signals (PSs)-how they are found and the function they serve; (ii) the viral components that recognize the PS in order to bring about selective gRNA packaging; (iii) coronavirus nucleocapsid structure and assembly; and (iv) the relationship between nucleocapsid protein phosphorylation and nucleocapsid assembly versus RNA synthesis. Current understanding of these areas has benefited immensely from advances made by recent studies, most of which were performed in response to the emergence of the coronavirus responsible for the COVID-19 pandemic. Throughout this review, emphasis is placed on the counterintuitive distinction between coronavirus selective gRNA packaging and nucleocapsid assembly.},
}
@article {pmid41504815,
year = {2026},
author = {Doyle, P and McHugh, S and O'Neill, D},
title = {Nursing home research in Ireland before and after the pandemic.},
journal = {Irish journal of medical science},
volume = {195},
number = {2},
pages = {1159-1162},
pmid = {41504815},
issn = {1863-4362},
mesh = {*Nursing Homes ; Ireland/epidemiology ; Humans ; *COVID-19/epidemiology ; Pandemics ; Bibliometrics ; Nursing Home Residents ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Nursing home residents in Ireland experienced a disproportionate burden of illness and death during the COVID-19 pandemic, highlighting longstanding systemic deficiencies in governance, staffing, and research engagement. Prior to the pandemic, this vulnerable population, characterised by high levels of multimorbidity and disability, received limited research attention. A subgroup from the National Clinical Programme for Older People recommended the development of a research agenda in nursing homes, including resident involvement. This study aimed to characterise the extent and nature of Irish nursing home research from 1966 to 2024. METHODS: A bibliometric review was conducted using PubMed to identify publications related to Irish nursing homes from January 1966 to March 2020 (pre-pandemic) and April 2020 to July 2024 (post-pandemic). Data extracted included publication type, number of authors, institutional affiliations, countries of origin, disciplines involved, and acknowledgement of nursing home staff or residents. Descriptive analysis was performed using Excel and SPSS. RESULTS: A total of 144 publications were identified. Most papers (n = 106; 73.6%) were published pre-pandemic, while 38 (26.4%) appeared in the shorter post-pandemic period, showing a substantial increase in publication rate (1.9 to 9.5/year). Original research comprised 81.3% of papers Interdisciplinary authorship was common (53%), yet only 12.5% of papers listed a nursing home as an author affiliation, primarily from public or voluntary sectors. Less than 40% of papers acknowledged staff or resident contributions. While COVID-19-focused publications increased markedly post-2020, broader topics in nursing home care remained underrepresented. CONCLUSION: Irish nursing home research remains limited, especially in the private sector. A national strategy is needed to expand stakeholder involvement and research breadth. Better use of the interRAI system, the national assessment tool since 2011, could substantially strengthen quality improvement and research capacity. Long-term investment will be essential to guide evidence-based policy and care.},
}
@article {pmid41504868,
year = {2026},
author = {Khan, S and Tang, P and Yang, P and Li, J and Wu, H},
title = {Dual-function cytokines as modulators of autophagy: reprogramming inflammatory resolution in severe COVID-19.},
journal = {Inflammation research : official journal of the European Histamine Research Society ... [et al.]},
volume = {75},
number = {1},
pages = {11},
pmid = {41504868},
issn = {1420-908X},
mesh = {Humans ; *Autophagy/immunology ; *Cytokines/immunology/physiology ; *COVID-19/immunology ; SARS-CoV-2 ; Inflammation/immunology ; Animals ; },
abstract = {BACKGROUND: Acute respiratory distress syndrome (ARDS) and systemic immune-mediated damage are two of the severe COVID-19 outcomes that are primarily caused by cytokine storms triggered by dysregulated immune responses. The limited benefits of current immunosuppressive treatments highlight the need for mechanistic understanding to direct focused interventions.<br><br>OBJECTIVE: The dual functions of cytokines in controlling autophagy during SARS-CoV-2 infection are examined in this review, along with the potential for autophagy modulation to limit hyperinflammation and restore immune homeostasis.<br><br>KEY FINDINGS: Emerging evidence suggests that autophagy critically modulates the balance between pro- and anti-inflammatory cytokines in COVID-19. Through anti-inflammatory feedback mechanisms, cytokines contribute to resolution while promoting inflammation in the early stages. The IRE1&#x3b1;-XBP1 axis is activated by SARS-CoV-2-induced endoplasmic reticulum stress, which increases cytokine production and modifies autophagic flux. Concurrently, extracellular vesicles containing cytokines, damage-associated molecular patterns, and viral components are released as secretory autophagy reroutes cytoplasmic cargo toward multivesicular bodies and amphisomes, increasing paracrine immune activation. Suppressed degradative autophagy and increased secretory autophagy-mediated inflammatory signaling are the hallmarks of this pathological state.<br><br>CONCLUSIONS: In severe COVID-19, targeted autophagy restoration is a promising therapeutic approach to restore immune responses, reduce excessive inflammation, and encourage the resolution of cytokine storms. Restoring immune homeostasis through more targeted immunointerventions may be made possible by modifying autophagy pathways.},
}
@article {pmid41506147,
year = {2026},
author = {Huai, Y and Wang, X and Yan, J and Li, S and Zhao, H and Liao, B},
title = {Emerging viroporins, RBP dynamics, and skeletal remodeling: Targeting liquid-liquid phase separation for dual antiviral and bone-protective therapies.},
journal = {Molecular aspects of medicine},
volume = {107},
number = {},
pages = {101445},
doi = {10.1016/j.mam.2026.101445},
pmid = {41506147},
issn = {1872-9452},
mesh = {Humans ; *Antiviral Agents/pharmacology/therapeutic use ; Phase Separation ; *Bone Remodeling/drug effects ; *RNA-Binding Proteins/metabolism ; Animals ; SARS-CoV-2 ; Stress Granules/metabolism ; },
abstract = {Emerging and re-emerging viral pathogens, particularly Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Zika virus (ZIKV), and Chikungunya virus (CHIKV), are currently recognized as a significant global public health issue, commonly leading to devastating persistent complications including inflammatory bone disorders and long-lasting arthralgia. Although systemic cytokine storm has been reported as a significant factor, the particular intracellular processes through which these viruses affect bone homeostasis are still poorly understood. Recent studies underscore Liquid-Liquid Phase Separation (LLPS) and RNA-Binding Proteins (RBPs) as significant regulatory mechanisms manipulated by these viruses. Particularly, the SARS-CoV-2 Nucleocapsid protein exploits its intrinsically disordered regions to promote LLPS, facilitating viral assembly by the active inhibition of a key host anti-viral mechanism, known as host Stress Granules. Studies suggest that this biophysical interaction can affect the stability of the HuR RBD, impairing the nuclear β-catenin localization and then Wnt-mediated osteogenesis. Despite increasing recognition of post-viral musculoskeletal complications, the mechanistic links between viral persistence, host RBP dysfunction, and impaired bone remodeling remain poorly defined. This review incorporates viral LLPS, stress granule impairment, and osteogenic signaling into a unified 'Two-Hit' pathogenic framework. It also addresses key knowledge gaps, including the lack of longitudinal clinical validation and in vivo evidence associating LLPS impairment to skeletal disorders. Interestingly, this framework represents translational opportunities for dual-action therapeutic strategies that simultaneously impair viral condensates and recover host RBP-associated osteogenic signaling. Targeting the virus-host phase interface can introduce a potential approach not only for antiviral therapies but also for inhibiting post-viral musculoskeletal complications.},
}
@article {pmid41506494,
year = {2026},
author = {Tran, MT and Doan, TD and Wu, HC and Chu, CY},
title = {Vaccine development for porcine epidemic diarrhea virus and porcine Deltacoronavirus: Updated progress, challenges, and future perspectives.},
journal = {Microbial pathogenesis},
volume = {212},
number = {},
pages = {108286},
doi = {10.1016/j.micpath.2026.108286},
pmid = {41506494},
issn = {1096-1208},
mesh = {Animals ; Swine ; *Porcine epidemic diarrhea virus/immunology ; *Viral Vaccines/immunology ; *Swine Diseases/prevention &amp; control/virology/immunology ; *Coronavirus Infections/prevention &amp; control/veterinary/immunology/virology ; *Vaccine Development/trends ; *Deltacoronavirus/immunology ; Vaccine Efficacy ; Antibodies, Viral/immunology ; Immunity, Mucosal ; Cross Protection ; },
abstract = {Porcine Epidemic Diarrhea Virus (PEDV) and Porcine Deltacoronavirus (PDCoV) are considered the greatest threats to the world swine industry since they cause a very high morbidity rate in piglets. Although vaccines with various formulations have been tested and validated in different settings, they still cannot be considered to provide long-lasting, comprehensive protection against these pathogens under real-world conditions. This review provides a comprehensive and critical overview of parallel efforts to develop vaccines against PEDV and PDCoV, with particular emphasis on vaccine formulation strategies, virus strains used in challenge studies, and the geographical applicability of these vaccines. Recent advances in vaccine development are discussed, highlighting the use of newly developed adjuvants and advanced delivery systems to enhance vaccine efficacy, especially in terms of inducing mucosal immune responses. Rather than merely summarizing progress in vaccine development to date, this review presents challenges, including viral diversity, lack of cross-protection, and maternal antibody interference, which reduce vaccine efficacy. Additionally, we discuss novel directions for future research on broadly protective next-generation antigen-detection systems and integrated approaches targeting different porcine coronaviruses. Thus, this review offers an up-to-date, in-depth overview of the current state of PEDV and PDCoV vaccine research, while also outlining future perspectives to drive innovation toward practical and sustainable disease control.},
}
@article {pmid41506930,
year = {2026},
author = {He, WT and Jiang, ZW and Veit, M and Merits, A and Zhang, FN and Wang, D and Su, S},
title = {Multiscale imaging of RNA virus: bridging structural mapping and functional insights.},
journal = {Trends in microbiology},
volume = {34},
number = {3},
pages = {305-317},
doi = {10.1016/j.tim.2025.12.002},
pmid = {41506930},
issn = {1878-4380},
mesh = {*RNA Viruses/ultrastructure/physiology ; *Cryoelectron Microscopy/methods ; Humans ; Electron Microscope Tomography/methods ; Animals ; SARS-CoV-2/ultrastructure ; },
abstract = {RNA viruses, exemplified by the COVID-19 pandemic, pose a significant threat to global health. Their rapid mutation and host adaptability highlight the need for advanced tools for efficient viral studies and timely countermeasure development. Imaging technologies, such as cryo-electron microscopy and super-resolution microscopy, have been pivotal in advancing our understanding of viral structures, infection mechanisms, and virus-host interactions. However, each technique has limitations in the field of view or resolution. Recent advancements have focused on developing integrated multiscale imaging to better understand RNA virus pathogenesis. In this review, we examine recent progress in RNA virus imaging across molecular, cellular, and tissue scales, including cryo-electron tomography and correlative multiscale imaging, which link structural mapping with functional insights.},
}
@article {pmid41509876,
year = {2026},
author = {Ärlebrant, L and Schimmer, R and Edin-Liljegren, A},
title = {Patients' experiences of video consultations: A qualitative systematic review.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076251404513},
pmid = {41509876},
issn = {2055-2076},
abstract = {INTRODUCTION: Video consultation (VC) became vital for improving healthcare access during COVID-19 pandemic and remains so. Despite evidence of effectiveness, concerns including technology literacy and inconsistencies in experience highlight the need for larger, patient-focused studies. While patients appreciate the convenience of VC, challenges during complex issues and patients' preferences for in-person care persists. Synthesising qualitative studies offers insights into the fragmented understanding of patient experiences with VC. This review explores adult patients' experiences of VC.<br><br>METHODS: A systematic literature search was conducted for studies published between 2011 and 2024 and reported according to the PRISMA statement. Study quality was assessed using the CASP checklist, and data were analysed through thematic synthesis. Confidence in the findings was evaluated using GRADE-CERQual.<br><br>RESULTS: In total, 3203 unique studies were retrieved; 13 were included in the final synthesis, resulting in four main themes: (1) suitable for less complex issues when technical problems can be solved; (2) feeling secure, relaxed, and having mutual focus in an equitable partnership; (3) limitations regarding personal needs and practical help; and (4) increased vulnerability and lack of emotional feedback.<br><br>CONCLUSION: VC is experienced as ideal for managing less complex issues but is challenging for emotional topics due to technical concerns. It empowers patients by providing a neutral place for focused conversations but can create vulnerability and distance that can challenge the patient-professional relationship. Success requires technological adaptation, sufficient time during VC, and emotional support. VC should complement - not replace - traditional care, with its use determined in dialogue with patients.},
}
@article {pmid41510348,
year = {2025},
author = {Tachibana, S and Bourgeois Yoshioka, CK},
title = {Take Fatigue or Fatigues into Account in Physiotherapy Interventions? A Rapid Scoping Review.},
journal = {Physical therapy research},
volume = {28},
number = {3},
pages = {157-173},
pmid = {41510348},
issn = {2189-8448},
abstract = {Fatigue is one of the most common symptoms encountered in rehabilitation and during physical therapy interventions. Although this phenomenon is known and experienced by everyone, its assessment is not straightforward. The lack of consensus on its definition, complex etiology, and multidimensional nature means that a large number of outcomes exist and continue to be reviewed. However, it seems essential that its assessment be better defined and standardized to understand the effects of physical therapy. To provide an initial exploratory overview, we conducted a rapid scoping review of the various fatigue assessments used in physiotherapy interventions or performed by physical therapists. A total of 139 articles published between 2020 and July 31, 2025 were included and explored. We found 43 different outcomes used across 46 population groups. While the most well-known chronic conditions such as cancer, multiple sclerosis (MS), and coronavirus disease 2019 (COVID-19) are representative, their assessment methods do not appear to be harmonized. These findings from the study support the idea that fatigue remains a complex phenomenon to assess. However, it appears that the lack of justification for the choice of an outcome prevents a better understanding of the reproducible effects on fatigue in physiotherapy interventions.},
}
@article {pmid41512080,
year = {2026},
author = {Lee, D and Malathi, K and Okano, T and Nakajima, K and Cobat, A and Morio, T and Casanova, JL and Zhang, SY},
title = {The OAS-RNase L pathway: Insights from experiments of nature.},
journal = {Science immunology},
volume = {11},
number = {115},
pages = {eads9407},
pmid = {41512080},
issn = {2470-9468},
support = {/HHMI/Howard Hughes Medical Institute/United States ; R15 AI169398/AI/NIAID NIH HHS/United States ; R21 AI160576/AI/NIAID NIH HHS/United States ; UL1 TR001866/TR/NCATS NIH HHS/United States ; },
mesh = {Humans ; *2',5'-Oligoadenylate Synthetase/genetics/metabolism/immunology ; *Endoribonucleases/metabolism/immunology/genetics ; Animals ; *SARS-CoV-2/immunology/physiology ; Inflammation/immunology ; Virus Replication ; Signal Transduction ; },
abstract = {The 2'-5' oligoadenylate synthetases (OASs) are type I interferon-inducible enzymes that, with ribonuclease L (RNase L), have been studied in the context of their coupled action as antiviral effectors. RNase L degrades host and viral ssRNA, affecting diverse cellular processes including translational arrest, interferon response, and apoptosis, all of which are thought to restrict viral replication. Recent studies of recessive inborn errors of human OAS1, OAS2, and RNase L, however, revealed that for SARS-CoV-2 infection, the main protective action of this pathway in natura may be through restricting phagocyte-driven postviral inflammation rather than restricting early viral replication in the respiratory tract. This finding is consistent with the identification of gain-of-function OAS1 mutations in humans with autoinflammation also driven by myeloid cells. Here, we retrace the investigation of the OAS-RNase L pathway, focusing on these recent in natura studies in humans that reposition the pathway as a determinant of the inflammatory response under natural conditions of infection.},
}
@article {pmid41512436,
year = {2026},
author = {Chau, MT and Spuur, KM and Vu, H},
title = {Health human resources shortages in radiography and sustainable workforce development in Australia.},
journal = {Radiography (London, England : 1995)},
volume = {32},
number = {2},
pages = {103319},
doi = {10.1016/j.radi.2025.103319},
pmid = {41512436},
issn = {1532-2831},
mesh = {Humans ; Australia ; *Health Workforce ; COVID-19/epidemiology ; Pandemics ; SARS-CoV-2 ; Sustainable Development ; },
abstract = {OBJECTIVES: Health Human Resources (HHR) are critical for the effective functioning of healthcare systems, yet significant shortages exist, particularly in radiography. The increasing demand for diagnostic radiography services, driven by advancements in medical technology, an aging population, and the prevalence of chronic diseases, exacerbates these shortages. The COVID-19 pandemic further highlighted workforce vulnerabilities, increasing workloads and burnout. This review examines HHR shortages in radiography in Australia and proposes strategies for sustainable workforce development.<br><br>KEY FINDINGS: The aging radiography workforce, with a significant portion nearing retirement, intensifies HHR shortages. The pandemic disrupted education and training, delaying the entry of new professionals and increasing turnover intentions among existing staff. The result being delayed imaging services, increased wait times, and potentially compromised patient outcomes. To address these challenges, a multifaceted strategy is proposed. Policy changes and government initiatives, including funding educational programs and recognizing internationally trained radiographers, can provide immediate relief. Expanding enrolment capacities and developing new training programs are essential. Retention strategies, including improving working conditions and career advancement opportunities, are crucial for workforce stability. Promoting advanced practice models can optimize task distribution and better utilize specialized skills. Leveraging technology, such as artificial intelligence and telehealth, can enhance productivity and extend service reach.<br><br>CONCLUSION: A comprehensive approach combining policy changes, educational initiatives, retention strategies, technology integration, international recruitment, and awareness campaigns is essential for addressing HHR shortages in radiography. By implementing these strategies, the radiography workforce can be better equipped to meet the growing demands of healthcare, ensuring optimal patient outcomes and the sustainability of health services.<br><br>IMPLICATIONS FOR PRACTICE: Strengthening the radiography workforce will ensure timely and effective healthcare delivery, support health interventions, and progress towards universal health coverage and Sustainable Development Goals.},
}
@article {pmid41513512,
year = {2026},
author = {Llanes, AC and Bandhlish, A and Pipavath, S and Lima, APS},
title = {Refining the Radiologic Recognition of Pulmonary Alveolar Proteinosis: A Crazy-Paving Pattern Approach.},
journal = {Seminars in roentgenology},
volume = {61},
number = {},
pages = {150961},
doi = {10.1053/j.ro.2025.09.004},
pmid = {41513512},
issn = {1558-4658},
mesh = {Humans ; *Pulmonary Alveolar Proteinosis/diagnostic imaging/pathology ; *Tomography, X-Ray Computed/methods ; Diagnosis, Differential ; COVID-19/diagnostic imaging ; SARS-CoV-2 ; Lung/diagnostic imaging ; Lung Diseases, Interstitial/diagnosis ; },
abstract = {Pulmonary alveolar proteinosis (PAP) is a rare airspace disease classically associated with the crazy-paving pattern on high-resolution computed tomography (HRCT). While highly suggestive, this imaging pattern is not pathognomonic and appears across a wide spectrum of pulmonary pathologies. In this review, we adopt a phenotype-first approach, using representative imaging cases to walk the reader through the differential diagnosis of crazy-paving, with attention to radiologic distribution, clinical context, and disease acuity. We emphasize distinguishing features between PAP and its mimics-including pulmonary edema, diffuse alveolar hemorrhage, organizing pneumonia, mucinous adenocarcinoma, exogenous lipoid pneumonia, acute fulminant PAP, and COVID-19 pneumonia-using side-by-side imaging and contextual pearls. Special attention is given to the radiologic clues favoring autoimmune versus secondary PAP, including geographic distribution of ground-glass opacities, subpleural sparing, and lower lobe predominance. The review concludes with a summary of diagnostic strategies, pathologic correlation, and treatment options, including insights from post-pandemic diagnostic pitfalls. This pattern-based framework is designed for the radiologist and serves as a practical guide for recognizing PAP within the broader spectrum of airspace diseases.},
}
@article {pmid41513611,
year = {2026},
author = {Nunes, M and Kell, L and Slaghekke, A and Wüst, RC and Fielding, BC and Kell, DB and Pretorius, E},
title = {Virus-induced endothelial senescence as a cause and driving factor for ME/CFS and long COVID: mediated by a dysfunctional immune system.},
journal = {Cell death &amp; disease},
volume = {17},
number = {1},
pages = {16},
pmid = {41513611},
issn = {2041-4889},
support = {NNF20CC0035580//Novo Nordisk Fonden (Novo Nordisk Foundation)/ ; },
mesh = {Humans ; *COVID-19/immunology ; *Cellular Senescence ; SARS-CoV-2 ; *Fatigue Syndrome, Chronic/immunology/virology/pathology ; Post-Acute COVID-19 Syndrome ; Animals ; *Endothelial Cells/pathology/virology/immunology ; *Endothelium, Vascular/immunology/pathology/virology ; *Immune System ; },
abstract = {Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are two post-viral diseases, which share many common symptoms and pathophysiological alterations. Yet a mechanistic explanation of disease induction and maintenance is lacking. This hinders the discovery and implementation of biomarkers and treatment options, and ultimately the establishment of effective clinical resolution. Here, we propose that acute viral infection results in (in)direct endothelial dysfunction and senescence, which at the blood-brain barrier, cerebral arteries, gastrointestinal tract, and skeletal muscle can explain symptoms. The endothelial senescence-associated secretory phenotype (SASP) is proinflammatory, pro-oxidative, procoagulant, primed for vasoconstriction, and characterized by impaired regulation of tissue repair, but also leads to dysregulated inflammatory processes. Immune abnormalities in ME/CFS and long COVID can account for the persistence of endothelial senescence long past the acute infection by preventing their clearance, thereby providing a mechanism for the chronic nature of ME/CFS and long COVID. The systemic and tissue-specific effects of endothelial senescence can thus explain the multisystem involvement in and subtypes of ME/CFS and long COVID, including dysregulated blood flow and perfusion deficits. This can occur in all tissues, but especially the brain as evidenced by findings of reduced cerebral blood flow and impaired perfusion of various brain regions, post-exertional malaise (PEM), gastrointestinal disturbances, and fatigue. Paramount to this theory is the affected endothelium, and the bidirectional sustainment of immune abnormalities and endothelial senescence. The recognition of endothelial cell dysfunction and senescence as a core element in the aetiology of both ME/CFS and Long COVID should aid in the establishment of effective biomarkers and treatment regimens.},
}
@article {pmid41514815,
year = {2026},
author = {Vasinioti, VI and Lucente, MS and Catella, C and Buonavoglia, C and Decaro, N and Pratelli, A and Capozza, P},
title = {Feline Infectious Peritonitis: A Challenging Diagnostic and Therapeutic Labyrinth.},
journal = {Animals : an open access journal from MDPI},
volume = {16},
number = {1},
pages = {},
pmid = {41514815},
issn = {2076-2615},
abstract = {Feline coronaviruses (FCoVs) are ubiquitous pathogens, exhibiting high prevalence across feline populations worldwide. Although the virulent mutated biotype feline infectious peritonitis virus (FIPV) is observed in only a small percentage of cats, it causes a systemic and often fatal disease. Diagnosis of feline infectious peritonitis (FIP) is challenging due to its non-specific clinical signs and the difficulty in differentiating between the two biotypes, feline enteric coronavirus (FECV) and FPIV. Currently, veterinarians rely on a combination of diagnostic methods, integrating laboratory tests, anamnesis and clinical signs to improve the diagnostic accuracy of FIP. Once considered untreatable, FIP now benefits from recent pharmacological advances that suggest promising therapeutic options, including antiviral drugs and immunomodulatory therapies. Despite these developments, the lack of an effective vaccine and definitive curative treatment highlights the need for continued research. This review provides a comprehensive analysis of the current literature on diagnostic and treatment approaches for FIP. The aim is to improve understanding of the available options and strategies for FIP to mitigate its severe consequences.},
}
@article {pmid41515644,
year = {2026},
author = {Azman, SA and Kennedy, MP},
title = {Single-Use Flexible Bronchoscopy: Advances in Technology and Applications.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {1},
pages = {},
pmid = {41515644},
issn = {2075-4418},
abstract = {With advances in scope and imaging technology, the use of single-use flexible bronchoscopy (SUFB) has broadened beyond intensive care units and operating rooms to bronchoscopy units, with an expanding body of literature suggesting adequate and comparable procedure outcomes, including airway inspection, bronchoalveolar lavage, endobronchial brushing and endobronchial biopsy, in comparison to standard reusable flexible bronchoscopy (RFB). Advantages such as mobility, ease of use and lack of requirement for cleaning staff during the COVID-19 pandemic led to a global increase in usage, with many companies developing SUFB as part of their bronchoscopy portfolio. In parallel, there has been more attention and initiatives to minimise the risk of infection transmission related to bronchoscopy. RFB requires maximum adherence to manufacturer-recommended cleaning protocols. However, evidence of transmissible organisms after cleaning is reported in healthcare settings of all types. After initial benchtop, retrospective and single-arm studies, comparative bronchoscopy studies are identifying that SUFB are as versatile and non-inferior to RFB. However, cost-effectiveness and sustainability factors have to be included in deciding the use of SUFB in routine practice.},
}
@article {pmid41516024,
year = {2025},
author = {Cuppen, JJM and Savelkoul, HFJ},
title = {Immune Delay, Beyond Immune Evasion, as a Driver of Pathogen Propagation Competence Through Neutrophil Dysregulation, to be Mitigated by Low-Frequency Electromagnetic Fields (LF-EMF).},
journal = {International journal of molecular sciences},
volume = {27},
number = {1},
pages = {},
pmid = {41516024},
issn = {1422-0067},
mesh = {*Neutrophils/immunology/radiation effects ; Humans ; *Electromagnetic Fields ; *Immune Evasion/immunology ; Animals ; *Bacterial Infections/immunology ; *Virus Diseases/immunology ; Neutrophil Activation/immunology/radiation effects ; Host-Pathogen Interactions/immunology ; },
abstract = {This paper proposes that immune delay, beyond immune evasion, is key in the propagation competence of major viral and bacterial infections, and that the dynamics of infection and immune response suggest possibilities for mitigating the ensuing infectious diseases. Recent data show a critical role of neutrophils at various stages of viral and bacterial infections, revealing how early activation of neutrophils could help mitigate infectious diseases. It could prevent the gradual overactivation of subclasses of neutrophils and probably not induce it. In respiratory virus infections, an immune delay of several days allows the development of a high viral load supporting infectivity towards further hosts when a delayed and increased immune response takes place. Virus variants will optimize immune delay towards highest infectivity, supporting pandemic potential. The influenza virus, coronavirus, and several major bacterial infections exhibit such immune delay capability. Recurrent urinary tract infections (rUTI) are common, often associated with the causative uropathogenic E. coli (UPEC) that has this capability, suggesting that immune delay is crucial in the pathogenesis of rUTI and other widespread bacterial infections. Counteracting immune delay, therefore, is a promising approach for mitigating infectious diseases with epidemic and pandemic presence or potential. Previously proven low-frequency electromagnetic field (LF-EMF)-induced neutrophil activation is such an approach.},
}
@article {pmid41516027,
year = {2025},
author = {Yang, J and Qu, Y and Yuan, Z and Lun, Y and Kuang, J and Shao, T and Qi, Y and Li, Y and Zhu, L},
title = {Targeting Host Dependency Factors: A Paradigm Shift in Antiviral Strategy Against RNA Viruses.},
journal = {International journal of molecular sciences},
volume = {27},
number = {1},
pages = {},
pmid = {41516027},
issn = {1422-0067},
mesh = {Humans ; *RNA Viruses/drug effects/physiology ; *Antiviral Agents/pharmacology/therapeutic use ; *Host-Pathogen Interactions/drug effects ; Virus Replication/drug effects ; Animals ; *RNA Virus Infections/drug therapy/virology ; Host-Directed Therapy ; Virus Internalization/drug effects ; },
abstract = {RNA viruses, such as SARS-CoV-2 and influenza, pose a persistent threat to global public health. Their high mutation rates undermine the effectiveness of conventional direct-acting antivirals (DAAs) and facilitate drug resistance. As obligate intracellular parasites, RNA viruses rely extensively on host cellular machinery and metabolic pathways throughout their life cycle. This dependency has prompted a strategic shift in antiviral research-from targeting the mutable virus to targeting relatively conserved host dependency factors (HDFs). In this review, we systematically analyze how RNA viruses exploit HDFs at each stage of infection: utilizing host receptors for entry; remodeling endomembrane systems to establish replication organelles; hijacking transcriptional, translational, and metabolic systems for genome replication and protein synthesis; and co-opting trafficking and budding machinery for assembly and egress. By comparing strategies across diverse RNA viruses, we highlight the broad-spectrum potential of HDF-targeting approaches, which offer a higher genetic barrier to resistance, providing a rational framework for developing host-targeting antiviral therapies.},
}
@article {pmid41516190,
year = {2025},
author = {Mcmillan, P and Turner, AJ and Uhal, BD},
title = {The Central Role of Macrophages in Long COVID Pathophysiology.},
journal = {International journal of molecular sciences},
volume = {27},
number = {1},
pages = {},
pmid = {41516190},
issn = {1422-0067},
mesh = {Humans ; *Macrophages/immunology/pathology ; *COVID-19/immunology/physiopathology/pathology/virology ; Post-Acute COVID-19 Syndrome ; Macrophage Activation ; Immunity, Innate ; SARS-CoV-2/immunology ; Epigenesis, Genetic ; Animals ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {This review article attempts to provide a unifying hypothesis to explain the myriad of symptoms and predispositions underlying the development of PASC (Postacute Sequelae of COVID), often referred to as Long COVID. The hypothesis described here proposes that Long COVID is best understood as a disorder of persistent immune dysregulation, with chronic macrophage activation representing the fundamental underlying pathophysiology. Unlike transient post-viral syndromes, Long COVID involves a sustained innate immune response, particularly within monocyte-derived macrophages, driven by persistent spike protein (peripherally in MAIT cells and centrally in Microglial cells), epigenetic imprinting, and gut-related viral reservoirs. These macrophages are not merely activated temporarily but also become epigenetically "trained" into a prolonged inflammatory state, as demonstrated by enduring histone acetylation markers such as H3K27acDNA Reprogramming. It is proposed that recognizing macrophage activation as the central axis of Long COVID pathology offers a framework for personalized risk assessment, targeted intervention, and therapeutic recalibration.},
}
@article {pmid41516301,
year = {2025},
author = {Stojanovic, M and Djuric, M and Nenadic, I and Bojic, S and Andrijevic, A and Popovic, A and Pesic, S},
title = {Vascular Complications of Long COVID-From Endothelial Dysfunction to Systemic Thrombosis: A Systematic Review.},
journal = {International journal of molecular sciences},
volume = {27},
number = {1},
pages = {},
pmid = {41516301},
issn = {1422-0067},
mesh = {Humans ; *COVID-19/complications/pathology ; *Thrombosis/etiology/pathology ; *Endothelium, Vascular/physiopathology/pathology ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated not only with respiratory illness but also with profound vascular and coagulation disturbances. Long COVID (LC) is characterized by persistent symptoms such as fatigue, dyspnea, cognitive impairment, and palpitations. Mechanistically, SARS-CoV-2 induces direct endothelial injury, promotes a pro-inflammatory cytokine milieu, and activates platelets, leading to immunothrombosis and impaired fibrinolysis. Consequently, patients exhibit microthrombosis, elevated plasma D-dimer, fibrinogen dysregulation, and persistent hypercoagulability. Clinically, this translates into an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as well as arterial thrombotic events such as myocardial infarction and stroke, which may persist months after acute infection. Understanding the interplay between endothelial injury, inflammation, and coagulation is crucial for risk stratification and the development of preventive and therapeutic strategies. We conducted a systematic narrative review of the literature, including human clinical and mechanistic studies identified through PubMed, Scopus and Web of Science up to 30 September 2025. This review synthesizes current evidence on vascular complications in LC, highlighting endothelial dysfunction as a central pathophysiological nexus linking the acute phase of SARS-CoV-2 infection with chronic LC manifestations.},
}
@article {pmid41516418,
year = {2026},
author = {Barajas, A and Riquelme-Alacid, G and Vera-Montecinos, A and Ramos, B},
title = {Cognition, Cytokines, Blood-Brain Barrier, and Beyond in COVID-19: A Narrative Review.},
journal = {International journal of molecular sciences},
volume = {27},
number = {1},
pages = {},
pmid = {41516418},
issn = {1422-0067},
support = {PI21/00059//Instituto de Salud Carlos III/ ; },
mesh = {Humans ; *Blood-Brain Barrier/metabolism ; *COVID-19/complications ; *Cytokines/blood/metabolism ; SARS-CoV-2/isolation &amp; purification ; *Cognition/physiology ; *Cognitive Dysfunction/etiology ; Post-Acute COVID-19 Syndrome ; },
abstract = {Numerous studies report cognitive impairment in COVID-19 patients from the acute to post-acute phases, linked to blood inflammation affecting blood-brain barrier (BBB) permeability and causing leakage of glial and neuronal proteins. However, a clear classification of these cognitive deficits and molecular blood events over time is still lacking. This narrative review summarizes the neuropsychological consequences of COVID-19 and evidence of altered cytokines and BBB disruption as potential mediators of cognitive impairment across post-infection phases. Post-COVID-19 cognitive dysfunction appears to follow a temporal course, evolving from acute focal deficits in attention, working memory, and executive function to more persistent multidomain impairments. We reviewed key cytokines released into the blood during COVID-19 infection, including antiviral (IFNγ, CXCL1, CXCL10), inflammatory (IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, GM-CSF, TNFα), and monocyte chemoattractants (MCP1/CCL2, MCP3/CCL7, MIP-1α/CCL3, GM-CSF, G-CSF). This analysis shows that several inflammatory and viral cytokines remain elevated beyond the acute phase and are associated with cognitive deficits, including IL-6, IL-13, IL-8, IL-1β, TNFα, and MCP1 in long-term post-COVID-19 patients. In addition, we examined studies analyzing changes over time in neurovascular unit proteins as biomarkers of BBB disruption, including extracellular matrix proteins (PPIA, MMP-9), astrocytes (S100β, GFAP), and neurons (NFL). These proteins are elevated in acute COVID-19 but generally return to control levels within six months, suggesting BBB restoration. However, in patients followed for over a year, BBB disruption persists only in those with cognitive impairment and is associated with systemic inflammation, with TGFβ as a related biomarker. Although cognitive sequelae can persist for over 12 months after SARS-CoV-2 infection, further studies are needed to investigate long-term neurocognitive outcomes and their link to sustained proinflammatory cytokine elevation and brain impact.},
}
@article {pmid41516981,
year = {2025},
author = {Huang, WH and Ho, YF and Yeh, JY and Liu, PY and Huang, PH},
title = {Hospital Influenza Outbreak Management in the Post-COVID Era: A Narrative Review of Evolving Practices and Feasibility Considerations.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {1},
pages = {},
pmid = {41516981},
issn = {2227-9032},
abstract = {Background: Hospital-acquired influenza remains a persistent threat that amplifies morbidity, mortality, length of stay, and operational strain, particularly among older and immunocompromised inpatients. The COVID-19 era reshaped control norms-normalizing N95 use during surges, ventilation improvements, and routine multiplex PCR-creating an opportunity to strengthen hospital outbreak management. Methods: We conducted a targeted narrative review of WHO/CDC/Infectious Diseases Society of America (IDSA) guidance and peer-reviewed studies (January 2015-August 2025), emphasizing adult inpatient care. This narrative review synthesizes recent evidence and discusses theoretical implications for practice, rather than establishing formal guidelines. Evidence was synthesized into pragmatic practice statements on detection, diagnostics, isolation/cohorting, antivirals, chemoprophylaxis, vaccination, surveillance, and communication. Results: Early recognition and test-based confirmation are pivotal. For inpatients, nucleic-acid amplification tests are preferred; negative antigen tests warrant PCR confirmation, and lower-respiratory specimens improve yield in severe disease. A practical outbreak threshold is ≥2 epidemiologically linked, laboratory-confirmed cases within 72 h on the same ward. Effective control may require immediate isolation or cohorting with dedicated staff, strict droplet/respiratory protection, and daily active surveillance. Early oseltamivir (≤48 h from onset or on admission) reduces mortality and length of stay; short-course post-exposure prophylaxis for exposed patients or staff lowers secondary attack rates. Integrated vaccination efforts for healthcare personnel and high-risk patients reinforce workforce resilience and reduce transmission. Conclusions: A standardized, clinician-led bundle-early molecular testing, do-not-delay antivirals, decisive cohorting and Personal protective equipment (PPE), targeted chemoprophylaxis, vaccination, and disciplined communication- could help curb transmission, protect vulnerable patients and staff, and preserve capacity. Hospitals should codify COVID-era layered controls for seasonal influenza and rehearse unit-level outbreak playbooks to accelerate response and recovery. These recommendations target clinicians and infection-prevention leaders in acute-care hospitals.},
}
@article {pmid41517347,
year = {2025},
author = {Boccatonda, A and Brighenti, A and D'Ardes, D and Vetrugno, L},
title = {High-Flow Nasal Cannula Outside the ICU: A Systematic Review and Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {1},
pages = {},
pmid = {41517347},
issn = {2077-0383},
abstract = {Background: Use of high-flow nasal cannula (HFNC) expanded from ICUs to internal medicine/respiratory wards during and after the COVID-19 pandemic, but safety and effectiveness in non-ICU settings remain uncertain. Methods: We performed a systematic review and meta-analysis of adults (≥18 years) initiated on HFNC in non-ICU wards. Primary outcomes were in-hospital (or 28-day) mortality and ICU transfer; where available, we compared mortality for HFNC vs. conventional oxygen therapy (COT) in do-not-intubate (DNI) cohorts. Observational studies and trials were eligible. Random-effects models synthesized proportions and risk ratios; risk of bias (ROBINS-I/RoB 2) and certainty (GRADE) were assessed. Results: Ten studies met the inclusion criteria for any-ward HFNC; subsets contributed data to pooled analyses. Across all non-ICU wards (general wards plus step-up IMCU/HDU), pooled mortality was 14.0% (95% CI 4.6-35.5; I[2] ≈ 92%). Pooled ICU transfer after ward/step-up HFNC start was 20.0% (95% CI 6.3-48.1; I[2] ≈ 97%). Restricted to internal medicine/respiratory wards, pooled mortality was 19.8% (95% CI 7.1-44.2; I[2] ≈ 95%) and ICU transfer 31.2% (95% CI 9.9-65.0; I[2] ≈ 97%). In step-up units (IMCU/HDU), ICU transfer appeared lower and less variable (22.0% [95% CI 16.5-28.8]; I[2] ≈ 10%), suggesting environment-dependent outcomes. In a multicenter DNI COVID-19 cohort, HFNC vs. COT showed no clear mortality difference (RR ≈ 0.90, 95% CI 0.75-1.08; adjusted OR ≈ 0.72, 95% CI 0.34-1.54). Certainty of evidence for all critical outcomes was very low due to observational design, high inconsistency, and imprecision. Conclusions: HFNC outside the ICU is feasible, but it is related to nontrivial mortality and frequent escalation-particularly on general wards-while step-up units demonstrate more reproducible trajectories. Outcomes appear strongly conditioned by care environment, staffing, monitoring, and escalation pathways. Given very low certainty and substantial heterogeneity, institutions should pair ward HFNC with protocolized reassessment and rapid response/ICU outreach, and future research should prospectively compare ward HFNC pathways against optimized COT/NIV using standardized outcomes.},
}
@article {pmid41517591,
year = {2026},
author = {Cotet, IG and Mateescu, DM and Gavrilescu, DM and Marginean, A and Serban, S and Ilie, AC and Guse, C and Pah, AM and Badalica-Petrescu, M and Iurciuc, S and Craciun, ML and Avram, A and Tudoran, C},
title = {Surgical Timing and Safety of Breast Cancer Operations After COVID-19: A Prospective-Only Meta-Analysis of Cohort Studies.},
journal = {Journal of clinical medicine},
volume = {15},
number = {1},
pages = {},
pmid = {41517591},
issn = {2077-0383},
support = {Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
abstract = {Background: The COVID-19 pandemic raised uncertainties regarding the safe timing of breast cancer surgery after SARS-CoV-2 infection, and robust prospective evidence has remained limited. Methods: We conducted a systematic review and meta-analysis of prospective cohort studies (2020-2024) investigating postoperative outcomes in breast cancer patients with confirmed SARS-CoV-2 infection ≤90 days before surgery versus contemporaneous non-infected controls treated at the same institutions and in the same period. PROSPERO CRD420251174613. Random-effects models (DerSimonian-Laird with Hartung-Knapp adjustment) were used to pool odds ratios (ORs) and 95% confidence intervals (CIs). Study quality was assessed with the Newcastle-Ottawa Scale, and certainty of evidence was rated using GRADE. Results: Twelve prospective cohort studies, including 7812 patients, compared breast cancer surgery after recent confirmed SARS-CoV-2 infection over 90 days with contemporaneous non-infected controls treated at the same centres. Overall, recent infection was associated with higher 30-day postoperative complications (Clavien-Dindo ≥ II) compared to. non-infected patients (OR 2.01, 95% CI 1.44-2.81) and increased venous thromboembolism (3.6%vs. 1.2%; OR 3.12, 95% CI 1.29-7.55). Early surgery 14 days after infection carried the highest risk of complications (OR 4.38, 95 CI 2.31-8.30), whereas operations performed ≥6 weeks yielded outcomes comparable to non-infected controls (OR 1.03, 95 CI 0.81-1.31); 30-day mortality remained very low (0.3). Conclusions: Breast cancer surgery after SARS-CoV-2 infection is associated with excess perioperative risk only when performed within the first two weeks. Delaying surgery to approximately six weeks minimises complications and VTE without compromising short-term safety.},
}
@article {pmid41517681,
year = {2026},
author = {Escobar-Segovia, K and Domínguez-Salas, S and García-Iglesias, JJ and López-López, D and Allande-Cussó, R and Ruiz-Frutos, C and Artero-García, A and Gómez-Salgado, J},
title = {Psychological distress in Spanish-speaking countries during the COVID-19 pandemic: A systematic review and meta-analysis.},
journal = {Medicine},
volume = {105},
number = {2},
pages = {e47062},
pmid = {41517681},
issn = {1536-5964},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Psychological Distress ; *Stress, Psychological/epidemiology ; Prevalence ; SARS-CoV-2 ; Female ; Pandemics ; Spain/epidemiology ; },
abstract = {BACKGROUND: Psychological distress (PD) has increased significantly during the coronavirus disease 2019 (COVID-19) pandemic. In Spanish-speaking countries, with their cultural, social, and economic diversity, this phenomenon has become particularly relevant and has been aggravated by factors such as socioeconomic inequalities and unequal access to mental health services. The aim of this systematic review was to consolidate the available knowledge on PD in Spanish-speaking population groups by assessing both the prevalence of symptoms and the associated factors in different demographic groups and geographic contexts, during the COVID-19 pandemic.<br><br>METHODS: A systematic review following the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement was conducted in the Web of Science, PubMed, and Scopus electronic databases in January 2025. The search included studies published from the beginning of the pandemic until May 2023. The Joanna Briggs Institute's critical assessment tool was used to evaluate the chosen studies' methodological quality.<br><br>RESULTS: A total of 53 studies were included in the review, which involved research conducted in Spain, Peru, Chile, Ecuador, Argentina, and Colombia. The results revealed a high prevalence of PD in these countries, especially among healthcare workers, women, and young people. The assessment methods used included the General Health Questionnaire (GHQ, GHQ-12, and GHQ-28 versions), the Kessler scale (K-6 and K-10 versions), and the 90-symptom checklist questionnaire (SCL-90-R), that allowed obtaining various dimensions of PD. The studies also highlighted the importance of the sense of coherence and work engagement as protective factors.<br><br>CONCLUSIONS: In the COVID-19 pandemic, PD was analyzed to be severe in Spanish-speaking countries, pointing to the need for specific and culturally adapted interventions to address this public mental health crisis. This is why public health policies must focus on the prevention and treatment of PD, with special attention to the most vulnerable groups.},
}
@article {pmid41518867,
year = {2026},
author = {Amirav, I and Ben Yosef, H and Zelniker, N and Be'er, M and Dennett, L and Besor, O and Lavie, M and Pillay, J},
title = {Risk of small-volume nebulizer treatments in the transmission of bacteria and viruses: a systematic review.},
journal = {The Journal of hospital infection},
volume = {168},
number = {},
pages = {144-160},
doi = {10.1016/j.jhin.2025.10.022},
pmid = {41518867},
issn = {1532-2939},
mesh = {Humans ; *Nebulizers and Vaporizers ; *Cross Infection/transmission ; *Bacterial Infections/transmission ; Aerosols ; COVID-19/transmission ; },
abstract = {BACKGROUND: Nebulized aerosol therapy is widely used for treating respiratory diseases, including those caused by severe acute respiratory syndrome coronavirus-2. During pandemics, some guidelines recommend avoiding nebulizers, yet supporting evidence is limited.<br><br>OBJECTIVE: To undertake a systematic review of evidence on the risk of cross-infection linked to nebulizer use in healthcare settings.<br><br>DATA SOURCES: Databases including Medline and Embase were searched from June 2020 to February 2024. Two independent reviewers conducted study selection and data extraction; discrepancies were resolved by a third reviewer.<br><br>DATA EXTRACTION: Risk of bias was assessed using the Newcastle-Ottawa Scale for case-control and cohort studies, an adapted version for cross-sectional studies, and a custom tool for experimental/simulation studies. Meta-analysis was performed on comparative clinical data. Certainty of evidence was rated using the Grading of Recommendation, Assessment, Development and Evaluation approach.<br><br>SYNTHESIS: Twenty-six studies met the inclusion criteria (six case-control, three cohort, one cross-sectional, four case series, 12 experimental/simulation). None of them reported that nebulizer use is free from risk of cross-infection. Meta-analysis of 10 comparative clinical studies (N=8536) found an association between nebulizer use and increased risk of infection (odds ratio 3.20, 95% confidence interval 1.59-6.44; P=0.0001), although certainty was low. Nine of 12 experimental/simulation studies demonstrated aerosol dispersion of particles or pathogens.<br><br>CONCLUSIONS: Nebulizer exposure may elevate the risk of infection compared with non-exposure. Nebulizer use in hospital settings should be limited during pandemics or when cross-infection is a concern. When necessary, additional precautions are warranted.},
}
@article {pmid41519993,
year = {2026},
author = {Azhar, LE and Samkari, DA and Hassan, AM and Alsayed, SM and Azhar, EI},
title = {The Emergence and Characterization of SARS-CoV-2 Variant XFG ("Stratus"): Comparative Virological, Epidemiological, and Public-Health Perspectives.},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {8},
pmid = {41519993},
issn = {2210-6014},
mesh = {Humans ; *COVID-19/epidemiology/virology/immunology ; *SARS-CoV-2/genetics/immunology ; Public Health ; },
abstract = {BACKGROUND: SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions. OBJECTIVE: To synthesize the current virological, immunological, epidemiological, and clinical evidence on XFG, and to contextualize its public-health significance through comparison with the closely related Omicron-derived lineages JN.1 and NB.1.8.1.… APPROACH: This narrative review integrates available molecular and immune data with surveillance observations and emerging clinical reports, translating technical findings into implications that are relevant for healthcare systems and the people they serve. KEY FINDINGS: Across available datasets, XFG shows modest immune escape and a moderate growth advantage, yet there is no signal of increased clinical severity compared with recent Omicron sublineages. Current evidence supports the continued effectiveness of vaccines and antivirals, reinforcing that incremental viral adaptation is compatible with stable clinical outcomes in immunologically experienced populations. CONCLUSIONS: XFG exemplifies ongoing, “quiet” SARS-CoV-2 evolution—more consistent with antigenic fine-tuning than a shift toward greater virulence. For individuals, the practical message remains steady: stay updated with vaccination when eligible and seek timely care when at higher risk. For health systems, sustained genomic surveillance, targeted protection of vulnerable groups, and measured risk communication remain central to resilient coexistence with SARS-CoV-2.},
}
@article {pmid41521058,
year = {2026},
author = {Keefer, S and Lorenzo-Leal, AC and Bach, H},
title = {Advancements in nanotrap technology for the prevention, diagnosis and treatment of infectious diseases.},
journal = {Nanomedicine (London, England)},
volume = {21},
number = {3},
pages = {375-385},
pmid = {41521058},
issn = {1748-6963},
mesh = {Humans ; *Communicable Diseases/diagnosis/therapy/drug therapy ; *Nanoparticles/chemistry/therapeutic use ; Animals ; Nanotechnology/methods ; SARS-CoV-2/isolation &amp; purification ; Bacterial Infections/diagnosis/prevention &amp; control ; Nanomedicine/methods ; COVID-19/prevention &amp; control/diagnosis ; Virus Diseases/diagnosis/prevention &amp; control/therapy ; },
abstract = {Nanotraps are particles designed to capture and concentrate target molecules and have numerous applications in infectious diseases. This review outlines how nanotrap technologies may improve the detection and treatment of bacterial and viral pathogens, including Mycobacterium tuberculosis, Borrelia burgdorferi, Yersinia pestis, HIV, SARS-CoV-2, and others. Nanotraps can enhance the sensitivity of diagnostic tools and support treatment by neutralizing bacterial toxins, capturing inflammatory mediators, and preserving viral proteins for detection. Nanotraps have also been investigated for vaccine development. While results from in vitro and in vivo models are encouraging, there is significant room for further research regarding safety and other unexplored applications of these technologies. Nanotraps offer a flexible platform with the potential to improve how we diagnose and manage a multitude of infectious diseases.},
}
@article {pmid41521363,
year = {2026},
author = {Singh, D},
title = {mRNA-Encoded antibodies as a next-generation therapeutic paradigm: a rapid and adaptive platform for the prevention and treatment of emerging and re-emerging infectious diseases - A critical review.},
journal = {Immunologic research},
volume = {74},
number = {1},
pages = {7},
pmid = {41521363},
issn = {1559-0755},
mesh = {Humans ; SARS-CoV-2/immunology ; Animals ; COVID-19/immunology/prevention &amp; control ; *Antibodies, Neutralizing/genetics/therapeutic use/immunology ; *Antibodies, Viral/genetics/therapeutic use/immunology ; *Communicable Diseases, Emerging/therapy/prevention &amp; control/immunology ; *RNA, Messenger/genetics/immunology ; Spike Glycoprotein, Coronavirus/immunology ; Nanoparticles ; Pandemics/prevention &amp; control ; Liposomes ; },
abstract = {Messenger RNA (mRNA)-encoded antibodies represent a transformative therapeutic platform with the potential to rapidly combat emerging infectious diseases by enabling in situ expression of potent neutralizing antibodies directly in the patient's body. Unlike conventional monoclonal antibody (mAb) therapies, which rely on labor-intensive and time-consuming cell culture production, mRNA-encoded antibodies offer a faster, scalable, and cell-free approach that bypasses protein purification and cold-chain constraints. This strategy has demonstrated considerable promise during the COVID-19 pandemic, where Moderna's mRNA-1940, an mRNA-based neutralizing antibody targeting the SARS-CoV-2 spike protein, entered preclinical and early-phase trials within months of viral emergence, underscoring the potential for rapid response in outbreak settings. The platform leverages advances in nucleoside-modified mRNA, codon optimization, and lipid nanoparticle (LNP) delivery systems to achieve transient, high-level expression of functional antibodies with reduced innate immune activation. Beyond COVID-19, mRNA-encoded antibody approaches have been explored in preclinical models of Zika virus, Ebola virus, and rabies, where a single intramuscular dose provided prophylactic and therapeutic benefits in animal models. As the world faces recurrent viral threats, the development of mRNA-encoded antibodies as a plug-and-play system offers a compelling, adaptable, and clinically feasible strategy for infectious disease preparedness. This review explores the mechanistic foundation, delivery technologies, translational progress, case studies, safety considerations, and future clinical potential of mRNA-encoded antibodies in combating both pandemic and endemic infections.},
}
@article {pmid41522108,
year = {2025},
author = {Liu, X and Cai, Q and Lin, L and Deng, H and Zeng, R and Shi, J and Huang, L and Liu, H and Li, C and Li, J and Cheng, B and Liu, H and Thiery, JP and Liang, W and He, J},
title = {Novel insights into diagnosis and management of hyperreactivity: a narrative review.},
journal = {Journal of thoracic disease},
volume = {17},
number = {12},
pages = {11429-11453},
pmid = {41522108},
issn = {2072-1439},
abstract = {BACKGROUND AND OBJECTIVE: Hyperreactivity (HR) refers to an exaggerated biological response to a given stimulus that is within the normal physiological range, resulting from a lowered activation threshold of the involved system or effector cells. It commonly occurs after surgery, lung transplantation, and coronavirus disease 2019 (COVID-19) infection but lacks a unified concept and systematic understanding. This review aims to elucidate the concept, mechanisms, and disease spectrum of HR as an independent clinical entity, systematically explore its roles in postoperative conditions, lung transplantation, and COVID-19, and develop a biomarker-based hierarchical management framework, thereby providing a new paradigm for its precise recognition and intervention.<br><br>METHODS: We systematically searched the PubMed, Web of Science, Scopus, and China National Knowledge Infrastructure databases for literature published from January 1, 1968, to November 1, 2025, including reviews, randomized controlled trials, and observational studies, human or animal studies related to HR mechanisms or clinical phenotypes, while excluding non-peer-reviewed materials such as case reports and conference abstracts.<br><br>KEY CONTENT AND FINDINGS: This study first proposes that HR arises from a four-dimensional imbalance across the nervous, endocrine, immune, and microenvironmental systems, characterized by thoroughness, early onset/persistence, and individual variability. The mechanisms underlying HR in postoperative, transplant-related, and COVID-19 conditions are systematically summarized, and a hierarchical, biomarker-based management framework is developed, highlighting the need for marker validation and trajectory modeling.<br><br>CONCLUSIONS: HR represents an independent clinical entity that transcends traditional disease boundaries. This review provides a new paradigm for its precise recognition and intervention and is expected to advance the conceptual and practical development of this field. Future research, clinical practice, and policy formulation should be individualized and mechanism-driven.},
}
@article {pmid41522210,
year = {2026},
author = {Zhang, Z and Fang, X and Gao, J and Sun, H and Xu, T and Wang, J},
title = {Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis.},
journal = {Canadian respiratory journal},
volume = {2026},
number = {},
pages = {8812779},
pmid = {41522210},
issn = {1916-7245},
mesh = {Humans ; *Pyridones/therapeutic use/adverse effects ; *COVID-19/complications ; *Lung Diseases, Interstitial/drug therapy/etiology ; *COVID-19 Drug Treatment ; SARS-CoV-2 ; *Antifibrotic Agents/therapeutic use ; Treatment Outcome ; },
abstract = {BACKGROUND: Although post-COVID-19 interstitial lung abnormalities (ILAs) are common, the use of antifibrotic agents to prevent their onset and progression is controversial. We aimed to investigate the effectiveness and safety of pirfenidone to mitigate the onset and progression of ILAs in patients with severe COVID-19.<br><br>METHODS: We systematically searched literature published before July 21, 2025, from PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, China Biology Medicine, Weipu, and Wanfang databases, without language limitation. Randomized controlled trials and cohort studies that evaluated the effect of pirfenidone on COVID-19-induced ILAs were included. Risk of bias was determined using the Revised Cochrane Randomized Trial Risk Bias Tool Version 2 and the Newcastle-Ottawa Scale. The efficacy and safety of pirfenidone for ILAs in COVID-19 were analyzed by Review Manager 5.4 software.<br><br>RESULTS: Eight studies were included, comprising 335 patients in pirfenidone treatment groups and 302 controls. Risk of bias ranged from low to moderate. Pirfenidone significantly decreased chest high-resolution CT (HRCT) scores during early- and late-stage COVID-19 and significantly improved forced expiratory volume in 1&#x2009;s, especially in late-stage COVID-19. Pirfenidone treatment was associated with statistically nonsignificant trends toward improved forced vital capacity and decreased all-cause mortality. Furthermore, HRCT scores, pulmonary function, and inflammatory cytokine levels following pirfenidone treatment were superior to those obtained after glucocorticoid therapy. The incidence of gastrointestinal adverse events was higher in the pirfenidone than the control group, but no serious adverse events or fatalities occurred.<br><br>CONCLUSION: Pirfenidone therapy may mitigate ILAs and preserve pulmonary function among survivors of COVID-19 pneumonia. Furthermore, pirfenidone exhibited acceptable safety and tolerability profiles.},
}
@article {pmid41522489,
year = {2026},
author = {Ren, Q and Wang, Y and Ma, H and Xie, J and Jin, J and Tian, R and Yu, H and Gao, X and Chen, N},
title = {Recent Advances in Lateral Flow Immunoassay for Rapid Diagnosis of Viral Diseases.},
journal = {Transboundary and emerging diseases},
volume = {2026},
number = {},
pages = {5701806},
pmid = {41522489},
issn = {1865-1682},
mesh = {Animals ; Immunoassay/methods/veterinary ; *Virus Diseases/diagnosis/veterinary/virology ; Humans ; Rapid Diagnostic Tests ; },
abstract = {Viral diseases are a major threat to human and animal health, as illustrated by recent pandemics like COVID-19 and African swine fever (ASF). Timely, accurate detection of viral infections is critical for effective disease control. Among diverse diagnostic techniques, lateral flow immunoassay (LFIA) has become a widely used on-site testing tool, owing to its speed, simplicity, affordability, and portability. The application of LFIA for detecting human and animal viruses is feasible, which highlights its practical utility in veterinary settings. This review summarizes key advances in LFIA for the rapid diagnosis of viral diseases over the past decade, focusing on its technical principles, practical applications, core advantages, existing limitations, and potential effective strategies to provide comprehensive knowledge for virus detection.},
}
@article {pmid41523846,
year = {2025},
author = {Fraga, RO and Fraga, ASA and Conte, AAM and Skupien, JA and Schuch, NJ},
title = {Prevalence of burnout among Brazilian Army soldiers during the COVID-19 pandemic: a cross-sectional analysis.},
journal = {Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT},
volume = {23},
number = {4},
pages = {e20251467},
pmid = {41523846},
issn = {1679-4435},
abstract = {INTRODUCTION: The COVID-19 pandemic significantly impacted the mental health of frontline workers, including military personnel.<br><br>OBJECTIVES: To determine the prevalence of burnout syndrome among Brazilian Army personnel during the pandemic and identify associated predictive variables.<br><br>METHODS: A cross-sectional study was conducted with 602 volunteer military personnel in the city of Santa Maria, Brazil. The Maslach Burnout Inventory was used to assess burnout syndrome, defined by high levels of emotional exhaustion, depersonalization, or low personal accomplishment. Logistic regression was performed to identify associated factors.<br><br>RESULTS: The prevalence ofburnout syndrome was 48.7%. High levels of emotional exhaustion, depersonalization, and low personal accomplishment were found in 53.8%, 58.4%, and 27.0% of participants, respectively. Emotional exhaustion was more common in those with over 10 years of service (p = 0.001), higher rank (p < 0.001), and age > 40 years (p = 0.008). Low personal accomplishment was associated with lower rank (p = 0.007) and administrative duties (p = 0.032).<br><br>CONCLUSIONS: Burnout syndrome was highly prevalent among military personnel in Brazil during the pandemic, with findings similar to those observed in other professional groups.},
}
@article {pmid41524162,
year = {2025},
author = {Maleev, VV and Fomin, VV and Manakhov, KM and Volkova, OS},
title = {[Cardio-renal syndrome: perspectives of research in infectious diseases].},
journal = {Terapevticheskii arkhiv},
volume = {97},
number = {11},
pages = {902-907},
doi = {10.26442/00403660.2025.11.203463},
pmid = {41524162},
issn = {0040-3660},
mesh = {Humans ; *Cardio-Renal Syndrome/epidemiology/etiology/therapy/physiopathology/diagnosis ; *COVID-19/complications/epidemiology ; *Hemorrhagic Fever with Renal Syndrome/epidemiology/therapy ; SARS-CoV-2 ; Prognosis ; },
abstract = {Clinical and prognostic significance of cardio-renal syndrome in various infectious diseases are discussed. Incidence and prognosis, as well as pathogenesis of cardio-renal syndrome in patients with infectious diseases, admitted to ICU of infectious hospitals, as well as hemorrhagic fever with renal syndrome and in COVID-19 are reviewed.},
}
@article {pmid41525173,
year = {2026},
author = {Umstattd Meyer, MR and Wende, ME and Stroope, J and Kellstedt, DK and Johnson, AM and Gamble, A and Edwards, MB and Beck, AM and Moore, JB and Abshire, DA and Anderson, RE and Aytur, SA and Balis, LE and Davis, K and Gabbert, KD and Gustat, J and John, D and Maruca, DL and King, KA and Needham-Arnold, BD and Orzech, KM and Pickett, AC and Rhoades, RR and Riveron, N and Slater, SJ and Smock, CR and Villwock-Witte, NM and Wilson, K and Baskin, ML and Perry, CK and Abildso, CG},
title = {Rural Active Living: A Call to Action 2.0, 10-Year Review and Recommendations to Advance the Field.},
journal = {Journal of public health management and practice : JPHMP},
volume = {32},
number = {2},
pages = {197-213},
pmid = {41525173},
issn = {1550-5022},
support = {K01 HL171860/HL/NHLBI NIH HHS/United States ; P50 MD017338/MD/NIMHD NIH HHS/United States ; U48 DP006381/DP/NCCDPHP CDC HHS/United States ; },
mesh = {Humans ; *Rural Population/statistics &amp; numerical data/trends ; *Exercise/psychology ; United States ; *Health Promotion/methods/trends ; },
abstract = {CONTEXT OBJECTIVE: Written a decade ago, the 2015 Rural Active Living: A Call to Action (published in 2016) described rural-specific efforts in the fields of active living and physical activity (PA) and identified 8 recommendations to guide rural active living research and practice. Given that rural populations continue to experience a higher burden of PA-related chronic health conditions, the objective of this review was to revisit the 8 Rural Active Living Calls to Action, reassess the evidence base, summarize advances in each area, and identify emerging areas that warrant examination or further study.<br><br>METHODS: We leveraged expertise from researchers and practitioners within the CDC-funded Physical Activity Policy Research and Evaluation Network Rural Active Living Workgroup and reviewed literature published since the original call to action. Teams were formed for each of the original 8 calls to action. Each team reviewed the literature, synthesized findings, and developed recommendations for future research.<br><br>RESULTS: Academic and practice-based progress was evident across multiple of the original calls to action. Despite these findings, the need persists for rural-specific national surveillance data scaled to small geographies (census tract and block group) that accounts for differences within and across rural communities, various forms of rural governance, and how these factors interplay with active living opportunities. Six emerging areas of research (best practices, social issues, COVID-19 effects, collaboration, implementation science, and implications of rural health-related funding changes) are discussed and warrant further study.<br><br>CONCLUSIONS: In summarizing progress since the original Call to Action, we recommend strategies to continue advancing rural active living and identify emerging focus areas.},
}
@article {pmid41525859,
year = {2026},
author = {Kumar, P and Ahir, P and Sharma, S and Thakur, V and Verma, P and Kumar, I and Bharti, V and Kumar, S},
title = {Exploring molecular interactions of drugs in different biologically active solvents: A comprehensive review for safe and efficient drug delivery systems.},
journal = {International journal of biological macromolecules},
volume = {340},
number = {Pt 2},
pages = {150197},
doi = {10.1016/j.ijbiomac.2026.150197},
pmid = {41525859},
issn = {1879-0003},
mesh = {*Solvents/chemistry ; Humans ; *Drug Delivery Systems/methods ; COVID-19 Drug Treatment ; Solubility ; SARS-CoV-2 ; Antiviral Agents/chemistry ; COVID-19 ; Pharmaceutical Preparations/chemistry ; },
abstract = {In this review, the interactions between drugs and biologically active solvents have been extensively investigated due to their importance in optimizing pharmaceutical formulation performance for effective therapeutic efficacy and safe drug delivery. These interactions determine the molecular stability, reactivity and solubility of drugs in different biocompatible solvents. The knowledge about their absorption, distribution, metabolism, transport and bioavailability can be enhanced from their molecular interactions data. There have been reports of improved solubility and stability of drugs like metformin hydrochloride and hydralazine hydrochloride in aqueous solutions of carbohydrates and amino acids, which has an immediate effect on their bioavailability and treatment efficacy. Moreover, the COVID-19 pandemic has reestablished the importance of this review, as some drugs were clinically approved after proving their activity and efficacy during this phase. The antivirals favipiravir, remdesivir and two repurposed drugs, antimalarial hydroxychloroquine and metabolic inhibitor 2-deoxy-d-glucose (2-DG) were approved during this phase based on their available physicochemical data. These results established the clinical efficacy and dependency of drugs on their solvation environment, highlighting the pharmacological importance of studying molecular interactions in addition to their theoretical significance. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) model was adopted to conduct this systematic review, covering scientific articles from 2000 to 2025 to ensure a careful evaluation of recent advancements. This review focuses on the molecular interactions of various drugs with different biological solvent systems, using physicochemical, spectroscopic, and computational methods. It critically examines drug-solvent interactions by specifying quantitative physicochemical (free energy changes), spectral (binding constant) and computational metrics (binding affinity). This integrated approach provides a novel molecular-level insight into the structural, solvation, and interaction behavior of drugs under physiological conditions. The integration of molecular dynamics, artificial intelligence/machine learning tools, and experimental validation represents a prospective approach for addressing current limitations, contributing to the development of precision in drug delivery strategies for personalized medications. This review could be substantial for biochemical and medicinal sectors with important implications in formulation, stability, bioavailability, and solubility of drugs in clinical pharmacology. The outcome may provide an important basis for advanced research in future, serving the scientific community in understanding pharmacokinetics and pharmacodynamics of drug interactions. This can further strengthen the advanced research in future, involving drug-solvent interactions, which ultimately improves the safety, treatment efficacy and delivery performance of the drugs.},
}
@article {pmid41526978,
year = {2026},
author = {Munteanu, V and Saldana, MA and Dreifuss, D and Ouyang, WO and Ferdous, J and Mohebbi, F and Roseberry, JS and Ciorba, D and Bostan, V and Gordeev, V and Drabcinski, N and Su, JM and Kasianchuk, N and Sharma, NK and Knyazev, S and Aßmann, E and Lobiuc, A and Covasa, M and Crandall, KA and Wu, NC and Mason, CE and Tierney, BT and Lucaci, AG and Ophoff, RA and Gibas, C and Rzymski, P and Skums, P and Solo-Gabriele, H and Niko, B and Zelikovsky, A and Hölzer, M and Smith, A and Mangul, S},
title = {SARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities.},
journal = {Genome biology},
volume = {27},
number = {1},
pages = {1},
pmid = {41526978},
issn = {1474-760X},
mesh = {Humans ; *SARS-CoV-2/genetics ; *Wastewater/virology ; *Genome, Viral ; *COVID-19/virology ; *Genomics/methods ; Computational Biology ; },
abstract = {Wastewater-based genomic surveillance (WWGS) has proven effective for monitoring SARS-CoV-2 and other viruses within communities. It enables rapid detection of known and emerging mutations and provides insights into circulating lineages. Despite its advantages, WWGS faces challenges in sample processing and computational analysis, particularly in distinguishing similar lineages and identifying novel ones. Recent methods for wastewater sequencing (WWS) analysis remain largely untested amid declining clinical surveillance and ongoing viral evolution. This review examines opportunities and limitations of WWGS, focusing on sample preparation, sequencing technologies, and bioinformatics approaches, and highlights its potential to strengthen public health monitoring systems.},
}
@article {pmid41527398,
year = {2026},
author = {Glock, M and Erdekian, A and Rueb, M and Uhl, F and Husemann, R and Stoffers-Winterling, J and Lindner, S and Tüscher, O and Hölzel, LP and Lieb, K and Adorjan, K and Wiegand, HF},
title = {Utilization of mental health services during the first year of the COVID-19 pandemic - a systematic review and meta-analysis.},
journal = {European psychiatry : the journal of the Association of European Psychiatrists},
volume = {69},
number = {1},
pages = {e10},
pmid = {41527398},
issn = {1778-3585},
support = {01KX2021//Bundesministerium f&#xfc;r Bildung und Forschung/ ; 01KX2121//Bundesministerium f&#xfc;r Bildung und Forschung/ ; },
mesh = {Humans ; *COVID-19/psychology ; Emergency Service, Hospital/statistics &amp; numerical data ; *Mental Disorders/therapy ; *Mental Health Services/statistics &amp; numerical data ; *Patient Acceptance of Health Care/statistics &amp; numerical data ; SARS-CoV-2 ; Telemedicine/statistics &amp; numerical data ; },
abstract = {BACKGROUND: The COVID-19 pandemic presented significant challenges to infectious disease management and mental health services (MHS). Service demand and delivery changed due to fear of infection, economic hardships, and the psychological effects of protective measures. This systematic review with meta-analysis aims to quantify these impacts on different mental health service settings.<br><br>METHODS: Comprehensive searches were conducted in PubMed, Embase, and PsycINFO, focusing on studies published from the initial outbreak of COVID-19, starting in November 2019. Studies were included comparing the utilization of mental health inpatient, emergency department (ED), and outpatient services (including telemedicine and medication prescriptions) before and during the COVID-19 pandemic. A random-effects model was employed to estimate pooled effects, with study quality assessed using a modified Newcastle-Ottawa Scale.<br><br>RESULTS: Among 128 studies, significant decreases in utilization were observed during the initial phase of the pandemic for inpatient services (RR: 0.75, 95% CI: 0.67 to 0.85) and ED visits (RR: 0.87, 95% CI: 0.69 to 1.10). Outpatient services showed a similar decline (RR: 0.78, 95% CI: 0.66 to 0.92), while no significant change was found in psychotropic medication prescriptions (RR: 0.90, CI: 0.77 to 1.05). In contrast, telemedicine utilization increased significantly (RR: 7.57, 95% CI: 3.63 to 15.77).<br><br>CONCLUSIONS: The findings reveal substantial shifts in mental health service utilization during the pandemic, with the largest reductions in inpatient services and significant increases in telemedicine use. These results emphasize the need for flexible healthcare models. Further research is essential to evaluate the consequences of reduced MHS utilization.},
}
@article {pmid41527944,
year = {2026},
author = {Wang, QH and Ye, JJ and Chen, ZY and Zhang, CC and Liao, XY and Zheng, L and Chen, K and Tu, X and Liu, LR and Wei, Q and Bao, YG},
title = {Current risk factors for male infertility and semen parameters: an umbrella review of systematic reviews and meta-analyses.},
journal = {Asian journal of andrology},
volume = {28},
number = {3},
pages = {284-296},
pmid = {41527944},
issn = {1745-7262},
mesh = {Humans ; Male ; *Infertility, Male/etiology/epidemiology ; Meta-Analysis as Topic ; Risk Factors ; Semen Analysis ; Sperm Count ; Sperm Motility ; Systematic Reviews as Topic ; },
abstract = {Male infertility poses a substantial healthcare challenge and severely impacts the lives of patients. We aimed to investigate the risk factors for infertility and abnormal semen parameters. We conducted a comprehensive search of the articles published in Web of Science, MEDLINE, and Embase databases from January 2000 to February 2025. Infertility, semen volume, sperm concentration, sperm count, sperm morphology, sperm motility, and sperm progressive motility were used as endpoints to evaluate the relevance of risk factors. A total of 43 studies were included, covering 67 risk factors associated with infertility and abnormal sperm parameters. A total of 249 effect sizes were scored individually using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool, of which 136 (54.6%) were classified as "very low", 59 (23.7%) as "low", and 54 (21.7%) as "moderate". Suffering from type 1 diabetes, metabolic syndrome, hyperthyroidism, systemic lupus erythematosus, chronic prostatitis, and leukocytospermia may increase the risk of abnormal semen parameters. Poor lifestyle habits (obesity, sleep disorders, and smoking), exposure to pollutants and various compounds (carbon disulfide, organophosphates, and lead), the use of medications (sulfasalazine, mesalazine, and selective serotonin reuptake inhibitors), and even some viral infections (severe acute respiratory syndrome coronavirus 2, human papillomavirus, and hepatitis viruses) were associated with decreased semen quality. Regular physical exercise, nut consumption, and adherence to a healthy dietary pattern may reverse this process. An increasing number of factors are associated with infertility; however, some of the aforementioned studies lack verification of causal relationships. Future studies need to be well designed to further confirm these relationships.},
}
@article {pmid41528042,
year = {2026},
author = {Ye, J and Xu, T and Xu, C and Liu, X and Chen, Y},
title = {Fluorescence Resonance Energy Transfer Assay at the Crossroad: Urgent Reexamination of Assay Design for Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors.},
journal = {Journal of medical virology},
volume = {98},
number = {1},
pages = {e70801},
doi = {10.1002/jmv.70801},
pmid = {41528042},
issn = {1096-9071},
support = {2024AH051890//University Natural Science Research Project of Anhui Province, China/ ; 2022yjsds052//Outstanding Young Graduate Supervisors Program of Anhui Province, China/ ; },
mesh = {Humans ; *Antiviral Agents/pharmacology ; Coronavirus 3C Proteases/antagonists &amp; inhibitors ; COVID-19 ; *COVID-19 Drug Treatment ; *Fluorescence Resonance Energy Transfer/methods ; High-Throughput Screening Assays/methods ; *Protease Inhibitors/pharmacology ; *SARS-CoV-2/drug effects/enzymology ; },
abstract = {The main protease (Mpro) from coronaviruses represents an attractive therapeutic target for antiviral development. The fluorescence resonance energy transfer (FRET) assay is widely used for high-throughput screening (HTS) of Mpro inhibitors, but there has been a significant increase in false positives stemming from flawed assay design in previous studies. Here, we provide an overview of the FRET assay, discuss the key points of this method design, and highlight the corresponding solutions. We hope that this issue should receive increased attention from researchers.},
}
@article {pmid41529879,
year = {2026},
author = {Lotfi, M and Kaderali, L},
title = {Data-driven strategies for model-informed decision-making during the COVID-19 pandemic: a systematic review.},
journal = {BMJ open},
volume = {16},
number = {1},
pages = {e107660},
pmid = {41529879},
issn = {2044-6055},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *Decision Making ; SARS-CoV-2 ; *Pandemics/prevention &amp; control ; },
abstract = {OBJECTIVES: To systematically review data-driven modelling studies that evaluated the effectiveness of interventions implemented during the COVID-19 pandemic and to identify which measures were most frequently reported as effective in controlling disease spread.<br><br>DESIGN: Systematic review of modelling studies focused on data-driven, model-informed decision-making for COVID-19 interventions.<br><br>DATA SOURCES: A comprehensive literature search was conducted in PubMed, Web of Science and Embase, covering publications from 1 January 2020 to 16 October 2024.<br><br>ELIGIBILITY CRITERIA: Studies were included if they: (1) used real-world data; (2) had sufficient sample sizes and (3) assessed at least one intervention with measurable outcomes.Meta-analyses and purely theoretical modelling studies were excluded. Papers were further filtered using a structured screening process to ensure empirical and intervention-based modelling.<br><br>DATA EXTRACTION AND SYNTHESIS: Data were extracted from eligible studies and categorised according to modelling approaches, data sources, intervention types and reported effectiveness. Descriptive synthesis was performed to summarise modelling trends and intervention performance. Studies were classified into major intervention categories, including tracing, testing and isolation (TTI); physical and social distancing (PSD); vaccination; lockdowns; mask-wearing; home office or stay-at-home (HOSH) and health infrastructure enhancement (HIE).<br><br>RESULTS: Out of 2297 studies identified, 126 met inclusion criteria. Compartmental models were the most frequently used approach, primarily relying on case and death counts to assess intervention impact. The most commonly reported effective interventions were TTI, PSD, vaccination, lockdowns, mask-wearing and HOSH. When considering effectiveness relative to study frequency, the top six interventions were TTI, HOSH, mask-wearing, HIE, PSD and lockdowns. The relatively lower representation of vaccination reflects that most included studies were conducted during the early stages of the pandemic, before widespread vaccine rollout and availability of empirical vaccination data.<br><br>CONCLUSIONS: This review highlights the critical role of data-driven models in guiding COVID-19 response strategies. Evidence supports the combined effectiveness of non-pharmaceutical interventions, robust testing and tracing systems and health infrastructure strengthening. Real-world impact, however, remains dependent on local healthcare capacity, socioeconomic conditions and cultural contexts. Continued research is essential to refine adaptive modelling approaches and strengthen preparedness for future public health emergencies.},
}
@article {pmid41530799,
year = {2026},
author = {Zhang, Y and Dong, Z and Zheng, F and Zhu, H},
title = {Crossed cerebellar diaschisis in a COVID-19 patient with hemiconvulsion-hemiplegia syndrome: a case report and literature review.},
journal = {Italian journal of pediatrics},
volume = {52},
number = {1},
pages = {8},
pmid = {41530799},
issn = {1824-7288},
support = {Y202148132//Scientific Research Fund of the Zhejiang Provincial Education Department/ ; Y20220270//Science and Technology Plan Project of Wenzhou Municipality/ ; },
mesh = {Humans ; Male ; *COVID-19/complications ; Infant ; *Hemiplegia/diagnosis/etiology/complications ; *Cerebellar Diseases/diagnosis/diagnostic imaging/etiology ; Fatal Outcome ; Magnetic Resonance Imaging ; SARS-CoV-2 ; *Systemic Inflammatory Response Syndrome/complications ; Pandemics ; },
abstract = {BACKGROUND: Crossed cerebellar diaschisis (CCD) is rare in patients with hemiconvulsion-hemiplegia syndrome (HHS). This report presents a novel and instructive case of CCD combined with HHS in a 7-month-old infant with coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C). MAIN BODY: A previously healthy 7-month-old male infant presented with high-grade fever, frequent left-sided seizures, and subsequent left-sided paralysis. Diagnosed with COVID-19 and MIS-C, he exhibited critical hyperinflammation and multi-organ dysfunction. Brain magnetic resonance imaging (MRI) was pivotal, revealing unilateral cytotoxic edema in the right cerebral hemisphere and restricted diffusion in the contralateral cerebellum, confirming the diagnoses of HHS and CCD. Despite management with anticonvulsants and immunomodulation, his condition deteriorated rapidly, leading to death within 45 h. The pathophysiology is proposed to center on the MIS-C-triggered cytokine storm, which likely creates a substrate for excitotoxic injury and diaschisis. CONCLUSION: This case represents, to our knowledge, the first documented fatal instance of CCD associated with HHS in a pediatric patient with acute COVID-19 and MIS-C. It underscores the potential for severe neurological complications in this population and broadens the recognized spectrum of neurovascular injuries linked to COVID-19. The early detection of CCD in such settings may serve as a critical radiological marker for a high-risk disease course.},
}
@article {pmid41532066,
year = {2026},
author = {Feng, X and Wang, Y and Li, Y and Long, J and Liu, F and Yang, H},
title = {Application of the humanized mouse model in research into SARS-CoV-2 infection (Review).},
journal = {Medicine international},
volume = {6},
number = {1},
pages = {9},
pmid = {41532066},
issn = {2754-1304},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a profound impact on global public health. The complexity of its pathogenic mechanisms and host interactions urgently requires high-fidelity animal models to support research. Humanized mouse models break the species barrier through gene editing and immune reconstitution technologies, providing a key tool to simulate human infection characteristics and pathological processes. A number of studies have reported the application of humanized mouse models in the fields of COVID-19 research, such as SARS-CoV-2 pathogenesis, anti-SARS-CoV-2 drug discovery and vaccine development, etc. The present review aimed to systematically document the latest advances in the application of humanized mouse models based on different construction strategies, such as receptor humanization, immune system humanization and composite humanization. These models have not only elucidated the pathogenicity differences and immune escape mechanisms of SARS-CoV-2 variants, but have also validated the efficacy of broad-spectrum anti-SARS-CoV-2 strategies, including angiotensin-converting enzyme 2-targeted therapies, antibody cocktail regimens and mucosal vaccines. Additionally, humanized mouse models have played a pivotal role in investigating the mechanisms underlying long COVID. By revealing the multi-system pathogenic mechanisms of pulmonary fibrosis, neurodegeneration and intestinal microbiota dysregulation, these models provide a theoretical foundation for the development of targeted intervention strategies.},
}
@article {pmid41532626,
year = {2025},
author = {Pechanova, O and Paulis, L},
title = {Nitric Oxide at the Nexus of ACE2 Biology and COVID-19: Implications for Cardiovascular and Neurodegenerative Comorbidities.},
journal = {Physiological research},
volume = {74},
number = {Suppl 2},
pages = {S171-S184},
pmid = {41532626},
issn = {1802-9973},
mesh = {Humans ; *Nitric Oxide/metabolism ; *COVID-19/metabolism/epidemiology/virology ; *Angiotensin-Converting Enzyme 2/metabolism ; *Cardiovascular Diseases/metabolism/epidemiology ; *Neurodegenerative Diseases/metabolism/epidemiology ; Animals ; *SARS-CoV-2 ; Renin-Angiotensin System ; Comorbidity ; },
abstract = {SARS-CoV-2 engages ACE2 for cell entry, perturbing the counter-regulatory ACE2/Ang-(1-7)/Mas axis and shifting the renin angiotensin system toward ACE/Ang II/AT1 signaling, with a concomitant reduction in nitric oxide (NO) bioavailability. NO sits at the crossroads of these pathways, acting both as an antiviral modulator of spike-ACE2 interactions and as a downstream mediator of Mas-dependent endothelial protection. This review summarizes evidence on NO across three layers: (i) viral entry (S nitrosylation of spike/ACE2, protease modulation), (ii) cardiovascular comorbidities (hypertension, obesity, diabetes) where ACE2 downregulation impairs endothelial NO synthase (eNOS)-dependent NO production and promotes thrombosis and microvascular dysfunction, and (iii) neurovascular/ neurodegenerative sequelae, in which renin-angiotensin-aldosterone system (RAAS) dysregulation along with imbalance between protective eNOS/nNOS and inflammatory iNOS fosters blood-brain barrier disruption, microthrombosis, and cognitive impairment. Shared mechanisms - endotheliitis, microvascular dysfunction, and neuroinflammation may explain convergent risks for cardiac injury and cognitive decline in long COVID-19. Putative therapeutic strategies may include restoring physiological NO (via Mas agonism, Ang-(1-7), inhibition of Ang 1-7 degradation and recombinant ACE2), pulmonary-selective inhaled NO, hybrid S nitrosylated agents, and selective attenuation of iNOS/peroxynitrite alongside endothelial support. Targeted modulation - enhancing eNOS/nNOS while constraining iNOS offers a unified framework to mitigate both cardiovascular and neurodegenerative consequences of COVID-19.},
}
@article {pmid41533521,
year = {2026},
author = {Zhang, Y},
title = {Comparative analysis of point-of-care diagnostic techniques for respiratory infectious diseases. Lessons we learned from the COVID-19 pandemic and future consideration on more competent alternatives.},
journal = {Pathogens and global health},
volume = {120},
number = {3},
pages = {160-177},
pmid = {41533521},
issn = {2047-7732},
mesh = {Humans ; *COVID-19/diagnosis ; SARS-CoV-2/isolation &amp; purification ; *Point-of-Care Systems ; Rapid Diagnostic Tests ; Surface Plasmon Resonance/methods ; Pandemics ; *Point-of-Care Testing ; COVID-19 Testing/methods ; },
abstract = {Our unpreparedness in responding to the prompt emergence of COVID-19 in its early stage of outbreak, especially the lack of rapid and early diagnostic techniques for mass screening which should have been prioritized, contributed to the virus' spread alongside other factors. This article provides an overview of the common diagnostic techniques with special focus on the reported and/or authorized point-of-care methods for early COVID-19 diagnosis, including lateral flow assays and localized surface plasmon resonance-based approaches. The inherent limitations of these techniques are critically examined. We then propose a potentially more competent alternative, i.e. direct detection of viral particles with aptamer-conjugated gold nanoparticles in liquid solution in combination with noninvasive breath sampling or saliva sampling, for further improvement in early diagnostic capability for infectious respiratory diseases like COVID-19. In addition, an integration of air sampling with in-situ direct colorimetric detection of viral particles could represent a potential option for airborne virus detection, thus minimizing the transmission of infectious diseases and their impact on the economy and life in the future.},
}
@article {pmid41534044,
year = {2026},
author = {Lampert, R and Harmon, KG},
title = {Sudden Cardiac Arrest in Athletes.},
journal = {The New England journal of medicine},
volume = {394},
number = {3},
pages = {268-280},
doi = {10.1056/NEJMra2312555},
pmid = {41534044},
issn = {1533-4406},
mesh = {Humans ; *Athletes/statistics &amp; numerical data ; COVID-19/complications/diagnosis/epidemiology ; *Death, Sudden, Cardiac/prevention &amp; control/etiology/epidemiology ; Incidence ; Mass Screening/standards ; Primary Prevention/methods/standards ; Return to Sport ; Risk Factors ; Sports/standards ; Cardiomyopathies/complications/diagnosis/mortality/therapy ; Arrhythmias, Cardiac/complications/diagnosis/mortality/therapy ; Coronary Vessel Anomalies/complications/diagnosis/mortality/therapy ; Practice Guidelines as Topic ; },
abstract = {The incidence of sudden cardiac arrest in athletes varies according to age, race and ethnic group, sex, sport, and social determinants of health. The common causes of sudden cardiac arrest include cardiomyopathies, electrical disorders, coronary-artery anomalies, and other cardiac structural abnormalities. There has not been an increase in the incidence of sudden cardiac arrest in athletes during the time frame of the coronavirus disease 2019 (Covid-19) pandemic. Primary prevention is based on cardiovascular screening before participation, and secondary prevention on implementation of emergency action plans. Diagnostic evaluation of athletes who survive sudden cardiac arrest should mirror that of age-matched nonathletes, with additional sport-specific considerations, and should be performed by medical professionals with expertise in the interpretation of test results in the context of athletic adaptation. An increasing body of evidence indicates that many athletes can return to play after disease-specific treatment, without an increase in risk, and professional societies now consider return to participation in sports to be reasonable or appropriate through shared decision making for numerous cardiac conditions.},
}
@article {pmid41535509,
year = {2026},
author = {da Silva Ebone, R and Doleski, PH and Jantsch, MH and da Silveira, RP and Leal, DBR},
title = {P2Y14 receptor activation and neutrophil signaling: linking inflammation to systemic pathophysiology.},
journal = {Purinergic signalling},
volume = {22},
number = {1},
pages = {5},
pmid = {41535509},
issn = {1573-9546},
support = {88887.902884/2023-00//Coordena&#xe7;&#xe3;o de Aperfei&#xe7;oamento de Pessoal de N&#xed;vel Superior/ ; 409156/2024-8//Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico/ ; },
mesh = {Humans ; *Neutrophils/metabolism/immunology ; *Inflammation/metabolism/immunology/physiopathology ; *Signal Transduction/physiology ; *Receptors, Purinergic P2/metabolism ; Animals ; },
abstract = {Neutrophils are essential effector cells of the innate immune system, acting as the first line of defense against infection and tissue injury. Among the purinergic receptors expressed in these cells, P2Y14 has gained increasing attention in recent years for its role in modulating neutrophil recruitment and activation in inflammatory contexts. This receptor is activated mainly by uridine diphosphoglucose (UDP-glucose) and other UDP-sugars released during cellular stress or damage. Through the activation of G protein-coupled pathways, particularly via Gi/o and RhoA signaling, P2Y14 influences key neutrophil functions, including chemotaxis, cytoskeletal rearrangements, and oxidative responses. Despite its pro-inflammatory potential, and the increasing amount of literature data in recent years, P2Y14's complete physiological and pathological roles remain underexplored. Literature data also highlight its involvement in diseases like glioblastoma and COVID-19, where, due to increased neutrophil infiltration, it exacerbates inflammation, tissue damage, and stress. Therefore, targeting P2Y14 may be a promising strategy to modulate neutrophil chemotaxis and mitigate unwanted harmful inflammatory responses. This review discusses the characteristics and signaling mechanisms of P2Y14 in neutrophils, as well as the relevant implications of this pathway for neutrophil function.},
}
@article {pmid41536535,
year = {2025},
author = {García, CF and Cantero-García, M and Dorta-Afonso, D and Rueda-Extremera, M},
title = {Factors associated with suicidal ideation in healthcare personnel: a systematic review.},
journal = {Frontiers in psychology},
volume = {16},
number = {},
pages = {1717231},
pmid = {41536535},
issn = {1664-1078},
abstract = {AIM: This paper investigates suicidal ideation among healthcare professionals, a growing concern that affects their mental well-being and the quality of healthcare delivery. The study aims to identify key risk factors, such as work-related stress, exposure to death, and lack of institutional support, that contribute to suicidal ideation in this population. It also explores protective factors, including resilience, social support, and institutional resources, that may mitigate these risks.<br><br>METHOD: A systematic review was conducted on studies published between 2020 and 2024. The literature search spanned databases such as PubMed, Scopus, Web of Science, PsycINFO, Dialnet, and Scielo. The review followed the PRISMA guidelines to ensure thoroughness and transparency in study selection. To assess the quality of the included studies, standardized tools like the Newcastle-Ottawa Scale were applied.<br><br>RESULTS: The review identified that the COVID-19 pandemic has intensified factors leading to suicidal ideation among healthcare professionals, with a notable increase in prevalence during this period. Identified risk factors included high levels of occupational stress, frequent exposure to death and suffering, and insufficient institutional support. Conversely, protective factors like resilience, social support, and access to institutional resources were found to reduce susceptibility to suicidal ideation.<br><br>CONCLUSION: The findings highlight an urgent need for comprehensive prevention strategies and support programs targeting healthcare personnel. Recommendations for interventions span individual, organizational, and public policy levels. Enhancing resilience and providing institutional support could be crucial steps in reducing the incidence of suicidal ideation in this vulnerable group, ultimately improving both their mental health and the quality of healthcare services.},
}
@article {pmid41538482,
year = {2026},
author = {Silva, JH and Brito, ALA and Taiar, R and Moraes, BA and Xavier, AB and Leite, WS and Araújo, MDGR and Brandão, DC and Andrade, AFD and Campos, SL},
title = {Effect of non-invasive ventilation and high-flow nasal cannula on hospital mortality in COVID-19-induced acute respiratory failure: a meta-analysis.},
journal = {Einstein (Sao Paulo, Brazil)},
volume = {24},
number = {},
pages = {eRW0695},
pmid = {41538482},
issn = {2317-6385},
mesh = {Humans ; *COVID-19/mortality/complications/therapy ; *Noninvasive Ventilation/methods/mortality ; *Oxygen Inhalation Therapy/methods ; *Hospital Mortality ; *Respiratory Insufficiency/therapy/mortality/virology/etiology ; Cannula ; SARS-CoV-2 ; Intubation, Intratracheal/statistics &amp; numerical data ; Adult ; },
abstract = {BACKGROUND: Non-invasive respiratory support strategies, such as high-flow nasal cannula therapy and non-invasive ventilation, were widely employed during the coronavirus disease 2019 (COVID-19) pandemic, yet their comparative effectiveness remains uncertain.<br><br>OBJECTIVE: To compare the effects of high-flow nasal cannula therapy, non-invasive ventilation, and conventional oxygen therapy on intubation rates and hospital mortality in adults with COVID-19-related acute respiratory failure.<br><br>METHODS: A systematic review and meta-analysis was conducted following PRISMA and Cochrane guidelines, with searches performed in nine databases for publications up to May 2023. Eligible studies were those on adults (&#x2265;18 years) with confirmed severe acute respiratory syndrome coronavirus 2 infection and that included intubation and mortality as primary outcomes. Risk of bias was assessed using the National Institutes of Health Quality Assessment Tool for Observational Cohorts and the Cochrane Risk of Bias tool. Pooled results were reported as odds ratios (ORs) with 95% confidence intervals (95%CIs).<br><br>RESULTS: Forty-one studies were included in the review and ten in the meta-analysis (2,843 patients). High-flow nasal cannula therapy did not differ from non-invasive ventilation in terms of the intubation rate (OR=1.07, 95%CI=0.89-1.29, p=0.45) but was superior to oxygen therapy (OR=0.79, 95%CI=0.64-0.97, p=0.02). High-flow nasal cannula therapy was also associated with lower mortality than non-invasive ventilation (OR=0.62, 95%CI=0.51-0.76, p<0.0001) but did not differ from oxygen therapy (OR=1.06, 95%CI=0.84-1.33, p=0.64). Substantial heterogeneity was observed in the subgroup analyses (I2=64%-90%).<br><br>INTERPRETATION: High-flow nasal cannula therapy may reduce the need for intubation compared with oxygen therapy and may lower the hospital mortality rate compared with non-invasive ventilation. However, heterogeneity in the studies suggests that patient-specific factors and disease severity may influence outcomes.<br><br>CONCLUSION: High-flow nasal cannula therapy shows potential benefits over oxygen therapy and non-invasive ventilation for COVID-19-related acute respiratory failure, particularly in the mortality rate. Clinical use of these therapies should be context-specific, given the need for cautious interpretation of our results and for further high-quality trials.<br><br>ID CRD 42020226936.},
}
@article {pmid41539672,
year = {2026},
author = {Rickard, NS and Kurt, P and Meade, T},
title = {Navigating the Digital Landscape for Potential Use of Mental Health Apps in Clinical Practice: Scoping Review.},
journal = {JMIR mental health},
volume = {13},
number = {},
pages = {e75640},
pmid = {41539672},
issn = {2368-7959},
mesh = {Humans ; *Attitude of Health Personnel ; COVID-19 ; Mental Disorders/therapy ; *Mental Health Services ; *Mobile Applications ; Smartphone ; Telemedicine ; },
abstract = {BACKGROUND: The global demand for mental health services has significantly increased over the past decade, exacerbated by the COVID-19 pandemic. Digital resources, particularly smartphone apps, offer a flexible and scalable means of addressing the research-to-practice gap in mental health care. Clinicians play a crucial role in integrating these apps into mental health care, although practitioner-guided digital interventions have traditionally been considered more effective than stand-alone apps.<br><br>OBJECTIVE: This scoping review explored mental health practitioners' views on potential use or integration of smartphone apps into clinical practice. We asked, "What is known about how mental health practitioners view the integration of smartphone apps into their practice?" Further, this scoping review explored the factors that might influence integration of smartphone apps into practice, such as practitioner and client characteristics, app design and functionality, and practitioner views.<br><br>METHODS: We conducted a systematic search of 3 databases that yielded 38 studies published between 2018 and 2025, involving 1894 participants across various mental health disciplines, most predominantly psychologists and psychiatrists. Data were collected on practitioner and client characteristics, app functionality, and factors deemed important or influencing practitioners' opinions about app integration.<br><br>RESULTS: The included studies were most likely to explore use of apps outside the clinical session and focused on self-management apps for mental health monitoring and tracking, and for collecting data from the patient. Fewer studies explored use of apps within-session, or practitioner-guided apps. Practitioners prioritized app features aligned with the American Psychological Association's evaluation criteria, with practitioners prioritizing engagement and interoperability, but also noted the importance of training and resourcing to support integration.<br><br>CONCLUSIONS: While practitioners recognize the potential of apps in mental health care, integration into clinical practice remains limited. This study highlights the need for further research on practical implementation, clinical effectiveness, and practitioner training to facilitate the transition from potential to actual use of apps in mental health care settings. Recommendations include evaluating effectiveness of app integration through experimental studies and developing training modules to develop practitioners' digital competencies and confidence in app use.},
}
@article {pmid41539985,
year = {2026},
author = {Mija, C and Sberna, G and Maggi, F},
title = {Microplastics and Nanoplastics as Carriers for Viral Transmission: Effects on Viral Properties, Infection, Immune Response, and Public Health.},
journal = {Reviews in medical virology},
volume = {36},
number = {1},
pages = {e70106},
pmid = {41539985},
issn = {1099-1654},
support = {Ricerca Corrente-Linea 1//Ministero della Salute/ ; },
mesh = {Humans ; *Microplastics/adverse effects ; Public Health ; *COVID-19/transmission/virology/immunology ; Animals ; *Virus Diseases/transmission/virology ; SARS-CoV-2 ; *Plastics/adverse effects ; },
abstract = {The extensive use of plastics since the industrial revolution has raised significant environmental and health concerns. Despite their advantages in terms of durability, affordability, and ease of production, the accumulation of plastics has resulted in considerable pollution. The SARS-CoV-2 pandemic further exacerbated plastic consumption, particularly in medical supplies, intensifying the plastic waste crisis. The majority of plastics are not recycled and eventually degrade into microplastics (MPs) and nanoplastics (NPs), which pose substantial risks to ecosystems and human health. MPs and NPs enter the body through inhalation, ingestion, or skin contact and have been found in biological samples such as blood, faeces, and lung fluids. Their presence has been linked to diseases affecting the lungs, cardiovascular system, and intestines, as well as cancer and viral infections. This review highlights how MPs and NPs contribute to the spread of infectious diseases by creating a habitat called the "plastisphere," which promotes microbial growth and serves as a reservoir for pathogens, emphasising their effects on viral persistence, infection dynamics, and immune modulation. Unlike previous reviews mainly focused on toxicological or microbiological aspects, this work integrates environmental, virological, and immunological evidence to outline how MPs/NPs may reshape virus-host interactions. By identifying critical knowledge gaps, such as the quantitative impact of MPs/NPs on viral stability and immune disruption, this review provides a background for future experimental and epidemiological research. This value-added perspective not only advances scientific understanding but also supports policy development in waste management.},
}
@article {pmid41540524,
year = {2025},
author = {Bhattacharya, S and Easmin, N and Panja, A and Nayak, A and Sur, D},
title = {mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects.},
journal = {Protein and peptide letters},
volume = {32},
number = {11},
pages = {776-790},
doi = {10.2174/0109298665402963251022054441},
pmid = {41540524},
issn = {1875-5305},
mesh = {Humans ; *Cancer Vaccines/immunology/therapeutic use/genetics ; *Neoplasms/therapy/immunology ; Antigens, Neoplasm/immunology/genetics ; Nanoparticles/chemistry ; *RNA, Messenger/immunology/genetics/therapeutic use ; Animals ; Immunotherapy/methods ; mRNA Vaccines/immunology ; Nanovaccines ; COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; Liposomes ; },
abstract = {Messenger RNA (mRNA) has gained increasing attention as a valuable tool to cure various human diseases, particularly malignant tumors. Such growing interest has been triggered largely by the phenomenal clinical success of mRNA vaccines developed using lipid nanoparticle (LNP) technology against COVID-19. mRNA may be used to produce cancer immunotherapies in numerous different ways, including cancer vaccines to induce or enhance immunity to tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs). mRNA can also be used to adoptively transfer T-cells for the expression of antigen receptors, such as chimeric antigen receptors (CARs), therapeutic antibodies, and immunomodulatory proteins to re-engineer the tumor microenvironment. However, the therapeutic potential of mRNA-based cancer immunotherapy is not fully utilized due to a few limitations, such as mRNA instability, production of immunogenicity, and a lack of efficient in-vivo delivery methods. This review provides an overview of the current advancements and future directions of mRNA-based cancer therapies, including various delivery routes and therapeutic platforms. It addresses the mechanistic basis of mRNA cancer vaccines, non-replicating and self-amplifying mRNA, as well as their clinical development, personalized vaccines, and applications of mRNA for encoding antigen receptors, antibodies, and immunomodulatory proteins. Moreover, the review addresses nanoparticle-based platforms, such as lipid nanoparticles (LNPs), polymeric nanoparticles, and peptide-based nanoparticles, all used to improve the therapeutic effectiveness of mRNA-based drugs by improving their targeted delivery to tissues. This review aims to provide insights into the use of state-of-the-art mRNA-based cancer immunotherapy.},
}
@article {pmid41540891,
year = {2026},
author = {Chen, IC and Chen, YH and Phanumartwiwath, A},
title = {Community-Based Care Interventions for Frail Older Adults: A Scoping Review of Multidimensional Strategies Across Pandemic Eras.},
journal = {Public health nursing (Boston, Mass.)},
volume = {43},
number = {2},
pages = {511-520},
doi = {10.1111/phn.70071},
pmid = {41540891},
issn = {1525-1446},
mesh = {Humans ; *Frail Elderly ; COVID-19 ; *Pandemics ; Aged ; *Community Health Services/organization &amp; administration ; Quality of Life ; SARS-CoV-2 ; Telemedicine ; Aged, 80 and over ; *Geriatric Nursing ; },
abstract = {OBJECTIVE: This scoping review evaluates the effectiveness of community-based interventions addressing frailty's multidimensional impacts (physical, nutritional, and psychosocial) in older adults, emphasizing nurses' roles in crisis-responsive care during pandemics.<br><br>DESIGN: A scoping review was conducted using Arksey &amp; O'Malley's framework and PRISMA-ScR guidelines.<br><br>SAMPLE: Thirty-one studies were from 2019 to 2023, sourced from PubMed and Scopus, spanning five continents.<br><br>MEASUREMENTS: Study quality was assessed with the Newcastle-Ottawa Scale; outcomes included frailty reduction and quality-of-life metrics.<br><br>INTERVENTION: Interventions included physical rehabilitation (e.g., Otago Exercise Program), nutritional optimization, psychosocial support, technology-enhanced models (e.g., telemedicine), and social engagement.<br><br>RESULTS: Multicomponent interventions outperformed single-domain approaches, improving gait speed, reducing frailty progression, and mitigating depression. Telemedicine maintained 78% care continuity during lockdowns. Asian family-centered models excelled, but 84% of evidence came from high-income countries, highlighting low- and middle-income country (LMIC) gaps.<br><br>CONCLUSIONS: Gerontological nurses are pivotal in delivering culturally adapted care by coordinating interprofessional home-based teams, integrating gerotechnology in resource-limited settings, and advocating for policy reforms to bridge urban-rural disparities. These findings underscore nursing's role in equitable, resilient frailty management.},
}
@article {pmid41541110,
year = {2023},
author = {Layug, EJV and Apor, ADAO and Kuhn, RV and Tan, MA},
title = {Mechanisms of pediatric ischemic strokes in COVID-19: a systematic review.},
journal = {Frontiers in stroke},
volume = {2},
number = {},
pages = {1197714},
pmid = {41541110},
issn = {2813-3056},
abstract = {BACKGROUND: Coronavirus disease 2019 (COVID-19) has been shown to cause vasculopathic and hemostatic derangements predisposing to cerebrovascular and thrombotic disorders in adults. Data in children, however, are limited to case reports and series. Given the unique risk factors and potential pathomechanisms in children, it is imperative to characterize stroke in children with COVID-19. Understanding these mechanisms is essential in drafting an appropriate management protocol to improve outcomes in a population where stroke carries higher disability-adjusted life years.<br><br>METHODS: A systematic literature search was done in MEDLINE, EMBASE, Web of Science and Google Scholar using the terms "pediatric ischemic stroke," "cerebral sinovenous thrombosis," "SARS-CoV-2," and "COVID-19." Patient demographics, clinical profile, stroke risk factors, neuroimaging findings, interventions and outcomes were recorded.<br><br>RESULTS: The search produced 776 records. After preliminary review of titles, abstracts and selected full texts, 52 articles comprising of 74 patients were studied. The cohort has slight female predominance (51.5%), with mean age of 9.2 years (&#xb1;2SD 5.6). Pediatric ischemic strokes were categorized as arterial ischemic strokes (82.40%), cerebral sinovenous thrombosis (12.20%) and combined arterial and venous strokes (5.41%). Mechanisms of ischemic stroke included thrombophilia (47.3%), vasculopathies (27%) and cardioembolism (6.8%). Twenty cases (27%) had comorbidities predisposing to stroke and only 18.9% met the criteria for multisystem inflammatory syndrome in children (MIS-C). Outcomes ranged from complete recoveries (13/58), residual deficits (35/58), and mortalities (10/58).<br><br>CONCLUSION: This study presents a comprehensive summary of the currently available published literature on pediatric ischemic strokes in the background of COVID-19. The clinical profiles and outcomes of patients reviewed support prior hypotheses that the virus can cause both a vasculopathy and induce a derangement in the coagulation system, predisposing to ischemic strokes.<br><br>STUDY REGISTRATION: This paper's protocol has been registered in PROSPERO with ID number CRD42022315219.},
}
@article {pmid41542888,
year = {2026},
author = {Tzigkounakis, G and Brown, J},
title = {From ancient remedy to modern COVID-19 adjunct: a narrative review of mechanistic, in vitro, and clinical evidence on propolis.},
journal = {Journal of complementary &amp; integrative medicine},
volume = {23},
number = {2},
pages = {240-252},
pmid = {41542888},
issn = {1553-3840},
mesh = {*Propolis/therapeutic use/pharmacology ; Humans ; *COVID-19 Drug Treatment ; *Antiviral Agents/therapeutic use/pharmacology ; *SARS-CoV-2/drug effects ; Anti-Inflammatory Agents/therapeutic use/pharmacology ; Animals ; COVID-19 ; },
abstract = {INTRODUCTION: Despite the global rollout of COVID-19 vaccines, limited access, vaccine hesitancy, and the emergence of viral variants continue to underscore the need for complementary antiviral strategies. Propolis, a resinous bee product widely used in traditional medicine, has attracted scientific interest due to its reported antiviral, anti-inflammatory, immunomodulatory, and antioxidant properties.<br><br>CONTENT: This narrative review examines the therapeutic potential of propolis as a candidate adjunctive treatment for COVID-19, focusing on mechanistic, in vitro, and clinical evidence. A comprehensive review was conducted using PubMed, Scopus, and Europe PMC (January 2020 to May 2025), covering molecular docking reports, in vitro assays, and human clinical studies evaluating propolis or its key constituents against SARS-CoV-2. In silico reports describe interactions of more than forty propolis constituents with key host and viral targets, providing mechanistic context. In vitro evidence demonstrates inhibition at entry and replication targets alongside attenuation of inflammatory signaling. Limited clinical data, spanning seven studies and two case reports, suggest milder symptoms and shorter hospital stays, with no serious adverse events observed.<br><br>SUMMARY AND OUTLOOK: Preclinical and early clinical evidence suggest propolis may be a useful adjunct in COVID-19 therapy. Large, placebo-controlled trials with well characterized and standardized extracts are needed to confirm efficacy and safety.},
}
@article {pmid41543095,
year = {2026},
author = {Cho, HE and Lee, JJ and Cho, SY},
title = {Serum Calprotectin - What is the Scope of Clinical Application?.},
journal = {Clinical laboratory},
volume = {72},
number = {1},
pages = {},
doi = {10.7754/Clin.Lab.2025.250516},
pmid = {41543095},
issn = {1433-6510},
mesh = {Humans ; *Leukocyte L1 Antigen Complex/blood ; Biomarkers/blood ; *Inflammation/blood/diagnosis ; COVID-19/blood/diagnosis ; Prognosis ; Arthritis, Rheumatoid/blood/diagnosis ; Inflammatory Bowel Diseases/blood/diagnosis ; SARS-CoV-2 ; Severity of Illness Index ; },
abstract = {BACKGROUND: Calprotectin (CLP), a heterodimer of S100A8 and S100A9, is a calcium-binding protein with key intracellular and extracellular roles, especially in inflammatory processes. Predominantly expressed by neutrophils and monocytes, CLP is released in response to infection or inflammation and serves as a potent antimicrobial and pro-inflammatory mediator.<br><br>METHODS: We performed a systematic search of electronic databases to identify studies evaluating serum CLP in inflammatory diseases.<br><br>RESULTS: Serum CLP levels are elevated in numerous inflammatory conditions, making it a valuable biomarker for disease activity, prognosis, and therapeutic monitoring. In rheumatoid arthritis (RA), CLP reflects disease severity more accurately than conventional markers like CRP and ESR, correlates with radiographic progression, and is strongly expressed at inflammation sites. In juvenile idiopathic arthritis (JIA), serum CLP levels are significantly higher in active, treatment-na&#xef;ve patients and correlate well with clinical activity. In spondyloarthritis (SpA), especially ankylosing spondylitis, CLP levels tend to be elevated, though results vary among studies. In inflammatory bowel disease (IBD), CLP is proposed as a non-invasive marker for disease burden and response to treatment. It is especially useful in systemic inflammation assessment. Elevated CLP levels are also observed in psoriasis, Beh&#xe7;et's disease, ANCA-associated vasculitis, and preeclampsia. CLP has emerged as a promising prognostic marker in bacterial infection and coronavirus disease 2019 (COVID-19), with higher levels correlating with ICU admission and disease severity.<br><br>CONCLUSIONS: Serum CLP is a promising inflammatory biomarker, though disease specificity remains limited.},
}
@article {pmid41543642,
year = {2026},
author = {Blandi, L and Del Riccio, M},
title = {From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention.},
journal = {Aging clinical and experimental research},
volume = {38},
number = {1},
pages = {72},
pmid = {41543642},
issn = {1720-8319},
mesh = {Humans ; *Dementia/prevention &amp; control ; *Influenza Vaccines ; *Influenza, Human/prevention &amp; control/complications ; *Vaccination ; },
abstract = {Aging populations require scalable strategies to delay or prevent dementia. Beyond the prevention of neurological injury associated with seasonal influenza, vaccination may help mitigate vascular and neuroinflammatory injury underlying cognitive impairment. Influenza infection can cause a marked short‑term increase in myocardial infarction risk, and acute infections have also been associated with transient increases in stroke risk. Experimental models show prolonged microglial activation and synaptic loss even from non-neurotropic strains - processes likely modulated by vaccination. Epidemiologic data consistently support this evidence; a 2023 meta-analysis, including observational studies, of ~ 2.09 million adults identified a 31% lower risk of incident dementia; US matched cohorts demonstrated 40% lower risk of Alzheimer's disease (absolute decrease 3.4%); Veterans Health data showed a 0.86 hazard ratio for dementia; and UK Biobank data showed lower risk for all-cause (0.83 h), and vascular dementia (0.58 h) with a dose-response association by vaccination term. Randomized trials suggest fewer adverse cardiovascular events in vaccine recipients giving even more biological plausibility to this concept. Despite that, prevention through influenza vaccination is not fully realized in older adults due to low levels of perceived risk, vaccine confidence, and variations in clinical practice guidance. This public health perspective reviews the physiopathological and epidemiological evidence in support of influenza vaccination as a pragmatic, dementia risk-modifying intervention within healthy aging strategies and encourages the inclusion of vaccination status in hospital discharge and chronic-care pathways, integration of cognitive outcomes in monitoring, and equity-centered research to eliminate barriers to behavioral and implementation.},
}
@article {pmid41543809,
year = {2026},
author = {Bozkir, C and Kartal, T and Hokelek, B},
title = {Obesity and Nutritional Vulnerability in long COVID: A Neuroinflammatory and Cognitive Perspective.},
journal = {Current nutrition reports},
volume = {15},
number = {1},
pages = {5},
pmid = {41543809},
issn = {2161-3311},
mesh = {Humans ; *Obesity/complications/physiopathology ; *COVID-19/complications/physiopathology ; *Neuroinflammatory Diseases/etiology ; Post-Acute COVID-19 Syndrome ; *Nutritional Status ; *Cognition Disorders/etiology ; *Cognition ; SARS-CoV-2 ; *Malnutrition/complications ; Inflammation ; },
abstract = {PURPOSE OF REVIEW: To examine the interplay between obesity, nutritional vulnerability, and long COVID, with a particular focus on neuroinflammatory and cognitive outcomes. This review synthesizes emerging evidence on shared pathophysiological pathways and evaluates the therapeutic potential of dietary and weight management strategies.<br><br>RECENT FINDINGS: Cognitive symptoms such as brain fog and memory deficits are among the most persistent and disabling features of long COVID. Obesity is associated with more severe manifestations through pathways involving chronic systemic inflammation, compromised blood-brain barrier integrity, and neuroimmune dysregulation. Concurrently, malnutrition and poor diet quality including low intake of antioxidants, omega-3 fatty acids, and micronutrients may impair neuroplasticity and delay recovery. Interventions such as Mediterranean and ketogenic dietary patterns, as well as structured weight loss programs, show promise in reducing inflammation and improving cognitive outcomes. Obesity and suboptimal nutritional status amplify the neurocognitive burden of long COVID through shared pathophysiological mechanisms. Integrated care models that incorporate metabolic screening, nutritional assessment, and individualized dietary interventions may improve recovery trajectories. Public health strategies that address food quality, obesity prevention, and equitable access to nutrition care are essential for long-term resilience in the post-COVID era.},
}
@article {pmid41544597,
year = {2026},
author = {Nasrin, N and Hasan Mumu, A and Hasan Pranto, A and Islam, MR},
title = {The emergence of JN.1 variant resurgent COVID-19 wave in India and South Asia is a global public health concern.},
journal = {Journal of infection and public health},
volume = {19},
number = {3},
pages = {103146},
doi = {10.1016/j.jiph.2026.103146},
pmid = {41544597},
issn = {1876-035X},
mesh = {Humans ; *SARS-CoV-2/genetics/pathogenicity/immunology ; *COVID-19/epidemiology/transmission/virology/immunology/prevention &amp; control ; India/epidemiology ; Public Health ; Asia, Southern/epidemiology ; Mutation ; Immune Evasion ; Spike Glycoprotein, Coronavirus/genetics ; Global Health ; Antiviral Agents/therapeutic use ; },
abstract = {The emergence of the JN.1 variant of SARS-CoV-2 has heightened global health concerns. Here, we aimed to evaluate viral characteristics, epidemiology, transmissibility, infectivity, immune evasion, effectiveness of current antiviral therapies, immunization options, genomic surveillance and public awareness against the stealthy JN.1. We searched across key databases to identify recent insights regarding JN.1 variant. This review provides a comprehensive overview of the virological characteristics and public health implications. Early genomic analyses reveal notable mutations in the spike protein, which may enhance viral transmissibility and immune escape. The findings indicate JN.1 to exhibit greater infectivity and enhanced ability to circumvent immune defenses attributable to one mutation identified as L455S. Public health agencies worldwide are enhancing monitoring, genomic surveillance, data sharing, revising containment strategies, promoting booster vaccination campaigns Furthermore, it is imperative to promote public adherence and global collaboration in encouraging the practice of preventive strategies to mitigate potential threat posed by JN.1.},
}
@article {pmid41544794,
year = {2026},
author = {Shen, H and Cheng, D and Liu, L and Li, M and Zhou, Y and Bai, D and Huangyang, P and Feng, H},
title = {RNAi therapy targeting coronavirus genomes, pulmonary delivery strategies and design principles: A review.},
journal = {International journal of biological macromolecules},
volume = {341},
number = {Pt 2},
pages = {150223},
doi = {10.1016/j.ijbiomac.2026.150223},
pmid = {41544794},
issn = {1879-0003},
mesh = {Humans ; *RNA, Small Interfering/genetics/administration &amp; dosage/therapeutic use ; *RNA Interference ; *Genome, Viral ; SARS-CoV-2/genetics ; COVID-19/therapy ; *RNAi Therapeutics/methods ; Animals ; Virus Replication/genetics/drug effects ; Lung/virology/metabolism ; *Coronavirus/genetics ; },
abstract = {With the persistent global outbreak of Coronavirus Disease 2019 (COVID-19), the development of effective antiviral strategies has become a top priority in public health. RNA interference (RNAi), an effective gene-silencing technique, presents a novel therapeutic approach to combat coronavirus replication. RNA interference (RNAi) is a potent gene-silencing approach that offers a therapeutic route to suppress coronavirus replication. Clinical translation of small interfering RNA (siRNA), however, faces substantial obstacles, notably cross-strain universality, off-target effects, and targeted delivery. This review summarizes recent advances in RNAi-mediated inhibition of coronaviruses at the genomic level, emphasizing RNAi applications to impede SARS-CoV-2 replication and transmission. By evaluating RNAi strategies aimed at specific viral components-RNA-dependent RNA polymerase (RdRp), spike protein (S), envelope protein (E), membrane protein (M), nucleocapsid protein (N), and other essential genes-we illustrate the distinct specificity and efficacy of RNAi across binding sites and identify candidate universal targets for human-transmitted coronaviruses. We also assess the strengths and limitations of delivery platforms, including liposomes, polymers, nanoparticles, and viral vectors. Finally, we highlight inhalation-based and other targeted delivery approaches as promising routes for siRNA therapeutics against COVID-19 and other pulmonary diseases. Advances in gene editing and nanotechnology continue to broaden the prospects for effective siRNA delivery.},
}
@article {pmid41545629,
year = {2026},
author = {Heidler, P and Dam, L and King, I and Hamza, N and Abdeljawad, MM and Alaraby, D and Fahlevi, M and Anjum, T and Marzo, RR and Wagner, M and Bhattacharya, S and Chahal, P},
title = {Is anybody out there? Tackling intimate partner violence as a hidden pandemic during COVID times and beyond: factors, impact, and recommendations, a systematic review and meta-analyses.},
journal = {Archives of women's mental health},
volume = {29},
number = {1},
pages = {20},
pmid = {41545629},
issn = {1435-1102},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; *Intimate Partner Violence/psychology/statistics &amp; numerical data/prevention &amp; control ; Female ; SARS-CoV-2 ; Pandemics ; Male ; },
abstract = {PURPOSE: Intimate partner violence is a pervasive issue deeply affecting public health, and its escalation during the COVID-19 pandemic has raised serious concerns. While the escalating impact of intimate partner violence during the COVID-19 pandemic has been widely acknowledged, there remains a need for a comprehensive systematic review that synthesizes existing literature. This review seeks to address this gap by providing an inclusive assessment of the global landscape of intimate partner violence during and after the pandemic, thereby informing more effective prevention and intervention strategies.<br><br>METHODS: A systematic literature search was conducted on PubMed, Google Scholar, and Scopus databases using different MeSH terms. A total of 445 relevant articles were identified initially, and after thorough screening, 54 articles were included in the review.<br><br>RESULTS: The lockdown had several negative consequences, including job losses, economic vulnerability, and health issues due to prolonged loneliness and uncertainty. An increase in emergency hotline or Women's Helpline calls was observed. Globally, intimate partner violence surged during the lockdown and persisted into 2023, causing severe and lasting health, psychological, and reproductive consequences for victims. Our results showed that COVID-19 increased the risk of partner violence: post-COVID intimate partner violence risk greater than pre-COVID risk (0.33 vs. 0.28, respectively).<br><br>CONCLUSION: Although COVID-19 increased the risk of intimate partner violence, this review also stresses a high global prevalence of intimate partner violence, not restricted to the pandemic and lockdowns. To prevent partner violence and reduce long-lasting severe health, psychological, and reproductive consequences of partner violence, broad cooperation between governments, communities, health professionals, and the media is necessary.},
}
@article {pmid41547457,
year = {2026},
author = {Petakh, P and Halabitska, I and Petrecka, H and Huber, W and Kamyshnyi, O},
title = {Complex interactions between stress, nutrition, gut microbiota, and infectious diseases and their impact on health in global conflicts: A narrative review.},
journal = {The Journal of nutritional biochemistry},
volume = {151},
number = {},
pages = {110267},
doi = {10.1016/j.jnutbio.2026.110267},
pmid = {41547457},
issn = {1873-4847},
mesh = {Humans ; *Gastrointestinal Microbiome ; *Stress, Psychological/microbiology ; *Nutritional Status ; *Communicable Diseases/microbiology ; *COVID-19/epidemiology ; Diet ; SARS-CoV-2 ; Feeding Behavior ; },
abstract = {Following the global recovery from the COVID-19 pandemic, wars and conflicts have escalated to levels unseen since the Cold War. It is well known that conflict is accompanied not only by significant losses among both military personnel and civilians but also by rising levels of stress and stress-related disorders within the general population. Stress is bidirectionally connected with the state of the gut microbiota through the gut-brain axis. Dietary factors and eating behaviours also play crucial roles in shaping gut microbiota composition. On the one hand, conflict negatively affects food availability and dietary patterns, leading to reduced meal frequency and potentially diminishing microbiota diversity. On the other hand, stress-induced alterations in eating behaviour, such as bulimia or anorexia, can further impair gut microbiota composition. Additionally, individuals in conflict zones face heightened risks of infectious diseases due to disrupted vaccination schedules, poor sanitation, and limited access to clean drinking water. Stress-related immune changes may increase susceptibility to infections and raise the likelihood of adverse outcomes. Moreover, the frequent use of antibiotics to treat infections during conflicts contributes to reduced gut microbiota diversity. This review narratively examines the complex interactions among stress, immune responses, dietary patterns, infectious diseases, and gut microbiota in conflict-affected areas, and provides new perspectives on the role of artificial intelligence in modelling such comorbid pathologies.},
}
@article {pmid41548364,
year = {2026},
author = {Taba, M and Fajardo, MA and Ferguson, E and Keast, R and Basseal, JM and McCaffery, K and Bonner, C},
title = {Science translation strategies to the public during health emergencies: A systematic review of RCTs.},
journal = {Patient education and counseling},
volume = {145},
number = {},
pages = {109479},
doi = {10.1016/j.pec.2026.109479},
pmid = {41548364},
issn = {1873-5134},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; Randomized Controlled Trials as Topic ; SARS-CoV-2 ; *Translational Science, Biomedical ; *Public Health ; *Emergencies ; Pandemics ; },
abstract = {INTRODUCTION: Effective science translation is essential during public health emergencies. During the COVID-19 pandemic, rapidly evolving research had to be translated to the public under challenging conditions.<br><br>OBJECTIVES: This review aimed to identify randomised trials of COVID-19 science translation strategies targeting the public and evaluated their effectiveness in improving psychological, behavioural and/or health outcomes.<br><br>METHODS: A literature search was done across PubMed, Embase, Scopus, CINAHL, and PsycINFO in July 2023 and November 2024. Studies were screened and extracted according to PRISMA guidelines. Interventions reporting behavioural outcomes were coded using the Behaviour Change Technique (BCT) taxonomy and the Cochrane risk-of-bias tool was used to assess study quality.<br><br>RESULTS: Of 345 records screened, 48 eligible studies were included. Most were online experiments testing message framing, with a smaller number conducted in applied settings such as health professional-delivered education. Significant positive effects were reported in most studies; 30 out of 40 studies with psychological outcomes (e.g. knowledge), 28 out of 40 studies with behavioural outcomes (e.g. intention to mask). Only one study measured a health outcome, with no significant effect. Effective features commonly included video and animation formats and messages from health experts and credible sources. The most frequent BCTs were 'information about health consequences' (33 studies) and 'credible source' (19 studies). Risk of bias was low in 42 studies.<br><br>CONCLUSIONS: These findings highlight a diverse range of strategies that improved outcomes during the COVID-19 pandemic. Better use of behavioural science taxonomies and core outcome sets could help researchers advance the field further during future emergencies.<br><br>PRACTICE IMPLICATIONS: This review provides insights for a range of stakeholders involved in science translation during emergencies (i.e. scientists and researchers, healthcare providers, health communicators and government officials) and highlights areas requiring further investigation.<br><br>PROSPERO REGISTRATION NUMBER: CRD42023446093.},
}
@article {pmid41549659,
year = {2026},
author = {Okinaka, K and Schiffer, JT},
title = {Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era.},
journal = {The Journal of antimicrobial chemotherapy},
volume = {81},
number = {2},
pages = {},
pmid = {41549659},
issn = {1460-2091},
support = {R01 AI177512/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; *Hematologic Neoplasms/complications/immunology ; *COVID-19/prevention &amp; control/complications ; Antiviral Agents/therapeutic use ; SARS-CoV-2 ; Immunocompromised Host ; Pre-Exposure Prophylaxis/methods ; *Pandemics/prevention &amp; control ; Antibodies, Monoclonal/therapeutic use ; Betacoronavirus ; },
abstract = {Despite a decrease in disease severity since the emergence of the severe acute respiratory syndrome coronavirus 2 Omicron variant, coronavirus disease-2019 (COVID-19) continues to pose a significant threat to patients with haematological malignancies (HM). Although repeated booster vaccinations enhance protection against severe illnesses in immunocompromised individuals, they remain at heightened risk of adverse outcomes. This underscores the crucial need for effective pharmacologic strategies to prevent and treat infection. This review examines current strategies for preventing severe COVID-19 in patients with HM, focusing on pre-exposure prophylaxis and early treatment of COVID-19. New monoclonal antibodies have been developed, offering effective pre-exposure prophylaxis. Antiviral agents and monoclonal antibodies demonstrated efficacy in limiting severe COVID-19 outcomes in patients with HM, though some patients, particularly the elderly, remain at risk of critical illness and death. Prolonged infection over months is also common, particularly in patients with lymphoid malignancies. Sustained viral shedding and ongoing mutation may be associated with chronic symptoms and is the likely source of several novel variants of concern that prolonged the pandemic. While HM subtype and advanced age are risk factors for severe or persistent COVID-19, there are no accurate tools for predicting individual risk. Given this uncertainty, prompt medical consultation, timely prescription of antiviral agents, and close monitoring are essential to minimize the risk of adverse outcomes in this vulnerable population.},
}
@article {pmid41550658,
year = {2025},
author = {Wang, M and Jia, H and Liu, X and Zhan, P},
title = {Conquering viral drug resistance: Structural and mechanistic paradigms for antiresistance drug design.},
journal = {Pharmaceutical science advances},
volume = {3},
number = {},
pages = {100094},
pmid = {41550658},
issn = {2773-2169},
abstract = {Viral drug resistance remains a critical challenge in antiviral therapy. This perspective highlights five studies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human immunodeficiency virus type 1 (HIV-1), monkeypox virus (MPXV), influenza A virus (IAV), and Hepatitis B virus (HBV), revealing novel resistance mechanisms and innovative strategies. For SARS-CoV-2, GC376's flexible benzyl group overcomes nirmatrelvir resistance. HIV-1's non-nucleoside reverse transcriptase inhibitors (NNRTIs) 5i3 adapts to resistant mutants via a quinazoline scaffold, while MPXV's tecovirimat acts as a "molecular glue" stabilizing F13 dimers. Expanding these paradigms, we present groundbreaking insights: An indazole-based IAV inhibitor (compound 24) disrupts the conserved PA-PB1 heterodimer, showing sub-micromolar potency against resistant strains. For HBV, a hydrophobic tagging degrader (HyT-S7) induces HBc degradation, bypassing resistance mutations impairing traditional capsid modulators. Key strategies include dynamic flexibility, multivalent interactions, and oligomerization control, integrated with AI-driven design and real-time surveillance. This perspective bridges structural insights with translational applications, offering a roadmap for next-generation, mutation-resilient antivirals.},
}
@article {pmid41550683,
year = {2026},
author = {Piazza, M and Gori, A and Capristo, C and Boner, AL},
title = {Bronchiolitis and recurrent respiratory infections: The role of oxidative stress from early life inflammation to long-term outcomes - A narrative review.},
journal = {The World Allergy Organization journal},
volume = {19},
number = {1},
pages = {101162},
pmid = {41550683},
issn = {1939-4551},
abstract = {Bronchiolitis, primarily caused by respiratory syncytial virus (RSV), is a common respiratory infection in infants and a known precursor to recurrent wheezing and asthma. This review explores the role of oxidative stress and trace element deficiencies in the pathogenesis of bronchiolitis and its long-term sequelae. Infants with reduced lung function due to prematurity or congenital airway anomalies exhibit heightened susceptibility to RSV infection. Growing evidence implicates oxidative stress and deficiencies in zinc, selenium, and magnesium as significant contributors to disease progression. Impaired antioxidant defenses exacerbate viral inflammatory responses, leading to prolonged symptoms and recurrent wheezing with potential developmental delays. Studies consistently demonstrate that children with bronchiolitis exhibit elevated oxidative stress markers and reduced antioxidant capacity, with trace element deficiencies correlating with disease severity. Reduced defenses against oxidative stress may be associated with recurrent wheezing episodes, which are more frequent after rhinovirus bronchiolitis than after RSV bronchiolitis. Thus, RSV and rhinovirus (RV) bronchiolitis may unmask pre-existing vulnerabilities rather than directly causing long-term damage associated with later asthma. Micronutrient supplementation, particularly zinc and selenium, has shown potential in reducing respiratory infection duration and severity. COVID-19 pandemic evidence further supports nutritional status as a key modulator of respiratory disease outcomes, with nutraceuticals like curcumin and flavonoids demonstrating anti-inflammatory benefits. Given the safety and accessibility of micronutrient supplementation, early nutritional assessment and intervention in high-risk infants may offer a cost-effective strategy to improve long-term respiratory outcomes. Bronchiolitis should be viewed as a clinical signal warranting proactive, holistic pediatric care rather than merely an acute illness.},
}
@article {pmid41550947,
year = {2025},
author = {Hotchkiss, RS and DiPersio, JF and Yee, C and Pachynski, RK and Van Den Brink, MRM},
title = {IL-7: a potential next-generation adjuvant for immune cell therapies.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1736931},
pmid = {41550947},
issn = {1664-3224},
support = {P30 CA015704/CA/NCI NIH HHS/United States ; P50 CA171963/CA/NCI NIH HHS/United States ; P01 AG052359/AG/NIA NIH HHS/United States ; UM1 CA154967/CA/NCI NIH HHS/United States ; R35 GM126928/GM/NIGMS NIH HHS/United States ; U01 CA154967/CA/NCI NIH HHS/United States ; R35 CA210084/CA/NCI NIH HHS/United States ; },
mesh = {Humans ; *Interleukin-7/therapeutic use/immunology ; Animals ; Immunotherapy, Adoptive/methods ; *Adjuvants, Immunologic/therapeutic use ; *Neoplasms/therapy/immunology ; SARS-CoV-2/immunology ; *Cell- and Tissue-Based Therapy/methods ; },
abstract = {Cell-based immune therapies ranging from CAR-T cells to tumor infiltrating lymphocytes (TILs) and endogenous T-cell products, have produced unprecedented clinical responses in hematologic malignancies and are currently under active investigation for solid tumors. Nevertheless, several key challenges continue to limit the durability and breadth of clinical benefit. IL-7 is a pleiotropic cytokine that increases both the number and function of lymphocytes. Although not yet clinically approved, IL-7 has been used in over 620 adult and pediatric patients for a variety of reasons including, for example, to hasten bone marrow recovery after allogenic stem cell transplantation, to reverse lymphopenia due to HIV and idiopathic etiologies, to treat patients with various malignancies, and to boost vaccine responses. IL-7 is generally well-tolerated and effective in producing a durable increase in the number and function of CD4 and CD8 T cells. Recently, IL-7 has been used clinically in multiple myeloma patients receiving CAR-T cell therapy, in patients with urothelial cancer who are receiving checkpoint inhibitors, in patients undergoing endogenous lymphocyte cell therapy, and in critically-ill lymphopenic patients with COVID-19. The authors, all of whom have used IL-7 clinically, discuss how IL-7 effectively addresses all the major problems currently limiting adoptive cell therapies. Peering into the future, we believe that IL-7 will be a major advance as an adjuvant treatment in many cell therapies and hope that this commentary will expedite IL-7's testing in multiple clinical settings.},
}
@article {pmid41551283,
year = {2025},
author = {Agyapong-Opoku, N and Agyapong-Opoku, F and Agyapong, B and Greenshaw, AJ},
title = {Anxiety and depressive symptoms among medical students-A scoping review of systematic reviews and meta-analyses.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1710333},
pmid = {41551283},
issn = {2296-2565},
mesh = {Humans ; *Anxiety/epidemiology ; *Depression/epidemiology ; Meta-Analysis as Topic ; Prevalence ; *Students, Medical/psychology/statistics &amp; numerical data ; Systematic Reviews as Topic ; },
abstract = {BACKGROUND: Medical schools are globally recognized as higher education institutions requiring extreme dedication from students. The intensive nature of physician training demands heavy workloads, inconsistent sleep, and study-leisure imbalances. Such stressors are linked to poor student mental health, with anxiety and depression symptoms among the most documented disorders. These burdens negatively affect academic performance and are associated with dropout intentions, misconduct, burnout, and suicidal ideation.<br><br>OBJECTIVE: This scoping review summarizes recent evidence on the prevalence of anxiety and depression symptoms among medical students and identifies correlated factors.<br><br>METHODS: The review followed PRISMA guidelines and Arksey and O'Malley's five-stage methodological framework. Searches were conducted on July 5, 2025, in PubMed, MEDLINE, Web of Science, Scopus, and PsycINFO. Boolean operators combined terms related to prevalence, and correlates of depressive and anxiety symptoms, and medical students, limited to systematic reviews and meta-analyses published in English between January 2021 and July 2025. Sixteen studies met the inclusion criteria after screening. Data were charted for study characteristics, prevalence estimates, contributing factors, and methodological approaches.<br><br>RESULTS: The studies included in this review reported wide-ranging prevalence estimates, with the prevalence of depression symptoms in the included meta-analysis ranging from lowest of 18.1% to highest of 50.0% and anxiety symptoms from 17 to 54% although there was high heterogeneity in the screening instruments or measurement scales Biological sex differences in prevalence were frequently noted, with most studies reporting a higher prevalence among females; however, findings varied by region. Regional disparities were additionally observed, with some continents and countries reporting significantly higher prevalence rates than others. Factors associated with increased risk included early years of study, poor sleep quality, and academic stress. During COVID-19, most studies reported a higher prevalence of depression and anxiety symptoms than pre-pandemic levels.<br><br>CONCLUSIONS: Anxiety and depressive symptoms remain widespread among medical students, driven by individual and contextual factors. Targeted interventions and early preventive strategies are urgently needed to address mental health challenges and protect student wellbeing.},
}
@article {pmid41552096,
year = {2025},
author = {Li, X and Liu, Y and Xu, S and Liu, H and Zeng, C and Wang, R and Yue, Y and Wang, X},
title = {Progress in the Application of Pirfenidone in Post-COVID-19 Pulmonary Fibrosis: A Review.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e99490},
pmid = {41552096},
issn = {2168-8184},
abstract = {Pulmonary fibrosis following infection with the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a significant long-term complication among survivors of coronavirus disease 2019 (COVID-19), profoundly affecting their quality of life and clinical outcomes. This review provides a comprehensive overview of the pathophysiological mechanisms underlying post-COVID-19 pulmonary fibrosis and elucidates the pharmacological actions of pirfenidone, a multi-targeted antifibrotic agent in this context. We summarize the current clinical evidence on the efficacy and safety of pirfenidone for managing fibrosis secondary to SARS-CoV-2 infection, drawing on recent advances in basic and clinical research. Furthermore, we discuss existing challenges, unresolved questions, and prospective directions for optimizing antifibrotic therapy in COVID-19 convalescents. By systematically analyzing these aspects, this article aims to offer theoretical support and practical guidance to clinicians and researchers addressing the management of post-COVID-19 pulmonary fibrosis.},
}
@article {pmid41552427,
year = {2026},
author = {Wang, H and Patzi-Churqui, M and Andius, LD and Nyström, K and Lagging, M},
title = {Genetic insights into hepatitis E virus through environmental surveillance in Europe.},
journal = {One health (Amsterdam, Netherlands)},
volume = {22},
number = {},
pages = {101302},
pmid = {41552427},
issn = {2352-7714},
abstract = {Zoonotic hepatitis E has been a growing public health concern in Europe, but the transmission of its causative agent, hepatitis E virus (HEV), remains incompletely understood. Environmental surveillance, particularly through wastewater monitoring, has proven valuable for tracking viral circulation and variant shift during the COVID-19 pandemic, yet its application to HEV is still limited. In this review, we systematically analyzed HEV sequences across Europe, focusing on environmental sources from a genetic perspective. Of more than 13,100 HEV sequences deposited in the NCBI database, only 2.4 % (316/13,118) originated from environmental samples, including wastewater, surface water, and biosolids. Additional typing data from the literature revealed highly uneven geographic distribution, with 97 % of environmental sequences reported from Italy, France, the United Kingdom (UK), Spain, Sweden, and Germany. HEV-3 was the dominant genotype, while HEV-1 and HEV-4 were occasionally detected. Subtypes 3c and 3f were most common, but their prevalence varied across countries and sample types. Some countries, such as France, Sweden, and the UK, exhibited divergent subtype patterns between humans, animals, and environmental sources, whereas others, such as Spain and Germany, showed more consistent distributions. These findings highlight the importance of integrating clinical, veterinary, and environmental surveillance to better understand HEV transmission in Europe under a One Health framework. However, the scarcity of environmental data, technical challenges in sequencing, and lack of standardized protocols limit comprehensive assessment of HEV circulation. Expanding sequencing efforts, improving detection methods, and coordinating international surveillance frameworks will be critical to strengthen HEV monitoring and preparedness against emerging HEV threats.},
}
@article {pmid41553427,
year = {2026},
author = {Zhu, R and Oh, YJ and Hinterdorfer, P},
title = {Single molecule force spectroscopy for evaluating inhibitors of SARS-CoV-2 variants of concern.},
journal = {European biophysics journal : EBJ},
volume = {},
number = {},
pages = {},
pmid = {41553427},
issn = {1432-1017},
abstract = {The binding between the SARS-CoV-2 Spike protein and its cellular receptor ACE2 is essential for viral entry and infection and, therefore, represents a critical target for antiviral intervention. Single-molecule force spectroscopy (SMFS), conducted using atomic force microscopy (AFM), allows direct investigation of Spike–ACE2 interactions at the single-molecule level, providing insights into binding mechanisms not easily captured by conventional methods. This review discusses recent applications of SMFS to assess molecular inhibitors of Spike–ACE2 interactions, focusing specifically on soluble ACE2 and glycan-binding lectins (Clec4g, hCLEC4G, and engineered H84T-Banlec). These inhibitors demonstrated potent, concentration-dependent activity against multiple SARS-CoV-2 variants, including Delta and Omicron, achieving IC50 values in the low nanomolar range (soluble ACE2: 0.25–0.38 nM; Clec4g/hCLEC4G: 36–58 nM; H84T-Banlec: 2.6–5.2 nM). Notably, single-molecule IC50 measurements closely correlated with EC50 values from cell-based assays, validating the physiological relevance and predictive capability of the SMFS method. Collectively, these findings underscore the utility of AFM-SMFS as a powerful approach for inhibitor evaluation and antiviral discovery, particularly for strategies targeting conserved structural features of the Spike protein to achieve broad-spectrum efficacy against current and emerging viral variants.},
}
@article {pmid41553516,
year = {2026},
author = {Herpertz, G and Roesch, F and Abramovich, I and Trinks, A and Ghezel-Ahmadi, V and Nowak-Machen, M and Becke-Jakob, K},
title = {[Work-related fatigue in anesthesia and intensive care medicine : Review article on a structural problem].},
journal = {Die Anaesthesiologie},
volume = {75},
number = {2},
pages = {117-124},
pmid = {41553516},
issn = {2731-6866},
mesh = {Humans ; *Fatigue/epidemiology/prevention &amp; control/psychology/etiology ; *Critical Care ; COVID-19/epidemiology ; Germany/epidemiology ; Work Schedule Tolerance ; *Anesthesiology ; Shift Work Schedule ; *Occupational Diseases/prevention &amp; control ; },
abstract = {Work-related fatigue is a serious psychophysiological phenomenon characterized by exhaustion, impaired concentration, reduced alertness and diminished decision-making capacity. It often results from disrupted sleep patterns and shift work and increases the risk of critical incidents in the clinical practice. Anesthetists are particularly affected as irregular working hours and frequent night shifts disrupt their circadian rhythms. Although fatigue is reversible with appropriate measures, it remains largely unrecognized as a structural issue within the German healthcare system.Over recent decades the working conditions across European healthcare settings have steadily deteriorated, a trend that culminated during the COVID-19 pandemic. This period clearly highlighted the urgent need to prioritize the well-being of healthcare professionals. The aim of this review article is to raise awareness of fatigue and provide insights into effective management strategies. It explores both international concepts and local solutions relevant to the German system.This review and analysis are based on studies and material developed as part of the European "Fatigue Project" and the "Fight Fatigue" campaign. It examines the effects of fatigue across all career stages and identifies practical strategies for risk reduction.The results show that fatigue affects anesthetists at all stages of their careers. Structured fatigue management is therefore a vital component of sustainable healthcare provision. In particular, fatigue risk management systems and optimized shift work planning have proven effective in reducing the burden on personnel and enhancing patient safety.},
}
@article {pmid41554283,
year = {2026},
author = {Oskvarek, JJ and Leubitz, A and Rahman, N and Sure, B and Pines, JM},
title = {Emergency department crowding in the modern era: a systematic review (2018-2025).},
journal = {Clinical and experimental emergency medicine},
volume = {13},
number = {2},
pages = {119-139},
pmid = {41554283},
issn = {2383-4625},
abstract = {OBJECTIVE: This study systematically reviews the causes, effects, and potential solutions to emergency department (ED) crowding, with emphasis on challenges amplified by the COVID-19 pandemic.<br><br>METHODS: Following PRISMA guidelines, we searched MEDLINE, CINAHL, and the Web of Science for peer reviewed studies published from January 1, 2018, to January 31, 2025, that investigated ED crowding. Studies were included if they evaluated crowding causes, consequences, or interventions, using metrics such as ED length of stay, boarding, or left without being seen. Four reviewers independently screened titles, abstracts, and full texts. Study quality was assessed using the SIGN critical appraisal tools. This review was registered in PROSPERO (No. CRD420251117676).<br><br>RESULTS: Of 23,408 studies identified, 226 met inclusion criteria. Most studies were retrospective (83%) and of low (62%) or acceptable (35%) quality. Crowding was primarily driven by input (high patient volumes, limited primary care access), throughput (staffing shortages, laboratory and imaging delays), and output (boarding, late discharges) factors. Adverse effects included increased mortality, treatment delays, prolonged inpatient stays, higher rates of patients leaving without being seen, and reduced patient satisfaction. Effective strategies included provider-in-triage, nurse-initiated orders, and split-flow models. Output-focused interventions, such as active bed management and early discharge protocols, required system-wide coordination. The COVID-19 pandemic shifted patient volumes and led to innovative solutions such as drivethrough clinics and repurposed spaces to alleviate surges.<br><br>CONCLUSION: ED crowding is a persistent global issue with significant clinical and operational consequences. While promising interventions exist, high-quality evidence remains limited, underscoring the need for system-level and multifaceted solutions.},
}
@article {pmid41555196,
year = {2025},
author = {D'angelo, MA and Nicolai, R and Di Nicolantonio, S and Pietropaoli, D and Monaco, A and Ortu, E},
title = {Comparison of Teledentistry and Traditional Clinical Examination for Detection of DMFT Index in Children: A Systematic Review.},
journal = {Pediatric dentistry},
volume = {47},
number = {6},
pages = {380-387},
pmid = {41555196},
issn = {1942-5473},
mesh = {Humans ; Child ; *DMF Index ; *Dental Caries/diagnosis ; *Telemedicine ; COVID-19/epidemiology ; Reproducibility of Results ; },
abstract = {Purpose: This study systematically analyzed the published literature to evaluate the reliability of the caries experience index detection conducted in children (younger than 18 years of age) through teledental systems, comparing it with data obtained through traditional dental consultations. The question to be explored was whether dentists could use teledentistry to assess the caries risk index by calculating the DMFT (decayed, missing, and filled permanent teeth) score, thereby potentially reducing consultation time. Methods: A systematic English-language literature review was conducted, including the period from 2014 to 2024, that included the MeSH terms (("telemedicine"[Mesh]) AND "dental caries"[Mesh]) AND "DMF index"[Mesh]). Inclusion and exclusion criteria were defined according to the PICO methodology. A total of 11 manuscripts met the inclusion criteria. The methodological quality of these studies was assessed using the Newcastle-Ottawa Scale (NOS) with specific tools for cross-over studies. Results: From the 11 studies reviewed, it was suggested that teledentistry, through the use of intraoral photographs or video recordings, may represent a reliable, noninvasive, and efficient alternative for the detection of the caries experience index, compared to clinical examinations performed according to the traditional method. In most cases, the results were comparable between the two approaches. Conclusion: Incorporating teledentistry in combination with regular dental appointments could streamline clinical processes, enable effective treatment planning, and facilitate remote monitoring of the oral health status of patients, making it a timely and contemporary solution for a connected and health-conscious society-which is particularly valuable during public health crises such as the COVID-19 pandemic.},
}
@article {pmid41555409,
year = {2026},
author = {Baseri, S and Izadi, M and Alimohammadi, M and Khoshnazar, SM and Nikdel, R and Hushmandi, K},
title = {Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials.},
journal = {European journal of medical research},
volume = {31},
number = {1},
pages = {111},
pmid = {41555409},
issn = {2047-783X},
mesh = {Humans ; *Atorvastatin/therapeutic use/pharmacology ; Randomized Controlled Trials as Topic ; Biomarkers/blood ; *Lung Diseases/drug therapy/physiopathology/blood ; Respiratory Function Tests ; *Lipids/blood ; Liver/enzymology/drug effects ; },
abstract = {BACKGROUND: Pulmonary diseases are important causes of morbidity globally. Atorvastatin's pleiotropic effects, which include anti-inflammatory and lipid-lowering properties, may be beneficial for individuals with respiratory diseases. This meta-analysis evaluated the atorvastatin's effect on inflammatory biomarkers, lipid profile, liver enzymes, and pulmonary function in lung disease patients.<br><br>METHODS: We systematically searched PubMed/MEDLINE, Scopus, Web of Science, Embase, CENTRAL, and Google Scholar for English-language RCTs until March 2025. The study evaluated inflammatory markers (CRP, IL-6, TNF-&#x3b1;), lipid profile (LDL, HDL, TC, TG), liver enzymes (ALT, AST), pulmonary function tests, and physical performance. Pooled weighted mean differences (WMDs) with 95% confidence intervals were calculated using random-effects models. Subgroup, heterogeneity, and publication bias analyses were conducted.<br><br>RESULTS: Seventeen RCTs (22 datasets; n&#x2009;=&#x2009;1,344) on asthma, COPD, COVID-19, pulmonary hypertension, and associated disorders were analyzed. Atorvastatin substantially decreased TNF-&#x3b1; (WMD: -&#xa0;0.20&#xa0;pg/mL; 95% CI -&#xa0;0.28 to -&#xa0;0.11), LDL cholesterol (WMD: -&#xa0;21.48&#xa0;mg/dL; 95% CI -&#xa0;30.82 to -&#xa0;12.14), and TC (WMD: -&#xa0;15.24&#xa0;mg/dL; 95% CI -&#xa0;28.28 to -&#xa0;2.20), while improving 6MWD (WMD: 0.71; 95% CI 0.24 to 1.17) and FEF25-75 in COPD subgroups. Evening peak expiratory flow (PEF) was considerably lower (WMD: -&#xa0;8.72; 95% CI -&#xa0;14.96 to -&#xa0;2.47), indicating worsening in airway airflow throughout the evening. There were no significant overall effects for CRP, IL-6, triglycerides, HDL, FEV1, FVC, or oxygen saturation.<br><br>CONCLUSIONS: Atorvastatin demonstrates anti-inflammatory and lipid-lowering efficacy in pulmonary disease patients, with mild functional respiratory benefits and modest improvements in physical performance. Additional large-scale studies are needed to validate clinical benefits and effective treatment methods.},
}
@article {pmid41558303,
year = {2026},
author = {Kalgutkar, AS and Eng, H and Dantonio, AL and Kadar, EP and Di, L and Walker, GS and Boras, B and Obach, RS},
title = {Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir.},
journal = {Drug metabolism and disposition: the biological fate of chemicals},
volume = {54},
number = {2},
pages = {100226},
doi = {10.1016/j.dmd.2025.100226},
pmid = {41558303},
issn = {1521-009X},
mesh = {Humans ; *Drug Discovery/methods ; *COVID-19 Drug Treatment ; *SARS-CoV-2/drug effects/enzymology ; *Proline/analogs &amp; derivatives/pharmacokinetics ; *Antiviral Agents/pharmacokinetics/administration &amp; dosage ; Animals ; Ritonavir/administration &amp; dosage ; *Coronavirus 3C Proteases/antagonists &amp; inhibitors/metabolism ; Tissue Distribution ; *Protease Inhibitors/pharmacokinetics ; Drug Development/methods ; Pyrrolidinones ; Azabicyclo Compounds ; },
abstract = {The severe acute respiratory syndrome coronavirus-2 main protease inhibitor PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid), has been approved by the US Food and Drug Administration as an oral treatment option for coronavirus disease 2019 patients. In this perspective, we share the expediated absorption, distribution, metabolism, and excretion strategies, which were incorporated as part of discovery efforts, to design orally active severe acute respiratory syndrome coronavirus-2 main protease inhibitors. PF-07321332 (nirmatrelvir) emerged as a potential oral clinical candidate within ∼ 6 months from the time discovery efforts were first initiated. The review also delves into a discussion around the successful use of quantitative fluorine-19 nuclear magnetic resonance spectroscopy in the characterization of the human mass balance and excretion pathways of nirmatrelvir. Human absorption, distribution, metabolism, and excretion data that emerged from the fluorine-19 nuclear magnetic resonance study were used to support the Emergency Use Authorization and new drug application filing, which was accepted by regulatory agencies worldwide. Efficient operational and technical strategies, incorporating the elements of speed without sacrificing data quality, which were crucial to the success of the program, are highlighted. SIGNIFICANCE STATEMENT: This perspective discusses the expedited absorption, distribution, metabolism, and excretion efforts utilized in the discovery and development of the orally active severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir, which in combination with the cytochrome P450 3A inhibitor ritonavir (Paxlovid), is used in the oral treatment of COVID-19. Paxlovid was granted an Emergency Use Authorization by global regulatory agencies in less than 2 years from the initiation of the discovery program and has since been fully approved by the US Food and Drug Administration.},
}
@article {pmid41558692,
year = {2026},
author = {Richie, RC},
title = {Evaluating Cardiovascular Disease Risk.},
journal = {Journal of insurance medicine (New York, N.Y.)},
volume = {53},
number = {1},
pages = {90-97},
doi = {10.17849/insm-53-1-1-8.2},
pmid = {41558692},
issn = {0743-6661},
mesh = {Humans ; *Cardiovascular Diseases/epidemiology/mortality ; Risk Assessment/methods ; Heart Disease Risk Factors ; Risk Factors ; COVID-19/epidemiology ; },
abstract = {There was a steady decrease in cardiovascular disease (CVD ischemic heart disease and stroke) mortality from 1960 to 2020, but since then, this decline has reversed. There have been over 228,000 excess CVD deaths through 2022,1 undoubtedly partially due to the COVID-19 pandemic, but the mortality rate continues to rise (arguably due to the rising epidemic of obesity and diabetes). CVD remains the leading cause of death in developed countries, accounting for over 30% of deaths, and risk estimation is a cornerstone approach to guiding CVD prevention in clinical medicine. Data from the CDC reveal that 36% of US adults have no CVD risk factors, 35% have 1, and 29% have 2 or more risk factors. The age-adjusted percentage of adults with 2 or more CVD risk factors has increased between 2013-2014 to August 2021-August 2023, especially in older age groups.2 Assessing the risk for CVD mortality is essential for the disability and life insurance industry required to assess that risk at a single point in time (at the issuance of an insurance policy). Evaluating this risk requires careful attention to modifiable and non-modifiable factors, including hypertension and other co-morbidities, abnormal lipid profiles, and lifestyle inequalities. The goal of this treatise is to evaluate the various CVD calculators, but also to review other risk factors that may not be routinely sought in estimating CVD risk. The importance of apolipoproteinB (apoB) and lipoprotein A (LpA) as better risk predictors than just elevated LDL levels will be emphasized, and evidence of systemic inflammation and insulin resistance will be proposed as essential early indicators of future cardiovascular disease.},
}
@article {pmid41559316,
year = {2026},
author = {Shi, Y and Li, B and Zheng, Y and Xue, C and Zhu, J},
title = {Therapeutic effect of anti-neuroinflammatory supplement combined with olfactory training on post-covid olfactory dysfunction: a systematic review and meta-analysis.},
journal = {European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery},
volume = {283},
number = {6},
pages = {3503-3512},
pmid = {41559316},
issn = {1434-4726},
mesh = {Humans ; *Amides/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; *COVID-19/complications ; Dietary Supplements ; *Ethanolamines/therapeutic use ; *Luteolin/therapeutic use ; *Olfaction Disorders/therapy/etiology ; *Olfactory Training ; *Palmitic Acids/therapeutic use ; },
abstract = {BACKGROUND: There is no established specific treatment for post-COVID olfactory dysfunction (PCOD) currently. Olfactory training (OT) is the only effective intervention supported by clinical evidence. The anti-neuroinflammatory supplement palmitoylethanolamide and luteolin (PEA-LUT) has shown potential in alleviating the symptoms of post-COVID, but its therapeutic effect on olfactory dysfunction and the gain effect when combined with OT remain to be evaluated.<br><br>METHODS: We comprehensively searched the online databases EMBASE, PubMed, ScienceDirect, Web of Science, Cochrane Library, Google Scholar, and ClinicalTrials.govfor the literature related to the treatment of PCOD, identified studies reporting the efficacy of PEA-LUT combined with OT, extracted the treatment outcome data, and performed data synthesis.<br><br>RESULTS: A total of 7 eligible RCTs published between 2021 and 2024 were included, comprising 525 patients with PCOD. Of the seven studies, five (71.4%) used the full Threshold-Discrimination-Identification (TDI) scoresystem to assess olfactory function, while two (28.6%) used only the Identification ("I") subscale; 332 patients (63.2%) received PEA-LUT&#x2009;+&#x2009;OT therapy and 203 (38.8%) received OT alone. Meta-analysis of these studies showed that patients receiving PEA-LUT combined with OT had significantly higher TDI scores compared to those receiving OT alone (Standard mean difference (SMD)&#x2009;=&#x2009;0.90; 95% CI: 0.24-1.58; P&#x2009;<&#x2009;0.01). The overall response rate was also significantly higher in the combination group (Risk difference (RD)&#x2009;=&#x2009;0.33; 95% CI: 0.01-0.64; P&#x2009;=&#x2009;0.04).<br><br>CONCLUSION: The neuroprotective properties of PEA-LUT appear to enhance recovery from post-COVID olfactory dysfunction. When combined with olfactory training, this treatment shows promising potential as a novel therapeutic approach.},
}
@article {pmid41559432,
year = {2026},
author = {Arziman, S and Aydemir, S and Bozok, V},
title = {Decoding miRNA-Mediated Immunoregulation in SARS-CoV-2, HBV, HIV, and HSV Infections.},
journal = {Genes and immunity},
volume = {27},
number = {1},
pages = {1-12},
pmid = {41559432},
issn = {1476-5470},
mesh = {Humans ; *MicroRNAs/genetics/immunology ; Signal Transduction ; *HIV Infections/immunology/genetics ; *COVID-19/immunology/genetics ; SARS-CoV-2/immunology ; *Hepatitis B/immunology/genetics ; *Herpesviridae Infections/immunology/genetics ; Hepatitis B virus/immunology ; },
abstract = {Eukaryotic cells regulate gene expression through multiple checkpoints, including post-transcriptional mechanisms mediated by microRNAs (miRNAs). These small non-coding RNAs inhibit translation by binding to target mRNAs, often within a complex regulatory network involving other RNA species such as circular RNAs and long non-coding RNAs. miRNAs are now recognised as central players in the pathogenesis, immune modulation, and progression of infectious diseases. In this review, we thoroughly examine studies published over the past five years, focusing on miRNAs involved in immune regulation during four major viral infections: severe acute respiratory syndrome coronavirus 2, hepatitis B virus, human immunodeficiency virus, and herpes simplex virus. Our analysis centres on the core signalling pathways most frequently targeted by miRNAs: NF-κB, MAPK, JAK-STAT, TGF-β/Smad, and pattern-recognition receptor-associated cascades. Among the miRNAs most prominently implicated are miR-21, miR-146a, miR-150, and miR-155. These miRNAs modulate key signalling pathways, thereby influencing macrophage polarisation, T- and natural killer cell activity, antigen presentation, and inflammatory cytokine production. In addition, virus-encoded miRNAs and ceRNA or extracellular vesicle-mediated interactions are discussed where mechanistically validated, illustrating virus-specific regulatory layers. Collectively, this integrative synthesis underscores the pivotal roles of miRNAs in orchestrating antiviral immunity and highlights their potential as biomarkers and therapeutic targets in viral infections. A better understanding of miRNA-mediated immunoregulation may pave the way for precision interventions aimed at improving immune control and patient outcomes.},
}
@article {pmid41559622,
year = {2026},
author = {Galletta, MAK and Hashimoto, AS and de Almeida Estrambk, G and Verardo, IPS and Cantagalli, MHI and Peres, SV and Francisco, RPV},
title = {Prevalence of postpartum depression in the COVID-19 pandemic and associated factors: systematic review and meta-analysis.},
journal = {BMC pregnancy and childbirth},
volume = {26},
number = {1},
pages = {157},
pmid = {41559622},
issn = {1471-2393},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; Female ; *Depression, Postpartum/epidemiology ; Prevalence ; Risk Factors ; Pregnancy ; SARS-CoV-2 ; Pandemics ; Global Health ; },
abstract = {BACKGROUND: The COVID-19 pandemic created a disruptive scenario with an increase in the prevalence of postpartum depression (PPD) and new associated risk factors, which deserve to be better studied, in different global contexts, which led to the present systematic review study.<br><br>METHODS: Observational studies published in English, Portuguese, and Spanish between 2020 and 2025 were included, and a meta-analysis was conducted using a random-effects model.<br><br>RESULTS: An initial survey of 1741 articles, of which 90 studies were selected with a total of 64,6994 women evaluated for PPD, with a range between 50 (1) and 5,134 (2) women. The overall prevalence of postpartum depression during the COVID-19 pandemic was 28.48% (25.14-31.94), with rates of 23.52% (18.961-28.40) in studies that used the Edinburgh Postnatal Depression Scale (EPDS) as a diagnostic instrument with a cutoff point&#x2009;&#x2265;&#x2009;13. Studies from 31 countries were included, with higher prevalence observed in Latin America (34.08%), with lower rates in Europe (31.50%), the Middle East (29.31%), USA/Canada (24.26%), and Asia (22.32%). There was a higher prevalence of PPD in countries with a lower Human Development Index (HDI) (30.95%), with higher COVID-19 CFR (32.56%), higher maternal mortality (30.43%); and with the highest Gender Inequality Index (GII) (35.41%). PPD rates increased with postpartum time, varying between 18.31% (up to 1&#xa0;month), 20.78% (up to 3&#xa0;months), 34.67% (up to 6&#xa0;months) and 36.55% (up to 12&#xa0;months). Additionally, 11 protective factors and 53 risk factors were identified, most related to the pandemic, but also with the presence of factors already consolidated in the literature before the pandemic.<br><br>DISCUSSION: There was a global increase in the prevalence of PPD during the pandemic, with an intensification of pre-existing regional differences, causing the impact of the pandemic to be different according to the region.<br><br>CONCLUSIONS: The social and health crisis of the pandemic negatively impacted postpartum mental health, with significant regional differences.<br><br>TRIAL REGISTRATION: The study was registered in PROSPERO with the code CRD42023392973.},
}
@article {pmid41559816,
year = {2026},
author = {Ahmad, A and Gundeti, MS and R, M and Wilson, E and Itrat, M and Javed, G and Quamri, MA and Chalia, DS and Yadav, P and P, AT and P, KK and S, AC and S, MH and Dileep, A and P, SS and R, G},
title = {Status of evidence on efficacy and safety of Indian traditional medicine (Ayush) for COVID-19: a qualitative review and evidence map synthesis.},
journal = {Systematic reviews},
volume = {15},
number = {1},
pages = {},
pmid = {41559816},
issn = {2046-4053},
mesh = {Humans ; India ; *COVID-19/therapy/epidemiology ; *Medicine, Ayurvedic ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; },
abstract = {BACKGROUND: The novel coronavirus (COVID-19), caused by SARS-CoV-2, was first reported in Wuhan, China, in December 2019. Its rapid spread, high mutation rate, and challenges in containment led the WHO to declare it a global pandemic on March 11, 2020. Traditional medicine played a supportive role during the COVID-19 pandemic by offering immune-boosting and symptom-relieving remedies, especially in regions with limited access to conventional healthcare. Several countries, including India, have integrated traditional therapies with modern treatment protocols to enhance patient outcomes and reduce disease burden.<br><br>OBJECTIVES: This review aims to critically synthesize the existing evidence on the efficacy and safety of Ayush interventions in the management of COVID-19 in India. It seeks to qualitatively analyze published literature and clinical trial data, and to develop an evidence map categorizing interventions by type and associated clinical outcomes.<br><br>METHODS: A comprehensive literature search was conducted across seven electronic databases, including the National Repository on R&amp;D Initiatives of the Ministry of Ayush, WHO COVID-19 dashboard for clinical trials, AYUSH Research Portal, PubMed, Cochrane Library, WHO ICTRP, and CTRI. Studies published between 2019 and June 2024 were considered. A total of 3626 records were identified (2572 from indexed databases and 1054 from trial registries). After removing 640 duplicates, 2986 studies were screened for title and abstract. Following exclusion of 802 records, full-text assessment was performed on the remaining studies. After screening, 304 studies were included in the final review (178 Ayurveda, 22 Siddha, 31 Homeopathy, 22 Unani, and 51 Yoga). Risk of bias was assessed using the ROB 2 and ROBINS-I tools. Data extraction and collation were performed in accordance with the PRISMA guidelines. The study protocol was registered in PROSPERO.<br><br>RESULTS: A total of 304 studies were included, comprising 58 (19.1%) prophylaxis studies, 151 (49.7%) treatment studies, and 17 (5.6%) post-COVID rehabilitation studies across different Ayush systems. Ayurveda accounted for the largest proportion of publications (n&#x2009;=&#x2009;178), followed by Yoga (n&#x2009;=&#x2009;51). Among the randomized controlled trials, approximately half were assessed as having low-to-moderate risk of bias, whereas the remaining studies exhibited high or unclear risk of bias, primarily due to inadequate reporting of randomization procedures, allocation concealment, and blinding. Considerable methodological variability was observed across studies, including differences in intervention type, duration, outcome measures, and quality assessment scores.<br><br>CONCLUSION: While there is significant data on Ayush and COVID-19, current studies vary too widely to be definitive. Future research must prioritize rigorous scientific standards if these systems are to be effectively integrated into public health responses.},
}
@article {pmid41560849,
year = {2026},
author = {McKeague, S and Seymour, JF},
title = {Triplet regimens for frontline treatment of CLL-Great company or just a crowd?.},
journal = {HemaSphere},
volume = {10},
number = {1},
pages = {e70303},
pmid = {41560849},
issn = {2572-9241},
abstract = {Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed-duration venetoclax-based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high-risk biological subgroups, and indefinite covalent Bruton tyrosine kinase inhibitor (cBTKI) is associated with cumulative cardiovascular and infectious toxicity. Triplet regimens for treatment of CLL involve simultaneous use of cBTKI, venetoclax, and anti-CD20 monoclonal antibody. Three major frontline Phase 3 trials (CLL-13/GAIA, AMPLIFY, and A041702) have demonstrated higher rates of undetectable minimal residual disease (uMRD) and longer remissions with triplets than doublets, particularly in patients with IGHV-unmutated (IGHV-U) disease. However, this comes at the cost of increased infectious toxicity, particularly with COVID-19, and thus has translated into a variable impact on progression-free survival (PFS) and, to-date, no overall survival (OS) benefit. Although there are promising Phase 2 data for triplets in patients with TP53 aberrant or relapsed disease, the heterogeneity of treatment duration/MRD definition, lack of control arm, and potential increased toxicity make it premature to use triplets in these groups. We recommend considering triplets in treatment naïve CLL patients with IGHV-U, TP53 wild type, anticipated low incidence/good tolerance of Gr ≥ 3 infection (<70 years old, no major comorbidity and fully immunized) who are well informed and prioritize maximal time off therapy at the expense of increased short-term logistical complexity. Future triplet research should focus on randomized trials in specific genomic subgroups, incorporating novel agents (e.g., non-covalent BTKI, BTK degrader, and next-generation BCL2 inhibitors) and new ways of adapting treatment duration to maximize efficacy and minimize toxicity.},
}
@article {pmid41561503,
year = {2025},
author = {Bravo-Valenzuela, NJM and Panizzi, TT and de Souza, KA and Stutz, GB and Aurelio, RVM and Rodrigues, MCF and de Almeida, RG and Lemos, FMCF and Araújo, AL and Sztajnbok, FR and Fonseca, AR},
title = {Cardiovascular abnormalities in multisystem inflammatory syndrome in children related to COVID-19.},
journal = {Frontiers in pediatrics},
volume = {13},
number = {},
pages = {1635723},
pmid = {41561503},
issn = {2296-2360},
abstract = {INTRODUCTION: The COVID-19 pandemic began with the identification of SARS-CoV-2 in December 2019. Although children usually have milder acute symptoms, they can develop severe systemic symptoms termed pediatric multisystem inflammatory syndrome (MIS-C). This study reviews research in children and adolescents diagnosed with MIS-C, focusing on cardiovascular abnormalities.<br><br>METHODOLOGY: This systematic review was conducted following PRISMA guidelines. The review protocol was prospectively registered in the Prospective Register of Systematic Reviews (PROSPERO; registration number: CDR420251232497). A search strategy was constructed to identify the studies focusing on cardiovascular abnormalities in children and adolescents with MIS-C published in Portuguese and English at PubMed and Scielo from January 2020 to February 2025. The eligibility criteria and data extraction strategy were guided by the PICO framework.<br><br>CONCLUSIONS: Myocardial dysfunction and coronary abnormalities are the most frequent cardiovascular features in patients with MIS-C. Strain technology in echocardiography identifies early myocardial dysfunction, with studies showing persistent subclinical injuries. Despite ejection fraction and coronary anomalies returning to normal short to medium term, long-term cardiovascular effects of MIS-C remain uncertain, necessitating ongoing cardiology monitoring.},
}
@article {pmid41561654,
year = {2026},
author = {Bakare, IS and Olaiya, VO and Badero, OJ and Okirie, CF},
title = {Neurological Complications Associated With COVID-19 Compared to Other Viral Infections: A Systematic Review of Current Evidence.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e101817},
pmid = {41561654},
issn = {2168-8184},
abstract = {Neurological complications have become one of the most concerning features of COVID-19, yet clinicians still lack a clear comparison between these findings and what is seen in other viral infections. Understanding where SARS-CoV-2 fits, whether it behaves like influenza and dengue or follows an entirely different pattern, is essential for diagnosis, management, and planning long-term care. We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO: CRD420251064831). Searches across PubMed, Scopus, and Web of Science (2000-2025) identified 24 eligible studies, including observational cohorts, clinical trials, case series, autopsy work, and national surveillance data. Because of the wide variation in study design and reporting, a narrative synthesis was used. Across the 24 studies, COVID-19 exhibited the widest and most severe spectrum of neurological involvement. Reported central nervous system complications included ischemic stroke, encephalopathy or encephalitis, seizures, and extensive microglial and white-matter injury in fatal cases. Peripheral complications were also prominent, such as anosmia, demyelinating neuropathies, Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy, functional movement disorders, and persistent abnormalities on nerve conduction testing long after recovery. In contrast, neurological complications from influenza were less frequent and mostly involved encephalitis/encephalopathy, seizures, meningitis, GBS, or myelitis, with generally low mortality. Dengue virus has been associated with a spectrum of direct neurotropic effects and immune-mediated syndromes, including encephalitis, GBS, myelitis, brachial neuritis, and myositis. Most patients recovered, and mortality remained low. Compared with influenza and dengue, COVID-19 stands out for both the breadth and severity of its neurological manifestations, as well as the persistence of symptoms in many survivors. These findings highlight the need for early neurological evaluation in COVID-19, structured follow-up after recovery, and more consistent research methods to allow better comparisons across viral infections.},
}
@article {pmid41561870,
year = {2025},
author = {Huang, W and Xing, Y and Zhao, F and Wang, Y},
title = {Mobile apps, AI, and teletherapy: a comprehensive review of digital mental health tools for nurses.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1686766},
pmid = {41561870},
issn = {2296-2565},
mesh = {Humans ; *Mobile Applications ; Mental Health Teletherapy ; COVID-19/epidemiology ; Digital Health ; Burnout, Professional/prevention &amp; control ; Telemedicine ; *Nurses/psychology ; Mental Health ; Depression ; },
abstract = {Chronic understaffing, workplace violence, moral distress, rotating shifts, and administrative burdens have created a global mental health crisis for nurses. Around half to two-thirds of nurses report symptoms of burnout, and large surveys have found high levels of depression and anxiety among nursing staff. The COVID-19 pandemic exacerbated these issues, increasing absenteeism, turnover, and error rates. Barriers to care-such as stigma, cost, and limited access in rural areas-mean that many nurses remain untreated. Digital mental health interventions (DMHIs) offer scalable, flexible, and often anonymous support tailored to nurses' schedules and risks. These include teletherapy platforms, AI-driven chatbots and support systems, mobile mental health apps, and hybrid digital-human models. Recent studies (2020-2025) suggest DMHIs can reduce anxiety, depression, and burnout while improving resilience, job satisfaction, and retention. However, obstacles such as unequal access, variable digital literacy, privacy concerns, and limited long-term evidence slow adoption. This review synthesizes current research on DMHI types and efficacy, and examines factors affecting their accessibility and integration into nursing practice. We also discuss cultural and ethical considerations and strategies for involving nurses in designing these tools. Our analysis identifies gaps and opportunities for developing nurse-centered digital mental health solutions that strengthen the workforce and improve patient care.},
}
@article {pmid41562595,
year = {2026},
author = {Kotsias-Konopelska, S and Thielecke, M},
title = {Infections After International Travel: Relevant Diagnoses in Children and Adolescents.},
journal = {Deutsches Arzteblatt international},
volume = {123},
number = {3},
pages = {84-92},
pmid = {41562595},
issn = {1866-0452},
mesh = {Humans ; Child ; *Travel ; Adolescent ; Germany/epidemiology ; *Communicable Diseases/epidemiology/diagnosis ; Female ; Child, Preschool ; },
abstract = {BACKGROUND: Families can acquire infections that are rare or nonexistent in Germany by international travel for business or private reasons and by migration between countries. Children and adolescents have special risk profiles, and their course of illness may be nonspecific and/or severe. A structured travel history is essential so that regionally specific infections will not be overlooked.<br><br>METHODS: This narrative review is based on publications of the last 25 years that were retrieved by a PubMed search on infections after international travel, with an emphasis on retrospective and prospective studies and on articles with separate data on minors. Further information from books, guidelines, surveillance studies, reports of the Federal Statistical Office of Germany, meta-analyses, reviews, and position statements was considered as well.<br><br>RESULTS: Reported case numbers of infectious diseases imported from abroad fell during the COVID-19 pandemic and have since risen again. Among diseases that are usually or exclusively acquired abroad, those most commonly affecting children and adolescents were giardiasis, tuberculosis, hepatitis A and malaria, with 695, 372, 344, and 128 cases in 2024. Less common ones included dengue fever (81 cases) and typhoid fever/paratyphoid fever (45 cases).<br><br>CONCLUSION: Regionally specific infections should be considered in the differential diagnosis of fever, gastrointestinal disturbances, and skin conditions in children and adolescents after international travel. It is critical that relevant diseases including malaria and typhoid fever/paratyphoid fever must be promptly diagnosed or ruled out. Because resistance patterns differ across regions of the globe, targeted determination of the pathogenic organism including a resistogram is important. The possibility of chronic infection should be considered in particular after long stays abroad.},
}
@article {pmid41562685,
year = {2026},
author = {Ghibu, AM and Maniu, I and Birlutiu, V},
title = {Severity Scores in SARS-CoV-2 Infection-A Comprehensive Bibliometric Review and Visualization Analysis.},
journal = {Epidemiologia (Basel, Switzerland)},
volume = {7},
number = {1},
pages = {},
pmid = {41562685},
issn = {2673-3986},
abstract = {BACKGROUND/OBJECTIVES: Discovered in 2019, COVID-19 spread rapidly worldwide, leading from mild forms of the disease to critical forms or death, predominantly among vulnerable patients. Severity scores help clinicians in stratifying the risk of complications and death among patients diagnosed with SARS-CoV-2 infection.<br><br>METHODS: This study aims to identify the severity scores used in this type of infection, while bibliometric analysis carried out provided a comprehensive overview of global research patterns, trends, and cooperation in scientific literature on the chosen topic.<br><br>RESULTS: We conducted a literature screening to identify severity scores used in SARS-CoV-2 infection. Scores including CURB-54, COVID-GRAM, NEWS, APACHE II, SOFA, qSOFA, CALL, MuLBSTA, ISARIC 4C, and PADUA were identified with different performance indices.<br><br>CONCLUSIONS: There were different results obtained depending on the geographical area of applicability, patient groups analyzed, and individual patient characteristics.},
}
@article {pmid41562814,
year = {2025},
author = {Hattori, T},
title = {Neutrophil-Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review.},
journal = {Reports (MDPI)},
volume = {9},
number = {1},
pages = {},
pmid = {41562814},
issn = {2571-841X},
abstract = {Beyond their traditional role as short-lived antimicrobial cells, neutrophils are increasingly recognized as key regulators of adaptive immunity and tumor progression. This AI-assisted integrative review investigated the neutrophil-T-cell axis, particularly the role of Galectin-9 (Gal-9), across adult T-cell leukemia/lymphoma (ATL), Sézary syndrome (SS), coronavirus disease 2019 (COVID-19), and psoriasis. Leveraging AI tools (GPT-5 and Adobe Acrobat AI Assistant) for literature synthesis (2000-2025) and expert validation, we aimed to identify common immunological mechanisms. Across all conditions, neutrophils displayed persistent activation, elevated Gal-9 expression, and modulated T-cell interactions. In ATL and SS, neutrophilia correlated with poor survival and TCR signaling dysregulation, suggesting Gal-9-mediated immune modulation. In COVID-19 and psoriasis, neutrophil-derived Gal-9-linked innate hyperactivation to T-cell exhaustion and IL-17-driven inflammation. These findings define a recurring neutrophil-Gal-9 regulatory module connecting innate and adaptive immune responses. This study underscores the feasibility of combining AI-driven literature synthesis with expert review to identify unifying immunological mechanisms and therapeutic targets across malignancy and inflammation.},
}
@article {pmid41563477,
year = {2026},
author = {Giesen, N and Mellinghoff, SC and Khatamzas, E and Korell, F and Hentrich, M and Einsele, H and Henze, L and Heußel, CP and Hohmann, C and Jensen, BO and Monin, MB and Schafhausen, P and Schalk, E and Spiekermann, K and Voigt, S and von Lilienfeld-Toal, M and Teschner, D and Cornely, OA and Rieger, C and Busch, E},
title = {Prevention, diagnosis and management of community acquired respiratory virus infections including COVID-19 in patients with cancer: 2025 updated evidence-based guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO).},
journal = {Annals of hematology},
volume = {105},
number = {2},
pages = {46},
pmid = {41563477},
issn = {1432-0584},
mesh = {Humans ; *Community-Acquired Infections/diagnosis/prevention &amp; control/therapy ; *COVID-19/prevention &amp; control/diagnosis/therapy/epidemiology/complications ; Evidence-Based Medicine ; Germany/epidemiology ; Hematology/standards ; Immunocompromised Host ; Medical Oncology/standards ; *Neoplasms/complications/therapy ; *Respiratory Tract Infections/diagnosis/prevention &amp; control/therapy ; Societies, Medical ; },
abstract = {Community-acquired respiratory viruses (CARV), such as influenza-, parainfluenza- or respiratory syncytial virus, pose a significant threat to immunocompromised patients with cancer. Following the COVID-19 pandemic, SARS-CoV-2 has now joined the ranks of endemic respiratory viruses and continues to be a cause of significant morbidity and mortality in patients with cancer. Strategies to protect this vulnerable patient population both by prevention of infection and by early therapeutic intervention in case of infectious disease are therefore of utmost importance. This guideline provides updated evidence-based recommendations on diagnosis, prophylaxis and treatment of CARV infections including COVID-19 in patients with solid tumors or hematologic malignancies to support clinicians in offering optimal care. The guideline is based on a systematic review of currently available data and was developed until the beginning of 2025 by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).},
}
@article {pmid41563924,
year = {2026},
author = {Taylor, FE and Guo, H and Patel, T and Burns, F},
title = {A mixed methods systematic review on the impact of COVID-19 on healthcare workers' knowledge, attitudes and practices of infection prevention and control in the UK.},
journal = {The Journal of hospital infection},
volume = {167},
number = {},
pages = {124-136},
doi = {10.1016/j.jhin.2025.10.011},
pmid = {41563924},
issn = {1532-2939},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *Health Personnel/psychology/statistics &amp; numerical data ; *Health Knowledge, Attitudes, Practice ; United Kingdom/epidemiology ; *Infection Control/methods ; Personal Protective Equipment ; SARS-CoV-2 ; *Attitude of Health Personnel ; Cross Infection/prevention &amp; control ; },
abstract = {Coronavirus disease 2019 (COVID-19) continues to cause healthcare-associated infections (HCAIs) in the UK. It is important to understand if infection prevention and control (IPC) guidelines are being followed to prevent future outbreaks and improve preparedness for the emergence of infectious disease. This mixed-methods systematic review aimed to explore the COVID-19 IPC knowledge, attitudes and practices (KAP) of healthcare workers (HCWs) within the UK. Database searches carried out during April 2023 and July 2024 revealed 24 eligible papers (12 quantitative, eight qualitative, four mixed methods). A convergent integrated approach was used during qualitative synthesis. Doctors were most represented, followed by nurses then pharmacists. Personal protective equipment (PPE) was the most reported IPC measure. In terms of knowledge, articles reported moderate-to-poor knowledge of correct aerosol-generating procedures (range 33-35%), and donning and doffing procedures (range 3-82%). Intensive care workers and doctors tended to have better knowledge compared with other settings or HCWs. Regarding attitudes, PPE and gatekeeping visitation caused strain, and some HCWs felt that guidance lacked relevance to their setting. Finally, regarding practices, this review found that HCWs would risk assess what PPE to wear. An enhanced level of PPE than advised was worn when patients were symptomatic. However, HCWs would remove PPE when they felt it reduced effective communication or patient safety was at risk. Clearer communication of the evidence behind IPC guidance and tailored guidance for each setting may improve HCWs' KAP and thus reduce HCAIs. Future research should determine KAP of other IPC apart from PPE. Non-medical HCWs should also be included as they constitute a significant proportion of patient-facing staff.},
}
@article {pmid41564096,
year = {2025},
author = {Rae-Dupree, J},
title = {From Melanoma Detection to Diabetes Monitoring: The Promise of Microneedle Patches.},
journal = {IEEE pulse},
volume = {16},
number = {5},
pages = {13-16},
doi = {10.1109/MPULS.2025.3618457},
pmid = {41564096},
issn = {2154-2317},
mesh = {Humans ; *Needles ; *Melanoma/diagnosis ; Biosensing Techniques/instrumentation ; *Blood Glucose Self-Monitoring/instrumentation ; Continuous Glucose Monitoring ; *Diabetes Mellitus/diagnosis/blood ; Microneedle Drug Delivery ; Digital Health ; },
abstract = {Postage-stamp-sized arrays of infinitesimal needles are being developed that may one day provide the foundation for at-home cancer detection kits and wearable biosensors that can alert diabetes patients in real time as their blood sugar fluctuates. Microneedle arrays-medical patches embedded with micro-scale projections-are an emerging class of devices that are creating pain-free access to the interstitial fluid that surrounds cells just under the surface of the skin. Packed with the same enzymes and metabolites as blood, interstitial fluid also contains many unique biomarkers not found in blood. Researchers have demonstrated that the arrays can be used for inexpensive, biopsy-free melanoma detection, reported using a test strip similar to at-home COVID-19 detectors, and in a diabetes management wristband that combines continuous glucose monitoring with other chemical and cardiovascular signals to alert patients to dangerous trends that today's glucose monitors would miss.},
}
@article {pmid41564315,
year = {2026},
author = {Bustamante, C and Pinilla-Bonilla, LB and Patiño Soler, M and Estravis, M},
title = {Neuraltherapeutic Medicine in Post-Acute COVID-19 Vaccination Syndrome (PACVS): A Critical Review with a Case Report.},
journal = {Restorative neurology and neuroscience},
volume = {44},
number = {3},
pages = {349-359},
pmid = {41564315},
issn = {1878-3627},
mesh = {Humans ; Aged ; *COVID-19 Vaccines/adverse effects ; Post-Acute COVID-19 Syndrome ; *Vaccination/adverse effects ; *COVID-19/prevention &amp; control ; Male ; },
abstract = {IntroductionPost-acute COVID-19 vaccination syndrome (PACVS) emerges as a syndrome of persistent symptoms of a multisystemic nature, even in previously healthy people. Its pathophysiology involves a neural phase characterized by the neuroimmune reflex and persistent secondary neurogenic inflammation. Frequent manifestations such as dysautonomia, neurological alterations, and musculoskeletal symptoms have been described.ObjectiveTo review the current evidence on PACVS and explore the therapeutic potential of Neuraltherapeutic Medicine (NTM), illustrated with a clinical case.Material and methodsA targeted literature review search was conducted in MEDLINE (up to June 2024) using the terms "post-COVID-19 vaccination syndrome", "covid vaccine adverse effects", "inflammatory reflex" and "neural therapy". In addition, a clinical case of a 75-year-old patient with persistent musculoskeletal pain post-vaccination, treated with NTM, was documented.ResultsThe pathophysiology of PACVS includes neuroimmune mechanisms such as response, neurogenic inflammation, and autonomic dysfunction. NTM has shown the ability to modulate the nervous system by desensitizing sources of irritation. In the case presented, the application of 0.5% procaine to the vaccination site and contralateral reflex zone resulted in complete resolution of pain within 48 h and sustained functional improvement during the three months of follow-up.ConclusionsNTM could represent a therapeutic option in the management of PACVS and other syndromes involving neurogenic inflammation. Controlled studies are required to validate its efficacy and establish standardized protocols.},
}
@article {pmid41564537,
year = {2026},
author = {Asokan, S and Damilare, II and Kumar, S and Pandey, RK and Verma, G and Banerjee, N and Radhamanalan, G and Vijayan, S and Jacob, T and Rajeswary, D},
title = {From pandemic influenza to novel coronaviruses: emerging infectious diseases of the 21st century.},
journal = {Diagnostic microbiology and infectious disease},
volume = {114},
number = {4},
pages = {117277},
doi = {10.1016/j.diagmicrobio.2026.117277},
pmid = {41564537},
issn = {1879-0070},
mesh = {Humans ; *Communicable Diseases, Emerging/epidemiology/virology ; Animals ; *Pandemics ; *Influenza, Human/epidemiology ; Zoonoses/epidemiology ; SARS-CoV-2 ; COVID-19 ; },
abstract = {Emerging infectious diseases have risen significantly in the twenty-first century as ecological disruption, climate change, expanding human-animal interfaces, and global mobility intensify opportunities for pathogen transmission. This review synthesizes historical and contemporary evidence across viral, bacterial, fungal, and parasitic threats to characterize how diverse pathogens emerge and spread. Foundational events such as the 1918 influenza pandemic, mid-century influenza pandemics, the emergence of HIV/AIDS, and the eradication of smallpox provide context for understanding modern disease dynamics. In recent decades, coronaviruses including SARS, MERS, and SARS-CoV-2, pandemic H1N1, avian influenza subtypes, and major arboviruses such as dengue, chikungunya, Zika, West Nile virus, and yellow fever have demonstrated the rapidity with which zoonotic pathogens can disseminate globally. Viral hemorrhagic fevers including Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever remain critical threats, especially in regions with limited health-care capacity. Concurrently, antimicrobial resistance, the emergence of Candida auris, and the climate-driven expansion of endemic mycoses involving Histoplasma, Coccidioides, and Blastomyces highlight the increasing importance of fungal pathogens. Parasitic diseases such as artemisinin-resistant malaria, zoonotic trypanosomiasis, and expanding Leishmania transmission reflect shifting ecological conditions. These patterns are shaped by intersecting drivers including deforestation, wildlife trade, agricultural intensification, urban crowding, conflict, and rapid microbial evolution that enable spillover and sustained transmission. Although advances in genomic surveillance, metagenomic diagnostics, mRNA vaccines, monoclonal antibodies, and broad-spectrum antivirals have strengthened global response capacity, substantial gaps persist in equity, surveillance, and access to countermeasures. Strengthening One Health systems and resilient public health infrastructures is essential to anticipate and mitigate emerging infectious threats.},
}
@article {pmid41564655,
year = {2026},
author = {Joseph, SS and Al-Jarrah, L and Ahmed, MH and El-Menyar, A and Khan, NA and Abdelrahman, H and Consunji, R and Abdulrahman, Y and Rizoli, S and Al-Thani, H},
title = {Scoping review on motorcycle crashes patterns, risk factors, and potential in setting policy priorities in the gulf cooperation council countries (GCC).},
journal = {Injury},
volume = {57},
number = {3},
pages = {113017},
doi = {10.1016/j.injury.2026.113017},
pmid = {41564655},
issn = {1879-0267},
mesh = {Humans ; *Motorcycles/statistics &amp; numerical data ; *Accidents, Traffic/statistics &amp; numerical data/prevention &amp; control/mortality ; Risk Factors ; Middle East/epidemiology ; *Wounds and Injuries/epidemiology/prevention &amp; control ; Head Protective Devices/statistics &amp; numerical data ; Craniocerebral Trauma/epidemiology/prevention &amp; control ; Male ; },
abstract = {BACKGROUND: Although road traffic injuries (RTIs) pose a significant public health burden in the Gulf Cooperation Council countries (GCC), the true extent of motorcycle crash injuries (MCCIs) remains unclear because of limited published data from this region. Emerging evidence suggests that MCCIs are on the rise because of the growing use of motorcycles for transport and delivery services, even though road safety overall has improved. We sought to review regional evidence on MCCIs' patterns, key risk factors, and temporal trends to inform policy interventions and research priorities for effective prevention.<br><br>METHODS: A scoping review was conducted in accordance with the PRISMA-ScR guidelines. Articles on GCC MCCIs published from July 2008 to October 2025, examining injury patterns, mortality, and safety practices, were included in the review. Search was conducted across PubMed, Scopus, Google Scholar, and grey literature sources. The GCC consists of six countries: Saudi Arabia (KSA), Qatar, Kuwait, the United Arab Emirates (UAE), Bahrain, and Oman.<br><br>RESULTS: Of 1344 studies identified, 9 met the inclusion criteria and were analyzed. The GCC has seen an increase in the number of motorcycles registered, resulting in higher MCC rates over time. During the COVID-19 pandemic, these rates surged again as the delivery sector grew. MCCI victims were mainly young males (mean age of 29 years). Extremity injuries were the most frequent (two-thirds), followed by head injuries (20-41%), often associated with poor helmet use compliance (range 13-17%). Delivery riders represented a high-risk subgroup, reflecting occupational exposure, fatigue, and time pressure. Despite advances in trauma care, geographic gaps persist. Helmet use non-compliance, alcohol use, and inadequate documentation remain significant risk factors. Extremity injuries were the most common in the GCC.<br><br>CONCLUSION: MCCIs in the GCC are on the rise with high rates of extremity and head trauma. Poor helmet use compliance is a significant factor. Therefore, we suggest strengthening helmet use laws and safety standards, increasing community efforts, and establishing motorcycle lanes with lower speed limits. Protection for riders at work should be enhanced. Road infrastructure and robust data systems also need improvement.},
}
@article {pmid41564840,
year = {2026},
author = {Faijue, DD and Bouaddi, O and Mackey, K and Deal, A and Cinar, EN and Morais, B and Bojang, S and Al-Sharabi, I and Seale, H and Ssali, A and Le Doare, K and Hargreaves, S},
title = {Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.},
journal = {Vaccine},
volume = {75},
number = {},
pages = {128249},
doi = {10.1016/j.vaccine.2026.128249},
pmid = {41564840},
issn = {1873-2518},
mesh = {Humans ; *Refugees/statistics &amp; numerical data ; Adolescent ; Developing Countries ; *Vaccination/methods/statistics &amp; numerical data ; *Transients and Migrants/statistics &amp; numerical data ; Adult ; COVID-19/prevention &amp; control ; Vaccination Coverage ; *Immunization Programs ; Child ; },
abstract = {BACKGROUND: Catch-up vaccination helps close immunity gaps among migrants, refugees and internally displaced people (IDPs) in low- and middle-income countries (LMICs). Despite immunisation life-course policies and global guidelines promoting catch-up vaccination of arriving migrants, vaccination strategies for adolescent and adult populations are poorly described. We synthesised evidence on catch-up vaccination strategies and interventions, delivery platforms, uptake and coverage, and contextual barriers and enablers in LMICs.<br><br>METHODS: We searched Embase, Medline, PsycINFO, Global Health, Web of Science and grey literature sources (including websites of international and national public health organisations and agencies) for primary studies and reports on catch-up vaccination strategies and interventions, delivery platforms, uptake and coverage, and contextual barriers and enablers targeting adolescents (9-18&#xa0;years) and, or adults (&#x2265;19&#xa0;years) in migrants (foreign-born, including refugees) and internally displaced people (IDPs; displaced within national borders) across 136 LMICs, (from January 1st 2000 to February 1st 2025; all languages). Study quality was accessed using ROBINS-I, CASP, AACODS and, AGREE II tools.<br><br>RESULTS: Thirty-seven records met the inclusion criteria (13 peer-reviewed, 24 grey literature), reporting catch-up vaccination activities across 16 LMICs. Most studies were conducted in Uganda (n&#xa0;=&#xa0;6), Bangladesh (n&#xa0;=&#xa0;4), Lebanon (n&#xa0;=&#xa0;3), and Kenya (n&#xa0;=&#xa0;3). Interventions reached &#x2265;48,000 migrants, refugees, and IDPs (primarily Rohingya refugees in Bangladesh during COVID-19 catch-up campaigns). Populations targeted included mostly refugees (n&#xa0;=&#xa0;16 studies; 43.2%), general migrants (n&#xa0;=&#xa0;14; 37.8%), and IDPs (n&#xa0;=&#xa0;5; 13.5%), with a smaller number involving mixed or other migrant groups (n&#xa0;=&#xa0;4; 10.8%). The most frequently delivered vaccines were measles-rubella (n&#xa0;=&#xa0;12; 32.4%), COVID-19 primary-series catch-up (n&#xa0;=&#xa0;9; 24.3%), HPV (n&#xa0;=&#xa0;6; 16.2%), polio OPV/IPV (n&#xa0;=&#xa0;5; 13.5%), and Hepatitis B (n&#xa0;=&#xa0;3; 8.1%). Catch-up vaccine delivery most commonly occurred through primary care via opportunistic offers (n&#xa0;=&#xa0;11) and mobile/outreach delivery (n&#xa0;=&#xa0;11), with additional implementation in fixed posts in camps/settlements (n&#xa0;=&#xa0;7), supplemental immunisation activities (SIAs) (n&#xa0;=&#xa0;6), school-linked delivery (n&#xa0;=&#xa0;5), and hospital/outpatient opportunistic vaccination (n&#xa0;=&#xa0;4). High uptake (&#x2265;85%) was reported where access barriers were minimised (e.g., walk-in availability, extended hours) was paired with community or peer engagement and simple recall systems (SMS or e-booking). Reported barriers included documentation/entitlement checks, language barriers, and fragmented or non-interoperable vaccination records.<br><br>CONCLUSIONS: Migrants remain at risk of under-immunisation, and greater emphasis must be placed on promotion of vaccination across the life-course for missed vaccines, doses, and boosters. Strengthening catch-up vaccination in adolescents and adults, and improving migration-disaggregated data and delivery systems, are urgently needed.},
}
@article {pmid41564895,
year = {2026},
author = {Gray, GC and Vlasova, AN and Lednicky, JA and Nguyen-Tien, T and Shittu, I and Li, F},
title = {Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018.},
journal = {Emerging infectious diseases},
volume = {32},
number = {1},
pages = {1-6},
pmid = {41564895},
issn = {1080-6059},
mesh = {Animals ; Humans ; *Coronavirus, Canine ; Dogs ; *Coronavirus Infections/epidemiology/virology/veterinary ; *Communicable Diseases, Emerging/epidemiology/virology ; *Deltainfluenzavirus ; *Orthomyxoviridae Infections/epidemiology/virology ; *Influenza, Human/epidemiology/virology ; *Dog Diseases/virology/epidemiology ; *Respiratory Tract Infections/virology/epidemiology ; },
abstract = {In 2009 and again in 2019, public health warnings were confirmed by the emergence, rapid widespread transmission, and lethality of novel influenza and coronaviruses. The world continues to suffer disease from these respiratory viruses. Two newly recognized emergent respiratory viruses, influenza D and canine coronavirus HuPn-2018, have been shown to have considerable potential for causing future human epidemics, but diagnostics and surveillance for the viruses are lacking. We reviewed data regarding influenza D virus and coronavirus canine coronavirus HuPn-2018. Those data strongly indicate that these viruses are major newly recognized threats. However, little is being done to respond to or prevent disease associated with these viruses, warranting the question of whether we will learn from previous pandemics.},
}
@article {pmid41565938,
year = {2026},
author = {Bingham-Hendricks, C and Peters-Mosquera, A and Aronowitz, SV and Woods, C and Aronowitz, T},
title = {Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.},
journal = {Nursing open},
volume = {13},
number = {1},
pages = {e70437},
pmid = {41565938},
issn = {2054-1058},
mesh = {Humans ; *American Indian or Alaska Native/statistics &amp; numerical data ; *COVID-19/epidemiology ; Drug Overdose ; Health Services Accessibility ; *Opiate Substitution Treatment/methods ; *Opioid-Related Disorders/drug therapy/ethnology/therapy ; Pandemics ; United States/epidemiology ; },
abstract = {BACKGROUND: The United States (US) declared drug overdose a public health emergency in 2017. Despite this, two million people reported having an opioid use disorder (OUD) in 2018. However, following the beginning of COVID-19 there was a 53% increase in overdose deaths, with American Indian/Alaska Native (AI/AN) individuals experiencing the highest rates of all racial groups. In response to the COVID-19 pandemic and OUD treatment access challenges, OUD treatment policies were changed to improving access to care.<br><br>PURPOSE: This review examines how the state- and federal-level policies impacted access to medications for opioid use disorder (MOUD) during the COVID-19 pandemic. Due to the devastating impact of overdose and COVID-19 on AI/AN communities, as a secondary aim, we examined the inclusion of these populations in the samples of the included studies.<br><br>METHODS: We completed a narrative review using a data-based convergent synthesis design.<br><br>RESULTS: Forty-four studies met the inclusion criteria. Most of the studies were quantitative descriptive studies (n =&#x2009;25). Only two studies offer AI/AN as a category for ethnicity and both had less that 4% of the sample that identified as an AI/AN individual.<br><br>CONCLUSION AND IMPLICATIONS: Telehealth OUD treatment increased initiation and retention for patients taking buprenorphine. No increase in overdose rates was associated with allowing for additional take-home doses of methadone. However, access to treatment, even telehealth, remains difficult for individuals due to a lack of OUD treatment providers and access to the internet. More needs to be done to address the opioid overdose crisis, especially among AI/AN communities. Research focused on cultural strategies to address this health disparity is desperately needed. We included nursing implications in response to this health disparity among AI/AN individuals.},
}
@article {pmid41566283,
year = {2026},
author = {Jiang, ZJ and Jin, PF and Zhang, MR and Jiang, GL and Hu, L and Niu, Q and Zhang, ZJ and Li, JX},
title = {[Progress in research of influence of gene polymorphisms on vaccine immune response].},
journal = {Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi},
volume = {47},
number = {1},
pages = {180-186},
doi = {10.3760/cma.j.cn112338-20250709-00473},
pmid = {41566283},
issn = {0254-6450},
support = {2023YFC2307601//National Key Research and Development Program of China/ ; },
mesh = {Humans ; *Polymorphism, Genetic ; *HLA Antigens/genetics ; *Vaccines/immunology ; COVID-19 Vaccines/immunology ; Influenza Vaccines/immunology ; COVID-19/prevention &amp; control ; SARS-CoV-2 ; },
abstract = {To introduce the recent progress in the research of gene polymorphisms and differences in vaccine immune responses, this paper systematically summarizes current findings of the associations between human leukocyte antigen (HLA) polymorphisms and other key immunoregulatory gene variations with vaccine responses across different domains, including COVID-19 and influenza vaccines. Furthermore, it discusses the impact of different genotypes on antibody production, immune protection, and the risk for breakthrough infections. To address the challenges posed by genetic polymorphisms, this paper further summarizes several key strategies for vaccine optimization, including conserved epitope targeting, multivalent vaccine design, and peptide-carrier conjugation approaches. Although genomics has laid a theoretical foundation for precise vaccine design, multiple challenges still persist in current research, such as the complexity of gene-environment interactions and ethical concerns regarding data sharing and privacy protection. Future investigations should further evaluate the effects of specific gene polymorphisms, such as detailed HLA subtypes, on the variations in vaccine immune responses, and elucidate underlying mechanisms by integrating functional studies Exploring and establishing genomics and multi-omics-based precise immunization strategies will provide more effective solutions for vaccine-preventable diseases.},
}
@article {pmid41566983,
year = {2026},
author = {Rahmadina, F and Ahmad, RA and Ramadona, AL},
title = {Association of Particulate Matter (PM2.5) With COVID-19 Infection and Mortality in Low-and Middle-income Asian Countries: A Systematic Review and Meta-analysis.},
journal = {Journal of preventive medicine and public health = Yebang Uihakhoe chi},
volume = {59},
number = {1},
pages = {12-24},
pmid = {41566983},
issn = {2233-4521},
mesh = {*Particulate Matter/adverse effects/analysis ; Humans ; Asia/epidemiology ; *COVID-19/mortality/epidemiology ; Developing Countries ; SARS-CoV-2 ; *Environmental Exposure/adverse effects ; Pandemics ; Air Pollution/adverse effects ; Air Pollutants/adverse effects ; },
abstract = {OBJECTIVES: Low-income and middle-income countries in Asia bear a disproportionate burden of particulate matter with an aerodynamic diameter of 2.5 micrometers or less (PM2.5) pollution, yet data remain scarce. This systematic review and meta-analysis aimed to quantify the association between PM2.5 exposure and the risks of coronavirus disease 2019 (COVID-19) infection and mortality in this vulnerable region.<br><br>METHODS: A systematic search was conducted in PubMed, Scopus, and other major databases for studies published up to December 31, 2024. We included observational studies reporting associations between PM2.5 and COVID-19 outcomes in low-income and middle-income Asian countries. Pooled effect sizes and 95% confidence intervals (CIs) were calculated using a random-effects model. The study was registered with PROSPERO (CRD42022316008).<br><br>RESULTS: Fourteen studies met the inclusion criteria. Separate analyses demonstrated statistically significant positive associations between PM2.5 exposure and COVID-19 infection for both short-term exposure (pooled risk ratio [RR], 1.12; 95% CI, 1.07 to 1.18) and long-term exposure (pooled RR, 1.41; 95% CI, 1.28 to 1.56). For mortality, the analysis identified a statistically non-significant positive association with short-term exposure (pooled RR, 1.37; 95% CI, 0.80 to 2.33). Substantial heterogeneity was observed across all analyses (I&#xb2;>75%); however, sensitivity analyses confirmed that the findings for infection were robust.<br><br>CONCLUSIONS: Our findings provide robust evidence that PM2.5 exposure is a significant risk factor for COVID-19 infection in low-income and middle-income Asian countries. The available evidence was insufficient to establish a clear association with mortality. These results underscore the urgent need for strengthened air quality control policies as a critical component of public health strategies to mitigate the burden of respiratory pandemics.},
}
@article {pmid41567206,
year = {2025},
author = {Zhou, K and Chen, Y and Pang, J and Zhang, J and Lu, J},
title = {The endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1681764},
pmid = {41567206},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/complications/pathology ; *Sepsis/immunology/virology/pathology ; *SARS-CoV-2/immunology ; *Cytokine Release Syndrome/immunology ; *Endothelial Cells/immunology/pathology/virology ; Animals ; *Endothelium, Vascular/immunology/pathology ; *Thrombosis/immunology ; Complement Activation ; T-Cell Exhaustion ; },
abstract = {Taking COVID-19 as an illustrative example, this review systematically elucidates the central pathological mechanism of viral sepsis, termed the endothelial-immunothrombotic storm. This mechanism is initiated by the direct viral infection of endothelial cells, which provokes excessive immune activation and disrupts coagulation through immunothrombosis, including cytokine storms, NETosis, and complement activation. Meanwhile, these processes establish a vicious cycle leading to multiple organ failure. Compared with classical bacterial sepsis, viral sepsis exhibits distinctive features such as interferon dysregulation, direct endothelial damage, a hypercoagulable state, and T-cell exhaustion. This review integrates the latest research findings, contrasts the pathophysiological differences between viral and bacterial sepsis, and proposes precision strategies focused on endothelial protection, immune modulation, and anticoagulation. Finally, we discuss the clinical translational prospects of these approaches and suggests directions for future research.},
}
@article {pmid41567315,
year = {2025},
author = {Vargas Cornejo, HM and Jiménez Prado, CA and Guillén Galarza, MF},
title = {Glossopharyngeal neuralgia after SARS-CoV-2 infection: A case report.},
journal = {Journal of clinical and experimental dentistry},
volume = {17},
number = {12},
pages = {e1550-e1553},
pmid = {41567315},
issn = {1989-5488},
abstract = {Glossopharyngeal neuralgia (GN) is a rare neuropathic disorder characterized by sudden, unilateral, electric shock-like pain in the areas innervated by the glossopharyngeal nerve. Its diagnosis is frequently delayed because of its clinical overlap with odontogenic and otorhinolaryngological conditions. In the context of the COVID-19 pandemic, different cranial neuropathies have been reported, suggesting possible post-infectious mechanisms. We describe the case of a 54-year-old male dentist, without relevant medical history, who developed recurrent episodes of intense pain in the right pharynx and base of tongue after confirmed SARS-CoV-2 infection. Symptoms were triggered by swallowing, coughing, and salivary stimulation, reaching maximum intensity on the visual analogue scale (EVA 10/10). Brain and neck magnetic resonance imaging revealed no structural abnormalities. Treatment with carbamazepine (600 mg/day) partially reduced frequency and severity of attacks, while pregabalin (300 mg/day) showed no benefit. This case highlights the need to consider SARS-CoV-2 infection as a potential trigger of GN, underscores the importance of recent infectious history in the differential diagnosis, and emphasizes the relevance of early pharmacological management in clinical improvement.},
}
@article {pmid41567360,
year = {2026},
author = {Shahid, F and Farooq, H and Abeer, H and Mahmood, GM and Sheikh, H and Ameer, MZ and Fatima, L and Ameer, F and Amjad, Z and Ahmad, TZ and Rehman, G and Rehman, AU},
title = {The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.},
journal = {Clinical medicine insights. Arthritis and musculoskeletal disorders},
volume = {19},
number = {},
pages = {11795441251414673},
pmid = {41567360},
issn = {1179-5441},
abstract = {BACKGROUND: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are interrelated inflammatory conditions, and evidence suggests that infection and vaccination might act as a trigger for these conditions. This descriptive systematic review summarizes the published case reports and case series on new-onset PMR and GCA following COVID-19 vaccination, highlighting their clinical features, diagnostic findings, and treatment outcomes.<br><br>OBJECTIVES: To do a systematic analysis of available literature regarding the association between COVID-19 vaccination and the first onset or flare of PMR and/or GCA.<br><br>DESIGN: Systematic review of case reports and case series.<br><br>DATA SOURCES AND METHODS: A systematic literature search was conducted using PubMed/MEDLINE, Cochrane, ScienceDirect, and Google Scholar. Data on patient demographics, clinical features, outcomes, and latency periods were extracted and analyzed. Quality assessment of included studies was performed using the Joanna Briggs Institute Critical Appraisal Tool.<br><br>RESULTS: A total of 32 articles, documenting 50 new-onset cases (30 PMR and 20 GCA), were identified for inclusion. The mean age for patients with PMR was 71.06&#x2009;years, and 72.85&#x2009;years for GCA. A slight female predominance was observed (60%) for both PMR and GCA. Pfizer-BioNTech (48%) and AstraZeneca (38%) vaccines were most frequently associated with disease onset. The mean latency period from vaccination to symptom onset was 11.03&#x2009;days for PMR and 5.3&#x2009;days for GCA, indicating a temporal relationship. Most of these studies originated from North America and Europe mimicking the global scale of vaccination. Most patients responded well to symptomatic treatment with corticosteroids.<br><br>CONCLUSIONS: There exists a temporal association between COVID-19 mRNA or viral vector-based vaccines and the onset of PMR and GCA. While causality is not proven, this review underscores the need for clinicians to be aware of this potential association to ensure timely diagnosis and treatment, particularly as booster vaccinations continue to be administered. Larger epidemiological studies with long-term follow-up are essential to further explore this association.},
}
@article {pmid41567375,
year = {2025},
author = {Bouayad, A},
title = {An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.},
journal = {International journal of molecular epidemiology and genetics},
volume = {16},
number = {3},
pages = {16-41},
pmid = {41567375},
issn = {1948-1756},
abstract = {COVID-19 vaccination, both in healthy individuals and those with comorbid medical disorders, has proven highly effective in mitigating critical disease progression and mortality rates. Nevertheless, although rare, induction of autoantibodies and new-onset autoimmune conditions in apparently healthy individuals receiving COVID-19 vaccination have been documented. These autoimmune phenomena can be broadly classified into organ-specific autoimmune disorders (e.g., subacute thyroiditis (SAT)) and systemic autoimmune disorders, with many being generally transient (e.g., vaccine-induced thrombotic thrombocytopenia (VITT)) and others causing chronic disability (e.g., systemic vasculitis). Recent studies have highlighted significant associations between COVID-19 vaccine-associated autoimmunity and human leukocyte antigen (HLA) loci. For example, HLA class I alleles such as HLA-B*35 and HLA-C*04 have been associated with COVID-19 vaccine-induced SAT, while HLA class II alleles, including HLA-DRB1*11:04, HLA-DQA1*05:01, HLA-DQB1*02:01, and HLA-DPB1*17:01, have been linked to VITT. This review synthesizes the reported associations between classical HLA loci and COVID-19 vaccine-induced autoimmunity, providing insights into potential mechanisms and clinical implications.},
}
@article {pmid41567412,
year = {2026},
author = {Ssebibubbu, S and Ssekamwa, F and Muhumuza, N and Mulumba, M},
title = {Reforming Uganda's digital health data systems: A policy analysis for inclusive, equitable, and decolonised data governance.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076251408532},
pmid = {41567412},
issn = {2055-2076},
abstract = {Uganda has rapidly digitised many health services, but persistent challenges in data governance - including fragmented systems, variable data quality, and the exclusion of vulnerable populations - hinder effective care and equity. This analysis reviews recent developments (2023-2025) in Uganda's digital health policy and practice, drawing on strategy documents, conference reports, and stakeholder input. It highlights how the COVID-19 pandemic accelerated innovation while exposing systemic weaknesses. For example, the Ministry of Health's (MoH) 2023 strategy explicitly targets data accessibility and integration, and the 2024 guidelines standardise management across the sector. Yet, execution gaps remain due to resource constraints and organisational silos. This article proposes an inclusive data governance framework with five pillars (inclusive governance, equity, interoperability, privacy, and capacity) and recommends concrete actions. By adopting these reforms, Uganda can transform its digital health systems into people-centred, equitable platforms that build trust, protect rights, and advance universal health coverage.},
}
@article {pmid41567589,
year = {2026},
author = {Safi, D and El Rassi, C and Abou Mansour, M and Sleem, B and El Rassi, I and Arabi, M},
title = {Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children: Exploring the Complexities of Pediatric Cardiac Inflammatory Disorders.},
journal = {Sage open pediatrics},
volume = {13},
number = {},
pages = {30502225251411149},
pmid = {41567589},
issn = {3050-2225},
abstract = {Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) are both pediatric inflammatory conditions that pose significant challenges in diagnosis and management due to their overlapping clinical features and distinct pathophysiological profiles. KD is a well-established acute vasculitis that primarily affects children under 5. In contrast, MIS-C is a recently identified condition associated with SARS-CoV-2 infection, typically affecting older children and adolescents. Reported mortality for MIS-C remains below 2%, compared with less than 0.1% for KD, although both can result in significant cardiac morbidity if untreated. This review highlights the critical differences between KD and MIS-C, including their genetic underpinnings, clinical manifestations, and responses to treatment. While KD has a well-established treatment protocol involving intravenous immunoglobulin and aspirin, MIS-C treatment is still evolving. The manuscript underscores the importance of distinguishing between these conditions for accurate diagnosis and tailored treatment, which is crucial for improving patient outcomes.},
}
@article {pmid41568029,
year = {2025},
author = {Shao, F and Zhu, X and Yi, M and Gao, H and Wu, J and Fang, R and Xie, Y and Han, J and Lu, H},
title = {TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions.},
journal = {Frontiers in microbiology},
volume = {16},
number = {},
pages = {1740572},
pmid = {41568029},
issn = {1664-302X},
abstract = {Toll-like receptors (TLRs) play a pivotal role in the innate immune system by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), thereby initiating immune responses against viral infections. TLR agonists have emerged as promising adjuvants to enhance the efficacy of viral vaccines by modulating immune responses, improving antigen presentation, and promoting both humoral and cellular immunity. This review comprehensively summarizes the classification, signaling mechanisms, and immunomodulatory functions of cell-surface and intracellular TLRs. It further discusses the application of TLR agonists as adjuvants in vaccines against major viruses, including HBV, HCV, HIV, SARS-CoV-2, influenza, and flaviviruses. Key findings from preclinical and clinical studies highlight the potential of TLR agonists to overcome immune tolerance, enhance vaccine immunogenicity, and provide broad-spectrum protection. Finally, it points toward the "integration of precision adjuvants with novel vaccine platforms" as a core future direction, laying a theoretical and applied foundation for TLR agonists to become the next generation of viral vaccine adjuvants.},
}
@article {pmid41569003,
year = {2026},
author = {Chopra, I and Yang, J and Yehoshua, A and Mendoza, CF and Di Fusco, M},
title = {Incorporating underreporting of epidemiological burden in COVID-19 models: a targeted literature review.},
journal = {Journal of medical economics},
volume = {29},
number = {1},
pages = {193-212},
doi = {10.1080/13696998.2026.2613591},
pmid = {41569003},
issn = {1941-837X},
mesh = {Humans ; *COVID-19/epidemiology/economics/mortality ; Hospitalization/statistics &amp; numerical data ; *Cost of Illness ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Underreporting of infections, hospitalizations, and deaths can pose challenges to accurately estimating the true burden of COVID-19. Consequently, health burden assessments and economic evaluations may underestimate the public health impact of interventions such as vaccination.<br><br>METHODS: This targeted literature review summarized economic evaluations of COVID-19 that reported having adjusted for underreporting of epidemiological burden. Searches were performed in PubMed through 08/31/2025 with no geographic restrictions. Key study characteristics extracted: country, time period, population, parameters adjusted for underreporting, and the adjustment multipliers used. A high-level quality assessment of evidence was conducted, building on Drummond checklist and CHEERS. Given the qualitative nature of the question and the expected heterogeneity in study designs, the results were summarized qualitatively.<br><br>RESULTS: A total of 20 studies met the inclusion criteria. Of these, 14 (70%) reported numerical adjustment factors, and the remaining 30% did not report a numerical factor. The studies covered diverse geographic regions and time frames, with adjustments applied to parameters such as infections, hospitalizations, and mortality. The study quality was moderate to high. The multipliers used ranged widely across studies: 1 to 5 for mortality, 1 to 5 for hospitalizations, and 1 to 10 for infections, where a value higher than 1.0 reflects an adjustment factor for underreporting. The methodologies used to estimate underreporting varied, including comparisons to excess mortality data, Monte Carlo simulations, and validation against external datasets.<br><br>LIMITATIONS: Most studies used pandemic time horizons.<br><br>CONCLUSIONS: This review identified 14 modelling studies reporting numerical adjustment factors. The studies used diverse approaches and adjustment factors, reflecting variability in data availability and estimation methods. Recognizing and standardizing these adjustments is crucial for improving the accuracy and comparability of health economic analyses that inform policy decisions. Further research could refine underreporting estimates and assess their impact on economic model outcomes.},
}
@article {pmid41569327,
year = {2026},
author = {Al-Shbailat, SA and Alqato, S and Alkhalaileh, AY and Suleiman, R and Zein Eddin, S and Karajeh, A and Al-Shbeilat, RG and Hussein, R and Hatamleh, H and Jaradat, JH and Alsagarat, K and Asfour, LK},
title = {Risk Factors and Outcomes of Immunoglobulin A Vasculitis in Patients with Inflammatory Bowel Disease and vice versa: A Systematic Review of the current literature.},
journal = {Current gastroenterology reports},
volume = {28},
number = {1},
pages = {6},
pmid = {41569327},
issn = {1534-312X},
mesh = {Humans ; *Inflammatory Bowel Diseases/complications/immunology/drug therapy ; Risk Factors ; COVID-19 ; *IgA Vasculitis/immunology/etiology/epidemiology ; *Immunoglobulin A/immunology ; },
abstract = {PURPOSE OF REVIEW: This systematic review sought to thoroughly investigate the relationship between Inflammatory Bowel Disease (IBD) and Immunoglobulin A Vasculitis (IgAV), pinpointing both factors that increase risk and those that provide protection, laying the groundwork for future studies on specific treatments approaches to enhance the wellbeing of patients with IgAV and / or IBD.<br><br>RECENT FINDINGS: There is a new and quickly expanding body of literature on this subject, indicating a rising interest in it. Recent research has sought to investigate the connection between newly emerged viruses, such as COVID-19, or medications like Anti-Tumor Necrosis Factor Alpha (anti-TNF-&#x3b1;), and the development, progression, and treatment approaches of IgAV in IBD patients, and vice versa. Certain recent research is centered on a particular age groups or the condition of the initial illness. IgAV has been observed for numerous years following the diagnosis of IBD, displaying manifestations in the skin, joints, kidneys, and gastrointestinal tract. IBD encompassing Crohn's disease and ulcerative colitis, and IgAV share immunological overlaps via dysregulated IgA production, genetic loci like HLA-DQA1/DQB1, and environmental triggers such as infections amid gut dysbiosis. IgAV often emerges as an IBD sequela or anti-TNF-&#x3b1; therapy complication, with TNF blockade potentially disrupting B-cell maturation, fostering Gd-IgA1 complexes, and neutrophil-driven inflammation. (31) studies encompassing (83) patients with co-occurring IBD and IgAV, predominantly males (60.2%) and younger individuals with confirmed dual diagnoses (95.2%). Compared to UC, more severe CD phenotypes and extended disease duration correlate with increased IgAV risk. Anti-TNF inhibitors appear to substantially contribute to IgAV onset in IBD patients. Most affected individuals develop IBD initially, followed by IgAV, whereas only a minority experience IBD subsequent to IgAV diagnosis. Ceasing anti-TNF-&#x3b1; therapy post-IgAV diagnosis may lead to IgAV resolution but could also trigger disease recurrence. The study's limited sample size has hindered the researchers from reaching conclusions via a meta-analysis. Additionally, the criteria utilized for IBD diagnosis have displayed inconsistency across all studies. Patients with IBD are at higher risk of developing IgAV, thus a high level of suspicion and prompt diagnostic assessment are crucial. To date, there have been no previous systematic reviews or meta-analyses highlighting a link between IgAV and IBD. Therefore, this systematic review is a pivotal endeavor to elucidate the complex relationship between these conditions, shaping future research in this area.},
}
@article {pmid41569498,
year = {2026},
author = {Killassy, N and Arbuthnot, P and Maepa, MB},
title = {Structural mimics of SARS-CoV-2.},
journal = {Infection},
volume = {54},
number = {2},
pages = {575-588},
pmid = {41569498},
issn = {1439-0973},
mesh = {Humans ; *SARS-CoV-2/immunology ; *COVID-19/prevention &amp; control/virology ; COVID-19 Vaccines/immunology ; Antiviral Agents/therapeutic use/pharmacology ; Pandemics/prevention &amp; control ; Animals ; Viral Vaccines/immunology ; Spike Glycoprotein, Coronavirus/immunology/chemistry ; },
abstract = {Since its first detection in 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected approximately 778 million people and claimed 7.1 million lives globally. A deeper understanding of the biology of SARS-CoV-2 was instrumental in facilitating the development of protective vaccines and new therapeutics, as well as evaluating the impact of drug re-purposing to limit the pandemic. To date, approximately 13.64 billion vaccine doses have been administered; with approximately 67% of the global population having completed their primary series of COVID-19 vaccinations. The FDA has authorised the use of several repurposed drugs to combat the disease and while these developments have been instrumental in curbing the pandemic, the approved therapies have shown poor efficacy in cases of severe disease. Furthermore, several vaccine candidates received FDA approval following clinical trials where they proved to be both safe and efficacious. These vaccines were sanctioned for emergency roll-out to the global population, conferring herd immunity and reducing both infections and related mortalities. However, these vaccines are not without flaws and are limited by short term immune responses and poor efficacy against emerging variants, which has resulted in slip-through infections. Hence, efforts to develop potent drugs and vaccines are continuing. In these efforts, physiologically relevant models of SARS-CoV-2 infection are critical. This review describes available SARS-CoV-2 particle mimics, their contribution to COVID-19 research and the development of new vaccines and therapies.},
}
@article {pmid41569821,
year = {2026},
author = {Hesketh, KR and Smith, AD and Amichay, Y and van Sluijs, EMF},
title = {Correlates of Parental Physical Activity: A Quantitative Systematic Review.},
journal = {Journal of physical activity &amp; health},
volume = {23},
number = {5},
pages = {618-638},
doi = {10.1123/jpah.2025-0604},
pmid = {41569821},
issn = {1543-5474},
mesh = {Humans ; *Parents/psychology ; *Exercise ; Child ; Cross-Sectional Studies ; Child, Preschool ; Self Report ; Female ; Adolescent ; Infant ; },
abstract = {BACKGROUND: Despite the benefits of physical activity (PA), evidence suggests around 25% of adults fail to meet PA guidelines, parents, and mothers in particular, and engage in less PA on average than their childless peers. This review sought to determine the correlates of parental PA, stratifying evidence by self-report and device-based measures.<br><br>METHODS: Quantitative studies (cross-sectional and longitudinal) investigating associations between correlates and parental PA (ie,&#xa0;parents with children aged 0-18&#xa0;y) were identified across 4 databases (MEDLINE, EMBASE, PsycINFO and Scopus) up to October 2024. Correlates (assessed in 3 or more studies) and direction of associations were extracted, described, and synthesized narratively according to the socioecological model (individual, interpersonal, organizational, environmental, societal).<br><br>RESULTS: Of 4632 studies identified, 269 full texts were assessed and 105 studies included in the review. A total of 117 correlates were identified across all studies (103 for self-report measures, 55 for device-based). 53 correlates were assessed in 3/+ independent associations (n = 51 self-report, n = 14 device, n = 12 both). Consistently, partner PA was positively associated with parent PA regardless of measure used. Child PA, pet ownership, and environmental aesthetics were positively associated with (mothers') PA, whereas car ownership was negatively associated with PA. Only one policy-level factor (COVID-19 restrictions) was assessed, being negatively associated with parental PA.<br><br>CONCLUSIONS: Family-based correlates of PA were positively associated with parental PA, suggesting these may support wider family engagement in PA. Evidence from fathers and from low- and middle-income countries is needed to gain a better understanding of parental PA in these groups.},
}
@article {pmid41572466,
year = {2026},
author = {Kothandan, SV and Basu, S and Singh, S},
title = {Dry Eye Disease After Ocular or Systemic Infection: A Systematic Review.},
journal = {Eye &amp; contact lens},
volume = {52},
number = {2},
pages = {83-91},
doi = {10.1097/ICL.0000000000001236},
pmid = {41572466},
issn = {1542-233X},
support = {N/A//Hyderabad Eye Research Foundation/ ; },
mesh = {Humans ; *Dry Eye Syndromes/etiology/diagnosis ; *Eye Infections/complications ; COVID-19/complications ; Tears ; },
abstract = {PURPOSE: To study the characteristics of dry eye disease (DED) secondary to ocular or systemic infections.<br><br>METHODS: PubMed, Scopus, and Cochrane databases were systematically reviewed for DED development after systemic and ocular infections. The severity of DED symptoms and signs, type of infection, and management outcomes were analyzed.<br><br>RESULTS: Of the 28 included studies, eight were related to HIV infection, five had hepatitis C, four to COVID-19, and 11 studies had DED secondary to herpes keratitis, Mycoplasma pneumoniae, viral conjunctivitis, Chlamydia infection, Mycobacterium leprae, and Chikungunya infections. The organisms implicated in conjunctivitis associated with DED were Coxsackie A24virus, Staphylococcus, and Mycoplasma. There were no immunocompromised patients in any of the studies except HIV. Nine studies established DED diagnosis based on symptoms alone, seven on signs alone, and 12 on symptoms and signs (at least abnormal Schirmer or tear break-up time, but not DEWS II criteria). The severity of DED symptoms was usually mild. HIV and hepatitis C showed no difference in tear volume and stability between cases and healthy controls. Advanced stages of hepatitis (stage 4 to stage 6) showed worse tear film parameters than the initial stages. Tear volume and stability were affected in 1/5th of patients post-COVID-19. Absolute tear deficiency (zero Schirmer) was reported in two patients after Epstein-Barr virus and HIV infection that improved with intravenous acyclovir, cyclosporin A, and prednisolone in EBV infection only. Very few studies reported the management of postinfectious DED with artificial tears and had fair outcomes.<br><br>CONCLUSION: Bacterial and viral infections can have DED as sequelae, although the infectious agent has not been isolated from the ocular surface in reported studies. DED is usually mild to moderate symptomatically, and tear film parameter levels do not meet DEWS II diagnostic criteria. The nonuniformity in reporting disease duration, tear film changes, and DED symptoms makes it difficult to understand the role of infection in causing DED.},
}
@article {pmid41573202,
year = {2025},
author = {Zhang, Y and Chen, Z and Sun, L and Guo, W},
title = {An overview of hypopituitarism's causes.},
journal = {Frontiers in endocrinology},
volume = {16},
number = {},
pages = {1695833},
pmid = {41573202},
issn = {1664-2392},
mesh = {Humans ; *Hypopituitarism/etiology/diagnosis/therapy ; Pituitary Neoplasms/complications ; COVID-19/complications ; Adenoma/complications ; Immunotherapy/adverse effects ; },
abstract = {The widespread application of tumor therapies such as immune checkpoint inhibitors and the emergence of new infectious diseases such as COVID-19 are promoting the continued expansion of the cause spectrum of hypopituitarism, making its scope significantly beyond traditional causes such as pituitary tumors and craniocerebral trauma. Faced with this evolution, a comprehensive and in-depth understanding of its etiology has become a top priority, which has also put forward new requirements for clinical diagnosis and differential diagnosis. This review aims to systematically sort out and deeply explore the etiology and pathogenesis of this disease. The content not only covers traditional factors such as pituitary tumors, radiation injury, and pituitary surgery, but also the latest progress in emerging fields such as immunotherapy, new infections, and autoimmunity. It aims to provide reliable reference for clinicians' diagnosis and treatment practice and lay a theoretical foundation for future research in this field.},
}
@article {pmid41573445,
year = {2025},
author = {Verma, M and Maan, HS and Konatam, S and Verma, Y and Kumar, R and Chaurasia, D and Dave, L and Sharma, S},
title = {Geographical and Ecological Drivers of Zoonotic Viral Spillover: A Review of Emerging and Re-emerging Outbreaks.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e99820},
pmid = {41573445},
issn = {2168-8184},
abstract = {Over the past two decades, outbreaks of zoonotic viruses have become increasingly frequent and severe, posing substantial threats to public health systems and the global economy. The viruses responsible for these outbreaks, such as SARS-CoV, MERS-CoV, Zika, Ebola, Nipah, avian influenza, and, most recently, SARS-CoV-2, typically originate in wildlife, highlighting the complex relationship between ecological systems and human activities. Human-wildlife interactions have markedly increased due to disruptions in environmental and geographic boundaries, primarily driven by urbanization, deforestation, intensified agricultural practices, and climate change. These factors contribute to an environment that facilitates zoonotic transmission spillover. This narrative review summarizes current research on the ecological, geographic, and human factors influencing zoonotic virus transmissions. It emphasizes how these viruses adapt to human hosts and cross species barriers via direct contact, vector-borne transmission, intermediate carriers, and environmental contamination. Moreover, the review discusses how the genomic plasticity of viruses enhances their transmissibility and facilitates adaptation to new hosts, thereby increasing the risk of epidemics and pandemics. The review further underscores the importance of ecological boundaries in mitigating spillover events and advocates for a One Health approach that integrates human, animal, and environmental health. This approach is essential for predicting, detecting, and preventing future outbreaks. In conclusion, the review emphasizes the importance of interdisciplinary research, proactive surveillance, habitat preservation, and policy interventions that address the underlying ecological factors contributing to zoonotic outbreaks. Restoring ecological barriers and implementing sustainable practices to minimize the interaction between wildlife and humans, while bolstering global biosecurity, are essential measures to mitigate the risk of future pandemics.},
}
@article {pmid41573565,
year = {2025},
author = {Chiyyeadu, A and Khan, B and Ehrhardt, K and Büning, H and Morgan, M and Schambach, A},
title = {Therapeutic antibody delivery: vector tools to boost efficacy and affordability.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1714390},
pmid = {41573565},
issn = {1664-3224},
mesh = {Humans ; *Genetic Vectors/genetics ; *SARS-CoV-2/immunology ; Animals ; *COVID-19/immunology/therapy ; *Gene Transfer Techniques ; Genetic Therapy/methods ; Dependovirus/genetics ; Lentivirus/genetics ; },
abstract = {Antibody (Ab)-based therapeutics have become powerful tools across diverse disease areas, with advances in bioengineering giving rise to next-generation molecules designed to outperform conventional Abs. Yet, large-scale production and purification of such complex proteins remain costly and can restrict patient access. A promising alternative is to improve in vivo expression capabilities, which will reduce manufacturing burdens and improve safety and tolerability. Multiple gene delivery platforms - ranging from mRNA and viral vectors to engineered cell therapies - have matured considerably, as a direct result of years of clinical experience and growing regulatory confidence. The rapid deployment of mRNA vaccines against SARS-CoV-2, the clinical success of adeno-associated virus (AAV)- and lentiviral-based interventions, and the approval of chimeric antigen receptor (CAR)-T cell therapies highlight the potential of these technologies to transform how we deliver Ab therapeutics. While these approaches hold the promise to treat genetic aberrations in patients, they may also contribute considerably to advancing conventional Ab therapeutics against viral infections and other diseases through local persistence of the proteins. Looking forward, in situ expression may confer even more benefits for engineered Ab-like molecules, thereby compensating for possibly shorter half-lives and overcoming challenges in in vitro production and purification. Therefore, in this review, we critically evaluate how these established and emerging gene therapy platforms can be harnessed to expand access, and discuss possibilities to improve in situ availability through the choice of transient or stable expression systems to increase the efficacy of Abs and other therapeutic proteins. Furthermore, we explore the current landscape of technological advancements, identify key translational challenges, and project future directions for optimizing these approaches towards widely applicable clinical interventions.},
}
@article {pmid41573583,
year = {2025},
author = {Liu, S and Zhao, Z and Li, Y and Tan, Y and Tian, H and Xie, F},
title = {When viral infections meet the anti-MDA5 antibody-positive dermatomyositis.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1649489},
pmid = {41573583},
issn = {1664-3224},
mesh = {Humans ; *Interferon-Induced Helicase, IFIH1/immunology ; *Dermatomyositis/immunology ; *Autoantibodies/immunology/blood ; *SARS-CoV-2/immunology ; *Virus Diseases/immunology/complications ; Lung Diseases, Interstitial/immunology ; *COVID-19/immunology/complications ; Animals ; },
abstract = {Anti-melanoma differentiation-related gene 5 (MDA5) antibody-positive dermatomyositis (anti-MDA5[+] DM) is recognized as a distinct subtype of dermatomyositis, characterized by its frequent association with interstitial lung disease (ILD), particularly rapidly progressive ILD (RP-ILD), which is associated with a poor prognosis and high mortality. MDA5 functions as a cytoplasmic sensor for viral double-stranded RNA. The expression level of anti-MDA5 antibodies is positively correlated with disease severity. Notably, anti-MDA5 antibodies have been detected in patients infected with SARS-CoV-2. While the mechanisms underlying the generation of anti-MDA5 antibodies and their pathogenic role remain incompletely understood, accumulating data support the hypothesis that viral infections may trigger the production of these antibodies. This review provides a comprehensive analysis of the interplay between anti-MDA5 antibodies and viral infections in patients with anti-MDA5[+] dermatomyositis (DM), with a focus on the potential mechanisms by which viral infections induce autoantibody formation.},
}
@article {pmid41573792,
year = {2025},
author = {Kiggundu, R and Waswa, JP and Mwanja, H and Hope, M and Kambugu, A and Kakooza, F and Byonanebye, DM},
title = {Leveraging disease outbreak news to strengthen the global response to antimicrobial resistance: a call for action.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1710596},
pmid = {41573792},
issn = {2296-2565},
mesh = {Humans ; COVID-19/epidemiology ; *Disease Outbreaks/prevention &amp; control ; *Drug Resistance, Microbial ; *Global Health ; Public Health ; World Health Organization ; },
abstract = {Antimicrobial resistance (AMR) is an escalating global health threat, with low- and middle-income countries (LMICs) bearing the greatest burden as healthcare facilities become breeding grounds for resistant pathogens, leading to increased morbidity, mortality, and straining of already limited resources. The World Health Organization's Disease Outbreak News (DONs) has proven invaluable for early warnings and coordinated responses to infectious disease outbreaks like Ebola and COVID-19, yet AMR events remain largely absent from this system, leading to under-detection, limited global visibility, and ineffective interventions. In this paper, we review the historical evolution of DONs, its supporting frameworks, and the dynamics of AMR outbreaks in LMIC healthcare settings to explore how DONs could be adapted for AMR. We recommend standardizing AMR outbreaks reporting, integrating DONs into response efforts, linking AMR surveillance to DONs workflows, and expanding the definition of Public Health Emergencies of International Concern (PHEIC) to include high-morbidity AMR events, steps that would elevate AMR from a "silent pandemic" to a visible priority.},
}
@article {pmid41576591,
year = {2026},
author = {Ali, M and Younis, AB and Duru, CI and Sherchan, SP},
title = {A review of AI/ML approaches in wastewater surveillance advancement.},
journal = {The Science of the total environment},
volume = {1015},
number = {},
pages = {181364},
doi = {10.1016/j.scitotenv.2026.181364},
pmid = {41576591},
issn = {1879-1026},
mesh = {*Artificial Intelligence ; *Wastewater/virology ; *Machine Learning ; Predictive Learning Models ; Random Forest ; *Wastewater-Based Epidemiological Monitoring ; Long Short Term Memory ; COVID-19/epidemiology ; Prediction Algorithms ; *Environmental Monitoring/methods ; Humans ; Data Analytics ; },
abstract = {Wastewater-based epidemiology (WBE) has emerged as a powerful tool for early detection and monitoring of infectious diseases, particularly during pandemics such as COVID-19. This study systematically evaluates the application of artificial intelligence (AI) and machine learning (ML) models in WBE over the past five years, focusing on their effectiveness in pathogen detection and disease trend forecasting. Various supervised, unsupervised, deep learning, and time-series models were compared based on their predictive accuracy, scalability, interpretability, computational demands, and real-time feasibility. Comparative analysis showed that Random Forest (RF) achieved R[2] values of 0.80 and Root Mean Square Error (RMSE) 0.54 for COVID-19 trend forecasting, outperforming linear regression. Support Vector Machines (SVM) improved pathogen classification accuracy by ∼20% compared with traditional analytical techniques. Artificial Neural Networks (ANN) estimated pathogen prevalence with R = 0.81-0.92 and mean squared, while Long Short-Term Memory (LSTM) networks achieved R[2] ≈ 0.81 (test) and 0.94 (train) for multi-community forecasting. Time-series machine learning models (TSML) frameworks consistently produced lower RMSE and Mean Absolute Error (MAE) values than ARIMAX models, confirming their real-time prediction power. Unsupervised models like K-means clustering supported outbreak pattern identification, when labeled data were limited. Additionally, a decision-support framework was proposed to guide model selection based on prediction objectives, data type, and temporal dependencies. The findings emphasize the importance of integrating hybrid modeling approaches and environmental metadata to enhance WBE systems, and they offer a foundation for real-time, adaptive surveillance strategies.},
}
@article {pmid41577338,
year = {2026},
author = {Yang, Z and Yan, H and Wang, S and Liu, Y and Luo, Y and Tang, Y and Zhang, T},
title = {Moral injury in nurses during COVID-19: A systematic review and meta-analysis.},
journal = {Nursing ethics},
volume = {33},
number = {3},
pages = {945-962},
doi = {10.1177/09697330251407217},
pmid = {41577338},
issn = {1477-0989},
mesh = {Humans ; *COVID-19/psychology/nursing ; *Nurses/psychology ; *Morals ; SARS-CoV-2 ; },
abstract = {BackgroundThe COVID-19 pandemic has posed unprecedented challenges for nurses, including resource shortages, heavier workloads, and ethical decision-making pressures, putting them at high risk for moral injury. This threatens their physical and mental health, job stability, and the quality of care.AimThe aim was to systematically assess the level of moral injury among nurses during the COVID-19 pandemic.MethodsA comprehensive search was conducted on 12 databases (PubMed, Web of Science, MEDLINE, ProQuest, Embase, CINAHL, Scopus, PsycINFO, CBM, CNKI, VIP, WanFang Data) for cross-sectional studies published up to 20 July 2025, that reported the level of moral injury among nurses using the Moral Injury Symptoms Scale-Health Professionals Version. A systematic review and meta-analysis were conducted. Two researchers independently screened the literature, extracted data, and assessed methodological quality. The pooled mean score was calculated using random-effects or fixed-effects models, with subgroup analysis to explore heterogeneity.Ethical considerationsEthical approval was not required as the review synthesized publicly available data.ResultsThis study included 16 articles, involving 5824 participants. The meta-analysis showed that the pooled mean total MISS-HP score for nurses was 42.12 (95% CI: 40.70-43.53). Among the dimensions, the pooled mean score for Loss of religion/spiritual faith was the highest at 5.68 (95% CI: 4.61-6.74), while the pooled mean score for religious struggles was the lowest at 2.26 (95% CI: 1.13-3.40). Subgroup analysis results indicated significant differences in moral injury levels among nurses based on Survey year and department (p < .001).ConclusionsUnder the context of the COVID-19 pandemic, nurses experienced moderate to high levels of moral injury, particularly during the early stages of the pandemic in 2020, with emergency department nurses being most affected. To support nurses' well-being and mental health, healthcare institutions should strengthen ethical support systems, improve management, and consider the role of religion/spiritual faith in alleviating moral injury.},
}
@article {pmid41577399,
year = {2026},
author = {José Álvarez García, F and Iofrío de Arce, A and Álvarez Aldeán, J and Garrote Llanos, E and López Granados, L and Navarro Gómez, ML and Pineda Solas, V and Rivero Calle, I and Ruiz-Contreras, J and Salamanca de la Cueva, I and Serrano Marchuet, P and , },
title = {Vaccination and immunization schedule of the Pediatric Spanish Association: 2026 recommendations.},
journal = {Anales de pediatria},
volume = {104},
number = {1},
pages = {504051},
doi = {10.1016/j.anpede.2025.504051},
pmid = {41577399},
issn = {2341-2879},
mesh = {Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Infant, Newborn ; *Immunization Schedule ; Pediatrics ; Spain ; *Vaccination/standards ; Male ; },
abstract = {The 2026 Vaccination and Immunization Schedule recommended by the Spanish Association of Pediatrics (AEP) for children, adolescents and pregnant women residing in Spain includes the following new features: introduction of routine vaccination against hepatitis A with a single-dose schedule at 12-15 months; universal vaccination against influenza in children from 6 months and adolescents up to 17 years of age; catch-up vaccination and reengagement campaigns added to the routine immunization schedule and a new table featuring the vaccinations recommended for specific chronic diseases or risk conditions. The following recommendations from the 2025 schedule, among others, are maintained: immunization with nirsevimab in infants younger than 6 months, or up to 12 months in the case of preterm infants born before 35 weeks of gestation and up to 24 months in children with risk factors; routine vaccination against meningococcal disease (MenB in infancy [starting at 2 months] and at 12 years, plus booster doses for those vaccinated in childhood with 4CMenB; MenACWY at 4 months, 12 months and 12 years); advancing the second doses of MMR and varicella vaccines to 24 months and the Tdap at 10-12 years; and vaccination against SARS-CoV-2 for children older than 6 months with risk factors. During pregnancy, vaccination with Tdap and against influenza and COVID-19 is indicated. Vaccination against RSV in pregnant women is available, although not funded, as it is not currently approved as a public health strategy.},
}
@article {pmid41577420,
year = {2026},
author = {Schuster, AM and Alwan, NA and Callard, F and Chen, EYH and Gilbody, S and Graham, BM and Hatch, SL and Jones, E and Jordan, A and Knapp, M and López-Jaramillo, C and Nakimuli-Mpungu, E and Pathare, S and Ressler, KJ and Wessely, S and White, LA and , and Jones, PB},
title = {The implications of the COVID-19 pandemic for clinical mental health care.},
journal = {The lancet. Psychiatry},
volume = {13},
number = {2},
pages = {140-161},
doi = {10.1016/S2215-0366(25)00247-0},
pmid = {41577420},
issn = {2215-0374},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Mental Health Services/organization &amp; administration ; *Mental Disorders/therapy/epidemiology ; SARS-CoV-2 ; Mental Health ; Post-Acute COVID-19 Syndrome ; Pandemics ; },
abstract = {A Position Paper published in The Lancet Psychiatry in 2020 suggested an agenda for research about the effects of the COVID-19 pandemic on mental health, following which an interdisciplinary Lancet Psychiatry standing commission was established in 2022 to examine the emerging evidence and refine recommendations for more research. In this first Series paper from the standing commission, we focus on changes in the delivery of clinical mental health care during the COVID-19 pandemic. The second paper in the Series focuses on public mental health and policy perspectives, and the third will address neuropsychiatric consequences of infection by SARS-CoV-2. Evidence from high-quality longitudinal studies with pre-pandemic baseline data, controlled intervention trials, or systematic reviews took time to accrue. During the early months of the COVID-19 pandemic, symptoms of anxiety and depression became more prevalent, and many mental health services were compromised by pandemic-related factors; however, whether the COVID-19 pandemic accelerated pre-existing long-term trends of increasing incidence of mental health disorders, especially in children and adolescents, is unclear. Little research has been done in low-income and middle-income countries, or regarding post-COVID-19 condition (also known as long COVID), which emerged as a multisystem condition with mental health implications. Vulnerable populations, including socioeconomically disadvantaged and minoritised groups, faced disproportionate mental health impacts and limited access to care during the COVID-19 pandemic, reflecting systemic, pre-pandemic inequalities. Bold implementation of existing evidence-based mental health support for vulnerable communities, ambitious trials of novel interventions, and systematic pooling of rapidly accumulating evidence about best healh care should be priorities in future pandemics.},
}
@article {pmid41577421,
year = {2026},
author = {Nakimuli-Mpungu, E and Arango, C and Dandona, R and Ford, T and John, A and Jordan, A and Cherop, R and Kola, L and López-Jaramillo, C and Schuster, AM and Knapp, M and Walbaum, M and Opiepie, K and Musoro, F and White, LA and Martsenkovskyi, D and Michael, BD and O'Connor, R and , and Jones, PB},
title = {Policy and public health implications for mental health after the COVID-19 pandemic.},
journal = {The lancet. Psychiatry},
volume = {13},
number = {2},
pages = {162-174},
doi = {10.1016/S2215-0366(25)00358-X},
pmid = {41577421},
issn = {2215-0374},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; *Public Health ; *Mental Health Services/organization &amp; administration ; *Mental Health ; *Health Policy ; SARS-CoV-2 ; Public Health Infrastructure ; Pandemics ; },
abstract = {The COVID-19 pandemic revealed essential weaknesses in mental health systems and intensified existing inequities, highlighting the need for a comprehensive assessment of policy responses and strategies for future resilience. Guided by four questions relating to system adaptations, approaches to inequities, financing strategies, and evidence gaps, we synthesised evidence from a structured literature search (2020-24), expert consultation, and lived experience. We found that public health systems embedded infodemic management, expanded digital services, and mobilised community workforces, but responses varied in equity and effectiveness. Although gender, age, socioeconomic, and racial disparities worsened during the COVID-19 pandemic, social protection, gender-sensitive policies, school-based services, and culturally adapted interventions showed promise. High-income countries buffered shocks with welfare measures while low-income and middle-income countries faced sharp fiscal constraints. Few studies evaluated cost-effectiveness or equity impacts of psychosocial interventions. Building resilient, equitable mental health systems requires integrated policies spanning communication, digital and community care, gender-responsive and youth-responsive strategies, and sustainable financing, alongside investment in longitudinal and cross-national research.},
}
@article {pmid41577930,
year = {2026},
author = {Ochoa-Gutierrez, V and Saiko, G},
title = {Pulse Oximeters: Accuracy and Artifacts.},
journal = {Advances in experimental medicine and biology},
volume = {1498},
number = {},
pages = {277-283},
pmid = {41577930},
issn = {0065-2598},
mesh = {Humans ; *Oximetry/instrumentation/methods/standards ; *Artifacts ; *COVID-19/blood/epidemiology ; SARS-CoV-2 ; Skin Pigmentation ; Calibration ; Oxygen Saturation ; *Oxygen/blood ; Reproducibility of Results ; },
abstract = {Oximetry is used to quantify the presence of oxygen in human blood within soft tissues of the human body. Among multiple implementations of this technology, pulsatile oxygen saturation (SpO2) is a core medical technology and is being rapidly adopted in consumer health. However, despite its long history of clinical use, recent findings indicate that the accuracy of pulse oximetry may be affected by various factors and biases. For example, the COVID-19 pandemic showed that pulse oximeters exhibited flaws in accuracy due to the skin pigmentation of patients with darker skin. Thus, the future of this technology, particularly in consumer health devices, needs to be built on foundations that account for such biases. This chapter reviews the principles of pulse oximetry, sources of its artifacts, calibration methods, and the factors that may cause inaccuracy in pulse oximeters, particularly pertinent to two-wavelength pulse oximetry. Drawing upon recent research and clinical insights, we review the multifaceted nature of pulse oximetry biases, including motion artifacts, skin pigmentation, body mass index, environmental variables, device calibration, and nail polish, among others.},
}
@article {pmid41578296,
year = {2026},
author = {Rubini, E and Trentin, M and Maffi, P and Aammar, B and Gaievskyi, S and Bahattab, A and Lamine, H and Kordi-Kaiser, M and Staub, K and Ragazzoni, L},
title = {Challenges in healthcare facilities' response to past outbreaks: a systematic review of reviews.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {141},
pmid = {41578296},
issn = {1472-6963},
support = {101168124//HORIZON EUROPE Framework Programme/ ; },
mesh = {Humans ; *Disease Outbreaks/prevention &amp; control ; COVID-19/epidemiology ; Europe/epidemiology ; *Health Facilities ; Pandemic Preparedness ; Pandemics ; SARS-CoV-2 ; Surge Capacity ; },
abstract = {INTRODUCTION: The frequency of infectious diseases outbreaks is increasing, but these challenges are not always thoroughly investigated. To date, no systematic reviews of reviews have comprehensively mapped the challenges and gaps faced during past epidemics and pandemics in Europe at healthcare facility level. This systematic review of reviews aims at filling this gap and at contributing to documenting the challenges and informing policy recommendations. METHODS : This review was conducted within the Horizon Europe project PREPSHIELD. The search was conducted in October 2024 on PubMed, Scopus, and Web of Science. Reviews published in English between the years 2009–2024, reporting data on COVID-19, H1N1, influenza or seasonal flu, measles, or Mpox, and documenting gaps or challenges in the response to these outbreaks at healthcare facility level were included. RESULTS : A total of 21 reviews were included: they were systematic, scoping, narrative, rapid, or integrative. The studies included in the reviews were mostly conducted in the United Kingdom, Italy, Spain, and France. The studies included different levels of healthcare facilities, namely hospitals, primary healthcare, and prehospital settings. Findings were classified according to the 4S surge capacity framework and were related to staff (n = 18), stuff (n = 14), space (n = 7), and system (n = 18). The most reported challenges in the included reviews were increased workload, mental health, and task shifting or redeployment, resource shortages, intensive care unit/emergency department space limitations and repurposing, and telemedicine challenges. CONCLUSION : Key issues described highlight the need for training, peer-to-peer support mechanisms, and improved inter-institutional collaboration. Technology was described as both an opportunity and a challenge in pandemic response if not adequately supported by health staff training. A whole-of-society strategy, combining all-hazards and hazard-specific approaches, and moving beyond crisis mode, can strengthen future outbreak preparedness and response.},
}
@article {pmid41578455,
year = {2026},
author = {Ghoshal, UC and Singh, R and Goenka, MK},
title = {Post-Coronavirus Disease (COVID)-19 Irritable Bowel Syndrome: What We've Learned So Far.},
journal = {Neurogastroenterology and motility},
volume = {38},
number = {1},
pages = {e70250},
doi = {10.1111/nmo.70250},
pmid = {41578455},
issn = {1365-2982},
mesh = {Humans ; *Irritable Bowel Syndrome/epidemiology/physiopathology/etiology ; *COVID-19/complications ; SARS-CoV-2 ; Pandemics ; Post-Infectious Disorders ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND: The COVID-19 pandemic has unveiled a hidden epidemic of disorders of gut-brain interaction (DGBIs), notably post-infection irritable bowel syndrome (PI-IBS), driven by SARS-CoV-2 GI tropism and pandemic stressors.<br><br>PURPOSE: This review synthesizes and critically appraises current evidence on the prevalence, clinical spectrum, and predictors of post-COVID-19 IBS, integrating mechanistic insights. Topics discussed in this review will advance understanding of pathophysiological mechanisms, identify therapeutic targets, inform phenotype-tailored management and clinical care, and outline research priorities for post-COVID-19 IBS.<br><br>METHODS: A narrative review was performed by the authors.<br><br>KEY RESULTS: Recent evidence indicates that approximately 7.2% of individuals develop IBS after SARS-CoV-2 infection, with 2.6-fold higher odds vs. non-infected controls. At the population level, a nationally representative U.S. survey (>&#x2009;160,000 adults) showed a pandemic-era surge in IBS prevalence (predominantly IBS-M) and a modest increase in chronic idiopathic constipation (CIC), while other Rome IV DGBIs remained stable. Mechanisms are multifactorial, involving ACE2-linked epithelial/neuromuscular effects, persistent low-grade inflammation, microbiota dysbiosis with reduced short-chain fatty acids, altered serotonin signaling, barrier dysfunction, and psychosocial stress acting along the gut-brain axis. Emerging data indicate dyspnea and depression further mediate the COVID-19-to-IBS pathway, underscoring biopsychosocial endotypes.<br><br>CONCLUSIONS AND INFERENCES: This review indicates that following infection with SARS-CoV-2, DGBI, particularly IBS, occurs in 7.2% patients on follow-up. Clinically, a positive diagnosis framework and phenotype-tailored, multidisciplinary care are recommended. Future studies on post-infection IBS including post-COVID-19 IBS should be undertaken using upcoming Rome V criteria, controlling for confounding factors, and defining mechanistic endotypes to unlock precision therapies.},
}
@article {pmid41579008,
year = {2026},
author = {Vera-Cáceres, CH and García-Huguet, M and Gil de Genover, A and Sagula, SD and Martín Muñóz, L and López Domínguez, D},
title = {Dysautonomia after COVID-19 infection: A case report.},
journal = {Neurologia},
volume = {41},
number = {1},
pages = {101891},
doi = {10.1016/j.nrleng.2025.101891},
pmid = {41579008},
issn = {2173-5808},
mesh = {Humans ; COVID-19/complications ; Female ; Middle Aged ; *Primary Dysautonomias/etiology ; SARS-CoV-2 ; *Guillain-Barre Syndrome/complications/etiology/diagnosis ; Pandemics ; Magnetic Resonance Imaging ; Posterior Leukoencephalopathy Syndrome/etiology/diagnostic imaging ; Tomography, X-Ray Computed ; Inappropriate ADH Syndrome/etiology ; },
abstract = {INTRODUCTION: This case report discusses a case of a patient who experienced acute autonomic dysfunction during the parainfectious phase of COVID-19, attributed to Guillain-Barre Syndrome (GBS). This is the first well-documented case of such an association.<br><br>CASE PRESENTATION: A 64-year-old woman, previously infected with COVID-19, was admitted to the emergency department due to altered mental status. Brain computed tomography (CT) revealed bilateral occipital diffuse hypodensity. Throughout her hospitalization, she exhibited elevated blood pressure necessitating intravenous treatment. The initial brain MRI revealed T2-weighted image hyperintensity at the parietal and occipital levels, indicative of vasogenic edema. These neuroimaging findings were suggestive of posterior reversible encephalopathy syndrome (PRES). Euvolemic hyponatremia with concurrent low serum osmolality and high urine osmolality and sodium was observed, indicating a syndrome of inappropriate antidiuretic hormone (SIADH). Throughout the patient's stay, her level of consciousness exhibited significant improvement. However, she developed ascending symmetrical limb weakness and progressive loss of reflexes, along with a severe motor deficit and gait disturbance, accompanied by arterial blood pressure fluctuations and other signs of autonomic dysfunction. Clinical manifestations, neurophysiological findings, and laboratory results were indicative of Guillain-Barre Syndrome (GBS), leading to a conclusive diagnosis of GBS with dysautonomia triggered by a COVID-19 infection.<br><br>CONCLUSION: This case reveals the relevance of diagnosing autonomic dysfunction (including PRES) as the initial manifestation of GBS linked to COVID-19 infection and the importance of early diagnosis to prevent potential complications.},
}
@article {pmid41579048,
year = {2026},
author = {Chao, CM and Liu, JW and Tang, HJ and Lai, CC},
title = {The escalating threat of multidrug-resistant organisms: COVID-19 impact, global burden, and the Taiwanese experience.},
journal = {Expert review of anti-infective therapy},
volume = {24},
number = {1},
pages = {63-73},
doi = {10.1080/14787210.2026.2623135},
pmid = {41579048},
issn = {1744-8336},
mesh = {Humans ; Taiwan/epidemiology ; *COVID-19/epidemiology ; *Anti-Bacterial Agents/therapeutic use ; Pandemics ; *Drug Resistance, Multiple, Bacterial ; SARS-CoV-2 ; Cross Infection/epidemiology/drug therapy/microbiology ; Global Health ; Antimicrobial Stewardship ; Infection Control/methods ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has intensified global health challenges, including a silent but escalating crisis: multidrug-resistant organisms (MDROs). As healthcare systems strained under viral outbreaks, infection control and antimicrobial stewardship efforts suffered, accelerating the spread of antimicrobial resistance (AMR).<br><br>AREAS COVERED: This review examines the indirect effects of the COVID-19 pandemic on AMR, emphasizing changes in antibiotic utilization, healthcare-associated infections, and resistance trends. Global and regional epidemiological data are presented, with a special focus on Taiwan's evolving MDROs landscape, clinical burden, and strategic responses.<br><br>EXPERT OPINION: COVID-19&#xa0;has both exposed and intensified vulnerabilities in AMR control. While the pandemic fostered certain infection control practices, it also disrupted antimicrobial oversight, leading to surges in MDROs prevalence. Taiwan's experience underscores the value of coordinated guidelines, real-time diagnostics, and artificial intelligence-driven stewardship. Rebuilding and future-proofing AMR responses requires integrated global policies, sustained surveillance, and innovation in diagnostics and therapeutics. Unless comprehensive action is taken, MDROs may emerge as the defining post-pandemic threat to modern medicine.},
}
@article {pmid41580734,
year = {2026},
author = {Fang, H and Wang, Q},
title = {The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.},
journal = {Journal of translational medicine},
volume = {24},
number = {1},
pages = {266},
pmid = {41580734},
issn = {1479-5876},
mesh = {Humans ; *COVID-19/complications/epidemiology ; SARS-CoV-2 ; Pandemics ; *Diabetes Mellitus/epidemiology/physiopathology/etiology ; *Diabetes Mellitus, Type 2/epidemiology/physiopathology ; Post-Acute COVID-19 Syndrome ; Risk Factors ; Biomarkers/metabolism ; },
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has presented extraordinary challenges to global public health, with impacts reaching beyond acute respiratory manifestations to include long-term metabolic disturbances. Emerging evidence indicates a significant link between SARS-CoV-2 infection and the onset of diabetes mellitus, establishing this condition as a major element of the post-acute sequelae of COVID-19, often referred to as Long COVID. MAIN BODY: This review synthesizes epidemiological findings that demonstrate a elevated incidence of new-onset diabetes following COVID-19, particularly among certain high-risk demographic groups. We examine the molecular mechanisms underpinning this association, such as viral entry into pancreatic β-cells via ACE2 receptors, systemic inflammation leading to insulin resistance, and the potential diabetogenic effects of glucocorticoids used in COVID-19 treatment. Furthermore, this review outlines biomarker profiles that distinguish COVID-19-associated diabetes from traditional type 2 diabetes, underscoring important pathophysiological differences. Additionally, we evaluate advances and ongoing challenges in developing predictive risk models that combine clinical and molecular data to identify individuals at elevated risk for post-COVID diabetes. CONCLUSIONS: By integrating multidisciplinary evidence, this comprehensive narrative review aims to guide future research and shape clinical approaches for early detection, prevention, and management of diabetes following COVID-19, thereby confronting a latent health crisis emerging within the broader pandemic context.},
}
@article {pmid41581920,
year = {2026},
author = {Morimoto, Y and Higashi, H and Izumi, H and Tomonaga, T and Nishida, C and Yamato, H and Eguchi, H and Kawanami, S and Suzuki, K and Yatera, K and Nakata, A},
title = {[Factors that contribute to the death/severity and onset of COVID-19 infection in working generation: Investigation of general health examination items by narrative review].},
journal = {Sangyo eiseigaku zasshi = Journal of occupational health},
volume = {68},
number = {2},
pages = {39-54},
doi = {10.1539/sangyoeisei.2025-023-A},
pmid = {41581920},
issn = {1349-533X},
mesh = {Humans ; *COVID-19/mortality/epidemiology ; *Pandemics/prevention &amp; control ; Risk Factors ; SARS-CoV-2 ; *Occupational Health ; Japan/epidemiology ; *Workplace ; Working Conditions ; Sex Factors ; Smoking/adverse effects ; Alcohol Drinking/adverse effects ; Severity of Illness Index ; Obesity ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic that affected Japan remains vivid in our collective memory. Currently classified as a Category 5 virus (for which medical institutions and individuals primarily implement preventive measures independently, without significant administrative intervention such as isolation), COVID-19 infections continue to peak biannually, currently driven by the Nimbus variant, a derivative of the Omicron strain. This situation necessitates ongoing vigilance in infection prevention efforts. While it is well-established that environmental factors, such as proper ventilation, are crucial in mitigating the risk of COVID-19 transmission, it has become evident that variations in individual susceptibility exist; some individuals contract the virus while others do not, even in identical environments. Personal factors, including pre-existing medical conditions, influence this disparity. This narrative review examines personal factors related to general health assessments within the workplace, incorporating data from systematic reviews and meta-analyses, as well as insights from both international and domestic academic societies. Although the strength of evidence varies, factors such as male gender, smoking, alcohol consumption, obesity, inadequate sleep, insufficient physical activity, hypertension, hyperlipidemia, diabetes, and chronic obstructive pulmonary disease have been identified as contributors to the severity and onset of COVID-19, as well as its associated mortality.},
}
@article {pmid41581933,
year = {2026},
author = {Malemnganba, T and Baghel, K and Mehrotra, S and Prajapati, VK},
title = {Unlocking the power of antimicrobial peptides to combat infectious agents.},
journal = {Advances in protein chemistry and structural biology},
volume = {149},
number = {},
pages = {203-244},
doi = {10.1016/bs.apcsb.2024.11.013},
pmid = {41581933},
issn = {1876-1631},
mesh = {Humans ; *Antimicrobial Peptides/pharmacology/therapeutic use/chemistry ; Animals ; *Anti-Infective Agents/pharmacology/therapeutic use ; Bacteria/drug effects ; SARS-CoV-2/drug effects ; COVID-19 Drug Treatment ; },
abstract = {The rapid rise of antibiotic-resistant bacteria has become a major clinical challenge, creating an urgent need for alternative therapeutic strategies. Antimicrobial peptides (AMPs) have emerged as promising candidates in the fight against these resistant pathogens. Naturally produced by a wide variety of organisms, AMPs are a crucial part of the innate immune system, offering a broad-spectrum antimicrobial effect against bacteria, fungi, viruses, and parasites. Unlike traditional antibiotics, AMPs primarily target microbial membranes, which reduces the likelihood of resistance development. Beyond their pathogen-destroying properties, AMPs enhance immune responses, aid in wound healing, and exhibit anticancer properties. Their ability to act swiftly and in synergy with the host immune system offers a distinct advantage over conventional antibiotics. Furthermore, AMPs hold the potential to be developed into novel treatments for infections that have become resistant to all available therapies. However, bacterial resistance mechanisms to AMPs-such as membrane modifications, protease production, and biofilm formation-underscore the complex interactions between hosts and pathogens. Despite these challenges, AMPs present an exciting avenue across multiple sectors, including medicine, agriculture, and food safety. Recent research also highlights their potential in treating viral infections, including COVID-19, showcasing their versatile applications. This chapter discusses the role of AMPs in addressing antibiotic resistance, their mechanisms of action, and their diverse therapeutic applications beyond bacterial infections.},
}
@article {pmid41582574,
year = {2026},
author = {Chaudhary, V and Singh, AP and Sharma, H and Taumar, D},
title = {Advances in Fragment-based Drug Design: Lessons and Innovations from the Post-COVID Drug Discovery Landscape.},
journal = {Mini reviews in medicinal chemistry},
volume = {26},
number = {7},
pages = {497-509},
pmid = {41582574},
issn = {1875-5607},
mesh = {Humans ; *Drug Discovery/methods ; *Drug Design ; SARS-CoV-2/drug effects ; *Antiviral Agents/chemistry/pharmacology/therapeutic use ; Artificial Intelligence ; COVID-19 ; *COVID-19 Drug Treatment ; *Protease Inhibitors/chemistry/pharmacology ; Pandemics ; },
abstract = {Fragment-based drug discovery (FBDD) has emerged as a transformative strategy in modern medicinal chemistry, offering a rational and efficient alternative to traditional highthroughput screening (HTS). By utilizing small, low-molecular-weight fragments with moderate binding affinity, FBDD enables systematic optimization into potent lead compounds with improved physicochemical properties. Its modular and ligand-centric nature has proven particularly advantageous in accelerating early-stage drug discovery. The COVID-19 pandemic highlighted the adaptability of FBDD, as fragment screening and computational modeling rapidly identified inhibitors of the SARS-CoV-2 main protease (M[pro]). Integration with artificial intelligence (AI) and cloud-based platforms further enhanced the speed and global accessibility of fragment campaigns, setting a precedent for collaborative, open-science initiatives. Beyond infectious diseases, FBDD has demonstrated significant promise in oncology, antibacterial therapy, and neurodegenerative disorders, reflecting its versatility across diverse therapeutic landscapes. Recent technological advances have expanded the scope of FBDD. High-resolution cryo-electron microscopy and AI-driven structural prediction now enable the exploration of previously inaccessible or dynamic protein targets. Emerging modalities, such as PROTACs and RNA-targeted therapeutics, also intersect with fragment-based strategies, opening avenues for addressing so-called "undruggable" proteins. Despite persistent challenges, including the need for sensitive biophysical methods and sophisticated infrastructure, the approach continues to evolve. Looking ahead, the convergence of FBDD with machine learning, open-access fragment libraries, and global research collaboration positions it as a scalable, adaptive platform for drug discovery. As future health threats demand rapid innovation, FBDD is poised to remain a cornerstone of both academic and industrial research pipelines.},
}
@article {pmid41583170,
year = {2025},
author = {Hassan Awaji, HH and Sahli, RN and Albalwi, FB and Albalawi, WS and Muhawish, TA and Albalawi, HM and Alsubiti, AK and Alanazi, JS and Hamdi, A and Alshehri, N and Qarni, FS and Abu Salem, N and Albalawi, FN},
title = {The Impact of Bacillus Calmette-Guérin (BCG) Revaccination on COVID-19 Infection Among Healthcare Workers: A Systematic Review and Meta-Analysis.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e99986},
pmid = {41583170},
issn = {2168-8184},
abstract = {The Bacillus Calmette-Guérin (BCG) vaccine has been hypothesized to confer nonspecific immune protection against viral infections, including coronavirus disease 2019 (COVID-19). This meta-analysis evaluates the protective role of BCG vaccination in preventing COVID-19 among healthcare workers (HCWs). A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) that reported the effect of BCG vaccination for COVID-19 prevention in HCWs compared with placebo. Nine RCTs were included, with a total of 10,295 HCWs. Pooled odds ratios (ORs) and mean differences (MDs) were calculated using random- and fixed-effects models to assess the impact on symptomatic COVID-19, severe disease, hospitalization, seropositivity, duration of illness, and serious adverse events. Heterogeneity was evaluated using I[2] statistics. BCG vaccination did not significantly reduce the risk of symptomatic COVID-19 (OR = 1.05, 95% CI: 0.94-1.17, p = 0.43, I[2] = 47%), severe COVID-19 (OR = 1.20, 95% CI: 0.97-1.48, p = 0.09, I[2] = 0%), or hospitalization (OR = 1.04, 95% CI: 0.71-1.50, p = 0.86, I[2] = 0%). There was no significant difference in the duration of symptomatic illness (MD = 0.09 days, 95% CI: -1.41-1.59, p = 0.90, I[2] = 80%) or in rates of COVID-19 seropositivity (OR = 1.27, 95% CI: 0.81-1.98, p = 0.30, I[2] = 76%). The incidence of serious adverse events was not significantly different between groups (OR = 1.43, 95% CI: 0.34-5.97, p = 0.62, I[2] = 81%). This meta-analysis found no significant protective effect of BCG vaccination against any clinical or serological endpoint of COVID-19 in HCWs. The results do not support the use of BCG as a preventive measure against COVID-19 in this population.},
}
@article {pmid41583464,
year = {2025},
author = {Grunst, MW and Li, W and Mothes, W},
title = {Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1733684},
pmid = {41583464},
issn = {1664-3224},
support = {T32 AI055403/AI/NIAID NIH HHS/United States ; R01 AI194920/AI/NIAID NIH HHS/United States ; F31 AI176650/AI/NIAID NIH HHS/United States ; R01 AI163395/AI/NIAID NIH HHS/United States ; R37 AI150560/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; *Virus Internalization ; *SARS-CoV-2/immunology/physiology ; *HIV-1/immunology/physiology ; *COVID-19/immunology/virology ; *HIV Infections/immunology/virology ; Antibodies, Neutralizing/immunology ; *Antibodies, Viral/immunology ; Animals ; *Viral Fusion Proteins/immunology ; },
abstract = {Enveloped viruses such as Human Immunodeficiency Virus (HIV-1) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have caused some of the deadliest pandemics in human history. These viruses utilize Class 1 viral fusion glycoproteins to bind their host receptor and subsequently fuse the virus and host cell membranes to mediate entry. Viral fusion glycoproteins are prominent antigens on the surface of virions and are essential for the virus life cycle. Therefore, they are a primary target for the humoral immune system and the basis for the design of vaccines. Antibodies which target viral fusion glycoproteins can neutralize viral infectivity and activate the immune system in several distinct ways. In this review, we compare mechanisms of how class 1 viral fusion glycoproteins mediate viral entry and cover diverse ways in which antibodies targeting these glycoproteins can neutralize viruses and activate the immune system to clear virus-infected cells.},
}
@article {pmid41584182,
year = {2025},
author = {Efremova, MI and Cho, Y and Miglietta, E and Pinto da Costa, M},
title = {Burnout scales used in healthcare workers during the COVID-19 pandemic and their psychometric properties: a systematic review.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1661548},
pmid = {41584182},
issn = {2296-2565},
mesh = {Humans ; *Psychometrics ; *COVID-19/psychology/epidemiology ; *Burnout, Professional/diagnosis/psychology ; *Health Personnel/psychology ; Pandemics ; Reproducibility of Results ; Surveys and Questionnaires ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Burnout has been assessed by a variety of screening instruments worldwide. This systematic review investigated the characteristics and psychometric properties of these scales used during the COVID-19 pandemic to assess burnout among healthcare workers.<br><br>METHODS: A systematic literature search and review was conducted based on four operational criteria: burnout scales, healthcare workers, psychometric properties, and COVID-19. We retrieved records from APA PsycInfo, APA PsycArticles, MEDLINE, Academic Search Complete, and EMBASE. All peer reviewed articles that assessed burnout in healthcare workers during COVID-19 were included.<br><br>RESULTS: A total of 794 articles met the inclusion criteria, and 27 burnout scales were identified, two of which were developed during the pandemic. The scales varied in number of items, subscales, response options, language, and country of development. At least one psychometric property was reported for 19 of the 27 scales, and 15 scales demonstrated desirable internal consistency in this novel context. For validity, 9 out of 27 scales reported at least one psychometric property. This was predominantly for measures on structural validity.<br><br>CONCLUSION: Although a wide range of scales were used to assess burnout in healthcare workers during COVID-19, the psychometric properties reported were predominantly on reliability rather than validity. The findings of this review can be used to guide appropriate instrument selection for burnout in crisis contexts such as the COVID-19 pandemic.<br><br>PROSPERO registration database: CRD42023414070.},
}
@article {pmid41584279,
year = {2025},
author = {Wang, C and Fan, Y and Li, C and Chang, B and Wang, J and Cao, X and Liang, G and Liang, Y and Sun, K},
title = {The prevalence of orthostatic intolerance, postural orthostatic tachycardia syndrome and orthostatic hypotension in post-acute sequelae of COVID-19.},
journal = {Frontiers in cardiovascular medicine},
volume = {12},
number = {},
pages = {1679252},
pmid = {41584279},
issn = {2297-055X},
abstract = {BACKGROUND: The COVID-19 pandemic has resulted in over 776 million confirmed cases worldwide, with post-acute sequelae of COVID-19 now recognized as a significant public health concern. Autonomic dysfunction-including orthostatic intolerance (OI), postural orthostatic tachycardia syndrome (POTS), and orthostatic hypotension (OH)-constitutes a major complication of post-acute sequelae of COVID-19. However, reliable epidemiological estimates remain scarce. As a result, we aim to provide the first global prevalence estimates of autonomic dysfunction in post-acute sequelae of COVID-19.<br><br>METHODS: This systematic review and meta-analysis adhered to PRISMA 2020 guidelines, including 21 observational studies. Random-effects models were utilized to estimate pooled prevalence, and sensitivity and meta-regression analyses were conducted to explore heterogeneity. GRADE assessments evaluated evidence certainty.<br><br>RESULTS: The pooled prevalence estimates demonstrated 70.6% for OI, 36.2% for POTS, and 18.6% for OH. Advancing age exhibited a significant negative association with POTS and OH. In contrast, prolonged post-acute sequelae of COVID-19 duration and female sex showed no significant association with the incidence rates of these conditions. Subgroup analyses indicated higher POTS and OH incidence in mild vs. moderate or severe COVID-19 cases. Publication bias was minimal for OH but evident for POTS.<br><br>CONCLUSION: This study provides the first global prevalence estimates of autonomic dysfunction in post-acute sequelae of COVID-19, highlighting its disproportionate burden among younger populations and non-linear temporal trends. The findings advance epidemiological understanding and inform evidence-based public health strategies to address post-COVID complications.<br><br>https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=556546, PROSPERO CRD42024556546.},
}
@article {pmid41584416,
year = {2025},
author = {Soica, IL and Kupeli, N and Eyitayo-Olonade, K and Davies, N},
title = {A Systematic Review of Advance Care Planning with People Living with Dementia: Learnings from the Covid-19 Pandemic.},
journal = {Current health sciences journal},
volume = {51},
number = {3},
pages = {299-310},
pmid = {41584416},
issn = {2067-0656},
abstract = {This study focused on exploring the experiences of people with dementia (PD) with advance care planning (ACP) during the pandemic. We analyzed the barriers and facilitators to implementing ACP and made recommendations for research, practice and policy. Regarding the design, the review followed Joanna Briggs Institute (JBI) guidelines. The protocol was registered on PROSPERO. Three databases (CINAHL, PUBMED, Embase) were searched, and records from 2019-2023 were screened against eligibility criteria. The experiences of PD in various international settings, including care homes, community hospitals, tertiary health settings and research facilities were explored. More precisely, we followed PD and their carers who engaged with ACP tools during the pandemic, while applying qualitative and quantitative measurements. The results were based on nine studies that were included. Themes related to timing of ACP, methods used to conduct ACP during the pandemic and the topics discussed. The pandemic prompted discussions about goals of care and PD found digital interventions to be a viable alternative to in-person ACP. Barriers to this included accessibility issues, difficulty with using technology, and lack of electronic means. In conclusion, digital ACP interventions are a viable method of delivering ACP, but they should be adapted and used alongside in-person consultations.},
}
@article {pmid41585255,
year = {2025},
author = {Wang, Y and Liu, X and Cui, W and Hu, Y and Song, W and Zhu, L and Wang, Z and Ji, X and Wang, Y},
title = {Visualization of childhood allergic diseases based on VOSviewer and CiteSpace.},
journal = {Frontiers in medicine},
volume = {12},
number = {},
pages = {1615154},
pmid = {41585255},
issn = {2296-858X},
abstract = {INTRODUCTION: Childhood allergic diseases, such as eczema, allergic rhinitis, bronchial asthma, and cough-variant asthma, are a growing health concern around the world. There is a lot of research about these diseases, but a clear and complete study is still needed to better understand them and help guide future research.<br><br>METHODS: This study used a bibliometric analysis of research on childhood allergic diseases from 2014 to 2024. The main goal was to find patterns in publications, main researchers, research focuses, teamwork between groups, and new topics. Data were collected from Web of Science, Scopus, and PubMed. The study included English-language articles and reviews only. The tools VOSviewer and CiteSpace were used to study publication patterns, where research was done, which authors and journals worked together, how often papers were cited together, which papers were cited the most, and how keywords appeared and formed groups.<br><br>RESULTS: The amount of research was different for each disease. Eczema got the most attention and kept growing. Cough-variant asthma had fewer studies. The United States and China were the main countries that did most of the work and had well-known authors. The focus of studies changed from general studies about disease spread to more detailed topics like the microbiome, genetics, special treatments, environmental causes, other health problems that happen together, and the effects of COVID-19. The way researchers worked together was not the same for all diseases. This showed that research was more developed and better connected for some diseases and less developed for others, mainly for cough-variant asthma.<br><br>CONCLUSION: This study gives a short look at recent research on childhood allergic diseases. It shows that eczema research is growing fast, but cough-variant asthma is still studied much less, with only 110 papers in 10 years. This big difference shows a clear lack of knowledge. These results can help make better research plans and improve medical care in this field.},
}
@article {pmid41585361,
year = {2025},
author = {Wakai, TN and Yensii, NG and Kernyuy, FB and Bella-Omunagbe, M and Chinedu, SN and Afolabi, IS},
title = {Global research landscape of telomere biology in infectious diseases: mechanistic links between host-pathogen interactions and immune ageing.},
journal = {Frontiers in aging},
volume = {6},
number = {},
pages = {1729868},
pmid = {41585361},
issn = {2673-6217},
abstract = {Telomeres, nucleoprotein structures located at the ends of chromosomes, maintain genomic stability and regulate cellular lifespan, particularly in immune cells. Telomere shortening, driven by cell division and limited telomerase activity, accelerates immune ageing and increases susceptibility to infectious diseases. Chronic infections like HIV and tuberculosis exacerbate telomere attrition through sustained immune activation and oxidative stress. This study presents a bibliometric review of research on telomere length and infectious diseases from 2005 to 2025. Data from the Web of Science Core Collection were analysed using VOSviewer and CiteSpace, software tools for visualising co-authorship, citation, and keyword networks, to assess publication trends, collaborations, and themes. A total of 123 publications were identified, showing steady growth with a 60% increase in publications from 2020 to 2022 during the COVID-19 pandemic. Leading journals included Frontiers in Immunology, PLoS ONE, and Scientific Reports. The United States produced the largest share of publications, followed by Canada and Spain, with notable contributions from the University of British Columbia and Université de Montréal. Influential authors such as Côté HCF, Pick N, and Maan EJ have advanced research, particularly in the areas of HIV and tuberculosis. Keyword analysis highlighted two dominant themes: immune ageing and infection-related stress. Malaria research was comparatively scarce, underscoring a gap for future investigation. These findings inform future research on telomere-targeted interventions and epidemiological studies aimed at enhancing infectious disease management. This review provides a comprehensive overview of the field's progress and identifies key areas for future investigation.},
}
@article {pmid41585373,
year = {2025},
author = {Koyou, HL and Ramachandran, V and Salleh, MN and Wan Sulaiman, WA and Mohamed, MH and Mohd Badrin, MJQ and Jelemie, CS},
title = {S100 Protein and Interleukin Biomarkers Among COVID-19 Subjects With and Without Pneumonia: A Systematic Review and Meta-Analysis.},
journal = {British journal of biomedical science},
volume = {82},
number = {},
pages = {15355},
pmid = {41585373},
issn = {2474-0896},
mesh = {Humans ; *COVID-19/blood ; Biomarkers/blood ; *S100 Proteins/blood ; SARS-CoV-2 ; *Interleukins/blood ; Interleukin-10/blood ; Severity of Illness Index ; Interleukin-6/blood ; },
abstract = {BACKGROUND: The global spread of COVID-19, caused by SARS-CoV-2, has resulted in a wide spectrum of clinical manifestations, ranging from asymptomatic cases to severe complications, such as pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ failure. Identifying effective biomarkers is essential for predicting disease severity and improving patient management.<br><br>OBJECTIVES: This meta-analysis aims to assess the significance of S100 proteins (S100A4, S100A8, S100A9, S100A12, S100B, S100P) and interleukins (IL) (IL-6, IL-8, IL-10, IL-17, IL-1&#x3b2;) in COVID-19 patients, comparing those with and without pneumonia or organ failure.<br><br>METHODS: A systematic literature search was conducted on different databases, yielding 47 relevant studies published between 2020 and 2024. Data on the prevalence of IL and S100 protein levels were extracted and analyzed using pooled standardized mean differences (SMD) and heterogeneity (I[2]) to evaluate their associations with disease severity.<br><br>RESULTS: IL-6 and IL-10 levels were significantly elevated in COVID-19 patients suffering from pneumonia or organ failure. IL-6 levels were notably higher in pneumonia patients compared to those without (SMD = 0.34 [95% CI: 0.17, 0.52], I[2] = 29%). Similarly, elevated S100B levels were observed in severe cases (SMD = 0.51 [95% CI: 0.19, 0.83], I[2] = 0%). While IL-10 levels showed high variability (I[2] = 90%), they remained consistently linked with worse outcomes.<br><br>CONCLUSION: This meta-analysis underscores the potential of IL-6, IL-10, and S100 proteins as important biomarkers in evaluating COVID-19 severity, offering valuable insights to help clinical management.},
}
@article {pmid41586005,
year = {2025},
author = {Martín-Rodríguez, A and González-Prieto, N},
title = {Influence of physical activity on perceived stress and mental health in university students: a systematic review.},
journal = {Frontiers in sports and active living},
volume = {7},
number = {},
pages = {1710832},
pmid = {41586005},
issn = {2624-9367},
abstract = {University students are a population particularly vulnerable to stress, anxiety, and reduced wellbeing. Physical activity has been proposed as a protective factor, but existing findings are heterogeneous. This systematic review examined the relationship between physical activity and mental health in university students, focusing on perceived stress, anxiety, depression, and psychological wellbeing. It was conducted in accordance with PRISMA guidelines, and the study protocol was registered in PROSPERO (CRD420251179614). A total of 38 studies published between 2020 and 2025 were analyzed, involving more than 20,000 participants from various countries. Most studies were cross-sectional, although some longitudinal and quasi-experimental studies were also included. The results showed a consistent association between higher levels of physical activity and lower levels of stress, depression, and anxiety, as well as an increase in subjective wellbeing. In addition, mediators such as sleep quality and resilience, and moderators such as gender or internet use, were identified. The effects were more significant when physical activity was combined with other healthy habits such as good sleep and low sedentary behavior. Although most of the studies were not experimental, the evidence suggested a possible beneficial causal effect of exercise. The need for comprehensive interventions in universities was highlighted, promoting physical activity as a preventive and therapeutic strategy to improve the mental health of students. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251179614, PROSPERO, CRD420251179614.},
}
@article {pmid41586257,
year = {2025},
author = {Heendeniya, SN and Chen, S and Bhatti, S and Zahra, QUA and Rahimizadeh, K and Poudel, BH and Wilton, SD and Veedu, RN},
title = {Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications.},
journal = {Experimental biology and medicine (Maywood, N.J.)},
volume = {250},
number = {},
pages = {10784},
pmid = {41586257},
issn = {1535-3699},
mesh = {Humans ; *RNA, Messenger/therapeutic use/genetics ; *Drug Design ; *COVID-19 Vaccines/genetics/immunology/therapeutic use ; *SARS-CoV-2/genetics/immunology ; COVID-19/genetics/immunology ; Animals ; },
abstract = {Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn't integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5'cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA's molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.},
}
@article {pmid41588352,
year = {2026},
author = {Du, R and Yang, J and Yang, W and Liao, P},
title = {The efficacy and safety of convalescent plasma for COVID-19 patients: a meta-analysis based on double-blinded parallel-arm randomized placebo-controlled trials.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {147},
pmid = {41588352},
issn = {1471-2334},
mesh = {Humans ; *COVID-19/therapy/mortality ; *COVID-19 Serotherapy/adverse effects/methods ; Double-Blind Method ; Hospitalization/statistics &amp; numerical data ; Immunization, Passive/adverse effects/methods ; Randomized Controlled Trials as Topic ; Respiration, Artificial/statistics &amp; numerical data ; SARS-CoV-2/immunology ; Treatment Outcome ; },
abstract = {BACKGROUND: Convalescent plasma (CP) showed promising benefits in previous coronavirus pandemics regarding efficacy and safety. However, the efficacy of CP from COVID-19 patients remains controversial and uncertain based on current randomized controlled trials (RCTs). There is an urgent need to establish the efficacy and safety of CP for COVID-19 patients as soon as possible.<br><br>OBJECTIVE: To verify the efficacy and safety of CP using high-quality, double-blinded, parallel-arm, placebo-controlled randomized clinical trials, and to provide evidence-based support for the clinical application of CP against COVID-19.<br><br>METHODS: Electronic databases such as Embase, PubMed, and Web of Science were searched from inception to October 18, 2024. This meta-analysis synthesized dichotomous outcomes, including 28-day mortality, hospitalization rates, invasive mechanical ventilation, adverse events (AEs), and serious AEs, using an intention-to-treat (ITT) analysis. Statistical analysis was performed using Review Manager (RevMan) 5.4.1, the Mantel-Haenszel (M-H) statistical method, and a random effects (RE) analysis model. Risk ratios (RRs) and their 95% confidence intervals (CIs) were used as effect measures. Two reviewers independently searched, screened, and included eligible clinical trials, extracted relevant data, and assessed risks of bias (ROB) using the Cochrane ROB tool 1.0 and RevMan 5.4.1. The RRs and 95% CIs in this meta-analysis were computed as dichotomous outcomes. Statistical heterogeneity, subgroup analysis, and sensitivity analysis were conducted to explore heterogeneities and their causes. The quality of evidence was evaluated, and recommendations for clinical practice were based on the GRADE approach. The prospective meta-analysis protocol was registered on PROSPERO.<br><br>RESULTS: A total of 996 references were identified through database and manual searches. Nine eligible double-blinded, parallel-arm, placebo-controlled randomized clinical trials, involving 1898 subjects in the intervention group and 1696 in the control group, were included in the meta-analysis. Seven, four, three, three, and three trials were judged as low ROB for mortality, hospitalization rates, invasive mechanical ventilation, AEs, and serious AEs, respectively. The remaining trials were deemed high-risk for their respective outcomes. The meta-analysis on hospitalization rates was abandoned due to high heterogeneity (I&#xb2;=92%) among the included trials. The RRs, 95% CIs, and P-values were as follows: 0.78 [0.62, 0.97], P&#x2009;=&#x2009;0.03 for mortality; 0.84 [0.50, 1.42], P&#x2009;=&#x2009;0.51 for invasive mechanical ventilation; 1.01 [0.78, 1.32], P&#x2009;=&#x2009;0.92 for AEs; and 0.96 [0.73, 1.28], P&#x2009;=&#x2009;0.80 for serious AEs, all with low or medium levels of heterogeneity. These results suggest that CP infusion in COVID-19 patients reduced mortality by 22% and exhibited excellent safety without reducing the incidence of invasive mechanical ventilation. Sensitivity analysis on mortality, using the combined effect measure (RR 0.83 [0.66, 1.06], I&#xb2;=0%, Z&#x2009;=&#x2009;1.46, P&#x2009;=&#x2009;0.14) after excluding the study by O'Donnell, showed no significant difference between the intervention and control groups, implying that the excluded study might have a stronger effect in reducing mortality. Subgroup analysis based on age indicated that CP therapy in COVID-19 patients aged&#x2009;&#x2264;&#x2009;60 years reduced mortality by 36%. Sensitivity and subgroup analyses for other outcomes demonstrated robust pooled results. The PROSPERO registration code is CRD42022324324.<br><br>CONCLUSIONS: Administration of CP to COVID-19 patients, especially those aged&#x2009;&#x2264;&#x2009;60 years, may reduce mortality with excellent safety without more AEs, and serious AEs, but does not reduce the incidence of invasive mechanical ventilation.},
}
@article {pmid41588689,
year = {2026},
author = {Diab, SS and Alvarez, I and Ramirez-Barrios, R and Reddy, A and Carvallo, FR},
title = {A review of infectious interstitial and bronchointerstitial pneumonia in cattle with an algorithm for the detection of infectious and non-infectious causes.},
journal = {Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc},
volume = {38},
number = {4},
pages = {653-675},
pmid = {41588689},
issn = {1943-4936},
mesh = {Animals ; Cattle ; *Cattle Diseases/diagnosis/microbiology/virology/parasitology/etiology ; *Lung Diseases, Interstitial/veterinary/diagnosis/microbiology/virology/etiology/parasitology ; Algorithms ; },
abstract = {Bovine interstitial and bronchointerstitial pneumonias are common and important diseases of cattle, caused by several infectious and non-infectious causes. Here, we review the roles of bovine respiratory syncytial virus, bovine parainfluenza virus 3, bovine alphaherpesvirus 1, bovine viral diarrhea virus, bovine coronavirus, influenza D virus, malignant catarrhal fever virus, and bovine adenovirus in interstitial or bronchointerstitial pneumonia. We describe the possible causes, pathogenesis, and diagnosis of bacterial septicemias that result in interstitial pneumonia, including E. coli, Salmonella, and Pasteurella multocida septicemias. We also review the parasitic causes of interstitial or bronchointerstitial pneumonia, primarily Dictyocaulus viviparus. Reaching a definitive postmortem etiologic diagnosis of interstitial or bronchointerstitial pneumonia can be challenging because infectious and non-infectious causes may look very similar grossly. Moreover, other conditions-that do not cause interstitial or bronchointerstitial pneumonia but rather pulmonary edema, congestion, and hemorrhage-can resemble interstitial pneumonia grossly. To guide the process of diagnosing interstitial and bronchointerstitial pneumonia, we offer an algorithm that integrates findings obtained from postmortem examination and ancillary laboratory testing. Our algorithm includes details on the gross characteristics of the lungs with interstitial or bronchointerstitial pneumonia, and we discuss other disease processes that may grossly resemble interstitial pneumonia. We highlight the key histologic features for differentiating specific causes and describe the most common ancillary laboratory tests to detect infectious and non-infectious causes.},
}
@article {pmid41588957,
year = {2026},
author = {Vineeth, ES and Saha, S and Nishtala, VB},
title = {A Mini Review on Metal Complexes as Potential Anti-SARS-CoV-2 Agents: Insights from Molecular Docking Studies.},
journal = {Mini reviews in medicinal chemistry},
volume = {26},
number = {6},
pages = {399-411},
pmid = {41588957},
issn = {1875-5607},
mesh = {*Antiviral Agents/chemistry/pharmacology/therapeutic use ; *Molecular Docking Simulation ; Humans ; *SARS-CoV-2/drug effects ; *Coordination Complexes/chemistry/pharmacology/therapeutic use ; *COVID-19 Drug Treatment ; Spike Glycoprotein, Coronavirus/metabolism/antagonists &amp; inhibitors/chemistry ; },
abstract = {There is an urgent need to develop effective antiviral treatments against SARS-CoV-2. Despite the availability of vaccines, drug discovery remains critical for combating emerging variants. Molecular docking studies have become a vital computational tool for identifying antiviral drugs capable of inhibiting different SARS-CoV-2 proteins. This review explores the role of metal complexes as promising viral inhibitors through in silico molecular docking approaches. The binding abilities of several coordination complexes derived from iron, copper, palladium, and zinc ions have been evaluated against major viral proteins such as the spike glycoprotein, RNA-dependent RNA polymerase (RdRp), and the main protease (Mpro), which are responsible for viral infection. Comparative docking studies of specific metal-based compounds with conventional antiviral drugs highlight their superior binding affinities and inhibitory potential. Furthermore, ADME (Absorption, Distribution, Metabolism, and Excretion) analyses, molecular dynamics simulations, and drugdelivery strategies are discussed to assess pharmacokinetics and therapeutic viability. Overall, this review emphasizes the importance of molecular docking in the rational design of metal complexes as antiviral agents and its relevance for developing effective therapeutic strategies to combat COVID-19.},
}
@article {pmid41589019,
year = {2026},
author = {Murugavel, A and Ramakrishnan, J},
title = {Virulence and pathogenicity of secondary fungal infections.},
journal = {Critical reviews in microbiology},
volume = {52},
number = {1},
pages = {139-158},
doi = {10.1080/1040841X.2025.2537423},
pmid = {41589019},
issn = {1549-7828},
mesh = {Humans ; Virulence ; Virulence Factors/metabolism/genetics ; *Mycoses/microbiology ; *COVID-19/complications/microbiology/immunology ; *Candida/pathogenicity/genetics ; Aspergillus/pathogenicity/genetics ; *Mucorales/pathogenicity/genetics ; Immunocompromised Host ; *Coinfection/microbiology ; SARS-CoV-2 ; },
abstract = {Fungal infections pose a significant global health threat, particularly among immunocompromised individuals facing life-threatening complications. The severity of secondary fungal infections is driven by the expression of virulence factors in immunocompromised individuals. The COVID-19 pandemic has highlighted the susceptibility of immunocompromised patients to secondary fungal infections, prompting a closer examination of the underlying mechanisms. This review provides a comprehensive overview of the virulence mechanisms of major fungal pathogens (Aspergillus, Candida, and Mucorales) in COVID-19-associated secondary infections. The review systematically categorizes key virulence factors, including thermotolerance, adhesins, hydrolytic enzymes, mycotoxins, and biofilm formation, and explores their interplay with the host's immune status, particularly under corticosteroid therapy. Focusing on the intersection of fungal pathogenesis and COVID-19, the article examines molecular mechanisms underlying Aspergillus, Mucorales, and Candida pathogenicity, including iron metabolism, spore coat proteins, and immune evasion strategies. Followed by linking the molecular mechanisms to therapeutic strategies and clinical outcomes.},
}
@article {pmid41589190,
year = {2025},
author = {Alrehaili, RS and Almuzaini, S and Alrajhi, J and Dashti, A and Alsuroor, O and Alzahrani, F and Albishri, A and Almousa, M and Homdi, L and Alshammakhy, R and Alfaifi, F and Alkharfi, A and Aldhafeeri, G and Alzahrani, TM},
title = {Teledentistry in the Era of Digital Dentistry: Clinical Applications, Patient Experience, and Equity-Oriented Policy Implications.},
journal = {Cureus},
volume = {17},
number = {12},
pages = {e100137},
pmid = {41589190},
issn = {2168-8184},
abstract = {Teledentistry has shifted from small pilot projects and emergency use during the COVID-19 pandemic to a realistic option for delivering parts of routine oral healthcare. However, its role in long-term service models, equity, and health-system performance remains incompletely defined. This narrative review aimed to provide an up-to-date synthesis of the evidence on teledentistry across clinical specialties, populations, and settings, and to discuss implications for practice, policy, and future research. Electronic databases were searched from inception to December 2025 for studies evaluating teledentistry or related digital remote dental services. Eligible sources included observational and interventional studies, reviews, economic evaluations, implementation reports, and key professional or policy documents. Data were organized thematically around clinical effectiveness, patient and provider experience, cost and resource use, equity and access, regulatory frameworks, and emerging technologies. Across settings, teledentistry supports accurate diagnosis and triage for selected indications, particularly in orthodontics, pediatric dentistry, and community-based screening. Most studies report gains in access, reduced need for travel, and high levels of patient satisfaction, especially in rural, institutionalized, and otherwise underserved groups. Evidence for long-term clinical outcomes, cost-effectiveness, and the impact on oral-health inequities is promising but remains heterogeneous and often limited by small samples, short follow-up, and methodological constraints. Successful programs depend on reliable infrastructure, integration with electronic records, clear clinical protocols, appropriate training, and supportive legal and reimbursement frameworks, while concerns persist about data protection, medico-legal responsibility, and the potential for digital services to widen rather than narrow gaps between population groups. Overall, teledentistry should be viewed as a component of planned hybrid oral healthcare models rather than a substitute for in-person care. Future work needs pragmatic comparative studies, robust economic analyses, and equity-focused evaluations. Under these conditions, teledentistry has the potential to contribute meaningfully to more accessible, continuous, and person-centered oral healthcare.},
}
@article {pmid41590208,
year = {2026},
author = {Parikh, RR and Shetty, NU and Singhal, C and Patel, P and Manghani, P and Pillai, AA and Chocontá-Piraquive, LA and Butler, ME},
title = {Telehealth for Sexual and Reproductive Healthcare: Evidence Map of Effectiveness, Patient and Provider Experiences and Preferences, and Patient Engagement Strategies.},
journal = {Clinics and practice},
volume = {16},
number = {1},
pages = {},
pmid = {41590208},
issn = {2039-7275},
abstract = {OBJECTIVE: The aim of this study was to systematically map evidence to inform best practices for sexual and reproductive healthcare delivered via telehealth (TeleSRH) in United States-based Title X-funded clinics.<br><br>METHODS: We searched three databases (2017-2025) for studies evaluating effectiveness, harms, patient and provider experiences, barriers/facilitators, and engagement strategies encompassing TeleSRH for sexually transmitted infections (STIs), contraceptive care/family planning (CC/FP), and sexual wellness, in countries with a human development index of &#x2265;0.8.<br><br>RESULTS: From 5963 references and 436 articles, we included 142 eligible publications. TeleSRH use declined since the COVID-19 pandemic's peak but remains higher than pre-pandemic. Evidence comes mostly from poor-quality studies. TeleSRH increases access and adherence to STI prevention (e.g., pre-exposure prophylaxis for HIV). Tele-follow-up may safely facilitate HIV care continuity. For CC/FP, TeleSRH is comparable to in-person care for patient satisfaction and uptake; patients are less likely to select long-acting reversible contraception but post-initiation tele-follow-up may increase its continuation rates. Vasectomy completion rates may be similar between pre-procedural counseling via telehealth versus in-person. TeleSRH's potential benefits might include reduced travel time, wait times, no-show rates, and clinic human resource burden (via tele-triaging) and increased preventative screening rates for STIs and non-communicable diseases, prescription refill rates, ability to receive confidential care in preferred settings, and rural/marginalized community outreach. Implementation challenges span technological and capital constraints, provider availability, staff capability building, restrictive policies, language incompatibility, and patient mistrust. Supplementing synchronous TeleSRH with asynchronous communication (e.g., mobile application) may improve continued patient engagement.<br><br>CONCLUSIONS: Preventive, diagnostic, and therapeutic TeleSRH can be effective, with high patient acceptability; however, effectiveness and adoption hinge on contextual factors outlined in this review.},
}
@article {pmid41590554,
year = {2025},
author = {Klimonda, A and Kowalska, I},
title = {From Environmental Threat to Control: A Review of Technologies for Removal of Quaternary Ammonium Compounds from Wastewater.},
journal = {Membranes},
volume = {16},
number = {1},
pages = {},
pmid = {41590554},
issn = {2077-0375},
support = {825 305 0501//Wroc&#x142;aw University of Science and Technology/ ; },
abstract = {Cationic surfactants from the group of quaternary ammonium compounds (QACs) are widely used in disinfectants, cosmetics, and household and industrial products. Their strong antimicrobial activity and chemical stability make them valuable in applications but also highly persistent and toxic when released into aquatic environments. This problem has become increasingly relevant during and after the COVID-19 pandemic, when global use of QAC-based disinfectants increased drastically, resulting in their frequent detection in municipal, hospital, and industrial effluents. The concentrations of QACs reported in wastewater range from trace levels to several mg/L, often reaching inhibitory thresholds for biological treatment processes. Although surfactants are not listed in any current European directive, the revised Directive (EU) 2024/1440 classifies micropollutants as a priority group, imposing stricter environmental quality standards and mandatory monitoring requirements. Within this regulatory framework, QACs are recognized as compounds of emerging concern, and their effective removal from wastewater has become a critical challenge. This review summarizes the current knowledge on conventional treatment technologies (coagulation, adsorption, ion exchange, advanced oxidation, and biological processes) and membrane-based methods (ultrafiltration, nanofiltration, reverse osmosis, forward osmosis, and hybrid systems) for the removal of cationic surfactants from water and wastewater. Mechanisms of separation, performance, and operational limitations are discussed.},
}
@article {pmid41591417,
year = {2026},
author = {Faria, C and Daneshi, K and Baser, A and Mauersberger, H and G-Medhin, A and Soneson, E and White, S and Anderson, J and Ford, T},
title = {The global prevalence of eating disorders in children and young people: a systematic review and meta-analysis.},
journal = {European child &amp; adolescent psychiatry},
volume = {35},
number = {4},
pages = {1093-1106},
pmid = {41591417},
issn = {1435-165X},
support = {(NIHR203312//National Institute for Health and Care Research/ ; },
mesh = {Adolescent ; Child ; Humans ; *COVID-19/epidemiology ; *Feeding and Eating Disorders/epidemiology ; *Global Health/statistics &amp; numerical data ; Prevalence ; Young Adult ; },
abstract = {The increase in eating disorder (ED) presentations among children and young people (CYP) during the Covid-19 pandemic represents a global health concern, given the associated morbidity and mortality associated with these conditions. We conducted a meta-analysis to estimate the worldwide pooled prevalence of EDs in CYP at a population level. We searched MEDLINE, EMBASE, PsycINFO and LILACS for all English-language studies reporting population level ED prevalence data between January 2013 to February 27th, 2024. The primary outcome was overall prevalence of EDs. We used a random-effects model for the meta-analysis, I[2] statistics to assess heterogeneity, and the Hoy scale for quality assessment. This study is registered with PROSPERO, number CRD42022333223. Sixteen studies including 77,714 children and young people from 12 countries met eligibility criteria and were included in the systematic review, whilst twelve studies with 56,758 participants provided data suitable for inclusion in the meta-analysis. Study quality was moderate; ten studies were classified with a low risk of bias, one with moderate and five with high. The global point prevalence for any ED was 5.23% (95% confidence interval (CI) 0.41 to 10.05, I[2]= 99.95%). The commonest type was Other Specified Feeding or ED (point prevalence of 4.88%, 95% CI 1.46 to 8.30, I[2]= 99.42%), which, like all types of ED was more common among girls (5.25%, 95% CI 0.32 to 10.18, I[2]= 99.69%) than boys (3.97%, 95% CI 0.45 to 7.49, I[2]= 97.77%), although confidence intervals overlapped. Our findings illustrate the urgent need to expand service provision as well as to evaluate and develop strategies for early ED identification in children and young people, given a global prevalence of 1 in 20.},
}
@article {pmid41592222,
year = {2026},
author = {Song, X and Lian, Z and Wang, R and Li, R and Yang, Z and Luo, X and Feng, L and Ma, Z and Pu, Z and Wang, Q and Ge, L and Li, C and Chen, Y and Yang, K and Lavis, J},
title = {The Phases of Living Evidence Synthesis Using AI AI: Living Evidence Synthesis (Version 1).},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e76130},
pmid = {41592222},
issn = {1438-8871},
mesh = {*Artificial Intelligence ; Humans ; SARS-CoV-2 ; COVID-19 ; },
abstract = {BACKGROUND: Living evidence (LE) synthesis refers to the method of continuously updating systematic evidence reviews to incorporate new evidence. It has emerged to address the limitations of the traditional systematic review process, particularly the absence of or delays in publication updates. The emergence of COVID-19 accelerated the progress in the field of LE synthesis, and currently, the applications of artificial intelligence (AI) in LE synthesis are expanding rapidly. However, in which phases of LE synthesis should AI be used remains an unanswered question.<br><br>OBJECTIVE: This study aims to (1) document the phases of LE synthesis where AI is used and (2) investigate whether AI improves the efficiency, accuracy, or utility of LE synthesis.<br><br>METHODS: We searched Web of Science, PubMed, the Cochrane Library, Epistemonikos, the Campbell Library, IEEE Xplore, medRxiv, COVID-19 Evidence Network to support Decision-making, and McMaster Health Forum. We used Covidence to facilitate the monthly screening and extraction processes to maintain the LE synthesis process. Studies that used or developed AI or semiautomated tools in the phases of LE synthesis were included.<br><br>RESULTS: A total of 24 studies were included, including 17 on LE syntheses, with 4 involving tool development, and 7 on living meta-analyses, with 3 involving tool development. First, a total of 34 AI or semiautomated tools were involved, comprising 12 AI tools and 22 semiautomated tools. The most frequently used AI or semiautomated tools were machine learning classifiers (n=5) and the Living Interactive Evidence synthesis platform (n=3). Second, 20 AI or semiautomated tools were used for the data extraction or collection and risk of bias assessment phase, and only 1 AI tool was used for the publication update phase. Third, 3 studies demonstrated the improvement in efficiency achieved based on time, workload, and conflict rate metrics. Nine studies applied AI or semiautomated tools in LE synthesis, obtaining a mean recall rate of 96.24%, and 6 studies achieved a mean F1-score of 92.17%. Additionally, 8 studies reported precision values ranging from 0.2% to 100%.<br><br>CONCLUSIONS: AI and semiautomated tools primarily facilitate data extraction or collection and risk of bias assessment. The use of AI or semiautomated tools in LE synthesis improves efficiency, leading to high accuracy, recall, and F1-scores, while precision varies across tools.},
}
@article {pmid41592552,
year = {2026},
author = {Song, J and Lee, JH and Park, H and Jang, MJ and Yoon, SH},
title = {Long-Term Pulmonary Function and Radiologic Abnormalities Up to 3 Years After COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Korean journal of radiology},
volume = {27},
number = {2},
pages = {174-185},
pmid = {41592552},
issn = {2005-8330},
mesh = {Humans ; *COVID-19/physiopathology/diagnostic imaging/complications ; *Tomography, X-Ray Computed/methods ; Respiratory Function Tests ; *Lung/diagnostic imaging/physiopathology ; SARS-CoV-2 ; Male ; Middle Aged ; Female ; Time Factors ; },
abstract = {OBJECTIVE: To systematically evaluate the long-term trajectory of pulmonary function test (PFT) and CT findings in COVID-19 survivors.<br><br>MATERIALS AND METHODS: A systematic literature search of PubMed and EMBASE was performed to identify studies published from January 2020 to June 2024 reporting PFT and/or chest CT outcomes at &#x2265;6 months post-COVID-19, up to 36 months. The reference lists of relevant articles were also manually reviewed. Two investigators independently extracted study characteristics, patient demographics, and PFT and CT outcomes at prespecified follow-up intervals (6, 12, 24, and 36 months). Multivariate meta-analyses were conducted to evaluate temporal trends in lung function and radiological abnormalities. Sensitivity analyses, including stratification by disease severity and pooled analyses of studies with multiple follow-up time points, were performed to confirm the robustness of the findings.<br><br>RESULTS: In total, 152 studies (n = 25,766; mean age, 56.7 &#xb1; 13.2 years; 14,999 men) were included: 133 reporting PFT outcomes and 80 reporting CT findings. Diffusion capacity (DLCO) impairment was the most common abnormality, showing gradual improvement from 42% at 6 months to 35% at 36 months (P = 0.008) with a corresponding increase in the % predicted DLCO. Similarly, the prevalence of forced vital capacity (FVC) impairment decreased over time, accompanied by an increase in the % predicted FVC. On chest CT, the proportion of patients with no relevant findings remained stable at 30%-40% (P = 0.14). The prevalence of ground-glass opacities (GGO) decreased from 32% at 6 months to 20% at 36 months (P = 0.01), while that of fibrosis persisted at 27%-47% without a significant change (P = 0.28). Subgroup analysis based on disease severity revealed similar temporal trends in both low-severity and high-severity cohorts.<br><br>CONCLUSION: DLCO, FVC, and GGO findings improved gradually up to 36 months post-COVID-19; however, over one-third of the patients continued to exhibit reduced DLCO. Fibrosis persists with limited evidence of resolution over a 3-year period, suggesting a stable but nonprogressive pattern.},
}
@article {pmid41592662,
year = {2026},
author = {Dağdeviren, &#x130; and Uygur, MM and Keleş, E&#xc7;},
title = {The impact of thyroid dysfunction on COVID-19 severity and mortality: A systematic review and Meta-Analysis.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {584},
number = {},
pages = {120851},
doi = {10.1016/j.cca.2026.120851},
pmid = {41592662},
issn = {1873-3492},
mesh = {Humans ; *COVID-19/blood/complications/diagnosis/mortality ; Pandemics ; SARS-CoV-2 ; Severity of Illness Index ; *Thyroid Diseases/blood/complications/diagnosis ; Thyrotropin/blood ; Triiodothyronine/blood ; },
abstract = {Thyroid function abnormalities have been increasingly reported in patients with coronavirus disease 2019 (COVID-19), yet the clinical significance of these alterations remains uncertain. Because early identification of individuals at risk for severe illness is essential, this study systematically evaluated the association between thyroid dysfunction and COVID-19 severity. A comprehensive search of major databases identified 4260 records, of which 13 observational studies met the eligibility criteria, yielding a total of 2829 patients from diverse geographical regions. Mild, moderate, and non-ICU patients were categorized as the non-severe group, while the severe-to-critical group included patients classified as severe or critical, those requiring ICU admission, or hospitalized in dedicated COVID-19 wards according to the criteria used in the original studies. The pooled analysis demonstrated that total and free triiodothyronine (TT3 and FT3) levels were consistently lower in patients with more severe disease, and thyroid dysfunction was associated with 4.8-fold higher odds of severe-to-critical COVID-19. Although thyroid-stimulating hormone (TSH) levels were reduced in patients with COVID-19 compared with non-infected individuals, TSH alone did not predict disease severity. Higher TT3 and FT3 concentrations were consistently associated with a milder clinical course. These findings suggest that thyroid function tests may provide useful prognostic information in patients with COVID-19. The observed hormonal patterns may reflect alterations along the hypothalamic-pituitary-thyroid axis; however, this interpretation remains hypothetical and requires confirmation through studies incorporating direct pituitary hormone assessment. Low TT3 and FT3 levels appear to be associated with worse clinical outcomes in COVID-19 patients, suggesting their potential utility as prognostic indicators. However, further prospective studies are needed before recommending routine monitoring for clinical management.},
}
@article {pmid41592860,
year = {2026},
author = {Sullivan, DJ and Reik, R and Prichard, A and Pagan, M and Tobian, AAR and Caturegli, P and Pekosz, A and Klein, SL and Bloch, EM and Shoham, S and Gebo, KA and Joyner, MJ and Senefeld, JW and Franchini, M and Focosi, D and Pandey, S and Lane, K and McBee, NA and Pirofski, LA and Casadevall, A and Hanley, DF},
title = {COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.},
journal = {Expert review of anti-infective therapy},
volume = {24},
number = {1},
pages = {97-111},
pmid = {41592860},
issn = {1744-8336},
support = {R01 AI152078/AI/NIAID NIH HHS/United States ; U24 TR001609/TR/NCATS NIH HHS/United States ; },
mesh = {Humans ; COVID-19 Serotherapy ; *COVID-19/therapy/immunology ; Immunization, Passive/methods ; *SARS-CoV-2/immunology ; *Antibodies, Viral/blood/therapeutic use/immunology ; Drug Approval ; United States ; Antibodies, Neutralizing ; Immunocompromised Host ; Randomized Controlled Trials as Topic ; United States Food and Drug Administration ; },
abstract = {INTRODUCTION: COVID-19 convalescent plasma with high anti-SARS-CoV-2 antibody levels transfused within 6 months from donor collection was formally approved by the Food and Drug Administration in December 2024 for COVID-19 treatment in immunocompromised patients. Here we summarize the safety and efficacy data submitted for the Biologics License Application.<br><br>AREAS COVERED: Safety evaluation in over 100,000 individuals in the expanded access program and 24,000 in randomized controlled trials, showed no serious adverse event increases. Robust randomized controlled trials established efficacy in four distinct disease stages: outpatient, inpatient, newly mechanically ventilated, and in those immunocompromised to prevent acute disease progression or eliminate persistent viral carriage. Pharmacokinetics revealed a three-liter distribution volume with viral specific antibody effective dose near 2-50 mg. Major SARS-CoV-2 antibody-mediated antiviral actions included direct neutralization by viral-binding interference to cell receptors and fragment-crystallizable mediated antiviral effects that reduce virions. Virus neutralization correlated with high anti-Spike antibody levels and antibody levels in the top donor plasma deciles retains therapeutic neutralization against future variants.<br><br>EXPERT OPINION: With pandemic progression, the COVID-19 convalescent plasma safety and efficacy evidence quality increased. Ultimate regulatory approval required robust randomized control efficacy data. Future infectious disease outbreaks require randomized controlled trials in the convalescent plasma roadmap.},
}
@article {pmid41593575,
year = {2026},
author = {Güzel, S and Baysal, HY and Türkoğlu, N and Polat, H and Arslan, MA and Kurşun, E},
title = {Factors ınfluencing vaccine refusal in children: an umbrella review on COVID-19 and childhood vaccinations.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {680},
pmid = {41593575},
issn = {1471-2458},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; *Vaccination Refusal/psychology/statistics &amp; numerical data ; Child ; *Vaccination Hesitancy/psychology/statistics &amp; numerical data ; *COVID-19 Vaccines/administration &amp; dosage ; *Parents/psychology ; *Vaccination/psychology ; },
abstract = {Vaccination is a fundamental public health intervention that saves millions of lives and extends human lifespan. However, vaccine hesitancy and refusal have grown into a global threat due to misinformation. The COVID-19 pandemic has highlighted the critical role of vaccines in reducing mortality rates and controlling outbreaks. Parents' attitudes toward vaccines directly affect children's health and vaccination rates in the community. Therefore, understanding the underlying reasons for parents' refusal of childhood vaccines and the COVID-19 vaccine is of great importance for combating epidemics and public health. The umbrella review method was used in this study. Systematic reviews and meta-analyses conducted between January 1, 2020, and December 30, 2024, were examined in this context. The pandemic period and recent history were considered due to the increase in systematic reviews examining the rapidly rising rates of vaccine refusal after the COVID-19 pandemic. Studies published in English in the PubMed, Wos, and Scopus databases were searched. Fifteen studies were included in the research. In conclusion, socio-demographic factors were found to be a major factor in COVID-19 vaccine refusal, whereas factors such as the "information factor," "vaccine-related factors," and "Cognitive Factors" were found to be more prominent in childhood vaccine refusal.},
}
@article {pmid41593595,
year = {2026},
author = {Abusbaitan, HA and Gondwe, KW and Pirsch, A and Eyadat, A and Alshakhshir, NS and Vilakazi, N and Nkhoma-Mussa, Y and Hearst, MO and Mkandawire-Valhmu, L and Lopez, AA and Schadewald, DM and Dressel, A},
title = {Food insecurity and gender-based violence against women during the COVID-19 pandemic: a systematic review.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {668},
pmid = {41593595},
issn = {1471-2458},
mesh = {Humans ; *Food Insecurity ; *COVID-19/epidemiology ; Female ; *Gender-Based Violence/statistics &amp; numerical data ; Pandemics ; },
abstract = {BACKGROUND: Gender-based violence (GBV) and food insecurity are conditions that affect women and may also exacerbate each other, as women experience disproportionately higher levels of both globally. Both of these conditions also increased during the COVID-19 pandemic. The purpose of this systematic review was to describe how the association between food insecurity and GBV across multiple global regions during the COVID-19 pandemic impacted women. The review aims to inform equity-driven interventions and policy development in the event for use during future emergency crises.<br><br>METHODS: The social-ecological model (SEM) and the intersectionality framework were the frameworks used for this systematic review. The PRISMA guidelines guided this systematic review methodology. The literature search was conducted using the APA PsycINFO, CINAHL, MEDLINE, PubMed, and Web of Science databases in November 2025. The inclusion criteria were as follows: (1) studies conducted during the COVID-19 pandemic; (2) studies that assessed the association between food insecurity and GBV among women during the COVID-19 pandemic; and (3) studies published in English in peer-reviewed journals. The exclusion criterion was any study that was not primary research. The Quality Assessment Tool for Studies with Diverse Designs (QATSDD) was used for quality appraisal. Thematic analysis, guided by Hennink and colleagues (2020), was used to synthesize the results.<br><br>RESULTS: Thirty-two studies were included in the data analysis. At the individual level, food insecurity and GBV during the COVID-19 pandemic were associated with a greater likelihood of reporting mental health conditions such as anxiety and depression. Additionally, being an immigrant was associated with a high risk of experiencing food insecurity and GBV. At the relationship level, food insecurity and GBV were associated with household instability and family dysfunction. At the community level, the association was influenced by poverty and limited employment opportunities. At the societal level, restrictive COVID-19 policies and prevailing cultural norms contributed to intensifying food insecurity and GBV.<br><br>CONCLUSION: This study offers support for strengthening crisis&#x2012;response systems across socio-ecological levels that incorporate gender-sensitive food security and violence prevention strategies during public health emergencies. New policies are needed to create effective support systems to promote women's health, especially marginalized groups, who experience the greatest vulnerability.},
}
@article {pmid41594447,
year = {2026},
author = {Ortello, C and Pace, L and Farina, D and Manzulli, V and Rondinone, V and Cipolletta, D and Galante, D},
title = {Suidae Coronaviruses: Epidemiology, Transmission, and Molecular Diagnosis.},
journal = {Animals : an open access journal from MDPI},
volume = {16},
number = {2},
pages = {},
pmid = {41594447},
issn = {2076-2615},
support = {PE00000007//EU funding within the NextGeneration EU-MUR PNRR/ ; },
abstract = {The emergence and spread of swine coronaviruses represent a growing challenge for both veterinary medicine and public health. These viruses exhibit high mutation rates, recombination potential, and the capacity for cross-species transmission. Among the most relevant pathogens are PEDV, TGEV, PRCV, PHEV, PDCoV, and SADS-CoV, which have caused significant outbreaks in swine production systems worldwide, with severe economic consequences. Recent evidence demonstrates coronavirus circulation in wild boar populations across Europe, including Italy, Spain, and Germany. Although wild boars are not confirmed as primary reservoirs, their ecological behavior and increasing overlap with domestic pigs raise concern over their potential role in maintaining viral circulation. Future research priorities should focus on developing a more integrated and coordinated system for the control of swine coronaviruses, including strengthened surveillance in both domestic pigs and wild boar populations, the use of molecular epidemiology techniques to identify emerging variants, and structured collaboration among veterinary, ecological, health, and regulatory sectors. Finally, investment is needed in the development of next-generation vaccines and diagnostic tools to address the considerable genetic variability of swine coronaviruses and to improve the prevention and early detection of and response to future epidemic threats.},
}
@article {pmid41594651,
year = {2026},
author = {Lefebvre, M and Chahinian, H and Yahi, N and Fantini, J},
title = {The Enigmatic Conserved Q134-F135-N137 Triad in SARS-CoV-2 Spike Protein: A Conformational Transducer?.},
journal = {Biomolecules},
volume = {16},
number = {1},
pages = {},
pmid = {41594651},
issn = {2218-273X},
mesh = {*Spike Glycoprotein, Coronavirus/chemistry/metabolism/genetics ; *SARS-CoV-2 ; Humans ; Protein Domains ; Gangliosides/metabolism/chemistry ; Protein Conformation ; Models, Molecular ; COVID-19/virology ; },
abstract = {Lipid raft-associated gangliosides facilitate the early stages of SARS-CoV-2 entry by triggering the exposure of the receptor-binding domain (RBD) within the trimeric spike protein, which is initially sequestered. A broad range of in silico, cryoelectron microscopy and physicochemical approaches indicate that the RBD becomes accessible after a ganglioside-induced conformational rearrangement originating in the N-terminal domain (NTD) of one protomer and propagating to the neighboring RBD. We previously identified a triad of amino acids, Q134-F135-N137, as a strictly conserved element on the NTD. In the present review, we integrate a series of structural and experimental data revealing that this triad may act as a conformational transducer connected to a chain of residues that are capable of transmitting an internal conformational wave within the NTD. This wave is generated at the triad level after physical interactions with lipid raft gangliosides of the host cell membrane. It propagates inside the NTD and collides with the RBD of a neighboring protomer, triggering its unmasking. We also identify a chain of aromatic residues that are capable of controlling electron transfer through the NTD, leading us to hypothesize the existence of a dual conformational/quantum wave. In conclusion, the complete conservation of the Q134-F135-N137 triad despite six years of extensive NTD remodeling underscores its critical role in the viral life cycle. This triad represents a potential Achilles' heel within the hyper-variable NTD, offering a stable target for therapeutic or vaccinal interventions to disrupt the conformational wave and prevent infection. These possibilities are discussed.},
}
@article {pmid41594655,
year = {2026},
author = {Baindara, P and Dinata, R and Kumar, R},
title = {Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era.},
journal = {Biomolecules},
volume = {16},
number = {1},
pages = {},
pmid = {41594655},
issn = {2218-273X},
mesh = {Humans ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; *Saccharomyces cerevisiae/genetics/immunology ; Protein Subunit Vaccines ; Pandemics/prevention &amp; control ; Vaccine Development ; Vaccines, Synthetic/immunology ; Vaccines, Subunit/immunology ; Saccharomycetales/genetics ; },
abstract = {The COVID-19 pandemic accelerated vaccine innovation but also exposed weaknesses in global access and manufacturing. Yeast-based platforms, particularly Saccharomyces cerevisiae and Pichia pastoris, also known as Komagataella phaffii, offer a practical complement to vector systems. These eukaryotic microorganisms combine safety, scalability, and cost-effectiveness with the ability to express complex antigens and assemble virus-like particles. Building on the success of the recombinant hepatitis B vaccine, recent advances in glycoengineering, CRISPR-based host optimization, and surface display technologies have expanded the utility of yeast-based platforms for the rapid development of vaccines. Yeast-derived SARS-CoV-2 receptor-binding domain (RBD) subunit vaccines, such as Corbevax and Abdala (CIGB-66), demonstrate that affordable, immunogenic, and thermostable products are feasible at scale. Emerging innovations in glycan humanization, thermostable formulations, and oral or mucosal delivery highlight the potential of yeast-based vaccines for decentralized manufacturing and equitable pandemic preparedness. This review summarizes recent technical and clinical progress in yeast-based vaccine research, positioning these platforms as accessible and adaptable tools for future outbreak responses and global immunization strategies.},
}
@article {pmid41594661,
year = {2026},
author = {Förster, CY and Shityakov, S},
title = {A Possible Role for the Vagus Nerve in Physical and Mental Health.},
journal = {Biomolecules},
volume = {16},
number = {1},
pages = {},
pmid = {41594661},
issn = {2218-273X},
support = {Fo-315/5-1//Deutsche Forschungsgemeinschaft/ ; },
mesh = {Humans ; *Vagus Nerve Stimulation/methods ; *Vagus Nerve/physiology ; Animals ; *Mental Health ; Mental Disorders/therapy ; },
abstract = {For decades, researchers have explored the therapeutic potential of the vagus nerve through vagus nerve stimulation (VNS). Initially developed for epilepsy, VNS has since been applied to treat resistant depression, stroke recovery, and inflammatory conditions. Transcutaneous VNS (tVNS) now offers a noninvasive alternative, fueling clinical trials in disorders ranging from rheumatoid arthritis and migraines to long COVID-19. Mechanistic studies suggest that afferent and efferent vagal fibers modulate immune responses, mood regulation, and neurotransmitter systems. The SPARC initiative has accelerated mapping of vagal circuits, enabling more precise approaches to stimulation. Despite progress, the results remain mixed: while some patients experience lasting symptom relief, others respond no better than to placebo. Depression studies, in particular, highlight both the promise and the complexity of VNS, as inflammation, motivation circuits, and gut-brain signaling emerge as key modulators. Next-generation closed-loop devices and circuit-specific targeting may improve efficacy and reduce adverse effects. VNS research thus lies at the intersection of neuromodulation, psychiatry, and immunology-offering hope for hard-to-treat conditions, yet demanding rigorous trials to separate myths from medicine. In this article, we review the current clinical and experimental applications of tVNS, analyze its mixed efficacy across psychiatric, immunological, and neurological disorders, and highlight the mechanistic insights, stimulation parameters, and emerging technologies that may shape next-generation therapies.},
}
@article {pmid41594835,
year = {2026},
author = {Kostev, K and Konrad, M and Bohlken, J},
title = {Real-World Evidence for Psychiatric Disorders from the German Disease Analyzer Database: A Narrative Review.},
journal = {Brain sciences},
volume = {16},
number = {1},
pages = {},
pmid = {41594835},
issn = {2076-3425},
abstract = {The German IQVIA Disease Analyzer (DA) database has become an increasingly important source of real-world evidence for psychiatric research. Over the past decade, and particularly since 2020, DA-based studies have addressed a broad spectrum of psychiatric outcomes including depression, anxiety disorders, schizophrenia, bipolar disorder, dementia, sleep disorders, and the mental health consequences of chronic somatic diseases and of contracting COVID-19. Using large, representative outpatient cohorts, these studies have examined factors associated with the incidence of psychiatric disorders, patterns of psychiatric and somatic comorbidity, treatment trajectories, and long-term outcomes under routine care conditions. The DA database's longitudinal structure, nationwide coverage, and inclusion of multiple medical specialties enable it to capture psychiatric disorders throughout patient lifetimes and across different clinical contexts. This narrative review summarizes psychiatric research using the DA database that has been published since 2020, focusing on study design, main findings, methodological strengths and limitations, and implications for future psychiatric epidemiology and clinical research.},
}
@article {pmid41595814,
year = {2025},
author = {Lim, L and Mukasheva, A and Alegbe, AO and Emehel, AN and Aubakirova, B and Semenova, Y},
title = {Public Health Communication Challenges in Eastern Europe and Central Asia: A Scoping Review.},
journal = {International journal of environmental research and public health},
volume = {23},
number = {1},
pages = {},
pmid = {41595814},
issn = {1660-4601},
support = {001/WHO_/World Health Organization/International ; },
mesh = {Humans ; *Public Health ; Asia, Central ; Europe, Eastern ; *Health Communication ; COVID-19/epidemiology ; *Communication ; },
abstract = {This scoping review examines public health communication across nine Eastern European and Central Asian states-Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzbekistan-highlighting how these systems have transitioned from Soviet-era legacies to contemporary practices. Eligibility criteria included the English- and Russian-language literature published from 1998 onwards, focusing on nine post-Soviet states. Sources of evidence comprised searches in Google Scholar, ScienceDirect, SSRN, Heliyon, MEDLINE/PubMed, and official government websites. Data were charted by three independent reviewers using a standardized form, with discrepancies resolved by senior reviewers. The review identifies persistent gaps in communication during health crises, with a particular focus on the COVID-19 pandemic, where centralized and hierarchical information flows often undermine transparency and responsiveness, as well as further increased health inequalities between rural and urban health outcomes. Despite ongoing reforms, the communication dimension of healthcare systems remains underdeveloped. Findings reveal that centralized and top-down communication remains a dominant feature across the region, hindering timely dissemination of information and limiting the capacity to counter misinformation, as both misinformation and disinformation sometimes emerge from the government. Ultimately, this review contributes a critical analysis of these systematic communication failures and underscores the need to strengthen public health communication and reduce health inequalities. To do it, governments must prioritize transparency, disclose decision-making processes, and rely on evidence-based messaging to build trust. Effective crisis response requires not only government leadership but also the active engagement of the medical and patient communities, supported by civil society and independent media. This review points out the need for more inclusive, transparent, and trust-oriented communication strategies to enhance public health preparedness and resilience in nine Eastern European and Central Asian contexts.},
}
@article {pmid41595987,
year = {2025},
author = {Morelli, S and Giansanti, D},
title = {Recent Advances in AI-Driven Mobile Health Enhancing Healthcare-Narrative Insights into Latest Progress.},
journal = {Bioengineering (Basel, Switzerland)},
volume = {13},
number = {1},
pages = {},
pmid = {41595987},
issn = {2306-5354},
abstract = {BACKGROUND: The integration of artificial intelligence (AI) into mobile health (mHealth) applications has been accelerated by the widespread adoption of smartphones and recent technological advances, particularly in the wake of the COVID-19 pandemic. This experience has expanded the role of AI-powered apps in real-time health monitoring, early detection, and personalized treatment pathways.<br><br>AIM: This review aims to summarize recent evidence on the use of AI in healthcare-related mobile applications, with a focus on clinical trends, practical implications, and future directions.<br><br>METHODS: Studies were prioritized based on methodological rigor, with systematic reviews forming the core of the analysis. Additional literature was considered to capture emerging trends and applications where a relevant rigorous screening and scoring procedure was applied to ensure methodological quality and relevance. Only studies addressing healthcare applications, rather than computational or computer science frameworks, were included to reflect the journal's clinical scope.<br><br>RESULTS AND DISCUSSION: Fifty-six secondary studies were analyzed in detail. Thematic synthesis revealed a post-pandemic shift toward applications targeting mental health, chronic care management, and preventive services. Additional screening showed that, despite their increasing use in clinical contexts, few AI-based apps were formally classified as medical devices. This highlights a gap between technological innovation and regulatory oversight. Ethical concerns-including algorithm transparency, clinical responsibility, and data protection-were frequently reported across studies.<br><br>CONCLUSIONS: This review underscores the growing impact of AI in mobile health, while drawing attention to unresolved challenges related to regulation, safety, and clinical accountability. A more robust integration into health systems will require clearer governance frameworks, validation standards, and interdisciplinary dialogue between developers, clinicians, and regulators.},
}
@article {pmid41596113,
year = {2025},
author = {Țocu, G and Ștefănescu, BI and Stavăr Matei, L and Țocu, L},
title = {Phagocyte NADPH Oxidase NOX2-Derived Reactive Oxygen Species in Antimicrobial Defense: Mechanisms, Regulation, and Therapeutic Potential-A Narrative Review.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
pmid = {41596113},
issn = {2076-3921},
abstract = {ROS derived from NADPH oxidase, particularly NOX2, are central to antimicrobial defense, coupling direct pathogen killing with redox signaling that shapes inflammation. This narrative review integrates recent advances on NOX2 structure, assembly, and spatiotemporal control in phagocytes, and outlines how ROS interact with NF-κB, MAPK, and Nrf2 networks to coordinate microbicidal activity and immune modulation. We summarize evidence that both ROS deficiency, as in chronic granulomatous disease, and uncontrolled excess, as in sepsis and severe COVID-19, drive clinically significant pathology, emphasizing the need for precise redox balance. Emerging therapeutic strategies include selective NOX2 inhibitors that limit pathological oxidative bursts, redox-modulating peptides that disrupt upstream activation cues, and Nrf2 activators that enhance endogenous antioxidant capacity, with attention to dosing challenges that preserve host defense while mitigating tissue injury. Key gaps remain in biomarker standardization, real-time in vivo ROS monitoring, and translation from animal models to patients, motivating personalized, combination approaches to redox medicine in infectious diseases.},
}
@article {pmid41596124,
year = {2026},
author = {Ayyubova, G and Bablu, FE and Rahimli, N and Aghayeva, L and Springer, EM and Alghenaim, FA and Suzuki, YJ},
title = {Roles of Reactive Oxygen Species in Relationships Between Viral Infections and Alzheimer's Disease and Related Dementia.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
pmid = {41596124},
issn = {2076-3921},
abstract = {Emerging evidence suggests that viral infections may contribute to the onset and progression of Alzheimer's disease (AD) and other forms of dementia. Understanding the mechanism of viral involvement in the pathogenesis of AD and related dementia (ADRD) could contribute to reducing the burden caused by these conditions, which affect a large portion of the aging population. Some studies indicate the link between AD and viral infections, notably coronaviruses and herpesviruses. In AD, excessive production of reactive oxygen species (ROS) results in the modifications of lipids, proteins, and nucleic acids, contributing to synaptic dysfunction and cognitive impairments. Experimental evidence suggests that viral infections linked to ADRD induce the cellular production of ROS, possibly contributing to the pathogenesis of these conditions. Despite significant advances in defining the roles of ROS in neurological disorders and viral infections, the specific roles of ROS in virus-associated ADRD have not been thoroughly investigated. The main objective of this review article is to comprehensively provide information on the experimental evidence for the production of ROS by viruses to help the readers investigate the role of ROS in the relationship between viral infections with ADRD.},
}
@article {pmid41596316,
year = {2026},
author = {Hayashi, H and Kubo, Y and Tanaka, Y},
title = {Host Responses to SARS-CoV-2 with an Emphasis on Cytokines.},
journal = {International journal of molecular sciences},
volume = {27},
number = {2},
pages = {},
pmid = {41596316},
issn = {1422-0067},
mesh = {Humans ; *Cytokines/immunology/metabolism ; SARS-CoV-2 ; COVID-19/immunology ; Pandemics ; Animals ; Cytokine Release Syndrome/immunology ; Immunity, Innate ; Interferons/immunology ; },
abstract = {The COVID-19 pandemic has profoundly affected societies around the world. Although the emergency phase of coronavirus disease 2019 (COVID-19) has ended, the threat it poses remains persistent. This review aims to clarify the mechanisms of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection to support effective management of the disease. A central focus is the host cellular response to the viral infection, with particular emphasis on the role of cytokines. Cytokines play a dual role in antiviral defense: they contribute to the inhibition of viral replication and facilitate the clearance of pathogens, yet dysregulated cytokine responses can result in severe immunopathology. Interferons (type I, type II, and type III) and other cytokines are pivotal in activating intracellular antiviral mechanisms and in orchestrating the recruitment of immune cells through extracellular signaling. Effective immune responses to viral infections are governed not only by primary immune cells-such as dendritic cells, T lymphocytes, and B lymphocytes-but also by the local cytokine milieu shaped by infected and neighboring cells. Given the presence of endogenous inhibitors and autoantibodies in vivo, it is essential to evaluate the functional activity of cytokines in clinical samples. We propose a novel approach to quantify biologically active cytokine levels.},
}
@article {pmid41596537,
year = {2026},
author = {Muntean, ST and Cozac-Szoke, AR and Tinca, AC and Kosovski, IB and Vultur, S and Vultur, M and Cotoi, OS and Sin, AI},
title = {Molecular Aspects of Viral Pathogenesis in Emerging SARS-CoV-2 Variants: Evolving Mechanisms of Infection and Host Response.},
journal = {International journal of molecular sciences},
volume = {27},
number = {2},
pages = {},
pmid = {41596537},
issn = {1422-0067},
mesh = {Humans ; *SARS-CoV-2/pathogenicity/genetics/physiology ; *COVID-19/virology/immunology/pathology ; Virus Internalization ; Spike Glycoprotein, Coronavirus/genetics/chemistry/metabolism ; Serine Endopeptidases/metabolism/genetics ; Host-Pathogen Interactions ; Mutation ; Viral Nonstructural Proteins/genetics/metabolism ; Neuropilin-1/metabolism/genetics ; },
abstract = {Although the SARS-CoV-2 pandemic no longer poses a global emergency, the virus continues to diversify and acquire immunoevasive properties. Understanding the molecular pathways that shape SARS-CoV-2 pathogenesis has become essential. In this paper, we summarize the most recent current evidence on how the spike protein structurally evolves, on changes in key non-structural proteins, such as nsp14, and on host factors, such as TMPRSS2 and neuropilin-1. These changes, together, shape viral entry, replication fidelity and interferon antagonism. Given the emerging Omicron variants of SARS-CoV-2, recent articles in the literature, cryo-EM analyses, and artificial intelligence-assisted mutational modeling were analyzed to infer and contextualize mutation-driven mechanisms. It is through these changes that the virus adapts and evolves, such as optimizing angiotensin-converting enzyme binding, modifying antigenic surfaces, and accumulating mutations that affect CD8[+] T-cell recognition. Multi-omics data studies further support SARS-CoV-2 pathogenesis through convergent evidence linking viral adaptation to host immune and metabolic reprogramming, as occurs in myocarditis, liver injury, and acute kidney injury. By integrating proteomic, transcriptomic, and structural findings, this work presents how the virus persists and dictates disease severity through interferon antagonism (ORF6, ORF9b, and nsp1), adaptive immune evasion, and metabolic rewiring. All these insights underscore the need for next-generation interventions that provide a multidimensional framework for understanding the evolution of SARS-CoV-2 and guiding future antiviral strategies.},
}
@article {pmid41596670,
year = {2026},
author = {Smola-Dmochowska, A and Śmigiel-Gac, N and Jelonek, K and Lewicka-Brzoza, K and Bojdol, J and Dobrzyński, P},
title = {Antithrombotic Polymers: A Narrative Review on Current and Future Strategies for Their Design, Synthesis, and Application.},
journal = {International journal of molecular sciences},
volume = {27},
number = {2},
pages = {},
pmid = {41596670},
issn = {1422-0067},
mesh = {Humans ; *Polymers/chemistry/chemical synthesis/therapeutic use/pharmacology ; *Fibrinolytic Agents/chemistry/therapeutic use/chemical synthesis/pharmacology ; *Thrombosis/drug therapy/prevention &amp; control ; Animals ; COVID-19/complications ; Drug Design ; SARS-CoV-2 ; },
abstract = {Bleeding and thromboembolism are among the leading causes of mortality worldwide. Thrombosis encompasses both arterial forms-primarily associated with atherosclerosis and leading to heart attacks or strokes-and venous forms. Microvascular thrombosis typically arises in the context of sepsis or systemic inflammation, and it became particularly prominent during the COVID-19 pandemic, substantially contributing to increased mortality. Given this burden, the rapid development of new therapies using advanced techniques and materials to prevent and treat these conditions is essential. This review summarizes recent advances in the design of antithrombotic polymers, discussing mechanisms of action, surface-modification strategies, and current clinical and preclinical applications. It also outlines criteria for evaluating hemocompatibility, describes in vitro and in vivo testing methods, and highlights key barriers to translating these materials into clinical practice. The review concludes by identifying promising directions for future research, including multifunctional approaches that combine antifouling properties, controlled drug release, and bioresistance strategies with the greatest potential to reduce thromboembolic complications associated with medical materials. It further evaluates the progress made to date in combating thrombotic diseases and identifies remaining gaps in the development and clinical implementation of new antithrombotic materials.},
}
@article {pmid41596677,
year = {2026},
author = {Smith, E and Scholey, J},
title = {The Renin Angiotensin System: Insights into the Role of ACE2 in Glomerular Injury Including SARS-CoV-2 Infection.},
journal = {International journal of molecular sciences},
volume = {27},
number = {2},
pages = {},
pmid = {41596677},
issn = {1422-0067},
mesh = {Humans ; *Angiotensin-Converting Enzyme 2/metabolism ; *Renin-Angiotensin System/physiology ; *COVID-19/pathology/metabolism ; *Kidney Glomerulus/pathology/metabolism/injuries ; *Peptidyl-Dipeptidase A/metabolism ; SARS-CoV-2 ; Animals ; Angiotensin II/metabolism ; Receptors, Virus/metabolism ; },
abstract = {The circulating renin-angiotensin-aldosterone system (RAAS) plays a key role in regulating blood volume and electrolyte levels. While important for the maintenance of intravascular volume systemically, the local activation of tissue RAAS and the generation of angiotensin II contribute to inflammation and fibrosis. In the kidney, angiotensin II plays a key role in the development and progression of glomerular injury. Angiotensin-converting enzyme 2 (ACE2), an enzyme that degrades angiotensin II, is expressed in the glomerulus, focusing attention not only on the complexity of the RAAS but also identifying a potential new determinant of glomerular injury. Accordingly, we performed a narrative review using the search terms ACE2 and glomerulus in PubMed and Google Scholar to summarize the current understanding of the role of ACE2 in glomerular injury. We also discuss the role of ACE2 as a cellular receptor for SARS-CoV-2 and the potential impact of this function on glomerular injury in the setting of COVID-19.},
}
@article {pmid41596805,
year = {2026},
author = {Głuchowski, A and Czarniecka-Skubina, E and Pielak, M},
title = {Effect of the Sous-Vide Method on the Quality of Vegetables-A Review.},
journal = {Foods (Basel, Switzerland)},
volume = {15},
number = {2},
pages = {},
pmid = {41596805},
issn = {2304-8158},
abstract = {Modern gastronomy strives to combine high-quality food with the preservation of nutritional value, microbiological safety, and the sustainable use of raw materials. With the development of culinary technologies, precise heat treatment methods are gaining increasing importance, enabling better process control and more consistent quality results. This analysis aims to present the effects of the sous-vide (SV) method on the quality of vegetables in comparison with conventional heat treatment methods, such as boiling in water, steaming, cooking under increased pressure, cooking in a microwave oven, baking, grilling, and the cook-vide method. Analysis of the scientific literature has shown that the sous-vide method usually allows for the retention of greater amounts of vitamins (especially vitamin C), phenolic compounds and minerals, resulting in products with higher nutritional value and bioavailability of bioactive ingredients. Maintaining a controlled, low temperature in a vacuum environment reduces the loss of water and volatile components, which has a positive impact on the process yield as well as the color, texture, and aroma of vegetables. SV processing enhances product digestibility, preserves natural appearance, and improves food safety. Due to its hermetic packaging and limited oxygen access, this method ensures good microbiological quality and extends product shelf life. In the food service industry, SV allows for repeatable results, high sensory and technological quality, and reduced food waste. In the context of contemporary nutritional challenges and the experiences of the COVID-19 pandemic, sous-vide technology is gaining importance as a method supporting food safety, sustainability, and efficient resource management in the food service industry.},
}
@article {pmid41597083,
year = {2026},
author = {Alhumaid, S and Alkhamees, AA and Al Dossary, N and Almuslim, AA and Majzoub, RA and Alalwan, QM and Alsaeed, MJ and Aljowaisem, FM and Alqahtani, MA and Alamer, AI and ALDuhailan, MI and Al Nasser, DA and Almuhanna, MS and Al-Kamees, MA and Alhadab, HA and Alsultan, AA and Bukhamseen, AN and Alabdullah, AA and Alhaddad, KS and Alhumaid, MA and Almusabeh, HM and Almubarak, YS and AlShayeb, RA and Alnami, DA and Alatiyyah, YY and Al Alawi, Z and Alabdulqader, M},
title = {Long-Term Kidney Outcomes After SARS-CoV-2 Infection in Children Aged 0-12 Years: A Systematic Review.},
journal = {Children (Basel, Switzerland)},
volume = {13},
number = {1},
pages = {},
pmid = {41597083},
issn = {2227-9067},
abstract = {Background: Acute kidney injury (AKI) is increasingly recognised in children with acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C), yet the long-term renal consequences in younger paediatric populations remain unclear. Most studies focus on acute illness or mixed-age cohorts, with limited data specific to children aged 0-12 years. Objectives: This study aimed to systematically identify, evaluate, and synthesise evidence on post-acute (≥30 days) and long-term (≥90 days) kidney outcomes following SARS-CoV-2 infection or MIS-C in children aged 0-12 years, including chronic kidney disease (CKD), eGFR decline, proteinuria, haematuria, hypertension, and need for kidney replacement therapy. Methods: We searched MEDLINE, Embase, CINAHL, and PubMed (December 2019-30 November 2025), following PRISMA 2020 guidelines and a registered PROSPERO protocol (CRD420251241949). Observational studies reporting kidney outcomes ≥30 days post-infection in children aged 0-12 years were included. Risk of bias was assessed using the Newcastle-Ottawa Scale or ROBINS-I. Owing to heterogeneity and absence of ≥3 comparable datasets, a narrative synthesis was performed. Results: Seven studies met inclusion criteria (five MIS-C cohorts, two acute COVID-19 cohorts). Only a subset provided extractable data specific to children aged 0-12 years. Follow-up ranged from 30 days to 12 months; four studies reported outcomes ≥ 180 days. Across all studies, no incident CKD, sustained eGFR decline, or kidney replacement therapy were reported among children completing long-term follow-up; however, most long-term outcome data were derived from MIS-C cohorts with median ages around 8-11 years that included some adolescents, rather than exclusively children aged 0-12 years. One MIS-C study reported long-term hypertension in 14% of children. A cross-sectional Italian cohort of mild COVID-19 demonstrated hyperfiltration, proteinuria, and microhaematuria at ~3 months, though chronicity could not be assessed due to absence of baseline values. A large US EHR-based cohort identified increased CKD risk after COVID-19 in the broader < 21-year population; however, 0-12-year-specific event counts were not reported, preventing quantitative synthesis for young children. Conclusions: Evidence on long-term kidney outcomes after SARS-CoV-2 infection in children aged 0-12 years remains limited, and only a small subset of studies provided extractable, age-specific data. On the other hand, MIS-C cohorts generally show favourable renal recovery, small sample sizes, lack of control groups, and short follow-up restrict confidence in these findings. Large paediatric EHR studies suggest potential long-term renal risk in broader paediatric populations, highlighting the need for age-stratified, prospective cohorts with serial eGFR, urine studies, and blood pressure assessments. Until definitive evidence emerges, structured renal follow-up may be warranted for children with AKI or MIS-C during COVID-19.},
}
@article {pmid41597107,
year = {2026},
author = {Álvarez-Fernández, ML and Rodríguez, C},
title = {Socio-Emotional Wellbeing in Parents of Children with Neurodevelopmental Disorders: A Systematic Review.},
journal = {Children (Basel, Switzerland)},
volume = {13},
number = {1},
pages = {},
pmid = {41597107},
issn = {2227-9067},
support = {PID2021-1244011NB-I00//Spanish Ministry of Science and Innovation 444 (MCIN/AEI/10.13039/501100011033/FEDER, UE)/ ; },
abstract = {Background/Objectives: Neurodevelopmental disorders (NDDs) require contextual approaches emphasizing family roles. Parents of children with NDDs face a complex socio-emotional reality. They may experience high levels of stress, fatigue, depression, and feelings of guilt and uncertainty, and they are often left feeling isolated and unsupported. All of these factors increase their socio-emotional vulnerability and affect their children's wellbeing. A significant part of the available evidence has focused on parents of typically developing children or on a single construct. For these reasons, and considering the impact of the COVID-19 pandemic, the aim of this study was to review interventions targeting the improvement of the socio-emotional wellbeing of parents of children with NDDs, in order to characterise recent research, the specific constructs addressed, and the effectiveness of interventions. Methods: No prior protocol/registration. ERIC and Web of Science databases (selected for their broad multidisciplinary coverage in psychology and social sciences) were searched from 2020-2025 (last search: 7 September 2025), limited to English/Spanish publications. Inclusion criteria encompassed parents/primary family caregivers of children with NDDs receiving socio-emotional programs. Two independent reviewers screened the titles/abstracts and full texts, resolving disagreements through discussion. Following PRISMA 2020 guidelines, this systematic review employed narrative synthesis without risk-of-bias assessment and included 16 studies (approximately, 1100 participants). Results: The analysis indicated a scarce but growing scientific output, with a complex methodological landscape showing promising preliminary convergence in intervention outcomes. Interventions effects appeared mediated by cultural suitability, accessibility, and contextual alignment. Conclusions: Future work should pursue multisystemic approaches engaging diverse societal contexts and agents to optimize child and family wellbeing.},
}
@article {pmid41597174,
year = {2026},
author = {Sisk, CK and Turner, LM and Meraj, S and Yusuf, N},
title = {Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms.},
journal = {Cells},
volume = {15},
number = {2},
pages = {},
pmid = {41597174},
issn = {2073-4409},
mesh = {Humans ; *Dendritic Cells/immunology ; *Cancer Vaccines/immunology/administration &amp; dosage/therapeutic use ; *Melanoma/immunology/therapy ; *Nanoparticles/chemistry ; *RNA, Messenger/immunology ; *Lipids/chemistry ; Animals ; mRNA Vaccines ; Antigens, Neoplasm/immunology ; Nanovaccines ; Liposomes ; },
abstract = {Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.},
}
@article {pmid41597249,
year = {2026},
author = {Stigliano, E and Tocci, A and Florio, R and Arena, V and Amadoro, G},
title = {Olfactory Dysfunction and Cognitive Deterioration in Long COVID: Pathomechanisms and Clinical Implications in Development of Alzheimer's Disease.},
journal = {Cells},
volume = {15},
number = {2},
pages = {},
pmid = {41597249},
issn = {2073-4409},
support = {RF-2021-12374//Italian Ministry of Health/ ; 971925//Alzheimer's Association Research Grant/ ; FOE D.M865/2019//Fondo Ordinario Enti/ ; },
mesh = {Humans ; *COVID-19/complications ; *Alzheimer Disease/virology/etiology ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; *Olfaction Disorders/virology ; *Cognitive Dysfunction/virology ; Anosmia ; },
abstract = {Complete or partial loss of smell (anosmia), sometimes in association with distorted olfactory perceptions (parosmia), is a common neurological symptom affecting nearly 60% of patients suffering from post-acute neurological sequelae of COronaVIrus Disease of 2019 (COVID-19) syndrome, called long COVID. Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) may gain access from the nasal cavity to the brain (neurotropism), and the olfactory route has been proposed as a peripheral site of virus entry. COVID-19 is a risk factor for developing Alzheimer's Disease (AD), an age-dependent and progressive neurodegenerative disorder characterized in affected patients by early olfaction dysfunction that precedes signs of cognitive decline associated with neurodegeneration in vulnerable brain regions of their limbic system. Here, we summarize the recent literature data supporting the causal correlation between the persistent olfactory deterioration following SARS-CoV-2 infection and the long-delayed manifestation of AD-like memory impairment. SARS-CoV-2 infection of the olfactory neuroepithelium is likely to trigger a pattern of detrimental events that, directly and/or indirectly, affect the anatomically interconnected hippocampal and cortical areas, thus resulting in tardive clinical dementia. We also delineate future advancement on pharmacological and rehabilitative treatments to improve the olfactory dysfunction in patients recovering even from the acute/mild phase of COVID-19. Collectively, the present review aims at highlighting the physiopathological nexus between COVID-19 anosmia and post-pandemic mental health to favor the development of best-targeted and more effective therapeutic strategies in the fight against the long-term neurological complications associated with SARS-CoV-2 infection.},
}
@article {pmid41597308,
year = {2025},
author = {Carbone, RG and Nagoti, S and Monselise, A and Wille, KM and Puppo, F and Shah, PL},
title = {COVID-19 and Interstitial Lung Disease.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {1},
pages = {},
pmid = {41597308},
issn = {1648-9144},
mesh = {Humans ; *Lung Diseases, Interstitial/etiology/therapy/diagnosis/physiopathology/virology ; *COVID-19/complications ; Tomography, X-Ray Computed ; Risk Factors ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Lung/pathology ; Respiratory Function Tests ; },
abstract = {Background and Objectives: COVID-19 is an infection caused by the SARS-CoV-2 coronavirus that may develop several complications. Interstitial lung disease (ILD) is the major long-term complication of COVID-19 disease leading to progressive lung fibrosis and reduced respiratory function. The aim of this narrative review is to provide an updated overview of post-COVID-19 ILD by examining research publications and clinical guidelines selected from PubMed, Web of Science, and major respiratory medicine journals from 2020 to 2025. Methods: ILDs are diagnosed by medical history, physiological examination, pulmonary function tests, and chest X-ray or high-resolution computed tomography (HRCT) scan. Lung biopsy, especially cryobiopsy or video-assisted thoracoscopic (VATS) biopsy, can be performed to define histological patterns and confirm the diagnosis. Results: Post-COVID-19 ILD is a chronic condition characterized by long-term respiratory symptoms, radiological findings, and reduced lung function. Fibrotic injury is a consequence of the initial infection and could be influenced by persistent inflammation and dysregulated tissue repair. Risk factors include severe acute illness, advanced age, male sex, and smoking. Clinical course and prognosis of post-COVID-19 ILD is uncertain, as most patients experience gradual improvement or stability, whereas others develop progressive lung function decline. Treatment of post-COVID-19 ILD is not presently defined by guidelines but comprises corticosteroids, antifibrotics (including new drugs such as nerandomilast), supportive oxygen, pulmonary physiotherapy rehabilitation, smoking cessation, and vaccination. Conclusions: ILD represents a significant long-term complication of COVID-19 infection. Further investigations are required to better understand its pathophysiology and clinical management. As research progresses, more effective diagnostic and therapeutic strategies are expected to emerge.},
}
@article {pmid41597563,
year = {2025},
author = {Usserbayev, B and Zhugunissov, K and Smekenov, I and Akmyrzayev, N and Abdykalyk, A and Abeuov, K and Zhumadil, B and Melisbek, A and Shirinbekov, M and Zhaksylyk, S and Nagymzhanova, Z and Seidakhmetova, A and Beltramo, C and Peletto, S and Kerimbaev, A and Nurabaev, S and Chervyakova, O and Kozhabergenov, N},
title = {Alpha- and Beta-Coronaviruses in Humans and Animals: Taxonomy, Reservoirs, Hosts, and Interspecies Transmission.},
journal = {Microorganisms},
volume = {14},
number = {1},
pages = {},
pmid = {41597563},
issn = {2076-2607},
support = {IRN BR24992948//Development of new diagnostic test systems for particularly dangerous viral infections (2024-2026) (IRN BR24992948) with the support of the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan./ ; },
abstract = {The Coronaviridae family represents a broad group of RNA-containing viruses that infect humans and animals. This family belongs to the order Nidovirales and is divided into four main genera: α-CoV, β-CoV, γ-CoV and δ-CoV. It is particularly noteworthy that representatives of β-CoV have caused serious epidemics in humans, such as the outbreaks of SARS-CoV, MERS-CoV, and COVID-19 caused by SARS-CoV-2. Although the clinical manifestations of CoVs can range from mild cold-like symptoms to severe respiratory diseases, they share common features in their structure, modes of transmission, and natural reservoirs. Identifying natural reservoirs, as well as establishing intermediate hosts, is crucial for understanding the mechanisms of interspecies transmission of CoVs. These processes are often mediated by molecular interactions between viral spike (S) proteins and cellular receptors of different species, which contribute to zoonotic outbreaks. Thus, the interaction of various species and the study of these processes of viral spread, cross-species transmission, and pathogen evolution play a key role in ensuring global biological safety. Therefore, we conducted this review to summarize the data from existing studies focused on the taxonomy of CoVs, their main types, natural reservoirs, intermediate hosts, pathways of interspecies transmission, and the significance of the One Health concept as an interdisciplinary approach to monitoring, prevention and control of CoV infections at the intersection of human, animal, and environmental health. We examined databases such as PubMed, Science Direct, Web of Science, and Google Scholar to identify relevant scientific articles in English available for such a review. The aim of this work is to study the taxonomy and classification of coronaviruses, as well as to identify their natural reservoirs, intermediate hosts, and applicable control measures. A review of human and animal coronaviruses has revealed their evolutionary diversity, their main natural reservoirs, their intermediate hosts, and their interactions with cellular receptors. This information allows for a better understanding of the mechanisms by which the viruses are transmitted from animals to humans. The concept of One Health demonstrated the interconnections between human, animal and environmental factors.},
}
@article {pmid41597670,
year = {2026},
author = {Soyfoo, M and Sarrand, J},
title = {Plasmablast Storms: Microbial Drivers of Acute and Chronic Autoimmune Flares.},
journal = {Microorganisms},
volume = {14},
number = {1},
pages = {},
pmid = {41597670},
issn = {2076-2607},
abstract = {Autoimmune flares are often accompanied by abrupt surges of circulating plasmablasts-short-lived, high-output antibody-secreting cells generated through extrafollicular B-cell activation in response to microbial cues. Three categories of microbial input appear to repeatedly trigger these "plasmablast storms": latent herpesvirus reactivations (Epstein-Barr virus, cytomegalovirus, human herpesvirus-6, varicella-zoster virus), acute respiratory or gastrointestinal infections including SARS-CoV-2, and chronic oral or gut dysbiosis. Although biologically distinct, these stimuli converge on innate sensing pathways driven by pathogen-associated molecular patterns such as unmethylated CpG DNA, single-stranded RNA, lipopolysaccharide, and bacterial lipoglycans. Through Toll-like receptors and type I interferon signalling, microbial signatures accelerate class switching, amplify inflammatory cytokine milieus, and lower B-cell activation thresholds, enabling rapid plasmablast mobilisation. Dysbiosis further maintains B cells in a hyper-responsive state by disrupting mucosal homeostasis and altering microbial metabolite profiles, thereby reducing the stimulus required to trigger plasmablast bursts. Once generated, these waves of oligoclonal plasmablasts home to inflamed tissues, where chemokine and adhesion landscapes shape their retention during flares. Emerging evidence suggests that such episodic plasmablast expansions promote autoantibody diversification, somatic hypermutation, and epitope spreading, progressively eroding tolerance. This review synthesizes these insights into a unified model in which infections and dysbiosis promote microbe-licensed plasmablast storms that influence the tempo and severity of autoimmune disease.},
}
@article {pmid41597712,
year = {2026},
author = {Mour, G and Paudel, SD and Modi, P and Goswami, U and Shubeilat, J and Ptak, L and Parajuli, S},
title = {The Role of Vaccination in Adult Solid Organ Transplantation: Updated Reviews with Recent Guidelines.},
journal = {Microorganisms},
volume = {14},
number = {1},
pages = {},
pmid = {41597712},
issn = {2076-2607},
abstract = {Vaccination remains a cornerstone of infection prevention in adult solid organ transplant (SOT) recipients, a population at heightened risk for vaccine-preventable diseases due to chronic immunosuppression and comorbidities. Updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (AST IDCOP) and other international bodies emphasize the need for timely and comprehensive vaccination strategies before and after transplantation. This review synthesizes current literature and practice guidelines on vaccination in adult solid organ transplant (SOT) candidates and recipients. Published peer-reviewed studies, clinical trials, and consensus guidelines were evaluated, with emphasis on vaccination timing, safety, immunogenicity, dosing strategies, and serologic response monitoring in the SOT population. Comprehensive vaccination planning before transplantation, combined with appropriate post-transplant booster strategies, remains vital to improving long-term outcomes in SOT recipients. This review provides clinicians with an updated, evidence-based framework for integrating evolving vaccination guidelines into the care of adult transplant patients.},
}
@article {pmid41598213,
year = {2025},
author = {Park, JY and Lee, HM},
title = {PEDV Structural Proteins with Emphasis on M Protein as an Immunomodulatory Factor in Porcine Innate Immunity.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {1},
pages = {},
pmid = {41598213},
issn = {2075-1729},
support = {RS-2025-25400025//National Research Foundation of Korea/ ; },
abstract = {Porcine epidemic diarrhea virus (PEDV) is an enteric alphacoronavirus that causes severe diarrhea and high mortality in neonatal pigs, leading to substantial economic loss in the porcine industry. Previous studies have primarily focused on the spike protein because of its role in viral entry and induction of neutralizing antibody responses. However, accumulating evidence indicates that other viral components also contribute to host immune modulation and pathogenesis. This review summarizes the current knowledge on PEDV structural proteins, with an emphasis on membrane proteins as regulators of porcine innate immune responses. The molecular characteristics and intracellular localization of membrane proteins were described, and the reported effects on interferon signaling, inflammatory pathways, and cellular stress responses were examined. Findings from related coronaviruses were incorporated to highlight the conserved features and virus-specific differences in membrane protein-mediated host modulation. Available evidence suggests that membrane protein-associated interference with innate immune signaling may contribute to intestinal immune dysregulation and disease severity in neonatal piglets. The implications of these observations on PEDV pathogenesis and intervention strategies are also discussed. By shifting attention from spike-centered frameworks to structural protein-driven host interactions, this review highlights membrane proteins as an underexplored but biologically relevant factor in porcine coronavirus research.},
}
@article {pmid41598316,
year = {2026},
author = {Vieru, AM and Radulescu, D and Streba, L and Trasca, ET and Cazacu, SM and Statie, RC and Popa, P and Ciurea, T},
title = {Learning from an Emerging Infection: How the COVID-19 Pandemic Reshaped Gastric Cancer Care.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {1},
pages = {},
pmid = {41598316},
issn = {2075-1729},
abstract = {Background/Objectives: The COVID-19 pandemic profoundly disrupted gastric cancer care, reducing access to screening, delaying diagnosis, and altering therapeutic pathways worldwide. Beyond clinical challenges, it exposed structural weaknesses in healthcare systems but also accelerated innovation. Methods: We conducted a narrative review supported by a structured literature search (PubMed/MEDLINE, Scopus, Web of Science; 1 January 2014-30 November 2025), with a narrative synthesis of observational studies, registry analyses, and meta-analyses addressing COVID-19-related changes in gastric cancer epidemiology, diagnosis, treatment, vaccination, and telemedicine. A PRISMA-style flow diagram was used to illustrate study selection. Results: Elective endoscopy volumes fell by up to 80%, leading to diagnostic backlogs and increased proportions of advanced-stage gastric cancer. Surgical postponements, modified chemotherapy and radiotherapy schedules, and reduced molecular/genetic testing further compromised outcomes. Conversely, vaccination, telemedicine, capsule endoscopy, and adaptive triage frameworks enabled partial recovery of services. Geographical variations were observed in the recovery of gastric cancer care services, with regions that had established screening infrastructure generally resuming activity more rapidly, whereas others experienced ongoing delays and diagnostic backlogs. Conclusions: This review integrates epidemiological, diagnostic, and therapeutic evidence to demonstrate how COVID-19 redefined gastric cancer care. By highlighting regional disparities and outlining a conceptual model for oncologic resilience, it provides an innovative framework for future crisis preparedness. The lessons of the pandemic-digital health integration, flexible treatment protocols, and international collaboration-represent a foundation for more robust, equitable gastric cancer management in the post-pandemic era.},
}
@article {pmid41598392,
year = {2026},
author = {Vaira, LA and Micheluzzi, V and Lechien, JR and Maniaci, A and Maglitto, F and Cammaroto, G and Troise, S and Chiesa-Estomba, CM and Consorti, G and Cirignaco, G and Saibene, AM and Iannella, G and Navarro-Cuéllar, C and Soro, GM and Salzano, G and Casu, G and De Riu, G},
title = {Telemedicine in Oral and Maxillofacial Surgery: A Narrative Review of Clinical Applications, Outcomes and Future Directions.},
journal = {Journal of clinical medicine},
volume = {15},
number = {2},
pages = {},
pmid = {41598392},
issn = {2077-0383},
support = {00000038//Ministero dell'universit&#xe0; e della ricerca/ ; },
abstract = {Objectives: Telemedicine has rapidly expanded in oral and maxillofacial surgery (OMFS), especially during the COVID-19 pandemic, but its specific roles and limitations across the care pathway remain unclear. This narrative review aimed to map telemedicine modalities and indications in OMFS, summarize reported outcomes, and identify priorities for future research. Methods: A narrative synthesis was undertaken after a systematic search of medical and engineering databases to 10 October 2025. Studies applying telemedicine, telehealth, telepresence or teleradiology to OMFS practice were eligible, including trials, observational cohorts, technical reports and surveys. Data were extracted in duplicate and organized thematically; heterogeneity precluded meta-analysis. Results: Fifty studies met the inclusion criteria. Telemedicine was mainly used for preoperative consultation and triage, postoperative follow-up, trauma teleradiology and tele-expertise, oncologic and oral medicine follow-up, temporomandibular disorders, and education or humanitarian work. In low-risk outpatient and postoperative settings, remote consultations showed high concordance with in-person plans, similar complication or reattendance rates, reduced travel, and high satisfaction. In trauma networks, telemedicine supported timely triage and reduced unnecessary inter-hospital transfers. Evidence in oral oncology and complex mucosal disease was more cautious, favouring hybrid models and escalation to face-to-face assessment. Data on cost-effectiveness and impacts on equity were limited. Conclusions: Telemedicine in OMFS has moved from niche innovation to a pragmatic adjunct across the clinical pathway. Current evidence supports its use for selected pre- and postoperative care and trauma triage within risk-stratified hybrid models, while underscoring the need for stronger comparative and implementation studies, clear governance on equity and data protection, and alignment with wider digital and AI-enabled health systems.},
}
@article {pmid41598742,
year = {2026},
author = {Vink, M and Vink-Niese, A},
title = {An Overview of Severe Myalgic Encephalomyelitis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {2},
pages = {},
pmid = {41598742},
issn = {2077-0383},
abstract = {In this article, we have reviewed the literature on severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS is a clinical diagnosis in the absence of a diagnostic test. However, in research settings and disability disputes, 2-day cardiopulmonary exercise testing can be used to diagnose and document the abnormal response to exercise. Biomedical research into this disease has been scarce and underfunded for decades. Consequently, there are no effective treatments. In its most severe form, it is more disabling than many other diseases, and patients are bedbound 24/7, dependent on carers, and spend their days in dark and quiet rooms. Even the soft sound of a human voice can lead to further deterioration. Some of the very severely ill suffer from life-threatening malnutrition and need to be tube-fed. The COVID-19 pandemic has led to a sharp increase in the number of patients with post-infectious diseases, and many of them fulfill ME/CFS criteria. Dedicated, focused research using advanced medical technologies is needed to gain further understanding of the underlying disease mechanism. This will enable us to find effective pharmacological treatments and address the unmet medical needs of these very ill people.},
}
@article {pmid41599016,
year = {2025},
author = {Gonepudi, NK and Baffour Awuah, H and Xu, W and Katte, RH and Lu, M},
title = {Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
pmid = {41599016},
issn = {2076-0817},
support = {R01 AI181600/AI/NIAID NIH HHS/United States ; R35 GM151169/GM/NIGMS NIH HHS/United States ; R35GM151169/GM/NIGMS NIH HHS/United States ; R01AI181600//National Institute of Allergy and Infectious Diseases/ ; },
mesh = {*Viral Fusion Proteins/chemistry/antagonists &amp; inhibitors/metabolism ; Humans ; *Peptides/chemistry/pharmacology ; Virus Internalization/drug effects ; *Antiviral Agents/pharmacology/chemistry ; *Viral Fusion Protein Inhibitors/chemistry/pharmacology ; *Drug Design ; },
abstract = {Viral fusion proteins are indispensable mediators of viral entry that orchestrate the fusion of viral and host membranes, making them primary targets for antiviral interventions. Class I fusion proteins, displayed on the surface of enveloped viruses (such as HIV-1, RSV, SARS-CoV-2, Nipah, influenza, and Ebola viruses), share conserved structural features, including the fusion peptide or loop and heptad repeat regions. These elements are essential for the formation of the post-fusion six-helix bundle during membrane fusion. Peptide inhibitors that mimic heptad repeat motifs have consequently emerged as an effective strategy for blocking the fusion process. This review summarizes design strategies for such inhibitors and highlights how sequence and structural insights have enabled their optimization via α-helical stabilization, hydrocarbon stapling, lactam bridges, lipid conjugation, macrocyclization, and multivalency. Using representative examples across major viral systems, this review illustrates how these strategies have led to the development of potent, stable, and even broad-spectrum antiviral peptides. This review provides insights to guide the rational design of next-generation peptide-based fusion inhibitors targeting viral membrane fusion.},
}
@article {pmid41599045,
year = {2026},
author = {Abdul Jabar, K and Romli, NIA and Vellasamy, KM and Pallath, V and Al-Maleki, AR},
title = {Predictors of Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Scoping Review.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
pmid = {41599045},
issn = {2076-0817},
mesh = {Humans ; *Pseudomonas aeruginosa/drug effects ; *Pseudomonas Infections/mortality/microbiology/drug therapy ; Risk Factors ; *Bacteremia/mortality/microbiology ; COVID-19/mortality ; Anti-Bacterial Agents/therapeutic use ; SARS-CoV-2 ; Drug Resistance, Multiple, Bacterial ; },
abstract = {Pseudomonas aeruginosa bloodstream infections (PABSIs) are a major clinical challenge due to their association with significant mortality and antimicrobial resistance mechanisms. The COVID-19 pandemic changed antimicrobial practices, intensive care management, and patient risk profiles, potentially influencing the epidemiology and outcomes of PABSIs. In the post-pandemic period, practices were expected to revert to normal. The objective of this scoping review was to identify and summarize reported mortality rates and risk factors for PABSIs in studies published between 2023 and 2025. Literature searches were conducted across PubMed, Web of Science, Embase, and Scopus. Screening was performed in accordance with PRISMA-ScR guidelines. Twenty-two eligible studies were included. Mortality rates varied across the study setting and populations; however, several consistent predictors were consistently identified, including carbapenem exposure, multidrug-resistant Pseudomonas aeruginosa, hematologic disease or malignancy, corticosteroid therapy, sepsis or septic shock, mechanical ventilation, and higher severity-of-illness scores. Few studies have linked molecular mechanisms to patient outcomes, highlighting important gaps in knowledge. Notably, only a small number of studies included the post-pandemic period but did not analyze the data separately. Despite limited available evidence, critically ill and immunocompromised patients remain at greatest risk of death from PABSIs. This review highlights the need for a broader comparative analysis in future.},
}
@article {pmid41599072,
year = {2026},
author = {Dave, RS and Fox, HS},
title = {Synergy of SARS-CoV-2 and HIV-1 Infections in the Human Brain.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
pmid = {41599072},
issn = {2076-0817},
mesh = {Humans ; *Brain/virology/pathology ; *HIV Infections/pathology/virology/complications ; *COVID-19/pathology/virology/complications/epidemiology ; *HIV-1/pathogenicity ; *SARS-CoV-2 ; Microglia/virology/pathology ; Cytokines/metabolism ; Coinfection/virology ; },
abstract = {This review explores the interplay between SARS-CoV-2 and HIV-1 infections within the human brain, highlighting the significant neurological implications of these viral infections. SARS-CoV-2 can infect the central nervous system (CNS), with evidence of the virus detected in various brain regions, including the hypothalamus, cerebellum, and olfactory bulb. This infection is linked to microglial activation and neuroinflammation, which can lead to severe neurological outcomes in affected individuals. Autopsy studies revealed microglial changes, including downregulation of the P2RY12 receptor, indicating a shift from homeostatic to inflammatory phenotype. Similar changes in microglia are found in the brains of people with HIV-1 (PWH). In SARS-CoV-2, the correlation between inflammatory cytokines, such as IL-1, IL-6, and MCP-1, found in cerebrospinal fluid and brain tissues, indicates significant neurovascular inflammation. Astrogliosis and microglial nodules were observed, further emphasizing the inflammatory response triggered by the viral infections, again in parallel to those found in the brains of PWH. Epidemiologic data indicate that although SARS-CoV-2 infection rates in PWH mirror those in People without HIV (PWoH) populations, Long-COVID prevalence is markedly higher among PWH. Evidence of overlapping cognitive impairment, mental health burden, and persistent neuroinflammation highlights diagnostic complexity and therapeutic gaps. Despite plausible mechanistic synergy, direct neuropathological confirmation remains scarce, warranting longitudinal, biomarker-driven studies. Understanding these interactions is critical for developing targeted interventions to mitigate CNS injury and improve outcomes.},
}
@article {pmid41599373,
year = {2026},
author = {Wan, X and Cui, X and Liang, K and Huang, J and Chen, K and Chen, W and Song, G},
title = {The Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {2},
pages = {},
pmid = {41599373},
issn = {1420-3049},
support = {2025A1515010495//Guangdong Basic and Applied Basic Research Foundation/ ; 2024KQNCX197//Youth Innovative Talents Project from the Department of Education of Guangdong Province/ ; },
mesh = {*Antiviral Agents/chemistry/pharmacology/therapeutic use ; *SARS-CoV-2/drug effects ; Humans ; *Pentacyclic Triterpenes/chemistry/pharmacology/therapeutic use ; *COVID-19 Drug Treatment ; Spike Glycoprotein, Coronavirus/metabolism ; Saponins/chemistry/pharmacology ; },
abstract = {The continuous emergence of SARS-CoV-2 variants, especially the Omicron strain with its heightened transmissibility, has posed ongoing challenges to the efficacy of existing vaccine and drug regimens. This situation highlights the pressing demand for antiviral drugs employing novel mechanisms of action. Pentacyclic triterpenoids (PTs), a structurally varied group of compounds derived from plants, exhibit both antiviral and anti-inflammatory activities, making them attractive candidates for further therapeutic development. These natural products, along with their saponin derivatives, show broad-spectrum inhibitory effects against multiple SARS-CoV-2 variants (from Alpha to Omicron) via interactions with multiple targets, such as the spike protein, main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and inflammatory signaling pathways. This review consolidates recent findings on PTs and their saponins, emphasizing their influence on the key structural features required for inhibiting viral attachment, membrane fusion, reverse transcription, and protease function. We systematically summarized the structure-activity relationships and their antiviral results of PTs based on different target proteins in existing studies. Furthermore, this work points toward new strategies for designing multi-target PT-based inhibitors with improved efficacy against Omicron and future variants.},
}
@article {pmid41600411,
year = {2026},
author = {Tiwari, AK and Gupta, MK and Mishra, SK and Meena, R and Patolsky, F and Narayan, RJ},
title = {Nanobiosensors: A Potential Tool to Decipher the Nexus Between SARS-CoV-2 Infection and Gut Dysbiosis.},
journal = {Sensors (Basel, Switzerland)},
volume = {26},
number = {2},
pages = {},
pmid = {41600411},
issn = {1424-8220},
mesh = {Humans ; *Dysbiosis/virology/diagnosis/microbiology ; *COVID-19/diagnosis ; SARS-CoV-2 ; *Biosensing Techniques/methods ; *Gastrointestinal Microbiome ; *Nanotechnology/methods ; Pandemics ; },
abstract = {The emergence of SARS-CoV-2 posed a great global threat and emphasized the urgent need for diagnostic tools that are rapid, reliable, sensitive and capable of real-time monitoring of SARS-CoV-2 infections. Recent investigations have identified a potential connection between SARS-CoV-2 infection and gut dysbiosis, highlighting the sophisticated interplay between the virus and the host microbiome. This review article discusses the eminence of nanobiosensors, as state-of-the-art tools, to investigate and clarify the connection between SARS-CoV-2 pathogenesis and gut microbiome imbalance. Nanobiosensors are uniquely advantageous owing to their sensitivity, selectivity, specificity, and reliable monitoring capabilities, making them well-suited for identifying both viral particles and microbial markers in biological samples. We explored a range of nanobiosensor platforms and their potential use for concurrently monitoring the gut dysbiosis induced by different pathological conditions. Additionally, we explore how advanced sensing technologies can shed light on the mechanisms driving virus-induced dysbiosis, and the implications for disease progression and patient outcomes. The integration of nanobiosensors with microfluidic devices and artificial intelligence algorithms has also been explored, highlighting the potential of developing point-of-care diagnostic tools that provide comprehensive insights into both viral infection and gut health. Utilizing nanotechnology, scientists and healthcare professionals may gain a more profound insight into the complex interaction dynamics between SARS-CoV-2 infection and the gut microenvironment. This could pave the way for enhanced diagnostic and prognostic approaches, treatment courses, and patient care for COVID-19.},
}
@article {pmid41600776,
year = {2025},
author = {Giuliani, AAM and Chen, V and Law, N},
title = {Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
pmid = {41600776},
issn = {1999-4915},
mesh = {Humans ; Antiviral Agents/therapeutic use ; Respiratory Syncytial Virus Infections/prevention &amp; control/drug therapy ; Antibodies, Monoclonal/therapeutic use ; *Respiratory Tract Infections/prevention &amp; control/drug therapy/virology ; Influenza, Human/prevention &amp; control ; COVID-19/prevention &amp; control ; SARS-CoV-2 ; *Virus Diseases/prevention &amp; control/drug therapy ; *Transplant Recipients ; Post-Exposure Prophylaxis ; },
abstract = {Transplant patients experience high morbidity and mortality caused by respiratory viral infections (RVIs). In the past decade, numerous methods of prophylaxis and treatment have rapidly developed and continue to expand, with dozens of novel agents in preclinical and clinical trials. This includes recent scientific breakthroughs in virus structure, which have enabled the creation of respiratory syncytial virus (RSV) vaccines. While new vaccines, antivirals, monoclonal antibodies, and non-vaccine agents are becoming more available, their utility and safety in the transplant populations are often uncertain. This review summarizes the current landscape of RVIs in the transplant population, including approaches to pre- and post-exposure prophylaxis and treatment. We discuss the data behind vaccine timing, safety, and efficacy and current pre- and post-transplant recommendations, with a particular focus on influenza, SARS-CoV-2, and RSV. We also examine the potential benefits of antivirals, monoclonal antibodies, and novel agents used as prophylaxis, treatment, or adjuncts. While there remain many knowledge gaps, these new methods and ongoing advancements in RVI treatment and prevention promise to improve transplant patient outcomes.},
}
@article {pmid41600815,
year = {2025},
author = {Hamza, IA and Mao, K and Gao, C and Hamza, H and Zhang, H},
title = {Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
pmid = {41600815},
issn = {1999-4915},
support = {FS-2024-34//CAS-ANSO/ ; 2023415//Chinese Academy of Sciences/ ; 24291703Z//Hebei Provincial Science and Technology Projects/ ; Qiankehe Platform Talents-GCC [2023] 046//Guizhou Provincial Science and Technology Projects/ ; },
mesh = {Humans ; *Disease Outbreaks/prevention &amp; control ; Animals ; Pandemics/prevention &amp; control ; Pandemic Preparedness ; COVID-19/prevention &amp; control/epidemiology ; SARS-CoV-2 ; *Virus Diseases/prevention &amp; control/epidemiology/diagnosis ; Public Health Infrastructure ; Public Health ; Communicable Diseases, Emerging/prevention &amp; control/epidemiology ; },
abstract = {Emerging and re-emerging viruses continue to pose major threats to public health. Their ability to adapt, cross species barriers, and spread rapidly can trigger severe outbreaks or even pandemics. Strengthening preparedness with comprehensive and efficient strategies is therefore essential. Here, we explore the key components of viral outbreak preparedness, including surveillance systems, diagnostic capacity, prevention and control measures, non-pharmaceutical interventions, antiviral therapeutics, and research and development. We emphasize the increasing importance of genomic surveillance, wastewater-based surveillance, real-time data sharing, and the One Health approach to better anticipate zoonotic spillovers. Current challenges and future directions are also discussed. Effective preparedness requires transparent risk communication and equitable access to diagnostics, vaccines, and therapeutics. The COVID-19 pandemic highlighted both the promise of next-generation vaccine platforms and the necessity of maintaining diagnostic capacity, as early testing delays hindered containment efforts. Countries adopted various non-pharmaceutical interventions: risk communication and social distancing proved to be the most effective, while combined workplace infection-prevention measures outperformed single strategies. These experiences highlight the importance of early detection, rapid response, and multisectoral collaboration in mitigating the impact of viral outbreaks. By applying best practices and lessons learned from recent events, global health systems can strengthen resilience and improve readiness for future viral threats.},
}
@article {pmid41600887,
year = {2026},
author = {Maslov, DE and Osipov, ID and Zabelina, DS and Pak, AA and Netesov, SV},
title = {Respiratory Syncytial Virus Prevalence and Genotypic Distribution in the Countries of the Former Soviet Union: A Systematic Review and Meta-Analysis.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
pmid = {41600887},
issn = {1999-4915},
support = {FSUS-2025-0017 and FSUS-2025-0012//Ministry of Science and Higher Education, Russian Federation/ ; The "Prioritet-2030" program//Novosibirsk State University/ ; },
mesh = {Adult ; Child ; Child, Preschool ; Humans ; Infant ; COVID-19/epidemiology/virology ; Genotype ; Prevalence ; *Respiratory Syncytial Virus Infections/epidemiology/virology ; *Respiratory Syncytial Virus, Human/genetics/classification ; Seasons ; USSR/epidemiology ; },
abstract = {Respiratory syncytial virus (RSV) is among leading global causes of lower respiratory tract infections, yet data from Russia and other states of the Former Soviet Union (FSU) remain fragmented and structurally inconsistent. This systematic review aims to map and synthesize existing evidence on RSV epidemiology and genotypic distribution across the FSU. Published studies from eLIBRARY and PubMed databases queried for RSV prevalence data, together with public health surveillance datasets, were used to summarize RSV prevalence research across eight FSU countries. Random-effects meta-analysis across age strata showed high prevalence in children before 6 (21%) and a progressive decline with age, which is in agreement with global data. Prevalence estimates showed a high degree of variability partially explained by study scope and clinical presentation. We observed COVID-19-related seasonal disruptions of RSV seasonality, followed by gradual post-pandemic stabilization. Genotypic data reflects global trends with two cosmopolitan clades, A.D and B.D, and their descendants, dominating in the region. The review is limited by uneven geographical and temporal coverage, and scarce data on adults. The review provides the first integrated summary of RSV epidemiology across the FSU and underscores the need for expanded regional surveillance and genomic reporting.},
}
@article {pmid41600927,
year = {2025},
author = {Esposito, S and Aurelio, C and Cifaldi, M and Lazzara, A and Viafora, F and Principi, N},
title = {Prevention of Respiratory Infections in Children with Congenital Heart Disease: Current Evidence and Clinical Strategies.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
pmid = {41600927},
issn = {2076-393X},
abstract = {Background: Children with congenital heart disease (CHD) are at substantially increased risk for respiratory infections, which occur more frequently and with greater severity than in healthy peers. This heightened vulnerability stems from multifactorial immune impairment, including defects in innate and adaptive immunity, chronic inflammation related to abnormal hemodynamics and hypoxia, reduced thymic function, and genetic syndromes affecting both cardiac and immune development. Viral pathogens-particularly respiratory syncytial virus (RSV), influenza viruses, and SARS-CoV-2-account for most infections, although bacterial pathogens remain relevant, especially in postoperative settings. Methods: This narrative review summarizes current evidence on infection susceptibility in children with CHD, the epidemiology and clinical relevance of major respiratory pathogens, and the effectiveness of available preventive measures. Literature evaluating immunological mechanisms, infection burden, vaccine effectiveness, and passive immunization strategies was examined, along with existing national and international immunization guidelines. Results: Children with CHD consistently exhibit higher rates of hospitalization, intensive care unit admission, mechanical ventilation, and mortality following respiratory infections. RSV, influenza, and SARS-CoV-2 infections are particularly severe in this population, while bacterial infections, though less common, contribute substantially to postoperative morbidity. Preventive options-including routine childhood vaccines, pneumococcal and Haemophilus influenzae type b vaccines, influenza vaccines, COVID-19 mRNA vaccines, and RSV monoclonal antibodies-demonstrate strong protective effects. New long-acting RSV monoclonal antibodies and maternal vaccination markedly enhance prevention in early infancy. However, vaccine coverage remains insufficient due to parental hesitancy, provider uncertainty, delayed immunization, and limited CHD-specific evidence. Conclusions: Respiratory infections pose a significant and preventable health burden in children with CHD. Enhancing the use of both active and passive immunization is essential to reduce morbidity and mortality. Strengthening evidence-based guidelines, improving coordination between specialists and primary care providers, integrating immunization checks into routine CHD management, and providing clear, condition-specific counseling to families can substantially improve vaccine uptake and clinical outcomes in this vulnerable population.},
}
@article {pmid41600988,
year = {2026},
author = {Alkhidir, M and Sridharan, K},
title = {Efficacy and Safety of mRNA-Based COVID-19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
pmid = {41600988},
issn = {2076-393X},
abstract = {BACKGROUND: Solid organ transplant recipients (SOTRs) are highly vulnerable to severe COVID-19 infection, yet initial vaccine trials provided limited data on efficacy and safety in this immunocompromised population. Heterogeneous seroconversion rates and conflicting safety reports complicate the formulation of clear clinical guidelines. This systematic review and meta-analysis aim to aggregate existing evidence to determine the precise seroconversion and safety profiles of COVID-19 vaccines and identify key factors influencing immune response in SOTRs.<br><br>METHODS: A comprehensive literature search was conducted identifying 125 studies evaluating WHO/FDA-authorized vaccines in SOTRs. Outcomes were the pooled seroconversion proportion and safety profile. Subgroup analyses were performed based on vaccine type, transplanted organ, number of doses, and prior SARS-CoV-2 infection status, confirmed by leave-one-out sensitivity analysis and bootstrap methods.<br><br>RESULTS: Most studies assessed mRNA-based vaccines (123/125, 98.4%). The overall pooled seroconversion proportion across all SOTRs was significantly blunted at 0.49 (95% CI, 0.43 to 0.55), demonstrating high heterogeneity (I[2] = 94.2%). Seroconversion showed a clear positive dose-response relationship, increasing from 27% after one dose to 84% after four doses. Prior COVID-19 infection was the strongest predictor of a response, resulting in a pooled seroconversion of 0.90 (95% CI, 0.82 to 0.94; I[2] = 0%). Organ-specific analyses revealed the highest response in Liver recipients (0.80) and the lowest in Lung recipients (0.29). Vaccine platform analysis showed that the highest response was with mRNA-1273 (0.55) and the lowest with CoronaVac (0.29). The safety profile was limited.<br><br>CONCLUSIONS: SOTRs exhibit profound hypo responsiveness to COVID-19 vaccines; however, the extreme heterogeneity observed across studies necessitates a cautious interpretation of pooled seroconversion estimates. While the data indicates a significant dose-response relationship favoring an aggressive, multi-dose strategy, the apparent safety profile may reflect under-reporting and limited follow-up rather than confirmed safety equivalence. Rare but clinically critical outcomes, such as acute allograft rejection, remain inadequately characterized in the current literature. Consequently, while the prioritization of multi-dose regimens and hybrid immunity is supported to maximize protection, clinicians must recognize that individual responses remain highly variable, and the long-term immunological impact of repeated stimulation requires further standardized investigation.},
}
@article {pmid41601020,
year = {2026},
author = {See, KC},
title = {Vaccination Against Respiratory Infections in Adults with Cancer: A Concise Guide for Clinicians.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
pmid = {41601020},
issn = {2076-393X},
abstract = {Global cancer incidence reached 20 million new cases across 185 countries in 2022, with approximately 10 million cancer-related deaths annually. Among adults with solid tumors and hematological malignancies, infections are a major contributor to morbidity and mortality, with respiratory infections playing a particularly significant role. These infections not only reduce life expectancy but can also delay cancer therapy, negatively affect treatment outcomes, and increase healthcare costs. In recent years, the burden of respiratory infections in this population has been driven by influenza virus, SARS-CoV-2, respiratory syncytial virus, Streptococcus pneumoniae, and Bordetella pertussis. Effective vaccines are available for all these pathogens and are recommended for adults with cancer, yet vaccination uptake remains suboptimal despite their heightened vulnerability. This review provides practical guidance for healthcare professionals on vaccinating adults with cancer against respiratory infections, summarizing key information to help clinicians address vaccination-related complacency, confidence, and convenience. Evidence from studies in both the general population and cancer patients consistently shows that vaccination benefits outweigh potential risks, with adverse event rates comparable to those seen in individuals without cancer. Early vaccination is encouraged, as there is limited justification for delaying immunization even when immune responses may be reduced. Vaccine dosing aligns with recommendations for the general population, with important exceptions. Live attenuated vaccines should be avoided because of the risk of replication and disease in immunocompromised patients, and selected groups may require booster doses to achieve adequate protection. Notably, cancer immunotherapy does not appear to impair vaccine-induced immune responses.},
}
@article {pmid41602864,
year = {2025},
author = {Dasgupta, T and Russell, E and Carbajal, C and Horgan, G and Peterson, L and Mistry, HD and Buabeng, R and Wilson, M and Smith, V and Boulding, H and Sheen, KS and Van Citters, AD and Nelson, EC and Duncan, EL and von Dadelszen, P and , and Silverio, SA and Magee, LA},
title = {Seeking digital maternity healthcare during the pandemic health system shock: a systematic review of women's experiences in low- and middle-income countries.},
journal = {Frontiers in reproductive health},
volume = {7},
number = {},
pages = {1734456},
pmid = {41602864},
issn = {2673-3153},
abstract = {BACKGROUND: The pandemic created global disruption acting as a health system shock not seen before in living memory. As a consequence, there were significant implications for healthcare delivery in low- and middle-income countries. Challenges such as lockdown restrictions created substantial modifications to the delivery of maternity care. This review aims to explore the experiences of maternity care by women, specifically in low- and middle-income countries, during the pandemic global health system shock.<br><br>METHODS: A systematic search was conducted for qualitative literature published about maternity healthcare experiences during the pandemic. Studies which provided qualitative data on women's experiences of digital healthcare, and other maternity care reconfigurations in low- and middle-income countries were included. The studies underwent quality assessment using twelve criteria adapted from the quality appraisal tool developed by the Evidence for Policy &amp; Practice Information (EPPI) Centre. Thematic synthesis was employed.<br><br>RESULTS: Of the 21,860 records identified, 30 met the inclusion criteria for this review. Across the 4 key predetermined areas of study: (1) Care seeking and experience; (2) Digital health; (3) Vaccination; and (4) Ethical future of maternity services; 10 concepts were reported upon, namely: (1.1) Emotional challenges and uncertainty, (1.2) Disruption of services, (1.3) Stigma and discrimination, and (1.4) Changing support systems; (2.1) Safety and reassurance, (2.2) Locus of responsibility; (3.1) Vaccine understanding and acceptance; and (4.1) Improvements for maternity care delivery, (4.2) Implementation of virtual care, (4.3) Education and empowerment.<br><br>CONCLUSION: Our findings suggest emotional challenges, isolation, and limited access to maternity services were prominent among pregnant individuals in low- and middle-income countries. This synthesis provides insights into how pandemic associated adaptations, which have been retained beyond, such as digital health solutions were experienced by women within constrained health systems, revealing both opportunities and persistent gaps in digital health access and equity. Although a review of low- and middle-income countries-there is learning to be taken from these settings which could easily be applied not only across low- and middle-income countries, but also in high-income settings, in the form of reverse (or "trickle-up") innovation to improve maternity care as we recover and re-build from the pandemic and offer more resilient ways of providing maternity care through future health system shocks. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022355948, identifier CRD42022355948.},
}
@article {pmid41603321,
year = {2026},
author = {Silveira, IB and Silva, GP and Sampaio, AVH and Tomé, MR and Chen, JE and de Jesus, AVS and Cançado, GGL},
title = {Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis.},
journal = {Journal of viral hepatitis},
volume = {33},
number = {3},
pages = {e70144},
pmid = {41603321},
issn = {1365-2893},
mesh = {Humans ; *Telemedicine ; *Antiviral Agents/therapeutic use ; Sustained Virologic Response ; *Hepatitis C/drug therapy ; *Hepatitis C, Chronic/drug therapy ; COVID-19 ; Health Services Accessibility ; Treatment Outcome ; },
abstract = {Inequitable access to HCV treatment persists, particularly for rural and marginalised populations. Synchronous telemedicine (TM) could mitigate access barriers, but its comparative effectiveness versus in-person care is uncertain. We performed a systematic review and meta-analysis comparing synchronous TM with in-person care for HCV. The primary outcome was sustained virologic response (SVR); secondary outcomes were treatment initiation and completion. Subgroup analyses examined study design, therapy era (interferon vs. direct-acting antivirals [DAAs]), and setting (rural vs. non-rural). Narrative synthesis addressed people who use drugs (PWUD), incarcerated populations, pandemic-era cohorts, and economic evaluations. Fifteen studies involving 7.459 patients (2 RCTs, 13 observational) were included (13 meta-analysed). For SVR, the pooled effect showed no significant difference between interventions (odds ratio [OR] 1.60, 95% CI 0.69-3.68). Treatment initiation and completion were also not significantly different overall (initiation OR 7.59, 95% CI 0.79-72.81; completion OR 2.50, 95% CI 0.76-8.25), although exclusion of single influential studies yielded significant benefits for TM in sensitivity analyses. Subgroups suggested context-specific advantages: TM favoured SVR in rural settings (OR = 4.19, 95% CI 1.28-13.73) and in RCTs (OR = 10.42, 95% CI 7.41-14.67). Narrative evidence indicated that TM improved linkage and cure among PWUD and incarcerated individuals, preserved efficacy during COVID-19, and reduced costs. Overall, synchronous TM seems comparable to in-person care overall and may be superior in rural and marginalised populations.},
}
@article {pmid41604346,
year = {2026},
author = {Cénat, JM and Darius, WP and Moshirian Farahi, SMM and Kibret, TC and Samson, E and Chen, R and Kuk, SW and Ogbuaku Jnr, K and Steacy, E and Labelle, PR and Madigan, S and Dalexis, RD},
title = {Prevalence and Correlates of Post-Traumatic Stress Disorder Symptoms During the COVID-19 Pandemic in Canada: A Systematic Review and Meta-analysis: Prévalence et corrélats des symptômes du trouble de stress post-traumatique pendant la pandémie de COVID-19 au Canada : Revue systématique et méta-analyse.},
journal = {Canadian journal of psychiatry. Revue canadienne de psychiatrie},
volume = {},
number = {},
pages = {7067437251408179},
pmid = {41604346},
issn = {1497-0015},
abstract = {BackgroundInfectious disease outbreaks have been associated with significant psychological distress and trauma. In Canada, the COVID-19 pandemic's social disruptions have heightened mental health risks. While global studies report elevated posttraumatic stress disorder (PTSD) symptoms, Canadian findings remain limited and inconsistent. This meta-analysis estimated pooled prevalence of PTSD symptoms in Canada during the COVID-19 pandemic and examined potential moderators.MethodsA comprehensive search strategy was executed by research librarians across five databases (APA PsycInfo, CINAHL, Embase, MEDLINE and Web of Science) and on LitCovid. The PRISMA guidelines were used for data extraction and reporting. Random-effects meta-analyses were conducted to estimate pooled PTSD symptoms prevalence and explore potential moderators using the metaprop command in STATA/SE 19.5.ResultsThirty studies conducted between 2020 and 2022, with 52,565 participants aged 18 and older were included (65% weighted women). The pooled prevalence of PTSD symptoms was 22.2% (95% CI, 15.7% to 29.4%; I[2]=99.69). Prevalence was 32.1% in women, 26.1% in men (p = 0.399) and ranged from 16.1% in Quebec to 29.7% in Ontario (p = 0.091). Meta-regressions showed lower PTSD symptoms prevalence in Quebec (B=-0.16, p = 0.029). No significant differences in PTSD symptoms were found according to sex, healthcare worker status, assessment tool used, or data collection year.ConclusionsThis meta-analysis reveals a concerning prevalence of PTSD symptoms in the Canadian population during the COVID-19 pandemic. Contrary to expectations, no significant differences were found by sex or healthcare worker status, suggesting widespread psychological distress across the population. However, the substantial heterogeneity across studies limits the interpretation of these findings in the context of the COVID-19 pandemic. The results emphasize the need for inclusive and accessible mental health responses and further research on post-pandemic Canadians' mental health. Future studies should better disaggregate data by sex, age and race to address disparities and inform targeted public health policies and interventions.},
}
@article {pmid41604358,
year = {2026},
author = {Palacio Varona, J and Rojas Manjarres, AM and Gómez-Buitrago, MI and Castro-Caro, J and Gonzalez-Parra, JD and Del Portillo, MC and Prada, A and Villegas-Gomez, GA},
title = {Global, regional and national patterns in ROP research up to the pre-COVID-19 era: A systematic bibliometric review between 1950 to 2020.},
journal = {European journal of ophthalmology},
volume = {36},
number = {3},
pages = {542-552},
doi = {10.1177/11206721261415977},
pmid = {41604358},
issn = {1724-6016},
mesh = {Humans ; Infant, Newborn ; *Bibliometrics ; *Biomedical Research/trends/statistics &amp; numerical data ; *COVID-19/epidemiology ; Global Health ; *Retinopathy of Prematurity/epidemiology ; SARS-CoV-2 ; },
abstract = {Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, predominantly affecting preterm infants. Global disparities in neonatal care and research capacity influence the volume and visibility of scientific production devoted to ROP across regions. This systematic bibliometric review aimed to characterize global, regional, and national patterns of ROP research published between 1950 and 2020, including temporal trends, geographic distribution, thematic focus, and citation impact. A systematic search of PubMed, Scopus, Web of Science, and SciELO identified 4,932 eligible articles. Most publications originated from the Region of the Americas (Pan American Health Organization, PAHO; 44.2%), the European Region (EURO; 28.0%), and the Western Pacific Region (WPRO; 16.0%). High-income countries accounted for 73.4% of the total output, whereas lower-middle- and low-income countries were markedly underrepresented. The most frequent research themes were risk/protective factors (25.0%) and treatment and outcomes (23.5%), while studies addressing surveillance and public health policies were scarce (6.3%). Scientific output increased markedly after the 1980s, with particularly rapid growth in recent decades in the Western Pacific and South-East Asia Regions. Citation analysis revealed substantial regional inequalities, with publications from high-income regions accounting for the majority of global citations and higher per-article impact. Overall, ROP research remains highly concentrated in high-income settings, reflecting persistent global disparities in scientific production and visibility. Strengthening research capacity and output in underrepresented regions is essential to promote more equitable evidence generation and to support informed decision-making in global eye health.},
}
@article {pmid41604670,
year = {2026},
author = {Sun, M and Tang, F and Min, L and Wen, S and Wang, S and Jiang, H},
title = {Effects of Telehealth Interventions for People With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.},
journal = {JMIR mHealth and uHealth},
volume = {14},
number = {},
pages = {e70994},
pmid = {41604670},
issn = {2291-5222},
mesh = {Humans ; *Parkinson Disease/therapy/psychology ; *Telemedicine/standards/statistics &amp; numerical data ; Quality of Life/psychology ; Randomized Controlled Trials as Topic ; Activities of Daily Living/psychology ; COVID-19/epidemiology ; Depression ; },
abstract = {BACKGROUND: The global integration of telehealth into the management of Parkinson disease (PD) addresses critical gaps in health care access, especially for patients with limited mobility in underserved regions. Despite accelerated adoption during the COVID-19 pandemic, evidence regarding telehealth's multidimensional efficacy remains inconsistent. Previous meta-analyses reported conflicting outcomes for quality of life (QOL), motor symptoms, and neuropsychiatric comorbidities.<br><br>OBJECTIVE: This study aimed to quantitatively synthesize the effects of telehealth interventions across six core PD domains: (1) QOL, (2) depression, (3) anxiety, (4) motor symptoms, (5) activities of daily living (ADL), and (6) cognition.<br><br>METHODS: PubMed, Embase, Cochrane Library, Scopus, and Web of Science were systematically searched until June 21, 2024. In adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, English-language randomized controlled trials evaluating telehealth interventions for PD were included. Study quality was assessed using the Cochrane Risk of Bias tool. A dual analytical approach using random-effects models was applied to address heterogeneity. Studies reporting a single effect size were analyzed using the Hartung-Knapp-Sidik-Jonkman correction. Studies with multiple dependent effect sizes were analyzed using a 3-level random-effects meta-analysis with t-distribution inference, accounting for sampling, within-study, and between-study variance. Effect sizes were expressed as standardized mean differences (SMD) with 95% CIs. Heterogeneity was quantified using the &#x3c4;[2]; prediction intervals were not calculated due to the limited number of studies. Prespecified subgroup analyses examined intervention types (digital vs traditional telehealth) and follow-up durations. Sensitivity analyses and assessments for small-study effects (multilevel Egger tests, funnel plots) were conducted.<br><br>RESULTS: A total of 15 randomized controlled trials (765 participants) demonstrated significant telehealth benefits: QOL significantly improved on the Medical Outcomes Study 36-Item Short Form Health Survey and Brunnsviken Brief Quality of Life Scale (SMD 0.39, 95% CI 0.06-0.72; P=.03), with marginal improvement on the Parkinson Disease Questionnaire-8 (SMD -0.42, 95% CI -0.88 to 0.03; P=.07). Telephone-based interventions outperformed digital approaches (P=.002). Depression symptoms were significantly reduced (SMD -0.64, 95% CI -0.93 to 0.34; P<.001), particularly with traditional telehealth (P<.001). Anxiety also decreased significantly (SMD -0.64, 95% CI -0.92 to 0.35; P=.003) with negligible heterogeneity (I[2]=0%). Motor symptoms improved (SMD -0.46, 95% CI -0.69 to 0.24; P=.001), and ADL showed substantial impairment reduction (SMD -0.79, 95% CI -1.04 to -0.54; P=.002). Cognition was significantly enhanced (SMD 1.12, 95% CI 0.03 to 2.20; P=.045) though with moderate heterogeneity (I[2]=52.3%) and significant publication bias (P<.001). Follow-up duration did not significantly moderate effects.<br><br>CONCLUSIONS: Telehealth interventions significantly enhance multiple PD domains, with traditional (telephone/tablet-based) approaches demonstrating particular advantages for QOL and depression. Digital interventions showed more limited efficacy. These findings support telehealth as a multifaceted management tool for PD, although cognition outcomes require further investigation.<br><br>TRIAL REGISTRATION: PROSPERO CRD42024520169; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024520169.},
}
@article {pmid41604674,
year = {2026},
author = {Jahanaray, M and Pasha, A and Jahanaray, A},
title = {Burnout and psychological distress across U.S. postgraduate trainees, fellows, and students: A comprehensive meta-analysis.},
journal = {Journal of American college health : J of ACH},
volume = {74},
number = {6},
pages = {1772-1785},
doi = {10.1080/07448481.2025.2611276},
pmid = {41604674},
issn = {1940-3208},
mesh = {Humans ; United States/epidemiology ; COVID-19/psychology/epidemiology ; *Burnout, Professional/psychology/epidemiology ; *Psychological Distress ; *Students, Medical/psychology/statistics &amp; numerical data ; Emotional Exhaustion ; *Stress, Psychological/epidemiology ; },
abstract = {Objective: This meta-analysis explored the relationship between burnout and psychological distress across different academic disciplines, measurement tools, institutional contexts, and the pandemic. Method: We synthesized 76 effect sizes from 29 studies involving 20,037 students, residents, and fellows in the United States. Results: The correlation between burnout and psychological distress was (r = 0.44), with stress showing the strongest correlation (r = 0.48). Notably, the correlations were higher during the pandemic (r = 0.46) compared to pre-pandemic (r = 0.44). Our subgroup analysis indicated that medical students exhibited a stronger association (r = 0.5) than fellows and residents. Additionally, samples from a multiple organization yielded higher correlations (r = 0.46). Conclusions: Among the dimensions of burnout, emotional exhaustion demonstrated a stronger correlation with psychological distress. Meta-regression confirmed that the students' disciplines, sample locations, and COVID-19 moderated the overall effect size. Findings highlight the urgent need for targeted interventions to address environmental stressors within medical training.},
}
@article {pmid41604899,
year = {2026},
author = {Saxena, SK and Yadav, J and Kishan, H and Harnam, AS and Kumar, S and Maurya, VK and Ansari, S and Paweska, JT and Ratho, RK},
title = {Pathogenesis and current advancement in treatment and prevention strategies for Human metapneumovirus.},
journal = {Virology},
volume = {617},
number = {},
pages = {110798},
doi = {10.1016/j.virol.2026.110798},
pmid = {41604899},
issn = {1096-0341},
mesh = {Humans ; *Metapneumovirus/pathogenicity/genetics/immunology/drug effects/physiology ; *Paramyxoviridae Infections/prevention &amp; control/therapy/virology/drug therapy/diagnosis/epidemiology ; Antiviral Agents/therapeutic use ; Viral Vaccines/immunology ; Animals ; },
abstract = {Human metapneumovirus (HMPV) is a well-identified paramyxovirus that has emerged as a significant global health threat, particularly following recent outbreaks in 2024-2025. It preferentially infects the respiratory epithelium and affects infants, the elderly, and immunocompromised populations. The clinical manifestations of the HMPV range from mild upper respiratory symptoms to severe diffuse bronchopneumonia. As of late 2024 and early 2025, HMPV has been responsible for 6.2% of positive respiratory illness tests and 5.4% of respiratory-associated hospitalizations in China, surpassing COVID-19, rhinovirus, and adenovirus. HMPV is a non-segmented, negative-sense single-stranded RNA virus with a genome of about 13.3 kb, and it is genetically related to Orthopneumovirus, particularly respiratory syncytial virus (RSV). Its transmission occurs primarily within households, and the virus poses significant risks to vulnerable populations. Immunologic responses to HMPV infections are diverse, with limited lasting immunity, leading to frequent reinfections. Diagnosis is problematic due to overlapping clinical manifestations of the disease alongside other respiratory viruses like RSV and influenza. Presently, no vaccines or antiviral treatments are available for HMPV, though several vaccine candidates are under investigation, including mRNA-1653 and IVX-A12, which have shown promising results in Phase I and Phase II clinical trials. Recent advances in understanding HMPV's molecular biology and immune modulation have led to exploring new therapeutic strategies, including monoclonal antibodies, fusion inhibitors, and RNA interference-based therapies.},
}
@article {pmid41605062,
year = {2026},
author = {Mattedi, FZ and Ribeiro, HS and Busatto, GF and Carvalho, CRR and Zanetta, DMT and Burdmann, EA and , },
title = {Acute respiratory distress syndrome and acute kidney injury in critically ill patients: A scoping review on this lung-kidney crosstalk.},
journal = {Journal of critical care},
volume = {93},
number = {},
pages = {155445},
doi = {10.1016/j.jcrc.2026.155445},
pmid = {41605062},
issn = {1557-8615},
mesh = {Humans ; *Acute Kidney Injury/epidemiology/physiopathology/therapy/etiology ; *Critical Illness ; Hospital Mortality ; Renal Replacement Therapy ; *Respiratory Distress Syndrome/complications/physiopathology/epidemiology ; Risk Factors ; },
abstract = {INTRODUCTION: The incidence of acute kidney injury (AKI) in patients with acute respiratory distress syndrome (ARDS) is high; nonetheless, the lung-kidney crosstalk remains unclear.<br><br>OBJECTIVE: Describe the association between ARDS and AKI in critically ill patients.<br><br>METHODS: This scoping review was conducted according to the JBI and PRISM-ScR and included studies that investigated critically ill patients with ARDS (Participants), described AKI-related outcomes (Concept), and were conducted in hospitals (Context). MEDLINE, Embase, and LILACS databases were searched for articles published up to January 2024. Only observational studies were considered. Data on the diagnosis of ARDS-AKI and other kidney-related outcomes were extracted.<br><br>RESULTS: A total of 2943 studies were screened, of which 28 were included in this review. Most studies were prospective and the majority originated from Europe. AKI was diagnosed using the KDIGO criteria in most studies and the pooled overall rate of AKI development across the studies was 46.8% (95% CI: 40.8-52.8). Two reports identified ARDS as an independent risk factor for AKI. Kidney replacement therapy was described in 17 studies. AKI recovery was described in only three studies. Seventeen studies evaluated hospital mortality, specifically in patients with ARDS-AKI, and found a greater mortality risk as compared to only ARDS.<br><br>CONCLUSIONS: This scoping review emphasizes the variability of the evidence, which hinders definitive conclusions about the association between ARDS and AKI, despite their common occurrence in critically ill patients. Therefore, a significant gap remains in our understanding of this lung-kidney interaction.},
}
@article {pmid41605119,
year = {2026},
author = {Groen, K and Hale, BG},
title = {Human autoantibodies against type I interferons in severe viral disease.},
journal = {Current opinion in virology},
volume = {74},
number = {},
pages = {101511},
doi = {10.1016/j.coviro.2026.101511},
pmid = {41605119},
issn = {1879-6265},
mesh = {Humans ; *Interferon Type I/immunology ; *Virus Diseases/immunology/virology ; *Autoantibodies/immunology ; Animals ; Antibodies, Neutralizing/immunology ; },
abstract = {Type I interferons (IFN-Is) are critical antiviral cytokines that restrict viral replication and limit viral disease. A remarkable recent discovery is that human autoantibodies (autoAbs) neutralizing the activities of IFN-Is phenocopy inborn errors of immunity and markedly exacerbate susceptibility to life-threatening infections. Development of these pathogenic autoAbs in humans is strongly linked to genetic and nongenetic factors affecting thymic function, and they are estimated to be present in >100 million people worldwide with a prevalence that increases with age. Here, we review major advances from the last few years that have improved our mechanistic understanding of human IFN-I autoAb development and function, as well as their association with a significant proportion of different severe viral diseases. In particular, we highlight how neutralizing IFN-I autoAbs can persist in individuals for decades, compromising IFN-I-mediated defenses, and underlying subsequent critical infections with diverse pathogens, including SARS-CoV-2, West Nile virus, tick-borne encephalitis virus, seasonal influenza viruses, herpesviruses, and rare zoonoses caused by MERS-CoV, flaviviruses, and avian H5N1 influenza A virus. Furthermore, we discuss how neutralizing IFN-I autoAbs facilitate severe adverse events with live-attenuated viral vaccines, such as the yellow fever or chikungunya virus vaccines, and suggest how implementation of IFN-I autoAb diagnostics in at-risk populations may be clinically beneficial with current prophylactic or therapeutic options. Finally, in the context of new experimental insights into how autoAbs block the ability of IFN-Is to engage with the IFNAR1/IFNAR2 receptors, we detail future opportunities to design advanced novel therapeutic strategies that might specifically mitigate IFN-I autoAb pathogenic effects.},
}
@article {pmid41605546,
year = {2026},
author = {Dunn, M and 't Hoen, E and Boulet, P and Mara, K and Perehudoff, K},
title = {TRIPS flexibilities help change policy and practice to increase access to medicines: evidence from 2001 to 2024.},
journal = {BMJ global health},
volume = {11},
number = {1},
pages = {},
pmid = {41605546},
issn = {2059-7908},
mesh = {Humans ; COVID-19 ; Developed Countries ; Developing Countries ; *Health Policy ; *Health Services Accessibility/legislation &amp; jurisprudence ; *Intellectual Property ; Patents as Topic/legislation &amp; jurisprudence ; Pharmaceutical Preparations/supply &amp; distribution ; },
abstract = {INTRODUCTION: Millions of people lack access to safe and effective pharmaceuticals because they are unaffordable or unavailable, particularly in 'developing' and 'least-developed' countries (DCs, LDCs), and increasingly in high-income countries (HICs). Management of intellectual property (IP) related to new medicines has a significant impact on access to safe, affordable and effective medicines. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) provides the international legal framework for IP protection and mandates 20-year patents in all technological fields, including pharmaceuticals. TRIPS contains flexibilities, such as compulsory licensing (CL) and transition provisions for LDCs, which governments can use to facilitate access to health technologies. The use of these flexibilities is underreported in the literature, and a thorough analysis has not been undertaken since the COVID-19 pandemic.<br><br>METHODS: A scoping review of three medical and legal databases and temporal analysis of all known instances of use or potential use of CLs and the LDC pharmaceutical transition measure between 2001-2024.<br><br>RESULTS: 61% of the 149 CL instances were executed. The relative rates of CL use between countries have shifted: HICs represent over half of CL instances in the last decade. CLs are increasingly considered for chronic, non-communicable and rare diseases. The threat of CL use continues to provide impetus for price negotiations, voluntary licences or other measures to improve access. Almost all eligible countries have invoked the right to use the LDC transition measure.<br><br>CONCLUSIONS: TRIPS flexibilities have been used to facilitate access to medicines (including vaccines) over the quarter-century since the adoption of the World Trade Organization's Doha Declaration on TRIPS and Public Health. The flexibilities play a vital role in ensuring that new medicines are affordable and are likely to continue to be in a future where geopolitical forces have drastically altered the financing structures of medicines provision in DCs and LDCs.},
}
@article {pmid41605610,
year = {2026},
author = {Oreskovic, E and Petzold, A and Petropoulos, IN and Hau, S},
title = {Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review.},
journal = {The British journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1136/bjo-2025-328181},
pmid = {41605610},
issn = {1468-2079},
abstract = {Corneal confocal microscopy (CCM) is a non-invasive imaging technique that enables quantification of the corneal sub-basal nerve plexus and has emerged as a potential surrogate biomarker for peripheral neurodegeneration. This scoping review evaluated current evidence on the use of CCM in assessing corneal nerve fibre changes across neurodegenerative diseases (NDDs) and explored its potential as a paraclinical diagnostic and monitoring tool. A comprehensive search of PubMed and Scopus was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines to identify studies reporting quantitative CCM metrics, including corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fibre length (CNFL). Both cross-sectional and longitudinal studies of patients with NDDs were included, and findings were narratively synthesised. 50 studies were included: Parkinson's disease (n=13), multiple sclerosis (n=11), cerebrovascular accidents (n=7), post-COVID-19 neuropathy (n=5), amyotrophic lateral sclerosis (n=4), chronic inflammatory demyelinating polyneuropathy (n=4), Alzheimer's disease (n=3), Fabry disease (n=2) and neurofibromatosis type 1 (n=1). CNFL and CNFD were consistently reduced in Parkinson's disease, multiple sclerosis, cerebrovascular accidents, amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy and post-COVID-19 neuropathy, whereas CNBD results were inconsistent. The strongest evidence supported the role of CCM in Parkinson's disease and multiple sclerosis. CNFL and CNFD emerged as the most reliable CCM-derived metrics across NDDs, supporting their potential as objective biomarkers for neurodegeneration. While findings support the potential of CCM as a paraclinical diagnostic tool, methodological heterogeneity in image acquisition, analysis software and study design limited comparability. Standardised imaging and analysis protocols are needed to enable broader clinical application and validation across NDDs.},
}
@article {pmid41605818,
year = {2026},
author = {Keels, JN and LaPlante, RD and Lee, CS and Dwyer, AA},
title = {Prevalence of new-onset diabetes following COVID-19 infection: A systematic review and meta-analysis.},
journal = {Diabetes, obesity &amp; metabolism},
volume = {28},
number = {4},
pages = {3182-3192},
pmid = {41605818},
issn = {1463-1326},
support = {1F31NR021624-01/NR/NINR NIH HHS/United States ; },
mesh = {Humans ; *COVID-19/complications/epidemiology ; Prevalence ; *Diabetes Mellitus, Type 2/epidemiology/virology ; SARS-CoV-2 ; Female ; Adult ; Pandemics ; *Diabetes Mellitus, Type 1/epidemiology ; Post-Acute COVID-19 Syndrome ; },
abstract = {AIM: To estimate the prevalence of new-onset diabetes in adults (≥ 18 years) following SARS-CoV-2 infection.<br><br>MATERIALS AND METHODS: This meta-analysis includes studies written in English that measured the number of adults (&#x2265;&#x2009;18&#x2009;years) diagnosed with diabetes following SARS-CoV-2 infection. Studies underwent dual independent review; quality was assessed by using the New Castle Ottawa Scale. A random-effects meta-analysis was conducted to obtain the pooled estimate of new-onset diabetes. To understand the relationship between patient characteristics (age, sex) and study variable (duration of follow-up), a random effects meta-regression was used.<br><br>RESULTS: A total of 33 articles were retained for analysis. The overall estimated prevalence of new-onset diabetes (combined T1DM and T2DM or undefined) was 8.33% (95% CI 7.47, 9.18%, z&#x2009;=&#x2009;19.04, p&#x2009;<&#x2009;0.001; Q&#x2009;=&#x2009;6791.24, I[2], 99.68%). The overall estimated prevalence of new-onset T2DM in COVID-19 was 8.92% (95% CI 7.88%, 9.96%, z&#x2009;=&#x2009;16.77, p&#x2009;<&#x2009;0.001; Q&#x2009;=&#x2009;27659.74; p&#x2009;<&#x2009;0.001, I[2]&#x2009;=&#x2009;99.96%). The overall estimated prevalence of new-onset T1DM was 0.86% (95% CI 0.0072%, 0.0099%, z&#x2009;=&#x2009;12.59, p&#x2009;<&#x2009;0.001; Q&#x2009;=&#x2009;9456.28; p&#x2009;<&#x2009;0.001, I[2]&#x2009;=&#x2009;99.94%). At the study level, there was no significant relationship identified with age, sex, or follow-up duration.<br><br>CONCLUSIONS: This systematic review and meta-analysis revealed a notable increase in T2DM or combined (T1DM, T2DM, or undefined) conditions. As such, it may be important to understand the underlying factors contributing to increased prevalence.},
}
@article {pmid41606213,
year = {2026},
author = {Ferreira, AGS and Garcia, HWC and da Silva, SS and da Silva, FAMF and Ferreira, JWL and da Silva Lopes, IMS},
title = {The role of sense of control and locus of control in depressive and anxious symptoms during COVID-19: an integrative review.},
journal = {Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS},
volume = {39},
number = {1},
pages = {5},
pmid = {41606213},
issn = {0102-7972},
abstract = {BACKGROUND: The COVID-19 pandemic triggered a series of psychological impacts, resulting in significant increases in anxiolytic and depressive disorders, influenced by isolation measures, health insecurity, and abrupt social changes. Two key concepts for understanding emotional responses during this period include Sense of Control (SoC) and Locus of Control (LoC). The SoC refers to the general perception of personal agency, while the LoC is a more specific framework that classifies control perceptions as either internal (believing one has control over life events) or external (attributing outcomes to external forces). Previous studies indicate that a more external LoC and a low SoC are associated with greater psychological vulnerability in stressful contexts, such as during the pandemic, which can amplify symptoms of anxiety and depression. This integrative review aims to gather and synthesize studies that explore the relationship between LoC and/or SoC and symptoms of anxiety and depression during the COVID-19 pandemic. MAIN TEXT: A systematic search was conducted in PubMed, Scopus, and BVS databases, focusing on studies published within the last 5 years. Quantitative studies with adult samples were considered eligible while excluding those with specific pre-existing conditions. After removing duplicates, titles and abstracts were screened, resulting in 12 full-text studies to be reviewed. Of these, nine met inclusion and exclusion criteria and were included in the analysis. An emerging pattern showed that individuals with external LoC and low SoC had higher levels of anxiety and depression during the COVID-19 pandemic. The role of LoC and SoC as moderators of psychological distress was documented, reinforcing prior evidence that individuals with an external LoC are more vulnerable to mental health challenges in times of crisis. Furthermore, these constructs influenced behavioral responses to the pandemic, with higher SoC and internal LoC associated with more proactive and responsible coping strategies. CONCLUSION: Both LoC and SoC play critical roles in understanding the psychological impacts of the pandemic. Despite populational and methodological diversity, most studies point to a clear correlation between perception of control and levels of anxiety and depression, highlighting the importance of interventions that increase the perception of personal control to reduce psychological distress.},
}
@article {pmid41606239,
year = {2026},
author = {Salem, GM and Azamor, T and Familiar-Macedo, D and Onwubueke, C and Cambou, MC and Chen, W and Nielsen-Saines, K and Foo, SS},
title = {Mechanistic insights into the impact of prenatal viral infections on maternal and offspring immunity.},
journal = {Npj viruses},
volume = {4},
number = {1},
pages = {7},
pmid = {41606239},
issn = {2948-1767},
support = {N/A//Cleveland Clinic/ ; },
abstract = {Global outbreaks of human immunodeficiency virus (HIV) and respiratory viruses - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza, accounted for ~50 million infections in 2024. Prenatal exposure to these viruses poses substantial risks to maternal and fetal health, yet the underlying immunological mechanisms remain incompletely understood. Despite differences in viral biology and transmission, mounting evidence reveals a convergent theme of maternal immune activation during pregnancy. Even without vertical transmission, virus-elicted maternal immune responses alter the maternal-fetal interface and gut microbiome, reshaping fetal immunity and birth outcomes. These immune perturbations increase susceptibility to infections, neurodevelopmental disorders, and immune-mediated diseases later in life. Here, we discuss viral immune evasion strategies that modulate maternal immunity and review current clinical and emerging therapeutic approaches aimed at mitigating long-term consequences in exposed children. Understanding how prenatal viral exposure shapes lifelong health is critical for developing targeted interventions and reducing postnatal disease burden.},
}
@article {pmid41606631,
year = {2026},
author = {Kyriakopoulos, AM and McCullough, PA and Seneff, S},
title = {Taurine intake ameliorates lactic acidosis and hyperferritinemia occurring after mRNA SARS-CoV-2 vaccination in a patient with β-thalassemia trait: a case report and review of literature.},
journal = {Journal of medical case reports},
volume = {20},
number = {1},
pages = {},
pmid = {41606631},
issn = {1752-1947},
support = {6950759//Quanta Computer, Inc./ ; },
mesh = {Humans ; Male ; Adult ; *Taurine/therapeutic use/administration &amp; dosage ; *beta-Thalassemia/complications ; *Acidosis, Lactic/etiology/drug therapy ; *Hyperferritinemia/etiology/drug therapy ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/adverse effects ; Ferritins/blood ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Taurine is a powerful antioxidant necessary for mitochondrial function. Lactic acidosis is a complication encountered in the condition mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), which can be successfully treated with supplemental taurine. Furthermore, taurine regulates the production of iron-dependent proteins such as ferritin that can act as chelating agents to sequester labile iron.<br><br>CASE PRESENTATION: A 38-year-old Greek male with a &#x3b2;-zero thalassemia trait developed multiple severe symptoms soon after his first and only mRNA (Pfizer) SARS-CoV-2 vaccination that included hematological stress to be a candidate for blood transfusion. Amongst the hematological readings, the patient had lactate levels&#x2009;>&#x2009;4&#xa0;mmol/ml, indicating lactic acidosis, and ferritin levels&#x2009;>&#x2009;820 ng/ml, representing hyperferritinemia. Moreover, the patient has organic acid and plasma metabolite levels in the urine that are indicative of mitochondrial dysfunction. Regular taurine intake (500 mg/day) for years helped the patient control lactate and ferritin levels and avoid more serious clinical decompensation.<br><br>CONCLUSION: Regular taurine intake helps to avoid lactic acidosis and reverse hyperferritinemia after mRNA SARS-CoV-2 vaccination in a patient with &#x3b2;-zero thalassemia trait with no obvious genetic trait linked to mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Taurine seemed to be protective for mitochondria.},
}
@article {pmid41606968,
year = {2026},
author = {, },
title = {[Expert consensus on quality management of multi-pathogen surveillance for acute respiratory infectious diseases].},
journal = {Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]},
volume = {60},
number = {2},
pages = {135-145},
doi = {10.3760/cma.j.cn112150-20251114-01080},
pmid = {41606968},
issn = {0253-9624},
mesh = {Humans ; Acute Disease ; Consensus ; COVID-19 ; Quality Control ; *Respiratory Tract Infections/epidemiology/prevention &amp; control ; SARS-CoV-2 ; *Sentinel Surveillance ; },
abstract = {Since 2024, the National Disease Control and Prevention Administration has implemented sentinel surveillance for acute respiratory infectious (ARI) diseases to monitor the epidemiology and etiology of multiple pathogens such as influenza virus and SARS-CoV-2. To ensure scientific rigor, standardized procedures, accurate and reliable data, and the efficient operation of network laboratories, a multidisciplinary expert panel-including representatives from the disease control and prevention system, sentinel hospitals, schools of public health, and research institutes-jointly developed the Expert Consensus on Quality Management for Sentinel Surveillance of ARI Diseases. The consensus was formulated through multiple rounds of discussion, investigation, and public consultation, incorporating national surveillance protocols, technical guidelines, scientific evidence, and practical experience. Focusing on establishing a comprehensive quality control system for the entire multi-pathogen surveillance process for ARI diseases, the consensus outlines key components covering all stages: target population definition; specimen collection, transport, aliquoting, and storage; laboratory infrastructure and equipment management; multiplex pathogen detection and gene sequencing; quality assurance of test results; biosafety; personnel training and assessment; and data management and analysis. This document aims to provide end-to-end technical guidance for quality control in ARI sentinel surveillance in China.},
}
@article {pmid41607097,
year = {2026},
author = {Han, Z and Han, J and Zhao, Y and Xu, C and Leng, X and Jia, B and Diao, N and Liu, F and Cui, C and Liang, J and Jiang, Y and Du, R},
title = {Research Progress of Coronavirus Reverse Genetics Technology.},
journal = {Journal of medical virology},
volume = {98},
number = {2},
pages = {e70792},
doi = {10.1002/jmv.70792},
pmid = {41607097},
issn = {1096-9071},
support = {2023DJ07//Research and Demonstration on Key Technologies for Prevention and Control of Important Diseases and Antibiotic-Free Breeding of Sika Deer/ ; 20230204010YY//Jilin Provincial Department of Human Resources and Social Security - Innovative and Entrepreneurial Talents and the Analysis of Pathogen Diversity in Sika Deer Breeding Environment and Integration and Demonstration of Supporting Prevention and Control Technology System/ ; //Jilin Provincial Department of Science and Technology - Key Research and Development/ ; },
mesh = {*Reverse Genetics/methods ; Humans ; SARS-CoV-2/genetics ; Genome, Viral ; *Coronavirus/genetics ; Animals ; COVID-19/virology ; },
abstract = {In recent years, coronavirus, a kind of virus with a wide host range and high variability, has a large and complex genome. Research on the reverse genetics of coronaviruses has always been a hot spot. Coronavirus cannot only infect mammals, but also infect humans, showing its wide host adaptability. The mutation ability of the coronavirus is extremely strong. Recently, the rapid mutation rate of SARS-CoV-2 has made the development of vaccines and therapeutic methods face great challenges. At present, reverse genetics technology is a molecular biology tool. This process primarily involves cloning the full-length genome cDNA of the virus onto a vector, and then reproducing the modified progeny virus in the cell to achieve accurate modification of the virus's genetic characteristics. This technology can explore the external characteristics of mutants and the evolution of their traits through artificial operations, such as knockout and site-directed mutagenesis of specific genes, and then reveal the biological functions of genes. This article will review the research progress of the coronavirus reverse genetic operating system. In the past research, reverse genetics technology has made remarkable progress in the field of coronavirus research. Researchers have successfully constructed various reverse genetic systems for coronaviruses, including IBV, SARS-CoV-2, and MERS-CoV. In addition, the reverse genetic system has also been used to study the cross-species transmission capacity of the virus, which is of great significance for preventing possible future novel coronavirus epidemics.},
}
@article {pmid41607599,
year = {2025},
author = {Sahoo, DP},
title = {Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.},
journal = {Mediterranean journal of rheumatology},
volume = {36},
number = {4},
pages = {509-523},
pmid = {41607599},
issn = {2529-198X},
abstract = {Adult-onset Still's disease (AOSD) is a rare autoinflammatory disorder characterized by spiking fevers, arthralgia, and a transient salmon-pink rash, with an incidence of 0.16-0.4 per 100,000. AOSD shares overlapping clinical and immunological features with systemic juvenile idiopathic arthritis (sJIA), supporting a disease continuum and shared treatment approaches. The COVID-19 pandemic has impacted AOSD care, with SARS-CoV-2 infection and vaccination occasionally triggering disease flares, necessitating adaptive management strategies. Driven by innate immune dysregulation and overproduction of proinflammatory cytokines (IL-1, IL-6, IL-18), AOSD presents in systemic and articular phenotypes, with severe complications like macrophage activation syndrome (MAS), fulminant hepatitis, and parenchymal lung disease. Diagnosis, based on Yamaguchi or Fautrel criteria and biomarkers (ferritin, IL-18), is challenging due to nonspecific symptoms. Biologic therapies (anakinra, canakinumab, tocilizumab) achieve remission in 80-90% of systemic cases. This review synthesises diagnostic challenges, novel biomarkers (e.g., gasdermin D), and emerging therapies (e.g., IL-18 binding protein), emphasising precision medicine and future research needs.},
}
@article {pmid41607619,
year = {2026},
author = {Aguiar, CEO and Costa, JMC and Oliveira, MMGL and Lopes, CF and Lima, PHM and Dietrich, VC and Grenfell, RFQ and de Melo, FF},
title = {Cardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers.},
journal = {World journal of cardiology},
volume = {18},
number = {1},
pages = {112466},
pmid = {41607619},
issn = {1949-8462},
abstract = {Long coronavirus disease (LC) is a condition characterized by a persistent state, with recurrent/remitting or progressive episodes, that may affect one or multiple organ systems following severe acute respiratory syndrome coronavirus 2 infection. The cardiovascular system is particularly impacted by this condition. This review aims to discuss the cardiovascular implications in LC and its potential mechanisms. We offer an updated summary of established and emerging biomarkers with clinical potential for diagnosis, risk stratification, and therapy monitoring. Conventional markers with established clinical roles, such as cardiac troponins, natriuretic peptides (B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide), D-dimer, and inflammatory markers (e.g., C-reactive protein, interleukin-6), coexist with less established but promising biomarkers, such as growth differentiation factor-15, galectin-3, von Willebrand factor, endothelin-1, and circulating microRNAs. The incomplete understanding of the mechanisms and their diverse clinical manifestations, underscores the urgent need for efficient diagnostic tests and predictive models. In this context, besides the lack of standardization in biomarker testing and the absence of validated longitudinal predictive models, the use of biomarker-based strategies represents a potential tool to improve early detection of high-risk patients, enable personalized follow-up, and support more effective prevention of cardiovascular complications in LC patients in clinical practice.},
}
@article {pmid41609696,
year = {2026},
author = {Gouveia, A and Buclin, CP and Hibbert, D and Mbadu Mbuzi, E and Mussard, L and Kokkinakis, I and Selby, K and Von Plessen, C and Clair, C and Bodenmann, P},
title = {[2025 scientific breakthroughs in ambulatory general internal medicine].},
journal = {Revue medicale suisse},
volume = {22},
number = {947},
pages = {204-209},
doi = {10.53738/REVMED.2026.22.947.48272},
pmid = {41609696},
issn = {1660-9379},
mesh = {Humans ; *Internal Medicine/trends ; COVID-19/prevention &amp; control ; *General Practice/trends ; *Ambulatory Care/trends/methods ; COVID-19 Vaccines/administration &amp; dosage ; },
abstract = {In this article, we present eight studies published in the last 2 years that are likely to influence the practice of general practitioners in 2026. The key messages highlight the effectiveness of metformin for knee pain treatment, recent advances in the management of poorly controlled asthma, and the absence of contraindications to administering influenza and Covid-19 vaccines simultaneously. In addition, several articles describe the association between sleep duration and hypertension, blood pressure measurement protocols, the effects of vitamin K2 on nocturnal leg cramps, and the effects of intermittent fasting on weight loss. Finally, the Thrombosis Risk Prediction in Patients with Cast Immobilization Score can be used to assess whether therapeutic anticoagulation is indicated in cases of lower-limb immobilization.},
}
@article {pmid41611193,
year = {2026},
author = {Kharkivska, Y and Shkel, O and Kim, YK},
title = {Syntenins at the crossroads of host-virus interactions.},
journal = {Methods (San Diego, Calif.)},
volume = {247},
number = {},
pages = {175-183},
doi = {10.1016/j.ymeth.2026.01.009},
pmid = {41611193},
issn = {1095-9130},
mesh = {*Syntenins/metabolism/genetics ; Humans ; Animals ; PDZ Domains ; *Host-Pathogen Interactions ; *Virus Diseases/virology/metabolism ; Coronavirus ; Human Papillomavirus Viruses ; Virus Replication ; },
abstract = {Syntenin is a multifunctional PDZ-domain adaptor protein that orchestrates membrane trafficking, cytoskeletal remodeling, and exosome biogenesis. Initially identified as a syndecan-binding molecule, syntenin has since emerged as a central hub connecting membrane receptors to intracellular signaling pathways that regulate adhesion, motility, immune signaling, and cellular plasticity. While extensively studied in cancer and neural development, recent discoveries reveal that a wide range of viruses exploit syntenin to facilitate their replication, assembly, or dissemination. This review consolidates current evidence across diverse viral infections to elucidate the molecular mechanisms underlying the interaction between syntenin and viruses. Coronaviruses utilize syntenin to link PDZ-binding motifs to p38 MAPK-driven inflammation and endosomal entry. Papillomaviruses and Epstein-Barr virus hijack the CD63-syntenin-ALIX complex to control vesicle-mediated trafficking. Hepatitis C virus employs it to secrete E2-coated, antibody-resistant exosomes. Dengue virus harnesses its mosquito homolog AeSyntenin to package sfRNA for transmission. Human T-cell leukemia virus type 1 employs its Tax-1 oncoprotein to bind the PDZ domains of syntenin, remodel extracellular vesicle cargo, and promote viral spread. In contrast, during human immunodeficiency virus infection, syntenin restricts viral fusion at the plasma membrane, though the nucleocapsid mimics its PDZ tandem to promote virion release. Collectively, these findings establish syntenin as a dynamic regulator at the host-virus interface, capable of exerting both proviral and antiviral effects. Emerging pharmacological strategies targeting syntenin PDZ domains further underscore its potential as a broad-spectrum, host-directed antiviral target.},
}
@article {pmid41612083,
year = {2026},
author = {Grant, A and Kabbani, D and Vuong, A and Skidmore, B and Hsu, AT and Sanmugalingham, G and de Vries, R and Logan, S and Gongal, P and Piotrowski, CC and Thavorn, K and , },
title = {Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.},
journal = {PharmacoEconomics - open},
volume = {10},
number = {3},
pages = {423-455},
pmid = {41612083},
issn = {2509-4254},
abstract = {BACKGROUND: High-risk populations, including transplant recipients, are at increased risk of severe Coronavirus disease 2019 (COVID-19) outcomes. Certain treatments and pre-exposure prophylaxis (PrEP) have been approved to reduce the risk of severe illness. However, data on the cost effectiveness of currently approved COVID-19 therapeutics and preventative treatments are limited for those at high-risk of severe disease.<br><br>OBJECTIVE: The aim of this study was to systematically review the cost effectiveness of COVID-19 treatments and PrEP in high-risk, immunocompromised, and transplant populations.<br><br>METHODS: Electronic databases were searched from inception to September 2025 for studies comparing costs and effectiveness of monoclonal antibodies PrEP or COVID-19 therapeutics in high-risk, immunocompromised or transplant populations. Two reviewers independently screened studies, extracted data, and critically appraised them using the Joanna Briggs Institute checklist for economic evaluations. Cost data are presented in 2025 US dollars.<br><br>RESULTS: Of 8905 studies identified, 60 met inclusion criteria, with seven focused on or including transplant populations. Most studies were cost-utility analyses published between 2020 and 2025. Nirmatrelvir-ritonavir, tixagevimab-cilgavimab, casirivimab-imdevimab, sotrovimab, remdesivir, molnupiravir, and fluvoxamine were compared with no prophylaxis or standard of care. Among transplant populations, the incremental cost-effectiveness ratio (ICER) for tixagevimab-cilgavimab PrEP following vaccination was US$76,024 per quality-adjusted life year (QALY), while ICERs for COVID-19 therapeutics ranged from US$440 to US$126,676 per QALY.<br><br>CONCLUSION: Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations.},
}
@article {pmid41612314,
year = {2026},
author = {Roshdi, G and Motealleh, A},
title = {Telerehabilitation in the management of urinary incontinence in women: a narrative review.},
journal = {BMC women's health},
volume = {26},
number = {1},
pages = {},
pmid = {41612314},
issn = {1472-6874},
mesh = {Humans ; Female ; *Urinary Incontinence/rehabilitation ; *Telerehabilitation ; Exercise Therapy/methods ; },
abstract = {Urinary incontinence (UI) is a prevalent condition affecting millions worldwide, particularly women, with significant impacts on physical, psychological, and socioeconomic aspects of life (Haylen et al., Neurourol Urodyn 29:4–20, 2010; Aoki et al., Nat Rev Dis Primers 3:1–20, 2017). Conventional management includes behavioral therapy, pelvic floor muscle training (PFMT), and pharmacological interventions, but barriers such as social stigma, access to specialists, and poor treatment adherence persist (Nitti Rev Urol 3, 2001; Sinclair et al., Obstet Gynaecol 13:143-8, 2011; Minassian et al., 111:324-31, 2008; Milsom et al., Eur Urol 65:79-95, 2014). Telerehabilitation—defined as the delivery of rehabilitation services via electronic information and communication technologies (e.g., video conferencing and phone calls for improved access; mobile apps, websites, and virtual reality (VR) for enhanced engagement and self-management)—offers a potentially promising alternative to overcome these obstacles (Buckingham et al., JMIRx Med 3:e30516, 2022). This narrative review synthesizes evidence from studies conducted between January 2000 and November 6, 2025 on telerehabilitation’s role in UI management in women, focusing on stress UI, PFMT efficacy, and comparative outcomes with in-person therapy. It addresses gaps in prior systematic reviews by focusing on patient-centered designs and cultural adaptations. Key findings from 25 included studies indicate that telerehabilitation is feasible, effective in reducing UI symptoms, improving quality of life (QoL), and enhancing adherence, particularly through mobile apps and group-based interventions (Asklund et al., Neurourol Urodyn 36:1369-76, 2017; Sjostrom et al., BJU Int 112:362-72, 2013; Hoffman et al., Gynecol Scand 96:1180-7, 2017). However, limitations include heterogeneity in interventions, small sample sizes in many studies, lack of long-term data, absence of male participants, limited validation in rural or cognitively impaired populations, and insufficient cultural adaptations for diverse groups. Recommendations include developing tailored telerehabilitation programs incorporating biofeedback and interdisciplinary approaches to address UI holistically. This review highlights telerehabilitation’s potential as a scalable, cost-effective intervention, particularly post-COVID-19, and calls for further research in diverse female populations.},
}
@article {pmid41612572,
year = {2026},
author = {Viana, IRMN and Peixoto, HM},
title = {Vaccination Coverage and Factors Associated With Incomplete Vaccination Schedules in Children Under 5 in a Peripheral Area of the Federal District of Brazil.},
journal = {Public health nursing (Boston, Mass.)},
volume = {43},
number = {3},
pages = {543-553},
pmid = {41612572},
issn = {1525-1446},
support = {//Institute for Health Assessment and Translation for Chronic and Neglected Diseases of High Relevance/ ; //Coordination for the Improvement of Higher Education Personnel/ ; },
mesh = {Humans ; Brazil ; Male ; Cross-Sectional Studies ; Child, Preschool ; *Vaccination Coverage/statistics &amp; numerical data ; Infant ; Female ; *Immunization Schedule ; *COVID-19/prevention &amp; control/epidemiology ; Surveys and Questionnaires ; Vaccination/statistics &amp; numerical data ; },
abstract = {OBJECTIVE: To estimate vaccination coverage (VC) and analyze the factors associated with the incomplete vaccination schedule (IVS) in children under 5 years of age in two Basic Health Units in the Federal District of Brazil.<br><br>DESIGN: A cross-sectional study.<br><br>SAMPLE: The study included 162 children in two Basic Health Units; 54.94% were male, and all were under 5 years of age.<br><br>MEASUREMENTS: Guardians were interviewed using a structured questionnaire, and their vaccination booklets were photographed. VC was estimated and prevalence ratios (PR) were calculated using Poisson regression analysis.<br><br>RESULTS: Twenty percent of the children had an IVS. None of the vaccines evaluated reached the VC considered correct in terms of age and interval between doses. Factors associated with IVS were age under 2 years (adjusted PR: 2.55; 95% CI: 1.53-4.24), difficulties arising from the COVID-19 pandemic (adjusted PR: 2.71; 95% CI: 1.51-4.86) and a negative response when asked whether all vaccines were administered in the same location (adjusted PR: 1.97; 95% CI: 1.13-3.44).<br><br>CONCLUSIONS: A high proportion of children presented IVS, associated with factors such as age, lack of continuity of vaccination in the same location and difficulties caused by the COVID-19 pandemic.},
}
@article {pmid41613329,
year = {2025},
author = {Cherian, JJ and Das, S and Bagepally, BS and Eerike, M and Nath, S and Khadwal, A},
title = {Efficacy and safety of stem cell therapy vs. standard of care in patients diagnosed with acute respiratory distress syndrome: an updated systematic review and meta-analysis of randomized controlled trials.},
journal = {Frontiers in medicine},
volume = {12},
number = {},
pages = {1674720},
pmid = {41613329},
issn = {2296-858X},
abstract = {OBJECTIVES: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of stem cell therapies as compared to the standard of care (SOC) in patients with acute respiratory distress syndrome (ARDS).<br><br>METHODS: Search of PubMed, Embase, Cochrane CENTRAL, and Web of Science databases for randomized controlled trials was performed. The protocol was registered in PROSPERO (ID: CRD42023467612). The primary outcomes were all-cause mortality on day 28 and serious adverse events. Risk ratios (RR) and mean differences were pooled using Stata software version 17.0. Quality of the evidence was assessed by GRADE approach.<br><br>RESULTS: Out of 5,537 articles screened, 17 were included. Treatment with stem cells led to no significant difference in the risk of 28-day mortality [RR, 0.809 (95% CI: 0.651-1.005), p = 0.06; I [2] = 0%] or the risk of serious adverse events [RR, 0.94 (95% CI: 0.80-1.12), p = 0.36; I [2]= 8.58%] as compared to treatment with SOC. Additionally, no significant differences were observed in the duration of hospitalization, the number of ventilator-free days till day 28, 60-day all-cause mortality, intensive care unit (ICU)-free days till day 28, change in quality-of-life (QoL) score, and the duration of ICU stay, PaO2/FiO2 ratio, change in SOFA score, and change in serum interleukin 6 and 8 levels. The GRADE of evidence was low or very low for the critical outcomes.<br><br>CONCLUSION: There was no significant improvement in critical outcomes following stem cell therapy as compared to the SOC in ARDS. The certainty of evidence was low to very low, indicating limited confidence in the findings.<br><br>SYSTEMATIC TRIAL REGISTRATION: PROSPERO (ID: CRD42023467612).},
}
@article {pmid41613493,
year = {2026},
author = {Danchenko, P and Rudenko, K and Rzhanyi, M and Hrubiak, L and Ishchenko, M and Kozhanov, M},
title = {Contemporary surgical treatment of hypertrophic obstructive cardiomyopathy: insights from the Ukrainian National Referral Center.},
journal = {Indian journal of thoracic and cardiovascular surgery},
volume = {42},
number = {2},
pages = {282-290},
pmid = {41613493},
issn = {0970-9134},
abstract = {PURPOSE: Hypertrophic obstructive cardiomyopathy (HOCM) remains a prevalent and clinically significant condition with a global prevalence of 1:200 to 1:500. In Ukraine, the estimated burden is approximately 75,000 patients, although national data remain limited. Since 2016, the Amosov National Institute of Cardiovascular Surgery in Kyiv has been a leading center for HOCM surgery, primarily performing septal myectomy (SM) with concomitant mitral valve (MV) repair. This review summarizes the evolution of the Institute's surgical program, outcomes, and challenges faced under extraordinary circumstances.<br><br>METHODS: Institutional experience with SM and MV repair between 2016 and 2025 was reviewed. Preoperative evaluation included transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR) imaging, and/or computed tomography (CT). A refined transaortic SM technique was applied to optimize septal resection, relieve left ventricular outflow tract (LVOT) obstruction, and address dynamic mitral regurgitation (MR).<br><br>RESULTS: SM consistently reduced LVOT gradients and eliminated MR in the majority of patients. In-hospital mortality remained below 1%, with a low incidence of major complications directly attributable to myectomy. Despite significant external pressures, including the coronavirus disease 2019 (COVID-19) pandemic and the ongoing full-scale war in Ukraine, surgical activity continued without interruption. Innovations in operative techniques and perioperative management further enhanced safety and outcomes.<br><br>CONCLUSION: The Amosov Institute has established a high-performing national program for HOCM surgery, demonstrating durable results despite unprecedented challenges. Ongoing refinement of minimally invasive strategies and strengthened international collaboration remain essential to address the global shortage of experienced myectomy surgeons and ensure wider access to advanced surgical care.<br><br>SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-025-02125-0.},
}
@article {pmid41613884,
year = {2025},
author = {Rozhnova, TM and Starynina, DV and Bubnova, AM and Vinnik, YY and Moiseeva, AV and Kostyuk, SV and Rozhnova, KS and Nikolenko, VN and Orlov, YL},
title = {The COVID-19 pandemic and its consequences on men's reproductive health.},
journal = {Biophysical reviews},
volume = {17},
number = {5},
pages = {1643-1650},
pmid = {41613884},
issn = {1867-2450},
abstract = {The COVID-19 pandemic has significantly impacted global health; key questions remain regarding its effects on male reproductive function. Male infertility represents both a biomedical challenge and a societal concern. Our review considers COVID-19's biophysical mechanisms affecting the male reproductive system and focuses on the prognostic implication. Current evidence highlights two primary pathways of SARS-CoV-2 impact: hyperthermia and oxidative stress. The first pathway, as reported, significantly increases sperm aneuploidy and, as a result, has adverse effects on spermatogenesis and causes sperm DNA breaks. The second pathway of coronavirus impact on infertility is oxidative stress. During it, the level of formation of reactive oxygen species (ROS) increases and damages sperm membrane by lipid peroxidation. These mechanisms are interrelated, as fever-induced oxidative stress may alter redox-active metal homeostasis, further exacerbating cellular damage. Understanding these pathogenic processes enables targeted therapeutic development and preventive strategies for COVID-19-related male reproductive dysfunction.},
}
@article {pmid41614075,
year = {2025},
author = {Zhang, Z and Li, X and Zhou, J and Li, Y},
title = {Xuebijing injection in the treatment of COVID-19: An update on clinical studies, potentially active metabolites and mechanisms.},
journal = {Frontiers in pharmacology},
volume = {16},
number = {},
pages = {1667022},
pmid = {41614075},
issn = {1663-9812},
abstract = {INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an epidemic respiratory disease caused due to the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In China, the National Health Commission of China announced that patients with COVID-19 who were treated with traditional Chinese medicines (TCMs) combined with antiviral drugs effectively alleviated their symptoms and recovered. Among these TCMs, Xuebijing (XBJ) injection plays an important role in the treatment of patients with COVID-19. However, this was a puzzle that what will be the clinical efficacy and safety of XBJ injection for COVID-19 treatment, and what are the potential mechanisms behind XBJ injection?<br><br>METHODS: To search for articles on "Xuebijing injection in the treatment of COVID-19" in PubMed, use the following query: (Xuebijing injection OR Xuebijing) AND (COVID-19 OR SARS-CoV-2 OR severe pneumonia). We added filters for "Clinical Trial," "Randomized Controlled Trial," or "Review" to focus on specific study types, and limit the search to recent years (2010-2025) and English-language articles for more targeted results.<br><br>RESULTS: XBJ injection in combination with regular therapy has been shown to improve overall efficacy, reduce 28-day mortality, improve lung CT recovery and reduce pro-inflammatory markers in patients with COVID-19. The high affinity for angiotensin converting enzyme 2, inhibition of neutrophil extracellular trap release and prevention of cell death and inflammation may be the main molecular mechanisms of XBJ injection in the treatment of COVID-19.<br><br>CONCLUSION: This review synthesizes the current evidence on the clinical efficacy and safety of XBJ injection in the treatment of COVID-19. Our analysis indicates that XBJ injection, when used in combination with standard therapy, significantly improves overall efficacy, reduces 28-day mortality, enhances lung CT recovery, and decreases pro-inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6). These findings suggest that Xuebijing injection is a promising adjunctive treatment for COVID-19, particularly in severe cases, although it must be confirmed through rigorous pharmacological and clinical studies.},
}
@article {pmid41614415,
year = {2026},
author = {Zhamaliyeva, L and Batyrova, A and Ablakimova, N and Veklenko, G and Malsova, B and Tautanova, A and Grjibovski, AM},
title = {Global research trends on depression-related stigma in the 21st century: a bibliometric analysis.},
journal = {Global health action},
volume = {19},
number = {1},
pages = {2612390},
pmid = {41614415},
issn = {1654-9880},
mesh = {Humans ; *Bibliometrics ; *Social Stigma ; *Depression/psychology ; *Global Health ; *Research/trends ; },
abstract = {BACKGROUND: Depression is a leading contributor to the global burden of diseases. Stigma associated with mental illness significantly hinders help-seeking, diagnosis, treatment, and recovery. While research on mental health stigma has expanded over the past two decades, a systematic examination of its evolution, particularly in the context of depression, is almost non-existent.<br><br>OBJECTIVE: To map and analyze global research on depression stigma, focusing on publication trends, leading contributors, international collaborations, and thematic developments.<br><br>METHODS: We analyzed 947 peer-reviewed articles indexed in the Scopus database using bibliometric software in R-studio. Quantitative indicators included annual publication growth, citation analysis, leading countries, institutions, and authors, as well as international collaboration patterns. Additionally, keyword co-occurrence and thematic evolution analyses were conducted to explore conceptual developments within the field.<br><br>RESULTS: The number of publications steadily increased from 2013 to 2025. The United States, China, the UK, and Canada accounted for the highest research and citation impact, while contributions from low- and middle-income countries (LMIC) remained limited despite these regions carrying most of the global disease burden. Thematic mapping revealed a strong focus on clinical and psychosocial dimensions, with increasing attention to concepts such as resilience, social support, and the mental health effects of the COVID-19 pandemic in recent years.<br><br>CONCLUSIONS: The volume of research on depression stigma has grown, yet significant geographical and conceptual disparities continue to persist. Strengthening collaboration, supporting LMIC research capacity, and integrating stigma reduction into global mental health frameworks are essential to achieving equitable mental health outcomes worldwide.},
}
@article {pmid41614579,
year = {2026},
author = {Okasha, T and Shaker, NM and Abdel Aziz, K and Aly El-Gabry, D},
title = {Egypt's innovations in mental health: bridging cultural heritage and digital psychiatry.},
journal = {International review of psychiatry (Abingdon, England)},
volume = {},
number = {},
pages = {1-12},
doi = {10.1080/09540261.2026.2621823},
pmid = {41614579},
issn = {1369-1627},
abstract = {Egypt's mental-health landscape represents a unique continuum in which ancient cultural heritage, community-based healing traditions, and contextually adapted psychiatric strategies intersect with modern psychiatric innovations. This review explores how deeply rooted explanatory models continue to define help-seeking pathways and patient expectations. These cultural foundations exist alongside contemporary systemic challenges. In response, Egypt has pioneered contextually grounded adaptive approaches, such as task shifting, integrating mental health into primary care, and developing culturally-adapted psychosocial interventions led by trained non-specialists. The COVID-19 pandemic accelerated this trajectory of modernization. Telepsychiatry services, nationwide psychosocial support hotlines, AI-driven tools, and the establishment of Egypt's dedicated psychiatric COVID-19 hospital highlight the country's capacity for rapid, context-sensitive adaptation to innovate while remaining anchored in its cultural fabric. Together, these developments illustrate how mental health systems can evolve by embracing tradition as a resource rather than a barrier, and by leveraging technology to expand equity, accessibility, and cultural relevance. This review positions Egypt as a powerful case study of how cultural heritage and adaptive, problem-driven strategies can be innovatively harmonized to shape the future of mental health care in the region, where originality lies in contextual responses rather than technological novelty.},
}
@article {pmid41614609,
year = {2026},
author = {Chigozie, VU and Nnamani, MN and Igwe, KN and Ogbonna, BO},
title = {Integrating infodemiology and infodemics management to address antimicrobial resistance and vaccine hesitancy challenges in Nigeria/Africa.},
journal = {Journal of communication in healthcare},
volume = {19},
number = {2},
pages = {131-153},
doi = {10.1080/17538068.2026.2623348},
pmid = {41614609},
issn = {1753-8076},
mesh = {Humans ; Nigeria ; *Vaccination Hesitancy ; *Infodemic ; *Drug Resistance, Microbial ; COVID-19/prevention &amp; control ; Africa ; Health Literacy ; },
abstract = {BACKGROUND: Antimicrobial resistance (AMR) and vaccine hesitancy (VH) are significant public health threats in Nigeria/Africa, due to limited healthcare infrastructure and health literacy, thus encouraging misinformation, which further exacerbates these issues.<br><br>METHODS: This review examines recent literature to explore how Infodemiology and Infodemics management can be integrated into strategies addressing AMR and VH in Nigeria and Africa. A narrative review methodology was employed, sourcing studies mostly from 2020 onwards to ensure contemporary relevance.<br><br>RESULTS: Infodemiology offers tools for addressing the dual public health threats of AMR and VH in Nigeria/Africa. Evidence reveals AMR behaviors are strongly influenced by misconceptions about antibiotics, such as their efficacy against viral infections, perpetuated by social media and word-of-mouth misinformation. Similarly, VH is fueled by cultural beliefs and mistrust in health systems, amplified during the COVID-19 pandemic, where myths about infertility and harmful ingredients led to skepticism. Infodemiology enables real-time tracking of misinformation trends through digital tools, allowing health authorities to identify hotspots and intervene with targeted campaigns.<br><br>CONCLUSION: Integrating infodemiology into AMR and VH management strategies enhances public health outcomes by addressing misinformation at its roots and promoting evidence-based practices. By leveraging digital tools and engaging trusted local figures, health systems can foster trust and literacy among communities. African governments must invest in digital health infrastructure, establish supportive policies, and foster partnerships with social media platforms to sustainably manage infodemics. These strategies are ivotal for reducing AMR and increasing vaccine acceptance, ultimately safeguarding health across human, animal, and environmental domains.},
}
@article {pmid41614748,
year = {2025},
author = {Altamura, C and Marinaccio, L and Dimiccoli, V and Mollica, A and Stefanucci, A},
title = {Contribution of [18]F-Fluorodeoxyglucose to the Identification of Dubious Lesions Caused by SARS-CoV-2.},
journal = {Current issues in molecular biology},
volume = {47},
number = {12},
pages = {},
pmid = {41614748},
issn = {1467-3045},
abstract = {Coronavirus disease, caused by the SARS-CoV-2 virus, has caused a global health crisis. While RT-PCR remains the gold standard for diagnosis, its limited sensitivity, especially in the early stages, has highlighted the need for complementary diagnostic tools. Among these, [[18]F]FDG PET/CT has gained attention for its potential role in detecting inflammation and metabolic activity associated with COVID-19. This review aims to provide an overview of current diagnostic techniques for COVID-19 and to explore the application of [[18]F]FDG PET/CT imaging in the detection and monitoring of SARS-CoV-2 infection. A comprehensive literature review was conducted on molecular, serological, and imaging-based diagnostic techniques for COVID-19, with a focus on the biological mechanism, clinical applications, and diagnostic performance of [[18]F]FDG PET/CT in COVID-19 patients. [[18]F]FDG PET/CT has demonstrated the ability to detect increased metabolic activity in COVID-19 associated pulmonary lesions, particularly ground-glass opacities, often preceding detectable morphological changes on CT. The imaging also revealed uptake in lymph nodes, bone marrow, and extrapulmonary tissues, reflecting systemic inflammation. [[18]F]FDG PET/CT represents a promising additional tool for the evaluation of inflammation and disease progression in COVID-19. However, further studies are required to define its role, optimize protocols, and assess its risk-benefit profile in the clinical setting.},
}
@article {pmid41614763,
year = {2025},
author = {Stoimeni, A and Gkiourtzis, N and Karatisidou, V and Charitakis, N and Makedou, K and Tramma, D and Panagopoulou, P},
title = {Neutrophil Extracellular Traps in Pediatric Infections: A Systematic Review.},
journal = {Current issues in molecular biology},
volume = {47},
number = {12},
pages = {},
pmid = {41614763},
issn = {1467-3045},
abstract = {BACKGROUND: Neutrophil extracellular traps (NETs) are granule- and nucleus-derived structures that support innate immunity. While the contribution of NETs to adult infections and autoimmune diseases is well studied, evidence in children is still inconsistent. This review aimed to summarize current findings on NETs in pediatric infections.<br><br>METHODS: This study followed the Cochrane Handbook for Systematic Reviews of Interventions and adhered to the PRISMA guidelines. A search was conducted in major databases (MEDLINE/PubMed and Scopus) from inception until 5 September 2025. The study quality was evaluated using the modified Newcastle-Ottawa Scale.<br><br>RESULTS: Eleven studies were included in the systematic review. In respiratory disease, the role of NETs was well described and their formation correlated with severity. Patients with febrile urinary tract infections showed elevated urinary NET-associated markers. In COVID-19 infection, NET levels were unchanged in uncomplicated cases but elevated in multisystem inflammatory syndrome in children. Findings in sepsis were inconsistent.<br><br>CONCLUSIONS: This systematic review presents the published evidence on NET formation in the pediatric population, assessing the current knowledge and identifying the gaps to guide research. Future studies should aim to standardize NET detection methods, evaluate their prognostic value in large prospective cohorts, and explore the various NET-associated mechanisms in children.},
}
@article {pmid41615790,
year = {2025},
author = {Beran, J and Slíva, J},
title = {The last ten years with inosine pranobex - from an "old" therapeutic agent to vaccine research, including anti-cancer vaccines.},
journal = {Casopis lekaru ceskych},
volume = {164},
number = {7-8},
pages = {321-323},
pmid = {41615790},
issn = {0008-7335},
mesh = {Humans ; *Inosine Pranobex/therapeutic use/pharmacology ; *Cancer Vaccines/therapeutic use ; Adjuvants, Immunologic/therapeutic use ; },
abstract = {Inosine pranobex (IP), also known as inosine pranobex dimepranol, is an immunomodulatory drug with a history spanning more than fifty years. It was first introduced in the 1970s and has since been licensed in more than 50 countries around the world. It was originally considered a potential drug for AIDS, which raised high hopes at the time of the discovery of the HIV virus. However, after initial interest, its use in this area declined, and for a long time, IP was no longer discussed significantly in professional literature or clinical practice. Renewed interest came only in the last decade, when IP began to reappear in connection with the treatment of acute respiratory infections, diseases caused by human papillomavirus (HPV), and other viral diseases, including COVID-19. It also began to be used as an adjuvant in the foot-and-mouth disease vaccine, and research began on an IP-based anti-tumor vaccine.},
}
@article {pmid41617522,
year = {2026},
author = {Alias, A and Idrus, IAM and Daring, D and Azhar, N and Lotfi, WHWM and Ramdzan, AR and Rahim, AIA},
title = {Challenges in delivering healthcare services among immigrants from Southeast Asia: A scoping review.},
journal = {The Medical journal of Malaysia},
volume = {81},
number = {1},
pages = {163-171},
pmid = {41617522},
issn = {0300-5283},
mesh = {Humans ; Asia, Southeastern ; *Emigrants and Immigrants ; *Health Services Accessibility ; *Delivery of Health Care ; COVID-19/epidemiology ; Southeast Asian People ; },
abstract = {INTRODUCTION: Cross-border migration presents increasing challenges to healthcare systems globally. Ensuring equitable healthcare access for immigrant populations, particularly in Southeast Asia, requires a thorough understanding of the barriers to effective service delivery. This scoping review aimed to synthesize the existing literature on the challenges related to the delivery of healthcare services to immigrant communities from Southeast Asia. While previous studies (e.g., Brandenberger et al., 2019) applied the 3C framework to migrants and refugees globally, this review generates new insights by focusing specifically on Southeast Asia, a region underrepresented in the literature. By applying the 3C model in this context, our review identifies region-specific challenges, such as immigration policies, financial barriers, and COVID-19 impacts, that extend beyond the findings of earlier global reviews.<br><br>MATERIALS AND METHODS: A comprehensive search was conducted in ProQuest, PubMed, ScienceDirect, and Scopus databases on October 13, 2024, for studies published between January 1, 2011, and October 13, 2024. The search strategy used tailored keywords, including "challenges," "healthcare services," "immigrants," and "Asia." Inclusion criteria focused on peer-reviewed, English-language articles reporting on challenges in healthcare service delivery among immigrant populations in Southeast Asia. Data extraction and synthesis were guided by the 3C model: communication, continuation of care, and confidence in the healthcare system.<br><br>RESULTS: The search identified 656 records, of which 7 studies met the inclusion criteria after a multi-stage screening process. Key challenges identified across the included studies were: Communication barriers, including language differences, cultural misunderstandings, and limited health literacy; Issues with continuation of care, such as poor health literacy, difficulties navigating healthcare systems, barriers to accessing services (e.g., due to legal status or financial constraints), and lack of coordination between healthcare and social services; and Lack of confidence in the healthcare system, stemming from distrust, lack of understanding, and negative experiences, including perceived discrimination.<br><br>CONCLUSION: This review highlights the complex challenges in delivering healthcare services to immigrants from Southeast Asia. These challenges, encompassing communication, continuation of care, and confidence, necessitate targeted and multifaceted interventions. Addressing these issues through culturally competent care, enhanced communication strategies, and policy reforms that promote equitable access is crucial for improving the health and well-being of immigrant populations and fostering more inclusive healthcare systems within the region.},
}
@article {pmid41618047,
year = {2026},
author = {Seet, SM and Tan, YZ and Koh, BMS and Koh, YZ and Aoyama, R and Leow, O and Wang, F and Lin, JB and Ong, HT and Ramasamy, Y and Saini, AG and Ng, NBH and Han, VX},
title = {Comparison of febrile seizures associated with SARS-CoV-2 infection in pre-Omicron and Omicron-predominant periods: a systematic review and meta-analysis.},
journal = {European journal of pediatrics},
volume = {185},
number = {2},
pages = {115},
pmid = {41618047},
issn = {1432-1076},
mesh = {Humans ; *Seizures, Febrile/epidemiology/virology ; *COVID-19/complications/epidemiology ; Incidence ; SARS-CoV-2 ; Child ; Pandemics ; Child, Preschool ; Infant ; },
abstract = {UNLABELLED: Emerging studies suggest increased febrile seizures during the Omicron period of SARS-CoV-2. This study compares the incidence of seizures before and during the Omicron variant period to determine if certain variants increase risk. Using PRISMA-P protocol, four databases (PubMed, Embase, Scopus, Web of Science) were searched. Cohort studies reporting febrile seizures in children (up to 18 years of age) with confirmed SARS-CoV-2 infection were included. We provide descriptive summaries of the incidence of febrile seizures across hospital, emergency, and community settings, as well as a meta-analysis between Omicron-predominant and pre-Omicron periods. We included 36 studies comprising 82,591 children with SARS-CoV-2 infection, of whom 2051 experienced febrile seizures. In 29 studies of hospitalized children with SARS-CoV-2, the incidence of febrile seizures varied widely, with a median of 7 per 100 (range 1.06-25.54) children. High heterogeneity was observed, and studies from emergency and community settings were underpowered. Seven studies found that unvaccinated children hospitalized with SARS-CoV-2 had more febrile seizures during the Omicron-predominant (median 11.8 per 100) than during the pre-Omicron period (median 0.7 per 100). The pooled incidence was 11.27 per 100 cases for the Omicron-predominant and 0.66 per 100 for the pre-Omicron period (p < 0.0001).<br><br>CONCLUSION: There was a trend toward more reported febrile seizures among hospitalized children with SARS-CoV-2 during the Omicron-predominant than the pre-Omicron period. However, estimates are limited by small samples and moderate heterogeneity and should not be considered population-based incidences. We hypothesize that SARS-CoV-2 variants may influence febrile seizure risk in children; larger studies are needed to better understand this association. PROSPERO registration: CRD420251054193.<br><br>WHAT IS KNOWN: &#x2022; Neurological complications, including febrile seizures, occur in children with SARS-CoV-2 infection. &#x2022; Prior to the Omicron variant, febrile seizures were relatively uncommon in pediatric COVID-19 cases.<br><br>WHAT IS NEW: &#x2022; There was a trend toward more reported febrile seizures among hospitalized children with SARS-CoV-2 during the Omicron-predominant period compared to the pre-Omicron period. &#x2022; There are potential associations between SARS-CoV-2 variants and febrile seizure risks.},
}
@article {pmid41618273,
year = {2026},
author = {Zou, H and Huang, S and Mu, Z and Luo, G and An, W},
title = {Comparative efficacy of medications and compound interventions against porcine epidemic diarrhea virus replication in vitro: a systematic review and meta-analysis.},
journal = {BMC veterinary research},
volume = {22},
number = {1},
pages = {},
pmid = {41618273},
issn = {1746-6148},
support = {KQN202503510//scientific research project of chongqing municipal education commission/ ; sxyc202410//"three gorges talent" modern animal husbandry faculty innovation team, chongqing three gorges vocational college/ ; sxzybs-202401//scientific research start-up project for doctoral talent introduction of chongqing three gorges vocational college/ ; },
mesh = {*Porcine epidemic diarrhea virus/drug effects/physiology ; Animals ; *Antiviral Agents/pharmacology/therapeutic use ; *Virus Replication/drug effects ; Swine ; *Coronavirus Infections/drug therapy/veterinary/virology ; *Swine Diseases/drug therapy/virology ; },
abstract = {BACKGROUND: Porcine epidemic diarrhea virus (PEDV) infection induces severe intestinal disease in neonatal piglets, resulting in substantial economic losses to the swine industry. Despite the availability of vaccines, their limited efficacy and the lack of effective antiviral treatments underscore the need for alternative therapeutic approaches. Several studies have reported the antiviral activity of various drugs and compounds against PEDV. To systematically compare the efficacy of these agents, we conducted a systematic review and meta-analysis to evaluate the inhibitory effects of various drugs or compounds on PEDV replication in vitro using cell based- models. METHODS: A comprehensive literature search was conducted in PubMed, Web of Science and ScienceDirect, encompassing publications from the inception of each database to May 30,2025. Eligible studies primarily focused on the effects of pharmacological and combination interventions on PEDV replication in vitro. Changes in the tissue culture infectious dose (TCID50) served as the primary outcome measure, with standardized mean difference (SMD) used to quantify effect sizes. RESULTS: Thirty-two eligible studies involving 41 distinct drugs and 63 effect sizes were analyzed. A random-effects model revealed an overall SMD of -12.30 (95% confidence interval: -13.64 to -10.95) for the antiviral efficacy of drugs at safe concentrations. Moderate heterogeneity was observed (I[2]=64.2%, P < 0.001), with subgroup analyses identifying cell type, viral strain, genotype, drug concentration and intervention duration as significant influencing factors (P < 0.05). Intrinsic antiviral activity emerged as the primary source of heterogeneity. Quality assessment using BRISQ guidelines rated 15 studies as high quality and 17 as medium quality, while modified ROBINS-I classified 26 studies as low risk of bias and 6 as moderate risk. Publication bias was suggested by funnel plots and egger’s test. However, sensitivity analyses confirmed the robustness of the results. CONCLUSION: Forty-one of drugs and compounds demonstrate effective inhibition of PEDV replication in vitro, with antiviral efficacy influenced by experimental variables and predominantly determined by intrinsic antiviral activity. These findings offer valuable guidance for optimizing the design of PEDV antiviral studies and contribute insights for future in vivo efficacy and mechanistic research. SYSTEMATIC REVIEW REGISTRATION: Open science framework (https://doi.org/10.17605/OSF.IO/V4C8Y).},
}
@article {pmid41618506,
year = {2026},
author = {Abbasi, M and Najafizadeh, K and Latifi, M and Ghobadi, O and Sadeghi, MH and Zali, A},
title = {Impact of opt-in versus opt-out organ donation legislation on donation rates: A systematic review.},
journal = {Journal of perioperative practice},
volume = {},
number = {},
pages = {17504589251390742},
doi = {10.1177/17504589251390742},
pmid = {41618506},
issn = {2515-7949},
abstract = {PURPOSE: This systematic review analyses existing studies on organ donation rates from various countries to provide insights that may inform policy decisions and improve organ donation rates globally.<br><br>DESIGN/METHODOLOGY/APPROACH: A systematic search was initially conducted on 3 October 2024 and updated on 20 October 2024 across electronic databases including PubMed, Scopus, Cochrane, and Science Direct. Following an initial pilot screening, all unique references were screened by title and abstract, then full text, by at least two independent reviewers against predefined inclusion criteria. Disagreements between reviewers were resolved by double-checking at each step. Extracted data were compiled and summarised.<br><br>FINDING: Fifteen studies on organ donation policies were identified, with 13 high-quality studies included after rigorous screening. Based on these studies, opt-out consent systems show mixed outcomes across countries. Policy effectiveness varies significantly between nations. The COVID-19 pandemic substantially disrupted organ donation rates. Factors beyond legislation, such as public awareness, cultural attitudes, media campaigns, and health care infrastructure, also influence donation success.Practical impact:While presumed consent may increase deceased donor rates, it is not a universal solution. Effective organ donation strategies require a holistic approach involving public education, trust-building, and nuanced policy implementation tailored to specific national contexts.},
}
@article {pmid41618987,
year = {2026},
author = {Lee, AH and Downs, J and Parlatini, V and Zhang, S and Simonoff, E and Ching, BC},
title = {Ethnic and socioeconomic inequalities in the mental health of children and young people with pre-existing mental health and neurodevelopmental conditions during the COVID-19 pandemic: a systematic review of longitudinal studies.},
journal = {European child &amp; adolescent psychiatry},
volume = {35},
number = {5},
pages = {1589-1603},
pmid = {41618987},
issn = {1435-165X},
mesh = {Adolescent ; Child ; Humans ; *COVID-19 ; *Ethnicity/psychology/statistics &amp; numerical data ; Longitudinal Studies ; Low Socioeconomic Status ; *Mental Disorders/ethnology ; *Mental Health/ethnology ; *Neurodevelopmental Disorders/ethnology/epidemiology ; Socioeconomic Disparities in Health ; },
abstract = {The COVID-19 pandemic may have amplified existing inequalities and disproportionately impacted the mental health of children and young people (CYP) with pre-existing mental health and neurodevelopmental conditions. Evidence suggests the mental health impact on this clinical group was heterogeneous, but the role of ethnicity and socioeconomic position on longitudinal mental health outcomes is unclear. This systematic review investigates the longitudinal association between ethnic and socioeconomic inequalities and the mental health outcomes of CYP with pre-existing conditions during the pandemic. OVID Medline, EMBASE, APA PsycInfo, and Global Health databases were searched between January 2020 and November 2025 (PROSPERO CRD42024611865). Eligible papers included longitudinal studies that assessed mental health outcomes at multiple timepoints before and/or during the pandemic in CYP with pre-existing conditions and examined the effect of ethnicity and socioeconomic position on outcomes. Included studies were narratively synthesised. Ten studies (N = 3,887) were included. We found evidence that CYP from lower income brackets and who experienced financial hardship reported greater levels of internalising, neurodevelopmental, post-traumatic stress, and obsessive-compulsive symptoms. Weak associations were found between ethnicity and internalising symptoms. However, the findings were inconsistent across mental health outcomes, timepoints, and ethnic and socioeconomic position groups. There is some evidence for the association between lower socioeconomic position and increased mental health outcomes in CYP with pre-existing conditions during the pandemic. Further robust longitudinal research is warranted to examine the long-term consequences of the pandemic to better understand how ethnic and socioeconomic inequalities contribute to mental health outcomes.},
}
@article {pmid41619215,
year = {2026},
author = {Nesari, AM and MotieGhader, H and Ghorbian, S},
title = {Advances and challenges in single-cell RNA sequencing data analysis: a comprehensive review.},
journal = {Briefings in bioinformatics},
volume = {27},
number = {1},
pages = {},
pmid = {41619215},
issn = {1477-4054},
mesh = {Humans ; *Single-Cell Analysis/methods ; Single-Cell Gene Expression Analysis ; *Sequence Analysis, RNA/methods ; Computational Biology/methods ; COVID-19/genetics/virology ; },
abstract = {Single-cell RNA sequencing (scRNA-seq) has transformed the resolution of cellular heterogeneity, offering insights into dynamic biological processes from tumor evolution to immune regulation. However, its clinical translation is limited by challenges such as data sparsity, batch effects (differences caused by technical variation rather than biology), and the absence of standardized benchmarks for core pipelines like Seurat and Scanpy. This review outlines emerging computational strategies that address these limitations: (A) robust preprocessing, including SCTransform for zero-inflation(an excess of zero counts in gene-expression data) correction and Harmony for batch integration-achieving 30% faster alignment than BBKNN in cohorts exceeding 100,000 cells; (B) transformer-based annotation tools such as scGPT and CellTypist, which reach >95% accuracy in immune profiling using models pretrained on 33 million cells; and (C) multimodal integration with spatial transcriptomics (e.g., 10x Visium, cell2location v2), which delineate microenvironmental niches and rare CX3CR1+ T-cell subsets in disease contexts like glioblastoma and severe COVID-19. We further assess how scANVI bridges scRNA-seq and ATAC-seq to uncover epigenetic mechanisms underlying therapy resistance, and how spatial methods elucidate tumor-immune crosstalk at subcellular resolution. Despite these advances, ethical risks remain, particularly around re-identification of rare patient-derived clones such as pre-metastatic cells. To promote clinical adoption, we propose a roadmap that prioritizes benchmarked workflows (e.g., scverse ecosystem), privacy-aware data sharing via federated learning, and causal AI approaches to disentangle biological signal from technical artifact. By synthesizing computational innovations with translational case studies, this review equips researchers to navigate both the analytical and ethical complexities of scRNA-seq in pursuit of actionable diagnostics.},
}
@article {pmid41620360,
year = {2026},
author = {López-Padilla, D and Poberezhets, V and Roche, N and Moor, CC and Bruyneel, M and Ribeiro, C and Pinnock, H},
title = {Telemonitoring in Respiratory Diseases: Current Evidence, Clinical Experience, and Future Challenges.},
journal = {Archivos de bronconeumologia},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.arbres.2026.01.001},
pmid = {41620360},
issn = {1579-2129},
abstract = {This narrative review summarizes current evidence and clinical experience regarding telemonitoring across major respiratory diseases and care settings, including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung diseases, obstructive sleep apnea, as well as non-invasive ventilation and pulmonary rehabilitation programmes. Advances in connectivity, artificial intelligence (AI), and wearable devices are facilitating the early detection of clinical deterioration, personalized interventions, and improved self-management, thereby optimizing the use of healthcare resources. Strong evidence supports the benefits of telemonitoring in COPD, particularly in reducing exacerbations and hospital admissions, whereas results are more heterogeneous in asthma and emerging conditions such as interstitial lung diseases. Telemonitoring systems leverage AI-driven analytical frameworks and interoperable digital platforms to process and interpret large volumes of patient data, enabling both automated responses and targeted human interventions. Key challenges include ensuring patient engagement, addressing digital literacy and inequities in access, safeguarding data privacy, and integrating digital solutions into standard care and reimbursement frameworks. The COVID-19 pandemic accelerated the adoption of telemonitoring, confirming its feasibility and acceptability, but also revealed persistent gaps in long-term cost-effectiveness and implementation strategies. Future directions should focus on integrating telemonitoring with AI-supported, coordinated clinical decision-making, enhancing system interoperability, and above all, prioritizing equitable access to digital care. Telemonitoring is poised to become a central component of respiratory patient management, although its large-scale implementation will require overcoming existing technical, ethical, and organizational barriers to fully realize its clinical potential.},
}
@article {pmid41620714,
year = {2026},
author = {Xie, H and Pan, S and Zhang, Z and Fan, J and Zhang, H and Wang, J and Tian, X},
title = {Antifungal prophylaxis among critically ill COVID-19 patients: a meta-analysis and systematic review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {41620714},
issn = {1471-2334},
mesh = {Humans ; *Antifungal Agents/therapeutic use/administration &amp; dosage ; Critical Illness ; *COVID-19/complications/mortality ; Intensive Care Units ; Amphotericin B/therapeutic use/administration &amp; dosage ; *Pulmonary Aspergillosis/prevention &amp; control/mortality ; SARS-CoV-2 ; Triazoles/therapeutic use/administration &amp; dosage ; },
abstract = {BACKGROUND: COVID-19-associated pulmonary aspergillosis (CAPA) affects a significant proportion of patients admitted to the ICU and is associated with increased mortality, underscoring the need for effective prophylaxis. While observational studies suggest a benefit from antifungal prophylaxis, its efficacy remains unconfirmed by randomized trials, and its impact on clinical outcomes is unclear. METHODS: We conducted a systematic review and meta-analysis (PROSPERO: CRD42023462988) of nine ICU-based studies, comparing antifungal prophylaxis (primarily inhaled amphotericin B or systemic posaconazole) with standard care. The primary outcome was CAPA incidence; secondary outcomes included mortality, time to CAPA onset, and ICU length of stay. Risk of bias was assessed using ROBINS-I, with publication bias evaluated via Egger’s test and funnel plot symmetry. Subgroup and sensitivity analyses were performed to assess heterogeneity and robustness. RESULTS: Among 1,321 patients included, antifungal prophylaxis significantly reduced CAPA incidence (RR 0.21, 95% CI 0.14–0.33; p < 0.001) and CAPA risk (OR 0.22, 95% CI 0.12–0.40; p < 0.001). Inhaled amphotericin B demonstrated consistent benefit (RR 0.18, 95% CI 0.06–0.52; p = 0.001), whereas systemic posaconazole showed variable results. No significant effects were observed on mortality (RR 1.05; p = 0.69), time to CAPA onset (MD −0.33 days; p = 0.73), or ICU stay duration (MD 1.59 days; p = 0.34). Efficacy was most evident in retrospective cohorts and among patients receiving invasive mechanical ventilation. Sensitivity analyses excluding high-bias studies confirmed the findings. CONCLUSION: This meta-analysis suggests a potential role for antifungal prophylaxis, especially topical amphotericin B, in reducing the risk of CAPA among critically ill COVID-19 patients, albeit survival or ICU stay was unaffected. The favorable profile of topical amphotericin B necessitates direct comparison with systemic azoles in future trials. Prospective, randomized studies are imperative to validate these findings for universal application, refine prophylactic regimens for broader populations, and assess long-term clinical and economic impacts.},
}
@article {pmid41621349,
year = {2026},
author = {De Los Reyes, A and Talbott, E and Yusuf, A and Dryburgh, NSJ and Goodman, KL},
title = {Lack of improvements in youth psychotherapies or lack of investments in detecting improvements? Future directions in psychological assessment.},
journal = {Clinical psychology review},
volume = {124},
number = {},
pages = {102705},
doi = {10.1016/j.cpr.2026.102705},
pmid = {41621349},
issn = {1873-7811},
mesh = {Humans ; *Psychotherapy/standards/methods ; *Mental Disorders/therapy/diagnosis ; *COVID-19 ; Adolescent ; *Mental Health Services/standards ; },
abstract = {Youth were experiencing mental health crises before the onset of the COVID-19 pandemic. Following this onset, their needs for mental health services have only increased. Yet, researchers encounter barriers to confronting these crises. The effects of therapies tested in controlled trials in the present day appear to be no more potent than those of their predecessors tested in trials conducted decades ago. Across these decades of scholarly work, researchers have invested far more of their efforts toward improving technologies for therapies than they have toward improving technologies for the assessment tools used to estimate therapeutic effects. The tools used today look a lot like those used in the 1970s-mainly surveys and interviews-and our strategies for integrating the data these tools produce focus on the sliver of their data that converge or yield the same results about youth mental health. Decades of work reveal that these integration strategies are incompatible with the data conditions that typify youth mental health assessments. We must invest in innovative assessment tools and integration strategies that capitalize on all the valid data produced by these conditions. This paper details pioneering directions in future research about psychological assessment. We describe the conceptual foundations underlying these research directions and highlight recent work by the authors and others supporting this pursuit. If we empower the assessment researchers of today to develop technologically innovative assessment tools and integration strategies, then we equip the therapy researchers of tomorrow to demonstrate that investing in therapy technologies pays off.},
}
@article {pmid41621370,
year = {2026},
author = {Mogensen, TH},
title = {Inborn errors of autophagy underlying severe viral infections in humans.},
journal = {Current opinion in virology},
volume = {75},
number = {},
pages = {101510},
doi = {10.1016/j.coviro.2026.101510},
pmid = {41621370},
issn = {1879-6265},
mesh = {Humans ; *Autophagy/genetics/immunology ; *Virus Diseases/immunology/genetics ; COVID-19/immunology/genetics ; SARS-CoV-2/immunology ; },
abstract = {Inborn errors of immunity can underlie susceptibility to severe viral infection in humans. and the majority relate to defective induction of or response to antiviral type I interferon (IFN). However there is increasing awareness of defects in other cellular processes, that can predispose to severe infectious disease. Recently, defects in autophagy-related genes or -processes have been demonstrated to predispose to life-threatening viral diseases, including defects in autophagy-related genes in patients with herpes simplex virus and varicella zoster virus infections in the central nervous system, as well as impairment of noncanonical antiviral immunity in critical COVID-19. However, the molecular mechanisms and complex intersections between autophagy, metabolism, cell death, and inflammation, and how defects in autophagy-related proteins may interfere with these cellular processes, are only now starting to emerge. This review presents the current knowledge on inborn errors of autophagy discovered in patients with severe viral infection and discusses some of the remaining knowledge gaps in our understanding of how autophagy processes act against viruses, how immunopathology and lack of viral control ensues when they fail, and how these insights may be translated into clinical medicine.},
}
@article {pmid41621401,
year = {2026},
author = {Ramatsokotla, S and Soul, B and Duah, E and Sekwele, L and Thompson, G and Maluleke, K and Mbonambi, L and Mashamba-Thompson, T},
title = {Evidence of point-of-care diagnostics in forensic death investigations: A scoping review.},
journal = {Journal of forensic and legal medicine},
volume = {118},
number = {},
pages = {103086},
doi = {10.1016/j.jflm.2026.103086},
pmid = {41621401},
issn = {1878-7487},
mesh = {Humans ; *Point-of-Care Systems ; *Forensic Medicine ; *Point-of-Care Testing ; Triage ; Rapid Diagnostic Tests ; *Forensic Sciences ; Cause of Death ; },
abstract = {BACKGROUND: Point-of-care (POC) diagnostics represent promising health-technology tools capable of providing rapid, on-site analytical support for forensic investigations. This scoping review aimed to systematically map the available evidence on applying POC diagnostics in forensic investigations. The focus is on their potential ability to act as rapid screening and triage tools to assist in determining the cause of death and exploring the challenges and opportunities associated with their implementation on a global scale.<br><br>METHODS: A comprehensive literature search was conducted across multiple databases, including PubMed, ProQuest Central, Academic Search Complete, Africa Wide, CINAHL, MEDLINE, and Web of Science. Out of the 7603 records screened, four studies met the eligibility criteria and were included in the review. Reporting adhered to the PRISMA-ScR guidelines.<br><br>RESULTS: These studies demonstrated the expanding role of POC devices in various aspects of forensic investigations, including rapid triage in overdose cases, malaria diagnosis in travel-related deaths, SARS-CoV-2 screening, and hemoglobin testing in child deaths. These studies also highlighted the limitations of POC devices in the postmortem context, emphasizing the need for careful calibration, confirmation, and interpretation of the results. This review identified POC diagnostics as a potential bridge between forensic investigations and public health surveillance, with findings indicating both cause-of-death determination and broader public health strategies. Operational, ethical, and policy considerations for using POC devices in forensic investigations were also discussed.<br><br>CONCLUSION: This review revealed challenges in ensuring the standardization, accuracy, and integration of POC diagnostics into established forensic practices. Further research is required to evaluate the diagnostic accuracy, cost-effectiveness, and performance of POC tools in forensic settings. Comprehensive guidelines and standardized operating procedures should be developed to ensure the successful implementation of POC diagnostics in forensic investigations. Given the limited and heterogeneous evidence, POC devices in forensic death investigations should be seen as preliminary aids rather than diagnostic instruments.},
}
@article {pmid41621452,
year = {2026},
author = {Waclawovsky, AJ and de Oliveira, J and de Carvalho, CP and Adornes, ME and Dos Santos, E and Wolf, S and Cristi-Montero, C and Teychenne, M and Stubbs, B and Deslandes, AC and Schuch, FB},
title = {Higher physical activity is associated with reduced odds of depressive symptoms among university students: A meta-analysis of over 66,000 participants.},
journal = {Journal of affective disorders},
volume = {401},
number = {},
pages = {121319},
doi = {10.1016/j.jad.2026.121319},
pmid = {41621452},
issn = {1573-2517},
mesh = {Humans ; *Students/psychology/statistics &amp; numerical data ; *Exercise/psychology ; Universities ; *Depression/epidemiology/psychology ; Female ; Young Adult ; COVID-19/psychology ; Male ; },
abstract = {Depression is highly prevalent among university students, who also exhibit low levels of physical activity. Although physical activity is associated with a lower likelihood of depressive symptoms, the magnitude of its effect in this population has not been systematically assessed. This study reviewed and performed a meta-analysis of the association between physical activity and depressive symptoms in university students. The Embase, PubMed, Web of Science, PsycINFO, and SPORTDiscus databases were searched from inception to January 24, 2025, for relevant studies. Random-effects meta-analyses were used to calculate adjusted (aOR) and unadjusted (OR) odds ratios for depressive symptoms based on physical activity levels. The protocol was registered in PROSPERO (CRD42024591429). Twenty-two studies, involving 66,683 students (median age: 21 years, 56.5% female), were included. Students with higher levels of physical activity had lower odds of depressive symptoms compared to those with lower levels (adjusted OR = 0.614, 95% CI: 0.540-0.698, I[2] = 47.5%). Subgroup analyses revealed no differences between studies conducted during or outside the COVID-19 pandemic. Among students in health sciences programs, higher physical activity was associated with a 34% lower likelihood of depressive symptoms (adjusted OR = 0.66, 95% CI: 0.49-0.88, I[2] = 33.2%). These findings indicate that increased physical activity is associated with a lower likelihood of depressive symptoms in university students, supporting its promotion as a mental health intervention.},
}
@article {pmid41621991,
year = {2026},
author = {Milner, KA and Marmo, S},
title = {Open Visitation: Enabling Family Presence, Centered Care, and Engagement in Intensive Care Unit.},
journal = {Critical care nursing clinics of North America},
volume = {38},
number = {1},
pages = {151-164},
doi = {10.1016/j.cnc.2025.10.007},
pmid = {41621991},
issn = {1558-3481},
mesh = {Humans ; *Intensive Care Units/organization &amp; administration ; COVID-19 ; *Visitors to Patients/psychology ; *Family/psychology ; *Patient-Centered Care ; Pandemics ; *Professional-Family Relations ; },
abstract = {Family-centered care (FCC) emphasizes collaboration, dignity, respect, and shared decision-making between families and health care teams. In the ICU, FCC relies on family presence at the bedside, facilitated by open visitation policies. However, the COVID-19 pandemic disrupted this model, as restrictive visitation policies eliminated family presence, leading to adverse outcomes such as loneliness and delirium in patients, distress and grief among families, and moral injury and burnout in staff. As health systems recover, there is a need to reestablish FCC by prioritizing open visitation while balancing infection control and operational demands.},
}
@article {pmid41622196,
year = {2026},
author = {Sun, S and Zhang, Y and Ma, J and Chen, L and Wang, Y},
title = {Clinical characteristics and treatment outcomes in thymoma- related aplastic anemia: a case report and literature review.},
journal = {Journal of cardiothoracic surgery},
volume = {21},
number = {1},
pages = {},
pmid = {41622196},
issn = {1749-8090},
mesh = {Humans ; Female ; *Thymoma/complications/surgery/diagnosis ; *Anemia, Aplastic/etiology/therapy/diagnosis ; Middle Aged ; *Thymus Neoplasms/complications/surgery ; *Thymectomy/adverse effects ; Treatment Outcome ; Fatal Outcome ; Hematopoietic Stem Cell Transplantation ; },
abstract = {Thymoma-related aplastic anemia is a rare entity. This article retrospectively analyzes the clinical features and treatment course of a patient who developed aplastic anemia (AA) post-thymectomy, complemented by a systematic review of relevant literature. A 47-year-old female was diagnosed with thymoma, myasthenia gravis (MG), and severe AA (SAA). SAA onset occurred two weeks after total thymectomy, and the patient ultimately succumbed to concurrent COVID-19 infection following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We also reviewed the clinical characteristics, treatment strategies, and prognosis of 47 thymoma-related aplastic anemia patients reported in the literature. AA may present prior to thymoma diagnosis, concurrently with thymoma, or post-thymectomy. Some patients progress to pure red cell aplasia (PRCA) and/or megakaryocytic aplasia, often following prior chemotherapy or radiotherapy. Similar to Good syndrome and PRCA, thymectomy fails to alleviate AA, and spontaneous improvement is rare. Treatment options for thymoma-related aplastic anemia include cyclosporine A (CsA) monotherapy, CsA combined with glucocorticoids, thrombopoietin receptor agonists (TPO-RAs), and allo-HSCT. However, regimens of cyclophosphamide plus methylprednisolone and glucocorticoid monotherapy show limited efficacy. The overall one-year mortality rate is alarmingly high at 29.8%. For young thymoma-related aplastic anemia patients with SAA and suitable donors, allo-HSCT remains the preferred treatment.},
}
@article {pmid41622815,
year = {2026},
author = {Hussain, I and Rasul, A and Hassan, M and Rawat, R and Tutar, Y},
title = {Lariciresinol: a potent natural compound with diverse therapeutic and health benefits.},
journal = {Natural product research},
volume = {},
number = {},
pages = {1-16},
doi = {10.1080/14786419.2025.2611424},
pmid = {41622815},
issn = {1478-6427},
abstract = {Scientific research has identified lariciresinol among lignan types, which shows potential against cancer development and bacterial infections in addition to serving as an antioxidant that affects oestrogen activity while blocking inflammation. The review analyses the detailed medical and biological properties of lariciresinol. The two Brassicaceae plant genera Isatis indigotica and Brassica oleracea contain this substance, which exists in various plant types. The compound demonstrated anticancer properties through its mechanisms of stopping cancer cell multiplication and triggering programmed cell death. Recent research found that lariciresinol can block the function of the virus that causes COVID-19 by reducing its ability to enter the cells and proliferate. Lariciresinol antiviral actions have been shown to reduce RNA and viral protein production. The diverse impacts indicate that lariciresinol is a potential compound for novel health solutions and future therapeutic innovations.},
}
@article {pmid41622853,
year = {2026},
author = {Ferrari, F and Goulart, CDL and Franzoni, LT and Cipriano, G and Stein, R},
title = {Effects of different exercise training modalities in post-COVID-19 individuals: a systematic review of randomized controlled trials.},
journal = {Disability and rehabilitation},
volume = {},
number = {},
pages = {1-15},
doi = {10.1080/09638288.2026.2619815},
pmid = {41622853},
issn = {1464-5165},
abstract = {PURPOSE: Although the COVID-19 pandemic has ended, long-term effects persist. Exercise training (ET) supports recovery, but evidence on optimal modalities is limited. This study evaluated the effects of different ET modalities in post-COVID-19 individuals.<br><br>METHODS: A systematic search identified randomized controlled trials (RCTs) up to 23 September 2025, involving adults with COVID-19. Studies compared &#x2265;4-week interventions-aerobic training, high-intensity interval training (HIIT), or combined training (aerobic plus resistance training)-with usual care (UC). Risk of bias and certainty of evidence were assessed using RoB 2.0 and GRADE.<br><br>RESULTS: Eighteen RCTs (N&#xa0;=&#xa0;1171) were included. Interventions varied in intensity and duration. Most studies had "some concerns" regarding bias, and overall certainty of evidence was low to very low. Overall, ET modalities were associated with improvements in functional capacity (VO2peak or six-minute walk distance) and muscle strength, although not all studies showed significant differences vs. UC. HIIT demonstrated the greatest VO2peak gain (mean difference: 6.17&#x2009;ml.kg[-1].min[-1]). Effects on quality of life, anxiety, and depression were inconsistent. Most cardiopulmonary parameters (VE/VCO2 slope, OUES) showed no significant changes, with mixed results for O2 pulse and ventilation.<br><br>CONCLUSIONS: Despite heterogeneous protocols and low certainty of evidence, structured ET appears beneficial for post-COVID-19 recovery. Multiple ET approaches may be effective rather than a single "optimal" approach.},
}
@article {pmid41623340,
year = {2025},
author = {Sumo, R and Jong, S},
title = {Use of Blockchain Technology to Accelerate Digital Health Transformation Programs.},
journal = {Blockchain in healthcare today},
volume = {8},
number = {2},
pages = {},
pmid = {41623340},
issn = {2573-8240},
abstract = {Disruptive digital health technologies are reshaping how patients interact with health professionals, how data are shared among providers, and how treatment plans and health outcomes are determined. While the COVID-19 pandemic has accelerated the adoption of digital technologies, challenges remain in realizing the potential of digital transformation programs in healthcare. Specifically, health data need to remain secure, usable, and shareable across multiple stakeholder groups in a world where silos between organizations and information systems persist. The implementation of innovative and disruptive digital technologies such as blockchain can offer a solution to these challenges. This article explores how blockchain technology can be used to accelerate digital health transformation programs. It provides an overview of the technology applications (i.e. data management, Internet of Medical Things [IoMT], supply chain management, and health insurance) and key players based on a literature review and secondary data. It also identifies challenges and success factors in implementing blockchain in healthcare. At the organizational level, we discuss the careful planning and specialized expertise required to overcome the technical, regulatory, and adoption-related hurdles associated with implementing blockchain technology. At the system level, the authors discuss the regulatory constraints, standardization and interoperability issues, and stakeholder engagement challenges linked to implementing blockchain technology.},
}
@article {pmid41623576,
year = {2026},
author = {Birla, S and Angural, A and Madathumchalil, A and Shende, RV and Shastry, SV and Shekar, PK and Mahadevappa, M and Vishwanath, P and Prashant, A},
title = {"Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era".},
journal = {International journal of cardiology. Cardiovascular risk and prevention},
volume = {28},
number = {},
pages = {200576},
pmid = {41623576},
issn = {2772-4875},
abstract = {Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.},
}
@article {pmid41623712,
year = {2026},
author = {Shang, S and Wang, X and Zhang, E and Zhang, Y and Li, Y and Fang, Q},
title = {Digital interventions to promote vaccine uptake among older adults: A systematic review and network meta-analysis.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076261416313},
pmid = {41623712},
issn = {2055-2076},
abstract = {OBJECTIVE: To systematically evaluate the effect of digital intervention on improving routine vaccination in the elderly and to conduct a comparative analysis of different intervention modalities using network meta-analysis (NMA).<br><br>METHODS: PubMed, Web of Science, The Cochrane Library, Embase, Scopus, CINAHL, and WanFang Data were searched for randomized controlled trials (RCTs) using digital interventions to promote vaccination in older populations from inception to 15 June 2024. We performed a final update of the literature search in May 2025; no additional eligible studies were identified. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the included studies, and an NMA was performed using RevMan 5.4 and R Studio, PROSPERO Registration Number: CRD42024527483.<br><br>RESULTS: Eleven RCTs were included. The traditional meta-analysis demonstrated a small but statistically significant increase in influenza vaccination rates (RR&#x2009;=&#x2009;1.01, 95% CI [1.01, 1.01], P&#x2009;<&#x2009;0.00001), accompanied by substantial heterogeneity (I [2]&#x2009;=&#x2009;86%). Pneumococcal vaccine uptake was significantly enhanced (RR&#x2009;=&#x2009;1.11, 95% CI [1.03, 1.18], P&#x2009;<&#x2009;0.01), with moderate heterogeneity (I [2]&#x2009;=&#x2009;46%). The single study on the herpes zoster vaccine reported a statistically significant effect, whereas COVID-19 vaccine reminder interventions showed no significant efficacy. In the NMA, video-based interventions ranked first based on the surface under the cumulative ranking curve, but all pairwise comparisons between different intervention modes crossed the null value.<br><br>CONCLUSION: Digital interventions show a significant, yet highly heterogeneous, positive impact on vaccination rates in older adults. While video-based education showed the highest ranking probability, the current evidence is insufficient to conclude that any specific digital modality is statistically superior to others. Due to the limited included studies, the findings need to be supplemented by more high-quality studies. Future research should focus on newer digital technologies to help the older population keep up with the "digital intelligence era."},
}
@article {pmid41623887,
year = {2025},
author = {Bradway, M and Wang, B and Nybakke, HL and Ingebrigtsen, SA and Dyb, K and Rødseth, E},
title = {Rethinking the digital divide in health: a critical interpretive synthesis of research literature.},
journal = {Frontiers in digital health},
volume = {7},
number = {},
pages = {1683565},
pmid = {41623887},
issn = {2673-253X},
abstract = {BACKGROUND: The digital divide in health has rapidly expanded during and after the COVID-19 pandemic, with fragmented understanding and an unclear implementation process, for the formal integration of digital health into the healthcare system, which challenges actionable policy development.<br><br>METHODS: This critical interpretive synthesis (CIS) of the literature aimed to capture the complexity of the digital divide in health. This began with a scoping review of literature published between 2013 and 2023 describing the digital divide in health within the WHO's European Region, in Web of Science, Medline (via Ovid), PsycInfo (via Ovid), and Sociological Abstract (via ProQuest). Three sets of two reviewers independently conducted the selection, and all contributed to the synthesis process.<br><br>RESULTS: Of 4,967 original articles identified, 49 articles were included for review. Results revealed a synthesizing argument that the digital divide should be considered as more of a dynamic, entangled, and reciprocal collection of "areas" of phenomenon affecting service users, rather than "levels". Results describe the three synthetic constructs that describe this synthesizing argument.<br><br>CONCLUSION: Findings suggest that digital health solutions should respectfully consider the pace of human healing, long-term user engagement and adaptability. We call for the importance of inter- and multidisciplinary collaboration to ensure effective and context-sensitive implementation in future studies.},
}
@article {pmid41624230,
year = {2026},
author = {Kokubun, K},
title = {Workplace Safety Management Practices, Fear, Resources, and Employee Involvement During the COVID-19 Pandemic: A Narrative Review.},
journal = {AJPM focus},
volume = {5},
number = {2},
pages = {100456},
pmid = {41624230},
issn = {2773-0654},
abstract = {INTRODUCTION: There are important workplace health lessons to be learned from the pandemic.<br><br>METHODS: This study summarizes the relationships between workplace safety practices, fear, resources, and employee engagement during the COVID-19 pandemic through a narrative review on articles published between January 2020 and June 2025 using a primary literature search base.<br><br>RESULTS: Organizations have had to implement workplace safety management practices aligned with their occupational safety and health management systems in response to COVID-19. Safety management practices include safety initiatives and training as well as employee involvement. Methods to increase employee involvement include fear and anxiety. However, although fear and anxiety promote safety compliance and safe behavior, they also wear down employees and increase their work distraction and turnover intentions. Therefore, social and psychological resources need to be strengthened to overcome this dilemma. These resources can also help safety management practices today as the pandemic begins to wind down.<br><br>CONCLUSIONS: Future research should focus on identifying ways to strengthen employees' social and psychological resources without relying on disasters. To this end, an integration of conservation of resource theory and behavioral theory may be useful.},
}
@article {pmid41624517,
year = {2026},
author = {Navid Talemi, M and Ramezani Farani, M and Alipour Eskandani, N and Mirzaee, D and Alipourfard, I and Huh, YS},
title = {Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation.},
journal = {Materials today. Bio},
volume = {37},
number = {},
pages = {102774},
pmid = {41624517},
issn = {2590-0064},
abstract = {RNA therapeutics have come of age as clinically validated modalities including mRNA, siRNA, antisense oligonucleotides (ASOs), and in vivo genome editing, with lipid nanoparticles (LNPs) as the main non-viral delivery system. This review defines programmable LNPs as systems whose composition and interfacial chemistry are tuned to control organ tropism, cell specificity, intracellular trafficking, and immune interactions. We summarize design rules across four core components (ionizable lipid, phospholipid, cholesterol, PEG-lipid) and highlight levers like apparent pKa optimization (∼6-7 for hepatic delivery), biodegradable linkers, PEG-anchor-dependent shedding, ligands (e.g., GalNAc), and selective organ-targeting (SORT) lipids that redirect biodistribution beyond the liver. We survey advances in data-guided formulation, including DNA-barcoded in vivo libraries, machine learning, and physics-based prediction, plus scalable manufacturing (microfluidics, confined impinging-jet mixing, tangential-flow filtration) and Quality-by-Design with process-analytical technologies. A comprehensive characterization toolkit (size/ζ-potential, cryo-EM/SAXS, RNA encapsulation and integrity, apparent pKa, in vivo barcoding) maps to critical quality attributes. Applications span vaccines, protein replacement, siRNA/ASO delivery, and CRISPR platforms, with clinical examples like patisiran, COVID-19 and RSV mRNA vaccines, in-human transthyretin (TTR) editing, and individualized melanoma vaccination. We analyze translational constraints like endosomal escape, reactogenicity and anti-PEG immunity, complement activation, and lot-to-lot control, plus success factors: corona-aware design, dose-efficient potency at low lipid burden, redosing strategies, and fit-for-purpose biomarkers. Together, programmable LNPs offer a generalizable path to extrahepatic, cell-aware RNA medicine when coupled to rigorous analytics and platform manufacturing.},
}
@article {pmid41625501,
year = {2024},
author = {Avcı, E and Muharremoğlu, ZD and Bozkurt, ENN and Kaygusuz, S},
title = {Changing Epidemiology of Tuberculosis and Actions Taken in the World and Türkiye.},
journal = {Journal of clinical practice and research},
volume = {46},
number = {5},
pages = {421-430},
pmid = {41625501},
issn = {2980-2156},
abstract = {Tuberculosis (TB) is an airborne, contagious illness caused by Mycobacterium tuberculosis, which can affect all tissues and organs, primarily the lungs. Tuberculosis remains a significant public health problem worldwide, with 10 million people contracting the disease and 1.5 million deaths annually. It is the second most common cause of death from communicable diseases globally, following Coronavirus Disease 2019 (COVID-19). To combat tuberculosis globally, the Global Tuberculosis Program is carried out by the World Health Organization (WHO). The WHO began the Directly Observed Treatment Strategy in 1995, the Stop Tuberculosis Strategy in 2006, and the End Tuberculosis Strategy in 2015. The End Tuberculosis Strategy aims to end the global tuberculosis epidemic by 2035. Due to the COVID-19 pandemic, global tuberculosis goals were missed or off-target. The fight against TB requires continuity. The National Tuberculosis Control Program, which includes the End Tuberculosis Strategy, has been implemented successfully for many years in alignment with global targets in Türkiye. In this article, the changing epidemiology of TB in the world and Türkiye is evaluated, and control activities carried out within the scope of combating TB are included.},
}
@article {pmid41625593,
year = {2026},
author = {Bai, Y and Ma, Y and Li, X},
title = {The research progress of ferroptosis in acute lung injury.},
journal = {Biochemistry and biophysics reports},
volume = {45},
number = {},
pages = {102434},
pmid = {41625593},
issn = {2405-5808},
abstract = {Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly recognized as a pivotal mechanism in the pathogenesis of acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS). Its core molecular machinery, including glutathione peroxidase 4 (GPX4), acyl-CoA synthetase long-chain family member 4 (ACSL4), and the cystine/glutamate antiporter system Xc-, becomes dysregulated across various ALI subtypes, such as sepsis, ischemia-reperfusion, and COVID-19.This review delineates how ferroptosis contributes to ALI through iron overload, uncontrolled lipid peroxidation, and failure of antioxidant defenses, ultimately leading to pulmonary endothelial and epithelial cell death. We further summarize subtype-specific mechanisms and evaluate emerging therapeutic strategies, including ferroptosis inhibitors (e.g., liproxstatin-1), Nrf2 activators, and iron chelators, highlighting their potential for targeted intervention in ALI/ARDS.},
}
@article {pmid41626197,
year = {2026},
author = {Chikuse, D and Badacho, AS and Uwimana-Nicol, J and Hendricks, L and Nyasulu, JCY},
title = {The Landscape on Access to Maternal and Child Health Services During the COVID-19 Pandemic in South Africa: A Scoping Review.},
journal = {Interdisciplinary perspectives on infectious diseases},
volume = {2026},
number = {},
pages = {9065224},
pmid = {41626197},
issn = {1687-708X},
abstract = {BACKGROUND: In early March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. In South Africa, the first case was confirmed in early March 2020. According to the WHO, disruptions in essential services due to the COVID-19 pandemic occurred worldwide. The COVID-19 pandemic affected access to maternal and child health (MCH) services in many countries, including South Africa. The study aimed to map and describe the existing evidence on the impact of the COVID-19 pandemic on the access to and delivery of maternal, neonatal, and child health (MNCH) services in South Africa.<br><br>METHODOLOGY: This was a scoping review of studies published between 2020 and 2023. We searched databases such as PubMed, MEDLINE, EBSCOhost, and Google Scholar. Data were exported to the Rayyan software, where screening, checking of duplicates, and selection of final studies for review were performed. The information from the identified studies was exported to ATLAS.ti 23.1 software for analysis. Content analysis was performed, and data were presented in predetermined themes using the MCH cascade.<br><br>RESULTS: The results from 25 articles showed a mixed view, whereby some studies showed a decrease at the beginning of the pandemic in April 2020, in the uptake of family planning, antenatal care, labor and delivery, postnatal care, under-five immunizations, and cervical cancer screening services. However, other studies found increased uptake of family planning, antenatal care, labor and delivery, and under-five immunization services. Some studies showed resilience in the overall first antenatal visits, adolescents' visits to family planning, and postnatal care, as they remained constant.<br><br>CONCLUSION: The findings show both positive and negative impacts of the COVID-19 pandemic on MNCH services in South Africa. While the pandemic significantly disrupted access to essential services, some areas demonstrated resilience, with increased visits for antenatal care, adolescent family planning, and postnatal services. These insights are critical for guiding decision-makers, health managers, and frontline healthcare workers in preparing for future public health emergencies. Ensuring continuity of MNCH services during crises must be a priority. Strengthening the health system and building resilience are essential to safeguard MCH, even in the face of disruptions.},
}
@article {pmid41626364,
year = {2025},
author = {de Jong, M and de Korne-Elenbaas, J and Fanoy, E and Medema, G and de Graaf, M and Prins, M and van der Loeff, MFS and Daams, J and Husman, AMR and Heijne, JCM},
title = {Public health actions in response to pathogen detection in wastewater and the environment: a scoping review.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1675742},
pmid = {41626364},
issn = {2296-2565},
support = {U24 AI183840/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; COVID-19/prevention &amp; control ; *Environmental Monitoring/methods ; *Public Health ; SARS-CoV-2 ; *Wastewater/microbiology/virology ; },
abstract = {INTRODUCTION: Rapid detection of infectious disease agents is crucial for timely public health responses. Wastewater and environmental surveillance (WES) offers a complementary approach by detecting pathogens shed by infected individuals, including asymptomatic cases. This scoping review provides an overview of reported public health actions in response to WES for human pathogens. It also summarizes sampling and analysis methods and offers insights for future implementation.<br><br>METHODS: The protocol for this review was registered in the PROCEED open-access registry. A systematic search was conducted in MEDLINE, EMBASE, and Web of Science for peer-reviewed literature published up to 31 July 2024. Studies were included if they reported public health actions in response to WES related to infectious diseases in human populations. Two reviewers independently screened studies and extracted data on public health responses, sampling, and analytical methods.<br><br>RESULTS: Of the 6,630 articles screened, 49 met the inclusion criteria. Most studies (92%) were published between 2021 and 2024, with SARS-CoV-2 as the primary focus (82%), followed by poliovirus (16%). Research was largely conducted in high-income regions: North America (51%), Asia (22%), and Europe (14%). Target populations included urban residents (57%) and on-campus students (31%) and local authorities were more often involved in WES efforts than national agencies (51% vs. 33%). In 75% of studies, at least two public health actions were implemented, and 20% reported five or more. The most common actions related to reactive disease control (n = 69), including testing, isolation, and contact tracing. Proactive disease control actions (n = 33) and public health communication (n = 22) were also described. Weekly sampling (57%) and composite methods (67%) were most used. Manhole sampling, despite equal frequency with treatment plant sampling (35%), led to significantly more public health actions (61 vs. 35). Long-term surveillance was often reported but rarely sustained. Quantitative and molecular analyses dominated; sequencing was rarely used (4%).<br><br>CONCLUSION: While reporting on public health actions following WES remains limited, this review illustrates its potential to inform timely, local interventions. Future studies should broaden pathogen targets, embed public health action planning in study design, and expand WES use in low-resource settings.},
}
@article {pmid41626890,
year = {2026},
author = {Maxwell, L and Shreedhar, P and Merson, L and Levis, B and Debray, TPA and de Jong, VMT and Ximenes, RAA and Jaenisch, T and Gustafson, P and Carabali, M},
title = {How to conduct an individual participant data meta-analysis in response to an emerging pathogen: Lessons learned from Zika and COVID-19.},
journal = {Research synthesis methods},
volume = {17},
number = {1},
pages = {1-29},
pmid = {41626890},
issn = {1759-2887},
support = {01886-000//Institute of Genetics/ ; 825746//H2020 Health/ ; },
mesh = {Humans ; *Meta-Analysis as Topic ; *COVID-19/epidemiology ; *Zika Virus Infection/epidemiology ; SARS-CoV-2 ; Data Interpretation, Statistical ; *Communicable Diseases, Emerging/epidemiology ; Zika Virus ; Research Design ; },
abstract = {Sharing, harmonizing, and analyzing participant-level data is of central importance in the rapid research response to emerging pathogens. Individual participant data meta-analyses (IPD-MAs), which synthesize participant-level data from related primary studies, have several advantages over pooling study-level effect estimates in a traditional meta-analysis. IPD-MAs enable researchers to more effectively separate spurious heterogeneity related to differences in measurement from clinically relevant heterogeneity from differences in underlying risk or distribution of factors that modify disease progression. This tutorial describes the steps needed to conduct an IPD-MA of an emerging pathogen and how IPD-MAs of emerging pathogens differ from those of well-studied exposures and outcomes. We discuss key statistical issues, including participant- and study-level missingness and complex measurement error, and present recommendations. We review how IPD-MAs conducted during the COVID-19 response addressed these statistical challenges when harmonizing and analyzing participant-level data related to an emerging pathogen. The guidance presented here is based on lessons learned in our conduct of IPD-MAs in the research response to emerging pathogens, including Zika virus and COVID-19.},
}
@article {pmid41627487,
year = {2026},
author = {Malik, J and Singh, S and Shrivastav, D and Verma, VV and Pal, RK and Mishra, MK and Sharma, VK},
title = {Therapeutic milestones against multidrug resistant Acinetobacter baumannii: from legacy antibiotics to Zosurabalpin.},
journal = {Archives of microbiology},
volume = {208},
number = {4},
pages = {177},
pmid = {41627487},
issn = {1432-072X},
mesh = {*Acinetobacter baumannii/drug effects/genetics ; *Drug Resistance, Multiple, Bacterial ; *Anti-Bacterial Agents/therapeutic use/pharmacology ; Humans ; *Acinetobacter Infections/drug therapy/microbiology ; Carbapenems/pharmacology/therapeutic use ; Biofilms/drug effects ; },
abstract = {Antimicrobial resistance (AMR) in Acinetobacter baumannii represents a critical global health challenge, particularly in intensive care settings where the pathogen causes severe, refractory infections. As a leading member of the ESKAPE group, A. baumannii has accumulated extensive resistance to multiple antibiotic classes, including carbapenems, resulting in the widespread emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) strains. This review provides a chronological overview of the evolution of antimicrobial therapies used against A. baumannii, spanning the early era of penicillins and tetracyclines to contemporary agents such as eravacycline and ceftazidime-avibactam. We delineate the molecular mechanisms underlying resistance development, including carbapenemase production, robust RND efflux systems, horizontal gene transfer, biofilm formation, and the global dissemination of high-risk international clones (IC1-IC9). The compounding impact of the COVID-19 pandemic on the spread of carbapenem-resistant A. baumannii (CRAB) is also examined. A special emphasis is placed on Zosurabalpin, a first-in-class macrocyclic peptide antibiotic with a unique mechanism of action that targets the LptB2FG complex essential for lipooligosaccharide (LOS) transport and outer membrane assembly. Preclinical data and emerging clinical findings highlight its potent activity against highly resistant CRAB strains and its ability to circumvent conventional resistance pathways, marking it as a promising candidate in the antimicrobial pipeline. Finally, we evaluate the limitations of current treatment modalities and explore emerging strategies, including phage therapy, novel target discovery, and non-traditional therapeutics, offering a forward-looking perspective on restoring and sustaining effective anti-Acinetobacter interventions.},
}
@article {pmid41627575,
year = {2026},
author = {Abu-Raddad, LJ and Chemaitelly, H and Wald, A and Johnston, C},
title = {Herpes Simplex Virus Type 2 Screening in Persons with and Without HIV: Evidence, Challenges, and Future Directions.},
journal = {Current HIV/AIDS reports},
volume = {23},
number = {1},
pages = {3},
pmid = {41627575},
issn = {1548-3576},
mesh = {Humans ; *Herpesvirus 2, Human/isolation &amp; purification/immunology ; *Herpes Genitalis/diagnosis/epidemiology ; *HIV Infections/complications/prevention &amp; control ; *Mass Screening/methods ; Female ; Pregnancy ; },
abstract = {PURPOSE OF REVIEW: Herpes simplex virus type 2 (HSV-2) infection is one of the most prevalent sexually transmitted infections worldwide, with implications for HIV acquisition, transmission, and disease progression. This review synthesizes current evidence and guidance on HSV-2 serologic screening, emphasizing its relevance for HIV prevention and care. RECENT FINDINGS: International guidelines advise against routine general population-level serologic screening for HSV-2 in asymptomatic persons. Key limitations include poor test specificity, the absence of potent antivirals or therapeutic vaccines, lack of curative therapy, no demonstrated population-level benefit, and psychosocial harms associated with diagnosis. Current practice instead emphasizes diagnostic testing in symptomatic persons and targeted screening in defined contexts—such as among people with HIV in specific clinical situations, sex partners of those with HSV-2 infection, certain pregnant women, persons seeking sexual health care, and persons with recurrent or atypical symptoms—where results may directly inform management. Emerging technologies, including highly specific assays, novel potent antivirals, therapeutic vaccines, and curative strategies, may eventually shift the cost–benefit balance of general screening. Evidence supports targeted rather than general population-level screening to maximize clinical benefit while minimizing harm. New evidence demonstrating that interventions can achieve measurable population-level reductions in disease burden or transmission, together with future advances in diagnostics and therapeutics, may eventually justify integrating routine HSV-2 screening into broader contexts, including into HIV prevention and care.},
}
@article {pmid41629068,
year = {2026},
author = {Kshatriya, M and Syal, R and Als, D and Muralidharan, O and Akindole, B and Padhani, ZA and Das, J and Bhutta, ZA},
title = {Implementation of health and health-related sustainable development goals: progress, challenges and opportunities-a systematic literature review update.},
journal = {BMJ global health},
volume = {11},
number = {2},
pages = {},
pmid = {41629068},
issn = {2059-7908},
mesh = {*Sustainable Development ; Humans ; *Global Health ; COVID-19/epidemiology ; *Goals ; Pandemics ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: A prior systematic review assessed progress in health and health-related sustainable development goals (HHSDGs) from 2015 to 2019, identifying an important need for countries to strengthen implementation of multisectoral work, capacity building, financial stability and data availability. We undertook an updated systematic review to assess additional progress, challenges and opportunities for HHSDG implementation from 2019 to 2025, including the pandemic periods. This update aims to assess where countries are presently in HHSDG implementation and if further recommendations can be made in the final stretch to the 2030 targets.<br><br>METHODS: We followed a comparable comprehensive search strategy as the first review, focusing on implementation and acceleration strategies for HHSDGs. We undertook a qualitative synthesis from peer-reviewed and grey literature for specific databases, including studies and reports published from June 2019 to January 2025.<br><br>RESULTS: A total of 192 publications were included in the review of which 150 provided national-level information and 42 provided multicountry or regional information. Findings suggest a high level of political commitment in most countries and many HHSDG efforts being aligned with existing national development strategies. There was a noteworthy shift towards decentralised, subnational approaches to provide contextually relevant interventions. Multisectoral, multistakeholder, integrated approaches for implementation are increasing and proving to be effective. Diverse monitoring and evaluation strategies were employed, and (cross-country) knowledge sharing was instrumental to SDG policy and programme planning. Service disruptions incurred by the COVID-19 pandemic, lack of quality data and obtaining sustainable funding were frequently cited challenges to implementation.<br><br>CONCLUSIONS: Ensuring continuous financial investments and strengthening data availability are essential to accelerate HHSDG implementation. Recommendations for progress include strengthening primary healthcare, fostering multisectoral collaboration and addressing deep-rooted societal perceptions around gender inequity. Future research should examine the interplay of multiple SDGs, and the impact of factors such as cost-effective cross-regional approaches for project implementation.},
}
@article {pmid41629862,
year = {2026},
author = {Meşe, EA and Basmaci, F and Bulut, AC and Topallı, D and Şenel, F and Cagiltay, NE},
title = {The role of extended reality technologies in hygiene education and training: a systematic review of applications, benefits, and challenges.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {272},
pmid = {41629862},
issn = {1471-2334},
mesh = {Humans ; *Virtual Reality ; *Hygiene/education ; *Augmented Reality ; *Infection Control/methods ; *Health Personnel/education ; COVID-19/prevention &amp; control ; },
abstract = {BACKGROUND: The emergence of the Metaverse and Extended Reality (XR) technologies, including Virtual Reality (VR), Augmented Reality (AR), and Mixed Reality (MR), has created innovative opportunities for healthcare education and training. These immersive technologies show promise in enhancing infection prevention and control, especially during infectious disease outbreaks. OBJECTIVES: This systematic review aims to evaluate the current application of XR technologies in infection control education, identifying key trends, benefits, and limitations of VR and AR-based interventions. METHODS: A comprehensive literature search was conducted on January 12, 2025, for the Web of Science and PubMed databases using keywords related to hygiene, infection prevention, and XR technologies. An initial pool of 162 articles was screened, resulting in 38 studies that met inclusion criteria. These studies were descriptively analyzed to assess their contributions, focus areas, and outcomes. RESULTS: The review indicates most studies show XR tools effectively improve practical skills, behaviors, or attitudes, while a smaller number reveal limited or no significant gains, especially in knowledge and compliance. This result shows that XR tools have the potential to improve knowledge retention, practical skills, and provide real-time feedback, outperforming traditional training methods. XR tools specifically enhanced hand hygiene, proper use of personal protective equipment, and emergency response training, areas critical during outbreaks like COVID-19. Nevertheless, widespread adoption remains limited due to the need for more long-term efficacy data and strategies for integrating XR into standard curricula. To fully realize this potential, it is essential to address existing limitations related to cost, safety, and validation, while establishing robust frameworks for curriculum integration and policy implementation. CONCLUSION: XR technologies play a crucial role in advancing infection control education by offering potential benefits for healthcare training and education. Future research should prioritize evaluating long-term outcomes and developing effective implementation strategies to facilitate broader adoption, maximize their educational impact and, and mitigate potential barriers. CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid41630128,
year = {2026},
author = {Halabi, S and Arora, N and Durran, A and Qian, Q and Ummer, S and Ginsbach, K and Aneja, K},
title = {No fault vaccine injury compensation after COVID-19: A systematic literature review and proposed typology.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2620849},
pmid = {41630128},
issn = {2164-554X},
mesh = {Humans ; *Compensation and Redress ; *COVID-19/prevention &amp; control ; *COVID-19 Vaccines/adverse effects/economics ; *Liability, Legal ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic brought about a unique and rapid period of global vaccine innovation. It revealed structural challenges not only in global vaccine affordability and distribution but in the liability and indemnity structures that can both impede access and affect fair outcomes for the small number of people who suffer severe side effects. This review examines vaccine injury and compensation mechanisms, including no-fault compensation schemes, aimed at addressing both the liability and indemnity concerns of developers and the compensation due those suffering severe side effects. The ultimate aim of the review is to provide a classification of systems for those countries that are considering adopting NFCS as part of their broader public health readiness and preparedness strategies.},
}
@article {pmid41630161,
year = {2026},
author = {Quagliarini, E and Pozzi, D and Caracciolo, G},
title = {From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function.},
journal = {Advanced healthcare materials},
volume = {15},
number = {16},
pages = {e05261},
pmid = {41630161},
issn = {2192-2659},
mesh = {*Nanoparticles/chemistry ; *Lipids/chemistry ; Humans ; *DNA/chemistry ; *RNA/chemistry ; Liposomes/chemistry ; Animals ; COVID-19 Vaccines/chemistry ; SARS-CoV-2 ; Gene Transfer Techniques ; },
abstract = {Lipid nanoparticles (LNPs) have become the leading platform for delivering genetic material, gaining global recognition through the success of mRNA-based COVID-19 vaccines such as mRNA-1273 (SpikeVax, Moderna) and BNT162b2 (Comirnaty, BioNTech/Pfizer). Yet, while RNA-LNPs have reached clinical maturity, their DNA counterparts remain comparatively underexplored, despite holding great promise for gene replacement and genome-editing therapies. In this review, we turn the spotlight on DNA-loaded LNPs, examining how their structure, composition, and biological behavior differ from RNA-LNPs, their natural point of reference, and from earlier lipid-based systems such as cationic liposome/DNA complexes (lipoplexes). DNA-LNPs tend to form larger, more heterogeneous, and often multilamellar particles due to the intrinsic stiffness and high charge density of DNA. These distinctive features call for dedicated design strategies, including the use of cationic lipids, pre-condensation agents, and optimized PEGylation schemes. Moreover, DNA profoundly influences the biomolecular corona that forms in biological fluids, which in turn shapes immune recognition, circulation, and tissue targeting. By highlighting these unique physical and biological challenges, this review underscores the need to move beyond simply adapting RNA-based formulations. Instead, a cargo-informed design approach will be key to unlocking the full therapeutic potential of DNA-LNPs in next-generation gene delivery.},
}
@article {pmid41630338,
year = {2026},
author = {Fan, C and Dai, Y and Du, H and Su, T and Guo, X and Yan, Z and Fang, H and Yao, Y and Zhou, X},
title = {Successful treatment of severe cerebral malaria with artificial liver blood purification technology: A case report.},
journal = {Medicine},
volume = {105},
number = {5},
pages = {e47528},
pmid = {41630338},
issn = {1536-5964},
mesh = {Humans ; Male ; *Malaria, Cerebral/therapy/complications ; Adult ; *Malaria, Falciparum/complications/therapy ; *Continuous Renal Replacement Therapy/methods ; Antimalarials/therapeutic use ; Plasmodium falciparum/isolation &amp; purification ; Acute Kidney Injury/therapy ; Treatment Outcome ; Artemether/therapeutic use ; },
abstract = {RATIONALE: Plasmodium falciparum infection can lead to acute thrombocytopenia, severe hemolytic anemia, and acute liver and kidney failure, among which the fatality rate of cerebral malaria is as high as 20% to 30%. Continuous bedside blood purification technology is an important intervention measure for severe malaria. The artificial liver blood purification technology, with its multimode clearance advantage, is widely used in the treatment of critical conditions such as liver failure, sepsis, and novel coronavirus infection. We described a case of severe cerebral malaria complicated with severe liver and kidney injury, cerebral edema and heart failure. The patient was cured after treatment with artificial liver blood purification technology. A literature review was also conducted.<br><br>PATIENT CONCERNS: A 43-year-old male patient was admitted to our hospital due to fever and confusion. The patient had frequently traveled to Nigeria on business in the past 10 years. Three days ago, he developed high fever and confusion. Blood smear examination revealed infection with Plasmodium falciparum. He also suffered from acute liver and kidney function impairment, severe thrombocytopenia, coagulation dysfunction, cerebral edema, and anuria.<br><br>DIAGNOSES: Peripheral blood smear, for the diagnosis of malignant malaria parasite infection.<br><br>INTERVENTIONS: The patient received treatments such as artemether for antimalarial parasites, artificial liver blood purification, and ICU support.<br><br>OUTCOMES: Through continuous renal replacement therapy combined with artificial liver blood purification technology for fluid management, immune complex clearance, and correction of water, electrolyte and acid-base disorders, the patient was successfully treated.<br><br>LESSONS: The integration of artificial liver blood purification with continuous renal replacement therapy may serve as an effective rescue therapy for severe malaria with multi-organ failure, potentially by mitigating the systemic inflammatory response and supporting organ recovery. This case highlights the potential of combined extracorporeal support in managing critical tropical infections.},
}
@article {pmid41630899,
year = {2026},
author = {Nicolai, M and Ullrich, A and Ruck, J and Jaspers, B and Bialobrzeski, A and Degutsch, R and Oechsle, K and Radbruch, L and Gágyor, I and Hettich-Damm, N},
title = {Unraveling the complexities: A scoping review of the collateral effects on informal caregivers during and beyond the COVID-19 pandemic.},
journal = {Palliative care and social practice},
volume = {20},
number = {},
pages = {26323524251399233},
pmid = {41630899},
issn = {2632-3524},
abstract = {Due to the COVID-19 pandemic, various infection control measures were introduced that had a profound effect on caregiving dynamics and created burdens in the daily lives of informal caregivers (ICs). A scoping review was conducted to identify burden and support factors for ICs during and beyond the pandemic. Studies were included when they examined ICs' care work during the official time period of the COVID-19 pandemic (March 2020-May 2023) and care hours worked per day or week were specified. Only studies with adult participants and studies in German or English language were incorporated. The scoping review considered quantitative cross-sectional and longitudinal studies involving randomized/quasi-randomized controlled trials, cohort studies, case studies, mixed-methods, and qualitative studies as well as reviews and meta-analyses. The electronic databases PubMed, the Cochrane COVID-19 Study Register, and EBSCO Host were systematically searched. The search was limited to articles published between 2020 and 2024. The scoping review was conducted in accordance with the Joanna Briggs Institute methodology for scoping reviews. Overall, 42 studies with 51,183individuals met the inclusion criteria and were included in the scoping review. Main findings suggested that the pandemic-related measures caused additional care burden for ICs and worsened the already poor situation of informal care. In particular, the lack of support from health services and the increase in care hours were described as burdensome. Additionally, studies indicated an increase in rates of depression and overall poor mental health, particularly affecting female ICs. Social and formal care support were mentioned as main support factors. Consequently, preparation of future crises should focus on formal health services and structures to promote social support and mental health of ICs during pandemics.},
}
@article {pmid41631378,
year = {2026},
author = {Berger do Rosário, M and da Silva, DW and Wawrzeniak, IC and Ziegelmann, PK and Rios Vieira, SR and Boniatti, MM and Teixeira, C and Oliveira, VM},
title = {Extended Prone Positioning in ARDS: A Systematic Review and Meta-Analysis.},
journal = {Respiratory care},
volume = {71},
number = {4},
pages = {417-425},
doi = {10.1177/19433654251405270},
pmid = {41631378},
issn = {1943-3654},
mesh = {Humans ; *COVID-19/complications/therapy ; *Patient Positioning/methods ; Prone Position ; *Respiration, Artificial/methods ; *Respiratory Distress Syndrome/therapy/mortality ; SARS-CoV-2 ; Time Factors ; },
abstract = {BACKGROUND: Prone positioning is a recommended therapy for patients with moderate-to-severe ARDS; however, the optimal duration of this maneuver is still unknown.<br><br>METHODS: We performed a systematic review and meta-analysis comparing clinical outcomes of extended (&#x2265;24 h) versus traditional prone positioning (16-24 h) of adults with moderate-to-severe ARDS receiving&#xa0;invasive mechanical ventilation.<br><br>RESULTS: Ten studies involving 2,412 subjects&#xa0;met the inclusion criteria, including one randomized controlled trial and 9 observational studies, all with COVID-19-related ARDS. Extended prone positioning was associated with reduced mortality compared with the traditional approach (risk ratio [RR]: 0.76, 95% CI 0.66-0.86, I[2] = 12.8%). Sensitivity and subgroup analyses confirmed consistency across risk of bias, baseline PaO2/FiO2, and PEEP levels. No differences were found in duration of mechanical ventilation (mean difference [MD]: 2.43 days, 95% CI -1.06 to 5.92, I[2] = 70%) or ICU stay (MD: 1.31 days, 95% CI -1.07 to 3.68, I[2] = 55%). The extended strategy was associated with a higher incidence of pressure injuries (RR: 1.30, 95% CI 1.02-1.65, I[2] = 56%) but no differences in device displacement or hemodynamic instability. Certainty of evidence was rated as low to very low.<br><br>CONCLUSIONS: Extended prone positioning was associated with reduced mortality in ARDS but increased risk of pressure injuries, without impact on ventilator duration or ICU stay. While this strategy appears feasible and potentially beneficial, further randomized trials are warranted to confirm its role in routine practice.<br><br>TRIAL REGISTRATION: PROSPERO no. CRD42024529311.},
}
@article {pmid41631916,
year = {2026},
author = {Goss, AL},
title = {Neurologic Complications of Drug and Alcohol Use.},
journal = {Continuum (Minneapolis, Minn.)},
volume = {32},
number = {1},
pages = {277-309},
doi = {10.1212/cont.0000000000001676},
pmid = {41631916},
issn = {1538-6899},
mesh = {Humans ; *Substance-Related Disorders/complications ; *Nervous System Diseases/etiology/chemically induced ; COVID-19/complications ; Male ; Female ; },
abstract = {OBJECTIVE: This article reviews the neurologic syndromes associated with substance use and suggests an approach for identifying and managing substance use disorders.<br><br>LATEST DEVELOPMENTS: Substance use and overdose mortality, largely associated with fentanyl, rose sharply during the COVID-19 pandemic. Although recent data indicate modest decreases, current rates of overdose remain higher than before the pandemic. A wide variety of opioid-related toxic encephalopathies have been identified recently. Many novel psychoactive substances are unregulated and easily obtained online or in stores; several have been associated with seizures and other neurologic complications. The use of cannabis and hallucinogens is rising as more states legalize or decriminalize their use, and some studies suggest an independent association between cannabis use and ischemic stroke.<br><br>ESSENTIAL POINTS: Neurologists often encounter severe complications of substance use and have an opportunity to guide patients with substance use disorders toward treatment.},
}
@article {pmid41633725,
year = {2026},
author = {Cavanna, AE},
title = {Clinical presentation of tics and Gilles de la Tourette syndrome.},
journal = {Handbook of clinical neurology},
volume = {215},
number = {},
pages = {11-27},
doi = {10.1016/B978-0-443-13554-5.00013-4},
pmid = {41633725},
issn = {0072-9752},
mesh = {Humans ; *Tourette Syndrome/diagnosis/physiopathology/epidemiology ; *Tics/diagnosis/physiopathology ; *Tic Disorders/diagnosis ; Diagnosis, Differential ; COVID-19/epidemiology ; },
abstract = {Tics are the most common hyperkinetic manifestations during development. The clinical phenomenology of motor tics ranges from mild twitches affecting a single facial muscle to orchestrated contractions of different muscular districts resembling purposeful behaviors. Likewise, the repertoire of vocal tics (also called phonic tics) covers the whole spectrum between isolated grunting noises and meaningful strings of words. Simple and complex tics arguably sit on a continuum of symptom severity and respond to the same treatment interventions. The diagnosis of Gilles de la Tourette syndrome (GTS) is based on the presence of multiple motor tics plus at least one vocal tic, with onset before the age of 18 years and chronic course. It has been argued that the different tic disorders belong to a spectrum of increasing complexity, from the transient form (provisional tic disorder), through persistent motor or vocal tic disorder, to GTS. However, the clinical phenotype of GTS stands out because of the frequent association with specific behavioral problems, ranging from tic-related obsessive-compulsive disorder to other neurodevelopmental conditions. The diagnosis of tic disorders is based on clinical observation and requires expertise. The recent outbreak of functional tics, documented across several countries during the COVID-19 pandemic, introduced unprecedented challenges to the differential diagnosis of neurodevelopmental tics.},
}
@article {pmid41633747,
year = {2026},
author = {Alruwaita, AA and Lang, AE and Ganos, C},
title = {Functional tics and tic-like behaviors.},
journal = {Handbook of clinical neurology},
volume = {215},
number = {},
pages = {55-62},
doi = {10.1016/B978-0-443-13554-5.00017-1},
pmid = {41633747},
issn = {0072-9752},
mesh = {Humans ; *Tic Disorders/diagnosis/physiopathology/therapy ; *Tics/diagnosis/physiopathology ; Diagnosis, Differential ; COVID-19 ; },
abstract = {Functional tics and tic-like behaviors belong to the wide spectrum of functional movement disorders. Until the early 2010s, functional tic disorders were rather uncommon in the differential diagnosis of tics, and only few cases describing their features had been published. However, over the past 10 years there has been a steady increase in the frequency of these cases that peaked throughout the COVID-19 pandemic. On the one hand, the rise in functional tic cases created new challenges of diagnosis and treatment. At the same time, it also pushed the field forward to delineate helpful clinical clues, as well as to work toward specific consensus diagnostic criteria for functional tics and tic-like behaviors. Here, we first provide a historical summary on the debate between neurodevelopmental and functional tics. We then track relevant literature on functional tics and tic-like cases and discuss their salient features, such as an acute onset with severe symptoms and complex repetitive behaviors that typically occur in late adolescence or early adulthood, a large variability of symptoms including spontaneous symptom remissions and re-emergence, and a high prevalence of phonations and vocalizations with the common use of swearwords or variable sentences. In addition, it is common to see an overlap with additional functional neurologic symptoms, such as functional tremor or nonepileptic seizures. In diagnostically challenging cases, neurophysiologic evaluation, including surface electromyography and electroencephalography, may be useful, and markers such as the premotor potential (Bereitschaftspotential) and event-related desynchronization/synchronization may hold promise. Effective management of functional tics begins with an accurate diagnosis and often requires a multidisciplinary approach. Cognitive-behavioral therapy and the Comprehensive Behavioral Intervention for Tics may be particularly useful, alongside addressing comorbid psychiatric conditions. Currently there is an absence of standardized treatment protocols; individualized care plans tailored to each patient's specific needs are generally the most effective approach.},
}
@article {pmid41634606,
year = {2026},
author = {Migliaccio-Walle, K and Mugwagwa, T and Cha-Silva, AS and Gong, CL and Campbell, D and Quercia, R and Bergroth, T and Veenstra, DL and Moran, MM and Dzingina, M},
title = {Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {41634606},
issn = {1471-2334},
mesh = {Humans ; *Hospitalization/statistics &amp; numerical data ; *Ritonavir/therapeutic use ; United States/epidemiology ; *COVID-19 Drug Treatment ; *COVID-19/mortality ; SARS-CoV-2 ; Drug Combinations ; *Lopinavir/therapeutic use ; *Antiviral Agents/therapeutic use ; Female ; Male ; Aged ; },
abstract = {BACKGROUND: No study has systematically reviewed published estimates of real-world risk of hospitalization and death among untreated COVID-19 patients. We aimed to characterize the risk of hospitalization and death in real-world US clinical practice for untreated patients at high-risk for progression to severe COVID-19 and critically assess differences in patient populations. METHODS: We conducted a systematic literature review to identify US real-world evidence studies (December 21, 2021 – January 30, 2024) of patients aged 12 years and older diagnosed with mild-to-moderate COVID-19, at high risk for progression to severe COVID-19, and treated with nirmatrelvir/ritonavir (NMV/r) or untreated/best supportive care. Primary outcomes were reported risks of all-cause hospitalization, death, and hospitalization or death at 1 month. To account for heterogeneity across studies and confounding within studies, outcomes were estimated as: 1) observed risk, untreated risk as reported, 2) within-study adjusted risk, applying an adjusted treatment effect within studies to calculate risk in the untreated population, and 3) adjusted and standardized estimate, using the relative risk reduction for all-cause hospitalization or death from the study with highest validity. RESULTS: Of 1023 studies screened, we retained 23 for data extraction after applying inclusion and exclusion criteria (384,793 NMV/r patients from 22 studies; 1,062,757 no treatment from 14 studies). Studies were heterogenous, primarily retrospective, utilizing claims (e.g., TriNetX) and integrated health system data (e.g., Veterans Affairs). Most (n = 21, 91%) were US only; 20 (87%) were cohorts from December 2021 onward. Risk of all-cause hospitalization ranged from 0.9–7.7% (observed), 0.8–2.0% (within-study adjusted), and 2.3–6.9% (adjusted and standardized). Hospitalization or death ranged from 0.6–10.2% (observed), 0.4–5.6% (within-study adjusted), and 1.0–15.6% (adjusted and standardized). Death risk ranged from 0.1–3.1% (observed) and 0.0–0.9% (within-study adjusted). CONCLUSIONS: Estimating the risk of hospitalization and death for untreated high-risk COVID-19 patients from the literature is limited by inherent differences in study designs, patient populations, and reporting. Observed risk of hospitalization ranges from 1 to 8%, and the risk of death from 0 to 3%. Understanding the hospitalization risk among untreated patients provides context for the clinical and economic value of current antiviral treatments. This study was sponsored by Pfizer, Inc.},
}
@article {pmid41634728,
year = {2026},
author = {Tang, Z and Zha, L and Liang, R and Li, T},
title = {Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.},
journal = {Journal of hematology &amp; oncology},
volume = {19},
number = {1},
pages = {15},
pmid = {41634728},
issn = {1756-8722},
support = {I01 BX003895/BX/BLRD VA/United States ; CU000157/L0008//VA-Lung Precision Oncology Program/ ; I01BX003895//Office of Research and Development/ ; },
mesh = {Humans ; *Cancer Vaccines/therapeutic use/immunology ; *Lung Neoplasms/immunology/therapy/drug therapy ; *Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Antigens, Neoplasm/immunology ; Animals ; Tumor Microenvironment/immunology ; },
abstract = {Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of lung cancer over the past decade, markedly improving antitumor responses, overall survival, and quality of life. However, durable clinical benefit is achieved in only a subset of patients, and resistance to ICIs remains a major clinical challenge. Mechanistically, resistance arises from multiple, often overlapping processes, including inadequate tumor antigen presentation, dysfunctional T-cell priming and expansion, and the presence of physical and immunosuppressive barriers within the tumor microenvironment that limit immune cell infiltration and effector function. Cancer vaccines have re-emerged as a rational immunotherapeutic strategy to overcome these obstacles by inducing de novo or amplifying pre-existing tumor-specific immune responses, thereby enhancing long-term immunological memory while maintaining a favorable safety profile. Advances in antigen discovery, neoantigen prediction, and vaccine platforms have accelerated the development of both personalized and off-the-shelf neoantigen vaccines. Although personalized neoantigen vaccines have gained considerable attention following the success of mRNA-based COVID-19 vaccines, off-the-shelf approaches offer advantages in scalability, cost, and manufacturing timelines, facilitating broader clinical implementation. Accumulating preclinical and clinical evidence suggests that cancer vaccines are more effective in the adjuvant setting than in the metastatic setting, where high tumor burden and an immunosuppressive tumor microenvironment constrain vaccine-induced immune responses. Consistent with their limited efficacy as monotherapy, contemporary clinical trials increasingly evaluate cancer vaccines in combination with ICIs or other immunotherapeutic agents to enhance T-cell activation, reverse immune suppression, and restore antitumor immunity. This review synthesizes current mechanistic insights, highlights ongoing clinical efforts, and discusses future directions for rational cancer vaccine development in lung cancer, with an emphasis on overcoming resistance to ICI.},
}
@article {pmid41635308,
year = {2025},
author = {Liu, G and Tan, R and Wu, Y and Wang, M and Huang, B and Tan, W},
title = {Advances in the development of infectious clones of human coronaviruses and related applications.},
journal = {Biosafety and health},
volume = {7},
number = {1},
pages = {59-73},
pmid = {41635308},
issn = {2590-0536},
abstract = {Coronaviruses can infect humans, mammals, and birds, leading to respiratory, gastrointestinal, and neurological diseases. These viruses are significant zoonotic pathogens with nine known types capable of infecting humans. The coronavirus genome, approximately 30 kb in size, is the largest known ribonucleic acid (RNA) virus genome, and its complexity makes assembly and manipulation time-consuming and labor-intensive. Reverse genetic systems are widely used to engineer recombinant viruses that can be adapted at Biosafety Level 2 (BSL-2) for studying viral gene function, replication, pathogenesis, vaccines, and therapeutics. The infectious clones, which enabled the recovery of various viruses after DNA recombinant technology, were indispensable tools for the reverse genetics of viruses. Various techniques for constructing infectious clones of human coronaviruses (HCoV) have been developed, encompassing methods such as vaccinia virus vectors method, in vitro ligation, bacterial artificial chromosome systems, yeast artificial chromosome systems, circular polymerase extension reaction, and the recently reported infectious sub-genomic amplicons technology. This review summarizes the status of various techniques for constructing infectious clones of human coronaviruses and related applications.},
}
@article {pmid41635346,
year = {2026},
author = {Pawar, B and Loganathan, S and Mukkatira Belliappa, K and Ranganathan, LB and Thekdi, KP and Hiware, SD},
title = {A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e100608},
pmid = {41635346},
issn = {2168-8184},
abstract = {The trend of vaccine development over the last few years is that the traditional platform has been abandoned and moved towards newer modalities, and the current COVID-19 pandemic has accelerated this shift. Classical approaches (such as inactivated, live attenuated, and recombinant) can be shown to have reduced the burden of infectious diseases; however, they are also limited by their inability to scale production and prolonged development, as well as cold-chain limitations. The lacks became apparent through the pandemic and drove the demand for more agile, adaptive technology that COVID-19 has highlighted. The current review questions the goal of streamlining the immunization approaches in the face of emerging pathogens through a structured narrative comparison of immunogenicity, safety, efficacy, and platform stability of modern vaccination platforms within a narrative review framework. This analysis is anchored by a narrative synthesis of immunological, regulatory, and clinical literature between 2018 and 2025. Messenger RNA (mRNA)-based vaccines have demonstrated strong immunogenicity and practical efficacy in the real world, as well as varying safety profiles across platforms and the potential of new modalities that will be developed both to treat infectious diseases and to be applied in other contexts. The discussion also dwells upon the flexibility of regulation, unequal distribution, and surveillance-based pharmacovigilance. This review can be used to compile a thoroughly comparative view of modern vaccines, based on bringing together mechanistic insights and implementation barriers, which can guide future innovation and policy reconciliation and global resilience. It makes inferences in support of the more progressive, equity-based paradigm of pandemic preparedness and immunization strategy in the 21st century. This review highlights how mRNA technology has transformed the landscape of vaccinology, offering a foundation for faster, safer, and more equitable global immunization strategies in the post-pandemic era.},
}
@article {pmid41635704,
year = {2025},
author = {Montgomery, MP and Praphasiri, P and Ditsungnoen, D and Akarasewi, P and Chittaganpitch, M and Puthavathana, P and Limpakarnjanarat, K and Wirachwong, P and Chotpitayasunondh, T and Sawanpanyalert, N and Sonthichai, C and Davis, WW and Olsen, SJ and Chunsuttiwat, S},
title = {Influenza surveillance and vaccine policy in Thailand-a historical perspective.},
journal = {The Lancet regional health. Southeast Asia},
volume = {41},
number = {},
pages = {100663},
pmid = {41635704},
issn = {2772-3682},
abstract = {Prior to 2000, influenza burden in Thailand and other low- and middle-income countries was underappreciated, and influenza vaccination was uncommon. For the last two decades, Thailand Ministry of Public Health (MOPH) and U.S. Centers for Disease Control and Prevention have collaborated to understand influenza burden and the costs and benefits of influenza vaccination in Thailand. Built on a long-standing national disease notification system, Thailand MOPH established robust surveillance platforms for pneumonia and influenza, which provided insights into seasonality, disease incidence, and populations at risk for severe disease. In 2004, human cases of avian influenza brought attention to influenza's pandemic potential. Concern for an influenza pandemic combined with evidence of the cost effectiveness of influenza vaccination accelerated vaccine policy. Surveillance and vaccination policy were leveraged for and strengthened by the 2009 influenza H1N1 and COVID-19 pandemics. This personal view documents Thailand's experience in developing influenza surveillance and influenza vaccination policy.},
}
@article {pmid41637169,
year = {2026},
author = {Göldel, JM and Warschburger, P},
title = {Psychological adjustment in parents of children and adolescents with chronic health conditions during the COVID-19 pandemic - a meta-analysis.},
journal = {Health psychology review},
volume = {20},
number = {2},
pages = {453-481},
doi = {10.1080/17437199.2026.2616461},
pmid = {41637169},
issn = {1743-7202},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Parents/psychology ; Child ; Chronic Disease/psychology ; *Stress, Psychological/epidemiology/psychology ; Anxiety/epidemiology/psychology ; Depression/epidemiology/psychology ; Adolescent ; *Adaptation, Psychological ; Parenting/psychology ; Prevalence ; },
abstract = {Caring for a child with a chronic health condition (CC) involves numerous challenges, which may have multiplied during the COVID-19 pandemic. Therefore, this meta-analysis aimed (1) to quantify the prevalence of clinically elevated anxiety, depression, general stress, and parenting stress symptoms in afflicted parents, (2) to examine potential moderator variables, and (3) to compare the outcomes between parents of children with and without CCs. A systematic literature search was conducted across four databases (PsycInfo, PubMed, CENTRAL, PSYNdex). A total of 79 studies were included. The pooled prevalence estimates of clinically elevated anxiety, depression, general and parenting stress symptoms were 31.04%, 27.37%, 64.27%, and 26.70%, respectively. Significant moderators were identified only for anxiety symptoms, namely geopolitical region, child CC, and child age. Anxiety and depression, but not general and parenting stress, were significantly higher in parents of children with than without CCs. Compared to published data from before the pandemic, prevalence rates of clinically elevated anxiety and depression symptoms decreased, while stress levels no longer differed between parents of children with and without CCs. We hypothesise that parents of children with CCs experienced some beneficial effects during the COVID-19 pandemic and had already acquired resilience to buffer its psychosocial impact.},
}
@article {pmid41637737,
year = {2026},
author = {Siegel, ZM and Quinkert, E and Pai, J and Miller, CH and Lewis, MW},
title = {Lessons Learned About Digital Health Tool Acceptability Among Rural Older Adults: Systematic Review Guided by the Technology Acceptance Model.},
journal = {JMIR aging},
volume = {9},
number = {},
pages = {e70012},
pmid = {41637737},
issn = {2561-7605},
mesh = {Humans ; Digital Health ; Aged ; *Telemedicine ; *Rural Population/statistics &amp; numerical data ; *COVID-19/epidemiology ; *Patient Acceptance of Health Care/statistics &amp; numerical data ; Middle Aged ; },
abstract = {BACKGROUND: Digital health tools are increasingly vital in rural health care due to widespread hospital closures and the rapid adoption of telehealth during the COVID-19 pandemic. Rural older adults, a uniquely vulnerable population, face barriers to accessing these tools due to rurality and usability challenges. Although a growing body of literature examines the acceptability and usability of digital tools among rural older adults, no study has synthesized this research to establish best practices.<br><br>OBJECTIVE: This study aims to review existing literature on digital health tools for rural older adults, highlighting key lessons learned about their acceptability and identifying strategies to improve usability for this population.<br><br>METHODS: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, this study reviewed literature that investigated the role of digital health tools on the health outcomes of rural older adults (ie, at least 60 years old). The literature was retrieved from 5 electronic databases through June 2023. This study and all reviewed literature were conducted in the United States. Guided by a systematic process, 2 reviewers assessed relevant articles for eligibility, analyzed data, and extracted relevant content. The extracted findings were organized according to the evidence-based technology acceptance model, which assesses the acceptability of a technology by its usefulness, ease of use, and intention to use.<br><br>RESULTS: The preliminary title review produced 7728 results, and 38 eligible manuscripts were included in the final review. Studies included both rural older adults and providers of rural older adults as participants. Digital health tools included, but were not limited to, videoconferencing, phone calls, telehealth monitoring, telemedicine appointments, and computer-based interventions. Findings on the usefulness of digital health tools by rural older adults were mixed. While digital health tools were useful for overcoming barriers to accessing care, these tools were less useful for rural older adults with limited digital literacy. Additionally, some studies described that the technology was easy but difficult to use when faced with environmental barriers, equipment issues, and discomfort with the technology. Rural older adults often reported an intention to use the technology after the study. Yet, on a few occasions, participants who preferred in-person care visits or did not have buy-in on the technology reported no intention to use the technology again.<br><br>CONCLUSIONS: Our review highlights that rural older adults and their providers generally view digital health tools as acceptable for delivering care and, in some cases, as a viable alternative to in-person clinic visits. While certain barriers impacted the acceptance of these tools among rural older adults, many of these challenges were not directly linked to their age or rural location; thus, they are potentially applicable to urban older adults.<br><br>TRIAL REGISTRATION: PROSPERO CRD42021287924; https://www.crd.york.ac.uk/PROSPERO/view/CRD42021287924.},
}
@article {pmid41638514,
year = {2026},
author = {Jalili, M and Jalilian, FA},
title = {A review of targeting microRNAs as potential therapeutic strategies against respiratory viruses: Current insights and future directions.},
journal = {Microbial pathogenesis},
volume = {213},
number = {},
pages = {108346},
doi = {10.1016/j.micpath.2026.108346},
pmid = {41638514},
issn = {1096-1208},
mesh = {*MicroRNAs/genetics/metabolism ; Humans ; *Respiratory Tract Infections/virology/therapy/genetics/drug therapy ; Animals ; Virus Replication/genetics ; Host-Pathogen Interactions/genetics ; Immunity, Innate ; Antiviral Agents/therapeutic use/pharmacology ; *Virus Diseases/therapy/genetics ; },
abstract = {Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses continue to impose a global health burden due to their high transmissibility and limited antiviral options. MicroRNAs (miRNAs) have emerged as critical regulators of host pathogen interactions by modulating innate immunity, inflammatory signaling, and viral replication. This review focuses on respiratory RNA and DNA viruses that primarily infect the airways, including influenza viruses, RSV, human metapneumovirus, rhinoviruses, adenoviruses, and SARS-CoV-2. Several miRNAs, including miR-155 and miR-146a, are upregulated during infections with SARS-CoV-2, influenza, and RSV, where they fine-tune interferon and NF-κB signaling pathways. In contrast, downregulation of miR-21, miR-223, and let-7 family members has been linked to enhanced viral replication and dysregulated immune responses. Moreover, miR-122, miR-29a, and miR-124 have gained attention as potential therapeutic targets or prognostic biomarkers due to their roles in modulating viral load, cytokine production, and tissue injury. This review synthesizes current evidence on miRNA-mediated regulation of respiratory viruses, evaluates their promise as therapeutic candidates and diagnostic tools, and discusses delivery systems designed for targeted miRNA modulation. Despite promising advances, challenges remain in achieving tissue-specific delivery, avoiding immune off-target effects, and validating efficacy in clinical settings. Most of the available data are derived from in vitro or animal models and heterogeneous clinical cohorts, so conclusions about causality and therapeutic efficacy should be viewed as provisional and highlight significant translational gaps. Finally, we outline major challenges and future research directions needed to translate miRNA-targeted therapies into clinically viable antiviral strategies. Insights from these emerging studies position miRNA-targeted interventions as a potential new class of antiviral therapeutics and underscore the need for rigorous, translational research to realize their clinical utility.},
}
@article {pmid41638540,
year = {2026},
author = {Nuber-Champier, A and Bréville, G and Lalive, PH and Assal, F and Péron, JA},
title = {Immune-cognitive relationships across viral infections: A transnosological systematic review.},
journal = {Neuroscience and biobehavioral reviews},
volume = {184},
number = {},
pages = {106588},
doi = {10.1016/j.neubiorev.2026.106588},
pmid = {41638540},
issn = {1873-7528},
mesh = {Humans ; *Virus Diseases/immunology/psychology/complications ; *Cognition/physiology ; Cytokines/immunology ; *COVID-19/immunology ; *Cognition Disorders/immunology ; },
abstract = {The emergence of SARS-CoV-2 has renewed interest in the relationship between immunity and cognition. Despite decades of work, the impact of viral exposure, mainly in the field of HIV, herpes and hepatitis infections, on distinct cognitive processes remains unclear, as most studies use global screening tools (e.g., MoCA) in isolation in each infectious context. This systematic narrative review adopts a transnosological approach, summarizing previously reported immune-cognition relationships across viral infections. Of 931 studies, 32 met inclusion criteria (N = 25,325) spanning SARS-CoV-2, HIV, herpes, hepatitis, Epstein-Barr virus, and multiple infections. Reported studies on immuno-cognitive relationships reveal several consistent findings. Elevated circulating CD14[+]CD16[+] intermediate monocytes correlated with slower processing speed, reduced episodic memory and mental flexibility. Higher CD4[+] T cells were associated with better processing speed, while reduced T cells and B cells levels together with elevated IgG predicted deficits in memory and attention. Most proinflammatory cytokines (e.g., IL-6, TNF-α, IFN-γ) were associated with impairments in overlapping cognitive domains (e.g., memory), whereas IL-10, an anti-inflammatory cytokine, consistently supported executive and memory performance.},
}
@article {pmid41639496,
year = {2026},
author = {Berra, L and Kamenshchikov, N and Tal, A and Safaee Fakhr, B and Rezoagli, E and Thomson, R and Yu, B and , },
title = {The therapeutic potential of high-dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions.},
journal = {Intensive care medicine experimental},
volume = {14},
number = {1},
pages = {13},
pmid = {41639496},
issn = {2197-425X},
abstract = {Inhaled nitric oxide (iNO), long used as a selective pulmonary vasodilator, has demonstrated potential antimicrobial and antiviral properties when administered at high concentrations (> 20 parts per million, ppm). While definitive evidence is still lacking, this narrative review synthesizes the emerging clinical and mechanistic properties supporting high-dose iNO as a potential therapeutic strategy for lower respiratory tract infections, including drug-resistant bacterial pneumonias, COVID-19, nontuberculous mycobacteria, and bronchiolitis. We summarize safety data from laboratory studies, Phase I trials, clinical findings from 27 predominantly early-phase studies, and highlight its as both hospital-based and home-based therapy. High-dose iNO acts through multiple pathways, including direct microbial killing, biofilm disruption, immune modulation, and mucociliary enhancement, and holds promise in addressing unmet needs in respiratory infection management. We also propose a roadmap for future research to optimize dosing, delivery, and efficacy endpoints in well-defined patient populations.},
}
@article {pmid41639776,
year = {2026},
author = {Aboulwafa, A and Lebbe, A and Khalil, A and Bayraktar, N and Mushannen, B and Ayoub, S and Sarker, S and Abdalla, MN and Laws, S and Mohammed, I and Yagan, L and Mushannen, M and Zakaria, D},
title = {New onset of severe and long-term hepatobiliary diseases post-COVID-19 infection: a systematic review.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {253},
pmid = {41639776},
issn = {1471-2334},
mesh = {Humans ; *COVID-19/complications ; *Liver Diseases/etiology/virology ; *Biliary Tract Diseases/etiology/virology ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND: The COVID-19 pandemic has resulted in a surge of reports linking the virus to various systemic complications, including hepatobiliary disorders. Understanding the spectrum and severity of hepatobiliary diseases following COVID-19 infection is crucial for comprehensive patient management and long-term health outcomes. METHODS: A systematic review was conducted to identify studies reporting on hepatobiliary manifestations post-COVID-19 infection. PubMed, Medline, Embase, Scopus, Web of Science, Science Direct and Cochrane Library databases were searched in October 2023, with set inclusion and exclusion criteria in place to select papers documenting new onset hepatobiliary diseases following COVID-19 infection. RESULTS: A total of 23 studies met the inclusion criteria, covering a diverse range of hepatobiliary conditions such as acute hepatitis, cholestasis, autoimmune liver diseases, and gallbladder pathology. CONCLUSION: This systematic review underscores the emerging evidence of severe and long-term hepatobiliary diseases following COVID-19 infection. Healthcare providers should maintain a high index of suspicion for hepatobiliary complications in patients recovering from COVID-19, emphasizing the need for prolonged monitoring and specialized management strategies to mitigate long-term morbidity and mortality."},
}
@article {pmid41639856,
year = {2026},
author = {Walker, KA and Craig, S and Anderson, T and Stark, P and Brown Wilson, C and Carter, G and McEvoy, C and Creighton, L and Henderson, E and Porter, S and Alhalaiqa, F and Ferranti, E and Murali, KP and Zheng, Y and Sammut, R and Shaban, MM and Tam, HL and Buzás, N and Leidl, D and Mitchell, G},
title = {Diabetes educational interventions in care homes: a scoping review.},
journal = {BMC medical education},
volume = {26},
number = {1},
pages = {},
pmid = {41639856},
issn = {1472-6920},
support = {SB\ZA\101010662\898090//Burdett Trust for Nursing/ ; COM/5755/23//Health and Social Care Northern Ireland/ ; },
mesh = {Humans ; *Nursing Homes ; *Diabetes Mellitus/therapy ; Nursing Home Residents ; *Patient Education as Topic ; },
abstract = {BACKGROUND: Diabetes affects approximately 10.5% of the global adult population and is more prevalent in care homes due to residents’ advanced age and multimorbidity. Effective diabetes management in these settings is essential to prevent complications and maintain quality of life, yet evidence addressing the specific needs of this population remains limited. High-quality care relies on access to appropriate clinical education. This scoping review will synthesise evidence on educational interventions to support diabetes care provision in care home settings. METHODS: This scoping review was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. A comprehensive literature search was conducted across three electronic databases: CINAHL Plus, Medline, and PsycINFO. Methodological quality of the included primary studies was assessed using the Mixed Methods Appraisal Tool (MMAT). RESULTS: In total, 10 studies were included in the review, encompassing evidence from a range of international contexts. Analysis revealed three prominent themes; Firstly, educating nurses about diabetes can improve practice and behaviour. Secondly, educational interventions can increase staff knowledge and confidence, which is linked to enhancing the quality of care. Finally, a range of facilitators and barriers influencing the delivery of diabetes training in care homes were identified. DISCUSSION: The review suggests that educational interventions in care homes can enhance diabetes care. However, while the current evidence is encouraging, there are a lack of empirically tested educational interventions for diabetes education in this setting. Further, current educational programmes appear to lack key detail including footcare, eye care and COVID-19. To ensure the provision of high-quality diabetic care, it is therefore important to enhance the training and education of staff members.},
}
@article {pmid41639918,
year = {2026},
author = {Carpenteri, F and Cilloniz, C and Torres, A},
title = {Corticosteroids in severe community-acquired pneumonia: friend, foe or both?.},
journal = {Pneumonia (Nathan Qld.)},
volume = {18},
number = {1},
pages = {5},
pmid = {41639918},
issn = {2200-6133},
support = {CIBERES CB06/06/0028//Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Epidemiolog&#xed;a y Salud P&#xfa;blica/ ; },
abstract = {In most patients with CAP, corticosteroids should be avoided due to complications such as immunosuppression and hyperglycaemia. Studies of hydrocortisone have shown corticosteroids might be of benefit in patients with severe CAP and high inflammation measured by CRP. Differences in results between trials of corticosteroid therapy suggest heterogenicity in study populations and the need for future studies in standardized populations. Scientific evidence shows corticosteroid use can reduce short-term mortality and the need for mechanical ventilation in hospitalized patients with severe CAP. However, this approach should not be generalized to all patients with CAP. Use should be guided by biomarkers such as CRP to identify patients who will benefit the most. Corticosteroids should not be routinelly used in viral pneumonia, with the exception of hypoxemic SARS-CoV-2 pneumonia, in which their benefit is well established.},
}
@article {pmid41640416,
year = {2025},
author = {Pompilio, A and Di Bonaventura, G},
title = {The COVID-19 pandemic: an underlying factor for increased Stenotrophomonas maltophilia infections-A literature review and case study analysis.},
journal = {Frontiers in microbiology},
volume = {16},
number = {},
pages = {1746742},
pmid = {41640416},
issn = {1664-302X},
abstract = {Stenotrophomonas maltophilia is increasingly recognized as a major cause of healthcare-associated infections in intensive care units. It presents serious risks for immunocompromised patients and can cause severe lung infections in individuals with cystic fibrosis. Recent studies have documented a rising occurrence of S. maltophilia infections among hospitalized COVID-19 patients. However, understanding of these infections in this setting remains limited or inconsistent, with only one review specifically examining S. maltophilia infections in COVID-19 patients. This review critically evaluates all relevant studies from the literature, along with a case series, to explore the clinical significance of S. maltophilia infections in patients with COVID-19. In particular, the review discusses the prevalence, risk factors, phenotypic traits, clinical consequences, and treatment options for S. maltophilia infections in this clinical context.},
}
@article {pmid41640608,
year = {2026},
author = {Velikova, T and Ali, H and Batselova, H and Chervenkov, L and Miteva, D and Peruhova, M and Gulinac, M and Tomov, L and Mitova-Mineva, Y and Velev, V},
title = {Interplay between viral infections and gut microbiota dysbiosis: Mechanisms and therapeutic potential.},
journal = {World journal of gastroenterology},
volume = {32},
number = {3},
pages = {112437},
pmid = {41640608},
issn = {2219-2840},
mesh = {Humans ; *Dysbiosis/therapy/immunology/microbiology/virology ; Fecal Microbiota Transplantation ; COVID-19/immunology ; Probiotics/therapeutic use ; SARS-CoV-2 ; *Gastrointestinal Microbiome/immunology ; Prebiotics/administration &amp; dosage ; *Virus Diseases/immunology/microbiology/therapy ; Animals ; Pandemics ; Host-Pathogen Interactions ; },
abstract = {Viral infections, particularly those triggered by emerging pathogens like severe acute respiratory syndrome coronavirus 2, are increasingly recognized for their profound impact on the gut microbiota, causing dysbiosis, a condition characterized by an imbalance in microbial communities. Recent studies suggest that alterations in gut microbiota can influence disease progression, immune responses, and clinical outcomes. The bidirectional relationship between the gut microbiota and the host immune system is crucial in shaping responses to infection. Furthermore, dysbiosis has been linked to exacerbated inflammation, impaired mucosal barrier function, and altered drug metabolism, thereby complicating both disease pathogenesis and treatment efficacy. This review examines the interplay between viral infections and gut microbiota dysbiosis, with a focus on the underlying mechanisms and potential therapeutic strategies to modulate host immunity. We also evaluate the potential of microbiome-based interventions, such as probiotics, prebiotics, and fecal microbiota transplantation, as therapeutic strategies for restoring microbial balance and mitigating the severity of infections. The paper underscores the need for further research to optimize microbiota-targeted therapies and integrate them into clinical practice, offering a comprehensive approach to managing dysbiosis in viral infectious diseases.},
}
@article {pmid41641003,
year = {2025},
author = {Leclerc, L and Poudrier, J and Power, C and Lam, GY and Falcone, EL},
title = {Intestinal barrier compromise, viral persistence, and immune dysregulation converge on neurological sequelae in Long COVID.},
journal = {Frontiers in aging neuroscience},
volume = {17},
number = {},
pages = {1744415},
pmid = {41641003},
issn = {1663-4365},
abstract = {Long COVID (LC) is a multisystem, post-infectious conditions diagnosed ≥3 months after acute SARS-CoV-2 infection and marked by relapsing, persistent, or progressive symptoms, especially fatigue, post-exertional symptom exacerbation and neuropsychiatric syndromes. We synthesized evidence suggesting that LC arises from intersecting pathways including viral persistence, intestinal dysbiosis and barrier compromise with microbial translocation, innate immune activation with neutrophil extracellular traps (NET) and thromboinflammation, and immune dysregulation with features of exhaustion and autoimmunity. These processes adversely impact blood-brain barrier (BBB) function and lead to neuroinflammation. We propose a mechanistic model in which viral antigens and translocated microbial products amplify pro-inflammatory networks promoting immunothrombosis and tissue hypoperfusion. Hematogenous and gut-brain pathways may then deliver inflammatory mediators to the central nervous system (CNS), resulting in BBB disruption and glial activation that underpin nervous system disorders in LC. Treatment regimens aimed at lowering antigen load, restoring mucosal barrier integrity and modulating myeloid/coagulation pathways may warrant investigation as novel therapeutic strategies to treat LC.},
}
@article {pmid41641244,
year = {2025},
author = {Wang, D and Yang, T and Cui, Y and Qu, Y and Feng, C and Sun, Z and Zhang, M},
title = {From tradition to healing: the promise of acupuncture in managing chronic fatigue syndrome.},
journal = {Frontiers in medicine},
volume = {12},
number = {},
pages = {1724290},
pmid = {41641244},
issn = {2296-858X},
abstract = {Chronic fatigue syndrome (CFS) is a global public health problem affecting more than 65 million patients worldwide. The combined prevalence rate of CFS was 45.2% after 4 weeks in patients with novel coronavirus. Women, people over 40 years of age, and low-income people are susceptible groups, which have a significant impact on immune, nervous, endocrine, and other system functions. First, from the perspective of epidemiology, this paper reviews the global epidemic trend of CFS, the differences in incidence and prevalence in different regions and populations, and risk factors such as heredity, infection, and childhood trauma. Second, the development of diagnostic techniques for CFS, including the evolution of clinical diagnostic criteria, research progress on immune and metabolic biomarkers, and the application of MRI and other imaging techniques in the diagnosis of CFS, is described, followed by an in-depth discussion of the genetics of CFS, including genetic susceptibility, genomic association, and familial aggregation. The pathophysiological mechanism of CFS was also analyzed, revealing abnormalities in NK cell function and immune factors in the immune system, dysfunction of the hypothalamic-pituitary-adrenal axis in the neuroendocrine system, and disorders of energy and lipid metabolism in the metabolic system. This paper focuses on the study of acupuncture and moxibustion treatment of CFS, traces back to the historical application of acupuncture and moxibustion treatment of CFS, analyzes the relationship between the pathological mechanism of CFS and acupuncture and moxibustion intervention, expounds the theoretical basis of traditional Chinese medicine and modern mechanism of action of acupuncture and moxibustion treatment, and introduces the results of clinical trials, efficacy evaluation methods, and individualized treatment strategies for acupuncture and moxibustion treatment of CFS. The innovative application of acupuncture techniques, such as electroacupuncture and acupoint catgut embedding, as well as the synergistic effect of acupuncture combined with traditional Chinese medicine and psychotherapy, are shown. At the same time, disputes and challenges in the efficacy, safety, and ethics of acupuncture treatment for CFS were pointed out, and future research directions, potential breakthroughs, and international cooperation opportunities of acupuncture treatment for CFS are discussed. This study provides a comprehensive reference for clinical treatment and research on CFS.},
}
@article {pmid41641375,
year = {2026},
author = {Zhang, J and Liu, Y and Ren, S and Wang, Z and Li, Y and Peng, L and Fang, R},
title = {Natural Products as Potential Resource Library for Control of Major Swine Enteric Viruses.},
journal = {Transboundary and emerging diseases},
volume = {2026},
number = {},
pages = {4368881},
pmid = {41641375},
issn = {1865-1682},
mesh = {Animals ; Swine ; *Swine Diseases/virology/prevention &amp; control/drug therapy ; *Biological Products/pharmacology/therapeutic use ; *Antiviral Agents/pharmacology ; Transmissible gastroenteritis virus/drug effects ; Porcine epidemic diarrhea virus/drug effects ; Deltacoronavirus/drug effects ; },
abstract = {Major swine enteric viruses (SEVs), including porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), transmissible gastroenteritis virus (TGEV), swine acute diarrhea syndrome coronavirus (SADS-CoV), and porcine rotavirus (PoRV), cause severe gastrointestinal diseases in pigs, leading to huge economic losses to the swine industry around the world. In the absence of specific drugs and vaccines for controlling SEVs in the pig production, this review summarizes the inhibitory effects of natural products against these major porcine enteric viruses. Specifically, it focuses on recent studies regarding the anti-SEVS activities of traditional Chinese medicine (TCM) compound formulas, herbal extracts, pharmaceutical monomers, and natural metabolites. The review elaborates on how these natural products exert antiviral activities against SEVs, highlighting their potential as alternative or complementary agents for controlling porcine enteric viral infections. Overall, this work provides a comprehensive overview of the research progress in natural products against porcine enteric viruses and demonstrates the new strategies for medicine discovery, which will be helpful for further development of effective antiviral strategies in the swine industry.},
}
@article {pmid41643087,
year = {2026},
author = {Di Líbero, E and Duarte, A and Kaneshiro, V and Gañete, M and Aronson, S and López Furst, MJ},
title = {[Management of Community-Acquired Pneumonia in Adults - Argentine Society of Infectious Diseases].},
journal = {Medicina},
volume = {86},
number = {1},
pages = {145-165},
pmid = {41643087},
issn = {1669-9106},
mesh = {Adult ; Humans ; Anti-Bacterial Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Argentina ; *Community-Acquired Pneumonia/drug therapy/diagnosis ; COVID-19 ; Influenza, Human/drug therapy ; },
abstract = {Community-acquired pneumonia (CAP) is responsible for substantial morbidity and mortality worldwide. Epidemiological surveillance indicates that Streptococcus pneumoniae remains the most frequent etiological agent and the leading cause of mortality. However, with the advent of new diagnostic techniques, viral etiology has gained priority. Chest X-ray is considered mandatory to confirm the diagnosis and establish the spread. Microbiological, antigen, molecular, biomarker, and carriage tests have specific indications and a role to play in reconsidering empirical treatments. Severity scales are useful for defining the site of care, and the most validated prognostic models are PSI and CURB-65. When antibacterial treatment is appropriate, aminopenicillins ± beta-lactamase inhibitors are the preferred treatment, with the addition of a macrolide in severe cases. Pseudomonas and methicillin-resistant Staphylococcus aureus should be considered primarily in patients with a history of prior infection/colonization or severe structural lung disease. Shortened courses have gained support in the literature, and once clinical stability is achieved, it is suggested that treatment be continued for 3-5 days for CAP managed in an outpatient/general ward setting, and 5-7 days for CAP requiring intensive care. The role of corticosteroids in reducing mortality has been documented in severe forms. The benefit of neuraminidase inhibitors for influenza is of low certainty and relatively marginal. Treatments that have had an impact on reducing mortality from severe-critical COVID-19 are corticosteroids, IL-6 receptor blockers, and baricitinib.},
}
@article {pmid41643088,
year = {2026},
author = {Beltramino, MF and Gasser, FB and Stassi, AF and Ortega, HH and Baravalle, ME},
title = {[Evaluation of reproductive and developmental toxicity: its importance in the preclinical phase of new vaccines].},
journal = {Medicina},
volume = {86},
number = {1},
pages = {166-178},
pmid = {41643088},
issn = {1669-9106},
mesh = {Animals ; *Reproduction/drug effects ; Drug Evaluation, Preclinical/methods ; Humans ; Female ; *COVID-19 Vaccines/toxicity/adverse effects ; Pregnancy ; COVID-19/prevention &amp; control ; *Vaccines/toxicity ; },
abstract = {Preclinical trials in laboratory animals, particularly those aimed at evaluating potential effects on reproduction and offspring development, have gained importance in recent years due to the development of new drugs and vaccines intended for both children and individuals of reproductive age. The current challenge lies in the need for reliable and rapidly obtainable data to enable the transition of new compounds to clinical phases and eventual approval. Since pregnant and breastfeeding women are often excluded from clinical vaccine trials, including those assessing toxicity, there is limited knowledge about this vulnerable population and their offspring. In this context, preclinical studies designed to assess the effects of vaccine and therapeutic candidates on reproduction and development must rely on in vivo models that accurately replicate key aspects of the pathogenesis observed in human disease. When evaluating the reproductive toxicity of vaccines, it is essential not only to assess potential effects on fertility, embryogenesis, development, and reproduction, but also to consider the interactions of the vaccine with the immune system of both the mother and her offspring. This review updates and describes preclinical studies in laboratory animals for new vaccines, particularly those developed against COVID-19, highlighting published studies on reproductive and developmental toxicity, as well as the current regulatory framework governing such studies.},
}
@article {pmid41643233,
year = {2026},
author = {Anderson, SA and Smith, ER and Wan, Z and Amend, KL and Secora, A and Djibo, DA and Kazemi, K and Song, J and Parlett, LE and Seeger, JD and Selvam, N and McMahill-Walraven, CN and Hu, M and Chillarige, Y and Forshee, RA},
title = {Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.},
journal = {Vaccine},
volume = {75},
number = {},
pages = {128225},
doi = {10.1016/j.vaccine.2026.128225},
pmid = {41643233},
issn = {1873-2518},
mesh = {Humans ; *Seizures, Febrile/epidemiology/etiology ; Child, Preschool ; Male ; United States/epidemiology ; Vaccination/adverse effects ; BNT162 Vaccine/adverse effects ; Female ; *COVID-19/prevention &amp; control ; Incidence ; *2019-nCoV Vaccine mRNA-1273/adverse effects ; SARS-CoV-2/immunology ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage ; },
abstract = {OBJECTIVE: To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2-5 years.<br><br>METHODS: The primary analysis evaluated children who had a febrile seizure outcome in the 0-1&#xa0;days following COVID-19 vaccination. A self-controlled case series analysis was performed in three commercial insurance databases to compare the risk of seizure in the risk interval (0-1&#xa0;days) to a control interval (8-63&#xa0;days). The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA vaccinations. The primary outcome was febrile seizure (0-1&#xa0;day risk interval). A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-analyses were used to pool results across databases.<br><br>RESULTS: The primary meta-analysis found a statistically significant increased incidence of febrile seizure, in the 0-1&#xa0;days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses&#xa0;=&#xa0;3.22 (95% CI -0.31 to 6.75)). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95% CI: 0.48 to 4.11, RD/100,000 doses&#xa0;=&#xa0;-0.25 (95% CI -2.75 to 2.24).<br><br>CONCLUSIONS: Among children aged 2-5&#xa0;years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0-1&#xa0;days following the mRNA-1273 vaccination.},
}
@article {pmid41644038,
year = {2026},
author = {Ogoti, B and Riitho, V and Wildemann, J and Mutono, N and Mureithi, M and Oyugi, J and Rodon, J and Corman, VM and Drosten, C and Thumbi, SM and Müller, MA},
title = {Epidemiology and genomic features of MERS coronavirus in Africa: a systematic and meta-analysis review.},
journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
volume = {165},
number = {},
pages = {108456},
doi = {10.1016/j.ijid.2026.108456},
pmid = {41644038},
issn = {1878-3511},
mesh = {Humans ; *Middle East Respiratory Syndrome Coronavirus/genetics ; Animals ; *Coronavirus Infections/epidemiology/virology/veterinary ; Africa/epidemiology ; Camelus/virology ; Genome, Viral ; Seroepidemiologic Studies ; Phylogeny ; Genomics ; Prevalence ; },
abstract = {OBJECTIVES: We explored factors contributing to the low human MERS-CoV prevalence in Africa by assessing MERS-CoV epidemiological and genomic features.<br><br>METHODS: We followed the PRISMA guidelines. We searched for articles on epidemiological and virological MERS-CoV characteristics in humans and camels in Africa until August 2025. We used a generalised linear mixed-effects model to calculate pooled proportions. We identified relevant polymorphisms in African MERS-CoV lineages compared with the prototypic EMC/2012 and contemporary Arabian MERS-CoV (clade B5).<br><br>RESULTS: We included 53 articles, with 31 used in the meta-analysis. Kenya, Egypt, and Ethiopia contributed to 66.03% of all included studies. Pooled MERS-CoV RNA positivity in African dromedaries was 6.09%, with juveniles (15.29%) having a higher incidence than adults (4.51%). The pooled MERS-CoV seroprevalence was 73.67%, with adults (80.96%) higher than juveniles (36.02%). In human-focused studies, only nine PCR-confirmed MERS cases were reported, six travel-associated and three autochthonous cases, despite a pooled seroprevalence of 2.4%. Genomic analyses identified MERS-CoV clade C-specific polymorphisms in the Spike and accessory genes with putative phenotypic impact.<br><br>CONCLUSION: We found the highest MERS-CoV RNA positivity in young dromedaries. Elevated MERS-CoV seroprevalence in mainly asymptomatic camel-exposed humans suggests an underestimation of MERS-CoV infections in Africa. The ongoing MERS-CoV evolution emphasises the need for active genomic surveillance to monitor signatures of human adaptation.},
}
@article {pmid41644304,
year = {2026},
author = {Fung, IC and Liang, H and Pierce, KJ and Kraay, ANM and Kwok, KO and Akhmetzhanov, AR and Baiden, FE and Unwin, HJT and Kengne, FB and Alhassan, F and Chowell, G},
title = {Excess mortality in Mainland China after the end of the Zero COVID policy: A systematic review.},
journal = {Epidemiology and infection},
volume = {154},
number = {},
pages = {e29},
pmid = {41644304},
issn = {1469-4409},
mesh = {Humans ; China/epidemiology ; *COVID-19/mortality/epidemiology ; Pandemics ; },
abstract = {After the Zero COVID policy ended on December 7, 2022, ~90% of mainland Chinese were infected in a COVID-19 wave. This systematic review synthesized research estimating excess mortality during that wave in mainland China. We searched seven databases in May 2024 and updated our search in July-August 2025. Peer-reviewed research (Chinese or English), published since January 1, 2023, estimating excess deaths in the COVID-19 wave post-Zero-COVID was included. Risk of bias was assessed using a modified Newcastle-Ottawa Scale. Two authors independently conducted abstract screening, full-text review, data extraction, and risk-of-bias assessment. Seven articles were included. Two studies analysed the death records of a town and a district in Shanghai, estimating the excess mortality rates of 153.6% and 174.3%, respectively. Using indirect methods, four studies estimated national excess mortality (range: 0.71-1.87 million). Another study estimated excess mortality in Taiyuan. Studies used diverse methods to estimate excess deaths, resulting in widely varying and uncertain estimates. Choice of reference period, seasonality, and other factors affect expected mortality estimates.},
}
@article {pmid41645649,
year = {2026},
author = {Loubet, P and Fourati, S},
title = {An evaluation of sipavibart for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.},
journal = {Expert review of anti-infective therapy},
volume = {24},
number = {1},
pages = {89-96},
doi = {10.1080/14787210.2026.2624614},
pmid = {41645649},
issn = {1744-8336},
mesh = {Humans ; *COVID-19/prevention &amp; control/immunology ; *SARS-CoV-2/immunology/drug effects ; *Immunocompromised Host ; *Pre-Exposure Prophylaxis/methods ; *Antibodies, Monoclonal/therapeutic use/pharmacology ; Spike Glycoprotein, Coronavirus/immunology ; Animals ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has disproportionately affected immunocompromised individuals, who remain at risk for severe disease despite widespread vaccination efforts. Poor vaccine-induced humoral responses in this population necessitate additional preventive strategies. Sipavibart (AZD3152) is a next-generation long-acting monoclonal antibody designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein and provide broad-spectrum neutralization against divergent variants.<br><br>AREAS COVERED: This review evaluates sipavibart's preclinical pharmacology, pivotal and supportive clinical trial data, and early real-world evidence, including the SUPERNOVA Phase 3 trial and national early-access programs. We discuss its safety profile, variant-specific activity, and resistance challenges.<br><br>EXPERT OPINION: Sipavibart was the first monoclonal antibody to show efficacy and safety in preventing symptomatic COVID-19 among immunocompromised individuals, protecting for up to six months. However, the widespread circulation of variants harboring S:F456L currently limits its clinical utility, and use should be restricted. Maintaining access to Sipavibart remains justified, as future antigenic shifts could restore its activity. Its deployment should rely on genomic surveillance and local epidemiology. At the same time, next-generation mAbs should prioritize conserved spike regions and multi-epitope cocktails to counter viral evolution and prolong therapeutic value.},
}
@article {pmid41646510,
year = {2026},
author = {Melo-Oliveira, MES and Lourenço, RA and Louzada, EB and Moutinho, M and Barbosa, AF and Moreira, VG and Porto, LC},
title = {Systematic Review of Dyspnea and Chronic Fatigue in Patients With Long COVID: Clinical Characteristics and Associated Laboratory Parameters.},
journal = {Pulmonary medicine},
volume = {2026},
number = {},
pages = {5426125},
pmid = {41646510},
issn = {2090-1844},
mesh = {Humans ; *Dyspnea/etiology/physiopathology ; *Fatigue/etiology/physiopathology ; *Fatigue Syndrome, Chronic/etiology/physiopathology ; *Post-Acute COVID-19 Syndrome/complications/physiopathology ; Quality of Life ; },
abstract = {ABSTRACT: Dyspnea and chronic fatigue stand out as prevalent manifestations in the postacute phase of COVID, resulting in substantial adverse effects on patients' quality of life and functional capacity. Although these symptoms have been widely documented, there is no clear consensus on the pathophysiological mechanisms that underlie them. The available literature reveals a dispersion of clinical and laboratory data, and the variability in the methods of assessment of fatigue and dyspnea, as well as in the laboratory variables examined, limits the standardized understanding of this complex condition.<br><br>OBJECTIVE: This study was aimed at identifying and synthesizing the evidence on the main clinical and laboratory characteristics related to dyspnea and fatigue in patients during long COVID from 2021 onwards.<br><br>METHODS: The main databases used to select the studies were PubMed and Medline, also using LitCovid and Embase.<br><br>RESULTS: A total of 42 articles that met the inclusion criteria were included, covering a total population of 30,682 patients diagnosed with COVID-19. The findings underscore the significant impact of long COVID on patients' quality of life, with persistent symptoms such as fatigue and dyspnea affecting a considerable proportion of individuals for durations ranging from 1 to 24 months.<br><br>CONCLUSION: The heterogeneity in research approaches highlights the urgent need for collaborative initiatives to elucidate the determinants of long COVID symptomatology and create more consistent evaluation protocols.},
}
@article {pmid41646984,
year = {2025},
author = {Müller, L and Gebicka, P and Handtke, S and Schönborn, L and Thiele, T},
title = {Advances in our understanding of anti-PF4 related immunothrombosis.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1724207},
pmid = {41646984},
issn = {1664-3224},
mesh = {Humans ; *Platelet Factor 4/immunology ; *Thrombosis/immunology ; *SARS-CoV-2/immunology ; COVID-19/immunology/prevention &amp; control ; Animals ; Blood Platelets/immunology ; *Autoantibodies/immunology/blood ; COVID-19 Vaccines/adverse effects/immunology ; *Thrombocytopenia/immunology ; Platelet Activation/immunology ; Heparin/adverse effects ; },
abstract = {This article focuses on the central role of antibodies against platelet factor 4 (PF4) in mediating immunothrombosis, from classical heparin-induced thrombocytopenia (HIT) to vaccine-induced immune thrombocytopenia and thrombosis (VITT). The latter condition gained international attention during the rollout of vaccines against SARS-CoV-2. Since then, an increased awareness for anti-PF4 mediated disorders arose and patients were recognized with anti-PF4 disorders occurring without prior heparin or adenoviral vector vaccine exposure. These disorders include various acute and chronic VITT-like conditions, i.e. post-viral VITT, diaplacentally transmitted anti-PF4 antibodies in neonatal stroke, monoclonal gammopathies of thrombotic significance (MGTS) and chronic autoimmune VITT of unknown origin. All anti-PF4 related disorders share key serological and immunopathological features with VITT, such as the formation of immune complexes and platelet activation via the Fcγ receptor IIA (FcγRIIA). Via their activation, platelets form procoagulant, aggregatory and secretory phenotypes shaping their interplay with neutrophils, monocytes, and coagulation factors to amplify thrombotic responses. Integrating recent mechanistic insights, clinical observations and diagnostic developments, this review proposes an updated conceptual framework for anti PF4-related immunothrombosis. We aim to raise awareness among clinicians and researchers, to promote early diagnosis and encourage further translational research towards improved therapeutic strategies in this clinically significant area.},
}
@article {pmid41647062,
year = {2025},
author = {Ghorbani Shirkouhi, S and Khatami, SS and Niroomand, Z and Sadigh-Eteghad, S and Yousefzadeh-Chabok, S and Andalib, S},
title = {Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19.},
journal = {Innovations in clinical neuroscience},
volume = {22},
number = {10-12},
pages = {14-23},
pmid = {41647062},
issn = {2158-8333},
abstract = {OBJECTIVE: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a wide range of neurological symptoms and neuropsychiatric conditions. SARS-CoV-2 shows various degrees of neurotropism. SARS-CoV-2 primarily targets respiratory and gastrointestinal tracts; however, it can affect other organs. Neurological and neuropsychological manifestations of COVID-19 have been reported. Several mechanisms are involved in these manifestations in COVID-19. Therefore, the present narrative review will take account of mechanisms underlying the neurological and neuropsychological manifestations in COVID-19.<br><br>METHODS: A literature search for relevant articles in different databases was made with a focus on recent publications for this narrative review.<br><br>RESULTS: Inflammation and thrombosis have been suggested to be mechanisms contributing to these manifestations. Also, renin-angiotensin system (RAS), transmembrane serine protease 2 (TMPRSS2), cathepsin B and L, furin, neuropilin-1 (NRP1), and sterile alpha motif and HD domain-containing protein 1 (SAMHD1) have been proposed to be involved in pathogenesis of SARS-CoV-2. Moreover, cluster of differentiation 147 (CD147) and dipeptidyl peptidase 4 (DPP4) have been suggested to have a role in SARS-CoV-2 entry into the central nervous system (CNS).<br><br>CONCLUSION: Further investigation on the underlying mechanisms leading to SARS-CoV-2-associated neurological and neuropsychological manifestations is pivotal. Insights into these mechanisms will help the treatment strategies for patients with COVID-19 and such manifestations.},
}
@article {pmid41648868,
year = {2026},
author = {Zhu, T and Wang, L and Yan, C},
title = {Local and systemic host responses to influenza and concurrent or sequential SARS-CoV-2 infection.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1725731},
pmid = {41648868},
issn = {2235-2988},
mesh = {Humans ; *Influenza, Human/immunology/pathology/virology/complications ; *Coinfection/immunology/virology/pathology ; SARS-CoV-2 ; *COVID-19/immunology/pathology ; Pandemics ; Lung/pathology/virology/immunology ; Animals ; },
abstract = {Influenza is an acute respiratory infectious disease caused by the influenza virus, which has been circulating in humans for over a century. In contrast, COVID-19, caused by the novel SARS-CoV-2, emerged recently in December 2019. Following nearly four years of pandemic, the acute phase of SARS-CoV-2 has transitioned towards an endemic state, suggesting a trend of long-term coexistence with humans. Concurrent or sequential coinfection with influenza and SARS-CoV-2 has been clinically observed to exacerbate pulmonary pathology and systemic inflammation in affected individuals. This review discusses the impact and elucidates the potential underlying mechanisms by which influenza and SARS-CoV-2 coinfection aggravates local lung injury and systemic host responses, aiming to inform improved prevention and clinical management strategies.},
}
@article {pmid41648943,
year = {2026},
author = {Song, F and Liu, Y and Zhao, Z and Shang, X and Wang, Y and Lai, M and He, M and Chen, Y},
title = {Clinical manifestations, prevalence, and risk factors of asthenopia: a systematic review and meta-analysis.},
journal = {Journal of global health},
volume = {16},
number = {},
pages = {04053},
pmid = {41648943},
issn = {2047-2986},
mesh = {Humans ; *Asthenopia/epidemiology/etiology ; Risk Factors ; Prevalence ; *COVID-19/epidemiology ; },
abstract = {BACKGROUND: This meta-analysis aims to determine the clinical manifestations, prevalence, and risk factors of asthenopia across diverse populations.<br><br>METHODS: We systematically searched PubMed up to April 2024 for studies published within the last five years on asthenopia, without language or design restrictions. Reference lists were also reviewed. The study quality was evaluated using the Newcastle-Ottawa Scale. A random-effects meta-analysis was conducted to calculate proportions, prevalence rates, odds ratios (ORs) and their 95% confidence intervals (CIs).<br><br>RESULTS: Overall, 63 studies were included. The pooled prevalence of asthenopia detected via questionnaires or symptom report was 51% (95% CI&#x2009;=&#x2009;50%, 52%). Subgroup analyses showed high prevalence among digital device users (90%) and computer workers (77%). During the COVID-19 pandemic, prevalence rose among adults (39%-45%), university students (36%-57%), and school-aged children (45%-64%). The most frequent ocular symptoms were eye tiredness (65%, 95% CI&#x2009;=&#x2009;46%, 84%), eye strain (47%, 95% CI&#x2009;=&#x2009;37%, 58%), and burning/irritation (43%, 95% CI&#x2009;=&#x2009;35%, 51%). Musculoskeletal symptoms, including neck pain (45%, 95% CI&#x2009;=&#x2009;28%, 62%) and shoulder pain (30%, 95% CI&#x2009;=&#x2009;12%, 48%) were also prevalent. Neuropsychological symptoms included headache (50%, 95% CI&#x2009;=&#x2009;41%, 59%) and difficulty concentrating (44%, 95% CI&#x2009;=&#x2009;32%, 56%). Risk factors included short sleep duration (OR&#x2009;=&#x2009;1.28; 95% CI&#x2009;=&#x2009;1.04, 1.57), prior eye disease (OR&#x2009;=&#x2009;2.59; 95% CI&#x2009;=&#x2009;1.43, 4.69), prolonged screen time (OR&#x2009;=&#x2009;1.15; 95% CI&#x2009;=&#x2009;1.09, 1.21), and ambient conditions like air conditioning use (OR&#x2009;=&#x2009;23.02; 95% CI&#x2009;=&#x2009;4.94, 107.18). Protective measures included anti-glare filters (OR&#x2009;=&#x2009;0.34; 95% CI&#x2009;=&#x2009;0.19, 0.64), regular breaks (OR&#x2009;=&#x2009;0.21; 95% CI&#x2009;=&#x2009;0.09, 0.51), and computer use knowledge (OR&#x2009;=&#x2009;0.20; 95% CI&#x2009;=&#x2009;0.13, 0.30).<br><br>CONCLUSIONS: Asthenopia is prevalent across diverse populations, characterised by a wide range of symptoms and influenced by modifiable risk factors. Our findings support a unified definition to improve clinical recognition and offer preliminary evidence to help shape future research on preventive strategies.<br><br>REGISTRATION: PROSPERO: CRD42024536841.},
}
@article {pmid41650498,
year = {2026},
author = {Keenan Chong, WH and Dan Ong, WJ and Khan, FA and Sajeed, S and Souza, JD and Kansal, MG and Kansal, A},
title = {Clinical benefits of prolonged versus standard prone positioning in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: A systematic review, meta-analysis, and trial-sequential analysis.},
journal = {Australian critical care : official journal of the Confederation of Australian Critical Care Nurses},
volume = {39},
number = {2},
pages = {101531},
doi = {10.1016/j.aucc.2026.101531},
pmid = {41650498},
issn = {1036-7314},
mesh = {Humans ; Prone Position ; *COVID-19/therapy ; *Respiration, Artificial ; *Respiratory Distress Syndrome/therapy ; *Patient Positioning/methods ; Time Factors ; },
abstract = {OBJECTIVES: The optimal duration of prone positioning for improving outcomes in acute respiratory distress syndrome remains uncertain. This meta-analysis compared clinical outcomes of prolonged versus standard prone positioning in adult coronavirus disease 2019 patients with moderate-to-severe acute respiratory distress syndrome.<br><br>METHODS: PubMed, SCOPUS, and Cochrane databases were systematically searched for randomised controlled trials (RCTs) and observational studies. Prolonged prone positioning was defined as a mean duration >24 h per session and standard as &#x2264; 24 h. Outcomes included mortality, pressure injuries, oxygenation, and respiratory parameters. A trial sequential analysis was conducted for mortality and pressure injuries.<br><br>RESULTS: Seven studies (six observational and one RCT) involving 996 patients (592 prolonged and 404 standard) were included in the study. Prolonged prone positioning showed a nonsignificant trend towards lower mortality (33.8% vs. 39.8%, RR: 0.81, 95% confidence interval: 0.60-1.09; P = 0.16) and a borderline increase in pressure injuries (30.2% vs. 26.2%; relative risk (RR) 1.27, 95% confidence interval: 1.00-1.62; P = 0.05). The trial sequential analysis indicated that current evidence is insufficient to confirm benefit or harm. No significant differences were observed in intensive care unit length of stay (mean difference [MD]: 2.74 days; P = 0.13) or changes in positive end-expiratory pressure or driving pressure in both groups. Oxygenation improved significantly during (partial pressure of arterial oxygen-to-fraction of inspired oxygen ratio MD: 17.42 mmHg; P = 0.003) and after prone positioning (partial pressure of arterial oxygen-to-fraction of inspired oxygen ratio MD: 23.83 mmHg; P = 0.008).<br><br>CONCLUSION: Prolonged prone positioning was associated with trends towards lower mortality and higher frequency of pressure injury risk, but evidence remains inconclusive. While oxygenation improved, clinical outcomes of intensive care unit length of stay and respiratory parameters were unchanged. Additional high-quality RCTs are needed to clarify the balance of benefits and risks and guide future recommendations.},
}
@article {pmid41650532,
year = {2026},
author = {Labied, S and Atifi, F and Wahnou, H and Mabrouk, M and Jeddoub, O and Allaoui, A and Jalali, F and Zaid, Y},
title = {Megakaryocytes and afucosylated IgG in post-acute COVID-19: Bridging immune dysregulation and vascular pathology - A narrative review.},
journal = {Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie},
volume = {196},
number = {},
pages = {119049},
doi = {10.1016/j.biopha.2026.119049},
pmid = {41650532},
issn = {1950-6007},
mesh = {Humans ; *COVID-19/immunology/complications/pathology ; *Megakaryocytes/immunology/pathology ; Post-Acute COVID-19 Syndrome ; *Immunoglobulin G/immunology ; SARS-CoV-2/immunology ; Glycosylation ; Animals ; },
abstract = {Post-acute sequelae of SARS-CoV-2 infection (PASC), also referred to as long COVID, encompasses a constellation of persistent symptoms lasting for at least three months after acute SARS-CoV-2 infection and not explained by alternative diagnoses. The multifactorial pathophysiology underlying PASC remains incompletely understood, limiting the development of effective management strategies. Increasing evidence suggests that both immune dysregulation and hemostatic imbalance play central roles in post-COVID-19 complications. Megakaryocytes, key regulators of platelet production and coagulation, have emerged as potential contributors to sustained thrombo-inflammatory processes following SARS-CoV-2 infection. In parallel, afucosylated IgG antibodies have been strongly implicated in exaggerated immune activation and hyperinflammatory responses during acute COVID-19. The persistence of such antibody glycosylation patterns beyond the acute phase raises the possibility that they may also contribute to chronic immune and vascular alterations observed in PASC. This narrative review explores the potential interplay between megakaryocyte dysfunction and afucosylated IgG antibodies in the pathogenesis of PASC. By examining mechanisms identified during acute SARS-CoV-2 infection, we discuss how prolonged immune-hemostatic crosstalk may promote persistent inflammation, endothelial dysfunction, and microvascular abnormalities. Understanding these interconnected pathways may provide mechanistic insight into the heterogeneity of PASC manifestations and help identify novel therapeutic targets for long-term post-COVID-19 sequelae.},
}
@article {pmid41651428,
year = {2026},
author = {Wang, Y and Zhao, F and Zhao, Q and Du, S and Wen, Y and Wu, R and Cao, S and Cong, F and Huang, X},
title = {Cell entry mechanisms of porcine enteric coronaviruses.},
journal = {The Journal of biological chemistry},
volume = {302},
number = {3},
pages = {111250},
pmid = {41651428},
issn = {1083-351X},
mesh = {Animals ; Swine ; *Coronavirus/physiology ; *Virus Internalization ; Humans ; *Coronavirus Infections/virology ; Transmissible gastroenteritis virus/physiology ; Deltacoronavirus/physiology ; *Swine Diseases/virology ; Porcine epidemic diarrhea virus/physiology ; Alphacoronavirus ; },
abstract = {Porcine enteric coronaviruses, including transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), swine acute diarrhea syndrome coronavirus (SADS-CoV), and porcine deltacoronavirus (PDCoV), cause severe watery diarrhea, vomiting, dehydration, and high mortality in piglets, leading to enormous economic losses in the swine industry worldwide. They have the capability to infect a variety of cell lines from pigs, humans, and other animals, with high risks of interspecies transmission and potential threats to public health. These viruses employ their spike glycoproteins to engage with various receptors, coreceptors, cofactors, and other host factors that further mediate membrane fusion to accomplish the entry process. This review summarizes the recent findings regarding the pathways, receptors, coreceptors, cofactors, and other host factors utilized by TGEV, PEDV, SADS-CoV, and PDCoV for cellular entry. Several important targets for antiviral therapeutics and some key aspects of the entry process for these viruses that await discovery are highlighted. A comprehensive understanding of the entry mechanisms of porcine enteric coronaviruses will provide new insight into the development of novel antiviral therapeutic strategies.},
}
@article {pmid41652425,
year = {2026},
author = {Halder, P and Khaiwal, R and Goel, S and Kumar, N and Sarkar, M and Soni, M and Nongkynrih, B and Prabhakar, MC and Mamgai, A and Rathor, S},
title = {Burden of chronic obstructive pulmonary disease among Indian adults: systematic review and meta‑analysis.},
journal = {BMC pulmonary medicine},
volume = {26},
number = {1},
pages = {},
pmid = {41652425},
issn = {1471-2466},
mesh = {*Pulmonary Disease, Chronic Obstructive/epidemiology/diagnosis ; Humans ; India/epidemiology ; Prevalence ; Spirometry ; Adult ; *Cost of Illness ; },
abstract = {BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a long-standing respiratory illness marked by ongoing airflow obstruction and inflammation. It continues to be a major contributor to global disease, and death, with low- and middle-income countries (LMICs) experiencing a disproportionate impact. India, as one of the largest LMICs, plays a significant role in global COPD-related mortality and disability-adjusted life years (DALYs). In India, COPD continues to be underrecognized owing to limited spirometry availability, inconsistent diagnostic approaches, and weak surveillance systems. Previous prevalence estimates are both outdated and methodologically inconsistent, while the COVID-19 pandemic may have further shifted disease trends. This systematic review and meta-analysis seeks to bridge these gaps by delivering current, standardized, and comprehensive prevalence data. OBJECTIVE: To estimate the pooled prevalence of spirometry-confirmed COPD among Indian adults and identify key demographic and environmental correlates through a systematic review and meta-analysis of observational studies. METHODS: This systematic review and meta-analysis aimed to determine the prevalence of spirometry-confirmed COPD among Indian adults. The study was registered in PROSPERO (CRD420251140678) and conducted in accordance with PRISMA guidelines. Literature searches were carried out in PubMed, EMBASE, Scopus, and Web of Science up to June 9, 2025, using relevant MeSH terms and keywords on COPD, prevalence, and India. Eligible studies included observational designs reporting spirometry-based COPD prevalence in adults; studies relying on non-spirometry diagnosis, qualitative designs, interventions, or non-English publications were excluded. Three reviewers independently screened records, extracted study and population data, and evaluated methodological quality using the Joanna Briggs Institute (JBI) checklist. Pooled prevalence was calculated using a random-effects model. Heterogeneity was assessed with I2 and Cochran’s Q, complemented by Baujat and Galbraith plots. Subgroup and sensitivity analyses examined variations by diagnostic criteria, demographics, and exposures, while publication bias was tested using funnel plots, Egger’s and Begg’s methods, and trim-and-fill analysis. RESULTS: Twenty-three studies comprising 27,319 Indian adults were included. The pooled prevalence of COPD was 13% (95% CI: 9%–18%), with substantial heterogeneity (I2 = 99.8%). Higher prevalence was observed among smokers (37%), elderly adults (≥ 60 years: 27%), males (16%), and biomass fuel users (8%). Studies using GOLD criteria reported a higher prevalence (15%) than those using FEV1/FVC < LLN (10%). Hospital-based studies showed a greater prevalence (27%) than community-based ones (12%). Regional variation was notable, with North India reporting the highest prevalence (19%) and West India the lowest (7%). Sensitivity analyses confirmed the robustness of findings; publication bias was minimal and did not significantly affect pooled estimates. CONCLUSION: COPD remains a significant and underrecognized public health challenge in India. As all included studies were appraised as good quality using the JBI tool, the evidence base is strong and supports reliable pooled estimates. Therefore, our conclusions emphasize the importance of routine spirometry-based screening, targeted interventions for high-risk groups, and integration of COPD surveillance into India’s NCD framework, while reinforcing gender-sensitive strategies and clean fuel initiatives as evidence-based measures to reduce disease burden and guide policy planning.},
}
@article {pmid41653012,
year = {2026},
author = {Asis, A and Rodríguez, A and Reyes, LF and Díaz, E and Nseir, S and Martín-Loeches, I},
title = {The double threat: bacterial and fungal co-/superinfection in viral pneumonia.},
journal = {Expert review of respiratory medicine},
volume = {20},
number = {7},
pages = {847-858},
doi = {10.1080/17476348.2026.2629003},
pmid = {41653012},
issn = {1747-6356},
mesh = {Humans ; *Superinfection/epidemiology/diagnosis/microbiology ; COVID-19 ; *Coinfection/epidemiology/diagnosis ; *Pneumonia, Bacterial/epidemiology/diagnosis ; Influenza, Human/epidemiology ; SARS-CoV-2 ; Pandemics ; Intensive Care Units ; *Pulmonary Aspergillosis/epidemiology/diagnosis ; Antimicrobial Stewardship ; },
abstract = {INTRODUCTION: Respiratory viral pneumonias are a leading cause of severe respiratory failure and intensive care unit (ICU) admission worldwide. Although viral infection itself drives significant morbidity and mortality, secondary bacterial and fungal superinfections represent a critical 'double threat' in critically ill adults, exacerbating lung injury, prolonging organ dysfunction, and complicating antimicrobial management. Experience from the Influenza A (H1N1) pdm09 and SARS-CoV-2 pandemics highlights a persistent mismatch between low documented bacterial co-infection rates and widespread empiric antibiotic exposure, underscoring diagnostic uncertainty and antimicrobial stewardship challenges in the ICU.<br><br>AREAS COVERED: This review examines the epidemiology, immunopathogenesis, and diagnostic approaches to bacterial and fungal superinfection in adult ICU patients with severe viral pneumonia. Evidence is synthesized from large ICU cohorts, pandemic data, and established consensus definitions for influenza- and COVID-19-associated pulmonary aspergillosis (IAPA, CAPA). The review discusses advances in molecular diagnostics, lower respiratory tract sampling, bronchoalveolar lavage - based mycology, and biomarker-guided strategies, with a focused literature search of ICU-specific studies.<br><br>EXPERT OPINION: Bacterial and fungal superinfections, while infrequent, carry substantial clinical impact in severe viral pneumonia. A multimodal, ICU-adapted diagnostic strategy integrating pathogen detection with host-response assessment is essential to support timely therapy, enable antimicrobial de-escalation, and align superinfection management with stewardship principles.},
}
@article {pmid41653115,
year = {2026},
author = {Hu, Q and Mai, Z and Wang, B and Sun, N and Zhu, W and Wang, J and Ge, J and Gao, M},
title = {Trained Immunity Empowers Vaccine Design and Application.},
journal = {ACS infectious diseases},
volume = {12},
number = {3},
pages = {913-936},
doi = {10.1021/acsinfecdis.5c00840},
pmid = {41653115},
issn = {2373-8227},
mesh = {*Trained Immunity ; Humans ; *Vaccine Development/methods ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/immunology ; Animals ; *SARS-CoV-2/immunology ; Adjuvants, Immunologic ; Cross Protection/immunology ; },
abstract = {The COVID-19 pandemic has exposed the limitations of traditional vaccine development models: these approaches rely excessively on pathogen-specific antigen design, feature lengthy development cycles, and struggle to address threats from rapidly mutating pathogens and emerging pathogens. Even before the pandemic, certain traditional vaccines (such as BCG) demonstrated "cross-protection" effects beyond their target diseases. The trained immunity (TRIM) theory offers a promising path to develop broad-spectrum, effective, and durable vaccines. This review summarizes core advances in TRIM within vaccinology, systematically outlining vaccine design strategies based on this concept for the first time. These strategies encompass vaccine-mediated cross-protection, methods to enhance vaccine potency and persistence, pathways to achieve broad-spectrum effects, and regulatory characteristics involving immune recognition, antigen delivery, safety, and tolerability. This study explores the synergistic effects and application prospects of TRIM adjuvants such as β-glucan and Toll-like receptor (TLR) agonists. The impact of transgenerational immune effects on offspring immune function provides a crucial direction for future research. It also highlights current limitations in studies regarding persistence, individual variability, and risks of excessive inflammation. Existing vaccines capable of inducing TRIM will inspire next-generation vaccine development. Innovative applications of this vaccine category can propel the advancement of trained immunity-based vaccines (TIbVs). This review proposes an innovative approach─the "Vaccine Immunity Foundation Hypothesis." This lays the groundwork for designing next-generation vaccines and advancing the clinical translation of TRIM therapies, establishing a theoretical foundation for developing broad-spectrum, highly effective, durable, and safe immune protection strategies.},
}
@article {pmid41653615,
year = {2026},
author = {Honchar, O and Мykhailenko, O and Holovchenko, O and Georgiyants, V},
title = {Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review.},
journal = {Phytomedicine : international journal of phytotherapy and phytopharmacology},
volume = {153},
number = {},
pages = {157880},
doi = {10.1016/j.phymed.2026.157880},
pmid = {41653615},
issn = {1618-095X},
mesh = {*Pelargonium/chemistry ; Humans ; *Plant Extracts/pharmacology/chemistry/therapeutic use ; Ethnopharmacology ; Evidence-Based Medicine ; Phytotherapy ; Respiratory Tract Infections/drug therapy ; Phytochemicals/pharmacology ; Plant Roots/chemistry ; },
abstract = {BACKGROUND: Pelargonium sidoides DC. (Geraniaceae) has a long history of traditional use among indigenous peoples of Southern Africa for treating respiratory and gastrointestinal disorders. Its transformation into the modern pharmaceutical product Umckaloabo (EPs® 7630) exemplifies the transition from traditional medicine to evidence-based therapeutics.<br><br>PURPOSE: To provide a systematic analysis of P. sidoides, spanning from its botanical characteristics and ethnobotanical roots to its development as a regulated phytomedicine. The review focuses on the plant's unique phytochemical profile and provides a detailed synthesis of its molecular and systems-biological mechanisms of action, cultivation sustainability, and clinical efficacy in managing respiratory tract infections.<br><br>STUDY DESIGN AND METHODS: A systematic search was conducted across PubMed, Scopus, and Cochrane Library up to December 2025 following PRISMA guidelines. Sources included scientific articles, pharmacopoeias, patents, and ethnobotanical records in English and Ukrainian.<br><br>RESULTS: The systematic synthesis of identified records characterizes the chemical diversity of P. sidoides, focusing on specialized metabolites such as highly substituted benzopyranones, prodelphinidins, and unique coumarin sulfates. The review discusses modern cultivation practices, sustainability issues, and comparative extraction techniques, while analytical methods such as HPLC, LC-MS, and TLC for standardization are summarized. The pharmacological profile is defined by multi-target activity, encompassing immunomodulatory, antibacterial, and antiviral effects, including studies on SARS-CoV-2 and other respiratory pathogens. Analysis of available clinical data validates the therapeutic use of P. sidoides root preparations for managing acute bronchitis, rhinosinusitis, and tonsillopharyngitis.<br><br>CONCLUSION: This study demonstrates that the integration of P. sidoides into modern healthcare is supported by the synergy between traditional knowledge and molecular and clinical validation. By mapping the developmental trajectory - from wild harvesting to systems-biological evidence - this review identifies P. sidoides as a model for the pharmaceutical translation of ethnobotanical resources into standardized, evidence-based phytomedicines.},
}
@article {pmid41654195,
year = {2026},
author = {Shan, Z and Li, J and Ye, Z and Chen, Y and Chen, J and Chen, Y and Wang, X and Gao, C and Jiang, S and Zhang, N},
title = {Advances in human respiratory organoid models for studying the pathogenesis and intervention strategies of COVID-19.},
journal = {Virologica Sinica},
volume = {41},
number = {1},
pages = {23-34},
pmid = {41654195},
issn = {1995-820X},
mesh = {Humans ; *Organoids/virology/pathology ; SARS-CoV-2 ; *COVID-19 ; *Respiratory System/virology/pathology ; Antiviral Agents/pharmacology ; Microphysiological Systems ; COVID-19 Drug Treatment ; },
abstract = {Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affects multiple organ systems, with the respiratory system being the primary target. Respiratory organoids, which closely mimic the structure and function of the human respiratory tract, have emerged as essential tools for studying SARS-CoV-2 infection. This review summarizes current methods for generating various respiratory organoids, including nasal, tonsil, airway, bronchial, and alveolar organoids, and highlights their application in investigating the mechanism of SARS-CoV-2 infection and evaluating potential therapeutic agents. Meanwhile, this review also introduces respiratory organoid-on-a-chip technology, which can precisely regulate culture conditions and incorporate vascularization and immune cells to enhance physiological complexity, thereby providing crucial support for investigating SARS-CoV-2-induced lung injury, immune responses, and conducting high-throughput drug screening. The aim of this review is to provide valuable insights for further research into the pathogenesis and intervention strategies of COVID-19.},
}
@article {pmid41655454,
year = {2026},
author = {Chen, K and Xu, Q and Li, J and Wu, G and Wu, H and Tie, X and Xu, J and Li, J and Zhang, Y},
title = {Cytokine storm divergence in viral infections of the upper respiratory tract.},
journal = {Cytokine &amp; growth factor reviews},
volume = {88},
number = {},
pages = {108-123},
doi = {10.1016/j.cytogfr.2026.01.008},
pmid = {41655454},
issn = {1879-0305},
mesh = {Humans ; *Cytokine Release Syndrome/immunology/virology ; *Cytokines/immunology ; *Respiratory Tract Infections/immunology/virology ; SARS-CoV-2/immunology ; Animals ; COVID-19/immunology ; *Virus Diseases/immunology ; },
abstract = {Cytokine storm (CS) is a pathological state of dysregulated, hyperactive host immunity that arises in the context of infection, malignancy, or immunotherapy. CS is characterized by the sustained, markedly elevated release of multiple pro-inflammatory mediators, ultimately leading to tissue damage and multi-organ dysfunction. Upper respiratory viral infections, including SARS, MERS, SARS-CoV-2, influenza, adenovirus, and respiratory syncytial virus (RSV), are among the most prominent CS triggers. Inflammatory storms triggered by different pathogens exhibit distinct variations in their cytokine profiles and downstream immune signaling pathways. Underlying comorbidities-such as diabetes, obesity, and cardiovascular disease-together with complications such as coagulopathies and secondary infections, can profoundly alter both the threshold and the magnitude of the cytokine storm. This review systematically compares cytokine profiles elicited by distinct upper respiratory pathogens, with population stratification by age and underlying comorbidities, to clarify how these patterns relate to disease severity and complication risk. Collectively, the available evidence supports a shared inflammatory backbone across respiratory virus-induced cytokine storms, overlaid by pathogen-specific cytokine fingerprints and host-dependent plasticity that shapes clinical trajectories and outcomes.},
}
@article {pmid41656017,
year = {2026},
author = {Temte, JL},
title = {Primary Care Clinics and Surveillance of Infectious Diseases.},
journal = {Primary care},
volume = {53},
number = {1},
pages = {17-29},
doi = {10.1016/j.pop.2025.09.003},
pmid = {41656017},
issn = {1558-299X},
mesh = {Humans ; *Primary Health Care/organization &amp; administration ; Influenza, Human/epidemiology ; *Communicable Diseases/epidemiology ; COVID-19/epidemiology ; Public Health Infrastructure ; },
abstract = {Public health surveillance for infectious diseases is highly compatible with the practice of primary care medicine and is enhanced by contextual and population-based elements when grounded in primary care. Moreover, there have been long and successful partnerships between primary care and public health for influenza monitoring. Surveillance programs can be based on sentinel, laboratory, or mechanistic approaches and need to reflect the needs of clinicians and the realities of the primary care environment. Participation in, and access to, surveillance information improves patient care through situational awareness, improving diagnostic acuity, and improving antimicrobial stewardship.},
}
@article {pmid41656465,
year = {2025},
author = {Kazachinskaia, EI and Zibareva, LN and Kononova, YV and Shestopalov, AM and Voevoda, MI and Chepurnov, AA},
title = {Antiviral Activity of Plant-Based Preparations against SARS-CoV-2 and Herpes Simplex Virus Type 2 In Vitro: A Review of Experimental Findings.},
journal = {Bulletin of experimental biology and medicine},
volume = {180},
number = {1},
pages = {1-10},
pmid = {41656465},
issn = {1573-8221},
mesh = {*Antiviral Agents/pharmacology/chemistry/isolation &amp; purification ; *Plant Extracts/pharmacology/chemistry ; *Herpesvirus 2, Human/drug effects ; *SARS-CoV-2/drug effects ; Humans ; Animals ; Plant Leaves/chemistry ; COVID-19 Drug Treatment ; },
abstract = {We reviewed published data on the efficacy of plant-derived preparations, including the authors' original in vitro findings on the antiviral activity of aqueous and dry ethanol extracts against the RNA virus SARS-CoV-2 and the DNA virus herpes simplex virus type 2 (HSV-2). The study evaluates the activity of an aqueous extract prepared from fermented leaves of Epilobium angustifolium L., as well as dry ethanol extracts obtained from clove spice (Syzygium aromaticum L.), black and green tea (Camellia sinensis L.), leaves of Rhaponticum carthamoides, the basidiomycete fungus chaga (Inonotus obliquus (Ach. ex Pers.) Pil.), and four lichen species: Cetraria islandica L., Usnea L., Pseudevernia furfuracea L., and Cladonia stellaris Opiz. HPLC analysis of several dry ethanol extracts suggests that their antiviral activity may be attributed to polyphenolic compounds and ecdysteroids. These findings may serve as a basis both for the identification of individual bioactive plant-derived compounds and for the development of cost-effective therapeutic or prophylactic agents against COVID-19 and for reducing the recurrence rate of chronic genital herpes.},
}
@article {pmid41656612,
year = {2026},
author = {Gauffin, K},
title = {Who is worthy of protection? Revisiting a theoretical model on the social origins of health inequities during the COVID-19 pandemic.},
journal = {Scandinavian journal of public health},
volume = {54},
number = {4},
pages = {397-408},
pmid = {41656612},
issn = {1651-1905},
mesh = {Humans ; *COVID-19/epidemiology ; *Models, Theoretical ; Socioeconomic Disparities in Health ; *Health Status Disparities ; *Pandemics ; },
abstract = {AIMS: This article examines how the Diderichsen model has been used and adapted in research on health inequalities during COVID-19, and explores how the pandemic has prompted further theoretical development. This review therefore addresses the question of how a well-established theoretical framework has helped researchers understand pandemic-related health inequalities and what opportunities exist for its continued refinement.<br><br>METHODS: A narrative literature review was conducted using Google Scholar, Web of Science, PubMed and Scopus. Included studies cited a key publication presenting the Diderichsen model and addressed COVID-19 as a central topic. After screening 298 articles, 24 were included for full analysis. The studies were categorised by how they engaged with the model - conceptually, empirically or through further development.<br><br>RESULTS: The Diderichsen model was commonly used to frame discussions of health inequality or to interpret pandemic-related disparities in exposure, vulnerability and outcomes. Several studies emphasised occupational and housing-related exposure, class-based comorbidities and the unequal social consequences of COVID-19. A smaller number of studies proposed expanded frameworks, incorporating multilevel and temporal dimensions and introducing new mechanisms related to pandemic responses. These adaptations often focused on migrants, ethnic minorities and other particularly affected groups.<br><br>CONCLUSIONS: The review confirms the ongoing relevance of the Diderichsen model in pandemic health inequality research. It argues that the model can be further strengthened by explicitly incorporating concepts of political decision-making, symbolic recognition and social justice. This would improve its capacity to capture the full complexity of health inequalities in times of crisis.},
}
@article {pmid41656850,
year = {2026},
author = {Hatchett, RJ},
title = {Best Practices in Preparing for the Worst Case.},
journal = {Disaster medicine and public health preparedness},
volume = {20},
number = {},
pages = {e34},
doi = {10.1017/dmp.2025.10201},
pmid = {41656850},
issn = {1938-744X},
mesh = {Humans ; COVID-19/epidemiology/prevention &amp; control ; *Civil Defense/methods/standards/trends ; Pandemic Preparedness ; *Disaster Planning/methods ; Disease Outbreaks/prevention &amp; control ; },
abstract = {The convergence of nuclear and radiological preparedness with epidemic and pandemic response, reveals valuable opportunities for cross-disciplinary learning and capability development. Insights from the extensive career of Dr. C. Norman Coleman illustrate how methodologies from radiation medical countermeasures can inform strategies for managing emerging infectious diseases. While nuclear incidents are infrequent, infectious disease outbreaks occur regularly, underscoring the need for sustained, adaptable capabilities to detect and respond to such threats. To draw on some examples, case studies on the development and deployment of vaccines against filoviruses highlight measurable advances in response speed and efficacy, while persistent challenges related to equitable access to medical countermeasures during public health emergencies can be addressed drawing lessons from the COVID-19 pandemic. Iterative improvement, strategic planning and performance optimization is very important, as is, the value of understanding the structure of a problem to find its solution.},
}
@article {pmid41656855,
year = {2026},
author = {Lazarus, R and Williams, V and Cochrane, H and Rees, S and Seale, H},
title = {Attitudes to vaccine co-administration in adults: A scoping review of qualitative evidence.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2616140},
pmid = {41656855},
issn = {2164-554X},
mesh = {Adult ; Humans ; *Health Knowledge, Attitudes, Practice ; *Vaccination/psychology ; *Vaccines/administration &amp; dosage ; },
abstract = {Providing multiple vaccinations to adults at a single appointment, known as co-administration, could help increase vaccine coverage by making the process more convenient for the public. Despite vaccine co-administration policies, there are many missed opportunities to offer multiple vaccines. A qualitative understanding of the public attitude to co-administration may allow the development of interventions to increase implementation of co-administration policies. We undertook a scoping review following the Joanna Briggs Institute framework to collate the available qualitative literature to identify barriers, and facilitators to vaccine co-administration as well as potential research gaps. We created and used an iterative search strategy to retrieve articles published between 1/10/2010 and 11/12/2024 in three scientific databases. None of the articles retrieved fulfilled the inclusion criteria. There were nine articlesthat used quantitative surveys to measure attitudes, barriers and facilitators. Qualitative studies to understand barriers and facilitators to vaccine co-administration are needed to inform future policy implementation.},
}
@article {pmid41656902,
year = {2026},
author = {Biswas, R and Roy, A and Kayal, T and Basu, S and Ghosh, S and Ramaiah, S and Anbarasu, A},
title = {Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2626088},
pmid = {41656902},
issn = {2164-554X},
mesh = {Humans ; *Immunization, Secondary/methods/trends ; *COVID-19/prevention &amp; control/immunology ; *Immunization Programs ; Global Health ; Vaccination/methods ; COVID-19 Vaccines/immunology ; SARS-CoV-2/immunology ; Influenza, Human/prevention &amp; control/immunology ; Pandemics/prevention &amp; control ; Whooping Cough/prevention &amp; control/immunology ; },
abstract = {The problem of waning immunity is a major global concern of vaccine programs, with immunity against diseases such as COVID-19 (reduction in efficacy by ~25% in six months), pertussis (waning in 4-12 y), and influenza (annual updates needed) expected to decrease with time. While boosters reduce serious results in high-risk categories, these effects are short-term (4-6 months) and encourage global imbalances, where low-income areas lag in primary vaccination (<2%). Computational models have shown that primary vaccination in underserved regions prevents ~60% of hospitalizations worldwide, surpassing booster-focused measures (~47%). To maintain protection, variant-responsive boosters, rapid booster-design pipelines, universal vaccine platforms (including pan-coronavirus vaccines), and equity-based solutions (decentralized production) need to be integrated. Aligning with frameworks like the Immunization Agenda 2030 of the World Health Organization, plans should balance the expansion of high-risk groups while broadening primary access, providing infrastructure investment, and real-time surveillance to address evolving pathogens and systemic disparities.},
}
@article {pmid41657321,
year = {2026},
author = {Zhang, Z and Ong, YH and Yang, B and Fan, B and Yang, YY and Ni, Q},
title = {Chemical engineering strategies to enhance mRNA-LNP stability for therapeutic applications.},
journal = {Biomaterials science},
volume = {14},
number = {6},
pages = {1370-1392},
doi = {10.1039/d5bm01635e},
pmid = {41657321},
issn = {2047-4849},
mesh = {*RNA Stability ; Humans ; *RNA, Messenger/chemistry/genetics/immunology ; *Chemical Engineering/methods ; *COVID-19 Vaccines/chemistry/genetics/immunology ; mRNA Vaccines ; Animals ; COVID-19/prevention &amp; control ; SARS-CoV-2/genetics ; },
abstract = {The inception of mRNA vaccines for COVID-19 has catalyzed a transformative shift in the field of vaccination, offering expeditious, scalable, and potent countermeasures to a global health emergency. Despite significant advances, mRNA remains inherently unstable under physiological conditions due to its susceptibility to degradation by ubiquitous ribonucleases and physicochemical factors, making its storage, transport and clinical application challenging. This review explores the critical determinants influencing mRNA stability and discusses how chemical engineering strategies are suited to enhance mRNA stability, including 5' cap modification, poly(A) tail engineering, optimization of untranslated regions, as well as coding sequence refinements, reversible 2'-OH acylation, the development of circular RNA constructs and self-amplifying RNA systems. We also discuss efforts towards mRNA immunogenicity regulation and advanced mRNA delivery systems, along with progress in storage and transport solutions, which have further contributed to addressing stability concerns. Finally, we discuss the remaining challenges in clinical translation and provide forward-looking perspectives on emerging mRNA-based technologies.},
}
@article {pmid41657453,
year = {2026},
author = {Yang, T and Hu, Y and Bao, Y},
title = {Psychological impact and intervention strategies for unaccompanied patients in pediatric intensive care units: a narrative review.},
journal = {Translational pediatrics},
volume = {15},
number = {1},
pages = {20},
pmid = {41657453},
issn = {2224-4344},
abstract = {BACKGROUND AND OBJECTIVE: The pediatric intensive care unit (PICU) is a high-stress medical environment. Family-Centered Care (FCC), which ensures parental presence and participation, is recognized as the standard of practice to mitigate psychological distress and trauma in critically ill children. However, infection control mandates [most notably during the coronavirus disease 2019 (COVID-19) pandemic] and resource limitations often necessitate restrictive visitation policies, leaving children in an "unaccompanied" state. This separation from parents constitutes a significant deviation from the standard care model and poses a unique psychological risk. A systematic synthesis of the specific psychological impacts of this parental absence and adaptive strategies to effectively intervene within this context remains underdeveloped. This narrative review aims to analyze the primary psychological consequences of parental absence for children in the PICU and to explore the intervention strategies adapted to mitigate these effects.<br><br>METHODS: We reviewed journal articles from the past 15 years (2010-2024) that analyze and discuss the psychological impact and intervention strategies of unaccompanied patients in pediatric intensive care units.<br><br>KEY CONTENT AND FINDINGS: Our analysis indicates that an unaccompanied state is a significant, independent risk factor for psychological morbidity in PICU patients, markedly exacerbating separation anxiety, fear, loneliness, and depressive symptoms, which may also impede physiological recovery. Effective interventions must focus on mitigating the trauma of separation. The core strategy identified is "Virtual Family-Centered Care" (e.g., re-establishing family connection and participation in rounds via video technology). Other critical interventions include alternative socio-emotional support from the healthcare team (especially Child Life Specialists), professional psychological therapies, and environmental optimization to reduce threat perception.<br><br>CONCLUSIONS: We conclude that while parental presence is irreplaceable, PICUs must adopt innovative interventions, particularly technology-assisted virtual connections, to protect the psychological well-being of unaccompanied children whenever visitation is necessarily restricted.},
}
@article {pmid41658241,
year = {2026},
author = {Gil Arias, BS and Blandón Andrade, JC and Sidorov, G and Morales-Ríos, A},
title = {Computational methods for the identification of suicidal ideation: a systematic review.},
journal = {Frontiers in artificial intelligence},
volume = {9},
number = {},
pages = {1704818},
pmid = {41658241},
issn = {2624-8212},
abstract = {INTRODUCTION: Suicide is one of the leading causes of death among young people, to the extent that in many countries it is considered a public health issue. It is important to attempt to reduce the growth of this trend, especially among susceptible individuals, considering that it increased because of the COVID-19 pandemic. Natural language processing (NLP) provides various tools that allow for the analysis of texts to predict the presence of suicidal ideation. This work aims to conduct a systematic literature review to extract the computational techniques for identifying suicidal ideation in texts written in natural language.<br><br>METHODS: The PRISMA 2020 method was used, which was divided into nine phases, and three inclusion criteria and two exclusion criteria were established for the selection of studies. The searches were conducted through high-level academic databases such as Scopus, IEEE Xplore, ACM Digital Library, Springer, and Web of Science. The risk of bias was assessed using AMSTAR 2. Potential biases identified include a lack of linguistic and cultural diversity and the predominance of data from social networks. A narrative synthesis was used to analyze and compare the findings qualitatively.<br><br>RESULTS: In the end, 25 studies related to computational methods for detecting suicidal ideation in texts written in natural language were identified. The techniques mainly focus on transformer-based models such as BERT and hybrid methods, which combine this architecture with neural networks such as CNN and LSTM. There are also approaches with hierarchical attention mechanisms. Some studies employed additional techniques such as feature extraction with TF-IDF and pre-trained embeddings to improve model performance.<br><br>DISCUSSION: Limitations in the evidence include the lack of linguistic and cultural diversity and the predominance of data from social networks. These results indicate that computational techniques have high potential to support early prevention strategies for suicidal ideation. However, expanding the diversity of linguistic contexts and improving understanding of the models among non-experts, such as physicians and other interested individuals, is necessary.},
}
@article {pmid41658735,
year = {2026},
author = {Lakhani, HA and Baidya, OP and Alex, A and Binorkar, SV and Das, D and Hazra, A},
title = {New-Onset and Flare Episodes of Adult-Onset Still's Disease Following COVID-19 Vaccination: A Systematic Review of Published Case Reports.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e100889},
pmid = {41658735},
issn = {2168-8184},
abstract = {This systematic review provides a descriptive synthesis of published case reports documenting new-onset or flare episodes of adult-onset Still's disease (AOSD) temporally occurring after COVID-19 vaccination. A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar identified 13 eligible case reports published between 2020 and 2024. Because all available evidence consisted solely of individual case descriptions without comparator groups, the review followed PRISMA 2020 guidelines and employed qualitative narrative synthesis rather than meta-analysis. Across the included cases, patients consistently presented with hallmark features of AOSD, including high spiking fever, arthritis or arthralgia, markedly elevated ferritin levels, and, in several instances, the characteristic salmon-colored rash. Symptom onset typically occurred within four to fifteen days following vaccination. Although these cases demonstrate recognisable clinical patterns, the absence of denominator data, lack of population-based studies, and inherent publication bias prevent estimation of incidence or risk, and no causal relationship with vaccination can be inferred. All reported patients responded favorably to corticosteroids, with some requiring biologic therapy for disease control. These findings highlight the importance of clinician awareness when evaluating persistent febrile or inflammatory symptoms in recently vaccinated individuals, while emphasising that COVID-19 vaccination remains overwhelmingly safe. Larger registries, pharmacovigilance data, and controlled studies are needed to clarify potential risk factors and guide future revaccination decisions.},
}
@article {pmid41660233,
year = {2026},
author = {Sakkos, A and Saint-John, B and Tyml, T and Myskova, E and Aureli, L and Inman, JL and Snijders, AM and Mouncey, NJ and Mukundan, H and Schulz, F},
title = {Agnostic capture of pathogens for the detection and diagnostics of emerging threats.},
journal = {iScience},
volume = {29},
number = {2},
pages = {114684},
pmid = {41660233},
issn = {2589-0042},
abstract = {The continued emergence of pathogens, whether novel, re-emerging, or engineered, poses a persistent global biosecurity and public health challenge. Recent outbreaks, including COVID-19, Lassa fever, Marburg virus, mpox, and avian influenza, underscore the urgent need for robust systems that enable rapid surveillance, early diagnosis, and timely countermeasures before widespread human transmission occurs. In this article, we focus on early detection technologies and systematically evaluate current diagnostic and sensing modalities. We highlight sequencing and spectroscopy as two complementary approaches capable of providing broad, agnostic detection and rich biological insight. Our analysis emphasizes that scientific innovation alone is insufficient: effective preparedness also requires improved data curation, integration, and sharing to build AI-ready resources that accelerate future responses. We argue for coordinated advances in both technological capabilities and supporting infrastructure to enable the rapid identification and characterization of emerging pathogens and to fully leverage modern science against evolving infectious threats.},
}
@article {pmid41661491,
year = {2026},
author = {Garg, RK and Jain, A and Pandey, S and Paliwal, V and Suresh, V and Singhal, S},
title = {Infection-associated Opsoclonus: A Systematic Review.},
journal = {Cerebellum (London, England)},
volume = {25},
number = {1},
pages = {16},
pmid = {41661491},
issn = {1473-4230},
mesh = {Humans ; *Ocular Motility Disorders/therapy/etiology/diagnosis/epidemiology ; *COVID-19/complications ; *Virus Diseases/complications ; },
abstract = {Opsoclonus is a chaotic, multidirectional eye movement characterized by rapid saccades. We aimed to systematically review infection-associated opsoclonus to define its pathogen spectrum, clinical features, treatments, and outcomes. PRISMA 2020 compliant review, PROSPERO registered (CRD420251161567). PubMed, Embase, Scopus and Google Scholar were searched. All search results were imported into EndNote 21 for deduplication. Two reviewers independently conducted screening and data extraction. Quality was assessed by Murad et al. and Newcastle–Ottawa Scales. In this analysis of 210 published cases of opsoclonus, the mean age was 35 years, with Asia contributing 43% of reports and India being the most frequent reporting country. Most patients were immunocompetent or presumed immunocompetent (78%). Viral infections predominated (63%), led by Severe Acute Respiratory Syndrome Coronavirus 2 (30%), followed by scrub typhus, Human Immunodeficiency Virus, West Nile virus, Borrelia, Epstein–Barr virus, Mycoplasma pneumoniae, and dengue virus. Latency was short, with 62% presenting within two weeks, supporting a para-infectious immune mechanism. Cerebrospinal fluid was normal in 43% and magnetic resonance imaging in 67%, indicating that normal investigations should not delay treatment. Management was mainly immunotherapy-based, with corticosteroids alone (40%) or combined with intravenous immunoglobulin (24%). Outcomes were favourable, with 43% recovering within one week and 41% within eight weeks. Immune mediation was inferred in 78%, a pattern consistently reproduced across sixteen cohort studies. Infection-associated opsoclonus is a treatable neurological syndrome arising from a broad infectious spectrum, predominantly viral. Early diagnosis and prompt immunotherapy are associated with rapid clinical improvement.},
}
@article {pmid41661551,
year = {2026},
author = {Sundaram, ME},
title = {Vaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2607893},
pmid = {41661551},
issn = {2164-554X},
mesh = {Humans ; *Immune Checkpoint Inhibitors/adverse effects/therapeutic use ; *Neoplasms/drug therapy/immunology ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage/immunology ; *Influenza Vaccines/adverse effects/administration &amp; dosage ; COVID-19/prevention &amp; control ; Vaccination/adverse effects ; },
abstract = {Some individuals with cancer may receive immunomodulatory treatment such as immune checkpoint inhibitors (ICIs). ICIs are now part of standard of care for many cancers and have improved survival for cancer patients. However, they are also associated with immune-related adverse events (irAEs), which can affect any organ or system, and can range from mild to severe. It has been hypothesized that vaccination of these individuals could increase the risk of irAEs or other vaccine-associated adverse events. This narrative review of 28 primary research articles presents findings from existing literature on vaccine safety for individuals receiving ICIs, and makes recommendations for future research on this topic. The existing evidence suggests that influenza and COVID-19 vaccines are safe for individuals receiving ICIs and do not pose additional risks of irAEs beyond baseline risks associated with ICI therapy.},
}
@article {pmid41662196,
year = {2026},
author = {Sirohi, A and Trivedi, YV and Katoch, T and Walters, B and Bansal, V and Pahal, S and Jain, R},
title = {The resurgence of Tuberculosis in the United States: Health implications, pathophysiological and clinical insights, emerging trends, strategic responses, and post-COVID-19 challenges.},
journal = {Chronic illness},
volume = {22},
number = {1},
pages = {17-35},
doi = {10.1177/17423953261417345},
pmid = {41662196},
issn = {1745-9206},
mesh = {Humans ; United States/epidemiology ; *COVID-19/epidemiology ; *Tuberculosis/epidemiology/diagnosis/therapy/drug therapy ; Latent Tuberculosis/epidemiology/diagnosis ; Health Services Accessibility ; SARS-CoV-2 ; Socioeconomic Disparities in Health ; Social Stigma ; Antitubercular Agents/therapeutic use ; Social Determinants of Health ; },
abstract = {ObjectivesTo address the challenges of tuberculosis (TB) control in the United States post-COVID-19, focusing on high-risk populations, current diagnostic and treatment strategies, and the importance of addressing clinical and social determinants of health to achieve TB elimination goals.MethodsA review of the latest evidence-based guidelines and literature on TB diagnostics, treatment regimens, and latent TB infection (LTBI) management was conducted. Key public health challenges and interventions targeting socioeconomic disparities, stigma, and healthcare access among high-risk populations were analyzed.ResultsHigh-risk groups, including immigrants and ethnic minorities, continue to bear a disproportionate burden of TB due to socioeconomic disparities and comorbidities. Advancements in diagnostic modalities and treatment regimens offer promising outcomes, but gaps remain in LTBI screening and management. Addressing social determinants, such as healthcare access and stigma, is essential for enhancing TB control efforts.DiscussionEffective TB elimination requires collaborative efforts among healthcare professionals, policymakers, and communities to implement evidence-based strategies. Prioritizing both clinical precision and social interventions is critical for overcoming barriers and achieving national TB control and elimination goals.},
}
@article {pmid41662710,
year = {2026},
author = {Sommer, I and Dobrescu, A and Gadinger, A and Sharifan, A and Pinte, L and Fangmeyer, M and Klerings, I and Gartlehner, G},
title = {Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).},
journal = {Annals of internal medicine},
volume = {179},
number = {4},
pages = {524-534},
doi = {10.7326/ANNALS-25-03691},
pmid = {41662710},
issn = {1539-3704},
mesh = {Humans ; *Antiviral Agents/therapeutic use/adverse effects ; COVID-19 ; SARS-CoV-2 ; *Ambulatory Care ; *COVID-19 Drug Treatment ; Pandemics ; },
abstract = {BACKGROUND: Clinicians and patients need updated information on antiviral treatments for COVID-19.<br><br>PURPOSE: To provide a final update on the benefits and harms of COVID-19 antiviral treatments in adult outpatients.<br><br>DATA SOURCES: Ovid/MEDLINE, Epistemonikos COVID-19 L&#xb7;OVE platform, and iSearch COVID-19 portfolio (22 January 2025); Ovid/MEDLINE (24 September 2025).<br><br>STUDY SELECTION: Two reviewers screened 20% of abstracts and full texts, then single screening. Randomized controlled trials were included for benefits and harms, and cohort studies were included for harms.<br><br>DATA EXTRACTION: One reviewer extracted data and assessed risk of bias and certainty of evidence (CoE); a second reviewer verified.<br><br>DATA SYNTHESIS: Seven studies from the Omicron period were included. 125 mg of ensitrelvir may not reduce time to recovery and may result in no difference in serious adverse events (both low CoE) but may increase adverse events (44.2% vs. 24.8%; low CoE). Molnupiravir probably improves recovery (31.8% vs. 22.6%) and reduces time to recovery (9 vs. 15 median days) and persistent symptoms from 3 to 6 months (8.5% vs. 11.0%), with no effect on mortality, hospitalization, serious adverse events, and adverse events (all moderate CoE). Nirmatrelvir-ritonavir may increase recovery (70.7% vs. 53.6%; low CoE) and reduce time to recovery (no data, P&#x2009;=&#x2009;0.011; low CoE) but probably increases adverse events (1.3% vs. 1.0%; moderate CoE). Simnotrelvir-ritonavir reduces time to recovery (-35.8 median hours; high CoE) and probably increases adverse events (28.9% vs. 21.6%; moderate CoE). There was no difference in recovery between molnupiravir and favipiravir (high CoE) and nirmatrelvir-ritonavir and molnupiravir (low CoE).<br><br>LIMITATION: Evidence for many outcomes is limited.<br><br>CONCLUSION: Three COVID-19 antivirals improved or accelerated recovery, with varying adverse event profiles. Molnupiravir probably offers long-term benefits.<br><br>PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD420251029146; OSF: https://osf.io/ywp6u).},
}
@article {pmid41662713,
year = {2026},
author = {Qaseem, A and Obley, AJ and Yost, J and Abraham, GM and Andrews, RA and Jokela, JA and Miller, MC and Humphrey, LL and , and Haeme, R and Krain, A and Poonacha, T and Saini, SD and Wilt, TJ and Carroll, K and Etxeandia-Ikobaltzeta, I and Harrod, CS and Shamliyan, T and Vigna, C},
title = {Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).},
journal = {Annals of internal medicine},
volume = {179},
number = {4},
pages = {559-563},
doi = {10.7326/ANNALS-25-03766},
pmid = {41662713},
issn = {1539-3704},
mesh = {Humans ; *Antiviral Agents/therapeutic use ; COVID-19 ; *Ambulatory Care ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; Pandemics ; Adult ; United States ; },
abstract = {DESCRIPTION: The American College of Physicians (ACP) maintains living, rapid practice points on antiviral treatment in the outpatient setting for COVID-19.<br><br>METHODS: The Population Health and Medical Science Committee (PHMSC) developed this version 3 based on evidence from a focused update of a living, rapid review conducted by the ACP Center for Evidence Reviews at Cochrane Austria. This version addresses the SARS-CoV-2 Omicron variant and reaffirms previous practice points on the use of antiviral treatments of confirmed COVID-19 in unvaccinated or vaccinated and symptomatic patients in the outpatient setting.<br><br>PRACTICE POINT 1: Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease.<br><br>PRACTICE POINT 2: Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease.<br><br>PRACTICE POINT 3: Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.<br><br>PRACTICE POINT 4: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.<br><br>RETIREMENT FROM LIVING STATUS: The PHMSC is retiring this topic from living status considering that this update and previous surveillance have not yielded important changes to the practice points.},
}
@article {pmid41663803,
year = {2026},
author = {Karimi, F and Rajaie, S and Azari, S and Abbaszadeh, MS and Karimi, Z},
title = {Economic evaluation of direct oral anticoagulants (DOACs) for venous thromboembolism with different etiologies: a systematic review.},
journal = {Health economics review},
volume = {16},
number = {1},
pages = {},
pmid = {41663803},
issn = {2191-1991},
abstract = {BACKGROUND: Venous thromboembolism (VTE) imposes significant clinical and economic burdens. While direct oral anticoagulants (DOACs) offer favorable efficacy and safety, their cost-effectiveness across diverse VTE etiologies remains incompletely synthesized. OBJECTIVE: To systematically evaluate the cost-effectiveness of DOACs versus comparators for VTE management stratified by etiology. METHODS: A PRISMA-compliant systematic search was conducted in MEDLINE, Web of Science, Scopus, and NHS EED (2020–2025). Economic evaluations reporting cost-effectiveness or cost-utility outcomes were included. Study quality was assessed using the Drummond checklist. RESULTS: Twenty studies were included (9 CAT, 3 post-surgical, 6 hospitalized VTE, 2 COVID-19). DOACs were cost-effective or dominant in 18/20 studies. For cancer-associated thrombosis (CAT), DOACs dominated LMWHs and were cost-effective versus placebo (ICERs: $5,794–$11,947/QALY). DOACs were also dominant for post-surgical prophylaxis and in general hospitalized VTE (ICERs: -$1,862/QALY to $125.68/QALY), while rivaroxaban was cost-effective for post-COVID-19 prophylaxis (ICER: $5,386/QALY). CONCLUSION: DOACs, particularly apixaban and rivaroxaban, are an economically dominant strategy for VTE across most etiologies. Their adoption as a first-line therapy can improve patient outcomes while significantly reducing healthcare costs.},
}
@article {pmid41665282,
year = {2026},
author = {Oda, M and Yoshimori, Y and Yamada, T and Amagasa, S and Fukuda, Y},
title = {Health of teleworkers: a scoping review on the assessment of the work-from-home environment.},
journal = {Journal of occupational health},
volume = {68},
number = {1},
pages = {},
pmid = {41665282},
issn = {1348-9585},
mesh = {Humans ; Working Conditions ; *Teleworking ; *Occupational Health ; COVID-19/epidemiology ; SARS-CoV-2 ; Workplace ; },
abstract = {OBJECTIVES: Inappropriate telework environments, including work-from-home (WFH) settings, have been linked to physical and mental health problems. However, no systematic assessment has been conducted regarding the WFH environment (WFH-E). The aim of this study was to clarify the current methods used to assess the WFH-E and its association with health- and work-related outcomes through a scoping review.<br><br>METHODS: We searched PubMed, Web of Science, and Ichushi for literature published since 2010 on WFH-E assessment. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines, assessment methods were summarized using 18 items categorized into 9 domains. Additionally, associations between the WFH-E and health- and work-related outcomes were reviewed.<br><br>RESULTS: Of 1669 articles collected, 37 studies published from 2020 were ultimately included in this review. Thirty-four articles involved subjective assessments, and 9 involved objective assessments. The most frequently assessed item was artificial lighting, followed by thermal conditions and noise. Items such as color, greenery, building materials, and odor were rarely assessed. Most studies showed significant associations between the WFH-E and health- and work-related outcomes.<br><br>CONCLUSIONS: Studies on the WFH-E increased following the COVID-19 pandemic, showing significant associations between the WFH-E and health- and work-related outcomes. However, most assessments were subjective, with objective assessments remaining rare. Additionally, the assessment items were limited and biased, indicating that interior design elements were insufficiently assessed. Developing additional objective and comprehensive methods for assessing the WFH-E is needed.},
}
@article {pmid41665459,
year = {2026},
author = {Gomez Rial, J and Redondo, E and Rivero-Calle, I and Mascarós, E and Ocaña, D and Jimeno, I and Gil, &#xc1; and Linares, M and Onieva-García, M&#xc1; and González-Romo, F and Yuste, J and Martinón-Torres, F},
title = {Immunofitness in the elderly: The role of vaccination in promoting healthy aging.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2624234},
pmid = {41665459},
issn = {2164-554X},
mesh = {Humans ; *Vaccination/methods ; *Immunosenescence/immunology ; *Healthy Aging/immunology ; Aged ; Trained Immunity ; COVID-19 Vaccines/immunology/administration &amp; dosage ; Pneumococcal Vaccines/immunology/administration &amp; dosage ; Influenza Vaccines/immunology ; *Aging/immunology ; Herpes Zoster Vaccine/immunology ; Adjuvants, Immunologic/administration &amp; dosage ; Vaccines/immunology ; COVID-19/prevention &amp; control/immunology ; Respiratory Syncytial Virus Vaccines/immunology ; },
abstract = {Aging reshapes immunity through immunosenescence and inflammaging, increasing susceptibility to infection, exacerbating chronic conditions, and blunting vaccine responses. This review frames "immunofitness" as a practical goal of healthy aging and examines how adult vaccination builds immune resilience. Vaccination strengthens adaptive memory, leverages adjuvants to optimize antigen presentation, and can reprogramme innate cells (trained immunity), yielding heterologous benefits beyond target pathogens. We integrate evidence in older adults for influenza, respiratory syncytial virus, pneumococcal, COVID-19, and recombinant zoster vaccines, including reductions in respiratory events, cardiovascular outcomes, hospitalization, and mortality. We highlight emerging platforms and precision vaccinology to tailor schedules by immune age, comorbidity, and frailty. Integrating routine, age-appropriate vaccination with lifestyle measures is a feasible, high-impact strategy to promote immunofitness.},
}
@article {pmid41665756,
year = {2026},
author = {Karaçam, Z and Ofei, P and Uzunoğlu, G and Güneş Öztürk, G},
title = {The effect of prenatal education on the fear of childbirth: A systematic review and meta-analysis.},
journal = {Archives of women's mental health},
volume = {29},
number = {1},
pages = {37},
pmid = {41665756},
issn = {1435-1102},
mesh = {Humans ; Female ; *Fear/psychology ; Pregnancy ; *Prenatal Education/methods ; *Parturition/psychology ; *Pregnant People/psychology ; COVID-19/epidemiology ; *Prenatal Care ; *Delivery, Obstetric/psychology ; Postpartum Period ; },
abstract = {PURPOSE: To evaluate the effect of prenatal education on the fear of childbirth among pregnant women based on previously conducted studies.<br><br>METHODS: A systematic review and meta-analysis of randomized controlled trials and quasi-experimental studies was conducted following the PRISMA guidelines. The data were pooled through meta-analysis. ROBINS-I and RoB2 were used to assess the quality of the studies. The GRADE approach was used for evaluating the certainty of evidence.<br><br>RESULTS: The meta-analysis included 28 studies and the total sample size of the studies was 3073. The results showed that statistically, prenatal education significantly reduced the fear of childbirth during both the antepartum and postpartum period (SMD: -1.12, z&#x2009;=&#x2009;9.14, p&#x2009;<&#x2009;0.001; MD: -24.35, z&#x2009;=&#x2009;6.18, p&#x2009;<&#x2009;0.001 respectively). The meta-regression performed indicated that the study design, the course of the COVID-19 pandemic, data collection tools, the countries of the studies and features of education had no effect on the results of fear of childbirth in pregnancy. Moreover, the meta-analyses showed that prenatal education increased the likelihood of vaginal birth and the preference for vaginal birth approximately by two times and three times respectively (OR: 2.00, z&#x2009;=&#x2009;4.82, p&#x2009;<&#x2009;0.001; OR: 2.87, z&#x2009;=&#x2009;3.89, p&#x2009;=&#x2009;0.001 respectively). The certainty of evidence was low for fear of childbirth during pregnancy, moderate for fear of childbirth in the postpartum period and high for vaginal birth and preference for vaginal birth.<br><br>CONCLUSION: This study revealed that prenatal education was effective for reducing the fear of childbirth and therefore, increasing vaginal births.<br><br>REGISTRATION NUMBER: CCRD42022378547.},
}
@article {pmid41666787,
year = {2026},
author = {Cao, Q and Du, S and Yang, K and Liu, M and Xiao, L and Wang, Q and Fu, J and Zhu, H},
title = {Assessing the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive techniques outcomes: an umbrella review.},
journal = {Vaccine},
volume = {76},
number = {},
pages = {128293},
doi = {10.1016/j.vaccine.2026.128293},
pmid = {41666787},
issn = {1873-2518},
mesh = {Humans ; *COVID-19/prevention &amp; control/complications ; Male ; Female ; *Fertility ; Pregnancy ; *Reproductive Techniques, Assisted/statistics &amp; numerical data ; *COVID-19 Vaccines/adverse effects/administration &amp; dosage ; *Vaccination/adverse effects ; SARS-CoV-2 ; Semen Analysis ; Sperm Count ; Sperm Motility ; },
abstract = {OBJECTIVE: To assess the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive technology (ART) outcomes.<br><br>STUDY DESIGN: This is an Umbrella Review of Meta-analyses. We searched major databases until December 30, 2023. The quality of evidence was assessed by a Measurement Tool to Assess Systematic Reviews and the Grading of Recommendations, Assessment, Development and Evaluation.<br><br>RESULTS: Of 647 studies identified, 14 studies with 40 outcomes were included. COVID-19 infection may decrease semen quality in men, including semen volume (WMD, -0.48&#xa0;ml; 95% CI, -0.59 to -0.36&#xa0;ml), total sperm count (WMD, -34.84&#xa0;&#xd7;&#xa0;10^6; 95% CI, -43.51 to -26.17&#xa0;&#xd7;&#xa0;10^6), sperm concentration (WMD, -16.23&#xa0;&#xd7;&#xa0;10^6/ml; 95% CI, -25.56&#xa0;&#xd7;&#xa0;10^6 to -6.89&#xa0;&#xd7;&#xa0;10^6), viability (SMD, -0.66; 95% CI, -1.27 to -0.06), and total sperm motility (SMD, -0.61; 95% CI, -0.96 to -0.25), and elevated levels of estradiol (SMD 0.652; 95% CI, 0.254 to 1.049; p&#xa0;=&#xa0;0.001) and prolactin (SMD 0.305; 95% CI, 0.045 to 0.566; p&#xa0;=&#xa0;0.022). However, it did not significantly affect testosterone levels. Notably, even after recovery (over 90&#xa0;days), sperm concentration and motility remained lower compared to uninfected individuals. Conversely, COVID-19 showed minimal impact on female ovarian reserve (including antral follicle count, AMH) or ART outcomes (including oocyte number and quality, embryo quality, implantation rates, clinical pregnancy rates and miscarriage rates). Vaccination also had minimal effects on both sexes. Evidence quality was generally very low, highlighting the need for high-quality, long-term studies.<br><br>CONCLUSION: SARS-CoV-2 infection primarily affects male fertility, leading to reductions in sperm quality, count, and motility. However, female fertility and ART outcomes show little to no impact. COVID-19 vaccination shows minimal impact on fertility and ART outcomes. The quality of evidence is rated as very low to low. High-quality prospective studies with longer follow-up periods are needed.},
}
@article {pmid41666990,
year = {2026},
author = {Mahroum, N and Elsalti, A and Alsharif, M and Jabri, A and Ouban, A},
title = {Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19.},
journal = {Autoimmunity reviews},
volume = {25},
number = {3},
pages = {104002},
doi = {10.1016/j.autrev.2026.104002},
pmid = {41666990},
issn = {1873-0183},
mesh = {Humans ; *Immune Checkpoint Inhibitors/adverse effects/therapeutic use ; *Autoimmune Diseases/epidemiology/immunology ; *COVID-19/immunology/epidemiology/complications ; *Autoimmunity/drug effects ; *SARS-CoV-2/immunology ; Female ; *Neoplasms/drug therapy/immunology ; COVID-19 Drug Treatment ; },
abstract = {Immune checkpoint inhibitors (ICIs) have markedly improved the prognosis of previously fatal malignancies, as evidenced by substantial gains in overall and progression-free survival in multiple clinical trials. The mechanism of action of ICIs is based on altering the immune response while the reported side effects display clear autoimmune features. Designated as immune-related adverse events (irAEs) affect nearly every organ system, including the gastrointestinal tract, liver, and thyroid gland, and share features with autoimmune disorders of the same organs. The severity of irAEs ranges from mild to life-threatening reactions. Many cases require systemic corticosteroids, hospitalization, and in many instances the discontinuation of ICI therapy. In this review, we present the history of ICIs, their indications, and the reported irAEs in a systematic manner. We then focus on the autoimmune nature of these side effects, with particular attention to the epidemiology of autoimmune diseases, including their female preponderance in certain age groups. In the final sections, we discuss how irAEs may be altering the epidemiology of autoimmune disease and address the possible effect of COVID-19 as a potential trigger.},
}
@article {pmid41668135,
year = {2026},
author = {Mayers, T and Terunuma, Y and Inokuchi, R and Guantai, F and Ring, HZ and Akashi, J},
title = {Barriers and facilitators to healthcare access for refugee, immigrant, and migrant populations during the COVID-19 pandemic: an overview of reviews.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {41668135},
issn = {1472-6963},
mesh = {Humans ; *COVID-19/epidemiology ; *Health Services Accessibility ; *Refugees/statistics &amp; numerical data ; *Emigrants and Immigrants/statistics &amp; numerical data ; *Transients and Migrants/statistics &amp; numerical data ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Refugee, immigrant, and migrant (RIM) populations experienced unique obstacles to healthcare during the COVID-19 pandemic. Already facing displacement, insecure legal status, and economic instability, RIM populations were further affected by service disruptions, discrimination, and systemic weaknesses. The objective of this overview of reviews was to synthesize evidence on barriers and facilitators to healthcare access for RIM populations during the COVID-19 pandemic. METHODS: This review followed the PRISMA 2020 guidelines and the protocol was registered in PROSPERO (CRD42024552590). Systematic searches of Embase, CINAHL, MEDLINE, PubMed, CENTRAL, Web of Science, and Google Scholar (January 2020 onward) identified systematic reviews addressing healthcare access for RIM during COVID-19. Two reviewers independently screened studies, extracted data, and assessed methodological quality using AMSTAR 2. Narrative synthesis was used to categorize barriers and facilitators into cross-cutting domains following a socio-ecological model framework. RESULTS: Nine systematic reviews (published 2021–2024) met inclusion criteria, encompassing 14–256 primary studies each, and spanning low-, middle-, and high-income settings across the Americas, Europe, Africa, the Middle East, and Asia. Nine interacting domains of barriers and facilitators emerged involving legal constraints, economic concerns, service provision, physical and digital access, trust and confidence, information and communication, cultural and social influences, psychological and perceptual factors, and structural/systemic weaknesses. Common barriers included fear of deportation, exclusion from national health or social protection systems, job and income loss, high direct and indirect costs, service closures, overcrowded housing, discrimination, and misinformation. Facilitators included suspension of exclusionary policies, telemedicine and digital tools, mobile clinics, multilingual and culturally appropriate communication, messaging from trusted clinicians and community leaders, and civil society engagement. CONCLUSIONS: This overview shows that the pandemic both intensified long-standing barriers and prompted innovative solutions for RIM healthcare access. Lessons from the pandemic can help guide future sustainable, inclusive health systems for displaced populations.},
}
@article {pmid41668138,
year = {2026},
author = {Parks, OB and Kalavacharla, A and Williams, JV},
title = {Respiratory virus immune response in the aged host.},
journal = {Immunity &amp; ageing : I &amp; A},
volume = {23},
number = {1},
pages = {10},
pmid = {41668138},
issn = {1742-4933},
support = {R21 AI180460/AI/NIAID NIH HHS/United States ; R01 AI085062/AI/NIAID NIH HHS/United States ; F30 HL159915/HL/NHLBI NIH HHS/United States ; HL159915/HL/NHLBI NIH HHS/United States ; AI085062//National Institute of Allergy and Infectious Diseases/ ; T32 GM008208/GM/NIGMS NIH HHS/United States ; },
abstract = {Viruses are a major cause of acute respiratory illness in older adults and pose a substantial burden as the elderly population continues to grow. In the current COVID-19 global health crisis, achieving a better understanding of the aging immune system proves to be an imperative step in preventing and treating respiratory viral infections in older patients. Furthermore, many common respiratory viruses infecting older adults, including human metapneumovirus and parainfluenza virus, do not have licensed vaccines, thereby increasing the risk of severe infection in the aged host. Moreover, given the slowed immune response of older adults, vaccine efficacy for respiratory viruses such as influenza in older adults is minimal, indicating the need to develop more potent vaccines. A better understanding of the aging immune system would allow vaccines to target immunological deficits in the aged host. Three aspects of the aging immune system affect the response to respiratory viruses and vaccines: [1] innate immunity [2], the “inflammaging” hypothesis, and [3] the adaptive immune response. Several innate immune cells (neutrophils, macrophages, dendritic cells, and natural killer cells) as well as adaptive immune cells (T and B lymphocytes) exhibit significant functional impairment in older adults. The inflammaging hypothesis bridges the innate and adaptive arms of the immune system. This review aims to consolidate current knowledge and fill gaps in our understanding of the aged immune response to respiratory viruses.},
}
@article {pmid41668155,
year = {2026},
author = {Tiwary, P and Oswal, K and Tzvetkov, NT and Litvinova, O and Atanasov, AG and Varghese, R},
title = {Travel microbiota: a novel frontier in travel medicine exploring microbial shifts across transportation modes.},
journal = {Tropical diseases, travel medicine and vaccines},
volume = {12},
number = {1},
pages = {9},
pmid = {41668155},
issn = {2055-0936},
abstract = {BACKGROUND: Between 2010 and 2019, international travel increased by approximately 52.2%, highlighting the world's dependence on transportation for global connectivity. Although travel enhances global interactions, it also poses risks to public health through the potential transmission of diseases. The rapid global transmission of infectious diseases, exemplified by the outbreaks of COVID-19 and Zika virus, underscores the critical need for in-depth research into travel-associated disease dissemination. When individuals travel, they are exposed to a variety of diverse microbial environments, which can affect their healthy microbiome. In this review, we introduce the concept of "travel microbiota" to encapsulate the dynamic shifts in human microbial communities induced by travel across different transportation modes. This disruption can affect metabolic and immune functions and potentially facilitate the spread of diseases. Given these implications, it is crucial to investigate how different modes of transportation affect the human microbiota. Our study reviews the impact of travel on the human microbiota, highlighting differences across transportation modes. The objective is to establish a framework for understanding travel health and the role of microbiota in managing travel-related health risks. A comprehensive understanding of this relationship is essential for developing preventive strategies to safeguard and restore the human microbiota.<br><br>METHODS: To provide the specific content, relevant publications were identified on Google Scholar, PubMed, and Science Direct using specific keywords such as dysbiosis, gut, health, microbiome, microbiota, pathogens, travel, and transportation. We did not add any limits to the publication date during the inclusion of papers. However, it is noteworthy that the initial reports, including the aforementioned keywords, have been published starting from 2015.<br><br>CONCLUSION: Travel has a profound impact on the human microbiota, and it is essential to consider the implications associated with various modes of transportation. Traveling through various modes of transportation, such as roadways, airways, and maritime, has significantly influenced human microbiota. Moreover, it acts as a dynamic interface for microbial exchange driving rapid shift in microbial diversity, community convergence, and the diversification of resistant genes. However, the underlying mechanism of these changes remains elusive. By integrating evidence across multiple modes of transportation, this review highlights travel as an underrecognized determinant of microbiome variability and introduces the term "Travel microbiota". Moreover, this review is pivotal for understanding the ways in which travel alters microbial diversity and developing effective interventions. It is imperative to conduct future research that focuses on conducting large-scale longitudinal studies to assess the effects of traveling on microbial composition and to develop potential preventive measures.},
}
@article {pmid41668172,
year = {2026},
author = {Kim, DY and Youn, J and Kang, N and Cho, SI and Ha, IH},
title = {Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review.},
journal = {Journal of translational medicine},
volume = {24},
number = {1},
pages = {},
pmid = {41668172},
issn = {1479-5876},
mesh = {Humans ; *COVID-19/therapy/complications ; *Fatigue Syndrome, Chronic/therapy/physiopathology ; Post-Acute COVID-19 Syndrome ; Electroacupuncture ; *Brain-Gut Axis/physiology ; SARS-CoV-2 ; Adult ; *Brain ; Female ; Male ; Middle Aged ; },
abstract = {BACKGROUND: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID share clinical features including persistent fatigue, post-exertional malaise (PEM), and gastrointestinal (GI) dysfunction. Growing evidence implicates brain-gut axis dysregulation, characterized by dysbiosis, neuroinflammation within the central nervous system (CNS), increased intestinal permeability, and microbial translocation in their pathophysiology. However, therapeutic strategies targeting these pathways remain poorly defined.<br><br>METHODS: We report a case of post-COVID ME/CFS successfully treated with electroacupuncture (EA)-based deep peroneal nerve stimulation which was employed to potentiate the vagal reflex. Fatigue trajectories were assessed using the Multidimensional Fatigue Inventory over 12&#x2009;weeks. Based on the case, a systematic review of randomized controlled trials (RCTs) evaluating brain-gut axis-modulating interventions in ME/CFS or Long COVID was conducted.<br><br>RESULTS: The patient exhibited a significant reduction in total fatigue, with early improvements in motivation and mental fatigue, and delayed improvement in physical fatigue following transient systemic symptom flares. Across included RCTs (n&#x2009;=&#x2009;8, 790 participants), four investigated gut microbiome-modulating therapies and four employed nerve stimulation. Synbiotic and herbal interventions demonstrated benefits for fatigue or PEM, accompanied by alterations in specific bacterial populations or CNS metabolisms. Regarding nerve stimulation, transcranial direct current stimulation (tDCS) combined with exercise program improved fatigue, whereas standalone tDCS, auricular or peripheral TENS showed limited efficacy.<br><br>CONCLUSION: Brain-gut axis-based interventions may alleviate fatigue in ME/CFS and Long COVID by potentially modulating neuroinflammation, restoring microbiome balance, and improving epithelial barrier function. EA-based vagal stimulation represents a feasible option for patients with severe or treatment-resistant symptoms. Larger mechanistic studies and rigorously designed RCTs are needed to establish therapeutic targets and optimize intervention strategies.},
}
@article {pmid41671715,
year = {2026},
author = {Antunez Martinez, OF and Vallejo Bustamante, YI and Varela Zuniga, NO},
title = {Mapping the advanced practice nursing in emergency and intensive care units: A scoping review.},
journal = {International emergency nursing},
volume = {85},
number = {},
pages = {101764},
doi = {10.1016/j.ienj.2026.101764},
pmid = {41671715},
issn = {1878-013X},
mesh = {Humans ; *Advanced Practice Nursing/methods ; *Intensive Care Units/organization &amp; administration ; *Nurse's Role ; *Emergency Service, Hospital/organization &amp; administration ; Clinical Competence ; Leadership ; Nurse Practitioners ; },
abstract = {BACKGROUND: Advanced Practice Nurses (APNs), including Nurse Practitioners and Clinical Nurse Specialists, contribute significantly to quality, efficiency, and leadership in emergency departments (EDs) and intensive care units (ICUs). However, role variability, inconsistent regulation, and limited post-pandemic evidence remain challenges.<br><br>PURPOSE: To synthesize recent global evidence on APN roles, competencies, outcomes, and implementation challenges in EDs and ICUs, and identify strategies for effective integration.<br><br>METHOD: A scoping review, following Arksey and O'Malley's framework and PRISMA-ScR guidelines, searched six databases. Eligible sources focused on APNs in EDs or ICUs. Two reviewers independently screened, extracted, and synthesized data descriptively and thematically.<br><br>FINDINGS: Twenty-five studies were included, showing APNs' main competences as advanced clinical reasoning, procedural skills, leadership, and evidence-based practice. Challenges involved role ambiguity, regulatory gaps, and limited autonomy. Post-COVID-19 developments expanded APN responsibilities but exposed workforce and educational gaps. Solutions proposed included standardized competencies, policy reform, postgraduate education, and interprofessional collaboration.<br><br>CONCLUSIONS: APNs enhance outcomes and efficiency in EDs and ICUs, but variability in role definitions limits impact. The current body of evidence surrounding APN practice in ICUs and EDs is primarily based on studies with low levels of evidence. Future implementation should be accompanied by rigorous evaluations to generate robust statistical evidence that supports the transferability of APN-led models.},
}
@article {pmid41672424,
year = {2026},
author = {Gracidas, C and Levy, R and Varon, J and Halma, M},
title = {Lactate, Capnia, and Fat Oxidation as Therapeutic Axes for SARS-CoV-2 Spike Protein-Induced Sequelae.},
journal = {Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme},
volume = {58},
number = {3},
pages = {90-102},
doi = {10.1055/a-2794-9646},
pmid = {41672424},
issn = {1439-4286},
mesh = {Humans ; Oxidation-Reduction ; *COVID-19/metabolism ; *Lactic Acid/metabolism ; *Spike Glycoprotein, Coronavirus/metabolism ; Post-Acute COVID-19 Syndrome ; *SARS-CoV-2/metabolism ; *Carbon Dioxide/metabolism ; Lipid Metabolism ; *Fatty Acids/metabolism ; Energy Metabolism ; },
abstract = {Metabolic alterations characterize a large subset of those with post-acute COVID-19 syndrome, and similar symptoms affect those with post-acute COVID-19 vaccination syndrome. These symptoms are characterized by the triumvirate of post-acute COVID-19 (vaccination) syndrome symptoms: post-exertional malaise, fatigue, and cognitive impairment, commonly referred to as brain fog. These symptoms can be recreated through perturbations that disrupt mitochondria, and spike protein has been observed to disrupt mitochondria in vitro, providing mechanistic support for this relationship. Post-acute COVID-19 (vaccination) syndrome patients suffer from a severely decreased lactate threshold and can experience symptoms of overexertion even at low power output. Furthermore, biopsies have revealed disrupted mitochondria, and energetics and physiological studies have shown that lipid oxidation constitutes a significantly reduced fraction of total energy production/consumption in post-acute COVID-19 (vaccination) syndrome patients. This review explores the therapeutic axes of lactate, carbon dioxide, and fatty acid oxidation for resolving the energy production challenges in post-acute COVID-19 (vaccination) syndrome, suggesting interventions that increase the lactate threshold, increase tissue oxygenation (paradoxically through increasing partial pressure of CO2), and increase the rates at which lipids are oxidized relative to carbohydrates. Analogies from the world of exercise science are introduced, comparing post-acute COVID-19 (vaccination) syndrome to an overabundance of fast-twitch muscle fibers, with oxygenation similar to that experienced at high altitude, and presenting as an inverse 'fat adaptation' phenomenon, as observed in endurance athletes, especially those adopting low-carbohydrate diets.},
}
@article {pmid41673122,
year = {2026},
author = {Pan, Q and Wang, W and Janssen, HLA and Zhong, Z},
title = {Status and outlook of mRNA therapeutics for viral diseases.},
journal = {EMBO molecular medicine},
volume = {18},
number = {3},
pages = {861-872},
pmid = {41673122},
issn = {1757-4684},
support = {12K0323N//Fonds Wetenschappelijk Onderzoek (FWO)/ ; 91719300//ZonMw (Netherlands Organisation for Health Research and Development)/ ; },
mesh = {Humans ; *Virus Diseases/therapy ; *RNA, Messenger/therapeutic use/genetics ; Animals ; SARS-CoV-2/genetics ; COVID-19/therapy/immunology ; Antiviral Agents/therapeutic use ; },
abstract = {Endemic and emerging viral diseases continue to impose significant health, economic, and societal burdens worldwide. Vaccines and therapeutics represent two key pillars in the fight against these threats. Since the clinical success of mRNA vaccines during the COVID-19 pandemic, mRNA therapeutics have rapidly evolved from a niche innovation into a validated and versatile medical platform. While early efforts focused primarily on vaccine development, recent advances have expanded the scope to antiviral applications of in vitro-transcribed mRNA. Emerging strategies include in vivo expression of neutralizing antibodies for passive immunization, delivery of innate immune effectors such as interferons and antiviral peptides, and programmable CRISPR-based antiviral systems. In parallel, progress in mRNA delivery technologies has enabled clinical translation, although challenges related to stability, specificity, and immunogenicity remain. In this Perspective article, we review recent preclinical and clinical advances in mRNA therapeutics for viral infections. We also highlight key scientific, technical, and regulatory challenges, and propose strategic solutions to address the pressing need for controlling endemic viral diseases and enhancing global pandemic preparedness.},
}
@article {pmid41673927,
year = {2026},
author = {Gasmi, M and Torabinasab, K and Williams-Hooker, R and Marsigliante, S and Muscella, A},
title = {The neutrophil-to-lymphocyte ratio as a marker of immunosenescence and COVID-19 outcomes in the elderly: A narrative review.},
journal = {Physiological reports},
volume = {14},
number = {3},
pages = {e70682},
pmid = {41673927},
issn = {2051-817X},
mesh = {Humans ; *Immunosenescence ; *COVID-19/immunology/blood ; *Neutrophils/immunology ; *Lymphocytes/immunology ; Biomarkers/blood ; Aged ; *Aging/immunology ; SARS-CoV-2 ; Lymphopenia/immunology/blood ; },
abstract = {Older adults are highly vulnerable to severe COVID-19. Unlike our previous work on broad immunosenescence, this review focuses on peripheral hematological markers as practical indicators of risk. To examine lymphopenia, neutrophilia, and the neutrophil-to-lymphocyte ratio (NLR) as clinically accessible markers of immune aging and COVID-19 severity in older adults. Literature search of PubMed, Scopus, and Web of Science (up to 2025) for studies on aging, immunosenescence, lymphopenia, neutrophilia, NLR, and COVID-19. These markers consistently correlate with worse COVID-19 outcomes; NLR is a simple, reliable indicator of immune dysregulation, systemic inflammation, and mortality risk. Lymphopenia, neutrophilia, and elevated NLR are low-cost, readily measurable markers associated with COVID-19 severity, highlighting their prognostic value and complementing prior immunosenescence research.},
}
@article {pmid41674460,
year = {2026},
author = {McTiernan, K and Hughes, C and Gilheaney, &#xd3;},
title = {Cognitive Communication, Voice and Swallowing Difficulties Experienced by Adults With Long-COVID: A Scoping Review.},
journal = {Health expectations : an international journal of public participation in health care and health policy},
volume = {29},
number = {1},
pages = {e70595},
pmid = {41674460},
issn = {1369-7625},
mesh = {Adult ; Humans ; *Communication Disorders/etiology ; COVID-19/complications ; *Deglutition Disorders/etiology ; Pandemics ; *Post-Acute COVID-19 Syndrome/pathology ; SARS-CoV-2 ; *Voice Disorders/etiology ; },
abstract = {BACKGROUND: Adults with Long-COVID frequently experience impairments in cognitive-communication, voice and swallowing, however, few comprehensive reviews of the existing literature has yet to be conducted to map the current research landscape. To go some way toward addressing this gap, this scoping review collected and analysed relevant published studies to identify reported symptoms related to cognitive communication, voice and swallowing in post COVID-19 patients and the assessments used to identify these difficulties.<br><br>OBJECTIVE: This study aimed to systematically map the existing literature on cognitive-communication, voice and swallowing difficulties in individuals living with Long-COVID and the assessments used to identify these difficulties.<br><br>METHODS: Four databases were searched to identify original research articles aligned with the study's objectives. Studies meeting the inclusion criteria were selected, and the findings were analysed with a specific focus on three key symptom domains: cognitive-communication, voice and swallowing.<br><br>RESULTS: Nineteen studies met the inclusion criteria. A broad range of assessments were used, and a broad range of symptoms were identified related to cognitive-communication, voice and swallowing difficulties in patients with Long-COVID-19. The symptoms reported most frequently in the selected studies included memory deficits, incomplete or inefficient glottic closure, paradoxical vocal fold motion during inspiration, episodes of choking, globus sensation, premature spillage and pyriform sinus residue.<br><br>CONCLUSION: Despite limited prior research in this area, the findings underscore the significant impact that COVID-19 infection may have on cognitive communication, voice and swallowing functions. Post-COVID-19 patients report a wide array of challenges in these domains. As a result, further clinical research is essential to develop patient-centred care strategies and to equip healthcare professionals with the expertise required for effective management of this group of patients.},
}
@article {pmid41675121,
year = {2026},
author = {Elizabeth, L and Shanthi, B and Cherupanakkal, C and Joseph, JJ and Anirudhan, A and Vaidyanathan, K},
title = {Exploring the Interplay Between Micronutrients and Cytokine Storm in Children with Multisystem Inflammatory Syndrome: 'A Potential Mechanical Insight'.},
journal = {Indian journal of clinical biochemistry : IJCB},
volume = {41},
number = {1},
pages = {5-16},
pmid = {41675121},
issn = {0970-1915},
abstract = {Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition linked to SARS-CoV-2 infection. MIS-C is characterized by inflammation in several organ systems, including the heart, lungs, kidneys, brain, skin, and eyes. Although MIS-C symptoms can vary widely, typical symptoms include fever, stomach ache, nausea, vomiting, diarrhea, rash, red eyes, and exhaustion. Although the pathogenesis of MIS-C is not yet fully understood, studies have shown that an uncontrolled immunological response known as a "cytokine storm" may play a role in the development of MIS-C. Several studies have related micronutrient deficiencies to chronic immunological activation, increased inflammation, increased cytokine production, and increased chance of developing a persistent viral infection. Studies have shown that children with MIS-C had lower micronutrients, including vitamin D, C, and zinc, than do healthy kids. Deficits in these nutrients, which are crucial for controlling the immunological response, may make the immune system less able to fight off infections and cause MIS-C. In conclusion, research on the connection between MIS-C and micronutrient deficiencies is still in its early stages. Although there is some evidence linking the two, additional research is required to determine a cause and effect.},
}
@article {pmid41675728,
year = {2026},
author = {Ahsan, A and Ibrahim, O and Ayesha, M and Hassni, AA and Saif, S and Mahin, FE and Khan, S and Tague, C},
title = {Fusion of molecular mimicry, epigenetic predisposition, and new onset GBS: a narrative review of current understanding and future directions.},
journal = {Annals of medicine and surgery (2012)},
volume = {88},
number = {2},
pages = {1532-1540},
pmid = {41675728},
issn = {2049-0801},
abstract = {Guillain-Barré syndrome (GBS) is a severe immune-driven polyneuropathy marked by the acute onset of flaccid paralysis, areflexia, and in severe cases, life-threatening autonomic or respiratory failure. Although the clinical presentation and diagnostic criteria are widely established, the precise mechanisms underlying GBS are complex and poorly understood. This review summarizes current literature on the interplay of post-infectious triggers, molecular mimicry, and host susceptibility as influenced by genetic and epigenetic variables. Infectious pathogens such as Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and, more recently, Zika and SARS-CoV-2 operate as initiators via molecular mimicry, in which pathogen antigens imitate peripheral nerve components, triggering the formation of autoreactive antibody and T-cell responses. Acute inflammatory demyelinating polyneuropathy (AIDP) is characterized by demyelination and inflammatory cytokine responses, whereas acute motor axonal neuropathy (AMAN) is associated with ganglioside-targeting antibodies and axonal loss. Genetic polymorphisms, such as those in HLA, TLR4, MMP9, and CD1A, influence vulnerability to the disease and its progression. Given that many patients experience persistent sensory, motor, and autonomic dysfunction despite treatment, the identification of long-term complications highlights the necessity of customized rehabilitation and long-term follow-up. Traditional therapeutic techniques, such as plasma exchange and intravenous immunoglobulin, remain in use, but current trials on complement inhibitors, antibody-degrading enzymes, and mesenchymal stem cell therapies indicate a move toward mechanism-driven approaches. Despite these advances, significant knowledge gaps remain regarding predictors of poor outcomes and underlying causes of persistent disabilities and complications, highlighting the need for continued translational and clinical research.},
}
@article {pmid41675944,
year = {2026},
author = {Madi, M},
title = {Viral Contributions to Periodontal and Peri-implant Disease: A Narrative Review.},
journal = {Saudi journal of medicine &amp; medical sciences},
volume = {14},
number = {1},
pages = {14-22},
pmid = {41675944},
issn = {2321-4856},
abstract = {Periodontal diseases, particularly periodontitis, are chronic inflammation with complex microbial and immunological etiologies. While bacterial pathogens such as Porphyromonas gingivalis are well-known contributors, emerging evidence indicates the role of viruses, especially herpesviruses, in the onset and progression of periodontal tissue destruction. In this review, the interplay between viral infections and periodontal health was explored, with an emphasis on the immunopathological mechanisms in which different viruses such as human herpesvirus, Epstein-Barr virus, and human cytomegalovirus aggravate periodontal tissue destruction. These viruses impair host defenses, promote bacterial colonization, and alter cytokine responses, leading to periodontal tissue damage. The review also addresses the impact of systemic viral infections, such as HIV and COVID-19, on periodontal diseases. Elevation in inflammatory mediators, including interleukin-6, link periodontitis with adverse clinical outcomes in viral infections. Moreover, interactions between P. gingivalis and respiratory viruses suggest oral pathogens may also influence systemic disease severity. Advances in diagnosis using molecular technology have improved viral detection in periodontal tissues, and previous studies support the use of antiviral therapies and gene-targeted interventions as potential adjuncts to traditional periodontal care. The integration of preventive strategies, such as vaccination and enhanced oral hygiene, is crucial in reducing the systemic consequences of viral-periodontal interactions. This review highlights the need for interdisciplinary collaboration and continued research to fully comprehend the virological dimensions of periodontal disease and develop effective, targeted therapeutic approaches.},
}
@article {pmid41677183,
year = {2026},
author = {Rubin, DT and Danese, S and Nakase, H and Ungaro, RC and Wolf, DC and Alekseeva, O and Petersen, A and Liu, Z and Mehra, D and Jain, A and Osterman, MT and Krakovich, A and Riolo, JV and DeBoer, E and Appio, J and Sinh, P and Cree, BAC and Cohen, JA and Irving, P},
title = {Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.},
journal = {Inflammatory bowel diseases},
volume = {32},
number = {5},
pages = {954-962},
pmid = {41677183},
issn = {1536-4844},
support = {//Bristol Myers Squibb, Princeton, NJ, United States/ ; //Bristol Myers Squibb/ ; //Peloton Advantage/ ; //OPEN Health company/ ; },
mesh = {Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; *Colitis, Ulcerative/drug therapy ; Follow-Up Studies ; *Indans/adverse effects/therapeutic use ; *Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Nasopharyngitis/chemically induced ; *Oxadiazoles/adverse effects/therapeutic use ; Severity of Illness Index ; *Sphingosine 1 Phosphate Receptor Modulators/adverse effects/therapeutic use ; Treatment Outcome ; Clinical Trials, Phase II as Topic ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic ; },
abstract = {BACKGROUND: Ozanimod is a once-daily oral selective sphingosine 1-phosphate receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) or relapsing multiple sclerosis (RMS). Previous analyses in both indications demonstrated favorable long-term safety profiles of ozanimod. Here we report an integrated analysis of the long-term safety of ozanimod in patients with UC or RMS.<br><br>METHODS: Data were pooled in patients with UC who received ozanimod in phase 2, phase 3, and open-label extension (OLE) trials and in patients with RMS who received ozanimod in an OLE trial after completing any phase 1-3 parent trial. Safety assessments included treatment-emergent adverse events (TEAEs) and laboratory abnormalities.<br><br>RESULTS: Overall, 3652 patients with UC or RMS had 16&#x2009;144 patient-years (PY) of ozanimod exposure over 10&#x2009;years of follow-up. The most common TEAEs were nasopharyngitis, headache, and coronavirus disease 2019. Rates of TEAEs leading to treatment discontinuation (1.4/100 PY) and TEAEs of special interest, including serious infections (1.0/100 PY), herpes zoster (0.5/100 PY), malignancies (0.4/100 PY), bradycardia (0.1/100 PY), sinus bradycardia (0.04/100 PY), complete atrioventricular block (0.01/100 PY), and macular edema (0.1/100 PY), were low. No serious hepatic events or Hy's law cases occurred. Absolute lymphocyte count of&#x2009;<&#x2009;200 cells/&#xb5;L was not temporally associated with serious or opportunistic infections.<br><br>CONCLUSIONS: Long-term exposure to ozanimod is well tolerated in patients with moderate to severe UC or RMS, confirming the previously established safety profile of ozanimod.<br><br>CLINICAL TRIAL REGISTRY: NCT01647516; NCT02435992; NCT02576717.},
}
@article {pmid41677601,
year = {2026},
author = {Muir, KC and Harris, DD and Kanuparthy, M and Hu, J and Nho, JW and Stone, C and Banerjee, D and Sellke, FW and Feng, J},
title = {Cellular and Molecular Mechanisms of SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction.},
journal = {Cells},
volume = {15},
number = {3},
pages = {},
pmid = {41677601},
issn = {2073-4409},
support = {P20GM103652/GF/NIH HHS/United States ; 1R56HL169501-01/GF/NIH HHS/United States ; R01HL179089/GF/NIH HHS/United States ; 1R01HL176640-01/GF/NIH HHS/United States ; T32HL16051703/GF/NIH HHS/United States ; R01HL46716/GF/NIH HHS/United States ; R01HL128831/GF/NIH HHS/United States ; },
mesh = {Humans ; *Spike Glycoprotein, Coronavirus/metabolism ; *COVID-19/virology ; SARS-CoV-2 ; *Endothelium, Vascular/metabolism/pathology/virology/physiopathology ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; *Betacoronavirus/metabolism ; Endothelial Cells/metabolism/pathology ; Signal Transduction ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by the viral spike proteins, which are key structural components that mediate host cell binding and entry and alter downstream signaling through multiple interactions with endothelial surface receptors. Endothelial dysfunction is a central consequence of COVID-19, contributing to vascular inflammation, barrier disruption, thrombosis, and multi-organ injury affecting the pulmonary, cardiovascular, cerebral, and renal systems. Emerging evidence demonstrates that spike protein-mediated effects, independent of productive viral infection, disrupt endothelial homeostasis through angiotensin-converting enzyme 2 (ACE2) dysregulation, integrin engagement, altered calcium signaling, junctional protein remodeling, oxidative stress, and pro-inflammatory and pro-apoptotic pathways. This review is intentionally focused on spike (S) protein-driven mechanisms of endothelial dysfunction; pathogenic vascular effects attributed to other SARS-CoV-2 structural proteins, including the nucleocapsid (N) protein, are beyond the scope of this discussion. In this review, we synthesize current experimental and translational data detailing the molecular mechanisms by which the SARS-CoV-2 spike protein drives endothelial dysfunction across multiple organ systems and discuss potential therapeutic strategies aimed at preserving endothelial integrity in acute COVID-19 and its long-term vascular sequela.},
}
@article {pmid41678053,
year = {2026},
author = {Lewis, MG and Lone, MA and Chowdhury, OR and Ghosh, P and Talukdar, R and Nair, NS and Das, S and Kanungo, S},
title = {Mortality among Children Aged 1-59 Months in India: Evidence from a Systematic Review and Meta-Analysis (2009-2024).},
journal = {Journal of epidemiology and global health},
volume = {16},
number = {1},
pages = {},
pmid = {41678053},
issn = {2210-6014},
support = {INTR-IG-2024-01-0020//Indian Council of Medical Research/ ; },
mesh = {Humans ; India/epidemiology ; Infant ; Child, Preschool ; *Infant Mortality/trends ; *Child Mortality/trends ; Female ; Cause of Death/trends ; Risk Factors ; *Hospital Mortality/trends ; Male ; },
abstract = {BACKGROUND: Mortality among Indian children aged 1–59 months remains a concern, yet evidence arises from hospital and community settings that reflect different populations and metrics. A setting-specific synthesis is needed to clarify mortality trends, causes, and associated factors. METHODS: We reviewed observational studies (2009–2024) on deaths, causes, or risk factors among children aged 1–59 months. Two reviewers independently extracted data. Hospital and community studies were analyzed separately, using setting-specific mortality definitions. Random-effects GLM models pooled mortality and risk factors. Cause-of-death distributions and trends were synthesized only for hospital studies due to limited community data. FINDINGS: Sixty-seven studies were included: 50 hospital-based, 11 community-based, and six case-control. The pooled in-hospital mortality was 8.1%, with substantial heterogeneity (0.1%-65%); largely reflecting cohorts restricted to critically ill children. Pneumonia (38%), congenital anomalies (32%) and central nervous system infections (23%), accounted for most clinically ascertained deaths. Deaths declined over time (2.4%) particularly during the pre-COVID period; while post-COVID trends were imprecise; a regional decline (3%) was detected only in northern India. Community mortality was highly heterogeneous, with a pooled estimate of 3.3% and data were insufficient for trend analysis. Female sex and lack of immunization were significantly associated with in hospital mortality, while no significant risk factors were identified in community analyses. CONCLUSION: India achieved meaningful reductions in child mortality, although recent trends remain uncertain following the COVID-19 period. Persistent heterogeneity across settings and sex differences in hospital-based mortality underscore the need for strengthened community surveillance and standardized reporting to sustain and accelerate national gains.},
}
@article {pmid41678250,
year = {2026},
author = {Lebel, RD and Sanders, J and Menges, JI},
title = {Beyond positivity: A review of the functional outcomes of negative emotions at work.},
journal = {Journal of occupational health psychology},
volume = {31},
number = {1},
pages = {1-15},
doi = {10.1037/ocp0000422},
pmid = {41678250},
issn = {1939-1307},
mesh = {Humans ; *Emotions ; *COVID-19/psychology ; *Workplace/psychology ; SARS-CoV-2 ; },
abstract = {Organizational scholars examining the effects of emotions on employees generally assume that negative emotions produce negative outcomes. However, a nascent body of research challenges this view, suggesting that negative emotions can help employees navigate work demands arising from disruptive external events. We draw on the COVID-19 pandemic-a salient, prolonged event that stimulated widespread negative emotions-as a theoretically meaningful context to explore when and why negative emotions may yield beneficial outcomes. Specifically, we provide an integrative conceptual review synthesizing research from applied and social psychology conducted during the pandemic that identifies two pathways through which negative emotions produce functional individual-level outcomes at work. The first pathway captures direct effects driven by the unique action tendencies associated with discrete negative emotions. The second pathway, informed by the personality systems interaction theory, highlights contingent effects shaped by self-regulatory factors and external support from leaders, teams, or organizational policies. Our findings challenge and extend discrete emotion and affective shift theories by detailing how and under what conditions negative emotions from disruptive events can have functional outcomes. We bring necessary nuance to prevailing emotion theories and offer practical implications for leaders and organizations seeking to manage negative emotions during the times of hardship. (PsycInfo Database Record (c) 2026 APA, all rights reserved).},
}
@article {pmid41678920,
year = {2026},
author = {Ogawa, T and Sunyi, J and Kawachi, K and Murakami, J and Masuta, S and Fukuchi, J and Yoshida, S and Sawanobori, K and Matsukura, Y},
title = {Regulatory approaches for platform-based vaccine development in Japan: Insights from PMDA's experience with COVID-19 and RSV vaccines.},
journal = {Vaccine},
volume = {76},
number = {},
pages = {128315},
doi = {10.1016/j.vaccine.2026.128315},
pmid = {41678920},
issn = {1873-2518},
mesh = {Humans ; Japan/epidemiology ; *COVID-19 Vaccines/immunology ; *Vaccine Development/legislation &amp; jurisprudence/methods ; COVID-19/prevention &amp; control ; *Respiratory Syncytial Virus Vaccines/immunology ; *Respiratory Syncytial Virus Infections/prevention &amp; control/immunology ; SARS-CoV-2/immunology ; Vaccines, Synthetic/immunology ; Drug Approval ; Pandemics/prevention &amp; control ; },
abstract = {The concept of a "platform" in vaccine development and regulatory evaluation has emerged as a strategic framework for accelerating responses to infectious disease outbreaks. By leveraging prior knowledge and applying consistent manufacturing and analytical procedures across multiple products-such as mRNA, viral vector and recombinant protein vaccines-platform approaches enable streamlined development and efficient regulatory reviews. This article presents a Japanese regulatory perspective on platform-based vaccine development, drawing on the Pharmaceuticals and Medical Devices Agency (PMDA)'s experience with both emergency and routine evaluations. Through case-based analyses of COVID-19 vaccines reviewed under emergency conditions and the subsequent post-pandemic evaluation of RSV vaccines under standard timelines, we illustrate how prior knowledge and regulatory flexibility supported timely and robust reviews. These insights contribute to the global dialogue on regulatory science and offer practical considerations for future vaccine innovation.},
}
@article {pmid41678951,
year = {2026},
author = {Lailaturrahmi, L and Caliph, S and Vu, T and Larson, I},
title = {Teaching clinical skills online in pharmacy education: a scoping review.},
journal = {Currents in pharmacy teaching &amp; learning},
volume = {18},
number = {5},
pages = {102607},
doi = {10.1016/j.cptl.2026.102607},
pmid = {41678951},
issn = {1877-1300},
mesh = {Humans ; *Education, Pharmacy/methods ; *Clinical Competence/standards ; *Education, Distance/methods ; Curriculum/trends ; Teaching ; },
abstract = {Background The integration of online teaching and learning in pharmacy curricula has increased since the worldwide rapid transition to remote teaching during the COVID-19 pandemic. However, how clinical skills were taught online in pharmacy education, including the types of skills, approaches and technologies used, and the outcomes remain poorly understood. Objective To provide an overview of the types of clinical skills taught online in pharmacy education; and to identify the purposes, teaching strategies, technologies used, educational settings, enabling and limiting factors, and reported outcomes to inform future curriculum development in pharmacy education. Methods The scoping review was conducted in accordance with the Joanna Briggs Institute (JBI) Scoping Review methodology. A systematic literature search was conducted in MEDLINE, CINAHL, and ERIC databases using predefined inclusion and exclusion criteria, and the records were independently screened by four reviewers. Any discrepancies during the screening process were resolved through discussion. The data were extracted and then analyzed using content analysis and thematic analysis. Results A total of 349 studies were retrieved and proceeded to title and abstract screening. After applying the inclusion and exclusion criteria, 152 full-text articles were assessed for eligibility, of which sixty-four articles were included in the final review. Online synchronous, asynchronous, and blended learning were implemented in pharmacy education to teach clinical skills, including communication skills and therapeutic decision-making skills. Clinical skills were most often taught online to improve the learning process. Learning outcomes measured by self-assessment or by educators were most commonly reported. Enablers, including institutional readiness and technology infrastructure, and barriers, including institutional unpreparedness and inadequate design, were also identified. Conclusion This scoping review provides guiding information to integrate online teaching and learning into pharmacy curricula, particularly for clinical skills development. By including multiple stakeholders' perspectives, this review offers useful insight for academics and faculty leaders to successfully teach clinical skills online to pharmacy students.},
}
@article {pmid41681438,
year = {2026},
author = {Ibrahim, YM and Liu, C and Yu, Y and Yang, L and Chen, Q and Ma, W and Werid, GM and Li, S and Luo, J and Gao, S and Zhang, S and Fu, L and Wang, Y},
title = {Swine Enteric Coronaviruses: An Updated Overview of Epidemiology, Diagnosis, Prevention, and Control.},
journal = {Animals : an open access journal from MDPI},
volume = {16},
number = {3},
pages = {},
pmid = {41681438},
issn = {2076-2615},
support = {(cstc2022ycjh-bgzxm0183 and 22509C) and (2024YFHZ0110)//this work was supported by grants from the National Center of Technology Innovation for Pigs (NCTIP-XD/B19); the Chongqing Talent plan "contract system" project (cstc2022ycjh-bgzxm0183 and 22509C); the Sichuan Provincial Regional Innovation Cooperation Pr/ ; },
abstract = {Swine enteric coronaviruses (SECoVs), including transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), and swine acute diarrhea syndrome coronavirus (SADS-CoV), are major enteric pathogens causing severe diarrhea, dehydration, high neonatal mortality, and substantial global economic losses. Rapid viral evolution and recombination continually generate antigenically diverse variants that limit cross-protection and undermine vaccine efficacy, particularly for PEDV genogroup II strains that now dominate worldwide circulation. This review synthesizes current knowledge on epidemiology, diagnostic innovations, and emerging vaccine platforms, with emphasis on advances since 2022. Recent progress includes molecular surveillance tools, rapid point-of-care diagnostics, and next-generation vaccine technologies such as mRNA-based and virus-like particle platforms. However, significant knowledge gaps persist regarding viral evolution dynamics, co-infection synergies, and zoonotic spillover potential, particularly following documented human infections with PDCoV. Effective long-term control requires integrated genomic surveillance, strengthened farm-level biosecurity, rationally designed multivalent vaccines targeting conserved epitopes, and harmonized international surveillance systems to reduce outbreak risk and enhance pandemic preparedness at the human-animal interface.},
}
@article {pmid41682696,
year = {2026},
author = {Grosu, IA and Dobrin, ME and Marginean, C and Esanu, IM and Melinte, OE and Stavarache, IE and Dumitrache-Rujinski, S and Cioroiu, IB and Crisan-Dabija, RA and Vicol, C and Trofor, AC},
title = {Integrated Approach of Hematological Parameters and Glutathione as Predictors of Pulmonary TB Evolution: A Comprehensive Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {3},
pages = {},
pmid = {41682696},
issn = {2077-0383},
abstract = {In recent decades, the burden of TB has been gradually declining; however, with the emergence of COVID-19 and ongoing political conflicts, including the war in Ukraine, the proper functioning of healthcare services and TB control programs has been jeopardized. Recently, research has emphasized the importance of hematological parameters associated with inflammation, which can be easily analyzed through routine blood tests. Combining these parameters may have predictive value for various diseases, including pulmonary tuberculosis and even help monitor the effectiveness of treatment. Since there is no single hematological or inflammatory biomarker that provides precise and dynamic information about the success or failure of treatment, identifying individual markers or sets of biomarkers with higher sensitivity and specificity is essential. This is particularly important since sputum culture conversion at two months remains insufficiently sensitive and microscopy conversion has limited sensitivity and specificity in detecting treatment failure. Also, the analysis of the impact of the standard directly observed treatment, short-course regimen on pathogenic mechanisms also focuses on how it influences the interaction between inflammation and oxidative tissue degradation, by measuring plasma levels of glutathione. Utilizing a combination of hematological, inflammatory, and antioxidant biomarkers offers significant insights into systemic inflammatory responses in pulmonary tuberculosis patients, both before commencing treatment and during the entire duration of antituberculosis therapy. Combining different inflammatory parameters into a multiple biomarker can significantly enhance the accuracy of predicting prognosis and response to antibiotic chemotherapy. Identifying an optimal combination of biomarkers with predictive value is crucial for assessing treatment response and evaluating the effectiveness of anti-TB medication. Rather than developing or testing a composite prediction model, this review summarizes reported performance metrics from individual studies and highlights priorities for future prospective validation of integrated biomarker panels.},
}
@article {pmid41682807,
year = {2026},
author = {Carlini, F and Chiesa, AM and Verzina, M and Sassetti, C and Rigante, D and Esposito, S},
title = {Cutaneous Clues in Kawasaki Disease: Clinical Implications and Differential Diagnosis with Multisystem Inflammatory Syndrome in Children.},
journal = {Journal of clinical medicine},
volume = {15},
number = {3},
pages = {},
pmid = {41682807},
issn = {2077-0383},
abstract = {Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) are pediatric inflammatory conditions with overlapping mucocutaneous features that may complicate early diagnosis. We performed a narrative review of the literature to characterize and compare cutaneous manifestations reported in children with KD and MIS-C and to assess their diagnostic relevance. Published studies describing dermatologic findings in patients aged 0-18 years were reviewed. The analysis revealed a broad heterogeneity of skin manifestations in both conditions, ranging from classic polymorphous rash and acral erythema to atypical presentations, including annular, psoriasiform, vesiculobullous, urticarial, and erythema nodosum-like lesions. Reactivation at Bacillus Calmette-Guérin vaccination sites and associated mucocutaneous findings, such as conjunctivitis and oral changes, emerged as supportive diagnostic clues, particularly for incomplete KD. Considerable overlap in cutaneous phenotypes between KD and MIS-C was observed, especially in patients with persistent fever and systemic inflammation, highlighting the risk of diagnostic delay. These findings underscore the importance of recognizing atypical dermatologic patterns as part of an integrated diagnostic approach, as delayed identification may increase the risk of cardiovascular complications. Early recognition of cutaneous clues can support timely initiation of immunomodulatory therapy and improve clinical outcomes.},
}
@article {pmid41683451,
year = {2026},
author = {Wang, J and Xu, Y and Yang, Y and Zhang, B and Chen, S and Li, Z and Zhu, H and Yang, H and Wang, H and Zhou, Y and Cao, P and Zhai, B and Gong, Y},
title = {Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {3},
pages = {},
pmid = {41683451},
issn = {1420-3049},
support = {KZ202210005001//R&amp;D Program of Beijing Municipal Education Commission/ ; 242102311178//Science and technology project of Henan Province/ ; 252102520079//Henan Provincial International Science and Technology Cooperation Project/ ; },
mesh = {*SARS-CoV-2/enzymology/drug effects ; Humans ; *Antiviral Agents/chemistry/pharmacology ; Ligands ; *Protease Inhibitors/chemistry/pharmacology ; Binding Sites ; Models, Molecular ; *Coronavirus 3C Proteases/chemistry/antagonists &amp; inhibitors/metabolism ; *Viral Nonstructural Proteins/antagonists &amp; inhibitors/chemistry/metabolism ; COVID-19 Drug Treatment ; Catalytic Domain ; Coronavirus Papain-Like Proteases ; },
abstract = {Papain-like protease (PLpro), a crucial functional domain of the SARS-CoV-2 non-structural protein 3 (nsp3), plays a dual role in both hydrolyzing viral polyprotein precursors and modulating host immune responses. These critical functions position PLpro as a key target in the ongoing development of antiviral therapies for SARS-CoV-2. This review analyzes more than 100 PLpro-ligand co-crystal structures and summarizes the major binding modes between these ligands and PLpro. Most of these ligands bind to sites analogous to those targeted by the classical non-covalent inhibitor GRL0617, primarily involving the P3 and P4 subsites and the BL2 loop. Based on these structural insights, optimized inhibitors have expanded targeting beyond the canonical binding site to auxiliary regions such as the BL2 groove and the Val70 site, and in some cases toward the catalytic Cys111 buried within a narrow pocket. Certain ligands identified through various screening approaches bind to non-canonical or allosteric regions, such as the S1 and S2 sites or the zinc-finger domain, engaging PLpro through distinct interaction modes and thereby offering additional opportunities for PLpro inhibitor design. The review also discusses potential strategies for future PLpro inhibitor development informed by recent structural advances. Taken together, these structural and functional insights support ongoing efforts in the structure-guided design and optimization of PLpro inhibitors.},
}
@article {pmid41683516,
year = {2026},
author = {Leka, K and Mamede, L and Vandeberg, E and Garigliany, MM and Ledoux, A},
title = {Natural Alkaloids as Antiviral Agents Against RNA Viruses: A Comprehensive and Mechanistic Review.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {3},
pages = {},
pmid = {41683516},
issn = {1420-3049},
support = {40009257//Fund for Scientific Research/ ; 40021286//Fund for Scientific Research/ ; },
mesh = {*Antiviral Agents/pharmacology/chemistry/therapeutic use ; Humans ; *Alkaloids/pharmacology/chemistry/therapeutic use ; *RNA Viruses/drug effects ; Animals ; Virus Replication/drug effects ; *RNA Virus Infections/drug therapy/virology ; SARS-CoV-2/drug effects ; *Biological Products/pharmacology/chemistry ; },
abstract = {RNA viruses pose a persistent global threat due to their high mutation rates, zoonotic potential, and rapid adaptability. Emergence events have risen steadily, as demonstrated by major outbreaks caused by Influenza A, Ebola, Zika, and Chikungunya viruses, followed by the coronavirus epidemics of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-1) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and culminating in the COVID-19 pandemic. These characteristics frequently compromise the durability of existing vaccines and antiviral therapies, highlighting the urgent need for new antiviral agents. Alkaloids, a structurally diverse class of nitrogen-containing natural compounds, have gained attention for their ability to interfere with multiple stages of the viral life cycle, including entry, replication, protein synthesis, and host immune modulation. To our knowledge, this review compiles all currently reported alkaloids with antiviral activity against RNA viruses and summarizes their proposed mechanisms of action, distinguishing evidence from in vitro, in vivo, and in silico studies. Quaternary alkaloids are discussed separately because their permanent ionic charge enables distinctive interactions with membranes and host pathways. Although many findings are promising, clinical translation remains limited by incomplete mechanistic validation, scarce in vivo data, suboptimal bioavailability, narrow therapeutic windows, and inconsistent experimental methodologies. To advance the field, future research should prioritize RT-qPCR-based antiviral evaluation to accurately quantify viral replication, incorporate mechanistic assays to clarify modes of action, apply structure-activity relationship (SAR) approaches for rational optimization, and expand in vivo pharmacokinetic and efficacy studies to assess therapeutic feasibility. Overall, alkaloids represent a promising yet underdeveloped reservoir for next-generation antiviral discovery against rapidly evolving RNA viruses.},
}
@article {pmid41683812,
year = {2026},
author = {Mahajan, S and Mahajan, S and Gusain, A},
title = {Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses.},
journal = {International journal of molecular sciences},
volume = {27},
number = {3},
pages = {},
pmid = {41683812},
issn = {1422-0067},
mesh = {Humans ; *COVID-19/immunology/pathology/therapy/virology ; *SARS-CoV-2/immunology ; *Interleukins/immunology/metabolism ; *COVID-19 Vaccines/immunology ; },
abstract = {The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by profound immune dysregulation where interleukins play a central role in determining disease severity and response to interventions. This review summarizes the role of interleukins in the immunopathogenesis of COVID-19, with particular emphasis on differences observed across major SARS-CoV-2 variants. Pro-inflammatory interleukins like IL-1β, IL-6, IL-2, IL-17 and IL-18 are critically involved in cytokine storm, hyperinflammation, and acute respiratory distress syndrome, whereas anti-inflammatory cytokines like IL-10 contribute to immune regulation and resolution of inflammation. Elevated levels of IL-1α, IL-1β, IL-4, IL-8, IL-9, IL-16, IL-18 have been documented in the Delta variant as compared with the Omicron variant, with IL-6 being the most frequent interleukin reported to be increased across all SARS-CoV-2 variants relative to the ancestral Wuhan strain. Elevated IL-2, IL-4, IL-6, and IL-10 levels have been associated with Omicron sub-variants. The review encompasses interleukin-based therapeutic strategies, where several IL-1 and IL-6 inhibitors were studied across clinical trials, but only tocilizumab has shown some promise against severe COVID-19. IL-2, IL-6, IL-15 and IL-21 levels were positively correlated with IgG and neutralizing antibody activity after vaccination with longevity of post-vaccination immunity being determined by IL-2 and IL-7.},
}
@article {pmid41683839,
year = {2026},
author = {Chen, JJ and Hsu, CW and Wang, HY and Stubbs, B and Chen, TY and Liang, CS and Chen, YW and Zeng, BS and Tseng, PT},
title = {Audiovestibular Dysfunction Related to Long COVID-19 Syndrome: A Systematic Review of Characteristics, Pathophysiology, Diagnosis, and Management.},
journal = {International journal of molecular sciences},
volume = {27},
number = {3},
pages = {},
pmid = {41683839},
issn = {1422-0067},
mesh = {Humans ; *COVID-19/complications/physiopathology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2/isolation &amp; purification ; *Vestibular Diseases/diagnosis/therapy/etiology/physiopathology ; },
abstract = {Long COVID-19 syndrome (or so-called post-COVID-19) is indicated by miscellaneous symptoms, usually starting 3 months from the COVID-19 infection and lasting for at least 2 months, which cannot be explained by an alternative diagnosis. There has been more and more reports addressing the audiovestibular dysfunction related to long COVID-19 syndrome. Emerging evidence suggests that the linkage between audiovestibular dysfunction and long COVID-19 syndrome might rely on (a) direct inner ear system damage related to viral invasion and consequent inflammation, (b) micro thromboembolic events, which might result from the COVID-19-induced autoimmune reaction against endothelial cells, and consequent transient-ischemia and hypoxia of the auditory pathways, (c) the disturbed nerve conduction in vestibulocochlear nerves due to viral invasion, and finally (d) altered auditory cortex function, either imbalanced central gain or neurotransmitter disturbance. However, most of the aforementioned mechanism remained hypothetic and still needed further studies to approve or refute. This systematic review synthesizes current evidence on the characteristics, pathophysiology, diagnostic approaches, and management of audiovestibular dysfunction related to long COVID-19 syndrome. Literature searches across PubMed, Embase, ClinicalKey, Web of Science, and ScienceDirect (up to 15 December 2025) were conducted in accordance with PRISMA guidelines. Through this systematic review, we provided a schematic diagram of the physiopathology of long COVID-19 syndrome-related audiovestibular dysfunction. Further, we summarized the currently available diagnostic tools to explore the audiovestibular function in such patients. The currently available treatment, either pharmacotherapy or nonpharmacotherapy, mainly tackles idiopathic audiovestibular dysfunction but not specifically long COVID-19 syndrome-related audiovestibular dysfunction. Timely recognition and intervention may prevent progression to permanent hearing loss or vestibular disability, improving quality of life. Trial registration: PROSPERO CRD420251265741.},
}
@article {pmid41684026,
year = {2026},
author = {Oh, H and Thi Thuy Tien, V and Ahmed, S and Choi, J and Ryu, KJ and Yang, J},
title = {Host Glycan-Lectin Interplay in SARS-CoV-2 Infection.},
journal = {International journal of molecular sciences},
volume = {27},
number = {3},
pages = {},
pmid = {41684026},
issn = {1422-0067},
support = {RS-2023-00219399//National Research Foundation of Korea/ ; RS-2025-02214302//Korea Health Industry Development Institute/Republic of Korea ; },
mesh = {Humans ; *Polysaccharides/metabolism/chemistry ; SARS-CoV-2/physiology ; *Lectins/metabolism/chemistry ; *Spike Glycoprotein, Coronavirus/metabolism/chemistry ; COVID-19/metabolism/virology ; Virus Internalization ; Virus Attachment ; Host-Pathogen Interactions ; Animals ; },
abstract = {Glycan-mediated processes can be critical determinants of viral attachment and entry, yet for enveloped RNA viruses, including SARS-CoV-2, their mechanistic roles remain incompletely defined. This review synthesizes current structural and functional evidence for glycan engagement during SARS-CoV-2 attachment and entry. We describe the general viral entry pathways and their reliance on glycan recognition, followed by the interactions of the SARS-CoV-2 spike glycoprotein with host glycans, including ABO(H) blood group antigens, sialylated glycans, and endogenous lectins. Based on structural biology, glycobiology, and virology, we focus on how the spike protein exploits both glycan motifs and lectin receptors to enhance attachment, promote cellular uptake, or modulate host tropism. We contextualize these mechanisms by comparing glycan dependencies across other human viruses, including the influenza virus, HIV, and norovirus. Finally, we provide a comparative virological perspective to derive broad evolutionary insights into how enveloped viruses exploit the host glycans.},
}
@article {pmid41684611,
year = {2026},
author = {Phanphairoj, K and Wisesrith, W and Chumwichan, S},
title = {Mapping research trends and competency domains in nursing-related digital and artificial intelligence technologies: A bibliometric analysis.},
journal = {International journal of nursing sciences},
volume = {13},
number = {1},
pages = {36-44},
pmid = {41684611},
issn = {2352-0132},
abstract = {OBJECTIVES: This study aimed to explore the research trends, thematic structures, and core competency domains in the field of nursing-related digital and artificial intelligence (AI) technologies.<br><br>METHODS: A bibliometric analysis was conducted in accordance with the PRISMA 2020 statement. Peer-reviewed articles published in English from 2015 to 2025 were retrieved from Scopus, Web of Science, and PubMed. Thematic clustering was conducted using the Louvain algorithm and cosine similarity. A subset of 66 frequently cited articles was then qualitatively synthesized to capture core competencies across clusters.<br><br>RESULTS: A total of 83,807 articles were included for bibliometric analysis. Of these, 66 articles were chosen for thematic analysis. Five major thematic clusters were identified: remote care in primary settings, oncology and palliative care, nurse education and training, safety and quality in nursing practice, and geriatric and dementia care. Additionally, four competency domains were identified: telehealth and remote communication, health systems and informatics, digital tools in practice, and AI-powered decision support. A clear shift in research focus was observed, with the emphasis transitioning from foundational digital skills before the COVID-19 pandemic to more advanced competencies during the post-pandemic digital transformation, encompassing ethical reasoning, immersive technology use, and AI integration.<br><br>CONCLUSIONS: Integrating digital and AI technologies is reshaping nursing practice across various thematic areas and competency domains, highlighting a transition from foundational digital tasks to AI-supported decision-making and ethically informed technology use. This study provides a structured overview of evolving competencies in digital nursing and synthesizes evidence to support future research, curriculum design, and policy planning.},
}
@article {pmid41685028,
year = {2026},
author = {Gabunia, L and Khetsuriani, S and Gamkrelidze, N and Gvajaia, N and Ratiani, L and Janigashvili, G},
title = {Pathogenesis and Pharmacotherapy of Acute Respiratory Distress Syndrome Induced by Pandemic Viral Infections: A Narrative Review.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e101316},
pmid = {41685028},
issn = {2168-8184},
abstract = {Acute respiratory distress syndrome (ARDS) is a severe, life-threatening condition characterized by acute hypoxemic respiratory failure, bilateral pulmonary infiltrates, and non-cardiogenic pulmonary edema caused by increased alveolar-capillary permeability. ARDS is highly heterogeneous, with diverse etiologies and clinical presentations that complicate diagnosis and management. Viral infections, including influenza A (H1N1 and H5N1) and coronaviruses such as SARS-CoV-2, are major contributors to ARDS and can trigger severe lung injury, hyperinflammation, and dysregulated immune responses. Ongoing viral evolution and periodic emergence of novel strains continue to pose a substantial threat to global public health. This narrative review analyzes pandemic-associated viral causes of ARDS, summarizes key mechanisms of pathogenesis, and evaluates current and emerging pharmacotherapeutic approaches. A comprehensive literature search was conducted using PubMed, supplemented by additional sources where appropriate. The review highlights that the increasing prominence of viral pneumonia as a cause of ARDS requires both established supportive care and tailored therapeutic strategies that target the underlying mechanisms of lung injury. Despite progress, virus-associated ARDS remains a major clinical challenge with high morbidity and mortality and may require management approaches distinct from those used for other ARDS etiologies.},
}
@article {pmid41685167,
year = {2026},
author = {Su, K and Qiu, J and Xu, T and Liu, S},
title = {Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery.},
journal = {Acta pharmaceutica Sinica. B},
volume = {16},
number = {2},
pages = {709-727},
pmid = {41685167},
issn = {2211-3835},
abstract = {Lipid nanoparticles (LNPs) hold significant potential for mRNA-based therapeutics, as evidenced by their successful use in SARS-CoV-2 mRNA vaccines. LNPs effectively protect and transport mRNA to target sites, thereby ensuring its stability and efficient transfection. Despite the progress, some challenges remain in the development of mRNA-LNP delivery systems, such as limited targeting specificity, the complexity of formulations, and the time-consuming and high-throughput screening process. Artificial intelligence (AI) has emerged as a powerful tool to address these challenges, accelerating the design and optimization process of LNPs. AI-guided approaches can improve the efficiency of lipid structure and formulation screening by rapidly identifying key design parameters and employing predictive modeling to optimize LNP properties. The combination of AI and LNP technology offers significant advantages, including enabling the design of more personalized and precise delivery systems, streamlining the development process, and reducing the cost. This review discusses recent advancements in AI-guided mRNA-LNP delivery systems and highlights their potential to revolutionize mRNA therapeutics.},
}
@article {pmid41687973,
year = {2026},
author = {Milligan, T and Nair, R and Cowansage, K and Boyd, C and Morgan, MA and Kotzab, D and Bellanti, DM and Shank, LM and Berman, DE and Chari, S and Evatt, DP and Kelber, MS},
title = {Mental health risk factors for psychological disorders after COVID-19 infection: A systematic review and meta-analysis.},
journal = {Journal of affective disorders},
volume = {402},
number = {},
pages = {121377},
doi = {10.1016/j.jad.2026.121377},
pmid = {41687973},
issn = {1573-2517},
mesh = {Humans ; *COVID-19/psychology ; Risk Factors ; *Stress Disorders, Post-Traumatic/psychology/etiology/epidemiology ; *Adjustment Disorders/psychology/etiology ; Depression/psychology/etiology ; Anxiety/psychology ; Post-Acute COVID-19 Syndrome ; Mental Health ; SARS-CoV-2 ; },
abstract = {The coronavirus disease 2019 (COVID-19) global pandemic was a time of uncertainty and rapid change that has had demonstrable effects on the mental health of those who experienced it. For individuals who contracted the illness, some types of risk factors for adverse mental health post-COVID have been examined (e.g., demographics), but how pre-COVID psychiatric risk factors may have contributed to worsened outcomes has not been systematically evaluated. This systematic review and meta-analysis examines mental health risk factors (e.g., general psychiatric history, trauma history) for depression, anxiety, posttraumatic stress disorder (PTSD), and adjustment disorder in individuals after resolution of acute COVID-19 infection. We searched three databases (PubMed, PsycInfo, Scopus) and included 27 studies (15 cohort, 12 cross-sectional). Studies were dually extracted and assessed for quality. We conducted meta-analyses by study design and outcome for the risk factor of a general psychiatric history. Medium-to-large effect sizes were found for psychiatric history on post-COVID infection depression, anxiety, and PTSD. No studies examined adjustment disorder as an outcome. Studies of mental health risk factors that could not be incorporated into the meta-analyses (e.g., history of trauma) showed small-to-large effect sizes on post-COVID mental health. These results consistently show that mental health factors predict worse psychological health after acute COVID-19 infection. More robust study designs would improve this body of research.},
}
@article {pmid41688142,
year = {2026},
author = {Le Bui, N and Nguyen, KL and Phan Van, B and Khuong, YN and Chu, DT},
title = {Cell-free systems for vaccine production.},
journal = {Progress in molecular biology and translational science},
volume = {219},
number = {},
pages = {93-106},
doi = {10.1016/bs.pmbts.2025.08.001},
pmid = {41688142},
issn = {1878-0814},
mesh = {Humans ; Cell-Free System ; *Vaccines/biosynthesis ; Animals ; *Vaccine Development/methods ; },
abstract = {Cell-free (CF) systems is harness cellular components including tRNAs, ribosomes, and polymerase to synthesize proteins in vitro. Owing to their significant CF systems offer substantial advantages over traditional cell-based systems, including higher speed, biosafety, and portability. As a result, CF systems have emerged as a powerful platform for biomedical research, with particularly promising applications in biosensing and diagnostics, protein production, synthetic biology and vaccine development. In this chapter, we provided a comprehensive overview of CF system applications in the field of biomedical sciences, with an emphasis on vaccine development and production. We also discussed their successful applications in the expression of antigens from challenging pathogens, such as Plasmodium falciparum, Chlamydia muridarum, and SARS-CoV-2. Moreover, this chapter proposed several promising innovations to address current limitations of CF platforms such as the shortage of post-translational modifications, endotoxin presence, and high production cost. Emerging solutions include glycoengineering to introduce functional glycosylation, freeze-drying for improving storage and distribution, exosome-based delivery for designing next generation vaccines, and even machine learning integration, to optimize the production pipelines.},
}
@article {pmid41689404,
year = {2026},
author = {Pereira-Dias, F and de Espíndola, MB},
title = {Integrating Digital Technologies Into Biochemistry Education: A Decade of Efforts, Pandemic Impacts, and Emerging Insights.},
journal = {Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology},
volume = {54},
number = {2},
pages = {195-216},
pmid = {41689404},
issn = {1539-3429},
support = {//Funda&#xe7;&#xe3;o de Amparo &#xe0; Pesquisa e Inova&#xe7;&#xe3;o do Estado de Santa Catarina/ ; },
mesh = {Humans ; *Biochemistry/education ; Digital Media ; *Digital Technology ; Education, Distance ; *Pandemics ; },
abstract = {This review critically examines the integration of Digital Information and Communication Technologies (TDICs) in biochemistry education over the past decade, highlighting both the benefits and challenges from a critical theoretical perspective. A systematic review was conducted to identify relevant literature, followed by thematic analysis and a detailed synthesis of the findings. Grounded in Feenberg's critical theory of technology and Selwyn's scholarship on education and digital technology, this review examines the implications of virtual laboratories, augmented reality, gamification, and online platforms in biochemistry education, as well as their implications related to the pandemic. We observed that digital technologies can enhance certain aspects of student engagement and learning outcomes; however, they can also hinder equitable access and hands-on laboratory skills. This review also highlights the key elements of critical reflection on the socio-political and ethical implications of digital technologies in biochemistry education, with a particular focus on pandemic-era concerns, including data privacy, algorithmic bias, and the commercialization of teaching practices. Future research should focus on these dimensions to ensure that technological advancements do not perpetuate or amplify educational inequities.},
}
@article {pmid41689447,
year = {2026},
author = {Coker, KL and Morgan, EL},
title = {High-Risk HPV in Men: A Hidden Threat to Public Health?.},
journal = {Reviews in medical virology},
volume = {36},
number = {2},
pages = {e70115},
pmid = {41689447},
issn = {1099-1654},
mesh = {Humans ; *Papillomavirus Infections/epidemiology/prevention &amp; control/virology/transmission ; Male ; *Human Papillomavirus Viruses/genetics/pathogenicity ; *Public Health ; Papillomavirus Vaccines/administration &amp; dosage/immunology ; Prevalence ; Vaccination ; Risk Factors ; Uterine Cervical Neoplasms/prevention &amp; control/virology ; },
abstract = {High-risk human papillomavirus (HR-HPV) infection is a leading cause of several cancers, including those of the genital and oropharyngeal regions. While public health efforts have largely focused on women due to its link to cervical cancer, HPV also poses significant risks to men, particularly in the oropharyngeal regions. HR-HPV prevalence in men is high, with global estimates of 21% for male genital infections. While the HPV vaccination programme has expanded to include boys, challenges remain, including a decline in vaccine uptake due to COVID-19 disruptions, vaccine hesitancy, and misinformation. These barriers hinder the full potential of vaccination efforts. Furthermore, HPV transmission is complex and multifactorial, making it difficult to track, while its prevalence, clearance, and persistence vary based on factors such as sexual behaviour and immune status. Additionally, data from lower socio-economic regions is limited, highlighting a critical gap in research. Specific data on these epidemiological characteristics for male patients is lacking, prompting the need for gender-balanced approaches. Here, we explore the prevalence, risks, and public health implications of high-risk HPV (HR-HPV) in men. We suggest a more inclusive approach to HPV prevention, emphasising the need for targeted vaccination and screening programs for men. A gender-neutral approach is crucial to reducing the global burden of HPV-related diseases and moving closer to the goal of eradicating HPV infections worldwide.},
}
@article {pmid41690153,
year = {2026},
author = {Ortiz-Tallo, A and Izquierdo, A and Calvo, A and Lara, E and Ayuso-Mateos, JL and Cabello, M},
title = {A systematic review of the bidirectional relationship between psychosis and loneliness.},
journal = {Journal of psychiatric research},
volume = {196},
number = {},
pages = {115-122},
doi = {10.1016/j.jpsychires.2026.02.018},
pmid = {41690153},
issn = {1879-1379},
mesh = {Humans ; *Loneliness/psychology ; *Psychotic Disorders/psychology/epidemiology ; Risk Factors ; },
abstract = {BACKGROUND: and hypothesis: Loneliness, defined as a subjective feeling of isolation, has been significantly correlated with psychotic experiences in general and clinical populations, although less is known about the direction of this relationship. This paper aims to systematically review the longitudinal relationship between loneliness and psychosis spectrum continuum, addressing two fundamental questions: (1) is loneliness a risk factor for the development of psychosis, and (2) does psychosis increase the risk of experiencing loneliness?<br><br>STUDY DESIGN: A comprehensive search of 5 electronic databases yielded a total of 4386 records, from which 10 observational studies were finally included.<br><br>STUDY RESULTS: Six studies investigated the first research question, and all of them identified a significant association between loneliness and the subsequent incidence of psychosis (question 1). Conversely, 4 studies explored the second research question, with 3 suggesting that individuals within the psychosis spectrum may face heightened susceptibility to loneliness (question 2). The remaining study, conducted during the COVID-19 pandemic, did not yield significant findings. Assessment of methodological quality indicated predominantly moderate-to-high-quality studies.<br><br>CONCLUSIONS: The findings underscore the need for further research, particularly longitudinal prospective studies, to clarify whether the observed association between loneliness and psychosis is direct or whether it is instead moderated or mediated by other variables. Overall, the available evidence provides stronger support for loneliness as a potential risk factor for the onset of psychosis, although the number of longitudinal studies addressing this question remains very limited. Addressing these gaps in knowledge could inform the development of targeted prevention programs and interventions for people with psychotic spectrum disorders.},
}
@article {pmid41690197,
year = {2026},
author = {Shang, X and Zheng, J and Liu, X and Guo, K and Zhang, N and He, R and Gan, Y and Zhang, WH and Jia, P and Yang, L and Zhu, B},
title = {Climatic factors drive global viral respiratory infections with regional heterogeneity: A systematic review and meta-analysis.},
journal = {Environment international},
volume = {208},
number = {},
pages = {110120},
doi = {10.1016/j.envint.2026.110120},
pmid = {41690197},
issn = {1873-6750},
mesh = {Humans ; *Respiratory Tract Infections/epidemiology/virology ; *Climate ; *Climate Change ; Temperature ; Humidity ; *Virus Diseases/epidemiology ; },
abstract = {BACKGROUND: Climate change is altering global respiratory virus transmission, yet pathogen-specific climate sensitivities remain unclear across diverse geographical settings.<br><br>METHODS: We searched six databases (inception-10 May 2024) for studies quantifying associations between climate factors and virus respiratory infections (VRIs). Random-effects models pooled relative risks (RRs) per unit increase in temperature, relative humidity, precipitation, and wind speed, with climate sensitivity assessed by K&#xf6;ppen-Geiger zones.<br><br>RESULTS: From 108 studies comprising 9.22 million VRI cases, three climate patterns emerged. First, temperature was the dominant driver: each 1&#xb0;C increase reduced respiratory syncytial virus (RSV; RR 0.13, 95% CI 0.08-0.22), influenza virus (IV; RR 0.37, 95% CI 0.23-0.58), human metapneumovirus (HMPV; RR 0.48, 95% CI 0.32-0.73), SARS-CoV-2 (RR 0.52, 95% CI 0.35-0.78), and human coronavirus (HCoV; RR 0.21, 95% CI 0.07-0.61) risks, but increased parainfluenza virus (PIV; RR 2.35, 95% CI 1.46-3.77) and human bocavirus (HBoV; RR 1.86, 95% CI 1.04-3.32) risks. Second, other climate factors showed selective effects: higher humidity decreased IVB risk (RR 0.61, 95% CI 0.40-0.94) but increased enterovirus risk (RR 2.21, 95% CI 1.08-4.51); precipitation decreased IV risk (RR 0.67, 95% CI 0.51-0.89) but increased PIV risk (RR 1.91, 95% CI 1.21-2.99); wind speed amplified IV (RR 1.51, 95% CI 1.01-2.27) and HCoV transmission (RR 5.36, 95% CI 3.43-8.38). Third, climate-zone analyses revealed substantial heterogeneity: in temperate regions, low temperature and humidity increased the risk of most infections (except PIV and HBoV); risks of SARS-CoV-2 and SARS-CoV risks decreased in temperate but increased in continental regions; RSV and HMPV showed greater sensitivity in tropical regions; while in arid regions, MERS-CoV risk increased with temperature but decreased with humidity and wind speed.<br><br>CONCLUSION: This analysis identified climate-sensitive VRIs with temperature as key predictor, pathogen-specific sensitivities, and distinct regional patterns, informing targeted climate-based intervention strategies.},
}
@article {pmid41691687,
year = {2026},
author = {Pawłuszkiewicz, K and Augustynowicz, G and Paluch, E and Porebska, B and Bielenin, Z and Faltus, AM and Madziarska, K and Kluz, J and Bronowicka-Szydelko, A},
title = {COVID-19 Impact on Lipid Profile and Metabolome in Patients with Type 2 Diabetes Mellitus: Mini-Review.},
journal = {Current diabetes reviews},
volume = {22},
number = {7},
pages = {e15733998404775s},
doi = {10.2174/0115733998404775251202121401},
pmid = {41691687},
issn = {1875-6417},
mesh = {Humans ; *Diabetes Mellitus, Type 2/metabolism/complications/blood ; *COVID-19/metabolism/complications ; *Metabolome/physiology ; *Lipid Metabolism/physiology ; SARS-CoV-2 ; *Lipids/blood ; },
abstract = {AIM: This review aims to explore the pathophysiological mechanisms by which SARS-- CoV-2 affects lipid metabolism and the metabolome in patients with Type 2 Diabetes Mellitus (T2DM). It compares these alterations with those observed in non-diabetic individuals and proposes strategies to mitigate potential long-term metabolic complications.<br><br>METHODS: A narrative review was conducted using PubMed, Scopus, and Google Scholar to identify studies published between 2004 and 2025 concerning adult T2DM patients during or after COVID-19 infection. The analysis focused on lipid profiles, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, along with hemoglobin A1C levels and COVID-19 severity. Search terms included: (Post-COVID-19) AND (Diabetes Mellitus Type 2), ((Post-COVID-19) AND (Diabetes Mellitus Type 2)) AND (Lipid Profile), ((- COVID-19) AND (Lipid Profile)) AND (Diabetes Mellitus Type 2), (Post-COVID-19) AND (Lipid Metabolism), (COVID-19) AND (Lipid Metabolism), (Post-COVID-19) AND (Metabolome), (COVID-19) AND (Metabolome).<br><br>RESULTS: Post-COVID-19, patients with T2DM exhibit persistent disturbances in lipid metabolism and broader metabolic pathways. SARS-CoV-2 infection amplifies metabolic dysregulation, leading to decreased levels of total cholesterol, HDL, and LDL, while triglyceride levels remain variable. Mechanistically, the virus disrupts lipid homeostasis by upregulating genes such as CD36 and peroxisome proliferator-activated receptor gamma (PPAR-&#x3b3;) and by altering amino acid metabolism, particularly within the tryptophan-kynurenine and glutamine pathways.<br><br>DISCUSSION: Enhanced oxidative stress and lipid peroxidation contribute to systemic inflammation and endothelial dysfunction. Furthermore, glycemic control worsens due to increased insulin resistance and pancreatic interactions involving angiotensin-converting enzyme 2 (ACE2).<br><br>CONCLUSION: COVID-19 significantly alters lipid metabolism and the metabolomic profile in individuals with T2DM. Longitudinal studies are warranted to clarify the duration and clinical impact of these changes and to develop personalized therapeutic strategies for this high-risk population.},
}
@article {pmid41693062,
year = {2026},
author = {Deane-King, J and Howell, J and Maguire, R},
title = {Experiences of Individuals With Chronic Obstructive Pulmonary Disease and Their Caregivers During the Pandemic: A Systematic Review.},
journal = {Nursing open},
volume = {13},
number = {2},
pages = {e70462},
pmid = {41693062},
issn = {2054-1058},
mesh = {Humans ; *Pulmonary Disease, Chronic Obstructive/psychology ; *Caregivers/psychology ; *COVID-19/psychology/epidemiology ; SARS-CoV-2 ; Pandemics ; Mental Health ; },
abstract = {AIM: To explore the experiences of individuals with Chronic Obstructive Pulmonary Disease (IwCOPD) and their caregivers during the COVID-19 pandemic.<br><br>DESIGN: Systematic review, adhering to PRISMA guidelines (PROSPERO ID: CRD42022327424).<br><br>DATA SOURCES: PsycINFO, PubMed, EMBASE and Web of Science.<br><br>METHODS: Databases were searched in April 2022 using keywords relating to COPD, caregivers/patients and COVID-19. Studies collecting data on experiences of IwCOPD or their informal caregivers during the COVID-19 pandemic were included. Following screening and quality appraisal by two reviewers, a qualitative synthesis was conducted.<br><br>RESULTS: Of 2931 abstracts screened, 24 articles met the inclusion criteria. For IwCOPD, pandemic impacts on physical and mental health were found, including fears of contracting COVID-19, changes in exacerbation levels, reductions in physical activity, and increases in depression and anxiety. Changes to healthcare management, including access to telemedicine, and positive adaptations, such as increased medication adherence, self-preservation and self-care, were also reported in the studies reviewed. Caregivers expressed fear of their care recipient contracting COVID-19 and changes in the home environment.<br><br>CONCLUSION: While the pandemic led to considerable negative experiences for IwCOPD, review findings suggest that some positive experiences were also reported.<br><br>Findings may help inform the development of physical and mental health supports for IwCOPD and their caregivers.<br><br>IMPACT: This study sheds light on the limited evidence regarding experiences of IwCOPD and their caregivers during the height of the COVID-19 pandemic. As many IwCOPD continue to be impacted by COVID-19, these findings have the potential to inform healthcare providers how they may better support IwCOPD and their caregivers in numerous aspects of their healthcare management and their daily lives.<br><br>The lead author's experience as a COPD caregiver acted as Public and Patient involvement input. WHAT DOES THIS PAPER CONTRIBUTE TO THE WIDER GLOBAL CLINICAL COMMUNITY?: (1) The review sheds light on the considerable impact the pandemic had on the mental and physical health of IwCOPD. (2) It identifies vulnerable areas where support could be improved for IwCOPD and their caregivers, and how support could be improved.<br><br>RELEVANCY TO NURSING OPEN: People with chronic obstructive pulmonary disease require considerable care and support from nursing professionals. This review highlights the care needs and support that may be beneficial for this group and is relevant to Nursing Open on nursing practice and research.},
}
@article {pmid41694172,
year = {2026},
author = {Chatzidou, P and Stratos, A and Chint, M and Niakou, A and Pissiotis, A and Kamalakidis, S},
title = {Denture-Associated Candidiasis and Mucormycosis in Post-COVID-19 Older Adults Managed Through an Integrated Prosthodontic and Infectious Disease Approach: A Narrative Review.},
journal = {Cureus},
volume = {18},
number = {2},
pages = {e103448},
pmid = {41694172},
issn = {2168-8184},
abstract = {The COVID-19 pandemic has exposed significant vulnerabilities among older adults, particularly denture wearers, to opportunistic fungal infections, including mucormycosis and oral candidiasis. This narrative review, following PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Narrative Reviews) guidelines, collected evidence from 2020 to 2025 to examine the connection between denture use, systemic comorbidities, and fungal complications in elderly individuals after COVID-19. A total of 21 of 104 studies were included, covering case-control, cross-sectional, cohort, and retrospective studies from India, Europe, the Middle East, and North America. Several studies have reported higher rates of oral fungal colonization among denture wearers,with Candida albicans being the most frequently isolated species, followed by resistant strains such as Candida auris. However, these observations are primarily derived from heterogeneous observational studies and should therefore be interpreted as associative rather than causal. COVID-19-related mucormycosis (CAM) was primarily reported as rhino-orbito-cerebral disease, with oral manifestations including palatal necrosis, gingival ulcers, and tooth mobility. Key risk factors identified include diabetes mellitus, corticosteroid therapy, prolonged intensive care unit (ICU) stays, and poor denture hygiene. Mortality related to CAM ranged from 18% to 56%, while candidiasis, though less deadly, significantly affected oral function, nutrition, and overall quality of life. Diagnostic methods included clinical and intraoral examinations, microbiological cultures, imaging techniques, and emerging salivary biomarkers. Treatments included systemic antifungal medications, surgical removal, and prosthesis disinfection, highlighting the important role of prosthodontists in prevention and rehabilitation. Knowledge gaps remain regarding the predictive value of oral lesions for systemic infections, the long-term effects of COVID-19 on the oral microbiome, and the need to standardize denture hygiene protocols. This review emphasizes the importance of integrated dental and medical care in reducing morbidity and mortality among denture-wearing older adults recovering from COVID-19, while recognizing that early oral findings may serve as warning indicators rather than definitive predictors of systemic infection.},
}
@article {pmid41695592,
year = {2026},
author = {Ince, I and Sposito, F and Charras, A and McCann, LJ and Hedrich, CM},
title = {How loss-of-function mutations in IFIH1 contribute to infectious and/or inflammatory disease - a systematic review.},
journal = {Journal of translational autoimmunity},
volume = {12},
number = {},
pages = {100353},
pmid = {41695592},
issn = {2589-9090},
abstract = {The IFIH1 gene encodes for the cytoplasmic innate immune receptor Melanoma Differentiation-Associated protein 5 (MDA5) that detects viral double-stranded RNA to initiate type I interferon (IFN) responses. While gain-of-function mutations in IFIH1 have been linked with systemic inflammatory diseases, loss-of-function remains less well understood. This systematic review, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidance, explored how IFIH1/MDA5 loss-of-function affects susceptibility to virus infections and/or contributes to inflammatory diseases. Sixteen loss-of-function variants affecting IFIH1 were discussed across 33 studies. Loss-of-function variants were consistently associated with increased susceptibility and/or severity of virus infections, including severe acute respiratory syndrome coronavirus (SARS-CoV2) and human immunodeficiency virus (HIV). Several rare biallelic IFIH1 mutations lead to profound immunodeficiency, while heterozygous mutations associate with milder clinical presentations. Likely through dampening IFN responses, several variants protect from the development of inflammatory diseases, including type 1 diabetes and hypothyroidism. However, IFIH1 deficiency is also implicated in the development of inflammatory diseases, including inflammatory bowel disease. Moreover, the presence of inactivating anti-MDA5 antibodies may alter the clinical phenotypes and prognosis of dermatomyositis and infections with SARS-CoV2. Though their exact impact on MDA5 function has not been confirmed experimentally, anti-MDA5 antibodies may result in loss-of-function and impaired host defence against viruses. Loss of IFIH1/MDA5 activity has diverse effects on anti-viral immunity, associated damage and susceptibility to inflammatory disease, but also protection against organ-specific immune-mediated pathology. Findings highlight the importance of IFIH1 in immune regulation and warrant future studies exploring its potential as a diagnostic and therapeutic target.},
}
@article {pmid41695980,
year = {2026},
author = {Hanifian, H and Nateghpour, M},
title = {Iran's Journey Through Malaria: From Past Challenges to Future Elimination-A Narrative Review.},
journal = {Journal of tropical medicine},
volume = {2026},
number = {},
pages = {4251955},
pmid = {41695980},
issn = {1687-9686},
abstract = {BACKGROUND: Malaria remains a persistent public health concern in Iran, particularly in southeastern regions bordering Afghanistan and Pakistan. Despite substantial progress over recent decades, challenges such as cross-border transmission, insecticide resistance, and health system disruptions continue to threaten elimination goals.<br><br>METHODS: This narrative review synthesized evidence from the World Health Organization (WHO) World Malaria Reports, national surveillance summaries, and peer-reviewed publications indexed in PubMed and Scopus from 2000 to 2025. Emphasis was placed on case trends, intervention coverage, and cross-border dynamics.<br><br>RESULTS: Iran reduced indigenous malaria cases dramatically from thousands in the early 2000s to fewer than 300 annually by the mid-2010s and subsequently recorded multiple consecutive years with zero indigenous transmission, according to the WHO surveillance reports. Key achievements included integrated vector management, community engagement, and strengthened cross-border initiatives. However, interruptions during the COVID-19 pandemic and a resurgence of malaria in 2022, largely associated with imported infections, operational disruptions, and emerging vector threats, highlighted vulnerabilities in elimination-phase systems. Additional challenges such as insecticide resistance and the spread of Anopheles stephensi further complicate the elimination trajectory.<br><br>CONCLUSION: Iran's experience illustrates the need for adaptive, multisectoral approaches to malaria control in complex socioecological settings. While elimination remains within reach, achieving the WHO certification will require transparent surveillance metrics, reinforce cross-border collaboration, and sustain political and financial commitment.},
}
@article {pmid41696091,
year = {2026},
author = {Rezaei, Z and Khorraminia, A and Shi, D and Banad, YM},
title = {Network-based artificial intelligence in mental healthcare: A systematic review of chatbots, artificial intelligence/machine learning models and ethical considerations in global healthcare networks.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076261421688},
pmid = {41696091},
issn = {2055-2076},
abstract = {OBJECTIVE: This systematic review examines how artificial intelligence (AI), including machine learning (ML) models and AI-powered chatbots, contributes to the diagnosis, treatment and ethical governance of mental healthcare. It explores how AI-driven systems form interconnected healthcare networks that enhance accessibility, personalization and resilience of mental health services, aligning with the United Nations Sustainable Development Goal 3: Good Health and Well-Being.<br><br>METHODS: A comprehensive search across PubMed, IEEE Xplore and Google Scholar (2017-2024) was conducted using Boolean combinations of "AI," "machine learning," "chatbots" and "mental health." Screening followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, yielding 37 high-quality studies for qualitative synthesis. Extracted data were categorized into three domains: (1) AI- and ML-based diagnostic models, (2) chatbot-enabled mental health support systems and (3) ethical and privacy considerations. Analytical dimensions included algorithmic performance, clinical outcomes, data governance and equity of access.<br><br>RESULTS: AI-driven interventions improved accessibility, diagnostic accuracy and therapeutic personalization. Chatbots such as Woebot, Wysa and Tess effectively reduced symptoms of depression and anxiety, increased user engagement and provided scalable support, particularly during the COVID-19 pandemic. ML models, including MentalBERT, MentalRoBERTa and SR-BERT, achieved F1 scores of 68-93% in mental health classification tasks. However, limitations included dataset bias, lack of longitudinal evidence and limited cross-cultural generalizability. Ethical analyses revealed persistent challenges concerning privacy, informed consent, algorithmic bias and accountability.<br><br>CONCLUSION: AI technologies, when integrated with human oversight, offer transformative potential for global mental health systems by creating interconnected and adaptive care networks. These technologies can enhance efficiency, reduce barriers to care and support data-driven public health strategies. However, successful deployment depends on clear ethical frameworks that promote transparency, respect cultural contexts and preserve human oversight. Future research should prioritize longitudinal studies, inclusive datasets and ethical frameworks that maintain human-centered values in AI-enabled mental health systems.},
}
@article {pmid41696228,
year = {2026},
author = {de Araújo, AB and S Azul, FVC and Carneiro, YC and de Sousa, CNS and de Vasconcelos, SMM and Rios, FJ and Leal, LKAM},
title = {Neuroinflammation and Oxidative Stress in Parkinson's Disease, Alzheimer's Disease, and COVID-19: Microglia-Neutrophil Interaction.},
journal = {ACS omega},
volume = {11},
number = {5},
pages = {6922-6938},
pmid = {41696228},
issn = {2470-1343},
abstract = {Abnormal activation of the immune system and oxidative stress are crucial factors in neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease. Microglia, neutrophils, oxidative stress mediators such as reactive oxygen species (ROS), lipid peroxidation products (e.g., malondialdehyde), and nitrosative stress markers (e.g., nitrite and nitrate) play important roles in neuroinflammatory mechanisms. Microglial cells acquire a proinflammatory phenotype through interactions with endogenous or exogenous compounds, including cell debris, abnormally modified proteins (including Aβ species and alpha-synuclein), and pathogens (e.g., SARS-CoV-2). They produce many inflammatory mediators and promote the activation of adjacent brain cells and leukocyte infiltration, including polymorphonuclear neutrophils. Accumulation of neutrophils in the central nervous system (CNS) leads to the secretion of more proinflammatory mediators, such as cytokines, proteases, and oxidants, and the formation of neutrophil extracellular traps (NETs). These processes are associated with the pathological activation of microglial cells, cell death, consequent influence on neuronal functions, or even neuronal death, which is a hallmark of CNS disorders. In this review, we address the importance of inflammatory mechanisms and oxidative stress in the CNS associated with Parkinson's disease, Alzheimer's disease, and the neuronal effects observed in coronavirus disease 2019 (COVID-19), as observed by the abnormal activation of central and peripheral immune cells, such as microglia and neutrophils. We also discuss emerging evidence linking SARS-CoV-2 infection to neuroinflammatory mechanisms that could contribute to neurodegenerative complications.},
}
@article {pmid41696621,
year = {2026},
author = {Nguyen Hai, C},
title = {Invasive pulmonary aspergillosis in the post-COVID-19 era: diagnosis, treatment, and what lies ahead.},
journal = {Therapeutic advances in infectious disease},
volume = {13},
number = {},
pages = {20499361251406189},
pmid = {41696621},
issn = {2049-9361},
abstract = {Invasive pulmonary aspergillosis (IPA) is a severe opportunistic fungal infection that predominantly affects immunocompromised individuals, including those with hematologic malignancies, organ transplants, and, more recently, patients with post-COVID-19 immune dysregulation. Despite advancements in medical mycology, IPA continues to pose significant diagnostic and therapeutic challenges, contributing to high global morbidity and mortality. Diagnostic accuracy remains limited due to nonspecific clinical manifestations and the suboptimal performance of conventional tools such as bronchoalveolar lavage culture and galactomannan testing. However, recent innovations including polymerase chain reaction-based molecular assays, lateral flow devices, and immuno-positron emission tomography/magnetic resonance imaging offer improved sensitivity, specificity, and speed. Therapeutically, triazoles remain the cornerstone of IPA management, complemented by echinocandins and liposomal amphotericin B in refractory cases. The role of combination therapy and antifungal susceptibility testing is growing in response to rising azole resistance. Additionally, novel antifungal agents and immunotherapeutic approaches are currently under clinical investigation. Effective management of IPA requires a timely, multidisciplinary approach that combines advanced diagnostics with personalized antifungal strategies. Continued research is essential to standardize molecular techniques, refine immunotherapy, and expand access to next-generation antifungals to reduce the global burden of this life-threatening infection. This review aims to synthesize current evidence on the diagnosis and treatment of IPA, critically evaluate the strengths and limitations of existing diagnostic and therapeutic approaches, and explore emerging strategies to enhance clinical outcomes in the context of rising antifungal resistance.},
}
@article {pmid41696692,
year = {2025},
author = {Badran, EF and Rayyan, A and Al Jaberi, M and Azzam, M and Ramadan, R and Khader, Y and Alqutob, R and Bakri, FG and Qasrawi, R and Yacoub, T and Sharaqa, A and Fraihat, N and Trigui, H and Sokhn, E and Tayyem, R and Musa, E and Kong, JD},
title = {Infectious disease burden and surveillance challenges in Jordan and Palestine: a systematic review and meta-analysis.},
journal = {Frontiers in digital health},
volume = {7},
number = {},
pages = {1713089},
pmid = {41696692},
issn = {2673-253X},
abstract = {BACKGROUND: Jordan and Palestine face public health challenges due to infectious diseases, with the added detrimental factors of long-term conflict, forced relocation, and lack of resources. Added to these are the increased rates of morbidity and mortality from having limited healthcare services available due to a lack of funding, poor disease surveillance systems, and entrenched systemic weaknesses. The purpose of this systematic review was to report the prevalence of infectious diseases in Jordan and Palestine in order to inform the development of targeted public health programs that use both standard and novel approaches to reduce the region's disease burden.<br><br>METHOD: As defined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the review included prospective, retrospective, cross-sectional, and case series studies published from January 2021 to February 2024. Non-English studies were excluded due to resource limitations, as were studies published before the COVID-19 pandemic (i.e., before January 2021) to focus on post-COVID-19-pandemic trends. We used diagnostic techniques (screening, laboratory, and confirmatory tests) to test for microorganisms in adults and children from at-risk populations in Jordan and Palestine. Test-negative controls were contrasted with patients who had positive test results. A manual reference screening process was added to a systematic search of PubMed and Scopus. Full-text, English-language publications published after January 2021 were eligible; protocols, reviews, case reports, and articles written in languages other than English were not. The Rayyan platform was used by two reviewers to independently screen studies. Infection type, causative microorganism, symptoms, mortality, risk factors, seasonal fluctuations, and study details (author, year, location, design, and participant characteristics) were among the extracted data. The Hoy 2012 Checklist was used to evaluate the risk of bias. Open Meta (Analyst) was used to analyze the 13 studies that satisfied the inclusion criteria. Study design, risk of bias, heterogeneity, publication bias, indirection, imprecision, effect size, and residual confounding were all considered when grading the quality of the evidence using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.<br><br>RESULTS: The results revealed that four studies addressed the prevalence of Brucella infection in Jordan and Palestine. The pooled estimate was 42.2% (95% CI: 18.8%-65.6%, I [2]: 99.7%, P: 0.001, n&#x2009;=&#x2009;4 studies, 4,483 patients). In the studies that addressed diarrhea, in 31 of 159 (19.5%) cases, 20 were caused by Entamoeba (12.6%), 10 were caused by Blastocystis (6.3%), and 1 (0.6%) was caused by Cryptosporidium. As some cases had more than one parasite, the certainty of evidence (COE) was assessed as very low. The pooled estimate for viral causative agents of respiratory tract infections was 60% (95% CI: 11.8%-100%), while for bacterial causes, the pooled estimate was 24.4% (95% CI: 0%-68.3%). Respiratory syncytial virus (RSV) was the most common agent, with a pooled estimate of 57.9% (95% CI: 29.8%-85.9%), while influenza had a pooled estimate of 28.4% (95% CI: 5.3%-51.5%). Furthermore, two studies addressed the prevalence of meningitis in pediatric patients. In adult patients, of 192 patients known to have meningitis, a causative agent was identified in only 86 cases, with 83 (49%) classified as aseptic meningitis.<br><br>CONCLUSION: The review addressed the limitations of diagnostic capacity, reporting systems, and population-level data concerning high-burden and emerging pathogens within Jordan and Palestine. Specifically, the growth in the number of cases with respiratory tract infections, protozoal diarrheal diseases, and brucellosis indicates that improvements in surveillance systems and diagnostic processes need to be standardized and implemented throughout Jordan and Palestine to provide accurate and reliable diagnoses. In addition, improving the quality and quantity of the data and incorporating new technologies and other innovative approaches as a complement to existing public health indicators within Jordan and Palestine would be beneficial for better detecting these diseases at the earliest possible time and would provide the opportunity to establish evidence-based disease management strategies within the region.},
}
@article {pmid41696706,
year = {2025},
author = {Yu, P and Zhu, P and Kudiza, A and Kaburu, FM and Intizar, M and Tong, C and Zhang, R and Jiang, J and Yu, X and Kuang, Q and Chen, R and da Veiga, CP and Xiang, YT and Su, Z},
title = {Help, near and far: a systematic review of post-COVID digital mental health solutions for domestic violence victims.},
journal = {Frontiers in public health},
volume = {13},
number = {},
pages = {1687396},
pmid = {41696706},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Domestic Violence/psychology ; Digital Health ; *Mental Health ; Digital Media ; *Crime Victims/psychology ; *Survivors/psychology ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: Domestic violence (DV), as a global pandemic, poses a significant challenge within the field of public health, gravely impacting the mental and physical health of victims. Modern digital technologies have been proposed as promising interventions for DV-related mental health problems. We therefore evaluated their effectiveness.<br><br>OBJECTIVE: To systematically review digital interventions targeting the mental health of DV survivors and to summarize implications for health professionals and policy makers.<br><br>METHODS: We searched PubMed, EBSCO, and Web of Science (January 1, 2020-April 23, 2024) following PRISMA guidelines. Two reviewers independently screened records, applied predefined eligibility criteria, and extracted data. Owing to heterogeneity, we performed a narrative synthesis. Meanwhile, based on the results of the literature review, this paper proposes a series of policy recommendations from a post-COVID-19 era perspective, integrating societal context and relevant policies.<br><br>RESULTS: Nine studies met the inclusion criteria. Three reported no significant mental-health benefits, whereas the remainder showed improvements in outcomes such as depression, anxiety, PTSD symptoms, emotion regulation, perceived support, or safety preparedness using tools including mobile apps, web-based programs, virtual reality, chatbots, and video adjuncts.<br><br>CONCLUSION: Digital interventions show promise for improving mental-health outcomes among DV survivors, but their implementation requires attention to safety, engagement, cultural adaptation, and integration with offline services.<br><br>PROSPERO, https://www.crd.york.ac.uk/PROSPERO/view/CRD42023488560.},
}
@article {pmid41696833,
year = {2026},
author = {Martinez-Morga, M and Garrigos, D and Martinez-Morga, S and Martinez, S},
title = {[Consequences of congenital COVID-19 on the cognitive development of affected children].},
journal = {Medicina},
volume = {86 Suppl 1},
number = {},
pages = {2-7},
pmid = {41696833},
issn = {1669-9106},
mesh = {Humans ; *COVID-19/congenital/complications ; Pregnancy ; Female ; *Pregnancy Complications, Infectious/virology ; Infant, Newborn ; *Developmental Disabilities/virology/etiology/epidemiology ; SARS-CoV-2 ; Infectious Disease Transmission, Vertical ; Neurodevelopment ; *Neurodevelopmental Disorders/virology/etiology ; Pandemics ; *Prenatal Exposure Delayed Effects/virology ; *Child Development ; Child ; },
abstract = {Congenital COVID-19 refers to infection with the SARS-CoV-2 virus acquired in utero as a result of maternal infection during pregnancy. Although vertical transmission of the virus from mother to fetus appears to be relatively infrequent, growing clinical and epidemiological evidence indicates that prenatal exposure to SARSCoV-2, as well as to the maternal immune response it elicits, may have significant implications for early neurological development. Therefore, understanding the potential cognitive consequences of congenital COVID-19 is essential for the long-term monitoring of child health in affected individuals and for the implementation of early intervention strategies. This post-pandemic perspective on the consequences for neural development has been supported by observations showing that neonates exposed to congenital COVID-19 infection have a tenfold higher incidence of developmental delay compared with those not exposed to the virus. In this review, we examine the pathogenic mechanisms that may explain the increased incidence of neurodevelopmental alterations.},
}
@article {pmid41697443,
year = {2026},
author = {Camara, B and Buonsenso, D},
title = {Biomarkers of long COVID in children and young adults: a scoping review.},
journal = {European journal of pediatrics},
volume = {185},
number = {3},
pages = {132},
pmid = {41697443},
issn = {1432-1076},
mesh = {Adolescent ; Child ; Humans ; Young Adult ; *Biomarkers/blood ; COVID-19/complications/diagnosis ; *Post-Acute COVID-19 Syndrome/blood/diagnosis/pathology ; SARS-CoV-2/physiology ; },
abstract = {UNLABELLED: Following the SARS-CoV-2 pandemic, a significant percentage of people are now experiencing long-term symptoms, despite a continuing lack of concrete documentation of physiological and risk profiles that hinders diagnosis and treatment, particularly in pediatric contexts. This review aims to highlight the existing evidence for measurable physiological markers for post-acute sequelae of SARS-CoV-2 infection (long COVID) in children, adolescents, and young adults. Titles providing data related to measurable biomarkers distinguishing young long COVID patients from controls were compiled and analyzed. Results were displayed in table and diagram form for optimal qualitative evaluation of the relationship between markers and symptomatology within the context of each organ system. Only human studies published in English, Italian, Portuguese, German, and Spanish between the 5th of February 2025 and the 31st of December 2025 were considered, and no other time constraints were applied. Following search and criteria evaluation, nine studies were included, totaling 41 occurrences identified in diseased patients with statistically significant variation from healthy controls. Markers suggest the presence of organic manifestations based on published literature, although more data and future studies will be necessary to establish clear connections.<br><br>CONCLUSION: The data compiled for this review adds to the body of evidence indicating a physiological manifestation of long COVID and its consequences. Further investigation into potential risk factors, pre- and post-pubescent manifestations, and specific inflammatory and immune pathways will be necessary for a more concrete understanding of long COVID and its effects on children, adolescents, and young adults.<br><br>WHAT IS KNOWN: &#x2022; Long COVID is estimated to affect a significant population of patients, despite the lack of concrete physiological diagnostic and prognostic measures. &#x2022; Pediatric incidence of the disease is still largely debated, and published data are scarce.<br><br>WHAT IS NEW: &#x2022; A total of 41 biomarker occurrences were identified by selected studies, which were consistent with expected physiology behind reported symptoms. &#x2022; The body of data discussed suggests the presence of physiological phenomena behind the long-term symptoms experienced by pediatric long- COVID patients.},
}
@article {pmid41697483,
year = {2026},
author = {Sheikholeslami, MA and Parvardeh, S and Ghafghazi, S and Zarei, M},
title = {Modulation of immune responses by opioids through toll-like and P2X receptor signaling in COVID-19.},
journal = {Purinergic signalling},
volume = {22},
number = {2},
pages = {22},
pmid = {41697483},
issn = {1573-9546},
mesh = {Humans ; *COVID-19/immunology/metabolism ; *Signal Transduction/drug effects/immunology ; *Toll-Like Receptors/immunology/metabolism ; *Analgesics, Opioid/pharmacology ; *Receptors, Purinergic P2X/immunology/metabolism ; Animals ; SARS-CoV-2 ; Immunity, Innate/drug effects ; },
abstract = {The pathogenesis of COVID-19 involves complex interactions between viral replication and host immune dysregulation, mediated by toll-like receptors (TLRs) and P2X receptors (P2XRs). These receptors detect pathogen- and damage-associated molecular patterns (PAMPs and DAMPs), triggering inflammatory cascades. Opioids, beyond their analgesic role, modulate innate and adaptive immune responses via opioid receptors and indirectly through TLR and P2X signaling. This narrative review integrates experimental, clinical, and bioinformatic evidence to explore the mechanistic crosstalk between opioid signaling, TLRs (notably TLR2, TLR4, TLR9), and P2XRs (notably P2X4 and P2X7) in COVID-19 immunopathology. Chronic opioid exposure may either enhance or suppress inflammation depending on dose, duration, and immune context. In COVID-19, the hyperactivation of TLR4, TLR7, and TLR9 drives cytokine storms, while the release of ATP from damaged cells activates P2X7, thereby amplifying the inflammatory response. ATP breakdown into adenosine further modulates immunity via A2A and A2B receptors. Targeting TLR4 and P2X7 offers a promising therapeutic strategy to mitigate hyperinflammation and improve outcomes in COVID-19 and related inflammatory diseases. In addition, we outline how the Contact System, the Kallikrein-Kinin System (KKS), the Renin-Angiotensin System (RAS), and the NLRP3 inflammasome provide the innate inflammatory backdrop through which opioids and P2 receptor signaling may shape immune dysregulation in COVID-19. Notably, direct clinical evidence for opioid-P2 receptor interactions in COVID-19 remains limited, highlighting the need for targeted translational studies.},
}
@article {pmid41697791,
year = {2026},
author = {Ayalew, AF and Delie, AM and Tiruneh, C and Mulat, S and Fornah, L and Ma, W},
title = {Safety knowledge gaps among Ethiopian health professionals: A systematic review and meta-analysis.},
journal = {Work (Reading, Mass.)},
volume = {84},
number = {3},
pages = {680-694},
doi = {10.1177/10519815261420215},
pmid = {41697791},
issn = {1875-9270},
mesh = {Humans ; COVID-19/prevention &amp; control ; Ethiopia ; *Health Knowledge, Attitudes, Practice ; *Health Personnel/psychology/statistics &amp; numerical data ; },
abstract = {BackgroundThere are knowledge gaps regarding safety measures among healthcare professionals (HPs) in Ethiopia. Safety measures are critical for safeguarding HPs and clients.ObjectiveTo assess the pooled knowledge and areas of gaps related to safety measures among HPs in Ethiopia.MethodsThis systematic review and meta-analysis included published Ethiopian studies as of August 2024, sourced from June 1 to August 30, 2024. Databases included PubMed, Web of Science, Epistemonikos, Semantic Scholar, and Google Scholar. Data were extracted using Microsoft Excel and analyzed using STATA 17. A random-effects model was used to estimate pooled knowledge, and heterogeneity was assessed using the I[2] statistic (I[2] = 98.68%, p < 0.001). Publication bias was assessed using funnel plots, Egger's test (P = 0.3239), and Begg's test (P = 0.2465). We used subgroup analyses to see variation across different variables.ResultsWe included 64 studies involving 23,257 HPs. The pooled knowledge was 67.19% (95% CI: 63%-72.81%). In subgroup analysis, 77.39% were aware of COVID-19 prevention measures, and 76.55% were aware of hospital-acquired infections. Knowledge was lower for HIV prophylaxis (57.12%) and healthcare waste management (56.52%). Key consistent influencing factors included training, guideline availability, work experience, professional role, and education.ConclusionsEthiopian HPs had moderate knowledge of safety measures and relatively low knowledge of HIV prophylaxis and healthcare waste management. We recommended standardized assessment tools, targeted training interventions, and expanded coverage to underrepresented regions.},
}
@article {pmid41698791,
year = {2026},
author = {Saiding, Q and Xiao, F and Khan, MM and Kong, N and Huang, X and Tao, W},
title = {Lipid-Polymer Hybrid Nanoparticles (LPHNPs) for RNA Delivery.},
journal = {Accounts of chemical research},
volume = {59},
number = {5},
pages = {762-775},
doi = {10.1021/acs.accounts.5c00874},
pmid = {41698791},
issn = {1520-4898},
mesh = {Humans ; *Nanoparticles/chemistry ; *Lipids/chemistry ; *Polymers/chemistry ; RNA, Small Interfering/chemistry ; Animals ; *RNA/chemistry/administration &amp; dosage ; },
abstract = {RNA-based therapeutics are now revolutionizing modern medicine, with examples like COVID-19 mRNA vaccines and the siRNA drug Leqvio, validating their potential in infectious diseases and chronic diseases. However, the broad clinical translation of RNA therapeutics remains critically dependent on the development of safe and effective delivery systems that are capable of overcoming physiological barriers and achieving precise spatiotemporal upregulation or downregulation of target proteins. Lipid nanoparticles (LNPs) have attracted significant attention due to their clinical success, yet they still struggle to overcome context-specific delivery barriers, such as poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting, which hinder the full implementation of RNA therapeutics across a broad spectrum of diseases. To tackle the unmet needs in RNA-based therapeutics, developing new types of delivery platforms with different nanoparticle structures is therefore highly attractive and needed. Over the past decade, our group has focused on developing novel lipid-polymer hybrid nanoparticles (LPHNPs) for the delivery of RNA therapeutics across diverse biomedical applications. By incorporating biodegradable polymers with tailored properties, for example, poly(lactic-co-glycolic acid) (PLGA) for structural stability, hyaluronic acid (HA) for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) (Cys-PDSA) for redox-responsive release in the tumor microenvironment, these LPHNPs exhibit highly tunable architectures that integrate efficient RNA encapsulation, site-specific delivery, and controlled RNA release, providing more tools and choices for RNA delivery. In this Account, we summarize recent advances from our group in the design and synthesis of LPHNPs for RNA therapeutics, as well as their translational applications across diverse disease contexts. We highlight rational material pairings and design principles that optimize key performance metrics, including colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy. We also provide case studies demonstrating the translational potential of RNA-LPHNPs across various administration routes and disease models, including oral, inhaled, intravenous, and intravesical delivery, using the LPHNP platforms developed in our laboratory. These platforms have achieved promising therapeutic efficacy in models of cancers, inflammatory diseases, and respiratory conditions by enabling local or systemic delivery of mRNA or siRNA to immune cells, epithelial cells, and tumor microenvironments. By outlining optimized design strategies and future challenges, this Account aims to serve as a roadmap for researchers seeking to develop next-generation RNA delivery platforms that are modular, functionally versatile, and translatable.},
}
@article {pmid41699407,
year = {2026},
author = {Ben Ghezala, I and Peiffer-Smadja, N and Solas, C and Nougairède, A and Touret, F and Bardou, M},
title = {How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19.},
journal = {Clinical and translational science},
volume = {19},
number = {2},
pages = {e70505},
pmid = {41699407},
issn = {1752-8062},
mesh = {Humans ; *Antiviral Agents/therapeutic use/pharmacology/pharmacokinetics ; *Drug Repositioning/methods ; Animals ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; COVID-19 ; Pandemics ; Hydroxychloroquine/pharmacology/therapeutic use/pharmacokinetics ; Clinical Trials as Topic ; Azithromycin/pharmacology/therapeutic use/pharmacokinetics ; Adenosine Monophosphate/analogs &amp; derivatives/pharmacokinetics/pharmacology ; },
abstract = {The Covid-19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS-CoV-2 but has not yielded successful treatments. This narrative review critically examines the pharmacological and methodological factors that contributed to these unsuccessful outcomes, paying particular attention to tests of azithromycin and hydroxychloroquine. There are many reasons the promise of repurposed drugs was not realized. Many repurposed compounds displayed promising in vitro antiviral activity that did not translate into clinical efficacy. Major pharmacokinetic (PK) limitations, for example, poor oral bioavailability, low concentrations in pulmonary tissue, and extensive plasma protein binding, prevented these drugs from reaching therapeutic levels in humans. Preclinical research often relied on non-human cell lines and animal models that inadequately reflected human physiology, leading to misleading experimental outcomes. Clinical trials were often undermined by methodological limitations, including endpoints with uncertain clinical significance, suboptimal comparators, and insufficient attention paid to key PK and pharmacodynamic (PD) parameters such as half maximal effective concentration (EC50) values. This narrative review emphasizes the importance of integrating comprehensive PK/PD assessments, relevant experimental models, and rigorous trial design to strengthen drug development during future health crises. The relative success of antivirals including molnupiravir, nirmatrelvir, and remdesivir, which were either novel or previously unapproved compounds, suggests the value of designing and developing targeted antivirals. We must coordinate global research, develop pharmacologically sound strategies, and use evidence-based decision-making to effectively prepare for future pandemics and quickly produce effective treatments.},
}
@article {pmid41700931,
year = {2026},
author = {Dhawan, S and Hughes, J and Matveyenko, AV and Poitout, V},
title = {Staying Functional Through Connection and Adaptation: When Islets Inspire Islet Biologists.},
journal = {Diabetes},
volume = {75},
number = {4},
pages = {596-602},
pmid = {41700931},
issn = {1939-327X},
support = {//J.W. Kieckhefer Foundation/ ; R01DK140088/DK/NIDDK NIH HHS/United States ; //Diabetes Canada/ ; R01DK138974/DK/NIDDK NIH HHS/United States ; RGPIN-2022-03732//Natural Sciences and Engineering Research Council of Canada/ ; R01DK140365/DK/NIDDK NIH HHS/United States ; R01DK098468/DK/NIDDK NIH HHS/United States ; PJT-469193//Institute of Nutrition, Metabolism and Diabetes/ ; R01DK132597/DK/NIDDK NIH HHS/United States ; R01 DK140088/DK/NIDDK NIH HHS/United States ; },
mesh = {*Islets of Langerhans/physiology/metabolism ; Humans ; Animals ; COVID-19 ; Adaptation, Physiological/physiology ; SARS-CoV-2 ; },
abstract = {In response to the lockdowns and travel bans during the coronavirus disease 2019 pandemic, Peter C. Butler at the University of California, Los Angeles (UCLA), started a virtual islet biology seminar series. After the authors of this article joined him as co-organizers, this initiative became the Islet Research Seminar Series (IRSS). Like islets of Langerhans adapt to their changing environment, the islet biology community quickly embraced this new format. The IRSS evolved into a lasting scientific forum that convenes weekly and is attended by islet biologists from the U.S., Canada, Europe, and Israel. The series covers a range of topics in islet biology, with presentations from scientists representing all career stages. It has proven particularly valuable for trainees and early-stage investigators in exposing them to a variety of topics in islet biology without travel required and facilitating more spontaneous interactions with senior scientists than at in-person meetings. While the online format is not meant to replace live scientific conferences, we believe that the IRSS plays a unique role in keeping the islet biology community connected and abreast of the most recent scientific discoveries in our field. The success of this platform stands as a testament to the scientific community to adapt and thrive through challenges. This article is dedicated to Peter C. Butler, UCLA, who initiated the IRSS.},
}
@article {pmid41702131,
year = {2026},
author = {Wang, Z and Ren, B and Rawaf, S and Tabche, C},
title = {Impact of the COVID-19 pandemic on cancer screening in Europe: A systematic review of disruptions, barriers, and policy responses.},
journal = {Cancer treatment and research communications},
volume = {47},
number = {},
pages = {101115},
doi = {10.1016/j.ctarc.2026.101115},
pmid = {41702131},
issn = {2468-2942},
mesh = {Humans ; Europe/epidemiology ; *COVID-19/epidemiology ; *Early Detection of Cancer/statistics &amp; numerical data/methods ; *Neoplasms/diagnosis/epidemiology ; SARS-CoV-2 ; Health Policy ; Pandemics ; Mass Screening ; },
abstract = {BACKGROUND: Cancer screening is a cornerstone of cancer control, but the COVID-19 pandemic caused unprecedented disruption to preventive healthcare worldwide. In Europe, national screening programmes were severely affected, with consequences extending beyond screening to diagnosis, treatment, and equity. While several country-specific studies exist, cross-regional syntheses remain scarce. Understanding the scale, determinants, and outcomes of these disruptions is crucial to building resilient, equiTable screening systems.<br><br>AIM/OBJECTIVE: This systematic review synthesises evidence on the impact of the COVID-19 pandemic on cancer screening across Europe, examining differences by cancer type, screening modality, and national context. It also explores downstream effects, barriers, enablers, and policy responses to guide future preparedness.<br><br>METHODS: Following PRISMA guidelines, six databases and grey literature sources were searched for studies published between December 2019 and January 2025. Eligible studies included quantitative and qualitative analyses of screening activity during the pandemic. Data were extracted on study characteristics, outcomes, and contextual factors. Given the heterogeneity of measures, findings were summarised using descriptive statistics and thematic synthesis.<br><br>RESULT: Forty-five studies from 18 European countries revealed a 30-60 % reduction in screening participation at peak disruption, varying by cancer type and country. Consequences included delayed diagnoses, stage migration, increased projected mortality, and widening inequalities. Major barriers included service suspension, staff redeployment, and fear of infection. Enablers comprised adaptive communication, safety protocols, and digital innovations.<br><br>CONCLUSION: COVID-19 caused substantial and uneven disruption to European cancer screening. Protecting continuity, institutionalising innovations, and addressing inequities are critical to enhancing resilience for future health crises.},
}
@article {pmid41702338,
year = {2026},
author = {Hazenberg, P and Duncan, CJ},
title = {Human genetics of susceptibility to live-attenuated viral vaccines.},
journal = {Current opinion in virology},
volume = {75},
number = {},
pages = {101512},
doi = {10.1016/j.coviro.2026.101512},
pmid = {41702338},
issn = {1879-6265},
mesh = {Humans ; *Vaccines, Attenuated/immunology/administration &amp; dosage/adverse effects ; *Viral Vaccines/immunology/administration &amp; dosage/adverse effects/genetics ; *Virus Diseases/prevention &amp; control/immunology/genetics/virology ; *Genetic Predisposition to Disease ; Vaccination ; Animals ; },
abstract = {Alongside the development of antibiotics, vaccination is the medical innovation with arguably the greatest impact on human health. Testament to its success is the eradication of infectious diseases, such as smallpox, that devastated human populations for almost 4000 years. Live-attenuated vaccines (LAV), which retain the capacity for infection and replication, were the first to be developed and remain highly efficacious, underpinning successful human vaccination campaigns (e.g. polio virus, measles virus, yellow fever virus). The cost of this success is the capacity of LAVs to cause disease in a small proportion of recipients, typically owing to overt or previously unappreciated immunodeficiency. From the careful investigation of such rare events, major clinical and scientific lessons about human antiviral immunity have been drawn. Here, we review features of pathogenic LAV dissemination, which continue to inform our understanding of critical steps in the immune control of LAVs. We discuss recent data on specific variants identified in geographically isolated populations and reflect on more common phenocopies of these monogenic defects, with potential implications for vaccine practice and policy. Collectively, these insights may inform approaches to the growing population of individuals rendered more vulnerable to LAVs by aging, multimorbidity or medical intervention. They also serve to highlight the clinical need for therapeutic strategies to combat pathogenic LAV dissemination.},
}
@article {pmid41702386,
year = {2026},
author = {Yadegari, H},
title = {Von Willebrand Factor at the Crossroads of Hemostasis and Inflammation.},
journal = {Hamostaseologie},
volume = {46},
number = {1},
pages = {34-43},
doi = {10.1055/a-2755-5477},
pmid = {41702386},
issn = {2567-5761},
mesh = {Humans ; *von Willebrand Factor/immunology/metabolism ; *Hemostasis/immunology ; *Inflammation/immunology/blood ; Immunity, Innate ; Animals ; COVID-19/immunology/blood ; },
abstract = {Von Willebrand factor (VWF) is a large multimeric glycoprotein critical for hemostasis, mediating platelet adhesion to injured vessels and stabilizing circulating factor VIII. However, accumulating evidence reveals a complex, context-dependent role for VWF in inflammation and innate immunity that extends well beyond coagulation. VWF acts not only as a biomarker of endothelial activation but also as an active participant in immune responses. VWF directly interacts with major immune cell types-including macrophages, polymorphonuclear leukocytes (neutrophils), and dendritic cells-through both its endothelial-anchored and plasma forms. VWF facilitates leukocyte recruitment and transmigration across the vessel wall, while its interactions also promote macrophage and neutrophil activation as well as NET formation. VWF's immunomodulatory functions are further highlighted by its binding to extracellular DNA, smooth muscle cells, complement components (C1q and C3), and bacterial pathogens under flow conditions. Furthermore, VWF indirectly influences inflammation via its crucial role in Weibel-Palade body formation, a process that co-packages vital inflammatory mediators like P-selectin and angiopoietin-2. Markedly elevated VWF levels are consistently observed across acute and chronic inflammatory conditions such as sepsis, COVID-19, and autoimmune disorders, confirming its relevance as both a diagnostic marker and a therapeutic target. A comprehensive understanding of VWF's diverse functions in vascular inflammation is crucial for developing targeted therapeutics-including nanobodies, ADAMTS13 variants, and VWF interaction inhibitors-capable of modulating pathological thrombo-inflammation while preserving physiological hemostasis.},
}
@article {pmid41702637,
year = {2026},
author = {Torres Munguía, JA and Martínez-Zarzoso, I},
title = {Global trends of pandemic-prone and epidemic-prone disease outbreaks in 2024.},
journal = {BMJ global health},
volume = {11},
number = {2},
pages = {},
pmid = {41702637},
issn = {2059-7908},
mesh = {Humans ; *Pandemics ; COVID-19/epidemiology ; *Disease Outbreaks/statistics &amp; numerical data ; *Global Health/statistics &amp; numerical data ; SARS-CoV-2 ; },
abstract = {During 2024, the number of pandemic-prone and epidemic-prone disease outbreaks worldwide was estimated at 301. The data highlight a shift in disease outbreak patterns, with a decline in the number of countries reporting public health events of concern linked to COVID-19 and a rise in those reporting outbreaks of viral diseases transmitted by vectors.About 90% of the outbreaks in 2024 were associated with COVID-19, dengue, yellow fever, Oropouche virus disease and influenza (linked to identified zoonotic or pandemic influenza virus). Although disease outbreaks can affect any country anywhere, they tend to disproportionately occur in countries facing many other socio-economic development, climatic and humanitarian challenges. In this regard, sub-Saharan Africa and the subregion of Latin America and the Caribbean-home to just 23.3% of the world's population-reported the highest number of disease outbreaks in 2024 with about 57% of the total. Particularly, the sub-Saharan Africa region has been the site of nearly 32% of recorded outbreaks since 1996. Future research should include efforts to improve the quality and availability of disease outbreaks data-particularly in the most exposed or vulnerable regions-and to promote the scientific use of such information for foresight purposes and for forecasting future health events of concern to support anticipatory action.},
}
@article {pmid41703981,
year = {2026},
author = {Tuschick, E and Smith, J and Harrison, B and Youngman, M and Giles, EL},
title = {Food Insecurity in Families With Children or Young People With Autism: A Systematic Review and Meta-Analysis.},
journal = {Nutrition bulletin},
volume = {51},
number = {2},
pages = {185-199},
pmid = {41703981},
issn = {1467-3010},
mesh = {Humans ; *Food Insecurity ; Child ; Adolescent ; COVID-19/epidemiology ; *Autism Spectrum Disorder ; *Autistic Disorder ; Prevalence ; *Family ; Feeding Behavior ; Caregivers/psychology ; SARS-CoV-2 ; Child, Preschool ; },
abstract = {Food insecurity is frequently reported among families of children with autism spectrum conditions (ASC), yet there is limited evidence synthesising its prevalence and impact. This systematic review aimed to examine and meta-analyse the existing literature on food insecurity in families of children and young people with ASC. A comprehensive search across nine databases identified 39 papers, of which 11 met the inclusion criteria. Studies were included if they involved autistic children or young people under the age of 25 (and/or their family members) and focused on food insecurity. Eligible studies were critically appraised, and data were synthesised using both narrative and meta-analytic approaches. Meta-analyses of nine studies estimated a pooled prevalence of food insecurity at 29% (SE: 5%; 95% CI: 17%-40%; z = 5.35, p < 0.001), which increased to 31% following adjustment for publication bias. The review also found that food insecurity worsened during the COVID-19 pandemic, contributing to increased caregiver stress and disruptions in eating behaviours. This review demonstrates the high prevalence of food insecurity among families of children with ASC and the complex interplay of social, economic and behavioural challenges they face. Addressing food insecurity in autistic households requires policy responses that extend beyond financial aid to consider the sensory, behavioural and nutritional needs specific to ASC. Future research should adopt standardised measures and prioritise the development and evaluation of inclusive, tailored food support systems that reflect the lived experiences of neurodiverse families.},
}
@article {pmid41704166,
year = {2026},
author = {Gerrie, A and Bellman, S and Pollock, D},
title = {Experiences of people with diabetes mellitus during the COVID-19 pandemic utilizing telehealth for diabetes management: a qualitative systematic review.},
journal = {JBI evidence synthesis},
volume = {24},
number = {6},
pages = {1102-1155},
doi = {10.11124/JBIES-25-00355},
pmid = {41704166},
issn = {2689-8381},
mesh = {Humans ; *Telemedicine ; *COVID-19 ; *Diabetes Mellitus/therapy ; Pandemics ; SARS-CoV-2 ; Qualitative Research ; Digital Health ; },
abstract = {OBJECTIVE: The objective of this review was to explore the experiences of people with diabetes mellitus who utilized telehealth for diabetes management due to COVID-19 pandemic.<br><br>INTRODUCTION: COVID-19 intensified globally from January 2020, eliciting a multinational response to infection control for health preservation, including social distancing in public areas and health. The outcome had significant impact on the health care system, where persons with chronic diseases such as diabetes were required to transition a majority of their care to telehealth to align with social restrictions. To date, research has not addressed a synthesis or critical analysis in systematic reviews addressing the experiences of people with diabetes mellitus receiving care, and what effect this rapid shift to telehealth had compared with traditional in-person consultations.<br><br>ELIGIBILITY CRITERIA: This review included primary qualitative or mixed methods studies of any research design that examined the experiences of adult with diabetes transitioning from in-person consultations to telehealth during the COVID-19 pandemic. Exclusions included quantitative studies; secondary, tertiary, and gray literature; and literature pre-COVID-19.<br><br>METHODS: This review was conducted according to JBI guidance on qualitative systematic reviews. A search of CINAHL (EBSCOhost), Scopus, Embase, Emcare (Ovid), PubMed, and ProQuest Central was conducted. Studies from January 2020 onward in any language were assessed for eligibility. Two reviewers independently screened studies and assessed the methodological quality of the included studies using the JBI Qualitative Critical Appraisal Tool. The included studies were synthesized using JBI meta-aggregation, and the confidence in the findings was assessed with ConQual.<br><br>RESULTS: The reviewers screened 1491 titles and abstracts, and 9 studies were selected for inclusion. Three synthesized findings were identified: i) The provision of care and diabetes self-management capabilities utilizing telehealth was based on the awareness and acceptance of services, the perceived quality of communication, and the ability for patients to access safe and quality health assessments and care; ii) Telehealth was seen as logistically convenient, saving effort, money, and time through reduced travel for patients; and iii) Telehealth requires user-friendly infrastructure that considers accessibility, connectivity, compatibility, and digital health literacy.<br><br>CONCLUSIONS: The review validates the existing utilization of telehealth for diabetes care, further suggesting implementation of formalized telehealth as a hybrid model service for diabetes care delivery beyond the pandemic.<br><br>REVIEW REGISTRATION: PROSPERO CRD4202342466.},
}
@article {pmid41705169,
year = {2025},
author = {Dost, G},
title = {Belongingness and loneliness in higher education: a meta-analysis of pre- and post-pandemic trends.},
journal = {Frontiers in psychology},
volume = {16},
number = {},
pages = {1625957},
pmid = {41705169},
issn = {1664-1078},
abstract = {INTRODUCTION: This meta-analysis seeks to explore how the complex relationship between loneliness and belongingness in higher education students can be explained by a set of pre- and post-COVID-19 pandemic dynamics.<br><br>METHODS: A meta-analysis including 56 studies and involving a total of 30,062 participants was conducted, and the review explores direct relations and moderation through age, education, and country.<br><br>RESULTS: Results indicate a moderate-to-strong negative relationship between loneliness and belongingness (r = -0.48, 95% CI [-0.529, -0.422]), such that a consistent association was found across situations such that increases in one's level of loneliness is associated with decreases in one's level of belongingness. Nevertheless, there was no small-degree of inter-study heterogeneity (Q = 1058.86, p&#x202f;<&#x202f;0.0001, I[2] = 94.33%), which is a potential reason for the differences in the study populations and methods, employing a random-effects model to account for these discrepancies. After further scrutiny of the results, location, and year of study, and country did not moderate the effect size, which in turn reflects the stability of the association across context and time. In the subgroup analysis the effect size of the relationship between the level of the Information Technology (IT) usage and the externalisation was lower in the time of the pandemic than in the time preceding the pandemic. The effect size of the pre-pandemic group is -0.515 (95% CI: -0.589 to -0.441, p&#x202f;<&#x202f;0.001 < 0.001) and the effect size of pandemic group is slightly smaller with -0.427 (95% CI: -0.502 to -0.352, p&#x202f;<&#x202f;0.001 < 0.001). This means that although the level of loneliness have normalised, there have been a subtonic influence on perceived belonging of the novelty stressor caused by breakdowns in social connection from pandemic-level influences. In addition, no significant publication bias was observed.<br><br>DISCUSSION: Overall, these findings confirm the strong negative association between loneliness and sense of belonging and emphasise the important role in providing community support for students, especially during social disruptions.},
}
@article {pmid41707545,
year = {2026},
author = {Goren, T and Vashdi, DR and Beeri, I},
title = {Political trust and health compliance during a health crisis: A systematic literature review from the COVID-19 pandemic.},
journal = {Social science &amp; medicine (1982)},
volume = {395},
number = {},
pages = {119093},
doi = {10.1016/j.socscimed.2026.119093},
pmid = {41707545},
issn = {1873-5347},
mesh = {Humans ; *Trust ; COVID-19 ; *Politics ; *Pandemics/prevention &amp; control ; SARS-CoV-2 ; },
abstract = {Political trust is considered crucial for enhancing civic compliance with government policies and instructions, particularly during a health crisis. However, evidence from the COVID-19 pandemic, a major global health crisis, suggest a more nuanced relationship. Aiming to explore and clarify the nature of and the conditions for the political trust and civic compliance relationship in the context of a health crisis in the general population, at the overall societal-level, this study systematically reviews relevant literature from the COVID-19 pandemic, across 62 countries. Our findings indicate that the positive relationship between political trust and compliance is not self-evident, as 42% of the reviewed studies (63 of 151) report non-significant, mixed or negative results. Moreover, conceptual and methodological features seem to affect the likelihood of this association, such as the object of trust and compliance behavior, the behavior's execution timeframe and its legal status, and the manner in which political trust and compliance are measured. Potential consequences are discussed.},
}
@article {pmid41707618,
year = {2026},
author = {Xu, Q and Zhao, M and Wang, Q and He, Y and Ye, G and Yang, J and Huang, W and Ren, J},
title = {Chronic fatigue syndrome: From etiology and mechanism to diagnosis and treatment.},
journal = {Journal of psychiatric research},
volume = {196},
number = {},
pages = {171-184},
doi = {10.1016/j.jpsychires.2026.02.026},
pmid = {41707618},
issn = {1879-1379},
mesh = {Humans ; *Fatigue Syndrome, Chronic/diagnosis/therapy/etiology ; *COVID-19/complications ; },
abstract = {Myalgic encephalomyelitis (ME), commonly known as chronic fatigue syndrome (CFS), is a long-lasting neurological disease. The cause of ME remains uncertain, characterized by unrelenting or recurring fatigue not alleviated by rest. In recent times, CFS incidence has been on the rise annually, showing a tendency towards younger sufferers. Especially post-COVID-19, its prevalence has surged, posing a significant threat to 21st-century health. CFS symptoms are intricate and diverse. Patients typically endure extreme fatigue lasting over six months, accompanied by physical and neuropsychiatric symptoms like sore throat, muscle/joint pain, anxiety, and distress. These severely disrupt daily life and work, heightening illness risks and financial strain. With the unknown etiology, current treatments have limited success and may induce psychological issues such as anxiety and depression. This paper delivers an extensive and thorough overview of the latest developments in the studies concerning the pathogenesis, diagnostic standards, and therapeutic approaches for chronic fatigue syndrome. Integrating and assessing the existing knowledge body related to this field systematically, we aim to facilitate continuous research and gain a deeper understanding of this complex medical problem whose mechanism remains largely unknown. Moreover, valuable insights and practical recommendations for future related treatments and research are also provided.},
}
@article {pmid41708119,
year = {2026},
author = {Radtke, T and Pham-Ngoc, H and Hua-Huy, T and Hsia, CCW and Dressel, H and Dinh-Xuan, AT},
title = {Pulmonary diffusing capacity for nitric oxide in disease: a scoping review.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {179},
pages = {},
pmid = {41708119},
issn = {1600-0617},
mesh = {Humans ; *COVID-19/physiopathology ; *Lung/physiopathology/metabolism ; *Lung Diseases/physiopathology/diagnosis/metabolism ; *Nitric Oxide/metabolism ; Predictive Value of Tests ; *Pulmonary Diffusing Capacity ; },
abstract = {OBJECTIVE: This scoping review aims to map the available studies on single-breath pulmonary diffusing capacity for nitric oxide (D LNO) in various clinical diseases and identify gaps for future research.<br><br>METHODS: We followed the JBI methodology for scoping reviews. A systematic literature search was conducted in Embase, MEDLINE (EBSCOhost), PubMed, Scopus, Web of Science and the Cochrane Library to identify studies on D LNO from 1983 to 2025. Two reviewers screened abstracts using Rayyan software and extracted data using standardised templates implemented into REDCap (Research Electronic Data Capture).<br><br>RESULTS: We identified 1638 studies, of which 69 met the eligibility criteria. These studies represented respiratory (n=22), immunological/genetic/systemic (n=14), post-COVID-19 sequelae (n=13), cardiovascular (n=9), metabolic/endocrine/renal (n=6), environmental-related (n=3) and other (n=2) conditions. There was substantial heterogeneity in disease categories, sample sizes and reporting methods. Nearly half of the studies (49.3%) used convenience sampling, where participant selection processes are often poorly described; 62.3% included <50 participants. Only 18.8% reported a sample size calculation, and 10.1% registered or published a study protocol. Disparate findings within disease categories were often difficult to interpret; and small sample sizes limited generalisability. In some specific conditions, D LNO showed sensitivity in detecting interstitial and fibrotic changes compared to conventional single-breath pulmonary diffusing capacity for carbon monoxide (D LCO) while simultaneous D LNO-D LCO measurements permitted the detection of pulmonary vascular-haematological perturbations.<br><br>CONCLUSION: Single-breath D LNO-D LCO may provide additional pathophysiological insight by assessing the relative contributions from membrane and blood resistance of diffusion. Larger studies are required to clarify its interpretation across disease states.},
}
@article {pmid41709444,
year = {2026},
author = {Park, JJ and Na, SH and Park, H and Lee, J and Seo, Y},
title = {Layout Types and Efficiency Improvement Strategies for Open Points of Dispensing in Vaccine and Antibiotic Distribution: A Scoping Review.},
journal = {Prehospital and disaster medicine},
volume = {41},
number = {1},
pages = {e1},
doi = {10.1017/S1049023X26108838},
pmid = {41709444},
issn = {1945-1938},
mesh = {Humans ; *Anti-Bacterial Agents/supply &amp; distribution ; *Vaccines/supply &amp; distribution ; *Efficiency, Organizational ; COVID-19/prevention &amp; control ; Workflow ; Pandemics/prevention &amp; control ; },
abstract = {INTRODUCTION: Regarding pandemics or bioterrorism incidents, prompt and secure distribution of vaccines and prophylactic antibiotics is crucial. Open Points of Dispensing (PODs) are established to serve the public, and their effectiveness depends on the internal spatial layout and operational workflow design. However, studies on systematic classifications of open POD configurations and comprehensive syntheses of strategies for enhancing operational efficiency are lacking.<br><br>STUDY OBJECTIVE: This scoping review aimed to classify open POD layout types used for vaccine and antibiotic distribution and to consolidate strategies that improve efficiency across various workflow stations.<br><br>METHODS: A scoping review was conducted following the PRISMA-ScR guidelines. A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases, spanning from January 2001 through July 2025. The search strategy involved incorporating keyword combinations related to "points of dispensing," "mass vaccination," "mass prophylaxis," and specific pathogens such as anthrax, influenza, and COVID-19. Extracted data included the POD layout typologies, process designs, and efficiency metrics. The findings were synthesized using a narrative approach.<br><br>RESULTS: Nineteen studies met the inclusion criteria and were analyzed. Vaccine PODs were classified into four primary layouts, namely station-based sequential-flow, cell-based, fixed-seat service, and pop-up PODs. Antibiotic PODs were categorized into two types, namely sequential processing and selective-expedited processing. Each layout exhibited unique operational characteristics, including sequential versus integrated clinical stations (for vaccine PODs) and standard versus expedited dispensing lines (for antibiotic PODs). Efficiency enhancement strategies across workflow stations included task integration, use of digital tools, simplification of documentation, optimization of medication preparation, and staffing adjustments guided by simulation modeling.<br><br>CONCLUSION: This review provides a systematic classification of open POD layouts and summarizes the strategies for improving efficiency across workflow stations. The derived insights offer practical guidance for planning and operating PODs in future public health emergency responses.},
}
@article {pmid41709949,
year = {2026},
author = {Vatankhah, H and Vatanparast, M and Royani, Z and Mansouri, G},
title = {Lessons from a Low-Resource Country: A Narrative Review of Virtual Learning Adoption and Challenges in Medical Education in Iran During COVID-19.},
journal = {Advances in medical education and practice},
volume = {17},
number = {},
pages = {561822},
pmid = {41709949},
issn = {1179-7258},
abstract = {OBJECTIVE: The global COVID-19 pandemic has had a profound impact on the education system. Education shifted to virtual methods, while there was not enough time to plan and choose a proper educational platform. In this study, we present an up-to-date review of the most commonly used virtual education platforms in Iran during the COVID-19 pandemic.<br><br>METHODS: This narrative review systematically searched Persian and English articles (2020-2024) in Medline, EMBASE, Scopus, Web of Science, ERIC, SID, CIVILICA, and PubMed using keywords: "COVID-19", "virtual learning", "online learning", "distance learning", "post-COVID infection", "real and virtual simulation", and "educational platforms".<br><br>RESULTS: Virtual classes have become increasingly popular during the pandemic. Adobe Connect, Sky Room, Skype, Big Blue Button, Google Meet, Gharar, Zoom, and Navaid System were the most commonly used platforms during the COVID pandemic in Iran. The most frequently utilized systems included Shad (predominant in general education and training) and Navid (leading in medical sciences). Shad had excelled in scalability and institutional integration but faced connectivity issues in rural areas. Despite its technical strengths, Navid was criticized because of insufficient interactivity and misalignment with learner needs in medical English.<br><br>DISCUSSION: During COVID-19, online medical education in Iran relied mainly on domestic platforms, which have some limitations. To ensure future equity and competency, a shift toward hybrid models incorporating offline-capable Learning Management Systems (LMS), simulation, and digital literacy training is essential.},
}
@article {pmid41710161,
year = {2026},
author = {Andreadis, I and Vasilopoulou, S},
title = {The populism-euroscepticism nexus in a contested Europe: The EUPopLink COST Action.},
journal = {Open research Europe},
volume = {6},
number = {},
pages = {27},
pmid = {41710161},
issn = {2732-5121},
abstract = {The EUPopLink COST Action (CA23102) addresses the complex and changing relationship between populism and Euroscepticism in contemporary Europe. While often viewed as "two sides of the same coin," the nexus between these two phenomena is contingent and strategic rather than deterministic. Not all populists are Eurosceptic, and Euroscepticism is not always populist in nature. This publication synthesizes current scholarly debates, highlighting how the European Union (EU) is frequently framed as the populist "other", i.e., a remote, technocratic elite standing in opposition to the "pure people". The nature of this opposition varies significantly across the ideological spectrum, e.g. right-wing populism targets the EU primarily through a "traditionalist-authoritarian-nationalist" (TAN) lens, viewing it as a threat to national sovereignty and cultural identity, while left-wing populism critiques the EU based on socio-economic cleavages, challenging neoliberal governance and austerity while often advocating for a more democratic "Social Europe". The analysis further explores how the polycrisis era-marked by financial instability, the COVID-19 pandemic, and geopolitical conflict-has led to a sophisticated two-level strategy among populist actors. This involves increased institutional pragmatism coupled with radicalized, opportunistic communication, particularly on social media. Finally, the publication outlines the EUPopLink mandate, which seeks to standardize conceptual frameworks and generate an unprecedented body of comparative data through forthcoming country reports. By linking the supply and demand sides of electoral competition, the project aims to provide policymakers and scholars with the tools necessary to mitigate the negative consequences of these disruptive political forces.},
}
@article {pmid41710305,
year = {2026},
author = {Paterson, A and Spies, R and Zauchenberger, CZ and Cheyne, A and Olliaro, PL and Rojek, A},
title = {Effectiveness of stigma reduction interventions and outbreak response adaptations in infectious disease outbreaks: a systematic review.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1755092},
pmid = {41710305},
issn = {2296-2565},
mesh = {Humans ; *Disease Outbreaks/prevention &amp; control ; *Social Stigma ; *COVID-19/psychology/epidemiology ; Severe Acute Respiratory Syndrome/psychology/epidemiology ; SARS-CoV-2 ; Hemorrhagic Fever, Ebola/psychology/epidemiology ; },
abstract = {INTRODUCTION: Stigma is a common and recurring feature of infectious disease outbreaks where it may have detrimental effects on individual wellbeing and undermine outbreak response. This systematic review explores stigma reduction interventions in infectious disease outbreaks.<br><br>METHODS: Eligible studies were searched for in Medline, Embase, PsycINFO, and Global Health databases and through reference screening. Risk of bias was assessed using study design-specific tools and the results of included studies underwent narrative synthesis.<br><br>RESULTS: Eleven studies conducted across coronavirus disease 2019 (COVID-19), Ebola disease, mpox, severe acute respiratory syndrome (SARS), and a hypothetical infectious-disease scenario, met the inclusion criteria. Five studies reported reductions in stigma, four reported mixed or null results, and two reported increases in stigma. The most promising strategies for outbreak-related stigma reduction were embedding anti-stigma messaging within health communication, providing psychosocial support, and fostering genuinely participatory community involvement.<br><br>DISCUSSION: Evidence on how to effectively reduce stigma during outbreaks remains limited. Strengthening the theoretical foundations, measurement tools, and evaluation designs of stigma-reduction interventions will be essential to inform evidence-based outbreak preparedness and response policies. This would help decision-makers ensure that risk communication, community engagement, and service delivery minimise stigma and improve uptake of testing, care, and preventive measures.},
}
@article {pmid41710320,
year = {2026},
author = {Kerai, T and Woolhouse, M and Nyazema, NZ and Mutapi, F},
title = {A narrative review of heterogeneity in SARS-CoV-2 infection outcomes and vaccine efficacy: strategizing pandemic preparedness in Africa.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1761547},
pmid = {41710320},
issn = {2296-2565},
mesh = {Humans ; *COVID-19/epidemiology/prevention &amp; control/immunology ; Pandemic Preparedness ; Africa/epidemiology ; *Vaccine Efficacy ; *COVID-19 Vaccines/immunology ; SARS-CoV-2 ; Pandemics/prevention &amp; control ; },
abstract = {Disease epidemiology during the COVID-19 pandemic differed greatly across the globe. In contrast to early pandemic predictions, Africa recorded the fewest SARS-CoV-2 related hospitalizations and deaths. Hypotheses proposed to explain this paradox include underreporting, age demographics, climate, national mitigation strategies, lifestyle factors, pre-existing cross-reactive protection, and host genetic determinants. This traditional, narrative review evaluates these hypotheses investigated in the published literature, and highlights knowledge gaps which limit our understanding and obscure validation of potential explanations. It also discusses how responses to vaccines, the primary intervention sought to control infectious disease outbreaks, may vary both within the African population and across other continents. Potential explanations in the literature include pre-existing immunity, poor nutrition, immune modulating co-infections, comorbidities, microbiome composition, genetic polymorphisms, and demographic factors. Previous studies have shown that pre-existing (infection-derived) immunity or cross-reactive immune responses can augment vaccine-elicited positive responses and can protect against reinfection in a way similar to immunization. Conversely, there are also studies showing that prior immunity interferes with the efficacy of new vaccines through mechanisms like original antigenic sin and immune imprinting. Thus, there is need for more immunology studies to understand the relative contribution of pre-existing cross-reactive immune responses to the epidemiology of new pathogens. These studies are particularly essential to understand the differences between pandemic preparedness and population vulnerability, as well as to inform vaccine development and vaccine effectiveness monitoring studies. SARS-CoV-2 serves as an important case study to understand heterogeneity between and within populations in immune responses to both the pathogen and to vaccination. This understanding is crucial in informing vaccine research and development aimed at supporting the 100-day mission for when the next pandemic threat emerges.},
}
@article {pmid41710557,
year = {2025},
author = {Muzard, C and Seguin, J and Bonnefoy, J and Salkini, N and Serra, V and Alhareth, K and Lemdani, K and Mignet, N},
title = {Pre-clinical evaluation of mRNA-lipid nanoparticles' potency and toxicity: current practices and future directions.},
journal = {In vitro models},
volume = {4},
number = {3-4},
pages = {177-194},
pmid = {41710557},
issn = {2731-3441},
abstract = {Over the last few years, the success of COVID-19 mRNA vaccines has resulted in the emergence of RNA lipid nanoparticles (LNPs) with promising prospects for the prevention and treatment of various diseases. The context of the SARS-CoV-2 pandemic has led to the rapid development of vaccines with abbreviated non-clinical programs. However, there are currently no official guidelines defining the required standards for global marketing of mRNA based therapeutic products. Nevertheless, to guarantee a well-controlled product, it is essential to characterize both the drug substance and the final product in terms of their structure, composition, formulation, physico-chemical features, potency, and safety. This lack of guidance has resulted in a wide variety of heterogeneous in vitro tests being used to assess the potency and cytotoxicity of RNA-LNP. This review discusses the commonly used in vitro assays, primarily 2D monolayer assays, employed to evaluate the biological properties of RNA-LNP. We then explore novel alternative methods to bridge the gap between in vitro and in vivo results. We summarize (i) co-culture models, (ii) multilayer 3D assays and (iii) in vivo replacement models, exploring their potential applications in assessing the potency and safety of RNA-LNPs. Finally, we discuss the use of in silico and machine learning as models for optimizing and predicting the biological behavior of RNA-LNPs.},
}
@article {pmid41710600,
year = {2026},
author = {Almohammadi, AA},
title = {The role of vaccination and infection prevention in reducing perioperative complications: A public health-anesthesia nexus.},
journal = {Saudi journal of anaesthesia},
volume = {20},
number = {1},
pages = {166-173},
pmid = {41710600},
issn = {1658-354X},
abstract = {The intersection of vaccination strategies, infection prevention protocols, and perioperative care represents a critical nexus in modern anesthetic practice and public health. This comprehensive review examines the evolving role of immunization and infection control measures in reducing perioperative complications, with particular emphasis on the Saudi Arabian healthcare context. The coronavirus disease 2019 pandemic has highlighted the importance of vaccination timing in relation to elective surgery, while established infection prevention practices continue to form the cornerstone of safe perioperative care. In Saudi Arabia, national initiatives have demonstrated significant improvements in healthcare-associated infection rates, with central line-associated bloodstream infections decreasing from 2.5 per 1000 catheter-days in 2021 to 1.28 per 1000 catheter-days by 2024. The implementation of evidence-based vaccination protocols and comprehensive infection prevention strategies has shown measurable benefits in reducing surgical site infections, respiratory complications, and overall perioperative morbidity. Anesthesiologists play a pivotal role in this public health framework, serving as key stakeholders in perioperative optimization through vaccination status assessment, infection control adherence, and risk stratification. The Saudi healthcare system's commitment to infection prevention excellence, aligned with Vision 2030 objectives, provides a unique model for integrating public health principles into anesthetic practice. Current evidence supports the strategic timing of vaccinations relative to elective procedures, with recommendations for postponing elective surgery 3-7 days after inactivated vaccines and 14-21 days following live vaccines. This review synthesizes current evidence, identifies best practices, and proposes future directions for optimizing the vaccination-infection prevention-anesthesia nexus to improve patient outcomes and advance public health goals within the Saudi healthcare landscape.},
}
@article {pmid41710641,
year = {2026},
author = {Alabdulhadi, O and Almashari, Y and Alharbi, M},
title = {Virtual hospitals in the Kingdom of Saudi Arabia: A scoping review.},
journal = {Saudi journal of anaesthesia},
volume = {20},
number = {1},
pages = {188-196},
pmid = {41710641},
issn = {1658-354X},
abstract = {Virtual health hospitals have been on the rise significantly since COVID-19 globally. The Kingdom of Saudi Arabia has established several initiatives as part of Vision 2030, where Tele/Virtual Health is key part of this vision. The purpose of this review is to evaluate and establish the expected challenges and the potential value in virtual hospitals in Saudi Arabia. It also aims to identify and analyze gaps in existing knowledge to ideally aid the planning and commissioning of future research on this subject. Results of this review highlight several themes from the literature evolved as follow: 1) need for improvement in Saudi healthcare, 2) emergence of virtual healthcare due to COVID-19, 3) Virtual healthcare has many pros and cons to consider, and, 4) Virtual healthcare has many challenges.},
}
@article {pmid41710827,
year = {2026},
author = {Chapman, SR and Willner, L and Abouafech, A and Roberti, C and Willner, C},
title = {Diagnostic Performance of Artificial Intelligence in Detecting COVID-19 Pneumonia on Chest Imaging.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e101775},
pmid = {41710827},
issn = {2168-8184},
abstract = {The COVID-19 pandemic highlighted the need for rapid, accurate, and accessible diagnostic tools. Chest imaging modalities, including chest radiography (CXR) and computed tomography (CT), provided valuable diagnostic information and prompted the development of artificial intelligence (AI) systems to support image interpretation and improve workflow efficiency. This literature review synthesizes current evidence on the diagnostic performance, limitations, and clinical implications of AI models in COVID-19 pneumonia detection through CXR and CT evaluation. A PubMed search was conducted through October 2025 to identify studies evaluating AI systems for the detection of COVID-19 pneumonia using CXR and CT. Studies reporting diagnostic performance metrics, including sensitivity, specificity, accuracy, or area under the curve (AUC), were included. Study quality and risk of bias were assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Eleven studies met the inclusion criteria. CXR-based AI systems demonstrated sensitivities from 80% to 98% and specificities from 82% to 96%, often comparable to radiologist performance. CT-based AI models achieved accuracies between 90% and 96%. AI models demonstrated strong internal diagnostic performance on CXR and CT but showed reduced accuracy with external validation, underscoring limitations related to generalizability and retrospective study designs. AI models demonstrate promising diagnostic performance for detecting COVID-19 pneumonia on chest imaging and may enhance radiologist efficiency. However, challenges related to generalizability, model adaptability, and clinician trust remain. Future research should prioritize external validation and transparent reporting to ensure the safe and effective integration of AI into clinical practice.},
}
@article {pmid41710955,
year = {2026},
author = {Anderson, AS},
title = {Vaccines against antimicrobial resistance.},
journal = {Philosophical transactions of the Royal Society of London. Series B, Biological sciences},
volume = {381},
number = {1944},
pages = {},
doi = {10.1098/rstb.2025.0007},
pmid = {41710955},
issn = {1471-2970},
support = {//Pfizer/ ; GAMRIF//UKRI/MRC Wellcome/ ; GAMRIF//UK Department of Health and Social Care/ ; },
mesh = {*Drug Resistance, Bacterial ; *Bacterial Vaccines ; Humans ; *Viral Vaccines ; Anti-Bacterial Agents/pharmacology ; *Drug Resistance, Microbial ; },
abstract = {Antimicrobial resistance (AMR) is a global clinical and economic threat due to the impact that it has on how potentially deadly infections can be treated. Without intervention, it is estimated that AMR will be responsible for 10 million deaths a year by 2050, with a cost of 100 trillion USD. Sustainable prevention strategies are urgently needed to control the spread of AMR in communities and healthcare settings. Vaccines play an important role, not only in protection against emerging drug-resistant pathogens, but also in reducing antibiotic consumption by preventing infections before antimicrobial intervention begins. This review provides an overview of several existing bacterial and viral vaccines that have demonstrated effectiveness in reducing this burden and discusses the importance of development of further vaccines to tackle AMR, with a particular focus on Clostridioides difficile and group B streptococcus, for which long-awaited vaccines may be on the horizon. This article is part of the Royal Society Science+ meeting issue 'Vaccines and antimicrobial resistance: from science to policy'.},
}
@article {pmid41712028,
year = {2026},
author = {Chakraborty, C and Bhattacharya, M and Chatterjee, S and Lee, SS},
title = {Long COVID-associated neurological symptoms and brain fog: Understanding the mechanism of neuroinflammation, BBB disruption, diagnostics, and therapeutics.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {401},
pmid = {41712028},
issn = {1573-4978},
mesh = {Humans ; Post-Acute COVID-19 Syndrome ; *Blood-Brain Barrier/pathology/metabolism ; *COVID-19/complications ; *Neuroinflammatory Diseases/diagnosis/therapy/virology ; SARS-CoV-2 ; Animals ; *Nervous System Diseases/diagnosis/therapy/etiology/virology ; Brain/pathology ; Pandemics ; },
abstract = {Long COVID affects at least 10% of those with severe disease, and many experience neurological symptoms and brain fog. More than 200 symptoms are reported, yet a detailed understanding remains limited. This article summarizes current knowledge of neurological symptoms, brain fog, molecular mechanisms, neuroinflammation, blood-brain barrier disruption, diagnostics, and available therapeutics. Our review highlights the lack of diagnostics and treatments for these patients. We catalog the ongoing clinical trials, identify the urgent need for further therapeutics, and stress that advances in understanding pathophysiology will drive new treatments. We urge prioritizing animal model studies and improving diagnostics to accelerate the discovery and delivery of effective treatments for long COVID neurological symptoms.},
}
@article {pmid41712936,
year = {2026},
author = {Jamieson, DJ and Munoz, FM and Rasmussen, SA},
title = {Maternal Immunization.},
journal = {Obstetrics and gynecology},
volume = {147},
number = {5},
pages = {661-678},
pmid = {41712936},
issn = {1873-233X},
mesh = {Humans ; Female ; Pregnancy ; *Immunity, Maternally-Acquired ; *Pregnancy Complications, Infectious/prevention &amp; control ; *Immunization/methods ; *Vaccination/methods ; },
abstract = {Vaccines administered to women during pregnancy can provide protection against serious infectious diseases for the mother, the child, or both. Maternal immunization boosts the concentration of maternal antibodies that can be transferred across the placenta to directly protect children too young to be immunized. In addition, indirect protection through prevention of maternal infection and breast-milk antibodies can be achieved through maternal immunization. In general, inactivated vaccines are considered safe for pregnant women and fetuses, whereas live attenuated vaccines are avoided due to the theoretical potential risk of infection to the fetus. However, the potential risks of vaccines need to be weighed against the risk of the disease itself and the benefits of vaccination in terms of protection of the mother and child against infectious disease. Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap); influenza; coronavirus disease 2019 (COVID-19); and respiratory syncytial virus (RSV) vaccines are routinely recommended for all pregnant women in the United States. Maternal immunization has the potential to improve the health of mothers and young children; therefore, other diseases of relevance during this period are now targets of active research and vaccine development, including group B streptococcus (GBS). Similarly, several vaccines can be administered during pregnancy in special circumstances when maternal health, travel, or other special situations arise. This article reviews the current recommendations for vaccination of women during pregnancy.},
}
@article {pmid41712960,
year = {2026},
author = {Wang, X and Xie, Y and Chen, X and Yang, J and Li, R and Gao, W and Yan, Z and Zhou, H and Ye, Z},
title = {Securing Federated Learning With Blockchain in the Medical Field: Systematic Literature Review.},
journal = {Journal of medical Internet research},
volume = {28},
number = {},
pages = {e79052},
pmid = {41712960},
issn = {1438-8871},
mesh = {*Federated Learning ; *Blockchain ; Humans ; Computer Security ; Information Dissemination ; Telemedicine ; },
abstract = {BACKGROUND: The exponential growth of medical data and advancements in artificial intelligence (AI) have accelerated the development of data-driven health care. However, the secure and efficient sharing of sensitive medical data across institutions remains a major challenge due to privacy concerns, data silos, and regulatory restrictions. Traditional centralized systems are prone to data breaches and single points of failure, while existing privacy-preserving techniques face high computational and communication costs.<br><br>OBJECTIVE: This study aims to provide a comprehensive review of the recent advances in blockchain-based federated learning (BCFL) within the medical field. By exploring the synergistic integration of federated learning and blockchain, this review evaluates how BCFL enhances data security, supports privacy-preserving cross-institutional collaboration, and facilitates practical applications in health care, including medical data sharing, Internet of Medical Things, public health surveillance, and telemedicine.<br><br>METHODS: We conducted a systematic literature review using databases such as PubMed, IEEE Xplore, Web of Science, and Google Scholar. Boolean logic and domain-specific keywords were used to retrieve studies from 2018 to 2025. After automated deduplication and multistage manual screening, over 100 high-quality papers were included. These works cover BCFL's theoretical foundations, system architectures, application domains, limitations, and future directions.<br><br>RESULTS: BCFL frameworks combine the decentralized trust and auditability of blockchain with the privacy-preserving collaborative learning capabilities of federated learning. This integration mitigates risks such as model tampering, data leakage, and a lack of incentives in federated systems. Applications span across cross-institutional medical data sharing, Internet of Medical Things, epidemic forecasting, and telemedicine. Architectures including fully coupled, flexibly coupled, and loosely coupled models offer varying trade-offs between efficiency, scalability, and security.<br><br>CONCLUSIONS: BCFL represents a transformative paradigm for secure, collaborative, and privacy-preserving medical AI. By combining decentralized trust, incentive-driven participation, and privacy-enhancing machine learning, BCFL paves the way for next-generation smart health care systems. Despite current technical and practical challenges, BCFL demonstrates strong potential to support precision medicine, global health data collaboration, and large-scale AI deployment in health care.},
}
@article {pmid41713622,
year = {2026},
author = {Zhang, X and Xu, Y and Jiang, Y and Huang, J and Li, X},
title = {From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for M[pro] of SARS-CoV-2.},
journal = {Biochemical pharmacology},
volume = {248},
number = {},
pages = {117791},
doi = {10.1016/j.bcp.2026.117791},
pmid = {41713622},
issn = {1873-2968},
mesh = {Humans ; *Antiviral Agents/chemistry/pharmacology ; *SARS-CoV-2/drug effects/enzymology ; *Protease Inhibitors/chemistry/pharmacology ; *Coronavirus 3C Proteases/antagonists &amp; inhibitors/metabolism/chemistry ; *COVID-19 Drug Treatment ; Peptidomimetics/chemistry/pharmacology ; Proteolysis Targeting Chimera ; Drug Design ; COVID-19/virology ; },
abstract = {While the immediate global threat of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has subsided, the virus remains a persistent cause of regional outbreaks and public health concerns. The main protease (M[pro]), essential for viral polyprotein processing and replication, remains one of the most validated and strategically important antiviral targets. In this comprehensive review, we critically evaluate the landscape of M[pro] inhibitor development from 2020 to 2025, encompassing four key categories: peptidomimetic inhibitors, non-peptide small molecules, natural product-derived compounds, and proteolysis-targeting chimeras (PROTACs). By integrating mechanistic insights with structural and technological advancements, this work highlights emerging opportunities for the rational design of next-generation M[pro]-targeted antivirals capable of addressing both current and future coronavirus threats.},
}
@article {pmid41713871,
year = {2026},
author = {Dalrymple, WA and Ratliff, JB},
title = {A New Dawn: Resident Recruitment in the United States in the Post-COVID Era.},
journal = {Seminars in neurology},
volume = {46},
number = {3},
pages = {263-274},
doi = {10.1055/a-2794-0336},
pmid = {41713871},
issn = {1098-9021},
mesh = {Humans ; United States ; *COVID-19 ; *Internship and Residency ; *Personnel Selection/methods ; Pandemics ; *Interviews as Topic ; },
abstract = {The widespread adoption of virtual residency interviews in response to the COVID-19 pandemic led to an explosion in literature comparing the pros and cons of virtual and in-person interviews, but also led to an explosion in already-high residency application and interview volumes. While virtual interviews were substantially cheaper for all involved, there is fear that applicants and programs cannot judge one another as well as during in-person interviews. Likewise, increases in application volumes have made holistic application review more challenging for program directors, but the recent rise in "preference signaling" seems to be an optimal solution to that issue. 2020 also saw increased awareness of systemic inequities in the United States, and medical education and residency recruitment was not immune from scrutiny. Finally, the rise of artificial intelligence could again fundamentally change the resident selection process. It is imperative that the GME community continues to adapt to a changing world.},
}
@article {pmid41714597,
year = {2026},
author = {Kasai, M and Sakuma, H and Suzuki, M and Nishiyama, M and Kawata, N and Lin, JJ and Lin, KL and Han, V and Mohammad, SS and Dale, RC and Thomas, T and Muramatsu, K and Mitani, O and Kobayashi, Y and Ishida, K and Abe, Y and Kuki, I and Takanashi, JI},
title = {Life-Threatening SARS-CoV-2-Associated Encephalopathy and Multiorgan Failure in Children, Asia and Oceania, 2022-2024.},
journal = {Emerging infectious diseases},
volume = {32},
number = {2},
pages = {169-179},
pmid = {41714597},
issn = {1080-6059},
mesh = {Humans ; *Multiple Organ Failure/epidemiology/virology/etiology/mortality ; Female ; Male ; Child, Preschool ; *Brain Diseases/virology/epidemiology/etiology/mortality ; *COVID-19/complications/epidemiology/mortality ; Child ; *SARS-CoV-2 ; Infant ; Brain Edema ; Asia/epidemiology ; Australia/epidemiology ; Taiwan/epidemiology ; Japan/epidemiology ; Adolescent ; Singapore/epidemiology ; Cytokines/blood ; },
abstract = {SARS-CoV-2 infections in children occasionally manifest with severe neurologic signs. We report a case series of life-threatening encephalopathy associated with SARS-CoV-2 in 25 children in Australia, Japan, Singapore, and Taiwan during February 2022-January 2024. All children had severe encephalopathy develop, characterized by rapidly progressive cerebral edema, conditions known as acute shock with encephalopathy and multiorgan failure or acute fulminant cerebral edema. Among the 25 patients, 22 (88%) eventually died; 11 (44%) children died within 24 hours of hospitalization. In addition, 18 (72%) had illness manifest with shock, and 14 (56%) had multiorgan failure develop within 6 hours of neurologic onset. Serum concentrations of cytokines/chemokines including interleukin 6 and tumor necrosis factor-α were significantly higher within 24 hours of onset than for controls. SARS-CoV-2-associated encephalopathy cases such as those described here represent an emerging neurologic crisis with high mortality rate resulting from rapidly progressive brain edema and multiorgan failure.},
}
@article {pmid41715908,
year = {2026},
author = {Qtait, M and Farajalla, F and Alqaissi, N and Jaradat, Y},
title = {Implementation and Impact of Tele-Intensive Care Unit (Tele-ICU) Models on Critical Care Outcomes: A Systematic Review.},
journal = {Nursing in critical care},
volume = {31},
number = {2},
pages = {e70401},
doi = {10.1111/nicc.70401},
pmid = {41715908},
issn = {1478-5153},
mesh = {Humans ; *Telemedicine/organization &amp; administration ; *Intensive Care Units/organization &amp; administration ; *Critical Care/organization &amp; administration ; *COVID-19/epidemiology ; *Critical Care Outcomes ; },
abstract = {BACKGROUND: Tele-Intensive Care Unit (Tele-ICU) models have expanded rapidly in response to global critical care workforce shortages, rising patient acuity and the demands of the COVID-19 pandemic. Contemporary evidence shows substantial variation in Tele-ICU configurations and outcomes, underscoring the need for an updated synthesis that evaluates clinical, staff-related and system-level effects across diverse settings.<br><br>AIM: To examine the implementation and impact of Tele-ICU models on critical care outcomes and to compare results across hub-and-spoke, hybrid, consultative and tele-recovery configurations.<br><br>STUDY DESIGN: A systematic review was conducted and reported according to PRISMA 2020 and Joanna Briggs Institute guidelines. PubMed, CINAHL, Scopus, Web of Science and Google Scholar were searched for peer-reviewed studies published between January 2020 and October 2025. Owing to heterogeneity in Tele-ICU models, outcomes and effect measures, a narrative synthesis was performed.<br><br>RESULTS: Sixteen studies published between 2020 and 2025 were included, comprising quantitative, qualitative and mixed-methods designs conducted across high-, middle- and low-resource healthcare settings. Overall, Tele-ICU implementation was associated with reductions in ICU and hospital mortality, improved adherence to evidence-based clinical protocols, enhanced interprofessional communication and reduced clinician documentation burden. Hub-and-spoke and hybrid Tele-ICU models demonstrated the most consistent clinical and workforce benefits, whereas consultative and low-cost models primarily improved access to specialist care in resource-limited contexts. Across studies, nursing roles expanded to include digital patient surveillance, tele-round coordination, protocol facilitation and virtual family communication. Evidence regarding long-term sustainability and cost-effectiveness was limited and inconsistently reported.<br><br>CONCLUSIONS: Tele-ICU models enhance clinical performance, support nursing practice and improve system-level responsiveness across diverse contexts. While benefits are consistent, outcomes vary by model design, local infrastructure and implementation readiness. Longitudinal and economic evaluations are needed to inform sustainable, scalable Tele-ICU strategies.<br><br>Tele-ICU models support bedside nurses by improving access to specialist input, strengthening adherence to evidence-based care and enhancing patient safety. Evidence shows that Tele-ICU reduces workload, improves communication and enables nurses to coordinate digital monitoring and family updates, contributing to more consistent and equitable critical care delivery, particularly in high-acuity and resource-limited settings.},
}
@article {pmid41716011,
year = {2026},
author = {Roe, K},
title = {Lymphocyte Suppression and Exhaustion, Conventional, and Accelerated.},
journal = {APMIS : acta pathologica, microbiologica, et immunologica Scandinavica},
volume = {134},
number = {2},
pages = {e70175},
doi = {10.1111/apm.70175},
pmid = {41716011},
issn = {1600-0463},
mesh = {Humans ; T-Cell Exhaustion ; *COVID-19/immunology ; Killer Cells, Natural/immunology ; Animals ; B-Lymphocytes/immunology ; T-Lymphocytes/immunology ; SARS-CoV-2/immunology ; Immune System Exhaustion ; *Lymphocytes/immunology ; },
abstract = {The essential mammalian immune system lymphocytes include T cells, B cells, and natural killer cells. Any impairments of their functionalities can have severe consequences, since these lymphocytes each contribute as an interactive team in responding to pathogen infections or cancers. Such impairments include lymphocyte exhaustion, such as T cell, B cell, or natural killer cell exhaustion, or lymphocyte suppression impairing one or more of these cells. Lymphocyte exhaustion can have any intensity from mild to severe, having a severity scale worsened by various exposures and time periods of constant antigenic activation. Lymphocyte exhaustion can potentially have a conventional timing pathway or a hypothesized accelerated (pipelined) timing pathway. Lymphocyte suppressions initiated from pathogen infections are also possible, and this can also impair multiple types of lymphocytes. Finally, accelerated T cell exhaustion is possible, and this can explain several puzzling characteristics of virulent viral pandemics, especially in individuals having pathogen or cancer comorbidities. For instance, accelerated T cell exhaustion can explain a substantial percentage of the SARS-CoV-2 pandemic fatalities and also explain the relatively small, but significant, numbers of hyperinflammatory diseases or autoimmune diseases which were initiated in small percentages of individuals by SARS-CoV-2 infections.},
}
@article {pmid41716714,
year = {2026},
author = {Bannister-Tyrrell, M and Teague, K and Strachan, DL and Barrett, A and Marthias, T and Strachan, CE and Doungngern, P and Thakur, N and Kamal, M and Brindle, H and Jinnai, Y and Kato, M and Vogt, F},
title = {Performance and utility of contact tracing for COVID-19 in the WHO South-East Asia Region: implications for future pandemic preparedness.},
journal = {The Lancet regional health. Southeast Asia},
volume = {45},
number = {},
pages = {100728},
pmid = {41716714},
issn = {2772-3682},
abstract = {UNLABELLED: Contact tracing was widely implemented during the COVID-19 pandemic, but its real-world performance and utility for decision-making remain poorly understood. A qualitative study was conducted to appraise the performance and utility of contact tracing for COVID-19 in the WHO South-East Asia Region, based on interviews with government and non-governmental organisation technical staff and decision makers in Indonesia, Nepal and Thailand. Our findings highlight the good performance of contact tracing when sufficiently resourced and when case load is low, but reveal declining utility as case incidence increases. This study presents key definitions and a pragmatic approach for appraising contact tracing performance and utility throughout a major health emergency response. Countries should prospectively define objectives for contact tracing, establish monitoring and evaluation frameworks, adjust their contact tracing approaches informed by risk assessments, and consider other available public health interventions when its performance and utility decline.<br><br>FUNDING: Governments of Germany and Australia.},
}
@article {pmid41716970,
year = {2026},
author = {Palwankar, P and Palaniappan, J and Kuttappan, K and Pandey, R and Verma, S and Bhardwaj, A and Shunmugavelu, K},
title = {Oral and maxillofacial manifestations of COVID-19.},
journal = {GMS hygiene and infection control},
volume = {21},
number = {},
pages = {Doc05},
pmid = {41716970},
issn = {2196-5226},
abstract = {An overview of oral and maxillofacial manifestations associated with COVID-19 is provided. The symptoms range from white, red and mixed inflamed mucosal areas, necrosis, swelling, ulcers, vesicle, bulla, pustule, pigmentation, depapillated and fissured tongue and bleeding in the ulcers. Pre-COVID symptoms included complete loss of taste, along with reduced sense of taste and alterations in the taste perception.},
}
@article {pmid41717886,
year = {2026},
author = {Cucunawangsih, C and Ansori, ANM and Vatvani, AD and Hariyanto, TI},
title = {Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.},
journal = {Expert review of anti-infective therapy},
volume = {24},
number = {2},
pages = {271-284},
doi = {10.1080/14787210.2026.2636175},
pmid = {41717886},
issn = {1744-8336},
mesh = {Humans ; *COVID-19/complications ; *COVID-19 Drug Treatment ; Drug Combinations ; Outpatients ; Post-Acute COVID-19 Syndrome/epidemiology ; *Ritonavir/therapeutic use/administration &amp; dosage ; SARS-CoV-2 ; *Pyrrolidinones/therapeutic use ; *Azabicyclo Compounds/therapeutic use ; },
abstract = {BACKGROUND: This study systematically synthesized existing evidence to evaluate whether outpatient treatment with nirmatrelvir/ritonavir during the acute phase reduces the incidence of long COVID.<br><br>METHODS: We conducted a systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library from inception to 15 September 2025. Eligible studies compared COVID-19 outpatients prescribed nirmatrelvir/ritonavir during the acute phase with those who did not receive the drug. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.<br><br>RESULTS: Nineteen studies met inclusion criteria. Overall, nirmatrelvir/ritonavir use during acute infection was associated with a significant reduction in the likelihood of developing post-COVID-19 condition (OR 0.85; 95% CI: 0.80-0.91; p&#x2009;<&#x2009;0.00001; I[2]&#x2009;=&#x2009;99%). Protective effects were consistently observed across multiple clinical domains, including cardiovascular (arrhythmia, ischemic disease, heart failure), pulmonary (dyspnea, COPD), thromboembolic (DVT, PE), neurological (stroke, cognitive impairment, headache), psychiatric (depression), gastrointestinal, metabolic (new-onset diabetes), renal (AKI), and general symptoms (malaise and fatigue). Conversely, no significant differences were noted for cough, asthma, dysautonomia, anxiety, PTSD, sleep disturbances, musculoskeletal pain, or olfactory/gustatory dysfunction.<br><br>CONCLUSIONS: Early outpatient treatment with nirmatrelvir/ritonavir may mitigate the risk of developing several domains of long COVID, though its benefits are not uniform across all symptom categories.},
}
@article {pmid41718064,
year = {2026},
author = {Trimarco, V and Gallo, P and Ghazihosseini, S and Izzo, A and Rozza, PI and Spinelli, A and Cristiano, S and De Rosa, C and Rozza, F and Morisco, C},
title = {The Role of L-Arginine and Liposomal Vitamin C Supplementation as an Adjunct in Seasonal Respiratory Viral Infection Recovery.},
journal = {Advances in respiratory medicine},
volume = {94},
number = {1},
pages = {},
pmid = {41718064},
issn = {2543-6031},
mesh = {Humans ; *Ascorbic Acid/therapeutic use/administration &amp; dosage ; *Arginine/therapeutic use ; Dietary Supplements ; Liposomes ; *Respiratory Tract Infections/drug therapy/virology ; Seasons ; Influenza, Human/drug therapy ; *Vitamins/therapeutic use ; },
abstract = {Respiratory seasonal viral infections remain one of the most important issues in community medicine. The heterogeneity of etiological agents and the characteristics of the hosts airway antiviral defenses account for the complex management of these infections. The clinical consequence of this picture is that, despite the widespread use of vaccination as the primary prevention strategy, the rates of acute respiratory complications remain still high. In addition, they determine post-infectious fatigue and organ dysfunction. Inflammation and oxidative stress are the principal pathogenic mechanisms responsible for clinical complications during respiratory seasonal viral infections. Nowadays, a growing body of evidence indicates that adjunctive nutritional support can contribute to relieve the symptoms during the acute and subacute phases of respiratory viral infections. We assess the data in the literature regarding the combination of L-Arginine and Liposomal Vitamin C as adjuvant treatment for respiratory seasonal viral infections. The database of the National Library of Medicine (PubMed) was searched using the keywords "L-Arginine, Vitamin C, dietary supplements, seasonal respiratory viral infections". The treatment of symptoms during acute and post-acute respiratory viral infections requires an integrated approach that includes vitamins and nutritional supplementation. The combination of L-Arginine and Liposomal Vitamin C seems to represent a nutritional support able to mitigate symptoms occurring during the acute or post-acute phase of infection.},
}
@article {pmid41718104,
year = {2026},
author = {Nebuwa, CN and Orjichukwu, CK and Orjichukwu, RO and Akpunonu, PK and Ugwu, PC and Nnabuife, SG},
title = {Cardiovascular Complications of Seasonal Influenza in the Pre- and Post-COVID-19 Era: Epidemiology, Mechanisms, and Clinical Implications.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {1},
pages = {},
pmid = {41718104},
issn = {2076-3271},
mesh = {Humans ; *Influenza, Human/epidemiology/complications ; *COVID-19/epidemiology/complications ; *Cardiovascular Diseases/epidemiology/etiology ; Pandemics ; SARS-CoV-2 ; Seasons ; },
abstract = {Influenza has long been a well-documented contributor to cardiovascular morbidity and mortality, particularly among high-risk groups. COVID-19 has notably altered the seasonality and natural history of pandemic influenza, with broad implications for related cardiac complications. This review examines the interaction between influenza and cardiovascular illness, especially myocardial infarction, congestive heart failure, stroke, and other acute cardiac events. We review the impact of the COVID-19 pandemic on influenza transmission dynamics, public health policy, and the evolving burden of cardiovascular complications. New evidence indicates that both diseases exacerbate endothelial dysfunction, systemic inflammation, and prothrombotic states, thereby increasing cardiovascular risk. A comparative analysis of pre- and post-COVID-19 influenza-related cardiac complications clarifies evolving trends and guides future preventive strategies. In light of the recent resurgence of influenza following the relaxation of COVID-19 mitigation measures, maximizing vaccine coverage and collaborating to manage viral infections in patients with cardiovascular disease are critical. This review focuses on key research needs to understand long-term cardiac consequences and the urgent requirement for targeted public health strategies to counter viral-mediated cardiovascular threats. In the post-COVID era, integrating influenza and COVID-19 vaccination strategies into cardiovascular risk management may represent a critical opportunity to reduce virus-triggered cardiovascular morbidity and mortality.},
}
@article {pmid41718141,
year = {2026},
author = {Manole, OM and Petre, BA and Onofrei, V},
title = {Proteomic Insights into Venous Thromboembolism.},
journal = {Medical sciences (Basel, Switzerland)},
volume = {14},
number = {1},
pages = {},
pmid = {41718141},
issn = {2076-3271},
mesh = {Humans ; *Proteomics/methods ; *Venous Thromboembolism/metabolism/diagnosis ; Pulmonary Embolism/diagnosis/metabolism ; Venous Thrombosis/diagnosis/metabolism ; Biomarkers/blood/metabolism ; COVID-19/complications ; Prognosis ; },
abstract = {Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), remains a major cause of morbidity and mortality worldwide, with significant clinical challenges in diagnosis and risk stratification. Traditional diagnostic tools, including clinical prediction scores, D-dimer testing, and imaging, are limited by suboptimal specificity or sensitivity. In this context, proteomics-based approaches have emerged as powerful tools to elucidate the molecular mechanisms of VTE and to identify novel diagnostic and prognostic biomarkers. This review synthesizes recent advances in proteomic research relevant to VTE. We searched four databases (PubMed, ScienceDirect, Springer Nature, and Wiley) using the keywords "acute pulmonary embolism", "acute venous thromboembolism", and "proteomics". Thirty proteomic studies investigating VTE were examined. Across these studies, proteomic profiling consistently revealed alterations in pathways related to coagulation, inflammation, platelet activation, endothelial dysfunction, and fibrin clot structure. Multiple protein classes, including acute-phase reactants, complement components, coagulation factors, and platelet-derived proteins, have demonstrated potential value in improving diagnostic accuracy and refining prognostic stratification. Proteomic analyses have also revealed distinct molecular signatures between isolated PE and isolated DVT, supporting the concept of biologically heterogeneous VTE phenotypes. Furthermore, emerging evidence from COVID-19-associated thrombosis, cancer-associated VTE, and non-invasive sources such as exhaled breath condensate underscores the expanding clinical relevance of proteomic approaches. Although technical limitations and heterogeneity across studies remain challenges, the integration of proteomic data with clinical and genetic information holds promise for advancing precision medicine in VTE.},
}
@article {pmid41718962,
year = {2026},
author = {Sheikhi, RA and Heidari, M and Kahrizsangi, MB},
title = {Mosques as Community Resilience Centers During Disasters: A Systematic Review of COVID-19 Interventions.},
journal = {Journal of community health},
volume = {51},
number = {3},
pages = {400-412},
pmid = {41718962},
issn = {1573-3610},
support = {6867//Sahrekord University of Medical Sciences/ ; },
mesh = {Humans ; *COVID-19/prevention &amp; control ; *Pandemics/prevention &amp; control ; *Resilience, Psychological ; SARS-CoV-2 ; *Disasters ; Disaster Planning ; },
abstract = {OBJECTIVE: This systematic review seeks to delineate the multifaceted functions of mosques during the Coronavirus Disease 2019 (COVID-19) pandemic. Furthermore, it proposes evidence-based strategies to enhance their integration into formal disaster management frameworks and leverage their latent potential for bolstering community resilience. METHOD: The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary databases used for literature searches were PubMed, Web of Science (WOS), Scopus, ProQuest, and Google Scholar. To identify relevant published literature, the title of this systematic review was divided into two key components: keywords related to COVID-19 and mosque, along with their synonyms. Equivalent terms were derived from Medical Subject Headings (MeSH) and expert opinions and extracted from related articles. RESULTS: Out of 82 initially identified articles, 19 met the inclusion criteria and were analyzed qualitatively. Four major themes emerged: the preventive role of mosques in curbing COVID-19 through education, support, healthcare collaboration, and vaccination efforts; religious adaptation through modified rituals and flexible jurisprudence; contributions to economic resilience via aid distribution, employment programs, and financial support; and the critical influence of spiritual leadership, highlighting both constructive and controversial responses during the pandemic. CONCLUSION: Mosques have emerged as multifaceted institutions capable of delivering integrated public health interventions, psychosocial support, and spiritual guidance during the COVID-19 crisis. Evidence suggests that institutionalizing mosque-based crisis response mechanisms through structured preparedness planning and cross-sectoral collaboration (with healthcare systems and government agencies) could substantially improve community resilience and optimize faith-based responses to future public health emergencies.},
}
@article {pmid41718988,
year = {2026},
author = {Wang, Y and Gandy, S},
title = {Golgi Fragmentation as a Potential Link Between SARS-CoV-2 Infection and Alzheimer's Disease: Mechanisms and Implications for Neurodegeneration in Long COVID.},
journal = {Sub-cellular biochemistry},
volume = {111},
number = {},
pages = {463-482},
pmid = {41718988},
issn = {0306-0225},
mesh = {Humans ; *Alzheimer Disease/pathology/metabolism/virology ; *Golgi Apparatus/pathology/metabolism/virology ; *COVID-19/metabolism/pathology/complications ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Pandemics ; },
abstract = {The COVID-19 pandemic has impacted millions of people worldwide, and recent studies have shown that SARS-CoV-2 infection can lead to an Alzheimer's-like neuropathological and biomarker phenotype, as well as clinical symptoms of "brain fog". This raises an intriguing question: "How and where might the molecular pathways underlying SARS-CoV-2 infection and Alzheimer's disease (AD) converge?" One common feature of both SARS-CoV-2 infection and AD is the alteration of the endomembrane system, particularly the fragmentation of the Golgi apparatus. In this review article, we summarize the existing literature on SARS-CoV-2 infection biology and speculate about the potential mechanisms linking Golgi defects, SARS-CoV-2 infection, and neurodegeneration.},
}
@article {pmid41719175,
year = {2026},
author = {Martins Bruno, AC and José de Castro Moura Duarte, F},
title = {Designing Hybrid Work Organization in the Post-Pandemic Era: A Systematic Literature Review.},
journal = {Work (Reading, Mass.)},
volume = {},
number = {},
pages = {10519815261423140},
doi = {10.1177/10519815261423140},
pmid = {41719175},
issn = {1875-9270},
abstract = {BackgroundIn the post-COVID-19 context, hybrid work (HW) expanded rapidly, often without systematic organizational design or alignment to task demands, generating conceptual ambiguities and limited guidance for configuring HW as an organizational system.ObjectiveTo update the conceptualization of HW and identify elements for designing hybrid work organization (HWO) from a task-based perspective.MethodsA systematic literature review was conducted from June to August 2025 following PRISMA guidelines. Peer-reviewed English-language articles (2020-2025) were retrieved from Scopus, and grey literature (2022-2025) was incorporated through complementary searches and snowballing. Research quality was appraised using MMAT and AACODS tools. Of 363 records screened, 110 full texts were assessed, and 25 met inclusion criteria.ResultsHW emerges as a sociotechnical phenomenon embedded in the digital transformation of work. A multidimensional lens - spatial, temporal, digital/virtual, and social - applied to task categories (individual, collaborative, coordination) identified key designable elements for HWO. Findings indicate that HW extends beyond fixed remote-on-site ratios, emphasizing intentional alternation, task-fit configurations, and dynamic adjustments as work evolves.ConclusionsHWO is context-specific and adaptive, shaped by task requirements rather than predefined schedules or locations. No single model prevails; instead, tailored configurations reflect the variability of real work. Advancing HW as a sociotechnical system requires rethinking organizational culture and management logic, shifting from presence and control-oriented paradigms toward flexible, task-driven, and performance-focused approaches. Progress depends on treating organizational design as a participatory process that aligns arrangements with demands.},
}
@article {pmid41719449,
year = {2026},
author = {Nilormi, A and Bensimon, CM and Thomas, M and Wiles, S and Wilson, K},
title = {A scoping review of vaccine certificate implementation in Canada and OECD countries during the COVID-19 pandemic: Outcomes and lessons learned.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2622178},
pmid = {41719449},
issn = {2164-554X},
mesh = {Humans ; *COVID-19/prevention &amp; control/epidemiology ; Canada/epidemiology ; *COVID-19 Vaccines/administration &amp; dosage ; Organisation for Economic Co-Operation and Development ; Public Health ; *Vaccination ; SARS-CoV-2/immunology ; Pandemics/prevention &amp; control ; },
abstract = {Vaccine certificates were introduced during the COVID-19 pandemic to document vaccination status, promote uptake and enable safer reopening of society. While these policies supported public health efforts, their implementation raised operational, ethical and legal concerns, sparking debate about their future use in health emergencies. We conducted a scoping review to synthesize the implementation processes, challenges and outcomes of vaccine certificate systems in Canada and other OECD countries. An academic search was conducted in August 2024, across Ovid MEDLINE, Embase and Scopus using controlled vocabulary and key words for sources published from 2020 onward. Grey literature was searched using Google and targeted government and organizational websites. Data were synthesized descriptively and analyzed deductively based on three pre-identified themes - public health, technological, and ethical-legal considerations - derived from the UK Royal Society's framework on COVID-19 vaccine certificate design. The search captured 128 sources (72 academic and 56 gray literature), covering all OECD countries except Chile, Colombia, Costa Rica, Mexico and Norway. Identified subthemes included: (1) purpose and trade-offs; (2) public health, socio-economic and health system impacts, (3) technological infrastructure and data security; (4) equity and accessibility; (5) privacy and surveillance; and (6) public acceptance and trust. Vaccine certificates aimed to support public health goals but posed challenges in digital implementation, particularly in creating secure and interoperable systems and raised concerns around equity, discrimination and privacy. Vaccine certificates show promise for future public health use. However, their success will depend on addressing ethical concerns, ensuring interoperability and strengthening digital infrastructure, regulations and public trust.},
}
@article {pmid41719864,
year = {2026},
author = {Chandra, LA and Nugroho, DB and Thobari, JA and Dimaguila, GL and Buttery, J},
title = {Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review.},
journal = {Vaccine},
volume = {77},
number = {},
pages = {128341},
doi = {10.1016/j.vaccine.2026.128341},
pmid = {41719864},
issn = {1873-2518},
mesh = {Humans ; Adverse Drug Reaction Reporting Systems ; COVID-19/prevention &amp; control ; *COVID-19 Vaccines/adverse effects ; *Influenza Vaccines/adverse effects/administration &amp; dosage ; Influenza, Human/prevention &amp; control ; Pandemics/prevention &amp; control ; *Product Surveillance, Postmarketing/methods ; *Vaccination/adverse effects ; },
abstract = {INTRODUCTION: Active post-vaccination surveillance is vital for ensuring vaccine safety, particularly in monitoring Adverse Events of Special Interest (AESIs). This scoping review synthesises evidence on methodologies employed in active surveillance studies, with a focus on influenza and COVID-19 vaccines.<br><br>METHODS: Literature was identified via PubMed, Embase, Web of Science, Scopus, Google Scholar, and manual searches, using key terms including influenza, COVID-19, vaccine, and AESI. Two authors independently screened studies and extracted data on study characteristics, methods, and outcomes. Findings were synthesised narratively and presented in tables and figures, following the PRISMA-ScR guideline.<br><br>RESULTS: Of 427 included studies, most were published after 2020 (74.0%) and focused on COVID-19 vaccines (69.3%), particularly mRNA platforms (51.3%). The majority were conducted in North America and Europe, with 85.5% from high-income countries; multinational studies accounted for 6.6%, and single-centre studies with national or subnational coverage for 63.0%. Cohort designs predominated (40.5%), mostly retrospective (74.2%), utilising registries (24.0%) and electronic health records (22.4%), including artificial intelligence for signal detection and prediction (2.7%). Nearly half (49.6%) linked multiple data sources, though outcome verification was reported in fewer than half (45.9%). Incidence rates (16.5%) and risk/hazard ratios (14.8%) were the most reported measures. Neurological (21.8%) and cardiac (21.3%) AESIs, particularly Guillain-Barr&#xe9; Syndrome and myocarditis, were most frequently investigated.<br><br>CONCLUSION: Active surveillance for vaccine safety has increased but remains concentrated in high-income countries. Methodological approaches to detection, verification, and validation vary widely. Introducing active surveillance methodologies in low- and middle-income countries is crucial to achieving more equitable global monitoring of vaccine safety.},
}
@article {pmid41721085,
year = {2026},
author = {Alvarado-Gamarra, G and Alcala-Marcos, K and Celis, CR and Balmaceda-Nieto, P and Cieza, L and Morán-Mariños, C and Grados-Espinoza, P and Alva-Díaz, C and Ecker, L and Ochoa, TJ and Franchi, LM and Howard, LM and Grijalva, CG and Lanata, CF},
title = {Post-MIS-C cardiovascular outcomes: a systematic review.},
journal = {European journal of pediatrics},
volume = {185},
number = {3},
pages = {},
pmid = {41721085},
issn = {1432-1076},
support = {D43 TW012468/TW/FIC NIH HHS/United States ; D43TW012468/TW/FIC NIH HHS/United States ; },
mesh = {Humans ; *Systemic Inflammatory Response Syndrome/complications ; *COVID-19/complications ; *Cardiovascular Diseases/etiology ; Child ; },
abstract = {Limited knowledge and variability in findings exist regarding the resolution of cardiovascular outcomes following Multisystem Inflammatory Syndrome in Children (MIS-C). We conducted a systematic review to estimate the frequency of cardiovascular outcomes following MIS-C. A systematic search was conducted in Pubmed/Medline, Scopus, Embase, SciELO, LILACS, Cochrane Library, Web of Science, and medRxiv were searched up to February 2024. We included studies reporting cardiovascular events that began in acute MIS-C and persisted after discharge. Screening and data extraction were performed by independent reviewers. We performed a random-effects meta-analysis and assessed the certainty of the evidence using the GRADE approach. Eighty-four studies (n = 4,778) were included; seven had a comparator group. The frequency of cardiovascular outcomes-including coronary abnormalities (Z-score ≥ 2), left ventricle ejection fraction < 55%, diastolic dysfunction, myocarditis, and pericardial effusion-decreased over time, with most resolving by 6 to 9 months. However, cardiac magnetic resonance imaging studies identified myocardial edema and/or fibrosis persisting up to 12 months, and two studies reported coronary abnormalities at 18- to 24-month follow-up. Evidence certainty was very low. Compared to children with COVID-19 or healthy controls, MIS-C showed more cardiovascular events and greater subclinical myocardial dysfunction, as assessed by strain analysis, during a 6-month follow-up. Compared with other etiologies of myocarditis, MIS-C myocarditis was associated with better cardiovascular outcomes but shorter exercise duration and lower aerobic capacity on stress testing. Conclusions: Cardiovascular outcomes following MIS-C improved over time, but certain subclinical cardiac abnormalities persisted up to 12 to 24 months. These findings may support long-term follow-up after MIS-C.Trial registration: Protocol registration number: PROSPERO, CRD42022336784.},
}
@article {pmid41721422,
year = {2026},
author = {Abuhay, AE and Assaye, MM and Zeleke, TA and Mihret, SA and Getahun, AB and Zeleke, ME and Defersha, KK and Asrie, AE and Anteneh, DE and Mengistie, BA},
title = {Knowledge and attitude toward monkeypox (mpox) among healthcare providers in Sub-Saharan Africa: a systematic review and meta-analysis.},
journal = {Systematic reviews},
volume = {15},
number = {1},
pages = {},
pmid = {41721422},
issn = {2046-4053},
mesh = {Humans ; Africa South of the Sahara/epidemiology ; *Health Knowledge, Attitudes, Practice ; *Health Personnel/psychology ; *Mpox, Monkeypox/epidemiology/prevention &amp; control ; *Attitude of Health Personnel ; Sub-Saharan African People ; },
abstract = {BACKGROUND: Mpox is an emerging global health threat with increasing frequency and geographic spread recently. Healthcare providers play a pivotal role in outbreak prevention, early detection, isolation, and response. This systematic review and meta-analysis aimed to assess the pooled prevalence of knowledge and attitude toward Mpox among healthcare providers in Sub-Saharan Africa (SSA).<br><br>METHODS: This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. A comprehensive literature search was performed in PubMed, ScienceDirect, Hinari, and Google Scholar to identify eligible studies published between 2 July 2015 and 2 July 2025. Data were extracted and managed using Microsoft Excel and analyzed using STATA version 17. Pooled prevalence estimates were calculated using a random-effects model. The methodological quality of included studies was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist. Publication bias was examined using funnel plots and Egger's regression test, and statistical heterogeneity was assessed using the I[2] statistic. The review protocol was registered in PROSPERO (CRD420251123652).<br><br>RESULTS: This systematic review and meta-analysis included seven studies from Sub-Saharan Africa, comprising a total of 3379 healthcare providers. The pooled prevalence of adequate knowledge and a positive attitude toward Mpox was 40.52% (95% CI, 30.17-50.88) and 51.20% (95% CI, 44.48-57.91), respectively, with high heterogeneity (I[2]&#x2009;>&#x2009;90%). Factors associated with higher knowledge included age over 40&#xa0;years (AOR&#x2009;=&#x2009;5.90; 95% CI, 1.27-27.41), being married (AOR&#x2009;=&#x2009;1.58; 95% CI, 1.24-2.01), being a physician (AOR&#x2009;=&#x2009;6.82; 95% CI, 1.38-33.56), having 5-10&#xa0;years of work experience (AOR&#x2009;=&#x2009;7.02; 95% CI, 1.51-32.74), prior information about Mpox (AOR&#x2009;=&#x2009;1.82; 95% CI, 1.11-2.97), and a history of COVID-19 vaccination (AOR&#x2009;=&#x2009;1.98; 95% CI, 1.47-2.68). Regarding attitude, higher education (AOR&#x2009;=&#x2009;2.09; 95% CI, 1.38-3.18) and male sex (AOR&#x2009;=&#x2009;1.50; 95% CI, 1.12-1.91) were positively associated. Prevalence was pooled through meta-analysis, while associated factors were reported individually from each study, as pooling adjusted odds ratios was not appropriate due to differences in covariates and outcome definitions. These findings should be interpreted with caution due to high heterogeneity, the small number of studies, and uneven geographic representation.<br><br>CONCLUSIONS: The findings of this systematic review and meta-analysis indicate that knowledge and attitudes toward Mpox among healthcare providers in Sub-Saharan Africa are generally suboptimal. However, these results should be interpreted with caution due to high heterogeneity across studies, the limited number of included studies, and uneven geographic representation. Nonetheless, the findings underscore the need for context-specific capacity-building interventions, including targeted training, improved access to up-to-date clinical guidelines, and enhanced preparedness strategies to support healthcare providers in responding to Mpox and other emerging infectious diseases.},
}
@article {pmid41722060,
year = {2026},
author = {Mousavi, T and Moosazadeh, M and Jalali, H},
title = {Comparison of Azvudine and Nirmatrelvir-Ritonavir in Hospitalised Patients With COVID-19: A Systematic Review and Meta-Analysis.},
journal = {Reviews in medical virology},
volume = {36},
number = {2},
pages = {e70114},
doi = {10.1002/rmv.70114},
pmid = {41722060},
issn = {1099-1654},
mesh = {Humans ; *Ritonavir/therapeutic use ; *COVID-19 Drug Treatment ; SARS-CoV-2/drug effects ; *Antiviral Agents/therapeutic use ; COVID-19/virology/mortality ; Hospitalization ; },
abstract = {Azvudine is a nucleoside reverse transcriptase inhibitor (NRTI) and belongs to the family of 2', 3'-dideoxynucleoside (ddNs) that can mimic natural nucleosides and block viral DNA or RNA chain synthesis and prevent viral replication. Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, Azvudine has been used to treat patients with COVID-19. Therefore, the objective of this meta-analysis study was to compare Azvudine and Nirmatrelvir-Ritonavir in hospitalised patients. The global online databases were used to identify relevant studies published between January 2019 and October 2024. The quality of all articles was determined using the Newcastle-Ottawa Scale (NOS) checklist. In this study, heterogeneity assay was assessed using the Cochran's Q-test and the I2 index, and STATA software version.14 (StataCorp) was used for statistical analysis. Egger's test, Begg's test, and funnel plot were performed to estimate of the publication bias, and the impact of each study on the overall estimate was assessed using sensitivity analysis. In this study, 19 studies were included in this meta-analysis. The results of the meta-analysis showed that the relative risk of death in the Azvudine treatment group compared with the Nirmatrelvir-Ritonavir treatment group was 0.64 (95% CI: 0. 44, 0. 93). These results suggest that treatment with Azvudine may provide significant clinical benefit in patients hospitalised with COVID-19.},
}
@article {pmid41723336,
year = {2026},
author = {Huang, X and Huang, D and Wang, W and Huang, Y and Huang, C and Wang, G},
title = {Prevalence, risk factors, and early prediction of refractory pneumonia caused by Mycoplasma pneumoniae in children: a systematic review and meta-analysis.},
journal = {European journal of pediatrics},
volume = {185},
number = {3},
pages = {},
pmid = {41723336},
issn = {1432-1076},
support = {2024B1020//Social Public Welfare and Basic Research Special Project of Zhongshan City, Guangdong Province, China/ ; },
mesh = {Humans ; *Pneumonia, Mycoplasma/epidemiology/drug therapy/diagnosis ; Risk Factors ; Prevalence ; Child ; *Mycoplasma pneumoniae ; Anti-Bacterial Agents/therapeutic use ; Child, Preschool ; Infant ; },
abstract = {UNLABELLED: Refractory Mycoplasma pneumoniae pneumonia (rMPP) poses significant challenges in pediatric care due to delayed recognition and limited systematic evidence. This meta-analysis evaluates the prevalence, risk factors, and predictive accuracy of models for rMPP. We systematically searched PubMed, Cochrane Library, and Web of Science until November 2024 for observational studies involving children aged 0-18 years with rMPP. Study quality was assessed using Newcastle-Ottawa and JBI scales. Data were analyzed via R4.4.2. Fifty-three studies (n = 35,275) revealed an overall rMPP prevalence of 37.8% (95% CI 30.5-45.5%), with significant temporal variation: 33.1% pre-COVID-19, 42.0% during, and 86.5% post-pandemic. Independent risk factors included elevated lactate dehydrogenase (OR = 1.018), C-reactive protein (OR = 1.106), procalcitonin (OR = 1.825), interleukin-6 (OR = 2.440), neutrophil count (OR = 2.955), pleural effusion (OR = 4.469), mucus plugs (OR = 5.456), and older age (OR = 1.188). Eleven prediction models demonstrated high accuracy, with ROC-AUCs of 0.913 (training) and 0.895 (validation).<br><br>CONCLUSION: &#xa0;The prevalence of rMPP in children is significant and has increased markedly since the COVID-19 pandemic. Key biomarkers and clinical features facilitate early risk stratification, and validated predictive models improve clinical decision-making. These findings highlight the urgent need for targeted surveillance and customized interventions for high-risk populations.<br><br>WHAT IS KNOWN: &#x2022; Pneumonia caused by Mycoplasma pneumoniae in children can be effectively controlled by first-line macrolide therapy. &#x2022; However, there is still a proportion of children who do not respond well to this treatment regimen and develop refractory Mycoplasma pneumoniae due to macrolide resistance.<br><br>WHAT IS NEW: &#x2022; This review and meta-analysis show the incidence of refractory Mycoplasma pneumonia and its potential risk factors. &#x2022; Finding the feasibility of constructing a predictive model that facilitates early prediction, to provide evidence-based evidence for further in-depth clinical understanding of this disease.},
}
@article {pmid41723349,
year = {2026},
author = {Wu, D and Li, Y and Chen, P and Zhu, K and Cao, C},
title = {Comparison of the efficacy and safety of selective COX-2 inhibitors and non-steroidal anti-inflammatory drugs in the treatment of COVID-19 patients: a systematic review and network meta-analysis.},
journal = {BMC infectious diseases},
volume = {26},
number = {1},
pages = {},
pmid = {41723349},
issn = {1471-2334},
mesh = {Humans ; *Cyclooxygenase 2 Inhibitors/therapeutic use/adverse effects ; *Anti-Inflammatory Agents, Non-Steroidal/therapeutic use/adverse effects ; *COVID-19 Drug Treatment ; COVID-19/mortality ; SARS-CoV-2 ; Respiration, Artificial ; Treatment Outcome ; },
abstract = {BACKGROUND: The global epidemic of novel coronaviruses remains severe, and COX-2 selective inhibitors have attracted attention due to their promising clinical potential. METHODS: Pertinent articles published up to 1 April 2025 were systematically searched and retrieved, including randomized controlled trials and cohort studies. To assess the efficacy of COX-2 selective inhibitors versus other NSAIDs, we analysed five aspects, including death, mechanical ventilation, ICU admission, oxygen uptake, and composite adverse effects. RESULTS: The results showed that COX-2 selective inhibitors significantly reduced the risk of death, with third-highest SUCRA ranking. Regarding the risk of mechanical ventilation, COX-2 inhibitors were associated with a reduced risk and ranked first according to SUCRA compared with other interventions. COX-2 inhibitors were also effective in reducing the risk of ICU admission and endotracheal intubation, again ranking first by SUCRA. In addition, COX-2 inhibitors demonstrated therapeutic potential in reducing the risk of composite adverse effects compared with other NSAIDs. CONCLUSION: Although this study shows that COX-2 inhibitors have good promise for the treatment of COVID-19, there is still a lack of high-quality RCTs to support the conclusions, and there is still room for improvement. TRIAL REGISTRATION: (PROSPERO. CRD CRD42023445987) THE CLINICAL TRIAL NUMBER: Not applicable.},
}
@article {pmid41723405,
year = {2026},
author = {Tosanguan, K and Kessomboon, N and Udomaksorn, K and Nerapusee, O and Laichapis, M and Sakulbumrungsil, R},
title = {Bridging public health emergency and pharmaceutical supply chain preparedness: a scoping review and framework synthesis.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {41723405},
issn = {1472-6963},
mesh = {Humans ; *Public Health ; Pharmaceutical Preparations/supply &amp; distribution ; Public Health Infrastructure ; COVID-19/epidemiology ; *Disaster Planning/organization &amp; administration ; *Civil Defense/organization &amp; administration ; },
abstract = {BACKGROUND: Recent public health emergencies, including the COVID-19 pandemic and large-scale natural disasters, have exposed vulnerabilities in pharmaceutical and health-product supply chains. These events demonstrate that preparedness relies not only on surveillance or clinical capacity but also on the effective management of medicine logistics systems. This scoping review aimed to identify existing assessment tools for public health emergency (PHE) preparedness and health supply chain (HSC) management and to develop an integrated framework that links these two areas to support more comprehensive evaluation of system readiness. METHODS: A scoping review was conducted following the Arksey and O’Malley framework and PRISMA-ScR guidelines. MEDLINE (PubMed) and Scopus were searched for records published between January 2002 and July 2024, complemented by grey literature searches and expert consultation. Predefined inclusion and exclusion criteria were applied, and data were mapped using the Flower Framework, which combines domains of PHE management with pharmaceutical supply chain functions. RESULTS: Of 3,965 records identified (3,920 from databases and 45 from grey literature), 23 assessment tools met the inclusion criteria. Fourteen tools were developed in academic or research settings and nine in policy or programmatic grey literature. Instruments focused on PHE preparedness tended to emphasize governance, coordination, and core public health capacities, whereas HSC tools highlighted forecasting, procurement, inventory management, and warehousing. Only a few instruments bridged both perspectives. CONCLUSION: This scoping review reveals that no single instrument currently provides a comprehensive assessment of pharmaceutical system readiness across governance, regulatory, and operational dimensions. While existing tools offer situational benchmarking, they often fail to capture functional synergy and pharmaceutical-specific requirements like cold-chain integrity and regulatory constraints. Synthesizing findings through the Flower Framework, this study proposes an integrated model that bridges the gap between static capacity and real-world resilience, emphasizing the need for functional evaluations—such as stress tests and simulations—to more accurately reflect system adaptability during crises.},
}
@article {pmid41723461,
year = {2026},
author = {Mulumba, M and Oga, J and Baguma, C and Nantaba, J and Ruano, AL},
title = {Health equity and the global social contract: beyond incrementalism and illusionary solidarity.},
journal = {International journal for equity in health},
volume = {25},
number = {1},
pages = {},
pmid = {41723461},
issn = {1475-9276},
mesh = {Humans ; *Health Equity ; *Social Justice ; *Global Health ; Sustainable Development ; COVID-19 ; *International Cooperation ; },
abstract = {The Millennium Development Goals (MDGs) and Sustainable Development Goals (SDGs) have been celebrated as global social contracts, yet their reliance on voluntary commitments and aspirational targets conceals a structural flaw. By divorcing poverty and inequity from colonial histories, debt regimes, and extractive global finance, these frameworks function as a neocolonial placebo: soothing global conscience while entrenching asymmetries of power and resources. Drawing on examples from debt distress, vaccine apartheid, and intellectual property monopolies during COVID-19, this commentary demonstrates that global health governance operates less as solidarity than as economic containment. Reparative justice provides the necessary rupture. A post-2030 Global Social Contract must impose enforceable obligations on former colonial powers, embed structural restitution through debt and tax justice, and democratise health governance under the principle of Common but Differentiated Responsibilities. Anything less risks reproducing selective generosity while abandoning equity to the logics of extraction and impunity.},
}
@article {pmid41723495,
year = {2026},
author = {Abreu, AR and Gonçalves, F and Oliveira, S and Ribeiro, I},
title = {Workplace violence against healthcare workers: a scoping review of reporting practices, barriers to reporting and institutional responses (2020-2025).},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {41723495},
issn = {1472-6963},
mesh = {Humans ; *Health Personnel/statistics &amp; numerical data/psychology ; *Workplace Violence/statistics &amp; numerical data/prevention &amp; control ; Portugal ; Working Conditions ; },
abstract = {BACKGROUND: Violence against healthcare workers (HCWs) is a widespread global problem that has gained increasing attention due to its substantial impact on HCWs well-being and the quality of care they provide. This scoping review aimed to identify current reporting practices, institutional and organisational barriers to reporting violent incidents against HCWs, and critical research gaps in this area, integrating global evidence with a specific focus on Portugal. METHODS: Following the methodological framework of Arksey and O’Malley (2005), refined by Levac et al. (2010), and reported per PRISMA-ScR (2018) guidelines, a comprehensive search was conducted in PubMed, Scopus, and Web of Science (January 2020–June 2025). Studies in English, Portuguese, or Spanish addressing reporting practices, barriers to reporting, digital platforms, or policies regarding WPV against HCWs were included. Two reviewers independently screened and extracted data using a structured matrix, resolving discrepancies by consensus. Results were summarized narratively with frequency analysis. RESULTS: From the initial 232 records, 35 studies met inclusion criteria, from 19 geographic areas across 5 continents. Most studies originated from Asia and Europe. Verbal violence was the most frequently reported form (20–91%), and over half reported underreporting rates exceeding 50%. The most frequently reported individual barrier was the belief that reporting is ineffective (60%), while the most cited systemic barrier was ineffective reporting systems (63%). National digital platforms reporting included the WVIRS system (California), the Synergic system (Sweden), the White Code system (Turkey), and the NOTIFICA, SAGRIS and HER+ systems (Portugal). Effective strategies to reporting combined staff training with awareness campaigns, supported by leadership engagement and policy frameworks. The COVID-19 pandemic intensified workplace tensions and may have influenced both the occurrence and reporting of violent incidents. CONCLUSION: Underreporting of workplace violence persists despite the existence of policies and reporting platforms. This review highlights persistent barriers to reporting workplace violence among HCWs and emphasizes the need for user-friendly and supportive reporting systems. Findings call for institutional accountability, better feedback mechanisms, and targeted policies to foster a culture of safety and transparency, both globally and in Portugal.},
}
@article {pmid41723921,
year = {2026},
author = {Li, R and Vafeiadis, M and Shen, F and Hou, Z},
title = {The role of health beliefs in COVID-19 vaccination acceptance: A Meta-analysis.},
journal = {Vaccine},
volume = {77},
number = {},
pages = {128379},
doi = {10.1016/j.vaccine.2026.128379},
pmid = {41723921},
issn = {1873-2518},
mesh = {Humans ; *COVID-19/prevention &amp; control/psychology ; *COVID-19 Vaccines/administration &amp; dosage ; *Vaccination/psychology ; *Vaccination Hesitancy/psychology ; *Patient Acceptance of Health Care/psychology ; *Health Belief Model ; SARS-CoV-2 ; *Health Knowledge, Attitudes, Practice ; Pandemics/prevention &amp; control ; },
abstract = {This study employed a meta-analytic approach to examine the relationships between the Health Belief Model (HBM) constructs and COVID-19 vaccination acceptance. A comprehensive literature search identified 77 eligible studies with a combined sample size of 83,995 participants. Quantitative synthesis of the extracted data revealed that perceived benefits (r = 0.40) was the strongest positive predictor of individuals' vaccine acceptance, indicating a medium-to-large effect. Perceived severity (r = 0.17) and susceptibility (r = 0.18) to COVID-19 were also significant positive predictors, each with small-to-medium effect sizes. Cues to action (r = 0.11) and self-efficacy (r = 0.10) were also positively associated with vaccine acceptance, although the effects were small. In contrast, perceived barriers to vaccination (r = -0.25) were negatively associated with vaccine acceptance, approaching a medium effect in size. Several of these associations were moderated by study characteristics, including how the variables were operationalized (intention, hesitancy, refusal, etc.), the vulnerability of the study sample, the respondent type (parents vaccinating children vs. adults vaccinating themselves), the vaccine development stage, and the variant phase. Overall, these findings contribute to a deeper understanding of the psychological mechanisms underlying vaccine acceptance and hesitancy, and offer practical implications for developing targeted communication strategies to promote COVID-19 and other vaccinations.},
}
@article {pmid41724028,
year = {2026},
author = {Moreta-Gil, E and Rivera-Picón, C and Conty-Serrano, R and Polonio-López, B and Martín-Conty, JL and Martín-Rodríguez, F and Sanz-García, A},
title = {Prehospital early warning scores for predicting clinical deterioration of COVID-19 patients: An integrative review.},
journal = {Enfermeria intensiva},
volume = {37},
number = {2},
pages = {500584},
doi = {10.1016/j.enfie.2026.500584},
pmid = {41724028},
issn = {2529-9840},
mesh = {Humans ; *COVID-19/diagnosis ; *Early Warning Score ; *Clinical Deterioration ; SARS-CoV-2 ; Pandemics ; *Emergency Medical Services ; },
abstract = {INTRODUCTION: Triage, and in particular scales, are a tool that allows patients with clinical risk to be managed for early, effective and efficient care.<br><br>OBJECTIVE: To identify the most precise and specific prehospital score for the detection of clinical worsening risk in COVID19 patients.<br><br>METHODS: The protocol followed for the integrative review was the PRISMA method 2020. A literature search was performed in five databases: Scopus, Cochrane Library, Pubmed, Embase, Prospero and Lit covid-nih-nlm. Based on 19 keywords, 5 inclusion and 5 exclusion points. Finally, 22 articles were selected.<br><br>RESULTS: Twenty-two studies were identified that addressed effective outcomes for early measures such as telephone triage, web, protocols or tools such as scales. We compared the functionality of 12 scales in patients with Covid-19, showing that the most important variables for this early assessment of clinical worsening were systolic blood pressure, temperature, oxygen saturation and the need for oxygen supplementation. The best predictive value for clinical deterioration and mortality was obtained by NEWS score, with sensitivities and specificities ranging from 77% to 88%.<br><br>CONCLUSIONS: Prehospital scales are still under development, with few research studies and a relative confidence in their statistical values. Nonetheless, it has been observed that the scale that best fit the covid-19 was NEWS with an optimal prediction for patients. This could pave the way for its use under other relevant clinical scenarios, such as acute respiratory infections, exacerbations of chronic diseases or future health emergencies.},
}
@article {pmid41724302,
year = {2026},
author = {Pascual-Alonso, I and Arrebola-Sánchez, Y and Almeida-García, F and Frómeta-Fuentes, T and Acén-Ravelo, T and Del Valle-Pelaiz, S and Escandel-Barreto, A and Ojeda Del Sol, D and Valdés-Tresanco, ME and Sánchez-Ramírez, B and Bergado, G and Chao, L and Fundora Barrios, T and Melchy, E and Chipres-Naranjo, LE and Gutiérrez-Mariscal, M and Charli, JL and Rosenstein, Y},
title = {Biochemistry, physiology and implications in human diseases of mammalian aminopeptidase N: A review.},
journal = {International journal of biological macromolecules},
volume = {350},
number = {},
pages = {151030},
doi = {10.1016/j.ijbiomac.2026.151030},
pmid = {41724302},
issn = {1879-0003},
mesh = {Humans ; Animals ; *CD13 Antigens/chemistry/metabolism/genetics/antagonists &amp; inhibitors ; Neoplasms/enzymology ; },
abstract = {Aminopeptidases are proteases that selectively hydrolyze an amino acid residue from the amino terminus of proteins and peptides, leading to their activation or inactivation. These enzymes are predominantly metallopeptidases. One of them, membrane alanyl aminopeptidase, also known as aminopeptidase N (APN, EC 3.4.11.2), a M1 family metallo-aminopeptidase, plays essential roles in mammals. APN regulates pain sensitivity, central nervous system control of blood pressure, the final steps of protein degradation, cell motility and adhesion, and coronavirus entry. Furthermore, upregulated expression of APN has been implicated in the pathogenesis of various human disorders, including cancers, inflammation, and pressure dysregulation. APN is a multifunctional protein, and its ligation or inhibition of enzymatic activity may have therapeutic applications. Here, we focus on human and porcine enzymes as models to review the most important structural and functional features of mammalian APN, its roles in mammalian physiology, and the pathophysiological aspects in humans, with particular emphasis on cancer. We illustrate how APN is a tool for diagnosing and monitoring cancer and other pathologies, and discuss the obstacles to the therapeutic use of its inhibitors.},
}
@article {pmid41724536,
year = {2026},
author = {Carbotti, G and van den Berg, DM and Carvalho, AL and Senore, C and Heijnsdijk, EA and de Koning, HJ and Lansdorp-Vogelaar, I and , },
title = {Developments in the roll-out and performance of CRC screening in Europe.},
journal = {Best practice &amp; research. Clinical gastroenterology},
volume = {80},
number = {},
pages = {102043},
doi = {10.1016/j.bpg.2025.102043},
pmid = {41724536},
issn = {1532-1916},
mesh = {Humans ; Europe/epidemiology ; *Colorectal Neoplasms/diagnosis/epidemiology/mortality ; *Early Detection of Cancer/methods/trends ; Incidence ; *Mass Screening/trends/methods/organization &amp; administration ; },
abstract = {The heterogeneous implementation of colorectal cancer screening programs across Europe makes performance comparison challenging. This study computed and analyzed seven key indicators of screening performance for eighteen European programs between 2011 and 2022. Trends in colorectal cancer incidence and mortality were also examined in relation to when each screening program was introduced. Coverage indicators showed considerable variation across programs but generally increased until the onset of the COVID pandemic. Yield indicators remained stable overall, whereas jumps were associated to protocol changes. In most countries, a decline in incidence followed the introduction of the screening program, whereas the connection of screening with mortality was less evident. The analysis of comparable screening performance indicators over time allows for cross-country and longitudinal monitoring of the programs. The observed decline in incidence following the implementation of fully rolled-out programs highlights the importance and effectiveness of well-organized screening in reducing the burden of the disease.},
}
@article {pmid41724540,
year = {2026},
author = {de Jonge, L and Lansdorp-Vogelaar, I and Doria-Rose, VP and Portillo, I and Novak Mlakar, D and Buron, A and Quintin, C and Espinàs, JA and Plaine, J and Škrjanec, AL and Kofol Bric, T and Binefa, G and Font, R and Bulliard, JL and Chubak, J and Ziebell, R and McCurdy, BR and Rabeneck, L and Senore, C and , },
title = {Global impact of COVID-19 on organized CRC screening programs: lessons learned.},
journal = {Best practice &amp; research. Clinical gastroenterology},
volume = {80},
number = {},
pages = {102047},
doi = {10.1016/j.bpg.2025.102047},
pmid = {41724540},
issn = {1532-1916},
mesh = {Humans ; *Colorectal Neoplasms/diagnosis/epidemiology ; *COVID-19/epidemiology ; *Early Detection of Cancer/statistics &amp; numerical data/methods/trends ; *Mass Screening/organization &amp; administration ; Retrospective Studies ; SARS-CoV-2 ; Pandemics ; Global Health ; },
abstract = {Using a standardized data template, this study retrospectively collected data about colorectal cancer (CRC) screening activity in 2020 and 2021 to estimate the impact of the COVID-19 pandemic compared to the pre-pandemic period (2018 or 2019). Data were collected from 17 programs in 14 countries of which 15 were population-based programs. Invitation coverage was decreased by up to 53.7 % in 2020. Participation among those invited was similar in both periods for all programs. The maximum backlog in invitations was less than 7.4 months in 2020 and 3.3 months for 2021. Nine out of 15 programs observed a decrease in the number of detected CRCs in 2020. Four programs showed a positive percentage change in CRCs detected in 2021 relative to the pre-pandemic period. Half of the countries observed a worse stage-distribution in 2020/2021. Overall, organized CRC screening programs operated at lower screening activity, but screening outcomes were similar compared to the pre-pandemic period.},
}
@article {pmid41725107,
year = {2026},
author = {Belland, KM and DeJohn, CA},
title = {Comprehensive Review: Ultraviolet-C (UVC) Disinfection in Aircraft Cabins.},
journal = {Health security},
volume = {24},
number = {1},
pages = {35-38},
doi = {10.1177/23265094261424116},
pmid = {41725107},
issn = {2326-5108},
mesh = {*Disinfection/methods ; *Ultraviolet Rays ; *Aircraft ; Humans ; COVID-19/prevention &amp; control ; SARS-CoV-2/radiation effects ; },
abstract = {Ultraviolet-C (UVC) disinfection has gained considerable attention as a continuous, real-time method to mitigate the transmission of airborne pathogens within aircraft cabins. Recent investigations have demonstrated its potential to inactivate viruses such as SARS-CoV-2, influenza, and other emerging infectious agents in situ, thereby reducing both immediate infection risks and broader public health burdens. This commentary evaluates how continuous UVC disinfection-applied in tandem with established preventive measures-may effectively curtail disease transmission, reassure passengers, and inform the future direction of in-flight health and safety standards.},
}
@article {pmid41727479,
year = {2026},
author = {Parra-González, M and Nájera-Maldonado, L and Peralta-Cuevas, E and Gutierrez-Onofre, A and Jaimes-López, LA and Juarez-Antonio, JA and Degollado-Hernández, NY and Garcia-Atutxa, I and Villanueva-Flores, F},
title = {Dengue-SARS-CoV-2 interactions: immune crosstalk, variant emergence, and clinical outcomes.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1650425},
pmid = {41727479},
issn = {1664-3224},
mesh = {Humans ; *Dengue/immunology/epidemiology/virology ; *COVID-19/immunology/epidemiology/virology ; *SARS-CoV-2/immunology/genetics ; *Coinfection/immunology ; *Dengue Virus/immunology/genetics ; Antibody-Dependent Enhancement/immunology ; Cross Reactions/immunology ; Animals ; Cytokines/immunology ; Host-Pathogen Interactions ; },
abstract = {This review aims to provide an overview of dengue-COVID-19 co-infection, emphasizing recently described immunological, genomic, and eco-epidemiological interactions that may influence clinical outcomes and viral evolution. It brings together molecular evidence, immunological perspectives, and epidemiological insights to summarize current hypotheses and working models of these complex disease interactions. We summarize and critically discuss evidence on antibody-dependent enhancement (ADE), cross-reactive immune responses, and cytokine amplification pathways, and propose mechanisms that could underlie exacerbated disease severity. Published clinical data indicate heterogeneity in co-infection outcomes globally, from mild presentations to severe complications, such as hemorrhagic stroke, acute kidney injury, and increased mortality, particularly among populations with prior dengue exposure. Diagnostic complexities arising from serological cross-reactivity underscore the need for simultaneous molecular testing to ensure accurate pathogen identification. Additionally, we review current evidence on reciprocal selective pressures between SARS-CoV-2 variants and dengue serotypes, highlighting potential evolutionary impacts arising from their co-circulation. The available evidence suggests that co-infection may exacerbate inflammatory pathways, lead to increased vascular and organ damage, and complicate patient management. However, definitive clinical evidence for ADE remains inconclusive, underscoring an ongoing need for targeted mechanistic studies. By outlining significant knowledge gaps and summarizing proposed research directions, this review aims to provide a valuable reference for clinicians, immunologists, epidemiologists, and policymakers managing concurrent dengue and COVID-19 outbreaks.},
}
@article {pmid41727556,
year = {2026},
author = {Millar, BC and Cates, MJ and Torrisi, MS and Round, AJ and Warde, A and Lowery, CJ and Moore, JE},
title = {Antimicrobial Resistance: The Answers.},
journal = {British journal of biomedical science},
volume = {83},
number = {},
pages = {15559},
pmid = {41727556},
issn = {2474-0896},
mesh = {Humans ; *Anti-Bacterial Agents/therapeutic use/pharmacology ; SARS-CoV-2 ; COVID-19 ; Pandemics ; *Drug Resistance, Bacterial ; *Drug Resistance, Microbial ; Betacoronavirus ; *Bacterial Infections/drug therapy ; },
abstract = {Antimicrobial resistance (AMR) has caused a global public health crisis, contributing to approximately five million deaths in 2019 and predicted deaths of approximately ten million annually by 2050. This equates to approximately 1.4-fold more deaths annually from AMR in 2050 than the entire COVID-19 pandemic to date. To tackle this AMR pandemic, regulatory and policy frameworks have been prepared at local, national and international levels with multi-faceted proposals and advances encompassing surveillance, diagnostics, infection prevention, antibiotic prescribing and variation of existing and novel treatment approaches. This narrative review primarily focuses on research and development which have been documented over the last five years in relation to therapeutic approaches at various stages in clinical development and the potential role that vaccines can play in the fight against AMR. This review provides an overview on antibacterial drugs, including novel classes of antibiotics, which have been recently approved, as well as combination antibiotic therapy and the potential of repurposed drugs. The potential role of novel antimicrobial, antibiofilm and quorum sensing inhibitors, such as antimicrobial peptides, nanomaterials and compounds from the extreme and natural environments, as well as ethnopharmacology including the antimicrobial effects of plants, spices, honey and venoms are explored. Novel therapeutic approaches are critically discussed in terms of their realistic clinical potential, detailing recent and ongoing trials to highlight the current interest of these approaches, including immunotherapy, bacteriophage therapy, antimicrobial photodynamic therapy (aPDT), antimicrobial sonodynamic therapy (aSDT), nitric oxide therapy and microbiome manipulation including faecal microbiota transplantation (FMT). The potential of predatory bacteria as living antimicrobial agents is also discussed. Importantly, there have been many technological developments which have enhanced bioprospecting and research and development of novel antimicrobials which this review draws attention to, including artificial intelligence, machine learning and Organ-on-a-Chip devices. Finally, key messages from the recent World Health Organization report into the role of vaccines against AMR provides an interesting perspective relating to prevention which can be of significance in tackling the AMR burden.},
}
@article {pmid41728596,
year = {2026},
author = {Tang, CT and Lim, LJH and Lee, CTM and Heah, AJE and Yeo, DST and Tan, SM},
title = {The utilization of virtual reality in the training of de-escalation of aggression for both providers and users of public and healthcare services from the new millennium to the COVID-19 era: a systematic review.},
journal = {Frontiers in medicine},
volume = {13},
number = {},
pages = {1657986},
pmid = {41728596},
issn = {2296-858X},
abstract = {INTRODUCTION: Virtual reality (VR) is a promising modality for the effective delivery of training in the de-escalation of aggression. This review aims to assess how VR has been utilized in training for the de-escalation of aggression among both providers and users of public and healthcare services from the new millennium to the COVID-19 era (2000-2022).<br><br>METHODS: A systematic review was conducted in accordance with a pre-registered protocol and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Seven key databases were searched, yielding 2373 studies for screening, of which 15 were included. Quality appraisal was performed using the widely used Critical Appraisal Skills Programme (CASP) tool.<br><br>RESULTS: VR training for the de-escalation of aggression was implemented using a variety of approaches, ranging from verbal interaction and emotion-recognition tasks to selection from multiple-choice response menus. Most studies assessed participants' responses to the intervention, but none evaluated whether VR training had an impact at the organizational level. Overall, VR training content, modes of interaction, and reported improvements in participants' confidence were viewed positively. However, some studies reported limitations related to the emotional impact, realism of virtual characters, and learning effectiveness. Additional features that may enhance the VR experience were discussed, with personalized, context-specific scenarios identified as an important area for development.<br><br>CONCLUSION: Larger-scale studies are required to determine which specific training domains may benefit most from VR-based approaches, given the heterogeneity of populations and methodologies across studies conducted between 2000 and 2022.<br><br>https://www.crd.york.ac.uk/PROSPERO/view/CRD42022307138, identifier CRD42022307138.},
}
@article {pmid41729334,
year = {2026},
author = {Gaddafi, MS and Lawal, H and Musawa, IA and Garba, B and Goni, MD and Jolayemi, KO and El-Yakub, AU and Jibril, AH and Saeed, SI and Bitrus, AA and Salman, M and Fasina, FO and Yakubu, Y},
title = {Serological and virological evidence of MERS-CoV infection among dromedary camels in Africa: a systematic review and Meta-analysis.},
journal = {Veterinary research communications},
volume = {50},
number = {2},
pages = {},
pmid = {41729334},
issn = {1573-7446},
mesh = {Animals ; *Camelus/virology ; *Middle East Respiratory Syndrome Coronavirus/isolation &amp; purification ; *Coronavirus Infections/veterinary/epidemiology/virology ; Seroepidemiologic Studies ; Africa/epidemiology ; Zoonoses/virology/epidemiology ; Female ; Risk Factors ; },
abstract = {Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a zoonotic pathogen of major public health concern due to its pandemic potential. Dromedary camels are the principal reservoir, and Africa harbors over 60% of the global dromedary population. This systematic review and meta-analysis assessed the serological, molecular, and geographical distribution of MERS-CoV infection and associated risk factors among African dromedary camels over the past decade. A systematic search of Web of Science, PubMed, Scopus, and African Journals Online (AJOL) was conducted for studies published between 2012 and 2025, following PRISMA 2020 guidelines. Thirty-nine eligible studies from 13 African countries were included, predominantly from East Africa, followed by North and West Africa. The pooled seroprevalence and viral RNA prevalence of MERS-CoV among dromedaries were 75.1% (95% CI: 68.2%-82.0%; I2 = 99.4) and 6.2% (95% CI: 3.5%-8.9%; I2 = 99.7), respectively, indicating extensive exposure history. Subgroup analysis showed regional variation, with the highest pooled seroprevalence in North Africa and highest viral RNA prevalence in West Africa (5.5%). Adult camels had higher seroprevalence (78.5%) than juvenile camels (42.5%), while viral RNA detection was slightly higher in young (5.5%). Female camels showed slightly higher (descriptive) pooled seroprevalence (69.7%) than males (65.8%), whereas males had slightly higher pooled viral RNA prevalence (5.1%) compared to females (4.0%). Nine studies examined human infection among camel handlers, yielding a pooled prevalence of 12.3% (95% CI: 1.4%-25.9%; I2 = 99.9). These findings highlight widespread MERS-CoV circulation in African camels and the urgent need for coordinated One Health surveillance to mitigate zoonotic risks.},
}
@article {pmid41729563,
year = {2026},
author = {Li, Q and Zeng, M and Lv, W and Ye, J and Wu, S},
title = {Current landscape of clinical trials for mRNA-based therapeutics.},
journal = {Human vaccines &amp; immunotherapeutics},
volume = {22},
number = {1},
pages = {2635868},
pmid = {41729563},
issn = {2164-554X},
mesh = {Humans ; *Clinical Trials as Topic/statistics &amp; numerical data ; *mRNA Vaccines/therapeutic use ; *RNA, Messenger/therapeutic use ; },
abstract = {Beyond coronavirus disease 2019 (COVID-19) vaccines, messenger RNA (mRNA)-based therapeutics have increasingly demonstrated potential across other treatment areas. To summarize the clinical research landscape for such products and provide valuable references for researchers working in related fields, mRNA clinical trials registered on ClinicalTrials.gov (CTg) and the Chinese Clinical Trial Registry (ChiCTR) up to June 7, 2025, were analyzed. Twelve key items, including registration number, study title, target disease, interventions, blinding, sponsor, phases, enrollment, funder type, study type and start date, and locations, were analyzed to describe trial characteristics. A total of 557 clinical trials of mRNA-based therapeutics were identified. Most of these studies were conducted in phases 0-3 (n = 412, 73.97%), primarily focusing on infectious diseases (n = 410, 73.61%), and predominantly open-label designs (n = 338, 60.68%). Interventional studies accounted for 85.82% (n = 478) of all registered trials. Industry sponsors were the primary source of funding (n = 299, 53.68%). Approximately 45.06% of the projects (n = 251) aimed to enroll 0-100 participants. Most of the studies involved mRNA vaccines (n = 507, 91.02%). Further, 22 trials investigated mRNA-based therapeutics for rare diseases. Among the newly registered projects in 2024 and 2025, the proportion of phase 0-1 trials significantly increased, accounting for 61.67% and 78.13%, respectively. The top three regions that conducted mRNA clinical studies were North America (n = 186; primarily the United States [n = 178]), Asia (n = 184; China [n = 72]), and Europe (n = 90), based on studies registered in both CTg and ChiCTR. Most mRNA products remain in preapproval clinical trials. Further phase 3 clinical evidence will be essential to support its broader application.},
}
@article {pmid41729699,
year = {2026},
author = {Hoy-Schulz, YE and Damhorst, GL and Lam, WA},
title = {Accelerating Diagnostics for Pandemic Preparedness.},
journal = {Annual review of analytical chemistry (Palo Alto, Calif.)},
volume = {19},
number = {1},
pages = {279-306},
doi = {10.1146/annurev-anchem-082824-031734},
pmid = {41729699},
issn = {1936-1335},
mesh = {Humans ; Pandemic Preparedness ; *COVID-19/diagnosis/epidemiology ; SARS-CoV-2/isolation &amp; purification/genetics ; Pandemics ; *COVID-19 Testing/methods ; },
abstract = {Diagnostics are central to pandemic preparedness, guiding surveillance, clinical care, and public health response. The COVID-19 pandemic exposed limitations in diagnostic infrastructure but also accelerated innovation across assay types, created accessible testing mechanisms, and demonstrated the value of public-private partnerships. This review outlines the critical roles diagnostics play across pandemic phases, from early detection to post recovery surveillance. We review the current diagnostic landscape for pandemic priority pathogens and unmet needs and challenges and examine recent advances in analytical technologies, including isothermal amplification, CRISPR-based methods, alternative sample types, and novel platforms, with a focus on their potential for rapid deployment and field use. We also explore the emergence of diagnostic accelerators and biorepositories that support assay validation and global test availability. For analytical chemists, pandemic preparedness presents a call to action: to develop, validate, and translate innovative tools that can adapt to meet urgent diagnostic needs during future health emergencies.},
}
@article {pmid41729872,
year = {2026},
author = {Bhattacharya, K and Sharma, D},
title = {Surgery in the shadow of Nipah: Preparedness, precautions, and protocols.},
journal = {Tropical doctor},
volume = {56},
number = {3},
pages = {453-455},
doi = {10.1177/00494755261425726},
pmid = {41729872},
issn = {1758-1133},
mesh = {Humans ; Nipah Virus ; *Henipavirus Infections/prevention &amp; control/transmission/epidemiology ; Animals ; COVID-19 ; Pandemics/prevention &amp; control ; Cross Infection/prevention &amp; control ; *Infection Control/methods ; SARS-CoV-2 ; Disease Outbreaks/prevention &amp; control ; Operating Rooms ; Pandemic Preparedness ; },
abstract = {Nipah virus (NiV) is a highly lethal zoonotic infection with a case fatality rate of 70-75% and is recognized by the World Health Organization as a priority pathogen with epidemic potential. Recent cases in India highlight the ongoing risk of re-emergence, particularly in resource-constrained health systems. While surveillance and outbreak containment are often emphasized, the implications of NiV for surgical and perioperative care remain less often discussed. Operating rooms are high-risk environments for nosocomial transmission owing to aerosol-generating procedures and exposure to body fluids. Drawing on lessons from past infectious disease outbreaks and recent global experiences with COVID-19, we wish to outline perioperative risks, evidence-informed precautions, and system-level preparedness strategies tailored for surgical teams.},
}
@article {pmid41730209,
year = {2026},
author = {Dobrescu, A and Pinte, L and Sharifan, A and Gadinger, A and Moser, I and Cooper, C and Gartlehner, G},
title = {Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {179},
number = {5},
pages = {673-684},
doi = {10.7326/ANNALS-25-05044},
pmid = {41730209},
issn = {1539-3704},
mesh = {Humans ; *COVID-19 Vaccines/adverse effects ; *COVID-19/prevention &amp; control ; *Vaccine Efficacy ; Adult ; SARS-CoV-2 ; Hospitalization/statistics &amp; numerical data ; },
abstract = {BACKGROUND: The SARS-CoV-2 Omicron variant continues to pose a global health burden.<br><br>PURPOSE: To assess the effectiveness, comparative effectiveness, and harms of COVID-19 vaccines in nonpregnant, nonimmunocompromised adults.<br><br>DATA SOURCES: Medline via Ovid and DynaMedex from January 2022 to September 2025.<br><br>STUDY SELECTION: Two reviewers independently selected English-language randomized controlled trials (RCTs) and nonrandomized studies of interventions (NRSIs).<br><br>DATA EXTRACTION: One reviewer extracted data and assessed the certainty of evidence (CoE), and a second reviewer verified; 2 reviewers independently assessed risk of bias.<br><br>DATA SYNTHESIS: Five RCTs and 18 NRSIs were included. In adults of all ages, Omicron-adapted vaccination probably reduces all-cause mortality (vaccine effectiveness [VE] ranged from 26.6% [95% CI, 5.5% to 42.3%] to 75.2% [CI, 70.6% to 79.9%]; moderate CoE) and COVID-19-related hospitalization (VE ranged from 16.6% [CI, 6.5% to 25.8%] to 67.8% [CI, 63.1% to 72.5%]; moderate CoE) compared with no Omicron-adapted vaccination. When administered more than 365 days after the prior vaccine, it probably reduces all-cause mortality (VE, 36.1% [CI, 14.8% to 54.1%]; moderate CoE) and COVID-19-related hospitalization (VE, 22.2% [CI, 11.4% to 32.0%]; moderate CoE). When administered earlier, it may result in no difference in COVID-19-related hospitalization. Omicron-adapted vaccination may increase myocarditis (incidence rate ratio, 2.7 [CI, 1.0 to 7.0]; low CoE) in adults aged 50 years or older. The mRNA-1283.222 bivalent vaccine probably results in no difference in all-cause mortality or serious adverse events compared with mRNA-1273.222 in adults of all ages.<br><br>LIMITATIONS: No RCTs assessed the effectiveness of Omicron-adapted versus no Omicron-adapted vaccination. Evidence on harms was limited.<br><br>CONCLUSION: Omicron-adapted vaccines improve protection compared with no Omicron-adapted vaccines, particularly when administered more than 365 days after the prior vaccination.<br><br>PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD420251136017).},
}
@article {pmid41730216,
year = {2026},
author = {Qaseem, A and Obley, AJ and Harrod, CS and Wilt, TJ and Carroll, K and Humphrey, LL and , and Haeme, R and Krain, A and Poonacha, T and Saini, SD and Vigna, C},
title = {COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {179},
number = {5},
pages = {728-733},
doi = {10.7326/ANNALS-25-05026},
pmid = {41730216},
issn = {1539-3704},
mesh = {Humans ; *COVID-19 Vaccines/adverse effects ; Adult ; *COVID-19/prevention &amp; control/epidemiology ; Middle Aged ; Aged ; Female ; Adolescent ; Young Adult ; United States ; Vaccine Efficacy ; SARS-CoV-2 ; },
abstract = {DESCRIPTION: The American College of Physicians (ACP) developed these rapid practice points addressing the effectiveness, comparative effectiveness, and harms of Omicron-adapted COVID-19 vaccines in adults (aged ≥18 years) who are not pregnant or immunocompromised.<br><br>METHODS: The ACP Population Health and Medical Science Committee developed the rapid practice points on the basis of a rapid review by the ACP Center for Evidence Reviews at Cochrane Austria and national disease surveillance data on the epidemiology and baseline risks for COVID-19.<br><br>UNLABELLED: The following practice points apply to those who are not pregnant or immunocompromised.<br><br>PRACTICE POINT 1: Adults aged 65 years or older should receive an updated 2025-2026 mRNA-based COVID-19 vaccine.<br><br>PRACTICE POINT 2: Adults aged 18 to 64 years at increased risk for severe COVID-19 should receive an updated 2025-2026 mRNA-based COVID-19 vaccine.<br><br>PRACTICE POINT 3: Adults aged 18 to 64 years who are not at increased risk for severe COVID-19 may consider receiving an updated 2025-2026 mRNA-based COVID-19 vaccine.},
}
@article {pmid41730897,
year = {2026},
author = {Soriano, JB and Lumbreras, S},
title = {The rise of artificial intelligence in respiratory primary care and pulmonology: a scoping review.},
journal = {NPJ primary care respiratory medicine},
volume = {36},
number = {1},
pages = {},
pmid = {41730897},
issn = {2055-1010},
mesh = {Humans ; *Artificial Intelligence ; *Primary Health Care ; *Pulmonary Medicine/methods/trends ; COVID-19 ; Pandemics ; SARS-CoV-2 ; Digital Health ; },
abstract = {Artificial intelligence (AI) is rapidly advancing respiratory disease management, from diagnosis to population lung health. This scoping review synthesizes the most promising uses of AI in respiratory medicine, with a particular focus on pulmonologists and family physicians interested in lung health. In diagnostics, deep-learning systems streamline chest-imaging workflows by triaging radiographs, detecting COVID-19 pneumonia, and classifying lung nodules on CT. In pulmonary function testing, algorithms detect technical errors and classify spirometric patterns, some claiming to outperforming pulmonologists. Acoustic analysis of cough, breathing, and speech captured on smartphones or wearables offers non-invasive decision support. For monitoring and prediction, AI helps shorten weaning from mechanical ventilation and guides closed-loop strategies for acute respiratory distress. In chronic care, connected devices integrated with environmental data help to forecast asthma and COPD exacerbations, while telehealth and predictive models enable earlier, more personalized interventions. Additional gains are emerging in paediatrics, sleep medicine, lung ultrasounds, and public health. Realizing these benefits will require rigorous multicentre validation and real-world evidence. It will also require proactive bias detection and mitigation with inclusive sampling and equity audits. High-quality, interoperable data and explainable models are needed to enable human oversight. Practical issues such as digital literacy, device access, and usability for children, older adults, and other vulnerable populations also matter for applications requiring patient interaction. With sustained collaboration among clinicians, engineers, AI experts, industry, regulators, and scientific societies, AI can increase the time invested in a satisfactory clinician-patient relationship. With all likelihood, AI can also measurably improve efficiency and accuracy across multiple domains of respiratory care.},
}
@article {pmid41732619,
year = {2026},
author = {Manoukian, G and Kundukulam, S and Asatorian, G and Johnson, DM and Masood, MH and Venugopal, A and Manoukian, M and Aswathappa, S},
title = {Post-COVID Syndrome in Patients With Comorbid Hypertension or Diabetes: A Narrative Review of Long-Term Outcomes.},
journal = {Cureus},
volume = {18},
number = {1},
pages = {e102117},
pmid = {41732619},
issn = {2168-8184},
abstract = {Post-COVID syndrome (PCS), or long COVID, refers to a cluster of enduring symptoms that extend beyond the acute phase of the initial SARS-CoV-2 infection. Acute infection predominantly impacts the respiratory tract, but there is growing evidence for the multisystem involvement, such as cardiovascular, metabolic, and neurological, to be responsible for the prolonged presentation in PCS. Underlying cardiometabolic vulnerability may contribute to a high degree of susceptibility in patients with comorbidities like hypertension (HTN) and diabetes mellitus (DM). This narrative review summarizes current literature regarding PCS in patients with HTN and/or DM, focusing on proposed pathophysiological mechanisms, clinical manifestations, and reported long-term outcomes. In these populations, PCS has been linked across studies to processes including endothelial dysfunction, chronic low-grade inflammation, autonomic imbalance, and potential dysregulation of the renin-angiotensin-aldosterone system (RAAS). Persistent cardiovascular, metabolic, and neurocognitive symptoms are reported, but the magnitude and patterns of risk vary across studies, while comparative findings across HTN and DM remain heterogeneous. Symptoms reported frequently include fatigue, cognitive impairment ("brain fog"), and psychological distress, supporting the multisystem complexity of PCS. Although, previous work has indicated that cardiometabolic comorbidities could interact and moderate PCS severity and persistence, there is an important shortfall of both causality and prognosis, as well as the management of PCS. Longitudinal studies are needed for future research regarding risk stratification, disease course, and targeted interventions in individuals with PCS with comorbid high blood pressure and diabetes.},
}
@article {pmid41733130,
year = {2026},
author = {Tang, JW},
title = {The landscape of aerosol transmission after COVID-19.},
journal = {Current opinion in pulmonary medicine},
volume = {32},
number = {3},
pages = {182-187},
doi = {10.1097/MCP.0000000000001263},
pmid = {41733130},
issn = {1531-6971},
mesh = {Humans ; *COVID-19/transmission/prevention &amp; control ; SARS-CoV-2 ; Aerosols ; *Pandemics/prevention &amp; control ; *Infection Control/methods ; },
abstract = {PURPOSE OF REVIEW: This review describes how the COVID-19 pandemic stimulated a radical shift around the concepts and definitions of aerosol transmission, and how this new understanding led to a rethink around related infection control interventions that were vital to reduce the spread of SARS-CoV-2, and, potentially, other respiratory viruses.<br><br>RECENT FINDINGS: A revision of the terminology for aerosol-transmitted pathogens by the WHO, together with its accompanying open access platform (ARIA), to allow users to define their own exposure scenarios and calculate related transmission risks, are just two of many multidisciplinary collaborations that have paved the way for a more effective pandemic response in the future, for aerosol-transmitted, novel pathogens.<br><br>SUMMARY: A multipronged approach is needed for any next pandemic, including expertise from laboratory microbiologists and virologists, clinical infectious diseases and infection control teams, public health physicians and epidemiologists, aerosol scientists and engineers. We need to develop a rapid evidence pipeline to collate robust scientific data about any new pathogen, how it is transmitted, how it infects and affects humans, and how to control, treat and prevent it. This article briefly outlines how far we have come and proposes some options to better prepare for the next pandemic.},
}
@article {pmid41733396,
year = {2026},
author = {Henjeroei, FM and Nosratabadi, N and Pourghadamyari, H and Anaeigoudari, A and Sedghy, F and Nosratabadi, R},
title = {Neutrophils in Coronavirus Disease 2019: Guardians or Triggers of Immunopathology?.},
journal = {Cell biochemistry and function},
volume = {44},
number = {2},
pages = {e70186},
doi = {10.1002/cbf.70186},
pmid = {41733396},
issn = {1099-0844},
mesh = {Humans ; *Neutrophils/immunology/pathology ; *COVID-19/immunology/pathology ; SARS-CoV-2/immunology ; Immunity, Innate ; Extracellular Traps/immunology ; Reactive Oxygen Species/metabolism/immunology ; Pandemics ; Animals ; },
abstract = {COVID-19 (coronavirus disease 2019) is a respiratory viral disease with a wide range of clinical symptoms that emerged in December 2019. Innate immunity serves as a rapid immune system that can fight off pathogens before they can spread and cause an active infection. Neutrophils, the most abundant innate immune cells, are the first cells to migrate to the site of infection, where they defend against invading pathogens. Once activated at the inflammatory site, neutrophils mediate host protection through multiple mechanisms, including the phagocytosis of pathogens, the release of antimicrobial and pro-inflammatory enzymes, the production of reactive oxygen species (ROS), and the extrusion of their chromatin to form neutrophil extracellular traps (NETs) that bind to extracellular pathogens. Furthermore, neutrophils can move toward the source of the stimulus through a mechanism called chemotaxis, which is mediated by adhesion molecules and chemokine-chemokine receptor axes. However, neutrophil overactivation can have deleterious effects on various organs through the induction of cytokine storms, ROS production, and NET formation. Moreover, the contribution of distinct neutrophil subsets and their plasticity over the course of infection and recovery remain poorly understood. This review summarizes the current knowledge of the interplay between neutrophils and SARS-CoV-2, highlighting the most important mechanisms involved in the pathogenesis of COVID-19, to advance our understanding of this disease.},
}
@article {pmid41733677,
year = {2026},
author = {Wang, X and Schröder, HC and Neufurth, M and Müller, WEG},
title = {Mucosal Wound Repair: Reinforcement of Respiratory Mucus Barrier Function by Inorganic Polyphosphate.},
journal = {Progress in molecular and subcellular biology},
volume = {63},
number = {},
pages = {175-207},
pmid = {41733677},
issn = {0079-6484},
mesh = {Humans ; *Polyphosphates/pharmacology/therapeutic use ; Animals ; *Mucus/drug effects/metabolism ; *Wound Healing/drug effects ; *Respiratory Mucosa/drug effects/pathology ; Mucins/metabolism ; Nanoparticles/chemistry ; },
abstract = {Epithelial cell damage affects not only the skin, which covers the external surface of the human body, but also the non-keratinized epithelia, the mucosa, that lines the surfaces of internal organs, including the nasopharynx and lungs. This mucosa is characterized by a moist surface formed by the mucus overlying the epithelial cells. In the respiratory tract in particular, mucosa cells are constantly exposed to large amounts of environmental pathogens and stressors, including bacteria and viruses inhaled as aerosols. Therefore, mucins, a group of glycoproteins that constitute a major component of the mucus, play an important role in the innate immune defense provided by the protective mucus shield. This barrier function of the mucus can be disrupted by a number of agents, such as fine dust (particulate matter). Recent results have shown that inorganic polyphosphate (polyP), which can be administered, for example, in the form of a nasopharyngeal spray, offers a promising way to strengthen or repair impaired mucus function. This chapter describes the structure and formation of the mucus and its mucin building blocks, as well as the mode of action of polyP and drug-loaded polyP nanoparticles in restoring the mucus barrier, particularly with regard to their protective function against coronavirus infection.},
}
@article {pmid41734323,
year = {2026},
author = {Löwy, I},
title = {[Long Covid: a long story].},
journal = {Medecine sciences : M/S},
volume = {42},
number = {2},
pages = {187-193},
doi = {10.1051/medsci/2026017},
pmid = {41734323},
issn = {1958-5381},
mesh = {Humans ; *Post-Acute COVID-19 Syndrome/complications/psychology ; *Psychophysiologic Disorders/psychology/diagnosis/etiology ; SARS-CoV-2 ; },
abstract = {Patients with long Covid experience multiple, often very debilitating symptoms, yet their test results frequently appear normal. In the absence of objective indicators of a recognized disease, some professionals may conclude that the patient is suffering from a psychosomatic disorder. These patients face an epistemic injustice, that is, a failure to recognize their suffering as real. This injustice is rooted in a longstanding history of medically invisible disorders, which are diagnosed mainly on the basis of the patient's own narrative. The difficulties experienced by patients with long Covid cannot be dissociated from this history.},
}
@article {pmid41734553,
year = {2025},
author = {Xiao, K and Li, L and Zhang, X and Ye, Y and Yao, Y and Liu, Y and Chen, W and Wang, X and Gu, C and He, M and Liang, L and Liu, YC and Zhu, Z},
title = {Global prevalence of dry Eye: A systematic review and meta-analysis.},
journal = {Contact lens &amp; anterior eye : the journal of the British Contact Lens Association},
volume = {49},
number = {2},
pages = {102627},
doi = {10.1016/j.clae.2026.102627},
pmid = {41734553},
issn = {1476-5411},
mesh = {Humans ; COVID-19/epidemiology ; *Dry Eye Syndromes/epidemiology ; Global Health/statistics &amp; numerical data ; *Pandemics ; Prevalence ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: Dry eye significantly impacts global quality of life and productivity, yet existing epidemiological data remain fragmented and outdated, hindering effective prevention and management strategies. This study aimed to estimate the global prevalence of dry eye and examine variations across regions, demographics, diagnostic criteria, study settings, and the COVID-19 pandemic.<br><br>METHODS: A systematic search of PubMed, Web of Science, Embase, and Cochrane Library identified 119 cohort or cross-sectional studies involving 15,251,528 participants. Two reviewers independently screened records, extracted data, and assessed study quality using the Joanna Briggs Institute checklist. A random-effects model pooled prevalence estimates, with subgroup analyses exploring heterogeneity.<br><br>RESULTS: The global pooled prevalence of dry eye was 34.6% (95% CI: 30.2%-39.4%). Regional disparities were pronounced, with the highest prevalence in Africa 43.9% (95% CI: 31.5%-57.2%) and the lowest in North America 20.9% (95% CI: 8.2%-43.8%). Higher rates were observed in females 39.1% (95% CI: 32.8%-45.8%) vs. males 30.8% (95% CI: 24.8%-37.7%), individuals aged&#x202f;>&#x202f;40&#x202f;years 37.0% (95% CI: 29.1%-45.7%) vs.&#x202f;&#x2264;&#x202f;40&#x202f;years 35.0% (95% CI: 25.4%-46.0%), institutional settings 45.2% (95% CI: 36.2%-54.5%), and during COVID-19 44.5% (95% CI: 28.0%-62.2%). Diagnostic criteria significantly influenced estimates, ranging from 6.9% (95% CI: 1.9%-21.7%) (ICD-9-based) to 53.8% (95% CI: 46.7%-60.8%) (OSDI&#x202f;&#x2265;&#x202f;13).<br><br>CONCLUSIONS: Dry eye represents a major global public health challenge, with prevalence shaped by geographic, demographic, environmental, and methodological factors. The pandemic exacerbated dry eye burden, underscoring the urgency for standardized diagnostic protocols and targeted interventions to mitigate its growing impact.},
}
@article {pmid41734932,
year = {2026},
author = {Dræbel, TA and Birhanu, Z and Lien, L and Soerensen, JB and Andersen, LS and Terefe Tucho, G and Mekonnen, H},
title = {Mental health impact of the COVID-19 pandemic on frontline healthcare workers in Ethiopia: a scoping review of associated mental health risk and protective factors.},
journal = {BMJ open},
volume = {16},
number = {2},
pages = {e107175},
pmid = {41734932},
issn = {2044-6055},
mesh = {Humans ; Ethiopia/epidemiology ; *COVID-19/psychology/epidemiology ; *Frontline Workers/psychology ; *Mental Health ; Risk Factors ; Protective Factors ; SARS-CoV-2 ; *Health Personnel/psychology ; Pandemics ; Female ; },
abstract = {OBJECTIVES: The mental health impacts of COVID-19 on frontline healthcare workers have been reported globally; however, there is limited evidence from low-income countries such as Ethiopia. We reviewed the literature to understand how COVID-19 impacted the mental health of frontline healthcare workers, including the associated risk and protective factors.<br><br>DESIGN: A scoping review of peer-reviewed research was conducted between 2020-2025 to explore the mental health and well-being of frontline healthcare workers in Ethiopia during COVID-19. The process adhered to the guidelines for data extraction outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Our search identified 35 studies, of which 29 studies were included in the final synthesis.<br><br>DATA SOURCES: Three online databases, PubMed, Web of Science and PsycInfo, were systematically searched for data.<br><br>ELIGIBILITY CRITERIA: Studies were considered for inclusion in the review if they focused on mental health conditions and psychosocial well-being among healthcare workers during COVID-19 in Ethiopia. Studies were only included if published in English and excluded if they were conference abstracts, case studies, reviews, commentaries, contained incomplete data or lacked variables of interest.<br><br>DATA EXTRACTION AND SYNTHESIS: Data extraction was conducted manually by two reviewers by using a data extraction sheet created in Excel.<br><br>RESULTS: Most frontline healthcare workers experienced symptoms of insomnia, psychological distress, stress, anxiety, post-traumatic stress disorder and depression during COVID-19. Female frontline healthcare workers, nurses, midwives and laboratory technicians reported higher rates of adverse mental health outcomes. Our results found that being married, living together with a spouse and having a high educational level were risk factors for adverse mental health outcomes.<br><br>CONCLUSION: The mental health and well-being of frontline healthcare workers is at risk during a global health crisis; however, there is a limited understanding of how to protect the mental health of frontline healthcare workers in low-income countries, such as Ethiopia, at such a critical time. Additional research is needed to better inform mental health preparedness interventions for frontline healthcare workers in these contexts, particularly given predictions of another pandemic occurring within the next decade.},
}
@article {pmid41735249,
year = {2026},
author = {Du, S and Hu, X and Li, P and Xu, S and Kim, M and Liu, X and Zhan, P},
title = {Antiviral drug discovery and development: challenges and future directions.},
journal = {Signal transduction and targeted therapy},
volume = {11},
number = {1},
pages = {},
pmid = {41735249},
issn = {2059-3635},
mesh = {Humans ; *Antiviral Agents/therapeutic use/chemistry ; *Drug Discovery/trends/methods ; SARS-CoV-2/drug effects ; COVID-19 ; Pandemics ; *COVID-19 Drug Treatment ; Artificial Intelligence ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has stimulated extensive endeavors toward the development of therapeutic interventions targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human proteins for viral infection control, encompassing numerous potential drugs and thousands of patients participating in clinical trials. These concerted efforts have resulted in significant advancements in antiviral drug discovery and development. In this review, we present a comprehensive timeline detailing the development of antiviral drugs, tracing the progression from early viral inhibitors to modern broad-spectrum antiviral agents. We also outline the current status of advancements in antiviral drug discovery, encompassing target-based strategies, innovative mechanism-based approaches, and pharmacokinetic optimization. Furthermore, we discuss the challenges and future prospects gained from COVID-19 and other infectious diseases, covering knowledge of artificial intelligence strategies, the utilization of medicinal chemistry tools, and advancements in nanotechnology applications. The application of artificial intelligence in drug discovery is increasingly prevalent, particularly in the areas of protein structure prediction, drug target identification, and bioactivity forecasting. Nanotechnology has played a crucial role in the delivery of antiviral drugs and the development of vaccines, exemplified by the use of lipid nanoparticles in mRNA vaccines. Additionally, we highlight potential future directions for drug discovery, such as targeting membraneless organelles (liquid‒liquid phase separation).},
}
@article {pmid41735932,
year = {2026},
author = {Medeiros, MC and Martins, EB and Guaraldo, L and Calvet, GA},
title = {Cerebral venous thrombosis in non-bacterial infections: a systematic review.},
journal = {BMC neurology},
volume = {26},
number = {1},
pages = {},
pmid = {41735932},
issn = {1471-2377},
mesh = {Humans ; *Venous Thrombosis/etiology ; *Intracranial Thrombosis/etiology ; *Virus Diseases/complications ; },
abstract = {BACKGROUND: This systematic review summarizes evidence on cerebral venous thrombosis (CVT) following non-bacterial (viral, fungal, parasitic) infections, excluding COVID-19, by describing etiology, clinical features, management, and outcomes. METHODS: Following PRISMA guidelines and PROSPERO registration (CRD42023445694), we searched MEDLINE/PubMed, Scopus, Web of Science, Embase, and LILACS from inception to July 31, 2025. Two reviewers independently performed study selection, data extraction, and quality assessment using Joanna Briggs Institute tools. RESULTS: From 14,127 records, 278 publications from 1958 to 2025 (262 case reports and 16 case series), encompassing 322 patients were included. Median age was 39 years (IQR 25–55); 54% were male. Viral infections (35%; primarily varicella zoster and HIV) and fungal mucormycosis (35%) were the most common etiologies. While neuroimaging was performed in 95% of cases, specific pathogen identification (biopsy, culture, PCR) was used in fewer than half. Mucormycosis typically involved the cavernous sinus and was observed alongside high mortality (68%). Viral infections often affected multiple sinuses and were reported in association with more favorable outcomes (54% favorable). Anticoagulants were administered in 93% of viral cases, but were administered less frequently in mucormycosis (25%). Direct oral anticoagulants (DOACs) were prescribed for only nine patients. Recanalization was reported in 17% of cases, although follow-up data were unavailable or unreported for most (81%). CONCLUSIONS: Non-bacterial infections, notably viral pathogens and mucormycosis, are significant causes of CVT with distinct clinical profiles. Management strategies varied substantially by specific etiology, emphasizing urgent diagnostic intervention. Future guidelines should prioritize specific pathogen diagnostics and investigate the role of DOACs for infectious CVT.},
}
@article {pmid41735986,
year = {2026},
author = {Lutz, CS and Zhang, H and Knoll, MD and Sparrow, EG and Chen, H and Feikin, DR},
title = {Respiratory syncytial virus positivity among hospital admissions for acute respiratory illness in children younger than 5 years of age in low- and middle-income countries: a systematic review and meta-analysis.},
journal = {BMC public health},
volume = {26},
number = {1},
pages = {},
pmid = {41735986},
issn = {1471-2458},
support = {INV-005318/GATES/Gates Foundation/United States ; },
mesh = {Humans ; *Respiratory Syncytial Virus Infections/epidemiology ; *Developing Countries/statistics &amp; numerical data ; Infant ; *Hospitalization/statistics &amp; numerical data ; Child, Preschool ; *Respiratory Tract Infections/epidemiology/virology ; Infant, Newborn ; Acute Disease ; },
abstract = {OBJECTIVES: To estimate the proportion RSV-positive among children aged < 5 years hospitalized with ARI in low- and middle-income countries (LMIC), where 97% of RSV mortality occurs. METHODS: We conducted a systematic literature search for studies conducted pre-COVID-19 and published 2010—2022 (PROSPERO registration CRD42022361351). We estimated the RSV percent positivity and 95% confidence interval (CI) using random-effects meta-analyses. We assessed heterogeneity in RSV percent positivity using subgroup analyses and univariable meta-regression models. We assessed the influence of study sample size in sensitivity analyses. RESULTS: Seventy-three studies conducted in 37 LMICs were included. The summary estimate of percent RSV-positive from the meta-analysis of children < 5 years hospitalized with ARI was 26.2% (95% CI: 24.3–28.3%), ranging from 18.9% (16.4–21.6%) among children 6– < 60 months to 41.3% (36.4–46.4%) among children 0– < 6 months. Only five studies included children aged < 2 months, but RSV positivity was high among this group (40.2% [35.8–44.7%]). Percent positivity stratified by WHO region ranged from 23.6% in the Africa and Southeast Asian regions to 37.5% in the European region. RSV positivity was similar across country income groups. Univariable meta-regression models indicated that there was significant heterogeneity in RSV percent positivity across subgroups defined by mid-year of the study period, WHO region, number of study sites, recruitment method, hospital type, and specimen type (p < 0.05). CONCLUSIONS: RSV detection was high among children aged < 5 years hospitalized with ARI in LMICs across all WHO regions, especially among infants aged < 6 months, among whom RSV may account for almost up to one-half of all ARI hospital admissions. Recent WHO-recommended RSV immunization for all countries may protect young infants aged < 6 months against severe RSV disease.},
}
@article {pmid41736116,
year = {2026},
author = {Saikat, S and Shivji, S and Seifeldin, R and Zhang, Y and Shah, A and Schmets, G and Sreedharan, R and Chungong, S},
title = {Health policy, collaboration and investment in the post-COVID era: a review from UHC and health security integration perspective.},
journal = {Globalization and health},
volume = {22},
number = {1},
pages = {},
pmid = {41736116},
issn = {1744-8603},
mesh = {Humans ; *COVID-19 ; *Health Policy ; *Universal Health Insurance/organization &amp; administration ; Pandemics ; Global Health ; SARS-CoV-2 ; Public Health Infrastructure ; International Cooperation ; *Cooperative Behavior ; },
abstract = {BACKGROUND: The COVID-19 pandemic exposed weaknesses in health systems globally, highlighting chronic underinvestment, fragmentation, and a lack of preparedness with catastrophic impact on public health, economies and societies. Lessons learned reconfirmed the necessity to build health systems resilience, integrating efforts to achieve Universal Health Coverage (UHC) and health security in tandem. RESULTS: This study identified 63 global and regional policies, collaborations, and investments (collectively termed “initiatives”) that came out post-COVID-19 and reviewed them in reference to their focus on integration of UHC and health security through the lens of WHO’s seven policy recommendations for building resilient health systems. The findings indicate that while efforts to align UHC and health security are evident at global and regional levels, they vary in depth and coherence. 81% of initiatives align with at least four of the seven WHO policy recommendations. While there is emphasis for health security preparedness, focus on primary care and health promotion is less pronounced. Policy initiatives show stronger alignment with WHO policy recommendations compared to Collaborations or Investments, indicating synergies between policies, while apparently a gap between policy and practice. Multilateral groups, including UN agencies, and government-affiliated organizations show greater alignment with the WHO policy recommendations too, while there is less alignment with those from non-governmental and other entities. CONCLUSIONS: This review shows that while post COVID-19 policies increasingly articulate visions for integrated health systems strengthening, existing collaborations and investments have not demonstrated comparable commitment to the implementation of these visions. This underscores a prevailing disconnect among global health actors and the mostly reactive and short-term nature of external investments and partnerships. In low-income and fragile health system contexts, this misalignment risks the inefficient use of global support and may perpetuate foundational weaknesses in health systems. Moreover, this is particularly problematic given worsening fiscal constraints from reductions in overseas development assistance and country-level economic contractions. By (re)orienting global health policies, collaborations, and investments toward more unified approaches to achieving UHC and health security, the international community can more effectively support countries in building health systems capable of withstanding future crises, maintaining essential health services and safeguarding gains in health equity.},
}
@article {pmid41736159,
year = {2026},
author = {Soriano Puig, A and Monforte, V and Camprubí-Rimblas, M and Artigas, A and Ceccato, A},
title = {Biomarker-guided use of corticosteroids in pneumonia.},
journal = {Pneumonia (Nathan Qld.)},
volume = {18},
number = {1},
pages = {},
pmid = {41736159},
issn = {2200-6133},
abstract = {Community-acquired pneumonia (CAP) is one of the leading causes of death worldwide. Although corticosteroids have been proposed as immunomodulatory, controversies surrounding the results of clinical trials have limited their widespread use. This review aims to determine which biomarker-guided corticosteroid treatment for CAP is generally agreed upon in the latest published studies and to discuss the main aspects to be taken into consideration based on lessons learnt from patients with conditions such as influenza, SARS-CoV-2 infection or the recently identified subphenotypes in acute respiratory distress syndrome (ARDS). Most studies have demonstrated that high C-reactive protein concentrations at the time of admission are associated with a hyperinflammatory state and that patients are more likely to benefit from corticosteroid treatment if they have high concentrations. High levels of C-reactive protein (CRP) were used as an inclusion criterion in one clinical trial, demonstrating that treatment failure was reduced in the corticosteroid group. A post-hoc analysis of the results of several studies also showed that CRP levels above 200 mg/L were associated with benefits in patients receiving corticosteroids. Recent guidelines have proposed the use of corticosteroids in patients with severe CAP or septic shock. Corticosteroids could be more beneficial for patients with a hyperinflammatory subphenotype; however, there are currently no prospective studies evaluating this approach. Further studies are needed to clarify the role of biomarkers in personalised medicine for patients with CAP. In the meantime, patients with severe CAP or high CRP levels should be treated with corticosteroids.},
}
@article {pmid41736351,
year = {2026},
author = {V Rey-Matias, BM and S Ignacio, ML and D Leochico, CF and Rathore, FA},
title = {Telerehabilitation for the Evaluation and Management of a Dizzy Patient: A Mini-Review.},
journal = {JPMA. The Journal of the Pakistan Medical Association},
volume = {76},
number = {1},
pages = {118-120},
doi = {10.47391/JPMA.26-08},
pmid = {41736351},
issn = {0030-9982},
mesh = {Humans ; *Telerehabilitation ; *Dizziness/rehabilitation ; *COVID-19/epidemiology ; Quality of Life ; SARS-CoV-2 ; *Vertigo/rehabilitation ; },
abstract = {Dizziness and vertigo are common, disabling symptoms, especially in older adults. They can negatively affect quality of life and independence of the person. Vestibular rehabilitation is a key treatment, but access is often limited by physical, geographic, and socioeconomic factors. Telerehabilitation has emerged as a viable alternative, particularly during the COVID-19 pandemic. This mini review synthesizes available evidence on vestibular telerehabilitation, focussing on feasibility, delivery methods, outcomes, and future directions. We have included commonly used outcomes measures like balance, gait, gaze stability, dizziness, psychological health, and quality of life. Findings suggest telerehabilitation is an effective alternative to in-person therapy. However, further research is needed to standardize protocols, evaluate cognitive outcomes, and ensure inclusivity across diverse populations. Digital innovations are a promising options for more accessible, patient-centered vestibular care.},
}
@article {pmid41736688,
year = {2026},
author = {İşcan, G and Çöme, O},
title = {Security and privacy in e-health technologies: a scoping review of challenges and strategies in primary care.},
journal = {Family practice},
volume = {43},
number = {2},
pages = {},
doi = {10.1093/fampra/cmag006},
pmid = {41736688},
issn = {1460-2229},
mesh = {Humans ; *Primary Health Care ; *Telemedicine ; Digital Health ; *Computer Security ; *Confidentiality ; Electronic Health Records ; COVID-19/epidemiology ; *Privacy ; SARS-CoV-2 ; },
abstract = {BACKGROUND: The rapid integration of e-health technologies-such as telehealth, mobile health (mHealth), and electronic health records-has transformed primary care delivery, especially during the COVID-19 pandemic. However, this transformation has revealed significant vulnerabilities in data privacy and security, particularly in decentralized and resource-limited primary care settings. This scoping review aims to map current evidence on privacy and security concerns related to e-health technologies in primary care and to identify mitigation strategies and research gaps.<br><br>METHODS: A systematic search was conducted in PubMed, ACM, Scopus, and Web of Science for studies published between 2019 and 2024. Eligible studies addressed both privacy/security issues and e-health technology use in primary care. A two-stage screening process and full-text review were applied. Data were extracted and thematically synthesized.<br><br>RESULTS: Fifty-two studies were included. E-health technologies examined included teleconsultations, patient portals, digital decision support tools, and artificial intelligence (AI)-based systems. Among included studies, telehealth accounted for 28%, mHealth and wearables 20%, electronic health records 16%, and AI applications 6%. Common concerns involved data breaches, insufficient encryption, lack of interoperability, consent ambiguity, and challenges in securing virtual consultations. Vulnerable groups-such as older adults and low-literacy populations-faced higher risks. Recommended strategies included privacy-by-design principles, secure infrastructure, user-centered design, clearer governance policies, provider training, and hybrid care models.<br><br>CONCLUSION: Addressing privacy and security in e-health requires more than technical solutions. Equitable, safe, and trustworthy systems must incorporate legal, ethical, and human-centered approaches. In primary care, privacy must be positioned as a core element of digital health equity, not an optional enhancement.},
}
@article {pmid41736834,
year = {2026},
author = {Souza, ECSG and Dos Santos Junior, AG and Félix, AMS and Borges, JPA and de Oliveira, LB and Carneiro, LM and de Sousa, AFL},
title = {Use of Artificial Intelligence in Public Health Education for Pandemic Preparedness and Response.},
journal = {Annals of global health},
volume = {92},
number = {1},
pages = {21},
pmid = {41736834},
issn = {2214-9996},
mesh = {Humans ; *Artificial Intelligence ; *Public Health/education ; *Pandemic Preparedness ; *Health Education/methods ; COVID-19 ; *Pandemics/prevention &amp; control ; },
abstract = {Background: The rapid evolution of artificial intelligence (AI) has enabled new approaches for health education, particularly during public health emergencies. However, evidence remains fragmented on how AI-based educational strategies support preparedness, response, and recovery phases of pandemics and epidemics. Objective: To map the use of AI-based technologies in health education strategies addressing preparedness, response, and recovery during public health emergencies, identifying target populations, intervention characteristics, outcomes, scalability, and knowledge gaps. Methods: This scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR guidelines. Searches were conducted in PubMed/MEDLINE, Scopus, Web of Science, Embase, IEEE Xplore, and LILACS, complemented by gray literature from Google Scholar. Studies published from 2010 onward in English, Portuguese, or Spanish were included. Eligible designs comprised primary studies, methodological or implementation research, and reviews with explicit educational components. Data extraction covered context, populations, AI modalities, educational purposes, delivery channels, supervision requirements, pandemic-cycle phase, scalability, outcomes, and evidence gaps. Results: Forty-one studies met the inclusion criteria. Conversational AI (chatbots and large language models) and algorithmic curation tools using machine learning and natural language processing predominated. Most interventions supported health literacy, risk communication, and misinformation management; others addressed personalized learning, microtraining, and clinical simulation for students and health professionals. Delivery channels included mobile applications, messaging platforms, websites/YouTube, and clinical AI systems. Human oversight (expert validation and curation) was consistently reported as essential for safety and reliability. Interventions mainly targeted the response phase, with emerging applications for preparedness. Major gaps included standardized learning measures, cost-effectiveness evaluations, equity analyses, and governance frameworks ensuring privacy, transparency, and bias control. Conclusions: AI-enabled educational technologies can strengthen rapid, scalable, and personalized learning during health emergencies. Future research should prioritize multicenter studies using standardized indicators, economic and equity assessments, and robust governance frameworks to ensure ethical, safe, and inclusive adoption.},
}
@article {pmid41737288,
year = {2026},
author = {Muto, T and Machida, S and Imaizumi, S and Kamoi, K},
title = {Relationship Between COVID-19 and Retinal Artery Occlusions.},
journal = {Journal of ophthalmology},
volume = {2026},
number = {},
pages = {5545707},
pmid = {41737288},
issn = {2090-004X},
abstract = {The relationship between coronavirus disease 2019 (COVID-19) infection or vaccination and retinal artery occlusions (RAOs) remains controversial. COVID-19 infection or vaccination can sometimes cause thrombin formation. RAOs occur due to thrombin in the retinal artery. The average age of occurrence after COVID-19 infection was 48.7 ± 17.2 years in central RAO (CRAO) and 41.3 ± 17.8 years in branch RAO (BRAO). After COVID-19 vaccination, the average age was 54.7 ± 17.1 years in CRAO and 62.3 ± 21.2 years in BRAO. The mean time from COVID-19 diagnosis to symptom onset was 10.5 ± 9.3 days in CRAO and 48.3 ± 39.6 days in BRAO. After vaccination, the mean time was 7.3 ± 6.8 days in CRAO and 21.0 ± 24.9 days in BRAO. Initial visual acuity (VA) after COVID-19 infection was 2.53 ± 0.65 in CRAO and 0.09 ± 0.07 in BRAO. Final VA was 2.73 ± 0.12 in CRAO, but data for BRAO were unavailable. After vaccination, initial VA was 2.28 ± 0.97 in CRAO and -0.02 ± 0.16 in BRAO. Final VA was 2.12 ± 1.24 in CRAO and could not be calculated in BRAO. The relationship between COVID-19 or its vaccination and RAOs was investigated through past case reports. Two types of reports existed regarding RAO incidence after the COVID-19 pandemic-some indicated an increase, while others found no change. No reports suggested a decrease in RAO occurrence. The current evidence does not clarify the relationship between COVID-19 or its vaccine and RAOs. However, this relationship cannot be ruled out. Further investigations are necessary, as future infectious disease pandemics may occur.},
}
@article {pmid41737593,
year = {2026},
author = {Thangaleela, S and Wang, CK},
title = {Impact of nutrition on long COVID.},
journal = {Sports medicine and health science},
volume = {8},
number = {2},
pages = {128-144},
pmid = {41737593},
issn = {2666-3376},
abstract = {Long COVID is characterized by a group of persistent symptoms following the acute SARS-COV2 infection, which presented a multifaceted challenge to the healthcare systems all over the globe. The long COVID symptoms span various organ systems including the respiratory, cardiovascular, gastrointestinal, and neurological manifestations. Mitochondrial dysfunction and immune dysregulation play crucial roles in the long COVID pathophysiology. Recently nutritional intervention gained much attention in managing post-viral syndromes. Effective interventions like supplementation of omega-3 fatty acid, macro and micro nutrients, and vitamins help to reduce systemic inflammation and counteract muscle wasting. Other approaches like nutritional recovery, dietetic interventions, continuous nutritional care post-hospital discharge, nutritional rehabilitation programs, whole-diet approaches like Mediterranean diet, plant-based diet, and caloric optimization, improve overall functional recovery. Physical activity and exercise regimes have been shown to improve fatigue, dyspnea, and cognitive function. Tailored exercise regimes may promote safe rehabilitation. Certain ineffective interventions, such as non-personalized approaches, high dose of antioxidants, use of herbal products that are not clinically validated need to be addressed. Dietary interventions such as personalized nutritional counseling have been demonstrated to improve physical performance in long COVID patients. Further research is needed to refine protocols and identify optimal combinations of dietary and movement-based therapies to support the recovery of long-COVID patients. This narrative review focuses on the ongoing researches that reveals the intricate relationship between nutrition and long COVID recovery and also establishes effective protocols for nutritional care.},
}
@article {pmid41738365,
year = {2026},
author = {Akhavan, M and Yousefi, P and Tabibzadeh, A},
title = {Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E.},
journal = {Immunity, inflammation and disease},
volume = {14},
number = {2},
pages = {e70386},
pmid = {41738365},
issn = {2050-4527},
mesh = {Humans ; *Asthma/immunology/therapy ; *Immunoglobulin E/immunology/blood ; *Respiratory Tract Infections/immunology/complications/virology ; *COVID-19/immunology/complications ; *SARS-CoV-2/immunology ; Th2 Cells/immunology ; },
abstract = {BACKGROUND: Viral-respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID-19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma. Other viral respiratory infections and asthma are critical concerns, either. The current study aimed to discuss how elevated IgE levels can influence viral LRTI and potentially exacerbate asthma symptoms, as well as biological treatments targeting IgE in managing asthma.<br><br>MATERIALS AND METHODS: The search was conducted in electronical databases (including PubMed, Scopus, Google Scholar, and so on). all obtained documents were listed and reviewed by two independent authors. All relevant studies were included and used for final assessment and data collection.<br><br>RESULTS: IgE is a crucial mediator in the pathophysiology of asthma, particularly in type 2-high (T2-high) asthma, where it drives allergic responses and airway inflammation. The interaction between COVID-19 and asthma has illustrated that asthmatic patients may experience increased respiratory symptoms following COVID-19 infection. Interestingly, T2-high asthmatics may have had some protection against severe COVID-19 outcomes, highlighting the need for a nuanced understanding of asthma management during and after the pandemic.<br><br>CONCLUSION: Viral infections, particularly those caused by human rhinoviruses, are a significant trigger for asthma exacerbations. These infections can lead to heightened serum IgE levels, which play a vital role in the immune response and the worsening of asthma symptoms. The Th2 inflammatory pathway is frequently upregulated during these infections, associated with increased production of cytokines such as IL-4, IL-5, and IL-13, which aggravate asthma symptoms. Additionally, viral infections can compromise the airway epithelium, resulting in greater exposure to allergens and irritants, and disrupt the balance between Th1 and Th2 cytokines, leading to more severe exacerbations.},
}
@article {pmid41739653,
year = {2026},
author = {Sharma, L and Maheshwari, N and Maheshwari, N and Teli, G and Chelvam, V},
title = {Therapeutic Approaches to Treat SARS-CoV-2.},
journal = {ChemMedChem},
volume = {21},
number = {4},
pages = {e202500387},
doi = {10.1002/cmdc.202500387},
pmid = {41739653},
issn = {1860-7187},
support = {IITI 2023-25//Indian Institute of Technology Indore/ ; },
abstract = {Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), also known as COVID-19, spread across the globe, leading to a pandemic. Initially, the drug remdesivir is approved by the FDA for the treatment of SARS-CoV-2. Significant efforts have been directed toward epidemiology of the SARS-CoV-2 virus to discover potential drug targets that may contribute to the development of effective prevention and treatment strategies. The structure and functions of SARS-CoV-2 proteins that may be potential drug targets, including the spike protein, main protease, papain-like protease, RNA-dependent RNA polymerase, host proteins like angiotensin-converting enzyme 2, and transmembrane protease and serine 2, have been thoroughly studied. Biological screening platforms and repurposing have resulted in the discovery of drugs such as nirmatrelvir-ritonavir (Paxlovid), remdesivir (Veklury), molnupiravir (Lagevrio), anakinra (Kineret), vilobelimab (Gohibic), baricitinib (Olumiant), and tocilizumab (Actemra). The present analysis provides details on the pathogenesis, prevention, diagnosis, clinical characteristics, and potential treatment options currently available worldwide.},
}
@article {pmid41740281,
year = {2026},
author = {Dandotiya, J and Sadhu, S and Chandwaskar, RR and Awasthi, A},
title = {Emerging roles of IL-9 and Th9 cells in respiratory viral illnesses.},
journal = {Seminars in immunology},
volume = {81},
number = {},
pages = {102017},
doi = {10.1016/j.smim.2026.102017},
pmid = {41740281},
issn = {1096-3618},
mesh = {*Interleukin-9/immunology/metabolism/genetics ; Animals ; Humans ; *T-Lymphocytes, Helper-Inducer/immunology ; *COVID-19/immunology ; *SARS-CoV-2/immunology ; *Respiratory Tract Infections/immunology ; Receptors, Interleukin-9/genetics ; Cell Differentiation ; },
abstract = {Upon antigenic stimulation and cytokine cues, CD4[+] T cells differentiate into specialized helper subsets, giving rise to Th1, Th2, Th9 and Th17 cell lineages. These subsets orchestrate distinct immune functions that protect the host but can also drive immunopathology when dysregulated. The classical Th1-Th2 paradigm expanded with the discovery of Th17 and Th9 cells, revealing greater diversity and complexity in Th cell biology. Th9 cells, generated under the influence of TGF-β and IL-4, are defined by robust production of interleukin-9 (IL-9). IL-9 is now recognized as a multifunctional mediator produced by Th9 cells, mast cells, ILC2s, Tregs and certain Th17 subsets. Fate-mapping and reporter mouse models have improved our understanding of IL-9-producing immunocytes, though limitations remain in defining temporal and tissue-specific dynamics. As shown earlier, IL-9 promotes mastcell proliferation, mucus hypersecretion, epithelial changes and airway remodelling in allergic inflammation and asthma. Genetic studies have linked IL-9/IL-9 receptor variants to increased susceptibility to allergic diseases such as asthma. Similarly, during respiratory viral infections, including RSV and COVID-19, IL-9 amplifies type 2 inflammation, granulocyte recruitment and mucus production, exacerbating airway obstruction. In fact, emerging evidence implicates a Foxo1-IL-9 axis in COVID-19, where IL-9 enhances lung inflammation and impairs antiviral interferon-stimulated gene responses. Collectively, IL-9 represents a context-dependent driver of virus-induced lung pathology and a promising therapeutic target requiring deeper mechanistic and translational investigation.},
}
@article {pmid41740316,
year = {2026},
author = {Spedding, M and Aerts, J and Alexander, S and Bellozzi Woestelandt, AG and Chiricozzi, E and Henriques, A and Lledo, PM and Loeffler, JP and Perera, R and Platt, FM and Pradat, PF and Rene, F and Schapira, A and St Clair, L and Talbot, K and Taquet, M and Toborek, M and Turner, B and Zandi, M and Gressens, P},
title = {Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids.},
journal = {Pharmacological reviews},
volume = {78},
number = {2},
pages = {100113},
doi = {10.1016/j.pharmr.2026.100113},
pmid = {41740316},
issn = {1521-0081},
support = {T32AI007417-28//NIH/National Institute of Health NIAID/ ; F32AI186453-01//NIH/National Institute of Health NIAID/ ; L70AG084124-01//NIH National Institute of Health /NIA/ ; },
mesh = {Humans ; *Neurodegenerative Diseases/metabolism/virology/etiology ; *COVID-19/metabolism/complications ; *Glycosphingolipids/metabolism ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Animals ; Pandemics ; G(M1) Ganglioside/metabolism ; },
abstract = {Glycosphingolipids (GSLs) play major roles in viral infections by mediating viral entry and egress from cells in lipid rafts; however, GSLs are also important in neurodegenerative diseases. The role of GSLs in acute COVID-19 infection is critical but remains less-studied in the sequelae of long COVID (post-COVID condition); because the same enzymes that regulate GSL metabolism are critical for viral entry and exit, neuromuscular junctions, neurological function, and cellular metabolism, it is important to determine whether long COVID may increase the risk of subsequent neurodegeneration. SARS-CoV-2 infection alters lipid metabolism and oxygen use and can bind to and modify the expression of neurotrophic GSLs such as GM1 ganglioside. GM1 (N-acetylneuraminic acid) is human-specific and probably evolved as a result of a pandemic 3-2.5 million years ago that drove its selection. GM1 functions as a coreceptor with angiotensin-converting enzyme 2 for SARS-CoV-2 while also being a neurotrophin. Viral multiplication takes place in the endoplasmic reticulum/Golgi apparatus, where GSLs are synthesized. This review defines the complex interaction between viruses, GSLs, and neurodegeneration, which provides new perspectives on the interlinked metabolic changes. A European working group has been set up to assess the risks of neurodegeneration with long COVID, based on potential GSL-mediated mechanisms. SIGNIFICANCE STATEMENT: The SARS-CoV-2 pandemic has resulted in a large number of subjects living with long-term consequences (long COVID). Glycosphingolipids and gangliosides are involved in both viral infections and neurodegeneration; hence, it is important to evaluate whether long COVID may increase the risk of neurodegeneration via this route. This study is the result of a European consortium formed to evaluate this possibility.},
}
@article {pmid41740458,
year = {2026},
author = {Sohn, WY and Goody, SMG and Reid, DW and Edwards, DK and Urdaneta, V and Doyle, BP and Straus, WL and Henry, C and Rizkalla, B},
title = {Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines.},
journal = {Vaccine},
volume = {77},
number = {},
pages = {128394},
doi = {10.1016/j.vaccine.2026.128394},
pmid = {41740458},
issn = {1873-2518},
mesh = {Humans ; *COVID-19 Vaccines/adverse effects/immunology ; *COVID-19/prevention &amp; control ; SARS-CoV-2/immunology ; Animals ; mRNA Vaccines/adverse effects ; Vaccines, Synthetic/adverse effects/immunology ; RNA, Messenger ; 2019-nCoV Vaccine mRNA-1273 ; Pandemics/prevention &amp; control ; },
abstract = {Messenger RNA (mRNA) COVID-19 vaccines have been administered globally at unprecedented scale and have demonstrated strong effectiveness against severe disease, hospitalization, and death. Extensive safety monitoring across randomized clinical trials, national surveillance systems, and global pharmacovigilance programs has consistently supported a favorable benefit-risk profile for these vaccines. Despite this evidence, a range of questions and mechanistic hypotheses continue to circulate, including assertions of increased risk of malignancies, autoimmune diseases, and all-cause mortality, as well as proposed mechanisms involving product-related impurities (e.g. DNA contamination), biodistribution and antigen persistence, non-canonical translation (e.g. ribosomal frame-shifting), and immune modulation. This targeted narrative review synthesizes nonclinical, clinical, pharmacoepidemiologic, and regulatory evidence relevant to these mechanistic and safety related questions. Published literature, regulatory assessments, and surveillance data were qualitatively evaluated in the context of biological plausibility, methodological rigor, and consistency across independent data sources. Across the body of evidence, findings do not support increased long-term mortality, malignancy, autoimmune disease, genotoxicity or other long-term safety issues attributable to mRNA COVID-19 vaccination. On the contrary, several large population-based studies have reported lower all-cause mortality among vaccinated individuals. Residual DNA levels are within established regulatory limits when measured using validated methods, and no credible mechanism supports genomic integration. Biodistribution studies demonstrate expected localization to the injection site and lymphoid tissues with no persistence. Immunologic findings, including IgG4 subclass responses, have not been associated with impaired protection in real-world vaccine effectiveness studies. Collectively, the evidence supports the safety and effectiveness of mRNA COVID-19 vaccines. Ongoing surveillance and rigorous evaluation remain essential to inform public health policy. Importantly, vaccine safety questions should be assessed using transparent, structured frameworks that systematically weigh benefits, harms, quality of evidence, values, and feasibility.},
}
@article {pmid41740848,
year = {2026},
author = {Lee, GM and Yun, S and Jung, YW and Kim, JH and Chae, YM},
title = {Cancer care disruptions among vulnerable populations during the COVID-19 pandemic: A scoping review.},
journal = {Journal of cancer policy},
volume = {48},
number = {},
pages = {100716},
doi = {10.1016/j.jcpo.2026.100716},
pmid = {41740848},
issn = {2213-5383},
mesh = {Humans ; *COVID-19/epidemiology ; Early Detection of Cancer ; *Neoplasms/therapy/diagnosis/epidemiology ; Pandemics ; Patient Acceptance of Health Care/statistics &amp; numerical data ; Socioeconomic Disparities in Health ; *Vulnerable Populations/statistics &amp; numerical data ; },
abstract = {BACKGROUND: Infectious disease outbreaks, particularly COVID-19, have disrupted cancer care worldwide and disproportionately affected vulnerable populations.<br><br>OBJECTIVE: To identify vulnerable groups and characterize patterns of disruption in cancer screening and treatment during the COVID-19 pandemic.<br><br>METHODS: Following the Arksey and O'Malley framework, we conducted a scoping review of studies published between 2002 and 2023. Searches were performed in MEDLINE, EMBASE, the Cochrane Library, and Google Scholar. Thirty-four studies were included and analyzed with a focus on healthcare utilization, screening delays, and treatment disruptions across the cancer care continuum.<br><br>RESULTS: Older adults, women, immigrant and ethnic minority populations, individuals with low income or education, and patients with comorbidities were most frequently identified as vulnerable. Screening disruptions were more commonly associated with lower educational attainment, whereas treatment delays were concentrated among low-income individuals, newly diagnosed patients, and those with comorbidities. Health system strain, mobility restrictions, fear of infection, and socioeconomic barriers were key contributing factors.<br><br>CONCLUSION: This review demonstrates that vulnerability in cancer care during the COVID-19 pandemic is stage-specific and shaped by both population-level and health system-level factors. Mapping these patterns provides evidence to inform stage-specific and population-sensitive strategies to protect cancer care continuity during future public health emergencies.},
}
@article {pmid41741003,
year = {2026},
author = {Michaelchuk, W and Soril, LJJ and Chiarieri-Hirsch, D and Giroux, E and Shatto, J and Gershon, AS and Gupta, S and Stickland, MK and Lam, GY},
title = {Assessment and management of post-COVID-19 pulmonary complications: a rapid review.},
journal = {European respiratory review : an official journal of the European Respiratory Society},
volume = {35},
number = {179},
pages = {},
pmid = {41741003},
issn = {1600-0617},
mesh = {Humans ; *COVID-19/complications/therapy/epidemiology/diagnosis ; *Lung Diseases/therapy/diagnosis/etiology ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; },
abstract = {The rising global prevalence of post-COVID-19 condition (PCC) underscores the substantial and ongoing burden faced by individuals following severe acute respiratory syndrome coronavirus 2 infection. The volume of emerging evidence regarding pulmonary-related PCC complications highlights the urgent need for current, evidence-informed guidelines to ensure timely assessment and effective treatment for those affected by PCC. Thus, the aim of this review was to synthesise existing research on the management and treatment of pulmonary complications in individuals with PCC. A rapid review of published and grey literature focused on pulmonary-related PCC complications was completed in November 2023 and updated in June 2025, in accordance with PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. We identified 73 unique articles, including 12 guidance documents, 24 secondary studies (including 11 systematic reviews with meta-analyses, eight systematic reviews and three scoping reviews) and 37 primary research studies (13 randomised controlled trials) and narratively synthesised their findings. Guidance documents addressed workup and management for pulmonary-related PCC complications, recommending the use of pulmonary function testing with diffusing capacity and the importance of ruling out other conditions. Although evidence regarding the use of medical and pharmacological interventions for treatment of pulmonary-related PCC complications were limited and inconclusive, the current evidence base suggested potential effectiveness of a multidisciplinary rehabilitation approach for pulmonary-related PCC treatment, involving specialist consultations and tailored rehabilitation programmes. The heterogeneity in study quality and risk of bias warrants cautious interpretation of the findings. The current evidence and evolving healthcare landscape suggest the need for updated, evidence-informed clinical guidance.},
}
@article {pmid41741975,
year = {2026},
author = {Hou, L and Sha, Y and Feng, L and Liang, C and Hui, X and Lian, Z and Li, Y and Zhang, Y and Ge, L and Yang, K},
title = {Analysis of the Conceptualization, Frameworks, and Operationalization of Health System Resilience in Empirical Research.},
journal = {Journal of evidence-based medicine},
volume = {19},
number = {1},
pages = {e70122},
doi = {10.1111/jebm.70122},
pmid = {41741975},
issn = {1756-5391},
support = {19ZDA142//Major Project of the National Social Science Fund of China/ ; 21JZD037//Ministry of Education philosophy and social science research major project/ ; },
mesh = {*Delivery of Health Care/organization &amp; administration ; *Empirical Research ; },
abstract = {AIM: Health system resilience (HSR) has gained prominence in response to acute shocks and chronic stressors, particularly following the COVID-19 pandemic. This study aimed to analyze the conceptualization, frameworks, and operationalization of HSR in empirical research.<br><br>METHODS: We searched PubMed, Web of Science, and Global Health databases from inception to January 26, 2024 to identify empirical HSR studies. We screened studies independently, and systematically extracted data. Analyzed were conducted across study characteristics, shocks/stressors types, conceptualizations/definitions, framework traditions, and methodological approaches.<br><br>RESULTS: A total of 125 empirical studies were included, with a marked increase from 2020 onward. Most studies examined acute shocks (84%), with the largest share in the Europe (23.3%) and Africa (16.8%). HSR was predominantly conceptualized as a system capacity to absorb and adapt to shocks, while learning and transformation were less frequently operationalized. Health system-specific frameworks (e.g., Kruk; Blanchet) were most commonly used, primarily as analytical lenses rather than measurement tools. Qualitative methods predominated, although mixed-methods approaches are emerging. Evidence on continuity of essential functions and everyday resilience remained limited.<br><br>CONCLUSIONS: Despite growing conceptual sophistication, empirical HSR research remains constrained by fragmented frameworks use and limited operationalization. Advancing the field requires clearer conceptual boundaries, improved methodological integration, and greater attention to how resilience is enacted in routine system functioning.},
}
@article {pmid41742211,
year = {2026},
author = {Ortiz-Prado, E and Cadena-Padilla, MP and Vélez-Páez, JL and Vasconez-Gonzalez, J and Izquierdo-Condoy, JS and Vergara, M and Viscor, G},
title = {Chronic hypoxia adaptation at high altitude: a perspective on Its potential role in mortality in viral pneumonia-associated ARDS and implications for personalized critical care.},
journal = {Critical care (London, England)},
volume = {30},
number = {1},
pages = {},
pmid = {41742211},
issn = {1466-609X},
mesh = {Humans ; *Altitude ; *Respiratory Distress Syndrome/mortality/etiology/physiopathology/therapy ; *Hypoxia/physiopathology/mortality ; *Pneumonia, Viral/mortality/complications ; *Critical Care/methods ; COVID-19 ; *Adaptation, Physiological/physiology ; Precision Medicine/methods ; Pandemics ; *Coronavirus Infections/mortality/complications ; },
abstract = {Acute respiratory distress syndrome (ARDS) secondary to viral pneumonias, predominantly COVID-19 but also influenza and adenovirus, remains a major ICU mortality driver, with rates exceeding 40%. Chronic high-altitude adaptation (≥ 2,500 m) modifies human pulmonary physiology through hypoxia-inducible factor (HIF-1α/2α) stabilization, ACE2 downregulation, enhanced capillary recruitment, and anti-inflammatory shifts, potentially reducing ARDS severity. Across published observational studies, findings remain heterogeneous; however, several cohorts have reported lower mortality at moderate-to-high altitude (approximately 30–50% in some reports), along with proposed altitude-appropriate SpO2 targets (89–93%) and alternative interpretations of oxygenation indices (e.g., barometric pressure–adjusted P/F ratios). Protection is strongest in younger, comorbidity-free patients, but attenuates in diabetics/hypertensives. In this perspective, we critically examine the evidence on how altitude may influence the clinical course and survival of critically ill patients, exploring potential pulmonary adaptive mechanisms and reflecting on their implications for monitoring and management in intensive care units.},
}
@article {pmid41742356,
year = {2026},
author = {Ogbu-Nwobodo, L and Hwong, AR and Murphy, K and Goldman, ML and Dilley, JW},
title = {Long COVID in Populations With Serious Mental Illness: Clinical and Policy Implications.},
journal = {Psychiatric services (Washington, D.C.)},
volume = {77},
number = {5},
pages = {449-456},
doi = {10.1176/appi.ps.20240457},
pmid = {41742356},
issn = {1557-9700},
mesh = {Humans ; Comorbidity ; Health Policy ; *Mental Disorders/therapy/epidemiology ; *Post-Acute COVID-19 Syndrome/complications/epidemiology/psychology ; Quality of Life ; },
abstract = {As the world recovers from the height of the COVID-19 pandemic with ongoing plans for a strengthened behavioral health infrastructure-from crisis services to long-term care-one of the health conditions that has emerged is long COVID. This multisystem condition is characterized by persistent symptoms that develop after the acute phase of COVID-19 infection. Although the full clinical and scientific understanding of long COVID's neuropsychiatric impact is still evolving, a sizable cohort of patients has emerged with various long-term and often confusing symptoms, which can include cognitive impairment, mood dysregulation (e.g., anxiety or depression), sleep disturbances, posttraumatic symptoms, and chronic fatigue. Recognizing long COVID's debilitating impact on quality of life and wide-ranging societal consequences, the authors sought to summarize current knowledge about long COVID among individuals with a preexisting serious mental illness and to propose care and treatment recommendations for clinicians and public policy makers.},
}
@article {pmid41743132,
year = {2026},
author = {Qu, J and Liu, M and Zhou, C},
title = {Rewriting the viral script: post-translational modifications orchestrating SARS-CoV-2 pathogenesis and immune evasion.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1748470},
pmid = {41743132},
issn = {1664-302X},
abstract = {SARS-CoV-2 reprograms host cell biology not solely through its genomic content but also through a sophisticated arsenal of post-translational modifications (PTMs) that modulate viral protein function, host signaling networks, and immune responses. Despite increasing recognition of PTMs as dynamic regulators of infection, their full functional breadth and therapeutic potential remain incompletely defined. Here, we provide a comprehensive, PTM-centric synthesis of SARS-CoV-2 pathogenesis, detailing how phosphorylation, ubiquitination, SUMOylation, glycosylation, acetylation, succinylation, ISGylation, and ADP-ribosylation cooperatively shape virus-host interplay. We dissect the mechanistic roles of individual modifications, such as phosphorylation-mediated transitions in nucleocapsid function, ubiquitin-driven degradation of immune factors, and SUMOylation-guided viral assembly, while revealing higher-order regulatory circuits and crosstalk among PTMs. Additionally, we highlight emerging computational tools for PTM site prediction and identify shared enzymatic nodes exploitable for host-directed antiviral strategies. This integrative framework positions PTMs as not merely bystanders but as central modulators of viral fitness and host vulnerability, offering novel avenues for therapeutic intervention against SARS-CoV-2 and future pandemic threats.},
}
@article {pmid41743347,
year = {2026},
author = {Miyano, S and Nozaki, I and Hachiya, M and Miyamoto, T and Takei, T},
title = {Regional health security architecture in ASEAN countries: Lessons from regional CDC models and Japan's strategic partnership for ACPHEED development.},
journal = {Global health &amp; medicine},
volume = {8},
number = {1},
pages = {1-7},
pmid = {41743347},
issn = {2434-9194},
abstract = {The COVID-19 pandemic exposed critical gaps in regional health security mechanisms, prompting ASEAN to establish the ASEAN Centre for Public Health Emergencies and Emerging Diseases (ACPHEED), with functions distributed across Indonesia, Thailand, and Vietnam. This policy analysis examines strategic development approaches for ACPHEED through comprehensive benchmarking of the European Centre for Disease Prevention and Control (ECDC), Africa Centres for Disease Control and Prevention (Africa CDC), and Gulf CDC, supported by consultations in Indonesia (2024) and Sweden (2025) involving ASEAN member states and international partners. A comparative analysis reveals distinct organizational models: the ECDC operates within European Union (EU) institutional frameworks emphasizing functional specialization; the Africa CDC employs decentralized Regional Coordination Centers; and the Gulf CDC implements hybrid governance via Permanent Communication Networks. Each model offers valuable lessons for ACPHEED's development, particularly concerning governance structures that balance regional coordination with national sovereignty. ACPHEED faces unique challenges due to ASEAN's consensus-based, nonlegislative institutional nature and its tri-country operational structure. Critical success factors include phased surveillance emphasizing a defined scope and capacity building; inclusive governance mechanisms ensuring equitable member-state ownership; and operational frameworks applying subsidiarity principles to complement existing ASEAN mechanisms. Sustainable financing remains paramount given ASEAN's limited budgetary authority. Japan's strategic partnership should capitalize on its technical expertise in laboratory systems, digital surveillance, and disaster preparedness through comprehensive institutional support. ACPHEED's success depends on sustained political commitment, realistic financial arrangements, and effective integration into global health security architectures. This analysis provides a strategic roadmap for ACPHEED's preparatory phase so that it can serve as a regional health security leader while addressing ASEAN-specific institutional constraints.},
}
@article {pmid41743408,
year = {2026},
author = {Bsat, D and Safi, D and Arabi, M},
title = {Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.},
journal = {The Canadian journal of infectious diseases &amp; medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale},
volume = {2026},
number = {},
pages = {4700812},
pmid = {41743408},
issn = {1712-9532},
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has presented a significant global health challenge that necessitated the immediate search for various therapeutic modalities. Remdesivir, an antiviral drug inhibiting RNA-dependent RNA polymerase (RdRp), was among the most heavily used drugs against COVID-19. Of the several randomized controlled trials studying the efficacy of remdesivir, the vast majority were studied on the adult population. Results remain contradictory, with some studies supporting the high efficacy of remdesivir while others highlighting the lack of significance of its antiviral effects. Given the lack of focus on the pediatric population, the antiviral effects of remdesivir in cardiac pediatric patients, who are particularly vulnerable, remain especially under-investigated. This literature review explores current literature on remdesivir's mechanism of action and efficacy against COVID-19, especially in the pediatric cardiac population. Therefore, by combining results of studies from randomized controlled trials and retrospective studies in the adult and pediatric populations, this literature review underlines current knowledge gaps and highlights the need for studies targeting specific ages and comorbidities to effectively treat patients at higher risk of adverse events.},
}
@article {pmid41743708,
year = {2026},
author = {Tang, W and Gai, Q and Yang, J and Chen, J and Lyu, Z},
title = {PhIP-Seq: unveiling the complexity of antibody repertoires in health and disease.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1735735},
pmid = {41743708},
issn = {1664-3224},
mesh = {Humans ; *High-Throughput Nucleotide Sequencing/methods ; Peptide Library ; Animals ; SARS-CoV-2/immunology ; Autoantigens/immunology ; Cell Surface Display Techniques ; Lupus Erythematosus, Systemic/immunology/genetics ; COVID-19/immunology ; Multiple Sclerosis/immunology/genetics ; Plasmodium falciparum/immunology ; Antigens, Neoplasm/immunology ; },
abstract = {Phage-Immunoprecipitation Sequencing (PhIP-Seq) merges phage display with next-generation sequencing to enable high-throughput profiling of antibody repertoires. This review synthesizes the technical evolution of the PhIP-Seq platform, critically assessing the workflow from peptide library design and immunoprecipitation to bioinformatics analysis. We evaluate strategies for optimizing library diversity and minimizing non-specific binding, while addressing inherent limitations such as the detection of conformational epitopes and post-translational modifications. The clinical utility of PhIP-Seq is examined through its application in identifying novel autoantigens in systemic lupus erythematosus and multiple sclerosis, mapping viral epitopes in SARS-CoV-2 and Plasmodium falciparum, and detecting tumor-associated antigens. Finally, we discuss the trajectory of the field toward integration with multi-omics datasets and the development of point-of-care diagnostic tools.},
}
@article {pmid41744151,
year = {2026},
author = {Domachowske, JB and Zimet, GD and Hanage, W and Beck, E and Sule, P and Wahid, R and Vicic, N},
title = {Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges.},
journal = {Expert review of vaccines},
volume = {25},
number = {1},
pages = {2632657},
doi = {10.1080/14760584.2026.2632657},
pmid = {41744151},
issn = {1744-8395},
mesh = {Humans ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology/administration &amp; dosage ; *SARS-CoV-2/immunology ; 2019-nCoV Vaccine mRNA-1273 ; Vaccine Efficacy ; Spike Glycoprotein, Coronavirus/immunology ; Vaccines, Synthetic/immunology ; Immunogenicity, Vaccine ; },
abstract = {INTRODUCTION: Next-generation COVID-19 vaccines hold promise to reduce severe outcomes in populations most at risk. While the original mRNA COVID-19 vaccine, mRNA-1273, targets the full-length SARS-CoV-2 spike protein, mRNA-1283 is a novel next-generation mRNA COVID-19 vaccine that specifically targets immunodominant domains within the spike protein.<br><br>AREAS COVERED: This review summarizes literature on the development of mRNA-1283, from its design and preclinical evaluation to phase 1-3 clinical trial findings, with a particular focus on immunogenicity and efficacy in at-risk populations, specifically older adults and adults with comorbidities. The potential public health impact of this next-generation vaccine is explored, along with ongoing challenges facing COVID-19 vaccination.<br><br>EXPERT OPINION: Phase 1-3 clinical trials demonstrated that mRNA-1283 was well-tolerated and no safety concerns were identified. Furthermore, mRNA-1283 demonstrated higher point estimates of immunogenicity and relative vaccine efficacy than mRNA-1273, including among older adults and individuals with underlying conditions who are most susceptible to severe COVID-19. Initial modeling studies indicate that mRNA-1283 could prevent more hospitalizations than current COVID-19 vaccines. Evidence to date suggests that the novel next-generation mRNA-1283 vaccine holds promise to advance progress in reducing the ongoing burden of COVID-19 across vulnerable populations.},
}
@article {pmid41744170,
year = {2026},
author = {Domnich, A and Pariani, E},
title = {Beyond the laboratory: how COVID-19 reshaped specimen collection, testing workflows, and diagnostic algorithms.},
journal = {Expert review of molecular diagnostics},
volume = {26},
number = {2},
pages = {127-139},
doi = {10.1080/14737159.2026.2638743},
pmid = {41744170},
issn = {1744-8352},
mesh = {Humans ; *COVID-19/diagnosis/virology/epidemiology ; *Specimen Handling/methods ; *SARS-CoV-2/isolation &amp; purification ; Algorithms ; Workflow ; Pandemics ; *COVID-19 Testing/methods ; Rapid Diagnostic Tests ; },
abstract = {INTRODUCTION: The SARS-CoV-2 pandemic forced a radical expansion of essential public health laboratory services that went beyond basic testing. This perspective highlights key shifts in laboratory function, specifically toward decentralized testing, self-sampling, less invasive specimen types, point-of-care devices, and novel surveillance strategies.<br><br>AREAS COVERED: The surge in testing demand favored decentralized solutions, including rapid lateral flow tests, due to their flexibility, speed, and affordability. However, several challenges arose from the variable diagnostic accuracy of rapid self-tests and alternative specimen types when compared to reference laboratory-based molecular assays using nasopharyngeal swabs. For instance, the use of self-collected saliva, which is often preferred by patients, was hindered by a lack of internationally standardized processing protocols. A post-pandemic rebound in the circulation of respiratory pathogens other than SARS-CoV-2 was likely driven by both immunity debt and increased testing, including of less severe cases, commonly performed through more costly multiplex respiratory panels.<br><br>EXPERT OPINION: Moving forward, while over-the-counter self-tests for common respiratory viruses are now common, stricter regulatory oversight and improved data connectivity are essential. Local decision-makers must weigh the trade-offs between broad testing access and clinical performance, and implement robust diagnostic stewardship programs for acute respiratory infections.},
}
@article {pmid41744596,
year = {2026},
author = {Barbinta-Patrascu, ME and Negut, I and Bita, B},
title = {Virus Biomimetic-Delivery Systems for the Production of Vaccines.},
journal = {Biomimetics (Basel, Switzerland)},
volume = {11},
number = {2},
pages = {},
pmid = {41744596},
issn = {2313-7673},
abstract = {The persistent emergence of infectious diseases has underscored the critical demand for next-generation vaccine technologies that are safe, effective, and scalable. This review explores virus biomimetic delivery systems, focusing on virus-like particles (VLPs) and virosomes as promising platforms for vaccine and therapeutic development. VLPs are self-assembled nanostructures composed of viral structural proteins that mimic native virions without carrying genetic material, while virosomes are reconstituted viral envelopes that retain functional glycoproteins but lack a nucleocapsid. Both systems provide strong immunogenicity and safety by mimicking viral architecture while eliminating the risk of replication. The paper examines various expression platforms for VLP production, including bacterial, yeast, insect, mammalian, and plant-based systems, highlighting their respective advantages, challenges, and optimization strategies. Mechanistic insights into antigen presentation, immune activation, and cellular uptake pathways are discussed to explain their superior performance in eliciting humoral and cellular immune responses. Furthermore, current applications of VLPs and virosomes in vaccines against major pathogens such as SARS-CoV-2, influenza, Newcastle disease virus, malaria, hepatitis, and respiratory syncytial virus are reviewed, demonstrating their versatility and clinical potential. By integrating molecular engineering, nanotechnology, and biofabrication strategies, virus biomimetic systems represent a transformative frontier in vaccinology, immunotherapy, and targeted drug delivery.},
}
@article {pmid41745098,
year = {2026},
author = {Zoccali, F and Fratini, C and Pennacchia, F and Cascone, F and de Vincentiis, M and Petrella, C and Barbato, C and Minni, A},
title = {Hyperbaric Oxygen Therapy on Long COVID Symptoms: A Breath of Fresh Air.},
journal = {Diseases (Basel, Switzerland)},
volume = {14},
number = {2},
pages = {},
pmid = {41745098},
issn = {2079-9721},
abstract = {Long COVID is defined as "the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanations", as reported by the World Health Organization. A growing number of people are dealing with a variety of lingering symptoms even after recovering from an acute infection. These can include fatigue, muscle pain, shortness of breath, headaches, cognitive issues, neurodegenerative symptoms, anxiety, depression, and a feeling of hopelessness, and therapeutic options for long COVID are investigated. The potential of hyperbaric oxygen therapy (HBOT) to improve chronic fatigue, cognitive impairments, and neurological disorders has been established; therefore, the use of HBOT to treat long COVID has also been studied. The aim of this literature search is to analyze the state of the art of a potential role of HBOT to improve chronic fatigue, cognitive impairments and neurological disorders. A literature analysis was performed, focusing on the clinical efficacy of HBOT for treating long COVID symptoms. The results from January 2021 to October 2025, using a standard registry database, showed 21 studies, including one case report, ten randomized controlled trial, eight systematic reviews and three studies regarding the molecular mechanism and markers changing after HBOT. They suggested that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms and cardiopulmonary functions. HBOT is a safe treatment and has shown some benefits for long COVID symptoms. To precisely define indications, protocols, and post-treatment evaluations, we need to conduct more in-depth, large-scale studies.},
}
@article {pmid41745309,
year = {2026},
author = {Kostev, K and Konrad, M and Luedde, M},
title = {Real-World Cardiovascular Research Using the German IQVIA Disease Analyzer Database: Methods, Evidence, and Limitations (2000-2025).},
journal = {Journal of cardiovascular development and disease},
volume = {13},
number = {2},
pages = {},
pmid = {41745309},
issn = {2308-3425},
abstract = {Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. This increases the demand for real-world evidence to complement findings from randomized controlled trials. The German IQVIA Disease Analyzer (DA) database, which is populated with anonymized electronic medical records from general practitioners and specialists, has become an increasingly valuable source for cardiovascular research. Over the past two decades, and especially between 2020 and 2025, numerous epidemiological studies have used this database to explore associations between cardiovascular risk factors, comorbidities, therapeutic patterns, and cardiovascular outcomes in large, broadly representative outpatient populations. This review synthesizes evidence from 13 selected DA-based studies examining atrial fibrillation, heart failure, cardiometabolic disease, lipid management, non-alcoholic fatty liver disease (NAFLD)-related cardiovascular risks, cerebrovascular complications, COVID-19-associated vascular events, and modifiable behavioral and anthropometric factors. These studies were selected based on predefined criteria including cardiovascular relevance, methodological rigor, large sample size, and representativeness of key disease domains across the 2000-2025 period. Eligible studies were identified through targeted searches of peer-reviewed literature using the German IQVIA Disease Analyzer database and were selected to reflect major cardiovascular disease domains, risk factors, and therapeutic areas. Across disease domains, the reviewed studies consistently demonstrate the DA database's capacity to identify reproducible associations between cardiometabolic risk factors, comorbidities, and cardiovascular outcomes in routine outpatient care. While causal inference is not possible, the database enables the identification of clinically meaningful associations that inform hypothesis generation, help quantify disease burden, and highlight gaps in prevention or treatment. The database's strengths include large sample sizes (often exceeding 100,000 patients), long follow-up periods, and high external validity, while limitations relate to coding accuracy, residual confounding, and the absence of detailed clinical measures. Collectively, the evidence underscores the importance of the DA database as a crucial platform for real-world cardiovascular research.},
}
@article {pmid41746040,
year = {2026},
author = {Timmer, MSM and Connor, LM and Stocker, BL},
title = {Targeting the MR1-MAIT Cell Axis for Vaccination Against Infectious Disease.},
journal = {Vaccines},
volume = {14},
number = {2},
pages = {},
pmid = {41746040},
issn = {2076-393X},
support = {24-VUW-152//Royal Society Te Ap&#x101;rangi/ ; },
abstract = {Mucosal-associated invariant T (MAIT) cells exist in high numbers in the body and have a unique and highly conserved T cell receptor (TCR). They can be activated in a TCR-dependent manner by ligands presented on the monomorphic protein MHC class I-related protein 1 (MR1) which is found on many cell types, including professional antigen presenting cells (APCs) and epithelial cells. This has sparked interest in the potential to exploit the MR1-MAIT cell axis for the development of vaccines against infectious disease. Within this context an MR1 ligand, typically 5-(2-oxopropylideneamino)-d-ribitylaminouracil (5-OP-RU), is administered with or without a Toll-like receptor (TLR) ligand or cytokine in a pan vaccination approach that would prime the immune response to provide protection against a variety of bacterial and viral pathogens. This strategy has led to enhanced protection in murine models of Legionella longbeachae, Francisella tularensis, Klebsiella pneumoniae, Streptococcus pneumoniae and influenza infection. However, studies against Mycobacterium tuberculosis infection have proven less successful. The second vaccination approach involves pairing the MR1 ligand with more conventional antigens that could activate CD4[+] and/or CD8[+] T cells. This approach has been successful in murine models of cholera, influenza, and SARS-CoV-2, including in the context of subunit vaccines. However, there are several challenges when using MR1-MAIT cell-mediated vaccine adjuvants. These include the inherent instability of 5-OP-RU and the need for more advanced studies to better understand how the use of MR1 ligands would translate to applications in humans. This review will discuss these aspects and highlight the mechanistic studies that have been undertaken to understand how MAIT cells might elicit their effects within the context of MAIT cell-mediated vaccines for infectious disease.},
}
@article {pmid41746075,
year = {2026},
author = {Sarabia, LE and Williams, E and Date, K and Méroc, E and Eeuwijk, J and Gessner, B and Bresee, J and Fry, A and Begier, E},
title = {Vaccination Strategies Against Respiratory Pathogens in the Adult Population: A Narrative Review.},
journal = {Vaccines},
volume = {14},
number = {2},
pages = {},
pmid = {41746075},
issn = {2076-393X},
support = {NA//Pfizer (United Kingdom)/ ; },
abstract = {Respiratory infections cause substantial morbidity and mortality in older adults and other at-risk adult populations. Despite the availability of effective vaccines, adult vaccination coverage remains suboptimal. This narrative review examines strategies designed to improve vaccine uptake among non-pregnant adults aged ≥18 years and inform future adult vaccination strategies. We conducted a targeted literature search using keywords for vaccination, respiratory diseases, strategy/program/implementation, and adults in PubMed database and CDC, WHO, and ECDC websites, between 2014 and 2024. A snowball search of literature reviews and key references was also performed to identify additional relevant studies. Eligible publications focused on vaccination strategies against influenza, COVID-19, and pneumococcal disease targeting non-pregnant adults (≥18 years). We categorized the strategies by intervention type to describe their influence on vaccination campaigns and vaccine uptake/coverage. We included 45 publications, encompassing strategies focused on individual decision-making, healthcare system functions, and national policy. Educational and awareness interventions (such as healthcare worker/provider recommendations during consultation, phone calls, letters, text messages, and social media outreach) reportedly raised vaccination rates. Access-related factors, including convenient vaccination sites and free or subsidized vaccines, were reported to be important factors in improving coverage in underserved communities. Within healthcare settings, strategies such as continuous vaccine provider training and workflow/process optimization were shown to enhance vaccination delivery. At the local or national policy levels, legislation governing program targets shaped immunization efforts and facilitated collaborations and partnerships to expand campaign reach. The findings may inform policymakers and public health/immunization practitioners in designing context-specific immunization initiatives that effectively reach adult populations.},
}
@article {pmid41746079,
year = {2026},
author = {Oh, T},
title = {Advances in Spatial Transcriptomics for Infectious Disease Research: Insight for Vaccine Development.},
journal = {Vaccines},
volume = {14},
number = {2},
pages = {},
pmid = {41746079},
issn = {2076-393X},
support = {2025//Dankook University/ ; },
abstract = {Spatial transcriptomics (ST) enables genome-wide gene expression profiling while preserving tissue architecture, bridging the gap between bulk, single-cell, and histological analyses. Originating in 2016 and rapidly evolving since, ST has transformed infectious disease research by mapping host-pathogen interactions directly within intact tissues. Current platforms fall into two categories: sequencing-based methods (Visium, GeoMx, Stereo-seq) offering whole-transcriptome coverage at modest resolution and imaging-based platforms (Xenium, CosMx, MERFISH) providing single-cell or subcellular detail with targeted gene panels. These technologies reveal spatially organized immune responses, local tissue remodeling, and pathogen niches across viruses, bacteria, and parasites. In viral infection, ST uncovered heterogeneity in COVID-19 lung microenvironments, spatial immune activation in lymphoid tissues, and variant-specific inflammatory patterns. In bacterial disease, ST delineated granuloma architecture in tuberculosis and mapped vaccine-induced lung responses in Shigella studies. Parasitic infection studies identified localized inflammatory hotspots and microenvironmental control of T-cell differentiation in malaria. Despite powerful insights, ST faces constraints including RNA quality limitations, tradeoffs between resolution and transcript breadth, high cost, and analytical complexity. Nonetheless, ST increasingly informs vaccine design by identifying tissue-specific immune programs and protective microenvironments and is poised to become a standard tool for infectious disease biology.},
}
@article {pmid41746093,
year = {2026},
author = {Karczmarzyk, K and Kęsik-Brodacka, M},
title = {Challenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine.},
journal = {Vaccines},
volume = {14},
number = {2},
pages = {},
pmid = {41746093},
issn = {2076-393X},
support = {2019/35/B/NZ6/04002//National Science Centre/ ; },
abstract = {The development of a universal SARS-CoV-2 vaccine holds great promise for achieving broad and durable protection against existing and future coronavirus variants. The identification, selection, and rational redesign of conserved viral epitopes constitute the direct immunological foundation of universal SARS-CoV-2 vaccine development. The breadth and durability of protection are therefore primarily determined at the level of antigen and epitope design, whereas adjuvants, delivery platforms, and routes of administration serve as enabling and amplifying components rather than primary drivers of universality. Accordingly, this review discusses key determinants of universal vaccine design, including antigen selection, adjuvant utilization, and route of administration. The spike protein, particularly its receptor-binding domain, is a major antigenic target, but its high mutation rate challenges long-term vaccine efficacy. Strategies focusing on conserved epitopes in antigen designs show potential to elicit cross-neutralizing immune responses. Nanoparticle-based vaccines capable of presenting multiple homologous or heterologous antigens have demonstrated enhanced immunogenicity, broad protection in preclinical models and safety in clinical trials. The addition of next-generation adjuvants further amplifies humoral and cellular immunity beyond the capabilities of traditional aluminum-based adjuvants. Moreover, mucosal vaccine delivery may provide superior local protection at viral entry sites and limit transmission. Importantly, integrating these technological advances with epitope-centered antigen design and immunological data from vaccinated individuals will accelerate the identification of conserved epitopes and inform future vaccine design. A multidisciplinary approach combining optimized antigen engineering, novel adjuvant systems, and innovative delivery strategies is essential for the realization of a broadly protective universal SARS-CoV-2 vaccine.},
}
@article {pmid41747602,
year = {2026},
author = {Cui, Y and Song, P and Zhao, X and Tong, Z and Gao, GF},
title = {Virus-induced onychomadesis: Exploring the role of viral infection in nail shedding.},
journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
volume = {183},
number = {},
pages = {105928},
doi = {10.1016/j.jcv.2026.105928},
pmid = {41747602},
issn = {1873-5967},
mesh = {Humans ; *Nail Diseases/virology/etiology ; *Nails/virology/pathology ; *Hand, Foot and Mouth Disease/virology/complications ; *Virus Diseases/complications/virology ; },
abstract = {Onychomadesis, characterized by proximal detachment of the nail plate due to temporary arrest of matrix proliferation, has been increasingly recognized as a complication following viral infections. Enterovirus-associated hand-foot-and-mouth disease (HFMD) is the most frequently reported cause. Recent studies demonstrate that some enteroviruses, including Coxsackievirus A10, utilize the host receptor KREMEN1 (KRM1) to impair Wnt/β-catenin signaling and suppress nail stem cell differentiation, thereby providing a molecular basis for infection-induced nail shedding. Additionally, cases of onychomadesis linked to other viral infections, including KRM1-independent enteroviruses, influenza virus, SARS-CoV-2, varicella-zoster virus, and co-infections involving HIV and mpox, have also been documented. Despite growing recognition of the virus-induced onychomadesis, in most cases the exact pathogeneses are yet elusive, thereof lack of approved treatments. Understanding the molecular mechanisms of onychomadesis and other sequelae can enhance diagnostics and therapies, guiding future drug development for virus-induced nail disorders and related complications. A comprehensive literature search was conducted using PubMed up to Dec 2025, including the search terms: onychomadesis, Beau's line, infection or virus, and follow-up. This review aims to explore the molecular pathophysiology of virus-induced onychomadesis and to examine the underlying molecular mechanisms, including the roles of viral receptors and signaling pathways in nail stem cell differentiation. It scrutinizes the currently available literatures of link between viral infections, particularly HFMD, and onychomadesis, focusing on the molecular mechanisms involved, and explores potential therapeutic insights.},
}
@article {pmid41748273,
year = {2026},
author = {Evaborhene, NA and Oga, J and Adebisi, YA and Udokanma, EE and Runyowa, N and Kafuko, Z and Bandara, S and Onyeaghala, C},
title = {The WHO pandemic agreement-securing Africa's leadership in a fragmenting global order.},
journal = {BMJ global health},
volume = {11},
number = {2},
pages = {},
pmid = {41748273},
issn = {2059-7908},
mesh = {Humans ; *COVID-19/epidemiology ; *Leadership ; *Pandemics/prevention &amp; control ; *International Cooperation ; Africa/epidemiology ; *World Health Organization ; SARS-CoV-2 ; *Global Health ; Pandemic Preparedness ; *Health Policy ; *Pneumonia, Viral/epidemiology ; },
abstract = {In May 2025, the World Health Assembly adopted the historic WHO Pandemic Agreement, aimed at strengthening global pandemic preparedness and equity. This legally binding treaty emerged from years of negotiation shaped by the COVID-19 pandemic's stark inequities-particularly those experienced by African nations. While the treaty introduces important innovations, notably the Pathogen Access and Benefit-Sharing system, significant challenges remain. Ambiguities in equity commitments, geopolitical fragmentation and rising nationalism threaten effective implementation. For Africa, realising the treaty's promise requires robust legal frameworks, enhanced manufacturing and regulatory capacities and sustainable financing mechanisms that reduce donor dependency. This analysis critically examines the treaty's provisions and political economy, emphasising the need for enforceable obligations, continental leadership and multi-sectoral accountability. We propose the establishment of a Pandemic Peer Review Mechanism to embed political accountability at national and regional levels. Only through coordinated African leadership, institutional investment and global solidarity can the Pandemic Agreement deliver equitable health outcomes in a fracturing global order.},
}
@article {pmid41748726,
year = {2026},
author = {Smith, EA and Fleming, DF and Lackritz, EM and Ulrich, AK},
title = {Inequities and global declines in SARS-CoV-2 genomic data availability hinder response to emerging variants.},
journal = {Npj viruses},
volume = {4},
number = {1},
pages = {},
pmid = {41748726},
issn = {2948-1767},
abstract = {Genomic epidemiology has transformed the way public health scientists detect, monitor, and respond to infectious disease threats such as SARS-CoV-2 on a global scale. Early in the COVID-19 pandemic, vast inequities in whole-genome sequence data availability between high- and low-income countries were highlighted, but the persistence of these disparities five years into a global pandemic has not been quantified. Also, while it is generally known that genomic surveillance of SARS-CoV-2 largely declined following the end of the COVID-19 public health emergency, this has not been formally measured, and how it impacts our ability to detect and characterize new variants, remains unknown. Therefore, we performed an analysis of SARS-CoV-2 sequence submissions on the Global Initiative for Sharing All Influenza Data (GISAID) platform from 2020 to 2025, by country and World Bank income classification. There were large differences in SARS-CoV-2 sequence submissions by income classification, indicating a disparity in our ability to monitor SARS-CoV-2 evolution worldwide, which has important consequences for preventative measures such as vaccine strain selection. Nevertheless, there are important barriers to sustainable sharing of SARS-CoV-2 sequence data, which we discuss in detail, along with their relevance to other pathogens of public health importance. Also, the decrease in sequence submissions in high income countries from 577 million at the peak of the pandemic, to under 50 million in 2024, represents a loss of capacity to monitor SARS-CoV-2 evolution in countries with known capabilities. Ultimately, data drive the impact of genomic epidemiology, and long-term investments in genomic surveillance programs, as well as incentives for timely data sharing, are urgently needed to detect and characterize new viral variants worldwide.},
}
@article {pmid41749676,
year = {2026},
author = {Farì, G and Quarta, F and Bressi, F and La Russa, R and Paolucci, T and Bernetti, A},
title = {Effects of Exercise-Based Telerehabilitation for Knee Osteoarthritis: A Systematic Review and a Study Protocol.},
journal = {Bioengineering (Basel, Switzerland)},
volume = {13},
number = {2},
pages = {},
pmid = {41749676},
issn = {2306-5354},
abstract = {BACKGROUND: Knee osteoarthritis causes considerable pain and disability. Telerehabilitation has emerged as a promising treatment option, especially after the Coronavirus Disease 2019 pandemic, but it still faces challenges regarding solid scientific evidence about its multiple benefits. This systematic review aimed to analyze the reported beneficial effects of telerehabilitation based on therapeutic exercise for the management of knee osteoarthritis. Methodsː PubMed, PEDro, Web of Science and Cochrane Library databases were used to identify eligible studies. This review followed the PRISMA guidelines and was registered at PROSPERO (n° CRD42024579836). The selected studies underwent a qualitative assessment using the Modified Jadad Score.<br><br>RESULTS: Ten studies, including a total of 1354 participants, were included. From the selected studies, a wide variety of outcome measures emerged to evaluate the efficacy of telerehabilitation in the relief of pain and its clinical consequences. Seven studies specifically assessed pain, with four showing significant improvements in pain reduction in the intervention group compared with the control group. Telerehabilitation was found to be more effective or non-inferior to traditional rehabilitation in relieving pain, as reported across various pain scales. Limitations include the heterogeneity of interventions, the exclusion of non-recent studies, and the exclusive focus on therapeutic exercise. Conclusions&#x2d0; The results of this systematic review suggest that telerehabilitation provides pain relief, improves physical function, and enhances quality of life, while preliminary evidence indicates potential cost-related advantages. However, some studies did not find TR to be superior to control interventions, highlighting mixed evidence. Additional high-quality studies are required to better support this promising rehabilitation approach.},
}
@article {pmid41750353,
year = {2026},
author = {Makki, R and Kassem-Moussa, S and Al Nemer, F and El Majzoub, R and Fayyad-Kazan, H and Rachidi, W and Badran, B and Fayyad-Kazan, M},
title = {MicroRNAs in Long COVID: Key Regulators, Biomarkers, and Therapeutic Targets of Post-SARS-CoV-2 Sequelae.},
journal = {Biomolecules},
volume = {16},
number = {2},
pages = {},
pmid = {41750353},
issn = {2218-273X},
mesh = {Humans ; *MicroRNAs/genetics/metabolism/blood ; *COVID-19/genetics ; Biomarkers/blood/metabolism ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
abstract = {COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is clinically defined by persistent symptoms that endure beyond acute infection and affect multiple organ systems, including the immune, cardiopulmonary, neurological, and metabolic axes. The underlying mechanisms remain poorly resolved, limiting the development of targeted diagnostics and therapeutics. MicroRNAs (miRNAs), as key post-transcriptional regulators of gene expression, control inflammatory networks, antiviral responses, mitochondrial bioenergetics, and fibrotic pathways, all of which are implicated in long COVID pathogenesis. Recent studies show durable changes in circulating miRNA signatures months after recovery from the acute phase, suggesting a role in maintaining chronic immune activation and metabolic dysfunction. Importantly, circulating miRNAs are stable, quantifiable in biofluids, and reflect systems-level dysregulation, positioning them as promising biomarker candidates for patient stratification, symptom clustering, and disease monitoring. Moreover, miRNA-directed interventions, such as mimics and antagomiRs, represent an emerging precision-medicine strategy to correct sustained molecular disturbances. This review summarizes current evidence linking miRNAs to long COVID, highlights their biomarker potential, and discusses therapeutic avenues that may help advance mechanism-based interventions for this globally emerging chronic condition.},
}
@article {pmid41750595,
year = {2026},
author = {Dawi, J and Affa, S and Misakyan, Y and Gonzalez, E and Affa, S and Venketaraman, V},
title = {Glutathione-Mediated Redox Regulation of Immune Dysfunction in COVID-19 and Tuberculosis.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {2},
pages = {},
pmid = {41750595},
issn = {2076-3921},
support = {R15 HL143545/HL/NHLBI NIH HHS/United States ; },
abstract = {Tuberculosis and coronavirus disease 2019, also known as COVID-19, remain major global health challenges that disproportionately affect individuals with metabolic disorders, chronic inflammation, and limited access to healthcare. Although these diseases are caused by different pathogens, they share important host-related determinants of severity, including immune dysfunction, oxidative stress, endothelial injury, and maladaptive inflammatory responses. Glutathione, the primary intracellular antioxidant and a key regulator of redox balance, has emerged as an important host factor connecting these processes across infectious diseases. This review integrates experimental, translational, and clinical evidence supporting the role of glutathione in regulating immune function, oxidative stress, and tissue damage in tuberculosis and COVID-19. In tuberculosis, glutathione deficiency compromises macrophage antimicrobial activity, disrupts granuloma structure, and alters T helper cell responses, leading to impaired immune containment and disease progression. In COVID-19, reduced glutathione levels are associated with redox imbalance, excessive cytokine signaling, endothelial dysfunction, and thromboinflammatory complications, especially in high-risk populations. In both diseases, glutathione depletion reduces host resilience and increases vulnerability to severe outcomes through shared immune and vascular pathways. By unifying disease-specific findings within a host-directed framework, this review highlights glutathione and redox signaling as common vulnerability pathways that help explain overlapping risk profiles for severe tuberculosis and COVID-19. It also places glutathione biology within the broader context of host-directed immunotherapy, emphasizing its potential role in prevention-focused and resilience-based strategies that complement pathogen-targeted treatments. Although current evidence does not support simple claims of disease prevention, it provides strong mechanistic justification for further investigation of glutathione as a modifiable host factor in high-risk populations.},
}
@article {pmid41751338,
year = {2026},
author = {Notarte, KI and Catahay, JA and Velasco, JV and Ver, AT and Lee, J and Rizk, JG and Lippi, G and Fernández-de-Las-Peñas, C},
title = {Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis.},
journal = {Biomedicines},
volume = {14},
number = {2},
pages = {},
pmid = {41751338},
issn = {2227-9059},
abstract = {Background/Objective: Long COVID is an important cause of disability following SARS-CoV-2 infection; yet, its underlying mechanisms are not completely understood. One proposed mechanism is the long-lasting dysregulation of the immune complement system. This systematic review is the first to summarize the current evidence and evaluate the potential role of long-lasting complement activation in people with long COVID. Methods: A systematic electronic search on PubMed, MEDLINE, CINAHL, and Embase was conducted up to 15 October 2025, to identify studies investigating complement activation in people with the post-COVID-19 condition. The Newcastle-Ottawa Scale was used to evaluate the risk of bias and methodological quality. Results: Among the 247 studies initially identified, eleven met the inclusion criteria, comprising 1435 individuals (age: 48.5 years, 70% females) with long COVID and 1124 controls (age: 43.6 years, 60% females). All studies were of a high quality, with scores ranging from 7 to 8 stars (mean: 7.6 ± 0.5). The activation of the classical complement pathway was investigated in nine studies, whereas the lectin, alternative, and terminal complement pathways were each assessed in three studies. Multiple studies investigated several complement pathways. The results were heterogeneous since several markers of complement activation spanning the classical (C2, C4a, C4b, and C1s-C1INH), alternative (Ba, iC3b, and Factor D), and terminal (C5bC6, C5a, C9, and TCC) pathways were elevated, whereas other markers were not significantly different (C3, C4, and C4d) between patients with/without long COVID. In addition, markers spanning the lectin complement pathway (MBL, and MASP1-C1INH) were not significantly different between individuals with and without long COVID. Conclusions: The current evidence suggests potential long-lasting complement system dysregulation in individuals with long COVID, although the clinical significance remains controversial, due to heterogenous findings. Specific post-COVID symptom clusters, such as fatigue, dyspnea, or brain fog, have been linked to a distinct pattern of complement dysregulation. Substantial methodological heterogeneity, including differences in follow-up periods, complement markers, assessment methods, and control groups, along with the small number of available studies, underscores the need for further research to clarify the mechanisms linking complement dysregulation to long COVID.},
}
@article {pmid41751767,
year = {2026},
author = {Zieniuk, B and Wierzchowska, K and Jasińska, K and Kobus, J and Piotrowicz, A and Uğur, &#x15e; and Fabiszewska, A},
title = {Yeast as a Model for Human Disease.},
journal = {International journal of molecular sciences},
volume = {27},
number = {4},
pages = {},
pmid = {41751767},
issn = {1422-0067},
mesh = {Humans ; Neurodegenerative Diseases/metabolism/genetics/pathology ; Saccharomyces cerevisiae/genetics/metabolism ; *Models, Biological ; Mitochondrial Diseases/metabolism/genetics ; Animals ; *Yeasts/metabolism/genetics ; Metabolic Diseases/metabolism/genetics ; },
abstract = {Yeasts, especially the conventional species Saccharomyces cerevisiae and Schizosaccharomyces pombe, as well as some unconventional species such as Pichia pastoris, Kluyveromyces marxianus and Yarrowia lipolytica, have become fundamental model organisms for understanding the molecular mechanisms underlying human diseases. Their eukaryotic cell organization, genetic simplicity, and strong conservation of essential biological pathways make them indispensable in biomedical research. This review provides a comprehensive overview of the role of different yeast species in modeling human disorders, highlighting historical milestones and groundbreaking discoveries that have shaped current knowledge. The article discusses the applications of yeast models in studying neurodegenerative diseases such as Alzheimer's and Huntington's, as well as metabolic diseases, infectious diseases and mitochondrial disorders, and their growing importance in cancer research and drug discovery. Special attention is given to humanized yeast models, which enable the expression and functional analysis of human genes and the heterologous synthesis of human proteins within yeast cells. Finally, the paper addresses the limitations and challenges of yeast as a model system while outlining future directions and emphasizing the organism's continued relevance in personalized medicine and functional genomics.},
}
@article {pmid41752703,
year = {2026},
author = {Hostiuc, S and Gherghiceanu, F},
title = {Burnout, PTSD, and Medical Error: The Medico-Legal Implications of the Mental Health Crisis Among Frontline Healthcare Professionals During COVID-19.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {2},
pages = {},
pmid = {41752703},
issn = {1648-9144},
mesh = {Humans ; *Stress Disorders, Post-Traumatic/epidemiology/psychology ; *COVID-19/psychology/epidemiology ; *Burnout, Professional/epidemiology/psychology ; *Medical Errors/psychology/statistics &amp; numerical data ; Frontline Workers/psychology ; *Health Personnel/psychology ; Prevalence ; SARS-CoV-2 ; Mental Health ; Pandemics ; Emotional Exhaustion ; },
abstract = {Background and Objectives: The COVID-19 pandemic has led to an unprecedented mental health crisis among workers in the healthcare field, with average burnout rates increasing from about 32% before the pandemic to 46-52% during peak times and post-traumatic stress disorder (PTSD) affecting 24-34% of frontline staff. The primary objective of this article is to synthesize evidence on the prevalence of burnout and PTSD among healthcare workers before and during the COVID-19 pandemic. The secondary objectives are: (a) to examine the mechanisms and empirical evidence linking clinician mental health to medical errors and patient safety outcomes and (b) to analyze the medico-legal implications of this relationship, including malpractice liability, institutional responsibility, and opportunities for policy reform. Materials and Methods: We conducted a narrative review searching PubMed (November 2025-January 2026) using predefined keyword combinations. Inclusion criteria comprised original research, systematic reviews, and meta-analyses examining mental health outcomes or patient safety among clinical staff. Data were synthesized narratively across five thematic domains. Results: Burnout prevalence increased from approximately 32% pre-pandemic to 46-52% during peak periods, with emotional exhaustion reaching 67.5% in some settings. PTSD rates rose to 24-34% among frontline staff, exceeding pre-pandemic levels of 15-20%, with ICU staff particularly affected (27-40%). Substantial overlap exists between conditions (86-98% comorbidity). Physician burnout is associated with 2.72 times higher odds of self-reported errors (95% CI: 2.19-3.37), with each point increase in emotional exhaustion raising the error risk by 5-11%. Mechanisms include cognitive impairment (reduced executive function, g = -0.39; impaired working memory, g = -0.36) and sleep disturbance. Malpractice litigation compounds psychological harm, increasing depression and suicidal ideation. Conclusions: This review, synthesizing data from over 500,000 healthcare workers, demonstrates bidirectional relationships among burnout, PTSD, and medical errors with significant medico-legal ramifications. Addressing this crisis requires systemic interventions including workload management, psychological support, blame-free reporting cultures, and policy reforms balancing accountability with recognition of system-level contributors to error.},
}
@article {pmid41752709,
year = {2026},
author = {Pah, AM and Gavrilescu, DM and Mateescu, DM and Cotet, IG and Craciun, ML and Florescu, E and Crisan, S and Avram, A},
title = {Association of Chronic Hyperglycemia and Glycemic Variability with Mortality in COVID-19: Meta-Analysis of Cohort Studies.},
journal = {Medicina (Kaunas, Lithuania)},
volume = {62},
number = {2},
pages = {},
pmid = {41752709},
issn = {1648-9144},
support = {Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara//Victor Babe&#x219; University of Medicine and Pharmacy Timi&#x219;oara/ ; },
mesh = {Humans ; *Blood Glucose/analysis ; Chronic Disease ; Cohort Studies ; *COVID-19/mortality/complications/blood ; Glycemic Control ; *Hyperglycemia/mortality/complications/blood ; Intensive Care Units ; },
abstract = {Background and Objectives: Dysglycemia is a major determinant of adverse outcomes in COVID-19, yet the separate contributions of poor glycemic control and glycemic variability (GV) remain incompletely defined. We conducted a systematic review and meta-analysis of observational cohort studies (both prospective and retrospective) to quantify the impact of chronic hyperglycemia and glucose instability on disease severity, intensive care requirements, and mortality in patients with COVID-19. Materials and Methods: We searched PubMed, Scopus, and Web of Science from January 2020 to October 2024 for observational cohort studies reporting clinically relevant COVID-19 outcomes stratified by glycemic control or GV. Dysglycemia definitions varied across studies (HbA1c-based chronic hyperglycemia, fasting glucose, or admission/in-hospital hyperglycemia). GV was assessed using metrics including mean amplitude of glycemic excursions (MAGE), standard deviation (SD), coefficient of variation (CV), or maximum daily glucose difference. Twelve studies met inclusion criteria and were included in qualitative synthesis; five studies were eligible for quantitative synthesis of clinical outcomes. Random-effects DerSimonian-Laird models were applied due to anticipated clinical heterogeneity. Heterogeneity was evaluated using Cochran's Q, τ[2], and I[2] statistics. Results: Overall, 12 observational studies (9 prospective and 3 retrospective cohorts; n = 1,008,310 patients) were included. In quantitative analyses of five eligible cohorts, poor glycemic control was associated with a significantly increased risk of severe or critical COVID-19 (pooled RR = 1.75, 95% CI: 1.45-2.11; I[2] = 29%), ICU admission (RR = 1.54, 95% CI: 1.18-2.01), and mechanical ventilation (RR = 1.72, 95% CI: 1.31-2.26). Three studies evaluating GV demonstrated a strong association with adverse outcomes (pooled RR = 2.07, 95% CI: 1.71-2.50; I[2] = 0%); this low heterogeneity should be interpreted cautiously given the limited number of studies. GV remained associated with mortality in multivariable models, indicating that glycemic variability is separately associated with mortality as a clinically relevant prognostic risk marker in hospitalized COVID-19 patients. Conclusions: Both chronic hyperglycemia and elevated glycemic variability are each associated with increased risk of severe COVID-19 outcomes. Glycemic variability appeared to be a consistent, low-heterogeneity prognostic marker of mortality, being separately associated with higher death risk in hospitalized COVID-19 patients, highlighting its potential utility as a dynamic metabolic biomarker. Early identification and targeted management of dysglycemia-especially glucose instability-may improve prognosis in hospitalized COVID-19 patients. PROSPERO: CRD420251250718.},
}
@article {pmid41752904,
year = {2026},
author = {Siliste, RN and Benea, S and Homentcovschi, C and Deaconu, T and Caruntu, C and Savulescu-Fiedler, I},
title = {Myocardial and Vascular Involvement in COVID-19 and Post-Vaccination States: Understanding Injury Pathways and Clinical Implications.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {2},
pages = {},
pmid = {41752904},
issn = {2075-1729},
abstract = {Myocardial and vascular injury secondary to SARS-CoV-2 infection and vaccination has emerged as a clinically relevant phenomenon, with distinct but overlapping mechanisms. Myocardial injury in COVID-19 results from a complex interplay between direct viral effects and immune-mediated inflammation, supported by histopathological studies revealing macrophage-rich infiltrates, microthrombosis, and supporting fibrosis in isolated areas. In contrast, vaccine-associated myocarditis-reported predominantly following mRNA vaccines-has a self-limiting clinical course, with mechanisms likely involving molecular mimicry, aberrant immune activation, or hypersensitivity reactions, although these pathways require further validation. Although mRNA vaccines have been associated with a small increase in myocarditis, particularly in young men, the risk is significantly lower than that associated with COVID-19 infection, and the cardiovascular benefits of vaccination far outweigh these rare adverse events in most populations. After the end of the pandemic, the number of patients with severe forms of COVID-19 has decreased significantly, but we consider that cardiac involvement remains an important issue for the acute and long-term prognosis of patients with SARS-CoV-2 infection. Our paper synthesizes the latest epidemiological and mechanistic evidence on the link between COVID-19, vaccination, and myocardial and/or vascular injuries, highlighting the clinical implications and providing practical recommendations for management, as well as future perspectives on risk assessment, targeted immunotherapy, advanced diagnostic tools, and long-term monitoring.},
}
@article {pmid41753016,
year = {2026},
author = {Cadena Barberis, ED and Oh, HR and Vélez Ordóñez, LD and Calvopiña, VS and Rodas, JA and Leon-Rojas, JE},
title = {Relationship Between Substance Use and Suicide Behavior During the COVID-19 Pandemic: A Systematic Review and Random-Effects Proportions Meta-Analysis.},
journal = {Journal of clinical medicine},
volume = {15},
number = {4},
pages = {},
pmid = {41753016},
issn = {2077-0383},
support = {592.A.XVII.25//Universidad de Las Am&#xe9;ricas/ ; },
abstract = {Background/Objectives: The COVID-19 pandemic disrupted social structures, healthcare access, and psychological well-being, potentially intensifying substance use and suicidal behavior. Although both phenomena have been independently studied, their co-occurrence during the pandemic has not been systematically synthesized. To evaluate the prevalence and patterns of suicidal behavior among individuals with substance use during the COVID-19 pandemic through a systematic review and random-effects proportions meta-analysis. Methods: A systematic search of PubMed, Scopus, Web of Science, and EBSCO Host was conducted from 11 March 2020 to 15 October 2022 for studies published between March 2020 and October 2022. Eligible studies included observational designs reporting substance use and suicidal behavior in adults during the pandemic. Risk of bias was assessed using National Institutes of Health tools. Proportional meta-analyses were performed using a random-effects model with Freeman-Tukey double arcsine transformation. Heterogeneity was quantified using the I[2] statistic. Results: Twenty studies comprising 70,684 individuals were included. Substance use during the pandemic was reported in 24.6 percent of participants, while 30.7 percent exhibited suicidal behavior. A total of 16.1 percent presented with both substance use and suicidal behavior. The pooled prevalence of any suicidal behavior among individuals with substance use was 33.8 percent (95 percent CI, 22.8 to 45.7), with substantial heterogeneity. Alcohol showed a pooled prevalence of 36.2 percent, cannabis 48.1 percent, and tobacco 11.5 percent. Suicidal ideation was the most frequent outcome, with a pooled prevalence of 36.8 percent among substance users. Most studies reported an increased association between substance use and suicidal behavior compared with pre-pandemic periods. Conclusions: Substance use and suicidal behavior frequently co-occurred during the COVID-19 pandemic, particularly suicidal ideation and alcohol use. These findings highlight the need for integrated mental health and substance use interventions during public health crises.},
}
@article {pmid41753114,
year = {2026},
author = {Kloni, M and Heraclides, A and Panteli, T and Klonis, A and Rentzias, P and Karagiannis, C},
title = {Incentive Spirometer in COVID-19: A Systematic Review.},
journal = {Journal of clinical medicine},
volume = {15},
number = {4},
pages = {},
pmid = {41753114},
issn = {2077-0383},
abstract = {Background/Objectives: COVID-19 and its sequelae have affected millions worldwide, with many individuals experiencing persistent symptoms such as dyspnea, fatigue and reduced quality of life. Respiratory physiotherapy is commonly used to support patients with pulmonary conditions. This systematic review aimed to evaluate the effects of the incentive spirometer on cardiopulmonary, functional and patient-reported outcomes in adults during the acute and post-COVID-19 phases. Methods: A systematic literature search was conducted in PubMed, CINAHL, Scopus, Clinical Trials.gov and Google Scholar to identify studies published between January 2020 and April 2025. Owing to substantial heterogeneity in study design, populations, interventions and outcome measures, quantitative synthesis was not feasible and findings were synthesized narratively. Results: Twelve studies involving 573 participants were included. Within-group analyses showed improvements in pulmonary outcomes (including FEV1, FVC, and oxygen saturation), reductions in dyspnea, and improvements in quality of life following incentive spirometer. Improvements in pulmonary function were reported primarily in post-COVID-19 populations, whereas reductions in anxiety and improvements in quality of life were reported mainly in acute COVID-19 settings. Between-group comparisons demonstrated statistically significant differences in favor of the incentive spirometer for selected pulmonary and functional outcomes (including FVC, DLCO, oxygen saturation, six-minute walk test, and 30 s sit-to-stand test), while no significant differences were observed for other outcomes such as peak expiratory flow, respiratory rate, or heart rate variability. Randomized controlled trials were judged to have a moderate risk of bias, non-randomized studies a moderate-to-serious risk, and certainty of evidence ranged from very low to moderate. Conclusions: Incentive spirometer may support respiratory, functional, and psychological recovery in adults during the acute and post-COVID-19 phases. However, effects vary across outcomes and comparator interventions, and the overall certainty of evidence is low to moderate. Further high-quality research is required to confirm effectiveness and guide optimal clinical use.},
}
@article {pmid41753604,
year = {2026},
author = {Chen, M and Ren, W and Wu, X and Khan, JM and Nazir, H and Rehman, SU and Ali, F and Li, J},
title = {Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives.},
journal = {Microorganisms},
volume = {14},
number = {2},
pages = {},
pmid = {41753604},
issn = {2076-2607},
abstract = {Monkeypox (Mpox), a zoonotic viral disease caused by the Monkeypox Virus (MPXV), has gained significant attention in recent years due to its increasing incidence and the grave threat it poses to global health. MPXV has spread at a rapid pace during the COVID-19 pandemic, causing 10,000+ confirmed cases and ~300 fatalities in 122 countries. This virus comprises two major clades, Clade I (Central African), which is evidently more virulent, and Clade II (West African), which has caused the recent outbreaks across the world and caused fewer deaths. Clinically, Mpox presents as a milder form with fever, lymphadenopathy, and vesiculopustular rash similar to smallpox. Diagnostic measures such as polymerase chain reaction (PCR) are the main diagnostic confirmatory tools. Advanced diagnostics involve electronic microscopy, serology, and immunohistochemistry. Alternative drugs like tecovirimat and brincidofovir have demonstrated potential for treating smallpox, but there is scanty evidence on their efficacy against MPXV. Most recent advancements in the study of vaccines have resulted in the creation and introduction of MVA-BN (JYNNEOS/Imvanex/Imvamune) and ACAM2000 vaccines, which conferred cross-protection against MPXV. MVA-BN is suggested to perform better than other types due to its enhanced safety and immunogenicity. Researchers are also developing DNA and protein subunit vaccines against Mpox to induce specific immune responses by presenting viral proteins. The discovery of novel vaccine candidates and antiviral treatments will be needed to prevent future outbreaks and reduce the global health burden of Mpox. This review focuses on the characterization of MPXV, summarizing current knowledge on its genomic structure, pathogenesis, replication, potential targets of anti-MPXV drugs, clinical features, and epidemiological patterns, along with recent advances in vaccine development.},
}
@article {pmid41753974,
year = {2026},
author = {Haimi, M},
title = {Nurse-Led Telephone Triage in Contemporary Healthcare: Bridging the Gap Between Patient Need and Resource Allocation.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
pmid = {41753974},
issn = {2227-9032},
abstract = {Background: Nurse teletriage has emerged as a component of modern healthcare delivery, utilizing telecommunication technologies to assess patient conditions remotely and guide appropriate care decisions. As healthcare systems face increasing demand and the need for cost-effective care delivery, teletriage services have expanded, particularly following the COVID-19 pandemic. Objective: This narrative review examines the current state of nurse teletriage practice, its effectiveness, safety outcomes, and implementation considerations. A comparative analysis with physician-led teletriage models is provided, and the emerging role of artificial intelligence is explored. Methods: A narrative review of the literature was conducted through searches of multiple databases including PubMed/MEDLINE, CINAHL, Cochrane Library, Embase, Web of Science, and Google Scholar. This approach was selected due to the heterogeneous nature of the teletriage literature, which spans diverse study designs, populations, and outcomes that are not amenable to formal systematic synthesis. Peer-reviewed articles published between 1970 and 2024 examining safety outcomes, effectiveness, and implementation frameworks were reviewed. Results: The available evidence suggests that nurse-led teletriage systems, particularly when supported by computerized decision support systems, can improve patient access to care while maintaining safety standards. Studies indicate that telephone triage nursing does not increase mortality, hospitalization rates, or emergency department referrals when properly implemented. One well-documented physician-led model in Israel reported diagnosis accuracy rates of 98.5% and decision reasonableness rates of 92%, though generalizability across settings requires caution. Key success factors appear to include the use of evidence-based protocols, staff training, technology infrastructure, and quality assurance programs. While these findings are promising, the heterogeneous nature of the included studies and absence of formal quality assessment warrant cautious interpretation. Conclusions: Nurse teletriage appears to be an effective and safe approach to healthcare delivery that addresses challenges in modern healthcare systems. The choice between nurse-led and physician-led models should consider population complexity, case types, available resources, and economic factors. Artificial intelligence technologies offer potential opportunities to enhance teletriage, though careful validation is essential. Future research should focus on long-term outcomes, comparative effectiveness across healthcare systems, and rigorous evaluation of AI applications. Highlights: Telephone triage services, where nurses or physicians assess patients remotely and guide them to appropriate care, have become increasingly important in modern healthcare. This narrative review examines the evidence on nurse-led telephone triage, comparing it with physician-led models and exploring emerging technologies like artificial intelligence. The available evidence suggests that nurse-led systems, when supported by appropriate protocols and training, can safely improve patient access to care while reducing healthcare costs. Physician-led models may offer advantages for complex cases but at higher costs. While artificial intelligence shows promise for enhancing triage accuracy, current evidence specific to telephone triage remains limited. Healthcare organizations should carefully consider their population needs, available resources, and local context when implementing teletriage services.},
}
@article {pmid41754057,
year = {2026},
author = {Malik, Z and Skapetis, T},
title = {A Contemporary Mini-Review of Interprofessional Education and Technology-Assisted Management of Dental Emergencies in the Emergency Department.},
journal = {Healthcare (Basel, Switzerland)},
volume = {14},
number = {4},
pages = {},
pmid = {41754057},
issn = {2227-9032},
abstract = {BACKGROUND: Dental emergencies are increasing in frequency. Numerous studies have reported minimal knowledge and/or skills by emergency department staff regarding dental emergencies. The COVID-19 pandemic has prompted a paradigm shift in emergency dental care management away from traditional management approaches. However, there have been no reviews of contemporary literature pertaining to either technology-assisted or interprofessional education and dental emergency management in the emergency department setting. This mini-review aimed to synthesise current evidence of interprofessional education, utilising technology-assisted modalities, for the management of dental emergencies in hospital emergency departments.<br><br>METHODS: A comprehensive search was carried out across four electronic databases, Medline, Embase, CINAHL, and Google Scholar from 2018 to 2025.<br><br>RESULTS: A total of three papers were identified and included in the mini-review. Two of the three papers addressed the subject of dental emergencies in the emergency department as a primary finding.<br><br>DISCUSSION: Included papers were of low-quality evidence and referenced simulation-based education, tele-dentistry, and artificial intelligence as contemporary approaches relating to dental emergency management.<br><br>CONCLUSIONS: This mini-review revealed minimal advances in contemporary approaches relating to both the use of technology-assisted modalities and interprofessional education for the management of dental emergencies within the hospital emergency department setting. This review provides a timely literature update for both the medical and dental professions and identifies a large gap in research surrounding this topic.},
}
@article {pmid41754151,
year = {2026},
author = {Caliman-Sturdza, OA and Gheorghita, RE and Soldanescu, I and Dimian, M and Mangul, S},
title = {Vitamin D in Infectious Diseases: A Narrative Review Focusing on COVID-19, Long COVID, and Influenza.},
journal = {Nutrients},
volume = {18},
number = {4},
pages = {},
pmid = {41754151},
issn = {2072-6643},
mesh = {Humans ; *Vitamin D/therapeutic use/blood/analogs &amp; derivatives/administration &amp; dosage/immunology ; *Influenza, Human/immunology/drug therapy ; *COVID-19/immunology ; Post-Acute COVID-19 Syndrome ; *Vitamin D Deficiency/immunology/complications/drug therapy ; SARS-CoV-2 ; Immunity, Innate/drug effects ; Dietary Supplements ; Pandemics ; },
abstract = {Vitamin D is a secosteroid hormone traditionally recognized for its role in bone and mineral metabolism, but it is increasingly understood to also function as an important immunomodulator influencing susceptibility to and outcomes of infectious diseases. This narrative review summarizes current evidence on the immunological, clinical, and preventive effects of vitamin D in the context of novel coronavirus disease (COVID-19), post-acute sequelae of SARS-CoV-2 infection (long COVID), and influenza. Mechanistically, vitamin D enhances innate immune defenses through the induction of antimicrobial peptides, including cathelicidin and defensins, and modulates adaptive immunity by suppressing maladaptive Th1/Th17 responses while promoting regulatory T-cell activity. Observational studies have frequently associated vitamin D deficiency with more severe COVID-19 outcomes; however, these associations may be influenced by confounding factors and reverse causality. Some meta-analyses suggest that vitamin D supplementation reduced rates of intensive care unit admission and ventilatory support, particularly among older adults and individuals with low baseline serum 25-hydroxyvitamin D concentrations. Emerging evidence also indicates that inadequate vitamin D status may be associated with an increased risk and symptom burden of long COVID, although causality has not been established. In the case of influenza, a limited number of randomized controlled trials (RCTs) and meta-analyses report a modest but statistically significant reduction in infection risk, especially with daily or weekly vitamin D supplementation in populations with low baseline vitamin D levels. Clinical guidelines consistently recommend maintaining adequate vitamin D status for general health but do not endorse high-dose vitamin D as a treatment for COVID-19 due to inconsistent trial findings. Overall, vitamin D should not be considered a standalone therapeutic agent; rather, maintaining sufficient vitamin D levels represents a low-risk, potentially beneficial strategy to support immune resilience against respiratory viral infections.},
}
@article {pmid41754496,
year = {2026},
author = {Federico, M},
title = {Potential Impact of SARS-CoV-2 Spike Protein on HIV-1 Reservoir in People Living with HIV.},
journal = {Viruses},
volume = {18},
number = {2},
pages = {},
pmid = {41754496},
issn = {1999-4915},
support = {RIP-1//Ministry of Health, Italy/ ; },
mesh = {Humans ; *Spike Glycoprotein, Coronavirus/immunology/genetics ; *HIV-1/physiology ; *HIV Infections/virology/immunology ; Virus Latency ; *SARS-CoV-2/immunology/physiology ; *COVID-19 Vaccines/immunology ; *COVID-19/prevention &amp; control/virology/immunology ; Virus Activation ; },
abstract = {People living with HIV-1 (PLWH) are part of the so-called "fragile" populations to which COVID-19 vaccines were/are strongly recommended. The fact that most widely used COVID-19 vaccines rely on the production of a biologically active SARS-CoV-2 Spike protein expressed by synthetic mRNA poses the relevant question of whether and how this vaccination influences the fate of the HIV-1 reservoir. This report presents a detailed analysis of the literature data on the effects of SARS-CoV-2 Spike and COVID-19 vaccines on HIV-1 latently infected cells. Despite being limited in number, the experimental evidences consistently indicate that vaccine mRNA and/or SARS-CoV-2 Spike can effectively reactivate latent HIV-1. This conclusion has been drawn after "in vitro", "ex vivo", and "in vivo" assays, and with virus-associated Spike, soluble Spike, or its intracellular expression, as well as with COVID-19 mRNA vaccines. On the other hand, real-world observations on vaccinated PLWH under antiretroviral therapy (ART) provided evidence of HIV-1 reactivation almost exclusively in PLWH with unsuppressed viremia, as measured in terms of size of the HIV-1 reservoir. Although several issues still need to be clarified through urgent additional investigations, these data suggest the possibility that the Spike protein and/or the vaccine mRNA molecules affect the HIV-1 latency in PLWH.},
}
@article {pmid41754526,
year = {2026},
author = {Siniscalchi, C and Basaglia, M and Imbalzano, E and Di Micco, P},
title = {The Platelet-Virus Axis in Human Disease.},
journal = {Viruses},
volume = {18},
number = {2},
pages = {},
pmid = {41754526},
issn = {1999-4915},
mesh = {Humans ; *Blood Platelets/virology/immunology ; *Host-Pathogen Interactions/immunology ; *Virus Diseases/immunology/virology ; Platelet Activation ; Immunity, Innate ; Thrombosis/virology ; SARS-CoV-2 ; },
abstract = {Platelets have traditionally been viewed as passive cellular elements involved in hemostasis and vascular integrity. However, growing evidence over the last decade has radically changed this paradigm, revealing platelets as dynamic immune and inflammatory effectors that actively participate in host-pathogen interactions. In viral infections, platelets are not merely innocent bystanders but represent key players in a bidirectional and tightly regulated platelet-virus axis that influences viral dissemination, immune activation, endothelial dysfunction, and the development of thrombotic and hemorrhagic complications. Several clinically relevant viruses, including SARS-CoV-2, influenza virus, HIV, dengue virus, and viral hemorrhagic fever-associated pathogens, have been shown to directly or indirectly interact with platelets through surface receptors, immune complexes, and inflammatory mediators, leading to platelet activation, phenotypic reprogramming, and accelerated clearance. These processes contribute to the paradoxical coexistence of thrombocytopenia and hypercoagulability that characterizes many severe viral diseases. Moreover, platelets can act as immune sentinels by sensing viral components, releasing cytokines and chemokines, forming platelet-leukocyte aggregates, and modulating both innate and adaptive immune responses, thereby shaping the clinical course of infection. In this review, we synthesize current evidence on the molecular and cellular mechanisms governing virus-platelet interactions, with particular emphasis on their role in immune-thrombosis, endothelial injury, and organ dysfunction. We further discuss the clinical implications of platelet dysregulation in viral infections, including its potential value as a biomarker of disease severity and as a therapeutic target. Understanding the platelet-virus axis provides a unifying framework to explain the thrombo-inflammatory phenotype of viral diseases and may open new avenues for risk stratification and targeted interventions in affected patients.},
}
@article {pmid41754548,
year = {2026},
author = {Deák, G and Lupu, L and Prangate, R},
title = {A Systematic Review of Methodological Approaches to SARS-CoV-2 Wastewater Surveillance.},
journal = {Viruses},
volume = {18},
number = {2},
pages = {},
pmid = {41754548},
issn = {1999-4915},
support = {Support to Member States for the establishment of national systems, local collection points and digital infrastructure for the monitoring of COVID-19 and its variants in wastewater-Romania//This work was supported by the European Commission DG Environment [060701/2021/864662/SUB/ENV]. C2] Emergency Support under Council Regulation (EU) 2016/369 as amended by Council Regulation (EU) 2020/521/ ; },
mesh = {Humans ; *SARS-CoV-2/isolation &amp; purification/genetics ; *Wastewater/virology ; *COVID-19/epidemiology/virology/transmission ; RNA, Viral/isolation &amp; purification/genetics ; *Wastewater-Based Epidemiological Monitoring ; },
abstract = {Following the COVID-19 pandemic, researchers have increasingly focused on monitoring the spread of the virus and improving methods to detect changes in the SARS-CoV-2 genome. Although clinical surveillance provides direct and reliable results, it has limited applicability. Wastewater-based epidemiology (WBE) has therefore emerged as a valuable, non-invasive complementary tool for disease surveillance. It provides a comprehensive picture of virus circulation in a population, including asymptomatic individuals and those who do not seek healthcare. In addition, it facilitates early detection of outbreaks and the collection of epidemiologic data at the community level. However, WBE also presents technical challenges, including variations in sampling and testing protocols, the presence of inhibitors that affect viral RNA extraction, and the need for standardised procedures between studies. These challenges should be addressed for possible future infectious disease outbreaks. One of the challenges facing researchers was to develop efficient methods that could overcome the extraction and detection problems related to inhibitors present in wastewater. To this aim, this systematic review highlights the potential use of WBE, the variety of techniques, and the most effective methods for the detection and quantification of SARS-CoV-2 in wastewater samples. A reproducible electronic search of the literature was conducted in the Web of Science (WoS) and PubMed databases for articles published between 2020 and 2024. Our search revealed that the majority of observed WBE applications emphasised a correlation between SARS-CoV-2 RNA concentration trends in wastewater and epidemiological data. Another relevant issue that the articles often discussed and compared was the techniques used in different steps of sample processing, such as sample collection, concentration and detection, hence the lack of standardised procedures. This paper provides a framework regarding previous research on WBE to gain a better understanding that will lead to functional solutions.},
}
@article {pmid41754590,
year = {2026},
author = {De Stefanis, S and Colavita, F and Maggi, F and Antonioli, M},
title = {SARS-CoV-2 Persistence and the Gut Microbiota: New Insights into Long COVID Pathogenesis.},
journal = {Viruses},
volume = {18},
number = {2},
pages = {},
pmid = {41754590},
issn = {1999-4915},
support = {Ricerca Corrente Linea 1 - Progetto 1 to IRCCS INMI L. Spallanzani//Ministero della Salute/ ; Ricerca di Ateneo 2024- Dipartimento di Biologia (AutoCuRC)//University of Rome Tor Vergata/ ; },
mesh = {Humans ; *COVID-19/microbiology ; *Gastrointestinal Microbiome ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Dysbiosis ; Pandemics ; Gastrointestinal Tract/microbiology/virology ; Inflammatory Bowel Diseases ; Inflammation ; },
abstract = {In December 2019, the world experienced the emergence of a new virus, SARS-CoV-2, which caused the 2020 pandemic. SARS-CoV-2 causes COVID-19, primarily affecting the respiratory system, as well as the gastrointestinal tract. Remarkably, one in eight COVID-19 patients develops Long COVID, which is linked to SARS-CoV-2 persistence in the gastrointestinal tract, resulting in chronic inflammation and microbiota dysregulation. Given that gut microbiota dysbiosis plays a pivotal role in antiviral defense and gastrointestinal conditions, here we examine emerging evidence on how persistent SARS-CoV-2 infection may contribute to the aetiology of enteric disorders. In particular, we emphasise the intricate connection between chronic inflammation caused by persistent SARS-CoV-2 infection (e.g., irritable bowel syndrome and inflammatory bowel disease) and the possible development of diseases such as Crohn's disease and ulcerative colitis.},
}
@article {pmid41754983,
year = {2026},
author = {Anaya, BJ and Osorio-Vargas, E and Monterrosa-Moreno, S and Tirado, DF and González-Burgos, E and Serrano, DR},
title = {Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.},
journal = {Pharmaceutics},
volume = {18},
number = {2},
pages = {},
pmid = {41754983},
issn = {1999-4923},
support = {PID2024-156769OB-I00//Ministerio de Ciencia, Innovaci&#xf3;n y Universidades/ ; 971089//universidad complutense de Madrid/ ; Call No. 885 of 2020//Ministerio de Ciencia, Tecnolog&#xed;a e Innovaci&#xf3;n/ ; },
abstract = {Pulmonary drug delivery has emerged as a powerful strategy for the treatment of respiratory infectious diseases, including bacterial, fungal, and viral infections such as influenza and COVID-19, by enabling high local drug concentrations while minimizing systemic exposure. However, the clinical success of inhaled anti-infective therapies critically depends on the precise engineering of particle properties that govern lung deposition, cellular targeting, and therapeutic efficacy. In this review, we provide a comprehensive and technology-driven overview of cutting-edge formulation and manufacturing strategies for pulmonary drug delivery, with particular emphasis on the key process and formulation parameters required to generate effective inhalable systems for the treatment of infectious diseases. Advanced particle-engineering approaches, including spray drying, spray freeze drying, jet milling, and supercritical fluid technologies are discussed as enabling tools to tightly control aerodynamic particle size, morphology, and solid-state properties. In parallel, emerging platforms such as nanoparticle-based delivery systems are examined for their ability to target specific lung cell populations, including epithelial cells and alveolar macrophages, thereby enhancing antimicrobial efficacy. Finally, innovative manufacturing concepts such as microfluidics and three-dimensional (3D) printing are highlighted as promising strategies to improve particle size uniformity, reproducibility, and formulation customization. By integrating formulation science with advanced manufacturing technologies, this review identifies the critical design and processing parameters that underpin effective pulmonary delivery of anti-infective therapies and outlines future directions for the development of next-generation inhaled treatments.},
}
@article {pmid41755466,
year = {2026},
author = {Zang, N and Wu, Y and Li, P and Liu, Y and Wang, S and Leng, J and Zhan, L and Lyu, X and Pang, L and Wang, J},
title = {Viral Pathogens and Pulmonary Fibrosis: EMT-Driven Mechanisms and Insights From Traditional Chinese Medicine.},
journal = {Reviews in medical virology},
volume = {36},
number = {2},
pages = {e70118},
pmid = {41755466},
issn = {1099-1654},
mesh = {Humans ; *Epithelial-Mesenchymal Transition/drug effects ; *Medicine, Chinese Traditional ; Signal Transduction/drug effects ; *Idiopathic Pulmonary Fibrosis/virology/drug therapy/pathology ; SARS-CoV-2/pathogenicity/drug effects ; Animals ; COVID-19/virology/complications ; *Virus Diseases/virology/drug therapy/complications ; *Pulmonary Fibrosis/virology/drug therapy ; },
abstract = {Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial-mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long-lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re-emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT-linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF-β, Wnt/β-catenin, PI3K/AKT, and NF-κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross-talk between viral pathogens, particularly SARS-CoV-2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM-derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus-related EMT dysregulation.},
}
@article {pmid41755747,
year = {2026},
author = {Zuccotti, G and Sassi, R and Vertemati, M and Calcaterra, V},
title = {Advances in pediatrics: new technologies in clinical practice.},
journal = {La Pediatria medica e chirurgica : Medical and surgical pediatrics},
volume = {48},
number = {1},
pages = {},
doi = {10.4081/pmc.2026.380},
pmid = {41755747},
issn = {2420-7748},
mesh = {Humans ; *Pediatrics/trends/methods ; *Telemedicine/trends ; *COVID-19/epidemiology ; Digital Health ; Artificial Intelligence ; Child ; },
abstract = {Over the past decades, digital innovation has profoundly transformed pediatric care, promoting more integrated, personalized, and continuous models of assistance across hospital, community, and home settings. This contribution explores the impact of three key technological domains: telemedicine, virtual and augmented reality, and artificial intelligence. Telemedicine has expanded access to healthcare services, improved monitoring of chronic conditions, and strengthened communication between healthcare professionals and families. Its rapid development during the COVID-19 pandemic demonstrated its value in ensuring continuity of care and supporting vulnerable pediatric populations. Virtual and augmented reality offer new possibilities in surgical planning, medical training, rehabilitation, and psychological support, helping reduce anxiety and pain during procedures while enhancing understanding of clinical pathways. Artificial intelligence enables the analysis of large volumes of clinical and behavioral data, supporting early diagnosis, predictive modeling, and personalized clinical decision-making. Despite these opportunities, the integration of emerging technologies into pediatric practice requires careful attention to ethical, organizational, and educational issues, including data security, equitable access, and professional training. Overall, digital technologies are reshaping pediatrics toward more accessible, efficient, family-centered care.},
}
@article {pmid41756288,
year = {2026},
author = {Guan, C and Zhang, R and Zhao, P and Zhang, Y and Yu, L and Cui, H and Jiang, L and Wu, T and Liu, F and Wu, Y and Huang, L and Nan, H and Wang, J and Xu, P},
title = {Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1739730},
pmid = {41756288},
issn = {1664-3224},
mesh = {Humans ; *Myasthenia Gravis/immunology/epidemiology ; *Vaccination/adverse effects ; *COVID-19/prevention &amp; control/immunology ; *COVID-19 Vaccines/immunology/adverse effects ; *SARS-CoV-2/immunology ; Vaccine Efficacy ; },
abstract = {BACKGROUND: Myasthenia gravis (MG) is a rare autoimmune disorder characterized by fluctuating muscle weakness due to impaired neuromuscular transmission. Vaccination remains a cornerstone of infectious disease prevention, yet concerns persist regarding potential autoimmune exacerbation in susceptible individuals. This systematic review and meta-analysis aimed to synthesize available evidence on the association between vaccination and MG, evaluating both vaccine effectiveness and safety in this population.<br><br>METHODS: Observational studies in cohort or case-control formats were identified through systematic searches of PubMed, Web of Science, Embase, Cochrane Library, SinoMed, CNKI, Wanfang, and VIP databases from inception to June 24, 2025. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models based on heterogeneity. Publication bias was assessed using funnel plots and Egger's test.<br><br>RESULTS: Five studies encompassing 27,193 participants (22,618 vaccinated and 4,575 unvaccinated) met inclusion criteria. Meta-analysis demonstrated a significant protective effect of vaccination against COVID-19 infection (fixed-effects model: OR = 0.23, 95% CI [0.20-0.26], P < 0.001). Conversely, vaccination was not associated with a statistically significant increase in MG exacerbation (random-effects model: OR = 0.67, 95% CI [0.10-4.54], P = 0.68).<br><br>CONCLUSIONS: This study provides quantitative evidence that COVID-19 vaccination effectively reduces infection risk without significantly increasing MG exacerbation. These findings support the safety and clinical utility of vaccination in MG patients, emphasizing the need for individualized risk-benefit assessment and ongoing pharmacovigilance in this population.<br><br>https://www.crd.york.ac.uk/prospero/, identifier CRD420251078995.},
}
@article {pmid41756780,
year = {2026},
author = {Ferriero, AM and Di Lella, R and Farroni, C and Aiello, A and Giarratano, A and Todaro, M and Bocci, MG and Nicastri, E and Goletti, D},
title = {Host-pathogen interaction in community-acquired pneumonia: a focus on the immune response.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {1731074},
pmid = {41756780},
issn = {2235-2988},
mesh = {Humans ; *Community-Acquired Pneumonia/immunology/microbiology/epidemiology/diagnosis/virology ; Adaptive Immunity ; *Host-Pathogen Interactions/immunology ; Immunity, Innate ; *Pneumonia, Viral/immunology/epidemiology ; *Pneumonia, Bacterial/immunology/microbiology ; Streptococcus pneumoniae/pathogenicity/immunology ; SARS-CoV-2 ; *Community-Acquired Infections/immunology ; },
abstract = {Community-acquired pneumonia (CAP) remains one of the leading causes of morbidity and mortality worldwide, affecting individuals of all ages. Various pathogens can cause this condition, and growing antibiotic resistance makes treatment more difficult while raising the risk of severe outcomes. Despite substantial advances in diagnostics, antimicrobial therapy, and supportive care, CAP continues to represent a significant clinical and public health challenge. In this review, we provide a comprehensive overview of CAP, summarizing key aspects of its epidemiology, pathogen frequency, and recent progress in diagnostic tools and biomarkers. We also describe the innate and adaptive immune responses involved in CAP, with a particular focus on pneumonia caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, and Influenza A and B viruses. A deeper understanding of CAP immunopathogenesis may support the development of improved diagnostic and therapeutic approaches for pneumonia management.},
}
@article {pmid41757222,
year = {2026},
author = {Ravinetto, R and Bottieau, E and Fusco, D and Marrone, R and Van Den Broucke, S and Tarrafeta-Sayas, MB and Rinaldi, L and Losada-Galván, I and Calleri, G and Albonico, M},
title = {Inequitable access to medicines for neglected tropical diseases in Europe: health system vulnerabilities and a call for coordinated action.},
journal = {The Lancet regional health. Europe},
volume = {63},
number = {},
pages = {101616},
pmid = {41757222},
issn = {2666-7762},
abstract = {The COVID-19 pandemic has exposed the vulnerability of the European medicine supply systems, but the lack of access to medicines for diseases of poverty, including neglected tropical diseases (NTDs), is unfrequently brought to the attention of the European policy makers. As a result, clinicians in Europe are forced to "bricolage solutions" to treat NTDs: ad hoc donations from companies, product-specific donations via the World Health Organization (WHO) or WHO collaborating centres, case-by-case importation -sometimes from poorly regulated countries-, and possibly the recourse to compounding pharmacies. Noteworthy, NTDs are unlikely to decrease in the next years in Europe, due to increasing global mobility, and climate change expanding the parasites' habitat. This serious but neglected problem was discussed at the 2025 European Congress in Tropical Medicine and International Health (ECTMIH) in Hamburg, Germany. This viewpoint analyses the availability, affordability and accessibility challenges in some countries in Europe, and their consequences at patient and health system level. It also proposes a set of interconnected recommendations and policy measures to make quality-assured medicines for NTDs sustainably available and affordable across Europe. Restoring access to these essential and sometimes life-saving medicines is critical for restoring the right to health for all in Europe, while protecting continental public health.},
}
@article {pmid41758633,
year = {2026},
author = {Marefat, M and Tran, D and Watson, RM and Abdulghani, H and Fortino, M},
title = {A practical model for integrated temporomandibular disorder assessment in the routine oral examination.},
journal = {General dentistry},
volume = {74},
number = {2},
pages = {57-61},
pmid = {41758633},
issn = {0363-6771},
mesh = {Humans ; Facial Pain/diagnosis/etiology ; Physical Examination ; *Temporomandibular Joint Disorders/complications/diagnosis ; },
abstract = {The COVID-19 era has seen an increase in orofacial pain related to temporomandibular disorders (TMDs). The increased relevance and awareness of these conditions, including the enactment of accreditation standards dictating the inclusion of TMD education in dental school curricula, highlights the need for a simplified TMD screening and evaluation model. A literature review was conducted to establish whether a widely accepted, comprehensive, and clinically practical approach to screening and evaluation for TMDs during routine oral examination was available. Previous studies and available medical and dental history forms were reviewed. While medical and dental history forms currently available to practitioners contain TMD-related questions, they are presented in a nonsequential, sporadic manner that may not lead to intuitive diagnosis from the dental practitioner. This article introduces a proposed model and questionnaire for incorporating TMD examinations into routine examinations. The inclusion of a more practical TMD screening and evaluation model in routine examination is intended to facilitate the dentist's identification and assessment of TMD signs and symptoms, leading to a more targeted approach in diagnosis and referral. This proposed model has not yet been validated clinically; the next steps include further development, implementation within a clinical setting, and evaluation of its effectiveness.},
}
@article {pmid41758637,
year = {2026},
author = {Kozdrowicki, M and Szczepaniak, P and Kyslyi, V and Carnevale, L and Carnevale, D and Lembo, G and Guzik, TJ and Mikołajczyk, TP},
title = {The impact of inflammation, neuromodulation, and gut microbiota on developing cardiac fibrosis and hypertension.},
journal = {Cardiovascular research},
volume = {122},
number = {6},
pages = {681-706},
pmid = {41758637},
issn = {1755-3245},
support = {ERA-CVD/NEMO/7/2019//Polish National Centre for Research and Development/ ; ERA-CVD/Gut-brain/8/2021//Polish National Centre for Research and Development/ ; ERA-CVD/JTC2020/25/ImmuneHyper/Cog/2022//Polish National Centre for Research and Development/ ; //Ministry of Health/ ; },
mesh = {Humans ; *Hypertension/physiopathology/metabolism/immunology/microbiology/therapy ; Animals ; Fibrosis ; *Myocardium/pathology/metabolism/immunology ; *Gastrointestinal Microbiome ; *Inflammation Mediators/metabolism ; Signal Transduction ; *Blood Pressure ; *Inflammation/physiopathology/metabolism ; *Heart Failure/physiopathology/pathology/metabolism ; Epigenesis, Genetic ; },
abstract = {Cardiovascular diseases (CVD) are the leading cause of premature mortality worldwide. Due to pressure overload and cardiac fibrosis, CVD often begin with hypertension and gradually progress to heart failure. Cardiac fibrosis reduces the number of functional cardiomyocytes and the force of contraction while increasing oxygen demand. It has been noted that myofibroblasts, which produce excessive amounts of extracellular matrix in the failing heart, express specific proteins such as periostin, tenascin C, thrombospondin, and osteopontin. Their activation involves immune cells that have a well-documented effect on the pathogenesis of hypertension. Moreover, dysregulation of the autonomic nervous system and sympathetic hyperactivity heightens peripheral inflammation and fosters fibrosis. In this review, we outline and summarize the most significant and recent findings concerning the molecular pathways of immune activation, neuromodulation, epigenetic modifications, and the impact of gut microbiota on myofibroblast activation and fibrosis in the heart, as well as potential therapeutic options (e.g. experimental anti-inflammatory treatments, epigenetic modulators, and vagus nerve stimulation). We will also highlight how current heart failure treatments, including renin-angiotensin-aldosterone system (RAA) inhibitors, β-adrenergic receptor (β-AR) antagonists, sodium-glucose co-transporter 2 (SGLT2) inhibitors, the Dietary Approaches to Stop Hypertension (DASH), and the Mediterranean diet, affect these processes at a molecular level. A comprehensive understanding of the neuroimmune mechanisms involved in the pathogenesis of heart failure and hypertension is particularly crucial in light of the increased risk of CVD following the COVID-19 pandemic, which resulted from the 'cytokine storm' during SARS-CoV-2 infection.},
}
@article {pmid41758742,
year = {2025},
author = {Al-Talhi, AA and AlRajhi, B and Almalki, AHS and Alqazenli, M and AlGhamdi, MA and Munhish, FA and Sumaily, I},
title = {Effectiveness of Intranasal Insulin for the Treatment of Olfactory Dysfunction: A Systematic Review.},
journal = {ORL; journal for oto-rhino-laryngology and its related specialties},
volume = {87},
number = {5-6},
pages = {197-207},
doi = {10.1159/000550990},
pmid = {41758742},
issn = {1423-0275},
mesh = {Humans ; Administration, Intranasal ; *Olfaction Disorders/drug therapy ; *Insulin/administration &amp; dosage ; *Hypoglycemic Agents/administration &amp; dosage ; Treatment Outcome ; Female ; },
abstract = {INTRODUCTION: The aim of the study was to assess the effectiveness and safety of intranasal insulin (INI) for the treatment of olfactory dysfunction (OD) in patients with anosmia and/or hyposmia compared to placebo or no treatment.<br><br>METHODS: We searched four databases: Medline, Scopus, Directory of Open Access Journals (DOAJ), and Springer Nature. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42023456891). The protocol design was in accordance with the PRISMA. Participants with hyposmia or anosmia aged &#x2265;18 years were included. Patients with an altered sense of smell due to anatomical malformations, trauma, neurodegenerative diseases, surgery, or intranasal lesions were excluded from the study.<br><br>RESULTS: Five studies with 131 participants were included. There were 131 participants, of whom 63 were men and 68 were women. The participants' ages ranged from 16 to 56 years. Almost all studies used a dose of 40 IU, except one that used different doses for different participants. Glycemic assessment was performed in three studies, which showed a very slight decrease in glucose, except in one study in which the drop in glucose reached 10.4 mg/dL. All studies agreed that olfactory function improved after INI administration.<br><br>CONCLUSION: This systematic review concluded that INI can be an effective treatment option for patients with OD. However, further well-designed clinical trials are required to establish robust clinical recommendations.},
}
@article {pmid41759027,
year = {2026},
author = {Hussein, R and Shafiai, N and Fakrurrozi, A and Sabbagh, J},
title = {The impact of COVID-19 on dental practice and care: Adapting to unprecedented times.},
journal = {Wiadomosci lekarskie (Warsaw, Poland : 1960)},
volume = {79},
number = {1},
pages = {223-231},
doi = {10.36740/WLek/216768},
pmid = {41759027},
issn = {0043-5147},
mesh = {Humans ; *COVID-19 ; Pandemics ; *Dental Care ; SARS-CoV-2 ; Dentist-Patient Relations ; Telemedicine ; },
abstract = {OBJECTIVE: Aim: This review aims to shed light on the ways dental practices and patient care strategies have evolved in response to the pandemic. It also investigates how patients' perspectives and dentist-patient dynamics have shifted, highlighting lessons for the future of dental healthcare systems.<br><br>PATIENTS AND METHODS: Materials and methods: The study is based on a comprehensive analysis of previously published research articles and clinical reports on how dental practitioners adapted their practices during the COVID-19 pandemic. It includes qualitative and quantitative data reflecting both professional and patient experiences. The pandemic led to the rapid adoption of new technologies, heightened hygiene protocols, and increased mental health burdens on both patients and practitioners. Tele-dentistry, limited in-person visits, and stricter sterilization practices became the norm. Patients expressed both fear and appreciation for enhanced safety, altering their expectations of dental care, resilience and adaptability in dental settings.<br><br>CONCLUSION: Conclusions The lessons learned from COVID-19 experience underline the importance of incorporating dentistry into broader public health strategies. Moving forward, there is a need to invest in innovative technologies, uphold rigorous hygiene standards, and provide mental workers and patients. These steps are essential to prepare for future health emergencies and ensure the sustainability of dental care delivery.},
}
@article {pmid41759616,
year = {2026},
author = {Girndt, M},
title = {Vaccinations to Prevent Infections in Adult Individuals With CKD and After Kidney Transplantation: A Review.},
journal = {American journal of kidney diseases : the official journal of the National Kidney Foundation},
volume = {87},
number = {6},
pages = {841-851},
doi = {10.1053/j.ajkd.2025.10.021},
pmid = {41759616},
issn = {1523-6838},
mesh = {Humans ; *Kidney Transplantation/adverse effects ; *Vaccination/methods ; *Renal Insufficiency, Chronic/immunology/surgery/complications/therapy ; Adult ; Influenza, Human/prevention &amp; control ; Immunosuppressive Agents ; Influenza Vaccines ; Respiratory Syncytial Virus Infections/prevention &amp; control ; },
abstract = {Patients with chronic kidney disease (CKD), especially those undergoing dialysis, are at high risk of infections that lead to hospitalizations, morbidity, and mortality. Influenza, pneumococcal pneumonia, and respiratory syncytial virus infections account for a significant proportion of typical infectious complications and are preventable by vaccination. The immune system is weakened in CKD, reducing vaccination efficacy. Additionally, some patients with CKD receive immunosuppressive medications. The reduced seroreactivity to various vaccines must be considered when selecting vaccines, vaccine doses, and schedules for patients with CKD. Vaccinations are generally safe in CKD and should be widely used in accordance with public health recommendations to reduce morbidity. Immunosuppression after kidney transplant further impairs vaccination responses. Nevertheless, vaccinations can still be effective and provide protection in a relevant number of patients. Patients who have received transplants should generally not receive live vaccines because of the risk of vaccine-induced complications. Vaccination is usually recommended 6 months after transplant, when immunosuppression is less intense than in the early months. This approach may conflict with seasonal vaccinations, which are often omitted. Data show that at least the influenza vaccination can be administered as early as 4 weeks after transplant without additional risk. In all patients with CKD or posttransplant status, omitting recommended vaccinations is a missed opportunity to prevent relevant infectious complications.},
}
@article {pmid41760558,
year = {2026},
author = {Laudani, C and Bujak, K and Occhipinti, G and Rinaldi, R and Imbesi, A and Sanchez, JS and Galli, M and Abbate, A and Ortega-Paz, L and Capodanno, D and Angiolillo, DJ},
title = {Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta-Analysis of 20 Randomized Trials.},
journal = {Clinical pharmacology and therapeutics},
volume = {119},
number = {6},
pages = {1431-1439},
doi = {10.1002/cpt.70246},
pmid = {41760558},
issn = {1532-6535},
mesh = {Humans ; *Colchicine/adverse effects/therapeutic use ; Randomized Controlled Trials as Topic ; *Coronary Artery Disease/drug therapy/mortality/diagnosis ; Treatment Outcome ; },
abstract = {Recent evidence questioned the overall safety and efficacy of colchicine in patients with coronary artery disease (CAD), as novel evidence focusing on acute coronary syndromes (ACSs) gave neutral results, while trials focusing on chronic coronary syndrome supported colchicine administration to improve long-term outcomes. However, no study has ever explored whether there is a true therapeutic difference across the populations or these discrepancies are due to additional confounders. Against this background, we performed a systematic review and meta-analysis of randomized trials of colchicine in patients with CAD. The primary endpoints were trial-defined major adverse cardiovascular events (MACE) and serious adverse events (SAEs). Secondary endpoints included all-cause death, measures of ischemia (cardiovascular death, myocardial infarction [MI], any revascularization, stroke) and measures of safety (serious infections or sepsis and gastrointestinal adverse events). All analyses included an interaction term for the clinical presentation. Sensitivity analyses were performed to explore sources of heterogeneity. After literature search, 20 trials encompassing a total of 21,486 patients (65.4% ACS) were included. Colchicine significantly reduced MACE (incidence rate ratio [IRR]: 0.70; 95% CI 0.55-0.87) without increasing risk for SAEs. Colchicine also reduced MI (IRR 0.81; 95% CI 0.70-0.94) and any revascularization (IRR 0.71; 95% CI 0.51-0.99), while increasing the risk of gastrointestinal adverse events (IRR 1.68; 95% CI 1.23-2.28). No statistically significant interaction was noted for clinical presentation for any endpoint, but a significant interaction for the drug dosage administered and the relationship with the COVID-19 pandemic was noted. In conclusion, the use of colchicine in patients with CAD reduces MACE without significantly increasing SAEs compared to control, although increasing gastrointestinal adverse events, without interaction by clinical presentation.},
}
@article {pmid41761197,
year = {2026},
author = {Yu, E and Wang, M and Berdugo, J and Towheed, S and Yang, J and Moosavi, I and Lalji-Mawji, S and Czapla, CS and Ostermeyer, BK and Olagunju, AT},
title = {Mental health issues and associated factors amongst healthcare workers in US forensic-correctional settings: a systematic review of literature since the COVID-19 pandemic.},
journal = {BMC health services research},
volume = {26},
number = {1},
pages = {},
pmid = {41761197},
issn = {1472-6963},
mesh = {Humans ; *COVID-19/epidemiology/psychology ; United States/epidemiology ; *Health Personnel/psychology ; *Mental Health ; Risk Factors ; *Mental Disorders/epidemiology ; SARS-CoV-2 ; Frontline Workers ; Working Conditions ; Pandemics ; *Prisons ; Female ; },
abstract = {BACKGROUND: Healthcare professionals provide essential services to populations in the criminal justice system, often at the expense of their own well-being. This review synthesized literature findings on mental health challenges faced by healthcare professionals working in the US forensic-correctional settings since the COVID-19 pandemic. We investigated the prevalence of mental health conditions, their risk-protective factors, the impacts of these mental health issues on workplace retention, and highlighted relevant recommendations.<br><br>METHODS: This study followed PRISMA guidelines. A comprehensive search of major databases (PubMed/MEDLINE, PsycINFO, Web of Science, CINAHL, and Embase) was conducted and supplemented with citation chaining to identify eligible reports spanning January 1st 2020 up to March 18th, 2025. Article screening, full-text review, and data extraction were completed by two independent investigators. Study quality was assessed using the NIH tool for quantitative studies and the Critical Appraisal Skills Program (CASP) framework for qualitative studies.<br><br>RESULTS: A total of 10,005 identified reports were screened, with seven fair-to-good eligible studies included in the final review. Both quantitative (n&#x2009;=&#x2009;4) and qualitative (n&#x2009;=&#x2009;3) studies were included, and spanned multiple states, with most studies (n&#x2009;=&#x2009;3, 42.9%) conducted in California. Healthcare workers reported various mental health conditions such as depression (48%), anxiety (18.8-51.1%), sleep disorders (17.4%), burnout (47.2%) and PTSD (49.3%), albeit significant heterogeneity constrains comparative analysis. Qualitatively, workers experienced considerable isolation, personality shifts, and cognitive dissonance. Risk factors predictive of mental health conditions included increased workload (&#x3b2;&#x2009;=&#x2009;0.18, p&#x2009;<&#x2009;0.001), workplace conflict (&#x3b2;&#x2009;=&#x2009;0.15, p&#x2009;<&#x2009;0.001), female sex (&#x3b2;&#x2009;=&#x2009;0.10, p&#x2009;=&#x2009;0.04), younger age, chronic medical conditions (&#x3b2;&#x2009;=&#x2009;0.09, p&#x2009;=&#x2009;0.03), fears around COVID-19 (&#x3b2;&#x2009;=&#x2009;0.14, p&#x2009;<&#x2009;0.001), and a lack of pandemic safety training (p&#x2009;=&#x2009;0.033). Protective factors included resilience, administrator and peer support, access to needed resources, and a sense of fulfilment and purpose from working with populations in forensic-correctional settings.<br><br>CONCLUSIONS: Systemic reforms including decreased mandatory overtime, staffing, workload distribution, organizational support, training, improved communication, access to adequate resources and psychosocial interventions may help promote wellness and optimize the ability of healthcare workers to provide care in forensic-correctional settings. However, the preliminary nature of the study findings suggests caution in their interpretations. Further high-quality research is needed to support evidence-informed decision-making and translation.},
}
@article {pmid41761217,
year = {2026},
author = {Lim, O and Ling, RR and Mak, V and Lim, SL and Ramanathan, K and Orosz, J and Pound, G and Jones, D and Subramaniam, A},
title = {Prevalence and outcomes of in-hospital cardiac arrest in the intensive care unit: a systematic review and meta-analysis.},
journal = {Critical care (London, England)},
volume = {30},
number = {1},
pages = {},
pmid = {41761217},
issn = {1466-609X},
mesh = {Humans ; *Intensive Care Units/statistics &amp; numerical data/organization &amp; administration ; *Heart Arrest/epidemiology/mortality ; Prevalence ; Hospital Mortality ; COVID-19/epidemiology/complications ; Critical Illness ; },
abstract = {BACKGROUND: Cardiac arrest in the intensive care unit (ICU-CA) is distinct from other in-hospital cardiac arrests, involving critically ill patients in monitored settings. Its prevalence and outcomes remain unclear. This systematic review and meta-analysis aimed to fill this evidence gap and identify areas for future research to improve outcomes in this patient population. METHODS: We searched MEDLINE, Embase and Scopus databases from inception until 26 November 2025 for studies reporting on ICU-CA in adults. We performed random effects meta-analyses with the generalised linear mixed model. We used the Joanna Briggs Institute Checklist to assess risk of bias and the GRADE approach to assess the certainty of evidence. The primary outcome was the prevalence of patients with ICU-CA; secondary outcomes included ICU and in-hospital mortality. We performed subgroup analyses based on geographical region (continent), study source (registry vs. non-registry), and COVID-19 status (infected vs. non-infected). RESULTS: We included 35 observational studies including 36 cohorts in the meta-analysis. The pooled proportion of ICU-CA was 3.23% (95% CI: 2.08–4.98, moderate certainty). The proportion of ICU-CA was significantly higher (p < 0.001) in patients with COVID-19 (10.6%, 95%-CI: 5.4–19.7) compared with non-COVID-19 cohorts (2.3%, 95%-CI: 1.5–3.5). Pooled ICU mortality was 74.0% (95%-CI: 63.7–82.1, moderate certainty) and in-hospital mortality was 82.0% (95%-CI: 75.9–86.9, high certainty). Meta-regression found that proportion of shockable rhythm was inversely associated with ICU mortality, but not in-hospital mortality. CONCLUSION: Cardiac arrest in the ICU was associated with poor survival, with a higher prevalence in patients with COVID-19. Future studies should focus on peri-arrest characteristics to guide prognostication and management of individuals who experience ICU-CA.},
}
@article {pmid41761653,
year = {2026},
author = {Gavor, E and Choong, YK and Singh, S and Sivaraman, H and Yin, ES and Sivaraman, J},
title = {Structural Basis of MERS-CoV Receptor Interactions and Antibody Neutralisations.},
journal = {Reviews in medical virology},
volume = {36},
number = {2},
pages = {e70113},
pmid = {41761653},
issn = {1099-1654},
support = {//J.S. acknowledges partial support from Ministry of Education, Singapore grants R154-000-A72114, R-154-000-B03-112, and R-154-000-697-112./ ; },
mesh = {*Middle East Respiratory Syndrome Coronavirus/immunology/genetics/chemistry ; Humans ; *Antibodies, Neutralizing/immunology ; *Antibodies, Viral/immunology ; *Coronavirus Infections/virology/immunology/prevention &amp; control ; Animals ; *Receptors, Virus/chemistry/metabolism/immunology ; *Spike Glycoprotein, Coronavirus/immunology/chemistry/genetics/metabolism ; },
abstract = {Increasing outbreaks of coronaviruses underscore the importance of antivirals and vaccines that can combat a wide range of coronaviruses. Neutralising antibodies (nAbs), along with vaccines and small-molecule drugs, are among the most promising treatments and prevention options against coronaviruses. Here, we focus on Middle East Respiratory Syndrome coronavirus (MERS-CoV) and discuss receptor usage and current progress in antibody research against MERS-CoV infections. First detected in Saudi Arabia and Jordan in 2012, MERS-CoV is a lethal zoonotic pathogen. MERS-CoV infections have been reported by 27 countries between April 2012 till now, with 953 deaths (∼35% mortality) (5 new infections and 4 fatalities reported as of 1 October 2024). WHO identified MERS-CoV as a high-threat pathogen due to its severity, high mortality rate, and potential for epidemic or pandemic spread with recent outbreaks and deaths raising more concerns amidst the COVID-19 pandemic. As of now, there is no antiviral drugs or vaccine against MERS-CoV available. Here we provide a perspective on receptor usage, the risk of MERS-CoV and other CoVs evolution on future pandemics, and the mechanisms of MERS-CoV-derived nAbs. We offer insight into how these antibodies cross-react and cross-neutralise by analysing available structures of spike glycoprotein-antibody complexes. This review provides an update and a basis for the development of antibodies and vaccines for MERS-CoV, and possibly for the designing of next-generation pan-coronavirus vaccines and antivirals.},
}
@article {pmid41761906,
year = {2026},
author = {Morand-Grondin, D and Berthod, J and Sigouin, J and Beaulieu-Bonneau, S and Kairy, D},
title = {Paving the road for more ethical and equitable policies and practices in telerehabilitation in psychology and neuropsychology: A rapid review.},
journal = {Health informatics journal},
volume = {32},
number = {1},
pages = {14604582261431026},
doi = {10.1177/14604582261431026},
pmid = {41761906},
issn = {1741-2811},
mesh = {Humans ; *Neuropsychology/methods/ethics ; *Telerehabilitation/ethics ; COVID-19/epidemiology ; Telemedicine/ethics ; *Psychology ; SARS-CoV-2 ; Canada ; },
abstract = {BackgroundTelerehabilitation (TR) has been increasingly used to deliver psychological and neuropsychological care remotely, especially since the COVID-19 pandemic. As health services continue to shift toward telehealth, ensuring ethical and equitable TR delivery is essential to establish sustainable TR models.ObjectiveThe objective of this review is to synthesize existing evidence on the ethical and equity-related benefits and pitfalls associated with the use of TR in a psychological and neuropsychological context for individuals with physical disabilities.MethodsThis rapid review included reviews (2010-2020) and original studies (2020-2023) that focused on TR interventions for people with physical disabilities in the context of psychology and neuropsychology rehabilitation.ResultsA total of 16 reviews and 82 original articles were included. Key ethical concerns centered around privacy, confidentiality, caregiver burden, and clinician-patient relationship quality. Equity concerns centered around access disparities (e.g., geographic location, income), digital literacy, and demographic underrepresentation.ConclusionThis review is part of a pan-Canadian initiative aimed at informing policy development and clinical practice in TR. Findings highlight the need for clear guidelines and targeted interventions to ensure that TR in psychology and neuropsychology is both ethically sound and equitable.},
}
@article {pmid41762078,
year = {2026},
author = {Wimalasundera, MO and Mohammad, ZMW and Choudhury, S and Mandour, Y},
title = {Understanding E-Consent in Anaesthesia: A Review of Clinical, Legal, and Ethical Dimensions.},
journal = {British journal of hospital medicine (London, England : 2005)},
volume = {87},
number = {2},
pages = {50953},
doi = {10.31083/BJHM50953},
pmid = {41762078},
issn = {1759-7390},
mesh = {Humans ; *Informed Consent/legislation &amp; jurisprudence/ethics ; *COVID-19/epidemiology ; *Anesthesia ; *Anesthesiology/legislation &amp; jurisprudence/ethics ; SARS-CoV-2 ; },
abstract = {The integration of electronic consent (e-consent) into anaesthetic practice has accelerated since the Coronavirus Disease 2019 (COVID-19) pandemic, offering new opportunities to enhance patient autonomy, documentation fidelity, and clinical efficiency. This review examines the clinical, legal, and ethical dimensions of e-consent, situating it within the statutory and common law frameworks, such as the Mental Capacity Act 2005 and the principles established in Montgomery v Lanarkshire Health Board. It further interrogates the challenges posed by digital exclusion, cybersecurity vulnerabilities, and the environmental implications of transitioning to digital platforms. The emerging role of artificial intelligence in tailoring and strengthening consent processes is explored, while highlighting the imperative to preserve ethical integrity and legal validity.},
}
@article {pmid41762443,
year = {2026},
author = {Balakrishnar, K and Long, BS and Lo, J and Fiorini, LA and Gohar, B and Nowrouzi-Kia, B},
title = {Assessing the antecedents behind after-hours work in teleworkers: a scoping review.},
journal = {Journal of public health (Oxford, England)},
volume = {48},
number = {2},
pages = {582-593},
pmid = {41762443},
issn = {1741-3850},
mesh = {Humans ; *Teleworking/statistics &amp; numerical data ; *COVID-19/epidemiology ; Working Conditions ; Work Schedule Tolerance ; },
abstract = {BACKGROUND: Since the start of the COVID-19 pandemic, telework arrangements have become increasingly prevalent, driven by benefits such as greater autonomy, reduced work-related stress, decreased commuting time and cost, and enhanced flexibility. Despite these advantages, teleworkers are more likely to engage in after-hours work, creating additional strain that may impact health and organizational outcomes.<br><br>METHODS: A systematic search was conducted across seven online databases: Medline via OVID, Embase via OVID, APA PsycINFO via OVID, International Bibliography of Social Sciences via ProQuest, Sociological Abstracts via ProQuest, Business Source Premier via EBSCOhost, and CINAHL via EBSCOhost. Studies were included if they were empirical, peer-reviewed, published between 2010 and 2024, examined the antecedents of after-hours work, and focused on adults aged 18 to 65 engaged in telework. Descriptive thematic analysis was conducted to develop themes and sub-themes.<br><br>RESULTS: Findings: A total of 17 studies were included in the review: 13 cross-sectional studies, three qualitative studies, and one longitudinal study. Using the Person-Environment-Occupation framework, three overarching themes were identified: (i) misalignment between personal capacities and occupational demands; (ii) environmental constraints that undermine healthy role balance; and (iii) occupational role strain in the context of remote work.<br><br>CONCLUSIONS: These findings may help to inform the development of targeted interventions that reduce cases of after-hours work among teleworkers and promote their overall health and well-being. Future research should examine these antecedents in non-Western contexts and explore the interplay between the individual, environmental, and occupational factors shaping after-hours work behaviors.},
}
@article {pmid41762542,
year = {2026},
author = {Sagués, T and Ferrer, A and Delgado, JF and Julià, G and Rodríguez-González, R and Ruiz, &#xc0; and Estrada, F and Soria, V and Palao, DJ and Labad, J and Montalvo, I},
title = {Clozapine use and COVID-19 risk: A systematic review, meta-analysis, and retrospective cohort evidence.},
journal = {Psychiatry research},
volume = {359},
number = {},
pages = {117040},
doi = {10.1016/j.psychres.2026.117040},
pmid = {41762542},
issn = {1872-7123},
mesh = {Humans ; *Clozapine/adverse effects/therapeutic use ; *Antipsychotic Agents/adverse effects/therapeutic use ; *COVID-19/epidemiology ; Retrospective Studies ; *Schizophrenia, Treatment-Resistant/drug therapy ; Severity of Illness Index ; },
abstract = {BACKGROUND: Clozapine's immune-modulating effects, including neutropenia and suppression of adaptive immunity, have raised concerns about its potential impact on SARS-CoV-2 infection risk and COVID-19 severity in individuals with treatment-resistant schizophrenia. Findings in the literature remain inconsistent.<br><br>METHODS: First, we conducted a longitudinal retrospective study in which we analysed 995 outpatients with severe mental disorders receiving antipsychotic treatment to assess the association between clozapine use and SARS-CoV-2 infection and disease severity. Secondly, we performed a systematic review of the literature and searched for studies published up to July 2025 examining the link between clozapine exposure and SARS-CoV-2 infection. Eight cohort studies plus our dataset were meta-analysed using a random-effects model.<br><br>RESULTS: In our cohort, clozapine users demonstrated a higher rate of SARS-CoV-2 infection (18% vs. 10%, p < 0.001) and increased COVID-19 severity compared to non-users. The meta-analysis comprised 155,945 participants, with individual study ORs ranging from 0.40 to 2.80. The pooled random-effects OR was 1.53 (95% CI: 1.02-2.30, p = 0.044), indicating a significant association between clozapine exposure and increased infection risk. However, high heterogeneity (I&#xb2; = 91.2%) suggests variation in effects across studies.<br><br>CONCLUSIONS: Clozapine treatment is associated with an increased risk and severity of SARS-CoV-2 infection. Although meta-analytic results support this association, substantial heterogeneity in pooled estimates highlights the need for further research to clarify underlying clinical and methodological factors influencing risk.},
}
@article {pmid41763558,
year = {2026},
author = {Li, M and Sharma, K and Chon, JE and Yehia, NA and Retnakaran, R and Harris, SB and Hanley, AJ},
title = {The impact of COVID-19 illness on metabolic phenotypes underlying type 2 diabetes mellitus: a systematic review.},
journal = {Diabetes research and clinical practice},
volume = {235},
number = {},
pages = {113163},
doi = {10.1016/j.diabres.2026.113163},
pmid = {41763558},
issn = {1872-8227},
mesh = {Humans ; *Diabetes Mellitus, Type 2/metabolism/complications/epidemiology ; *COVID-19/metabolism/complications/epidemiology ; *Insulin Resistance/physiology ; *Insulin-Secreting Cells/metabolism ; SARS-CoV-2 ; Phenotype ; },
abstract = {We aimed to systematically review literature investigating the impact of COVID-19 on insulin resistance and beta-cell dysfunction in humans. Ovid MEDLINE and Embase were searched for studies published between December 2019 and May 2024. Observational studies examining adults with no history of type 2 diabetes comparing the development of insulin resistance and beta-cell dysfunction between COVID-19 exposed groups vs. controls were included. Risk of bias was assessed using adapted Newcastle-Ottawa and Joanna Briggs Institute scales. Among 6901 studies screened, 10 met the inclusion criteria. Across these studies, 37 individual measures of insulin resistance and beta-cell dysfunction were reported. Insulin resistance worsened significantly in 16 of 25 (64.0%) comparisons, whereas beta-cell dysfunction worsened significantly in 7 of 12 (58.3%) measures among COVID-19 patients when compared to controls. Five studies were considered low risk of bias. COVID-19 was associated with worsened insulin resistance and beta-cell dysfunction, suggesting infection may be a metabolic stressor that overwhelms gluco-regulatory mechanisms. Results, especially those for beta-cell function, should be interpreted cautiously given methodological limitations in the utilized measures. These findings highlight the pathophysiological aspects of type-2 diabetes impacted by COVID-19 infection and support the development of targeted monitoring and therapeutic strategies.},
}
@article {pmid41764591,
year = {2026},
author = {Çivilidağ, A and Durmaz, &#x15e;},
title = {The relationship of flexible working arrangements on work-family conflict, work-life balance and organizational commitment: a systematic review and meta-analysis.},
journal = {BMC psychology},
volume = {14},
number = {1},
pages = {},
pmid = {41764591},
issn = {2050-7283},
mesh = {*Work-Life Balance ; Humans ; *Work Schedule Tolerance/psychology ; Role Conflict ; *Employment/psychology ; *Personnel Loyalty ; Working Conditions ; },
abstract = {BACKGROUND: Technological advances and the COVID–19 pandemic have fundamentally reshaped the global work landscape, establishing flexible work arrangements (FWAs)—such as schedule flexibility and remote work—as a permanent feature of contemporary employment. This shift necessitates a rigorous quantitative synthesis of how FWAs relate to critical employee and organizational outcomes. This study examines the associations between FWAs and work–life balance (WLB), work–family conflict (WFC), and organizational commitment (OC). METHODS: A systematic review and meta–analysis was conducted across five electronic databases. Initially, 3,777 records were identified. Following the application of strict inclusion and quality criteria, 38 studies from 19 countries (N = 83,951) were selected for analysis. Data were synthesized using the Comprehensive Meta–Analysis (CMA 3.0) software, employing a random–effects model to calculate pooled effect sizes. RESULTS: The findings revealed significant and relatively large positive correlations between FWAs and WLB (r = .39, p < .001) and between FWAs and OC (r = .29, p < .001). Conversely, while the correlation between FWAs and WFC was positive (r= .25), it was statistically non–significant (p > .05). Meta–regression identified between countries the level of economic development as a significant moderator (p < .001), with the positive relationship of flexibility being significantly more pronounced in developed countries compared to developing nations. CONCLUSION: This meta–analysis provides robust evidence that FWAs are an effective strategic tool for enhancing WLB and substantially strengthening OC. However, their impact on reducing WFC remains less conclusive and is highly context–sensitive. Organizations are encouraged to formally adopt and support FWAs to improve employee well–being and foster loyalty, while remaining mindful of the macro–level institutional frameworks that shape flexibility outcomes.},
}
@article {pmid41765092,
year = {2026},
author = {Tsiodras, S and Gupta, N and Hanscheid, T and Jokelainen, P and Drexler, JF and Barac, A and Gkrania-Klotsas, E and Mora-Rillo, M and Bulescu, C and Paño-Pardo, JR and Lescure, FX and Grobusch, MP},
title = {Language, trust, and the polio endgame: words matter in vaccine communication.},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {32},
number = {8},
pages = {1286-1292},
doi = {10.1016/j.cmi.2026.02.023},
pmid = {41765092},
issn = {1469-0691},
mesh = {Humans ; *Poliomyelitis/prevention &amp; control/epidemiology ; *Vaccination Hesitancy/psychology ; *Trust ; *Poliovirus Vaccine, Oral/adverse effects/administration &amp; dosage ; Communication ; Terminology as Topic ; *Health Communication ; *Language ; COVID-19 ; Vaccination/psychology ; Disease Eradication ; Poliovirus Vaccines ; },
abstract = {SCOPE: Vaccine hesitancy remains a major public health challenge, particularly in the post-COVID-19 era, and is exacerbated by misinformation and social distrust. Terminology used in scientific and public health communication may influence perceptions of vaccine safety and credibility. This Position Paper examines the use of the term 'vaccine-derived poliovirus' (VDPV) and its potential impact on vaccine confidence during the final phase of polio eradication.<br><br>METHODS: We reviewed published epidemiological, virological, and social science literature on circulating VDPV, vaccine hesitancy, and health communication. Institutional guidance from the WHO and the Global Polio Eradication Initiative was also examined. Evidence from qualitative studies exploring community perceptions of the term 'vaccine-derived poliovirus' was considered alongside broader literature on risk communication.<br><br>We examine the scientific basis and epidemiology of oral poliovirus vaccine use and circulating VDPV emergence, the evolving landscape of vaccine hesitancy, communication challenges surrounding the term VDPV, historical precedents in vaccine communication, the role of disinformation, and the potential risks and benefits of revising established terminology. We recommend that stakeholders formally evaluate the implications of current nomenclature, consider alternative terms and dual-layer communication strategies that distinguish technical from public-facing language, and ensure that any modification of terminology is accompanied by transparent justification.},
}
@article {pmid41765322,
year = {2026},
author = {Yezli, S and Bonanni, P and Dinleyici, EC and Divyesh, T and Kumar, V and Leng, S and Coste, F and Taha, MK},
title = {Invasive meningococcal disease rebound in older adults post-COVID-19 pandemic: A targeted literature and surveillance review.},
journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
volume = {166},
number = {},
pages = {108502},
doi = {10.1016/j.ijid.2026.108502},
pmid = {41765322},
issn = {1878-3511},
mesh = {Humans ; *COVID-19/epidemiology ; Aged ; *Meningococcal Infections/epidemiology/mortality ; Incidence ; Neisseria meningitidis/classification ; Aged, 80 and over ; SARS-CoV-2 ; Pandemics ; },
abstract = {OBJECTIVES: Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, remains a significant public health concern due to its rapid progression, high case fatality rate (CFR), and evolving epidemiology. Recent trends suggest a demographic shift toward older adults. This review examined post-COVID-19 changes in IMD epidemiology among adults aged ≥65 years, including regional variations, serogroup distribution, and mortality.<br><br>METHODS: A targeted literature review was conducted using OVID (Embase, MEDLINE) following PICOS-T criteria, including full-text English-language studies published between January 2021 and June 2024, supplemented by surveillance reports.<br><br>RESULTS: Of 1639 records screened, four peer-reviewed publications and ten surveillance reports met inclusion criteria. During the COVID-19 pandemic, IMD incidence declined sharply across all age groups, including older adults. Post-pandemic data indicate a re-emergence of IMD among older populations, with incidence in several regions returning to or exceeding pre-pandemic levels by 2023. Across multiple locations, serogroup Y emerged as the dominant or increasingly prevalent serogroup among older adults. CFR varied by region and serogroup and consistently remained high in this age group.<br><br>CONCLUSION: These findings demonstrate the re-emergence of IMD among older adults and highlight the need for strengthened IMD surveillance and serogroup monitoring in this population, to guide prevention strategies and inform public health policy.},
}
@article {pmid41765382,
year = {2026},
author = {Ratnasabesar, V and Kunadian, V},
title = {Health inequalities across England and their impact on cardiovascular diseases.},
journal = {Heart (British Cardiac Society)},
volume = {},
number = {},
pages = {},
doi = {10.1136/heartjnl-2025-327508},
pmid = {41765382},
issn = {1468-201X},
abstract = {Cardiovascular disease (CVD) remains one of the leading causes of mortality in England, with its burden disproportionately concentrated in the North. Studies in the last few decades have highlighted that factors such as low education, high levels of unemployment, poor housing and reduced access to healthy food are strongly associated with the higher incidence of lifestyle risks-smoking, obesity and physical inactivity. These in turn increase rates of hypertension, dyslipidaemia and diabetes in the population. Beyond lifestyle factors, psychosocial mechanisms such as chronic stress and associated increase in allostatic load, due to long-standing deprivation, contribute to the biological risk of CVD. Early life disadvantage, ethnic and gender inequalities, and delayed management of intermediate risk factors further exacerbate the regional divide in England. Furthermore, the long-term impacts of COVID-19 and healthcare-associated national policies, including austerity-related funding deductions, have intensified pre-existing disparities. Evidence demonstrates that current preventative strategies, such as the National Health Service Health Check, have had limited success in reaching underserved communities, highlighting the need for targeted therapies. The National Institute of Health and Care Research Inequalities Challenge is a remarkable opportunity for the United Kingdom's (UK) leading research organisations to help tackle these inequalities associated with CVD and make a significant difference. Without such efforts, the excess CVD burden is likely to persist, perpetuating entrenched health inequalities. This review examines the different social determinants of health underlying these disparities, with a particular focus on socioeconomic deprivation, lifestyle risk factors, environmental and structural issues.},
}
@article {pmid41765774,
year = {2026},
author = {Andoh, JE and Fu, J and Nwanyanwu, KH},
title = {Impact of United States federal funding on equity and vision research: lessons from history, justice, and politics, 1968-2025.},
journal = {Current opinion in ophthalmology},
volume = {37},
number = {3},
pages = {162-167},
doi = {10.1097/ICU.0000000000001212},
pmid = {41765774},
issn = {1531-7021},
mesh = {United States ; Humans ; *Biomedical Research/economics ; *Politics ; *Financing, Government/history ; History, 20th Century ; Diversity, Equity, Inclusion ; *Health Equity ; History, 21st Century ; *Ophthalmology ; COVID-19/epidemiology ; },
abstract = {PURPOSE OF REVIEW: Federal policy has long shaped the scope and inclusivity of vision research in the United States. This narrative review and opinion article evaluates the evolution of equity in vision research over time, from the landmark National Institutes of Health Revitalization Act of 1993 to the direct impact of federal policies in today's political landscape.<br><br>RECENT FINDINGS: Equity in vision research originated from early epidemiologic studies identifying social and behavioral determinants of health in the 1970s. The post-2020 period accelerated attention to structural disparities in healthcare, catalyzed by the COVID-19 pandemic and a national conversation on race. However, recent executive orders have reversed equity oriented federal policies, restricted terminology and data access, and changed research funding operations. These ongoing developments pose risks to progress in all areas of research.<br><br>SUMMARY: Equity in vision research in the United States remains vulnerable to federal priorities that serve to support or destabilize. The current political environment underscores the need for the ophthalmologic research community to safeguard data integrity, sustain diverse participation, and continue methodologically rigorous protocols to ensure continued progress toward equitable vision health.},
}
@article {pmid41766004,
year = {2026},
author = {Halawi, M},
title = {Disparities in Outpatient and Short-Stay Arthroplasty Surgery: a Critical Review and Proposed Equity-Centered Framework.},
journal = {Current reviews in musculoskeletal medicine},
volume = {19},
number = {1},
pages = {},
pmid = {41766004},
issn = {1935-973X},
abstract = {PURPOSE OF REVIEW: Over the past decade, outpatient and short-stay total joint arthroplasty (TJA) has transitioned from exception to expectation, driven by enhanced recovery protocols, regulatory changes, and the COVID-19 pandemic. This review synthesizes evidence from 2015 to 2025 regarding inequities in this transition, clarifies key definitions and methodological challenges, and examines the contributing factors and controversies surrounding equitable access to ambulatory surgery. RECENT FINDINGS: Evidence indicates a widening gap in access and outcomes based on race, ethnicity, and gender. Black and Hispanic patients remain significantly less likely than White patients to undergo outpatient TJA, even when controlling for clinical comorbidities. Recent data also suggests that residence in socioeconomically disadvantaged neighborhoods is associated with longer lengths of stay and higher early healthcare utilization. Furthermore, sex-based differences have emerged in postoperative pain management, with women demonstrating higher rates of opioid exposure and persistence. While younger, healthier, and privately insured patients have disproportionately benefited from outpatient pathways, those with public insurance or higher comorbidity burdens face persistent structural barriers to candidacy and safe discharge. Achieving equitable outpatient TJA requires a shift from exclusionary risk-screening to an equity-centered framework. This proposed model spans inclusive candidacy, optimization through prehabilitation, care navigation, and the use of site-of-service metrics. Ultimately, mitigating these disparities will require coordinated, multilevel action across policy reform, clinical practice innovation, and community engagement to ensure that the benefits of surgical innovation are accessible to all patient populations.},
}
@article {pmid41766236,
year = {2026},
author = {Chen, S and Li, H and Jiang, Z and Liang, J and Zhou, A},
title = {Effects of Traditional Chinese Medicine on Restoroing the immune balance of mild-to-moderate Patients with new coronavirus.},
journal = {Indian journal of pharmacology},
volume = {58},
number = {2},
pages = {114-125},
pmid = {41766236},
issn = {1998-3751},
mesh = {Humans ; COVID-19/immunology ; *COVID-19 Drug Treatment ; *Drugs, Chinese Herbal/therapeutic use ; *Medicine, Chinese Traditional ; Pandemics ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: Coronavirus disease 2019 (COVID-19) which brings the epidemic situation to the public has spread rapidly and produce multiple variations. At present, Western medicine still lacks the specific medicine or vaccines for coronavirus. However, amount of evidence shows that traditional Chinese medicine (TCM) has advantages in releasing the symptoms of mild-to-moderate COVID patients. Those treatments are not only improving the course of the primary disease but also curb progress to severe pneumonia or acute respiratory distress syndrome. Therefore, taking TCM intervention or combined treatments appropriately to prevent worsening illness is of vital significance. This study mainly focuses on the data analysis on the effects of TCM in restoring the immune balance of COVID patients. By collecting clinical data from mild to moderate patients, we expected to figure out if TCM only plays the role of curbing inflammation or having a two-way influence in balancing the immune microenvironment.<br><br>METHODS: Seven digital databases including PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, China Science and Technology Journal Database (VIP), Wanfang Database, and China Biology Medicine were searched from December 2019 to August 2022 nothingness of language restrictions. The studies retrieved from the database were selected and the data extracted to assess the methodological quality of the included randomized controlled trials (RCTs). Statistical analysis was completed. Pulmonary computed tomography, clinical cure rate, rate of conversion to severe cases, length of hospital stay, and scores of TCM syndrome were defined as the primary outcomes, the secondary outcomes were white blood cell count, lymphocyte (LYM) count, and C-reactive protein (CRP). This study was registered with PROSPERO (CRD42022341482).<br><br>RESULTS: Nine eligible RCTs including 1159 participants were included in this meta-analysis. Compared with Western medicine treatment alone, our meta-analyses found that traditional Chinese combined Western medicine treatment has a higher clinical cure rate, better absorption of lung inflammation, and significantly shorter hospital stay. In terms of inflammatory factors, TCM can significantly reduce the CRP content compared with Western medicine methods, but the leukocyte and LYM content was not significantly different between the two treatments. In some research, TCM even has a trend accelerating the inflammation process on some specific stages of the disease.<br><br>CONCLUSION: Chinese herbal medicine combined with conventional therapy is significantly effective and invulnerable in the treatment of mild-to-moderate COVID-19. In terms of control inflammation, TCM does not only block the disease onset by simply inhibiting inflammation but balancing the human environment through bidirectional regulation of inflammatory cells. However, considering of the lack of research into how TCM could activate the natural immune response, the discussion of the mechanism cannot be stretched, more high-quality RCTs are still needed in the future.},
}
@article {pmid41766239,
year = {2026},
author = {Meena, J and Agarwal, A and Sandhu, A and Pradhan, P and Singh, M},
title = {Efficacy and safety of remdesivir for patients with severe acute respiratory syndrome coronavirus 2 infection: A systematic review of randomized controlled trials.},
journal = {Indian journal of pharmacology},
volume = {58},
number = {2},
pages = {137-141},
pmid = {41766239},
issn = {1998-3751},
mesh = {Humans ; *Adenosine Monophosphate/analogs &amp; derivatives/therapeutic use/adverse effects ; *Alanine/analogs &amp; derivatives/therapeutic use/adverse effects ; *Antiviral Agents/therapeutic use/adverse effects ; Randomized Controlled Trials as Topic ; COVID-19 Drug Treatment ; COVID-19 ; SARS-CoV-2 ; Treatment Outcome ; Pandemics ; },
abstract = {In view of the pandemic of coronavirus disease 2019 (COVID-19), there is a need to identify a specific antiviral therapy. We performed this systematic review to assess the efficacy of remdesivir in the treatment of COVID-19. We searched three electronic databases for clinical trials investigating remdesivir for COVID-19 and included this systematic review. Five trials evaluating 13,558 participants were eligible for this study. Remdesivir, as compared to standard care, increases the rate of clinical improvement at 2 weeks (risk ratio: 1.10; 95% confidence interval: 1.04-1.18). Time to clinical recovery was shorter in the remdesivir group than the standard care group. The mortality rate was lower at 2 weeks in the remdesivir group, but no difference was observed at 4 weeks postrandomization. Extending the duration of remdesivir from 5 days to 10 days did not improve efficacy but increased the risk of adverse events. Findings from this systematic review suggested that remdesivir may slightly improve recovery time and rate of clinical improvement.},
}
@article {pmid41766448,
year = {2026},
author = {Taxiarchis, A and Pruner, I},
title = {Messengers of coagulopathy: complement-carrying extracellular vesicles in SARS-CoV-2 infection.},
journal = {Current opinion in hematology},
volume = {33},
number = {3},
pages = {105-112},
doi = {10.1097/MOH.0000000000000916},
pmid = {41766448},
issn = {1531-7048},
mesh = {Humans ; *COVID-19/blood/complications/immunology ; *Extracellular Vesicles/metabolism/immunology/pathology ; *Complement Activation ; *SARS-CoV-2 ; *Complement System Proteins/metabolism ; *Blood Coagulation Disorders/etiology/blood ; Complement Membrane Attack Complex/metabolism ; Blood Platelets/metabolism ; },
abstract = {PURPOSE OF REVIEW: SARS-CoV-2 disease (COVID-19) is increasingly recognized as a thromboinflammatory vascular disorder characterized by dysregulated complement activation, endothelial injury, and sustained hypercoagulability. This review examines emerging evidence that extracellular vesicles act as key intermediaries linking complement activation to coagulation in acute and postacute COVID-19 infection.<br><br>RECENT FINDINGS: Recent studies demonstrate that extracellular vesicles released from platelets, endothelial cells, and neutrophils are markedly increased in COVID-19 and exhibit a combined procoagulant and complement-active phenotype. Sub-lytic complement attack, particularly membrane attack complex (MAC) deposition, triggers phosphatidylserine exposure and extracellular vesicle shedding, generating vesicles that support thrombin generation and propagate complement activity in the circulation. Extracellular vesicle-associated complement components, including C1q, C3 fragments, MASP2, and preassembled MACs, promote tissue factor decryption, platelet activation, and assembly of the prothrombinase complex, establishing a self-amplifying thromboinflammatory loop. Proteomic profiling further reveals compartment-specific extracellular vesicle signatures, with systemic extracellular vesicles enriched in complement and coagulation pathways. Importantly, complement-bearing and tissue factor-bearing extracellular vesicles persist beyond acute infection and are increasingly implicated in postacute sequelae of COVID-19.<br><br>SUMMARY: Extracellular vesicles serve as mobile platforms integrating complement activation with coagulation, providing a mechanistic framework for acute and chronic immunothrombosis in COVID-19. Targeting extracellular vesicle-mediated complement-coagulation crosstalk may offer novel diagnostic and therapeutic opportunities.},
}
@article {pmid41766626,
year = {2026},
author = {Jones, M and Krockow, EM and Tromans, SJ and Mukaetova-Ladinska, EB},
title = {Antidepressant prescribing trends for adult patients in the UK and Ireland during the COVID-19 pandemic: systematic review.},
journal = {BJPsych open},
volume = {12},
number = {2},
pages = {e77},
pmid = {41766626},
issn = {2056-4724},
abstract = {BACKGROUND: Recent decades have seen a steady increase in antidepressant prescribing, but little is known about prescribing trends during and following the COVID-19 pandemic.<br><br>AIMS: This preregistered systematic review, following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, aimed to investigate antidepressant prescribing trends for adults in the UK and Republic of Ireland during and after the pandemic. It also compared prescriptions by drug and location.<br><br>METHOD: We searched six databases: APA PsycInfo, CINAHL, MEDLINE, Scopus, medRxiv and Preprints.org. The review included primary research articles reporting trends in antidepressant prescriptions, including at least one time point after March 2020 in the UK and Republic of Ireland. This review has been preregistered on PROSPERO (ID: CRD42024498503).<br><br>RESULTS: We identified 7,320 studies, of which ten met the search criteria for the review. Studies were grouped on the basis of time period (2020: n = 5; 2021: n = 3; 2022: n = 2), location (England, Scotland, Northern Ireland, Republic of Ireland, UK) and drug type (serotonin-noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclics, and others (e.g. monoamine oxidase inhibitors)). Most studies (eight of ten) demonstrated increased antidepressant prescribing over time. Two studies highlighted a decrease between March and May 2020. Demographic variables reflected higher rates of prescribing for women, and the modal group receiving antidepressants comprised middle-aged adults.<br><br>CONCLUSIONS: The commonly reported increase in antidepressant prescribing corroborates pre-pandemic trends and may suggest further, increased demands for mental health support to meet the unique challenges of the pandemic. Future research is required to evaluate the appropriateness of treatment decisions and to explore psychosocial factors that influence individual prescribing choices.},
}
@article {pmid41766628,
year = {2026},
author = {Szemray, H and Lawler, NG and Lodge, S and Wist, J and Whiley, L},
title = {Dynamic Lipidomic Responses to Inflammation and Physical Insult: A Comparative Review Across Blunt Force Trauma, Thermal Burn Injury, and Viral Infection.},
journal = {Expert reviews in molecular medicine},
volume = {28},
number = {},
pages = {e11},
pmid = {41766628},
issn = {1462-3994},
support = {//Dementia Australia Research Foundation/ ; },
mesh = {Humans ; *Burns/metabolism/pathology/blood ; *Lipidomics/methods ; *COVID-19/metabolism/pathology ; *Inflammation/metabolism ; *Brain Injuries, Traumatic/metabolism/blood/pathology ; SARS-CoV-2 ; *Wounds, Nonpenetrating/metabolism ; Lipid Metabolism ; Lipoproteins/blood ; Biomarkers/blood ; *Lipids/blood ; },
abstract = {Acute insults ranging from blunt force trauma and thermal injury to pathogenic infection elicit systemic inflammatory cascades intended to limit further tissue damage. These responses are accompanied by metabolic disturbances that generate distinct biochemical signatures measurable through advanced analytical platforms, such as mass spectrometry and nuclear magnetic resonance spectroscopy (NMR). Although numerous studies have examined these metabolic alterations, findings remain fragmented across clinical and analytical disciplines, leaving it unclear whether the systemic metabolic response to acute insult is fundamentally conserved or insult-specific. In this comparative review, we consolidate evidence across diverse injury and infection contexts to identify shared metabolic patterns, context-dependent differences, and critical gaps in current understanding. Here, we focus on lipid and lipoprotein profiling of blood plasma and serum. We present exemplar case studies spanning traumatic brain injury, burn injury, and SARS-CoV-2 infection to illustrate how lipid and lipoprotein perturbations differ or converge across insult types. Notable observations include consistently elevated palmitic acid (16:0) and reduced phosphatidylcholine species across all three conditions, suggesting these features may represent cross-condition biomarkers and highlighting the value of comparative metabolic profiling. By integrating evidence across diverse contexts, we propose a framework describing the interplay between lipid metabolism, lipoprotein dynamics, and inflammatory activation. Finally, we discuss the translational potential of metabolic phenotyping in enhancing patient stratification, refining prognostic modelling, and improving patient outcomes.},
}
@article {pmid41767143,
year = {2026},
author = {Liu, SC and Cheah, KSL and Syed Ali, SKB and Qu, HM and Wang, ZL},
title = {A bibliometric and visualization analysis for global research trends in Wushu and mental health (1981-2024).},
journal = {Frontiers in psychiatry},
volume = {17},
number = {},
pages = {1737574},
pmid = {41767143},
issn = {1664-0640},
abstract = {BACKGROUND: Mental health has become one of the most urgent public health issues in the 21st century, and the COVID-19 pandemic has significantly increased this problem. As a traditional mind-body practice, Wushu (e.g., Tai Chi, Qigong) is increasingly recognized for its therapeutic potential in mental health. However, bibliometric studies in this eld remain scarce.<br><br>METHODS: This study aims to visualize the Wushu and mental health (WMH) related research through bibliometric analysis of the Web of Science database (1981-2024). It examines publication trends, core journals, international collaboration, leading authors, and thematic evolution. A systematic search using Boolean operators identified 536 articles. To conduct a complementary analysis of the findings, this study compared the 23 clinical trials identified from PubMed (2020-2024) with the research trends obtained from the bibliometric analysis.<br><br>RESULTS: The study found that the number of published articles and cited times increased significantly in the past five years, which confirmed the influence of COVID-19 in this field. China and the United States, represented by Harvard University, are the main pushing forces in this area. The research focus has shifted from rehabilitation orientation to comprehensive mental and public health perspectives. Future development trends may include strengthening international cooperation, standardizing intervention programs, and cross-cultural research.<br><br>CONCLUSION: This multi-database analysis provides researchers and policymakers with a scientific reference for the WMH field. It clearly reflects current research trends and future research directions in WMH.},
}
@article {pmid41767314,
year = {2026},
author = {González, S and Arellano, J and Reza-Zaldivar, EE and Mena-Munguía, S and Minjarez, B and Rodríguez-Yáñez, Y},
title = {Viral mechanisms, tropism, and clinical relevance regarding the ophthalmic manifestations of SARS-CoV-2 infection.},
journal = {International journal of ophthalmology},
volume = {19},
number = {3},
pages = {619-629},
pmid = {41767314},
issn = {2222-3959},
abstract = {To explore the mechanisms underlying ocular infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we conducted a comprehensive review of current literature, focusing on viral entry pathways, receptor expression in ocular tissues, and associated clinical manifestations. This review encompasses studies published within the last five years with a focus on original research and systematic reviews that provide molecular, histological, or clinical evidence. The findings show that SARS-CoV-2 can infect ocular tissues through multiple receptors beyond angiotensin-converting enzyme 2 (ACE2), including transmembrane serine protease 2 (TMPRSS2), CD147, alanyl aminopeptidase N (ANPEP), dipeptidyl peptidase 4 (DPP4), angiotensin II receptor type 2 (AGTR2), and polymeric immunoglobulin receptor (PIGR), which are expressed in retinal, conjunctival, corneal, limbal, and photoreceptor cells. The virus may also reach ocular structures via neurovascular invasion. Clinically, patients with coronavirus disease 2019 (COVID-19) may present with a broad spectrum of ophthalmic manifestations, including conjunctivitis, hyperreflective lesions in the inner retinal layers, flame-shaped hemorrhages, cotton-wool spots, retinal pallor, hard exudates, and various forms of maculopathy, such as paracentral acute middle maculopathy and acute macular neuroretinopathy (AMN). These signs reflect both direct viral damage and secondary effects of systemic inflammation and microvascular injury. Understanding the molecular and clinical spectrum of ocular involvement is essential for early diagnosis, appropriate ophthalmologic care, and the prevention of long-term visual sequelae in patients affected by COVID-19.},
}
@article {pmid41767650,
year = {2026},
author = {Birdi, S and Patel, A and Rabet, R and Singh, N and Durant, S and Vosoughi, T and Kapra, F and Shergill, M and Mesfin, E and Ziegler, C and Ali, S and Buckeridge, D and Ghassemi, M and Gibson, J and John-Baptiste, A and Macklin, J and Mccradden, M and Mckenzie, K and Mishra, S and Naraei, P and Owusu-Bempah, A and Rosella, L and Shaw, J and Upshur, R and Pinto, AD},
title = {Machine Learning Used in Communicable Disease Control: A Scoping Review.},
journal = {Public health reviews},
volume = {47},
number = {},
pages = {1608074},
pmid = {41767650},
issn = {0301-0422},
abstract = {OBJECTIVES: Communicable diseases continue to threaten global health, with COVID-19 as a recent example. Rapid data analysis using machine learning (ML) is crucial for detecting and controlling outbreaks. We aimed to identify how ML approaches have been applied to achieve public health objectives in communicable disease control and to explore algorithmic biases in model design, training, and implementation, and strategies to mitigate these biases.<br><br>METHODS: We searched MEDLINE, Embase, Cochrane Central, Scopus, ACM DL, INSPEC, and Web of Science to identify peer-reviewed studies from 1 January 2000, to 15 July 2022. Included studies applied ML models in population and public health to address ten communicable diseases with high prevalence.<br><br>RESULTS: 28,378 citations were retrieved, and 209 met our inclusion criteria. ML for communicable diseases has risen since 2020, particularly for SARS-CoV-2 (n = 177), followed by malaria, HIV, and tuberculosis. Eighteen studies (8.61%) considered bias, and only eleven implemented mitigation strategies.<br><br>CONCLUSION: A growing number of studies used ML for disease surveillance. Addressing biases in model design should be prioritized in future research to improve reliability and equity in public health outcomes.},
}
@article {pmid41767904,
year = {2026},
author = {Jagasia, K and Malyan, HH and Kim, J and Kabakibi, M and Moore, AA and Nguyen, AL},
title = {Cannabis Use Among Caregivers of Older Adults: A Systematic Literature Review.},
journal = {Sage open aging},
volume = {12},
number = {},
pages = {30495334261426511},
pmid = {41767904},
issn = {3049-5334},
abstract = {As the global population ages, the number of caregivers has risen accordingly. Though caregiving has many rewards, it may also cause psychological stress. To manage this burden, caregivers may adopt various coping strategies, including cannabis use. This systematic review aimed to synthesize existing literature on cannabis use among caregivers for older adults. A database search in PubMed, PsycINFO, and CINAHL identified 357 unique peer-reviewed articles to screen and five were included in the review. Studies were included if they reported empirical data on cannabis use among caregivers for older adults. Of the five included studies, four studies found that caregivers reporting high stress or emotional burden used cannabis to cope, with two finding new or increased use during the COVID-19 pandemic. One study found that using cannabis improved caregivers' self-reported health and well-being; another found positive caregiver attitudes toward recreational cannabis. Two studies found higher caregiver anxiety was associated with increased cannabis use. Despite limited research, these studies underscore the role of cannabis as a potential coping mechanism for caregivers of older adults experiencing emotional burden. Additional research should seek to characterize longitudinal patterns of cannabis use among caregivers and its potential impact on both caregiver and care recipients.},
}
@article {pmid41768578,
year = {2026},
author = {Castellanos-Hernández, DI and Mayoral-Chávez, MA and Matias-Cervantes, CA and Alpuche, J},
title = {Association between nucleic acid COVID-19 vaccines and acute myocardial infarction in adults: a systematic review.},
journal = {Frontiers in cardiovascular medicine},
volume = {13},
number = {},
pages = {1752169},
pmid = {41768578},
issn = {2297-055X},
abstract = {BACKGROUND: Post-marketing surveillance has documented cardiovascular adverse events following COVID-19 vaccination, including acute myocardial infarction (AMI); however, evidence regarding causal associations remains contradictory.<br><br>OBJECTIVE: To determine whether a causal association exists between nucleic acid-based COVID-19 vaccines (mRNA and DNA platforms) and AMI in adults aged 18-80 years.<br><br>METHODS: A systematic review following PRISMA 2020 guidelines searched PubMed, Cochrane CENTRAL, and Google Scholar for studies evaluating mRNA vaccines (Pfizer-BioNTech, Moderna) and DNA-based vaccines (AstraZeneca) with AMI as primary outcome. Quality assessment used the Newcastle-Ottawa Scale.<br><br>RESULTS: Twenty-nine studies from 16 countries were analyzed, including 14 population-based cohorts (>142.5 million individuals, >130,000 AMI cases), 12 case reports (54 AMI events), and three pharmacovigilance studies. Large cohorts demonstrated no significant association between nucleic acid vaccines and AMI. A Swedish study (8.1 million) showed protective effects (HR: 0.81; 95% CI: 0.74-0.89 for third dose). A Malaysian study (22.2 million) found no significant increase after BNT162b2 (dose 1 IRR: 0.97; dose 2 IRR: 1.08) or ChAdOx1 (dose 1 IRR: 1.02; dose 2 IRR: 1.58). Case reports documented temporal associations but had substantial methodological limitations. Quality assessment revealed low-to-moderate bias in population studies but high bias in case reports and pharmacovigilance data.<br><br>CONCLUSIONS: High-quality population-based evidence from 14 independent cohorts does not support a causal association between nucleic acid-based COVID-19 vaccines and AMI. Case reports lack the methodological rigor to establish causality. The documented protective effects after booster doses and consistency across diverse populations demonstrate vaccine cardiovascular safety, supporting continued vaccination policies.},
}
@article {pmid41769275,
year = {2025},
author = {Mohammad, K and Mohaddeseh, B and Amir Hossein, M},
title = {COVID-19 and ACE2 Receptor in Different Tissues: From Pathophysiologic Function To Therapeutic Responses.},
journal = {Archives of Razi Institute},
volume = {80},
number = {3},
pages = {591-604},
pmid = {41769275},
issn = {2008-9872},
mesh = {Humans ; *Angiotensin-Converting Enzyme 2/metabolism ; *COVID-19 ; *SARS-CoV-2/physiology ; *Receptors, Virus/metabolism ; *Peptidyl-Dipeptidase A/metabolism ; Pandemics ; Animals ; *Betacoronavirus/physiology ; Virus Internalization ; },
abstract = {SARS-CoV-2, the virus responsible for COVID-19, is characterized by its high transmission rate, leading to a global pandemic. Millions of people have lost their lives due to the infection caused by this virus. The ability of the virus to spread rapidly and infect large numbers of people has highlighted the need to understand its mechanisms of infection. Angiotensin-converting enzyme 2 (ACE2) is an essential receptor for SARS-CoV-2 cell entry. SARS-CoV-2 exhibits a high affinity to this receptor and shows high infectivity, leading to an explosive increase in patients infected with COVID-19. ACE2 is the carboxypeptidase homolog of ACE, which produces angiotensin II, the main active peptide of the renin-angiotensin system. From a pathophysiological perspective, this system regulates vital processes across different organs. Additionally, ACE2 enzyme activity could play a protective role against acute respiratory distress syndrome (ARDS) caused by viral pneumonia. Upon infection, SARS-CoV-2 downregulates the expression of ACE2, which is possibly related to the pathogenesis of ARDS. Since this receptor is present in various other tissues such as the heart, kidney, gastrointestinal tract, reproductive system, and sensory organs, it may contribute to pathological symptoms in these organs. Thus, ACE2 is not only a receptor for SARS-CoV-2 but may also play a crucial role in various aspects of the pathogenesis of COVID-19 and potential post-COVID-19 syndromes. Administering ACE2 could competitively bind to SARS-CoV, thereby reducing viral spike protein from attaching to transmembrane ACE2 and consequently reducing viral cell entry into cells and COVID-19 symptoms. In this review, we first examine the role of ACE2 in the pathophysiology of SARS-CoV-2 across different tissues and propose treatment strategies for COVID-19 that involve ACE2.},
}
@article {pmid41769292,
year = {2025},
author = {Abdol Ghaffar, E and Zeliha, S and Hamdia Yousif, I and Elifsena Canan, AA and Shahid, A},
title = {Next-Generation Vaccines and Antiviral Platforms: Molecular Advancements in the Struggle against Emerging Zoonotic and Viral Diseases.},
journal = {Archives of Razi Institute},
volume = {80},
number = {3},
pages = {555-568},
pmid = {41769292},
issn = {2008-9872},
mesh = {Animals ; Humans ; *Viral Vaccines/immunology ; *Virus Diseases/prevention &amp; control/virology ; *Zoonoses/prevention &amp; control/virology ; *Viral Zoonoses/prevention &amp; control/virology ; Antiviral Agents ; *Communicable Diseases, Emerging/prevention &amp; control/virology ; Vaccine Development ; },
abstract = {The ongoing occurrence of zoonotic and viral diseases, such as SARS-CoV-2, H5N1, Nipah, and Ebola viruses, underscores the requirement for transformative innovations in vaccine and antiviral development. Classic vaccine technologies like inactivated or live-attenuated virus products have lengthy production cycles, cold-chain storage, and are poorly suited to reacting rapidly to emerging threats This review synthesizes the most recent advances in molecular virology, immunogen design, and biotechnology that will propel the next generation of prevention and treatment tools. We begin with the genomic and structural characteristics of high-consequence zoonotic viruses, highlighting the molecular determinants for virulence, host switching, and immune evasion. The review then provides a comparative review of the emerging vaccine platforms such as mRNA, DNA, viral vector, subunit, and inactivated vaccines based on design rationale, delivery systems, immunogenicity profiles, and global rollouts. At the same time, molecular mechanisms of antiviral drugs acting against viral polymerases, proteases, and entry mechanisms are discussed, and the new challenge of resistance evolution is emphasized. We also highlight recently developed molecular diagnostic tools like CRISPR-based tools, nanopore sequencing, and isothermal amplification technologies that are transforming real-time pathogen diagnosis in veterinary and human medicine. Last, the One Health aspect is introduced through veterinary applications of vaccines to zoonotic spillover prevention and antimicrobial resistance. In conclusion, this review gives a vision-orientated account of molecular strategies that bring together human and animal medicine to combat future pandemics. Our aggregated tables and visualizations are an asset for researchers, clinicians, and policymakers interested in the improvement of epidemic preparedness and cross-species disease surveillance.},
}
@article {pmid41769697,
year = {2026},
author = {Rouhana El Feghali, Y and Rabih, L and Abdul Khalek, J and Arabi, M},
title = {Remdesivir in COVID-19: pros and cons.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1731244},
pmid = {41769697},
issn = {1663-9812},
abstract = {BACKGROUND: Beginning in late 2019, the COVID-19 pandemic caused by SARS-CoV-2 rapidly evolved into a global health crisis. High rates of severe illness, hospitalizations, and long-term complications highlighted an urgent need for effective therapeutic agents. This necessity drove unprecedented efforts in drug discovery and repurposing. Remdesivir, developed by Gilead Sciences in 2009, was initially designed as a broad-spectrum antiviral targeting Ebola virus disease. Following observations of broad antiviral activity against coronaviruses, remdesivir was granted Emergency Use Authorization by the FDA in May 2020 for hospitalized patients with severe COVID-19. The FDA subsequently issued full approval in October 2020, expanding remdesivir's use to hospitalized adults and pediatric patients aged 12 years or older and weighing at least 40 kg.<br><br>AIM: This paper aims to assess the advantages and limitations of remdesivir in the treatment of COVID-19, drawing on evidence from clinical trials and examining its application in patients with congenital heart disease (CHD).<br><br>METHODS: The literature review was conducted until September 2025 using PubMed and Google Scholar searching for recent clinical trials in addition to relevant reviews.<br><br>RESULTS AND CONCLUSION: Remdesivir has been shown to shorten recovery time and lower mortality risk, particularly in patients at an early stage of infection with mild disease severity or requiring oxygen support. Although early guidelines advised against its use in patients with severe renal impairment, subsequent studies confirmed its safety prompting an FDA label update to allow use regardless of renal function. While some trials reported limited effects, the overall body of evidence supports remdesivir's role in improving clinical outcomes in COVID-19 treatment. In patients with CHD, the uncertain effects of both COVID-19 and remdesivir highlight a key research gap, emphasizing the need to refine existing therapies while following National Institutes of Health (NIH) treatment guidelines.},
}
@article {pmid41769699,
year = {2026},
author = {Wan, C and Liu, X and Xu, Y and Kang, L and Yu, X and Wang, M and Zhao, M and Li, X and Chen, Z and Wu, J and Liu, L and Xu, X},
title = {Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1752467},
pmid = {41769699},
issn = {1663-9812},
abstract = {Respiratory diseases constitute a heterogeneous group of disorders that primarily involve the lungs. Driven by worsening air pollution, tobacco use, occupational exposures, the COVID-19 pandemic, and population aging, they show persistently high incidence with rising mortality and disability, posing a major global public-health challenge. Current pharmacotherapies-principally antibiotics, glucocorticoids, β2-adrenoceptor agonists, and antiviral agents-yield only limited benefit and are constrained by adverse reactions such as gastrointestinal disturbances and hepatorenal toxicity, alongside the escalating problem of drug resistance. The development of safer and more effective therapeutics is therefore of considerable clinical and socioeconomic importance. Plant-derived natural products have attracted increasing interest in the management of respiratory diseases. Polydatin (resveratrol-3-O-β-D-glucoside; also known as piceid; PD) is a stilbenoid polyphenol of plant origin that is widely distributed in Polygonum cuspidatum (Japanese knotweed), Polygonum multiflorum, grapes, peanuts, mulberries, blueberries, and rhubarb. Accumulating evidence indicates that PD exerts anti-inflammatory, antioxidant, antimicrobial, immunomodulatory, and metabolic-regulatory activities and shows potential therapeutic value in pulmonary fibrosis, acute lung injury/acute respiratory distress syndrome, pneumonia, lung cancer, and asthma. This review provides a comprehensive synthesis of the multi-target and multi-pathway mechanisms by which PD acts against respiratory diseases, offering a mechanistic rationale and evidence base to support its clinical development.},
}
@article {pmid41771782,
year = {2026},
author = {DiFrancesco, R and Wood, TD and Cha, R and Hochreiter, JS and Rosenkranz, SL and Farhad, M and Whitson, KR and Gould, CE and Hill, LE and Hale, LL and Lindhorst, PH and Ghazal, D and Taylor, CR and Quraishi, M and Siminski, SM and Cramer, Y and Sprenger, HL and Morse, GD},
title = {Clinical Pharmacology Quality Assurance Program for Global HIV and Co-Infection Drug Development.},
journal = {Clinical pharmacology and therapeutics},
volume = {119},
number = {5},
pages = {1205-1215},
pmid = {41771782},
issn = {1532-6535},
support = {D43 TW010313/TW/FIC NIH HHS/United States ; },
mesh = {Humans ; *HIV Infections/drug therapy ; *Pharmacology, Clinical/standards ; *Coinfection/drug therapy ; *Drug Development/standards/methods ; United States ; Quality Control ; *Anti-HIV Agents/therapeutic use ; *Quality Assurance, Health Care ; },
abstract = {When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics. The clinical trials networks included laboratory centers with academic pharmacology laboratories measuring drug concentrations to allow for the estimation of pharmacokinetic parameters and correlation with pharmacodynamic outcomes. Adoption of comprehensive quality assurance initiatives was key to ensuring the integrity of pharmacology sampling and laboratory data provided by clinical sites and laboratories. Subsequently, this infrastructure facilitated rapid responses to co-infection pathogens such as hepatitis C virus, Mycobacterium tuberculosis, and severe acute respiratory syndrome coronavirus 2. In 2008, the Center for Integrated Global Biomedical Sciences at the University at Buffalo was awarded the initial National Institute of Allergy and Infectious Diseases contract for the Clinical Pharmacology Quality Assurance Program. Since 2015, over 4,500 tutorial certificates for research staff and laboratories have been awarded on topics including the conduct of clinical pharmacology research protocols and bioanalytical method validation for antiretroviral assays. A bioanalytical peer review program for ensuring the quality of the assay methods has approved over 350 assays for > 100 analytes in 21 human biological matrices. An ISO-17043 accredited external proficiency testing program has completed 35 rounds for 15 analytes. Also, a laboratory assessment program was established that utilizes international laboratory and regulatory standards, and multiple mechanisms for training, assistance and guidance to participants. This report summarizes the development of the CPQA program over the last decade.},
}
@article {pmid41772834,
year = {2026},
author = {Kucharska, K and Ali, AH and Moriarty, F},
title = {Exploring perspectives of interest-holders on the use of health and genomic data from deceased participants in research: An updated systematic review.},
journal = {Journal of genetic counseling},
volume = {35},
number = {2},
pages = {e70186},
pmid = {41772834},
issn = {1573-3599},
mesh = {Humans ; *Information Dissemination ; *Genomics ; COVID-19/epidemiology ; *Research Subjects/psychology ; },
abstract = {The use of research biobanks and databases often involves prolonged storage of data, meaning that an increasing amount of deceased participants' data is being used in research. Research participants are not always informed of the intent to continue using their data post-mortem, and using such data affects the privacy of decedents and their surviving relatives. It is therefore important to assess the perspectives of interest-holders in this respect, considering the rapid progress of big-data technologies, new privacy regulations in the EU and unprecedented data sharing during the COVID-19 pandemic. This paper aimed to update a systematic review by Bak et al., to investigate the views of interest-holders on post-mortem data sharing in research. This systematic review followed the same search strategy and inclusion criteria as the previous review, focusing on new empirical evidence on the views of interest-holders regarding the post-mortem sharing or re-use of genetic or health data of research participants, from studies published in 2019-2025. It is reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRIMSA) statement. Findings of included studies were narratively synthesized. The updated systematic review identified seven studies involving 2151 participants, which were of high quality. The main themes of these studies related to perceived acceptability of post-mortem data sharing, aspects of consent (including broad consent), sharing clinical findings with relatives, and barriers and facilitators to data sharing. The findings illustrate that post-mortem genetic and health-related data use remains a relatively under-explored subject, with evident gaps in legislation and guidance.},
}
@article {pmid41773392,
year = {2026},
author = {Muzamhindo, DN and Chironda, G and Tsoka-Gwegweni, JM},
title = {Implementation of malaria control programmes during the COVID-19 pandemic in the Southern African Development Community Elimination 8 countries: A scoping review.},
journal = {African journal of primary health care &amp; family medicine},
volume = {18},
number = {1},
pages = {e1-e12},
pmid = {41773392},
issn = {2071-2936},
mesh = {Humans ; *COVID-19/epidemiology ; *Malaria/prevention &amp; control/epidemiology ; *Pandemics ; Africa, Southern/epidemiology ; SARS-CoV-2 ; *Disease Eradication ; Evidence Gaps ; },
abstract = {BACKGROUND: Malaria is one of the communicable diseases affecting the whole world. The World Health Organization (WHO) African Region is the most affected, with the Southern African Development Community (SADC) and the Malaria Elimination 8 (E8) countries accounting for 90% and 95% of the cases, respectively. The WHO tasked the SADC Malaria E8 countries to eliminate malaria by 2030, yet the COVID-19 pandemic response disrupted health programmes.<br><br>AIM: &#xa0;The review aims to map and synthesise the evidence on malaria control programmes during the COVID-19 pandemic in the SADC E8 countries to identify gaps, inform policy, enhance planning for future pandemics and promote the attainment of the SADC 2030 Malaria E8 goal.<br><br>METHOD: &#xa0;The reviewers conducted this review using the Joanna Briggs Institute (JBI) methodology. The population, concept and context (PCC) guided inclusion and exclusion criteria. Information relevant to the review questions was extracted using data extraction tools.<br><br>RESULTS: &#xa0;Of the 658 articles retrieved, only 7 met the inclusion criteria. Half of the publications were done in 2021, and nothing was published in 2020. The publishers were predominantly public health experts.<br><br>CONCLUSION: &#xa0;There is limited research on the malaria programmes during the COVID-19 pandemic in the Malaria E8 countries.Contribution:&#xa0;The review brings out the need for research on the topic, policies that promote the continuation of malaria programmes during a pandemic and the employment of coping strategies.},
}
@article {pmid41773597,
year = {2026},
author = {Alsulami, AS and Al-Kuraishy, HM and Waheeb, TS and El-Saber Batiha, G},
title = {Colchicine in COVID-19: Mechanistic Insights and Clinical Uncertainties.},
journal = {Reviews in medical virology},
volume = {36},
number = {2},
pages = {e70126},
doi = {10.1002/rmv.70126},
pmid = {41773597},
issn = {1099-1654},
mesh = {Humans ; *Colchicine/therapeutic use/adverse effects ; COVID-19/immunology/virology ; SARS-CoV-2/drug effects ; *COVID-19 Drug Treatment ; Autophagy/drug effects ; Oxidative Stress/drug effects ; },
abstract = {Coronavirus Disease 2019 (COVID-19) which caused by the novel coronavirus SARS-CoV-2 has been emerged as a global health crisis characterised by severe immune dysregulation and inflammatory complications. The hyper-activation of the immune response in COVID-19 patients is associated with disease progression and severity. As a result, immunomodulatory therapies such as colchicine have been suggested to control exaggerated immune response in COVID-19. However, the therapeutic role of colchicine in COVID-19 remains a subject of debate due to conflicting evidence. This review highlights both the beneficial and potentially harmful effects of colchicine in the context of COVID-19. Notably, the therapeutic advantages of colchicine are linked to the suppression of immune cell over-activation, attenuation of oxidative stress, and prevention of thrombo-inflammatory events. Conversely, colchicine may exert negative effects by disrupting microtubule function, impairing autophagic processes, and inducing mitochondrial dysfunction in COVID-19. In conclusion, the overall clinical impact of colchici